PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Cannon, CP; Pratley, R; Dagogo-Jack, S; Mancuso, J; Huyck, S; Masiukiewicz, U; Charbonnel, B; Frederich, R; Gallo, S; Cosentino, F; Shih, WJ; Gantz, I; Terra, SG; Cherney, DZI; McGuire, DK				Cannon, Christopher P.; Pratley, Richard; Dagogo-Jack, Samuel; Mancuso, James; Huyck, Susan; Masiukiewicz, Urszula; Charbonnel, Bernard; Frederich, Robert; Gallo, Silvina; Cosentino, Francesco; Shih, Weichung J.; Gantz, Ira; Terra, Steven G.; Cherney, David Z. I.; McGuire, Darren K.		VERTIS CV Investigators	Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EMPAGLIFLOZIN; MORTALITY; DISEASE	BACKGROUND The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P=0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events.	[Cannon, Christopher P.] Harvard Med Sch, Brigham & Womens Hosp, Cardiovasc Div, Boston, MA 02115 USA; [Pratley, Richard] AdventHlth Translat Res Inst, Orlando, FL USA; [Dagogo-Jack, Samuel] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Mancuso, James; Masiukiewicz, Urszula; Frederich, Robert; Terra, Steven G.] Pfizer, Groton, CT USA; [Huyck, Susan; Gantz, Ira] Merck, Kenilworth, NJ USA; [Charbonnel, Bernard] Univ Nantes, Dept Endocrinol, Nantes, France; [Shih, Weichung J.] Rutgers Sch Publ Hlth, New Brunswick, NJ USA; [Shih, Weichung J.] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA; [Gallo, Silvina] Pfizer, Berlin, Germany; [Cosentino, Francesco] Karolinska Inst, Unit Cardiol, Stockholm, Sweden; [Cosentino, Francesco] Karolinska Univ Hosp, Stockholm, Sweden; [Cherney, David Z. I.] Univ Toronto, Toronto, ON, Canada; [McGuire, Darren K.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA; [McGuire, Darren K.] Parkland Hlth & Hosp Syst, Dallas, TX USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Adventist Health Services; AdventHealth; (AdventHealth) Central Florida Division; Central Florida Hospital - South; AdventHealth Orlando; University of Tennessee System; University of Tennessee Health Science Center; Pfizer; Merck & Company; Nantes Universite; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Pfizer; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; University of Toronto; University of Texas System; University of Texas Southwestern Medical Center Dallas	Cannon, CP (corresponding author), Brigham & Womens Hosp, 360 Longwood Ave,7th Fl, Boston, MA 02115 USA.	cpcannon@bwh.harvard.edu	Ma, Ronald/C-2788-2009; Malynovsky, Yaroslav/T-1898-2017; McGuire, Darren K./AAL-4172-2021; Nikolaev, Konstantin/P-4750-2017; Panina, Svitlana/W-2900-2019	Ma, Ronald/0000-0002-1227-803X; Malynovsky, Yaroslav/0000-0002-9118-1104; Nikolaev, Konstantin/0000-0003-4601-6203; Panina, Svitlana/0000-0003-1080-7185; Kravchenko, Oleksii/0000-0003-2829-6491; tripathy, devjit/0000-0003-2797-0659; Soldat Stankovic, Valentina/0000-0002-9858-5646	Merck Sharp Dohme; Pfizer	Merck Sharp Dohme(Merck & Company); Pfizer(Pfizer)	Supported by Merck Sharp & Dohme (a subsidiary of Merck) and Pfizer.	Arnold SV, 2018, DIABETES OBES METAB, V20, P2000, DOI 10.1111/dom.13303; Cannon CP, 2018, AM HEART J, V206, P11, DOI 10.1016/j.ahj.2018.08.016; Cinti F, 2017, DRUG DES DEV THER, V11, P2905, DOI 10.2147/DDDT.S114932; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; European Medicines Agency, 2018, STEGL ERT SUMM PROD; Food and Drug Administration, 2008, FED REGISTER, V73, P77724; Food and Drug Administration, 2017, STEGL ERT PRESCR INF; Maurer W, 2013, STAT BIOPHARM RES, V5, P311, DOI 10.1080/19466315.2013.807748; Neal B, 2017, NEW ENGL J MED, V377, P644, DOI 10.1056/NEJMoa1611925; Perkovic V, 2019, NEW ENGL J MED, V380, P2295, DOI 10.1056/NEJMoa1811744; Rawshani A, 2017, NEW ENGL J MED, V376, P1407, DOI 10.1056/NEJMoa1608664; Rocco MV, 2012, AM J KIDNEY DIS, V60, P857, DOI 10.1053/j.ajkd.2012.07.005; Thomas MC, 2016, CURR CARDIOL REV, V12, P249, DOI 10.2174/1573403X12666160606120254; Thomas MC, 2016, NAT REV NEPHROL, V12, P73, DOI 10.1038/nrneph.2015.173; Wanner C, 2016, NEW ENGL J MED, V375, P1801, DOI [10.1056/NEJMoa1515920, 10.1056/NEJMc1611290]; Wiviott SD, 2019, NEW ENGL J MED, V380, P347, DOI 10.1056/NEJMoa1812389; Zinman B, 2015, NEW ENGL J MED, V373, P2117, DOI 10.1056/NEJMoa1504720	17	542	552	12	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 8	2020	383	15					1425	1435		10.1056/NEJMoa2004967	http://dx.doi.org/10.1056/NEJMoa2004967			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OD1NS	32966714	Bronze			2023-01-03	WOS:000579622800010
J	Wang, JP; Paz, C; Padalino, G; Coghlan, A; Lu, ZG; Gradinaru, I; Collins, JNR; Berriman, M; Hoffmann, KF; Collins, JJ				Wang, Jipeng; Paz, Carlos; Padalino, Gilda; Coghlan, Avril; Lu, Zhigang; Gradinaru, Irina; Collins, Julie N. R.; Berriman, Matthew; Hoffmann, Karl F.; Collins, James J.			Large-scale RNAi screening uncovers therapeutic targets in the parasite Schistosoma mansoni	SCIENCE			English	Article							IN-VITRO; INHIBITOR; POTENT; DISRUPTION; PROTEASOME; EXPRESSION; MECHANISM; DISCOVERY; PROTEINS; COVALENT	Schistosome parasites kill 250,000 people every year. Treatment of schistosomiasis relies on the drug praziquantel. Unfortunately, a scarcity of molecular tools has hindered the discovery of new drug targets. Here, we describe a large-scale RNA interference (RNAi) screen in adult Schistosoma mansoni that examined the function of 2216 genes. We identified 261 genes with phenotypes affecting neuromuscular function, tissue integrity, stem cell maintenance, and parasite survival. Leveraging these data, we prioritized compounds with activity against the parasites and uncovered a pair of protein kinases (TAO and STK25) that cooperate to maintain muscle-specific messenger RNA transcription. Loss of either of these kinases results in paralysis and worm death in a mammalian host. These studies may help expedite therapeutic development and invigorate studies of these neglected parasites.	[Wang, Jipeng; Paz, Carlos; Gradinaru, Irina; Collins, Julie N. R.; Collins, James J.] UT Southwestern Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; [Padalino, Gilda; Hoffmann, Karl F.] Aberystwyth Univ, Inst Biol Environm & Rural Sci IBERS, Aberystwyth, Dyfed, Wales; [Coghlan, Avril; Lu, Zhigang; Berriman, Matthew] Wellcome Sanger Inst, Wellcome Genome Campus, Cambridge C810 1SA, England	University of Texas System; University of Texas Southwestern Medical Center Dallas; Aberystwyth University; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Institute of Biological, Environmental, Rural & Sciences (IBERS)	Collins, JJ (corresponding author), UT Southwestern Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA.	jamesj.collins@utsouthwestem.edu		Hoffmann, Karl/0000-0002-3932-5502; Wang, Jipeng/0000-0003-0107-424X; Coghlan, Avril/0000-0002-2775-5951; Lu, Zhigang/0000-0001-6553-5944; Padalino, Gilda/0000-0001-8580-1293; Paz, Carlos/0000-0001-7277-4329	National Institutes of Health [R01AI121037]; Welch Foundation [I-1948-20180324]; Burroughs Wellcome Fund; Wellcome Trust [107475/Z/15/Z, 206194]; Howard Hughes Medical Institute Gilliam Fellowship; National Science Foundation Graduate Research Fellowship [SPA0001848]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Welch Foundation(The Welch Foundation); Burroughs Wellcome Fund(Burroughs Wellcome Fund); Wellcome Trust(Wellcome TrustEuropean Commission); Howard Hughes Medical Institute Gilliam Fellowship(Howard Hughes Medical Institute); National Science Foundation Graduate Research Fellowship(National Science Foundation (NSF))	The work was supported by the National Institutes of Health R01AI121037 (J.J.C.), the Welch Foundation I-1948-20180324 (J.J.C.), the Burroughs Wellcome Fund (J.J.C.), and the Wellcome Trust 107475/Z/15/Z (J.J.C., K.F.H., M.B.) and 206194 (M.B.). C.P. was supported by a Howard Hughes Medical Institute Gilliam Fellowship and National Science Foundation Graduate Research Fellowship SPA0001848.	Alsford S, 2011, GENOME RES, V21, P915, DOI 10.1101/gr.115089.110; Amrutkar M, 2015, DIABETES, V64, P2791, DOI 10.2337/db15-0060; Anderson DJ, 2015, CANCER CELL, V28, P653, DOI 10.1016/j.ccell.2015.10.002; [Anonymous], 2019, NAT GENET, V51, P163, DOI [10.1038/s41588-018-0262-1, DOI 10.1038/s41588-018-0262-1]; Arts J, 2009, CLIN CANCER RES, V15, P6841, DOI 10.1158/1078-0432.CCR-09-0547; BASCH PF, 1981, J PARASITOL, V67, P179, DOI 10.2307/3280632; Bibo-Verdugo B, 2019, ACS INFECT DIS, V5, P1802, DOI 10.1021/acsinfecdis.9b00237; Bolt BJ, 2018, METHODS MOL BIOL, V1757, P471, DOI 10.1007/978-1-4939-7737-6_15; Bowes J, 2012, NAT REV DRUG DISCOV, V11, P909, DOI 10.1038/nrd3845; Bushell E., CELL, V170, P260; Bushell E, 2017, CELL, V170, P260, DOI 10.1016/j.cell.2017.06.030; Buszczak M, 2014, CELL, V159, P242, DOI 10.1016/j.cell.2014.09.016; Caceres G, 2003, ANTI-CANCER DRUG, V14, P569, DOI 10.1097/00001813-200308000-00010; Ceccarelli DF, 2011, J BIOL CHEM, V286, P25056, DOI 10.1074/jbc.M110.213777; Collins J., 2020, DRYAD, DOI [10.5061/dryad.zs7h44j4v, DOI 10.5061/DRYAD.ZS7H44J4V]; Collins JJ, 2016, ELIFE, V5, DOI 10.7554/eLife.12473; Collins JJ, 2013, NATURE, V494, P476, DOI 10.1038/nature11924; Collins JJ, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001009; Collins JJ, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000509; Collins JNR, 2016, PLOS PATHOG, V12, DOI 10.1371/journal.ppat.1005963; Craig R, 2004, BIOINFORMATICS, V20, P1466, DOI 10.1093/bioinformatics/bth092; Elias JE, 2007, NAT METHODS, V4, P207, DOI 10.1038/nmeth1019; Geer LY, 2004, J PROTEOME RES, V3, P958, DOI 10.1021/pr0499491; Guidi A, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003801; Harris TW, 2020, NUCLEIC ACIDS RES, V48, pD762, DOI 10.1093/nar/gkz920; Janes J, 2018, P NATL ACAD SCI USA, V115, P10750, DOI 10.1073/pnas.1810137115; Jin CH, 2014, J MED CHEM, V57, P4213, DOI 10.1021/jm500115w; Kupperman E, 2010, CANCER RES, V70, P1970, DOI 10.1158/0008-5472.CAN-09-2766; Lamore SD, 2017, TOXICOL SCI, V158, P213, DOI 10.1093/toxsci/kfx082; Lasko LM, 2017, NATURE, V550, P128, DOI 10.1038/nature24028; Lundgren K, 2009, MOL CANCER THER, V8, P921, DOI 10.1158/1535-7163.MCT-08-0758; Lynch JJ, 2017, J PHARMACOL TOX MET, V87, P108, DOI 10.1016/j.vascn.2017.02.020; Maes T, 2018, CANCER CELL, V33, P495, DOI 10.1016/j.ccell.2018.02.002; Magnaghi P, 2013, NAT CHEM BIOL, V9, P548, DOI [10.1038/NCHEMBIO.1313, 10.1038/nchembio.1313]; Marcellino C, 2012, PLOS NEGLECT TROP D, V6, DOI 10.1371/journal.pntd.0001494; Mendez D, 2019, NUCLEIC ACIDS RES, V47, pD930, DOI 10.1093/nar/gky1075; Menezes DL, 2012, MOL CANCER THER, V11, P730, DOI 10.1158/1535-7163.MCT-11-0667; Muraki M, 2004, J BIOL CHEM, V279, P24246, DOI 10.1074/jbc.M314298200; Nabhan JF, 2007, EXP PARASITOL, V117, P337, DOI 10.1016/j.exppara.2007.08.002; Newton K, 2008, CELL, V134, P668, DOI 10.1016/j.cell.2008.07.039; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; Poon CLC, 2018, DEV CELL, V47, P564, DOI 10.1016/j.devcel.2018.09.024; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Rojo-Arreola L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087594; Rozanski A, 2019, NUCLEIC ACIDS RES, V47, pD812, DOI 10.1093/nar/gky1070; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Scuto A, 2008, BLOOD, V111, P5093, DOI 10.1182/blood-2007-10-117762; Sidik SM, 2016, CELL, V166, P1423, DOI 10.1016/j.cell.2016.08.019; SLATER EE, 1988, DRUGS, V36, P72, DOI 10.2165/00003495-198800363-00016; Stuart T., 2019, CELL, V177, P1888, DOI [DOI 10.1016/J.CELL.2019.05.031, DOI 10.1016/j.cell.2019.05.031]; Thurmond J, 2019, NUCLEIC ACIDS RES, V47, pD759, DOI 10.1093/nar/gky1003; Treiman M, 1998, TRENDS PHARMACOL SCI, V19, P131, DOI 10.1016/S0165-6147(98)01184-5; Trudgian D.C., 2012, J PROTEOM BIOINFORM, V5, P283; Trudgian DC, 2012, J PROTEOME RES, V11, P6282, DOI 10.1021/pr300694b; Trudgian DC, 2010, BIOINFORMATICS, V26, P1131, DOI 10.1093/bioinformatics/btq081; Wang JP, 2019, PLOS BIOL, V17, DOI 10.1371/journal.pbio.3000254; Wendt G, 2020, SCIENCE, V369, P1644, DOI 10.1126/science.abb7709; Wendt GR, 2018, ELIFE, V7, DOI [10.7554/eLife.33221, 10.7554/elife.33221]; Whatley KCL, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007693; Whiteland HL, 2018, INT J PARASITOL-DRUG, V8, P465, DOI 10.1016/j.ijpddr.2018.10.009; Zhou HJ, 2015, J MED CHEM, V58, P9480, DOI 10.1021/acs.jmedchem.5b01346	61	26	26	6	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 25	2020	369	6511					1649	+		10.1126/science.abb7699	http://dx.doi.org/10.1126/science.abb7699			32	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV9TD	32973031	Green Submitted, Green Accepted			2023-01-03	WOS:000574653300039
J	Krause, M; Douin, DJ; Tran, TT; Fernandez-Bustamante, A; Aftab, M; Bartels, K				Krause, Martin; Douin, David J.; Tran, Timothy T.; Fernandez-Bustamante, Ana; Aftab, Muhammad; Bartels, Karsten			Association between procalcitonin levels and duration of mechanical ventilation in COVID-19 patients	PLOS ONE			English	Article								Background Patients diagnosed with COVID-19 frequently require mechanical ventilation. Knowledge of laboratory tests associated with the prolonged need for mechanical ventilation may guide resource allocation. We hypothesized that an elevated plasma procalcitonin level (>0.1 ng/ml) would be associated with the duration of invasive mechanical ventilation. Methods Patients diagnosed with COVID-19, who were admitted to any of our health system's hospitals between March 9(th)-April 20(th), 2020 and required invasive mechanical ventilation, were eligible for this observational cohort study. Demographics, comorbidities, components of the Sequential Organ Failure Assessment score, and procalcitonin levels on admission were obtained from the electronic health record. The primary outcome was the duration of mechanical ventilation; secondary outcomes included 28-day mortality and time to intubation. Outcomes were assessed within the first 28 days of admission. Baseline demographics and comorbidities were summarized by descriptive statistics. Univariate comparisons were made using Pearson's chi-square test for binary outcomes and Mann-Whitney U test for continuous outcomes. A multiple linear regression was fitted to assess the association between procalcitonin levels and the duration of mechanical ventilation. Results Patients with an initial procalcitonin level >0.1 ng/ml required a significantly longer duration of mechanical ventilation than patients with a level of <= 0.1 ng/ml (p = 0.021) in the univariate analysis. There was no significant difference in 28-day mortality or time to intubation between the two groups. After adjusted analysis using multivariable linear regression, the duration of mechanical ventilation was, on average, 5.6 (p = 0.016) days longer in patients with an initial procalcitonin level >0.1 ng/ml. Conclusion In this cohort of 93 mechanically ventilated COVID-19 patients, we found an association between an initial plasma procalcitonin level >0.1 ng/ml and the duration of mechanical ventilation. These findings may help to identify patients at risk for prolonged mechanical ventilation upon admission.	[Krause, Martin; Douin, David J.; Tran, Timothy T.; Fernandez-Bustamante, Ana; Bartels, Karsten] Univ Colorado, Dept Anesthesiol, Sch Med, Aurora, CO 80045 USA; [Aftab, Muhammad; Bartels, Karsten] Univ Colorado, Sch Med, Dept Surg, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Bartels, K (corresponding author), Univ Colorado, Dept Anesthesiol, Sch Med, Aurora, CO 80045 USA.; Bartels, K (corresponding author), Univ Colorado, Sch Med, Dept Surg, Aurora, CO 80045 USA.	karsten.bartels@ucdenver.edu	Bartels, Karsten/ABE-9152-2020	Tran, Tim/0000-0002-4375-6583; Bartels, Karsten/0000-0003-2028-4664	National Institutes of Health (NIH) [K23DA040923]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the National Institutes of Health (NIH), Award Number K23DA040923 to Karsten Bartels. The content of this report is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The NIH had no involvement in study design, collection, analysis, interpretation of data, writing of the report, or the decision to submit the article for publication.	Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Gattinoni L, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02880-z; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Gupta E, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2646-8; Hermans G, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0993-7; Ji Y, LANCET GLOB HLTH, V8, pe480; Krause M, 2021, J INTENSIVE CARE MED, V36, P271, DOI 10.1177/0885066620954806; Kutz A, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0792-1; Lambden S, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2663-7; Lippi G, 2020, CLIN CHIM ACTA, V505, P190, DOI 10.1016/j.cca.2020.03.004; Pan A, 2020, JAMA-J AM MED ASSOC, V323, P1915, DOI 10.1001/jama.2020.6130; Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; SEDGWICK P, 2015, BMJ-BRIT MED J, V350, DOI DOI 10.1136/bmj.h560; Shehabi Y, 2014, AM J RESP CRIT CARE, V190, P1102, DOI 10.1164/rccm.201408-1483OC; Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548; Yehya N, 2019, AM J RESP CRIT CARE, V200, P828, DOI 10.1164/rccm.201810-2050CP; Zhang JJ, 2020, ALLERGY, V75, P1809, DOI 10.1111/all.14316; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	29	17	17	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2020	15	9							e0239174	10.1371/journal.pone.0239174	http://dx.doi.org/10.1371/journal.pone.0239174			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU7WV	32946466	gold, Green Published			2023-01-03	WOS:000573851100028
J	Poschenrieder, F; Rotter, M; Gschwendtner, A; Hamer, OW				Poschenrieder, Florian; Rotter, Michael; Gschwendtner, Andreas; Hamer, Okka W.			E-cigarette-induced lung disease: from acute to chronic	LANCET			English	Editorial Material									[Poschenrieder, Florian; Hamer, Okka W.] Univ Med Ctr Regensburg, Inst Radiol, D-93053 Regensburg, Germany; [Rotter, Michael] Univ Med Ctr Regensburg, Inst Pathol, Regensburg, Germany; [Gschwendtner, Andreas] Klinikum Kulmbach, Inst Pathol, Kulmbach, Germany	University of Regensburg; University of Regensburg	Poschenrieder, F (corresponding author), Univ Med Ctr Regensburg, Inst Radiol, D-93053 Regensburg, Germany.	florian.poschenrieder@ukr.de							0	4	4	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 22	2020	396	10250					564	564						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OC4LV	32828188				2023-01-03	WOS:000579130500022
J	Godinho, MH				Godinho, Maria Helena			When the smallest details count	SCIENCE			English	Editorial Material							PHASE		[Godinho, Maria Helena] Univ Nova Lisboa, Ctr Invest Mat CENIMAT I3N, Dept Mat Sci, Fac Sci & Technol, Campus,Caparica, P-2829516 Caparica, Portugal	Universidade Nova de Lisboa	Godinho, MH (corresponding author), Univ Nova Lisboa, Ctr Invest Mat CENIMAT I3N, Dept Mat Sci, Fac Sci & Technol, Campus,Caparica, P-2829516 Caparica, Portugal.	mhg@fct.unl.pt	Godinho, Maria/J-3679-2013	Godinho, Maria/0000-0002-9760-5983	Portuguese Foundation for Science and Technology [M-ERA-NET2/0007/2016, UID/CTM/50025/2019]; European Topology Interdisciplinary Action (EUTOPIA) [CA17139]	Portuguese Foundation for Science and Technology(Portuguese Foundation for Science and Technology); European Topology Interdisciplinary Action (EUTOPIA)	M.H.G. is supported by the Portuguese Foundation for Science and Technology under project nos.UID/CTM/50025/2019 and M-ERA-NET2/0007/2016 (CellColor) and by the European Topology Interdisciplinary Action (EUTOPIA CA17139).	Almeida APC, 2018, ADV MATER, V30, DOI 10.1002/adma.201703655; Bawden FC, 1936, NATURE, V138, P1051, DOI 10.1038/1381051a0; BOULIGAND Y, 1965, CR HEBD ACAD SCI, V261, P4864; Dozov I, 2001, EUROPHYS LETT, V56, P247, DOI 10.1209/epl/i2001-00513-x; Fernandez-Rico C, 2020, SCIENCE, V369, P950, DOI 10.1126/science.abb4536; Gerbode SJ, 2012, SCIENCE, V337, P1087, DOI 10.1126/science.1223304; ONSAGER L, 1949, ANN NY ACAD SCI, V51, P627, DOI 10.1111/j.1749-6632.1949.tb27296.x; Paterson DA, 2016, SOFT MATTER, V12, P6827, DOI 10.1039/c6sm00537c; REVOL JF, 1994, LIQ CRYST, V16, P127, DOI 10.1080/02678299408036525; Silva PES, 2017, SOFT MATTER, V13, P6678, DOI 10.1039/c7sm01280b; Yang Y, 2016, J AM CHEM SOC, V138, P68, DOI 10.1021/jacs.5b11546	12	3	3	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	2020	369	6506			SI		918	919		10.1126/science.abd3548	http://dx.doi.org/10.1126/science.abd3548			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NE2OL	32820111				2023-01-03	WOS:000562436800024
J	Molnar, AO; Bota, S; Jeyakumar, N; McArthur, E; Battistella, M; Garg, AX; Sood, MM; Brimble, KS				Molnar, Amber O.; Bota, Sarah; Jeyakumar, Nivethika; McArthur, Eric; Battistella, Marisa; Garg, Amit X.; Sood, Manish M.; Brimble, K. Scott			Potentially inappropriate prescribing in older adults with advanced chronic kidney disease	PLOS ONE			English	Article							MEDICATION USE; RENAL-DISEASE; PRIMARY-CARE; TIME-SERIES; MANAGEMENT; CKD; PREVALENCE; OUTCOMES	Background Older adults with chronic kidney disease (CKD) are at heightened risk for polypharmacy. We examined potentially inappropriate prescribing in this population and whether introducing pharmacists into the ambulatory kidney care model was associated with improved prescribing practices. Methods Retrospective cohort study using linked administrative databases. We included patients with an eGFR <= 30 mL/min/1.73 m(2)>= 66 years of age followed in multidisciplinary kidney clinics in Ontario, Canada (n = 25,016 from 28 centres). The primary outcome was the absence of a statin prescription or the receipt of a potentially inappropriate prescription defined by the American Geriatric Society Beers Criteria(R)and a modified Delphi panel that identified key drugs of concern in CKD. We calculated the crude cumulative incidence and incidence rate for the primary outcome and used change-point regression to determine if a change occurred following pharmacist introduction. Results There were 6,007 (24%) and 16,497 patients (66%) not prescribed a statin and with >= 1 potentially inappropriate prescription, respectively. The rate of potentially inappropriate prescribing was 125.6 per 100 person-years and was higher in more recent years. The change-point regression analysis included 2,275 patients from two centres. No immediate change was detected at pharmacist introduction, but potentially inappropriate prescribing was increasing pre-pharmacist introduction, and this rising trend was reversed post-pharmacist introduction. The incidence of potentially inappropriate prescribing still remained high post-pharmacist introduction. Conclusions Potentially inappropriate prescribing practices were common. Incorporating pharmacists into the kidney care model may improve prescribing practices. The role of pharmacists in the ambulatory kidney care team warrants further investigation in a randomized controlled trial.	[Molnar, Amber O.; Brimble, K. Scott] McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada; [Molnar, Amber O.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Molnar, Amber O.; Bota, Sarah; Jeyakumar, Nivethika; McArthur, Eric] ICES, Toronto, ON, Canada; [Battistella, Marisa] Univ Toronto, Univ Hlth Network, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Garg, Amit X.] Western Univ, Dept Med, Div Nephrol, London, ON, Canada; [Sood, Manish M.] Univ Ottawa, Dept Med, Div Nephrol, Ottawa, ON, Canada; [Sood, Manish M.] Ottawa Hosp Res Inst, Epidemiol, Ottawa, ON, Canada	McMaster University; McMaster University; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Western University (University of Western Ontario); University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Molnar, AO (corresponding author), McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada.; Molnar, AO (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.; Molnar, AO (corresponding author), ICES, Toronto, ON, Canada.	amolnar@stjosham.on.ca	Brimble, K. Scott/AAE-7943-2021	Battistella, Marisa/0000-0001-9456-4365	Cancer Care Ontario through Government of Ontario; ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC); Academic Medical Organization of Southwestern Ontario; Schulich School of Medicine and Dentistry, Western University; Lawson Health Research Institute; KRESCENT Foundation; McMaster Department of Medicine; Jindal Research Chair for the Prevention of Kidney Disease	Cancer Care Ontario through Government of Ontario; ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario); Academic Medical Organization of Southwestern Ontario; Schulich School of Medicine and Dentistry, Western University; Lawson Health Research Institute; KRESCENT Foundation; McMaster Department of Medicine; Jindal Research Chair for the Prevention of Kidney Disease	This study was conducted with the support of Cancer Care Ontario through funding provided by the Government of Ontario (awarded to AOM). The sponsor had no role in the study design, conduct, data analysis or manuscript preparation. This study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). This study was completed at the ICES Western site, where core funding is provided by the Academic Medical Organization of Southwestern Ontario, the Schulich School of Medicine and Dentistry, Western University, and the Lawson Health Research Institute. Amber O. Molnar receives salary support from the KRESCENT Foundation and the McMaster Department of Medicine. ManishM Sood is supported by the Jindal Research Chair for the Prevention of Kidney Disease.	Al Raiisi F, 2019, INT J CLIN PHARM-NET, V41, P630, DOI 10.1007/s11096-019-00816-4; [Anonymous], 2019, IBM MICROMEDEX; [Anonymous], 2017, TOP DRUG CLASS; Aronoff GR, 2007, DRUG PRESCRIBING REN, V5th; Assiri GA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019101; Bailie GR, 2005, NEPHROL DIAL TRANSPL, V20, P1110, DOI 10.1093/ndt/gfh771; Breton G, 2011, NEPHROL DIAL TRANSPL, V26, P2852, DOI 10.1093/ndt/gfq827; Chang F, 2015, J AM GERIATR SOC, V63, P2290, DOI 10.1111/jgs.13790; Chau DL, 2008, CLIN INTERV AGING, V3, P273, DOI 10.2147/CIA.S1847; Coca SG, 2006, JAMA-J AM MED ASSOC, V296, P1377, DOI 10.1001/jama.296.11.1377; Davison SN, 2019, CLIN J AM SOC NEPHRO, V14, P917, DOI 10.2215/CJN.05180418; 2019, J AM COLL RADIOL, V16, pS141, DOI 10.1016/j.jacr.2019.02.015; Farag A, 2014, AM J KIDNEY DIS, V63, P422, DOI 10.1053/j.ajkd.2013.09.009; Farrell B, 2017, CAN FAM PHYSICIAN, V63, P354; Gallieni M, 2015, NEPHROL DIAL TRANSPL, V30, P342, DOI 10.1093/ndt/gfu191; Gomes T, 2018, ANN INTERN MED, V169, P732, DOI 10.7326/M18-1136; Gomes T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002396; Gressler LE, 2018, PAIN, V159, P451, DOI 10.1097/j.pain.0000000000001111; Gupta V, 2007, AM J MED, V120, P841, DOI 10.1016/j.amjmed.2007.02.023; Hamrahian SM, 2017, ADV EXP MED BIOL, V956, P307, DOI 10.1007/5584_2016_84; Harrison SL, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0704-8; Hawkins EJ, 2019, J CLIN PSYCHIAT, V80, DOI 10.4088/JCP.18m12689; Huntsberry AM, 2019, SR CARE PHARM, V34, P325, DOI 10.4140/TCP.n.2019.325; Jaynes M, 2018, THER ADV DRUG SAF, V10, DOI 10.1177/2042098618809927; Jones SA, 2013, POSTGRAD MED J, V89, P247, DOI 10.1136/postgradmedj-2012-130889; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67; Manoj PDS, 2015, IEEE T COMPUT, V64, P3022, DOI 10.1109/TC.2015.2389827; Matzke GR, 2011, KIDNEY INT, V80, P1122, DOI 10.1038/ki.2011.322; Morgan Steven G, 2016, CMAJ Open, V4, pE346, DOI 10.9778/cmajo.20150131; Moriarty F, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008656; Munar MY, 2007, AM FAM PHYSICIAN, V75, P1487; National Institute of Diabetes and Digestive and Kidney Diseases, 2015, CKD DRUG DOS INF; Nehra AK, 2018, MAYO CLIN PROC, V93, P240, DOI 10.1016/j.mayocp.2017.10.022; Nicholls SG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125620; Papaioannou A, 2000, J AM GERIATR SOC, V48, P1470, DOI 10.1111/j.1532-5415.2000.tb02639.x; Peiffer-Smadja N, 2019, J GEN INTERNAL MED; Ponticelli C, 2015, MAYO CLIN PROC, V90, P633, DOI 10.1016/j.mayocp.2015.01.016; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Ramkumar S, 2016, ACTA CARDIOL SIN, V32, P631, DOI 10.6515/ACS20160611A; Salgado TM, 2012, NEPHROL DIAL TRANSPL, V27, P276, DOI 10.1093/ndt/gfr287; Schmidt IM, 2019, CLIN KIDNEY J, V12, P663, DOI 10.1093/ckj/sfz046; Stemer G, 2011, BMC NEPHROL, V12, DOI 10.1186/1471-2369-12-35; Stevens LA, 2010, ADV CHRONIC KIDNEY D, V17, P293, DOI 10.1053/j.ackd.2010.03.010; Taji L, 2020, ANN PHARMACOTHER, V54, P625, DOI 10.1177/1060028019897371; Tesfaye WH, 2017, INT J CLIN PRACT, V71, DOI 10.1111/ijcp.12960; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Wanner C, 2014, KIDNEY INT, V85, P1303, DOI 10.1038/ki.2014.31; Wijarnpreecha K, 2017, DIGEST DIS SCI, V62, P2821, DOI 10.1007/s10620-017-4725-5; Zhu JXG, 2019, NEPHROL DIAL TRANSPL, V34, P642, DOI 10.1093/ndt/gfy072	50	7	7	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2020	15	8							e0237868	10.1371/journal.pone.0237868	http://dx.doi.org/10.1371/journal.pone.0237868			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NG9QD	32818951	gold, Green Published			2023-01-03	WOS:000564315600049
J	Stojanov, A; Bering, JM; Halberstadt, J				Stojanov, Ana; Bering, Jesse M.; Halberstadt, Jamin			Does Perceived Lack of Control Lead to Conspiracy Theory Beliefs? Findings from an online MTurk sample	PLOS ONE			English	Article							COMPENSATORY CONTROL; STATISTICAL POWER; ANXIETY; ORDER; ASSOCIATIONS; UNCERTAINTY; PREDICTORS; PSYCHOLOGY; MENTALITY; IDENTITY	It is widely believed that conspiracy theory beliefs are the product of perceived lack of control. However, to date there is mixed evidence, at best, to support this claim. We consider the reasons why conspiracy theory beliefs do not appear to be based in any straightforward way on control beliefs, interrogating existing findings and presenting new data that call the relationship into question. Across six studies conducted online using MTurk samples, we observed no effect of control manipulations on conspiracy theory beliefs, while replicating previously reported correlational evidence of their association. The results suggest that conspiracy beliefs are not suitable for compensating for threats to control. We discuss possible reasons for the discrepancy between experimental and correlational effects and examine the limitations of the studies.	[Stojanov, Ana; Halberstadt, Jamin] Univ Otago, Dept Psychol, Dunedin, New Zealand; [Bering, Jesse M.] Univ Otago, Ctr Sci Commun, Dunedin, New Zealand	University of Otago; University of Otago	Stojanov, A (corresponding author), Univ Otago, Dept Psychol, Dunedin, New Zealand.	ana.stojanov@postgrad.otago.ac.nz		Stojanov, Ana/0000-0002-8377-4372				Abalakina-Paap M, 1999, POLIT PSYCHOL, V20, P637, DOI 10.1111/0162-895X.00160; Brotherton R., 2015, SUSPICIOUS MINDS; Brotherton R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124125; Brotherton R, 2014, APPL COGNITIVE PSYCH, V28, P238, DOI 10.1002/acp.2995; Chen CY, 2017, J CONSUM RES, V43, P1031, DOI 10.1093/jcr/ucw068; Cichocka A, 2016, BRIT J PSYCHOL, V107, P556, DOI 10.1111/bjop.12158; Cichocka A, 2016, SOC PSYCHOL PERS SCI, V7, P157, DOI 10.1177/1948550615616170; ClarkCarter D, 1997, BRIT J PSYCHOL, V88, P71, DOI 10.1111/j.2044-8295.1997.tb02621.x; Clarke S, 2002, PHILOS SOC SCI, V32, P131, DOI 10.1177/004931032002001; COHEN J, 1962, J ABNORM PSYCHOL, V65, P145, DOI 10.1037/h0045186; Committee on Homeland Security and Governmental Affairs, 2006, HURR KATR NAT UNPR S; Cutright KM, 2013, J MARKETING RES, V50, P365, DOI 10.1509/jmr.10.0202; Cutright KM, 2012, J CONSUM RES, V38, P775, DOI 10.1086/661563; Douglas I, 2015, URBAN ECOLOGY: AN INTRODUCTION, P183; Douglas KM, 2018, EUR REV SOC PSYCHOL, V29, P256, DOI 10.1080/10463283.2018.1537428; Douglas KM, 2017, CURR DIR PSYCHOL SCI, V26, P538, DOI 10.1177/0963721417718261; Douglas KM, 2016, THINK REASONING, V22, P57, DOI 10.1080/13546783.2015.1051586; Fisher ZF, 2015, ARXIV; Goode C., 2014, J SOC POLIT PSYCHOL, V2, P313, DOI [DOI 10.5964/JSPP.V2I1.372, 10.5964/jspp.v2i1.372]; Goode C, 2017, EUR J SOC PSYCHOL, V47, P259, DOI 10.1002/ejsp.2259; Green R, 2018, PERS INDIV DIFFER, V125, P30, DOI 10.1016/j.paid.2017.12.023; Grzesiak-Feldman M, 2013, CURR PSYCHOL, V32, P100, DOI 10.1007/s12144-013-9165-6; Hart J, 2018, J INDIVID DIFFER, V39, P229, DOI 10.1027/1614-0001/a000268; Hauser DJ, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00998; Heine SJ, 2006, PERS SOC PSYCHOL REV, V10, P88, DOI 10.1207/s15327957pspr1002_1; Imhoff R., 2015, CONSPIRACY THEORIES, P122; Imhoff R, 2018, EUR J SOC PSYCHOL, V48, P909, DOI 10.1002/ejsp.2494; Imhoff R, 2014, EUR J PERSONALITY, V28, P25, DOI 10.1002/per.1930; Jolley D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089177; Kay A. C., 2013, ADV CULTURAL PSYCHOL, V3, P181, DOI [10.1093/acprof:oso/9780199930449.003.0004, DOI 10.1093/ACPROF:OSO/9780199930449.003.0004]; Kay A. C., 2015, APA HDB PERSONALITY, V1, P309, DOI DOI 10.1037/14341-010; Kay AC, 2008, J PERS SOC PSYCHOL, V95, P18, DOI 10.1037/0022-3514.95.1.18; Kay AC, 2013, J SOC ISSUES, V69, P564, DOI 10.1111/josi.12029; Kay AC, 2010, PERS SOC PSYCHOL REV, V14, P37, DOI 10.1177/1088868309353750; Kay AC, 2009, CURR DIR PSYCHOL SCI, V18, P264, DOI 10.1111/j.1467-8721.2009.01649.x; Keeley BL, 1999, J PHILOS, V96, P109, DOI 10.2307/2564659; Kluger J., 2018, TIME; Kossowska M., 2015, PSYCHOL CONSPIRACY 2, P145; Lachman ME, 2012, MEM COGNITION, V40, P287, DOI 10.3758/s13421-011-0140-x; Landau MJ, 2015, PSYCHOL BULL, V141, P694, DOI 10.1037/a0038703; Lantian A, 2018, EUR J SOC PSYCHOL, V48, P939, DOI 10.1002/ejsp.2498; Laurin K, 2008, J EXP SOC PSYCHOL, V44, P1559, DOI 10.1016/j.jesp.2008.07.007; Ledrich J, 2013, PSYCHOL PSYCHOTHER-T, V86, P413, DOI 10.1111/j.2044-8341.2012.02067.x; Ma AY, 2017, ORGAN BEHAV HUM DEC, V140, P46, DOI 10.1016/j.obhdp.2017.04.001; Marchlewska M, 2018, EUR J SOC PSYCHOL, V48, P109, DOI 10.1002/ejsp.2308; Mashuri A., 2014, INT J RES STUDIES PS, V3; Mashuri A, 2015, INT J PSYCHOL RES, V8, P24, DOI 10.21500/20112084.642; Masson MEJ, 2011, BEHAV RES METHODS, V43, P679, DOI 10.3758/s13428-010-0049-5; Nyhan B, 2018, J POLIT, V80, P1400, DOI 10.1086/698663; Oaklander M., 2015, TIME; PEARLIN LI, 1981, J HEALTH SOC BEHAV, V22, P337, DOI 10.2307/2136676; PEARLIN LI, 1978, J HEALTH SOC BEHAV, V19, P2, DOI 10.2307/2136319; Pichaske K., 2018, PULLING THREAD; Prooijen J-W, 2018, PSYCHOL CONSPIRACY T; Raftery AE, 1995, SOCIOL METHODOL, V25, P111, DOI 10.2307/271063; Rutjens BT, 2017, CURR ISS SOC PSYCHOL, P83; Rutjens BT, 2013, CURR DIR PSYCHOL SCI, V22, P250, DOI 10.1177/0963721412469810; Rutjens BT, 2013, J EXP PSYCHOL GEN, V142, P313, DOI 10.1037/a0028716; Rutjens BT, 2010, SOC PSYCHOL PERS SCI, V1, P246, DOI 10.1177/1948550610361782; Rutjens BT, 2010, J EXP SOC PSYCHOL, V46, P1078, DOI 10.1016/j.jesp.2010.07.009; Seligman M., 1992, HELPLESSNESS DEPRESS; Shepherd S, 2011, J EXP SOC PSYCHOL, V47, P949, DOI 10.1016/j.jesp.2011.03.026; Shermer M., 2014, SCI AM, P94; Stojanov A., J SOC PSYCHOL; Stojanov A, 2020, EUR J SOC PSYCHOL, V50, P955, DOI 10.1002/ejsp.2690; Stojanov A, 2019, SOC PSYCHOL-GERMANY, V50, P215, DOI 10.1027/1864-9335/a000381; Sullivan D, 2010, J PERS SOC PSYCHOL, V98, P434, DOI 10.1037/a0017457; Swami V, 2016, PERS INDIV DIFFER, V99, P72, DOI 10.1016/j.paid.2016.04.084; Swami V, 2011, BRIT J PSYCHOL, V102, P443, DOI 10.1111/j.2044-8295.2010.02004.x; Swami V, 2010, APPL COGNITIVE PSYCH, V24, P749, DOI 10.1002/acp.1583; van Elk M, 2018, COLLABRA-PSYCHOL, V4, DOI 10.1525/collabra.155; van Prooijen JW, 2018, EUR J SOC PSYCHOL, V48, P320, DOI 10.1002/ejsp.2331; van Prooijen JW, 2017, MEM STUD, V10, P323, DOI 10.1177/1750698017701615; Van Prooijen JW, 2015, APPL COGNITIVE PSYCH, V29, P753, DOI 10.1002/acp.3161; Van Prooijen JW, 2013, EUR J SOC PSYCHOL, V43, P109, DOI 10.1002/ejsp.1922; Wagenmakers EJ, 2007, PSYCHON B REV, V14, P779, DOI 10.3758/BF03194105; Whitson JA, 2008, SCIENCE, V322, P115, DOI 10.1126/science.1159845; Wood M., 2020, CONSPIRACY THEORIES, P245; Yong E., 2008, NATIONALGEOGRAPHIC; [No title captured]	80	10	10	3	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2020	15	8							e0237771	10.1371/journal.pone.0237771	http://dx.doi.org/10.1371/journal.pone.0237771			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NF8BJ	32804940	Green Published, gold			2023-01-03	WOS:000563517800042
J	Paul, JD; Cifu, AS				Paul, Jonathan D.; Cifu, Adam S.			Management of Acute Pulmonary Embolism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VENOUS THROMBOEMBOLISM	This JAMA Clinical Guidelines Synopsis summarizes the European Society of Cardiology's 2019 guidelines for diagnosis and management of acute pulmonary embolism.	[Paul, Jonathan D.; Cifu, Adam S.] Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA	University of Chicago	Cifu, AS (corresponding author), Univ Chicago, 5841 S Maryland Ave,MC 3051, Chicago, IL 60637 USA.	adamcifu@uchicago.edu						Hoeper MM, 2014, LANCET RESP MED, V2, P573, DOI 10.1016/S2213-2600(14)70089-X; Konstantinides SV, 2020, EUR HEART J, V41, P543, DOI 10.1093/eurheartj/ehz405; Marti C, 2015, EUR HEART J, V36, P605, DOI 10.1093/eurheartj/ehu218; Meyer G, 2014, NEW ENGL J MED, V370, P1402, DOI 10.1056/NEJMoa1302097; Rogers MAM, 2012, CIRCULATION, V125, P2092, DOI 10.1161/CIRCULATIONAHA.111.084467; Tritschler T, 2018, JAMA-J AM MED ASSOC, V320, P1583, DOI 10.1001/jama.2018.14346; van der Hulle T, 2014, J THROMB HAEMOST, V12, P320, DOI 10.1111/jth.12485	7	3	3	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	2020	324	6					597	598		10.1001/jama.2020.3905	http://dx.doi.org/10.1001/jama.2020.3905			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE8HM	32780129				2023-01-03	WOS:000562845100023
J	Burmester, GR; Buttgereit, F; Bernasconi, C; Alvaro-Gracia, JM; Castro, N; Dougados, M; Gabay, C; van Laar, JM; Nebesky, JM; Pethoe-Schramm, A; Salvarani, C; Donath, MY; John, MR				Burmester, Gerd R.; Buttgereit, Frank; Bernasconi, Corrado; Alvaro-Gracia, Jose M.; Castro, Nidia; Dougados, Maxime; Gabay, Cem; van Laar, Jacob M.; Nebesky, Jan Michael; Pethoe-Schramm, Attila; Salvarani, Carlo; Donath, Marc Y.; John, Markus R.		SEMIRA Collaborators	Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial	LANCET			English	Article							MODIFYING ANTIRHEUMATIC DRUGS; POLYMYALGIA-RHEUMATICA; EULAR RECOMMENDATIONS; ORAL CORTICOSTEROIDS; TOCILIZUMAB; METHOTREXATE; MANAGEMENT; CLASSIFICATION; PREDNISOLONE; REDUCTION	Background Patients with inflammatory diseases, such as rheumatoid arthritis, often receive glucocorticoids, but long-term use can produce adverse effects. Evidence from randomised controlled trials to guide tapering of oral glucocorticoids is scarce. We investigated a scheme for tapering oral glucocorticoids compared with continuing low-dose oral glucocorticoids in patients with rheumatoid arthritis. Methods The Steroid EliMination In Rheumatoid Arthritis (SEMIRA) trial was a double-blind, multicentre, two parallel-arm, randomised controlled trial done at 39 centres from six countries (France, Germany, Italy, Russia, Serbia, and Tunisia). Adult patients with rheumatoid arthritis receiving tocilizumab and glucocorticoids 5-15 mg per day for 24 weeks or more were eligible for inclusion if they had received prednisone 5 mg per day for 4 weeks or more and had stable low disease activaity, confirmed by a Disease Activity Score for 28 joints-erythrocyte sedimentation rate (DAS 28-ESR) of 3.2 or less 4-6 weeks before and on the day of randomisation. Patients were randomly assigned 1:1 to either continue masked prednisone 5 mg per day for 24 weeks or to taper masked prednisone reaching 0 mg per day at week 16. All patients received tocilizumab (162 mg subcutaneously every week or 8 mg/kg intravenously every 4 weeks) with or without csDMARDs maintained at stable doses during the entire 24-week study. The primary outcome was the difference in mean DAS 28-E SR change from baseline to week 24, with a difference of more than 0.6 defined as clinically relevant between the continued-prednisone group and the tapered-prednisone group. The trial is registered with ClinicalTrials.gov , NCTO 2573012. Findings Between Oct 21, 2015, and June 9, 2017, 421 patients were screened and 259 (200 [77%] women and 59 [23%] men) were recruited onto the trial. In all 128 patients assigned to the continued-prednisone regimen, disease activity control was superior to that in all 131 patients assigned to the tapered-prednisone regimen; the estimated mean change in DAS 28-ESR from baseline to week 24 was 0.54 (95% CI 0.35-0.73) with tapered prednisone and -0.08 (-0.27 to 0.12) with continued prednisone (difference 0.61 [0.35-0.88]; p<0.0001), favouring continuing prednisone 5 mg per day for 24 weeks. Treatment was regarded as successful (defined as low disease activity at week 24, plus absence of rheumatoid arthritis flare for 24 weeks and no confirmed adrenal insufficiency) in 99 (77%) patients in the continued-prednisone group versus 85 (65%) patients in the tapered-prednisone group (relative risk 0.83; 95% CI 0.71-0.97). Serious adverse events occurred in seven (5%) patients in the tapered-prednisone group and four (3%) patients in the continued-prednisone group; no patients had symptomatic adrenal insufficiency. Interpretation In patients who achieved low disease activity with tocilizumab and at least 24 weeks of glucocorticoid treatment, continuing glucocorticoids at 5 mg per day for 24 weeks provided safe and better disease control than tapering glucocorticoids, although two-thirds of patients were able to safely taper their glucocorticoid dose. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Burmester, Gerd R.; Buttgereit, Frank] Free Univ, Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, D-10117 Berlin, Germany; [Burmester, Gerd R.; Buttgereit, Frank] Humboldt Univ, D-10117 Berlin, Germany; [Bernasconi, Corrado; Castro, Nidia; Nebesky, Jan Michael; Pethoe-Schramm, Attila; John, Markus R.] F Hoffmann La Roche, Pharmaceut Div, Basel, Switzerland; [Alvaro-Gracia, Jose M.] Univ Complutense Madrid, Hosp Gen Univ Gregorio Maranon, Madrid, Spain; [Dougados, Maxime] Univ Paris 05, Rheumatol Serv, Paris, France; [Gabay, Cem] Geneva Univ Hosp, Hop Cochin, Dept Rheumatol, Geneva, Switzerland; [Gabay, Cem] Geneva Sch Med, Geneva, Switzerland; [van Laar, Jacob M.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Salvarani, Carlo] Univ Modena & Reggio Emilia, Dept Rheumatol & Clin Immunol, Reggio Emilia, Italy; [Salvarani, Carlo] IRCCS Reggio Emilia, Azienda Unita Sanit Locale, Reggio Emilia, Italy; [Donath, Marc Y.] Univ Hosp Basel, Dept Rheumatol, Basel, Switzerland	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin; Roche Holding; Complutense University of Madrid; General University Gregorio Maranon Hospital; UDICE-French Research Universities; Universite Paris Cite; University of Geneva; University of Geneva; Utrecht University; Utrecht University Medical Center; Universita di Modena e Reggio Emilia; University of Basel	Burmester, GR (corresponding author), Free Univ, Charite Univ Med Berlin, Dept Rheumatol & Clin Immunol, D-10117 Berlin, Germany.; Burmester, GR (corresponding author), Humboldt Univ, D-10117 Berlin, Germany.	gerd.burmester@charite.de	Salvarani, Carlo/K-2431-2018	Bernasconi, Corrado/0000-0002-1019-5468; Buttgereit, Frank/0000-0003-2534-550X	F Hoffmann-La Roche	F Hoffmann-La Roche(Hoffmann-La Roche)	F Hoffmann-La Roche.	Albrecht K, 2015, RHEUMATOL INT, V35, P1377, DOI 10.1007/s00296-015-3229-x; Aletaha D, 2005, CLIN EXP RHEUMATOL, V23, pS100; Aletaha D, 2010, ANN RHEUM DIS, V69, P1580, DOI [10.1136/ard.2010.138461, 10.1002/art.27584]; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; Bakker MF, 2012, ANN INTERN MED, V156, P329, DOI 10.7326/0003-4819-156-5-201203060-00004; Black RJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166468; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; Borresen SW, 2017, EUR J ENDOCRINOL, V177, P287, DOI 10.1530/EJE-17-0251; Buckley L, 2018, NEW ENGL J MED, V379, P2547, DOI 10.1056/NEJMcp1800214; Buttgereit F, 2016, JAMA-J AM MED ASSOC, V315, P2442, DOI 10.1001/jama.2016.5444; Buttgereit F, 2013, ANN RHEUM DIS, V72, P204, DOI 10.1136/annrheumdis-2011-201067; Bykerk VP, 2016, RMD OPEN, V2, DOI 10.1136/rmdopen-2015-000225; Caporali R, 2015, NEUROIMMUNOMODULAT, V22, P104, DOI 10.1159/000362730; Choy E, 2019, RHEUMATOLOGY, V58, P1056, DOI 10.1093/rheumatology/key393; Dejaco C, 2015, ANN RHEUM DIS, V74, P1799, DOI 10.1136/annrheumdis-2015-207492; Dougados M, 2015, ARTHRIT CARE RES, V67, P1762, DOI 10.1002/acr.22633; Dougados M, 2013, ANN RHEUM DIS, V72, P43, DOI 10.1136/annrheumdis-2011-201282; Fortunet C, 2015, RHEUMATOLOGY, V54, P672, DOI 10.1093/rheumatology/keu339; Overman RA, 2013, ARTHRIT CARE RES, V65, P294, DOI 10.1002/acr.21796; Pazianas M, 2015, TRENDS ENDOCRIN MET, V26, P111, DOI 10.1016/j.tem.2015.01.004; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Ribbens C, 2014, ANN RHEUM DIS, V73, P495, DOI 10.1136/annrheumdis-2014-eular.1992; Roubille C, 2017, ANN RHEUM DIS, V76, P1797, DOI 10.1136/annrheumdis-2016-210135; Saraux A, 2016, CLIN EXP RHEUMATOL, V34, P303; Schuetz P, 2015, EUR J ENDOCRINOL, V173, P19, DOI 10.1530/EJE-15-0182; Singh JA, 2016, ARTHRITIS RHEUMATOL, V68, P1, DOI 10.1002/art.39480; Smolen JS, 2017, ANN RHEUM DIS, V76, P960, DOI 10.1136/annrheumdis-2016-210715; Smolen JS, 2014, ANN RHEUM DIS, V73, P492, DOI 10.1136/annrheumdis-2013-204573; van Staa TP, 2000, QJM-MON J ASSOC PHYS, V93, P105, DOI 10.1093/qjmed/93.2.105; Vestergaard P, 2008, CALCIFIED TISSUE INT, V82, P249, DOI 10.1007/s00223-008-9124-7; Volkmann ER, 2013, J RHEUMATOL, V40, P1646, DOI 10.3899/jrheum.130019; Wilson JC, 2019, ARTHRIT CARE RES, V71, P498, DOI 10.1002/acr.23611; YAGIZ B, 2018, ARTHRITIS RHEUMAT S9, V70	33	40	40	1	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	2020	396	10246					267	276						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK8ZY	32711802				2023-01-03	WOS:000567020100017
J	Middleton, G; Fletcher, P; Popat, S; Savage, J; Summers, Y; Greystoke, A; Gilligan, D; Cave, J; O'Rourke, N; Brewster, A; Toy, E; Spicer, J; Jain, P; Dangoor, A; Mackean, M; Forster, M; Farley, A; Wherton, D; Mehmi, M; Sharpe, R; Mills, TC; Cerone, MA; Yap, TA; Watkins, TBK; Lim, E; Swanton, C; Billingham, L				Middleton, Gary; Fletcher, Peter; Popat, Sanjay; Savage, Joshua; Summers, Yvonne; Greystoke, Alastair; Gilligan, David; Cave, Judith; O'Rourke, Noelle; Brewster, Alison; Toy, Elizabeth; Spicer, James; Jain, Pooja; Dangoor, Adam; Mackean, Melanie; Forster, Martin; Farley, Amanda; Wherton, Dee; Mehmi, Manita; Sharpe, Rowena; Mills, Tara C.; Cerone, Maria Antonietta; Yap, Timothy A.; Watkins, Thomas B. K.; Lim, Emilia; Swanton, Charles; Billingham, Lucinda			The National Lung Matrix Trial of personalized therapy in lung cancer	NATURE			English	Article							PHASE CLINICAL-TRIALS; MUTATIONS; CTDNA	The majority of targeted therapies for non-small-cell lung cancer (NSCLC) are directed against oncogenic drivers that are more prevalent in patients with light exposure to tobacco smoke(1-3). As this group represents around 20% of all patients with lung cancer, the discovery of stratified medicine options for tobacco-associated NSCLC is a high priority. Umbrella trials seek to streamline the investigation of genotype-based treatments by screening tumours for multiple genomic alterations and triaging patients to one of several genotype-matched therapeutic agents. Here we report the current outcomes of 19 drug-biomarker cohorts from the ongoing National Lung Matrix Trial, the largest umbrella trial in NSCLC. We use next-generation sequencing to match patients to appropriate targeted therapies on the basis of their tumour genotype. The Bayesian trial design enables outcome data from open cohorts that are still recruiting to be reported alongside data from closed cohorts. Of the 5,467 patients that were screened, 2,007 were molecularly eligible for entry into the trial, and 302 entered the trial to receive genotype-matched therapy-including 14 that re-registered to the trial for a sequential trial drug. Despite pre-clinical data supporting the drug-biomarker combinations, current evidence shows that a limited number of combinations demonstrate clinically relevant benefits, which remain concentrated in patients with lung cancers that are associated with minimal exposure to tobacco smoke. Current outcomes are reported from the ongoing National Lung Matrix Trial, an umbrella trial for the treatment of non-small-cell lung cancer in which patients are triaged according to their tumour genotype and matched with targeted therapeutic agents.	[Middleton, Gary] Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England; [Middleton, Gary] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Fletcher, Peter; Savage, Joshua; Wherton, Dee; Mehmi, Manita; Sharpe, Rowena; Billingham, Lucinda] Univ Birmingham, Canc Res UK Clin Trials Unit, Birmingham, W Midlands, England; [Popat, Sanjay] Royal Marsden Hosp, London, England; [Summers, Yvonne] The Christie, Manchester, Lancs, England; [Greystoke, Alastair] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England; [Gilligan, David] Addenbrookes Hosp, Cambridge, England; [Cave, Judith] Southampton Univ Hosp NHS Trust, Southampton, Hants, England; [O'Rourke, Noelle] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland; [Brewster, Alison] Velindre Canc Ctr, Cardiff, Wales; [Toy, Elizabeth] Royal Devon & Exeter Fdn NHS Trust, Exeter, Devon, England; [Spicer, James] Kings Coll London, Guys Hosp, London, England; [Jain, Pooja] St James Univ Hosp, Leeds, W Yorkshire, England; [Dangoor, Adam] Bristol Haematol & Oncol Ctr, Bristol, Avon, England; [Mackean, Melanie] Western Gen Hosp, Edinburgh, Midlothian, Scotland; [Forster, Martin] Univ Coll Hosp, London, England; [Farley, Amanda] Univ Birmingham, Inst Appl Hlth Res, Birmingham, W Midlands, England; [Mills, Tara C.; Cerone, Maria Antonietta] Canc Res UK, London, England; [Yap, Timothy A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Watkins, Thomas B. K.; Lim, Emilia; Swanton, Charles] Francis Crick Inst, London, England; [Swanton, Charles] UCL, Inst Canc, Canc Res UK Lung Canc Ctr Excellence, London, England	University of Birmingham; University of Birmingham; Cancer Research UK; University of Birmingham; Royal Marsden NHS Foundation Trust; Christie NHS Foundation Trust; Christie Hospital; Newcastle University - UK; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Southampton; University Hospital Southampton NHS Foundation Trust; Beatson Oncology Centre; Velindre Cancer Centre; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Saint James's University Hospital; Bristol Haematology & Oncology Centre; University of Edinburgh; University of London; University College London; University of Birmingham; Cancer Research UK; University of Texas System; UTMD Anderson Cancer Center; Francis Crick Institute; Cancer Research UK; University of London; University College London	Middleton, G (corresponding author), Univ Birmingham, Inst Immunol & Immunotherapy, Birmingham, W Midlands, England.; Middleton, G (corresponding author), Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England.	g.middleton@bham.ac.uk	Popat, Sanjay/AAO-1634-2021; Savage, Joshua/A-8738-2008	Popat, Sanjay/0000-0003-2087-4963; Savage, Joshua/0000-0003-0599-0245; Middleton, Gary/0000-0001-5695-3474; Billingham, Lucinda/0000-0001-8581-4262; Fletcher, Peter/0000-0001-5905-831X; Spicer, James/0000-0003-3732-8491	CRUK [C11497/A19363, C11497/A22209, C22436/A25354]; Pfizer; Mirati; Experimental Cancer Medicine Centres (ECMC); ECMC Network; AstraZeneca	CRUK(Cancer Research UK); Pfizer(Pfizer); Mirati; Experimental Cancer Medicine Centres (ECMC); ECMC Network; AstraZeneca(AstraZeneca)	The Investigators and Sponsor thank all the patients and their families who participated in this trial, as well as the NHS Trusts and staff and the members of the Trial Steering Committee, chaired by R. Kaplan, who have supported this trial. We thank our patient and public representatives, M. Baker on the Trial Steering Committee and T. Haswell on the Trial Management Group. This is an investigator-initiated and investigator-led trial funded by CRUK grant C11497/A19363 and C11497/A22209. Trial drugs were supplied free of charge by AstraZeneca (AZD4547, vistusertib, selumetinib, capivasertib, osimertinib and durvalumab), Pfizer (palbociclib and crizotinib) and Mirati (sitravatinib), who also supported the programme through the funding of SMP2. The Cancer Research UK Clinical Trials Unit at the University of Birmingham is supported by CRUK grant C22436/A25354. The National Lung Matrix Trial was supported by Experimental Cancer Medicine Centres (ECMC) funding and by the ECMC Network. This trial has been independently peer reviewed and has been adopted by the National Institute for Health Research Clinical Research Network Portfolio.	Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364; Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]; Basu B, 2015, CLIN CANCER RES, V21, P3412, DOI 10.1158/1078-0432.CCR-14-2422; Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345; Berry SM, 2010, CH CRC BIOSTAT SER, P1, DOI 10.1201/EBK1439825488; Carr TH, 2016, NAT REV CANCER, V16, P319, DOI 10.1038/nrc.2016.35; Castiglione R, 2019, MODERN PATHOL, V32, P627, DOI 10.1038/s41379-018-0182-8; Cheng JQ, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-8-r80; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; de Bruin EC, 2014, SCIENCE, V346, P251, DOI 10.1126/science.1253462; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Gautschi O, 2017, J CLIN ONCOL, V35, P1403, DOI 10.1200/JCO.2016.70.9352; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288; Kim IA, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4691-0; Kim S, 2018, NAT METHODS, V15, P591, DOI 10.1038/s41592-018-0051-x; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Liao RG, 2013, CANCER RES, V73, P5195, DOI 10.1158/0008-5472.CAN-12-3950; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; McFadden DG, 2016, P NATL ACAD SCI USA, V113, pE6409, DOI 10.1073/pnas.1613601113; Morgan P, 2012, DRUG DISCOV TODAY, V17, P419, DOI 10.1016/j.drudis.2011.12.020; Offin M, 2019, CLIN CANCER RES, V25, P1063, DOI 10.1158/1078-0432.CCR-18-1102; Pengelly RJ, 2013, GENOME MED, V5, DOI 10.1186/gm492; Rothwell DG, 2019, NAT MED, V25, P738, DOI 10.1038/s41591-019-0380-z; Schmid P, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.00368; Subbiah V, 2018, CANCER DISCOV, V8, P836, DOI 10.1158/2159-8290.CD-18-0338; Thall PF, 2005, CLIN TRIALS, V2, P467, DOI 10.1191/1740774505cn121oa; Van Loo P, 2010, P NATL ACAD SCI USA, V107, P16910, DOI 10.1073/pnas.1009843107; Wang K, 2007, GENOME RES, V17, P1665, DOI 10.1101/gr.6861907; WANG QW, 2016, BIOINFORMATICS, P1209; Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898	31	57	62	2	31	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 30	2020	583	7818					807	812		10.1038/s41586-020-2481-8	http://dx.doi.org/10.1038/s41586-020-2481-8		JUL 2020	6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV5HR	32669708	Green Accepted, Green Submitted, Green Published			2023-01-03	WOS:000552814800004
J	de Kruif, AJ; Chrifou, R; Langeslag, GL; Sondaal, AEC; Franssen, MMM; Kampman, E; Winkels, RM; de Boer, MR; Visser, M; Westerman, MJ				de Kruif, Anja JThCM; Chrifou, Rabab; Langeslag, Ghislaine L.; Sondaal, Annemijn E. C.; Franssen, Margret M. M.; Kampman, Ellen; Winkels, Renate M.; de Boer, Michiel R.; Visser, Marjolein; Westerman, Marjan J.			Perceptions of non-Western immigrant women on having breast cancer and their experiences with treatment-related changes in body weight and lifestyle: A qualitative study	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; HEALTH BEHAVIORS; OF-LIFE; MIGRANTS; MORTALITY; SURVIVORS; RISK; GAIN; 1ST-GENERATION; CHEMOTHERAPY	Background The number of non-Western immigrants with breast cancer in the Netherlands has increased over the past decades and is expected to triple by 2030. Due to insufficient representation in clinical studies, it is unclear what the specific experiences and needs of these women are. Understanding how culture and religion affect these women's experience of breast cancer and how they deal with chemotherapy and treatment-related changes in body weight and lifestyle is crucial for health care professionals to be able to provide effective support. Methods A qualitative study was conducted using semi-structured interviews with 28 immigrant women with a history of breast cancer treated with chemotherapy. Results Women often associated breast cancer with taboo, death or bad luck. Religion offered these women guidance, strength and meaning to the disease, but also limited the women to openly talk about their disease. Women perceived lifestyle factors to have little influence on the development and treatment of cancer. After treatment, however, their thinking changed and these lifestyle factors became of paramount importance to them. They realised that they missed out on information about managing their own diet, exercise and body weight and were eager to share their experiences with other women in their culture with newly diagnosed breast cancer. Conclusion Women became aware during and after breast cancer treatment that it was difficult for them to actively deal with their illness under the influence of their culture and religion. Based on their own experiences and acquired knowledge, they would like to give advice to newly diagnosed women on how to deal with breast cancer within their own culture and religion. Their recommendations could be used by mosques, churches, support groups and health care professionals, to ensure interventions during breast cancer treatment meet their religious and cultural needs and thus improve their quality of life.	[de Kruif, Anja JThCM; Chrifou, Rabab; Langeslag, Ghislaine L.; Sondaal, Annemijn E. C.; Franssen, Margret M. M.; de Boer, Michiel R.; Visser, Marjolein; Westerman, Marjan J.] Vrije Univ Amsterdam, Fac Sci, Amsterdam Publ Hlth Res Inst, Dept Hlth Sci, Amsterdam, Netherlands; [de Kruif, Anja JThCM; Westerman, Marjan J.] Amsterdam UMC Locat VUmc, Dept Epidemiol & Biostat, Amsterdam, Netherlands; [Chrifou, Rabab] Amsterdam UMC Locat VUmc, Dept Publ & Occupat Hlth, Amsterdam, Netherlands; [Kampman, Ellen; Winkels, Renate M.] Wageningen Univ, Div Human Nutr, Wageningen, Netherlands	Vrije Universiteit Amsterdam; Wageningen University & Research	de Kruif, AJ (corresponding author), Vrije Univ Amsterdam, Fac Sci, Amsterdam Publ Hlth Res Inst, Dept Hlth Sci, Amsterdam, Netherlands.; de Kruif, AJ (corresponding author), Amsterdam UMC Locat VUmc, Dept Epidemiol & Biostat, Amsterdam, Netherlands.	j.dekruif@amsterdamumc.nl		de Boer, Michiel/0000-0001-9240-0199; Kruif, de;Kruif, de, Anja;Anja/0000-0002-1801-0798; Westerman, Marjan J./0000-0002-9827-6958; Visser, Marjolein/0000-0002-5136-298X	Dutch Cancer Society [UW2011 -4987 EK, UW2011 -5268 EK]	Dutch Cancer Society(KWF Kankerbestrijding)	This study was funded by the Dutch Cancer Society, htpps//www.KWF.nl (grant numbers UW2011 -4987 EK and UW2011 -5268 EK) The authors are responsible for the study design, data collection and analysis, discussion, decision to publish, and preparation of the manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, THER ADV MED ONCOL, V3, pS7; [Anonymous], 2015, URBAN RAPID RAIL TRA; [Anonymous], 2008, CHINESE J PHARMACOVI, V3, P186; Arnold M, 2010, EUR J CANCER, V46, P2647, DOI 10.1016/j.ejca.2010.07.050; Basaran G, 2011, MED ONCOL, V28, P409, DOI 10.1007/s12032-010-9463-x; Blanchard CM, 2008, J CLIN ONCOL, V26, P2198, DOI 10.1200/JCO.2007.14.6217; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brown JC, 2012, COMPR PHYSIOL, V2, P2775, DOI 10.1002/cphy.c120005; Demark-Wahnefried W, 2000, CANCER-AM CANCER SOC, V88, P674, DOI 10.1002/(SICI)1097-0142(20000201)88:3&lt;674::AID-CNCR26&gt;3.0.CO;2-R; Demark-Wahnefried W, 2012, CANCER-AM CANCER SOC, V118, P2277, DOI 10.1002/cncr.27466; DeSantis C, 2014, CA-CANCER J CLIN, V64, P52, DOI 10.3322/caac.21203; Doyle Susanna, 2007, Health Care Women Int, V28, P888, DOI 10.1080/07399330701615325; Faith MS, 1998, OBES RES, V6, P430, DOI 10.1002/j.1550-8528.1998.tb00375.x; Flynn KJ, 1998, ANN BEHAV MED, V20, P13, DOI 10.1007/BF02893804; Green J, 2013, QUALITATIVE METHODS; Gunusen NP, 2013, ASIAN PAC J CANCER P, V14, P3143, DOI 10.7314/APJCP.2013.14.5.3143; Halbert CH, 2008, BREAST J, V14, P182, DOI 10.1111/j.1524-4741.2007.00551.x; Inan FS, 2016, J TRANSCULT NURS, V27, P262, DOI 10.1177/1043659614550488; Irwin ML, 2005, J CLIN ONCOL, V23, P774, DOI 10.1200/JCO.2005.04.036; Kellen E, 2009, BREAST CANCER RES TR, V114, P13, DOI 10.1007/s10549-008-9990-8; Khalis Mohamed, 2016, Asian Pac J Cancer Prev, V17, P5211; Kroenke CH, 2005, J CLIN ONCOL, V23, P1370, DOI 10.1200/JCO.2005.01.079; Lee J, 2005, CANCER NURS, V28, P249; Majd S Samani, 2008, J ENV STUDY, V33, P1; McNeely ML, 2006, CAN MED ASSOC J, V175, P34, DOI 10.1503/cmaj.051073; Nijhuis HGJ, 2006, ALLOCHTONEN KANKER; Paxton RJ, 2012, CANCER-AM CANCER SOC, V118, P4024, DOI 10.1002/cncr.27389; Paxton RJ, 2011, CANCER-AM CANCER SOC, V117, P3805, DOI 10.1002/cncr.25957; Pollard A, 2009, CANC FORUM 2009, V184; Richardson EM, 2017, PSYCHO-ONCOLOGY, V26, P724, DOI 10.1002/pon.4213; Rock CL, 1999, J AM DIET ASSOC, V99, P1212, DOI 10.1016/S0002-8223(99)00298-9; Sarfati D, 2006, CANCER CAUSE CONTROL, V17, P671, DOI 10.1007/s10552-005-0583-0; Smith Selina A, 2016, J Ga Public Health Assoc, V5, P259; Soo H, 2015, PSYCHO-ONCOLOGY, V24, P70, DOI 10.1002/pon.3596; Spallek J, 2012, EUR J EPIDEMIOL, V27, P915, DOI 10.1007/s10654-012-9746-y; Spark LC, 2013, J CANCER SURVIV, V7, P74, DOI 10.1007/s11764-012-0246-6; Statistics Netherlands, ANN REP INT 2016; Stirbu I, 2006, INT J CANCER, V119, P2665, DOI 10.1002/ijc.22200; Stolley MR, 2006, HEALTH EDUC BEHAV, V33, P604, DOI 10.1177/1090198106290845; Taylor M, 1999, SEMIN AVIAN EXOT PET, V8, P139, DOI 10.1016/S1055-937X(99)80049-8; van Leeuwaarde RS, 2011, BREAST CANCER RES TR, V128, P873, DOI 10.1007/s10549-011-1404-7; Visser O, 2004, BRIT J CANCER, V90, P2135, DOI 10.1038/sj.bjc.6601821; Weathers B, 2006, PSYCHO-ONCOLOGY, V15, P174, DOI 10.1002/pon.939; White A, 2013, J CANCER SURVIV, V7, P93, DOI 10.1007/s11764-012-0248-4; Williams G, 2013, CANCER CAUSE CONTROL, V24, P1375, DOI 10.1007/s10552-013-0217-x	45	2	2	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2020	15	7							e0235662	10.1371/journal.pone.0235662; 10.1371/journal.pone.0235662.r001; 10.1371/journal.pone.0235662.r002; 10.1371/journal.pone.0235662.r003; 10.1371/journal.pone.0235662.r004	http://dx.doi.org/10.1371/journal.pone.0235662; 10.1371/journal.pone.0235662.r001; 10.1371/journal.pone.0235662.r002; 10.1371/journal.pone.0235662.r003; 10.1371/journal.pone.0235662.r004			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MN1ZE	32634154	Green Published, gold			2023-01-03	WOS:000550645600021
J	Shrank, WH; Russell, K; Emanuel, EJ				Shrank, William H.; Russell, Kristin; Emanuel, Ezekiel J.			Hospice Carve-In-Aligning Benefits With Patient and Family Needs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Shrank, William H.; Russell, Kristin] Humana Inc, 500 W Main St, Louisville, KY 40202 USA; [Emanuel, Ezekiel J.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA	Humana Inc.; University of Pennsylvania; Pennsylvania Medicine	Shrank, WH (corresponding author), Humana Inc, 500 W Main St, Louisville, KY 40202 USA.	wshrank@humana.com						Belanger E, 2019, JAMA INTERN MED, V179, P829, DOI 10.1001/jamainternmed.2018.8615; Centers for Medicare and Medicaid Services, 2018, MED HOSP UT PAYM PUB; Cross SH, 2019, NEW ENGL J MED, V381, P2369, DOI 10.1056/NEJMc1911892; Medicare Payment Advisory Commission, 2019, C MED HLTH CAR DEL S; Truog RD, 2020, JAMA-J AM MED ASSOC, V323, P934, DOI 10.1001/jama.2019.22522	5	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2020	324	1					35	36		10.1001/jama.2020.8459	http://dx.doi.org/10.1001/jama.2020.8459			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM5FX	32496529				2023-01-03	WOS:000568123600015
J	Cirera, L; Galatas, B; Alonso, S; Paaijmans, K; Mamuquele, M; Marti-Soler, H; Guinovart, C; Munguambe, H; Luis, F; Nhantumbo, H; Montana, J; Bassat, Q; Candrinho, B; Rabinovich, R; Macete, E; Aide, P; Alonso, P; Saute, F; Sicuri, E				Cirera, Laia; Galatas, Beatriz; Alonso, Sergi; Paaijmans, Krijn; Mamuquele, Miler; Marti-Soler, Helena; Guinovart, Caterina; Munguambe, Humberto; Luis, Fabiao; Nhantumbo, Hoticha; Montana, Julia; Bassat, Quique; Candrinho, Baltazar; Rabinovich, Regina; Macete, Eusebio; Aide, Pedro; Alonso, Pedro; Saute, Francisco; Sicuri, Elisa			Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control	PLOS ONE			English	Article							ERADICATION; HEALTH	Background As new combinations of interventions aiming at interrupting malaria transmission are under evaluation, understanding the associated economic costs and benefits is critical for decision-making. This study assessed the economic cost and cost-effectiveness of the Magude project, a malaria elimination initiative implemented in a district in southern Mozambique (i.e. Magude) between August 2015-June 2018. This project piloted a combination of two mass drug administration (MDA) rounds per year for two consecutive years, annual rounds of universal indoor residual spraying (IRS) and a strengthened surveillance and response system on the back of universal long-lasting insecticide treated net (LLIN) coverage and routine case management implemented by the National Malaria Control Program (NMCP). Although local transmission was not interrupted, the project achieved large reductions in the burden of malaria in the target district. Methods We collected weekly economic data, estimated costs from the project implementer perspective and assessed the incremental cost-effectiveness ratio (ICER) associated with the Magude project as compared to routine malaria control activities, the counterfactual. We estimated disability-adjusted life years (DALYs) for malaria cases and deaths and assessed the variation of the ICER over time to capture the marginal costs and effectiveness associated with subsequent phases of project implementation. We used deterministic and probabilistic sensitivity analyses to account for uncertainty and built an alternative scenario by assuming the implementation of the interventions from a governmental perspective. Economic costs are provided in constant US$2015. Results After three years, the Magude project averted a total of 3,171 DALYs at an incremental cost of $2.89 million and an average yearly cost of $20.7 per targeted person. At an average cost of $19.4 per person treated per MDA round, the social mobilization and distribution of door-to-door MDA contributed to 53% of overall resources employed, with personnel and logistics being the main cost drivers. The ICER improved over time as a result of decreasing costs and improved effectiveness. The overall ICER was $987 (CI95% 968-1,006) per DALY averted, which is below the standard cost-effectiveness (CE) threshold of $1,404/DALY averted, three times the gross domestic product (GDP) per capita of Mozambique, but above the threshold of interventions considered highly cost-effective (one time the GDP per capita or $468/DALY averted) and above the recently suggested thresholds based on the health opportunity cost ($537 purchasing power parity/ DALY averted). A significantly lower ICER was obtained in the implementation scenario from a governmental perspective ($441/DALY averted). Conclusion Despite the initial high costs and volume of resources associated with its implementation, MDA in combination with other existing malaria control interventions, can be a cost-effective strategy to drastically reduce transmission in areas of low to moderate transmission in sub-Saharan Africa. However, further studies are needed to understand the capacity of the health system and financial affordability to scale up such strategies at regional or national level.	[Cirera, Laia; Galatas, Beatriz; Paaijmans, Krijn; Marti-Soler, Helena; Guinovart, Caterina; Montana, Julia; Bassat, Quique; Rabinovich, Regina; Alonso, Pedro; Sicuri, Elisa] Univ Barcelona, ISGlobal, Hosp Clin, Barcelona, Spain; [Galatas, Beatriz; Paaijmans, Krijn; Mamuquele, Miler; Munguambe, Humberto; Luis, Fabiao; Nhantumbo, Hoticha; Montana, Julia; Bassat, Quique; Macete, Eusebio; Aide, Pedro; Alonso, Pedro; Saute, Francisco] Ctr Invest Saude Manhica CISM, Manhica, Mozambique; [Alonso, Sergi] Queen Mary Univ London, Ctr Primary Care & Publ Hlth, Barts & London Sch Med & Dent, London, England; [Paaijmans, Krijn] Arizona State Univ, Ctr Evolut & Med, Sch Life Sci, Tempe, AZ USA; [Paaijmans, Krijn] Arizona State Univ, Biodesign Ctr Immunotherapy Vaccines & Virotherap, Sch Life Sci, Tempe, AZ USA; [Bassat, Quique] Univ Barcelona, Pediat Infect Dis Unit, Dept Pediat, Hosp St Joan de Deu, Barcelona, Spain; [Bassat, Quique] ICREA, Barcelona, Spain; [Candrinho, Baltazar] Minist Hlth, Natl Malaria Control Program, Maputo, Mozambique; [Rabinovich, Regina] Harvard TH Chan Sch Publ Hlth, Boston, MA USA; [Macete, Eusebio; Aide, Pedro] Minist Hlth, Natl Inst Hlth, Maputo, Mozambique; [Sicuri, Elisa] Imperial Coll London, Dept Infect Dis Epidemiol, Hlth Econ Grp, Sch Publ Hlth, London, England; [Alonso, Pedro] WHO, Global Malaria Program, Geneva, Switzerland	ISGlobal; University of Barcelona; Hospital Clinic de Barcelona; Centro de Investigacao em Saude de Manhica; University of London; Queen Mary University London; Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; University of Barcelona; ICREA; Harvard University; Harvard T.H. Chan School of Public Health; Imperial College London; World Health Organization	Cirera, L (corresponding author), Univ Barcelona, ISGlobal, Hosp Clin, Barcelona, Spain.	laia.cirera@isglobal.org	Alonso, Sergi/GQZ-1236-2022; Alonso, Sergi/AAL-1960-2021; Guinovart, Caterina/ABH-2981-2020; Paaijmans, Krijn/ABC-9928-2020; Bassat, Quique/P-2341-2016; Galatas, Beatriz/AAP-4362-2020; Alonso, Pedro L/AAZ-3645-2020; Sicuri, Elisa/L-8012-2014	Alonso, Sergi/0000-0001-6664-3736; Bassat, Quique/0000-0003-0875-7596; Alonso, Pedro L/0000-0003-3292-3443; Sicuri, Elisa/0000-0002-2499-2732; Galatas, PhD, Beatriz/0000-0002-9546-6385; Marti-Soler, Helena/0000-0002-7127-205X; Cirera Criville, Laia/0000-0002-1133-487X	Spanish Ministry of Science, Innovation and Universities through the "Centro de Excelencia Severo Ochoa 2019-2023" Program [CEX2018-000806-S]; Generalitat de Catalunya through the CERCA Program; Government of Mozambique; Spanish Agency for International Development (AECID); Bill and Melinda Gates Foundation [NCT02914145]; Obra Social "la Caixa" Partnership for the Elimination of Malaria in Southern Mozambique [NCT02914145, OPP1115265]	Spanish Ministry of Science, Innovation and Universities through the "Centro de Excelencia Severo Ochoa 2019-2023" Program; Generalitat de Catalunya through the CERCA Program; Government of Mozambique; Spanish Agency for International Development (AECID); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Obra Social "la Caixa" Partnership for the Elimination of Malaria in Southern Mozambique	We acknowledge support from the Spanish Ministry of Science, Innovation and Universities through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. CISM is supported by the Government of Mozambique and the Spanish Agency for International Development (AECID). The Magude project (NCT02914145) was funded by the Bill and Melinda Gates Foundation and Obra Social "la Caixa" Partnership for the Elimination of Malaria in Southern Mozambique (OPP1115265). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aide P, 2019, MALARIA J, V18, DOI 10.1186/s12936-019-2832-9; Alonso PL, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1000406; [Anonymous], 2016, EL MAL; Barrett S, 2007, PUBLIC CHOICE, V130, P179, DOI 10.1007/s11127-006-9079-z; Barrett S, 2013, PHILOS T R SOC B, V368, DOI 10.1098/rstb.2012.0149; Barrett S, 2009, HEALTH AFFAIR, V28, P1079, DOI 10.1377/hlthaff.28.4.1079; Bleakley H, 2007, Q J ECON, V122, P73, DOI 10.1162/qjec.121.1.73; Briggs AH, 2012, VALUE HEALTH, V15, P835, DOI 10.1016/j.jval.2012.04.014; Churcher TS, 2014, SCIENCE, V344, P1230, DOI 10.1126/science.1251449; Cico A, 2018, PMI IRS COUNTRY PROG; CNTD, 2019, MOZ INT MDA IMPL; Cutler D, 2010, AM ECON J-APPL ECON, V2, P72, DOI 10.1257/app.2.2.72; Deng CS, 2018, CLIN INFECT DIS, V67, P1670, DOI 10.1093/cid/ciy364; Drummond M.F., 2015, METHODS EC EVALUATIO, V4; Eisele TP, 2016, J INFECT DIS, V214, P1831, DOI 10.1093/infdis/jiw416; Elbasha EH, 2004, HEALTH ECON, V13, P21, DOI 10.1002/hec.793; Fitzpatrick C, 2016, PLOS NEGLECT TROP D, V10, DOI 10.1371/journal.pntd.0005037; Galatas B, 2020, PLOD MED UNPUB; Galatas B, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-033985; Goodman CA, 1999, LANCET, V354, P378, DOI 10.1016/S0140-6736(99)02141-8; IMF, 2018, WORLD EC OUTL DAT CO; Johns B, 2005, HEALTH POLICY PLANN, V20, P1, DOI 10.1093/heapol/czi001; Kastner RJ, 2016, ADV PARASIT, V94, P393, DOI 10.1016/bs.apar.2016.08.004; Kastner RJ, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005934; Kim YE, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0004056; Lucas AM, 2010, AM ECON J-APPL ECON, V2, P46, DOI 10.1257/app.2.2.46; MISAU, 2017, NORM TRAT MAL MOC; Morel CM, 2005, BMJ-BRIT MED J, V331, P1299, DOI 10.1136/bmj.38639.702384.AE; Newby G, 2015, AM J TROP MED HYG, V93, P125, DOI 10.4269/ajtmh.14-0254; OANDA, 2019, HIST CURR CONV 2019, P2019; Poirot E, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008846.pub2; Sabot O, 2010, LANCET, V376, P1604, DOI 10.1016/S0140-6736(10)61355-4; Shah NK, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000312; Sicuri E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013407; Smith RD, 2003, B WORLD HEALTH ORGAN, V81, P475; Turner HC, 2018, CLIN INFECT DIS, V66, P1298, DOI 10.1093/cid/cix1001; von Seidlein L, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002745; WageIndicator, 2019, WAG 2019 MEUS ORG MO, p[2019, 2017]; WHO, 2009, WHO GUID ID EC CONS; WHO, 2015, MASS DRUG ADM MASS S; WHO, 2015, GLOB TECHN STRAT MAL; WHO, 2015, REV DEL COST DAT MAS; WHO, 2003, WHO GUIDE COST EFFEC; WHO, WORLD HLTH ORG COST; Woods B, 2016, VALUE HEALTH, V19, P929, DOI 10.1016/j.jval.2016.02.017; World Health Organization, 2017, WHO METH DAT SOURC G; World Health Organization, 2018, MAL SURV MON EV REF	47	4	5	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2020	15	7							e0235631	10.1371/journal.pone.0235631; 10.1371/journal.pone.0235631.r001; 10.1371/journal.pone.0235631.r002; 10.1371/journal.pone.0235631.r003; 10.1371/journal.pone.0235631.r004	http://dx.doi.org/10.1371/journal.pone.0235631; 10.1371/journal.pone.0235631.r001; 10.1371/journal.pone.0235631.r002; 10.1371/journal.pone.0235631.r003; 10.1371/journal.pone.0235631.r004			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MM3OG	32628741	Green Published, gold			2023-01-03	WOS:000550068700061
J	Palacios, S; Colli, E; Regidor, PA				Palacios, S.; Colli, E.; Regidor, P. A.			Bleeding profile of women using a drospirenone-only pill 4 mg over nine cycles in comparison with desogestrel 0.075 mg	PLOS ONE			English	Article							OVARIAN ACTIVITY	Background Progestin-only pills are associated with irregular bleeding pattern including amenorrhea. Desogestrel 75mcg even being a pill that inhibits ovulation shows a poor cycle control that limits a more common use. A drospirenone (DRSP)-only pill was developed to improve the bleeding profile. Methods A phase III study in healthy women aged 18 to 45 years was performed to compare the bleeding profile and safety of women taking a DRSP only pill in a regime of 24 days of 4 mg of DRSP tablets followed by 4 days of placebo versus desogestrel 0.075 mg per day continuously over 9 cycles. A total of 858 women with 6691 drospirenone and 332 women with 2487 desogestrel treatment cycles were analyzed. The primary endpoint was the proportion of women with bleeding/spotting days in each cycle from cycles 2 to 9 and cumulative in cycles 2 to 4 and cycles 7 to 9 including and excluding those with amenorrhea. Findings In each cycle, up to cycle 7, the proportion of women with unscheduled bleeding including those which did not bleed was statistically significantly lower in the DRSP group than in the DSG group (p = 0.0001, chi-square test). The mean [SD] number of unscheduled bleeding and spotting days during cycles 2-9 was statistically significantly lower in the DRSP group than in the DSG group (21.5 [22.86] days vs. 34.7 [33.73] days, p = 0.0003, Wilcoxon-rank-sum-test). Excluding amenorrhoeic women following results were obtained: In the cycles 2-6, the proportion of women with unscheduled bleeding was statistically significantly lower in the DRSP group than in the DSG group (p = 0.0001, chi-square test). The mean [SD] number of bleeding days was 8.6 [8.52] days vs. 12.9 [16.47] days, p = 0.0233. Conclusions This report describes the improvement in bleeding profile of women using the new DRSP only oral contraceptive in comparison to DSG providing a better quality of live and adherence to the contraceptive method. EudraCT registration number: 2011-002396-42.	[Palacios, S.] Inst Palacios, Salud & Med Mujer, Madrid, Spain; [Colli, E.] Exeltis HealthCare Madrid, Madrid, Spain; [Regidor, P. A.] Exeltis Europe, Ismaning, Germany		Regidor, PA (corresponding author), Exeltis Europe, Ismaning, Germany.	pedro-antonio.regidor@exeltis.com		Palacios, Santiago/0000-0003-2229-1200; Regidor, Pedro-Antonio/0000-0002-9551-2847	Insud Pharma, Spain	Insud Pharma, Spain	Enrico Colli and Pedro Antonio Regidor are employees of Exeltis. The funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors' salaries and/or research materials. The funder provided support in the form of salaries for the authors Enrico Colli and Pedro-Antonio Regidor but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section. The study was funded by Insud Pharma, Spain.	[Anonymous], 1998, Eur J Contracept Reprod Health Care, V3, P169; Archer DF, 2015, CONTRACEPTION, V92, P439, DOI 10.1016/j.contraception.2015.07.014; Duijkers IJM, 2016, CONTRACEPTION, V93, P303, DOI 10.1016/j.contraception.2015.12.007; Duijkers IJM, 2015, EUR J CONTRACEP REPR, V20, P419, DOI 10.3109/13625187.2015.1044082; Edelman A, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004695.pub3; Healthcare Bayer, 2015, YAZ SUMM PROD CHAR; Jabbour HN, 2006, ENDOCR REV, V27, P17, DOI 10.1210/er.2004-0021; Kiley JW, 2011, INT J WOMENS HEALTH, V3, P281, DOI 10.2147/IJWH.S22645; Kovacs G, 1996, HUM REPROD, V11, P20, DOI 10.1093/humrep/11.suppl_2.20; Lidegaard O, 2012, NEW ENGL J MED, V366, P2257, DOI 10.1056/NEJMoa1111840; MCCANN MF, 1994, CONTRACEPTION S1, V50, P9; Moreau C, 2007, CONTRACEPTION, V76, P267, DOI 10.1016/j.contraception.2007.06.008; NOYES RW, 1950, FERTIL STERIL, V1, P3, DOI 10.1016/s0015-0282(16)30062-0; Regidor Pedro-Antonio, 2018, Oncotarget, V9, P34628, DOI 10.18632/oncotarget.26015; Rice C, 1996, HUM REPROD, V11, P737; Smith Oliver P. Milling, 2005, Angiogenesis, V8, P117, DOI 10.1007/s10456-005-9003-z; Trussell J, 2011, CONTRACEPTION, V83, P397, DOI 10.1016/j.contraception.2011.01.021; Villavicencio J, 2016, OPEN ACCESS J CONTR, V7, P43, DOI 10.2147/OAJC.S85565; WHO, 2015, WHO REC ASS HIV TEST	19	7	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 29	2020	15	6							e0231856	10.1371/journal.pone.0231856	http://dx.doi.org/10.1371/journal.pone.0231856			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG9OL	32598387	Green Published, gold			2023-01-03	WOS:000546361900029
J	Zaar, M; Herzig, MC; Fedyk, CG; Montgomery, RK; Prat, N; Parida, BK; Hinojosa-Laborde, C; Muniz, GW; Shade, RE; Bauer, C; Delacruz, W; Bynum, JA; Convertino, VA; Cap, AP; Pidcoke, HF; Goswami, N; Goswami, N; Goswami, N				Zaar, Morten; Herzig, Maryanne C.; Fedyk, Chriselda G.; Montgomery, Robbie K.; Prat, Nicolas; Parida, Bijaya K.; Hinojosa-Laborde, Carmen; Muniz, Gary W.; Shade, Robert E.; Bauer, Cassondra; Delacruz, Wilfred; Bynum, James A.; Convertino, Victor A.; Cap, Andrew P.; Pidcoke, Heather F.; Goswami, Nandu; Goswami, Nandu; Goswami, Nandu			Similar hemostatic responses to hypovolemia induced by hemorrhage and lower body negative pressure reveal a hyperfibrinolytic subset of non-human primates	PLOS ONE			English	Article							BLOOD-LOSS; FIBRINOLYSIS SHUTDOWN; AGGREGOMETRY; ACTIVATION; MODEL	Background To study central hypovolemia in humans, lower body negative pressure (LBNP) is a recognized alternative to blood removal (HEM). While LBNP mimics the cardiovascular responses of HEM in baboons, similarities in hemostatic responses to LBNP and HEM remain unknown in this species. Methods Thirteen anesthetized baboons were exposed to progressive hypovolemia by HEM and, four weeks later, by LBNP. Hemostatic activity was evaluated by plasma markers, thromboelastography (TEG), flow cytometry, and platelet aggregometry at baseline (BL), during and after hypovolemia. Results BL values were indistinguishable for most parameters although platelet count, maximal clot strength (MA), protein C, thrombin anti-thrombin complex (TAT), thrombin activatable fibrinolysis inhibitor (TAFI) activity significantly differed between HEM and LBNP. Central hypovolemia induced by either method activated coagulation; TEG R-time decreased and MA increased during and after hypovolemia compared to BL. Platelets displayed activation by flow cytometry; platelet count and functional aggregometry were unchanged. TAFI activity and protein, Factors V and VIII, vWF, Proteins C and S all demonstrated hemodilution during HEM and hemoconcentration during LBNP, whereas tissue plasminogen activator (tPA), plasmin/anti-plasmin complex, and plasminogen activator inhibitor-1 did not. Fibrinolysis (TEG LY30) was unchanged by either method; however, at BL, fibrinolysis varied greatly. Post-hoc analysis separated baboons into low-lysis (LY30 <2%) or high-lysis (LY30 >2%) whose fibrinolytic state matched at both HEM and LBNP BL. In high-lysis, BL tPA and LY30 correlated strongly (r = 0.95;P<0.001), but this was absent in low-lysis. In low-lysis, BL TAFI activity and tPA correlated (r = 0.88;P<0.050), but this was absent in high-lysis. Conclusions Central hypovolemia induced by either LBNP or HEM resulted in activation of coagulation; thus, LBNP is an adjunct to study hemorrhage-induced pro-coagulation in baboons. Furthermore, this study revealed a subset of baboons with baseline hyperfibrinolysis, which was strongly coupled to tPA and uncoupled from TAFI activity.	[Zaar, Morten; Hinojosa-Laborde, Carmen; Muniz, Gary W.; Delacruz, Wilfred; Convertino, Victor A.] US Army, Inst Surg Res, Ctr Human Integrat Physiol, Ft Sam Houston, TX 78234 USA; [Herzig, Maryanne C.; Fedyk, Chriselda G.; Montgomery, Robbie K.; Prat, Nicolas; Parida, Bijaya K.; Bynum, James A.; Cap, Andrew P.; Pidcoke, Heather F.] US Army, Inst Surg Res, Coagulat & Blood Res, Ft Sam Houston, TX 78234 USA; [Prat, Nicolas] French Armed Forces Biomed Res Inst IRBA, Bretigny Sur Orge, France; [Shade, Robert E.; Bauer, Cassondra] Texas Biomed Res Inst, Southwest Natl Primate Res Ctr, San Antonio, TX USA; [Bauer, Cassondra] Charles River Labs, Ashland, OH USA; [Delacruz, Wilfred] San Antonio Mil Med Ctr, Hematol Oncol, Ft Sam Houston, TX USA; [Pidcoke, Heather F.] Colorado State Univ, Translat Med Inst, Ft Collins, CO 80523 USA	Texas Biomedical Research Institute; San Antonio Military Medical Center; Colorado State University	Herzig, MC (corresponding author), US Army, Inst Surg Res, Coagulat & Blood Res, Ft Sam Houston, TX 78234 USA.	maryanne.c.herzig.ctr@mail.mil	Cap, Andrew Peter/GQZ-4426-2022; Goswami, Nandu/B-4021-2011	Convertino, Victor/0000-0001-9246-0554; Shade, Robert/0000-0002-2979-5279	United States Army, Medical Research and Development Command	United States Army, Medical Research and Development Command	This study was funded by the United States Army, Medical Research and Development Command. Charles Rivers Laboratories provided support in the form of salary for author CB during the editing of this manuscript but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. All other authors have no other specific funding to declare.	Bagot CN, 2008, BRIT J HAEMATOL, V143, P180, DOI 10.1111/j.1365-2141.2008.07323.x; Barcroft H, 1944, LANCET, V1, P489; Chapman MP, 2016, J TRAUMA ACUTE CARE, V80, P16, DOI 10.1097/TA.0000000000000885; Colic L, 2018, EUR NEUROPSYCHOPHARM, V28, P701, DOI 10.1016/j.euroneuro.2018.03.014; Cooke WH, 2004, J APPL PHYSIOL, V96, P1249, DOI 10.1152/japplphysiol.01155.2003; Cvirn G, 2019, J APPL PHYSIOL, V126, P1214, DOI 10.1152/japplphysiol.00940.2018; Cvirn G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042221; Dugan G, 2015, PLATELETS, V26, P730, DOI 10.3109/09537104.2014.988694; Goswami N, 2019, PHYSIOL REV, V99, P807, DOI 10.1152/physrev.00006.2018; HARRISON P, 1993, BLOOD REV, V7, P52, DOI 10.1016/0268-960X(93)90024-X; Hinojosa-Laborde C, 2016, AM J PHYSIOL-REG I, V310, pR1154, DOI 10.1152/ajpregu.00304.2015; Hinojosa-Laborde C, 2014, J APPL PHYSIOL, V116, P406, DOI 10.1152/japplphysiol.00640.2013; Johnson BD, 2014, J APPL PHYSIOL, V117, P131, DOI 10.1152/japplphysiol.00070.2014; Moore HB, 2017, J TRAUMA ACUTE CARE, V83, P1014, DOI 10.1097/TA.0000000000001718; Moore HB, 2014, J TRAUMA ACUTE CARE, V77, P811, DOI 10.1097/TA.0000000000000341; Rickards CA, 2015, J APPL PHYSIOL, V119, P677, DOI 10.1152/japplphysiol.00127.2015; Ruttmann TG, 2003, ANAESTH INTENS CARE, V31, P40, DOI 10.1177/0310057X0303100107; Toth O, 2006, THROMB HAEMOSTASIS, V96, P781, DOI 10.1160/TH06-05-0242; van Helmond N, 2016, EXP PHYSIOL, V101, P1265, DOI 10.1113/EP085952; van Helmond N, 2015, AM J PHYSIOL-HEART C, V309, pH1591, DOI 10.1152/ajpheart.00435.2015; von Kanel R, 2000, EUR J HAEMATOL, V65, P357, DOI 10.1034/j.1600-0609.2000.065006357.x; Zaar M, 2009, CLIN PHYSIOL FUNCT I, V29, P427, DOI 10.1111/j.1475-097X.2009.00890.x; Zaar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116174; Zaar M, 2014, BLOOD COAGUL FIBRIN, V25, P592, DOI 10.1097/MBC.0000000000000114	24	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2020	15	6							e0234844	10.1371/journal.pone.0234844	http://dx.doi.org/10.1371/journal.pone.0234844			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MF9GS	32579572	gold, Green Published			2023-01-03	WOS:000545646600021
J	Pezzali, JG; Suprabha-Raj, A; Siliveru, K; Aldrich, CG				Pezzali, Julia Guazzelli; Suprabha-Raj, Anu; Siliveru, Kaliramesh; Aldrich, Charles Gregory			Characterization of white and red sorghum flour and their potential use for production of extrudate crisps	PLOS ONE			English	Article							PHYSICAL-PROPERTIES; EXTRUSION; STARCH; FRACTIONS; SNACKS; BREAD	In the human food industry, the wheat-free market sales have increased over the years due to awareness of wheat gluten allergy and celiac disease. Sorghum is a gluten-free grain with great potential to address shortcomings in this market. The aim of this study was to evaluate the milling process and flour quality of one white and one red sorghum varieties and evaluate extrusion as a potential process to produce sorghum crisps. The white and red sorghum grains were milled into flour in three production cycles. Flour quality was evaluated by determination of nutritional composition, pasting, and thermal profile. Extrusion processing of white and red sorghum flour was performed, and macrostructure of final product was evaluated. The white and red sorghum used in this study yielded similar flour content (P > 0.05). Chemical analyses revealed a higher protein and lower starch content for white sorghum than red sorghum flour (P < 0.05); however, their pasting properties did not differ. Initial and peak gelatinization temperatures were higher (P < 0.05) for red sorghum compared to white sorghum flour. Regarding particle size, white sorghum flour presented lower d10 and d50 compared to the red sorghum flour (P < 0.05). However, these differences did not impact the extrusion conditions, and white and red sorghum crisps had similar macrostructure characteristics. In conclusion, although differences in nutritional, thermal, and particle size properties were observed between the sorghum flours used in this study, changes in extrusion parameters were not needed in order to produce sorghum crisps with similar characteristics.	[Pezzali, Julia Guazzelli; Suprabha-Raj, Anu; Siliveru, Kaliramesh; Aldrich, Charles Gregory] Kansas State Univ, Dept Grain Sci & Ind, Manhattan, KS 66506 USA; [Pezzali, Julia Guazzelli] Univ Guelph, Dept Anim Biosci, Guelph, ON, Canada	Kansas State University; University of Guelph	Aldrich, CG (corresponding author), Kansas State Univ, Dept Grain Sci & Ind, Manhattan, KS 66506 USA.	aldrich4@ksu.edu			Kansas Department of Agriculture through the U.S. Department of Agriculture Federal State Marketing Improvement Program [PP35176]	Kansas Department of Agriculture through the U.S. Department of Agriculture Federal State Marketing Improvement Program	This research was funded by the Kansas Department of Agriculture through the U.S. Department of Agriculture Federal State Marketing Improvement Program, grant number PP35176. CGA received the award/funding. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. https://www.ams.usda.gov/services/grants/fsmip.	Al-Rabadi GJ, 2012, J CEREAL SCI, V56, P396, DOI 10.1016/j.jcs.2012.04.009; Alvarenga IC, 2018, J CEREAL SCI, V82, P121, DOI 10.1016/j.jcs.2018.05.013; Anton AA, 2009, FOOD CHEM, V113, P989, DOI 10.1016/j.foodchem.2008.08.050; Arbex PM, 2018, J FUNCT FOODS, V42, P346, DOI 10.1016/j.jff.2018.01.010; Baik BK, 2004, CEREAL CHEM, V81, P94, DOI 10.1094/CCHEM.2004.81.1.94; Bisharat GI, 2013, FOOD RES INT, V53, P1, DOI 10.1016/j.foodres.2013.03.043; Boudries N, 2009, CARBOHYD POLYM, V78, P475, DOI 10.1016/j.carbpol.2009.05.010; Ding QB, 2005, J FOOD ENG, V66, P283, DOI 10.1016/j.jfoodeng.2004.03.019; Duizer LM, 2006, J TEXTURE STUD, V37, P1, DOI 10.1111/j.1745-4603.2006.00035.x; Frederick EJ, 2009, THESIS; Hagerman AE, 1998, J AGR FOOD CHEM, V46, P1887, DOI 10.1021/jf970975b; Kim YS, 1999, CEREAL CHEM, V76, P957, DOI 10.1094/CCHEM.1999.76.6.957; Liang X, 2003, J FOOD SCI, V68, P832, DOI 10.1111/j.1365-2621.2003.tb08251.x; Liu LM, 2012, J CEREAL SCI, V55, P31, DOI 10.1016/j.jcs.2011.09.007; Liu Y, 2000, J FOOD SCI, V65, P1253, DOI 10.1111/j.1365-2621.2000.tb10274.x; Martin JM, 2007, CROP SCI, V47, P497, DOI 10.2135/cropsci2006.05.0342; Palavecino PM, 2016, STARCH-STARKE, V68, P1055, DOI 10.1002/star.201600111; McCallum L, 2013, FOODBORNE PATHOG DIS, V10, P159, DOI 10.1089/fpd.2012.1282; Mesquita CD, 2013, FOOD SCI TECH-BRAZIL, V33, P404, DOI 10.1590/S0101-20612013005000073; MORAD MM, 1984, J FOOD SCI, V49, P1070, DOI 10.1111/j.1365-2621.1984.tb10394.x; Moraes EA, 2015, FOOD CHEM, V180, P116, DOI 10.1016/j.foodchem.2015.02.023; Saad M, 2011, J FOOD ENG, V102, P293, DOI 10.1016/j.jfoodeng.2010.08.020; Schober TJ, 2005, CEREAL CHEM, V82, P394, DOI 10.1094/CC-82-0394; Shibanuma Y, 1996, CARBOHYD POLYM, V29, P253, DOI 10.1016/0144-8617(96)00026-4; Smith J, 2011, PROC FOOD SCI, V1, P1573, DOI 10.1016/j.profoo.2011.09.233; Trappey EF, 2015, FOOD SCI TECHNOL INT, V21, P188, DOI 10.1177/1082013214523632; Verlinden A, 2006, CRIT REV FOOD SCI, V46, P259, DOI 10.1080/10408390591001117; Wieser H, 2008, CEREAL CHEM, V85, P1, DOI 10.1094/CCHEM-85-1-0001; Winger M, 2014, J FOOD QUALITY, V37, P95, DOI 10.1111/jfq.12080	30	8	8	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2020	15	6							e0234940	10.1371/journal.pone.0234940	http://dx.doi.org/10.1371/journal.pone.0234940			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ME9KK	32574219	gold, Green Published			2023-01-03	WOS:000544972400053
J	Rieckert, A; Reeves, D; Altiner, A; Drewelow, E; Esmail, A; Flamm, M; Hann, M; Johansson, T; Klaassen-Mielke, R; Kunnamo, I; Loffler, C; Piccoliori, G; Sommerauer, C; Trampisch, US; Vogele, A; Woodham, A; Sonnichsen, A				Rieckert, Anja; Reeves, David; Altiner, Attila; Drewelow, Eva; Esmail, Aneez; Flamm, Maria; Hann, Mark; Johansson, Tim; Klaassen-Mielke, Renate; Kunnamo, Ilkka; Loeffler, Christin; Piccoliori, Giuliano; Sommerauer, Christina; Trampisch, Ulrike S.; Voegele, Anna; Woodham, Adrine; Soennichsen, Andreas			Use of an electronic decision support tool to reduce polypharmacy in elderly people with chronic diseases: cluster randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICATIONS	OBJECTIVE To evaluate the effects of a computerised decision support tool for comprehensive drug review in elderly people with polypharmacy. DESIGN Pragmatic, multicentre, cluster randomised controlled trial. SETTING 359 general practices in Austria, Germany, Italy, and the United Kingdom. PARTICIPANTS 3904 adults aged 75 years and older using eight or more drugs on a regular basis, recruited by their general practitioner. INTERVENTION A newly developed electronic decision support tool comprising a comprehensive drug review to support general practitioners in deprescribing potentially inappropriate and non-evidence based drugs. Doctors were randomly allocated to either the electronic decision support tool or to provide treatment as usual. MAIN OUTCOME MEASURES The primary outcome was the composite of unplanned hospital admission or death by 24 months. The key secondary outcome was reduction in the number of drugs. RESULTS 3904 adults were enrolled between January and October 2015. 181 practices and 1953 participants were assigned to electronic decision support (intervention group) and 178 practices and 1951 participants to treatment as usual (control group). The primary outcome (composite of unplanned hospital admission or death by 24 months) occurred in 871 (44.6%) participants in the intervention group and 944 (48.4%) in the control group. In an intention-totreat analysis the odds ratio of the composite outcome was 0.88 (95% confidence interval 0.73 to 1.07; P=0.19, 997 of 1953 v 1055 of 1951). In an analysis restricted to participants attending practice according to protocol, a difference was found favouring the intervention (odds ratio 0.82, 95% confidence interval 0.68 to 0.98; 774 of 1682 v 873 of 1712, P=0.03). By 24 months the number of prescribed drugs had decreased in the intervention group compared with control group (uncontrolled mean change -0.42 v0.06: adjusted mean difference -0.45, 95% confidence interval -0.63 to -0.26; P<0.001). CONCLUSIONS In intention-to-treat analysis, a computerised decision support tool for comprehensive drug review of elderly people with polypharmacy showed no conclusive effects on the composite of unplanned hospital admission or death by 24 months. Nonetheless, a reduction in drugs was achieved without detriment to patient outcomes.	[Rieckert, Anja; Sommerauer, Christina; Trampisch, Ulrike S.] Witten Herdecke Univ, Inst Gen Practice & Family Med, Alfred Herrhausen Str 50, D-58448 Witten, Germany; [Reeves, David; Esmail, Aneez; Woodham, Adrine; Soennichsen, Andreas] Univ Manchester, Sch Hlth Sci, Natl Inst Hlth Res, Sch Primary Care Res, Manchester, Lancs, England; [Altiner, Attila; Drewelow, Eva; Loeffler, Christin] Rostock Univ, Med Ctr, Inst Gen Practice, Rostock, Germany; [Flamm, Maria; Johansson, Tim] Paracelsus Med Univ, Inst Gen Practice Family Med & Prevent Med, Salzburg, Austria; [Hann, Mark] Univ Manchester, Sch Hlth Sci, Ctr Biostat, Manchester, Lancs, England; [Klaassen-Mielke, Renate] Ruhr Univ Bochum, Dept Med Informat Biometry & Epidemiol, Bochum, Germany; [Kunnamo, Ilkka] Duodecim Med Publicat, Helsinki, Finland; [Piccoliori, Giuliano] Inst Gen Practice Bolzano, Bolzano, Italy; [Voegele, Anna] Inst Mt Emergency Med, Eurac Res, Bolzano, Italy; [Soennichsen, Andreas] Med Univ Vienna, Ctr Publ Hlth, Dept Gen Practice & Family Med, Vienna, Austria	University of Manchester; University of Rostock; Paracelsus Private Medical University; University of Manchester; Ruhr University Bochum; European Academy of Bozen-Bolzano; Medical University of Vienna	Rieckert, A (corresponding author), Witten Herdecke Univ, Inst Gen Practice & Family Med, Alfred Herrhausen Str 50, D-58448 Witten, Germany.	Anja.Rieckert@uni-wh.de	Rieckert, Anja/AAW-1526-2020; Trampisch, Ulrike/GYC-6024-2022; Reeves, David/H-6203-2014	Trampisch, Ulrike/0000-0002-6030-3383; Reeves, David/0000-0001-6377-6859; Flamm, Maria/0000-0003-0816-6657; Rieckert, Anja/0000-0002-9735-378X; Hann, Mark/0000-0002-4508-5584; Piccoliori, Giuliano/0000-0003-1974-4184; Esmail, Aneez/0000-0001-7061-7434	seventh Framework Programme of the European Union [Health-2012Innovation-1-2.2.2-2, 305388-2]	seventh Framework Programme of the European Union	This study was funded by the seventh Framework Programme of the European Union, theme Health-2012Innovation-1-2.2.2-2 (grant agreement No 305388-2). The funder had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or in the decision to submit the article for publication. All authors confirm that they worked independently from funders. All authors had full access to all of the data (including statistical reports and tables) in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.	Bokhof B, 2016, DRUG AGING, V33, P249, DOI 10.1007/s40266-016-0354-5; Carson RG, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.02249; Garfinkel D, 2007, ISR MED ASSOC J, V9, P430; Garfinkel D, 2010, ARCH INTERN MED, V170, P1648, DOI 10.1001/archinternmed.2010.355; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Howard RL, 2007, BRIT J CLIN PHARMACO, V63, P136, DOI 10.1111/j.1365-2125.2006.02698.x; Johansson T, 2016, BRIT J CLIN PHARMACO, V82, P532, DOI 10.1111/bcp.12959; Martinez YV, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0570-9; Maruish MEE, USERS MANUAL SF 12V2; Meinshausen M, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0572-7; Organisation for Economic Co-operation and Development, 1999, CLASS ED PROGR MAN I; Reeve E, 2017, EUR J INTERN MED, V38, P3, DOI 10.1016/j.ejim.2016.12.021; Renom-Guiteras A, 2015, EUR J CLIN PHARMACOL, V71, P861, DOI 10.1007/s00228-015-1860-9; Rieckert A, J AM MED INFORM ASSN, DOI [10.1093/jamia/ocz104/29521023/ocz104, DOI 10.1093/JAMIA/OCZ104/29521023/OCZ104]; Rieckert A, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0795-5; Rieckert A, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0789-3; Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051; Schlender L, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0574-5; Schott G, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0571-8; Sonnichsen A, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1177-8; Sonnichsen AC, 2010, BMC FAM PRACT, V11, DOI 10.1186/1471-2296-11-86; SOMMERAUER C, 2017, BMC GERIATR S1, V17, DOI DOI 10.1186/S12877-017-; Sommerauer C, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-017-0663-5; Sullivan TR, 2018, STAT METHODS MED RES, V27, P2610, DOI 10.1177/0962280216683570; Vogele A, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0575-4; WHO, AN THER CHEM CLASS S; Wilson T, 2005, BMJ-BRIT MED J, V330, P657, DOI 10.1136/bmj.330.7492.657; World Health Organization, CLASS DIS ICD; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	29	28	28	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 18	2020	369								m1822	10.1136/bmj.m1822	http://dx.doi.org/10.1136/bmj.m1822			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OI3JW	32554566	hybrid, Green Published			2023-01-03	WOS:000583180300001
J	Zhang, JMX				Zhang, James X.			Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition	PLOS ONE			English	Article								The affordability of pharmaceuticals has been a major challenge in US health care. Generic substitution has been proposed as an important tool to reduce the costs, yet little is known how the prices of more expensive brand-name drugs would be affected by an increased utilization of generics. We aimed to examine the trend of overall utilization and the total costs of brand-name oral contraceptive pills (OCPs), the most widely used form of contraception, and its association with the pharmaceutical market concentration among the OCPs. Data from the Medical Expenditure Panel Survey (MEPS) 2011-2014, a nationally representative survey of healthcare utilization, were extracted on the utilization of generic and brand-name OCPs. A multiple logit regression analysis was conducted to assess the trend in utilization of brand-name OCPs over time. Total costs, including the costs to the payers and consumers, were synthesized. The Herfindahl-Hirschman Index (HHI), an index describing market concentration, was constructed, and a multiple regression analysis was conducted to evaluate the association between the brand-name OCP prices and the market share of individual brand-name drugs. The odds of utilizing brand-name drugs decreased steadily in 2012, 2013, and 2014 compared to 2012 (AOR 0.87, 0.73, 0.55, respectively, p<0.05) controlling for patient mix. Despite significant decline in total utilization, there was a 90% increase in the price of brand-name OCPs, resulting an 18% increase in revenue from 2011 to 2014 for the industry. During this time, pharmaceutical market concentration for OCPs increased (HHI increased from 1105 in 2011 to 2415 in 2014). Each percentage point increase in the market share by a brand-name OCPs was associated with a $3.12 increase in its price. Market mechanisms matter. Practitioners and policy makers need to take market mechanisms into account in order to realize the benefits of generic substitutions.	[Zhang, James X.] Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA	University of Chicago	Zhang, JMX (corresponding author), Univ Chicago, Dept Med, 5841 S Maryland Ave, Chicago, IL 60637 USA.	xzhang1@medicine.bsd.uchicago.edu	Zhang, James/HHS-8616-2022; Zhang, James X./AFN-7901-2022	Zhang, James X./0000-0002-6251-0474				Chee M, 2020, J AM ASSOC NURSE PRA, V32, P24, DOI 10.1097/JXX.0000000000000349; Chee M, 2018, JAMA INTERN MED, V178, P561, DOI 10.1001/jamainternmed.2017.7849; Colgan S, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008915; Collins SR, 2015, RISE HLTH CARE COVER; Darrow J, 2018, HLTH AFFAIRS; Dayal M, 2001, SEMIN REPROD MED, V19, P295, DOI 10.1055/s-2001-18637; Fuchs VR, 2018, JAMA-J AM MED ASSOC, V320, P971, DOI 10.1001/jama.2018.10779; Kaiser Family Foundation, OR CONTR PILLS; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Lenti G, 2019, J CLIN PHARM THER, V44, P579, DOI 10.1111/jcpt.12853; Samuelson, 2001, MICROECONOMICS; Segal JB, 2020, THER INNOV REGUL SCI, V54, P151, DOI 10.1007/s43441-019-00039-9; Shrank WH, 2009, HEALTH AFFAIR, V28, P546, DOI 10.1377/hlthaff.28.2.546; The United States Department of Justice, HERF HIRSCHM IND; The United States Department of Justice, HOR MERG GUID; The United States Department of Labor, MEAS PRIC CHANG CPI; Toverud EL, 2015, APPL HEALTH ECON HEA, V13, pS35, DOI 10.1007/s40258-014-0145-2; U.S Food and Drug Administration, GEN DRUGS QUEST ANSW; U.S. Food and Drug Administration, TYP APPL; Warraich H, 2018, JAMA INTERN MED, V178, P1140, DOI 10.1001/jamainternmed.2018.3047; World Health Organization, DRUGS MONEY PRICES A	21	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2020	15	6							e0234463	10.1371/journal.pone.0234463	http://dx.doi.org/10.1371/journal.pone.0234463			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6QL	32525965	Green Published, gold			2023-01-03	WOS:000542036800092
J	Generaal, JD; Lansdorp, CA; Boonstra, O; van Leeuwen, BL; Vanhauten, HAM; Stevenson, MG; Been, LB				Generaal, Jasmijn D.; Lansdorp, Corine A.; Boonstra, Onno; van Leeuwen, Barbara L.; Vanhauten, Hubertus A. M.; Stevenson, Marc G.; Been, Lukas B.			Hyperbaric oxygen therapy for radiation-induced tissue injury following sarcoma treatment: A retrospective analysis of a Dutch cohort	PLOS ONE			English	Article							SOFT-TISSUE; POSTOPERATIVE RADIOTHERAPY; WOUND COMPLICATIONS; OUTCOMES; SURGERY; PREDICTORS; GROWTH; TRIAL	Background and objectives Sarcomas are commonly managed by surgical resection combined with radiotherapy. Sarcoma treatment is frequently complicated by chronic wounds and late radiation tissue injury (LRTI). This study aims to gain insight in the use and results of hyperbaric oxygen therapy (HBOT) for radiation-induced complications following sarcoma treatment. Methods All sarcoma patients treated between 2006 and 2017 in one of the five centers of the Institute for Hyperbaric Oxygen in the Netherlands were included for retrospective analysis. Results Thirty patients were included, 18 (60.0%) patients were treated for chronic wounds and 12 (40.0%) for LRTI. Two patients with chronic wounds were excluded from analysis as HBOT was discontinued within five sessions. In 11 of 16 (68.8%) patients treated for chronic wounds, improved wound healing was seen. Nine of 12 (75.0%) patients treated for LRTI reported a decline in pain. Reduction of fibrosis was seen in five of eight patients (62.5%) treated for LRTI. Conclusions HBOT is safe and beneficial for treating chronic wounds and LRTI in the sarcoma population. Awaiting further prospective results, we recommend referring to HBOT centers more actively in patients experiencing impaired wound healing or symptoms of delayed radiation-induced tissue injury following multimodality sarcoma treatment.	[Generaal, Jasmijn D.; van Leeuwen, Barbara L.; Stevenson, Marc G.; Been, Lukas B.] Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Div Surg Oncol, Groningen, Netherlands; [Lansdorp, Corine A.; Boonstra, Onno] Inst Hyperbar Med, Rotterdam, Netherlands; [Vanhauten, Hubertus A. M.] Univ Groningen, Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands	University of Groningen; University of Groningen	Been, LB (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Div Surg Oncol, Groningen, Netherlands.	l.b.been@umcg.nl						Albertsmeier M, 2018, ANN SURG ONCOL, V25, P754, DOI 10.1245/s10434-017-6081-2; Allen S, 2012, SUPPORT CARE CANCER, V20, P2467, DOI 10.1007/s00520-012-1379-x; [Anonymous], SOFT TISS BON SARC S; [Anonymous], SOFT TISS BON SARC I; Bennett MH, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005005.pub4; Brown KR, 2011, J VASC SURG, V53, p15S, DOI 10.1016/j.jvs.2010.06.175; Clarke RE, 2008, INT J RADIAT ONCOL, V72, P134, DOI 10.1016/j.ijrobp.2007.12.048; Dalla-Favera R., 2014, CANCER CELL, V25, pe131, DOI DOI 10.1093/annonc/mdu254; Dalla-Favera R., 2014, CANCER CELL, V25, pe131, DOI DOI 10.1093/annonc/mdu256; Davis AM, 2005, RADIOTHER ONCOL, V75, P48, DOI 10.1016/j.radonc.2004.12.020; Davis AM, 2002, J CLIN ONCOL, V20, P4472, DOI 10.1200/JCO.2002.03.084; Davis AM, 2000, J SURG ONCOL, V73, P206, DOI 10.1002/(SICI)1096-9098(200004)73:4<206::AID-JSO4>3.0.CO;2-5; De Ru VJ, 1996, RADIOLOGIE STRALINGS, P25; Delanian S, 2004, RADIOTHER ONCOL, V73, P119, DOI 10.1016/j.radonc.2004.08.021; Felderhof JM, 2013, ACTA ONCOL, V52, P745, DOI 10.3109/0284186X.2012.709947; Feldmeier J, 2003, UNDERSEA HYPERBAR M, V30, P1; Feldmeier JJ, 2000, UNDERSEA HYPERBAR M, V27, P15; Feldmeier JJ, 2012, UNDERSEA HYPERBAR M, V39, P1121; Fletcher CDM., 2013, WHO CLASSIFICATION T, V5; Haas RLM, 2012, INT J RADIAT ONCOL, V84, P572, DOI 10.1016/j.ijrobp.2012.01.062; Hampson NB, 2012, CANCER-AM CANCER SOC, V118, P3860, DOI 10.1002/cncr.26637; Hills BA, 1999, MED HYPOTHESES, V52, P259, DOI 10.1054/mehy.1997.0640; MARX RE, 1990, AM J SURG, V160, P519, DOI 10.1016/S0002-9610(05)81019-0; MARX RE, 1983, J ORAL MAXIL SURG, V41, P283, DOI 10.1016/0278-2391(83)90294-X; Milovanova TN, 2009, J APPL PHYSIOL, V106, P711, DOI 10.1152/japplphysiol.91054.2008; Neovius EB, 1997, HEAD NECK-J SCI SPEC, V19, P315, DOI 10.1002/(SICI)1097-0347(199707)19:4<315::AID-HED10>3.0.CO;2-8; O'Sullivan B, 2002, LANCET, V359, P2235, DOI 10.1016/S0140-6736(02)09292-9; Stevenson MG, 2018, EJSO-EUR J SURG ONC, V44, P816, DOI 10.1016/j.ejso.2018.02.002; STINSON SF, 1991, INT J RADIAT ONCOL, V21, P1493, DOI 10.1016/0360-3016(91)90324-W; Teguh DN, 2009, INT J RADIAT ONCOL, V75, P711, DOI 10.1016/j.ijrobp.2008.11.056; Thom SR, 2006, AM J PHYSIOL-HEART C, V290, pH1378, DOI 10.1152/ajpheart.00888.2005; Tibbs MK, 1997, RADIOTHER ONCOL, V42, P99, DOI 10.1016/S0167-8140(96)01880-4	32	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2020	15	6							e0234419	10.1371/journal.pone.0234419	http://dx.doi.org/10.1371/journal.pone.0234419			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ0RE	32511259	Green Published, gold			2023-01-03	WOS:000540938100017
J	Wang, YP; Nakajima, T; Diao, P; Yamada, Y; Nakamura, K; Nakayama, J; Tanaka, N; Aoyama, T; Kamijo, Y				Wang, Yaping; Nakajima, Takero; Diao, Pan; Yamada, Yosuke; Nakamura, Kozo; Nakayama, Jun; Tanaka, Naoki; Aoyama, Toshifumi; Kamijo, Yuji			Polyunsaturated fatty acid deficiency affects sulfatides and other sulfated glycans in lysosomes through autophagy-mediated degradation	FASEB JOURNAL			English	Article						amyloid precursor protein; Erk1; 2; glycosaminoglycans; lysosome enzyme; mTOR; nutritional deprivation	ACTIVATED RECEPTOR-ALPHA; EARLY ALZHEIMERS-DISEASE; CHONDROITIN SULFATE; BETA-GLUCURONIDASE; HEPARAN-SULFATE; KIDNEY; BRAIN; MTOR; CELLS; GLYCOSAMINOGLYCANS	Metabolic changes in sulfatides and other sulfated glycans have been related to various diseases, including Alzheimer's disease (AD). However, the importance of polyunsaturated fatty acids (PUFA) in sulfated lysosomal substrate metabolism and its related disorders is currently unknown. We investigated the effects of deficiency or supplementation of PUFA on the metabolism of sulfatides and sulfated glycosaminoglycans (sGAGs) in sulfatide-rich organs (brain and kidney) of mice. A PUFA-deficient diet for over 5 weeks significantly reduced the sulfatide expression by increasing the sulfatide degradative enzymes arylsulfatase A and galactosylceramidase in brain and kidney. This sulfatide degradation was clearly associated with the activation of autophagy and lysosomal hyperfunction, the former of which was induced by suppression of the Erk/mTOR pathway. A PUFA-deficient diet also activated the degradation of sGAGs in the brain and kidney and that of amyloid precursor proteins in the brain, indicating an involvement in general lysosomal function and the early developmental process of AD. PUFA supplementation prevented all of the above abnormalities. Taken together, a PUFA deficiency might lead to sulfatide and sGAG degradation associated with autophagy activation and general lysosomal hyperfunction and play a role in many types of disease development, suggesting a possible benefit of prophylactic PUFA supplementation.	[Wang, Yaping; Nakajima, Takero; Diao, Pan; Yamada, Yosuke; Tanaka, Naoki; Aoyama, Toshifumi; Kamijo, Yuji] Shinshu Univ, Dept Metab Regulat, Sch Med, Matsumoto, Nagano, Japan; [Yamada, Yosuke; Kamijo, Yuji] Shinshu Univ, Dept Nephrol, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan; [Nakamura, Kozo] Shinshu Univ, Dept Biosci & Biotechnol, Fac Agr, Minamiminowa, Japan; [Nakayama, Jun] Shinshu Univ, Dept Mol Pathol, Sch Med, Matsumoto, Nagano, Japan	Shinshu University; Shinshu University; Shinshu University; Shinshu University	Kamijo, Y (corresponding author), Shinshu Univ, Dept Nephrol, Sch Med, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	yujibeat@shinshu-u.ac.jp		Tanaka, Naoki/0000-0002-3212-3836	 [18K08204]		Grant-in-Aid for Scientific Research (Kakenhi) in Japan, Grant/Award Number: 18K08204	Aggleton JP, 2016, BRAIN, V139, P1877, DOI 10.1093/brain/aww083; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Ashabi G, 2013, TOXICOL IN VITRO, V27, P1780, DOI 10.1016/j.tiv.2013.05.005; Bankaitis VA, 2015, EMBO J, V34, P978, DOI 10.15252/embj.201591392; Bazinet RP, 2014, NAT REV NEUROSCI, V15, P771, DOI 10.1038/nrn3820; Belibi F, 2011, AM J PHYSIOL-RENAL, V300, pF1235, DOI 10.1152/ajprenal.00348.2010; Cheng BJ, 2018, FOOD CHEM TOXICOL, V122, P143, DOI 10.1016/j.fct.2018.10.030; Cheng H, 2013, J NEUROCHEM, V127, P733, DOI 10.1111/jnc.12368; Cheng H, 2010, J LIPID RES, V51, P1599, DOI 10.1194/jlr.D004077; DECATERINA R, 1994, AM J KIDNEY DIS, V24, P397, DOI 10.1016/S0272-6386(12)80896-1; Dehay B, 2010, J NEUROSCI, V30, P12535, DOI 10.1523/JNEUROSCI.1920-10.2010; DESHMUKH GD, 1994, J LIPID RES, V35, P1611; DONADIO JV, 1991, MAYO CLIN PROC, V66, P1018, DOI 10.1016/S0025-6196(12)61725-X; Dunlop EA, 2014, SEMIN CELL DEV BIOL, V36, P121, DOI 10.1016/j.semcdb.2014.08.006; Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123; Fabelo N, 2011, MOL MED, V17, P1107, DOI 10.2119/molmed.2011.00119; Han XL, 2010, MOL NEUROBIOL, V41, P97, DOI 10.1007/s12035-009-8092-x; Han XL, 2002, J NEUROCHEM, V82, P809, DOI 10.1046/j.1471-4159.2002.00997.x; HARA A, 1978, ANAL BIOCHEM, V90, P420, DOI 10.1016/0003-2697(78)90046-5; Harvey SJ, 2012, METHODS MOL BIOL, V836, P259, DOI 10.1007/978-1-61779-498-8_17; He LY, 2014, NEPHRON CLIN PRACT, V127, P56, DOI 10.1159/000363677; Honke K, 2002, P NATL ACAD SCI USA, V99, P4227, DOI 10.1073/pnas.032068299; Hosono T, 2015, BRAIN RES, V1613, P92, DOI 10.1016/j.brainres.2015.04.005; Hu BL, 2015, AUTOPHAGY, V11, P503, DOI 10.1080/15548627.2015.1017184; Huang XY, 2013, J NEPHROL, V26, P960, DOI 10.5301/jn.5000284; INNIS SM, 1991, PROG LIPID RES, V30, P39, DOI 10.1016/0163-7827(91)90006-Q; Ishibashi T, 2002, J NEUROSCI, V22, P6507; Ishii M, 2015, CELL METAB, V22, P761, DOI 10.1016/j.cmet.2015.08.016; Ishizuka I, 1997, PROG LIPID RES, V36, P245, DOI 10.1016/S0163-7827(97)00011-8; Jeon SB, 2008, J IMMUNOL, V181, P8077, DOI 10.4049/jimmunol.181.11.8077; Jonsson M, 2012, DEMENT GERIATR COGN, V34, P61, DOI 10.1159/000341576; Kadomatsu K, 2014, ARCH BIOCHEM BIOPHYS, V558, P36, DOI 10.1016/j.abb.2014.06.009; Kamijo Y, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000018403.61042.56; Kamijo Y, 2007, J AM SOC NEPHROL, V18, P3089, DOI 10.1681/ASN.2007020238; Kelsey KM, 2020, CELL TISSUE RES, V379, P561, DOI 10.1007/s00441-019-03144-1; Kim IC, 2016, J MASS SPECTROM, V51, P182, DOI 10.1002/jms.3736; Kim SG, 2013, MOL CELLS, V35, P463, DOI 10.1007/s10059-013-0138-2; Kocaturk NM, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00128; Lafourcade M, 2011, NAT NEUROSCI, V14, P345, DOI 10.1038/nn.2736; Lemos CCS, 2013, BRAZ J MED BIOL RES, V46, P567, DOI 10.1590/1414-431X20132339; Lensen JFM, 2005, J AM SOC NEPHROL, V16, P1279, DOI 10.1681/ASN.2004050413; Li G, 2007, ANAL BIOCHEM, V362, P1, DOI 10.1016/j.ab.2006.12.024; Li HY, 2016, AUTOPHAGY, V12, P1472, DOI 10.1080/15548627.2016.1190071; Li XJ, 2017, ACTA HISTOCHEM, V119, P439, DOI 10.1016/j.acthis.2017.04.001; Li YL, 2015, NEUROSCI LETT, V600, P206, DOI 10.1016/j.neulet.2015.06.024; Lindahl B, 1996, J BIOL CHEM, V271, P16991, DOI 10.1074/jbc.271.29.16991; Lu J, 2003, J NUTR, V133, P180, DOI 10.1093/jn/133.1.180; Ludewig S, 2017, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00161; Maeda N, 2011, NEUROCHEM RES, V36, P1228, DOI 10.1007/s11064-010-0324-y; Marcus J, 2006, GLIA, V53, P372, DOI 10.1002/glia.20292; Marsching C, 2011, ANAL BIOANAL CHEM, V401, P53, DOI 10.1007/s00216-011-4802-0; Masola V, 2014, NEPHROL DIAL TRANSPL, V29, pI74, DOI 10.1093/ndt/gft389; McLaughlin RW, 2006, PROTEIN SCI, V15, P1710, DOI 10.1110/ps.051997606; Mehra S, 2018, J BIOL CHEM, V293, P12975, DOI 10.1074/jbc.RA118.004267; Melk A, 2016, AUTOPHAGY, V12, P596, DOI 10.1080/15548627.2015.1135284; Huynh MB, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0209573; Miyata S, 2016, FRONT BIOSCI-LANDMRK, V21, P1330, DOI 10.2741/4460; Moriyama T, 2018, INTERNAL MED, V57, P173, DOI 10.2169/internalmedicine.9155-17; Nakajima T, 2017, TOHOKU J EXP MED, V242, P229, DOI 10.1620/tjem.242.229; Niso-Santano M, 2015, AUTOPHAGY, V11, P575, DOI 10.1080/15548627.2015.1017222; Niso-Santano M, 2015, EMBO J, V34, P1025, DOI 10.15252/embj.201489363; Nixon RA, 2005, J NEUROPATH EXP NEUR, V64, P113, DOI 10.1093/jnen/64.2.113; Palmieri M, 2011, HUM MOL GENET, V20, P3852, DOI 10.1093/hmg/ddr306; POLLACK SJ, 1995, NEUROSCI LETT, V197, P211, DOI 10.1016/0304-3940(95)11939-T; Puglielli L, 2003, J BIOL CHEM, V278, P19777, DOI 10.1074/jbc.M300466200; Reine TM, 2013, J HISTOCHEM CYTOCHEM, V61, P606, DOI 10.1369/0022155413494392; Ren HX, 2017, FASEB J, V31, P282, DOI 10.1096/fj.201600896; Rice HC, 2019, SCIENCE, V363, P143, DOI 10.1126/science.aao4827; Schreiber A, 2014, BBA-MOL CELL RES, V1843, P163, DOI 10.1016/j.bbamcr.2013.03.019; Settembre C, 2012, EMBO J, V31, P1095, DOI 10.1038/emboj.2012.32; Settembre C, 2011, SCIENCE, V332, P1429, DOI 10.1126/science.1204592; Sharma A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050751; SNOW AD, 1990, AM J PATHOL, V137, P1253; Spector AA, 2015, J LIPID RES, V56, P11, DOI 10.1194/jlr.R055095; Spence Justin, 2017, Consult Pharm, V32, P412, DOI 10.4140/TCP.n.2017.412; Stettner P, 2013, P NATL ACAD SCI USA, V110, P9998, DOI 10.1073/pnas.1217775110; Su HM, 2010, J NUTR BIOCHEM, V21, P364, DOI 10.1016/j.jnutbio.2009.11.003; Su LY, 2015, AUTOPHAGY, V11, P1745, DOI 10.1080/15548627.2015.1082020; SUKEGAWA K, 1985, J INHERIT METAB DIS, V8, P145, DOI 10.1007/BF01819300; Sun YJ, 2013, FOOD CHEM TOXICOL, V51, P53, DOI 10.1016/j.fct.2012.09.012; Sun Y, 2013, AUTOPHAGY, V9, P1115, DOI 10.4161/auto.24919; Suttkus A, 2016, MOL NEUROBIOL, V53, P73, DOI 10.1007/s12035-014-8990-4; Takahashi T, 2012, J LIPID RES, V53, P1437, DOI 10.1194/jlr.R026682; Thomas J, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/172801; Vogler C, 2003, P NATL ACAD SCI USA, V100, P2669, DOI 10.1073/pnas.0437941100; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xiao SY, 2013, ADV EXP MED BIOL, V991, P27, DOI 10.1007/978-94-007-6331-9_3; Xing SH, 2012, AUTOPHAGY, V8, P63, DOI 10.4161/auto.8.1.18217; Yamada Y, 2019, GLYCOCONJUGATE J, V36, P1, DOI 10.1007/s10719-018-9850-7; Yu WH, 2004, INT J BIOCHEM CELL B, V36, P2531, DOI 10.1016/j.biocel.2004.05.010; ZALC B, 1978, FEBS LETT, V92, P92, DOI 10.1016/0014-5793(78)80729-7; Zeng YC, 2008, J NEUROCHEM, V106, P1275, DOI 10.1111/j.1471-4159.2008.05481.x; Zhang BY, 2019, J VIROL, V93, DOI 10.1128/JVI.00172-19; Zhang J, 2012, J NEUROCHEM, V120, P564, DOI 10.1111/j.1471-4159.2011.07496.x; Zhang Z, 2016, NAGOYA J MED SCI, V78, P293; Zheng H, 2018, BBA-MOL BASIS DIS, V1864, P263, DOI 10.1016/j.bbadis.2017.10.028	96	2	2	2	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2020	34	7					9594	9614		10.1096/fj.202000030RR	http://dx.doi.org/10.1096/fj.202000030RR		JUN 2020	21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MG8UN	32501606	Green Submitted, Green Published			2023-01-03	WOS:000539539500001
J	Angus, DC; Derde, L; Al-Beidh, F; Annane, D; Arabi, Y; Beane, A; Van Bentum-Puijk, W; Berry, L; Bhimani, Z; Bonten, M; Bradbury, C; Brunkhorst, F; Buxton, M; Buzgau, A; Cheng, AC; de Jong, M; Detry, M; Estcourt, L; Fitzgerald, M; Goossens, H; Green, C; Haniffa, R; Higgins, AM; Horvat, C; Hullegie, SJ; Kruger, P; Lamontagne, F; Lawler, PR; Linstrum, K; Litton, E; Lorenzi, E; Marshall, J; McAuley, D; McGlothin, A; McGuinness, S; McVerry, B; Montgomery, S; Mouncey, P; Murthy, S; Nichol, A; Parke, R; Parker, J; Rowan, K; Sanil, A; Santos, M; Saunders, C; Seymour, C; Turner, A; van de Veerdonk, F; Venkatesh, B; Zarychanski, R; Berry, S; Lewis, RJ; McArthur, C; Webb, SA; Gordon, AC				Angus, Derek C.; Derde, Lennie; Al-Beidh, Farah; Annane, Djillali; Arabi, Yaseen; Beane, Abigail; Van Bentum-Puijk, Wilma; Berry, Lindsay; Bhimani, Zahra; Bonten, Marc; Bradbury, Charlotte; Brunkhorst, Frank; Buxton, Meredith; Buzgau, Adrian; Cheng, Allen C.; de Jong, Menno; Detry, Michelle; Estcourt, Lise; Fitzgerald, Mark; Goossens, Herman; Green, Cameron; Haniffa, Rashan; Higgins, Alisa M.; Horvat, Christopher; Hullegie, Sebastiaan J.; Kruger, Peter; Lamontagne, Francois; Lawler, Patrick R.; Linstrum, Kelsey; Litton, Edward; Lorenzi, Elizabeth; Marshall, John; McAuley, Daniel; McGlothin, Anna; McGuinness, Shay; McVerry, Bryan; Montgomery, Stephanie; Mouncey, Paul; Murthy, Srinivas; Nichol, Alistair; Parke, Rachael; Parker, Jane; Rowan, Kathryn; Sanil, Ashish; Santos, Marlene; Saunders, Christina; Seymour, Christopher; Turner, Anne; van de Veerdonk, Frank; Venkatesh, Balasubramanian; Zarychanski, Ryan; Berry, Scott; Lewis, Roger J.; McArthur, Colin; Webb, Steven A.; Gordon, Anthony C.			Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								IMPORTANCE Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. OBJECTIVE To determine whether hydrocortisone improves outcome for patients with severe COVID-19. DESIGN, SETTING, AND PARTICIPANTS An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. INTERVENTIONS The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). MAIN OUTCOMES AND MEASURES The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). RESULTS After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0(IQR, -1 to 15), 0(IQR, -1 to 13), and 0(-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. CONCLUSIONS AND RELEVANCE Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions.	[Angus, Derek C.; Horvat, Christopher; Linstrum, Kelsey; Montgomery, Stephanie; Seymour, Christopher] Univ Pittsburgh, Clin Res Invest & Syst Modeling Acute Illness CRI, Dept Crit Care Med, Sch Med, Pittsburgh, PA 15261 USA; [Angus, Derek C.; Horvat, Christopher; Montgomery, Stephanie; Seymour, Christopher] UPMC Hlth Syst Off Healthcare Innovat, Pittsburgh, PA USA; [Derde, Lennie; Van Bentum-Puijk, Wilma; Bonten, Marc; Hullegie, Sebastiaan J.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Derde, Lennie] Univ Med Ctr Utrecht, Intens Care Ctr, Utrecht, Netherlands; [Al-Beidh, Farah; Gordon, Anthony C.] Imperial Coll London, Dept Surg & Canc, Div Anaesthet Pain Med & Intens Care Med, London, England; [Al-Beidh, Farah; Gordon, Anthony C.] Imperial Coll Healthcare NHS Trust, London, England; [Annane, Djillali] Hop Raymond Poincare, AP HP, Intens Care Unit, Paris, France; [Annane, Djillali] Univ Versailles, Simone Veil Sch Med, Versailles, France; [Annane, Djillali] Univ Paris Saclay, Garches, France; [Arabi, Yaseen] King Saud Bin Abdulaziz Univ Hlth Sci, Coll Med, King Abdullah Int Med Res Ctr, Intens Care Dept,King Abdulaziz Med City, Riyadh, Saudi Arabia; [Beane, Abigail] Univ Oxford, Nuffield Dept Clin Med, Oxford, England; [Berry, Lindsay; Detry, Michelle; Fitzgerald, Mark; Lorenzi, Elizabeth; McGlothin, Anna; Sanil, Ashish; Saunders, Christina; Berry, Scott; Lewis, Roger J.] Berry Consultants LLC, Austin, TX USA; [Bhimani, Zahra; Marshall, John; Santos, Marlene] St Michaels Hosp, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Bonten, Marc] Univ Med Ctr Utrecht, Dept Med Microbiol, Utrecht, Netherlands; [Bradbury, Charlotte] Bristol Royal Informatory, Bristol, Avon, England; [Bradbury, Charlotte] Univ Bristol, Bristol, Avon, England; [Brunkhorst, Frank] Jena Univ Hosp, Ctr Clin Studies & Ctr Sepsis Control & Care CSCC, Dept Anesthesiol & Intens Care Med, Jena, Germany; [Buxton, Meredith] Global Coalit Adapt Res, San Francisco, CA USA; [Buzgau, Adrian] Monash Univ, Helix, Melbourne, Vic, Australia; [Cheng, Allen C.] Alfred Hlth, Infect Prevent & Healthcare Epidemiol Unit, Melbourne, Vic, Australia; [Cheng, Allen C.; Green, Cameron; Higgins, Alisa M.; McGuinness, Shay; Nichol, Alistair; Parker, Jane; Webb, Steven A.] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Sch Epidemiol & Prevent Med, Melbourne, Vic, Australia; [de Jong, Menno] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Med Microbiol, Amsterdam, Netherlands; [Goossens, Herman] Antwerp Univ Hosp, Dept Microbiol, Antwerp, Belgium; [Estcourt, Lise] NHS Blood & Transplant, Bristol, Avon, England; [Estcourt, Lise] Univ Oxford, Med Sci Div, Transfus Med, Oxford, England; [Haniffa, Rashan] Network Improving Crit Care Syst & Training, Colombo, Sri Lanka; [Haniffa, Rashan] Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand; [Kruger, Peter] Princess Alexandra Hosp, Intens Care Unit, Brisbane, Qld, Australia; [Lamontagne, Francois] Univ Sherbrooke, Sherbrooke, PQ, Canada; [Lawler, Patrick R.] Univ Toronto, Univ Hlth Network, Peter Munk Cardiac Ctr, Interdept Div Crit Care Med,Cardiac Intens Care U, Toronto, ON, Canada; [Litton, Edward; Webb, Steven A.] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia; [Marshall, John] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [McAuley, Daniel] Queens Univ Belfast, Ctr Expt Med, Sch Med Dent & Biomed Sci, Belfast, Antrim, North Ireland; [McGuinness, Shay; Parke, Rachael] Auckland City Hosp, Cardiothorac & Vasc Intens Care Unit, Auckland, New Zealand; [McGuinness, Shay; Parke, Rachael] Hlth Res Council New Zealand, Wellington, New Zealand; [McGuinness, Shay; Parke, Rachael; Turner, Anne; McArthur, Colin] Med Res Inst New Zealand, Wellington, New Zealand; [McVerry, Bryan] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA; [Mouncey, Paul; Rowan, Kathryn] Intens Care Natl Audit & Res Ctr ICNARC, Clin Trials Unit, London, England; [Murthy, Srinivas] Univ British Columbia, Sch Med, Vancouver, BC, Canada; [Nichol, Alistair] St Vincents Univ Hosp, Dept Anesthesia & Intens Care, Dublin, Ireland; [Nichol, Alistair] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland; [Nichol, Alistair] Alfred Hlth, Dept Intens Care, Melbourne, Vic, Australia; [Parke, Rachael] Univ Auckland, Sch Nursing, Auckland, New Zealand; [van de Veerdonk, Frank] Radboud Univ Nijmegen, Radboud Inst Mol Life Sci, Med Ctr, Nijmegen, Netherlands; [Venkatesh, Balasubramanian] Princess Alexandra Hosp, Southside Clin Unit, Brisbane, Qld, Australia; [Venkatesh, Balasubramanian] George Inst Global Hlth, Sydney, NSW, Australia; [Zarychanski, Ryan] Univ Manitoba, Dept Med Crit Care & Hematol Med Oncol, Winnipeg, MB, Canada; [Lewis, Roger J.] Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA; [Lewis, Roger J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Emergency Med, Los Angeles, CA 90095 USA; [McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [Webb, Steven A.] St John God Hosp, Subiaco, WA, Australia	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Imperial College London; Imperial College London; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay; King Saud Bin Abdulaziz University for Health Sciences; University of Oxford; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; Utrecht University; Utrecht University Medical Center; University of Bristol; Friedrich Schiller University of Jena; Monash University; Monash University; University of Amsterdam; University of Antwerp; University of Oxford; Mahidol Oxford Tropical Medicine Research Unit (MORU); University of Sherbrooke; University of Toronto; Peter Munk Cardiac Centre; University Toronto Affiliates; University Health Network Toronto; University of Western Australia; University of Toronto; Queens University Belfast; Auckland City Hospital; Medical Research Institute Of New Zealand; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Intensive Care National Audit & Research Centre; University of British Columbia; University College Dublin; Saint Vincent's University Hospital; University College Dublin; University of Auckland; Radboud University Nijmegen; George Institute for Global Health; University of Sydney; University of Manitoba; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Auckland City Hospital; St John of God Health Care	Angus, DC (corresponding author), Univ Pittsburgh, Dept Crit Care Med, 3550 Terrace St,614 Scaife Hall, Pittsburgh, PA 15261 USA.	angusdc@upmc.edu	Carrier, François Martin/AAE-4623-2021; Gordon, Anthony/A-3472-2012; Zarychanski, Ryan/AAB-6369-2022; Forton, Daniel/AAN-6669-2020; McVerry, Bryan/AAS-7790-2021; Dushianthan, Ahilanandan/T-8390-2019; Parke, Rachael/AAX-4004-2021; Bégin, Philippe/AAU-9126-2021; Neal, Matthew/GMW-5601-2022; Muller, Grégoire/I-2650-2018; Tong, Steven/N-2353-2013; van de Veerdonk, Frank L/C-7256-2008; Derde, Lennie/AAF-2725-2021; Presneill, Jeffrey/B-4894-2012; Fysh, Edward/E-2855-2018; litton, edward/C-5384-2017; Summers, Charlotte/A-6973-2012	Carrier, François Martin/0000-0003-0310-0616; Gordon, Anthony/0000-0002-0419-547X; McVerry, Bryan/0000-0002-1175-4874; Dushianthan, Ahilanandan/0000-0002-0165-3359; Parke, Rachael/0000-0003-4209-0334; Neal, Matthew/0000-0001-8931-6236; Muller, Grégoire/0000-0002-9284-3560; Tong, Steven/0000-0002-1368-8356; van de Veerdonk, Frank L/0000-0002-1121-4894; Derde, Lennie/0000-0002-3577-5629; Farahi, Neda/0000-0001-5793-3205; Jhanji, Shaman/0000-0002-1116-628X; Munoz, Rosana/0000-0002-9210-3976; Young, Paul/0000-0002-3428-3083; Murthy, Srinivas/0000-0002-9476-839X; Lamontagne, Francois/0000-0002-0360-3427; Dark, Paul/0000-0003-3309-0164; Binnie, Alexandra/0000-0003-2969-8177; Puxty, Kathryn/0000-0002-5742-6171; Presneill, Jeffrey/0000-0001-7177-7667; Duffy, Eamon/0000-0002-4515-5116; Beane, Abigail/0000-0001-7046-1580; Kiiski, Heikki/0000-0002-5235-1772; King, Andrew/0000-0002-9809-0563; Venkatesh, Bala/0000-0002-3234-5244; McGlothlin, Anna/0000-0002-9079-6166; Hormis, Anil/0000-0001-5510-7639; Parekh, Dhruv/0000-0002-1508-8362; Hagel, Stefan/0000-0003-2999-6131; Fysh, Edward/0000-0003-1126-3773; Marin-Corral, Judith/0000-0003-1320-4427; Lowe, Benjamin/0000-0001-6131-7050; Haniffa, Rashan/0000-0002-8288-449X; McGuinness, Shay/0000-0003-0620-4787; Turner, Anne/0000-0002-4092-1424; Bannard-Smith, Jonathan/0000-0001-7120-480X; Hills, Thomas/0000-0003-0322-5822; Charlewood, Richard/0000-0002-1798-1189; PARRILLA, FRANCISCO JOSE/0000-0002-9770-2759; Nikitas, Nikitas/0000-0002-1750-1579; Hays, Leanne/0000-0002-6936-1459; Rowan, Kathryn/0000-0001-8217-5602; Laffan, Michael/0000-0002-8268-3268; litton, edward/0000-0002-5125-6829; Mouncey, Paul/0000-0002-8510-8517; Summers, Charlotte/0000-0002-7269-2873; Baillie, John Kenneth/0000-0001-5258-793X; Nichol, Alistair/0000-0002-4689-1238; Forton, Daniel/0000-0002-0903-9169	Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) consortium by the European Union, FP7-HEALTH-2013-INNOVATION-1 [602525]; Australian National Health and Medical Research Council [APP1101719]; New Zealand Health Research Council [161 631]; Canadian Institute of Health Research Strategy for Patient -Oriented Research Innovative Clinical Trials Program [158584]; UK National Institute for Health Research (NIHR); NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland [CTN 2014-012]; Breast Cancer Research Foundation; French Ministry of Health [PHRC-20-0147]; Minderoo Foundation; UPMC Learning While Doing Program	Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) consortium by the European Union, FP7-HEALTH-2013-INNOVATION-1; Australian National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); New Zealand Health Research Council(Health Research Council of New Zealand); Canadian Institute of Health Research Strategy for Patient -Oriented Research Innovative Clinical Trials Program(Canadian Institutes of Health Research (CIHR)); UK National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Imperial Biomedical Research Centre; Health Research Board of Ireland; Breast Cancer Research Foundation; French Ministry of Health; Minderoo Foundation; UPMC Learning While Doing Program	This study was supported by the Platform for European Preparedness Against (Re-) emerging Epidemics (PREPARE) consortium by the European Union, FP7-HEALTH-2013-INNOVATION-1 (grant 602525), the Australian National Health and Medical Research Council (grant APP1101719), the New Zealand Health Research Council (grant 161 631), the Canadian Institute of Health Research Strategy for Patient -Oriented Research Innovative Clinical Trials Program (grant 158584), the UK National Institute for Health Research (NIHR) and the NIHR Imperial Biomedical Research Centre, the Health Research Board of Ireland (grant CTN 2014-012), the UPMC Learning While Doing Program, the Breast Cancer Research Foundation, the French Ministry of Health (grant PHRC-20-0147), and the Minderoo Foundation.	Alhazzani W, 2020, INTENS CARE MED, V48, P440, DOI [10.1097/CCM.0000000000004363, DOI 10.1007/s00134-020-06022-5]; Angus DC, 2020, ANN AM THORAC SOC, V17, P879, DOI 10.1513/AnnalsATS.202003-192SD; Angus DC, 2015, JAMA-J AM MED ASSOC, V314, P767, DOI 10.1001/jama.2015.7762; Annane D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002243.pub3; [Anonymous], 2020, JAMA, DOI 10.1001/jama.2020.17023; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Brenner EJ, 2020, GASTROENTEROLOGY, V159, P481, DOI 10.1053/j.gastro.2020.05.032; China National Health Commission, CHIN CLIN GUID COVID, V7th; Chopra Amit, 2020, Crit Care Explor, V2, pe0143, DOI 10.1097/CCE.0000000000000143; Ewald H, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006150.pub2; Fadel R, 2020, CLIN INFECT DIS, V71, P2114, DOI 10.1093/cid/ciaa601; Horby P, 2020, NEW ENGL J MED, DOI [10.1101/2020.06.22.20137273:24, DOI 10.1056/NEJMOA2021436, 10.1101/2020.06.22.20137273, 10.1101/2020.06.22.20137273v1, DOI 10.1101/2020.07.15.20151852]; Johns Hopkins University of Medicine Coronavirus Resource Center, COVID 19 US; Kumbhani DJ, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.117.003610; Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093; Laterre PF, 2019, JAMA-J AM MED ASSOC, V322, P1476, DOI 10.1001/jama.2019.14607; Li H, 2020, LEUKEMIA, V34, P1503, DOI [10.1038/s41375-020-0848-3, 10.1007/s11263-020-01364-5]; Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7; Quintana M, 2017, JAMA-J AM MED ASSOC, V318, P1605, DOI 10.1001/jama.2017.15574; Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2; Siemieniuk RAC, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2980; World Health Organization, WHO CLIN MAN COVID 1; Ye ZK, 2020, CAN MED ASSOC J, V192, pE756, DOI 10.1503/cmaj.200645	23	409	422	2	41	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	2020	324	13					1317	1329		10.1001/jama.2020.17022	http://dx.doi.org/10.1001/jama.2020.17022			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OS4SZ	32876697	Green Published, Green Submitted, Bronze, Green Accepted			2023-01-03	WOS:000590156000016
J	Yin, HP; Ma, XC; He, YL; Liang, RJ; Wang, YX; Zhang, M; Mao, L; Jing, MX				Yin, Hongpo; Ma, Xiaochen; He, Yanli; Liang, Rujiang; Wang, Yongxin; Zhang, Mei; Mao, Lu; Jing, Mingxia			Effect of an outpatient copayment scheme on health outcomes of hypertensive adults in a community-managed population in Xinjiang, China	PLOS ONE			English	Article							FACILITY QUALITY IMPROVEMENT; DIFFERENCE-IN-DIFFERENCES; BLOOD-PRESSURE; INSURANCE-COVERAGE; BURDEN; STROKE; MORTALITY; NIGERIA; EQ-5D; RISK	Hypertension remains the leading risk factor for death and disability in China, and the ability of hypertensive patients to pay for outpatient care and medication has become a critical issue. To report the effect of an outpatient copayment scheme on health outcomes of hypertensive adults in a community-managed population in Xinjiang, we compared changes in outcomes between insured and uninsured groups from baseline to the first follow-up appointment in a community-managed hypertensive population and evaluated these changes based on propensity score matching and the difference-in-difference method. A total of 1,095 individuals in a community-managed hypertension population were selected for investigation at baseline, among which 805 (73.5%) had follow-up data and 749 (68.4%) were included in our analysis. After accounting for the self-reported severity of hypertension and individual characteristics, there were statistically significant improvements in drug treatment of hypertension and self-reported health. We also found increases in drug treatment for hypertension between groups, after correcting for confounding variables (Odds Ratio, OR 8.05, 95% Confidence interval, CI, 1.31-49.35), and in self-reported health between groups after correcting confounders (OR 1.96, 95% CI, 1.12 to 3.42). Adjusted estimates (confounding variables) were corrected for age, sex, income, marital status, education level, employment, family size, self-reported severity of hypertension, course of hypertension, and number of medications. As a result, decreased outpatient copayment was associated with an increase in antihypertensive treatment coverage, and an improvement in self-reported health among community-managed hypertensive populations in Xinjiang, China.	[Yin, Hongpo; He, Yanli; Liang, Rujiang; Wang, Yongxin; Zhang, Mei; Mao, Lu; Jing, Mingxia] Shihezi Univ, Sch Med, Dept Publ Hlth, Shihezi, Xinjiang, Peoples R China; [Ma, Xiaochen] Peking Univ, China Ctr Hlth Dev Studies, Beijing, Peoples R China	Shihezi University; Peking University	Jing, MX (corresponding author), Shihezi Univ, Sch Med, Dept Publ Hlth, Shihezi, Xinjiang, Peoples R China.	jingmngxia163@163.com			National Natural Science Foundation of China [71363047]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project was funded by the National Natural Science Foundation of China, grant number 71363047.(http://www.nsfc.gov.cn/) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Acharya A, 2013, WORLD BANK RES OBSER, V28, P236, DOI 10.1093/wbro/lks009; article GG, 2017, STAT COMM 2016; Baicker K, 2013, NEW ENGL J MED, V368, P1713, DOI 10.1056/NEJMsa1212321; Bureau. XPaCCHRaSS, 2016, OP FURTH IMPR LEV ME; CALDWELL JR, 1970, J CHRON DIS, V22, P579, DOI 10.1016/0021-9681(70)90034-2; China. NBoSo, 2015, CHIN STAT YB 2015; COLLINS R, 1994, BRIT MED BULL, V50, P272, DOI 10.1093/oxfordjournals.bmb.a072892; D?az Y., 2013, IMPACT UNIVERSAL COV; De Geest Sabina, 2003, Eur J Cardiovasc Nurs, V2, P323; Dimick JB, 2014, JAMA-J AM MED ASSOC, V312, P2401, DOI 10.1001/jama.2014.16153; Doiron D, 2015, APPL ECON, V47, P180, DOI 10.1080/00036846.2014.967382; Donald SG, 2007, REV ECON STAT, V89, P221, DOI 10.1162/rest.89.2.221; Erlangga D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219731; Finkelstein A, 2012, Q J ECON, V127, P1057, DOI 10.1093/qje/qjs020; Freeman JD, 2008, MED CARE, V46, P1023, DOI 10.1097/MLR.0b013e318185c913; Furberg CD, 2002, JAMA-J AM MED ASSOC, V288, P2981; Gao Y., 2014, THESIS; Guo SY, 2014, PROPENSITY SCORE ANA; Hadley J, 2007, JAMA-J AM MED ASSOC, V297, P1073, DOI 10.1001/jama.297.10.1073; Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X; Hendriks ME, 2016, INT J CARDIOL, V202, P477, DOI 10.1016/j.ijcard.2015.09.036; Hendriks ME, 2014, JAMA INTERN MED, V174, P555, DOI 10.1001/jamainternmed.2013.14458; Institute for Health Metrics and Evaluation (IHME), 2015, GBD COMP DAT VIS; Kiiskinen U, 1998, J HYPERTENS, V16, P1103, DOI 10.1097/00004872-199816080-00004; Kim AS, 2011, CIRCULATION, V124, P314, DOI 10.1161/CIRCULATIONAHA.111.018820; Lewington S, 2002, LANCET, V360, P1903, DOI 10.1016/S0140-6736(02)11911-8; Lewington S, 2016, JAMA INTERN MED, V176, P524, DOI 10.1001/jamainternmed.2016.0190; Li YC, 2017, INT J CARDIOL, V227, P516, DOI 10.1016/j.ijcard.2016.10.110; Liu GG, 2014, VALUE HEALTH, V17, P597, DOI 10.1016/j.jval.2014.05.007; Liu Ming, 2014, Beijing Da Xue Xue Bao Yi Xue Ban, V46, P782; Lu JP, 2017, LANCET, V390, P2549, DOI [10.1016/S0140-6736(17)32478-9, 10.1016/s0140-6736(17)32478-9]; Maridell'Olmo M, 2010, WORLD BANK PUBLICATI, V25, P441; Mechanisms Clinical Strategies., 2015, 12 INT C AD PD NIC F, V15, P1, DOI DOI 10.1520/D6415; Miilunpalo S, 1997, J CLIN EPIDEMIOL, V50, P517, DOI 10.1016/S0895-4356(97)00045-0; Olsen MH, 2016, LANCET, V388, P2665, DOI 10.1016/S0140-6736(16)31134-5; Osborne NH, 2015, JAMA-J AM MED ASSOC, V313, P496, DOI 10.1001/jama.2015.25; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Rabin R, 2001, ANN MED, V33, P337, DOI 10.3109/07853890109002087; Ryan AM, 2015, HEALTH SERV RES, V50, P1211, DOI 10.1111/1475-6773.12270; Shea DG, 1997, IND LABOR RELATI JUL; Sommers BD, 2017, NEW ENGL J MED, V377, P586, DOI 10.1056/NEJMsb1706645; Stryjewski TP, 2014, HEALTH SERV RES, V49, P2086, DOI 10.1111/1475-6773.12196; Thomas H, 2018, GLOB HEART, V13, P143, DOI 10.1016/j.gheart.2018.09.511; Wang J, 2017, J STROKE CEREBROVASC, V26, P509, DOI 10.1016/j.jstrokecerebrovasdis.2016.12.002; Wang ZW, 2018, CIRCULATION, V137, P2344, DOI 10.1161/CIRCULATIONAHA.117.032380; World Health Organization. WPRO, WPRO GLOB STAT REP N; Wouters OJ, 2016, HEALTH ECON POLICY L, V11, P321, DOI 10.1017/S1744133116000025; Xi B, 2014, INT J CARDIOL, V174, P736, DOI 10.1016/j.ijcard.2014.04.098; Xiang-Jun LI, 2014, CHINESE HLTH EC; Xue XD, 2015, CHINESE J HLTH POLIC; Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15083-4	51	2	2	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2020	15	9							e0238980	10.1371/journal.pone.0238980	http://dx.doi.org/10.1371/journal.pone.0238980			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NR9MU	32915916	Green Published, gold			2023-01-03	WOS:000571887500078
J	Tedla, K; Medhin, G; Berhe, G; Mulugeta, A; Berhe, N				Tedla, Kiros; Medhin, Girmay; Berhe, Gebretsadik; Mulugeta, Afework; Berhe, Nega			Factors associated with treatment initiation delay among new adult pulmonary tuberculosis patients in Tigray, Northern Ethiopia	PLOS ONE			English	Article							DIAGNOSIS	Background Delayed treatment initiation of Tuberculosis patients results in increased infectivity, poor treatment outcome, and increased mortality. However, there is a paucity of evidence on the delay in new adult pulmonary Tuberculosis patients to initiate treatment in Tigray, Northern Ethiopia. Objective To assess the factors associated with treatment initiation delay among new adult pulmonary tuberculosis patients in Tigray, Northern Ethiopia. Methods The study design was cross-sectional. A total of 875 new adult pulmonary tuberculosis patients were recruited from 21 health facilities from October 2018 to October 2019. Health facilities were selected by simple random sampling technique and tuberculosis cases from the health facilities were consecutively enrolled. Data were collected using structured questionnaire within the first 2 weeks of treatment initiation. Delay was categorized as patient, health system and total delays. Data were analyzed using SPSS version 21 and logistic regression was used to identify factors associated with the odds of delays to initiate treatment. A p-value of less than 0.05 was reported as statistically significant. Results The median patient, health system and total delays were 30, 18 and 62 days, respectively. Rural residence, being poor, visiting non-formal medication sources, being primary health care and the private clinic had higher odds of patient delay whereas being HIV positive had lower odds of patient delay. Illiteracy, first visit to primary health care and private clinic had higher odds of health system delay whereas a visit to health facility one time and have no patient delay had lower odds of health system delay. Conclusion The median patient delay was higher than the median health system delay before initiating treatment. Hence, improved awareness of the community and involving the informal medication sources in the tuberculosis pathways would reduce patient delay. Similarly, improved cough screening and diagnostic efficiency of the lower health facilities would shorten health system delay.	[Tedla, Kiros] Mekelle Univ, Coll Hlth Sci, Inst Biomed Sci, Mekelle, Ethiopia; [Medhin, Girmay; Berhe, Nega] Addis Ababa Univ, Aklillu Lema Inst Pathobiol, Addis Ababa, Ethiopia; [Berhe, Gebretsadik; Mulugeta, Afework] Mekelle Univ, Coll Hlth Sci, Sch Publ Hlth, Mekelle, Ethiopia	Mekelle University; Addis Ababa University; Mekelle University	Tedla, K (corresponding author), Mekelle Univ, Coll Hlth Sci, Inst Biomed Sci, Mekelle, Ethiopia.	kirosmerry12@gmail.com		Mulugeta, Afework/0000-0003-0707-4363; Medhin, Girmay/0000-0003-2146-4261	Mekelle University	Mekelle University	We would like to express our gratitude to Aklilu Lemma Institute of Pathobiology, Addis Ababa University, for giving us the opportunity to undertake research. We would like also to thank Mekelle University for giving us full sponsorship to conduct this study. We would also like to thank all health professionals working in the health facilities where this study was conducted, the study participants and Tigray regional health bureau.	[Anonymous], 2010, ANSWERS, V5, P12; [Anonymous], 2017, TIGR REG HLTH BUR 20; Asefa A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102884; Asres A, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-4089-x; Awoke Netsanet, 2019, HINDAWI INTERDISCIPL, V1, P14; Belay M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-369; Gebreegziabher SB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159579; Gele AA, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-5; Hamza A., 2015, OPEN ACCESS LIB J, V2, P1; Hussen Awol, 2012, BMC Res Notes, V5, P320, DOI 10.1186/1756-0500-5-320; KNCV WHO JATA, 2008, TOOL EST PAT; Kumar V., 2007, ROBBINS BASIC PATHOL, P516; Lusignani LS, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-168; Masjedi M R, 2002, East Mediterr Health J, V8, P324; Mauch V, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-43; Mesfin M. M., 2005, Ethiopian Journal of Health Development, V19, P7; Mesfin MM, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-173; Mesfin MM, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-53; Mfinanga SG, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-158; Mondal MNI, 2014, AFR HEALTH SCI, V14, DOI 10.4314/ahs.v14i4.13; Ngamvithayapong J, 2001, INT J TUBERC LUNG D, V5, P1013; Ngangro NN, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-513; Nigri F, 2016, SURG NEUROL INT S31, V7, pS785; Odusanya OO, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-18; Rabin AS, 2013, INT J TUBERC LUNG D, V17, P214, DOI 10.5588/ijtld.12.0395; Seid A, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-5823-9; Storla DG, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-15; Temesgen C, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0593-2; Tuberculosis Research Advisory committee, 2013, ROADM TUB OP RES ETH; Virenfeldt J, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-004818; Wandwalo ER, 2000, INT J TUBERC LUNG D, V4, P133; WHO, 2019, GLOB TUB REP; World Health Organization, 2006, DIAGN TREATM DEL TUB; Xu B, 2005, INT J TUBERC LUNG D, V9, P784; Xu L, 2008, T ROY SOC TROP MED H, V102, P797, DOI 10.1016/j.trstmh.2008.04.027; Yimer S, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-112; Yimer SA, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-19; Zeleke Z Z, 2014, SCI J PUBLIC HLTH, V2, P402, DOI DOI 10.11648/j.sjph.20140205.15	38	3	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2020	15	8							e0235411	10.1371/journal.pone.0235411	http://dx.doi.org/10.1371/journal.pone.0235411			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG6GN	32822368	Green Published, gold			2023-01-03	WOS:000564080300049
J	Munir, H; Fromowitz, J; Goldfarb, M				Munir, Haroon; Fromowitz, Jake; Goldfarb, Michael			Early mobilization post-myocardial infarction: A scoping review	PLOS ONE			English	Review							INTENSIVE-CARE-UNIT; ACUTE MYOCARDIAL-INFARCTION; ACUTE CORONARY SYNDROMES; ASSOCIATION TASK-FORCE; AMERICAN-COLLEGE; EUROPEAN-SOCIETY; EARLY AMBULATION; EARLY MOBILITY; MANAGEMENT; GUIDELINES	Bedrest and immobilization following a myocardial infarction (MI) can lead to functional impairment that can persist following hospitalization. Early mobilization (EM) is associated with good functional and clinical outcomes in critical care, medical and surgical settings. However, the impact and current role of EM in post-MI care has not been well-defined. Our objective was to assess the evidence for post-MI mobilization, define current post-MI mobilization practice, and understand perspectives of cardiovascular professionals toward mobilization. A scoping review related to "early mobilization" and "myocardial infarction" was performed using the Joanna Briggs Institute Methodology. Pubmed, Embase, Google Scholar, Cochrane Library and CINAHL databases were included. Results were categorized into six topic areas. There were 59 references included in the analysis. There was evidence for the effectiveness and safety of earlier mobilization in experimental studies of the pre-revascularization era, but there was a lack of strong evidence for EM in contemporary post-MI care. Mobilization appears to be safe following arterial catheterization and is associated with minimal hemodynamic and respiratory compromise. Most people are delayed in mobilizing post-MI and spend the majority of the initial hospitalization period lying in bed. Only 1 of 7 current major cardiovascular professional societies guidelines recommend EM post-MI. There were no studies exploring the perspectives of cardiovascular professionals toward mobilization. EM may be beneficial in the post-MI care. However, there is an evidence gap for the impact of EM post-MI in the contemporary literature. More robust evidence from randomized clinical trials is required to inform clinicians and influence practice.	[Munir, Haroon; Goldfarb, Michael] McGill Univ, Div Expt Med, Montreal, PQ, Canada; [Fromowitz, Jake] Nova Southeastern Univ, Ft Lauderdale, FL 33314 USA; [Goldfarb, Michael] McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ, Canada	McGill University; Nova Southeastern University; McGill University	Goldfarb, M (corresponding author), McGill Univ, Div Expt Med, Montreal, PQ, Canada.; Goldfarb, M (corresponding author), McGill Univ, Jewish Gen Hosp, Div Cardiol, Montreal, PQ, Canada.	michael.i.goldfarb@mcgill.ca	Goldfarb, Michael/AAY-2362-2021	Munir, Haroon/0000-0002-9240-4568	Fonds de Recherche du Quebec -Sante (FRQS) [292023]	Fonds de Recherche du Quebec -Sante (FRQS)	HM was supported a grant provided by the Fonds de Recherche du Quebec -Sante (FRQS) (Grant: 292023). No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ADGEY AAJ, 1969, BRIT HEART J, V31, P750; Adler Joseph, 2012, Cardiopulm Phys Ther J, V23, P5; Amsterdam, 2014, CIRCULATION, V130, pE433, DOI [10.1161/CIR.0000000000000151, 10.1161/CIR.0000000000000134]; Anekwe D.E., 2017, J INTENSIVE CARE MED; Antman Elliott M, 2004, J Am Coll Cardiol, V44, P671, DOI 10.1016/j.jacc.2004.07.002; Asgari M.R., 2014, KOOMESH, V16, P175; Azoulay Elie, 2003, Curr Opin Crit Care, V9, P545; Bakhru RN, 2016, ANN AM THORAC SOC, V13, P1527, DOI 10.1513/AnnalsATS.201601-078OC; Bauer J, 2013, J AM MED DIR ASSOC, V14, P542, DOI 10.1016/j.jamda.2013.05.021; BLOCH A, 1974, AM J CARDIOL, V34, P152, DOI 10.1016/0002-9149(74)90193-3; BOYLE DM, 1972, LANCET, V2, P57; BRUMMER P, 1966, ACTA MED SCAND, V180, P231; Burtin C, 2009, CRIT CARE MED, V37, P2499, DOI 10.1097/CCM.0b013e3181a38937; Cassina T, 2016, ANN CARD ANAESTH, V19, P425, DOI 10.4103/0971-9784.185524; Chew DP, 2016, HEART LUNG CIRC, V25, P895, DOI 10.1016/j.hlc.2016.06.789; Cortes OL, 2015, CLIN NURS RES, V24, P139, DOI 10.1177/1054773813508132; Cortes OL, 2009, INT J NURS STUD, V46, P1496, DOI 10.1016/j.ijnurstu.2009.03.012; Damluji A, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2013.01.006; Davidson JE, 2017, CRIT CARE MED, V45, P103, DOI 10.1097/CCM.0000000000002169; Dima D., 2019, J CLIN NURS; Dolansky MA, 2008, WESTERN J NURS RES, V30, P163, DOI 10.1177/0193945907303061; Ferreira D.D.C., 2019, REV BRAS TER INTENSI; Fimognari F.L., 2016, J GERONTOL A-BIOL, V72, P102; Forman DE, 2011, J AM COLL CARDIOL, V57, P1801, DOI 10.1016/j.jacc.2011.02.014; FOWLOW B, 1995, HEART LUNG, V24, P28, DOI 10.1016/S0147-9563(05)80092-5; Genc A, 2010, INTENS CARE MED, V36, pS390; Goldfarb M, 2018, J CRIT CARE, V47, P9, DOI 10.1016/j.jcrc.2018.05.013; Gosselink R, 2008, INTENS CARE MED, V34, P1188, DOI 10.1007/s00134-008-1026-7; Harrold ME, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1033-3; Herkner H, 2007, Cochrane Database Syst Rev, pCD003836; Herkner H, 2003, J CLIN EPIDEMIOL, V56, P775, DOI 10.1016/S0895-4356(03)00121-5; Hodgson CL, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0658-y; Howie-Esquivel J, 2013, CARDIOL RES, V4, P15, DOI 10.4021/cr244w; Hunter OO, 2017, INTENS CRIT CARE NUR, V40, P44, DOI 10.1016/j.iccn.2016.10.005; HUTTER AM, 1973, NEW ENGL J MED, V288, P1141, DOI 10.1056/NEJM197305312882201; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Institute J.B, 2015, J BRIGGS I REV MAN 2, P1; IRVIN CW, 1950, NEW ENGL J MED, V243, P486, DOI 10.1056/NEJM195009282431304; Joseph I, 2019, CRIT CARE NURS CLIN, V31, P501, DOI 10.1016/j.cnc.2019.07.005; Kagoshima M, 2000, J Cardiol, V36, P251; Kim C., 2018, AUSTR CRITICAL CARE; Kim K, 2013, EUR J CARDIOVASC NUR, V12, P429, DOI 10.1177/1474515112462519; Koo Karen K Y, 2016, CMAJ Open, V4, pE448; Krumholz HM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.1938; LAMERS HJ, 1973, BMJ-BRIT MED J, V1, P257, DOI 10.1136/bmj.1.5848.257; Lavi S, 2017, J AM HEART ASSOC, V6, DOI 10.1161/JAHA.116.005029; Levine GN, 2016, CATHETER CARDIO INTE, V87, P1001, DOI 10.1002/ccd.26325; LEVINE SA, 1952, JAMA-J AM MED ASSOC, V148, P1365, DOI 10.1001/jama.1952.02930160001001; Levine SA, 1929, J CLIN ENDOCRINOL, V8, P245; Li Q, 2015, BMC CARDIOVASC DISOR, V15, DOI 10.1186/1471-2261-15-9; Mah J, 1999, Can J Cardiovasc Nurs, V10, P23; Morris PE, 2011, AM J MED SCI, V341, P373, DOI 10.1097/MAJ.0b013e31820ab4f6; Nydahl P, 2017, ANN AM THORAC SOC, V14, P766, DOI 10.1513/AnnalsATS.201611-843SR; O'Gara PT, 2013, CIRCULATION, V127, pE362, DOI 10.1161/CIR.0b013e3182742cf6; Perme Christiane, 2013, Cardiopulm Phys Ther J, V24, P12; Rebel A, 2019, AUST CRIT CARE, V32, P139, DOI 10.1016/j.aucc.2018.03.004; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Rulli V, 1980, SELECTED TOPICS EXER, P21; Stiller Kathy, 2004, Physiotherapy Theory and Practice, V20, P175, DOI 10.1080/09593980490487474; Tiso B, 1971, Munch Med Wochenschr, V113, P1406; Toleva O, 2015, OPEN HEART, V2, DOI 10.1136/openhrt-2014-000235; Toonstra AL, 2016, ANN AM THORAC SOC, V13, P699, DOI 10.1513/AnnalsATS.201506-359OC; Umei N, 2016, INTENS CRIT CARE NUR, V35, P16, DOI 10.1016/j.iccn.2016.02.001; Vollman KM, 2013, CRIT CARE NURS Q, V36, P17, DOI 10.1097/CNQ.0b013e3182750767; Wegiel M, 2018, J CLIN MED, V7, DOI 10.3390/jcm7120564; Winkelman C, 2007, CRIT CARE CLIN, V23, P21, DOI 10.1016/j.ccc.2006.11.002; Wong GC, 2019, CAN J CARDIOL, V35, P107, DOI 10.1016/j.cjca.2018.11.031; Zang K, 2020, NURS CRIT CARE, V25, P360, DOI 10.1111/nicc.12455	68	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 17	2020	15	8							e0237866	10.1371/journal.pone.0237866	http://dx.doi.org/10.1371/journal.pone.0237866			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NF8BJ	32804979	gold, Green Published			2023-01-03	WOS:000563517800005
J	Abbasi, J				Abbasi, Jennifer			Regulatory T Cells Tested in Patients With COVID-19 ARDS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	2020	324	6					539	539		10.1001/jama.2020.13765	http://dx.doi.org/10.1001/jama.2020.13765			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE8HM	32780125	Bronze			2023-01-03	WOS:000562845100005
J	Han, BG; Lee, JY; Kim, MR; Shin, H; Kim, JS; Yang, JW; Kim, JY				Han, Byoung-Geun; Lee, Jun Young; Kim, Mi Ryung; Shin, Hanwul; Kim, Jae-Seok; Yang, Jae-Won; Kim, Jong Yeon			Fluid overload is a determinant for cardiac structural and functional impairments in type 2 diabetes mellitus and chronic kidney disease stage 5 not undergoing dialysis	PLOS ONE			English	Article							VENTRICULAR DIASTOLIC DYSFUNCTION; HEART-FAILURE; EJECTION FRACTION; VOLUME OVERLOAD; CLINICAL IMPACT; RISK-FACTORS; CARDIOMYOPATHY; HYPERTROPHY; ASSOCIATION; MORTALITY	Background Fluid overload is common in patients with diabetes and chronic kidney disease (DM and CKD; DMCKD) and can lead to structural and functional cardiac abnormalities including left ventricular hypertrophy (LVH) and left ventricular diastolic dysfunction (LVDD). Fluid overload represents a crucial step in the pathophysiological pathways to chronic heart failure in patients with end-stage renal disease. We evaluated the impact of fluid overload on cardiac alterations in patients with diabetes and non-dialysis-dependent CKD stage 5 (DMCKD5-ND) without intrinsic heart disease. Methods Bioimpedance spectroscopy, echocardiography, and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) measurement were performed in 135 consecutive patients on the same day. Patients were divided into groups by tertiles of overhydration/extracellular water (OH/ECW) per bioimpedance spectroscopy. Results Fluid balance markers including OH/ECW and NT-proBNP were significantly higher in the LVDD+LVH group. OH/ECW and its exacerbation were positively associated with the ratio between early mitral inflow and annular early diastolic velocities (E/e ' ratio) and left ventricular mass index (LVMI). The prevalence of LVH progressively increased across increasing tertiles of OH/ECW. In multiple regression analyses, OH/ECW as a continuous and categorical variable was independently associated with the E/e ' ratio and LVMI after adjustment for multiple confounding factors. Conclusions Fluid overload was independently associated with LVDD and LVH in patients with DMCKD5-ND. Our study suggests that structural and functional cardiac abnormalities and volume status should be evaluated simultaneously in patients with early-stage DMCKD rather than only DMCKD5-ND, in addition to intensive blood pressure and glycemic control, regardless of evident cardiovascular disease.	[Han, Byoung-Geun; Lee, Jun Young; Kim, Mi Ryung; Shin, Hanwul; Kim, Jae-Seok; Yang, Jae-Won] Yonsei Univ, Dept Nephrol, Wonju Coll Med, Wonju, Kang Won, South Korea; [Kim, Jong Yeon] Yonsei Univ, Dept Neurosurg, Wonju Coll Med, Wonju, Kang Won, South Korea	Yonsei University; Yonsei University	Kim, JY (corresponding author), Yonsei Univ, Dept Neurosurg, Wonju Coll Med, Wonju, Kang Won, South Korea.	jjongse@yonsei.ac.kr	Lee, Jun Young/CAF-6397-2022; Lee, Jun Young/CAI-2335-2022	Lee, Jun Young/0000-0001-8047-4190; Lee, Jun Young/0000-0001-8047-4190; Kim, Jongyeon/0000-0002-9407-0127				Artham SM, 2009, PROG CARDIOVASC DIS, V52, P153, DOI 10.1016/j.pcad.2009.05.002; Asp AM, 2015, CLIN PHYSIOL FUNCT I, V35, P223, DOI 10.1111/cpf.12154; Athithtan L, 2019, WORLD J DIABETES, V10, P490, DOI 10.4239/wjd.v10.i10.490; Borghetti G, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01514; Boyer JK, 2004, AM J CARDIOL, V93, P870, DOI 10.1016/j.amjcard.2003.12.026; Bugger H, 2014, DIABETOLOGIA, V57, P660, DOI 10.1007/s00125-014-3171-6; Chamney PW, 2007, AM J CLIN NUTR, V85, P80, DOI 10.1093/ajcn/85.1.80; Ciftel S, 2012, DIABETES RES CLIN PR, V96, P179, DOI 10.1016/j.diabres.2011.12.021; Dawson A, 2005, DIABETOLOGIA, V48, P1971, DOI 10.1007/s00125-005-1896-y; Dillmann WH, 2019, CIRC RES, V124, P1160, DOI 10.1161/CIRCRESAHA.118.314665; Farshid A, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-280; Fontes-Carvalho R, 2015, CARDIOVASC DIABETOL, V14, DOI 10.1186/s12933-014-0168-x; Grigorescu ED, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9030121; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Houston BA, 2015, MAYO CLIN PROC, V90, P1247, DOI 10.1016/j.mayocp.2015.05.002; Hung SC, 2014, KIDNEY INT, V85, P703, DOI 10.1038/ki.2013.336; Jia GH, 2018, CIRC RES, V122, P624, DOI 10.1161/CIRCRESAHA.117.311586; Jia GH, 2016, NAT REV ENDOCRINOL, V12, P144, DOI 10.1038/nrendo.2015.216; Kalantar-Zadeh K, 2009, CIRCULATION, V119, P671, DOI 10.1161/CIRCULATIONAHA.108.807362; Lahnwong S, 2018, CARDIOVASC DIABETOL, V17, DOI 10.1186/s12933-018-0745-5; Lang RM, 2015, J AM SOC ECHOCARDIOG, V28, P1, DOI 10.1016/j.echo.2014.10.003; Lee WS, 2017, KOREAN J INTERN MED, V32, P404, DOI 10.3904/kjim.2016.208; Mishra RK, 2013, AM J CARDIOL, V111, P432, DOI 10.1016/j.amjcard.2012.10.019; Nagueh SF, 2009, EUR J ECHOCARDIOGR, V10, P165, DOI 10.1093/ejechocard/jep007; Nardi E, 2009, J HYPERTENS, V27, P633, DOI 10.1097/HJH.0b013e3283220ecd; Ogawa T, 2018, CONTRIB NEPHROL, V195, P81, DOI 10.1159/000486938; Otsuka T, 2009, J CARDIOL, V54, P199, DOI 10.1016/j.jjcc.2009.05.002; Paulus WJ, 2007, EUR HEART J, V28, P2539, DOI 10.1093/eurheartj/ehm037; Rawshani A, 2018, NEW ENGL J MED, V379, P633, DOI 10.1056/NEJMoa1800256; Romano S, 2010, CARDIOVASC DIABETOL, V9, DOI 10.1186/1475-2840-9-89; RUBLER S, 1972, AM J CARDIOL, V30, P595, DOI 10.1016/0002-9149(72)90595-4; Sattar N, 2016, DIABETOLOGIA, V59, P1333, DOI 10.1007/s00125-016-3956-x; Tentolouris A, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16162965; Tuegel C, 2017, HEART, V103, P1848, DOI 10.1136/heartjnl-2016-310794; Vetrone LM, 2019, ACTA DIABETOL, V56, P331, DOI 10.1007/s00592-018-1253-5; Vidal-Petiot E, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.010278; Wabel P, 2009, BLOOD PURIFICAT, V27, P75, DOI 10.1159/000167013; Zabalgoitia M, 2001, AM J CARDIOL, V87, P320, DOI 10.1016/S0002-9149(00)01366-7; Zoccali C, 2017, J AM SOC NEPHROL, V28, P2491, DOI 10.1681/ASN.2016121341	39	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2020	15	7							e0235640	10.1371/journal.pone.0235640	http://dx.doi.org/10.1371/journal.pone.0235640			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW2PD	32730268	Green Published, gold			2023-01-03	WOS:000556884700014
J	Mallahid, N; Badro, DA; Figueiras, A; Takkouche, B				Mallahid, Narmeen; Badro, Danielle A.; Figueiras, Adolfo; Takkouche, Bahi			Association of knowledge and beliefs with the misuse of antibiotics in parents: A study in Beirut (Lebanon)	PLOS ONE			English	Article							SELF-MEDICATION; PUBLIC KNOWLEDGE; ATTITUDES; POPULATION; RESPONDENTS; COMMUNITY; BEHAVIOR; ADULTS	Background Antibiotic resistance is a major public health concern. It has been associated with factors such as uncontrolled consumption, lack of knowledge, beliefs, and sociodemographic characteristics. Lebanon is characterized by high levels of antibiotic misuse, as almost half of the population self-medicates with antibiotics and over 30% of the antibiotics are dispensed without prescription. To-date, no studies determined adequately the association between knowledge, beliefs and antibiotic misuse in Lebanon. Objective To assess the association between level of knowledge and beliefs about antibiotics, and antibiotic misuse in Lebanon. Methods We conducted a cross-sectional study among 1,421 parents of schoolchildren using an anonymous self-administered Knowledge, Attitude and Practices questionnaire. The participants level of agreement with each item of knowledge and beliefs was measured using a Likert-type (0-10) scale. Misuse practices in the last month were detected through a series of questions aimed at determining the level of compliance with physicians instructions in terms of dosage and duration. Data were analyzed using logistic regression. Results 277 participants (16%) acknowledged using antibiotics in the previous month, 41% of whom showed at least one misuse behavior. Misconceptions and beliefs about antibiotics substantially increased the odds of their misuse. For instance, participants who believed that antibiotics were effective in treating viruses, cold, or sore throat infections were twice as likely to misuse antibiotics [Adjusted Interquartile Odds Ratio (aIqOR): 2.08 (95%CI: 1.32, 3.19), aIqOR: 1.81 (95%CI: 1.41, 2.29), aIqOR: 2.19 (95%CI: 1.61, 2.93), respectively]. Parents who usually keep antibiotics at home antibiotics for future use were more likely to misuse antibiotics [aIqOR: 2.44 (95%CI: 1.68, 3.46)]. Conclusions Our findings indicate that the low level of knowledge and the existence of erroneous beliefs about antibiotics are associated with increased odds of antibiotic misuse. Key elements including rationale prescription and control of dispensing should be addressed when designing educational campaigns against antibiotic misuse.	[Mallahid, Narmeen; Figueiras, Adolfo; Takkouche, Bahi] Univ Santiago de Compostela, Dept Prevent Med, Santiago De Compostela, Spain; [Mallahid, Narmeen; Figueiras, Adolfo; Takkouche, Bahi] Ctr Invest Biomed Red Epidemiol & Salud Publ CIBE, Madrid, Spain; [Badro, Danielle A.] Amer Univ Sci & Technol, Fac Hlth Sci, Beirut, Lebanon; [Figueiras, Adolfo; Takkouche, Bahi] Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain	Universidade de Santiago de Compostela; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; American University of Science & Technology - Lebanon; Complexo Hospitalario Universitario de Santiago de Compostela	Takkouche, B (corresponding author), Univ Santiago de Compostela, Dept Prevent Med, Santiago De Compostela, Spain.; Takkouche, B (corresponding author), Ctr Invest Biomed Red Epidemiol & Salud Publ CIBE, Madrid, Spain.; Takkouche, B (corresponding author), Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain.	bahi.takkouche@usc.es	Mallah, Narmeen/O-3696-2019; Figueiras Guzman, Adolfo/K-8563-2015	Mallah, Narmeen/0000-0002-3711-3792; Badro, Danielle A/0000-0003-4487-9144; Takkouche, Bahi/0000-0002-0739-2241; Figueiras Guzman, Adolfo/0000-0002-5766-8672	Regional Ministry of Education, Universities and Vocational Training, Santiago de Compostela, Spain [ED431C 2018/20]; American University of Science and Technology in Lebanon	Regional Ministry of Education, Universities and Vocational Training, Santiago de Compostela, Spain; American University of Science and Technology in Lebanon	This study was funded by a grant from the Regional Ministry of Education, Universities and Vocational Training, Santiago de Compostela, Spain, (ED431C 2018/20), and by the American University of Science and Technology in Lebanon.	Anderson A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204878; [Anonymous], 2020, LEBANON IMMIGRATION; Awad AI, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117910; Barah F., 2010, Eastern Mediterranean Health Journal, V16, P516; Bert F, 2017, EUR J PUBLIC HEALTH, V27, P506, DOI 10.1093/eurpub/ckw209; BUTLER CC, 2009, BRIT MED J, V338; Cheaito L, 2014, INT J PUBLIC HEALTH, V59, P319, DOI 10.1007/s00038-013-0493-y; European Commission, 2017, EUR 1 HLTH ACT PLAN; Farah R, 2015, J INFECT PUBLIC HEAL, V8, P37, DOI 10.1016/j.jiph.2014.07.003; Frost I, 2019, J TRAVEL MED, V26, DOI 10.1093/jtm/taz036; Institute of Health Management and Social Protection, 2012, NAT HLTH STAT REP LE; Jamhour A, 2017, AM J INFECT CONTROL, V45, P384, DOI 10.1016/j.ajic.2016.11.026; Jassim Abdul-Mohsin, 2010, Oman Med J, V25, P79, DOI 10.5001/omj.2010.25; Klein EY, 2018, P NATL ACAD SCI USA, V115, pE3463, DOI 10.1073/pnas.1717295115; Lopez-Vazquez P, 2012, J EVAL CLIN PRACT, V18, P473, DOI 10.1111/j.1365-2753.2010.01610.x; Moienzadeh A, 2017, INT J PHARM PRACT, V25, P133, DOI 10.1111/ijpp.12233; Mor A, 2015, INFECTION, V43, P453, DOI 10.1007/s15010-015-0768-8; Morgan DJ, 2011, LANCET INFECT DIS, V11, P692, DOI 10.1016/S1473-3099(11)70054-8; Mouhieddine TH, 2015, J INFECT PUBLIC HEAL, V8, P20, DOI 10.1016/j.jiph.2014.07.010; Ocan M, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2109-3; Oh AL, 2011, J INFECT DEV COUNTR, V5, P338; ONeill J., 2016, TACKLING DRUG RESIST; Purdie DM, 2002, J EPIDEMIOL COMMUN H, V56, P748, DOI 10.1136/jech.56.10.748; Ramalhinho I, 2014, INT J CLIN PHARM-NET, V36, P1039, DOI 10.1007/s11096-014-9992-z; Rothman KJ, 2013, INT J EPIDEMIOL, V42, P1012, DOI 10.1093/ije/dys223; Rouusounides A, 2011, INT J ENV RES PUB HE, V8, P3246, DOI 10.3390/ijerph8083246; Saleh Nadine, 2015, Infection Ecology & Epidemiology, V5, P27094, DOI 10.3402/iee.v5.27094; Shehadeh M, 2012, SAUDI PHARM J, V20, P125, DOI 10.1016/j.jsps.2011.11.005; Tolonen H, 2005, EUR J EPIDEMIOL, V20, P887, DOI 10.1007/s10654-005-2672-5; von Wintersdorff CJH, 2014, EMERG INFECT DIS, V20, P649, DOI [10.3201/eid.2004.131718, 10.3201/eid2004.131718]; You JHS, 2008, INFECTION, V36, P153, DOI 10.1007/s15010-007-7214-5; Zahreddine L, 2018, PHARM PRACT-GRANADA, V16, DOI [10.18549/PharmPract.2018.03.1194, 10.18549/pharmpract.2018.03.1194]	32	11	11	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2020	15	7							e0232464	10.1371/journal.pone.0232464	http://dx.doi.org/10.1371/journal.pone.0232464			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX7SC	32697808	Green Published, gold			2023-01-03	WOS:000575905100001
J	Kaptchuk, TJ; Hemond, CC; Miller, FG				Kaptchuk, Ted J.; Hemond, Christopher C.; Miller, Franklin G.			Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROLLED-TRIALS; LOW-BACK-PAIN; NEUROPATHIC PAIN; INFORMED-CONSENT; PHYSICIAN COMMUNICATION; NONCONSCIOUS ACTIVATION; FIBROMYALGIA SYNDROME; CONDITIONED PLACEBO; PREDICTION ERRORS; DOSE REDUCTION	Despite their ubiquitous presence, placebos and placebo effects retain an ambiguous and unsettling presence in biomedicine. Specifically focused on chronic pain, this review examines the effect of placebo treatment under three distinct frameworks: double blind, deception, and open label honestly prescribed. These specific conditions do not necessarily differentially modify placebo outcomes. Psychological, clinical, and neurological theories of placebo effects are scrutinized. In chronic pain, conscious expectation does not reliably predict placebo effects. A supportive patient-physician relationship may enhance placebo effects. This review highlights "predictive coding" and "bayesian brain" as emerging models derived from computational neurobiology that offer a unified framework to explain the heterogeneous evidence on placebos. These models invert the dogma of the brain as a stimulus driven organ to one in which perception relies heavily on learnt, top down, cortical predictions to infer the source of incoming sensory data. In predictive coding/bayesian brain, both chronic pain (significantly modulated by central sensitization) and its alleviation with placebo treatment are explicated as centrally encoded, mostly non-conscious, bayesian biases. The review then evaluates seven ways in which placebos are used in clinical practice and research and their bioethical implications. In this way, it shows that placebo effects are evidence based, clinically relevant, and potentially ethical tools for relieving chronic pain.	[Kaptchuk, Ted J.] Harvard Med Sch, Beth Israel Hosp, Boston, MA 02139 USA; [Hemond, Christopher C.] Univ Massachusetts, Med Sch, Worcester, MA 01655 USA; [Miller, Franklin G.] Weill Cornell Med, New York, NY 10065 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Massachusetts System; University of Massachusetts Worcester; Cornell University	Kaptchuk, TJ (corresponding author), Harvard Med Sch, Beth Israel Hosp, Boston, MA 02139 USA.	ted_kaptchuk@hms.harvard.edu	Hemond, Christopher/AAJ-7568-2020	Hemond, Christopher/0000-0002-2408-4638	NIH/NCCIH [R01AT008573, R61/33AT009306]; Foundation for the Science of the Therapeutic Encounter	NIH/NCCIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Foundation for the Science of the Therapeutic Encounter	TJK is partially funded by NIH/NCCIH grants #R01AT008573 and #R61/33AT009306 and the Foundation for the Science of the Therapeutic Encounter.	Ader R, 2010, PSYCHOSOM MED, V72, P192, DOI 10.1097/PSY.0b013e3181cbd38b; Amanzio M, 1999, J NEUROSCI, V19, P484, DOI 10.1523/JNEUROSCI.19-01-00484.1999; American Medical Association, US PLAC CLIN PRACT C; Anchisi D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117270; Apud I, 2020, ANTHROPOL MED, V27, P160, DOI 10.1080/13648470.2019.1649542; Arakawa A, 2015, CLIN DRUG INVEST, V35, P67, DOI 10.1007/s40261-014-0259-1; Ashar J, 2019, 2 OFF SIPS C SOC INT; Babel P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181856; Baliki MN, 2012, NAT NEUROSCI, V15, P1117, DOI 10.1038/nn.3153; Ballou S, 2018, CLIN GASTROENTEROL H, V16, P1738, DOI 10.1016/j.cgh.2018.04.009; Ballou S, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1964-x; Bannuru RR, 2015, ANN INTERN MED, V163, P365, DOI 10.7326/M15-0623; Barnard D., 1995, CHRONIC ILLNESS EXPE; Barrett LF, 2015, NAT REV NEUROSCI, V16, P419, DOI 10.1038/nrn3950; Bateson G, 1972, STEPS ECOLOGY MIND; Bellesi G, 2019, BRAIN INJURY, V33, P1272, DOI 10.1080/02699052.2019.1641621; BERGMANN JF, 1994, CLIN TRIAL META-ANAL, V29, P41; Bishop FL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101822; Blease CR, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j463; Blease C, 2016, BIOETHICS, V30, P407, DOI 10.1111/bioe.12245; Brooks JCW, 2007, PAIN, V128, P1, DOI 10.1016/j.pain.2006.12.025; Buchel C, 2014, NEURON, V81, P1223, DOI 10.1016/j.neuron.2014.02.042; Burke MJ, 2019, JAMA NEUROL, V76, P1417, DOI 10.1001/jamaneurol.2019.3043; Carvalho C, 2016, PAIN, V157, P2766, DOI 10.1097/j.pain.0000000000000700; Cepeda MS, 2012, PAIN MED, V13, P575, DOI 10.1111/j.1526-4637.2012.01340.x; Chen X, 2017, CLIN RHEUMATOL, V36, P1623, DOI 10.1007/s10067-017-3595-8; Clark Andy, 2016, SURFING UNCERTAINTY, DOI DOI 10.1093/ACPROF:OSO/9780190217013.001.0001; Colloca L, 2020, NEW ENGL J MED, V382, P554, DOI 10.1056/NEJMra1907805; Colloca L, 2016, PAIN, V157, P1590, DOI 10.1097/j.pain.0000000000000566; Cousin G, 2012, PATIENT EDUC COUNS, V87, P193, DOI 10.1016/j.pec.2011.08.004; Cragg JJ, 2016, PAIN, V157, P530, DOI 10.1097/j.pain.0000000000000431; Crombez G, 2011, PAIN, V152, P1449, DOI 10.1016/j.pain.2011.02.028; Cunningham NR, 2019, PAIN REP, V4, DOI 10.1097/PR9.0000000000000767; Doering BK, 2012, TRENDS PHARMACOL SCI, V33, P165, DOI 10.1016/j.tips.2011.12.001; Doya K, 2011, BAYESIAN BRAIN PROBA; Eaves ER, 2016, CULT MED PSYCHIAT, V40, P35, DOI 10.1007/s11013-015-9465-4; Edwards MJ, 2012, BRAIN, V135, P3495, DOI 10.1093/brain/aws129; Egner T, 2010, J NEUROSCI, V30, P16601, DOI 10.1523/JNEUROSCI.2770-10.2010; Egorova N, 2015, SCI REP-UK, V5, DOI 10.1038/srep16809; Emanuel EJ, 2001, NEW ENGL J MED, V345, P915, DOI 10.1056/NEJM200109203451211; Enck P, 2018, INT REV NEUROBIOL, V139, P85, DOI 10.1016/bs.irn.2018.07.018; Fassler M, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-15; Farrar JT, 2014, PAIN, V155, P1622, DOI 10.1016/j.pain.2014.05.009; Finniss D, 2019, PAIN REP, V4, DOI 10.1097/PR9.0000000000000744; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Ford AC, 2010, ALIMENT PHARM THER, V32, P144, DOI 10.1111/j.1365-2036.2010.04328.x; Foster NE, 2010, EUR J PAIN, V14, P402, DOI 10.1016/j.ejpain.2009.06.010; Frenkel O, 2008, J MED PHILOS, V33, P58, DOI 10.1093/jmp/jhm005; Friston KJ, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002327; Friston KJ, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000081; Fuentes J, 2014, PHYS THER, V94, P477, DOI 10.2522/ptj.20130118; Gendler TS, 2008, J PHILOS, V105, P634, DOI 10.5840/jphil20081051025; Gershman SJ, 2015, SCIENCE, V349, P273, DOI 10.1126/science.aac6076; GRACELY RH, 1985, LANCET, V1, P43; Grahl A, 2018, ELIFE, V7, DOI [10.7554/elife.32930, 10.7554/eLife.32930]; Griffin SJ, 2004, ANN FAM MED, V2, P595, DOI 10.1370/afm.142; Haanstra TM, 2012, HEALTH QUAL LIFE OUT, V10, DOI 10.1186/1477-7525-10-152; Hauser W, 2012, CLIN EXP RHEUMATOL, V30, pS78; Hauser W, 2011, PAIN, V152, P1709, DOI 10.1016/j.pain.2011.01.050; Harris RE, 2005, ARTHRITIS RHEUM, V52, P3670, DOI 10.1002/art.21407; Harte SE, 2018, J APPL BIOBEHAV RES, V23, DOI 10.1111/jabr.12137; Hashmi JA, 2013, BRAIN, V136, P2751, DOI 10.1093/brain/awt211; Haug M, 2011, PHILOS PSYCHOL, V24, P679, DOI 10.1080/09515089.2011.559624; Hechler T, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01638; Hesselmann G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009926; Hoekman DR, 2017, J PEDIATR-US, V182, P155, DOI 10.1016/j.jpeds.2016.12.022; Hohwy J, 2013, PREDICTIVE MIND; Howick J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058247; Hull SC, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f3757; Institute of Medicine (US) Committee on Advancing Pain Research Care and Education, 2011, REL PAIN AM BLUEPR T; Irizarry MC, 2009, CLIN J PAIN, V25, P469, DOI 10.1097/AJP.0b013e31819ddded; Jensen K, 2015, P NATL ACAD SCI USA, V112, P7863, DOI 10.1073/pnas.1504567112; Jensen KB, 2015, CEREB CORTEX, V25, P3903, DOI 10.1093/cercor/bhu275; Jensen KB, 2012, P NATL ACAD SCI USA, V109, P15959, DOI 10.1073/pnas.1202056109; Jung WM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172609; Kam-Hansen S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3006175; Kaptchuk TJ, 2008, BMJ-BRIT MED J, V336, P999, DOI 10.1136/bmj.39524.439618.25; Kaptchuk TJ, 2018, PERSPECT BIOL MED, V61, P311, DOI 10.1353/pbm.2018.0045; Kaptchuk TJ, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k3889; Kaptchuk TJ, 2015, NEW ENGL J MED, V373, P8, DOI 10.1056/NEJMp1504023; Kaptchuk TJ, 2011, PHILOS T R SOC B, V366, P1849, DOI 10.1098/rstb.2010.0385; Kaptchuk TJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015591; Kaptchuk TJ, 2009, CULT MED PSYCHIAT, V33, P382, DOI 10.1007/s11013-009-9141-7; Kaptchuk TJ, 2000, J CLIN EPIDEMIOL, V53, P786, DOI 10.1016/S0895-4356(00)00206-7; Kaptchuk TJ, 1998, LANCET, V351, P1722, DOI 10.1016/S0140-6736(97)10111-8; Kaptchuk TJ, 1998, B HIST MED, V72, P389, DOI 10.1353/bhm.1998.0159; KIHLSTROM JF, 1987, SCIENCE, V237, P1445, DOI 10.1126/science.3629249; Kirchhof J, 2018, P NATL ACAD SCI USA, V115, P4223, DOI 10.1073/pnas.1720548115; Kleine-Borgmann J, 2019, PAIN, V160, P2891, DOI 10.1097/j.pain.0000000000001683; Knapp M, 2007, NONVERBAL COMMUNICAT; Krishna R, 2010, J CLIN DIAGN RES, V4, P2320; Kube T, 2019, PERSPECT BIOL MED, V62, P591, DOI 10.1353/pbm.2019.0035; Kuten-Shorrer M, 2014, ORAL DIS, V20, pe1, DOI 10.1111/odi.12192; LEVINE JD, 1984, NATURE, V312, P755, DOI 10.1038/312755a0; Linde K, 2007, PAIN, V128, P264, DOI 10.1016/j.pain.2006.12.006; Linde K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092938; Macedo A, 2006, EUR J CLIN PHARMACOL, V62, P161, DOI 10.1007/s00228-005-0088-5; Macedo A, 2008, EUR J PAIN, V12, P68, DOI 10.1016/j.ejpain.2007.03.002; Maixner W, 2016, J PAIN, V17, pT93, DOI 10.1016/j.jpain.2016.06.002; Mandt Stephan, 2017, ARXIV170404289; Mansour AR, 2013, PAIN, V154, P2160, DOI 10.1016/j.pain.2013.06.044; Martin AL, 2010, PAIN, V149, P208, DOI 10.1016/j.pain.2009.12.004; Meissner K, 2013, JAMA INTERN MED, V173, P1941, DOI 10.1001/jamainternmed.2013.10391; Miller FG, 2005, PLOS MED, V2, P853, DOI 10.1371/journal.pmed.0020262; Miller FG, 2004, SCI ENG ETHICS, V10, P157, DOI 10.1007/s11948-004-0073-x; Miller FG, 2008, J NEUROSCI, V28, P4841, DOI 10.1523/JNEUROSCI.1493-08.2008; O'Reilly JX, 2012, EUR J NEUROSCI, V35, P1169, DOI 10.1111/j.1460-9568.2012.08010.x; Olliges E, 2019, 2 OFF SIPS C SOC INT; Ongaro G, 2019, PAIN, V160, P1, DOI 10.1097/j.pain.0000000000001367; Patel SM, 2005, NEUROGASTROENT MOTIL, V17, P332, DOI 10.1111/j.1365-2982.2005.00650.x; Perlis M, 2015, SLEEP MED, V16, P1160, DOI 10.1016/j.sleep.2015.06.015; Pitz M, 2005, CLIN GASTROENTEROL H, V3, P237, DOI 10.1016/S1542-3565(04)00626-3; Pocock S, 1999, CLIN TRIALS PRACTICA; Pollo A, 2001, PAIN, V93, P77, DOI 10.1016/S0304-3959(01)00296-2; Prady SL, 2015, COMPLEMENT THER MED, V23, P185, DOI 10.1016/j.ctim.2015.01.007; Reiter-Niesert S, 2016, OSTEOARTHR CARTILAGE, V24, P1007, DOI 10.1016/j.joca.2016.01.002; Remahl AIMN, 2003, CEPHALALGIA, V23, P504, DOI 10.1046/j.1468-2982.2003.00531.x; Rose M, 2005, J COGNITIVE NEUROSCI, V17, P918, DOI 10.1162/0898929054021193; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Roy M, 2014, NAT NEUROSCI, V17, P1607, DOI 10.1038/nn.3832; Sandler AD, 2010, J DEV BEHAV PEDIATR, V31, P369, DOI 10.1097/DBP.0b013e3181e121ed; Schenk LA, 2017, J NEUROSCI, V37, P9715, DOI 10.1523/JNEUROSCI.1101-17.2017; Seth AK, 2016, PHILOS T R SOC B, V371, DOI 10.1098/rstb.2016.0007; Sherman KJ, 2010, SPINE, V35, P1471, DOI 10.1097/BRS.0b013e3181c2a8d3; Skyt I, 2020, PAIN, V161, P11, DOI 10.1097/j.pain.0000000000001682; Smallwood RF, 2013, J PAIN, V14, P663, DOI 10.1016/j.jpain.2013.03.001; Spilker B., 1991, GUIDE CLIN TRIALS; Street RL, 2012, PATIENT EDUC COUNS, V89, P245, DOI 10.1016/j.pec.2012.06.032; Suarez-Almazor ME, 2010, ARTHRIT CARE RES, V62, P1229, DOI 10.1002/acr.20225; Sullivan M, 2005, J PAIN, V6, P215, DOI 10.1016/j.jpain.2005.01.347; Sun HH, 2013, JAMA PEDIATR, V167, P243, DOI 10.1001/jamapediatrics.2013.872; Talley NJ, 2006, ALIMENT PHARM THERAP, V23, P923, DOI 10.1111/j.1365-2036.2006.02845.x; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Tenenbaum JB, 2011, SCIENCE, V331, P1279, DOI 10.1126/science.1192788; Tilburt JC, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1938; Tracey I, 2019, NEURON, V101, P783, DOI 10.1016/j.neuron.2019.02.019; Treister R, 2019, PAIN, V160, P1522, DOI 10.1097/j.pain.0000000000001538; Treister R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197844; Trouvin AP, 2019, BEST PRACT RES CL RH, V33, DOI 10.1016/j.berh.2019.04.007; Tsang A, 2008, J PAIN, V9, P883, DOI 10.1016/j.jpain.2008.05.005; Vachon-Presseau E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05859-1; Van den Bergh O, 2017, NEUROSCI BIOBEHAV R, V74, P185, DOI 10.1016/j.neubiorev.2017.01.015; Vase L, 2015, PAIN, V156, P1795, DOI 10.1097/j.pain.0000000000000217; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Wager TD, 2015, NAT REV NEUROSCI, V16, P403, DOI 10.1038/nrn3976; Wager TD, 2013, NEW ENGL J MED, V368, P1388, DOI 10.1056/NEJMoa1204471; Wanigasekera V, 2018, BRIT J ANAESTH, V120, P299, DOI 10.1016/j.bja.2017.11.064; Wartolowska K, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3253; Wechsler ME, 2011, NEW ENGL J MED, V365, P119, DOI 10.1056/NEJMoa1103319; White P, 2012, PAIN, V153, P455, DOI 10.1016/j.pain.2011.11.007; Whiteside N, 2018, CLIN RHEUMATOL, V37, P1375, DOI 10.1007/s10067-017-3948-3; Wiech K, 2016, SCIENCE, V354, P584, DOI 10.1126/science.aaf8934; Wise RA, 2009, J ALLERGY CLIN IMMUN, V124, P436, DOI 10.1016/j.jaci.2009.05.041; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; Yunus MB, 2015, CURR RHEUMATOL REV, V11, P70, DOI 10.2174/157339711102150702112236; Zhang W, 2008, ANN RHEUM DIS, V67, P1716, DOI 10.1136/ard.2008.092015; Zolnierek KBH, 2009, MED CARE, V47, P826, DOI 10.1097/MLR.0b013e31819a5acc; Zou K, 2016, ANN RHEUM DIS, V75, P1964, DOI 10.1136/annrheumdis-2015-208387; Zunhammer M, 2018, JAMA NEUROL, V75, P1321, DOI 10.1001/jamaneurol.2018.2017	160	58	56	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 20	2020	370								m1668	10.1136/bmj.m1668	http://dx.doi.org/10.1136/bmj.m1668			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MS7HY	32690477				2023-01-03	WOS:000554447700001
J	Nie, JX; Wei, XY; Xu, X; Li, NQ; Li, YH; Zhao, YH; Guan, Y; Ge, FF; Guan, XW				Nie, Jiaxun; Wei, Xiaoyan; Xu, Xing; Li, Nanqin; Li, Yuehan; Zhao, Yonghua; Guan, Yun; Ge, Feifei; Guan, Xiaowei			Electro-acupuncture alleviates adolescent cocaine exposure-enhanced anxiety-like behaviors in adult mice by attenuating the activities of PV interneurons in PrL	FASEB JOURNAL			English	Article						adolescent cocaine exposure; adult PrL; electro-acupuncture; PV GABA interneuron	PREFRONTAL CORTEX; ALZHEIMERS-DISEASE; ACUPUNCTURE; PARVALBUMIN; NEUROTRANSMISSION; SCHIZOPHRENIA; EXPRESSION; NEURONS; SYSTEM; PERIOD	We recently found that adolescent cocaine exposure (ACE) resulted in an enhancement of the gamma-aminobutyric acid (GABA) neurotransmitter system in the prelimbic cortex (PrL) of adult mice. Here, we aim to further investigate the role of GABAergic transmission, especially parvalbumin (PV) interneurons within PrL in the development of ACE-induced anxiety-like behavior, and to assess whether and how electro-acupuncture (EA) therapeutically manage the ACE-induced abnormal behaviors in adulthood. ACE mice exhibited the enhanced anxiety-like behaviors in their adulthood, accompanied by increased GABAergic transmission and PV interneurons in PrL. Chemogenetic blocking PV interneurons in PrL alleviated ACE-enhanced anxiety-like behaviors in mice. Importantly, 37-day EA treatments (mixture of 2 Hz/100 Hz, 1 mA, 30 minutes once a day) at the acupoints of Yintang (GV29) and Baihui (GV20) also alleviated ACE-induced anxiety-like behaviors, and rescued ACE-impaired GABAergic neurotransmitter system and PV interneurons in PrL. In parallel, EA treatments further suppressed the activities of pyramidal neurons in PrL, suggesting that EA treatments seem to perform it beneficial effects on the ACE-induced abnormal emotional behaviors by "calming down" the whole PrL. Collectively, these findings revealed that hyper-function of GABAergic transmission, especially mediating by PV interneurons in PrL may be key etiology underlying ACE-induced anxiety-like behaviors. At least by normalizing the function of GABAergic and PV interneurons, EA may represent a promising therapeutic strategy for managing adolescent substance use-related emotional disorders.	[Nie, Jiaxun; Wei, Xiaoyan; Xu, Xing; Li, Nanqin; Li, Yuehan; Ge, Feifei; Guan, Xiaowei] Nanjing Univ Chinese Med, Dept Human Anat & Histoembryol, 138 Xianlin Ave, Nanjing 210023, Peoples R China; [Zhao, Yonghua] Univ Macau, Inst Chinese Med Sci, Macau, Peoples R China; [Guan, Yun] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21205 USA	Nanjing University of Chinese Medicine; University of Macau; Johns Hopkins University	Ge, FF; Guan, XW (corresponding author), Nanjing Univ Chinese Med, Dept Human Anat & Histoembryol, 138 Xianlin Ave, Nanjing 210023, Peoples R China.	ffge@njucm.edu.cn; guanxw918@njucm.edu.cn	Zhao, Yonghua/AAC-4728-2019	Zhao, Yonghua/0000-0001-8714-0476; Ge, Feifei/0000-0003-1336-8587	National Natural Science Foundation of China [81571303, 81901353]; Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions	National Natural Science Foundation of China, Grant/Award Number: 81571303 and 81901353; Priority Academic Program Development of Jiangsu Higher Education Institutions	Abbas AI, 2018, NEURON, V100, P926, DOI 10.1016/j.neuron.2018.09.029; Baho E, 2019, J NEUROSCI, V39, P4489, DOI 10.1523/JNEUROSCI.2881-18.2019; Belleau EL, 2019, BIOL PSYCHIAT, V85, P443, DOI 10.1016/j.biopsych.2018.09.031; Butt SJB, 2017, CURR OPIN NEUROBIOL, V43, P149, DOI 10.1016/j.conb.2017.03.011; Caffino L, 2017, PSYCHOPHARMACOLOGY, V234, P1217, DOI 10.1007/s00213-017-4559-z; Chambers RA, 2003, AM J PSYCHIAT, V160, P1041, DOI 10.1176/appi.ajp.160.6.1041; Chang BH, 2014, AM J ADDICTION, V23, P129, DOI 10.1111/j.1521-0391.2013.12079.x; Chang S, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax1342; Chung DW, 2016, AM J PSYCHIAT, V173, P1131, DOI 10.1176/appi.ajp.2016.16010025; Chung DW, 2016, AM J PSYCHIAT, V173, P60, DOI 10.1176/appi.ajp.2015.15020150; Conrod PJ, 2016, J CHILD PSYCHOL PSYC, V57, P371, DOI 10.1111/jcpp.12516; Duan GX, 2020, BRAIN IMAGING BEHAV, V14, P2269, DOI 10.1007/s11682-019-00178-5; Ferguson BR, 2018, FRONT NEURAL CIRCUIT, V12, DOI 10.3389/fncir.2018.00037; Fuhrmann D, 2015, TRENDS COGN SCI, V19, P558, DOI 10.1016/j.tics.2015.07.008; Garcia-Cabrerizo R, 2019, J PSYCHOPHARMACOL, V33, P154, DOI 10.1177/0269881118812353; Giannotti G, 2015, PSYCHOPHARMACOLOGY, V232, P713, DOI 10.1007/s00213-014-3708-x; Hou Wei-Qing, 2018, Shengli Xuebao, V70, P463, DOI 10.13294/j.aps.2018.0066; Jia YJ, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-2064-x; Jin W, 2018, ADDICT BIOL, V23, P165, DOI 10.1111/adb.12499; Kim DH, 2018, NEUROSCI LETT, V664, P38, DOI 10.1016/j.neulet.2017.11.008; Kim H, 2016, CELL, V164, P208, DOI 10.1016/j.cell.2015.11.038; Larson TA, 2018, J PSYCHOPHARMACOL; Leng L, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011905; Lim L, 2018, NEURON, V100, P294, DOI 10.1016/j.neuron.2018.10.009; Lin LX, 2019, FRONT BEHAV NEUROSCI, V13, DOI 10.3389/fnbeh.2019.00239; Liu WL, 2017, FREE RADICAL BIO MED, V112, P174, DOI 10.1016/j.freeradbiomed.2017.07.024; Luo ZY, 2020, BIOL PSYCHIAT, V87, P926, DOI 10.1016/j.biopsych.2019.10.021; Miyamae T, 2017, J NEUROSCI, V37, P4883, DOI 10.1523/JNEUROSCI.3325-16.2017; Nolan A, 2018, J NEUROTRAUM, V35, P2425, DOI 10.1089/neu.2018.5731; Page CE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56424-9; Page CE, 2019, NEUROSCI BIOBEHAV R, V105, P39, DOI 10.1016/j.neubiorev.2019.07.024; Park J, 2017, NEUROSCIENCE, V345, P193, DOI 10.1016/j.neuroscience.2016.06.013; Pilkington K, 2013, INT REV NEUROBIOL, V111, P197, DOI 10.1016/B978-0-12-411545-3.00010-9; Pozzi L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091486; Reichelt AC, 2019, FOOD FUNCT, V10, P1985, DOI [10.1039/c8fo02118j, 10.1039/C8FO02118J]; Rice J, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0829-9; Saitoh A, 2018, BEHAV BRAIN RES, V336, P77, DOI 10.1016/j.bbr.2017.08.041; Salmanzadeh H, 2020, BRAIN RES BULL, V156, P105, DOI 10.1016/j.brainresbull.2020.01.007; Scheggia D, 2020, NAT NEUROSCI, V23, P47, DOI 10.1038/s41593-019-0551-8; Shi PB, 2019, FASEB J, V33, P8614, DOI 10.1096/fj.201802192RR; Trantham-Davidson H, 2017, NEUROPSYCHOPHARMACOL, V42, P1024, DOI 10.1038/npp.2016.190; Tu CH, 2019, FRONT PSYCHIATRY, V10, DOI 10.3389/fpsyt.2019.00014; Volk DW, 2016, SCHIZOPHR RES, V177, P3, DOI 10.1016/j.schres.2016.03.001; Wang HY, 2018, AM J CHINESE MED, V46, P1387, DOI 10.1142/S0192415X18500738; Yan W, 2020, MOL PSYCHIATR, V25, P3113, DOI 10.1038/s41380-019-0391-7; Yan W, 2018, MOL PSYCHIATR, V23, DOI 10.1038/mp.2017.219; Yu J., 2016, EVID-BASED COMPL ALT, V2016; Yue N, 2018, FRONT MOL NEUROSCI, V11, DOI 10.3389/fnmol.2018.00149; Zhang Y, 2019, BRAIN BEHAV IMMUN, V79, P256, DOI 10.1016/j.bbi.2019.02.010; Zhao ZL, 2015, NEUROSCI LETT, V597, P143, DOI 10.1016/j.neulet.2015.04.045	50	6	6	2	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2020	34	9					11913	11924		10.1096/fj.202000346RR	http://dx.doi.org/10.1096/fj.202000346RR		JUL 2020	12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NK8TC	32683743				2023-01-03	WOS:000553200500001
J	Ncube, NBQ; Knight, L; Bradley, HA; Schneider, H; Laing, R				Ncube, Nondumiso B. Q.; Knight, Lucia; Bradley, Hazel Anne; Schneider, Helen; Laing, Richard			Health system actors' perspectives of prescribing practices in public health facilities in Eswatini: A Qualitative Study	PLOS ONE			English	Article							DAR-ES-SALAAM; RESISTANCE; ATTITUDES	Background Rational medicines use (RMU) is the prescribing/dispensing of good quality medicines to meet individual patient's clinical needs. Policy-makers, managers and frontline providers play critical roles in safeguarding medicine usage thus ensuring their rational use. This study investigated perspectives of key health system actors on prescribing practices and factors influencing these in Eswatini. Public sector healthcare service delivery is through health facilities (public sector, not-for-profit faith-based, industrial) and community-based care. Methods A qualitative, exploratory study using semi-structured in-depth interviews with seven policymakers and managers, and 32 facility-based actors was conducted. Drawing on Social Practice Theory, material (health system context), competence (provider) and cultural (patient and provider) factors influencing prescribing practices were explored. Results Participants were aged between 21-57years, had been practicing for 1-30 years, and were a mix of doctors, nurses, pharmacists and pharmacy-technicians. Factors contributing to irrational medicines use included: poor use of treatment guidelines, lack of RMU policies, poorly-functioning pharmaceutical and therapeutics committees, stock-outs of medicines, lack of pharmacy personnel in primary healthcare facilities, and restrictions of medicines by level of care. Provider-related factors included: knowledge, experience and practice ethic, symptomatic prescribing, high patient numbers. Patient-related factors included late presentation, language, and the need to be prescribed many medicines. Conclusion In Eswatini, prescribing practices are influenced by the interaction of factors (health system, provider and patient) that span levels (facility, region, and policy-making) of the health system. Promoting RMU thus goes beyond the availability of guidelines and provider training and requires concerted efforts of multiple stakeholders.	[Ncube, Nondumiso B. Q.; Knight, Lucia; Bradley, Hazel Anne; Schneider, Helen; Laing, Richard] Univ Western Cape, Sch Publ Hlth, Dept Community & Hlth Sci, Cape Town, South Africa; [Laing, Richard] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA	University of the Western Cape; Boston University	Ncube, NBQ (corresponding author), Univ Western Cape, Sch Publ Hlth, Dept Community & Hlth Sci, Cape Town, South Africa.	nncube@uwc.ac.za		Knight, Lucia/0000-0001-9938-6887	Institute of Tropical Medicine, University of the Western Cape; School of Public Health, University of the Western Cape; Institute of Tropical Medicine (ITM) through the School of Public Health at the University of the Western Cape	Institute of Tropical Medicine, University of the Western Cape; School of Public Health, University of the Western Cape; Institute of Tropical Medicine (ITM) through the School of Public Health at the University of the Western Cape	NBQN received support towards doing a PhD at the School of Public through an agreement between the Institute of Tropical Medicine and the School of Public Health, University of the Western Cape. The funders had no role in study design, data collection and analyses, decision to publish, or preparation of the manuscript.; The Institute of Tropical Medicine (ITM), financially supported the conduct of this study through the School of Public Health at the University of the Western Cape. The ICAP at Columbia University Eswatini office assisted with transport to go to health facilities and office space to work on the study. Dr Ferdinand Mukumbang provided technical support to this study. Dr Nkosinathi Ncube provided financial, moral and emotional support; Ms Sibonisiwe Ncube transcribed; and Mr Bheki Ginindza drove with me around Eswatini to show me some of the facilities.	Altiner A, 2007, J ANTIMICROB CHEMOTH, V60, P638, DOI 10.1093/jac/dkm254; [Anonymous], 2012, STAND TREATM GUID ES, V1st; BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; Birhanu Demeke W, J DRUG DELIV THER; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; CARRIN G, 1987, HEALTH POLICY, V7, P73, DOI 10.1016/0168-8510(87)90048-0; Chatterton T., INTRO THINKING ENERG; Cockburn J, 1997, BRIT MED J, V315, P520, DOI 10.1136/bmj.315.7107.520; De Bruycker M, 2013, PUBLIC HEALTH ACTION, V3, P118, DOI 10.5588/pha.12.0060; DiCicco-Bloom B, 2006, MED EDUC, V40, P314, DOI 10.1111/j.1365-2929.2006.02418.x; Forster DP, BR J GEN PRACT, DOI [10.1201/9781351071901-5, DOI 10.1201/9781351071901-5]; Fugelli P, TROP MED INT HEALTH, DOI [10.1046/j.1365-3156.2002.00842.x, DOI 10.1046/J.1365-3156.2002.00842.X]; Gale NK, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-117; HOGERZEIL HV, 1993, LANCET, V342, P1408, DOI 10.1016/0140-6736(93)92760-Q; Hunter DJ, 2018, P WORLDWIDE NURSING; Kamuhabwa AAR, 2015, TROP J PHARM RES, V14, P2107, DOI 10.4314/tjpr.v14i11.22; King LM., 2014, P 30 ANN ARCOM C, P13; Kumar S, 2003, BMJ-BRIT MED J, V326, P138, DOI 10.1136/bmj.326.7381.138; Kunene K, SWAZILAND PHARM STRA; Lincoln Y.S., 1985, NATURALISTIC INQUIRY, V9, P438; Magagula S V., 2017, CASE STUDY SWAZILAND; MASSELE AY, 1994, E AFR MED J, V71, P314; MORTONJONES T, 1993, BRIT MED J, V306, P1731, DOI 10.1136/bmj.306.6894.1731; Ofori-Asenso R, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3428-8; Prosser H, 2003, FAM PRACT, V20, P61, DOI 10.1093/fampra/20.1.61; Reckwitz A., 2016, EUR J SOC THEORY, V5, P243, DOI [10.1177/13684310222225432, DOI 10.1177/13684310222225432]; Reid-Searl K, 2012, J CLIN NURS, V21, P1998, DOI 10.1111/j.1365-2702.2011.03976.x; Robson C., REAL WORLD RES RESOU, V2; Schumock GT, 2004, ANN PHARMACOTHER, V38, P557, DOI 10.1345/aph.1D390; Shove E., 2012, DYNAMICS SOCIAL PRAC, DOI DOI 10.4135/9781446250655; Song Y, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0507-3; The Government of the Kingdom of Swaziland, 2017, REP PRIM MIN INT TAS; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Umnuaypornlert A, 2014, MAHIDOL U J PHARM SC, V41, P11; Vancelik S, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-122; Vazquez-Lago JM, 2012, FAM PRACT, V29, P352, DOI 10.1093/fampra/cmr084; Watkins C, 2003, QUAL SAF HEALTH CARE, V12, P29, DOI 10.1136/qhc.12.1.29; WHO, INVESTIGATE DRUG USE; Wood F, 2013, J ANTIMICROB CHEMOTH, V68, P237, DOI 10.1093/jac/dks338; World Health Organization, 1985, C EXP NAIR; World Health Organization, PROM RAT US MED COR; Yang LP, 2015, SOC SCI MED, V145, P201, DOI 10.1016/j.socscimed.2015.08.044	42	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2020	15	7							e0235513	10.1371/journal.pone.0235513	http://dx.doi.org/10.1371/journal.pone.0235513			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MQ0QU	32645026	Green Published, gold			2023-01-03	WOS:000552602700047
J	Dalhammar, K; Malmstrom, M; Schelin, M; Falkenback, D; Kristensson, J				Dalhammar, Karin; Malmstrom, Marlene; Schelin, Maria; Falkenback, Dan; Kristensson, Jimmie			The impact of initial treatment strategy and survival time on quality of end-of-life care among patients with oesophageal and gastric cancer: A population-based cohort study	PLOS ONE			English	Article							PALLIATIVE CARE; DEATH; REGISTER; AGGRESSIVENESS; CHEMOTHERAPY; SURGERY	Background Oesophageal and gastric cancer are highly lethal malignancies with a 5-year survival rate of 15-29%. More knowledge is needed about the quality of end-of-life care in order to understand the burden of the illness and the ability of the current health care system to deliver timely and appropriate end-of-life care. The aim of this study was to describe the impact of initial treatment strategy and survival time on the quality of end-of-life care among patients with oesophageal and gastric cancer. Methods This register-based cohort study included patients who died from oesophageal and gastric cancer in Sweden during 2014-2016. Through linking data from the National Register for Esophageal and Gastric Cancer, the National Cause of Death Register, and the Swedish Register of Palliative Care, 2156 individuals were included. Associations between initial treatment strategy and survival time and end-of-life care quality indicators were investigated. Adjusted risk ratios (RRs) with 95% confidence intervals were calculated using modified Poisson regression. Results Patients with a survival of <= 3 months and 4-7 months had higher RRs for hospital death compared to patients with a survival >= 17 months. Patients with a survival of <= 3 months also had a lower RR for end-of-life information and bereavement support compared to patients with a survival >= 17 months, while the risks of pain assessment and oral assessment were not associated with survival time. Compared to patients with curative treatment, patients with no tumour-directed treatment had a lower RR for pain assessment. No significant differences were shown between the treatment groups regarding hospital death, end-of-life information, oral health assessment, and bereavement support. Conclusions Short survival time is associated with several indicators of low quality end-of-life care among patients with oesophageal and gastric cancer, suggesting that a proactive palliative care approach is imperative to ensure quality end-of-life care.	[Dalhammar, Karin; Malmstrom, Marlene; Schelin, Maria; Kristensson, Jimmie] Lund Univ, Inst Palliat Care, Lund, Sweden; [Dalhammar, Karin; Malmstrom, Marlene; Kristensson, Jimmie] Lund Univ, Dept Hlth Sci, Fac Med, Lund, Sweden; [Schelin, Maria; Falkenback, Dan] Lund Univ, Dept Clin Sci, Fac Med, Lund, Sweden; [Falkenback, Dan] Skane Univ Hosp, Dept Surg, Lund, Sweden	Lund University; Lund University; Lund University; Lund University; Skane University Hospital	Dalhammar, K (corresponding author), Lund Univ, Inst Palliat Care, Lund, Sweden.; Dalhammar, K (corresponding author), Lund Univ, Dept Hlth Sci, Fac Med, Lund, Sweden.	Karin.dalhammar@med.lu.se		Malmstrom, Marlene/0000-0001-9575-0311	ALF (Swedish NHS) [ALF 2018:0092]; Sjoberg Foundation [Sjoberg F2019/210]	ALF (Swedish NHS); Sjoberg Foundation	This work was supported by the ALF (governmental founding from the Swedish NHS; grant number ALF 2018:0092; URL:https://www.med.lu.se/intramed/styrning_organisation/ekonomi_alf/alf) and the Sjoberg Foundation (grant number Sjoberg F2019/210; URL: https://sjobergstiftelsen.se) awarded to JK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Accordino MK, 2017, BREAST CANCER RES TR, V166, P549, DOI 10.1007/s10549-017-4420-4; Addington-Hall JM, 2009, PALLIATIVE MED, V23, P190, DOI 10.1177/0269216309102525; American Society of Clinical Oncology, 2019, QUAL ONC PRACT IN; [Anonymous], 2017, STATISTIKDATABAS DOD; Bergquist H, 2007, DIS ESOPHAGUS, V20, P523, DOI 10.1111/j.1442-2050.2007.00741.x; Bischoff KE, 2013, J AM GERIATR SOC, V61, P209, DOI 10.1111/jgs.12105; Blazeby JM, 2000, CANCER, V88, P1781; Boxer MM, 2011, CANCER-AM CANCER SOC, V117, P5112, DOI 10.1002/cncr.26149; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; British Geriatrics Society, 2010, PALL END LIF CAR OLD; Brooke HL, 2017, EUR J EPIDEMIOL, V32, P765, DOI 10.1007/s10654-017-0316-1; Brooks GA, 2017, J PALLIAT MED, V20, P42, DOI 10.1089/jpm.2016.0231; Brooks GA, 2014, J CLIN ONCOL, V32, P496, DOI 10.1200/JCO.2013.52.4330; ECOG-ACRIN Cancer Research Group, EC PERF STAT; Ethier JL, 2018, J PALLIAT CARE, V33, P125, DOI 10.1177/0825859718762287; Gani F, 2018, J PALLIAT MED, V21, P428, DOI 10.1089/jpm.2017.0295; Gieniusz M, 2018, AM J HOSP PALLIAT ME, V35, P21, DOI 10.1177/1049909116682470; Glare P, 2003, BRIT MED J, V327, P195, DOI 10.1136/bmj.327.7408.195; Gomes B, 2012, ANN ONCOL, V23, P2006, DOI 10.1093/annonc/mdr602; Hong JH, 2013, CANCER RES TREAT, V45, P270, DOI 10.4143/crt.2013.45.4.270; Hunt RW, 2018, J PALLIAT CARE; Janah A, 2019, CLIN EPIDEMIOL, V11, P443, DOI 10.2147/CLEP.S198499; Janmaat VT, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004063.pub4; Johnson PC, 2019, J ONCOL PRACT, V15, pE420, DOI 10.1200/JOP.18.00595; Kauppila JH, 2020, ANN SURG, V271, P311, DOI 10.1097/SLA.0000000000002972; Kelly M, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0285-5; Kempf E, 2017, EUR J CANCER, V79, P31, DOI 10.1016/j.ejca.2017.03.029; Kross EK, 2014, CHEST, V145, P313, DOI 10.1378/chest.13-1351; Lee SS, 2014, INT J SURG, V12, P700, DOI 10.1016/j.ijsu.2014.05.067; Linder G, 2016, BRIT J SURG, V103, P1326, DOI 10.1002/bjs.10234; Lundstrom S, 2012, PALLIATIVE MED, V26, P313, DOI 10.1177/0269216311414758; Malmstrom M, 2013, INT J NURS STUD, V50, P44, DOI 10.1016/j.ijnurstu.2012.08.011; Martinsson L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186804; Merchant SJ, 2017, J PALLIAT CARE, V32, P92, DOI 10.1177/0825859717738464; Mokadem I, 2019, GASTRIC CANCER, V22, P1263, DOI 10.1007/s10120-019-00956-6; Morrison RS, 2013, CURR OPIN SUPPORT PA, V7, P201, DOI 10.1097/SPC.0b013e32836103e5; Olmsted CL, 2014, JAMA SURG, V149, P1169, DOI 10.1001/jamasurg.2014.2101; Prater LC, 2019, AM J HOSP PALLIAT ME, V36, P1089, DOI 10.1177/1049909119848987; Regionala Cancercentrum i Samverkan, 2016, NAT VARDPR PALL VARD; Rouvelas I, 2005, LANCET ONCOL, V6, P864, DOI 10.1016/S1470-2045(05)70347-8; Sheffield KM, 2011, CANCER-AM CANCER SOC, V117, P5003, DOI 10.1002/cncr.26115; Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208; Sohda M, 2017, ANN THORAC CARDIOVAS, V23, P1, DOI 10.5761/atcs.ra.16-00162; Svenska Palliativregistret, 2017, RSRAPP SVENSK PALL V; Task Force on Surgical Palliative care, 2005, Bull Am Coll Surg, V90, P34; Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3; Van den Block L, 2007, BMC HEALTH SERV RES, V7, DOI 10.1186/1472-6963-7-69; Wagner AD, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub4; Wang SM, 2014, AM J MANAG CARE, V20, pE353; Whitney RL, 2019, J ONCOL PRACT, V15, P37, DOI 10.1200/JOP.18.00254; Whitney RL, 2017, J CLIN ONCOL, V35, P3610, DOI 10.1200/JCO.2017.72.4963; WHO | WHO Definition of Palliative Care, 2018, WHO DEF PALL CAR; Wright AA, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1219; Wu CC, 2016, ONCOLOGIST, V21, P771, DOI 10.1634/theoncologist.2015-0445; Yamashita K, 2017, WORLD J SURG, V41, P2337, DOI 10.1007/s00268-017-4024-5; Ziegler LE, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018284	56	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2020	15	6							e0235045	10.1371/journal.pone.0235045	http://dx.doi.org/10.1371/journal.pone.0235045			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC8RX	32569329	gold, Green Published			2023-01-03	WOS:000543547900006
J	Espanol, AJ; Salem, A; Di Bari, M; Cristofaro, I; Sanchez, Y; Tata, AM; Sales, ME				Espanol, Alejandro J.; Salem, Agustina; Di Bari, Maria; Cristofaro, Ilaria; Sanchez, Yamila; Tata, Ada M.; Sales, Maria E.			The metronomic combination of paclitaxel with cholinergic agonists inhibits triple negative breast tumor progression. Participation of M-2 receptor subtype	PLOS ONE			English	Article							NITRIC-OXIDE SYNTHASE; MUSCARINIC RECEPTORS; MULTIDRUG-RESISTANCE; COLON-CANCER; ACTIVATION; EGFR; PROLIFERATION; ANGIOGENESIS; EXPRESSION; LUNG	Triple negative tumors are more aggressive than other breast cancer subtypes and there is a lack of specific therapeutic targets on them. Since muscarinic receptors have been linked to tumor progression, we investigated the effect of metronomic therapy employing a traditional anti-cancer drug, paclitaxel plus muscarinic agonists at low doses on this type of tumor. We observed that MDA-MB231 tumor cells express muscarinic receptors, while they are absent in the non-tumorigenic MCF-10A cell line, which was used as control. The addition of carbachol or arecaidine propargyl ester, a non-selective or a selective subtype 2 muscarinic receptor agonist respectively, plus paclitaxel reduces cell viability involving a down-regulation in the expression of ATP "binding cassette" G2 drug transporter and epidermal growth factor receptor. We also detected an inhibition of tumor cell migration and anti-angiogenic effects produced by those drug combinationsin vitroandin vivo(in NUDE mice) respectively. Our findings provide substantial evidence about subtype 2 muscarinic receptors as therapeutic targets for the treatment of triple negative tumors.	[Espanol, Alejandro J.; Salem, Agustina; Sanchez, Yamila; Sales, Maria E.] Consejo Nacl Invest Cient & Tecn, Ctr Pharmacol & Bot Studies CEFYBO, Buenos Aires, DF, Argentina; [Espanol, Alejandro J.; Salem, Agustina; Sanchez, Yamila; Sales, Maria E.] Univ Buenos Aires, Sch Med, Dept Pharmacol, Buenos Aires, DF, Argentina; [Espanol, Alejandro J.; Di Bari, Maria; Cristofaro, Ilaria; Tata, Ada M.] Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, Rome, Italy; [Tata, Ada M.] Sapienza Univ Rome, Ctr Neurobiol Daniel Bovet, Rome, Italy	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; Sapienza University Rome; Sapienza University Rome	Espanol, AJ (corresponding author), Consejo Nacl Invest Cient & Tecn, Ctr Pharmacol & Bot Studies CEFYBO, Buenos Aires, DF, Argentina.; Espanol, AJ (corresponding author), Univ Buenos Aires, Sch Med, Dept Pharmacol, Buenos Aires, DF, Argentina.; Espanol, AJ; Tata, AM (corresponding author), Sapienza Univ Rome, Dept Biol & Biotechnol Charles Darwin, Rome, Italy.; Tata, AM (corresponding author), Sapienza Univ Rome, Ctr Neurobiol Daniel Bovet, Rome, Italy.	aespan_1999@yahoo.com; adamaria.tata@uniroma1.it		Espanol, Alejandro/0000-0001-8222-4259	ANPCyT PICT [2396]; Agencia Nacional de Promocion Cientifica y Tecnologica; CONICET PIP [201501 00239]; Consejo Nacional de Investigaciones Cientificas y Tecnicas; UBA UBACYT, Universidad de Buenos Aires [20020130100168BA]	ANPCyT PICT(ANPCyT); Agencia Nacional de Promocion Cientifica y Tecnologica(ANPCyT); CONICET PIP(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); Consejo Nacional de Investigaciones Cientificas y Tecnicas(Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)); UBA UBACYT, Universidad de Buenos Aires	AJE; ANPCyT PICT 2015-2017, 2396. Agencia Nacional de Promocion Cientifica y Tecnologica. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. MES, CONICET PIP 2015-2017, 201501 00239; Consejo Nacional de Investigaciones Cientificas y Tecnicas; UBA UBACYT 2014-2017, 20020130100168BA Universidad de Buenos Aires. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alessandrini F, 2015, INT IMMUNOPHARMACOL, V29, P105, DOI 10.1016/j.intimp.2015.05.032; Baig AM, 2017, ANTI-CANCER DRUG, V28, P75, DOI 10.1097/CAD.0000000000000432; Basu M, 2013, CANCER-AM CANCER SOC, V119, P2524, DOI 10.1002/cncr.28024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai XJ, 2017, ONCOTARGET, V8, P84248, DOI 10.18632/oncotarget.20539; Chavez Kathryn J, 2010, Breast Dis, V32, P35, DOI 10.3233/BD-2010-0307; CHEN TR, 1977, EXP CELL RES, V104, P255, DOI 10.1016/0014-4827(77)90089-1; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cristofaro I, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030657; Curtis MJ, 2018, BRIT J PHARMACOL, V175, P987, DOI 10.1111/bph.14153; Dai XX, 2018, CANCER MANAG RES, V10, P3069, DOI 10.2147/CMAR.S159660; Davel Lilia E., 2004, Angiogenesis, V7, P45, DOI 10.1023/B:AGEN.0000037329.45326.a8; Dei Tos Angelo Paolo, 2013, EJC Suppl, V11, P23, DOI 10.1016/j.ejcsup.2013.07.027; Di Bari M, 2015, NEUROCHEM INT, V90, P261, DOI 10.1016/j.neuint.2015.09.008; Doherty MR, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1136-x; Sales ME, 2016, CURR PHARM DESIGN, V22, P2170, DOI 10.2174/1381612822666160229115317; Espanol AJ, 2004, INT J MOL MED, V13, P311; Farhana L, 2016, STEM CELL RES THER, V7, DOI 10.1186/s13287-016-0439-4; Fiszman GL, 2007, CANCER BIOL THER, V6, P1106, DOI 10.4161/cbt.6.7.4330; Fiszman Gabriel L., 2008, Current Immunology Reviews, V4, P176, DOI 10.2174/157339508785160732; Giacomini KM, 2010, NAT REV DRUG DISCOV, V9, P215, DOI 10.1038/nrd3028; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Hanahan D, 2000, J CLIN INVEST, V105, P1045, DOI 10.1172/JCI9872; Hu T, 2016, WORLD J GASTROENTERO, V22, P6876, DOI 10.3748/wjg.v22.i30.6876; Islam MS, 2020, J CELL PHYSIOL, V235, P8114, DOI 10.1002/jcp.29466; Espanol AJ, 2015, INT IMMUNOPHARMACOL, V29, P87, DOI 10.1016/j.intimp.2015.03.018; Espanol AJ, 2013, ANTI-CANCER AGENT ME, V13, P1273, DOI 10.2174/18715206113139990136; Ji XM, 2017, CANCER LETT, V386, P24, DOI 10.1016/j.canlet.2016.10.031; Lee MJ, 2016, J CANCER RES CLIN, V142, P125, DOI 10.1007/s00432-015-2009-z; Li CR, 2015, MOL CANCER THER, V14, P2049, DOI 10.1158/1535-7163.MCT-15-0155; Liu BH, 2015, BRAIN RES, V1611, P93, DOI 10.1016/j.brainres.2015.03.023; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; MONTE M, 1994, FREE RADICAL BIO MED, V17, P259, DOI 10.1016/0891-5849(94)90081-7; Pacini L, 2014, CANCER BIOL THER, V15, P1489, DOI 10.4161/15384047.2014.955740; Paleari L, 2008, SEMIN CANCER BIOL, V18, P211, DOI 10.1016/j.semcancer.2007.12.009; Pelegrina LT, 2013, J CLIN IMMUNOL, V33, P427, DOI 10.1007/s10875-012-9804-y; Pollock NI, 2015, CLIN CANCER RES, V21, P4597, DOI 10.1158/1078-0432.CCR-14-3338; Said AH, 2017, BIOCHEM J, V474, P647, DOI 10.1042/BCJ20160704; Sales ME, 2019, CURR CLIN PHARMACOL, V14, P91, DOI 10.2174/1574884714666181203095437; Schettini F, 2016, CANCER TREAT REV, V46, P20, DOI 10.1016/j.ctrv.2016.03.012; Schmitt NC, 2015, MOL CANCER THER, V14, P2103, DOI 10.1158/1535-7163.MCT-15-0305; Spindel ER, 2016, CURR PHARM DESIGN, V22, P2152, DOI 10.2174/1381612822666160127114237; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Turner TH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58438-0; Yotsumoto F, 2013, MOL CANCER RES, V11, P506, DOI 10.1158/1541-7786.MCR-12-0428; Zhang L, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/357485	46	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2020	15	9							e0226450	10.1371/journal.pone.0226450	http://dx.doi.org/10.1371/journal.pone.0226450			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR9ME	32911509	Green Published, gold, Green Submitted			2023-01-03	WOS:000571885900049
J	Blazhenkova, O; Dogerlioglu-Demir, K				Blazhenkova, Olesya; Dogerlioglu-Demir, Kivilcim			The shape of the pill: Perceived effects, evoked bodily sensations and emotions	PLOS ONE			English	Article							SCHEMA CONGRUITY; PRODUCT DESIGN; MENTAL-IMAGERY; PREFERENCE; EXPECTATIONS; RECOGNITION; PERCEPTION; MECHANISMS; AESTHETICS; COLORS	Current research examined the differential effects of pills' shape (angular vs. curvy) on the perceived efficacy of the medicine, evoked bodily sensations and emotions. We investigated these effects by using different types of angular vs. curved stimuli: abstract drawn shapes (Study 1), 3D-printed mockup pills (Study 2) and photographs of the existing pills (Study 3). Participants were asked to imagine 'taking' angular and curved pills. They had to focus on the bodily sensations and report the evoked activations/deactivations in different body parts. Across three studies, we found that the angular pills evoke overall more activations in the body compared to curvy pills. We further reported differences in the topography of angular vs. curved pills'-triggered sensations in different body parts. Our results also revealed that angularity is linked with an energizing effect while roundness is associated with a calming effect. The shape effects were demonstrated not only in self-reported energized vs. calm subjective feelings but also in performance on a timed cognitive test. Compared to incongruent designs, pill designs (angular vs. curved) congruent with proposed drug benefits (energizing vs. calming) were perceived as more effective. Moreover, we found differences in emotions triggered by pills of different shapes. The present research provided new findings on angularity vs. curvature perception that may be valuable for cognitive psychology, marketing, pharmaceutical and supplements industry, and other applied fields.	[Blazhenkova, Olesya] Sabanci Univ, Fac Arts & Social Sci, Istanbul, Turkey; [Dogerlioglu-Demir, Kivilcim] Sabanci Univ, Sabanci Business Sch, Istanbul, Turkey	Sabanci University; Sabanci University	Blazhenkova, O (corresponding author), Sabanci Univ, Fac Arts & Social Sci, Istanbul, Turkey.	olesya.blazhenkova@sabanciuniv.edu	Blazhenkova, Olesya/H-8367-2016	Blazhenkova, Olesya/0000-0002-9513-7258	Sabanci University	Sabanci University(Sabanci University)	The authors received no specific funding for this work. All expenses regarding 3D printing of pills were paid from the researchers' Individual Research Fund provided by Sabanci University.	Aggarwal P, 2007, J CONSUM RES, V34, P468, DOI 10.1086/518544; [Anonymous], 2014, DIABETES CARE, V38, pS1; ARONOFF J, 1992, J PERS SOC PSYCHOL, V62, P1050, DOI 10.1037/0022-3514.62.6.1050; Bar M, 2007, NEUROPSYCHOLOGIA, V45, P2191, DOI 10.1016/j.neuropsychologia.2007.03.008; Bar M, 2006, PSYCHOL SCI, V17, P645, DOI 10.1111/j.1467-9280.2006.01759.x; BASSILI JN, 1979, J PERS SOC PSYCHOL, V37, P2049, DOI 10.1037/0022-3514.37.11.2049; Basulto D, 2015, ARCHIT REV, V237, P34; Becker L, 2011, FOOD QUAL PREFER, V22, P17, DOI 10.1016/j.foodqual.2010.06.007; BLACKWELL B, 1972, LANCET, V1, P1279; Blazhenkova O, 2017, CURVED VS ANGULAR SH; Blazhenkova O., 2017, PREFERENCES ANGULAR; Blazhenkova O, 2018, PERCEPTION, V47, P67, DOI 10.1177/0301006617731048; BUCKALEW LW, 1982, PERCEPT MOTOR SKILL, V55, P915, DOI 10.2466/pms.1982.55.3.915; BUCKALEW LW, 1982, J CLIN PSYCHOPHARM, V2, P245; Carbon CC, 2010, ACTA PSYCHOL, V134, P233, DOI 10.1016/j.actpsy.2010.02.004; Doyle JR, 2006, J CONSUM PSYCHOL, V16, P112, DOI 10.1207/s15327663jcp1602_2; Ekstrom R.B., 1976, KIT FACTOR REFERENCE; Ganis G, 2004, COGNITIVE BRAIN RES, V20, P226, DOI 10.1016/j.cogbrainres.2004.02.012; Ghoshal T, 2016, PSYCHOLOGY OF DESIGN: CREATING CONSUMER APPEAL, P91; Goyanes A, 2015, INT J PHARMACEUT, V494, P657, DOI 10.1016/j.ijpharm.2015.04.069; Hevner K, 1935, J APPL PSYCHOL, V19, P385, DOI 10.1037/h0055538; Horton WS, 2003, PSYCHON B REV, V10, P104, DOI 10.3758/BF03196473; HUSSAIN MZ, 1972, BRIT J PSYCHIAT, V120, P507, DOI 10.1192/bjp.120.558.507; Ilyuk Veronika., 2014, INNOVATION MARKETING, P315; ISHAI A, 1995, SCIENCE, V268, P1772, DOI 10.1126/science.7792605; Jamroz W, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2454-x; Jiang YW, 2016, J CONSUM RES, V42, P709, DOI 10.1093/jcr/ucv049; Khan A, 2010, PSYCHOPHARMACOLOGY, V211, P113, DOI 10.1007/s00213-010-1874-z; Kocher S, 2019, J CONSUM BEHAV, V18, P179, DOI 10.1002/cb.1756; Kohler W, 1929, GESTALT PSYCHOL LIVE; Kotler P., 1984, J BUS STRAT, V5, P16, DOI [10.1108/eb039054, DOI 10.1108/EB039054]; Kotta S, 2018, CURR PHARM DESIGN, V24, P5039, DOI 10.2174/1381612825666181206123828; Leder H, 2011, PERCEPTION, V40, P649, DOI 10.1068/p6845; Lorenz V., 1986, B VOLCANOL, V48, P265, DOI [DOI 10.1007/BF01081755, 10.1007/BF01081755]; Luffarelli J, 2019, J MARKETING RES, V56, P89, DOI 10.1177/0022243718820548; Lundholm H, 1921, PSYCHOL REV, V28, P43, DOI 10.1037/h0072647; Mandler G.P., 1982, AFFECT COGNITION 17; MEYERSLEVY J, 1989, J CONSUM RES, V16, P39, DOI 10.1086/209192; Munar E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141106; Notman N, 2018, INDOOR AIR, V28, P789, DOI 10.1111/ina.12498; Nummenmaa L, 2014, P NATL ACAD SCI USA, V111, P646, DOI 10.1073/pnas.1321664111; Palmer SE, 2013, ANNU REV PSYCHOL, V64, P77, DOI 10.1146/annurev-psych-120710-100504; Palumbo L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140043; Pearson J, 2015, TRENDS COGN SCI, V19, P590, DOI 10.1016/j.tics.2015.08.003; PILDITCH C, 1976, CHASQUI, V6, P77, DOI 10.2307/29739284; Poffenberger AT, 1924, J APPL PSYCHOL, V8, P187, DOI 10.1037/h0073513; Ramachandran VS, 2001, P ROY SOC B-BIOL SCI, V268, P979, DOI 10.1098/rspb.2000.1576; SCHAPIRA K, 1970, BMJ-BRIT MED J, V2, P446, DOI 10.1136/bmj.2.5707.446; Schlegel K, 2014, PSYCHOL ASSESSMENT, V26, P666, DOI 10.1037/a0035246; Shiv B, 2005, J MARKETING RES, V42, P383, DOI 10.1509/jmkr.2005.42.4.383; Silvia P.J., 2009, EMPIR STUD ARTS, V27, P25, DOI DOI 10.2190/EM.27.1.B; Silvia PJ, 2010, PSYCHOL AESTHET CREA, V4, P75, DOI 10.1037/a0017081; The Sedona Conference, 2010, SEDONA C J, V11, P267; Turner SA, 2006, EMOTION, V6, P670, DOI 10.1037/1528-3542.6.4.670; Veryzer RW, 1995, ADV CONSUM RES, V22, P641; Westerman SJ, 2012, PSYCHOL MARKET, V29, P595, DOI 10.1002/mar.20546; Zhang YL, 2006, PERS SOC PSYCHOL B, V32, P794, DOI 10.1177/0146167206286626; Zwaan RA, 2016, PSYCHON B REV, V23, P1028, DOI 10.3758/s13423-015-0864-x	58	6	6	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2020	15	9							e0238378	10.1371/journal.pone.0238378	http://dx.doi.org/10.1371/journal.pone.0238378			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NQ6EE	32898184	gold, Green Published			2023-01-03	WOS:000570962500020
J	Chaijan, M; Panpipat, W				Chaijan, Manat; Panpipat, Worawan			Nutritional composition and bioactivity of germinated Thai indigenous rice extracts: A feasibility study	PLOS ONE			English	Article							GAMMA-AMINOBUTYRIC-ACID; ANTIOXIDANT ACTIVITY; BARLEY; MALT; THIAMINE; SOAKING; GRAIN; GABA	The feasibility of the production of germinated rice extracts using indigenous rice from Southern Thailand, includingKhemtong(KHT) andKhai Mod Rin(KMR) from a single location at the Pak Phanang River Basin in Nakhon Si Thammarat, was investigated. The nutritional composition and bioactivity of the germinated rice extracts from both cultivars were evaluated. Optimum germination time for both rices was 96 h, leading to the highest GABA, thiamine, free amino acid, total sugar, and alpha-amylase activity (p<0.05). Germinated KHT had a higher alpha-amylase activity than germinated KMR at all germination times. Mashing at 60 degrees C/pH 5.5 rendered the extract with the highest GABA content (p<0.05) and desirable contents of other nutrients. In comparison with germinatedSungyod(local colored rice) andJasmine(commercial Thai rice) extracts, KHT and KMR showed a higher scavenging activity against DPPH center dot, OH center dot, and H2O2(p<0.05) with a comparable ABTS(center dot+)inhibition. For metal chelation, reducing power and ACE inhibitory activity, the germinatedSungyodextract was greater than KHT/KMR. The results demonstrated the potential use of germinated local Thai rice for the production of functional beverages.	[Chaijan, Manat; Panpipat, Worawan] Walailak Univ, Sch Agr Technol, Dept Agroind, Food Technol & Innovat Res Ctr Excellence, Thasala, Nakhon Si Thamm, Thailand	Walailak University	Panpipat, W (corresponding author), Walailak Univ, Sch Agr Technol, Dept Agroind, Food Technol & Innovat Res Ctr Excellence, Thasala, Nakhon Si Thamm, Thailand.	pworawan@wu.ac.th			Thailand Research Fund; Walailak University under Area Based Research Community (ABC) program [WU-TRF_ABC60_03]; New Strategic Research (P2P) project, Walailak University, Thailand	Thailand Research Fund(Thailand Research Fund (TRF)); Walailak University under Area Based Research Community (ABC) program; New Strategic Research (P2P) project, Walailak University, Thailand	This study was funded by the Thailand Research Fund and Walailak University under Area Based Research Community (ABC) program [grant No. WU-TRF_ABC60_03]. This research was partially supported by the New Strategic Research (P2P) project, Walailak University, Thailand. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson JW, 2009, NUTR REV, V67, P188, DOI 10.1111/j.1753-4887.2009.00189.x; AOAC, 2000, OFFICIAL METHODS ANA, V17th; BAKER JE, 1991, INSECT BIOCHEM, V21, P303, DOI 10.1016/0020-1790(91)90020-F; Benjakul S, 1997, J AGR FOOD CHEM, V45, P3423, DOI 10.1021/jf970294g; Bera S, 2018, J FOOD SCI TECH MYS, V55, P704, DOI 10.1007/s13197-017-2981-1; Buglass AJ, 2014, HDB FOOD CHEM, P1; Carvalho DO, 2016, COMPR REV FOOD SCI F, V15, P927, DOI 10.1111/1541-4337.12218; CUSHMAN DW, 1971, BIOCHEM PHARMACOL, V20, P1637, DOI 10.1016/0006-2952(71)90292-9; Diana M, 2014, J FUNCT FOODS, V10, P407, DOI 10.1016/j.jff.2014.07.004; Elkhalil EAI, 2001, FOOD CHEM, V72, P29, DOI 10.1016/S0308-8146(00)00195-3; Fellows PJ, 2017, PRINCIPLES PRACTICE, V4th; Goufo P, 2014, FOOD SCI NUTR, V2, P75, DOI 10.1002/fsn3.86; Hassani A, 2014, FOOD SCI TECHNOL INT, V20, P453, DOI 10.1177/1082013213490710; Hidalgo M, 2012, GENES NUTR, V7, P295, DOI 10.1007/s12263-011-0263-5; Kahkonen MP, 2003, J AGR FOOD CHEM, V51, P628, DOI 10.1021/jf025551i; Kajimoto O, 2004, J JPN SOC FOOD SCI, V51, P79, DOI 10.3136/nskkk.51.79; Komatsuzaki N, 2007, J FOOD ENG, V78, P556, DOI 10.1016/j.jfoodeng.2005.10.036; Kuhbeck F, 2005, J I BREWING, V111, P316; Limsuwanmanee J, 2014, LWT-FOOD SCI TECHNOL, V57, P718, DOI 10.1016/j.lwt.2014.01.042; Liu Q, 2007, FOOD CHEM, V102, P732, DOI 10.1016/j.foodchem.2006.06.051; Liu SP, 2002, J PHARMACEUT BIOMED, V30, P685, DOI 10.1016/S0731-7085(02)00356-4; Mohan BH, 2010, LWT-FOOD SCI TECHNOL, V43, P784, DOI 10.1016/j.lwt.2010.01.002; Obuzor G. U., 2010, African Journal of Food Science, V4, P585; Owuama CI, 1999, J I BREWING, V105, P23, DOI 10.1002/j.2050-0416.1999.tb00002.x; PALMIANO EP, 1972, PLANT PHYSIOL, V49, P751, DOI 10.1104/pp.49.5.751; Pantoa T, 2020, J CEREAL SCI, V93, DOI 10.1016/j.jcs.2020.102970; Patil SB, 2011, J FOOD SCI TECH MYS, V48, P661, DOI 10.1007/s13197-011-0232-4; Pereira GK, 1997, J MOL STRUC-THEOCHEM, V392, P169; Pothitirat W, 2009, FITOTERAPIA, V80, P442, DOI 10.1016/j.fitote.2009.06.005; Prodanov M, 1997, Z LEBENSM UNTERS F A, V205, P48, DOI 10.1007/s002170050122; Solgajova M, 2014, J MICROB BIOTEC FOOD, V3, P281; Usansa U, 2011, J I BREW, V11, P739; WINDHEUSER JJ, 1962, J PHARM SCI, V51, P354, DOI 10.1002/jps.2600510415; Zhang Q, 2014, J FUNCT FOODS, V10, P283, DOI 10.1016/j.jff.2014.06.009	34	8	8	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2020	15	8							e0237844	10.1371/journal.pone.0237844	http://dx.doi.org/10.1371/journal.pone.0237844			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NI7TB	32834013	Green Published			2023-01-03	WOS:000565550400031
J	Khushhal, A; Nichols, S; Carroll, S; Abt, G; Ingle, L				Khushhal, Alaa; Nichols, Simon; Carroll, Sean; Abt, Grant; Ingle, Lee			Characterising the application of the "progressive overload" principle of exercise training within cardiac rehabilitation: A United Kingdom-based community programme	PLOS ONE			English	Article							MYOCARDIAL-INFARCTION; DISEASE	Background Recent concerns have cast doubt over the effectiveness of cardiac rehabilitation [CR] programmes for improving cardiorespiratory fitness [CRF] in patients with a history of cardiac disease in the United Kingdom [UK]. We aimed to characterise the weekly progression of exercise training dose over an 8-week Phase III CR programme as we felt this may be partly responsible for the lack of improvement in CRF reported in previous studies. Design Observational study. Methods We evaluated a community-based Phase III CR programme in the UK. During each training session, patients wore an Apple Watch and the weekly progression of exercise training dose/load was quantified. The analysis was based on 332 individual training sessions. Exercise intensity [% heart rate reserve] during the cardiovascular [CV] exercise training component [%HRR-CV], CV training duration; estimated changes in cardiorespiratory fitness [change in estimated metabolic equivalents (METs)]; session rating of perceived exertion [sRPE], sRPE training load [sRPE-TL], and exercise training impulse [TRIMP] were evaluated. Results Thirty cardiac patients [83% male; age [SD] 67.0 [10.0] years; body mass index [SD] 28.3 [4.6] kg center dot m(-2)] were recruited to an 8-week programme [16 sessions in total]. Bayesian repeated-measures ANOVA indicated anecdotal evidence for the alternative hypothesis for changes in %HRR-CV (BF10= 0.61), sRPE (BF10= 1.1), and change in estimated METs (BF10= 1.2) during CR. Conversely, Bayesian repeated-measures ANOVA showed extreme evidence for changes in CV training duration (BF10= 2.438e+26), TRIMP (BF10= 71436), and sRPE-TL (BF10= 779570). Conclusion The key exercise training principle of progressive overload was only partially applied. Increases observed in exercise dose were due to increases in the duration of CV training, rather than combined with increases in exercise intensity [%HRR-CV and sRPE]. Accordingly, allied health professionals must ensure that exercise intensity is more consistently progressed to optimise the exercise stimulus and improvements in CRF and patient outcomes.	[Khushhal, Alaa; Carroll, Sean; Abt, Grant; Ingle, Lee] Univ Hull, Dept Sport Hlth & Exercise Sci, Kingston Upon Hull, Yorks, England; [Nichols, Simon] Sheffield Hallam Univ, Ctr Sport & Exercise Sci, Collegiate Campus, Sheffield, S Yorkshire, England	University of Hull; Sheffield Hallam University	Ingle, L (corresponding author), Univ Hull, Dept Sport Hlth & Exercise Sci, Kingston Upon Hull, Yorks, England.	l.ingle@hull.ac.uk		Khushhal, Alaa/0000-0002-6051-5650; Nichols, Simon/0000-0003-0377-6982; Ingle, Lee/0000-0001-6155-5577; Abt, Grant/0000-0002-4079-9270; Khushhal, Alaa/0000-0003-4690-1042				ACPICR, 2015, STAND PHYS ACT EX CA, V3; Allen J, 2007, PHYSIOL MEAS, V28, pR1, DOI 10.1088/0967-3334/28/3/R01; BACPR, 2012, CARD DIS PREV REH; Banister E., 1991, PHYSL TESTING HIGH P; Cohen J., 2013, STAT POWER ANAL BEHA; Doherty P, 2017, OPEN HEART, V4, DOI 10.1136/openhrt-2016-000519; Foster C, 2001, J STRENGTH COND RES, V15, P109, DOI 10.1519/00124278-200102000-00019; Foster C, 1996, Wis Med J, V95, P370; Gecelter R, 2021, J NUCL CARDIOL, V28, P375, DOI 10.1007/s12350-020-02039-x; Heran BS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub3, 10.1002/14651858.CD001800.pub2]; IBM Corp, 2019, IBM SPSS STAT WIND V; Iellamo F, 2014, INT J CARDIOL, V176, P394, DOI 10.1016/j.ijcard.2014.07.076; INBAR O, 1994, MED SCI SPORT EXER, V26, P538; Ingle L, 2013, HEART, V99, P1298, DOI 10.1136/heartjnl-2013-304015; JASP Team, 2019, JASP VERS 0 10 2 COM; Khushhal A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217654; Khushhal Alaa, 2017, Sports Med Int Open, V1, pE206, DOI 10.1055/s-0043-120195; Lee M. D., 2013, BAYESIAN COGNITIVE M, DOI DOI 10.1017/CBO9781139087759; LONDEREE BR, 1982, RES Q EXERCISE SPORT, V53, P297, DOI 10.1080/02701367.1982.10605252; Nichols S, 2018, CLIN PHYSIOL FUNCT I, V38, P681, DOI 10.1111/cpf.12468; Pymer S, 2019, EUR J PREV CARDIOL, V22; Sandercock GRH, 2013, HEART, V99, P785, DOI 10.1136/heartjnl-2012-303055; Seki E, 2008, CIRC J, V72, P1230, DOI 10.1253/circj.72.1230; Volterrani Maurizio, 2016, Card Fail Rev, V2, P63, DOI 10.15420/cfr.2015:26:1; Well RP, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019656; West RR, 2012, HEART, V98, P637, DOI 10.1136/heartjnl-2011-300302; Zheng H, 2008, J REHABIL MED, V40, P776, DOI 10.2340/16501977-0254	27	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2020	15	8							e0237197	10.1371/journal.pone.0237197	http://dx.doi.org/10.1371/journal.pone.0237197			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE5VG	32790796	Green Published, Green Accepted, gold			2023-01-03	WOS:000562668300076
J	Tamamura, Y; Matsuura, M; Shiba, S; Nishikimi, T				Tamamura, Yusuke; Matsuura, Micihko; Shiba, Sumiko; Nishikimi, Toshio			Heart failure assessed based on plasma B-type natriuretic peptide (BNP) levels negatively impacts activity of daily living in patients with hip fracture	PLOS ONE			English	Article							CARDIAC REHABILITATION; FUNCTIONAL RECOVERY; ELDERLY-PATIENTS; FOCUSED UPDATE; EXERCISE; PREDICTORS; DIAGNOSIS; POLYPEPTIDE; GUIDELINES; MANAGEMENT	Several studies have shown that nutrition and muscle strength were associated with functional recovery in patients with hip fracture. However, the impact of heart failure on the improvement of activity of daily living (ADL) in patients with hip fracture have not been fully investigated. The purpose was investigating the effect of heart failure on the ADL improvement by rehabilitation in patients with hip fracture. A total of 116 patients with hip fracture discharged from our convalescent rehabilitation ward were studied. Heart failure was assessed based on plasma B-type natriuretic peptide (BNP) levels on admission. ADL was assessed based on rehabilitation effectiveness (REs), which was calculated using the FIM instrument. Clinical, demographic, and nutritional variables were measured. Multiple regression analysis was performed with REs as the dependent variable; variables showing significant correlation with REs in univariate analyses were selected as independent variables. Based on plasma BNP levels, we assigned 39 patients to a Low group: 22 (17-25) median (interquartile) pg/mL, 39 to a Middle group: 52 (42-65) pg/mL, and 38 to a High group: 138 (93-209) pg/mL. REs, handgrip strength, Hb, albumin, and GNRI were higher and age was younger in the Low group than High group (each p < 0.01, respectively). Multiple linear regression analysis revealed that age (p < 0.05), sex (p < 0.05), handgrip strength (p < 0.01), FOIS at admission (p < 0.01), rehabilitation time per day (p < 0.01), and BNP (p < 0.05) were significantly associated with REs. The effect of rehabilitation on ADL improvement was significantly blunted in the High group compared to the Low group. In conclusion, these results suggest that heart failure assessed based on plasma BNP levels negatively impacts improvements in ADL achieved through rehabilitation in patients with hip fracture.	[Tamamura, Yusuke; Matsuura, Micihko] Wakakusa Tatsuma Rehabil Hosp, Dept Rehabil, Daito City, Osaka, Japan; [Shiba, Sumiko] Konan Womens Univ, Dept Phys Therapy, Higashinada Ku, Kobe, Hyogo, Japan; [Nishikimi, Toshio] Wakakusa Tatsuma Rehabil Hosp, Dept Med, Daito City, Osaka, Japan; [Nishikimi, Toshio] Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto, Japan	Kyoto University	Nishikimi, T (corresponding author), Wakakusa Tatsuma Rehabil Hosp, Dept Med, Daito City, Osaka, Japan.; Nishikimi, T (corresponding author), Kyoto Univ, Grad Sch Med, Dept Cardiovasc Med, Sakyo Ku, Kyoto, Japan.	nishikim@kuhp.kyoto-u.ac.jp		Shiba, Sumiko/0000-0001-5313-6866	Ministry of Education, Culture, Sports, Science and Technology of Japan [18K08103]	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This study was supported in part by Scientific Research Grants-in-Aid 18K08103 (to TN) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, which had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alegre-Lopez J, 2005, OSTEOPOROSIS INT, V16, P729, DOI 10.1007/s00198-004-1740-0; Dyer SM, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0332-0; Ensrud KE, 2013, J GERONTOL A-BIOL, V68, P1236, DOI 10.1093/gerona/glt092; Haentjens P, 2010, ANN INTERN MED, V152, P380, DOI 10.7326/0003-4819-152-6-201003160-00008; Hamaguchi S, 2011, CIRC J, V75, P2403, DOI 10.1253/circj.CJ-11-0267; Haykowsky MJ, 2016, CAN J CARDIOL, V32, pS382, DOI 10.1016/j.cjca.2016.06.001; HEINEMANN AW, 1987, ARCH NEUROL-CHICAGO, V44, P1167, DOI 10.1001/archneur.1987.00520230051013; Hunt SA, 2009, J AM COLL CARDIOL, V53, pE1, DOI 10.1016/j.jacc.2008.11.013; Inoue T, 2017, CLIN NUTR, V36, P1320, DOI 10.1016/j.clnu.2016.08.021; Itagaki Atsunori, 2019, J Phys Ther Sci, V31, P277, DOI 10.1589/jpts.31.277; Kanis JA, 2012, OSTEOPOROSIS INT, V23, P2239, DOI 10.1007/s00198-012-1964-3; Kinugasa Y, 2017, HEART, V103, P184, DOI 10.1136/heartjnl-2016-309995; Koh GCH, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003483; Lieberman D, 2006, ARCH PHYS MED REHAB, V87, P167, DOI 10.1016/j.apmr.2005.10.002; Maisel A, 2013, J AM COLL CARDIOL, V61, P1726, DOI 10.1016/j.jacc.2013.01.052; Mathew RO, 2013, AM J PHYS MED REHAB, V92, P686, DOI 10.1097/PHM.0b013e318282bc67; McCullough PA, 2002, CIRCULATION, V106, P416, DOI 10.1161/01.CIR.0000025242.79963.4C; Morrison LK, 2002, J AM COLL CARDIOL, V39, P202, DOI 10.1016/S0735-1097(01)01744-2; NISHIKIMI T, 1986, J HYPERTENS, V4, pS546; NISHIKIMI T, 1988, AM HEART J, V115, P753, DOI 10.1016/0002-8703(88)90875-7; NISHIKIMI T, 1986, AM J CARDIOL, V58, P1119, DOI 10.1016/0002-9149(86)90131-1; Nishikimi T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053233; Nishikimi T, 2011, J CARDIOL, V57, P131, DOI 10.1016/j.jjcc.2011.01.002; Nishioka S, 2018, J ACAD NUTR DIET, V118, P1270, DOI 10.1016/j.jand.2018.02.012; Obokata M, 2018, EUR HEART J, V39, P2810, DOI 10.1093/eurheartj/ehy268; Okura Y, 2008, CIRC J, V72, P489, DOI 10.1253/circj.72.489; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Ponikowski P, 2016, EUR HEART J, V37, P2129, DOI 10.1093/eurheartj/ehw128; Reddy YNV, 2019, EUR HEART J, V40, P3721, DOI 10.1093/eurheartj/ehz713; Rossignol P, 2019, LANCET, V393, P1034, DOI 10.1016/S0140-6736(18)31808-7; Selakovic I, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213223; Semel J, 2010, PM&R, V2, P799, DOI 10.1016/j.pmrj.2010.04.019; Shiba N, 2011, CIRC J, V75, P823, DOI 10.1253/circj.CJ-11-0135; Shyu YIL, 2004, OSTEOPOROSIS INT, V15, P475, DOI 10.1007/s00198-003-1557-2; Troughton RW, 2007, ANN MED, V39, P242, DOI 10.1080/07853890701232057; Yancy CW, 2017, J AM COLL CARDIOL, V70, P776, DOI [10.1016/j.jacc.2017.04.025, 10.1161/CIR.0000000000000509]; YASUE H, 1994, CIRCULATION, V90, P195, DOI 10.1161/01.CIR.90.1.195; Zwisler AD, 2016, INT J CARDIOL, V221, P963, DOI 10.1016/j.ijcard.2016.06.207	38	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2020	15	8							e0237387	10.1371/journal.pone.0237387	http://dx.doi.org/10.1371/journal.pone.0237387			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE5VG	32790735	gold, Green Published			2023-01-03	WOS:000562668300011
J	Brosseau, G; Page, N; de Jaham, C; del Castillo, JMRE				Brosseau, Gabrielle; Page, Nadia; de Jaham, Caroline; del Castillo, Jerome R. E.			Medical honey for canine nasal intertrigo: A randomized, blinded, placebo-controlled, adaptive clinical trial to support antimicrobial stewardship in veterinary dermatology	PLOS ONE			English	Article							SYSTEMIC ANTIMICROBIALS; SUGGESTED GUIDELINES; TOPICAL APPLICATION; ATOPIC-DERMATITIS; SEVERITY SCALE; SKIN; MANUKA; STAPHYLOCOCCUS; INFECTIONS; METHYLGLYOXAL	Intertrigo is a skin fold dermatitis often requiring recurrent treatment with topical antiseptics or antibiotics, which can select antimicrobial resistance. To minimize this risk, we tested the effectiveness of medical-grade Manuka honey at treating intertrigo as compared to a placebo hydrogel. We additionally characterized the culturable microbial flora of intertrigo and recorded any adverse effect with either treatment. During this randomized, placebo-controlled, double-blinded, adaptive group-sequential trial, the owners washed the affected sites on their dog with water, dried and applied a thin film of either the honey or the placebo product once daily for 21 days. Cytological and lesional composite scores, owner-assessed pruritus, and microbial cultures were assessed prior to treatment and on Day-22. The fixed effects of time, treatment, and animal-related variables on the pruritus and on each composite score, accounting for random dog effect, were estimated separately with generalized linear mixed models for repeated count outcomes (alpha = 0.05). The null hypothesis of equal treatment effects was rejected at the first interim analysis. The placebo (n = 16 dogs) outperformed the medical honey (n = 13 dogs) at improving both the cytological score (TreatmentxTime = -0.35 +/- 0.17; P = 0.04) and clinical score (TreatmentxTime = -0.28 +/- 0.13; P = 0.04). A microbial burden score higher than 4 increased the severity of the cytological score (dichotomous score: 0.29 +/- 0.11; P = 0.01), which in turn increased the severity of the clinical score and pruritus score. For every unit increase in cytological score, the linear predictor of clinical score increased by 0.042 +/- 0.019 (P = 0.03), and the one of pruritus score increased by 0.12 +/- 0.05 (P = 0.01). However, medical honey outperformed the placebo at alleviating the dog's owner-assessed pruritus after statistically controlling for masking effects (Time = -0.94 +/- 0.24; P = 0.002; and TreatmentxTime = 0.80 +/- 0.36; P = 0.04). Unilateral tests of the least-square mean estimates revealed that honey only significantly improved the pruritus (Hommel-adjusted P = 0.003), while the placebo only improved the cytological and clinical scores (Hommel-adjusted P = 0.01 and 0.002, respectively). Taken together, these results question the value of Manuka honey at treating nasal intertrigo in dogs.	[Brosseau, Gabrielle; Page, Nadia; de Jaham, Caroline] Ctr Vet DMV, Dept Dermatol, Montreal, PQ, Canada; [del Castillo, Jerome R. E.] Univ Montreal, Dept Vet Biomed, Quebecs Anim Pharmacol Res Grp GREPAQ, St Hyacinthe, PQ, Canada	Universite de Montreal	Brosseau, G (corresponding author), Ctr Vet DMV, Dept Dermatol, Montreal, PQ, Canada.	gbrosseau@centredmv.com	del Castillo, Jérôme RE/J-6976-2013; del Castillo, Jerome/AAM-9409-2020	del Castillo, Jérôme RE/0000-0001-5046-7926; del Castillo, Jerome/0000-0001-5046-7926	Canadian Academy of Veterinary Dermatology Research Grant; Centre Veterinaire DMV	Canadian Academy of Veterinary Dermatology Research Grant; Centre Veterinaire DMV	The study was supported by the Canadian Academy of Veterinary Dermatology Research Grant (https://www.cavd.ca/) attributed to GB and the Centre Veterinaire DMV (https://centredmv.com/en/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, METH ID CULT MICR US; Bannoehr J, 2012, VET DERMATOL, V23, DOI 10.1111/j.1365-3164.2011.01021.x; Banovic F, 2019, VET DERMATOL, V30, DOI [10.1111/vde.12754 31038263, DOI 10.1111/VDE.12754 31038263]; Beco L, 2013, VET REC, V172, P72, DOI 10.1136/vr.101069; Beco L, 2013, VET REC, V172, P156, DOI 10.1136/vr.101070; Benjamini Y, 2001, ANN STAT, V29, P1165; Bischofberger AS, 2016, AUST VET J, V94, P27, DOI 10.1111/avj.12405; BUDACH SC, 2012, VET DERMATOL, V23, DOI DOI 10.1111/J.1365-3164.2012.01057.X22731400; Budach SC, 2012, VET DERMATOL, V23, DOI 10.1111/j.1365-3164.2012.01075.x; Burns DT, 2018, FOOD ANAL METHOD, V11, P1561, DOI 10.1007/s12161-018-1154-9; Casadevall A, 2017, CLIN INFECT DIS, V64, P823, DOI 10.1093/cid/cix067; Chan CW, 2013, FOOD CHEM, V141, P1772, DOI 10.1016/j.foodchem.2013.04.092; Choi JK, 2014, FOOD CHEM TOXICOL, V68, P135, DOI 10.1016/j.fct.2014.03.021; CLSI, 2021, PERFORMANCE STANDARD, V5th; Cokcetin NN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167780; Cooper RA, 2010, EUR J CLIN MICROBIOL, V29, P1237, DOI 10.1007/s10096-010-0992-1; Cremers N, 2020, VET DERMATOL, V31, P90, DOI 10.1111/vde.12811; Danby SG, 2013, PEDIATR DERMATOL, V30, P42, DOI 10.1111/j.1525-1470.2012.01865.x; Desai KM, 2010, CAN J PHYSIOL PHARM, V88, P273, DOI 10.1139/Y10-001; Doelle M, 2016, VET DERMATOL, V27, P140, DOI 10.1111/vde.12300; Elman SA, 2016, J INVEST DERMATOL, V136, P1325, DOI 10.1016/j.jid.2016.02.807; Fessler AT, 2018, VET MICROBIOL, V221, P153, DOI 10.1016/j.vetmic.2018.06.001; Frey E, 2018, JAVMA-J AM VET MED A, V253, P1396, DOI 10.2460/javma.253.11.1396; Fukuyama T, 2017, EUR J PHARMACOL, V794, P20, DOI 10.1016/j.ejphar.2016.11.020; Givol O, 2019, WOUND REPAIR REGEN, V27, P548, DOI 10.1111/wrr.12737; Gonzales AJ, 2013, VET DERMATOL, V24, P48, DOI 10.1111/j.1365-3164.2012.01098.x; Grego E, 2016, SCHWEIZ ARCH TIERH, V158, P521, DOI 10.17236/sat00075; Hardy BT, 2012, J VET INTERN MED, V26, P334, DOI 10.1111/j.1939-1676.2011.00868.x; Hicks CW, 2012, INTENS CARE MED, V38, P2063, DOI 10.1007/s00134-012-2735-5; Hillier A, 2014, VET DERMATOL, V25, P163, DOI 10.1111/vde.12118; HOMMEL G, 1988, BIOMETRIKA, V75, P383, DOI 10.1093/biomet/75.2.383; Jakobsson Z., 2011, PILOTSTUDIE ATT UTVA; Johnson RC, 2015, J CLIN MICROBIOL, V53, P3677, DOI 10.1128/JCM.01771-15; Kalapos MP, 2008, CHEM-BIOL INTERACT, V171, P251, DOI 10.1016/j.cbi.2007.11.009; Knight SM, 2013, J AM ANIM HOSP ASSOC, V49, P237, DOI 10.5326/JAAHA-MS-5858; Kurita G, 2019, J INFECT CHEMOTHER, V25, P531, DOI 10.1016/j.jiac.2019.02.017; Lansdown ABG, 2007, WOUND REPAIR REGEN, V15, P2, DOI 10.1111/j.1524-475X.2006.00179.x; Leong AG, 2012, INNATE IMMUN-LONDON, V18, P459, DOI 10.1177/1753425911422263; Lloyd DH, 2018, MICROBIOL SPECTR, V6, DOI 10.1128/microbiolspec.ARBA-0023-2017; Lozano C, 2017, VECTOR-BORNE ZOONOT, V17, P268, DOI 10.1089/vbz.2016.2048; Lu J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54576-2; Majid A, 2015, INT J MOL SCI, V16, P24048, DOI 10.3390/ijms161024048; Mandal Manisha Deb, 2011, Asian Pacific Journal of Tropical Biomedicine, V1, P154, DOI 10.1016/S2221-1691(11)60016-6; Matafome P, 2017, MED RES REV, V37, P368, DOI 10.1002/med.21410; Mavric E, 2008, MOL NUTR FOOD RES, V52, P483, DOI 10.1002/mnfr.200700282; McDonald CM, 2018, NPJ SCI FOOD, V2, DOI 10.1038/s41538-018-0016-6; Miller WH, 2013, SOLAR DERMATITIS MUL, V7th, P659; Morris DO, 2017, VET DERMATOL, V28, P304, DOI 10.1111/vde.12444; Nijhuis W A, 2012, Br J Nurs, V21, P9; NYBY MD, 1977, J CLIN MICROBIOL, V6, P87; O'Neill DG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217928; O'Neill Dan G, 2018, Canine Genet Epidemiol, V5, P3, DOI 10.1186/s40575-018-0057-9; O'Neill Dan G, 2016, Canine Genet Epidemiol, V3, P4, DOI 10.1186/s40575-016-0034-0; Olivry T, 2014, VET DERMATOL, V25, P77, DOI 10.1111/vde.12107; Oryan A, 2016, ANN PLAS SURG, V77, P37, DOI 10.1097/SAP.0000000000000239; Paul NC, 2011, ZOONOSES PUBLIC HLTH, V58, P533, DOI 10.1111/j.1863-2378.2011.01398.x; Pullar JM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9080866; Rodrigues H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093519; Rossi CC, 2019, VET MICROBIOL, V232, P65, DOI 10.1016/j.vetmic.2019.04.009; Rybnicek J, 2009, VET DERMATOL, V20, P115, DOI 10.1111/j.1365-3164.2008.00728.x; SAS Institute I, 2017, SAS STAT 143 US GUID, P8476; Selleri P, 2015, JAVMA-J AM VET MED A, V246, P639, DOI 10.2460/javma.246.6.639; Song SJ, 2013, ELIFE, V2, DOI 10.7554/eLife.00458; Stroup WW, 2013, GEN LINEAR MIXED MOD, Vxxv; Tausk F, 2013, CLIN DERMATOL, V31, P86, DOI 10.1016/j.clindermatol.2011.11.012; Terkelsen LH, 2000, SCAND J PLAST RECONS, V34, P15; Thiele JJ, 2007, MOL ASPECTS MED, V28, P646, DOI 10.1016/j.mam.2007.06.001; Tramuta C, 2017, SCHWEIZ ARCH TIERH, V159, P117, DOI 10.17236/sat00106; Udenberg TJ, 2014, VET DERMATOL, V25, P435, DOI 10.1111/vde.12138; van Duijkeren E, 2011, VET MICROBIOL, V150, P338, DOI 10.1016/j.vetmic.2011.02.012; Weese JS, 2015, J VET INTERN MED, V29, P487, DOI 10.1111/jvim.12562; Weese JS, 2013, VET DERMATOL, V24, P137, DOI 10.1111/j.1365-3164.2012.01076.x; Wheeler JJ, 2019, ACTA DERM-VENEREOL, V99, P1131, DOI 10.2340/00015555-3297; White RAS, 2006, VET CLIN N AM-SMALL, V36, P895, DOI 10.1016/j.cvsm.2006.04.004; Williamson Deborah A, 2017, Clin Microbiol Rev, V30, P827, DOI 10.1128/CMR.00112-16; Zhao SN, 2019, J CARDIOVASC PHARM T, V24, P278, DOI 10.1177/1074248418810809	76	0	0	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2020	15	8							e0235689	10.1371/journal.pone.0235689	http://dx.doi.org/10.1371/journal.pone.0235689			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC2EP	32760092	gold, Green Published			2023-01-03	WOS:000561027200009
J	Yasui, D; Yamane, A; Itoh, H; Kobayashi, M; Kumita, S				Yasui, Daisuke; Yamane, Aya; Itoh, Hiroshi; Kobayashi, Masayuki; Kumita, Shin-ichiro			In vivo evaluation of a monodisperse solid-in-oil-in-water miriplatin/ lipiodol emulsion in transcatheter arterial chemoembolization using a rabbit VX2 tumor model	PLOS ONE			English	Article							UNRESECTABLE HEPATOCELLULAR-CARCINOMA; TRANSARTERIAL CHEMOEMBOLIZATION; CHEMOTHERAPY; EPIRUBICIN; EFFICACY; MICRODROPLETS; SAFETY; DAMAGE; TRIAL; AGENT	Transcatheter arterial chemoembolization (TACE) is a standard treatment for unresectable hepatocellular carcinoma; however, it does not always result in tumor control. Nevertheless, treatment outcome can be improved with monodisperse emulsions of anticancer agents. In this study, the distribution of a monodisperse miriplatin-Lipiodol emulsion in the tumor and its safety were evaluated in ten Japanese white rabbits. VX2 tumor was implanted into the left liver lobe. The animals were divided into control and experimental groups (of five animals each) and respectively administered a conventional miriplatin suspension or the emulsion via the left hepatic artery. Computed tomography (CT) was performed before, immediately after, and two days following TACE. All rabbits were sacrificed two days after the procedure. Each tumor was removed and cut in half for assessment of iodine concentration in one half by mass spectroscopy and evaluation of Lipiodol accumulation and adverse events in the other half. Mean Hounsfield unit (HU) values were measured using plain CT images taken before and after TACE. Iodine concentration was higher in the experimental group [1100 (750-1500) ppm, median (range)] than in the control group [840 (660-1800) ppm], although statistically not significant. Additionally, the HU value for the experimental group was higher than that for the control group immediately after [199.6 (134.0-301.7) vs. 165.3 (131.4-280.5)] and two days after [114.2 (56.1-229.8) vs. 58.3 (42.9-132.5)] TACE, although statistically not significant. Cholecystitis was observed in one rabbit in the control group. Ischemic bile duct injury was not observed in any group. The results show that Lipiodol accumulation and retention in VX2 tumor can possibly be improved with a monodisperse emulsion; however, it should be verified with a larger study. Moreover, no significant adverse events are associated with the use of the emulsion.	[Yasui, Daisuke; Kumita, Shin-ichiro] Nippon Med Sch, Dept Radiol, Tokyo, Japan; [Yamane, Aya] Nippon Med Sch, Dept Radiol, Musashi Kosugi Hosp, Kawasaki, Kanagawa, Japan; [Itoh, Hiroshi; Kobayashi, Masayuki] Adv Anim Med Ctr, Shizuoka, Shizuoka, Japan	Nippon Medical School; Nippon Medical School	Yasui, D (corresponding author), Nippon Med Sch, Dept Radiol, Tokyo, Japan.	ledhotcp@nms.ac.jp			Japan society for the promotion of science [DY 17K16489]	Japan society for the promotion of science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	DY 17K16489 Japan society for the promotion of science https://www.jsps.go.jp/j-grantsinaid/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arai H, 2015, HEPATOL RES, V45, P663, DOI 10.1111/hepr.12403; Bannangkoon K, 2019, CLIN MOL HEPATOL, V25, P74, DOI 10.3350/cmh.2018.0072; Golfieri R, 2014, BRIT J CANCER, V111, P255, DOI 10.1038/bjc.2014.199; Hanada M, 2009, CANCER CHEMOTH PHARM, V64, P473, DOI 10.1007/s00280-008-0895-3; Heimbach JK, 2018, HEPATOLOGY, V67, P358, DOI 10.1002/hep.29086; Higashi S, 1999, J PHARMACOL EXP THER, V289, P816; HIGASHI S, 1995, CANCER, V75, P1245, DOI 10.1002/1097-0142(19950315)75:6<1245::AID-CNCR2820750606>3.0.CO;2-U; Ikeda M, 2018, J GASTROENTEROL, V53, P281, DOI 10.1007/s00535-017-1374-6; Irie T, 2013, CARDIOVASC INTER RAD, V36, P706, DOI 10.1007/s00270-012-0476-z; Iwazawa J, 2014, HEPATOL RES, V44, P201, DOI 10.1111/hepr.12104; Iwazawa Jin, 2012, Cancer Manag Res, V4, P113, DOI 10.2147/CMAR.S30431; Kishimoto S, 2018, ANTICANCER RES, V38, P247, DOI 10.21873/anticanres.12214; Kora S, 2013, HEPATOL RES, V43, P1100, DOI 10.1111/hepr.12050; Lammer J, 2010, CARDIOVASC INTER RAD, V33, P41, DOI 10.1007/s00270-009-9711-7; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Masada T, 2020, J VASC INTERV RADIOL, V31, P347, DOI 10.1016/j.jvir.2019.06.015; Matsui O, 2011, ABDOM IMAGING, V36, P264, DOI 10.1007/s00261-011-9685-1; Okusaka T, 2004, INVEST NEW DRUG, V22, P169, DOI 10.1023/B:DRUG.0000011793.72775.d1; Otsuji K, 2015, HEPATOL RES, V45, P514, DOI 10.1111/hepr.12376; Seko Y, 2013, HEPATOL RES, V43, P942, DOI 10.1111/hepr.12041; Yanagie H, 2017, BRIT J RADIOL, V90, DOI 10.1259/bjr.20170004; Yasui D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/359296	22	2	2	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2020	15	8							e0222553	10.1371/journal.pone.0222553	http://dx.doi.org/10.1371/journal.pone.0222553			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB3DK	32756561	Green Published, Green Submitted, gold			2023-01-03	WOS:000560393300013
J	Pedron, S; Dumontoy, S; Dimauro, J; Haffen, E; Andrieu, P; Van Waes, V				Pedron, Solene; Dumontoy, Stephanie; Dimauro, Julien; Haffen, Emmanuel; Andrieu, Patrice; Van Waes, Vincent			Open-tES: An open-source stimulator for transcranial electrical stimulation designed for rodent research	PLOS ONE			English	Article							NONINVASIVE BRAIN-STIMULATION; THERAPEUTIC-USE; MOTOR CORTEX; TDCS; MODEL; EXCITABILITY; DEPRESSION; PLASTICITY; MODULATION; MECHANISMS	Non-invasive neuromodulatory techniques, including transcranial direct current stimulation (tDCS), have been shown to modulate neuronal function and are used both in cognitive neuroscience and to treat neuropsychiatric conditions. In this context, animal models provide a powerful tool to identify the neurobiological mechanisms of action of tDCS. However, finding a current generator that is easily usable and which allows a wide range of stimulation parameters can be difficult and/or expensive. Here, we introduce the Open-tES device, a project under a Creative Commons License (CC BY, SA 4.0) shared on the collaborative platform Git-Hub. This current generator allows tDCS (and other kinds of stimulations) to be realized, is suitable for rodents, is easy to use, and is low-cost. Characterization has been performed to measure the precision and accuracy of the current delivered. We also aimed to compare its effects with a commercial stimulator used in clinical trials (DC-Stimulator Plus, NeuroConn, Germany). To achieve this, a behavioral study was conducted to evaluate its efficacy for decreasing depression related-behavior in mice. The stimulator precision and accuracy were better than 250 nA and 25 nA, respectively. The behavioral evaluation performed in mice in the present study did not reveal any significant differences between the commercial stimulator used in clinical trials and the Open-tES device. Accuracy and precision of the stimulator ensure high repeatability of the stimulations. This current generator constitutes a reliable and inexpensive tool that is useful for preclinical studies in the field of non-invasive electrical brain stimulation.	[Pedron, Solene; Dumontoy, Stephanie; Dimauro, Julien; Haffen, Emmanuel; Andrieu, Patrice; Van Waes, Vincent] Univ Bourgogne Franche Comte, Lab Integrat & Clin Neurosci EA481, Besancon, France	Universite de Franche-Comte	Van Waes, V (corresponding author), Univ Bourgogne Franche Comte, Lab Integrat & Clin Neurosci EA481, Besancon, France.	vincent.van_waes@univ-fcomte.fr	haffen, emmanuel/R-2765-2017	haffen, emmanuel/0000-0002-4091-518X; Van Waes, Vincent/0000-0003-0568-7836	region Bourgogne-Franche Comte; University of Franche-Comte; city of Besancon; Fondation pour la Recherche en Alcoologie	region Bourgogne-Franche Comte(Region Bourgogne-Franche-Comte); University of Franche-Comte; city of Besancon(Region Bourgogne-Franche-Comte); Fondation pour la Recherche en Alcoologie	This work was supported in part by the region Bourgogne-Franche Comte (VVW), the University of Franche-Comte (VVW), the city of Besancon (SP, VVW) and the Fondation pour la Recherche en Alcoologie (VVW). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Batsikadze G, 2013, J PHYSIOL-LONDON, V591, P1987, DOI 10.1113/jphysiol.2012.249730; Bennabi D, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00159; Brighina F, 2019, FRONT HUM NEUROSCI, V13, DOI 10.3389/fnhum.2019.00040; Moreira SFD, 2016, LIFE SCI, V145, P233, DOI 10.1016/j.lfs.2015.10.011; Donde C, 2017, PROG NEURO-PSYCHOPH, V78, P123, DOI 10.1016/j.pnpbp.2017.05.021; Ekhtiari H, 2019, NEUROSCI BIOBEHAV R, V104, P118, DOI 10.1016/j.neubiorev.2019.06.007; Elsner B, 2017, J NEUROENG REHABIL, V14, DOI 10.1186/s12984-017-0301-7; Hadar R, 2020, MOL PSYCHIATR, V25, P896, DOI 10.1038/s41380-019-0356-x; Iodice R, 2017, RESTOR NEUROL NEUROS, V35, P497, DOI 10.3233/RNN-170735; Jackson MP, 2016, CLIN NEUROPHYSIOL, V127, P3425, DOI 10.1016/j.clinph.2016.08.016; Kouzani AZ, 2016, IEEE T NEUR SYS REH, V24, P192, DOI 10.1109/TNSRE.2015.2468579; Lefaucheur JP, 2017, CLIN NEUROPHYSIOL, V128, P56, DOI 10.1016/j.clinph.2016.10.087; Liebetanz D, 2009, CLIN NEUROPHYSIOL, V120, P1161, DOI 10.1016/j.clinph.2009.01.022; Marquez-Ruiz J, 2012, P NATL ACAD SCI USA, V109, P6710, DOI 10.1073/pnas.1121147109; Monai H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11100; Monte-Silva K, 2013, BRAIN STIMUL, V6, P424, DOI 10.1016/j.brs.2012.04.011; Monte-Silva K, 2010, J NEUROPHYSIOL, V103, P1735, DOI 10.1152/jn.00924.2009; Nitsche MA, 2003, J PHYSIOL-LONDON, V553, P293, DOI 10.1113/jphysiol.2003.049916; Paulus W, 2011, NEUROPSYCHOL REHABIL, V21, P602, DOI 10.1080/09602011.2011.557292; Peanlikhit T, 2017, BRAIN STIMUL, V10, P748, DOI 10.1016/j.brs.2017.03.012; Pedron S, 2013, EUROPEAN PSYCHIAT, V28, P1, DOI [10.1016/j.eurpsy.2011.07.002, DOI 10.1016/J.EURPSY.2011.07.002]; Pedron S, 2017, ADDICT BIOL, V22, P1267, DOI 10.1111/adb.12415; Pedron S, 2014, NEUROPSYCHOPHARMACOL, V39, P981, DOI 10.1038/npp.2013.298; Pellicciari MC, 2018, J ECT, V34, P193, DOI 10.1097/YCT.0000000000000539; PODDA MV, 2016, SCI REP, V6, DOI DOI 10.1038/S41598-016-0015-2; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Regner GG, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00189; Rohan JG, 2015, J NEUROSCI, V35, P12824, DOI 10.1523/JNEUROSCI.2376-15.2015; Shirahige L, 2016, HEADACHE, V56, P1565, DOI 10.1111/head.12981; Souza A, 2018, BRAIN RES, V1682, P14, DOI 10.1016/j.brainres.2017.12.005; Adachi LNS, 2015, EXP BRAIN RES, V233, P1377, DOI 10.1007/s00221-015-4212-1; Adachi LNS, 2012, BRAIN RES, V1489, P17, DOI 10.1016/j.brainres.2012.10.009; Starnes K, 2019, BRAIN SCI, V9, DOI 10.3390/brainsci9100283; Tortella G, 2015, WORLD J PSYCHIATR, V5, P88, DOI 10.5498/wjp.v5.i1.88; WEN HZ, 2017, FRONT BEHAV NEUROSCI, V11, DOI DOI 10.3389/FNBEH.2017.00011	35	2	2	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2020	15	7							e0236061	10.1371/journal.pone.0236061	http://dx.doi.org/10.1371/journal.pone.0236061			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ3BK	32663223	Green Published, gold			2023-01-03	WOS:000552771400013
J	Song, E; Wang, RS; Leopold, JA; Loscalzo, J				Song, Euijun; Wang, Rui-Sheng; Leopold, Jane A.; Loscalzo, Joseph			Network determinants of cardiovascular calcification and repositioned drug treatments	FASEB JOURNAL			English	Article						blood vessel; calcification; protein interaction; smooth muscle cell; therapeutics	CORONARY-ARTERY CALCIFICATION; SMOOTH-MUSCLE-CELLS; INTIMA-MEDIA THICKNESS; PROTEOME-SCALE MAP; VASCULAR CALCIFICATION; HUMAN INTERACTOME; SIGNALING PATHWAY; MAMMALIAN TARGET; DISEASE; INFLAMMATION	Ectopic cardiovascular calcification is a highly prevalent pathology for which there are no effective novel or repurposed pharmacotherapeutics to prevent disease progression. We created a human calcification endophenotype module (ie, the "calcificasome") by mapping vascular calcification genes (proteins) to the human vascular smooth muscle-specific protein-protein interactome (218 nodes and 632 edges,P < 10(-5)). Network proximity analysis was used to demonstrate that the calcificasome overlapped significantly with endophenotype modules governing inflammation, thrombosis, and fibrosis in the human interactome (P < 0.001). A network-based drug repurposing analysis further revealed that everolimus, temsirolimus, and pomalidomide are predicted to target the calcificasome. The efficacy of these agents in limiting calcification was confirmed experimentally by treating human coronary artery smooth muscle cells in an in vitro calcification assay. Each of the drugs affected expression or activity of their predicted target in the network, and decreased calcification significantly (P < 0.009). An integrated network analytical approach identified novel mediators of ectopic cardiovascular calcification and biologically plausible candidate drugs that could be repurposed to target calcification. This methodological framework for drug repurposing has broad applicability to other diseases.	[Song, Euijun; Wang, Rui-Sheng; Loscalzo, Joseph] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA; [Leopold, Jane A.] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Loscalzo, J (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.	jloscalzo@rics.bwh.harvard.edu	Loscalzo, Joseph/ABD-8980-2021	Wang, Ruisheng/0000-0003-4920-4357; Song, Jun-Seop/0000-0002-5886-4210	National Heart, Lung, and Blood Institute (NHLBI) [HG007690, HL108630, HL119145, HL125215]; American Heart Association (AHA) [D700382, 19AIML34980000]	National Heart, Lung, and Blood Institute (NHLBI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); American Heart Association (AHA)(American Heart Association)	National Heart, Lung, and Blood Institute (NHLBI), Grant/Award Number: HG007690, HL108630, HL119145 and HL125215; American Heart Association (AHA), Grant/Award Number: D700382 and 19AIML34980000	Alyesh DM, 2019, CIRC-ARRHYTHMIA ELEC, V12, DOI 10.1161/CIRCEP.118.007023; Balcells M, 2010, CIRCULATION, V121, P2192, DOI 10.1161/CIRCULATIONAHA.109.877282; Barabasi AL, 2011, NAT REV GENET, V12, P56, DOI 10.1038/nrg2918; Budoff MJ, 2010, JACC-CARDIOVASC IMAG, V3, P1229, DOI 10.1016/j.jcmg.2010.08.018; Budoff MJ, 2009, AM HEART J, V158, P554, DOI 10.1016/j.ahj.2009.08.007; Cai ZJ, 2016, CIRC RES, V119, P422, DOI 10.1161/CIRCRESAHA.116.308301; Calderon-Margalit R, 2014, ARTERIOSCL THROM VAS, V34, P2688, DOI 10.1161/ATVBAHA.114.304136; Chen FL, 2020, NAT PROD RES, V34, P2816, DOI 10.1080/14786419.2019.1596092; Cheng FX, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05116-5; Demer LL, 2008, CIRCULATION, V117, P2938, DOI 10.1161/CIRCULATIONAHA.107.743161; Doherty TM, 2003, P NATL ACAD SCI USA, V100, P11201, DOI 10.1073/pnas.1932554100; Ewing RM, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100134; Folsom AR, 2008, ARCH INTERN MED, V168, P1333, DOI 10.1001/archinte.168.12.1333; Fox EA, 2005, THROMB HAEMOSTASIS, V94, P362, DOI 10.1160/TH05-04-0266; Frauscher B, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01866; Ganesan AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110662; Garcia-Gras E, 2006, J CLIN INVEST, V116, P2012, DOI 10.1172/JCI27751; Ghiassian SD, 2016, SCI REP-UK, V6, DOI 10.1038/srep27414; Goh KI, 2007, P NATL ACAD SCI USA, V104, P8685, DOI 10.1073/pnas.0701361104; Guney E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10331; Gysi DM, 2020, ARXIV200407229; Havugimana PC, 2012, CELL, V150, P1068, DOI 10.1016/j.cell.2012.08.011; Hein MY, 2015, CELL, V163, P712, DOI 10.1016/j.cell.2015.09.053; Henaut L, 2016, EXPERT OPIN THER TAR, V20, P89, DOI 10.1517/14728222.2015.1081685; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Huttlin EL, 2017, NATURE, V545, P505, DOI 10.1038/nature22366; Huttlin EL, 2015, CELL, V162, P425, DOI 10.1016/j.cell.2015.06.043; Jayalath RW, 2005, EUR J VASC ENDOVASC, V30, P476, DOI 10.1016/j.ejvs.2005.04.030; Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21; Koschutzki D, 2008, GENE REGUL SYST BIO, V2, P193, DOI 10.4137/GRSB.S702; Kristensen AR, 2012, NAT METHODS, V9, P907, DOI 10.1038/nmeth.2131; Krusche CA, 2011, BASIC RES CARDIOL, V106, P617, DOI 10.1007/s00395-011-0175-y; Lebwohl D, 2013, ANN NY ACAD SCI, V1291, P14, DOI 10.1111/nyas.12122; Lee KM, 2011, BBA-MOL CELL RES, V1813, P448, DOI 10.1016/j.bbamcr.2011.01.005; Li JF, 2011, MOL CELL BIOL, V31, P1134, DOI 10.1128/MCB.01025-10; Liabeuf S, 2014, CARDIOVASC DIABETOL, V13, DOI 10.1186/1475-2840-13-85; Libby P, 2001, CIRCULATION, V103, P1718, DOI 10.1161/01.CIR.103.13.1718; Liu YB, 2015, FASEB J, V29, P4829, DOI 10.1096/fj.15-274050; Lopez-Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119; Loscalzo J, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100163; Meigs JB, 2002, DIABETES CARE, V25, P1313, DOI 10.2337/diacare.25.8.1313; Menche J, 2015, SCIENCE, V347, DOI 10.1126/science.1257601; Newman RH, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.12; Pilichou K, 2009, J EXP MED, V206, P1787, DOI 10.1084/jem.20090641; Rajamannan NM, 2011, CIRCULATION, V124, P1783, DOI 10.1161/CIRCULATIONAHA.110.006767; Rogers MA, 2019, NAT REV CARDIOL, V16, P261, DOI 10.1038/s41569-018-0123-8; Rolland T, 2014, CELL, V159, P1212, DOI 10.1016/j.cell.2014.10.050; Rual JF, 2005, NATURE, V437, P1173, DOI 10.1038/nature04209; Schlotter F, 2018, CIRCULATION, V138, P377, DOI 10.1161/CIRCULATIONAHA.117.032291; Sim HJ, 2016, MOL CELL BIOCHEM, V419, P157, DOI 10.1007/s11010-016-2760-8; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Talbott EO, 2004, J CLIN ENDOCR METAB, V89, P5454, DOI 10.1210/jc.2003-032237; Turei D, 2016, NAT METHODS, V13, P965, DOI 10.1038/nmeth.4077; Venkatesan K, 2009, NAT METHODS, V6, P83, DOI 10.1038/NMETH.1280; Vinayagam A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001699; Wan CH, 2015, NATURE, V525, P339, DOI 10.1038/nature14877; Wang RS, 2014, NEW J PHYS, V16, DOI 10.1088/1367-2630/16/10/105014; Wei R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46824-2; Xu JZ, 2006, BIOINFORMATICS, V22, P2800, DOI 10.1093/bioinformatics/btl467; Yachie N, 2016, MOL SYST BIOL, V12, DOI 10.15252/msb.20156660; Yang XP, 2016, CELL, V164, P805, DOI 10.1016/j.cell.2016.01.029; Yang Z, 2006, CIRC RES, V99, P646, DOI 10.1161/01.RES.0000241482.19382.c6; Yao L, 2017, J CELL BIOCHEM, V118, P4708, DOI 10.1002/jcb.26137; Yu HY, 2011, NAT METHODS, V8, P478, DOI [10.1038/NMETH.1597, 10.1038/nmeth.1597]; Zeng ZH, 2007, BLOOD, V109, P3509, DOI 10.1182/blood-2006-06-030833; Zhan JK, 2014, CAN J CARDIOL, V30, P568, DOI 10.1016/j.cjca.2013.11.005; Zhao Y, 2015, KIDNEY INT, V88, P711, DOI 10.1038/ki.2015.160; Zhou XZ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5212; Zhou YD, 2020, CELL DISCOV, V6, DOI 10.1038/s41421-020-0153-3; Zickler D, 2018, NEPHROL DIAL TRANSPL, V33, P574, DOI 10.1093/ndt/gfx316	70	12	12	2	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2020	34	8					11087	11100		10.1096/fj.202001062R	http://dx.doi.org/10.1096/fj.202001062R		JUL 2020	14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NE3EW	32638415	hybrid, Green Published			2023-01-03	WOS:000547534000001
J	Quyen, PN; Nga, HT; Chaffee, B; Ngu, T; King, JC				Quyen, Phi N.; Nga, Hoang T.; Chaffee, Benjamin; Ngu, Tu; King, Janet C.			Effect of maternal prenatal food supplementation, gestational weight gain, and breast-feeding on infant growth during the first 24 months of life in rural Vietnam	PLOS ONE			English	Article							ENERGY SUPPLEMENTATION; NUTRITION; PREGNANCY; WOMEN; AGE	Growth faltering among children during the first five years of life is a common problem among low and middle-income countries. The purpose of this study was to determine the effect of a nutrient-rich, food-based supplement given to Vietnamese rural women prior to and/or during pregnancy on the growth of their infants during first 24 months of life and to identify maternal and newborn factors associated with the infant's growth. This prospective cohort study included 236 infants born to mothers who had received nutritional advice or a food supplement from pre-conception to term or from mid-gestation to term as part of a prior randomized controlled trial. Infant anthropometry and feeding information were monitored monthly and the infant weight for age Z-score (WAZ), length for age Z-score (LAZ), and weight for length Z-score (WLZ) were assessed at 6, 12, 18, and 24 months of age using mixed-effects regression modeling. Compared to the non-supplemented mothers, infants born to mothers receiving food supplementation from mid-gestation to term had significantly higher WLZ only at 18 months (p = 0.03) and did not differ in other outcomes. Supplementation from pre-conception to term did not affect infant growth at any time point during the first 24 months. In the entire study cohort, maternal height and gestational weight gain were positively associated with the infant's WAZ and LAZ from 6 to 24 months of age. Programs designed to improve gestational weight gain among women performing demanding physical work throughout a reproductive cycle may improve postnatal infant growth.	[Quyen, Phi N.; Nga, Hoang T.; Ngu, Tu] Natl Inst Nutr, Hanoi, Vietnam; [Chaffee, Benjamin] Univ Calif San Francisco, San Francisco, CA 94143 USA; [King, Janet C.] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA	University of California System; University of California San Francisco; Children's Hospital Oakland Research Institute; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Benioff Children's Hospital Oakland	King, JC (corresponding author), Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA.	jking@chori.org		King, Janet/0000-0002-8484-7940	Nestle Research Foundation; Thrasher Research Fund	Nestle Research Foundation(Nestle SA); Thrasher Research Fund	Nestle Research Foundation and Thrasher Research Fund. TAwards for the research were received by JCK and TN. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ashorn P, 2015, J NUTR, V145, P1345, DOI 10.3945/jn.114.207225; Nguyen BKL, 2013, BRIT J NUTR, V110, pS45, DOI 10.1017/S0007114513002080; Deierlein AL, 2012, PEDIATR OBES, V7, P134, DOI 10.1111/j.2047-6310.2011.00025.x; Devakumar D, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0633-3; Dewey KG, 2016, MATERN CHILD NUTR, V12, P27, DOI 10.1111/mcn.12282; Gibson RS, 2005, PRINC NUTR ASSESS, V2005, P2; Haider BA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004905; Hall AG, 2017, J NUTR, V147, P1200, DOI 10.3945/jn.116.241968; Hambidge K, 2019, AM J CIN NUTR; Hanieh S, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-339; Heerman WJ, 2014, ACAD PEDIATR, V14, P463, DOI 10.1016/j.acap.2014.05.005; Imdad A, 2012, PAEDIATR PERINAT EP, V26, P178, DOI 10.1111/j.1365-3016.2012.01308.x; Institute of Medicine, 2009, WEIGHT GAIN PREGNANC; Khan AI, 2011, NUTR J, V10, DOI 10.1186/1475-2891-10-134; KUSIN JA, 1992, LANCET, V340, P623, DOI 10.1016/0140-6736(92)92168-F; Lanou H, 2014, PEDIATRICS, V133, pE1001, DOI 10.1542/peds.2013-2850; LECHTIG A, 1975, AM J CLIN NUTR, V28, P1223, DOI 10.1093/ajcn/28.11.1223; Li C, 2019, NUTR J, V18, DOI 10.1186/s12937-019-0432-8; Nga HT, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232197; Roberfroid D, 2012, AM J CLIN NUTR, V95, P916, DOI 10.3945/ajcn.111.029033; Stevens B, 2015, MATERN CHILD NUTR, V11, P415, DOI 10.1111/mcn.12183; Vietnam WB, 2012, WELL DONE NOT YET DO; Villar J, 2016, LANCET, V387, P844, DOI 10.1016/S0140-6736(16)00384-6; Wahlqvist M., 2015, WORLD NUTR, V6, P613; WHO, 2011, WHO ANTHR MACR VERS; WHO, 2006, GROWTH REF DAT 5 19; Wieringa FT, 2010, EUR J CLIN NUTR, V64, P1072, DOI 10.1038/ejcn.2010.115; Young MF, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203201; Young MF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170192	30	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2020	15	6							e0233671	10.1371/journal.pone.0233671	http://dx.doi.org/10.1371/journal.pone.0233671			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG0TI	32584881	gold, Green Published			2023-01-03	WOS:000545747200081
J	Saillard, C; Mallet, D; Chow-Chine, L; Bisbal, M; Faucher, M; Sannini, A; Mokart, D				Saillard, Colombe; Mallet, Damien; Chow-Chine, Laurent; Bisbal, Magali; Faucher, Marion; Sannini, Antoine; Mokart, Djamel			Non-invasive ventilation indication for critically ill cancer patients admitted to the intensive care unit for acute respiratory failure (ARF) with associated cardiac dysfunction: Results from an observational study	PLOS ONE			English	Article							MECHANICAL VENTILATION; HEMATOLOGY PATIENTS; IMMUNOCOMPROMISED PATIENTS; INCREASED MORTALITY; DISTRESS-SYNDROME; MALIGNANCY; OUTCOMES; GROUPE; TRENDS; OXYGEN	Background Acute respiratory failure (ARF) is a life-threatening complication in onco-hematology patients. Optimal ventilation strategy in immunocompromised patients has been highly controversial over the last decade. Data are lacking on patients presenting with ARF associating isolated cardiac dysfunction or in combination with another etiology. The aim of this study was to assess prognostic impact of initial ventilation strategy in onco-hematology patients presenting ARF with associated cardiac dysfunction. Methods We conducted an observational retrospective study in Institut Paoli-Calmettes, a cancer-referral center, assessing all critically ill cancer patients admitted to the ICU for a ARF with cardiac dysfunction. Results Between 2010-2017, 127 patients were admitted. ICU and hospital mortality were 29% and 57%. Initial ventilation strategy was invasive mechanical ventilation (MV) in 21%. Others ventilation strategies were noninvasive ventilation (NIV) in 50%, associated with oxygen in 21% and high flow nasal oxygen (HFNO) in 29%, HFNO alone in 6% and standard oxygen in 23%. During ICU stay, 48% of patients required intubation. Multivariate analysis identified 3 independent factors associated with ICU mortality: SAPSII at admission (OR = 1.07/point, 95%CI = 1.03-1.11, p<0.001), invasive fungal infection (OR = 7.65, 95%CI = 1.7-34.6, p = 0.008) and initial ventilation strategy (p = 0.015). Compared to NIV, HFNO alone and standard oxygen alone were associated with an increased ICU mortality, with respective OR of 19.56 (p = 0.01) and 10.72 (p = 0.01). We realized a propensity score analysis including 40 matched patients, 20 in the NIV arm and 20 receiving others ventilation strategies, excluding initial MV patients. ICU mortality was lower in patients treated with NIV (10%), versus 50% in the other arm (p = 0.037). Conclusion In onco-hematology patients admitted for ARF with associated cardiac dysfunction, severity at ICU admission, invasive fungal infections and initial ventilation strategy were independently associated with ICU mortality. NIV was a protective factor on ICU mortality.	[Saillard, Colombe] Inst Paoli Calmettes, Dept Hematol, Marseille, France; [Mallet, Damien; Chow-Chine, Laurent; Bisbal, Magali; Faucher, Marion; Sannini, Antoine; Mokart, Djamel] Inst Paoli Calmettes, Polyvalent Intens Care Unit, Dept Anesthesiol & Crit Care, Marseille, France	UNICANCER; Institut Paoli-Calmette (IPC); UNICANCER; Institut Paoli-Calmette (IPC)	Mokart, D (corresponding author), Inst Paoli Calmettes, Polyvalent Intens Care Unit, Dept Anesthesiol & Crit Care, Marseille, France.	mokartd@ipc.unicancer.fr						Adda M, 2008, CRIT CARE MED, V36, P2766, DOI 10.1097/CCM.0b013e31818699f6; Azoulay E, 2012, BONE MARROW TRANSPL, V47, P469, DOI 10.1038/bmt.2011.232; Azoulay E, 2006, INTENS CARE MED, V32, P808, DOI 10.1007/s00134-006-0129-2; Azoulay E, 2017, INTENS CARE MED, V43, P1808, DOI 10.1007/s00134-017-4947-1; Azoulay E, 2014, INTENS CARE MED, V40, P1106, DOI 10.1007/s00134-014-3354-0; Azoulay E, 2013, J CLIN ONCOL, V31, P2810, DOI 10.1200/JCO.2012.47.2365; Burghi G, 2011, INTENS CARE MED, V37, P1605, DOI 10.1007/s00134-011-2344-8; Contejean A, 2016, ANN INTENSIVE CARE, V6, DOI 10.1186/s13613-016-0202-0; Demoule A, 2016, INTENS CARE MED, V42, P82, DOI 10.1007/s00134-015-4087-4; Ewig S, 1998, EUR RESPIR J, V12, P116, DOI 10.1183/09031936.98.12010116; Frat JP, 2015, NEW ENGL J MED, V372, P2185, DOI 10.1056/NEJMoa1503326; Frat JP, 2016, LANCET RESP MED; Frutos-Vivar F, 2014, INTENS CARE MED, V40, P1449, DOI 10.1007/s00134-014-3362-0; Gristina GR, 2011, CRIT CARE MED, V39, P2232, DOI 10.1097/CCM.0b013e3182227a27; Hilbert G, 2001, NEW ENGL J MED, V344, P481, DOI 10.1056/NEJM200102153440703; Lagier D, 2016, ANAESTHESIA, V71, P1081, DOI 10.1111/anae.13542; Lemiale V, 2015, JAMA-J AM MED ASSOC, V314, P1711, DOI 10.1001/jama.2015.12402; Lemiale V, 2015, ANN INTENSIVE CARE, V5, DOI 10.1186/s13613-015-0070-z; Masip J, 2005, JAMA-J AM MED ASSOC, V294, P3124, DOI 10.1001/jama.294.24.3124; Mokart D, 2015, INTENS CARE MED, V41, P296, DOI 10.1007/s00134-014-3615-y; Mokart D, 2015, INTENSIVE CARE MED; Mokart D, 2007, CRIT CARE, V11, DOI 10.1186/cc5721; Mokart D, 2014, INTENS CARE MED, V40, P1570, DOI 10.1007/s00134-014-3433-2; Mokart D, 2013, LEUKEMIA LYMPHOMA, V54, P1724, DOI 10.3109/10428194.2012.753446; Molina R, 2012, CRIT CARE, V16, DOI 10.1186/cc11438; Mourad M, 2014, BRIT J ANAESTH, V112, P102, DOI 10.1093/bja/aet296; Pene F, 2014, INTENS CARE MED, V40, P1573, DOI 10.1007/s00134-014-3412-7; Saillard C, 2016, BONE MARROW TRANSPLA; Schnell D, 2014, INTENS CARE MED, V40, P582, DOI 10.1007/s00134-014-3222-y; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI [10.1016/j.jclinepi.2007.11.008, 10.2471/BLT.07.045120]	30	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2020	15	6							e0234495	10.1371/journal.pone.0234495	http://dx.doi.org/10.1371/journal.pone.0234495			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC0EC	32520960	Green Published, gold			2023-01-03	WOS:000542969500015
J	Ward, AM; Yaman, R; Ebbert, JO				Ward, Alexandra M.; Yaman, Rola; Ebbert, Jon O.			Electronic nicotine delivery system design and aerosol toxicants: A systematic review	PLOS ONE			English	Review							TOBACCO-SPECIFIC NITROSAMINES; FREE-RADICAL FORMATION; E-CIGARETTE; CARBONYL-COMPOUNDS; FLAVORING CHEMICALS; HEATING COIL; LIQUID; TEMPERATURE; EMISSIONS; ALDEHYDES	Background Electronic nicotine delivery systems (ENDS; e-cigarettes), consisting of a battery, heating element and e-liquid, have evolved significantly with wide variation in design, components, operating powers, and chemical constituents. Generated aerosols have been reported to contain potentially toxic substances. We conducted a systematic review to assess what is known about the presence of toxicants in ENDS aerosols in order to inform how system design could mitigate risk. Methods Articles reporting on or evaluating design characteristics of ENDS and aerosol constituents were included and summarized. Results The search identified 2,305 articles, of which 92 were included after full-text review. Findings were grouped into 6 major categories of potentially harmful chemicals: carbonyls, volatile organic chemicals, trace elements, reactive oxygen species and free radicals, polycyclic aromatic hydrocarbons, and tobacco-specific nitrosamines. In general, higher concentrations of aerosol toxicants are associated with increased power or voltage. Aerosol toxicants are also associated with e-liquid flavoring agents existing as primary ingredients or as products of thermal degradation. Conclusions Improved ENDS design can reduce toxicant levels. Additional research is needed to develop a framework for optimizing system characteristics to minimize exposure, especially with respect to heating power and e-liquids. Both manufacturers and regulatory agencies have roles in reducing toxicants and potential health risks from ENDS.	[Ward, Alexandra M.; Ebbert, Jon O.] Mayo Clin, Nicotine Dependence Ctr, Inhaled Particle Aerosol Lab, Rochester, MN 55905 USA; [Yaman, Rola] Queens Univ, Kingston, ON, Canada	Mayo Clinic; Queens University - Canada	Ebbert, JO (corresponding author), Mayo Clin, Nicotine Dependence Ctr, Inhaled Particle Aerosol Lab, Rochester, MN 55905 USA.	ebbert.jon@mayo.edu						Abdel-Shafy Hussein I., 2016, Egyptian Journal of Petroleum, V25, P107, DOI 10.1016/j.ejpe.2015.03.011; Allen JG, 2016, ENVIRON HEALTH PERSP, V124, P733, DOI 10.1289/ehp.1510185; Andrikopoulos Gozde Isik, 2019, Current Opinion in Toxicology, V13, P81, DOI 10.1016/j.cotox.2018.09.002; [Anonymous], 2019, PR NEWSWIRE RES MARK; [Anonymous], POL AR HYDR PAHS; [Anonymous], 2018, OBSTET GYNECOL, V13, pe49; Balbo S, 2018, CHEM RES TOXICOL, V31, P823, DOI 10.1021/acs.chemrestox.8b00214; Bansal V, 2016, TRAC-TREND ANAL CHEM, V78, P120, DOI 10.1016/j.trac.2016.02.015; Beauval N, 2019, INT J HYG ENVIR HEAL, V222, P136, DOI 10.1016/j.ijheh.2018.08.015; Beauval N, 2017, J ANAL TOXICOL, V41, P670, DOI 10.1093/jat/bkx054; Behar RZ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25575-6; Behar RZ, 2016, TOB CONTROL, V25, pii94, DOI 10.1136/tobaccocontrol-2016-053224; Bekki K, 2014, INT J ENV RES PUB HE, V11, P11192, DOI 10.3390/ijerph111111192; Belushkin M, 2020, CHEM RES TOXICOL, V33, P657, DOI 10.1021/acs.chemrestox.9b00470; Bitzer ZT, 2019, CHEM RES TOXICOL, V32, P130, DOI 10.1021/acs.chemrestox.8b00235; Bitzer ZT, 2018, FREE RADICAL BIO MED, V120, P72, DOI 10.1016/j.freeradbiomed.2018.03.020; Bitzer ZT, 2018, CHEM RES TOXICOL, V31, P4, DOI 10.1021/acs.chemrestox.7b00116; Blair SL, 2015, AEROSOL SCI TECH, V49, P816, DOI 10.1080/02786826.2015.1076156; Brown CJ, 2014, TOB CONTROL, V23, P4, DOI 10.1136/tobaccocontrol-2013-051476; Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion, 2010, TOB SMOK CAUS DIS BI; Cheng TR, 2014, TOB CONTROL, V23, P11, DOI 10.1136/tobaccocontrol-2013-051482; Conklin DJ, 2018, AEROSOL SCI TECH, V52, P1219, DOI 10.1080/02786826.2018.1500013; Dawkins L, 2013, ADDICTION, V108, P1115, DOI 10.1111/add.12150; Duell AK, 2019, CHEM RES TOXICOL, V32, P1241, DOI 10.1021/acs.chemrestox.9b00047; Eddingsaas N, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15020323; Edwards SH, 2017, CHEM RES TOXICOL, V30, P540, DOI 10.1021/acs.chemrestox.6b00268; El-Hage R, 2018, AEROSOL SCI TECH, V52, P377, DOI 10.1080/02786826.2018.1433293; El-Hellani A, 2019, CHEM RES TOXICOL, V32, P312, DOI 10.1021/acs.chemrestox.8b00324; EL-Hellani A, 2018, NICOTINE TOB RES, V20, P215, DOI 10.1093/ntr/ntw280; Erythropel HC, 2019, NICOTINE TOB RES, V21, P1248, DOI 10.1093/ntr/nty192; Farsalinos KE, 2018, FOOD CHEM TOXICOL, V115, P212, DOI 10.1016/j.fct.2018.02.059; Farsalinos KE, 2018, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.01119; Farsalinos KE, 2018, FOOD CHEM TOXICOL, V111, P64, DOI 10.1016/j.fct.2017.11.002; Farsalinos KE, 2017, FOOD CHEM TOXICOL, V109, P90, DOI 10.1016/j.fct.2017.08.044; Farsalinos KE, 2015, INT J ENV RES PUB HE, V12, P9046, DOI 10.3390/ijerph120809046; Farsalinos KE, 2015, ADDICTION, V110, P1352, DOI 10.1111/add.12942; Farsalinos KE, 2015, NICOTINE TOB RES, V17, P168, DOI 10.1093/ntr/ntu176; Flora JW, 2016, REGUL TOXICOL PHARM, V74, P1, DOI 10.1016/j.yrtph.2015.11.009; Garcia-Gomez D, 2016, CHEM-EUR J, V22, P2452, DOI 10.1002/chem.201504450; Gaur S, 2019, BIOL TRACE ELEM RES, V188, P295, DOI 10.1007/s12011-018-1423-x; Geiss O, 2016, INT J HYG ENVIR HEAL, V219, P268, DOI 10.1016/j.ijheh.2016.01.004; Gillman IG, 2016, REGUL TOXICOL PHARM, V75, P58, DOI 10.1016/j.yrtph.2015.12.019; Gillman IG, 2020, REGUL TOXICOL PHARM, V112, DOI 10.1016/j.yrtph.2020.104588; Goel R, 2015, CHEM RES TOXICOL, V28, P1675, DOI 10.1021/acs.chemrestox.5b00220; Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859; Haddad C, 2019, J ANAL TOXICOL, V43, P45, DOI 10.1093/jat/bky065; Hajek P, 2019, NEW ENGL J MED, V380, P629, DOI 10.1056/NEJMoa1808779; Hasan F, 2020, ENVIRON SCI TECHNOL, V54, P5710, DOI 10.1021/acs.est.0c00351; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; Herrington JS, 2015, J CHROMATOGR A, V1418, P192, DOI 10.1016/j.chroma.2015.09.034; Jensen RP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42549; Jensen RP, 2015, NEW ENGL J MED, V372, P392, DOI 10.1056/NEJMc1413069; Jo SH, 2016, J CHROMATOGR A, V1429, P369, DOI 10.1016/j.chroma.2015.12.061; Jones L, 2019, BBC NEWS; Khlystov A, 2016, ENVIRON SCI TECHNOL, V50, P13080, DOI 10.1021/acs.est.6b05145; KIM YH, 2015, SCI REP-UK, V5, DOI DOI 10.1038/SREP1638326553711; Klager S, 2017, ENVIRON SCI TECHNOL, V51, P10806, DOI 10.1021/acs.est.7b02205; Korzun T, 2018, ACS OMEGA, V3, P30, DOI 10.1021/acsomega.7b01521; Kosmider L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63292-1; Kosmider L, 2018, NICOTINE TOB RES, V20, P998, DOI 10.1093/ntr/ntx162; Kosmider L, 2016, THORAX, V71, P376, DOI 10.1136/thoraxjnl-2015-207895; Kosmider L, 2014, NICOTINE TOB RES, V16, P1319, DOI 10.1093/ntr/ntu078; Laugesen M, 2015, NEW ZEAL MED J, V128, P77; Lee MS, 2017, ENVIRON HEALTH-GLOB, V16, DOI 10.1186/s12940-017-0249-x; Lee MH, 2018, ENVIRON MONIT ASSESS, V190, DOI 10.1007/s10661-018-6553-2; Lerner CA, 2015, ENVIRON POLLUT, V198, P100, DOI 10.1016/j.envpol.2014.12.033; Li YC, 2020, ENVIRON SCI TECHNOL, V54, P5640, DOI 10.1021/acs.est.9b07387; Liu QQ, 2020, J ENVIRON SCI, V91, P168, DOI 10.1016/j.jes.2020.01.023; Mallock N, 2020, ARCH TOXICOL, V94, P1985, DOI 10.1007/s00204-020-02716-3; Margham J, 2016, CHEM RES TOXICOL, V29, P1662, DOI 10.1021/acs.chemrestox.6b00188; McRobbie H, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010216.pub2; Mikheev VB, 2016, NICOTINE TOB RES, V18, P1895, DOI 10.1093/ntr/ntw128; Nathanson Tedd, 1995, INDOOR AIR QUALITY O; Nicol J, 2020, CHEM RES TOXICOL, V33, P789, DOI 10.1021/acs.chemrestox.9b00442; Ogunwale MA, 2017, ACS OMEGA, V2, P1207, DOI 10.1021/acsomega.6b00489; Olmedo P, 2018, ENVIRON HEALTH PERSP, V126, DOI 10.1289/EHP2175; Palazzolo DL, 2017, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00663; Pankow JF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173055; Papousek R, 2014, CHROMATOGRAPHIA, V77, P1145, DOI 10.1007/s10337-014-2729-2; Park RM, 2018, J OCCUP ENVIRON MED, V60, P496, DOI 10.1097/JOM.0000000000001303; Pellegrino R M, 2012, Ann Ig, V24, P279; Primack BA, 2018, AM J MED, V131, DOI 10.1016/j.amjmed.2017.11.005; Prokopowicz A, 2019, NICOTINE TOB RES, V21, P1198, DOI 10.1093/ntr/nty161; Qu Y, 2018, ENVIRON RES, V166, P324, DOI 10.1016/j.envres.2018.06.013; Rawlinson C, 2017, J CHROMATOGR A, V1497, P144, DOI 10.1016/j.chroma.2017.02.050; Reilly SM, 2019, NICOTINE TOB RES, V21, P1274, DOI 10.1093/ntr/nty221; Rudd K., 2020, APP VITRO TOXICOL, V6, P11, DOI [10.1089/ aivt.2019.0015, DOI 10.1089/AIVT.2019.0015]; Sala C, 2017, EUR J MASS SPECTROM, V23, P64, DOI 10.1177/1469066717699078; Salamanca JC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25907-6; Salamanca JC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11499-0; Saliba NA, 2018, J ANAL APPL PYROL, V134, P520, DOI 10.1016/j.jaap.2018.07.019; Shein M, 2019, CHEM RES TOXICOL, V32, P1289, DOI 10.1021/acs.chemrestox.9b00085; Sleiman M, 2016, ENVIRON SCI TECHNOL, V50, P9644, DOI 10.1021/acs.est.6b01741; Son Y, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082767; Son Y, 2019, CHEM RES TOXICOL, V32, P1087, DOI 10.1021/acs.chemrestox.8b00400; Soussy S, 2016, TOB CONTROL, V25, pii88, DOI 10.1136/tobaccocontrol-2016-053220; Stephens WE, 2019, CHEM RES TOXICOL, V32, P2053, DOI 10.1021/acs.chemrestox.9b00214; Talih S, 2019, TOB CONTROL, V28, P678, DOI 10.1136/tobaccocontrol-2018-054616; Talih S, 2017, CHEM RES TOXICOL, V30, P1791, DOI 10.1021/acs.chemrestox.7b00212; Talih S, 2016, NICOTINE TOB RES, V18, P453, DOI 10.1093/ntr/ntv080; Ting CY, 2020, J ENVIRON SCI HEAL A, V55, P55, DOI 10.1080/10934529.2019.1665950; Uchiyama S, 2020, CHEM RES TOXICOL, V33, P576, DOI 10.1021/acs.chemrestox.9b00410; Uchiyama S, 2016, ANAL SCI, V32, P549, DOI 10.2116/analsci.32.549; Uchiyama S, 2013, ANAL SCI, V29, P1219, DOI 10.2116/analsci.29.1219; van Rooy FGBGJ, 2009, OCCUP ENVIRON MED, V66, P105, DOI 10.1136/oem.2008.039560; Vreeke S, 2018, ACS OMEGA, V3, P7165, DOI 10.1021/acsomega.8b00842; Vreeke S, 2018, AEROSOL SCI TECH, V52, P370, DOI 10.1080/02786826.2018.1424316; Wagner KA, 2018, REGUL TOXICOL PHARM, V95, P153, DOI 10.1016/j.yrtph.2018.03.012; Wang P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169811; WHO, 2016, EL NIC DEL SYST EL N; Williams M, 2019, ENVIRON RES, V175, P156, DOI 10.1016/j.envres.2019.05.014; Williams M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175430; Williams M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138933; Williams M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057987; Zhao D, 2019, ENVIRON RES, V174, P125, DOI 10.1016/j.envres.2019.04.003; Zhao JY, 2018, INHAL TOXICOL, V30, P78, DOI 10.1080/08958378.2018.1450462; Zhao TK, 2016, ATMOS ENVIRON, V134, P61, DOI 10.1016/j.atmosenv.2016.03.027	117	23	23	2	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2020	15	6							e0234189	10.1371/journal.pone.0234189	http://dx.doi.org/10.1371/journal.pone.0234189			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6PX	32497139	Green Published, gold			2023-01-03	WOS:000542035200098
J	Kim, HS; Kang, J; Hwang, D; Han, JK; Yang, HM; Kang, HJ; Koo, BK; Rhew, JY; Chun, KJ; Lim, YH; Bong, JM; Bae, JW; Lee, BK; Park, KW				Kim, Hyo-Soo; Kang, Jeehoon; Hwang, Doyeon; Han, Jung-Kyu; Yang, Han-Mo; Kang, Hyun-Jae; Koo, Bon-Kwon; Rhew, Jay Young; Chun, Kook-Jin; Lim, Young-Hyo; Bong, Jung Min; Bae, Jang-Whan; Lee, Bong Ki; Park, Kyung Woo		HOST-REDUCE-POLYTECH-ACS	Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCE-POLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial	LANCET			English	Article							DIPHOSPHATE RECEPTOR INHIBITORS; MYOCARDIAL-INFARCTION PATIENTS; EXPERT CONSENSUS STATEMENT; EAST-ASIAN PATIENTS; DOSE CLOPIDOGREL; 10 MG; TICAGRELOR; INSIGHTS; EVENTS; IMPACT	Background A potent P2Y12 inhibitor-based dual antiplatelet therapy is recommended for up to 1 year in patients with acute coronary syndrome receiving percutaneous coronary intervention (PCI). The greatest benefit of the potent agent is during the early phase, whereas the risk of excess bleeding continues in the chronic maintenance phase. Therefore, de-escalation of antiplatelet therapy might achieve an optimal balance between ischaemia and bleeding. We aimed to investigate the safety and efficacy of a prasugrel-based dose de-escalation therapy. Methods HOST-REDUCE-POLYTECH-ACS is a randomised, open-label, multicentre, non-inferiority trial done at 35 hospitals in South Korea. We enrolled patients with acute coronary syndrome receiving PCI. Patients meeting the core indication for prasugrel were randomly assigned (1:1) to the de-escalation group or conventional group using a web-based randomisation system. The assessors were masked to the treatment allocation. After 1 month of treatment with 10 mg prasugrel plus 100 mg aspirin daily, the de-escalation group received 5 mg prasugrel, while the conventional group continued to receive 10 mg. The primary endpoint was net adverse clinical events (all-cause death, non-fatal myocardial infarction, stent thrombosis, repeat revascularisation, stroke, and bleeding events of grade 2 or higher according to Bleeding Academic Research Consortium [BARC] criteria) at 1 year. The absolute non-inferiority margin for the primary endpoint was 2.5%. The key secondary endpoints were efficacy outcomes (cardiovascular death, myocardial infarction, stent thrombosis, and ischaemic stroke) and safety outcomes (bleeding events of BARC grade >= 2). The primary analysis was in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT02193971. Results From Sept 30, 2014, to Dec 18, 2018, 3429 patients were screened, of whom 1075 patients did not meet the core indication for prasugrel and 16 were excluded due to randomisation error. 2338 patients were randomly assigned to the de-escalation group (n=1170) or the conventional group (n=1168). The primary endpoint occurred in 82 patients (Kaplan-Meier estimate 7.2%) in the de-escalation group and 116 patients (10.1%) in the conventional group (absolute risk difference -2.9%, p(non-inferiority)<0.0001; hazard ratio 0.70 [95% CI 0.52-0.92], p(equivalence)=0.012). There was no increase in ischaemic risk in the de-escalation group compared with the conventional group (0.76 [0.40-1.45]; p=0.40), and the risk of bleeding events was significantly decreased (0.48 [0.32-0.73]; p=0.0007). Interpretation In east Asian patients with acute coronary syndrome patients receiving PCI, a prasugrel-based dose de-escalation strategy from 1 month after PCI reduced the risk of net clinical outcomes up to 1 year, mainly driven by a reduction in bleeding without an increase in ischaemia. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Kim, Hyo-Soo; Kang, Jeehoon; Hwang, Doyeon; Han, Jung-Kyu; Yang, Han-Mo; Kang, Hyun-Jae; Koo, Bon-Kwon; Park, Kyung Woo] Seoul Natl Univ Hosp, Seoul 03080, South Korea; [Rhew, Jay Young] Presbyterian Med Ctr, Jeonju, South Korea; [Chun, Kook-Jin] Pusan Natl Univ, Yangsan Hosp, Yangsan, South Korea; [Lim, Young-Hyo] Hanyang Univ, Seoul Hosp, Seoul, South Korea; [Bong, Jung Min] Hanlim Gen Hosp, Incheon, South Korea; [Bae, Jang-Whan] Chungbuk Natl Univ, Cheongju, South Korea; [Lee, Bong Ki] Kangwon Natl Univ, Chunchon, South Korea	Seoul National University (SNU); Seoul National University Hospital; Pusan National University; Pusan National University Hospital; Hanyang University; Chungbuk National University; Kangwon National University	Park, KW (corresponding author), Seoul Natl Univ Hosp, Seoul 03080, South Korea.	kwparkmd@snu.ac.kr	kang, Hyun-Jae/D-6121-2012	kang, Hyun-Jae/0000-0002-3500-1746	Daiichi Sankyo; Boston Scientific; Terumo; Biotronik; Qualitech Korea; Dio	Daiichi Sankyo(Daiichi Sankyo Company Limited); Boston Scientific(Boston Scientific); Terumo; Biotronik; Qualitech Korea; Dio	Daiichi Sankyo, Boston Scientific, Terumo, Biotronik, Qualitech Korea, and Dio.; This study was supported by Daiichi Sankyo, Boston Scientific, Terumo, Biotronik, Qualitech Korea, and Dio.	Alexopoulos D, 2014, THROMB HAEMOSTASIS, V112, P551, DOI 10.1160/TH14-02-0119; Angiolillo DJ, 2017, CIRCULATION, V136, P1955, DOI 10.1161/CIRCULATIONAHA.117.031164; Bagai A, 2015, EUR HEART J-ACUTE CA, V4, P499, DOI 10.1177/2048872614564082; Cuisset T, 2017, EUR HEART J, V38, P3070, DOI 10.1093/eurheartj/ehx175; De Luca L, 2017, EUROINTERVENTION, V13, P459, DOI 10.4244/EIJ-D-17-00092; Erlinge D, 2013, J AM COLL CARDIOL, V62, P577, DOI 10.1016/j.jacc.2013.05.023; Gajanana D, 2020, AM J CARDIOL, V125, P1631, DOI 10.1016/j.amjcard.2020.02.032; Gallone G, 2018, J AM COLL CARDIOL, V72, P2886, DOI 10.1016/j.jacc.2018.09.052; Garcia-Garcia HM, 2018, CIRCULATION, V137, P2635, DOI 10.1161/CIRCULATIONAHA.117.029289; Gurbel PA, 2006, NAT CLIN PRACT CARD, V3, P387, DOI 10.1038/ncpcardio0602; Habib A, 2015, PHARMACOL RES, V93, P22, DOI 10.1016/j.phrs.2014.12.003; Hahn JY, 2018, LANCET, V391, P1274, DOI 10.1016/S0140-6736(18)30493-8; Huo Y, 2019, SCI BULL, V64, P166, DOI 10.1016/j.scib.2018.12.020; Jeong YH, 2015, EUR HEART J, V36, P1044; Kang J, 2019, THROMB HAEMOSTASIS, V119, P149, DOI 10.1055/s-0038-1676545; Kang J, 2018, KOREAN CIRC J, V48, P537, DOI 10.4070/kcj.2018.0166; Kang J, 2018, THROMB HAEMOSTASIS, V118, P591, DOI 10.1055/s-0038-1626697; Lee JM, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0925-5; Levine GN, 2014, NAT REV CARDIOL, V11, P597, DOI 10.1038/nrcardio.2014.104; Masiero G, 2020, EUR HEART J SUPPL, V22, pE132, DOI 10.1093/eurheartj/suaa078; Mehran R, 2019, NEW ENGL J MED, V381, P2032, DOI 10.1056/NEJMoa1908419; Oh IY, 2012, HEART, V98, P139, DOI 10.1136/hrt.2011.227272; Park DW, 2019, CIRCULATION, V140, P1865, DOI 10.1161/CIRCULATIONAHA.119.041766; Savonitto S, 2018, CIRCULATION, V137, P2435, DOI 10.1161/CIRCULATIONAHA.117.032180; Schupke S, 2019, NEW ENGL J MED, V381, P1524, DOI 10.1056/NEJMoa1908973; Sibbing D, 2019, JACC-CARDIOVASC INTE, V12, P1521, DOI 10.1016/j.jcin.2019.03.034; Sibbing D, 2017, LANCET, V390, P1747, DOI 10.1016/S0140-6736(17)32155-4; Straub N, 2014, THROMB HAEMOSTASIS, V111, P290, DOI 10.1160/TH13-08-0679; Urban P, 2019, EUR HEART J, V40, P2632, DOI 10.1093/eurheartj/ehz372; Wallentin L, 2009, NEW ENGL J MED, V361, P1045, DOI 10.1056/NEJMoa0904327; Wiviott SD, 2007, CIRCULATION, V116, P2923, DOI 10.1161/CIRCULATIONAHA.107.740324; Wiviott SD, 2007, NEW ENGL J MED, V357, P2001, DOI 10.1056/NEJMoa0706482; Wiviott SD, 2013, LANCET, V382, P605, DOI 10.1016/S0140-6736(13)61451-8; Yokoi H, 2012, THROMB RES, V129, P623, DOI 10.1016/j.thromres.2011.11.023; Zettler ME, 2017, AM HEART J, V183, P62, DOI 10.1016/j.ahj.2016.10.006	35	66	71	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	2020	396	10257					1079	1089		10.1016/S0140-6736(20)31791-8	http://dx.doi.org/10.1016/S0140-6736(20)31791-8			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OC4TP	32882163				2023-01-03	WOS:000579151000029
J	Tomazini, BM; Maia, IS; Cavalcanti, AB; Berwanger, O; Rosa, RG; Veiga, VC; Avezum, A; Lopes, RD; Bueno, FR; Silva, MVAO; Baldassare, FP; Costa, ELV; Moura, RAB; Honorato, MO; Costa, AN; Damiani, LP; Lisboa, T; Kawano-Dourado, L; Zampieri, FG; Olivato, GB; Righy, C; Amendola, CP; Roepke, RML; Freitas, DHM; Forte, DN; Freitas, FGR; Fernandes, CCF; Melro, LMG; Junior, GFS; Morais, DC; Zung, S; Machado, FR; Azevedo, LCP				Tomazini, Bruno M.; Maia, Israel S.; Cavalcanti, Alexandre B.; Berwanger, Otavio; Rosa, Regis G.; Veiga, Viviane C.; Avezum, Alvaro; Lopes, Renato D.; Bueno, Flavia R.; Silva, Maria Vitoria A. O.; Baldassare, Franca P.; Costa, Eduardo L., V; Moura, Ricardo A. B.; Honorato, Michele O.; Costa, Andre N.; Damiani, Lucas P.; Lisboa, Thiago; Kawano-Dourado, Leticia; Zampieri, Fernando G.; Olivato, Guilherme B.; Righy, Cassia; Amendola, Cristina P.; Roepke, Roberta M. L.; Freitas, Daniela H. M.; Forte, Daniel N.; Freitas, Flavio G. R.; Fernandes, Caio C. F.; Melro, Livia M. G.; Junior, Gedealvares F. S.; Morais, Douglas Costa; Zung, Stevin; Machado, Flavia R.; Azevedo, Luciano C. P.		COALITION COVID-19 Brazil III Inve	Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19 The CoDEX Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE-UNIT; MULTICENTER; SAPS-3	IMPORTANCE Acute respiratory distress syndrome (ARDS) due to coronavirus disease 2019 (COVID-19) is associated with substantial mortality and use of health care resources. Dexamethasone use might attenuate lung injury in these patients. OBJECTIVE To determine whether intravenous dexamethasone increases the number of ventilator-free days among patients with COVID-19-associated ARDS. DESIGN, SETTING, AND PARTICIPANTS Multicenter, randomized, open-label, clinical trial conducted in 41 intensive care units (ICUs) in Brazil. Patients with COVID-19 and moderate to severe ARDS, according to the Berlin definition, were enrolled from April 17 to June 23, 2020. Final follow-up was completed on July 21, 2020. The trial was stopped early following publication of a related study before reaching the planned sample size of 350 patients. INTERVENTIONS Twenty mg of dexamethasone intravenously daily for 5 days, 10 mg of dexamethasone daily for 5 days or until ICU discharge, plus standard care (n = 151) or standard care alone (n = 148). MAIN OUTCOMES AND MEASURES The primary outcome was ventilator-free days during the first 28 days, defined as being alive and free from mechanical ventilation. Secondary outcomes were all-cause mortality at 28 days, clinical status of patients at day 15 using a 6-point ordinal scale (ranging from 1, not hospitalized to 6, death), ICU-free days during the first 28 days, mechanical ventilation duration at 28 days, and Sequential Organ Failure Assessment (SOFA) scores (range, 0-24, with higher scores indicating greater organ dysfunction) at 48 hours, 72 hours, and 7 days. RESULTS A total of 299 patients (mean [SD] age, 61 [14] years; 37% women) were enrolled and all completed follow-up. Patients randomized to the dexamethasone group had a mean 6.6 ventilator-free days (95% CI, 5.0-8.2) during the first 28 days vs 4.0 ventilator-free days (95% CI, 2.9-5.4) in the standard care group (difference, 2.26; 95% CI, 0.2-4.38; P =.04). At 7 days, patients in the dexamethasone group had a mean SOFA score of 6.1 (95% CI, 5.5-6.7) vs 7.5 (95% CI, 6.9-8.1) in the standard care group (difference, -1.16; 95% CI, -1.94 to -0.38; P = .004). There was no significant difference in the prespecified secondary outcomes of all-cause mortality at 28 days, ICU-free days during the first 28 days, mechanical ventilation duration at 28 days, or the 6-point ordinal scale at 15 days. Thirty-three patients (21.9%) in the dexamethasone group vs 43 (29.1%) in the standard care group experienced secondary infections, 47 (31.1%) vs 42 (28.3%) needed insulin for glucose control, and 5 (3.3%) vs 9 (6.1%) experienced other serious adverse events. CONCLUSIONS AND RELEVANCE Among patients with COVID-19 and moderate or severe ARDS, use of intravenous dexamethasone plus standard care compared with standard care alone resulted in a statistically significant increase in the number of ventilator-free days (days alive and free of mechanical ventilation) over 28 days.	[Tomazini, Bruno M.; Bueno, Flavia R.; Silva, Maria Vitoria A. O.; Baldassare, Franca P.; Costa, Eduardo L., V; Moura, Ricardo A. B.; Honorato, Michele O.; Costa, Andre N.; Forte, Daniel N.; Azevedo, Luciano C. P.] Hosp Sirio Libanes, Rua Prof Daher Cutait 69, BR-01308060 Sao Paulo, Brazil; [Tomazini, Bruno M.; Roepke, Roberta M. L.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Dept Cirurgia, Sao Paulo, Brazil; [Maia, Israel S.; Cavalcanti, Alexandre B.; Damiani, Lucas P.; Lisboa, Thiago; Kawano-Dourado, Leticia; Zampieri, Fernando G.] HCor Res Inst, Sao Paulo, Brazil; [Maia, Israel S.; Cavalcanti, Alexandre B.; Rosa, Regis G.; Veiga, Viviane C.; Lisboa, Thiago; Zampieri, Fernando G.; Freitas, Flavio G. R.; Machado, Flavia R.; Azevedo, Luciano C. P.] Brazilian Res Intens Care Network BRICNet, Sao Paulo, Brazil; [Berwanger, Otavio; Olivato, Guilherme B.] Hosp Israelita Albert Einstein, Acad Res Org, Sao Paulo, Brazil; [Rosa, Regis G.] Hosp Moinhos Vento, Porto Alegre, RS, Brazil; [Veiga, Viviane C.] BP Beneficencia Portuguesa Sao Paulo, Sao Paulo, Brazil; [Avezum, Alvaro] Hosp Alemao Oswaldo Cruz, Int Res Ctr, Sao Paulo, Brazil; [Lopes, Renato D.] Brazilian Clin Res Inst, Sao Paulo, Brazil; [Lopes, Renato D.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA; [Costa, Eduardo L., V; Freitas, Daniela H. M.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, UTI Resp,Inst Coracao Incor, Sao Paulo, Brazil; [Costa, Andre N.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Dept Cardiopneumol,Inst Coracao Incor, Sao Paulo, Brazil; [Lisboa, Thiago] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Olivato, Guilherme B.] Hosp Vila Santa Catarina, Sao Paulo, Brazil; [Righy, Cassia] Inst Estadual Cerebro Paulo Niemeyer, Rio De Janeiro, Brazil; [Righy, Cassia] Fundacao Oswaldo Cruz, Lab Med Intens, Inst Nacl Infectol, Rio De Janeiro, Brazil; [Amendola, Cristina P.] Barretos Canc Hosp, Barretos, Brazil; [Roepke, Roberta M. L.] AC Camargo Canc Ctr, Intens Care Unit, Sao Paulo, Brazil; [Forte, Daniel N.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, UTI 09DN, Sao Paulo, Brazil; [Freitas, Flavio G. R.; Machado, Flavia R.] Univ Fed Sao Paulo, Anesthesiol Pain & Intens Care Dept, Sao Paulo, Brazil; [Fernandes, Caio C. F.] Hosp Mario Covas, FMABC, Santo Andre, SP, Brazil; [Melro, Livia M. G.] Hosp Samaritano Paulista, Sao Paulo, Brazil; [Junior, Gedealvares F. S.] Hosp Evangel Vila Velha, Vila Velha, Brazil; [Morais, Douglas Costa; Zung, Stevin] Ache Labs Farmaceut, Sao Paulo, Brazil; [Azevedo, Luciano C. P.] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Disciplina Emergencias Clin, Sao Paulo, Brazil	Universidade de Sao Paulo; Hospital do Coracao - HCor; Hospital Israelita Albert Einstein; Duke University; Universidade de Sao Paulo; Universidade de Sao Paulo; Fundacao Oswaldo Cruz; Hospital de Cancer de Barretos; A.C.Camargo Cancer Center; Universidade de Sao Paulo; Universidade Federal de Sao Paulo (UNIFESP); Faculdade de Medicina do ABC; Universidade de Sao Paulo	Azevedo, LCP (corresponding author), Hosp Sirio Libanes, Rua Prof Daher Cutait 69, BR-01308060 Sao Paulo, Brazil.	luciano.azevedo@hsl.org.br	Avezum, Alvaro/AAP-7687-2020; Shinotsuka, Cássia Righy/H-9181-2013; Carvalho, Carlos Roberto R/N-9827-2018; Roepke, Roberta/GQP-2543-2022; Veiga, Viviane/AAQ-9783-2021; Ramos, Ana Carolina/AAT-4320-2021; Lisboa, Thiago/W-2973-2019; Rosa, Regis Goulart/P-6422-2019; Azevedo, Luciano CP/H-2652-2012; Roepke, Roberta Muriel Longo/AAN-6414-2020; Tomazini, Bruno/AAZ-6149-2020	Shinotsuka, Cássia Righy/0000-0002-9206-9552; Carvalho, Carlos Roberto R/0000-0002-1618-8509; Veiga, Viviane/0000-0002-0287-3601; Lisboa, Thiago/0000-0003-4306-2212; Azevedo, Luciano CP/0000-0001-6759-3910; Roepke, Roberta Muriel Longo/0000-0003-2214-5166; Ramos, Ana Carolina Simoes/0000-0002-2523-0190; Reis, AlessanRSS/0000-0001-8486-7469; Martins Tomazini, Bruno/0000-0001-6763-6132				Ackermann M, 2020, NEW ENGL J MED, V383, P120, DOI 10.1056/NEJMoa2015432; [Anonymous], 2020, US SUPP UN PRINC DES; Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC; Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Becluneau G, 2017, AM J RESP CRIT CARE, V195, P772, DOI [10.1164/1-ccin.201602-032006, DOI 10.1164/1-CCIN.201602-032006]; Beduneau G, 2017, AM J RESP CRIT CARE, V195, P772, DOI 10.1164/rccm.201602-0320OC; Cao B, 2016, CRIT CARE MED, V44, pE318, DOI 10.1097/CCM.0000000000001616; Cavalcanti AB, 2017, JAMA-J AM MED ASSOC, V318, P1335, DOI 10.1001/jama.2017.14171; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Grasselli G, 2020, JAMA INTERN MED, V180, P1345, DOI 10.1001/jamainternmed.2020.3539; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Horby P, 2020, NEW ENGL J MED, DOI [10.1101/2020.06.22.20137273:24, DOI 10.1056/NEJMOA2021436, 10.1101/2020.06.22.20137273, 10.1101/2020.06.22.20137273v1, DOI 10.1101/2020.07.15.20151852]; Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006; Lehmann E.L., 1975, NONPARAMETRICS STAT; Metnitz PGH, 2005, INTENS CARE MED, V31, P1336, DOI 10.1007/s00134-005-2762-6; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5; Ni YN, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2395-8; Qin C, 2020, CLIN INFECT DIS, V71, P762, DOI 10.1093/cid/ciaa248; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Richardson Safiya, 2020, JAMA, V323, P2052, DOI 10.1001/jama.2020.6775; Neto AS, 2016, LANCET RESP MED, V4, P882, DOI 10.1016/S2213-2600(16)30305-8; Steinberg KP, 2006, NEW ENGL J MED, V354, P1671; Tomazini BM, 2020, REV BRAS TER INTENSI; Villar J, 2020, LANCET RESP MED, V8, P267, DOI 10.1016/S2213-2600(19)30417-5; Wang Y, 2020, AM J RESP CRIT CARE, V201, P1430, DOI 10.1164/rccm.202003-0736LE; WHO, 2020, COVID 19 THER TRIAL; WHO, 2020, WHO DIR GEN OP REM M; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	30	585	612	9	54	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	2020	324	13					1307	1316		10.1001/jama.2020.17021	http://dx.doi.org/10.1001/jama.2020.17021			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OS4SZ	32876695	Green Published, Bronze			2023-01-03	WOS:000590156000015
J	Nawka, MT; Hanning, U; Guerreiro, H; Flottmann, F; Van Horn, N; Buhk, JH; Fiehler, J; Frolich, AM				Nawka, Marie Teresa; Hanning, Uta; Guerreiro, Helena; Flottmann, Fabian; Van Horn, Noel; Buhk, Jan-Hendrik; Fiehler, Jens; Froelich, Andreas Maximilian			Feasibility of a customizable training environment for neurointerventional skills assessment	PLOS ONE			English	Article							THROMBECTOMY; MODEL	Objective To meet increasing demands to train neuroendovascular techniques, we developed a dedicated simulator applying individualized three-dimensional intracranial aneurysm models ('HANNES'; Hamburg Anatomic Neurointerventional Endovascular Simulator). We hypothesized that HANNES provides a realistic and reproducible training environment to practice coil embolization and to exemplify disparities between neurointerventionalists, thus objectively benchmarking operators at different levels of experience. Methods Six physicians with different degrees of neurointerventional procedural experience were recruited into a standardized training protocol comprising catheterization of two internal carotid artery (ICA) aneurysms and one basilar tip aneurysm, followed by introduction of one framing coil into each aneurysm and finally complete coil embolization of one determined ICA aneurysm. The level of difficulty increased with every aneurysm. Fluoroscopy was recorded and assessed for procedural characteristics and adverse events. Results Physicians were divided into inexperienced and experienced operators, depending on their experience with microcatheter handling. Mean overall catheterization times increased with difficulty of the aneurysm model. Inexperienced operators showed longer catheterization times (median; IQR: 47; 30-84s) than experienced operators (21; 13-58s, p = 0.011) and became significantly faster during the course of the attempts (rho = -0.493, p = 0.009) than the experienced physicians (rho = -0.318, p = 0.106). Number of dangerous maneuvers throughout all attempts was significantly higher for inexperienced operators (median; IQR: 1.0; 0.0-1.5) as compared to experienced operators (0.0; 0.0-1.0, p = 0.014). Conclusion HANNES represents a modular neurointerventional training environment for practicing aneurysm coil embolization in vitro. Objective procedural metrics correlate with operator experience, suggesting that the system could be useful for assessing operator proficiency.	[Nawka, Marie Teresa; Hanning, Uta; Guerreiro, Helena; Flottmann, Fabian; Van Horn, Noel; Buhk, Jan-Hendrik; Fiehler, Jens; Froelich, Andreas Maximilian] Univ Med Ctr Hamburg Eppendorf, Dept Diagnost & Intervent Neuroradiol, Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Nawka, MT (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Diagnost & Intervent Neuroradiol, Hamburg, Germany.	m.nawka@uke.de	van Horn, Noel/AAW-5274-2020	van Horn, Noel/0000-0001-5764-1982; Hanning, Uta/0000-0002-7543-8555; Guerreiro, Helena/0000-0003-0221-8954	German Ministry for Education and Research (BMBF) [031L0068B]	German Ministry for Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF))	This work was supported by the German Ministry for Education and Research (BMBF Grant 031L0068B). The sponsor encourages publication but had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abla AA, 2015, WORLD NEUROSURG, V83, P35, DOI 10.1016/j.wneu.2014.01.015; [Anonymous], 2018, PHYS TRAINING PROTOC; [Anonymous], 2019, VALIDATION STUDIES V; [Anonymous], 2019, EVALUATION MODULAR I; [Anonymous], 2013, SIMULATED DIAGNOSTIC; [Anonymous], 2018, UPDATE RAYMOND ROY O; [Anonymous], 2012, EFFECTIVENESS MECH E; [Anonymous], 2016, 3D PRINTING INTRACRA; [Anonymous], 2012, SIMULATOR BASED ANGI; [Anonymous], 2011, CEREBROVASCULAR BIOM; Bechstein M, 2021, CLIN NEURORADIOL, V31, P181, DOI 10.1007/s00062-019-00870-5; Bender MT, 2017, WORLD NEUROSURG, V106, P919, DOI [10.1016/J.WNEU.2017.07.074, 10.1016/j.wneu.2017.07.074]; Chan Y H, 2003, Singapore Med J, V44, P614; Chueh JY, 2013, STROKE, V44, P1396, DOI 10.1161/STROKEAHA.111.670463; Gruber A, 1997, MINIM INVAS NEUROSUR, V40, P121, DOI 10.1055/s-2008-1053431; Ihn YK, 2018, INTERV NEURORADIOL, V24, P237, DOI 10.1177/1591019918758493; Issenberg SB, 2005, MED TEACH, V27, P10, DOI 10.1080/01421590500046924; Mokin M, 2015, J NEUROINTERV SURG, V7, P453, DOI 10.1136/neurintsurg-2014-011148; Reddy AS, 2021, J NEUROSURG, V134, P1190, DOI 10.3171/2020.1.JNS192732; Sorkin GC, 2014, NEUROSURGERY, V74, pS191, DOI 10.1227/NEU.0000000000000222; Sullivan S, 2018, J NEUROSURG-PEDIATR, V22, P672, DOI 10.3171/2018.6.PEDS17696; Wang JL, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011103; Wortmann Nadine, 2019, T ADDITIVE MANUFACTU, V1, DOI [10.18416/AMMM.2019.1909S04T03, DOI 10.18416/AMMM.2019.1909S04T03]; Zhou G, 2017, NEUROSURG FOCUS, V42, DOI 10.3171/2017.3.FOCUS16450	24	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2020	15	9							e0238952	10.1371/journal.pone.0238952	http://dx.doi.org/10.1371/journal.pone.0238952			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU7VY	32941466	Green Published, gold			2023-01-03	WOS:000573848800064
J	Crosby, S; Younie, S; Williamson, I; Laird, K				Crosby, Sapphire; Younie, Sarah; Williamson, Iain; Laird, Katie			Evaluating approaches to designing effective Co-Created hand-hygiene interventions for children in India, Sierra Leone and the UK	PLOS ONE			English	Article							RISK; COMMUNITY	Effective and culturally appropriate hand-hygiene education is essential to promote health-related practices to control and prevent diseases such as Diarrhoea, Ebola and COVID-19. In this paper we outline and evaluate the Co-Creation processes underpinning a handwashing intervention for young children (A Germ's Journey) developed and delivered in India, Sierra Leone and the UK, and consider the implications surrounding Imperialist/Colonial discourse and the White Saviour Complex. The paper focuses both on the ways Co-Creation was conceptualised by our collaborators in all three countries and the catalysts and challenges encountered. Qualitative data have been drawn from in-depth interviews with five key stakeholders, focus group data from 37 teachers in Sierra Leone and responses to open-ended questionnaires completed by teachers in India (N = 66) and UK (N = 63). Data were analysed using thematic analysis and three themes, each with three constituent subthemes are presented. In the theme 'Representations of and Unique Approaches to Co-Creation' we explore the ways in which Co-Creation was constructed in relation to teamwork, innovative practice and more continuous models of evaluation. In 'Advantages of Co-Creation' we consider issues around shared ownership, improved outcomes and more meaningful insights alongside the mitigation of risks and short-circuiting of problems. In 'Challenges of Co-Creation' we discuss issues around timing and organisation, attracting and working with appropriate partners and understanding the importance of local context with inherent social, economic and structural barriers, especially in low-and-middle-income countries. We consider how theoretical elements of Co-Creation can inform effective international public health interventions; crucial during a global pandemic in which handwashing is the most effective method to control the transmission of COVID-19. Finally we reflect on some of the methodological challenges of our own work and in managing the potentially conflicting goals of the ethical and participatory values of Co-Creation with pragmatic considerations about ensuring an effective final 'product'.	[Crosby, Sapphire; Younie, Sarah] De Montfort Univ, Inst Res Criminol Commun Educ & Social Justice, Leicester, Leics, England; [Williamson, Iain] De Montfort Univ, Inst Psychol Sci, Leicester, Leics, England; [Laird, Katie] De Montfort Univ, Leicester Inst Pharmaceut Innovat, Infect Dis Res Grp, Leicester, Leics, England	De Montfort University; De Montfort University; De Montfort University	Crosby, S (corresponding author), De Montfort Univ, Inst Res Criminol Commun Educ & Social Justice, Leicester, Leics, England.	p13212007@my365.dmu.ac.uk		Younie, Sarah/0000-0001-8981-6476; Laird, Katie/0000-0001-7187-0415; Crosby, Sapphire/0000-0002-8423-2356	Faculty of Health and Life Sciences, De Montfort University	Faculty of Health and Life Sciences, De Montfort University	The authors received funding for this work from the Faculty of Health and Life Sciences, De Montfort University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aiello AE, 2008, AM J PUBLIC HEALTH, V98, P1372, DOI 10.2105/AJPH.2007.124610; Allen R. L., 2001, EDUC THEORY, V51, DOI DOI 10.1111/J.1741-5446.2001.00467.X; [Anonymous], 2013, MUSLIM MAGAZINE, V4, P28; Aronson B.A., 2017, J CRITICAL THOUGHT P, V6, P36, DOI [10.31274/jctp-180810-83, DOI 10.31274/JCTP-180810-83]; Bendapudi N, 2003, J MARKETING, V67, P14, DOI 10.1509/jmkg.67.1.14.18592; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; British Educational Research Association (BERA), 2018, ETH GUID RES; Cairncross S, 2006, DISEASE CONTROL PRIORITIES IN DEVELOPING COUNTRIES, 2ND EDITION, P771; Chandler D., 2003, ACTION RES, V1, P133, DOI [10.1177/14767503030012002, DOI 10.1177/14767503030012002]; Cole Teju, 2012, ATLANTIC; Crosby S, 2019, HLTH ED J, V79, P123; Crosby S, 2019, INT J EARLY YEARS ED, V27, P374, DOI 10.1080/09669760.2019.1628010; Curtis V, 2003, LANCET INFECT DIS, V3, P275, DOI 10.1016/S1473-3099(03)00606-6; Curtis V, 2011, LANCET INFECT DIS, V11, P312, DOI 10.1016/S1473-3099(10)70224-3; Dewey J., 1916, DEMOCRACY ED; Ehlen CG, 2015, COCREATION INNOVATIO, P111; Ejemot-Nwadiaro RI, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004265.pub3; Freeman MC, 2014, TROP MED INT HEALTH, V19, P906, DOI 10.1111/tmi.12339; Freeman MC, 2013, AM J TROP MED HYG, V89, P875, DOI 10.4269/ajtmh.13-0237; Freiere P, 1972, PLACE PUBLICATION NO; Gao J, 2020, PLOS ONE, V15; Gillis A, 2002, RES NURSES METHODS I; Greenland K, 2013, TROPICAL MED INT HLT; Haque N, 2019, CAN GERIATR J, V22, P1, DOI 10.5770/cgj.22.266; Heymann DL, 2020, LANCET, V395, P542, DOI 10.1016/S0140-6736(20)30374-3; hooks bell., 1994, TEACHING TRANSGRESS; Hopkins N, 2018, EDUC 3-13, V46, P433, DOI 10.1080/03004279.2018.1445477; Jansen S., 2017, 7 PRINCIPLES COMPLET; Kambil A, 1999, OUTLOOK, V2, P38; Kambil A, 1996, IS9621 STERN NYU, P1; Kumar R., 2011, RES METHODOLOGY STEP, V3rd; Laird K, 2017, GERMS JOURNEY DIRTY; Leask CF., 2019, RES INVOLV ENGAGEM, V5, P1, DOI [10.1186/s40900-018-0136-9, DOI 10.1186/S40900-018-0136-9]; Lombardo S, 2017, IND MARKET MANAG, V61, P155, DOI 10.1016/j.indmarman.2016.06.005; Lukman H., 2014, J ARG SCI, V15, P11; MacDonald C, CANADIAN J ACTION RE, V13, P34; Mcfadden SM, 2020, PLOS ONE, P1; McNiff J, 2014, ALL YOU NEED KNOW AC; Rabie T, 2006, TROP MED INT HEALTH, V11, P258, DOI 10.1111/j.1365-3156.2006.01568.x; Reason P., 2008, SAGE HDB ACTION; Seidman Irving., 2019, INTERVIEWING QUALITA, V5th; The Lancet Planetary Health, 2017, LANCET PLANET HLTH, V1, pe209; UNICEF, 2019, DIARRH DIS; Vollman A.R., 2004, CANADIAN COMMUNITY P; WHO, 2019, INF PREV CONTR EV CL; Younie S, PLOS ONE	46	3	3	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2020	15	9							e0239234	10.1371/journal.pone.0239234	http://dx.doi.org/10.1371/journal.pone.0239234			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NU1BO	32931509	gold, Green Published			2023-01-03	WOS:000573375500029
J	Wargo, JA				Wargo, Jennifer A.			Modulating gut microbes Fecal microbiota transplant and modulation of microbial species show therapeutic promise	SCIENCE			English	Editorial Material									[Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Wargo, Jennifer A.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wargo, JA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.; Wargo, JA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77030 USA.	jwargo@mdanderson.org			National Institutes of Health [1R01CA219896-01A1]; Melanoma Research Alliance [4022024]; American Association for Cancer Research Stand Up To Cancer [SU2C-AACR-IRG-19-17]; MD Anderson Melanoma Moonshot Program	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Melanoma Research Alliance; American Association for Cancer Research Stand Up To Cancer; MD Anderson Melanoma Moonshot Program	J.A.W. is supported by the National Institutes of Health (1R01CA219896-01A1), the Melanoma Research Alliance (4022024),American Association for Cancer Research Stand Up To Cancer (SU2C-AACR-IRG-19-17),and the MD Anderson Melanoma Moonshot Program.J.A.W. is an inventor on U.S. patent application (PCT/US17/53.717) and receives compensation from and is on the advisory boards for Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, Physician Education Resource, AstraZeneca, Bristol-Myers Squibb, and Ella Therapeutics.	Allegretti JR, 2019, LANCET, V394, P420, DOI 10.1016/S0140-6736(19)31266-8; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Cammarota G, 2019, GUT, V68, P2111, DOI 10.1136/gutjnl-2019-319548; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; DeFilipp Z, 2019, NEW ENGL J MED, V381, P2043, DOI 10.1056/NEJMoa1910437; EISEMAN B, 1958, SURGERY, V44, P854; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; McQuade JL, 2019, LANCET ONCOL, V20, pE77, DOI 10.1016/S1470-2045(18)30952-5; Olesen S.W., 2019, MEDRXIV; Olesen SW, 2020, LANCET GASTROENTEROL, V5, P241, DOI 10.1016/S2468-1253(19)30452-2; Peled JU, 2020, NEW ENGL J MED, V382, P822, DOI 10.1056/NEJMoa1900623; Suez J, 2019, NAT MED, V25, P716, DOI 10.1038/s41591-019-0439-x; Yelin I, 2019, NAT MED, V25, P1728, DOI 10.1038/s41591-019-0626-9; Zhang FM, 2012, AM J GASTROENTEROL, V107, P1755, DOI 10.1038/ajg.2012.251	15	33	35	4	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	2020	369	6509			SI		1302	1303		10.1126/science.abc3965	http://dx.doi.org/10.1126/science.abc3965			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NO9YB	32913089				2023-01-03	WOS:000569840300031
J	Knight, SR; Ho, A; Pius, R; Buchan, I; Carson, G; Drake, TM; Dunning, J; Fairfield, CJ; Gamble, C; Green, CA; Gupta, R; Halpin, S; Hardwick, HE; Holden, KA; Horby, PW; Jackson, C; Mclean, KA; Merson, L; Nguyen-Van-Tam, JS; Norman, L; Noursadeghi, M; Olliaro, PL; Pritchard, MG; Russell, CD; Shaw, CA; Sheikh, A; Solomon, T; Sudlow, C; Swann, OV; Turtle, LCW; Openshaw, PJM; Baillie, JK; Semple, MG; Docherty, AB; Harrison, EM				Knight, Stephen R.; Ho, Antonia; Pius, Riinu; Buchan, Iain; Carson, Gail; Drake, Thomas M.; Dunning, Jake; Fairfield, Cameron J.; Gamble, Carrol; Green, Christopher A.; Gupta, Rishi; Halpin, Sophie; Hardwick, Hayley E.; Holden, Karl A.; Horby, Peter W.; Jackson, Clare; Mclean, Kenneth A.; Merson, Laura; Nguyen-Van-Tam, Jonathan S.; Norman, Lisa; Noursadeghi, Mahdad; Olliaro, Piero L.; Pritchard, Mark G.; Russell, Clark D.; Shaw, Catherine A.; Sheikh, Aziz; Solomon, Tom; Sudlow, Cathie; Swann, Olivia, V; Turtle, Lance C. W.; Openshaw, Peter J. M.; Baillie, J. Kenneth; Semple, Malcolm G.; Docherty, Annemarie B.; Harrison, Ewen M.		ISARIC4C Investigators	Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; SEVERITY; PERFORMANCE; CURB-65; SEPSIS; ADULTS; CURVE	OBJECTIVE To develop and validate a pragmatic risk score to predict mortality in patients admitted to hospital with coronavirus disease 2019 (covid-19). DESIGN Prospective observational cohort study. SETTING International Severe Acute Respiratory and emerging Infections Consortium (ISARIC) World Health Organization (WHO) Clinical Characterisation Protocol UK (CCP-UK) study (performed by the ISARIC Coronavirus Clinical Characterisation ConsortiumISARIC-4C) in 260 hospitals across England, Scotland, and Wales. Model training was performed on a cohort of patients recruited between 6 February and 20 May 2020, with validation conducted on a second cohort of patients recruited after model development between 21 May and 29 June 2020. PARTICIPANTS Adults (age a18 years) admitted to hospital with covid-19 at least four weeks before final data extraction. MAIN OUTCOME MEASURE In-hospital mortality. RESULTS 35 463 patients were included in the derivation dataset (mortality rate 32.2%) and 22 361 in the validation dataset (mortality rate 30.1%). The final 4C Mortality Score included eight variables readily available at initial hospital assessment: age, sex, number of comorbidities, respiratory rate, peripheral oxygen saturation, level of consciousness, urea level, and C reactive protein (score range 0-21 points). The 4C Score showed high discrimination for mortality (derivation cohort: area under the receiver operating characteristic curve 0.79, 95% confidence interval 0.78 to 0.79; validation cohort: 0.77, 0.76 to 0.77) with excellent calibration (validation: calibrationin-the-large=0, slope=1.0). Patients with a score of at least 15 (n=4158, 19%) had a 62% mortality (positive predictive value 62%) compared with 1% mortality for those with a score of 3 or less (n=1650, 7%; negative predictive value 99%). Discriminatory performance was higher than 15 pre-existing risk stratification scores (area under the receiver operating characteristic curve range 0.61-0.76), with scores developed in other covid-19 cohorts often performing poorly (range 0.63-0.73). CONCLUSIONS An easy-to-use risk stratification score has been developed and validated based on commonly available parameters at hospital presentation. The 4C Mortality Score outperformed existing scores, showed utility to directly inform clinical decision making, and can be used to stratify patients admitted to hospital with covid-19 into different management groups. The score should be further validated to determine its applicability in other populations. STUDY REGISTRATION ISRCTN66726260	[Knight, Stephen R.; Pius, Riinu; Drake, Thomas M.; Fairfield, Cameron J.; Mclean, Kenneth A.; Norman, Lisa; Shaw, Catherine A.; Sheikh, Aziz] Univ Edinburgh, Usher Inst, Med Informat Ctr, Edinburgh, Midlothian, Scotland; [Ho, Antonia] Univ Glasgow Ctr Virus Res, Med Res Council, Glasgow, Lanark, Scotland; [Ho, Antonia] Queen Elizabeth Univ Hosp, Dept Infect Dis, Glasgow, Lanark, Scotland; [Buchan, Iain] Univ Liverpool, Inst Populat Hlth Sci, Liverpool, Merseyside, England; [Carson, Gail] Univ Oxford, Nuffield Dept Med, ISARIC Global Support Ctr, Ctr Trop Med & Global Hlth, Oxford, England; [Dunning, Jake] Publ Hlth England, Natl Infect Serv, London, England; [Dunning, Jake] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Gamble, Carrol; Halpin, Sophie; Jackson, Clare] Univ Liverpool, Liverpool Clin Trials Ctr, Liverpool, Merseyside, England; [Green, Christopher A.] Univ Birmingham, Inst Microbiol Infect, Birmingham, W Midlands, England; [Gupta, Rishi] UCL, Inst Global Hlth, London, England; [Hardwick, Hayley E.; Holden, Karl A.; Solomon, Tom; Sudlow, Cathie; Turtle, Lance C. W.; Semple, Malcolm G.] Univ Liverpool, Inst Infect, Fac Hlth & Life Sci, NIHR Hlth Protect Res Unit, Liverpool, Merseyside, England; [Nguyen-Van-Tam, Jonathan S.] Univ Nottingham, Div Epidemiol & Publ Hlth, Sch Med, Nottingham, England; [Noursadeghi, Mahdad] UCL, Div Infect & Immun, London, England; [Olliaro, Piero L.; Pritchard, Mark G.] Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England; [Russell, Clark D.] Univ Edinburgh, Med Res Inst, Edinburgh, Midlothian, Scotland; [Solomon, Tom] Walton Ctr NHS Fdn Trust, Liverpool, Merseyside, England; [Sudlow, Cathie] Hlth Data Res UK, London, England; [Swann, Olivia, V] Univ Edinburgh, Dept Child Life & Hlth, Edinburgh, Midlothian, Scotland; [Turtle, Lance C. W.] Royal Liverpool Univ Hosp, Infect Dis Unit, Liverpool, Merseyside, England; [Baillie, J. Kenneth] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland; [Baillie, J. Kenneth; Docherty, Annemarie B.] Royal Infirm Edinburgh NHS Trust, Intens Care Unit, Edinburgh, Midlothian, Scotland; [Semple, Malcolm G.] Univ Liverpool, Inst Pk, Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England; [Harrison, Ewen M.] Univ Edinburgh, Dept Clin Surg, Edinburgh, Midlothian, Scotland	University of Edinburgh; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); Queen Elizabeth University Hospital (QEUH); University of Liverpool; University of Oxford; Public Health England; Imperial College London; University of Liverpool; University of Birmingham; University of London; University College London; University of Liverpool; University of Nottingham; University of London; University College London; University of Oxford; University of Edinburgh; Walton Centre; University of Edinburgh; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; University of Liverpool; University of Edinburgh	Semple, MG (corresponding author), Univ Liverpool, Inst Infect, Fac Hlth & Life Sci, NIHR Hlth Protect Res Unit, Liverpool, Merseyside, England.; Semple, MG (corresponding author), Univ Liverpool, Inst Pk, Alder Hey Childrens Hosp, Liverpool L12 2AP, Merseyside, England.	m.g.semple@liverpool.ac.uk	Knight, S R/AFR-5534-2022; Thomson, Emma C/M-8690-2017; Dushianthan, Ahilanandan/T-8390-2019; Dunning, Jake/U-7181-2019; Asiimwe, Innocent/AAD-7175-2022; Semple, Malcolm Gracie/A-8790-2008; Baillie, John Kenneth/F-3124-2011; Moore, Shona C/AAY-5049-2021; Baillie, Kenneth/AEK-6650-2022; Laha, Shondipon/AAN-9181-2020; Dorival, Isabel Garcia/AAX-5807-2020; Buchan, Iain/H-5767-2013; Pritchard, Mark/F-3683-2017; Summers, Charlotte/A-6973-2012	Knight, S R/0000-0003-0448-3719; Thomson, Emma C/0000-0003-1482-0889; Dushianthan, Ahilanandan/0000-0002-0165-3359; Dunning, Jake/0000-0002-4035-4562; Asiimwe, Innocent/0000-0002-1196-1822; Semple, Malcolm Gracie/0000-0001-9700-0418; Baillie, John Kenneth/0000-0001-5258-793X; Moore, Shona C/0000-0001-8610-2806; Baillie, Kenneth/0000-0001-5258-793X; Laha, Shondipon/0000-0001-8748-9766; Dorival, Isabel Garcia/0000-0002-5654-5662; Lillie, Patrick/0000-0002-4811-4774; Noursadeghi, Mahdad/0000-0002-4774-0853; Pollakis, Georgios/0000-0002-9659-5461; Green, Christopher/0000-0002-1984-4014; Lett, Lauren/0000-0002-3623-0321; Gupta, Rishi/0000-0002-6257-1285; Mentzer, Alexander/0000-0002-4502-2209; Buchan, Iain/0000-0003-3392-1650; Pritchard, Mark/0000-0003-1726-8989; Lant, Suzannah/0000-0003-0852-7803; Mok, Quen/0000-0003-4807-9275; Hodgson, Luke/0000-0002-8278-9513; McDonald, Sarah/0000-0003-2776-7415; Dark, Paul/0000-0003-3309-0164; Sheikh, Aziz/0000-0001-7022-3056; Summers, Charlotte/0000-0002-7269-2873; Sigfrid, Louise/0000-0003-2764-1177; Harrison, Ewen/0000-0002-5018-3066; Paxton, William/0000-0002-2654-5186; Leiner, Tamas/0000-0002-7910-0084; Ustianowski, Andrew/0000-0002-6134-7855; Koukorava, Chrysa/0000-0001-5723-0390; Scott, Janet/0000-0001-8030-5223; Hartshorn, Stuart/0000-0003-0419-1564; Fletcher, Tom/0000-0002-3712-415X; Thwaites, Ryan/0000-0003-3052-2793; Paxton, William/0000-0001-5200-0801; Peters, Mark/0000-0003-3653-4808; Hormis, Anil/0000-0001-5510-7639; Chand, Meera/0000-0001-9697-0340	National Institute for Health Research (NIHR) [CO-CIN-01]; Medical Research Council (MRC) [MC_PC_19059]; NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool; Public Health England (PHE); Liverpool School of Tropical Medicine [200907]; University of Oxford [200907]; NIHR HPRU in Respiratory Infections at Imperial College London [200927]; PHE [200927]; Wellcome Trust [215091/Z/18/Z, 205228/Z/16/Z]; Department for International Development (DID) [215091/Z/18/Z]; Bill and Melinda Gates Foundation [OPP1209135]; Liverpool Experimental Cancer Medicine Centre [C18616/A25153]; NIHR Biomedical Research Centre at Imperial College London [IS-BRC-1215-20013]; EU Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE) [602525]; NIHR [201385]; WT investigator award [207511/Z/17/Z]; NIHR University College London Hospitals Biomedical Research Centre; MRC [MC_PC_19025, MR/R005982/1, MC_PC_19059, MC_PC_19026, MC_UU_12014/9, MR/V033441/1] Funding Source: UKRI; UKRI [MR/S032304/1] Funding Source: UKRI	National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool; Public Health England (PHE); Liverpool School of Tropical Medicine; University of Oxford; NIHR HPRU in Respiratory Infections at Imperial College London; PHE; Wellcome Trust(Wellcome Trust); Department for International Development (DID); Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Liverpool Experimental Cancer Medicine Centre; NIHR Biomedical Research Centre at Imperial College London; EU Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE); NIHR(National Institute for Health Research (NIHR)); WT investigator award; NIHR University College London Hospitals Biomedical Research Centre(General Electric); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UKRI	This work is supported by grants from: the National Institute for Health Research (NIHR; award CO-CIN-01), the Medical Research Council (MRC; grant MC_PC_19059), and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford (award 200907), NIHR HPRU in Respiratory Infections at Imperial College London with PHE (award 200927), Wellcome Trust and Department for International Development (DID; 215091/Z/18/Z), the Bill and Melinda Gates Foundation (OPP1209135), Liverpool Experimental Cancer Medicine Centre (grant reference C18616/A25153), NIHR Biomedical Research Centre at Imperial College London (IS-BRC-1215-20013), EU Platform for European Preparedness Against (Re-)emerging Epidemics (PREPARE; FP7 project 602525), and NIHR Clinical Research Network for providing infrastructure support for this research. PJMO is supported by a NIHR senior investigator award (201385). LT is supported by the Wellcome Trust (award 205228/Z/16/Z). MN is funded by a WT investigator award (207511/Z/17/Z) and the NIHR University College London Hospitals Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the Department of Health and Social Care, DID, NIHR, MRC, Wellcome Trust, or PHE.	[Anonymous], 2020, WELCOME RECOVERY TRI; [Anonymous], 2020, BUSINESSWIRE; Barrio I, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-83; Bauer TT, 2006, J INTERN MED, V260, P93, DOI 10.1111/j.1365-2796.2006.01657.x; Buchan IE, 2017, J EPIDEMIOL COMMUN H, V71, P928, DOI 10.1136/jech-2017-209195; Caramelo F, 2020, ESTIMATION RISK FACT, DOI [10.1101/2020.02.24.20027268, DOI 10.1101/2020.02.24.20027268]; Charles PGP, 2008, CLIN INFECT DIS, V47, P375, DOI 10.1086/589754; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen JH, 2010, THORAX, V65, P971, DOI 10.1136/thx.2009.129627; Collins GS, 2015, ANN INTERN MED, V162, P55, DOI [10.7326/M14-0697, 10.1161/CIRCULATIONAHA.114.014508, 10.1038/bjc.2014.639, 10.1136/bmj.g7594, 10.1016/j.eururo.2014.11.025, 10.1016/j.jclinepi.2014.11.010, 10.7326/M14-0698, 10.1002/bjs.9736, 10.1186/s12916-014-0241-z]; Docherty AB, 2020, ISARIC4C INVESTIGATO; Dunning JW, 2014, LANCET INFECT DIS, V14, P8, DOI 10.1016/S1473-3099(13)70327-X; Dwyer R, 2013, BMJ OPEN RESPIR RES, V1, DOI 10.1136/bmjresp-2014-000038; Yandiola PPE, 2009, CHEST, V135, P1572, DOI 10.1378/chest.08-2179; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020; Gupta Rishi K, 2020, Eur Respir J, V56, DOI 10.1183/13993003.03498-2020; Hacking JM, 2011, TRENDS MORTALITY 196; Harrison EM, 2020, ETHNICITY OUTCOMES C; Johns Hopkins Coronavirus Resource Center, 2020, COVID 19 MAP; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Liang W, 2020, DEV VALIDATION CLIN; Lim WS, 2003, THORAX, V58, P377, DOI 10.1136/thorax.58.5.377; Liu JL, 2016, SCI REP-UK, V6, DOI 10.1038/srep22911; Luo X., 2020, MEDRXIV; Mandrekar JN, 2010, J THORAC ONCOL, V5, P1315, DOI 10.1097/JTO.0b013e3181ec173d; Miyashita N, 2006, INTERNAL MED, V45, P419, DOI 10.2169/internalmedicine.45.1691; Office of National Statistics, 2020, DEATHS INV COVID 19; Pavlou M, 2015, DEV MORE ACCURATE RI; Peduzzi P, 1995, J CLIN EPIDEMIOL, V48, P1503, DOI 10.1016/0895-4356(95)00048-8; RCP London, 2017, NAT EARL WARN SCOR N; Riley RD, 2020, CALCULATING SAMPLE S; Rubin Donald B., 1987, MULTIPLE IMPUTATION, DOI 10.1002/9780470316696; Sattar N, 2020, CIRCULATION, V142, P4, DOI 10.1161/CIRCULATIONAHA.120.047659; Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Song Y, 2021, IEEE ACM T COMPUT BI, V18, P2775, DOI 10.1109/TCBB.2021.3065361; Sterne J. A., 2009, MULTIPLE IMPUTATION; Steyerberg EW, 2010, EPIDEMIOLOGY, V21, P128, DOI 10.1097/EDE.0b013e3181c30fb2; Tolksdorf K, 2020, EUROSURVEILLANCE, V25, P7, DOI 10.2807/1560-7917.ES.2020.25.11.2000258; Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Who, 2022, WEEKL OP UPD COVID 1; Williams R.D., 2020, MEDRXIV, DOI 10.1101/2020.05.26.20112649; Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328; Xie J, 2020, DEV EXTERNAL VALIDAT, DOI [10.2139/ssrn.3562456, 10.1101/2020.03.28.20045997]; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Zhang H., 2020, RISK PREDICTION POOR, DOI [10.1101/2020.04.28.20082222%JmedRxiv, DOI 10.1101/2020.04.28.20082222%JMEDRXIV, 10.1101/2020.04.28.20082222]	48	459	462	10	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2020	370								m3339	10.1136/bmj.m3339	http://dx.doi.org/10.1136/bmj.m3339			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP5VZ	32907855	Green Submitted, Green Published, hybrid, Green Accepted			2023-01-03	WOS:000570245200024
J	Lin, YC; Lee, TC; Chen, CY; Lin, SJ; Hwang, SJ; Lin, MY				Lin, Yu-Ciou; Lee, Tien-Ching; Chen, Chung-Yu; Lin, Shun-Jin; Hwang, Shang-Jyh; Lin, Ming-Yen			Effectiveness of antiresorptive medications in women on long-term dialysis after hip fracture: A population-based cohort study	PLOS ONE			English	Article							BONE-MINERAL DENSITY; POSTMENOPAUSAL WOMEN; CARDIOVASCULAR EVENTS; HEMODIALYSIS-PATIENTS; RENAL-FUNCTION; RALOXIFENE; OSTEOPOROSIS; RISK; CALCIFICATION; BISPHOSPHONATES	There is no clear evidence how effective the antiresorptive (AR) drugs alendronate and raloxifene are at reducing risk of second hip fracture and mortality in dialysis populations. The purpose of this study was to compare the risk of hospitalization for second hip fracture and risk of mortality between AR user and non-user groups in Taiwanese women on long-term dialysis with hip fractures. We conducted a retrospective cohort study using Taiwan National Health Insurance Research Datasets. Long-term dialysis women older than 50 years with newly diagnosed hip fractures and new to AR therapy from 2005 to 2011 were recruited. The patients were divided into AR users and non-users and matched by propensity score. We used Cox Proportional Hazards models to assess association of AR with risks of second hip fracture and mortality. Totally, 1,079 dialysis patients were included, and after matching, we were left with 74 AR users and 74 non-users. AR users did not show a significant reduction in the incidence of second hip fracture compared with non-users (adjusted Hazard Ratio (HR): 0.91, 95% CI: 0.30-2.76), and alendronate users exhibited higher risk of second hip fracture compared with raloxifene users (adjusted HR: 2.80, 95% CI: 0.42-18.79). In addition, AR users were found to have significantly lower 1- and 2-year mortality rates than the non-users (1- year: adjusted HR 0.25, 95% CI, 0.07-0.90; 2-year: 0.35, 95%CI: 0.17-0.72). AR treatment did not significantly improve the risk of second hip fracture but significantly reduce mortality in older women on dialysis. Further clinical trials on effectiveness of AR medications for dialysis populations should be warranted.	[Lin, Yu-Ciou; Lin, Shun-Jin] Kaohsiung Med Univ, Grad Inst Clin Pharm, Coll Pharm, Kaohsiung, Taiwan; [Lee, Tien-Ching] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Coll Med, Orthopaed Res Ctr, Kaohsiung, Taiwan; [Lee, Tien-Ching; Hwang, Shang-Jyh] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan; [Lee, Tien-Ching] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Orthoped, Kaohsiung, Taiwan; [Lee, Tien-Ching] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Orthoped, Kaohsiung, Taiwan; [Chen, Chung-Yu; Lin, Shun-Jin] Kaohsiung Med Univ, Sch Pharm, Coll Pharm, Kaohsiung, Taiwan; [Hwang, Shang-Jyh; Lin, Ming-Yen] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan; [Hwang, Shang-Jyh; Lin, Ming-Yen] Kaohsiung Med Univ, Dept Renal Care, Coll Med, Kaohsiung, Taiwan; [Hwang, Shang-Jyh] Natl Hlth Res Inst, Inst Populat Hlth Sci, Miaoli, Taiwan; [Lin, Ming-Yen] Natl Taiwan Univ, Master Publ Hlth Degree Program, Coll Publ Hlth, Taipei, Taiwan	Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Municipal Ta-Tung Hospital; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; Kaohsiung Medical University; National Health Research Institutes - Taiwan; National Taiwan University	Lin, MY (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Internal Med, Div Nephrol, Kaohsiung, Taiwan.; Lin, MY (corresponding author), Kaohsiung Med Univ, Dept Renal Care, Coll Med, Kaohsiung, Taiwan.; Lin, MY (corresponding author), Natl Taiwan Univ, Master Publ Hlth Degree Program, Coll Publ Hlth, Taipei, Taiwan.	mingyenlin3@gmail.com	Lee, Tien-Ching/ABF-4544-2021; Lin, Ming Yen/A-8637-2010	Lee, Tien-Ching/0000-0002-1510-8079; Lin, Ming Yen/0000-0002-8194-4833	Kaohsiung Medical University Hospital; Kaohsiung Medical University; Taiwan National Health Research Institutes; Taiwan Ministry of Science and Technology; Kaohsiung Medical University [KMUH104-4R09, KMUH1055R16, KMUH105-5R17, KMUH106-6R21]; Taiwan National Health Research Institutes [NHRI-EX108-10505PI]; Taiwan Ministry of Science and Technology [MOST: 104-2314-B-037-073-MY3, MOST: 107-2314-B-037-020-MY2, MOST:105-2314-B-037-065-, MOST: 106-2314-B-002-253-, MOST:107-2314-B-037122-, MOST-108-2314-B-037-110]	Kaohsiung Medical University Hospital; Kaohsiung Medical University; Taiwan National Health Research Institutes; Taiwan Ministry of Science and Technology; Kaohsiung Medical University; Taiwan National Health Research Institutes; Taiwan Ministry of Science and Technology	Any grants or fellowships supporting the writing of the paper: We would like to thank the Kaohsiung Medical University Hospital, Kaohsiung Medical University, Taiwan National Health Research Institutes, and Taiwan Ministry of Science and Technology for partly supporting this study. SJH is supported by Kaohsiung Medical University Hospital, Kaohsiung Medical University (grant number: KMUH104-4R09 and KMUH1055R16), Taiwan National Health Research Institutes (grant number: NHRI-EX108-10505PI) and Taiwan Ministry of Science and Technology (grant number: MOST: 104-2314-B-037-073-MY3 and MOST: 107-2314-B-037-020-MY2). MYL is supported by Kaohsiung Medical University Hospital, Kaohsiung Medical University (grant number: KMUH105-5R17 and KMUH106-6R21), Taiwan Ministry of Science and Technology (grant number: MOST:105-2314-B-037-065-, MOST: 106-2314-B-002-253-, MOST:107-2314-B-037122-and MOST-108-2314-B-037-110). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abrahamsen B, 2009, OSTEOPOROSIS INT, V20, P1633, DOI 10.1007/s00198-009-0920-3; [Anonymous], 2017, CLJ, V7, P33, DOI DOI 10.17430/1002944; [Anonymous], 2015, J ENDOUROL S1, V29, pP1, DOI 10.1089/end.2015.29003.abstracts; Ariyoshi T, 2006, CLIN DRUG INVEST, V26, P215, DOI 10.2165/00044011-200626040-00006; Barrett-Connor E, 2002, JAMA-J AM MED ASSOC, V287, P847, DOI 10.1001/jama.287.7.847; Barrett-Connor E, 2006, NEW ENGL J MED, V355, P125, DOI 10.1056/NEJMoa062462; Beaupre LA, 2011, OSTEOPOROSIS INT, V22, P983, DOI 10.1007/s00198-010-1411-2; Blacher J, 1999, CIRCULATION, V99, P2434, DOI 10.1161/01.CIR.99.18.2434; Black DM, 1996, LANCET, V348, P1535, DOI 10.1016/S0140-6736(96)07088-2; Bondo L, 2013, OSTEOPOROSIS INT, V24, P245, DOI 10.1007/s00198-012-2024-8; Brozek W, 2016, OSTEOPOROSIS INT, V27, P387, DOI 10.1007/s00198-015-3415-4; Cai G, 2020, OSTEOPOROSIS INT, V31, P1741, DOI 10.1007/s00198-020-05430-z; Cannata-Andia JB, 2011, NEPHROL DIAL TRANSPL, V26, P3429, DOI 10.1093/ndt/gfr591; Chen CH, 2015, FAM PRACT, V32, P41, DOI 10.1093/fampra/cmu059; Lima GAC, 2014, ARQ BRAS ENDOCRINOL, V58, P530, DOI 10.1590/0004-2730000003360; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Ensrud KE, 2007, ARCH INTERN MED, V167, P133, DOI 10.1001/archinte.167.2.133; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P637, DOI 10.1001/jama.282.7.637; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Goldshtein I, 2016, ADV THER, V33, P1374, DOI 10.1007/s12325-016-0360-3; Grady D, 2010, AM J MED, V123, DOI 10.1016/j.amjmed.2009.12.018; Granger BB, 2005, LANCET, V366, P2005, DOI 10.1016/S0140-6736(05)67760-4; Hashiba H, 2006, THER APHER DIAL, V10, P59, DOI 10.1111/j.1744-9987.2006.00345.x; Hernandez E, 2003, KIDNEY INT, V63, P2269, DOI 10.1046/j.1523-1755.2003.00005.x; Huybrechts KF, 2006, BONE, V38, P922, DOI 10.1016/j.bone.2005.10.022; Jager KJ, 2019, SINGLE NUMBER ADVOCA; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; Levesque LE, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5087; Li L, 2012, MENOPAUSE, V19, P33, DOI 10.1097/gme.0b013e318221bacd; Lin HC, 2008, STROKE, V39, P2744, DOI 10.1161/STROKEAHA.108.519090; Lindberg JS, 1999, SEMIN NEPHROL, V19, P115; Nagatoya K, 2015, CLIN EXP NEPHROL, V19, P939, DOI 10.1007/s10157-014-1065-z; Ott SM, 2012, KIDNEY INT, V82, P833, DOI 10.1038/ki.2012.253; Parsons, 2001, P 26 ANN SAS US GROU; Price PA, 2001, ARTERIOSCL THROM VAS, V21, P817, DOI 10.1161/01.ATV.21.5.817; Saito O, 2012, INT J ENDOCRINOL MET, V10, P464, DOI 10.5812/ijem.3794; Saito O, 2011, CLIN EXP NEPHROL, V15, P126, DOI 10.1007/s10157-010-0366-0; Sarah L West SAJ, 2012, INT J CLIN RHEUMTOL, V7, P453; SHERRARD DJ, 1993, KIDNEY INT, V43, P436, DOI 10.1038/ki.1993.64; Siris ES, 2006, MAYO CLIN PROC, V81, P1013, DOI 10.4065/81.8.1013; So Y, 2014, USING PHREG PROCEDUR; Soong YK, 2013, OSTEOPOROSIS INT, V24, P511, DOI 10.1007/s00198-012-1984-z; Steiner JF, 1997, J CLIN EPIDEMIOL, V50, P105, DOI 10.1016/S0895-4356(96)00268-5; The Taiwanese Osteoporosis Association, 2015, TAIW CONS GUID PREV; Weiss TW, 2007, CURR MED RES OPIN, V23, P2193, DOI 10.1185/030079907X226069; Wetmore JB, 2005, NEPHROLOGY, V10, P393, DOI 10.1111/j.1440-1797.2005.00436.x	46	1	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2020	15	9							e0238248	10.1371/journal.pone.0238248	http://dx.doi.org/10.1371/journal.pone.0238248			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN6DP	32877436	Green Published, gold			2023-01-03	WOS:000568877100025
J	Maust, DT; Strominger, J; Bynum, JPW; Langa, KM; Gerlach, LB; Zivin, K; Marcus, SC				Maust, Donovan T.; Strominger, Julie; Bynum, Julie P. W.; Langa, Kenneth M.; Gerlach, Lauren B.; Zivin, Kara; Marcus, Steven C.			Prevalence of Psychotropic and Opioid Prescription Fills Among Community-Dwelling Older Adults With Dementia in the US	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Maust, Donovan T.; Gerlach, Lauren B.; Zivin, Kara] Univ Michigan, Dept Psychiat, 2800 Plymouth Rd,NCRC 016-226W, Ann Arbor, MI 48109 USA; [Strominger, Julie] VA Ann Arbor Healthcare Syst, Ctr Clin Management Res, Ann Arbor, MI USA; [Bynum, Julie P. W.; Langa, Kenneth M.] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA	University of Michigan System; University of Michigan; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Ann Arbor Healthcare System; University of Michigan System; University of Michigan; University of Pennsylvania	Maust, DT (corresponding author), Univ Michigan, Dept Psychiat, 2800 Plymouth Rd,NCRC 016-226W, Ann Arbor, MI 48109 USA.	maustd@umich.edu		Zivin, Kara/0000-0001-8246-6864; Gerlach, Lauren/0000-0003-1943-0150; Langa, Kenneth/0000-0002-2798-1836	National Institute on Aging [R01AG056407]	National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by National Institute on Aging grant R01AG056407.	Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767; Maust DT, 2018, JAMA INTERN MED, V178, P640, DOI 10.1001/jamainternmed.2018.0379; Moore TJ, 2017, JAMA INTERN MED, V177, P274, DOI 10.1001/jamainternmed.2016.7507; Rattinger GB, 2013, J AM GERIATR SOC, V61, P723, DOI 10.1111/jgs.12210; Rhee Y, 2011, J AM GERIATR SOC, V59, P2100, DOI 10.1111/j.1532-5415.2011.03660.x; US Government Accountability Office, ANT DRUG US HHS HAS	6	17	17	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2020	324	7					706	+		10.1001/jama.2020.8519	http://dx.doi.org/10.1001/jama.2020.8519			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG9GI	32808997	Bronze, Green Published			2023-01-03	WOS:000564288700029
J	Hwang, JT; Yoon, KJ; Park, CH; Choi, JH; Park, HJ; Park, YS; Lee, YT				Hwang, Jin Tae; Yoon, Kyung Jae; Park, Chul-Hyun; Choi, Jae Hyeoung; Park, Hee-Jin; Park, Young Sook; Lee, Yong-Taek			Follow-up of clinical and sonographic features after extracorporeal shock wave therapy in painful plantar fibromatosis	PLOS ONE			English	Article							DUPUYTRENS DISEASE; PEYRONIES-DISEASE; FASCIITIS; MANAGEMENT; METAANALYSIS; ULTRASOUND	Background Extracorporeal shock wave therapy (ESWT) has been used as a safe alternative treatment for refractory musculoskeletal diseases, such as plantar fasciitis, Achilles tendinopathy and gluteal tendinopathy, and various forms of fibromatosis including palmar or penile fibromatosis. However, there is limited published data for clinical and sonographic features of plantar fibromatosis after ESWT. The purpose of this study was to evaluate the long-term clinical outcome of ESWT in ultrasonography-confirmed plantar fibromatosis and ultrasonographic changes of plantar fibroma after ESWT. Methods Medical charts of 26 patients (30 feet) with plantar fibromatosis confirmed by ultrasonography were reviewed. Finally, a total of 10 feet who underwent ESWT for "Poor" or "Fair" grade of Roles-Maudsley Score (RMS) and symptoms persisted for >6 months were included in this study. Short-term follow-up was conducted one week after ESWT and long-term follow-up time averaged 34.0 months. The Numerical Rating Scale (NRS) and RMS were collected for the evaluation of clinical features. Follow-up ultrasonography was conducted at long-term follow-up and changes of plantar fibroma was assessed. A greater than 50% reduction in the NRS and achievement of a "good" or "excellent" grade in the RMS were regarded as treatment success. Additionally, medical charts of 144 patients (168 feet) with plantar fasciitis confirmed by ultrasonography were reviewed and subsequently, 42 feet who underwent ESWT with the same protocol were included for the comparison of clinical features. Results In plantar fibromatosis, baseline NRS (6.2 +/- 1.3) and RMS (3.5 +/- 0.5) were significantly improved at short-term follow-up (NRS, 1.8 +/- 1.0; RMS, 2.0 +/- 0.8,P< .001, respectively) and long-term follow-up (NRS, 0.6 +/- 1.1; RMS, 1.4 +/- 0.8,P< .001, respectively). Treatment success was recorded in seven feet (70.0%) at short-term follow-up and 8 feet (80%) at long-term follow-up, which is comparable to that of the plantar fasciitis group (28 feet, 66.7%; 35 feet, 83.3%, respectively). In long-term follow-up ultrasonography, mean fibroma thickness was reduced from 4.4 +/- 1.0 to 2.6 +/- 0.8 mm (P= .003); however, length and width were not significantly changed. There were no serious adverse effects. Conclusion While these are preliminary findings, and must be confirmed in a randomized placebo control study, ESWT can have a beneficial long-term effect on pain relief and functional outcomes in painful plantar fibromatosis. However, ESWT is unlikely to affect the ultrasonographic morphology of plantar fibroma, with the exception of reducing the thickness.	[Hwang, Jin Tae; Yoon, Kyung Jae; Park, Chul-Hyun; Choi, Jae Hyeoung; Lee, Yong-Taek] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Phys & Rehabil Med, Sch Med, Seoul, South Korea; [Park, Hee-Jin] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Radiol, Sch Med, Seoul, South Korea; [Park, Young Sook] Sungkyunkwan Univ, Samsung Changwon Hosp, Dept Phys & Rehabil Med, Sch Med, Seoul, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Lee, YT (corresponding author), Sungkyunkwan Univ, Kangbuk Samsung Hosp, Dept Phys & Rehabil Med, Sch Med, Seoul, South Korea.	yongtaek1.lee@gmail.com	Lee, Yong-Taek/ABB-3200-2020; Yoon, Kyung Jae/ABB-3785-2021	Lee, Yong-Taek/0000-0001-6611-0999				Abdulsalam AJ, 2019, EUR J PHYS REHAB MED, V55, P862, DOI 10.23736/S1973-9087.18.05498-9; Ahn J, 2010, ANN REHABIL MED-ARM, V34, P565; Aqil A, 2013, CLIN ORTHOP RELAT R, V471, P3645, DOI 10.1007/s11999-013-3132-2; Bedi DG, 2001, J CLIN ULTRASOUND, V29, P499, DOI 10.1002/jcu.10014; Capogrosso P, 2019, J SEX MED, V16, P1490, DOI 10.1016/j.jsxm.2019.07.016; Cohen BE, 2018, J ULTRAS MED, V37, P2725, DOI 10.1002/jum.14615; de Bree E, 2004, AM J SURG, V187, P33, DOI 10.1016/j.amjsurg.2002.11.002; Espert M, 2018, FOOT ANKLE INT, V39, P751, DOI 10.1177/1071100718768051; Fausto de Souza Dominique, 2010, J Clin Aesthet Dermatol, V3, P45; Fojecki GL, 2017, WORLD J UROL, V35, P1, DOI 10.1007/s00345-016-1834-2; Frairia Roberto, 2011, Muscles Ligaments Tendons J, V1, P138; Frizziero A, 2017, JCR-J CLIN RHEUMATOL, V23, P63, DOI 10.1097/RHU.0000000000000462; Gudmundsson KG, 2013, FOOT ANKLE INT, V34, P841, DOI 10.1177/1071100713475352; Hatzichristodoulou G, 2013, J SEX MED, V10, P2815, DOI 10.1111/jsm.12275; Hatzimouratidis K, 2012, EUR UROL, V62, P543, DOI 10.1016/j.eururo.2012.05.040; Husain J, 2000, BJU INT, V86, P466, DOI 10.1046/j.1464-410X.2000.00827.x; Knobloch Karsten, 2012, BMC Res Notes, V5, P542, DOI 10.1186/1756-0500-5-542; Knobloch K, 2011, MED HYPOTHESES, V76, P635, DOI 10.1016/j.mehy.2011.01.018; Lebret T, 2002, UROLOGY, V59, P657, DOI 10.1016/S0090-4295(02)01527-3; Lee JY, 2017, ANN REHABIL MED-ARM, V41, P42, DOI 10.5535/arm.2017.41.1.42; Lou J, 2017, AM J PHYS MED REHAB, V96, P529, DOI 10.1097/PHM.0000000000000666; McMillan AM, 2009, J FOOT ANKLE RES, V2, DOI 10.1186/1757-1146-2-32; Mohseni-Bandpei MA, 2014, ULTRASOUND MED BIOL, V40, P1737, DOI 10.1016/j.ultrasmedbio.2014.03.001; Notarnicola A, 2017, J BIOL REG HOMEOS AG, V31, P775; Ogden JA, 2001, CLIN ORTHOP RELAT R, P22; Palmieri A, 2009, EUR UROL, V56, P363, DOI 10.1016/j.eururo.2009.05.012; Park JW, 2014, ANN REHABIL MED-ARM, V38, P534, DOI 10.5535/arm.2014.38.4.534; Reilly JM, 2018, PM&R, V10, P1385, DOI 10.1016/j.pmrj.2018.05.007; Schmitz C, 2013, J ORTHOP SURG RES, V8, DOI 10.1186/1749-799X-8-31; Seo KH, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197460; Tsai WC, 2000, SCAND J RHEUMATOL, V29, P255; van der Veer WM, 2008, PLAST RECONSTR SURG, V122, P486, DOI 10.1097/PRS.0b013e31817d61ab; Veith NT, 2013, FOOT ANKLE INT, V34, P1742, DOI 10.1177/1071100713505535; Wang CJ, 2012, J ORTHOP SURG RES, V7, DOI 10.1186/1749-799X-7-11; Yoon K., 2002, J KOREAN ACAD REHABI, V26, P181; Young JR, 2019, ORTHOP RES REV, V11, P1, DOI 10.2147/ORR.S154289	36	0	1	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2020	15	8							e0237447	10.1371/journal.pone.0237447	http://dx.doi.org/10.1371/journal.pone.0237447			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC7KJ	32776988	gold, Green Published			2023-01-03	WOS:000561393800036
J	Negredo, PN; Yeo, RW; Brunet, A				Negredo, Paloma Navarro; Yeo, Robin W.; Brunet, Anne			Aging and Rejuvenation of Neural Stem Cells and Their Niches	CELL STEM CELL			English	Review							ADULT HIPPOCAMPAL NEUROGENESIS; FATTY-ACID OXIDATION; CENTRAL-NERVOUS-SYSTEM; AGE-RELATED-CHANGES; SUBVENTRICULAR ZONE; DENTATE GYRUS; SELF-RENEWAL; COGNITIVE FUNCTION; EPENDYMAL CELLS; STEM/PROGENITOR CELLS	Aging has a profound and devastating effect on the brain. Old age is accompanied by declining cognitive function and enhanced risk of brain diseases, including cancer and neurodegenerative disorders. A key question is whether cells with regenerative potential contribute to brain health and even brain "rejuvenation.'' This review discusses mechanisms that regulate neural stem cells (NSCs) during aging, focusing on the effect of metabolism, genetic regulation, and the surrounding niche. We also explore emerging rejuvenating strategies for old NSCs. Finally, we consider how new technologies may help harness NSCs' potential to restore healthy brain function during physiological and pathological aging.	[Negredo, Paloma Navarro; Yeo, Robin W.; Brunet, Anne] Stanford Univ, Dept Genet, Stanford, CA 94305 USA; [Brunet, Anne] Glenn Labs Biol Aging, Stanford, CA 94305 USA	Stanford University	Brunet, A (corresponding author), Stanford Univ, Dept Genet, Stanford, CA 94305 USA.; Brunet, A (corresponding author), Glenn Labs Biol Aging, Stanford, CA 94305 USA.	abrunet1@stanford.edu			NIH [P01 AG036695, R01AG056290]; Glenn Laboratories for the Biology of Aging; International Human Frontier Science Program Organization [LT000136/2018]; Stanford Graduate Fellowship; Genentech Foundation Predoctoral Fellowship	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Glenn Laboratories for the Biology of Aging; International Human Frontier Science Program Organization(Human Frontier Science Program); Stanford Graduate Fellowship(Stanford University); Genentech Foundation Predoctoral Fellowship	We thank the members of the Brunet lab for helpful discussions. This work was supported by NIH P01 AG036695, NIH R01AG056290, and the Glenn Laboratories for the Biology of Aging (to A.B.); a long-term fellowship (LT000136/2018) from the International Human Frontier Science Program Organization (to P.N.N.); and a Stanford Graduate Fellowship and a Genentech Foundation Predoctoral Fellowship (to R.W.Y.). All figures were created with BioRender.com.	Adams KL, 2018, NAT NEUROSCI, V21, P9, DOI 10.1038/s41593-017-0033-9; Ahn JH, 2019, NATURE, V572, P62, DOI 10.1038/s41586-019-1419-5; Aimone JB, 2014, PHYSIOL REV, V94, P991, DOI 10.1152/physrev.00004.2014; Alonso SB, 2019, EMBO J, V38, DOI 10.15252/embj.201798791; Alunni A, 2016, DEVELOPMENT, V143, P741, DOI 10.1242/dev.122796; Alvarez-Saavedra M, 2016, CELL REP, V17, P862, DOI 10.1016/j.celrep.2016.09.030; Anacker C, 2018, NATURE, V559, P98, DOI 10.1038/s41586-018-0262-4; Apple DM, 2019, AGING-US, V11, P115, DOI 10.18632/aging.101731; Artegiani B, 2017, CELL REP, V21, P3271, DOI 10.1016/j.celrep.2017.11.050; Aspelund A, 2015, J EXP MED, V212, P991, DOI 10.1084/jem.20142290; Audesse AJ, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008097; Bachstetter AD, 2011, NEUROBIOL AGING, V32, P2030, DOI 10.1016/j.neurobiolaging.2009.11.022; Bao HC, 2017, CELL STEM CELL, V21, P604, DOI 10.1016/j.stem.2017.10.003; Barcena C, 2019, NAT MED, V25, P1234, DOI 10.1038/s41591-019-0504-5; Baruch K, 2014, SCIENCE, V346, P89, DOI 10.1126/science.1252945; Basak O, 2018, P NATL ACAD SCI USA, V115, pE610, DOI 10.1073/pnas.1715911114; Basak O, 2012, J NEUROSCI, V32, P5654, DOI 10.1523/JNEUROSCI.0455-12.2012; Baser A, 2019, NATURE, V566, P100, DOI 10.1038/s41586-019-0888-x; Beckervordersandforth R, 2017, NEURON, V93, P1518, DOI 10.1016/j.neuron.2017.03.008; Ben Abdallah NMB, 2010, NEUROBIOL AGING, V31, P151, DOI 10.1016/j.neurobiolaging.2008.03.002; Benner EJ, 2013, NATURE, V497, P369, DOI 10.1038/nature12069; Berdugo-Vega G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14026-z; Bergmann O, 2012, NEURON, V74, P634, DOI 10.1016/j.neuron.2012.03.030; Bertolini JA, 2019, CELL STEM CELL, V24, P462, DOI 10.1016/j.stem.2019.02.004; Blomfield IM, 2019, ELIFE, V8, DOI 10.7554/eLife.48561; Bohnert KA, 2017, NATURE, V551, P629, DOI 10.1038/nature24620; Bolborea M, 2013, TRENDS NEUROSCI, V36, P91, DOI 10.1016/j.tins.2012.12.008; Boldrini M, 2018, CELL STEM CELL, V22, P589, DOI 10.1016/j.stem.2018.03.015; Bonaguidi MA, 2011, CELL, V145, P1142, DOI 10.1016/j.cell.2011.05.024; Bond AM, 2015, CELL STEM CELL, V17, P385, DOI 10.1016/j.stem.2015.09.003; Bondolfi L, 2004, NEUROBIOL AGING, V25, P333, DOI 10.1016/S0197-4580(03)00083-6; Bowers M, 2020, CELL STEM CELL, V27, P98, DOI 10.1016/j.stem.2020.04.002; Brandhorst S, 2015, CELL METAB, V22, P86, DOI 10.1016/j.cmet.2015.05.012; Breton-Provencher V, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12659; Buckley SM, 2012, CELL STEM CELL, V11, P783, DOI 10.1016/j.stem.2012.09.011; Buenostro JD, 2015, NATURE, V523, P486, DOI 10.1038/nature14590; Calzolari F, 2015, NAT NEUROSCI, V18, P490, DOI 10.1038/nn.3963; Capilla-Gonzalez V, 2014, GLIA, V62, P790, DOI 10.1002/glia.22642; Carrasco-Garcia E, 2015, AGING CELL, V14, P710, DOI 10.1111/acel.12343; Castellano JM, 2017, NATURE, V544, P488, DOI 10.1038/nature22067; Cavallucci V, 2016, TRENDS ENDOCRIN MET, V27, P756, DOI 10.1016/j.tem.2016.06.007; Chaker Z, 2015, AGING CELL, V14, P847, DOI 10.1111/acel.12365; Chantranupong L, 2015, CELL, V161, P67, DOI 10.1016/j.cell.2015.02.041; Choi SH, 2018, SCIENCE, V361, P991, DOI 10.1126/science.aan8821; Chorna NE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077845; Cipriani S, 2018, CEREB CORTEX, V28, P2458, DOI 10.1093/cercor/bhy096; Corsini NS, 2009, CELL STEM CELL, V5, P178, DOI 10.1016/j.stem.2009.05.004; Cortez I, 2017, BEHAV BRAIN RES, V322, P212, DOI 10.1016/j.bbr.2016.10.023; Crouch EE, 2015, J NEUROSCI, V35, P4528, DOI 10.1523/JNEUROSCI.1188-14.2015; Cui D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19051315; Da Mesquita S, 2018, NATURE, V560, P185, DOI 10.1038/s41586-018-0368-8; De Groof G, 2009, J NEUROSCI, V29, P13557, DOI 10.1523/JNEUROSCI.1788-09.2009; Diaz-Aparicio I, 2020, J NEUROSCI, V40, P1453, DOI 10.1523/JNEUROSCI.0993-19.2019; Doetsch F, 1997, J NEUROSCI, V17, P5046; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; Dulken B, 2019, NATURE, V571, P205, DOI 10.1038/s41586-019-1362-5; Dulken BW, 2017, CELL REP, V18, P777, DOI 10.1016/j.celrep.2016.12.060; Duman C, 2019, CELL METAB, V30, P274, DOI 10.1016/j.cmet.2019.04.004; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Durante MA, 2020, NAT NEUROSCI, V23, P323, DOI 10.1038/s41593-020-0587-9; Eckert A, 2015, STEM CELL TRANSL MED, V4, P841, DOI 10.5966/sctm.2014-0184; Egerman MA, 2015, CELL METAB, V22, P164, DOI 10.1016/j.cmet.2015.05.010; Encinas JM, 2011, CELL STEM CELL, V8, P566, DOI 10.1016/j.stem.2011.03.010; Engler A, 2018, CELL REP, V22, P992, DOI 10.1016/j.celrep.2017.12.094; Enwere E, 2004, J NEUROSCI, V24, P8354, DOI 10.1523/JNEUROSCI.2751-04.2004; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Ernst A, 2015, PLOS BIOL, V13, DOI 10.1371/journal.pbio.1002045; Ernst A, 2014, CELL, V156, P1072, DOI 10.1016/j.cell.2014.01.044; Fabel K, 2009, FRONT NEUROSCI-SWITZ, V3, DOI 10.3389/neuro.22.002.2009; Faiz M, 2015, CELL STEM CELL, V17, P624, DOI 10.1016/j.stem.2015.08.002; Feierstein CE, 2010, FRONT BEHAV NEUROSCI, V4, DOI 10.3389/fnbeh.2010.00176; Flor-Garcia M, 2020, NAT PROTOC, V15, P668, DOI 10.1038/s41596-019-0267-y; Fonseca RS, 2016, STEM CELLS DEV, V25, P542, DOI 10.1089/scd.2015.0319; Frankland PW, 2013, TRENDS NEUROSCI, V36, P497, DOI 10.1016/j.tins.2013.05.002; Freund J, 2015, NEUROSCIENCE, V309, P140, DOI 10.1016/j.neuroscience.2015.05.027; Freund J, 2013, SCIENCE, V340, P756, DOI 10.1126/science.1235294; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gage FH, 2013, NEURON, V80, P588, DOI 10.1016/j.neuron.2013.10.037; Gao AJ, 2018, J NEUROSCI, V38, P3190, DOI 10.1523/JNEUROSCI.3126-17.2018; Gebara E, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00145; Gheusi C, 2000, P NATL ACAD SCI USA, V97, P1823, DOI 10.1073/pnas.97.4.1823; Goffart Nicolas, 2013, Cancers (Basel), V5, P1049, DOI 10.3390/cancers5031049; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Gontier G, 2018, CELL REP, V22, P1974, DOI 10.1016/j.celrep.2018.02.001; Graham V, 2003, NEURON, V39, P749, DOI 10.1016/S0896-6273(03)00497-5; Gregorian C, 2009, J NEUROSCI, V29, P1874, DOI 10.1523/JNEUROSCI.3095-08.2009; Gu MX, 2014, AGE, V36, P129, DOI 10.1007/s11357-013-9552-9; Guo NN, 2018, NAT MED, V24, P438, DOI 10.1038/nm.4491; Hamilton LK, 2015, CELL STEM CELL, V17, P397, DOI 10.1016/j.stem.2015.08.001; Han MJ, 2021, J COMP NEUROL, V529, P595, DOI 10.1002/cne.24967; Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001; Ho TT, 2017, NATURE, V543, P205, DOI 10.1038/nature21388; Hochgerner H, 2018, NAT NEUROSCI, V21, P290, DOI 10.1038/s41593-017-0056-2; Hotting K, 2013, NEUROSCI BIOBEHAV R, V37, P2243, DOI 10.1016/j.neubiorev.2013.04.005; Huang L, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt519; Hutton CP, 2015, NEUROSCIENCE, V308, P180, DOI 10.1016/j.neuroscience.2015.09.005; Hwang B, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09203-z; Cuartero MI, 2019, J CLIN INVEST, V129, P1536, DOI 10.1172/JCI120412; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Jin KL, 2006, P NATL ACAD SCI USA, V103, P13198, DOI 10.1073/pnas.0603512103; Jobe Emily M, 2017, Brain Plast, V3, P5, DOI 10.3233/BPL-160034; Johanson CE, 2011, METHODS MOL BIOL, V686, P101, DOI 10.1007/978-1-60761-938-3_4; Kalamakis G, 2019, CELL, V176, P1407, DOI 10.1016/j.cell.2019.01.040; Katsimpardi L, 2014, SCIENCE, V344, P630, DOI 10.1126/science.1251141; Kempermann G., 2015, COLD SPRING HARB PER, V8, DOI DOI 10.1101/CSHPERSPECT.A018986; Kempermann G, 2019, NAT REV NEUROSCI, V20, P235, DOI 10.1038/s41583-019-0120-x; Kempermann G, 2018, CELL STEM CELL, V23, P25, DOI 10.1016/j.stem.2018.04.004; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kim JA, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.138; Klemm SL, 2019, NAT REV GENET, V20, P207, DOI 10.1038/s41576-018-0089-8; Knobloch M, 2017, CELL REP, V20, P2144, DOI 10.1016/j.celrep.2017.08.029; Knobloch M, 2017, CURR OPIN NEUROBIOL, V42, P45, DOI 10.1016/j.conb.2016.11.006; Knobloch M, 2013, NATURE, V493, P226, DOI 10.1038/nature11689; Knoth R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008809; Kobayashi T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13203-4; Korholz JC, 2018, ELIFE, V7, DOI 10.7554/eLife.35690; Konefal S, 2013, FRONT NEUROANAT, V7, DOI 10.3389/fnana.2013.00021; Kratz A, 2006, AM J CLIN PATHOL, V125, P296, DOI 10.1309/PRF5N7P2XM6E243H; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kumar D., 2020, NEURON; Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517; Lee JH, 2018, NATURE, V560, P243, DOI 10.1038/s41586-018-0389-3; Leeman DS, 2018, SCIENCE, V359, P1277, DOI 10.1126/science.aag3048; Leiter O, 2019, STEM CELL REP, V12, P667, DOI 10.1016/j.stemcr.2019.02.009; Levone BR, 2015, NEUROBIOL STRESS, V1, P147, DOI 10.1016/j.ynstr.2014.11.003; Li JX, 2012, NAT CELL BIOL, V14, P999, DOI 10.1038/ncb2562; Li L, 2010, J NEUROSCI, V30, P9038, DOI 10.1523/JNEUROSCI.5691-09.2010; Li LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066069; Li L, 2010, GLIA, V58, P1610, DOI 10.1002/glia.21033; Li R, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00385; Llorens-Bobadilla E, 2015, CELL STEM CELL, V17, P329, DOI 10.1016/j.stem.2015.07.002; Lodygin D, 2019, NATURE, V566, P503, DOI 10.1038/s41586-019-0964-2; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Louveau A, 2017, J CLIN INVEST, V127, P3210, DOI 10.1172/JCI90603; Louyeau A, 2015, TRENDS IMMUNOL, V36, P569, DOI 10.1016/j.it.2015.08.006; Lu L, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00205; Luo J, 2006, AGING CELL, V5, P139, DOI 10.1111/j.1474-9726.2006.00197.x; Luo YP, 2015, CELL, V161, P1175, DOI 10.1016/j.cell.2015.04.001; Lupo G, 2018, AGING CELL, V17, DOI 10.1111/acel.12745; Malik A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139655; Manzanero S, 2014, J CEREBR BLOOD F MET, V34, P897, DOI 10.1038/jcbfm.2014.36; Marschallinger J, 2020, NAT NEUROSCI, V23, P194, DOI 10.1038/s41593-019-0566-1; Martynoga B, 2013, GENE DEV, V27, P1769, DOI 10.1101/gad.216804.113; Marx V, 2018, NAT METHODS, V15, P411, DOI 10.1038/s41592-018-0016-0; Maslov AY, 2004, J NEUROSCI, V24, P1726, DOI 10.1523/JNEUROSCI.4608-03.2004; McAvoy KM, 2016, NEURON, V91, P1356, DOI 10.1016/j.neuron.2016.08.009; McGinley LM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33017-6; Micheli L, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00010; Mihaylova MM, 2018, CELL STEM CELL, V22, P769, DOI 10.1016/j.stem.2018.04.001; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Mirzadeh Z, 2008, CELL STEM CELL, V3, P265, DOI 10.1016/j.stem.2008.07.004; Mitchell SJ, 2019, CELL METAB, V29, P221, DOI 10.1016/j.cmet.2018.08.011; Mizrahi A, 2006, P NATL ACAD SCI USA, V103, P1912, DOI 10.1073/pnas.0506297103; Mizrak D, 2019, CELL REP, V26, P394, DOI 10.1016/j.celrep.2018.12.044; Molofsky AV, 2006, NATURE, V443, P448, DOI 10.1038/nature05091; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Montagne A, 2015, NEURON, V85, P296, DOI 10.1016/j.neuron.2014.12.032; Moon HY, 2016, CELL METAB, V24, P332, DOI 10.1016/j.cmet.2016.05.025; Moore DL, 2015, SCIENCE, V349, P1334, DOI 10.1126/science.aac9868; Moreno-Cugnon L, 2020, AGING-US, V12, P6030, DOI 10.18632/aging.102994; Moreno-Jimenez EP, 2019, NAT MED, V25, P554, DOI 10.1038/s41591-019-0375-9; Morrow CS, 2020, CELL STEM CELL, V26, P558, DOI 10.1016/j.stem.2020.01.018; Mrdjen D, 2018, IMMUNITY, V48, P599, DOI 10.1016/j.immuni.2018.02.014; Murray KD, 2020, ENEURO, V7, DOI 10.1523/ENEURO.0030-20.2020; Newman JC, 2017, CELL METAB, V26, P547, DOI 10.1016/j.cmet.2017.08.004; Nieto-Estevez V, 2016, STEM CELLS, V34, P2194, DOI 10.1002/stem.2397; Nokia MS, 2016, J PHYSIOL-LONDON, V594, P1855, DOI 10.1113/JP271552; NOTTEBOHM F, 1985, ANN NY ACAD SCI, V457, P143, DOI 10.1111/j.1749-6632.1985.tb20803.x; Obernier K, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.156059; Obernier K, 2018, CELL STEM CELL, V22, P221, DOI 10.1016/j.stem.2018.01.003; Oboti L, 2015, BMC BIOL, V13, DOI 10.1186/s12915-015-0211-8; Ocampo A, 2016, CELL, V167, P1719, DOI 10.1016/j.cell.2016.11.052; Ogbonnaya ES, 2015, BIOL PSYCHIAT, V78, pE7, DOI 10.1016/j.biopsych.2014.12.023; Ogrodnik M, 2019, CELL METAB, V29, P1061, DOI [10.1016/j.cmet.2018.12.008, 10.1016/j.cmet.2019.01.013]; Ortega F, 2013, NAT CELL BIOL, V15, P602, DOI 10.1038/ncb2736; Ortiz-Alvarez G, 2019, NEURON, V102, P159, DOI 10.1016/j.neuron.2019.01.051; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Paik JH, 2009, CELL STEM CELL, V5, P540, DOI 10.1016/j.stem.2009.09.013; Paredes MF, 2018, CELL STEM CELL, V23, P780, DOI 10.1016/j.stem.2018.11.006; Paul A, 2017, SCIENCE, V356, P1383, DOI 10.1126/science.aal3839; Pellegrino G, 2018, J COMP NEUROL, V526, P1419, DOI 10.1002/cne.24376; Pereira L, 2015, FRONT CELL NEUROSCI, V9, DOI [10.3382/fncel.2015.00270, 10.3389/fncel.2015.00270]; Perez-Campo FM, 2014, STEM CELLS, V32, P1591, DOI 10.1002/stem.1606; Pierani A, 1999, CELL, V97, P903, DOI 10.1016/S0092-8674(00)80802-8; Pilz GA, 2018, SCIENCE, V359, P658, DOI 10.1126/science.aao5056; Pineda JR, 2013, EMBO MOL MED, V5, P548, DOI 10.1002/emmm.201202197; Platel JC, 2019, ELIFE, V8, DOI 10.7554/eLife.44830; Pluvinage JV, 2019, NATURE, V568, P187, DOI 10.1038/s41586-019-1088-4; Rajasethupathy P, 2016, CELL, V165, P524, DOI 10.1016/j.cell.2016.03.047; Rebo J, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13363; Reekmans K, 2012, STEM CELL REV REP, V8, P262, DOI 10.1007/s12015-011-9266-2; Renault VM, 2009, CELL STEM CELL, V5, P527, DOI 10.1016/j.stem.2009.09.014; Ring KL, 2012, CELL STEM CELL, V11, P100, DOI 10.1016/j.stem.2012.05.018; Ritzel RM, 2016, J IMMUNOL, V196, P3318, DOI 10.4049/jimmunol.1502021; Roberts MN, 2017, CELL METAB, V26, P539, DOI 10.1016/j.cmet.2017.08.005; Rodriques SG, 2019, SCIENCE, V363, P1463, DOI 10.1126/science.aaw1219; Ryall JG, 2015, CELL STEM CELL, V16, P171, DOI 10.1016/j.stem.2014.12.004; Sakamoto M, 2011, P NATL ACAD SCI USA, V108, P8479, DOI 10.1073/pnas.1018782108; Sanai N, 2011, NATURE, V478, P382, DOI 10.1038/nature10487; Sawamoto K, 2006, SCIENCE, V311, P629, DOI 10.1126/science.1119133; Schaffner I, 2018, NEURON, V99, P1188, DOI 10.1016/j.neuron.2018.08.017; SCHARFMAN HE, 1995, J NEUROPHYSIOL, V74, P179, DOI 10.1152/jn.1995.74.1.179; Schlesinger M, 2015, INT J CANCER, V136, P2504, DOI 10.1002/ijc.28927; Segel M, 2019, NATURE, V573, P130, DOI 10.1038/s41586-019-1484-9; Seib DRM, 2013, CELL STEM CELL, V12, P204, DOI 10.1016/j.stem.2012.11.010; Sha SJ, 2019, JAMA NEUROL, V76, P35, DOI 10.1001/jamaneurol.2018.3288; Shah PT, 2018, CELL, V173, P1045, DOI 10.1016/j.cell.2018.03.063; Shen Q, 2008, CELL STEM CELL, V3, P289, DOI 10.1016/j.stem.2008.07.026; Shi ZP, 2018, PROTEIN CELL, V9, P351, DOI 10.1007/s13238-017-0450-2; Shigemoto-Mogami Y, 2014, J NEUROSCI, V34, P2231, DOI 10.1523/JNEUROSCI.1619-13.2014; Shin J, 2015, CELL STEM CELL, V17, P360, DOI 10.1016/j.stem.2015.07.013; Sierra A, 2010, CELL STEM CELL, V7, P483, DOI 10.1016/j.stem.2010.08.014; Silva-Vargas V, 2016, CELL STEM CELL, V19, P643, DOI 10.1016/j.stem.2016.06.013; Silva-Vargas V, 2013, CURR OPIN NEUROBIOL, V23, P935, DOI 10.1016/j.conb.2013.09.004; Singh R, 2011, CELL METAB, V13, P495, DOI 10.1016/j.cmet.2011.04.004; Smith LK, 2015, NAT MED, V21, P932, DOI 10.1038/nm.3898; Smith P, 2017, ELIFE, V6, DOI 10.7554/eLife.27014; Smith SC, 2015, CIRC RES, V117, P926, DOI 10.1161/CIRCRESAHA.115.307527; So JH, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00013; Song J, 2012, NATURE, V489, P150, DOI 10.1038/nature11306; Soriano-Canton R, 2015, AGING CELL, V14, P453, DOI 10.1111/acel.12328; Sorrells SF, 2018, NATURE, V555, P377, DOI 10.1038/nature25975; Spalding KL, 2013, CELL, V153, P1219, DOI 10.1016/j.cell.2013.05.002; Spanjaard B, 2018, NAT BIOTECHNOL, V36, P469, DOI 10.1038/nbt.4124; Spassky N, 2005, J NEUROSCI, V25, P10, DOI 10.1523/JNEUROSCI.1108-04.2005; Spassky N, 2017, NAT REV MOL CELL BIO, V18, P423, DOI 10.1038/nrm.2017.21; Stoll EA, 2015, STEM CELLS, V33, P2306, DOI 10.1002/stem.2042; Stuart T, 2019, NAT REV GENET, V20, P257, DOI 10.1038/s41576-019-0093-7; Sulzer D, 2017, NATURE, V546, P656, DOI 10.1038/nature22815; Sun GJ, 2015, NAT NEUROSCI, V18, P1722, DOI 10.1038/nn.4159; Tang YW, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.504; Tartt AN, 2018, CELL STEM CELL, V23, P782, DOI 10.1016/j.stem.2018.10.025; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Tobin MK, 2019, CELL STEM CELL, V24, P974, DOI 10.1016/j.stem.2019.05.003; Trinchero MF, 2017, CELL REP, V21, P1129, DOI 10.1016/j.celrep.2017.09.064; Urban N, 2016, SCIENCE, V353, P292, DOI 10.1126/science.aaf4802; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Vilchez D, 2012, NATURE, V489, P304, DOI 10.1038/nature11468; Villeda SA, 2014, NAT MED, V20, P659, DOI 10.1038/nm.3569; Villeda SA, 2011, NATURE, V477, P90, DOI 10.1038/nature10357; Vonk WIM, 2020, MOL CELL, V78, P329, DOI 10.1016/j.molcel.2020.03.009; Wahl D, 2018, CELL REP, V25, P2234, DOI 10.1016/j.celrep.2018.10.070; Wan P, 2018, NEUROPHOTONICS, V5, DOI 10.1117/1.NPh.5.3.035007; Wang CM, 2011, CELL RES, V21, P1534, DOI 10.1038/cr.2011.83; Wang J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11206-9; Wang X, 2018, SCIENCE, V361, DOI 10.1126/science.aat5691; Wang YM, 2016, NAT MED, V22, P1050, DOI 10.1038/nm.4154; Whitman MC, 2007, DEV NEUROBIOL, V67, P1079, DOI 10.1002/dneu.20389; Wolf SA, 2009, J IMMUNOL, V182, P3979, DOI 10.4049/jimmunol.0801218; Woods JA, 2012, AGING DIS, V3, P130; Xiao YZ, 2020, CELL METAB, V31, P534, DOI 10.1016/j.cmet.2020.01.002; Xie LL, 2013, SCIENCE, V342, P373, DOI 10.1126/science.1241224; Yeh CY, 2018, NEURON, V99, P493, DOI 10.1016/j.neuron.2018.07.010; Yeo H, 2013, EMBO J, V32, P2589, DOI 10.1038/emboj.2013.186; Yousef H, 2019, NAT MED, V25, P988, DOI 10.1038/s41591-019-0440-4; Yousef H, 2015, ONCOTARGET, V6, P11959, DOI 10.18632/oncotarget.3851; Zelentsova-Levytskyi K, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00124; Zhang L, 2013, STROKE, V44, P1965, DOI 10.1161/STROKEAHA.111.000831; Zhang RR, 2019, CELL REP, V28, P1485, DOI 10.1016/j.celrep.2019.07.014; Zhang YL, 2017, NATURE, V548, P52, DOI 10.1038/nature23282; Zhao YH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19752; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629; Ziv Y, 2008, BRAIN BEHAV IMMUN, V22, P167, DOI 10.1016/j.bbi.2007.08.006; Zywitza V, 2018, CELL REP, V25, P2457, DOI 10.1016/j.celrep.2018.11.003	265	41	41	7	34	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	1934-5909	1875-9777		CELL STEM CELL	Cell Stem Cell	AUG 6	2020	27	2					202	223		10.1016/j.stem.2020.07.002	http://dx.doi.org/10.1016/j.stem.2020.07.002			22	Cell & Tissue Engineering; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	MY8AK	32726579	Bronze, Green Accepted			2023-01-03	WOS:000558637500008
J	Pukos, N; McTigue, DM				Pukos, Nicole; McTigue, Dana M.			Delayed short-term tamoxifen treatment does not promote remyelination or neuron sparing after spinal cord injury	PLOS ONE			English	Article							SITE-SPECIFIC RECOMBINATION; CELLULAR INFLAMMATORY RESPONSE; IMPROVES LOCOMOTOR RECOVERY; AXONAL PHYSIOLOGY; PROGENITOR CELLS; BREAST-CANCER; OLIGODENDROCYTE; ESTROGEN; EXPRESSION; CONTUSION	The tamoxifen-dependent Cre/lox system in transgenic mice has become an important research tool across all scientific disciplines for manipulating gene expression in specific cell types. In these mouse models, Cre-recombination is not induced until tamoxifen is administered, which allows researchers to have temporal control of genetic modifications. Interestingly, tamoxifen has been identified as a potential therapy for spinal cord injury (SCI) and traumatic brain injury patients due to its neuroprotective properties. It is also reparative in that it stimulates oligodendrocyte differentiation and remyelination after toxin-induced demyelination. However, it is unknown whether tamoxifen is neuroprotective and neuroreparative when administration is delayed after SCI. To properly interpret data from transgenic mice in which tamoxifen treatment is delayed after SCI, it is necessary to identify the effects of tamoxifen alone on anatomical and functional recovery. In this study, female and male mice received a moderate mid-thoracic spinal cord contusion. Mice were then gavaged with corn oil or a high dose of tamoxifen from 19-22 days post-injury, and sacrificed 42 days post-injury. All mice underwent behavioral testing for the duration of the study, which revealed that tamoxifen treatment did not impact hindlimb motor recovery. Similarly, histological analyses revealed that tamoxifen had no effect on white matter sparing, total axon number, axon sprouting, glial reactivity, cell proliferation, oligodendrocyte number, or myelination, but tamoxifen did decrease the number of neurons in the dorsal and ventral horn. Semi-thin sections confirmed that axon demyelination and remyelination were unaffected by tamoxifen. Sex-specific responses to tamoxifen were also assessed, and there were no significant differences between female and male mice. These data suggest that delayed tamoxifen administration after SCI does not change functional recovery or improve tissue sparing in female or male mice.	[Pukos, Nicole] Ohio State Univ, Neurosci Grad Program, Columbus, OH 43210 USA; [Pukos, Nicole; McTigue, Dana M.] Ohio State Univ, Belford Ctr Spinal Cord Injury, Columbus, OH 43210 USA; [McTigue, Dana M.] Ohio State Univ, Wexner Med Ctr, Dept Neurosci, Columbus, OH 43210 USA	Ohio State University; Ohio State University; Ohio State University	McTigue, DM (corresponding author), Ohio State Univ, Belford Ctr Spinal Cord Injury, Columbus, OH 43210 USA.; McTigue, DM (corresponding author), Ohio State Univ, Wexner Med Ctr, Dept Neurosci, Columbus, OH 43210 USA.	Dana.McTigue@osumc.edu		Pukos, Nicole/0000-0002-2441-5820	National Institute of Neurological Disorders and Stroke [NS100522, P30 NS104177]	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The grants NS100522 and P30 NS104177 were awarded to DMM from the National Institute of Neurological Disorders and Stroke (https://www.ninds.nih.gov/) and funded this research. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alizadeh A, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00282; Arancibia-Carcamo IL, 2014, ACTA NEUROPATHOL, V128, P161, DOI 10.1007/s00401-014-1305-z; Arvanian VL, 2009, EXP NEUROL, V216, P471, DOI 10.1016/j.expneurol.2009.01.004; Assinck P, 2017, J NEUROSCI, V37, P8635, DOI 10.1523/JNEUROSCI.2409-16.2017; Azcoitia I, 2019, FRONT NEUROENDOCRIN, V55, DOI 10.1016/j.yfrne.2019.100787; Bao YJ, 2011, MOL CELL NEUROSCI, V48, P185, DOI 10.1016/j.mcn.2011.07.004; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Beattie MS, 2002, PROG BRAIN RES, V137, P37; Behjati S, 2009, CURR MED CHEM, V16, P3076, DOI 10.2174/092986709788803042; Biegon A, 1996, CANCER RES, V56, P4328; Buss A, 2003, GLIA, V42, P424, DOI 10.1002/glia.10220; Buss A, 2004, BRAIN, V128, P356; Church JS, 2017, GLIA, V65, P883, DOI 10.1002/glia.23132; Clarke LE, 2012, J NEUROSCI, V32, P8173, DOI 10.1523/JNEUROSCI.0928-12.2012; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; Colon JM, 2018, EXP NEUROL, V299, P109, DOI 10.1016/j.expneurol.2017.10.006; Colon JM, 2016, NEURAL REGEN RES, V11, P1208, DOI 10.4103/1673-5374.189164; Colon JM, 2016, J NEUROTRAUM, V33, P1696, DOI 10.1089/neu.2015.4111; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Datto JP, 2015, J NEUROTRAUM, V32, P1146, DOI 10.1089/neu.2014.3702; de la Torre Valdovinos B, 2016, J VET MED, V2016, P1; Denk F, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0255-6; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Duncan GJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05473-1; Dutertre M, 2000, J PHARMACOL EXP THER, V295, P431; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; Farooque M, 2006, SPINAL CORD, V44, P182, DOI 10.1038/sj.sc.3101816; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fleming JC, 2006, BRAIN, V129, P3249, DOI 10.1093/brain/awl296; Gallo MA, 1997, SEMIN ONCOL S1, V24; GLEDHILL RF, 1973, EXP NEUROL, V38, P472, DOI 10.1016/0014-4886(73)90169-6; Gonzalez GA, 2016, SCI REP-UK, V6, DOI 10.1038/srep31599; Greenhalgh AD, 2014, J NEUROSCI, V34, P6316, DOI 10.1523/JNEUROSCI.4912-13.2014; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Guest JD, 2005, EXP NEUROL, V192, P384, DOI 10.1016/j.expneurol.2004.11.033; Guptarak J, 2014, J NEUROTRAUM, V31, P268, DOI 10.1089/neu.2013.3108; Hesp ZC, 2015, J NEUROSCI, V35, P1274, DOI 10.1523/JNEUROSCI.2568-14.2015; Horky LL, 2006, J COMP NEUROL, V498, P525, DOI 10.1002/cne.21065; Horner PJ, 2000, J NEUROSCI, V20, P2218; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Jordan VC, 2003, NAT REV DRUG DISCOV, V2, P205, DOI 10.1038/nrd1031; Karimi-Abdolrezaee S, 2004, EUR J NEUROSCI, V19, P577, DOI 10.1111/j.0953-816X.2004.03164.x; Karki P, 2014, MOL CELL ENDOCRINOL, V389, P58, DOI 10.1016/j.mce.2014.01.010; Kerschensteiner M, 2005, NAT MED, V11, P572, DOI 10.1038/nm1229; Kim IY, 1996, CLIN CANCER RES, V2, P1255; Kim LA, 2014, INVEST OPHTH VIS SCI, V55, P4747, DOI 10.1167/iovs.13-13662; Kimelberg HK, 2000, NEUROREPORT, V11, P2675, DOI 10.1097/00001756-200008210-00014; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Latourelle JC, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-23; Lee JY, 2012, ENDOCRINOLOGY, V153, P3815, DOI 10.1210/en.2012-1068; Lim SW, 2018, WORLD NEUROSURG, V112, pE278, DOI 10.1016/j.wneu.2018.01.036; Marin MA, 2017, NEURAL REGEN RES, V12, P1276, DOI 10.4103/1673-5374.213543; Marin-Husstege M, 2004, DEV NEUROSCI-BASEL, V26, P245, DOI 10.1159/000082141; McTigue DM, 2001, J NEUROSCI, V21, P3392, DOI 10.1523/JNEUROSCI.21-10-03392.2001; METZGER D, 1995, P NATL ACAD SCI USA, V92, P6991, DOI 10.1073/pnas.92.15.6991; Mickley KR, 2004, NEUROENDOCRINOLOGY, V79, P305, DOI 10.1159/000079710; Mosquera L, 2014, BRAIN RES, V1561, P11, DOI 10.1016/j.brainres.2014.03.002; Nashmi R, 2000, EUR J NEUROSCI, V12, P491, DOI 10.1046/j.1460-9568.2000.00926.x; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; National Spinal Cord Injury Statistical Center, 2019, FACTS FIG GLANC; Pfaffl MW, 2001, APMIS, V109, P345, DOI 10.1034/j.1600-0463.2001.090503.x; POPOVICH PG, 1993, J NEUROTRAUM, V10, P37, DOI 10.1089/neu.1993.10.37; Popovich PG, 1997, J COMP NEUROL, V377, P443, DOI 10.1002/(SICI)1096-9861(19970120)377:3<443::AID-CNE10>3.0.CO;2-S; QIN MM, 1994, P NATL ACAD SCI USA, V91, P1706, DOI 10.1073/pnas.91.5.1706; Rabchevsky AG, 2007, GLIA, V55, P831, DOI 10.1002/glia.20508; Rasband MN, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a020495; Schonberg DL, 2007, J NEUROPATH EXP NEUR, V66, P1124, DOI 10.1097/nen.0b013e31815c2530; Schwab JM, 2014, EXP NEUROL, V258, P121, DOI 10.1016/j.expneurol.2014.04.023; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Strehlow K, 2003, CIRC RES, V93, P170, DOI 10.1161/01.RES.0000082334.17947.11; Sun F, 2010, GLIA, V58, P1304, DOI 10.1002/glia.21009; Sun LM, 2016, QJM-INT J MED, V109, P103, DOI 10.1093/qjmed/hcv072; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; TATOR CH, 1991, J NEUROSURG, V75, P15, DOI 10.3171/jns.1991.75.1.0015; Tee MK, 2004, MOL BIOL CELL, V15, P1262, DOI 10.1091/mbc.E03-06-0360; Tian DS, 2009, J NEUROCHEM, V109, P1658, DOI 10.1111/j.1471-4159.2009.06077.x; Totoiu MO, 2005, J COMP NEUROL, V486, P373, DOI 10.1002/cne.20517; Tripathi R, 2007, GLIA, V55, P698, DOI 10.1002/glia.20491; Tripathi RB, 2010, J NEUROSCI, V30, P16383, DOI 10.1523/JNEUROSCI.3411-10.2010; Tsai YT, 2014, J SURG RES, V189, P106, DOI 10.1016/j.jss.2014.02.009; Vogel VG, 2006, JAMA-J AM MED ASSOC, V295, P2727, DOI 10.1001/jama.295.23.joc60074; WADE GN, 1993, AM J PHYSIOL, V264, pR1219, DOI 10.1152/ajpregu.1993.264.6.R1219; WALLACE MC, 1987, SURG NEUROL, V27, P209, DOI 10.1016/0090-3019(87)90031-0; Wanner IB, 2013, J NEUROSCI, V33, P12870, DOI 10.1523/JNEUROSCI.2121-13.2013; Yang G, 2013, PHARMACOL THERAPEUT, V139, P392, DOI 10.1016/j.pharmthera.2013.05.005; Yang LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009851; Young KM, 2013, NEURON, V77, P873, DOI 10.1016/j.neuron.2013.01.006; Zai LJ, 2005, GLIA, V50, P247, DOI 10.1002/glia.20176; Zawadzka M, 2010, CELL STEM CELL, V6, P578, DOI 10.1016/j.stem.2010.04.002	93	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2020	15	7							e0235232	10.1371/journal.pone.0235232	http://dx.doi.org/10.1371/journal.pone.0235232			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NO3EK	32735618	gold, Green Published			2023-01-03	WOS:000569367100009
J	Bitew, ZW; Alebel, A; Worku, T; Alemu, A				Bitew, Zebenay Workneh; Alebel, Animut; Worku, Teshager; Alemu, Ayinalem			Recovery rate and its predictors among children with severe acute malnutrition in Addis Ababa, Ethiopia: A retrospective cohort study	PLOS ONE			English	Article							MORTALITY	Introduction Malnutrition is a public health problem in under-five children in several parts of the world even after decades of the implementation of management protocols. An estimated 17 million children under the age of five years are living with severe acute malnutrition and the majorities are found in Asia and Africa, including Ethiopia. Objective The main objective of this study was to determine the recovery rate and its predictors among under-five children who were admitted to St. Paul's Hospital Millennium Medical College from 2012 to 2019. Methods An institution based retrospective cohort study was employed at St. Paul's Hospital Millennium Medical College from May 20, 2019 to June 28, 2019. Data were collected by reviewing children's' medical records using a structured checklist. A total of 534 charts were selected using a simple random sampling method and 515 of them were used for the final analysis. Ep-info version 7 software was used for data entry and STATA Version 15 for analysis. The Kaplan Meier failure estimate with Log-rank test was used to determine the survival estimates. Bi-variable and multivariable Cox proportional hazards regression model were fitted to identify predictors of mortality. Finally, variables with p-values less than 0.05 in the multivariable Cox regression were considered as independent predictors. The proportional hazards assumption was checked using the Schoenfeld residuals test and the final model fitness was checked using the Cox-Snail residual test. Result In this study, a total of 515 subjects were followed for 8672 child-days and 79% of the subjects recovered from SAM with the median time of 17 days. The incidence density rate of recovery was 46 per 1000 child-days. Tuberculosis (AHR(Adjusted Hazard Ratio) 0.44 & 95% CI: 0.32, 0.62), pale conjunctiva (AHR,0.67 & 95% CI: 0.52, 0.88), IV fluid infusion (AHR, 0.71 & 95 CI: 0.51, 0.98), feeding F100 (AHR, 1.63 & 95% CI:1.04,2.54), Vitamin A supplementation (AHR, 1.3 & 95% CI:1.07, 1.59) and bottle feeding (AHR, 0.79 & 95CI%: 0.64-0.98) were the independent predictors of time to recovery from SAM. Conclusion In conclusion, the recovery rate was relatively higher than the Sphere standard and the national SAM management protocol. Co-morbidities and the treatments given were the main determinants of recovery of children. Co-morbidities must be managed as early as possible and the treatments given during the SAM management process need to be given with precaution.	[Bitew, Zebenay Workneh] St Pauls Hosp, Dept Pediat Nursing, Sch Nursing, Millennium Med Coll, Addis Ababa, Ethiopia; [Alebel, Animut] Debre Markos Univ, Coll Hlth Sci, Debre Markos, Ethiopia; [Worku, Teshager] Haramaya Univ, Coll Hlth & Med Sci, Sch Nursing & Midwifery, Harar, Ethiopia; [Alemu, Ayinalem] Ethipian Publ Hlth Inst, Dept Med Microbiol, Addis Ababa, Ethiopia	Haramaya University	Bitew, ZW (corresponding author), St Pauls Hosp, Dept Pediat Nursing, Sch Nursing, Millennium Med Coll, Addis Ababa, Ethiopia.	zedo2015@gmail.com	Alebel, Animut/L-4278-2019	Alebel, Animut/0000-0003-2822-2062				Abate HK, 2019, CLIN NUTR ESPEN, V33, P98, DOI 10.1016/j.clnesp.2019.07.001; Adal TG, 2016, INCIDENCE PREDICTORS, V6; Admasu A, 2017, J NUTR HLTH FOOD SCI; Amsalu Solomon, 2006, Ethiop Med J, V44, P151; Asres DT, 2018, BMC NUTR, V4, DOI 10.1186/s40795-018-0224-0; Derseh B, 2018, NUTR J, V17, DOI 10.1186/s12937-018-0423-1; Desalegn M., 2016, INT J NUTR METAB, V8, P12, DOI [10.5897/IJNAM2015.0193, DOI 10.5897/IJNAM2015.0193]; Desta K., 2015, J NUTR DISORD THER, V5, P160, DOI DOI 10.4172/2161-0509.1000160; Dubale S, 2019, BIOMEDICAL J SCI TEC, V20, P14888; Federal democratic Republic of Ethiopia MoH, 2013, TRAIN COURS MAN SEV; Fikrie A, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0642-x; FMOH/Ethiopia, 2019, KEY IND MIN HLTH SUR; Gebremichael DY, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-2593-5; Gebrezgi D, 2019, INT J NUTR, V3, P1; Girum T, 2017, THER CLIN RISK MANAG, V13, P101, DOI 10.2147/TCRM.S119826; GLOBALNUTRITIONREPORT.ORG, 2018, BURD MALN; Golden M., 2011, GUIDELINES INTEGRATE; Gordon DM, 2013, J TROP PEDIATRICS, V59, P350, DOI 10.1093/tropej/fmt031; Guesh Gebremicael, 2018, BMC Res Notes, V11, P832, DOI 10.1186/s13104-018-3937-x; Hassen SL, 2019, J NUTR METAB, V2019, DOI 10.1155/2019/2643531; Hayashi C, 2017, UNICEF WHO WORLD BAN; Jarso H, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0398-4; Mekuria Getnet, 2017, BMC Nutr, V3, P42, DOI 10.1186/s40795-017-0161-3; Melaku G, 2014, OPEN ACCESS LIB J, V1, P1, DOI DOI 10.4236/OALIB.1100446; Mena MB, 2018, INT J PEDIAT, V2018, DOI 10.1155/2018/8686501; Mengesha MM, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.30704; Misganaw C, 2014, J DIAGN, V1, P18, DOI [10.18488/journal.98.1.1/98.1.18.27, DOI 10.18488/JOURNAL.98.1.1/98.1.18.27, DOI 10.18488/journal.98/2014.1.1/98.1.18.27]; Munthali Tendai, 2017, BMC Res Notes, V10, P206, DOI 10.1186/s13104-017-2529-5; Oumer A, 2016, E AFR J HLTH BIOMED, V1, P13; Pravana NK, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017084; Shanka N., 2015, J NUTR DISORD THER, V5, P155, DOI [10.4172/2161-0509.1000155, DOI 10.4172/2161-0509.1000155]; Sheshukov, 2019, ENVIRON GEOCHEM HLTH, P1; Shiferaw W, 2015, ETHIOP J PEDIAT CHIL, V11, P29; Shoham MMJ, 2019, FIELD EXCHANGE, V60, P2; Tefera Chane, 2014, Journal of Nutrition and Food Sciences, V4, P329; Tekeste Asayehegn, 2012, Cost Eff Resour Alloc, V10, P4, DOI 10.1186/1478-7547-10-4; Teshome G, 2019, BMC PEDIATR, V19, DOI 10.1186/s12887-019-1407-9; Thurstans S., 2011, FIELD EXCHANGE, V41, P36; Tirore Mengistu Girma, 2017, BMC Nutr, V3, P66, DOI 10.1186/s40795-017-0186-7; UNICEF, 2019, STAT WORLDS CHILDR 2; UNICEF-WHO-The World Bank Joint Child Malnutrition Estimates, LEV TRENDS CHILD MAL; USAID, 2018, ETH NUTR PROF PDF; Wagnew F, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211628; Webb P, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k2238	44	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2020	15	7							e0235259	10.1371/journal.pone.0235259	http://dx.doi.org/10.1371/journal.pone.0235259			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX7VK	32701985	Green Published, gold			2023-01-03	WOS:000575913700013
J	Ebinger, JE; Achamallah, N; Ji, HW; Claggett, BL; Sun, N; Botting, P; Nguyen, TT; Luong, E; Kim, EH; Park, E; Liu, YX; Rosenberry, R; Matusov, Y; Zhao, S; Pedraza, I; Zaman, T; Thompson, M; Raedschelders, K; Berg, AH; Grein, JD; Noble, PW; Chugh, SS; Merz, CNB; Marban, E; Van Eyk, JE; Solomon, SD; Albert, CM; Chen, P; Cheng, SS				Ebinger, Joseph E.; Achamallah, Natalie; Ji, Hongwei; Claggett, Brian L.; Sun, Nancy; Botting, Patrick; Nguyen, Trevor-Trung; Luong, Eric; Kim, Elizabeth H.; Park, Eunice; Liu, Yunxian; Rosenberry, Ryan; Matusov, Yuri; Zhao, Steven; Pedraza, Isabel; Zaman, Tanzira; Thompson, Michael; Raedschelders, Koen; Berg, Anders H.; Grein, Jonathan D.; Noble, Paul W.; Chugh, Sumeet S.; Merz, C. Noel Bairey; Marban, Eduardo; Van Eyk, Jennifer E.; Solomon, Scott D.; Albert, Christine M.; Chen, Peter; Cheng, Susan			Pre-existing traits associated with Covid-19 illness severity	PLOS ONE			English	Article							RESPIRATORY SYNDROME CORONAVIRUS; COMORBIDITY MEASURES; ACE2 EXPRESSION	Importance Certain individuals, when infected by SARS-CoV-2, tend to develop the more severe forms of Covid-19 illness for reasons that remain unclear. Objective To determine the demographic and clinical characteristics associated with increased severity of Covid-19 infection. Design Retrospective observational study. We curated data from the electronic health record, and used multivariable logistic regression to examine the association of pre-existing traits with a Covid-19 illness severity defined by level of required care: need for hospital admission, need for intensive care, and need for intubation. Setting A large, multihospital healthcare system in Southern California. Participants All patients with confirmed Covid-19 infection (N = 442). Results Of all patients studied, 48% required hospitalization, 17% required intensive care, and 12% required intubation. In multivariable-adjusted analyses, patients requiring a higher levels of care were more likely to be older (OR 1.5 per 10 years, P< 0.001), male (OR 2.0, P = 0.001), African American (OR 2.1, P = 0.011), obese (OR 2.0, P = 0.021), with diabetes mellitus (OR 1.8, P = 0.037), and with a higher comorbidity index (OR 1.8 per SD, P< 0.001). Several clinical associations were more pronounced in younger compared to older patients (P-interaction< 0.05). Of all hospitalized patients, males required higher levels of care (OR 2.5, P = 0.003) irrespective of age, race, or morbidity profile. Conclusions and relevance In our healthcare system, greater Covid-19 illness severity is seen in patients who are older, male, African American, obese, with diabetes, and with greater overall comorbidity burden. Certain comorbidities paradoxically augment risk to a greater extent in younger patients. In hospitalized patients, male sex is the main determinant of needing more intensive care. Further investigation is needed to understand the mechanisms underlying these findings.	[Ebinger, Joseph E.; Sun, Nancy; Botting, Patrick; Nguyen, Trevor-Trung; Luong, Eric; Kim, Elizabeth H.; Liu, Yunxian; Rosenberry, Ryan; Raedschelders, Koen; Chugh, Sumeet S.; Merz, C. Noel Bairey; Van Eyk, Jennifer E.; Albert, Christine M.; Cheng, Susan] Cedars Sinai Med Ctr, Dept Cardiol, Los Angeles, CA 90048 USA; [Ebinger, Joseph E.; Sun, Nancy; Botting, Patrick; Nguyen, Trevor-Trung; Luong, Eric; Kim, Elizabeth H.; Liu, Yunxian; Rosenberry, Ryan; Chugh, Sumeet S.; Merz, C. Noel Bairey; Marban, Eduardo; Albert, Christine M.; Cheng, Susan] Cedars Sinai Med Ctr, Smidt Heart Inst, Los Angeles, CA 90048 USA; [Achamallah, Natalie; Matusov, Yuri; Zhao, Steven; Pedraza, Isabel; Zaman, Tanzira; Grein, Jonathan D.; Noble, Paul W.; Chen, Peter] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA; [Achamallah, Natalie; Matusov, Yuri; Zhao, Steven; Pedraza, Isabel; Zaman, Tanzira; Chen, Peter] Cedars Sinai Med Ctr, Div Pulm & Crit Care Med, Los Angeles, CA 90048 USA; [Ji, Hongwei] Tongji Univ, Shanghai Peoples Hosp 10, Shanghai, Peoples R China; [Ji, Hongwei; Claggett, Brian L.; Solomon, Scott D.] Brigham & Womens Hosp, Cardiovasc Div, 75 Francis St, Boston, MA 02115 USA; [Park, Eunice; Thompson, Michael] Cedars Sinai Med Ctr, Enterprise Informat Syst Data Intelligence Team, Los Angeles, CA 90048 USA; [Raedschelders, Koen; Van Eyk, Jennifer E.] Cedars Sinai Med Ctr, Adv Clin Biosyst Inst, Los Angeles, CA 90048 USA; [Berg, Anders H.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA; [Grein, Jonathan D.] Cedars Sinai Med Ctr, Dept Epidemiol, Los Angeles, CA 90048 USA; [Noble, Paul W.; Chen, Peter] Cedars Sinai Med Ctr, Womens Guild Lung Inst, Los Angeles, CA 90048 USA; [Merz, C. Noel Bairey; Van Eyk, Jennifer E.; Cheng, Susan] Cedars Sinai Med Ctr, Barbra Streisand Womens Heart Ctr, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Tongji University; Harvard University; Brigham & Women's Hospital; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center	Cheng, SS (corresponding author), Cedars Sinai Med Ctr, Dept Cardiol, Los Angeles, CA 90048 USA.; Cheng, SS (corresponding author), Cedars Sinai Med Ctr, Smidt Heart Inst, Los Angeles, CA 90048 USA.; Chen, P (corresponding author), Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA.; Chen, P (corresponding author), Cedars Sinai Med Ctr, Div Pulm & Crit Care Med, Los Angeles, CA 90048 USA.; Chen, P (corresponding author), Cedars Sinai Med Ctr, Womens Guild Lung Inst, Los Angeles, CA 90048 USA.; Cheng, SS (corresponding author), Cedars Sinai Med Ctr, Barbra Streisand Womens Heart Ctr, Los Angeles, CA 90048 USA.	peter.chen@cshs.org; susan.cheng@cshs.org	Ji, Hongwei/HHC-5850-2022; Chen, Peter/AAH-9639-2021; Grein, Jonathan/GXZ-6282-2022; Marban, Eduardo/GWC-8514-2022	Ji, Hongwei/0000-0003-3657-4666; Cheng, Susan/0000-0002-4977-036X; Chen, Peter/0000-0002-5330-1718; Park, Eunice/0000-0003-1159-2374; Albert, Christine/0000-0002-2081-1121; Nguyen, Trevor/0000-0001-7720-8019	Erika J. Glazer Family Foundation	Erika J. Glazer Family Foundation	This work was supported in part by the Erika J. Glazer Family Foundation (JEE; JEVE; CNBM; SC). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Alghamdi IG, 2014, INT J GEN MED, V7, P417, DOI 10.2147/IJGM.S67061; AlGhatrif M, 2020, JAMA CARDIOL, V5, P747, DOI 10.1001/jamacardio.2020.1329; Channappanavar R, 2017, J IMMUNOL, V198, P4046, DOI 10.4049/jimmunol.1601896; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Dalpiaz PLM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127515; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Garg S Kim  L, 2020, HOSPITALIZATION RATE; Garland A, 2012, MED CARE, V50, pE1, DOI 10.1097/MLR.0b013e318245a754; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guo WN, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3319; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Holshue ML, 2020, NEW ENGL J MED, V382, P929, DOI 10.1056/NEJMoa2001191; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Karlberg J, 2004, AM J EPIDEMIOL, V159, P229, DOI 10.1093/aje/kwh056; Kinross P, 2020, EUROSURVEILLANCE, V25, P2, DOI 10.2807/1560-7917.ES.2020.25.11.2000285; Lai CC, 2020, INT J ANTIMICROB AG, V55, DOI 10.1016/j.ijantimicag.2020.105946; Lely AT, 2004, J PATHOL, V204, P587, DOI 10.1002/path.1670; Lew TWK, 2003, JAMA-J AM MED ASSOC, V290, P374, DOI 10.1001/jama.290.3.374; Liu K, 2020, CHINESE MED J-PEKING, V133, P1025, DOI 10.1097/CM9.0000000000000744; Livingston Edward, 2020, JAMA, V323, P1335, DOI 10.1001/jama.2020.4344; Ma RCW, 2020, DIABETIC MED, V37, P723, DOI 10.1111/dme.14300; Maddaloni E, 2020, DIABETES-METAB RES, V36, DOI 10.1002/dmrr.3321; Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m641; Muniyappa R, 2020, AM J PHYSIOL-ENDOC M, V318, pE736, DOI 10.1152/ajpendo.00124.2020; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Patel A, 2020, MMWR-MORBID MORTAL W, V69, P140, DOI 10.15585/mmwr.mm6905e1; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Quan HD, 2011, AM J EPIDEMIOL, V173, P676, DOI 10.1093/aje/kwq433; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Ryan DH, 2020, OBESITY, V28, P847, DOI 10.1002/oby.22808; Sampson AK, 2012, GENDER MED, V9, P21, DOI 10.1016/j.genm.2011.12.003; Sharabiani MTA, 2012, MED CARE, V50, P1109, DOI 10.1097/MLR.0b013e31825f64d0; Shi Y, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-2833-7; Simonnet A, 2020, OBESITY, V28, P1195, DOI 10.1002/oby.22831; Southern DA, 2004, MED CARE, V42, P355, DOI 10.1097/01.mlr.0000118861.56848.ee; Stukenborg GJ, 2001, MED CARE, V39, P727, DOI 10.1097/00005650-200107000-00009; Vaduganathan M, 2020, NEW ENGL J MED, V382, P1653, DOI 10.1056/NEJMsr2005760; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Xie XD, 2006, LIFE SCI, V78, P2166, DOI 10.1016/j.lfs.2005.09.038; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	48	75	75	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2020	15	7							e0236240	10.1371/journal.pone.0236240	http://dx.doi.org/10.1371/journal.pone.0236240			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX7VK	32702044	gold, Green Submitted, Green Published			2023-01-03	WOS:000575913700060
J	Lebwohl, MG; Papp, KA; Gold, LS; Gooderham, MJ; Kircik, LH; Draelos, ZD; Kempers, SE; Zirwas, M; Smith, K; Osborne, DW; Trotman, ML; Navale, L; Merritt, C; Berk, DR; Welgus, H				Lebwohl, Mark G.; Papp, Kim A.; Gold, Linda Stein; Gooderham, Melinda J.; Kircik, Leon H.; Draelos, Zoe D.; Kempers, Steven E.; Zirwas, Mathew; Smith, Kathleen; Osborne, David W.; Trotman, Marie-Louise; Navale, Lynn; Merritt, Charlotte; Berk, David R.; Welgus, Howard		ARQ-151 201 Study Investigators	Trial of Roflumilast Cream for Chronic Plaque Psoriasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; EFFICACY; MODERATE; SAFETY; MULTICENTER; SCALE	BackgroundSystemic oral phosphodiesterase type 4 (PDE-4) inhibitors have been effective in the treatment of psoriasis. Roflumilast cream contains a PDE-4 inhibitor that is being investigated for the topical treatment of psoriasis. MethodsIn this phase 2b, double-blind trial, we randomly assigned adults with plaque psoriasis in a 1:1:1 ratio to use roflumilast 0.3% cream, roflumilast 0.15% cream, or vehicle (placebo) cream once daily for 12 weeks. The primary efficacy outcome was the investigator's global assessment (IGA) of a status of clear or almost clear at week 6 (assessed on a 5-point scale of plaque thickening, scaling, and erythema; a score of 0 indicates clear, 1 almost clear, and 4 severe). Secondary outcomes included an IGA score indicating clear or almost clear plus a 2-grade improvement in the IGA score for the intertriginous area and the change in the Psoriasis Area and Severity Index (PASI) score (range, 0 to 72, with higher scores indicating worse disease). Safety was also assessed. ResultsAmong 331 patients who underwent randomization, 109 were assigned to roflumilast 0.3% cream, 113 to roflumilast 0.15% cream, and 109 to vehicle cream. An IGA score indicating clear or almost clear at week 6 was observed in 28% of the patients in the roflumilast 0.3% group, in 23% in the roflumilast 0.15% group, and in 8% in the vehicle group (P<0.001 and P=0.004 vs. vehicle for roflumilast 0.3% and 0.15%, respectively). Among the approximately 15% of patients overall who had baseline intertriginous psoriasis of at least mild severity, an IGA score at week 6 indicating clear or almost clear plus a 2-grade improvement in the intertriginous-area IGA score occurred in 73% of the patients in the roflumilast 0.3% group, 44% of those in the roflumilast 0.15% group, and 29% of those in the vehicle group. The mean baseline PASI scores were 7.7 in the roflumilast 0.3% group, 8.0 in the roflumilast 0.15% group, and 7.6 in the vehicle group; the mean change from baseline at week 6 was -50.0%, -49.0%, and -17.8%, respectively. Application-site reactions occurred with similar frequency in the roflumilast groups and the vehicle group. ConclusionsRoflumilast cream administered once daily to affected areas of psoriasis was superior to vehicle cream in leading to a state of clear or almost clear at 6 weeks. Longer and larger trials are needed to determine the durability and safety of roflumilast in psoriasis. (Funded by Arcutis Biotherapeutics; ARQ-151 201 ClinicalTrials.gov number, NCT03638258.) A cream formulation of the phosphodiesterase type 4 inhibitor roflumilast, in two concentrations, led to higher percentages of patients with clearance or near-clearance of psoriatic lesions at 6 weeks than placebo. Difficult-to-treat intertriginous areas also improved as compared with placebo.	[Lebwohl, Mark G.; Kircik, Leon H.] Icahn Sch Med Mt Sinai, 5 E 98th St,5th Fl, New York, NY 10029 USA; [Papp, Kim A.] Prob Med Res, Waterloo, ON, Canada; [Papp, Kim A.] K Papp Clin Res, Waterloo, ON, Canada; [Gooderham, Melinda J.] SkiN Ctr Dermatol, Prob Med Res, Peterborough, ON, Canada; [Gooderham, Melinda J.] Queens Univ, Peterborough, ON, Canada; [Gold, Linda Stein] Henry Ford Med Ctr, Detroit, MI USA; [Kircik, Leon H.] Indiana Med Ctr, Indianapolis, IN USA; [Kircik, Leon H.] Phys Skin Care & DermRes, Louisville, KY USA; [Draelos, Zoe D.] Dermatol Consulting Serv, High Point, NC USA; [Kempers, Steven E.] Minnesota Clin Study Ctr, Fridley, MN USA; [Zirwas, Mathew] Prob Med Res, Dermatologists Cent States, Bexley, OH USA; [Zirwas, Mathew] Ohio Univ, Bexley, OH USA; [Smith, Kathleen; Osborne, David W.; Navale, Lynn; Merritt, Charlotte; Berk, David R.; Welgus, Howard] Arcutis Biotherapeut, Westlake Village, CA USA; [Trotman, Marie-Louise] ML Trotman Consulting, Newbury Pk, CA USA	Icahn School of Medicine at Mount Sinai; Queens University - Canada; Henry Ford Health System; University System of Ohio; Ohio University	Lebwohl, MG (corresponding author), Icahn Sch Med Mt Sinai, 5 E 98th St,5th Fl, New York, NY 10029 USA.	mark.lebwohl@mssm.edu			Arcutis Biotherapeutics	Arcutis Biotherapeutics	Supported by Arcutis Biotherapeutics.	[Anonymous], 2018, DECIBEL; [Anonymous], 2019, SHENZHEN STAT YB; [Anonymous], 2017, PRAVILA REGULIROVANI; Card GL, 2004, STRUCTURE, V12, P2233, DOI 10.1016/j.str.2004.10.004; Coondoo Arijit, 2014, Indian Dermatol Online J, V5, P416, DOI 10.4103/2229-5178.142483; Ference JD, 2009, AM FAM PHYSICIAN, V79, P135; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; Globe D, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-62; Green LJ, 2018, J DRUGS DERMATOL, V17, P1062; Langley RGB, 2015, J DERMATOL TREAT, V26, P23, DOI 10.3109/09546634.2013.865009; Lebwohl M, 2005, ARCH DERMATOL, V141, P1154, DOI 10.1001/archderm.141.9.1154; Lebwohl M, 2014, INT J DERMATOL, V53, P714, DOI 10.1111/j.1365-4632.2012.05798.x; Li H, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01048; Menter A, 2013, J DRUGS DERMATOL, V12, P92; Moustafa Farah, 2014, Dermatol Online J, V20, P22608; Naegeli AN, 2015, INT J DERMATOL, V54, P715, DOI 10.1111/ijd.12645; Papp KA, 2020, AM AC DERM VIRT M JU; Patrizi A, 1999, ACTA DERM-VENEREOL, V79, P477; Pincelli C, 2018, J DRUGS DERMATOL, V17, P835; Strober B, 2016, INT J DERMATOL, V55, pE147, DOI 10.1111/ijd.13117; Strober BE, 2013, VALUE HEALTH, V16, P1014, DOI 10.1016/j.jval.2013.07.002; Sugarman JL, 2017, J DRUGS DERMATOL, V16, P197; Weinstein GD, 2003, J AM ACAD DERMATOL, V48, P760, DOI 10.1067/mjd.2003.103	23	29	30	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	2020	383	3					229	239		10.1056/NEJMoa2000073	http://dx.doi.org/10.1056/NEJMoa2000073			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ8TN	32668113	Bronze			2023-01-03	WOS:000553165300013
J	Jadid, N; Kurniawan, E; Himayani, CES; Andriyani; Prasetyowati, I; Purwani, KI; Muslihatin, W; Hidayati, D; Tjahjaningrum, ITD				Jadid, Nurul; Kurniawan, Erwin; Himayani, Chusnul Eka Safitri; Andriyani; Prasetyowati, Indah; Purwani, Kristanti Indah; Muslihatin, Wirdhatul; Hidayati, Dewi; Tjahjaningrum, Indah Trisnawati Dwi			An ethnobotanical study of medicinal plants used by the Tengger tribe in Ngadisari village, Indonesia	PLOS ONE			English	Article							ACORUS-CALAMUS; COMMUNITIES; KNOWLEDGE; KASHMIR; PARK	The people of Tengger, Indonesia have used plants as traditional medicine for a long time. However, this local knowledge has not been well documented until recently. Our study aims to understand the utilization of plants in traditional medicine by the people of Tengger, who inhabit the Ngadisari village, Sukapura District, Probolinggo Regency, Indonesia. We conducted semi-structured and structured interviews with a total of 52 informants that represented 10% of the total family units in the village. The parameters observed in this study include species use value (SUV), family use value (FUV), plant part use (PPU), and the relative frequency of citation that was calculated based on fidelity level (FL). We successfully identified 30 species belonging to 28 genera and 20 families that have been used as a traditional medicine to treat 20 diseases. We clustered all the diseases into seven distinct categories. Among the recorded plant families, Poaceae and Zingiberaceae were the most abundant. Plant species within those families were used to treat internal medical diseases, respiratory-nose, ear, oral/dental, and throat problems. The plant species with the highest SUV wasFoeniculum vulgareMill. (1.01), whereas the Aloaceae family (0.86) had the highest FUV.Acorus calamusL. (80%) had the highest FL percentage. The leaves were identified as the most used plant part and decoction was the dominant mode of a medicinal preparation. Out of the plants and their uses documented in our study, 26.7% of the medicinal plants and 71.8% of the uses were novel. In conclusion, the diversity of medicinal plant uses in the Ngadisari village could contribute to the development of new plant-based drugs and improve the collective revenue of the local society.	[Jadid, Nurul; Kurniawan, Erwin; Himayani, Chusnul Eka Safitri; Andriyani; Prasetyowati, Indah; Purwani, Kristanti Indah; Muslihatin, Wirdhatul; Hidayati, Dewi; Tjahjaningrum, Indah Trisnawati Dwi] Inst Teknol Sepuluh Nopember, Dept Biol, Surabaya, Indonesia	Institut Teknologi Sepuluh Nopember	Jadid, N (corresponding author), Inst Teknol Sepuluh Nopember, Dept Biol, Surabaya, Indonesia.	nuruljadid@bio.its.ac.id	Indah Purwani, Kristanti/GQR-2663-2022; Jadid, Nurul/J-4109-2017; Jadid, Nurul/AFD-8550-2022; Hidayati, Dewi/AAC-9051-2021	Indah Purwani, Kristanti/0000-0002-8212-3906; Jadid, Nurul/0000-0001-9387-4919; Jadid, Nurul/0000-0001-9387-4919; Prasetyowati, Indah/0000-0001-8637-0851; Trisnawati, Indah D.T./0000-0001-8805-3796	Kementerian Riset Teknologi dan Pendidikan Tinggi Republik Indonesia [890/PKS/ITS/2019, 1204/PKS/ITS/2020]; Ministry of Research, Technology and Higher Education of the Republic of Indonesia	Kementerian Riset Teknologi dan Pendidikan Tinggi Republik Indonesia(Ministry of Research and Technology of the Republic of Indonesia (RISTEK)); Ministry of Research, Technology and Higher Education of the Republic of Indonesia(Ministry of Research and Technology of the Republic of Indonesia (RISTEK))	This work is financially supported by Kementerian Riset Teknologi dan Pendidikan Tinggi Republik Indonesia (Contract no. 890/PKS/ITS/2019 and contract no. 1204/PKS/ITS/2020). NJ received grant from Ministry of Research, Technology and Higher Education of the Republic of Indonesia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelgadir HA, 2013, S AFR J BOT, V88, P204, DOI 10.1016/j.sajb.2013.07.021; Abu Bakar FI, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00261; Acharya K. P., 2005, SCI WORLD, V3, P44; Ahmad KS, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0196-1; Ahmed HM, 2016, J ETHNOBIOL ETHNOMED, V12, DOI 10.1186/s13002-016-0081-3; [Anonymous], 2020, PUS PENG PEN INF GEO; Badan Pusat Statistik Kabupaten Probolinggo, 2017, KEC SYK DAL ANGK; Badgujar SB, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/842674; Barber CV, 1999, MENYELAMATKAN SISA H; Barkaoui M, 2017, J ETHNOPHARMACOL, V198, P338, DOI 10.1016/j.jep.2017.01.023; Batoro J, 2019, ADV LIFE SCI, V9, P1; Batoro J., 2012, THESIS; Bradacs G, 2011, J ETHNOPHARMACOL, V137, P434, DOI 10.1016/j.jep.2011.05.050; Calzada F, 2020, J ETHNOPHARMACOL, V253, DOI 10.1016/j.jep.2020.112676; Chaachouay N, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02191; Cholil M., 2017, J INDONESIAN ISLAM, V11, P459; Dalimartha S, 1999, ATLAS TUMBUHAN OBAT; El Amri J., 2015, J RES BIOL, V4, P1568; Elfahmi, 2014, J HERB MED, V4, P51, DOI 10.1016/j.hermed.2014.01.002; Ezuruike UF, 2014, J ETHNOPHARMACOL, V155, P857, DOI 10.1016/j.jep.2014.05.055; Farooq A, 2019, J ETHNOBIOL ETHNOMED, V15, DOI 10.1186/s13002-019-0323-2; Foster M., 2011, HERBAL MED BIOMOLECU, V2nd; FRIEDMAN J, 1986, J ETHNOPHARMACOL, V16, P275, DOI 10.1016/0378-8741(86)90094-2; Gomez-Beloz A, 2002, ECON BOT, V56, P231, DOI 10.1663/0013-0001(2002)056[0231:PUKOTW]2.0.CO;2; Grace OM, 2008, J ETHNOPHARMACOL, V119, P604, DOI 10.1016/j.jep.2008.07.002; GROSVENOR PW, 1995, J ETHNOPHARMACOL, V45, P75, DOI 10.1016/0378-8741(94)01209-I; Hassan-Abdallah A, 2013, J ETHNOPHARMACOL, V148, P701, DOI 10.1016/j.jep.2013.05.033; Heinrich M, 2000, PHYTOTHER RES, V14, P479, DOI 10.1002/1099-1573(200011)14:7&lt;479::AID-PTR958&gt;3.0.CO;2-2; Hoffman B., 2007, Ethnobotany Research and Applications, V5, P201; Hussain S, 2019, REV BRAS FARMACOGN, V29, P665, DOI 10.1016/j.bjp.2019.06.008; Jadid N Sutikno, 2017, AIP C P, V1908; Jiang XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062315; Kassa Z, 2020, J ETHNOBIOL ETHNOMED, V16, DOI 10.1186/s13002-020-0358-4; Kayani S, 2015, J ETHNOPHARMACOL, V164, P186, DOI 10.1016/j.jep.2015.02.004; Khan I., 2014, EVID-BASED COMPL ALT, V2014, P1; Leto C, 2013, J ETHNOPHARMACOL, V146, P90, DOI 10.1016/j.jep.2012.11.042; Mahanal S., 2019, BIODIVERSITAS, V20, P1264, DOI [10.13057/biodiv/d200516, DOI 10.13057/biodiv/d200516]; Malik K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00789; Nahdi M. S., 2016, Biodiversitas: Journal of Biological Diversity, V17, P900, DOI 10.13057/biodiv/d170268; Ouedraogo K, 2019, J ETHNOBIOL ETHNOMED, V15, DOI 10.1186/s13002-019-0305-4; PHILLIPS O, 1993, ECON BOT, V47, P33, DOI 10.1007/BF02862204; Pieroni A, 2007, J ETHNOPHARMACOL, V113, P100, DOI 10.1016/j.jep.2007.05.009; Putra W. E., 2019, EURASIA J BIOSCI, V13, P2293; Qaseem MF, 2019, APPL ECOL ENV RES, V17, P2799, DOI 10.15666/aeer/1702_27992829; Rajeswari R., 2012, J PHARMACOGN PHYTOCH, V1, P118; Rajput SB, 2014, PHYTOMEDICINE, V21, P268, DOI 10.1016/j.phymed.2013.09.020; Rehman K, 2015, J ETHNOPHARMACOL, V165, P251, DOI 10.1016/j.jep.2015.02.035; Reimers EAL, 2019, PLANTS-BASEL, V8, DOI 10.3390/plants8080246; ROHMAN F, 2019, IOP C SER EARTH ENV, V276, P40373, DOI DOI 10.1088/1755-1315/276/1/012042; Rosita SMD, 2007, B RES SPICE MED CROP, VXVIII, P13; Sabran SF, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/2850845; Salehi B, 2018, INT J MOL SCI, V19, DOI [10.3390/ijms19092843, 10]; Sauini T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0232288; Shaheen Humaira, 2017, PLoS One, V12, pe0183956, DOI 10.1371/journal.pone.0183956; Sharifi-Rad M, 2017, MOLECULES, V22, DOI 10.3390/molecules22122145; Sharma V, 2014, NAT PROD RES, V28, P1454, DOI 10.1080/14786419.2014.915827; Shu H, 2018, ACTA SOC BOT POL, V87, DOI 10.5586/asbp.3585; Somanadhan B, 1999, J ETHNOPHARMACOL, V65, P103, DOI 10.1016/S0378-8741(98)00201-3; Sujarwo W, 2015, J ETHNOPHARMACOL, V169, P34, DOI 10.1016/j.jep.2015.03.079; Sujarwo W, 2014, ECON BOT, V68, P426, DOI 10.1007/s12231-014-9288-1; Umair M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177912; Van Steenis CGGJ, 2013, FLORA UNTUK SEKOLAH; Widyowati R, 2018, CHEM PHARM BULL, V66, P506, DOI 10.1248/cpb.c17-00983; Yeung AWK, 2020, J ETHNOPHARMACOL, V250, DOI 10.1016/j.jep.2019.112414; Zahoor M, 2017, J ETHNOBIOL ETHNOMED, V13, DOI 10.1186/s13002-017-0151-1; Zheng XL, 2009, J ETHNOPHARMACOL, V124, P197, DOI 10.1016/j.jep.2009.04.042	66	14	15	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2020	15	7							e0235886	10.1371/journal.pone.0235886	http://dx.doi.org/10.1371/journal.pone.0235886			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ1AQ	32658902	Green Published, gold			2023-01-03	WOS:000552629600006
J	Asghar, MA; Zahir, E; Asghar, MA; Iqbal, J; Rehman, AA				Asghar, Muhammad Asif; Zahir, Erum; Asghar, Muhammad Arif; Iqbal, Javed; Rehman, Ahad Abdul			Facile, one-pot biosynthesis and characterization of iron, copper and silver nanoparticles usingSyzygium cuminileaf extract: As an effective antimicrobial and aflatoxin B(1)adsorption agents	PLOS ONE			English	Article							SEED EXTRACT; ADSORPTION; CONTAMINATION; EQUILIBRIUM; ANTIFUNGAL; MECHANISMS; KINETICS; EFFICACY; GREEN; LEAF	In this study, a facile, ecological and economical green method is described for the fabrication of iron (Fe), copper (Cu) and silver (Ag) nanoparticles (NPs) from the extract ofSyzygium cuminileaves. The obtained metal NPs were categorized using UV/Vis, SEM, TEM, FTIR and EDX-ray spectroscopy techniques. The Fe-, Cu- and Ag-NPs were crystalline, spherical and size ranged from 40-52, 28-35 and 11-19 nm, respectively. The Ag-NPs showed excellent antimicrobial activities against methicillin- and vancomycin-resistanceStaphylococcus aureusbacterial strains andAspergillus flavusandA.parasiticusfungal species. Furthermore, the aflatoxins (AFs) production was also significantly inhibited when compared with the Fe- and Cu-NPs. In contrast, the adsorption results of NPs with aflatoxin B-1(AFB(1)) were observed as following order Fe->Cu->Ag-NPs. The Langmuir isotherm model well described the equilibrium data by the sorption capacity of Fe-NPs (105.3 ng mg(-1)), Cu-NPs (88.5 ng mg(-1)) and Ag-NPs (81.7 ng mg(-1)). The adsorption was found feasible, endothermic and follow the pseudo-second order kinetic model as revealed by the thermodynamic and kinetic studies. The present findings suggests that the green synthesis of metal NPs is a simple, sustainable, non-toxic, economical and energy-effective as compared to the others conventional approaches. In addition, synthesized metal NPs might be a promising AFs adsorbent for the detoxification of AFB(1)in human and animal food/feed.	[Asghar, Muhammad Asif] PCSIR Labs Complex, Food & Feed Safety Lab, Food & Marine Resources Res Ctr, Karachi, Pakistan; [Asghar, Muhammad Asif; Zahir, Erum] Univ Karachi, Dept Chem, Karachi, Pakistan; [Asghar, Muhammad Arif] Jinnah Sindh Med Univ, Dept Pharmaceut, Fac Pharm, Karachi, Pakistan; [Iqbal, Javed] Univ Limerick, Bernal Inst, Pharmaceut Mfg Technol Ctr, Limerick, Ireland; [Rehman, Ahad Abdul] Jinnah Sindh Med Univ, Dept Pharmacol, Fac Pharm, Karachi, Pakistan	PCSIR Laboratories Complex; University of Karachi; Jinnah Sindh Medical University - Pakistan; University of Limerick; Jinnah Sindh Medical University - Pakistan	Asghar, MA (corresponding author), Jinnah Sindh Med Univ, Dept Pharmaceut, Fac Pharm, Karachi, Pakistan.	m.arifasgher@hotmail.com	Asgher, Muhammad/AAY-6792-2020	Asghar, Muhammad Arif/0000-0002-3220-8418	Feed and Feed Safety Laboratory, FMRRC, PCSIR Laboratories Complex, Karachi-Pakistan	Feed and Feed Safety Laboratory, FMRRC, PCSIR Laboratories Complex, Karachi-Pakistan	The authors gratefully thanks to the Feed and Feed Safety Laboratory, FMRRC, PCSIR Laboratories Complex, Karachi-Pakistan for the supporting of current research work.	Aisida SO, 2020, EUR POLYM J, V122, DOI 10.1016/j.eurpolymj.2019.109371; Aisida SO, 2019, SURF INTERFACES, V17, DOI 10.1016/j.surfin.2019.100359; Aisida SO, 2020, APPL NANOSCI, V10, P305, DOI 10.1007/s13204-019-01099-x; Aisida SO, 2019, MATER CHEM PHYS, V237, DOI 10.1016/j.matchemphys.2019.121859; Aisida SO, 2019, J POLYM RES, V26, DOI 10.1007/s10965-019-1897-z; Asghar M. A., 2015, RES J AGR BIOL SCI, V11, P9; Asghar MA, 2018, LWT-FOOD SCI TECHNOL, V90, P98, DOI 10.1016/j.lwt.2017.12.009; Asghar MA, 2017, FOOD CONTROL, V78, P169, DOI 10.1016/j.foodcont.2017.02.058; Asghar MA, 2014, IRAN J PUBLIC HEALTH, V43, P291; Avantaggiato G, 2007, J AGR FOOD CHEM, V55, P4810, DOI 10.1021/jf0702803; Avantaggiato G, 2014, J AGR FOOD CHEM, V62, P497, DOI 10.1021/jf404179h; Banerjee J, 2011, DIG J NANOMATER BIOS, V6, P961; Behera S, 2013, WORLD J NANO SCI TEC, V2, P62, DOI DOI 10.5829/idosi.wjnst.2013.2.1.211311; Behravan M, 2019, INT J BIOL MACROMOL, V124, P148, DOI 10.1016/j.ijbiomac.2018.11.101; Bondarenko O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064060; Bryden WL, 2007, ASIA PAC J CLIN NUTR, V16, P95; DUBININ MM, 1960, CHEM REV, V60, P235, DOI 10.1021/cr60204a006; Freundlich H. M. F., 1906, J PHYS CHEM-US, V57, P385, DOI 10.1515/zpch-1907-5723; George JM, 2018, MICROCHIM ACTA, V185, DOI 10.1007/s00604-018-2894-3; Ghadim EE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079254; Hasanpoor M, 2015, PROC MAT SCI, V11, P320, DOI 10.1016/j.mspro.2015.11.101; Hassan A. A., 2013, STUDIES CHEM PROCESS, V1, P66; Hoet Peter Hm, 2004, J Nanobiotechnology, V2, P12, DOI 10.1186/1477-3155-2-12; Huwig A, 2001, TOXICOL LETT, V122, P179, DOI 10.1016/S0378-4274(01)00360-5; Iravani S, 2014, RES PHARM SCI, V9, P385; Kao CH, 2011, J MICROBIOL IMMUNOL, V44, P215, DOI 10.1016/j.jmii.2011.01.023; Kumar V, 2010, J CHEM TECHNOL BIOT, V85, P1301, DOI 10.1002/jctb.2427; Kuppusamy Palaniselvam, 2016, Saudi Pharm J, V24, P473, DOI 10.1016/j.jsps.2014.11.013; Langmuir I, 1916, J AM CHEM SOC, V38, P2221, DOI 10.1021/ja02268a002; Li YH, 2011, CHEM BIOCHEM ENG Q, V25, P483; Li YC, 2015, NANOSCALE, V7, P5209, DOI 10.1039/c4nr06481j; Machado S, 2013, SCI TOTAL ENVIRON, V445, P1, DOI 10.1016/j.scitotenv.2012.12.033; Madubuonu N, 2020, APPL PHYS A-MATER, V126, DOI 10.1007/s00339-019-3249-6; Madubuonu N, 2019, J PHOTOCH PHOTOBIO B, V199, DOI 10.1016/j.jphotobiol.2019.111601; Martins LM, 2017, FOOD RES INT, V97, P178, DOI 10.1016/j.foodres.2017.03.052; Mayakaduwa SS, 2016, CHEMOSPHERE, V144, P2516, DOI 10.1016/j.chemosphere.2015.07.080; Mobeen A. K., 2011, Journal of Pharmacy and Nutrition Sciences, V1, P1; Naik S., 2017, APPL ORGANOMET CHEM, V31, pe3549, DOI 10.1002/aoc.3549; Nasrollahi A, 2011, INT J NANO DIMENS, V1, P233, DOI 10.7508/ijnd.2010.03.007; Nath D, 2015, B MATER SCI, V38, P1533, DOI 10.1007/s12034-015-0974-0; Park J, 2016, BIOMATERIALS, V101, P285, DOI 10.1016/j.biomaterials.2016.06.007; Reidy B, 2013, MATERIALS, V6, P2295, DOI 10.3390/ma6062295; Salleh MAM, 2011, DESALINATION, V280, P1, DOI 10.1016/j.desal.2011.07.019; Salunke BK, 2016, WORLD J MICROB BIOT, V32, DOI 10.1007/s11274-016-2044-1; Shar ZH, 2016, FOOD ADDIT CONTAM A, V33, P849, DOI 10.1080/19440049.2016.1175155; Sprynskyy M, 2012, COLLOID SURFACE B, V94, P7, DOI 10.1016/j.colsurfb.2011.12.024; Stoimenov PK, 2002, LANGMUIR, V18, P6679, DOI 10.1021/la0202374; Sun XH, 2009, J PHYS CHEM C, V113, P16002, DOI 10.1021/jp9038682; Tripathi Smita, 2009, International Journal of Food Safety, Nutrition and Public Health, V2, P69, DOI 10.1504/IJFSNPH.2009.026920; Ugwoke E, 2020, SURF INTERFACES, V18, DOI 10.1016/j.surfin.2019.100419; Venkatesan J, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6120235; Yadav A, 2015, BIOTECHNOL LETT, V37, P2099, DOI 10.1007/s10529-015-1901-6; Ye S., 2009, AUST J BASIC APPL SC, V3, P1296; Zahoor M, 2018, ARAB J CHEM, V11, P729, DOI 10.1016/j.arabjc.2014.08.025; Zhang HX, 2009, NANOSCALE RES LETT, V4, P705, DOI 10.1007/s11671-009-9301-2	55	22	22	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2020	15	7							e0234964	10.1371/journal.pone.0234964	http://dx.doi.org/10.1371/journal.pone.0234964			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM1IV	32614844	Green Published, gold			2023-01-03	WOS:000549913100036
J	Gil-Anton, J; Mielgo, VE; Rey-Santano, C; Galbarriatu, L; Santos, C; Unceta, M; Lopez-Fernandez, Y; Redondo, S; Morteruel, E				Gil-Anton, Javier; Mielgo, Victoria E.; Rey-Santano, Carmen; Galbarriatu, Lara; Santos, Carlos; Unceta, Maria; Lopez-Fernandez, Yolanda; Redondo, Silvia; Morteruel, Elvira			Addition of terlipressin to initial volume resuscitation in a pediatric model of hemorrhagic shock improves hemodynamics and cerebral perfusion	PLOS ONE			English	Article							BRAIN-DAMAGE; VASOPRESSIN; PRESSURE	Hemorrhagic shock is one of the leading causes of mortality and morbidity in pediatric trauma. Current treatment based on volume resuscitation is associated to adverse effects, and it has been proposed that vasopressors may be used in the pharmacological management of trauma. Terlipressin has demonstrated its usefulness in other pediatric critical care scenarios and its long half-life allows its use as a bolus in an outpatient critical settings. The aim of this study was to analyze whether the addition of a dose of terlipressin to the initial volume expansion produces an improvement in hemodynamic and cerebral perfusion at early stages of hemorrhagic shock in an infant animal model. We conducted an experimental randomized animal study with 1-month old pigs. After 30 minutes of hypotension (mean arterial blood pressure [MAP]<45 mmHg) induced by the withdrawal of blood over 30 min, animals were randomized to receive either normal saline (NS) 30 mL/kg (n = 8) or a bolus of 20 mcg/kg of terlipressin plus 30 mL/kg of normal saline (TP) (n = 8). Global hemodynamic and cerebral monitoring parameters, brain damage markers and histology samples were compared. After controlled bleeding, significant decreases were observed in MAP, cardiac index (CI), central venous pressure, global end-diastolic volume index (GEDI), left cardiac output index, SvO(2), intracranial pressure, carotid blood flow, bispectral index (BIS), cerebral perfusion pressure (CPP) and increases in systemic vascular resistance index, heart rate and lactate. After treatment, MAP, GEDI, CI, CPP and BIS remained significantly higher in the TP group. The addition of a dose of terlipressin to initial fluid resuscitation was associated with hemodynamic improvement, intracranial pressure maintenance and better cerebral perfusion, which would mean protection from ischemic injury. Brain monitoring through BIS was able to detect changes caused by hemorrhagic shock and treatment.	[Gil-Anton, Javier] Univ Basque Country, UPV EHU, Dept Pediat,Cruces Univ Hosp, Pediat Intens Care Unit,Biocruces Bizkaia Hlth Re, Baracaldo, Bizkaia, Spain; [Mielgo, Victoria E.; Rey-Santano, Carmen] Biocruces Bizkaia Hlth Res Inst, Anim Res Unit, Baracaldo, Bizkaia, Spain; [Galbarriatu, Lara] Cruces Univ Hosp, Dept Neurosurg, Baracaldo, Bizkaia, Spain; [Santos, Carlos] Cruces Univ Hosp, Dept Neurophysiol, Baracaldo, Bizkaia, Spain; [Unceta, Maria] Cruces Univ Hosp, Biochem Lab, Baracaldo, Bizkaia, Spain; [Lopez-Fernandez, Yolanda; Redondo, Silvia; Morteruel, Elvira] Cruces Univ Hosp, Pediat Intens Care Unit, Biocruces Bizkaia Hlth Res Inst, Baracaldo, Bizkaia, Spain	Hospital Universitario Cruces; University of Basque Country; Hospital Universitario Cruces; Hospital Universitario Cruces; Hospital Universitario Cruces; Hospital Universitario Cruces	Gil-Anton, J (corresponding author), Univ Basque Country, UPV EHU, Dept Pediat,Cruces Univ Hosp, Pediat Intens Care Unit,Biocruces Bizkaia Hlth Re, Baracaldo, Bizkaia, Spain.; Mielgo, VE (corresponding author), Biocruces Bizkaia Hlth Res Inst, Anim Res Unit, Baracaldo, Bizkaia, Spain.	javier.gilanton@osakidetza.eus; victoriaeugenia.mielgoturuelo@osakidetza.eus		Santos Sanchez, Carlos/0000-0001-9958-4875	Basque Government [GIU19/026]; Spanish Society of pediatric critical care (Ruza Grant 2017)	Basque Government(Basque Government); Spanish Society of pediatric critical care (Ruza Grant 2017)	This work was partially supported by Basque Government Grant (GIU19/026) to VEM and Spanish Society of pediatric critical care (Ruza Grant 2017) to JG.	Bayram B, 2012, AM J EMERG MED, V30, P1176, DOI 10.1016/j.ajem.2011.09.007; Beloncle F, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-13; Ben Sivarajan V, 2011, PEDIATR CRIT CARE ME, V12, pS2, DOI 10.1097/PCC.0b013e318220e7ea; Bougle A, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-1; Cavus E, 2010, RESUSCITATION, V81, P1183, DOI 10.1016/j.resuscitation.2010.05.018; Christiaans SC, 2014, SHOCK, V41, P476, DOI 10.1097/SHK.0000000000000151; Cohn SM, 2011, WORLD J SURG, V35, P430, DOI 10.1007/s00268-010-0875-8; Cossu AP, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/421291; ERICSSON BF, 1971, ACTA CHIR SCAND, V137, P729; Gil-Anton J, 2010, PEDIATR CRIT CARE ME, V11, P139, DOI 10.1097/PCC.0b013e3181ae7834; Hamzaoui O, 2010, CRIT CARE, V14, DOI 10.1186/cc9207; Healey MA, 2001, J TRAUMA, V50, P826, DOI 10.1097/00005373-200105000-00009; Hildebrand F, 2013, SHOCK, V40, P247, DOI 10.1097/SHK.0b013e3182a3cd74; Hirsch M, 2015, LANCET, V386, P2535, DOI 10.1016/S0140-6736(15)01063-6; Hwabejire JO, 2013, J TRAUMA ACUTE CARE, V75, P968, DOI 10.1097/TA.0b013e31829a021a; Ida KK, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0825-9; Lafuente H, 2011, PEDIATR RES, V70, P272, DOI 10.1203/PDR.0b013e3182276b11; Lee CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095821; Lienhart HG, 2007, ANAESTHESIST, V56, P145, DOI 10.1007/s00101-006-1114-4; Lienhart HG, 2008, CURR OPIN CRIT CARE, V14, P247, DOI 10.1097/MCC.0b013e3282fce62a; Masarwa R, 2017, CRIT CARE, V21, DOI 10.1186/s13054-016-1589-6; Meybohm P, 2008, RESUSCITATION, V76, P449, DOI 10.1016/j.resuscitation.2007.09.002; Nemeth M, 2014, ACTA ANAESTH SCAND, V58, P611, DOI 10.1111/aas.12312; Rodriguez-Nunez A, 2010, ANN PHARMACOTHER, V44, P1545, DOI 10.1345/aph.1P254; Salluh JIF, 2007, ACTA ANAESTH SCAND, V51, P505, DOI 10.1111/j.1399-6576.2006.01252.x; Spahn DR, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2347-3; Spahn DR, 2013, CRIT CARE, V17, DOI 10.1186/cc12685; Sperry JL, 2008, J TRAUMA, V64, P9, DOI 10.1097/TA.0b013e31815dd029; Urbano J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121678; Voelckel WG, 2010, J TRAUMA, V69, pS69, DOI 10.1097/TA.0b013e3181e44937	30	3	3	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2020	15	7							e0235084	10.1371/journal.pone.0235084	http://dx.doi.org/10.1371/journal.pone.0235084			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM1IV	32614837	Green Published, gold			2023-01-03	WOS:000549913100004
J	Sheikhalishahi, S; Balaraman, V; Osmani, V				Sheikhalishahi, Seyedmostafa; Balaraman, Vevake; Osmani, Venet			Benchmarking machine learning models on multi-centre eICU critical care dataset	PLOS ONE			English	Article							HOSPITAL MORTALITY; ACUTE PHYSIOLOGY; SYSTEM; RISK	Progress of machine learning in critical care has been difficult to track, in part due to absence of public benchmarks. Other fields of research (such as computer vision and natural language processing) have established various competitions and public benchmarks. Recent availability of large clinical datasets has enabled the possibility of establishing public benchmarks. Taking advantage of this opportunity, we propose a public benchmark suite to address four areas of critical care, namely mortality prediction, estimation of length of stay, patient phenotyping and risk of decompensation. We define each task and compare the performance of both clinical models as well as baseline and deep learning models using eICU critical care dataset of around 73,000 patients. This is the first public benchmark on amulti-centrecritical care dataset, comparing the performance of clinical gold standard with our predictive model. We also investigate the impact of numerical variables as well as handling of categorical variables on each of the defined tasks. The source code, detailing our methods and experiments is publicly available such that anyone can replicate our results and build upon our work.	[Sheikhalishahi, Seyedmostafa; Balaraman, Vevake] Univ Trento, Trento, Italy; [Sheikhalishahi, Seyedmostafa; Balaraman, Vevake; Osmani, Venet] Fdn Bruno Kessler, Res Inst, Trento, Italy	University of Trento; Fondazione Bruno Kessler	Osmani, V (corresponding author), Fdn Bruno Kessler, Res Inst, Trento, Italy.	vosmani@fbk.eu		Sheikhalishahi, Seyedmostafa/0000-0002-0121-0160; Balaraman, Vevake/0000-0002-1741-4969; Osmani, Venet/0000-0001-7306-2972	European Commission's Horizon 2020 Project, WellCo [769765]	European Commission's Horizon 2020 Project, WellCo	VO was supported by European Commission's Horizon 2020 Project, WellCo, under grant agreement No 769765 (https://cordis.europa.eu/project/id/769765).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bellomo R, 2009, CRIT CARE MED, V37, P3114, DOI 10.1097/CCM.0b013e3181bc7bd5; Berkhahn F., 2016, ENTITY EMBEDDINGS CA; Celi LA, 2012, J PERS MED, V2, P138, DOI 10.3390/jpm2040138; Darabi HR, 2018, PROCEDIA COMPUT SCI, V140, P306, DOI 10.1016/j.procs.2018.10.313; Denaxas S, 2019, ANAL HETEROGENETTY R, P685156; Denaxas S, 2019, STUD HEALTH TECHNOL, V262, P220, DOI 10.3233/SHTI190058; Harutyunyan H, 2019, SCI DATA, V6, DOI 10.1038/s41597-019-0103-9; Ho JC, 2014, PROCEEDINGS OF THE 20TH ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING (KDD'14), P115, DOI 10.1145/2623330.2623658; Hochreiter S, 1997, NEURAL COMPUT, V9, P1735, DOI [10.1162/neco.1997.9.1.1, 10.1007/978-3-642-24797-2]; Johnson AEW, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.35; Kidney Dis Improving Global, 2017, KIDNEY INT SUPPL, V7, P1, DOI 10.1016/j.kisu.2017.04.001; Kilic M, 2019, TURK J ANAESTHESIOL, V47, P142, DOI 10.5152/TJAR.2019.80445; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Lancet Global Health, 2019, LANCET GLOBAL HLTH, V7, pe1; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Lipton Z. C., 2016, ARXIV151103677; Ma X, 2020, COMPUT METH PROG BIO, V186, DOI 10.1016/j.cmpb.2019.105224; McGinley A, 2012, NATL EARLY WARNING S; Molnar C., 2022, INTERPRETABLE MACHIN, DOI DOI 10.1007/S10290-014-0202-9; Payen D, 2008, CRIT CARE, V12, pR74, DOI 10.1186/cc6916; Pollard TJ, 2018, SCI DATA, V5, DOI 10.1038/sdata.2018.178; Purushotham S, 2018, J BIOMED INFORM, V83, P112, DOI 10.1016/j.jbi.2018.04.007; Razavian N., 2016, JMLR WORKSHOP C P, P73; Ren O., 2018, 2018 IEEE INT C HEAL, P144; RUMELHART DE, 1986, NATURE, V323, P533, DOI 10.1038/323533a0; Russakovsky O, 2015, INT J COMPUT VISION, V115, P211, DOI 10.1007/s11263-015-0816-y; Schuster M, 1997, IEEE T SIGNAL PROCES, V45, P2673, DOI 10.1109/78.650093; Sotoodeh Mani, 2019, AMIA Jt Summits Transl Sci Proc, V2019, P425; Stubbs A, 2019, J AM MED INFORM ASSN, V26, P1163, DOI 10.1093/jamia/ocz163; The WHO Alliance for Maternal and Newborn Health Improvement late pregnancy dating study group, 2020, LANCET GLOB HLTH, V8, pe545; TU JV, 1993, COMPUT BIOMED RES, V26, P220, DOI 10.1006/cbmr.1993.1015; Xu YB, 2018, KDD'18: PROCEEDINGS OF THE 24TH ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY & DATA MINING, P2565, DOI 10.1145/3219819.3220051; Zhang ZH, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.05.32; Zhou JY, 2014, PROCEEDINGS OF THE 20TH ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING (KDD'14), P135, DOI 10.1145/2623330.2623711; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0	35	8	8	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2020	15	7							e0235424	10.1371/journal.pone.0235424	http://dx.doi.org/10.1371/journal.pone.0235424			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM1IV	32614874	Green Published, Green Submitted, Green Accepted, gold			2023-01-03	WOS:000549913100067
J	Gutzmer, R; Stroyakovskiy, D; Gogas, H; Robert, C; Lewis, K; Protsenko, S; Pereira, RP; Eigentler, T; Rutkowski, P; Demidov, L; Manikhas, GM; Yan, YB; Huang, KC; Uyei, A; McNally, V; McArthur, GA; Ascierto, PA				Gutzmer, Ralf; Stroyakovskiy, Daniil; Gogas, Helen; Robert, Caroline; Lewis, Karl; Protsenko, Svetlana; Pereira, Rodrigo P.; Eigentler, Thomas; Rutkowski, Piotr; Demidov, Lev; Manikhas, Georgy Moiseevich; Yan, Yibing; Huang, Kuan-Chieh; Uyei, Anne; McNally, Virginia; McArthur, Grant A.; Ascierto, Paolo A.			Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial	LANCET			English	Article							COMBINED NIVOLUMAB; BRAF; IPILIMUMAB; PEMBROLIZUMAB; DABRAFENIB; SURVIVAL; TRAMETINIB; INHIBITORS	Background IMspire150 aimed to evaluate first-line combination treatment with BRAF plus MEK inhibitors and immune checkpoint therapy in BRAF(V600) mutation-positive advanced or metastatic melanoma. Methods IMspire150 was a randomised, double-blind, placebo-controlled phase 3 study done at 112 institutes in 20 countries. Patients with unresectable stage IIIc-IV, BRAF(V600) mutation-positive melanoma were randomly assigned 1:1 to 28-day cycles of atezolizumab, vemurafenib, and cobimetinib (atezolizumab group) or atezolizumab placebo, vemurafenib, and cobimetinib (control group). In cycle 1, all patients received vemurafenib and cobimetinib only; atezolizumab placebo was added from cycle 2 onward. Randomisation was stratified by lactate dehydrogenase concentration and geographical region. Blinding for atezolizumab was achieved by means of an identical intravenous placebo, and blinding for vemurafenib was achieved by means of a placebo tablet. The primary outcome was investigator-assessed progression-free survival. This trial (ClinicalTrials.gov, NCT02908672) is ongoing but no longer recruiting patients. Findings Between Jan 13, 2017, and April 26, 2018, 777 patients were screened and 514 were enrolled and randomly assigned to the atezolizumab group (n=256) or control group (n=258). At a median follow-up of 18.9 months (IQR 10.4-23.8), progression-free survival as assessed by the study investigator was significantly prolonged with atezolizumab versus control (15.1 vs 10.6 months; hazard ratio [HR] 0.78; 95% CI 0.63-0.97; p=0.025). Common treatment-related adverse events (>30%) in the atezolizumab and control groups were blood creatinine phosphokinase increased (51.3% vs 44.8%), diarrhoea (42.2% vs 46.6%), rash (40.9%, both groups), arthralgia (39.1% vs 28.1%), pyrexia (38.7% vs 26.0%), alanine aminotransferase increased (33.9% vs 22.8%), and lipase increased (32.2% vs 27.4%); 13% of patients in the atezolizumab group and 16% in the control group stopped all treatment because of adverse events. Interpretation The addition of atezolizumab to targeted therapy with vemurafenib and cobimetinib was safe and tolerable and significantly increased progression-free survival in patients with BRAF(V600) mutation-positive advanced melanoma. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Gutzmer, Ralf] Hannover Med Sch, Klin Dermatol Allergol & Venerol, Haut Tumor Zentrum Hannover, Hannover, Germany; [Stroyakovskiy, Daniil] Moscow City Oncol Hosp, Number 62 Moscow Healthcare Dept, Moscow, Russia; [Gogas, Helen] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Dept Med 1, Athens, Greece; [Robert, Caroline] Gustave Roussy, Villejuif, France; [Robert, Caroline] Univ Paris Saclay, Villejuif, France; [Lewis, Karl] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA; [Protsenko, Svetlana] NN Petrov Natl Med Res Ctr Oncol, Dept Chemotherapy & Innovat Technol, St Petersburg, Russia; [Pereira, Rodrigo P.] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Eigentler, Thomas] Univ Hosp Tubingen, Tubingen, Germany; [Rutkowski, Piotr] Maria Sklodowska Curie Natl Res Inst Oncol, Soft Tissue Bone Sarcoma & Melanoma, Warsaw, Poland; [Demidov, Lev] Minist Hlth, NN Blokhin Russian Canc Res Ctr, Moscow, Russia; [Manikhas, Georgy Moiseevich] St Petersburg Oncol Hosp, St Petersburg, Russia; [Yan, Yibing; Huang, Kuan-Chieh; Uyei, Anne] Genentech Inc, San Francisco, CA USA; [McNally, Virginia] Roche Prod, Welwyn Garden City, Herts, England; [McArthur, Grant A.] Peter MacCallum Canc Ctr, Melanoma & Skin Serv, Melbourne, Vic, Australia; [McArthur, Grant A.] Peter MacCallum Canc Ctr, Canc Therapeut Program, Melbourne, Vic, Australia; [Ascierto, Paolo A.] Ist Nazl Tumori IRCCS Fdn G Pascale, Naples, Italy; [Uyei, Anne] Kartos Therapeut, Redwood City, CA USA	Hannover Medical School; Laiko General Hospital; National & Kapodistrian University of Athens; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; University of Colorado System; University of Colorado Anschutz Medical Campus; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Ministry of Health of the Russian Federation; N.N. Blokhin Russian Cancer Research Center; Roche Holding; Genentech; Roche Holding; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; IRCCS Fondazione Pascale	Gutzmer, R (corresponding author), Hannover Med Sch, D-30625 Hannover, Germany.	gutzmer.ralf@mh-hannover.de	Rutkowski, Piotr/B-3907-2013; Robert, Caroline/G-6157-2018; Eigentler, Thomas/K-8570-2015	Rutkowski, Piotr/0000-0002-8920-5429; Robert, Caroline/0000-0002-9493-0238; Eigentler, Thomas/0000-0003-0019-2770; Stroyakovskiy, Daniil/0000-0003-1973-1092	F Hoffmann-La Roche; Genentech	F Hoffmann-La Roche(Hoffmann-La Roche); Genentech(Roche HoldingGenentech)	F Hoffmann-La Roche and Genentech.	AJCC, 2015, AM JOINT COMMITTEE C; [Anonymous], 2019, TEC AT INJ INTR US; Ascierto PA, 2018, ANN ONCOL, V29, P442; Ascierto PA, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1468955; Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X; Ascierto PA, 2019, NAT MED, V25, P941, DOI 10.1038/s41591-019-0448-9; Burton EM, 2019, ANN ONCOL S5, V30, P534; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Ferrucci PF, 2019, INT C SOC MEL RES NO; Fine GD, 2007, DRUG INF J, V41, P535, DOI 10.1177/009286150704100412; Fleming T.R., 1991, COUNTING PROCESSES S; Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630; Hamid O, 2019, CLIN CANCER RES, V25, P6061, DOI 10.1158/1078-0432.CCR-18-3488; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Kakadia S, 2018, ONCOTARGETS THER, V11, P7095, DOI 10.2147/OTT.S182721; Khair DO, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00453; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Lewis K, 2019, EUR J CANCER, V116, P45, DOI 10.1016/j.ejca.2019.05.002; Long GV, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.9531; Pelster MS, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919830826; Ribas A, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.3003; Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093; Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Sullivan RJ, 2019, NAT MED, V25, P929, DOI 10.1038/s41591-019-0474-7; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Wang YC, 2019, JAMA ONCOL, V5, P1008, DOI 10.1001/jamaoncol.2019.0393; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Wolchok JD, 2017, NEW ENGL J MED, V377, P1345, DOI 10.1056/NEJMoa1709684	30	248	256	5	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	2020	395	10240					1835	1844						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NH4GA	32534646				2023-01-03	WOS:000564628700026
J	Ogata, M; Kotaka, M; Ogata, T; Hatachi, Y; Yasui, H; Kato, T; Tsuji, A; Satake, H				Ogata, Misato; Kotaka, Masahito; Ogata, Takatsugu; Hatachi, Yukimasa; Yasui, Hisateru; Kato, Takeshi; Tsuji, Akihito; Satake, Hironaga			Regorafenib vs trifluridine/tipiracil for metastatic colorectal cancer refractory to standard chemotherapies: A multicenter retrospective comparison study in Japan	PLOS ONE			English	Article							DOUBLE-BLIND; TAS-102; MONOTHERAPY; PLUS	Regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) showed survival benefits in metastatic colorectal cancer patients previously treated with standard chemotherapies; therefore, we compared the efficacy and safety of these two treatments. Patients with metastatic colorectal cancer treated with REG or FTD/TPI as a salvage-line therapy from May 2014 to December 2017 were included. We retrospectively analyzed long-term survival, safety, and clinical outcomes. Among 134 patients, 57 and 77 received REG and FTD/TPI, respectively. The REG group received more prior systemic chemotherapies and significantly more frequent additional chemotherapies than the FTD/TPI group did. The median follow-up was 6.2 months, whereas the median overall survival was 9.9 and 11.4 months in the REG and FTD/TPI groups, respectively (hazard ratio = 0.954, p = 0.837). The median progression-free survival was 2.0 and 3.3 months in the REG and FTD/TPI groups, respectively (hazard ratio = 0.52, p = 0.00047), indicating significant differences, whereas the objective response and disease control rates did not differ. The median overall survival of patients with additional subsequent chemotherapies after disease progression was longer than that of patients without additional chemotherapy. The most frequent grade >= 3 adverse events were hypertension and neutropenia in the REG and FTD/TPI groups, respectively. Our study suggested that sequential use of both drugs may prolong survival.	[Ogata, Misato; Ogata, Takatsugu; Hatachi, Yukimasa; Yasui, Hisateru; Satake, Hironaga] Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Hyogo, Japan; [Kotaka, Masahito] Sano Hosp, Gastrointestinal Canc Ctr, Kobe, Hyogo, Japan; [Kato, Takeshi] Osaka Natl Hosp, Dept Surg, Osaka, Osaka, Japan; [Tsuji, Akihito] Kagawa Univ, Fac Med, Dept Clin Oncol, Kitagun, Kagawa, Japan; [Satake, Hironaga] Kansai Med Univ Hosp, Canc Treatment Ctr, Hirakata, Osaka, Japan	Kobe City Medical Center General Hospital; Osaka National Hospital; Kagawa University	Satake, H (corresponding author), Kobe City Med Ctr Gen Hosp, Dept Med Oncol, Kobe, Hyogo, Japan.; Satake, H (corresponding author), Kansai Med Univ Hosp, Canc Treatment Ctr, Hirakata, Osaka, Japan.	takeh1977@gmail.com	Satake, Hironaga/G-6243-2013; Satake, Hironaga/AAI-9730-2020	Satake, Hironaga/0000-0001-7629-6803; Ogata, Misato/0000-0003-0793-4247; Kotaka, Masahito/0000-0001-5976-613X				Bekaii-Saab TS, 2019, LANCET ONCOL, V20, P1070, DOI 10.1016/S1470-2045(19)30272-4; Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X; Kuboki Y, 2017, LANCET ONCOL, V18, P1172, DOI 10.1016/S1470-2045(17)30425-4; Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7; Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325; Moriwaki T, 2018, ONCOLOGIST, V23, P7, DOI 10.1634/theoncologist.2017-0275; Shinagawa T, 2018, ANN GASTROENT SURG, V2, P6, DOI 10.1002/ags3.12047; Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235; Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864; Yoshino T, 2012, LANCET ONCOL, V13, P993, DOI 10.1016/S1470-2045(12)70345-5	10	7	7	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2020	15	6							e0234314	10.1371/journal.pone.0234314	http://dx.doi.org/10.1371/journal.pone.0234314			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6QP	32530932	Green Published, gold			2023-01-03	WOS:000542037200003
J	Robinson, JC				Robinson, James C.			Lower Prices and Greater Patient Access - Lessons from Germany's Drug-Purchasing Structure	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								The German system for determining drug prices features collective negotiations on the part of competing health plans. It also creates incentives for agreement, limits price increases not justified by new evidence, and avoids heavy burdens on physicians and patients.	[Robinson, James C.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Robinson, JC (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.			Robinson, James/0000-0003-0056-3017				[Anonymous], 2019, BIOSIMILARS ZAHLEN; Berkemeier F, 2019, J MANAG CARE SPEC PH, V25, P1310, DOI 10.18553/jmcp.2019.25.12.1310; Cardiovascular Disease and Risk Management, 2019, DIABETES CARE, V2, pS103, DOI 10.2337/dc19-S010; Robinson JC, 2018, JAMA-J AM MED ASSOC, V319, P2169, DOI 10.1001/jama.2018.5367; Robinson JC., 2019, DRUG PRICES ARE NEGO	5	8	8	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	2020	382	23					2177	2179		10.1056/NEJMp2000341	http://dx.doi.org/10.1056/NEJMp2000341			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LV0NI	32492300				2023-01-03	WOS:000538140600008
J	Powell, CD; Wilson, WM; Olesaningo, G; Manyama, M; Jamniczky, H; Spritz, R; Cross, JC; Lukowiak, K; Hallgrimsson, B; Gonzalez, PN				Powell, Christopher D.; Wilson, Warren M.; Olesaningo, Godwin; Manyama, Mange; Jamniczky, Heather; Spritz, Richard; Cross, James C.; Lukowiak, Kenneth; Hallgrimsson, Benedikt; Gonzalez, Paula N.			Lack of head sparing following third-trimester caloric restriction among Tanzanian Maasai	PLOS ONE			English	Article							LOW-BIRTH-WEIGHT; LATE PREGNANCY; FETAL-GROWTH; FOOD-INTAKE; IN-UTERO; HEALTH; QUESTIONNAIRE; CIRCUMFERENCE; PASTORALISTS; POPULATION	The reduction of food intake during pregnancy is part of many cultural and religious traditions around the world. The impact of such practices on fetal growth and development are poorly understood. Here, we examined the patterns of diet intake among Maasai pregnant women and assessed their effect on newborn morphometrics. We recruited 141 mother-infant pairs from Ngorongoro Conservation Area (NCA) in Northern Tanzania and quantified dietary intake and changes in maternal diet during pregnancy. We obtained measurements of body weight (BW) and head circumference (HC) at birth. We found that Maasai women significantly reduced their dietary intake during the third trimester, going from an average of 1601 kcal/day during the first two trimesters to 799 kcal/day in the final trimester. The greatest proportion of nutrient reduction was in carbohydrates. Overall, 40% of HC Z-scores of the NCA sample were more than 2 standard deviations below the WHO standard. Nearly a third of neonates classify as low birth weight (< 2500g). HC was smaller relative to BW in this cohort than predicted using the WHO standard. This contrasts markedly to a Tanzanian birth cohort obtained at the same time in an urban context in which only 12% of infants exhibited low weight, only two individuals had HC Z-scores < 2 and HC's relative to birth weight were larger than predicted using the WHO standards. The surprising lack of head sparing in the NCA cohort suggests that the impact of third trimester malnutrition bears further investigation in both animal models and human populations, especially as low HC is negatively associated with long term health outcomes.	[Powell, Christopher D.; Hallgrimsson, Benedikt] Univ Calgary, Cumming Sch Med, Dept Cell Biol & Anat, Calgary, AB, Canada; [Wilson, Warren M.; Jamniczky, Heather] Univ Calgary, Dept Anthropol & Archaeol, Calgary, AB, Canada; [Olesaningo, Godwin] Endulen Hosp, Ngorongoro Conservat Area, Mwanza, Tanzania; [Manyama, Mange] Catholic Univ Hlth & Allied Sci, Mwanza, Tanzania; [Manyama, Mange] Weill Cornell Med, Div Med Educ, Ar Rayyan, Qatar; [Jamniczky, Heather] Univ Calgary, McCaig Bone & Joint Inst, Calgary, AB, Canada; [Spritz, Richard] Univ Colorado, Sch Med, Dept Pediat, Denver, CO USA; [Spritz, Richard] Univ Colorado, Sch Med, Human Med Genet & Genom Program, Denver, CO USA; [Cross, James C.] Univ Calgary, Fac Vet Med, Dept Comparat Biol & Expt Med, Calgary, AB, Canada; [Cross, James C.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada; [Cross, James C.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada; [Lukowiak, Kenneth] Univ Calgary, Cumming Sch Med, Hotchkiss Brain Inst, Calgary, AB, Canada; [Gonzalez, Paula N.] Uiversidad Nacl Arturo Jauretche, Hosp El Cruce Dr Nestor Kirchner, CONICET, Unidad Ejecutora Estudios Neurociencias & Sistema, Buenos Aires, DF, Argentina	University of Calgary; University of Calgary; Qatar Foundation (QF); Weill Cornell Medical College Qatar; University of Calgary; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Calgary; Alberta Childrens Hospital; University of Calgary; University of Calgary; University of Calgary; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET)	Gonzalez, PN (corresponding author), Uiversidad Nacl Arturo Jauretche, Hosp El Cruce Dr Nestor Kirchner, CONICET, Unidad Ejecutora Estudios Neurociencias & Sistema, Buenos Aires, DF, Argentina.	pgonzalez@fcnym.unlp.edu.ar	Hallgrimsson, Benedikt/A-9616-2008; Cross, James/F-4814-2011	Hallgrimsson, Benedikt/0000-0002-7192-9103; Lukowiak, Ken/0000-0001-9028-1931; gonzalez, paula/0000-0001-6335-7363; Wilson, Warren/0000-0002-0057-6873; Jamniczky, Heather/0000-0002-2514-8226; Cross, James/0000-0003-0956-9378	National Institute of Dental and Craniofacial Research [1U01DE020054]; Natural Sciences of Engineering Research Council of Canada [238992-12]	National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); Natural Sciences of Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	This project was supported by: National Institute of Dental and Craniofacial Research to RS and BH (Grant number: 1U01DE020054) https://www.nidcr.nih.gov/Natural Sciences of Engineering Research Council of Canada to BH (Grant number: 238992-12) http://www.nserccrsng.gc.ca/index_eng.asp No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe Y, 2007, HYPERTENS RES, V30, P627, DOI 10.1291/hypres.30.627; [Anonymous], 2010, CROSSROADS PUBLICATI, V14, P9; Archie JG, 2006, AM J CLIN PATHOL, V126, P256, DOI 10.1309/FK9D5WBA1UEPT5BB; Baasher T, 1979, WHO EMRO TECHNICAL P, V2, P71; Baker J, 2010, AM J HUM BIOL, V22, P206, DOI 10.1002/ajhb.20979; Barbeito-Andres J, 2018, NEUROSCIENCE, V380, P14, DOI 10.1016/j.neuroscience.2018.03.049; Bartholomeusz HH, 2002, NEUROPEDIATRICS, V33, P239, DOI 10.1055/s-2002-36735; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; BEATON GH, 1979, AM J CLIN NUTR, V32, P2546, DOI 10.1093/ajcn/32.12.2546; Beddada B, 1979, WHO EMRO TECHNICAL P, V2, P47; Bishop E, 2007, NOMAD PEOPLES, V11, P9, DOI 10.3167/np.2007.110202; Bloomfield FH, 2006, ARCH DIS CHILD-FETAL, V91, pF299, DOI 10.1136/adc.2005.076646; Boone RB, 2006, HUM ECOL, V34, P809, DOI 10.1007/s10745-006-9031-3; Borghi E, 2006, STAT MED, V25, P247, DOI 10.1002/sim.2227; Coast E, 2001, MAASAI DEMOGRAPHY; Cole JB, 2018, J ANAT, V232, P250, DOI 10.1111/joa.12748; COOKE RWI, 1977, EARLY HUM DEV, V1, P145, DOI 10.1016/0378-3782(77)90015-9; Crawford M. A., 1993, Nutrition and Health (Bicester), V9, P81; Creswell JW, 2018, QUAL INQ; de Onis Mercedes, 2003, Forum Nutr, V56, P238; de Onis M, 2013, WORLD REV NUTR DIET, V106, P75, DOI 10.1159/000342550; DJAZAYERY A, 1992, ECOL FOOD NUTR, V28, P105, DOI 10.1080/03670244.1992.9991263; Eikenes L, 2012, PEDIATR RES, V72, P649, DOI 10.1038/pr.2012.129; El Shalazi H, 1979, WHO EMRO TECHNICAL P, V2, P100; Elvander C, 2012, ACTA OBSTET GYN SCAN, V91, P470, DOI 10.1111/j.1600-0412.2012.01358.x; FAO, 2001, REP JOINT FAO WHO UN; Ferland S, 2003, J REPROD MED, V48, P86; Galvin KA, 1994, AFRICAN PASTORALIST; Galvin KA, 2009, ANNU REV ANTHROPOL, V38, P185, DOI 10.1146/annurev-anthro-091908-164442; Garza Cutberto, 2004, Food Nutr Bull, V25, pS5; Geraedts EJ, 2011, HORM RES PAEDIAT, V75, P213, DOI 10.1159/000321192; Gonzalez PN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152227; Henrichs J, 2010, DEV MED CHILD NEUROL, V52, P644, DOI 10.1111/j.1469-8749.2009.03513.x; Henrichs J, 2009, DEV PSYCHOBIOL, V51, P119, DOI 10.1002/dev.20351; HUNTER DJ, 1988, AM J EPIDEMIOL, V127, P1240, DOI 10.1093/oxfordjournals.aje.a114916; Hutter I, 1996, TROP MED INT HEALTH, V1, P399, DOI 10.1046/j.1365-3156.1996.d01-53.x; Kelly A, 1996, INT J GYNECOL OBSTET, V53, P219, DOI 10.1016/0020-7292(96)02652-5; Kigutha NH, 1997, AM J CLIN NUTR, V65, p68S; Kiserud T, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002220; KRAMER MS, 1989, PEDIATRICS, V84, P717; Lagiou P, 2004, EUR J CLIN NUTR, V58, P231, DOI 10.1038/sj.ejcn.1601771; Lassale C, 2009, J HUM NUTR DIET, V22, P559, DOI 10.1111/j.1365-277X.2009.00990.x; LAWRENCE M, 1987, LANCET, V2, P1072, DOI 10.1016/S0140-6736(87)91492-9; Lennox J, 2017, GHRP, V2, P1, DOI [10.1186/s41256-017-0028-922., DOI 10.1186/S41256-017-0028-922]; Low FM, 2012, EVOL BIOL, V39, P650, DOI 10.1007/s11692-011-9157-0; Lukmanji Z., 2008, TANZANIA FOOD COMPOS; Martin H, 2014, AM J RES COMM, V2, P12; McCabe JT, 2010, HUM ECOL, V38, P322, DOI 10.1007/s10745-010-9312-8; Merchant KM, 2001, BRIT J OBSTET GYNAEC, V108, P689, DOI 10.1111/j.1471-0528.2001.00181.x; Michels KB, 2005, AM J EPIDEMIOL, V161, P987, DOI 10.1093/aje/kwi115; Miller LC, 2016, PAEDIATR INT CHILD H, V36, P91, DOI 10.1080/20469047.2015.1133517; Moore SE, 1999, INT J EPIDEMIOL, V28, P1088, DOI 10.1093/ije/28.6.1088; Mpoke S, 1993, West J Nurs Res, V15, P298, DOI 10.1177/019394599301500303; Natale V, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-003735; NESTEL PS, 1989, ECOL FOOD NUTR, V23, P17, DOI 10.1080/03670244.1989.9991085; NICHTER M, 1983, HUM ORGAN, V42, P235, DOI 10.17730/humo.42.3.43081445235366lk; Peleg D, 1998, AM FAM PHYSICIAN, V58, P453; Peng YM, 2005, ACTA PAEDIATR, V94, P843, DOI 10.1080/08035250510027589; POOL R, 1987, SOC SCI MED, V25, P389, DOI 10.1016/0277-9536(87)90277-2; Powell CD, 2012, THESIS; PRENTICE AM, 1989, BRIT J NUTR, V62, P5, DOI 10.1079/BJN19890004; RAO M, 1985, ECOL FOOD NUTR, V16, P93, DOI 10.1080/03670244.1985.9990852; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; Risnes KR, 2011, INT J EPIDEMIOL, V40, P647, DOI 10.1093/ije/dyq267; Rock M, 2009, SOC SCI MED, V68, P991, DOI 10.1016/j.socscimed.2008.12.047; Rosenberg K, 2002, BJOG-INT J OBSTET GY, V109, P1199, DOI 10.1046/j.1471-0528.2002.00010.x; Rosenberg Karen, 1995, Evolutionary Anthropology, V4, P161, DOI 10.1002/evan.1360040506; Samuelsen GB, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.02.011; Savitri AI, 2014, BRIT J NUTR, V112, P1503, DOI 10.1017/S0007114514002219; SIBERT JR, 1978, BRIT MED J, V1, P1517, DOI 10.1136/bmj.1.6126.1517; Skull SA, 1997, MED J AUSTRALIA, V166, P412, DOI 10.5694/j.1326-5377.1997.tb123191.x; SOBELL J, 1989, AM J EPIDEMIOL, V130, P173, DOI 10.1093/oxfordjournals.aje.a115310; Solomon B, 1991, ILCA SYSTEMS STUDY; Spear Thomas, 1993, BEING MAASAI ETHNICI; Sutter K, 1997, Pediatr Nurs, V23, P485; THOMPSON FE, 1994, J NUTR, V124, pS2245, DOI 10.1093/jn/124.suppl_11.2245s; van Assema P, 2001, J HUM NUTR DIET, V14, P377, DOI 10.1046/j.1365-277X.2001.00310.x; van den Broek AJM, 2010, EARLY HUM DEV, V86, P379, DOI 10.1016/j.earlhumdev.2010.04.007; VANSELST M, 1994, Q J EXP PSYCHOL-A, V47, P631, DOI 10.1080/14640749408401131; von Mitzlaff U, 1994, MAASAI WOMEN LIFE PA; Walker SP, 2007, EARLY HUM DEV, V83, P355, DOI 10.1016/j.earlhumdev.2006.07.006; Wang KCW, 2012, CLIN EXP PHARMACOL P, V39, P958, DOI 10.1111/j.1440-1681.2012.05743.x; Wang ST, 1998, PUBLIC HEALTH, V112, P331, DOI 10.1038/sj.ph.1900482; Wells JCK, 2015, PHILOS T R SOC B, V370, DOI 10.1098/rstb.2014.0067; Wells JCK, 2012, AM J PHYS ANTHROPOL, V149, P40, DOI 10.1002/ajpa.22160; WHO Multicentre Growth Reference Study Group, 2007, WHO CHILD GROWTH STA, DOI 10.1093/tropej/fmn002; Yaroch AL, 2000, J AM DIET ASSOC, V100, P1050, DOI 10.1016/S0002-8223(00)00306-0; Young S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041934; Zinsstag J, 2006, TROP MED INT HEALTH, V11, P565, DOI 10.1111/j.1365-3156.2006.01615.x	89	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2020	15	9							e0237700	10.1371/journal.pone.0237700	http://dx.doi.org/10.1371/journal.pone.0237700			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NX4NF	32966295	Green Published, gold			2023-01-03	WOS:000575688700014
J	Lecocq, T; Hicks, SP; Van Noten, K; van Wijk, K; Koelemeijer, P; De Plaen, RSM; Massin, F; Hillers, G; Anthony, RE; Apoloner, MT; Arroyo-Solorzano, M; Assink, JD; Buyukakpinar, P; Cannata, A; Cannavo, F; Carrasco, S; Caudron, C; Chaves, EJ; Cornwell, DG; Craig, D; den Ouden, OFC; Diaz, J; Donner, S; Evangelidis, CP; Evers, L; Fauville, B; Fernandez, GA; Giannopoulos, D; Gibbons, SJ; Girona, T; Grecu, B; Grunberg, M; Hetenyi, G; Horleston, A; Inza, A; Irving, JCE; Jamalreyhani, M; Kafka, A; Koymans, MR; Labedz, CR; Larose, E; Lindsey, NJ; McKinnon, M; Megies, T; Miller, MS; Minarik, W; Moresi, L; Marquez-Ramirez, VH; Mollhoff, M; Nesbitt, IM; Niyogi, S; Ojeda, J; Oth, A; Proud, S; Pulli, J; Retailleau, L; Rintamaki, AE; Satriano, C; Savage, MK; Shani-Kadmiel, S; Sleeman, R; Sokos, E; Stammler, K; Stott, AE; Subedi, S; Sorensen, MB; Taira, T; Tapia, M; Turhan, F; van der Pluijm, B; Vanstone, M; Vergne, J; Vuorinen, TAT; Warren, T; Wassermann, J; Xiao, H				Lecocq, Thomas; Hicks, Stephen P.; Van Noten, Koen; van Wijk, Kasper; Koelemeijer, Paula; De Plaen, Raphael S. M.; Massin, Frederick; Hillers, Gregor; Anthony, Robert E.; Apoloner, Maria-Theresia; Arroyo-Solorzano, Mario; Assink, Jelle D.; Bueyuekakpinar, Pinar; Cannata, Andrea; Cannavo, Flavio; Carrasco, Sebastian; Caudron, Corentin; Chaves, Esteban J.; Cornwell, David G.; Craig, David; den Ouden, Olivier F. C.; Diaz, Jordi; Donner, Stefanie; Evangelidis, Christos P.; Evers, Laslo; Fauville, Benoit; Fernandez, Gonzalo A.; Giannopoulos, Dimitrios; Gibbons, Steven J.; Girona, Tarsilo; Grecu, Bogdan; Grunberg, Marc; Hetenyi, Gyorgy; Horleston, Anna; Inza, Adolfo; Irving, Jessica C. E.; Jamalreyhani, Mohammadreza; Kafka, Alan; Koymans, Mathijs R.; Labedz, Celeste R.; Larose, Eric; Lindsey, Nathaniel J.; McKinnon, Mika; Megies, Tobias; Miller, Meghan S.; Minarik, William; Moresi, Louis; Marquez-Ramirez, Victor H.; Mollhoff, Martin; Nesbitt, Ian M.; Niyogi, Shankho; Ojeda, Javier; Oth, Adrien; Proud, Simon; Pulli, Jay; Retailleau, Lise; Rintamaki, Annukka E.; Satriano, Claudio; Savage, Martha K.; Shani-Kadmiel, Shahar; Sleeman, Reinoud; Sokos, Efthimios; Stammler, Klaus; Stott, Alexander E.; Subedi, Shiba; Sorensen, Mathilde B.; Taira, Taka'aki; Tapia, Mar; Turhan, Fatih; van der Pluijm, Ben; Vanstone, Mark; Vergne, Jerome; Vuorinen, Tommi A. T.; Warren, Tristram; Wassermann, Joachim; Xiao, Han			Global quieting of high-frequency seismic noise due to COVID-19 pandemic lockdown measures	SCIENCE			English	Article							AUCKLAND VOLCANIC FIELD; POWER SPECTRA; OBSPY	Human activity causes vibrations that propagate into the ground as high-frequency seismic waves. Measures to mitigate the coronavirus disease 2019 (COVID-19) pandemic caused widespread changes in human activity, leading to a months-long reduction in seismic noise of up to 50%. The 2020 seismic noise quiet period is the longest and most prominent global anthropogenic seismic noise reduction on record. Although the reduction is strongest at surface seismometers in populated areas, this seismic quiescence extends for many kilometers radially and hundreds of meters in depth. This quiet period provides an opportunity to detect subtle signals from subsurface seismic sources that would have been concealed in noisier times and to benchmark sources of anthropogenic noise. A strong correlation between seismic noise and independent measurements of human mobility suggests that seismology provides an absolute, real-time estimate of human activities.	[Lecocq, Thomas; Van Noten, Koen] Royal Observ Belgium, Seismol Gravimetry, Brussels, Belgium; [Hicks, Stephen P.] Imperial Coll London, Dept Earth Sci & Engn, London, England; [van Wijk, Kasper] Univ Auckland, Dept Phys, Auckland, New Zealand; [Koelemeijer, Paula] Royal Holloway Univ London, Dept Earth Sci, Egham, Surrey, England; [De Plaen, Raphael S. M.; Marquez-Ramirez, Victor H.] Univ Nacl Autonoma Mexico, Ctr Geociencias, Campus Juriquilla, Queretaro, Mexico; [Massin, Frederick] Swiss Fed Inst Technol, Swiss Seismol Serv, Zurich, Switzerland; [Hillers, Gregor; Rintamaki, Annukka E.; Vuorinen, Tommi A. T.] Univ Helsinki, Inst Seismol, Helsinki, Finland; [Anthony, Robert E.] US Geol Survey, Albuquerque Seismol Lab, Albuquerque, NM USA; [Apoloner, Maria-Theresia] Zentralanstalt Meteorol & Geodynam ZAMG, Vienna, Austria; [Arroyo-Solorzano, Mario] Univ Costa Rica, Escuela Ctr Amer Geol, San Jose, Costa Rica; [Assink, Jelle D.; den Ouden, Olivier F. C.; Evers, Laslo; Koymans, Mathijs R.; Sleeman, Reinoud] Royal Netherlands Meteorol Inst KNMI, R&D Seismol & Acoust, De Bilt, Netherlands; [Bueyuekakpinar, Pinar; Turhan, Fatih] Bogazici Univ, Kandilli Observ, Istanbul, Turkey; [Bueyuekakpinar, Pinar; Turhan, Fatih] Bogazici Univ, Earthquake Res Inst, Istanbul, Turkey; [Bueyuekakpinar, Pinar; Jamalreyhani, Mohammadreza] GFZ German Res Ctr Geosci, Potsdam, Germany; [Cannata, Andrea] Univ Catania, Dipartimento Sci Biol Geol & Ambientali, Catania, Italy; [Cannata, Andrea; Cannavo, Flavio] Osservatorio Etneo, Ist Nazl Geofis & Vulcanol, Catania, Italy; [Carrasco, Sebastian] Univ Cologne, Bensberg Observ, Cologne, Germany; [Caudron, Corentin; Larose, Eric] Univ Grenoble Alpes, IFSTTAR, CNRS,IRD, Univ Savoie Mt Blanc,ISTerre, Grenoble, France; [Chaves, Esteban J.] Univ Natl OVSICORI UNA, Volcanol & Seismol Observ Costa Rica, Heredia, Costa Rica; [Cornwell, David G.] Univ Aberdeen, Kings Coll, Sch Geosci, Dept Geol & Geophys, Aberdeen, Scotland; [Craig, David; Mollhoff, Martin] Dublin Inst Adv Studies, Geophys Sect, Dublin, Ireland; [den Ouden, Olivier F. C.; Evers, Laslo; Koymans, Mathijs R.; Shani-Kadmiel, Shahar] Delft Univ Technol, Dept Geosci & Engn, Delft, Netherlands; [Diaz, Jordi] CSIC, Geosci Barcelona, Barcelona, Spain; [Donner, Stefanie; Stammler, Klaus] Fed Inst Geosci & Nat Resources BGR, Hannover, Germany; [Evangelidis, Christos P.] Natl Observ Athens, Inst Geodynam, Athens, Greece; [Fauville, Benoit] Brussels Environm, Noise Dept, Brussels, Belgium; [Fernandez, Gonzalo A.] Observ San Calixto, La Paz, Bolivia; [Giannopoulos, Dimitrios] Seismotech SA, Athens, Greece; [Giannopoulos, Dimitrios; Kafka, Alan] Hellen Mediterranean Univ, Dept Environm & Nat Resources Engn, Lab Geophys & Seismol, Khania, Greece; [Gibbons, Steven J.] Norges Geotekniske Inst, Oslo, Norway; [Girona, Tarsilo] Univ Alaska Fairbanks, Inst Geophys, Fairbanks, AK 99775 USA; [Grecu, Bogdan] Natl Inst Earth Phys, Magurele, Romania; [Grunberg, Marc] Univ Strasbourg, CNRS, Reseau Natl Surveillance Sism RENASS, EOST UMS830, Strasbourg, France; [Hetenyi, Gyorgy; Subedi, Shiba] Univ Lausanne, Fac Geosci & Environm, Inst Earth Sci, Lausanne, Switzerland; [Horleston, Anna; Irving, Jessica C. E.] Univ Bristol, Sch Earth Sci, Queens Rd, Bristol, Avon, England; [Inza, Adolfo] Inst Geofis Peru, Lima, Peru; [Irving, Jessica C. E.] Princeton Univ, Dept Geosci, Princeton, NJ 08544 USA; [Jamalreyhani, Mohammadreza] Univ Tehran, Inst Geophys, Tehran, Iran; [Pulli, Jay] Boston Coll, Dept Earth & Environm Sci, Weston Observ, Weston, MA USA; [Labedz, Celeste R.] CALTECH, Seismol Lab, Pasadena, CA 91125 USA; [Lindsey, Nathaniel J.] Stanford Univ, Dept Phys, Stanford, CA 94305 USA; [McKinnon, Mika] SETI Inst, Mountain View, CA USA; [McKinnon, Mika] Univ British Columbia, Fac Sci, Dept Earth Ocean & Atmospher Sci, Vancouver, BC, Canada; [Megies, Tobias; Wassermann, Joachim] Ludwig Maximilians Univ Munchen, Munich, Germany; [Miller, Meghan S.; Moresi, Louis] Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT, Australia; [Minarik, William] McGill Univ, Dept Earth & Planetary Sci, Montreal, PQ, Canada; [Minarik, William] GEOTOP Res Ctr, Montreal, PQ, Canada; [Nesbitt, Ian M.] Raspberry Shake SA, Boquete, Chiriqui, Panama; [Nesbitt, Ian M.] Univ Maine, Dept Earth & Climate Sci, Orono, ME USA; [Niyogi, Shankho] Univ Calif Riverside, Riverside, CA 92521 USA; [Ojeda, Javier] Univ Chile, Dept Geofis, Santiago, Chile; [Oth, Adrien] European Ctr Geodynam & Seismol, Walferdange, Luxembourg; [Proud, Simon] Univ Oxford, Natl Ctr Earth Observat, Dept Phys, Oxford, England; [Pulli, Jay] Raytheon BBN Technol, Arlington, VA USA; [Retailleau, Lise; Satriano, Claudio] Univ Paris, Inst Phys Globe Paris, Paris, France; [Retailleau, Lise] Inst Phys Globe Paris, Observ Volcanol Piton de la Fournaise, La Plaine Des Cafres, France; [Savage, Martha K.] Victoria Univ Wellington, Sch Geog Environm & Earth Sci, Wellington, New Zealand; [Sokos, Efthimios] Univ Patras, Dept Geol, Patras, Greece; [Stott, Alexander E.] Imperial Coll London, Dept Elect & Elect Engn, South Kensington Campus, London, England; [Sorensen, Mathilde B.] Univ Bergen, Dept Earth Sci, Bergen, Norway; [Taira, Taka'aki] Univ Calif Berkeley, Berkeley Seismol Lab, Berkeley, CA 94720 USA; [Tapia, Mar] Inst Estudis Catalans LEGEF IEC, Lab Estudis Geofis Eduard Fontsere, Barcelona, Spain; [van der Pluijm, Ben] Univ Michigan, Dept Earth & Environm Sci, Ann Arbor, MI 48109 USA; [Vanstone, Mark] Truro Sch, Geol Dept, Truro, Cornwall, England; [Vergne, Jerome] Univ Strasbourg, Inst Phys Globe Strasbourg, CNRS, EOST,UMR 7516, Strasbourg, France; [Warren, Tristram] Univ Oxford, Dept Phys, Oxford, England; [Xiao, Han] Univ Calif Santa Barbara, Dept Earth Sci, Santa Barbara, CA 93106 USA; [Xiao, Han] Univ Calif Santa Barbara, Earth Res Inst, Santa Barbara, CA 93106 USA	Imperial College London; University of Auckland; University of London; Royal Holloway University London; Universidad Nacional Autonoma de Mexico; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Helsinki; United States Department of the Interior; United States Geological Survey; Universidad Costa Rica; Royal Netherlands Meteorological Institute; Bogazici University; Bogazici University; Helmholtz Association; Helmholtz-Center Potsdam GFZ German Research Center for Geosciences; University of Catania; Istituto Nazionale Geofisica e Vulcanologia (INGV); University of Cologne; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Gustave-Eiffel; Universite de Savoie; University of Aberdeen; Dublin Institute for Advanced Studies; Delft University of Technology; Consejo Superior de Investigaciones Cientificas (CSIC); National Observatory of Athens; Hellenic Mediterranean University; University of Alaska System; University of Alaska Fairbanks; National Institute for Earth Physics (NIEP); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Lausanne; University of Bristol; Princeton University; University of Tehran; Boston College; California Institute of Technology; Stanford University; University of British Columbia; University of Munich; Australian National University; McGill University; University of Maine System; University of Maine Orono; University of California System; University of California Riverside; Universidad de Chile; University of Oxford; Raytheon Technologies; Raytheon BBN Technologies; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Victoria University Wellington; University of Patras; Imperial College London; University of Bergen; University of California System; University of California Berkeley; University of Michigan System; University of Michigan; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Oxford; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara	Lecocq, T (corresponding author), Royal Observ Belgium, Seismol Gravimetry, Brussels, Belgium.	thomas.lecocq@seismology.be	Taira, Taka'aki/AHD-8524-2022; Satriano, Claudio/A-4718-2009; Massin, Frédérick/AAK-9207-2021; Minarik, William/F-5590-2013; Ojeda, Javier/B-1802-2019; Giannopoulos, Dimitrios/N-8501-2017; Hicks, Stephen P/I-7155-2012; Shani-Kadmiel, Shahar/ABG-5451-2020; Anthony, Rob/J-2212-2017; Grecu, Bogdan/G-1939-2010; Jamalreyhani, Mohammadreza/AAE-7013-2022; /AAV-3551-2021; Donner, Stefanie/ABG-1555-2021; Sokos, Efthimios/AAP-1226-2021; Evangelidis, Christos/AAE-3528-2019; Carrasco Morales, Sebastian/ABE-6275-2021; Taira, Taka'aki/L-5839-2013; Diaz, Jordi/A-8034-2008; Vergne, Jérôme/F-8592-2014; Gibbons, Steven J./AAV-5334-2020; Proud, Simon/A-4239-2015; Van Noten, Koen/B-4767-2012; Koelemeijer, Paula/J-5641-2013; Cornwell, David/A-9641-2011	Taira, Taka'aki/0000-0002-6170-797X; Satriano, Claudio/0000-0002-3039-2530; Massin, Frédérick/0000-0002-7532-5139; Minarik, William/0000-0001-5509-5543; Ojeda, Javier/0000-0002-7188-8356; Giannopoulos, Dimitrios/0000-0002-8314-0759; Hicks, Stephen P/0000-0002-7476-3284; Shani-Kadmiel, Shahar/0000-0003-2215-6164; Grecu, Bogdan/0000-0002-7662-996X; Jamalreyhani, Mohammadreza/0000-0003-4181-7175; Donner, Stefanie/0000-0001-7351-8079; Sokos, Efthimios/0000-0002-7742-7251; Evangelidis, Christos/0000-0001-8733-8984; Carrasco Morales, Sebastian/0000-0002-6207-8757; Taira, Taka'aki/0000-0002-6170-797X; Diaz, Jordi/0000-0003-1801-0541; Vergne, Jérôme/0000-0003-1731-9360; Gibbons, Steven J./0000-0002-7822-0244; Evers, Laslo/0000-0003-2825-6211; Miller, Meghan/0000-0001-5494-2296; Mollhoff, Martin/0000-0003-1848-1554; Irving, Jessica C.E./0000-0002-0866-8246; Sorensen, Mathilde Bottger/0000-0002-8589-7480; Anthony, Robert/0000-0001-7089-8846; Lecocq, Thomas/0000-0002-4988-6477; Proud, Simon/0000-0003-3880-6774; van wijk, kasper/0000-0003-4994-8030; Hillers, Gregor/0000-0003-2341-1892; Van Noten, Koen/0000-0001-8933-4426; Koelemeijer, Paula/0000-0001-5153-3040; Warren, Tristram/0000-0003-3877-0046; Oth, Adrien/0000-0003-4859-6504; Horleston, Anna/0000-0002-6748-6522; /0000-0001-5381-9042; Cornwell, David/0000-0002-9843-7811; Apoloner, Maria-Theresia/0000-0002-4006-1284; Vuorinen, Tommi/0000-0002-8186-012X; Sleeman, Reinoud/0000-0002-1928-5056; Grunberg, Marc/0000-0002-1307-7790; De Plaen, Raphael/0000-0003-3477-2001; Megies, Tobias/0000-0002-5033-9921; Buyukakpinar, Pinar/0000-0001-8461-674X; Nesbitt, Ian/0000-0001-5828-6070; Turhan, Fatih/0000-0003-4612-7421	Royal Society University Research Fellowship [URF\R1\180377]; International Training Course "Seismology and Seismic Hazard Assessment" - GeoForschungsZentrum Potsdam (GFZ); German Federal Foreign Office through the German Humanitarian Assistance program [S08-60 321.50 ALL 03/19]; Bogazici University Research Fund [BAP 15683]; Human Frontier Science Program (HFSP project) [RGY0072/2017]; VIDI project from the Dutch Research Council (NWO project) [864.14.005]; Air Force Technical Application Center (AFTAC); NSF [DGE-1745301]; UNAM-DGAPA postdoctoral scholarship; Agencia Nacional de Investigacion y Desarrollo (Scholarship ANID-PFCHA/Doctorado Nacional) [21200903]; Natural Environment Research Council [NE/R013144/1]; K.H. Renlund foundation; New Zealand Earthquake Commission (EQC project) [20796]; Multidisciplinary Research on the Coronavirus and its Impacts (MRCI) grant from UC Santa Barbara; AuScope; Belgian Federal Science Policy [SR/00/305]; Luxembourg National Research Fund; HELPOS Project "Hellenic Plate Observing System" [MIS 5002697]; CONACYT [299766]; NERC [NE/R013144/1, NE/V00946X/1] Funding Source: UKRI	Royal Society University Research Fellowship(Royal Society of London); International Training Course "Seismology and Seismic Hazard Assessment" - GeoForschungsZentrum Potsdam (GFZ); German Federal Foreign Office through the German Humanitarian Assistance program; Bogazici University Research Fund(Bogazici University); Human Frontier Science Program (HFSP project); VIDI project from the Dutch Research Council (NWO project); Air Force Technical Application Center (AFTAC); NSF(National Science Foundation (NSF)); UNAM-DGAPA postdoctoral scholarship; Agencia Nacional de Investigacion y Desarrollo (Scholarship ANID-PFCHA/Doctorado Nacional); Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC)); K.H. Renlund foundation; New Zealand Earthquake Commission (EQC project); Multidisciplinary Research on the Coronavirus and its Impacts (MRCI) grant from UC Santa Barbara; AuScope; Belgian Federal Science Policy(Belgian Federal Science Policy Office); Luxembourg National Research Fund(Luxembourg National Research Fund); HELPOS Project "Hellenic Plate Observing System"; CONACYT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); NERC(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))	P.K. was funded by a Royal Society University Research Fellowship (URF\R1\180377). P.B. and M.J. acknowledge support from the International Training Course "Seismology and Seismic Hazard Assessment" funded by the GeoForschungsZentrum Potsdam (GFZ) and the German Federal Foreign Office through the German Humanitarian Assistance program (grant S08-60 321.50 ALL 03/19). P.B. also acknowledges financial support from the Bogazici University Research Fund (BAP 15683). O.F.C.d.O acknowledges funding from a Young Investigator Grant from the Human Frontier Science Program (HFSP project RGY0072/2017). C.P.E. and E.S. acknowledge funding from the HELPOS Project "Hellenic Plate Observing System" (MIS 5002697). L.E. and S.S.-K. acknowledge funding from a VIDI project from the Dutch Research Council (NWO project 864.14.005). G.A.F. acknowledges contributions from the Observatorio San Calixto, which is supported by the Air Force Technical Application Center (AFTAC). C.R.L. acknowledges funding from the NSF Graduate Research Fellowship Program (grant DGE-1745301). V.-H.M. and R.D.P. acknowledge support from grant CONACYT-299766. R.D.P. acknowledges support from the UNAM-DGAPA postdoctoral scholarship. J.O. acknowledges support from the Agencia Nacional de Investigacion y Desarrollo (Scholarship ANID-PFCHA/Doctorado Nacional/2020-21200903). S.P. acknowledges financial support from the Natural Environment Research Council (NE/R013144/1). A.E.R. acknowledges support from the K.H. Renlund foundation. M.K.S. acknowledges the New Zealand Earthquake Commission (EQC project 20796). H.X. acknowledges support from a Multidisciplinary Research on the Coronavirus and its Impacts (MRCI) grant from UC Santa Barbara. The Australian Seismometers in Schools data used in this research are supported by AuScope, enabled by the Australian Commonwealth NCRIS program. A.O. acknowledges support from the project RESIST, funded by the Belgian Federal Science Policy (contract SR/00/305) and the Luxembourg National Research Fund.	AK: Alaska Earthquake Center U. O. A. F., 1987, AL REG NETW; Aktay A., ARXIV200404145CSCR; Aktay A., 2020, GOOGLE COVID 19 COMM; Anderson RM, 2020, LANCET, V395, P931, DOI 10.1016/S0140-6736(20)30567-5; Anthony R. E., 2020, SEISMOLOGICAL RES LE, V91, P3; Anthony RE, 2020, SEISMOL RES LETT, V91, P1694, DOI 10.1785/0220190212; Anthony RE, 2019, SEISMOL RES LETT, V90, P219, DOI 10.1785/0220180251; Ashenden CL, 2011, NAT HAZARDS, V59, P507, DOI 10.1007/s11069-011-9773-0; AU: Geoscience Australia (GA), 1994, GEOSCIENCE AUSTR; Bauwens M, 2020, GEOPHYS RES LETT, V47, DOI 10.1029/2020GL087978; BE: Royal Observatory of Belgium, 1985, BELG SEISM NETW; Beyreuther M, 2010, SEISMOL RES LETT, V81, P530, DOI 10.1785/gssrl.81.3.530; BK: Northern California Earthquake Data Center, 2014, BERK DIG SEISM NETW, DOI 10.7932/BDSN; BL: Universidade de Sao Paulo USP, 1988, BRAZ LITH SEISM PROJ; BLACKMAN RB, 1958, AT&T TECH J, V37, P185, DOI 10.1002/j.1538-7305.1958.tb03874.x; Boese CM, 2015, B SEISMOL SOC AM, V105, P285, DOI 10.1785/0120130288; Brenguier F, 2019, GEOPHYS RES LETT, V46, P9529, DOI 10.1029/2019GL083438; British Geological Survey, 1970, GREAT BRIT SEISM NET; British Geological Survey, 1970, GREAT BRIT SEISM NET; Brune JN., 1959, B SEISMOL SOC AM, V49, P349; BX: Department of Geological Survey of Botswana, 2001, BOTSW SEISM NETW BSN; Center for International Earth Science Information Network CIESIN Columbia University, GRIDD POP WORLD VERS; CESSARO RK, 1994, B SEISMOL SOC AM, V84, P142; CH: Swiss Seismological Service (SED) At ETH Zurich, 1983, NAT SEISM NETW SWITZ; Chinazzi M, 2020, SCIENCE, V368, P395, DOI 10.1126/science.aba9757; CN: Geological Survey of Canada, 1989, CAN NAT SEISM NETW; Cochran ES, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04790-9; Denton P, 2018, SEISMOL RES LETT, V89, P1902, DOI 10.1785/0220180078; Diaz J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15499-y; EI: INSN, 1993, IR NAT SEISM NETW OP; FR: RESIF, 1995, RESIF RLBP FRENCH BR; GB: British Geological Survey, 1970, GREAT BRIT SEISM NET; GO: Ilia State University- Seismic Monitoring Centre of Georgia (Georgia), 1988, NAT SEISM NETW GEORG; GR: Federal Institute for Geosciences and Natural Resources (BGR), 1976, GERM REG SEISM NETW, DOI 10.25928/mbx6-hr74; Green DN, 2017, SEISMOL RES LETT, V88, P113, DOI 10.1785/0220160128; Groos JC, 2009, GEOPHYS J INT, V179, P1213, DOI 10.1111/j.1365-246X.2009.04343.x; Gutenberg B., 1944, B SEISMOL SOC AM, V34, P185, DOI DOI 10.1785/BSSA0340040185; Hillers G, 2012, J GEOPHYS RES-SOL EA, V117, DOI 10.1029/2011JB008999; Hoque A., 2020, ASIAN J MULTIDISCIPL, V3, P52; Hunter JD, 2007, COMPUT SCI ENG, V9, P90, DOI 10.1109/MCSE.2007.55; IM, 1965, INT MISC STAT IMS; Institut de Physique du Globe de Paris, 1980, DAT US THIS STUD WER; Institut De Physique Du Globe De Paris (IPGP) & Ecole Et Observatoire Des Sciences De La Terre De Strasbourg (EOST), 1982, GEOSCOPE FRENCH GLOB, DOI [DOI 10.18715/GEOSCOPE.G, 10.18715/GEOSCOPE.G]; Kluyver T, 2016, POSITIONING AND POWER IN ACADEMIC PUBLISHING: PLAYERS, AGENTS AND AGENDAS, P87, DOI 10.3233/978-1-61499-649-1-87; Kraemer MUG, 2020, SCIENCE, V368, P493, DOI 10.1126/science.abb4218; Krischer Lion, 2015, Computational Science and Discovery, V8, DOI 10.1088/1749-4699/8/1/014003; Krischer L, 2018, SEISMOL RES LETT, V89, P2413, DOI 10.1785/0220180167; Lacassin R., 2020, GEOSCI COMMUN, V3, P129, DOI [10.5194/gc-3-129-2020, DOI 10.5194/GC-3-129-2020]; Laing T, 2020, EXTRACT IND SOC, V7, P580, DOI 10.1016/j.exis.2020.04.003; Lau H, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa037; LD: Lamont Doherty Earth Observatory (LDEO) Columbia University, 1970, LAM DOH EARTH OBS LD; Lecocq T., 2020, ZENODO, DOI [10.5281/zenodo.3944739., DOI 10.5281/ZENODO.3944739]; Lecocq T., 2020, ZENODO, DOI 10.5281/zenodo.3944739.; Lecocq T., 2020, SEISMORMS A SIMPLE P; Lehujeur M., 2015, GEOTHERM ENERGY, V3, DOI [10.1186/s40517-014-0020-2, DOI 10.1186/S40517-014-0020-2]; Lindsey NJ, 2020, GEOPHYS RES LETT, V47, DOI 10.1029/2020GL089931; McCall GJH, 1998, GEOL SOC ENG GEOL SP, P309; McNamara D. E., 2010, 20101292 US GEOL SUR; McNamara D. E., 2010, 20101292 US GEOL SUR, P41; McNamara DE, 2004, B SEISMOL SOC AM, V94, P1517, DOI 10.1785/012003001; Megies T, 2011, ANN GEOPHYS-ITALY, V54, P47, DOI 10.4401/ag-4838; MN: MedNet Project Partner Institutions, 1990, MED VER BROAD SEISM, DOI [10.13127/SD/fBBBtDtd6q, DOI 10.13127/SD/FBBBTDTD6Q]; MQ: Institut de Physique du Globe de Paris, 1935, DAT US THIS STUD WER; Nicola M, 2020, INT J SURG, V77, P206, DOI 10.1016/j.ijsu.2020.04.001; NL: KNMI, 1993, NETH SEISM AC NETW, DOI 10.21944/e970fd34-23b9-3411-b366-e4f72877d2c5; Picozzi M, 2009, GEOPHYS J INT, V176, P164, DOI 10.1111/j.1365-246X.2008.03966.x; Poli P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66368-0; Proud SR, 2020, AEROSPACE-BASEL, V7, DOI 10.3390/aerospace7020016; PT: Pacific Tsunami Warning Center, 1965, PAC TSUN WARN SEISM; QGIS Development Team, 2020, QGIS VERS 3 16 HANN; QM: Bureau de Recherches Geologiques et Minieres (BRGM), 2019, COM SEISM NETW COM S; Raspberry Shake Community, 2016, RASPB SHAK COMM 2; Riahi N, 2015, GEOPHYS RES LETT, V42, P2674, DOI 10.1002/2015GL063558; Ross ZE, 2019, SCIENCE, V364, P767, DOI 10.1126/science.aaw6888; Schafer M, 2014, PROCEEDINGS OF THE 13TH INTERNATIONAL SYMPOSIUM ON INFORMATION PROCESSING IN SENSOR NETWORKS (IPSN' 14), P83, DOI 10.1109/IPSN.2014.6846743; Scripps Institution of Oceanography, 1986, IRIS IDA SEISM NETW; Shapiro NM, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019491; Sherburn S, 2007, NEW ZEAL J GEOL GEOP, V50, P1, DOI 10.1080/00288300709509814; Sohrabi C, 2020, INT J SURG, V76, P71, DOI 10.1016/j.ijsu.2020.02.034; Subedi S, 2020, FRONT EARTH SC-SWITZ, V8, DOI 10.3389/feart.2020.00073; Tian HY, 2020, SCIENCE, V368, P638, DOI 10.1126/science.abb6105; WELCH PD, 1967, IEEE T ACOUST SPEECH, VAU15, P70, DOI 10.1109/TAU.1967.1161901; Wilson D, 2002, B SEISMOL SOC AM, V92, P3335, DOI 10.1785/0120010234; Xiao H, 2020, SEISMOL RES LETT, V91, P2757, DOI 10.1785/0220200147; Zhang JJ, 2020, SCIENCE, V368, P1481, DOI 10.1126/science.abb8001; Zurn W, 2007, GEOPHYS J INT, V171, P780, DOI 10.1111/j.1365-246X.2007.03553.x	86	131	136	17	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 11	2020	369	6509			SI		1338	1343		10.1126/science.abd2438	http://dx.doi.org/10.1126/science.abd2438			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NO9YB	32703907	Green Submitted			2023-01-03	WOS:000569840300046
J	Moustaqim-Barrette, A; Papamihali, K; Mamdani, Z; Williams, S; Buxton, JA				Moustaqim-Barrette, Amina; Papamihali, Kristi; Mamdani, Zahra; Williams, Sierra; Buxton, Jane A.			Accessing Take-Home Naloxone in British Columbia and the role of community pharmacies: Results from the analysis of administrative data	PLOS ONE			English	Article							OPIOID OVERDOSE; PROGRAM	Introduction British Columbia's (BC) Take-Home Naloxone (THN) program provides naloxone to bystanders for use in cases of suspected opioid overdose. This study seeks to provide trends and analysis from the provincial BC THN program since inception in 2012 to the end of 2018. Materials and methods BC THN shipment and distribution records from 2012-2018 were retrieved. Frequency distributions were used to describe characteristics of individuals accessing the program. To evaluate correlates of distribution after the addition of hundreds of pharmacy distribution sites, an analytic sample was limited to records from 2018, and multivariate logistic regression was used to evaluate correlates of collecting naloxone at a pharmacy site. Results Since program inception to the end of 2018, there were 398,167 naloxone kits shipped to distribution sites, 149,999 kits reported distributed, and 40,903 kits reported used to reverse an overdose in BC. There was a significant increasing trend in the number of naloxone kits used to reverse an overdose over time (p<0.01), and more than 90% of kits that were reported used were distributed to persons at risk of an overdose. Individuals not personally at risk of overdose had higher odds of collecting naloxone at a pharmacy site, compared to other community sites (including harm reduction supply distribution sites, peer led organizations, drop-in centers, and supportive housing sites) (Adjusted Odds Ratio (AOR): 2.69; 95% CI: 2.50-2.90). Conclusions This study documents thousands of opioid overdose reversals facilitated through the BC THN program. While those at highest risk of overdose may preferentially access naloxone through community sites, naloxone distribution through pharmacies has allowed the BC THN program to expand dramatically, increasing naloxone availability through longer opening hours on evenings and weekends. and in rural and remote regions. A diversity of naloxone distribution sites and strategies is crucial to prevent rising opioid overdose deaths.	[Moustaqim-Barrette, Amina; Papamihali, Kristi; Mamdani, Zahra; Williams, Sierra; Buxton, Jane A.] BC Ctr Dis Control, Vancouver, BC, Canada; [Buxton, Jane A.] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada	University of British Columbia	Buxton, JA (corresponding author), BC Ctr Dis Control, Vancouver, BC, Canada.; Buxton, JA (corresponding author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.	jane.buxton@bccdc.ca		Moustaqim-Barrette, Amina/0000-0003-1601-1604; Williams, Sierra/0000-0002-1094-7324; Mamdani, Zahra/0000-0002-3158-9618	British Columbia Ministry of Health; Canadian Research Initiative in Substance Misuse (CRISM); Canadian Institute of Health Research (CIHR)	British Columbia Ministry of Health; Canadian Research Initiative in Substance Misuse (CRISM); Canadian Institute of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	The BC THN program is made possible with funding from the British Columbia Ministry of Health. Author AMB is supported by the Canadian Research Initiative in Substance Misuse (CRISM) and the Canadian Institute of Health Research (CIHR). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amina Moustaqim-Barrette, 2019, TAKE HOME NALOXONE R, P33; Amina Moustaqim-Barrette Tara Elton-Marshall, 2019, ENV SCAN NALOXONE AC; Andrea Woo, 2020, VIRUS MEASURES MAY B; [Anonymous], 2019, CANC DISCOV, V9, pOF3, DOI 10. 1158/2159-8290. CD-NB2018-158; [Anonymous], 2017, TRANSFUSION, V57, p3A; BC Centre for Disease Control, 2020, TRAIN RES; BC Centre on Substance Use (BCCSU), 2020, COVID 19 INF OP AG T; BC Coroners Service, ILL DRUG TOX DEATHS; Boyer EW, 2012, NEW ENGL J MED, V367, P146, DOI 10.1056/NEJMra1202561; Bozat-Emre S, 2018, HEALTH PROMOT CHRON, V38, P252, DOI 10.24095/hpcdp.38.6.06; Canada H, 2020, EX PRACT PHARM PRESC; Choremis B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223589; Coroners Service BC, 2019, ILL DRUG OV DEATHS B; Coroners Service of BC, 2020, ILL DRUG TOX DEATHS; Freeman LK, 2017, CAN J PUBLIC HEALTH, V108, pE398, DOI [10.17269/cjph.108.5989, 10.17269/CJPH.108.5989]; Health Canada, 2018, OV NAT DAT OP REL HA; Hosmer DW, 2013, WILEY SER PROBAB ST, P89; Irvine MA, 2019, ADDICTION, V114, P1602, DOI 10.1111/add.14664; Irvine MA, 2018, LANCET PUBLIC HEALTH, V3, pE218, DOI 10.1016/S2468-2667(18)30044-6; Kim HK, 2015, EXPERT OPIN DRUG SAF, V14, P1137, DOI 10.1517/14740338.2015.1037274; Leece PN, 2013, CAN J PUBLIC HEALTH, V104, pE200, DOI 10.17269/cjph.104.3788; Lindsay Bethany, 2020, CBC NEWS; McDonald R, 2016, ADDICTION, V111, P1177, DOI 10.1111/add.13326; Ministry of Health, CURR HLTH TOP PROV B; Pearce LA, 2019, INT J PRISON HEALTH, V15, P46, DOI 10.1108/IJPH-12-2017-0058; The R Foundation, 2019, R R PROJ STAT COMP; WHO, 2020, WHO ANNOUNCES COVID; Zahra Mamdani, 2019, EVALUATION BRIT COLU; Zaller ND, 2013, SUBST USE MISUSE, V48, P590, DOI 10.3109/10826084.2013.793355; Zhang ZH, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.02.15	30	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2020	15	9							e0238618	10.1371/journal.pone.0238618	http://dx.doi.org/10.1371/journal.pone.0238618			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NR9MU	32915834	gold, Green Published			2023-01-03	WOS:000571887500039
J	Solomons, L; Lee, JJY; Bruce, M; White, LD; Scott, A				Solomons, Lyndal; Lee, Jenny J. Y.; Bruce, Margaret; White, Lynita D.; Scott, Alex			Intramuscular stimulation vs sham needling for the treatment of chronic midportion Achilles tendinopathy: A randomized controlled clinical trial	PLOS ONE			English	Article							TOPICAL GLYCERYL TRINITRATE; PLATELET-RICH PLASMA; DOUBLE-BLIND; PAIN; ACUPUNCTURE; INJECTION; THERAPY; SPORTS	Background The insertion of filiform needles intramuscularly (a.k.a. intramuscular stimulation/dry needling) has been suggested as a possible treatment for various painful musculoskeletal conditions. Our aim was to answer the question, is intramuscular stimulation more effective than sham intramuscular stimulation/dry needling for the treatment of Achilles tendinopathy? Methods 52 participants with persistent midportion Achilles tendinopathy began and 46 completed one of three treatment protocols which were randomly assigned: (G3) a 12-week rehabilitation program of progressive tendon loading plus intramuscular stimulation (n = 25), (G2) the same rehabilitation program but with sham intramuscular stimulation (n = 19), or (G1) a reference group of rehabilitation program alone (as an additional control) (n = 8). Thea prioriprimary outcome measure was change in VISA-A score at 12 weeks-VISA-A was also measured at 6 weeks, and at 6 and 12 months. Secondary outcome measures include the proportion of patients who rated themselves as much or very much improved (%), dorsiflexion range of motion (degrees), and tendon thickness (mm). Results The study retention was 94% at 12 weeks and 88% at 1 year. VISA-A score improved in all three groups over time (p<0.0001), with no significant difference among the three groups in VISA-A score at the start of the study (mean +/- SD: G3 59 +/- 13, G2 57 +/- 17, G1 56 +/- 22), at 12 weeks (G3 76 +/- 14, G2 76 +/- 15, G1 82 +/- 11) or at any other timepoint. The percentage of patients who rated themselves as much or very much improved (i.e. treatment success) was not different after 12 weeks (G3 70%, G2 89%, G1 86% p = 0.94), or at 26 (p = 0.62) or 52 weeks (p = 0.71). No clinically significant effects of intervention group were observed in any of the secondary outcome measures. Conclusion The addition of intramuscular stimulation to standard rehabilitation for Achilles tendinopathy did not result in any improvement over the expected clinical benefit achieved with exercise-based rehabilitation alone.	[Solomons, Lyndal; White, Lynita D.; Scott, Alex] Univ British Columbia, Dept Phys Therapy, Vancouver, BC, Canada; [Solomons, Lyndal] Allan McGavin Sports Med Ctr, Vancouver, BC, Canada; [Lee, Jenny J. Y.; Scott, Alex] Vancouver Coastal Hlth Res Inst, Ctr Hip Hlth & Mobil, Vancouver, BC, Canada; [Bruce, Margaret] Kinet Rehabil Ctr, N Vancouver, BC, Canada; [White, Lynita D.] Tall Tree Physiotherapy & Hlth Ctr, Vancouver, BC, Canada	University of British Columbia; University of British Columbia; Vancouver Coastal Health Research Institute	Scott, A (corresponding author), Univ British Columbia, Dept Phys Therapy, Vancouver, BC, Canada.; Scott, A (corresponding author), Vancouver Coastal Hlth Res Inst, Ctr Hip Hlth & Mobil, Vancouver, BC, Canada.	ascott@mail.ubc.ca		Scott, Alex/0000-0003-0366-8404	University of British Columbia Chan Gunn Intramuscular Stimulation/Neruopathic Pain Research Fund [20R08223]; Physiotherapy Foundation of Canada [13-00162]	University of British Columbia Chan Gunn Intramuscular Stimulation/Neruopathic Pain Research Fund; Physiotherapy Foundation of Canada	Funding for the study was received by AS from the University of British Columbia Chan Gunn Intramuscular Stimulation/Neruopathic Pain Research Fund (20R08223) in two instalments one for the initial (pilot) phase and one for the follow-up (continuation) phase. https://istop.wildapricot.org/resources/Documents/IMSNeuropathic-Pain-Research-Application-Pkg.pdf Funding was also received by AS and LS from the Physiotherapy Foundation of Canada, 13-00162 https://physiotherapy.ca/make-an-impact The funders played no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alfredson H, 2005, KNEE SURG SPORT TR A, V13, P338, DOI 10.1007/s00167-004-0585-6; [Anonymous], 2011, MILLENNIUM J INT STU, V39, P607; ASTROM M, 1992, ACTA ORTHOP SCAND, V63, P631; Audette JF, 2004, AM J PHYS MED REHAB, V83, P368, DOI 10.1097/01.PHM.0000118037.61143.7C; Baltes TPA, 2017, KNEE SURG SPORT TR A, V25, P1817, DOI 10.1007/s00167-016-4062-9; Boesen AP, 2019, SCAND J MED SCI SPOR, V29, P1223, DOI 10.1111/sms.13450; Bussin ER, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015126; Challoumas D, 2019, BMJ OPEN SPORT EXERC, V5, DOI 10.1136/bmjsem-2019-000528; Costa ML, 2005, CLIN ORTHOP RELAT R, P199, DOI 10.1097/01.blo.0000180451.03425.48; Cox J, 2016, J ORTHOP SPORT PHYS, V46, P409, DOI 10.2519/jospt.2016.6270; de Vos RJ, 2010, JAMA-J AM MED ASSOC, V303, P144, DOI 10.1001/jama.2009.1986; Ebbesen BH, 2018, KNEE SURG SPORT TR A, V26, P2038, DOI 10.1007/s00167-017-4675-7; Eckenrode BJ, 2019, INT J SPORTS PHYS TH, V14, P945, DOI 10.26603/ijspt20190945; Florit D, 2019, J SPORT SCI MED, V18, P780; Fredberg U, 2004, SCAND J RHEUMATOL, V33, P94, DOI 10.1080/03009740310004126; Furlan AD, 2005, SPINE, V30, P944, DOI 10.1097/01.brs.0000158941.21571.01; Gunn C, 1990, ACUPUNCTURE SCI INT, V1, P168; GUNN C C, 1990, Annals of Sports Medicine, V5, P138; Gunn CC., 1996, GUNN APPROACH TREATM; Hsieh YL, 2011, ARCH PHYS MED REHAB, V92, P1098, DOI 10.1016/j.apmr.2010.11.018; Kane TPC, 2008, AM J SPORT MED, V36, P1160, DOI 10.1177/0363546508314423; Kearney RS, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010960.pub2; Konor MM, 2012, INT J SPORTS PHYS TH, V7, P279; Krogh TP, 2016, AM J SPORT MED, V44, P1990, DOI 10.1177/0363546516647958; Kujala UM, 2005, CLIN J SPORT MED, V15, P133, DOI 10.1097/01.jsm.0000165347.55638.23; Martin RL, 2018, J ORTHOP SPORT PHYS, V48, pA1, DOI 10.2519/jospt.2018.0302; Murphy M, 2018, INT J SPORTS PHYS TH, V13, P283, DOI 10.26603/ijspt20180283; Murphy M, 2018, SPORTS MED, V48, P1875, DOI 10.1007/s40279-018-0932-2; Paoloni JA, 2004, J BONE JOINT SURG AM, V86A, P916, DOI 10.2106/00004623-200405000-00005; Plinsinga ML, 2018, BRIT J SPORT MED, V52, P284, DOI 10.1136/bjsports-2016-097163; Rasmussen S, 2008, ACTA ORTHOP, V79, P249, DOI 10.1080/17453670710015058; Rio EK, 2020, BRIT J SPORT MED, V54, P627, DOI 10.1136/bjsports-2019-100957; Schubert TEO, 2005, ANN RHEUM DIS, V64, P1083, DOI 10.1136/ard.2004.029876; Scott A, 2013, BRIT J SPORT MED, V47, P536, DOI 10.1136/bjsports-2013-092329; Shah JP, 2005, J APPL PHYSIOL, V99, P1977, DOI 10.1152/japplphysiol.00419.2005; Tompra N, 2016, BRIT J SPORT MED, V50, P1004, DOI 10.1136/bjsports-2015-095476; Toner P, 2010, PAC PHILOS QUART, V91, P587, DOI 10.1111/j.1468-0114.2010.01379.x; Tran PHT, 2020, FASEB J, V34, P776, DOI 10.1096/fj.201901309R; Vahdatpour B, 2018, J RES MED SCI, V23, DOI 10.4103/jrms.JRMS_413_16; van der Vlist AC, 2019, BRIT J SPORT MED, V53, P1352, DOI 10.1136/bjsports-2018-099991; Zhang BM, 2013, CHIN J INTEGR MED, V19, P900, DOI 10.1007/s11655-012-1218-4; Zhou W, 2014, J ACUPUNCT MERIDIAN, V7, P186, DOI 10.1016/j.jams.2014.02.008; Ziaeifar M, 2014, J BODYW MOV THER, V18, P298, DOI 10.1016/j.jbmt.2013.11.004	43	6	6	3	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2020	15	9							e0238579	10.1371/journal.pone.0238579	http://dx.doi.org/10.1371/journal.pone.0238579			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ6EE	32898170	gold, Green Published			2023-01-03	WOS:000570962500013
J	Jacobi, CJ; Thiel, D; Allum, N				Jacobi, Christopher Justin; Thiel, Darren; Allum, Nick			Enabling and constraining successful reablement: Individual and neighbourhood factors	PLOS ONE			English	Article							HOME-CARE REABLEMENT; SOCIOECONOMIC-STATUS; OLDER-ADULTS; HEALTH; DEPRIVATION; PROGRAM; SERVICE; INCOME; FRAIL; EXPERIENCES	Using multilevel logistic regression to analyse management data of reablement episodes collected by Essex County Council, a UK local authority, this article identifies constraining and enabling factors for successful reablement. Overall, 59.5% of reablement clients were classed as able to care for themselves when assessed after 13 weeks following the reablement intervention (N = 8,118). Several age-related, disability, referral, and social factors were found to constrain reablement, but some of the largest constraining effects were neighbourhood deprivation as measured through the Index of Multiple Deprivation and, particularly, unfavourable geodemographic profiles as measured through Experian Mosaic consumer classifications. The results suggest that in order to optimise reablement, programmes should consider broader social and environmental influences on reablement rather than only individual and organisational aspects. Reablement might also be better tailored and intensified for client groups with particular underlying disabilities and for those displaying specific geodemographic characteristics.	[Jacobi, Christopher Justin] Univ Oxford, Nuffield Coll, Dept Sociol, Oxford, Oxon, England; [Thiel, Darren; Allum, Nick] Univ Essex, Dept Sociol, Colchester, Essex, England	University of Oxford; University of Essex	Jacobi, CJ (corresponding author), Univ Oxford, Nuffield Coll, Dept Sociol, Oxford, Oxon, England.	chris.jacobi@nuffield.ox.ac.uk	thiel, darren/GQZ-1552-2022	Thiel, Darren/0000-0003-4531-5420; Jacobi, Christopher Justin/0000-0002-0752-8428	University of Essex [FR1213187, 1368980]	University of Essex	Funding for initial analyses of the dataset was provided by an internal grant from the University of Essex under its Frontrunner Scheme (https://www1.essex.ac.uk/frontrunners/).The award (FR1213187) was jointly hosted and managed by DT (Department of Sociology). CJJ was selected as the recipient of the student funds of the award. All co-authors were all based at the University of Essex at the beginning of the project. CJJ's ESRC studentship grant (1368980) at the University of Oxford supported training in statistical methods. The funding bodies did not play any role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. There was no additional external funding received for this study.	Adler NE, 1999, ANN NY ACAD SCI, V896, P3, DOI 10.1111/j.1749-6632.1999.tb08101.x; [Anonymous], 2002, Aging Male, V5, P1; Aspinal F, 2016, AGE AGEING, V45, P574, DOI 10.1093/ageing/afw094; Avellar S, 2007, EFFECTS MARRIAGE HLT; Beresford B, 2019, HEALTH SOC CARE COMM, V27, P1438, DOI 10.1111/hsc.12814; Berkman LF., 2003, NEIGHBORHOODS HLTH; Bernard P, 2007, SOC SCI MED, V65, P1839, DOI 10.1016/j.socscimed.2007.05.037; Bodker MN, 2019, SOCIOL HEALTH ILL, V41, P1358, DOI 10.1111/1467-9566.12946; Bodker MN, 2019, HEALTH SOC CARE COMM, V27, pE871, DOI 10.1111/hsc.12815; Bragstad Line Kildal, 2012, Int J Integr Care, V12, pe4; Cochrane A, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010825.pub2; Diez-Roux AV, 1998, AM J PUBLIC HEALTH, V88, P216, DOI 10.2105/AJPH.88.2.216; Doh D, 2020, AGEING SOC, V40, P1371, DOI 10.1017/S0144686X18001770; Duran AC, 2013, HEALTH PLACE, V23, P39, DOI 10.1016/j.healthplace.2013.05.001; Eliassen M, 2019, J INTERPROF CARE, V33, P512, DOI 10.1080/13561820.2018.1541877; FEINSTEIN JS, 1993, MILBANK Q, V71, P279, DOI 10.2307/3350401; Fransham M, 2019, APPL SPAT ANAL POLIC, V12, P275, DOI 10.1007/s12061-017-9242-6; Gelman A, 2008, STAT MED, V27, P2865, DOI 10.1002/sim.3107; Gill TM, 2002, NEW ENGL J MED, V347, P1068, DOI 10.1056/NEJMoa020423; Gitlin LN, 2006, J AM GERIATR SOC, V54, P809, DOI 10.1111/j.1532-5415.2006.00703.x; Glendinning C., 2010, HOME CARE REABLEMENT; Glendinning C, 2008, J INTEGR CARE, V16, P32, DOI 10.1108/14769018200800031; Hjelle KM, 2017, HEALTH SOC CARE COMM, V25, P1581, DOI 10.1111/hsc.12324; Hjelle KM, 2016, J MULTIDISCIP HEALTH, V9, P575, DOI 10.2147/JMDH.S115588; Hu FW, 2020, GERIATR GERONTOL INT, V20, P436, DOI 10.1111/ggi.13891; Jeon YH, 2018, INT PSYCHOGERIATR, V30, P915, DOI 10.1017/S1041610217001533; Johnson NJ, 2000, ANN EPIDEMIOL, V10, P224, DOI 10.1016/S1047-2797(99)00052-6; Jokela M, 2015, J EPIDEMIOL COMMUN H, V69, P899, DOI 10.1136/jech-2014-204513; Jokstad K, 2019, HEALTH SOC CARE COMM, V27, P907, DOI 10.1111/hsc.12708; Kennedy BP, 1998, BRIT MED J, V317, P917; King AII, 2012, HEALTH SOC CARE COMM, V20, P365, DOI 10.1111/j.1365-2524.2011.01039.x; Langeland E, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1038-x; Legg L, 2016, CLIN REHABIL, V30, P741, DOI 10.1177/0269215515603220; Lewin G, 2014, HEALTH SOC CARE COMM, V22, P328, DOI 10.1111/hsc.12092; Lewin G, 2013, HEALTH SOC CARE COMM, V21, P69, DOI 10.1111/j.1365-2524.2012.01088.x; Lewin Gill F, 2013, Clin Interv Aging, V8, P1273, DOI 10.2147/CIA.S49164; Liaaen J, 2019, INT J OLDER PEOPLE N, V14, DOI 10.1111/opn.12270; Limited Experian, 2007, EXP DEM DAT 2004 200; Limited Experian, 2004, MOSAIC UK CONS CLASS; Malomo F, 2018, OCEAN COAST MANAGE, V151, P92, DOI 10.1016/j.ocecoaman.2017.10.018; Markle-Reid M, 2006, J ADV NURS, V54, P381, DOI 10.1111/j.1365-2648.2006.03817.x; Michael Stepner, 2017, MAPTILE STATA MODULE; Moe A, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2715-0; Moe C, 2018, HEALTH SOC CARE COMM, V26, P113, DOI 10.1111/hsc.12471; Moon G, 2019, SOC SCI MED, V227, P47, DOI 10.1016/j.socscimed.2018.06.029; MOSAIC E, 2010, EXPERIAN MOSAIC; Newbronner L, 2007, RES LONGER TERM EFFE; Nnoaham KE, 2010, J PUBLIC HEALTH-UK, V32, P572, DOI 10.1093/pubmed/fdq025; Noble M, 2006, ENVIRON PLANN A, V38, P169, DOI 10.1068/a37168; O'Campo P, 2009, HEALTH PLACE, V15, P56, DOI 10.1016/j.healthplace.2008.02.004; Pickett KE, 2001, J EPIDEMIOL COMMUN H, V55, P111, DOI 10.1136/jech.55.2.111; Pilkington G., 2013, J CARE SERVICES MANA, V2, P354, DOI [10.1179/csm.2008.2.4.354, DOI 10.1179/CSM.2008.2.4.354]; Plane J, 2013, SOC SCI MED, V99, P1, DOI 10.1016/j.socscimed.2013.10.008; Pooley A, 2017, ALMSHOUSE REIMAGINED; Poulos Christopher J, 2017, Alzheimers Dement (N Y), V3, P450, DOI 10.1016/j.trci.2017.06.005; Reidy H., 2013, EVALUATION SOUTHWARK; Robles TF, 2003, PHYSIOL BEHAV, V79, P409, DOI 10.1016/S0031-9384(03)00160-4; ROUX AVD, 2003, NEIGHBORHOODS HLTH, P45, DOI DOI 10.1093/ACPROF:OSO/9780195138382.003.0003; Ryburn B, 2009, HEALTH SOC CARE COMM, V17, P225, DOI 10.1111/j.1365-2524.2008.00809.x; Sharma A, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-755; Sims-Gould J, 2017, J AM MED DIR ASSOC, V18, P653, DOI 10.1016/j.jamda.2016.12.070; Slater P, 2018, J INTEGR CARE, V26, P140, DOI 10.1108/JICA-11-2017-0042; Tessier Annie, 2016, Healthc Policy, V11, P49; Tinetti ME, 2002, JAMA-J AM MED ASSOC, V287, P2098, DOI 10.1001/jama.287.16.2098; UK Department of Health, 2012, CARING FOR OUR FUTUR; Wami WM, 2019, HEALTH PLACE, V57, P238, DOI 10.1016/j.healthplace.2019.05.005; Warwickshire Observatory, 2012, US MOS BETT UND HOUS; Webber R., 2001, J TARGETING MEASUREM, V10, P55; Wilde A, 2012, HEALTH SOC CARE COMM, V20, P583, DOI 10.1111/j.1365-2524.2012.01072.x; Williams R, 2012, STATA J, V12, P308, DOI 10.1177/1536867X1201200209; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816	71	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 4	2020	15	9							e0237432	10.1371/journal.pone.0237432	http://dx.doi.org/10.1371/journal.pone.0237432			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NQ7QN	32886657	Green Accepted, Green Submitted, Green Published, gold			2023-01-03	WOS:000571064300033
J	Cooper, HLF; Cloud, DH; Young, AM; Freeman, PR				Cooper, Hannah L. F.; Cloud, David H.; Young, April M.; Freeman, Patricia R.			When Prescribing Isn't Enough - Pharmacy-Level Barriers to Buprenorphine Access	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Cooper, Hannah L. F.; Cloud, David H.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Social & Hlth Educ Sci, Atlanta, GA 30322 USA; [Young, April M.] Univ Kentucky, Dept Epidemiol, Coll Publ Hlth, Lexington, KY 40506 USA; [Freeman, Patricia R.] Univ Kentucky, Coll Pharm, Dept Pharm Practice & Sci, Lexington, KY 40506 USA	Emory University; Rollins School Public Health; University of Kentucky; University of Kentucky	Cooper, HLF (corresponding author), Emory Univ, Rollins Sch Publ Hlth, Dept Behav Social & Hlth Educ Sci, Atlanta, GA 30322 USA.		Young, April/I-9518-2012	Young, April/0000-0003-3969-3249				[Anonymous], 2017, TRANSFUSION, V57, p3A; Cooper HL, 2020, INT J DRUG POLICY, DOI DOI 10.1186/s13722-014-0023-0; Hagemeier NE, 2014, RES SOC ADMIN PHARM, V10, P562, DOI 10.1016/j.sapharm.2013.07.004; Ventricelli DJ, 2020, SUBST USE MISUSE, V55, P349, DOI 10.1080/10826084.2019.1670210; Ventricelli DJ, 2020, RX DRUG AB HER SUMM	5	19	19	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	2020	383	8					703	705		10.1056/NEJMp2002908	http://dx.doi.org/10.1056/NEJMp2002908			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NG2MJ	32813945				2023-01-03	WOS:000563818700008
J	Tomazoni, SS; Casalechi, HL; Ferreira, CDB; Serra, AJ; Delle, H; Brito, RBD; de Melo, BL; Vanin, AA; Ribeiro, NF; Pereira, AL; Monteiro, KKDS; Marcos, RL; de Carvalho, PDC; Frigo, L; Leal, ECP				Tomazoni, Shaiane Silva; Casalechi, Heliodora Leao; Bacelar Ferreira, Cheila de Sousa; Serra, Andrey Jorge; Delle, Humberto; de Oliveira Brito, Rodrigo Barbosa; de Melo, Brunno Lemes; Vanin, Adriane Aver; Ribeiro, Neide Firmo; Pereira, Amanda Lima; Damasceno Soares Monteiro, Kadma Karenina; Marcos, Rodrigo Labat; Camillo de Carvalho, Paulo de Tarso; Frigo, Lucio; Pinto Leal-Junior, Ernesto Cesar			Can photobiomodulation therapy be an alternative to pharmacological therapies in decreasing the progression of skeletal muscle impairments of mdx mice?	PLOS ONE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; LEVEL LASER THERAPY; SUPER-PULSED LASER; ANIMAL-MODELS; PERFORMANCE; FATIGUE; PHOTOTHERAPY; MYOGENESIS; PREDNISOLONE; COMBINATION	Objective To compare the effects of photobiomodulation therapy (PBMT) and pharmacological therapy (glucocorticoids and non-steroidal anti-inflammatory drugs) applied alone and in different combinations inmdxmice. Methods The animals were randomized and divided into seven experimental groups treated with placebo, PBMT, prednisone, non-steroidal anti-inflammatory drug (NSAIDs), PBMT plus prednisone and PBMT plus NSAID. Wild type animals were used as control. All treatments were performed during 14 consecutive weeks. Muscular morphology, protein expression of dystrophin and functional performance were assessed at the end of the last treatment. Results Both treatments with prednisone and PBMT applied alone or combined, were effective in preserving muscular morphology. In addition, the treatments with PBMT (p = 0.0005), PBMT plus prednisone (p = 0.0048) and PBMT plus NSAID (p = 0.0021) increased dystrophin gene expression compared to placebo-control group. However, in the functional performance the PBMT presented better results compared to glucocorticoids (p<0.0001). In contrast, the use of NSAIDs did not appear to add benefits to skeletal muscle tissue inmdxmice. Conclusion We believe that the promising and optimistic results about the PBMT in skeletal muscle ofmdxmice may in the future contribute to this therapy to be considered a safe alternative for patients with Duchenne Muscular Dystrophy (DMD) in a washout period (between treatment periods with glucocorticoids), allowing them to remain receiving effective and safe treatment in this period, avoiding at this way periods without administration of any treatment.	[Tomazoni, Shaiane Silva; Pinto Leal-Junior, Ernesto Cesar] Univ Bergen, Dept Global Publ Hlth & Primary Care, Physiotherapy Res Grp, Bergen, Norway; [Casalechi, Heliodora Leao; Bacelar Ferreira, Cheila de Sousa; Vanin, Adriane Aver; Ribeiro, Neide Firmo; Pereira, Amanda Lima; Damasceno Soares Monteiro, Kadma Karenina; Frigo, Lucio; Pinto Leal-Junior, Ernesto Cesar] Univ Nove Julho UNINOVE, Lab Phototherapy & Innovat Technol Hlth LaPIT, Sao Paulo, SP, Brazil; [Serra, Andrey Jorge; de Melo, Brunno Lemes] Univ Fed Sao Paulo UNIFESP, Postgrad Program Med, Sao Paulo, SP, Brazil; [Delle, Humberto; de Oliveira Brito, Rodrigo Barbosa] Univ Nove Julho UNINOVE, Postgrad Program Med, Sao Paulo, SP, Brazil; [Vanin, Adriane Aver; Ribeiro, Neide Firmo; Damasceno Soares Monteiro, Kadma Karenina; Camillo de Carvalho, Paulo de Tarso; Pinto Leal-Junior, Ernesto Cesar] Univ Nove Julho UNINOVE, Postgrad Program Rehabil Sci, Sao Paulo, SP, Brazil; [Marcos, Rodrigo Labat] Univ Nove Julho UNINOVE, Postgrad Program Biophoton Appl Hlth Sci, Sao Paulo, SP, Brazil; [Frigo, Lucio] Univ Guarulhos UnG, Dept Periodontol, Dent Res Div, Guarulhos, SP, Brazil	University of Bergen; Universidade Nove de Julho; Universidade Federal de Sao Paulo (UNIFESP); Universidade Nove de Julho; Universidade Nove de Julho; Universidade Nove de Julho; Universidade Guarulhos	Leal, ECP (corresponding author), Univ Bergen, Dept Global Publ Hlth & Primary Care, Physiotherapy Res Grp, Bergen, Norway.; Leal, ECP (corresponding author), Univ Nove Julho UNINOVE, Lab Phototherapy & Innovat Technol Hlth LaPIT, Sao Paulo, SP, Brazil.; Leal, ECP (corresponding author), Univ Nove Julho UNINOVE, Postgrad Program Rehabil Sci, Sao Paulo, SP, Brazil.	ernesto.leal.junior@gmail.com	Frigo, Lucio/K-1564-2015; Serra, Andrey Jorge/E-7460-2015; Tomazoni, Shaiane Silva/H-9000-2016; Dellê, Humberto/N-6353-2019; Leal-Junior, Ernesto Cesar/H-8920-2016; Lemes, Brunno/AAJ-1652-2020	Serra, Andrey Jorge/0000-0002-5407-8183; Tomazoni, Shaiane Silva/0000-0002-0822-4864; Dellê, Humberto/0000-0001-6072-3671; Leal-Junior, Ernesto Cesar/0000-0001-6393-7616; 	Brazilian Council of Science and Technology Development -CNPq [310281/2017-2, 429765/2018-5]; Sao Paulo Research Foundation (FAPESP) [2015/21012-2]	Brazilian Council of Science and Technology Development -CNPq; Sao Paulo Research Foundation (FAPESP)(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP))	This study was supported by research grants #310281/2017-2 and #429765/2018-5 from Brazilian Council of Science and Technology Development -CNPq (Professor Ernesto Cesar Pinto Leal-Junior), and #2015/21012-2, Sao Paulo Research Foundation (FAPESP) (Professor Lucio Frigo). The funders had no role in study design; data collection and analysis, decision to publish, or preparation of the manuscript.	Albuquerque-Pontes GM, 2018, LASER MED SCI, V33, P755, DOI 10.1007/s10103-017-2405-5; Antonialli FC, 2014, LASER MED SCI, V29, P1967, DOI 10.1007/s10103-014-1611-7; Biggar WD, 2006, NEUROMUSCULAR DISORD, V16, P249, DOI 10.1016/j.nmd.2006.01.010; Bushby K, 2010, LANCET NEUROL, V9, P77, DOI 10.1016/S1474-4422(09)70271-6; Casalechi HL, 2020, LASER MED SCI, V35, P1253, DOI 10.1007/s10103-019-02898-y; De Marchi T, 2019, LASER MED SCI, V34, P139, DOI 10.1007/s10103-018-2643-1; De Marchi T, 2012, LASER MED SCI, V27, P231, DOI 10.1007/s10103-011-0955-5; Silva AAD, 2015, LASER MED SCI, V30, P1719, DOI 10.1007/s10103-015-1777-7; de Paiva PRV, 2020, BMC SPORTS SCI MED R, V12, DOI 10.1186/s13102-020-00171-2; Dornelles MP, 2019, LASER MED SCI, V34, P1177, DOI 10.1007/s10103-018-02709-w; Eagle M, 2002, NEUROMUSCULAR DISORD, V12, P926, DOI 10.1016/S0960-8966(02)00140-2; EMERY AEH, 1990, LANCET, V335, P1289, DOI 10.1016/0140-6736(90)91364-G; Fairclough RJ, 2011, EXP PHYSIOL, V96, P1101, DOI 10.1113/expphysiol.2010.053025; Grandinetti VD, 2015, LASER MED SCI, V30, P1575, DOI 10.1007/s10103-015-1755-0; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Janssen PML, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088360; Leal-Junior Ernesto Cesar Pinto, 2015, Lasers Med Sci, V30, P925, DOI 10.1007/s10103-013-1465-4; Lopes-Martins RAB, 2006, PHOTOMED LASER SURG, V24, P197, DOI 10.1089/pho.2006.24.197; Macagnan FE, 2019, LASER MED SCI, V34, P835, DOI 10.1007/s10103-018-2593-7; Macedo AB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128567; Manning J, 2015, J MUSCLE RES CELL M, V36, P155, DOI 10.1007/s10974-015-9406-4; Manzur AY, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003725.pub3; Markham LW, 2005, PEDIATR CARDIOL, V26, P768, DOI 10.1007/s00246-005-0909-4; Matthews E, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003725.pub4; McGreevy JW, 2015, DIS MODEL MECH, V8, P195, DOI 10.1242/dmm.018424; METZINGER L, 1993, NEUROSCI LETT, V155, P171, DOI 10.1016/0304-3940(93)90700-U; Miranda EF, 2019, LASER MED SCI, V34, P711, DOI 10.1007/s10103-018-2645-z; Miranda EF, 2018, LASER MED SCI, V33, P719, DOI 10.1007/s10103-017-2396-2; Miranda EF, 2015, LASER MED SCI, V30, P437, DOI 10.1007/s10103-014-1690-5; Ogura Y, 2014, FRONT CELL DEV BIOL, V2, DOI 10.3389/fcell.2014.00011; PASSAQUIN AC, 1993, J NEUROSCI RES, V35, P363, DOI 10.1002/jnr.490350403; Pinto HD, 2016, J STRENGTH COND RES, V30, P3329, DOI 10.1519/JSC.0000000000001439; Leal ECP, 2019, BRAZ J PHYS THER, V23, P71, DOI 10.1016/j.bjpt.2018.12.002; Leal ECP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089453; Salmaninejad A, 2018, INT J NEUROSCI, V128, P854, DOI 10.1080/00207454.2018.1430694; Santos LA, 2014, LASER MED SCI, V29, P1617, DOI 10.1007/s10103-014-1560-1; Serra F, 2012, MUSCLE NERVE, V46, P773, DOI 10.1002/mus.23432; SHARP NJH, 1992, GENOMICS, V13, P115, DOI 10.1016/0888-7543(92)90210-J; Sinha M, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/258209; SKLAR RM, 1991, J NEUROL SCI, V101, P73, DOI 10.1016/0022-510X(91)90019-4; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Tamma R, 2013, LAB INVEST, V93, P592, DOI 10.1038/labinvest.2013.46; Tomazoni SS, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/6239058; van Westering TLE, 2015, MOLECULES, V20, P8823, DOI 10.3390/molecules20058823; Vanin AA, 2018, LASER MED SCI, V33, P181, DOI 10.1007/s10103-017-2368-6; Vanin AA, 2017, LASER MED SCI, V32, P253, DOI 10.1007/s10103-016-2121-6; Verhaert D, 2011, CIRC-CARDIOVASC IMAG, V4, P67, DOI 10.1161/CIRCIMAGING.110.960740; de Paiva PRV, 2016, LASER MED SCI, V31, P1925, DOI 10.1007/s10103-016-2071-z; Wong BLY, 2002, J CHILD NEUROL, V17, P183, DOI 10.1177/088307380201700306	49	3	3	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2020	15	8							e0236689	10.1371/journal.pone.0236689	http://dx.doi.org/10.1371/journal.pone.0236689			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND3HD	32785240	gold, Green Published			2023-01-03	WOS:000561793900060
J	Chen, HL; Chen, P; Zhang, Y; Xing, Y; Guan, YY; Cheng, DX; Li, XW				Chen, Hong-Li; Chen, Pei; Zhang, Yu; Xing, Ying; Guan, Yuan-Yuan; Cheng, Dao-Xiang; Li, Xian-Wen			Retention of volunteers and factors influencing program performance of the Senior Care Volunteers Training Program in Jiangsu, China	PLOS ONE			English	Article							QUALITY-OF-CARE; PALLIATIVE CARE; ATTITUDES; CLIMATE	Background As the country with the largest aging population, China faces an enormous challenge with its elderly support and care. One of the proposed solutions is the development of volunteerism for elderly care. The Senior Care Volunteers Training Program (SCVTP) was initiated by the Red Cross Society of China with the purpose of training volunteers to care for community seniors. As one of the four pilot provinces, Jiangsu Province launched the program since 2017. Aims The present study was conducted to investigate the dropout rate of trained volunteer group leaders, the characteristics of the retained trained volunteer group leaders and the activities that their groups conducted. Additionally, the exploration of the factors influencing the SCVTP's performance was listed as another aim. Methods A cross-sectional study was designed. The study used purposive sampling to select participants who meet the criteria from all the trained volunteer group leaders (n = 623). Demographic questionnaire, volunteer role identity (VRI) scale, attitude toward helping others (AHO) scale, team climate and atmosphere (TCA) scale, and volunteer program performance evaluation (VPPE) questionnaire were used to collect the data online. Descriptive statistics were used to determine the dropout rate and general characteristics of the retained volunteers and the activities. A multiple linear regression equation was developed to study the factors that influence program performance. Results In total, 307 questionnaires were valid in the study. About 67.9%, 53.7%, and 30.0% of the trained volunteer group leaders dropped out of the program in the year of 2017, 2018, and 2019, respectively. The retained trained volunteer group leaders were more likely to be females (84.7%), those in excellent health (75.2%) and with a bachelor's degree or above (87.6%). Less attention has been paid to frailty care (n = 76) than other volunteer caring activities (e.g., safe care: n = 277, diet care: n = 250, drug management care: n = 226). VRI (beta = 0.118, p = 0.017), AHO (beta = 0.134, p = 0.021), TCA (beta = 0.459, p<0.001), and financial sustainability (beta = 0.179, p<0.001) affected the SCVTP's performance significantly (adjusted R-2= 0.356). Conclusion High rate of trained volunteer group leaders' dropout should be brought to the policymaker's attention. The characteristics of the retained trained volunteer group leaders provide a useful reference for the recruitment of trainees in the future. Frailty care may need more training by the volunteer service provider. In order to enhance program performance, a better team climate and atmosphere, financial sustainability, and volunteers with appropriate attitude and role identity are also necessary for the volunteer program.	[Chen, Hong-Li; Chen, Pei; Zhang, Yu; Xing, Ying; Guan, Yuan-Yuan; Li, Xian-Wen] Nanjing Med Univ, Sch Nursing, Nanjing, Jiangsu, Peoples R China; [Cheng, Dao-Xiang] Red Cross Soc, Jiangsu Branch, Nanjing, Jiangsu, Peoples R China	Nanjing Medical University	Li, XW (corresponding author), Nanjing Med Univ, Sch Nursing, Nanjing, Jiangsu, Peoples R China.	xwli0201@njmu.educn		Li, Xianwen/0000-0003-1935-2391	Project of Philosophy and Social Science Research in Colleges and Universities in Jiangsu Province [2017SJB0285]	Project of Philosophy and Social Science Research in Colleges and Universities in Jiangsu Province	This work was supported by the Project of Philosophy and Social Science Research in Colleges and Universities in Jiangsu Province (2017SJB0285). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Agency for Healthcare Research and Quality, 2019, TEAM ASS QUEST; Alqahtani F., 2015, INT J SCI ENG RES, V6, P670; Anunda JS, 2016, THESIS; Beleiu I., 2015, INT MANAG RES, V11, P59; Black K., 2019, BUSINESS STAT CONT D; Blair A, 2019, AUSTRALAS J AGEING, V38, P34, DOI 10.1111/ajag.12612; Bock JO, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1360-3; Bower P, 2003, QUAL SAF HEALTH CARE, V12, P273, DOI 10.1136/qhc.12.4.273; Bowling NA, 2016, J PERS SOC PSYCHOL, V111, P218, DOI 10.1037/pspp0000085; Burbeck R, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-3; CALLERO PL, 1987, SOC PSYCHOL QUART, V50, P247, DOI 10.2307/2786825; Campbell SM, 2001, BMJ-BRIT MED J, V323, P784, DOI 10.1136/bmj.323.7316.784; Candy B, 2015, INT J NURS STUD, V52, P756, DOI 10.1016/j.ijnurstu.2014.08.007; Chen Hong-Li, 2019, CHINESE HLTH SERVICE, V36, P325; Claxton-Oldfield S, 2015, PALLIAT SUPPORT CARE, V13, P809, DOI 10.1017/S1478951514000674; Das D, 2017, IIMB MANAG REV, V29, P276, DOI 10.1016/j.iimb.2017.11.005; Department of Economic and Social Affairs Population Division European Union, 2020, WORLD POP AG 2019; Department of Economic and Social Affairs Population Dynamics European Union, 2019, WORLD POP PROSP 2019, V1; Desimone JA, 2015, J ORGAN BEHAV, V36, P171, DOI 10.1002/job.1962; Essays UK, 2018, FACT WHICH INFL TEAM; Fletcher TD, 2004, SEX ROLES, V51, P109, DOI 10.1023/B:SERS.0000032319.78926.54; Ford LR, 2006, LEADERSHIP QUART, V17, P258, DOI 10.1016/j.leaqua.2006.02.005; Grube JA, 2000, PERS SOC PSYCHOL B, V26, P1108, DOI 10.1177/01461672002611007; Hartgerink JM, 2014, J ADV NURS, V70, P791, DOI 10.1111/jan.12233; Hettiarachchi H.A.H., 2014, J BUSINESS MANAGEMEN, V16, P74; International Federation of the Red Cross and Red Crescent, 2011, PROJ PROGR MON EV M; Kilgore Lindsay, 2016, Home Healthc Now, V34, P115, DOI 10.1097/NHH.0000000000000345; Klein KJ, 2001, J APPL PSYCHOL, V86, P3, DOI 10.1037/0021-9010.86.1.3; Korner M, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0888-y; Latif KF, 2017, EVAL PROGRAM PLANN, V64, P20, DOI 10.1016/j.evalprogplan.2017.05.004; Lopez-Zapata E, 2019, EUR RES STUD J, V22, P68, DOI 10.35808/ersj/1457; Marta E, 2008, J ADULT DEV, V15, P35, DOI 10.1007/s10804-007-9033-4; Mugo KJ, 2013, THESIS; Muriithi CW, 2014, THESIS; National Bureau of Statistics, 2020, OV PERF NAT EC WER S; PHILLIPS JD, 1990, PERS J, V69, P58; Quinn FF, 2014, BUSINESS STUDIES J, V6, P67; Rahiman M.H.U., 2017, BRIT J EC FINANCE MA, V13, P93; Red Cross Society of China, 2017, GUID INV RED CROSS E; RENTSCH JR, 1990, J APPL PSYCHOL, V75, P668, DOI 10.1037/0021-9010.75.6.668; Riketta M, 2008, J APPL PSYCHOL, V93, P472, DOI 10.1037/0021-9010.93.2.472; Rokach A, 2009, PSYCHOL ED, V46, P7; Scott R., 2015, EUR J PALLIAT CARE, V22, P80; Shahab M.A., 2014, INT J MANAG STUD RES, V2, P69; Sharma J. P., 2010, INT B BUSINESS ADM, V9, P7; Singer E, 2013, ANN AM ACAD POLIT SS, V645, P112, DOI 10.1177/0002716212458082; Soderhamn U, 2017, BMC PALLIAT CARE, V16, DOI 10.1186/s12904-017-0193-0; Tal KN, 2005, SMALL GR RES, V36, P437, DOI [10.1177/1046496405275233, DOI 10.1177/1046496405275233]; Tapp A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218597; Tsai YF, 2011, BMC HEALTH SERV RES, V11, DOI 10.1186/1472-6963-11-98; van Ingen E, 2017, NONPROF VOLUNT SEC Q, V46, P29, DOI 10.1177/0899764016659765; Jimenez MLV, 2010, SPAN J PSYCHOL, V13, P343, DOI 10.1017/S1138741600003905; Watanabe O, 2016, J INT HLTH, V31, P1, DOI [10.11197/jaih.31.1, DOI 10.11197/JAIH.31.1]; Webb DJ, 2000, J ACAD MARKET SCI, V28, P299, DOI 10.1177/0092070300282010; Weerakkody WAS, 2013, KELANIYA J HUMAN RES, V8, P179, DOI [10.4038/kjhrm.v8i2.8, DOI 10.4038/KJHRM.V8I2.8]	55	0	0	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2020	15	8							e0237390	10.1371/journal.pone.0237390	http://dx.doi.org/10.1371/journal.pone.0237390			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NC7KJ	32776995	gold, Green Published			2023-01-03	WOS:000561393800012
J	Pillemer, K; Subramanian, L; Hupert, N				Pillemer, Karl; Subramanian, Lakshminarayanan; Hupert, Nathaniel			The Importance of Long-term Care Populations in Models of COVID-19	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Pillemer, Karl] Cornell Univ, Weill Cornell Med, Div Geriatr & Palliat Med, Dept Human Dev, New York, NY 10065 USA; [Subramanian, Lakshminarayanan] NYU, Courant Inst Math Sci, New York, NY USA; [Hupert, Nathaniel] Weill Cornell Med, Cornell Inst Dis & Disaster Preparedness, Dept Med & Populat Hlth Sci, New York, NY USA	Cornell University; New York University; Cornell University	Pillemer, K (corresponding author), Cornell Univ, Weill Cornell Med, Div Geriatr & Palliat Med, 1300 York Ave, New York, NY 10065 USA.	kap6@cornell.edu		Pillemer, Karl/0000-0002-7700-3563; Subramanian, Lakshminarayanan/0000-0001-8101-1243				Barnett M. L., 2020, JAMA HLTH FORUM; CDC COVID-19 Response Team, 2020, MMWR-MORBID MORTAL W, V69, P343, DOI 10.15585/mmwr.mm6915e4; Kaiser Family Foundation, STAT REP LONG TERM C; Neil M., 2020, IMPERIAL COLL LONDON; Shen MW, 2015, SCI REP-UK, V5, DOI 10.1038/srep15818; State of New Jersey, IS STAT US DAT MAK D; State of New Jersey, WHAT IS STAT DOING P	7	19	19	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2020	324	1					25	26		10.1001/jama.2020.9540	http://dx.doi.org/10.1001/jama.2020.9540			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM5FX	32501504	Bronze			2023-01-03	WOS:000568123600010
J	Lanza, E; Masetti, C; Messana, G; Muglia, R; Pugliese, N; Ceriani, R; de Nalda, AL; Rimassa, L; Torzilli, G; Poretti, D; D'Antuono, F; Politi, LS; Pedicini, V; Aghemo, A				Lanza, Ezio; Masetti, Chiara; Messana, Gaia; Muglia, Riccardo; Pugliese, Nicola; Ceriani, Roberto; de Nalda, Ana Lleo; Rimassa, Lorenza; Torzilli, Guido; Poretti, Dario; D'Antuono, Felice; Politi, Letterio Salvatore; Pedicini, Vittorio; Aghemo, Alessio		Humanitas HCC Multidisciplinary Gr	Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma	PLOS ONE			English	Article								Sarcopenia has been associated with lower overall survival in patients with cirrhosis and hepatocellular carcinoma (HCC) undergoing surgical resection, TACE, TARE, or transplantation. This monocentric study evaluated the prognostic significance of sarcopenia in patients affected by HCC who received bland transarterial embolization (TAE) therapy, by analyzing its impact on survival and treatment-related complications. All consecutive patients who underwent the 1st TAE between March 1st 2011 and July 1st 2019 in our Institution were retrospectively studied. To evaluate sarcopenia, the skeletal muscle index (SMI) was calculated by normalizing the cross-sectional muscle area at the level of L3 on an abdominal CT scan prior to embolization (cm2) by patient height (m2). SMI cut-off values for sarcopenia were considered <= 39 cm2/m2 for women and <= 55 cm2/m2 for men. Data about age, gender, body mass index (BMI), underlying liver disease, liver function, MELD score, Child-Pugh score, multifocal disease, performance status, previous interventions, length of stay (LOS), complications after the procedure, readmission rate within 30 days, survival time from TAE and total number and type of TAE received following the first procedure were collected. From 2011 to 2019, 142 consecutive patients underwent 305 TAEs. Observation time ranged from 1.4 to 100.5 months (median 20.1 SD = 22). Sarcopenia at baseline was present in 121 (85%) patients. Overall 87 (61.2%) patients died during follow-up with survival rates at 1-, 2-, 3-, 4-, and 5-year of 71%, 41%, 22%, 16% and 11% respectively. After multivariate analysis sarcopenia (HR = 2.22, p = 0.046), previous ablation/resection (HR = 0.51, p = 0.005) and multifocal disease (HR = 1.84, p = 0.02) were associated with reduced survival. Sarcopenia did not influence the safety of TAE in terms of LOS (2 days vs 1.5 days, p = 0.2), early complications rate (8% vs 5%, p = 0.5) and readmission rate within 30 days (7% vs 5%, p = 0.74). Sarcopenia, estimated by the L3SMI method, is an emerging prognostic factor in patients with HCC undergoing bland TAE therapy as it is associated with increased mortality, without impairing the safety of the locoregional treatment. Measures to ameliorate the SMI, such as nutritional support and physical exercise, should be evaluated in clinical trials for HCC patients receiving liver embolization to determine their impact on overall survival.	[Lanza, Ezio; Muglia, Riccardo; Poretti, Dario; D'Antuono, Felice; Pedicini, Vittorio] Humanitas Res Hosp IRCCS, Dept Radiol, Div Intervent Radiol, Rozzano, Italy; [Masetti, Chiara; Muglia, Riccardo; Pugliese, Nicola; Ceriani, Roberto; de Nalda, Ana Lleo; Aghemo, Alessio] Humanitas Res Hosp IRCCS, Dept Gastroenterol, Div Internal Med & Hepatol, Rozzano, Italy; [Messana, Gaia; Muglia, Riccardo; Pugliese, Nicola; de Nalda, Ana Lleo; Rimassa, Lorenza; Politi, Letterio Salvatore; Aghemo, Alessio] Humanitas Univ, Dept Biomed Sci, Milan, Italy; [Rimassa, Lorenza; Politi, Letterio Salvatore] Humanitas Clin & Res Ctr IRCCS, Humanitas Canc Ctr, Med Oncol & Hematol Unit, Milan, Italy; [Torzilli, Guido; Politi, Letterio Salvatore] Humanitas Clin & Res Ctr IRCCS, Dept Surg, Div Hepatobiliary & Gen Surg, Rozzano, Italy; [Politi, Letterio Salvatore] Humanitas Clin & Res Ctr IRCCS, Dept Radiol, Rozzano, Italy	IRCCS Humanitas Research Hospital; IRCCS Humanitas Research Hospital; Humanitas University	Lanza, E (corresponding author), Humanitas Res Hosp IRCCS, Dept Radiol, Div Intervent Radiol, Rozzano, Italy.	eziolanza@gmail.com; guido.torzilli@humanitas.it	pugliese, nicola/ABC-7622-2020; Lanza, Ezio/AAO-8516-2020; D'Antuono, Felice/AAV-2822-2020; Politi, Letterio Salvatore/AAB-1092-2021; Rimassa, Lorenza/N-4884-2016; Aghemo, Alessio/ABE-5976-2021; LLEO, Ana/AAA-5759-2019	pugliese, nicola/0000-0001-6466-1412; Lanza, Ezio/0000-0003-1889-8798; D'Antuono, Felice/0000-0002-9973-0593; Politi, Letterio Salvatore/0000-0002-6190-6688; Rimassa, Lorenza/0000-0001-9957-3615; Aghemo, Alessio/0000-0003-0941-3226; pedicini, vittorio/0000-0001-7830-6307; Masetti, Chiara/0000-0002-1689-4876; Messana, Gaia/0000-0002-3212-5305; LLEO, Ana/0000-0002-0561-7902; Ceriani, Roberto/0000-0003-4838-7366				Chang KV, 2018, LIVER CANCER, V7, P90, DOI 10.1159/000484950; Cruz-Jentoft AJ, 2010, AGE AGEING, V39, P412, DOI 10.1093/ageing/afq034; Dimitroulis D, 2017, WORLD J GASTROENTERO, V23, P5282, DOI 10.3748/wjg.v23.i29.5282; Dolan E, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110642; Donadon M, 2019, UPDATES SURG, V71, P57, DOI 10.1007/s13304-019-00626-3; Fearon K, 2011, LANCET ONCOL, V12, P489, DOI 10.1016/S1470-2045(10)70218-7; Foerster F, 2018, EUR J INTERN MED, V55, P57, DOI 10.1016/j.ejim.2018.05.024; Forner A, 2019, JHEP REP, V1, P17, DOI 10.1016/j.jhepr.2019.02.003; Harimoto N, 2013, BRIT J SURG, V100, P1523, DOI 10.1002/bjs.9258; Ikeda M, 2018, JPN J CLIN ONCOL, V48, P103, DOI 10.1093/jjco/hyx180; Kaido T, 2019, HEPATOBIL SURG NUTR, V8, P59, DOI 10.21037/hbsn.2018.11.05; Katsanos K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184597; Koya S, 2019, J GASTROEN HEPATOL, V34, P580, DOI 10.1111/jgh.14538; Lanza E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227711; Lanza E, 2017, NUCL MED COMMUN, V38, P826, DOI 10.1097/MNM.0000000000000719; Lanza E, 2017, LIVER CANCER, V6, P27, DOI 10.1159/000449347; Liguori I, 2018, CLIN INTERV AGING, V13, P913, DOI 10.2147/CIA.S149232; Loosen SH, 2019, CANCERS, V11, DOI 10.3390/cancers11101503; Martinez-Arnau FM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102504; Menyhart O, 2018, ROY SOC OPEN SCI, V5, DOI 10.1098/rsos.181006; Nishikawa H, 2017, ONCOL LETT, V14, P1637, DOI 10.3892/ol.2017.6287; Phu S, 2015, J CLIN DENSITOM, V18, P488, DOI 10.1016/j.jocd.2015.04.011; Portal D, 2019, CANCER MANAG RES, V11, P2579, DOI 10.2147/CMAR.S195869; Tamandl D, 2016, EUR RADIOL, V26, P1359, DOI 10.1007/s00330-015-3963-1	24	18	18	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2020	15	6							e0232371	10.1371/journal.pone.0232371	http://dx.doi.org/10.1371/journal.pone.0232371			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB7DG	32555707	Green Published, gold			2023-01-03	WOS:000542759600010
J	Miguel, TP; Laurienzo, CE; Faria, EF; Sarri, AJ; Castro, IQ; Affonso, RJ; Andrade, CEMD; Vieira, MD; dos Reis, R				Miguel, Tais Pereira; Laurienzo, Carla Elaine; Faria, Eliney Ferreira; Sarri, Almir Jose; Castro, Isabela Queiroz; Affonso Junior, Renato Jose; Mattos da Cunha Andrade, Carlos Eduardo; Vieira, Marcelo de Andrade; dos Reis, Ricardo			Chemoradiation for cervical cancer treatment portends high risk of pelvic floor dysfunction	PLOS ONE			English	Article							RECEPTOR ISOFORM-ALPHA; BETA MESSENGER RNA; URINARY-INCONTINENCE; SEXUAL FUNCTION; MUSCLE FUNCTION; VAGINAL TISSUE; RADIOTHERAPY; PREMENOPAUSAL; EXPRESSION; CARCINOMA	Goal To assess the impact of chemoradiation on pelvic floor (PF) muscle function after the treatment of cervical cancer (CC). Methods We performed a prospective cohort study of women between the ages of 20 and 70 years old who had a diagnosis of CC. Patients were treated with chemoradiation at the Barretos Cancer Hospital (BCH), between August 2016 and July 2017. We performed three evaluations at different time points after chemoradiation treatment to compare changes in muscle function. Pelvic floor muscle function was assessed through perineometry (PNM) and surface electromyography (EMG) at the following time points: Pretreatment Moment 1 (M1): evaluated before chemoradiation; Moment 2 (M2): at the first follow-up medical visit (usually 3 to 4 months after treatment); and Moment 3 (M3): at the second follow-up medical visit (usually after 6 to 9 months after treatment). Mean vaginal squeeze pressure levels were determined by PNM and muscle electromyographic activity by EMG and the results were evaluated by Generalized Linear Model comparisons. Results Forty-nine patients were evaluated at M1; 35 at M2; and 32 at M3, so that 32 patients had all three muscle evaluations performed. There was a statistically significant increase in the frequency of women with urgency urinary incontinence at the M2 evaluation time (41.9%), compared to pretreatment M1 (18.6%), p<0.001. The means of the vaginal squeeze pressures reduced through M1 to M3 in the phasic (M1: 17.7 mmHg; M3: 11.27mmHg) and tonic contractions (M1: 10.56 mmHg; M3: 7.52mmHg),p= 0.01 andp= 0.03 respectively. There was no difference in pelvic floor function in the three evaluations M1-M3, measured by EMG. The pelvic floor strength assessed by PMN and their interactions with anthropometric, parity and hormonal status variables, showed that a high body mass index (BMI) significantly influenced decreases in pelvic floor muscle function before and after treatment. Conclusion These results show that chemoradiation causes reduction of muscle function of the pelvic floor, especially in the late phase after the end of treatment. Both the high BMI and urgent urinary incontinence symptoms were related to decreased muscle strength.	[Miguel, Tais Pereira; Laurienzo, Carla Elaine; Sarri, Almir Jose] Barretos Canc Hosp, Dept Physiotherapy, Sao Paulo, Brazil; [Faria, Eliney Ferreira] Barretos Canc Hosp, Dept Urol, Sao Paulo, Brazil; [Castro, Isabela Queiroz] Barretos Canc Hosp, Dept Epidemiol & Biostat, Sao Paulo, Brazil; [Affonso Junior, Renato Jose] Barretos Canc Hosp, Dept Radiat Theraphy, Sao Paulo, Brazil; [Mattos da Cunha Andrade, Carlos Eduardo; Vieira, Marcelo de Andrade; dos Reis, Ricardo] Barretos Canc Hosp, Dept Gynecol Oncol, Barretos, SP, Brazil	Hospital de Cancer de Barretos; Hospital de Cancer de Barretos; Hospital de Cancer de Barretos; Hospital de Cancer de Barretos; Hospital de Cancer de Barretos	Miguel, TP (corresponding author), Barretos Canc Hosp, Dept Physiotherapy, Sao Paulo, Brazil.	taispereiramiguel@hotmail.com	Faria, Eliney/ABA-3296-2021	Miguel, Tais/0000-0002-0474-8900; Faria, Eliney Ferreira/0000-0002-8297-3417				Baracho E, 2012, FISIOTERAPIA APLICAD; Barnett GC, 2009, NAT REV CANCER, V9, P134, DOI 10.1038/nrc2587; Batista RLA, 2011, BRAZ J PHYS THER, V15, P386, DOI 10.1590/S1413-35552011005000026; Bernard S, 2017, PHYS THER, V97, P438, DOI 10.1093/ptj/pzx012; Bland DR, 2001, AM J OBSTET GYNECOL, V185, P1330; Bo K, 2005, PHYS THER, V85, P269; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; de Noronha AF, 2013, INT BRAZ J UROL, V39, P46, DOI 10.1590/S1677-5538.IBJU.2013.01.07; Dursun M, 2014, INT UROL NEPHROL, V46, P2297, DOI 10.1007/s11255-014-0832-9; Neto IJFC, 2017, OBES SURG, V27, P1822, DOI 10.1007/s11695-017-2559-z; Frigato S, 2003, REV BRASILEIRA CANCE, V49, P209; Gebhart JB, 2001, AM J OBSTET GYNECOL, V185, P1325, DOI 10.1067/mob.2001.119627; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hazewinkel MH, 2010, GYNECOL ONCOL, V117, P281, DOI 10.1016/j.ygyno.2010.01.034; Hermens H.J, 1999, SENIAM EUROPEAN RECO; Howick J, 2011, 2011 OXFORD CEBM EVI, DOI [10.1136/ebm1155, DOI 10.1136/EBM1155]; Jensen PT, 2015, TRANSL ANDROL UROL, V4, P186, DOI 10.3978/j.issn.2223-4683.2015.04.06; Kanat O, 2017, WORLD J CLIN ONCOL, V8, P329, DOI 10.5306/wjco.v8.i4.329; Morin M, 2004, NEUROUROL URODYNAM, V23, P668, DOI 10.1002/nau.20069; Mutch DG., 2009, GYNECOL ONCOL, V115, P325, DOI [10.1016/j.ygyno.2009.10.050, DOI 10.1016/J.YGYNO.2009.10.050, DOI 10.1016/J.YGYN0.2009.10.050]; Oh JK, 2012, INT NEUROUROL J, V16, P91, DOI 10.5213/inj.2012.16.2.91; Petignat P, 2007, BMJ-BRIT MED J, V335, P765, DOI 10.1136/bmj.39337.615197.80; Pomian A, 2016, MED SCI MONITOR, V22, P1880, DOI 10.12659/MSM.896331; Rossetti SR, 2016, ARCH ITAL UROL ANDRO, V88, P28, DOI 10.4081/aiua.2016.1.28; Santos Jr. Júlio César Monteiro dos, 2006, Rev bras. colo-proctol., V26, P348, DOI 10.1590/S0101-98802006000300019; Smeenk RJ, 2012, INT J RADIAT ONCOL, V83, P636, DOI 10.1016/j.ijrobp.2011.08.007; Vomvas D, 2012, ANTICANCER RES, V32, P657; Wente K, 2018, CURRENT GERIATRICS R; WHO, BMI CLASSIFICATION, DOI DOI 11/44679/INDEX.HTM; Yeoh E, 1996, INT J RADIAT ONCOL, V35, P1003, DOI 10.1016/0360-3016(96)00147-2; Yeoh EEK, 2004, AM J GASTROENTEROL, V99, P361, DOI 10.1111/j.1572-0241.2004.04037.x	31	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2020	15	6							e0234389	10.1371/journal.pone.0234389	http://dx.doi.org/10.1371/journal.pone.0234389			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6QP	32530941	Green Published, gold			2023-01-03	WOS:000542037200057
J	Argenziano, MG; Bruce, SL; Slater, CL; Tiao, JR; Baldwin, MR; Barr, RG; Chang, BP; Chau, KH; Choi, JJ; Gavin, N; Goyal, P; Mills, AM; Patel, AA; Romney, MLS; Safford, MM; Schluger, NW; Sengupta, S; Sobieszczyk, ME; Zucker, JE; Asadourian, PA; Bell, FM; Boyd, R; Cohen, MF; Colquhoun, MI; Colville, LA; de Jonge, JH; Dershowitz, LB; Dey, SA; Eiseman, KA; Girvin, ZP; Goni, DT; Harb, AA; Herzik, N; Householder, S; Karaaslan, LE; Lee, H; Lieberman, E; Ling, A; Lu, R; Shou, AY; Sisti, AC; Snow, ZE; Sperring, CP; Xiong, YQ; Zhou, HW; Natarajan, K; Hripcsak, G; Chen, RJ				Argenziano, Michael G.; Bruce, Samuel L.; Slater, Cody L.; Tiao, Jonathan R.; Baldwin, Matthew R.; Barr, R. Graham; Chang, Bernard P.; Chau, Katherine H.; Choi, Justin J.; Gavin, Nicholas; Goyal, Parag; Mills, Angela M.; Patel, Ashmi A.; Romney, Marie-Laure S.; Safford, Monika M.; Schluger, Neil W.; Sengupta, Soumitra; Sobieszczyk, Magdalena E.; Zucker, Jason E.; Asadourian, Paul A.; Bell, Fletcher M.; Boyd, Rebekah; Cohen, Matthew F.; Colquhoun, MacAlistair I.; Colville, Lucy A.; de Jonge, Joseph H.; Dershowitz, Lyle B.; Dey, Shirin A.; Eiseman, Katherine A.; Girvin, Zachary P.; Goni, Daniella T.; Harb, Amro A.; Herzik, Nicholas; Householder, Sarah; Karaaslan, Lara E.; Lee, Heather; Lieberman, Evan; Ling, Andrew; Lu, Ree; Shou, Arthur Y.; Sisti, Alexander C.; Snow, Zachary E.; Sperring, Colin P.; Xiong, Yuqing; Zhou, Henry W.; Natarajan, Karthik; Hripcsak, George; Chen, Ruijun			Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series	BMJ-BRITISH MEDICAL JOURNAL			English	Article								OBJECTIVE To characterize patients with coronavirus disease 2019 (covid-19) in a large New York City medical center and describe their clinical course across the emergency department, hospital wards, and intensive care units. DESIGN Retrospective manual medical record review. SETTING NewYork-Presbyterian/Columbia University Irving Medical Center, a quaternary care academic medical center in New York City. PARTICIPANTS The first 1000 consecutive patients with a positive result on the reverse transcriptase polymerase chain reaction assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) who presented to the emergency department or were admitted to hospital between 1 March and 5 April 2020. Patient data were manually abstracted from electronic medical records. MAIN OUTCOME MEASURES Characterization of patients, including demographics, presenting symptoms, comorbidities on presentation, hospital course, time to intubation, complications, mortality, and disposition. RESULTS Of the first 1000 patients, 150 presented to the emergency department, 614 were admitted to hospital (not intensive care units), and 236 were admitted or transferred to intensive care units. The most common presenting symptoms were cough (732/1000), fever (728/1000), and dyspnea (631/1000). Patients in hospital, particularly those treated in intensive care units, often had baseline comorbidities including hypertension, diabetes, and obesity. Patients admitted to intensive care units were older, predominantly male (158/236, 66.9%), and had long lengths of stay (median 23 days, interquartile range 12-32 days); 78.0% (184/236) developed acute kidney injury and 35.2% (83/236) needed dialysis. Only 4.4% (6/136) of patients who required mechanical ventilation were first intubated more than 14 days after symptom onset. lime to intubation from symptom onset had a bimodal distribution, with modes at three to four days, and at nine days. As of 30 April, 90 patients remained in hospital and 211 had died in hospital. CONCLUSIONS Patients admitted to hospital with covid-19 at this medical center faced major morbidity and mortality, with high rates of acute kidney injury and inpatient dialysis, prolonged intubations, and a bimodal distribution of time to intubation from symptom onset.	[Argenziano, Michael G.; Bruce, Samuel L.; Slater, Cody L.; Tiao, Jonathan R.; Asadourian, Paul A.; Bell, Fletcher M.; Boyd, Rebekah; Cohen, Matthew F.; Colquhoun, MacAlistair I.; Colville, Lucy A.; de Jonge, Joseph H.; Dershowitz, Lyle B.; Dey, Shirin A.; Eiseman, Katherine A.; Girvin, Zachary P.; Goni, Daniella T.; Harb, Amro A.; Herzik, Nicholas; Householder, Sarah; Karaaslan, Lara E.; Lee, Heather; Lieberman, Evan; Ling, Andrew; Lu, Ree; Shou, Arthur Y.; Sisti, Alexander C.; Snow, Zachary E.; Sperring, Colin P.; Xiong, Yuqing; Zhou, Henry W.] Columbia Univ, Vagelos Coll Phys & Surg, New York, NY USA; [Argenziano, Michael G.; Bruce, Samuel L.; Slater, Cody L.; Tiao, Jonathan R.; Sengupta, Soumitra; Natarajan, Karthik; Hripcsak, George; Chen, Ruijun] Columbia Univ, Irving Med Ctr, Dept Biomed Informat, 622 West 168th St,PH-20, New York, NY 10032 USA; [Baldwin, Matthew R.; Schluger, Neil W.] Columbia Univ, Irving Med Ctr, Div Pulm Allergy & Crit Care Med, Dept Med,New York Presbyterian, New York, NY USA; [Barr, R. Graham; Patel, Ashmi A.] Columbia Univ, Irving Med Ctr, New York Presbyterian, Div Gen Med,Dept Med, New York, NY USA; [Chang, Bernard P.; Gavin, Nicholas; Mills, Angela M.; Romney, Marie-Laure S.] Columbia Univ, Irving Med Ctr, New York Presbyterian, Dept Emergency Med, New York, NY USA; [Chau, Katherine H.] Columbia Univ, Irving Med Ctr, New York Presbyterian, Div Cardiol,Dept Med, New York, NY USA; [Choi, Justin J.; Goyal, Parag; Safford, Monika M.; Chen, Ruijun] Weill Cornell Med, Dept Med, New York, NY 10065 USA; [Sobieszczyk, Magdalena E.; Zucker, Jason E.] Columbia Univ, Irving Med Ctr, New York Presbyterian, Div Infect Dis,Dept Med, New York, NY USA	Columbia University; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital; Cornell University; Columbia University; NewYork-Presbyterian Hospital	Chen, RJ (corresponding author), Columbia Univ, Irving Med Ctr, Dept Biomed Informat, 622 West 168th St,PH-20, New York, NY 10032 USA.; Chen, RJ (corresponding author), Weill Cornell Med, Dept Med, New York, NY 10065 USA.	ruijun.chen@columbia.edu	Baldwin, Matthew/GQY-7234-2022; Slater, Cody/AAR-1194-2020; Schluger, Neil/ABA-1793-2021; Zucker, Jason/H-7241-2019	Zucker, Jason/0000-0001-6987-6412; Chen, RuiJun/0000-0001-5281-4143; Gavin, Nicholas/0000-0001-6900-3953; Ling, Andrew/0000-0001-7351-8650; Harb, Amro/0000-0002-1400-0648; Cohen, Matthew/0000-0001-9087-2678; Argenziano, Michael/0000-0003-3374-9037; Zhou, Henry/0000-0003-4060-8187	US National Institute of Health [R01HL077612, R01HL093081]; National Heart Lung and Blood Institute [R01 HL141811, R01 HL146911]; US National Institutes of Health/National Heart, Lung, and Blood Institute [T32HL007854]; US National Institute of Health/National Center for Advancing Translational Science; US National Institute of Health/National Library of Medicine [R01 LM006910, T15 LM007079];  [UL1 TR001873]	US National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Heart Lung and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); US National Institutes of Health/National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); US National Institute of Health/National Center for Advancing Translational Science; US National Institute of Health/National Library of Medicine; 	This study received no specific funding or grant from any agency in the public, commercial, or not-for-profit sectors. MRB is supported by UL1 TR001873. RGB is supported by grant R01HL077612 and R01HL093081 from the US National Institute of Health. BPC is supported by grants R01 HL141811 and R01 HL146911 from the National Heart Lung and Blood Institute. KHC is supported by grant T32HL007854 from US National Institutes of Health/National Heart, Lung, and Blood Institute. JJC is supported by grants from the US National Institute of Health/National Center for Advancing Translational Science. GH is supported by grant R01 LM006910 from the US National Institute of Health/National Library of Medicine. RC is supported by grant T15 LM007079 from the US National Institute of Health/National Library of Medicine. No funding organization or sponsor was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Arentz M, 2020, JAMA-J AM MED ASSOC, V323, P1612, DOI 10.1001/jama.2020.4326; Beumer MC, 2019, J CRIT CARE, V50, P59, DOI 10.1016/j.jcrc.2018.11.013; Bhatraju PK, 2020, NEW ENGL J MED, V382, P2012, DOI 10.1056/NEJMoa2004500; Cascella M., 2020, FEATURES EVALUATION; Cummings Matthew J, 2020, medRxiv, DOI [10.1016/S0140-6736(20)31189-2, 10.1101/2020.04.15.20067157]; Emanuel EJ, 2020, NEW ENGL J MED, V382, P2049, DOI 10.1056/NEJMsb2005114; Fletcher SN, 2003, CRIT CARE MED, V31, P1012, DOI 10.1097/01.CCM.0000053651.38421.D9; Goyal P, 2020, NEW ENGL J MED, V382, P2372, DOI 10.1056/NEJMc2010419; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HARTIGAN PM, 1985, J R STAT SOC C-APPL, V34, P320; Helms J, 2020, NEW ENGL J MED, V382, P2268, DOI 10.1056/NEJMc2008597; Hollander JE, 2020, NEW ENGL J MED, V382, P1679, DOI 10.1056/NEJMp2003539; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Kim MJ, 2015, ANN REHABIL MED-ARM, V39, P763, DOI 10.5535/arm.2015.39.5.763; NYC Department of Health, 2020, COVID 19 DAT BAS; NYS Department of Health, 2020, NYS HLTH PROF; Petrilli CM, 2020, FACTORS ASS HOSP CRI, V369, pm1966, DOI [10.1136/bmj.m1966, DOI 10.1136/BMJ.M1966]; Prin M, 2012, CURR OPIN CRIT CARE, V18, P700, DOI 10.1097/MCC.0b013e32835914d5; R Core Team, 2021, R LANG ENV STAT COMP; Ranney ML, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMp2006141; Rello J, 2009, CRIT CARE, V13, DOI 10.1186/cc8044; Richardson S, 2020, JAMA, DOI [10.1001/jama.2020.6775, DOI 10.1001/JAMA.2020.6775]; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	26	332	337	2	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 29	2020	369								m1996	10.1136/bmj.m1996	http://dx.doi.org/10.1136/bmj.m1996			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV3KB	32471884	hybrid, Green Published			2023-01-03	WOS:000538337500001
J	Liu, YY; Wang, XP; Li, WS; Xu, YJ; Zhuo, YT; Li, MY; He, Y; Wang, XS; Guo, QL; Zhao, L; Qiang, L				Liu, Yunyao; Wang, Xiaoping; Li, Wenshu; Xu, Yujiao; Zhuo, Yating; Li, Mengyuan; He, Yuan; Wang, Xiaosheng; Guo, Qinglong; Zhao, Li; Qiang, Lei			Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1 alpha mediated XPC transcription	ONCOGENE			English	Article							NUCLEOTIDE EXCISION-REPAIR; DNA-DAMAGE RECOGNITION; CELL LUNG-CANCER; MULTIDRUG-RESISTANCE; INDUCIBLE FACTOR-1; TUMOR HYPOXIA; CHEMORESISTANCE; EXPRESSION; SENSITIVITY; PHOSPHORYLATION	Hypoxia is a key concern during the treatment of non-small cell lung cancer (NSCLC), and hypoxia-inducible factor 1 alpha (HIF-1 alpha) has been associated with increased tumor resistance to therapeutic modalities such as cisplatin. Compensatory activation of nucleotide excision repair (NER) pathway is the major mechanism that accounts for cisplatin resistance. In the present study, we suggest a novel strategy to improve the treatment of NSCLC and overcome the hypoxia-induced cisplatin resistance by cotreatment with Oroxylin A, one of the main bioactive flavonoids ofScutellariae radix. Based on the preliminary screening, we found that xeroderma pigmentosum group C (XPC), an important DNA damage recognition protein involved in NER, dramatically increased in hypoxic condition and contributed to hypoxia-induced cisplatin resistance. Further data suggested that Oroxylin A significantly reversed the hypoxia-induced cisplatin resistance through directly binding to HIF-1 alpha bHLH-PAS domain and blocking its binding to HRE3 transcription factor binding sites onXPCpromoter which is important to hypoxia-inducedXPCtranscription. Taken together, our findings not only demonstrate a crucial role of XPC dependent NER in hypoxia-induced cisplatin resistance, but also suggest a previously unrecognized tumor suppressive mechanism of Oroxylin A in NSCLC which through sensitization of cisplatin-mediated growth inhibition and apoptosis under hypoxia.	[Liu, Yunyao; Wang, Xiaoping; Li, Wenshu; Xu, Yujiao; Zhuo, Yating; He, Yuan; Guo, Qinglong; Qiang, Lei] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, State Key Lab Nat Med, Nanjing, Peoples R China; [Li, Mengyuan; Wang, Xiaosheng] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Biomed Informat Res Lab, Nanjing, Peoples R China; [Zhao, Li] China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Nanjing, Peoples R China	China Pharmaceutical University; China Pharmaceutical University; China Pharmaceutical University	Qiang, L (corresponding author), China Pharmaceut Univ, Sch Basic Med & Clin Pharm, State Key Lab Nat Med, Nanjing, Peoples R China.; Zhao, L (corresponding author), China Pharmaceut Univ, Sch Basic Med & Clin Pharm, Nanjing, Peoples R China.	zhaoli@cpu.edu.cn; lqiang@cpu.edu.cn	Qiang, Lei/B-2763-2012; Wang, Xiaosheng/AAN-6410-2020; Li, Mengyuan/GZM-6335-2022	Qiang, Lei/0000-0002-7164-3164; Wang, Xiaosheng/0000-0002-7199-7093; Li, Mengyuan/0000-0001-6856-6463	China Postdoctoral Science Foundation [2019M652035]; General Program of National Natural Science Foundation of China [81772911, 81974425, 81903648]; Natural Science Foundation of Jiangsu Province [BK20170744]; Six Talent Peaks Project in Jiangsu Province [SWYY-095]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); General Program of National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Jiangsu Province(Natural Science Foundation of Jiangsu Province); Six Talent Peaks Project in Jiangsu Province	This work was supported by the China Postdoctoral Science Foundation Grant (2019M652035); the General Program of National Natural Science Foundation of China (81772911, 81974425, and 81903648); the Natural Science Foundation of Jiangsu Province (BK20170744); the Six Talent Peaks Project in Jiangsu Province (SWYY-095).	Akanji MA, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8547846; An HC, 2018, J MED CHEM, V61, P9266, DOI 10.1021/acs.jmedchem.8b00971; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brown LM, 2006, MOL PHARMACOL, V69, P411, DOI 10.1124/mol.105.015743; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Chang A, 2011, LUNG CANCER, V71, P3, DOI 10.1016/j.lungcan.2010.08.022; Chun YS, 2002, J KOREAN MED SCI, V17, P581, DOI 10.3346/jkms.2002.17.5.581; Deben C, 2016, CRIT REV ONCOL HEMAT, V99, P63, DOI 10.1016/j.critrevonc.2015.11.019; Furuta T, 2002, CANCER RES, V62, P4899; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gao HB, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00188; Ha J, 2012, BIOCHEM CELL BIOL, V90, P521, DOI [10.1139/o2012-005, 10.1139/O2012-005]; Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8; Hu LB, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00290; Jin J, 2018, BIOMED PHARMACOTHER, V97, P385, DOI 10.1016/j.biopha.2017.10.140; Jung YW, 2007, CHEM REV, V107, P1387, DOI 10.1021/cr068207j; Kaluz S, 2008, CLIN CHIM ACTA, V395, P6, DOI 10.1016/j.cca.2008.05.002; Kothari S, 2003, ONCOGENE, V22, P4734, DOI 10.1038/sj.onc.1206666; Kwon DY, 2015, J MED CHEM, V58, P7659, DOI 10.1021/acs.jmedchem.5b01220; Lai TC, 2011, ONCOL REP, V25, P1243, DOI 10.3892/or.2011.1184; Lee JY, 2016, EXP THER MED, V12, P151, DOI 10.3892/etm.2016.3320; Lee K, 2007, J MED CHEM, V50, P1675, DOI 10.1021/jm0610292; Li WJ, 2017, MOL CARCINOGEN, V56, P863, DOI 10.1002/mc.22540; Li ZH, 2019, J MED CHEM, V62, P5725, DOI 10.1021/acs.jmedchem.8b01596; Liu RY, 2011, ONCOGENE, V30, P4814, DOI 10.1038/onc.2011.189; Liu YB, 2012, CARCINOGENESIS, V33, P1187, DOI 10.1093/carcin/bgs142; Liu YB, 2018, CELL PHYSIOL BIOCHEM, V46, P1971, DOI 10.1159/000489418; Lu L, 2016, PHYTOTHER RES, V30, P1765, DOI 10.1002/ptr.5694; Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238; Masoud GN, 2015, ACTA PHARM SIN B, V5, P378, DOI 10.1016/j.apsb.2015.05.007; Mazumdar J, 2010, P NATL ACAD SCI USA, V107, P14182, DOI 10.1073/pnas.1001296107; Naik R, 2012, J MED CHEM, V55, P10564, DOI 10.1021/jm301419d; Nardinocchi L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-1; Olcina MM, 2013, MOL CELL, V52, P758, DOI 10.1016/j.molcel.2013.10.019; Qiang L, 2016, AUTOPHAGY, V12, P357, DOI 10.1080/15548627.2015.1110667; Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770; Selvakumaran M, 2003, CANCER RES, V63, P1311; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shannon AM, 2003, CANCER TREAT REV, V29, P297, DOI 10.1016/S0305-7372(03)00003-3; Slyskova J, 2018, NUCLEIC ACIDS RES, V46, P9537, DOI 10.1093/nar/gky764; Song XR, 2006, CANCER CHEMOTH PHARM, V58, P776, DOI 10.1007/s00280-006-0224-7; Sowa T, 2017, CANCER MED-US, V6, P288, DOI 10.1002/cam4.991; Teng X, 2019, ONCOL REP, V41, P1875, DOI 10.3892/or.2019.6959; To KKW, 2006, EMBO J, V25, P4784, DOI 10.1038/sj.emboj.7601369; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Wei M, 2019, J CELL PHYSIOL, V234, P17392, DOI 10.1002/jcp.28361; Wirthner R, 2008, CARCINOGENESIS, V29, P2306, DOI 10.1093/carcin/bgn231; Wohlkoenig C, 2011, CANCER LETT, V308, P134, DOI 10.1016/j.canlet.2011.03.014; Wood RD, 2000, COLD SPRING HARB SYM, V65, P173, DOI 10.1101/sqb.2000.65.173; Xie XQ, 2019, J CANCER, V10, P1039, DOI 10.7150/jca.25814; Yang HY, 2012, MOL CARCINOGEN, V51, P185, DOI 10.1002/mc.20789; Yang SL, 2016, J HUAZHONG U SCI-MED, V36, P321, DOI 10.1007/s11596-016-1586-7; Yohena T, 2009, J THORAC ONCOL, V4, P284, DOI 10.1097/JTO.0b013e31819852d5; Zhou J, 2006, CANCER LETT, V237, P10, DOI 10.1016/j.canlet.2005.05.028; Zhu BB, 2012, TOXICOL APPL PHARM, V259, P387, DOI 10.1016/j.taap.2012.01.019; Zhu LT, 2013, TOXICOL LETT, V219, P107, DOI 10.1016/j.toxlet.2013.01.019	58	24	24	5	30	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 5	2020	39	45					6893	6905		10.1038/s41388-020-01474-x	http://dx.doi.org/10.1038/s41388-020-01474-x		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ON7IM	32978517				2023-01-03	WOS:000572714000001
J	Gordon, JL; Balsom, AA				Gordon, Jennifer L.; Balsom, Ashley A.			The psychological impact of fertility treatment suspensions during the COVID-19 pandemic	PLOS ONE			English	Article							INFERTILE WOMEN; DEFENSIVE PESSIMISM; SOCIAL SUPPORT; CHRONIC PAIN; PREVALENCE; ACCEPTANCE; ANXIETY; ADJUSTMENT; DEPRESSION; THERAPY	Purpose To examine the psychological impact of fertility treatment suspensions resulting from the COVID-19 pandemic and to clarify psychosocial predictors of better or worse mental health. Methods 92 women from Canada and the United States (ages 20-45 years) whose fertility treatments had been cancelled were recruited via social media. Participants completed a battery of questionnaires assessing depressive symptoms, perceived mental health impact, and change in quality of life related to treatment suspensions. Potential predictors of psychological outcomes were also examined, including several personality traits, aspects of social support, illness cognitions, and coping strategies. Results 52% of respondents endorsed clinical levels of depressive symptoms. On a 7-point scale, participants endorsed a significant decline in overall quality of life (M(SD) = -1.3(1.3), p < .0001) as well as a significant decline in mental health related to treatment suspensions on a scale from -5 to +5 (M(SD) = -2.1(2.1), p < .001). Several psychosocial variables were found to positively influence these outcomes: lower levels of defensive pessimism (r = -.25, p < .05), greater infertility acceptance (r = .51, p < .0001), better quality social support (r = .31, p < .01), more social support seeking (r = .35, p < .001) and less avoidance of infertility reminders (r = -.23, p = .029). Conclusion Fertility treatment suspensions have had a considerable negative impact on women's mental health and quality of life. However, these findings point to several protective psychosocial factors that can be fostered in the future to help women cope.	[Gordon, Jennifer L.; Balsom, Ashley A.] Univ Regina, Dept Psychol, Regina, SK, Canada	University of Regina	Gordon, JL (corresponding author), Univ Regina, Dept Psychol, Regina, SK, Canada.	jennifer.gordon@uregina.ca	Balsom, Ashley/AAS-1161-2020	Balsom, Ashley/0000-0002-1795-8093; Gordon, Jennifer/0000-0001-6401-6827	Saskatchewan Health Research Foundation [4577]; Canadian Institutes of Health Research, Tier II Canada Research Chair	Saskatchewan Health Research Foundation; Canadian Institutes of Health Research, Tier II Canada Research Chair(Canadian Institutes of Health Research (CIHR))	JLG: Saskatchewan Health Research Foundation, grant #4577, www.shrf.ca JLG: Canadian Institutes of Health Research, Tier II Canada Research Chair, https://cihr-irsc.gc.ca/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bromham D.R., 1989, J REPROD INFANT PSYC, V7, P195, DOI DOI 10.1080/02646838908403594; Bushnik T, 2012, HUM REPROD, V27, P738, DOI 10.1093/humrep/der465; Canadian Fertility Andrology Society Guidelines and Resources, 2020, CFAS COMM COVID 19; Carleton RN, 2007, J ANXIETY DISORD, V21, P105, DOI 10.1016/j.janxdis.2006.03.014; Chen TH, 2004, HUM REPROD, V19, P2313, DOI 10.1093/humrep/deh414; DOMAR AD, 1993, J PSYCHOSOM OBST GYN, V14, P45; Driscoll MA, 2016, ANN BEHAV MED, V50, P272, DOI 10.1007/s12160-015-9750-z; Esteve R, 2007, ANN BEHAV MED, V33, P179, DOI 10.1007/BF02879899; Faramarzi M, 2008, J AFFECT DISORDERS, V108, P159, DOI 10.1016/j.jad.2007.09.002; HAYES SC, 1994, BEHAV ANALYST, V17, P289, DOI 10.1007/BF03392677; HYNES GJ, 1992, BRIT J MED PSYCHOL, V65, P269, DOI 10.1111/j.2044-8341.1992.tb01707.x; Jimenez F. J. R., 2012, INT J PSYCHOL PSYCHO, V12, P333, DOI DOI 10.1016/J.BETH.2011.07.004; Kee BS, 2000, J ASSIST REPROD GEN, V17, P445; KEMP B, 2001, TOP SPINAL CORD INJU, V6, P116; Koszycki D, 2012, ARCH WOMEN MENT HLTH, V15, P193, DOI 10.1007/s00737-012-0277-z; Lauwerier E, 2010, INT J BEHAV MED, V17, P90, DOI 10.1007/s12529-009-9059-z; Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006; Lund R, 2009, HUM REPROD, V24, P2810, DOI 10.1093/humrep/dep257; Martins MV, 2014, HUM REPROD, V29, P83, DOI 10.1093/humrep/det403; McCracken LA, 2008, HEALTH PSYCHOL, V27, P215, DOI 10.1037/0278-6133.27.2.215; Mindes EJ, 2003, SOC SCI MED, V56, P2165, DOI 10.1016/S0277-9536(02)00221-6; Motta P., 2020, INT J SOC QUAL, V10, P100102, DOI [10.3167/IJSQ.2020.100102, DOI 10.3167/IJSQ.2020.100102]; Myers LB, 1996, AM J FAM THER, V24, P9, DOI 10.1080/01926189508251012; Nelson CJ, 2008, J SEX MED, V5, P1907, DOI 10.1111/j.1743-6109.2008.00880.x; NOREM JK, 1986, J PERS SOC PSYCHOL, V51, P1208, DOI 10.1037/0022-3514.51.6.1208; Peterson BD, 2006, HUM REPROD, V21, P2443, DOI 10.1093/humrep/del145; Peterson BD, 2011, COGN BEHAV PRACT, V18, P577, DOI 10.1016/j.cbpra.2010.03.004; SCHEIER MF, 1994, J PERS SOC PSYCHOL, V67, P1063, DOI 10.1037/0022-3514.67.6.1063; Spencer SM, 1996, PERS SOC PSYCHOL B, V22, P354, DOI 10.1177/0146167296224003; Turocy JM, 2020, EMOTIONAL IMPACT ASR; Van den Broeck U, 2010, PATIENT EDUC COUNS, V81, P422, DOI 10.1016/j.pec.2010.10.009; Viane I, 2003, PAIN, V106, P65, DOI 10.1016/S0304-3959(03)00291-4; Volgsten H, 2008, HUM REPROD, V23, P2056, DOI 10.1093/humrep/den154; Yu YJ, 2014, PSYCHIAT RES, V215, P401, DOI 10.1016/j.psychres.2013.10.032	34	28	28	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2020	15	9							e0239253	10.1371/journal.pone.0239253	http://dx.doi.org/10.1371/journal.pone.0239253			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NU7WV	32946479	gold, Green Published			2023-01-03	WOS:000573851100030
J	Goutaudier, R; Coizet, V; Carcenac, C; Carnicella, S				Goutaudier, Raphael; Coizet, Veronique; Carcenac, Carole; Carnicella, Sebastien			Compound 21, a two-edged sword with both DREADD-selective and off-target outcomes in rats	PLOS ONE			English	Article							VENTRAL TEGMENTAL AREA; SUBSTANTIA-NIGRA; SUPERIOR COLLICULUS; DOPAMINE; CHEMOGENETICS; ACTIVATION; NEURONS; BEHAVIOR	Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) represent a technical revolution in integrative neuroscience. However, the first used ligands exhibited dose-dependent selectivity for their molecular target, leading to potential unspecific effects. Compound 21 (C21) was recently proposed as an alternative, butin vivocharacterization of its properties is not sufficient yet. Here, we evaluated its potency to selectively modulate the activity of nigral dopaminergic (DA) neurons through the canonical DREADD receptor hM4Di usingTH-Crerats. In males, 1 mg.kg(-1)of C21 strongly increased nigral neurons activity in control animals, indicative of a significant off-target effect. Reducing the dose to 0.5 mg.kg(-1)circumvented this unspecific effect, while activated the inhibitory DREADDs and selectively reduced nigral neurons firing. In females, 0.5 mg.kg(-1)of C21 induced a transient and residual off-target effect that may mitigated the inhibitory DREADDs-mediated effect. This study raises up the necessity to test selectivity and efficacy of chosen ligands for each new experimental condition.	[Goutaudier, Raphael; Coizet, Veronique; Carcenac, Carole; Carnicella, Sebastien] Univ Grenoble Alpes, Grenoble Inst Neurosci, U1216, INSERM, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Carnicella, S (corresponding author), Univ Grenoble Alpes, Grenoble Inst Neurosci, U1216, INSERM, Grenoble, France.	sebastien.carnicella@inserm.fr		Goutaudier, Raphael/0000-0003-3125-1307	Institut National de la Sante et de la Recherche Medicale (Inserm); Agence Nationale de la Recherche [ANR-16-CE16-0002]; Grenoble Alpes University	Institut National de la Sante et de la Recherche Medicale (Inserm)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Agence Nationale de la Recherche(French National Research Agency (ANR)); Grenoble Alpes University	This work was supported by the Institut National de la Sante et de la Recherche Medicale (Inserm), the Agence Nationale de la Recherche (ANR-16-CE16-0002, to SC) and Grenoble Alpes University.	Aldrin-Kirk P, 2019, METHOD MOL BIOL, DOI [10.1007/978-1-4939-9065-8_4, DOI 10.1007/978-1-4939-9065-8_430706390]; [Anonymous], 2016, IEEE-ASME T MECH, VPP, P1, DOI DOI 10.1109/IEEESTD.2016.7460875; Armbruster BN, 2007, P NATL ACAD SCI USA, V104, P5163, DOI 10.1073/pnas.0700293104; Beloate LN, 2016, J NEUROSCI, V36, P9949, DOI 10.1523/JNEUROSCI.0937-16.2016; Bonaventura J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12236-z; Brentzen S, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00187; Campbell EJ, 2018, BRIT J PHARMACOL, V175, P994, DOI 10.1111/bph.14146; Chen X, 2015, ACS CHEM NEUROSCI, V6, P476, DOI 10.1021/cn500325v; Choleris E, 2018, NEUROSCI BIOBEHAV R, V85, P126, DOI 10.1016/j.neubiorev.2017.07.005; Coizet V, 2006, NEUROSCIENCE, V139, P1479, DOI 10.1016/j.neuroscience.2006.01.030; Coizet V, 2003, EUR J NEUROSCI, V17, P28, DOI 10.1046/j.1460-9568.2003.02415.x; Cornea-Hebert V, 1999, CORNEA HEBERT, V209, P187, DOI [10.1088/1741-2560/10/2/026010, DOI 10.1088/1741-2560/10/2/02601023428937]; Di Giovanni G, 1999, NEUROSCIENCE, V91, P587, DOI 10.1016/S0306-4522(98)00655-1; Dringenberg HC, 1998, N-S ARCH PHARMACOL, V358, P423, DOI 10.1007/PL00005274; Drui G, 2014, MOL PSYCHIATR, V19, P358, DOI 10.1038/mp.2013.3; Fink KB, 2007, PHARMACOL REV, V59, P360, DOI 10.1124/pr.107.07103; Girdhar A, 2018, IET IMAGE PROCESS, V12, P1, DOI 10.1049/iet-ipr.2017.0162; Gomez JL, 2017, SCIENCE, V357, P503, DOI 10.1126/science.aan2475; Goutaudier R, 2019, ENEURO, V6, DOI 10.1523/ENEURO.0171-19.2019; Jendryka M, 2019, SCI REP, V9, P1; Korotkova TM, 2002, NEUROSCI LETT, V320, P133, DOI 10.1016/S0304-3940(02)00050-2; Levine TR, 2002, HUM COMMUN RES, V28, P612, DOI 10.1111/j.1468-2958.2002.tb00828.x; MacLaren DAA, 2016, ENEURO, V3, DOI 10.1523/ENEURO.0219-16.2016; Mahler SV, 2018, NEUROPSYCHOPHARMACOL, V43, P934, DOI 10.1038/npp.2017.299; Mahler SV, 2014, NAT NEUROSCI, V17, P577, DOI 10.1038/nn.3664; Nair-Roberts RG, 2008, NEUROSCIENCE, V152, P1024, DOI 10.1016/j.neuroscience.2008.01.046; Paxinos G., 2007, RAT BRAIN STEREOTAXI; Roth BL, 2016, NEURON, V89, P683, DOI 10.1016/j.neuron.2016.01.040; Runegaard AH, 2019, PHARMACOL REV, V71, P123, DOI 10.1124/pr.117.013995; S BE, 2018, J CROHNS COLITIS, V12, pS049; Saloman JL, 2016, J NEUROSCI, V36, P10769, DOI 10.1523/JNEUROSCI.3480-15.2016; Thompson KJ, 2018, ACS PHARMACOL TRANSL, V1, P61, DOI 10.1021/acsptsci.8b00012; Ungless MA, 2012, TRENDS NEUROSCI, V35, P422, DOI 10.1016/j.tins.2012.02.003; Whissell PD, 2016, FRONT GENET, V7, DOI 10.3389/fgene.2016.00070; Xia F, 2017, ELIFE, V6, DOI 10.7554/eLife.27868	35	5	5	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2020	15	9							e0238156	10.1371/journal.pone.0238156	http://dx.doi.org/10.1371/journal.pone.0238156			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU7WV	32946510	Green Submitted, gold, Green Published			2023-01-03	WOS:000573851100022
J	Mulissa, Z; Wendrad, N; Bitewulign, B; Biadgo, A; Abate, M; Alemu, H; Abate, B; Kiflie, A; Magge, H; Parry, G				Mulissa, Zewdie; Wendrad, Naod; Bitewulign, Befikadu; Biadgo, Abera; Abate, Mehiret; Alemu, Haregeweyni; Abate, Biruk; Kiflie, Abiyou; Magge, Hema; Parry, Gareth			Effect of data quality improvement intervention on health management information system data accuracy: An interrupted time series analysis	PLOS ONE			English	Article								Background As part of a partnership between the Institute for Healthcare Improvement and the Ethiopian Federal Ministry of Health, woreda-based quality improvement collaboratives took place between November 2016 and December 2017 aiming to accelerate reduction of maternal and neonatal mortality in Lemu Bilbilu, Tanqua Abergele and Duguna Fango woredas. Before starting the collaboratives, assessments found inaccuracies in core measures obtained from Health Management Information System reports. Methods and results Building on the quality improvement collaborative design, data quality improvement activities were added and we used the World Health Organization review methodology to drive a verification factor for the core measures of number of pregnant women that received their first antenatal care visit, number of pregnant women that received antenatal care on at least four visits, number of pregnant women tested for syphilis and number of births attended by skilled health personnel. Impact of the data quality improvement was assessed using interrupted time series analysis. We found accurate data across all time periods for Tanqua Abergele. In Lemu Bilbilu and Duguna Fango, data quality improved for all core metrics over time. In Duguna Fango, the verification factor for number of pregnant women that received their first antenatal care visit improved from 0.794 (95%CI 0.753, 0.836; p<0.001) pre-intervention by 0.173 (95%CI 0.128, 0.219; p<0.001) during the collaborative; and the verification factor for number of pregnant women tested for syphilis improved from 0.472 (95%CI 0.390, 0.554; p<0.001) pre-intervention by 0.460 (95%CI 0.369, 0.552; p<0.001) during the collaborative. In Lemu Bilbilu, the verification factor for number of pregnant women receiving a fourth antenatal visit rose from 0.589 (95%CI 0.513, 0.664; p<0.001) at baseline by 0.358 (95%CI 0.258, 0.458; p<0.001) post-intervention; and skilled birth attendance rose from 0.917 (95%CI 0.869, 0.965) at baseline by 0.083 (95%CI 0.030, 0.136; p<0.001) during the collaborative. Conclusions A Data quality improvement initiative embedded within woreda clinical improvement collaborative improved accuracy of data used to monitor maternal and newborn health services in Ethiopia.	[Mulissa, Zewdie; Bitewulign, Befikadu; Biadgo, Abera; Abate, Mehiret; Alemu, Haregeweyni; Kiflie, Abiyou; Magge, Hema] Inst Healthcare Improvement, Addis Ababa, Ethiopia; [Wendrad, Naod] Fed Minist Hlth Ethiopia, Med Serv Directorate, Addis Ababa, Ethiopia; [Abate, Biruk] Fed Minist Hlth Ethiopia, Policy Planning Monitoring & Evaluat Directorate, Addis Ababa, Ethiopia; [Magge, Hema] Brigham & Womens Hosp, Div Global Hlth Equ, 75 Francis St, Boston, MA 02115 USA; [Magge, Hema] Boston Childrens Hosp, Div Gen Pediat, Boston, MA USA; [Parry, Gareth] Inst Healthcare Improvement, Boston, MA USA; [Parry, Gareth] Harvard Med Sch, Longwood Ave, Boston, MA 02115 USA	Federal Ministry of Health - Ethiopia (FMOH); Federal Ministry of Health - Ethiopia (FMOH); Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Institute for Healthcare Improvement; Harvard University; Harvard Medical School	Mulissa, Z (corresponding author), Inst Healthcare Improvement, Addis Ababa, Ethiopia.	zmulissa@yahoo.com	Beletew, Biruk/ABC-3508-2020; Parry, Gareth/CAF-6975-2022	Mulissa, Zewdie/0000-0002-3947-9579				Bernal JL, 2017, INT J EPIDEMIOL, V46, P348, DOI 10.1093/ije/dyw098; Braa J, 2012, B WORLD HEALTH ORGAN, V90, P379, DOI [10.2471/BLT.11.099580, 10.2471/BLT.11.99580]; Douglas G P, 2005, AMIA Annu Symp Proc, P942; Endriyas M, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-3991-7; Huaman MA, 2009, BMC MED INFORM DECIS, V9, DOI 10.1186/1472-6947-9-16; Mphatswe W, 2012, B WORLD HEALTH ORGAN, V90, P176, DOI 10.2471/BLT.11.092759; Mutale W, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-S2-S9; Nwankwo B, 2018, PAN AFR MED J, V30, DOI 10.11604/pamj.2018.30.289.15802; Otwombe KN, 2007, B WORLD HEALTH ORGAN, V85, P315, DOI 10.2471/BLT.06.033712; Ouedraogo M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213600; Penfold RB, 2013, ACAD PEDIATR, V13, pS38, DOI 10.1016/j.acap.2013.08.002; Wagenaar BH, 2016, HEALTH POLICY PLANN, V31, P129, DOI 10.1093/heapol/czv029; WHO, DAT QUAL REV DQR TOO	13	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2020	15	8							e0237703	10.1371/journal.pone.0237703	http://dx.doi.org/10.1371/journal.pone.0237703			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE5WK	32797091	gold, Green Published			2023-01-03	WOS:000562671300008
J	DiNardo, CD; Jonas, BA; Pullarkat, V; Thirman, MJ; Garcia, JS; Wei, AH; Konopleva, M; Dohner, H; Letai, A; Fenaux, P; Koller, E; Havelange, V; Leber, B; Esteve, J; Wang, J; Pejsa, V; Hajek, R; Porkka, K; Illes, A; Lavie, D; Lemoli, RM; Yamamoto, K; Yoon, SS; Jang, JH; Yeh, SP; Turgut, M; Hong, WJ; Zhou, Y; Potluri, J; Pratz, KW				DiNardo, C. D.; Jonas, B. A.; Pullarkat, V.; Thirman, M. J.; Garcia, J. S.; Wei, A. H.; Konopleva, M.; Doehner, H.; Letai, A.; Fenaux, P.; Koller, E.; Havelange, V.; Leber, B.; Esteve, J.; Wang, J.; Pejsa, V.; Hajek, R.; Porkka, K.; Illes, A.; Lavie, D.; Lemoli, R. M.; Yamamoto, K.; Yoon, S. -S.; Jang, J. -H.; Yeh, S. -P.; Turgut, M.; Hong, W. -J.; Zhou, Y.; Potluri, J.; Pratz, K. W.			Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONVENTIONAL CARE REGIMENS; BCL-2 INHIBITION; ELDERLY-PATIENTS; SURVIVAL; ABT-199; RECOMMENDATIONS; DIAGNOSIS; ABT-737; PROTEIN; ADULTS	Background Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase 1b study. Methods We randomly assigned previously untreated patients with confirmed AML who were ineligible for standard induction therapy because of coexisting conditions, because they were 75 years of age or older, or both to azacitidine plus either venetoclax or placebo. All patients received a standard dose of azacitidine (75 mg per square meter of body-surface area subcutaneously or intravenously on days 1 through 7 every 28-day cycle); venetoclax (target dose, 400 mg) or matching placebo was administered orally, once daily, in 28-day cycles. The primary end point was overall survival. Results The intention-to-treat population included 431 patients (286 in the azacitidine-venetoclax group and 145 in the azacitidine-placebo [control] group). The median age was 76 years in both groups (range, 49 to 91). At a median follow-up of 20.5 months, the median overall survival was 14.7 months in the azacitidine-venetoclax group and 9.6 months in the control group (hazard ratio for death, 0.66; 95% confidence interval, 0.52 to 0.85; P<0.001). The incidence of complete remission was higher with azacitidine-venetoclax than with the control regimen (36.7% vs. 17.9%; P<0.001), as was the composite complete remission (complete remission or complete remission with incomplete hematologic recovery) (66.4% vs. 28.3%; P<0.001). Key adverse events included nausea of any grade (in 44% of the patients in the azacitidine-venetoclax group and 35% of those in the control group) and grade 3 or higher thrombocytopenia (in 45% and 38%, respectively), neutropenia (in 42% and 29%), and febrile neutropenia (in 42% and 19%). Infections of any grade occurred in 85% of the patients in the azacitidine-venetoclax group and 67% of those in the control group, and serious adverse events occurred in 83% and 73%, respectively. Conclusions In previously untreated patients who were ineligible for intensive chemotherapy, overall survival was longer and the incidence of remission was higher among patients who received azacitidine plus venetoclax than among those who received azacitidine alone. The incidence of febrile neutropenia was higher in the venetoclax-azacitidine group than in the control group. (Funded by AbbVie and Genentech; VIALE-A ClinicalTrials.gov number,.) In more than 400 older patients with AML who could not receive myeloablative therapy, the incidence of composite complete remission was higher (66.4% vs. 28.3) and the median overall survival was longer (14.7 vs. 9.6 months) among patients who received azacitidine plus venetoclax (a B-cell lymphoma 2 antagonist) than among those who received azacitidine alone.	[DiNardo, C. D.; Konopleva, M.] Univ Texas MD Anderson Canc Ctr, Div Canc Med, Dept Leukemia, Houston, TX 77030 USA; [Jonas, B. A.] Univ Calif Davis, Sch Med, Div Hematol & Oncol, Dept Internal Med, Sacramento, CA 95817 USA; [Pullarkat, V.] City Hope Comprehens Canc Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA; [Pullarkat, V.] City Hope Comprehens Canc Ctr, Gehr Family Ctr Leukemia Res, Duarte, CA USA; [Hong, W. -J.] Genentech Inc, San Francisco, CA USA; [Thirman, M. J.] Univ Chicago, Univ Chicago Med, Dept Med, Sect Hematol & Oncol, Chicago, IL USA; [Zhou, Y.; Potluri, J.] AbbVie, N Chicago, IL USA; [Garcia, J. S.; Letai, A.] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Wei, A. H.] Alfred Hosp, Australian Ctr Blood Dis, Melbourne, Vic, Australia; [Wei, A. H.] Monash Univ, Melbourne, Vic, Australia; [Doehner, H.] Ulm Univ Hosp, Dept Internal Med 3, Ulm, Germany; [Fenaux, P.] Hop St Louis, AP HP, Paris, France; [Fenaux, P.] Univ Paris, Paris, France; [Koller, E.] Hanusch Hosp, Med Dept Hematol & Oncol, Vienna, Austria; [Havelange, V.] Clin Univ St Luc, Dept Hematol, Brussels, Belgium; [Leber, B.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Esteve, J.] August Pi i Sunyer Biomed Res Inst, Hosp Clin, Dept Hematol, Barcelona, Spain; [Wang, J.] Chinese Acad Med Sci, Inst Hematol & Hosp Blood Dis, Peking Union Med Coll, Tianjin, Peoples R China; [Pejsa, V.] Univ Zagreb, Sch Med, Univ Hosp Dubrava, Dept Hematol, Zagreb, Croatia; [Hajek, R.] Univ Hosp Ostrava Poruba, Dept Clin Subjects, Ostrava, Czech Republic; [Porkka, K.] Univ Helsinki, Helsinki Univ Hosp, Comprehens Canc Ctr, Helsinki, Finland; [Illes, A.] Univ Debrecen, Dept Hematol, Fac Med, Debrecen, Hungary; [Lavie, D.] Hadassah Med Ctr, Jerusalem, Israel; [Lemoli, R. M.] Univ Genoa, Dept Internal Med, Clin Hematol, Genoa, Italy; [Lemoli, R. M.] San Martino Hosp IRCCS, Genoa, Italy; [Yamamoto, K.] Aichi Canc Ctr, Dept Hematol & Cell Therapy, Nagoya, Aichi, Japan; [Yoon, S. -S.] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; [Jang, J. -H.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Hematol Oncol, Seoul, South Korea; [Yeh, S. -P.] China Med Univ Hosp, Dept Internal Med, Taichung, Taiwan; [Turgut, M.] Ondokuz Mayis Univ, Div Hematol, Dept Internal Med, Fac Med, Samsun, Turkey; [Pratz, K. W.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA	University of Texas System; UTMD Anderson Cancer Center; University of California System; University of California Davis; City of Hope; City of Hope; Roche Holding; Genentech; University of Chicago; AbbVie; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Florey Institute of Neuroscience & Mental Health; Monash University; Ulm University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; WGKK - Hanusch Hospital; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; McMaster University; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Hematology & Blood Diseases Hospital - CAMS; Peking Union Medical College; University of Zagreb; University of Helsinki; Helsinki University Central Hospital; University of Debrecen; Hebrew University of Jerusalem; Hadassah University Medical Center; University of Genoa; University of Genoa; IRCCS AOU San Martino IST; Aichi Cancer Center; Seoul National University (SNU); Sungkyunkwan University (SKKU); Samsung Medical Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; Ondokuz Mayis University; University of Pennsylvania; Pennsylvania Medicine	DiNardo, CD (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 428, Houston, TX 77030 USA.	cdinardo@mdanderson.org	Hajek, Roman/I-6639-2017; LEMOLI, ROBERTO/AAC-2370-2022; Jonas, Brian/AAS-3639-2020; Porkka, Kimmo/O-2323-2016	Hajek, Roman/0000-0001-6955-6267; LEMOLI, ROBERTO/0000-0001-9000-562X; Jonas, Brian/0000-0002-4921-5809; Wei, Andrew/0000-0002-7514-3298; Porkka, Kimmo/0000-0003-4112-5902	AbbVie; Genentech	AbbVie(AbbVie); Genentech(Roche HoldingGenentech)	Supported by AbbVie and Genentech.	Adams CM, 2019, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00636; Bogenberger JM, 2015, LEUKEMIA LYMPHOMA, V56, P226, DOI 10.3109/10428194.2014.910657; CAMPOS L, 1993, BLOOD, V81, P3091; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; Cortes JE, 2019, LEUKEMIA, V33, P379, DOI 10.1038/s41375-018-0312-9; DiNardo CD, 2020, BLOOD, V135, P85, DOI 10.1182/blood.2019001239; DiNardo CD, 2019, BLOOD, V133, P7, DOI 10.1182/blood-2018-08-868752; DiNardo CL, 2018, LANCET ONCOL, V19, P216, DOI 10.1016/S1470-2045(18)30010-X; Dohner H, 2017, BLOOD, V129, P424, DOI 10.1182/blood-2016-08-733196; Dombret H, 2015, BLOOD, V126, P291, DOI 10.1182/blood-2015-01-621664; Fenaux P, 2010, J CLIN ONCOL, V28, P562, DOI 10.1200/JCO.2009.23.8329; Howlader N., 2019, SEER CANC STAT REV, V1; Jin S, 2020, CLIN CANCER RES, V26, P3371, DOI 10.1158/1078-0432.CCR-19-1900; Jonas BA, 2019, LEUKEMIA, V33, P2795, DOI 10.1038/s41375-019-0612-8; Karakas T, 2002, LEUKEMIA, V16, P846, DOI 10.1038/sj.leu.2402434; Konopleva M, 2006, CANCER CELL, V10, P375, DOI 10.1016/j.ccr.2006.10.006; Konopleva M, 2016, CANCER DISCOV, V6, P1106, DOI 10.1158/2159-8290.CD-16-0313; Krauss AC, 2019, CLIN CANCER RES, V25, P2685, DOI 10.1158/1078-0432.CCR-18-2990; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Mehta SV, 2013, NEOPLASMA, V60, P666, DOI 10.4149/neo_2013_085; National Cancer Institute National Institutes of Health, COMM TERM CRIT ADV E; Pan RQ, 2014, CANCER DISCOV, V4, P362, DOI 10.1158/2159-8290.CD-13-0609; Pollyea DA, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-117179; Richard-Carpentier G, 2019, THER ADV HEMATOL, V10, DOI 10.1177/2040620719882822; Schuurhuis GJ, 2018, BLOOD, V131, P1275, DOI 10.1182/blood-2017-09-801498; Song XL, 2018, ACTA HAEMATOL-BASEL, V139, P115, DOI 10.1159/000486228; Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048	28	714	722	18	91	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 13	2020	383	7					617	629		10.1056/NEJMoa2012971	http://dx.doi.org/10.1056/NEJMoa2012971			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE7HD	32786187	Bronze			2023-01-03	WOS:000562771200009
J	Luo, Y; Eran, A; Palmer, N; Avillach, P; Levy-Moonshine, A; Szolovits, P; Kohane, IS				Luo, Yuan; Eran, Alal; Palmer, Nathan; Avillach, Paul; Levy-Moonshine, Ami; Szolovits, Peter; Kohane, Isaac S.			A multidimensional precision medicine approach identifies an autism subtype characterized by dyslipidemia	NATURE MEDICINE			English	Article							CHOLESTEROL-METABOLISM; SPECTRUM; DISCOVERY; CHILDREN	Integration of large datasets of familial whole-exome sequencing, neurodevelopmental gene expression, electronic health records and healthcare claims led to the identification of a subtype of autism spectrum disorder that is associated with lipid dysregulation. The promise of precision medicine lies in data diversity. More than the sheer size of biomedical data, it is the layering of multiple data modalities, offering complementary perspectives, that is thought to enable the identification of patient subgroups with shared pathophysiology. In the present study, we use autism to test this notion. By combining healthcare claims, electronic health records, familial whole-exome sequences and neurodevelopmental gene expression patterns, we identified a subgroup of patients with dyslipidemia-associated autism.	[Luo, Yuan] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Div Hlth & Biomed Informat, Chicago, IL 60611 USA; [Luo, Yuan] Northwestern Univ, Clin & Translat Sci Inst, Chicago, IL 60611 USA; [Luo, Yuan] Northwestern Univ, Inst Augmented Intelligence Med, Chicago, IL 60611 USA; [Luo, Yuan] Northwestern Univ, Ctr Hlth Informat Partnerships, Chicago, IL 60611 USA; [Eran, Alal] Boston Childrens Hosp, Computat Hlth Informat Program, Boston, MA USA; [Eran, Alal; Palmer, Nathan; Avillach, Paul; Kohane, Isaac S.] Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA; [Eran, Alal] Ben Gurion Univ Negev, Dept Life Sci, Beer Sheva, Israel; [Eran, Alal] Ben Gurion Univ Negev, Zlotowski Ctr Neurosci, Beer Sheva, Israel; [Levy-Moonshine, Ami] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA USA; [Szolovits, Peter] MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Northwestern University; Northwestern University; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Ben Gurion University; Ben Gurion University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT)	Kohane, IS (corresponding author), Harvard Med Sch, Dept Biomed Informat, Boston, MA 02115 USA.	isaac_kohane@harvard.edu	Eran, Alal/AAA-8776-2021; Luo, Yuan/K-5563-2016	Luo, Yuan/0000-0003-0195-7456; Szolovits, Peter/0000-0001-8411-6403; Eran, Alal/0000-0001-6784-7597	National Institutes for Health (NIH) [2042, 1918, 2004]; US National Institutes of Health [1R21LM012618, 5UL1TR001422, U01HG007530, OT3OD025466, OT3HL142480, U54HG007963, 1U01TR002623-01, 1U54HD090255-01]; National Institute of Mental Health [P50MH106933]; Israeli Ministry of Science and Technology [17708]; PrecisionLink Initiative at BCH; Aetna Life Insurance Co	National Institutes for Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Israeli Ministry of Science and Technology(Ministry of Science, Technology and Space (MOST), Israel); PrecisionLink Initiative at BCH; Aetna Life Insurance Co	Data analyzed in this manuscript reside in the National Institutes for Health (NIH)-supported NIMH Data Archive's NDAR as Collection nos. 1918, 2004 and 2042. We thank all the families at the participating Simons Simplex Collection sites, as well as the principal investigators (A. Beaudet, R. Bernier, J. Constantino, E. Cook, E. Fombonne, D. Geschwind, R. Goin-Kochel, E. Hanson, D. Grice, A. Klin, D. Ledbetter, C. Lord, C. Martin, D. Martin, R. Maxim, J. Miles, O. Ousley, K. Pelphrey, B. Peterson, J. Piggot, C. Saulnier, M. State, W. Stone, J. Sutcliffe, C. Walsh, Z. Warren and E. Wijsman). We thank SFARI Base for access to their phenotypic data. Approved researchers can obtain the Simons Simplex Collection population dataset described in the present study (https://base.sfari.org/ordering/phenotype/sfari-phenotype/download?code=11) by applying at https://base.sfari.org.We thank J. Eichler, D. Margulies and members of the Kohane lab for fruitful discussions. We thank somersault18:24 (www.somersault1824.com) for illustrations. Y.L. was supported by the US National Institutes of Health (1R21LM012618 and 5UL1TR001422). A.E., P.S. and I.S.K. were supported by the National Institute of Mental Health (P50MH106933). A.E. was supported by the Israeli Ministry of Science and Technology (grant no. 17708) and by the PrecisionLink Initiative at BCH. N.P. received funding support from Aetna Life Insurance Co. P.A. was supported by the US National Institutes of Health (U01HG007530, OT3OD025466, OT3HL142480, U54HG007963, 1U01TR002623-01 and 1U54HD090255-01).	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, DOI 10.1176/appi.books.9780890425596; [Anonymous], 1996, ICD 9 CM INT CLASS D; Bateni M, 2017, ADV NEUR IN, V30; Beffert U, 2004, J LIPID RES, V45, P403, DOI 10.1194/jlr.R300017-JLR200; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; BRAMER G R, 1988, World Health Statistics Quarterly, V41, P32; Buchovecky CM, 2013, NAT GENET, V45, P1013, DOI 10.1038/ng.2714; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Coleman DM, 2019, J CHILD ADOL PSYCHOP, V29, P107, DOI 10.1089/cap.2018.0121; Csardi G., 2006, INT J COMPLEX SYSTEM; David MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157937; de la Torre-Ubieta L, 2016, NAT MED, V22, P345, DOI 10.1038/nm.4071; Denny JC, 2013, NAT BIOTECHNOL, V31, P1102, DOI 10.1038/nbt.2749; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; DUNN OJ, 1961, J AM STAT ASSOC, V56, P52, DOI 10.2307/2282330; El-Ansary A, 2012, LIPIDS HEALTH DIS, V11, DOI 10.1186/1476-511X-11-160; Everitt B., 2006, CAMBRIDGE DICT STAT; Fisher R. A., 1946, Statistical methods for research workers.; Fu BQ, 2017, IMMUNITY, V47, P1100, DOI [10.1016/j.immuni.2017.11.018, 10.15585/mmwr.ss6904a1]; Gong HL, 2013, J HISTOCHEM CYTOCHEM, V61, P857, DOI 10.1369/0022155413505601; Grissom NM, 2018, MOL PSYCHIATR, V23, P544, DOI 10.1038/mp.2017.184; Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011; Jung H, 2018, NAT NEUROSCI, V21, P1218, DOI 10.1038/s41593-018-0208-z; Kang HJ, 2011, NATURE, V478, P483, DOI 10.1038/nature10523; Kim EK, 2010, NUTR RES, V30, P255, DOI 10.1016/j.nutres.2010.04.002; Kohane IS, 2012, J AM MED INFORM ASSN, V19, P181, DOI 10.1136/amiajnl-2011-000492; Krumm N, 2015, NAT GENET, V47, P582, DOI 10.1038/ng.3303; Kyle SM, 2016, HUM MOL GENET, V25, P3029, DOI 10.1093/hmg/ddw156; Kysenius K, 2012, CELL MOL LIFE SCI, V69, P1903, DOI 10.1007/s00018-012-0977-6; Lawrence M, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003118; Li JJ, 2014, MOL SYST BIOL, V10, DOI 10.15252/msb.20145487; Lord C, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-019-0138-4; National Research Council Committee on a Framework for Developing a New Taxonomy of Disease, 2011, PREC MED BUILD KNOWL; Neale Benjamin, 2012, STAT GENETICS; Noreen E. W., 1989, COMPUTER INTENSIVE M; Parikshak NN, 2013, CELL, V155, P1008, DOI 10.1016/j.cell.2013.10.031; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Rosenson R., UPTODATE; Rosvall M, 2008, P NATL ACAD SCI USA, V105, P1118, DOI 10.1073/pnas.0706851105; Shi L, 2016, SCI REP, V6; Sikora DM, 2006, AM J MED GENET A, V140A, P1511, DOI 10.1002/ajmg.a.31294; Su CH, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00012; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tierney E, 2001, AM J MED GENET, V98, P191, DOI 10.1002/1096-8628(20010115)98:2<191::AID-AJMG1030>3.0.CO;2-M; Tierney E, 2006, AM J MED GENET B, V141B, P666, DOI 10.1002/ajmg.b.30368; Wong CT, 2016, J NEUROSCI RES, V94, P759, DOI 10.1002/jnr.23759; Wong CT, 2015, EUR J NEUROSCI, V42, P2742, DOI 10.1111/ejn.13028; Zhang M, 2019, NEURON, V101, P690, DOI 10.1016/j.neuron.2019.01.022	51	18	18	3	11	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2020	26	9								10.1038/s41591-020-1007-0	http://dx.doi.org/10.1038/s41591-020-1007-0		AUG 2020	17	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PF3EM	32778826				2023-01-03	WOS:000558228200002
J	Sintayehu, Y; Desalew, A; Geda, B; Tiruye, G; Mezmur, H; Shiferaw, K; Mulatu, T				Sintayehu, Yitagesu; Desalew, Assefa; Geda, Biftu; Tiruye, Getahun; Mezmur, Haymanot; Shiferaw, Kasiye; Mulatu, Teshale			Basic neonatal resuscitation skills of midwives and nurses in Eastern Ethiopia are not well retained: An observational study	PLOS ONE			English	Article							NEWBORN CARE; HEALTH; RETENTION; KNOWLEDGE; DEATH	Background Neonatal resuscitation is a life-saving intervention for birth asphyxia, a leading cause of neonatal mortality. Worldwide, four million neonate deaths happen annually, and birth asphyxia accounts for one million deaths. Improving providers' neonatal resuscitation skills is critical for delivering quality care and for morbidity and mortality reduction. However, retention of these skills has been challenging in developing countries, including Ethiopia. Hence, this study aimed to assess neonatal resuscitation skills retention and associated factors among midwives and nurses in Eastern Ethiopia. Methods An institution-based cross-sectional study was conducted using a pre-tested, structured, observational checklist. A total of 427 midwives and nurses were included from 28 public health facilities by cluster sampling and simple random sampling methods. Data were collected on facility type, availability of essential resuscitation equipment, socio-demographic characteristics of participants, current working unit, years of professional experience, whether a nurse or midwife received refresher training, and skills and knowledge related to neonatal resuscitation. Binary logistic regression was used to analyse the association between neonatal resuscitation skill retention and independent variables. Results About 11.2% of nurses and midwives were found to have retention of neonatal resuscitation skills. Being a midwife (AOR, 7.39 [95% CI: 2.25, 24.24]), ever performing neonatal resuscitation (AOR, 3.33 [95% CI: 1.09, 10.15]), bachelor sciences degree or above (AOR, 4.21 [95% CI: 1.60, 11.00]), and good knowledge of neonatal resuscitation (AOR, 3.31 [95% CI: 1.41, 7.73]) were significantly associated with skill retention of midwives and nurses. Conclusion Basic neonatal resuscitation skills of midwives and nurses in Eastern Ethiopia are not well retained. This could increase the death of neonates due to asphyxia. Being a midwife, Bachelor Sciences degree or above educational status, ever performing neonatal resuscitation, and good knowledge were associated with skill retention. Providers should be encouraged to upgrade their educational level to build their skill retention and expose themselves to NR. Further, understanding factors affecting how midwives and nurses gain and retain skills using high-level methodology are essential.	[Sintayehu, Yitagesu; Desalew, Assefa; Geda, Biftu; Tiruye, Getahun; Mezmur, Haymanot; Shiferaw, Kasiye; Mulatu, Teshale] Haramaya Univ, Coll Hlth & Med Sci, Sch Nursing & Midwifery, Harar, Ethiopia	Haramaya University	Sintayehu, Y (corresponding author), Haramaya Univ, Coll Hlth & Med Sci, Sch Nursing & Midwifery, Harar, Ethiopia.	yitagesu.sintayehu@gmail.com	Desalew, Assefa +251913083613/C-5524-2019; Shiferaw, Kasiye/GLS-4627-2022; Sintayehu, Yitagesu/AAI-8506-2021	Shiferaw, Kasiye/0000-0001-6087-1682; Sintayehu, Yitagesu/0000-0002-4325-4241; , getahun/0000-0002-0441-0440; Desalew, Assefa/0000-0001-6065-0708	CIRHT-Ethiopia	CIRHT-Ethiopia	CIRHT-Ethiopia provided support in the form of per diem for data collectors, supervisors and provided training for the team. No additional external funding was received for this study.	Abrha MW, 2019, INT J PEDIAT, V2019, DOI 10.1155/2019/8571351; Agravat N., 2013, REV INTERVENTIONS AP, P1; Alhassan A, 2019, NURS RES PRACT, V2019, DOI 10.1155/2019/3652608; Ameh CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167270; Antonucci R, 2014, J PEDIATR NEONATAL I, V3, DOI 10.7363/030269; Ashish KC, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0853-5; Aslam HM, 2014, ITAL J PEDIATR, V40, DOI 10.1186/s13052-014-0094-2; Averting Maternal Death and Disability Program (AMDD), 2009, NEEDS ASS EM OBST NE; Bang A, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1141-3; Bansal SC, 2014, INT J PEDIAT, V2014, DOI 10.1155/2014/676374; Beck D, 2004, CUIDADOS AO RECEM NA, P18; Benazeera SGS, 2014, J BIOMED PHARM RES, V3, P67; Berglund S, 2012, ARCH DIS CHILD-FETAL, V97, pF204, DOI 10.1136/archdischild-2011-300295; Bhutta ZA, 2014, MANSONS TROPICAL INF; Bhutta ZA, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-S1-S7; Bogale TN, 2017, BMC PEDIATR, V17, DOI 10.1186/s12887-017-0967-9; Bookman L, 2010, RESUSCITATION, V81, P1180, DOI 10.1016/j.resuscitation.2010.04.034; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Cavagnero E, 2008, LANCET, V371, P1284, DOI 10.1016/S0140-6736(08)60563-2; Central Statistical Agency (CSA) and ICF, ETH DEM HLTH SURV 20; Danzhen You, 2015, JAN BEISE PI WORLD C, P74; Daripa Mandira, 2013, Rev. paul. pediatr., V31, P37; Das MK, 2018, J CLIN NEONATOL, V7, P89, DOI 10.4103/jcn.JCN_9_18; De Bernardo G, 2016, ITAL J PEDIATR, V42, DOI 10.1186/s13052-016-0313-0; Desa U.N., 2016, TRANSF OUR WORLD 203; Devi S, 2015, INT J SCI RES, V4, P432; DRAKE M, 2019, BMC PEDIATR, V19, DOI DOI 10.1186/S12887-018-1376-4; Eblovi D, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1387985; Gebreegziabher E, 2014, WORLD J EMERG MED, V5, P196, DOI [10.5847/wjem.j.1920-8642.2014.03.007, 10.5847/wjem.j.issn.1920-8642.2014.03.007]; Halloran DR, 2009, J PERINATOL, V29, P243, DOI 10.1038/jp.2008.192; Keyes EB, 2011, INT J GYNECOL OBSTET, V115, P94, DOI 10.1016/j.ijgo.2011.07.009; Kim YM, 2013, BMC PEDIATR, V13, DOI 10.1186/1471-2431-13-140; Kinzie B, 2004, GUIDE SKILLED PROVID; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; Lawn JE., 2009, MILLION NEONATAL DEA, VI, P1; Lee ACC, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-S3-S12; Makene CL, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/s12884-014-0381-3; Maynard KR, 2015, PAEDIATR INT CHILD H, V35, P192, DOI 10.1179/2046905515Y.0000000034; Mekonnen Biruk Tensou, 2013, BMC PUBLIC HLTH 2013, V13, P471; Mirkuzie AH, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-354; Murila F, 2012, PAN AFR MED J, V8688, P4; Nanthini Subbiah, 2012, Health and Population - Perspectives and Issues, V35, P36; Oza S, 2015, B WORLD HEALTH ORGAN, V93, P19, DOI 10.2471/BLT.14.139790; Patel J, 2012, PEDIATRICS, V130, P515, DOI 10.1542/peds.2012-0149; Seid A., 2015, KNOWLEDGE PRACTICE N; Stanton C, 2006, LANCET, V367, P1487, DOI 10.1016/S0140-6736(06)68586-3; Tabangin ME, 2018, INT HEALTH, V10, P163, DOI 10.1093/inthealth/ihy017; UNICEF WHO World Bank, 2015, LEV TRENDS CHILD MOR; UNICEF WHO & World Bank Group., 2021, LEVELS TRENDS CHILD; Vijayan A, 2015, INT J ADV RES, V3, P1200; WALL S, 2010, INT J GYNECOL OBSTET, V107, P1, DOI DOI 10.1016/J.IJG0.2009.07.013; Wang HD, 2014, LANCET, V384, P957, DOI 10.1016/S0140-6736(14)60497-9; World Health Organization,, 2012, GUID BAS NEWB RES; World Health Organization, 2018, MON HLTH SDGS SUST D; Wyckoff MH, 2015, PEDIATRICS, V136, pS196, DOI 10.1542/peds.2015-3373G	55	3	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2020	15	7							e0236194	10.1371/journal.pone.0236194	http://dx.doi.org/10.1371/journal.pone.0236194			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OD5ZL	32706775	Green Published, gold			2023-01-03	WOS:000579931700018
J	Kim, JS; Kim, J; Gelegjamts, D				Kim, Jin Sun; Kim, Jinhee; Gelegjamts, Delgersuren			Knowledge, attitude and self-efficacy towards palliative care among nurses in Mongolia: A cross-sectional descriptive study	PLOS ONE			English	Article							DYING PATIENTS; BAD-NEWS; COMMUNICATION; PROVISION; CANCER; DEATH	Background Nurses have a primary role in providing palliative and end-of-life (EOL) care. Their knowledge of EOL care, attitudes toward care of the dying, and palliative care self-efficacy are important in care delivery. Little is known regarding palliative care preparedness among Mongolian nurses. This study examines palliative care knowledge, attitude towards death and dying, and self-efficacy among Mongolian nurses, and examines predictors of self-efficacy. Methods A cross-sectional descriptive study was conducted. Participants were 141 nurses employed at the National Cancer Center in Mongolia. Data was collected using a self-administered questionnaire. Results The median score for the knowledge of palliative care was 8.0/20. "Psychosocial and spiritual care" was the lowest score on the palliative care knowledge subscale. The mean score for attitude toward care of the dying was 69.1%, indicating positive attitudes. The mean score for the palliative care self-efficacy was 33.8/48. Nurses reported low self-efficacy toward communicating with dying patients and their families, and managing delirium. Palliative care knowledge and duration of experience as an oncology nurse significantly predicted self-efficacy toward palliative care, accounting for 14.0% of the variance. Conclusions Palliative education for nurses should address the knowledge gaps in EOL care and focus in increasing palliative care self-efficacy. Considering palliative care knowledge and nursing experience as an oncology nurse were significant predictors of self-efficacy toward palliative care, more effort is needed to fill the knowledge gaps in EOL care among nurses, especially for less experienced nurses.	[Kim, Jin Sun; Kim, Jinhee] Chosun Univ, Dept Nursing, Gwangju, South Korea; [Gelegjamts, Delgersuren] Chosun Univ, Grad Sch, Gwangju, South Korea; [Gelegjamts, Delgersuren] Mongolian Natl Univ, Dept Nursing, Ulaanbaatar, Mongolia	Chosun University; Chosun University; National University of Mongolia	Kim, J (corresponding author), Chosun Univ, Dept Nursing, Gwangju, South Korea.	jinheeara@chosun.ac.kr		Kim, Jinsun/0000-0001-9755-3987; Kim, Jinhee/0000-0002-8037-9174	Chosun University	Chosun University	This study was supported by research fund from Chosun University, 2017.	Anila G.D., 2015, INT J SCI RES, V4, P1790; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Bjorgaas Malfrid Holmaas, 2012, Tidsskr Nor Laegeforen, V132, P546, DOI 10.4045/tidsskr.11.1031; Braun Michal, 2010, Oncol Nurs Forum, V37, pE43, DOI 10.1188/10.ONF.E43-E49; Broglio K, 2014, J HOSP PALLIAT NURS, V16, P420, DOI 10.1097/NJH.0000000000000089; Bumb M, 2017, CLIN J ONCOL NURS, V21, P573, DOI 10.1188/17.CJON.573-580; Challinor Julia M, 2016, J Glob Oncol, V2, P154, DOI 10.1200/JGO.2015.001974; Choi M, 2012, J CONTIN EDUC NURS, V43, P379, DOI 10.3928/00220124-20120615-35; Chover-Sierra E, 2017, REV LAT-AM ENFERM, V25, DOI 10.1590/1518-8345.1610.2847; Davaasuren O., 2017, BAOJ PALLIAT MED, V3; Davaasuren O, 2007, J PAIN SYMPTOM MANAG, V33, P568, DOI 10.1016/j.jpainsymman.2007.02.017; Davaasuren O, 2018, J PAIN SYMPTOM MANAG, V55, pS59, DOI 10.1016/j.jpainsymman.2017.02.022; Fang ML, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0282-6; Frommelt K H, 1991, Am J Hosp Palliat Care, V8, P37, DOI 10.1177/104990919100800509; Fuoto A, 2019, J HOSP PALLIAT NURS, V21, P124, DOI 10.1097/NJH.0000000000000493; Gibbs KD, 2015, J PAIN SYMPTOM MANAG, V49, P1102, DOI 10.1016/j.jpainsymman.2014.12.004; Grassi L, 2015, CURR PSYCHIAT REP, V17, DOI 10.1007/s11920-015-0550-8; Grubb C, 2016, PALLIATIVE MED, V30, P83, DOI 10.1177/0269216315616762; Gysels M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034188; Hannon B, 2016, J CLIN ONCOL, V34, P62, DOI 10.1200/JCO.2015.62.1615; Harden K, 2017, CLIN J ONCOL NURS, V21, pE232, DOI 10.1188/17.CJON.E232-E238; Henoch I, 2013, J PAIN SYMPTOM MANAG, V46, P785, DOI 10.1016/j.jpainsymman.2013.01.013; Hsu Hsang-Yu, 2019, Hu Li Za Zhi, V66, P32, DOI 10.6224/JN.201910_66(5).06; Iranmanesh S, 2014, PALLIAT SUPPORT CARE, V12, P203, DOI 10.1017/S1478951512001058; Jafari M, 2015, INDIAN J PALLIAT CAR, V21, P192, DOI 10.4103/0973-1075.156497; Jang Bo Jung, 2018, Journal of Hospice and Palliative Care, V21, P65, DOI 10.14475/kjhpc.2018.21.2.65; Kalogeropoulou M, 2016, WORLD J SOC SCI RES, V3, P381; Kim Boon Han, 2012, [Korean Journal of Adult Nursing, 성인간호학회지], V24, P390; Kim HS, 2011, J HOSP PALLIAT NURS, V13, P222, DOI 10.1097/NJH.0b013e318210fdec; Kurnia TA., 2019, J NERS, V13, P219, DOI [10.20473/jn.v13i2.9986, DOI 10.20473/JN.V13I2.9986]; Lange M, 2008, ONCOL NURS FORUM, V35, P955, DOI 10.1188/08.ONF.955-959; Logan Janice, 2018, Nurs Stand, V33, P63, DOI 10.7748/ns.2018.e10888; Malloy P, 2010, J HOSP PALLIAT NURS, V12, P166, DOI 10.1097/NJH.0b013e3181d99fee; Nairamdal J, 2017, 59 RES C MNUMS, P30; Nunes, 2018, NEUROPSYCHIATRY-LOND, V8, P484, DOI DOI 10.4172/NEUROPSYCHIATRY.1000370; Nyatanga Brian, 2017, Br J Community Nurs, V22, P152, DOI 10.12968/bjcn.2017.22.3.152; Oyunchimeg B, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1576-8; Phillips J, 2011, INT J NURS STUD, V48, P1096, DOI 10.1016/j.ijnurstu.2011.02.015; Qadire MA., 2014, J HOSP PALLIAT NURS, V16, P1, DOI [10.1097/NJH.0000000000000017, DOI 10.1097/NJH.0000000000000017]; Ross MM, 1996, J ADV NURS, V23, P126; Sato K, 2014, JPN J CLIN ONCOL, V44, P718, DOI 10.1093/jjco/hyu075; Shen MJ, 2018, J GLOB ONCOL, V4, DOI 10.1200/JGO.17.00160; Sleeman KE, 2019, LANCET GLOB HEALTH, V7, pE883, DOI 10.1016/S2214-109X(19)30172-X; Tait V, 2015, INT J PALLIAT CARE, DOI [10.1155/2015/, DOI 10.1155/2015/]; ten Koppel M, 2019, INT J NURS STUD, V92, P135, DOI 10.1016/j.ijnurstu.2018.09.019; Wang LP, 2018, INT J PALLIAT NURS, V24, P33, DOI 10.12968/ijpn.2018.24.1.33; Wilson Olivia, 2016, Br J Nurs, V25, P600, DOI 10.12968/bjon.2016.25.11.600; World Health Organization, 2015, WHO GUID TRANSL AD I, P4	48	15	15	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2020	15	7							e0236390	10.1371/journal.pone.0236390	http://dx.doi.org/10.1371/journal.pone.0236390			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NX7VK	32702007	Green Published, gold			2023-01-03	WOS:000575913700086
J	Zhou, T; Damsky, W; Weizman, OE; McGeary, MK; Hartmann, KP; Rosen, CE; Fischer, S; Jackson, R; Flavell, RA; Wang, J; Sanmamed, MF; Bosenberg, MW; Ring, AM				Zhou, Ting; Damsky, William; Weizman, Orr-El; McGeary, Meaghan K.; Hartmann, K. Patricia; Rosen, Connor E.; Fischer, Suzanne; Jackson, Ruaidhri; Flavell, Richard A.; Wang, Jun; Sanmamed, Miguel F.; Bosenberg, Marcus W.; Ring, Aaron M.			IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy	NATURE			English	Article							T-CELL RESPONSE; METASTATIC MELANOMA; ACTIVATION; INSIGHTS; AUGMENTATION; MUTATIONS; THERAPY	Cytokines were the first modern immunotherapies to produce durable responses in patients with advanced cancer, but they have only modest efficacy and limited tolerability(1,2). In an effort to identify alternative cytokine pathways for immunotherapy, we found that components of the interleukin-18 (IL-18) pathway are upregulated on tumour-infiltrating lymphocytes, suggesting that IL-18 therapy could enhance anti-tumour immunity. However, recombinant IL-18 previously did not demonstrate efficacy in clinical trials(3). Here we show that IL-18BP, a high-affinity IL-18 decoy receptor, is frequently upregulated in diverse human and mouse tumours and limits the anti-tumour activity of IL-18 in mice. Using directed evolution, we engineered a 'decoy-resistant' IL-18 (DR-18) that maintains signalling potential but is impervious to inhibition by IL-18BP. Unlike wild-type IL-18, DR-18 exerted potent anti-tumour effects in mouse tumour models by promoting the development of poly-functional effector CD8(+)T cells, decreasing the prevalence of exhausted CD8(+)T cells that express the transcriptional regulator of exhaustion TOX, and expanding the pool of stem-like TCF1(+)precursor CD8(+)T cells. DR-18 also enhanced the activity and maturation of natural killer cells to effectively treat anti-PD-1 resistant tumours that have lost surface expression of major histocompatibility complex class I molecules. These results highlight the potential of the IL-18 pathway for immunotherapeutic intervention and implicate IL-18BP as a major therapeutic barrier. An engineered version of IL-18 that is resistant to binding by the soluble decoy receptor IL-18BP shows strong anti-tumour activity in mouse models of cancer.	[Zhou, Ting; Weizman, Orr-El; Hartmann, K. Patricia; Rosen, Connor E.; Fischer, Suzanne; Jackson, Ruaidhri; Flavell, Richard A.; Bosenberg, Marcus W.; Ring, Aaron M.] Yale Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; [Damsky, William; Bosenberg, Marcus W.] Yale Sch Med, Dept Dermatol, New Haven, CT USA; [McGeary, Meaghan K.; Bosenberg, Marcus W.] Yale Sch Med, Dept Pathol, New Haven, CT USA; [Flavell, Richard A.] Howard Hughes Med Inst, Chevy Chase, MD USA; [Wang, Jun] NYU, Dept Pathol, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA; [Sanmamed, Miguel F.] Clin Univ Navarra, Dept Oncol, Pamplona, Spain; [Ring, Aaron M.] Yale Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University; Yale University; Yale University; Howard Hughes Medical Institute; New York University; NYU Langone Medical Center; University of Navarra; Yale University	Ring, AM (corresponding author), Yale Sch Med, Dept Immunobiol, New Haven, CT 06510 USA.; Ring, AM (corresponding author), Yale Sch Med, Dept Pharmacol, New Haven, CT 06510 USA.	aaron.ring@yale.edu	; F Sanmamed, Miguel/I-5572-2017	Flavell, Richard/0000-0003-4461-0778; McGeary, Meaghan/0000-0002-8505-7158; Wang, Jun/0000-0002-6346-2929; Zhou, Ting/0000-0001-8783-8380; Ring, Aaron/0000-0003-3699-2446; F Sanmamed, Miguel/0000-0002-7295-6074				[Anonymous], SCI REP; Apetoh L, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2014.998538; Ardolino M, 2014, J CLIN INVEST, V124, P4781, DOI 10.1172/JCI74337; Atkins MB, 2000, CANCER J SCI AM, V6, pS11; Belkaya S, 2019, J EXP MED, V216, P1777, DOI 10.1084/jem.20190669; Best JA, 2013, NAT IMMUNOL, V14, P404, DOI 10.1038/ni.2536; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Carbotti G, 2013, CLIN CANCER RES, V19, P4611, DOI 10.1158/1078-0432.CCR-13-0568; Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289; Gattinoni L, 2009, NAT MED, V15, P808, DOI 10.1038/nm.1982; Gubin MM, 2018, CELL, V175, P1014, DOI 10.1016/j.cell.2018.09.030; Guo LY, 2012, TRENDS IMMUNOL, V33, P598, DOI 10.1016/j.it.2012.07.006; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Hirakawa M, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.89278; Hu BL, 2017, CELL REP, V20, P3025, DOI 10.1016/j.celrep.2017.09.002; Hudson WH, 2019, IMMUNITY, V51, P1043, DOI 10.1016/j.immuni.2019.11.002; Jeannet G, 2010, P NATL ACAD SCI USA, V107, P9777, DOI 10.1073/pnas.0914127107; Kim SHM, 2001, P NATL ACAD SCI USA, V98, P3304, DOI 10.1073/pnas.051634098; Kurtulus S, 2019, IMMUNITY, V50, P181, DOI 10.1016/j.immuni.2018.11.014; Ma ZF, 2016, CLIN CANCER RES, V22, P2969, DOI 10.1158/1078-0432.CCR-15-1655; Mantovani A, 2019, IMMUNITY, V50, P778, DOI 10.1016/j.immuni.2019.03.012; Miller BC, 2019, NAT IMMUNOL, V20, P326, DOI 10.1038/s41590-019-0312-6; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Nakamura K, 2018, CANCER CELL, V33, P634, DOI 10.1016/j.ccell.2018.02.007; Park CC, 2001, J IMMUNOL, V167, P1644, DOI 10.4049/jimmunol.167.3.1644; Robertson MJ, 2008, CLIN CANCER RES, V14, P3462, DOI 10.1158/1078-0432.CCR-07-4740; Robertson MJ, 2006, CLIN CANCER RES, V12, P4265, DOI 10.1158/1078-0432.CCR-06-0121; Rosenberg SA, 2014, J IMMUNOL, V192, P5451, DOI 10.4049/jimmunol.1490019; Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w; Salmon H, 2016, IMMUNITY, V44, P924, DOI 10.1016/j.immuni.2016.03.012; Scott AC, 2019, NATURE, V571, P270, DOI 10.1038/s41586-019-1324-y; Seo H, 2019, P NATL ACAD SCI USA, V116, P12410, DOI 10.1073/pnas.1905675116; Simoni Y, 2018, NATURE, V557, P575, DOI 10.1038/s41586-018-0130-2; Singer M, 2016, CELL, V166, P1500, DOI 10.1016/j.cell.2016.08.052; Spangler JB, 2015, ANNU REV IMMUNOL, V33, P139, DOI 10.1146/annurev-immunol-032713-120211; Street SEA, 2002, J EXP MED, V196, P129, DOI 10.1084/jem.20020063; Tarhini AA, 2009, CANCER-AM CANCER SOC, V115, P859, DOI 10.1002/cncr.24100; Terme M, 2011, CANCER RES, V71, P5393, DOI 10.1158/0008-5472.CAN-11-0993; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Vidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734, DOI 10.1073/pnas.97.2.734; Waldmann TA, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028472; Wang J, 2017, PIGM CELL MELANOMA R, V30, P428, DOI 10.1111/pcmr.12591; Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862	43	83	91	2	56	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 23	2020	583	7817					609	+		10.1038/s41586-020-2422-6	http://dx.doi.org/10.1038/s41586-020-2422-6			29	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MP1EM	32581358	Green Accepted			2023-01-03	WOS:000551954700012
J	Okazaki, M; Inaguma, D; Imaizumi, T; Hishida, M; Kurasawa, S; Kubo, Y; Kato, S; Yasuda, Y; Katsuno, T; Kaneda, F; Maruyama, S				Okazaki, Masaki; Inaguma, Daijo; Imaizumi, Takahiro; Hishida, Manabu; Kurasawa, Shimon; Kubo, Yoko; Kato, Sawako; Yasuda, Yoshinari; Katsuno, Takayuki; Kaneda, Fumika; Maruyama, Shoichi			Impact of old age on the association between in-center extended-hours hemodialysis and mortality in patients on incident hemodialysis	PLOS ONE			English	Article							QUALITY-OF-LIFE; CONVENTIONAL HEMODIALYSIS; DIALYSIS OUTCOMES; PRACTICE PATTERNS; BODY-COMPOSITION; MALNUTRITION; RECOVERY; SURVIVAL; REGISTRY	With the global problem of aging, it has become more difficult to improve the prognosis of older dialysis patients. Extended-hours hemodialysis offers longer treatment time compared to conventional hemodialysis regimen and provides favorable metabolic status, hemodynamic stability, and increased dietary intake. Despite prior studies reporting that in-center extended-hours hemodialysis can reduce the mortality rate, the treatment impact on elderly patients remains unclear. Therefore, we examined the association between extended-hours hemodialysis compared to conventional hemodialysis and all-cause mortality. Survival analyses using Cox proportional hazard model with multivariable adjustments and propensity-score based method were performed to compare mortality risk between 198 consecutive patients who started in-center extended-hours hemodialysis (Extended-HD) and 1407 consecutive patients who initiated conventional hemodialysis. The median age was 67.1 years in the Extended-HD group and 70.7 years in the conventional hemodialysis group. Extended-HD was associated with lower all-cause mortality in overall patients and the subgroup >70 years (adjusted hazard ratios of 0.60 [95% CI, 0.39-0.91] and 0.35 [95% CI, 0.18-0.69], respectively). There was a significant interaction between age >70 years and Extended-HD. In conclusion, extended-hours hemodialysis was associated with a lower mortality rate, especially in elderly patients.	[Okazaki, Masaki; Imaizumi, Takahiro; Hishida, Manabu; Kurasawa, Shimon; Kato, Sawako; Yasuda, Yoshinari; Maruyama, Shoichi] Nagoya Univ, Grad Sch Med, Dept Nephrol, Nagoya, Aichi, Japan; [Okazaki, Masaki] Natl Hosp Org Nagoya Med Ctr, Dept Clin Trials & Res, Nagoya, Aichi, Japan; [Inaguma, Daijo] Fujita Hlth Univ, Sch Med, Dept Nephrol, Toyoake, Aichi, Japan; [Imaizumi, Takahiro] Nagoya Univ Hosp, Dept Adv Med, Nagoya, Aichi, Japan; [Imaizumi, Takahiro] Univ Penn, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Hishida, Manabu] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Kubo, Yoko] Nagoya Univ, Grad Sch Med, Dept Prevent Med, Nagoya, Aichi, Japan; [Katsuno, Takayuki] Aichi Med Univ, Sch Med, Dept Nephrol & Rheumatol, Nagakute, Aichi, Japan; [Kaneda, Fumika] Kamome Clin, Hitachi, Ibaraki, Japan	Nagoya University; Nagoya Medical Center; Fujita Health University; Nagoya University; University of Pennsylvania; Pennsylvania Medicine; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Nagoya University; Aichi Medical University	Maruyama, S (corresponding author), Nagoya Univ, Grad Sch Med, Dept Nephrol, Nagoya, Aichi, Japan.	marus@med.nagoya-u.ac.jp	Kurasawa, Shimon/GXF-8141-2022; Okazaki, Masaki/GWZ-4494-2022	Kurasawa, Shimon/0000-0001-6692-2380; Hishida, Manabu/0000-0002-6068-8228	Aichi Kidney Foundation [11 in 2018]	Aichi Kidney Foundation	The present study was supported by the Aichi Kidney Foundation (Grant number 11 in 2018). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aikawa A., 2018, REN REPLACE THER, V4; [Anonymous], AM J KIDNEY DIS, DOI DOI 10.1053/J.AJKD.2018.01.014; Badve SV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114897; Burton JO, 2009, CLIN J AM SOC NEPHRO, V4, P1925, DOI 10.2215/CJN.04470709; Chang TI, 2017, NEPHROL DIAL TRANSPL, V32, P1549, DOI 10.1093/ndt/gfw373; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Daugirdas JT, 2015, AM J KIDNEY DIS, V66, P884, DOI 10.1053/j.ajkd.2015.07.015; David S, 2009, NEPHROL DIAL TRANSPL, V24, P2232, DOI 10.1093/ndt/gfp029; Fahal IH, 2014, NEPHROL DIAL TRANSPL, V29, P1655, DOI 10.1093/ndt/gft070; Flythe JE, 2015, J AM SOC NEPHROL, V26, P724, DOI 10.1681/ASN.2014020222; Flythe JE, 2011, KIDNEY INT, V79, P250, DOI 10.1038/ki.2010.383; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; Ghaffar Umbar, 2015, Nephrol News Issues, V29, ppassim; Hellemans R, 2015, TRANSPLANT REV-ORLAN, V29, P197, DOI 10.1016/j.trre.2015.09.002; Hishida M, 2020, J RENAL NUTR, V30, P154, DOI 10.1053/j.jrn.2019.06.002; Hishida M, 2016, CLIN EXP NEPHROL, V20, P795, DOI 10.1007/s10157-015-1206-z; Hole B, 2018, NEPHRON, V139, P13, DOI 10.1159/000490959; Inaguma D, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0495-8; Kalantar-Zadeh K, 2003, AM J KIDNEY DIS, V42, P864, DOI 10.1016/j.ajkd.2003.07.016; Kalantar-Zadeh K, 2014, MAYO CLIN PROC, V89, P1033, DOI 10.1016/j.mayocp.2014.06.015; Kanda E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214524; Kaneda H, 2003, NEPHROL DIAL TRANSPL, V18, P1631, DOI 10.1093/ndt/gfg205; Knauf F, 2009, J AM SOC NEPHROL, V20, P2093, DOI 10.1681/ASN.2009070715; Kukita K, 2015, THER APHER DIAL, V19, P1, DOI 10.1111/1744-9987.12296; Kurella M, 2007, ANN INTERN MED, V146, P177, DOI 10.7326/0003-4819-146-3-200702060-00006; Lacson E, 2012, J AM SOC NEPHROL, V23, P687, DOI 10.1681/ASN.2011070674; Lindsay RM, 2006, CLIN J AM SOC NEPHRO, V1, P952, DOI 10.2215/CJN.00040106; Marcelli D, 2016, J RENAL NUTR, V26, P72, DOI 10.1053/j.jrn.2015.10.001; Marshall MR, 2018, KIDNEY INT, V93, P10, DOI 10.1016/j.kint.2017.09.014; Masakane I, 2017, REN REPLACE THER, V3; Masakane I., 2018, RENAL REPLACE THER, V4, DOI [10.1186/s41100-018-0149-8, DOI 10.1186/S41100-018-0149-8]; Murtagh FEM, 2007, NEPHROL DIAL TRANSPL, V22, P1955, DOI 10.1093/ndt/gfm153; Ok E, 2011, NEPHROL DIAL TRANSPL, V26, P1287, DOI 10.1093/ndt/gfq724; Park J, 2014, PROG CARDIOVASC DIS, V56, P415, DOI 10.1016/j.pcad.2013.10.005; Ramirez SPB, 2012, DIABETES CARE, V35, P2527, DOI 10.2337/dc12-0573; Rao PS, 2007, TRANSPLANTATION, V83, P1069, DOI 10.1097/01.tp.0000259621.56861.31; Rayner HC, 2014, AM J KIDNEY DIS, V64, P86, DOI 10.1053/j.ajkd.2014.01.014; Rhee CM, 2014, SEMIN DIALYSIS, V27, P135, DOI 10.1111/sdi.12198; Ricks J, 2012, DIABETES, V61, P708, DOI 10.2337/db11-1015; Sands JJ, 2014, HEMODIAL INT, V18, P415, DOI 10.1111/hdi.12138; Sarkar SR, 2006, KIDNEY INT, V70, P1832, DOI 10.1038/sj.ki.5001895; Schaible UE, 2007, PLOS MED, V4, P806, DOI 10.1371/journal.pmed.0040115; Watanabe Y, 2015, THER APHER DIAL, V19, P67, DOI 10.1111/1744-9987.12294; Wong B, 2017, AM J KIDNEY DIS, V70, P218, DOI 10.1053/j.ajkd.2017.01.047	44	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2020	15	7							e0235900	10.1371/journal.pone.0235900	http://dx.doi.org/10.1371/journal.pone.0235900			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ0RG	32649701	Green Published, gold			2023-01-03	WOS:000552603900036
J	Hallifax, RJ; McKeown, E; Sivakumar, P; Fairbairn, I; Peter, C; Leitch, A; Knight, M; Stanton, A; Ijaz, A; Marciniak, S; Cameron, J; Bhatta, A; Blyth, KG; Reddy, R; Harris, MC; Maddekar, N; Walker, S; West, A; Laskawiec-Szkonter, M; Corcoran, JP; Gerry, S; Roberts, C; Harvey, JE; Maskell, N; Miller, RF; Rahman, NM				Hallifax, Rob J.; McKeown, Edward; Sivakumar, Parthipan; Fairbairn, Ian; Peter, Christy; Leitch, Andrew; Knight, Matthew; Stanton, Andrew; Ijaz, Asim; Marciniak, Stefan; Cameron, James; Bhatta, Amrithraj; Blyth, Kevin G.; Reddy, Raja; Harris, Marie-Clare; Maddekar, Nadeem; Walker, Steven; West, Alex; Laskawiec-Szkonter, Magda; Corcoran, John P.; Gerry, Stephen; Roberts, Corran; Harvey, John E.; Maskell, Nick; Miller, Robert F.; Rahman, Najib M.			Ambulatory management of primary spontaneous pneumothorax: an open-label, randomised controlled trial	LANCET			English	Article							CHEST TUBE SIZE; EPIDEMIOLOGY	Background Primary spontaneous pneumothorax occurs in otherwise healthy young patients. Optimal management is not defined and often results in prolonged hospitalisation. Data on efficacy of ambulatory options are poor. We aimed to describe the duration of hospitalisation and safety of ambulatory management compared with standard care. Methods In this open-label, randomised controlled trial, adults (aged 16-55 years) with symptomatic primary spontaneous pneumothorax were recruited from 24 UK hospitals during a period of 3 years. Patients were randomly assigned (1:1) to treatment with either an ambulatory device or standard guideline-based management (aspiration, standard chest tube insertion, or both). The primary outcome was total length of hospital stay including re-admission up to 30 days after randomisation. Patients with available data were included in the primary analysis and all assigned patients were included in the safety analysis. The trial was prospectively registered with the International Standard Randomised Clinical Trials Number, ISRCTN79151659. Findings Of 776 patients screened between July, 2015, and March, 2019, 236 (30%) were randomly assigned to ambulatory care (n=117) and standard care (n=119). At day 30, the median hospitalisation was significantly shorter in the 114 patients with available data who received ambulatory treatment (0 days [IQR 0-3]) than in the 113 with available data who received standard care (4 days [IQR 0-8]; p<0.0001; median difference 2 days [95% CI 1-3]). 110 (47%) of 236 patients had adverse events, including 64 (55%) of 117 patients in the ambulatory care arm and 46 (39%) of 119 in the standard care arm. All 14 serious adverse events occurred in patients who received ambulatory care, eight (57%) of which were related to the intervention, including an enlarging pneumothorax, asymptomatic pulmonary oedema, and the device malfunctioning, leaking, or dislodging. Interpretation Ambulatory management of primary spontaneous pneumothorax significantly reduced the duration of hospitalisation including re-admissions in the first 30 days, but at the expense of increased adverse events. This data suggests that primary spontaneous pneumothorax can be managed for outpatients, using ambulatory devices in those who require intervention.	[Hallifax, Rob J.] Univ Oxford, Oxford Ctr Resp Med, Oxford OX3 7LE, England; [Laskawiec-Szkonter, Magda; Rahman, Najib M.] Univ Oxford, Oxford Resp Trials Unit, Oxford, England; [McKeown, Edward] Royal Berkshire Natl Hlth Serv NHS Fdn Trust, Reading, Berks, England; [Sivakumar, Parthipan; West, Alex] Guys & St Thomas NHS Fdn Trust, London, England; [Fairbairn, Ian] NHS Fife, Queen Margaret Hosp, Dunfermline, Fife, Scotland; [Peter, Christy] Royal United Hosp Bath NHS Fdn Trust, Bath, Avon, England; [Leitch, Andrew] NHS Lothian, Western Gen Hosp, Edinburgh, Midlothian, Scotland; [Knight, Matthew] West Hertfordshire Hosp NHS Trust, Watford, England; [Stanton, Andrew] Great Western Hosp NHS Fdn Trust, Swindon, Wilts, England; [Ijaz, Asim] Univ Hosp Morecambe Bay NHS Fdn Trust, Lancaster, England; [Marciniak, Stefan] Univ Cambridge, Dept Med, Cambridge, England; [Cameron, James; Harvey, John E.] North Bristol NHS Trust, Bristol, Avon, England; [Bhatta, Amrithraj] Blackpool Fylde & Wyre Hosp NHS Fdn Trust, Blackpool, England; [Blyth, Kevin G.] Queen Elizabeth Univ Hosp, Glasgow, Lanark, Scotland; [Blyth, Kevin G.] Univ Glasgow, Inst Canc Sci, Glasgow, Lanark, Scotland; [Reddy, Raja] Kettering & Dist Gen Hosp, Kettering, England; [Harris, Marie-Clare] NHS Lothian, Royal Infirm Edinburgh, Edinburgh, Midlothian, Scotland; [Maddekar, Nadeem] Univ Hosp North Midlands, Stoke On Trent, Staffs, England; [Walker, Steven; Maskell, Nick] Univ Bristol, Acad Resp Unit, Bristol, Avon, England; [Corcoran, John P.] Univ Hosp Plymouth NHS Trust, Plymouth, Devon, England; [Gerry, Stephen; Roberts, Corran] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Ctr Stat Med, Oxford, England; [Miller, Robert F.] UCL, Inst Global Hlth, London, England	University of Oxford; University of Oxford; Guy's & St Thomas' NHS Foundation Trust; University of Edinburgh; University of Cambridge; North Bristol NHS Trust; Queen Elizabeth University Hospital (QEUH); University of Glasgow; Royal Infirmary of Edinburgh; University of Bristol; University of Oxford; University of London; University College London	Hallifax, RJ (corresponding author), Univ Oxford, Oxford Ctr Resp Med, Oxford OX3 7LE, England.	robert.hallifax@ndm.ox.ac.uk	, Matthew/AAZ-4939-2020	Miller, Robert/0000-0003-2067-4291; Rahman, Najib M/0000-0003-1195-1680; Sivakumar, Parthipan/0000-0003-3740-2612; maskell, nick/0000-0002-1276-6500; Knight, Matthew/0000-0003-1761-0115; Hallifax, Rob/0000-0002-9467-668X	UK National Institute for Health Research; MRC [MR/R009120/1] Funding Source: UKRI	UK National Institute for Health Research(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	UK National Institute for Health Research.	Bobbio A, 2015, THORAX, V70, P653, DOI 10.1136/thoraxjnl-2014-206577; Brims FJH, 2013, THORAX, V68, P664, DOI 10.1136/thoraxjnl-2012-202875; Brown SGA, 2020, NEW ENGL J MED, V382, P405, DOI 10.1056/NEJMoa1910775; Chee CBE, 1998, RESP MED, V92, P757, DOI 10.1016/S0954-6111(98)90008-7; Gupta D, 2000, THORAX, V55, P666, DOI 10.1136/thorax.55.8.666; Hallifax R, 2019, BMJ OPEN RESPIR RES, V6, DOI 10.1136/bmjresp-2019-000403; Hallifax RJ, 2018, JAMA-J AM MED ASSOC, V320, P1471, DOI 10.1001/jama.2018.14299; MacDuff A, 2010, THORAX, V65, P18, DOI 10.1136/thx.2010.136986; Mishra EK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123798; National Institute for Health Research, 2019, GOOD CLIN PRACT; Psallidas I, 2017, BMJ OPEN RESPIR RES, V4, DOI [10.1136/bmjresp-2016-000171, 10.1136/bmjresp-2017-000225]; Rahman NM, 2015, JAMA-J AM MED ASSOC, V314, P2641, DOI 10.1001/jama.2015.16840; Rahman NM, 2011, NEW ENGL J MED, V365, P518, DOI 10.1056/NEJMoa1012740; Rahman NM, 2010, CHEST, V137, P536, DOI 10.1378/chest.09-1044; SCHOENENBERGER RA, 1991, ARCH SURG-CHICAGO, V126, P764; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; United States Food and Drug Administration, 2016, FDA EXP US XALK TREA	17	34	35	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 4	2020	396	10243					39	49						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND0VO	32622394	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000561626100015
J	Theron, G; Limberis, J; Venter, R; Smith, L; Pietersen, E; Esmail, A; Calligaro, G; te Riele, J; de Kock, M; van Helden, P; Gumbo, T; Clark, TG; Fennelly, K; Warren, R; Dheda, K				Theron, Grant; Limberis, Jason; Venter, Rouxjeane; Smith, Liezel; Pietersen, Elize; Esmail, Aliasgar; Calligaro, Greg; te Riele, Julian; de Kock, Marianna; van Helden, Paul; Gumbo, Tawanda; Clark, Taane G.; Fennelly, Kevin; Warren, Robin; Dheda, Keertan			Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis	NATURE MEDICINE			English	Article							MYCOTB MIC PLATE; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; TRANSMISSION; INFECTIOUSNESS; PREDICTION; OUTCOMES; VARIABILITY; EVOLUTION; DISEASE	CulturableMycobacterium tuberculosiscan be detected in cough aerosol from a high proportion of individuals infected with drug-resistantM. tuberculosisand correlate with a strong cough and low symptom score, indicating the need to focus on targeted interventions. A burgeoning epidemic of drug-resistant tuberculosis (TB) threatens to derail global control efforts. Although the mechanisms remain poorly clarified, drug-resistant strains are widely believed to be less infectious than drug-susceptible strains. Consequently, we hypothesized that lower proportions of patients with drug-resistant TB would have culturableMycobacterium tuberculosisfrom respirable, cough-generated aerosols compared to patients with drug-susceptible TB, and that multiple factors, including mycobacterial genomic variation, would predict culturable cough aerosol production. We enumerated the colony forming units in aerosols (<= 10 mu m) from 452 patients with TB (227 with drug resistance), compared clinical characteristics, and performed mycobacterial whole-genome sequencing, dormancy phenotyping and drug-susceptibility analyses onM. tuberculosisfrom sputum. After considering treatment duration, we found that almost half of the patients with drug-resistant TB were cough aerosol culture-positive. Surprisingly, neither mycobacterial genomic variants, lineage, nor dormancy status predicted cough aerosol culture positivity. However, mycobacterial sputum bacillary load and clinical characteristics, including a lower symptom score and stronger cough, were strongly predictive, thereby supporting targeted transmission-limiting interventions. Effective treatment largely abrogated cough aerosol culture positivity; however, this was not always rapid. These data question current paradigms, inform public health strategies and suggest the need to redirect TB transmission-associated research efforts toward host-pathogen interactions.	[Theron, Grant; Limberis, Jason; Smith, Liezel; Pietersen, Elize; Esmail, Aliasgar; Calligaro, Greg; Dheda, Keertan] Univ Cape Town, Div Pulmonol, Dept Med, Ctr Lung Infect & Immun, Cape Town, South Africa; [Theron, Grant; Limberis, Jason; Smith, Liezel; Pietersen, Elize; Esmail, Aliasgar; Calligaro, Greg; Dheda, Keertan] Univ Cape Town, UCT Lung Inst, Cape Town, South Africa; [Theron, Grant; Limberis, Jason; Smith, Liezel; Pietersen, Elize; Esmail, Aliasgar; Calligaro, Greg; Dheda, Keertan] Univ Cape Town, South African MRC UCT Ctr Study Antimicrobial Res, Cape Town, South Africa; [Theron, Grant; Venter, Rouxjeane; Smith, Liezel; de Kock, Marianna; van Helden, Paul; Warren, Robin] Stellenbosch Univ, DSI NRF Ctr Excellence Biomed TB Res, Div Mol Biol & Human Genet, Fac Med & Hlth Sci, Cape Town, South Africa; [Theron, Grant; Venter, Rouxjeane; Smith, Liezel; de Kock, Marianna; van Helden, Paul; Warren, Robin] Stellenbosch Univ, South African Med Res Ctr TB Res, Div Mol Biol & Human Genet, Fac Med & Hlth Sci, Cape Town, South Africa; [te Riele, Julian] Brooklyn Chest Hosp, Cape Town, South Africa; [Gumbo, Tawanda] Baylor Univ, Med Ctr, Ctr Infect Dis Res & Expt Therapeut, Dallas, TX USA; [Clark, Taane G.; Dheda, Keertan] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England; [Clark, Taane G.] London Sch Hyg & Trop Med, Fac Epidemiol & Publ Hlth, London, England; [Fennelly, Kevin] NHLBI, Pulm Branch, Div Intramural Res, NIH, Bldg 10, Bethesda, MD 20892 USA	University of Cape Town; University of Cape Town; University of Cape Town; Stellenbosch University; Stellenbosch University; Baylor University; Baylor University Medical Center; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Dheda, K (corresponding author), Univ Cape Town, Div Pulmonol, Dept Med, Ctr Lung Infect & Immun, Cape Town, South Africa.; Dheda, K (corresponding author), Univ Cape Town, UCT Lung Inst, Cape Town, South Africa.; Dheda, K (corresponding author), Univ Cape Town, South African MRC UCT Ctr Study Antimicrobial Res, Cape Town, South Africa.; Dheda, K (corresponding author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London, England.	keertan.dheda@uct.ac.za	Theron, Grant/ABB-1167-2020; Clark, Taane G./AAM-2570-2020; Limberis, Jason/X-9553-2018	Theron, Grant/0000-0002-9216-2415; Clark, Taane G./0000-0001-8985-9265; Limberis, Jason/0000-0002-7893-8416; Dheda, Keertan/0000-0001-7709-5341; Warren, Robin/0000-0001-5741-7358; Venter, Rouxjeane/0000-0002-8710-8166; Calligaro, Gregory/0000-0001-7324-0775; Pietersen, Elize/0000-0001-5286-4749	National Institutes of Health [1R01AI104817-01]; Wellcome Trust [099854/Z/12/Z, MR/S027777/1]; South African Medical Research Council [RFA-IFSP-01-2013, RFA-EMU-02-2017]; National Research Foundation of South Africa; EDCTP2 programme - European Union [SF1401]; Faculty of Medicine and Health Sciences, Stellenbosch University; EDCTP [TMA-2015SF-1043, TMA-1051-TESAII, TMA-CDF2015]; UK Medical Research Council [MR/S03563X/1]; Intramural Research Program of the National Institutes of Health, National Heart, Lung, and Blood Institute; National Research Foundation; MRC [MR/S03563X/1] Funding Source: UKRI	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Wellcome Trust(Wellcome TrustEuropean Commission); South African Medical Research Council(South African Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Research Foundation of South Africa(National Research Foundation - South Africa); EDCTP2 programme - European Union; Faculty of Medicine and Health Sciences, Stellenbosch University; EDCTP; UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Intramural Research Program of the National Institutes of Health, National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Research Foundation; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We are indebted to the patients who participated. The study would not have been possible without the remarkable efforts of R. Wilson and G. Pretorius. We also thank for their invaluable assistance M. Pienaar and M. Pretorius, P. Spiller, M. Barnard, J. Simpson, T. Dolby, R. van Aarde, C. Clarke and B. Derendinger. The WGS computations were done using facilities provided by the University of Cape Town's ICTS High Performance Computing team. The project was funded by the National Institutes of Health (grant no. 1R01AI104817-01), Wellcome Trust (grant no. 099854/Z/12/Z), South African Medical Research Council (Career Development Award, Self-initiated Research Award) and the National Research Foundation of South Africa. The content is solely the responsibility of the authors and does not necessarily represent the official views of the South African Medical Research Council. G.T. acknowledges funding from the South African Medical Research Council (grant no. RFA-IFSP-01-2013), the EDCTP2 programme supported by the European Union (grant no. SF1401, OPTIMAL DIAGNOSIS) and the Faculty of Medicine and Health Sciences, Stellenbosch University. K.D. acknowledges funding from the South African Medical Research Council (grant no. RFA-EMU-02-2017), EDCTP (grant nos. TMA-2015SF-1043, TMA-1051-TESAII and TMA-CDF2015), UK Medical Research Council (grant no. MR/S03563X/1) and the Wellcome Trust (grant no. MR/S027777/1). K.F. was supported by the Intramural Research Program of the National Institutes of Health, National Heart, Lung, and Blood Institute. We acknowledge the financial assistance of the National Research Foundation toward this research. The opinions expressed and conclusions arrived at are those of the author(s) and should not necessarily to be attributed to the National Research Foundation.	Acuna-Villaorduna C, 2019, OPEN FORUM INFECT DI, V6, DOI 10.1093/ofid/ofz184; [Anonymous], 2009, 6 2 STAG VIABL SAMPL; [Anonymous], 2011, AUTOMATED RAL TIME N; [Anonymous], 1998, PUBLIC HLTH SERVICE; Ashley K., 2017, NIOSH MANUAL ANAL ME, V5th; Calligaro GL, 2017, LANCET INFECT DIS, V17, P441, DOI 10.1016/S1473-3099(16)30384-X; Casali N, 2014, NAT GENET, V46, P279, DOI 10.1038/ng.2878; Chengalroyen MD, 2016, AM J RESP CRIT CARE, V194, P1532, DOI 10.1164/rccm.201604-0769OC; Coll F, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0164-0; Coll F, 2012, BIOINFORMATICS, V28, P2991, DOI 10.1093/bioinformatics/bts544; Comas I, 2012, NAT GENET, V44, P106, DOI 10.1038/ng.1038; De Stavola BL, 2008, BIOMETRIKA, V95, P992, DOI 10.1093/biomet/asn039; de Vos M, 2013, ANTIMICROB AGENTS CH, V57, P827, DOI 10.1128/AAC.01541-12; Demay C, 2012, INFECT GENET EVOL, V12, P755, DOI 10.1016/j.meegid.2012.02.004; Dharmadhikari AS, 2014, INT J TUBERC LUNG D, V18, P1019, DOI 10.5588/ijtld.13.0834; Dharmadhikari AS, 2011, TUBERCULOSIS, V91, P329, DOI 10.1016/j.tube.2011.03.002; Dheda K, 2018, AM J RESP CRIT CARE, V198, P1208, DOI [10.1164/rccm.201711-2333OC, 10.1164/rccm.201711-2333oc]; Dheda K, 2017, LANCET RESP MED, V5, P291, DOI [10.1016/s2213-2600(17)30079-6, 10.1016/S2213-2600(17)30079-6]; Dheda K, 2017, LANCET RESP MED, V5, P269, DOI [10.1016/s2213-2600(16)30433-7, 10.1016/S2213-2600(16)30433-7]; Escombe AR, 2007, CLIN INFECT DIS, V44, P1349, DOI 10.1086/515397; Farhat MR, 2013, NAT GENET, V45, P1183, DOI 10.1038/ng.2747; Fennelly KP, 2012, AM J RESP CRIT CARE, V186, P450, DOI 10.1164/rccm.201203-0444OC; Fennelly KP, 2004, AM J RESP CRIT CARE, V169, P604, DOI 10.1164/rccm.200308-1101OC; Fitzwater SP, 2010, CLIN INFECT DIS, V51, P371, DOI 10.1086/655127; Gagneux S, 2006, PLOS PATHOG, V2, P603, DOI 10.1371/journal.ppat.0020061; Garton NJ, 2002, MICROBIOL-SGM, V148, P2951, DOI 10.1099/00221287-148-10-2951; Johnson R, 2010, INT J TUBERC LUNG D, V14, P119; Jones-Lopez EC, 2016, CLIN INFECT DIS, V63, P10, DOI 10.1093/cid/ciw199; Jones-Lopez EC, 2013, AM J RESP CRIT CARE, V187, P1007, DOI 10.1164/rccm.201208-1422OC; Kodama C, 2017, EUR RESPIR J, V50, DOI 10.1183/13993003.01044-2017; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lee J, 2014, ANTIMICROB AGENTS CH, V58, P11, DOI 10.1128/AAC.01209-13; Lin PL, 2006, INFECT IMMUN, V74, P3790, DOI 10.1128/IAI.00064-06; Lloyd-Smith JO, 2005, NATURE, V438, P355, DOI 10.1038/nature04153; McCreesh N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23797-2; Melsew YA, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3870-1; NOBLE RC, 1981, AM J INFECT CONTROL, V9, P6, DOI 10.1016/S0196-6553(81)80003-X; Pietersen E, 2014, LANCET, V383, P1230, DOI 10.1016/S0140-6736(13)62675-6; R-Core-Team, 2016, LANG ENV STAT COMP; RILEY RL, 1962, AM REV RESPIR DIS, V85, P511; ROUILLON A, 1976, TUBERCLE, V57, P275, DOI 10.1016/S0041-3879(76)80006-2; Sirgel FA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059414; Sloan DJ, 2015, CLIN INFECT DIS, V61, P1, DOI 10.1093/cid/civ195; Song T, 2014, MOL MICROBIOL, V91, P1106, DOI 10.1111/mmi.12520; South African Department of Health Management of Drug-Resistant Tuberculosis, 2011, S AFRICAN DEP HLTH M; Stoltz A. C, 2020, AM THOR SOC 2017 INT; SULTAN L, 1960, AM REV RESPIR DIS, V82, P358; te Riele JB, 2019, INT J INFECT DIS, V79, P65, DOI 10.1016/j.ijid.2018.10.026; Tostmann A, 2008, CLIN INFECT DIS, V47, P1135, DOI 10.1086/591974; Trauner A, 2014, DRUGS, V74, P1063, DOI 10.1007/s40265-014-0248-y; van Geuns H A, 1975, Bull Int Union Tuberc, V50, P107; Walker TM, 2015, LANCET INFECT DIS, V15, P1193, DOI 10.1016/S1473-3099(15)00062-6; Walker TM, 2013, LANCET INFECT DIS, V13, P137, DOI 10.1016/S1473-3099(12)70277-3; Warren R, 2006, J CLIN MICROBIOL, V44, P254, DOI 10.1128/JCM.44.1.254-256.2006; Wejse C, 2008, SCAND J INFECT DIS, V40, P111, DOI 10.1080/00365540701558698; Whitfield MG, 2015, J CLIN MICROBIOL, V53, P3633, DOI 10.1128/JCM.01001-15; Woolhouse MEJ, 1997, P NATL ACAD SCI USA, V94, P338, DOI 10.1073/pnas.94.1.338; World Health Organization, 2014, MYC LAB MAN; World Health Organization, 2016, GLOBAL TUBERCULOSIS; World Health Organization, 2016, WHOHTMTB201604; World Health Organization, 2013, DEFINITIONS REPORTIN; Yates TA, 2016, LANCET INFECT DIS, V16, P227, DOI 10.1016/S1473-3099(15)00499-5; Ypma RJF, 2013, EPIDEMIOLOGY, V24, P395, DOI 10.1097/EDE.0b013e3182878e19; Yu X, 2016, INT J TUBERC LUNG D, V20, P329, DOI 10.5588/ijtld.15.0573	65	13	14	0	9	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2020	26	9								10.1038/s41591-020-0940-2	http://dx.doi.org/10.1038/s41591-020-0940-2		JUN 2020	20	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PF3EM	32601338	Green Accepted			2023-01-03	WOS:000544159600005
J	Ionova, Y; Wilson, L				Ionova, Yelena; Wilson, Leslie			Biologic excipients: Importance of clinical awareness of inactive ingredients	PLOS ONE			English	Article							ACUTE-RENAL-FAILURE; POLYSORBATE-80; ANAPHYLAXIS; IMMUNOGLOBULIN; ALLERGY	Due to the complexity and fragility of biological drug products, several challenges exist in their formulation development. Excipients are added to increase product stability, maintain tonicity, and facilitate drug delivery. The potential implications of these additive substances merit clinical consideration. We assessed the safety risk of excipients on the basis of their type and variability through an assessment framework, which quantifies excipient complexity in 230 biological formulations, and identifies excipient-related adverse events through published case reports. A biologic on average contained 4.45 excipients, half of that found in oral medications. The frequency distribution was heavily skewed towards the most commonly occurring excipients: water (40.4%), sodium chloride (38.3%), polysorbate 80 (28.7%), sucrose (24.4%), and mannitol (20.9%), with 44.4% of formulations not listing the concentration of the most commonly occurring inactive ingredients. A literature search revealed only 17 case reports of excipient-related adverse events, suggesting the need for more clarity for clinicians on the safety of chemical additives. These cases included injection site reactions, anaphylaxis, hyperglycemia, and acute renal failure. With the expansion of the biopharmaceutical market, it is important to consider the safety data of biologic excipients, so that therapy can be tailored appropriately for a specific patient.	[Ionova, Yelena] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA; [Wilson, Leslie] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Wilson, Leslie] Univ Calif San Francisco, Dept Pharm, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Ionova, Y (corresponding author), Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA.	yelena.ionova@ucsf.edu		, Yelena/0000-0002-9635-350X	U.S. Pharmacopeia	U.S. Pharmacopeia	This work was funded by a grant from U.S. Pharmacopeia, who participated in the design and conduct of the study, analysis and interpretation of the data, and review of the final manuscript, although the decision to submit the manuscript for publication was the authors' alone.	[Anonymous], 2014, PREV CHRONIC DIS, V11, pE62; [Anonymous], 2019, US PHARM 42 NAT FORM; Caballero ML, 2016, J INVEST ALLERG CLIN, V26, P398, DOI 10.18176/jiaci.0089; Chakraborty S, 2016, J NEURO-ONCOL, V128, P405, DOI 10.1007/s11060-016-2099-8; Chi EY., PHARM EXCIPIENTS PRO, DOI [10.1002/9781118992432.ch4, DOI 10.1002/9781118992432.CH4]; Pastor AIE, 2018, J INVEST ALLERG CLIN, V28, P419, DOI 10.18176/jiaci.0298; Findlay SR, 1984, J ALLERGY CLIN IMM 1, V73, P83; GIN H, 1987, DIABETES CARE, V10, P789, DOI 10.2337/diacare.10.6.789; Ha E, 2002, J PHARM SCI-US, V91, P2252, DOI 10.1002/jps.10216; Haskin JA, 1999, ANN PHARMACOTHER, V33, P800, DOI 10.1345/aph.18305; Hegde VL, 2004, CLIN EXP ALLERGY, V34, P1602, DOI 10.1111/j.1365-2222.2004.02079.x; Mahjoubi N, 2017, IRAN J PHARM RES, V16, P103; Morikawa Miki, 2016, Arerugi, V65, P200, DOI 10.15036/arerugi.65.200; Muelas MW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-54288-7; Perez-Perez L, 2011, BRIT J DERMATOL, V164, P1119, DOI 10.1111/j.1365-2133.2011.10220.x; Perino E, 2018, ANN ALLERG ASTHMA IM, V120, P664, DOI 10.1016/j.anai.2018.02.018; Price KS, 2007, ALLERGY ASTHMA PROC, V28, P313, DOI 10.2500/aap.2007.28.3003; Reker D, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau6753; Roncati L, 2013, FORENSIC SCI INT, V228, pE28, DOI 10.1016/j.forsciint.2013.02.036; Singh SK, 2018, J PHARM SCI-US, V107, P2735, DOI 10.1016/j.xphs.2018.07.016; Singh SK, 2011, J PHARM SCI-US, V100, P354, DOI 10.1002/jps.22276; Singh SR, 2012, AAPS PHARMSCITECH, V13, P422, DOI 10.1208/s12249-012-9759-6; Stone CA, 2017, J ALLERGY CLIN IMMUN, V139, P1710, DOI 10.1016/j.jaci.2016.10.037; Subtirelu MM, 2005, PEDIATR TRANSPLANT, V9, P801, DOI 10.1111/j.1399-3046.2005.00379.x; U.S. Food and Drug Administration, 2019, BEST PRACT DRUG BIOL, DOI [10.18553/jmcp.2019.19041, DOI 10.18553/JMCP.2019.19041]; U.S. Food and Drug Administration, 2018, COMMUNICATION    JUL; US Food and Drug Administration, 2018, BIOS ACT PLAN BAL IN; Usach I, 2019, ADV THER, V36, P2986, DOI 10.1007/s12325-019-01101-6; Usmani SS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181748; Wajanaponsan Non, 2004, Hawaii Med J, V63, P266; Weber C, 2015, TOXICOL REP, V2, P194, DOI 10.1016/j.toxrep.2014.11.019; Yalcin AD, 2014, CLIN LAB, V60, P1561, DOI 10.7754/Clin.Lab.2013.130302	32	20	20	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2020	15	6							e0235076	10.1371/journal.pone.0235076	http://dx.doi.org/10.1371/journal.pone.0235076			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG0TI	32584876	Green Published, gold			2023-01-03	WOS:000545747200053
J	Zaeh, SE; Hayes, MM; Eakin, MN; Rand, CS; Turnbull, AE				Zaeh, Sandra E.; Hayes, Margaret M.; Eakin, Michelle N.; Rand, Cynthia S.; Turnbull, Alison E.			Housestaff perceptions on training and discussing the Maryland Orders for Life Sustaining Treatment Form (MOLST)	PLOS ONE			English	Article							RESUSCITATE ORDERS; PHYSICIAN ORDERS; MEDICAL ORDERS; CODE STATUS; RESIDENTS; COMMUNICATION; PROGRAM; SKILLS	Background On-line tutorials are being increasingly used in medical education, including in teaching housestaff skills regarding end of life care. Recently an on-line tutorial incorporating interactive clinical vignettes and communication skills was used to prepare housestaff at Johns Hopkins Hospital to use the Maryland Orders for Life Sustaining Treatment (MOLST) form, which documents patient preferences regarding end of life care. 40% of housestaff who viewed the module felt less than comfortable discussing choices on the MOLST with patients. We sought to understand factors beyond knowledge that contributed to housestaff discomfort in MOLST discussions despite successfully completing an on-line tutorial. Methods We conducted semi-structured telephone interviews with 18 housestaff who completed the on-line MOLST training module. Housestaff participants demonstrated good knowledge of legal and regulatory issues related to the MOLST compared to their peers, but reported feeling less than comfortable discussing the MOLST with patients. Transcripts of interviews were coded using thematic analysis to describe barriers to using the MOLST and suggestions for improving housestaff education about end of life care discussions. Results Qualitative analysis showed three major factors contributing to lack of housestaff comfort completing the MOLST form: [1] physician barriers to completion of the MOLST, [2] perceived patient barriers to completion of the MOLST, and [3] design characteristics of the MOLST form. Housestaff recommended a number of adaptations for improvement, including in-person training to improve their skills conducting conversations regarding end of life preferences with patients. Conclusions Some housestaff who scored highly on knowledge tests after completing a formal on-line curriculum on the MOLST form reported barriers to using a mandated form despite receiving training. On-line modules may be insufficient for teaching communication skills to housestaff. Additional training opportunities including in-person training mechanisms should be incorporated into housestaff communication skills training related to end of life care.	[Zaeh, Sandra E.; Eakin, Michelle N.; Rand, Cynthia S.; Turnbull, Alison E.] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21218 USA; [Hayes, Margaret M.] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Hayes, Margaret M.] Harvard Med Sch, Shapiro Inst Educ & Res, Boston, MA 02115 USA; [Hayes, Margaret M.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; [Turnbull, Alison E.] Johns Hopkins Univ, Outcomes Crit Illness & Surg OACIS Grp, Baltimore, MD USA; [Turnbull, Alison E.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Zaeh, SE (corresponding author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21218 USA.	szaeh1@jhmi.edu		Hayes, Margaret M/0000-0002-5848-6088; Zaeh, Sandra/0000-0002-5091-1975	Johns Hopkins Department of Medical Affairs; National Heart, Blood, and Lung Institute [T32HL007534-36]	Johns Hopkins Department of Medical Affairs; National Heart, Blood, and Lung Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr. Turnbull was supported by the Johns Hopkins Department of Medical Affairs. Dr. Zaeh was supported by the National Heart, Blood, and Lung Institute under Grant T32HL007534-36. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2018, OBSTET GYNECOL, V13, pe49; Buss Mary Kathleen, 2005, J Palliat Med, V8, P363, DOI 10.1089/jpm.2005.8.363; Calam B, 2000, CAN MED ASSOC J, V163, P1255; Dimeff LA, 2009, BEHAV RES THER, V47, P921, DOI 10.1016/j.brat.2009.07.011; Farrelly CA, COMMUNICATION; Fromme EK, 2012, JAMA-J AM MED ASSOC, V307, P34, DOI 10.1001/jama.2011.1956; Gorman TE, 2005, ACAD MED, V80, P622, DOI 10.1097/00001888-200507000-00004; Hickman SE, 2015, J AM GERIATR SOC, V63, P341, DOI 10.1111/jgs.13248; Hickman SE, 2011, J AM GERIATR SOC, V59, P2091, DOI 10.1111/j.1532-5415.2011.03656.x; Hope AA, 2015, ANN AM THORAC SOC, V12, P505, DOI 10.1513/AnnalsATS.201501-040OC; KOLB 8DAVID A., 2015, EXPERIENTIAL LEARNIN; Mann Karen V, 2002, J Contin Educ Health Prof, V22, P69, DOI 10.1002/chp.1340220202; Mirarchi FL, 2015, J PATIENT SAF, V11, P1, DOI 10.1097/PTS.0000000000000165; Moore KA, 2016, JAMA-J AM MED ASSOC, V315, P259, DOI 10.1001/jama.2015.17362; National POLST Paradigm, POLST PAR FUND; Office of Health Care Quality, MAR MOLST MED ORD LI; Schwartz Charles E, 2003, J Palliat Med, V6, P37, DOI 10.1089/10966210360510109; Siddiqui MF, 2011, AM J HOSP PALLIAT ME, V28, P94, DOI 10.1177/1049909110374599; Stevens L, 2002, CRIT CARE MED, V30, P290, DOI 10.1097/00003246-200202000-00004; Sulmasy DP, 1996, J GEN INTERN MED, V11, P657, DOI 10.1007/BF02600156; Szmuilowicz E, 2012, J PALLIAT MED, V15, P768, DOI 10.1089/jpm.2011.0446; Tarzian AJ, 2017, J PALLIAT MED, V20, P939, DOI 10.1089/jpm.2016.0440; Turnbull AE, 2016, ANN AM THORAC SOC, V13, P926, DOI 10.1513/AnnalsATS.201511-738OC; van den Eertwegh V, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125958; Williams DM, 2011, AM J HOSP PALLIAT ME, V28, P328, DOI 10.1177/1049909110391646; Wittenberg-Lyles E, 2014, J PALLIAT MED, V17, P400, DOI 10.1089/jpm.2013.0270; Zante B, 2019, J INTENSIVE CARE MED, V34, P301, DOI 10.1177/0885066617716057	27	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2020	15	6							e0234973	10.1371/journal.pone.0234973	http://dx.doi.org/10.1371/journal.pone.0234973			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC4LX	32559244	gold, Green Published			2023-01-03	WOS:000543261600046
J	Imeah, B; Penz, E; Rana, M; Trask, C				Imeah, Biaka; Penz, Erika; Rana, Masud; Trask, Catherine		Needle-Less Injector Study Team	Economic analysis of new workplace technology including productivity and injury: The case of needle-less injection in swine	PLOS ONE			English	Article							MILKING SYSTEM; WORK; UNCERTAINTY; COSTS	Increasing intensification in swine production has led to new and specialized technologies, but the occupational health and safety impacts are rarely quantified in the business plans for adoption. Needle-less injection has potential to increase productivity and eliminate needle stick injury in workers, but it is not clear whether these benefits offset high capital investment and potential increases in musculoskeletal loads. This economic evaluation employed probabilistic scenario analysis using injury, cost, and production data gathered from interviews with swine producers in Manitoba and Saskatchewan. After adoption of needle-less injection, rates of needle-stick injury went down with no measureable effect on upper limb musculoskeletal disorders, resulting in lower health and safety costs for needle-less injectors. Needle-less injection duration was 40% faster once workers acclimatized, but large start-up costs mean economic benefits are realized only after the first year. The incremental benefit cost ratio promoted adoption of needle-less injectors over conventional needles for the base case of a 1200 sow barn; the conventional method is beneficial for barns with 600 sows or less. Findings indicate that well-designed technologies have the potential to achieve the dual ergonomics goals of enhancing human wellbeing and system performance. We anticipate that the economic and decision models developed in this study can be applied to other new technologies in agriculture and animal production.	[Imeah, Biaka; Trask, Catherine] Univ Saskatchewan, Coll Med, Canadian Ctr Hlth & Safety Agr, Saskatoon, SK, Canada; [Penz, Erika] Univ Saskatchewan, Coll Med, Saskatoon, SK, Canada; [Rana, Masud] Univ Saskatchewan, Collaborat Program Biostat, Saskatoon, SK, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Trask, C (corresponding author), Univ Saskatchewan, Coll Med, Canadian Ctr Hlth & Safety Agr, Saskatoon, SK, Canada.	catherine.trask@usask.ca	Penz, Erika/AAZ-9541-2020	Penz, Erika/0000-0003-2610-8450; Trask, Catherine/0000-0003-0799-1735	Canada Research Chairs program [228136]; Workers Compensation Board of Manitoba	Canada Research Chairs program(Canada Research Chairs); Workers Compensation Board of Manitoba	CT & EP: Workers Compensation Board of Manitoba https://www.wcb.mb.ca/research-andworkplace-innovation-program-0 CT: Canada Research Chairs program [#228136] http://www.chairs-chaires.gc.ca/chairholders-titulaires/profileeng.aspx?profileId=3030 The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, LANCET HIV, V2017, pPE475; [Anonymous], 2020, FAO STAT ONL DAT; Bath B, 2019, PHYSIOTHER CAN, V71, P24, DOI 10.3138/ptc.2017-65; Blaha T.G., 2001, PREHARVEST FOOD SAFE; Daniels C., 2009, PREVALENCE CARCASS D; Douphrate DI, 2009, J AGROMEDICINE, V14, P406, DOI 10.1080/10599240903260444; Drugs C.A.f., 2006, GUIDELINES EC EVALUA; Escorpizo R, 2008, INT J IND ERGONOM, V38, P291, DOI 10.1016/j.ergon.2007.10.018; EVANS JS, 1994, REGUL TOXICOL PHARM, V20, P15, DOI 10.1016/S0273-2300(05)80003-0; FAO, 2012, STAT YB 2012; FAO F.a.A.O., 2007, SUST AGR RUR DEV SAR; Fenwick E, 2004, HEALTH ECON, V13, P405, DOI 10.1002/hec.903; Government of Saskatchewan, 2017, SASK VAR GUID 2017 S; Grimes DA, 2002, LANCET, V359, P248, DOI 10.1016/S0140-6736(02)07451-2; Hafer A. L., 1996, Swine Health and Production, V4, P128; Houser T., 2003, FEASIBILITY TRANSDER; Jakob M, 2011, J AGROMEDICINE, V16, P280, DOI 10.1080/1059924X.2011.605713; Janssen B, 2017, J AGROMEDICINE, V22, P47, DOI [10.1080/1059924X.2016.1249444, 10.1080/1059924x.2016.1249444]; Khushrushahi N., INVESTOR GUIDANCE OC; Lash TL, 2014, INT J EPIDEMIOL, V43, P1969, DOI 10.1093/ije/dyu149; Lash TL, 2011, APPL QUANTITATIVE BI; Leigh JP, 2001, PUBLIC HEALTH REP, V116, P235, DOI 10.1093/phr/116.3.235; Leigh JP, 1997, ARCH INTERN MED, V157, P1557, DOI 10.1001/archinte.157.14.1557; Marino S, 2008, J THEOR BIOL, V254, P178, DOI 10.1016/j.jtbi.2008.04.011; Mousel MR, 2008, J ANIM SCI, V86, P1468, DOI 10.2527/jas.2007-0839; Nonnenmann MW, 2010, J OCCUP ENVIRON HYG, V7, P483, DOI 10.1080/15459624.2010.487036; Peters JC, 2008, J ANIM SCI, V86, P2261, DOI 10.2527/jas.2007-0577; Rey M, 2015, CAN VET J, V56, P405; Saia M, 2010, BIOMED INT, V1, P41; Schneeweiss S, 2005, J CLIN EPIDEMIOL, V58, P323, DOI 10.1016/j.jclinepi.2004.10.012; Stal M, 2003, ANN AGR ENV MED, V10, P67; StatisticsCanada, 2015, CHANG FAC CAN HOG IN; Temple D, 2017, PORCINE HEALTH MANAG, V3, DOI 10.1186/s40813-017-0056-3; Vansickle J., 2001, BROKEN NEEDLES ONE I; Wohl M., 1984, TRANSPORTATION INVES; Wu JY, 2013, J R SOC INTERFACE, V10, DOI 10.1098/rsif.2012.1018; Zeng XK, 2018, CAN VET J, V59, P871; Zhang Y., 2008, PLOS ONE, V3, pe3933; 2013, ANCIENT NEAR E MONOG, V5, P14	39	7	7	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2020	15	6							e0233599	10.1371/journal.pone.0233599	http://dx.doi.org/10.1371/journal.pone.0233599			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MB7DG	32555636	Green Published, gold			2023-01-03	WOS:000542759600022
J	Mitchell, WG; Pande, R; Robinson, TE; Jones, GD; Hou, I; Celi, LA				Mitchell, William Greig; Pande, Rohit; Robinson, Tom Edward; Jones, Gabriel Davis; Hou, Isabella; Celi, Leo Anthony			The weekend effect for stroke patients admitted to intensive care: A retrospective cohort analysis	PLOS ONE			English	Article							IN-HOSPITAL MORTALITY; ADMISSION; OUTCOMES; ICU; ASSOCIATION; SEVERITY; UNITS	Objectives To examine the effect of weekend admission on short and long-term morbidity and mortality, for patients admitted to intensive care after suffering a cerebrovascular accident (stroke). Design, setting, and participants A hospital-wide, retrospective cohort study of 3,729 adult stroke patients admitted to the Beth Israel Deaconess Medical Centre (BIDMC) intensive care unit (ICU) between 2001 and 2012, using the Medical Information Mart for Intensive Care III (MIMIC-III) database. Primary outcome measures Primary outcome measures were ICU length-of-stay and mortality, hospital length-of-stay and mortality, proportions of patients discharged home after admission, and 6-month mortality. Results Overall, 23% of BIDMC ICU stroke admissions occurred over the weekend. Those admitted over the weekend were likelier to have suffered haemorrhagic stroke than those admitted during the week (60.6% vs 47.9%). Those admitted on the weekend were younger, and likelier to be male and unmarried, with similar ethnic representation. The OASIS severity of illness (32.5 vs. 32) and lowest day-one GCS (12.6 vs. 12.9) were similar between groups. Unadjusted ICU-mortality was significantly higher for patients admitted over the weekend (OR 1.32, CI 1.08-1.61), but when adjusted for type of stroke, became non-significant (OR 1.17, CI 0.95-1.44). In-hospital mortality was significantly higher for patients admitted to ICU over the weekend in both unadjusted (OR 1.45, CI 1.22-1.73) and adjusted (OR 1.31, CI 1.09-1.58) analyses. There was no significant difference in ICU or hospital length of stay. While patients admitted on the weekend appeared less likely to be discharged back to home and more at risk of 6-month mortality compared to weekday admissions, results were non-significant. Conclusions The effect of weekend ICU-admission for stroke patients appears to be significant for in-hospital mortality. There were no significant differences in adjusted ICU-mortality, ICU or hospital length-of-stay, or longer-term morbidity and mortality measures.	[Mitchell, William Greig] Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Pande, Rohit] Whitireia Community Polytech, Porirua, New Zealand; [Robinson, Tom Edward] Univ Auckland, Auckland, New Zealand; [Jones, Gabriel Davis] Univ Oxford, Oxford, England; [Hou, Isabella] Southern Cross Hlth Soc, Auckland, New Zealand; [Celi, Leo Anthony] MIT, Harvard Med Sch, Beth Israel Deaconess Med Ctr, 77 Massachusetts Ave, Cambridge, MA 02139 USA	Harvard University; Harvard T.H. Chan School of Public Health; Whitireia Community Polytechnic; University of Auckland; University of Oxford; Harvard University; Beth Israel Deaconess Medical Center; Massachusetts Institute of Technology (MIT)	Mitchell, WG (corresponding author), Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.	william.greig.mitchell@gmail.com		Pande, Rohit/0000-0002-2598-4689; Mitchell, William/0000-0002-2122-6741				Andersen KK, 2009, STROKE, V40, P2068, DOI 10.1161/STROKEAHA.108.540112; [Anonymous], 2019, CANC DISCOV, V9, pOF3, DOI 10. 1158/2159-8290. CD-NB2018-158; [Anonymous], 2020, TYP STROK AM STROK A; Barnett MJ, 2002, MED CARE, V40, P530, DOI 10.1097/00005650-200206000-00010; Bell CM, 2001, NEW ENGL J MED, V345, P663, DOI 10.1056/NEJMsa003376; Black N, 2016, JAMA-J AM MED ASSOC, V316, P2593, DOI 10.1001/jama.2016.16410; Cavallazzi R, 2010, CHEST, V138, P68, DOI 10.1378/chest.09-3018; Crowley RW, 2009, STROKE, V40, P2387, DOI 10.1161/STROKEAHA.108.546572; Ensminger SA, 2004, CHEST, V126, P1292, DOI 10.1378/chest.126.4.1292; Galloway M, 2018, CRIT CARE MED, V46, P290, DOI 10.1097/CCM.0000000000002837; Hoh BL, 2010, STROKE, V41, P2323, DOI 10.1161/STROKEAHA.110.591081; Inoue T, 2015, J STROKE CEREBROVASC, V24, P2787, DOI 10.1016/j.jstrokecerebrovasdis.2015.08.010; Johnson AEW, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.35; Johnson AEW, 2013, CRIT CARE MED, V41, P1711, DOI 10.1097/CCM.0b013e31828a24fe; Laupland KB, 2008, J CRIT CARE, V23, P317, DOI 10.1016/j.jcrc.2007.09.001; Levy MM, 2008, ANN INTERN MED, V148, P801, DOI 10.7326/0003-4819-148-11-200806030-00002; Luyt CE, 2007, CRIT CARE MED, V35, P3, DOI 10.1097/01.CCM.0000249832.36518.11; Meynaar IA, 2009, CRIT CARE, V13, DOI 10.1186/cc7904; Patel AA, 2016, NEUROHOSPITALIST, V6, P51, DOI 10.1177/1941874415601164; Pronovost PJ, 1999, JAMA-J AM MED ASSOC, V281, P1310, DOI 10.1001/jama.281.14.1310; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Uematsu H, 2016, RESPIROLOGY, V21, P905, DOI 10.1111/resp.12788; Uusaro A, 2003, INTENS CARE MED, V29, P2144, DOI 10.1007/s00134-003-2035-1; Zampieri FG, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018541	24	0	0	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2020	15	6							e0234521	10.1371/journal.pone.0234521	http://dx.doi.org/10.1371/journal.pone.0234521			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC0EC	32520977	gold, Green Published			2023-01-03	WOS:000542969500046
J	Naci, H; Kesselheim, AS				Naci, Huseyin; Kesselheim, Aaron S.			Specialty Drugs - A Distinctly American Phenomenon	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								Various stakeholders in the pharmaceutical supply chain assign the specialty label to drugs on the basis of a combination of several unrelated factors, including whether a drug treats a rare condition. But the single most common feature of specialty drugs is high cost.	[Naci, Huseyin] London Sch Econ & Polit Sci, Dept Hlth Policy, London, England; [Naci, Huseyin; Kesselheim, Aaron S.] Harvard Med Sch, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Brigham & Womens Hosp, Boston, MA 02115 USA	University of London; London School Economics & Political Science; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Naci, H (corresponding author), London Sch Econ & Polit Sci, Dept Hlth Policy, London, England.; Naci, H (corresponding author), Harvard Med Sch, Div Pharmacoepidemiol & Pharmacoecon, Dept Med, Brigham & Womens Hosp, Boston, MA 02115 USA.							Congressional Budget Office, 2019, PRIC SPEND SPEC DR D; Cubanski Juliette., 2019, OUT OF POCKET COST D; Dusetzina SB, 2016, HEALTH AFFAIR, V35, P1241, DOI 10.1377/hlthaff.2015.1657; Hartung DM, 2019, HEALTH AFFAIR, V38, P303, DOI 10.1377/hlthaff.2018.05357	4	6	6	2	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	2020	382	23					2179	2181		10.1056/NEJMp1909513	http://dx.doi.org/10.1056/NEJMp1909513			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LV0NI	32492301	Green Published			2023-01-03	WOS:000538140600009
J	Wang, ZQ; Jones, G; Winzenberg, T; Cai, GQ; Laslett, LL; Aitken, D; Hopper, I; Singh, A; Jones, R; Fripp, J; Ding, CH; Antony, B				Wang, Zhiqiang; Jones, Graeme; Winzenberg, Tania; Cai, Guoqi; Laslett, Laura L.; Aitken, Dawn; Hopper, Ingrid; Singh, Ambrish; Jones, Robert; Fripp, Jurgen; Ding, Changhai; Antony, Benny			Effectiveness of Curcuma longa Extract for the Treatment of Symptoms and Effusion-Synovitis of Knee Osteoarthritis A Randomized Trial	ANNALS OF INTERNAL MEDICINE			English	Article							VITAMIN-D SUPPLEMENTATION; CLINICAL-TRIALS; BACK-PAIN; HIP; INFLAMMATION; ASSOCIATION; EFFICACY; CRITERIA; SAFETY; VOLUME	Background: Current pharmacologic therapies for patients with osteoarthritis are suboptimal. Objective: To determine the efficacy of Curcuma longa extract (CL) for reducing knee symptoms and effusion-synovitis in patients with symptomatic knee osteoarthritis and knee effusion-synovitis. Design: Randomized, double-blind, placebo-controlled trial. (Australian New Zealand Clinical Trials Registry: ACTRN12618000080224). Setting: Single-center study with patients from southern Tasmania, Australia. Participants: 70 participants with symptomatic knee osteoarthritis and ultrasonography-defined effusion-synovitis. Intervention: 2 capsules of CL (n = 36) or matched placebo (n = 34) per day for 12 weeks. Measurements: The 2 primary outcomes were changes in knee pain on a visual analogue scale (VAS) and effusion-synovitis volume on magnetic resonance imaging (MRI). The key secondary outcomes were change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain and cartilage composition values. Outcomes were assessed over 12 weeks. Results: CL improved VAS pain compared with placebo by -9.1 mm (95% CI, -17.8 to -0.4 mm [P = 0.039]) but did not change effusion-synovitis volume (3.2 mL [CI, -0.3 to 6.8 mL]). CL also improved WOMAC knee pain (-47.2 mm [CI, -81.2 to -13.2 mm]; P = 0.006) but not lateral femoral cartilage T2 relaxation time (-0.4 ms [CI, -1.1 to 0.3 ms]). The incidence of adverse events was similar in the CL (n = 14 [39%]) and placebo (n = 18 [53%]) groups (P = 0.16); 2 events in the CL group and 5 in the placebo group may have been treatment related. Limitation: Modest sample size and short duration. Conclusion: CL was more effective than placebo for knee pain but did not affect knee effusion-synovitis or cartilage composition. Multicenter trials with larger sample sizes are needed to assess the clinical significance of these findings.	[Wang, Zhiqiang; Jones, Graeme; Winzenberg, Tania; Cai, Guoqi; Laslett, Laura L.; Aitken, Dawn; Singh, Ambrish; Antony, Benny] Univ Tasmania, Menzies Inst Med Res, Private Bag 23, Hobart, Tas 7000, Australia; [Hopper, Ingrid] Monash Univ, Alfred Ctr, 99 Commercial Rd, Melbourne, Vic 3004, Australia; [Jones, Robert] Royal Hobart Hosp, 48 Liverpool St, Hobart, Tas 7000, Australia; [Fripp, Jurgen] Univ Queensland, Brisbane, Qld, Australia; [Ding, Changhai] Univ Tasmania, Private Bag 23, Hobart, Tas 7000, Australia; [Ding, Changhai] Southern Med Univ, Guangzhou, Peoples R China; [Fripp, Jurgen] Univ Queensland, Hlth Sci Bldg 901-16, Herston, Qld 4029, Australia	University of Tasmania; Menzies Institute for Medical Research; Monash University; Royal Hobart Hospital; University of Queensland; University of Tasmania; Southern Medical University - China; University of Queensland	Antony, B (corresponding author), Univ Tasmania, Menzies Inst Med Res, Private Bag 23, Hobart, Tas 7000, Australia.	Benny.EathakkattuAntony@utas.edu.au	Wang, Zhiqiang/AAF-3634-2021; Cai, Guoqi/HGE-7097-2022; Fripp, Jurgen/A-8763-2011; Singh, Ambrish/W-2163-2017; Laslett, Laura/G-3973-2011; Aitken, Dawn/L-6882-2013	Wang, Zhiqiang/0000-0002-8087-436X; Fripp, Jurgen/0000-0001-9705-0079; Singh, Ambrish/0000-0002-4618-7507; Laslett, Laura/0000-0002-4336-0095; Aitken, Dawn/0000-0001-5685-7634; Eathakkattu Antony, Benny Samuel/0000-0001-8704-6084; Winzenberg, Tania/0000-0002-4112-3491	Natural Remedies Private Limited (Bengaluru)	Natural Remedies Private Limited (Bengaluru)	This investigator-initiated trial received partial funding from Natural Remedies Private Limited (Bengaluru). Curcuma longa extract and placebo capsules were supplied by Natural Remedies, according to the investigators' requirements. The company had no role in the design, implementation, or data analyses of the study. None of the investigators have received any other financial support from the company.	ALTMAN R, 1986, ARTHRITIS RHEUM, V29, P1039, DOI 10.1002/art.1780290816; Altman RD, 2007, OSTEOARTHR CARTILAGE, V15, pA1, DOI 10.1016/j.joca.2006.11.009; Angst F, 2001, ARTHRIT RHEUM-ARTHR, V45, P384, DOI 10.1002/1529-0131(200108)45:4<384::AID-ART352>3.0.CO;2-0; Conaghan PG, 2010, ANN RHEUM DIS, V69, P644, DOI 10.1136/ard.2008.099564; D'Agostino MA, 2005, ANN RHEUM DIS, V64, P1703, DOI 10.1136/ard.2005.037994; Dobson F, 2013, OSTEOARTHR CARTILAGE, V21, P1042, DOI 10.1016/j.joca.2013.05.002; Dworkin RH, 2011, J PAIN, V12, P416, DOI 10.1016/j.jpain.2010.07.009; Fedorov A, 2012, MAGN RESON IMAGING, V30, P1323, DOI 10.1016/j.mri.2012.05.001; Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016; Gregori D, 2018, JAMA-J AM MED ASSOC, V320, P2564, DOI 10.1001/jama.2018.19319; Hawthorne G, 1999, QUAL LIFE RES, V8, P209, DOI 10.1023/A:1008815005736; Henrotin Y, 2019, ARTHRITIS RES THER, V21, DOI 10.1186/s13075-019-1960-5; Hunter DJ, 2011, NAT REV RHEUMATOL, V7, P13, DOI 10.1038/nrrheum.2010.178; Jin XZ, 2016, JAMA-J AM MED ASSOC, V315, P1005, DOI 10.1001/jama.2016.1961; Jin XZ, 2015, ANN RHEUM DIS, V74, P703, DOI 10.1136/annrheumdis-2013-204494; Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012; Kraus VB, 2015, OSTEOARTHR CARTILAGE, V23, P1233, DOI 10.1016/j.joca.2015.03.036; Kunnumakkara AB, 2017, BRIT J PHARMACOL, V174, P1325, DOI 10.1111/bph.13621; Kuptniratsaikul V, 2014, CLIN INTERV AGING, V9, P451, DOI 10.2147/CIA.S58535; Laslett LL, 2012, OSTEOARTHR CARTILAGE, V20, P1209, DOI 10.1016/j.joca.2012.07.019; Machado GC, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1225; Madhu K, 2013, INFLAMMOPHARMACOLOGY, V21, P129, DOI 10.1007/s10787-012-0163-3; McAlindon TE, 2014, OSTEOARTHR CARTILAGE, V22, P363, DOI 10.1016/j.joca.2014.01.003; Onakpoya IJ, 2017, INT J RHEUM DIS, V20, P420, DOI 10.1111/1756-185X.13069; Pham T, 2004, OSTEOARTHR CARTILAGE, V12, P389, DOI 10.1016/j.joca.2004.02.001; Prasad S, 2014, CANCER RES TREAT, V46, P2, DOI 10.4143/crt.2014.46.1.2; Robinson WH, 2016, NAT REV RHEUMATOL, V12, P580, DOI 10.1038/nrrheum.2016.136; Stannus O, 2010, OSTEOARTHR CARTILAGE, V18, P1441, DOI 10.1016/j.joca.2010.08.016; Stratford PW, 2007, OSTEOARTHR CARTILAGE, V15, P266, DOI 10.1016/j.joca.2006.09.005; Tubach F, 2012, ARTHRIT CARE RES, V64, P1699, DOI 10.1002/acr.21747; Tubach F, 2005, ANN RHEUM DIS, V64, P29, DOI 10.1136/ard.2004.022905; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wang X, 2017, OSTEOARTHR CARTILAGE, V25, P1304, DOI 10.1016/j.joca.2017.02.804; Wang X, 2016, ANN RHEUM DIS, V75, P519, DOI 10.1136/annrheumdis-2014-206676; Wang X, 2016, J RHEUMATOL, V43, P121, DOI 10.3899/jrheum.150355	35	33	34	4	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	2020	173	11					861	+		10.7326/M20-0990	http://dx.doi.org/10.7326/M20-0990			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OZ7ZT	32926799				2023-01-03	WOS:000595140400006
J	Doheny, D; Sirkisoon, S; Carpenter, RL; Aguayo, NR; Regua, AT; Anguelov, M; Manore, SG; Arrigo, A; Abu Jalboush, S; Wong, GL; Yu, Y; Wagner, CJ; Chan, M; Ruiz, J; Thomas, A; Strowd, R; Lin, J; Lo, HW				Doheny, Daniel; Sirkisoon, Sherona; Carpenter, Richard L.; Aguayo, Noah Reeve; Regua, Angelina T.; Anguelov, Marlyn; Manore, Sara G.; Arrigo, Austin; Jalboush, Sara Abu; Wong, Grace L.; Yu, Yang; Wagner, Calvin J.; Chan, Michael; Ruiz, Jimmy; Thomas, Alexandra; Strowd, Roy; Lin, Jiayuh; Lo, Hui-Wen			Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis	ONCOGENE			English	Article							SIGNALING PATHWAY; SONIC HEDGEHOG; THERAPEUTIC TARGET; GENE-EXPRESSION; FACTOR RECEPTOR; SPLICE VARIANT; UP-REGULATION; SELF-RENEWAL; STAT3; ACTIVATION	Triple-negative breast cancer (TNBC) and HER2-positive breast cancer are particularly aggressive and associated with unfavorable prognosis. TNBC lacks effective treatments. HER2-positive tumors have treatment options but often acquire resistance to HER2-targeted therapy after initial response. To address these challenges, we determined whether novel combinations of JAK2-STAT3 and SMO-GLI1/tGLI1 inhibitors synergistically target TNBC and HER2 breast cancer since these two pathways are concurrently activated in both tumor types and enriched in metastatic tumors. Herein, we show that novel combinations of JAK2 inhibitors (ruxolitinib and pacritinib) with SMO inhibitors (vismodegib and sonidegib) synergistically inhibited in vitro growth of TNBC and HER2-positive trastuzumab-resistant BT474-TtzmR cells. Synergy was also observed against breast cancer stem cells. To determine if the combination is efficacious in inhibiting metastasis, we treated mice with intracardially inoculated TNBC cells and found the combination to inhibit lung and liver metastases, and prolong host survival without toxicity. The combination inhibited orthotopic growth, VEGF-A expression, and tumor vasculature of both TNBC and HER2-positive trastuzumab-refractory breast cancer. Lung metastasis of orthotopic BT474-TtzmR xenografts was suppressed by the combination. Together, our results indicated that dual targeting of JAK2 and SMO resulted in synergistic suppression of breast cancer growth and metastasis, thereby supporting future clinical testing.	[Doheny, Daniel; Sirkisoon, Sherona; Carpenter, Richard L.; Aguayo, Noah Reeve; Regua, Angelina T.; Anguelov, Marlyn; Manore, Sara G.; Arrigo, Austin; Jalboush, Sara Abu; Wong, Grace L.; Yu, Yang; Wagner, Calvin J.; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27103 USA; [Chan, Michael; Ruiz, Jimmy; Thomas, Alexandra; Strowd, Roy; Lo, Hui-Wen] Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Comprehens Canc Ctr, Winston Salem, NC 27103 USA; [Chan, Michael] Wake Forest Univ, Bowman Gray Sch Med, Dept Radiat Oncol, Winston Salem, NC USA; [Ruiz, Jimmy; Thomas, Alexandra] Wake Forest Univ, Bowman Gray Sch Med, Dept Hematol & Oncol, Winston Salem, NC USA; [Strowd, Roy] Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27103 USA; [Lin, Jiayuh] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; [Carpenter, Richard L.] Indiana Univ Sch Med, Dept Biochem & Mol Biol, JH 308 1001 E 3rd St, Bloomington, IN 47405 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University System of Maryland; University of Maryland Baltimore; Indiana University System; Indiana University Bloomington	Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27103 USA.; Lo, HW (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Wake Forest Comprehens Canc Ctr, Winston Salem, NC 27103 USA.	hlo@wakehealth.edu		Manore, Sara/0000-0003-1962-5505; Regua, Angelina/0000-0003-2595-8242; Doheny, Daniel/0000-0002-1455-3090	NIH [R01NS087169, T32CA079448, R01NS087169-3S1, 1T32CA247819-01, P30CA012197, 1R01CA228137-01A1]; DoD [W81XWH-17-1-0044, W81XWH-19-1-0072, W81XWH-19-1-0753, W81XWH-20-1-0044]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DoD(United States Department of Defense)	We would like to acknowledge the Massague laboratory for gifting the 231-BoM and 231-BrM breast cancer cell lines and Dr. Dihua Yu for gifting the BT474-TtzmR cell line. We acknowledge funding support for this project from NIH grants, R01NS087169 (HWL), T32CA079448 (RLC), R01NS087169-3S1 (HWL and SS), 1T32CA247819-01 (ATR), P30CA012197 (BP), 1R01CA228137-01A1 (HWL), as well as, DoD grants, W81XWH-17-1-0044 (HWL), W81XWH-19-1-0072 (HWL), W81XWH-19-1-0753 (HWL), and W81XWH-20-1-0044 (HWL and JL).	Ackerman Z, 2015, BIOL TRACE ELEM RES, V163, P169, DOI 10.1007/s12011-014-0110-9; Aditya Suruchi, 2013, Indian Dermatol Online J, V4, P365, DOI 10.4103/2229-5178.120685; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Mahmood S, 2018, DRUG DELIV TRANSL RE, V8, P1483, DOI 10.1007/s13346-018-0551-3; Atwood SX, 2015, CANCER CELL, V27, P342, DOI 10.1016/j.ccell.2015.02.002; Balko JM, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad3001; Balko JM, 2014, CANCER DISCOV, V4, P232, DOI 10.1158/2159-8290.CD-13-0286; Baron JM, 2015, J ONCOL PHARM PRACT, V21, P132, DOI 10.1177/1078155214527144; Bigelow RLH, 2004, J BIOL CHEM, V279, P1197, DOI 10.1074/jbc.M310589200; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200; Cao X, 2012, ONCOGENE, V31, P104, DOI 10.1038/onc.2011.219; Carpenter RL, 2015, ONCOTARGET, V6, P22653, DOI 10.18632/oncotarget.4248; Carpenter RL, 2014, CANCERS, V6, P897, DOI 10.3390/cancers6020897; Carpenter RL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078836; Carpenter RL, 2013, J CARCINOG MUTAGEN, P2013; Chen WW, 2011, P NATL ACAD SCI USA, V108, P9589, DOI 10.1073/pnas.1017945108; Choi HJ, 2012, BBA-MOL CELL RES, V1823, P1082, DOI 10.1016/j.bbamcr.2012.03.015; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Fan C, 2006, NEW ENGL J MED, V355, P560, DOI 10.1056/NEJMoa052933; Fernandez A, 2009, GENE DEV, V23, P2729, DOI 10.1101/gad.1824509; Fiaschi M, 2009, CANCER RES, V69, P4810, DOI 10.1158/0008-5472.CAN-08-3938; Foshay KM, 2008, STEM CELLS DEV, V17, P269, DOI 10.1089/scd.2007.0098; Gruber R, 2016, GASTROENTEROLOGY, V151, P526, DOI 10.1053/j.gastro.2016.05.006; Guo CC, 2012, P NATL ACAD SCI USA, V109, P17603, DOI 10.1073/pnas.1208807109; Han W, 2013, CANC HALLMARKS, V1, P28, DOI DOI 10.1166/CH.2013.1006; Hindley C, 2013, BIOCHEM J, V451, P135, DOI 10.1042/BJ20121627; Howie LJ, 2019, CLIN CANCER RES, V25, P2949, DOI 10.1158/1078-0432.CCR-18-3003; Howlader NNA, 2019, SEER CANC STAT REV 1, V2020, P1975; Hsu TH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04052-6; Jain S, 2017, ONCOTARGETS THER, V10, DOI 10.2147/OTT.S130910; Jiao X, 2012, GENE CHROMOSOME CANC, V51, P480, DOI 10.1002/gcc.21935; Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8; Kameda C, 2009, ANTICANCER RES, V29, P871; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; Kiuchi N, 1999, J EXP MED, V189, P63, DOI 10.1084/jem.189.1.63; Kuba S, 2014, JPN J CLIN ONCOL, V44, P1025, DOI 10.1093/jjco/hyu126; Kusaba T, 2006, ONCOL REP, V15, P1445; Lebert JM, 2018, CURR ONCOL, V25, pS142, DOI 10.3747/co.25.3954; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lo HW, 2010, MOL CANCER RES, V8, P232, DOI 10.1158/1541-7786.MCR-09-0391; Lo HW, 2009, CANCER RES, V69, P6790, DOI 10.1158/0008-5472.CAN-09-0886; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Loh CY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00048; Machold R, 2003, NEURON, V39, P937, DOI 10.1016/S0896-6273(03)00561-0; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Okumura F, 2011, BBA-MOL CELL RES, V1813, P1784, DOI 10.1016/j.bbamcr.2011.05.013; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; PAIK S, 1990, J CLIN ONCOL, V8, P103, DOI 10.1200/JCO.1990.8.1.103; Palmieri C, 2010, NAT REV CLIN ONCOL, V7, P561, DOI 10.1038/nrclinonc.2010.122; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Qin JJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1206-z; Ramos A, 2012, TRENDS CELL BIOL, V22, P339, DOI 10.1016/j.tcb.2012.04.006; Rimkus TK, 2018, CANCER RES, V78, P2589, DOI 10.1158/0008-5472.CAN-17-2933; Rimkus TK, 2016, CANCERS, V8, DOI 10.3390/cancers8020022; Riobo-Del Galdo NA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040375; Ruiz-Borrego M, 2019, INVEST NEW DRUG, V37, P98, DOI 10.1007/s10637-018-0614-9; Ryan Q, 2008, ONCOLOGIST, V13, P1114, DOI 10.1634/theoncologist.2008-0816; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sirkisoon SR, 2020, ONCOGENE, V39, P64, DOI 10.1038/s41388-019-0959-3; Sirkisoon SR, 2018, ONCOGENE, V37, P2502, DOI 10.1038/s41388-018-0132-4; Snigdha K, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00085; Tavallai M, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00142; Teperino R, 2014, SEMIN CELL DEV BIOL, V33, P81, DOI 10.1016/j.semcdb.2014.05.007; Wang T, 2015, ONCOTARGET, V6, P44191, DOI 10.18632/oncotarget.6176; Wang Y, 2018, CANCER LETT, V415, P117, DOI 10.1016/j.canlet.2017.12.003; Xie JW, 1997, CANCER RES, V57, P2369; Zaidi AH, 2013, CANCER INVEST, V31, P480, DOI 10.3109/07357907.2013.820317; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhu C, 2015, ACTA BIOCH BIOPH SIN, V47, P16, DOI 10.1093/abbs/gmu110; Zhu H, 2014, CANCER LETT, V343, P51, DOI 10.1016/j.canlet.2013.09.014	80	24	26	0	17	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6589	6605		10.1038/s41388-020-01454-1	http://dx.doi.org/10.1038/s41388-020-01454-1		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32929154	Green Accepted			2023-01-03	WOS:000569499000002
J	Muyyarikkandy, MS; McLeod, M; Maguire, M; Mahar, R; Kattapuram, N; Zhang, CE; Surugihalli, C; Muralidaran, V; Vavilikolanu, K; Mathews, CE; Merritt, ME; Sunny, NE				Muyyarikkandy, Muhammed S.; McLeod, Marc; Maguire, Meghan; Mahar, Rohit; Kattapuram, Nathan; Zhang, Christine; Surugihalli, Chaitra; Muralidaran, Vaishna; Vavilikolanu, Kruthi; Mathews, Clayton E.; Merritt, Matthew E.; Sunny, Nishanth E.			Branched chain amino acids and carbohydrate restriction exacerbate ketogenesis and hepatic mitochondrial oxidative dysfunction during NAFLD	FASEB JOURNAL			English	Article						fatty liver; hepatic insulin resistance; lipogenesis; liver mitochondria	NONALCOHOLIC FATTY LIVER; TCA CYCLE; DIET; GLUCOSE; ADAPTATION; METABOLISM; STRESS; HUMANS; MICE; ACETOACETATE	Mitochondrial adaptation during non-alcoholic fatty liver disease (NAFLD) include remodeling of ketogenic flux and sustained tricarboxylic acid (TCA) cycle activity, which are concurrent to onset of oxidative stress. Over 70% of obese humans have NAFLD and ketogenic diets are common weight loss strategies. However, the effectiveness of ketogenic diets toward alleviating NAFLD remains unclear. We hypothesized that chronic ketogenesis will worsen metabolic dysfunction and oxidative stress during NAFLD. Mice (C57BL/6) were kept (for 16-wks) on either a low-fat, high-fat, or high-fat diet supplemented with 1.5X branched chain amino acids (BCAAs) by replacing carbohydrate calories (ketogenic). The ketogenic diet induced hepatic lipid oxidation and ketogenesis, and produced multifaceted changes in flux through the individual steps of the TCA cycle. Higher rates of hepatic oxidative fluxes fueled by the ketogenic diet paralleled lower rates of de novo lipogenesis. Interestingly, this metabolic remodeling did not improve insulin resistance, but induced fibrogenic genes and inflammation in the liver. Under a chronic "ketogenic environment," the hepatocyte diverted more acetyl-CoA away from lipogenesis toward ketogenesis and TCA cycle, a milieu which can hasten oxidative stress and inflammation. In summary, chronic exposure to ketogenic environment during obesity and NAFLD has the potential to aggravate hepatic mitochondrial dysfunction.	[Muyyarikkandy, Muhammed S.; Maguire, Meghan; Kattapuram, Nathan; Zhang, Christine; Surugihalli, Chaitra; Muralidaran, Vaishna; Vavilikolanu, Kruthi; Sunny, Nishanth E.] Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA; [McLeod, Marc; Mahar, Rohit; Mathews, Clayton E.; Merritt, Matthew E.] Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	University System of Maryland; University of Maryland College Park; State University System of Florida; University of Florida	Sunny, NE (corresponding author), Univ Maryland, Dept Anim & Avian Sci, College Pk, MD 20742 USA.	nsunny@umd.edu	Muyyarikkandy, Muhammed/AAG-3402-2020	Muyyarikkandy, Muhammed/0000-0003-3405-5440; MAHAR, ROHIT/0000-0002-9801-4173; Merritt, Matthew/0000-0003-4617-9651; Kattapuram, Nathan/0000-0002-6766-7235	HHS | National Institutes of Health (NIH) [RO1-DK-112865, P41-122698, 5U2CDK119889, R01-105346]	HHS | National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	HHS | National Institutes of Health (NIH), Grant/Award Number: RO1-DK-112865, P41-122698, 5U2CDK119889 and R01-105346	Abbasi J, 2018, JAMA-J AM MED ASSOC, V319, P215, DOI 10.1001/jama.2017.20639; Anekwe CV, 2020, CUREUS, V12, DOI 10.7759/cureus.6605; Antoniewicz MR, 2006, METAB ENG, V8, P324, DOI 10.1016/j.ymben.2006.01.004; Begriche K, 2013, HEPATOLOGY, V58, P1497, DOI 10.1002/hep.26226; Belopolsky Y, 2020, J TRANSL INTERN MED, V8, P26, DOI 10.2478/jtim-2020-0005; Boland ML, 2018, WORLD J GASTROENTERO, V24, P1748, DOI 10.3748/wjg.v24.i16.1748; Caprio M, 2019, J ENDOCRINOL INVEST, V42, P1365, DOI 10.1007/s40618-019-01061-2; Cotter DG, 2014, J CLIN INVEST, V124, P5175, DOI 10.1172/JCI76388; Crown SB, 2015, METAB ENG, V28, P151, DOI 10.1016/j.ymben.2015.01.001; Delgado TC, 2009, NMR BIOMED, V22, P310, DOI 10.1002/nbm.1327; Duarte JAG, 2014, J LIPID RES, V55, P2541, DOI 10.1194/jlr.M052308; Ericksen RE, 2019, CELL METAB, V29, P1151, DOI 10.1016/j.cmet.2018.12.020; Fernandez CA, 1996, J MASS SPECTROM, V31, P255, DOI 10.1002/(SICI)1096-9888(199603)31:3<255::AID-JMS290>3.0.CO;2-3; Fletcher JA, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127737; Forrester SJ, 2018, CIRC RES, V122, P877, DOI 10.1161/CIRCRESAHA.117.311401; Garbow JR, 2011, AM J PHYSIOL-GASTR L, V300, pG956, DOI 10.1152/ajpgi.00539.2010; Green CR, 2016, NAT CHEM BIOL, V12, P15, DOI [10.1038/NCHEMBIO.1961, 10.1038/nchembio.1961]; Jain SK, 1998, FREE RADICAL BIO MED, V25, P1083, DOI 10.1016/S0891-5849(98)00140-3; Jain SK, 2002, DIABETES, V51, P2287, DOI 10.2337/diabetes.51.7.2287; Joshi S, 2019, JAMA INTERN MED, V179, P1163, DOI 10.1001/jamainternmed.2019.2633; Kanikarla-Marie P, 2015, CELL PHYSIOL BIOCHEM, V35, P364, DOI 10.1159/000369702; Koliaki C, 2015, CELL METAB, V21, P739, DOI 10.1016/j.cmet.2015.04.004; Kosinski C, 2017, NUTRIENTS, V9, DOI 10.3390/nu9050517; Kujala UM, 2016, FRONT MED-LAUSANNE, V3, P1, DOI 10.3389/fmed.2016.00057; Lerin C, 2016, MOL METAB, V5, P926, DOI 10.1016/j.molmet.2016.08.001; Li T, 2017, CELL METAB, V25, P374, DOI 10.1016/j.cmet.2016.11.005; Luukkonen PK, 2020, P NATL ACAD SCI USA, V117, P7347, DOI 10.1073/pnas.1922344117; Mills EL, 2016, CELL, V167, P457, DOI 10.1016/j.cell.2016.08.064; Moore MP, 2020, APPL PHYSIOL NUTR ME, V45, P35, DOI 10.1139/apnm-2019-0042; Musso G, 2011, ANN MED, V43, P617, DOI 10.3109/07853890.2010.518623; Nishikata N, 2011, NUTR DIABETES, V1, DOI 10.1038/nutd.2011.1; Noguchi Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012057; Patterson RE, 2016, AM J PHYSIOL-ENDOC M, V310, pE484, DOI 10.1152/ajpendo.00492.2015; Puchalska P, 2017, CELL METAB, V25, P262, DOI 10.1016/j.cmet.2016.12.022; Quinlan CL, 2012, J BIOL CHEM, V287, P27255, DOI 10.1074/jbc.M112.374629; Ragavan M, 2017, AM J PHYSIOL-HEART C, V312, pH1215, DOI 10.1152/ajpheart.00016.2017; Rinella ME, 2015, JAMA-J AM MED ASSOC, V313, P2263, DOI 10.1001/jama.2015.5370; Rosenbaum M, 2019, OBESITY, V27, P971, DOI 10.1002/oby.22468; Satapati S, 2016, J CLIN INVEST, V126, P1605, DOI 10.1172/JCI86695; Satapati S, 2012, J LIPID RES, V53, P1080, DOI 10.1194/jlr.M023382; Schmid AI, 2011, DIABETES CARE, V34, P448, DOI 10.2337/dc10-1076; Schugar RC, 2012, CURR OPIN CLIN NUTR, V15, P374, DOI 10.1097/MCO.0b013e3283547157; Sunny NE, 2011, J ANIM SCI, V89, P3945, DOI 10.2527/jas.2011-3985; Sunny NE, 2017, TRENDS ENDOCRIN MET, V28, P250, DOI 10.1016/j.tem.2016.11.006; Sunny NE, 2015, AM J PHYSIOL-ENDOC M, V309, pE311, DOI 10.1152/ajpendo.00161.2015; Sunny NE, 2011, CELL METAB, V14, P804, DOI 10.1016/j.cmet.2011.11.004; Sunny NE, 2010, AM J PHYSIOL-ENDOC M, V298, pE1226, DOI 10.1152/ajpendo.00033.2010; Trimboli P, 2020, REV ENDOCR METAB DIS, V21, P1, DOI 10.1007/s11154-020-09546-9; Xin LJ, 2018, FRONT NUTR, V5, DOI 10.3389/fnut.2018.00062; Young JD, 2014, BIOINFORMATICS, V30, P1333, DOI 10.1093/bioinformatics/btu015; Young JD, 2008, BIOTECHNOL BIOENG, V99, P686, DOI 10.1002/bit.21632; Zhang FY, 2016, EBIOMEDICINE, V13, P157, DOI 10.1016/j.ebiom.2016.10.013; Zhenyukh O, 2018, J CELL MOL MED, V22, P4948, DOI 10.1111/jcmm.13759	53	11	11	3	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2020	34	11					14832	14849		10.1096/fj.202001495R	http://dx.doi.org/10.1096/fj.202001495R		SEP 2020	18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	OP5RX	32918763	Green Accepted			2023-01-03	WOS:000570677900001
J	Hamel, C; Esmaeilisaraji, L; Thuku, M; Michaud, A; Sikora, L; Fung-Kee-Fung, K				Hamel, Candyce; Esmaeilisaraji, Leila; Thuku, Micere; Michaud, Alan; Sikora, Lindsey; Fung-Kee-Fung, Karen			Antenatal and postpartum prevention of Rh alloimmunization: A systematic review and GRADE analysis	PLOS ONE			English	Review							NEGATIVE PREGNANT-WOMEN; RHO(D) IMMUNE GLOBULIN; ANTI-D; HEMOLYTIC-DISEASE; CLINICAL-TRIAL; PROPHYLAXIS; ISOIMMUNIZATION; EXPERIENCE; IMMUNIZATION; QUALITY	Background Existing systematic reviews of Rh immunoprophylaxis include only data from randomized controlled trials, have dated searches, and some do not report on all domains of risk of bias or evaluate the certainty of the evidence. Our objective was to perform an updated review, by including new trials, any comparative observational studies, and assessing the certainty of the evidence using the GRADE framework. Methods We searched MEDLINE, Embase and the Cochrane Library from 2000 to November 26, 2019. Relevant websites and bibliographies of systematic reviews and guidelines were searched for studies published before 2000. Outcomes of interest were sensitization and adverse events. Risk of bias was evaluated with the Cochrane tool and ROBINS-I. The certainty of the evidence was performed using the GRADE framework. Results Thirteen randomized trials and eight comparative cohort studies were identified, evaluating 12 comparisons. Although there is some evidence of beneficial treatment effects (e.g., at 6-months postpartum, fewer women who received RhIg at delivery compared to no RhIg became sensitized [70 fewer sensitized women per 1,000 (95%CI: 67 to 71 fewer); I-2= 73%]), due to very low certainty of the evidence, the magnitude of the treatment effect may be overestimated. The certainty of the evidence was very low for most outcomes often due to high risk of bias (e.g., randomization method, allocation concealment, selective reporting) and imprecision (i.e., few events and small sample sizes). There is limited evidence on prophylaxis for invasive fetal procedures (e.g. amniocentesis) in the comparative literature, and few studies reported adverse events. Conclusion Serious risk of bias and low to very low certainty of the evidence is found in existing RCTs and comparative observational studies addressing optimal effectiveness of Rh immunoprophylaxis. Guideline development committees should exercise caution when assessing the strength of the recommendations that inform and influence clinical practice in this area.	[Hamel, Candyce; Esmaeilisaraji, Leila; Thuku, Micere; Michaud, Alan] Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Sikora, Lindsey] Univ Ottawa, Hlth Sci Lib, Ottawa, ON, Canada; [Fung-Kee-Fung, Karen] Ottawa Hosp, Dept Obstet & Gynecol, Div Maternal Fetal Med, Ottawa, ON, Canada; [Fung-Kee-Fung, Karen] Univ Ottawa, Fac Med, Div Maternal Fetal Med, Ottawa, ON, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Hamel, C (corresponding author), Ottawa Hosp, Res Inst, Ottawa, ON, Canada.	cahamel@ohri.ca	; Sikora, Lindsey/R-1530-2017	Hamel, Candyce/0000-0002-5871-2137; Sikora, Lindsey/0000-0002-9715-8634	Strategy for Patient Oriented Research (SPOR) Evidence Alliance	Strategy for Patient Oriented Research (SPOR) Evidence Alliance	The original systematic review RCT portion did not receive specific funding. The observational studies portion and RCT update of this review was funded by the Strategy for Patient Oriented Research (SPOR) Evidence Alliance (https://sporevidencealliance.ca/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 1966, Br Med J, V2, P907; [Anonymous], 2017, Obstet Gynecol, V130, pe57, DOI 10.1097/AOG.0000000000002232; [Anonymous], 1969, Can Med Assoc J, V100, P1021; [Anonymous], 1974, Br Med J, V2, P75; Ascari W Q, 1968, JAMA, V205, P71, DOI 10.1001/jama.205.1.71; ASCARI WQ, 1969, BMJ-BRIT MED J, V1, P399, DOI 10.1136/bmj.1.5641.399; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Baskett TF, 2019, J OBSTET GYNAECOL CA, V41, pS207, DOI 10.1016/j.jogc.2019.08.038; BERAL V, 1990, BMJ-BRIT MED J, V300, P1229; Bhaumik Soumyadeep, 2017, Trop Parasitol, V7, P65, DOI 10.4103/tp.TP_6_17; Bichler J, 2003, BJOG-INT J OBSTET GY, V110, P39, DOI 10.1046/j.1471-0528.2003.02158.x; Bishop G J, 1968, Med J Aust, V1, P1122; BISHOP GJ, 1969, MED J AUSTRALIA, V2, P171, DOI 10.5694/j.1326-5377.1969.tb105689.x; BOWMAN JM, 1978, CAN MED ASSOC J, V118, P627; BOWMAN JM, 1985, OBSTET GYNECOL, V66, P749; BOWMAN JM, 1978, CAN MED ASSOC J, V118, P623; Bryant E C, 1969, Can Med Assoc J, V101, P82; BUCHANAN DI, 1969, LANCET, V2, P288; CLARKE CA, 1968, BRIT MED BULL, V24, P3, DOI 10.1093/oxfordjournals.bmb.a070589; CLARKE CA, 1965, LANCET, V2, P343; Clarke M, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-39; Crowther C, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000021, DOI 10.1002/14651858.CD000021]; Darlington M, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2114-5; de Haas M, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i5789; Delamothe T, 2004, BMJ-BRIT MED J, V328, P1, DOI 10.1136/bmj.328.7430.1; DEWIT CD, 1968, BMJ-BRIT MED J, V4, P477, DOI 10.1136/bmj.4.5629.477; FEDRICK J, 1978, BRIT J OBSTET GYNAEC, V85, P1, DOI 10.1111/j.1471-0528.1978.tb15816.x; FINN R, 1968, TRANSFUSION, V8, P148, DOI 10.1111/j.1537-2995.1968.tb04893.x; FREDA VJ, 1966, SCIENCE, V151, P828, DOI 10.1126/science.151.3712.828; FREDA VJ, 1975, NEW ENGL J MED, V292, P1014, DOI 10.1056/NEJM197505082921906; FREDA VJ, 1967, J AMER MED ASSOC, V199, P390, DOI 10.1001/jama.199.6.390; Fung Kee Fung Karen, 2003, J Obstet Gynaecol Can, V25, P765; Galetsi P, 2019, SOC SCI MED, V241, DOI 10.1016/j.socscimed.2019.112533; GODEL JC, 1968, BMJ-BRIT MED J, V4, P479, DOI 10.1136/bmj.4.5629.479; Gordon LG, 2017, PRENATAL DIAG, V37, P1245, DOI 10.1002/pd.5176; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Haimila K, 2017, ACTA OBSTET GYN SCAN, V96, P1228, DOI 10.1111/aogs.13191; Higgins JPT, 2011, COCHRANE HDB; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; HUCHET J, 1987, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V16, P101; Intitute of Medicine (US), 2011, CLIN PRACTICE GUIDEL; JENNINGS ER, 1968, TRANSFUSION, V8, P146, DOI 10.1111/j.1537-2995.1968.tb04892.x; JOSEPH KS, 1991, BRIT J OBSTET GYNAEC, V98, P369, DOI 10.1111/j.1471-0528.1991.tb13427.x; Karanth L, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009617.pub2; Khangura S, 2012, SYST REV, V1, DOI 10.1186/2046-4053-1-10; LEE D, 1995, TRANSFUSION MED, V5, P15, DOI 10.1111/j.1365-3148.1995.tb00180.x; MacKenzie IZ, 2004, EUR J OBSTET GYN R B, V117, P154, DOI 10.1016/j.ejogrb.2004.03.009; MacKenzie IZ, 1999, BRIT J OBSTET GYNAEC, V106, P492, DOI 10.1111/j.1471-0528.1999.tb08304.x; McBain RD, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000020.pub3; McGowan J, 2016, J CLIN EPIDEMIOL, V75, P40, DOI 10.1016/j.jclinepi.2016.01.021; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; POLLACK W, 1968, TRANSFUSION, V8, P151, DOI 10.1111/j.1537-2995.1968.tb04895.x; RANZCOG, 2015, GUID US RHD IMM ANT; RCOG, 2010, GEST TROPH DIS GREEN; RCOG, 2011, RHES D PROPH US ANT; RCOG, 2014, RED CELL ANT PREG MA; Review Manager (RevMan), 2014, REV MAN REVMAN VERS; ROBERTSON J G, 1969, Journal of Obstetrics and Gynaecology of the British Commonwealth, V76, P252; ROBERTSON JG, 1968, TRANSFUSION, V8, P149, DOI 10.1111/j.1537-2995.1968.tb04894.x; SCHUMACHER GF, 1971, J REPROD MED, V6, P232; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; Silva-Fernandez L, 2019, CLIN RHEUMATOL, V38, P2027, DOI 10.1007/s10067-019-04666-3; Sperling JD, 2018, AM J PERINAT, V35, P110, DOI 10.1055/s-0037-1606609; STENCHEVER MA, 1970, AM J OBSTET GYNECOL, V106, P316, DOI 10.1016/0002-9378(70)90286-3; Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919; Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002; STEWART FH, 1978, OBSTET GYNECOL, V51, P318, DOI 10.1097/00006250-197803000-00013; Teitelbaum L, 2015, ULTRASOUND OBST GYN, V45, P84, DOI 10.1002/uog.14723; The World Bank, 2019, BIRTHS FERT DAT; THORNTON JG, 1989, BMJ-BRIT MED J, V298, P1671, DOI 10.1136/bmj.298.6689.1671; Tiblad E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070984; TOVEY LAD, 1983, LANCET, V2, P244; TROLLE B, 1989, ACTA OBSTET GYN SCAN, V68, P45, DOI 10.3109/00016348909087688; VISSCHER RD, 1972, AM J OBSTET GYNECOL, V113, P158, DOI 10.1016/0002-9378(72)90765-X; Visser GHA, 2019, AM J OBSTET GYNECOL, V221, P227, DOI 10.1016/j.ajog.2019.05.019; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; WHITE CA, 1970, OBSTET GYNECOL, V36, P341; White SW, 2019, MED J AUSTRALIA, V211, P261, DOI 10.5694/mja2.50266; Williamson P, 2012, J HEALTH SERV RES PO, V17, P1, DOI 10.1258/jhsrp.2011.011131; Williamson PR, 2011, TRIALS S1, V12, pA70, DOI DOI 10.1186/1745-6215-12-S1-A70; WOODROW JC, 1965, BRIT MED J, V1, P279, DOI 10.1136/bmj.1.5430.279; WOODROW JC, 1971, BMJ-BRIT MED J, V2, P610, DOI 10.1136/bmj.2.5762.610; Zhang Y, 2019, RES SYNTH METHODS, V10, P312, DOI 10.1002/jrsm.1313	83	0	0	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 10	2020	15	9							e0238844	10.1371/journal.pone.0238844	http://dx.doi.org/10.1371/journal.pone.0238844			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR9ME	32913362	gold, Green Published			2023-01-03	WOS:000571885900021
J	Mao, DD; Tian, XY; Mao, D; Hung, SW; Wang, CC; Lau, CBS; Lee, HM; Wong, CK; Chow, E; Ming, X; Cao, HY; Ma, RC; Chan, PKS; Kong, APS; Li, JJX; Rutter, GA; Tam, WH; Chan, JCN				Mao, Dandan; Tian, Xiao Yu; Mao, Di; Hung, Sze Wan; Wang, Chi Chiu; Lau, Clara Bik San; Lee, Heung Man; Wong, Chun Kwok; Chow, Elaine; Ming, Xing; Cao, Huanyi; Ma, Ronald C.; Chan, Paul K. S.; Kong, Alice P. S.; Li, Joshua J. X.; Rutter, Guy A.; Tam, Wing Hung; Chan, Juliana C. N.			A polysaccharide extract from the medicinal plant Maidong inhibits the IKK-NF-kappa B pathway and IL-1 beta-induced islet inflammation and increases insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						Ophiopogonis Radix; diabetes; inflammation; obesity; insulin secretion; beta cell	PI3K/AKT PATHWAY; GLUCOSE; OBESITY; MDG-1; FAT	The herb dwarf lilyturf tuber (Maidong,Ophiopogonis Radix) is widely used in Chinese traditional medicine to manage diabetes and its complications. However, the role of Maidong polysaccharide extract (MPE) in pancreatic beta-cell function is unclear. Here, we investigated whether MPE protects beta-cell function and studied the underlying mechanisms. We treateddb/dband high-fat diet (HFD)-induced obese mice with 800 or 400 mg/kg MPE or water for 4 weeks, followed by an oral glucose tolerance test. Pancreas and blood were collected for molecular analyses, and clonal MIN6 beta-cells and primary islets from HFD-induced obese mice and normal chow diet-fed mice were used in additional analyses.In vivo, MPE both increased insulin secretion and reduced blood glucose in thedb/dbmice but increased only insulin secretion in the HFD-induced obese mice. MPE substantially increased the beta-cell area in both models (3-fold and 2-fold,p< 0.01, fordb/dband HFD mice, respectively). We observed reduced nuclear translocation of the p65 subunit of NF-kappa B in islets of MPE-treated db/db mice, coinciding with enhanced glucose-stimulated insulin secretion (GSIS).In vitro, MPE potentiated GSIS and decreased interleukin 1 beta (IL-1 beta) secretion in MIN6 beta-cells. Incubation of MIN6 cells with tumor necrosis factor alpha (TNF alpha), interferon-gamma, and IL-1 beta amplified IL-1 beta secretion and inhibited GSIS. These effects were partially reversed with MPE or the I kappa B kinase beta inhibitor PS1145, coinciding with reduced activation of p65 and p-I kappa B in the NF-kappa B pathway. We conclude that MPE may have potential for therapeutic development for beta-cell protection.	[Mao, Dandan; Lee, Heung Man; Chow, Elaine; Ming, Xing; Cao, Huanyi; Ma, Ronald C.; Kong, Alice P. S.; Chan, Juliana C. N.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China; [Mao, Di; Hung, Sze Wan; Wang, Chi Chiu; Tam, Wing Hung] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Obstet & Gynaecol, Hong Kong, Peoples R China; [Wong, Chun Kwok] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Hong Kong, Peoples R China; [Chow, Elaine] Chinese Univ Hong Kong, Prince Wales Hosp, Phase Clin Trial Ctr 1, Hong Kong, Peoples R China; [Ma, Ronald C.; Kong, Alice P. S.; Chan, Juliana C. N.] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong Inst Diabet & Obes, Hong Kong, Peoples R China; [Ma, Ronald C.; Kong, Alice P. S.; Chan, Juliana C. N.] Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Hlth Sci, Hong Kong, Peoples R China; [Chan, Paul K. S.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med Microbiol, Hong Kong, Peoples R China; [Li, Joshua J. X.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; [Tian, Xiao Yu] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Lau, Clara Bik San] Chinese Univ Hong Kong, Inst Chinese Med, Hong Kong, Peoples R China; [Lau, Clara Bik San] Chinese Univ Hong Kong, State Key Lab Res Bioact & Clin Applicat Med Plan, Hong Kong, Peoples R China; [Rutter, Guy A.] Imperial Coll London, Dept Metab Digest & Reprod, Div Diabet Endocrinol & Metab, London, England; [Rutter, Guy A.] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore, Singapore	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Imperial College London; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Chan, JCN (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Peoples R China.; Chan, JCN (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong Inst Diabet & Obes, Hong Kong, Peoples R China.; Chan, JCN (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Li Ka Shing Hlth Sci, Hong Kong, Peoples R China.	jchan@cuhk.edu.hk	Tam, Hung/AAE-3628-2020; Chow, Elaine/HJB-2197-2022; Li, Joshua/ABI-1498-2020; Ming, Xing/GQZ-6385-2022; Tian, Xiao Yu/P-1092-2016; Lau, Clara Bik-San/AAF-3989-2020; Li, Joshua/ACB-6944-2022; Ma, Ronald/C-2788-2009; Chan, Paul KS/J-9360-2013; wang, ronald/C-6541-2014	Tam, Hung/0000-0003-1189-740X; Chow, Elaine/0000-0002-4147-3387; Tian, Xiao Yu/0000-0003-3472-9898; Lau, Clara Bik-San/0000-0002-7409-1270; Ma, Ronald/0000-0002-1227-803X; Chan, Paul KS/0000-0002-6360-4608; Hung, Sze Wan/0000-0003-0576-4707; Rutter, Guy/0000-0001-6360-0343; wang, ronald/0000-0002-3928-7278	HKOG Trust Fund [6903757]; CUHK Direct Grant [4054110]; CUHK Diabetes Research and Education Fund [7105545]; CUHK Postdoctoral Fellowship Scheme; Wellcome Trust [WT098424AIA, 212625/Z/18/Z]; MRC Programme [MR/R022259/1, MR/J0003042/1, MR/L020149/1]; Experimental Challenge Grant DIVA [MR/L02036X/1]; MRC [MR/N00275X/1]; Diabetes UK [BDA/11/0004210, BDA/15/0005275, BDA 16/0005485]; MRC [MR/R022259/1, MR/L020149/1] Funding Source: UKRI; Medical Research Council [MR/N00275X/1] Funding Source: researchfish	HKOG Trust Fund; CUHK Direct Grant(Chinese University of Hong Kong); CUHK Diabetes Research and Education Fund; CUHK Postdoctoral Fellowship Scheme; Wellcome Trust(Wellcome Trust); MRC Programme(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Experimental Challenge Grant DIVA; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Diabetes UK(Diabetes UK); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work was supported by the HKOG Trust Fund (project code: 6903757), a CUHK Direct Grant (project code: 4054110), the CUHK Diabetes Research and Education Fund (project code: 7105545), and the CUHK Postdoctoral Fellowship Scheme. G. A. R. was supported by Wellcome Trust Senior Investigator (WT098424AIA) and Investigator (212625/Z/18/Z) awards; MRC Programme Grants MR/R022259/1, MR/J0003042/1, and MR/L020149/1; Experimental Challenge Grant DIVA, MR/L02036X/1; MRC Grant MR/N00275X/1; and Diabetes UK Grants BDA/11/0004210, BDA/15/0005275, and BDA 16/0005485.	Ackermann AM, 2007, J MOL ENDOCRINOL, V38, P193, DOI 10.1677/JME-06-0053; Ahren B, 1998, EUR J ENDOCRINOL, V139, P461, DOI 10.1530/eje.0.1390461; Bayer Inc, 2014, PR GLUCOBAY TM AC 50; Boni-Schnetzler M, 2018, CELL REP, V22, P1774, DOI 10.1016/j.celrep.2018.01.063; Cerf Marlon E, 2013, Front Endocrinol (Lausanne), V4, P37, DOI 10.3389/fendo.2013.00037; Cernea S, 2013, BIOCHEM MEDICA, V23, P266; Cho NH, 2018, DIABETES RES CLIN PR, V138, P271, DOI 10.1016/j.diabres.2018.02.023; Cunha DA, 2008, J CELL SCI, V121, P2308, DOI 10.1242/jcs.026062; Dalboge LS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082813; Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800; Ding LW, 2012, PHYTOTHER RES, V26, P101, DOI 10.1002/ptr.3505; Eguchi K, 2013, DIABETES OBES METAB, V15, P152, DOI 10.1111/dom.12168; Flannick J, 2019, NATURE, V570, P71, DOI 10.1038/s41586-019-1231-2; Gao CF, 2019, CHIN MED-UK, V14, DOI 10.1186/s13020-019-0245-x; Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009; Hankard RG, 1997, DIABETES, V46, P1535, DOI 10.2337/diabetes.46.10.1535; Hsieh HY, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-115; Huang XJ, 2018, INT J BIOL SCI, V14, P1483, DOI 10.7150/ijbs.27173; Illuri Ramanaiah, 2015, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V14, P53; Jablecka A, 2012, EUR REV MED PHARMACO, V16, P342; Kim Ji-Eun, 2012, Lab Anim Res, V28, P181, DOI 10.5625/lar.2012.28.3.181; Ko CH, 2014, J DIABETES, V6, P323, DOI 10.1111/1753-0407.12117; Lawless MW, 2009, CURR DIABETES REV, V5, P201, DOI 10.2174/157339909788920956; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Liu YH, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/349790; Maedler K, 2002, J CLIN INVEST, V110, P851, DOI 10.1172/JCI200215318; Maedler K, 2017, J CLIN INVEST, V127, P1589, DOI 10.1172/JCI92172; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; Nair Anroop B, 2016, J Basic Clin Pharm, V7, P27, DOI 10.4103/0976-0105.177703; Ni Q, 2011, CHIN J INTEGR MED, V17, P116, DOI 10.1007/s11655-011-0639-9; Piatti P, 2001, DIABETES CARE, V24, P875, DOI 10.2337/diacare.24.5.875; Sidarala V, 2016, RECENT PATENTS ENDOC, V10, P76, DOI 10.2174/1872214810666161020154905; Sousa SG, 2018, CARBOHYD POLYM, V197, P515, DOI 10.1016/j.carbpol.2018.06.042; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; Tahrani AA, 2011, LANCET, V378, P182, DOI 10.1016/S0140-6736(11)60207-9; Wang LY, 2012, J ETHNOPHARMACOL, V143, P347, DOI 10.1016/j.jep.2012.06.050; Wang P, 2015, NAT MED, V21, P383, DOI 10.1038/nm.3820; WHO, 2016, GLOBAL REPORT DIABET, P6; Xu J, 2011, INT J BIOL MACROMOL, V49, P657, DOI 10.1016/j.ijbiomac.2011.06.026; Yabe D, 2016, LANCET DIABETES ENDO, V4, P2, DOI 10.1016/S2213-8587(15)00389-7; Yang HP, 2012, ACTA PHARM SIN B, V2, P396, DOI 10.1016/j.apsb.2012.05.003; Yin Jun, 2008, Endocrine Metabolic & Immune Disorders-Drug Targets, V8, P99, DOI 10.2174/187153008784534330; Zhao HL, 2012, DIABETES, V61, P933, DOI 10.2337/db11-1164	43	6	9	3	26	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 4	2020	295	36					12573	12587		10.1074/jbc.RA120.014357	http://dx.doi.org/10.1074/jbc.RA120.014357			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NQ9DL	32605924	Green Published, hybrid			2023-01-03	WOS:000571166700002
J	Moghadam, F; LeGraw, R; Velazquez, JJ; Yeo, NC; Xu, CX; Park, J; Chavez, A; Ebrahimkhani, MR; Kiani, S				Moghadam, Farzaneh; LeGraw, Ryan; Velazquez, Jeremy J.; Yeo, Nan Cher; Xu, Chenxi; Park, Jin; Chavez, Alejandro; Ebrahimkhani, Mo R.; Kiani, Samira			Synthetic immunomodulation with a CRISPR super-repressor in vivo	NATURE CELL BIOLOGY			English	Article							ENDOTHELIAL-CELLS; TLR9-MYD88 PATHWAY; IMMUNE-RESPONSES; GENE ACTIVATION; TRANSCRIPTION; EXPRESSION; MYD88; CAS9; TRANSDUCTION; THERAPY	Moghadam et al. developed a CRISPR transcriptional repressor to silence MyD88 expression in vivo to modulate immune response against AAV gene therapy and septicaemia. Transient modulation of the genes involved in immunity, without exerting a permanent change in the DNA code, can be an effective strategy to modulate the course of many inflammatory conditions. CRISPR-Cas9 technology represents a promising platform for achieving this goal. Truncation of guide RNA (gRNA) from the 5 ' end enables the application of a nuclease competent Cas9 protein for transcriptional modulation of genes, allowing multifunctionality of CRISPR. Here, we introduce an enhanced CRISPR-based transcriptional repressor to reprogram immune homeostasis in vivo. In this repressor system, two transcriptional repressors-heterochromatin protein 1 (HP1a) and Kruppel-associated box (KRAB)-are fused to the MS2 coat protein and subsequently recruited by gRNA aptamer binding to a nuclease competent CRISPR complex containing truncated gRNAs. With the enhanced repressor, we demonstrate transcriptional repression of the Myeloid differentiation primary response 88 (Myd88) gene in vitro and in vivo. We demonstrate that this strategy can efficiently downregulateMyd88expression in lung, blood and bone marrow of Cas9 transgenic mice that receive systemic injection of adeno-associated virus (AAV)2/1-carrying truncated gRNAs targetingMyd88and the MS2-HP1a-KRAB cassette. This downregulation is accompanied by changes in downstream signalling elements such asTNF-alpha andICAM-1. Myd88repression leads to a decrease in immunoglobulin G (IgG) production against AAV2/1 and AAV2/9 and this strategy modulates the IgG response against AAV cargos. It improves the efficiency of a subsequent AAV9/CRISPR treatment for repression of proprotein convertase subtilisin/kexin type 9 (PCSK9), a gene that, when repressed, can lower blood cholesterol levels. We also demonstrate that CRISPR-mediatedMyd88repression can act as a prophylactic measure against septicaemia in both Cas9 transgenic and C57BL/6J mice. When delivered by nanoparticles, this repressor can serve as a therapeutic modality to influence the course of septicaemia. Collectively, we report that CRISPR-mediated repression of endogenousMyd88can effectively modulate the host immune response against AAV-mediated gene therapy and influence the course of septicaemia. The ability to controlMyd88transcript levels using a CRISPR-based synthetic repressor can be an effective strategy for AAV-based CRISPR therapies, as this pathway serves as a key node in the induction of humoral immunity against AAV serotypes.	[Moghadam, Farzaneh; LeGraw, Ryan; Velazquez, Jeremy J.; Ebrahimkhani, Mo R.; Kiani, Samira] Univ Pittsburgh, Pittsburgh Liver Res Ctr, Sch Med, Pittsburgh, PA 15213 USA; [Moghadam, Farzaneh; LeGraw, Ryan; Velazquez, Jeremy J.; Ebrahimkhani, Mo R.; Kiani, Samira] Univ Pittsburgh, Sch Med, Dept Pathol, Div Expt Pathol, Pittsburgh, PA 15213 USA; [Moghadam, Farzaneh; LeGraw, Ryan; Velazquez, Jeremy J.; Ebrahimkhani, Mo R.; Kiani, Samira] Arizona State Univ, Sch Biol & Hlth Syst Engn, Ira A Fulton Sch Engn, Tempe, AZ 85281 USA; [Yeo, Nan Cher] Univ Alabama Birmingham, Dept Pharmacol & Toxicol, Birmingham, AL USA; [Yeo, Nan Cher] Univ Alabama Birmingham, Precis Med Inst, Birmingham, AL USA; [Xu, Chenxi; Park, Jin] Arizona State Univ, Ctr Personalized Diagnost, Biodesign Inst, Tempe, AZ USA; [Chavez, Alejandro] Columbia Univ Coll Phys & Surg, Dept Pathol & Cell Biol, 630 W 168th St, New York, NY 10032 USA; [Ebrahimkhani, Mo R.; Kiani, Samira] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Arizona State University; Arizona State University-Tempe; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Arizona State University; Arizona State University-Tempe; Columbia University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ebrahimkhani, MR; Kiani, S (corresponding author), Univ Pittsburgh, Pittsburgh Liver Res Ctr, Sch Med, Pittsburgh, PA 15213 USA.; Ebrahimkhani, MR; Kiani, S (corresponding author), Univ Pittsburgh, Sch Med, Dept Pathol, Div Expt Pathol, Pittsburgh, PA 15213 USA.; Ebrahimkhani, MR; Kiani, S (corresponding author), Arizona State Univ, Sch Biol & Hlth Syst Engn, Ira A Fulton Sch Engn, Tempe, AZ 85281 USA.; Ebrahimkhani, MR; Kiani, S (corresponding author), Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA.	mo.ebr@pitt.edu; skiani@pitt.edu		Kiani, Samira/0000-0003-2695-1501; Ebrahimkhani, Mo R./0000-0001-5753-6779	NHLBI NIH HHS [R01 HL141805] Funding Source: Medline; NIBIB NIH HHS [U01 EB029372, R01 EB028532, R01 EB024562, T32 EB001026] Funding Source: Medline; NIDDK NIH HHS [U01 DK127713, P30 DK120531] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abifadel M, 2003, NAT GENET, V34, P154, DOI 10.1038/ng1161; Breinig M, 2019, NAT METHODS, V16, P51, DOI 10.1038/s41592-018-0262-1; Canzio D, 2014, TRENDS CELL BIOL, V24, P377, DOI 10.1016/j.tcb.2014.01.002; Canzio D, 2011, MOL CELL, V41, P67, DOI 10.1016/j.molcel.2010.12.016; Castle MJ, 2016, METHODS MOL BIOL, V1382, P133, DOI 10.1007/978-1-4939-3271-9_10; Chavez A, 2016, NAT METHODS, V13, P563, DOI [10.1038/NMETH.3871, 10.1038/nmeth.3871]; Chen SF, 2005, HUM GENE THER, V16, P235, DOI 10.1089/hum.2005.16.235; Cho SY, 2014, INFECT CHEMOTHER, V46, P1, DOI [10.3947/ic.2014.46.3.199, 10.3947/ic.2014.46.1.1]; Dandekar A, 2016, J BIOL CHEM, V291, P23149, DOI 10.1074/jbc.M116.755728; Duan YJ, 2016, J BIOL CHEM, V291, P16339, DOI 10.1074/jbc.M116.729467; Evers B, 2016, NAT BIOTECHNOL, V34, P631, DOI 10.1038/nbt.3536; Gilbert LA, 2014, CELL, V159, P647, DOI 10.1016/j.cell.2014.09.029; Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044; Hiragami K, 2005, CELL MOL LIFE SCI, V62, P2711, DOI 10.1007/s00018-005-5287-9; Huang XP, 2010, EXPERT OPIN THER TAR, V14, P787, DOI 10.1517/14728222.2010.501333; Janssens S, 2002, TRENDS BIOCHEM SCI, V27, P474, DOI 10.1016/S0968-0004(02)02145-X; Kearns NA, 2015, NAT METHODS, V12, P401, DOI 10.1038/nmeth.3325; Kiani S, 2015, NAT METHODS, V12, P1051, DOI [10.1038/nmeth.3580, 10.1038/NMETH.3580]; Konermann S, 2015, NATURE, V517, P583, DOI 10.1038/nature14136; Konermann S, 2013, NATURE, V500, P472, DOI 10.1038/nature12466; La Russa MF, 2015, MOL CELL BIOL, V35, P3800, DOI 10.1128/MCB.00512-15; Liao HK, 2017, CELL, V171, P1495, DOI 10.1016/j.cell.2017.10.025; Liao HK, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7413; Lin XF, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/329405; Lu YQ, 2009, P NATL ACAD SCI USA, V106, P17158, DOI 10.1073/pnas.0909520106; Ma XY, 2016, MILITARY MED RES, V3, DOI 10.1186/s40779-016-0104-3; Markel SF, 2017, J NEUROCHEM, V140, P216, DOI 10.1111/jnc.13861; Matharu N, 2019, SCIENCE, V363, P246, DOI 10.1126/science.aau0629; Maxwell KN, 2004, P NATL ACAD SCI USA, V101, P7100, DOI 10.1073/pnas.0402133101; Meehan RR, 2003, EMBO J, V22, P3164, DOI 10.1093/emboj/cdg306; Moghadam F, 2020, PROTOC EXCH, DOI [10.21203/rs.3.pex-1027/v1, DOI 10.21203/RS.3.PEX-1027/V1]; Moreno AM, 2018, MOL THER, V26, P1818, DOI 10.1016/j.ymthe.2018.04.017; Park GS, 2015, MOL CELLS, V38, P821, DOI 10.14348/molcells.2015.0174; Plant L, 2006, INFECT IMMUN, V74, P3538, DOI 10.1128/IAI.00128-06; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Sudres M, 2012, MOL THER, V20, P1571, DOI 10.1038/mt.2012.101; Thakore PI, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04048-4; Thakore PI, 2016, NAT METHODS, V13, P127, DOI [10.1038/NMETH.3733, 10.1038/nmeth.3733]; Thakore PI, 2015, NAT METHODS, V12, P1143, DOI 10.1038/nmeth.3630; Thakore P, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02703-w; VANDENAKKER TW, 1988, IMMUNOLOGY, V65, P31; Veron P, 2007, J VIROL, V81, P5385, DOI 10.1128/JVI.02516-06; Warner N, 2013, J IMMUNOL, V190, P3, DOI 10.4049/jimmunol.1203103; Xu L, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw1048; Xu XB, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05766-5; Yao ZL, 2016, J IMMUNOL, V197, P2390, DOI 10.4049/jimmunol.1600702; Yeo NC, 2018, NAT METHODS, V15, P611, DOI 10.1038/s41592-018-0048-5; Yu MJ, 2014, J EXP MED, V211, P887, DOI 10.1084/jem.20131314; Yu XF, 2018, CANCER RES, V78, P2457, DOI 10.1158/0008-5472.CAN-18-0215; Zhang HJ, 2016, STEM CELL REP, V6, P940, DOI 10.1016/j.stemcr.2016.05.002; Zheng Y, 2018, NAT NEUROSCI, V21, P447, DOI 10.1038/s41593-018-0077-5; Zhou HB, 2018, NAT NEUROSCI, V21, P440, DOI 10.1038/s41593-017-0060-6; Zhu JG, 2009, J CLIN INVEST, V119, P2388, DOI 10.1172/JCI37607	54	17	18	3	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2020	22	9					1143	+		10.1038/s41556-020-0563-3	http://dx.doi.org/10.1038/s41556-020-0563-3			25	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	NJ1ME	32884147	Green Accepted			2023-01-03	WOS:000565806900015
J	Ademas, A; Adane, M; Sisay, T; Kloos, H; Eneyew, B; Keleb, A; Lingerew, M; Derso, A; Alemu, K				Ademas, Ayechew; Adane, Metadel; Sisay, Tadesse; Kloos, Helmut; Eneyew, Betelhiem; Keleb, Awoke; Lingerew, Mistir; Derso, Atimen; Alemu, Kassahun			Does menstrual hygiene management and water, sanitation, and hygiene predict reproductive tract infections among reproductive women in urban areas in Ethiopia?	PLOS ONE			English	Article								Reproductive tract infections (RTIs) are a public health concern in Ethiopia. However, the relationship between menstrual hygiene management (MHM) and water, sanitation, and hygiene (WASH) factors to RTIs have not been well addressed. A community-based cross-sectional study was conducted from January to March 2019 among 602 systematically selected reproductive-age women aged 15-49 years in Dessie City. Data were collected using a questionnaire and a direct observation checklist. RTIs were identified by the presence during one year before data collection of one or more signs of vaginal discharge, itching/irritation or ulcers/lesions around the vulva, pain during urination and sexual intercourse, and lower abdominal pain and lower back pain. Data were analyzed using multivariable logistic regression analysis with 95%CI (confidence interval). The self-reported prevalence of RTIs was 11.0%(95%CI:8.5-13.7%) during one year prior to the survey. The most commonly reported symptoms of RTI were burning micturition (9.1%) and vaginal discharge (6.1%). Three-fourths 443(75.0%) of households used traditional pit latrines and the majority of the study participants 527(89.2%) did not meet the basic access requirement of 20 liters of water per capita per day. The majority 562(95.1%) of the study participants did not have multiple sexual partners during the last year and 97.8% did not practiced sexual intercourse during menstruation. The most common type of blood-absorbent material used was a sanitary pad 497(84.8%) followed by cloth 89(15.2%). Factors significantly associated with RTIs were using unclean latrines (AOR: 4.20; 95%CI:2.00-8.80), not washing hands with soap before touching the genital area (AOR: 3.94; 95%CI:1.49-10.45), history of symptoms of RTIs in the past year (AOR: 5.88; 95%CI:2.30-14.98), having multiple sexual partners in the past year (AOR: 4.46; 95%CI:1.59-12.53), changing absorbent material only once per day (AOR: 8.99; 95%CI:4.51-17.92), and washing the genital area only once per day during menstruation (AOR: 5.76; 95%CI:2.07-16.05). The self-reported prevalence of RTI showed that one women experienced RTI among ten reproductive-age women. Designing a women's health policy that focuses on ensuring availability of WASH facilities and improving MHM at the community level is key for sustainably preventing RTIs.	[Ademas, Ayechew; Adane, Metadel; Sisay, Tadesse; Eneyew, Betelhiem; Keleb, Awoke; Lingerew, Mistir; Derso, Atimen] Wollo Univ, Coll Med & Hlth Sci, Dept Environm Hlth, Dessie, Ethiopia; [Kloos, Helmut] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA USA; [Alemu, Kassahun] Univ Gondar, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia	University of California System; University of California San Francisco; University of Gondar	Adane, M (corresponding author), Wollo Univ, Coll Med & Hlth Sci, Dept Environm Hlth, Dessie, Ethiopia.	metadel.adane2@gmail.com	Ademas, Ayechew/AAO-4212-2021; Keleb, Awoke/AGX-2940-2022; Adane, Metadel/AFQ-9478-2022; Ademas, Ayechew/AAG-5984-2021	Ademas, Ayechew/0000-0003-2602-162X; Keleb, Awoke/0000-0002-7510-3448; Adane, Metadel/0000-0002-7039-4768; Ademas, Ayechew/0000-0003-2602-162X	Wollo University	Wollo University	Wollo University Funded this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; Adane M, 2018, J COMMUN HEALTH, V43, P400, DOI 10.1007/s10900-017-0437-1; Adane M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182783; Adane M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181516; Ajari E.E., 2020, EUROPEAN J ENV PUBLI, V4; [Anonymous], 2015, AICHI PREFECTURE HYG, V2021; [Anonymous], 2017, NCCN PRACT GUIDEL, V2017, P1, DOI DOI 10.1155/2017/2683789; [Anonymous], 2014, INT J SCI TECHNOLOGY; Baker KK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188234; Balamurugan Sangeetha S, 2012, Indian J Community Med, V37, P34, DOI 10.4103/0970-0218.94020; Bearak J, 2020, LANCET GLOB HEALTH, V8, pE1152, DOI 10.1016/S2214-109X(20)30315-6; Bhilwar Meenakshi, 2015, J Nat Sci Biol Med, V6, pS29, DOI 10.4103/0976-9668.166059; Campbell OMR, 2015, TROP MED INT HEALTH, V20, P252, DOI 10.1111/tmi.12439; Chanchuey T., 2016, J COMMUNITY MED HLTH, V2016, P1; CSA PAI. Centre for the Study of Adolescence (CSA) and Population Action International (PAI), 2009, MEAS COMM WOM SEX RE; DCA, 2018, DESS CIT CADM HLTH O; Dilip SR, 2017, INT J COMMUNITY MED, V4, P4182; EPHI. The Ethiopian Public Health Institue (EPHI), 2015, REP SENT SURV SEX TR; Francis SC, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002512; GHP, 2018, STAT HANDW 2017 ANN; Hosmer JD, 2013, APPL LOGISTIC REGRES; House S., 2013, REPROD HEALTH MATTER, V21, P257, DOI [DOI 10.1016/S0968-8080(13)41712-3, 10.1016/S0968-8080(13)41712-3]; Juyal R, 2014, BANGLADESH J MED SCI, V13, P170, DOI 10.3329/bjms.v13i2.14257; Kamini B, 2018, INT J COMMUNITY MED, V5, P336; Kelsey J.L., 1996, METHODS OBSERVATIONA; Muual D, 2006, MALAWI MED J, V18, P176; Pandit M, 2017, WOM REPR HLTH, V4, P106, DOI DOI 10.1080/23293691.2017; Patel DA, 2003, REPROD TRACT INFECT; Ramesh J, 2018, INT J COMMUNITY MED, V5, P129; Rani V, 2015, NATL J COMMUNITY MED, V7, P35; Ratnaprabha GT, 2011, INT J MED SCI PUBLIC, V4, P1691; Sabarwal S, 2012, INT PERSPECT SEX R H, V38, P90, DOI 10.1363/3809012; Sumpter C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062004; Thekdi KP, 2014, INT J RES MED SCI, V2, P215; UNICEF, P MENSTR HYG MAN SCH; Vyas S, 2006, CONSTRUCTING SOCIOEC, P460, DOI [DOI 10.1093/HEAPOL/CZL029, 10.1093/heapol/czl029]; WHO, 2016, SEX TRANSM INF STIS, DOI [10.1109/LPT.2009.2019620, DOI 10.1109/LPT.2009.2019620]; WHO, 2001, GUID MAN SEX TRANSM, DOI [10.1136/sti.77.2.107, DOI 10.1136/STI.77.2.10711287688]; World Health Organization, 2005, SEX TRANSM OTH REPR; Yimam YT, 2014, PAN AFR MED J, V18, DOI 10.11604/pamj.2014.18.334.4206	40	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2020	15	8							e0237696	10.1371/journal.pone.0237696	http://dx.doi.org/10.1371/journal.pone.0237696			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG6GN	32822377	Green Published, gold			2023-01-03	WOS:000564080300091
J	Ahmed, A; Hameed, A; Saeed, S				Ahmed, Alia; Hameed, Amjad; Saeed, Shazia			Biochemical profile and bioactive potential of thirteen wild folk medicinal plants from Balochistan, Pakistan	PLOS ONE			English	Article							ARABIAN TETRAENA MAXIM.; TRIBULUS-TERRESTRIS; PHYLOGENETIC-RELATIONSHIPS; PEGANUM-HARMALA; AERIAL PARTS; ANTIOXIDANT; EXTRACT; L.; ZYGOPHYLLACEAE; PHARMACOLOGY	The recent focus is on the analysis of biological activities of extracts from thirteen folk medicinal plants from arid and semi-arid zones of Balochistan, Pakistan. Only a small proportion of them have been scientifically analyzed. Therefore the present investigation explores the biochemical and bioactive potential of different plant parts. Superoxide dismutase was detected maximum inFagonia indica, (184.7 +/- 5.17 units/g), ascorbate peroxidase inTribulus pentandrus(947.5 +/- 12.5 units/g), catalase and peroxidase were higher inPeganum harmala(555.0 +/- 5.0 and 2597.8 +/- 0.4 units/g, respectively). Maximum esterase and alpha-amylase activity was found inZygophyllum fabago(14.3 +/- 0.44 and 140 +/- 18.8 mg/g, respectively). Flavonoid content was high inT.pentandrus(666.1 +/- 49 mu g/ml). The highest total phenolic content and tannin was revealed inF.olivieri(72125 +/- 425 and 37050 +/- 1900 mu M/g, respectively). The highest value of ascorbic acid was depicted inF.bruguieri(F.b.N) (448 +/- 1.5 mu g/g). Total soluble proteins and reducing sugars were detected higher inP.harmala(372.3 +/- 54 and 5.9 +/- 0.1 mg/g, respectively). The maximum total antioxidant capacity was depicted inTetraena simplex(16.9 +/- 0.01 mu M/g). The highest value of lycopene and total carotenoids exhibited inT.terrestris(7.44 +/- 0.2 and 35.5 +/- 0.0 mg/g, respectively). Chlorophyll contents were found maximum inT.pentandrusvar.pterophorus(549.1 +/- 9.9, 154.3 +/- 10, and 703.4 +/- 20.2 ug/g, respectively). All taxa exhibited anti-inflammatory activity and anti-diabetic potential.Z.eurypterumseeds exhibited the highest anti-inflammatory potential (96%), along with other taxa indicated (96-76%) activity when compared with the standard drug diclofenac sodium (79%). Seeds ofT.pentandrus(85%) exhibited the highest anti-diabetic activity. The other taxa also exhibited inhibitory activity of alpha-amylase ranging from (85-69%) compared with Metformin (67%) standard drug. Phytochemical screening revealed that selected taxa proved to be the potential source of natural antioxidants and could further be explored forin-vivostudies and utilized in pharmaceutical industries as potent therapeutic agents validating their ethno-pharmacological uses.	[Ahmed, Alia; Saeed, Shazia] Univ Balochistan, Dept Bot, Quetta, Pakistan; [Hameed, Amjad] Nucl Inst Agr & Biol NIAB, Faisalabad, Pakistan	University of Balochistan; Nuclear Institute for Agriculture & Biology - Pakistan	Hameed, A (corresponding author), Nucl Inst Agr & Biol NIAB, Faisalabad, Pakistan.	amjad46pk@yahoo.com	Ahmed, Alia/GYV-1564-2022; Saeed, Shazia/AAN-3519-2021	Ahmed, Alia/0000-0003-4675-6359				Agbor GA, 2011, AFRICAN J TRADITIONA, V8; Ahmed H, 2013, TURK J BIOL, V37, P39, DOI 10.3906/biy-1110-29; Ainsworth EA, 2007, NAT PROTOC, V2, P875, DOI 10.1038/nprot.2007.102; Alici E.H., 2016, ANN RES REV BIOL, P1, DOI DOI 10.9734/ARRB/2016/29809; Alqasoumi SI, 2011, AFR J PHARM PHARMACO, V5, P1996, DOI 10.5897/AJPP11.190; Altan VM, 2003, CURR MED CHEM, V10, P1317, DOI 10.2174/0929867033457287; Alzahrani DA, 2018, BANGL J PLANT TAXON, V25, P19, DOI 10.3329/bjpt.v25i1.37177; Alzahrani DA, 2017, BANGL J PLANT TAXON, V24, P155, DOI 10.3329/bjpt.v24i2.35111; Aziz MA, 2016, J ETHNOBIOL ETHNOMED, V12, DOI 10.1186/s13002-016-0126-7; Baky MH, 2020, CHEMISTRYSELECT, V5, P1907, DOI 10.1002/slct.201903454; Beier BA, 2003, PLANT SYST EVOL, V240, P11, DOI 10.1007/s00606-003-0007-0; Bellstedt DU, 2008, MOL PHYLOGENET EVOL, V47, P932, DOI 10.1016/j.ympev.2008.02.019; Benarous K, 2015, BIOORG CHEM, V62, P1, DOI 10.1016/j.bioorg.2015.06.005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burm F., 2011, RES J MED PLANT, V201, P1; Cavusoglu K., 2015, Journal of Agricultural and Biological Science, V10, P124; CHANCE B, 1955, METHOD ENZYMOL, V2, P764, DOI 10.1016/S0076-6879(55)02300-8; CHEN GX, 1989, PLANT CELL PHYSIOL, V30, P987; Del Campo JA, 2007, APPL MICROBIOL BIOT, V74, P1163, DOI 10.1007/s00253-007-0844-9; Dixit V, 2001, J EXP BOT, V52, P1101, DOI 10.1093/jexbot/52.358.1101; Erel O, 2005, CLIN BIOCHEM, V38, P1103, DOI 10.1016/j.clinbiochem.2005.08.008; Fowler M.J., 2008, CLIN DIABETES, V26, P77, DOI [10.2337/diaclin.26.2.77, DOI 10.2337/DIACLIN.26.2.77]; Gangwar S., 2014, EMERGING TECHNOLOGIE, P215, DOI DOI 10.1016/B978-0-12-800875-1.00010-7; Ghafoor A., 1974, FLORA PAKISTAN 76; GIANNOPOLITIS CN, 1977, PLANT PHYSIOL, V59, P315, DOI [10.1104/pp.59.2.315, 10.1104/pp.59.2.309]; Halder N, 2003, J ETHNOPHARMACOL, V86, P113, DOI 10.1016/S0378-8741(03)00052-7; Hamidi N, 2014, ASIAN J NATL APPL SC, V3, P53; Harma M, 2005, AM J OBSTET GYNECOL, V192, P656, DOI 10.1016/j.ajog.2004.07.094; Hashim S, 2014, PAK J BOT, V46, P399; HASSANEAN HA, 1992, PHYTOCHEMISTRY, V31, P3293, DOI 10.1016/0031-9422(92)83503-Q; Houghton PJ, 2007, J ETHNOPHARMACOL, V110, P391, DOI 10.1016/j.jep.2007.01.032; Hyun E, 2004, BRIT J PHARMACOL, V143, P618, DOI 10.1038/sj.bjp.0705854; Iqbal P, 2014, ASIAN PAC J TROP MED, V7, pS473, DOI 10.1016/S1995-7645(14)60277-7; Iwalewa E, 2007, AFRICAN J BIOTECHNOL, V6; Jin L, 2008, EUR J PHARMACOL, V582, P162, DOI 10.1016/j.ejphar.2007.12.011; Joshi L.S., 2015, NAT PROD CHEM RES, V3, P170, DOI DOI 10.18035/EMJ.V3I1.261; Khan AM, 2011, J MED PLANTS RES, V5, P4665; Lichtenthaler HK., 1983, DETERMINATIONS TOTAL; Liu DH, 2008, LWT-FOOD SCI TECHNOL, V41, P1344, DOI 10.1016/j.lwt.2007.08.001; Mahdy A., 2015, EC PHARM SCI, V2, P239; MILLER GL, 1959, ANAL CHEM, V31, P426, DOI 10.1021/ac60147a030; Moattar F. S., 2015, Journal of Biological Sciences, V15, P194; Mohammed Mona Salih, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, P203, DOI 10.1016/S2221-1691(14)60232-X; Murugan Rajan, 2014, Journal of King Saud University Science, V26, P267, DOI 10.1016/j.jksus.2013.09.006; Nenadis N, 2007, J AGR FOOD CHEM, V55, P5452, DOI 10.1021/jf070473q; Oshaghi Ebrahim Abbasi, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P720, DOI 10.1016/j.apjtb.2015.06.012; Ferrer-Gallego PP, 2018, TAXON, V67, P1005, DOI 10.12705/675.11; Panda T, 2005, APPL MICROBIOL BIOT, V67, P160, DOI 10.1007/s00253-004-1840-y; Polya G., 2003, BIOCH TARGETS PLANT; Prabhakar PK, 2014, PHYTOMEDICINE, V21, P123, DOI 10.1016/j.phymed.2013.08.020; Rashid U, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-167; Rashid U, 2016, BMC COMPLEM ALTERN M, V16, DOI 10.1186/s12906-016-1445-x; Rates SMK, 2001, TOXICON, V39, P603, DOI 10.1016/S0041-0101(00)00154-9; Rawal A. K., 2009, INT J APPL RES NAT P, V2, P19; Rayan M, 2020, PROCESSES, V8, DOI 10.3390/pr8010117; Salem JH, 2011, FOOD CHEM, V124, P486, DOI 10.1016/j.foodchem.2010.06.059; Semerdjieva IB, 2019, NAT PROD COMMUN, V14, DOI 10.1177/1934578X19868394; Shah K, 2001, PLANT SCI, V161, P1135, DOI 10.1016/S0168-9452(01)00517-9; Sharifi-Rad J, 2015, 3 BIOTECH, V5, P677, DOI 10.1007/s13205-014-0266-1; Shawky E, 2019, J ADV PHARM RES, V3, P1, DOI DOI 10.21608/aprh.2019.5699.1066; Smati D, 2004, J ETHNOPHARMACOL, V95, P405, DOI 10.1016/j.jep.2004.08.011; Srivastava J.P., 1996, MED PLANTS EXPANDING; Sudipta KM., 2014, PLANT CELL BIOTECHNO, V15, P127; Tahraoui A, 2007, J ETHNOPHARMACOL, V110, P105, DOI 10.1016/j.jep.2006.09.011; Temraz A, 2006, PHYTOCHEMISTRY, V67, P1011, DOI 10.1016/j.phytochem.2006.03.007; Thomas M, 2005, CURR DIABETES REV, V1, P107, DOI 10.2174/1573399052952587; Tulyaganov TS, 2003, CHEM NAT COMPD+, V39, P292, DOI 10.1023/A:1025482821368; Ullah M, 2013, J ETHNOPHARMACOL, V150, P918, DOI 10.1016/j.jep.2013.09.032; Umair M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177912; Uniyal SK, 2006, J ETHNOBIOL ETHNOMED, V2, DOI 10.1186/1746-4269-2-14; VANASPEREN K, 1962, J INSECT PHYSIOL, V8, P401, DOI 10.1016/0022-1910(62)90074-4; Varavinit S., 2002, SCI ASIA, V28, P247, DOI DOI 10.2306/SCIENCEASIA1513-1874.2002.28.247; Vayalil PK, 2002, J AGR FOOD CHEM, V50, P610, DOI 10.1021/jf010716t; Vicuna D., 2005, ROLE PEROXIDASES DEV; Vos T, 2012, LANCET, V380, P2163, DOI 10.1016/S0140-6736(12)61729-2; Wu B, 2006, EXP BIOL MED, V231, P91; Xu TH, 2009, FITOTERAPIA, V80, P354, DOI 10.1016/j.fitote.2009.05.002; Zayed R, 2005, Z NATURFORSCH C, V60, P451	78	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2020	15	8							e0231612	10.1371/journal.pone.0231612	http://dx.doi.org/10.1371/journal.pone.0231612			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF7CD	32810139	gold, Green Submitted, Green Published			2023-01-03	WOS:000563451300032
J	Whittington, K; Simpson, L; Clay, M; Tierney, J; Harris, D				Whittington, Kathleen; Simpson, Leigh; Clay, Michael; Tierney, Joanna; Harris, Dixie			Identi?cation and treatment of obstructive sleep apnea by a primary care team with a subset focus on chronic pain management	PLOS ONE			English	Article							POSITIVE AIRWAY PRESSURE; MORTALITY; RISK	Background Patients diagnosed with obstructive sleep apnea (OSA), who also consume prescription opioids, have a greater likelihood of morbidity and mortality. This study evaluated whether a primary care team, focused on chronic pain care management, could use a validated questionnaire (STOP-Bang) and motivational follow-up, to increase identification and treatment of OSA. Methods This study was a retrospective, dual arm, pre/post controlled study. Participants of this study included the complete chronic pain management sub group treated by this primary care team. Participants were >= 18 years old and prescribed daily opioids for treatment of chronic pain. All participants had a multifaceted, individualized, educational meeting that included completing a STOP-Bang questionnaire. Participants who received a score >= three were advised to follow up with their primary care physician. Participants were seen quarterly throughout the study. Results The primary outcome of this study was that 65% of participants with likely OSA were using CPAP for a minimum of 12 months (range of 12-25 months, 18-month average) post-intervention vs. 37% CPAP-use in the control group (12 months of observation), both groups were chronic opioid users with OSA. This was a 28% relative improvement (p = 0.0034). A secondary outcome was that 8.9% of non-prior CPAP users obtained CPAP post- intervention; a 56.7% pre-post improvement (p = 0.0064, x(2)= 10.08 with 1 degree of freedom). Also, participants who were likely to have OSA (STOP-Bang score >= 3 or had a positive polysomnography (AHI >5 with comorbidities)) compared to those unlikely to have OSA (STOP-Bang score <3 or had a negative polysomnography (AHI <5)) in this study were more likely to be male, have a higher BMI, have hypertension, have cardiovascular disease and/or have diabetes (all types). Conclusion Team based care management for participants taking prescription opioids, where STOP-Bang questionnaires were completed, were associated with an increase in the identification and treatment of OSA.	[Whittington, Kathleen] Intermt Healthcare, Internal Med, Sandy, UT 84094 USA; [Whittington, Kathleen; Simpson, Leigh; Tierney, Joanna] Intermt Healthcare, Sandy, UT 84094 USA; [Clay, Michael; Harris, Dixie] Intermt Healthcare, Pulm & Sleep Med, Sandy, UT USA	Intermountain Healthcare; Intermountain Medical Center; Intermountain Healthcare; Intermountain Medical Center; Intermountain Healthcare; Intermountain Medical Center	Whittington, K (corresponding author), Intermt Healthcare, Internal Med, Sandy, UT 84094 USA.; Whittington, K (corresponding author), Intermt Healthcare, Sandy, UT 84094 USA.	kathleenwhittington32@gmail.com						Abrishami A, 2010, CAN J ANAESTH, V57, P423, DOI 10.1007/s12630-010-9280-x; Anttalainen U, 2007, SLEEP BREATH, V11, P171, DOI 10.1007/s11325-007-0102-5; Babor TF, 1996, AM J PUBLIC HEALTH, V86, P948; Barbor TF, 2001, BRIEF INTERVENTION H; Centers for Disease Control and Prevention, 2019, DRUG OVERDOSE DEATHS; Cozowicz C, 2018, ANESTH ANALG, V127, P988, DOI 10.1213/ANE.0000000000003549; DAGOSTINO RB, 1990, AM STAT, V44, P316, DOI 10.2307/2684359; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; Edwards A, 1948, PSYCHOMETRIKA B, P185; Eglin P, 2003, MONTREAL MASSACRE: A STORY OF MEMBERSHIP CATEGORIZATION ANALYSIS, P3; Farney RJ, 2011, J CLIN SLEEP MED, V7, P459, DOI 10.5664/JCSM.1306; Kim Heejin, EUROPEAN ARCH OTORHI, V270, P2885; Kumar S, 2010, CHEST S, V138, P779; Liang YY, 2015, J PAIN, V16, P318, DOI 10.1016/j.jpain.2014.11.007; Mador MJ, 2014, J CLIN SLEEP MED, V10, P853, DOI 10.5664/jcsm.3952; Manne Mahesh B., 2017, CLEVELAND CLIN J MED; Marshall NS, 2008, SLEEP, V31, P1079; Onen SH, 2005, CLIN J PAIN, V21, P422, DOI 10.1097/01.ajp.0000129757.31856.f7; Ong TH, 2010, SLEEP BREATH, V14, P371, DOI 10.1007/s11325-010-0350-7; Pelletier-Fleury N, 2001, SLEEP MED, V2, P225, DOI 10.1016/S1389-9457(00)00063-0; Philippe Jaoude, 2016, J CLIN SLEEP MED, V12; SAUNDERS B, 1995, ADDICTION, V90, P415, DOI 10.1046/j.1360-0443.1995.90341510.x; Schneiderhan J, 2017, JAMA-J AM MED ASSOC, V317, P2367, DOI 10.1001/jama.2017.5787; Sin DD, 2002, CHEST, V121, P430, DOI 10.1378/chest.121.2.430; Substance Abuse and Mental Health Services Administration Drug Abuse Warning Network, 2011, HHS PUBL, V39; Vasu TS, 2010, ARCH OTOLARYNGOL, V136, P1020, DOI 10.1001/archoto.2010.1020; Walker James M, 2007, J CLIN SLEEP MED JCS; Webster LR, 2008, PAIN MED, V9, P425, DOI 10.1111/j.1526-4637.2007.00343.x; Ye LC, 2009, J CLIN SLEEP MED, V5, P512; Young T, 2008, SLEEP, V31, P1071	30	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2020	15	8							e0237359	10.1371/journal.pone.0237359	http://dx.doi.org/10.1371/journal.pone.0237359			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE5VG	32790789	gold, Green Published			2023-01-03	WOS:000562668300090
J	Kaufman, AR; Hersh, ED				Kaufman, Aaron R.; Hersh, Eitan D.			The political consequences of opioid overdoses	PLOS ONE			English	Article							UNITED-STATES; DRUG; MOBILIZATION; OWNERSHIP; WAR	The United States suffered a dramatic and well-documented increase in drug-related deaths from 2000 to 2018, primarily driven by prescription and non-prescription opioids, and concentrated in white and working-class areas. A growing body of research focuses on the causes, both medical and social, of this opioid crisis, but little work as yet on its larger ramifications. Using novel public records of accidental opioid deaths linked to behavioral political outcomes, we present causal analyses showing that opioid overdoses have significant political ramifications. Those close to opioid victims vote at lower rates than those less affected by the crisis, even compared to demographically-similar friends and family of other unexpected deaths. Moreover, among those friends and family affected by opioids, Republicans are 25% more likely to defect from the party than the statewide average Republican, while Democrats are no more likely to defect; Independents are moderately more likely to register as Democrats. These results illustrate an important research design for inferring the effects of tragic events and speak to the broad social and political consequences of what is becoming the largest public health crisis in modern United States history.	[Kaufman, Aaron R.] New York Univ Abu Dhabi, Div Social Sci, Abu Dhabi, U Arab Emirates; [Hersh, Eitan D.] Tufts Univ, Dept Polit Sci, Medford, MA 02155 USA	Tufts University	Kaufman, AR (corresponding author), New York Univ Abu Dhabi, Div Social Sci, Abu Dhabi, U Arab Emirates.	aaronkaufman@nyu.edu						Achen CH, 2012, WORKING PAPER; Barnett ML, 2017, NEW ENGL J MED, V376, P663, DOI 10.1056/NEJMsa1610524; Bateson R, 2012, AM POLIT SCI REV, V106, P570, DOI 10.1017/S0003055412000299; Belanger E, 2008, ELECT STUD, V27, P477, DOI 10.1016/j.electstud.2008.01.001; Bennett WL, 2008, POLIT COMMUN, V25, P269, DOI 10.1080/10584600802197434; Betz HG, 2009, PATTERNS PREJUDICE, V43, P313, DOI 10.1080/00313220903109235; Campbell J. N, 2018, TIME RELEASE HIST OP; Chein I, ROAD H NARCOTICS DEL; Crowson HM, 2009, J PSYCHOL, V143, P449, DOI 10.3200/JRL.143.5.449-463; Csete J, 2016, LANCET, V387, P1427, DOI 10.1016/S0140-6736(16)00619-X; Dancey L, 2013, AM J POLIT SCI, V57, P312, DOI 10.1111/j.1540-5907.2012.00621.x; Dasgupta N, 2018, AM J PUBLIC HEALTH, V108, P182, DOI 10.2105/AJPH.2017.304187; De Benedictis-Kessner Justin, 2019, AM POLIT SCI REV, V113, P1078, DOI 10.1017/S0003055419000443; Dowell D, 2017, JAMA-J AM MED ASSOC, V318, P1065, DOI 10.1001/jama.2017.9308; Enos RyanD., 2019, AM POLIT SCI REV, V113, P1012, DOI [10.1017/S0003055419000340, DOI 10.1017/S0003055419000340]; Goggin SN, 2017, POLIT BEHAV, V39, P675, DOI 10.1007/s11109-016-9375-3; Graves RL, 2018, SUBST USE MISUSE, V53, P2132, DOI 10.1080/10826084.2018.1458319; Hart CL, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-017-0055; Hersh ED, 2013, P NATL ACAD SCI USA, V110, P20959, DOI 10.1073/pnas.1315043110; Huddy L, 2005, AM J POLIT SCI, V49, P593, DOI 10.1111/j.1540-5907.2005.00144.x; Iacus SM, 2012, POLIT ANAL, V20, P1, DOI 10.1093/pan/mpr013; Ojeda C, 2015, SOC SCI QUART, V96, P1226, DOI 10.1111/ssqu.12173; Scholl L, 2019, MMWR-MORBID MORTAL W, V67, P1419; Timberlake JM, 2003, POLICY STUD J, V31, P71, DOI 10.1111/1541-0072.00004; Vadivelu N, 2018, CURR PAIN HEADACHE R, V22, DOI 10.1007/s11916-018-0670-z; Volkow ND, 2017, NEW ENGL J MED, V377, P391, DOI 10.1056/NEJMsr1706626; Wall R, 2000, J URBAN HEALTH, V77, P688, DOI 10.1007/BF02344032; Weir HK, 2016, PREV CHRONIC DIS, V13, DOI 10.5888/pcd13.160211	28	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2020	15	8							e0236815	10.1371/journal.pone.0236815	http://dx.doi.org/10.1371/journal.pone.0236815			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NA7PQ	32750079	gold, Green Published			2023-01-03	WOS:000560009200014
J	Alfaro, AU; Guthrie, DM; McGraw, C; Wittich, W				Urqueta Alfaro, Andrea; Guthrie, Dawn M.; McGraw, Cathy; Wittich, Walter			Older adults with dual sensory loss in rehabilitation show high functioning and may fare better than those with single sensory loss	PLOS ONE			English	Article							DEPRESSION RATING-SCALE; POPULATION AGED 75; MINIMUM DATA SET; QUALITY-OF-LIFE; IN-HOME CARE; HEARING IMPAIRMENT; STANDARDIZED ASSESSMENT; VISION; ASSOCIATION; IMPACT	The population of older adults that have Dual Sensory Loss (DSL) is increasing, yet most research to date has focused on single sensory impairment and is inconclusive as to whether DSL is associated with worse impact on health and well-being over single sensory loss. The primary aim of this study was to characterize the health and functioning of community-dwelling older adults with DSL who were receiving sensory rehabilitation, using an understudied assessment: the interRAI Community Health Assessment (CHA). The secondary aim was to investigate whether older adults with DSL had worse health-related outcomes than their peers with only vision loss (VL) or only hearing loss (HL). We report and compare the interRAI CHA results in a sample of 200 older adults (61+ years of age) who had DSL, VL or HL. Overall, all sensory impairment groups showed high functioning in the areas of cognition, communication, activities of daily living, depression, and psycho-social well-being. DSL was not always associated with worse outcomes compared to a single sensory loss. Rather, the results varied depending on the tasks assessed, as well as which groups were compared. Our findings highlight that despite the negative impact of sensory losses, community-dwelling older adults receiving sensory rehabilitation services tend to have overall good health and a high level of independence. These results also show that DSL is not always associated with worse outcomes compared to a single sensory loss. Further research is needed to better characterize older adults with DSL who have more severe sensory and cognitive difficulties than those in our sample, and among those who are not receiving rehabilitation services.	[Urqueta Alfaro, Andrea; Wittich, Walter] Univ Montreal, Sch Optometry, Montreal, PQ, Canada; [Urqueta Alfaro, Andrea] Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada; [Guthrie, Dawn M.] Wilfrid Laurier Univ, Dept Kinesiol & Phys Educ, Waterloo, ON, Canada; [Guthrie, Dawn M.] Wilfrid Laurier Univ, Dept Hlth Sci, Waterloo, ON, Canada; [McGraw, Cathy; Wittich, Walter] CRIR Lethbridge Layton Mackay Rehabil Ctr West Ce, Montreal, PQ, Canada; [Wittich, Walter] CISSS Monteregie Ctr, CRIR Inst Nazareth & Louis Braille, Montreal, PQ, Canada	Universite de Montreal; Universite de Montreal; Wilfrid Laurier University; Wilfrid Laurier University	Alfaro, AU (corresponding author), Univ Montreal, Sch Optometry, Montreal, PQ, Canada.; Alfaro, AU (corresponding author), Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada.	andrea.urqueta.alfaro@umontreal.ca	Wittich, Walter/AAH-2145-2020; Guthrie, Dawn/AAO-6453-2021	Wittich, Walter/0000-0003-2184-6139; Guthrie, Dawn/0000-0003-3241-6580	Canadian Consortium on Neurodegeneration and Aging (CCNA); Canadian Institutes of Health Research (CIHR); Foundation of the CRIR/Centre de readaptation LethbridgeLayton-Mackay du CIUSSS du Centre-Ouest-del'I le-de-Montreal; Fondation En Vue of the CRIR/Institut Nazareth et Louis-Braille du CISSS de la Monteregie-Centre	Canadian Consortium on Neurodegeneration and Aging (CCNA); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Foundation of the CRIR/Centre de readaptation LethbridgeLayton-Mackay du CIUSSS du Centre-Ouest-del'I le-de-Montreal; Fondation En Vue of the CRIR/Institut Nazareth et Louis-Braille du CISSS de la Monteregie-Centre	This study was funded by the Canadian Consortium on Neurodegeneration and Aging (CCNA; http://ccna-ccnv.ca/en).The CCNA is supported by a grant from the Canadian Institutes of Health Research (CIHR; http://www.cihr-irsc.gc.ca/e/193.html) with funding from several partners. Funding was also provided by the Foundation of the CRIR/Centre de readaptation LethbridgeLayton-Mackay du CIUSSS du Centre-Ouest-del'I le-de-Montreal, and the Fondation En Vue of the CRIR/Institut Nazareth et Louis-Braille du CISSS de la Monteregie-Centre.	[Anonymous], 2018, 2017 PROFILE OLDER A; [Anonymous], 2006, HEARING AIDS; Armstrong TW, 2016, REHABIL PSYCHOL, V61, P240, DOI 10.1037/rep0000083; Brennan M, 2005, GERONTOLOGIST, V45, P337, DOI 10.1093/geront/45.3.337; Brennan Mark, 2007, Trends Amplif, V11, P281, DOI 10.1177/1084713807308210; Brennan M, 2006, J REHABIL RES DEV, V43, P777, DOI 10.1682/JRRD.2005.06.0109; Bruce ML, 2002, AM J PSYCHIAT, V159, P1367, DOI 10.1176/appi.ajp.159.8.1367; Burrows AB, 2000, AGE AGEING, V29, P165, DOI 10.1093/ageing/29.2.165; Capella-McDonnall NE, 2005, INT J GERIATR PSYCH, V20, P855, DOI 10.1002/gps.1368; Chia EM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1465, DOI 10.1001/archopht.124.10.1465; Chou KL, 2008, J AFFECT DISORDERS, V106, P191, DOI 10.1016/j.jad.2007.05.028; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; Cosh S, 2018, INT J GERIATR PSYCH, V33, P598, DOI 10.1002/gps.4827; Dalby DM, 2009, J VISUAL IMPAIR BLIN, V103, P7, DOI 10.1177/0145482X0910300103; Davidson JGS, 2019, J AGING HEALTH, V31, P85, DOI 10.1177/0898264317723407; Dawes P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119616; Fisher D, 2014, AGE AGEING, V43, P69, DOI 10.1093/ageing/aft122; Glickman ME, 2014, J CLIN EPIDEMIOL, V67, P850, DOI 10.1016/j.jclinepi.2014.03.012; Gopinath B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055054; Gouvernement du Quebec, 2020, FREE ACC PRESCR DRUG; Guthrie DM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192971; Guthrie DM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155073; Guthrie DM, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-137; Guthrie DM, 2011, J REHABIL RES DEV, V48, P545, DOI 10.1682/JRRD.2010.09.0175; Han JH, 2019, EPIDEMIOL PSYCH SCI, V28, P343, DOI 10.1017/S2045796018000045; Harada S, 2008, PREV MED, V47, P433, DOI 10.1016/j.ypmed.2008.06.011; Hawes C, 2007, GERONTOLOGIST, V47, P378, DOI 10.1093/geront/47.3.378; HEINE C, 2019, FRONT PUBLIC HEALTH, V0007; Heine C, 2015, GERONTOLOGIST, V55, P913, DOI 10.1093/geront/gnv074; Heine C, 2014, FRONT AGING NEUROSCI, V6, DOI [10.3389/fnagi.2014.00083, 10.3389/fnagi.2014.00348]; Hirdes JP, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-277; Hogeveen SE, 2017, BMC MED INFORM DECIS, V17, DOI 10.1186/s12911-017-0547-9; Huddle MG, 2016, J AM GERIATR SOC, V64, P1735, DOI 10.1111/jgs.14210; Jaiswal A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203772; Kiely Kim M, 2013, Front Hum Neurosci, V7, P837, DOI 10.3389/fnhum.2013.00837; Kim H, 2015, RELIABILITY INTERRAI, P220, DOI [10.1111/ggi.1233025163513, DOI 10.1111/GGI.1233025163513]; LAGATI S, 1995, J VISUAL IMPAIR BLIN, V89, P306; Landi F, 2000, MED CARE, V38, P1184, DOI 10.1097/00005650-200012000-00005; Lehane CM, 2018, J AGING HEALTH, V30, P1205, DOI 10.1177/0898264317713135; Loprinzi P.D., 2013, DIABETES SPECTR, V26, P6, DOI [DOI 10.2337/DIASPECT.26.1.6, 10.2337/diaspect.26.1.6]; Lupsakko T, 2002, INT J GERIATR PSYCH, V17, P808, DOI 10.1002/gps.689; Lupsakko TA, 2002, J AM GERIATR SOC, V50, P1748, DOI 10.1046/j.1532-5415.2002.50476.x; Maharani A, 2018, J AM GERIATR SOC, V66, P1130, DOI 10.1111/jgs.15363; Martin L, 2008, AGE AGEING, V37, P51, DOI 10.1093/ageing/afm162; McDonnall MC, 2009, J AGING HEALTH, V21, P1179, DOI 10.1177/0898264309350077; McDonnall MC, 2009, AGING MENT HEALTH, V13, P569, DOI 10.1080/13607860902774410; Miyawaki A, 2020, J EPIDEMIOL, V30, P67, DOI 10.2188/jea.JE20180198; Morris PJ, 2010, INT J AEROACOUST, V9, P1, DOI 10.1260/1475-472X.9.1-2.1; Mudie LI, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199889; Mueller-Schotte S, 2019, J GERONTOL A-BIOL, V74, P936, DOI 10.1093/gerona/gly155; Munroe S., 2001, DEV NATL VOLUNTEER R, V2011, P1; Saunders GH, 2012, J REHABIL RES DEV, V49, P1043, DOI 10.1682/JRRD.2010.08.0157; Schneider JM, 2011, J AGING HEALTH, V23, P1309, DOI 10.1177/0898264311408418; Sinn CLJ, 2018, CAN J AGING, V37, P60, DOI 10.1017/S0714980817000538; St-Amour L, 2019, OPTOMETRY VISION SCI, V96, P345, DOI 10.1097/OPX.0000000000001374; Statement STROBE, 2007, STROBE CHECKL COH CA, P12, DOI [10.1016/S0140-6736(07)61602-X, DOI 10.1016/S0140-6736(07)61602-X]; Szczerbinska K, 2012, AM J GERIAT PSYCHIAT, V20, P1045, DOI 10.1097/JGP.0b013e3182331702; Trillo AH, 2012, INVEST OPHTH VIS SCI, V53, P4234, DOI 10.1167/iovs.12-9580; Tye-Murray N., 2015, FDN AURAL REHABILITA; Urqueta Alfaro A, 2019, PLOS ONE, V14, P1, DOI [10.1371/journal.pone.022312331581243, DOI 10.1371/JOURNAL.PONE.022312331581243]; Viljanen A, 2014, EUR J AGEING, V11, P155, DOI 10.1007/s10433-013-0291-7; Wahl HW, 2013, GERONTOLOGIST, V53, P950, DOI 10.1093/geront/gnt013; WFDB, 2018, COMPLIANCE RISK CONT; Williams JR, 2008, B WORLD HEALTH ORGAN, V86, P650, DOI 10.2471/BLT.08.050955; Wittich W, 2016, DISABIL REHABIL-ASSI, V11, P564, DOI 10.3109/17483107.2015.1042076; Wittich W, 2013, BRIT J VISUAL IMPA, V31, P198, DOI 10.1177/0264619613490519; Wittich W, 2012, OPHTHAL PHYSL OPT, V32, P242, DOI 10.1111/j.1475-1313.2012.00897.x	67	3	3	4	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2020	15	8							e0237152	10.1371/journal.pone.0237152	http://dx.doi.org/10.1371/journal.pone.0237152			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NA7OS	32745118	Green Published, gold			2023-01-03	WOS:000560006800014
J	Sarpatwari, A; Kaltenboeck, A; Kesselheim, AS				Sarpatwari, Ameet; Kaltenboeck, Anna; Kesselheim, Aaron S.			Missed Opportunities on Emergency Remdesivir Use	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Sarpatwari, Ameet; Kesselheim, Aaron S.] Harvard Med Sch, Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA; [Kaltenboeck, Anna] Mem Sloan Kettering Canc Ctr, Ctr Hlth Policy & Outcomes, Drug Pricing Lab, 1275 York Ave, New York, NY 10021 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Memorial Sloan Kettering Cancer Center	Sarpatwari, A (corresponding author), Harvard Med Sch, Brigham & Womens Hosp, Program Regulat Therapeut & Law PORTAL, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, 1620 Tremont St,Ste 3030, Boston, MA 02120 USA.	asarpatwari@bwh.harvard.edu			Arnold Ventures; Harvard-MIT Center for Regulatory Science	Arnold Ventures; Harvard-MIT Center for Regulatory Science	Dr Sarpatwari and Dr Kesselheim's work was supported by Arnold Ventures and the Harvard-MIT Center for Regulatory Science. Ms Kaltenboeck's work was supported by Arnold Ventures.	Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Institute for Clinical and Economic Review, ALT PRIC MOD REMD OT; Ison MG, 2020, JAMA-J AM MED ASSOC, V323, P2365, DOI 10.1001/jama.2020.8863; Langreth R., BLOOMBERG NEWS; Sarpatwari A, 2019, JAMA-J AM MED ASSOC, V321, P651, DOI 10.1001/jama.2019.0236; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; White DB, 2020, JAMA-J AM MED ASSOC, V323, P1773, DOI 10.1001/jama.2020.5046	9	15	15	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	2020	324	4					331	332		10.1001/jama.2020.11932	http://dx.doi.org/10.1001/jama.2020.11932			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE8JP	32579163	Bronze			2023-01-03	WOS:000562851000015
J	Ramaraju, S; Roula, MA; McCarthy, PW				Ramaraju, Sriharsha; Roula, Mohammed A.; McCarthy, Peter W.			Transcranial direct current stimulation and working memory: Comparison of effect on learning shapes and English letters	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; PREFRONTAL CORTEX; BRAIN-STIMULATION; MOTOR CORTEX; MAGNETIC STIMULATION; NEGATIVE SYMPTOMS; TDCS; HEALTHY; SCHIZOPHRENIA; FACILITATION	We present the results of a study investigating whether there is an effect of Anodal-Transcranial Direct Current Stimulation (A-tDCS) on working memory (WM) performance. The relative effectiveness of A-tDCS onWM is investigated using a 2-back test protocol using two commonly used memory visual stimuli (shapes and letters). In a double-blinded, randomised, crossover, sham-controlled experiment, real A-tDCS and sham A-tDCS were applied separately to the left dorsolateral prefrontal cortex (L-DLPFC) of twenty healthy subjects. There was a minimal interval of one week between sham and real A-tDCS sessions. For the letters based stimulus experiment, 2-back test recall accuracy was measured for a set of English letters (A-L) which were presented individually in a randomised order where each was separated by a blank interval. A similar 2-back protocol was used for the shapes based stimuli experiment where instead of letters, a set of 12 geometric shapes were used. The working memory accuracy scores measured appeared to be significantly affected by memory stimulus type used and by the application of A-tDCS (repeated measures ANOVA p< 0.05). A large effect size (d = 0.98) and statistical significance between sham and real A-tDCSWM scores (p = 0.01) was found when shapes were used as a visual testing stimulus, while low (d = 0.38) effect size and insignificant difference (p = 0.15) was found when letters were used. This results are important as they show that recollection different stimuli used in working memory can be affected differently by A-tDCS application. This highlights the importance of considering using multiple methods ofWM testing when assessing the effectiveness of A-tDCS.	[Ramaraju, Sriharsha] Newcastle Univ, Interdisciplinary Comp & Complex Bio Syst ICOS Fa, Newcastle Upon Tyne, Tyne & Wear, England; [Roula, Mohammed A.] Univ South Wales, Med Elect & Signal Proc Res Unit, Treforest, Wales; [McCarthy, Peter W.] Univ South Wales, Clin Technol & Diagnost Res Unit, Treforest, Wales	Newcastle University - UK; University of South Wales; University of South Wales	Roula, MA (corresponding author), Univ South Wales, Med Elect & Signal Proc Res Unit, Treforest, Wales.	ali.roula@southwales.ac.uk		Ramaraju, Sriharsha/0000-0001-5958-0976	SR University of South Wales centenary PhD Scholarship University of South Wales	SR University of South Wales centenary PhD Scholarship University of South Wales	SR University of South Wales centenary PhD Scholarship University of South Wales https://www.southwales.ac.uk/No, The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrews SC, 2011, BRAIN STIMUL, V4, P84, DOI 10.1016/j.brs.2010.06.004; Antal A, 2004, EUR J NEUROSCI, V19, P2888, DOI 10.1111/j.1460-9568.2004.03367.x; Berryhill ME, 2012, NEUROSCI LETT, V521, P148, DOI 10.1016/j.neulet.2012.05.074; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Brunye TT, 2015, NEUROREPORT, V26, P296, DOI 10.1097/WNR.0000000000000348; BUCHANAN CM, 1992, PSYCHOL BULL, V111, P62, DOI 10.1037/0033-2909.111.1.62; Courtney SM, 1998, PHILOS T R SOC B, V353, P1819, DOI 10.1098/rstb.1998.0334; D'Esposito M, 1998, COGNITIVE BRAIN RES, V7, P1, DOI 10.1016/S0926-6410(98)00004-4; DYMOND AM, 1975, BIOL PSYCHIAT, V10, P101; Fiori V, 2011, J COGNITIVE NEUROSCI, V23, P2309, DOI 10.1162/jocn.2010.21579; Floel A, 2008, J COGNITIVE NEUROSCI, V20, P1415, DOI 10.1162/jocn.2008.20098; Floel A, 2007, BRAIN RES REV, V53, P250, DOI 10.1016/j.brainresrev.2006.08.006; Fregni F, 2005, EXP BRAIN RES, V166, P23, DOI 10.1007/s00221-005-2334-6; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Goldman-Rakic PS, 1994, J NEUROPSYCHIATRY CL; GRAFMAN J, 1994, NEUROREPORT, V5, P1157, DOI 10.1097/00001756-199405000-00034; Harvey PD, 2001, AM J PSYCHIAT, V158, P176, DOI 10.1176/appi.ajp.158.2.176; Hautzel H, 2002, NEUROSCI LETT, V323, P156, DOI 10.1016/S0304-3940(02)00125-8; Hoy KE, 2013, NEUROPSYCHOLOGIA, V51, P1777, DOI 10.1016/j.neuropsychologia.2013.05.018; Hur J, 2017, COGNITION EMOTION, V31, P1294, DOI 10.1080/02699931.2016.1213703; Izzidien A, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/1584947; Jacobson L, 2012, EXP BRAIN RES, V216, P1, DOI 10.1007/s00221-011-2891-9; Jahanshahi M, 1998, BRAIN, V121, P1533, DOI 10.1093/brain/121.8.1533; Jones KT, 2015, NEUROIMAGE, V105, P238, DOI 10.1016/j.neuroimage.2014.11.012; Keshvari F, 2013, BASIC CLIN NEUROSCI, V4, P224; Klencklen G, 2017, LEARN MOTIV, V57, P48, DOI 10.1016/j.lmot.2017.01.007; Lindenmayer JP, 2007, J CLIN PSYCHIAT, V68, P368, DOI 10.4088/JCP.v68n0303; Martin DM, 2013, INT J NEUROPSYCHOPH, V16, P1927, DOI 10.1017/S1461145713000539; Matsumoto H, 2017, CLIN NEUROPHYS PRACT, V2, P19, DOI 10.1016/j.cnp.2016.12.003; Miller KM, 2009, ARCH CLIN NEUROPSYCH, V24, P711, DOI 10.1093/arclin/acp063; Morris R.G., 1994, NEUROPSYCHOLOGY, V8, P544; Mottaghy FM, 2000, NEUROSCI LETT, V280, P167, DOI 10.1016/S0304-3940(00)00798-9; Mull BR, 2001, CLIN NEUROPHYSIOL, V112, P1672, DOI 10.1016/S1388-2457(01)00606-X; Nilsson J, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00230; Nitsche MA, 2001, NEUROLOGY, V57, P1899, DOI 10.1212/WNL.57.10.1899; Nitsche MA, 2003, J COGNITIVE NEUROSCI, V15, P619, DOI 10.1162/089892903321662994; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nitsche MA, 2003, CLIN NEUROPHYSIOL, V114, P600, DOI 10.1016/S1388-2457(02)00412-1; Nozari N, 2013, NEUROPSYCHOLOGIA, V51, P2770, DOI 10.1016/j.neuropsychologia.2013.08.019; Nystrom LE, 2000, NEUROIMAGE, V11, P424, DOI 10.1006/nimg.2000.0572; Ohn SH, 2008, NEUROREPORT, V19, P43, DOI 10.1097/WNR.0b013e3282f2adfd; Oliveira JF, 2013, NEUROSCI LETT, V537, P60, DOI 10.1016/j.neulet.2013.01.023; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Park SH, 2014, NEUROREPORT, V25, P122, DOI 10.1097/WNR.0000000000000080; Reiser B, 1999, CONFIDENCE INTERVALS; Riedel M, 2007, EUR ARCH PSY CLIN N, V257, P360, DOI 10.1007/s00406-007-0739-x; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; Slaby I, 2015, NEUROREPORT, V26, P988, DOI 10.1097/WNR.0000000000000456; Smith EE, 1997, COGNITIVE PSYCHOL, V33, P5, DOI 10.1006/cogp.1997.0658; Tsuchida A, 2009, J COGNITIVE NEUROSCI, V21, P2263, DOI 10.1162/jocn.2008.21172; Winograd-Gurvich C, 2006, BRAIN RES BULL, V70, P312, DOI 10.1016/j.brainresbull.2006.06.007; Woods AJ, 2016, CLIN NEUROPHYSIOL, V127, P1031, DOI 10.1016/j.clinph.2015.11.012; Wykes T, 1999, SCHIZOPHRENIA BULL, V25, P291, DOI 10.1093/oxfordjournals.schbul.a033379; Wykes T, 2007, BRIT J PSYCHIAT, V190, P421, DOI 10.1192/bjp.bp.106.026575; Zaehle T, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-2; Zimmer HD, 2008, NEUROSCI BIOBEHAV R, V32, P1373, DOI 10.1016/j.neubiorev.2008.05.016	56	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2020	15	7							e0222688	10.1371/journal.pone.0222688	http://dx.doi.org/10.1371/journal.pone.0222688			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OD5ZL	32706780	Green Published, gold			2023-01-03	WOS:000579931700002
J	Bagshaw, SM; Wald, R; Adhikari, NKJ; Bellomo, R; da Costa, BR; Dreyfuss, D; Gallagher, MP; Gaudry, S; Hoste, EA; Lamontagne, F; Joannidis, M; Landoni, G; Liu, KD; McAuley, DF; McGuinness, SP; Neyra, JA; Nichol, AD; Ostermann, M; Palevsky, PM; Pettila, V; Quenot, JP; Qiu, HB; Rochwerg, B; Schneider, AG; Smith, OM; Thome, F; Thorpe, KE; Vaara, S; Weir, M; Wang, AY; Young, P; Zarbock, A				Bagshaw, Sean M.; Wald, Ron; Adhikari, Neill K. J.; Bellomo, Rinaldo; da Costa, Bruno R.; Dreyfuss, Didier; Gallagher, Martin P.; Gaudry, Stephane; Hoste, Eric A.; Lamontagne, Francois; Joannidis, Michael; Landoni, Giovanni; Liu, Kathleen D.; McAuley, Daniel F.; McGuinness, Shay P.; Neyra, Javier A.; Nichol, Alistair D.; Ostermann, Marlies; Palevsky, Paul M.; Pettila, Ville; Quenot, Jean-Pierre; Qiu, Haibo; Rochwerg, Bram; Schneider, Antoine G.; Smith, Orla M.; Thome, Fernando; Thorpe, Kevin E.; Vaara, Suvi; Weir, Matthew; Wang, Amanda Y.; Young, Paul; Zarbock, Alexander			Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CRITICALLY-ILL PATIENTS; MORTALITY; DIALYSIS; TRIALS	BackgroundAcute kidney injury is common in critically ill patients, many of whom receive renal-replacement therapy. However, the most effective timing for the initiation of such therapy remains uncertain. MethodsWe conducted a multinational, randomized, controlled trial involving critically ill patients with severe acute kidney injury. Patients were randomly assigned to receive an accelerated strategy of renal-replacement therapy (in which therapy was initiated within 12 hours after the patient had met eligibility criteria) or a standard strategy (in which renal-replacement therapy was discouraged unless conventional indications developed or acute kidney injury persisted for >72 hours). The primary outcome was death from any cause at 90 days. ResultsOf the 3019 patients who had undergone randomization, 2927 (97.0%) were included in the modified intention-to-treat analysis (1465 in the accelerated-strategy group and 1462 in the standard-strategy group). Of these patients, renal-replacement therapy was performed in 1418 (96.8%) in the accelerated-strategy group and in 903 (61.8%) in the standard-strategy group. At 90 days, death had occurred in 643 patients (43.9%) in the accelerated-strategy group and in 639 (43.7%) in the standard-strategy group (relative risk, 1.00; 95% confidence interval [CI], 0.93 to 1.09; P=0.92). Among survivors at 90 days, continued dependence on renal-replacement therapy was confirmed in 85 of 814 patients (10.4%) in the accelerated-strategy group and in 49 of 815 patients (6.0%) in the standard-strategy group (relative risk, 1.74; 95% CI, 1.24 to 2.43). Adverse events occurred in 346 of 1503 patients (23.0%) in the accelerated-strategy group and in 245 of 1489 patients (16.5%) in the standard-strategy group (P<0.001). ConclusionsAmong critically ill patients with acute kidney injury, an accelerated renal-replacement strategy was not associated with a lower risk of death at 90 days than a standard strategy. (Funded by the Canadian Institutes of Health Research and others; STARRT-AKI ClinicalTrials.gov number, NCT02568722.) The most effective timing for renal-replacement therapy in critically ill patients is unclear. In this randomized trial, patients with acute kidney injury who were assigned to an accelerated strategy did not have a lower risk of death at 90 days than those assigned to a standard strategy.	[Bagshaw, Sean M.] Univ Alberta, Fac Med & Dent, Dept Crit Care Med, Edmonton, AB, Canada; [Bagshaw, Sean M.] Alberta & Hlth Serv, Edmonton, AB, Canada; [Wald, Ron] St Michaels Hosp, Div Nephrol, Toronto, ON, Canada; [Wald, Ron; da Costa, Bruno R.; Smith, Orla M.; Thorpe, Kevin E.] Univ Toronto, Li Ka Shing Knowledge Inst, Toronto, ON, Canada; [Wald, Ron; Smith, Orla M.] Univ Toronto, Dept Med, Toronto, ON, Canada; [da Costa, Bruno R.; Thorpe, Kevin E.] Univ Toronto, Appl Hlth Res Ctr, Toronto, ON, Canada; [Thorpe, Kevin E.] Univ Toronto, St Michaels Hosp, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Wald, Ron; da Costa, Bruno R.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Adhikari, Neill K. J.] Sunnybrook Hlth Sci Ctr, Dept Crit Care Med, Toronto, ON, Canada; [Adhikari, Neill K. J.] Univ Toronto, Toronto, ON, Canada; [Lamontagne, Francois] Univ Sherbrooke, Dept Med, Sherbrooke, PQ, Canada; [Lamontagne, Francois] Ctr Hosp Univ CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ, Canada; [Bellomo, Rinaldo] McMaster Univ, Juravinski Hosp, Div Crit Care, Hamilton, ON, Canada; [Weir, Matthew] London Hlth Sci Ctr, Div Nephrol, London, ON, Canada; [Bellomo, Rinaldo; Nichol, Alistair D.] Univ Melbourne, Dept Intens Care, Austin Hosp, Melbourne, Vic, Australia; [Bellomo, Rinaldo; Nichol, Alistair D.] Univ Melbourne, Royal Melbourne Hosp, Sch Med, Melbourne, Vic, Australia; [Bellomo, Rinaldo; Nichol, Alistair D.] Monash Univ, New Zealand Intens Care Res Ctr, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Gallagher, Martin P.; Wang, Amanda Y.] Univ Sydney, Fac Med, George Inst Global Hlth, Concord Clin Sch, Sydney, NSW, Australia; [da Costa, Bruno R.] Univ Bern, Inst Primary Hlth Care, Bern, Switzerland; [Schneider, Antoine G.] CHU Vaudois, Dept Crit Care Med, Lausanne, Switzerland; [Dreyfuss, Didier] Hop Louis Mourier, Colombes, France; [Gaudry, Stephane] Univ Leonard Vinci, Courbevoie, France; [Gaudry, Stephane] Sorbonne Univ, INSEAM Unite UMR S1155, Paris, France; [Gaudry, Stephane] Univ Paris, Paris, France; [Gaudry, Stephane] Hop Avicenne, Bobigny, France; [Quenot, Jean-Pierre] Hop Univ Francois Mitterrand, Lipness Team, Res Ctr Lipids Nutr Canc, UMR 1231,INSERM, Dijon, France; [Quenot, Jean-Pierre] CHU Dijon Bourgogne, Lab Excellence LipSTIC, Ctr Invest Clin, Epidemiol Clin, Dijon, France; [Quenot, Jean-Pierre] Univ Bourgogne, INSERM, Ctr Invest Clin 1432, Dijon, France; [da Costa, Bruno R.] Peking Union Med Coll Hosp, Dept Crit Care Med, Beijing, Peoples R China; [Qiu, Haibo] Southeast Univ, Dept Crit Care Med, Zhongda Hosp, Nanjing, Peoples R China; [Hoste, Eric A.] Univ Ghent, Dept Intens Care, Ghent, Belgium; [Joannidis, Michael] Med Univ Innsbruck, Dept Internal Med, Div Intens Care & Emergency Med, Innsbruck, Austria; [Landoni, Giovanni] Vita Salute San Rafiaele Univ, Milan, Italy; [Landoni, Giovanni] IRCCS, San Raffaele Sci Inst, Milan, Italy; [Liu, Kathleen D.] Univ Calif San Francisco, Div Nephrol, San Francisco, CA 94143 USA; [Liu, Kathleen D.] Univ Calif San Francisco, Div Crit Care Med, San Francisco, CA 94143 USA; [McAuley, Daniel F.] Queens Univ, Wellcome Wolfson Inst Expt Med, Belfast, Antrim, North Ireland; [McAuley, Daniel F.] Royal Victoria Hosp, Reg Intens Care Unit, Belfast, Antrim, North Ireland; [Ostermann, Marlies] Kings Coll London, Guys & St Thomas Hosp, London, England; [McGuinness, Shay P.] Auckland City Hosp, Cardiothorac & Vasc Intens Care Unit, Auckland, New Zealand; [Young, Paul] Wellington Reg Hosp, Intens Care Unit, Wellington, New Zealand; [Young, Paul] Med Res Inst New Zealand, Wellington, New Zealand; [Neyra, Javier A.] Univ Kentucky, Div Nephrol Bone & Mineral Metab, Lexington, KY USA; [Nichol, Alistair D.] Univ Coll Dublin, Clin Res Ctr, St Vincents Univ Hosp, Dublin, Ireland; [Palevsky, Paul M.] Univ Pittsburgh, Div CriNephrol, Pittsburgh, PA USA; [Palevsky, Paul M.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA; [Pettila, Ville; Vaara, Suvi] Univ Helsinki, Dept Intens Care, Helsinki, Finland; [Pettila, Ville; Vaara, Suvi] Helsinki Univ Hosp, Helsinki, Finland; [Thome, Fernando] Hosp Clin Porto Alegre, Porto Alegre, RS, Brazil; [Zarbock, Alexander] Univ Hosp Munster, Dept Anesthesiol Intens Care & Pain Med, Munster, Germany	University of Alberta; Alberta Health Services (AHS); University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; Li Ka Shing Knowledge Institute; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Sherbrooke; McMaster University; London Health Sciences Centre; Florey Institute of Neuroscience & Mental Health; University of Melbourne; Royal Melbourne Hospital; University of Melbourne; Monash University; George Institute for Global Health; University of Sydney; University of Bern; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; CHU Dijon Bourgogne; Institut Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; CHU Dijon Bourgogne; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Southeast University - China; Ghent University; Medical University of Innsbruck; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Queens University Belfast; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Auckland City Hospital; Medical Research Institute Of New Zealand; University of Kentucky; University College Dublin; Saint Vincent's University Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Pittsburgh Healthcare System; University of Helsinki; University of Helsinki; Helsinki University Central Hospital; University of Munster	Bagshaw, SM (corresponding author), Univ Alberta, Fac Med & Dent, Dept Crit Care Med, Edmonton, AB, Canada.; Bagshaw, SM (corresponding author), Alberta & Hlth Serv, Edmonton, AB, Canada.; Wald, R (corresponding author), St Michaels Hosp, Div Nephrol, Toronto, ON, Canada.; Wald, R (corresponding author), Univ Toronto, Li Ka Shing Knowledge Inst, Toronto, ON, Canada.; Wald, R (corresponding author), Univ Toronto, Dept Med, Toronto, ON, Canada.	bagshaw@ualberta.ca; ron.wald@unityhealth.to	Qiu, Haibo/AAS-9047-2021; Hoste, Eric/A-6353-2008; Veenith, Tonny/AAI-3067-2020; Joannidis, Michael/AAZ-8790-2020; Schneider, Antoine/L-2480-2019; Ostermann, Marlies/AAH-8160-2021; Camporota, Luigi/G-2390-2017; Ostermann, Marlies/B-8777-2015; DUFOUR, Nicolas/U-4634-2018	Qiu, Haibo/0000-0001-8589-4717; Hoste, Eric/0000-0001-9301-8055; Veenith, Tonny/0000-0002-4125-8804; Schneider, Antoine/0000-0003-0576-7094; Gallagher, Martin/0000-0001-9187-6187; McGuinness, Shay/0000-0003-0620-4787; Hodgson, Luke/0000-0002-8278-9513; CARLES, MICHEL/0000-0001-5485-1511; QUENOT, Jean-Pierre/0000-0003-2351-682X; wyncoll, duncan/0000-0003-4685-5154; Wang, Ying/0000-0002-0367-6677; Camporota, Luigi/0000-0001-5600-1676; Ostermann, Marlies/0000-0001-9500-9080; TITECA BEAUPORT, dimitri/0000-0003-2514-4193; Mazer, Cyril David/0000-0003-2566-4308; Lamontagne, Francois/0000-0002-0360-3427; Doran, Peter/0000-0003-2064-5335; Wax, Randy/0000-0001-9084-8264; Shelley, Ben/0000-0001-6771-9659; DUFOUR, Nicolas/0000-0002-1359-6689; Rozec, Bertrand/0000-0002-2226-3982; LANDONI, Giovanni/0000-0002-8594-5980; Barbar, Saber Davide/0000-0002-5089-8088; Rigatto, Claudio/0000-0002-8306-8072; Young, Paul/0000-0002-3428-3083; Tobiasch, Anna/0000-0002-9440-2312; Bellomo, Rinaldo/0000-0002-1650-8939; Liu, Jingfeng/0000-0003-2624-8701; ZANGRILLO, Alberto/0000-0002-7687-7648; Nichol, Alistair/0000-0002-4689-1238; Bellmann, Romuald/0000-0003-2861-3258	Canadian Institutes of Health Research; STARRT-AKI	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); STARRT-AKI	Funded by the Canadian Institutes of Health Research and others; STARRT-AKI ClinicalTrials.gov number, NCT02568722.	Bagshaw S, 2019, CRIT CARE RESUSC, V21, P162; Bagshaw SM, 2017, INTENS CARE MED, V43, P841, DOI 10.1007/s00134-017-4762-8; Bagshaw SM, 2009, J CRIT CARE, V24, P129, DOI 10.1016/j.jcrc.2007.12.017; Barbar SD, 2018, NEW ENGL J MED, V379, P1431, DOI 10.1056/NEJMoa1803213; CONGER JD, 1990, SEMIN DIALYSIS, V3, P146, DOI 10.1111/j.1525-139X.1990.tb00031.x; Eckardt KU, 2012, KIDNEY INT SUPPL, V2, P7, DOI 10.1038/kisup.2012.8; Fayad AI, 2018, COCHRANE SYST REV, V12, P10612; Gaudry S, 2016, NEW ENGL J MED, V375, P122, DOI 10.1056/NEJMoa1603017; Herdman M, 2011, QUAL LIFE RES, V20, P1727, DOI 10.1007/s11136-011-9903-x; Hoste E, 2015, INTENS CARE MED, V41, P1411, DOI 10.1007/s00134-015-3934-7; Liborio AB, 2015, CLIN J AM SOC NEPHRO, V10, P21, DOI 10.2215/CJN.04750514; Liu KD, 2006, CLIN J AM SOC NEPHRO, V1, P915, DOI 10.2215/CJN.01430406; Marants R, 2019, J AM SOC NEPHROL, V30, P1086, DOI 10.1681/ASN.2018121194; Nisula S, 2013, INTENS CARE MED, V39, P420, DOI 10.1007/s00134-012-2796-5; PARSONS FM, 1961, LANCET, V1, P129; Schoenfeld DA, 2002, CRIT CARE MED, V30, P1772, DOI 10.1097/00003246-200208000-00016; Semler MW, 2018, NEW ENGL J MED, V378, P1951, DOI 10.1056/NEJMc1804294; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; The STARRT-AKI Investigators, 2019, CAN J KIDNEY HLTH DI, V6, p2054358119852937; Tolwani A, 2012, NEW ENGL J MED, V367, P2505, DOI 10.1056/NEJMct1206045; Vaara ST, 2014, CLIN J AM SOC NEPHRO, V9, P1577, DOI 10.2215/CJN.12691213; Wald R, 2017, AM J KIDNEY DIS, V69, P14, DOI 10.1053/j.ajkd.2016.09.009; Wald R, 2015, KIDNEY INT, V88, P897, DOI 10.1038/ki.2015.184; Yang L, 2010, NAT MED, V16, P535, DOI 10.1038/nm.2144; Zarbock A, 2016, JAMA-J AM MED ASSOC, V315, P2190, DOI 10.1001/jama.2016.5828	25	200	215	6	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 16	2020	383	3					240	251		10.1056/NEJMoa2000741	http://dx.doi.org/10.1056/NEJMoa2000741			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ8TN	32668114	Green Published, Bronze			2023-01-03	WOS:000553165300014
J	Zhang, AL; Paidassi, H; Lacy-Hulbert, A; Savill, J				Zhang, Ailiang; Paidassi, Helena; Lacy-Hulbert, Adam; Savill, John			Apoptotic cells induce CD103 expression and immunoregulatory function in myeloid dendritic cell precursors through integrin alpha(v) and TGF-beta activation	PLOS ONE			English	Article							REGULATORY T-CELLS; GROWTH-FACTOR-BETA; MEDIATED PHAGOCYTOSIS; VITRONECTIN RECEPTOR; RECOGNITION; HOMEOSTASIS; NEUTROPHILS; INGESTION; COLITIS; CD36	In the mammalian gut CD103+ve myeloid DCs are known to suppress inflammation threatened by luminal bacteria, but stimuli driving DC precursor maturation towards this beneficial phenotype are incompletely understood. We isolated CD11+ve DCs from mesenteric lymph nodes (MLNs) of healthy mice; CD103+ve DCs were 8-24 fold more likely than CD103-ve DCs to exhibit extensive of prior phagocytosis of apoptotic intestinal epithelial cells. However, CD103+ve and CD103-ve MLN DCs exhibited similar ex vivo capacity to ingest apoptotic cells, indicating that apoptotic cells might drive immature DC maturation towards the CD103+ve phenotype. When cultured with apoptotic cells, myeloid DC precursors isolated from murine bone marrow and characterised as lineage-ve CD103-ve, displayed enhanced expression of CD103 and beta 8 integrin and acquired increased capacity to induce T regulatory lymphocytes (Tregs) after 7d in vitro. However, DC precursors isolated from alpha(v)-tie2 mice lacking alpha(v) integrins in the myeloid line exhibited reduced binding of apoptotic cells and complete deficiency in the capacity of apoptotic cells and/or latent TGF-beta 1 to enhance CD103 expression in culture, whereas active TGF-beta 1 increased DC precursor CD103 expression irrespective of alpha(v) expression. Fluorescence microscopy revealed clustering of alpha(v) integrin chains and latent TGF-beta 1 at points of contact between DC precursors and apoptotic cells. We conclude that myeloid DC precursors can deploy alpha(v) integrin to orchestrate binding of apoptotic cells, activation of latent TGF-beta 1 and acquisition of the immunoregulatory CD103 +ve beta 8+ ve DC phenotype. This implies that a hitherto unrecognised consequence of apoptotic cell interaction with myeloid phagocytes is programming that prevents inflammation.	[Zhang, Ailiang; Savill, John] Univ Edinburgh, Med Res Council Ctr Inflammat Res, Queens Med Res Inst, Edinburgh BioQuarter, Edinburgh, Midlothian, Scotland; [Paidassi, Helena] Inserm U1111, Lyon, France; [Lacy-Hulbert, Adam] Benaroya Res Inst Virginia Mason, Seattle, WA USA	University of Edinburgh; Institut National de la Sante et de la Recherche Medicale (Inserm); Benaroya Research Institute; Virginia Mason Medical Center	Savill, J (corresponding author), Univ Edinburgh, Med Res Council Ctr Inflammat Res, Queens Med Res Inst, Edinburgh BioQuarter, Edinburgh, Midlothian, Scotland.	john.savill@ed.ac.uk		Paidassi, Helena/0000-0001-9915-4365	UK Medical Research Council [G0802069]; US National Institutes of Health (NIH) [U19 AI125378]; MRC [G0802069] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); US National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by a grant from the UK Medical Research Council to J.S. (G0802069) and by a grant from the US National Institutes of Health (NIH) to A.L-H. (U19 AI125378). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; Annacker O, 2005, J EXP MED, V202, P1051, DOI 10.1084/jem.20040662; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Coombes JL, 2007, SEMIN IMMUNOL, V19, P116, DOI 10.1016/j.smim.2007.01.001; Cummings RJ, 2016, NATURE, V539, P565, DOI 10.1038/nature20138; del Rio ML, 2008, J IMMUNOL, V181, P6178, DOI 10.4049/jimmunol.181.9.6178; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Freire-de-Lima CG, 2006, J BIOL CHEM, V281, P38376, DOI 10.1074/jbc.M605146200; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; Jaensson E, 2008, J EXP MED, V205, P2139, DOI 10.1084/jem.20080414; Johansson-Lindbom B, 2005, J EXP MED, V202, P1063, DOI 10.1084/jem.20051100; Lacy-Hulbert A, 2007, P NATL ACAD SCI USA, V104, P15823, DOI 10.1073/pnas.0707421104; Lucas M, 2006, J IMMUNOL, V177, P4047, DOI 10.4049/jimmunol.177.6.4047; Mikolajczyk TP, 2009, IMMUNOLOGY, V128, P103, DOI 10.1111/j.1365-2567.2009.03087.x; Paidassi H, 2011, GASTROENTEROLOGY, V141, P1813, DOI 10.1053/j.gastro.2011.06.076; Paidassi H, 2010, ANN NY ACAD SCI, V1209, P68, DOI 10.1111/j.1749-6632.2010.05783.x; Park SY, 2017, EXP MOL MED, V49, DOI 10.1038/emm.2017.52; Rubartelli A, 1997, EUR J IMMUNOL, V27, P1893, DOI 10.1002/eji.1830270812; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Savill J, 2003, SCIENCE, V302, P1516, DOI 10.1126/science.1092533; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SCHULTZCHERRY S, 1993, J CELL BIOL, V122, P923, DOI 10.1083/jcb.122.4.923; Stuart LM, 2002, J IMMUNOL, V168, P1627, DOI 10.4049/jimmunol.168.4.1627; Suffner J, 2010, J IMMUNOL, V184, P1810, DOI 10.4049/jimmunol.0902420; Travis MA, 2007, NATURE, V449, P361, DOI 10.1038/nature06110; Worthington JJ, 2012, IMMUNOBIOLOGY, V217, P1259, DOI 10.1016/j.imbio.2012.06.009; Wu Y, 2005, J CELL SCI, V118, P539, DOI 10.1242/jcs.01632	31	1	1	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2020	15	7							e0232307	10.1371/journal.pone.0232307	http://dx.doi.org/10.1371/journal.pone.0232307			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB3GI	32667911	Green Submitted, Green Published, gold			2023-01-03	WOS:000560402000001
J	Dang, CP; Leelahavanichkul, A				Dang, Cong Phi; Leelahavanichkul, Asada			Over-expression of miR-223 induces M2 macrophage through glycolysis alteration and attenuates LPS-induced sepsis mouse model, the cell-based therapy in sepsis	PLOS ONE			English	Article							ACUTE LUNG INJURY; PROTEIN-SYNTHESIS; POLARIZATION; ACTIVATION; IMMUNOMETABOLISM; INDUCTION	The attenuation of hyper-inflammation in sepsis with the administration of anti-inflammatory macrophages is an interesting adjuvant therapy for sepsis. Because the induction of anti-inflammatory macrophages by microRNA (miR), a regulator of mRNA, has been mentioned, the exploration on miR-induced anti-inflammatory macrophages was performed. The over-expression of miR-223 and miR-146a in RAW264.7 induced M2 macrophage-polarization (anti-inflammatory macrophages) as evaluated by the enhanced expression ofArginase-1andFizz. However, miR-223 over-expressed cells demonstrated the more potent anti-inflammatory property against LPS stimulation as lesseriNOSexpression, lower supernatant IL-6 and higher supernatant IL-10 compared with miR-146a over-expressed cells. Interestingly, LPS stimulation in miR-223 over-expressed cells, compared with LPS-stimulated control cells, demonstrated lower activity of glycolysis pathway and higher mitochondrial respiration, as evaluated by the extracellular flux analysis, and also down-regulatedHIF-1 alpha, an important enzyme of glycolysis pathway. In addition, the administration of miR-223 over-expressed macrophages with IL-4 pre-conditioning, but not IL-4 stimulated control cells, attenuated sepsis severity in LPS injected mice as evaluated by serum creatinine, liver enzymes, lung histology and serum cytokines. In conclusion, miR-223 interfered with the glycolysis pathway through the down-regulation ofHIF-1 alpha, resulting in the anti-inflammatory status. The over-expression of miR-223 in macrophages prevented the conversion into M1 macrophage polarization after LPS stimulation. The administration of miR-223 over-expressed macrophages, with IL-4 preconditioning, attenuated sepsis severity in LPS model. Hence, a proof of concept in the induction of anti-inflammatory macrophages through the cell-energy interference for sepsis treatment was proposed as a basis of cell-based therapy in sepsis.	[Dang, Cong Phi] Chulalongkorn Univ, Grad Sch, Interdisciplinary & Int Program, Med Microbiol, Bangkok, Thailand; [Dang, Cong Phi; Leelahavanichkul, Asada] Chulalongkorn Univ, Dept Microbiol, Fac Med, Bangkok, Thailand; [Leelahavanichkul, Asada] Chulalongkorn Univ, Dept Microbiol, Translat Res Inflammat & Immunol Res Unit TRIRU, Bangkok, Thailand	Chulalongkorn University; Chulalongkorn University; Chulalongkorn University	Leelahavanichkul, A (corresponding author), Chulalongkorn Univ, Dept Microbiol, Fac Med, Bangkok, Thailand.; Leelahavanichkul, A (corresponding author), Chulalongkorn Univ, Dept Microbiol, Translat Res Inflammat & Immunol Res Unit TRIRU, Bangkok, Thailand.	aleelahavanit@gmail.com			Thailand Government Fund [RSA6080023]; Thailand Government Fund 2016 to 2018; Ratchadapisek Sompoch Endowment Fund Chulalongkorn University [760001-HR]; 100th Anniversary Chulalongkorn University Fund	Thailand Government Fund; Thailand Government Fund 2016 to 2018; Ratchadapisek Sompoch Endowment Fund Chulalongkorn University; 100th Anniversary Chulalongkorn University Fund	Asada Leelahavanichkul was supported by Thailand Government Fund (RSA6080023), Thailand Government Fund 2016 to 2018 and Ratchadapisek Sompoch Endowment Fund Chulalongkorn University (760001-HR). Cong Dang Phi was supported the scholarship from The 100th Anniversary Chulalongkorn University Fund for Doctoral Scholarship.	Brown JM, 2017, CLIN CANCER RES, V23, P3241, DOI 10.1158/1078-0432.CCR-16-3122; Chen QY, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0037149, 10.1371/journal.pone.0042971]; Corcoran SE, 2016, J CLIN INVEST, V126, P3699, DOI 10.1172/JCI84431; Covarrubias AJ, 2016, ELIFE, V5, DOI 10.7554/eLife.11612; Curtale G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00799; DANDREA A, 1995, J EXP MED, V181, P537, DOI 10.1084/jem.181.2.537; Doi K, 2009, J CLIN INVEST, V119, P2868, DOI 10.1172/JCI39421; Domblides C, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7070068; Duvel K, 2010, MOL CELL, V39, P171, DOI 10.1016/j.molcel.2010.06.022; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Essandoh K, 2016, SHOCK, V46, P122, DOI 10.1097/SHK.0000000000000604; Fleming BD, 2015, J LEUKOCYTE BIOL, V98, P395, DOI 10.1189/jlb.2A1114-560R; Gao M, 2015, J IMMUNOL, V195, P672, DOI 10.4049/jimmunol.1403155; Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580-018-0045-7; Gerasimovskaya E, 2012, AM J PHYSIOL-LUNG C, V302, pL1014, DOI 10.1152/ajplung.00357.2011; Gupta N, 2007, J IMMUNOL, V179, P1855, DOI 10.4049/jimmunol.179.3.1855; Hamidzadeh K, 2017, ANNU REV PHYSIOL, V79, P567, DOI 10.1146/annurev-physiol-022516-034348; Hotchkiss RS, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.45; Huang C, 2016, INT IMMUNOPHARMACOL, V32, P46, DOI 10.1016/j.intimp.2016.01.009; Huang SCC, 2016, IMMUNITY, V45, P817, DOI 10.1016/j.immuni.2016.09.016; Koelwyn GJ, 2018, NAT IMMUNOL, V19, P526, DOI 10.1038/s41590-018-0113-3; Kong XN, 2007, J EXP MED, V204, P2719, DOI 10.1084/jem.20062611; Kowal J, 2019, IMMUNOTHERAPY-UK, V11, P677, DOI 10.2217/imt-2018-0156; Leelahavanichkul A, 2016, SHOCK, V46, P506, DOI 10.1097/SHK.0000000000000645; Leelahavanichkul A, 2015, AM J PHYSIOL-REG I, V309, pR223, DOI 10.1152/ajpregu.00238.2014; Li CX, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22039-9; Li J, 2012, J ASIA TEFL, V9, P1, DOI 10.1186/1476-9255-9-33; Li XB, 2015, THORAC CANCER, V6, P17, DOI 10.1111/1759-7714.12148; Major J, 2002, J IMMUNOL, V168, P2456, DOI 10.4049/jimmunol.168.5.2456; Murray PJ, 2017, ANNU REV PHYSIOL, V79, P541, DOI 10.1146/annurev-physiol-022516-034339; Nemeth K, 2009, NAT MED, V15, P42, DOI 10.1038/nm.1905; Nishi K, 2008, ANTIOXID REDOX SIGN, V10, P983, DOI 10.1089/ars.2007.1825; O'Neill LAJ, 2016, NAT REV IMMUNOL, V16, P553, DOI 10.1038/nri.2016.70; Ondee T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091064; Ondee T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061354; Ouimet M, 2015, J CLIN INVEST, V125, P4334, DOI 10.1172/JCI81676; Perske C, 2010, AM J PATHOL, V177, P2046, DOI 10.2353/ajpath.2010.091111; Rajaiah R, 2013, J IMMUNOL, V190, P4763, DOI 10.4049/jimmunol.1202407; Riedemann NC, 2003, EXPERT OPIN BIOL TH, V3, P339, DOI 10.1517/eobt.3.2.339.21156; Rosen DA, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau5266; Roy S, 2000, SURGERY, V128, P219, DOI 10.1067/msy.2000.108063; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Singer M, 2016, JAMA-J AM MED ASSOC, V315, P801, DOI 10.1001/jama.2016.0287; Subramaniam S, 2019, CLIN CHEM, V65, P1090, DOI 10.1373/clinchem.2018.299651; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Tan Z, 2015, J IMMUNOL, V194, P6082, DOI 10.4049/jimmunol.1402469; Tangtanatakul P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15160-8; Taratummarat S, 2018, BMC MICROBIOL, V18, DOI 10.1186/s12866-018-1227-3; Tran TH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152024; Thapa B, 2019, BMB REP, V52, P360, DOI 10.5483/BMBRep.2019.52.6.140; Thim-uam A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57275-0; Van den Bossche J, 2017, TRENDS IMMUNOL, V38, P395, DOI 10.1016/j.it.2017.03.001; Varol C, 2015, ANNU REV IMMUNOL, V33, P643, DOI 10.1146/annurev-immunol-032414-112220; Vergadi E, 2014, J IMMUNOL, V192, P394, DOI 10.4049/jimmunol.1300959; Vinuesa E, 2008, J PATHOL, V214, P104, DOI 10.1002/path.2259; Wang FL, 2018, CELL METAB, V28, P463, DOI 10.1016/j.cmet.2018.08.012; Wang JF, 2010, BIOCHEM BIOPH RES CO, V394, P184, DOI 10.1016/j.bbrc.2010.02.145; Wang Tong, 2017, Biomed Res Int, V2017, P7378148, DOI 10.1155/2017/7378148; Wu XQ, 2016, IMMUNOLOGY, V148, P237, DOI 10.1111/imm.12608; Yang LW, 2016, J BIOL CHEM, V291, P15700, DOI 10.1074/jbc.M116.715805; Ying W, 2015, J CLIN INVEST, V125, P4149, DOI 10.1172/JCI81656; Zhao ZL, 2019, TRANSL PSYCHIAT, V9, DOI 10.1038/s41398-019-0609-0	62	42	42	3	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2020	15	7							e0236038	10.1371/journal.pone.0236038	http://dx.doi.org/10.1371/journal.pone.0236038			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ1AQ	32658933	gold, Green Published			2023-01-03	WOS:000552629600016
J	Afaya, A; Azongo, TB; Dzomeku, VM; Afaya, RA; Salia, SM; Adatara, P; Alhassan, RK; Amponsah, AK; Atakro, CA; Adadem, D; Asiedu, EO; Amuna, P; Ayanore, MA				Afaya, Agani; Azongo, Thomas Bavo; Dzomeku, Veronica Millicent; Afaya, Richard Adongo; Salia, Solomon Mohammed; Adatara, Peter; Kaba Alhassan, Robert; Amponsah, Abigail Kusi; Atakro, Confidence Alorse; Adadem, David; Asiedu, Emmanuel Opoku; Amuna, Paul; Amogre Ayanore, Martin			Women's knowledge and its associated factors regarding optimum utilisation of antenatal care in rural Ghana: A cross-sectional study	PLOS ONE			English	Article							DETERMINANTS; SERVICES	Introduction Improving maternal health is a global public health challenge especially in sub-Saharan Africa. The optimum utilisation of antenatal care (ANC) by pregnant women is known to improve maternal health outcomes. Maternal morbidity and mortality rates in Ghana remain unacceptably high, particularly in rural settings where skilled delivery care often times is disproportionally low. This study assessed factors associated with optimum utilisation of antenatal care in rural Ghana. Methods A cross-sectional design was applied to collect data among eligible participants between October 2018 and January 2019. A total of 322 women who gave birth and attended the postnatal clinic were recruited for the study. Consecutive sampling was employed in recruiting participants. The associations between the dependent variables (ANC service utilisation and knowledge of ANC) and independent variables (socio-demographic characteristics) were examined using ordinary least squares logistic regression at 95% confidence interval in STATA version 14.0. Results Of the 322 participants, 69.0% reported utilising at least four or more times ANC services. Determinants of women attending ANC for four or more times was significantly associated with age [OR = 4.36 (95%CI: 2.16-8.80), p<0.001], educational level [OR = 10.18 (95%CI: 3.86-26.87), p<0.001], and insured with National Health Insurance Scheme [OR = 3.42 (95%CI: 1.72-6.82), p<0.001]. Not married [OR = 0.65 (0.39-1.09), p = 0.011] or divorced [OR = 0.33 (95%CI: 0.13-0.83), p = 0.019] was negatively associated with utilisation of four or more ANC services. The majority (79.0%) of the participants had a good level of knowledge regarding antenatal care. Conclusion Although the majority of women in this study had good knowledge of ANC services, a significant number of them did not complete the recommended number of ANC visits for at least four times during a normal pregnancy. Awareness and further education to reproductive-age women on the significant role adequate ANC attendance plays in advancing health and well-being require further investments, particularly among rural women in Ghana.	[Afaya, Agani; Salia, Solomon Mohammed; Adatara, Peter; Adadem, David; Asiedu, Emmanuel Opoku] Univ Hlth & Allied Sci, Sch Nursing & Midwifery, Dept Nursing, Ho, Ghana; [Azongo, Thomas Bavo] Univ Dev Studies, Sch Allied Hlth Sci, Dept Publ Hlth, Tamale, Ghana; [Dzomeku, Veronica Millicent; Afaya, Richard Adongo; Amponsah, Abigail Kusi] Kwame Nkrumah Univ Sci & Technol, Dept Nursing, Kumasi, Ghana; [Kaba Alhassan, Robert] Univ Hlth & Allied Sci, Inst Hlth Res, Ctr Hlth Policy & Implementat Res, Ho, Ghana; [Atakro, Confidence Alorse] Christian Serv Univ Coll, Sch Nursing & Midwifery, Kumasi, Ghana; [Amuna, Paul; Amogre Ayanore, Martin] Univ Hlth & Allied Sci, Sch Publ Hlth, Ho, Ghana	University for Development Studies; Kwame Nkrumah University Science & Technology	Afaya, A (corresponding author), Univ Hlth & Allied Sci, Sch Nursing & Midwifery, Dept Nursing, Ho, Ghana.	aagani@uhas.edu.gh	Amponsah, Abigail Kusi/AAJ-4569-2021	Amponsah, Abigail Kusi/0000-0002-4591-4215; atakro, confidence/0000-0002-9944-8619; Ayanore, Martin/0000-0002-4095-3047; Alhassan, Robert Kaba/0000-0003-4227-4854				Afaya A, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-019-2698-4; Ali SA, 2018, J PREG NEONATAL MED, V2; Amoakoh-Coleman M, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007810; Anarfi JK, 2003, AIDS RES REV, V19, P27, DOI DOI 10.4314/RRIAS.V19I1.22866; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Arthur E, 2012, HEALTH ECON REV, V2, DOI 10.1186/2191-1991-2-14; Ashir Garba Mohammed, 2013, Glob J Health Sci, V5, P34, DOI 10.5539/gjhs.v5n3p34; Ayalew Teshager Workneh, 2018, BMC Res Notes, V11, P819, DOI 10.1186/s13104-018-3928-y; Ayamolowo SJ., 2013, INT J CARING SCI, V6, P531; Ayanore MA, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1654-5; Birmeta K, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-256; Bustreo F, 2013, LANCET GLOB HEALTH, V1, pE176, DOI 10.1016/S2214-109X(13)70059-7; Duku S, 2016, BARRIERS UPTAKE RENE; Fagbamigbe AF, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0527-y; Fagbamigbe AF., 2013, INT J MATERN CHILD H, V1, P7, DOI [10.12966/ijmch.05.02.2013, DOI 10.12966/IJMCH]; Ghana Health Service Family Health Division, 2016, ANN REPORT; Ghana Statistical Service (GSS) Ghana Health Service (GHS) and ICF, 2019, 2017 GHAN MAT HLTH S; GHS, 2002, COMM BAS HLTH PLANN; Gitonga E., 2017, ADV PUBLIC HLTH, V2017, P4; Gohl D, 2012, GMS PSYCHOSOCIAL MED, V9; Gong E, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4369-6; Gunawardena N, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00048; Gupta R. K., 2015, Tropical Journal of Medical Research, V18, P89; Hijazi HH, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0542-3; Kalule-Sabiti I., 2014, African Population Studies, V28, P515, DOI 10.11564/28-1-504; Kawungezi Peter Chris, 2015, Open J Prev Med, V5, P132; Manyeh AK, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-2738-0; Ministry of Environment Science and Technology (MEST), 2011, ZON GUID PLANN STAND; Ministry of Health, 2006, NAT COMM BAS HLTH PL; Nebeb GT, 2015, GYNECOL OBSTET, V5, P339, DOI [10.4172/2161-0932.1000339, DOI 10.4172/2161-0932.1000339]; Nketiah-Amponsah E, 2013, AFR J ECON MANAG STU, V4, P58, DOI 10.1108/20400701311303159; Ogunba BO, 2017, J NUTR HLTH SCI, V4, P207; Okedo-Alex IN, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-031890; Rurangirwa AA, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1328-2; Sakeah E, 2017, GLOBAL HEALTH ACTION, V10, DOI 10.1080/16549716.2017.1291879; Statistics YT, 1967, INTRO ANAL; Tiruaynet K, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2259-x; Tuladhar H., 2011, NEPAL J OBSTET GYNAE, V6, P37, DOI [10.3126/njog.v6i2.6755, DOI 10.3126/NJOG.V6I2.6755]; UNICEF, 2018, ANT CAR; WHO, 2022, WHO RECOMMENDATIONS; WHO: Global Health Observatory (GHO) data, GLOB OBS GHO DAT COU; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; World Health Organization, PREGN CHILDB POSTP N; World Health Organization, GLOB HLTH OBS DAT RE; World Health Organization UNICEF, 2003, ANT CAR DEV COUNTR P	46	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2020	15	7							e0234575	10.1371/journal.pone.0234575	http://dx.doi.org/10.1371/journal.pone.0234575			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ0QU	32645002	Green Published, gold			2023-01-03	WOS:000552602700093
J	Farmer, RE; Daniel, R; Ford, D; Cook, A; Musiime, V; Bwakura-Dangarembizi, M; Gibb, DM; Prendergast, AJ; Walker, AS				Farmer, Ruth E.; Daniel, Rhian; Ford, Deborah; Cook, Adrian; Musiime, Victor; Bwakura-Dangarembizi, Mutsa; Gibb, Diana M.; Prendergast, Andrew J.; Walker, A. Sarah		ARROW Trial Team	Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy	PLOS ONE			English	Article							ZIDOVUDINE; INFERENCE	Background The impact of nutritional supplements on weight gain in HIV-infected children on antiretroviral treatment (ART) remains uncertain. Starting supplements depends upon current weight-for-age or other acute malnutrition indicators, producing time-dependent confounding. However, weight-for-age at ART initiation may affect subsequent weight gain, independent of supplement use. Implications for marginal structural models (MSMs) with inverse probability of treatment weights (IPTW) are unclear. Methods In the ARROW trial, non-randomised supplement use and weight-for-age were recorded monthly from ART initiation. The effect of supplements on weight-for-age over the first year was estimated using generalised estimating equation MSMs with IPTW, both with and without interaction terms between baseline weight-for-age and time. Separately, data were simulated assuming no supplement effect, with use depending on current weight-for-age, and weight-for-age trajectory depending on baseline weight-for-age to investigate potential bias associated with different MSM specifications. Results In simulations, despite correctly specifying IPTW, omitting an interaction in the MSM between baseline weight-for-age and time produced increasingly biased estimates as associations between baseline weight-for-age and subsequent weight trajectory increased. Estimates were unbiased when the interaction between baseline weight-for-age and time was included, even if the data were simulated with no such interaction. In ARROW, without an interaction the estimated effect was +0.09 (95%CI +0.02,+0.16) greater weight-for-age gain per month's supplement use; this reduced to +0.03 (-0.04,+0.10) including the interaction. Discussion This study highlights a specific situation in which MSM model misspecification can occur and impact the resulting estimate. Since an interaction in the MSM (outcome) model does not bias the estimate of effect if the interaction does not exist, it may be advisable to include such a term when fitting MSMs for repeated measures.	[Farmer, Ruth E.; Ford, Deborah; Cook, Adrian; Gibb, Diana M.; Walker, A. Sarah] UCL Inst Clin Trials & Methodol, MRC Clin Trials Unit UCL, London, England; [Farmer, Ruth E.] London Sch Hyg & Trop Med, Dept Non Communicable Dis Epidemiol, London, England; [Daniel, Rhian] Univ Cardiff, Div Populat Med, Cardiff, Wales; [Musiime, Victor] Joint Clin Res Ctr, Kampala, Uganda; [Musiime, Victor] Makerere Univ, Dept Paediat & Child Hlth, Coll Hlth Sci, Kampala, Uganda; [Bwakura-Dangarembizi, Mutsa] Univ Zimbabwe, Clin Res Ctr, Harare, Zimbabwe; [Prendergast, Andrew J.] Queen Mary Univ London, London, England	Medical Research Council Clinical Trials Unit; University of London; London School of Hygiene & Tropical Medicine; Cardiff University; Joint Clinic Research Center - United Arab Emirates; Makerere University; University of Zimbabwe; University of London; Queen Mary University London	Farmer, RE (corresponding author), UCL Inst Clin Trials & Methodol, MRC Clin Trials Unit UCL, London, England.; Farmer, RE (corresponding author), London Sch Hyg & Trop Med, Dept Non Communicable Dis Epidemiol, London, England.	rmjlasw@ucl.ac.uk	Walker, Sarah/HDM-8717-2022	Gibb, Diana/0000-0002-9738-5490	Medical Research Council's Population Health Sciences Research Network [PHSRN47]; UK Medical Research Council [MC_UU_12023/21, MC_UU_12023/26]; Sir Henry Dale Fellowship - Wellcome Trust [107617/Z/15/Z]; Sir Henry Dale Fellowship - Royal Society [107617/Z/15/Z]; Wellcome Trust [108065/Z/15/Z]; UK Medical Research Council; UK Department for International Development [G0300400]; MRC [MC_UU_12023/26, MC_EX_G0300400, MC_U122886353, MC_UU_12023/21, MC_UU_12023/17] Funding Source: UKRI	Medical Research Council's Population Health Sciences Research Network(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Sir Henry Dale Fellowship - Wellcome Trust(Wellcome Trust); Sir Henry Dale Fellowship - Royal Society; Wellcome Trust(Wellcome TrustEuropean Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UK Department for International Development; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Medical Research Council's Population Health Sciences Research Network [PHSRN47] [DF ASW], core support to the UK Medical Research Council [MC_UU_12023/21, MC_UU_12023/26] [DF ASW DMG], a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant 107617/Z/15/Z) [RD], and a Senior Fellowship funded by the Wellcome Trust [108065/Z/15/Z] [AJP]. The main trial was funded by the UK Medical Research Council and the UK Department for International Development [G0300400] [AC VM MBD DMG ASW]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arpadi SM, 2000, J ACQ IMMUN DEF SYND, V25, pS37, DOI 10.1097/00126334-200010001-00006; Bolton-Moore C, 2007, JAMA-J AM MED ASSOC, V298, P1888, DOI 10.1001/jama.298.16.1888; Breskin A, 2018, EPIDEMIOLOGY, V29, P352, DOI 10.1097/EDE.0000000000000813; Daniel RM, 2013, STAT MED, V32, P1584, DOI 10.1002/sim.5686; de Onis M, 2007, B WORLD HEALTH ORGAN, V85, P660, DOI 10.2471/BLT.07.043497; Fewell Z, 2004, STATA J, V4, P402, DOI 10.1177/1536867X0400400403; Gibb DM, 2013, LANCET, V381, P1391, DOI 10.1016/S0140-6736(12)62198-9; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Hernan MA, 2002, STAT MED, V21, P1689, DOI 10.1002/sim.1144; Hernan MA, 2014, CAUSAL INFERENCE; Kekitiinwa A, 2008, 15 C RETR OPP INF BO; Keogh RH, 2018, AM J EPIDEMIOL, V187, P1085, DOI 10.1093/aje/kwx311; McGrath CJ, 2011, AIDS, V25, P345, DOI 10.1097/QAD.0b013e32834171db; Neugebauer R, 2007, J STAT PLAN INFER, V137, P419, DOI 10.1016/j.jspi.2005.12.008; PEPE MS, 1994, COMMUN STAT SIMULAT, V23, P939, DOI 10.1080/03610919408813210; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; ROSENBAUM PR, 1984, J ROY STAT SOC A STA, V147, P656, DOI 10.2307/2981697; StataCorp, 2015, STAT STAT SOFTW REL; Sutcliffe CG, 2008, LANCET INFECT DIS, V8, P477, DOI 10.1016/S1473-3099(08)70180-4; Wamalwa DC, 2007, JAIDS-J ACQ IMM DEF, V45, P311; World Health Organisation, 2006, ANT THER HIV INF INF	21	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2020	15	7							e0233877	10.1371/journal.pone.0233877	http://dx.doi.org/10.1371/journal.pone.0233877			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ0QU	32645021	Green Published, gold, Green Accepted			2023-01-03	WOS:000552602700020
J	Zander-Schellenberg, T; Collins, IM; Miche, M; Guttmann, C; Lieb, R; Wahl, K				Zander-Schellenberg, Thea; Collins, Isabella Mutschler; Miche, Marcel; Guttmann, Camille; Lieb, Roselind; Wahl, Karina			Does laughing have a stress-buffering effect in daily life? An intensive longitudinal study	PLOS ONE			English	Article							ACTIVATED RECORDER EAR; POSITIVE AFFECT; HEALTH; MORTALITY; SMILE	Positive affect is associated with alleviating mental and physiological stress responses. As laughter is a common physiological operationalization of positive affect, we investigated whether the effects of experiencing a stressful event on stress symptoms is lessened by frequency and intensity of daily laughter. Using an intensive longitudinal design, we ambulatory assessed the self-reported experience of stressful events, stress symptoms and the frequency as well as the intensity of laughter in university students' daily lives. Our hierarchical ecological momentary assessment data were analyzed with multilevel models. The results support the stress-buffering model of positive affect: We found that the frequency of laughter attenuated the association between stressful events and subsequent stress symptoms. The level of intensity of laughter, however, was found to have no significant effect. Future studies should use additional psychophysiological indicators of stress and straighten out the differential contributions of frequency and intensity of daily laughter.	[Zander-Schellenberg, Thea; Collins, Isabella Mutschler; Miche, Marcel; Guttmann, Camille; Lieb, Roselind; Wahl, Karina] Univ Basel, Dept Psychol, Div Clin Psychol & Epidemiol, Basel, Switzerland	University of Basel	Wahl, K (corresponding author), Univ Basel, Dept Psychol, Div Clin Psychol & Epidemiol, Basel, Switzerland.	karina.wahl@unibas.ch		Zander-Schellenberg, Thea/0000-0002-6009-5561; Mutschler Collins, Isabella/0000-0003-2738-5943; Guttmann, Charles/0000-0002-7006-9762				Abel EL, 2010, PSYCHOL SCI, V21, P542, DOI 10.1177/0956797610363775; [Anonymous], 2018, PSYCH PROCEDURES PER; Barr DJ, 2013, J MEM LANG, V68, P255, DOI 10.1016/j.jml.2012.11.001; Bolger N, 2013, INTENSIVE LONGITUDIN; Chida Y, 2008, PSYCHOSOM MED, V70, P741, DOI 10.1097/PSY.0b013e31818105ba; Dufner M, 2018, PSYCHOL SCI, V29, P147, DOI 10.1177/0956797617734315; Enders CK, 2007, PSYCHOL METHODS, V12, P121, DOI 10.1037/1082-989X.12.2.121; Faresjo A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073828; Fox J., 2003, J STAT SOFTW, V8, P1, DOI DOI 10.18637/JSS.V008.I15; Fredrickson B. L., 1998, REV GEN PSYCHOL, V2, P300; Fredrickson BL, 2000, MOTIV EMOTION, V24, P237, DOI 10.1023/A:1010796329158; Gross JJ, 2003, J PERS SOC PSYCHOL, V85, P348, DOI 10.1037/0022-3514.85.2.348; Hill AB, 1965, ENV DIS ASS CAUSATIO; Hu TQ, 2014, PSYCHOL REP, V114, P341, DOI 10.2466/03.20.PR0.114k22w4; Kim J, 2018, COMPUTATIONAL MATH M, V2018; King LA, 2006, J PERS SOC PSYCHOL, V90, P179, DOI 10.1037/0022-3514.90.1.179; Kraemer HC, 1997, ARCH GEN PSYCHIAT, V54, P337; Kraft TL, 2012, PSYCHOL SCI, V23, P1372, DOI 10.1177/0956797612445312; LaFrance M, 2003, PSYCHOL BULL, V129, P305, DOI 10.1037/0033-2909.129.2.305; Lorah J, 2018, LARGE-SCALE ASSESS E, V6, DOI 10.1186/s40536-018-0061-2; Martin RA, 1999, HUMOR, V12, P355, DOI 10.1515/humr.1999.12.4.355; Mehl MR, 2017, CURR DIR PSYCHOL SCI, V26, P184, DOI 10.1177/0963721416680611; Mehl MR, 2001, BEHAV RES METH INS C, V33, P517, DOI 10.3758/BF03195410; Miche M., 2019, ESMPREP DATA PREPARA; Okely JA, 2017, J PSYCHOSOM RES, V100, P53, DOI 10.1016/j.jpsychores.2017.07.005; Perez-Aranda A, 2019, EUR J PAIN, V23, P220, DOI 10.1002/ejp.1309; Pinheiro J., 2019, NLME LINEAR NONLINEA; Pressman SD, 2018, CURR DIR PSYCHOL SCI, V27, P339, DOI 10.1177/0963721418760214; Pressman SD, 2019, ANNU REV PSYCHOL, V70, P627, DOI 10.1146/annurev-psych-010418-102955; Pressman SD, 2017, EMOTION, V17, P778, DOI 10.1037/emo0000256; Pressman SD, 2005, PSYCHOL BULL, V131, P925, DOI 10.1037/0033-2909.131.6.925; Ruch W., 2001, EMOTION QUALIA CONSC, P426, DOI DOI 10.1142/9789812810687_0033; Satow L., 2012, STRESS UND COPING IN; Schneiderman N, 2005, ANNU REV CLIN PSYCHO, V1, P607, DOI 10.1146/annurev.clinpsy.1.102803.144141; Schonfeld P, 2016, INT J CLIN HLTH PSYC, V16, P1, DOI 10.1016/j.ijchp.2015.08.005; Seder JP, 2012, SOC PSYCHOL PERS SCI, V3, P407, DOI 10.1177/1948550611424968; Talhelm T, 2019, EMOTION, V19, P741, DOI 10.1037/emo0000459; Tomlinson ER, 2018, MINDFULNESS, V9, P23, DOI 10.1007/s12671-017-0762-6; Wickham H., 2016, GGPLOT2 ELEGANT GRAP, DOI [10.1007/978-3-319-24277-4, DOI 10.1007/978-3-319-24277-4]; Wilke C. O., 2019, COWPLOT STREAMLINED; Zhang YJ, 2016, PSYCH J, V5, P125, DOI 10.1002/pchj.129	41	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2020	15	7							e0235851	10.1371/journal.pone.0235851	http://dx.doi.org/10.1371/journal.pone.0235851			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MQ0QU	32645063	Green Accepted, gold, Green Published			2023-01-03	WOS:000552602700080
J	O'Shea, O; Woods, C; McDermott, L; Buys, R; Cornelis, N; Claes, J; Cornelissen, V; Gallagher, A; Newton, H; Moyna, N; McCaffrey, N; Susta, D; McDermott, C; McCormack, C; Budts, W; Moran, K				O'Shea, Orlagh; Woods, Catherine; McDermott, Lauri; Buys, Roselien; Cornelis, Nils; Claes, Jomme; Cornelissen, Veronique; Gallagher, Anne; Newton, Helen; Moyna, Niall; McCaffrey, Noel; Susta, Davide; McDermott, Clare; McCormack, Ciara; Budts, Werner; Moran, Kieran			A qualitative exploration of cardiovascular disease patients' views and experiences with an eHealth cardiac rehabilitation intervention: The PATHway Project	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; PARTICIPATION	The aim of this study is to explore participants' views and experiences of an eHealth phase 3 cardiac rehabilitation (CR) intervention: Physical Activity Towards Health (PATHway). Sixty participants took part in the PATHway intervention. Debriefs were conducted after the six-month intervention. All interviews were audio recorded and transcribed verbatim. Transcripts were analysed with Braun and Clarke's thematic analysis. Forty-four (71%) debriefs were conducted (n = 34 male, mean (SD) age 61 (10) years). Five key themes were identified: (1) Feedback on the components of the PATHway system, (2) Motivation, (3) Barriers to using PATHway, (4) Enablers to using PATHway, and (5) Post programme reflection. There were a number of subthemes within each theme, for example motivation explores participants motivation to take part in PATHway and participants motivation to sustain engagement with PATHway throughout the intervention period. Participant engagement with the components of the PATHway system was variable. Future research should focus on optimising participant familiarisation with eHealth systems and employ an iterative approach to development and evaluation.	[O'Shea, Orlagh] Royal Coll Surgeons Ireland, Sch Physiotherapy, Dublin, Ireland; [Woods, Catherine] Univ Limerick, Dept Phys Educ & Sport Sci, Phys Activ Hlth, Hlth Res Inst,Fac Educ & Hlth Sci, Limerick, Ireland; [McDermott, Lauri; McCaffrey, Noel] ExWell Med, Dublin, Ireland; [Buys, Roselien; Claes, Jomme; Budts, Werner] Katholieke Univ Leuven, Dept Cardiovasc Sci, Leuven, Belgium; [Cornelis, Nils; Cornelissen, Veronique] Katholieke Univ Leuven, Dept Rehabil Sci, Leuven, Belgium; [Gallagher, Anne] Mater Misericordiae Univ Hosp, Dublin, Ireland; [Newton, Helen] Beaumont Univ Hosp, Dublin, Ireland; [Moyna, Niall; Susta, Davide; McDermott, Clare; McCormack, Ciara; Moran, Kieran] Dublin City Univ, Dept Hlth & Human Performance, Dublin, Ireland; [Moran, Kieran] Dublin City Univ, Insight Ctr Data Analyt, Dublin, Ireland	Royal College of Surgeons - Ireland; University of Limerick; KU Leuven; KU Leuven; Mater Misericordiae University Hospital; University College Dublin; Dublin City University; Dublin City University	O'Shea, O (corresponding author), Royal Coll Surgeons Ireland, Sch Physiotherapy, Dublin, Ireland.	orlaghoshea@rcsi.com	McCormack, Ciara/AAZ-9622-2020; McDermott, Clare/AAM-5115-2021; Budts, Werner/AAG-1643-2019; Moran, Kieran/D-4220-2016	McDermott, Clare/0000-0002-9261-0564; Moran, Kieran/0000-0003-2015-8967; O'Shea, Orlagh/0000-0003-2961-6717; Cornelis, Nils/0000-0001-8403-0044; Woods, Catherine/0000-0002-0892-6591	European Union's Horizon 2020 Framework Programme for Research and Innovation Action [643491]	European Union's Horizon 2020 Framework Programme for Research and Innovation Action	This project has received funding from the European Union's Horizon 2020 Framework Programme for Research and Innovation Action under Grant Agreement no. 643491:https://ec.europa.eu/digital-single-market/en/policies/ehealth This was awarded to KM, CW, NM, NMcC, WB, VC, and RB. No the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ades PA, 2017, MAYO CLIN PROC, V92, P234, DOI 10.1016/j.mayocp.2016.10.014; Bjarnason-Wehrens B, CARDIAC REHABILITATI, P1741; Booth FW, 2017, PHYSIOL REV, V97, P1351, DOI 10.1152/physrev.00019.2016; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Claes J, 2020, J MED INTERNET RES, V22, DOI 10.2196/14221; Claes J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016781; Dunlay SM, 2009, AM HEART J, V158, P852, DOI 10.1016/j.ahj.2009.08.010; Eckerstorfer LV, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/10076; Ekelund U, 2016, LANCET, V388, P1302, DOI 10.1016/S0140-6736(16)30370-1; Grace SL, 2009, J CARDIOPULM REHABIL, V29, P183, DOI 10.1097/HCR.0b013e3181a3333c; Herber OR, 2017, J CLIN NURS, V26, P3529, DOI 10.1111/jocn.13722; Kanejima Y, 2019, AGING CLIN EXP RES, V31, P163, DOI 10.1007/s40520-018-0960-7; Loeckx M, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.9774; Michie S, 2013, ANN BEHAV MED, V46, P81, DOI 10.1007/s12160-013-9486-6; Moore GF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1258; Procter S, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-868; Rawstorn JC, 2016, HEART, V102, P1183, DOI 10.1136/heartjnl-2015-308966; Rickheim PL, 2002, DIABETES CARE, V25, P269, DOI 10.2337/diacare.25.2.269; s NA, 2018, LANCET INFECT DIS, V18, pe228; Saner H, 2016, EUR J PREV CARDIOL, V23, P5, DOI 10.1177/2047487316670256; Short CE, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9397; Trost SG, 2002, MED SCI SPORT EXER, V34, P1996, DOI 10.1097/00005768-200212000-00020; Walsh DMJ, 2018, J MED INTERNET RES, V20, DOI 10.2196/jmir.9181; Walsh DMJ, 2019, TRANSL BEHAV MED, V9, P76, DOI 10.1093/tbm/iby017; Webster R, 2010, RISK MANAG HEALTHC P, V3, P49, DOI 10.2147/RMHP.S8288; World Health Organization, 2019, WHO REL 1 GUID DIG H	26	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2020	15	7							e0235274	10.1371/journal.pone.0235274	http://dx.doi.org/10.1371/journal.pone.0235274			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM3OG	32628688	Green Published, gold			2023-01-03	WOS:000550068700059
J	Szczapa, T; Hozejowski, R; Krajewski, P				Szczapa, Tomasz; Hozejowski, Roman; Krajewski, Pawel		Study Grp	Implementation of less invasive surfactant administration in clinical practice-Experience of a mid-sized country	PLOS ONE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; PRETERM INFANTS; THERAPY; INTUBATION; FAILURE; CPAP	Objective There are differences in the adoption rates of less invasive surfactant administration (LISA) worldwide. We aimed to describe and analyze the process of LISA introduction at the country level. Methods A standardized training program (33 courses covering >500 neonatologists) was followed by a cohort study. Data regarding consecutive LISA procedures were acquired over 12 months in 31 tertiary neonatal centers, using a dedicated on-line platform. Results Of 500 LISA procedures, 75% were performed by specialists and 25% by residents. The mean percentage share of LISA in all surfactant therapies was 24%, which represents a 6-fold increase compared to previous years. After 12 months, 76% of the procedures were rated "easy/very easy" vs 59% at baseline (p<0.05). Surfactant re-treatment rate was 15%. Twenty-three percent of infants required mechanical ventilation within 72 hours of life. Oxygen desaturation and surfactant reflux were the most frequent complications. Unlike previous reports describing exclusive use of nasal continuous positive airway pressure (nCPAP) during LISA, majority of procedures (63%) were carried out using nasal intermittent positive pressure ventilation (NIPPV) or Bilevel Positive Airway Pressure (BiPAP). Efficacy of LISA with NIPPV or BiPAP was not significantly different from that with nCPAP (22.4% vs 24.5% of cases requiring intubation). Ventilation was provided with nasal cannulas or nasal masks (90%) and rarely with "RAM" cannulas or nasopharyngeal tubes. Rigid catheters were preferred (88.4%); tracheal insertion was successful at first attempt in 87% of cases. Majority of infants (79%) received no premedication prior to the procedure and almost all were given caffeine citrate. Median time of instillation was 1.5 minutes. Conclusions The LISA procedure does not appear to be technically difficult to master. Training combining theory with practical exercises is an efficient implementation strategy. Variations in adoption rates indicate the need for additional, more personalized teachings in some centers.	[Szczapa, Tomasz] Poznan Univ Med Sci, Dept Neonatol, Poznan, Poland; [Hozejowski, Roman] Chiesi Poland, Dept Med, Warsaw, Poland; [Krajewski, Pawel] Univ Ctr Mother & Newborns Hlth, Dept Neonatol, Warsaw, Poland	Poznan University of Medical Sciences	Szczapa, T (corresponding author), Poznan Univ Med Sci, Dept Neonatol, Poznan, Poland.	tszczapa@gmail.com		Krajewski, Pawel/0000-0002-3825-3375; Hozejowski, Roman/0000-0002-1261-4670; Szczapa, Tomasz/0000-0002-5214-2719	Chiesi Poland	Chiesi Poland(Chiesi Pharmaceuticals Inc)	This study and the LISA training program were carried out with financial support from Chiesi Poland, a subsidiary of Chiesi Farmaceutici, Italy. The protocol was designed collaboratively with the scientific overseeing committee, consisting of members of the Polish Neonatal Society and Dr. Roman Hozejowski (MD and employee of Chiesi). Data collection as well as statistical analysis was carried out by an independent contract research organization and the scientific committee had full access to the data and statistical analysis at all times. Dr. R. Hozejowski was involved in the preparation of the manuscript.	Aldana-Aguirre JC, 2017, ARCH DIS CHILD-FETAL, V102, pF17, DOI 10.1136/archdischild-2015-310299; [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953; Bhayat S, 2020, ACTA PAEDIATR, V109, P505, DOI 10.1111/apa.14995; Borszewska-Kornacka Maria Katarzyna, 2015, Dev Period Med, V19, P271; Downes KJ, 2012, J PERINATOL, V32, P927, DOI 10.1038/jp.2012.17; Fabbri L, 2018, ACTA PAEDIATR, V107, P780, DOI 10.1111/apa.14214; Fernandez C, 2020, AM J PERINAT, V37, P277, DOI 10.1055/s-0039-1678534; Green EA, 2019, ARCH DIS CHILD-FETAL, V104, pF535, DOI 10.1136/archdischild-2018-315838; Gulczynska E, 2019, NEONATOLOGY, V116, P171, DOI 10.1159/000499674; Heiring C, 2017, ACTA PAEDIATR, V106, P382, DOI 10.1111/apa.13694; Herting E, 2019, ARCH DIS CHILD-FETAL, V104, pF655, DOI 10.1136/archdischild-2018-316557; Isayama T, 2016, JAMA-J AM MED ASSOC, V316, P611, DOI 10.1001/jama.2016.10708; Janssen LCE, 2019, ARCH DIS CHILD-FETAL, V104, pF636, DOI 10.1136/archdischild-2018-316258; Jeffreys E, 2019, ARCH DIS CHILD-FETAL, V104, pF567, DOI 10.1136/archdischild-2018-316466; Kanmaz HG, 2013, PEDIATRICS, V131, pE502, DOI 10.1542/peds.2012-0603; Kann IC, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0494-4; Klotz D, 2017, EUR J PEDIATR, V176, P147, DOI 10.1007/s00431-016-2812-9; Kribs A, 2015, JAMA PEDIATR, V169, P723, DOI 10.1001/jamapediatrics.2015.0504; Kurepa D, 2019, J PERINATOL, V39, P426, DOI 10.1038/s41372-018-0302-9; Langhammer K, 2018, EUR J PEDIATR, V177, P1207, DOI 10.1007/s00431-018-3179-x; Lemyre B, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005384.pub2; Lista G, 2010, ARCH DIS CHILD-FETAL, V95, pF85, DOI 10.1136/adc.2009.169219; Petrillo F, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-019-0639-5; Rigo V, 2017, ACTA PAEDIATR, V106, P1091, DOI 10.1111/apa.13850; Rigo V, 2016, EUR J PEDIATR, V175, P1933, DOI 10.1007/s00431-016-2789-4; Schmolzer GM, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f5980; Sweet DG, 2019, NEONATOLOGY, V115, P432, DOI 10.1159/000499361; Vento M, 2019, NEONATOLOGY, V116, P211, DOI 10.1159/000502610	28	16	16	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2020	15	7							e0235363	10.1371/journal.pone.0235363	http://dx.doi.org/10.1371/journal.pone.0235363			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM3OG	32628732	Green Published, gold			2023-01-03	WOS:000550068700012
J	Stepnik, J; Kedra, A; Czaprowski, D				Stepnik, Jakub; Kedra, Agnieszka; Czaprowski, Dariusz			Short-term effect of osteopathic manual techniques (OMT) on respiratory function in healthy individuals	PLOS ONE			English	Article							ASTHMA; MANIPULATION; EXERCISE; THERAPY; COPD	Background Respiratory system diseases are some of the most common pathologies worldwide. Although osteopathic manual therapy (OMT) is used predominantly to treat other pathologies, certain OMT techniques have been shown to improve patients' respiratory function. Objectives The aim of this study was to assess the influence of osteopathic techniques on breathing. Methods Tests were performed with the use of a spirometer and the results were expressed as Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and Peak Expiratory Flow (PEF). Thirty healthy males and females between the age of 18 and 50 took part in the research. Fifteen individuals were randomly assigned to the experimental group and fifteen persons were assigned to the placebo group. The participants from the experimental group were treated with such osteopathic techniques aimed at the pulmonary system as the thoracic thrust (manipulations of vertebral joints and ribs), the sternal pump technique and stretching of the diaphragm. The placebo group was treated with soft tissue therapy (STT) techniques for the masseter muscle. Results The described set of osteopathic techniques exerts an influence on PEF in healthy individuals; however, it does not affect FVC and FEV1. Conclusion Osteopathic techniques do not seem to improve lung health, as reflected in FEV1 and FVC, but they improve the respiratory function aspects reflected by PEF in the participants without any history of lung disease.	[Stepnik, Jakub] Still Acad Osteopathy, Warsaw, Poland; [Kedra, Agnieszka] Jozef Pilsudski Univ Phys Educ Warsaw, Fac Phys Educ & Hlth, Biala Podlaska, Poland; [Czaprowski, Dariusz] Univ Med Sci, Physiotherapy Unit, Dept Hlth Sci, Poznan, Poland; [Czaprowski, Dariusz] Olsztyn Univ, Dept Hlth Sci, Olsztyn, Poland	Jozef Pilsudski University Physical Education in Warsaw; University of Warmia & Mazury	Kedra, A (corresponding author), Jozef Pilsudski Univ Phys Educ Warsaw, Fac Phys Educ & Hlth, Biala Podlaska, Poland.	agnieszka.kedra@poczta.fm		Kedra, Agnieszka/0000-0002-8128-4839				Ashraf AMA, 2015, INT J MED RES HEALTH, V4, P841, DOI 10.5958/2319-5886.2015.00167.8; Balon J, 1998, NEW ENGL J MED, V339, P1013, DOI 10.1056/NEJM199810083391501; Barinow-Wojewodzki A, 2013, ZESZYTY PROMOCJI REH, V2, P51; Bronfort G, 2001, J MANIP PHYSIOL THER, V24, P369, DOI 10.1067/mmt.2001.116417; Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4; Chaitow L, 2005, MANIPULACJE CZASZKOW, P283; Engel RM, 2007, J MANIP PHYSIOL THER, V30, P509, DOI 10.1016/j.jmpt.2007.07.006; Engel RM, 2009, MED HYPOTHESES, V72, P288, DOI 10.1016/j.mehy.2008.10.017; Ferguson GT, 2000, CHEST, V117, P1146, DOI 10.1378/chest.117.4.1146; Grieve GP, 1989, PHYSIOTHERAPY, V75, P445, DOI [10.1016/S0031-9406(10)62623-5, DOI 10.1016/S0031-9406(10)62623-5]; Guiney PA, 2005, J AM OSTEOPATH ASSOC, V105, P7; Hartman L, 1997, HDB OSTEOPATHIC TECH, P122; Hebgen EU, 2011, VISCERAL MANIPULATIO, P1; Lowhagen O, 2014, COMPLEMENT THER CLIN, V20, P276, DOI 10.1016/j.ctcp.2014.07.004; Maigne R, 1996, DIAGNOSIS TREATMENT, P133; Mehl-Madrona L, 2007, EXPLORE-NY, V3, P28, DOI 10.1016/j.explore.2006.10.003; Paul Frank A., 1996, Journal of the American Osteopathic Association, V96, P403; Stecco L, 2016, MANIPULACJA POWIZI L, P103; Swender DA, 2014, J AM OSTEOPATH ASSOC, V114, P450, DOI 10.7556/jaoa.2014.095; Vasconcelos LRM, 2015, MAN THER POSTUROLOGY, V13, P262	20	2	2	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2020	15	6							e0235308	10.1371/journal.pone.0235308	http://dx.doi.org/10.1371/journal.pone.0235308			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH8EZ	32603336	gold, Green Published			2023-01-03	WOS:000546956600028
J	Rivera, JN; Kierski, TM; Kasoji, SK; Abrantes, AS; Dayton, PA; Chang, SX				Rivera, Judith N.; Kierski, Thomas M.; Kasoji, Sandeep K.; Abrantes, Anthony S.; Dayton, Paul A.; Chang, Sha X.			Conventional dose rate spatially-fractionated radiation therapy (SFRT) treatment response and its association with dosimetric parameters-A preclinical study in a Fischer 344 rat model	PLOS ONE			English	Article							SYNCHROTRON MICROBEAM; RADIOTHERAPY; FEASIBILITY; IRRADIATION	Purpose To identify key dosimetric parameters that have close associations with tumor treatment response and body weight change in SFRT treatments with a large range of spatial-fractionation scale at dose rates of several Gy/min. Methods Six study arms using uniform tumor radiation, half-tumor radiation, 2mm beam array radiation, 0.3mm minibeam radiation, and an untreated arm were used. All treatments were delivered on a 320kV x-ray irradiator. Forty-two female Fischer 344 rats with fibrosarcoma tumor allografts were used. Dosimetric parameters studied are peak dose and width, valley dose and width, peak-to-valley-dose-ratio (PVDR), volumetric average dose, percentage volume directly irradiated, and tumor- and normal-tissue EUD. Animal survival, tumor volume change, and body weight change (indicative of treatment toxicity) are tested for association with the dosimetric parameters using linear regression and Cox Proportional Hazards models. Results The dosimetric parameters most closely associated with tumor response are tumor EUD (R-2= 0.7923, F-stat = 15.26*; z-test = -4.07***), valley (minimum) dose (R-2= 0.7636, F-stat = 12.92*; z-test = -4.338***), and percentage tumor directly irradiated (R-2= 0.7153, F-stat = 10.05*; z-test = -3.837***) per the linear regression and Cox Proportional Hazards models, respectively. Tumor response is linearly proportional to valley (minimum) doses and tumor EUD. Average dose (R-2= 0.2745, F-stat = 1.514 (no sig.); z-test = -2.811**) and peak dose (R-2= 0.04472, F-stat = 0.6874 (not sig.); z-test = -0.786 (not sig.)) show the weakest associations to tumor response. Only the uniform radiation arm did not gain body weight post-radiation, indicative of treatment toxicity; however, body weight change in general shows weak association with all dosimetric parameters except for valley (minimum) dose (R-2= 0.3814, F-stat = 13.56**), valley width (R-2= 0.2853, F-stat = 8.783**), and peak width (R-2= 0.2759, F-stat = 8.382**). Conclusions For a single-fraction SFRT at conventional dose rates, valley, not peak, dose is closely associated with tumor treatment response and thus should be used for treatment prescription. Tumor EUD, valley (minimum) dose, and percentage tumor directly irradiated are the top three dosimetric parameters that exhibited close associations with tumor response.	[Rivera, Judith N.; Kierski, Thomas M.; Kasoji, Sandeep K.; Dayton, Paul A.; Chang, Sha X.] Joint Program Univ North Carolina Chapel Hill & N, Dept Biomed Engn, Chapel Hill, NC 27515 USA; [Abrantes, Anthony S.] Univ N Carolina, Dept Biostat, Chapel Hill, NC 27515 USA; [Chang, Sha X.] Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Chang, SX (corresponding author), Joint Program Univ North Carolina Chapel Hill & N, Dept Biomed Engn, Chapel Hill, NC 27515 USA.; Chang, SX (corresponding author), Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27515 USA.	sha_chang@med.unc.edu						Allison M, 2010, NY TIMES BK REV, P5; [Anonymous], 2014, EARLY HUM DEV S1, V90, pS35; [Anonymous], [No title captured]; [Anonymous], 2015, AM J PHARM BENEFITS, V7, pe141; [Anonymous], 2018, OBSTET GYNECOL, V13, pe49; Bazyar S, 2017, PHYS MED BIOL, V62, P8924, DOI 10.1088/1361-6560/aa926b; Billena C, 2019, INT J RADIAT ONCOL, V104, P177, DOI 10.1016/j.ijrobp.2019.01.073; Bouchet A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081874; Brauer-Krisch E, 2010, MUTAT RES-REV MUTAT, V704, P160, DOI 10.1016/j.mrrev.2009.12.003; Bravin A, 2015, PHYS MEDICA, V31, P561, DOI 10.1016/j.ejmp.2015.06.002; Chang SX, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-5051; Dilmanian FA, 2015, INT J RADIAT ONCOL, V92, P469, DOI 10.1016/j.ijrobp.2015.01.018; Eling L, 2019, RADIOTHER ONCOL, V139, P56, DOI 10.1016/j.radonc.2019.06.030; Faustino-Rocha A, 2013, LAB ANIMAL, V42, P217, DOI 10.1038/laban.254; Favaudon V, 2015, CANCER RADIOTHER, V19, P526, DOI 10.1016/j.canrad.2015.04.006; Fontanella AN, 2015, RAD RES, P183; Gessner RC, 2013, INT JURNAL BIOMEDICA, V2013, DOI [10.1155/2013/154860, DOI 10.1155/2013/154860]; Ha JK, 2006, MED PHYS, V33, P76, DOI 10.1118/1.2140116; Hickman DL, 2010, J AM ASSOC LAB ANIM, V49, P155; Ibahim MJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100547; Kasoji SK, 2018, THERANOSTICS, V8, P156, DOI 10.7150/thno.19703; Kutner M.H., 2005, APPL LINEAR STAT MOD; Laissue JA, 2012, Z MED PHYS, V22, P90, DOI 10.1016/j.zemedi.2011.07.002; Martinez-Rovira I, 2017, MED PHYS, V44, P4223, DOI 10.1002/mp.12383; Mavroidis P, 2001, PHYS MED BIOL, V46, P2607, DOI 10.1088/0031-9155/46/10/307; Montay-Gruel P, 2018, RADIOTHER ONCOL, V129, P582, DOI 10.1016/j.radonc.2018.08.016; Narayanasamy G, 2017, ACTA ONCOL, V56, P1043, DOI 10.1080/0284186X.2017.1299219; Neuner G, 2012, INT J RADIAT ONCOL, V82, P1642, DOI 10.1016/j.ijrobp.2011.01.065; Niemierko A, 1997, MED PHYS, V24, P103, DOI 10.1118/1.598063; Piccolo R, 2017, CATHETER CARDIOVASC, V90, pE73, DOI 10.1002/ccd.26921; Prezado Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17543-3; Prezado Y, 2015, RADIAT RES, V184, P314, DOI 10.1667/RR14018.1; Prezado Y, 2012, J SYNCHROTRON RADIAT, V19, P60, DOI 10.1107/S0909049511047042; Priyadarshika RCU, 2011, BRIT J RADIOL, V84, P833, DOI 10.1259/bjr/58503354; Schroeder T, 2005, CANCER RES, V65, P5163, DOI 10.1158/0008-5472.CAN-04-3900; Serduc R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009028; Serduc R, 2009, PHYS MED BIOL, V54, P6711, DOI 10.1088/0031-9155/54/21/017; Society C-SbNCITR, 2018, WORKSH UND HIGH DOS; Terahara A, 1999, INT J RADIAT ONCOL, V45, P351, DOI 10.1016/S0360-3016(99)00146-7; Wu QW, 2002, INT J RADIAT ONCOL, V52, P224, DOI 10.1016/S0360-3016(01)02585-8; Yang YQ, 2019, RADIOTHER ONCOL, V133, P93, DOI 10.1016/j.radonc.2019.01.006; Zhang X, 2013, MED INNOVATION CHINA, V9, P5	42	11	11	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2020	15	6							e0229053	10.1371/journal.pone.0229053	http://dx.doi.org/10.1371/journal.pone.0229053			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC8RX	32569277	Green Published, Green Submitted, gold			2023-01-03	WOS:000543547900033
J	Eerdekens, R; Bouwmeester, S				Eerdekens, Rob; Bouwmeester, Sjoerd			Atrial septal defect and haemodynamic consequences of continuous positive airway pressure treatment	LANCET			English	Editorial Material									[Eerdekens, Rob; Bouwmeester, Sjoerd] Catharina Hosp, Dept Cardiol, NL-5623 Eindhoven, Netherlands	Catharina Hospital	Eerdekens, R (corresponding author), Catharina Hosp, Dept Cardiol, NL-5623 Eindhoven, Netherlands.	rob.eerdekens@catharinaziekenhuis.nl							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 13	2020	395	10240					1864	1864						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NH4GA	32534648				2023-01-03	WOS:000564628700029
J	Zhu, Z; Hua, X; Yu, Y; Zhu, P; Hong, KR; Ke, YF				Zhu, Zhe; Hua, Xin; Yu, Yong; Zhu, Pan; Hong, Kairui; Ke, Yefang			Effect of red blood cell transfusion on the development of retinopathy of prematurity: A systematic review and meta-analysis	PLOS ONE			English	Review							POSTNATAL RISK-FACTORS; BIRTH-WEIGHT INFANTS; PRETERM INFANTS; COMPLICATIONS; FREQUENCY; OUTCOMES; UNIT	Background The effect of red blood cell (RBC) transfusion on retinopathy of prematurity (ROP) is difficult to establish, because ROP may also be influenced by other factors. Therefore, we carried out a systematic review and meta-analysis to explore the relationship between RBC transfusion and the development of ROP. Methods The PubMed, Embase, Cochrane Library and Web of Science databases were searched from their inception to September 1, 2019. Observational studies that reported the relationship between RBC transfusion and ROP after adjusting for other potential risk factors were included. The combined result was analyzed by a random effect model. Heterogeneity and publication bias were tested, and sensitivity analysis was performed. Results Of the 2628 identified records, 18 studies including 15072 preterm infants and 5620 cases of ROP were included. A random effect model was used and revealed that RBC transfusion was significantly associated with ROP (pooled OR = 1.50, 95% CI: 1.27-1.76), with moderate heterogeneity among the included studies (I-2 = 44.2%). Subgroup analysis indicated that RBC transfusion was more closely related to ROP in the group with a gestational age (GA) <= 32 weeks (OR = 1.77, 95% CI: 1.29-2.43) but not in the groups with a GA <= 34 weeks (OR = 1.36, 95% CI: 0.85-2.18) or a GA <37 weeks (OR = 1.25, 95% CI: 0.86-1.82). No obvious publication bias was found based on the funnel plot and Egger's test. Removing any single study did not significantly alter the combined result in the sensitivity analysis. Conclusions Our study revealed that RBC transfusion is an independent risk factor for the development of ROP, especially in younger preterm infants. However, there seemed to be no evidence to support an effect of RBC transfusion on ROP in older groups. Further studies addressing this issue in older preterm neonates are warranted.	[Zhu, Zhe; Yu, Yong; Hong, Kairui] Univ Chinese Acad Sci, Hwa Mei Hosp, Dept Blood Transfus, Ningbo, Zhejiang, Peoples R China; [Zhu, Zhe; Hua, Xin; Yu, Yong; Hong, Kairui] Univ Chinese Acad Sci, Ningbo Inst life & Hlth Ind, Ningbo, Zhejiang, Peoples R China; [Hua, Xin] Univ Chinese Acad Sci, Hwa Mei Hosp, Dept Clin Lab, Ningbo, Zhejiang, Peoples R China; [Zhu, Pan] Ningbo Women & Childrens Hosp, Neonatal Intens Care Unit, Ningbo, Zhejiang, Peoples R China; [Ke, Yefang] Ningbo Women & Childrens Hosp, Dept Clin Lab, Ningbo, Zhejiang, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS	Ke, YF (corresponding author), Ningbo Women & Childrens Hosp, Dept Clin Lab, Ningbo, Zhejiang, Peoples R China.	173359932@qq.com		Ke, Yefang/0000-0003-0004-4583				Akcakaya AA, 2012, J PEDIAT OPHTH STRAB, V49, P21, DOI 10.3928/01913913-20110208-01; Akkawi MT, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1180-4; [Anonymous], 2001, NATURENS VERDEN, V84, pi; Bianchi M, 2015, NEONATOLOGY, V107, P81, DOI 10.1159/000368296; Christensen RD, 2014, TRANSFUSION, V54, P960, DOI 10.1111/trf.12510; Crawford TM, 2019, J PAEDIATR CHILD H, V55, P387, DOI 10.1111/jpc.14402; El Din ZME, 2015, INDIAN J PEDIATR, V82, P80, DOI 10.1007/s12098-014-1525-1; Figueras-Aloy J, 2010, AN PEDIATR, V73, P327, DOI 10.1016/j.anpedi.2010.09.001; Fortes JB, 2011, J PEDIATR-US, V158, P372, DOI 10.1016/j.jpeds.2010.08.051; Ghirardello S, 2017, AM J PERINAT, V34, P88, DOI 10.1055/s-0036-1584300; Hartnett ME, 2017, SURV OPHTHALMOL, V62, P257, DOI 10.1016/j.survophthal.2016.12.004; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Howarth C, 2018, NEONATOLOGY, V114, P7, DOI 10.1159/000486584; Huang HC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143248; Inder TE, 1997, J PEDIATR-US, V131, P541, DOI 10.1016/S0022-3476(97)70058-1; Isaza G, 2013, J PEDIAT OPHTH STRAB, V50, P27, DOI 10.3928/01913913-20121127-02; Kim SJ, 2018, SURV OPHTHALMOL, V63, P618, DOI 10.1016/j.survophthal.2018.04.002; Kim T, 2004, PAEDIATR PERINAT EP, V18, P130, DOI 10.1111/j.1365-3016.2003.00545.x; Kotowski M, 2017, J PHYSIOL PHARMACOL, V68, P921; Kucukevcilioglu M, 2013, TURKISH J PEDIATR, V55, P467; Ludwig CA, 2017, OSLI RETINA, V48, P553, DOI 10.3928/23258160-20170630-06; March MI, 2013, J PERINATOL, V33, P763, DOI 10.1038/jp.2013.70; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Mutlu FM, 2008, J PEDIAT OPHTH STRAB, V45, P291, DOI 10.3928/01913913-20080901-12; Pinheiro AM, 2009, ARQ BRAS OFTALMOL, V72, P451, DOI 10.1590/S0004-27492009000400005; Rabe H, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003248.pub3, 10.1002/14651858.CD003248.pub4]; Rao KA, 2013, INDIAN J OPHTHALMOL, V61, P640, DOI 10.4103/0301-4738.119347; Sathar A, 2018, CLIN EPIDEMIOL GLOB, V6, P44, DOI 10.1016/j.cegh.2017.02.002; Shulman JP, 2017, JAMA OPHTHALMOL, V135, P947, DOI 10.1001/jamaophthalmol.2017.2697; Strauss RG, 2010, BLOOD REV, V24, P221, DOI 10.1016/j.blre.2010.08.001; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Stutchfield CJ, 2017, EYE, V31, P1451, DOI 10.1038/eye.2017.76; The Lancet Planetary Health, 2017, LANCET PLANET HLTH, V1, pe209; Thomas K, 2015, J Neonatal Perinatal Med, V8, P207, DOI 10.3233/NPM-15814128; Tunay ZO, 2016, AM J OPHTHALMOL, V168, P201, DOI 10.1016/j.ajo.2016.05.022; Whyte R, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000512.pub2; Wu T, 2018, INVEST OPHTH VIS SCI, V59, P757, DOI 10.1167/iovs.17-23158; Yau GSK, 2016, ASIA-PAC J OPHTHALMO, V5, P185, DOI 10.1097/APO.0000000000000167; Yum SK, 2016, PEDIATR INT, V58, P1158, DOI 10.1111/ped.12996; Zarei M, 2019, J OPHTHAL VIS RES, V14, P291, DOI 10.18502/jovr.v14i3.4785; Zhu Li, 2011, Zhonghua Yi Xue Za Zhi, V91, P1749	41	12	12	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2020	15	6							e0234266	10.1371/journal.pone.0234266	http://dx.doi.org/10.1371/journal.pone.0234266			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ0RE	32512582	gold, Green Published			2023-01-03	WOS:000540938100042
J	del Amo, J; Polo, R; Moreno, S; Diaz, A; Martinez, E; Arribas, JR; Jarrin, I; Hernan, MA				del Amo, Julia; Polo, Rosa; Moreno, Santiago; Diaz, Asuncion; Martinez, Esteban; Ramon Arribas, Jose; Jarrin, Inma; Hernan, Miguel A.		Spanish HIV COVID-19 Collaboration	Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy A Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							INFECTION; AGE	Background: The incidence and severity of coronavirus disease 2019 (COVID-19) among HIV-positive persons receiving anti-retroviral therapy (ART) have not been characterized in large populations. Objective: To describe the incidence and severity of COVID-19 by nucleos(t)ide reverse transcriptase inhibitor (NRTI) use among HIV-positive persons receiving ART. Design: Cohort study. Setting: HIV clinics in 60 Spanish hospitals between 1 February and 15 April 2020. Participants: 77 590 HIV-positive persons receiving ART. Measurements: Estimated risks (cumulative incidences) per 10 000 persons and 95% CIs for polymerase chain reaction-confirmed COVID-19 diagnosis, hospitalization, intensive care unit (ICU) admission, and death. Risk and 95% CIs for COVID-19 diagnosis and hospital admission by use of the NRTIs tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), tenofovir alafen-amide (TAF)/FTC, abacavir (ABC)/lamivudine (3TC), and others were estimated through Poisson regression models. Results: Of 77 590 HIV-positive persons receiving ART, 236 were diagnosed with COVID-19, 151 were hospitalized, 15 were admitted to the ICU, and 20 died. The risks for COVID-19 diag-nosis and hospitalization were greater in men and persons older than 70 years. The risk for COVID-19 hospitalization was 20.3 (95% CI, 15.2 to 26.7) among patients receiving TAF/FTC, 10.5 (CI, 5.6 to 17.9) among those receiving TDF/FTC, 23.4 (CI, 17.2 to 31.1) among those receiving ABC/3TC, and 20.0 (CI, 14.2 to 27.3) for those receiving other regimens. The corresponding risks for COVID-19 diagnosis were 39.1 (CI, 31.8 to 47.6), 16.9 (CI, 10.5 to 25.9), 28.3 (CI, 21.5 to 36.7), and 29.7 (CI, 22.6 to 38.4), respectively. No patient receiving TDF/FTC was admitted to the ICU or died. Limitation: Residual confounding by comorbid conditions cannot be completely excluded. Conclusion: HIV-positive patients receiving TDF/FTC have a lower risk for COVID-19 and related hospitalization than those receiving other therapies. These findings warrant further investigation in HIV preexposure prophylaxis studies and randomized trials in persons without HIV.	[del Amo, Julia; Polo, Rosa] Minist Hlth, Natl Plan AIDS, Paseo Prado 19, Madrid 28004, Spain; [Moreno, Santiago] Univ Hosp Ramon Y Cajal, M-607,Km 9,100, Madrid 28034, Spain; [Diaz, Asuncion; Jarrin, Inma] Inst Hlth Carlos III, Natl Ctr Epidemiol, Av Monforte de Lemos 5, Madrid 28029, Spain; [Martinez, Esteban] Univ Hosp Clin, Carrer Villarroel 170, Barcelona 08036, Spain; [Ramon Arribas, Jose] Univ Hosp La Paz, IdiPAZ, Paseo Castellana 261, Madrid 28046, Spain; [Hernan, Miguel A.] Harvard TH Chan Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA; [Hernan, Miguel A.] Harvard Mit Div Hlth Sci & Technol, 677 Huntington Ave, Boston, MA 02115 USA	Hospital Universitario Ramon y Cajal; Hospital Universitario La Paz; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University	del Amo, J (corresponding author), Minist Hlth, Natl Plan AIDS, Paseo Prado 19, Madrid 28004, Spain.	jamo@mscbs.es; ijarrin@isciii.es	Rull, Anna/A-9438-2017; Portillo, Alexy Inciarte/AAH-1727-2022; Portillo, Alexy Inciarte/ACQ-2720-2022; Gómez, Javier/AAX-6677-2020; Pérez, Maria Ángeles Muñoz/ABH-4734-2020; Oteo, Jose A./AAB-3134-2020; Montejano, Rocio/H-5344-2017; Diaz, Asuncion/Q-6016-2017; Montero, Marta/H-7555-2017; Lopez.Cortes, Luis Fernando/S-5625-2018; Arribas, Jose/A-1595-2015; Moreno, Santiago/T-2653-2017	Rull, Anna/0000-0002-8907-7754; Portillo, Alexy Inciarte/0000-0003-1896-3457; Portillo, Alexy Inciarte/0000-0003-1896-3457; Oteo, Jose A./0000-0001-7080-6542; Montejano, Rocio/0000-0002-3446-0545; Diaz, Asuncion/0000-0002-8309-4270; Perez-Molina, Jose Antonio/0000-0001-8735-4124; Diaz-Brito, Vicens/0000-0002-9734-9334; Iniesta, Carlos/0000-0002-0928-2679; , IIS Galicia Sur/0000-0003-3812-7413; De Lazzari, Elisa/0000-0003-2614-6545; Garcia Perez, Jorge N./0000-0003-4986-6094; Martinez Sanchez, Elena Vanessa/0000-0003-1620-7113; Montero, Marta/0000-0002-3432-5394; Sanmarti Vilamala, Montserrat/0000-0002-0432-7073; Curran, Adrian/0000-0002-1263-0814; Espinosa, Nuria/0000-0003-2249-2352; Cabello-Ubeda, Alfonso/0000-0001-8429-8358; Lopez.Cortes, Luis Fernando/0000-0002-3804-3458; Arribas, Jose/0000-0002-7410-9450; Garcia de Lomas Guerrero, Jose Maria/0000-0001-8160-8488; JARRIN, INMA/0000-0002-7485-2252; Suarez-Garcia, Ines/0000-0002-7016-716X; de Lagarde, Maria/0000-0002-7712-6977; /0000-0001-7808-5479; Moreno, Santiago/0000-0002-2843-1094; Velasco Arribas, Maria/0000-0001-6554-2095; del Arco Jimenez, Alfonso/0000-0002-5432-4591; Mican, Rafael/0000-0002-6626-4266	Instituto de Salud Carlos III [COV20/01112, RD16/0002]; National Institutes of Health [R37 AI102634]	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	By grants COV20/01112 and RD16/0002 from Instituto de Salud Carlos III and grant R37 AI102634 from the National Institutes of Health.	Alejos B, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221598; Alejos B, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004727; Alvarez S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230339; Blanco JL, 2020, LANCET HIV, V7, pE314, DOI 10.1016/S2352-3018(20)30111-9; Borobia AM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061733; Chen XP, 2004, CLIN INFECT DIS, V38, P1030, DOI 10.1086/386340; Chien MC, 2020, J PROTEOME RES, V19, P4690, DOI [10.1021/acs.jproteome.0c00392, 10.1101/2020.03.18.997585]; Cottrell ML, 2017, J ANTIMICROB CHEMOTH, V72, P1731, DOI 10.1093/jac/dkx064; Deeks SG, 2011, ANNU REV MED, V62, P141, DOI 10.1146/annurev-med-042909-093756; Desai Seema, 2010, Curr HIV/AIDS Rep, V7, P4, DOI 10.1007/s11904-009-0038-4; Di Mascio M, 2009, ANTIMICROB AGENTS CH, V53, P4086, DOI 10.1128/AAC.00419-09; Elfiky AA, 2020, LIFE SCI, V253, DOI 10.1016/j.lfs.2020.117592; Elfiky AA, 2020, LIFE SCI, V248, DOI 10.1016/j.lfs.2020.117477; European Centre for Disease Prevention and Control, HIV AIDS SURVEILLANC; European Medicines Agency Committee for Medicinal Products for Human Use, 2020, ASSESSMENT REPORT VE; Government of Spain Ministry of Health, 2020, HOSPITAL SURVEY OF P; Government of Spain Ministry of Health, 2020, COVID 19 SITUATION I; Government of Spain Ministry of Health Alerts and Emergencies Coordination Center, 2019, SCIENTIFIC AND TECHN; Government of Spain National Center of Epidemiology-Institute of Health Carlos III/National AIDS Plan-Subdirectorate General Directorate of Public Health Quality and Innovation, 2016, ESTIMATES FOR HIV CO; Gross AM, 2016, MOL CELL, V62, P157, DOI 10.1016/j.molcel.2016.03.019; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Guo W., 2020, SSRN ELECT J, DOI 10.2139/ssrn.3550029; Harter G, 2020, INFECTION, V48, P681, DOI 10.1007/s15010-020-01438-z; Horvath S, 2015, J INFECT DIS, V212, P1563, DOI 10.1093/infdis/jiv277; Jockusch S., 2020, TRIPHOSPHATES 2 COMP, DOI 10.1101/2020.04.03.022939; Ju J., 2020, NUCLEOTIDE ANALOGUES, DOI 10.1101/2020.01.30.927574; Kostecka P, 2012, INT IMMUNOPHARMACOL, V12, P342, DOI 10.1016/j.intimp.2011.12.005; Lipsitch M, 2015, PLOS NEGLECT TROP D, V9, DOI 10.1371/journal.pntd.0003846; Melchjorsen J, 2011, JAIDS-J ACQ IMM DEF, V57, P265, DOI 10.1097/QAI.0b013e3182185276; Park D, 2020, MBIO, V11, DOI 10.1128/mBio.03328-19; Patterson KB, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003174; Peters HL, 2015, CURR MED CHEM, V22, P3910, DOI 10.2174/0929867322666150818103624; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Sanchez-Conde M, 2019, EPIGENOMICS-UK, V11, P501, DOI 10.2217/epi-2018-0130; Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019; Twigg Homer L. III, 2010, HIV Therapy, V4, P247, DOI 10.2217/HIV.10.5; Wang WJ, 2020, CELL MOL IMMUNOL, V17, P650, DOI 10.1038/s41423-020-0447-2; World Health Organization, CORONAVIRUS DISEASE; Wu F, 2020, NATURE, V579, P265, DOI 10.1038/s41586-020-2008-3; Yang JZY, INT J INFECT DIS; Zidek Z, 2003, EUR J PHARMACOL, V475, P149, DOI 10.1016/S0014-2999(03)02110-1; Zidek Z, 2001, ANTIMICROB AGENTS CH, V45, P3381, DOI 10.1128/AAC.45.12.3381-3386.2001	42	176	177	1	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 6	2020	173	7					536	+		10.7326/M20-3689	http://dx.doi.org/10.7326/M20-3689			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX4GS	32589451	Green Published			2023-01-03	WOS:000575671400009
J	Lawes, JC; Rijksen, EJT; Brander, RW; Franklin, RC; Daw, S				Lawes, Jasmin C.; Rijksen, Eveline J. T.; Brander, Robert W.; Franklin, Richard C.; Daw, Shane			Dying to help: Fatal bystander rescues in Australian coastal environments	PLOS ONE			English	Article							RIP CURRENT FATALITIES; SEA-BREEZE; BEACHES; RESUSCITATION; DEATHS; MEN	Bystanders who drown during a rescue attempt in aquatic waterways are becoming an increasingly important issue within drowning prevention. In the Australian context, the majority of these incidents occur in coastal water ways. This study documents and characterizes bystander rescuer fatalities within Australian coastal waterways that occurred between 1 July 2004 and 30 June 2019 in order to provide suggestions for future public safety interventions involving bystander rescuers. Data was sourced through Surf Life Saving Australia's (SLSA) Coastal Fatality Database, which collates information from multiple sources. Sixty-seven bystander rescuer fatalities in coastal waterways were reported during the 15-year period, an average of 4.5 per year, which is a significant proportion of the five fatalities previously reported across all Australian waterways. The majority of coastal bystander rescuer fatality incidents occurred in the state of New South Wales (49%), at beaches (64%), in regional or remote areas (71%), more than 1 km from the nearest lifesaving service (78%), during summer (45%), in the afternoon (72%), in the presence of rip currents (73%), and did not involve the use of flotation devices to assist rescue (97%). The majority of coastal bystander rescuer victims were Australian residents (88%) born in Australia/Oceania (68%), males (81%), aged between 30-44 years old (36%), visitors to the location (55%), either family (69%) or friends (15%) of the rescuee(s), and were attempting to rescue someone younger than 18 years old (64%). Our results suggest future safety intervention approaches should target males, parents and carers visiting beach locations in regional locations during holiday times and should focus on the importance of flotation devices when enacting a rescue and further educating visitors about the rip current hazard. Future research should examine the psychology of bystander rescue situations and evaluate the effectiveness of different safety intervention approaches.	[Lawes, Jasmin C.; Rijksen, Eveline J. T.; Daw, Shane] Surf Life Saving Australia, Sydney, NSW, Australia; [Lawes, Jasmin C.; Brander, Robert W.] UNSW Sydney, Sch Biol Earth & Environm Sci, Sydney, NSW, Australia; [Lawes, Jasmin C.; Franklin, Richard C.] James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, Australia	University of New South Wales Sydney; James Cook University	Lawes, JC (corresponding author), Surf Life Saving Australia, Sydney, NSW, Australia.; Lawes, JC (corresponding author), UNSW Sydney, Sch Biol Earth & Environm Sci, Sydney, NSW, Australia.; Lawes, JC (corresponding author), James Cook Univ, Coll Publ Hlth Med & Vet Sci, Townsville, Qld, Australia.	jlawes@slsa.asn.au	Brander, Robert/GZH-3081-2022; Lawes, Jasmin/S-2025-2019	Lawes, Jasmin/0000-0002-6652-3053; Daw, Shane/0000-0003-0904-3632; Brander, Robert/0000-0002-7268-2587				Arozarena I, 2015, NAT HAZARDS, V77, P753, DOI 10.1007/s11069-015-1626-9; Attard A, 2015, ACCIDENT ANAL PREV, V82, P70, DOI 10.1016/j.aap.2015.05.017; Australia RLSS, 2019, ROYAL LIF SAV NAT DR; Australian Bureau of Statistics, 2019, AUSTR DEM STAT; Barlas B, 2016, NAT HAZARDS, V80, P811, DOI 10.1007/s11069-015-1998-x; Brander RW, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212349; Brannstrom C, 2015, APPL GEOGR, V56, P61, DOI 10.1016/j.apgeog.2014.10.011; Brighton B, 2013, NAT HAZARD EARTH SYS, V13, P1069, DOI 10.5194/nhess-13-1069-2013; Brookes A., 2004, AUSTR J OUTDOOR ED, V8, P44; Castelle B, 2016, EARTH-SCI REV, V163, P1, DOI 10.1016/j.earscirev.2016.09.008; Cooney N., 2019, COASTAL SAFETY BRIEF; Franklin R, 2014, DROWNING PREVENTION, P419; Franklin RC, 2010, INJURY PREV, V16, pA81, DOI 10.1136/ip.2010.029215.294; Franklin RC, 2019, AUST NZ J PUBL HEAL, V43, P477, DOI 10.1111/1753-6405.12900; Franklin RC, 2011, J PAEDIATR CHILD H, V47, P44, DOI 10.1111/j.1440-1754.2010.01889.x; French MT, 2015, ECON INQ, V53, P745, DOI 10.1111/ecin.12157; Gensini VA, 2010, NAT HAZARDS, V54, P159, DOI 10.1007/s11069-009-9458-0; Health AGDo, 2019, DOCT LOC 2016; Houser C, 2017, NAT HAZARD EARTH SYS, V17, P1003, DOI 10.5194/nhess-17-1003-2017; Howland J, 1996, AM J PUBLIC HEALTH, V86, P93, DOI 10.2105/AJPH.86.1.93; Leggat PA, 2009, J TRAVEL MED, V16, P243, DOI 10.1111/j.1708-8305.2009.00302.x; Mackie IJ, 1999, MED J AUSTRALIA, V171, P587, DOI 10.5694/j.1326-5377.1999.tb123808.x; Masselink G, 1998, MAR GEOL, V146, P115, DOI 10.1016/S0025-3227(97)00121-7; Masselink G, 2001, J COASTAL RES, V17, P173; Matthews B, 2014, SAFETY SCI, V62, P312, DOI 10.1016/j.ssci.2013.09.003; McCool J.P., 2008, INT J AQUAT RES ED, V1, P7, DOI [10.25035/ijare.02.01.02, DOI 10.25035/IJARE.02.01.02]; McKay C, 2014, TOURISM MANAGE, V45, P71, DOI 10.1016/j.tourman.2014.03.007; Menard AD, 2018, NAT HAZARDS, V94, P953, DOI 10.1007/s11069-018-3424-7; Moran K, 2010, INT J AQUAT RES ED, V4, P115, DOI [10.25035/ijare.04.02.03, DOI 10.25035/IJARE.04.02.03]; Moran K., 2013, INT J AQUAT RES ED, V7, P290; Moran K, 2017, INT J INJ CONTROL SA, V24, P396, DOI 10.1080/17457300.2016.1224904; Moran K, 2011, ANN LEIS RES, V14, P260, DOI 10.1080/11745398.2011.615719; Optimal therapy report, 2009, CAN AGENCY DRUGS TEC, V3, pe0101; Orlowski JP, 2001, PEDIATR CLIN N AM, V48, P627, DOI 10.1016/S0031-3955(05)70331-X; Pearn JH, 2012, INT J AQUAT RES ED, V6, DOI 10.25035/ijare.06.04.07; Pearn JH., 2009, INT J AQUAT RES ED, V3, DOI [10.25035/ijare.03.03.09, DOI 10.25035/IJARE.03.03.09]; Peden AE, 2020, J PAEDIATR CHILD H, V56, P450, DOI 10.1111/jpc.14668; Peden AE, 2018, BMC PUBLIC HEALTH, V18, DOI 10.1186/s12889-018-6256-1; Pidgeon S., 2018, 10 YEAR NATL STUDY O; Short AD, 2007, J COASTAL RES, P7; Short AD, 2007, AUSTR BEACH SAFETY M; SK AZ, 2016, DIABETOLOGIE STOFFWE, V11, pS01; SLSA, 2019, NAT COAST SAF REP; SLSA, 2016, NAT COAST SAF REP 20; Surf Life Saving Australia (SLSA), 2018, NAT COAST SAF REP 20; Szpilman D, 2014, RESUSCITATION, V85, P1149, DOI 10.1016/j.resuscitation.2014.05.034; Turgut A, 2012, J SAFETY RES, V43, P129, DOI 10.1016/j.jsr.2012.05.001; Venema AM, 2010, RESUSCITATION, V81, P434, DOI 10.1016/j.resuscitation.2010.01.005; WHO, 2020, DROWN FACT SHEET WHO; Wilks J., 2003, J HOSP TOUR MANAG, V10, P79; Willcox-Pidgeon SM, 2020, INJURY PREVENTION; World Health Organization, 2014, GLOBAL REPORT DROWNI; World Health Organization, 2017, PREV DROWN IMPL GUID; 2015, SEWAGE DISPOSAL CLOV, V0015, pE631	54	14	14	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2020	15	9							e0238317	10.1371/journal.pone.0238317	http://dx.doi.org/10.1371/journal.pone.0238317			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU5BZ	32936817	gold, Green Published, Green Accepted			2023-01-03	WOS:000573658000010
J	Bongiovanni, D; Tosello, V; Saccomani, V; Dalla Santa, S; Amadori, A; Zanovello, P; Piovan, E				Bongiovanni, Deborah; Tosello, Valeria; Saccomani, Valentina; Dalla Santa, Silvia; Amadori, Alberto; Zanovello, Paola; Piovan, Erich			Crosstalk between Hedgehog pathway and the glucocorticoid receptor pathway as a basis for combination therapy in T-cell acute lymphoblastic leukemia	ONCOGENE			English	Article							FLOOR PLATE; TRANSCRIPTION; ACTIVATION; MECHANISM; AGONISTS; ROLES; GLI2; HES1	Notwithstanding intensified therapy, a considerable fraction of T-cell acute lymphoblastic leukemia (T-ALL) patients face a dismal prognosis due to primary resistance to treatment and relapse, raising the need for more efficient and targeted therapies. Hedgehog (HH) signaling is a major developmental pathway frequently deregulated in cancer, for which a role in T-ALL is emerging. Mounting evidence suggests that ligand-independent activation of HH pathway occurs in cancer including T-ALL, emphasizing the necessity of dissecting the complex interplay between HH and other signaling pathways regulating activation. In this work, we present a therapeutically relevant crosstalk between HH signaling and the glucocorticoid receptor (NR3C1) pathway acting at the level of GLI1 transcription factor. GLI inhibitor GANT61 and dexamethasone were shown to exert a synergistic anti-leukemic effect in vitro in T-ALL cell lines and patient-derived xenografts. Mechanistically, dexamethasone-activated NR3C1 impaired GLI1 function by dynamically modulating the recruitment of PCAF acetyltransferase and HDAC1 deacetylase. Increased GLI1 acetylation was associated with compromised transcriptional activity and reduced protein stability. In summary, our study identifies a novel crosstalk between GLI1 and NR3C1 signaling pathway which could be exploited in HH-dependent malignancies to increase therapeutic efficacy.	[Bongiovanni, Deborah; Saccomani, Valentina; Dalla Santa, Silvia; Amadori, Alberto; Zanovello, Paola; Piovan, Erich] Univ Padua, Dipartimento Sci Chirurg Oncol & Gastroenterol, Padua, Italy; [Tosello, Valeria; Amadori, Alberto; Piovan, Erich] Ist Oncol Veneto IOV IRCCS, UOC Immunol & Diagnost Mol Oncol, Padua, Italy	University of Padua; IRCCS Istituto Oncologico Veneto (IOV)	Piovan, E (corresponding author), Univ Padua, Dipartimento Sci Chirurg Oncol & Gastroenterol, Padua, Italy.; Piovan, E (corresponding author), Ist Oncol Veneto IOV IRCCS, UOC Immunol & Diagnost Mol Oncol, Padua, Italy.	erich.piovan@unipd.it	Piovan, Erich/L-1444-2016	Piovan, Erich/0000-0002-4241-563X; Bongiovanni, Deborah/0000-0001-8693-4776	Italian Foundation for Cancer Research (Fondazione AIRC) [22233]; Progetto di Ricerca di Ateneo (Universita di Padova) [SID19_01]; Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR); Istituto Oncologico Veneto 5 x 1000 fund	Italian Foundation for Cancer Research (Fondazione AIRC); Progetto di Ricerca di Ateneo (Universita di Padova); Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR)(Ministry of Education, Universities and Research (MIUR)); Istituto Oncologico Veneto 5 x 1000 fund	This work was supported by the Italian Foundation for Cancer Research (Fondazione AIRC) grants to EP (IG2018#22233); Progetto di Ricerca di Ateneo (SID19_01; Universita di Padova) to EP. Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR) Ex 60% to EP; Istituto Oncologico Veneto 5 x 1000 fund to EP.	Amakye D, 2013, NAT MED, V19, P1410, DOI 10.1038/nm.3389; Belver L, 2016, NAT REV CANCER, V16, P494, DOI 10.1038/nrc.2016.63; Burns MA, 2018, LEUKEMIA, V32, P2126, DOI 10.1038/s41375-018-0097-x; Canettieri G, 2010, NAT CELL BIOL, V12, P132, DOI 10.1038/ncb2013; Chiang MY, 2008, J CLIN INVEST, V118, P3181, DOI 10.1172/JCI35090; Coni S, 2017, SCI REP-UK, V7, DOI 10.1038/srep44079; Coni S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065718; Crompton T, 2007, NAT REV IMMUNOL, V7, P726, DOI 10.1038/nri2151; Dagklis A, 2016, BLOOD, V128, P2642, DOI 10.1182/blood-2016-03-703454; Dagklis A, 2015, HAEMATOLOGICA, V100, pE102, DOI 10.3324/haematol.2014.119248; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Dierks C, 2007, NAT MED, V13, P944, DOI 10.1038/nm1614; Ding Q, 1998, DEVELOPMENT, V125, P2533; Fuccillo M, 2006, NAT REV NEUROSCI, V7, P772, DOI 10.1038/nrn1990; Gallet A, 2011, TRENDS CELL BIOL, V21, P238, DOI 10.1016/j.tcb.2010.12.005; Gruber W, 2018, INT J CANCER, V142, P968, DOI 10.1002/ijc.31117; Gulino A, 2012, VITAM HORM, V88, P211, DOI 10.1016/B978-0-12-394622-5.00009-2; Hegde GV, 2008, MOL CANCER RES, V6, P1928, DOI 10.1158/1541-7786.MCR-08-0142; Heine VM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002731; Heine VM, 2009, J CLIN INVEST, V119, P267, DOI 10.1172/JCI36376; HOECK W, 1989, J BIOL CHEM, V264, P14396; Hou XM, 2014, BIOCHIMIE, V101, P50, DOI 10.1016/j.biochi.2013.12.019; Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972; Inaba H, 2010, LANCET ONCOL, V11, P1096, DOI 10.1016/S1470-2045(10)70114-5; Ingram WJ, 2008, ONCOGENE, V27, P1489, DOI 10.1038/sj.onc.1210767; Kassel O, 2007, MOL CELL ENDOCRINOL, V275, P13, DOI 10.1016/j.mce.2007.07.003; Malatesta M, 2013, CANCER RES, V73, P6323, DOI 10.1158/0008-5472.CAN-12-4660; Matise MP, 1998, DEVELOPMENT, V125, P2759; Newton R, 2007, MOL PHARMACOL, V72, P799, DOI 10.1124/mol.107.038794; Nieuwenhuis E, 2005, CLIN GENET, V67, P193, DOI 10.1111/j.1399-0004.2004.00360.x; Niewiadomski P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020147; Pak E, 2016, DEV CELL, V38, P333, DOI 10.1016/j.devcel.2016.07.026; Pandolfi S, 2015, EXPERT REV MOL MED, V17, DOI 10.1017/erm.2015.3; Persson M, 2002, GENE DEV, V16, P2865, DOI 10.1101/gad.243402; Petrova R, 2014, DEVELOPMENT, V141, P3445, DOI 10.1242/dev.083691; Pietrobono S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00556; Ramsbottom SA, 2016, J DEV BIOL, V4, DOI 10.3390/jdb4030023; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Rubin LL, 2006, NAT REV DRUG DISCOV, V5, P1026, DOI 10.1038/nrd2086; SCHMIDT TJ, 1994, RECEPTOR, V4, P229; Schrappe M, 2011, BLOOD, V118, P2077, DOI 10.1182/blood-2011-03-338707; Schreck KC, 2010, CLIN CANCER RES, V16, P6060, DOI 10.1158/1078-0432.CCR-10-1624; Schwartz JR, 2010, MOL CELL ENDOCRINOL, V320, P76, DOI 10.1016/j.mce.2010.02.014; Tosello V, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7100160; Wang JB, 2011, VITAM HORM, V87, P207, DOI 10.1016/B978-0-12-386015-6.00030-5; Wang JB, 2010, P NATL ACAD SCI USA, V107, P9323, DOI 10.1073/pnas.0910712107; Wang Y, 2012, CHEM BIOL, V19, P972, DOI 10.1016/j.chembiol.2012.06.012; Wu FJ, 2017, CELL CHEM BIOL, V24, P252, DOI 10.1016/j.chembiol.2017.02.010; Ying LT, 2000, NAT NEUROSCI, V3, P979, DOI 10.1038/79916	49	4	4	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2020	39	42					6544	6555		10.1038/s41388-020-01453-2	http://dx.doi.org/10.1038/s41388-020-01453-2		SEP 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA9HI	32917954	Green Published			2023-01-03	WOS:000568475200003
J	Hartman, CJ; Mester, JC; Hare, PM; Cohen, AI				Hartman, Colin J.; Mester, Joseph C.; Hare, Patrick M.; Cohen, Alan, I			Novel inactivation of the causative fungal pathogen of white-nose syndrome with methoxsalen plus ultraviolet A or B radiation	PLOS ONE			English	Article							PSORIASIS; PSORALEN; THERAPY; UVA; PHOTOCHEMOTHERAPY; FUROCOUMARINS; IRRADIATION; BACTERIA	White-nose syndrome is a fungal disease responsible for the rapid decline of North American bat populations. This study addressed a novel method for inactivatingPseudogymnoascus destructans, the causative agent of WNS, using ultraviolet A (UVA) or B (UVB) radiation in combination with methoxsalen, a photosensitizer from the furanocoumarin family of compounds. Fungal spore suspensions were diluted in micromolar concentrations of methoxsalen (50-500 mu M), then exposed to fixed doses of UVA radiation (500-5000 mJ/cm(2)), followed by plating on germination media. These plates were examined for two to four weeks for evidence of spore germination or inactivation, along with resultant growth or inhibition ofP.destructanscolonies. Pretreatment of fungal spores with low doses of methoxsalen resulted in a UVA dose-dependent inactivation of theP.destructansspores. All doses of methoxsalen paired with 500 mJ/cm(2) of UVA led to an approximate two-log(10)(similar to 99%) reduction in spore viability, and when paired with 1000 mJ/cm(2), a four-log(10) or greater (>99.99%) reduction in spore viability was observed. Additionally, actively growingP.destructanscolonies treated directly with methoxsalen and either UVA or UVB radiation demonstrated UV dose-dependent inhibition and termination of colony growth. This novel approach of using a photosensitizer in combination with UV radiation to control fungal growth may have broad, practical application in the future.	[Hartman, Colin J.; Mester, Joseph C.; Cohen, Alan, I] Northern Kentucky Univ, Dept Biol Sci, Highland Hts, KY 41099 USA; [Hare, Patrick M.] Northern Kentucky Univ, Dept Chem & Biochem, Highland Hts, KY USA	Northern Kentucky University; Northern Kentucky University	Mester, JC (corresponding author), Northern Kentucky Univ, Dept Biol Sci, Highland Hts, KY 41099 USA.	mesterj1@nku.edu			Northern Kentucky University Research Foundation Award SL2017; Dorothy Westerman Herrmann Undergraduate Research Award; Student Undergraduate Research and Creative Activity Award	Northern Kentucky University Research Foundation Award SL2017; Dorothy Westerman Herrmann Undergraduate Research Award; Student Undergraduate Research and Creative Activity Award	This work was funded by a Dorothy Westerman Herrmann Undergraduate Research Award to CJH, a Student Undergraduate Research and Creative Activity Award to CJH, and a Northern Kentucky University Research Foundation Award SL2017 (https://inside.nku.edu/gero/research/board.html) to JCM and AIC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amitay-Laish I, 2018, ACTA DERM-VENEREOL, V98, P951, DOI 10.2340/00015555-3013; [Anonymous], 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-018-0474-7; [Anonymous], 2019, CANC DISCOV, V9, pOF3, DOI 10. 1158/2159-8290. CD-NB2018-158; [Anonymous], 2012, REGEN MED S3, V7, pS14; [Anonymous], 2014, CANC DISCOV, V4, pOF1; Archier E, 2012, J EUR ACAD DERMATOL, V26, P11, DOI 10.1111/j.1468-3083.2012.04519.x; Begum M, 2009, INT J FOOD MICROBIOL, V129, P74, DOI 10.1016/j.ijfoodmicro.2008.11.020; Bernard RF, 2019, CONSERV SCI PRACT, V1, DOI 10.1111/csp2.106; Blehert DS, 2009, SCIENCE, V323, P227, DOI 10.1126/science.1163874; BOND CA, 1981, AM J HOSP PHARM, V38, P990, DOI 10.1093/ajhp/38.7.990; Borderie F, 2014, INT BIODETER BIODEGR, V93, P118, DOI 10.1016/j.ibiod.2014.05.014; Boyce JM, 2016, ANTIMICROB RESIST IN, V5, DOI 10.1186/s13756-016-0111-x; Brasch J, 2006, MYCOSES, V49, P1, DOI 10.1111/j.1439-0507.2005.01169.x; Camp RJ, 2019, CONDOR, V121, DOI 10.1093/condor/duz007; Cryan PM, 2010, BMC BIOL, V8, DOI 10.1186/1741-7007-8-135; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; de Menezes HD, 2014, J PHOTOCH PHOTOBIO B, V131, P74, DOI 10.1016/j.jphotobiol.2014.01.008; Dunnick JK, 1989, 359 NTP TR; Eichenfield LF, 2014, J AM ACAD DERMATOL, V70, P338, DOI 10.1016/j.jaad.2013.10.010; Eskew EA, 2013, EMERG INFECT DIS, V19, P379, DOI 10.3201/eid1093.120707; Frank CL, 2019, FRONT ZOOL, V16, DOI 10.1186/s12983-019-0340-y; Gasparro F P, 2000, Am J Clin Dermatol, V1, P337, DOI 10.2165/00128071-200001060-00002; GIBBS NK, 1988, J PHOTOCH PHOTOBIO B, V2, P109, DOI 10.1016/1011-1344(88)85040-1; Goodrich S, 2017, KENT AC SCI ANN M MU; Gorgus E, 2010, FOOD CHEM TOXICOL, V48, P93, DOI 10.1016/j.fct.2009.09.021; Grossweiner L I, 1984, Natl Cancer Inst Monogr, V66, P47; Grundmann-Kollmann M, 2002, BRIT J CLIN PHARMACO, V54, P535, DOI 10.1046/j.1365-2125.2002.01692.x; HAMERSKI D, 1988, EUR J BIOCHEM, V171, P369, DOI 10.1111/j.1432-1033.1988.tb13800.x; Hartman C, 2017, KENT AC SCI ANN M MU; HEARST JE, 1984, Q REV BIOPHYS, V17, P1, DOI 10.1017/S0033583500005242; Hermanson GT, 2013, BIOCONJUGATE TECHNIQUES, 3RD EDITION, P1, DOI 10.1016/B978-0-12-382239-0.00001-7; Holden WM, 2014, FUNGAL BIOL-UK, V118, P48, DOI 10.1016/j.funbio.2013.11.001; Serrano-Perez JJ, 2008, J PHYS CHEM B, V112, P14002, DOI 10.1021/jp805523d; Kim DK, 2018, APPL ENVIRON MICROB, V84, DOI 10.1128/AEM.01340-18; Kitamura N, 2005, J PHOTOCH PHOTOBIO C, V6, P168, DOI 10.1016/j.jphotochemrev.2005.08.002; Lai CF, 2008, ANAL CHEM, V80, P8790, DOI 10.1021/ac801520m; Loope L., 2016, GUIDANCE DOCUMENT RA; LOWE NJ, 1986, J AM ACAD DERMATOL, V14, P754, DOI 10.1016/S0190-9622(86)70089-3; Marroquin CM, 2017, NORTHEAST NAT, V24, P54, DOI 10.1656/045.024.0105; Martel A, 2020, CONSERV LETT, V13, DOI 10.1111/conl.12707; Meteyer CU, 2012, VIRULENCE, V3, P583, DOI 10.4161/viru.22330; Mustapha A, 2018, AM J INFECT CONTROL, V46, P584, DOI [10.1016/j.ajic.2017.10.025, 10.1016/j.ajic.2017.09.019]; Nguyen MN, 2010, PLOS ONE, V5, pe9907; OGINSKY EL, 1959, J BACTERIOL, V78, P821, DOI 10.1128/JB.78.6.821-833.1959; Oxsoralen-Ultra (Methoxsalen Capsules): Uses Dosage Side Effects Interactions Warning [Internet], OXS ULTR METH CAPS U; Palmer JM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02441-z; PARRISH JA, 1974, NEW ENGL J MED, V291, P1207, DOI 10.1056/NEJM197412052912301; PARSONS BJ, 1980, PHOTOCHEM PHOTOBIOL, V32, P813, DOI 10.1111/j.1751-1097.1980.tb04061.x; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; PubChem, PSOR; PubChem, SOD HYP; PubChem, 8 METH; Schmidt BR, 2009, AMPHIBIA-REPTILIA, V30, P313, DOI 10.1163/156853809788795245; Silva EBF, 2014, J PHOTOCH PHOTOBIO B, V130, P260, DOI 10.1016/j.jphotobiol.2013.11.012; Silva OP, 2015, PHARMACOGN MAG, V11, P170, DOI 10.4103/0973-1296.149734; STERN RS, 1991, ARCH DERMATOL, V127, P347, DOI 10.1001/archderm.127.3.347; Stern RS, 1997, NEW ENGL J MED, V336, P1041, DOI 10.1056/NEJM199704103361501; Timonen JM, 2018, J HETEROCYCLIC CHEM, V55, P2590, DOI 10.1002/jhet.3318; Turner GG, 2014, J WILDLIFE DIS, V50, P566, DOI 10.7589/2014-03-058; Valenzuela-Sanchez A, 2018, TRANSBOUND EMERG DIS, V65, P309, DOI 10.1111/tbed.12775; Verant Michelle L., 2014, BMC Physiology, V14, P10, DOI 10.1186/s12899-014-0010-4; Veras L, 2016, ASIA-PAC J CLIN ONCO, V12, pe196, DOI 10.1111/ajco.12129; Wentworth A, 2019, ASS SE BIOL ANN M ME; WHO, 2006, COMP DRINK WAT QUAL, P39; WHO, WHO UV RAD; Wibbelt G, 2010, EMERG INFECT DIS, V16, P1237, DOI 10.3201/eid1608.100002; Wolf P, 2016, BRIT J DERMATOL, V174, P11, DOI 10.1111/bjd.14341; Woodhams DC, 2012, DIS AQUAT ORGAN, V98, P11, DOI 10.3354/dao02429; Xiao Y, 2018, WATER RES, V141, P279, DOI 10.1016/j.watres.2018.05.021	69	2	3	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2020	15	9							e0239001	10.1371/journal.pone.0239001	http://dx.doi.org/10.1371/journal.pone.0239001			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR9MU	32915896	gold, Green Published			2023-01-03	WOS:000571887500082
J	Kuragano, T; Joki, N; Hase, H; Kitamura, K; Murata, T; Fujimoto, S; Fukatsu, A; Inoue, T; Itakura, Y; Nakanishi, T				Kuragano, Takahiro; Joki, Nobuhiko; Hase, Hiroki; Kitamura, Kenichiro; Murata, Toshiaki; Fujimoto, Shouichi; Fukatsu, Atushi; Inoue, Toru; Itakura, Yukihiro; Nakanishi, Takeshi			Low transferrin saturation (TSAT) and high ferritin levels are significant predictors for cerebrovascular and cardiovascular disease and death in maintenance hemodialysis patients	PLOS ONE			English	Article							FUNCTIONAL IRON-DEFICIENCY; SERUM FERRITIN; HEPCIDIN; ANEMIA; GUIDELINES; THERAPY	Patients with high serum ferritin and low transferrin saturation (TSAT) levels could be considered as presenting with dysutilization of iron for erythropoiesis. However, the long-term safety of iron administration in these patients has not been well established. An observational multicenter study was performed over 3 years. In 805 patients undergoing maintenance hemodialysis (MHD), we defined dysutilization of iron for erythropoiesis in patients with lower TSAT (<20%) and higher ferritin (>= 100 ng/mL) levels. A time-dependent Cox hazard model was used for the evaluation of the association between dysutilization of iron for erythropoiesis and adverse events and survival. Patients with low TSAT levels showed an increased risk of cerebrovascular and cardiovascular disease (CCVD) and death compared to patients with normal or higher TSAT levels. Patients with low ferritin and high TSAT levels had a significantly lower risk of CCVD and death compared with patients with high ferritin and low TSAT levels. Higher TSAT levels were associated with male gender, age, the absence of diabetes, low levels of high-sensitivity CRP, and low beta 2 microglobulin levels, but not with intravenous iron administration or ferritin levels. Although patients with low TSAT levels had a significantly higher risk of CCVD or death, high TSAT levels were not linked with iron administration. Patients, who were suspected of dysutilization of iron for erythropoiesis, had a higher risk of CCVD and death. The administration of iron should be performed cautiously for improving TSAT levels, as iron administration could sustain TSAT levels for a short term.	[Kuragano, Takahiro; Nakanishi, Takeshi] Hyogo Coll Med, Div Kidney & Dialysis, Dept Internal Med, Nisinomiya, Japan; [Joki, Nobuhiko; Hase, Hiroki] Toho Univ, Ohashi Med Ctr, Dept Nephrol, Tokyo, Japan; [Kitamura, Kenichiro] Univ Yamanashi, Fac Med, Dept Internal Med 3, Yamanashi, Japan; [Murata, Toshiaki] Murakami Karin Dou Hosp, Dept Nephrol, Fukuoka, Japan; [Fujimoto, Shouichi] Univ Miyazaki, Dept Hemovasc Med & Artificial Organs, Fac Med, Miyazaki, Japan; [Fukatsu, Atushi] Hekinan Municipal Hosp, Dept Nephrol, Hekinan, Japan; [Inoue, Toru] Yuseikai Clin, Dept Internal Med, Osaka, Japan; [Itakura, Yukihiro] Itakura Clin, Dept Internal Med, Hekinan, Japan	Hyogo College of Medicine; Toho University; University of Yamanashi; University of Miyazaki	Kuragano, T (corresponding author), Hyogo Coll Med, Div Kidney & Dialysis, Dept Internal Med, Nisinomiya, Japan.	kuragano@hyo-med.ac.jp						[Anonymous], 2014, REG ANESTH PAIN MED; Dallalio G, 2006, BLOOD, V107, P2702, DOI 10.1182/blood-2005-07-2854; Elsayed ME, 2016, ADV CLIN CHEM, V75, P71, DOI 10.1016/bs.acc.2016.03.002; Hashemi Seyed Mehdi, 2017, Int J Hematol Oncol Stem Cell Res, V11, P192; HASHEMI SM, 2017, INT J HEMATOL ONCOL, V0011, P00192; Kapoian T, 2008, J AM SOC NEPHROL, V19, P372, DOI 10.1681/ASN.2007050606; Kuragano T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147328; Kuragano T, 2014, KIDNEY INT, V86, P845, DOI 10.1038/ki.2014.114; Kuragano T, 2011, NEPHROL DIAL TRANSPL, V26, P2663, DOI 10.1093/ndt/gfq760; Kuragano T, 2010, AM J NEPHROL, V31, P534, DOI 10.1159/000312381; Li JJ, 2012, ARTERIOSCL THROM VAS, V32, P1158, DOI 10.1161/ATVBAHA.112.246108; Locatelli F, 2008, KIDNEY INT, V74, P1237, DOI 10.1038/ki.2008.299; Maruyama Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143430; Nakanishi T, 2011, NEPHROL DIAL TRANSPL, V26, P3092, DOI 10.1093/ndt/gfr410; Przybylowski P, 2016, TRANSPL P, V48, P173, DOI 10.1016/j.transproceed.2015.12.023; Stack AG, 2014, QJM-INT J MED, V107, P623, DOI 10.1093/qjmed/hcu045; Susantitaphong P, 2014, AM J NEPHROL, V39, P130, DOI 10.1159/000358336; Thomas DW, 2013, BRIT J HAEMATOL, V161, P639, DOI 10.1111/bjh.12311; Tsubakihara Y, 2010, THER APHER DIAL, V14, P240, DOI 10.1111/j.1744-9987.2010.00836.x; van der Weerd NC, 2013, NEPHROL DIAL TRANSPL, V28, P3062, DOI 10.1093/ndt/gfs488; Wish JB, 2006, CLIN J AM SOC NEPHRO, V1, pS4, DOI 10.2215/CJN.01490506; Yamamoto H., 2017, RENAL REPLACE THER, V3, P36, DOI [10.1186/s41100-017-0114-y, DOI 10.1186/S41100-017-0114-Y]	22	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2020	15	9							e0236277	10.1371/journal.pone.0236277	http://dx.doi.org/10.1371/journal.pone.0236277			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN6DP	32877424	Green Published, gold			2023-01-03	WOS:000568877100037
J	O'Connell, J; de Barra, E; McConkey, S				O'Connell, James; de Barra, Eoghan; McConkey, Samuel			Hospital inpatient care utilization among patients with tuberculosis, Republic of Ireland, 2015-2018	PLOS ONE			English	Article								Background The Republic of Ireland (ROI) has a low incidence of TB. A reform of TB services in 2003 recommended that the delivery of care to patients with TB should primarily be in the outpatient setting, with limited indications for hospitalization. Three hospitals were designated as TB centres. Our aim was to describe the utilization of hospital inpatient care by patients with TB in the ROI. Methods We searched public hospital coding data to identify discharges between 01/01/2015-31/12/18 where TB was the principal diagnosis. The cost of TB episodes of care was calculated using payment rules for public hospitals in the ROI. Results We identified 1185 discharges with TB as the principal diagnosis. Of these, 68% (801/1185) were emergency episodes of care and 32% (384/1185) were elective. We estimate that 65.1% (818/1257) patients with TB notified in the ROI from 2015 to 2018 who had an episode of care in a public hospital was 65.1% (818/1257) and that 50.8% (639/1257) of those notified had an emergency episode of care. The estimated mean annual cost of TB inpatient care per year in the ROI from 2015 to 2018 was euro2,638,828-2,955,047, with emergency episodes of care having a mean annual cost of euro2,250,926-2,557,397 per year. Conclusions The burden of TB on hospital inpatient care in the Republic of Ireland is significant.	[O'Connell, James; de Barra, Eoghan; McConkey, Samuel] Royal Coll Surgeons Ireland, Dept Int Hlth & Trop Med, Dublin, Ireland; [de Barra, Eoghan; McConkey, Samuel] Beaumont Univ Hosp, Dublin, Ireland	Royal College of Surgeons - Ireland	O'Connell, J (corresponding author), Royal Coll Surgeons Ireland, Dept Int Hlth & Trop Med, Dublin, Ireland.	jamesoconnell@rcsi.com		O'Connell, James/0000-0003-1553-4489	Royal College of Surgeons in Ireland - Royal College of Surgeons in Ireland	Royal College of Surgeons in Ireland - Royal College of Surgeons in Ireland	This study was funded by the Royal College of Surgeons in Ireland. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The salary of Dr James O'Connell was funded by the Royal College of Surgeons in Ireland.	Anderson C, 2014, THORAX, V69, P187, DOI 10.1136/thoraxjnl-2013-203751; [Anonymous], 1960, Bull World Health Organ, V23, P535; Browne NoelC., 1986, TIDE; Central Statistics Office, 2017, SURV INC LIV STAND 2; Central Statistics Office System of Health Accounts, 2017, SYST HLTH ACC ANN RE; Coker R, 1998, BRIT MED J PUBLISHIN; Comhairle na nOspideal, 2003, COMHAIRLE NOSPIDEAL; Committee NTA others, 2010, GUID PREV CONTR TUB; Davtyan K, 2015, EUR RESPIR J, V45, P289, DOI 10.1183/09031936.00118514; Deeny J, 1954, REPORT NATL TUBERCUL; Diel R, 2012, EUR RESPIR J, V40, P143, DOI 10.1183/09031936.00204611; European Centre for Disease Prevention and Control, 2018, SOC DET RISK FACT TU; Geary R, 1945, MORTALITY TUBERCULOS; Health Protection Surveillance Centre, 2017, NAT TB SURV IR; Health Protection Surveillance Centre, 2019, ANN EP REP TUB 2018; Health Protection Surveillance Centre, 2015, REP EP TUB IR; Health Protection Surveillance Centre, 2016, NAT TB SURV REP HLTH; Health Service Executive HSE PCRS, 2020, INT ADM ARR PHARM; Healthcare Pricing Office, 2019, ADM PAT PRIC LIST; Healthcare Pricing Office, 2016, NAT AUD ADM PAT INF; Healthcare Pricing Office, 2019, HOSP PAT ENQ DAT DIC; Jackson S.O'DonnellJ, 2019, TUBERCULOSIS IRELAND; Johnson H, 2017, INT J INTEGRATED CAR, V17; Lonnroth K, 1399, TUBERCULOSIS ELIMINA, P1399; Nutini S, 1999, INT J TUBERC LUNG D, V3, P985; Office of the Chief Information Officer Health Service Executive, 2015, NAT EL HLTH REC VID; Sundararajan V, 2004, J CLIN EPIDEMIOL, V57, P1288, DOI 10.1016/j.jclinepi.2004.03.012; Teljeur C, 2014, IRISH J MED SCI, V183, P207, DOI 10.1007/s11845-013-0991-1; Thomas JA, 2010, INT J TUBERC LUNG D, V14, P1603; Uplekar M, 2015, LANCET, V385, P1799, DOI 10.1016/S0140-6736(15)60570-0; World Health Organization, 1999, WHAT IS DOTS GUID UN	31	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2020	15	8							e0238142	10.1371/journal.pone.0238142	http://dx.doi.org/10.1371/journal.pone.0238142			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK7YQ	32853220	gold, Green Published			2023-01-03	WOS:000566948800066
J	Gajewski, TF; Higgs, EF				Gajewski, Thomas F.; Higgs, Emily F.			Immunotherapy with a sting	SCIENCE			English	Editorial Material							LEADS		[Gajewski, Thomas F.; Higgs, Emily F.] Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA	University of Chicago	Gajewski, TF (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.	tgajewsk@medicine.bsd.uchicago.edu		Higgs, Emily F./0000-0003-2477-8549	National Institutes of Health [F30CA250255, R35CA210098]; Aduro Biotech	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Aduro Biotech	The authors are funded by the National Institutes of Health (grants F30CA250255 to E.F.H. and R35CA210098 to T.F.G.). T.F.G. reports a licensing agreement and receives research support and consultancy fees from Aduro Biotech.	Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190; Chin EN, 2020, SCIENCE, V369, P993, DOI 10.1126/science.abb4255; Conlon J, 2013, J IMMUNOL, V190, P5216, DOI 10.4049/jimmunol.1300097; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Harrington KJ, 2018, ANN ONCOL, V29, P712; MERICBERNSTAM F, 2019, J CLIN ONCOL S, V37; Pan B.-S., 2020, SCIENCE, V369; Ramanjulu JM, 2018, NATURE, V564, P439, DOI 10.1038/s41586-018-0705-y; Reilley M, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS2669; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Trujillo JA, 2018, CANCER IMMUNOL RES, V6, P990, DOI 10.1158/2326-6066.CIR-18-0277; Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954; Vaddepally RK, 2020, CANCERS, V12, DOI 10.3390/cancers12030738; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017	15	24	24	5	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	2020	369	6506			SI		921	922		10.1126/science.abc6622	http://dx.doi.org/10.1126/science.abc6622			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NE2OL	32820113				2023-01-03	WOS:000562436800026
J	Berk, J				Berk, Justin			A Good Place to Start - Low-Threshold Buprenorphine Initiation	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Berk, Justin] Brown Univ, Dept Med, Warren Alpert Sch Med, Providence, RI 02912 USA; [Berk, Justin] Brown Univ, Dept Pediat, Warren Alpert Sch Med, Providence, RI 02912 USA	Brown University; Brown University	Berk, J (corresponding author), Brown Univ, Dept Med, Warren Alpert Sch Med, Providence, RI 02912 USA.; Berk, J (corresponding author), Brown Univ, Dept Pediat, Warren Alpert Sch Med, Providence, RI 02912 USA.		Berk, Justin/AAZ-8128-2020	Berk, Justin/0000-0002-2865-7464				Binswanger IA, 2007, NEW ENGL J MED, V356, P157, DOI 10.1056/NEJMsa064115; Green TC, 2018, JAMA PSYCHIAT, V75, P405, DOI 10.1001/jamapsychiatry.2017.4614; Krawczyk N, 2019, J SUBST ABUSE TREAT, V103, P1, DOI 10.1016/j.jsat.2019.05.002; Martin SA, 2018, ANN INTERN MED, V169, P628, DOI 10.7326/M18-1652; National Academies of Science Engineering and Medicine, 2019, MED OP US DIS SAV LI	5	3	3	1	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 20	2020	383	8					701	703		10.1056/NEJMp2017363	http://dx.doi.org/10.1056/NEJMp2017363			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NG2MJ	32813944				2023-01-03	WOS:000563818700007
J	Nagai, K; Ideguchi, H; Kajikawa, T; Li, XF; Chavakis, T; Cheng, J; Messersmith, PB; Heber-Katz, E; Hajishengallis, G				Nagai, Kosuke; Ideguchi, Hidetaka; Kajikawa, Tetsuhiro; Li, Xiaofei; Chavakis, Triantafyllos; Cheng, Jing; Messersmith, Phillip B.; Heber-Katz, Ellen; Hajishengallis, George			An injectable hydrogel-formulated inhibitor of prolyl-4-hydroxylase promotes T regulatory cell recruitment and enhances alveolar bone regeneration during resolution of experimental periodontitis	FASEB JOURNAL			English	Article						1,4-dihydrophenonthrolin-4-one-3-carboxylic acid; AMD3100; hypoxia-inducible factor 1 alpha; osteogenesis; T regulatory cells	HYPOXIA-INDUCIBLE FACTOR; STEM-CELLS; FACTOR-I; THERAPY; FACTOR-1-ALPHA; RECONSTRUCTION; SPECIALIZATION; IDENTIFICATION; ACTIVATION; CONSENSUS	The hypoxia-inducible factor 1 alpha (HIF-1 alpha) is critically involved in tissue regeneration. Hence, the pharmacological prevention of HIF-1 alpha degradation by prolyl hydroxylase (PHD) under normoxic conditions is emerging as a promising option in regenerative medicine. Using a mouse model of ligature-induced periodontitis and resolution, we tested the ability of an injectable hydrogel-formulated PHD inhibitor, 1,4-dihydrophenonthrolin-4-one-3-carboxylic acid (1,4-DPCA/hydrogel), to promote regeneration of alveolar bone lost owing to experimental periodontitis. Mice injected subcutaneously with 1,4-DPCA/hydrogel at the onset of periodontitis resolution displayed significantly increased gingival HIF-1 alpha protein levels and bone regeneration, as compared to mice treated with vehicle control. The 1,4-DPCA/hydrogel-induced increase in bone regeneration was associated with elevated expression of osteogenic genes, decreased expression of pro-inflammatory cytokine genes, and increased abundance of FOXP3(+)T regulatory (Treg) cells in the periodontal tissue. The enhancing effect of 1,4-DPCA/hydrogel on Treg cell accumulation and bone regeneration was reversed by AMD3100, an antagonist of the chemokine receptor CXCR4 that mediates Treg cell recruitment. In conclusion, the administration of 1,4-DPCA/hydrogel at the onset of periodontitis resolution promotes CXCR4-dependent accumulation of Treg cells and alveolar bone regeneration, suggesting a novel approach for regaining bone lost due to periodontitis.	[Nagai, Kosuke; Ideguchi, Hidetaka; Kajikawa, Tetsuhiro; Li, Xiaofei; Hajishengallis, George] Univ Penn, Lab Innate Immun & Inflammat, Dept Basic & Translat Sci, Sch Dent Med, Philadelphia, PA 19104 USA; [Nagai, Kosuke; Chavakis, Triantafyllos] Tech Univ Dresden, Inst Clin Chem & Lab Med, Fac Med Carl Gustav Carus, Dresden, Germany; [Ideguchi, Hidetaka] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Pathophysiol Periodontal Sci, Okayama, Japan; [Cheng, Jing; Messersmith, Phillip B.] Univ Calif Berkeley, Dept Bioengn, Berkeley, CA 94720 USA; [Cheng, Jing; Messersmith, Phillip B.] Univ Calif Berkeley, Dept Mat Sci & Engn, Berkeley, CA 94720 USA; [Cheng, Jing] Alcon, Formulat Grp R&D, Duluth, GA USA; [Heber-Katz, Ellen] Lankenau Inst Med Res, Lab Regenerat Med, Wynnewood, PA USA	University of Pennsylvania; Technische Universitat Dresden; Okayama University; University of California System; University of California Berkeley; University of California System; University of California Berkeley; Novartis; Alcon; Lankenau Medical Center; Lankenau Institute for Medical Research	Hajishengallis, G (corresponding author), Univ Penn, Lab Innate Immun & Inflammat, Dept Basic & Translat Sci, Sch Dent Med, Philadelphia, PA 19104 USA.	geoh@upenn.edu	Chavakis, Triantafyllos/ABE-8845-2020; Li, xiaofei/GXF-7187-2022		HHS \ NIH \ National Institute of Dental and Craniofacial Research (NIDCR) [DE026152, DE028561, DE021104]; Deutsche Forschungsgemeinschaft (DFG) [SFB1181]	HHS \ NIH \ National Institute of Dental and Craniofacial Research (NIDCR); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG))	HHS vertical bar NIH vertical bar National Institute of Dental and Craniofacial Research (NIDCR), Grant/Award Number: DE026152, DE028561 and DE021104; Deutsche Forschungsgemeinschaft (DFG), Grant/Award Number: SFB1181	Abe T, 2013, J IMMUNOL METHODS, V394, P49, DOI 10.1016/j.jim.2013.05.002; Arpaia N, 2015, CELL, V162, P1078, DOI 10.1016/j.cell.2015.08.021; Athanasopoulos AN, 2007, J BIOL CHEM, V282, P26746, DOI 10.1074/jbc.M705200200; Banerji B, 2005, CHEM COMMUN, P5438, DOI 10.1039/b510707e; Beikler T, 2011, PERIODONTOL 2000, V55, P87, DOI 10.1111/j.1600-0757.2010.00360.x; Benakanakere MR, 2019, APOPTOSIS, V24, P108, DOI 10.1007/s10495-018-01513-9; Brauchle F, 2013, INT DENT J, V63, P306, DOI 10.1111/idj.12042; Campbell DJ, 2011, NAT REV IMMUNOL, V11, P119, DOI 10.1038/nri2916; Chapple ILC, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2645; Chen SC, 2006, J PERIODONTAL RES, V41, P547, DOI 10.1111/j.1600-0765.2006.00904.x; Chen SY, 2016, J CELL BIOCHEM, V117, P267, DOI 10.1002/jcb.25283; Choudhry H, 2018, CELL METAB, V27, P281, DOI 10.1016/j.cmet.2017.10.005; Clambey ET, 2012, P NATL ACAD SCI USA, V109, pE2784, DOI 10.1073/pnas.1202366109; Cochran DL, 2015, J PERIODONTOL, V86, pS153, DOI 10.1902/jop.2015.140381; Colombo APV, 2012, J PERIODONTOL, V83, P1279, DOI 10.1902/jop.2012.110566; D'Alessio FR, 2009, J CLIN INVEST, V119, P2898, DOI 10.1172/JCI36498; Delacher M, 2017, NAT IMMUNOL, V18, P1160, DOI 10.1038/ni.3799; Demmer RT, 2010, PERIODONTOL 2000, V53, P28, DOI 10.1111/j.1600-0757.2009.00326.x; Donzella GA, 1998, NAT MED, V4, P72, DOI 10.1038/nm0198-072; Dutzan N, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0797; Dzobo K, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/2495848; Eke PI, 2015, J PERIODONTOL, V86, P611, DOI 10.1902/jop.2015.140520; Fan FQ, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf2304; Foster B L, 2005, Orthod Craniofac Res, V8, P285, DOI 10.1111/j.1601-6343.2005.00351.x; Frencken JE, 2017, J CLIN PERIODONTOL, V44, pS94, DOI 10.1111/jcpe.12677; Hajishengallis G, 2015, NAT REV IMMUNOL, V15, P30, DOI 10.1038/nri3785; Heber-Katz E, 2018, ADV DRUG DELIVER REV, V129, P254, DOI 10.1016/j.addr.2018.02.006; Heber-Katz E, 2017, TRENDS MOL MED, V23, P1024, DOI 10.1016/j.molmed.2017.08.008; Hong WX, 2014, ADV WOUND CARE, V3, P390, DOI 10.1089/wound.2013.0520; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Kassebaum NJ, 2014, J DENT RES, V93, P1045, DOI 10.1177/0022034514552491; Kinane DF, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.38; Koivunen P, 2018, TRENDS MOL MED, V24, P1021, DOI 10.1016/j.molmed.2018.10.004; Kourtzelis I, 2019, NAT IMMUNOL, V20, P40, DOI 10.1038/s41590-018-0249-1; Lamont RJ, 2018, NAT REV MICROBIOL, V16, P745, DOI 10.1038/s41579-018-0089-x; Lang NP, 2019, PERIODONTOL 2000, V79, P15, DOI 10.1111/prd.12240; Lei H, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00184; Li JT, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00585; Lin WP, 2017, J ORTHOP TRANSL, V9, P19, DOI 10.1016/j.jot.2017.03.002; Lin Z, 2015, J PERIODONTOL, V86, pS134, DOI 10.1902/jop.2015.130689; Liu Y, 2011, NAT MED, V17, P1594, DOI 10.1038/nm.2542; Love RJ, 2013, J BIOMED MATER RES A, V101, P3599, DOI 10.1002/jbm.a.34648; Maekawa T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9272; Miguel SMS, 2010, J PERIODONTAL RES, V45, P60, DOI 10.1111/j.1600-0765.2009.01201.x; Murakami S, 2017, EMERGING REGENERATIV, P135; Murakami S., 2001, PERIODONTOLOGY, V56, P188; Ng KT, 2011, J PERIODONTOL, V82, P136, DOI 10.1902/jop.2010.100100; Pacios S, 2012, FASEB J, V26, P1423, DOI 10.1096/fj.11-196279; Rahimi N, 2012, MOL CANCER THER, V11, P538, DOI 10.1158/1535-7163.MCT-11-0555; Roguljic H, 2013, J DENT RES, V92, P709, DOI 10.1177/0022034513493434; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Schipani E, 2009, J BONE MINER RES, V24, P1347, DOI [10.1359/JBMR.090602, 10.1359/jbmr.090602]; Sculean A, 2008, J CLIN PERIODONTOL, V35, P106, DOI 10.1111/j.1600-051X.2008.01263.x; Sculean A, 2015, PERIODONTOL 2000, V68, P182, DOI 10.1111/prd.12086; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Shin J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac5380; Somerman MJ, 1999, J PERIODONTAL RES, V34, P420, DOI 10.1111/j.1600-0765.1999.tb02276.x; Tang LX, 2014, J LEUKOCYTE BIOL, V96, P809, DOI 10.1189/jlb.4MA1213-647RR; Tonetti MS, 2011, J CLIN PERIODONTOL, V38, P114, DOI 10.1111/j.1600-051X.2010.01675.x; Tyagi AM, 2018, IMMUNITY, V49, P1116, DOI 10.1016/j.immuni.2018.10.013; Van Dyke TE, 2015, J DENT RES, V94, P148, DOI 10.1177/0022034514557331; Wan C, 2008, P NATL ACAD SCI USA, V105, P686, DOI 10.1073/pnas.0708474105; Yamamoto A, 2019, J CLIN INVEST, V129, P3640, DOI 10.1172/JCI124099; Yan M, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2869; Yuh D, 2020, J BIOL CHEM, V295, P7261, DOI 10.1074/jbc.RA120.013024; Zhang Y., 2015, SCI TRANSL MED, V7, P290; Zou LH, 2004, CANCER RES, V64, P8451, DOI 10.1158/0008-5472.CAN-04-1987	68	10	11	7	28	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2020	34	10					13726	13740		10.1096/fj.202001248R	http://dx.doi.org/10.1096/fj.202001248R		AUG 2020	15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY3XM	32812255	Bronze, Green Accepted			2023-01-03	WOS:000562900300001
J	Galerneau, LM; Bailly, S; Borel, JC; Jullian-Desayes, I; Joyeux-Faure, M; Benmerad, M; Bonsignore, MR; Tamisier, R; Pepin, JL				Galerneau, Louis-Marie; Bailly, Sebastien; Borel, Jean-Christian; Jullian-Desayes, Ingrid; Joyeux-Faure, Marie; Benmerad, Meriem; Bonsignore, Marisa R.; Tamisier, Renaud; Pepin, Jean-Louis			Long-term variations of arterial stiffness in patients with obesity and obstructive sleep apnea treated with continuous positive airway pressure	PLOS ONE			English	Article							PULSE-WAVE VELOCITY; EXPERT CONSENSUS DOCUMENT; AORTIC STIFFNESS; CARDIOVASCULAR EVENTS; PULMONARY-DISEASE; BLOOD-PRESSURE; RISK-FACTOR; ALL-CAUSE; CPAP; HYPERTENSION	Background Obstructive sleep apnea (OSA) is associated with cardiovascular co-morbidities and mortality. Arterial stiffness is an independent predictor of cardiovascular risk and mortality, and is influenced by the presence of OSA and related comorbidities. There is a paucity of data regarding long-term evolution of arterial stiffness in CPAP-treated OSA patients.We aimed to prospectively study long term PWV variations and determinants of PWV deterioration. Methods In a prospective obese OSA cohort, at time of diagnosis and after several years of follow-up we collected arterial stiffness measured by carotid-femoral pulse wave velocity (PWV), clinical and metabolic parameters, and CPAP adherence.Univariate and multivariate analyses were performed in order to determine contributing factors. Results Seventy two OSA patients (men: 52.8%, median age: 55.8 years and median BMI of 38.5 kg/m(2)) with a prevalence of hypertension: 58.3%, type 2 diabetes: 20.8%, hypercholesterolemia: 33.3%, current or past smoking: 59.7%, were evaluated after a median follow-up of 7.4 [5.8; 8.3] years. Over the period of follow-up, the median increase in PWV was 1.34 [0.10; 2.37] m/s. In multivariate analysis, the increase in PWV was associated with older age (10 extra years was associated with a 5.24 [1.35; 9.12] % increase in PWV) and hypertension (a significant increase in PWV of 8.24 [1.02; 15.57] %). No impact of CPAP adherence on PWV evolution was found. Conclusion PWV progression in CPAP-treated OSA patients is mainly related to pre-existing cardio-metabolic comorbidities and not influenced by CPAP adherence. In this high cardiovascular risk population, it is crucial to associated weight management and exercise with CPAP treatment.	[Galerneau, Louis-Marie; Bailly, Sebastien; Borel, Jean-Christian; Jullian-Desayes, Ingrid; Joyeux-Faure, Marie; Benmerad, Meriem; Tamisier, Renaud; Pepin, Jean-Louis] Univ Grenoble Alpes, HP2 Lab, INSERM U1042, Grenoble, France; [Galerneau, Louis-Marie; Bailly, Sebastien; Borel, Jean-Christian; Jullian-Desayes, Ingrid; Joyeux-Faure, Marie; Benmerad, Meriem; Tamisier, Renaud; Pepin, Jean-Louis] Grenoble Alpes Univ Hosp, EFCR Lab, Thorax & Vessels, Grenoble, France; [Bonsignore, Marisa R.] Univ Palermo, PROMISE Dept, Div Resp Med, Palermo, Italy; [Bonsignore, Marisa R.] IBIM CNR, Palermo, Italy	Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; UDICE-French Research Universities; Universite Grenoble Alpes (UGA); University of Palermo; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biomedicina e di Immunologia Molecolare "Alberto Monroy" (IBIM-CNR)	Galerneau, LM (corresponding author), Univ Grenoble Alpes, HP2 Lab, INSERM U1042, Grenoble, France.; Galerneau, LM (corresponding author), Grenoble Alpes Univ Hosp, EFCR Lab, Thorax & Vessels, Grenoble, France.	LMgalerneau@chu-grenoble.fr	Bonsignore, Maria/U-6440-2017; Borel, Jean Christian/AAC-5950-2019; Stefanadis, Christodoulos/ABH-2232-2020; BAILLY, Sébastien SB/H-4648-2013	Bonsignore, Maria/0000-0002-4875-7796; Borel, Jean Christian/0000-0003-4140-6210; Stefanadis, Christodoulos/0000-0001-5974-6454; BAILLY, Sébastien SB/0000-0002-2179-4650	French National Research Agency [ANR-12-TECS-0010, ANR-15-IDEX-02]; "e-health and integrated care" Chair of excellence of the University Grenoble Alpes Foundation; endowment fund "Agir pour les maladies chroniques"; ORKYN Society; Perimetre Association	French National Research Agency(French National Research Agency (ANR)); "e-health and integrated care" Chair of excellence of the University Grenoble Alpes Foundation; endowment fund "Agir pour les maladies chroniques"; ORKYN Society; Perimetre Association	This study was funded by an unrestricted grant from the French National Research Agency (ANR-12-TECS-0010) in the framework of the "Investissements d'avenir" program (ANR-15-IDEX-02), the "e-health and integrated care" Chair of excellence of the University Grenoble Alpes Foundation and the endowment fund "Agir pour les maladies chroniques". This study was funded in part by OYRKYN Society and Pe ' rimetre Association.	American Academy of Sleep Medicine, 2014, INT CLASSIFICATION S, V3rd; Aron-Wisnewsky J, 2016, METABOLISM, V65, P1124, DOI 10.1016/j.metabol.2016.05.004; ASMAR R, 1995, HYPERTENSION, V26, P485, DOI 10.1161/01.HYP.26.3.485; Berry RB, 2017, J CLIN SLEEP MED, V13, P665, DOI 10.5664/jcsm.6576; Berry RB, 2012, J CLIN SLEEP MED, V8, P597, DOI 10.5664/jcsm.2172; Bratton DJ, 2015, JAMA-J AM MED ASSOC, V314, P2280, DOI 10.1001/jama.2015.16303; Cecelja M, 2009, HYPERTENSION, V54, P1328, DOI 10.1161/HYPERTENSIONAHA.109.137653; Chirinos JA, 2014, NEW ENGL J MED, V370, P2265, DOI 10.1056/NEJMoa1306187; Chung S, 2010, RESPIRATION, V79, P363, DOI 10.1159/000228905; Doonan RJ, 2011, HYPERTENS RES, V34, P23, DOI 10.1038/hr.2010.200; Drager LF, 2007, CHEST, V131, P1379, DOI 10.1378/chest.06-2703; Drager LF, 2017, CIRCULATION, V136, P1840, DOI 10.1161/CIRCULATIONAHA.117.029400; Drager LF, 2011, CHEST, V140, P534, DOI 10.1378/chest.10-2223; Drager LF, 2010, ATHEROSCLEROSIS, V208, P490, DOI 10.1016/j.atherosclerosis.2009.08.016; Gay P, 2006, SLEEP, V29, P381, DOI 10.1093/sleep/29.3.381; Jelic S, 2008, CIRCULATION, V117, P2270, DOI 10.1161/CIRCULATIONAHA.107.741512; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Joyeux-Faure M, 2018, THORAX, V73, P1146, DOI 10.1136/thoraxjnl-2018-211513; Kaess BM, 2012, JAMA-J AM MED ASSOC, V308, P875, DOI 10.1001/2012.jama.10503; Koivistoinen T, 2011, ANN MED, V43, P312, DOI 10.3109/07853890.2010.549145; Laurent S, 2001, HYPERTENSION, V37, P1236, DOI 10.1161/01.HYP.37.5.1236; Laurent S, 2006, EUR HEART J, V27, P2588, DOI 10.1093/eurheartj/ehl254; Lee HM, 2012, CHEST, V142, P1118, DOI 10.1378/chest.11-2421; Levy P, 2009, EUR RESPIR J, V34, P243, DOI 10.1183/09031936.00166808; Levy P, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.15; Lin X, 2016, EUR ARCH OTO-RHINO-L, V273, P4081, DOI 10.1007/s00405-016-3914-8; Malhotra A, 2018, AM J RESP CRIT CARE, V197, P289, DOI 10.1164/rccm.201712-2510ST; Mancia G, 2013, J HYPERTENS, V31, P1281, DOI 10.1097/01.hjh.0000431740.32696.cc; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marin JM, 2010, AM J RESP CRIT CARE, V182, P325, DOI 10.1164/rccm.200912-1869OC; Mattace-Raso FUS, 2010, EUR HEART J, V31, P2338, DOI 10.1093/eurheartj/ehq165; McAllister DA, 2007, AM J RESP CRIT CARE, V176, P1208, DOI 10.1164/rccm.200707-1080OC; McEniery CM, 2005, J AM COLL CARDIOL, V46, P1753, DOI 10.1016/j.jacc.2005.07.037; McEvoy RD, 2016, NEW ENGL J MED, V375, P919, DOI 10.1056/NEJMoa1606599; Mitchell GF, 2010, CIRCULATION, V121, P505, DOI 10.1161/CIRCULATIONAHA.109.886655; Murphy AM, 2017, EUR RESPIR J, V49, DOI 10.1183/13993003.01731-2016; Pepin JL, 2016, LANCET RESP MED, V4, P407, DOI 10.1016/S2213-2600(16)00054-0; Pepin JL, 2013, SLEEP MED REV, V17, P3, DOI 10.1016/j.smrv.2012.11.002; Phillips CL, 2013, SLEEP MED REV, V17, P7, DOI 10.1016/j.smrv.2012.03.002; Pietri P, 2014, HYPERTENS RES, V37, P452, DOI 10.1038/hr.2013.148; Prenner SB, 2015, ATHEROSCLEROSIS, V238, P370, DOI 10.1016/j.atherosclerosis.2014.12.023; Safar ME, 2013, J AM COLL CARDIOL, V61, P12, DOI 10.1016/j.jacc.2012.01.088; Saito T, 2010, HYPERTENS RES, V33, P844, DOI 10.1038/hr.2010.77; Sateia MJ, 2014, CHEST, V146, P1387, DOI 10.1378/chest.14-0970; Shiina K, 2012, RESP MED, V106, P1335, DOI 10.1016/j.rmed.2012.05.006; Singh D, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00164-2019; Societe de Pneumologie de Langue Francaise, 2010, Rev Mal Respir, V27, P806, DOI 10.1016/j.rmr.2010.05.011; Stone IS, 2012, HEART, V98, P1055, DOI 10.1136/heartjnl-2012-301759; Tavil Y, 2007, J AM SOC ECHOCARDIOG, V20, P366, DOI 10.1016/j.echo.2006.09.005; Tsioufis C, 2007, J HYPERTENS, V25, P141, DOI 10.1097/HJH.0b013e32801092c1; Van Bortel LM, 2012, J HYPERTENS, V30, P445, DOI 10.1097/HJH.0b013e32834fa8b0; Van Ryswyk E, 2019, AM J RESP CRIT CARE, V199, P1433, DOI 10.1164/rccm.201811-2200LE; Vanfleteren LEGW, 2014, EUR RESPIR J, V43, P1306, DOI 10.1183/09031936.00169313; Vivodtzev I, 2018, THORAX, V73, P634, DOI 10.1136/thoraxjnl-2017-211152; Vivodtzev I, 2014, CHEST, V145, P861, DOI 10.1378/chest.13-1809; Vlachantoni IT, 2013, SLEEP MED REV, V17, P19, DOI 10.1016/j.smrv.2012.01.002; Vlachopoulos C, 2010, J AM COLL CARDIOL, V55, P1318, DOI 10.1016/j.jacc.2009.10.061; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG; Weir-McCall JR, 2015, RESP MED, V109, P1381, DOI 10.1016/j.rmed.2015.06.005; Williams B, 2018, J HYPERTENS, V36, P1953, DOI 10.1097/HJH.0000000000001940; Zamarron Carlos, 2008, Int J Chron Obstruct Pulmon Dis, V3, P671	61	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2020	15	8							e0236667	10.1371/journal.pone.0236667	http://dx.doi.org/10.1371/journal.pone.0236667			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB3DK	32756570	Green Published, gold			2023-01-03	WOS:000560393300016
J	Stahl, B; Gawron, B; Regenbrecht, F; Floel, A; Kotz, SA				Stahl, Benjamin; Gawron, Bianca; Regenbrecht, Frank; Floeel, Agnes; Kotz, Sonja A.			Formulaic Language Resources May Help Overcome Difficulties in Speech-Motor Planning after Stroke	PLOS ONE			English	Article							SYLLABLE FREQUENCY; APRAXIA; RECOVERY; APHASIA; EXPRESSIONS; MECHANISMS; REGRESSION	Purpose Decades of research have explored communication in cerebrovascular diseases by focusing on formulaic expressions (e.g., "Thank you"-"You're welcome"). This category of utterances is known for engaging primarily right-hemisphere frontotemporal and bilateral subcortical neural networks, explaining why left-hemisphere stroke patients with speech-motor planning disorders often produce formulaic expressions comparatively well. The present proof-of-concept study aims to confirm that using verbal cues derived from formulaic expressions can alleviate word-onset difficulties, one major symptom in apraxia of speech. Methods In a cross-sectional repeated-measures design, 20 individuals with chronic post-stroke apraxia of speech were asked to produce (i) verbal cues (e.g., /guMODIFIER LETTER TRIANGULAR COLON/) and (ii) subsequent German target words (e.g., "Tanz") with critical onsets (e.g., /t/). Cues differed, most notably, in aspects of formulaicity (e.g., stereotyped prompt: /guMODIFIER LETTER TRIANGULAR COLON/, based on formulaic phrase "Guten Morgen"; unstereotyped prompt: /muMODIFIER LETTER TRIANGULAR COLON/, based on non-formulaic control word "Mutig"). Apart from systematic variation in stereotypy and communicative-pragmatic embeddedness possibly associated with holistic language processing, cues were matched for consonant-vowel structure, syllable-transition frequency, noun-verb classification, meter, and articulatory tempo. Results Statistical analyses revealed significant increases in correctly produced word onsets after verbal cues with distinct features of formulaicity (e.g., stereotyped versus unstereotyped prompts: p < 0.001), as reflected in large effect sizes (Cohen's d(z) <= 2.2). Conclusions The current results indicate that using preserved formulaic language skills can relieve word-onset difficulties in apraxia of speech. This finding is consistent with a dynamic interplay of left perilesional and right intact language networks in post-stroke rehabilitation and may inspire new treatment strategies for individuals with apraxia of speech.	[Stahl, Benjamin; Floeel, Agnes] Univ Med Greifswald, Dept Neurol, Greifswald, Germany; [Stahl, Benjamin; Floeel, Agnes] Charite Univ Med Berlin, Dept Neurol, Berlin, Germany; [Stahl, Benjamin; Kotz, Sonja A.] Max Planck Inst Human Cognit & Brain Sci, Leipzig, Germany; [Stahl, Benjamin] Psychol Hsch Berlin, Berlin, Germany; [Gawron, Bianca] Martin Luther Univ Halle Wittenberg, Dept Speech Sci, Halle, Germany; [Regenbrecht, Frank] Univ Hosp Leipzig, Clin Cognit Neurol, Leipzig, Germany; [Floeel, Agnes] German Ctr Neurodegenerat Dis, Rostock, Germany; [Floeel, Agnes] German Ctr Neurodegenerat Dis, Greifswald, Germany; [Kotz, Sonja A.] Maastricht Univ, Fac Psychol & Neurosci, Dept Neuropsychol & Psychopharmacol, Maastricht, Netherlands	Greifswald Medical School; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Martin Luther University Halle Wittenberg; Leipzig University; Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); Maastricht University	Stahl, B (corresponding author), Univ Med Greifswald, Dept Neurol, Greifswald, Germany.; Stahl, B (corresponding author), Charite Univ Med Berlin, Dept Neurol, Berlin, Germany.; Stahl, B (corresponding author), Max Planck Inst Human Cognit & Brain Sci, Leipzig, Germany.; Stahl, B (corresponding author), Psychol Hsch Berlin, Berlin, Germany.	benjamin.stahl@charite.de			Else Kroner-Fresenius-Stiftung [2016_A51]; University of Greifswald; German Research Foundation [393148499]	Else Kroner-Fresenius-Stiftung; University of Greifswald; German Research Foundation(German Research Foundation (DFG))	The present study was supported by the Else Kroner-Fresenius-Stiftung (to BS, AF, and SAK; grant number: 2016_A51; www.ekfs.de).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The article processing charge was supported by Open-Access Publication Funds provided by the University of Greifswald and the German Research Foundation (grant number: 393148499).	Aichert I, 2004, BRAIN LANG, V88, P148, DOI 10.1016/S0093-934X(03)00296-7; Aichert I, 2016, NEUROPSYCHOLOGIA, V82, P171, DOI 10.1016/j.neuropsychologia.2016.01.009; ALAJOUANINE T, 1960, J NEUROL NEUROSUR PS, V23, P191, DOI 10.1136/jnnp.23.3.191; Baayen R. H., 1993, CELEX LEXICAL DATABA; Ballard KJ, 2015, AM J SPEECH-LANG PAT, V24, P316, DOI 10.1044/2015_AJSLP-14-0118; Bannard C, 2008, PSYCHOL SCI, V19, P241, DOI 10.1111/j.1467-9280.2008.02075.x; Brendel B, 2008, APHASIOLOGY, V22, P77, DOI 10.1080/02687030600965464; CANTER GJ, 1985, BRAIN LANG, V24, P204, DOI 10.1016/0093-934X(85)90131-2; CARAMAZZA A, 1991, NATURE, V349, P788, DOI 10.1038/349788a0; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; GRAVES R, 1985, ARCH NEUROL-CHICAGO, V42, P249, DOI 10.1001/archneur.1985.04060030067011; Heiss WD, 1999, ANN NEUROL, V45, P430, DOI 10.1002/1531-8249(199904)45:4<430::AID-ANA3>3.0.CO;2-P; Huber W, 1984, Adv Neurol, V42, P291; Hughlings-Jackson J., 1879, BRAIN, V2, P203, DOI 10.1093/brain/2.3.323; Hustad KC, 2003, J SPEECH LANG HEAR R, V46, P462, DOI 10.1044/1092-4388(2003/038); Mitchell AJ, 2017, GEN HOSP PSYCHIAT, V47, P48, DOI 10.1016/j.genhosppsych.2017.04.001; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Rammell CS, 2017, MENT LEX, V12, P234, DOI 10.1075/ml.16019.ram; Riecker A, 2008, BRAIN LANG, V107, P102, DOI 10.1016/j.bandl.2008.01.008; Rosen HJ, 2000, NEUROLOGY, V55, P1883, DOI 10.1212/WNL.55.12.1883; Sidtis DV, 2006, APHASIOLOGY, V20, P411, DOI 10.1080/02687030500538148; Sidtis JJ, 2018, BRAIN CONNECT, V8, P189, DOI 10.1089/brain.2017.0573; SPEEDIE LJ, 1993, NEUROLOGY, V43, P1768, DOI 10.1212/WNL.43.9.1768; Stahl B, 2016, CORTEX, V85, P90, DOI 10.1016/j.cortex.2016.09.021; Stahl B, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01526; Stahl B, 2011, BRAIN, V134, P3083, DOI 10.1093/brain/awr240; Tabossi P, 2009, MEM COGNITION, V37, P529, DOI 10.3758/MC.37.4.529; Tremblay Antoine, 2010, PERSPECTIVES FORMULA, P151; Van Lancker-Sidtis D, 2004, LANG COMMUN, V24, P207, DOI 10.1016/j.langcom.2004.02.003; Warburton E, 1999, J NEUROL NEUROSUR PS, V66, P155, DOI 10.1136/jnnp.66.2.155; Wertz R., 1984, APRAXIA SPEECH ADULT; Ziegler W, 2012, J SPEECH LANG HEAR R, V55, pS1485, DOI 10.1044/1092-4388(2012/12-0128)	32	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2020	15	6							e0233608	10.1371/journal.pone.0233608	http://dx.doi.org/10.1371/journal.pone.0233608			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MA6PX	32497064	Green Published, gold			2023-01-03	WOS:000542035200044
J	Basoulis, D; Liatis, S; Skouloudi, M; Makrilakis, K; Daikos, GL; Sfikakis, PP				Basoulis, Dimitrios; Liatis, Stavros; Skouloudi, Marina; Makrilakis, Konstantinos; Daikos, Georgios L.; Sfikakis, Petros P.			Survival predictors after intubation in medical wards: A prospective study in 151 patients	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; CHRONIC HEALTH EVALUATION; MECHANICAL VENTILATION; HOSPITAL MORTALITY; ACUTE PHYSIOLOGY; APACHE; OUTCOMES; FUTILE; SCORE; MODEL	Introduction In health care systems in need of additional intensive care unit (ICU) beds, the decision to mechanically ventilate critically ill patients in Internal Medicine (IM) Department wards needs to balance patients' health outcomes, possible futility, and logistics. We aimed to examine the survival rates and predictors in these patients. Methods We prospectively enrolled consecutive patients receiving mechanical ventilation during their care in the IM wards of a tertiary University hospital between April 2016 and December 2018. Primary outcome was 90-day mortality and secondary outcomes were in-hospital mortality and ICU transfer. Results Our cohort consisted of 151 unique patient intubations, of whom 74 (49%) patients were transferred to ICU within a median of 0 days (range 0-7). Compared to patients who remained in the wards, patients transferred to ICU had lower in-hospital and 90-day mortality (65% vs. 97%, and 70% vs. 99%, respectively, p<0.001 for both). Amongst several possible predictors of survival in the ICU, sequential organ failure assessment (SOFA) score at the time of intubation had the best prognostic accuracy with an AUROC of 0.818 and 0.855 for in-hospital and 90-day mortality, respectively. A baseline SOFA score <= 8 had a 100% sensitivity for survival prediction in ICU. However, out of 26 patients with SOFA score.8 who remained in the wards, only one survived, whereas 19 patients with SOFA score > 8 who were transferred to ICUs received futile care. Conclusion Mortality for patients receiving mechanical ventilation in IM wards is almost inevitable when ICU availability is lacking. Therefore, applying additional transfer criteria beyond the SOFA score is imperative.	[Basoulis, Dimitrios; Liatis, Stavros; Sfikakis, Petros P.] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Dept Propaedeut Internal Med 1, Athens, Greece; [Basoulis, Dimitrios; Skouloudi, Marina; Makrilakis, Konstantinos; Daikos, Georgios L.] Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Dept Internal Med 1, Athens, Greece	Laiko General Hospital; National & Kapodistrian University of Athens; Laiko General Hospital; National & Kapodistrian University of Athens	Basoulis, D (corresponding author), Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Dept Propaedeut Internal Med 1, Athens, Greece.; Basoulis, D (corresponding author), Natl & Kapodistrian Univ Athens, Laiko Gen Hosp, Dept Internal Med 1, Athens, Greece.	dimitris.basoulis@gmail.com	Liatis, Stavros/CAA-4315-2022					Bosslet GT, 2015, AM J RESP CRIT CARE, V191, P1318, DOI 10.1164/rccm.201505-0924ST; Capuzzo M, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0551-8; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Fedosiuk Roman N, 2018, Wiad Lek, V71, P1320; Fernandez R, 2015, MED INTENSIVA, V39, P537, DOI 10.1016/j.medin.2014.11.002; Hersch M, 2007, J CRIT CARE, V22, P13, DOI 10.1016/j.jcrc.2006.06.004; Hersch M, 2012, J CRIT CARE, V27, P694, DOI 10.1016/j.jcrc.2012.08.020; Higgins TL, 2007, CRIT CARE MED, V35, P827, DOI 10.1097/01.CCM.0000257337.63529.9F; Huynh TN, 2013, JAMA INTERN MED, V173, P1887, DOI 10.1001/jamainternmed.2013.10261; Karabatsou D, 2016, INTENS CRIT CARE NUR, V35, P66, DOI 10.1016/j.iccn.2016.01.001; Kelley MA, 2004, CHEST, V125, P1514, DOI 10.1378/chest.125.4.1514; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kranidiotis G, 2010, CRIT CARE, V14, DOI 10.1186/cc9380; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; Lieberman D, 2010, CRIT CARE, V14, DOI 10.1186/cc8935; Moreno RP, 2005, INTENS CARE MED, V31, P1345, DOI 10.1007/s00134-005-2763-5; Opgenorth D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201524; Pintado MC, 2013, SCI WORLD J, DOI 10.1155/2013/590837; Rockwood K, 2005, CAN MED ASSOC J, V173, P489, DOI 10.1503/cmaj.050051; Saric L, 2017, J BIOETHIC INQ, V14, P329, DOI 10.1007/s11673-017-9793-x; Sprung CL, 1999, CRIT CARE MED, V27, P1073, DOI 10.1097/00003246-199906000-00021; Tang WM, 2012, HONG KONG MED J, V18, P284; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wongsurakiat Phunsup, 2016, Journal of the Medical Association of Thailand, V99, P772; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0	28	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2020	15	6							e0234181	10.1371/journal.pone.0234181	http://dx.doi.org/10.1371/journal.pone.0234181			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ2AA	32479534	Green Published, gold			2023-01-03	WOS:000547893500057
J	Di Cosimo, S				Di Cosimo, Serena			Advancing immunotherapy for early-stage triple-negative breast cancer	LANCET			English	Editorial Material									[Di Cosimo, Serena] Fdn IRCCS Ist Nazl Tumori, Dept Appl Res & Technol Dev, Biomarkers Unit, I-20100 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan	Di Cosimo, S (corresponding author), Fdn IRCCS Ist Nazl Tumori, Dept Appl Res & Technol Dev, Biomarkers Unit, I-20100 Milan, Italy.	serena.dicosimo@istitutotumori.mi.it	, Di Cosimo Serena/E-9418-2017	, Di Cosimo Serena/0000-0002-4666-8052				Cardoso F, 2019, ANN ONCOL, V30, P1194, DOI 10.1093/annonc/mdz173; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; FDA, 2020, FDA ISS AL EFF POT S; Garrido-Castro AC, 2019, CANCER DISCOV, V9, P176, DOI 10.1158/2159-8290.CD-18-1177; Gianni L, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.SABCS19-GS3-04; Keenan TE, 2020, J NATL COMPR CANC NE, V18, P479, DOI 10.6004/jnccn.2020.7554; Loibl S, 2019, ANN ONCOL, V30, P1279, DOI 10.1093/annonc/mdz158; Mittendorf EA, 2020, LANCET, V396, P1090, DOI 10.1016/S0140-6736(20)31953-X; Nanda R, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.506; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Schmid P, 2020, NEW ENGL J MED, V382, P810, DOI 10.1056/NEJMoa1910549; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; Voorwerk L, 2019, NAT MED, V25, P920, DOI 10.1038/s41591-019-0432-4	13	15	15	1	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	2020	396	10257					1046	1048		10.1016/S0140-6736(20)31962-0	http://dx.doi.org/10.1016/S0140-6736(20)31962-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OC4TP	32966831				2023-01-03	WOS:000579151000002
J	Packer, M; Anker, SD; Butler, J; Filippatos, G; Pocock, SJ; Carson, P; Januzzi, J; Verma, S; Tsutsui, H; Brueckmann, M; Jamal, W; Kimura, K; Schnee, J; Zeller, C; Cotton, D; Bocchi, E; Bohm, M; Choi, DJ; Chopra, V; Chuquiure, E; Giannetti, N; Janssens, S; Zhang, J; Juanatey, JRG; Kaul, S; Brunner-La Rocca, HP; Merkely, B; Nicholls, SJ; Perrone, S; Pina, I; Ponikowski, P; Sattar, N; Senni, M; Seronde, MF; Spinar, J; Squire, I; Taddei, S; Wanner, C; Zannad, F				Packer, Milton; Anker, Stefan D.; Butler, Javed; Filippatos, Gerasimos; Pocock, Stuart J.; Carson, Peter; Januzzi, James; Verma, Subodh; Tsutsui, Hiroyuki; Brueckmann, Martina; Jamal, Waheed; Kimura, Karen; Schnee, Janet; Zeller, Cordula; Cotton, Daniel; Bocchi, Edimar; Boehm, Michael; Choi, Dong-Ju; Chopra, Vijay; Chuquiure, Eduardo; Giannetti, Nadia; Janssens, Stefan; Zhang, Jian; Juanatey, Jose R. Gonzalez; Kaul, Sanjay; Brunner-La Rocca, Hans-Peter; Merkely, Bela; Nicholls, Stephen J.; Perrone, Sergio; Pina, Ileana; Ponikowski, Piotr; Sattar, Naveed; Senni, Michele; Seronde, Marie-France; Spinar, Jindrich; Squire, Iain; Taddei, Stefano; Wanner, Christoph; Zannad, Faiez		EMPEROR-REDUCED Trial Investigat	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								BACKGROUND Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m(2) of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes.	[Packer, Milton] Baylor Univ, Med Ctr, Baylor Heart & Vasc Inst, Dallas, TX USA; [Packer, Milton] Imperial Coll, London, England; [Pocock, Stuart J.] London Sch Hyg & Trop Med, Dept Med Stat, London, England; [Sattar, Naveed] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland; [Squire, Iain] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Squire, Iain] Glenfield Hosp, Biomed Res Ctr, Natl Inst Hlth Res, Leicester, Leics, England; [Anker, Stefan D.] Charite, Dept Cardiol, Berlin, Germany; [Anker, Stefan D.] Charite, Berlin Inst Hlth Ctr Regenerat Therapies, German Ctr Cardiovasc Res Partner Site Berlin, Berlin, Germany; [Brueckmann, Martina; Jamal, Waheed] Boehringer Ingelheim Int, Ingelheim, Germany; [Brueckmann, Martina] Heidelberg Univ, Fac Med Mannheim, Mannheim, Germany; [Zeller, Cordula] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Boehm, Michael] Saarland Univ, Klin Innere Med 3, Homburg, Germany; [Wanner, Christoph] Univ Hosp Wurzburg, Dept Med, Wurzburg, Germany; [Butler, Javed] Univ Mississippi, Sch Med, Dept Med, Jackson, MS USA; [Filippatos, Gerasimos] Natl & Kapodistrian Univ Athens, Sch Med, Athens Univ Hosp Attikon, Athens, Greece; [Carson, Peter] Washington DC Vet Affairs Med Ctr, Washington, DC USA; [Januzzi, James] Harvard Med Sch, Div Cardiol, Boston, MA 02115 USA; [Januzzi, James] Massachusetts Gen Hosp, Boston, MA 02114 USA; [Verma, Subodh] Univ Toronto, St Michaels Hosp, Div Cardiac Surg, Toronto, ON, Canada; [Kimura, Karen] Boehringer Ingelheim Canada, Burlington, ON, Canada; [Giannetti, Nadia] McGill Univ, Div Cardiol, Montreal, PQ, Canada; [Giannetti, Nadia] Hlth Ctr, Montreal, PQ, Canada; [Tsutsui, Hiroyuki] Kyushu Univ, Dept Cardiovasc Med, Higashi Ku, Fukuoka, Japan; [Schnee, Janet; Cotton, Daniel] Boehringer Ingelheim Pharmaceut, Ridgefield, CT USA; [Bocchi, Edimar] Univ Sao Paulo, Heart Inst, Med Sch, Sao Paulo, Brazil; [Choi, Dong-Ju] Seoul Natl Univ, Dept Med, Seoul, South Korea; [Chopra, Vijay] Max Super Special Hosp, Dept Cardiol, New Delhi, India; [Chuquiure, Eduardo] Natl Inst Cardiol, Dept Clin Cardiol, Mexico City, DF, Mexico; [Janssens, Stefan] Univ Hosp Gasthuisberg Leuven, Dept Cardiol, Leuven, Belgium; [Zhang, Jian] Chinese Acad Med Sci & Peking Union Med Coll, Fuwai Hosp, Natl Ctr Cardiovasc Dis, Beijing, Peoples R China; [Juanatey, Jose R. Gonzalez] Univ Hosp, Cardiol Dept, Santiago De Compostela, Spain; [Kaul, Sanjay] Cedars Sinai Med Ctr, Dept Cardiol, Los Angeles, CA 90048 USA; [Brunner-La Rocca, Hans-Peter] Maastricht Heart & Vasc Ctr, Maastricht, Netherlands; [Merkely, Bela] Semmelweis Univ, Heart & Vasc Ctr, Budapest, Hungary; [Nicholls, Stephen J.] Victorian Heart Inst, Melbourne, Vic, Australia; [Nicholls, Stephen J.] Monash Univ, Melbourne, Vic, Australia; [Perrone, Sergio] Fleni Inst, Buenos Aires, DF, Argentina; [Perrone, Sergio] Hosp El Cruce Nestor Kirchner, Buenos Aires, DF, Argentina; [Pina, Ileana] Wayne State Univ, Dept Med, Detroit, MI 48202 USA; [Pina, Ileana] Cent Michigan Univ, Dept Med, Detroit, MI USA; [Ponikowski, Piotr] Wroclaw Med Univ, Ctr Heart Dis, Wroclaw, Poland; [Senni, Michele] Papa Giovanni XXIII Hosp, Cardiovasc Dept, Bergamo, Italy; [Taddei, Stefano] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy; [Seronde, Marie-France] Univ Hosp Jean Minjoz, Dept Cardiol, Besancon, France; [Zannad, Faiez] Univ Lorraine, Ctr Hosp Reg Univ, Invest Network Initiat Cardiovasc & Renal Clin Tr, INSERM, Nancy, France; [Spinar, Jindrich] Univ Hosp Brno, Internal Cardiol, Brno, Czech Republic	Baylor University; Baylor University Medical Center; Imperial College London; University of London; London School of Hygiene & Tropical Medicine; University of Glasgow; University of Leicester; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Boehringer Ingelheim; Ruprecht Karls University Heidelberg; Boehringer Ingelheim; Universitatsklinikum des Saarlandes; University of Wurzburg; University of Mississippi; Athens Medical School; National & Kapodistrian University of Athens; University Hospital Attikon; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Boehringer Ingelheim; McGill University; Kyushu University; Boehringer Ingelheim; Universidade de Sao Paulo; Seoul National University (SNU); National Institute of Cardiology - Mexico; KU Leuven; University Hospital Leuven; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Peking Union Medical College; Cedars Sinai Medical Center; Maastricht University; Maastricht University Medical Centre (MUMC); Semmelweis University; Monash University; Wayne State University; Central Michigan University; Wroclaw Medical University; ASST Papa Giovanni XXIII; University of Pisa; Universite de Franche-Comte; CHU Besancon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; University Hospital Brno	Packer, M (corresponding author), Baylor Heart & Vasc Inst, 621 N Hall St, Dallas, TX 75226 USA.	milton.packer@baylorhealth.edu	Birkenfeld, Andreas L./U-3954-2019; Brunner-La Rocca, Hans-Peter/AAF-7330-2021; Filippatos, Gerasimos/ABA-4656-2021; Piskorz, Daniel/AAJ-8751-2020	Birkenfeld, Andreas L./0000-0003-1407-9023; Piskorz, Daniel/0000-0002-8615-5446; Madej, Andrzej/0000-0002-7626-0840; Manzur, Fernando/0000-0001-6679-5609; CHUQUIURE-VALENZUELA, EDUARDO/0000-0003-4812-1090; Kietselaer, Bas/0000-0002-0096-8594; GALINIER, Michel/0000-0003-1735-3390; Brunner-La Rocca, Hans-Peter/0000-0002-4356-8566; Packer, Milton/0000-0003-1828-2387; Girerd, Nicolas/0000-0002-3278-2057	Boehringer Ingelheim; Eli Lilly	Boehringer Ingelheim(Boehringer Ingelheim); Eli Lilly(Eli Lilly)	Supported by Boehringer Ingelheim and Eli Lilly.	Donnan JR, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022577; Fitchett D, 2019, CIRCULATION, V139, P1384, DOI 10.1161/CIRCULATIONAHA.118.037778; Furtado RHM, 2019, CIRCULATION, V139, P2516, DOI 10.1161/CIRCULATIONAHA.119.039996; Ibrahim NE, 2020, JACC-HEART FAIL, V8, P347, DOI 10.1016/j.jchf.2019.12.010; Kato ET, 2019, CIRCULATION, V139, P2528, DOI 10.1161/CIRCULATIONAHA.119.040130; McMurray JJV, 2019, NEW ENGL J MED, V381, P1995, DOI 10.1056/NEJMoa1911303; Neal B, 2017, NEW ENGL J MED, V377, P644, DOI 10.1056/NEJMoa1611925; Packer M, 2020, DIABETES CARE, V43, P508, DOI 10.2337/dci19-0074; Packer M, 2019, EUR J HEART FAIL, V21, P1270, DOI 10.1002/ejhf.1536; Zelniker TA, 2019, LANCET, V393, P31, DOI 10.1016/S0140-6736(18)32590-X	10	1492	1540	20	120	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 8	2020	383	15					1413	1424		10.1056/NEJMoa2022190	http://dx.doi.org/10.1056/NEJMoa2022190			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OD1NS	32865377	Green Published, Green Accepted, Bronze			2023-01-03	WOS:000579622800009
J	Kang, HJ; Lee, HH; Jung, SE; Park, KS; Joo-Hyun, O; Jeon, YW; Choi, BO; Cho, SG				Kang, Hye Jin; Lee, Han Hee; Jung, Seung-Eun; Park, Kyung-Sin; Joo-Hyun, O.; Jeon, Young-Woo; Choi, Byung-Ock; Cho, Seok-Goo			Pattern of failure and optimal treatment strategy for primary gastric diffuse large B-cell lymphoma treated with R-CHOP chemotherapy	PLOS ONE			English	Article							RANDOMIZED CONTROLLED-TRIAL; NON-HODGKINS-LYMPHOMA; ELDERLY-PATIENTS; PLUS RITUXIMAB; THERAPY; INDEX	Purpose The optimal treatment for primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is still unknown. We evaluated unfavorable prognostic factors and pattern of failure in PG-DLBCL to determine the optimal treatment strategy. Methods Between April 2001 and November 2018, 120 patients with complete remission following rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy were retrospectively reviewed. According to the Lugano staging system, 80 patients (66.7%) had localized disease and 40 patients (33.3%) had advanced disease. A total of 93 (77.5%) patients had single gastric lesion and 27 (22.5%) patients had multiple gastric lesions. Ninety patients (75%) were treated with R-CHOP chemotherapy alone and 30 patients (25%) received R-CHOP chemotherapy with additional local treatment for gastric lesions. Results The 5-year locoregional failure-free survival (LRFS), progression-free survival (PFS), and overall survival (OS) rates in patients treated with R-CHOP chemotherapy with local treatment were 100%, 100%, and 100%, respectively, whereas the LRFS, PFS, and OS rates in patients treated with R-CHOP chemotherapy alone were 86.3%, 78.2%, and 87.4%, respectively (p= 0.031,p= 0.095, andp= 0.025, respectively). During the follow-up period, 17 patients (14.2%) had disease recurrence. Only 3 of the 17 patients had relapse in a completely new site without relapse in the initial involved site. All, except 2, cases of local recurrence included gastric failure. In the multivariate analysis, performance status and number of gastric lesions were independent prognostic factors for treatment outcome. Conclusions Patients with complete remission following R-CHOP chemotherapy showed a good prognosis. The main pattern of failure in patients with PG-DLBCL was local recurrence, especially in the stomach. Patients who received local treatment for gastric lesions showed improved gastric control. Therefore, in patients with unfavorable prognostic factors, we recommend R-CHOP chemotherapy with additional local treatment for gastric lesions.	[Kang, Hye Jin; Choi, Byung-Ock] Catholic Univ Korea, Catholic Univ Lymphoma Grp, Seoul St Marys Hosp, Coll Med,Dept Radiat Oncol, Seoul, South Korea; [Lee, Han Hee] Catholic Univ Korea, Catholic Univ Lymphoma Grp, Seoul St Marys Hosp, Dept Gastroenterol,Coll Med, Seoul, South Korea; [Jung, Seung-Eun] Catholic Univ Korea, Catholic Univ Lymphoma Grp, Seoul St Marys Hosp, Dept Radiol,Coll Med, Seoul, South Korea; [Park, Kyung-Sin] Catholic Univ Korea, Catholic Univ Lymphoma Grp, Seoul St Marys Hosp, Dept Pathol,Coll Med, Seoul, South Korea; [Joo-Hyun, O.] Catholic Univ Korea, Catholic Univ Lymphoma Grp, Seoul St Marys Hosp, Dept Nucl Med,Coll Med, Seoul, South Korea; [Jeon, Young-Woo] Catholic Univ Korea, Catholic Univ Lymphoma Grp, Yeouido St Marys Hosp, Dept Hematol,Coll Med, Seoul, South Korea; [Cho, Seok-Goo] Catholic Univ Korea, Catholic Univ Lymphoma Grp, Seoul St Marys Hosp, Dept Hematol,Coll Med, Seoul, South Korea	Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Seoul St. Mary's Hospital; Catholic University of Korea; Catholic University of Korea; Seoul St. Mary's Hospital	Choi, BO (corresponding author), Catholic Univ Korea, Catholic Univ Lymphoma Grp, Seoul St Marys Hosp, Coll Med,Dept Radiat Oncol, Seoul, South Korea.; Cho, SG (corresponding author), Catholic Univ Korea, Catholic Univ Lymphoma Grp, Seoul St Marys Hosp, Dept Hematol,Coll Med, Seoul, South Korea.	choibo67@catholic.ac.kr; chosg@catholic.ac.kr	Lee, Han Hee/AAB-7987-2022	Lee, Han Hee/0000-0002-8244-374X				Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; Barrington SF, 2014, J CLIN ONCOL, V32, P3048, DOI 10.1200/JCO.2013.53.5229; Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795; Cortelazzo S, 1999, ANN ONCOL, V10, P1433, DOI 10.1023/A:1008351427601; DAMORE F, 1991, EUR J CANCER, V27, P1201, DOI 10.1016/0277-5379(91)90081-N; Ferreri AJM, 1999, ONCOLOGY-BASEL, V56, P274, DOI 10.1159/000011978; Ferreri AJM, 2007, CRIT REV ONCOL HEMAT, V63, P65, DOI 10.1016/j.critrevonc.2007.01.003; Fischbach W, 2011, Z GASTROENTEROL, V49, P430, DOI 10.1055/s-0029-1246012; Ghimire P, 2011, WORLD J GASTROENTERO, V17, P697, DOI 10.3748/wjg.v17.i6.697; Habermann TM, 2006, J CLIN ONCOL, V24, P3121, DOI 10.1200/JCO.2005.05.1003; Horning SJ, 2004, J CLIN ONCOL, V22, P3032, DOI 10.1200/JCO.2004.06.088; Ishikawa E, 2018, CANCER MED-US, V7, P3510, DOI 10.1002/cam4.1595; Jegadeesh N, 2015, INT J RADIAT ONCOL, V92, P107, DOI 10.1016/j.ijrobp.2015.01.025; Koch P, 2005, J CLIN ONCOL, V23, P7050, DOI 10.1200/JCO.2005.04.031; Lin TL, 2012, ANN HEMATOL, V91, P1383, DOI 10.1007/s00277-012-1463-9; Liu X, 2016, INT J RADIAT ONCOL, V95, P712, DOI 10.1016/j.ijrobp.2016.01.027; Liu YZ, 2019, LEUKEMIA LYMPHOMA, V60, P934, DOI 10.1080/10428194.2018.1515942; Juarez-Salcedo LM, 2018, CANCER CONTROL, V25, DOI 10.1177/1073274818778256; Newton R, 1997, INT J CANCER, V72, P923, DOI 10.1002/(SICI)1097-0215(19970917)72:6<923::AID-IJC1>3.0.CO;2-R; Pfreundschuh M, 2008, LANCET ONCOL, V9, P105, DOI 10.1016/S1470-2045(08)70002-0; Pfreundschuh M, 2006, LANCET ONCOL, V7, P379, DOI 10.1016/S1470-2045(06)70664-7; ROHATINER A, 1994, ANN ONCOL, V5, P397, DOI 10.1093/oxfordjournals.annonc.a058869; Shi Z, 2013, INT J RADIAT ONCOL, V86, P569, DOI 10.1016/j.ijrobp.2013.02.007; Tomita N, 2013, BRIT J HAEMATOL, V161, P383, DOI 10.1111/bjh.12281; Yoon SS, 2004, ANN SURG, V240, P28, DOI 10.1097/01.sla.0000129356.81281.0c; Zhang J, 2012, LEUKEMIA LYMPHOMA, V53, P2175, DOI 10.3109/10428194.2012.680451	26	2	2	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2020	15	9							e0238807	10.1371/journal.pone.0238807	http://dx.doi.org/10.1371/journal.pone.0238807			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW6FH	32960887	Green Published, gold			2023-01-03	WOS:000575109500032
J	Duffin, J				Duffin, Jacalyn			The art of medicine An activist history of drug shortages and its silos	LANCET			English	Editorial Material									[Duffin, Jacalyn] Queens Univ, Kingston, ON K7L 3N, Canada	Queens University - Canada	Duffin, J (corresponding author), Queens Univ, Kingston, ON K7L 3N, Canada.	duffinj@queensu.ca	Duffin, Jacalyn/AAU-6284-2021						0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 12	2020	396	10253					750	751						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OA7BY	32919502				2023-01-03	WOS:000577936900013
J	Carrillo-Vega, MF; Salinas-Escudero, G; Garcia-Pena, C; Gutierrez-Robledo, LM; Parra-Rodriguez, L				Fernanda Carrillo-Vega, Maria; Salinas-Escudero, Guillermo; Garcia-Pena, Carmen; Miguel Gutierrez-Robledo, Luis; Parra-Rodriguez, Lorena			Early estimation of the risk factors for hospitalization and mortality by COVID-19 in Mexico	PLOS ONE			English	Article								Background Due to a high prevalence of chronic non-degenerative diseases, it is suspected that COVID 19 poses a high risk of fatal complications for the Mexican population. The present study aims to estimate the risk factors for hospitalization and death in the Mexican population infected by SARS-CoV-2. Methods and findings We used the publicly available data released by the Epidemiological Surveillance System for Viral Respiratory Diseases of the Mexican Ministry of Health (Secretaria de Salud, SSA). All records of positive SARS-CoV-2 cases were included. Two multiple logistic regression models were fitted to estimate the association between hospitalization and mortality, with other covariables. Data on 10,544 individuals (57.68% men), with mean age 46.47 +/- 15.62, were analyzed. Men were about 1.54 times more likely to be hospitalized than women (p<0.001, 95% C.I. 1.37-1.74); individuals aged 50-74 and >= 74 were more likely to be hospitalized than people aged 25-49 (OR 2.05, p<0.001, 95% C.I. 1.81-2.32, and OR 3.84, p<0.001, 95% C.I. 2.90-5.15, respectively). People with hypertension, obesity, and diabetes were more likely to be hospitalized than people without these comorbidities (p<0.01). Men had more risk of death in comparison to women (OR = 1.53, p<0.001, 95% C.I. 1.30-1.81) and individuals aged 50-74 and >= 75 were more likely to die than people aged 25-49 (OR 1.96, p<0.001, 95% C.I. 1.63-2.34, and OR 3.74, p<0.001, 95% C.I. 2.80-4.98, respectively). Hypertension, obesity, and diabetes presented in combination conveyed a higher risk of dying in comparison to not having these diseases (OR = 2.10; p<0.001, 95% C.I. 1.50-2.93). Hospitalization, intubation and pneumonia entail a higher risk of dying (OR 5.02, p<0.001, 95% C.I. 3.88-6.50; OR 4.27, p<0.001, 95% C.I. 3.26-5.59, and OR = 2.57; p<0.001, 95% C.I. 2.11-3.13, respectively). Our study's main limitation is the lack of information on mild (asymptomatic) or moderate cases of COVID-19. Conclusions The present study points out that in Mexico, where an important proportion of the population has two or more chronic conditions simultaneously, a high mortality rate is a serious risk for those infected by SARS-CoV-2.	[Fernanda Carrillo-Vega, Maria; Garcia-Pena, Carmen; Miguel Gutierrez-Robledo, Luis; Parra-Rodriguez, Lorena] Inst Nacl Geriatria, Res Dept, Mexico City, DF, Mexico; [Salinas-Escudero, Guillermo] Hosp Infantil Mexico Dr Federico Gomez, Ctr Econ & Social Studies Hlth, Mexico City, DF, Mexico	Hospital Infantil de Mexico Federico Gomez	Parra-Rodriguez, L (corresponding author), Inst Nacl Geriatria, Res Dept, Mexico City, DF, Mexico.	parra.lrn@gmail.com	Salinas, Guillermo/AGX-9751-2022	Salinas, Guillermo/0000-0003-4573-4844; Parra-Rodriguez, Lorena/0000-0002-1107-1571	Secretaria de Educacion, Ciencia, Tecnologia e Innovacion de la Ciudad de Mexico [CM-SECTEI/041/2020]	Secretaria de Educacion, Ciencia, Tecnologia e Innovacion de la Ciudad de Mexico	This project was supported by a grant from the Secretaria de Educacion, Ciencia, Tecnologia e Innovacion de la Ciudad de Mexico CM-SECTEI/041/2020 "Red colaborativa de Investigacion Traslacional para el Envejecimiento Saludable de la Ciudad de Mexico" (RECITES). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2019, OPTICS EXPRESS, V27, pA581; Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI [10.1056/NEJMoa2001316, 10.1001/jama.2020.2565]; Cai JH, 2020, CLIN INFECT DIS, V71, P1547, DOI 10.1093/cid/ciaa198; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Donders F, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10040243; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jamieson DJ, 2006, EMERG INFECT DIS, V12, P1638, DOI 10.3201/eid1211.060152; Lam CM, 2004, BJOG-INT J OBSTET GY, V111, P771, DOI 10.1111/j.1471-0528.2004.00199.x; Li LQ, 2020, J MED VIROL, V92, P577, DOI 10.1002/jmv.25757; Lippi G, 2020, J MED VIROL, V92, P1759, DOI 10.1002/jmv.25860; Panamerican Health Organization, 2020, 2 PAN HLTH ORG; Porcheddu R, 2020, J INFECT DEV COUNTR, V14, P125, DOI 10.3855/jidc.12600; Ren LL, 2020, CHINESE MED J-PEKING, V133, P1015, DOI 10.1097/CM9.0000000000000722; Rojas-Martinez R, 2020, SALUD PUBLICA MEXICO, V54, P7; *SECR SAL, 2020, BAS DAT COVID 19; Secretaria de Salud, 2020, NOT COM C MEX 2020; Wang DW, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-02895-6; Wang TB, 2020, LANCET, V395, pE52, DOI 10.1016/S0140-6736(20)30558-4; Wang WE, 2020, J MED VIROL, V92, P441, DOI 10.1002/jmv.25689; Wenham C, 2020, LANCET, V395, P846, DOI 10.1016/S0140-6736(20)30526-2; World Health Organization, 2020, 90 WHO; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	24	52	52	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2020	15	9							e0238905	10.1371/journal.pone.0238905	http://dx.doi.org/10.1371/journal.pone.0238905			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR9MU	32915872	gold, Green Published			2023-01-03	WOS:000571887500063
J	Azad, AK; Zhabyeyev, P; Vanhaesebroeck, B; Eitzen, G; Oudit, GY; Moore, RB; Murray, AG				Azad, Abul K.; Zhabyeyev, Pavel; Vanhaesebroeck, Bart; Eitzen, Gary; Oudit, Gavin Y.; Moore, Ronald B.; Murray, Allan G.			Inactivation of endothelial cell phosphoinositide 3-kinase beta inhibits tumor angiogenesis and tumor growth	ONCOGENE			English	Article							ANTIANGIOGENIC AGENT SUNITINIB; VASCULAR DEVELOPMENT; MEDIATES RESISTANCE; P110-ALPHA ISOFORM; THERAPY; CARCINOMA; PATHWAY; OXYGENATION; METASTASIS; EXPRESSION	Angiogenesis inhibitors, such as the receptor tyrosine kinase (RTK) inhibitor sunitinib, target vascular endothelial growth factor (VEGF) signaling in cancers. However, only a fraction of patients respond, and most ultimately develop resistance to current angiogenesis inhibitor therapies. Activity of alternative pro-angiogenic growth factors, acting via RTK or G-protein coupled receptors (GPCR), may mediate VEGF inhibitor resistance. The phosphoinositide 3-kinase (PI3K)beta isoform is uniquely coupled to both RTK and GPCRs. We investigated the role of endothelial cell (EC) PI3K beta in tumor angiogenesis. Pro-angiogenic GPCR ligands were expressed by patient-derived renal cell carcinomas (PD-RCC), and selective inactivation of PI3K beta reduced PD-RCC-stimulated EC spheroid sprouting. EC-specific PI3K beta knockout (Epsilon C-beta KO) in mice potentiated the sunitinib-induced reduction in subcutaneous growth of LLC1 and B16F10, and lung metastasis of B16F10 tumors. Compared to single-agent sunitinib treatment, tumors in sunitinib-treated Epsilon C-beta KO mice showed a marked decrease in microvessel density, and reduced new vessel formation. The fraction of perfused mature tumor microvessels was increased in Epsilon C-beta KO mice suggesting immature microvessels were most sensitive to combined sunitinib and PI3K beta inactivation. Taken together, EC PI3K beta inactivation with sunitinib inhibition reduces microvessel turnover and decreases heterogeneity of the tumor microenvironment, hence PI3K beta inhibition may be a useful adjuvant antiangiogenesis therapy with sunitinib.	[Azad, Abul K.; Zhabyeyev, Pavel; Oudit, Gavin Y.; Murray, Allan G.] Univ Alberta, Dept Med, Edmonton, AB, Canada; [Zhabyeyev, Pavel; Oudit, Gavin Y.] Univ Alberta, Dept Physiol, Edmonton, AB, Canada; [Vanhaesebroeck, Bart] UCL, UCL Canc Inst, London, England; [Eitzen, Gary] Univ Alberta, Dept Cell Biol, Edmonton, AB, Canada; [Moore, Ronald B.] Univ Alberta, Dept Oncol, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of London; University College London; University of Alberta; University of Alberta	Murray, AG (corresponding author), Univ Alberta, Dept Med, Edmonton, AB, Canada.	allan.murray@ualberta.ca	Moore, Ronald Brian/AET-3015-2022		Translational Research Fellowship award from the Department of Medicine at the University of Alberta; Canadian Cancer Society Research Institute	Translational Research Fellowship award from the Department of Medicine at the University of Alberta; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	AKA was supported by a Translational Research Fellowship award from the Department of Medicine at the University of Alberta. Operating funding was provided by the Canadian Cancer Society Research Institute to AGM. The authors acknowledge the technical assistance of Jessica DesAulniers.	Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549; Ackah E, 2005, J CLIN INVEST, V115, P2119, DOI 10.1172/JCI24726; Nieto MA, 2017, NAT CELL BIOL, V19, P416, DOI 10.1038/ncb3520; Bergerot P, 2019, MOL CANCER THER, V18, P2185, DOI 10.1158/1535-7163.MCT-18-1399; Bilanges B, 2019, NAT REV MOL CELL BIO, V20, P515, DOI 10.1038/s41580-019-0129-z; Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118; Bridgeman VL, 2017, J PATHOL, V241, P362, DOI 10.1002/path.4845; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; Charo DN, 2009, AM J PHYSIOL-HEART C, V297, pH1904, DOI 10.1152/ajpheart.00686.2009; Choueiri TK, 2017, NEW ENGL J MED, V376, P354, DOI 10.1056/NEJMra1601333; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; del Toro R, 2010, BLOOD, V116, P4025, DOI 10.1182/blood-2010-02-270819; Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Gougis P, 2017, CRIT REV ONCOL HEMAT, V119, P75, DOI 10.1016/j.critrevonc.2017.08.010; Graupera M, 2008, NATURE, V453, P662, DOI 10.1038/nature06892; Grepin R, 2012, ONCOGENE, V31, P1683, DOI 10.1038/onc.2011.360; Grepin R, 2014, CANCER RES, V74, P873, DOI 10.1158/0008-5472.CAN-13-1267; Grunstein J, 1999, CANCER RES, V59, P1592; Haddad G, 2014, BLOOD, V124, P2142, DOI 10.1182/blood-2014-02-557975; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang D, 2010, CANCER RES, V70, P1063, DOI 10.1158/0008-5472.CAN-09-3965; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281; Jimenez-Valerio G, 2016, CURR DRUG TARGETS, V17, P1728, DOI 10.2174/1389450117666160301101425; Kasai A, 2008, ARTERIOSCL THROM VAS, V28, P1717, DOI 10.1161/ATVBAHA.108.163402; Kryczek I, 2005, CANCER RES, V65, P465; Lyons YA, 2017, ONCOTARGET, V8, P96496, DOI [10.19632/oncotarget.20410, 10.18632/oncotarget.20410]; Ma Shaolin, 2018, F1000Res, V7, P326, DOI 10.12688/f1000research.11771.1; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Mastrella G, 2019, CANCER RES, V79, P2298, DOI 10.1158/0008-5472.CAN-18-0881; Mateo J, 2017, CLIN CANCER RES, V23, P5981, DOI 10.1158/1078-0432.CCR-17-0725; Matsumoto S, 2011, CANCER RES, V71, P6350, DOI 10.1158/0008-5472.CAN-11-2025; McDermott DF, 2018, NAT MED, V24, P749, DOI 10.1038/s41591-018-0053-3; Nowak-Sliwinska P, 2018, ANGIOGENESIS, V21, P425, DOI 10.1007/s10456-018-9613-x; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Seaman S, 2007, CANCER CELL, V11, P539, DOI 10.1016/j.ccr.2007.04.017; Sennino B, 2012, NAT REV CANCER, V12, P699, DOI 10.1038/nrc3366; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Soler A, 2013, J EXP MED, V210, P1937, DOI 10.1084/jem.20121571; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Strasser GA, 2010, BLOOD, V115, P5102, DOI 10.1182/blood-2009-07-230284; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Terry S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103044; Thomas JS, 2015, CRIT REV ONCOL HEMAT, V96, P527, DOI 10.1016/j.critrevonc.2015.07.009; Vanhaesebroeck B, 2016, J MOL MED, V94, P5, DOI 10.1007/s00109-015-1352-5; Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/j.ccr.2004.10.011; Yuan F, 1996, P NATL ACAD SCI USA, V93, P14765, DOI 10.1073/pnas.93.25.14765; Zhao L, 2008, ONCOGENE, V27, P5486, DOI 10.1038/onc.2008.244; Zhou L, 2016, ONCOGENE, V35, P2687, DOI 10.1038/onc.2015.343	57	8	8	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6480	6492		10.1038/s41388-020-01444-3	http://dx.doi.org/10.1038/s41388-020-01444-3		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32879446	Green Submitted			2023-01-03	WOS:000565482600001
J	Ranzuglia, V; Lorenzon, I; Pellarin, I; Sonego, M; Dall'Acqua, A; D'Andrea, S; Lovisa, S; Segatto, I; Coan, M; Polesel, J; Serraino, D; Sabatelli, P; Spessotto, P; Belletti, B; Baldassarre, G; Schiappacassi, M				Ranzuglia, Valentina; Lorenzon, Ilaria; Pellarin, Ilenia; Sonego, Maura; Dall'Acqua, Alessandra; D'Andrea, Sara; Lovisa, Sara; Segatto, Ilenia; Coan, Michela; Polesel, Jerry; Serraino, Diego; Sabatelli, Patrizia; Spessotto, Paola; Belletti, Barbara; Baldassarre, Gustavo; Schiappacassi, Monica			Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells	ONCOGENE			English	Article							OVARIAN-CANCER; CISPLATIN RESISTANCE; DUAL ROLE; PROTEIN; TARGET; ACTIVATION; ATPASE; AKT; MECHANISMS; INHIBITION	For many tumor types chemotherapy still represents the therapy of choice and many standard treatments are based on the use of platinum (PT) drugs. However, de novo or acquired resistance to platinum is frequent and leads to disease progression. In Epithelial Ovarian Cancer (EOC) patients, PT-resistant recurrences are very common and improving the response to treatment still represents an unmet clinical need. To identify new modulators of PT-sensitivity, we performed a loss-of-function screening targeting 680 genes potentially involved in the response of EOC cells to platinum. We found that SGK2 (Serum-and Glucocorticoid-inducible kinase 2) plays a key role in PT-response. We show here that EOC cells relay on the induction of autophagy to escape PT-induced death and that SGK2 inhibition increases PT sensitivity inducing a block in the autophagy cascade due to the impairment of lysosomal acidification. Mechanistically we demonstrate that SGK2 controls autophagy in a kinase-dependent manner by binding and inhibiting the V-ATPase proton pump. Accordingly, SGK2 phosphorylates the subunit V1H (ATP6V1H) of V-ATPase and silencing or chemical inhibition of SGK2, affects the normal autophagic flux and sensitizes EOC cells to platinum. Hence, we identified a new pathway that links autophagy to the survival of cancer cells under platinum treatment in which the druggable kinase SGK2 plays a central role. Our data suggest that blocking autophagy via SGK2 inhibition could represent a novel therapeutic strategy to improve patients' response to platinum.	[Ranzuglia, Valentina; Lorenzon, Ilaria; Pellarin, Ilenia; Sonego, Maura; Dall'Acqua, Alessandra; D'Andrea, Sara; Lovisa, Sara; Segatto, Ilenia; Coan, Michela; Spessotto, Paola; Belletti, Barbara; Baldassarre, Gustavo; Schiappacassi, Monica] IRCCS, Ctr Riferimento Oncol Aviano CRO, Div Mol Oncol, I-33081 Aviano, Italy; [Polesel, Jerry; Serraino, Diego] IRCCS, Ctr Riferimento Oncol Aviano CRO, Epidemiol, I-33081 Aviano, Italy; [Sabatelli, Patrizia] CNR, Inst Mol Genet, Bologna, Italy; [Sabatelli, Patrizia] Rizzoli Orthoped Inst, Bologna, Italy	IRCCS Aviano (CRO); IRCCS Aviano (CRO); Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); IRCCS Istituto Ortopedico Rizzoli	Baldassarre, G; Schiappacassi, M (corresponding author), IRCCS, Ctr Riferimento Oncol Aviano CRO, Div Mol Oncol, I-33081 Aviano, Italy.	gbaldassarre@cro.it; mschiappacassi@cro.it	Belletti, Barbara/J-2028-2018; Segatto, Ilenia/AAX-5513-2020; Schiappacassi, Monica/AAX-5505-2020; Lorenzon, Ilaria/AAY-6372-2020; Baldassarre, Gustavo/K-1350-2016; Lovisa, Sara/AAB-1141-2020; Spessotto, Paola/K-5005-2012; Serraino, Diego/J-3915-2018; Pellarin, Ilenia/AAY-2238-2020; Dall'Acqua, Alessandra/ABF-8020-2020; Sonego, Maura/AAX-5529-2020	Belletti, Barbara/0000-0003-2249-0285; Segatto, Ilenia/0000-0001-5282-1028; Schiappacassi, Monica/0000-0003-4804-4291; Lorenzon, Ilaria/0000-0001-6336-4678; Baldassarre, Gustavo/0000-0002-9750-8825; Lovisa, Sara/0000-0001-7776-2896; Spessotto, Paola/0000-0002-3033-404X; Serraino, Diego/0000-0003-0565-8920; Pellarin, Ilenia/0000-0002-1041-1722; Dall'Acqua, Alessandra/0000-0003-2297-1361; Sonego, Maura/0000-0002-9505-9771	Ministero della Salute [RF-2010-2309704, RF-2016-02361040, RF-2016-02361041]; Regione Friuli Venezia Giulia (Tichep Grant); 5x1000 CRO; AIRC biannual Fellowship [18171]	Ministero della Salute(Ministry of Health, Italy); Regione Friuli Venezia Giulia (Tichep Grant); 5x1000 CRO; AIRC biannual Fellowship	We thank Dr William Hahn and David Root for SGK2 vector (through Addgene), Dr Tamotsu Yoshimori for ptfLC3 vectors (through Addgene), Dr Roberta Maestro for pLPC vector and Laura Cesaratto and Sara Benevol for technical support. We are grateful to all members of our lab for helpful and stimulating discussions. This work was supported by grants from Ministero della Salute (RF-2010-2309704 and RF-2016-02361040), Regione Friuli Venezia Giulia (Tichep Grant) and 5x1000 CRO to GB; grants from 5x1000 CRO Intramural Young Investigator and from Ministero della Salute (RF-2016-02361041) to MSo. IS was supported by an AIRC biannual Fellowship (# 18171). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arencibia JM, 2013, BBA-PROTEINS PROTEOM, V1834, P1302, DOI 10.1016/j.bbapap.2013.03.010; Bago R, 2016, EMBO J, V35, P2263, DOI 10.15252/embj.201670010; Bast RC, 2009, NAT REV CANCER, V9, P415, DOI 10.1038/nrc2644; Berton S, 2014, CELL CYCLE, V13, P3100, DOI 10.4161/15384101.2014.949512; Biazik J, 2015, METHODS, V75, P44, DOI 10.1016/j.ymeth.2014.11.013; Bruhn Maressa A, 2013, Cancer Manag Res, V5, P281, DOI 10.2147/CMAR.S35178; Bruhn MA, 2010, GROWTH FACTORS, V28, P394, DOI 10.3109/08977194.2010.518616; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Castel P, 2016, CANCER CELL, V30, P229, DOI 10.1016/j.ccell.2016.06.004; Cotter K, 2015, TRENDS BIOCHEM SCI, V40, P611, DOI 10.1016/j.tibs.2015.08.005; Dall'Acqua A, 2017, EMBO MOL MED, V9, P1415, DOI 10.15252/emmm.201607012; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; Dikic I, 2018, NAT REV MOL CELL BIO, V19, P349, DOI 10.1038/s41580-018-0003-4; Eskelinen EL, 2005, AUTOPHAGY, V1, P1, DOI 10.4161/auto.1.1.1270; Eskelinen EL, 2011, CURR OPIN PHARMACOL, V11, P294, DOI 10.1016/j.coph.2011.03.009; Galluzzi L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.428; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Galluzzi L, 2017, EMBO J, V36, P1811, DOI 10.15252/embj.201796697; Galluzzi L, 2015, EMBO J, V34, P856, DOI 10.15252/embj.201490784; Gatti L, 2015, DRUG RESIST UPDATE, V20, P1, DOI 10.1016/j.drup.2015.04.001; He PJ, 2011, MOL BIOL CELL, V22, P3812, DOI 10.1091/mbc.E11-04-0328; Henke G, 2002, KIDNEY BLOOD PRESS R, V25, P370, DOI 10.1159/000068699; Holmes D, 2015, NATURE, V527, P219; Holmes D, 2015, NATURE, V527, pS217, DOI 10.1038/527S217a; Imai H, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0929-3; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jayson GC, 2014, LANCET, V384, P1376, DOI 10.1016/S0140-6736(13)62146-7; Kang X, 2015, CANCER BIOL MED, V12, P362, DOI 10.7497/j.issn.2095-3941.2015.0063; Katayama H, 2008, CELL STRUCT FUNCT, V33, P1, DOI 10.1247/csf.07011; Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004; Kimura S, 2007, AUTOPHAGY, V3, P452, DOI 10.4161/auto.4451; Klionsky DJ, 2011, AUTOPHAGY, V7, P1, DOI 10.4161/auto.7.1.14130; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kulshrestha A, 2016, MOL ONCOL, V10, P789, DOI 10.1016/j.molonc.2016.01.003; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Liu DL, 2011, MED ONCOL, V28, P105, DOI 10.1007/s12032-009-9397-3; Lo Russo G, 2017, CURR DRUG TARGETS, V18, P341, DOI 10.2174/1389450117666160502152331; Loos B, 2014, AUTOPHAGY, V10, P2087, DOI 10.4161/15548627.2014.973338; Lu ZN, 2017, CANCER CHEMOTH PHARM, V80, P925, DOI 10.1007/s00280-017-3426-2; Machiels JPH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-473; Marshansky V, 2008, CURR OPIN CELL BIOL, V20, P415, DOI 10.1016/j.ceb.2008.03.015; Massarelli E, 2015, ANN ONCOL, V26, P1476, DOI 10.1093/annonc/mdv194; Mauvezin C, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8007; Mindell JA, 2012, ANNU REV PHYSIOL, V74, P69, DOI 10.1146/annurev-physiol-012110-142317; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Mizushima N, 2010, CELL, V140, P313, DOI 10.1016/j.cell.2010.01.028; O'Keeffe BA, 2013, BIOCHIMIE, V95, P1258, DOI 10.1016/j.biochi.2013.01.019; Pao AC, 2007, AM J PHYSIOL-RENAL, V292, pF1741, DOI 10.1152/ajprenal.00027.2007; Pao AC, 2012, CURR OPIN NEPHROL HY, V21, P534, DOI 10.1097/MNH.0b013e32835571be; Pao AC, 2010, AM J PHYSIOL-RENAL, V299, pF1496, DOI 10.1152/ajprenal.00075.2010; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Patch AM, 2015, NATURE, V521, P489, DOI 10.1038/nature14410; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Pellarin I, 2020, ONCOGENE, V39, P4390, DOI 10.1038/s41388-020-1292-6; Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Rybstein MD, 2018, NAT CELL BIOL, V20, P243, DOI 10.1038/s41556-018-0042-2; Sherk AB, 2008, CANCER RES, V68, P7475, DOI 10.1158/0008-5472.CAN-08-1047; Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6; Sonego M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav3235; Sonego M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07005-1; Sonego M, 2013, EMBO MOL MED, V5, P707, DOI 10.1002/emmm.201201504; Song T, 2017, CANCER RES TREAT, V49, P595, DOI 10.4143/crt.2016.034; Thome MP, 2016, J CELL SCI, V129, P4622, DOI 10.1242/jcs.195057; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144; Yu H, 2011, EUR J CANCER, V47, P1585, DOI 10.1016/j.ejca.2011.01.019	69	7	7	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 1	2020	39	40					6370	6386		10.1038/s41388-020-01433-6	http://dx.doi.org/10.1038/s41388-020-01433-6		AUG 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NV5JK	32848212	hybrid, Green Published			2023-01-03	WOS:000563171700001
J	Sikstrom, L; Meyer, T; Katz, E; Choi, MM; Darragh, M; Cutler-Palma, A; Conforti, T; Kalocsai, C; Soklaridis, S				Sikstrom, Laura; Meyer, Tamar; Katz, Eva; Choi, Man-Man; Darragh, Margaret; Cutler-Palma, Amanda; Conforti, Theresa; Kalocsai, Csilla; Soklaridis, Sophie			Increasing participation in research with therapy dogs: A qualitative study at a large urban mental health and addiction hospital	PLOS ONE			English	Article							ANIMAL-ASSISTED THERAPY; DEPRESSION; MEDICINE; IMPACT	The benefits of involving patients as partners in research across diverse medical and psychiatric settings are well established in the literature. However, researchers continue to struggle to access, engage and retain participants from hard-to-reach populations. The main objective of this study was to co-create pet therapy activities with patients admitted for serious and complex mental illness to a large urban mental health and addiction hospital. Informed by the principles of participatory action research methodology, we conducted focus group discussions with 38 inpatients in seven different clinical units. An experienced volunteer handler and a certified therapy dog helped facilitate our discussions. Participating researchers, recreational therapists, volunteer handlers and our participants all reported that the presence of a certified therapy dog at each of our discussions was integral to their success. Certified therapy dogs increased themotivationto participate in our study, helped to buildrapportwith participants and createdconnectionsin our discussions that enriched our data. To our knowledge our study is the first to demonstrate the value of using a therapy dog as a participatory research tool in a healthcare setting. The authors believe that therapy dogs are a low-tech intervention that could be used effectively to engage hard-to-reach populations in research about their treatment and care in a diverse range of medical settings. These findings support the creation of a pilot study to test the value of including therapy dogs in patient-centered research with vulnerable and hard-to-reach populations.	[Sikstrom, Laura; Meyer, Tamar; Katz, Eva; Kalocsai, Csilla; Soklaridis, Sophie] Ctr Addict & Mental Hlth, Off Educ, Toronto, ON, Canada; [Choi, Man-Man; Cutler-Palma, Amanda] Ctr Addict & Mental Hlth, Geriatr Mental Hlth Serv, Toronto, ON, Canada; [Darragh, Margaret] Ctr Addict & Mental Hlth, Complex Care & Recovery Program, Toronto, ON, Canada; [Conforti, Theresa] Ctr Addict & Mental Hlth, Volunteer Serv, Toronto, ON, Canada; [Soklaridis, Sophie] Univ Toronto, Dept Psychiat, Toronto, ON, Canada; [Soklaridis, Sophie] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Soklaridis, Sophie] Univ Toronto, Univ Hlth Network, Wilson Ctr, Toronto, ON, Canada; [Soklaridis, Sophie] Univ Toronto, Fac Med, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Soklaridis, S (corresponding author), Ctr Addict & Mental Hlth, Off Educ, Toronto, ON, Canada.; Soklaridis, S (corresponding author), Univ Toronto, Dept Psychiat, Toronto, ON, Canada.; Soklaridis, S (corresponding author), Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.; Soklaridis, S (corresponding author), Univ Toronto, Univ Hlth Network, Wilson Ctr, Toronto, ON, Canada.; Soklaridis, S (corresponding author), Univ Toronto, Fac Med, Toronto, ON, Canada.	Sophie.soklaridis@camh.ca	Soklaridis, Sophie/ABG-2223-2020; Sikstrom, Laura/AAC-5294-2022; Kalocsai, Csilla/AAN-9990-2021	Soklaridis, Sophie/0000-0001-5119-8473; Sikstrom, Laura/0000-0001-9359-9574	Nestle-Purina Animal-Human Bond grant	Nestle-Purina Animal-Human Bond grant	Our study was funded by a Nestle-Purina Animal-Human Bond grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2012, FRONT PSYCHOL, DOI DOI 10.3389/FPSYG.2012.00234; Binfet JT, 2020, CANINE ASSISTED INTE; Bonevski B, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-42; Charmaz K., 2014, CONSTRUCTING GROUNDE, Vsecond; Charnetski CJ, 2004, PSYCHOL REP, V95, P1087, DOI 10.2466/PR0.95.7.1087-1091; Coakley Amanda Bulette, 2009, Complement Ther Clin Pract, V15, P141, DOI 10.1016/j.ctcp.2009.05.004; Dickson-Swift V., 2007, QUAL RES, V7, P327, DOI [10.1177/1468794107078515, DOI 10.1177/1468794107078515]; Dokken D, 2007, PEDIAT NURSING, V33, P356; Domecq JP, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-89; Filan SL, 2006, INT PSYCHOGERIATR, V18, P597, DOI 10.1017/S1041610206003322; Fox K., 2014, WATCHING ENGLISH HID; Gubrium A., 2013, PARTICIPATORY VISUAL; Hamann J, 2016, SOC PSYCH PSYCH EPID, V51, P617, DOI 10.1007/s00127-015-1089-z; Karnieli-Miller O, 2009, QUAL HEALTH RES, V19, P279, DOI 10.1177/1049732308329306; Kindon SL, 2007, ROUTL STUD HUM GEOGR, V22, P1; Krynicki CR, 2018, ACTA PSYCHIAT SCAND, V137, P380, DOI 10.1111/acps.12873; Kulick D, 2017, ANNU REV ANTHROPOL, V46, P357, DOI 10.1146/annurev-anthro-102116-041723; Levinson S.C., 2006, ROOTS HUM SOC CULT C, P39, DOI [10.4324/9781003135517-3, DOI 10.4324/9781003135517-3, DOI 10.3389/FPSYG.2015.00731]; Manafo E, 2018, HEALTH RES POLICY SY, V16, DOI 10.1186/s12961-018-0282-4; Marcus DA, 2013, PAIN MED, V14, P43, DOI 10.1111/j.1526-4637.2012.01522.x; McDonald AM, 2006, TRIALS, V7, DOI 10.1186/1745-6215-7-9; McNicholas J, 2000, BRIT J PSYCHOL, V91, P61, DOI 10.1348/000712600161673; Lasa SM, 2011, PANMINERVA MED, V53, P129; Murphy K, 2015, DEMENTIA-LONDON, V14, P800, DOI 10.1177/1471301213512489; Pendry P, 2019, AERA OPEN, V5, DOI 10.1177/2332858419852592; Porter N, 2019, MED ANTHROPOL Q, V33, P101, DOI 10.1111/maq.12459; Rogers WA, 2004, J MED ETHICS, V30, P141, DOI 10.1136/jme.2003.007062; Sockalingam Sanjeev, 2008, Issues Ment Health Nurs, V29, P73, DOI 10.1080/01612840701748847; Solomon O, 2010, ETHOS, V38, P143, DOI 10.1111/j.1548-1352.2010.01085.x; Souter MA, 2007, ANTHROZOOS, V20, P167, DOI 10.2752/175303707X207954; Stalmeijer RE, 2014, MED TEACH, V36, P923, DOI 10.3109/0142159X.2014.917165; Tambuyzer E, 2014, HEALTH EXPECT, V17, P138, DOI 10.1111/j.1369-7625.2011.00743.x; Wilson EO, 2009, BIOPHILIA HUMAN BOND	33	0	0	1	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2020	15	8							e0238096	10.1371/journal.pone.0238096	http://dx.doi.org/10.1371/journal.pone.0238096			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NK7YQ	32853258	Green Published, gold			2023-01-03	WOS:000566948800048
J	Vreeke, S; Zhu, XJ; Strongin, RM				Vreeke, Shawna; Zhu, Xijing; Strongin, Robert M.			A simple predictive model for estimating relative e-cigarette toxic carbonyl levels	PLOS ONE			English	Article							HEATING COIL; TEMPERATURE; PARAMETERS	E-cigarette devices are wide ranging, leading to significant differences in levels of toxic carbonyls in their respective aerosols. Power can be a useful method in predicting relative toxin concentrations within the same device, but does not correlate well to inter-device levels. Herein, we have developed a simple mathematical model utilizing parameters of an e-cigarette's coil and wick in order to predict relative levels of e-liquid solvent degradation. Model 1, which is coil length/(wick surface area*wraps), performed in the moderate-to-substantial range as a predictive tool (R-2= 0.69). Twelve devices, spanning a range of coil and wick styles, were analyzed. Model 1 was evaluated against twelve alternative models and displayed the best predictability. Relationships that included power settings displayed weak predictability, validating that power levels cannot be reliably compared between devices due to differing wicking and coil components and heat transfer efficiencies.	[Vreeke, Shawna; Zhu, Xijing; Strongin, Robert M.] Portland State Univ, Dept Chem, Portland, OR 97207 USA	Portland State University	Strongin, RM (corresponding author), Portland State Univ, Dept Chem, Portland, OR 97207 USA.	rmstrongin@gmail.com	Strongin, Robert M./F-1026-2010	Strongin, Robert/0000-0003-3777-8492	National Institutes of Health and Food and Drug Administration [R01ES025257]	National Institutes of Health and Food and Drug Administration	R.S. R01ES025257 National Institutes of Health and Food and Drug Administration NIH.gov FDA.gov The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2016, EVIDENCE, V8, pe1000; Atkins P.P., 2010, PHYS CHEM THERMODYNA, Vninth; Beauval N, 2019, INT J HYG ENVIR HEAL, V222, P136, DOI 10.1016/j.ijheh.2018.08.015; Breland A, 2017, ANN NY ACAD SCI, V1394, P5, DOI 10.1111/nyas.12977; Coresta, 2018, 74 COR; EL-Hellani A, 2018, NICOTINE TOB RES, V20, P215, DOI 10.1093/ntr/ntw280; Geiss O, 2016, INT J HYG ENVIR HEAL, V219, P268, DOI 10.1016/j.ijheh.2016.01.004; Gillman IG, 2016, REGUL TOXICOL PHARM, V75, P58, DOI 10.1016/j.yrtph.2015.12.019; Hair JF, 2014, EUR BUS REV, V26, P106, DOI 10.1108/EBR-10-2013-0128; Hess CA, 2017, ENVIRON RES, V152, P221, DOI 10.1016/j.envres.2016.09.026; Jensen RP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42549; Korzun T, 2018, ACS OMEGA, V3, P30, DOI 10.1021/acsomega.7b01521; Luikov A.V., 1964, ADV HEAT TRANSFER, V1, P123, DOI DOI 10.1016/S0065-2717(08)70098-4; Malek N, 2018, TOB REGUL SCI, V4, P47, DOI 10.18001/TRS.4.3.5; Martinez-Sanchez JM, 2018, GACETA SANITARIA; Ozisik N, 1985, FINITE DIFFERENCE ME; Reilly SM, 2018, NICOTINE TOB RES; Robinson RJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206341; Saliba NA, 2018, J ANAL APPL PYROL, V134, P520, DOI 10.1016/j.jaap.2018.07.019; Sleiman M, 2016, ENVIRON SCI TECHNOL, V50, P9644, DOI 10.1021/acs.est.6b01741; Soulet S, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15091853; Talih S, 2017, CHEM RES TOXICOL, V30, P1791, DOI 10.1021/acs.chemrestox.7b00212; Uchiyama S, 2016, ANAL SCI, V32, P549, DOI 10.2116/analsci.32.549; United States Environmental Protection Agency, 1996, 8315ASW846 US EPA; Vreeke S, 2018, ACS OMEGA, V3, P7165, DOI 10.1021/acsomega.8b00842; Vreeke S, 2018, AEROSOL SCI TECH, V52, P370, DOI 10.1080/02786826.2018.1424316; Wang P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169811; Zhao JY, 2018, INHAL TOXICOL, V30, P78, DOI 10.1080/08958378.2018.1450462; Zhao TK, 2016, ATMOS ENVIRON, V134, P61, DOI 10.1016/j.atmosenv.2016.03.027; Zinn S., 1988, ELEMENTS INDUCTION H	30	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 26	2020	15	8							e0238172	10.1371/journal.pone.0238172	http://dx.doi.org/10.1371/journal.pone.0238172			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NJ7ED	32845911	Green Published, gold			2023-01-03	WOS:000566205500027
J	Guha, S; Herman, A; Herbertson, L; Antonino, MJ; Silverstein, JS; Cooper, J; Myers, MR				Guha, Suvajyoti; Herman, Alexander; Herbertson, Luke; Antonino, Mark J.; Silverstein, Joshua S.; Cooper, Jeffrey; Myers, Matthew R.			Technical considerations for medical device manufacturers when designing gastrostomy tubes (G-tubes) using the new ISO 80369-3 connector	PLOS ONE			English	Article								Background Gastrostomy tubes (G-tubes) are typically used when people cannot eat food by mouth. The connector section that allows G-tubes to connect to other devices, such as feeding sets or syringes, has been modified on some of the devices to reduce misconnections in hospital settings. The narrow internal diameter of the new connector, standardized under ISO 80369-3, has caused some users to express concern about a reduced flow rate. Previous studies performed on commercial devices determined that it was not conclusive how much the ISO 80369-3 connector contributed towards the reduced flow rate, because when manufacturers designed these new connector-based devices, they often changed other geometric variables (such as distal tube diameter, or length) at the same time. Thus, it became difficult isolating the effect of the connector from other geometric variables. Method The key objective of this study was to investigate how different design variables impacted the flow rate through the G-tubes. 3D-printed devices were used to assess the geometric parameters in a systematic manner. Commercial diets and Newtonian analog fluids with matched viscosities were used for testing. Results The flow path length of the "transition section" encompassing the standardized ISO 80369-3 connector in the new devices was found to cause reduced flow. Additionally, results showed that a shortened (<= 10 mm) transition section, along with a 10% increase in the distal inner diameter of large bore devices (e.g., 24 Fr), can restore flow rates to levels consistent with the previous devices prior to the connector standardization. Conclusions The strategy for restoring flow rates to previous levels may help alleviate concerns raised by multiple stakeholders such as health care professionals, patients, caregivers and device manufacturers. In addition, the approach proposed here can be used as a tool for designing future G-tube devices.	[Guha, Suvajyoti; Herman, Alexander; Herbertson, Luke; Myers, Matthew R.] US FDA, Off Sci & Engn Labs, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA; [Antonino, Mark J.; Silverstein, Joshua S.; Cooper, Jeffrey] US FDA, Off Prod Evaluat & Qual, Ctr Devices & Radiol Hlth, Silver Spring, MD USA	US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)	Guha, S (corresponding author), US FDA, Off Sci & Engn Labs, Ctr Devices & Radiol Hlth, Silver Spring, MD 20993 USA.	Suvajyoti.Guha@fda.hhs.gov	Herman, Alexander/AAD-2113-2021	Herman, Alexander/0000-0002-8378-8184; Guha, Suvajyoti/0000-0002-7622-2721	Office of the Chief Scientist's Shared Resources program; Oak Ridge Associated Universities (ORAU)	Office of the Chief Scientist's Shared Resources program; Oak Ridge Associated Universities (ORAU)	3D Printing work was performed in the FDA Additive Manufacturing of Medical Products (AMMP) Lab, supported by the Office of the Chief Scientist's Shared Resources program.; Mr. A. Herman was funded through the Oak Ridge Associated Universities (ORAU) at the time of data collection.	Blumenstein I, 2014, WORLD J GASTROENTERO, V20, P8505, DOI 10.3748/wjg.v20.i26.8505; Cengel Y.A., 2010, FLUID MECH FUNDAMENT, V3rd ed.; Guha S, 2018, JPEN-PARENTER ENTER, V42, P1334, DOI 10.1002/jpen.1159; Hurt RT, 2016, CURR NUTR REP, V5, P240; Mundi MS, 2017, NUTR CLIN PRACT, V32, P799, DOI 10.1177/0884533617718472; Mundi MS, 2018, JPEN-PARENTER ENTER, V42, P522, DOI 10.1177/0148607117703959	6	1	1	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2020	15	7							e0236644	10.1371/journal.pone.0236644	http://dx.doi.org/10.1371/journal.pone.0236644			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW2PD	32730360	Green Published, gold			2023-01-03	WOS:000556884700102
J	Chen, WL; Peng, XY; Yu, JX; Chen, XX; Yuan, MG; Xiang, R; He, LM; Yu, DN; Kang, HH; Pan, YF; Xu, ZH				Chen, Wenlu; Peng, Xinyu; Yu, Jingxian; Chen, Xuanxuan; Yuan, Minggui; Xiang, Rong; He, Limei; Yu, Danni; Kang, Huahua; Pan, Yufang; Xu, Zhihong			FengLiao affects gut microbiota and the expression levels of Na plus /H plus exchangers, aquaporins and acute phase proteins in mice with castor oil-induced diarrhea	PLOS ONE			English	Article							UP-REGULATION; MEDICINE; SYSTEM	The severe side effects of chemosynthetic anti-diarrhea drugs have created an interest in low-toxic alternative plant-derived compounds. FengLiao consists ofPolygonum hydropiperLinn. andDaphniphyllum calycinumBench., and is widely used in China to treat diarrhea due to low levels of toxicity. In this study, the effects of FengLiao were analyzed in a castor oil-induced diarrhea model, using the anti-diarrhea drug, loperamide, as the positive control. The effects were evaluated using stool characteristics and the expression levels of various diarrhea-related factors in the jejunum and liver, as well as changes in the microbiota of the jejunum. The symptoms of diarrhea and stool consistency were improved through FengLiao and loperamide treatment. Furthermore, FengLiao down-regulated alpha 1-acid glycoprotein (AGP) and C-reactive protein (CRP) levels, and up-regulated transferrin (TRF) mRNA levels in the liver, and down-regulated Aquaporin 3 (AQP3) and Na+/H+ exchanger isoform 8 (NHE8) expression in the epithelial cells of the jejunum. It also increased the relative abundance ofBifidobacterium,Aerococcus,Corynebacterium_1 andPseudomonas, and lowered the Firmicutes/Bacteroidetes (F/B) ratio, which maintained the balance between immunity and intestinal health. Taken together, FengLiao alleviated castor oil-induced diarrhea by altering gut microbiota, and levels of jejunum epithelial transport proteins and acute phase proteins.	[Chen, Wenlu; Peng, Xinyu; Yuan, Minggui; Xiang, Rong; He, Limei; Yu, Danni; Kang, Huahua; Xu, Zhihong] Guangdong Acad Agr Sci, Inst Anim Hlth, Guangzhou, Peoples R China; [Chen, Wenlu; Chen, Xuanxuan; Pan, Yufang] Guangdong Pharmaceut Univ, Guangzhou, Peoples R China; [Peng, Xinyu; Yuan, Minggui; Xiang, Rong; Yu, Danni; Kang, Huahua; Xu, Zhihong] Key Lab Live Stock Dis Prevent Guangdong Prov, Guangzhou, Peoples R China; [Peng, Xinyu; Yuan, Minggui; Xiang, Rong; Yu, Danni; Kang, Huahua; Xu, Zhihong] Minist Agr, Sci Observing & Expt Stn Vet Drugs & Diagnost Tec, Guangzhou, Peoples R China; [Peng, Xinyu; Yuan, Minggui; Xiang, Rong; Yu, Danni; Kang, Huahua; Xu, Zhihong] Chinese Tradit Med Engn Technol Res Ctr Guangdong, Guangzhou, Peoples R China; [Yu, Jingxian] South China Agr Univ, Guangzhou, Peoples R China	Guangdong Academy of Agricultural Sciences; Guangdong Pharmaceutical University; Ministry of Agriculture & Rural Affairs; South China Agricultural University	Peng, XY (corresponding author), Guangdong Acad Agr Sci, Inst Anim Hlth, Guangzhou, Peoples R China.; Peng, XY (corresponding author), Key Lab Live Stock Dis Prevent Guangdong Prov, Guangzhou, Peoples R China.; Peng, XY (corresponding author), Minist Agr, Sci Observing & Expt Stn Vet Drugs & Diagnost Tec, Guangzhou, Peoples R China.; Peng, XY (corresponding author), Chinese Tradit Med Engn Technol Res Ctr Guangdong, Guangzhou, Peoples R China.	996202250@qq.com		Peng, Xinyu/0000-0002-9395-6284; Chen, Wen'lu/0000-0003-0199-015X	Institute of Animal Health, Guangdong Academy of Agricultural Sciences and Guangdong Pharmaceutical University; Special Fund for AgroScientific Research in the Public Interest Ministry of Agriculture of the People's Republic of China [201303040-16]; Agricultural Science and Technology Innovation and Major Projects of Guangdong Province (2018)	Institute of Animal Health, Guangdong Academy of Agricultural Sciences and Guangdong Pharmaceutical University; Special Fund for AgroScientific Research in the Public Interest Ministry of Agriculture of the People's Republic of China; Agricultural Science and Technology Innovation and Major Projects of Guangdong Province (2018)	This work was supported by the Institute of Animal Health, Guangdong Academy of Agricultural Sciences and Guangdong Pharmaceutical University. In addition, this work was supported by the Special Fund for AgroScientific Research in the Public Interest Ministry of Agriculture of the People's Republic of China (Grant No. 201303040-16) and Agricultural Science and Technology Innovation and Major Projects of Guangdong Province (2018) to XP. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, THESIS; Basler M, 2012, NATURE, V483, P182, DOI 10.1038/nature10846; Basler M, 2013, CELL, V152, P884, DOI 10.1016/j.cell.2013.01.042; Buffie CG, 2013, NAT REV IMMUNOL, V13, P790, DOI 10.1038/nri3535; Ceciliani F, 2012, J PROTEOMICS, V75, P4207, DOI 10.1016/j.jprot.2012.04.004; Chang CJ, 2015, NAT COMMUN, V6, DOI [10.1038/ncomms8489, 10.1038/ncomms8216]; Cheng KC, 2012, CURR PHARM DESIGN, V18, P4819, DOI 10.2174/138161212803216979; Chiadak JD, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17101742; Fang D.S., 1964, ACTA CHIN SIN, V30, P270; Ikarashi N, 2011, BIOL PHARM BULL, V34, P238, DOI 10.1248/bpb.34.238; Jain S, 2011, J PHARM BIOALLIED SC, V3, P118, DOI 10.4103/0975-7406.76489; Jiang Q, 2016, J SUPERCOMPUT, V72, P3826, DOI 10.1007/s11227-015-1610-x; Jin M, 2020, ARCH GYNECOL OBSTET, V301, P243, DOI 10.1007/s00404-019-05336-0; Kaiser EA, 2017, NEUROPEPTIDES, V64, P95, DOI 10.1016/j.npep.2016.11.004; Lam W, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001270; Lei XL, 2018, KOREAN J PHYSIOL PHA, V22, P269, DOI 10.4196/kjpp.2018.22.3.269; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2008, NAT REV MICROBIOL, V6, P776, DOI 10.1038/nrmicro1978; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Liang Y, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009359.pub2; Liu F, 2014, T DATA HIDING MULTIM, P1; Liu H, 2008, 2008 CHINESE CONTROL AND DECISION CONFERENCE, VOLS 1-11, P74, DOI 10.1109/CCDC.2008.4597273; Magnusdottir S, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00148; Mousa WK, 2017, NAT PROD REP, V34, P1302, DOI 10.1039/c7np00021a; Murata H, 2004, VET J, V168, P28, DOI 10.1016/S1090-0233(03)00119-9; Pelagalli A, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17081213; Poppleton DI, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.01215; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Qi FH, 2015, BIOSCI TRENDS, V9, P16, DOI 10.5582/bst.2015.01019; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Roberts M C, 1989, Equine Vet J Suppl, P60, DOI 10.1111/j.2042-3306.1989.tb05658.x; Sakai H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054788; Satta M, 2001, INT J PHOTOENERGY, V3; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; Smith MI, 2013, SCIENCE, V339, P548, DOI 10.1126/science.1229000; Urdaci MC, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.01537; Verruck S, 2020, FOOD RES INT, V127, DOI 10.1016/j.foodres.2019.108690; Wang KL, 2017, MOLECULES, V22, DOI 10.3390/molecules22030465; WHO,, 2017, DIARRH DIS; Xu H, 2018, COMPR PHYSIOL, V8, P555, DOI 10.1002/cphy.c170027; Xu H, 2011, AM J PHYSIOL-GASTR L, V300, pG647, DOI 10.1152/ajpgi.00546.2010; Yu B, 2019, PAK J PHARM SCI, V32, P1333; Yu HL, 2018, BIOCHIMIE, V144, P153, DOI 10.1016/j.biochi.2017.11.006; Yu JK, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/3687486; Zachos NC, 2005, ANNU REV PHYSIOL, V67, P411, DOI 10.1146/annurev.physiol.67.031103.153004; Zhang D, 2017, MICROB PATHOGENESIS, V107, P430, DOI 10.1016/j.micpath.2017.04.031; Zhang XP, 2012, MOLECULES, V17, P9641, DOI 10.3390/molecules17089641; Zhao SS, 2018, NEUROGASTROENT MOTIL, V30, DOI 10.1111/nmo.13364	48	4	5	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2020	15	7							e0236511	10.1371/journal.pone.0236511	http://dx.doi.org/10.1371/journal.pone.0236511			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW3BD	32722717	gold, Green Published			2023-01-03	WOS:000556916000033
J	Lindemann, J; Rakers, C; Matuskova, H; Simon, BJ; Kinfe, T; Petzold, GC				Lindemann, Jan; Rakers, Cordula; Matuskova, Hana; Simon, Bruce J.; Kinfe, Thomas; Petzold, Gabor C.			Vagus nerve stimulation reduces spreading depolarization burden and cortical infarct volume in a rat model of stroke	PLOS ONE			English	Article							CEREBRAL-ARTERY OCCLUSION; PERIINFARCT DEPOLARIZATIONS; DEPRESSION; BRAIN; ISCHEMIA; MIGRAINE; TRANSIENTS; INDUCTION; CHANNELS; SIZE	Cortical spreading depolarization (SD) waves negatively affect neuronal survival and outcome after ischemic stroke. We here aimed to investigate the effects of vagus nerve stimulation (VNS) on SDs in a rat model of focal ischemia. To this end, we delivered non-invasive VNS (nVNS) or invasive VNS (iVNS) during permanent middle cerebral artery occlusion (MCAO), and found that both interventions significantly reduced the frequency of SDs in the cortical peri-infarct area compared to sham VNS, without affecting relative blood flow changes, blood pressure, heart rate or breathing rate. In separate groups of rats subjected to transient MCAO, we found that cortical stroke volume was reduced 72 h after transient MCAO, whereas stroke volume in the basal ganglia remained unchanged. In rats treated with nVNS, motor outcome was improved 2 days after transient MCAO, but was similar to sham VNS animals 3 days after ischemia. We postulate that VNS may be a safe and efficient intervention to reduce the clinical burden of SD waves in stroke and other conditions.	[Lindemann, Jan; Rakers, Cordula; Matuskova, Hana; Petzold, Gabor C.] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany; [Simon, Bruce J.] ElectroCore Inc, Basking Ridge, NJ USA; [Kinfe, Thomas] Univ Hosp Bonn, Dept Neurosurg, Bonn, Germany; [Kinfe, Thomas] Univ Hosp Erlangen, Dept Neurosurg, Div Funct & Stereotact Neurosurg, Erlangen, Germany; [Petzold, Gabor C.] Univ Hosp Bonn, Dept Neurol, Div Vasc Neurol, Bonn, Germany	Helmholtz Association; German Center for Neurodegenerative Diseases (DZNE); University of Bonn; University of Erlangen Nuremberg; University of Bonn	Petzold, GC (corresponding author), German Ctr Neurodegenerat Dis DZNE, Bonn, Germany.; Petzold, GC (corresponding author), Univ Hosp Bonn, Dept Neurol, Div Vasc Neurol, Bonn, Germany.	gabor.petzold@dzne.de	Kinfe, Thomas/AAY-7093-2020	Kinfe, Thomas/0000-0002-4888-543X	German Science Foundation DFG [FOR 2795/PE1193/6-1]; DZNE (DEMDAS Intersite grant); electroCore Inc.	German Science Foundation DFG(German Research Foundation (DFG)); DZNE (DEMDAS Intersite grant); electroCore Inc.	This work was supported by grants to GCP from the German Science Foundation DFG (FOR 2795/PE1193/6-1) and the DZNE (DEMDAS Intersite grant). The funder electroCore Inc. provided support in the form of materials (electrodes and stimulators) and salary for author BJS, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.	Ay I, 2016, BRAIN STIMUL, V9, P166, DOI 10.1016/j.brs.2015.11.008; Ay I, 2011, BRAIN RES, V1392, P110, DOI 10.1016/j.brainres.2011.03.060; Ay I, 2009, NEUROSCI LETT, V459, P147, DOI 10.1016/j.neulet.2009.05.018; BENMENACHEM E, 1995, EPILEPSY RES, V20, P221, DOI 10.1016/0920-1211(94)00083-9; Bland ST, 2000, STROKE, V31, P1144, DOI 10.1161/01.STR.31.5.1144; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Chen SP, 2016, PAIN, V157, P797, DOI 10.1097/j.pain.0000000000000437; Cunningham JT, 2008, NEUROPSYCHOPHARMACOL, V33, P1884, DOI 10.1038/sj.npp.1301570; Dreier JP, 2018, NEUROPHARMACOLOGY, V134, P189, DOI 10.1016/j.neuropharm.2017.09.027; Dreier JP, 2015, NEURON, V86, P902, DOI 10.1016/j.neuron.2015.04.004; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Fisher M, 2009, STROKE, V40, P2244, DOI 10.1161/STROKEAHA.108.541128; Fornai F, 2011, EUR J NEUROSCI, V33, P2169, DOI 10.1111/j.1460-9568.2011.07707.x; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Ginsberg MD, 2003, ANN NEUROL, V54, P330, DOI 10.1002/ana.10659; Golanov EV, 1999, BRAIN RES, V818, P304, DOI 10.1016/S0006-8993(98)01169-X; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Hiraki T, 2012, J NEUROSCI RES, V90, P887, DOI 10.1002/jnr.22812; Lapilover EG, 2012, NEUROBIOL DIS, V48, P495, DOI 10.1016/j.nbd.2012.06.024; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; le Grand SM, 2011, HEADACHE, V51, P1152, DOI 10.1111/j.1526-4610.2011.01931.x; Lewine JD, 2019, NEUROMODULATION, V22, P564, DOI 10.1111/ner.12864; Liu AF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0858-0; Luckl J, 2009, J NEUROSCI RES, V87, P1219, DOI 10.1002/jnr.21933; Manta S, 2013, INT J NEUROPSYCHOPH, V16, P459, DOI 10.1017/S1461145712000387; Mestre H, 2020, SCIENCE, V367, P1211, DOI 10.1126/science.aax7171; Oshinsky ML, 2014, PAIN, V155, P1037, DOI 10.1016/j.pain.2014.02.009; Petzold GC, 2005, BRAIN RES, V1063, P9, DOI 10.1016/j.brainres.2005.09.048; Pusic KM, 2014, GLIA, V62, P1176, DOI 10.1002/glia.22672; Rakers C, 2019, GLIA, V67, P619, DOI 10.1002/glia.23544; Rakers C, 2017, GLIA, V65, P1550, DOI 10.1002/glia.23183; Rakers C, 2017, J CLIN INVEST, V127, P511, DOI 10.1172/JCI89354; Richter F, 2005, J CEREBR BLOOD F MET, V25, P1225, DOI 10.1038/sj.jcbfm.9600120; Sadeghian H, 2018, ANN NEUROL, V84, P409, DOI 10.1002/ana.25298; Schaar Krystal L, 2010, Exp Transl Stroke Med, V2, P13, DOI 10.1186/2040-7378-2-13; Yang YR, 2018, BRAIN STIMUL, V11, P689, DOI 10.1016/j.brs.2018.01.034	37	10	11	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2020	15	7							e0236444	10.1371/journal.pone.0236444	http://dx.doi.org/10.1371/journal.pone.0236444			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX7VK	32702055	gold, Green Published			2023-01-03	WOS:000575913700094
J	Sargent, J; Roberts, V; D'Souza, K; Wright, A; Gaffney, J; Frias, A				Sargent, James; Roberts, Victoria; D'Souza, Karen; Wright, Adam; Gaffney, Jessica; Frias, Antonio			Micro-anatomic alterations of the placenta in a non-human primate model of gestational protein-restriction	PLOS ONE			English	Article							MALNUTRITION; NUTRITION	Objectives Maternal protein malnutrition is associated with impaired fetal growth, and lifetime consequences for the offspring. Our group has previously developed a model of protein-restriction in the non-human primate, which was associated with fetal growth restriction, stillbirth, decreased placental perfusion, and evidence of fetal hypoxia, suggesting perturbed vascular development. Our objective was to histologically characterize the micro-anatomic alterations associated with adverse pregnancy outcomes taking an approach that permits investigation of the 3D vascular structure and surrounding histology without the requirement for 3D vascular casting or relying on 2D stereology which both have methodological limitations. Methods Rhesus macaques were assigned in the pre-gestational period to a control diet that contained 26% protein, or study diet containing 13% protein (50% PR diet). Placental tissue was collected at delivery and processed using a clarification, immunohistochemistry, and confocal microscopy protocol published previously by our group. Three dimensional reconstructions and quantitative assessment of the vascular micro-anatomy was performed using analysis software (Imaris (R)) and statistical analysis accounted for maternal and fetal confounders. Results In unadjusted analysis, when comparing those pregnancies on a 50% PR diet (n = 4) with those on a control diet (n = 4), protein-restriction diet was associated with decreased maternal pre-pregnancy weight (difference of -1.975kg, 95% CI -3.267 to -0.6826). When controlling for maternal pre-pregnancy weight, fetal sex, and latency from tissue collection to imaging, a gestational protein-restriction diet was associated with decreases in total vascular length, total vascular surface area, total vascular volume, and vascular density. Conclusion In this pilot study, a gestational protein-restriction diet altered the placental micro-vasculature with decreased vascular caliber and density, which may be related to the observed adverse pregnancy outcomes and perturbed placental perfusion previously demonstrated in this model.	[Sargent, James] Univ Texas Hlth Sci Houston, Houston, TX 77030 USA; [Roberts, Victoria; D'Souza, Karen; Wright, Adam; Gaffney, Jessica; Frias, Antonio] Oregon Natl Primate Res Ctr, Div Reprod & Dev Sci, Beaverton, OR USA; [Frias, Antonio] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA	University of Texas System; University of Texas Health Science Center Houston; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University	Sargent, J (corresponding author), Univ Texas Hlth Sci Houston, Houston, TX 77030 USA.	james.sargent@gmail.com		Wright, Adam/0000-0001-9524-2210; Sargent, James/0000-0002-9895-8561; DSouza, Karen/0000-0003-3230-5100	Bill & Melinda Gates Foundation [OPP1110865]; NIH [R01 HD086331]; Office of the Director, of the National Institutes of Health [P51OD011092]	Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of the Director, of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for this project was provided by The Bill & Melinda Gates Foundation (OPP1110865) and NIH R01 HD086331 (Frias). In addition, research reported in this publication was supported by the Office of the Director, of the National Institutes of Health under Award Number P51OD011092 to the Oregon National Primate Research Center. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Baker BC, 2018, REPRODUCTION, V156, pR69, DOI 10.1530/REP-18-0130; Bourke CD, 2016, TRENDS IMMUNOL, V37, P386, DOI 10.1016/j.it.2016.04.003; Connor KL, 2018, BIOL REPROD, V98, P579, DOI 10.1093/biolre/ioy002; Fall CHD, 2013, NESTLE NUTR WORKS SE, V74, P11, DOI 10.1159/000348384; FAO IFAD UNICEF WFP and WHO, 2018, STAT FOOD SEC NUTR W; Furuya M, 2008, VASC HEALTH RISK MAN, V4, P1301, DOI 10.2147/VHRM.S4009; Ghosh S, 2012, BRIT J NUTR, V108, pS77, DOI 10.1017/S0007114512002577; Gonzalez PN, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152227; Haeussner E, 2015, PLACENTA, V36, P1425, DOI 10.1016/j.placenta.2015.10.003; Junaid TO, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04379-0; Kovo M, 2015, REPROD SCI, V22, P316, DOI 10.1177/1933719114542024; Marques AH, 2015, BRAIN RES, V1617, P28, DOI 10.1016/j.brainres.2014.10.051; Papathakis PC, 2016, MOL CELL ENDOCRINOL, V435, P40, DOI 10.1016/j.mce.2016.01.024; RAMSEY EM, 1976, AM J OBSTET GYNECOL, V124, P647, DOI 10.1016/0002-9378(76)90068-5; Ribatti D, 2015, METHODS MOL BIOL, V1214, P1, DOI 10.1007/978-1-4939-1462-3; Roberts VHJ, 2018, REPROD SCI, V25, P110, DOI 10.1177/1933719117704907; Sargent JA, 2019, BIOTECHNIQUES, V66, P79, DOI 10.2144/btn-2018-0110; Semba RD, 2016, EBIOMEDICINE, V6, P246, DOI 10.1016/j.ebiom.2016.02.030; ZENG LX, 2008, BMJ-BRIT MED J, V337, DOI DOI 10.1136/BMJ.A2001; Zhou J, 2016, J PEDIATR-US, V178, P40, DOI 10.1016/j.jpeds.2016.06.017	20	3	3	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2020	15	7							e0235840	10.1371/journal.pone.0235840	http://dx.doi.org/10.1371/journal.pone.0235840			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX7VK	32702025	Green Published, gold			2023-01-03	WOS:000575913700028
J	Van Hecke, O; Raymond, M; Lee, JJ; Turner, P; Goyder, CR; Verbakel, JY; van den Bruel, A; Hayward, G				Van Hecke, Oliver; Raymond, Meriel; Lee, Joseph J.; Turner, Philip; Goyder, Clare R.; Verbakel, Jan Y.; van den Bruel, Ann; Hayward, Gail			In-vitro diagnostic point-of-care tests in paediatric ambulatory care: A systematic review and meta-analysis	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; RESPIRATORY-TRACT INFECTIONS; LOW-MALARIA TRANSMISSION; UK PRIMARY-CARE; CRP RAPID TEST; STREPTOCOCCAL PHARYNGITIS; ANTIBIOTIC USE; CHILDREN; IMPACT; MANAGEMENT	Introduction Paediatric consultations form a significant proportion of all consultations in ambulatory care. Point-of-care tests (POCTs) may offer a potential solution to improve clinical outcomes for children by reducing diagnostic uncertainty in acute illness, and streamlining management of chronic diseases. However, their clinical impact in paediatric ambulatory care is unknown. We aimed to describe the clinical impact of allin-vitrodiagnostic POCTs on patient outcomes and healthcare processes in paediatric ambulatory care. Methods We searched MEDLINE, EMBASE, Pubmed, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, and Web of Science from inception to 29 January 2020 without language restrictions. We included studies of children presenting to ambulatory care settings (general practice, hospital outpatient clinics, or emergency departments, walk-in centres, registered drug shops delivering healthcare) wherein-vitrodiagnostic POCTs were compared to usual care. We included all quantitative clinical outcome data across all conditions or infection syndromes reporting on the impact of POCTs on clinical care and healthcare processes. Where feasible, we calculated risk ratios (RR) with 95% confidence intervals (CI) by performing meta-analysis using random effects models. Results We included 35 studies. Data relating to at least one outcome were available for 89,439 children of whom 45,283 had a POCT across six conditions or infection syndromes: malaria (n = 14); non-specific acute fever 'illness' (n = 7); sore throat (n = 5); acute respiratory tract infections (n = 5); HIV (n = 3); and diabetes (n = 1). Outcomes centred around decision-making such as prescription of medications or hospital referral. Pooled estimates showed that malarial-POCTs (Plasmodium falciparum) better targeted antimalarial treatment by reducing over-treatment by a third compared to usual care (RR 0.67; 95% CI [0.58 to 0.77], n = 36,949). HIV-POCTs improved initiating earlier antiretroviral therapy compared to usual care (RR, 3.11; 95% CI [1.55 to 6.25], n = 912). Across the other four conditions, there was limited evidence for the benefit of POCTs in paediatric ambulatory care except for acute respiratory tract infections (RTI) in low-and-middle-income countries (LMICs), where POCT C-Reactive Protein (CRP) may reduce immediate antibiotic prescribing by a third (risk difference, -0.29 [-0.47, -0.11], n = 2,747). This difference was shown in randomised controlled trials in LMICs which included guidance on interpretation of POCT-CRP, specific training or employed a diagnostic algorithm prior to POC testing. Conclusion Overall, there is a paucity of evidence for the use of POCTs in paediatric ambulatory care. POCTs help to target prescribing for children with malaria and HIV. There is emerging evidence that POCT-CRP may better target antibiotic prescribing for children with acute RTIs in LMIC, but not in high-income countries. Research is urgently needed to understand where POCTs are likely to improve clinical outcomes in paediatric settings worldwide.	[Van Hecke, Oliver; Raymond, Meriel; Lee, Joseph J.; Turner, Philip; Goyder, Clare R.; Hayward, Gail] Univ Oxford, Nuffield Dept Primary Hlth Care Sci, Oxford, England; [Verbakel, Jan Y.; van den Bruel, Ann] Katholieke Univ Leuven, Acad Ctr Gen Practice, Leuven, Belgium	University of Oxford; KU Leuven	Van Hecke, O (corresponding author), Univ Oxford, Nuffield Dept Primary Hlth Care Sci, Oxford, England.	oliver.vanhecke@phc.ox.ac.uk	Verbakel, Jan/E-6758-2015	Verbakel, Jan/0000-0002-7166-7211; Hayward, Gail/0000-0003-0852-627X; Raymond, Meriel/0000-0002-0442-9280; Lee, Joseph/0000-0002-4033-0915; Turner, Philip/0000-0001-7299-8939; Goyder, Clare/0000-0002-7461-9661; van Hecke, Oliver/0000-0002-6229-5057	Wellcome Trust Doctoral Research Fellowship; NIHR Community Healthcare MedTech and IVD Co-operative Oxford at Oxford Health Foundation Trust [MIC2016-018]; National Instituate for Health Research (NIHR) Community Healthcare MedTech and In Vitro Diagnostics Co-operative at Oxford Health NHS Foundation Trust	Wellcome Trust Doctoral Research Fellowship(Wellcome Trust); NIHR Community Healthcare MedTech and IVD Co-operative Oxford at Oxford Health Foundation Trust; National Instituate for Health Research (NIHR) Community Healthcare MedTech and In Vitro Diagnostics Co-operative at Oxford Health NHS Foundation Trust	CRG is supported by a Wellcome Trust Doctoral Research Fellowship. PT and GH are supported through the NIHR Community Healthcare MedTech and IVD Co-operative Oxford at Oxford Health Foundation Trust (award MIC2016-018). This research was funded by the National Instituate for Health Research (NIHR) Community Healthcare MedTech and In Vitro Diagnostics Co-operative at Oxford Health NHS Foundation Trust. The funders did not have any role in the study design, data collection and analysis or preparation of the manuscript. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.	Aabenhus R, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010130.pub2; Agus MSD, 2010, PEDIATR DIABETES, V11, P450, DOI 10.1111/j.1399-5448.2009.00635.x; Althaus T, 2019, LANCET GLOB HEALTH, V7, pE119, DOI 10.1016/S2214-109X(18)30444-3; [Anonymous], 2016, SYSTEMATIC REV ASSES; [Anonymous], 2017, BMJ-BRIT MED J, V356, pj963, DOI 10.1136/bmj.j963pmid:28254739; [Anonymous], 2015, STAT STAT SOFTW REL; [Anonymous], 2018, BMJ-BRIT MED J, V361, pk2475; Ansah EK, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1019; Ansah EK, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c930; Ayanruoh S, 2009, PEDIATR EMERG CARE, V25, P748, DOI 10.1097/PEC.0b013e3181bec88c; Baiden F, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152960; Bianchi F, 2019, LANCET HIV, V6, pE373, DOI 10.1016/S2352-3018(19)30033-5; Bird C, 2018, PEDIATR EMERG CARE, V24, P24; Bisoffi Z, 2009, TROP MED INT HEALTH, V14, P491, DOI 10.1111/j.1365-3156.2009.02246.x; Bobrovitz N, 2017, BMC EMERG MED, V17, DOI 10.1186/s12873-017-0145-2; Bogoch II, 2019, PLOS NEGLECT TROP D, V13, DOI 10.1371/journal.pntd.0007315; Bossuyt PM, 2006, BRIT MED J, V332, P1089, DOI 10.1136/bmj.332.7549.1089; Butler CC, 2019, NEW ENGL J MED, V381, P111, DOI 10.1056/NEJMoa1803185; Cantais A, 2019, CLIN MICROBIOL INFEC, V25, P898, DOI 10.1016/j.cmi.2018.11.019; Cecil E, 2015, ANN FAM MED, V13, P214, DOI 10.1370/afm.1786; Chandler CIR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170998; Cochrane Collaboration, 2014, REV MAN REVMAN VERS; Cohen JF, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010502.pub2; Cohen R, 2008, ARCH PEDIATRIE, V15, P1126, DOI 10.1016/j.arcped.2008.03.007; Diederichsen HZ, 2000, SCAND J PRIM HEALTH, V18, P39; Doan QH, 2009, J PEDIATR-US, V154, P91, DOI 10.1016/j.jpeds.2008.07.043; Flenady V, 2017, BMC PREGNANCY CHILDB, V17, P35; Gialamas A, 2009, MED J AUSTRALIA, V191, P487, DOI 10.5694/j.1326-5377.2009.tb02910.x; Gill PJ, 2013, ARCH DIS CHILD, V98, P651, DOI 10.1136/archdischild-2012-302383corr1; Haenssgen MJ, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3215-9; Higgins Julian PT, 2011, COCHRANE HDB SYSTEMA, P649; Hobbs FDR, 2016, LANCET, V387, P2323, DOI 10.1016/S0140-6736(16)00620-6; Huang YF, 2013, BRIT J GEN PRACT, V63, pE787, DOI 10.3399/bjgp13X674477; Jani IV, 2018, AIDS, V32, P1453, DOI [10.1097/QAD.0000000000001846, 10.1097/qad.0000000000001846]; Kaehler N, 2019, INT HEALTH, V11, P166, DOI 10.1093/inthealth/ihy079; Keitel K, 2019, CLIN INFECT DIS, V69, P1926, DOI 10.1093/cid/ciz080; Lal S, 2016, AM J TROP MED HYG, V95, P1398, DOI 10.4269/ajtmh.16-0598; Lee JJ, 2019, INFECT DIS SOC AM, V18, P24; Lemiengre MB, 2018, BRIT J GEN PRACT, V68, pE204, DOI 10.3399/bjgp18X695033; Little P, 2013, LANCET, V382, P1175, DOI 10.1016/S0140-6736(13)60994-0; Malecki M., 2017, PEDIAT POLSKA, V92, P149, DOI [10.1016/j.pepo.2017.01.006, DOI 10.1016/J.PEPO.2017.01.006, DOI 10.1016/J.PEP0.2017.01.006]; Maltezou HC, 2008, J ANTIMICROB CHEMOTH, V62, P1407, DOI 10.1093/jac/dkn376; Mbonye AK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129545; McDonald CR, 2018, MALARIA J, V17, DOI 10.1186/s12936-018-2488-x; MEIER FA, 1990, ARCH INTERN MED, V150, P1696, DOI 10.1001/archinte.150.8.1696; Msellem MI, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000070; Mubi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019753; Mukanga D, 2012, AM J TROP MED HYG, V87, P21, DOI 10.4269/ajtmh.2012.11-0816; Mwenda R, 2018, CLIN INFECT DIS, V67, P701, DOI 10.1093/cid/ciy169; NCCN Clinical Practice, 2018, ACUTE MYELOID LEUKEM, VV2, pMS28; Ndyomugyenyi R, 2016, TROP MED INT HEALTH, V21, P1157, DOI 10.1111/tmi.12748; Nijman RG, 2015, PEDIATR EMERG CARE, V31, P633, DOI 10.1097/PEC.0000000000000466; Odaga J, 2011, COCHRANE DATABASE SY; ONeill J., 2016, TACKLING DRUG RESIST; Rebnord IK, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012992; Sands R, 2012, EMERG MED J, V29, P379, DOI 10.1136/emj.2010.106229; Saxena S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007484; Sayang C, 2009, AM J TROP MED HYG, V81, P343, DOI 10.4269/ajtmh.2009.81.343; Schols AMR, 2018, FAM PRACT, V35, P4, DOI 10.1093/fampra/cmx066; The Lancet Global Health, 2016, LANCET GLOB HEALTH, V4, pe427; Ukwaja KN, 2010, ETHIOP J HEALTH SCI, V20, P179; Van den Bruel Ann, 2006, BMC Fam Pract, V7, P23, DOI 10.1186/1471-2296-7-23; Van den Bruel A, 2016, ARCH DIS CHILD, V101, P382, DOI 10.1136/archdischild-2015-309228; Van den Bruel A, 2010, LANCET, V375, P834, DOI 10.1016/S0140-6736(09)62000-6; van Esso DL, 2019, PEDIATR INFECT DIS J, V38, pE187, DOI 10.1097/INF.0000000000002287; van Hecke O, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029260; Verbakel JY, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025036; Verbakel JY, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015760; Verbakel JY, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0679-2; von Seidlein L, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002745; Wabe N, 2019, MED J AUSTRALIA, V210, P316, DOI 10.5694/mja2.50049; Yeboah-Antwi K, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000340	72	7	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2020	15	7							e0235605	10.1371/journal.pone.0235605	http://dx.doi.org/10.1371/journal.pone.0235605			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM3OG	32628707	Green Published, gold			2023-01-03	WOS:000550068700008
J	Lozano-Hernandez, CM; Lopez-Rodriguez, JA; Leiva-Fernandez, F; Calderon-Larranaga, A; Barrio-Cortes, J; Gimeno-Feliu, LA; Poblador-Plou, B; del Cura-Gonzalez, I				Lozano-Hernandez, Cristina M.; Lopez-Rodriguez, Juan A.; Leiva-Fernandez, Francisca; Calderon-Larranaga, Amaia; Barrio-Cortes, Jaime; Gimeno-Feliu, Luis A.; Poblador-Plou, Beatriz; del Cura-Gonzalez, Isabel		MULTIPAP Grp	Social support, social context and nonadherence to treatment in young senior patients with multimorbidity and polypharmacy followed-up in primary care. MULTIPAP Study	PLOS ONE			English	Article							ADHERENCE; QUESTIONNAIRE; MEDICATION; VALIDATION; NONCOMPLIANCE; VALIDITY; ADULTS; SCALE	Objective To estimate the prevalence of nonadherence to treatment and its relationship with social support and social context in patients with multimorbidity and polypharmacy followed-up in primary care. Methods This was an observational, descriptive, cross-sectional, multicenter study with an analytical approach. A total of 593 patients between 65-74 years of age with multimorbidity (>= 3 diseases) and polypharmacy (>= 5 drugs) during the last three months and agreed to participate in the MULTIPAP Study. The main variable was adherence (Morisky-Green). The predictors were social support (structural support and functional support (DUFSS)); sociodemographic variables; indicators of urban objective vulnerability; health-related quality of life (EQ-5D-5L-VAS & QALY); and clinical variables. Descriptive, bivariate and multivariate analyses with logistic regression models and robust estimators were performed. Results Four out of ten patients were nonadherent, 47% had not completed primary education, 28.7% had an income <= 1050 euro/month, 35% reported four or more IUVs, and the average perceived health-related quality of life (HRQOL) EQ-5D-5L-VAS was 65.5. The items that measure functional support, with significantly different means between nonadherent and adherent patients were receiving love and affection (-0.23; 95%CI: -0.40;-0.06), help when ill (-0.25; 95%CI: -0.42;-0.08), useful advice (-0.20; 95%CI: -0.37;-0.02), social invitations (-0.22; 95%CI:-0.44;-0.01), and recognition (-0.29; 95%CI:-0.50;-0.08). Factors associated with nonadherence were belonging to the medium vs. low tertile of functional support (0.62; 95%CI: 0.42;0.94), reporting less than four IUVs (0.69; 95%CI: 0.46;1.02) and higher HRQOL perception (0.98; 95%CI: 0.98;0.99). Conclusions Among patients 65-74 years of age with multimorbidity and polypharmacy, lower functional support was related to nonadherence to treatment. The nonadherence decreased in those patients with higher functional support, lower urban vulnerability and higher perceived health status according to the visual analog scale of health-related quality of life.	[Lozano-Hernandez, Cristina M.; Lopez-Rodriguez, Juan A.; Barrio-Cortes, Jaime; del Cura-Gonzalez, Isabel] Primary Hlth Care Management, Res Unit, Madrid, Spain; [Lozano-Hernandez, Cristina M.] Rey Juan Carlos Univ, Interuniv Doctoral Program Epidemiol & Publ Hlth, Madrid, Spain; [Lozano-Hernandez, Cristina M.; Lopez-Rodriguez, Juan A.; Leiva-Fernandez, Francisca; Calderon-Larranaga, Amaia; Gimeno-Feliu, Luis A.; Poblador-Plou, Beatriz; del Cura-Gonzalez, Isabel] Res Network Hlth Serv Chron Dis REDISSEC ISCIII, Madrid, Spain; [Lozano-Hernandez, Cristina M.; Lopez-Rodriguez, Juan A.; Barrio-Cortes, Jaime] Biosanitary Res & Innovat Fdn Primary Care FIIBAP, Madrid, Spain; [Lopez-Rodriguez, Juan A.; del Cura-Gonzalez, Isabel] Rey Juan Carlos Univ, Dept Med Specialties & Publ Hlth, Fac Hlth Sci, Madrid, Spain; [Lopez-Rodriguez, Juan A.] Gen Ricardos Primary Hlth Care Ctr, Madrid, Spain; [Leiva-Fernandez, Francisca] Multiprofess Teaching Unit Family & Community Car, Malaga, Spain; [Leiva-Fernandez, Francisca] Andalusian Hlth Serv, Biomed Res Inst Malaga IBIMA, Malaga, Spain; [Calderon-Larranaga, Amaia] Joint Act Chron Dis JA CHRODIS European Commiss, Brussels, Belgium; [Calderon-Larranaga, Amaia] Karolinska Inst, Aging Res Ctr, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden; [Calderon-Larranaga, Amaia] Stockholm Univ, Stockholm, Sweden; [Calderon-Larranaga, Amaia; Gimeno-Feliu, Luis A.; Poblador-Plou, Beatriz] IIS Arago, Aragonese Inst Hlth Sci IACS, EpiChron Res Grp Chron Dis, Zaragoza, Spain; [Gimeno-Feliu, Luis A.] Aragon Hlth Serv, San Pablo Primary Hlth Care Ctr, Zaragoza, Spain; [Gimeno-Feliu, Luis A.] Univ Zaragoza, Dept Med Psychiat & Dermatol, Zaragoza, Spain; [Poblador-Plou, Beatriz] Miguel Servet Univ Hosp, Zaragoza, Spain	Universidad Rey Juan Carlos; Universidad Rey Juan Carlos; Universidad de Malaga; Karolinska Institutet; Stockholm University; University of Zaragoza; Miguel Servet University Hospital	Lozano-Hernandez, CM (corresponding author), Primary Hlth Care Management, Res Unit, Madrid, Spain.; Lozano-Hernandez, CM (corresponding author), Rey Juan Carlos Univ, Interuniv Doctoral Program Epidemiol & Publ Hlth, Madrid, Spain.; Lozano-Hernandez, CM (corresponding author), Res Network Hlth Serv Chron Dis REDISSEC ISCIII, Madrid, Spain.; Lozano-Hernandez, CM (corresponding author), Biosanitary Res & Innovat Fdn Primary Care FIIBAP, Madrid, Spain.	cristinamaria.lozano@salud.madrid.org	Lopez-Rodriguez, Juan A/F-2322-2010; Poblador-Plou, Beatriz/ABC-7915-2020; Calderón-Larrañaga, Amaia/ABC-6828-2021; Gimeno-Feliu, Luis Andrés/E-5390-2016; Prados-Torres, Alexandra/P-5818-2017; Gimeno-Miguel, Antonio/AAC-9611-2019; POLENTINOS-CASTRO, ELENA/B-7373-2019; Lozano Hernandez, Cristina Maria/G-9362-2018; del Cura-Gonzalez, Isabel/G-9040-2018	Lopez-Rodriguez, Juan A/0000-0002-4985-2314; Poblador-Plou, Beatriz/0000-0002-5119-5093; Calderón-Larrañaga, Amaia/0000-0001-9064-9222; Gimeno-Feliu, Luis Andrés/0000-0003-2928-6623; Prados-Torres, Alexandra/0000-0002-5704-6056; Gimeno-Miguel, Antonio/0000-0002-5440-1710; Barrio Cortes, Jaime/0000-0002-2582-0203; POLENTINOS-CASTRO, ELENA/0000-0001-9460-2966; Lozano Hernandez, Cristina Maria/0000-0002-6981-303X; del Cura-Gonzalez, Isabel/0000-0002-3931-5304; Rogero Blanco, Maria Eloisa/0000-0002-8732-6120; Azcoaga-Lorenzo, Amaya/0000-0003-3307-878X; Leiva-Fernandez, Francisca/0000-0001-6919-4817; Hernandez Santiago, Virginia/0000-0002-8544-1483	Fondo de Investigaciones Sanitarias ISCIII [PI15/00276, PI15/00572, PI15/00996, RD16/0001/0006, RD16/0001/0005, RD16/0001/0004]; European Regional Development Fund	Fondo de Investigaciones Sanitarias ISCIII(Instituto de Salud Carlos III); European Regional Development Fund(European Commission)	This study was funded by the Fondo de Investigaciones Sanitarias ISCIII (Grant Numbers PI15/00276, PI15/00572, PI15/00996), REDISSEC (Project Numbers RD16/0001/0006, RD16/0001/0005 and RD16/0001/0004), and the European Regional Development Fund ("A way to build Europe"). Funders had no role in study design or in the decision to submit the report for publication.	ALFONSO PIÑA LOPEZ JULIO, 2007, Cienc. enferm., V13, P53, DOI 10.4067/S0717-95532007000200007; AlGhurair SA, 2012, J CLIN HYPERTENS, V14, P877, DOI 10.1111/j.1751-7176.2012.00699.x; Alvarado Beatriz Eugenia, 2005, Cad. Saúde Pública, V21, P724, DOI 10.1590/S0102-311X2005000300006; Alves KB, 2018, EINSTEIN-SAO PAULO, V16, DOI [10.1590/S1679-45082018AO4036, 10.1590/s1679-45082018ao4036]; Ambrosio L, 2016, PARKINSONISM RELAT D, V25, P52, DOI 10.1016/j.parkreldis.2016.02.012; Ayala A, 2012, GAC SANIT, V26, P317, DOI 10.1016/j.gaceta.2011.08.009; Azpiazu Garrido M, 2003, ATEN PRIM, V30, P285, DOI [10.1157/13045701, DOI 10.1157/13045701]; Bellon Saameno J A, 1996, Aten Primaria, V18, P153; Blasco Patino F., 2005, INFORMACI N TERAP UT, V29, P152; Luz TCB, 2011, CAD SAUDE PUBLICA, V27, P269, DOI 10.1590/S0102-311X2011000200008; BROADHEAD WE, 1988, MED CARE, V26, P709, DOI 10.1097/00005650-198807000-00006; Conde P, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081617; COONS SJ, 1994, CLIN THER, V16, P110; Cottrell E, 2015, CHRONIC ILLN, V11, P279, DOI 10.1177/1742395315574764; Cuellar-Flores I, 2012, REV IBEROAM DIAGN EV, V1, P89; Curtis Sarah E, 2017, Am J Manag Care, V23, pe208; de la Revilla Ahumada L, 1991, Aten Primaria, V8, P688; DiMatteo MR, 2004, HEALTH PSYCHOL, V23, P207, DOI 10.1037/0278-6133.23.2.207; DiMatteo MR, 2004, MED CARE, V42, P200, DOI 10.1097/01.mlr.0000114908.90348.f9; Domingo-Salvany A, 2013, GAC SANIT, V27, P263, DOI 10.1016/j.gaceta.2012.12.009; DONOVAN JL, 1992, SOC SCI MED, V34, P507, DOI 10.1016/0277-9536(92)90206-6; Epino HM, 2012, AIDS CARE, V24, P1576, DOI 10.1080/09540121.2012.661840; Feehan M, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014435; Fomento Ministerio . Gobierno de Espana . Instituto Juan de Herrera DUYOT, 2010, ANALISIS URBANISTICO; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gottlieb BH, 2010, J PSYCHOSOM RES, V69, P511, DOI 10.1016/j.jpsychores.2009.10.001; HAYNES RB, 1980, GERIATRICS, V35, P91; Johnson VR, 2010, PATIENT EDUC COUNS, V79, P14, DOI 10.1016/j.pec.2009.07.002; Magrin ME, 2015, ANN BEHAV MED, V49, P307, DOI 10.1007/s12160-014-9663-2; Malmen M, 2019, SCIENCEDIRECT METHOD, P2, DOI [10.1016/j.jval.2018.08.006, DOI 10.1016/J.JVAL.2018.08.006]; Mansur N, 2012, AM J GERIATR PHARMAC, V10, P223, DOI 10.1016/j.amjopharm.2012.06.002; Martos-Mendez M.J., 2015, J BEHAV HLTH SOC ISS, V7, P19, DOI [10.5460/jbhsi.v7.2.52889, DOI 10.5460/JBHSI.V7.2.52889]; Mas-Exposito L, 2013, SOC PSYCH PSYCH EPID, V48, P1675, DOI 10.1007/s00127-012-0633-3; Mclane CG, 1995, FACTORS ASS MED NONC; Mondesir FL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198578; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Munoz-Cobos F, 2016, AN PSICOL-SPAIN, V32, P18, DOI 10.6018/analesps.32.1.186211; Naderi SH, 2012, AM J MED, V125, P882, DOI 10.1016/j.amjmed.2011.12.013; Oppe M, 2014, VALUE HEALTH, V17, P445, DOI 10.1016/j.jval.2014.04.002; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Prados-Torres A, 2017, ATEN PRIM, V49, P300, DOI 10.1016/j.aprim.2016.11.013; Prados-Torres A, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0584-x; Prados-Torres A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032190; Salive ME, 2013, EPIDEMIOL REV, V35, P75, DOI 10.1093/epirev/mxs009; Saracino R, 2015, PALLIAT SUPPORT CARE, V13, P1153, DOI 10.1017/S1478951514000996; Takahashi PY, 2016, HHS PUBLIC ACCESS, DOI [10.1136/jech-2015-205925.A, DOI 10.1136/JECH-2015-205925.A]; The Academy of Medical Sciences Working Group, 2018, MULT PRIOR GLOB HLTH, P1; THOITS PA, 1982, J HEALTH SOC BEHAV, V23, P145, DOI 10.2307/2136511; Thomson GE, 2006, EXAMINING HLTH DISPA, DOI [10.17226/11602, DOI 10.17226/1160221850786]; Uchino BN, 1996, PSYCHOL BULL, V119, P488, DOI 10.1037/0033-2909.119.3.488; Van der Wees PJ, 2014, MILBANK Q, V92, P754, DOI 10.1111/1468-0009.12091; Vermeire E, 2001, J CLIN PHARM THER, V26, P331, DOI 10.1046/j.1365-2710.2001.00363.x; Violan C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102149	53	4	4	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2020	15	6							e0235148	10.1371/journal.pone.0235148	http://dx.doi.org/10.1371/journal.pone.0235148			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MF9GS	32579616	Green Published, gold			2023-01-03	WOS:000545646600046
J	Hennegan, J; Brooks, DJ; Schwab, KJ; Melendez-Torres, GJ				Hennegan, Julie; Brooks, Deborah Jordan; Schwab, Kellogg J.; Melendez-Torres, G. J.			Measurement in the study of menstrual health and hygiene: A systematic review and audit	PLOS ONE			English	Review							ATTITUDE QUESTIONNAIRE; GIRLS; MANAGEMENT; VALIDITY; MENARCHE; BLIND; TRIAL; JOY	Background The lack of established measurement tools in the study of menstrual health and hygiene has been a significant limitation of quantitative studies to date. However, there has been limited exploration of existing measurement to identify avenues for improvement. Methods We undertook two linked systematic reviews of (1) trials of menstrual health interventions and their nested studies in low- and middle-income countries, (2) studies developing or validating measures of menstrual experiences from any location. Systematic searching was undertaken in 12 databases, together with handsearching. We iteratively grouped and audited concepts measured across included studies and extracted and compared measures of each concept. Results A total of 23 trials, 9 nested studies and 22 measure development studies were included. Trials measured a range of outcomes including menstrual knowledge, attitudes, and practices, school absenteeism, and health. Most measure validation studies focused on assessing attitudes towards menstruation, while a group of five studies assessed the accuracy of women's recall of their menstrual characteristics such as timing and cycle length. Measures of menstrual knowledge, attitudes, beliefs and restrictions were inconsistent and frequently overlapped. No two studies measured the same menstrual or hygiene practices, with 44 different practices assessed. This audit provides a summary of current measures and extant efforts to pilot or test their performance. Conclusions Inconsistencies in both the definition and operationalisation of concepts measured in menstrual health and hygiene research should be addressed. To improve measurement, authors should clearly define the constructs they aim to measure and outline how these were operationalised for measurement. Results of this audit indicate the need for the development and validation of new measures, and the evaluation of the performance of existing measures across contexts. In particular, the definition and measurement of menstrual practices, knowledge, attitudes, norms and restrictions should be addressed. Review protocol registration CRD42018089884. .	[Hennegan, Julie; Schwab, Kellogg J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth & Engn, Water Inst, Baltimore, MD 21205 USA; [Brooks, Deborah Jordan] Dartmouth Coll, John Sloan Dickey Ctr Int Understanding, Hanover, NH 03755 USA; [Brooks, Deborah Jordan] Dartmouth Coll, Dept Govt, Hanover, NH 03755 USA; [Melendez-Torres, G. J.] Univ Exeter, Peninsula Technol Assessment Grp, Coll Med & Hlth, Exeter, Devon, England	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Dartmouth College; Dartmouth College; University of Exeter	Hennegan, J (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth & Engn, Water Inst, Baltimore, MD 21205 USA.	jhenneg1@jhu.edu		Melendez-Torres, G.J./0000-0002-9823-4790; Hennegan, Julie/0000-0003-2011-1595	Osprey Foundation of Maryland	Osprey Foundation of Maryland	This study was funded by The Case for Her (http://www.thecaseforher.com/) and the Osprey Foundation of Maryland (http://www.ospreyfdn.org/) (JH, KS). The corresponding author (JH) had full access to all the data in the study and had final responsibility for the decision to submit for publication. The funders of the study had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abedian Z, 2011, J AM SCI, V7, P1; Alexander KT, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081682; Alimoradi Z, 2019, INT J ADOLESC MED HL, DOI [10.1515/ijamh-2018-0116, DOI 10.1515/IJAMH-2018-011630973825]; [Anonymous], 2015, CANC DISCOV, V5, pOF2; [Anonymous], 2007, ENCY JUDAICA, V17, P163; Aubeeluck A, 2002, PSYCHOL WOMEN QUART, V26, P160, DOI 10.1111/1471-6402.00054; Bargiota S, 2016, INT J INNOVATIVE RES, V5, P1754; Beksinska ME, 2015, J WOMENS HEALTH, V24, P151, DOI 10.1089/jwh.2014.5021; Benshaul-Tolonen A, 2019, 74 CDEPCGEP WP; Berkowitz A. D., 2003, SOCIAL NORMS APPROAC, P259; Bicchieri C., 2016, NORMS WILD DIAGNOSE; Blake S, 2018, J ADOLESCENT RES, V33, P623, DOI 10.1177/0743558417701246; Bobel C, 2019, MANAGED BODY; Bramwell RS, 2002, J REPROD INFANT PSYC, V20, P159, DOI 10.1080/026468302760270818; BROOKSGUNN J, 1980, PSYCHOSOM MED, V42, P503, DOI 10.1097/00006842-198009000-00005; Chandra-Mouli V, 2017, REPROD HEALTH, V14, DOI 10.1186/s12978-017-0293-6; CHRISLER JC, 1994, PSYCHOL WOMEN QUART, V18, P375, DOI 10.1111/j.1471-6402.1994.tb00461.x; Cooper R, 2006, J EPIDEMIOL COMMUN H, V60, P993, DOI 10.1136/jech.2005.043182; Darabi Fatemeh, 2018, J Reprod Infertil, V19, P229; Djalalinia S, 2012, INT J PREVENTIVE MED, V3, P622; Dolan CS, 2014, J INT DEV, V26, P643, DOI 10.1002/jid.2917; El-Mowafy RI., 2014, IOSR J NURSING HLTH, V3, P48, DOI DOI 10.9790/1959-03614855; Fakhri M, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-193; Fetohy Ebtisam M, 2007, J Egypt Public Health Assoc, V82, P105; Firat MZ, 2009, J ADV NURS, V65, P652, DOI 10.1111/j.1365-2648.2008.04919.x; Geertz A., 2016, MENSTRUAL HLTH INDIA; Goodman R, 1998, EUR CHILD ADOLES PSY, V7, P125, DOI 10.1007/s007870050057; Haver J, 2018, STUD SOC JUSTICE, V12, P372, DOI 10.26522/ssj.v12i2.1947; Heard KV, 1997, M SOC MENSTR CYCL RE; Hennegan J.M., 2017, WOMENS REPROD HLTH, V4, P212, DOI [10.1080/23293691.2017.1388720, DOI 10.1080/23293691.2017.1388720]; Hennegan J, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002803; Hennegan J, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0260-7; Hennegan J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146985; Jukic AMZ, 2008, AM J EPIDEMIOL, V167, P25, DOI 10.1093/aje/kwm265; Juma J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015429; Khan SM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189089; Leventhal KS, 2016, SOC SCI MED, V161, P37, DOI 10.1016/j.socscimed.2016.05.004; Leventhal KS, 2015, J ADOLESCENCE, V45, P284, DOI 10.1016/j.adolescence.2015.09.011; Leventhal KS, 2015, TRIALS, V16, DOI 10.1186/s13063-015-1008-3; Marvan Ma Luisa, 2006, Health Care Women Int, V27, P453, DOI 10.1080/07399330600629658; Mbizvo MT, 1997, SOC SCI MED, V44, P573, DOI 10.1016/S0277-9536(96)00204-3; Mohamed NG, 2014, J PHYSIOL ANTHROPOL, V33, DOI 10.1186/1880-6805-33-28; Montgomery P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166122; Montgomery P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048274; MOOS RH, 1968, PSYCHOSOM MED, V30, P853, DOI 10.1097/00006842-196811000-00006; Morse J M, 1993, Health Care Women Int, V14, P63; Morse J M, 1993, Health Care Women Int, V14, P39; Nyothach E., 2015, Waterlines, V34, P279, DOI 10.3362/1756-3488.2015.027; Oduor C., 2015, Waterlines, V34, P397, DOI 10.3362/1756-3488.2015.037; Oster E, 2012, J EUR ECON ASSOC, V10, P1263, DOI 10.1111/j.1542-4774.2012.01090.x; Oster E, 2011, AM ECON J-APPL ECON, V3, P91, DOI 10.1257/app.3.1.91; Phillips-Howard PA, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.33032; Phillips-Howard PA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-013229; Ramaiya A., 2018, TIME MONTH MIXED MET; Roberts TA, 2004, PSYCHOL WOMEN QUART, V28, P22, DOI 10.1111/j.1471-6402.2004.00119.x; Rusakaniko S, 1997, Cent Afr J Med, V43, P1; Sener DK, 2019, J POLICY PRACT INTEL, DOI [10.1111/jppi.12277.2019-18498-001, DOI 10.1111/JPPI.12277.2019-18498-001]; Setyowati, 2019, Asian Pac Isl Nurs J, V4, P84, DOI 10.31372/20190402.1041; Sharma R, 2015, INDAN J COMMUNITY HE, V27, P376; Shillingburg HT, 2012, FUNDAMENTALS OF FIXED PROSTHODONTICS, FOURTH EDITION, P27; Shin H, 2018, HEALTH CARE WOMEN IN, V39, P1090, DOI 10.1080/07399332.2017.1423487; Shrestha V, 2019, EC RES; Simavi, 2017, RIT NORM NAT BAS REP; Sommer M., 2019, MONITORING MENSTRUAL; Sommer M, 2013, AM J PUBLIC HEALTH, V103, P1556, DOI 10.2105/AJPH.2013.301374; Stadler A, 2006, CUTAN OCUL TOXICOL, V25, P273, DOI 10.1080/15569520601013244; Stubbs ML, 1988, DEV CHANGES MENSTRUA; Sumpter C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062004; Thornby J, 2019, SN APPL SCI, V1, DOI 10.1007/s42452-019-0696-9; Tribble MdC, 2016, HEART SURG FORUM, V19, pE286; UNICEF, 2019, GUID MENSTR HLTH HYG; van Eijk AM, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0582-8; van Eijk AM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010290; van ME, 2017, PEDIAT PHYS THER S3, V29, pS73; Varni JW, 2006, QUAL LIFE RES, V15, P203, DOI 10.1007/s11136-005-1388-z; Wegienka G, 2005, J WOMENS HEALTH, V14, P248, DOI 10.1089/jwh.2005.14.248; Weller A, 1998, J PSYCHOSOM OBST GYN, V19, P111, DOI 10.3109/01674829809048504; Wilson E, 2014, DEV PRACT, V24, P63, DOI 10.1080/09614524.2014.867305; WoMena, 2018, MENSTRUAL HLTH RHINO; World Bank, 2018, COUNTR LEND GROUPS; 2016, CANC DISCOV, V6	81	12	12	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2020	15	6							e0232935	10.1371/journal.pone.0232935	http://dx.doi.org/10.1371/journal.pone.0232935			32	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MA6PX	32497117	gold, Green Submitted, Green Published			2023-01-03	WOS:000542035200012
J	Maphumulo, A; Mahomed, O; Vennervald, B; Gundersen, SG; Taylor, M; Kjetland, EF				Maphumulo, A.; Mahomed, O.; Vennervald, B.; Gundersen, S. G.; Taylor, M.; Kjetland, E. F.			The cost of a school based mass treatment of schistosomiasis in Ugu District, KwaZulu Natal, South Africa in 2012	PLOS ONE			English	Article							CHILDREN	Introduction The Neglected Tropical Diseases Roadmap of the WHO set targets for potential elimination as a "public health problem" for the period 2012-2020 in multiple countries in Africa, with the aim of global elimination of schistosomiasis as a "public health problem" by 2025. Aim The purpose of the study was to estimate the cost from a provider's perspective of the Department of Health's Schistosomiasis Mass Drug Administration (MDA) in Ugu District, KwaZulu-Natal in 2012, with a view to project the costs for the entire KwaZulu Natal Province. Methods A total of 491 public schools and 16 independent schools in Ugu District, a predominantly rural district in KwaZulu-Natal with a total of 218 242 learners, were included in the schistosomiasis control programme. They were randomly selected from schools situated below an altitude of 300 meters, where schistosomiasis is endemic. A retrospective costing study was conducted using the provider's perspective to cost. Cost data were collected by reviewing existing records including financial statements, invoices, receipts, transport log books, equipment inventories, and information from personnel payroll, existing budget, and the staff diaries. Results A total of 15571 children were treated in 2012, resulting in a total cost of the MDA programme of ZAR 2 137 143 and a unit cost of ZAR 137. The three main cost components were Medication Costs (37%), Human Resources Cost (36%) and Capital items (16%). The total cost for treating all eligible pupils in KwaZulu-Natal will be ZAR 149 031 888. However, should the capital cost be excluded, then the unit cost will be ZAR 112 per patient and this will translate to a total cost of ZAR 121 836 288. Conclusions Low coverage exacerbates the cost of the programme and makes a decision to support such a programme difficult. However, a normative costing study based on the integration of the programme within the Department of Health should be conducted.	[Maphumulo, A.; Mahomed, O.; Taylor, M.; Kjetland, E. F.] Univ KwaZulu Natal, Publ Hlth Dept, Durban, South Africa; [Vennervald, B.] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark; [Gundersen, S. G.] Oslo Univ Hosp, Sorlandet Sykehus HF, Oslo, Norway; [Gundersen, S. G.] Univ Agder, Dept Global Dev & Planning, Kristiansand, Norway; [Kjetland, E. F.] Norwergian Ctr Imported & Trop Dis, Oslo, Norway	University of Kwazulu Natal; University of Copenhagen; University of Oslo; University of Agder	Mahomed, O (corresponding author), Univ KwaZulu Natal, Publ Hlth Dept, Durban, South Africa.	ozayr411@gmail.com	Mahomed, Ozayr/L-7570-2019	Mahomed, Ozayr/0000-0001-8076-0453; Maphumulo, Andile/0000-0002-5518-4113; Kjetland, Eyrun Floerecke/0000-0002-5552-1095; Vennervald, Birgitte/0000-0001-5721-3494	South-Eastern Regional Health Authority, Norway [2016055]; European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013)/ERC Grant [PIRSES-GA-2010-269245]	South-Eastern Regional Health Authority, Norway; European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013)/ERC Grant(European Research Council (ERC))	The research leading to these results has received funding from the South-Eastern Regional Health Authority, Norway no. 2016055 and European Research Council under the European Union's Seventh Framework Programme (FP7/2007-2013)/ERC Grant agreement no. PIRSES-GA-2010-269245. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."	Ahmed SH, 2016, SCHISTOSOMIASIS; [Anonymous], 2010, LIDER POSLOVNI TJEDN, V25, P30; Appleton C. C., 2006, Southern African Journal of Epidemiology & Infection, V21, P55; Brooker S, 2008, HEALTH POLICY PLANN, V23, P24, DOI 10.1093/heapol/czm041; Corcoran C, 2016, DIAGNOSING SCHISTOSO; Fenwick A, 2009, PARASITOLOGY, V136, P1719, DOI 10.1017/S0031182009990400; Fu SH, 2011, PLOS NEGL TROP DIS, V5, pe1231; Gabrielli AF, 2006, ACTA TROP, V99, P234, DOI 10.1016/j.actatropica.2006.08.008; Hill AM, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2017-000571; Hotez PJ, 2010, LANCET, V376, P496, DOI 10.1016/S0140-6736(10)60879-3; Jinabhai CC, 2001, ANN TROP PAEDIATR, V21, P50, DOI 10.1080/02724930020028920; Jordan P, 2000, ACTA TROP, V77, P9, DOI 10.1016/S0001-706X(00)00121-2; Kjetland EF, 2006, AIDS, V20, P593, DOI 10.1097/01.aids.0000210614.45212.0a; Lothe A, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3102-0; Magaisa K, 2015, S AFRICAN J SCI, V111; Magaisa K, 2015, S AFR J SCI, V111, P32, DOI 10.17159/sajs.2015/20140427; Moodley I, 2003, MODELLING SCHISTOSOM; [National Department of Health Health NDo], 2008, POL IMPL GUID 2008 R; National Institute of Communicable Diseases, 2014, SCHIST BILH FAQS; Randjelovic A, 2015, S AFR FAM PRACT, V57, P57, DOI 10.1080/20786190.2014.978121; Turner HC, 2018, CLIN INFECT DIS, V66, P1298, DOI 10.1093/cid/cix1001; uGu District Municipality, 2019, 2018 19 INT DEV PLAN; WHO, 2011, HELMINTH CONTROL IN SCHOOL-AGE CHILDREN: A GUIDE FOR MANAGERS OF CONTROL PROGRAMMES, SECOND EDITION, P1; WHO, 2011, WHO REP 2011 HELM CO; World Health Organization, 2017, SCIST FACT SHEET; World Health Organization (WHO), 2012, LOND DECL NEGL TROP	26	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2020	15	6							e0232867	10.1371/journal.pone.0232867	http://dx.doi.org/10.1371/journal.pone.0232867			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6PX	32497049	Green Published, gold			2023-01-03	WOS:000542035200068
J	Liu, SB; Wang, ZF; Su, YS; Ray, RS; Jing, XH; Wang, YQ; Ma, QF				Liu, Shenbin; Wang, Zhi-Fu; Su, Yang-Shuai; Ray, Russell S.; Jing, Xiang-Hong; Wang, Yan-Qing; Ma, Qiufu			Somatotopic Organization and Intensity Dependence in Driving Distinct NPY-Expressing Sympathetic Pathways by Electroacupuncture	NEURON			English	Article								The neuroanatomical basis behind acupuncture practice is still poorly understood. Here, we used intersectional genetic strategy to ablate NPY+ noradrenergic neurons and/or adrenal chromaffin cells. Using endotoxin-induced systemic inflammation as a model, we found that electroacupuncture stimulation (ES) drives sympathetic pathways in somatotopy- and intensity-dependent manners. Low-intensity ES at hindlimb regions drives the vagal-adrenal axis, producing anti-inflammatory effects that depend on NPY+ adrenal chromaffin cells. High-intensity ES at the abdomen activates NPY+ splenic noradrenergic neurons via the spinal-sympathetic axis; these neurons engage incoherent feedforward regulatory loops via activation of distinct adrenergic receptors (ARs), and their ES-evoked activation produces either anti- or pro-inflammatory effects due to disease-state-dependent changes in AR profiles. The revelation of somatotopic organization and intensity dependency in driving distinct autonomic pathways could form a road map for optimizing stimulation parameters to improve both efficacy and safety in using acupuncture as a therapeutic modality.	[Liu, Shenbin; Wang, Zhi-Fu; Su, Yang-Shuai; Ma, Qiufu] Harvard Univ, Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Liu, Shenbin; Wang, Zhi-Fu; Su, Yang-Shuai; Ma, Qiufu] Harvard Univ, Med Sch, Dept Neurobiol, Boston, MA 02115 USA; [Liu, Shenbin; Wang, Yan-Qing] Fudan Univ, Inst Acupuncture & Moxibust, Fudan Inst Integrat Med, Shanghai 200032, Peoples R China; [Liu, Shenbin; Wang, Yan-Qing] Fudan Univ, Inst Brain Sci, Sch Basic Med Sci, Dept Integrat Med & Neurobiol, Shanghai 200032, Peoples R China; [Su, Yang-Shuai; Jing, Xiang-Hong] China Acad Chinese Med Sci, Inst Acupuncture & Moxibust, Res Ctr Meridians, Beijing 100700, Peoples R China; [Ray, Russell S.] Baylor Coll Med, Memory Brain Res Ctr, Houston, TX 77030 USA; [Ray, Russell S.] Baylor Coll Med, Dept Neurosci, Houston, TX 77030 USA; [Ray, Russell S.] McNair Med Inst, Houston, TX USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Fudan University; Fudan University; China Academy of Chinese Medical Sciences; Institute of Acupuncture & Moxibustion, CACMS; Baylor College of Medicine; Baylor College of Medicine	Ma, QF (corresponding author), Harvard Univ, Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.; Ma, QF (corresponding author), Harvard Univ, Med Sch, Dept Neurobiol, Boston, MA 02115 USA.	qiufu_ma@dfci.harvard.edu	Jing, Xianghong/HHS-4003-2022	Ray, Russell/0000-0001-9610-2703	China Postdoctoral Science Foundation [KLF101846]; Development Project of Shanghai Peak Disciplines-Integrated Medicine [20150407]; China Scholarship Council (CSC) [201609110039]; Boston Children's Hospital IDDRC [1U54HD090255]; NIH [R01AT010629]; Harvard/MIT Joint Research Program in Basic Neuroscience; Wellcome Trust [200183/Z/15/Z]	China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Development Project of Shanghai Peak Disciplines-Integrated Medicine; China Scholarship Council (CSC)(China Scholarship Council); Boston Children's Hospital IDDRC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Harvard/MIT Joint Research Program in Basic Neuroscience; Wellcome Trust(Wellcome TrustEuropean Commission)	We thank Drs. Bing Zhu, Isaac M. Chiu, and Charles D. Stiles for helpful comments and thank Martyn Goulding, Susan M. Dymecki, and the Allen Brain Institute/the Jackson Laboratory/MMRRC at University of Davis for genetically modified mice. S.L.'s salary was partly supported by the China Postdoctoral Science Foundation (KLF101846) and by Development Project of Shanghai Peak Disciplines-Integrated Medicine (20150407). Y.-S.S.'s salary was supported by China Scholarship Council (CSC) (no. 201609110039). Z.-F.W.'s salary was partly supported by Fujian University of Traditional Chinese Medicine. Histochemical imaging was supported by Boston Children's Hospital IDDRC (1U54HD090255). The work was supported by the NIH grant (R01AT010629), the Harvard/MIT Joint Research Program in Basic Neuroscience, and the Wellcome Trust grant (200183/Z/15/Z) to Q.M.	Abe C, 2017, NAT NEUROSCI, V20, P700, DOI 10.1038/nn.4526; Agac D, 2018, BRAIN BEHAV IMMUN, V74, P176, DOI 10.1016/j.bbi.2018.09.004; Alon U, 2007, NAT REV GENET, V8, P450, DOI 10.1038/nrg2102; Archer T, 2000, Neurotox Res, V1, P235; Armbruster BN, 2007, P NATL ACAD SCI USA, V104, P5163, DOI 10.1073/pnas.0700293104; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; Borovikova LV, 2000, NATURE, V405, P458, DOI 10.1038/35013070; Bourane S, 2015, CELL, V160, P503, DOI 10.1016/j.cell.2015.01.011; Bratton BO, 2012, EXP PHYSIOL, V97, P1180, DOI 10.1113/expphysiol.2011.061531; Bronte V, 2013, IMMUNITY, V39, P806, DOI 10.1016/j.immuni.2013.10.010; da Silva HB, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00480; Deuchars SA, 2015, COMPR PHYSIOL, V5, P829, DOI 10.1002/cphy.c140020; Duan B, 2014, CELL, V159, P1417, DOI 10.1016/j.cell.2014.11.003; Fernandes ES, 2012, J IMMUNOL, V188, P5741, DOI 10.4049/jimmunol.1102147; Flierl MA, 2007, NATURE, V449, P721, DOI 10.1038/nature06185; Furlan A, 2016, NAT NEUROSCI, V19, P1331, DOI 10.1038/nn.4376; Gao XY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168200; Gerfen CR, 2013, NEURON, V80, P1368, DOI 10.1016/j.neuron.2013.10.016; Gu G, 2011, J INT MED RES, V39, P1783, DOI 10.1177/147323001103900521; Huang CL, 2007, ANESTH ANALG, V104, P646, DOI 10.1213/01.ane.0000255288.68199.eb; Huang JL, 2012, INFLAMMATION, V35, P527, DOI 10.1007/s10753-011-9342-4; Huang S., 2019, SENSORY NEURONS INNE, DOI [10.1101/833509, DOI 10.1101/833509]; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; Huston JM, 2006, J EXP MED, V203, P1623, DOI 10.1084/jem.20052362; Iskander KN, 2013, PHYSIOL REV, V93, P1247, DOI 10.1152/physrev.00037.2012; Janig W, 2000, PROG BRAIN RES, V122, P351; Ji RR, 1999, NAT NEUROSCI, V2, P1114, DOI 10.1038/16040; JOHNSON EM, 1976, J PHARMACOL EXP THER, V196, P53; Kadl A, 2007, SHOCK, V28, P582, DOI 10.1097/shk.0b013e31804d41dd; KOLIBALPEGHER S, 1994, J AUTONOM NERV SYST, V48, P113, DOI 10.1016/0165-1838(94)90027-2; Komegae EN, 2018, BRAIN BEHAV IMMUN, V73, P441, DOI 10.1016/j.bbi.2018.06.005; Li YQ, 2007, WORLD J GASTROENTERO, V13, P709, DOI 10.3748/wjg.v13.i5.709; Lim HD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151882; Lima D., 2008, SCI PAIN, P477; Liu Y, 2008, J NEUROSCI, V28, P125, DOI 10.1523/JNEUROSCI.4472-07.2008; Liu Y, 2010, NEURON, V68, P543, DOI 10.1016/j.neuron.2010.09.008; Longhurst JC, 2010, J ACUPUNCT MERIDIAN, V3, P67, DOI 10.1016/S2005-2901(10)60014-3; Martelli D, 2016, EXP PHYSIOL, V101, P1245, DOI 10.1113/EP085559; Martelli D, 2014, J PHYSIOL-LONDON, V592, P1677, DOI 10.1113/jphysiol.2013.268573; Martelli D, 2019, AM J PHYSIOL-REG I, V316, pR235, DOI 10.1152/ajpregu.00298.2018; MOLINOFF PB, 1984, DRUGS, V28, P1, DOI 10.2165/00003495-198400282-00002; NIELSEN GD, 1977, ACTA PHARMACOL TOX, V41, P209; ODONNELL SR, 1980, LIFE SCI, V27, P671, DOI 10.1016/0024-3205(80)90008-9; Parker JL., 2018, BIOELECTRONICS MED, V1, P71, DOI [10.2217/bem-2017-0005, DOI 10.2217/BEM-2017-0005]; Pavlov VA, 2017, NAT NEUROSCI, V20, P156, DOI 10.1038/nn.4477; Pereira MMA, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14967; Pinho-Ribeiro FA, 2018, CELL, V173, P1083, DOI 10.1016/j.cell.2018.04.006; Remick DG, 2000, SHOCK, V13, P110, DOI 10.1097/00024382-200013020-00004; Rosas-Ballina M, 2008, P NATL ACAD SCI USA, V105, P11008, DOI 10.1073/pnas.0803237105; ROUOT B, 1982, N-S ARCH PHARMACOL, V321, P253, DOI 10.1007/BF00498509; Salomao R, 2008, SHOCK, V30, P73, DOI 10.1097/SHK.0b013e318181af2a; Sato A, 1997, Neurosci Behav Physiol, V27, P610, DOI 10.1007/BF02463910; SELL R, 1958, PFLUG ARCH GES PHYS, V267, P566, DOI 10.1007/BF00362960; Song JG, 2012, ANESTHESIOLOGY, V116, P406, DOI 10.1097/ALN.0b013e3182426ebd; SPENGLER RN, 1994, J IMMUNOL, V152, P3024; Staedtke V, 2018, NATURE, V564, P273, DOI 10.1038/s41586-018-0774-y; Sun JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159474; Szelenyi J, 2000, J NEUROIMMUNOL, V103, P34, DOI 10.1016/S0165-5728(99)00234-9; THOENEN H, 1973, ANNU REV PHARMACOL, V13, P169, DOI 10.1146/annurev.pa.13.040173.001125; Torres-Rosas R, 2014, NAT MED, V20, P291, DOI 10.1038/nm.3479; Travagli RA, 2016, NAT REV GASTRO HEPAT, V13, P389, DOI 10.1038/nrgastro.2016.76; Ulloa L, 2017, TRENDS MOL MED, V23, P1103, DOI 10.1016/j.molmed.2017.10.006; van der Poll T, 2017, NAT REV IMMUNOL, V17, P407, DOI 10.1038/nri.2017.36; Vida G, 2011, FASEB J, V25, P4476, DOI 10.1096/fj.11-191007; Villegas-Bastida A, 2014, EVID-BASED COMPL ALT, V2014, DOI 10.1155/2014/451674; Vranjkovic O, 2012, J PHARMACOL EXP THER, V342, P541, DOI 10.1124/jpet.112.193615; Yaffe D, 2018, J GEN PHYSIOL, V150, P671, DOI 10.1085/jgp.201711980; Zhao YX, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/627023	68	78	89	14	81	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	NOV 11	2020	108	3					436	+		10.1016/j.neuron.2020.07.015	http://dx.doi.org/10.1016/j.neuron.2020.07.015			22	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	OT1CW	32791039	Green Accepted, Bronze			2023-01-03	WOS:000590592300007
J	Cherak, SJ; Rosgen, BK; Amarbayan, M; Plotnikoff, K; Wollny, K; Stelfox, HT; Fiest, KM				Cherak, Stephana J.; Rosgen, Brianna K.; Amarbayan, Mungunzul; Plotnikoff, Kara; Wollny, Krista; Stelfox, Henry T.; Fiest, Kirsten M.			Impact of social media interventions and tools among informal caregivers of critically ill patients after patient admission to the intensive care unit: A scoping review	PLOS ONE			English	Review							WEB CAMERA USE; PARENTS; INFANTS; TECHNOLOGY; SERVICES; INTERNET; PEOPLE; BIRTH; TELEMEDICINE; PREFERENCES	Background The use of social media in healthcare continues to evolve. The purpose of this scoping review was to summarize existing research on the impact of social media interventions and tools among informal caregivers of critically ill patients after patient admission to the intensive care unit (ICU). Methods This review followed established scoping review methods, including an extensive a priori-defined search strategy implemented in the MEDLINE, EMBASE, PsycINFO, CINAHL, and the Cochrane CENTRAL Register of Controlled Trials databases to July 10, 2020. Primary research studies reporting on the use of social media by informal caregivers for critically ill patients were included. Results We identified 400 unique citations and thirty-one studies met the inclusion criteria. Nine were interventional trials-four randomized controlled trials (RCTs)-and a majority (n = 14) were conducted (i.e., data collected) between 2013 to 2015. Communication platforms (e.g., Text Messaging, Web Camera) were the most commonly used social media tool (n = 17), followed by social networking sites (e.g., Facebook, Instagram) (n = 6), and content communities (e.g., YouTube, SlideShare) (n = 5). Nine studies' primary objective was caregiver satisfaction, followed by self-care (n = 6), and health literacy (n = 5). Nearly every study reported an outcome on usage feasibility (e.g., user attitudes, preferences, demographics) (n = 30), and twenty-three studies reported an outcome related to patient and caregiver satisfaction. Among the studies that assessed statistical significance (n = 18), 12 reported statistically significant positive effects of social media use. Overall, 16 of the 31 studies reported positive conclusions (e.g., increased knowledge, satisfaction, involvement) regarding the use of social media among informal caregivers for critically ill patients. Conclusions Social media has potential benefits for caregivers of the critically ill. More robust and clinically relevant studies are required to identify effective social media strategies used among caregivers for the critically ill.	[Cherak, Stephana J.; Rosgen, Brianna K.; Wollny, Krista; Stelfox, Henry T.; Fiest, Kirsten M.] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada; [Cherak, Stephana J.; Rosgen, Brianna K.; Amarbayan, Mungunzul; Plotnikoff, Kara; Stelfox, Henry T.; Fiest, Kirsten M.] Alberta Hlth Serv, Dept Crit Care Med, Calgary, AB, Canada; [Cherak, Stephana J.; Rosgen, Brianna K.; Wollny, Krista; Stelfox, Henry T.; Fiest, Kirsten M.] Univ Calgary, OBrien Inst Publ Hlth, Calgary, AB, Canada; [Cherak, Stephana J.; Rosgen, Brianna K.; Fiest, Kirsten M.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Wollny, Krista] Univ Calgary, Fac Nursing, Calgary, AB, Canada; [Fiest, Kirsten M.] Univ Calgary, Cumming Sch Med, Dept Psychiat, Calgary, AB, Canada	University of Calgary; Alberta Health Services (AHS); University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary	Fiest, KM (corresponding author), Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada.; Fiest, KM (corresponding author), Alberta Hlth Serv, Dept Crit Care Med, Calgary, AB, Canada.; Fiest, KM (corresponding author), Univ Calgary, OBrien Inst Publ Hlth, Calgary, AB, Canada.; Fiest, KM (corresponding author), Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.; Fiest, KM (corresponding author), Univ Calgary, Cumming Sch Med, Dept Psychiat, Calgary, AB, Canada.	kmfiest@ucalgary.ca	Wollny, Krista/AFV-4355-2022; Rosgen, Brianna/GYD-5108-2022	Wollny, Krista/0000-0002-7709-1030; Plotnikoff, Kara/0000-0001-5293-388X; Stelfox, Henry/0000-0003-1231-1490	CIHR Doctoral Research Award [394654]	CIHR Doctoral Research Award(Canadian Institutes of Health Research (CIHR))	This work was supported by a CIHR Doctoral Research Award to SC (#394654). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. URL: https://cihr-irsc.gc.ca/e/50513.html.	Alvarez-Jimenez M, 2014, SCHIZOPHR RES, V156, P96, DOI 10.1016/j.schres.2014.03.021; [Anonymous], 2012, REDOX SIGNALING, V17, P1; [Anonymous], 2018, DIABETES CARE S1, V4, pS4, DOI 10.2337/dc18-Srev01; [Anonymous], 2009, MMWR MORB MORTAL WKL, V58, pt341; Anstey MH, 2019, AUST CRIT CARE, V32, P378, DOI 10.1016/j.aucc.2018.08.008; Arksey H, 2003, HEALTH SOC CARE COMM, V11, P335, DOI 10.1046/j.1365-2524.2003.00433.x; Badke CM, 2019, PEDIATR CRIT CARE ME, V20, pE283, DOI 10.1097/PCC.0000000000001917; Barnes SS, 2018, DIABETES CARE S1, V2018, p885066618769599, DOI 10.1177/0885066618769599; Barrett KP, 2019, INT ANESTHESIOL CLIN, V57, P103, DOI 10.1097/AIA.0000000000000227; Bibas L, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.7229; Braner Dana A V, 2004, Pediatr Crit Care Med, V5, P434, DOI 10.1097/01.PCC.0000137358.72147.6C; Briggs AM, 2016, BEST PRACT RES CL RH, V30, P359, DOI 10.1016/j.berh.2016.09.009; Carroll CL, 2019, CHEST, V155, P671, DOI 10.1016/j.chest.2018.12.009; Coppola G, 2013, J MATERN-FETAL NEO M, V26, P1737, DOI 10.3109/14767058.2013.798281; Coulter A, 2007, BMJ-BRIT MED J, V335, P24, DOI 10.1136/bmj.39246.581169.80; Das A, 2019, CRIT CARE RESUSC, V21, P305; de Havenon A, 2015, J CRIT CARE, V30, P881, DOI 10.1016/j.jcrc.2015.05.027; Dictionary O, 2019, SOCIAL MEDIA OXFORD; Epstein EG, 2015, AM J CRIT CARE, V24, P290, DOI 10.4037/ajcc2015828; Fiest KM, 2018, BMC MED, V16, DOI 10.1186/s12916-018-1097-4; Flores-Fenlon N, 2019, CLIN PEDIATR, V58, P903, DOI 10.1177/0009922819848080; Gabbert TI, 2013, EUR J PEDIATR, V172, P1671, DOI 10.1007/s00431-013-2067-7; Globus O, 2016, J PERINATOL, V36, P739, DOI 10.1038/jp.2016.83; Gray JE, 2000, PEDIATRICS, V106, P1318, DOI 10.1542/peds.106.6.1318; Gund A, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-22; Gurol-Urganci Ipek, 2013, Cochrane Database Syst Rev, pCD007458, DOI 10.1002/14651858.CD007458.pub3; Hetland B, 2018, INTENS CRIT CARE NUR, V44, P67, DOI 10.1016/j.iccn.2017.08.008; Hoffmann M, 2018, WIEN KLIN WOCHENSCHR, V130, P645, DOI 10.1007/s00508-018-1377-1; Hughes Driscoll Colleen A, 2020, Biomed Instrum Technol, V54, P22, DOI 10.2345/0899-8205-54.1.22; Joanna Briggs Inst, 2011, NURS HEALTH SCI, V13, P378, DOI 10.1111/j.1442-2018.2011.00617.x; Jones CW, 2018, J PEDIATR NURS, V41, P110, DOI 10.1016/j.pedn.2018.03.011; Joshi A, 2016, CLIN MED RES, V14, P1, DOI 10.3121/cmr.2015.1286; Kaplan AM, 2010, BUS HORIZONS, V53, P59, DOI 10.1016/j.bushor.2009.09.003; Kaplan WA, 2006, GLOBALIZATION HEALTH, V2, DOI 10.1186/1744-8603-2-9; Kim HN, 2015, INT J HUM-COMPUT INT, V31, P44, DOI 10.1080/10447318.2014.959102; Kon AA, 2017, CRIT CARE NURSE, V37, P9, DOI 10.4037/ccn2017234; Krishna Santosh, 2008, J Diabetes Sci Technol, V2, P509; Lakshmanan A, 2014, CLIN PEDIATR, V53, P1278, DOI 10.1177/0009922814541801; Lavorgna L, 2018, MULT SCLER RELAT DIS, V25, P175, DOI 10.1016/j.msard.2018.07.046; Lindberg B, 2009, J NEONATAL NURS, V15, P47, DOI DOI 10.1016/J.JNN.2009.01.004; Loudet Cecilia Inés, 2017, Rev. bras. ter. intensiva, V29, P39, DOI [10.5935/0103-507x.20170007, 10.5935/0103-507X.20170007]; Mackie BR, 2019, SCAND J CARING SCI, V33, P359, DOI 10.1111/scs.12631; Mallow JA, 2018, Int J Nurs Sci, V5, P131, DOI 10.1016/j.ijnss.2018.03.009; Mistraletti G, 2017, INTENS CARE MED, V43, P69, DOI 10.1007/s00134-016-4592-0; Moccia M, 2018, NEUROL SCI, V39, P981, DOI 10.1007/s10072-018-3339-9; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moorhead SA, 2013, J MED INTERNET RES, V15, DOI 10.2196/jmir.1933; Morgan C, 2012, ADV MED EDUC PRACT, V3, P129, DOI 10.2147/AMEP.S29270; Nguyen YL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174292; Orr T, 2017, ADV NEONAT CARE, V17, P131, DOI 10.1097/ANC.0000000000000349; Perrin A., 2015, SOCIAL MEDIA USAGE 2; Phua Jason, 2020, Lancet Respir Med, V8, P506, DOI 10.1016/S2213-2600(20)30161-2; Piscotty Ronald, 2013, Nurs Manage, V44, P52, DOI 10.1097/01.NUMA.0000429012.15882.d9; Piscotty RJ, 2015, J NURS SCHOLARSHIP, V47, P287, DOI 10.1111/jnu.12138; Reinhard SC, 2008, ADV PATIENT SAFETY; Rhoads SJ, 2015, ADV NEONAT CARE, V15, P440, DOI 10.1097/ANC.0000000000000235; Richardson B, 2019, JMIR MHEALTH UHEALTH, V7, DOI 10.2196/11620; Robert R, 2020, ANN INTENSIVE CARE, V10, DOI 10.1186/s13613-020-00702-7; Robertson A, 2016, ART PSYCHOTHER, V50, P17, DOI 10.1016/j.aip.2016.05.006; Robinson C, 2016, ACTA PAEDIATR, V105, P902, DOI 10.1111/apa.13407; Safran C, 2005, STUD HEALTH TECHNOL, V116, P879; Selman LE, 2020, J PAIN SYMPTOM MANAG, V60, pE81, DOI 10.1016/j.jpainsymman.2020.04.024; Shiber J, 2016, AM J CRIT CARE, V25, pE38, DOI 10.4037/ajcc2016695; Simpson R, 2020, AM J PHYS MED REHAB, V99, P470, DOI 10.1097/PHM.0000000000001443; Smailhodzic E, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1691-0; Statista, 2019, SOC MED STAT FACTS; Statsita, 2019, LEAD SOC NETW WORLDW; Tricco AC, 2018, ANN INTERN MED, V169, P467, DOI 10.7326/M18-0850; Ventola C Lee, 2014, P T, V39, P491; Weems MF, 2016, J PERINATOL, V36, P997, DOI 10.1038/jp.2016.125; White DB, 2018, NEW ENGL J MED, V378, P2365, DOI 10.1056/NEJMoa1802637; Williams L, 2020, J PAEDIATR CHILD H, V56, P1121, DOI 10.1111/jpc.14842; Young SD, 2014, PREV MED, V63, P112, DOI 10.1016/j.ypmed.2014.01.024	73	2	2	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2020	15	9							e0238803	10.1371/journal.pone.0238803	http://dx.doi.org/10.1371/journal.pone.0238803			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NR9MU	32915848	gold, Green Published			2023-01-03	WOS:000571887500027
J	Asratie, MH; Muche, AA; Geremew, AB				Asratie, Melaku Hunie; Muche, Achenef Asmamaw; Geremew, Alehegn Bishaw			Completion of maternity continuum of care among women in the post-partum period: Magnitude and associated factors in the northwest, Ethiopia	PLOS ONE			English	Article							NEONATAL SURVIVAL; HEALTH; NEWBORN; CALL	Background Maternity continuum of care is a model of integrated components of maternal health service from pregnancy to the post-partum period to improve maternal, neonatal and child health. In Ethiopia, the magnitude of antenatal care, skilled delivery, and post-natal care have shown improvement. However, there is limited evidence of the woman who attends continuing from antenatal care to post-partum care. Objective To assess completion of maternity continuum of care and its associated factors among women, in Motta town and Hulet Eji Enese district, Northwest Ethiopia. Methods A community based cross-sectional study with a stratified cluster sampling technique was conducted among 819 women 6week-6month post-partum period in Motta town and Hulet Eji Enese district. The data were collected from March 12, 2019 to April1, 2019 by face to face interviews, using a pretested structured questionnaire. Binary logistic regression (bi-variable and multivariable) model was done. Adjusted odds ratio with respect to 95% confidence interval was employed in the strength and direction of the association between covariates and outcome variable. Besides, a P valueResults A total of 819 women with100% response rate participated and Completion of maternity continuum of care was found to be 47% (43.2%-50.2%) in the study. Educational attainment of Secondary school and above (adjusted odds ratio(AOR) = 3.5; 1.9-6.3), urban residence (AOR = 4.6; 95%CI 2.5-8.5), women reach to a health facility within 30minute(AOR = 2.1; 95%CI 1.2-3.7), a woman was the primary decision maker for attending maternity continuum of care(AOR = 3.5;95%CI 1.9-6.3), index pregnancy-related complication(AOR = 2.4;95%CI 1.1-5.3), starting antenatal care within second trimester (AOR = 3.4;95%CI 2.1-5.6) and antenatal care visit 3-4 times(AOR = 2.1;95%CI 1.2-3.8) were statistically significant with completion of maternity continuum of care. Conclusions The completion of maternity continuum of care is low in the study area. Improving the educational status of women, engaging the rural community, physical accessibility of health facility, woman empowerment for decision making, emphasis on giving care for pregnancy-related complication, and early gestational age antenatal care at least 3 or more visits suggested to increase completion of maternity continuum of care.	[Asratie, Melaku Hunie] Univ Gondar, Coll Med & Hlth Sci, Sch Midwifery, Dept Womens & Family Hlth, Gondar, Ethiopia; [Muche, Achenef Asmamaw] Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Epidemiol & Biostat, Gondar, Ethiopia; [Geremew, Alehegn Bishaw] Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Dept Reprod Hlth, Gondar, Ethiopia	University of Gondar; University of Gondar; University of Gondar	Asratie, MH (corresponding author), Univ Gondar, Coll Med & Hlth Sci, Sch Midwifery, Dept Womens & Family Hlth, Gondar, Ethiopia.	melakuhunie27@gmail.com	Geremew, Alehegn/GQQ-4746-2022	Geremew, Alehegn/0000-0003-4535-1798; Asratie, Melaku/0000-0002-2281-7519; Muche, Achenef/0000-0001-7971-3537				Adjiwanou V, 2013, SOC SCI MED, V86, P26, DOI 10.1016/j.socscimed.2013.02.047; Ahmed S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011190; Akinyemi JO, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1083-9; Alvesson HM, 2013, REPROD HEALTH MATTER, V21, P203, DOI 10.1016/S0968-8080(13)42748-9; Amare N.S., 2019, BIORXIV, P620120; [Anonymous], 2011, DIABETOL DOSW KLI SA, V11, pA1; Choulagai B, 2013, BMC INT HEALTH HUM R, V13, DOI 10.1186/1472-698X-13-49; Dadi LS, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2335-2; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; EDHS E., 2016, DEM HLTH SURV 2016 K; Firoz T, 2013, B WORLD HEALTH ORGAN, V91, P794, DOI 10.2471/BLT.13.117564; Hamed A. F., 2018, International Journal of Medical Science and Public Health, V7, P417; Hong R., 2015, LEV DET CONT CAR MAT; Iqbal S, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2111-9; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Kikuchi K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198829; Kikuchi K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164965; Kikuchi K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139288; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Kuruvilla S, 2014, B WORLD HEALTH ORGAN, V92, P533, DOI 10.2471/BLT.14.138131; Lawn JE, 2006, LANCET, V367, P1541, DOI 10.1016/S0140-6736(06)68587-5; LIEBOWITZ B, 1970, GERONTOLOGIST, V10, P11, DOI 10.1093/geront/10.1_Part_1.11; Martines J, 2005, LANCET, V365, P1189, DOI 10.1016/S0140-6736(05)71882-1; Mohan D, 2017, HEALTH POLICY PLANN, V32, P791, DOI 10.1093/heapol/czx005; Osaki K, 2013, GLOBAL HEALTH ACTION, V6, P1, DOI 10.3402/gha.v6i0.20429; Sakuma S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215635; Shah R., 2016, PEACEBUILDING ED ADV; Sines E, 2007, POLICY PERSPECTIVES, V1; Singh K, 2016, MATERN CHILD HLTH J, V20, P281, DOI 10.1007/s10995-015-1827-6; Tamang TM., 2017, FACTORS ASS COMPLETI; Wang WJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0497-0; Wang WJ, 2013, LANCET, V381, P145; Woldehanna T., 2018, GROWTH NUTR PRELIMIN; World Health Organization, 2016, BURN OPP CLEAN HOUS; World Health Organization, 2018, WORLD HLTH STAT MON; Yeji F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142849	36	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2020	15	8							e0237980	10.1371/journal.pone.0237980	http://dx.doi.org/10.1371/journal.pone.0237980			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK7YQ	32853268	gold, Green Published			2023-01-03	WOS:000566948800021
J	Karunasagara, S; Hong, GL; Jung, DY; Kim, KH; Cho, K; Jung, JY				Karunasagara, Shanika; Hong, Geum-Lan; Jung, Da-Young; Kim, Kyung-Hyun; Cho, Kyoungwon; Jung, Ju-Young			Protective effects of combination ofStauntonia hexaphyllaandCornus officinalison testosterone-induced benign prostatic hyperplasia through inhibition of 5 alpha- reductase type 2 and induced cell apoptosis	PLOS ONE			English	Article							URINARY-TRACT SYMPTOMS; ANDROGEN RECEPTOR; 5-ALPHA-REDUCTASE INHIBITORS; SERENOA-REPENS; ROLES; BPH; DIHYDROTESTOSTERONE; PROLIFERATION; DYSFUNCTION; MANAGEMENT	Benign prostatic hyperplasia (BPH) is a progressive pathological condition associated with proliferation of prostatic tissues, prostate enlargement, and lower-urinary tract symptoms. However, the mechanism underlying the pathogenesis of BPH is unclear. The aim of this study was to investigate the protective effects of a combination ofStauntonia hexaphyllaandCornus officinalis(SC extract) on a testosterone propionate (TP)-induced BPH model. The effect of SC extract was examined in a TP-induced human prostate adenocarcinoma cell line. Male Sprague-Dawley rats were randomly divided into 5 groups (n = 6) forin vivoexperiments. To induce BPH, all rats, except those in the control group, were administered daily with subcutaneous injections of TP (5 mg/kg) and orally treated with appropriate phosphate buffered saline/drugs (finasteride/saw palmetto/SC extract) for 4 consecutive weeks. SC extract significantly downregulated the androgen receptor (AR), prostate specific antigen (PSA), and 5 alpha-reductase type 2 in TP-induced BPHin vitro. Inin vivoexperiments, SC extract significantly reduced prostate weight, size, serum testosterone, and dihydrotestosterone (DHT) levels. Histologically, SC extract markedly recovered TP-induced abnormalities and reduced prostatic hyperplasia, thereby improving the histo-architecture of TP-induced BPH rats. SC extract also significantly downregulated AR and PSA expression, as assayed using immunoblotting. Immunostaining revealed that SC extract markedly reduced the 5 alpha-reductase type 2 and significantly downregulated the expression of proliferating cell nuclear antigen. In addition, immunoblotting of B-cell lymphoma 2 (Bcl-2) family proteins indicated that SC extract significantly downregulated anti-apoptotic Bcl-2 and markedly upregulated pro-apoptotic B cell lymphoma-associated X (Bax) expression. Furthermore, SC treatment significantly decreased the Bcl-2/Bax ratio, indicating induced prostate cell apoptosis in TP-induced BPH rats. Thus, our findings demonstrated that SC extract protects against BPH by inhibiting 5 alpha-reductase type 2 and inducing prostate cell apoptosis. Therefore, SC extract might be useful in the clinical treatment of BPH.	[Karunasagara, Shanika; Hong, Geum-Lan; Jung, Da-Young; Kim, Kyung-Hyun; Jung, Ju-Young] Chungnam Natl Univ, Dept Vet Med, Daejeon, South Korea; [Karunasagara, Shanika; Hong, Geum-Lan; Jung, Da-Young; Kim, Kyung-Hyun; Jung, Ju-Young] Chungnam Natl Univ, Inst Vet Sci, Daejeon, South Korea; [Cho, Kyoungwon] Chungnam Natl Univ, Coll Pharm, Dept Pharm, Daejeon, South Korea	Chungnam National University; Chungnam National University; Chungnam National University	Jung, JY (corresponding author), Chungnam Natl Univ, Dept Vet Med, Daejeon, South Korea.; Jung, JY (corresponding author), Chungnam Natl Univ, Inst Vet Sci, Daejeon, South Korea.	jyjung@cnu.ac.kr		JUNG, JU YOUNG/0000-0002-6355-5738	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the High Value-Added Food Technology Development Program - Ministry of Agriculture, Food and Rural Affairs (MAFRA) [117052-3]	Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the High Value-Added Food Technology Development Program - Ministry of Agriculture, Food and Rural Affairs (MAFRA)	This work was supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture and Forestry (IPET) through the High Value-Added Food Technology Development Program, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA) (117052-3). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Afriyie DK, 2014, J ETHNOPHARMACOL, V157, P90, DOI 10.1016/j.jep.2014.09.007; Andriole G, 2004, J UROLOGY, V172, P1399, DOI 10.1097/01.ju.0000139539.94828.29; [Anonymous], [No title captured]; Arruzazabala M L, 2006, Drugs R D, V7, P233, DOI 10.2165/00126839-200607040-00003; Briganti A, 2009, EUR UROL SUPPL, V8, P865, DOI 10.1016/j.eursup.2009.11.002; Bullock Travis L, 2006, Expert Opin Emerg Drugs, V11, P111, DOI 10.1517/14728214.11.1.111; Chang R T M, 2012, Practitioner, V256, P13; Chatterjee B, 2003, MOL CELL BIOCHEM, V253, P89, DOI 10.1023/A:1026057402945; Cheon YH, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0801-6; Colado-Velazquez JIII, 2015, PHYTOTHER RES, V29, P1525, DOI 10.1002/ptr.5406; Czerwinska ME, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00894; Dong Y, 2018, CHIN MED-UK, V13, DOI 10.1186/s13020-018-0191-z; Fagelman E, 2001, Rev Urol, V3, P134; Gravas S, 2010, WORLD J UROL, V28, P9, DOI 10.1007/s00345-009-0493-y; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Habib FK, 2009, EUR UROL SUPPL, V8, P887, DOI 10.1016/j.eursup.2009.11.005; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hetz C, 2008, TRENDS CELL BIOL, V18, P38, DOI 10.1016/j.tcb.2007.10.003; Hong GL, 2020, J ETHNOPHARMACOL, V250, DOI 10.1016/j.jep.2019.112446; HWANG SH, 2017, BIOMED RES INT, V2017, DOI DOI 10.1155/2017/4273257; Hwangbo H, 2018, NUTR RES PRACT, V12, P378, DOI 10.4162/nrp.2018.12.5.378; Izumi K, 2013, AM J PATHOL, V182, P1942, DOI 10.1016/j.ajpath.2013.02.028; Jin BR, 2018, MOLECULES, V23, DOI 10.3390/molecules23102638; Kapoor A, 2012, CAN J UROL, V19, P10; Vinh LB, 2019, BIOORG MED CHEM LETT, V29, P2085, DOI 10.1016/j.bmcl.2019.07.010; Vinh LB, 2019, BIOORG MED CHEM LETT, V29, P965, DOI 10.1016/j.bmcl.2019.02.022; Lee CH, 2011, ENDOCRIN METAB CLIN, V40, P565, DOI 10.1016/j.ecl.2011.05.012; Lepor Herbert, 2005, Rev Urol, V7 Suppl 4, pS3; Lepor H, 2012, CURR OPIN UROL, V22, P7, DOI 10.1097/MOU.0b013e32834d9bfd; Marino G, 2014, NAT REV MOL CELL BIO, V15, P81, DOI 10.1038/nrm3735; McVary KT, 2006, AM J MANAG CARE, V12, pS122; Nicholson TM, 2011, DIFFERENTIATION, V82, P184, DOI 10.1016/j.diff.2011.04.006; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Raft MC, 1992, NATURE, V256, P396, DOI [10.1038/356397a01557121, DOI 10.1038/356397A01557121]; Rosen R, 2003, EUR UROL, V44, P637, DOI 10.1016/j.eururo.2003.08.015; Salakou S, 2007, IN VIVO, V21, P123; Schonenberger F, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0618-9; Shin IS, 2012, FOOD CHEM TOXICOL, V50, P884, DOI 10.1016/j.fct.2012.01.007; Speakman M, 2015, BJU INT, V115, P508, DOI 10.1111/bju.12745; Suzuki M, 2009, ACTA PHARMACOL SIN, V30, P271, DOI 10.1038/aps.2009.1; Thompson IM, 2003, NEW ENGL J MED, V349, P215, DOI 10.1056/NEJMoa030660; Traish AM, 2011, J SEX MED, V8, P872, DOI 10.1111/j.1743-6109.2010.02157.x; Untergasser G, 2005, EXP GERONTOL, V40, P121, DOI 10.1016/j.exger.2004.12.008; Vacherot F, 2000, PROSTATE, V45, P259, DOI 10.1002/1097-0045(20001101)45:3<259::AID-PROS9>3.0.CO;2-G; Wang HB, 1998, PHYTOCHEMISTRY, V47, P467, DOI 10.1016/S0031-9422(97)00588-8; Wilson CM, 1996, MOL CELL ENDOCRINOL, V120, P51, DOI 10.1016/0303-7207(96)03819-1; Xu DL, 2017, EXCLI J, V16, P939, DOI 10.17179/excli2017-335; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zachary JF, 2012, PATHOLOGIC BASIS VET	49	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2020	15	8							e0236879	10.1371/journal.pone.0236879	http://dx.doi.org/10.1371/journal.pone.0236879			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE5VG	32790676	gold, Green Submitted, Green Published			2023-01-03	WOS:000562668300098
J	Home, BD; Grajower, MM; Anderson, JL				Home, Benjamin D.; Grajower, Martin M.; Anderson, Jeffrey L.			Limited Evidence for the Health Effects and Safety of Intermittent Fasting among Patients With Type 2 Diabetes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							GLYCEMIC CONTROL; MELLITUS		[Home, Benjamin D.; Anderson, Jeffrey L.] Intermt Med Ctr, Heart Inst, Salt Lake City, UT USA; Stanford Univ, Dept Med, Div Cardiovasc Med, Stanford, CA 94305 USA; [Grajower, Martin M.] Albert Einstein Coll Med, Div Endocrinol, Bronx, NY 10467 USA; [Anderson, Jeffrey L.] Univ Utah, Sch Med, Dept Internal Med, Cardiol Div, Salt Lake City, UT USA	Intermountain Healthcare; Intermountain Medical Center; Stanford University; Yeshiva University; Albert Einstein College of Medicine; Utah System of Higher Education; University of Utah	Home, BD (corresponding author), Intermt Heart Inst, 5121 S Cottonwood St, Salt Lake City, UT 84107 USA.	benjamin.horne@imail.org						Aminian A, 2019, JAMA-J AM MED ASSOC, V322, P1271, DOI 10.1001/jama.2019.14231; Ash S, 2003, INT J OBESITY, V27, P797, DOI 10.1038/sj.ijo.0802295; Carter S, 2016, DIABETES RES CLIN PR, V122, P106, DOI 10.1016/j.diabres.2016.10.010; Carter S, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.0756; Corley BT, 2018, DIABETIC MED, V35, P588, DOI 10.1111/dme.13595; Grajower MM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11040873; Jamshed H, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061234; Li CY, 2017, EXP CLIN ENDOCR DIAB, V125, P618, DOI 10.1055/s-0043-101700; Moller N, 2009, ENDOCR REV, V30, P152, DOI 10.1210/er.2008-0027; Trepanowski JF, 2017, JAMA INTERN MED, V177, P930, DOI 10.1001/jamainternmed.2017.0936	10	21	24	1	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	2020	324	4					341	342		10.1001/jama.2020.3908	http://dx.doi.org/10.1001/jama.2020.3908			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE8JP	32614382				2023-01-03	WOS:000562851000020
J	Wuestefeld, A; Fuermaier, ABM; Bernardo, M; de Sa-Caputo, DC; Rittweger, J; Schoenau, E; Stark, C; Marin, PJ; Seixas, A; Judex, S; Taiar, R; Nyakas, C; van der Zee, EA; van Heuvelen, MJG; Tucha, O				Wuestefeld, Anika; Fuermaier, Anselm B. M.; Bernardo-Filho, Mario; de Sa-Caputo, Danubia Cunha; Rittweger, Joern; Schoenau, Eckhard; Stark, Christina; Marin, Pedro J.; Seixas, Aderito; Judex, Stefan; Taiar, Redha; Nyakas, Csaba; van der Zee, Eddy A.; van Heuvelen, Marieke J. G.; Tucha, Oliver			Towards reporting guidelines of research using whole-body vibration as training or treatment regimen in human subjects-A Delphi consensus study	PLOS ONE			English	Article							QUALITY; RECOMMENDATIONS; RELIABILITY; PERFORMANCE; STRENGTH; BALANCE	Background Whole-body vibration (WBV) is a method utilizing vibrating platforms to expose individuals to mechanical vibration. In its various applications, it has been linked to improved muscular, skeletal, metabolic, or cognitive functioning, quality of life, and physiological parameters such as blood pressure. Most evidence concerning WBV is inconclusive and meta-analytical reviews may not readily produce insights since the research has a risk of misunderstandings of vibration parameters and incomplete reporting occurs. This study aims at laying an empirical foundation for reporting guidelines for human WBV studies to improve the quality of reporting and the currently limited comparability between studies. Method The Delphi methodology is employed to exploit the integrated knowledge of WBV experts to distil the specific aspects of WBV methodology that should be included in such guidelines. Over three rounds of completing online questionnaires, the expert panel (round 1/2/3: 51/40/37 experts respectively from 17 countries with an average of 19.4 years of WBV research experience) rated candidate items. Results A 40-item list was established based on the ratings of the individual items from the expert panel with a large final consensus (94.6%). Conclusion The final consensus indicates comprehensiveness and valuableness of the list. The results are in line with previous guidelines but expand these extensively. The present results may therefore serve as a foundation for updated guidelines for reporting human WBV studies in order to improve the quality of reporting of WBV studies, improve comparability of studies and facilitate the development of WBV study designs.	[Wuestefeld, Anika; Fuermaier, Anselm B. M.; Tucha, Oliver] Univ Groningen, Dept Clin & Dev Neuropsychol, Groningen, Netherlands; [Bernardo-Filho, Mario; de Sa-Caputo, Danubia Cunha] Univ Estado Rio de Janeiro, Lab Mech Vibrat & Integrat Practices, Rio De Janeiro, Brazil; [de Sa-Caputo, Danubia Cunha] Univ Estado Rio de Janeiro, Fac Bezerra Araujo, Physiotherapy Course, Rio De Janeirom, Brazil; [Rittweger, Joern] Univ Cologne, German Aerosp Ctr, Cologne, Germany; [Schoenau, Eckhard; Stark, Christina] Univ Cologne, Med Fac, Dept Pediat, Cologne, Germany; [Schoenau, Eckhard; Stark, Christina] Univ Cologne, Univ Hosp, Cologne, Germany; [Schoenau, Eckhard] Univ Cologne, Med Fac, Ctr Prevent & Rehabil, UniReha GmbH, Cologne, Germany; [Marin, Pedro J.] CyMO Res Inst, Valladolid, Spain; [Seixas, Aderito] Univ Fernando Pessoa, Escola Super Saude, Porto, Portugal; [Judex, Stefan] SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; [Taiar, Redha] Univ Reims, Reims, France; [Nyakas, Csaba] Semmelweis Univ, Fac Hlth Sci, Dept Morphol & Physiol, Budapest, Hungary; [van der Zee, Eddy A.] Univ Groningen, Dept Mol Neurobiol, Groningen, Netherlands; [van Heuvelen, Marieke J. G.] Univ Groningen, Univ Med Ctr Groningen, Ctr Human Movement Sci, Groningen, Netherlands	University of Groningen; Universidade do Estado do Rio de Janeiro; Universidade do Estado do Rio de Janeiro; Helmholtz Association; German Aerospace Centre (DLR); University of Cologne; University of Cologne; University of Cologne; University of Cologne; Universidade Fernando Pessoa; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Universite de Reims Champagne-Ardenne; Semmelweis University; University of Groningen; University of Groningen	Fuermaier, ABM (corresponding author), Univ Groningen, Dept Clin & Dev Neuropsychol, Groningen, Netherlands.	a.b.m.fuermaier@rug.nl	Seixas, Adérito/J-5018-2013; Taiar, Redha/Q-6769-2016; Rittweger, Jörn/A-4308-2009; van der Zee, Eddy/AAZ-2120-2020	Seixas, Adérito/0000-0002-6563-8246; Taiar, Redha/0000-0002-0227-3884; Rittweger, Jörn/0000-0002-2223-8963; Wuestefeld, Anika/0000-0003-1779-3388; Fuermaier, Anselm/0000-0002-2331-0840; Judex, Stefan/0000-0002-4511-1535				Alam MM, 2018, WORK, V59, P571, DOI 10.3233/WOR-182699; [Anonymous], 2019, EQUATOR NETWORK; Boerema AS, 2018, DOSE-RESPONSE, V16, DOI 10.1177/1559325818811756; Bogaerts A, 2007, GAIT POSTURE, V26, P309, DOI 10.1016/j.gaitpost.2006.09.078; Boulkedid R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020476; Brooks K., 1979, N CENTRAL ASS Q, V53, P377; Cardim AB, 2016, RESP CARE, V61, P1552, DOI 10.4187/respcare.04763; del Pozo-Cruz B, 2012, J ALTERN COMPLEM MED, V18, P29, DOI 10.1089/acm.2010.0691; Figueroa A, 2012, HYPERTENS RES, V35, P667, DOI 10.1038/hr.2012.15; Fincher S, 2009, ITICSE 2009: PROCEEDING OF THE 2009 ACM SIGSE ANNUAL CONFERENCE ON INNOVATION AND TECHNOLOGY IN COMPUTER SCIENCE EDUCATION, P4, DOI 10.1145/1595496.1562885; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Fischer M, 2019, FRONTIERS NEUROLOGY, V10; Fuermaier ABM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090747; Gevers DWM, 2014, APPETITE, V79, P51, DOI 10.1016/j.appet.2014.04.002; Green KC, 2007, FORESIGHT, V8; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Habibi A, 2014, INT J ENG SCI, V3, P8, DOI DOI 10.1016/S0169-2070(99)00018-7; Hahn EJ, 1999, TOB CONTROL, V8, P137, DOI 10.1136/tc.8.2.137; Hayes AF, 2007, COMMUN METHODS MEAS, V1, P77, DOI 10.1080/19312450709336664; Heesterbeek M., 2017, J NEUROLOGY TRANSLAT, V5, P1079; Hsu C, 2007, RES EVALUAT, V12, P10, DOI [10.7275/pdz9-th90, DOI 10.7275/PDZ9-TH90]; ISO 2631-1, 1997, MECH VIBRATION SHOCK; Junger S, 2017, PALLIATIVE MED, V31, P684, DOI 10.1177/0269216317690685; Kerlinger FN, 1973, FDN BEHAV RES, V2nd; Kiiski J, 2008, J BONE MINER RES, V23, P1318, DOI [10.1359/jbmr.080315, 10.1359/JBMR.080315]; KRIPPEND.K, 1970, EDUC PSYCHOL MEAS, V30, P61, DOI 10.1177/001316447003000105; Lam FMH, 2012, MATURITAS, V72, P206, DOI 10.1016/j.maturitas.2012.04.009; Leite HR, 2018, BRAZ J PHYS THER; LIN YK, 2017, BMC MED ETHICS, V18, DOI DOI 10.1186/S12910-017-0177-X; Lorenzen C, 2009, J SCI MED SPORT, V12, P676, DOI 10.1016/j.jsams.2008.06.008; Mbakwe AC, 2016, ACCIDENT ANAL PREV, V93, P135, DOI 10.1016/j.aap.2016.04.020; Milanese C, 2013, INT J MED SCI, V10, P307, DOI 10.7150/ijms.5161; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Moher D, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000217; Molnar FJ, 1999, CAN MED ASSOC J, V161, P393; Muller SV, 2002, ARCH PHYS MED REHAB, V83, P115, DOI 10.1053/apmr.2002.27472; Murphy MK., 1998, HLTH TECHNOLOGY ASSE, V2, pi, DOI [10.3310/hta2030, DOI 10.3310/HTA2030]; Needham DM, 2017, AM J RESP CRIT CARE, V196, P1122, DOI 10.1164/rccm.201702-0372OC; Nordlund MM, 2007, SCAND J MED SCI SPOR, V17, P12, DOI 10.1111/j.1600-0838.2006.00586.x; Pound P, 2004, BMJ-BRIT MED J, V328, P514, DOI 10.1136/bmj.328.7438.514; Powell C, 2003, J ADV NURS, V41, P376, DOI 10.1046/j.1365-2648.2003.02537.x; Rauch F, 2010, J MUSCULOSKEL NEURON, V10, P193; Rayens M. K., 2000, POL POLIT NURS PRACT, V1, P308, DOI DOI 10.1177/152715440000100409; Regterschot GRH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100506; Rittweger J, 2010, EUR J APPL PHYSIOL, V108, P877, DOI 10.1007/s00421-009-1303-3; Rowe G, 2001, INT SER OPER RES MAN, V30, P125, DOI 10.1007/978-0-306-47630-3_7; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; Sanders C, 1936, J AM MED ASS, V106; Santin-Medeiros F, 2017, RES SPORTS MED, V25, P101, DOI 10.1080/15438627.2016.1258638; Savage R, 2016, INT ARCH OCC ENV HEA, V89, P181, DOI 10.1007/s00420-015-1062-x; Schulz KF, 2010, J PHARMACOL PHARMACO, V1, P100, DOI [10.1016/j.jclinepi.2010.02.005, 10.4103/0976-500X.72352, 10.1016/j.ijsu.2011.09.004, 10.1186/1741-7015-8-18]; Slatkovska L, 2010, OSTEOPOROSIS INT, V21, P1969, DOI 10.1007/s00198-010-1228-z; Song GE, 2011, KOREAN J FAM MED, V32, P399, DOI 10.4082/kjfm.2011.32.7.399; Sumsion, 1998, BRIT J OCCUPATIONAL, V61, P153, DOI DOI 10.1177/030802269806100403; Teglas T, 2018, BEHAV BRAIN RES, V349, P163, DOI 10.1016/j.bbr.2018.04.036; van der Zee EA, 2019, WHOLE BODY VIBRATION, P151; Van der Zee EA, 2010, FEDERATION EUROPEAN, V5, P24; Verhulst ALJ, 2015, ONCOL REV, V9, DOI 10.4081/oncol.2015.263; Walker A, 1996, BR J THER REHABIL, V3, P677, DOI 10.12968/bjtr.1996.3.12.14731; Weir CR, 2006, AM J MED QUAL, V21, P382, DOI 10.1177/1062860606293150; WHEDON GD, 1949, AM J MED, V6, P684; Zapf A, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0200-9; 2016, AM PSYCHOL, V71, P900, DOI DOI 10.1037/AMP000010228032786	63	27	28	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 22	2020	15	7							e0235905	10.1371/journal.pone.0235905	http://dx.doi.org/10.1371/journal.pone.0235905			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MU0WZ	32697809	Green Accepted, gold, Green Published			2023-01-03	WOS:000555392700016
J	Islam, M; Rahman, M; Unicomb, L; Kafi, MAH; Rahman, M; Alam, M; Sen, D; Islam, S; Pickering, AJ; Hubbard, AE; Luby, SP; Arnold, BF; Colford, JM; Ercumen, A				Islam, Mahfuza; Rahman, Mahbubur; Unicomb, Leanne; Kafi, Mohammad Abdullah Heel; Rahman, Mostafizur; Alam, Mahfuja; Sen, Debashis; Islam, Sharmin; Pickering, Amy J.; Hubbard, Alan E.; Luby, Stephen P.; Arnold, Benjamin F.; Colford, John M., Jr.; Ercumen, Ayse			Child defecation and feces management practices in rural Bangladesh: Associations with fecal contamination, observed hand cleanliness and child diarrhea	PLOS ONE			English	Article							MIDDLE-INCOME COUNTRIES; DRINKING-WATER; SANITATION INTERVENTION; ESCHERICHIA-COLI; QUALITY; HYGIENE; GROWTH; TRANSMISSION; GROUNDWATER; EXPOSURE	Child open defecation is common in low-income countries and can lead to fecal exposure in the domestic environment. We assessed associations between child feces management practices vs. measures of contamination and child diarrhea among households with children <5 years in rural Bangladesh. We visited 360 households quarterly and recorded caregiver-reported diarrhea prevalence, and defecation and feces disposal practices for children E.coliin child and caregiver hand rinse and stored drinking water samples. Safe child defecation (in latrine/potty) and safe feces disposal (in latrine) was reported by 21% and 23% of households, respectively. Controlling for potential confounders, households reporting unsafe child defecation had higherE.coliprevalence on child hands (prevalence ratio [PR] = 1.12, 1.04-1.20) and in stored water (PR = 1.12,1.03-1.21). Similarly, households reporting unsafe feces disposal had higherE.coliprevalence on child hands (PR = 1.11, 1.02-1.21) and in stored water (PR = 1.10, 1.03-1.18). Effects onE.colilevels were similar. Children in households with unsafe defecation and feces disposal had higher diarrhea prevalence but the associations were not statistically significant. Our findings suggest that unsafe child feces management may present a source of fecal exposure for young children.	[Islam, Mahfuza; Rahman, Mahbubur; Unicomb, Leanne; Kafi, Mohammad Abdullah Heel; Rahman, Mostafizur; Alam, Mahfuja; Sen, Debashis; Islam, Sharmin] Icddr B, Environm Intervent Unit, Infect Dis Div, Dhaka, Bangladesh; [Pickering, Amy J.] Tufts Univ, Civil & Environm Engn, Medford, MA 02155 USA; [Hubbard, Alan E.; Colford, John M., Jr.] Univ Calif Berkeley, Div Epidemiol & Biostat, Berkeley, CA 94720 USA; [Luby, Stephen P.] Stanford Univ, Woods Inst Environm, Stanford, CA 94305 USA; [Arnold, Benjamin F.] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA; [Ercumen, Ayse] North Carolina State Univ, Dept Forestry & Environm Resources, Raleigh, NC USA	International Centre for Diarrhoeal Disease Research (ICDDR); Tufts University; University of California System; University of California Berkeley; Stanford University; University of California System; University of California San Francisco; University of North Carolina; North Carolina State University	Islam, M (corresponding author), Icddr B, Environm Intervent Unit, Infect Dis Div, Dhaka, Bangladesh.	mi_sheuli@icddrb.org	Unicomb, Leanne Elizabeth/AAW-4900-2021	Unicomb, Leanne Elizabeth/0000-0002-7757-5641; Sen, Debashis/0000-0001-6231-998X; Ercumen, Ayse/0000-0001-6002-1514	National Institutes of Health (NIH) [R01HD078912]	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was funded by National Institutes of Health (NIH) grant number R01HD078912.The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript'.	Ahmed KM, 2004, APPL GEOCHEM, V19, P181, DOI 10.1016/j.apgeochem.2003.09.006; Alam M, 2014, BANGLADESH NATL HYGI; ALAM N, 1989, INT J EPIDEMIOL, V18, P242, DOI 10.1093/ije/18.1.242; Arnold BF, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003476; Arnold BF, 2010, P NATL ACAD SCI USA; Azage M, 2015, ARCH PUBLIC HEALTH, V73, DOI 10.1186/s13690-015-0090-z; AZIZ KMA, 1990, T ROY SOC TROP MED H, V84, P433, DOI 10.1016/0035-9203(90)90353-G; Banda K, 2007, T ROY SOC TROP MED H, V101, P1124, DOI 10.1016/j.trstmh.2007.05.004; Bauza V, 2020, SCI TOTAL ENVIRON, V709, DOI 10.1016/j.scitotenv.2019.136169; Bauza V, 2019, ENVIRON SCI TECHNOL, V53, P8271, DOI 10.1021/acs.est.8b06583; Bauza V, 2019, AM J TROP MED HYG, V100, P1013, DOI 10.4269/ajtmh.18-0840; Bauza V, 2017, TROP MED INT HEALTH, V22, P1233, DOI 10.1111/tmi.12930; Briceno B., 2015, PROMOTING HANDWASHIN; Cantu-Soto EU, 2011, B ENVIRON CONTAM TOX, V87, P556, DOI 10.1007/s00128-011-0353-5; Clasen T, 2014, AM J TROP MED HYG, V91, P215; Ercumen A, 2018, ENVIRON SCI TECHNOL, V52, P12089, DOI 10.1021/acs.est.8b02988; Ercumen A, 2018, ENVIRON SCI TECHNOL, V52, P12078, DOI 10.1021/acs.est.8b05153; Ercumen A, 2017, ENVIRON SCI TECHNOL, V51, P8725, DOI 10.1021/acs.est.7b01710; Ercumen A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121907; Eshcol J, 2009, J WATER HEALTH, V7, P145, DOI 10.2166/wh.2009.094; ESREY SA, 1991, B WORLD HEALTH ORGAN, V69, P609; Esrey SA, 1996, AM J EPIDEMIOL, V143, P608, DOI 10.1093/oxfordjournals.aje.a008791; Feachem R.G., 1983, SANITATION DIS HLTH; Gil A, 2004, 11 BUR GLOB HLTH, P20523; Greene LE, 2012, AM J TROP MED HYG, V87, P385, DOI 10.4269/ajtmh.2012.11-0633; Haefliger P, 2009, ENVIRON HEALTH PERSP, V117, P1535, DOI 10.1289/ehp.0900696; HAMMAD ZH, 1982, APPL ENVIRON MICROB, V43, P1238, DOI 10.1128/AEM.43.6.1238-1243.1982; HARDINA CM, 1991, ENVIRON TOXIC WATER, V6, P185, DOI 10.1002/tox.2530060208; Heijnen M, 2015, AM J TROP MED HYG, V93, P263, DOI 10.4269/ajtmh.14-0812; Hoque BA, 2006, INT J HYG ENVIR HEAL, V209, P451, DOI 10.1016/j.ijheh.2006.04.008; Howe LD, 2012, INT J EPIDEMIOL, V41, P871, DOI 10.1093/ije/dys037; Huda TMN, 2019, AM J TROP MED HYG; Islam M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195218; Knappett PSK, 2012, J WATER HEALTH, V10, P565, DOI 10.2166/wh.2012.102; Knappett PSK, 2012, ENVIRON SCI TECHNOL, V46, P1361, DOI 10.1021/es202773w; Kwong LH, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13060563; Luby SP, 2018, LANCET GLOB HEALTH, V6, pE302, DOI 10.1016/S2214-109X(17)30490-4; Majorin F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089551; Mattioli MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084939; Mattioli MCM, 2015, ENVIRON SCI TECHNOL, V49, P1912, DOI 10.1021/es505555f; Morita T, 2016, TROP MED INT HEALTH, V21, P1403, DOI 10.1111/tmi.12773; Mukherjee A, 2006, J HEALTH POPUL NUTR, V24, P142; Park M. J., 2015, INT J SOC SCI HUM, V5, P429, DOI [10.7763/IJSSH.2015.V5.494, DOI 10.7763/IJSSH.2015.V5.494]; Parvez SM, 2018, TRIALS, V19, DOI 10.1186/s13063-018-2710-8; Patil SR, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001709; Pickering AJ, 2015, LANCET GLOB HEALTH, V3, pE701, DOI 10.1016/S2214-109X(15)00144-8; Pickering AJ, 2011, TROP MED INT HEALTH, V16, P233, DOI 10.1111/j.1365-3156.2010.02677.x; Pickering AJ, 2010, ENVIRON SCI TECHNOL, V44, P3267, DOI 10.1021/es903524m; Ram PK, 2011, AM J TROP MED HYG, V84, P510, DOI 10.4269/ajtmh.2011.10-0299; Sclar GD, 2016, INT J HYG ENVIR HEAL, V219, P709, DOI 10.1016/j.ijheh.2016.09.021; SHEARS P, 1995, ANN TROP MED PARASIT, V89, P297, DOI 10.1080/00034983.1995.11812955; Sinton LW, 1998, NEW ZEAL J MAR FRESH, V32, P323, DOI 10.1080/00288330.1998.9516828; Taniuchi M, 2013, J INFECT DIS, V208, P1794, DOI 10.1093/infdis/jit507; Trevett AF, 2005, INT J HYG ENVIR HEAL, V208, P153, DOI 10.1016/j.ijheh.2005.01.024; UNICEF, 2020, MULT IND CLUST SURV; Vyas S, 2006, HEALTH POLICY PLANN, V21, P459, DOI 10.1093/heapol/czl029; Walker CLF, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-220; Wedgworth JC, 2013, WATER QUAL EXPOS HEA, V5, P69, DOI 10.1007/s12403-013-0088-0; WHO, 2011, GUID DRINK WAT QAUL; Yakub GP, 2002, WATER ENVIRON RES, V74, P131, DOI 10.2175/106143002X139839	60	14	17	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 20	2020	15	7							e0236163	10.1371/journal.pone.0236163	http://dx.doi.org/10.1371/journal.pone.0236163			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MS0LL	32687513	gold, Green Published			2023-01-03	WOS:000553978400025
J	Dimopoulos, M; Quach, H; Mateos, MV; Landgren, O; Leleu, X; Siegel, D; Weisel, K; Yang, H; Klippel, Z; Zahlten-Kumeli, A; Usmani, SZ				Dimopoulos, Meletios; Quach, Hang; Mateos, Maria-Victoria; Landgren, Ola; Leleu, Xavier; Siegel, David; Weisel, Katja; Yang, Hui; Klippel, Zandra; Zahlten-Kumeli, Anita; Usmani, Saad Z.			Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study	LANCET			English	Article							STEM-CELL TRANSPLANTATION; LENALIDOMIDE MAINTENANCE; BORTEZOMIB; SURVIVAL; STRATEGIES; OUTCOMES; IMPACT	Background Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in combination with daratumumab has shown substantial efficacy with tolerable safety in relapsed or refractory multiple myeloma in a phase 1 study. In this study, we aimed to compare the efficacy and safety of carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Methods In this randomised, multicentre, open-label, phase 3 study, 466 patients recruited from 102 sites across North America, Europe, Australia, and Asia with relapsed or refractory multiple myeloma were randomly assigned 2:1 to carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd). All patients received twice per week carfilzomib at 56 mg/m(2) (20 mg/m(2); days 1 and 2 during cycle 1). Daratumumab (8 mg/kg) was administered intravenously on days 1 and 2 of cycle 1 and at 16 mg/kg weekly for the remaining doses of the first two cycles, then every 2 weeks for four cycles (cycles 3-6), and every 4 weeks thereafter. Patients received 40 mg dexamethasone weekly (20 mg for patients >= 75 years old starting on the second week). The primary endpoint was progression-free survival assessed by intention to treat. Adverse events were assessed in the safety population. This trial (NCT03158688) is registered with ClinicalTrials.gov, and is active but not recruiting. Findings Between June 13, 2017, and June 25, 2018, 466 patients of 569 assessed for eligibility were enrolled. After median follow-up of approximately 17 months, median progression-free survival was not reached in the KdD group versus 15.8 months in the Kd group (hazard ratio 0.63; 95% CI 0.46-0.85; p=0.0027). Median treatment duration was longer in the KdD versus the Kd group (70.1 vs 40.3 weeks). Grade 3 or higher adverse events were reported in 253 (82%) patients in the KdD group and 113 (74%) patients in the Kd group. The frequency of adverse events leading to treatment discontinuation was similar in both groups (KdD, 69 [22%]; Kd, 38 [25%]). Interpretation KdD significantly prolonged progression-free survival versus Kd in patients with relapsed or refractory multiple myeloma and was associated with a favourable benefit-risk profile.	[Dimopoulos, Meletios] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece; [Quach, Hang] Univ Melbourne, St Vincents Hosp, Fitzroy, Vic, Australia; [Mateos, Maria-Victoria] Univ Hosp Salamanca, Canc Res Ctr, Inst Invest Biomed Salamanca, Salamanca, Spain; [Landgren, Ola] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Leleu, Xavier] CHU Miletrie, Dept Hematol, Poitiers, France; [Leleu, Xavier] INSERM, CIC 1402, Poitiers, France; [Siegel, David] Hackensack Univ Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA; [Weisel, Katja] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany; [Yang, Hui; Klippel, Zandra; Zahlten-Kumeli, Anita] Amgen Inc, Thousand Oaks, CA USA; [Usmani, Saad Z.] Atrium Hlth, Charlotte, NC 28204 USA	Athens Medical School; National & Kapodistrian University of Athens; St Vincent's Hospital Melbourne; University of Melbourne; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); Memorial Sloan Kettering Cancer Center; CHU Poitiers; Universite de Poitiers; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Poitiers; Hackensack University Medical Center; University of Hamburg; University Medical Center Hamburg-Eppendorf; Amgen	Usmani, SZ (corresponding author), Atrium Hlth, Charlotte, NC 28204 USA.	usmani@atriumhealth.org	Usmani, Saad Z/H-2705-2012; Usmani, Saad Z/HCI-4676-2022	Usmani, Saad Z/0000-0002-5484-8731; QUACH, HANG/0000-0002-4796-3352	Amgen	Amgen(Amgen)	Amgen.	[Anonymous], 2018, DARATUMUMAB INJECTIO; [Anonymous], 2018, KYPROLIS CARFILZOMIB; Attal M, 2012, NEW ENGL J MED, V366, P1782, DOI 10.1056/NEJMoa1114138; Chari A, 2019, BLOOD, V134, P421, DOI 10.1182/blood.2019000722; Dimopoulos MA, 2016, NEW ENGL J MED, V375, P1319, DOI 10.1056/NEJMoa1607751; Dimopoulos MA, 2017, LANCET ONCOL, V18, P1327, DOI 10.1016/S1470-2045(17)30578-8; Dimopoulos MA, 2016, LANCET ONCOL, V17, P27, DOI 10.1016/S1470-2045(15)00464-7; Drayson MT, 2019, LANCET ONCOL, V20, P1760, DOI 10.1016/S1470-2045(19)30506-6; EMA, 2016, KYPR PROD INF; Facon T, 2018, BLOOD, V131, P301, DOI 10.1182/blood-2017-07-795047; Kazandjian D, 2018, JAMA ONCOL, V4, P1781, DOI 10.1001/jamaoncol.2018.5457; Kumar S, 2016, LANCET ONCOL, V17, pE328, DOI 10.1016/S1470-2045(16)30206-6; Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood-2007-10-116129; Martinez-Lopez J, 2014, BLOOD, V123, P3073, DOI 10.1182/blood-2014-01-550020; McCarthy PL, 2017, J CLIN ONCOL, V35, P3279, DOI 10.1200/JCO.2017.72.6679; Moreau P, 2017, LEUKEMIA, V31, P115, DOI 10.1038/leu.2016.186; Moreau P, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0200-1; Moreau P, 2018, LANCET ONCOL, V19, P953, DOI 10.1016/S1470-2045(18)30354-1; Nijhof IS, 2018, DRUGS, V78, P19, DOI 10.1007/s40265-017-0841-y; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Overdijk MB, 2015, MABS-AUSTIN, V7, P311, DOI 10.1080/19420862.2015.1007813; Palumbo A, 2016, NEW ENGL J MED, V375, P754, DOI 10.1056/NEJMoa1606038; Paquin AR, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-018-0163-7; Pulte ED, 2018, ONCOLOGIST, V23, P734, DOI 10.1634/theoncologist.2017-0440; Richardson PG, 2019, LANCET ONCOL, V20, P781, DOI 10.1016/S1470-2045(19)30152-4; Sonneveld P, 2017, CRIT REV ONCOL HEMAT, V112, P153, DOI 10.1016/j.critrevonc.2017.02.007; Spencer A, 2018, HAEMATOLOGICA, V103, P2079, DOI 10.3324/haematol.2018.194118; Stewart AK, 2015, NEW ENGL J MED, V372, P142, DOI 10.1056/NEJMoa1411321; US FDA, 2016, KYPR PROD INF; Usmani SZ, 2016, BLOOD, V128, P37, DOI 10.1182/blood-2016-03-705210; Usmani SZ., 2018, BLOOD, V132, P3288	31	176	179	2	16	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 18	2020	396	10245					186	197						12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN8IK	32682484				2023-01-03	WOS:000551085400018
J	Quinn, KL; Stukel, T; Stall, NM; Huang, AJ; Isenberg, S; Tanuseputro, P; Goldman, R; Cam, P; Kavalieratos, D; Detsky, AS; Bell, CM				Quinn, Kieran L.; Stukel, Therese; Stall, Nathan M.; Huang, Anjie; Isenberg, Sarina; Tanuseputro, Peter; Goldman, Russell; Cam, Peter; Kavalieratos, Dio; Detsky, Allan S.; Bell, Chaim M.			Association between palliative care and healthcare outcomes among adults with terminal non-cancer illness: population based matched cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							QUALITY-OF-LIFE; HEART-FAILURE; RANDOMIZED-TRIAL; END; DISEASE; TRAJECTORIES; INDICATORS; PATIENT; BURDEN; PLACE	OBJECTIVE To measure the associations between newly initiated palliative care in the last six months of life, healthcare use, and location of death in adults dying from non-cancer illness, and to compare these associations with those in adults who die from cancer at a population level. DESIGN Population based matched cohort study. SETTING Ontario, Canada between 2010 and 2015. PARTICIPANTS 113 540 adults dying from cancer and non-cancer illness who were given newly initiated physician delivered palliative care in the last six months of life administered across all healthcare settings. Linked health administrative data were used to directly match patients on cause of death, hospital frailty risk score, presence of metastatic cancer, residential location (according to 1 of 14 local health integration networks that organise all healthcare services in Ontario), and a propensity score to receive palliative care that was derived by using age and sex. MAIN OUTCOME MEASURES Rates of emergency department visits, admissions to hospital, and admissions to the intensive care unit, and odds of death at home versus in hospital after first palliative care visit, adjusted for patient characteristics (such as age, sex, and comorbidities). RESULTS In patients dying from non-cancer illness related to chronic organ failure (such as heart failure, cirrhosis, and stroke), palliative care was associated with reduced rates of emergency department visits (crude rate 1.9 (standard deviation 6.2) v 2.9 (8.7) per person year; adjusted rate ratio 0.88, 95% confidence interval 0.85 to 0.91), admissions to hospital (crude rate 6.1 (standard deviation 10.2) v 8.7 (12.6) per person year; adjusted rate ratio 0.88, 95% confidence interval 0.86 to 0.91), and admissions to the intensive care unit (crude rate 1.4 (standard deviation 5.9) v 2.9 (8.7) per person year; adjusted rate ratio 0.59, 95% confidence interval 0.56 to 0.62) compared with those who did not receive palliative care. Additionally increased odds of dying at home or in a nursing home compared with dying in hospital were found in these patients (n=6936 (49.5%) v n=9526 (39.6%); adjusted odds ratio 1.67, 95% confidence interval 1.60 to 1.74). Overall, in patients dying from dementia, palliative care was associated with increased rates of emergency department visits (crude rate 1.2 (standard deviation 4.9) v 1.3 (5.5) per person year; adjusted rate ratio 1.06, 95% confidence interval 1.01 to 1.12) and admissions to hospital (crude rate 3.6 (standard deviation 8.2) v 2.8 (7.8) per person year; adjusted rate ratio 1.33, 95% confidence interval 1.27 to 1.39), and reduced odds of dying at home or in a nursing home (n=6667 (72.1%) v n=13 384 (83.5%); adjusted odds ratio 0.68, 95% confidence interval 0.64 to 0.73). However, these rates differed depending on whether patients dying with dementia lived in the community or in a nursing home. No association was found between healthcare use and palliative care for patients dying from dementia who lived in the community, and these patients had increased odds of dying at home. CONCLUSIONS These findings highlight the potential benefits of palliative care in some non-cancer illnesses. Increasing access to palliative care through sustained investment in physician training and current models of collaborative palliative care could improve end-of-life care, which might have important implications for health policy.	[Quinn, Kieran L.; Cam, Peter; Detsky, Allan S.; Bell, Chaim M.] Univ Toronto, Dept Med, Toronto, ON, Canada; [Quinn, Kieran L.; Stukel, Therese; Huang, Anjie; Tanuseputro, Peter; Cam, Peter; Bell, Chaim M.] Inst Clin Evaluat Sci ICES, Toronto, ON, Canada; [Quinn, Kieran L.; Stukel, Therese; Huang, Anjie; Tanuseputro, Peter; Cam, Peter; Bell, Chaim M.] Inst Clin Evaluat Sci ICES, Ottawa, ON, Canada; [Quinn, Kieran L.; Stukel, Therese; Stall, Nathan M.; Cam, Peter; Detsky, Allan S.; Bell, Chaim M.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Quinn, Kieran L.; Cam, Peter; Detsky, Allan S.; Bell, Chaim M.] Sinai Hlth Syst, Dept Med, Toronto, ON, Canada; [Stall, Nathan M.] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada; [Stall, Nathan M.] Univ Toronto, Div Geriatr Med, Dept Med, Toronto, ON, Canada; [Isenberg, Sarina] Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada; [Isenberg, Sarina] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Isenberg, Sarina; Goldman, Russell] Temmy Latner Ctr Palliat Care, Toronto, ON, Canada; [Tanuseputro, Peter] Ottawa Hosp, Clin Epidemiol Program, Res Inst, Ottawa, ON, Canada; [Tanuseputro, Peter] Univ Ottawa, Sch Epidemiol Publ Hlth & Prevent Med, Ottawa, ON, Canada; [Tanuseputro, Peter] Bruyere Res Inst, Ottawa, ON, Canada; [Tanuseputro, Peter] Univ Ottawa, Dept Med, Ottawa, ON, Canada; [Goldman, Russell] Sinai Hlth Syst, Interdept Div Palliat Care, Toronto, ON, Canada; [Kavalieratos, Dio] Emory Univ, Dept Med, Atlanta, GA 30322 USA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Emory University	Quinn, KL (corresponding author), Sinai Hlth Syst, 60 Murray St,2nd Floor Room 404, Toronto, ON M5T 3L9, Canada.	kieran.quinn@sinaihealth.ca	Isenberg, Sarina/AAE-4407-2021; Kavalieratos, Dio/GLV-4567-2022; Kavalieratos, Dio/GLR-1388-2022	Kavalieratos, Dio/0000-0001-5283-0792; Quinn, Kieran/0000-0002-1681-5170	Institute for Clinical Evaluative Sciences (ICES); Sinai Health System Research Foundation; CIHR Vanier Scholarship Program; Eliot Phillipson Clinician-Scientist Training Program; Clinician Investigator Program at the University of Toronto; National Institutes of Health [K01HL133466]; Cystic Fibrosis Foundation; Milbank Foundation; Ontario Ministry of Health and Long term Care (MOHLTC)	Institute for Clinical Evaluative Sciences (ICES)(University of Toronto); Sinai Health System Research Foundation; CIHR Vanier Scholarship Program(Canadian Institutes of Health Research (CIHR)); Eliot Phillipson Clinician-Scientist Training Program; Clinician Investigator Program at the University of Toronto; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cystic Fibrosis Foundation(Italian Cystic Fibrosis Research Foundation); Milbank Foundation; Ontario Ministry of Health and Long term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario)	This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long term Care (MOHLTC). The analysis was supported by a research grant KLQ and CMB received from the Sinai Health System Research Foundation to perform this work. The opinions, results and conclusions reported in this paper are those of the authors and are independent from the funding sources. No endorsement by ICES or the Ontario MOHLTC is intended or should be inferred. Parts of this material are based on data and information compiled and provided by the Canadian Institute for Health Information (CIHI). However, the analyses, conclusions, opinions and statements expressed herein are those of the author, and not necessarily those of CIHI. We thank IMS Brogan for use of their Drug Information Database. KLQ and NMS receive funding from the CIHR Vanier Scholarship Program, the Eliot Phillipson Clinician-Scientist Training Program, and the Clinician Investigator Program at the University of Toronto. DK receives research funding from the National Institutes of Health (K01HL133466), the Cystic Fibrosis Foundation, and the Milbank Foundation.	Agar M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181020; Ahronheim J C, 2000, J Palliat Med, V3, P265, DOI 10.1089/jpm.2000.3.265; Aiken LS, 2006, J PALLIAT MED, V9, P111, DOI 10.1089/jpm.2006.9.111; Alla F, 2002, EUR J HEART FAIL, V4, P337, DOI 10.1016/S1388-9842(02)00006-5; Austin PC, 2010, J CLIN EPIDEMIOL, V63, P2, DOI 10.1016/j.jclinepi.2008.11.004; Austin PC, 2008, PHARMACOEPIDEM DR S, V17, P1218, DOI 10.1002/pds.1674; Bahadori Katayoon, 2007, Int J Chron Obstruct Pulmon Dis, V2, P241; Barbera Lisa, 2015, CMAJ Open, V3, pE292, DOI 10.9778/cmajo.20150005; Bekelman DB, 2018, JAMA INTERN MED, V178, P511, DOI 10.1001/jamainternmed.2017.8667; Brannstrom M, 2014, EUR J HEART FAIL, V16, P1142, DOI 10.1002/ejhf.151; Braun LT, 2016, CIRCULATION, V134, pE198, DOI 10.1161/CIR.0000000000000438; Brown CRL, 2018, PALLIATIVE MED, V32, P1334, DOI 10.1177/0269216318780223; Brumley R, 2007, J AM GERIATR SOC, V55, P993, DOI 10.1111/j.1532-5415.2007.01234.x; Courtright KR, 2018, ANN INTERN MED, V168, P71, DOI 10.7326/M17-2164; De Roo ML, 2013, J PAIN SYMPTOM MANAG, V46, P556, DOI 10.1016/j.jpainsymman.2012.09.013; De Schreye R, 2017, PALLIATIVE MED, V31, P932, DOI 10.1177/0269216317705099; Gaertner J, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j2925; Gershon AS, 2018, AM J RESP CRIT CARE, V198, P1389, DOI 10.1164/rccm.201803-0592OC; Gilbert T, 2018, LANCET, V391, P1775, DOI 10.1016/S0140-6736(18)30668-8; Gill TM, 2010, NEW ENGL J MED, V362, P1173, DOI 10.1056/NEJMoa0909087; Gomes B, 2013, BMC PALLIAT CARE, V12, DOI 10.1186/1472-684X-12-7; Gozalo P, 2011, NEW ENGL J MED, V365, P1212, DOI 10.1056/NEJMsa1100347; Harrison MB, 2002, MED CARE, V40, P271, DOI 10.1097/00005650-200204000-00003; Health Quality Ontario, 2016, PALL CAR END LIF; Howlett JG, 2016, CAN J CARDIOL, V32, P296, DOI 10.1016/j.cjca.2015.06.019; Hua M, 2017, J PALLIAT MED, V20, P372, DOI 10.1089/jpm.2016.0363; Kavalieratos D, 2017, J AM COLL CARDIOL, V70, P1919, DOI 10.1016/j.jacc.2017.08.036; Kavalieratos D, 2016, JAMA-J AM MED ASSOC, V316, P2104, DOI 10.1001/jama.2016.16840; Kelley AS, 2015, ANN INTERN MED, V163, P729, DOI 10.7326/M15-0381; Lang JJ, 2018, CAN MED ASSOC J, V190, pE1296, DOI 10.1503/cmaj.180698; Lunney JR, 2003, JAMA-J AM MED ASSOC, V289, P2387, DOI 10.1001/jama.289.18.2387; Maetens A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025180; McAlister F, 2019, BMJ QUAL SAF, V28, P284, DOI 10.1136/bmjqs-2018-008661; McDermott C, 2012, BRIT J GEN PRACT, V62, DOI 10.3399/bjgp12X653589; Mitchell SL, 2009, NEW ENGL J MED, V361, P1529, DOI 10.1056/NEJMoa0902234; Mizuno A, 2017, J CARDIOL, V70, P335, DOI 10.1016/j.jjcc.2017.02.010; Muggah E, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-452; Murray SA, 2005, BMJ-BRIT MED J, V330, P1007, DOI 10.1136/bmj.330.7498.1007; Nieminen MS, 2015, INT J CARDIOL, V191, P256, DOI 10.1016/j.ijcard.2015.04.235; Possin KL, 2019, JAMA INTERN MED, V179, P1658, DOI 10.1001/jamainternmed.2019.4101; Quinn KL, 2019, J GEN INTERN MED, V34, P2763, DOI 10.1007/s11606-019-05333-8; Qureshi D, 2018, J PALLIAT MED, V21, P1588, DOI 10.1089/jpm.2018.0049; Qureshi D, 2019, PALLIATIVE MED, V33, P150, DOI 10.1177/0269216318815794; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Radwany SM, 2014, POPUL HEALTH MANAG, V17, P106, DOI 10.1089/pop.2013.0017; Ray WA, 2003, AM J EPIDEMIOL, V158, P915, DOI 10.1093/aje/kwg231; Rogers JG, 2017, J AM COLL CARDIOL, V70, P332, DOI 10.1016/j.jacc.2017.05.030; Seow H, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021147; Seow H, 2016, J PALLIAT MED, V19, P16, DOI 10.1089/jpm.2015.0063; Seow H, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g3496; Sidebottom AC, 2015, J PALLIAT MED, V18, P134, DOI 10.1089/jpm.2014.0192; Singer AE, 2016, J PALLIAT MED, V19, P995, DOI 10.1089/jpm.2015.0367; Stall NM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.9557; Tanuseputro P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191322; Tanuseputro P, 2017, PALLIATIVE MED, V31, P247, DOI 10.1177/0269216316653524; Tanuseputro P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121759; Teno JM, 2018, JAMA-J AM MED ASSOC, V320, P264, DOI 10.1001/jama.2018.8981; Wong FKY, 2016, HEART, V102, P1100, DOI 10.1136/heartjnl-2015-308638; Yosick L, 2019, J PALLIAT MED, V22, P1075, DOI 10.1089/jpm.2018.0489; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	60	35	34	4	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 6	2020	370								m2257	10.1136/bmj.m2257	http://dx.doi.org/10.1136/bmj.m2257			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MJ5XW	32631907	Green Published, hybrid			2023-01-03	WOS:000548163900006
J	Teshale, AB; Tesema, GA				Teshale, Achamyeleh Birhanu; Tesema, Getayeneh Antehunegn			Prevalence and associated factors of delayed first antenatal care booking among reproductive age women in Ethiopia; a multilevel analysis of EDHS 2016 data	PLOS ONE			English	Article							LOGISTIC-REGRESSION	Background Early or timely initiation of antenatal care and regular visits based on the schedule have a tremendous effect on both maternal and fetal health. Despite the paramount benefits of early initiation of ANC within the first 12 weeks of pregnancy, women still do not have adequate and equal access to high-quality early antenatal care. Objective To determine the prevalence and factors associated with delayed first ANC booking in Ethiopia. Method A secondary data analysis was conducted using the 2016 Ethiopian demographic and health survey data. All reproductive age women who gave birth in the five years preceding the survey and who had ANC visit for their last child were included in this study. The total weighted sample size analyzed was 4,741. Due to the hierarchical nature of the EDHS data, Multi-level logistic regression model was used to identify the individual and community level factors associated with delayed first ANC booking. Result In this study, the prevalence of delayed first ANC booking was 67.31% [95% CI: 65.96% to 68.63%]. Women with secondary and higher education [Adjusted Odd Ratio (AOR) = 0.78; 95%CI: 0.61, 0.99] and [AOR = 0.61; 95%CI: 0.44, 0.83] respectively had lower odds of delayed first ANC booking. But woman who were multiparous and grand multiparous [AOR = 1.21; 95%CI: 1.01, 1.45] and [AOR = 1.50; 95%CI: 1.16, 1.93] respectively, women with the last pregnancy wanted no more [AOR = 1.52; 95%CI: 1.10, 2.09], a woman who was living in the rural area [AOR = 1.66; 95%CI: 1.25, 2.21], and a woman who was living in large central regions and small peripheral regions [AOR = 2.76; 95%CI: 2.20, 3.47] and [AOR = 2.70; 95%CI: 2.12, 3.45] respectively had higher odds of delayed first ANC booking. Conclusion Despite the documented benefits of early antenatal care initiation, late ANC booking is still predominant in Ethiopia as highlighted by this study. Maternal education, parity, wanted the last child, residence and region were significantly associated with delayed first ANC booking. Therefore, taking special attention for these high-risk groups could decrease delayed first ANC booking and this intern decreases maternal and fetal health problems by identifying and intervene early.	[Teshale, Achamyeleh Birhanu; Tesema, Getayeneh Antehunegn] Univ Gondar, Dept Epidemiol & Biostat, Inst Publ Hlth, Coll Med & Hlth Sci, Gondar, Ethiopia	University of Gondar	Teshale, AB (corresponding author), Univ Gondar, Dept Epidemiol & Biostat, Inst Publ Hlth, Coll Med & Hlth Sci, Gondar, Ethiopia.	achambir08@gmail.com	Teshale, Achamyeleh/HHN-8416-2022	Teshale, Achamyeleh/0000-0002-7572-9993				Abosse Z, 2010, ETHIOP J HEALTH SCI, V20, P75; Abrha S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3315-3; Aduloju OP, 2016, GESTATIONAL AGE INIT, P19; Alaa Ahmed M, 2019, PLoS One, V14, pe0213653, DOI 10.1371/journal.pone.0213653; Aliyu A, 2017, PREDICTORS DELAYED A, DOI [10.11604/pamj.2017.26.124.9861, DOI 10.11604/PAMJ.2017.26.124.9861]; [Anonymous], 2015, NAT METHODS, V12, P1; [Anonymous], 2012, AM J TRANSPLANT, V12, P1, DOI 10.1111/j.1600-6143.2011.03886.x; [Anonymous], 2007, STAND MAT NEON CAR; [Anonymous], 2013, J THORAC DIS S2, V5, pS168; [Anonymous], 2014, ATMOS CHEM PHYS DISC, V14, pC9360; [Anonymous], 2018, IEEE T SYSTEMS MAN C, P1, DOI DOI 10.2861/86313; [Anonymous], 2010, DRUG DISCOV TODAY-TE, V7, pe1; Aung TZ., 2017, INT J COMMUNITY MED, V3, P900; Austin PC, 2017, STAT MED, V36, P3257, DOI 10.1002/sim.7336; Bloom SS, 1999, HEALTH POLICY PLANN, V14, P38, DOI 10.1093/heapol/14.1.38; Central statistical agency (CSA) [Ethiopia] and ICF, 2016, ETH DEM HLTH SURV 20; Central Statistical Authority, 2012, 2007 POP HOUS CENS E; Chewe M. M., 2016, African Journal of Midwifery and Women's Health, V10, P169; Doku D, 2012, BMC INT HEALTH HUM R, V12, DOI 10.1186/1472-698X-12-29; Dowswell T, 2014, EUR PMC FUNDERS GR, V10, P15; Ejeta E, 2017, PANAFRICAN MED J, V8688, P1; Federal Democratic Republic of Ethiopia Ministry of Health, 2014, HLTH SECT DEV PROGR; Gravett CA, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001324; Gross K, 2012, BMC PREGNANCY CHILDB, V12, DOI 10.1186/1471-2393-12-16; Hanna G, TIMING 1 ANTENATAL C; Isawumi A, 2018, LATE ANTENATAL CARE; Mathai M, 2017, INTEGRATED MANAGEMEN; Medical Advisory Secretariat, 2008, Ont Health Technol Assess Ser, V8, P1; Merlo J, 2006, J EPIDEMIOL COMMUN H, V60, P290, DOI 10.1136/jech.2004.029454; Nieburg, 2012, GLOB HLTH POLICY OCT, P1; Njiku F, 2017, TANZAN J HLTH RES, V19, P1; Okedo-alex IN, 2019, DETERMINANTS ANTENAT, P1; Satti H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042700; Sinyange Nyambe, 2016, FACTORS ASS LATE ANT, V8688, P1; Sommet N, 2017, INT REV SOC PSYCHOL, V30, P203, DOI 10.5334/irsp.90; Tekelab T., 2014, SCI TECHNOL ARTS RES, V3, P108, DOI [10.4314/star.v3i1.17, DOI 10.4314/STAR.V3I1.17]; Tekelab T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0222566; Tolefac Paul Nkemtendong, 2017, Matern Health Neonatol Perinatol, V3, P29, DOI 10.1186/s40748-017-0067-8; Trinh LTT, 2006, REPRO HLTH, V3, P1; Tuniz C, 2014, SCIENCE OF HUMAN ORIGINS, P1; UNICEF, 2019, ANT CAR; Weinmayr G, 2017, INT J EPIDEMIOL, V46, P336, DOI 10.1093/ije/dyw274; WHO, 2022, WHO RECOMMENDATIONS; WHO, 1994, MOTH BAB PACK IMPL S, P114; WHO, 2019, WHO MOR WOM WORLDW R; Wolde HF, 2019, LATE INITIATION ANTE, P1; World Health Organization, 2018, MALN KEY FACTS, P1; World Health Organization, 2002, ANT CAR RAND TRIAL M; World Health Organization, 2015, STRAT END PREV MAT M, V6736, P1; Yaya S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187303; Zegeye AM, 2019, WOMENS HLTH ACTION R	51	16	16	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2020	15	7							e0235538	10.1371/journal.pone.0235538	http://dx.doi.org/10.1371/journal.pone.0235538			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM3OG	32628700	gold, Green Published			2023-01-03	WOS:000550068700020
J	Chan, EYY; Gobat, N; Kim, JH; Newnham, EA; Huang, Z; Hung, HD; Dubois, C; Hung, KKC; Wong, ELY; Wong, SYS				Chan, Emily Ying Yang; Gobat, Nina; Kim, Jean H.; Newnham, Elizabeth A.; Huang, Zhe; Hung, Heidi; Dubois, Caroline; Hung, Kevin Kei Ching; Wong, Eliza Lai Yi; Wong, Samuel Yeung Shan			Informal home care providers: the forgotten health-care workers during the COVID-19 pandemic	LANCET			English	Editorial Material									[Chan, Emily Ying Yang; Huang, Zhe; Hung, Heidi; Hung, Kevin Kei Ching] Chinese Univ Hong Kong, Collaborating Ctr Oxford Univ, Hong Kong, Peoples R China; [Chan, Emily Ying Yang; Huang, Zhe; Hung, Heidi; Hung, Kevin Kei Ching] Chinese Univ Hong Kong, CUHK Disaster & Med Humanitarian Response CCOUC, Hong Kong, Peoples R China; [Chan, Emily Ying Yang; Gobat, Nina] Univ Oxford, Nuffield Dept Med, Oxford OX3 7BN, England; [Chan, Emily Ying Yang; Kim, Jean H.; Huang, Zhe; Hung, Heidi; Wong, Eliza Lai Yi; Wong, Samuel Yeung Shan] Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China; [Chan, Emily Ying Yang; Dubois, Caroline] Chinese Univ Hong Kong, GX Fdn Phnom Penh Cambodia & Vientiane Laos, Hong Kong, Peoples R China; [Chan, Emily Ying Yang; Hung, Kevin Kei Ching] Chinese Univ Hong Kong, Accid & Emergency Med Acad Unit, Hong Kong, Peoples R China; [Newnham, Elizabeth A.] Curtin Univ, Sch Psychol, Perth, WA, Australia; [Chan, Emily Ying Yang; Newnham, Elizabeth A.] Harvard TH Chan Sch Publ Hlth, FXB Ctr Hlth & Human Rights, Boston, MA USA	Chinese University of Hong Kong; Chinese University of Hong Kong; University of Oxford; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Curtin University; Harvard University; Harvard T.H. Chan School of Public Health	Chan, EYY (corresponding author), Chinese Univ Hong Kong, Collaborating Ctr Oxford Univ, Hong Kong, Peoples R China.; Chan, EYY (corresponding author), Chinese Univ Hong Kong, CUHK Disaster & Med Humanitarian Response CCOUC, Hong Kong, Peoples R China.; Chan, EYY (corresponding author), Univ Oxford, Nuffield Dept Med, Oxford OX3 7BN, England.; Chan, EYY (corresponding author), Chinese Univ Hong Kong, JC Sch Publ Hlth & Primary Care, Hong Kong, Peoples R China.; Chan, EYY (corresponding author), Chinese Univ Hong Kong, GX Fdn Phnom Penh Cambodia & Vientiane Laos, Hong Kong, Peoples R China.; Chan, EYY (corresponding author), Chinese Univ Hong Kong, Accid & Emergency Med Acad Unit, Hong Kong, Peoples R China.; Chan, EYY (corresponding author), Harvard TH Chan Sch Publ Hlth, FXB Ctr Hlth & Human Rights, Boston, MA USA.	emily.chan@cuhk.edu.hk	Wong, Eliza Lai-Yi/ABI-2092-2020; Hung, Kevin KC/H-8327-2016; Gobat, Nina/AAW-8402-2021	Hung, Kevin KC/0000-0001-8706-7758; Dubois, Caroline/0000-0002-8810-4159; Wong, Eliza/0000-0001-9983-6219; Gobat, Nina/0000-0002-1558-557X				Chan EYY, 2020, GRAD GLOB HLTH SEC O; [中国老年医学学会精神医学与心理健康分会 Chinese Society of Geriatric Psychiatry], 2020, [中华精神科杂志, Chinese Journal of Psychiatry], V53, P89; Lloyd-Sherlock P, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1052; MacGregor H, 2020, SCOPING DOCUMENT CON; Mahase E, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1001; Thomas BE, 2020, COVID 19 FRAMEWORK I; Usher K, 2020, INT J MENT HEALTH NU, V29, P549, DOI 10.1111/inm.12735; Wang HL, 2020, LANCET, V395, P1190, DOI 10.1016/S0140-6736(20)30755-8; Wenham C, 2020, LANCET, V395, P846, DOI 10.1016/S0140-6736(20)30526-2; WHO, 2019, HLTH EM DIS RISK MAN; World Health Organization, 2020, COVID 19 MAKING CASE	11	44	46	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 27	2020	395	10242					1957	1959		10.1016/S0140-6736(20)31254-X	http://dx.doi.org/10.1016/S0140-6736(20)31254-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MJ0ZZ	32497509	Green Published, Bronze			2023-01-03	WOS:000547825600008
J	Tolu, LB; Jeldu, WG; Feyissa, GT				Tolu, Lemi Belay; Jeldu, Wondimu Gudu; Feyissa, Garumma Tolu			Effectiveness of utilizing the WHO safe childbirth checklist on improving essential childbirth practices and maternal and perinatal outcome: A systematic review and meta-analysis	PLOS ONE			English	Review							PROGRAM	Introduction The World Health Organization (WHO) Safe Childbirth Checklist (SCC) is a 29-item checklist based on essential childbirth practices to help health-care workers to deliver consistently high quality maternal and perinatal care. The Checklist was intended to reduce maternal and perinatal mortality and address the primary cause of maternal death, intrapartum stillbirth, and early neonatal death. The objective of this review was to locate international literature reporting on the effectiveness of utilizing the WHO safe childbirth checklist on improving essential childbirth practices, early neonatal death, stillbirth, maternal mortality, and morbidity. Methods We searched MEDLINE, google scholar, Cochrane Central Register of Controlled Trials (CENTRAL), met-Register of Controlled Trials (m-RCT) (), ClinicalTrials.gov () and the WHO International Clinical Trials Registry Platform (ICTRP) () to retrieve all available comparative studiespublished in English after 2008. Two reviewers did study selection, critical appraisal, and data extraction independently. We did a random or fixed-effect meta-analysis to pool studies together and effect estimates were expressed as an odds ratio. Quality of evidence for major outcomes was assessed using the Grading of Recommendations, Assessment, development, and evaluation(GRADE). Results We retained three cluster randomized trials and six pre-and-post intervention studies reporting on WHO SCC's. The WHO SCC utilization improved quality of preeclampsia management(moderate quality of evidence) (OR = 7.05 [95% CI 2.34-21.29]), maternal infection management(moderate quality of evidence) (OR = 7.29[95%CI 2.29-23.27]), Partograph utilization(moderate quality of evidence) (OR = 3.81 [95% 1.72-8.43]), postpartum counselling(low quality of evidence) (RR = 132.51[95% 49.27-356.36]) and still birth(moderate quality of evidence) (OR = 0.92[95% CI 0.87-0.96]). However, the utilization of the checklist had no impact on early neonatal death (very low quality of evidence) (OR = 1.07[95%CI [1.01-1.13]) and maternal death (low quality of evidence) (OR = 1.06[95% CI 0.77-1.45]). Conclusions Moderate quality of evidence indicates that WHO SCC utilization is effective in reducing stillbirth and Improving preeclampsia management, maternal infection management and partograph utilization Low quality of evidence indicates that WHO SCC is effective in enhancing postpartum danger sign counseling. Low and very low quality of evidence suggests that WHO SCC has no impact on maternal and early neonatal death, respectively.	[Tolu, Lemi Belay; Jeldu, Wondimu Gudu] St Pauls Hosp, Millennium Med Coll, Dept Obstet & Gynaecol, Addis Ababa, Ethiopia; [Feyissa, Garumma Tolu] Jimma Univ, Dept Hlth Behav & Soc, Jimma, Ethiopia	Jimma University	Tolu, LB (corresponding author), St Pauls Hosp, Millennium Med Coll, Dept Obstet & Gynaecol, Addis Ababa, Ethiopia.	lemi.belay@gmail.com	Feyissa, Garumma/AAP-9097-2020	Feyissa, Garumma/0000-0001-6179-0024; Tolu, Lemi Belay/0000-0001-6703-828X; Gudu, Wondimu/0000-0003-3850-6712				Albolino S, 2018, ERGONOMICS, V61, P185, DOI 10.1080/00140139.2017.1377772; [Anonymous], WHO SAF CHILDB CHECK; [Anonymous], 2017, ONCOGENESIS, V6, pe345; [Anonymous], 2009, KIDNEY INT, V6, pS1; Delaney MM, 2017, GLOB HEALTH-SCI PRAC, V5, P217, DOI 10.9745/GHSP-D-16-00410; Grade G, 2015, GRADEPRO GUID DEV TO, P435; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Kara N, 2017, GLOB HEALTH-SCI PRAC, V5, P232, DOI 10.9745/GHSP-D-16-00411; Kumar S, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-1139-x; Nababan HY, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1588-x; Patabendige M, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0436-0; Semrau KEA, 2017, NEW ENGL J MED, V377, P2313, DOI 10.1056/NEJMoa1701075; Senanayake H M, 2018, BMC Res Notes, V11, P896, DOI 10.1186/s13104-018-4009-y; Senanayake HM, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2040-6; Simon JL, 2018, BMJ-BRIT MED J; Spector JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035151; Tufanaru C, 2015, INT J EVID-BASED HEA, V13, P196, DOI 10.1097/XEB.0000000000000065; Tuyishime Eugene, 2018, Matern Health Neonatol Perinatol, V4, P7, DOI 10.1186/s40748-018-0075-3; Varaganti N, 2018, INT J REPROD CONTRAC; Varghese Beena, 2019, Matern Health Neonatol Perinatol, V5, P3, DOI 10.1186/s40748-019-0098-4	20	6	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2020	15	6							e0234320	10.1371/journal.pone.0234320	http://dx.doi.org/10.1371/journal.pone.0234320			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6QP	32530940	Green Published, gold			2023-01-03	WOS:000542037200029
J	Bin Abdullah, MFIL; Tan, KL; Isa, SM; Yusoff, NS; Chear, NJY; Singh, D				Bin Abdullah, Mohammad Farris Iman Leong; Kok Leng Tan; Isa, Salbiah Mohd; Yusoff, Nur Sabrina; Chear, Nelson Jeng Yeou; Singh, Darshan			Lipid profile of regular kratom (Mitragyna speciosaKorth.) users in the community setting	PLOS ONE			English	Article							TISSUE CHOLESTEROL; PARAMETERS; PLASMA; ABUSE	Background and aim Kratom, orMitragyna speciosaKorth., is a tropical plant that has been reported to exhibit opioid-like effects. Although opioids have been demonstrated to alter the lipid profile of regular users, data on the lipid-altering effects of kratom are scarce. This study aimed to compare the fasting lipid profile of regular kratom users to that of healthy subjects who do not use kratom. It also determined the association between various characteristics of kratom users and the serum triglycerides, total cholesterol, low-density lipoprotein (LDL), and high-density lipoprotein (HDL) levels of regular kratom users. Methods A total of 200 participants (n = 100 kratom users and n = 100 healthy subjects who do not use kratom) were recruited for this analytical cross-sectional study. Data on sociodemographic status, kratom use characteristics, cigarette smoking, physical activity, body mass index (BMI), fasting serum lipid profile, and liver function were collected from all participants. Results The liver parameters of the study participants were within normal range. The serum total cholesterol and LDL of kratom users were significantly lower than those of healthy subjects who do not use kratom. There were no significant differences in the serum triglyceride and HDL levels. However, higher average daily frequency of kratom use and increasing age were associated with increased serum total cholesterol among kratom users. Other kratom use characteristics such as age of first kratom intake, duration of kratom use, and quantity of daily kratom intake were not associated with increased serum triglyceride, total cholesterol, LDL, and HDL levels. Conclusions Our findings suggest regular kratom consumption was not linked to elevated serum lipids, except when there is a higher frequency of daily kratom intake. However, the study was limited by the small sample size, and hence a more comprehensive study with larger sample size is warranted to confirm the findings.	[Bin Abdullah, Mohammad Farris Iman Leong; Isa, Salbiah Mohd] Univ Sains Malaysia, Adv Med & Dent Inst, Lifestyle Sci Cluster, Kepala Batas, Pulau Pinang, Malaysia; [Kok Leng Tan] Univ Sains Malaysia, Adv Med & Dent Inst, Regenerat Med Cluster, Kepala Batas, Pulau Pinang, Malaysia; [Yusoff, Nur Sabrina; Chear, Nelson Jeng Yeou; Singh, Darshan] Univ Sains Malaysia, Ctr Drug Res, Minden, Pulau Pinang, Malaysia	Universiti Sains Malaysia; Universiti Sains Malaysia; Universiti Sains Malaysia	Bin Abdullah, MFIL (corresponding author), Univ Sains Malaysia, Adv Med & Dent Inst, Lifestyle Sci Cluster, Kepala Batas, Pulau Pinang, Malaysia.	farris@usm.my	Singh, Darshan/ABB-9359-2020; Leong Abdullah, Mohammad Farris Iman/I-9583-2017; Chear, Nelson/AAA-8621-2022; Chear, Nelson Jeng-Yeou/P-8222-2018; KokLeng, Tan/E-4949-2016	Leong Abdullah, Mohammad Farris Iman/0000-0002-7762-4052; Chear, Nelson/0000-0001-5050-8230; Chear, Nelson Jeng-Yeou/0000-0001-5050-8230; KokLeng, Tan/0000-0001-8798-4855	Fundamental Research Grant Scheme of the Ministry of Education Malaysia [203. CIPPT.6711626]	Fundamental Research Grant Scheme of the Ministry of Education Malaysia	Grant receiver: Mohammad Farris Iman Leong Bin Abdullah Grant number: 203. CIPPT.6711626 Full name of the funder: Fundamental Research Grant Scheme of the Ministry of Education Malaysia URL of the funder website: http://jpt.moe.gov.my Role of funder: The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aghadavoudi Omid, 2015, Adv Biomed Res, V4, P12, DOI 10.4103/2277-9175.148294; Agongo G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213233; ALBERS JJ, 1978, LIPIDS, V13, P926, DOI 10.1007/BF02533852; Aljandali A., 2017, MULTIVARIATE METHODS; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; Anwar M, 2016, MMWR-MORBID MORTAL W, V65, P748, DOI 10.15585/mmwr.mm6529a4; BRYANT HU, 1988, BIOCHEM PHARMACOL, V37, P3777, DOI 10.1016/0006-2952(88)90415-7; BRYANT HU, 1987, LIFE SCI, V41, P545, DOI 10.1016/0024-3205(87)90406-1; Bush MA, REPEATED DOSES KEY P; Coe MA, 2019, DRUG ALCOHOL DEPEN, V202, P24, DOI 10.1016/j.drugalcdep.2019.05.005; Corkery JM, 2019, J PSYCHOPHARMACOL, V33, P1102, DOI 10.1177/0269881119862530; Dorman C, 2015, HEPATOLOGY, V61, P1086, DOI 10.1002/hep.27612; Fernandes CT, 2019, J INVEST MED HIGH IM, V7, DOI 10.1177/2324709619836138; Garcia-Romeu A, 2020, DRUG ALCOHOL DEPEN, V208, DOI 10.1016/j.drugalcdep.2020.107849; Grundmann O, 2017, DRUG ALCOHOL DEPEN, V176, P63, DOI 10.1016/j.drugalcdep.2017.03.007; Hassan Z, 2013, NEUROSCI BIOBEHAV R, V37, P138, DOI 10.1016/j.neubiorev.2012.11.012; Johnson R, 1997, CLIN CHEM, V43, P2183; Kapp FG, 2011, J MED TOXICOL, V7, P227, DOI 10.1007/s13181-011-0155-5; Kouros D, 2010, AM J DRUG ALCOHOL AB, V36, P135, DOI 10.3109/00952991003734277; Kronstrand R, 2011, J ANAL TOXICOL, V35, P242, DOI 10.1093/anatox/35.4.242; Kruegel AC, 2016, J AM CHEM SOC, V138, P6754, DOI 10.1021/jacs.6b00360; Langsted A, 2019, PATHOLOGY, V51, P131, DOI 10.1016/j.pathol.2018.09.062; Lecubrier Y., 1998, J CLIN PSYCHIAT S20, V59, P22; Mitchell BD, 2019, J CLIN LIPIDOL, V13, P109, DOI 10.1016/j.jacl.2018.11.006; Najafipour H, 2016, FRONT PHYSIOL, V7, DOI 10.3389/fphys.2016.00436; Ni WQ, 2015, LIPIDS HEALTH DIS, V14, DOI 10.1186/s12944-015-0073-7; Osborne CS, 2019, J INVEST MED HIGH IM, V7, DOI 10.1177/2324709619826167; Post S, 2019, CLIN TOXICOL, V57, P847, DOI 10.1080/15563650.2019.1569236; Prozialeck WC, 2019, INT J DRUG POLICY, V70, P70, DOI 10.1016/j.drugpo.2019.05.003; Qasini A, 2013, ESCULAPIO, V9, P163; Rahimi Najmeh, 2014, Addict Health, V6, P1; Singh D, 2018, J ETHNOPHARMACOL, V214, P197, DOI 10.1016/j.jep.2017.12.017; Singh D, 2016, BRAIN RES BULL, V126, P41, DOI 10.1016/j.brainresbull.2016.05.004; SUWANLERT S, 1975, B NARCOTICS, V27, P21; Szapary Philippe O, 2003, Curr Cardiol Rep, V5, P488, DOI 10.1007/s11886-003-0112-2; Tabachnick B. G., 2012, SINGULAR SPECTRUM AN, V6h, DOI DOI 10.1007/978-1-4757-2514-8_3; Tayabali K, 2018, J COMMUNITY HOSP INT, V8, P107, DOI 10.1080/20009666.2018.1468693; Tietz N.W., 1990, CLIN GUIDE LAB TESTS, V2nd; U. S. Food and Drug Administration, 2019, FDA ISS WARN CO SELL; US Department of Health and Human Services, 2018, PHYS ACT GUID AM; Vicknasingam B, 2010, INT J DRUG POLICY, V21, P283, DOI 10.1016/j.drugpo.2009.12.003; World Health Organization, 2018, PHYS ACTIVITY; Ya K, 2019, ASIAN J PSYCHIATR, V43, P73, DOI 10.1016/j.ajp.2019.05.016; 2010, ZHONGGUO YIXUE QIANY, V4, P50	44	9	9	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2020	15	6							e0234639	10.1371/journal.pone.0234639	http://dx.doi.org/10.1371/journal.pone.0234639			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6QL	32525924	Green Published, gold			2023-01-03	WOS:000542036800015
J	Lenti, MV; Klersy, C; Brera, AS; Musella, V; Benedetti, I; Padovini, L; Ciola, M; Croce, G; Ballesio, A; Gorgone, MF; Bertolino, G; Di Sabatino, A; Corazza, GR				Lenti, Marco Vincenzo; Klersy, Catherine; Brera, Alice Silvia; Musella, Valeria; Benedetti, Irene; Padovini, Lucia; Ciola, Mariella; Croce, Gabriele; Ballesio, Alessia; Gorgone, Maria Fortunata; Bertolino, Giampiera; Di Sabatino, Antonio; Corazza, Gino Roberto			Clinical complexity and hospital admissions in the December holiday period	PLOS ONE			English	Article							PATIENT COMPLEXITY; VECTOR MODEL; MORTALITY; CARE; DEPRIVATION; CHRISTMAS; SCIENCE; TIME	Background Christmas and New Year's holidays are risk factors for hospitalization, but the causes of this "holiday effect" are uncertain. In particular, clinical complexity (CC) has never been assessed in this setting. We therefore sought to determine whether patients admitted to the hospital during the December holiday period had greater CC compared to those admitted during a contiguous non-holiday period. Methods This is a prospective, longitudinal study conducted in an academic ward of internal medicine in 2017-2019. Overall, 227 consecutive adult patients were enrolled, including 106 cases (mean age 79.4 +/- 12.8 years, 55 females; 15 December-15 January) and 121 controls (mean age 74.3 +/- 16.6 years, 56 females; 16 January-16 February). Demographic characteristics, CC, length of stay, and early mortality rate were assessed. Logistic regression analyses for the evaluation of independent correlates of being a holiday case were computed. Results Cases displayed greater CC (17.7 +/- 5.5 vs 15.2 +/- 5.9; p = 0.001), with greater impact of socioeconomic (3.51 +/- 1.7 vs 2.9 +/- 1.7; p = 0.012) and behavioral (2.36 +/- 1.6 vs 1.9 +/- 1.8; p = 0.01) CC components. Cases were also significantly frailer according to the Edmonton Frail Scale (8.0 +/- 2.8 vs 6.4 +/- 3.1; p<0.001), whilst having similar disease burden, as measured by the CIRS comorbidity index. Age (OR 1.02; p = 0.039), low income (OR 1.97, 95% CI 1.10-3.55; p = 0.023), and total CC (OR 1.06; p = 0.014) independently correlated with the cases. Also, cases showed a longer length of stay (median 15.5vs11 days; p = 0.0016) and higher in-hospital (12 vs 4 events; p = 0.021) and 30-day (14 vs 6 events; p = 0.035) mortality. Conclusions Patients hospitalized during the December holiday period had worse health outcomes, and this could be attributable to the grater CC, especially related to socioeconomic (social deprivation, low income) and behavioral factors (inappropriate diet). The evaluation of all CC components could potentially represent a useful tool for a more rational resource allocation over this time of the year.	[Lenti, Marco Vincenzo; Brera, Alice Silvia; Benedetti, Irene; Padovini, Lucia; Ciola, Mariella; Croce, Gabriele; Ballesio, Alessia; Bertolino, Giampiera; Di Sabatino, Antonio; Corazza, Gino Roberto] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Internal Med, Pavia, Italy; [Klersy, Catherine; Musella, Valeria] Univ Pavia, Fdn IRCCS Policlin San Matteo, Biometry & Clin Epidemiol, Pavia, Italy; [Gorgone, Maria Fortunata] Univ Pavia, Fdn IRCCS Policlin San Matteo, Direz Med Presidio, Pavia, Italy	IRCCS Fondazione San Matteo; University of Pavia; IRCCS Fondazione San Matteo; University of Pavia; IRCCS Fondazione San Matteo; University of Pavia	Corazza, GR (corresponding author), Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Internal Med, Pavia, Italy.	gr.corazza@smatteo.pv.it	Musella, Valeria/H-4458-2016; klersy, catherine/AAA-3003-2019; Lenti, Marco Vincenzo/F-9044-2018	Musella, Valeria/0000-0001-9517-2670; klersy, catherine/0000-0003-0314-8548; Lenti, Marco Vincenzo/0000-0002-6654-4911; Croce, Gabriele/0000-0002-3562-5321	San Matteo Hospital Foundation - Italian Ministry of Health	San Matteo Hospital Foundation - Italian Ministry of Health	This research is part of a project for the study of clinical complexity (SMAC study) funded by San Matteo Hospital Foundation - Italian Ministry of Health (Progetto di Ricerca Corrente 2017 - PI Prof. Gino Roberto Corazza). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Champagne CM, 2007, J AM DIET ASSOC, V107, P1886, DOI 10.1016/j.jada.2007.08.003; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Conway R, 2013, QJM-INT J MED, V106, P245, DOI 10.1093/qjmed/hcs233; Conway Richard, 2016, Acute Med, V15, P124; Corazza GR, 2019, EUR J INTERN MED, V61, P9, DOI 10.1016/j.ejim.2018.11.009; Corazza GR, 2017, INTERN EMERG MED, V12, P1313, DOI 10.1007/s11739-017-1709-6; Cournane S, 2015, EUR J INTERN MED, V26, P766, DOI 10.1016/j.ejim.2015.09.019; Dragano N, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-255; Dugravot A, 2020, LANCET PUBLIC HEALTH, V5, pE42, DOI 10.1016/S2468-2667(19)30226-9; EPSTEIN AM, 1990, NEW ENGL J MED, V322, P1122, DOI 10.1056/NEJM199004193221606; Grant RW, 2011, ANN INTERN MED, V155, P797, DOI 10.7326/0003-4819-155-12-201112200-00001; Hong CS, 2015, J GEN INTERN MED, V30, P1741, DOI 10.1007/s11606-015-3357-8; KATZMAN R, 1983, AM J PSYCHIAT, V140, P734; Knight J, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.116.005098; Lang IA, 2009, J AM GERIATR SOC, V57, P1776, DOI 10.1111/j.1532-5415.2009.02480.x; Lapointe-Shaw L, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4481; Lee TA, 2007, J GEN INTERN MED, V22, P403, DOI 10.1007/s11606-007-0277-2; Lenti MV, 2019, J GEN INTERN MED, V34, P2316, DOI 10.1007/s11606-019-05228-8; LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x; Luck J, 2007, J GEN INTERN MED, V22, P396, DOI 10.1007/s11606-007-0293-2; Magid DJ, 2005, JAMA-J AM MED ASSOC, V294, P803, DOI 10.1001/jama.294.7.803; MAHONEY F I, 1965, Md State Med J, V14, P61; Phillips D, 2010, SOC SCI MED, V71, P1463, DOI 10.1016/j.socscimed.2010.07.024; Phillips DP, 2004, CIRCULATION, V110, P3781, DOI 10.1161/01.CIR.0000151424.02045.F7; Pushparajah S, 2006, Chron Respir Dis, V3, P187, DOI 10.1177/1479972306070371; Rolfson DB, 2006, AGE AGEING, V35, P526, DOI 10.1093/ageing/afl041; Safford MM, 2007, J GEN INTERN MED, V22, P382, DOI 10.1007/s11606-007-0307-0; Stanaway JD, 2018, LANCET, V392, P1923, DOI [10.1016/S0140-6736(18)32225-6, 10.1016/s0140-6736(18)32225-6]; Trzeciak S, 2003, EMERG MED J, V20, P402, DOI 10.1136/emj.20.5.402; von Elm E, 2007, LANCET, V370, P1453, DOI 10.1016/S0140-6736(07)61602-X; Walker AS, 2017, LANCET, V390, P62, DOI [10.1016/S0140-6736(17)30782-1, 10.1016/s0140-6736(17)30782-1]	33	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2020	15	6							e0234112	10.1371/journal.pone.0234112	http://dx.doi.org/10.1371/journal.pone.0234112			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MA6QL	32525896	Green Published, gold			2023-01-03	WOS:000542036800029
J	Moreno, P; Ceron, A; Sosa, K; Morales, M; Grajeda, LM; Lopez, MR; McCraken, JP; Cordon-Rosales, C; Palmer, GH; Call, DR; Ramay, BM				Moreno, Purificacion; Ceron, Alejandro; Sosa, Karen; Morales, Marinees; Grajeda, Laura M.; Lopez, Maria Renee; McCraken, John P.; Cordon-Rosales, Celia; Palmer, Guy H.; Call, Douglas R.; Ramay, Brooke M.			Availability of over-the-counter antibiotics in Guatemalan corner stores	PLOS ONE			English	Article								Widespread availability of antibiotics without prescription potentially facilitates overuse and contributes to selection pressure for antimicrobial resistant bacteria. Prior to this study, anecdotal observations in Guatemala identified corner stores as primary antibiotic dispensaries, where people purchase antibiotics without prescriptions. We carried out a cross sectional study to document the number and types of antibiotics available in corner stores, in four study areas in Guatemala. A total of 443 corner stores were surveyed, of which 295 (67%) sold antibiotics. The most commonly available antibiotics were amoxicillin, found in 246/295 (83%) stores, and tetracycline, found in 195/295 (66%) stores. Over the counter sales result from laissez-faire enforcement of antibiotic dispensing regulations in Guatemala combined with patient demand. This study serves as a baseline to document changes in the availability of antibiotics in informal establishments in light of new pharmacy regulations for antibiotic dispensing, which were adopted after this study was completed.	[Moreno, Purificacion; Ceron, Alejandro; Grajeda, Laura M.; Lopez, Maria Renee; McCraken, John P.; Cordon-Rosales, Celia; Ramay, Brooke M.] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala; [Moreno, Purificacion; Sosa, Karen; Morales, Marinees; Ramay, Brooke M.] Univ Valle Guatemala, Dept Pharmaceut Chem, Guatemala City, Guatemala; [Ceron, Alejandro] Univ Denver, Dept Anthropol, Denver, CO USA; [Palmer, Guy H.; Call, Douglas R.; Ramay, Brooke M.] Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA	Universidad del Valle de Guatemala; Universidad del Valle de Guatemala; University of Denver; Washington State University	Ramay, BM (corresponding author), Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala.; Ramay, BM (corresponding author), Univ Valle Guatemala, Dept Pharmaceut Chem, Guatemala City, Guatemala.; Ramay, BM (corresponding author), Washington State Univ, Paul G Allen Sch Global Anim Hlth, Pullman, WA 99164 USA.	bramay@uvg.edu.gt		Ramay, Brooke/0000-0001-8527-4067; Cordon-Rosales, Celia/0000-0003-2381-4173; Grajeda, Laura/0000-0001-5386-4839	Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA	Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA	Funding for this project was provided in part by the Paul G. Allen School of Global Animal Health, Washington State University, Pullman, WA. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. There was no additional external funding received for this study.	[Anonymous], 2015, PLAN DES NIV MUN; Calva J, 1996, SOC SCI MED, V42, P1121, DOI 10.1016/0277-9536(95)00385-1; Gualano MR, 2015, PHARMACOEPIDEM DR S, V24, P2, DOI 10.1002/pds.3716; Instituto Nacional de Estadistica, 2018, NAT CENS DAT GUAT; Ministerio de Salud Publica y Asistencia Social de Guatemala, 2019, 1812019 MIN SAL PUBL; Morales M. R., 2018, THESIS; Morgan DJ, 2011, LANCET INFECT DIS, V11, P692, DOI 10.1016/S1473-3099(11)70054-8; ONeill J., 2016, TACKLING DRUG RESIST; Organizacion Mundial de la Salud, 2016, PLAN ACC MUND RES AN; Sleath B, 2009, PATIENT EDUC COUNS, V75, P279, DOI 10.1016/j.pec.2008.10.002; Sosa K., 2016, THESIS	11	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2020	15	9							e0239873	10.1371/journal.pone.0239873	http://dx.doi.org/10.1371/journal.pone.0239873			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY3AJ	32976542	Green Published, gold			2023-01-03	WOS:000576266600055
J	Caldeira, LD; Borba, HH; Tonin, FS; Wiens, A; Fernandez-Llimos, F; Pontarolo, R				Caldeira, Luciane de Fatima; Borba, Helena H.; Tonin, Fernanda S.; Wiens, Astrid; Fernandez-Llimos, Fernando; Pontarolo, Roberto			Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis	PLOS ONE			English	Review							CLOSTRIDIUM-DIFFICILE INFECTION; ACTIVE ULCERATIVE-COLITIS; EVIDENCE-BASED CONSENSUS; INTESTINAL MICROBIOTA; CLINICAL-RESPONSE; MANAGEMENT; EFFICACY; SAFETY; DIVERSITY; REMISSION	Objectives Current evidence on fecal microbiota transplantation for inflammatory bowel disease is inconclusive. We conducted a systematic review to gather evidence on the efficacy and safety of fecal microbiota transplantation for inflammatory bowel disease. Methods Systematic searches were conducted in PubMed, Scopus, and Web of Science. Clinical remission was considered as the primary endpoint. Pairwise meta-analyses were performed for the randomized controlled studies (Mantel Haenszel, random effects model). Proportion meta-analyses, accounting for weighted pooled rates reported in the interventional studies, were conducted using the mixed effects model. Subgroup analyses considering the type of stool, donor type, and disease subtype were also performed. Cumulative meta-analyses to assess further needs of evidence were conducted. Results Sixty studies were included, from which 36 could be synthesized in the quantitative analyses. Pairwise meta-analyses of six controlled trials showed significant differences in favor of fecal microbiota transplantation compared with placebo (clinical remission: RR 1.70 [95% CI 1.12, 2.56]; clinical response: RR 1.68 [95% CI 1.04, 2.72]). An overall clinical remission of 37%, overall clinical response of 54%, and a prevalence of 29% of adverse events were found for the interventional studies. Frozen fecal material and universal donors were related to better efficacy outcomes. In addition, Crohn's disease patients seemed to benefit more from the procedure. Conclusions The comparative analyses demonstrated that frozen fecal material from universal donors may be related to a higher rate of clinical remission, especially for Crohn's disease.	[Caldeira, Luciane de Fatima; Borba, Helena H.; Tonin, Fernanda S.; Wiens, Astrid; Pontarolo, Roberto] Univ Fed Parana, Pharmaceut Sci Postgrad Res Program, Curitiba, Parana, Brazil; [Fernandez-Llimos, Fernando] Univ Porto, Fac Pharm, Dept Drug Sci, Lab Pharmacol, Porto, Portugal	Universidade Federal do Parana; Universidade do Porto	Pontarolo, R (corresponding author), Univ Fed Parana, Pharmaceut Sci Postgrad Res Program, Curitiba, Parana, Brazil.	pontarolo@ufpr.br	Tonin, Fernanda S/O-2050-2017; Fernandez-Llimos, Fernando/B-8931-2008; Tonin, Fernanda S./AAE-3435-2022; Pontarolo, Roberto/G-6948-2014	Tonin, Fernanda S/0000-0003-4262-8608; Fernandez-Llimos, Fernando/0000-0002-8529-9595; Tonin, Fernanda S./0000-0003-4262-8608; Pontarolo, Roberto/0000-0002-7049-4363; Caldeira, Luciane de Fatima/0000-0002-9042-8689	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) [001]	Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This study was financed in part by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior - Brasil (CAPES) - Finance Code 001. No additional external funding was received for this study.	Adler E, 2019, DIGEST DIS SCI, V64, P2452, DOI 10.1007/s10620-019-05596-5; Anderson JL, 2012, ALIMENT PHARM THER, V36, P503, DOI 10.1111/j.1365-2036.2012.05220.x; [Anonymous], 2015, BMJ, V2015, ph1887; [Anonymous], 2017, MEDICINE, V96, pe6504; Cammarota G, 2019, GUT, V68, P2111, DOI 10.1136/gutjnl-2019-319548; Cammarota G, 2017, GUT, V66, P569, DOI 10.1136/gutjnl-2016-313017; Cold F, 2019, SCAND J GASTROENTERO, V54, P289, DOI 10.1080/00365521.2019.1585939; Colman RJ, 2014, J CROHNS COLITIS, V8, P1569, DOI 10.1016/j.crohns.2014.08.006; Costello SP, 2019, JAMA-J AM MED ASSOC, V321, P156, DOI 10.1001/jama.2018.20046; Damman CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133925; Dang XF, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228846; Edelstein C, 2016, CAN MED ASSOC J, V188, pE431, DOI 10.1503/cmaj.150672; Fabisiak N, 2017, J CLIN GASTROENTEROL, V51, P878, DOI 10.1097/MCG.0000000000000911; Fang YH, 2017, HONG KONG J PAEDIATR, V22, P199; Gomollon F, 2017, J CROHNS COLITIS, V11, P3, DOI 10.1093/ecco-jcc/jjw168; Goyal A, 2018, INFLAMM BOWEL DIS, V24, P410, DOI 10.1093/ibd/izx035; Gutin L, 2019, UNITED EUR GASTROENT, V7, P807, DOI 10.1177/2050640619845986; Hamilton MJ, 2012, AM J GASTROENTEROL, V107, P761, DOI 10.1038/ajg.2011.482; Harbord M, 2017, J CROHNS COLITIS, V11, P769, DOI 10.1093/ecco-jcc/jjx009; Heath RD, 2018, NORTH CLIN ISTANB, V5, P79, DOI 10.14744/nci.2017.10692; Herfarth Hans, 2019, Inflamm Intest Dis, V4, P1, DOI 10.1159/000497042; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Huedo-Medina TB, 2006, PSYCHOL METHODS, V11, P193, DOI 10.1037/1082-989X.11.2.193; Imdad A, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012774.pub2; Ishikawa D, 2017, INFLAMM BOWEL DIS, V23, P116, DOI 10.1097/MIB.0000000000000975; Jacob V, 2017, INFLAMM BOWEL DIS, V23, P903, DOI 10.1097/MIB.0000000000001132; Jung Lee Woo, 2015, Gastroenterol Hepatol (N Y), V11, P24; Karolewska-Bochenek K, 2018, ADV EXP MED BIOL, V1047, P81, DOI 10.1007/5584_2017_123; Kim KO, 2019, CLIN ENDOSC, V52, P137, DOI 10.5946/ce.2019.009; Konig J, 2017, ALIMENT PHARM THER, V45, P222, DOI 10.1111/apt.13868; Kump P, 2018, ALIMENT PHARM THER, V47, P67, DOI 10.1111/apt.14387; Kump PK, 2013, INFLAMM BOWEL DIS, V19, P2155, DOI 10.1097/MIB.0b013e31829ea325; Kunde S, 2013, J PEDIATR GASTR NUTR, V56, P597, DOI 10.1097/MPG.0b013e318292fa0d; Landy J, 2015, SCI REP-UK, V5, DOI 10.1038/srep12955; Lee CH, 2016, JAMA-J AM MED ASSOC, V315, P142, DOI 10.1001/jama.2015.18098; Maaser C., 2018, J CROHNS COLITIS; Mahadevan U, 2003, GASTROENTEROLOGY, V124, P1636, DOI 10.1016/S0016-5085(03)00325-1; Mizuno S, 2017, INTEST RES, V15, P68, DOI 10.5217/ir.2017.15.1.68; Moayyedi P, 2015, GASTROENTEROLOGY, V149, P102, DOI 10.1053/j.gastro.2015.04.001; Moore T, 2014, CLIN INFECT DIS, V58, P541, DOI 10.1093/cid/cit950; Narula N, 2017, INFLAMM BOWEL DIS, V23, P1702, DOI 10.1097/MIB.0000000000001228; Nishida A, 2017, J GASTROENTEROL, V52, P476, DOI 10.1007/s00535-016-1271-4; Papanicolas LE, 2019, EBIOMEDICINE, V41, P509, DOI 10.1016/j.ebiom.2019.02.023; Paramsothy S, 2017, J CROHNS COLITIS, V11, P1180, DOI 10.1093/ecco-jcc/jjx063; Paramsothy S, 2017, LANCET, V389, P1218, DOI 10.1016/S0140-6736(17)30182-4; Pihl-Lesnovska K, 2010, GASTROENTEROL NURS, V33, P37, DOI 10.1097/SGA.0b013e3181cd49d0; Qazi T, 2017, GUT MICROBES, V8, P574, DOI 10.1080/19490976.2017.1353848; Rossen NG, 2015, GASTROENTEROLOGY, V149, P110, DOI 10.1053/j.gastro.2015.03.045; Satokari R, 2015, ALIMENT PHARM THER, V41, P46, DOI 10.1111/apt.13009; Selvig D, 2020, DIGEST DIS SCI, V65, P1099, DOI 10.1007/s10620-019-05715-2; Sokol H, 2020, MICROBIOME, V8, DOI 10.1186/s40168-020-0792-5; Sood A, 2019, J CROHNS COLITIS, V13, P1311, DOI 10.1093/ecco-jcc/jjz060; Sood A, 2019, INTEST RES, V17, P78, DOI 10.5217/ir.2018.00089; Sunkara T, 2018, J INFLAMM RES, V11, P321, DOI 10.2147/JIR.S176190; Suskind DL, 2015, INFLAMM BOWEL DIS, V21, P556, DOI 10.1097/MIB.0000000000000307; Suskind DL, 2015, J PEDIATR GASTR NUTR, V60, P27, DOI 10.1097/MPG.0000000000000544; Tian Y, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1010-4; van der Sloot KWJ, 2017, INFLAMM BOWEL DIS, V23, P1499, DOI 10.1097/MIB.0000000000001217; van Enst WA, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-70; Vaughn BP, 2016, INFLAMM BOWEL DIS, V22, P2182, DOI 10.1097/MIB.0000000000000893; Vermeire S, 2016, J CROHNS COLITIS, V10, P387, DOI 10.1093/ecco-jcc/jjv203; Vindigni SM, 2016, THER ADV GASTROENTER, V9, P606, DOI 10.1177/1756283X16644242; Wang HG, 2018, ADV THER, V35, P1935, DOI 10.1007/s12325-018-0800-3; Wei Y, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0869-2; Weisshof R, 2018, ADV THER, V35, P1746, DOI 10.1007/s12325-018-0795-9; Wells GA, NEWCASTLE OTTAWA SCA; Xiang LY, 2020, MICROB BIOTECHNOL, V13, P760, DOI 10.1111/1751-7915.13536; Yang ZY, 2020, DIGEST DIS SCI, V65, P150, DOI 10.1007/s10620-019-05751-y; Yarlas A, 2018, J CROHNS COLITIS, V12, P600, DOI 10.1093/ecco-jcc/jjy024; Zhang T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158227; Zhou HY, 2021, IMMUNOL INVEST, V50, P323, DOI 10.1080/08820139.2020.1714650; Zou ML, 2020, FEBS OPEN BIO, V10, P41, DOI 10.1002/2211-5463.12744	72	29	30	6	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2020	15	9							e0238910	10.1371/journal.pone.0238910	http://dx.doi.org/10.1371/journal.pone.0238910			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU7WV	32946509	gold, Green Published			2023-01-03	WOS:000573851100015
J	Parikh, TJ; Stryczek, KC; Gillespie, C; Sayre, GG; Feemster, L; Udris, E; Majerczyk, B; Rinne, ST; Wiener, RS; Au, DH; Helfrich, CD				Parikh, Toral J.; Stryczek, Krysttel C.; Gillespie, Chris; Sayre, George G.; Feemster, Laura; Udris, Edmunds; Majerczyk, Barbara; Rinne, Seppo T.; Wiener, Renda Soylemez; Au, David H.; Helfrich, Christian D.			Provider anticipation and experience of patient reaction when deprescribing guideline discordant inhaled corticosteroids	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; OLDER-ADULTS; CLINICAL CONSEQUENCES; SAMPLE-SIZE; POLYPHARMACY; BELIEFS; MEDICATION	Introduction Despite evidence of possible patient harm and substantial costs, medication overuse is persistent. Patient reaction is one potential barrier to deprescribing, but little research has assessed this in specific instances of medication discontinuation. We sought to understand Veteran and provider experience when de-implementing guideline-discordant use of inhaled corticosteroids (ICS) in those with mild-to-moderate chronic obstructive pulmonary disease (COPD). Methods We conducted a mixed-methods analysis in a provider-randomized quality improvement project testing a proactive electronic-consultation from pulmonologists recommending ICS discontinuation when appropriate. PCPs at two Veterans Health Administration healthcare systems were included. We completed interviews with 16 unexposed providers and 6 intervention-exposed providers. We interviewed 9 patients within 3 months after their PCP proposed ICS discontinuation. We conducted inductive and deductive content analysis of qualitative data to explore an emergent theme of patient reaction. Forty-eight PCPs returned surveys (24 exposed and 24 unexposed, response rate: 35%). Results The unexposed providers anticipated their patients might resist ICS discontinuation because it seems counterintuitive to stop something that is working, patient's fear of worsening symptoms, or if the prescription was initiated by another provider. Intervention-exposed providers reported similar experiences in post-intervention interviews. Unexposed providers anticipated that patients may accept ICS discontinuation, citing tactical use of patient-centered care strategies. This was echoed by intervention-exposed providers who had successfully discontinued an ICS. Veterans reported acceding to their providers out of trust or deference to their advanced training, even after describing an ICS as a 'security blanket'. Our survey findings supported the subthemes from our interviews. Among providers who proposed discontinuation of an ICS, 76% reported that they were able to discontinue it or switch to another more appropriate medication. Conclusions While PCPs anticipated that patients would resist discontinuing an ICS, interviews with patient and intervention-exposed PCPs along with surveys suggest that patients were receptive to this change.	[Parikh, Toral J.; Sayre, George G.; Feemster, Laura; Udris, Edmunds; Majerczyk, Barbara; Au, David H.; Helfrich, Christian D.] VA Puget Sound Healthcare Syst, Seattle Denver Ctr Innovat Vet Ctr & Value Driven, Seattle, WA 98108 USA; [Parikh, Toral J.] Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA; [Stryczek, Krysttel C.] VA Northeast Ohio Healthcare Syst, Cleveland, OH USA; [Gillespie, Chris; Rinne, Seppo T.; Wiener, Renda Soylemez] Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA; [Sayre, George G.; Helfrich, Christian D.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA; [Feemster, Laura; Au, David H.] Univ Washington, Div Pulm Crit Care & Sleep Med, Seattle, WA 98195 USA; [Rinne, Seppo T.; Wiener, Renda Soylemez] Boston Univ, Sch Med, Pulm Ctr, Boston, MA 02118 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Boston University	Parikh, TJ (corresponding author), VA Puget Sound Healthcare Syst, Seattle Denver Ctr Innovat Vet Ctr & Value Driven, Seattle, WA 98108 USA.; Parikh, TJ (corresponding author), Univ Washington, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.	parikht@uw.edu	Wiener, Renda/AAO-1557-2020; Helfrich, Christian/D-2382-2016	Helfrich, Christian/0000-0002-9827-4768	United States (U.S.) Department of Veterans Affairs Quality Enhancement Research Initiative [QUE 15-271]; VA Office of Academic Affiliations' Advanced Fellowship in Health Services Research and Development [TPH 61-001]	United States (U.S.) Department of Veterans Affairs Quality Enhancement Research Initiative; VA Office of Academic Affiliations' Advanced Fellowship in Health Services Research and Development	This work was supported by grant #QUE 15-271 from the United States (U.S.) Department of Veterans Affairs Quality Enhancement Research Initiative awarded to CDH and DHA. In addition, this material is based on work supported by a VA Office of Academic Affiliations' Advanced Fellowship in Health Services Research and Development to Dr. Parikh (TJP) (#TPH 61-001). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson K, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006544; [Anonymous], 2004, J CIRC RYTHMS, V2, P7; Bokhof B, 2016, DRUG AGING, V33, P249, DOI 10.1007/s40266-016-0354-5; Cataldo D, 2018, INT J CHRONIC OBSTR, V13, P2089, DOI 10.2147/COPD.S164259; Charlesworth CJ, 2015, J GERONTOL A-BIOL, V70, P989, DOI 10.1093/gerona/glv013; CLEE MA, 1980, J CONSUM RES, V6, P389, DOI 10.1086/208782; Clyne B, 2017, BRIT J GEN PRACT, V67, pE507, DOI 10.3399/bjgp17X691073; Cresswell J.W., 2017, DESIGNING CONDUCTING; Department of Veterans Affairs, IMPR SAF QUAL EV BAS; Edelman M, 2019, DRUG AGING, V36, P1133, DOI 10.1007/s40266-019-00712-6; Elo S, 2008, J ADV NURS, V62, P107, DOI 10.1111/j.1365-2648.2007.04569.x; Field TS, 2005, MED CARE, V43, P1171, DOI 10.1097/01.mlr.0000185690.10336.70; Gibbs L, 2007, AUST NZ J PUBL HEAL, V31, P540, DOI 10.1111/j.1753-6405.2007.00140.x; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Helfrich CD, 2018, J EVAL CLIN PRACT, V24, P198, DOI 10.1111/jep.12855; Hill CE, 2005, J COUNS PSYCHOL, V52, P196, DOI 10.1037/0022-0167.52.2.196; Hill CE, 1997, COUNS PSYCHOL, V25, P517, DOI 10.1177/0011000097254001; Kew KM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010115.pub2; Kitson AL, 2008, IMPLEMENT SCI, V3, DOI 10.1186/1748-5908-3-1; Linsky A, 2015, PATIENT EDUC COUNS, V98, P220, DOI 10.1016/j.pec.2014.11.010; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; Malerba M, 2019, FRONT PHARMACOL, P10, DOI DOI 10.3389/FPHAR.2019.00390/FULL; Malterud K, 2016, QUAL HEALTH RES, V26, P1753, DOI 10.1177/1049732315617444; Mannino DM, 2015, CHRON OBSTR PULM DIS, V2, P223, DOI 10.15326/jcopdf.2.3.2014.0151; Martin P, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-015959; McCormack B, 2002, J ADV NURS, V38, P94, DOI 10.1046/j.1365-2648.2002.02150.x; Morgan DJ, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4534; Quick BL, 2007, COMMUN RES, V34, P255, DOI 10.1177/0093650207300427; Reeve E, 2018, JAMA INTERN MED, V178, P1673, DOI 10.1001/jamainternmed.2018.4720; Reeve E, 2016, BRIT J GEN PRACT, V66, pE552, DOI 10.3399/bjgp16X685669; Reeve E, 2015, BRIT J CLIN PHARMACO, V80, P1254, DOI 10.1111/bcp.12732; Reeve E, 2013, DRUG AGING, V30, P793, DOI 10.1007/s40266-013-0106-8; Rossi Michelle I, 2007, Am J Geriatr Pharmacother, V5, P317, DOI 10.1016/j.amjopharm.2007.12.001; Rycroft-Malone J, 2004, J ADV NURS, V47, P81, DOI 10.1111/j.1365-2648.2004.03068.x; Salazar JA, 2007, EXPERT OPIN DRUG SAF, V6, P695, DOI 10.1517/14740338.6.6.695; SANDELOWSKI M, 1995, RES NURS HEALTH, V18, P179, DOI 10.1002/nur.4770180211; Scott IA, 2015, JAMA INTERN MED, V175, P827, DOI 10.1001/jamainternmed.2015.0324; Simeone JC, 2017, INT J CHRONIC OBSTR, V12, P73, DOI 10.2147/COPD.S122013; Sobieraj DM, 2008, CLIN THER, V30, P1416, DOI 10.1016/j.clinthera.2008.08.004; Stryczek K, 2019, J GEN INTERN MED, DOI DOI 10.1007/S11606-019-05193-231396814; Tannenbaum C, 2014, JAMA INTERN MED, V174, P890, DOI 10.1001/jamainternmed.2014.949; Tashkin DP, 2018, INT J CHRONIC OBSTR, V13, P2587, DOI 10.2147/COPD.S172240; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Weir K, 2017, J GERONTOL B    1128, DOI [10.1093/geronb/gbx138/4668532, DOI 10.1093/GER0NB/GBX138/4668532]; Yawn BP, 2013, INT J CHRONIC OBSTR, V8, P295, DOI 10.2147/COPD.S42366	45	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2020	15	9							e0238511	10.1371/journal.pone.0238511	http://dx.doi.org/10.1371/journal.pone.0238511			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NU7VY	32941462	Green Published, gold			2023-01-03	WOS:000573848800009
J	Park, J; Lee, SH; Lee, JH; Min, JJ; Kwon, JH; Oh, AR; Carriere, K; Ahn, J				Park, Jungchan; Lee, Seung-Hwa; Lee, Jong-Hwan; Min, Jeong Jin; Kwon, Ji-Hye; Oh, Ah-Ran; Carriere, Keumhee; Ahn, Joonghyun			Volatile versus total intravenous anesthesia for 30-day mortality following non-cardiac surgery in patients with preoperative myocardial injury	PLOS ONE			English	Article							RANDOMIZED EVIDENCE; SEVOFLURANE; REMIFENTANIL; COMPLICATIONS; GUIDELINES; REDUCTION; PROPOFOL; KIDNEY; STRESS	We evaluated whether volatile anesthetics can improve the postoperative outcomes of non-cardiac surgery in patients with preoperative myocardial injury defined by the cardiac troponin elevation. From January 2010 to June 2018, 1254 adult patients with preoperative myocardial injury underwent non-cardiac surgery under general anesthesia and were enrolled in this study. Patients were stratified into following two groups according to anesthetic agents; 115 (9.2%) patients whose anesthesia was induced and maintained with continuous infusion of propofol and remifentanil (TIVA group) and 1139 (90.8%) patients whose anesthesia was maintainted with volatile anesthetics (VOLATILE group). The primary outcome was 30-day mortality. To diminish the remifentanil effect, a further analysis was conducted after excluding the patients who received only volatile anesthetics without remifentanil infusion. In a propensity-score matched analysis, 30-day mortality was higher in the TIVA group than the VOLATILE group (17.0%vs. 9.1%; hazard ratio [HR] 2.60; 95% confidence interval [CI], 1.14-5.93;p= 0.02). In addition, the TIVA group showed higher 30-day mortality than the VOLATILE group, even after eliminating the effect of remifentanil infusion (15.8%vs. 8.3%; HR 4.62; 95% CI, 1.82-11.74;p= 0.001). In our study, the use of volatile anesthetics showed the significant survival improvement after non-cardiac surgery in patients with preoperative myocardial injury, which appears to be irrelevant to the remifentanil use. Further studies are needed to confirm this beneficial effect of volatile anesthetics.	[Park, Jungchan; Lee, Jong-Hwan; Min, Jeong Jin; Kwon, Ji-Hye; Oh, Ah-Ran] Sungkyunkwan Univ, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Sch Med, Seoul, South Korea; [Lee, Seung-Hwa] Sungkyunkwan Univ, Samsung Med Ctr, Dept Cardiol, Sch Med, Seoul, South Korea; [Carriere, Keumhee; Ahn, Joonghyun] Sungkyunkwan Univ, Stat & Data Ctr, Samsung Med Ctr, Sch Med, Seoul, South Korea; [Carriere, Keumhee] Univ Alberta, Dept Math & Stat Sci, Edmonton, AB, Canada	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; University of Alberta	Lee, JH (corresponding author), Sungkyunkwan Univ, Samsung Med Ctr, Dept Anesthesiol & Pain Med, Sch Med, Seoul, South Korea.	jonghwanlee75@gmail.com		Ahn, Joong Hyun/0000-0002-5768-5990; Lee, Jong-Hwan/0000-0001-8249-5550; Park, Jungchan/0000-0002-7794-3547				Alsina E, 2014, CURR PHARM DESIGN, V20, P5449, DOI 10.2174/1381612820666140325105723; Devereaux PJ, 2020, EUR HEART J, V41, P3083, DOI 10.1093/eurheartj/ehz301; Devereaux PJ, 2018, LANCET, V391, P2325, DOI 10.1016/S0140-6736(18)30832-8; Devereaux PJ, 2017, JAMA-J AM MED ASSOC, V317, P1642, DOI 10.1001/jama.2017.4360; Devereaux PJ, 2015, NEW ENGL J MED, V373, P2258, DOI 10.1056/NEJMra1502824; Devereaux PJ, 2012, JAMA-J AM MED ASSOC, V307, P2295, DOI 10.1001/jama.2012.5502; Irwin MG, 2015, J CARDIOTHOR VASC AN, V29, pS23, DOI 10.1053/j.jvca.2015.01.021; Jakobsen CJ, 2007, J CARDIOTHOR VASC AN, V21, P664, DOI 10.1053/j.jvca.2007.03.002; Kristensen SD, 2014, EUR HEART J, V35, P2344, DOI 10.1093/eurheartj/ehu285; Landoni G, 2013, BRIT J ANAESTH, V111, P886, DOI 10.1093/bja/aet231; Landoni G, 2019, NEW ENGL J MED, V380, P1214, DOI 10.1056/NEJMoa1816476; Landoni G, 2017, J CARDIOTHOR VASC AN, V31, P719, DOI 10.1053/j.jvca.2016.07.017; Landoni G, 2012, J CARDIOTHOR VASC AN, V26, P764, DOI 10.1053/j.jvca.2012.04.018; Li G, 2009, ANESTHESIOLOGY, V110, P759, DOI 10.1097/ALN.0b013e31819b5bdc; Likhvantsev VV, 2016, J CARDIOTHOR VASC AN, V30, P1221, DOI 10.1053/j.jvca.2016.02.030; Lindholm EE, 2013, ANESTHESIOLOGY, V119, P802, DOI 10.1097/ALN.0b013e31829bd883; Machado MN, 2014, REV BRAS CIR CARDIOV, V29, P299, DOI 10.5935/1678-9741.20140049; Maile MD, 2016, ANESTH ANALG, V123, P135, DOI 10.1213/ANE.0000000000001309; McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401; Pagel PS, 2018, J CARDIOTHOR VASC AN, V32, P1112, DOI 10.1053/j.jvca.2017.12.029; Park J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177838; Saklad M., 1941, ANESTHESIOLOGY, V2, P281, DOI [10.1097/00000542-194105000-00004, DOI 10.1097/00000542-194105000-00004]; Sanchez-Conde P, 2008, ANESTH ANALG, V106, P371, DOI 10.1213/ane.0b013e318160580b; Sousa-Uva M, 2018, EUR J CARDIO-THORAC, V53, P5, DOI 10.1093/ejcts/ezx314; Thompson JP, 1998, BRIT J ANAESTH, V80, P467, DOI 10.1093/bja/80.4.467; THYGESEN K, 2018, J AM COLL CARDIOL, V72, P2231, DOI [10.1161/cir.0000000000000617, DOI 10.1016/J.JACC.2018.08.1038]; Twerenbold R, 2018, CIRCULATION, V137, P436, DOI 10.1161/CIRCULATIONAHA.117.028901; Uhlig C, 2016, ANESTHESIOLOGY, V124, P1230, DOI 10.1097/ALN.0000000000001120; Wong GTC, 2010, J CARDIOTHOR VASC AN, V24, P790, DOI 10.1053/j.jvca.2009.09.012; Zhang Y, 2004, ANESTHESIOLOGY, V101, P918, DOI 10.1097/00000542-200410000-00017; Zimmerman AM, 2016, J AM COLL SURGEONS, V223, P381, DOI 10.1016/j.jamcollsurg.2016.04.043	31	0	0	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2020	15	9							e0238661	10.1371/journal.pone.0238661	http://dx.doi.org/10.1371/journal.pone.0238661			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR9MU	32915840	gold, Green Published			2023-01-03	WOS:000571887500148
J	Astbury, NM; Albury, C; Nourse, R; Jebb, SA				Astbury, Nerys M.; Albury, Charlotte; Nourse, Rebecca; Jebb, Susan A.			Participant experiences of a low-energy total diet replacement programme: A descriptive qualitative study	PLOS ONE			English	Article							WEIGHT-CONTROL PRACTICES; PRIMARY-CARE; PERCEIVED BARRIERS; BEHAVIORS; OBESITY; ADULTS; EXPECTATIONS; RIGOUR; WOMEN; BIAS	Introduction The participants' experience of low-energy total diet replacement (TDR) programmes delivered by lay counsellors in the community for the routine treatment of obesity is currently unclear. We interviewed a sample of twelve participants who took part in the Doctor Referral of Overweight People to Low-Energy total diet replacement Treatment (DROPLET) trial and were randomised to the TDR programme. Methods We purposively sampled twelve patients who took part in the DROPLET trial, and conducted in-depth telephone interviews, which were audio-recorded and transcribed verbatim. Interview questions focused on participants' experiences and perceptions of the TDR programme. We conducted a thematic analysis, actively developing themes from the data, and used the one sheet of paper (OSOP) technique to develop higher-level concepts. Results Nine key themes were identified; Reasons for taking part, Expectations, Support and guidance from the counsellor, Time to build a personal relationship, Following the TDR Programme, Adverse events, Outcomes from the TDR, Weight Loss Maintenance, Recommending TDR to others. The relationship between participants and the counsellor was central to many of the themes. Close relationships with counsellors facilitated TDR adherence through providing one-to-one support (including during difficult times), sharing expert knowledge, and building a close relationship. Adherence was also supported by the rapid weight loss that patients reported experiencing. Overall participants reported positive experiences of the TDR, and emphasised the positive impact on their wellbeing. Discussion Patients reported that a TDR programme delivered by lay counsellors in the community was a positive experience and effective in helping them to lose weight. Future trials should consider the central role of the person providing support and advice as a key component in the programme.	[Astbury, Nerys M.; Albury, Charlotte; Nourse, Rebecca; Jebb, Susan A.] Univ Oxford, Radcliffe Primary Care, Nuffield Dept Primary Care Hlth Sci, Oxford, England; [Nourse, Rebecca] Deakin Univ, Sch Exercise & Nutr Sci, Fac Hlth, Melbourne, Vic, Australia	University of Oxford; Deakin University	Astbury, NM (corresponding author), Univ Oxford, Radcliffe Primary Care, Nuffield Dept Primary Care Hlth Sci, Oxford, England.	nerys.astbury@phc.ox.ac.uk	; ASTBURY, Nerys/O-6561-2018	Nourse, Rebecca/0000-0002-6410-7064; ASTBURY, Nerys/0000-0001-9301-7458; Jebb, Susan/0000-0001-9190-2920; Albury, Charlotte/0000-0002-1036-6626	NIHR Oxford Biomedical Research Centre (BRC); NIHR Applied Research Care (ARC) Oxford; Cambridge Weight Plan Ltd UK; National Institute for Health Research (NIHR) Applied Research Care (ARC) Oxford	NIHR Oxford Biomedical Research Centre (BRC); NIHR Applied Research Care (ARC) Oxford; Cambridge Weight Plan Ltd UK; National Institute for Health Research (NIHR) Applied Research Care (ARC) Oxford	NMA and SAJ are supported by funding from the NIHR Oxford Biomedical Research Centre (BRC). RN and SAJ were supported by funding from NIHR Applied Research Care (ARC) Oxford. SAJ is a NIHR) senior investigator. The main DROPLET trial was funded by a research grant from Cambridge Weight Plan Ltd UK to University of Oxford. We conducted this sub-study independently from the main trial, with separate funding from National Institute for Health Research (NIHR) Applied Research Care (ARC) Oxford. The funders had no input into the design, data collection, analysis decision to publish or preparation of the manuscripts. The authors had a right to publish regardless of the results. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care.	Ahern AL, 2017, LANCET, V389, P2214, DOI 10.1016/S0140-6736(17)30647-5; Ard JD, 2019, OBESITY, V27, P22, DOI 10.1002/oby.22303; Astbury NM, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3760; Astbury NM, 2019, OBESITY FACTS, V12, P26; Booth ML, 1997, PREV MED, V26, P131, DOI 10.1006/pmed.1996.9982; Bradshaw C, 2017, GLOB QUALIT NURS RES, V4, DOI 10.1177/2333393617742282; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Caelli K., 2003, INT J QUAL METHODS, V2, P1, DOI [10.1177/160940690300200201, DOI 10.1177/160940690300200201]; Cardiovascular Disease and Risk Management, 2019, DIABETES CARE, V2, pS103, DOI 10.2337/dc19-S010; COUGHLIN SS, 1990, J CLIN EPIDEMIOL, V43, P87, DOI 10.1016/0895-4356(90)90060-3; Council. GM, 2014, GOOD MED PRACTICE; Crawford D, 1998, AUST NZ J PUBL HEAL, V22, P73, DOI 10.1111/j.1467-842X.1998.tb01148.x; Dalle Grave R, 2005, OBES RES, V13, P1961, DOI 10.1038/oby.2005.241; Dugdale DC, 1999, J GEN INTERN MED, V14, pS34, DOI 10.1046/j.1525-1497.1999.00263.x; Elliott R, 2018, PSYCHOTHERAPY, V55, P399, DOI 10.1037/pst0000175; FISHER RJ, 1993, J CONSUM RES, V20, P303, DOI 10.1086/209351; Foster GD, 1997, J CONSULT CLIN PSYCH, V65, P79, DOI 10.1037/0022-006X.65.1.79; Guba E.G., 1989, 4 GENERATION EVALUAT; Harper C, 2018, OBES REV, V24, P24; Jebb SA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016709; Jebb SA, 2011, LANCET, V378, P1485, DOI 10.1016/S0140-6736(11)61344-5; JOHNSON CA, 1990, WOMEN HEALTH, V16, P177, DOI 10.1300/J013v16n03_10; Kent S, 2019, OBESITY, V27, P391, DOI 10.1002/oby.22407; KOCH T, 1994, J ADV NURS, V19, P976, DOI 10.1111/j.1365-2648.1994.tb01177.x; Kwan S, 2009, QUAL HEALTH RES, V19, P1223, DOI 10.1177/1049732309343952; LaRose JG, 2013, OBESITY, V21, P449, DOI 10.1002/oby.20053; Lean MEJ, 2017, LANCET; Love JG, 2016, INT J WOMENS HEALTH, V8, P299, DOI 10.2147/IJWH.S100385; Ostberg AL, 2011, SCAND J PUBLIC HEALT, V39, P98, DOI 10.1177/1403494810391524; Rehackova L, 2017, DIABETIC MED, V34, P1554, DOI 10.1111/dme.13426; Sandelowski M, 2000, RES NURS HEALTH, V23, P334, DOI 10.1002/1098-240X(200008)23:4<334::AID-NUR9>3.0.CO;2-G; Schneeweiss S, 2007, CIRCULATION, V115, P2128, DOI 10.1161/CIRCULATIONAHA.106.665992; Siu J, 2011, PUBLIC HEALTH NUTR, V14, P1768, DOI 10.1017/S1368980011000644; StriegelMoore RH, 1996, OBES RES, V4, P109, DOI 10.1002/j.1550-8528.1996.tb00522.x; Tobin GA, 2004, J ADV NURS, V48, P388, DOI 10.1111/j.1365-2648.2004.03207.x; Tudor K, 2020, BRIT J GEN PRACT, V70, pE348, DOI 10.3399/bjgp20X708797; Ziebland S, 2006, MED EDUC, V40, P405, DOI 10.1111/j.1365-2929.2006.02467.x	37	9	9	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2020	15	9							e0238645	10.1371/journal.pone.0238645	http://dx.doi.org/10.1371/journal.pone.0238645			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NQ6EE	32898176	gold, Green Published			2023-01-03	WOS:000570962500036
J	Fluckiger, A; Daillere, R; Sassi, M; Sixt, BS; Liu, P; Loos, F; Richard, C; Rabu, C; Alou, MT; Goubet, AG; Lemaitre, F; Ferrere, G; Derosa, L; Duong, CPM; Messaoudene, M; Gagne, A; Joubert, P; De Sordi, L; Debarbieux, L; Simon, S; Scarlata, CM; Ayyoub, M; Palermo, B; Facciolo, F; Boidot, R; Wheeler, R; Boneca, IG; Sztupinszki, Z; Papp, K; Csabai, I; Pasolli, E; Segata, N; Lopez-Otin, C; Szallasi, Z; Andre, F; Iebba, V; Quiniou, V; Klatzmann, D; Boukhalil, J; Khelaifia, S; Raoult, D; Albiges, L; Escudier, B; Eggermont, A; Mami-Chouaib, F; Nistico, P; Ghiringhelli, F; Routy, B; Labarriere, N; Cattoir, V; Kroemer, G; Zitvogel, L				Fluckiger, Aurelie; Daillere, Romain; Sassi, Mohamed; Sixt, Barbara Susanne; Liu, Peng; Loos, Friedemann; Richard, Corentin; Rabu, Catherine; Alou, Maryam Tidjani; Goubet, Anne-Gaelle; Lemaitre, Fabien; Ferrere, Gladys; Derosa, Lisa; Duong, Connie P. M.; Messaoudene, Meriem; Gagne, Andreanne; Joubert, Philippe; De Sordi, Luisa; Debarbieux, Laurent; Simon, Sylvain; Scarlata, Clara-Maria; Ayyoub, Maha; Palermo, Belinda; Facciolo, Francesco; Boidot, Romain; Wheeler, Richard; Boneca, Ivo Gomperts; Sztupinszki, Zsofia; Papp, Krisztian; Csabai, Istvan; Pasolli, Edoardo; Segata, Nicola; Lopez-Otin, Carlos; Szallasi, Zoltan; Andre, Fabrice; Iebba, Valerio; Quiniou, Valentin; Klatzmann, David; Boukhalil, Jacques; Khelaifia, Saber; Raoult, Didier; Albiges, Laurence; Escudier, Bernard; Eggermont, Alexander; Mami-Chouaib, Fathia; Nistico, Paola; Ghiringhelli, Francois; Routy, Bertrand; Labarriere, Nathalie; Cattoir, Vincent; Kroemer, Guido; Zitvogel, Laurence			Cross-reactivity between tumor MHC class I-restricted antigens and an enterococcal bacteriophage	SCIENCE			English	Article							CELLS; PEPTIDE; IDENTIFICATION; IMMUNOTHERAPY; AUTOIMMUNITY; EXPRESSION; INFECTION; PSMB4; HIRAE; TOOLS	Intestinal microbiota have been proposed to induce commensal-specific memory T cells that cross-react with tumor-associated antigens. We identified major histocompatibility complex (MHC) class I-binding epitopes in the tail length tape measure protein (TMP) of a prophage found in the genome of the bacteriophage Enterococcus hirae. Mice bearing E. hirae harboring this prophage mounted a TMP-specific H-2K(b)-restricted CD8(+) T lymphocyte response upon immunotherapy with cyclophosphamide or anti-PD-1 antibodies. Administration of bacterial strains engineered to express the TMP epitope improved immunotherapy in mice. In renal and lung cancer patients, the presence of the enterococcal prophage in stools and expression of a TMP-cross-reactive antigen by tumors correlated with long-term benefit of PD-1 blockade therapy. In melanoma patients, T cell clones recognizing naturally processed cancer antigens that are cross-reactive with microbial peptides were detected.	[Fluckiger, Aurelie; Daillere, Romain; Alou, Maryam Tidjani; Goubet, Anne-Gaelle; Lemaitre, Fabien; Ferrere, Gladys; Derosa, Lisa; Duong, Connie P. M.; Iebba, Valerio; Albiges, Laurence; Escudier, Bernard; Eggermont, Alexander; Zitvogel, Laurence] Gustave Roussy Canc Campus GRCC, Villejuif, France; [Fluckiger, Aurelie; Daillere, Romain; Alou, Maryam Tidjani; Goubet, Anne-Gaelle; Ferrere, Gladys; Derosa, Lisa; Duong, Connie P. M.; Iebba, Valerio; Zitvogel, Laurence] Inst Gustave Roussy, Inst Natl Sante & Rech Med, U1015, Villejuif, France; [Daillere, Romain; Lemaitre, Fabien] Gustave Roussy Canc Ctr, EverImmune, Villejuif, France; [Sassi, Mohamed; Cattoir, Vincent] Univ Rennes 1, Lab Biochim Pharmaceut, Inserm U1230 UPRES EA 2311, Rennes, France; [Sixt, Barbara Susanne] Umea Univ, Umea Ctr Microbial Res, Dept Mol Biol, Lab Mol Infect Med Sweden, S-90187 Umea, Sweden; [Sixt, Barbara Susanne; Liu, Peng; Loos, Friedemann; Kroemer, Guido] Gustave Roussy Canc, Cell Biol & Metabol Platforms, Villejuif, France; [Sixt, Barbara Susanne; Liu, Peng; Loos, Friedemann; Lopez-Otin, Carlos; Kroemer, Guido] Ctr Rech Cordeliers, Equipe 11 Labellisee Ligue Canc, Paris, France; [Sixt, Barbara Susanne; Liu, Peng; Loos, Friedemann; Lopez-Otin, Carlos; Kroemer, Guido] INSERM U1138, Paris, France; [Sixt, Barbara Susanne; Liu, Peng; Loos, Friedemann; Lopez-Otin, Carlos; Kroemer, Guido] Univ Paris, Paris, France; [Sixt, Barbara Susanne; Liu, Peng; Loos, Friedemann; Lopez-Otin, Carlos; Kroemer, Guido] Sorbonne Univ, Paris, France; [Richard, Corentin] Res Platform Biol Oncol, Dijon, France; [Richard, Corentin] GIMI Genet & Immunol Med Inst, Dijon, France; [Richard, Corentin] Univ Burgundy Franche Comte, Dijon, France; [Rabu, Catherine; Simon, Sylvain; Labarriere, Nathalie] Univ Nantes, INSERM, CRCINA, Univ Angers, Nantes, France; [Rabu, Catherine; Simon, Sylvain; Labarriere, Nathalie] LabEx IGO Immunotherapy Graft Oncol, Nantes, France; [Alou, Maryam Tidjani; Boukhalil, Jacques; Khelaifia, Saber; Raoult, Didier] Aix Marseille Univ, Inst Hosp Univ Mediterranee Infect, UMR MEPHI, IRD,AP HM, 19-21 Blvd Jean Moulin, F-13385 Marseille 05, France; [Derosa, Lisa; Zitvogel, Laurence] Univ Paris Saclay, F-94805 Villejuif, France; [Messaoudene, Meriem; Gagne, Andreanne; Joubert, Philippe; Routy, Bertrand] Inst Univ Cardiol & Pneumol Quebec, Res Ctr, Quebec City, PQ, Canada; [Messaoudene, Meriem; Gagne, Andreanne; Joubert, Philippe; Routy, Bertrand] Inst Univ Cardiol & Pneumol Quebec, Dept Cytol & Pathol, Quebec City, PQ, Canada; [De Sordi, Luisa; Debarbieux, Laurent] Inst Pasteur, Bacteriophage Bacterium Host Lab, F-75015 Paris, France; [De Sordi, Luisa] Sorbonne Univ, Ctr Rech St Antoine, INSERM UMRS 938, Paris, France; [Scarlata, Clara-Maria; Ayyoub, Maha] Canc Res Ctr Toulouse, INSERM UMR 1037, F-31037 Toulouse, France; [Scarlata, Clara-Maria; Ayyoub, Maha] Univ Toulouse III Paul Sabatier, F-31330 Toulouse, France; [Scarlata, Clara-Maria; Ayyoub, Maha] Inst Univ Canc Toulouse Oncopole, F-31100 Toulouse, France; [Palermo, Belinda; Nistico, Paola] IRCCS, Dept Res Adv Diagnost & Technol Innovat, Unit Tumor Immunol & Immunotherapy, Regina Elena Natl Canc Inst, Rome, Italy; [Facciolo, Francesco; Nistico, Paola] IRCCS, Dept Surg Oncol, Thorac Surg Unit, Regina Elena Natl Canc Inst, Rome, Italy; [Boidot, Romain] UNICANCER, Georges Francois Leclerc Anticanc Ctr, Dept Biol & Pathol Tumors, Unit Mol Biol, Dijon, France; [Wheeler, Richard; Boneca, Ivo Gomperts] Inst Pasteur, Unit Biol & Genet Bacterial Cell Wall, Paris, France; [Sztupinszki, Zsofia; Szallasi, Zoltan] Boston Childrens Hosp, Computat Hlth Informat Program CHIP, Boston, MA USA; [Papp, Krisztian; Csabai, Istvan] Eotvos Lorand Univ, Dept Phys Complex Syst, Budapest, Hungary; [Pasolli, Edoardo] Univ Naples Federico II, Dept Agr Sci, Naples, Italy; [Segata, Nicola] Univ Trento, Dept CIBIO, Trento, Italy; [Lopez-Otin, Carlos] Univ Oviedo, Inst Univ Oncol IUOPA, Dept Bioquim & Biol Mol, Oviedo, Spain; [Szallasi, Zoltan] Harvard Med Sch, Boston, MA 02115 USA; [Szallasi, Zoltan] Danish Canc Soc Res Ctr, Copenhagen, Denmark; [Szallasi, Zoltan] Semmelweis Univ, Brain Metastasis Res Grp, MTA SE NAP, Dept Pathol 2, Budapest, Hungary; [Andre, Fabrice] Gustave Roussy, Breast Canc Comm, Dept Canc Med, Villejuif, France; [Andre, Fabrice] Gustave Roussy, INSERM Unit 981, Villejuif, France; [Iebba, Valerio] Univ Trieste, Dept Med Sci, I-34137 Trieste, Italy; [Quiniou, Valentin; Klatzmann, David] Hop La Pitie Salpetriere, AP HP, Clin Invest Ctr Biotherapy CIC BTi, F-75651 Paris, France; [Quiniou, Valentin; Klatzmann, David] Hop La Pitie Salpetriere, AP HP, Immunol Inflammat Infectiol & Dermatol Dept 3iD, F-75651 Paris, France; [Quiniou, Valentin; Klatzmann, David] Sorbonne Univ, INSERM, Immunol Immunopathol Immunotherapy I3, F-75651 Paris, France; [Albiges, Laurence; Escudier, Bernard] Gustave Roussy, Dept Med Oncol, Villejuif, France; [Escudier, Bernard] GRCC, INSERM U981, Villejuif, France; [Eggermont, Alexander] Princess Maxima Ctr, NL-3584 CS Utrecht, Netherlands; [Mami-Chouaib, Fathia] Univ Paris Saclay, Univ Paris Sud, Fac Med,INSERM UMR 1186,Gustave Roussy, Integrat Tumor Immunol & Immunotherapy, F-94805 Villejuif, France; [Ghiringhelli, Francois] Ctr GF Leclerc, Dept Med Oncol, Dijon, France; [Routy, Bertrand] Ctr Hosp Univ Montreal CHUM, Div Hematooncol, Dept Med, Montreal, PQ, Canada; [Cattoir, Vincent] CHU Rennes, Serv Bacteriol Hyg Hosp, Hop Ponchaillou, Rennes, France; [Cattoir, Vincent] CNR, Resistance Antibiot Lab Ass Enterues, Rennes, France; [Kroemer, Guido] Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Pole Biol, Paris, France; [Kroemer, Guido] Karolinska Univ Hosp, Dept Womens & Childrens Hlth, S-1 Stockholm, Sweden; [Kroemer, Guido; Zitvogel, Laurence] Chinese Acad Med Sci, Suzhou Inst Syst Biol, Suzhou, Peoples R China; [Kroemer, Guido] Inst Univ France, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy; Universite de Rennes; Umea University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; Nantes Universite; CHU de Nantes; Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; UDICE-French Research Universities; Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; UNICANCER; Centre Georges-Francois Leclerc; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Harvard University; Boston Children's Hospital; Eotvos Lorand University; University of Naples Federico II; University of Trento; University of Oviedo; Instituto Universitario de Oncologia de Asturias; Harvard University; Harvard Medical School; Danish Cancer Society; Semmelweis University; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; University of Trieste; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UNICANCER; Centre Georges-Francois Leclerc; Universite de Montreal; CHU Rennes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; Universite Paris Cite; Karolinska Institutet; Karolinska University Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Institut Universitaire de France	Zitvogel, L (corresponding author), Gustave Roussy Canc Campus GRCC, Villejuif, France.; Zitvogel, L (corresponding author), Inst Gustave Roussy, Inst Natl Sante & Rech Med, U1015, Villejuif, France.; Kroemer, G (corresponding author), Gustave Roussy Canc, Cell Biol & Metabol Platforms, Villejuif, France.; Kroemer, G (corresponding author), Ctr Rech Cordeliers, Equipe 11 Labellisee Ligue Canc, Paris, France.; Kroemer, G (corresponding author), INSERM U1138, Paris, France.; Kroemer, G (corresponding author), Univ Paris, Paris, France.; Kroemer, G (corresponding author), Sorbonne Univ, Paris, France.; Zitvogel, L (corresponding author), Univ Paris Saclay, F-94805 Villejuif, France.; Kroemer, G (corresponding author), Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Pole Biol, Paris, France.; Kroemer, G (corresponding author), Karolinska Univ Hosp, Dept Womens & Childrens Hlth, S-1 Stockholm, Sweden.; Kroemer, G; Zitvogel, L (corresponding author), Chinese Acad Med Sci, Suzhou Inst Syst Biol, Suzhou, Peoples R China.; Kroemer, G (corresponding author), Inst Univ France, Paris, France.	kroemer@orange.fr; laurence.zitvogel@gustaveroussy.fr	Boneca, Ivo G/H-1677-2014; Liu, Peng/ABI-1773-2020; KROEMER, Guido/B-4263-2013; Sixt, Barbara/AAY-5140-2020; López-Otín, Carlos/AAB-2106-2020; DEROSA, LISA/E-6814-2015; Labarriere, Nathalie/H-8876-2015; Rabu, Catherine/K-7369-2015; Ayyoub, Maha/A-2074-2017; De Sordi, Luisa/ABC-2581-2021; RAOULT, Didier/A-8434-2008; Kroemer, Guido/AAY-9859-2020; ANDRE, Fabrice/AAL-2683-2020; WHEELER, Richard/AAB-8262-2022; Nistico, Paola/B-2862-2018; Iebba, Valerio/P-1194-2016; Scarlata, Clara Maria/A-2397-2017; Pasolli, Edoardo/K-5156-2016; Sassi, Mohamed/O-6617-2017	Boneca, Ivo G/0000-0001-8122-509X; Liu, Peng/0000-0002-1682-9222; KROEMER, Guido/0000-0002-9334-4405; Sixt, Barbara/0000-0002-5607-8902; López-Otín, Carlos/0000-0001-6964-1904; Labarriere, Nathalie/0000-0002-1407-6546; Rabu, Catherine/0000-0001-8405-2809; Ayyoub, Maha/0000-0003-2022-0898; RAOULT, Didier/0000-0002-0633-5974; ANDRE, Fabrice/0000-0001-5795-8357; WHEELER, Richard/0000-0002-9249-2377; ZITVOGEL, laurence/0000-0003-1596-0998; Nistico, Paola/0000-0003-4409-2261; Iebba, Valerio/0000-0002-0716-306X; Tidjani Alou, Maryam/0000-0002-0167-6235; GOUBET, Anne-Gaelle/0000-0003-3431-3067; Scarlata, Clara Maria/0000-0003-3429-2825; Palermo, Belinda/0000-0001-6293-0113; Derosa, Lisa/0000-0003-0527-2964; Facciolo, Francesco/0000-0002-7137-8946; Joubert, Philippe/0000-0001-7784-6387; Sztupinszki, Zsofia/0000-0002-8691-4086; ghiringhelli, francois/0000-0002-5465-8305; Pasolli, Edoardo/0000-0003-0799-3490; Quiniou, Valentin/0000-0002-0792-341X; BOU KHALIL, JACQUES YAACOUB/0000-0002-4272-5208; Papp, Krisztian/0000-0003-0619-8233; Sassi, Mohamed/0000-0002-0527-1171; Khelaifia, Saber/0000-0002-9303-3893	RHU Torino Lumiere [ANR-16-RHUS-0008]; Seerave Foundation; Ligue contre le Cancer (equipe labelisee); Agence Nationale de la Recherche (ANR); ANR Francogermanique under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases [ANR-19-CE150029]; Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Fondation pour la Recherche Medicale (FRM); European Research Council (ERC); High-end Foreign Expert Program in China, Institut National du Cancer (INCa) [GDW20171100085, GDW20181100051]; Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); CARE network; SIRIC Cancer Research and Personalized Medicine (CARPEM); National Research, Development and Innovation Fund of Hungary Project [FIEK_16-1-2016-0005]; Research and Technology Innovation Fund [NAP2-2017-1.2.1-NKP-0002]; Breast Cancer Research Foundation [BCRF-17-156]; Novo Nordisk Foundation Interdisciplinary Synergy Programme Grant [NNF15OC0016584]; Italian Association for Cancer Research [AIRC IG 19822]; TRiPoD ERC-Advanced EU [322856]; European Research Council [ERC-STG MetaPG-716575]; Institut Pasteur (Paris, France); ONCOBIOME H2020 network; Fondation Carrefour	RHU Torino Lumiere; Seerave Foundation; Ligue contre le Cancer (equipe labelisee); Agence Nationale de la Recherche (ANR); ANR Francogermanique under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases(French National Research Agency (ANR)); Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Fondation pour la Recherche Medicale (FRM); European Research Council (ERC)(European Research Council (ERC)European Commission); High-end Foreign Expert Program in China, Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; LabEx Immuno-Oncology; SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); CARE network; SIRIC Cancer Research and Personalized Medicine (CARPEM); National Research, Development and Innovation Fund of Hungary Project; Research and Technology Innovation Fund; Breast Cancer Research Foundation; Novo Nordisk Foundation Interdisciplinary Synergy Programme Grant; Italian Association for Cancer Research; TRiPoD ERC-Advanced EU; European Research Council; Institut Pasteur (Paris, France); ONCOBIOME H2020 network; Fondation Carrefour	L.Z. and G.K. were supported by RHU Torino Lumiere (ANR-16-RHUS-0008), ONCOBIOME H2020 network, the Seerave Foundation, the Ligue contre le Cancer (equipe labelisee); Agence Nationale de la Recherche (ANR) -Projets blancs; ANR Francogermanique ANR-19-CE150029 under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); Canceropole Ile-de-France; Fondation pour la Recherche Medicale (FRM); a donation by Elior; the European Research Council (ERC); Fondation Carrefour; High-end Foreign Expert Program in China (GDW20171100085 and GDW20181100051), Institut National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination (SOCRATE); CARE network (directed by X. Mariette, Kremlin Bicetre AP-HP), and the SIRIC Cancer Research and Personalized Medicine (CARPEM). The results shown here are based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov/.I.C.was supported by National Research, Development and Innovation Fund of Hungary Project (no. FIEK_16-1-2016-0005). Z.S. was supported by the Research and Technology Innovation Fund (NAP2-2017-1.2.1-NKP-0002) and Breast Cancer Research Foundation (BCRF-17-156). Z.S. and I.C. were supported by the Novo Nordisk Foundation Interdisciplinary Synergy Programme Grant (NNF15OC0016584). P.N. was supported by the Italian Association for Cancer Research (AIRC IG 19822). Mouse TCR sequencing was performed by the TRiPoD ERC-Advanced EU (322856) grants to D.K. N.S. is supported by the European Research Council (project ERC-STG MetaPG-716575). L.D.S. is funded by a Roux-Cantarini fellowship from the Institut Pasteur (Paris, France). Bristol-Myers-Squibb provided resources to support translational research related to the NIVOREN clinical trial enrolling kidney cancer patients.	Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; Belcaid M, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S9-S10; Bodinier M, 2000, NAT MED, V6, P707, DOI 10.1038/76292; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Bolotin DA, 2015, NAT METHODS, V12, P380, DOI 10.1038/nmeth.3364; Bradley CP, 2017, CELL HOST MICROBE, V22, P697, DOI 10.1016/j.chom.2017.10.007; Chai JN, 2017, SCI IMMUNOL, V2, DOI 10.1126/sciimmunol.aal5068; Cheng YC, 2018, CELL PHYSIOL BIOCHEM, V45, P819, DOI 10.1159/000487174; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; Feng ZE, 2014, HISTOPATHOLOGY, V64, P348, DOI 10.1111/his.12258; Galluzzi L, 2015, CANCER CELL, V28, P690, DOI 10.1016/j.ccell.2015.10.012; Gil-Cruz C, 2019, SCIENCE, V366, P881, DOI 10.1126/science.aav3487; Greiling TM, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan2306; Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010; Ji QY, 2010, NAT IMMUNOL, V11, P628, DOI 10.1038/ni.1888; Kelly TJ, 2011, MOL CELL BIOL, V31, P2696, DOI 10.1128/MCB.01242-10; Kennedy MJ, 2010, NAT METHODS, V7, P973, DOI 10.1038/NMETH.1524; Konig MF, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaj1921; Labarriere N, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/932318; LEBLANC DJ, 1992, PLASMID, V28, P130, DOI 10.1016/0147-619X(92)90044-B; Lee GY, 2014, CANCER RES, V74, P3114, DOI 10.1158/0008-5472.CAN-13-2683; Li JH, 2014, NAT BIOTECHNOL, V32, P834, DOI 10.1038/nbt.2942; Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503; Liu SC, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.453; Pasolli E, 2019, CELL, V176, P649, DOI 10.1016/j.cell.2019.01.001; Pasolli E, 2017, NAT METHODS, V14, P1023, DOI 10.1038/nmeth.4468; Pedulla ML, 2003, CELL, V113, P171, DOI 10.1016/S0092-8674(03)00233-2; Perez-Munoz ME, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144382; Piuri M, 2006, MOL MICROBIOL, V62, P1569, DOI 10.1111/j.1365-2958.2006.05473.x; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rong YH, 2017, EXP CELL RES, V358, P352, DOI 10.1016/j.yexcr.2017.07.009; Rose NR, 2017, CURR OPIN IMMUNOL, V49, P51, DOI 10.1016/j.coi.2017.08.014; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Rubio-Godoy V, 2002, J IMMUNOL, V169, P5696, DOI 10.4049/jimmunol.169.10.5696; Samb-Ba B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087419; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Seemann T, 2014, BIOINFORMATICS, V30, P2068, DOI 10.1093/bioinformatics/btu153; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Simon S, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01962; Tanoue T, 2019, NATURE, V565, P600, DOI 10.1038/s41586-019-0878-z; Treangen TJ, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0524-x; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Vujanovic L, 2007, CLIN CANCER RES, V13, P6796, DOI 10.1158/1078-0432.CCR-07-1909; Wang H, 2018, ONCOL REP, V40, P2343, DOI 10.3892/or.2018.6588; Weinbauer MG, 2004, FEMS MICROBIOL REV, V28, P127, DOI 10.1016/j.femsre.2003.08.001; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000; Yang Y, 2014, NATURE, V510, P152, DOI 10.1038/nature13279; Zhang XD, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317705767; Zitvogel L, 2018, SCIENCE, V359, P1366, DOI 10.1126/science.aar6918	52	114	115	11	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 21	2020	369	6506			SI		936	+		10.1126/science.aax0701	http://dx.doi.org/10.1126/science.aax0701			92	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE2OL	32820119	Green Submitted			2023-01-03	WOS:000562436800041
J	Lee, CG; Cefalu, WT				Lee, Christine G.; Cefalu, William T.			The Right Diabetes Medication for the Right Patient for the Right Outcome: Can a Network Meta-analysis Help Us Decide?	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Lee, Christine G.; Cefalu, William T.] NIDDK, NIH, 6707 Democracy Blvd,Room 7217, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Lee, CG (corresponding author), NIDDK, NIH, 6707 Democracy Blvd,Room 7217, Bethesda, MD 20892 USA.	Christine.lee2@nih.gov		Lee, Christine/0000-0001-5637-8924				Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS66, DOI 10.2337/dc20-S006; American Diabetes Association, 2020, Diabetes Care, V43, pS98, DOI 10.2337/dc20-S009; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; Karagiannis T, 2020, J GEN INTERN MED, DOI 10.1007/s11606-019-05608-0; Kent DM, 2020, ANN INTERN MED, V172, pW1, DOI 10.7326/M18-3668; Palmer SC, 2016, JAMA-J AM MED ASSOC, V316, P313, DOI 10.1001/jama.2016.9400; Riley RD, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j3932; Tsapas A, 2020, ANN INTERN MED, V173, P278, DOI 10.7326/M20-0864; Zheng SL, 2018, JAMA-J AM MED ASSOC, V319, P1580, DOI 10.1001/jama.2018.3024	9	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 18	2020	173	4					311	+		10.7326/M20-4266	http://dx.doi.org/10.7326/M20-4266			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK9TG	32598225				2023-01-03	WOS:000567070300025
J	Turcotte, JJ; Meisenberg, BR; MacDonald, JH; Menon, N; Fowler, MB; West, M; Rhule, J; Qureshi, SS; MacDonald, EB				Turcotte, Justin J.; Meisenberg, Barry R.; MacDonald, James H.; Menon, Nandakumar; Fowler, Marcia B.; West, Michaline; Rhule, Jane; Qureshi, Sadaf S.; MacDonald, Eileen B.			Risk factors for severe illness in hospitalized Covid-19 patients at a regional hospital	PLOS ONE			English	Article							CLINICAL CHARACTERISTICS	Background The Covid-19 pandemic threatens to overwhelm scarce clinical resources. Risk factors for severe illness must be identified to make efficient resource allocations. Objective To evaluate risk factors for severe illness. Design Retrospective, observational case series. Setting Single-institution. Participants First 117 consecutive patients hospitalized for Covid-19 from March 1 to April 12, 2020. Exposure None. Main outcomes and measures Intensive care unit admission or death. Results In-hospital mortality was 24.8% and average total length of stay was 11.82 days (95% CI: 10.01 to 13.63 days). 30.8% of patients required intensive care unit admission and 29.1% required mechanical ventilation. Multivariate regression identified the amount of supplemental oxygen required at admission (OR: 1.208, 95% CI: 1.011-1.443, p = .037), sputum production (OR: 6.734, 95% CI: 1.630-27.812, p = .008), insulin dependent diabetes mellitus (OR: 11.873, 95% CI: 2.218-63.555, p = .004) and chronic kidney disease (OR: 4.793, 95% CI: 1.528-15.037, p = .007) as significant risk factors for intensive care unit admission or death. Of the 48 patients who were admitted to the intensive care unit or died, this occurred within 3 days of arrival in 42%, within 6 days in 71%, and within 9 days in 88% of patients. Conclusions At our regional medical center, patients with Covid-19 had an average length of stay just under 12 days, required ICU care in 31% of cases, and had a 25% mortality rate. Patients with increased sputum production and higher supplemental oxygen requirements at admission, and insulin dependent diabetes or chronic kidney disease may be at increased risk for severe illness. A model for predicting intensive care unit admission or death with excellent discrimination was created that may aid in treatment decisions and resource allocation. Early identification of patients at increased risk for severe illness may lead to improved outcomes in patients hospitalized with Covid-19.	[Turcotte, Justin J.; MacDonald, James H.; Menon, Nandakumar; Fowler, Marcia B.; West, Michaline] Anne Arundel Med Ctr, Dept Orthoped, Annapolis, MD 21401 USA; [Meisenberg, Barry R.; MacDonald, Eileen B.] Anne Arundel Med Ctr, Dept Med, Annapolis, MD USA; [Rhule, Jane; Qureshi, Sadaf S.] Anne Arundel Med Ctr, Anne Arundel Res Inst, Annapolis, MD USA		Turcotte, JJ (corresponding author), Anne Arundel Med Ctr, Dept Orthoped, Annapolis, MD 21401 USA.	jturcotte@aahs.org						Alqahtani JS, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233147; Anderson TS, 2020, J GEN INTERN MED, V35, P3694, DOI 10.1007/s11606-020-05886-z; Bai X, 2020, PREDICTING COVID 19; CDC, 2020, COR DIS 2019 COVID 1; CDC, 2020, FLU SYMPT COMPL; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Gao C, 2020, EUR HEART J, V41, P2058, DOI 10.1093/eurheartj/ehaa433; Garg S, 2020, MMWR-MORBID MORTAL W, V69, P458, DOI 10.15585/mmwr.mm6915e3; Gong J, 2020, TOOL EARLY PREDICT S; Guan WJ, 2020, NEW ENGL J MED, V382, P1861, DOI 10.1056/NEJMc2005203; Guo LX, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02752; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Kim S, 2018, BIOMETRICS, V74, P734, DOI 10.1111/biom.12761; Liang WH, 2020, JAMA INTERN MED, V180, P1081, DOI 10.1001/jamainternmed.2020.2033; Lippi G, 2020, RESP MED, V167, DOI 10.1016/j.rmed.2020.105941; Medicine JHU, 2020, COVID 19 DASHB CTR S; Pan L, 2020, AM J GASTROENTEROL, V115, P766, DOI 10.14309/ajg.0000000000000620; Qi X, 2020, MACHINE LEARNING BAS, DOI DOI 10.1101/2020.02.29.20029603V1; Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; WASSERTHEIL S, 1970, BIOMETRICS, V26, P588, DOI 10.2307/2529115; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328; Xie J, 2020, DEV EXTERNAL VALIDAT; Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m792, 10.1136/bmj.m606]; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Yuan ML, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230548; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	31	23	23	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2020	15	8							e0237558	10.1371/journal.pone.0237558	http://dx.doi.org/10.1371/journal.pone.0237558			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ND3HD	32785285	gold, Green Published			2023-01-03	WOS:000561793900034
J	Pisa, R; Kapoor, TM				Pisa, Rudolf; Kapoor, Tarun M.			Chemical strategies to overcome resistance against targeted anticancer therapeutics	NATURE CHEMICAL BIOLOGY			English	Review							KINASE DOMAIN MUTATIONS; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; PROTEIN-DEGRADATION; DRUG-RESISTANCE; SELECTIVE DEGRADATION; CLINICAL-RESPONSE; EGFR MUTATIONS; ALK INHIBITOR; MECHANISMS	Emergence of resistance is a major factor limiting the efficacy of molecularly targeted anticancer drugs. Understanding the specific mutations, or other genetic or cellular changes, that confer drug resistance can help in the development of therapeutic strategies with improved efficacies. Here, we outline recent progress in understanding chemotype-specific mechanisms of resistance and present chemical strategies, such as designing drugs with distinct binding modes or using proteolysis targeting chimeras, to overcome resistance. We also discuss how targeting multiple binding sites with bifunctional inhibitors or identifying collateral sensitivity profiles can be exploited to limit the emergence of resistance. Finally, we highlight how incorporating analyses of resistance early in drug development can help with the design and evaluation of therapeutics that can have long-term benefits for patients.	[Pisa, Rudolf; Kapoor, Tarun M.] Rockefeller Univ, Lab Chem & Cell Biol, 1230 York Ave, New York, NY 10021 USA; [Pisa, Rudolf] Rockefeller Univ, Triinst PhD Program Chem Biol, 1230 York Ave, New York, NY 10021 USA; [Pisa, Rudolf] Harvard Med Sch, Dept Cell Biol, Boston, MA 02115 USA	Rockefeller University; Rockefeller University; Harvard University; Harvard Medical School	Kapoor, TM (corresponding author), Rockefeller Univ, Lab Chem & Cell Biol, 1230 York Ave, New York, NY 10021 USA.	kapoor@rockefeller.edu		Pisa, Rudolf/0000-0001-7571-7135	NIH/NIGMS [R35 GM130234-01]; Tri-Institutional Program in Chemical Biology	NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Tri-Institutional Program in Chemical Biology	The authors would like to thank NIH/NIGMS for funding (R35 GM130234-01). R.P. is grateful to the Tri-Institutional Program in Chemical Biology for support. The authors regret any omissions of prior work due to limits on space and the number of citations.	Andino R, 2015, VIROLOGY, V479, P46, DOI 10.1016/j.virol.2015.03.022; Ardini E, 2016, MOL CANCER THER, V15, P628, DOI 10.1158/1535-7163.MCT-15-0758; Barrio S, 2019, LEUKEMIA, V33, P447, DOI 10.1038/s41375-018-0216-8; Basu B, 2015, CLIN CANCER RES, V21, P3412, DOI 10.1158/1078-0432.CCR-14-2422; Baym M, 2016, SCIENCE, V351, DOI 10.1126/science.aad3292; Blencke S, 2004, CHEM BIOL, V11, P691, DOI 10.1016/j.chembiol.2004.02.029; Buhimschi AD, 2018, BIOCHEMISTRY-US, V57, P3564, DOI 10.1021/acs.biochem.8b00391; Burslem GM, 2020, CELL, V181, P102, DOI 10.1016/j.cell.2019.11.031; Burslem GM, 2019, CANCER RES, V79, P4744, DOI 10.1158/0008-5472.CAN-19-1236; Burslem GM, 2018, CELL CHEM BIOL, V25, P67, DOI 10.1016/j.chembiol.2017.09.009; Bussiere DE, 2020, NAT CHEM BIOL, V16, P15, DOI 10.1038/s41589-019-0411-6; Capdeville R, 2002, NAT REV DRUG DISCOV, V1, P493, DOI 10.1038/nrd839; Chait R, 2007, NATURE, V446, P668, DOI 10.1038/nature05685; Chamberlain PP, 2014, NAT STRUCT MOL BIOL, V21, P803, DOI 10.1038/nsmb.2874; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Clavel F, 2004, NEW ENGL J MED, V350, P1023, DOI 10.1056/NEJM2ra025195; Crompton BD, 2014, CANCER DISCOV, V4, P1326, DOI 10.1158/2159-8290.CD-13-1037; Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337; Cupido T, 2019, NAT CHEM BIOL, V15, P444, DOI 10.1038/s41589-019-0225-6; Dalton SE, 2020, CHEMBIOCHEM, V21, P1080, DOI 10.1002/cbic.201900674; Dhawan A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00791-8; Dobrovolsky D, 2019, BLOOD, V133, P952, DOI 10.1182/blood-2018-07-862953; Douglass EF, 2013, J AM CHEM SOC, V135, P6092, DOI 10.1021/ja311795d; Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448; Drilon A, 2016, ANN ONCOL, V27, P920, DOI 10.1093/annonc/mdw042; Drilon A, 2017, CANCER DISCOV, V7, P963, DOI 10.1158/2159-8290.CD-17-0507; Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885; Ercan D, 2015, CLIN CANCER RES, V21, P3913, DOI 10.1158/1078-0432.CCR-14-2789; Fang ZZ, 2013, ACS CHEM BIOL, V8, P58, DOI 10.1021/cb300663j; Faust TB, 2020, NAT CHEM BIOL, V16, P7, DOI 10.1038/s41589-019-0378-3; Fischer ES, 2014, NATURE, V512, P49, DOI 10.1038/nature13527; Friboulet L, 2014, CANCER DISCOV, V4, P662, DOI 10.1158/2159-8290.CD-13-0846; Furman RR, 2014, NEW ENGL J MED, V370, P2352, DOI 10.1056/NEJMc1402716; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; Gorre ME, 2001, SCIENCE, V293, P876, DOI 10.1126/science.1062538; Gottesman MM, 2016, ANNU REV PHARMACOL, V56, P85, DOI 10.1146/annurev-pharmtox-010715-103111; Han K, 2017, NAT BIOTECHNOL, V35, P463, DOI 10.1038/nbt.3834; Han T, 2017, SCIENCE, V356, DOI 10.1126/science.aal3755; Imamovic L, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006609; Ipsaro JJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172177; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; Jia J, 2009, NAT REV DRUG DISCOV, V8, P111, DOI 10.1038/nrd2683; Jost M, 2018, ACS CHEM BIOL, V13, P366, DOI 10.1021/acschembio.7b00965; Kapoor TM, 2017, TRENDS PHARMACOL SCI, V38, P1100, DOI 10.1016/j.tips.2017.09.003; Kasap C, 2014, NAT CHEM BIOL, V10, P626, DOI 10.1038/nchembio.1551; Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Konieczkowski DJ, 2018, CANCER CELL, V33, P801, DOI 10.1016/j.ccell.2018.03.025; Kronke J, 2014, SCIENCE, V343, P301, DOI 10.1126/science.1244851; Lai AC, 2017, NAT REV DRUG DISCOV, V16, P101, DOI 10.1038/nrd.2016.211; Lai AC, 2016, ANGEW CHEM INT EDIT, V55, P807, DOI 10.1002/anie.201507634; Liu RM, 2019, CHEM COMMUN, V55, P616, DOI 10.1039/c8cc08296k; Lu G, 2014, SCIENCE, V343, P305, DOI 10.1126/science.1244917; Ma LY, 2017, P NATL ACAD SCI USA, V114, P11751, DOI 10.1073/pnas.1708268114; Margeridon-Thermet S, 2009, J INFECT DIS, V199, P1275, DOI 10.1086/597808; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; Menden MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061318; Min JH, 2002, SCIENCE, V296, P1886, DOI 10.1126/science.1073440; Muller S, 2015, NAT CHEM BIOL, V11, P818, DOI 10.1038/nchembio.1938; Neggers JE, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02349-8; O'Hare T, 2007, BLOOD, V110, P2242, DOI 10.1182/blood-2007-03-066936; O'Hare T, 2011, CLIN CANCER RES, V17, P212, DOI 10.1158/1078-0432.CCR-09-3314; Ottis P, 2019, ACS CHEM BIOL, V14, P2215, DOI 10.1021/acschembio.9b00525; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Paiva SL, 2019, CURR OPIN CHEM BIOL, V50, P111, DOI 10.1016/j.cbpa.2019.02.022; Palmer AC, 2017, CELL, V171, P1678, DOI 10.1016/j.cell.2017.11.009; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pisa R, 2020, CELL CHEM BIOL, V27, P850, DOI 10.1016/j.chembiol.2020.05.003; Pisa R, 2019, CELL CHEM BIOL, V26, P1263, DOI 10.1016/j.chembiol.2019.06.001; Povedano JM, 2019, CELL CHEM BIOL, V26, P1315, DOI 10.1016/j.chembiol.2019.06.006; Qiang W, 2017, LEUKEMIA, V31, P2844, DOI 10.1038/leu.2017.264; Richman DD, 2006, ANTIVIR RES, V71, P117, DOI 10.1016/j.antiviral.2006.03.004; Rodrik-Outmezguine VS, 2016, NATURE, V534, P272, DOI 10.1038/nature17963; Russo M, 2016, CANCER DISCOV, V6, P36, DOI 10.1158/2159-8290.CD-15-0940; Sakamoto KM, 2001, P NATL ACAD SCI USA, V98, P8554, DOI 10.1073/pnas.141230798; Salverda MLM, 2010, FEMS MICROBIOL REV, V34, P1015, DOI 10.1111/j.1574-6976.2010.00222.x; Schoepfer J, 2018, J MED CHEM, V61, P8120, DOI 10.1021/acs.jmedchem.8b01040; Shah KN, 2019, NAT MED, V25, P111, DOI 10.1038/s41591-018-0264-7; Shah NP, 2002, CANCER CELL, V2, P117, DOI 10.1016/S1535-6108(02)00096-X; Shaw AT, 2016, NEW ENGL J MED, V374, P54, DOI 10.1056/NEJMoa1508887; Shi JW, 2015, NAT BIOTECHNOL, V33, P661, DOI 10.1038/nbt.3235; Shukla D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4397; Singh J, 2011, NAT REV DRUG DISCOV, V10, P307, DOI 10.1038/nrd3410; Strebhardt K, 2008, NAT REV CANCER, V8, P473, DOI 10.1038/nrc2394; Supek F, 2015, NATURE, V521, P81, DOI 10.1038/nature14173; SZYBALSKI W, 1952, J BACTERIOL, V64, P489, DOI 10.1128/JB.64.4.489-499.1952; Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854; Uehara T, 2017, NAT CHEM BIOL, V13, P675, DOI 10.1038/nchembio.2363; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wacker SA, 2012, NAT CHEM BIOL, V8, P235, DOI [10.1038/NCHEMBIO.779, 10.1038/nchembio.779]; Wagle N, 2014, NEW ENGL J MED, V371, P1426, DOI 10.1056/NEJMoa1403352; Wagle N, 2014, CANCER DISCOV, V4, P546, DOI 10.1158/2159-8290.CD-13-0353; Whitesides GM, 2005, Q REV BIOPHYS, V38, P385, DOI 10.1017/S0033583506004240; Wylie AA, 2017, NATURE, V543, P733, DOI 10.1038/nature21702; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733; Zhang L, 2019, MOL CANCER THER, V18, P1302, DOI 10.1158/1535-7163.MCT-18-1129; Zhao BY, 2016, CELL, V165, P234, DOI 10.1016/j.cell.2016.01.045; Zhao Z, 2014, ACS CHEM BIOL, V9, P1230, DOI 10.1021/cb500129t; Zhou WJ, 2009, NATURE, V462, P1070, DOI 10.1038/nature08622	100	20	20	10	40	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	AUG 1	2020	16	8					817	825		10.1038/s41589-020-0596-8	http://dx.doi.org/10.1038/s41589-020-0596-8			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NL1ME	32694636	Green Accepted			2023-01-03	WOS:000567187200004
J	Zhang, W; Sun, HY				Zhang, Wei; Sun, Huiying			Formal and informal care received by middle-aged and older adults with chronic conditions in Canada: CLSA data	PLOS ONE			English	Article							HOME-CARE; PEOPLE	Background Middle-aged and older adults are more likely to suffer from chronic conditions, which can increase their need for both formal and informal care. This study seeks to assess and compare the extent to which the use of formal and informal care is attributed to different chronic conditions among middle-aged and older women and men in Canada. Methods We used baseline data from the Canadian Longitudinal Study on Aging (CLSA). Outcomes of interest were the number of hours of formal care and informal care received during the past 12 months. All chronic conditions were first classified according to existing classification frameworks. If total formal and informal care hours for a particular condition differed greatly from other conditions, we considered it as a stand-alone classification. We used a two-part model consisting of a logistic regression for the probability of receiving formal/informal care and a generalized linear model for the hours of formal/informal care for those who received care. Results Our final analytic sample was 23,206 women and 22,903 men who did not have missing data. Among the 16 chronic conditions considered, multiple sclerosis, memory problems, Parkinsonism, and stroke had the greatest average marginal effects on overall hours of formal care among women (53.07, 13.95, 9.13 and 8.14 incremental hours annually, respectively) and men (152.17, 8.13, 13.95 and 6.00 incremental hours). Similarly, the average marginal effects of these four conditions on informal care were the greatest (77.78, 29.52, 26.18 and 34.95 incremental hours for women and 133.94, 34.99, 104.86 and 17.85 incremental hours for men). Conclusions Chronic conditions, especially multiple sclerosis, Parkinsonism, memory problems, and stroke, are associated with substantial time of formal and informal care in middle-aged and older women and men. Findings will help decision-makers assess the potential impact of chronic disease prevention and management programs in an aging population.	[Zhang, Wei] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada; [Zhang, Wei; Sun, Huiying] Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada	University of British Columbia	Zhang, W (corresponding author), Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC, Canada.; Zhang, W (corresponding author), Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada.	wzhang@cheos.ubc.ca	Zhang, Wei/P-3692-2016	Zhang, Wei/0000-0001-7988-1979	Faculty of Medicine, University of British Columbia; Michael Smith Foundation for Health Research Scholar Award; Government of Canada through the Canadian Institutes of Health Research [LSA 94473]; Canada Foundation for Innovation	Faculty of Medicine, University of British Columbia; Michael Smith Foundation for Health Research Scholar Award(Michael Smith Foundation for Health Research); Government of Canada through the Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Canada Foundation for Innovation(Canada Foundation for InnovationCGIAR)	This study is supported by the Start Up Funds from the Faculty of Medicine, University of British Columbia (WZ is the principal investigator https://mednet.med.ubc.ca/Research/FundingOpportunities/Pages/New-FacultyResearch-Award.aspx).WZ is supported by a Michael Smith Foundation for Health Research Scholar Award (https://www.msfhr.org/healthwork-and-society-improving-health-economic-evaluations).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was made possible with data/biospecimens collected by the Canadian Longitudinal Study on Aging (CLSA). Funding for the CLSA is provided by the Government of Canada through the Canadian Institutes of Health Research under grant reference: LSA 94473 and the Canada Foundation for Innovation. This research has been conducted using the CLSA data set, Baseline Tracking, Version 3.4, and Baseline Comprehensive, Version 4.0, under Application No. 180604. The CLSA is led by Drs. Parminder Raina, Christina Wolfson, and Susan Kirkland. This study was approved by the Hamilton Integrated Research Ethics Board (Ethics Certificate No. 0164). The opinions expressed in this manuscript are the authors' own and do not reflect the views of the CLSA. We also acknowledge editorial assistance from Julie Sou.	AARP and National Alliance for Caregiving, 2015, CAR US; Baitar A, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2594-4; Bremer P, 2017, HEALTH POLICY, V121, P613, DOI 10.1016/j.healthpol.2017.03.013; Charles KK, 2005, J HEALTH ECON, V24, P1174, DOI 10.1016/j.jhealeco.2005.05.001; CLSA, 2017, CLSA TECHNICAL DOCUM; CLSA, 2018, CAN LONG STUD AG IN; CLSA, 2018, DAT PREV PORT CAN LO; Costa N, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/852368; Ernstsson O, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159129; Griffith LE, 2019, J AM GERIATR SOC, V67, P1632, DOI 10.1111/jgs.15921; Hoell A, 2016, J AFFECT DISORDERS, V204, P247, DOI 10.1016/j.jad.2016.08.004; Jang SN, 2019, INT J EQUITY HEALTH, V18, DOI 10.1186/s12939-019-1008-0; Joo H, 2017, QUAL LIFE RES, V26, P1379, DOI 10.1007/s11136-016-1478-0; Katz SJ, 2000, JAMA-J AM MED ASSOC, V284, P3022, DOI 10.1001/jama.284.23.3022; Kirkland SA, 2015, CAN J AGING, V34, P366, DOI 10.1017/S071498081500029X; Public Health Agency of Canada, 2018, EC BURD ILLN CAN 201; Public Health Agency of Canada, 2018, CAN CHRON DIS IND; Raina PS, 2009, CAN J AGING, V28, P221, DOI 10.1017/S0714980809990055; Roine E, 2019, ANTICANCER RES, V39, P353, DOI 10.21873/anticanres.13119; Sasso ATL, 2016, INQUIRY J HLTH CARE, DOI [10.5034/inquiryjrnl_39.3.279, DOI 10.5034/INQUIRYJRNL_39.3.27912479539]; Schulz R, 2010, INFORMAL CAREGIVERS; Sharma A, 2014, 2014 INTERNATIONAL CONFERENCE ON COMPUTING FOR SUSTAINABLE GLOBAL DEVELOPMENT (INDIACOM), P895, DOI 10.1109/IndiaCom.2014.6828092; Stanfors M, 2019, SSM-POPUL HLTH, V9, DOI 10.1016/j.ssmph.2019.100501; Sun ZL, 2019, HEALTH SOC CARE COMM, V27, P437, DOI 10.1111/hsc.12664; Van Houtven CH, 2004, J HEALTH ECON, V23, P1159, DOI 10.1016/j.jhealeco.2004.04.008	25	5	6	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2020	15	7							e0235774	10.1371/journal.pone.0235774; 10.1371/journal.pone.0235774.r001; 10.1371/journal.pone.0235774.r002; 10.1371/journal.pone.0235774.r003; 10.1371/journal.pone.0235774.r004	http://dx.doi.org/10.1371/journal.pone.0235774; 10.1371/journal.pone.0235774.r001; 10.1371/journal.pone.0235774.r002; 10.1371/journal.pone.0235774.r003; 10.1371/journal.pone.0235774.r004			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MN1ZE	32634161	Green Published, gold			2023-01-03	WOS:000550645600040
J	Oladele, RO; Jordan, A; Akande, P; Akanmu, SA; Akase, IE; Aliyu, S; Denning, DW; Chiller, T				Oladele, Rita O.; Jordan, Alexander; Akande, Patrick; Akanmu, Sulaimon A.; Akase, Iorhen E.; Aliyu, Sani; Denning, David W.; Chiller, Tom			Tackling cryptococcal meningitis in Nigeria, one-step at a time; the impact of training	PLOS ONE			English	Article							THERAPY	Background Nigeria is estimated to have 25,000 cases of cryptococcal antigenemia (CrAg) annually. CrAg screening with pre-emptive fluconazole treatment is recommended but not yet implemented in Nigeria. Trainings were conducted to improve health-care provider (HCP) awareness and clinical skills in the management and prevention of cryptococcal meningitis (CM). Methods HCPs providing care for people living with HIV were targeted for training at 13 sites from April to November 2018 Course content was adapted from CDC Cryptococcal Screening Program Training Manual and LIFE-website. "Hands-on" training on CrAg testing and lumbar puncture was included. A 14-point pre and post-test assessment instrument was designed to capture the impact of the training and focus group discussions (FGDs) were conducted. Results A total of 761 HCPs were trained. 519 HCPs completed the pre-test evaluation while 470 (90.6%) took part in the post-test evaluation. Post-training, HCPs were significantly more likely to respond correctly to all 14 assessment items, with the mean percentage score rising to 91.0% from a pre-training value of 60.0%. FGDs revealed that many of the HCPs were not aware of the CrAg screening and pre-emptive treatment recommendations in Nigerian guidelines, and reported not having seen or managed a case of CM. Also, they highlighted challenges with routine CrAg screening due to a lack of access to CD4 testing, CrAg test kits, antifungal drugs, as well as the need for similar trainings across all tiers of care in Nigeria. Conclusion Training significantly improved HCPs' understanding of Nigerian policy on CrAg screening, CM diagnosis and best management practices. This training could be included in routine capacity building efforts for HCPs involved in HIV care in Nigeria.	[Oladele, Rita O.; Akanmu, Sulaimon A.; Akase, Iorhen E.] Univ Lagos, Coll Med, Lagos, Nigeria; [Jordan, Alexander; Chiller, Tom] Ctr Dis Control & Prevent CDC, Mycot Dis Branch, Atlanta, GA USA; [Akande, Patrick] APIN Publ Hlth Initiat, Abuja, Nigeria; [Aliyu, Sani] Natl Agcy Control AIDS NACA, Abuja, Nigeria; [Denning, David W.] Global Act Fund Fungal Infect GAFFI, Geneva, Switzerland	University of Lagos; Centers for Disease Control & Prevention - USA	Oladele, RO (corresponding author), Univ Lagos, Coll Med, Lagos, Nigeria.	oladelerita@gmail.com	Akande, Patrick A./AAB-4197-2019	Akande, Patrick A./0000-0002-4138-0594; Akanmu, Alani Sulaimon/0000-0001-7424-6060	CDC Foundation [950]	CDC Foundation(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	ROO is the PI for the grant awarded to Medical Mycology Society of Nigeria by the CDC Foundation (https://www.cdcfoundation.org) Grant no: 950.	Awofala AA, 2018, SAUDI J BIOL SCI, V25, P697, DOI 10.1016/j.sjbs.2016.03.006; Beardsley J, 2016, NEW ENGL J MED, V374, P542, DOI 10.1056/NEJMoa1509024; Dalhatu I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165528; Gomerep S S, 2010, Niger J Med, V19, P395; Meya David, 2015, Curr Trop Med Rep, V2, P81; Meya DB, 2010, CLIN INFECT DIS, V51, P448, DOI 10.1086/655143; Rajasingham R, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210105; Rajasingham R, 2017, LANCET INFECT DIS, V17, P873, DOI [10.1016/s1473-3099(17)30243-8, 10.1016/S1473-3099(17)30243-8]; Rolfes MA, 2014, CLIN INFECT DIS, V59, P1607, DOI 10.1093/cid/ciu596; Scott L, 2017, CURR OPIN HIV AIDS, V12, P129, DOI [10.1097/COH.0000000000000345, 10.1097/coh.0000000000000345]; Sungkanuparph S, 2009, CLIN INFECT DIS, V49, P931, DOI 10.1086/605497; UNAIDS, COUNTR DAT NIG; World Health Organization, 2018, GUID DIAGN PREV MAN; World Health Organization (WHO) Guideline Development group, 2011, RAP ADV DIAGN PREV M	14	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2020	15	7							e0235577	10.1371/journal.pone.0235577	http://dx.doi.org/10.1371/journal.pone.0235577			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM3OG	32628714	gold, Green Published			2023-01-03	WOS:000550068700025
J	Safe, IP; Lacerda, MVG; Printes, VS; Marins, AFP; Rabelo, ALR; Costa, AA; Tavares, MA; Jesus, JS; Souza, AB; Beraldi-Magalhaes, F; Neves, CP; Monteiro, WM; Sampaio, VS; Amaral, EP; Gomes, RS; Andrade, BB; Cordeiro-Santos, M; Goletti, D; Goletti, D; Goletti, D; Goletti, D				Safe, Izabella Picinin; Lacerda, Marcus Vinicius Guimaraes; Printes, Vitoria Silva; Praia Marins, Adriana Ferreira; Rebelo Rabelo, Amanda Lia; Costa, Amanda Araujo; Tavares, Michel Araujo; Jesus, Jaquelane Silva; Souza, Alexandra Brito; Beraldi-Magalhaes, Francisco; Neves, Cynthia Pessoa; Monteiro, Wuelton Marcelo; Sampaio, Vanderson Souza; Amaral, Eduardo P.; Gomes, Renata Spener; Andrade, Bruno B.; Cordeiro-Santos, Marcelo; Goletti, Delia; Goletti, Delia; Goletti, Delia; Goletti, Delia			Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study)	PLOS ONE			English	Article							GLUTATHIONE	Despite the availability of effective antimicrobials, tuberculosis (TB) is still a serious health threat. Mortality is even higher in people living with HIV who are diagnosed with TB. New therapies are needed to shorten the time required to cure TB and decrease fatality rates in this population. N-acetylcysteine (NAC) is a glutathione precursor and has shown recently in experimental setting to presentin vitroandin vivoanti-mycobacterial activity. We test the hypothesis that NAC is safe, well tolerated and secondarily efficacious as adjunctive anti-TB therapy in hospitalized individuals with HIV-associated TB. Patients were enrolled sequentially in a tertiary care center, in the Brazilian Amazon. We performed a randomized, parallel group, single-center, open study trial of two arms, in hospitalized patients over 18 years of age, with microbiologically confirmed pulmonary TB in HIV: one with rifampicin, isoniazid, pyrazinamide and ethambutol at standard doses (Control Group), and a second in which NAC 600 mg bid for eight weeks was added (NAC Group). A total of 21 and 18 patients were enrolled to the Control Group and NAC Group, respectively. Adverse event rates were similar in the two arms. Our findings suggest that in the more critical population of hospitalized patients with HIV-associated TB, the use of NAC was not unsafe, despite the low sample size, and a potential impact on faster negative cultures needs to be further explored in larger studies.	[Safe, Izabella Picinin; Lacerda, Marcus Vinicius Guimaraes; Printes, Vitoria Silva; Praia Marins, Adriana Ferreira; Costa, Amanda Araujo; Jesus, Jaquelane Silva; Neves, Cynthia Pessoa; Monteiro, Wuelton Marcelo; Sampaio, Vanderson Souza; Cordeiro-Santos, Marcelo] Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil; [Safe, Izabella Picinin; Lacerda, Marcus Vinicius Guimaraes; Rebelo Rabelo, Amanda Lia; Souza, Alexandra Brito; Beraldi-Magalhaes, Francisco; Neves, Cynthia Pessoa; Monteiro, Wuelton Marcelo; Sampaio, Vanderson Souza; Gomes, Renata Spener; Cordeiro-Santos, Marcelo] Univ Estado Amazonas, Programa Posgrad Med Trop, Manaus, Amazonas, Brazil; [Lacerda, Marcus Vinicius Guimaraes] Fiocruz MS, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil; [Tavares, Michel Araujo] Univ Fed Amazonas, Manaus, Amazonas, Brazil; [Amaral, Eduardo P.] NIAID, Immunobiol Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA; [Andrade, Bruno B.] Fundacao Oswaldo Cruz FIOCRUZ, Inst Goncalo Moniz, Lab Inflamacao & Biomarcadores, Salvador, BA, Brazil; [Andrade, Bruno B.] MONSTER Initiat, Multinatl Org Network Sponsoring Translat & Epide, Salvador, BA, Brazil; [Andrade, Bruno B.] Laureate Univ, Univ Salvador UNIFACS, Salvador, BA, Brazil; [Andrade, Bruno B.] Fac Tecnol & Ciencias, Curso Med, Salvador, BA, Brazil; [Andrade, Bruno B.] Escola Bahiana Med & Saude Publ EBMSP, Salvador, BA, Brazil; [Andrade, Bruno B.] Univ Cape Town UCT, Inst Infect Dis & Mol Med, Wellcome Ctr Infect Dis Res Africa CIDRI Africa, Cape Town, South Africa; [Andrade, Bruno B.] Vanderbilt Univ, Sch Med, Dept Med, Div Infect Dis, Nashville, TN 37212 USA	Universidade do Estado do Amazonas; Fundacao Oswaldo Cruz; Universidade Federal de Amazonas; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Fundacao Oswaldo Cruz; Universidade Salvador (UNIFACS); Escola Bahiana de Medicina e Saude Publica; University of Cape Town; Vanderbilt University	Lacerda, MVG (corresponding author), Fundacao Med Trop Dr Heitor Vieira Dourado, Manaus, Amazonas, Brazil.; Lacerda, MVG (corresponding author), Univ Estado Amazonas, Programa Posgrad Med Trop, Manaus, Amazonas, Brazil.; Lacerda, MVG (corresponding author), Fiocruz MS, Inst Leonidas & Maria Deane, Manaus, Amazonas, Brazil.	marcuslacerda.br@gmail.com	Printes, Vitória/AAC-7854-2022; Sampaio, Vanderson/M-4337-2015; Pinheiro Amaral, Eduardo/M-2456-2014; Lacerda, Marcus/D-3144-2013	Printes, Vitória/0000-0002-1471-4472; Sampaio, Vanderson/0000-0001-7307-8851; Pinheiro Amaral, Eduardo/0000-0001-5465-8113; Lacerda, Marcus/0000-0003-3374-9985	Brazilian Ministry of Health	Brazilian Ministry of Health	This work was supported by Cooperacao Interfederativa do Amazonas (Interfam), funded by the Brazilian Ministry of Health. MVGL, WMMand BBA are CNPq fellows.	Aguirre S, 2017, MEM I OSWALDO CRUZ, V112, P474, DOI 10.1590/0074-02760160443; Alam K, 2010, J IMMUNOL, V184, P2918, DOI 10.4049/jimmunol.0900439; Amaral EP, 2016, BMC MICROBIOL, V16, DOI 10.1186/s12866-016-0872-7; [Anonymous], 2013, EUR RESP J; Araujo-Mariz C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157725; Baniasadi S, 2010, EUR J GASTROEN HEPAT, V22, P1235, DOI 10.1097/MEG.0b013e32833aa11b; Carvalho BM de Monteiro AJ, 2008, BRAZ J INFECT DIS, DOI [10.1086/591946, DOI 10.1086/591946]; DAIDS, 2017, NAT I ALL INF DIS; de Castro AZ, 2018, REV SOC BRAS MED TRO, V51, P631, DOI 10.1590/0037-8682-0082-2018; De Rosa SC, 2000, EUR J CLIN INVEST, V30, P915, DOI 10.1046/j.1365-2362.2000.00736.x; El Bouazzi O, 2016, PAN AFR MED J, V25, DOI 10.11604/pamj.2016.25.167.10060; Ferreira MD, 2018, J BRAS PNEUMOL, V44, P118, DOI [10.1590/s1806-37562017000000316, 10.1590/S1806-37562017000000316]; Ford N, 2016, J INT AIDS SOC, DOI [10.7448/IAS.19.1.20714, DOI 10.7448/IAS.19.1.2071426765347]; Ford N, 2015, LANCET HIV, V2, pE438, DOI 10.1016/S2352-3018(15)00137-X; Garrido MDS, 2015, REV SOC BRAS MED TRO, V48, P63, DOI 10.1590/0037-8682-0055-2014; Grutzmacher LK, 2012, REV SOC BRAS MED TRO, V45, P95, DOI 10.1590/S0037-86822012000100018; Guerra C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028378; Tse HN, 2013, CHEST, V144, P106, DOI 10.1378/chest.12-2357; Kritski A, 2018, REV SOC BRAS MED TRO, V51, P2, DOI 10.1590/0037-8682-0349-2017; Lee HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103768; Mahakalkar Sunil M, 2017, Perspect Clin Res, V8, P132, DOI 10.4103/2229-3485.210450; Mokhtari V, 2017, CELL J; Morris D, 2013, J INTERF CYTOK RES, V33, P270, DOI 10.1089/jir.2012.0103; Morris D, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/734125; Pastore A, 2003, CLIN CHIM ACTA, V333, P19, DOI 10.1016/S0009-8981(03)00200-6; Teixeira Francine, 2018, Microbiol Insights, V11, p1178636118813367, DOI 10.1177/1178636118813367; Treitinger Aricio, 2004, Braz J Infect Dis, V8, P363, DOI 10.1590/S1413-86702004000500005; WHO, 2017, WHO MOD LIST ESS MED, DOI [10.1016/S1473-3099(14)70780-7, DOI 10.1016/S1473-3099(14)70780-7, 10.1016/S1473-3099(14)70780-7.]; World Health Organization, 2018, GLOBAL TUBERCULOSIS; World Health Organization (WHO), 2017, GUIDELINES TREATMENT, DOI [10.1586/17476348.1.1.85, DOI 10.1586/17476348.1.1.85]	30	10	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2020	15	6							e0235381	10.1371/journal.pone.0235381	http://dx.doi.org/10.1371/journal.pone.0235381			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG0YE	32589648	Green Published, gold			2023-01-03	WOS:000545759800027
J	Abbasi, SH; Aftab, RA; Chua, SS				Abbasi, Saad Hanif; Aftab, Raja Ahsan; Chua, Siew Siang			Risk factors associated with nosocomial infections among end stage renal disease patients undergoing hemodialysis: A systematic review	PLOS ONE			English	Review							C VIRUS-INFECTION; BLOOD-STREAM INFECTIONS; HEPATITIS-C; GLYCEMIC CONTROL; MOLECULAR EPIDEMIOLOGY; RESISTANT ENTEROCOCCI; MAINTENANCE DIALYSIS; VASCULAR ACCESS; KIDNEY-DISEASE; 3 CONTINENTS	Background Profound healthcare challenges confront societies with an increase in prevalence of end-stage renal disease (ESRD), which is one of the leading causes of morbidity and mortality worldwide. Due to several facility and patient related factors, ESRD is significantly associated with increased morbidity and mortality attributed to infections. Aims and objective The aim of this study was to assess systematically the characteristics of patients and risk factors associated with nosocomial infections among ESRD patients undergoing hemodialysis. Methods A systematic literature search was performed to identify eligible studies published during the period from inception to December 2018 pertaining to risk factors associated with nosocomial infections among hemodialysis patients. The relevant studies were generated through a computerized search on five databases (PubMed, EBSCOhost, Google Scholar, ScienceDirect and Scopus) using the Mesh Words: nosocomial infections, hospital acquired infections, healthcare associated infections, end stage renal disease, end stage renal failure, hemodialysis, and risk factors. The complete protocol has been registered under PROSPERO (CRD42019124099). Results Initially, 1411 articles were retrieved. Out of these, 24 were duplicates and hence were removed. Out of 1387 remaining articles, 1337 were removed based on irrelevant titles and/or abstracts. Subsequently, the full texts of 50 articles were reviewed and 41 studies were excluded at this stage due to lack of relevant information. Finally, nine articles were selected for this review. Longer hospital stay, longer duration on hemodialysis, multiple catheter sites, longer catheterization, age group, lower white blood cell count, history of blood transfusion, and diabetes were identified as the major risk factors for nosocomial infections among hemodialysis patients. Conclusion The results of this review indicate an information gap and potential benefits of additional preventive measures to further reduce the risk of infections in hemodialysis population. Moreover, several patient-related and facility-related risk factors were consistently observed in the studies included in this review, which require optimal control measures.	[Abbasi, Saad Hanif; Aftab, Raja Ahsan; Chua, Siew Siang] Taylors Univ, Fac Hlth & Med Sci, Sch Pharm, Subang Jaya, Malaysia	Taylor's University	Aftab, RA (corresponding author), Taylors Univ, Fac Hlth & Med Sci, Sch Pharm, Subang Jaya, Malaysia.	rajaahsan.aftab@taylors.edu.my	Chua, Siew Siang/AAH-9218-2021; Aftab, Raja Ahsan/J-1261-2014	Abbasi, Saad/0000-0001-7677-1985	Centre for Higher Degrees by Research (CHDR) of Taylor's University	Centre for Higher Degrees by Research (CHDR) of Taylor's University	The Centre for Higher Degrees by Research (CHDR) of Taylor's University provided a fellowship to SHA. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alashek WA, 2012, BMC INFECT DIS, V12, DOI 10.1186/1471-2334-12-265; [Anonymous], 2014, LANCET INFECT DIS, V14, P1, DOI 10.1016/S1473-3099(13)70368-2; [Anonymous], 2018, AM J TRANSPLANT S1, V18, P10, DOI DOI 10.1109/JSEN.2018.2870228; [Anonymous], 2007, ECOL B RUSS, V3, P8; [Anonymous], 2006, EUROPEAN DEFENCE AGE, V2, P9; [Anonymous], 2000, REV MUSEU ARQUEOLOGI, V9, P259; [Anonymous], 2017, AM J TRANSPLANT, V17, P1, DOI DOI 10.1093/jisesa/iew097; Ashkani-Esfahani S, 2017, WORLD J GASTROENTERO, V23, P151, DOI 10.3748/wjg.v23.i1.151; Assadian O, 2007, BMC INFECT DIS, V7, DOI 10.1186/1471-2334-7-52; Borzecki Andrzej, 2004, Ann Univ Mariae Curie Sklodowska Med, V59, P351; Brunner F P, 1992, Kidney Int Suppl, V38, pS4; Burdick RA, 2003, KIDNEY INT, V63, P2222, DOI 10.1046/j.1523-1755.2003.00017.x; Carrilho FJ, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-13; Caylan R, 2010, TURK J MED SCI, V40, P835, DOI 10.3906/sag-0908-236; CDC, 2019, CDC APPROACH BSI PRE; Comstock J., 1988, INFECT CONT HOSP EP, V9, P534, DOI 10.1086/645772; D'Agata EMC, 2000, AM J KIDNEY DIS, V35, P1083, DOI 10.1016/S0272-6386(00)70044-8; Dalrymple LS, 2015, CLIN J AM SOC NEPHRO, V10, P2170, DOI 10.2215/CJN.03050315; DENTICO P, 1992, CLIN NEPHROL, V38, P49; Fissell RB, 2004, KIDNEY INT, V65, P2335, DOI 10.1111/j.1523-1755.2004.00649.x; Fram Dayana, 2014, BMC Res Notes, V7, P882, DOI 10.1186/1756-0500-7-882; Fysaraki M, 2013, INT J MED SCI, V10, P1632, DOI 10.7150/ijms.6710; Garcia-Garcia G, 2015, CLIN KIDNEY J, V8, P3, DOI 10.1093/ckj/sfu124; Gilad J, 2005, CLIN MICROBIOL INFEC, V11, P547, DOI 10.1111/j.1469-0691.2005.01168.x; Gnass M, 2014, AM J INFECT CONTROL, V42, P182, DOI 10.1016/j.ajic.2013.08.014; Hajarizadeh B, 2005, AM INFER CON, V33, P93; HARDY NM, 1992, CLIN NEPHROL, V38, P44; Herzog R, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-154; Hinrichsen H, 2002, GUT, V51, P429, DOI 10.1136/gut.51.3.429; Hua G.H.H.W.H., 2005, INT MED HLTH GUIDANC, V14; Hui-juan L., 2013, CHINESE J NOSOCOMIOL, V11, P33; Ishida JH, 2014, SEMIN DIALYSIS, V27, P26, DOI 10.1111/sdi.12168; KAPLOWITZ LG, 1988, INFECT CONT HOSP EP, V9, P534; Karkar A, 2014, SAUDI J KIDNEY DIS T, V25, P496, DOI 10.4103/1319-2442.132150; Kato S, 2008, CLIN J AM SOC NEPHRO, V3, P1526, DOI 10.2215/CJN.00950208; Khan Hassan Ahmed, 2015, Asian Pacific Journal of Tropical Biomedicine, V5, P509, DOI 10.1016/j.apjtb.2015.05.001; Knezevic V, 2018, VOJNOSANIT PREGL, V75, P159, DOI 10.2298/VSP160205332K; Lata Chris, 2016, Can J Kidney Health Dis, V3, P24, DOI 10.1186/s40697-016-0115-8; Lim KB, 2005, J ELECTRON IMAGING, V14, DOI 10.1117/1.2137654; Lioussfi Z, 2014, SAUDI J KIDNEY DIS T, V25, P672, DOI 10.4103/1319-2442.132236; Liyanage T, 2015, LANCET, V385, P1975, DOI 10.1016/S0140-6736(14)61601-9; Lok CE, 2011, KIDNEY INT, V79, P587, DOI 10.1038/ki.2010.471; [毛艳卿 Mao Yanqing], 2012, [中华医院感染学杂志, Chinese Journal of Nosocomiology], V22, P2807; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Morioka T, 2001, DIABETES CARE, V24, P909, DOI 10.2337/diacare.24.5.909; Patel K., 2015, NATL J INTEGRATED RE, V6, P19; Pinheiro M.G., 2013, REV BRAS FARM, V94, P72; Purnamasidhi C.A.W., 2017, INDONESIAN J GASTROE, V17, P155; Qasaimeh GR, 2008, SOUTH MED J, V101, P508, DOI 10.1097/SMJ.0b013e31816c0155; Qian XiaoHui, 2010, Chinese Journal of Nosocomiology, V20, P3910; Ricks J, 2012, DIABETES, V61, P708, DOI 10.2337/db11-1015; Robson M., 2018, SUPPLEMENTARY MAT 5, V5; Saab S, 2001, AM J KIDNEY DIS, V37, P308, DOI 10.1053/ajkd.2001.21294; Sahli F, 2017, J INFECT PUBLIC HEAL, V10, P403, DOI 10.1016/j.jiph.2016.06.008; Samani S., 2015, Comparative Clinical Pathology, V24, P275, DOI 10.1007/s00580-014-1890-1; Sanavi S, 2007, SAUDI J KIDNEY DIS T, V18, P43; Saxena AK, 2004, J AM GERIATR SOC, V52, P242, DOI 10.1111/j.1532-5415.2004.52062.x; Schwanke AA, 2018, REV BRAS ENFERM, V71, P1115, DOI 10.1590/0034-7167-2017-0047; Schweiger A, NOSOCOMIAL INFECTION; Schweiger A, 2015, CONTRIB NEPHROL, V184, P205, DOI 10.1159/000366120; Serefhanoglu K, 2012, J FORMOS MED ASSOC, V111, P325, DOI 10.1016/j.jfma.2011.03.004; Shilling AM, 2008, BEST PRACT RES-CLIN, V22, P519, DOI 10.1016/j.bpa.2008.06.005; Shinzato T, 1999, KIDNEY INT, V55, P700, DOI 10.1046/j.1523-1755.1999.00297.x; Shurraw S, 2011, ARCH INTERN MED, V171, P1920, DOI 10.1001/archinternmed.2011.537; Slinin Y, 2006, KIDNEY INT, V70, P1135, DOI 10.1038/sj.ki.5001714; Spada E, 2008, J MED VIROL, V80, P261, DOI 10.1002/jmv.21088; Stevenson KB, 2002, AM J KIDNEY DIS, V39, P549, DOI 10.1053/ajkd.2002.31405; Su YY, 2013, J MED VIROL, V85, P425, DOI 10.1002/jmv.23486; Suleymanlar G., 1997, TURK J GASTROENTEROL, V8, P21; Tang L., 2016, CHINESE J INFECT CON, V15, P930; Tang LY, 2016, ACTA MEDICA MEDITERR, V32, P617; Taylor G, 2004, AM J INFECT CONTROL, V32, P155, DOI 10.1016/j.ajic.2003.05.007; The Lancet HIV, 2016, LANCET HIV, V3, pe191; Thomas B, 2015, J AM SOC NEPHROL, V26, P2621, DOI 10.1681/ASN.2014101017; Tokars JI, 2001, KIDNEY INT, V60, P1511, DOI 10.1046/j.1523-1755.2001.00955.x; Vidales-Braz BM, 2015, VIROL J, V12, DOI 10.1186/s12985-015-0238-z; Vladutiu DS, 2000, J VIRAL HEPATITIS, V7, P313; von Baum H, 1999, CLIN INFECT DIS, V29, P912, DOI 10.1086/520455; Wang PH, 2016, BMC INFECT DIS, V16, DOI 10.1186/s12879-016-1701-1; Waters D, 2009, TRUSTS TRUSTEES, V15, P12, DOI 10.1093/tandt/ttn116; Wong H., 2016, 24 REPORT MALAYSIAN; Yan-qing M., 2012, CHINESE J NOSOCOMIOL, V13, P42; Yuan- li X., 2009, CHINESE J NOSOCOMIOL, V11, P17; Zuo MH, 2018, INT J INFECT DIS, V68, P115, DOI 10.1016/j.ijid.2018.01.008	84	6	7	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2020	15	6							e0234376	10.1371/journal.pone.0234376	http://dx.doi.org/10.1371/journal.pone.0234376			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC8RX	32569265	Green Published, gold			2023-01-03	WOS:000543547900041
J	Arwert, EN; Milford, EL; Rullan, A; Derzsi, S; Hooper, S; Kato, T; Mansfield, D; Melcher, A; Harrington, KJ; Sahai, E				Arwert, Esther N.; Milford, Emma L.; Rullan, Antonio; Derzsi, Stefanie; Hooper, Steven; Kato, Takuya; Mansfield, David; Melcher, Alan; Harrington, Kevin J.; Sahai, Erik			STING and IRF3 in stromal fibroblasts enable sensing of genomic stress in cancer cells to undermine oncolytic viral therapy	NATURE CELL BIOLOGY			English	Article							INTRACELLULAR DNA; EXPRESSION	Tumour fibroblasts influence oncolytic viral therapy. Arwert et al. show that transcytosis of cancer cells into fibroblasts activates STING and IRF3 to upregulate interferon-beta 1, eliciting a transcriptional program to reduce the effectiveness of oncolytic viral therapy. Cancer-associated fibroblasts (CAFs) perform diverse roles and can modulate therapy responses(1). The inflammatory environment within tumours also influences responses to many therapies, including the efficacy of oncolytic viruses(2); however, the role of CAFs in this context remains unclear. Furthermore, little is known about the cell signalling triggered by heterotypic cancer cell-fibroblast contacts and about what activates fibroblasts to express inflammatory mediators(1,3). Here, we show that direct contact between cancer cells and CAFs triggers the expression of a wide range of inflammatory modulators by fibroblasts. This is initiated following transcytosis of cytoplasm from cancer cells into fibroblasts, leading to the activation of STING and IRF3-mediated expression of interferon-beta 1 and other cytokines. Interferon-beta 1 then drives interferon-stimulated transcriptional programs in both cancer cells and stromal fibroblasts and ultimately undermines the efficacy of oncolytic viruses, both in vitro and in vivo. Further, targeting IRF3 solely in stromal fibroblasts restores oncolytic herpes simplex virus function.	[Arwert, Esther N.; Milford, Emma L.; Rullan, Antonio; Derzsi, Stefanie; Hooper, Steven; Kato, Takuya; Sahai, Erik] Francis Crick Inst, Tumour Cell Biol Lab, London, England; [Arwert, Esther N.; Rullan, Antonio; Mansfield, David; Melcher, Alan; Harrington, Kevin J.] Inst Canc Res, London, England; [Kato, Takuya] Kitasato Univ, Sch Med, Sagamihara, Kanagawa, Japan	Francis Crick Institute; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Kitasato University	Sahai, E (corresponding author), Francis Crick Inst, Tumour Cell Biol Lab, London, England.	Erik.Sahai@crick.ac.uk		Harrington, Kevin/0000-0002-6014-348X; Rullan, Antonio Jose/0000-0002-7365-9629; Arwert, Esther/0000-0001-7475-9704; Sahai, Erik/0000-0002-3932-5086	Francis Crick Institute; Cancer Research UK [A23275, FC001144]; UK Medical Research Council [FC001144]; Wellcome Trust [FC001144, 096084/B/11/Z]; Spanish Society for Medical Oncology (Beca Fundacion SEOM); Biotechnology and Biological Sciences Research Council-GlaxoSmithKline CASE Fellowship; Royal Marsden; Institute of Cancer Research National Institute for Health Research Biomedical Research Centre; Marie-Curie action (HeteroCancerInvaison) [708651]; Japanese Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation	Francis Crick Institute; Cancer Research UK(Cancer Research UK); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome TrustEuropean Commission); Spanish Society for Medical Oncology (Beca Fundacion SEOM); Biotechnology and Biological Sciences Research Council-GlaxoSmithKline CASE Fellowship(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Royal Marsden; Institute of Cancer Research National Institute for Health Research Biomedical Research Centre; Marie-Curie action (HeteroCancerInvaison); Japanese Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation	We thank P. Chakravarty for assistance with Bioinformatics, S. Foo and R. Sadri for technical assistance, Joan Massague for discussion, colleagues in our laboratory for support and advice and A. Blanchard for provision of compounds. E.N.A, E.L.M., A.R., S.D., S.H. and E.S. are supported by the Francis Crick Institute, which receives its core funding from Cancer Research UK (FC001144), the UK Medical Research Council (FC001144) and the Wellcome Trust (FC001144). E.N.A. was additionally supported by the Wellcome Trust (096084/B/11/Z). A.R. was supported by the Spanish Society for Medical Oncology (Beca Fundacion SEOM), E.L.M. was supported by a Biotechnology and Biological Sciences Research Council-GlaxoSmithKline CASE Fellowship. K.J.H., A.M. and D.M. are supported by The Royal Marsden and The Institute of Cancer Research National Institute for Health Research Biomedical Research Centre and a Cancer Research UK grant (A23275). T.K. was funded by Marie-Curie action (HeteroCancerInvaison #708651) and the Japanese Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation.	Ablasser A, 2013, NATURE, V503, P530, DOI 10.1038/nature12640; Andtbacka RHI, 2015, J CLIN ONCOL, V33, P2780, DOI 10.1200/JCO.2014.58.3377; Armstrong SM, 2012, AM J PATHOL, V180, P1308, DOI 10.1016/j.ajpath.2011.12.002; Barros MR, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0802-7; Benci JL, 2019, CELL, V178, P933, DOI 10.1016/j.cell.2019.07.019; Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756; Chan YK, 2016, NAT REV MICROBIOL, V14, P360, DOI 10.1038/nrmicro.2016.45; Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268; Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Givel AM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03348-z; Gluck S, 2017, NAT CELL BIOL, V19, P1061, DOI 10.1038/ncb3586; Hassona Y, 2014, BRIT J CANCER, V111, P1230, DOI 10.1038/bjc.2014.438; Hirata E, 2015, CANCER CELL, V27, P574, DOI 10.1016/j.ccell.2015.03.008; Ilkow CS, 2015, NAT MED, V21, P530, DOI 10.1038/nm.3848; Ishikawa H, 2009, NATURE, V461, P788, DOI 10.1038/nature08476; Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73; Labernadie A, 2017, NAT CELL BIOL, V19, P224, DOI 10.1038/ncb3478; Lawler SE, 2017, JAMA ONCOL, V3, P841, DOI 10.1001/jamaoncol.2016.2064; MacKie RM, 2001, LANCET, V357, P525, DOI 10.1016/S0140-6736(00)04048-4; Marcus A, 2018, IMMUNITY, V49, P754, DOI 10.1016/j.immuni.2018.09.016; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Park D, 2019, NAT MATER, V2, P227; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Pol J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1117740; Puram SV, 2017, CELL, V171, P1611, DOI 10.1016/j.cell.2017.10.044; Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Schadt L, 2019, CELL REP, V29, P1236, DOI 10.1016/j.celrep.2019.09.065; Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Twyman-Saint Victor C, 2015, NATURE, V520, P373, DOI 10.1038/nature14292; Verhelst J, 2013, MICROBIOL MOL BIOL R, V77, P551, DOI 10.1128/MMBR.00024-13; Wongthida P, 2010, CANCER RES, V70, P4539, DOI 10.1158/0008-5472.CAN-09-4658; Xia TL, 2016, CELL REP, V14, P282, DOI 10.1016/j.celrep.2015.12.029; Yang ZZ, 2014, LEUKEMIA, V28, P1872, DOI 10.1038/leu.2014.84; Zhou Y, 2020, IMMUNITY, V52, P357, DOI 10.1016/j.immuni.2020.01.014	38	25	25	3	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	JUL	2020	22	7					758	+		10.1038/s41556-020-0527-7	http://dx.doi.org/10.1038/s41556-020-0527-7		JUN 2020	28	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	MH4LS	32483388	Green Accepted			2023-01-03	WOS:000537044700003
J	Patel, KK				Patel, Kavita K.			For the Love of Quality	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Patel, Kavita K.] Brookings Inst, Washington, DC 20036 USA	Brookings Institution	Patel, KK (corresponding author), Brookings Inst, Washington, DC 20036 USA.; Patel, KK (corresponding author), 1775 Massachusetts Ave NW, Washington, DC 20036 USA.	KPatel@brookings.edu						Agniel D, 2020, ANN INTERN MED, V173, P791, DOI 10.7326/M20-0718; Casalino LP, 2016, HEALTH AFFAIR, V35, P401, DOI 10.1377/hlthaff.2015.1258; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; Gale Arthur H, 2015, Mo Med, V112, P4; Shen AK, 2020, HLTH AFFAIRS BLOG, DOI [10.1377/hblog20200817.901186/fullon, DOI 10.1377/HBLOG20200817.901186/FULL]	5	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 17	2020	173	10					842	843		10.7326/M20-6095	http://dx.doi.org/10.7326/M20-6095			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OU5XD	32956598				2023-01-03	WOS:000591600700025
J	Lam, MY; Haunton, VJ; Panerai, RB; Robinson, TG				Lam, Man Y.; Haunton, Victoria J.; Panerai, Ronney B.; Robinson, Thompson G.			Cerebral hemodynamics in stroke thrombolysis (CHiST) study	PLOS ONE			English	Article							ACUTE ISCHEMIC-STROKE; TRANSCRANIAL DOPPLER ULTRASOUND; BLOOD-PRESSURE; FLOW VELOCITY; AUTOREGULATION; SENSITIVITY; PREDICTORS; DEATH	Despite careful patient selection, successful recanalization in intravenous thrombolysis is only achieved in approximately 50% of cases. Understanding changes in cerebral autoregulation during and following successful recanalization in acute ischemic stroke patients who receive intravenous thrombolysis, may inform the management of common physiological perturbations, including blood pressure, in turn reducing the risk of reperfusion injury. Cerebral blood velocity (Transcranial Doppler), blood pressure (Finometer) and end-tidal carbon dioxide (capnography) were continuously recorded in 11 acute ischemic stroke patients who received intravenous thrombolysis (5 female, mean +/- SD age 68 +/- 12 years) over 4-time points, during and at the following time intervals after intravenous thrombolysis: 23.9 +/- 2.6 hrs, 18.1 +/- 7.0 days and 89.6 +/- 4.2 days. Reductions in blood pressure (p = 0.04) were observed during intravenous thrombolysis. Reductions in heart rate (p<0.005) and critical closing pressure [Affected hemisphere (p = 0.02) and non-affected hemisphere (p<0.005)] were observed post intravenous thrombolysis. End-tidal CO(2)increased during the sub-acute and chronic stages (p = 0.028). Reduction in affected hemisphere phase at low frequency was observed during intravenous thrombolysis (p = 0.021) and at subsequent visits (p = 0.048). No changes were observed in cerebral blood velocity, coherence, gain and Autoregulation Index during the follow-up period. Intravenous thrombolysis in acute ischemic stroke patients induced changes in affected hemisphere phase and other key hemodynamic parameters, but not Autoregulation Index. Further investigation of cerebral autoregulation is warranted in a larger acute ischemic stroke cohort to inform its potential role in individualized management plans.	[Lam, Man Y.; Haunton, Victoria J.; Panerai, Ronney B.; Robinson, Thompson G.] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England; [Haunton, Victoria J.; Panerai, Ronney B.; Robinson, Thompson G.] Univ Leicester, Natl Inst Hlth Res, Leicester Biomed Res Ctr, Leicester, Leics, England	University of Leicester; University of Leicester	Lam, MY (corresponding author), Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England.	ml376@le.ac.uk		Lam, Man Yee/0000-0002-9001-5884; Haunton, Victoria/0000-0001-6078-5469; Robinson, Thompson/0000-0003-2144-2468	EPSRC [EP/K041207/1] Funding Source: UKRI	EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; Adeoye O, 2010, STROKE, V41, P2218, DOI 10.1161/STROKEAHA.110.592675; Ainslie PN, 2008, BRAIN RES, V1230, P115, DOI 10.1016/j.brainres.2008.07.048; Akopov S, 2002, STROKE, V33, P1274, DOI 10.1161/01.STR.0000013740.62456.A0; Anderson CS, 2019, LANCET, V393, P877, DOI 10.1016/S0140-6736(19)30038-8; [Anonymous], 2018, DIABETES CARE S1, V41, pS55; Appiah KO, 2018, CURR OPIN NEUROL, V31, P8, DOI 10.1097/WCO.0000000000000508; Aries MJH, 2010, STROKE, V41, P2697, DOI 10.1161/STROKEAHA.110.594168; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P824, DOI 10.1136/jnnp.53.10.824; Brodie FG, 2009, CLIN SCI, V116, P513, DOI 10.1042/CS20080236; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; BURTON AC, 1951, AM J PHYSIOL, V164, P319, DOI 10.1152/ajplegacy.1951.164.2.319; Chamorro A, 2007, J NEUROL SCI, V252, P29, DOI 10.1016/j.jns.2006.10.001; Claassen JAHR, 2016, J CEREBR BLOOD F MET, V36, P665, DOI 10.1177/0271678X15626425; Demchuk AM, 2000, NEUROL CLIN, V18, P455, DOI 10.1016/S0733-8619(05)70202-4; Eames PJ, 2002, J NEUROL NEUROSUR PS, V72, P467; Eriksson M, 2010, STROKE, V41, P1115, DOI 10.1161/STROKEAHA.109.577106; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; Grune F, 2015, J CEREBR BLOOD F MET, V35, P1470, DOI 10.1038/jcbfm.2015.63; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Hancock SM, 2003, ANESTH ANALG, V96, P847, DOI 10.1213/01.ANE.0000047273.85729.A7; Laffey JG, 2002, NEW ENGL J MED, V347, P43, DOI 10.1056/NEJMra012457; Malhotra K, 2019, J STROKE, V21, P78, DOI 10.5853/jos.2018.02369; Mazighi M, 2009, LANCET NEUROL, V8, P802, DOI 10.1016/S1474-4422(09)70182-6; Minhas JS, 2018, PHYSIOL MEAS, V39, DOI 10.1088/1361-6579/aac76b; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Orlandi G, 2000, ACTA NEUROL SCAND, V102, P317, DOI 10.1034/j.1600-0404.2000.102005317.x; Panerai RB, 2016, PHYSIOL MEAS, V37, P661, DOI 10.1088/0967-3334/37/5/661; Panerai RB, 2003, MED ENG PHYS, V25, P621, DOI 10.1016/S1350-4533(03)00027-4; Patarroyo SXF, 2012, THER ADV CHRONIC DIS, V3, P163, DOI 10.1177/2040622312450183; Petersen NH, 2015, CEREBROVASC DIS, V39, P144, DOI 10.1159/000368595; Puetz V, 2008, INT J STROKE, V3, P230, DOI 10.1111/j.1747-4949.2008.00221.x; Reinhard M, 2012, ACTA NEUROL SCAND, V125, P156, DOI 10.1111/j.1600-0404.2011.01515.x; Reinhard M, 2008, CEREBROVASC DIS, V26, P147, DOI 10.1159/000139662; Robinson TG, 1997, STROKE, V28, P1671, DOI 10.1161/01.STR.28.9.1671; Salinet ASM, 2014, CEREBROVASC DIS EXTR, V4, P186, DOI 10.1159/000366017; Salinet AS, 2018, J CEREB BLOOD FLOW M, V0, p0271678X18794835; Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959; Soares BP, 2010, STROKE, V41, pE34, DOI 10.1161/STROKEAHA.109.568766; Soares BP, 2009, STROKE, V40, pS24, DOI 10.1161/STROKEAHA.108.526814; Thanvi B, 2008, POSTGRAD MED J, V84, P412, DOI 10.1136/pgmj.2007.066118; The Lancet Global Health, 2018, LANCET GLOB HLTH, V6, pE593; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; WALLACE JD, 1981, JAMA-J AM MED ASSOC, V246, P2177, DOI 10.1001/jama.246.19.2177; Weyland A, 2000, J NEUROSURG ANESTH, V12, P210, DOI 10.1097/00008506-200007000-00002; Willie CK, 2011, J NEUROSCI METH, V196, P221, DOI 10.1016/j.jneumeth.2011.01.011; Zhang R, 1998, AM J PHYSIOL-HEART C, V274, pH233, DOI 10.1152/ajpheart.1998.274.1.H233	47	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2020	15	9							e0238620	10.1371/journal.pone.0238620	http://dx.doi.org/10.1371/journal.pone.0238620			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV8NR	32956367	Green Published, gold			2023-01-03	WOS:000574571500053
J	Shah, UA; Mailankody, S				Shah, Urvi A.; Mailankody, Sham			Emerging immunotherapies in multiple myeloma	BMJ-BRITISH MEDICAL JOURNAL			English	Review							CHIMERIC ANTIGEN RECEPTOR; CELL MATURATION ANTIGEN; LENALIDOMIDE PLUS DEXAMETHASONE; NATURAL-KILLER-CELLS; CAR-T-CELLS; OPEN-LABEL; DARATUMUMAB MONOTHERAPY; BISPECIFIC ANTIBODY; AUTOLOGOUS TRANSPLANTATION; MEDIATED CYTOTOXICITY	Despite considerable advances in treatment approaches in the past two decades, multiple myeloma remains an incurable disease. Treatments for myeloma continue to evolve with many emerging immunotherapies. The first immunotherapy used to treat hematologic cancers, including multiple myeloma, was an allogeneic stem cell transplant. In the mid-2000s, immunomodulatory drugs thalidomide, lenalidomide, and subsequently pomalidomide were proven to be effective in multiple myeloma and substantially improved survival. The next wave of immunotherapies for multiple myeloma included the monoclonal antibodies daratumumab and elotuzumab, which were approved by the Food and Drug Administration in 2015. Subsequently, a variety of immunotherapies have been developed for multiple myeloma, including chimeric antigen receptor T cells, bispecific antibodies, antibody drug conjugates, and checkpoint inhibitors. Many of these emerging treatments target the B cell maturation antigen, which is expressed on plasma cells, although several other novel receptors are also being studied. This review summarizes the evidence of these various immunotherapies, their mechanism of action, and data from clinical trials regarding the treatments' safety and efficacy.	[Shah, Urvi A.; Mailankody, Sham] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 530 East 74th St, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shah, UA (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, 530 East 74th St, New York, NY 10021 USA.	shahu@mskcc.org		Shah, Urvi/0000-0001-8419-1091	Memorial Sloan Kettering Core Grant [P30 CA008748]; Parker Institute for Cancer Immunotherapy	Memorial Sloan Kettering Core Grant; Parker Institute for Cancer Immunotherapy	Funding support for this publication was provided by the Memorial Sloan Kettering Core Grant (P30 CA008748) and Parker Institute for Cancer Immunotherapy.	Ali SA, 2016, BLOOD, V128, P1688, DOI 10.1182/blood-2016-04-711903; Attal M, 2017, NEW ENGL J MED, V376, P1311, DOI 10.1056/NEJMoa1611750; Attal M, 2012, NEW ENGL J MED, V366, P1782, DOI 10.1056/NEJMoa1114138; Avery DT, 2003, J CLIN INVEST, V112, P286, DOI 10.1172/JCI200318025; Avigan D, 2018, BLOOD, V131, P2640, DOI 10.1182/blood-2017-11-785873; Badros A, 2017, BLOOD, V130, P1189, DOI 10.1182/blood-2017-03-775122; Bahlis NJ, 2020, LEUKEMIA, V34, P1875, DOI 10.1038/s41375-020-0711-6; Benboubker L, 2014, NEW ENGL J MED, V371, P906, DOI 10.1056/NEJMoa1402551; Benson DM, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-111729; Berdeja JMD, 2020, AM SOC CLIN ONCOL, V38, P8505, DOI DOI 10.1200/JCO.2020.38.15_suppl.8505; BERNABEI L, 2018, BLOOD S, V132, P55600, DOI DOI 10.1182/BLOOD-2019-129405; Bjorklund CC, 2020, LEUKEMIA, V34, P1197, DOI 10.1038/s41375-019-0620-8; Bonifant CL, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.11; Borrello I, 2018, HEMATOL ONCOL, V11, P35, DOI [10.1186/s13045-018-0571-y, DOI 10.1186/S13045-018-0571-Y]; Borrello IM, 2015, BLOOD, V126, DOI 10.1182/blood.V126.23.4238.4238; Brudno JN, 2019, BLOOD REV, V34, P45, DOI 10.1016/j.blre.2018.11.002; Brudno JN, 2018, J CLIN ONCOL, V36, P2267, DOI 10.1200/JCO.2018.77.8084; Buelow B, 2019, BLOOD, V134, DOI 10.1182/blood-2019-123220; Carpenter RO, 2013, CLIN CANCER RES, V19, P2048, DOI 10.1158/1078-0432.CCR-12-2422; CHARI A, 2017, BLOOD S1, V130; Chari A, 2017, BLOOD, V130, P974, DOI 10.1182/blood-2017-05-785246; Chen KH, 2018, LEUKEMIA, V32, P402, DOI 10.1038/leu.2017.302; Cho SF, 2019, BLOOD, V134, DOI 10.1182/blood-2019-128528; Cho SF, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01821; Chu J, 2014, LEUKEMIA, V28, P917, DOI 10.1038/leu.2013.279; Cohen AD, 2020, CLIN CANCER RES, V26, P1541, DOI 10.1158/1078-0432.CCR-19-2111; Cohen AD, 2019, HEMATOL-AM SOC HEMAT, P266, DOI 10.1182/hematology.2019000068; Cohen AD, 2019, J CLIN INVEST, V129, P2210, DOI 10.1172/JCI126397; Cooper D, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126818; Costa LJ, 2019, BLOOD, V134, DOI 10.1182/blood-2019-122895; Costello CL, 2019, BLOOD, V134, DOI 10.1182/blood-2019-129562; COWAN AJ, 2019, BLOOD S, V134, DOI DOI 10.1182/BLOOD-2019-129405; Cowan AJ, 2018, JAMA ONCOL, V4, P1221, DOI 10.1001/jamaoncol.2018.2128; Cranert SA, 2019, BLOOD, V134, DOI 10.1182/blood-2019-131839; Curran KJ, 2012, J GENE MED, V14, P405, DOI 10.1002/jgm.2604; de Larrea CF, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126145; de Zafra C, 2017, BLOOD, V130; de Zafra CLZ, 2019, CLIN CANCER RES, V25, P3921, DOI 10.1158/1078-0432.CCR-18-2752; Depil S, 2020, NAT REV DRUG DISCOV, V19, P185, DOI 10.1038/s41573-019-0051-2; Dhakal B, 2016, BONE MARROW TRANSPL, V51, P492, DOI 10.1038/bmt.2015.325; Dimopoulos MA, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.31; Dimopoulos MA, 2016, NEW ENGL J MED, V375, P1319, DOI 10.1056/NEJMoa1607751; Dimopoulos M, 2007, NEW ENGL J MED, V357, P2123, DOI 10.1056/NEJMoa070594; Dimopoulos M, 2020, LANCET, V396, P186, DOI 10.1016/S0140-6736(20)30734-0; Dimopoulos M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0583-7; Dimopoulos MA, 2018, NEW ENGL J MED, V379, P1811, DOI 10.1056/NEJMoa1805762; Dimopoulos MA, 2018, HAEMATOLOGICA, V103, P2088, DOI 10.3324/haematol.2018.194282; Dimopoulos MA, 2018, CANCER-AM CANCER SOC, V124, P4032, DOI 10.1002/cncr.31680; Dimopoulos MA, 2017, BRIT J HAEMATOL, V178, P896, DOI 10.1111/bjh.14787; Dimopoulos MA, 2017, BRIT J HAEMATOL, V177, P404, DOI 10.1111/bjh.14549; Drent E, 2017, MOL THER, V25, P1946, DOI 10.1016/j.ymthe.2017.04.024; Drent E, 2016, HAEMATOLOGICA, V101, P616, DOI 10.3324/haematol.2015.137620; Durie BGM, 2017, LANCET, V389, P519, DOI 10.1016/S0140-6736(16)31594-X; Elkins K, 2012, MOL CANCER THER, V11, P2222, DOI 10.1158/1535-7163.MCT-12-0087; Facon T, 2019, NEW ENGL J MED, V380, P2104, DOI 10.1056/NEJMoa1817249; Frey Noelle, 2019, Biol Blood Marrow Transplant, V25, pe123, DOI 10.1016/j.bbmt.2018.12.756; Friedberg MW, 2017, JAMA INTERN MED, V177, P1058, DOI 10.1001/jamainternmed.2017.2142; Friedman KM, 2018, HUM GENE THER, V29, P585, DOI 10.1089/hum.2018.001; Ganguly S, 2019, MANY SHADES DISPARIT, P519; Ghosh A, 2018, LEUKEMIA LYMPHOMA, V59, P2056, DOI 10.1080/10428194.2017.1393668; Giralt S, 2020, BIOL BLOOD MARROW TR, V26, P798, DOI 10.1016/j.bbmt.2019.11.018; Gorgun G, 2015, CLIN CANCER RES, V21, P4607, DOI 10.1158/1078-0432.CCR-15-0200; Gogishvili T, 2017, BLOOD, V130, P2838, DOI 10.1182/blood-2017-04-778423; Gormley NJ, 2018, NEW ENGL J MED, V379, P1791, DOI 10.1056/NEJMp1803602; Green DJ, 2018, BLOOD, V132, P1011; Gregory T, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-111419; Greil C, 2019, HAEMATOLOGICA, V104, P370, DOI 10.3324/haematol.2018.200881; Gyawali B, 2017, NAT REV CLIN ONCOL, V14, P1, DOI 10.1038/nrclinonc.2017.27; Hengeveld PJ, 2015, BLOOD CANCER J, V5, DOI 10.1038/bcj.2015.3; Henley SJ, 2020, CANCER-AM CANCER SOC, V126, P2225, DOI 10.1002/cncr.32802; Hipp S, 2017, LEUKEMIA, V31, P2278, DOI 10.1038/leu.2017.219; Holstein SA, 2018, THER ADV HEMATOL, V9, P175, DOI 10.1177/2040620718775629; Holstein SA, 2017, DRUGS, V77, P505, DOI 10.1007/s40265-017-0689-1; Howlader NR, 2020, BREAST CANCER RES TR, V182, P739, DOI 10.1007/s10549-020-05738-8; Jain A, 2020, CLIN LYMPHOMA MYELOM; Jain T, 2020, BLOOD ADV, V4, P3776, DOI 10.1182/bloodadvances.2020002509; Jiang H, 2016, LEUKEMIA, V30, P399, DOI 10.1038/leu.2015.240; Jiang H, 2014, MOL ONCOL, V8, P297, DOI 10.1016/j.molonc.2013.12.001; Jorgensen Nicolai Gronne, 2016, Stem Cell Investig, V3, P95, DOI 10.21037/sci.2016.11.09; Kantarjian H, 2017, NEW ENGL J MED, V376, P836, DOI 10.1056/NEJMoa1609783; Kazandjian D, 2016, SEMIN ONCOL, V43, P676, DOI 10.1053/j.seminoncol.2016.11.004; Klebanoff CA, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.95103; Krishnan AY, 2019, BLOOD, V134, DOI 10.1182/blood-2019-128007; Kumar SK, 2014, LEUKEMIA, V28, P1122, DOI 10.1038/leu.2013.313; Kumar SK, 2008, BLOOD, V111, P2516, DOI 10.1182/blood-2007-10-116129; Lacy MQ, 2009, AM J HEMATOL, V84, P799, DOI 10.1002/ajh.21560; Landgren O, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126378; Lee DW, 2019, BIOL BLOOD MARROW TR, V25, P625, DOI 10.1016/j.bbmt.2018.12.758; Lee DW, 2014, BLOOD, V124, P188, DOI 10.1182/blood-2014-05-552729; Lee DH, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-111576; Lee L, 2018, BLOOD, V131, P746, DOI 10.1182/blood-2017-05-781351; Lee L, 2016, BRIT J HAEMATOL, V174, P911, DOI 10.1111/bjh.14145; Lesokhin AM, 2016, J CLIN ONCOL, V34, P2698, DOI 10.1200/JCO.2015.65.9789; Levine BL, 2017, MOL THER-METH CLIN D, V4, P92, DOI 10.1016/j.omtm.2016.12.006; Liu EL, 2020, NEW ENGL J MED, V382, P545, DOI 10.1056/NEJMoa1910607; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Lokhorst HM, 2015, NEW ENGL J MED, V373, P1207, DOI 10.1056/NEJMoa1506348; LONIAL S, 2019, J CLIN ONCOL S, V37, P55600; Lonial S, 2017, CL LYMPH MYELOM LEUK, V17, pS330, DOI 10.1016/j.clml.2017.07.142; Lonial S, 2020, LANCET ONCOL, V21, P207, DOI 10.1016/S1470-2045(19)30788-0; Lonial S, 2019, BLOOD, V134, DOI 10.1182/blood-2019-124298; Lonial S, 2020, J CLIN ONCOL, V38, P1126, DOI 10.1200/JCO.19.01740; Lonial S, 2016, LANCET, V387, P1551, DOI 10.1016/S0140-6736(15)01120-4; Lonial S, 2015, NEW ENGL J MED, V373, P621, DOI 10.1056/NEJMoa1505654; Ma TT, 2019, ANN HEMATOL, V98, P813, DOI 10.1007/s00277-018-03592-9; Madduri D, 2019, BLOOD, V134, DOI 10.1182/blood-2019-121731; Mailankody S, 2020, J CLIN ONCOL, V38; Mailankody S, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-119717; Mailankody S, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-113548; Maroto-Martin E, 2019, NKG2D BCMA CAR NK CE, DOI [10.1097/01.HS9.0000563120.66927.63, DOI 10.1097/01.HS9.0000563120.66927.63]; Martin T, 2017, BLOOD, V129, P3294, DOI 10.1182/blood-2016-09-740787; Mateos MV, 2018, NEW ENGL J MED, V378, P518, DOI 10.1056/NEJMoa1714678; Mateos MV, 2020, LANCET HAEMATOL, V7, pE370, DOI 10.1016/S2352-3026(20)30070-3; Mateos MV, 2020, LANCET, V395, P132, DOI 10.1016/S0140-6736(19)32956-3; Mateos MV, 2019, LANCET HAEMATOL, V6, pE459, DOI 10.1016/S2352-3026(19)30110-3; Mateos MV, 2019, BRIT J HAEMATOL, V186, pE117, DOI 10.1111/bjh.15946; Mateos MV, 2013, NEW ENGL J MED, V369, P438, DOI 10.1056/NEJMoa1300439; MATHUR R, 2017, BLOOD S1, V130; Maude SL, 2018, NEW ENGL J MED, V378, P439, DOI 10.1056/NEJMoa1709866; McCann KJ, 2015, CANCER IMMUNOL IMMUN, V64, P1021, DOI 10.1007/s00262-015-1703-7; McCarthy PL, 2012, NEW ENGL J MED, V366, P1770, DOI 10.1056/NEJMoa1114083; Mikhael J, 2019, BLOOD, V134, P123, DOI 10.1182/blood-2019-02-895193; Moreau P, 2016, NEW ENGL J MED, V374, P1621, DOI 10.1056/NEJMoa1516282; Moreau P, 2020, ISATUXIMAB PLUS CARF; Moreau P, 2019, LANCET, V394, P29, DOI 10.1016/S0140-6736(19)31240-1; Moreno L, 2019, CLIN CANCER RES, V25, P3176, DOI 10.1158/1078-0432.CCR-18-1597; Munshi NC, 2020, J CLIN ONCOL, V38; Neelapu SS, 2017, NEW ENGL J MED, V377, P2531, DOI 10.1056/NEJMoa1707447; Neelapu SS, 2019, HEMATOL ONCOL, V37, P48, DOI 10.1002/hon.2595; Neelapu SS, 2018, NAT REV CLIN ONCOL, V15, P47, DOI 10.1038/nrclinonc.2017.148; Nooka AK, 2020, J CLIN ONCOL, V38; Nooka AK, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.3267; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; O'Connor BP, 2004, J EXP MED, V199, P91, DOI 10.1084/jem.20031330; Orlowski RZ, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.TPS8055; Overdijk MB, 2016, J IMMUNOL, V197, P807, DOI 10.4049/jimmunol.1501351; Palumbo A, 2014, NEW ENGL J MED, V371, P895, DOI 10.1056/NEJMoa1402888; Palumbo A, 2016, NEW ENGL J MED, V375, P754, DOI 10.1056/NEJMoa1606038; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Park JH, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-117737; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Pianko MJ, 2018, LEUKEMIA LYMPHOMA, V59, P221, DOI 10.1080/10428194.2017.1320713; Pont MJ, 2019, BLOOD, V134, P1585, DOI 10.1182/blood.2019000050; Popat R, 2019, BLOOD, V134, DOI 10.1182/blood-2019-126689; Porter D, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0571-y; RAAB MS, 2018, BLOOD S, V132, P55600, DOI DOI 10.1182/BLOOD-2018-153; Raje N, 2019, NEW ENGL J MED, V380, P1726, DOI 10.1056/NEJMoa1817226; Raje NS, 2019, BLOOD, V134, DOI 10.1182/blood-2019-121805; Rajkumar SV, 2014, LANCET ONCOL, V15, pE538, DOI 10.1016/S1470-2045(14)70442-5; Rajkumar SV, 2018, VALUE COST MYELOMA T, P662, DOI [10.1200/EDBK_200867, DOI 10.1200/EDBK_200867]; Richardson PG, 2019, LANCET ONCOL, V20, P781, DOI 10.1016/S1470-2045(19)30152-4; Richardson PG, 2018, FUTURE ONCOL, V14, P1035, DOI 10.2217/fon-2017-0616; RICHARDSON PG, 2020, J CLIN ONCOL S, V38, P55600; Riegler LL, 2019, THER CLIN RISK MANAG, V15, P323, DOI 10.2147/TCRM.S150524; Ritchie D, 2018, CTS-CLIN TRANSL SCI, V11, P261, DOI 10.1111/cts.12532; Rosenblatt J, 2013, CLIN CANCER RES, V19, P3640, DOI 10.1158/1078-0432.CCR-13-0282; Rosenblatt J, 2011, BLOOD, V117, P393, DOI 10.1182/blood-2010-04-277137; Salwender H, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5600-x; Schuster SJ, 2019, NEW ENGL J MED, V380, P45, DOI 10.1056/NEJMoa1804980; Seckinger A, 2017, CANCER CELL, V31, P396, DOI 10.1016/j.ccell.2017.02.002; Shah N, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-116953; Shah N, 2015, BIOL BLOOD MARROW TR, V21, P1155, DOI 10.1016/j.bbmt.2015.03.002; Shah UA, 2020, BEST PRACT RES CL HA, V33, DOI 10.1016/j.beha.2020.101141; Shah UA, 2019, CANCER J, V25, P208, DOI 10.1097/PPO.0000000000000379; Siegel DS, 2020, LEUKEMIA, V34, P3286, DOI 10.1038/s41375-020-0813-1; Smith EL, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau7746; Sommer C, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-119227; Sonneveld P, 2019, J CLIN ONCOL, V37; Spencer A, 2018, HAEMATOLOGICA, V103, P2079, DOI 10.3324/haematol.2018.194118; Stewart AK, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0178-8; Stewart AK, 2015, NEW ENGL J MED, V372, P142, DOI 10.1056/NEJMoa1411321; Tai YT, 2014, BLOOD, V123, P3128, DOI 10.1182/blood-2013-10-535088; Topp MS, 2020, J CLIN ONCOL, V38, P775, DOI 10.1200/JCO.19.02657; Trudel S, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-019-0196-6; Trudel S, 2018, LANCET ONCOL, V19, P1641, DOI 10.1016/S1470-2045(18)30576-X; Usmani SZ, 2016, BLOOD, V128, P37, DOI 10.1182/blood-2016-03-705210; Usmani SZ, 2019, LANCET HAEMATOL, V6, pE448, DOI 10.1016/S2352-3026(19)30109-7; USMANI SZ, 2020, J CLIN ONCOL S, V38, P55600; Velasquez MP, 2018, BLOOD, V131, P30, DOI 10.1182/blood-2017-06-741058; Voorhees PM, 2020, BLOOD, V136, P936, DOI 10.1182/blood.2020005288; Voorhees PM, 2019, BLOOD, V134; Wang BY, 2019, BLOOD, V134, DOI 10.1182/blood-2019-124953; Wang XL, 2018, CLIN CANCER RES, V24, P106, DOI 10.1158/1078-0432.CCR-17-0344; Weber DM, 2007, NEW ENGL J MED, V357, P2133, DOI 10.1056/NEJMoa070596; Xing LJ, 2019, BLOOD, V134, DOI 10.1182/blood-2019-127135; Xing LJ, 2019, BLOOD, V134, DOI 10.1182/blood-2019-127163; Xu J, 2019, P NATL ACAD SCI USA, V116, P9543, DOI 10.1073/pnas.1819745116; Yan ZL, 2019, LANCET HAEMATOL, V6, pE521, DOI 10.1016/S2352-3026(19)30115-2; Yeku OO, 2016, BIOCHEM SOC T, V44, P412, DOI 10.1042/BST20150291; Zhao WH, 2018, BLOOD, V132, DOI 10.1182/blood-2018-99-110548; Zhao WH, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0681-6; Zonder JA, 2012, BLOOD, V120, P552, DOI 10.1182/blood-2011-06-360552; Zweegman S, 2019, J CLIN ONCOL, V37	193	34	38	1	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 21	2020	370								m3176	10.1136/bmj.m3176	http://dx.doi.org/10.1136/bmj.m3176			19	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY1FV	32958461				2023-01-03	WOS:000576144900002
J	Ogawa, C; Tsuchiya, K; Maeda, K				Ogawa, Chie; Tsuchiya, Ken; Maeda, Kunimi			High serum magnesium levels are associated with favorable prognoses in diabetic hemodialysis patients, retrospective observational study	PLOS ONE			English	Article							DIETARY MAGNESIUM; MORTALITY; HYPOMAGNESEMIA; PREDICTOR; SAMPLE	Background Recent studies have found hypomagnesemia is linked to a heightened risk of cardiovascular events and mortality in hemodialysis (HD) patients; however, the level of serum magnesium (s-Mg) necessary for promoting overall health in these patients and the effects of s-Mg in diabetes HD patients remains to be clarified. Methods HD outpatients (n = 148 under, age <= 70 y) were followed over a 6-y period. They were divided into four groups according to their average s-Mg during the first year (L; low level, H; high level) and if they had DM or not (non-DM). The endpoint was mortality and hospitalization for decline of Activities of Daily Living (death/hospitalization). A receiver operating characteristics curve was used in diagnostic tests to identify s-Mg associated with this endpoint. Kaplan-Meier, log-rank test, and a Cox proportional hazards model were used to evaluate prognoses. Fisher's exact test and multiple regressions examined the causes of the endpoints between the four groups and the factors predictive of s-Mg. Results s-Mg at 2.7 mg/dL was associated with death/hospitalization. The 5-y survival rate was 38.1%, 86.7%, 73.2% and 87.5%, in the DM/Mg(L), DM/Mg(H), non-DM/Mg(L) and non-DM/Mg(H) groups, respectively (P< 0.001). The Cox proportional hazards model showed significantly lower risk in other groups compared with that in the DM/Mg(L) group [DM/Mg(H); hazard ratio (HR): 0.22, 95% confidence interval (CI): 0.05-0.97,P= 0.046, non-DM/Mg(L); HR: 0.32, 95% CI: 0.15-0.68,P= 0.003, non-DM/Mg(H); HR: 0.17, 95% CI: 0.06-0.44,P< 0.001]. The frequency of the different causes of the endpoints for each group was not significant; s-Mg only associated with age in the DM group. Conclusions s-Mg greater than 2.7 mg/dL associated with a favorable prognosis in HD patients with DM, suggesting that s-Mg is a factor independent of diabetes.	[Ogawa, Chie; Maeda, Kunimi] Maeda Inst Renal Res, Kawasaki, Kanagawa, Japan; [Ogawa, Chie; Tsuchiya, Ken; Maeda, Kunimi] Biomarker Soc INC, Kawasaki, Kanagawa, Japan; [Tsuchiya, Ken] Tokyo Womens Med Univ, Dept Blood Purificat, Tokyo, Japan	Tokyo Women's Medical University	Ogawa, C (corresponding author), Maeda Inst Renal Res, Kawasaki, Kanagawa, Japan.; Ogawa, C (corresponding author), Biomarker Soc INC, Kawasaki, Kanagawa, Japan.	tato.ogawa@gmail.com			Maeda Institute of Renal Research	Maeda Institute of Renal Research	We received financial or material support from the Maeda Institute of Renal Research. C. Ogawa and K. Maeda received a salary from the Maeda Institute of Renal Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; Ago R, 2016, HEMODIAL INT, V20, P580, DOI 10.1111/hdi.12437; BRANNAN PG, 1976, J CLIN INVEST, V57, P1412, DOI 10.1172/JCI108410; Del Giorno R, 2018, CLIN EXP NEPHROL, V22, P620, DOI 10.1007/s10157-017-1494-6; Elin RJ, 2010, MAGNESIUM RES, V23, pS194, DOI 10.1684/mrh.2010.0213; Ford ES, 2003, J NUTR, V133, P2879, DOI 10.1093/jn/133.9.2879; Geiger H, 2012, CLIN KIDNEY J, V5, P25, DOI 10.1093/ndtplus/sfr165; Grober U, 2015, NUTRIENTS, V7, P8199, DOI 10.3390/nu7095388; Hruby A, 2014, DIABETES CARE, V37, P419, DOI 10.2337/dc13-1397; Jackson SE, 2018, NUTRIENTS, V10, DOI 10.3390/nu10121901; King DE, 2005, J AM COLL NUTR, V24, P166, DOI 10.1080/07315724.2005.10719461; Kircelli F, 2012, NEPHROL DIAL TRANSPL, V27, P514, DOI 10.1093/ndt/gfr321; Lacson E, 2015, AM J KIDNEY DIS, V66, P1056, DOI 10.1053/j.ajkd.2015.06.014; LAKATOS E, 1988, BIOMETRICS, V44, P229, DOI 10.2307/2531910; Liu JL, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122867; Nakashima A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143656; Pham PCT, 2007, CLIN J AM SOC NEPHRO, V2, P366, DOI 10.2215/CJN.02960906; Sakaguchi Y, 2018, J AM SOC NEPHROL, V29, P991, DOI 10.1681/ASN.2017080849; Sakaguchi Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116273; Sakaguchi Y, 2014, KIDNEY INT, V85, P174, DOI 10.1038/ki.2013.327; Selim GN, 2017, INT J ARTIF ORGANS, V40, P542, DOI 10.5301/ijao.5000611; Shimohata H, 2019, HEMODIAL INT, V23, P369, DOI 10.1111/hdi.12759; SHINZATO T, 1994, NEPHRON, V67, P280, DOI 10.1159/000187980; Turgut F, 2008, INT UROL NEPHROL, V40, P1075, DOI 10.1007/s11255-008-9410-3; Vormann J, 2016, AIMS PUBLIC HEALTH, V3, P329, DOI 10.3934/publichealth.2016.2.329; Wang S, 2002, ARCH PATHOL LAB MED, V126, P947; Weisinger JR, 1998, LANCET, V352, P391, DOI 10.1016/S0140-6736(97)10535-9; Yorifuji M, 2018, HEMODIAL INT, V22, P342, DOI 10.1111/hdi.12625; Yu L, 2017, BLOOD PURIFICAT, V43, P31, DOI 10.1159/000451052	29	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2020	15	9							e0238763	10.1371/journal.pone.0238763	http://dx.doi.org/10.1371/journal.pone.0238763			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU7VY	32941454	gold, Green Published			2023-01-03	WOS:000573848800033
J	Johnson, H; Yorganci, E; Evans, CJ; Barclay, S; Murtagh, FEM; Yi, D; Gao, W; Sampson, EL; Droney, J; Farquhar, M; Koffman, J				Johnson, Halle; Yorganci, Emel; Evans, Catherine J.; Barclay, Stephen; Murtagh, Fliss E. M.; Yi, Deokhee; Gao, Wei; Sampson, Elizabeth L.; Droney, Joanne; Farquhar, Morag; Koffman, Jonathan			Implementation of a complex intervention to improve care for patients whose situations are clinically uncertain in hospital settings: A multi-method study using normalisation process theory	PLOS ONE			English	Article							PALLIATIVE CARE; RECOVERY; BUNDLE; LIFE; END; FEASIBILITY; DESIGN	Purpose To examine the use of Normalisation Process Theory (NPT) to establish if, and in what ways, the AMBER care bundle can be successfully normalised into acute hospital practice, and to identify necessary modifications to optimise its implementation. Method Multi-method process evaluation embedded within a mixed-method feasibility cluster randomised controlled trial in two district general hospitals in England. Data were collected using (i) focus groups with health professionals (HPs), (ii) semi-structured interviews with patients and/or carers, (iii) non-participant observations of multi-disciplinary team meetings and (iv) patient clinical note review. Thematic analysis and descriptive statistics, with interpretation guided by NPT components (coherence; cognitive participation; collective action; reflexive monitoring). Data triangulated across sources. Results Two focus groups (26 HPs), nine non-participant observations, 12 interviews (two patients, 10 relatives), 29 clinical note reviews were conducted. While coherence was evident, with HPs recognising the value of the AMBER care bundle, cognitive participation and collective action presented challenges. Specifically: (1) HPs were unable and unwilling to operationalise the concept of 'risk of dying' intervention eligibility criteria (2) integration relied on a 'champion' to drive participation and ensure sustainability; and (3) differing skills and confidence led to variable engagement with difficult conversations with patients and families about, for example, nearness to end of life. Opportunities for reflexive monitoring were not routinely embedded within the intervention. Reflections on the use of the AMBER care bundle from HPs and patients and families, including recommended modifications became evident through this NPT-driven analysis. Conclusion To be successfully normalised, new clinical practices, such as the AMBER care bundle, must be studied within the wider context in which they operate. NPT can be used to the aid identification of practical strategies to assist in normalisation of complex interventions where the focus of care is on clinical uncertainty in acute hospital settings.	[Johnson, Halle; Yorganci, Emel; Evans, Catherine J.; Yi, Deokhee; Gao, Wei; Koffman, Jonathan] Kings Coll London, Florence Nightingale Fac Nursing Midwifery & Pall, Cicely Saunders Inst, London, England; [Evans, Catherine J.] Sussex Community NHS Fdn Trust, Brighton Gen Hosp, Brighton, E Sussex, England; [Barclay, Stephen] Univ Cambridge, Primary Care Unit, Dept Publ Hlth & Primary Care, Cambridge, England; [Murtagh, Fliss E. M.] Univ Hull, Wolfson Palliat Care Res Ctr, Hull York Med Sch, Kingston Upon Hull, N Humberside, England; [Sampson, Elizabeth L.] UCL, Marie Curie Palliat Care Res Dept, London, England; [Droney, Joanne] Royal Marsden NHS Fdn Trust, London, England; [Farquhar, Morag] Univ East Anglia, Fac Med & Hlth, Sch Hlth Sci, Norwich, Norfolk, England	University of London; King's College London; Brighton and Sussex University Hospitals NHS Trust; Brighton General Hospital; University of Cambridge; University of Hull; University of York - UK; University of London; University College London; Royal Marsden NHS Foundation Trust; University of East Anglia	Johnson, H (corresponding author), Kings Coll London, Florence Nightingale Fac Nursing Midwifery & Pall, Cicely Saunders Inst, London, England.	halle.johnson@kcl.ac.uk	Johnson, Halle/AAE-8109-2022; Murtagh, Fliss E M/C-3216-2009; Yi, Deokhee/F-5913-2015; Solari, Alessandra/AAO-1741-2021; Sampson, Elizabeth L/B-8647-2009	Murtagh, Fliss E M/0000-0003-1289-3726; Yi, Deokhee/0000-0003-4894-1689; Solari, Alessandra/0000-0001-9930-7579; Sampson, Elizabeth L/0000-0001-8929-7362; Koffman, Jonathan/0000-0001-8513-5681; Johnson, Halle/0000-0003-4018-4855; /0000-0001-8298-3415; Evans, Catherine/0000-0003-0034-7402; Droney, Joanne/0000-0002-5709-1703	National Institute for Health Research (NIHR) under Health Technology Assessment Programme [15/10/17]; NIHR Applied Research Collaboration South London; HEE/NIHR Senior Clinical Lectureship [ICA-SCL-2015-01-001]	National Institute for Health Research (NIHR) under Health Technology Assessment Programme(National Institute for Health Research (NIHR)); NIHR Applied Research Collaboration South London; HEE/NIHR Senior Clinical Lectureship	This paper presents independent research funded by the National Institute for Health Research (NIHR) under Health Technology Assessment Programme (15/10/17). This research was supported by the National Institute for Health Research Collaboration for Leadership in Applied Health Research South London (NIHR CLAHRC South London), now recommissioned as NIHR Applied Research Collaboration South London. CJE is funded by a HEE/NIHR Senior Clinical Lectureship (ICA-SCL-2015-01-001). The views and opinions expressed are those of the authors and do not necessarily reflect those of the NHS, the NIHR, MRC, NETSCC, the NIHR or the Department of Health. The funders had no role in study design, data collection and analysis of the study.	Almack K, 2012, BMC PALLIAT CARE, V11, DOI 10.1186/1472-684X-11-15; Anguera MT., 2018, QUAL QUAN, V52, P2757, DOI [10.1007/s11135-018-0700-2, DOI 10.1007/S11135-018-0700-2]; Bailey S-J, 2018, TALKING DYING BEGIN; Bernacki R, 2019, JAMA INTERN MED, V179, P751, DOI 10.1001/jamainternmed.2019.0077; Bernacki R, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009032; Brighton LJ, 2019, PATIENT EDUC COUNS, V102, P494, DOI 10.1016/j.pec.2018.10.013; Brighton LJ, 2018, BMJ SUPPORT PALLIAT, V8, P45, DOI 10.1136/bmjspcare-2017-001447; Bristowe K, 2018, PALLIATIVE MED, V32, P525, DOI 10.1177/0269216317711336; Bristowe K, 2015, PALLIATIVE MED, V29, P797, DOI 10.1177/0269216315578990; Campling N, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022021; Carey I, 2015, BMJ SUPPORT PALLIAT, V5, P12, DOI 10.1136/bmjspcare-2013-000634; Clinical Excellence Commission, 2019, AMBER CAR BUNDL NEW; Cor IS., 2016, IBS SPSS STAT WINDOW; Craig P, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1655; Cummings A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017056; Currow DC, 2013, BMJ SUPPORT PALLIAT, V3, P376, DOI 10.1136/bmjspcare-2013-000608; De Silva MJ, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-267; del Rio C, 2020, JAMA-J AM MED ASSOC, V323, P1339, DOI 10.1001/jama.2020.3072; Department of Health, 2013, MORE CARE LESS PATHW; Etkind SN, 2015, BMJ SUPPORT PALLIAT, V5, P95, DOI 10.1136/bmjspcare-2013-000640; Evans CJ, 2020, BMC MED, V18, DOI 10.1186/s12916-020-01654-2; Fisher M, 2012, CRIT CARE RESUSC, V14, P81; Fowell A, 2006, PALLIATIVE MED, V20, P799, DOI 10.1177/0269216306072554; Fritz Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070977; Gross J, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4135; Guest G, 2006, FIELD METHOD, V18, P59, DOI 10.1177/1525822X05279903; Hawkes CA, 2020, RESUSCITATION, V148, P98, DOI 10.1016/j.resuscitation.2020.01.003; Higginson IJ, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0177-2; Higginson IJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-213; Higginson IJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-111; Johnson MJ, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008592; Kimbell B, 2016, BMJ-BRIT MED J, V354, DOI 10.1136/bmj.i3802; Koffman J, 2019, TRIALS, V20, DOI 10.1186/s13063-019-3612-0; Koffman J, 2020, J ROY SOC MED, V113, P211, DOI 10.1177/0141076820930665; Koffman J, 2020, PALLIATIVE MED, V34, P829, DOI 10.1177/0269216320933750; Koffman J, 2019, HEALTH TECHNOL ASSES, V23, P1, DOI 10.3310/hta23550; Lund S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116629; May C, 2020, SOC SCI MED, V258, DOI 10.1016/j.socscimed.2020.113143; May C, 2014, INT J NURS STUD, V51, P289, DOI 10.1016/j.ijnurstu.2013.06.019; May C, 2009, SOCIOLOGY, V43, P535, DOI 10.1177/0038038509103208; May CR, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0758-1; May CR, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0506-3; Meador KG, 2018, J MED HUMANIT, V39, P93, DOI 10.1007/s10912-017-9480-2; Moore GF, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h1258; Murray E, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-63; National Guideline Centre (UK), 2019, END LIF CAR AD SERV; NHS England, 2015, TRANSF END LIF CAR A; Noble C, 2018, BMC PALLIAT CARE, V17, DOI 10.1186/s12904-018-0353-x; Oishi A, 2014, PALLIATIVE MED, V28, P1081, DOI 10.1177/0269216314531999; Rees S, 2020, J EVAL CLIN PRACT, V26, P56, DOI 10.1111/jep.13167; Richie J., 1994, ANAL QUALITATIVE DAT; Saunders B, 2018, QUAL QUANT, V52, P1893, DOI 10.1007/s11135-017-0574-8; Selman LE, 2017, J PAIN SYMPTOM MANAG, V54, P404, DOI 10.1016/j.jpainsymman.2017.04.007; Sharpe KK, 2018, INT J PALLIAT NURS, V24, P70, DOI 10.12968/ijpn.2018.24.2.70; Simpkin AL, 2016, NEW ENGL J MED, V375, P1713, DOI 10.1056/NEJMp1606402; Sleeman KE, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008242; SLEEMAN KE, 2013, BMJ-BRIT MED J, V347, DOI DOI 10.1136/BMJ.F4779; Spencer L, 2003, OCCASIONAL SERIES; Thompson G, 2015, DIGN CARE MANIT PALL; West AF, 2002, POSTGRAD MED J, V78, P319, DOI 10.1136/pmj.78.920.319; White N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161407; Wynants L, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1328; Yorganci E, 2020, PALLIATIVE MED, V34, P667, DOI 10.1177/0269216320905064	63	0	0	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2020	15	9							e0239181	10.1371/journal.pone.0239181	http://dx.doi.org/10.1371/journal.pone.0239181			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU5BZ	32936837	Green Published, Green Submitted, gold, Green Accepted			2023-01-03	WOS:000573658000005
J	Zhu, FL; Zhang, M; Wang, D; Hong, QQ; Zeng, C; Chen, W				Zhu, Feilong; Zhang, Ming; Wang, Dan; Hong, Qianqin; Zeng, Cheng; Chen, Wei			Yoga compared to non-exercise or physical therapy exercise on pain, disability, and quality of life for patients with chronic low back pain: A systematic review and meta-analysis of randomized controlled trials	PLOS ONE			English	Review							POPULATION; GUIDELINES; MANAGEMENT; VETERANS	Background Chronic low back pain (CLBP) is a common and often disabling musculoskeletal condition. Yoga has been proven to be an effective therapy for chronic low back pain. However, there are still controversies about the effects of yoga at different follow-up periods and compared with other physical therapy exercises. Objective To critically compare the effects of yoga for patients with chronic low back pain on pain, disability, quality of life with non-exercise (e.g. usual care, education), physical therapy exercise. Methods This study was registered in PROSPERO, and the registration number was CRD42020159865. Randomized controlled trials (RCTs) of online databases included PubMed, Web of Science, Cochrane Central Register of Controlled Trials, Embase which evaluated effects of yoga for patients with chronic low back pain on pain, disability, and quality of life were searched from inception time to November 1, 2019. Studies were eligible if they assessed at least one important outcome, namely pain, back-specific disability, quality of life. The Cochrane risk of bias tool was used to assess the methodological quality of included randomized controlled trials. The continuous outcomes were analyzed by calculating the mean difference (MD) or standardized mean difference (SMD) with 95% confidence intervals (CI) according to whether combining outcomes measured on different scales or not. Results A total of 18 randomized controlled trials were included in this meta-analysis. Yoga could significantly reduce pain at 4 to 8 weeks (MD = -0.83, 95% CI = -1.19 to -0.48, p<0.00001, I-2= 0%), 3 months (MD = -0.43, 95% CI = -0.64 to -0.23, p<0.0001, I-2= 0%), 6 to 7 months (MD = -0.56, 95% CI = -1.02 to -0.11, p = 0.02, I-2= 50%), and was not significant in 12 months (MD = -0.52, 95% CI = -1.64 to 0.59, p = 0.36, I-2= 87%) compared with non-exercise. Yoga was better than non-exercise on disability at 4 to 8 weeks (SMD = -0.30, 95% CI = -0.51 to -0.10, p = 0.003, I-2= 0%), 3 months (SMD = -0.31, 95% CI = -0.45 to -0.18, p<0.00001, I-2= 30%), 6 months (SMD = -0.38, 95% CI = -0.53 to -0.23, p<0.00001, I-2= 0%), 12 months (SMD = -0.33, 95% CI = -0.54 to -0.12, p = 0.002, I-2= 9%). There was no significant difference on pain, disability compared with physical therapy exercise group. Furthermore, it suggested that there was a non-significant difference on physical and mental quality of life between yoga and any other interventions. Conclusion This meta-analysis provided evidence from very low to moderate investigating the effectiveness of yoga for chronic low back pain patients at different time points. Yoga might decrease pain from short term to intermediate term and improve functional disability status from short term to long term compared with non-exercise (e.g. usual care, education). Yoga had the same effect on pain and disability as any other exercise or physical therapy. Yoga might not improve the physical and mental quality of life based on the result of a merging.	[Zhu, Feilong; Zhang, Ming; Wang, Dan; Hong, Qianqin; Chen, Wei] Xuzhou Med Univ, Xuzhou Rehabil Hosp, Affiliated Xuzhou Rehabil Hosp, Xuzhou, Jiangsu, Peoples R China; [Zhang, Ming; Chen, Wei] XuZhou Cent Hosp, Dept Rehabil Med, Xuzhou, Jiangsu, Peoples R China; [Zeng, Cheng] First Hosp Putian City, Dept Rehabil Med, Putian, Peoples R China	Xuzhou Medical University	Chen, W (corresponding author), Xuzhou Med Univ, Xuzhou Rehabil Hosp, Affiliated Xuzhou Rehabil Hosp, Xuzhou, Jiangsu, Peoples R China.; Chen, W (corresponding author), XuZhou Cent Hosp, Dept Rehabil Med, Xuzhou, Jiangsu, Peoples R China.	chenwei2339@163.com	Zhu, Feilong/AGE-8012-2022	Zhu, Feilong/0000-0001-5404-8745; Zhang, Ming/0000-0002-3734-446X	Jiangsu Provincial Medical Youth Talent [QNRC2016376]; Xuzhou Medical Young Talents Projects [2016015]	Jiangsu Provincial Medical Youth Talent; Xuzhou Medical Young Talents Projects	This work was supported by both (Jiangsu Provincial Medical Youth Talent) (http://kxjst.jiangsu.gov.cn/) grant number (QNRC2016376) and (Xuzhou Medical Young Talents Projects)(http://www.qianlima.com/hot2591316/) grant number (2016015). Ming Zhang was responsible for this. The sponsors decided to publish this study.	Airaksinen O, 2006, EUR SPINE J, V15, pS192, DOI 10.1007/s00586-006-1072-1; [Anonymous], 2004, SPIEGEL, V10, P56; Bekolay T, 2014, FRONT NEUROINFORM, V7, DOI 10.3389/fninf.2013.00048; Cerrada Christian J, 2014, BMC Res Notes, V7, P227, DOI 10.1186/1756-0500-7-227; Cheung WK, 2020, ULTRASOUND MED BIOL, V46, P1344, DOI 10.1016/j.ultrasmedbio.2020.02.004; Colgrove YM, 2019, INT J YOGA, V12, P252, DOI 10.4103/ijoy.IJOY_78_18; Cox Helen, 2010, Complement Ther Clin Pract, V16, P187, DOI 10.1016/j.ctcp.2010.05.007; Cramer H, 2013, CLIN J PAIN, V29, P450, DOI 10.1097/AJP.0b013e31825e1492; Cumpston M, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000142; Daubenmier J, 2012, BMC COMPLEM ALTERN M, V12, pO54, DOI DOI 10.1186/1472-6882-12-S1-O54; Foltz V, 2005, JOINT BONE SPINE, V72, P571, DOI 10.1016/j.jbspin.2005.03.018; Gati T, 2018, INT J BIOMETEOROL, V62, P897, DOI 10.1007/s00484-017-1491-1; Groessl EJ, 2017, AM J PREV MED, V53, P599, DOI 10.1016/j.amepre.2017.05.019; Groessl EJ, 2016, CONTEMP CLIN TRIALS, V48, P110, DOI 10.1016/j.cct.2016.04.006; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Hayden JA, 2020, BRIT J SPORT MED, V54, P1277, DOI 10.1136/bjsports-2019-101205; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Holtzman S, 2013, PAIN RES MANAG, V18, P267, DOI 10.1155/2013/105919; Jacobs BP, 2004, ALTERN THER HEALTH M, V10, P80; Johnsen LG, 2013, BMC MUSCULOSKEL DIS, V14, DOI 10.1186/1471-2474-14-148; Kuvacic G, 2018, COMPLEMENT THER CLIN, V31, P262, DOI 10.1016/j.ctcp.2018.03.008; Mansourian M, 2013, INT J PREVENTIVE MED, V4, P279; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Monticone M, 2012, EUR SPINE J, V21, P122, DOI 10.1007/s00586-011-1959-3; Morlion B, 2013, NAT REV NEUROL, V9, P462, DOI 10.1038/nrneurol.2013.130; Neyaz O, 2019, J ALTERN COMPLEM MED, V25, P938, DOI 10.1089/acm.2019.0140; O'Keeffe M, 2020, BRIT J SPORT MED, V54, P782, DOI 10.1136/bjsports-2019-100780; Papadopoulos D, 2020, PAIN MED, V21, P2713, DOI 10.1093/pm/pnaa025; Qin JW, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000017099; Saper RB, 2017, ANN INTERN MED, V167, P85, DOI 10.7326/M16-2579; Saper RB, 2009, ALTERN THER HEALTH M, V15, P18; Sherman HK, 2011, JAMA-J AM MED ASSOC, V307, P648, DOI [10.1001/archinternmed.2011.524, DOI 10.1001/ARCHINTERNMED.2011.524CN-00871625]; Sherman KJ, 2005, ANN INTERN MED, V143, P849, DOI 10.7326/0003-4819-143-12-200512200-00003; Sorosky S, 2008, CURR REV MUSCULOSKE, V1, P39, DOI 10.1007/s12178-007-9004-1; Tekur P, 2012, COMPLEMENT THER MED, V20, P107, DOI 10.1016/j.ctim.2011.12.009; Tekur P, 2008, J ALTERN COMPLEM MED, V14, P637, DOI 10.1089/acm.2007.0815; Teut M, 2016, J PAIN, V17, P796, DOI 10.1016/j.jpain.2016.03.003; Tilbrook HE, 2011, ANN INTERN MED, V155, P569, DOI 10.7326/0003-4819-155-9-201111010-00003; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; Wattamwar RB, 2013, INDIAN J OCCUPATIONA, V45, P13; Whitehead PB, 2018, CLIN NURSE SPEC, V32, P294, DOI 10.1097/NUR.0000000000000410; Wieland LS, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010671.pub2; Williams KA, 2005, PAIN, V115, P107, DOI 10.1016/j.pain.2005.02.016; Williams K, 2009, SPINE, V34, P2066, DOI 10.1097/BRS.0b013e3181b315cc; 2014, REV POETICA MEDIEVAL, V28, P119	45	13	13	7	17	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2020	15	9							e0238544	10.1371/journal.pone.0238544	http://dx.doi.org/10.1371/journal.pone.0238544			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN6BT	32870936	Green Published, gold			2023-01-03	WOS:000568872300031
J	Riberholt, CG; Wagner, V; Lindschou, J; Gluud, C; Mehlsen, J; Moller, K				Riberholt, Christian Gunge; Wagner, Vibeke; Lindschou, Jane; Gluud, Christian; Mehlsen, Jesper; Moller, Kirsten			Early head-up mobilisation versus standard care for patients with severe acquired brain injury: A systematic review with meta-analysis and Trial Sequential Analysis	PLOS ONE			English	Review							EARLY REHABILITATION TRIAL; ACUTE ISCHEMIC-STROKE; CEREBRAL-BLOOD-FLOW; QUALITY-OF-LIFE; DELAYED REHABILITATION; MONITORING BOUNDARIES; TILT-TABLE; GUIDELINES; SAFETY; AVERT	Background There is increasing focus on earlier rehabilitation in patients with traumatic or hypoxic brain injury or stroke. This systematic review evaluates the benefits and harms of early head-up mobilisation versus standard care in patients with severe acquired brain injury. Methods We searched Medline, CENTRAL, EMBASE, four other databases and 13 selected clinical trial registries until April 2020. Eligible randomised clinical trials compared early head-up mobilisation versus standard care in patients with severe acquired brain injury and were analysed conducting random- and fixed-effects meta-analyses and Trial Sequential Analysis (TSA). Certainty of evidence was assessed by GRADE. Main results We identified four randomised clinical trials (total n = 385 patients) with severe acquired brain injury (stroke 86% and traumatic brain injury 13%). Two trials were at low risk and two at high risk of bias. We found no evidence of a difference between early mobilisation vs. standard care on mortality or poor functional outcome at end of the intervention (relative risk (RR) 1.19, 95% CI 0.93 to 1.53; I(2)0%; very low certainty) or at maximal follow-up (RR 1.03, 95% CI 0.89 to 1.21; I(2)0%; very low certainty). We found evidence against an effect on quality of life at maximal follow-up. The proportion of patients with at least one serious adverse event did not differ at end of intervention or at maximal follow-up. For most comparisons, TSA suggested that further trials are needed. Conclusions We found no evidence of a difference between early mobilisation versus standard care for patients with severe acquired brain injury. Early mobilisation appeared not to exert a major impact on quality of life. This systematic review highlights the insufficient evidence in patients with severe brain injury, and no firm conclusions can be drawn from these data.	[Riberholt, Christian Gunge; Wagner, Vibeke] Copenhagen Univ Hosp, Rigshosp, Dept Neurorehabil, Traumat Brain Injury, Hvidovre, Denmark; [Riberholt, Christian Gunge; Moller, Kirsten] Univ Copenhagen, Fac Healthcare Sci, Dept Clin Med, Copenhagen, Denmark; [Lindschou, Jane; Gluud, Christian] Copenhagen Univ Hosp, Rigshosp, Ctr Clin Intervent Res, Copenhagen Trial Unit, Copenhagen, Denmark; [Mehlsen, Jesper] Copenhagen Univ Hosp, Rigshosp, Juliane Marie Ctr, Surg Pathophysiol Unit, Copenhagen, Denmark; [Moller, Kirsten] Univ Copenhagen, Rigshosp, Dept Neuroanaesthesiol, Copenhagen, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Riberholt, CG (corresponding author), Copenhagen Univ Hosp, Rigshosp, Dept Neurorehabil, Traumat Brain Injury, Hvidovre, Denmark.; Riberholt, CG (corresponding author), Univ Copenhagen, Fac Healthcare Sci, Dept Clin Med, Copenhagen, Denmark.	christian.riberholt@regionh.dk	Riberholt, Christian Gunge/AAC-9574-2019; Gluud, Christian/AAY-1027-2021; Wagner, Vibeke/GPX-1938-2022; Mehlsen, Jesper/AAA-5848-2022; Gluud, Christian/HGB-3191-2022; Moller, Kirsten/A-4751-2009	Riberholt, Christian Gunge/0000-0002-6170-1869; Gluud, Christian/0000-0002-8861-0799; Wagner, Vibeke/0000-0002-1712-1648; Moller, Kirsten/0000-0003-3058-1072	Danish Victims Fund [16-910-00043]; Danish Physical Therapists' Association [15242]	Danish Victims Fund; Danish Physical Therapists' Association	CGR received grants from the The Danish Victims Fund (grant 16-910-00043; http://www.offerfonden.dk/da/GlobalMenu/english.aspx) and The Danish Physical Therapists' Association (15242; https://www.fysio.dk/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altman DG, 2006, BRIT MED J, V332, P1080, DOI 10.1136/bmj.332.7549.1080; Andelic N, 2012, J NEUROTRAUM, V29, P66, DOI 10.1089/neu.2011.1811; Anderson CS, 2017, NEW ENGL J MED, V376, P2437, DOI 10.1056/NEJMoa1615715; [Anonymous], 1997, Int Dig Health Legis, V48, P231; [Anonymous], SAS STAT SOFTW; Bernhardt J, 2008, STROKE, V39, P390, DOI 10.1161/STROKEAHA.107.492363; Bernhardt J, 2016, NEUROLOGY, V86, P2138, DOI 10.1212/WNL.0000000000002459; Bernhardt J, 2015, LANCET, V386, P46, DOI 10.1016/S0140-6736(15)60690-0; Brok J, 2009, INT J EPIDEMIOL, V38, P287, DOI 10.1093/ije/dyn188; Brok J, 2008, J CLIN EPIDEMIOL, V61, P763, DOI 10.1016/j.jclinepi.2007.10.007; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Carney N, 2017, NEUROSURGERY, V80, P6, DOI 10.1227/NEU.0000000000001432; Castellini G, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-018-0770-1; CHALMERS TC, 1983, NEW ENGL J MED, V309, P1358, DOI 10.1056/NEJM198312013092204; Chang AT, 2004, ARCH PHYS MED REHAB, V85, P1972, DOI 10.1016/j.apmr.2004.03.024; Chippala P, 2016, CLIN REHABIL, V30, P669, DOI 10.1177/0269215515596054; Covidence, COV SYST REV SOFTW; Cumming TB, 2019, NEUROLOGY, V93, pE717, DOI 10.1212/WNL.0000000000007937; Cumming TB, 2011, STROKE, V42, P153, DOI 10.1161/STROKEAHA.110.594598; Diserens K, 2012, CLIN REHABIL, V26, P451, DOI 10.1177/0269215511425541; Endres Matthias, 2009, Handb Clin Neurol, V92, P31, DOI 10.1016/S0072-9752(08)01902-7; Fang YN, 2003, CLIN REHABIL, V17, P608, DOI 10.1191/0269215503cr655oa; Fink E, 2018, CRIT CARE MED, V46, P394, DOI 10.1097/01.ccm.0000528828.59765.02; Frazzitta G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158030; Gartlehner G, 2019, J CLIN EPIDEMIOL, V106, P50, DOI 10.1016/j.jclinepi.2018.10.009; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V127, P15, DOI 10.1016/B978-0-444-52892-6.00002-7; Hawthorne G, 1999, QUAL LIFE RES, V8, P209, DOI 10.1023/A:1008815005736; Higgins D, 2011, FAMILY MATTERS, P5; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Ioannidis JPA, 2009, ARCH INTERN MED, V169, P1737, DOI 10.1001/archinternmed.2009.313; Jakobsen JC, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-120; JENNETT B, 1976, LANCET, V1, P1031; Karic T, 2017, J NEUROSURG, V126, P518, DOI 10.3171/2015.12.JNS151744; Konigs M, 2018, ARCH PHYS MED REHAB, V99, P1149, DOI 10.1016/j.apmr.2018.01.013; Kotecha D, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1855; Krewer C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143180; Langhorne Peter, 2018, Cochrane Database Syst Rev, V10, pCD006187, DOI 10.1002/14651858.CD006187.pub3; Logan Angie, 2018, Pilot Feasibility Stud, V4, P66, DOI 10.1186/s40814-018-0254-z; Luft AR, 2016, STROKE, V47, P291, DOI 10.1161/STROKEAHA.115.010483; Luther MS, 2008, CLIN REHABIL, V22, P1034, DOI 10.1177/0269215508092821; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Momosaki R, 2016, CEREBROVASC DIS, V42, P41, DOI 10.1159/000444720; Morreale M, 2016, EUR J PHYS REHAB MED, V52, P81; Munoz-Venturelli P, 2015, TRIALS, V16, DOI 10.1186/s13063-015-0767-1; Nakase-Richardson R, 2011, J NEUROL NEUROSUR PS, V82, P494, DOI 10.1136/jnnp.2010.222489; National Institute for Health and Care Excellence (NICE) Guidelines, 2019, STROK TRANS ISCH ATT; NICE, 2014, HEAD INJ TRIAG ASS I; Nordic Cochrane Centre, REV MAN 5 REVMAN 5; Norman GR, 2003, MED CARE, V41, P582, DOI 10.1097/00005650-200305000-00004; Olavarria VV, 2014, CEREBROVASC DIS, V37, P401, DOI 10.1159/000362533; Oxman AD, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e2022; Pogue JM, 1997, CONTROL CLIN TRIALS, V18, P580, DOI 10.1016/S0197-2456(97)00051-2; RAGLAND DR, 1992, EPIDEMIOLOGY, V3, P434, DOI 10.1097/00001648-199209000-00009; Riberholt CG, 2020, NEUROREHABILITATION; Riberholt C, 2018, BRAIN INJURY, V32, P252, DOI 10.1080/02699052.2017.1408144; Riberholt CG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154831; Poletto SR, 2015, CEREBROVASC DIS EXTR, V5, P31, DOI 10.1159/000381417; Rucker G, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-79; Savovic J, 2012, ANN INTERN MED, V157, P429, DOI 10.7326/0003-4819-157-6-201209180-00537; Scottish Intercollegiate Guideline Network, 2010, MAN PAT STROK 591 RE; Shigemori M, 2012, NEUROL MED-CHIR, V52, P1; Storebo OJ, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012069.pub2; Thorlund K, USER MANUAL TRIAL SE; Thorlund K., 2011, USER MANUAL TRIAL SE; Thorlund K, 2009, INT J EPIDEMIOL, V38, P276, DOI 10.1093/ije/dyn179; Tipping CJ, 2017, INTENS CARE MED, V43, P171, DOI 10.1007/s00134-016-4612-0; Tong YN, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00113; Turner RM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059202; Turner-Stokes L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub3; Wetterslev J, 2008, J CLIN EPIDEMIOL, V61, P64, DOI 10.1016/j.jclinepi.2007.03.013; Wetterslev J, 2017, BMC MED RES METHODOL, V17, DOI 10.1186/s12874-017-0315-7; Wetterslev J, 2009, BMC MED RES METHODOL, V9, DOI 10.1186/1471-2288-9-86; WHO, 2006, NEUR DIS PUBL HLTH C; Xu Ben-Hua, 2004, Beijing Da Xue Xue Bao Yi Xue Ban, V36, P75; Yang F, 2018, BASIC CLIN PHARMACOL, V123, P23	77	3	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2020	15	8							e0237136	10.1371/journal.pone.0237136	http://dx.doi.org/10.1371/journal.pone.0237136			33	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE5VG	32790771	gold, Green Published			2023-01-03	WOS:000562668300051
J	Yoo, KH; Cho, J; Han, B; Kim, SH; Shin, DY; Hong, J; Kim, H; Kim, HJ; Zang, DY; Yoon, SS; Jin, JY; Lee, JH; Hong, DS; Park, SK				Yoo, Kwai Han; Cho, Jinhyun; Han, Boram; Kim, Se Hyung; Shin, Dong-Yeop; Hong, Junshik; Kim, Hawk; Kim, Hyo Jung; Zang, Dae young; Yoon, Sung-Soo; Jin, Jong-Youl; Lee, Jae Hoon; Hong, Dae-Sik; Park, Seong Kyu			Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults	PLOS ONE			English	Article							INTERNATIONAL WORKING GROUP; MYELODYSPLASTIC SYNDROME; RESPONSE CRITERIA; PATIENT; RECOMMENDATIONS; MULTICENTER; THERAPY; TRIAL; AML	Purpose We evaluated the outcomes of decitabine as first-line treatment in older patients with acute myeloid leukemia (AML) and investigated the predictors, including a baseline mini nutritional assessment short form (MNA-SF) score, of response and survival. Patients and methods Between 2010 and 2018, 96 AML patients aged 65 and above who received decitabine treatment at 6 centers in Korea were retrospectively evaluated. Response rates, hematologic improvements (HI), progression-free survival (PFS), and overall survival (OS) were analyzed. Results The median age at diagnosis was 73.9 years, and the median number of decitabine treatments administered to the patients was 4 (range, 1-29). Of 85 patients, 15 patients (17.6%) achieved complete remission (CR) or CR with incomplete blood count recovery. Twelve patients (14.1%) showed partial remission (PR), and 18 (21.2%) demonstrated HI without an objective response. The median PFS and OS were 7.0 (95% confidence interval [CI], 4.9-9.0) and 10.6 (95% CI, 7.7-13.5%) months, respectively. In multivariate analyses, MNA-SF score >= 8 and the absence of peripheral blood (PB) blasts were significant predictors for improved PFS and OS. Conclusions For older patients with newly diagnosed AML, a high MNA-SF score and the absence of PB blasts were independently associated with improved survival.	[Yoo, Kwai Han; Kim, Hawk; Lee, Jae Hoon] Gachon Univ, Coll Med, Gil Med Ctr, Div Hematol,Dept Internal Med, Incheon, South Korea; [Cho, Jinhyun] Inha Univ, Inha Univ Hosp, Sch Med, Div Hematol Oncol,Dept Internal Med, Incheon, South Korea; [Han, Boram; Kim, Hyo Jung; Zang, Dae young] Hallym Univ, Coll Med, Sacred Heart Hosp, Div Hematol Oncol,Dept Internal Med, Anyang, South Korea; [Kim, Se Hyung; Hong, Dae-Sik; Park, Seong Kyu] Soonchunhyang Univ, Bucheon Hosp, Dept Internal Med, Div Hematooncol, Bucheon, South Korea; [Shin, Dong-Yeop; Hong, Junshik; Yoon, Sung-Soo] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea; [Jin, Jong-Youl] Bucheon St Marys Hosp, Dept Internal Med, Div Hematooncol, Bucheon, South Korea	Gachon University; Inha University; Inha University Hospital; Hallym University; Soonchunhyang University; Seoul National University (SNU); Seoul National University Hospital	Park, SK (corresponding author), Soonchunhyang Univ, Bucheon Hosp, Dept Internal Med, Div Hematooncol, Bucheon, South Korea.; Hong, J (corresponding author), Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Internal Med, Seoul, South Korea.	alertjun@hanmail.net; skpark@schmc.ac.kr			Gachon University [GCU-2018-5260]; Korean Society of Hematology (KSH), Gyeonggi/Incheon Branch	Gachon University; Korean Society of Hematology (KSH), Gyeonggi/Incheon Branch	KHY was supported by the Gachon University Research Grants in 2018 (GCU-2018-5260). Gachon University (https://www.gachon.ac.kr) The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; This research was conducted under the auspices of the Korean Society of Hematology (KSH), Gyeonggi/Incheon Branch. We thank all centers that participated in this study.	Arber DA, 2016, BLOOD, V127, P2391, DOI 10.1182/blood-2016-03-643544; Bhatt VR, 2018, LEUKEMIA LYMPHOMA, V59, P29, DOI 10.1080/10428194.2017.1323275; Cheson BD, 2003, J CLIN ONCOL, V21, P4642, DOI 10.1200/JCO.2003.04.036; Cheson BD, 2006, BLOOD, V108, P419, DOI 10.1182/blood-2005-10-4149; CHOI EJ, 2018, BLOOD S, V132, DOI DOI 10.1182/BLOOD-2018-99-116102; DiNardo CD, 2016, AM J HEMATOL, V91, P227, DOI 10.1002/ajh.24252; Dohner H, 2017, BLOOD, V129, P424, DOI 10.1182/blood-2016-08-733196; Fili C, 2019, LEUKEMIA RES, V76, P33, DOI 10.1016/j.leukres.2018.11.015; Kaiser MJ, 2009, J NUTR HEALTH AGING, V13, P782, DOI 10.1007/s12603-009-0214-7; Kantarjian H, 2006, CANCER-AM CANCER SOC, V106, P1794, DOI 10.1002/cncr.21792; Kantarjian HM, 2007, CANCER-AM CANCER SOC, V109, P265, DOI 10.1002/cncr.22376; Kantarjian HM, 2012, J CLIN ONCOL, V30, P2670, DOI 10.1200/JCO.2011.38.9429; Krug U, 2017, LEUKEMIA RES, V60, P1, DOI 10.1016/j.leukres.2017.05.020; Loh KP, 2018, CANCERS, V10; Lubbert M, 2012, HAEMATOL-HEMATOL J, V97, P393, DOI 10.3324/haematol.2011.048231; Maakaron J, 2018, BLOOD S, V132, P5190; Mayer J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-69; Lozoya RM, 2017, PEERJ, V5, DOI 10.7717/peerj.3345; Nazha A, 2014, LEUKEMIA LYMPHOMA, V55, P979, DOI 10.3109/10428194.2013.828348; Oh SB, 2017, ANN HEMATOL, V96, P1801, DOI 10.1007/s00277-017-3104-9; Ossenkoppele G, 2015, BLOOD, V125, P767, DOI 10.1182/blood-2014-08-551499; Park H, 2017, YONSEI MED J, V58, P35, DOI 10.3349/ymj.2017.58.1.35; Rubenstein LZ, 2001, J GERONTOL A-BIOL, V56, pM366, DOI 10.1093/gerona/56.6.M366; Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254; Tallman MS, 2019, J NATL COMPR CANC NE, V17, P721, DOI 10.6004/jnccn.2019.0028; Walter RB, 2015, LEUKEMIA, V29, P770, DOI 10.1038/leu.2014.216; Williams WJ, 2016, WILLIAMS HEMATOLOGY; Yi Jun Ho, 2018, Oncotarget, V9, P6607, DOI 10.18632/oncotarget.23823	28	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 6	2020	15	8							e0235503	10.1371/journal.pone.0235503	http://dx.doi.org/10.1371/journal.pone.0235503			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC2EP	32760083	gold, Green Published			2023-01-03	WOS:000561027200050
J	Desgorces, FD; Hourcade, JC; Dubois, R; Toussaint, JF; Noirez, P				Desgorces, Francois-Denis; Hourcade, Jean-Christophe; Dubois, Romain; Toussaint, Jean-Francois; Noirez, Philippe			Training load quantification of high intensity exercises: Discrepancies between original and alternative methods	PLOS ONE			English	Article							PERFORMANCE; PERCEPTION; RECOVERY; QUANTIFY	The purpose of this study was to quantify training loads (TL) of high intensity sessions through original methods (TRIMP; session-RPE; Work-Endurance-Recovery) and their updated alternatives (TRIMPcumulative; RPEalone; New-WER). Ten endurance athletes were requested to perform five sessions until exhaustion. Session 1 composed by a 800m maximal performance and four intermittent sessions performed at the 800m velocity, three sessions with 400m of interval length and work:recovery ratios of 2:1, 1:1 and 1:2 and one with 200m intervals and 1:1. Total TL were quantified from the sessions' beginning to the cool-down period and an intermediate TL (TL800) was calculated when 800m running was accumulated within the sessions. At the end of the sessions high and similar RPE were reported (effect size, eta(2)= 0.12), while, at the intermediate 800m distance, the higher interval distances and work:recovery ratios the higher the RPE (eta(2)= 0.88). Our results show marked differences in sessions' total TL between original (e.g., lowest TL for the 800m and highest for the 200m-1:1 sessions) and alternative methods (RPE(alone)and New-WER; similar TL for each session). Differences appear in TL(800)notably between TRIMP and other methods which are negatively correlated. All TL report light to moderate correlations between original methods and their alternatives, original methods are strongly correlated together, as observed for alternative methods. Differences in TL quantification between original and alternative methods underline that they are not interchangeable. Because of high exercise volume influence, original methods markedly enhance TL of sessions with higher exercise volumes although these presented the easiest interval distances and work-recovery ratios. Alternative methods based on exhaustion level (New-WER) and exertion (RPEalone) provided a new and promising point of view of TL quantification where exhaustion determines the highest TL whatever the exercise. This remains to be tested with more extended populations submitted to wider ranges of exercises.	[Desgorces, Francois-Denis; Hourcade, Jean-Christophe; Toussaint, Jean-Francois; Noirez, Philippe] Inst Natl Sport Expertise Performance, Inst Rech BioMed Epidemiol Sport, Paris, France; [Desgorces, Francois-Denis; Toussaint, Jean-Francois; Noirez, Philippe] Univ Paris, Equipe Accueil, Paris, France; [Hourcade, Jean-Christophe] Acad Conseil Preparat Athlet ACPA Performance, Gradignan, France; [Dubois, Romain] Univ Pau & Pays Adour, Equipe Accueil, Mouvement, Equilibre,Performance,Sante, Tarbes, France; [Toussaint, Jean-Francois] Hop Hotel Dieu, AP HP, Ctr Invest Med Sport, Paris, France	UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Universite de Pau et des Pays de l'Adour; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	Desgorces, FD (corresponding author), Inst Natl Sport Expertise Performance, Inst Rech BioMed Epidemiol Sport, Paris, France.; Desgorces, FD (corresponding author), Univ Paris, Equipe Accueil, Paris, France.	francois.desgorces@unilim.fr		DESGORCES, FRANCOIS/0000-0003-2598-8599; Dubois, Romain/0000-0002-0051-244X				Achten J, 2003, SPORTS MED, V33, P517, DOI 10.2165/00007256-200333070-00004; Agostinho MF, 2015, J STRENGTH COND RES, V29, P1570, DOI 10.1519/JSC.0000000000000777; Banister EW, 1975, AUST J SPORTS MED, V7, P57; Ben Belgith A, 2012, SCI SPORT, V27, P169, DOI 10.1016/j.scispo.2011.06.012; Bourdon PC, 2017, INT J SPORT PHYSIOL, V12, P161, DOI 10.1123/IJSPP.2017-0208; Desgorces FD, 2008, PERCEPT MOTOR SKILL, V106, P104, DOI 10.2466/PMS.106.1.104-112; Desgorces FD, 2007, APPL PHYSIOL NUTR ME, V32, P762, DOI 10.1139/H07-037; Eston R, 2012, INT J SPORT PHYSIOL, V7, P175, DOI 10.1123/ijspp.7.2.175; FOSTER C, 1995, EUR J APPL PHYSIOL O, V70, P367, DOI 10.1007/BF00865035; Foster C, 2001, J STRENGTH COND RES, V15, P109, DOI 10.1519/00124278-200102000-00019; Garcia-Ramos A, 2015, EUR J SPORT SCI, V15, P85, DOI 10.1080/17461391.2014.922621; Halson SL, 2014, SPORTS MED, V44, pS139, DOI 10.1007/s40279-014-0253-z; Hourcade JC, 2017, SCI SPORT, V32, P221, DOI 10.1016/j.scispo.2017.03.004; Jean-Christophe H, 2018, BIOL SPORT, V35, P67, DOI 10.5114/biolsport.2018.70753; Joseph T, 2008, MED SCI SPORT EXER, V40, P381, DOI 10.1249/mss.0b013e31815a83f6; Lambert MI, 2010, INT J SPORT PHYSIOL, V5, P406, DOI 10.1123/ijspp.5.3.406; Manzi V, 2009, MED SCI SPORT EXER, V41, P2090, DOI 10.1249/MSS.0b013e3181a6a959; Morales J, 2016, INT J SPORT PHYSIOL, V11, P913, DOI 10.1123/ijspp.2015-0605; Noakes TD, 2004, J APPL PHYSIOL, V96, P1571, DOI 10.1152/japplphysiol.01124.2003; Smith DJ, 2003, SPORTS MED, V33, P1103, DOI 10.2165/00007256-200333150-00003; Stagno KM, 2007, J SPORT SCI, V25, P629, DOI 10.1080/02640410600811817; Taha T, 2003, SPORTS MED, V33, P1061, DOI 10.2165/00007256-200333140-00003; Tardieu-Berger M, 2004, EUR J APPL PHYSIOL, V93, P145, DOI 10.1007/s00421-004-1189-z	23	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2020	15	8							e0237027	10.1371/journal.pone.0237027	http://dx.doi.org/10.1371/journal.pone.0237027			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA7OS	32745112	gold, Green Published			2023-01-03	WOS:000560006800009
J	Rahman, MA; Khan, MN; Akter, S; Rahman, A; Alam, MM; Khan, MA; Rahman, MM				Rahman, Md Aminur; Khan, Md Nuruzzaman; Akter, Shahinoor; Rahman, Azizur; Alam, Md Mahmudul; Khan, Md Alam; Rahman, Md Mostafizur			Determinants of exclusive breastfeeding practice in Bangladesh: Evidence from nationally representative survey data	PLOS ONE			English	Article							DURATION	Background Exclusive breastfeeding (EBF) means that an infant should be breastfed only for the first six months of life to achieve optimal child development and to prevent infant morbidity and mortality. The aim of this analysis was to determine the individual-, household-, and community-level factors associated with EBF practice in Bangladesh. Methods A total of 1,440 women-child pairs data were analysed extracted from 2011 and 2014 Bangladesh Demographic and Health Survey. Multilevel logistic regression models were used separately for individual-, household-, and community level factors to identify the different level of factors associated with EBF practice. Results Around 61% women in Bangladesh practiced EBF with significant variation across several individual-, household-, and community-level factors. At the individual level, higher odds of EBF practice was found among mothers' received higher number of antenatal care and lower age of child. Mothers' higher education and engagement in formal jobs were found negatively associated with EBF practice. At the community level, higher odds of EBF was found among women live in Barishal, Dhaka, and Rajshahi divisions, and resided in the community with moderate level of female education, higher level of fertility, and higher use of antenatal and delivery care. Conclusions One in every three children in Bangladesh do not breastfeed exclusively which needs special attention for the policymakers. In this case, educated women engaged in income generating activities and women did not use antenatal care should be given priority. At the community level, priority should be given for the women's resides in the community with lower level of antenatal and delivery healthcare services use.	[Rahman, Md Aminur; Rahman, Md Mostafizur] Univ Rajshahi, Dept Populat Sci & Human Resource Dev, Rajshahi, Bangladesh; [Khan, Md Nuruzzaman] Jatiya Kabi Kazi Nazrul Islam Univ, Dept Populat Sci, Mymensingh, Bangladesh; [Akter, Shahinoor] Jagannath Univ, Dept Anthropol, Dhaka, Bangladesh; [Rahman, Azizur] Jatiya Kabi Kazi Nazrul Islam Univ, Dept Publ Adm & Governance Studies, Mymensingh, Bangladesh; [Alam, Md Mahmudul] Univ Rajshahi, Dept Stat, Rajshahi, Bangladesh; [Khan, Md Alam] Univ Rajshahi, Dept Pharm, Rajshahi, Bangladesh	University of Rajshahi; University of Rajshahi; University of Rajshahi	Khan, MN (corresponding author), Jatiya Kabi Kazi Nazrul Islam Univ, Dept Populat Sci, Mymensingh, Bangladesh.	sumonrupop@gmail.com	Akter, Shahinoor/AAY-5043-2020	Akter, Shahinoor/0000-0002-5236-3597; Khan, Md Nuruzzaman/0000-0002-4550-4363				Afrose L, 2012, FACTORS ASSOCIATED K, V3, P255; Agho KE, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-2; Akter SMJK, 2015, REPORT SITUATION INF; Asare BYA, 2018, INT BREASTFEED J, V13, DOI 10.1186/s13006-018-0156-y; Asemahagn MA, 2016, INT BREASTFEED J, V11, DOI 10.1186/s13006-016-0081-x; Balogun OO, 2015, MATERN CHILD NUTR, V11, P433, DOI 10.1111/mcn.12180; Barennes H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030634; Bbaale E, 2014, J HEALTH POPUL NUTR, V32, P249; Berkman LF., 2003, NEIGHBORHOODS HLTH; Black RE, 2008, LANCET, V371, P243, DOI 10.1016/S0140-6736(07)61690-0; Bora R., 2016, J NEONATAL BIOL, V5; Cai XD, 2012, INT BREASTFEED J, V7, DOI 10.1186/1746-4358-7-12; Dibley MJ, 2010, FOOD NUTR BULL, V31, P366, DOI 10.1177/156482651003100224; do Nascimento MBR, 2010, BREASTFEED MED, V5, P79, DOI 10.1089/bfm.2009.0008; Echamo M., 2012, HARAR B HLTH SCI, V5, P44; Hajeebhoy N, 2014, INT BREASTFEED J, V9, DOI 10.1186/1746-4358-9-12; Hanif HM, 2013, INT BREASTFEED J, V8, DOI 10.1186/1746-4358-8-10; Hossain M, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1076-0; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Khan MN, 2020, INT PERSPECT SEX R H, V46, P77, DOI 10.1363/46e8820; Khan MN, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4913-4; Khan MN, 2017, ARCH PUBLIC HEALTH, V75, DOI 10.1186/s13690-017-0181-0; Kramer MS, 2004, ADV EXP MED BIOL, V554, P63; Lenja A, 2016, INT BREASTFEED J, V11, DOI 10.1186/s13006-016-0091-8; Mazumder M. S., 2012, International Journal of Natural Sciences, V2, P49; Menon P, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002159; OCampo P, 2012, RETHINKING SOCIAL EPIDEMIOLOGY: TOWARDS A SCIENCE OF CHANGE, P1, DOI 10.1007/978-94-007-213808; Oddy WH, 2003, PAEDIATR PERINAT EP, V17, P81, DOI 10.1046/j.1365-3016.2003.00464.x; Okafor IP, 2014, NIGER J PAED, V41, P43, DOI DOI 10.4314/njp.v41i1.8; Seid AM, 2013, INT BREASTFEED J, V8, DOI 10.1186/1746-4358-8-14; Senarath U, 2012, MATERN CHILD NUTR, V8, P315, DOI 10.1111/j.1740-8709.2011.00321.x; Shetty P, 2014, B WORLD HEALTH ORGAN, V92, P234, DOI 10.2471/BLT.14.020414; Sumon MN., 2014, INT J SCI FOOTPR, V2, P52; TAN KL, 2011, INT BREASTFEED J, V6, P1; Tan KL, 2011, INT BREASTFEED J, V6, DOI 10.1186/1746-4358-6-2; Tanakam T, 2020, INCREASING FEMALE ED; Tuan NT, 2014, J NUTR, V144, P1811, DOI 10.3945/jn.114.198226; UNICEF, 2015, READ MAD GARM SECT C; Vieira TO, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-175; World Health Organization, 2001, OPT DUR EXCL BREASTF; Zar J., 1999, PEARSON, V4th ed.	41	10	10	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2020	15	7							e0236080	10.1371/journal.pone.0236080	http://dx.doi.org/10.1371/journal.pone.0236080			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB3GI	32667942	Green Published, gold			2023-01-03	WOS:000560402000028
J	Abshire, MA; Nolan, MT; Dy, SM; Gallo, JJ				Abshire, Martha A.; Nolan, Marie T.; Dy, Sydney M.; Gallo, Joseph J.			What matters when doctors die: A qualitative study of family perspectives	PLOS ONE			English	Article							OF-LIFE CARE; DECISION-MAKING; PALLIATIVE CARE; DIGNITY THERAPY; HEALTH LITERACY; END; PATIENT; DEATH; INTERVENTION; CAREGIVERS	Background The challenges of supporting the end-of-life preferences of patients and their families have often been attributed to poor understanding of the patient's condition. Understanding how physicians, as patients, communicate their end-of-life care preferences to their families may inform shared decision making at end of life. Objectives The purpose of this study was to understand what matters to families of physicians when decision making with and for a physician who is approaching the end of life. Design Cross-sectional qualitative design. Participants We conducted interviews with family members of deceased physicians. Approach We analyzed the data using the constant comparison method to identify themes. Key results Family members (N = 26) rarely were unclear about the treatment preferences of physicians who died. Three overarching themes emerged about what matters most to physicians' families: (1) honoring preferences for the context of end-of-life care; (2) supporting the patient's control and dignity in care; and, (3) developing a shared understanding of preferences. Families struggled to make decisions and provide the care needed by the physicians at the end of life, often encountering significant challenges from the healthcare system. Conclusions Even when disease and prognosis are well understood as in this group of physicians, families still experienced difficulties in end-of-life decision making. These findings highlight the need to specifically address preferences for caregiver, care setting and symptom management in shared end-of-life decision making conversations with patients and families.	[Abshire, Martha A.; Nolan, Marie T.; Gallo, Joseph J.] Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA; [Dy, Sydney M.] Johns Hopkins Univ, Dept Hlth Policy & Management, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA; [Gallo, Joseph J.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mental Hlth, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Abshire, MA (corresponding author), Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21218 USA.	mabshir1@jhu.edu		Abshire, Martha/0000-0003-1824-1542	National Institute of Nursing Research [R01 NR014068]	National Institute of Nursing Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))	JJG and MTN were co-PIs on R01 NR014068 funded by the National Institute of Nursing Research. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barry MJ, 2012, NEW ENGL J MED, V366, P780, DOI 10.1056/NEJMp1109283; Bernacki RE, 2014, JAMA INTERN MED, V174, P1994, DOI 10.1001/jamainternmed.2014.5271; Blecker S, 2016, JAMA-J AM MED ASSOC, V315, P301, DOI 10.1001/jama.2015.16976; Boeije H, 2002, QUAL QUANT, V36, P391, DOI 10.1023/A:1020909529486; Brazil K, 2005, PALLIATIVE MED, V19, P492, DOI 10.1191/0269216305pm1050oa; Chochinov HM, 2002, JAMA-J AM MED ASSOC, V287, P2253, DOI 10.1001/jama.287.17.2253; Chochinov HM, 2005, J CLIN ONCOL, V23, P5520, DOI 10.1200/JCO.2005.08.391; Fromme EK, 2004, J FAM PRACTICE, V53, P299; Gallo JJ, 2003, J AM GERIATR SOC, V51, P961, DOI 10.1046/j.1365-2389.2003.51309.x; Gallo JJ, 2019, J PAIN SYMPTOM MANAG, V57, P556, DOI 10.1016/j.jpainsymman.2018.12.328; GRAY C, 1980, CAN MED ASSOC J, V122, P206; Guo QH, 2014, PALLIATIVE MED, V28, P931, DOI 10.1177/0269216314528399; Jeon BM, 2018, NURS HEALTH SCI, V20, P472, DOI 10.1111/nhs.12537; Kamal AH, 2016, J PAIN SYMPTOM MANAG, V51, P497, DOI 10.1016/j.jpainsymman.2015.12.313; Kehl Karen A, 2006, Am J Hosp Palliat Care, V23, P277, DOI 10.1177/1049909106290380; Kim Y, 2017, PSYCHO-ONCOLOGY, V26, P484, DOI 10.1002/pon.4042; Klag M J, 1993, Ann Epidemiol, V3, P442; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; Krikorian A, 2020, J PAIN SYMPTOM MANAG, V59, P152, DOI 10.1016/j.jpainsymman.2019.07.033; Kwak J, 2005, GERONTOLOGIST, V45, P634, DOI 10.1093/geront/45.5.634; Martinez M, 2017, PALLIATIVE MED, V31, P492, DOI 10.1177/0269216316665562; Meier EA, 2016, AM J GERIAT PSYCHIAT, V24, P261, DOI 10.1016/j.jagp.2016.01.135; Melhado L, 2011, AM J HOSP PALLIAT ME, V28, P495, DOI 10.1177/1049909110398005; Morrow SL, 2005, J COUNS PSYCHOL, V52, P250, DOI 10.1037/0022-0167.52.2.250; Nilsson J, 2017, ASIA-PAC J CLIN ONCO, V13, P356, DOI 10.1111/ajco.12678; Odejide OO, 2016, J CLIN ONCOL, V34, P3126, DOI 10.1200/JCO.2016.67.8177; Pellegrino ED, 2008, HUMAN DIGNITY BIOETH; Puchalski CM, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2018-000465; Stjernsward J, 2003, PALLIATIVE MED GLOBA; Stjernsward J, 2007, J PAIN SYMPTOM MANAG, V33, P486, DOI 10.1016/j.jpainsymman.2007.02.016; Teno JM, 2015, J PALLIAT MED, V18, P662, DOI 10.1089/jpm.2015.0039; Vig EK, 2006, J AM GERIATR SOC, V54, P1688, DOI 10.1111/j.1532-5415.2006.00911.x; Virdun C, 2017, PALLIATIVE MED, V31, P587, DOI 10.1177/0269216316673547; Virdun C, 2015, PALLIATIVE MED, V29, P774, DOI 10.1177/0269216315583032; Volandes AE, 2008, J PALLIAT MED, V11, P754, DOI 10.1089/jpm.2007.0224; Wunsch H, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.7650; [No title captured]	37	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2020	15	6							e0235138	10.1371/journal.pone.0235138	http://dx.doi.org/10.1371/journal.pone.0235138			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ME9KK	32574209	gold, Green Published			2023-01-03	WOS:000544972400027
J	Rolnick, JA; Liao, JM; Emanuel, EJ; Huang, Q; Ma, XS; Shan, EZ; Dinh, C; Zhu, JS; Wang, ER; Cousins, D; Navathe, AS				Rolnick, Joshua A.; Liao, Joshua M.; Emanuel, Ezekiel J.; Huang, Qian; Ma, Xinshuo; Shan, Eric Z.; Dinh, Claire; Zhu, Jingsan; Wang, Erkuan; Cousins, Deborah; Navathe, Amol S.			Spending and quality after three years of Medicare's bundled payments for medical conditions: quasi-experimental difference-in-differences study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOSPITAL PARTICIPATION; READMISSION RATES; REPLACEMENT; PERFORMANCE; CARE; ASSOCIATION; VOLUNTARY; OUTCOMES; PROGRAM	OBJECTIVE To evaluate whether longer term participation in the bundled payments for care initiative (BPCI) for medical conditions in the United States, which held hospitals financially accountable for all spending during an episode of care from hospital admission to 90 days after discharge, was associated with changes in spending, mortality, or health service use. DESIGN Quasi-experimental difference-in-differences analysis. SETTING US hospitals participating in bundled payments for acute myocardial infarction, congestive heart failure, chronic obstructive pulmonary disease (COPD), or pneumonia, and propensity score matched to non-participating hospitals. PARTICIPANTS 238 hospitals participating in the Bundled Payments for Care Improvement initiative (BPCI) and 1415 non-BPCI hospitals. 226 BPCI hospitals were matched to 700 non-BPCI hospitals. MAIN OUTCOME MEASURES Primary outcomes were total spending on episodes and death 90 days after discharge. Secondary outcomes included spending and use by type of post-acute care. BPCI and non-BPCI hospitals were compared by patient, hospital, and hospital market characteristics. Market characteristics included population size, competitiveness, and post-acute bed supply. RESULTS In the 226 BPCI hospitals, episodes of care totaled 261 163 in the baseline period and 93 562 in the treatment period compared with 211 208 and 78 643 in the 700 matched non-BPCI hospitals, respectively, with small differences in hospital and market characteristics after matching. Differing trends were seen for some patient characteristics (eg, mean age change -0.3 years at BPCI hospitals v non-BPCI hospitals, P<0.001). In the adjusted analysis, participation in BPCI was associated with a decrease in total episode spending (-1.2%, 95% confidence interval -2.3% to -0.2%). Spending on care at skilled nursing facilities decreased (-6.3%, -10.0% to -2.5%) owing to a reduced number of facility days (-6.2%, -9.8% to -2.6%), and home health spending increased (4.4%, 1.4% to 7.5%). Mortality at 90 days did not change (-0.1 percentage points, 95% confidence interval -0.5 to 0.2 percentage points). CONCLUSIONS In this longer term evaluation of a large national programme on medical bundled payments in the US, participation in bundles for four common medical conditions was associated with savings at three years. The savings were generated by practice changes that decreased use of high intensity care after hospital discharge without affecting quality, which also suggests that bundles for medical conditions could require multiple years before changes in savings and practice emerge.	[Rolnick, Joshua A.; Navathe, Amol S.] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA 19104 USA; [Rolnick, Joshua A.] Univ Penn, Dept Med, Perelman Sch Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; [Rolnick, Joshua A.] Natl Clinician Scholars Program, Philadelphia, PA USA; [Liao, Joshua M.] Univ Washington, Sch Med, Seattle, WA USA; [Liao, Joshua M.; Navathe, Amol S.] Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Emanuel, Ezekiel J.; Huang, Qian; Ma, Xinshuo; Shan, Eric Z.; Dinh, Claire; Zhu, Jingsan; Wang, Erkuan; Cousins, Deborah; Navathe, Amol S.] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, 423 Guardian Dr, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Washington; University of Washington Seattle; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine	Navathe, AS (corresponding author), Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA 19104 USA.; Navathe, AS (corresponding author), Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.; Navathe, AS (corresponding author), Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, 423 Guardian Dr, Philadelphia, PA 19104 USA.	amol@wharton.upenn.edu		Dinh, Claire T./0000-0001-7597-1125; Navathe, Amol/0000-0001-7182-4988	Commonwealth Fund [20170816]	Commonwealth Fund	This work was funded by the Commonwealth Fund (grant No 20170816).	9 Meyer H, JOINT REPLACEMENT BU; Abdi H., 2010, ENCYCL RES, V3, P1; American Hospital Association, 2019, FAST FACTS US HOSP; Austin PC, 2011, PHARM STAT, V10, P150, DOI 10.1002/pst.433; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; Bratzler DW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017401; Centers for Medicare & Medicaid Services, 2019, 2018Q3 BPCI CTR MED; Centers for Medicare & Medicaid Services, 2019, BUNDL PAYM CAR IMPR; Centers for Medicare & Medicaid Services, 2020, RES STAT DAT; Centers for Medicare & Medicaid Services, 2020, BUNDL PAYM CAR IMPR; Centers for Medicare & Medicaid Services, 2019, BIOAN FIL; Centers for Medicare & Medicaid Services, 2020, BPCI ADV; Chamberlain AM, 2017, MAYO CLIN PROC, V92, P184, DOI 10.1016/j.mayocp.2016.11.009; de Bakker DH, 2012, HEALTH AFFAIR, V31, P426, DOI 10.1377/hlthaff.2011.0912; Donze J, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f7171; Dummit LA, 2016, JAMA-J AM MED ASSOC, V316, P1267, DOI 10.1001/jama.2016.12717; Ellis RP, 2014, BOSTON U DEP EC WORK, V1; Gillam SJ, 2012, ANN FAM MED, V10, P461, DOI 10.1370/afm.1377; Jha AK, 2018, JAMA-J AM MED ASSOC, V319, P431, DOI 10.1001/jama.2017.21623; Kahvecioglu DC, 2018, NEW ENGL J MED, V379, DOI 10.1056/NEJMc1811049; Krumholz HM, 2011, CIRC-CARDIOVASC QUAL, V4, P243, DOI 10.1161/CIRCOUTCOMES.110.957498; Krumholz HM, 2006, CIRCULATION, V113, P1683, DOI 10.1161/CIRCULATIONAHA.105.611186; Lewin Group, 2018, CMS BUNDL PAYM CAR I; Lewin Group, 2015, CMS BUNDL PAYM CAR I; Lewis VA, 2017, NEW ENGL J MED, V377, P1809, DOI 10.1056/NEJMp1709197; Liao JM, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.12270; Liao JM, 2019, HEALTH AFFAIR, V38, P44, DOI 10.1377/hlthaff.2018.05177; Maddox KEJ, 2018, NEW ENGL J MED, V379, P260, DOI [10.1056/NEJMsa1801369, 10.1056/NEJMsa1801569]; McWilliams JM, 2018, NEW ENGL J MED, V379, P1139, DOI 10.1056/NEJMsa1803388; Navathe AS, 2020, HEALTH AFFAIR, V39, P58, DOI 10.1377/hlthaff.2019.00466; Navathe AS, 2018, JAMA-J AM MED ASSOC, V320, P901, DOI 10.1001/jama.2018.12345; Navathe AS, 2018, HEALTH AFFAIR, V37, P854, DOI 10.1377/hlthaff.2017.1358; Navathe AS, 2017, JAMA INTERN MED, V177, P214, DOI 10.1001/jamainternmed.2016.8263; Navathe AS, 2018, HEALTH AFFAIR, DOI [10.1377/hblog20180828.844613/full/, DOI 10.1377/HBLOG20180828.844613/FULL/]; Porter ME, 2014, HARVARD BUSINESS S S; Pross C, 2017, MILBANK Q, V95, P136, DOI 10.1111/1468-0009.12248; Struijs JN, 2011, NEW ENGL J MED, V364, P990, DOI 10.1056/NEJMp1011849; Stuart EA, 2010, STAT SCI, V25, P1, DOI 10.1214/09-STS313; The Lewin Group, 2016, CMS BUNDL PAYM CAR I; The National Bureau of Economic Research, 2018, DIFF IN DIFF VAR TRE; van Walraven Carl, 2009, Med Care, V47, P626, DOI 10.1097/MLR.0b013e31819432e5; White RS, 2018, J RACIAL ETHN HEALTH, V5, P1202, DOI 10.1007/s40615-018-0467-0; Yang D, 2012, SAS GLOBAL FORUM	43	16	16	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 17	2020	369								m1780	10.1136/bmj.m1780	http://dx.doi.org/10.1136/bmj.m1780			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK1TJ	32554705	hybrid, Green Published			2023-01-03	WOS:000548568900003
J	Chen, R; Zeng, Z; Zhang, YY; Cao, C; Liu, HM; Li, W; Wu, Y; Xia, ZY; Ma, DQ; Meng, QT				Chen, Rong; Zeng, Zi; Zhang, Yun-yan; Cao, Chen; Liu, Hui-min; Li, Wei; Wu, Yang; Xia, Zhong-yuan; Ma, Daqing; Meng, Qing-tao			Ischemic postconditioning attenuates acute kidney injury following intestinal ischemia-reperfusion through Nrf2-regulated autophagy, anti-oxidation, and anti-inflammation in mice	FASEB JOURNAL			English	Article						acute kidney injury; autophagy; intestinal ischemia-reperfusion; ischemic postconditioning; Nrf2; HO-1 pathway	ACUTE LUNG INJURY; CEREBRAL-ISCHEMIA; CARDIAC-SURGERY; NRF2; PROTECTS; DAMAGE; DEFENSE; CANCER; RATS	Intestinal ischemia-reperfusion (IIR) often occurs during and following major cardiovascular or gut surgery and causes significant organ including kidney injuries. This study was to investigate the protective effect of intestinal ischemic postconditioning (IPo) on IIR-induced acute kidney injury (AKI) and the underling cellular signaling mechanisms with focus on the Nrf2/HO-1. Adult C57BL/6J mice were subjected to IIR with or without IPo. IIR was established by clamping the superior mesenteric artery (SMA) for 45 minutes followed by 120 minutes reperfusion. Outcome measures were: (i) Intestinal and renal histopathology; (ii) Renal function; (iii) Cellular signaling changes; (iv) Oxidative stress and inflammatory responses. IPo significantly attenuated IIR-induced kidney injury. Furthermore, IPo significantly increased both nuclear Nrf2 and HO-1 expression in the kidney, upregulated autophagic flux, inhibited IIR-induced inflammation and reduced oxidative stress. The protective effect of IPo was abolished by the administration of Nrf2 inhibitor (Brusatol) or Nrf2 siRNA. Conversely, a Nrf2 activator t-BHQ has a similar protective effect to that of IPo. Our data indicate that IPo protects the kidney injury induced by IIR, which was likely mediated through the Nrf2/HO-1 cellular signaling activation.	[Chen, Rong; Zeng, Zi; Zhang, Yun-yan; Liu, Hui-min; Li, Wei; Wu, Yang; Xia, Zhong-yuan; Meng, Qing-tao] Wuhan Univ, Dept Anesthesiol, Renmin Hosp, Wuhan 430060, Peoples R China; [Cao, Chen] 3rd Hosp Wuhan, Dept Endocrinol, Wuhan, Peoples R China; [Ma, Daqing] Imperial Coll London, Chelsea & Westminster Hosp, Div Anaesthet Pain Med & Intens Care, Dept Surg & Canc,Fac Med, London, England	Wuhan University; Imperial College London	Meng, QT (corresponding author), Wuhan Univ, Dept Anesthesiol, Renmin Hosp, Wuhan 430060, Peoples R China.	mengqingtao2018@126.com	Ma, Daqing/GLT-2735-2022	Ma, Daqing/0000-0003-1235-0537; xia, zhongyuan/0000-0002-5807-9554	National Natural Science Foundation of China (NSFC) [81671948, 81400698, 81401574]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by the National Natural Science Foundation of China (NSFC) (grand number 81671948, 81400698, 81401574)	Bell RM, 2014, EUR HEART J, V35, P138, DOI 10.1093/eurheartj/eht478; Chapple SJ, 2012, INT J BIOCHEM CELL B, V44, P1315, DOI 10.1016/j.biocel.2012.04.021; Chen R, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/6954764; CHIU CJ, 1970, ARCH SURG-CHICAGO, V101, P478; Decuypere JP, 2015, AM J KIDNEY DIS, V66, P699, DOI 10.1053/j.ajkd.2015.05.021; Diez ER, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235927; Guo C, 2017, MOL NEUROBIOL, V54, P833, DOI 10.1007/s12035-016-9690-z; He F, 2020, CARCINOGENESIS, V41, P405, DOI 10.1093/carcin/bgaa039; Hess DC, 2015, NAT REV NEUROL, V11, DOI 10.1038/nrneurol.2015.223; Hobel S, 2010, J GENE MED, V12, P287, DOI 10.1002/jgm.1431; Jeong WS, 2006, ANTIOXID REDOX SIGN, V8, P99, DOI 10.1089/ars.2006.8.99; Jiang Y, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/843721; Kazantzidou D, 2010, MINERVA CHIR, V65, P515; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Li N, 2004, J IMMUNOL, V173, P3467, DOI 10.4049/jimmunol.173.5.3467; Li S, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9040354; Liu L, 2013, WORLD J GASTROENTERO, V19, P9439, DOI 10.3748/wjg.v19.i48.9439; Liu TQ, 2015, FREE RADICAL BIO MED, V81, P170, DOI 10.1016/j.freeradbiomed.2014.10.509; Souza JRM, 2008, ARQ BRAS CARDIOL, V90, P94, DOI 10.1590/S0066-782X2008000200004; Meng QT, 2017, INT J MOL MED, V40, P1731, DOI 10.3892/ijmm.2017.3170; Meng QT, 2016, LAB INVEST, V96, P1087, DOI 10.1038/labinvest.2016.87; Myles PS, 2019, BRIT J ANAESTH, V122, P726, DOI 10.1016/j.bja.2019.01.010; Ologunde R, 2014, INT UROL NEPHROL, V46, P2337, DOI 10.1007/s11255-014-0766-2; Pac-Soo CK, 2015, BRIT J ANAESTH, V114, P204, DOI 10.1093/bja/aeu302; Piantadosi CA, 2008, FREE RADICAL BIO MED, V45, P562, DOI 10.1016/j.freeradbiomed.2008.05.013; Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008; Ren DM, 2011, P NATL ACAD SCI USA, V108, P1433, DOI 10.1073/pnas.1014275108; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Shokeir AA, 2014, ACTA PHYSIOL, V210, P342, DOI 10.1111/apha.12164; Spandou E, 2006, NEPHROL DIAL TRANSPL, V21, P330, DOI 10.1093/ndt/gfi177; Stiermaier T, 2019, CIRC RES, V124, P1482, DOI 10.1161/CIRCRESAHA.118.314500; Tan KP, 2008, FREE RADICAL BIO MED, V45, P1663, DOI 10.1016/j.freeradbiomed.2008.09.010; Teke Z, 2008, AM J SURG, V195, P861, DOI 10.1016/j.amjsurg.2007.06.025; Vaziri ND, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114881; Venditti P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21062173; Vollmar B, 2011, LANGENBECK ARCH SURG, V396, P13, DOI 10.1007/s00423-010-0727-x; Xiao LY, 2020, PHYTOMEDICINE, V70, DOI 10.1016/j.phymed.2020.153219; Yun N, 2014, FREE RADICAL BIO MED, V68, P168, DOI 10.1016/j.freeradbiomed.2013.12.014; Yurdakan G, 2012, KAOHSIUNG J MED SCI, V28, P16, DOI 10.1016/j.kjms.2011.06.030; Zarbock A, 2017, ANESTHESIOLOGY, V126, P787, DOI 10.1097/ALN.0000000000001598; Zarbock A, 2015, JAMA-J AM MED ASSOC, V313, P2133, DOI 10.1001/jama.2015.4189; Zhang MH, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/463815; Zhang YX, 2011, ANTIOXID REDOX SIGN, V15, P2867, DOI 10.1089/ars.2010.3685; Zhao HL, 2019, BRIT J ANAESTH, V123, P519, DOI 10.1016/j.bja.2019.05.041; Zhao HL, 2017, AM J PHYSIOL-LUNG C, V312, pL155, DOI 10.1152/ajplung.00449.2016; Zhao HL, 2013, FASEB J, V27, P4076, DOI 10.1096/fj.13-232173; Zhao HP, 2014, STROKE, V45, P2417, DOI 10.1161/STROKEAHA.114.006135; Zhao QF, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/231351; Zhao ZQ, 2010, CARDIOVASC DRUG THER, V24, P265, DOI 10.1007/s10557-010-6240-1; Zhong ZY, 2016, CELL, V166, P288, DOI 10.1016/j.cell.2016.05.051; Zhou B, 2017, CLIN SCI, V131, P1161, DOI 10.1042/CS20170052	51	9	9	2	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2020	34	7					8887	8901		10.1096/fj.202000274R	http://dx.doi.org/10.1096/fj.202000274R		JUN 2020	15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MG8UN	32519766				2023-01-03	WOS:000541521500001
J	Dobbie, F; Uny, I; Eadie, D; Duncan, E; Stead, M; Bauld, L; Angus, K; Hassled, L; MacInnes, L; Clegg, G				Dobbie, Fiona; Uny, Isa; Eadie, Douglas; Duncan, Edward; Stead, Martine; Bauld, Linda; Angus, Kathryn; Hassled, Liz; MacInnes, Lisa; Clegg, Gareth			Barriers to bystander CPR in deprived communities: Findings from a qualitative study	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; SOCIOECONOMIC-STATUS; SURVIVAL RATES; KNOWLEDGE	Study aim Rates of out of hospital cardiac arrest are higher in deprived communities. Bystander Cardiopulmonary Resuscitation (BCPR) can double the chance of survival but occurs less often in these communities in comparison to more affluent communities. People living in deprived communities are, therefore, doubly disadvantaged and there is limited evidence to explain why BCPR rates are lower. The aim of this paper is to examine the barriers to administering BCPR in deprived communities. Method Mixed method qualitative study with ten single sex focus groups (n = 61) conducted in deprived communities across central Scotland and 18 semi-structured interviews with stakeholders from the UK, Europe and the USA. Results Two key themes related to confidence and environmental factors were identified to summarise the perceived barriers to administering BCPR in deprived communities. Barriers related to confidence included: self-efficacy; knowledge and awareness of how, and when, to administer CPR; accessing CPR training; having previous experience of administering BCPR; who required CPR; and whether the bystander was physically fit to give CPR. Environmental barriers focused on the safety of the physical environment in which people lived, and fear of reprisal from gangs or the police. Conclusions Barriers to administering BCPR identified in the general population are relevant to people living in deprived communities but are exacerbated by a range of contextual, individual and environmental factors. A one-size-fits-all approach is not sufficient to promote 'CPR readiness' in deprived communities. Future approaches to working with disadvantaged communities should be tailored to the local community.	[Dobbie, Fiona; Bauld, Linda] Univ Edinburgh, Coll Med & Vet Med, Usher Inst, Edinburgh, Midlothian, Scotland; [Uny, Isa; Eadie, Douglas; Stead, Martine; Angus, Kathryn] Univ Stirling, Sch Hlth Sci, Inst Social Mkt & Hlth, Stirling, Scotland; [Duncan, Edward] Univ Stirling, Fac Hlth Sci & Sport, Nursing Midwifery & Allied Hlth Professionals Res, Stirling, Scotland; [Hassled, Liz; MacInnes, Lisa; Clegg, Gareth] Univ Edinburgh, Resuscitat Res Grp, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Stirling; University of Stirling; University of Edinburgh	Dobbie, F (corresponding author), Univ Edinburgh, Coll Med & Vet Med, Usher Inst, Edinburgh, Midlothian, Scotland.	fiona.dobbie@ed.ac.uk	; Dobbie, Fiona/L-5858-2016	Stead, Martine/0000-0002-3066-4604; Clegg, Gareth/0000-0002-4314-611X; Uny, Isabelle/0000-0002-9548-5332; Dobbie, Fiona/0000-0002-8294-8203	Chief Scientist Office [HIPS/17/10]	Chief Scientist Office	FD received funding for this study from the Chief Scientist Office HIPS/17/10 https://www.cso.scot.nhs.uk/outputs/cso-funded-research/hips2017/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	2011ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS, 2011, CIRCULATION, V124, pe54; Aaberg AMR, 2014, SCAND J TRAUMA RESUS, V22, DOI 10.1186/1757-7241-22-24; [Anonymous], 2014, REG ANESTH PAIN MED; [Anonymous], 2017, ONCOGENESIS, V6, pe345; Becker TK, 2019, EMERGENCY MED J; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Chen KY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211792; Craig P, 2013, INT J NURS STUD, V50, P585, DOI 10.1016/j.ijnurstu.2012.09.009; Dobbie F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193391; Frohlich KL, TAKING ACCOUNT CONTE; Global Resuscitation Alliance, 2016, IMPROVING SURVIVAL O; Jakubowski A, 2018, SUBST ABUS, V39, P233, DOI 10.1080/08897077.2017.1387213; Kanstad BK, 2011, RESUSCITATION, V82, P1053, DOI 10.1016/j.resuscitation.2011.03.033; Kramer CE, 2015, RESUSCITATION, V86, P82, DOI 10.1016/j.resuscitation.2014.10.016; Mathiesen WT, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-2017-x; Mitchell MJ, 2009, PREHOSP EMERG CARE, V13, P478, DOI 10.1080/10903120903144833; Moore G, 2014, J EPIDEMIOL COMMUN H, V68, P101, DOI 10.1136/jech-2013-202869; Nadarajan GD, 2018, RESUSCITATION, V132, P85, DOI 10.1016/j.resuscitation.2018.08.022; Nicholls M.C., 2014, QUALITATIVE RES PRAC, P177, DOI DOI 10.1186/1745-6215-14-166; O'Brien BC, 2014, ACAD MED, V89, P1245, DOI 10.1097/ACM.0000000000000388; Reinier K, 2011, CAN MED ASSOC J, V183, P1705, DOI 10.1503/cmaj.101512; Riegel B, 2006, RESUSCITATION, V70, P98, DOI 10.1016/j.resuscitation.2005.10.029; Riva G, 2019, CIRCULATION, V139, P2600, DOI 10.1161/CIRCULATIONAHA.118.038179; Sasson C, 2015, ANN EMERG MED, V65, P545, DOI [10.1016/j.annemergmed.2014.10.028, DOI 10.1016/J.ANNEMERGMED.2014.10.02825481112]; Sasson C, 2013, CIRC-CARDIOVASC QUAL, V6, P550, DOI 10.1161/CIRCOUTCOMES.111.000097; Sasson C, 2012, ACAD EMERG MED, V19, P139, DOI 10.1111/j.1553-2712.2011.01284.x; Sasson C, 2010, CIRC-CARDIOVASC QUAL, V3, P63, DOI 10.1161/CIRCOUTCOMES.109.889576; Scottish Government The Scottish G, 2015, OUT HOSP CARD ARR ST; Scottish Government The Scottish G, 2018, IN RES SCOTT OUT HOS; Smeeding Timothy., 2016, OXFORD HDB SOCIAL SC; Uny I, 2019, LETS BE CPR READY DE; Vaillancourt C, 2008, RESUSCITATION, V79, P417, DOI 10.1016/j.resuscitation.2008.07.012; Vaillancourt C, 2008, CAN J EMERG MED, V10, P51, DOI 10.1017/S1481803500010010; 2018, EUR UROL SUPPL, V17	34	5	5	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2020	15	6							e0233675	10.1371/journal.pone.0233675	http://dx.doi.org/10.1371/journal.pone.0233675			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC0EC	32520938	Green Published, gold, Green Accepted			2023-01-03	WOS:000542969500031
J	Sandal, PH; Kim, D; Fiebig, L; Winnard, A; Caplan, N; Green, DA; Weber, T				Sandal, Peter H.; Kim, David; Fiebig, Leonie; Winnard, Andrew; Caplan, Nick; Green, David A.; Weber, Tobias			Effectiveness of nutritional countermeasures in microgravity and its ground-based analogues to ameliorate musculoskeletal and cardiopulmonary deconditioning-A Systematic Review	PLOS ONE			English	Review							BED-REST; SKELETAL-MUSCLE; EXERCISE; SPACE; PROTEIN; SPACEFLIGHT; METABOLISM; BONE; FLIGHT; DIET	A systematic review was performed to evaluate the effectiveness of nutrition as a standalone countermeasure to ameliorate the physiological adaptations of the musculoskeletal and cardiopulmonary systems associated with prolonged exposure to microgravity. A search strategy was developed to find all astronaut or human space flight bed rest simulation studies that compared individual nutritional countermeasures with non-intervention control groups. This systematic review followed the guidelines of the Cochrane Handbook for Systematic Reviews and tools created by the Aerospace Medicine Systematic Review Group for data extraction, quality assessment of studies and effect size. To ensure adequate reporting this systematic review followed the guidelines of the Preferred Reporting Items for Systematic Review and Meta-Analyses. A structured search was performed to screen for relevant articles. The initial search yielded 4031 studies of which 10 studies were eligible for final inclusion. Overall, the effect of nutritional countermeasure interventions on the investigated outcomes revealed that only one outcome was in favor of the intervention group, whereas six outcomes were in favor of the control group, and 43 outcomes showed no meaningful effect of nutritional countermeasure interventions at all. The main findings of this study were: (1) the heterogeneity of reported outcomes across studies, (2) the inconsistency of the methodology of the included studies (3) an absence of meaningful effects of standalone nutritional countermeasure interventions on musculoskeletal and cardiovascular outcomes, with a tendency towards detrimental effects on specific muscle outcomes associated with power in the lower extremities. This systematic review highlights the limited amount of studies investigating the effect of nutrition as a standalone countermeasure on operationally relevant outcome parameters. Therefore, based on the data available from the included studies in this systematic review, it cannot be expected that nutrition alone will be effective in maintaining musculoskeletal and cardiopulmonary integrity during space flight and bed rest.	[Sandal, Peter H.; Kim, David; Fiebig, Leonie; Green, David A.; Weber, Tobias] European Space Agcy, Space Med Team, European Astronaut Ctr, Cologne, Germany; [Kim, David] Univ British Columbia, Fac Med, Vancouver, BC, Canada; [Fiebig, Leonie] German Sport Univ Cologne, Inst Biomech & Orthopaed, Cologne, Germany; [Winnard, Andrew; Caplan, Nick] Northumbria Univ, Fac Hlth & Life Sci, Newcastle Upon Tyne, Tyne & Wear, England; [Green, David A.] Kings Coll London, Ctr Human & Appl Physiol Sci, London, England; [Green, David A.; Weber, Tobias] KBR GmbH, Cologne, Germany	European Space Agency; University of British Columbia; German Sport University Cologne; Northumbria University; University of London; King's College London	Sandal, PH; Weber, T (corresponding author), European Space Agcy, Space Med Team, European Astronaut Ctr, Cologne, Germany.; Weber, T (corresponding author), KBR GmbH, Cologne, Germany.	Tobias.weber@esa.int; Peterhsandal@gmail.com		Kim, David/0000-0002-8097-810X; Sandal, Peter/0000-0002-0501-2903; Weber, Tobias/0000-0002-3015-3468	Space Medicine Team of the European Space Agency; KBR GmbH	Space Medicine Team of the European Space Agency; KBR GmbH	The project was funded by the Space Medicine Team of the European Space Agency and KBR GmbH. The funder (KBR GmbH) provided support in the form of salaries for authors [DAG, TW] but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.; This systematic review was performed as part of a project by the Aerospace Medicine Systematic Review Group and the Space Medicine Team of the European Space Agency at the European Astronaut Centre (EAC). Special thanks are given to Dr Anna Fogtman and Robert Ekman from the EAC and Dr Bernd Johannes from the German Aerospace Center for their support during the project.	Adams GR, 2003, J APPL PHYSIOL, V95, P2185, DOI 10.1152/japplphysiol.00346.2003; [Anonymous], 2002, SCNJ, V9-11, P1; [Anonymous], 2009, KIDNEY INT, V6, pS1; [Anonymous], 1994, ESSENTIAL WORKS, V1, pxxxiii; [Anonymous], 2016, EVIDENCE, V8, pe1000; Arbeille P, 2012, EUR J APPL PHYSIOL, V112, P277, DOI 10.1007/s00421-011-1935-y; Beller G, 2011, BONE, V49, P858, DOI 10.1016/j.bone.2011.06.021; Bergouignan A, 2016, NPJ MICROGRAVITY, V2, DOI 10.1038/npjmgrav.2016.29; Bosutti A, 2016, J APPL PHYSIOL, V121, P838, DOI 10.1152/japplphysiol.00936.2015; Buckey JC, 2006, SPACE PHYSL; Dawson-Hughes B, 2003, J NUTR, V133, p852S, DOI 10.1093/jn/133.3.852S; Ellis PD, 2010, J INT BUS STUD, V41, P1581, DOI 10.1057/jibs.2010.39; Ferrando AA, 2002, NUTRITION, V18, P837, DOI 10.1016/S0899-9007(02)00930-9; Fitts RH, 2001, J EXP BIOL, V204, P3201; Florian JP, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118812; Fu Q, 2019, CIRCULATION, V140, P729, DOI 10.1161/CIRCULATIONAHA.119.041050; Ham DJ, 2014, CLIN NUTR, V33, P937, DOI 10.1016/j.clnu.2014.09.016; Hargens AR, 2016, J APPL PHYSIOL, V120, P891, DOI 10.1152/japplphysiol.00935.2015; HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hoebel J, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00402; Knowles OE, 2018, J SCI MED SPORT, V21, P959, DOI 10.1016/j.jsams.2018.01.012; Lane HW, 2013, ADV NUTR, V4, P521, DOI 10.3945/an.113.004101; Lang T, 2017, NPJ MICROGRAVITY, V3, DOI 10.1038/s41526-017-0013-0; Laws JM, 2020, ACTA ASTRONAUT, V170, P665, DOI 10.1016/j.actaastro.2020.02.038; LEBLANC A, 1995, AVIAT SPACE ENVIR MD, V66, P1151; Lee SMC, 2015, AEROSP MED HUM PERF, V86, pA54, DOI 10.3357/AMHP.EC08.2015; Lee SMC, 2014, J APPL PHYSIOL, V116, P654, DOI 10.1152/japplphysiol.00590.2013; McNamara KP, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00627; Moore AD, 2014, J APPL PHYSIOL, V117, P231, DOI 10.1152/japplphysiol.01251.2013; Norsk P, 2020, ACTA PHYSIOL, V228, DOI 10.1111/apha.13434; Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4; Perhonen MA, 2001, CIRCULATION, V103, P1851; Petersen N, 2016, EXTREME PHYSIOL MED, V5, DOI 10.1186/s13728-016-0050-4; Platts SH, 2014, J WOMENS HEALTH, V23, P950, DOI 10.1089/jwh.2014.4912; Rejc E, 2015, EUR J APPL PHYSIOL, V115, P429, DOI 10.1007/s00421-014-3024-5; Rosenthal JA, 1996, J SOC SERV RES, V21, P37, DOI 10.1300/J079v21n04_02; Schneider SM, 2009, MED SCI SPORT EXER, V41, P2165, DOI 10.1249/MSS.0b013e3181aa04e5; Scott JPR, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00173; Sibonga JD, 2015, AEROSP MED HUM PERF, V86, pA38, DOI 10.3357/AMHP.EC06.2015; Smith SM, 2012, J BONE MINER RES, V27, P1896, DOI 10.1002/jbmr.1647; Smith SM, HUMAN ADAPTATION SPA; Stein TP, 2011, CRIT REV FOOD SCI, V51, P828, DOI 10.1080/10408398.2010.482679; STEIN TP, 1993, AM J PHYSIOL, V264, pE824, DOI 10.1152/ajpendo.1993.264.5.E824; Stein TP, 1996, J APPL PHYSIOL, V81, P82, DOI 10.1152/jappl.1996.81.1.82; Stein TP, 1999, AM J PHYSIOLENDOCRIN, V276; STUART CA, 1990, AM J CLIN NUTR, V52, P509, DOI 10.1093/ajcn/52.3.509; Sundblad P., 2014, GUIDELINES STANDARDI; Traon APL, 2007, EUR J APPL PHYSIOL, V101, P143, DOI 10.1007/s00421-007-0474-z; Trappe S, 2009, J APPL PHYSIOL, V106, P1159, DOI 10.1152/japplphysiol.91578.2008; Trappe TA, 2007, ACTA PHYSIOL, V191, P147, DOI 10.1111/j.1748-1716.2007.01728.x; Watson AM, 2017, CURR SPORT MED REP, V16, P413, DOI 10.1249/JSR.0000000000000418; Winnard A, 2017, AMSRG DATA EXTRACTIO, DOI 10.131140/RG.2.2.12487.19365/1; Winnard A, 2017, LANCET PLANET HLTH, V1, DOI 10.1311140/RG.2.2.21758.89925/1; Zwart SR, 2005, J APPL PHYSIOL, V99, P134, DOI 10.1152/japplphysiol.01406.2004; 2008, AM J PHYSL, V294, pR939; 2019, BMJ, V366	57	7	8	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2020	15	6							e0234412	10.1371/journal.pone.0234412	http://dx.doi.org/10.1371/journal.pone.0234412			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ1GC	32516346	gold, Green Published, Green Accepted			2023-01-03	WOS:000540977000006
J	Kang, M; Wei, JJ; Yuan, J; Guo, JX; Zhang, YT; Hang, J; Qu, YB; Qian, H; Zhuang, YL; Chen, XG; Peng, X; Shi, TX; Wang, J; Wu, J; Song, T; He, JF; Li, YG; Zhong, NS				Kang, Min; Wei, Jianjian; Yuan, Jun; Guo, Juxuan; Zhang, Yingtao; Hang, Jian; Qu, Yabin; Qian, Hua; Zhuang, Yali; Chen, Xuguang; Peng, Xin; Shi, Tongxing; Wang, Jun; Wu, Jie; Song, Tie; He, Jianfeng; Li, Yuguo; Zhong, Nanshan			Probable Evidence of Fecal Aerosol Transmission of SARS-CoV-2 in a High-Rise Building	ANNALS OF INTERNAL MEDICINE			English	Article							CORONAVIRUS; VENTILATION; PNEUMONIA; WUHAN	Background: The role of fecal aerosols in the transmission of severe acute respiratory syndrome coronavirus 2 has been suspected. Objective: To investigate the temporal and spatial distributions of 3 infected families in a high-rise apartment building and examine the associated environmental variables to verify the role of fecal aerosols. Design: Epidemiologic survey and quantitative reverse transcriptase polymerase chain reaction analyses on throat swabs from the participants; 237 surface and air samples from 11 of the 83 flats in the building, public areas, and building drainage systems; and tracer gas released into bathrooms as a surrogate for virus-laden aerosols in the drainage system. Setting: A high-rise apartment building in Guangzhou, China. Participants: 9 infected patients, 193 other residents of the building, and 24 members of the building's management staff. Measurements: Locations of infected flats and positive environmental samples, and spread of virus-laden aerosols. Results: 9 infected patients in 3 families were identified. The first family had a history of travel to the coronavirus disease 2019 (COVID-19) epicenter Wuhan, whereas the other 2 families had no travel history and a later onset of symptoms. No evidence was found for transmission via the elevator or elsewhere. The families lived in 3 vertically aligned flats connected by drainage pipes in the master bathrooms. Both the observed infections and the locations of positive environmental samples are consistent with the vertical spread of virus-laden aerosols via these stacks and vents. Limitation: Inability to determine whether the water seals were drieYd out in the flats of the infected families. Conclusion: On the basis of circumstantial evidence, fecal aerosol transmission may have caused the community outbreak of COVID-19 in this high-rise building.	[Kang, Min; Zhang, Yingtao; Qu, Yabin; Zhuang, Yali; Chen, Xuguang; Wu, Jie; He, Jianfeng] Guangdong Prov Ctr Dis Control & Prevent, Guangzhou 510000, Peoples R China; [Wei, Jianjian] Zhejiang Univ, Inst Refrigerat & Cryogen, Hangzhou, Peoples R China; [Wei, Jianjian] Zhejiang Univ, Key Lab Refrigerat & Cryogen Technol Zhejiang Pro, Hangzhou, Peoples R China; [Yuan, Jun; Shi, Tongxing; Song, Tie] Guangzhou Ctr Dis Control & Prevent, Guangzhou, Peoples R China; [Guo, Juxuan; Wang, Jun] Guangzhou Haizhu Dist Ctr Dis Control & Prevent, Guangzhou, Peoples R China; [Hang, Jian] Sun Yat Sen Univ, Sch Atmospher Sci, Guangzhou, Peoples R China; [Qian, Hua] Southeast Univ, Sch Energy & Environm, Nanjing, Peoples R China; [Peng, Xin] Guangzhou Nanshan Dist Ctr Dis Control & Prevent, Guangzhou, Peoples R China; [Li, Yuguo] Univ Hong Kong, Dept Mech Engn, Pokfulam Rd, Hong Kong, Peoples R China; [Li, Yuguo] Univ Hong Kong, Sch Publ Hlth, Pokfulam Rd, Hong Kong, Peoples R China; [Zhong, Nanshan] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou 510000, Peoples R China	Chinese Center for Disease Control & Prevention; Guangdong Provincial Center for Disease Control & Prevention; Zhejiang University; Zhejiang University; Sun Yat Sen University; Southeast University - China; University of Hong Kong; University of Hong Kong; Guangzhou Medical University; State Key Laboratory of Respiratory Disease	He, JF (corresponding author), Guangdong Prov Ctr Dis Control & Prevent, Guangzhou 510000, Peoples R China.; Li, YG (corresponding author), Univ Hong Kong, Dept Mech Engn, Pokfulam Rd, Hong Kong, Peoples R China.; Li, YG (corresponding author), Univ Hong Kong, Sch Publ Hlth, Pokfulam Rd, Hong Kong, Peoples R China.; Zhong, NS (corresponding author), Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Hlth, State Key Lab Resp Dis,Natl Clin Res Ctr Resp Dis, Guangzhou 510000, Peoples R China.	hjf@vip.sina.com; liyg@hku.hk; nanshan@vip.163.com	QIAN, Hua/A-1410-2009; Wei, Jianjian/AAW-4145-2021; Li, Yuguo/A-9469-2010; Wei, Jianjian/F-7788-2011	QIAN, Hua/0000-0002-7237-7806; Li, Yuguo/0000-0002-2281-4529; Wei, Jianjian/0000-0001-8859-8462	Key-Area Research and Development Program of Guangdong Province [2019B111103001]; Research Grants Council of Hong Kong [17202719, C7025-16G]	Key-Area Research and Development Program of Guangdong Province; Research Grants Council of Hong Kong(Hong Kong Research Grants Council)	By grant 2019B111103001 from the Key-Area Research and Development Program of Guangdong Province and grants 17202719 and C7025-16G from the Research Grants Council of Hong Kong.	Bai Y, 2020, JAMA-J AM MED ASSOC, V323, P1406, DOI [10.1056/NEJMoa2001316, 10.1001/jama.2020.2565]; Bivolarova M, 2017, INDOOR AIR, V27, P1201, DOI 10.1111/ina.12388; Centers for Disease Control and Prevention, 2020, 2019 NCOV SPREADS; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; GERBA CP, 1975, APPL MICROBIOL, V30, P229, DOI 10.1128/AEM.30.2.229-237.1975; Holshue M.L., 2020, NEW ENGL J MED, V382, P929, DOI [10.1056/NEJMoa2001191, DOI 10.1056/NEJMOA2001191, DOI 10.1056/NEJM0A2001191]; Lei H, 2018, INDOOR AIR, V28, P394, DOI 10.1111/ina.12445; Leung K, 2020, CORONAVIRUS LEAST 10; Li Y, 2007, POPULATION DYNAMICS; Li YG, 2000, BUILD ENVIRON, V35, P191, DOI 10.1016/S0360-1323(99)00011-6; Liu Y, 2020, NATURE, V582, P557, DOI 10.1038/s41586-020-2271-3; McDermott CV, 2020, J HOSP INFECT, V105, P397, DOI 10.1016/j.jhin.2020.04.024; National Health Commission of China, 2020, NEW COR PNEUM PREV C, V7th; Ong SWX, 2020, JAMA-J AM MED ASSOC, V323, P1610, DOI 10.1001/jama.2020.3227; Peiris JSM, 2003, LANCET, V361, P1767, DOI 10.1016/S0140-6736(03)13412-5; Phan LT, 2020, NEW ENGL J MED, V382, P872, DOI 10.1056/NEJMc2001272; Tian Y, 2020, ALIMENT PHARM THER, V51, P843, DOI 10.1111/apt.15731; Tsang D., 2020, CORONAVIRUS HONGKONG; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; WHO, 2020, INF PREV CONTR HLTH, P1; Yu ITS, 2004, NEW ENGL J MED, V350, P1731, DOI 10.1056/NEJMoa032867; Zhang H, 2020, GUT, V69, P1010, DOI 10.1136/gutjnl-2020-320953; Zhang W, 2020, EMERG MICROBES INFEC, V9, DOI 10.1080/22221751.2020.1729071; Zhang Y, 2020, CHINA CDC WEEKLY, V2, P123	24	114	118	27	114	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	2020	173	12					974	+		10.7326/M20-0928	http://dx.doi.org/10.7326/M20-0928			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PF2SU	32870707	Green Published			2023-01-03	WOS:000598911600010
J	Iwuji, C; Chimukuche, RS; Zuma, T; Plazy, M; Larmarange, J; Orne-Gliemann, J; Siedner, M; Shahmanesh, M; Seeley, J				Iwuji, Collins; Chimukuche, Rujeko Samanthia; Zuma, Thembelihle; Plazy, Melanie; Larmarange, Joseph; Orne-Gliemann, Joanna; Siedner, Mark; Shahmanesh, Maryam; Seeley, Janet			Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa	PLOS ONE			English	Article							QUALITATIVE RESEARCH; HIV; PREVENTION; INITIATION; INFECTION; CARE	Introduction Antiretroviral therapy (ART) has revolutionised the care of HIV-positive individuals resulting in marked decreases in morbidity and mortality, and markedly reduced transmission to sexual partners. However, these benefits can only be realised if individuals are aware of their HIV-positive status, initiated and retained on suppressive lifelong ART. Framed using the socio-ecological model, the present study explores factors contributing to poor ART uptake among community members despite high acceptance of HIV-testing within a Treatment as Prevention (TasP) trial. In this paper we identify barriers and facilitators to treatment across different levels of the socio-ecological framework covering individual, community and health system components. Methods This research was embedded within a cluster-randomised trial (ClinicalTrials.gov, number NCT01509508) of HIV treatment as Prevention in rural KwaZulu-Natal, South Africa. Data were collected between January 2013 and July 2014 from resident community members. Ten participants contributed to repeat in-depth interviews whilst 42 participants took part in repeat focus group discussions. Data from individual interviews and focus group discussions were triangulated using community walks to give insights into community members' perception of the barriers and facilitators of ART uptake. We used thematic analysis guided by a socio-ecological framework to analyse participants' narratives from both individual interviews and focus group discussions. Results Barriers and facilitators operating at the individual, community and health system levels influence ART uptake. Stigma was an over-arching barrier, across all three levels and expressed variably as fear of HIV disclosure, concerns about segregated HIV clinical services and negative community religious perceptions. Other barriers were individual (substance misuse, fear of ART side effects), community (alternative health beliefs). Facilitators cited by participants included individual (expectations of improved health and longer life expectancy following ART, single tablet regimens), community (availability of ART in the community through mobile trial facilities) and health system factors (fast and efficient service provided by friendly staff). Discussion We identified multiple barriers to achieving universal ART uptake. To enhance uptake in HIV care services, and achieve the full benefits of ART requires interventions that tackle persistent HIV stigma, and offer people with HIV respectful, convenient and efficient services. These interventions require evaluation in appropriately designed studies.	[Iwuji, Collins] Univ Sussex, Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Falmer, England; [Iwuji, Collins; Chimukuche, Rujeko Samanthia; Zuma, Thembelihle; Siedner, Mark; Shahmanesh, Maryam; Seeley, Janet] Africa Hlth Res Inst, Berea, Kwazulu Natal, South Africa; [Plazy, Melanie; Orne-Gliemann, Joanna] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, INSERM, Bordeaux, France; [Larmarange, Joseph] Ctr Populat & Dev Ceped, Inst Rech Dev IRD, Paris, France; [Siedner, Mark] Harvard Med Sch, Boston, MA 02115 USA; [Shahmanesh, Maryam] UCL, Inst Global Hlth, London, England; [Seeley, Janet] London Sch Hyg & Trop Med, London, England	University of Brighton; University of Sussex; Africa Health Research Institute; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite Paris Cite; Institut de Recherche pour le Developpement (IRD); Harvard University; Harvard Medical School; University of London; University College London; University of London; London School of Hygiene & Tropical Medicine	Iwuji, C (corresponding author), Univ Sussex, Brighton & Sussex Med Sch, Dept Global Hlth & Infect, Falmer, England.; Iwuji, C (corresponding author), Africa Hlth Res Inst, Berea, Kwazulu Natal, South Africa.	c.iwuji@bsms.ac.uk	Iwuji, Collins/AAS-3246-2020; Larmarange, Joseph/I-5889-2015; Chidawanyika, Rujeko/AAU-9737-2020	Larmarange, Joseph/0000-0001-7097-700X; Chidawanyika, Rujeko/0000-0002-4890-2105; Iwuji, Collins/0000-0003-2045-1717; Seeley, Janet/0000-0002-0583-5272; PLAZY, Melanie/0000-0002-8971-6878	French National Agency for Aids and Viral Hepatitis Research (ANRS) [ANRS 12249]; Deutsche Gesellschaft fur Internationale Zusammenarbeit (GIZ) GmbH [81151938]; International Initiative for Impact Evaluation, Inc. (3ie); Bill & Melinda Gates Foundation; Wellcome Trust; Academy of Medical Sciences, Grand Challenges Research Fund Networking Grant; HIV-Drug Resistance Elimination and Management (HDREAM) Network	French National Agency for Aids and Viral Hepatitis Research (ANRS)(ANRSFrench National Research Agency (ANR)); Deutsche Gesellschaft fur Internationale Zusammenarbeit (GIZ) GmbH; International Initiative for Impact Evaluation, Inc. (3ie); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Wellcome Trust(Wellcome TrustEuropean Commission); Academy of Medical Sciences, Grand Challenges Research Fund Networking Grant; HIV-Drug Resistance Elimination and Management (HDREAM) Network	The French National Agency for Aids and Viral Hepatitis Research (ANRS) is the sponsor and co-funder of the trial; http://www.anrs.fr (ANRS 12249). The study received additional support from the Deutsche Gesellschaft fur Internationale Zusammenarbeit (GIZ) GmbH; https://www.giz.de/en/html/index.html (81151938). The research was also co-funded by the International Initiative for Impact Evaluation, Inc. (3ie), a grantee of the Bill & Melinda Gates Foundation; http://www.3ieimpact.org.The trial is conducted with the support of Merck & Co. Inc and Gilead Sciences that provided the Atripla (R) drug supply. The Africa Health Research Institute receives core funding from the Wellcome Trust, https://wellcome.ac.uk/which provides the platform for the population-and clinic based research at the Centre. The analysis addressed within this manuscript was funded by the Academy of Medical Sciences, Grand Challenges Research Fund Networking Grant; https://acmedsci.ac.uk, awarded to Deenan Pillay and Collins Iwuji in support of the HIV-Drug Resistance Elimination and Management (HDREAM) Network. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ayieko J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202990; Bajunirwe F, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9619684; Bond V, 2019, HEALTH PLACE, V55, P87, DOI 10.1016/j.healthplace.2018.11.006; Bond V, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25117; Bor J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178249; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Camlin CS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011539; Chamie G, 2016, LANCET HIV, V3, pE111, DOI 10.1016/S2352-3018(15)00251-9; Chimbindi N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203193; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Dahab M, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-63; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; Grimsrud A, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.1.19984; Havlir D, 2018, 22 INT AIDS C 23 27; Havlir DV, 2019, NEW ENGL J MED, V381, P219, DOI 10.1056/NEJMoa1809866; Hayes B, 2017, FOOLPROOF, AND OTHER MATHEMATICAL MEDITATIONS, P71; Hayes R, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-57; Hayes RJ, 2019, NEW ENGL J MED, V381, P207, DOI 10.1056/NEJMoa1814556; Hosegood V, 2009, DEMOGR RES, V20, P279, DOI 10.4054/DemRes.2009.20.13; Iwuji CC, 2015, J AIDS CLIN RES, P6; Iwuji CC, 2018, LANCET HIV, V5, pE116, DOI 10.1016/S2352-3018(17)30205-9; Iwuji CC, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002107; Karim SSA, 2019, NEW ENGL J MED, V381, P286, DOI 10.1056/NEJMe1907279; Kawuma R, 2018, AJAR-AFR J AIDS RES, V17, P217, DOI 10.2989/16085906.2018.1490785; KITZINGER J, 1995, BRIT MED J, V311, P299, DOI 10.1136/bmj.311.7000.299; Kranzer K, 2012, J INT AIDS SOC, V15, DOI 10.7448/IAS.15.2.17383; Latkin CA, 2013, AM PSYCHOL, V68, P210, DOI 10.1037/a0032704; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Luque-Fernandez MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056088; Makhema J, 2019, NEW ENGL J MED, V381, P230, DOI 10.1056/NEJMoa1812281; Makhema MJ, 2018, 22 INT AIDS C 23 27; Musante K, 2010, PARTICIPANT OBSERVAT; Musheke M, 2013, AIDS PATIENT CARE ST, V27, P231, DOI 10.1089/apc.2012.0341; Orne-Gliemann J, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1344-y; Pantelic M, 2015, AIDS BEHAV, V19, P137, DOI 10.1007/s10461-014-0852-6; Perriat D, 2018, J INT AIDS SOC, V21, DOI 10.1002/jia2.25048; Petersen M, 2017, JAMA-J AM MED ASSOC, V317, P2196, DOI 10.1001/jama.2017.5705; Petty NJ, 2012, MANUAL THER, V17, P378, DOI 10.1016/j.math.2012.03.004; Plazy M, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20913; Probst C, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017955; Ritchie J., 2013, QUALITATIVE RES PRAC; Rodger AJ, 2016, JAMA-J AM MED ASSOC, V316, P171, DOI 10.1001/jama.2016.5148; Schwitters A, 2015, GLOB HEALTH-SCI PRAC, V3, P109, DOI 10.9745/GHSP-D-14-00145; Seeley J, 2019, AIDS BEHAV, V23, P929, DOI 10.1007/s10461-018-2335-7; Stangl AL, 2013, J INT AIDS SOC, V16, DOI 10.7448/IAS.16.3.18734; Szaflarski M, 2013, CURR HIV-AIDS REP, V10, P324, DOI 10.1007/s11904-013-0175-7; Treves-Kagan S, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2753-2; World health organisation (WHO), 2019, UN HLTH COV UHC; Yakob B, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2830-6; Zou J, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-75; Zuma T, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00073	51	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2020	15	9							e0239513	10.1371/journal.pone.0239513	http://dx.doi.org/10.1371/journal.pone.0239513			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NY2ZZ	32970730	Green Published, Green Accepted, gold			2023-01-03	WOS:000576265600094
J	Monari, S; Ferri, M; Vannini, M; Sisti, L; Marchese, P; Ehrnell, M; Xanthakis, E; Celli, A; Tassoni, A				Monari, Stefania; Ferri, Maura; Vannini, Micaela; Sisti, Laura; Marchese, Paola; Ehrnell, Maria; Xanthakis, Epameinondas; Celli, Annamaria; Tassoni, Annalisa			Cascade strategies for the full valorisation of Garganega white grape pomace towards bioactive extracts and bio-based materials	PLOS ONE			English	Article							BY-PRODUCTS; ANTIOXIDANT; POLYPHENOLS; COMPOSITES; FIBERS; FOOD; VALORIZATION; DEGRADATION; ASSAY; RED	Agro-waste reduction and reuse are among the current main social challenges. In this perspective, the present research was aimed at the complete valorisation of Garganega grape pomace by recovering bioactive phenol extracts and by testing the solid fibre extract residues in composite formulation for packaging applications. The pomace was derived from white wine production, therefore, respect to red pomace, it was promptly removed from must after pressing, and its exploitation can be particularly interesting and valuable as still rich in active compounds. Phenol extracts were obtained both via solvent-based and pressurised liquid extractions and their phytochemical compositions were compared in terms of total amount of phenols, flavonoids, flavanols, anthocyanins, hydroxycinnamic acids, and reducing sugars. Antioxidant activity and detailed phenol profiles were also achieved. The highest phenol yield was obtained via solvent-based extraction with 75% acetone (v/v), solid/liquid ratio 1:5, 2h incubation at 50 degrees C (77.9 gGAeq/kgDW). The fibrous solid residue of the extraction was characterized via thermogravimetric analysis and used for composite preparation by melt mixing with the renewable and biodegradable PHBV polymer through a green approach (solvent-less process). The composites resulted thermally stable at high temperatures, showing initial degradation processes only at temperatures higher than 250 degrees C. Differential scanning calorimetry analyses were carried out to study melting and crystallization phenomena, while mechanical properties were investigated by tensile tests. The materials finally showed properties similar to those of the matrix. The bio-composites can be considered as an alternative to plain PHBV, since they are less expensive and eco-friendlier thanks to a reduced polymeric content, and they could represent a suitable way for full agro-waste exploitation.	[Monari, Stefania; Ferri, Maura; Tassoni, Annalisa] Univ Bologna, Dept Biol Geol & Environm Sci, Bologna, Italy; [Ferri, Maura; Vannini, Micaela; Sisti, Laura; Marchese, Paola; Celli, Annamaria] Univ Bologna, Dept Civil Chem Environm & Mat Engn, Bologna, Italy; [Ehrnell, Maria; Xanthakis, Epameinondas] RISE Res Inst Sweden, Dept Agr & Food, Gothenburg, Sweden	University of Bologna; University of Bologna; RISE Research Institutes of Sweden	Tassoni, A (corresponding author), Univ Bologna, Dept Biol Geol & Environm Sci, Bologna, Italy.; Vannini, M (corresponding author), Univ Bologna, Dept Civil Chem Environm & Mat Engn, Bologna, Italy.	micaela.vannini@unibo.it; annalisa.tassoni2@unibo.it	Celli, Annamaria/K-7631-2013; TASSONI, ANNALISA/G-3981-2012	Celli, Annamaria/0000-0002-5974-1642; FERRI, MAURA/0000-0001-5428-4369; TASSONI, ANNALISA/0000-0002-3541-4030	European Union's Horizon 2020 research and innovation programme [688338]	European Union's Horizon 2020 research and innovation programme	This work was supported by the NoAW project ("Innovative approaches to turn agricultural waste into ecological and economic assets"), founded by the European Union ' s Horizon 2020 research and innovation programme (grant agreement No 688338) to EX, AC, AT. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ahmad B, 2020, SCI TOTAL ENVIRON, V719, DOI 10.1016/j.scitotenv.2020.137315; Amutio M, 2012, FUEL, V95, P305, DOI 10.1016/j.fuel.2011.10.008; Aoyagi Y, 2002, POLYM DEGRAD STABIL, V76, P53, DOI 10.1016/S0141-3910(01)00265-8; BAILEY MJ, 1992, J BIOTECHNOL, V23, P257, DOI 10.1016/0168-1656(92)90074-J; Balla VK, 2019, COMPOS PART B-ENG, V174, DOI 10.1016/j.compositesb.2019.106956; Benyahya S, 2014, IND CROP PROD, V53, P296, DOI 10.1016/j.indcrop.2013.12.045; Berthet MA, 2015, COMPOS PART A-APPL S, V72, P139, DOI 10.1016/j.compositesa.2015.02.006; Bledzki AK, 2010, COMPOS SCI TECHNOL, V70, P1687, DOI 10.1016/j.compscitech.2010.06.005; Considine JA, 2014, COMPLETE GUIDE QUALI; Deng Q, 2011, FOOD RES INT, V44, P2712, DOI 10.1016/j.foodres.2011.05.026; FAOSTAT, 2017, FOOD AGR DAT; Ferri M, 2009, PROTEOMICS, V9, P610, DOI 10.1002/pmic.200800386; Ferri M, 2020, J ADV RES, V24, P1, DOI 10.1016/j.jare.2020.02.015; Ferri M, 2017, NEW BIOTECHNOL, V39, P51, DOI 10.1016/j.nbt.2017.07.002; Ferri M, 2016, NEW BIOTECHNOL, V33, P338, DOI 10.1016/j.nbt.2015.12.004; Ferri M, 2013, J FOOD COMPOS ANAL, V30, P94, DOI 10.1016/j.jfca.2013.02.004; Fontana AR, 2013, J AGR FOOD CHEM, V61, P8987, DOI 10.1021/jf402586f; Garcia-Lomillo J, 2017, COMPR REV FOOD SCI F, V16, P3, DOI 10.1111/1541-4337.12238; Gonzalez-Centeno MR, 2013, J AGR FOOD CHEM, V61, P11579, DOI 10.1021/jf403168k; Gowman A, 2018, ACS OMEGA, V3, P15205, DOI 10.1021/acsomega.8b01675; Gowman AC, 2019, BIORESOURCES, V14, P10047, DOI 10.15376/biores.14.4.Gowman; Gullon P, 2018, SCI TOTAL ENVIRON, V624, P225, DOI 10.1016/j.scitotenv.2017.12.036; Hassaini L, 2017, POLYM TEST, V59, P430, DOI 10.1016/j.polymertesting.2017.03.004; Hogan S, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-71; Jayaprakasha GK, 2003, FOOD RES INT, V36, P117, DOI 10.1016/S0963-9969(02)00116-3; Kalli E, 2018, BIORESOUR BIOPROCESS, V5, DOI 10.1186/s40643-018-0232-6; Kawalec M, 2008, MACROMOL SYMP, V272, P63, DOI 10.1002/masy.200851208; Sanchez-Safont EL, 2016, J RENEW MATER, V4, P123, DOI 10.7569/JRM.2015.634127; Lucarini M, 2018, MOLECULES, V23, DOI 10.3390/molecules23081888; Madeddu C, 2021, WASTE BIOMASS VALORI, V12, P1143, DOI 10.1007/s12649-020-01082-6; Mantell C, 2003, ENG LIFE SCI, V3, P38, DOI 10.1002/elsc.200390004; Martins IM, 2016, FOOD RES INT, V89, P533, DOI 10.1016/j.foodres.2016.09.009; MCMURROUGH I, 1978, ANAL BIOCHEM, V91, P92, DOI 10.1016/0003-2697(78)90819-9; Moliner C., 2017, CHEM ENG T, V57, P1417, DOI DOI 10.3303/CET1757237; Muhlack RA, 2018, WASTE MANAGE, V72, P99, DOI 10.1016/j.wasman.2017.11.011; Mustafa A, 2011, ANAL CHIM ACTA, V703, P8, DOI 10.1016/j.aca.2011.07.018; Muthuraj R, 2017, J APPL POLYM SCI, V134, DOI 10.1002/app.44860; Nackz M, 2004, J CHROMATOGR A, V1054, P93; Nanni A, 2020, J APPL POLYM SCI, V137, DOI 10.1002/app.48869; Nanni A, 2018, POLYM DEGRAD STABIL, V149, P9, DOI 10.1016/j.polymdegradstab.2018.01.012; Pinelo M, 2005, J AGR FOOD CHEM, V53, P2111, DOI 10.1021/jf0488110; Pinta D, 2018, CROPS PROD, V111, P379, DOI DOI 10.1016/J.INDCROP.2017.10.038; Rasines-Perea Zurine, 2018, Diseases, V6, DOI 10.3390/diseases6030060; Righetti MC, 2019, MATERIALS, V12, DOI 10.3390/ma12060990; Rivera-Briso AL, 2018, POLYMERS-BASEL, V10, DOI 10.3390/polym10070732; Saccani A, 2019, POLYM COMPOSITE, V40, P1378, DOI 10.1002/pc.24870; Saccani A, 2018, J APPL POLYM SCI, V135, DOI 10.1002/app.46234; Shi J, 2003, J FOOD AGRIC ENVIRON, V1, P42; Sirohi R, 2020, BIORESOURCE TECHNOL, V314, DOI 10.1016/j.biortech.2020.123771; Sisti L, 2018, J ENVIRON CHEM ENG, V6, P4452, DOI 10.1016/j.jece.2018.06.066; Sisti L, 2016, IND CROP PROD, V81, P56, DOI 10.1016/j.indcrop.2015.11.045; Spitalsky Z, 2006, POLYM DEGRAD STABIL, V91, P856, DOI 10.1016/j.polymdegradstab.2005.06.019; Stefan MB, 2014, FOOD ANAL METHOD, V7, P326, DOI 10.1007/s12161-013-9630-8; Tassoni A, 2019, WASTES SOLUTIONS TRE, P440; Tassoni A, 2020, MOLECULES, V25, DOI 10.3390/molecules25061383; Teixeira A, 2014, INT J MOL SCI, V15, P15638, DOI 10.3390/ijms150915638; Torres-Giner S, 2018, FOOD PACKAGING SHELF, V17, P39, DOI 10.1016/j.fpsl.2018.05.002; Totaro G, 2018, COMPOS PART B-ENG, V139, P195, DOI 10.1016/j.compositesb.2017.11.055; Vaisanen T, 2017, J CLEAN PROD, V149, P582, DOI 10.1016/j.jclepro.2017.02.132; 2019, CAN J KIDNEY HLTH DI, V6, P1	60	4	4	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2020	15	9							e0239629	10.1371/journal.pone.0239629	http://dx.doi.org/10.1371/journal.pone.0239629			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU7WV	32946525	Green Published, gold			2023-01-03	WOS:000573851100059
J	McCoy, TH; Pellegrini, AM; Perlis, RH				McCoy, Thomas H., Jr.; Pellegrini, Amelia M.; Perlis, Roy H.			Differences among Research Domain Criteria score trajectories by Diagnostic and Statistical Manual categorical diagnosis during inpatient hospitalization	PLOS ONE			English	Article							DEPRESSIVE SYMPTOMS; PRECISION MEDICINE; RDOC; DSM-5; RISK	With brief psychiatric hospitalizations, the extent to which symptoms change is rarely characterized. We sought to understand symptomatic changes across Research Domain Criteria (RDoC) dimensions, and the extent to which such improvement might be associated with risk for readmission. We identified 3,634 individuals with 4,713 hospital admissions to the psychiatric inpatient unit of a large academic medical center between 2010 and 2015. We applied a natural language processing tool to extract estimates of the five RDoC domains to the admission note and discharge summary and calculated the change in each domain. We examined the extent to which symptom domains changed during admission, and their relationship to baseline clinical and sociodemographic features, using linear regression. Symptomatic worsening was rare in the negative valence (0.4%) and positive valence (5.1%) domains, but more common in cognition (25.8%). Most diagnoses exhibited improvement in negative valence, which was associated with significant reduction in readmission risk. Despite generally brief hospital stays, we detected reduction across multiple symptom domains, with greatest improvement in negative symptoms, and greatest probability of worsening in cognitive symptoms. This approach should facilitate investigations of other features or interventions which may influence pace of clinical improvement.	[McCoy, Thomas H., Jr.; Pellegrini, Amelia M.; Perlis, Roy H.] Massachusetts Gen Hosp, Ctr Quantitat Hlth, Boston, MA 02114 USA; [McCoy, Thomas H., Jr.; Perlis, Roy H.] Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA; [McCoy, Thomas H., Jr.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	McCoy, TH (corresponding author), Massachusetts Gen Hosp, Ctr Quantitat Hlth, Boston, MA 02114 USA.; McCoy, TH (corresponding author), Harvard Med Sch, Dept Psychiat, Boston, MA 02115 USA.; McCoy, TH (corresponding author), Harvard Med Sch, Dept Med, Boston, MA 02115 USA.	thmccoy@partners.org		McCoy, Thomas/0000-0002-5624-0439	Brain and Behavior Research Foundation; National Institute of Mental Health [1R01MH106577]; National Institute of Aging [R01MH104488]	Brain and Behavior Research Foundation; National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This study was funded by the Brain and Behavior Research Foundation, the National Institute of Mental Health (grant number 1R01MH106577), and the National Institute of Aging (Supplement to R01MH104488). The sponsors had no role in study design, writing of the report, or data collection, analysis, or interpretation.	Anda L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167390; Barbato A, 2011, NORD J PSYCHIAT, V65, P251, DOI 10.3109/08039488.2010.533387; Cancino RS, 2014, J HOSP MED, V9, P358, DOI 10.1002/jhm.2180; Casey BJ, 2013, NAT REV NEUROSCI, V14, P810, DOI 10.1038/nrn3621; Clapp JD, 2013, J CLIN PSYCHIAT, V74, P492, DOI 10.4088/JCP.12m07842; Clark LA, 2017, PSYCHOL SCI PUBL INT, V18, P72, DOI 10.1177/1529100617727266; Cuthbert BN, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-126; Fernandes BS, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0849-x; Fojo AT, 2017, J PSYCHIATR RES, V95, P147, DOI 10.1016/j.jpsychires.2017.08.008; Franke B, 2018, EUR NEUROPSYCHOPHARM, V28, P1059, DOI 10.1016/j.euroneuro.2018.08.001; Garvey MA, 2017, SCHIZOPHRENIA BULL, V43, P935, DOI 10.1093/schbul/sbx095; Insel T., 2013, NIMH DIRECTORS BLOG; Insel T, 2010, AM J PSYCHIAT, V167, P748, DOI 10.1176/appi.ajp.2010.09091379; Insel TR, 2015, SCIENCE, V348, P499, DOI 10.1126/science.aab2358; Insel TR, 2014, AM J PSYCHIAT, V171, P395, DOI 10.1176/appi.ajp.2014.14020138; McCoy TH, 2020, ALZHEIMERS DEMENTI S; McCoy TH, 2015, AM J PSYCHIAT, V172, P316, DOI 10.1176/appi.ajp.2014.14091177; McCoy TH, 2019, DEPRESS ANXIETY, V36, P392, DOI 10.1002/da.22882; McCoy TH, 2018, BIOL PSYCHIAT, V83, P997, DOI 10.1016/j.biopsych.2018.01.011; McCoy TH, 2018, BIOL PSYCHIAT, V83, P1005, DOI 10.1016/j.biopsych.2017.12.004; McMahon FJ, 2012, NEURON, V74, P773, DOI 10.1016/j.neuron.2012.05.004; Melchior H, 2016, PSYCHIAT RES, V238, P228, DOI 10.1016/j.psychres.2016.02.046; Mirza SS, 2016, LANCET PSYCHIAT, V3, P628, DOI 10.1016/S2215-0366(16)00097-3; Murphy Shawn N, 2007, AMIA Annu Symp Proc, P548; Murphy SN, 2010, J AM MED INFORM ASSN, V17, P124, DOI 10.1136/jamia.2009.000893; NEIMEYER RA, 1995, B MENNINGER CLIN, V59, P460; Patrick CJ, 2016, PSYCHOPHYSIOLOGY, V53, P281, DOI 10.1111/psyp.12613; van Mierlo M, 2018, DISABIL REHABIL, V40, P997, DOI 10.1080/09638288.2017.1292320; Yu S., CQH DIMENSIONAL PHEN; [No title captured]	30	4	4	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2020	15	8							e0237698	10.1371/journal.pone.0237698	http://dx.doi.org/10.1371/journal.pone.0237698			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NI7UF	32842139	Green Published, gold			2023-01-03	WOS:000565553400052
J	Baral, R; Fleming, J; Khan, S; Higgins, D; Hendrix, N; Pecenka, C				Baral, Ranju; Fleming, Jessica; Khan, Sadaf; Higgins, Deborah; Hendrix, Nathaniel; Pecenka, Clint			Inferring antenatal care visit timing in low- and middle-income countries: Methods to inform potential maternal vaccine coverage	PLOS ONE			English	Article								Background The timing of antenatal care (ANC) visits directly affect health intervention coverage and impact, especially for those interventions requiring strict gestational age windows for administration, such as maternal respiratory syncytial virus (RSV) vaccine. Existing nationally representative population-based surveys do not record the timing of ANC visits beyond the first, limiting the availability of reliable data around timing of subsequent ANC visits in most low- and middle-income countries (LMICs). Here, we describe a model that estimates the timing of ANC visits by gestational age using publicly available multi-country survey data. Methods and findings We used the Demographic and Health Surveys (DHS) data from 69 LMICs. We used several factors to estimate the timing of subsequent ANC visits by gestation age: the timing of the first ANC visit (ANC1) in a given pregnancy, derived from the DHS; the country's reported average ANC coverage at each ANC visit (ANC1 through the fourth ANC visit [ANC4]); and the World Health Organization's guidance on recommended ANC visit. We then used the timing of ANC visit by gestation age to predict the coverage of a potential maternal RSV vaccine administered at 24-36 weeks of gestation. We calculated the maternal immunization coverage by summing the number of eligible women vaccinated at any ANC visit divided by the total number of pregnant women. We find, in general, countries with higher ANC1 coverage were predicted to have higher vaccination coverage. In 82% of countries, the modeled vaccine coverage is less than ANC4 coverage. Conclusions The methods illustrated in this paper have implications on the precision of estimating impact and programmatic feasibility of time-critical interventions, especially for pregnant women. The methods can be easily adapted to vaccine demand forecasts models, vaccine impact assessments, and cost-effectiveness analyses and can be adapted to other maternal interventions that have administration timing restrictions.	[Baral, Ranju; Fleming, Jessica; Khan, Sadaf; Higgins, Deborah; Pecenka, Clint] PATH, Seattle, WA 98121 USA; [Hendrix, Nathaniel] Univ Washington, Comparat Hlth Outcomes Policy & Econ CHOICE Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Baral, R (corresponding author), PATH, Seattle, WA 98121 USA.	rbaral@path.org			Bill & Melinda Gates Foundation, Seattle, WA [OPP1088264]	Bill & Melinda Gates Foundation, Seattle, WA(Bill & Melinda Gates Foundation)	This work was supported by a grant (#OPP1088264) from the Bill & Melinda Gates Foundation, Seattle, WA. The findings and conclusions contained within are those of the authors and do not necessarily reflect positions or policies of the Bill & Melinda Gates Foundation.	Demographic and Health Surveys (DHS) Program, 2018, DEM HLTH SURV MOD WO; Gravett CA, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001324; indepth-network.org, INDEPTH NETW BETT HL; Initiative for Vaccine Research (IVR) of the Department of Immunization Vaccines and Biologicals, 2017, WHO PREF PROD CHAR R; Lawn JE, 2016, LANCET, V387, P587, DOI 10.1016/S0140-6736(15)00837-5; UNICEF, 2019, MICS TOOLS; UNICEF, 2019, UNICEF DAT ANT CAR; UNICEF, 2014, STAT MON MULT IND CL; United Nations Department of Economic and Social Affairs, 2019, WORLD POP PROSP; United Nations Inter-agency Group for Child Mortality Estimation, 2020, LEVELS TRENDS CHILD; USAID. The DHS Program Demographic and Health Surveys, DHS PROGR DEM HLTH S; Wax JR, 2016, OBSTET GYNECOL, V128, pE231; WHO, 2020, GLOB HLTH OBS GHO DA; World Health Organization (WHO), 2019, WHO REC SURV STAND N	14	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2020	15	8							e0237718	10.1371/journal.pone.0237718	http://dx.doi.org/10.1371/journal.pone.0237718			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG9QD	32817688	gold, Green Published			2023-01-03	WOS:000564315600014
J	Hall, WJ				Hall, William J.			In older adults, some antidepressants were associated with increased fracture risk	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									[Hall, William J.] Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Hall, WJ (corresponding author), Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA.							Fahrni ML, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219898; Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767	2	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 18	2020	173	4					JC23	JC23		10.7326/ACPJ202008180-023	http://dx.doi.org/10.7326/ACPJ202008180-023			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK9TG	32805165				2023-01-03	WOS:000567070300011
J	Weissenberger, M; Weissenberger, MH; Wagenbrenner, M; Heinz, T; Reboredo, J; Holzapfel, BM; Rudert, M; Groll, J; Evans, CH; Steinert, AF				Weissenberger, Manuel; Weissenberger, Manuela H.; Wagenbrenner, Mike; Heinz, Tizian; Reboredo, Jenny; Holzapfel, Boris M.; Rudert, Maximilian; Groll, Juergen; Evans, Christopher H.; Steinert, Andre F.			Different types of cartilage neotissue fabricated from collagen hydrogels and mesenchymal stromal cells via SOX9, TGFB1 or BMP2 gene transfer	PLOS ONE			English	Article							STEM-CELLS; IN-VITRO; CHONDROGENIC DIFFERENTIATION; REPAIR; CHONDROCYTES; TRANSPLANTATION; STIMULATION; SCAFFOLDS; DEFECTS; THERAPY	Objective As native cartilage consists of different phenotypical zones, this study aims to fabricate different types of neocartilage constructs from collagen hydrogels and human mesenchymal stromal cells (MSCs) genetically modified to express different chondrogenic factors. Design Human MSCs derived from bone-marrow of osteoarthritis (OA) hips were genetically modified using adenoviral vectors encoding sex-determining region Y-type high-mobility-group-box (SOX)9,transforming growth factor beta (TGFB) 1or bone morphogenetic protein (BMP) 2cDNA, placed in type I collagen hydrogels and maintained in serum-free chondrogenic media for three weeks. Control constructs contained unmodified MSCs or MSCs expressing GFP. The respective constructs were analyzed histologically, immunohistochemically, biochemically, and by qRT-PCR for chondrogenesis and hypertrophy. Results Chondrogenesis in MSCs was consistently and strongly induced in collagen I hydrogels by the transgenesSOX9,TGFB1andBMP2as evidenced by positive staining for proteoglycans, chondroitin-4-sulfate (CS4) and collagen (COL) type II, increased levels of glycosaminoglycan (GAG) synthesis, and expression of mRNAs associated with chondrogenesis. The control groups were entirely non-chondrogenic. The levels of hypertrophy, as judged by expression of alkaline phosphatase (ALP) and COL X on both the protein and mRNA levels revealed different stages of hypertrophy within the chondrogenic groups (BMP2>TGFB1>SOX9). Conclusions Different types of neocartilage with varying levels of hypertrophy could be generated from human MSCs in collagen hydrogels by transfer of genes encoding the chondrogenic factorsSOX9,TGFB1andBMP2. This technology may be harnessed for regeneration of specific zones of native cartilage upon damage.	[Weissenberger, Manuel; Weissenberger, Manuela H.; Wagenbrenner, Mike; Heinz, Tizian; Holzapfel, Boris M.; Rudert, Maximilian; Steinert, Andre F.] Julius Maximilians Univ Wurzburg, Orthopaed Ctr Musculoskeletal Res OCMR, Dept Orthopaed Surg, Konig Ludwig Haus, Wurzburg, Germany; [Reboredo, Jenny] Julius Maximilians Univ Wurzburg, Dept Tissue Engn & Regenerat Med, Wurzburg, Germany; [Groll, Juergen] Julius Maximilians Univ Wurzburg, Dept Funct Mat Med & Dent, Wurzburg, Germany; [Evans, Christopher H.] Mayo Clin, Musculoskeletal Gene Therapy Res Lab, Dept Phys Med & Rehabil, Rochester, MN USA; [Steinert, Andre F.] Rhon Klinikum, Dept Orthopaed Trauma Shoulder & Arthroplasty Sur, Campus Bad Neustadt, Bad Neustadt an der Saale, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg; Mayo Clinic; Rhon-Klinikum AG	Weissenberger, M (corresponding author), Julius Maximilians Univ Wurzburg, Orthopaed Ctr Musculoskeletal Res OCMR, Dept Orthopaed Surg, Konig Ludwig Haus, Wurzburg, Germany.	m-weissenberger.klh@uni-wuerzburg.de			Deutsche Forschungsgemeinschaft (DFG) [STE 105/3-1, STE 105/3-2]; Interdisciplinary Center for Clinical Research (IKZF) Wurzburg, Germany; German Research Foundation (DFG); University of Wuerzburg	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Interdisciplinary Center for Clinical Research (IKZF) Wurzburg, Germany; German Research Foundation (DFG)(German Research Foundation (DFG)); University of Wuerzburg	This research was supported in parts by grants STE 105/3-1 and 3-2 from the Deutsche Forschungsgemeinschaft (DFG) to AFS and JG from the Interdisciplinary Center for Clinical Research (IKZF) Wurzburg, Germany. This publication was funded by the German Research Foundation (DFG) and the University of Wuerzburg in the funding programme Open Acess Publishing.	Berebichez-Fridman Roberto, 2018, Sultan Qaboos Univ Med J, V18, pe264, DOI 10.18295/squmj.2018.18.03.002; Cao L, 2011, BIOMATERIALS, V32, P3910, DOI 10.1016/j.biomaterials.2011.02.014; Dickhut A, 2010, TISSUE ENG PT A, V16, P453, DOI [10.1089/ten.tea.2009.0168, 10.1089/ten.TEA.2009.0168]; Evans CH, 2000, CLIN ORTHOP RELAT R, pS214; FRIEDENSTEIN AJ, 1987, CELL TISSUE KINET, V20, P263, DOI 10.1111/j.1365-2184.1987.tb01309.x; Goodrich LR, 2007, J BONE JOINT SURG BR, V89B, P672, DOI 10.1302/0301-620X.89B5.18343; Gugjoo MB, 2016, INDIAN J MED RES, V144, P339, DOI 10.4103/0971-5916.198724; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; He CX, 2012, BIOTECHNOL APPL BIOC, V59, P163, DOI 10.1002/bab.1001; Huang BJ, 2016, BIOMATERIALS, V98, P1, DOI 10.1016/j.biomaterials.2016.04.018; Irawan V, 2018, TISSUE ENG REGEN MED, V15, P673, DOI 10.1007/s13770-018-0135-9; Izadifar Z, 2012, J FUNCT BIOMATER, V3, P799, DOI 10.3390/jfb3040799; Jiang XF, 2018, BIOMATER SCI-UK, V6, P1556, DOI 10.1039/c8bm00317c; Kaul G, 2006, J GENE MED, V8, P100, DOI 10.1002/jgm.819; Kino-Oka M, 2005, TISSUE ENG, V11, P597, DOI 10.1089/ten.2005.11.597; Kupcsik L, 2010, TISSUE ENG PT A, V16, P1845, DOI [10.1089/ten.tea.2009.0531, 10.1089/ten.TEA.2009.0531]; Kuroda R, 2007, OSTEOARTHR CARTILAGE, V15, P226, DOI 10.1016/j.joca.2006.08.008; Lee JM, 2012, BIOMATERIALS, V33, P2016, DOI 10.1016/j.biomaterials.2011.11.050; Leng P, 2012, KNEE, V19, P804, DOI 10.1016/j.knee.2012.03.009; Li L, 2019, J ORTHOP TRANSL, V17, P26, DOI 10.1016/j.jot.2018.09.003; Li WJ, 2005, BIOMATERIALS, V26, P599, DOI 10.1016/j.biomaterials.2004.03.005; Lu CH, 2014, MOL THER, V22, P186, DOI 10.1038/mt.2013.165; Mennan C, 2019, CARTILAGE, V10, P467, DOI 10.1177/1947603518769714; Mesure B, 2019, CURR STEM CELL RES T, V14, P337, DOI 10.2174/1574888X14666181205121658; Noth U, 2007, J BIOMED MATER RES A, V83A, P626, DOI 10.1002/jbm.a.31254; Noth U, 2002, TISSUE ENG, V8, P131, DOI 10.1089/107632702753503126; Orth P, 2011, KNEE SURG SPORT TR A, V19, P2119, DOI 10.1007/s00167-011-1448-6; Palmer Glyn D, 2003, Methods Mol Biol, V215, P235; Schenker H, 2017, ORTHOPADE, V46, P907, DOI 10.1007/s00132-017-3474-7; Schneider U, 2011, AM J SPORT MED, V39, P2558, DOI 10.1177/0363546511423369; Sharma Preeti, 2019, J Med Life, V12, P225, DOI 10.25122/jml-2019-0032; Steinert AF, 2008, INJURY, V39, pS97, DOI 10.1016/j.injury.2008.01.034; Steinert AF, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2195; Steinert AF, 2009, ARTHRITIS RES THER, V11, DOI 10.1186/ar2822; Steinert AF, 2009, TISSUE ENG PT A, V15, P1127, DOI 10.1089/ten.tea.2007.0252; Stellavato A, 2016, J CELL BIOCHEM, V117, P2158, DOI 10.1002/jcb.25556; Takahashi T, 2007, TISSUE ENG, V13, P1583, DOI 10.1089/ten.2006.0322; Trippel SB, 2004, GENE THER, V11, P351, DOI 10.1038/sj.gt.3302201; Venkatesan JK, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092635; Venkatesan JK, 2012, STEM CELL RES THER, V3, DOI 10.1186/scrt113; Wang X, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116061; Weissenberger M, 2020, BMC MUSCULOSKEL DIS, V21, DOI 10.1186/s12891-020-3137-4; Xia WY, 2009, BIOTECHNOL LETT, V31, P639, DOI 10.1007/s10529-009-9930-7; Yan X, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01534; Zhang L, 2012, J BIOMED MATER RES A, V100A, P2717, DOI 10.1002/jbm.a.34194; Zhang XM, 2018, CURR STEM CELL RES T, V13, P497, DOI 10.2174/1574888X12666171017160323; Zylinska B, 2018, IN VIVO, V32, P1289, DOI 10.21873/invivo.11379	47	5	5	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2020	15	8							e0237479	10.1371/journal.pone.0237479	http://dx.doi.org/10.1371/journal.pone.0237479			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE5VG	32790806	Green Published, gold			2023-01-03	WOS:000562668300085
J	Mizuno, M; Endo, K; Katano, H; Tsuji, A; Kojima, N; Watanabe, K; Shimizu, N; Morio, T; Sekiya, I				Mizuno, Mitsuru; Endo, Kentaro; Katano, Hisako; Tsuji, Ayako; Kojima, Naomi; Watanabe, Ken; Shimizu, Norio; Morio, Tomohiro; Sekiya, Ichiro			The environmental risk assessment of cell-processing facilities for cell therapy in a Japanese academic institution	PLOS ONE			English	Article							PSOCOPTERA LIPOSCELIDIDAE; MICROBIAL-CONTAMINATION; CONSTANT TEMPERATURES; POPULATION-GROWTH; STEM-CELLS; AIR; COMMUNITY; BACTERIA; INSECTS; WATER	Cell therapy is a promising treatment. One of the key aspects of cell processing products is ensuring sterility of cell-processing facilities (CPFs). The objective of this study was to assess the environmental risk factors inside and outside CPFs. We monitored the temperature, humidity, particle number, colony number of microorganisms, bacteria, fungi, and harmful insects in and around our CPF monthly over one year. The temperature in the CPF was constant but the humidity fluctuated depending on the humidity outside. The particle number correlated with the number of entries to the room. Except for winter, colonies of microorganisms and harmful insects were detected depending on the cleanliness of the room. Seven bacterial and two fungal species were identified by PCR analyses. Psocoptera and Acari each accounted for 41% of the total trapped insects. These results provide useful data for taking the appropriate steps to keep entire CPFs clean.	[Mizuno, Mitsuru; Endo, Kentaro; Katano, Hisako; Kojima, Naomi; Watanabe, Ken; Shimizu, Norio; Sekiya, Ichiro] Tokyo Med & Dent Univ, Ctr Stem Cell & Regenerat Med, Bunkyo Ku, Tokyo, Japan; [Mizuno, Mitsuru; Katano, Hisako; Tsuji, Ayako; Shimizu, Norio; Morio, Tomohiro; Sekiya, Ichiro] Tokyo Med & Dent Univ, Ctr Transfus Med & Cell Therapy, Bunkyo Ku, Tokyo, Japan; [Morio, Tomohiro] Tokyo Med & Dent Univ, Grad Sch, Dept Pediat & Dev Biol, Bunkyo Ku, Tokyo, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Sekiya, I (corresponding author), Tokyo Med & Dent Univ, Ctr Stem Cell & Regenerat Med, Bunkyo Ku, Tokyo, Japan.; Sekiya, I (corresponding author), Tokyo Med & Dent Univ, Ctr Transfus Med & Cell Therapy, Bunkyo Ku, Tokyo, Japan.	sekiya.arm@tmd.ac.jp	Mitsuru, Mizuno/K-3962-2017; Endo, Kentaro/M-9427-2019	Mitsuru, Mizuno/0000-0002-4410-3621; Endo, Kentaro/0000-0003-4790-4632	Japan Agency for Medical Research and Development (AMED) [JP18bk0104065]	Japan Agency for Medical Research and Development (AMED)(Japan Agency for Medical Research and Development (AMED))	The Research Project for Practical Applications of Regenerative Medicine (JP18bk0104065) supported IS from the Japan Agency for Medical Research and Development (AMED) to complete this study.	AHEARN DG, 1991, J IND MICROBIOL, V8, P277, DOI 10.1007/BF01576067; Balasubramanian R, 2012, AEROBIOLOGIA, V28, P375, DOI 10.1007/s10453-011-9242-y; Baz A., 2008, ENCY ENTOMOLOGY, P381, DOI 10.1007/0-306-48380-7_416; Chaves F, 2005, J CLIN MICROBIOL, V43, P4877, DOI 10.1128/JCM.43.9.4877-4879.2005; Cobo F, 2007, LETT APPL MICROBIOL, V44, P379, DOI 10.1111/j.1472-765X.2006.02095.x; Cooley JD, 1998, OCCUP ENVIRON MED, V55, P579, DOI 10.1136/oem.55.9.579; Damani N., 2019, MANUAL INFECT PREVEN; Gautam SG, 2010, J ECON ENTOMOL, V103, P1920, DOI 10.1603/EC10127; Gomez-Silvan C, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0453-0; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Gunar OV, 2011, PHARM CHEM J+, V45, P93, DOI 10.1007/s11094-011-0568-0; Gurung K, 2019, ENTOMOL EXP APPL, V167, P156, DOI 10.1111/eea.12768; Hamdy AM, 2018, OMICS, V22, P133, DOI 10.1089/omi.2017.0091; Hara A, 2014, THER INNOV REGUL SCI, V48, P681, DOI 10.1177/2168479014526877; Johnson M, 2008, NUCLEIC ACIDS RES, V36, pW5, DOI 10.1093/nar/gkn201; Kelley ST, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-2-202; Koenig DW, 1997, WATER SCI TECHNOL, V35, P59, DOI 10.1016/S0273-1223(97)00235-7; Konomi K, 2015, CELL STEM CELL, V16, P350, DOI 10.1016/j.stem.2015.03.012; Kubota H, 2012, APPL ENVIRON MICROB, V78, P3317, DOI 10.1128/AEM.07816-11; Landrin A, 2005, J HOSP INFECT, V61, P27, DOI 10.1016/j.jhin.2005.03.002; Leong LEX, 2018, EMERG INFECT DIS, V24, P2109, DOI 10.3201/eid2411.171929; Lestan D, 1999, WORLD J MICROB BIOT, V15, P349, DOI 10.1023/A:1008983521015; Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368; Merino N, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-018-5389-z; Mirhoseini SH, 2015, ANN AGR ENV MED, V22, P670, DOI 10.5604/12321966.1185772; Mizutani M, 2016, REGEN THER, V5, P25, DOI 10.1016/j.reth.2016.06.004; Mora M, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01573; Nadarasah G, 2011, FEMS MICROBIOL REV, V35, P555, DOI 10.1111/j.1574-6976.2011.00264.x; Novotny C, 2000, APPL MICROBIOL BIOT, V54, P850, DOI 10.1007/s002530000432; Ogawa Y, 2019, REGEN THER, V12, P36, DOI 10.1016/j.reth.2019.04.002; Opit GP, 2009, J ECON ENTOMOL, V102, P1360, DOI 10.1603/029.102.0364; Pacchioni F, 2018, BMC MICROBIOL, V18, DOI 10.1186/s12866-018-1267-8; Park HK, 2014, J APPL MICROBIOL, V116, P718, DOI 10.1111/jam.12416; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prussin AJ, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0144-z; Ruiu L, 2015, INSECTS, V6, P352, DOI 10.3390/insects6020352; Ryan MP, 2010, J HOSP INFECT, V75, P153, DOI 10.1016/j.jhin.2010.03.007; Ryan MP, 2006, J HOSP INFECT, V62, P278, DOI 10.1016/j.jhin.2005.08.015; Sandle T., 2015, PHARM MICROBIOLOGY; Sandle Tim, 2011, PDA J Pharm Sci Technol, V65, P392, DOI 10.5731/pdajpst.2011.00765; Scaltriti S, 2007, J HOSP INFECT, V66, P320, DOI 10.1016/j.jhin.2007.05.019; Schroeder Hilke, 2003, Leg Med (Tokyo), V5 Suppl 1, pS372; Sekiya I, 2019, CELL TRANSPLANT, V28, P1445, DOI 10.1177/0963689719863793; Sekiya I, 2015, CLIN ORTHOP RELAT R, V473, P2316, DOI 10.1007/s11999-015-4324-8; Stocks GW, 2010, AM J INFECT CONTROL, V38, P199, DOI 10.1016/j.ajic.2009.07.006; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takai K, 2000, APPL ENVIRON MICROB, V66, P5066, DOI 10.1128/AEM.66.11.5066-5072.2000; Tse H, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0052809 23285189, DOI 10.1371/JOURNAL.PONE.0052809 23285189]; Vijayakumar R, 2019, J APPL MICROBIOL, V126, P1011, DOI 10.1111/jam.14118; Whyte W, 1981, J Parenter Sci Technol, V35, P255; Yano T, 2013, MICROBES ENVIRON, V28, P87, DOI 10.1264/jsme2.ME12146; Zhao GZ, 2009, INT J SYST EVOL MICR, V59, P2383, DOI 10.1099/ijs.0.010256-0	52	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2020	15	8							e0236600	10.1371/journal.pone.0236600	http://dx.doi.org/10.1371/journal.pone.0236600			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB3DK	32756610	Green Published, gold			2023-01-03	WOS:000560393300060
J	Kim, H; Lim, YK; Goh, Y; Jeong, C; Hwang, UJ; Choi, SH; Cho, B; Kwak, J				Kim, Hojin; Lim, Young Kyung; Goh, Youngmoon; Jeong, Chiyoung; Hwang, Ui-Jung; Choi, Sang Hyoun; Cho, Byungchul; Kwak, Jungwon			Plan optimization with L0-norm and group sparsity constraints for a new rotational, intensity-modulated brachytherapy for cervical cancer	PLOS ONE			English	Article							BEAM ORIENTATION OPTIMIZATION; RADIATION-THERAPY; INTERSTITIAL BRACHYTHERAPY; CLINICAL IMPACT; RECOMMENDATIONS; DOSIMETRY; PRINCIPLES; PARAMETERS; ALGORITHM; TERMS	The aim of this work is to build a framework that comprehends inverse planning procedure and plan optimization algorithm tailored to a novel directional beam intensity-modulated brachytherapy (IMBT) of cervical cancer using a rotatable, single-channel radiation shield. Inverse planning is required for finding optimal beam emitting direction, source dwell position and dwell time, which begin with creating a kernel matrix for each structure based on Monte-Carlo simulated dose distribution in the rotatable shield. For efficient beam delivery and less transit dose, the number of source dwell positions and angles needs to be minimized. It can be solved by L0-norm regularization for fewest possible dwell points, and by group sparsity constraint in L2,p-norm (0 <= p<1) besides L0-norm for fewest active applicator rotating angles. The dose distributions from our proposed algorithms were compared to those of conventional tandem-based intracavitary brachytherapy (ICR) plans for six cervical cancer patients. The algorithmic performance was evaluated in delivery efficiency and plan quality relative to the unconstrained algorithm. The proposed framework yielded substantially enhanced plan quality over the conventional ICR plans. The L0-norm and (group sparsity+L0-norm) constrained algorithms reduced the number of source dwell points by 60 and 70% and saved 5 and 8 rotational angles on average (7 and 11 angles for highly modulated cases), relative to the unconstrained algorithm, respectively. Though both algorithms reduced the optimal source dwell positions and angles, the group sparsity constrained optimization with L0-norm was more effective than the L0-norm constraint only, mainly because of considering physical constraints of the new IMBT applicator. With much fewer dwell points compared to the unconstrained, the proposed algorithms led to statistically similar plan quality in dose volume histograms and iso-dose lines. It also demonstrated that the plan optimized by rotating the applicator resulted in much better plan quality than that of conventional applicator-based plans.	[Kim, Hojin; Goh, Youngmoon; Jeong, Chiyoung] Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea; [Lim, Young Kyung] Natl Canc Ctr, Proton Therapy Ctr, Goyang, South Korea; [Hwang, Ui-Jung] Chungnam Natl Univ Hosp, Dept Radiat Oncol, Daejeon, South Korea; [Choi, Sang Hyoun] Korea Canc Ctr Hosp, Dept Radiat Oncol, Seoul, South Korea; [Cho, Byungchul; Kwak, Jungwon] Univ Ulsan, Dept Radiat Oncol, Asan Med Ctr, Coll Med, Seoul, South Korea; [Kim, Hojin] Yonsei Univ, Dept Radiat Oncol, Yonsei Canc Ctr, Coll Med, Seoul, South Korea	University of Ulsan; Asan Medical Center; National Cancer Center - Korea (NCC); Chungnam National University; Chungnam National University Hospital; National Cancer Center - Korea (NCC); University of Ulsan; Asan Medical Center; Yonsei University; Yonsei University Health System	Lim, YK (corresponding author), Natl Canc Ctr, Proton Therapy Ctr, Goyang, South Korea.	jwkwak0301@gmail.com; yklim@ncc.re.kr	Goh, Youngmoon/ACK-0291-2022; Kim, Hojin/AAS-2315-2021	Goh, Youngmoon/0000-0003-4934-1730; Kim, Hojin/0000-0002-4652-8682	National Research Foundation of Korea (NRF) [NRF-2017R1D1A1B04033367, NRF-2016 M2A2A7A03913304]	National Research Foundation of Korea (NRF)(National Research Foundation of Korea)	This work was supported by the National Research Foundation of Korea (NRF) through grant number NRF-2017R1D1A1B04033367 and NRF-2016 M2A2A7A03913304.	[Anonymous], 1999, PIRS629R NAT RES COU; Beck A, 2009, SIAM J IMAGING SCI, V2, P183, DOI 10.1137/080716542; Berek J. S., 2012, BEREK NOVAKS GYNECOL; Bortfeld T, 2006, PHYS MED BIOL, V51, pR363, DOI 10.1088/0031-9155/51/13/R21; Boyd S, 2011, TRENDS MACH LEARN, V3, P1, DOI DOI 10.1561/2200000016; Candes EJ, 2006, IEEE T INFORM THEORY, V52, P489, DOI 10.1109/TIT.2005.862083; Candes EJ, 2008, J FOURIER ANAL APPL, V14, P877, DOI 10.1007/s00041-008-9045-x; Chambolle A, 2011, J MATH IMAGING VIS, V40, P120, DOI 10.1007/s10851-010-0251-1; Dimopoulos JCA, 2012, RADIOTHER ONCOL, V103, P113, DOI 10.1016/j.radonc.2011.12.024; Donoho DL, 2006, IEEE T INFORM THEORY, V52, P1289, DOI 10.1109/TIT.2006.871582; Ebert M. A., 2006, Australasian Physical & Engineering Sciences in Medicine, V29, P165, DOI 10.1007/BF03178889; Ebert MA, 2002, PHYS MED BIOL, V47, P2495, DOI 10.1088/0031-9155/47/14/309; Gerbaulet A, 2002, GEC ESTRO HDB BRACHY; Goh Y, 2018, INT J RADIAT ONCOL, V102, pS151, DOI 10.1016/j.ijrobp.2018.06.366; Goldstein T., 2009, SIAM J IMAGING SCI; Gu WB, 2018, MED PHYS, V45, P1338, DOI 10.1002/mp.12788; Haie-Meder C, 2005, RADIOTHER ONCOL, V74, P235, DOI 10.1016/j.radonc.2004.12.015; Han DY, 2014, INT J RADIAT ONCOL, V89, P666, DOI 10.1016/j.ijrobp.2014.02.039; Jia X, 2011, PHYS MED BIOL, V56, P6205, DOI 10.1088/0031-9155/56/19/004; Kang HC, 2010, RADIOTHER ONCOL, V97, P507, DOI 10.1016/j.radonc.2010.10.002; Kirisits C, 2006, INT J RADIAT ONCOL, V65, P624, DOI 10.1016/j.ijrobp.2006.01.036; Lang S, 2006, RADIOTHER ONCOL, V78, P185, DOI 10.1016/j.radonc.2006.01.001; Leibel SA, 2002, CANCER J, V8, P164, DOI 10.1097/00130404-200203000-00010; Lin LY, 2008, MED PHYS, V35, P240, DOI 10.1118/1.2815623; Mollenhoff T, 2015, INT WORKSH EN MIN ME; NATH R, 1995, MED PHYS, V22, P209, DOI 10.1118/1.597458; O'Connor D, 2017, FAST NONCOPLANAR BEA; Potter R, 2006, RADIOTHER ONCOL, V78, P67, DOI 10.1016/j.radonc.2005.11.014; Potter R, 2007, RADIOTHER ONCOL, V83, P148, DOI 10.1016/j.radonc.2007.04.012; Pugachev AB, 2000, MED PHYS, V27, P1238, DOI 10.1118/1.599001; Rivard MJ, 2004, MED PHYS, V31, P633, DOI 10.1118/1.1646040; Sadozye AH, 2012, CURR ONCOL REP, V14, P519, DOI 10.1007/s11912-012-0275-3; Shi CY, 2010, MED PHYS, V37, P3725, DOI 10.1118/1.3456598; Tanderup K, 2010, RADIOTHER ONCOL, V94, P173, DOI 10.1016/j.radonc.2010.01.001; Webster MJ, 2013, MED PHYS, V40, DOI 10.1118/1.4769416	35	2	2	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2020	15	7							e0236585	10.1371/journal.pone.0236585	http://dx.doi.org/10.1371/journal.pone.0236585			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW3BD	32722692	Green Published, gold			2023-01-03	WOS:000556916000017
J	Bai, Y; Jia, Q; Su, WW; Yan, ZH; Situ, WH; He, X; Peng, W; Yao, HL				Bai, Yang; Jia, Qiang; Su, Weiwei; Yan, Zenghao; Situ, Wenhui; He, Xiang; Peng, Wei; Yao, Hongliang			Integration of molecular networking and fingerprint analysis for studying constituents in Microctis Folium	PLOS ONE			English	Article							NATURAL-PRODUCTS; METABOLOMICS; PANICULATA; SEPARATION; ALKALOIDS; DISCOVERY; LEAVES	Microctis Folium is the dried leaves of a plant (Microcos paniculataL.) used to improve the digestive system, alleviate diarrhoea, and relieve fever, but information regarding its chemical composition has rarely been reported. The traditional research approach of determining chemical composition has included isolating, purifying, and identifying compounds with high-cost and time-consuming processes. In this study, molecular networking (MN) and fingerprint analysis were integrated as a comprehensive approach to study the chemical composition of Microctis Folium by an ultra fast liquid chromatography-photo diode array detector-triple-time of flight-tandem mass spectrometry (UFLC-DAD-Triple TOF-MS/MS). Large numbers of mass spectrometric data were processed to identify constituents, and the identified compounds and their unknown analogues were comprehensively depicted as visualized figures comprising distinct families by MN. A validated fingerprint methodology was established to quantitatively determine compounds in Microctis Folium. Ultimately, 165 constituents were identified in Microctis Folium for the first time and the identified compounds and approximately five hundred unknown analogues were applied to create visualized figures by MN, indicating compound groups and their chemical structure analogues in Microctis Folium. The validated fingerprint methodology was indicated to be specific, repeatable, precise, and stable and was used to determine 15 batches of samples during three seasons in three districts. Furthermore, seasonal or geographic environmental influences on the chemical profile were estimated by principal coordinate analysis. The results can be used to control the quality of Microctis Folium, observe seasonal or geographic environmental influences on the chemical profiles, and provide a reference for further exploitation of potential active unknown analogues in the future.	[Bai, Yang; Su, Weiwei; Yan, Zenghao; Situ, Wenhui; He, Xiang; Peng, Wei; Yao, Hongliang] Sun Yat Sen Univ, Guangdong Engn & Technol Res Ctr Qual & Efficacy, Sch Life Sci, Guangzhou, Peoples R China; [Bai, Yang; Su, Weiwei; Yan, Zenghao; Situ, Wenhui; He, Xiang; Peng, Wei; Yao, Hongliang] Sun Yat Sen Univ, Sch Life Sci, Guangdong Key Lab Plant Resources, Guangzhou, Peoples R China; [Jia, Qiang] Guangzhou City Polytech, Food Dept, Guangzhou, Peoples R China	Sun Yat Sen University; Sun Yat Sen University	Yao, HL (corresponding author), Sun Yat Sen Univ, Guangdong Engn & Technol Res Ctr Qual & Efficacy, Sch Life Sci, Guangzhou, Peoples R China.; Yao, HL (corresponding author), Sun Yat Sen Univ, Sch Life Sci, Guangdong Key Lab Plant Resources, Guangzhou, Peoples R China.	yaohliang@mail.sysu.edu.cn	su, wei/GZM-3986-2022	Bai, Yang/0000-0001-8257-956X; Su, Weiwei/0000-0002-1303-6331	Major Projects of Guangdong Education Department for Foundation Research and Applied Research (CN) [2017GKZDXM010]	Major Projects of Guangdong Education Department for Foundation Research and Applied Research (CN)	This work was supported by the Major Projects of Guangdong Education Department for Foundation Research and Applied Research (CN) (Grant No.2017GKZDXM010), http://edu.gd.gov.cn/.The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allard PM, 2016, ANAL CHEM, V88, P3317, DOI 10.1021/acs.analchem.5b04804; Aziz MA, 2015, J INTEGR MED-JIM, V13, P173, DOI 10.1016/S2095-4964(15)60179-0; Boudreau PD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133297; Chen YG, 2013, MOLECULES, V18, P4221, DOI 10.3390/molecules18044221; Fan H, 2010, MOLECULES, V15, P5547, DOI 10.3390/molecules15085547; Feng SX, 2008, J ASIAN NAT PROD RES, V10, P1155, DOI 10.1080/10286020802361289; Feng WW, 2018, ANAL CHIM ACTA, V1003, P56, DOI 10.1016/j.aca.2017.11.069; Forsberg EM, 2018, NAT PROTOC, V13, P633, DOI 10.1038/nprot.2017.151; Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092; Kersten RD, 2013, P NATL ACAD SCI USA, V110, pE4407, DOI 10.1073/pnas.1315492110; Kleigrewe K, 2015, J NAT PROD, V78, P1671, DOI 10.1021/acs.jnatprod.5b00301; Klitgaard A, 2015, ANAL CHEM, V87, P6520, DOI 10.1021/acs.analchem.5b01934; Krug D, 2014, NAT PROD REP, V31, P768, DOI 10.1039/c3np70127a; Li JWH, 2009, SCIENCE, V325, P161, DOI 10.1126/science.1168243; Moushome RA, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/3167085; Nonejuie P, 2013, P NATL ACAD SCI USA, V110, P16169, DOI 10.1073/pnas.1311066110; Oellig C, 2018, J CHROMATOGR A, V1558, P69, DOI 10.1016/j.chroma.2018.05.010; Rodrigues T, 2016, NAT CHEM, V8, P531, DOI [10.1038/nchem.2479, 10.1038/NCHEM.2479]; Sedio BE, 2017, NEW PHYTOL, V214, P952, DOI 10.1111/nph.14438; Smith CA, 2005, THER DRUG MONIT, V27, P747, DOI 10.1097/01.ftd.0000179845.53213.39; Still PC, 2013, J NAT PROD, V76, P243, DOI 10.1021/np3007414; Tistaert C, 2011, ANAL CHIM ACTA, V690, P148, DOI 10.1016/j.aca.2011.02.023; Wang MX, 2016, NAT BIOTECHNOL, V34, P828, DOI 10.1038/nbt.3597; Watrous J, 2012, P NATL ACAD SCI USA, V109, pE1743, DOI 10.1073/pnas.1203689109; Wishart DS, 2018, NUCLEIC ACIDS RES, V46, pD608, DOI 10.1093/nar/gkx1089; Wu HT, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3631565; Xu LY, 2017, ELECTROPHORESIS, V38, P3168, DOI 10.1002/elps.201700256; Zhang B, 2016, SCI REP-UK, V6, DOI 10.1038/srep21872; Zhang G, 2017, NAT PROD RES, V31, P169, DOI 10.1080/14786419.2016.1224868; Zhu GT, 2019, FOOD CHEM, V297, DOI 10.1016/j.foodchem.2019.124998	30	2	2	6	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2020	15	7							e0235533	10.1371/journal.pone.0235533	http://dx.doi.org/10.1371/journal.pone.0235533			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN1ZE	32634169	gold, Green Published			2023-01-03	WOS:000550645600039
J	Faverio, P; Compagnoni, MM; Della Zoppa, M; Pesci, A; Cantarutti, A; Merlino, L; Luppi, F; Corrao, G				Faverio, Paola; Compagnoni, Matteo Monzio; Della Zoppa, Matteo; Pesci, Alberto; Cantarutti, Anna; Merlino, Luca; Luppi, Fabrizio; Corrao, Giovanni			Rehospitalization for pneumonia after first pneumonia admission: Incidence and predictors in a population-based cohort study	PLOS ONE			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RISK-FACTORS; DISCHARGE; OUTCOMES; THERAPY; ADULTS; ASTHMA; RATES; OLDER	Background and objectives Hospital readmissions are a frequent complication of pneumonia. Most data regarding readmissions are obtained from the United States, whereas few data are available from the European healthcare utilization (HCU) systems. In a large cohort of Italian patients with a previous hospitalization for pneumonia, our aim was to evaluate the incidence and predictors of early readmissions due to pneumonia. Methods This is a observational retrospective, population based, cohort study. Data were retrieved from the HCU databases of the Italian Lombardy region. 203,768 patients were hospitalized for pneumonia between 2003 and 2012. The outcome was the first rehospitalization for pneumonia. The patients were followed up after the index hospital admission to estimate the hazard ratio, and relative 95% confidence interval, of the outcome associated with the risk factors that we had identified. Results 7,275 patients (3.6%) had an early pneumonia readmission. Male gender, age >= 70 years, length of stay of the first admission and a higher burden of comorbidities were significantly associated with the outcome. Chronic use of antidepressants, antiarrhythmics, glucocorticoids and drugs for obstructive airway diseases were also more frequently prescribed in patients requiring rehospitalization. Previous use of inhaled broncodilators, including both beta2-agonists and anticholinergics, but not inhaled steroids, were associated with an increased risk of hospital readmission. Conclusions Frail elderly patients with multiple comorbidities and complex drug regimens were at higher risk of early rehospitalization and, thus, may require closer follow-up and prevention strategies.	[Faverio, Paola; Della Zoppa, Matteo; Pesci, Alberto; Luppi, Fabrizio] Univ Milano Bicocca, Sch Med & Surg, Monza, Italy; [Faverio, Paola; Della Zoppa, Matteo; Pesci, Alberto; Luppi, Fabrizio] ASST Monza, San Gerardo Hosp, Resp Unit, Monza, Italy; [Compagnoni, Matteo Monzio; Cantarutti, Anna; Corrao, Giovanni] Univ Milano Bicocca, Natl Ctr Healthcare Res & Pharmacoepidemiol, Milan, Italy; [Compagnoni, Matteo Monzio; Cantarutti, Anna; Corrao, Giovanni] Univ Milano Bicocca, Unit Biostat Epidemiol & Publ Hlth, Lab Healthcare Res & Pharmacoepidemiol, Dept Stat & Quantitat Methods, Milan, Italy; [Merlino, Luca] Reg Hlth Minist, Milan, Lombardy Region, Italy	University of Milano-Bicocca; San Gerardo Hospital; University of Milano-Bicocca; University of Milano-Bicocca	Faverio, P (corresponding author), Univ Milano Bicocca, Sch Med & Surg, Monza, Italy.; Faverio, P (corresponding author), ASST Monza, San Gerardo Hosp, Resp Unit, Monza, Italy.	paola.faverio@unimib.it	Monzio Compagnoni, Matteo/CAH-6609-2022	Monzio Compagnoni, Matteo/0000-0002-2105-4572; Della Zoppa, Matteo/0000-0001-7764-6385; MERLINO, Luca Giuseppe/0000-0001-9232-9994; faverio, paola/0000-0002-0360-1237	Italian Ministry of Education, Universities and Research (MIUR) ("PRIN: Progetto di Ricerca di Interesse Nazionale", year 2017) [2017728JPK]	Italian Ministry of Education, Universities and Research (MIUR) ("PRIN: Progetto di Ricerca di Interesse Nazionale", year 2017)(Ministry of Education, Universities and Research (MIUR))	This study was funded by grants from the Italian Ministry of Education, Universities and Research (MIUR) ("PRIN: Progetto di Ricerca di Interesse Nazionale", year 2017, project 2017728JPK). MIUR had no role in the design of the study, the collection, analysis, and interpretation of the data, or the writing of the manuscript.	Abou-Karam N, 2016, SAGE OPEN MED, V4, DOI 10.1177/2050312116632426; Adamuz J, 2011, RESPIROLOGY, V16, P1119, DOI 10.1111/j.1440-1843.2011.02017.x; Almirall J, 2017, RESPIRATION, V94, P299, DOI 10.1159/000479089; [Anonymous], 2017, CANC DISCOVERY, V7, pOF12; Arfe A, 2016, RESP MED, V119, P7, DOI 10.1016/j.rmed.2016.05.004; Arfe A, 2016, COPD, V13, P540, DOI 10.3109/15412555.2016.1141877; Basille D, 2017, LUNG, V195, P201, DOI 10.1007/s00408-016-9973-1; Biffi A, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-016-0362-6; Breitling LP, 2016, DTSCH ARZTEBL INT, V113, P607, DOI 10.3238/arztebl.2016.0607; Capelastegui A, 2009, CHEST, V136, P1079, DOI 10.1378/chest.08-2950; Corrales-Medina VF, 2011, J INFECTION, V63, P187, DOI 10.1016/j.jinf.2011.06.009; Corrao G, 2018, EUR J INTERN MED, V47, P25, DOI 10.1016/j.ejim.2017.09.023; Corrao G, 2016, RESPIROLOGY, V21, P1034, DOI 10.1111/resp.12791; De Alba I, 2014, OCHSNER J, V14, P649; Epstein AM, 2011, NEW ENGL J MED, V365, P2287, DOI 10.1056/NEJMsa1101942; Faverio P, 2014, EUR J INTERN MED, V25, P312, DOI 10.1016/j.ejim.2013.12.001; Fry AM, 2005, JAMA-J AM MED ASSOC, V294, P2712, DOI 10.1001/jama.294.21.2712; Hirano R, 2018, INT J CHRONIC OBSTR, V13, P3503, DOI 10.2147/COPD.S180349; Joynt KE, 2011, JAMA-J AM MED ASSOC, V305, P675, DOI 10.1001/jama.2011.123; Lim WS, 2009, THORAX, V64, P1, DOI 10.1136/thx.2009.121434; Lu N, 2016, INT J QUAL HEALTH C, V28, P53, DOI 10.1093/intqhc/mzv090; O JH, 2018, NUCL MED MOLEC IMAG, V52, P1, DOI 10.1007/s13139-017-0507-4; Quan TP, 2016, THORAX, V71, P535, DOI 10.1136/thoraxjnl-2015-207688; Prescott Hallie C, 2014, Ann Am Thorac Soc, V11, P1091, DOI 10.1513/AnnalsATS.201404-142OC; Restrepo MI, 2013, CURR OPIN INFECT DIS, V26, P151, DOI 10.1097/QCO.0b013e32835ebc6d; Schneeweiss S, 2006, PHARMACOEPIDEM DR S, V15, P291, DOI 10.1002/pds.1200; Sibila O, 2015, PULM PHARMACOL THER, V32, P130, DOI 10.1016/j.pupt.2015.04.001; Strom BL, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P219; Voiriot G, 2011, CHEST, V139, P387, DOI 10.1378/chest.09-3102; Weinreich M, 2016, ANN AM THORAC SOC; Zycinska K, 2016, ADV EXP MED BIOL, V952, P59, DOI 10.1007/5584_2016_72	31	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2020	15	6							e0235468	10.1371/journal.pone.0235468; 10.1371/journal.pone.0235468.r001; 10.1371/journal.pone.0235468.r002; 10.1371/journal.pone.0235468.r003; 10.1371/journal.pone.0235468.r004; 10.1371/journal.pone.0235468.r005; 10.1371/journal.pone.0235468.r006	http://dx.doi.org/10.1371/journal.pone.0235468; 10.1371/journal.pone.0235468.r001; 10.1371/journal.pone.0235468.r002; 10.1371/journal.pone.0235468.r003; 10.1371/journal.pone.0235468.r004; 10.1371/journal.pone.0235468.r005; 10.1371/journal.pone.0235468.r006			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH8EZ	32603334	Green Published, gold			2023-01-03	WOS:000546956600022
J	Wu, FP; Wang, GY; Wang, J; Zhou, CX; Yang, CR; Niu, WB; Zhang, JF; Wang, GL; Yang, YF				Wu, Fengpeng; Wang, Guiying; Wang, Jun; Zhou, Chaoxi; Yang, Congrong; Niu, Wenbo; Zhang, Jianfeng; Wang, Guanglin; Yang, Yafan			Analysis of influencing factors of no/low response to preoperative concurrent chemoradiotherapy in locally advanced rectal cancer	PLOS ONE			English	Article							PATHOLOGICAL COMPLETE RESPONSE; TOTAL MESORECTAL EXCISION; RADIATION-THERAPY; RISK-FACTORS; ANASTOMOTIC LEAKAGE; INITIATING CELLS; TUMOR RESPONSE; BREAST-CANCER; CD44; EXPRESSION	The aim of this study is to investigate the influencing factors associated with no/low response to preoperative concurrent chemoradiotherapy (CCRT) for locally advanced rectal cancer (LARC) patients. A total of 79 patients were included in this prospective study. Fifteen factors that might affect the resistance to CCRT were included in this logistic regression analysis, these factors include the general clinical data of patients, the expression status of tumor stem cell marker CD44v6 and the volumetric imaging parameters of primary tumor lesions. We found that the no/low response status to preoperative CCRT was positively correlated with the real tumor volume (RTV), the total surface area of tumor (TSA), and CD44v6 expression, whereas negatively correlated with the tumor compactness (TC). According to the results of logistic regression analysis, two formulas that could predict whether or not no/low response to preoperative CCRT were established. The Area Under Curve (AUC) of the two formulas and those significant measurement data (RTV, TC, TSA) were 0.900, 0.858, 0.771, 0.754, 0.859, the sensitivity were 95.8%, 79.17%, 62.50%, 95.83%, 62.5%, the specificity were 70.9%, 74.55%, 83.64%,47.27%, 96.36%, the positive predictive values were 58.96%, 57.58%, 62.51%,44.23%, 88.23%, the negative predictive values were 97.48%, 89.13%, 83.64%, 96.29%, and 85.48%, respectively.	[Wu, Fengpeng; Wang, Jun; Yang, Congrong] Hebei Med Univ, Dept Radiat Oncol, Affiliated Hosp 4, Shijiazhuang, Hebei, Peoples R China; [Wu, Fengpeng; Wang, Guiying; Wang, Jun; Zhou, Chaoxi; Yang, Congrong; Niu, Wenbo; Zhang, Jianfeng; Wang, Guanglin; Yang, Yafan] Hebei Prov Tumor Hosp, Shijiazhuang, Hebei, Peoples R China; [Wang, Guiying; Zhou, Chaoxi; Niu, Wenbo; Zhang, Jianfeng; Wang, Guanglin; Yang, Yafan] Hebei Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 4, Shijiazhuang, Hebei, Peoples R China	Hebei Medical University; Hebei Medical University	Wang, GY (corresponding author), Hebei Prov Tumor Hosp, Shijiazhuang, Hebei, Peoples R China.; Wang, GY (corresponding author), Hebei Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp 4, Shijiazhuang, Hebei, Peoples R China.	wgywfp@163.com			Science and Technology Department of Hebei Province [17277750D]	Science and Technology Department of Hebei Province	This work was supported by the Science and Technology Department of Hebei Province ((Grant Number 17277750D), http://kjt.hebei.gov.cn/www/index.html. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aerts HJWL, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5006; Agner SC, 2014, RADIOLOGY, V272, P91, DOI 10.1148/radiol.14121031; Alison MR, 2011, J PATHOL, V223, P147, DOI 10.1002/path.2793; [Anonymous], 2015, ALBANIA INT J DISTRI, V6, P28; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Barbaro B, 2009, RADIOLOGY, V250, P730, DOI 10.1148/radiol.2503080310; Chen Y, 2016, J THORAC DIS, V8, DOI 10.21037/jtd.2016.04.08; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Crane CH, 2003, INT J RADIAT ONCOL, V57, P84, DOI 10.1016/S0360-3016(03)00532-7; Diaz LK, 2005, CLIN CANCER RES, V11, P3309, DOI 10.1158/1078-0432.CCR-04-2184; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; Fave X, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00665-z; Francesca D, 2016, ONCOTARGET, V7, P33374, DOI 10.18632/oncotarget.8133; Frieboes HB, 2006, CANCER RES, V66, P1597, DOI 10.1158/0008-5472.CAN-05-3166; Gao XF, 2013, CANCER RES, V73, P1481, DOI 10.1158/0008-5472.CAN-12-3429; Garland ML, 2014, INT J COLORECTAL DIS, V29, P301, DOI 10.1007/s00384-013-1821-7; Gentile M, 2003, Ann Ital Chir, V74, P555; Guillem JG, 2005, ANN SURG, V241, P829, DOI 10.1097/01.sla.0000161980.46459.96; Guy JB, 2016, B CANCER, V103, P41, DOI 10.1016/j.bulcan.2015.10.016; Hasan S, 2020, ANN SURG, V271, P716, DOI 10.1097/SLA.0000000000003051; Hsu CY, 2017, ONCOTARGET, V8, P7921, DOI 10.18632/oncotarget.13855; Huh JW, 2014, ANN SURG, V259, P508, DOI 10.1097/SLA.0b013e31829b3916; Jacobs PP, 2011, FEBS LETT, V585, P3148, DOI 10.1016/j.febslet.2011.07.039; Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036; Jestin P, 2008, COLORECTAL DIS, V10, P715, DOI 10.1111/j.1463-1318.2007.01466.x; Kim H, 2016, CLIN RADIOL, V71, P250, DOI 10.1016/j.crad.2015.11.011; Lagadec C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2479; Lee WS, 2008, WORLD J SURG, V32, P1124, DOI 10.1007/s00268-007-9451-2; Leijenaar RTH, 2015, ACTA ONCOL, V54, P1423, DOI 10.3109/0284186X.2015.1061214; Maretto I, 2007, ANN SURG ONCOL, V14, P455, DOI 10.1245/s10434-006-9269-4; MILAS L, 1994, CANCER RES, V54, P3506; Nancy Y.L., 2013, TARGET VOLUME DELINE, DOI [10.1007/978-3-642-28860-9, DOI 10.1007/978-3-642-28860-9]; Ni J, 2014, PROSTATE, V74, P602, DOI 10.1002/pros.22775; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Read TE, 2001, DIS COLON RECTUM, V44, P513, DOI 10.1007/BF02234323; Sagawa K, 2016, J LARYNGOL OTOL, V130, P843, DOI 10.1017/S0022215116008525; Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694; Schulenburg A, 2007, J PATHOL, V213, P152, DOI 10.1002/path.2220; Sinclair WK, 2012, RADIAT RES, V178, pAV112, DOI 10.1667/RRAV09.1; Strauss R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016186; Uzcudun AE, 2002, DIS COLON RECTUM, V45, P1349, DOI 10.1007/s10350-004-6424-5; Vliegen RFA, 2008, RADIOLOGY, V246, P454, DOI 10.1148/radiol.2462070042; Wheeler JMD, 2002, DIS COLON RECTUM, V45, P1051, DOI 10.1007/s10350-004-6359-x; Wu FP, 2019, J RADIAT RES, V60, P666, DOI 10.1093/jrr/rrz035; Xiao WW, 2012, CLIN EXP METASTAS, V29, P1, DOI 10.1007/s10585-011-9423-7; Xing XF, 2009, HISTOPATHOLOGY, V54, P309, DOI 10.1111/j.1365-2559.2009.03226.x; Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137; Zoccali MB, 2015, INT J COLORECTAL DIS, V30, P87, DOI 10.1007/s00384-014-2062-0	49	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2020	15	6							e0234310	10.1371/journal.pone.0234310	http://dx.doi.org/10.1371/journal.pone.0234310			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC0EC	32520954	gold, Green Published			2023-01-03	WOS:000542969500026
J	Chow, EJ; Rolfes, MA; O'Halloran, A; Anderson, EJ; Bennett, NM; Billing, L; Chai, S; Dufort, E; Herlihy, R; Kim, S; Lynfield, R; McMullen, C; Monroe, ML; Schaffner, W; Spencer, M; Talbot, HK; Thomas, A; Yousey-Hindes, K; Reed, C; Garg, S				Chow, Eric J.; Rolfes, Melissa A.; O'Halloran, Alissa; Anderson, Evan J.; Bennett, Nancy M.; Billing, Laurie; Chai, Shua; Dufort, Elizabeth; Herlihy, Rachel; Kim, Sue; Lynfield, Ruth; McMullen, Chelsea; Monroe, Maya L.; Schaffner, William; Spencer, Melanie; Talbot, H. Keipp; Thomas, Ann; Yousey-Hindes, Kimberly; Reed, Carrie; Garg, Shikha			Acute Cardiovascular Events Associated With Influenza in Hospitalized Adults A Cross-sectional Study	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; SEASONAL INFLUENZA; OBESITY PARADOX; VIRUS-INFECTION; HEART-DISEASE; UNITED-STATES; TIME-SERIES; STROKE; METAANALYSIS; VACCINATION	Background: Influenza may contribute to the burden of acute cardiovascular events during annual influenza epidemics. Objective: To examine acute cardiovascular events and determine risk factors for acute heart failure (aHF) and acute ischemic heart disease (aIHD) in adults with a hospitalization associated with laboratory-confirmed influenza. Design: Cross-sectional study. Setting: U.S. Influenza Hospitalization Surveillance Network during the 2010-to-2011 through 2017-to-2018 influenza seasons. Participants: Adults hospitalized with laboratory-confirmed influenza and identified through influenza testing ordered by a practitioner. Measurements: Acute cardiovascular events were ascertained using discharge codes from the International Classification of Diseases (ICD), Ninth Revision, Clinical Modification, and ICD, 10th Revision. Age, sex, race/ethnicity, tobacco use, chronic conditions, influenza vaccination, influenza antiviral medication, and influenza type or subtype were included as exposures in logistic regression models, and marginal adjusted risk ratios and 95% Cls were estimated to describe factors associated with aHF or aIHD. Results: Among 89 999 adults with laboratory-confirmed influenza, 80 261 had complete medical record abstractions and available ICD codes (median age, 69 years [interquartile range, 54 to 81 years]) and 11.7% had an acute cardiovascular event. The most common such events (non-mutually exclusive) were aHF (6.2%) and alHD (5.7%). Older age, tobacco use, underlying cardiovascular disease, diabetes, and renal disease were significantly associated with higher risk for aHF and alHD in adults hospitalized with laboratory-confirmed influenza. Limitation: Underdetection of cases was likely because influenza testing was based on practitioner orders. Acute cardiovascular events were identified by ICD discharge codes and may be subject to misclassification bias. Conclusion: In this population-based study of adults hospitalized with influenza, almost 12% of patients had an acute cardiovascular event. Clinicians should ensure high rates of influenza vaccination, especially in those with underlying chronic conditions, to protect against acute cardiovascular events associated with influenza. Primary Funding Source: Centers for Disease Control and Prevention.	[Chow, Eric J.; Rolfes, Melissa A.; O'Halloran, Alissa; Reed, Carrie; Garg, Shikha] Ctr Dis Control & Prevent, 1600 Clifton Rd NE,H24-7, Atlanta, GA 30333 USA; [Anderson, Evan J.] Emory Univ, Sch Med, Atlanta, GA 30322 USA; [Anderson, Evan J.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA; [Bennett, Nancy M.] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Billing, Laurie] Ohio Dept Hlth, 246 North High St, Columbus, OH 43215 USA; [Chai, Shua] Ctr Preparedness & Response, Atlanta, GA USA; [Dufort, Elizabeth] New York State Dept Hlth, Div Epidemiol, Emerging Infect Program, Empire State Plaza,Room 503 Corning Tower, Albany, NY 12237 USA; [Herlihy, Rachel] Colorado Dept Publ Hlth & Environm, Communicable Dis Epidemiol Program, 4300 Cherry Creek South Dr, Denver, CO 80246 USA; [Kim, Sue] Michigan Dept Hlth & Human Serv, Bur Epidemiol & Populat Hlth, 333 South Grand Ave, Lansing, MI 48833 USA; [Lynfield, Ruth] Minnesota Dept Hlth, 625 Roberts St North,POB 64975, St Paul, MN 55164 USA; [McMullen, Chelsea] New Mexico Dept Hlth, Infect Dis Epidemiol Bur, Epidemiol & Response Div, 1190 St Francis Dr,POB 26110, Santa Fe, NM 87502 USA; [Monroe, Maya L.] Maryland Dept Hlth, 201 West Preston St,3rd Floor, Baltimore, MD 21201 USA; [Schaffner, William; Talbot, H. Keipp] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Suite 2100,1500 21st Ave South, Nashville, TN 37212 USA; [Spencer, Melanie] Salt Lake Cty Hlth Dept, 610 South 200 East, Salt Lake City, UT 84111 USA; [Thomas, Ann] Oregon Publ Hlth Div, Acute & Communicable Dis Prevent Program, Off Dis Prevent & Epidemiol, 800 NE Oregon St,Suite 772, Portland, OR 97232 USA; [Yousey-Hindes, Kimberly] Yale Sch Publ Hlth, New Haven, CT USA	Centers for Disease Control & Prevention - USA; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; University of Rochester; State University of New York (SUNY) System; Colorado Department of Public Health & Environment; MDHHS - Michigan Department of Health & Human Services; Minnesota Department of Health (MHD); New Mexico Department of Health; Vanderbilt University; Yale University	Garg, S (corresponding author), Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd NE,H24-7, Atlanta, GA 30329 USA.	izj7@cdc.gov	Chow, Eric J./T-6061-2019	Chow, Eric J./0000-0003-3349-9330; Anderson, Evan/0000-0002-1576-4420; Rolfes, Melissa/0000-0002-0483-9941	CDC through the Emerging Infections Program cooperative agreement [CK17-1701]; 2008-2013 Influenza Hospitalization Surveillance Project (IHSP) cooperative agreement [5U38HM000414]; 2013-2018 IHSP cooperative agreement [5U380T000143]; 2018-2023 IHSP cooperative agreement [5NU380T000297]	CDC through the Emerging Infections Program cooperative agreement(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); 2008-2013 Influenza Hospitalization Surveillance Project (IHSP) cooperative agreement; 2013-2018 IHSP cooperative agreement; 2018-2023 IHSP cooperative agreement	By the CDC through the Emerging Infections Program cooperative agreement (grant CK17-1701), the 2008-2013 Influenza Hospitalization Surveillance Project (IHSP) cooperative agreement (grant 5U38HM000414), the 2013-2018 IHSP cooperative agreement (grant 5U380T000143), and the 2018-2023 IHSP cooperative agreement (grant 5NU380T000297).	Ang LW, 2017, AM J EPIDEMIOL, V186, P202, DOI 10.1093/aje/kwx001; [Anonymous], 1932, Public Health Rep, V47, P2159; Arriola C, 2017, CLIN INFECT DIS, V65, P1289, DOI 10.1093/cid/cix468; Babcock HM, 2006, INFECT CONT HOSP EP, V27, P266, DOI 10.1086/501539; Bhaskaran K, 2009, HEART, V95, P1760, DOI 10.1136/hrt.2009.175000; Blackburn R, 2018, CLIN INFECT DIS, V67, P8, DOI 10.1093/cid/cix1144; Bowles NE, 2003, J AM COLL CARDIOL, V42, P466, DOI 10.1016/S0735-1097(03)00648-X; Butler CC, 2020, LANCET, V395, P42, DOI 10.1016/S0140-6736(19)32982-4; Centers for Disease Control and Prevention, 2020, DIS BURD INFL; Centers for Disease Control and Prevention, 2019, FLU VACC COV US 2018; Centers for Disease Control and Prevention, 2020, FLUVIEW INT; Centers for Disease Control and Prevention, 2018, SEAS EST INFL DIS BU; Chaves SS, 2015, EMERG INFECT DIS, V21, P1543, DOI 10.3201/eid2109.141912; Chow EJ, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.1323; Cole SR, 2010, INT J EPIDEMIOL, V39, P417, DOI 10.1093/ije/dyp334; De Schutter A, 2016, INT J OBESITY, V40, P1730, DOI 10.1038/ijo.2016.125; Dobson J, 2015, LANCET, V385, P1729, DOI 10.1016/S0140-6736(14)62449-1; EDELEN JS, 1974, AM J EPIDEMIOL, V100, P79, DOI 10.1093/oxfordjournals.aje.a112019; Estabragh ZR, 2013, INT J CARDIOL, V167, P2397, DOI 10.1016/j.ijcard.2013.01.274; Fares Auda, 2013, N Am J Med Sci, V5, P266, DOI 10.4103/1947-2714.110430; FINLAND M, 1945, AM J MED SCI, V209, P455, DOI 10.1097/00000441-194504000-00005; Fleming DM, 2005, EPIDEMIOL INFECT, V133, P255, DOI 10.1017/S0950268804003231; Foster ED, 2013, EPIDEMIOL INFECT, V141, P735, DOI 10.1017/S0950268812002890; Harris JE, 2019, IJC HEART VASC, V22, P145, DOI 10.1016/j.ijcha.2018.12.013; Hartman L, 2018, J AM GERIATR SOC, V66, P467, DOI 10.1111/jgs.15298; Heidenreich PA, 2011, CIRCULATION, V123, P933, DOI 10.1161/CIR.0b013e31820a55f5; Hsu J, 2012, ANN INTERN MED, V156, P512, DOI 10.7326/0003-4819-156-7-201204030-00411; Kaji M, 2001, INTERNAL MED, V40, P594, DOI 10.2169/internalmedicine.40.594; Koupenova M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09607-x; Kwong JC, 2018, NEW ENGL J MED, V378, P345, DOI 10.1056/NEJMoa1702090; Kytomaa S, 2019, JAMA CARDIOL, V4, P363, DOI 10.1001/jamacardio.2019.0549; Lavie CJ, 2018, NUTRITION, V46, P122, DOI 10.1016/j.nut.2017.08.003; Lavie CJ, 2014, J AM COLL CARDIOL, V63, P1345, DOI 10.1016/j.jacc.2014.01.022; MacIntyre CR, 2016, HEART, V102, P1953, DOI 10.1136/heartjnl-2016-309983; Mamas MA, 2008, INT J CARDIOL, V130, P304, DOI 10.1016/j.ijcard.2008.04.044; Mittleman MA, 2011, CIRCULATION, V124, P346, DOI 10.1161/CIRCULATIONAHA.110.968776; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152; Muller CJ, 2014, INT J EPIDEMIOL, V43, P962, DOI 10.1093/ije/dyu029; Munoz P, 2019, CARDIOLOGY, V143, P85, DOI 10.1159/000501230; Musher DM, 2019, NEW ENGL J MED, V380, P171, DOI 10.1056/NEJMra1808137; Muthuri SG, 2014, LANCET RESP MED, V2, P395, DOI 10.1016/S2213-2600(14)70041-4; Muthuri SG, 2013, J INFECT DIS, V207, P553, DOI 10.1093/infdis/jis726; Nguyen JL, 2016, JAMA CARDIOL, V1, P274, DOI 10.1001/jamacardio.2016.0433; Nichol KL, 2003, NEW ENGL J MED, V348, P1322, DOI 10.1056/NEJMoa025028; O'Malley KJ, 2005, HEALTH SERV RES, V40, P1620, DOI 10.1111/j.1475-6773.2005.00444.x; Pandey Yadav, 2019, Perm J, V23, P18, DOI 10.7812/TPP/18-104; Panhwar MS, 2019, JACC-HEART FAIL, V7, P112, DOI 10.1016/j.jchf.2018.10.011; Panhwar MS, 2019, AM J CARDIOL, V123, P1478, DOI 10.1016/j.amjcard.2019.01.046; Reed C, 2014, CLIN INFECT DIS, V59, P166, DOI 10.1093/cid/ciu285; Reichert TA, 2004, AM J EPIDEMIOL, V160, P492, DOI 10.1093/aje/kwh227; Rolfes MA, 2018, INFLUENZA OTHER RESP, V12, P132, DOI 10.1111/irv.12486; Sellers SA, 2017, INFLUENZA OTHER RESP, V11, P372, DOI 10.1111/irv.12470; Shakir R, 2018, NAT REV NEUROL, V14, P447, DOI 10.1038/s41582-018-0036-5; Shakir R, 2017, LANCET, V389, P2373, DOI 10.1016/S0140-6736(17)31567-2; Sidhu Robinder S, 2016, Res Cardiovasc Med, V5, pe31546; Smeeth L, 2004, NEW ENGL J MED, V351, P2611, DOI 10.1056/NEJMoa041747; Spoto S, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-018-3606-7; Sun ZY, 2018, ENVIRON POLLUT, V241, P1106, DOI 10.1016/j.envpol.2018.06.045; Talbot HK, 2017, INFECT DIS CLIN N AM, V31, P757, DOI 10.1016/j.idc.2017.07.005; Thompson MG, 2018, VACCINE, V36, P5916, DOI 10.1016/j.vaccine.2018.07.028; Udell JA, 2013, JAMA-J AM MED ASSOC, V310, P1711, DOI 10.1001/jama.2013.279206; Uyeki TM, 2019, CLIN INFECT DIS, V68, pE1, DOI [10.1093/cid/ciy866, 10.1093/cid/ciy874]; Vardeny O, 2019, JACC-HEART FAIL, V7, P118, DOI 10.1016/j.jchf.2018.11.008; Vardeny O, 2016, JACC-HEART FAIL, V4, P152, DOI 10.1016/j.jchf.2015.10.012; Vejpongsa P, 2019, AM J MED, V132, P1173, DOI 10.1016/j.amjmed.2019.05.002; Warren-Gash C, 2013, HEART, V99, P1795, DOI 10.1136/heartjnl-2013-304748; Warren-Gash C, 2011, J INFECT DIS, V203, P1710, DOI 10.1093/infdis/jir171	67	46	47	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 20	2020	173	8					605	+		10.7326/M20-1509	http://dx.doi.org/10.7326/M20-1509			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OH7WZ	32833488	Green Accepted			2023-01-03	WOS:000582805500014
J	Mittendorf, EA; Zhang, H; Barrios, CH; Saji, S; Jung, KH; Hegg, R; Koehler, A; Sohn, J; Iwata, H; Telli, ML; Ferrario, C; Punie, K; Penault-Llorca, F; Patel, S; Duc, AN; Liste-Hermoso, M; Maiya, V; Molinero, L; Chui, SY; Harbeck, N				Mittendorf, Elizabeth A.; Zhang, Hong; Barrios, Carlos H.; Saji, Shigehira; Jung, Kyung Hae; Hegg, Roberto; Koehler, Andreas; Sohn, Joohyuk; Iwata, Hiroji; Telli, Melinda L.; Ferrario, Cristiano; Punie, Kevin; Penault-Llorca, Frederique; Patel, Shilpen; Anh Nguyen Duc; Liste-Hermoso, Mario; Maiya, Vidya; Molinero, Luciana; Chui, Stephen Y.; Harbeck, Nadia			Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial	LANCET			English	Article							CARBOPLATIN; WOMEN	Background Preferred neoadjuvant regimens for early-stage triple-negative breast cancer (TNBC) include anthracycline-cyclophosphamide and taxane-based chemotherapy. IMpassion031 compared efficacy and safety of atezolizumab versus placebo combined with nab-paclitaxel followed by doxorubicin plus cyclophosphamide as neoadjuvant treatment for early-stage TNBC. Methods This double-blind, randomised, phase 3 study enrolled patients in 75 academic and community sites in 13 countries. Patients aged 18 years or older with previously untreated stage II-III histologically documented TNBC were randomly assigned (1:1) to receive chemotherapy plus intravenous atezolizumab at 840 mg or placebo every 2 weeks. Chemotherapy comprised of nab-paclitaxel at 125 mg/m(2) every week for 12 weeks followed by doxorubicin at 60 mg/m(2) and cyclophosphamide at 600 mg/m(2) every 2 weeks for 8 weeks, which was then followed by surgery. Stratification was by clinical breast cancer stage and programmed cell death ligand 1 (PD-L1) status. Co-primary endpoints were pathological complete response in all-randomised (ie, all randomly assigned patients in the intention-to-treat population) and PD-L1-positive (ie, patients with PD-L1-expressing tumour infiltrating immune cells covering >= 1% of tumour area) populations. This study is registered with ClinicalTrials.gov (NCT03197935), Eudra (CT2016-004734-22), and the Japan Pharmaceutical Information Center (JapicCTI-173630), and is ongoing. Findings Between July 7, 2017, and Sept 24, 2019, 455 patients were recruited and assessed for eligibility. Of the 333 eligible patients, 165 were randomly assigned to receive atezolizumab plus chemotherapy and 168 to placebo plus chemotherapy. At data cutoff (April 3, 2020), median follow-up was 20.6 months (IQR 8.7-24.9) in the atezolizumab plus chemotherapy group and 19.8 months (8.1-24.5) in the placebo plus chemotherapy group. Pathological complete response was documented in 95 (58%, 95% CI 50-65) patients in the atezolizumab plus chemotherapy group and 69 (41%, 34-49) patients in the placebo plus chemotherapy group (rate difference 17%, 95% CI 6-27; one-sided p=0.0044 [significance boundary 0.0184]). In the PD-L1-positive population, pathological complete response was documented in 53 (69%, 95% CI 57-79) of 77 patients in the atezolizumab plus chemotherapy group versus 37 (49%, 38-61) of 75 patients in the placebo plus chemotherapy group (rate difference 20%, 95% CI 4-35; one-sided p=0.021 [significance boundary 0.0184]). In the neoadjuvant phase, grade 3-4 adverse events were balanced and treatment-related serious adverse events occurred in 37 (23%) and 26 (16%) patients, with one patient per group experiencing an unrelated grade 5 adverse event (traffic accident in the atezolizumab plus chemotherapy group and pneumonia in the placebo plus chemotherapy group). Interpretation In patients with early-stage TNBC, neoadjuvant treatment with atezolizumab in combination with nab-paclitaxel and anthracycline-based chemotherapy significantly improved pathological complete response rates with an acceptable safety profile. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Mittendorf, Elizabeth A.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02215 USA; [Zhang, Hong] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Barrios, Carlos H.] Pontificia Univ Catolica Rio Grande do Sul, Hosp Sao Lucas, Ctr Pesquisa Oncol, Porto Alegre, RS, Brazil; [Saji, Shigehira] Fukushima Med Univ, Fukushima, Japan; [Jung, Kyung Hae] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea; [Hegg, Roberto] Univ Sao Paulo, Sao Paulo, Brazil; [Koehler, Andreas] Gemeinschaftspraxis Haematol & Onkol Langen, Langen, Germany; [Sohn, Joohyuk] Yonsei Univ Hlth Syst, Yonsei Canc Ctr, Seoul, South Korea; [Iwata, Hiroji] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan; [Telli, Melinda L.] Stanford Univ, Sch Med, Stanford, CA 94305 USA; [Ferrario, Cristiano] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada; [Punie, Kevin] Univ Hosp Leuven, Leuven Canc Inst, Dept Gen Med Oncol, Leuven, Belgium; [Punie, Kevin] Univ Hosp Leuven, Leuven Canc Inst, Multidisciplinary Breast Ctr, Leuven, Belgium; [Penault-Llorca, Frederique] Ctr Jean Perrin, Dept Biopathol, Clermont Ferrand, France; [Penault-Llorca, Frederique] Univ Clermont Auvergne, INSERM, U1240, Clermont Ferrand, France; [Patel, Shilpen; Maiya, Vidya; Molinero, Luciana; Chui, Stephen Y.] Genentech Inc, San Francisco, CA 94080 USA; [Anh Nguyen Duc; Liste-Hermoso, Mario] F Hoffmann La Roche, Basel, Switzerland; [Harbeck, Nadia] Ludwig Maximilians Univ Munchen, Breast Ctr, Dept Gynecol & Obstet, Munich, Germany; [Harbeck, Nadia] Ludwig Maximilians Univ Munchen, Ctr Comprehens Canc, Munich, Germany	Harvard University; Dana-Farber Cancer Institute; Memorial Sloan Kettering Cancer Center; Pontificia Universidade Catolica Do Rio Grande Do Sul; Fukushima Medical University; University of Ulsan; Universidade de Sao Paulo; Yonsei University; Yonsei University Health System; Aichi Cancer Center; Stanford University; McGill University; KU Leuven; University Hospital Leuven; KU Leuven; University Hospital Leuven; UNICANCER; Centre Jean Perrin; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Clermont Auvergne (UCA); Roche Holding; Genentech; Roche Holding; University of Munich; University of Munich	Mittendorf, EA (corresponding author), Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02215 USA.	emittendorf@bwh.harvard.edu	Punie, Kevin/AAL-9232-2020; Punie, Kevin/AAP-9729-2021; Barrios, Carlos/HJG-7197-2022	Punie, Kevin/0000-0002-1162-7963; Barrios, Carlos/0000-0001-6021-667X; Sohn, Joohyuk/0000-0002-2303-2764; Hegg, Roberto/0000-0002-6453-8155	F Hoffmann-La Roche/Genentech - F Hoffmann-La Roche	F Hoffmann-La Roche/Genentech - F Hoffmann-La Roche	F Hoffmann-La Roche/Genentech.; We thank the patients participating in this trial and their families and the nurses, research coordinators, data managers, and clinical study site investigators (appendix p 2). Medical writing assistance for this Article was provided by Christopher Lum of Health Interactions, and funded by F Hoffmann-La Roche.	Bareche Y, 2018, ANN ONCOL, V29, P895, DOI 10.1093/annonc/mdy024; Bines J, 2014, ANN ONCOL, V25, P1079, DOI 10.1093/annonc/mdu007; Budd GT, 2015, J CLIN ONCOL, V33, P58, DOI 10.1200/JCO.2014.56.3296; Burstein HJ, 2019, ANN ONCOL, V30, P1541, DOI 10.1093/annonc/mdz235; Cardoso F, 2019, ANN ONCOL, V30, P1194, DOI 10.1093/annonc/mdz173; Cortazar P, 2014, LANCET, V384, P164, DOI 10.1016/S0140-6736(13)62422-8; Earl HM, 2014, LANCET ONCOL, V15, P201, DOI 10.1016/S1470-2045(13)70554-0; Foulkes WD, 2010, NEW ENGL J MED, V363, P1938, DOI 10.1056/NEJMra1001389; Gianni L, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.SABCS19-GS3-04; Gianni L, 2018, JAMA ONCOL, V4, P302, DOI 10.1001/jamaoncol.2017.4612; Hammond MEH, 2010, ARCH PATHOL LAB MED, V134, P907, DOI [10.1200/JCO.2009.25.6529, 10.1043/1543-2165-134.6.907, 10.1200/JOP.777003]; Harbeck N, 2019, NAT REV DIS PRIMERS, V5, DOI [10.1038/s41572-019-0122-z, 10.1038/s41572-019-0111-2]; Howlader N., 2013, SEER CANC STAT REV 1; Hutchinson KE, 2020, CLIN CANCER RES, V26, P657, DOI 10.1158/1078-0432.CCR-19-1773; Loibl S, 2019, ANN ONCOL, V30, P1279, DOI 10.1093/annonc/mdz158; Masuda N, 2017, NEW ENGL J MED, V376, P2147, DOI 10.1056/NEJMoa1612645; Mougalian SS, 2015, CANCER-AM CANCER SOC, V121, P2544, DOI 10.1002/cncr.29348; National Comprehensive Cancer Network, 2020, NCCN CLIN PRACT GUID; Duc AN, 2021, PHARM STAT, V20, P202, DOI 10.1002/pst.2066; Poggio F, 2018, ANN ONCOL, V29, P1497, DOI 10.1093/annonc/mdy127; Schmid P, 2018, NEW ENGL J MED, V379, P2108, DOI 10.1056/NEJMoa1809615; Schmid P, 2020, NEW ENGL J MED, V382, P810, DOI 10.1056/NEJMoa1910549; Schmid P, 2020, LANCET ONCOL, V21, P44, DOI 10.1016/S1470-2045(19)30689-8; Sikov WM, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.591; Soliman HH, 2017, ONCOTARGETS THER, V10, P101, DOI 10.2147/OTT.S122974; Untch M, 2016, LANCET ONCOL, V17, P345, DOI 10.1016/S1470-2045(15)00542-2; Valsecchi ME, 2015, REV RECENT CLIN TRIA, V10, P101, DOI 10.2174/1574887110666150624101343; von Minckwitz G, 2014, LANCET ONCOL, V15, P747, DOI 10.1016/S1470-2045(14)70160-3; Voorwerk L, 2019, NAT MED, V25, P920, DOI 10.1038/s41591-019-0432-4; Wang D, 2019, FUTURE ONCOL, V15, P2779, DOI 10.2217/fon-2019-0165; Wen S, 2020, BREAST CANCER-TARGET, V12, P27, DOI 10.2147/BCTT.S236483; Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984	32	345	360	15	68	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 10	2020	396	10257					1090	1100		10.1016/S0140-6736(20)31953-X	http://dx.doi.org/10.1016/S0140-6736(20)31953-X			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OC4TP	32966830				2023-01-03	WOS:000579151000030
J	Ding, HY; Xin, WX; Tong, YH; Sun, J; Xu, GQ; Ye, ZQ; Rao, YF				Ding, Haiying; Xin, Wenxiu; Tong, Yinghui; Sun, Jiao; Xu, Gaoqi; Ye, Ziqi; Rao, Yuefeng			Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review	PLOS ONE			English	Review							OF-CARE CHEMOTHERAPY; ECONOMIC-EVALUATION; 1ST-LINE TREATMENT; OPEN-LABEL; PEMBROLIZUMAB; PD-L1; DOCETAXEL; NIVOLUMAB; NSCLC; THERAPIES	Background Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC) have been rapidly evolving. ICIs are likely to be more effective but also lead to escalating healthcare costs. Objectives The aim of this study was to evaluate the cost effectiveness of immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC). Methods We searched the PubMed, Web of Science, and Cochrane Library for studies comparing the cost effectiveness of ICIs for NSCLC. Potential studies identified were independently checked for eligibility by two authors, with disagreement resolved by a third reviewer. Quality of the included studies was evaluated using Consolidated Health Economic Evaluation Reporting Standards checklists. Results A total of 22 economic studies were included. Overall reporting of the identified studies largely met CHEERS recommendations. In the first-line setting, for advanced or metastatic NSCLC patients with PD-L1 >= 50%, pembrolizumab appeared cost-effective compared with platinum-based chemotherapy in the US and Hong Kong (China), but not in the UK and China. The cost-effectiveness of pembrolizumab versus chemotherapy for first-line treatment of NSCLC in PD-L1 >= 1% patients remained obscure. Regardless of PD-L1 expression status, pembrolizumab in combination with chemotherapy could be a cost-effective first-line therapy in the US. On the contrary, addition of atezolizumab to the combination of bevacizumab and chemotherapy was not cost-effective for patients with metastatic non-squamous NSCLC from the US payer perspective. In the second-line setting compared with docetaxel, pembrolizumab was cost-effective; though nivolumab was not cost-effective in the base case, it could be by increased PD-L1 threshold. Results of the cost-effectiveness of atezolizumab second-line treatment remained inconsistent. In addition, the adoption of durvalumab consolidation therapy after chemoradiotherapy could be cost-effective versus no consolidation therapy for patients with stage III NSCLC. Conclusions Immunotherapy can be a cost-effective option for treatment of NSCLC in several scenarios. A discount of the agents or the use of PD-L1 expression as a biomarker improves the cost-effectiveness of immunotherapy.	[Ding, Haiying; Xin, Wenxiu; Tong, Yinghui; Sun, Jiao; Xu, Gaoqi] Chinese Acad Sci, Dept Pharm, Inst Canc & Basic Med IBMC, Univ Chinese Acad Sci,Zhejiang Canc Hosp,Canc Hos, Hangzhou, Peoples R China; [Ding, Haiying; Ye, Ziqi; Rao, Yuefeng] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Pharm, Hangzhou, Peoples R China	Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Zhejiang Cancer Hospital; Zhejiang University	Rao, YF (corresponding author), Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Pharm, Hangzhou, Peoples R China.	raoyf@zju.edu.cn	Xin, Wenxiu/AAH-1348-2021	Rao, Yuefeng/0000-0002-3098-2768	Natural Science Foundation of Zhejiang Province [LQ19H280001]; Projects of Medical and Health Technology Program in Zhejiang Province [2019KY037]	Natural Science Foundation of Zhejiang Province(Natural Science Foundation of Zhejiang Province); Projects of Medical and Health Technology Program in Zhejiang Province	The financial disclosure should be revised as follows: Financial Disclosure: This work was supported by Natural Science Foundation of Zhejiang Province (LQ19H280001); Projects of Medical and Health Technology Program in Zhejiang Province (2019KY037).	Addeo A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00264; Aguiar PN, 2017, ANN ONCOL, V28, P2256, DOI 10.1093/annonc/mdx305; [Anonymous], 2018, J MANAG CARE SPEC PH, V24; Antonia SJ, 2018, NEW ENGL J MED, V379, P2342, DOI 10.1056/NEJMoa1809697; Bramer WM, 2016, J MED LIBR ASSOC, V104, P240, DOI 10.3163/1536-5050.104.3.014; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cherny NI, 2015, ANN ONCOL, V26, P1547, DOI 10.1093/annonc/mdv249; Chouaid C, 2019, LUNG CANCER, V127, P44, DOI 10.1016/j.lungcan.2018.11.008; Criss SD, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.11952; Criss SD, 2019, JAMA ONCOL, V5, P358, DOI 10.1001/jamaoncol.2018.5449; Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005; Gao L, 2019, APPL HEALTH ECON HEA, V17, P371, DOI 10.1007/s40258-018-0452-0; Georgieva M, 2018, LUNG CANCER, V124, P248, DOI 10.1016/j.lungcan.2018.08.018; Goeree R, 2016, J MED ECON, V19, P630, DOI 10.3111/13696998.2016.1151432; Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231; Hu XH, 2018, LUNG CANCER, V123, P166, DOI 10.1016/j.lungcan.2018.07.012; Huang M, 2019, IMMUNOTHERAPY-UK, V11, P1463, DOI 10.2217/imt-2019-0178; Huang M, 2017, PHARMACOECONOMICS, V35, P831, DOI 10.1007/s40273-017-0527-z; Huang M, 2017, J MED ECON, V20, P140, DOI 10.1080/13696998.2016.1230123; Husereau D, 2013, PHARMACOECONOMICS, V31, P361, DOI 10.1007/s40273-013-0032-y; Husereau D, 2013, VALUE HEALTH, V16, pE1, DOI 10.1016/j.jval.2013.02.010; Husereau Don, 2013, Cost Eff Resour Alloc, V11, P6, DOI 10.1186/1478-7547-11-6; Iannazzo S, 2018, PHARMACOECONOMICS, V36, P189, DOI 10.1007/s40273-017-0577-2; Insinga RP, 2019, CURR MED RES OPIN, V35, P1241, DOI 10.1080/03007995.2019.1571297; Insinga RP, 2018, J MED ECON, V21, P1191, DOI 10.1080/13696998.2018.1521416; Liao WT, 2019, J MED ECON, V22, P344, DOI 10.1080/13696998.2019.1570221; Liu Q, 2020, CLIN DRUG INVEST, V40, P129, DOI 10.1007/s40261-019-00869-3; Loong HH, 2020, PHARMACOECON-OPEN, V4, P235, DOI 10.1007/s41669-019-00178-7; Mariotto AB, 2011, JNCI-J NATL CANCER I, V103, P117, DOI 10.1093/jnci/djq495; Matter-Walstra K, 2016, J THORAC ONCOL, V11, P1846, DOI 10.1016/j.jtho.2016.05.032; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326; Ondhia U, 2019, J MED ECON, V22, P625, DOI 10.1080/13696998.2019.1590842; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Ruiz-Negron N, 2019, PHARMACOECONOMICS, V37, P669, DOI 10.1007/s40273-018-00761-6; Schnipper LE, 2015, J CLIN ONCOL, V33, P2563, DOI 10.1200/JCO.2015.61.6706; Schuette W, 2005, J CLIN ONCOL, V23, P8389, DOI 10.1200/JCO.2005.02.3739; She LJ, 2019, LUNG CANCER, V138, P88, DOI 10.1016/j.lungcan.2019.10.017; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948; Tun AM, 2019, FUTUR SCI OA, V5, DOI 10.2144/fsoa-2019-0081; Verma V, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0442-7; Wan XM, 2019, CANCER-AM CANCER SOC, V125, P3526, DOI 10.1002/cncr.32368; Weng XH, 2020, ONCOL RES, V28, P117, DOI 10.3727/096504019X15707883083132; Yu PP, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0707-9; Zhou KX, 2019, LUNG CANCER, V136, P98, DOI 10.1016/j.lungcan.2019.08.028	48	11	12	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2020	15	9							e0238536	10.1371/journal.pone.0238536	http://dx.doi.org/10.1371/journal.pone.0238536			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN6DP	32877435	gold, Green Published			2023-01-03	WOS:000568877100039
J	Pierce, JP; Benmarhnia, T; Chen, RF; White, M; Abrams, DB; Ambrose, BK; Blanco, C; Borek, N; Choi, K; Coleman, B; Compton, WM; Cummings, KM; Delnevo, CD; Elton-Marshall, T; Goniewicz, ML; Gravely, S; Fong, GT; Hatsukami, D; Henrie, J; Kasza, KA; Kealey, S; Kimmel, HL; Limpert, J; Niaura, RS; Ramoa, C; Sharma, E; Silveira, ML; Stanton, CA; Steinberg, MB; Taylor, E; Bansal-Travers, M; Trinidad, DR; Gardner, LD; Hyland, A; Soneji, S; Messer, K				Pierce, John P.; Benmarhnia, Tarik; Chen, Ruifeng; White, Martha; Abrams, David B.; Ambrose, Bridget K.; Blanco, Carlos; Borek, Nicolette; Choi, Kelvin; Coleman, Blair; Compton, Wilson M.; Cummings, K. Michael; Delnevo, Cristine D.; Elton-Marshall, Tara; Goniewicz, Maciej L.; Gravely, Shannon; Fong, Geoffrey T.; Hatsukami, Dorothy; Henrie, James; Kasza, Karin A.; Kealey, Sheila; Kimmel, Heather L.; Limpert, Jean; Niaura, Raymond S.; Ramoa, Carolina; Sharma, Eva; Silveira, Marushka L.; Stanton, Cassandra A.; Steinberg, Michael B.; Taylor, Ethel; Bansal-Travers, Maansi; Trinidad, Dennis R.; Gardner, Lisa D.; Hyland, Andrew; Soneji, Samir; Messer, Karen			Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16	PLOS ONE			English	Article							SELF-REPORTED SMOKING; CESSATION; VALIDATION; COMMUNITY; SELECTION; TOBACCO	Background More smokers report using e-cigarettes to help them quit than FDA-approved pharmacotherapy. Objective To assess the association of e-cigarettes with future abstinence from cigarette and tobacco use. Design Cohort study of US sample, with annual follow-up. Participants US adult (ages 18+) daily cigarette smokers identified at Wave 1 (W1; 2013-14) of the PATH Study, who reported a quit attempt before W2 and completed W3 (n = 2443). Exposures Use of e-cigarettes, pharmacotherapy (including nicotine replacement therapy), or no product for last quit attempt (LQA), and current daily e-cigarette use at W2. Analysis Propensity score matching (PSM) of groups using different methods to quit. Outcome measures 12+ months abstinence at W3 from cigarettes and from all tobacco (including e-cigarettes). 30+ days abstinence at W3 was a secondary outcome. Results Among daily smokers with an LQA, 23.5% used e-cigarettes, 19.3% used pharmacotherapy only (including NRT) and 57.2% used no product. Cigarette abstinence for 12+ months at W3 was similar to 10% in each group. Half of the cigarette abstainers in the e-cigarette group were using e-cigarettes at W3. Different methods to help quitting had statistically comparable 12+ month cigarette abstinence at W3 (e-cigarettes vs no product: Risk Difference (RD) = 0.01, 95% CI: -0.04 to 0.06; e-cigarettes vs pharmacotherapy: RD = 0.02, 95% CI:-0.04 to 0.09). Likewise, daily e-cigarette users at W2 did not show a cessation benefit over comparable no-e-cigarette users and this finding was robust to sensitivity analyses. Abstinence for 30+ days at W3 was also similar across products. Limitations The frequency of e-cigarette use during the LQA was not assessed, nor was it possible to assess continuous abstinence from the LQA. Conclusion Among US daily smokers who quit cigarettes in 2014-15, use of e-cigarettes in that attempt compared to approved cessation aids or no products showed similar abstinence rates 1-2 years later.	[Pierce, John P.; Benmarhnia, Tarik; White, Martha; Kealey, Sheila; Trinidad, Dennis R.; Messer, Karen] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA; [Pierce, John P.; Benmarhnia, Tarik; Chen, Ruifeng; Trinidad, Dennis R.; Messer, Karen] Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA; [Abrams, David B.; Niaura, Raymond S.] NYU, Dept Social & Behav Sci, Coll Global Publ Hlth, New York, NY USA; [Ambrose, Bridget K.; Borek, Nicolette; Coleman, Blair; Henrie, James; Limpert, Jean; Ramoa, Carolina; Taylor, Ethel; Gardner, Lisa D.] US FDA, Off Sci, Ctr Tobacco Prod, Silver Spring, MD USA; [Blanco, Carlos; Compton, Wilson M.; Kimmel, Heather L.; Silveira, Marushka L.] NIDA, NIH, Bethesda, MD 20892 USA; [Choi, Kelvin] Natl Inst Minor Hlth & Hlth Dispar, NIH, Bethesda, MD USA; [Cummings, K. Michael] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; [Delnevo, Cristine D.; Steinberg, Michael B.] Rutgers Ctr Tobacco Studies, New Brunswick, NJ USA; [Elton-Marshall, Tara] Ctr Addict & Mental Hlth, Inst Mental Hlth Policy Res, London, ON, Canada; [Goniewicz, Maciej L.; Kasza, Karin A.; Bansal-Travers, Maansi; Hyland, Andrew] Roswell Pk Comprehens Canc Ctr, Dept Hlth Behav, Buffalo, NY USA; [Gravely, Shannon; Fong, Geoffrey T.] Univ Waterloo, Dept Psychol, Waterloo, ON, Canada; [Fong, Geoffrey T.] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON, Canada; [Fong, Geoffrey T.] MaRS Ctr, Ontario Inst Canc Res, Toronto, ON, Canada; [Hatsukami, Dorothy] Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; [Sharma, Eva; Stanton, Cassandra A.; Hyland, Andrew] Westat Corp, Rockville, MD USA; [Silveira, Marushka L.] Kelly Govt Solut, Rockville, MD USA; [Soneji, Samir] Gillings Sch Global Publ Hlth, Dept Hlth Behav, Chapel Hill, NC USA	University of California System; University of California San Diego; University of California System; University of California San Diego; New York University; US Food & Drug Administration (FDA); FDA Center for Tobacco Products (CTP); National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute on Minority Health & Health Disparities (NIMHD); Medical University of South Carolina; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Waterloo; University of Waterloo; Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; University of Minnesota System; University of Minnesota Twin Cities; Westat	Pierce, JP (corresponding author), Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA.; Pierce, JP (corresponding author), Univ Calif San Diego, Dept Family Med & Publ Hlth, San Diego, CA 92103 USA.	jppierce@ucsd.edu	Bansal-Travers, Maansi/AFM-0150-2022; Hyland, Andrew/ABE-6249-2020; Bansal-Travers, Maansi/AAH-2486-2022; Delnevo, Cristine D/D-5002-2015; Kimmel, Heather/AHC-3745-2022; Abrams, David B/AAY-7699-2020; Fong, Geoffrey T/H-2810-2014	Bansal-Travers, Maansi/0000-0002-7944-3570; Bansal-Travers, Maansi/0000-0002-7944-3570; Delnevo, Cristine D/0000-0001-9597-4307; Kimmel, Heather/0000-0001-8278-0095; Abrams, David B/0000-0002-0868-4350; Fong, Geoffrey T/0000-0001-9098-6472; Pierce, John/0000-0002-0075-7471; Niaura, Raymond/0000-0002-0856-3540; Goniewicz, Maciej/0000-0001-6748-3068	National Institute on Drug Abuse, National Institutes of Health; Center for Tobacco Products, Food and Drug Administration, Department of Health and Human Services [HHSN271201100027C]; Westat	National Institute on Drug Abuse, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); Center for Tobacco Products, Food and Drug Administration, Department of Health and Human Services; Westat	The PATH Study and this manuscript were supported by the National Institute on Drug Abuse, National Institutes of Health, and the Center for Tobacco Products, Food and Drug Administration, Department of Health and Human Services, under contract to Westat (Contract No. HHSN271201100027C). Authors from the Federal funding source (BKA, CB, NB, KC, BC, WMC, JH, HLK, JL, CR, MLS, ET, LDG) were involved in each phase of the study (design, conduct, reporting). Westat is a commercial research corporation that received Federally-funded contracts to conduct all parts of this study including study design, data collection and analysis, dissemination decisions, and manuscript preparation. All authors not from the federal funding source were funded under Westat's Federal contract to prepare this manuscript (DBA, TB, RC, KMC, CDD, TEM, GTF, MLG, SG, DH, AH, KAK, SK, KM, RSN, JPP, ES, SS, CAS, MS, AH, MT, DT, MW). The final manuscript required clearance from each federal agency with an author on the manuscript.	Austin PC, 2007, STAT MED, V26, P734, DOI 10.1002/sim.2580; Austin PC, 2018, STAT METHODS MED RES, V27, P1240, DOI 10.1177/0962280216658920; Benmarhnia T, 2018, AM J EPIDEMIOL, V187, P2397, DOI 10.1093/aje/kwy129; Berry KM, 2019, TOB CONTROL, V28, P42, DOI 10.1136/tobaccocontrol-2017-054108; Borland R, 2012, NICOTINE TOB RES, V14, P1483, DOI 10.1093/ntr/nts002; Caraballo RS, 2017, PREV CHRONIC DIS, V14, DOI 10.5888/pcd14.160600; Dennis ML, 2006, AM J ADDICTION, V15, P80, DOI 10.1080/10550490601006055; EFRON B, 1981, ANN STAT, V9, P586, DOI 10.1214/aos/1176345462; El Dib R, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-012680; Gilpin EA, 1997, J NATL CANCER I, V89, P572, DOI 10.1093/jnci/89.8.572; Giovenco DP, 2018, ADDICT BEHAV, V76, P129, DOI 10.1016/j.addbeh.2017.08.002; Hajek P, 2020, ADDICTION, V115, P1141, DOI 10.1111/add.14936; Hajek P, 2019, NEW ENGL J MED, V380, P629, DOI 10.1056/NEJMoa1808779; Hartmann-Boyce J, 2016, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD010216.pub4, 10.1002/14651858.CD010216.pub3]; Heinze G, 2018, BIOMETRICAL J, V60, P431, DOI 10.1002/bimj.201700067; Hernan MA, 2006, J EPIDEMIOL COMMUN H, V60, P578, DOI 10.1136/jech.2004.029496; Hyland A, 2017, TOB CONTROL, V26, P371, DOI 10.1136/tobaccocontrol-2016-052934; Judkins D., 1990, J OFF STAT, V6, P223; Kalkhoran S, 2020, NICOTINE TOB RES, V22, P728, DOI 10.1093/ntr/ntz114; Kalkhoran S, 2016, LANCET RESP MED, V4, P116, DOI 10.1016/S2213-2600(15)00521-4; Kasza KA, 2013, ADDICTION, V108, P193, DOI 10.1111/j.1360-0443.2012.04009.x; Leas EC, 2018, JNCI-J NATL CANCER I, V110, P581, DOI 10.1093/jnci/djx240; Lindson-Hawley N, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005231.pub3; McNeill A, 2018, EVIDENCE REV E CIGAR; Motschman CA, 2016, DRUG ALCOHOL DEPEN, V169, P180, DOI 10.1016/j.drugalcdep.2016.10.018; National Academies of Sciences Engineering and Medicine, 2018, PUBL HLTH CONS E CIG; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PIERCE JP, 1987, J CHRON DIS, V40, P689, DOI 10.1016/0021-9681(87)90105-6; Pierce JP, 2019, NICOTINE TOB RES; Rosen LJ, 2018, ADDICTION, V113, P805, DOI 10.1111/add.14134; Schlam TR, 2018, PSYCHOPHARMACOLOGY, V235, P2065, DOI 10.1007/s00213-018-4903-y; Shiffman S, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djy025; Strong DR, 2017, DRUG ALCOHOL DEPEN, V178, P257, DOI 10.1016/j.drugalcdep.2017.05.010; Sweet L, 2018, NICOTINE TOB RES; Tibshirani R, 2011, J R STAT SOC B, V73, P273, DOI 10.1111/j.1467-9868.2011.00771.x; U.S. Department of Health and Human Service, 2021, E CIGARETTE USE YOUT; US Department of Health and Human Services, 2000, RED TOB US REP SURG; US Department of Health and Human Services, 2020, SMOK CESS REP SURG G; van Walraven C, 2004, J CLIN EPIDEMIOL, V57, P672, DOI 10.1016/j.jclinepi.2003.12.008; Villanti AC, 2018, ADDICTION, V113, P391, DOI 10.1111/add.14020; Wang YJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081045; Willems RA, 2013, NICOTINE TOB RES, V15, P167, DOI 10.1093/ntr/nts104	42	36	36	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2020	15	9							e0237938	10.1371/journal.pone.0237938	http://dx.doi.org/10.1371/journal.pone.0237938			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NN6DP	32877429	Green Published, gold			2023-01-03	WOS:000568877100053
J	Connolly, SL; Nelson, S; Jones, T; Kahn, J; Constable, PD				Connolly, Sara L.; Nelson, Stuart; Jones, Tabitha; Kahn, Julia; Constable, Peter D.			The effect of age and sex on selected hematologic and serum biochemical analytes in 4,804 elite endurance-trained sled dogs participating in the Iditarod Trail Sled Dog Race pre-race examination program	PLOS ONE			English	Article							INSTITUTIONAL ANIMAL CARE; REFERENCE INTERVALS; CLINICAL PATHOLOGY; LABORATORY VALUES; CONSTITUENTS; BEAGLES; VARIABILITY; POPULATION; PREVALENCE; DEPENDENCY	Endurance-trained sled dogs provide a unique translational model to characterize changes in hematologic and serum biochemical analytes due to the aging process. The primary objective of this study was to determine the effect of age and sex on specific hematologic and serum biochemical parameters in the endurance trained sled dog. Longitudinal and cross-sectional data were analyzed from 9,746 blood and serum samples from 4,804 dogs collected over 7 years as part of the Iditarod Trail Sled Dog Race pre-race examination program. Mixed models analysis was used for statistical analysis and P < 0.01 was considered significant. Dogs ranged from 1-12 years of age and 39% were female. Serum total calcium and phosphorus concentrations and white blood cell count decreased nonlinearly to asymptotic values by 6.6, 3.1, and 6.9 years of age, respectively, equivalent to estimated physiologic ages in human years of 44, 27, and 46 years. Serum glucose concentrations reached their lowest value at 7.8 years of age, equivalent to an estimated human physiologic age of 50 years, after which time the concentration increased. Serum globulin concentrations increased with age, but nonlinearly for females and linearly for males. Most sex-related differences were <5%; however, females had lower serum urea nitrogen (14.7%) and creatinine (7.3%) concentrations, lower serum alanine aminotransferase activity (16.6%), and higher serum total bilirubin concentration (12.8%) and platelet count (6.0%). The endurance-trained sled dog provides an excellent model to separate the physiologic effects of age from those of a sedentary lifestyle on hematologic and serum biochemical analytes.	[Connolly, Sara L.; Constable, Peter D.] Univ Illinois, Coll Vet Med, Dept Vet Clin Med, Urbana, IL 61801 USA; [Nelson, Stuart; Jones, Tabitha] Iditarod Trail Comm, Wasilla, AK USA; [Kahn, Julia] Vet Specialty Ctr, Buffalo Grove, IL USA	University of Illinois System; University of Illinois Urbana-Champaign	Connolly, SL (corresponding author), Univ Illinois, Coll Vet Med, Dept Vet Clin Med, Urbana, IL 61801 USA.	sconnoll@illinois.edu		Connolly, Sara/0000-0001-9233-0338	Iditarod Trail Sled Dog Race Committee; Providence Alaska Medical Center	Iditarod Trail Sled Dog Race Committee; Providence Alaska Medical Center	This study was funded, in part, by the Iditarod Trail Sled Dog Race Committee and Providence Alaska Medical Center. Although two authors are members of or associated with the Iditarod Trail Sled Dog Race Committee, this committee as a whole did not play a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Remaining funding was obtained from the general research fund of one of the authors (PDC). There was no additional external funding received for this study. The commercial company "Veterinary Specialty Center" did not contribute to the funding of this project. The author currently employed by this institution was involved in the project before employment with this institution. The funder (Iditarod Trail Sled Dog Race Committee) provided support in the form of salaries for authors [SN, TJ], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Baneux PJR, 2014, ILAR J, V55, P200, DOI 10.1093/ilar/ilu005; Bellows J, 2015, JAVMA-J AM VET MED A, V246, P67, DOI 10.2460/javma.246.1.67; Bourges-Abella NH, 2015, J AM ASSOC LAB ANIM, V54, P17; Bramble DM, 2004, NATURE, V432, P345, DOI 10.1038/nature03052; BULLAMORE JR, 1970, LANCET, V2, P535; Chang YM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149650; CHANYEUNG M, 1981, AM J CLIN PATHOL, V75, P320; Constable PD, 2005, J VET INTERN MED, V19, P507, DOI 10.1892/0891-6640(2005)19[507:EDONPC]2.0.CO;2; CONSTABLE PD, 1994, J APPL PHYSIOL, V76, P433, DOI 10.1152/jappl.1994.76.1.433; Constable PD, 2000, AM J VET RES, V61, P582, DOI 10.2460/ajvr.2000.61.582; Constable P, 2019, J VET INTERN MED, V33, P1822, DOI 10.1111/jvim.15509; DAS BC, 1964, GERONTOLOGY, V9, P179, DOI 10.1159/000211253; Davis MS, 2003, J VET INTERN MED, V17, P311, DOI 10.1892/0891-6640(2003)017&lt;0311:POGLIR&gt;2.3.CO;2; De Martinis M, 2005, FEBS LETT, V579, P2035, DOI 10.1016/j.febslet.2005.02.055; Dennis MM, 2008, JAVMA-J AM VET MED A, V232, P564, DOI 10.2460/javma.232.4.564; DOUGHERTY JH, 1965, J GERONTOL, V20, P131, DOI 10.1093/geronj/20.2.131; FUKUDA S, 1989, JPN J VET SCI, V51, P636; GALLAGHER JC, 1978, CLIN RES, V26, pA680; GIORNO R, 1980, AM J CLIN PATHOL, V74, P765; Greeley EH, 2001, VET IMMUNOL IMMUNOP, V82, P57, DOI 10.1016/S0165-2427(01)00336-1; Guralnik Jack M, 2005, Hematology Am Soc Hematol Educ Program, P528; Hall JA, 2015, J VET INTERN MED, V29, P808, DOI 10.1111/jvim.12607; Harper EJ, 2003, J AM VET MED ASSOC, V223, P1436, DOI 10.2460/javma.2003.223.1436; Harridge SDR, 2017, PHYSIOLOGY, V32, P152, DOI 10.1152/physiol.00029.2016; Hinchcliff KW, 1997, AM J VET RES, V58, P1457; Hinchcliff KW, 1997, J AM VET MED ASSOC, V211, P1138; Hoffman JM, 2018, J GERONTOL A-BIOL, V73, P150, DOI 10.1093/gerona/glx061; Horowitz GLAS, 2008, CLIN LAB STANDARDS I, V28, P1; Hung M, 2017, POSTGRAD MED, V129, P902, DOI 10.1080/00325481.2017.1383820; Ionut V, 2010, AM J PHYSIOL-ENDOC M, V298, pE38, DOI 10.1152/ajpendo.00466.2009; JERNIGAN JA, 1980, J AM GERIATR SOC, V28, P308, DOI 10.1111/j.1532-5415.1980.tb00621.x; Kaser A, 2001, BLOOD, V98, P2720, DOI 10.1182/blood.V98.9.2720; KASPAR LV, 1977, LAB ANIM SCI, V27, P980; KELLY A, 1979, J GERONTOL, V34, P37, DOI 10.1093/geronj/34.1.37; Kendall LV, 2018, JAVMA-J AM VET MED A, V253, P980, DOI 10.2460/javma.253.8.980; Kleinert M, 2018, NAT REV ENDOCRINOL, V14, P140, DOI 10.1038/nrendo.2017.161; KUJALA UM, 1994, METABOLISM, V43, P1255, DOI 10.1016/0026-0495(94)90219-4; Laine MK, 2014, DIABETOLOGIA, V57, P270, DOI 10.1007/s00125-013-3105-8; Lawrence J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081288; Lowseth Lisa A., 1990, Vet Clin Pathol, V19, P13, DOI 10.1111/j.1939-165X.1990.tb00535.x; Mazzatenta A, 2017, SEMIN CELL DEV BIOL, V70, P141, DOI 10.1016/j.semcdb.2017.08.024; Medaille C, 2004, J VET MED A, V51, P119, DOI 10.1111/j.1439-0442.2004.00616.x; Megahed AA, 2019, J DAIRY SCI, V102, P5550, DOI 10.3168/jds.2018-15063; MIWA T, 1993, METHOD INFORM MED, V32, P211; Miyagawa Y, 2010, J VET MED SCI, V72, P1129, DOI 10.1292/jvms.09-0443; MOSIER JE, 1989, VET CLIN N AM-SMALL, V19, P1, DOI 10.1016/S0195-5616(89)50001-9; Patronek GJ, 1997, J GERONTOL A-BIOL, V52, pB171, DOI 10.1093/gerona/52A.3.B171; PICKRELL JA, 1974, AM J VET RES, V35, P897; Radakovich LB, 2017, VET CLIN PATH, V46, P34, DOI 10.1111/vcp.12459; Reynolds BS, 2010, J VET INTERN MED, V24, P809, DOI 10.1111/j.1939-1676.2010.0541.x; RUSHTON C, 1978, Age and Ageing, V7, P91, DOI 10.1093/ageing/7.2.91; Sharkey L, 2009, VET CLIN PATH, V38, P375, DOI 10.1111/j.1939-165X.2009.00134.x; Stern JA, 2013, AUST VET J, V91, P281, DOI 10.1111/avj.12076; STRASSER A, 1993, J VET MED A, V40, P720, DOI 10.1111/j.1439-0442.1993.tb00689.x; Thomassen R, 1972, CSU PHS COLLABORATIV, V105; Tiao JYH, 2002, CARDIOVASC SURG, V10, P445, DOI 10.1016/S0967-2109(02)00056-X; Visser M, 2005, AM J CLIN NUTR, V82, P531; Waters DJ, 2011, ILAR J, V52, P97, DOI 10.1093/ilar.52.1.97; WILDING P, 1972, CLIN CHIM ACTA, V41, P375, DOI 10.1016/0009-8981(72)90534-7; WISKE PS, 1979, NEW ENGL J MED, V300, P1419, DOI 10.1056/NEJM197906213002506; YIP R, 1984, AM J CLIN NUTR, V39, P427, DOI 10.1093/ajcn/39.3.427; Zaldivar-Lopez S, 2011, VET CLIN PATH, V40, P414, DOI 10.1111/j.1939-165X.2011.00360.x	62	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2020	15	8							e0237706	10.1371/journal.pone.0237706	http://dx.doi.org/10.1371/journal.pone.0237706			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NG9QD	32817656	gold, Green Published			2023-01-03	WOS:000564315600002
J	De Flora, S; Balansky, R; La Maestra, S				De Flora, Silvio; Balansky, Roumen; La Maestra, Sebastiano			Rationale for the use ofN-acetylcysteine in both prevention and adjuvant therapy of COVID-19	FASEB JOURNAL			English	Article						COVID-19; glutathione; inflammation; N-acetyl-L-cysteine; oxidative stress	ACETYL-L-CYSTEINE; N-ACETYLCYSTEINE; VIRUS-REPLICATION; GLUTATHIONE DEPLETION; ANTIOXIDANT ACTION; INFLUENZA-VIRUS; MOUSE MODEL; PATHWAY; INFLAMMATION; IMPROVEMENT	COVID-19 may cause pneumonia, acute respiratory distress syndrome, cardiovascular alterations, and multiple organ failure, which have been ascribed to a cytokine storm, a systemic inflammatory response, and an attack by the immune system. Moreover, an oxidative stress imbalance has been demonstrated to occur in COVID-19 patients.N- Acetyl-L-cysteine (NAC) is a precursor of reduced glutathione (GSH). Due to its tolerability, this pleiotropic drug has been proposed not only as a mucolytic agent, but also as a preventive/therapeutic agent in a variety of disorders involving GSH depletion and oxidative stress. At very high doses, NAC is also used as an antidote against paracetamol intoxication. Thiols block the angiotensin-converting enzyme 2 thereby hampering penetration of SARS-CoV-2 into cells. Based on a broad range of antioxidant and anti-inflammatory mechanisms, which are herein reviewed, the oral administration of NAC is likely to attenuate the risk of developing COVID-19, as it was previously demonstrated for influenza and influenza-like illnesses. Moreover, high-dose intravenous NAC may be expected to play an adjuvant role in the treatment of severe COVID-19 cases and in the control of its lethal complications, also including pulmonary and cardiovascular adverse events.	[De Flora, Silvio; La Maestra, Sebastiano] Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy; [Balansky, Roumen] Natl Oncol Ctr, Sofia, Bulgaria	University of Genoa; National Oncology Center - Bulgaria	De Flora, S (corresponding author), Univ Genoa, Dept Hlth Sci, Via A Pastore 1, I-16132 Genoa, Italy.	sdf@unige.it						Aldini G, 2018, FREE RADICAL RES, V52, P751, DOI 10.1080/10715762.2018.1468564; Amatore D, 2019, FASEB BIOADV, V1, P296, DOI 10.1096/fba.2018-00066; Andreou A, 2020, IN VIVO, V34, P1567, DOI 10.21873/invivo.11946; Arranz L, 2008, FREE RADICAL BIO MED, V45, P1252, DOI 10.1016/j.freeradbiomed.2008.07.014; ARUOMA OI, 1989, FREE RADICAL BIO MED, V6, P593, DOI 10.1016/0891-5849(89)90066-X; Balansky R, 2010, INT J CANCER, V126, P1047, DOI 10.1002/ijc.24942; Bauer Seth R, 2020, Cleve Clin J Med, DOI 10.3949/ccjm.87a.ccc046; Bazzini C, 2013, CELL PHYSIOL BIOCHEM, V32, P129, DOI 10.1159/000356633; Bernard GR, 1997, CHEST, V112, P164, DOI 10.1378/chest.112.1.164; BOESGAARD S, 1993, J PHARMACOL EXP THER, V265, P1239; Cai JY, 2003, FREE RADICAL BIO MED, V34, P928, DOI 10.1016/S0891-5849(03)00023-6; Calzetta L, 2018, EXPERT REV RESP MED, V12, P693, DOI 10.1080/17476348.2018.1495562; Cao Min, 2020, medRxiv, DOI 10.1101/2020.03.04.20030395; Cao XT, 2020, NAT REV IMMUNOL, V20, P269, DOI 10.1038/s41577-020-0308-3; Cugno M, 2020, J ALLERGY CLIN IMMUN, V146, P215, DOI 10.1016/j.jaci.2020.05.006; De Flora S, 2001, CARCINOGENESIS, V22, P999, DOI 10.1093/carcin/22.7.999; DeFlora S, 1997, EUR RESPIR J, V10, P1535, DOI 10.1183/09031936.97.10071535; DiNicolantonio JJ, 2020, MED HYPOTHESES; Ershad M, 2020, STATPEARLS; Fajgenbaum DC, 2020, INFECT DIS THER, V9, P435, DOI 10.1007/s40121-020-00303-8; Garozzo A, 2007, INT J IMMUNOPATH PH, V20, P349, DOI 10.1177/039463200702000215; Geiler J, 2010, BIOCHEM PHARMACOL, V79, P413, DOI 10.1016/j.bcp.2009.08.025; Ghezzi P, 2004, INT J IMMUNOPATH PH, V17, P99, DOI 10.1177/039463200401700114; Ghezzi P, 2011, INT J GEN MED, V4, P105, DOI 10.2147/IJGM.S15618; Gould NS, 2015, TOXICOL SCI, V147, P466, DOI 10.1093/toxsci/kfv143; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guglielmetti G, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03060-9; Haddad JJ, 2000, CYTOKINES CELL MOL T, V6, P177, DOI 10.1080/mccm.6.4.177.187; Hati S., 2020, IMPACT THOI DISULFID, DOI [10.1101/2020.05.07.083147, DOI 10.1101/2020.05.07.083147]; HO WZ, 1992, AIDS RES HUM RETROV, V8, P1249, DOI 10.1089/aid.1992.8.1249; Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052; Hui DSC, 2013, INFLUENZA OTHER RESP, V7, P52, DOI 10.1111/irv.12171; Istituto Superiore di Sanita, 2020, CHAR SARS COV 2 PAT; Izzotti A, 2003, FASEB J, V17, P1127, DOI 10.1096/fj.02-0967fje; Lai K. Y., 2015, Journal of Pulmonary and Respiratory Medicine, V5, P245; Lang JP, 2020, AM HEART J, V226, P29, DOI 10.1016/j.ahj.2020.04.025; Lee MF, 2013, ORAL ONCOL, V49, P129, DOI 10.1016/j.oraloncology.2012.08.003; Li XW, 2020, J PHARM ANAL, V10, P102, DOI 10.1016/j.jpha.2020.03.001; Liu M, 1998, CANCER RES, V58, P1723; Loscalzo J, 2001, CIRC RES, V88, P756, DOI 10.1161/hh0801.089861; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Maglakelidze N, 2020, PULM THER, V6, P169, DOI 10.1007/s41030-020-00118-5; Marchetti G, 1999, Cardiologia, V44, P633; Mata M, 2011, BIOCHEM PHARMACOL, V82, P548, DOI 10.1016/j.bcp.2011.05.014; McCarty MF, 2020, PROG CARDIOVASC DIS, V63, P383, DOI 10.1016/j.pcad.2020.02.007; Nasi A, 2020, TOXICOL REP, V7, P768, DOI 10.1016/j.toxrep.2020.06.003; Nencioni L, 2003, FASEB J, V17, P758, DOI 10.1096/fj.02-0508fje; Ong GJ, 2020, CONTEMP CLIN TRIALS, V90, DOI 10.1016/j.cct.2019.105894; Ortolani O, 2000, SHOCK, V13, P14, DOI 10.1097/00024382-200013010-00003; PACHT ER, 1991, CHEST, V100, P1397, DOI 10.1378/chest.100.5.1397; Palamara AT, 1996, AIDS RES HUM RETROV, V12, P1537, DOI 10.1089/aid.1996.12.1537; Pasupathy S, 2017, CIRCULATION, V136, P894, DOI 10.1161/CIRCULATIONAHA.117.027575; Patel K, 2017, J HEART LUNG TRANSPL, V36, pS371; Poe FL, 2020, MED HYPOTHESES, V143, DOI 10.1016/j.mehy.2020.109862; Polonikov A, 2020, ACS INFECT DIS, V6, P1558, DOI 10.1021/acsinfecdis.0c00288; Purwanto B, 2020, ACTA MED INDONES, V44, P140; Qi Q, 2019, RESP RES, V20, DOI 10.1186/s12931-019-1042-x; Rangel-Mendez JA, 2020, FUTURE MICROBIOL, V15, P959, DOI 10.2217/fmb-2020-0074; Sadowska AM, 2012, THER ADV RESPIR DIS, V6, P127, DOI 10.1177/1753465812437563; Salamon S, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8050111; Soltan-Sharifi MS, 2007, HUM EXP TOXICOL, V26, P697, DOI 10.1177/0960327107083452; Tardiolo G, 2018, MOLECULES, V23, DOI 10.3390/molecules23123305; van der Toorn M, 2007, AM J PHYSIOL-LUNG C, V293, pL1156, DOI 10.1152/ajplung.00081.2007; Van Schooten FJ, 2002, CANCER EPIDEM BIOMAR, V11, P167; Vardavas CI, 2020, TOB INDUC DIS, V18, DOI 10.18332/tid/119324; Wagener FADTG, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9060540; Wang LX, 2020, REDOX BIOL, V31, DOI 10.1016/j.redox.2019.101410; Wrotek S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041393; Zhang RH, 2014, INT IMMUNOPHARMACOL, V22, P1, DOI 10.1016/j.intimp.2014.06.013; Zhao N, 2018, CELL MOL LIFE SCI, V75, P3143, DOI 10.1007/s00018-018-2852-6; Zhou Y, 2018, DRUG DES DEV THER, V12, P4117, DOI 10.2147/DDDT.S179227; Zuin R, 2005, CLIN DRUG INVEST, V25, P401, DOI 10.2165/00044011-200525060-00005	72	85	86	2	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2020	34	10					13185	13193		10.1096/fj.202001807	http://dx.doi.org/10.1096/fj.202001807		AUG 2020	9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NY3XM	32780893	Green Published			2023-01-03	WOS:000558417100001
J	Guterres, AN; Villanueva, J				Guterres, Adam N.; Villanueva, Jessie			Targeting telomerase for cancer therapy	ONCOGENE			English	Review							TERT PROMOTER MUTATIONS; REVERSE-TRANSCRIPTASE; INHIBITOR IMETELSTAT; PEPTIDE VACCINE; BETA-1L ISOFORM; LUNG-CANCER; IN-VIVO; RECRUITMENT; LENGTH; CELLS	Telomere maintenance via telomerase reactivation is a nearly universal hallmark of cancer cells which enables replicative immortality. In contrast, telomerase activity is silenced in most adult somatic cells. Thus, telomerase represents an attractive target for highly selective cancer therapeutics. However, development of telomerase inhibitors has been challenging and thus far there are no clinically approved strategies exploiting this cancer target. The discovery of prevalent mutations in theTERTpromoter region in many cancers and recent advances in telomerase biology has led to a renewed interest in targeting this enzyme. Here we discuss recent efforts targeting telomerase, including immunotherapies and direct telomerase inhibitors, as well as emerging approaches such as targetingTERTgene expression driven byTERTpromoter mutations. We also address some of the challenges to telomerase-directed therapies including potential therapeutic resistance and considerations for future therapeutic applications and translation into the clinical setting. Although much work remains to be done, effective strategies targeting telomerase will have a transformative impact for cancer therapy and the prospect of clinically effective drugs is boosted by recent advances in structural models of human telomerase.	[Guterres, Adam N.; Villanueva, Jessie] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA; [Villanueva, Jessie] Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA	The Wistar Institute; The Wistar Institute	Villanueva, J (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.; Villanueva, J (corresponding author), Wistar Inst Anat & Biol, Melanoma Res Ctr, 3601 Spruce St, Philadelphia, PA 19104 USA.	jvillanueva@wistar.org			NIH [R01CA215733, R01CA226888, P01CA114046, P50CA174523, P30CA010815]; Department of Defense Melanoma Research Program [W81XWH-20-1-0356]; PA Department of Health; Martha W. Rogers Trust	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Melanoma Research Program; PA Department of Health; Martha W. Rogers Trust	L Work in our laboratory is supported by NIH grants R01CA215733, R01CA226888, P01CA114046, P50CA174523, P30CA010815, the Department of Defense Melanoma Research Program (W81XWH-20-1-0356), the PA Department of Health and Martha W. Rogers Trust.	Akincilar SC, 2016, CANCER DISCOV, V6, P1276, DOI 10.1158/2159-8290.CD-16-0177; Armanios M, 2015, NEW ENGL J MED, V373, P965, DOI 10.1056/NEJMe1508740; Asai A, 2003, CANCER RES, V63, P3931; Atkinson SP, 2005, CANCER RES, V65, P7585, DOI 10.1158/0008-5472.CAN-05-1715; Aviv A, 2017, TRENDS CANCER, V3, P253, DOI 10.1016/j.trecan.2017.02.005; Baell JB, 2016, J NAT PROD, V79, P616, DOI 10.1021/acs.jnatprod.5b00947; Baena-Del Valle JA, 2018, J PATHOL, V244, P11, DOI 10.1002/path.4980; Baerlocher GM, 2015, NEW ENGL J MED, V373, P920, DOI 10.1056/NEJMoa1503479; Bandaria JN, 2016, CELL, V164, P735, DOI 10.1016/j.cell.2016.01.036; Barthel FP, 2017, NAT GENET, V49, P349, DOI 10.1038/ng.3781; Bejarano L, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910292; Bell RJA, 2015, SCIENCE, V348, P1036, DOI 10.1126/science.aab0015; Biffi G, 2013, NAT CHEM, V5, P182, DOI [10.1038/NCHEM.1548, 10.1038/nchem.1548]; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bryan C, 2015, STRUCTURE, V23, P1934, DOI 10.1016/j.str.2015.08.006; Bullock M, 2019, THYROID, V29, P1623, DOI 10.1089/thy.2018.0314; Cao Y, 2008, CANCER SCI, V99, P1092, DOI 10.1111/j.1349-7006.2008.00815.x; Chen L, 2018, CELL, V174, P218, DOI 10.1016/j.cell.2018.04.039; Chiappori AA, 2015, ANN ONCOL, V26, P354, DOI 10.1093/annonc/mdu550; Chiba K, 2017, SCIENCE, V357, P1416, DOI 10.1126/science.aao0535; Chiba K, 2015, ELIFE, V4, DOI 10.7554/eLife.07918; Cong YS, 2000, J BIOL CHEM, V275, P35665, DOI 10.1074/jbc.C000637200; Damm K, 2001, EMBO J, V20, P6958, DOI 10.1093/emboj/20.24.6958; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Dilley RL, 2015, TRENDS CANCER, V1, P145, DOI 10.1016/j.trecan.2015.07.007; Drosopoulos WC, 2015, J CELL BIOL, V210, P191, DOI 10.1083/jcb.201410061; Duperret EK, 2018, MOL THER, V26, P435, DOI 10.1016/j.ymthe.2017.11.010; El-Daly H, 2005, BLOOD, V105, P1742, DOI 10.1182/blood-2003-12-4322; Gabler L, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0775-6; Garcia-Beccaria M, 2015, EMBO MOL MED, V7, P930, DOI 10.15252/emmm.201404497; Gillis AJ, 2008, NATURE, V455, P633, DOI 10.1038/nature07283; Greenberg RA, 1998, ONCOGENE, V16, P1723, DOI 10.1038/sj.onc.1201933; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; Griewank KG, 2014, JNCI-J NATL CANCER I, V106, P949; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Hackett JA, 2003, MOL CELL BIOL, V23, P8450, DOI 10.1128/MCB.23.23.8450-8461.2003; Haycock PC, 2017, JAMA ONCOL, V3, P636, DOI 10.1001/jamaoncol.2016.5945; Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071; Heaphy CM, 2011, AM J PATHOL, V179, P1608, DOI 10.1016/j.ajpath.2011.06.018; Hemann MT, 2000, NUCLEIC ACIDS RES, V28, P4474, DOI 10.1093/nar/28.22.4474; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Henson JD, 2005, CLIN CANCER RES, V11, P217; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Huppert JL, 2005, NUCLEIC ACIDS RES, V33, P2908, DOI 10.1093/nar/gki609; Jacobs JJL, 2004, CURR BIOL, V14, P2302, DOI 10.1016/j.cub.2004.12.025; Jiang JS, 2018, CELL, V173, P1179, DOI 10.1016/j.cell.2018.04.038; Kanaya N, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-2744; Kawashima T, 2004, CLIN CANCER RES, V10, P285, DOI 10.1158/1078-0432.CCR-1075-3; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Kim NW, 1994, SCIENCE, P266; Kim W, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.2000016; Kinde I, 2013, CANCER RES, V73, P7162, DOI 10.1158/0008-5472.CAN-13-2498; Koh CM, 2015, J CLIN INVEST, V125, P2109, DOI 10.1172/JCI79134; Labussiere M, 2014, NEUROLOGY, V83, P1200, DOI 10.1212/WNL.0000000000000814; Lai TP, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01291-z; Lee DD, 2019, J CLIN INVEST, V129, P223, DOI 10.1172/JCI121303; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; Li YH, 2016, P NATL ACAD SCI USA, V113, P14402, DOI 10.1073/pnas.1611106113; Li YH, 2015, NAT CELL BIOL, V17, P1327, DOI 10.1038/ncb3240; Lilleby W, 2017, CANCER IMMUNOL IMMUN, V66, P891, DOI 10.1007/s00262-017-1994-y; Liu RY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03033-1; Liu W, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04254-0; Ludlow AT, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05582-x; Makowski MM, 2016, PROTEOMICS, V16, P417, DOI 10.1002/pmic.201500327; Mancini A, 2018, CANCER CELL, V34, P513, DOI 10.1016/j.ccell.2018.08.003; Masutomi K, 2005, P NATL ACAD SCI USA, V102, P8222, DOI 10.1073/pnas.0503095102; McKerlie M, 2012, NUCLEIC ACIDS RES, V40, P3975, DOI 10.1093/nar/gks035; Mender I, 2018, NEOPLASIA, V20, P826, DOI 10.1016/j.neo.2018.06.002; Mender I, 2015, CANCER DISCOV, V5, P82, DOI 10.1158/2159-8290.CD-14-0609; Middleton G, 2014, LANCET ONCOL, V15, P829, DOI 10.1016/S1470-2045(14)70236-0; Min J, 2017, NUCLEIC ACIDS RES, V45, P2615, DOI 10.1093/nar/gkw1295; Mitchell TJ, 2018, CELL, V173, P611, DOI 10.1016/j.cell.2018.02.020; Morrison SJ, 1996, IMMUNITY, V5, P207, DOI 10.1016/S1074-7613(00)80316-7; Moye AL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8643; Mukherjee J, 2018, CANCER RES, V78, P2966, DOI 10.1158/0008-5472.CAN-17-2269; Nakashima M, 2013, J BIOL CHEM, V288, P33171, DOI 10.1074/jbc.M113.518175; Nandakumar J, 2012, NATURE, V492, P285, DOI 10.1038/nature11648; Napier CE, 2015, ONCOTARGET, V6, P16543, DOI 10.18632/oncotarget.3846; Nault JC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3218; Nemunaitis J, 2010, MOL THER, V18, P429, DOI 10.1038/mt.2009.262; Nitta E, 2011, BLOOD, V117, P4169, DOI 10.1182/blood-2010-08-297390; Notaro R, 1997, P NATL ACAD SCI USA, V94, P13782, DOI 10.1073/pnas.94.25.13782; O'Sullivan RJ, 2014, NAT STRUCT MOL BIOL, V21, P167, DOI 10.1038/nsmb.2754; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Ouellette MM, 2000, J BIOL CHEM, V275, P10072, DOI 10.1074/jbc.275.14.10072; Perera ON, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav4409; Peto R, 2016, INT J EPIDEMIOL, V45, P621, DOI 10.1093/ije/dyv199; Ramamoorthy M, 2015, CANCER CELL, V28, P357, DOI 10.1016/j.ccell.2015.08.003; Raval A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131722; Reyes-Uribe P, 2018, ONCOGENE, V37, P4058, DOI 10.1038/s41388-018-0247-7; Ristevski S, 2004, MOL CELL BIOL, V24, P5844, DOI 10.1128/MCB.24.13.5844-5849.2004; Sahm F, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv377; Sandri S, 2016, CANCER RES, V76, P2540, DOI 10.1158/0008-5472.CAN-15-2318; Sauerwald A, 2013, NAT STRUCT MOL BIOL, V20, P454, DOI 10.1038/nsmb.2530; Sayed ME, 2019, ONCOGENE, V38, P2937, DOI 10.1038/s41388-018-0639-8; Schmidt JC, 2015, GENE DEV, V29, P1095, DOI 10.1101/gad.263863.115; Seidel JA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00086; Sengupta S, 2018, MOL CANCER THER, V17, P1504, DOI 10.1158/1535-7163.MCT-17-0792; Shain AH, 2015, NEW ENGL J MED, V373, P1926, DOI 10.1056/NEJMoa1502583; Shain AH, 2018, CANCER CELL, V34, pe4; Song YS, 2019, ENDOCR-RELAT CANCER, V26, P629, DOI 10.1530/ERC-17-0562; Spahr H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04388-1; Spiegl-Kreinecker S, 2018, NEURO-ONCOLOGY, V20, P1584, DOI 10.1093/neuonc/noy104; Stern JL, 2012, MOL CELL BIOL, V32, P2384, DOI 10.1128/MCB.00379-12; Stern JL, 2015, GENE DEV, V29, P2219, DOI 10.1101/gad.269498.115; Sun CK, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-180; Tauchi T, 2006, ONCOGENE, V25, P5719, DOI 10.1038/sj.onc.1209577; Tefferi A, 2015, NEW ENGL J MED, V373, P908, DOI 10.1056/NEJMoa1310523; Nguyen THD, 2018, NATURE, V557, P190, DOI 10.1038/s41586-018-0062-x; Thompson PA, 2013, CLIN CANCER RES, V19, P6578, DOI 10.1158/1078-0432.CCR-13-1117; Tong AS, 2015, CELL REP, V13, P1633, DOI 10.1016/j.celrep.2015.10.041; Ugel S, 2010, BLOOD, V115, P1374, DOI 10.1182/blood-2009-07-233270; Vallarelli AF, 2016, ONCOTARGET, V7, P53127, DOI 10.18632/oncotarget.10634; Venteicher AS, 2009, SCIENCE, V323, P644, DOI 10.1126/science.1165357; Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185; Vonderheide RH, 2002, ONCOGENE, V21, P674, DOI 10.1038/sj.onc.1205074; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Xue HH, 2008, MOL CELL BIOL, V28, P4300, DOI 10.1128/MCB.01855-07; Yamaguchi H, 2005, NEW ENGL J MED, V352, P1413, DOI 10.1056/NEJMoa042980; Yuan XT, 2019, ONCOGENE, V38, P965, DOI 10.1038/s41388-018-0483-x; Zanetti M, 2017, NAT REV CLIN ONCOL, V14, P115, DOI 10.1038/nrclinonc.2016.67; Zeng XH, 2018, CELL REP, V23, P3031, DOI 10.1016/j.celrep.2018.05.020; Zhang CA, 2015, HUM MOL GENET, V24, P5356, DOI 10.1093/hmg/ddv252; Zhang G, 2018, CLIN CANCER RES, V24, P4771, DOI 10.1158/1078-0432.CCR-17-2773; Zhu X, 2016, SCI REP, V6, P518	127	51	51	12	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 3	2020	39	36					5811	5824		10.1038/s41388-020-01405-w	http://dx.doi.org/10.1038/s41388-020-01405-w		JUL 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NJ1HO	32733068	Green Accepted			2023-01-03	WOS:000557084000002
J	McKenzie, KC				McKenzie, Katherine C.			A Cruel COVID-19 Irony	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[McKenzie, Katherine C.] Yale Sch Med, Dept Internal Med, New Haven, CT USA	Yale University	McKenzie, KC (corresponding author), Yale Sch Med, Yale Ctr Asylum Med, Dept Internal Med, 367 Cedar St, New Haven, CT 06510 USA.	katherine.mckenzie@yale.edu							0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	2020	324	4					345	346		10.1001/jama.2020.11882	http://dx.doi.org/10.1001/jama.2020.11882			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE8JP	32602892	Bronze			2023-01-03	WOS:000562851000022
J	Caffa, I; Spagnolo, V; Vernieri, C; Valdemarin, F; Becherini, P; Wei, M; Brandhorst, S; Zucal, C; Driehuis, E; Ferrando, L; Piacente, F; Tagliafico, A; Cilli, M; Mastracci, L; Vellone, VG; Piazza, S; Cremonini, AL; Gradaschi, R; Mantero, C; Passalacqua, M; Ballestrero, A; Zoppoli, G; Cea, M; Arrighi, A; Odetti, P; Monacelli, F; Salvadori, G; Cortellino, S; Clevers, H; De Braud, F; Sukkar, SG; Provenzani, A; Longo, VD; Nencioni, A				Caffa, Irene; Spagnolo, Vanessa; Vernieri, Claudio; Valdemarin, Francesca; Becherini, Pamela; Wei, Min; Brandhorst, Sebastian; Zucal, Chiara; Driehuis, Else; Ferrando, Lorenzo; Piacente, Francesco; Tagliafico, Alberto; Cilli, Michele; Mastracci, Luca; Vellone, Valerio G.; Piazza, Silvano; Cremonini, Anna Laura; Gradaschi, Raffaella; Mantero, Carolina; Passalacqua, Mario; Ballestrero, Alberto; Zoppoli, Gabriele; Cea, Michele; Arrighi, Annalisa; Odetti, Patrizio; Monacelli, Fiammetta; Salvadori, Giulia; Cortellino, Salvatore; Clevers, Hans; De Braud, Filippo; Sukkar, Samir G.; Provenzani, Alessandro; Longo, Valter D.; Nencioni, Alessio			Fasting-mimicking diet and hormone therapy induce breast cancer regression	NATURE			English	Article							ESTROGEN-RECEPTOR; GROWTH-FACTOR; RESISTANCE; INSULIN; LEPTIN; INHIBITORS; PALBOCICLIB; FULVESTRANT; METABOLISM; ACTIVATION	Approximately 75% of all breast cancers express the oestrogen and/or progesterone receptors. Endocrine therapy is usually effective in these hormone-receptor-positive tumours, but primary and acquired resistance limits its long-term benefit(1,2). Here we show that in mouse models of hormone-receptor-positive breast cancer, periodic fasting or a fasting-mimicking diet(3-5) enhances the activity of the endocrine therapeutics tamoxifen and fulvestrant by lowering circulating IGF1, insulin and leptin and by inhibiting AKT-mTOR signalling via upregulation of EGR1 and PTEN. When fulvestrant is combined with palbociclib (a cyclin-dependent kinase 4/6 inhibitor), adding periodic cycles of a fasting-mimicking diet promotes long-lasting tumour regression and reverts acquired resistance to drug treatment. Moreover, both fasting and a fasting-mimicking diet prevent tamoxifen-induced endometrial hyperplasia. In patients with hormone-receptor-positive breast cancer receiving oestrogen therapy, cycles of a fasting-mimicking diet cause metabolic changes analogous to those observed in mice, including reduced levels of insulin, leptin and IGF1, with the last two remaining low for extended periods. In mice, these long-lasting effects are associated with long-term anti-cancer activity. These results support further clinical studies of a fasting-mimicking diet as an adjuvant to oestrogen therapy in hormone-receptor-positive breast cancer.	[Caffa, Irene; Valdemarin, Francesca; Becherini, Pamela; Piacente, Francesco; Cilli, Michele; Mastracci, Luca; Vellone, Valerio G.; Cremonini, Anna Laura; Gradaschi, Raffaella; Mantero, Carolina; Zoppoli, Gabriele; Cea, Michele; Odetti, Patrizio; Monacelli, Fiammetta; Sukkar, Samir G.; Nencioni, Alessio] IRCCS Osped Policlin San Martino, Genoa, Italy; [Spagnolo, Vanessa; Salvadori, Giulia; De Braud, Filippo] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy; [Spagnolo, Vanessa; Vernieri, Claudio; Salvadori, Giulia; Cortellino, Salvatore; Longo, Valter D.] FIRC Inst Mol Oncol, IFOM, Milan, Italy; [Vernieri, Claudio; De Braud, Filippo] Fdn IRCCS Ist Nazl Tumori, Med Oncol & Hematol Dept, Milan, Italy; [Valdemarin, Francesca; Becherini, Pamela; Ferrando, Lorenzo; Piacente, Francesco; Cremonini, Anna Laura; Zoppoli, Gabriele; Cea, Michele; Arrighi, Annalisa; Odetti, Patrizio; Monacelli, Fiammetta; Nencioni, Alessio] Univ Genoa, Dept Internal Med & Med Specialties, Genoa, Italy; [Wei, Min; Brandhorst, Sebastian; Longo, Valter D.] Univ Southern Calif, Leonard Davis Sch Gerontol, Longev Inst, Los Angeles, CA 90007 USA; [Wei, Min; Brandhorst, Sebastian; Longo, Valter D.] Univ Southern Calif, Dept Biol Sci, Los Angeles, CA 90007 USA; [Zucal, Chiara; Piazza, Silvano; Provenzani, Alessandro] Univ Trento, Dept Cellular Computat & Integrat Biol CIBIO, Trento, Italy; [Driehuis, Else] Royal Netherlands Acad Arts & Sci, Oncode Inst, Utrecht, Netherlands; [Driehuis, Else; Clevers, Hans] Royal Netherlands Acad Arts & Sci, Hubrecht Inst, Utrecht, Netherlands; [Driehuis, Else; Clevers, Hans] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Tagliafico, Alberto] Univ Genoa, Dept Hlth Sci, Genoa, Italy; [Mastracci, Luca; Vellone, Valerio G.] Univ Genoa, Dept Integrated Surg & Diagnost Sci, Genoa, Italy; [Passalacqua, Mario] Univ Genoa, Dept Expt Med, Genoa, Italy; [Clevers, Hans] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands	University of Milan; IFOM - FIRC Institute of Molecular Oncology; Fondazione IRCCS Istituto Nazionale Tumori Milan; University of Genoa; University of Southern California; University of Southern California; University of Trento; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center; University of Genoa; University of Genoa; University of Genoa	Nencioni, A (corresponding author), IRCCS Osped Policlin San Martino, Genoa, Italy.; Longo, VD (corresponding author), FIRC Inst Mol Oncol, IFOM, Milan, Italy.; Nencioni, A (corresponding author), Univ Genoa, Dept Internal Med & Med Specialties, Genoa, Italy.; Longo, VD (corresponding author), Univ Southern Calif, Leonard Davis Sch Gerontol, Longev Inst, Los Angeles, CA 90007 USA.; Longo, VD (corresponding author), Univ Southern Calif, Dept Biol Sci, Los Angeles, CA 90007 USA.	vlongo@usc.edu; alessio.nencioni@unige.it	Nencioni, Alessio/K-3692-2018; Passalacqua, Mario/W-1973-2019; Caffa, Irene/J-9835-2016; Ferrando, Lorenzo/AAA-9281-2022; Vellone, Valerio Gaetano/M-6139-2019; Cortellino, Salvatore/GPW-6929-2022; Salvadori, Giulia/AAC-2175-2022; Vernieri, Claudio/J-7426-2018; cea, Michele/K-3863-2018	Passalacqua, Mario/0000-0003-2779-6259; Caffa, Irene/0000-0003-1111-9915; Ferrando, Lorenzo/0000-0002-4025-7930; Vellone, Valerio Gaetano/0000-0002-5107-1584; Vernieri, Claudio/0000-0003-1577-8176; cea, Michele/0000-0002-1530-6729; sukkar, samir giuseppe/0000-0003-4194-1547; Spagnolo, Vanessa/0000-0002-6844-3639; Salvadori, Giulia/0000-0001-5175-2868; Piazza, Silvano/0000-0002-7156-5434; Cilli, Michele/0000-0003-4083-8986; NENCIONI, ALESSIO/0000-0001-5068-8884; Zucal, Chiara/0000-0001-8428-2495; CORTELLINO, Salvatore/0000-0001-8331-3800	Associazione Italiana per la Ricerca sul Cancro (AIRC) [17736, 22098, 17605, 21820, 22457, 21548, 22977]; Fondazione Umberto Veronesi; Italian Ministry of Health [GR-2011-02347192]; 5 x 1000 2014 Funds; Breast Cancer Research Program (US Department of Defense [BC161452, BC161452P1]; US National Institute on Aging-National Institutes of Health (NIA-NIH) [AG034906, AG20642]; Associazione Italiana contro le Leucemie-linfomi e Mieloma (AIL), Sezione Liguria	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Umberto Veronesi(Fondazione Umberto Veronesi); Italian Ministry of Health(Ministry of Health, Italy); 5 x 1000 2014 Funds; Breast Cancer Research Program (US Department of Defense(United States Department of Defense); US National Institute on Aging-National Institutes of Health (NIA-NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Associazione Italiana contro le Leucemie-linfomi e Mieloma (AIL), Sezione Liguria	This work was supported in part by the Associazione Italiana per la Ricerca sul Cancro (AIRC; IG#17736 and #22098 to A.N.; IG#17605 and IG#21820 to V.D.L.; AIRC Fellowship #22457 to G.S. and V.D.L.; IG#21548 to A.P.; and MFAG#22977 to C.V.), the Fondazione Umberto Veronesi (to A.N., I.C., F.P. and V.D.L.), the Italian Ministry of Health (GR-2011-02347192 to A.N.), the 5 x 1000 2014 Funds to the IRCCS Ospedale Policlinico San Martino (to A.N.), the BC161452 and BC161452P1 grants of the Breast Cancer Research Program (US Department of Defense; to V.D.L. and to A.N., respectively), the US National Institute on Aging-National Institutes of Health (NIA-NIH) grants AG034906 and AG20642 (to V.D.L.), and the Associazione Italiana contro le Leucemie-linfomi e Mieloma (AIL), Sezione Liguria. We thank the High Throughput Screening Facility of the University of Trento (Italy) and T. Bonfiglio (Department of Internal Medicine and Medical Specialties, University of Genoa) for their technical support.	Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; AlFakeeh A, 2018, CURR ONCOL, V25, pS18, DOI 10.3747/co.25.3752; Andre F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904; Araki K, 2018, BREAST CANCER-TOKYO, V25, P392, DOI 10.1007/s12282-017-0812-x; Arends J, 2017, CLIN NUTR, V36, P1187, DOI 10.1016/j.clnu.2017.06.017; Arends J, 2017, CLIN NUTR, V36, P11, DOI 10.1016/j.clnu.2016.07.015; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Brandhorst S, 2015, CELL METAB, V22, P86, DOI 10.1016/j.cmet.2015.05.012; Caffa I, 2015, ONCOTARGET, V6, P11820, DOI 10.18632/oncotarget.3689; Ciribilli Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010236; Creighton CJ, 2008, J CLIN ONCOL, V26, P4078, DOI 10.1200/JCO.2007.13.4429; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; DeVita V. J., 2019, DEVITA HELLMANN ROSE; Di Biase S, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2001951; Di Biase S, 2016, CANCER CELL, V30, P136, DOI 10.1016/j.ccell.2016.06.005; Di Leva G, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003311; Garofalo C, 2004, CLIN CANCER RES, V10, P6466, DOI 10.1158/1078-0432.CCR-04-0203; Grundmann O, 2015, EUR J CLIN NUTR, V69, P1290, DOI 10.1038/ejcn.2015.126; Hawley SA, 2014, BIOCHEM J, V459, P275, DOI 10.1042/BJ20131344; Hopkins BD, 2018, NATURE, V560, P499, DOI 10.1038/s41586-018-0343-4; Hu R, 2015, ONCOL LETT, V9, P1495, DOI 10.3892/ol.2015.2962; Ikeda H, 2011, CANCER SCI, V102, P2038, DOI 10.1111/j.1349-7006.2011.02050.x; Jarde T, 2011, EUR J CANCER, V47, P33, DOI 10.1016/j.ejca.2010.09.005; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KAREY KP, 1988, CANCER RES, V48, P4083; Lasham A, 2016, INT J CANCER, V139, P1157, DOI 10.1002/ijc.30137; Lee AV, 2001, CLIN CANCER RES, V7, p4429S; Lee C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003293; Lee CH, 2010, CANCER RES, V70, P1564, DOI 10.1158/0008-5472.CAN-09-3228; Liu CY, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0431-9; Massarweh S, 2008, CANCER RES, V68, P826, DOI 10.1158/0008-5472.CAN-07-2707; Massarweh S, 2006, CANCER RES, V66, P8266, DOI 10.1158/0008-5472.CAN-05-4045; Michaloglou C, 2018, MOL CANCER THER, V17, P908, DOI 10.1158/1535-7163.MCT-17-0537; Mishra AK, 2016, ONCOTARGET, V7, P56876, DOI 10.18632/oncotarget.10871; Piacente F, 2017, CANCER RES, V77, P3857, DOI 10.1158/0008-5472.CAN-16-3079; Pollak M, 2012, NAT REV CANCER, V12, P159, DOI 10.1038/nrc3215; Reidy PT, 2013, J NUTR, V143, P410, DOI 10.3945/jn.112.168021; Rossi F, 2019, EUR RADIOL, V29, P494, DOI 10.1007/s00330-018-5663-0; Sachs N, 2018, CELL, V172, P373, DOI 10.1016/j.cell.2017.11.010; Sanchez-Jimenez F, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00596; Sangar MLC, 2017, CLIN CANCER RES, V23, P5802, DOI 10.1158/1078-0432.CCR-16-2943; Saxena NK, 2007, CANCER RES, V67, P2497, DOI 10.1158/0008-5472.CAN-06-3075; Shajahan-Haq AN, 2017, ONCOTARGET, V8, P96865, DOI 10.18632/oncotarget.18292; Turner NC, 2015, NEW ENGL J MED, V373, P209, DOI 10.1056/NEJMoa1505270; Vijayaraghavan S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15916; Wei M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai8700	46	107	108	25	61	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 23	2020	583	7817					620	+		10.1038/s41586-020-2502-7	http://dx.doi.org/10.1038/s41586-020-2502-7			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QP5BG	32669709	Green Submitted, Green Accepted			2023-01-03	WOS:000623850400001
J	Kanakis, I; Alameddine, M; Scalabrin, M; van't Hof, RJ; Liloglou, T; Ozanne, SE; Goljanek-Whysall, K; Vasilaki, A				Kanakis, Ioannis; Alameddine, Moussira; Scalabrin, Mattia; van't Hof, Rob J.; Liloglou, Triantafillos; Ozanne, Susan E.; Goljanek-Whysall, Katarzyna; Vasilaki, Aphrodite			Low protein intake during reproduction compromises the recovery of lactation-induced bone loss in female mouse dams without affecting skeletal muscles	FASEB JOURNAL			English	Article						bone loss; lactation; microRNAs; protein restriction; recovery	MESENCHYMAL STEM-CELLS; OSTEOGENIC DIFFERENTIATION; ADIPOSE-TISSUE; DNA METHYLATION; MATERNAL CALCIUM; GENE-EXPRESSION; VITAMIN-D; PREGNANCY; METABOLISM; MASS	Lactation-induced bone loss occurs due to high calcium requirements for fetal growth but skeletal recovery is normally achieved promptly postweaning. Dietary protein is vital for fetus and mother but the effects of protein undernutrition on the maternal skeleton and skeletal muscles are largely unknown. We used mouse dams fed with normal (N, 20%) or low (L, 8%) protein diet during gestation and lactation and maintained on the same diets (NN, LL) or switched from low to normal (LN) during a 28 d skeletal restoration period post lactation. Skeletal muscle morphology and neuromuscular junction integrity was not different between any of the groups. However, dams fed the low protein diet showed extensive bone loss by the end of lactation, followed by full skeletal recovery in NN dams, partial recovery in LN and poor bone recovery in LL dams. Primary osteoblasts from low protein diet fed mice showed decreased in vitro bone formation and decreased osteogenic marker gene expression; promoter methylation analysis by pyrosequencing showed no differences inBmpr1a, Ptch1, Sirt1, Osx,andIgf1rosteoregulators, while miR-26a, -34a, and -125b expression was found altered in low protein fed mice. Therefore, normal protein diet is indispensable for maternal musculoskeletal health during the reproductive period.	[Kanakis, Ioannis; Alameddine, Moussira; Scalabrin, Mattia; van't Hof, Rob J.; Goljanek-Whysall, Katarzyna; Vasilaki, Aphrodite] Univ Liverpool, Inst Life Course & Med Sci, MRC Versus Arthrit Ctr Integrated Res Musculoskel, Liverpool, Merseyside, England; [Liloglou, Triantafillos] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Canc Med, Liverpool, Merseyside, England; [Ozanne, Susan E.] Univ Cambridge, MRC Metab Dis Unit, Metab Res Labs, Cambridge, England; [Goljanek-Whysall, Katarzyna] NUI Galway, Sch Med, Dept Physiol, Galway, Ireland; [Scalabrin, Mattia] Univ Leeds, Sch Biomed Sci, Leeds, W Yorkshire, England	University of Liverpool; University of Liverpool; University of Cambridge; Ollscoil na Gaillimhe-University of Galway; University of Leeds	Kanakis, I; Vasilaki, A (corresponding author), Univ Liverpool, Inst Life Course & Med Sci, Fac Hlth & Life Sci, William Henry Duncan Bldg,6 West Derby St, Liverpool L7 8TX, Merseyside, England.	i.kanakis@liverpool.ac.uk; vasilaki@liverpool.ac.uk	Kanakis, Ioannis/N-7874-2019	Kanakis, Ioannis/0000-0001-6410-1482; Ozanne, Susan/0000-0001-8753-5144; Scalabrin, Mattia/0000-0001-6663-7088	RCUK \ Biotechnology and Biological Sciences Research Council (BBSRC) [BB/P008429/1]; BBSRC [BB/P008429/1] Funding Source: UKRI; MRC [MR/P020941/1] Funding Source: UKRI	RCUK \ Biotechnology and Biological Sciences Research Council (BBSRC); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	RCUK vertical bar Biotechnology and Biological Sciences Research Council (BBSRC), Grant/Award Number: BB/P008429/1	Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005; Allard JS, 2009, MOL CELL ENDOCRINOL, V299, P58, DOI 10.1016/j.mce.2008.10.018; Ammann P, 2015, ENDOCRINOLOGY, V156, P419, DOI 10.1210/en.2014-1033; Ardeshirpour L, 2007, ENDOCRINOLOGY, V148, P3875, DOI 10.1210/en.2006-1467; Ardeshirpour L, 2015, ENDOCRINOLOGY, V156, P2762, DOI 10.1210/en.2015-1232; Bell AW, 2000, P NUTR SOC, V59, P119, DOI 10.1017/S0029665100000148; Bendre A, 2018, BONE, V106, P139, DOI 10.1016/j.bone.2017.10.018; Bowman BM, 2002, J BONE MINER RES, V17, P1954, DOI 10.1359/jbmr.2002.17.11.1954; Bueno-Vargas P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154120; Chen F, 2019, INT J ENV RES PUB HE, V16, P1, DOI DOI 10.3390/ijerph16142632; Chen S, 2014, MOL MED REP, V9, P1820, DOI 10.3892/mmr.2014.2024; Clowes EJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE564, DOI 10.1152/ajpendo.00198.2004; Clowes EJ, 2003, J ANIM SCI, V81, P753; Conigrave AD, 2008, ANNU REV NUTR, V28, P131, DOI 10.1146/annurev.nutr.28.061807.155328; Dang QJ, 2017, EXP THER MED, V14, P1633, DOI 10.3892/etm.2017.4708; Delgado-Calle Jesus, 2012, Biology (Basel), V1, P698, DOI 10.3390/biology1030698; Delgado-Calle J, 2012, J BONE MINER RES, V27, P926, DOI 10.1002/jbmr.1491; Delgado-Calle J, 2012, EPIGENETICS-US, V7, P83, DOI 10.4161/epi.7.1.18753; Dempster DW, 2013, J BONE MINER RES, V28, P1, DOI 10.1002/jbmr.1805; Devlin M J, 2018, Bone Rep, V8, P204, DOI 10.1016/j.bonr.2018.04.003; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; Elefteriou F, 2006, CELL METAB, V4, P441, DOI 10.1016/j.cmet.2006.10.010; Fan C, 2016, STEM CELL REP, V7, P236, DOI 10.1016/j.stemcr.2016.06.010; Ghayor C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091446; Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507; Goettsch C, 2011, AM J PATHOL, V179, P1594, DOI 10.1016/j.ajpath.2011.06.016; Grieger JA, 2015, NUTRIENTS, V7, P153, DOI 10.3390/nu7010153; Hopkinson JM, 2000, J NUTR, V130, P777, DOI 10.1093/jn/130.4.777; Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107; Hu R, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176099; Huang J, 2010, STEM CELLS, V28, P357, DOI 10.1002/stem.288; Jalabert A, 2016, DIABETOLOGIA, V59, P1049, DOI 10.1007/s00125-016-3882-y; Kanakis I, 2019, ARTHRITIS RHEUMATOL, V71, P571, DOI 10.1002/art.40765; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kang H, 2016, OSTEOPOROSIS INT, V27, P1493, DOI 10.1007/s00198-015-3381-x; Karlsson C, 2001, OSTEOPOROSIS INT, V12, P828, DOI 10.1007/s001980170033; Kelch S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16113-x; KENT GN, 1990, J BONE MINER RES, V5, P361, DOI 10.1002/jbmr.5650050409; Kim K, 2015, MOL CELLS, V38, P75, DOI 10.14348/molcells.2015.2241; Kirby BJ, 2011, J BONE MINER RES, V26, P1242, DOI 10.1002/jbmr.339; Kovacs CS, 2016, PHYSIOL REV, V96, P449, DOI 10.1152/physrev.00027.2015; Kovacs CS, 2012, ANNU REV NUTR, V32, P97, DOI 10.1146/annurev-nutr-071811-150742; Kovacs CS, 2011, ENDOCRIN METAB CLIN, V40, P795, DOI 10.1016/j.ecl.2011.08.002; Kovacs CS, 2006, ENDOCRIN METAB CLIN, V35, P21, DOI 10.1016/j.ecl.2005.09.004; Kovacs CS, 2005, J MAMMARY GLAND BIOL, V10, P105, DOI 10.1007/s10911-005-5394-0; Kovacs CS, 1997, ENDOCR REV, V18, P832, DOI 10.1210/er.18.6.832; Krishnan V, 2006, J CLIN INVEST, V116, P1202, DOI 10.1172/JCI28551; Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375; Kuhla B, 2011, J PROTEOME RES, V10, P4252, DOI 10.1021/pr200425h; Laxman N, 2015, RNA, V21, P1433, DOI 10.1261/rna.049148.114; Li Y, 2015, MOL THER, V23, P1349, DOI 10.1038/mt.2015.101; Li Y, 2013, BIOMATERIALS, V34, P5048, DOI 10.1016/j.biomaterials.2013.03.052; Li Z, 2008, P NATL ACAD SCI USA, V105, P13906, DOI 10.1073/pnas.0804438105; LISSNER L, 1991, CALCIFIED TISSUE INT, V48, P319, DOI 10.1007/BF02556151; Liu P, 2016, SCI REP-UK, V6, DOI 10.1038/srep32112; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Long FX, 2012, NAT REV MOL CELL BIO, V13, P27, DOI 10.1038/nrm3254; Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424; Luzi E, 2008, J BONE MINER RES, V23, P287, DOI 10.1359/JBMR.071011; MacDonell R, 2016, BONEKEY REP, V5, DOI 10.1038/bonekey.2016.58; MELTON LJ, 1993, OSTEOPOROSIS INT, V3, P76, DOI 10.1007/BF01623377; Mercken EM, 2014, AGING CELL, V13, P787, DOI 10.1111/acel.12220; Mizuno Y, 2008, BIOCHEM BIOPH RES CO, V368, P267, DOI 10.1016/j.bbrc.2008.01.073; Mohri T, 2009, INT J CANCER, V125, P1328, DOI 10.1002/ijc.24459; Moody L, 2019, NUTRIENTS, V11, DOI 10.3390/nu11092075; Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774; Olausson H, 2012, NUTR RES REV, V25, P40, DOI 10.1017/S0954422411000187; Paton LM, 2003, AM J CLIN NUTR, V77, P707, DOI 10.1093/ajcn/77.3.707; Patsch JM, 2011, METABOLISM, V60, P243, DOI 10.1016/j.metabol.2009.11.023; Pearson D, 2004, BONE, V34, P570, DOI 10.1016/j.bone.2003.11.005; Peterson CA, 2009, EUR J NUTR, V48, P84, DOI 10.1007/s00394-008-0765-0; Picke AK, 2018, BONE, V116, P120, DOI 10.1016/j.bone.2018.07.015; Prentice A, 2003, J NUTR, V133, p1693S, DOI 10.1093/jn/133.5.1693S; Cunha MCR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058872; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Schulz TJ, 2016, DIABETOLOGIA, V59, P1769, DOI 10.1007/s00125-016-3990-8; Seeliger C, 2014, J BONE MINER RES, V29, P1718, DOI 10.1002/jbmr.2175; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shaw RJ, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl424; Sims NA, 2016, INT J BIOCHEM CELL B, V79, P14, DOI 10.1016/j.biocel.2016.08.003; Smith MS, 2002, FRONT NEUROENDOCRIN, V23, P225, DOI 10.1016/S0091-3022(02)00002-X; SOWERS M, 1993, JAMA-J AM MED ASSOC, V269, P3130, DOI 10.1001/jama.269.24.3130; Stephens Alexandre S, 2011, BMC Res Notes, V4, P410, DOI 10.1186/1756-0500-4-410; Su X, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.221; Taylor Sarah E B, 2014, Bonekey Rep, V3, P585, DOI 10.1038/bonekey.2014.80; Tencerova M, 2018, J BONE MINER RES, V33, P1154, DOI 10.1002/jbmr.3408; Thomas M, 2006, AM J OBSTET GYNECOL, V194, P937, DOI 10.1016/j.ajog.2005.05.032; TRAYHURN P, 1982, NATURE, V298, P59, DOI 10.1038/298059a0; Vajda EG, 2001, BIOL REPROD, V65, P689, DOI 10.1095/biolreprod65.3.689; van't Hof RJ, 2017, BONE, V99, P69, DOI 10.1016/j.bone.2017.03.051; van't Hof RJ, 2012, METHODS MOL BIOL, V816, P461, DOI 10.1007/978-1-61779-415-5_27; Vimalraj S, 2014, J CELL PHYSIOL, V229, P1236, DOI 10.1002/jcp.24557; Wang H, 2019, J BONE MINER RES, V34, P1169, DOI 10.1002/jbmr.3677; Wang HQ, 2017, CELL PHYSIOL BIOCHEM, V41, P530, DOI 10.1159/000457013; Wang Z, 2015, SCI REP-UK, V5, DOI 10.1038/srep15280; Wendelboe MH, 2016, BONE, V87, P27, DOI 10.1016/j.bone.2016.03.012; Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104; Woodrow JP, 2006, ENDOCRINOLOGY, V147, P4010, DOI 10.1210/en.2005-1616; Wysolmerski JJ, 2002, J MAMMARY GLAND BIOL, V7, P267, DOI 10.1023/A:1022800716196; Zeni SN, 1999, BONE, V25, P681, DOI 10.1016/S8756-3282(99)00228-8; Zhang Y, 2011, P NATL ACAD SCI USA, V108, P9863, DOI 10.1073/pnas.1018493108	101	3	3	1	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2020	34	9					11844	11859		10.1096/fj.202001131R	http://dx.doi.org/10.1096/fj.202001131R		JUL 2020	16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NK8TC	32652768	hybrid, Green Submitted, Green Published			2023-01-03	WOS:000548010200001
J	Lopez, RF; Antoli, A				Fernandez Lopez, Rodrigo; Antoli, Adoracion			Computer-based cognitive interventions in acquired brain injury: A systematic review and meta-analysis of randomized controlled trials	PLOS ONE			English	Review							WORKING-MEMORY; EXECUTIVE FUNCTION; STROKE PATIENTS; OLDER-ADULTS; REHABILITATION; IMPAIRMENT; ATTENTION; PERFORMANCE; DEMENTIA; STRATEGY	Introduction Acquired brain injury (ABI) leads to cognitive deficits in a great variety of cognitive functions. Interventions aimed at reducing such deficits include the use of computer-based cognitive interventions. The present work synthetizes and quantitively analyses the effect of computer-based cognitive interventions in ABI. Methods PubMed, Scopus, Web of Science, ProQuest and Ovid databases were searched for randomized controlled trials (RCT) addressing this issue. A total number of 8 randomized-controlled trials were included for systematic review and meta-analysis. Univariate meta-analyses were conducted for every cognitive function, producing aggregates when a study contributed more than one effect size per cognitive domain. Results Random-effects meta-analyses showed an improvement of Visual and Verbal working memory, while other domains like Attention, Processing speed, Executive functions and Memory were not benefited by the interventions. Conclusions Computer-based cognitive interventions might be a beneficial intervention for ABI population to improve Visual and Verbal working memory, although no effect was found in other cognitive domains. Implications and possible future directions of the research are discussed.	[Fernandez Lopez, Rodrigo; Antoli, Adoracion] Univ Cordoba, Dept Psychol, Cordoba, Spain; [Antoli, Adoracion] Univ Cordoba, Reina Sofia Univ Hosp, Maimonides Inst Biomed Res Cordoba IMIBIC, Cordoba, Spain	Universidad de Cordoba; Universidad de Cordoba	Lopez, RF (corresponding author), Univ Cordoba, Dept Psychol, Cordoba, Spain.	rodrigofdezlo@gmail.com	Antolí, Adoración/V-7045-2018	Antolí, Adoración/0000-0001-7259-5080; Fernandez Lopez, Rodrigo/0000-0002-3399-8626	Andalusian Regional Government (Spain) [PIN0072-2016, UCO-FEDER 18 REF. 1265277 MD A1]; University of Cordoba (Spain) [PPG2018-UCOSOCIAL-11]	Andalusian Regional Government (Spain); University of Cordoba (Spain)	This work was supported by funds from the Andalusian Regional Government (Spain) (PIN0072-2016), (UCO-FEDER 18 REF. 1265277 MD A1), and the University of Cordoba (Spain) (PPG2018-UCOSOCIAL-11) to AA. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akerlund E, 2013, BRAIN INJURY, V27, P1649, DOI 10.3109/02699052.2013.830195; Garcia-Casal JA, 2017, AGING MENT HEALTH, V21, P454, DOI 10.1080/13607863.2015.1132677; Bjorkdahl A, 2013, BRAIN INJURY, V27, P1658, DOI 10.3109/02699052.2013.830196; Bogdanova Y, 2016, J HEAD TRAUMA REHAB, V31, P419, DOI 10.1097/HTR.0000000000000203; Borenstein M., 2009, INTRO META ANAL; Cho HY, 2015, J PHYS THER SCI, V27, P1029, DOI 10.1589/jpts.27.1029; Dams-O'Connor K, 2010, PSYCHIAT CLIN N AM, V33, P893, DOI 10.1016/j.psc.2010.08.002; Dikmen SS, 2003, OUTCOME 3 5 YEARS MO, V84, P9; Ehlhardt LA, 2008, NEUROPSYCHOL REHABIL, V18, P300, DOI 10.1080/09602010701733190; Fetta J, 2017, J NEUROSCI NURS, V49, P235, DOI 10.1097/JNN.0000000000000298; Gates NJ, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012277.pub2; Gustavsson A, 2011, EUR NEUROPSYCHOPHARM, V21, P718, DOI 10.1016/j.euroneuro.2011.08.008; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hill NTM, 2017, AM J PSYCHIAT, V174, P329, DOI 10.1176/appi.ajp.2016.16030360; Lampit A, 2014, PLOS MED, V11, DOI 10.1371/journal.pmed.1001756; Lau J, 2006, BMJ-BRIT MED J, V333, P597, DOI 10.1136/bmj.333.7568.597; Lin ZC, 2014, J INT MED RES, V42, P659, DOI 10.1177/0300060513505809; Lundqvist A, 2010, BRAIN INJURY, V24, P1173, DOI 10.3109/02699052.2010.498007; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Mahan S, 2017, J INT NEUROPSYCH SOC, V23, P254, DOI [10.1017/S1355617716001065, 10.1155/2017/7942515]; Man DWK, NRE, V21, P205; McEwen S, 2015, NEUROREHAB NEURAL RE, V29, P526, DOI 10.1177/1545968314558602; Melby-Lervag M, 2016, PERSPECT PSYCHOL SCI, V11, P512, DOI 10.1177/1745691616635612; Mewborn CM, 2017, NEUROPSYCHOL REV, V27, P403, DOI 10.1007/s11065-017-9350-8; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Morris SB, 2008, ORGAN RES METHODS, V11, P364, DOI 10.1177/1094428106291059; Orman J, 2011, TXB TRAUMATIC BRAIN; Park YH, 2015, J STROKE CEREBROVASC, V24, P554, DOI 10.1016/j.jstrokecerebrovasdis.2014.09.033; Piovesana A, 2017, CLIN REHABIL, V31, P1351, DOI 10.1177/0269215517695373; Polatajko HJ, 2012, AM J OCCUP THER, V66, P104, DOI 10.5014/ajot.2012.001784; Ponsford JL, 2014, J NEUROTRAUM, V31, P64, DOI 10.1089/neu.2013.2997; Rebok GW, 2014, J AM GERIATR SOC, V62, P16, DOI 10.1111/jgs.12607; Roman-Caballero R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207957; Sherman DS, 2017, NEUROPSYCHOL REV, V27, P440, DOI 10.1007/s11065-017-9363-3; Sidik K, 2007, STAT MED, V26, P1964, DOI 10.1002/sim.2688; Spencer-Smith M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119522; Sun JH, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.08.05; van de Ven RM, 2016, FRONT HUM NEUROSCI, V10, DOI 10.3389/fnhum.2016.00150; van de Ven RM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172993; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Virk S, 2015, NEUROREHABILITATION, V36, P367, DOI 10.3233/NRE-151225; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Winkens I, 2009, ARCH PHYS MED REHAB, V90, P1672, DOI 10.1016/j.apmr.2009.04.016; Yoo C, 2015, J PHYS THER SCI, V27, P2487, DOI 10.1589/jpts.27.2487; Zhang HF, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-027062	46	12	12	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2020	15	7							e0235510	10.1371/journal.pone.0235510	http://dx.doi.org/10.1371/journal.pone.0235510			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MQ0QU	32645046	Green Published, gold			2023-01-03	WOS:000552602700052
J	Semenas, E; Hultstrom, M				Semenas, Egidijus; Hultstrom, Michael			Patient satisfaction with continuous epidural analgesia after major surgical procedures at a Swedish University hospital	PLOS ONE			English	Article							POSTOPERATIVE PAIN MANAGEMENT; SUFENTANIL; ANESTHESIA	Objective The use of epidural analgesia after major surgery is a well-established analgesia method. Epidural analgesia for postoperative pain relief needs to be monitored regularly in order to evaluate patient satisfaction and avoid side effects. However, due to the new available regional techniques, the role of epidural analgesia is being questioned and data about patient satisfaction is lacking. The current study was designed to evaluate patient satisfaction with epidural analgesia, its efficacy and reasons for premature termination of epidural analgesia. Materials and methods We conducted a retrospective survey of all patients who undergone surgery at Uppsala University hospital between October 2012 and January 2014 requiring continuous epidural analgesia for postoperative pain relief. Patients' satisfaction with epidural analgesia and its effectiveness were evaluated by using paper questionnaire. Results During the study period 579 epidurals were inserted in patients scheduled for vascular, hepatobiliary, esophageal and other major abdominal surgery. The average treatment time was 3.8 +/- 1.8 days. Epidural analgesia consisted either of bupivacaine 0.1%+sufentanil 1 mu g/ml solution or ropivacaine 0.2% solution. If patient needed opiates during treatment with epidural analgesia, only ropivacaine 0,2% solution was used. 494 (87.9%) patients were satisfied with their analgesia with no difference in satisfaction between sexes being observed. In 62 cases (11.2%) patient controlled analgesia was used on top of epidural analgesia with ropivacaine 0.2% solution, and 50.8% of patients were satisfied in this group. 514 (91.4%) patients were reported as having a good effect, 24 (4.3%) patients reported or were tested to show some effect, and 24 (4.3%) had no effect. No major neurological complications (epidural hematoma or abscess) were observed. Conclusions Our retrospective survey indicates that patients are satisfied with continuous epidural analgesia used in major surgery.	[Semenas, Egidijus; Hultstrom, Michael] Uppsala Univ, Dept Surg Sci, Unit Anaesthesiol & Intens Care, Uppsala, Sweden; [Hultstrom, Michael] Uppsala Univ, Dept Med Cell Biol, Unit Integrat Physiol, Uppsala, Sweden	Uppsala University; Uppsala University	Semenas, E (corresponding author), Uppsala Univ, Dept Surg Sci, Unit Anaesthesiol & Intens Care, Uppsala, Sweden.	egidijus.semenas@gmail.com	Hultström, Michael/H-3642-2019	Hultström, Michael/0000-0003-4675-1099; Semenas, Egidijus/0000-0002-3543-5261				Broekema AA, 1996, ANESTH ANALG, V82, P754, DOI 10.1097/00000539-199604000-00014; Burmeister MA, 2001, ANASTH INTENSIV NOTF, V36, P219, DOI 10.1055/s-2001-12751; Dolin SJ, 2005, BRIT J ANAESTH, V95, P584, DOI 10.1093/bja/aei227; Golster M, 2014, EUR J ANAESTH, V31, P589, DOI 10.1097/EJA.0000000000000105; Hermanides J, 2012, BRIT J ANAESTH, V109, P144, DOI 10.1093/bja/aes214; Lawrence VA, 2006, ANN INTERN MED, V144, P596, DOI 10.7326/0003-4819-144-8-200604180-00011; Pan PH, 2004, INT J OBSTET ANESTH, V13, P227, DOI 10.1016/j.ijoa.2004.04.008; Popping DM, 2008, BRIT J ANAESTH, V101, P832, DOI 10.1093/bja/aen300; Rawal N, 2012, REGION ANESTH PAIN M, V37, P310, DOI 10.1097/AAP.0b013e31825735c6; Ready LB, 1999, REGION ANESTH PAIN M, V24, P499, DOI 10.1016/S1098-7339(99)90038-X; Revie EJ, 2011, HPB, V13, P206, DOI 10.1111/j.1477-2574.2010.00274.x; Rodgers A, 2000, BMJ-BRIT MED J, V321, P1493, DOI 10.1136/bmj.321.7275.1493; Tan T, 2011, IRISH J MED SCI, V180, P417, DOI 10.1007/s11845-010-0645-5; Wigfull J, 2001, ANAESTHESIA, V56, P70, DOI 10.1046/j.1365-2044.2001.01763-6.x	14	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2020	15	7							e0235636	10.1371/journal.pone.0235636	http://dx.doi.org/10.1371/journal.pone.0235636			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM1IV	32614891	Green Published, gold			2023-01-03	WOS:000549913100083
J	Amor, C; Feucht, J; Leibold, J; Ho, YJ; Zhu, CY; Alonso-Curbelo, D; Mansilla-Soto, J; Boyer, JA; Li, X; Giavridis, T; Kulick, A; Houlihan, S; Peerschke, E; Friedman, SL; Ponomarev, V; Piersigilli, A; Sadelain, M; Lowe, SW				Amor, Corina; Feucht, Judith; Leibold, Josef; Ho, Yu-Jui; Zhu, Changyu; Alonso-Curbelo, Direna; Mansilla-Soto, Jorge; Boyer, Jacob A.; Li, Xiang; Giavridis, Theodoros; Kulick, Amanda; Houlihan, Shauna; Peerschke, Ellinor; Friedman, Scott L.; Ponomarev, Vladimir; Piersigilli, Alessandra; Sadelain, Michel; Lowe, Scott W.			Senolytic CAR T cells reverse senescence-associated pathologies	NATURE			English	Article							CELLULAR SENESCENCE; UROKINASE RECEPTOR; STELLATE CELLS; LYMPHOCYTES; CANCER; CYTOTOXICITY; THERAPY; TUMORS	Cellular senescence is characterized by stable cell-cycle arrest and a secretory program that modulates the tissue microenvironment(1,2). Physiologically, senescence serves as a tumour-suppressive mechanism that prevents the expansion of premalignant cells(3,4)and has a beneficial role in wound-healing responses(5,6). Pathologically, the aberrant accumulation of senescent cells generates an inflammatory milieu that leads to chronic tissue damage and contributes to diseases such as liver and lung fibrosis, atherosclerosis, diabetes and osteoarthritis(1,7). Accordingly, eliminating senescent cells from damaged tissues in mice ameliorates the symptoms of these pathologies and even promotes longevity(1,2,8-10). Here we test the therapeutic concept that chimeric antigen receptor (CAR) T cells that target senescent cells can be effective senolytic agents. We identify the urokinase-type plasminogen activator receptor (uPAR)(11)as a cell-surface protein that is broadly induced during senescence and show that uPAR-specific CAR T cells efficiently ablate senescent cells in vitro and in vivo. CAR T cells that target uPAR extend the survival of mice with lung adenocarcinoma that are treated with a senescence-inducing combination of drugs, and restore tissue homeostasis in mice in which liver fibrosis is induced chemically or by diet. These results establish the therapeutic potential of senolytic CAR T cells for senescence-associated diseases. Chimeric antigen receptor (CAR) T cells targeting uPAR, a cell-surface protein that is upregulated on senescent cells, eliminate senescent cells in vitro and in vivo and reduce liver fibrosis in mice.	[Amor, Corina; Boyer, Jacob A.] Mem Sloan Kettering Canc Ctr, Louis V Gerstner Jr Grad Sch Biomed Sci, 1275 York Ave, New York, NY 10021 USA; [Amor, Corina; Leibold, Josef; Ho, Yu-Jui; Zhu, Changyu; Alonso-Curbelo, Direna; Li, Xiang; Houlihan, Shauna; Lowe, Scott W.] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Canc Biol & Genet, 1275 York Ave, New York, NY 10021 USA; [Feucht, Judith; Mansilla-Soto, Jorge; Giavridis, Theodoros; Sadelain, Michel] Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, 1275 York Ave, New York, NY 10021 USA; [Feucht, Judith; Mansilla-Soto, Jorge; Giavridis, Theodoros; Sadelain, Michel] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Immunol Program, 1275 York Ave, New York, NY 10021 USA; [Boyer, Jacob A.; Kulick, Amanda] Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Chem Program, 1275 York Ave, New York, NY 10021 USA; [Li, Xiang] Weill Cornell Grad Sch Med Sci, New York, NY USA; [Peerschke, Ellinor] Mem Sloan Kettering Canc Ctr, Dept Lab Med, 1275 York Ave, New York, NY 10021 USA; [Friedman, Scott L.] Icahn Sch Med Mt Sinai, Div Liver Dis, New York, NY 10029 USA; [Ponomarev, Vladimir] Mem Sloan Kettering Canc Ctr, Dept Radiol, 1275 York Ave, New York, NY 10021 USA; [Piersigilli, Alessandra] Rockefeller Univ, Lab Comparat Pathol, Weill Cornell Med, 1230 York Ave, New York, NY 10021 USA; [Piersigilli, Alessandra] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA; [Lowe, Scott W.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; Memorial Sloan Kettering Cancer Center; Icahn School of Medicine at Mount Sinai; Memorial Sloan Kettering Cancer Center; Cornell University; Rockefeller University; Memorial Sloan Kettering Cancer Center; Howard Hughes Medical Institute	Lowe, SW (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Dept Canc Biol & Genet, 1275 York Ave, New York, NY 10021 USA.; Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Ctr Cell Engn, 1275 York Ave, New York, NY 10021 USA.; Sadelain, M (corresponding author), Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, Immunol Program, 1275 York Ave, New York, NY 10021 USA.; Lowe, SW (corresponding author), Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.	m-sadelain@ski.mskcc.org; lowes@mskcc.org	Alonso Curbelo, Direna/AFT-1035-2022; Amor, Corina/AAZ-1904-2020	Alonso Curbelo, Direna/0000-0001-6674-3059; Giavridis, Theodoros/0000-0002-8716-781X; Ho, Yu-jui/0000-0002-7540-024X; Leibold, Josef/0000-0003-2336-1987; Amor, Corina/0000-0002-7654-6216; Zhu, Changyu/0000-0003-3583-3638	National Institute of Aging [AG065396]; Pasteur-Weizmann/Servier award; Memorial Sloan Kettering Cancer Center support grant [P30 CA008748]; National Institute of Diabetes and Digestive and Kidney Diseases [R01DK56621]; Department of Defense [CA150272]; P30 grant [CA165979]; La Caixa foundation; Harold E. Varmus graduate student fellowship from the Gerstner Sloan Kettering graduate school; Care-for-Rare Foundation; German Research Foundation (DFG); DFG; Shulamit Katzman Endowed Postdoctoral Research Fellowship; Fundacion Ramon Areces; Grayer postgraduate fellowship from the Gerstner Sloan Kettering graduate school; Geoffrey Been graduate student fellowship from the Gerstner Sloan Kettering graduate school; National Cancer Institute [U54 0D020355-01]	National Institute of Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Pasteur-Weizmann/Servier award; Memorial Sloan Kettering Cancer Center support grant; National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Department of Defense(United States Department of Defense); P30 grant; La Caixa foundation(La Caixa Foundation); Harold E. Varmus graduate student fellowship from the Gerstner Sloan Kettering graduate school; Care-for-Rare Foundation; German Research Foundation (DFG)(German Research Foundation (DFG)); DFG(German Research Foundation (DFG)); Shulamit Katzman Endowed Postdoctoral Research Fellowship; Fundacion Ramon Areces; Grayer postgraduate fellowship from the Gerstner Sloan Kettering graduate school; Geoffrey Been graduate student fellowship from the Gerstner Sloan Kettering graduate school; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank A. Lujambio and R. Brody and the Biorepository and Pathology Core at Icahn School of Medicine at Mount Sinai, and G. Askan and O. Basturk at the Department of Pathology at MSKCC, for tissue samples; L. Zender and H. Chen for sharing plasmids; N. Salgado, H. Chen, T. Baslan, S. Tian, A. Wuest, W. Luan and G. Gunset for technical assistance; and C. J. Sherr, E. de Stanchina, N. Kuhn, A. Dobrin, M. L. Sjostrand and other members of the Lowe and Sadelain laboratories for insightful discussions. This work was supported by a grant from the National Institute of Aging (AG065396) to S.W.L., the Pasteur-Weizmann/Servier award to M.S. and a Memorial Sloan Kettering Cancer Center support grant (P30 CA008748) to both S.W.L. and M.S. laboratories. S.L.F. was supported by a grant from the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK56621), a grant from the Department of Defense (CA150272) and the P30 grant (CA165979); C.A. was supported by a postgraduate fellowship from La Caixa foundation and is the recipient of the Harold E. Varmus graduate student fellowship from the Gerstner Sloan Kettering graduate school; J.F. was supported by the Care-for-Rare Foundation and the German Research Foundation (DFG); J.L. was supported by a fellowship from the DFG and a Shulamit Katzman Endowed Postdoctoral Research Fellowship; J.F. and J.L. are part of the Experimental Medicine Program at the University of Tuebingen; D.A.-C. was supported by a postdoctoral fellowship from Fundacion Ramon Areces; J.A.B. was supported by the Grayer postgraduate fellowship and the Geoffrey Been graduate student fellowship from the Gerstner Sloan Kettering graduate school; and A.K. was supported by a grant from the National Cancer Institute (U54 0D020355-01). S.W.L. is the Geoffrey Been Chair of Cancer Biology and a Howard Hughes Medical Institute Investigator. We thank the following MSKCC core facilities for support: SKI flow cytometry core facility, animal facility, antitumor assessment core, laboratory for comparative biology, bioinformatics core and integrated genomics operation core.	Aghajanian H, 2019, NATURE; Anderson KG, 2017, CANCER CELL, V31, P311, DOI 10.1016/j.ccell.2017.02.008; Baar MP, 2017, CELL, V169, P132, DOI 10.1016/j.cell.2017.02.031; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Belcher C, 1996, ANN RHEUM DIS, V55, P230, DOI 10.1136/ard.55.4.230; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Brentjens RJ, 2007, CLIN CANCER RES, V13, P5426, DOI 10.1158/1078-0432.CCR-07-0674; Brentjens RJ, 2003, NAT MED, V9, P279, DOI 10.1038/nm827; Brunt EM, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.80; BUGGE TH, 1995, J BIOL CHEM, V270, P16886, DOI 10.1074/jbc.270.28.16886; Chen EY, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-128; Childs BG, 2016, SCIENCE, V354, P472, DOI 10.1126/science.aaf6659; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Davila ML, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061338; Demaria M, 2014, DEV CELL, V31, P722, DOI 10.1016/j.devcel.2014.11.012; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Dobrenkov K, 2008, J NUCL MED, V49, P1162, DOI 10.2967/jnumed.107.047324; Du HW, 2019, CANCER CELL, V35, P221, DOI 10.1016/j.ccell.2019.01.002; Feucht J, 2019, NAT MED, V25, P82, DOI 10.1038/s41591-018-0290-5; Fujii M, 2013, MED MOL MORPHOL, V46, P141, DOI 10.1007/s00795-013-0016-1; Gargett T, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00235; Giavridis T, 2018, NAT MED, V24, P731, DOI 10.1038/s41591-018-0041-7; Guthoff M, 2017, SCI REP, V7; Hagani AB, 1999, J GENE MED, V1, P341; Hayek SS, 2015, NEW ENGL J MED, V373, P1916, DOI 10.1056/NEJMoa1506362; He SH, 2017, CELL, V169, P1000, DOI 10.1016/j.cell.2017.05.015; Kang TW, 2011, NATURE, V479, P547, DOI 10.1038/nature10599; Kirkland JL, 2017, EBIOMEDICINE, V21, P21, DOI 10.1016/j.ebiom.2017.04.013; Krizhanovsky V, 2008, CELL, V134, P657, DOI 10.1016/j.cell.2008.06.049; Kuhn NF, 2019, CANCER CELL, V35, P473, DOI 10.1016/j.ccell.2019.02.006; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Livshits G, 2018, ELIFE, V7, DOI 10.7554/eLife.35216; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lujambio A, 2013, CELL, V153, P449, DOI 10.1016/j.cell.2013.03.020; Maher J, 2002, NAT BIOTECHNOL, V20, P70, DOI 10.1038/nbt0102-70; Norelli M, 2018, NAT MED, V24, P739, DOI 10.1038/s41591-018-0036-4; Park JH, 2018, NEW ENGL J MED, V378, P449, DOI 10.1056/NEJMoa1709919; Paszkiewicz PJ, 2016, J CLIN INVEST, V126, P4262, DOI 10.1172/JCI84813; Pellegatta S, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat6463; Perna F, 2017, CANCER CELL, V32, P506, DOI 10.1016/j.ccell.2017.09.004; Puche JE, 2013, HEPATOLOGY, V57, P340, DOI 10.1002/hep.26053; Ruscetti M, 2018, SCIENCE, V362, P1416, DOI 10.1126/science.aas9090; Sadelain M, 2017, NATURE, V545, P423, DOI 10.1038/nature22395; Santos EB, 2009, NAT MED, V15, P338, DOI 10.1038/nm.1930; Schnabl B, 2003, HEPATOLOGY, V37, P653, DOI 10.1053/jhep.2003.50097; Schuliga M, 2017, SCI REP-UK, V7, DOI 10.1038/srep41770; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sharpless NE, 2015, NAT REV CANCER, V15, P397, DOI 10.1038/nrc3960; Simon DI, 1996, BLOOD, V88, P3185, DOI 10.1182/blood.V88.8.3185.bloodjournal8883185; Smith HW, 2010, NAT REV MOL CELL BIO, V11, P23, DOI 10.1038/nrm2821; Tasdemir N, 2016, CANCER DISCOV, V6, P612, DOI 10.1158/2159-8290.CD-16-0217; Van der Schueren B, 2015, INT J OBESITY, V39, P1254, DOI 10.1038/ijo.2015.58; Wang C, 2019, NATURE, V574, P268, DOI 10.1038/s41586-019-1607-3; Wang L, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109173; Wang XB, 2016, CELL METAB, V24, P848, DOI 10.1016/j.cmet.2016.09.016; Xu M, 2018, NAT MED, V24, P1246, DOI 10.1038/s41591-018-0092-9; Zhu CY, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat0344	58	335	348	42	239	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 2	2020	583	7814					127	+		10.1038/s41586-020-2403-9	http://dx.doi.org/10.1038/s41586-020-2403-9		JUN 2020	32	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ME6OV	32555459	Green Accepted			2023-01-03	WOS:000541024900011
J	Khamsi, R				Khamsi, Roxanne			COMPUTING CANCER'S WEAK SPOTS	SCIENCE			English	Editorial Material																			0	1	1	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 12	2020	368	6496					1174	1177		10.1126/science.368.6496.1174	http://dx.doi.org/10.1126/science.368.6496.1174			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MD5SF	32527812				2023-01-03	WOS:000544031400010
J	Donald, S; Sharples, K; Barson, D; Horsburgh, S; Parkin, L				Donald, Sarah; Sharples, Katrina; Barson, David; Horsburgh, Simon; Parkin, Lianne			Patterns of prescription medicine dispensing before and during pregnancy in New Zealand, 2005-2015	PLOS ONE			English	Article							DRUG-USE; MEDICATION USE; TERATOGENIC RISK; PRIMARY-CARE; WOMEN; PERCEPTION; COHORT; ASSOCIATION; INFORMATION; PREVALENCE	Objective To describe prescription medicine dispensing before and during pregnancy in New Zealand, 2005-2015. Methods Members of the New Zealand Pregnancy Cohort were linked with their dispensing records in a national database of prescription products dispensed from community pharmacies. We identified the proportion of pregnancies during which at least one prescription medicine was dispensed, the number of different medicines used and the most commonly dispensed medicine groups both during pregnancy and in the 270 days before conception. Dispensing during pregnancy was assessed by several maternal characteristics. Results 874,884 pregnancies were included. Over the study timeframe, the proportion of pregnancies exposed to a non-supplement prescription medicine increased from 38.5% to 67.2%. The mean number of different non-supplement medicines dispensed during pregnancy increased from 2.5 to 3.2. Dispensing during pregnancy was weakly associated with body mass index, smoking status and ethnicity. Pregnancy exposure was highest for Antibacterials (26.0%), Analgesics (16.7%) and Antinausea & Vertigo Agents (11.0%). Conclusions From 2005-2015, both the proportion of exposed pregnancies and the number of different medicines dispensed to pregnant women in New Zealand increased.	[Donald, Sarah; Sharples, Katrina; Barson, David; Horsburgh, Simon; Parkin, Lianne] Pharmacoepidemiol Res Network, Dunedin, New Zealand; [Donald, Sarah; Barson, David; Horsburgh, Simon; Parkin, Lianne] Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand; [Sharples, Katrina] Univ Otago, Dept Math & Stat, Dunedin, New Zealand; [Sharples, Katrina] Univ Otago, Dept Med, Dunedin, New Zealand	University of Otago; University of Otago; University of Otago	Donald, S (corresponding author), Pharmacoepidemiol Res Network, Dunedin, New Zealand.; Donald, S (corresponding author), Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand.	sarah.donald@otago.ac.nz	Horsburgh, Simon/C-9861-2009	Horsburgh, Simon/0000-0002-1011-7996; Donald, Sarah/0000-0002-7189-3200; Parkin, Lianne/0000-0002-6824-6176	Health Research Council of New Zealand [16/072]	Health Research Council of New Zealand(Health Research Council of New Zealand)	This research was supported by a Clinical Research Training Fellowship (SD) from the Health Research Council of New Zealand (grant number 16/072) (https://www.hrc.govt.nz/).The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adam MP, 2011, AM J MED GENET C, V157C, P175, DOI 10.1002/ajmg.c.30313; Andrade SE, 2004, AM J OBSTET GYNECOL, V191, P398, DOI 10.1016/j.ajog.2004.04.025; Artama M, 2011, PHARMACOEPIDEM DR S, V20, P729, DOI 10.1002/pds.2159; Bakker MK, 2006, BJOG-INT J OBSTET GY, V113, P559, DOI 10.1111/j.1471-0528.2006.00927.x; Berard A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093870; Bjorn Anne-Mette Bay, 2011, Clin Epidemiol, V3, P149, DOI 10.2147/CLEP.S17747; Charlton RA, 2014, PHARMACOEPIDEM DR S, V23, P586, DOI 10.1002/pds.3613; Cheung K, 2017, PHARMACOEPIDEM DR S, V26, P1119, DOI 10.1002/pds.4264; Cleary BJ, 2010, PHARMACOEPIDEM DR S, V19, P408, DOI 10.1002/pds.1906; Colvin L, 2009, PHARMACOEPIDEM DR S, V18, P211, DOI 10.1002/pds.1705; Daw JR, 2012, CLIN THER, V34, P239, DOI 10.1016/j.clinthera.2011.11.025; Daw JR, 2011, PHARMACOEPIDEM DR S, V20, P895, DOI 10.1002/pds.2184; de Jonge L, 2015, DRUG SAFETY, V38, P737, DOI 10.1007/s40264-015-0302-z; Demailly R, 2017, PHARMACOEPIDEM DR S, V26, P1126, DOI 10.1002/pds.4265; Dillon P, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0489-0; Donald S, 2018, PHARMACOEPIDEM DR S, V27, P1335, DOI 10.1002/pds.4671; Engeland A, 2008, BRIT J CLIN PHARMACO, V65, P653, DOI 10.1111/j.1365-2125.2008.03102.x; Gagne JJ, 2008, EUR J CLIN PHARMACOL, V64, P1125, DOI 10.1007/s00228-008-0546-y; Hardy JR, 2006, PHARMACOEPIDEM DR S, V15, P555, DOI 10.1002/pds.1269; Houghton LA, 2008, BEST PRACTICE J, P42; Huybrechts KF, 2019, PHARMACOEPIDEM DR S, V28, P906, DOI 10.1002/pds.4789; Huybrechts KF, 2018, JAMA-J AM MED ASSOC, V320, P2429, DOI 10.1001/jama.2018.18307; Irvine L, 2010, DRUG SAFETY, V33, P593, DOI 10.2165/11532330-000000000-00000; Jones MR, 2018, PAIN THER, V7, P13, DOI 10.1007/s40122-018-0097-6; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Kaplan YC, 2019, REPROD TOXICOL, V86, P1, DOI 10.1016/j.reprotox.2019.03.001; Lacroix I, 2009, EUR J CLIN PHARMACOL, V65, P839, DOI 10.1007/s00228-009-0647-2; Lo WY, 2002, OBSTET GYNECOL, V100, P465, DOI 10.1016/S0029-7844(02)02122-1; Lumley T, 2006, UW BIOSTATISTICS WOR; Lupattelli A, 2014, PATIENT EDUC COUNS, V96, P171, DOI 10.1016/j.pec.2014.04.014; Malm H, 2003, EUR J CLIN PHARMACOL, V59, P127, DOI 10.1007/s00228-003-0584-4; Ministry of Health, 2018, HELPFUL ADVICE PREGN; Ministry of Health, 2018, PHARM COLL; Ministry of Health, 2018, BARR ACC HLTH CAR; MITCHELL AA, 1986, AM J EPIDEMIOL, V123, P670, DOI 10.1093/oxfordjournals.aje.a114286; Mitchell AA, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.02.029; National Centre for Classification in Health, 2002, INT STAT CLASS DIS R; Nordeng H, 2010, EUR J CLIN PHARMACOL, V66, P207, DOI 10.1007/s00228-009-0744-2; Olesen C, 2001, EPIDEMIOLOGY, V12, P497, DOI 10.1097/00001648-200109000-00006; Olesen C, 2006, EUR J CLIN PHARMACOL, V62, P547, DOI 10.1007/s00228-006-0119-x; Palmsten K, 2015, OBSTET GYNECOL, V126, P465, DOI 10.1097/AOG.0000000000000982; Pisa FE, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0745-3; Riley EH, 2005, J WOMENS HEALTH, V14, P401, DOI 10.1089/jwh.2005.14.401; Sanz E, 2001, EUR J OBSTET GYN R B, V95, P127, DOI 10.1016/S0301-2115(00)00375-4; Sarangarm P, 2012, BIRTH DEFECTS RES A, V94, P153, DOI 10.1002/bdra.22888; Schirm E, 2004, EUR J OBSTET GYN R B, V114, P182, DOI 10.1016/j.ejogrb.2003.10.024; Singh S, 2010, STUD FAMILY PLANN, V41, P241, DOI 10.1111/j.1728-4465.2010.00250.x; Skurtveit S, 2014, NORWEGIAN J EPIDEMIO, V24, P209; Smolina K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128312; Stephansson Olof, 2011, Clin Epidemiol, V3, P43, DOI 10.2147/CLEP.S16305; White IR, 2010, STAT MED, V29, P2920, DOI 10.1002/sim.3944; Widnes SF, 2013, DRUG SAFETY, V36, P481, DOI 10.1007/s40264-013-0035-9; Zambelli-Weiner A, 2019, REPROD TOXICOL, V83, P14, DOI 10.1016/j.reprotox.2018.10.010; Zhang F, 2016, PHARMACOEPIDEM DR S, V25, P628, DOI 10.1002/pds.3947	54	2	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 2	2020	15	6							e0234153	10.1371/journal.pone.0234153	http://dx.doi.org/10.1371/journal.pone.0234153			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT4VF	32484824	Green Published, gold			2023-01-03	WOS:000554969700035
J	Saqib, F; Mujahid, K; Aslam, MA; Modhi, A; Moga, MA; Bobescu, E; Marceanu, L				Saqib, Fatima; Mujahid, Khizra; Aslam, Muhammad Arif; Modhi, Alotaibi; Moga, Marius Alexandru; Bobescu, Elena; Marceanu, Luigi			Ex vivo and in vivo studies of Viola tricolor Linn. as potential cardio protective and hypotensive agent: Inhibition of voltage-gated Ca++ ion channels	FASEB JOURNAL			English	Article						calcium channel blocker; cardiac depressant; histopathology; in vitro; in vivo; invasive blood pressure; Vasodilator; VDLCs	MYOCARDIAL INFARCTED RATS; ISOPROTERENOL; HYPERTROPHY; HYPERTENSION; EXTRACT; GEL	Viola tricolor Linn. is used as cardio-protective and anti-hypertensive agent in traditional medicine. Current study objective was to evaluate cardio-protective and hypotensive effects of Viola tricolor L. in vitro and in vivo studies. Viola tricolor L. crude extract (Vt.Cr) and its fractions (Aqueous and organic) were tested at rabbit atria and aorta coupled to Power Lab Data Acquisition System for cardio depressant and vasorelaxant effects in vitro whereas in vivo Blood Pressure was checked by invasive method in normotensive ketamine-diazepam anesthetized rats. Isoproterenol was employed for acute myocardial infarction (AMI) and left ventricular hypertrophy (LVH) development and cardioprotective effects of Vt.Cr were evaluated hemodynamically and histopathologically. Vt.Cr and its fractions decreased heart rate and contractile force in paired atria and relaxed Phenylephrine (1 mu M) and K+ (80 mM) stimulated contractions in aorta possibly mediated through Voltage dependent L-type calcium channels blockage supported by in vivo hypotensive action. In LVH, Vt.Cr lowered Angiotensin Converting Enzymes and renin, increased cyclic Guanosine Monophosphate and nitric oxide levels, decreased cardiomyocytes size and fibrosis attributed to Gallic acid as detected by High Performance Liquid Chromatography. Partial positive results were seen hemodynamically and histologically in AMI Viola tricolor L. showed vasorelaxant, cardio-relaxant, hypotensive, and cardio protective effect validating traditional practice in cardiovascular disorders.	[Saqib, Fatima; Mujahid, Khizra; Aslam, Muhammad Arif] Bahauddin Zakariya Univ, Fac Pharm, Multan, Pakistan; [Modhi, Alotaibi] Princess Nourah bint Abdulrahman Univ, Dept Biol, Coll Sci, Riyadh, Saudi Arabia; [Moga, Marius Alexandru; Bobescu, Elena; Marceanu, Luigi] Transilvania Univ Brasov, Fac Med, 56 Balcescu Nicolae St, Brasov 500019, Romania	Bahauddin Zakariya University; Princess Nourah bint Abdulrahman University; Transylvania University of Brasov	Bobescu, E (corresponding author), Transilvania Univ Brasov, Fac Med, 56 Balcescu Nicolae St, Brasov 500019, Romania.	elena.bobescu@gmail.com	MOGA, MARIUS ALEXANDRU/AHC-2310-2022; Aslam, Muhammad Arif/AAS-4577-2020; Bobescu, Elena/AAC-6840-2021; Bobescu, Elena/ABD-6951-2020	Aslam, Muhammad Arif/0000-0001-9747-658X; Bobescu, Elena/0000-0002-0945-9067	Deanship of Scientific Research at Princess Nourah bint Abdurrahman University through the Fast-track Research Funding Program	Deanship of Scientific Research at Princess Nourah bint Abdurrahman University through the Fast-track Research Funding Program(Princess Nourah bint Abdulrahman University)	This research was funded by the Deanship of Scientific Research at Princess Nourah bint Abdurrahman University through the Fast-track Research Funding Program	Aman Upaganlawar, 2011, Journal of Pharmacology and Toxicology, V6, P1; Ardjmand A, 2019, LIFE SCI, V227, P187, DOI 10.1016/j.lfs.2019.04.056; Bao D, 2015, DIS MODEL MECH, V8, P795, DOI 10.1242/dmm.021303; Cheng YL, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/274025; Doggrell SA, 1998, CARDIOVASC RES, V39, P89, DOI 10.1016/S0008-6363(98)00076-5; Fan Y, 2019, PHARMACOLOGY, V103, P291, DOI 10.1159/000496800; FOSTER RW, 1984, BRIT J PHARMACOL, V81, P499, DOI 10.1111/j.1476-5381.1984.tb10103.x; Ghorbani A, 2012, AFR J PHARM PHARMACO, V6, P2503, DOI 10.5897/AJPP10.721; Gilani AH, 2005, J ETHNOPHARMACOL, V98, P127, DOI 10.1016/j.jep.2005.01.017; Grzeszczuk M, 2016, ACTA SCI POL-HORTORU, V15, P109; Hellinger R, 2014, J ETHNOPHARMACOL, V151, P299, DOI 10.1016/j.jep.2013.10.044; Jahantab E., 2018, IRAN ADV HERB, V3, P12; Janbaz KH, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0697-1; Jin L., 2017, SCI REP-UK, V7, P1; Jin L, 2017, J HYPERTENS, V35, P1502, DOI 10.1097/HJH.0000000000001327; JIN LI, 2018, SCI REP-UK, V8, P1, DOI DOI 10.1038/S41598-018-27599-4; Kang N, 2015, ENVIRON TOXICOL PHAR, V39, P764, DOI 10.1016/j.etap.2015.02.006; Kim HY, 2011, J ETHNOPHARMACOL, V133, P315, DOI 10.1016/j.jep.2010.09.024; Kirichenko TV, 2016, PHYTOMEDICINE, V23, P1198, DOI 10.1016/j.phymed.2015.12.002; Lin PP, 2013, INT J MOL MED, V32, P1319, DOI 10.3892/ijmm.2013.1524; Loffredo FS, 2013, CELL, V153, P828, DOI 10.1016/j.cell.2013.04.015; Lu L, 2015, CELL BIOCHEM BIOPHYS, V72, P865, DOI 10.1007/s12013-015-0553-4; Meeran MFN, 2016, CHEM-BIOL INTERACT, V244, P159, DOI 10.1016/j.cbi.2015.12.006; Meeran MFN, 2012, EUR J PHARMACOL, V677, P116, DOI 10.1016/j.ejphar.2011.11.043; Mradu G., 2012, INT J PHARMACOGN PHY, V4, P162; Murugesan S, 2019, J ETHNOPHARMACOL, V237, P108, DOI 10.1016/j.jep.2019.03.049; NAGANO M, 1992, HYPERTENSION, V19, P708, DOI 10.1161/01.HYP.19.6.708; Ocaranza MP, 2002, J CARDIOVASC PHARM, V40, P246, DOI 10.1097/00005344-200208000-00010; Odigie IP, 2003, J ETHNOPHARMACOL, V86, P181, DOI 10.1016/S0378-8741(03)00078-3; Panda S, 2014, EUR J PHARMACOL, V723, P451, DOI 10.1016/j.ejphar.2013.10.049; Piana M, 2013, J ETHNOPHARMACOL, V150, P458, DOI 10.1016/j.jep.2013.08.040; Piana M, 2013, J CHROMATOGR SCI, V51, P406, DOI 10.1093/chromsci/bms155; Prince PSM, 2009, EUR J PHARMACOL, V615, P139, DOI 10.1016/j.ejphar.2009.05.003; Rahimi VB, 2019, IRAN J MED SCI, V44, P220; Ryu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep34790; Saqib F, 2019, B LATINOAM CARIBE PL, V18, P204; Saqib F, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0837-7; Seguro Luis Fernando Bernal da Costa, 2009, Arq Bras Cardiol, V93, P652; Sudhakumari A., 2012, INT J BASIC MED SCI, V2, P53; Syed AA, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00510; Takami T, 2003, CLIN EXP HYPERTENS, V25, P525, DOI 10.1081/CEH-120025336; TSE J, 1979, ENDOCRINOLOGY, V105, P246, DOI 10.1210/endo-105-1-246; Vukics V, 2008, J CHROMATOGR SCI, V46, P823, DOI 10.1093/chromsci/46.9.823; Vukics V, 2009, ANTIOXIDANT FLAVONOI, P222; Witkowska-Banaszczak E, 2005, FITOTERAPIA, V76, P458, DOI 10.1016/j.fitote.2005.03.005; World Health Organization, 2019, SAN; YIN FCP, 1982, AM J PHYSIOL, V243, pH941, DOI 10.1152/ajpheart.1982.243.6.H941; Yoon Na Young, 2013, Fisheries and Aquatic Sciences, V16, P237, DOI 10.5657/FAS.2013.0237; Zhang GX, 2005, CARDIOVASC RES, V65, P230, DOI 10.1016/j.cardiores.2004.08.013	49	4	4	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2020	34	7					9102	9119		10.1096/fj.202000658R	http://dx.doi.org/10.1096/fj.202000658R		MAY 2020	18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MG8UN	32475023				2023-01-03	WOS:000538126200001
J	Marshall, J; Devane, N; Talbot, R; Caute, A; Cruice, M; Hilari, K; MacKenzie, G; Maguire, K; Patel, A; Roper, A; Wilson, S				Marshall, Jane; Devane, Niamh; Talbot, Richard; Caute, Anna; Cruice, Madeline; Hilari, Katerina; MacKenzie, Gillian; Maguire, Kimberley; Patel, Anita; Roper, Abi; Wilson, Stephanie			A randomised trial of social support group intervention for people with aphasia: A Novel application of virtual reality	PLOS ONE			English	Article							QUALITY-OF-LIFE; LONG-TERM STROKE; COMMUNITY APHASIA; TREATMENT FIDELITY; THERAPY; SPEECH; COMMUNICATION; IDENTITY; WELL; PERSPECTIVES	About a third of strokes cause aphasia, or language loss, with profound consequences for the person's social participation and quality of life. These problems may be mitigated by group social support. But this intervention is not available to all individuals. This study investigated whether it is feasible to deliver group social support to people with aphasia via a multi-user, virtual reality platform. It also explored the indicative effects of intervention and the costs. Intervention aimed to promote wellbeing and communicative success. It enabled participants to form new social connections and share experiences of living with aphasia. It comprised 14 sessions delivered over 6 months and was led by community based co-ordinators and volunteers. Feasibility measures comprised: recruitment and retention rates, compliance with intervention and assessment of treatment fidelity. Effects of intervention were explored using a waitlist randomised controlled design, with outcome measures of wellbeing, communication, social connectedness and quality of life. Two intervention groups were randomised to an immediate condition and two were randomised to a delayed condition. The main analysis explored scores on the measures between two time points, between which those in the immediate condition had received intervention, but those in the delayed group had not (yet). A comprehensive approach to economic data collection ensured that all costs of treatment delivery were recorded. Feasibility findings showed that the recruitment target was met (N = 34) and 85.3% (29/34) of participants completed intervention. All groups ran the 14 sessions as planned, and participants attended a mean of 11.4 sessions (s.d. 2.8), which was 81.6% of the intended dose. Fidelity checking showed minimal drift from the manualised intervention. No significant change was observed on any of the outcome measures, although the study was not powered to detect these. Costs varied across the four groups, from 7,483 pound - 12,562 pound British Pounds Sterling ($10,972 - $18,419 US dollars), depending on travel costs, the relative contributions of volunteers and the number of hardware loans that were needed. The results suggest that a larger trial of remote group support, using virtual reality, would be merited. However the treatment content and regime, and the selection of outcome measures should be reviewed before conducting the trial.	[Marshall, Jane; Devane, Niamh; Talbot, Richard; Caute, Anna; Cruice, Madeline; Hilari, Katerina; MacKenzie, Gillian; Maguire, Kimberley; Roper, Abi] City Univ London, Ctr Language & Commun Sci Res, London, England; [Caute, Anna] Univ Essex, Sch Hlth & Social Care, Colchester, Essex, England; [Patel, Anita] Queen Mary Univ London, Anita Patel Hlth Econ Consulting Ltd, London, England; [Wilson, Stephanie] City Univ London, Ctr Human Comp Interact Design, London, England	City University London; University of Essex; University of London; Queen Mary University London; City University London	Marshall, J (corresponding author), City Univ London, Ctr Language & Commun Sci Res, London, England.	j.marshall@city.ac.uk	Wilson, Stephanie/AAX-1579-2020; Talbot, Richard/GYR-1597-2022	Wilson, Stephanie/0000-0001-6445-654X; Cruice, Madeline/0000-0001-7344-2262; Caute, Anna/0000-0001-7808-0256; Hilari, Katerina/0000-0003-2091-4849	The Stroke Association [TSA 2016/05]	The Stroke Association	The work reported in this paper was funded by a grant from The Stroke Association: https://www.stroke.org.uk The grant number was: TSA 2016/05. The grant holders were: JM, SW, MC and AP. The funder provided support in the form of salaries for ND, RT, AC and AR. The grant also covered consultancy fees for AP and all research costs. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. One author (AP) is employed by a commercial organisation: Director, Anita Patel Health Economics Consulting Ltd. The specific roles of this, and all other authors are articulated in the 'authors contributions' section.; We thank the Stroke Association who funded this work. We are particularly grateful to our 6 group co-ordinators: Jo Black (Speakeasy), Andrea Hall (Stroke Association), Caroline McDonald (Dyscover), John Miles (Greenhill aphasia group), Mike Richardson (Greenhill aphasia group) and Jane Sedgwick (Stroke Association). We thank the volunteers who supported the intervention groups and our many testers who administered the outcome measures. We are grateful to Nick Zwart who provides technical support to EVA Park research. We thank the 34 people with aphasia who took part in this study and helped to progress our understanding of remote group intervention.	Amaya A, 2018, APHASIOLOGY, V32, P538, DOI 10.1080/02687038.2018.1431831; [Anonymous], 2017, J PEDIAT REHAB MED, V10, ps1; [Anonymous], 2011, CANC DISCOV, V1, pOF1; Attard MC, 2020, DISABIL REHABIL, V42, P1382, DOI 10.1080/09638288.2018.1526336; Attard MC, 2018, APHASIOLOGY, V32, P105, DOI 10.1080/02687038.2017.1381877; Attard MC, 2015, APHASIOLOGY, V29, P983, DOI 10.1080/02687038.2015.1016888; BOWEN A, 2012, BMJ-BRIT MED J, V345, DOI [DOI 10.1136/BMJ.E4407, DOI 10.1136/bmj.e4407]; Brady MC, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000425.pub4; Breitenstein C, 2017, LANCET, V389, P1528, DOI 10.1016/S0140-6736(17)30067-3; Brogan E, 2019, APHASIOLOGY, V33, P759, DOI 10.1080/02687038.2019.1576442; Brown K, 2012, INT J SPEECH-LANG PA, V14, P141, DOI 10.3109/17549507.2011.632026; Carragher M., 2018, APHASIOLOGY, V32, P37, DOI [DOI 10.1080/02687038.2018.1484880, 10.1080/02687038.2018.1484880]; Caute A., DEV NOVEL DYNAMIC AS; Caute A, 2019, J SPEECH LANG HEAR R, V62, P4382, DOI 10.1044/2019_JSLHR-L-18-0484; Choi YH, 2016, TELEMED E-HEALTH, V22, P434, DOI 10.1089/tmj.2015.0138; Corsten S, 2015, INT J LANG COMM DIS, V50, P788, DOI 10.1111/1460-6984.12173; Corsten S, 2014, APHASIOLOGY, V28, P440, DOI 10.1080/02687038.2013.843154; Cruice M, 2006, APHASIOLOGY, V20, P1210, DOI 10.1080/02687030600790136; Dorning H, 2016, KNOWING YOURE NOT AL; Elman RJ, 1999, J SPEECH LANG HEAR R, V42, P411, DOI 10.1044/jslhr.4202.411; Enderby P, 1996, DISABIL REHABIL, V18, P238, DOI 10.3109/09638289609166307; Farrell C, 2008, BRIT J OCCUPATIONAL, V72, P163; Geddes JML, 1994, CLIN REHABIL, V8, P116, DOI DOI 10.1177/026921559400800204; Hall N, 2013, INT J TELEREHABILITA, V5, P27, DOI 10.5195/ijt.2013.6119; Hartke RJ, 2007, TOP STROKE REHABIL, V14, P26, DOI 10.1310/tsr1401-26; Hilari K, 2003, APHASIOLOGY, V17, P365, DOI 10.1080/02687030244000725; Hilari K, 2019, PILOT FEASIBILITY ST, V5, DOI 10.1186/s40814-019-0397-6; Hilari K, 2009, CLIN REHABIL, V23, P544, DOI 10.1177/0269215508101729; Hill AJ, 2009, APHASIOLOGY, V23, P627, DOI 10.1080/02687030801909659; Hinckley JJ, 2013, AM J SPEECH-LANG PAT, V22, pS279, DOI 10.1044/1058-0360(2012/12-0092); Holland A., 2007, COUNSELLING COMMUNIC; Holland A. L., 1999, COMMUNICATION ACTIVI; Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185; Kauhanen ML, 2000, CEREBROVASC DIS, V10, P455, DOI 10.1159/000016107; Kertesz A., 2006, J AM GERIATR SOC; Lanyon L, 2019, DISABIL REHABIL, V41, P1024, DOI 10.1080/09638288.2017.1419290; Lanyon LE, 2013, INT J SPEECH-LANG PA, V15, P359, DOI 10.3109/17549507.2012.752865; LEE RM, 1995, J COUNS PSYCHOL, V42, P232, DOI 10.1037/0022-0167.42.2.232; Marshall J, 1996, CLIN REHABIL, V10, P104; Marshall J, 2018, APHASIOLOGY, V32, P1054, DOI 10.1080/02687038.2018.1488237; Marshall J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160381; Naylor C, 2008, VOLUNTEERING HLTH CA; Northcott S, 2016, J SPEECH LANG HEAR R, V59, P772, DOI 10.1044/2016_JSLHR-L-15-0201; Organisation for Economic Co-operation and Development, PURCH POW PAR COMP P; Palsbo SE, 2007, J TELEMED TELECARE, V13, P40, DOI 10.1258/135763307779701121; Pearl G, 2017, TOP LANG DISORD, V37, P67, DOI 10.1097/TLD.0000000000000112; Pitt R, 2019, INT J SPEECH-LANG PA, V21, P513, DOI 10.1080/17549507.2018.1488990; Pitt R, 2018, APHASIOLOGY, V32, P1031, DOI 10.1080/02687038.2018.1482403; Pitt R, 2019, INT J SPEECH-LANG PA, V21, P23, DOI 10.1080/17549507.2017.1369567; Pound C, 2000, APHASIA; Power E, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007641; Pulvermuller F, 2001, STROKE, V32, P1621, DOI 10.1161/01.STR.32.7.1621; Rippon S., 2015, HEAD HANDS HEART ASS; Rodriguez AD, 2013, APHASIOLOGY, V27, P1339, DOI 10.1080/02687038.2013.825759; Rose ML, 2015, INT J SPEECH-LANG PA, V17, P241, DOI 10.3109/17549507.2015.1010582; Ross A, 2006, APHASIOLOGY, V20, P427, DOI 10.1080/02687030500532786; Seligman MEP, 2005, AM PSYCHOL, V60, P410, DOI 10.1037/0003-066X.60.5.410; Shadden B., 2007, GROUP TREATMENT NEUR, P111; Shadden BB, 2005, APHASIOLOGY, V19, P211, DOI 10.1080/02687930444000697; Shadden BB, 2004, TOP LANG DISORD, V24, P174, DOI 10.1097/00011363-200407000-00005; Sherratt S, 2016, APHASIOLOGY, V30, P1039, DOI 10.1080/02687038.2015.1092495; Shiggins C, 2020, APHASIOLOGY, V34, P70, DOI 10.1080/02687038.2018.1548690; Sim J, 2012, J CLIN EPIDEMIOL, V65, P301, DOI 10.1016/j.jclinepi.2011.07.011; Simmons-Mackie N, 2011, INT J LANG COMM DIS, V46, P312, DOI 10.3109/13682822.2010.507616; Tennant R, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-63; TREADWELL T, 2019, WOUNDS, V31; van der Gaag A, 2005, CLIN REHABIL, V19, P372, DOI 10.1191/0269215505cr785oa; van der Gaag A, 2008, INT J LANG COMM DIS, V43, P233, DOI 10.1080/13682820701560376; Verna A, 2009, INT J SPEECH-LANG PA, V11, P191, DOI 10.1080/17549500902726059; Vickers CP, 2010, APHASIOLOGY, V24, P902, DOI 10.1080/02687030903438532; Wallace SJ, 2019, INT J STROKE, V14, P180, DOI 10.1177/1747493018806200; Wenke R, 2014, INT J SPEECH-LANG PA, V16, P250, DOI 10.3109/17549507.2014.887777; Wilson S, 2015, CODESIGN, V11, P21, DOI 10.1080/15710882.2014.997744; Woolf C, 2016, CLIN REHABIL, V30, P359, DOI 10.1177/0269215515582074	74	12	13	3	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2020	15	9							e0239715	10.1371/journal.pone.0239715	http://dx.doi.org/10.1371/journal.pone.0239715			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NY2ZZ	32970784	gold, Green Accepted, Green Published			2023-01-03	WOS:000576265600032
J	Firouzmandi, M; Vasei, F; Giti, R; Sadeghi, H				Firouzmandi, Maryam; Vasei, Fateme; Giti, Rashin; Sadeghi, Hadis			Effect of silver diamine fluoride and proanthocyanidin on resistance of carious dentin to acid challenges	PLOS ONE			English	Article							GRAPE SEED EXTRACT; PRIMARY TEETH; ROOT CARIES; MECHANICAL-PROPERTIES; ORGANIC MATRIX; IN-VITRO; REMINERALIZATION; COLLAGEN; STIFFNESS; DEMINERALIZATION	The aim of this study was to evaluate the effect of silver diamine fluoride and grape seed extract on the microstructure and mechanical properties of carious dentin following exposure to acidic challenge. Ninety-eight molars with occlusal caries were used. In the control group the specimens were kept in distilled water. In the GSE group, the specimens were immersed in 6.5% grape seed extract solution for 30 minutes. In the SDF group, the specimens were immersed in 30% SDF solution for 4 minutes. In the GSE+SDF group, the specimens were immersed in 6.5% grape seed extract solution for 30 minutes and then exposed to 30% SDF solution for 4 minutes. All the groups underwent pH cycling model for 8 days. Microhardness measurements were taken at the baseline before surface treatments and after pH cycling. Elastic modulus was measured, after pH cycling. In the control group, the final hardness was significantly lower than the initial hardness (P = 0.001). In the SDF group, the final hardness was significantly higher than the initial hardness (P < 0.001). There was no significant difference between the initial and final hardness values in the GSE and GSE + SDF groups (p = 0.92, p = 0.07). The H-1-H(0)in the SDF group was significantly higher than the other groups (P<0.05). Moreover, elastic modulus of the experimental groups except GSE+SDF group was significantly higher than control. The highest mean elastic modulus was detected in the SDF group (P<0.001). The use of SDF and GSE prior to the acid challenge improved mechanical properties. Microstructural investigation, using scanning electron microscope showed dentin structure protection against acid challenges with SDF treatment and collagen matrix stabilization with GSE treatment. However combined use of these agents was not beneficious.	[Firouzmandi, Maryam] Shiraz Univ Med Sci, Oral & Dent Dis Res Ctr, Sch Dent, Dept Operat Dent, Shiraz, Iran; [Vasei, Fateme] Shiraz Univ Med Sci, Sch Dent, Dept Operat Dent, Shiraz, Iran; [Giti, Rashin] Shiraz Univ Med Sci, Sch Dent, Dept Prosthodont, Shiraz, Iran; [Sadeghi, Hadis] Shiraz Univ Med Sci, Sch Dent, Student Res Comm, Shiraz, Iran	Shiraz University of Medical Science; Shiraz University of Medical Science; Shiraz University of Medical Science; Shiraz University of Medical Science	Vasei, F (corresponding author), Shiraz Univ Med Sci, Sch Dent, Dept Operat Dent, Shiraz, Iran.	Fvj_anjell@yahoo.com	Giti, Rashin/H-5270-2016; firouzmandi, maryam/H-5759-2016	Giti, Rashin/0000-0003-1091-9574; firouzmandi, maryam/0000-0002-5510-0506; Vasei, Fateme/0000-0002-7800-3995	Shiraz University of Medical Sciences [8794123]	Shiraz University of Medical Sciences	This study was supported by the vice chancellor for research of Shiraz University of Medical Sciences (Grant#8794123).	Aydin B, 2019, DENT MATER, V35, P328, DOI 10.1016/j.dental.2018.11.029; Balalaie A, 2018, DENT MATER J, V37, P173, DOI 10.4012/dmj.2017-062; Banerjee A, 2017, BRIT DENT J, V223, P215, DOI 10.1038/sj.bdj.2017.672; Bedran-Russo AK, 2013, AM J DENT, V26, P244; Bedran-Russo AKB, 2008, J BIOMED MATER RES B, V86B, P330, DOI 10.1002/jmb.b.31022; Bedran-Russo AKB, 2007, J BIOMED MATER RES B, V80B, P268, DOI 10.1002/jbm.b.30593; Bertassoni LE, 2009, CARIES RES, V43, P70, DOI 10.1159/000201593; Cai J, 2019, ACTA BIOMATER, V88, P491, DOI 10.1016/j.actbio.2019.02.020; Carrilho MR, 2009, J BIOMED MATER RES B, V90B, P373, DOI 10.1002/jbm.b.31295; Castellan CS, 2010, J DENT, V38, P431, DOI 10.1016/j.jdent.2010.02.002; Chen A., 2012, J CAN DENT ASSOC, V20, P1; Chu CH, 2008, J DENT, V36, P387, DOI 10.1016/j.jdent.2008.02.013; Chu CH, 2002, J DENT RES, V81, P767, DOI 10.1177/0810767; Dos Santos PH, 2011, J BIOMECH, V44, P1691, DOI 10.1016/j.jbiomech.2011.03.030; Epasinghe DJ, 2015, AUST DENT J, V60, P463, DOI 10.1111/adj.12249; Epasinghe DJ, 2017, MAT SCI ENG C-MATER, V73, P293, DOI 10.1016/j.msec.2016.11.078; Firouzmandi Maryam, 2019, Eur J Dent, V13, P255, DOI 10.1055/s-0039-1693237; Frencken J E, 2016, Adv Dent Res, V28, P46, DOI 10.1177/0022034516639272; FUSAYAMA T, 1966, J DENT RES, V45, P1033, DOI 10.1177/00220345660450040401; Hara AT, 2005, CARIES RES, V39, P134, DOI 10.1159/000083159; Hara AT, 2003, CARIES RES, V37, P339, DOI 10.1159/000072165; Hiraishi N, 2011, J DENT, V39, P391, DOI 10.1016/j.jdent.2011.03.002; Isenburg JC, 2004, BIOMATERIALS, V25, P3293, DOI 10.1016/j.biomaterials.2003.10.001; Ito S, 2005, J BIOMED MATER RES B, V72B, P109, DOI 10.1002/jbm.b.30130; Jenson Larry, 2007, J Calif Dent Assoc, V35, P714; Kaushik Roy, 2013, Research Journal of Pharmaceutical, Biological and Chemical Sciences, V4, P1271; Kinney JH, 2003, CRIT REV ORAL BIOL M, V14, P13, DOI 10.1177/154411130301400103; KLETER GA, 1994, J DENT RES, V73, P1523, DOI 10.1177/00220345940730090701; Lee Y., 2012, SOL CELLS, V22, P2; Listl S, 2015, J DENT RES, V94, P1355, DOI 10.1177/0022034515602879; Liu Y, 2011, ADV MATER, V23, P975, DOI 10.1002/adma.201003882; Llodra JC, 2005, J DENT RES, V84, P721, DOI 10.1177/154405910508400807; Lou YL, 2011, J DENT, V39, P612, DOI 10.1016/j.jdent.2011.06.008; Marshall GW, 2001, J DENT RES, V80, P1768, DOI 10.1177/00220345010800081701; Mazzoni A, 2013, DENT MATER, V29, P1040, DOI 10.1016/j.dental.2013.07.010; Mei ML, 2018, J DENT RES, V97, P751, DOI 10.1177/0022034518774783; Mei ML, 2017, J DENT RES, V96, P1122, DOI 10.1177/0022034517709738; Mei ML, 2014, J DENT, V42, P395, DOI 10.1016/j.jdent.2013.12.007; Mei ML, 2014, J DENT, V42, P329, DOI 10.1016/j.jdent.2013.11.018; Mei ML, 2013, J DENT, V41, P809, DOI 10.1016/j.jdent.2013.06.009; Mei ML, 2012, DENT MATER, V28, P903, DOI 10.1016/j.dental.2012.04.011; Mei ML, 2013, MED ORAL PATOL ORAL, V18, pE824, DOI 10.4317/medoral.18831; Omidi S, 2018, GREEN CHEM LETT REV, V11, P544, DOI 10.1080/17518253.2018.1546410; Punyanirun K, 2018, J DENT, V69, P55, DOI 10.1016/j.jdent.2017.09.005; Quock RL, 2012, OPER DENT, V37, P610, DOI 10.2341/11-344-L; Reynolds EC, 2008, J DENT RES, V87, P344, DOI 10.1177/154405910808700420; Rosenblatt A, 2009, J DENT RES, V88, P116, DOI 10.1177/0022034508329406; Seseogullari-Dirihan R, 2015, DENT MATER, V31, P941, DOI 10.1016/j.dental.2015.05.002; Sun J, 2014, J MATER CHEM B, V2, P4544, DOI 10.1039/c4tb00451e; Tan HP, 2010, J DENT RES, V89, P1086, DOI 10.1177/0022034510375825; Tang CF, 2013, ARCH ORAL BIOL, V58, P1769, DOI 10.1016/j.archoralbio.2013.09.007; Tsao R, 2010, NUTRIENTS, V2, P1231, DOI 10.3390/nu2121231; Vollenweider M, 2007, ACTA BIOMATER, V3, P936, DOI 10.1016/j.actbio.2007.04.003; Wang JL, 2013, DIAM RELAT MATER, V31, P15, DOI 10.1016/j.diamond.2012.10.006; White D J, 1995, Adv Dent Res, V9, P175; Xie Q, 2008, J DENT, V36, P900, DOI 10.1016/j.jdent.2008.07.011; Yao P, 2018, J IND ENG CHEM, V58, P74, DOI 10.1016/j.jiec.2017.09.009; Zhang W, 2013, CARIES RES, V47, P284, DOI 10.1159/000346620	58	4	4	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2020	15	9							e0238590	10.1371/journal.pone.0238590	http://dx.doi.org/10.1371/journal.pone.0238590			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU7VY	32941456	gold, Green Published			2023-01-03	WOS:000573848800004
J	Saeterbakken, AH; Solstad, TEJ; Stien, N; Shaw, MP; Pedersen, H; Andersen, V				Saeterbakken, Atle Hole; Solstad, Tom Erik Jorung; Stien, Nicolay; Shaw, Matthew Peter; Pedersen, Helene; Andersen, Vidar			Muscle activation with swinging loads in bench press	PLOS ONE			English	Article							ELECTROMYOGRAPHIC ACTIVITY; TRAINING EXERCISES; UNSTABLE LOAD; CHEST PRESS; INSTABILITY; STRENGTH; FORCE; STABILITY; POSITION; CORE	The aim of the study was to compare the EMG amplitude in bench press (stable loads) to bench press using loads moving in anteroposterior and mediolateral directions. Seventeen resistance-trained men, with 9.4 +/- 4.7 years of resistance training experience were recruited. After a familiarization session assessing 1 repetition maximum (RM) in the bench press, participants performed: 1) bench press with traditional stable loading 2) bench press with loads (2x5kg) attached as pendulums swinging forward/backwards and 3) left/right in randomized order. The total load was 70% of the 1RM load. Electromyography was measured in the pectoralis major, anterior- and posterior deltoid, biceps brachii, triceps brachii and external obliques. Using stable loads, the pectoralis major demonstrated lower EMG amplitude compared to the two unstable conditions. In the external obliques, the stable conditions demonstrated lower EMG amplitude than the swing in the mediolateral direction, but not the anteroposterior direction. There were no differences between two swinging loads or the three conditions for the triceps brachii, biceps brachii, anterior deltoid or posterior deltoid. In conclusion, swinging in bench press resulted in similar EMG amplitude in the shoulder- and arm muscles, but greater pectoralis and external oblique (only mediolateral swing) activity compared to bench press.	[Saeterbakken, Atle Hole; Solstad, Tom Erik Jorung; Stien, Nicolay; Shaw, Matthew Peter; Pedersen, Helene; Andersen, Vidar] Western Norway Univ Appl Sci, Fac Educ Arts & Sports, Sogndal, Norway	Western Norway University of Applied Sciences	Saeterbakken, AH (corresponding author), Western Norway Univ Appl Sci, Fac Educ Arts & Sports, Sogndal, Norway.	atle.saeterbakken@hvl.no	Shaw, Matthew/AAJ-9009-2021	Shaw, Matthew/0000-0001-8382-8011				Alkner BA, 2000, MED SCI SPORT EXER, V32, P459, DOI 10.1097/00005768-200002000-00030; Anderson K, 2005, CAN J APPL PHYSIOL, V30, P33, DOI 10.1139/h05-103; Anderson KG, 2004, J STRENGTH COND RES, V18, P637; [Anonymous], 2005, J LAW POLICY, V19, P193; Behm D, 2012, INT J SPORTS PHYS TH, V7, P226; Behm DG, 2013, SPORTS HEALTH, V5, P500, DOI 10.1177/1941738113477815; Behm DG, 2010, APPL PHYSIOL NUTR ME, V35, P109, DOI 10.1139/H09-128; Behm DG, 2002, J STRENGTH COND RES, V16, P416; Cohen J., 2013, STAT POWER ANAL BEHA; Comfort P, 2012, J STRENGTH COND RES, V26, P1208, DOI 10.1519/JSC.0b013e3182510827n; Dunnick DD, 2015, J STRENGTH COND RES, V29, P3279, DOI 10.1519/JSC.0000000000001198; Goodman CA, 2008, J STRENGTH COND RES, V22, P88, DOI 10.1519/JSC.0b013e31815ef6b3; Hamlyn N, 2007, J STRENGTH COND RES, V21, P1108; Hermens HJ, 2000, J ELECTROMYOGR KINES, V10, P361, DOI 10.1016/S1050-6411(00)00027-4; Kohler JM, 2010, J STRENGTH COND RES, V24, P313, DOI 10.1519/JSC.0b013e3181c8655a; Lawrence MA, 2021, J STRENGTH COND RES, V35, pS120, DOI 10.1519/JSC.0000000000002788; Lawrence MA, 2017, J STRENGTH COND RES, V31, P1206, DOI 10.1519/JSC.0000000000001610; Lawrence MA, 2015, J STRENGTH COND RES, V29, P2949, DOI 10.1519/JSC.0000000000000955; Marshall PWM, 2006, J STRENGTH COND RES, V20, P745; Norwood JT, 2007, J STRENGTH COND RES, V21, P343, DOI 10.1519/R-17435.1; Ostrowski SJ, 2017, J STRENGTH COND RES, V31, P430, DOI 10.1519/JSC.0000000000001497; Saeterbakken AH, 2013, J STRENGTH COND RES, V27, P1824, DOI 10.1519/JSC.0b013e318276b873; Saeterbakken AH, 2013, J STRENGTH COND RES, V27, P1101, DOI 10.1519/JSC.0b013e3182606d3d; Saeterbakken AH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214302; Saeterbakken AH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212216; Saeterbakken AH, 2016, EUR J APPL PHYSIOL, V116, P2247, DOI 10.1007/s00421-016-3470-3; Sparkes R, 2010, J STRENGTH COND RES, V24, P1931, DOI 10.1519/JSC.0b013e3181df7fe4; Uribe BP, 2010, J STRENGTH COND RES, V24, P1028, DOI 10.1519/JSC.0b013e3181ca4fb8; van den Tillaar R, 2012, J SPORT SCI, V30, P591, DOI 10.1080/02640414.2012.658844; van den Tillaar R, 2010, J SPORT SCI, V28, P529, DOI 10.1080/02640411003628022; van den Tillaar R, 2009, MED SCI SPORT EXER, V41, P2056, DOI 10.1249/MSS.0b013e3181a8c360; Wilk KE, 1997, J ORTHOP SPORT PHYS, V25, P364, DOI 10.2519/jospt.1997.25.6.364; Willardson JM, 2009, INTJ SPORT PHYSIOL, V4, P97, DOI 10.1123/ijspp.4.1.97; WINTER DA, 1994, J ELECTROMYOGR KINES, V4, P15, DOI 10.1016/1050-6411(94)90023-X; 2010, CARPATH J EARTH ENV, V5, P177	35	3	3	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 17	2020	15	9							e0239202	10.1371/journal.pone.0239202	http://dx.doi.org/10.1371/journal.pone.0239202			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU7VY	32941526	Green Published, gold			2023-01-03	WOS:000573848800018
J	Vergara, D; Gaudino, R; Blank, T; Keegan, B				Vergara, Daniela; Gaudino, Reggie; Blank, Thomas; Keegan, Brian			Modeling cannabinoids from a large-scale sample of Cannabis sativa chemotypes	PLOS ONE			English	Article							CONSTITUENTS; MARIJUANA	The widespread legalization ofCannabishas opened the industry to using contemporary analytical techniques for chemotype analysis. Chemotypic data has been collected on a large variety of oil profiles inherent to the cultivars that are commercially available. The unknown gene regulation and pharmacokinetics of dozens of cannabinoids offer opportunities of high interest in pharmacology research. Retailers in many medical and recreational jurisdictions are typically required to report chemical concentrations of at least some cannabinoids. Commercial cannabis laboratories have collected large chemotype datasets of diverseCannabiscultivars. In this work a data set of 17,600 cultivars tested by Steep Hill Inc., is examined using machine learning techniques to interpolate missing chemotype observations and cluster cultivars into groups based on chemotype similarity. The results indicate cultivars cluster based on their chemotypes, and that some imputation methods work better than others at grouping these cultivars based on chemotypic identity. Due to the missing data and to the low signal to noise ratio for some less common cannabinoids, their behavior could not be accurately predicted. These findings have implications for characterizing complex interactions in cannabinoid biosynthesis and improving phenotypical classification ofCannabiscultivars.	[Vergara, Daniela] Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA; [Gaudino, Reggie; Blank, Thomas] Front Range Biosci, Lafayette, CO USA; [Keegan, Brian] Univ Colorado, Dept Informat Sci, Boulder, CO 80309 USA	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Vergara, D (corresponding author), Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA.; Keegan, B (corresponding author), Univ Colorado, Dept Informat Sci, Boulder, CO 80309 USA.	daniela.vergara@colorado.edu; brian.keegan@colorado.edu		Keegan, Brian/0000-0002-7793-398X; VERGARA, DANIELA/0000-0002-7682-6605	company Steep Hill Inc.	company Steep Hill Inc.	This research was supported by donations to the Agricultural Genomics Foundation, and is part of the joint research agreement between the University of Colorado Boulder and Steep Hill Inc. The company Steep Hill Inc. provided support in the form of salaries for authors R.G. and T.B., but did not have any additional role in the study design, and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section."	[Anonymous], 2011, DIABETOLOGIA PRAKTYC, V12, pA28; [Anonymous], 2017, ONCOGENESIS, V6, pe345; Auldridge ME, 2006, CURR OPIN PLANT BIOL, V9, P315, DOI 10.1016/j.pbi.2006.03.005; Chakraborty Sandeep, 2013, Methods Mol Biol, V978, P205, DOI 10.1007/978-1-62703-293-3_15; de Meijer EPM, 2003, GENETICS, V163, P335; ElSohly MA, 2005, LIFE SCI, V78, P539, DOI 10.1016/j.lfs.2005.09.011; ElSohly MA, 2016, BIOL PSYCHIAT, V79, P613, DOI 10.1016/j.biopsych.2016.01.004; Elzinga S., 2015, NAT PROD CHEM RES, V03, P10, DOI [10.4172/2329-6836.1000181, DOI 10.4172/2329-6836.1000181]; Franco OL, 2011, FEBS LETT, V585, P995, DOI 10.1016/j.febslet.2011.03.008; Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530; Grassa CJ., 2018, COMPLETE CANNABIS CH, DOI 10.1101/458083; Hill TDM, 2013, BRIT J PHARMACOL, V170, P679, DOI 10.1111/bph.12321; Hillig KW, 2005, GENET RESOUR CROP EV, V52, P161, DOI 10.1007/s10722-003-4452-y; Jikomes N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22755-2; Kovalchuk I, 2020, ANNU REV PLANT BIOL, V71, P713, DOI 10.1146/annurev-arplant-081519-040203; Laverty KU, 2019, GENOME RES, V29, P146, DOI 10.1101/gr.242594.118; Lynch RC, 2016, CRIT REV PLANT SCI, V35, P349, DOI 10.1080/07352689.2016.1265363; McInnes L.., 2018, UMAP UNIFORM MANIFOL, Patent No. [ArXiv180203426CsStat, 180203426]; McPartland JM., 2017, CANNABIS SATIVA L BO, P101, DOI DOI 10.1007/978-3-319-54564-6_4; McPartland JM, 2015, BRIT J PHARMACOL, V172, P737, DOI 10.1111/bph.12944; Onofri C, 2015, PHYTOCHEMISTRY; Page JE, 2014, GOOGLE PATENTS; Reimann-Philipp U, 2019, CANNABIS CHEMOVAR NO; Richins RD, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201119; Ross S. A., 1997, Bulletin on Narcotics, V49-50, P139; Ruhaak LR, 2011, BIOL PHARM BULL, V34, P774, DOI 10.1248/bpb.34.774; Sawler J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133292; Schwabe AL, 2019, 592725 BIORXIV, P592725; Trofin IG, 2012, REV CHIM-BUCHAREST, V63, P422; TURNER CE, 1979, J HETEROCYCLIC CHEM, V16, P1667, DOI 10.1002/jhet.5570160834; Valliere MA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08448-y; Van Der Maaten L., 2009, J MACH LEARN RES, V10, P13, DOI DOI 10.1080/13506280444000102; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Vergara D, 2019, AOB PLANTS, V11, DOI 10.1093/aobpla/plz074; Vergara D, 2017, SCI REP-UK, V7, DOI 10.1038/srep46528; Vergara D, 2016, CRIT REV PLANT SCI, V35, P364, DOI 10.1080/07352689.2016.1267496; Volkow ND, 2014, NEW ENGL J MED, V370, P2219, DOI 10.1056/NEJMra1402309; Weiblen GD, 2015, NEW PHYTOLOGIST; Zirpel B, 2018, J BIOTECHNOL, V284, P17, DOI 10.1016/j.jbiotec.2018.07.031	39	6	6	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2020	15	9							e0236878	10.1371/journal.pone.0236878	http://dx.doi.org/10.1371/journal.pone.0236878			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN6BT	32870907	Green Published, Green Submitted, gold			2023-01-03	WOS:000568872300008
J	Yang, CH; Chen, JJ; Yeh, JK; Kuo, G; Lee, CC; Hsieh, IC; Hsieh, MJ; Tian, YC; Chang, CH				Yang, Chia-Hung; Chen, Jia-Jin; Yeh, Jih-Kai; Kuo, George; Lee, Cheng-Chia; Hsieh, I-Chang; Hsieh, Ming-Jer; Tian, Ya-Chung; Chang, Chih-Hsiang			The incidence and survival after in-hospital cardiopulmonary cerebral resuscitation in end-stage kidney disease patients: A nationwide population-based study	PLOS ONE			English	Article							IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS; SUDDEN CARDIAC DEATH; DIALYSIS PATIENTS; HEMODIALYSIS-PATIENTS; ARREST; PREDICTORS; OUTCOMES; PREVENTION; FAILURE; TRENDS	Background This study analyzed the survival and protective predictors of in-hospital cardiopulmonary cerebral resuscitation (CPCR) to potentially help physicians create effective treatment plans for End-stage kidney disease (ESKD) patients. Methods We extracted the data of 7,116 ESKD patients who received their first in-hospital CPCR after initial dialysis between 2004 and 2012 from the National Health Insurance Research Database. The primary outcome was the survival rate during the first in-hospital CPCR. The secondary outcome was the median post-discharge survival. Results From 2004 through 2012, the incidence of in-hospital CPCR decreases from 3.97 to 3.67 events per 1,000 admission days (Pfor linear trend <0.001). The survival rate for the first in-hospital CPCR did not change significantly across the 9 years (Pfor trend = 0.244), whereas the median survival of post-discharge survival increased significantly from 3.0 months in 2004 to 6.8 months in 2011 (Pfor linear trend <0.001). In addition, multivariable analysis identified older age as a risk factor and prior intracardiac defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D) implantation as a protective factor for in-hospital death during the first in-hospital CPCR. Conclusion The incidence of in-hospital CPCR and the duration post-discharge among ESKD patients improved despite there being no significant difference in the survival rate of ESKD patients after CPCP. Either ICD or CRT-D implantation may be advisable for ESKD patients with a high risk of sudden cardiac death.	[Yang, Chia-Hung] Chang Gung Mem Hosp, New Taipei Municipal TuCheng Hosp, Dept Cardiol, Taoyuan, Taiwan; [Yang, Chia-Hung] Chang Gung Univ, Taoyuan, Taiwan; [Chen, Jia-Jin; Kuo, George; Lee, Cheng-Chia; Tian, Ya-Chung; Chang, Chih-Hsiang] Chang Gung Mem Hosp, Kidney Res Ctr, Linkou Med Ctr, Dept Nephrol, Taoyuan, Taiwan; [Chen, Jia-Jin; Chang, Chih-Hsiang] Chang Gung Univ, Coll Med, Sch Med, Taoyuan, Taiwan; [Yeh, Jih-Kai; Hsieh, I-Chang; Hsieh, Ming-Jer] Chang Gung Mem Hosp, Linkou Med Ctr, Dept Cardiol, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung Memorial Hospital	Chang, CH (corresponding author), Chang Gung Mem Hosp, Kidney Res Ctr, Linkou Med Ctr, Dept Nephrol, Taoyuan, Taiwan.; Chang, CH (corresponding author), Chang Gung Univ, Coll Med, Sch Med, Taoyuan, Taiwan.	franwisandsun@gmail.com	Kuo, George/ABA-3641-2021; Kuo, George/AGE-0252-2022; Chen, Jia-Jin/AAX-2147-2021; Chang, Chih-Hsiang/P-8662-2017	Kuo, George/0000-0002-5908-403X; Kuo, George/0000-0002-5908-403X; Chen, Jia-Jin/0000-0001-9508-5956; Chang, Chih-Hsiang/0000-0002-7342-335X; Lee, Cheng-Chia/0000-0002-6973-5908	Ministry of Science and Technology [106-2314-B-182A-118-MY3]; Chang Gung Memorial Hospital, Taiwan [CORPG3G0761]	Ministry of Science and Technology(Ministry of Science, ICT & Future Planning, Republic of Korea); Chang Gung Memorial Hospital, Taiwan(Chang Gung Memorial Hospital)	C-HC was supported by the Ministry of Science and Technology (106-2314-B-182A-118-MY3) and grants from Chang Gung Memorial Hospital, Taiwan (CMRPG3F1653, CMRPG5H0162). C-HY was supported by Chang Gung Memorial Hospital, Taiwan (CORPG3G0761).	Adabag S, 2017, JAMA CARDIOL, V2, P767, DOI 10.1001/jamacardio.2017.1413; Amann K, 2000, NEPHROL DIAL TRANSPL, V15, P964, DOI 10.1093/ndt/15.7.964; [Anonymous], 2018, MED BALTIMORE, V97, pe9654; [Anonymous], 2015, FOREIGN AFF, V5, P2, DOI DOI 10.4172/2161-0398.1000177; Axelsson C, 2012, RESUSCITATION, V83, P1253, DOI 10.1016/j.resuscitation.2012.01.043; Bleyer AJ, 1999, KIDNEY INT, V55, P1553, DOI 10.1046/j.1523-1755.1999.00391.x; Burton JO, 2009, CLIN J AM SOC NEPHRO, V4, P914, DOI 10.2215/CJN.03900808; Chen TH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099418; Chung CM, 2017, ATHEROSCLEROSIS, V267, P158, DOI 10.1016/j.atherosclerosis.2017.09.018; Cice G, 2003, J AM COLL CARDIOL, V41, P1438, DOI 10.1016/S0735-1097(03)00241-9; Davis TR, 2008, KIDNEY INT, V73, P933, DOI 10.1038/sj.ki.5002749; de Bie MK, 2008, CURR MED RES OPIN, V24, P2151, DOI 10.1185/03007990802237343; ECC Committee Subcommittees and Task Forces of the American Heart Association, 2005, Circulation, V112, pIV1; Girotra S, 2012, NEW ENGL J MED, V367, P1912, DOI 10.1056/NEJMoa1109148; Herzog CA, 2005, KIDNEY INT, V68, P818, DOI 10.1111/j.1523-1755.2005.00462.x; Herzog CA, 2003, KIDNEY INT, V63, pS197; Herzog CA, 2008, NEPHROL DIAL TRANSPL, V23, P2629, DOI 10.1093/ndt/gfn038; Hsing AW, 2015, JAMA INTERN MED, V175, P1527, DOI 10.1001/jamainternmed.2015.3540; Imbeault B, 2019, J AM SOC NEPHROL, V30, P369, DOI 10.1681/ASN.2019010046; Jadoul M, 2012, CLIN J AM SOC NEPHRO, V7, P765, DOI 10.2215/CJN.08850811; Kanbay M, 2010, BLOOD PURIFICAT, V30, P135, DOI 10.1159/000320370; Karnik JA, 2001, KIDNEY INT, V60, P350, DOI 10.1046/j.1523-1755.2001.00806.x; Kazaure HS, 2013, JAMA SURG, V148, P14, DOI 10.1001/jamasurg.2013.671; Lafrance JP, 2006, NEPHROL DIAL TRANSPL, V21, P1006, DOI 10.1093/ndt/gfk007; Martinell L, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1677-2; Matsue Y, 2013, INT J CARDIOL, V165, P519, DOI 10.1016/j.ijcard.2011.09.037; Melilli E, 2018, CLIN KIDNEY J, V11, P413, DOI 10.1093/ckj/sfx120; Merchant RM, 2011, CRIT CARE MED, V39, P2401, DOI 10.1097/CCM.0b013e3182257459; Pun PH, 2007, CLIN J AM SOC NEPHRO, V2, P491, DOI 10.2215/CJN.02360706; Pun PH, 2015, NEPHROL DIAL TRANSPL, V30, P829, DOI 10.1093/ndt/gfu274; Pun PH, 2011, KIDNEY INT, V79, P218, DOI 10.1038/ki.2010.315; Saeed F, 2015, J AM SOC NEPHROL, V26, P3093, DOI 10.1681/ASN.2014080766; Saravanan P, 2010, CIRC-ARRHYTHMIA ELEC, V3, P553, DOI 10.1161/CIRCEP.110.937888; Tang CH, 2016, J AM HEART ASSOC, V5, DOI 10.1161/JAHA.115.002584; Wan CP, 2014, ANN NONINVAS ELECTRO, V19, P247, DOI 10.1111/anec.12119; Wanner C, 2005, NEW ENGL J MED, V353, P238, DOI 10.1056/NEJMoa043545; Wong SSPY, 2015, JAMA INTERN MED, V175, P1028, DOI 10.1001/jamainternmed.2015.0406; 2018, CURR OPIN TOXICOL, V10	38	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2020	15	8							e0238029	10.1371/journal.pone.0238029	http://dx.doi.org/10.1371/journal.pone.0238029			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK7YA	32857782	Green Published, gold			2023-01-03	WOS:000566947200063
J	Desta, A; Biru, TT; Kefale, AT				Desta, Addisu; Biru, Tessema Tsehay; Kefale, Adane Teshome			Health related quality of life of people receiving highly active antiretroviral therapy in Southwest Ethiopia	PLOS ONE			English	Article							PREDICTIVE-VALIDITY; HIV; ADHERENCE	Background Highly Active Antiretroviral Therapy (HAART) is a standard of HIV management to suppress viral load and delay progression to AIDS. However, questions have been raised about the use of antiretroviral therapy and how it affects quality of life (QoL) of people living with HIV/AIDS (PLWHA). The study hence aimed to assess the QoL of PLWHA who were taking HAART at Mizan-Tepi University Teaching Hospital (MTUTH) and identify factors associated with QoL. Methods A cross sectional study was conducted among PLWHA receiving HAART at MTUTH from March 04-April 1, 2018. Patients were recruited consecutively and interviewed with structured questionnaire. A data abstraction tool was used to extract data from patient medical records. Quality of life was assessed using the World Health Organization Quality of Life HIV- BREF (WHOQOL-HIV-BREF) standard tool. Data was entered to Epi-Info version 3.5.3 and analyzed using SPSS version 22 for windows. A multivariable logistic regression analysis was fitted to identify factors associated with QoL. A statistical significance was established at a p value Results A total of 240 participants with the mean age of 35.11 (SD = 9.08) years were included in the study. This study found that 57.1% of the patients had high global score of QoL. Patients with normal current health (AOR = 3.38, 95% CI = 1.56-7.31)) and having family support (AOR = 3.12, 95% CI = 1.51-6.46) were positively associated with high global score of QoL, while patients with low HAART adherence (AOR = 0.40, 95%, CI = 0.19-0.86) were negatively associated with high global score of QoL. Conclusion The study revealed that more than half of the participants had high global score of QoL. Normal current health and family support were associated with better global score of QoL, while low HAART adherence was found to be associated with the lower global score of QoL.	[Desta, Addisu] Wachemo Univ, Dept Pharm, Hossaena, Ethiopia; [Biru, Tessema Tsehay] Wollo Univ, Dept Pharm, Dessie, Ethiopia; [Kefale, Adane Teshome] Debre Berhan Univ, Dept Pharm, Debre Berhan, Ethiopia; [Kefale, Adane Teshome] Univ Tasmania, Sch Pharm & Pharmacol, Hobart, Tas, Australia	University of Tasmania	Kefale, AT (corresponding author), Debre Berhan Univ, Dept Pharm, Debre Berhan, Ethiopia.; Kefale, AT (corresponding author), Univ Tasmania, Sch Pharm & Pharmacol, Hobart, Tas, Australia.	adane@mtu.edu.et	Kefale, Adane Teshome/AAP-6928-2020	Kefale, Adane Teshome/0000-0001-7254-4435				Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; Akinboro AO, 2014, PAN AFR MED J, V18, DOI 10.11604/pamj.2014.18.234.2816; [Anonymous], 2018, AM J TRANSPLANT S1, V18, P10, DOI DOI 10.1109/JSEN.2018.2870228; [Anonymous], 2018, ADV CIV ENG, V2018, P1, DOI DOI 10.1017/S1473550418000022; [Anonymous], 2014, PEERJ, V2, pe447; Tran BX, 2021, AIDS REV, V23, P91, DOI 10.24875/AIDSRev.20000135; Tran BX, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4613-0; Beard J, 2009, AIDS CARE, V21, P1343, DOI 10.1080/09540120902889926; Beyene K, 2010, AJAR-AFR J AIDS RES, V9, P31, DOI [10.2989/16085906.2010.484560, DOI 10.2989/16085906.2010.484560]; Deribew A, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-408; Ferguson NM, 2005, J ROY SOC INTERFACE, V2, P349, DOI 10.1098/rsif.2005.0037; Foca E, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-153; Harper A, 1998, PSYCHOL MED, V28, P551, DOI 10.1017/S0033291798006667; Imam M H, 2011, Bangladesh Med Res Counc Bull, V37, P1; Joint United Nations Programme on HIV/AIDS (UNAIDS), 2020, SEIZ MOM TACKL ENTR; Mekuria LA, 2015, AIDS CARE, V27, P934, DOI 10.1080/09540121.2015.1020748; MORISKY DE, 1986, MED CARE, V24, P67, DOI 10.1097/00005650-198601000-00007; Morisky DE, 2008, J CLIN HYPERTENS, V10, P348, DOI 10.1111/j.1751-7176.2008.07572.x; Motilewa1 O, 2015, J ANTIVIRALS ANTIRET, V7, P60; Ntshakala TT, 2012, QUALITY LIFE PEOPLE; O'Connell KA, 2012, AIDS BEHAV, V16, P452, DOI 10.1007/s10461-010-9863-0; Oguntibeju OO, 2012, HIV AIDS-RES PALLIAT, V4, P117, DOI 10.2147/HIV.S32321; Olusina AK, 2003, SOC PSYCH PSYCH EPID, V38, P707, DOI 10.1007/s00127-003-0691-7; Reis A, 2013, WORLD J AIDS, V3, P239; Robert AC, 1997, COMPREHENSIVE QUALIT; Safren SA, 2012, AIDS BEHAV, V16, P266, DOI 10.1007/s10461-011-9947-5; Sidibe M, 2018, 9789291739455 UNAIDS; Sun W, 2013, PLOS ONE, V8; Surur AS, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2714-1; Tesemma AL, 2019, HIV AIDS-RES PALLIAT, V11, P387, DOI 10.2147/HIV.S227244; Tesfaye M, 2016, INT J MENT HEALTH SY, V10, DOI 10.1186/s13033-016-0062-x; Tilahun HA, 2012, J HIV-AIDS SOC SERV, V11, P346, DOI 10.1080/15381501.2012.735169; Tran BX, 2020, AIDS CARE, V32, P637, DOI 10.1080/09540121.2019.1679708; UNAIDS, 2016, FACT SHEET 2016; Vu GV, 2020, INT J ENV RES PUBLIC, V17; WHO, 2010, ANT THER HIV INF AD; World Health O, 2007, REP WHO EXP CONS ART; World Health Organization, 1996, WHOQOL BREF INSTR AD; World Health Organization, 2016, CONS GUID US ANT DRU; World Health Organization (WHO), 2002, STRAT PLAN VIS 2020, P1; Xu JF, 2017, INFECT DIS POVERTY, V6, DOI 10.1186/s40249-017-0364-5; Yaya I, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4171-x; Zhang S, 2015, AIDS CARE, V27, P829, DOI 10.1080/09540121.2015.1021745; 2017, ETHIOPIA COUNTRY REG	44	6	6	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2020	15	8							e0237013	10.1371/journal.pone.0237013	http://dx.doi.org/10.1371/journal.pone.0237013			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NG9QD	32818950	Green Published, Green Accepted, gold			2023-01-03	WOS:000564315600034
J	Li, DN; Rooney, MR; Burmeister, LA; Basta, NE; Lutsey, PL				Li, Danni; Rooney, Mary R.; Burmeister, Lynn A.; Basta, Nicole E.; Lutsey, Pamela L.			Trends in Daily Use of Biotin Supplements Among US Adults, 1999-2016	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This pharmacoepidemiology study uses NHANES data to characterize the prevalence and trends in use of high-dosage biotin supplementation among US adults between 1999 and 2016.	[Li, Danni] Univ Minnesota, Dept Lab Med & Pathol, 420 Delaware St SE,MMC 609, Minneapolis, MN 55455 USA; [Rooney, Mary R.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; [Burmeister, Lynn A.] Univ Minnesota, Dept Med, Box 736 UMHC, Minneapolis, MN 55455 USA; [Basta, Nicole E.] McGill Univ, Dept Epidemiol Biostat & Occupat Hlth, Montreal, PQ, Canada; [Lutsey, Pamela L.] Univ Minnesota, Sch Publ Hlth, Div Epidemiol & Community Hlth, Minneapolis, MN USA	University of Minnesota System; University of Minnesota Twin Cities; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; University of Minnesota System; University of Minnesota Twin Cities; McGill University; University of Minnesota System; University of Minnesota Twin Cities	Li, DN (corresponding author), Univ Minnesota, Dept Lab Med & Pathol, 420 Delaware St SE,MMC 609, Minneapolis, MN 55455 USA.	dannili@umn.edu		Lutsey, Pamela/0000-0002-1572-1340; Li, Danni/0000-0002-0608-2831; Burmeister, Lynn/0000-0003-4795-2546	National Heart, Lung, and Blood Institute [T32HL007779]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Dr Rooney was support by training grant T32HL007779 from the National Heart, Lung, and Blood Institute.	Ahluwalia N, 2016, ADV NUTR, V7, P121, DOI 10.3945/an.115.009258; [Anonymous], 2016, LANCET, V387, P506, DOI 10.1016/S0140-6736(16)00267-1; [Anonymous], 2017, FDA WARNS BIOTIN MAY; Kantor ED, 2016, JAMA-J AM MED ASSOC, V316, P1464, DOI 10.1001/jama.2016.14403; Li D, 2017, JAMA-J AM MED ASSOC, V318, P1150, DOI 10.1001/jama.2017.13705	5	7	7	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	2020	324	6					605	607		10.1001/jama.2020.8144	http://dx.doi.org/10.1001/jama.2020.8144			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE8HM	32780133	Green Published			2023-01-03	WOS:000562845100027
J	Matsubara, M; Sakurada, Y; Sugiyama, A; Fukuda, Y; Parikh, R; Kashiwagi, K				Matsubara, Mio; Sakurada, Yoichi; Sugiyama, Atsushi; Fukuda, Yoshiko; Parikh, Ravi; Kashiwagi, Kenji			Response to photodynamic therapy combined with intravitreal aflibercept for polypoidal choroidal vasculopathy depending on fellow-eye condition:2-year results	PLOS ONE			English	Article							INDOCYANINE GREEN VIDEOANGIOGRAPHY; MACULAR DEGENERATION; SEVERITY SCALE; RANIBIZUMAB; ANGIOGRAPHY; MONOTHERAPY; THICKNESS; EFFICACY; DISEASE; SAFETY	We investigated whether response to photodynamic therapy (PDT) with intravitreal aflibercept injection (IAI) for polypoidal choroidal vasculopathy (PCV) differs depending on fellow eye condition. A retrospective review was conducted for consecutive 60 eyes with PCV treated with PDT combined with IAI as well as 2-years of follow-up data. Fellow eyes were divided into 4 groups; Group 0: no drusen, Group 1; pachydrusen, Group 2; soft drusen, Group 3: PCV/fibrovascular scarring. Best-corrected visual acuity improved at 24-months irrespective of groups and there were no significant differences in visual improvement among treated eyes among the 4 groups. Within 2-years, 35 (58.3%) required the retreatment. The need for retreatment including additional injection and the combination therapy was significantly less in Group 1(12.5%) compared to the others (P = 0.0038) and mean number of additional IAI was also less in Group 1 compared to the others (P = 0.017). The retreatment-free period from the initial combination therapy was longest in Group 1 (23.6 +/- 1.1 months) (P = 0.0055, Group 0: 19.1 +/- 6.9, Group 2: 12.8 +/- 7.9, Group 3: 11.5 +/- 9.9). The need for retreatment was significantly different according to fellow-eye condition. Among PCV patients, pachydrusen in fellow eyes appear to be a predictive characteristic for a decreased treatment burden at 2 years.	[Matsubara, Mio; Sakurada, Yoichi; Sugiyama, Atsushi; Fukuda, Yoshiko; Kashiwagi, Kenji] Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan; [Parikh, Ravi] NYU, Sch Med, New York, NY USA; [Parikh, Ravi] Manhattan Retina & Eye Consultants, New York, NY USA	University of Yamanashi; New York University	Sakurada, Y (corresponding author), Univ Yamanashi, Fac Med, Dept Ophthalmol, Kofu, Yamanashi, Japan.	sakurada@yamanashi.ac.jp		Parikh, Ravi/0000-0003-3369-4224; Sakurada, Yoichi/0000-0002-2894-0454; Kashiwagi, Kenji/0000-0001-8506-8503	Japan Society for the Promotion of Science KAKENHI [23791972]	Japan Society for the Promotion of Science KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Japan Society for the Promotion of Science KAKENHI Grant Number 23791972 (YS). The funder provided support in the form of salaries for authors but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Manhattan Retina and Eye Consultants has provided a salary for R.P. and did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section.	Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8; Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438; Chen L, 2018, INVEST OPHTH VIS SCI, V59, P5237, DOI 10.1167/iovs.18-25124; Cheng CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7063; Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114; Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484; Fukuda Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-48494-6; Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014; GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023; Huang LL, 2016, NAT GENET, V48, P640, DOI 10.1038/ng.3546; Kang SW, 2017, GRAEF ARCH CLIN EXP, V255, P281, DOI 10.1007/s00417-016-3452-5; Khan KN, 2016, PROG RETIN EYE RES, V53, P70, DOI 10.1016/j.preteyeres.2016.04.008; Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1; Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/srep44020; Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y; Kikushima W, 2017, JPN J OPHTHALMOL, V61, P61, DOI 10.1007/s10384-016-0479-4; Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030; Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8; Kuroda Y, 2015, OPHTHALMOLOGY, V122, P2303, DOI 10.1016/j.ophtha.2015.06.053; Lee J, 2020, RETINA-J RET VIT DIS, V40, P490, DOI 10.1097/IAE.0000000000002419; Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047; Matsumoto H, 2019, GRAEF ARCH CLIN EXP, V257, P1127, DOI 10.1007/s00417-019-04284-4; Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6; Nakai S, 2019, JPN J OPHTHALMOL, V63, P100, DOI 10.1007/s10384-018-0636-z; Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P448, DOI 10.1007/s10384-019-00692-5; Sakurada Y, 2019, JPN J OPHTHALMOL, V63, P374, DOI 10.1007/s10384-019-00680-9; Sakurada Y, 2018, RETINA-J RET VIT DIS, V38, P1977, DOI 10.1097/IAE.0000000000002294; Sakurada Y, 2018, GRAEF ARCH CLIN EXP, V256, P99, DOI 10.1007/s00417-017-3847-y; Sakurada Y, 2017, RETINA-J RET VIT DIS, V37, P1866, DOI 10.1097/IAE.0000000000001427; Sakurada Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149978; Sakurada Y, 2015, OPHTHALMIC RES, V53, P2, DOI 10.1159/000365487; Sakurada Y, 2013, J OCUL PHARMACOL TH, V29, P832, DOI 10.1089/jop.2013.0044; Sakurada Y, 2013, RETINA-J RET VIT DIS, V33, P841, DOI 10.1097/IAE.0b013e31826ffe9d; SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003; Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689; Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758; YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001; Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964	38	6	6	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 11	2020	15	8							e0237330	10.1371/journal.pone.0237330	http://dx.doi.org/10.1371/journal.pone.0237330			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE5TX	32780752	Green Published, gold			2023-01-03	WOS:000562664700039
J	Shi, JP; Li, J				Shi, Jinping; Li, Juan			Neutrophil-targeted engineered prodrug nanoparticles for anti-inflammation	FASEB JOURNAL			English	Editorial Material						anti-inflammation; brain stroke; drug delivery; immune response; neutrophil; sepsis		Inflammation response is a defense to infection induced by invading pathogen or tissue injury. However, exaggerated inflammation may cause autoimmune or inflammatory disorders, such as acute respiratory distress syndrome, sepsis, stroke and rheumatoid arthritis. Anti-inflammatory agents and anti-cytokine therapy have been developed to inhibit inflammation pathways and neutralize cytokine storm, but the off-targeting delivery and damage in immune system cause systemic severe side-effect. Selective targeting, precise intracellular drug delivery and induced programed apoptosis of neutrophils may be a potential strategy to regulate the inflammatory responses for immune homeostasis. In this commentary, we summarized that the assembled engineering prodrug nanoparticles carrying doxorubicin via pH-responsive bonds that specifically target to and efficiently induce the apoptosis of activated neutrophils for anti-inflammation with high therapeutic efficacy and no systemically toxicity could be a promising strategy for neutrophil-mediated diseases.	[Shi, Jinping; Li, Juan] Beijing Inst Technol, Adv Res Inst Multidisciplinary Sci, Beijing 100081, Peoples R China	Beijing Institute of Technology	Li, J (corresponding author), Beijing Inst Technol, Adv Res Inst Multidisciplinary Sci, Beijing 100081, Peoples R China.	jli@bit.edu.cn			National Natural Science Foundation of China (NSFC) [21902012]	National Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	National Natural Science Foundation of China (NSFC), Grant/Award Number: 21902012	Becher B, 2017, NAT REV IMMUNOL, V17, P49, DOI 10.1038/nri.2016.123; Cartwright JA, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00055; Dinarello CA, 2010, CELL, V140, P935, DOI 10.1016/j.cell.2010.02.043; Jaeger BN, 2012, J EXP MED, V209, P565, DOI 10.1084/jem.20111908; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kotzin JJ, 2016, NATURE, V537, P239, DOI 10.1038/nature19346; Nauseef WM, 2014, NAT IMMUNOL, V15, P602, DOI 10.1038/ni.2921; Sekheri M, 2020, P NATL ACAD SCI USA, V117, P7971, DOI 10.1073/pnas.1920193117; Soehnlein O, 2017, NAT REV IMMUNOL, V17, P248, DOI 10.1038/nri.2017.10; Wang ZJ, 2014, NAT NANOTECHNOL, V9, P204, DOI [10.1038/nnano.2014.17, 10.1038/NNANO.2014.17]; Zhang CY, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aax7964	11	3	3	3	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2020	34	8					9828	9831		10.1096/fj.202000978RR	http://dx.doi.org/10.1096/fj.202000978RR		JUL 2020	4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NE3EW	32614469				2023-01-03	WOS:000547288800001
J	Downer, S; Berkowitz, SA; Harlan, TS; Olstad, DL; Mozaffarian, D				Downer, Sarah; Berkowitz, Seth A.; Harlan, Timothy S.; Olstad, Dana Lee; Mozaffarian, Dariush			Food is medicine: actions to integrate food and nutrition into healthcare	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Downer, Sarah] Harvard Univ, Harvard Law Sch, Ctr Hlth Law & Policy Innovat, Cambridge, MA 02138 USA; [Berkowitz, Seth A.] Univ North Carolina Chapel Hill, Sch Med, Div Gen Med & Clin Epidemiol, Dept Med, Chapel Hill, NC USA; [Berkowitz, Seth A.] Univ North Carolina Chapel Hill, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC USA; [Harlan, Timothy S.] George Washington Univ, Sch Med & Hlth Sci, Sect Gen Internal Med, Culinary Med Program, Washington, DC 20052 USA; [Olstad, Dana Lee] Univ Calgary, Dept Community Hlth Sci, Cumming Sch Med, Calgary, AB, Canada; [Mozaffarian, Dariush] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA	Harvard University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; George Washington University; University of Calgary; Tufts University	Downer, S (corresponding author), Harvard Univ, Harvard Law Sch, Ctr Hlth Law & Policy Innovat, Cambridge, MA 02138 USA.	sdowner@law.harvard.edu	Mozaffarian, Dariush/ABC-2822-2020; Olstad, Dana Lee/R-2767-2016	Olstad, Dana Lee/0000-0001-9787-9952	Rockefeller Foundation; Laura and John Arnold Foundation; MAC AIDS Fund; Bristol-Myers Squibb Foundation; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [K23DK109200]; Aspen Institute; US Department of Agriculture; Robert Wood Johnson Foundation; Commonwealth Fund; Humana Foundation; Canadian Institutes of Health Research; Social Sciences and Humanities Research Council of Canada; O'Brien Institute for Public Health; I Can For Kids Foundation; Alberta Innovates; Alberta Health Services; Canadian Foundation for Dietetic Research; Calgary Centre for Clinical Research; SecondBite; University of Calgary; Heart and Stroke Foundation of Canada; Libin Cardiovascular Research Institute of Alberta; National Institutes of Health; Gates Foundation	Rockefeller Foundation; Laura and John Arnold Foundation; MAC AIDS Fund; Bristol-Myers Squibb Foundation(Bristol-Myers Squibb); National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Aspen Institute; US Department of Agriculture(United States Department of Agriculture (USDA)); Robert Wood Johnson Foundation(Robert Wood Johnson Foundation (RWJF)); Commonwealth Fund; Humana Foundation; Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Social Sciences and Humanities Research Council of Canada(Social Sciences and Humanities Research Council of Canada (SSHRC)); O'Brien Institute for Public Health; I Can For Kids Foundation; Alberta Innovates; Alberta Health Services; Canadian Foundation for Dietetic Research; Calgary Centre for Clinical Research; SecondBite; University of Calgary; Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); Libin Cardiovascular Research Institute of Alberta; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gates Foundation(Bill & Melinda Gates Foundation)	We have read and understood BMJ policy on declaration of interests and have the following interests to declare: SD reports organisational funding from the Rockefeller Foundation, the Laura and John Arnold Foundation, the MAC AIDS Fund, and the Bristol-Myers Squibb Foundation. She sits on the American Cancer Society's National Lung Cancer Roundtable (unpaid) and on the Advisory Board for the Aspen Institute Food and Society Program's food is medicine initiative. Funding for SAB's work on the studies cited in this article was provided by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health under award number K23DK109200. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. SAB has also received funding from the Aspen Institute, the US Department of Agriculture, the Robert Wood Johnson Foundation, and the Commonwealth Fund. He serves on the research advisory committee (unpaid) of the Social Intervention Research and Evaluation Network. TH reports past funding from the Robert Wood Johnson Foundation and the Humana Foundation; speaker fees from Optum, Omnia Education, beef.org, NACCME, DairyMAX; serves on the board of the Culinary Medicine Specialist Board; receives book royalties from Pritichett and Hull and Perseus; and is the owner and editor and chief of drgourmet.com and Dr Gourmet published materials. DLO reports research funding from the Canadian Institutes of Health Research, the Social Sciences and Humanities Research Council of Canada, the O'Brien Institute for Public Health, I Can For Kids Foundation, Alberta Innovates, Alberta Health Services, the Canadian Foundation for Dietetic Research, the Calgary Centre for Clinical Research, SecondBite, the University of Calgary, the Heart and Stroke Foundation of Canada, and the Libin Cardiovascular Research Institute of Alberta. DM reports research funding from the National Institutes of Health and the Gates Foundation; personal fees from GOED, Nutrition Impact, Bunge, Indigo Agriculture, Motif FoodWorks, Amarin, Acasti Pharma, Cleveland Clinic Foundation, America's Test Kitchen, and Danone; scientific advisory board, Brightseed, DayTwo, Elysium Health, Filtricine, HumanCo, and Tiny Organics; and chapter royalties from UpToDate.	[Anonymous], SECT GEN INT MED G W; Downer S, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2482	2	59	60	10	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 29	2020	369								m2482	10.1136/bmj.m2482	http://dx.doi.org/10.1136/bmj.m2482			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ5EF	32601089	Green Published, hybrid			2023-01-03	WOS:000548112700007
J	Weldearegay, HG; Kahsay, AB; Medhanyie, AA; Godefay, H; Petrucka, P				Weldearegay, Haftom Gebrehiwot; Kahsay, Alemayehu Bayray; Medhanyie, Araya Abrha; Godefay, Hagos; Petrucka, Pammla			Quality of and barriers to routine childbirth care signal functions in primary level facilities of Tigray, Northern Ethiopia: Mixed method study	PLOS ONE			English	Article							HEALTH; READINESS	Background Efforts to expand access to institutional delivery alone without quality of care do not guarantee better survival. However, little evidence documents the quality of childbirth care in Ethiopia, which limits our ability to improve quality. Therefore, this study assessed the quality of and barriers to routine childbirth care signal functions during intra-partum and immediate postpartum period. Methods A sequential explanatory mixed method study was conducted among 225 skilled birth attendants who attended 876 recently delivered women in primary level facilities. A multi stage sampling procedure was used for the quantitative phase whilst purposive sampling was used for the qualitative phase. The quantitative survey recruitment occurred in July to August 2018 and in April 2019 for the qualitative key informant interview and Focus Group Discussions (FGD). A validated quantitative tool from a previous validated measurement study was used to collect quantitative data, whereas an interview guide, informed by the literature and quantitative findings, was used to collect the qualitative data. Principal component analysis and a series of univariate and multivariate linear regression analysis were used to analyze the quantitative data. For the qualitative data, verbatim review of the data was iteratively followed by content analysis and triangulation with the quantitative results. Results This study showed that one out of five (20.7%, n = 181) mothers received high quality of care in primary level facilities. Primary hospitals (beta = 1.27, 95% CI:0.80,1.84, p = 0.001), facilities which had staff rotation policies (beta = 2.19, 95% CI:0.01,4.31, p = 0.019), maternal involvement in care decisions (beta = 0.92, 95% CI:0.38,1.47, p = 0.001), facilities with maternal and newborn health quality improvement initiatives (beta = 1.58, 95% CI:0.26, 3.43, p = 0.001), compassionate respectful maternity care training (beta = 0.08, 95% CI: 0.07,0.88, p = 0.021), client flow for delivery (beta = 0.19, 95% CI:-0.34, -0.04, p = 0.012), mentorship (beta = 0.02, 95% CI:0.01, 0.78, p = 0.049), and providers' satisfaction (beta = 0.16, 95% CI:0.03, 0.29, p = 0.013) were predictors of quality of care. This is complemented by qualitative research findings that poor quality of care during delivery and immediate postpartum related to: work related burnout, gap between providers' skill and knowledge, lack of enabling working environment, poor motivation scheme and issues related to retention, poor providers caring behavior, unable translate training into practice, mismatch between number of provider and facility client flow for delivery, and in availability of essential medicine and supplies. Conclusions There is poor quality of childbirth care in primary level facilities of Tigray. Primary hospitals, facilities with staff rotation, maternal and newborn health quality improvement initiatives, maternal involvement in care decisions, training on compassionate respectful maternity care, mentorship, and high provider satisfaction were found to have significantly increased quality of care. However, client flow for delivery service is negatively associated with quality of care. Efforts must be made to improve the quality of care through catchment-based mentorship to increase providers' level of adherence to good practices and standards. More attention and thoughtful strategies are required to minimize providers' work-related burnout.	[Weldearegay, Haftom Gebrehiwot; Kahsay, Alemayehu Bayray; Medhanyie, Araya Abrha] Mekelle Univ, Coll Hlth Sci, Mekelle, Ethiopia; [Godefay, Hagos] Tigray Reg Hlth Bur, Tigray, Ethiopia; [Petrucka, Pammla] Univ Saskatchewan, Coll Nursing, Saskatoon, SK, Canada; [Petrucka, Pammla] Nelson Mandela African Inst Sci & Technol, Arusha, Tanzania	Mekelle University; University of Saskatchewan; Nelson Mandela African Institution of Science & Technology	Weldearegay, HG (corresponding author), Mekelle Univ, Coll Hlth Sci, Mekelle, Ethiopia.	haftom1224@gmail.com		Petrucka, Pammla/0000-0003-3174-3328; Weldearegay, Haftom/0000-0003-1909-7853	Bill and Melinda Gates foundation; World Health Organization [201526690]	Bill and Melinda Gates foundation(Bill & Melinda Gates Foundation); World Health Organization(World Health Organization)	This study was financially supported by "Tigray KMC Project" which is funded by Bill and Melinda Gates foundation and World Health Organization; Grant Number: 201526690."The funders had no role in study design, data collection 548 and analysis, decision to publish, or preparation of the manuscript.	Agarwal R, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000907; [Anonymous], 2018, NAT CLIM CHANGE, V8, P1, DOI 10.1038/s41558-017-0058-9; [Anonymous], 2012, LANCET, V379, pP1851; [Anonymous], 2017, J PROSTHET DENT, V11, pe1; Baldisserotto ML, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0233-x; Bradley S, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0492-5; Central Statistics Agency Ethiopia, 2016, TD PROGR ICF U ROCKV; Delaney MM, 2017, GLOB HEALTH-SCI PRAC, V5, P217, DOI 10.9745/GHSP-D-16-00410; Delvaux Therese, 2007, Afr J Reprod Health, V11, P22, DOI 10.2307/30032485; Dettrick Z, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157110; Dewana Z., 2017, J GYNECOL OBSTET, V5, P31, DOI [10.11648/j.jgo.20170502.12, DOI 10.11648/J.JGO.20170502.12, DOI 10.11648/j.jgo.20170502.12]; Dolea C, 2010, B WORLD HEALTH ORGAN, V88, P379, DOI 10.2471/BLT.09.070607; DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; Enweronu-Laryea C, 2009, RESUSCITATION, V80, P1308, DOI 10.1016/j.resuscitation.2009.08.005; FDRE: Ministry of health, 2015, HLTH SECT TRANSF PLA; Fisseha G, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2184-z; Fogarty L, 2014, HUM RESOUR HEALTH, V12, DOI 10.1186/1478-4491-12-11; Freedman LP, 2014, LANCET, V384, pE42, DOI 10.1016/S0140-6736(14)60859-X; GiftCO AO, 2018, J MIDWIFERY REPROD H, V6, P1356; Haftom G, BMC REPROD HLTH; Hajian-Tilaki K, 2014, J BIOMED INFORM, V48, P193, DOI 10.1016/j.jbi.2014.02.013; Hole MK, 2012, INT J PEDIAT, V2012, DOI 10.1155/2012/408689; Kifle MM, 2017, OBSTET GYNECOL INT, V2017, DOI 10.1155/2017/3717408; Kigenyi O, 2013, BMC PREGNANCY CHILDB, V13, DOI 10.1186/1471-2393-13-162; Larson E, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-483; Lawn JE, 2014, LANCET, V384, P189, DOI 10.1016/S0140-6736(14)60496-7; Leslie HH, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002464; Leslie HH, 2017, B WORLD HEALTH ORGAN, V95, P738, DOI 10.2471/BLT.17.191916; Leslie HH, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002151; Marchant T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126840; Nesbitt RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081089; O'Neill K, 2013, B WORLD HEALTH ORGAN, V91, P923, DOI 10.2471/BLT.12.116798; Owili PO, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177756; Peet ED, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211500; Randive B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067452; Saima T, 2018, OPEN PUBLIC HLTH J, V11, P17, DOI [10.2174/1874944501811010017, DOI 10.2174/1874944501811010017]; Sharma J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171236; Souza JP, 2013, LANCET, V381, P1747, DOI 10.1016/S0140-6736(13)60686-8; Strand H, ACTA P DIATRICA; The Lancet Global Health, 2016, LANCET GLOB HEALTH, V4, pe427; The Lancet Global Health, 2018, LANCET GLOB HEALTH, V6, pE593; Tigray Region, 2017, PLAN FIN BUR ANN REP; Tripathi V, 2019, BMC PREGNANCY CHILDB, V19, DOI 10.1186/s12884-019-2281-z; Wang HD, 2016, LANCET, V388, P1725, DOI 10.1016/S0140-6736(16)31575-6; WHO, 2010, IT TAK WORKF DENS DO; Wilunda C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127827; World Health Organization, 2015, STRATEGIES ENDING PR; World Health Organization, 2015, SERV PROV ASS SERV A; World Health Organization, 2018, RECOMMENDATIONS INTR	49	5	5	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2020	15	6							e0234318	10.1371/journal.pone.0234318	http://dx.doi.org/10.1371/journal.pone.0234318			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6QP	32530944	Green Published, gold			2023-01-03	WOS:000542037200005
J	Haile, D; Kondale, M; Andarge, E; Tunje, A; Fikadu, T; Boti, N				Haile, Dereje; Kondale, Mekdes; Andarge, Eshetu; Tunje, Abayneh; Fikadu, Teshale; Boti, Nigussie			Level of completion along continuum of care for maternal and newborn health services and factors associated with it among women in Arba Minch Zuria woreda, Gamo zone, Southern Ethiopia: A community based cross-sectional study	PLOS ONE			English	Article								Background Completion along continuum of care for maternal and newborn health (MNH) services like antenatal care, skilled birth attendance and postnatal care services is advantageous over each segment of services. It is one of the currently recommended strategies to reduce both maternal and neonatal mortality and achieve the global target of ending preventable maternal and under-five children's mortality. Although studies on factors affecting each segment of MNH services have been well documented in Ethiopia, there is a dearth of evidence about the level of continuum of care and factors associated with it. This study was intended to fill this gap in evidence in the study area so that interventions could be taken to improve maternal and newborn health. Methods A community-basedcross-sectional study was conducted among 432 postnatal women who gave birth in the previous year in Arba Minch Health and Demographic Surveillance System (HDSS) site. Women were selected by computer generated random numbers from a list of women who stayed at least 6 weeks after birth. A pre-tested, structured, and interviewer-administered questionnaire was used for data collection. Data were entered and coded in Epi-data and analyzed using SPSS software version 23. Binary logistic regression model was fitted to identify factors associated with the dependent variable. Bivariate and multivariable analyses were fitted in steps to select candidate variables for multivariable analysis and to control for potential confounding effect respectively. Results The overall completion along the continuum of care was 42(9.7%). The factors significantly associated with completion of care along the continuumwere timely initiation of antenatalcare (before16weeks) [AOR: 10.7, CI (5.1, 22.7], birth preparedness and complication readiness [AOR: 2.9, CI (1.4, 6.1), pre-pregnancy contraception utilization [AOR: 3.9, CI: 1.4, 11.0], being employed [AOR: 2.6 CI:(1.3, 5.4)], and having a planned pregnancy [AOR:3.5 CI: (1.1, 11.4)]. Conclusion and recommendation Completion along the continuum of care for MNH services was low in the study area. Thus, efforts to improve the completion of care should focus on interventions that enhance early initiation of antenatal care, planned pregnancy, and birth preparedness and complication readiness.	[Haile, Dereje] Duguna Fango Hlth Off, Wolaita Zone Hlth Dept, Wolaita Sodo, Wolaita Zone, Ethiopia; [Kondale, Mekdes; Andarge, Eshetu; Boti, Nigussie] Arba Minch Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Reprod Hlth Unit, Arba Minch, Ethiopia; [Tunje, Abayneh; Fikadu, Teshale] Arba Minch Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Epidemiol & Biostat Unit, Arba Minch, Ethiopia	Arba Minch University; Arba Minch University	Andarge, E (corresponding author), Arba Minch Univ, Coll Med & Hlth Sci, Sch Publ Hlth, Reprod Hlth Unit, Arba Minch, Ethiopia.	andeshe7@gmail.com	Boti, Negussie/X-7354-2019; Haile, Dereje/AAA-4418-2021; Zeleke, Eshetu Andarge/GLT-2605-2022	Boti, Negussie/0000-0001-8949-573X; Fikadu, Teshale/0000-0002-4177-9159				Abdella M, 2017, GLOB J FERTILRES; Abota TL, 2018, ETHIOP J HEALTH SCI, V28, P267, DOI 10.4314/ejhs.v28i3.4; Agha S, 2016, BMC PREGNANCY CHILDB, V16, DOI 10.1186/s12884-016-0979-8; Andarge E, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1582-3; [Anonymous], 2014, PREV CHRONIC DIS, V11, pE62; [Anonymous], 2016, SENSORS, V16, pC1, DOI 10.1109/JSEN.2016.2517933; [Anonymous], 2014, PEERJ, V2, pe447; [Anonymous], 2007, COTTON STAT B, V36, P1; [Anonymous], GLOB REV KEY INT REL; [Anonymous], 2018, LEVELS TRENDS CHILD; [Anonymous], 2016, WASHINGTON TRAD 0615, V25, P2, DOI DOI 10.1002/pds.3891; Asefa A, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024783; Basha GW, 2019, OBSTET GYNECOL INT, V2019, DOI 10.1155/2019/5036783; Chaka EE, 2019, INT J MED SCI PUBLIC, DOI 10.4103%2Fijpvm.IJPVM_26_19; de l I, 2018, J CLIN GASTROENTEROL, V52, pe63; Demilew YM, 2016, AFR HEALTH SCI, V16, P10, DOI 10.4314/ahs.v16i1.2; Every Woman Every Child (EWEC), 2015, GLOBAL STRATEGY WOME; Ewunetie AA, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1748-7; Fadel SA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140448; FMOH, 2015, ETH HLTH SECT TRANSF; FMoH of Ethiopia, 2015, MAT NEWB CHILD CAR Q; Gebremeskel F, 2015, J ENVIRON PUBLIC HEA, V2015, DOI 10.1155/2015/971506; Hamed A. F., 2018, International Journal of Medical Science and Public Health, V7, P417; ICF CSA (CSA), 2016, ETH DEM HLTH SURV 20; Islam S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197693; Kapoor D, 2006, 2006 IEEE WORKSHOP ON MICROELECTRONICS AND ELECTRON DEVICES, P23, DOI 10.1109/WMED.2006.1678289; Kaso M, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-55; Kerber KJ, 2007, LANCET, V370, P1358, DOI 10.1016/S0140-6736(07)61578-5; Khatib N, 2009, INDIAN J MED SCI, V63, P10; Kikuchi K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198829; Kikuchi K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164965; Kikuchi K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139288; Kuhnt J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017122; Lemeshow S., 1990, TITLE ADEQUACY SAMPL; Leyandowski BA, 2012, INT J GYNECOL OBSTET, V118, pS167, DOI 10.1016/S0020-7292(12)60017-4; Limenih Miteku Andualem, 2016, Int J Reprod Med, V2016, P7095352, DOI 10.1155/2016/7095352; McDougal L, 2016, ASIA-PAC J PUBLIC HE, V28, P423, DOI 10.1177/1010539516654539; Mohan D, 2017, HEALTH POLICY PLANN, V32, P791, DOI 10.1093/heapol/czx005; Muchie KF, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1488-0; Nawal D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060957; Onyiapat JL, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1689-0; Oyerinde K, 2013, J COMMUNITY MED HLTH, V3, DOI 10.4172/2161-0711.1000e116; Pambe M. W., 2014, African Population Studies, V28, P1146; Sado L, 2014, SOC SCI MED, V114, P169, DOI 10.1016/j.socscimed.2014.05.047; Samari G, 2015, INDIVIDUAL HOUSEHOLD, P004; Sharma B, 2018, EFFECT WOMENS EMPOWE, V46, P95; Shibanuma A, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000786; Singh K, 2016, MATERN CHILD HLTH J, V20, P281, DOI 10.1007/s10995-015-1827-6; Stenberg K, 2014, LANCET, V383, P1333, DOI 10.1016/S0140-6736(13)62231-X; Tafere TE, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192428; Tsegay Y, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-30; UN-DESA, 2017, SUSTAINABLE DEV GOAL; UNICEF, 2019, PAK KEY DEM IND; UNICEF World Health Organization World Bank Group United Nations, 2017, LEV TRENDS CHILD MOR; USAID and CDC. Maternal and child survival programme, 2016, MAT CHILD SURV PROGR; Wang WJ, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0497-0; WHO, 2015, WHO REC HLTH PROM IN; WHO, 2013, PROGR STRAT POSTP FA; Workineh YG, 2014, SCI J PUBLIC HLTH, V2, P169, DOI [10.11648/j.sjph.20140203.15, DOI 10.11648/J.SJPH.20140203.15]; World Health Organization, 2015, TRENDS MAT MORT 1990; Yaya S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184934; Yeji F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142849	62	24	24	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 8	2020	15	6							e0221670	10.1371/journal.pone.0221670	http://dx.doi.org/10.1371/journal.pone.0221670			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LZ0RE	32511230	Green Published, Green Submitted, gold			2023-01-03	WOS:000540938100004
J	Bugger, H; Gollmer, J; Pregartner, G; Wunsch, G; Berghold, A; Zirlik, A; von Lewinski, D				Bugger, Heiko; Gollmer, Johannes; Pregartner, Gudrun; Wuensch, Gerit; Berghold, Andrea; Zirlik, Andreas; von Lewinski, Dirk			Complications and mortality of cardiovascular emergency admissions during COVID-19 associated restrictive measures	PLOS ONE			English	Article							MYOCARDIAL-INFARCTION; INFECTION	While hospital admissions for myocardial infarction (MI) and pulmonary embolism (PE) are decreased during the COVID-19 pandemic, controversy remains about respective complication and mortality rates. This study evaluated admission rates, complications, and intrahospital mortality for selected life-threatening cardiovascular emergencies (MI, PE, and acute aortic dissection (AAD)) during COVID-19-associated restrictive social measures (RM) in Styria, Austria. By screening a patient information system for International Statistical Classification of Diseases and Related Health Problems (ICD) diagnosis codes covering more than 85% of acute hospital admissions in the state of Styria (similar to 1.24 million inhabitants), we retrospectively identified patients with admission diagnoses for MI (I21, I22), PE (I26), and AAD (I71). Rates of complications such as cardiogenic shock and cardiopulmonary resuscitation, treatment escalations (thrombolysis for PE), and mortality were analyzed by patient chart review during 6 weeks following onset of COVID-19 associated RM, and during respective time frames in the years 2016 to 2019. 1,668 patients were included. Cumulative admissions for MI, PE and AAD decreased (RR 0.77; p<0.001) during RM compared to previous years. In contrast, intrahospital mortality increased by 65% (RR 1.65; p = 0.041), mainly driven by mortality following MI (RR 1.80; p = 0.042). PE patients received more frequently thrombolysis treatment (RR 3.63; p = 0.006), while rates of cardiogenic shock and cardiopulmonary resuscitation remained unchanged. Of 226 patients hospitalized during RM, 81 patients with suspected COVID-19 disease were screened for SARS-CoV-2 infection with only 5 testing positive. Thus, cumulative hospital admissions for cardiovascular emergencies decreased during COVID-19 associated RM while intrahospital mortality increased.	[Bugger, Heiko; Gollmer, Johannes; Zirlik, Andreas; von Lewinski, Dirk] Med Univ Graz, Div Cardiol, Graz, Austria; [Pregartner, Gudrun; Wuensch, Gerit; Berghold, Andrea] Med Univ Graz, Inst Med Informat Stat & Documentat, Graz, Austria	Medical University of Graz; Medical University of Graz	von Lewinski, D (corresponding author), Med Univ Graz, Div Cardiol, Graz, Austria.	dirk.von-lewinski@medunigraz.at	Bugger, Heiko/ABA-4180-2021; Zirlik, Andreas/A-6400-2011	Zirlik, Andreas/0000-0001-6290-3297; Bugger, Heiko/0000-0002-3524-0405; Gollmer, Johannes/0000-0002-8734-6359				Baldi E, 2020, NEW ENGL J MED, V383, P496, DOI 10.1056/NEJMc2010418; Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721; Benzakoun J, 2020, EUR J HEART FAIL, V22, P1046, DOI 10.1002/ejhf.1916; Bompard F, 2020, EUR RESPIR J, V56, DOI 10.1183/13993003.01365-2020; Bram JT, 2020, J PEDIATR ORTHOPED, V40, P373, DOI 10.1097/BPO.0000000000001600; Bunce PE, 2011, CLIN INFECT DIS, V52, pE14, DOI 10.1093/cid/ciq125; De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166; De Rosa S, 2020, EUR HEART J, V41, P2083, DOI 10.1093/eurheartj/ehaa409; Dinmohamed AG, 2020, LANCET ONCOL, V21, P750, DOI 10.1016/S1470-2045(20)30265-5; Guo T, 2020, JAMA CARDIOL, V5, P811, DOI 10.1001/jamacardio.2020.1017; Holt A, 2020, EUR HEART J, V41, P3072, DOI 10.1093/eurheartj/ehaa494; Ibanez B, 2018, EUR HEART J, V39, P119, DOI 10.1093/eurheartj/ehx393; Kiblboeck D, 2020, WIEN KLIN WOCHENSCHR, V132, P362, DOI 10.1007/s00508-020-01698-7; Kim IC, 2020, EUR HEART J, V41, P1859, DOI 10.1093/eurheartj/ehaa288; Klok FA, 2020, THROMB RES, V191, P145, DOI [10.1016/j.thromres.2020.04.013, 10.1016/j.thromres.2020.04.041]; Kucirka LM, 2020, ANN INTERN MED, V173, P262, DOI 10.7326/M20-1495; Lazzerini M, 2020, LANCET CHILD ADOLESC, V4, pE10, DOI 10.1016/S2352-4642(20)30108-5; Libby P, 2014, CIRC RES, V114, P1867, DOI 10.1161/CIRCRESAHA.114.302699; Lippi G, 2020, CLIN CHEM LAB MED, V58, P1131, DOI [10.1515/cclm-2020-1761, 10.1515/cclm-2020-0198]; Madjid M, 2020, JAMA CARDIOL, V5, P831, DOI 10.1001/jamacardio.2020.1286; Metzler B, 2020, EUR HEART J, V41, P1852, DOI 10.1093/eurheartj/ehaa314; Nishiga M, 2020, NAT REV CARDIOL, V17, P543, DOI 10.1038/s41569-020-0413-9; Nopp S, 2020, RES PRACT THROMB HAE, V4, P835, DOI 10.1002/rth2.12391; Poissy J, 2020, CIRCULATION, V142, P184, DOI 10.1161/CIRCULATIONAHA.120.047430; Rath D, 2020, CLIN RES CARDIOL, V109, P1491, DOI 10.1007/s00392-020-01683-0; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Sakelliadis EI, 2020, FORENSIC SCI INT, V313, DOI 10.1016/j.forsciint.2020.110365; Scholz KH, 2020, CLIN RES CARDIOL, V109, P1511, DOI 10.1007/s00392-020-01703-z; Shi SB, 2020, JAMA CARDIOL, V5, P802, DOI 10.1001/jamacardio.2020.0950; Solomon MD, 2020, NEW ENGL J MED, V383, P691, DOI 10.1056/NEJMc2015630; Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631; Tan W, 2020, CARDIOL RES, V11, P256, DOI 10.14740/cr1096; Taza F, 2020, BMJ CASE REP, V13, DOI 10.1136/bcr-2020-236561; Varga Z, 2020, LANCET, V395, P1417, DOI 10.1016/S0140-6736(20)30937-5; Vejpongsa P, 2019, AM J MED, V132, P1173, DOI 10.1016/j.amjmed.2019.05.002; Wilson SJ, 2020, CIRC-CARDIOVASC INTE, V13, DOI 10.1161/CIRCINTERVENTIONS.120.009438; Yang J, 2020, INT J INFECT DIS, V94, P91, DOI 10.1016/j.ijid.2020.03.017	37	17	17	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2020	15	9							e0239801	10.1371/journal.pone.0239801	http://dx.doi.org/10.1371/journal.pone.0239801			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY2ZZ	32970774	Green Published, gold			2023-01-03	WOS:000576265600058
J	Nguyen, DH; Vo, TNN; Nguyen, NT; Ching, YC; Thi, TTH				Nguyen, Dai Hai; Vo, Thanh Nguyet Nguyen; Nguyen, Ngoc Tung; Ching, Yern Chee; Hoang Thi, Thai Thanh			Comparison of biogenic silver nanoparticles formed byMomordica charantiaandPsidium guajavaleaf extract and antifungal evaluation	PLOS ONE			English	Article							L. LEAF	Exploiting plant extracts to form metallic nanoparticles has been becoming the promising alternative routes of chemical and physical methods owing to environmentally friendly and abundantly renewable resources. In this study,Momordica charantiaandPsidium guajavaleaf extract (MC.broth and PG.broth) are exploited to fabricate two kinds of biogenic silver nanoparticles (MC.AgNPs and PG.AgNPs). Phytoconstituent screening is performed to identify the categories of natural compounds in MC.broth and PG.broth. Both extracts contain wealthy polyphenols which play a role of reducing agent to turn silver (I) ions into silver nuclei. Trace alkaloids, rich saponins and other oxygen-containing compounds creating the organic corona surrounding nanoparticles act as stabilizing agents. MC.AgNPs and PG.AgNPs are characterized by UV-vis and FTIR spectrophotometry, EDS and TEM techniques. FTIR spectra indicate the presence of O-H, C = O, C-O-C and C = C groups on the surface of silver nanoparticles which is corresponded with three elements of C, O and Ag found in EDS analysis. TEM micrographs show the spherical morphology of MC.AgNPs and PG.AgNPs. MC.AgNPs were 17.0 nm distributed in narrow range of 5-29 nm, while the average size of PG.AgNPs were 25.7 nm in the range of 5-53 nm. Further, MC.AgNPs and PG.AgNPs exhibit their effectively inhibitory ability againstA.niger,A.flavusandF.oxysporumas dose-dependence. Altogether, MC.AgNPs and PG.AgNPs will have much potential in scaled up production and become the promising fungicides for agricultural applications.	[Nguyen, Dai Hai; Vo, Thanh Nguyet Nguyen] Vietnam Acad Sci & Technol, Inst Appl Mat Sci, Ho Chi Minh City, Vietnam; [Nguyen, Dai Hai] Vietnam Acad Sci & Technol, Grad Univ Sci & Technol, Hanoi, Vietnam; [Vo, Thanh Nguyet Nguyen; Hoang Thi, Thai Thanh] Ton Duc Thang Univ, Fac Sci Appl, Biomat & Nanotechnol Res Grp, Ho Chi Minh City, Vietnam; [Nguyen, Ngoc Tung] Vietnam Acad Sci & Technol, Ctr Res & Technol Transfer, Hanoi, Vietnam; [Ching, Yern Chee] Univ Malaya, Dept Chem Engn, Fac Engn, Kuala Lumpur, Malaysia	Vietnam Academy of Science & Technology (VAST); Vietnam Academy of Science & Technology (VAST); Ton Duc Thang University; Universiti Malaya	Thi, TTH (corresponding author), Ton Duc Thang Univ, Fac Sci Appl, Biomat & Nanotechnol Res Grp, Ho Chi Minh City, Vietnam.	hoangthithaithanh@tdtu.edu.vn	Hoang Thi, Thai Thanh/L-5117-2019; Ching, Chee Yern/D-6881-2011; Hoang, Thi Thai Thanh/GPS-6261-2022	Hoang Thi, Thai Thanh/0000-0002-2245-9029; Ching, Chee Yern/0000-0002-1611-1341; Nguyen, Dai Hai/0000-0003-3501-7390				Anjali Das CG, 2020, BIOCATALYSIS AGR BIO, V2020, P101593; [Anonymous], 2019, BRAIN STIMUL MAR; [Anonymous], 2020, J CLIN MED, V9; Bhagyashree SB, 2016, J PHARMACOGN PHYTOCH, V5, P345; Chen F, 2019, INT J BIOL MACROMOL, V138, P673, DOI 10.1016/j.ijbiomac.2019.07.129; Nguyen DH, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10030542; Das P, 2019, J MICROBIOL METH, V167, DOI 10.1016/j.mimet.2019.105766; Diaz-de-Cerio E, 2016, J FUNCT FOODS, V22, P376, DOI 10.1016/j.jff.2016.01.040; Diaz-de-Cerio E, 2015, J CHEM-NY, V2015, DOI 10.1155/2015/250919; 2019, J AM COLL RADIOL, V16, pS141, DOI 10.1016/j.jacr.2019.02.015; Farooqi AA, 2018, FOOD CHEM TOXICOL, V119, P98, DOI 10.1016/j.fct.2018.05.024; Hong T, 2020, POLYMERS-BASEL, V12, DOI 10.3390/polym12081772; Jebril S, 2020, MATER CHEM PHYS, V248, DOI 10.1016/j.matchemphys.2020.122898; Jia S, 2017, INT J MOL SCI, V18; Kalimuthu K, 2020, MICROCHEM J, V152, DOI 10.1016/j.microc.2019.104296; Kim H, 2019, J CONTROL RELEASE, V303, P55, DOI 10.1016/j.jconrel.2019.04.003; Kim Sang Woo, 2012, Mycobiology, V40, P53, DOI 10.5941/MYCO.2012.40.1.053; Koduru JR, 2018, ADV COLLOID INTERFAC, V256, P326, DOI 10.1016/j.cis.2018.03.001; Kubola J, 2008, FOOD CHEM, V110, P881, DOI 10.1016/j.foodchem.2008.02.076; Leesberg, 2012, THE NEW HOLLSTEIN, V1, plvi; Mashwani ZUR, 2016, ADV COLLOID INTERFAC, V234, P132, DOI 10.1016/j.cis.2016.04.008; Medici S, 2019, J MED CHEM, V62, P5923, DOI 10.1021/acs.jmedchem.8b01439; Le NTT, 2020, APPL SCI-BASEL, V10, DOI 10.3390/app10072505; Le NTT, 2021, J CLUST SCI, V32, P601, DOI 10.1007/s10876-020-01823-6; Thi PL, 2018, MAT SCI ENG C-MATER, V92, P52, DOI 10.1016/j.msec.2018.06.037; Prakash A., 2011, J BIOMATERIALS NANOB, V02, P155, DOI [10.4236/jbnb.2011.22020, DOI 10.4236/JBNB.2011.22020]; Rahimi M, 2020, CARBOHYD POLYM, V231, DOI 10.1016/j.carbpol.2019.115696; Siddhanta S, 2015, SOFT MATTER, V11, P7241, DOI 10.1039/c5sm01896j; Stensberg MC, 2011, NANOMEDICINE-UK, V6, P879, DOI [10.2217/nnm.11.78, 10.2217/NNM.11.78]; Stepien G, 2018, ACS APPL MATER INTER, V10, P4548, DOI 10.1021/acsami.7b18648; Wang JL, 2020, WATER RES, V176, DOI 10.1016/j.watres.2020.115722; Zhang F, 2016, INT J BIOL MACROMOL, V92, P246, DOI 10.1016/j.ijbiomac.2016.06.101; 2019, FRONTIERS PLANT SCI, V10, P1	33	12	12	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2020	15	9							e0239360	10.1371/journal.pone.0239360	http://dx.doi.org/10.1371/journal.pone.0239360			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW6FH	32960911	gold, Green Published			2023-01-03	WOS:000575109500006
J	Zhang, JL; Wong, CC; Leung, KT; Wu, F; Zhou, YH; Tong, JHM; Chan, RCK; Li, H; Wang, YF; Yan, H; Liu, LP; Wu, WKK; Chan, MWY; Cheng, ASL; Yu, J; Wong, NA; Lo, KW; To, KF; Kang, W				Zhang, Jinglin; Wong, Chi Chun; Leung, Kam Tong; Wu, Feng; Zhou, Yuhang; Tong, Joanna H. M.; Chan, Ronald C. K.; Li, Hui; Wang, Yifei; Yan, Huan; Liu, Liping; Wu, William K. K.; Chan, Michael W. Y.; Cheng, Alfred S. L.; Yu, Jun; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai; Kang, Wei			FGF18-FGFR2 signaling triggers the activation of c-Jun-YAP1 axis to promote carcinogenesis in a subgroup of gastric cancer patients and indicates translational potential	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; GENE AMPLIFICATION; FGFR2 GENE; CROSS-TALK; PATHWAYS; AZD4547; OVEREXPRESSION; EFFICACY; HEDGEHOG; WNT	Fibroblast growth factor receptor type 2 (FGFR2) has emerged as a key oncogenic factor that regulates gastric cancer (GC) progression, but the underlying mechanism of FGF-FGFR2 signaling pathway remains largely unknown. To identify the potential molecular mechanisms of the oncogenic FGFR2 in gastric carcinogenesis and convey a novel therapeutic strategy, we profiled the FGFR alterations and analyzed their clinical associations in TCGA and Hong Kong GC cohorts. We found that FGFR2 overexpression in GC cell lines and primary tumors predicted poor survival and was associated with advanced stages of GC. Functionally, growth abilities and cell cycle progression of GC were inhibited by inactivation of ERK-MAPK signal transduction after FGFR2 knockdown, while apoptosis was promoted. Meanwhile, the first-line anti-cancer drug sensitivity was enhanced. RNA-seq analysis further revealed that YAP1 signaling serves as a significant downstream modulator and mediates the oncogenic signaling of FGFR2. When stimulating FGFR2 by rhFGF18, we observed intensified F-actin, nuclear accumulation of YAP1, and overexpression of YAP1 targets, but these effects were attenuated by either FGFR2 depletion or AZD4547 administration. Additionally, the FGF18-FGFR2 signaling upregulated YAP1 expression through activating c-Jun, an effector of MAPK signaling. In our cohort, 28.94% of GC cases were characterized as FGFR2, c-Jun, and YAP1 co-positive and demonstrated worse clinical outcomes. Remarkably, we also found that co-targeting FGFR2 and YAP1 by AZD4547 and Verteporfin synergistically enhanced the antitumor effects in vitro and in vivo. In conclusion, we have identified the oncogenic FGF-FGFR2 regulates YAP1 signaling in GC. The findings also highlight the translational potential of FGFR2-c-Jun-YAP1 axis, which may serve as a prognostic biomarker and therapeutic target for GC.	[Zhang, Jinglin; Wu, Feng; Zhou, Yuhang; Tong, Joanna H. M.; Chan, Ronald C. K.; Li, Hui; Wang, Yifei; Yan, Huan; Lo, Kwok Wai; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Translat Oncol, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Zhang, Jinglin; Wong, Chi Chun; Zhou, Yuhang; Tong, Joanna H. M.; Li, Hui; Wang, Yifei; Yan, Huan; Yu, Jun; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, State Key Lab Digest Dis, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China; [Zhang, Jinglin; Zhou, Yuhang; Tong, Joanna H. M.; Li, Hui; Wang, Yifei; Yan, Huan; Wong, Nathalie; Lo, Kwok Wai; To, Ka Fai; Kang, Wei] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China; [Leung, Kam Tong] Chinese Univ Hong Kong, Dept Pediat, Hong Kong, Peoples R China; [Liu, Liping] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Hepatobiliary & Pancreat Surg, Shenzhen, Guangdong, Peoples R China; [Wu, William K. K.] Chinese Univ Hong Kong, Dept Anaesthesia & Intens Care, Hong Kong, Hong Kong, Peoples R China; [Chan, Michael W. Y.] Natl Chung Cheng Univ, Dept Life Sci, Chiayi, Taiwan; [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; [Wong, Nathalie] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Jinan University; Chinese University of Hong Kong; National Chung Cheng University; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong	To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Translat Oncol, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China.; To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, State Key Lab Digest Dis, Inst Digest Dis, Hong Kong, Hong Kong, Peoples R China.; To, KF; Kang, W (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Hong Kong, Peoples R China.	kfto@cuhk.edu.hk; weikang@cuhk.edu.hk	Leung, Kam Tong/I-8569-2017; Wu, William K.K./A-3277-2009; wu, william/HII-5817-2022; KANG, Wei/C-5451-2016	Leung, Kam Tong/0000-0002-7695-2513; Wu, William K.K./0000-0002-5662-5240; KANG, Wei/0000-0002-4651-677X; , Huan/0000-0003-3370-0479; Wong, Chi Chun/0000-0003-1362-3541; Chan, Michael/0000-0003-0314-2437	Research Grants Council of the Hong Kong Special Administrative Region, China [CUHK 14100019, 14118518]; CUHK Direct Grant for Research from The Chinese University of Hong Kong [2019.001]	Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); CUHK Direct Grant for Research from The Chinese University of Hong Kong	We thank the TCGA Research Network (http://ca ncergenome.nih.gov/), The UCSC Cancer Genomics Browser (https:// genome-cancer.ucsc.edu/), NCI Center for Cancer Genomics Office (http://gdc.nci.nih.gov/), and JASPAR 2020 database (http://jaspar.genereg.net/) for the gastric cancer dataset and analysis. We also appreciate the technical support from Core Utilities of Cancer Genomics and Pathobiology of Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong. The manuscript is under the support of Research Grants Council of the Hong Kong Special Administrative Region, China [Project No.: CUHK 14100019 and 14118518 (for GRF projects)], and CUHK Direct Grant for Research (2019.001) from The Chinese University of Hong Kong.	Ahn S, 2016, MODERN PATHOL, V29, P1095, DOI 10.1038/modpathol.2016.96; Babina IS, 2017, NAT REV CANCER, V17, P318, DOI 10.1038/nrc.2017.8; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bosetti C, 2008, ANN ONCOL, V19, P631, DOI 10.1093/annonc/mdm597; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brooks AN, 2012, CLIN CANCER RES, V18, P1855, DOI 10.1158/1078-0432.CCR-11-0699; Chang JJ, 2015, ONCOTARGET, V6, P2009, DOI 10.18632/oncotarget.2987; Dey JH, 2010, CANCER RES, V70, P4151, DOI 10.1158/0008-5472.CAN-09-4479; Dienstmann R, 2014, ANN ONCOL, V25, P552, DOI 10.1093/annonc/mdt419; Dudka AA, 2010, CANCER RES, V70, P3391, DOI 10.1158/0008-5472.CAN-09-3033; Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001; Farre D, 2003, NUCLEIC ACIDS RES, V31, P3651, DOI 10.1093/nar/gkg605; Fornes O, 2020, NUCLEIC ACIDS RES, V48, pD87, DOI 10.1093/nar/gkz1001; Haugsten EM, 2010, MOL CANCER RES, V8, P1439, DOI 10.1158/1541-7786.MCR-10-0168; Helsten T, 2016, CLIN CANCER RES, V22, P259, DOI 10.1158/1078-0432.CCR-14-3212; Hu B, 2012, J GASTROINTEST ONCOL, V3, P251, DOI 10.3978/j.issn.2078-6891.2012.021; Huang TT, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0493-7; Jang J, 2017, TRANSL ONCOL, V10, P469, DOI 10.1016/j.tranon.2017.03.001; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kang W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0134-0; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Karolchik D, 2004, NUCLEIC ACIDS RES, V32, pD493, DOI 10.1093/nar/gkh103; Katoh M, 2006, INT J ONCOL, V29, P163; Katoh M, 2006, CANCER BIOL THER, V5, P1059, DOI 10.4161/cbt.5.9.3151; Kim HS, 2019, J CANCER, V10, P20, DOI 10.7150/jca.28204; Lau WM, 2018, MOL CANCER THER, V17, P232, DOI 10.1158/1535-7163.MCT-17-0367; Leung WK, 2018, GASTROENTEROLOGY, V155, P67, DOI 10.1053/j.gastro.2018.03.028; Liao RG, 2013, CANCER RES, V73, P5195, DOI 10.1158/0008-5472.CAN-12-3950; Matsuda Y, 2012, MOL CANCER THER, V11, P2010, DOI 10.1158/1535-7163.MCT-12-0243; Messeguer X, 2002, BIOINFORMATICS, V18, P333, DOI 10.1093/bioinformatics/18.2.333; Mi HY, 2019, NUCLEIC ACIDS RES, V47, pD419, DOI 10.1093/nar/gky1038; Mitsuno Y, 2001, GUT, V49, P18, DOI 10.1136/gut.49.1.18; Ohta H, 2009, BRIT J CANCER, V100, P389, DOI 10.1038/sj.bjc.6604846; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; Shoji H, 2015, ANTICANCER RES, V35, P5055; Su X, 2014, BRIT J CANCER, V110, P967, DOI 10.1038/bjc.2013.802; Sun D, 2016, ONCOTARGET, V7, P81062, DOI 10.18632/oncotarget.13188; Thisse B, 2005, DEV BIOL, V287, P390, DOI 10.1016/j.ydbio.2005.09.011; Tsang Michael, 2004, Sci STKE, V2004, ppe17, DOI 10.1126/stke.2282004pe17; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Van Cutsem E, 2017, ANN ONCOL, V28, P1316, DOI 10.1093/annonc/mdx107; Xie L, 2013, CLIN CANCER RES, V19, P2572, DOI 10.1158/1078-0432.CCR-12-3898; Yanai K, 2008, CANCER LETT, V263, P145, DOI 10.1016/j.canlet.2007.12.030; Zhang CY, 2009, CLIN CANCER RES, V15, P4017, DOI 10.1158/1078-0432.CCR-08-2824; Zhang JL, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060637; Zhang JL, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20071576; Zhang JL, 2019, ONCOGENE, V38, P33, DOI 10.1038/s41388-018-0430-x	48	14	16	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 22	2020	39	43					6647	6663		10.1038/s41388-020-01458-x	http://dx.doi.org/10.1038/s41388-020-01458-x		SEP 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OF2UT	32934314	Green Published, hybrid			2023-01-03	WOS:000571179500001
J	Muri, L; Oberhansli, S; Buri, M; Le, ND; Grandgirard, D; Bruggmann, R; Muri, RM; Leib, SL				Muri, Lukas; Oberhansli, Simone; Buri, Michelle; Ngoc Dung Le; Grandgirard, Denis; Bruggmann, Remy; Muri, Rene M.; Leib, Stephen L.			Repetitive transcranial magnetic stimulation activates glial cells and inhibits neurogenesis after pneumococcal meningitis	PLOS ONE			English	Article							AGGRAVATES HIPPOCAMPAL APOPTOSIS; THETA-BURST STIMULATION; NEURAL STEM-CELLS; BACTERIAL-MENINGITIS; LEARNING-DEFICITS; FIELD STIMULATION; DENTATE GYRUS; BRAIN-DAMAGE; MOUSE MODEL; RAT	Pneumococcal meningitis (PM) causes damage to the hippocampus, a brain structure critically involved in learning and memory. Hippocampal injury-which compromises neurofunctional outcome-occurs as apoptosis of progenitor cells and immature neurons of the hippocampal dentate granule cell layer thereby impairing the regenerative capacity of the hippocampal stem cell niche. Repetitive transcranial magnetic stimulation (rTMS) harbours the potential to modulate the proliferative activity of this neuronal stem cell niche. In this study, specific rTMS protocols-namely continuous and intermittent theta burst stimulation (cTBS and iTBS)-were applied on infant rats microbiologically cured from PM by five days of antibiotic treatment. Following two days of exposure to TBS, differential gene expression was analysed by whole transcriptome analysis using RNAseq. cTBS provoked a prominent effect in inducing differential gene expression in the cortex and the hippocampus, whereas iTBS only affect gene expression in the cortex. TBS induced polarisation of microglia and astrocytes towards an inflammatory phenotype, while reducing neurogenesis, neuroplasticity and regeneration. cTBS was further found to induce the release of pro-inflammatory cytokinesin vitro. We conclude that cTBS intensified neuroinflammation after PM, which translated into increased release of pro-inflammatory mediators thereby inhibiting neuroregeneration.	[Muri, Lukas; Buri, Michelle; Ngoc Dung Le; Grandgirard, Denis; Leib, Stephen L.] Univ Bern, Inst Infect Dis, Neuroinfect Lab, Bern, Switzerland; [Muri, Lukas; Buri, Michelle; Ngoc Dung Le] Univ Bern, Grad Sch Cellular & Biomed Sci GCB, Bern, Switzerland; [Oberhansli, Simone; Bruggmann, Remy] Univ Bern, Interfac Bioinformat Unit, Bern, Switzerland; [Oberhansli, Simone; Bruggmann, Remy] Univ Bern, SIB Swiss Inst Bioinformat, Bern, Switzerland; [Muri, Rene M.] Univ Bern, Dept Neurol, Bern, Switzerland	University of Bern; University of Bern; University of Bern; Swiss Institute of Bioinformatics; University of Bern; University of Bern	Leib, SL (corresponding author), Univ Bern, Inst Infect Dis, Neuroinfect Lab, Bern, Switzerland.	stephen.leib@ifik.unibe.ch	Leib, Stephen L/A-7866-2011; Grandgirard, Denis/AAB-8786-2020	Leib, Stephen L/0000-0002-1106-6123; Grandgirard, Denis/0000-0002-4151-5196; Bruggmann, Remy/0000-0001-5629-6363; Muri, Lukas/0000-0001-8630-4272	Swiss National Science Foundation [189136]	Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission)	This work was supported by a grant from the Swiss National Science Foundation (Grant 189136 to SLL). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; [Anonymous], 2015, J CROHNS COLITIS S1, V9, pS15; Arias-Carrion O, 2004, J NEUROSCI RES, V78, P16, DOI 10.1002/jnr.20235; Baker CA, 2003, P NATL ACAD SCI USA, V100, P675, DOI 10.1073/pnas.0237313100; Bally L, 2016, ANTIMICROB AGENTS CH, V60, P1841, DOI 10.1128/AAC.02429-15; Baranger K, 2014, PROG BRAIN RES, V214, P313, DOI 10.1016/B978-0-444-63486-3.00014-1; Cazzoli D, 2012, BRAIN, V135, P3426, DOI 10.1093/brain/aws182; Chan P, 1999, J NEUROSCI RES, V55, P238, DOI 10.1002/(SICI)1097-4547(19990115)55:2<238::AID-JNR11>3.0.CO;2-T; Chen YH, 2015, PHARMACOL BIOCHEM BE, V136, P39, DOI 10.1016/j.pbb.2015.07.005; Cullen CL, 2016, FRONT NEURAL CIRCUIT, V10, DOI 10.3389/fncir.2016.00026; Czeh B, 2002, BIOL PSYCHIAT, V52, P1057, DOI 10.1016/S0006-3223(02)01457-9; David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053; David Y, 2009, J NEUROSCI, V29, P10588, DOI 10.1523/JNEUROSCI.2323-09.2009; Edmond K, 2010, LANCET INFECT DIS, V10, P317, DOI 10.1016/S1473-3099(10)70048-7; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Erni ST, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00570; Fang ZY, 2010, ELECTROMAGN BIOL MED, V29, P113, DOI 10.3109/15368378.2010.500568; Fujiki M, 1997, MOL BRAIN RES, V44, P301, DOI 10.1016/S0169-328X(96)00232-X; GEORGE MS, 1995, NEUROREPORT, V6, P1853, DOI 10.1097/00001756-199510020-00008; Gerber J, 2001, ACTA NEUROPATHOL, V101, P499; Grandgirard D, 2007, DEV NEUROSCI-BASEL, V29, P134, DOI 10.1159/000096218; Grandgirard D, 2007, ACTA NEUROPATHOL, V114, P609, DOI 10.1007/s00401-007-0304-8; Hofer S, 2011, J NEUROPATH EXP NEUR, V70, P890, DOI 10.1097/NEN.0b013e3182303f31; Hoffmann O, 2007, INFECT IMMUN, V75, P4289, DOI 10.1128/IAI.01679-06; Huang YZ, 2005, NEURON, V45, P201, DOI 10.1016/j.neuron.2004.12.033; Ivens S, 2007, BRAIN, V130, P535, DOI 10.1093/brain/awl317; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Klein M, 2019, CLIN MICROBIOL INFEC, V25, DOI 10.1016/j.cmi.2018.03.039; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Koedel U, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000461; Kozlova EN, 1999, GLIA, V27, P249, DOI 10.1002/(SICI)1098-1136(199909)27:3<249::AID-GLIA6>3.3.CO;2-5; Leib SL, 2003, PEDIATR RES, V54, P353, DOI 10.1203/01.PDR.0000079185.67878.72; Leib SL, 2000, INFECT IMMUN, V68, P615, DOI 10.1128/IAI.68.2.615-620.2000; Li Z, 2010, INDIAN J BIOCHEM BIO, V47, P359; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Liebetanz D, 2003, J PSYCHIATR RES, V37, P277, DOI 10.1016/S0022-3956(03)00017-7; Liechti FD, 2015, FUTURE MICROBIOL, V10, P1195, DOI 10.2217/fmb.15.43; Liechti FD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113607; Liechti FD, 2014, INFECT IMMUN, V82, P1710, DOI 10.1128/IAI.00073-14; Loeffler JM, 2001, J INFECT DIS, V183, P247, DOI 10.1086/317921; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Luo J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020455; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Mook-Kanamori BB, 2011, CLIN MICROBIOL REV, V24, P557, DOI 10.1128/CMR.00008-11; Muri L, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1549-6; Muri L, 2019, ANTIMICROB AGENTS CH, V63, DOI [10.1128/AAC.00220-19, 10.1128/aac.00220-19]; Muri L, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1272-8; Muri RM, 2016, THER RTMS NEUROL PRI, DOI [10.1007/978-3-319-25721-1_8, DOI 10.1007/978-3-319-25721-1_8]; Nau R, 1999, J NEUROPATH EXP NEUR, V58, P265, DOI 10.1097/00005072-199903000-00006; PascualLeone A, 1996, LANCET, V348, P233, DOI 10.1016/S0140-6736(96)01219-6; Perny M, 2016, J NEUROSCI, V36, P7740, DOI 10.1523/JNEUROSCI.0554-16.2016; Post A, 1999, EUR J NEUROSCI, V11, P3247, DOI 10.1046/j.1460-9568.1999.00747.x; Ptak R, 2013, FRONT HUM NEUROSCI, V7, DOI [10.3389/fnhum.2013.00248, 10.3389/fnhum.2013.00254]; Raus S, 2013, NEUROTOX RES, V23, P79, DOI 10.1007/s12640-012-9333-8; Ridding MC, 2007, NAT REV NEUROSCI, V8, P559, DOI 10.1038/nrn2169; Seiffert E, 2004, J NEUROSCI, V24, P7829, DOI 10.1523/JNEUROSCI.1751-04.2004; Sherafat MA, 2012, J MOL NEUROSCI, V48, P144, DOI 10.1007/s12031-012-9791-8; Slepko N, 1996, GLIA, V16, P241; Spreer A, 2006, PEDIATR RES, V60, P210, DOI 10.1203/01.pdr.0000227553.47378.9f; Takenaga K, 2006, GLIA, V53, P313, DOI 10.1002/glia.20284; Ueyama E, 2011, PSYCHIAT CLIN NEUROS, V65, P77, DOI 10.1111/j.1440-1819.2010.02170.x; Vazana U, 2016, J NEUROSCI, V36, P7727, DOI 10.1523/JNEUROSCI.0587-16.2016; Wagner T, 2007, ANNU REV BIOMED ENG, V9, P527, DOI 10.1146/annurev.bioeng.9.061206.133100; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Wang HN, 2014, J PSYCHIATR RES, V51, P79, DOI 10.1016/j.jpsychires.2014.01.004; Wang LG, 2012, BIOINFORMATICS, V28, P2184, DOI 10.1093/bioinformatics/bts356; Weissberg I, 2015, NEUROBIOL DIS, V78, P115, DOI 10.1016/j.nbd.2015.02.029; Wellmer A, 2000, NEUROSCI LETT, V296, P137, DOI 10.1016/S0304-3940(00)01645-1; Wittwer M, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-176; Zhang Y, 2014, MOL BRAIN, V7, DOI 10.1186/1756-6606-7-11; Zysset-Burri DC, 2013, BMC INFECT DIS, V13, DOI 10.1186/1471-2334-13-393	73	4	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2020	15	9							e0232863	10.1371/journal.pone.0232863	http://dx.doi.org/10.1371/journal.pone.0232863			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR9MU	32915781	gold, Green Published, Green Submitted			2023-01-03	WOS:000571887500102
J	Zhang, WW; Williams, A; Griffith, N; Gaskins, J; Bookstaver, PB				Zhang, Weiwei; Williams, Austin; Griffith, Nicole; Gaskins, Jessica; Bookstaver, P. Brandon			Online availability of fish antibiotics and documented intent for self-medication	PLOS ONE			English	Article							ANTIMICROBIAL DRUGS; LATINO COMMUNITY; BETA-LACTAM; RISK; PRESCRIPTION; RESISTANCE; DIAGNOSIS; EXPOSURE; ADULTS	Self-medication and antibiotic utilization without healthcare oversight may lead to delayed appropriate treatment, transmission of communicable infections, untoward adverse events, and contribute to antimicrobial resistance. Previous data suggest people obtain over-the-counter (OTC) animal antibiotics for their personal use. This study examined the availability of OTC fish antibiotics online and the documented intent for self-medication. The authors conducted a web-based cross-sectional study using Google search engine to identify vendor websites selling fish antibiotics in the United States. Vendor websites were included if product information, consumer reviews, and comments were publicly available. Nine fish antibiotics were chosen due to their possibility of having consequences to human misuse. The cost and availability of fish antibiotics was recorded. The proportion of reviews and comments related to human consumption was calculated. Consumer review traffic based on "likes" and "dislikes" received was compared between human- and non-human consumption-related reviews. Selected fish antibiotics were purchased and evaluated for physical appearance and compared to FDA-approved available equivalents. We found 24 website vendors with online ordering available for OTC fish antibiotics. Cost varied significantly by antibiotic and quantity ranging from USD $8.99 to $119.99. There were 2,288 reviews documented for the 9 selected antibiotics being sold. Among consumer reviews, 2.4% were potentially associated with human consumption. Human consumption-related reviews constituted 30.2% of all "likes" received and 37.5% of all "dislikes" received. Human consumption-related reviews received an average of 9.2 likes compared to 0.52 likes for non-human consumption-related reviews. The 8 fish antibiotics purchased were consistent with FDA-approved equivalents in physical appearance. Although infrequent, antibiotics intended for fish use are being purchased online without a prescription for self-medication to circumvent professional medical care. Reviews related to human consumption generate significant online traffic compared to reviews unrelated to human consumption.	[Zhang, Weiwei] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Clin Pharm, Beijing, Peoples R China; [Williams, Austin; Bookstaver, P. Brandon] Univ South Carolina, Coll Pharm, Columbia, SC 29208 USA; [Griffith, Nicole] Univ Virginia Hlth, Charlottesville, VA USA; [Gaskins, Jessica] South Carolina Aquarium, Charleston, SC USA; [Williams, Austin; Bookstaver, P. Brandon] Prisma Hlth Richland, Columbia, SC 29203 USA; [Griffith, Nicole] Univ Illinois, Infect Dis PGY2, Chicago, IL 60680 USA	Tsinghua University; University of South Carolina System; University of South Carolina Columbia; University of Virginia; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Zhang, WW (corresponding author), Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Clin Pharm, Beijing, Peoples R China.; Bookstaver, PB (corresponding author), Univ South Carolina, Coll Pharm, Columbia, SC 29208 USA.; Bookstaver, PB (corresponding author), Prisma Hlth Richland, Columbia, SC 29203 USA.	zwwa00410@btch.edu.cn; bookstaver@cop.sc.edu						Administration USFD, 2018, ORN FISH DRUGS YOU; Alshammari TM, 2014, AM J HEALTH-SYST PH, V71, P37, DOI 10.2146/ajhp130165; [Anonymous], **NON-TRADITIONAL**; [Anonymous], 2012, REGEN MED S3, V7, pS14; Association APP, 2019, PET IND MARK SIZ OWN; Augustine MR, 2017, INFECT CONT HOSP EP, V38, P266, DOI 10.1017/ice.2016.292; Auta A, 2019, J INFECTION, V78, P8, DOI 10.1016/j.jinf.2018.07.001; Awad A, 2005, J PHARM PHARM SCI, V8, P326; Bell BG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-13; Boyd SE, 2017, J ANTIMICROB CHEMOTH, V72, P1521, DOI 10.1093/jac/dkx003; Carbon C, 1998, BRIT MED J, V317, P663, DOI 10.1136/bmj.317.7159.663; Chen P-Y, 2004, J ICIS P, V58; Ciechalskl S, 2017, MEET PEOPLE USING FI; DeMarsh M, 2020, J GLOB ANTIMICROB RE, V21, P218, DOI 10.1016/j.jgar.2019.10.023; Floyd K, 2014, J RETAILING, V90, P217, DOI 10.1016/j.jretai.2014.04.004; Goff BJ, 2002, NEW ENGL J MED, V347, P223, DOI 10.1056/NEJM200207183470319; Grigoryan L, 2006, EMERG INFECT DIS, V12, P452, DOI 10.3201/eid1203.050992; Grigoryan L, 2019, ANN INTERN MED, V171, P257, DOI 10.7326/M19-0505; Guillemot D, 1998, JAMA-J AM MED ASSOC, V279, P365, DOI 10.1001/jama.279.5.365; Hensgens MPM, 2012, J ANTIMICROB CHEMOTH, V67, P742, DOI 10.1093/jac/dkr508; Hildreth Carolyn J, 2009, JAMA, V302, P816, DOI 10.1001/jama.302.7.816; Jansen J, 2010, ONLINE PRODUCT RES; Kitayama S, 2006, J PERS SOC PSYCHOL, V91, P890, DOI 10.1037/0022-3514.91.5.890; Kuster SP, 2014, CLIN INFECT DIS, V59, P944, DOI 10.1093/cid/ciu497; Larson E, 2004, J URBAN HEALTH, V81, P498, DOI 10.1093/jurban/jth133; Larson EL, 2006, NURS RES, V55, P94, DOI 10.1097/00006199-200603000-00004; Liu NW, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2015.07.007; Liu YC, 2001, ARCH INTERN MED, V161, P2366, DOI 10.1001/archinte.161.19.2366; Mainous AG, 2005, EMERG INFECT DIS, V11, P883, DOI 10.3201/EID1106.040960; Mainous AG, 2008, J AM BOARD FAM MED, V21, P128, DOI 10.3122/jabfm.2008.02.070149; Mainous AG, 2009, ANN FAM MED, V7, P431, DOI 10.1370/afm.999; Mitsi G, 2005, INT J ANTIMICROB AG, V25, P439, DOI 10.1016/j.ijantimicag.2005.02.009; Nepal G, 2018, CUREUS, V10, DOI 10.7759/cureus.2428; Phua J., 2016, J MARK COMMUN, V22, P544, DOI [10.1080/13527266.2014.941000, DOI 10.1080/13527266.2014.941000]; Prevention CfDCa, 2019, ANT PRESCR US; Pumawirawan N, 2015, J INTERACT MARK, V31, P17, DOI 10.1016/j.intmar.2015.05.001; Radio NP, 2020, MAN DIES WOM HOSP TA; Sakeena MHF, 2018, INT J ANTIMICROB AG, V52, P771, DOI 10.1016/j.ijantimicag.2018.09.022; Sharp R, 2017, BAD IS AM HEALTHCARE; Smith SA, 2019, FISH DIS MED; Thomas JK, 1998, ANTIMICROB AGENTS CH, V42, P521, DOI 10.1128/AAC.42.3.521; Torres MJ, 2003, ALLERGY, V58, P961, DOI 10.1034/j.1398-9995.2003.00280.x; Wei-Haas M, 2017, SCI SMITHSONIAN MAGA; World Health Organization, 2000, GUIDELINES REGULATOR; Zoorob R, 2016, ANTIMICROB AGENTS CH, V60, P5527, DOI 10.1128/AAC.00528-16	45	3	3	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2020	15	9							e0238538	10.1371/journal.pone.0238538	http://dx.doi.org/10.1371/journal.pone.0238538			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ7QD	32881969	Green Published, gold			2023-01-03	WOS:000571063300091
J	Ftwi, M; Gebretsadik, GGE; Berhe, H; Haftu, M; Gebremariam, G; Tesfau, YB				Ftwi, Mulu; Gebretsadik, Gebremedhin Gebre-egziabher; Berhe, Haftu; Haftu, Mebrahtom; Gebremariam, Gebrehiwot; Tesfau, Yemane Berhane			Coverage of completion of four ANC visits based on recommended time schedule in Northern Ethiopia: A community-based cross-sectional study design	PLOS ONE			English	Article								Background Despite decades of implementation of maternal health care programs, the uptake of antenatal care services based on the recommended gestational age continues to be below the national and regional targets. Thus, this study aimed to assess the prevalence and factors related to the completion of four antenatal care visits among mothers who gave birth 6 months preceding the study. Method We conducted a community-based cross-sectional study using both quantitative and qualitative approaches. The quantitative component included administering a pre-tested structured questionnaire to 466 mothers who gave birth 6 months preceding the study using a simple random sampling technique from respective Tabias. The quantitative result was analyzed using SPSS version 22. Bivariate and multivariate analysis was done to determine the association between independent and dependent variables. Variables were declared as statistically significant at P <= 0.05 in multivariable logistic regression model. The qualitative interview data were collected from eight mothers and four key informants recruited through purposive sampling method. Results The overall prevalence of completion of four ANC visits based on the recommended time schedule was 9.9% (95% CI, 7.1-12.4). However, 63.9% of the participants attended four visits or more regardless of the recommended time schedule. Being member of community health insurance (AOR 2.140, 95% CI, 1.032-4.436), walking on foot less than or equal one hour to reach the health facility (AOR 3.921, 95% CI, 1.915-8.031), having workload at home (AOR 0.369, 95% CI, 0.182-0.751), and husband supported during antenatal care (AOR 2.561, 95% CI, 1.252-5.240) were independently associated with the completion of four ANC visits based on the recommended time schedule in multivariable analysis. Conclusion The completion of four ANC contacts based on the recommended time schedule remains low in rural areas of Northern Ethiopia. Being a member of community health insurance, distance to the health facility, workload, and male involvement were associated with the completion of four ANC visits based on the recommended time schedule. The existing health system should consider improving the recommended ANC visits by integrating Community based interventions.	[Ftwi, Mulu; Gebretsadik, Gebremedhin Gebre-egziabher] Adigrat Univ, Coll Hlth Sci, Dept Midwifery, Adigrat, Ethiopia; [Berhe, Haftu; Haftu, Mebrahtom] Mekelle Univ, Coll Hlth Sci, Sch Nursing, Mekelle, Ethiopia; [Gebremariam, Gebrehiwot] Adigrat Univ, Coll Hlth Sci, Dept Publ Hlth, Adigrat, Ethiopia; [Tesfau, Yemane Berhane] Adigrat Univ, Coll Hlth Sci, Dept Nursing, Adigrat, Ethiopia	Mekelle University	Ftwi, M (corresponding author), Adigrat Univ, Coll Hlth Sci, Dept Midwifery, Adigrat, Ethiopia.	muluf99@gmail.com			Mekelle University	Mekelle University	We are very grateful to Mekelle University for providing financial support for this study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abou-Zahr CL, 2003, ANTENATAL CARE DEV C; Aliy J, 2012, ETHIOP J HEALTH DEV, V26, P265; Aliyu AA, 2017, PAN AFR MED J, P26, DOI DOI 10.11604/PAMJ.2017.26.124.986128533847; [Anonymous], 2011, DEM E HLTH SURV ADD; Arthur E, 2012, HEALTH ECON REV, V2, DOI 10.1186/2191-1991-2-14; Benova L, 2018, BMJ GLOB HEALTH, V3, DOI 10.1136/bmjgh-2018-000779; Bultu Abagero, 2017, Journal of Public Health and Epidemiology, V9, P251, DOI 10.5897/JPHE2017.0944; Chimatiro CS, 2018, REPROD HEALTH, V15, DOI 10.1186/s12978-018-0605-5; Chorongo D, 2016, PAN AFR MED J, V25, DOI 10.11604/pamj.supp.2016.25.2.10520; Falade-Fatila O, 2020, REPROD HEALTH, V17, DOI 10.1186/s12978-020-0850-2; Fisseha G, 2017, INT J WOMENS HEALTH, V9, P749, DOI 10.2147/IJWH.S140366; Gedefaw M, 2014, OPEN J EPIDEMIOL, V4, P208; Grum T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207922; Gupta S, 2014, PLOS ONE, V9, P7; ICF and CSACEa, 2016, ETH DEM HLTH SURV; ICF CSACEa, 2016, ETH DEM HLTH SURV 20; Islam MM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204752; Jira C, 2005, ETHIOPIAN J HLTH SCI, V15; Kinney MV, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000294; Magoma M, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-13; Manzi A, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-290; MUCHIE KF, 2017, BMC PREGNANCY CHILDB, V17, DOI DOI 10.1186/S12884-016-1183-6; Nsibu CN, 2016, OBSTET GYNECOL INT, V2016, DOI 10.1155/2016/5423413; Pell C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053747; Rockville M, 2019, ETHIOPIA MINIDEMOGRA; Singh S, 2009, ADDING IT COSTS BENE; Suandi D, 2019, INT HLTH; Tesfau YB, 2020, BMC PREGNANCY CHILDB, V20, DOI 10.1186/s12884-020-03003-w; Tewodros B, 2009, ETHIOP J HLTH SCI, V19; Wang W, 2011, LEVELS TRENDS USE MA; Wang WJ, 2017, HEALTH POLICY PLANN, V32, P366, DOI 10.1093/heapol/czw135; WHO, 2022, WHO RECOMMENDATIONS	32	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2020	15	8							e0236965	10.1371/journal.pone.0236965	http://dx.doi.org/10.1371/journal.pone.0236965			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF7CD	32810140	Green Published, gold			2023-01-03	WOS:000563451300028
J	Zaki, J				Zaki, Jamil			The art of medicine The caregiver's dilemma: in search of sustainable medical empathy	LANCET			English	Editorial Material									[Zaki, Jamil] Stanford Univ, Dept Psychol, Stanford, CA 94305 USA	Stanford University	Zaki, J (corresponding author), Stanford Univ, Dept Psychol, Stanford, CA 94305 USA.	jzaki@stanford.edu							0	3	3	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 15	2020	396	10249					458	459						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ND0TT	32798479	Bronze, Green Published			2023-01-03	WOS:000561621400008
J	Kampman, M; van Balkom, AJLM; Broekman, T; Verbraak, M; Hendriks, GJ				Kampman, Mirjam; van Balkom, Anton J. L. M.; Broekman, Theo; Verbraak, Marc; Hendriks, Gert-Jan			Stepped-care versus treatment as usual in panic disorder: A randomized controlled trial	PLOS ONE			English	Article							COGNITIVE-BEHAVIORAL THERAPY; ANXIETY DISORDER; QUESTIONNAIRE; PREDICTION; CBT	Stepped-care (SC) models for anxiety disorders are implemented on a large scale and are assumed to be as effective for the greater majority of patients as more intensive treatment schemes. To compare the outcomes of SC and international guideline-based treatment (Treatment as Usual: TAU) for panic disorder, a total of 128 patients were randomized to either SC or TAU (ratio 2: 1, respectively) using a computer generated algorithm. They were treated in four mental health care centres in the Netherlands after therapists had been trained in SC by a senior expert therapist. SC comprised 10-week guided self-help (pen-and-paper version) followed, if indicated, by 13-week manualized face-to-face cognitive behavioural therapy (CBT), with medication- if prescribed- kept constant. TAU consisted of 23-week regular face-to-face CBT (RCBT) with medication -when prescribed- also kept constant. The means of the attended sessions in the SC condition was 5.9 (SD = 4.8) for ITT and 9.6 (SD = 9.6) for the RCBT condition. The difference in the number of attended sessions between the conditions was significant (t(126) = -3.87,p< .001). Remission rates between treatment conditions did not differ significantly (SC: 44.5%; RCBT: 53.3%) and symptom reduction was similar. Stepping up SC treatment to face-to-face CBT showed a minimal additional effect. Importantly, drop-out rates differed significantly for the two conditions (SC: 48.2%; RCBT: 26.7%). SC was effective in the treatment of panic disorder in terms of symptom reduction and remission rate, but dropout rates were twice as high as those seen in RCBT, with the second phase of SC not substantially improving treatment response. However, SC required significantly less therapist contact time compared to RCBT, and more research is needed to explore predictors of success for guided self-help interventions to allow treatment intensity to be tailored to patients' needs and preferences.	[Kampman, Mirjam; Verbraak, Marc; Hendriks, Gert-Jan] OCD, Overwaal, Ctr Expertise Anxiety Disorders, Nijmegen, Netherlands; [Kampman, Mirjam; Verbraak, Marc; Hendriks, Gert-Jan] PTSD Part Inst Integrated Mental Hlth Care Pro Pe, Nijmegen, Netherlands; [Kampman, Mirjam; Verbraak, Marc; Hendriks, Gert-Jan] Radboud Univ Nijmegen, Behav Sci Inst, Nijmegen, Netherlands; [van Balkom, Anton J. L. M.] Vrije Univ, Amsterdam Publ Hlth Res Inst, Psychiat, Amsterdam UMC, Amsterdam, Netherlands; [van Balkom, Anton J. L. M.] Vrije Univ, GGZ InGeest, Specialized Mental Hlth Care, Amsterdam, Netherlands; [Broekman, Theo] Bur Beta, Nijmegen, Netherlands; [Verbraak, Marc] HSK Grp, Arnhem, Netherlands; [Hendriks, Gert-Jan] Radboud Univ Nijmegen, Dept Psychiat, Med Ctr Nijmegen, Nijmegen, Netherlands	Radboud University Nijmegen; University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Radboud University Nijmegen	Kampman, M (corresponding author), OCD, Overwaal, Ctr Expertise Anxiety Disorders, Nijmegen, Netherlands.; Kampman, M (corresponding author), PTSD Part Inst Integrated Mental Hlth Care Pro Pe, Nijmegen, Netherlands.; Kampman, M (corresponding author), Radboud Univ Nijmegen, Behav Sci Inst, Nijmegen, Netherlands.	mkampman@propersona.nl	Hendriks, Gert-Jan/ABC-1277-2020	Broekman, Theo/0000-0003-4182-819X	Netherlands Organisation for Health Research and Development (ZONMW) [2008/06431/ZONMW]; HSK Groep, a private practice with several branches in the Netherlands	Netherlands Organisation for Health Research and Development (ZONMW)(Netherlands Organization for Health Research and Development); HSK Groep, a private practice with several branches in the Netherlands	The study was granted by the Netherlands Organisation for Health Research and Development (ZONMW). Grant nr: 2008/06431/ZONMW https://www.zonmw.nl/en/The funder HSK Groep, a private practice with several branches in the Netherlands, provided support in the form of salaries for one of the authors [MV], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the `author contributions' section. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ali S, 2017, BEHAV RES THER, V94, P1, DOI 10.1016/j.brat.2017.04.006; American Psychiatric Association (APA), 2009, PRACT GUID TREATM PA; Bandelow B., 1999, PANIC AGORAPHOBIA SC; Barlow DH, 2000, JAMA-J AM MED ASSOC, V283, P2529, DOI 10.1001/jama.283.19.2529; Boswell JF, 2013, J CONSULT CLIN PSYCH, V81, P443, DOI 10.1037/a0031437; BOUMAN TK, 1998, GEDRAGSTHERAPIE, V31, P165; Bower P, 2005, BRIT J PSYCHIAT, V186, P11, DOI 10.1192/bjp.186.1.11; CHAMBLESS DL, 1985, BEHAV RES THER, V23, P35, DOI 10.1016/0005-7967(85)90140-8; CHAMBLESS DL, 1984, J CONSULT CLIN PSYCH, V52, P1090, DOI 10.1037/0022-006X.52.6.1090; Clark DM, 2009, BEHAV RES THER, V47, P910, DOI 10.1016/j.brat.2009.07.010; Craske M.G., 2007, CLIN HDB PSYCHOL DIS, P1; de Jong K, 2007, CLIN PSYCHOL PSYCHOT, V14, P288, DOI 10.1002/cpp.529; Delgadillo J, 2014, BRIT J CLIN PSYCHOL, V53, P114, DOI 10.1111/bjc.12031; Dow MGT, 2007, PSYCHOL MED, V37, P1503, DOI 10.1017/S0033291707000682; Ellsworth JR, 2006, CLIN PSYCHOL PSYCHOT, V13, P380, DOI 10.1002/cpp.503; GOULD RA, 1995, BEHAV THER, V26, P533, DOI 10.1016/S0005-7894(05)80099-1; Gyani A, 2013, BEHAV RES THER, V51, P597, DOI 10.1016/j.brat.2013.06.004; IBM Corporation, 2016, IBM SPSS STAT WIND V; Kampman M, 2008, BEHAV COGN PSYCHOTH, V36, P99, DOI 10.1017/S1352465807004018; Lambert M.J., 1999, USE PSYCHOL TESTING, P831; Muntingh A, 2014, PSYCHOTHER PSYCHOSOM, V83, P37, DOI 10.1159/000353682; Newman MG, 2000, J CONSULT CLIN PSYCH, V68, P549, DOI 10.1037//0022-006X.68.4.549; NICE (National Institute for Health and Care Excellence, 2019, CLIN GUID 113 GEN AN; Nordgreen T, 2016, BEHAV THER, V47, P166, DOI 10.1016/j.beth.2015.10.004; Oosterbaan DB, 2013, BRIT J PSYCHIAT, V203, P132, DOI 10.1192/bjp.bp.112.125211; Otto MW, 2012, DEPRESS ANXIETY, V29, P465, DOI 10.1002/da.21910; Schibbye P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100614; Seekles W, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-171; Sheehan DV, 1997, EUR PSYCHIAT, V12, P232, DOI 10.1016/S0924-9338(97)83297-X; Tasca GA, 2019, PSYCHOL MED, V49, P598, DOI 10.1017/S0033291718001277; Tiemens B, 2019, BMC PSYCHIATRY, V19, DOI 10.1186/s12888-019-2214-4; Tolin DF, 2011, DEPRESS ANXIETY, V28, P314, DOI 10.1002/da.20804; van Straten A, 2015, PSYCHOL MED, V45, P231, DOI 10.1017/S0033291714000701; Wilson GT, 2000, J CONSULT CLIN PSYCH, V68, P564, DOI 10.1037/0022-006X.68.4.564; Zhang JY, 2010, 2010 IEEE INTERNATIONAL CONFERENCE ON WIRELESS COMMUNICATIONS, NETWORKING AND INFORMATION SECURITY (WCNIS), VOL 1, P4	35	4	4	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2020	15	8							e0237061	10.1371/journal.pone.0237061	http://dx.doi.org/10.1371/journal.pone.0237061			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NE5VG	32790718	Green Published, gold			2023-01-03	WOS:000562668300060
J	Shitemaw, T; Jemal, B; Mamo, T; Akalu, L				Shitemaw, Tewoderos; Jemal, Bedru; Mamo, Temesgen; Akalu, Luelayehu			Incidence and associated factors for hypotension after spinal anesthesia during cesarean section at Gandhi Memorial Hospital Addis Ababa, Ethiopia	PLOS ONE			English	Article							RISK-FACTORS; MANAGEMENT; VOLUME	Background Spinal anesthesia is a type of regional anesthesia that has been practicing for obstetric anesthesia since the beginning of the 20th century. Despite the simplicity and lower maternal mortality risk, compared to general anesthesia, spinal anesthesia is linked to different adverse effects, of which hypotension is the most common complication. The main aim of this study was to determine the incidence and associated factors of hypotension after spinal anesthesia during cesarean section. Method Institution-based cross-sectional study was conducted with 410 clients. The study was conducted on cesarean section under spinal anesthesia from 5(th)January to 30(th)April 2019, at the Gandhi Memorial Hospital, Addis Ababa, Ethiopia. Both bivariable and multivariable logistic regression analysis were done on the associated factors. The level of statistical significance was represented at pResults The incidence of hypotension among mothers who underwent a cesarean section after spinal anesthesia was 64%. Newborn weight >= 4kg (AOR = 5.373; 95%CI: (1.627-17.740)) showed an increase risk of association with hypotension. A baseline systolic blood pressure < 120mmHg (AOR = 6.293; (95%CI: 2.999-13.204)) was found to be associated with increased risk of hypotension. Sensory block height >T6 AOR = 2.230; 95%CI: (1.329-3.741), the time interval between spinal induction and skin incision > 6minutes AOR = 1.803; 95%CI: (1.044-3.114) and anesthetist experience AOR = 5.033(95%CI: 2.144-11.818) were also associated with hypotension. Conclusion The identified risk factors for hypotension, after spinal anesthesia are sensory height block, weight of the baby, the time interval between spinal induction and skin incision, baseline systolic blood pressure, and anesthetist experience.	[Shitemaw, Tewoderos] Kotebe Metropolitan Univ, Menelik II Hlth & Med Sci Coll, Anesthesia Dept, Addis Ababa, Ethiopia; [Jemal, Bedru] Dilla Univ, Coll Hlth Sci & Med, Dept Anesthesiol, Dilla, Ethiopia; [Mamo, Temesgen] Wachamo Univ, Coll Hlth Sci & Med, Dept Anesthesiol, Wachamo, Ethiopia; [Akalu, Luelayehu] Addis Ababa Univ, Coll Hlth Sci & Med, Dept Anesthesiol, Addis Ababa, Ethiopia	Dilla University; Addis Ababa University	Jemal, B (corresponding author), Dilla Univ, Coll Hlth Sci & Med, Dept Anesthesiol, Dilla, Ethiopia.	bedruanst@gmail.com	Jemal, Bedru/AAX-4086-2020; ABAFITA, BEDRU JEMAL/GRR-2273-2022	Jemal, Bedru/0000-0002-4194-4724; ABAFITA, BEDRU JEMAL/0000-0002-4194-4724	found Addis Ababa University	found Addis Ababa University	Temesgen Mamo is author who received a found Addis Ababa University sponsored this study but, had no role in study design,data collection and analysis and decision to publish.	Bajwa Sukhminder Jit Singh, 2012, Int J Crit Illn Inj Sci, V2, P63, DOI 10.4103/2229-5151.97269; Brenck F, 2009, J CLIN MONIT COMPUT, V23, P85, DOI 10.1007/s10877-009-9168-x; Brull R., 2015, SPINAL EPIDURAL CAUD, Veighth, P1684, DOI DOI 10.1093/bja/aei066; Chumpathong Saowapark, 2006, Journal of the Medical Association of Thailand, V89, P1127; Fakherpour A, 2018, INDIAN J ANAESTH, V62, P36, DOI 10.4103/ija.IJA_416_17; Higuchi H, 2004, ANESTHESIOLOGY, V100, P106, DOI 10.1097/00000542-200401000-00019; Kinsella SM, 2018, ANAESTHESIA, V73, P71, DOI 10.1111/anae.14080; Lamacraft G, 2004, S AFR J ANAESTH ANAL, V10, P15, DOI [10.1080/22201173.2004.10872346, DOI 10.1080/22201173.2004.10872346]; Maayan-Metzger A, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.07.012; Morgan PJ, 2001, ANESTH ANALG, V92, P997; Ohpasanon Pitchya, 2008, Journal of the Medical Association of Thailand, V91, P675; Shikur B, 2018, ETHIOPIAN MED J, V56; Somboonviboon Wanna, 2008, Journal of the Medical Association of Thailand, V91, P181; Upadya Madhusudan, 2016, Anesth Essays Res, V10, P33, DOI 10.4103/0259-1162.164729; Wang X, 2015, MED SCI MONITOR, V21, P52, DOI 10.12659/MSM.892224	15	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2020	15	8							e0236755	10.1371/journal.pone.0236755	http://dx.doi.org/10.1371/journal.pone.0236755			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE5VG	32790681	gold, Green Published			2023-01-03	WOS:000562668300100
J	Wang, YY; Ma, WW; Peng, IF				Wang, Yan-Ying; Ma, Wei-Wei; Peng, I-Feng			Screening of sleep assisting drug candidates with a Drosophila model	PLOS ONE			English	Article							SUPRACHIASMATIC NUCLEUS; ALZHEIMERS-DISEASE; GINSENG EXTRACT; BEHAVIORS; MELATONIN; DISTURBANCES; COGNITION; PROTECT; MEMORY; BRAIN	Lately,Drosophilahas been favored as a model in sleep and circadian rhythm research due to its conserved mechanism and easily manageable operation. These studies have revealed the sophisticated parameters in whole-day sleep profiles ofDrosophila, drawing connections betweenDrosophilasleep and human sleep. In this study, we tested several sleep deprivation protocols (mechanical shakes and light interruptions) onDrosophilaand delineated their influences onDrosophilasleep. We applied a daytime light-deprivation protocol (DD) mimicking jet-lag to screen drugs that alleviate sleep deprivation. Characteristically, classical sleep-aid compounds exhibited different forms of influence: phenobarbital and pentobarbital modified total sleep time, while melatonin only shortened the latency to sleep. Such results construct the basis for further research on sleep benefits in other treatments inDrosophila. We screened seven herb extracts, and found very diverse results regarding their effect on sleep regulation. For instance,Panax notoginsengandWithania somniferaextracts displayed potent influence on total sleep time, whileMelissa officinalisincreased the number of sleep episodes. By comparing these treatments, we were able to rank drug potency in different aspects of sleep regulation. Notably, we also confirmed the presence of sleep difficulties in aDrosophilaAlzheimer's disease (AD) model with an overexpression of human Abeta, and recognized clear differences between the portfolios of drug screening effects in AD flies and in the control group. Overall, potential drug candidates and receipts for sleep problems can be identified separately for normal and ADDrosophilapopulations, outliningDrosophila'spotential in drug screening tests in other populations if combined with the use of other genetic disease tools.	[Wang, Yan-Ying; Ma, Wei-Wei; Peng, I-Feng] Suzhou Joekai Biotech LLC, Res Dept, Kunshan City, Jiangsu, Peoples R China; [Ma, Wei-Wei] Tsinghua Univ, Sch Life Sci, Beijing, Peoples R China	Tsinghua University	Peng, IF (corresponding author), Suzhou Joekai Biotech LLC, Res Dept, Kunshan City, Jiangsu, Peoples R China.	ifengpeng@joekaibiotech.com			Science and Technology Bureau of Kunshan City	Science and Technology Bureau of Kunshan City	YYW, WWMand IFP are full-time employees in Suzhou Joekai Biotechnology LLC (Joekai Biotech), Jiangsu, China. Joekai Biotech provided support in the form of salaries for authors [YYW, WWM, IFP], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section. IFP andWWMalso received Research Grants for International Collaborations (2017, 2018) from Science and Technology Bureau of Kunshan City.	Ahn J, 2006, BIOGERONTOLOGY, V7, P239, DOI 10.1007/s10522-006-9023-0; Awad R, 2009, PHYTOTHER RES, V23, P1075, DOI 10.1002/ptr.2712; BIANCHETTI A, 1995, DEMENTIA, V6, P108, DOI 10.1159/000106930; Blake MR, 2015, NEUROBIOL DIS, V77, P117, DOI 10.1016/j.nbd.2015.02.012; Bruneton J., 1999, PHARMACOGNOSIE PHYTO, P707; Bushey D, 2010, BMC NEUROSCI, V11, DOI 10.1186/1471-2202-11-56; Cajochen C, 2003, J NEUROENDOCRINOL, V15, P432, DOI 10.1046/j.1365-2826.2003.00989.x; Cases J, 2011, MEDITERR J NUTR META, V4, P211, DOI 10.1007/s12349-010-0045-4; Chase JE, 1997, ANN PHARMACOTHER, V31, P1218, DOI 10.1177/106002809703101015; Chen S, 2002, P NATL ACAD SCI USA, V99, P5664, DOI 10.1073/pnas.082102599; Chen YL, 2015, J ETHNOPHARMACOL, V171, P307, DOI 10.1016/j.jep.2015.05.045; Chinese Pharmacopoeia Commission, 2015, MIN HLTH PEOPL REP C, P265; Cicero AFG, 2000, J ETHNOPHARMACOL, V73, P387, DOI 10.1016/S0378-8741(00)00277-4; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Foley D, 2004, J PSYCHOSOM RES, V56, P497, DOI 10.1016/j.jpsychores.2004.02.010; GOLDBETER A, 1995, P ROY SOC B-BIOL SCI, V261, P319, DOI 10.1098/rspb.1995.0153; Guo F, 2016, NATURE, V536, P292, DOI 10.1038/nature19097; Han HJ, 2013, J ETHNOPHARMACOL, V149, P597, DOI 10.1016/j.jep.2013.07.005; Harper DG, 2001, ARCH GEN PSYCHIAT, V58, P353, DOI 10.1001/archpsyc.58.4.353; Hendricks JC, 2000, NEURON, V25, P129, DOI 10.1016/S0896-6273(00)80877-6; Huber R, 2004, SLEEP, V27, P628, DOI 10.1093/sleep/27.4.628; Ibarra A, 2010, PHYTOMEDICINE, V17, P397, DOI 10.1016/j.phymed.2010.01.012; Iijima K, 2004, P NATL ACAD SCI USA, V101, P6623, DOI 10.1073/pnas.0400895101; Iijima K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001703; IKEDA M, 1971, TOXICOL APPL PHARM, V20, P30, DOI 10.1016/0041-008X(71)90086-X; ITOH T, 1989, PLANTA MED, P429, DOI 10.1055/s-2006-962058; Jeon SJ, 2015, EUR J PHARMACOL, V762, P443, DOI 10.1016/j.ejphar.2015.06.037; Jo K, 2018, FOOD SCI BIOTECHNOL, V27, P1833, DOI 10.1007/s10068-018-0431-0; Kaun KR, 2012, HUM GENET, V131, P959, DOI 10.1007/s00439-012-1146-6; Kaur T, 2017, MOL CELL BIOCHEM, V427, P91, DOI 10.1007/s11010-016-2900-1; Kumar S, 2005, CHRONOBIOL INT, V22, P641, DOI 10.1080/07420520500179423; Lewy AJ, 1997, J BIOL RHYTHM, V12, P588, DOI 10.1177/074873049701200614; Liu C, 2019, CURR BIOL, V29, P3635, DOI 10.1016/j.cub.2019.08.079; Liu ZX, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105678; Ma H, 2009, PHYTOTHER RES, V23, P1340, DOI 10.1002/ptr.2773; Ma WW, 2017, CHIN J NAT MEDICINES, V15, P899, DOI 10.1016/S1875-5364(18)30005-0; Ma Y, 2008, J ETHNOPHARMACOL, V117, P318, DOI 10.1016/j.jep.2008.02.006; McCurry SM, 2000, SLEEP MED REV, V4, P603, DOI 10.1053/smrv.2000.0127; Mitolo M, 2018, DEMENT GERIATR COGN, V46, P371, DOI 10.1159/000494921; Nall AH, 2013, J NEUROSCI, V33, P8534, DOI 10.1523/JNEUROSCI.0253-13.2013; Peter-Derex L, 2015, SLEEP MED REV, V19, P29, DOI 10.1016/j.smrv.2014.03.007; PETKOV VD, 1987, AM J CHINESE MED, V15, P19, DOI 10.1142/S0192415X87000047; Pilcher JJ, 1997, J PSYCHOSOM RES, V42, P583, DOI 10.1016/S0022-3999(97)00004-4; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rihel J, 2010, SCIENCE, V327, P348, DOI 10.1126/science.1183090; Shaw PJ, 2002, NATURE, V417, P287, DOI 10.1038/417287a; Sterniczuk R, 2010, BRAIN RES, V1348, P139, DOI 10.1016/j.brainres.2010.05.013; Stopa EG, 1999, J NEUROPATH EXP NEUR, V58, P29, DOI 10.1097/00005072-199901000-00004; SWAAB DF, 1985, BRAIN RES, V342, P37, DOI 10.1016/0006-8993(85)91350-2; Tononi G, 2006, SLEEP MED REV, V10, P49, DOI 10.1016/j.smrv.2005.05.002; van Alphen B, 2013, J NEUROSCI, V33, P6917, DOI 10.1523/JNEUROSCI.0061-13.2013; Wang L, 2012, P NATL ACAD SCI USA, V109, P16743, DOI 10.1073/pnas.1208011109; Wolkove N, 2007, CAN MED ASSOC J, V176, P1299, DOI 10.1503/cmaj.060792; Xu T, 2016, J GINSENG RES, V40, P211, DOI 10.1016/j.jgr.2015.07.007	54	9	9	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2020	15	7							e0236318	10.1371/journal.pone.0236318	http://dx.doi.org/10.1371/journal.pone.0236318			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW2YL	32726319	Green Published, gold			2023-01-03	WOS:000556908900036
J	Garrett, MC; O'Shea, TM; Wollenberg, AL; Bernstein, AM; Hung, D; Staarman, B; Soto, H; Deming, TJ; Sofroniew, MV; Kornblum, HI				Garrett, Matthew C.; O'Shea, Timothy M.; Wollenberg, Alexander L.; Bernstein, Alexander M.; Hung, Derek; Staarman, Brittany; Soto, Horacio; Deming, Timothy J.; Sofroniew, Michael, V; Kornblum, Harley, I			Injectable diblock copolypeptide hydrogel provides platform to deliver effective concentrations of paclitaxel to an intracranial xenograft model of glioblastoma	PLOS ONE			English	Article							MALIGNANT GLIOMA; LOCAL-DELIVERY; RESECTION; MULTIFORME; THERAPY; EXTENT; SURVIVAL; TEMOZOLOMIDE; CONCOMITANT; TISSUE	Introduction Surgical resection and systemic chemotherapy with temozolomide remain the mainstay for treatment of glioblastoma. However, many patients are not candidates for surgical resection given inaccessible tumor location or poor health status. Furthermore, despite being first line treatment, temozolomide has only limited efficacy. Methods The development of injectable hydrogel-based carrier systems allows for the delivery of a wide range of chemotherapeutics that can achieve high local concentrations, thus potentially avoiding systemic side effects and wide-spread neurotoxicity. To test this modality in a realistic environment, we developed a diblock copolypeptide hydrogel (DCH) capable of carrying and releasing paclitaxel, a compound that we found to be highly potent against primary gliomasphere cells. Results The DCH produced minimal tissue reactivity and was well tolerated in the immune-competent mouse brain. Paclitaxel-loaded hydrogel induced less tissue damage, cellular inflammation and reactive astrocytes than cremaphor-taxol (typical taxol-carrier) or hydrogel alone. In a deep subcortical xenograft model of glioblastoma in immunodeficient mice, injection of paclitaxel-loaded hydrogel led to local tumor control and improved survival. However, the tumor cells were highly migratory and were able to eventually escape the area of treatment. Conclusions These findings suggest this technology may be ultimately applicable to patients with deepseated inoperable tumors, but as currently formulated, complete tumor eradication would be highly unlikely. Future studies should focus on targeting the migratory potential of surviving cells.	[Garrett, Matthew C.; Staarman, Brittany] Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA; [O'Shea, Timothy M.; Bernstein, Alexander M.; Sofroniew, Michael, V] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; [Wollenberg, Alexander L.; Hung, Derek; Deming, Timothy J.] Univ Calif Los Angeles, Dept Chem & Biochem, 405 Hilgard Ave, Los Angeles, CA 90024 USA; [Soto, Horacio] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurosurg, Los Angeles, CA 90095 USA; [Deming, Timothy J.] Univ Calif Los Angeles, Dept Bioengn, Los Angeles, CA USA; [Kornblum, Harley, I] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA; [Kornblum, Harley, I] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pharmacol, Los Angeles, CA 90095 USA; [Kornblum, Harley, I] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA; [Kornblum, Harley, I] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA	University System of Ohio; University of Cincinnati; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Garrett, MC (corresponding author), Univ Cincinnati, Coll Med, Dept Neurosurg, Cincinnati, OH 45267 USA.	garretm4@ucmail.uc.edu	Sofroniew, Michael/ABE-8857-2020	Garrett, Matthew/0000-0003-4567-7907; Deming, Timothy/0000-0002-0594-5025	Dr. Miriam and Sheldon G. Adelson Medical Foundation; US National Institutes of Health [NS084030, NS053563]; California Institute for Regenerative Medicine	Dr. Miriam and Sheldon G. Adelson Medical Foundation; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); California Institute for Regenerative Medicine(California Institute for Regenerative Medicine)	We thank the Microscopy Core Resource of the UCLA Broad Stem Cell Research CenterCIRM Laboratory. This work was supported by the Dr. Miriam and Sheldon G. Adelson Medical Foundation (M.V.S., T.J.D. and H.I.K.), the US National Institutes of Health (NS084030 to M.V.S. and NS053563 to H.I.K), and a training grant from the California Institute for Regenerative Medicine (M.C.G.).	Afra D, 2002, LANCET, V359, P1011; Chang SM, 2001, CANCER, V91, P417, DOI 10.1002/1097-0142(20010115)91:2<417::AID-CNCR1016>3.0.CO;2-9; Cui YN, 2013, BIOMATERIALS, V34, P8511, DOI 10.1016/j.biomaterials.2013.07.075; de la Puente P, 2018, J PHARM SCI-US, V107, P922, DOI 10.1016/j.xphs.2017.10.042; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; DuValla GA, 2009, ANTI-CANCER DRUG, V20, P89, DOI 10.1097/CAD.0b013e3283222c12; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; GRUBER ML, 1990, J NUCL MED, V31, P969; Hafner M, 2016, NAT METHODS, V13, P521, DOI [10.1038/nmeth.3853, 10.1038/NMETH.3853]; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hersh DS, 2016, NEUROSURGERY, V79, P643, DOI 10.1227/NEU.0000000000001399; Johnson BE, 2014, SCIENCE, V343, P189, DOI 10.1126/science.1239947; Kim Y, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00053; Kitange GJ, 2009, NEURO-ONCOLOGY, V11, P281, DOI 10.1215/15228517-2008-090; Kubben PL, 2011, LANCET ONCOL, V12, P1062, DOI 10.1016/S1470-2045(11)70130-9; Kuhnt D, 2011, NEURO-ONCOLOGY, V13, P1339, DOI 10.1093/neuonc/nor133; Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190; Laks DR, 2016, NEURO-ONCOLOGY, V18, P1367, DOI 10.1093/neuonc/now045; Lee SH, 1999, J CHROMATOGR B, V724, P357, DOI 10.1016/S0378-4347(98)00566-0; Moses MA, 2003, CANCER CELL, V4, P337, DOI 10.1016/S1535-6108(03)00276-9; Orringer D, 2012, J NEUROSURG, V117, P851, DOI 10.3171/2012.8.JNS12234; Patel P, 2016, J NEUROSURG, V125, P853, DOI 10.3171/2015.7.JNS15244; Rowland MJ, 2018, BIOMATERIALS, V179, P199, DOI 10.1016/j.biomaterials.2018.05.054; Sanai N, 2011, J NEUROSURG, V115, P3, DOI 10.3171/2011.2.JNS10998; Stummer W, 2008, NEUROSURGERY, V62, P564, DOI [10.1227/01.NEU.0000297118.47076.5F, 10.1227/01.NEU.0000346230.80425.3A, 10.1227/01.neu.0000317304.31579.17]; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Tyler B, 2010, J NEUROSURG, V113, P210, DOI 10.3171/2009.11.JNS08162; van der Sanden B, 2013, FUTURE ONCOL, V9, P817, DOI [10.2217/FON.13.30, 10.2217/fon.13.30]; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Yang CY, 2009, BIOMATERIALS, V30, P2881, DOI 10.1016/j.biomaterials.2009.01.056; Yonezawa H, 2017, MOL CLIN ONCOL, V6, P105, DOI 10.3892/mco.2016.1086; Zhang S, 2014, BIOMATERIALS, V35, P1989, DOI 10.1016/j.biomaterials.2013.11.005; Zhao MN, 2018, INT J PHARMACEUT, V548, P522, DOI 10.1016/j.ijpharm.2018.07.033	33	4	4	2	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2020	15	7							e0219632	10.1371/journal.pone.0219632	http://dx.doi.org/10.1371/journal.pone.0219632			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OD5ZL	32706829	Green Published, gold			2023-01-03	WOS:000579931700001
J	Pyeon, SY; Han, GH; Ki, KD; Lee, KB; Lee, JM				Pyeon, Seung Yeon; Han, Gwan Hee; Ki, Kyung Do; Lee, Kwang-Beom; Lee, Jong-Min			Effect of delayed palliative chemotherapy on survival of patients with recurrent ovarian cancer	PLOS ONE			English	Article							LIFE CARE; END; SURVEILLANCE	For patients with recurrent ovarian cancer, the goals of chemotherapy include palliation of disease-related symptoms with minimum treatment-related side effects. However, there is currently a paucity of data regarding the initiation of palliative chemotherapy. This study aimed to compare the differences in survival rates and toxicities between patients with recurrent ovarian cancer who started palliative chemotherapy immediately versus those who received delayed chemotherapy. Through a retrospective chart review, patients who received more than three lines of chemotherapy were included. Based on the timing of third-line chemotherapy initiation, the patients were divided into two groups: delayed (DTG) and immediate (ITG) treatment groups. The chi-square test or Fisher's exact tests, and t-test or Mann-Whitney U test were used for comparing variables, as appropriate. The Kaplan-Meier method was used for survival analysis. P-value of <0.05 was considered significant. Although there was no statistically significant difference, the total number of regimens and cycles was lower in the DTG than in the ITG. No differences in toxicities and survival rates were observed between the two groups. Overall, survival and toxicity did not differ significantly between the two groups. In a palliative care setting, our findings suggest that delaying the treatment had no adverse effect on survival. Despite the lack of evidence of a survival benefit with aggressive treatment, patients chose to continue chemotherapy. Because recurrent ovarian cancer is a complex condition, patients require sufficient explanation and time to fully understand the costs and benefits related to aggressive chemotherapy.	[Pyeon, Seung Yeon; Han, Gwan Hee; Ki, Kyung Do; Lee, Jong-Min] Kyung Hee Univ Hosp Gangdong, Dept Obstet & Gynecol, Seoul, South Korea; [Lee, Kwang-Beom] Gachon Univ, Gil Med Ctr, Dept Obstet & Gynecol, Coll Med, Incheon, South Korea	Kyung Hee University; Kyung Hee University Hospital; Gachon University	Lee, JM (corresponding author), Kyung Hee Univ Hosp Gangdong, Dept Obstet & Gynecol, Seoul, South Korea.	kgo02@hanmail.net		Ki, Kyung-Do/0000-0002-1060-2297; Pyeon, Seung Yeon/0000-0001-8601-1701; Lee, Jong-Min/0000-0002-0562-5443				Barbera L, 2010, GYNECOL ONCOL, V118, P196, DOI 10.1016/j.ygyno.2010.04.014; Coquan Elodie, 2012, Rev Prat, V62, P17; Corrado G, 2017, EXPERT REV ANTICANC, V17, P1147, DOI 10.1080/14737140.2017.1398088; Fauci J, 2012, GYNECOL ONCOL, V127, P175, DOI 10.1016/j.ygyno.2012.06.025; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Gadducci A, 2007, INT J GYNECOL CANCER, V17, P21, DOI 10.1111/j.1525-1438.2007.00826.x; Katsumata N, 2009, LANCET, V374, P1331, DOI 10.1016/S0140-6736(09)61157-0; National Comprehensive Cancer Network, OV CANC VERS 2; Pujade-Lauraine E, 2016, ANN ONCOL, V27, P63, DOI 10.1093/annonc/mdw079; Rustin GJS, 2010, LANCET, V376, P1155, DOI 10.1016/S0140-6736(10)61268-8; Schulkes KJG, 2018, EUR J CANCER CARE, V27, DOI 10.1111/ecc.12796; Tanner EJ, 2010, GYNECOL ONCOL, V117, P336, DOI 10.1016/j.ygyno.2010.01.014; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; Tsubamoto H, 2014, J OBSTET GYNAECOL RE, V40, P1399, DOI 10.1111/jog.12320; von Gruenigen V, 2008, CANCER, V112, P2221, DOI 10.1002/cncr.23391	15	1	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2020	15	7							e0236244	10.1371/journal.pone.0236244	http://dx.doi.org/10.1371/journal.pone.0236244			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX7VK	32701994	Green Published, gold			2023-01-03	WOS:000575913700062
J	Saeterbakken, AH; Andersen, V; van den Tillaar, R; Joly, F; Stien, N; Pedersen, H; Shaw, MP; Solstad, TEJ				Saeterbakken, Atle Hole; Andersen, Vidar; van den Tillaar, Roland; Joly, Florian; Stien, Nicolay; Pedersen, Helene; Shaw, Matthew Peter; Solstad, Tom Erik Jorung			The effects of ten weeks resistance training on sticking region in chest-press exercises	PLOS ONE			English	Article							BENCH PRESS; ELECTROMYOGRAPHIC ACTIVITY; MUSCLE ACTIVATION; FREE-WEIGHT; BACK SQUAT; STRENGTH; VELOCITY; PERFORMANCE; FORCE; FATIGUE	The aim of the study was to compare the effects of a 10-week chest-press resistance training on lifting regions in a trained exercise and a none-trained exercise; the barbell bench press (BBP). Thirty-five resistance trained men with 4.2 (+/- 2.3) years of resistance training experience were recruited. The participants were randomized to attend a resistance program, performing the chest-press, twice per week using either, Smith machine, dumbbells or laying on Swiss ball using a barbell. A six-repetitions maximum (6RM) test was conducted pre- and post-training in the trained chest-press exercise and non-trained BBP to examine lifting velocity, load displacement and the time of the pre-sticking, sticking and post-sticking regions. Additionally, the muscle activity in pectoralis major, triceps brachii, biceps brachii and deltoid anterior was examined. In the post-test, all three chest-press groups decreased lifting velocity and increased the time to reach the sticking- and post-sticking region. Independent of the type of chest-press exercise trained, no differences were observed in vertical displacement or in the muscle activity for the three lifting regions. In general, similar changes in kinematics in trained exercise and those observed in the BBP were observed for all three groups. This indicates that none of the three chest-press exercises (Swiss ball, Smith machine or dumbbells) were specific regarding the lifting regions but displaced a transferability towards the non-trained BBP. However, improved strength altered the sticking region among resistance trained men.	[Saeterbakken, Atle Hole; Andersen, Vidar; Stien, Nicolay; Pedersen, Helene; Shaw, Matthew Peter; Solstad, Tom Erik Jorung] Western Norway Univ Appl Sci, Fac Educ Arts & Sports, Sogndal, Norway; [van den Tillaar, Roland] Nord Univ, Dept Sport Sci & Phys Educ, Levanger, Norway; [Joly, Florian] Rennes Sch Sports, Rennes, France	Western Norway University of Applied Sciences; Nord University	Saeterbakken, AH (corresponding author), Western Norway Univ Appl Sci, Fac Educ Arts & Sports, Sogndal, Norway.	atle.saeterbakken@hvl.no	Shaw, Matthew/AAJ-9009-2021	Shaw, Matthew/0000-0001-8382-8011				Anderson KG, 2004, J STRENGTH COND RES, V18, P637; Anderson S, 2015, LIT LANG LEARN, P43; Augustsson J, 1998, J ORTHOP SPORT PHYS, V27, P3, DOI 10.2519/jospt.1998.27.1.3; Behm DG, 2006, J STRENGTH COND RES, V20, P716; BEHM DG, 1993, SPORTS MED, V15, P374, DOI 10.2165/00007256-199315060-00003; Bosquet L, 2010, J SPORT SCI MED, V9, P459; Clark RA, 2011, J STRENGTH COND RES, V25, P704, DOI 10.1519/JSC.0b013e3181c6a0ff; ELLIOTT BC, 1989, MED SCI SPORT EXER, V21, P450; Folland JP, 2007, SPORTS MED, V37, P145, DOI 10.2165/00007256-200737020-00004; Frost DM, 2010, SPORTS MED, V40, P303, DOI 10.2165/11319420-000000000-00000; Gonzalez-Badillo JJ, 2010, INT J SPORTS MED, V31, P347, DOI 10.1055/s-0030-1248333; Goodman CA, 2008, J STRENGTH COND RES, V22, P88, DOI 10.1519/JSC.0b013e31815ef6b3; Hakkinen K, 1998, J APPL PHYSIOL, V84, P1341, DOI 10.1152/jappl.1998.84.4.1341; HAKKINEN K, 1998, J GERONTOL A-BIOL, V53, pB41, DOI DOI 10.1093/GERONA/53A.6.B4159823737; Harriss DJ, 2017, INT J SPORTS MED, V38, P1126, DOI 10.1055/s-0043-124001; Helms ER, 2017, J STRENGTH COND RES, V31, P292, DOI 10.1519/JSC.0000000000001517; Hermens HJ, 2000, J ELECTROMYOGR KINES, V10, P361, DOI 10.1016/S1050-6411(00)00027-4; Kohler JM, 2010, J STRENGTH COND RES, V24, P313, DOI 10.1519/JSC.0b013e3181c8655a; LANDER JE, 1985, MED SCI SPORT EXER, V17, P344; MADSEN N, 1984, MED SCI SPORT EXER, V16, P376; Massey CD, 2004, J STRENGTH COND RES, V18, P518, DOI 10.1519/13263.1; McBride JM, 2010, INT J SPORT PHYSIOL, V5, P177, DOI 10.1123/ijspp.5.2.177; RUTHERFORD OM, 1986, EUR J APPL PHYSIOL O, V55, P100, DOI 10.1007/BF00422902; Saeterbakken AH, 2016, J STRENGTH COND RES, V30, P945, DOI 10.1519/JSC.0000000000001178; Saeterbakken AH, 2013, J STRENGTH COND RES, V27, P1101, DOI 10.1519/JSC.0b013e3182606d3d; Saeterbakken AH, 2011, J SPORT SCI, V29, P533, DOI 10.1080/02640414.2010.543916; Saeterbakken AH, 2011, J STRENGTH COND RES, V25, P712, DOI 10.1519/JSC.0b013e3181cc227e; Saeterbakken AH, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214302; Saeterbakken AH, 2016, EUR J APPL PHYSIOL, V116, P2247, DOI 10.1007/s00421-016-3470-3; Sakamoto A, 2012, EUR J APPL PHYSIOL, V112, P1015, DOI 10.1007/s00421-011-2059-0; THORSTENSSON A, 1976, ACTA PHYSIOL SCAND, V96, P392, DOI 10.1111/j.1748-1716.1976.tb10207.x; van den Tillaar R, 2014, J HUM KINET, V42, P63, DOI 10.2478/hukin-2014-0061; van den Tillaar R, 2014, J HUM KINET, V40, P57, DOI 10.2478/hukin-2014-0007; Van Den Tillaar R, 2013, J SPORT SCI, V31, P1823, DOI 10.1080/02640414.2013.803593; van den Tillaar R, 2013, J HUM KINET, V38, P63, DOI 10.2478/hukin-2013-0046; Van den Tillaar R, 2012, J STRENGTH COND RES, V26, P2962, DOI 10.1519/JSC.0b013e3182443430; van den Tillaar R, 2012, J SPORT SCI, V30, P591, DOI 10.1080/02640414.2012.658844; van den Tillaar R, 2010, J SPORT SCI, V28, P529, DOI 10.1080/02640411003628022; van den Tillaar R, 2009, MED SCI SPORT EXER, V41, P2056, DOI 10.1249/MSS.0b013e3181a8c360; Welsch EA, 2005, J STRENGTH COND RES, V19, P449, DOI 10.1519/14513.1; WINTER DA, 1994, J ELECTROMYOGR KINES, V4, P15, DOI 10.1016/1050-6411(94)90023-X	41	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2020	15	7							e0235555	10.1371/journal.pone.0235555	http://dx.doi.org/10.1371/journal.pone.0235555			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ0QU	32645111	Green Published, gold			2023-01-03	WOS:000552602700112
J	Prasanna, SMS; Cader, TSB; Sabalingam, S; Shanika, LGT; Samaranayake, NR				Prasanna, S. M. S.; Cader, T. S. B.; Sabalingam, S.; Shanika, L. G. T.; Samaranayake, N. R.			Are medications safely used by residents in elderly care homes? - A multi-centre observational study from Sri Lanka	PLOS ONE			English	Article							INAPPROPRIATE MEDICATION; NURSING-HOMES; OLDER-PEOPLE; ERRORS; PHARMACISTS; PREVALENCE; MEDICINES; FACILITIES; EVENTS	Background Most residents in elderly care homes in Sri Lanka do not receive formal, on-site, patient care services. Objective To evaluate the appropriateness of prescribing, dispensing, administration, and storage practices of medication used by residents in selected elderly care homes in Colombo District, Sri Lanka. Methodology This was a prospective, cross-sectional, multi-center study of 100 residents with chronic, non-communicable diseases, who resided in nine selected elderly care homes in Sri Lanka. Medication histories were obtained from each resident/caregiver and the appropriateness of medications in their current prescription was reviewed using standard treatment guidelines. Prescriptions were cross-checked against respective dispensing labels to identify dispensing errors. Medication administration was directly observed on two separate occasions per resident for accuracy of administration, and matched against the relevant prescription instructions. Medication storage was also observed in terms of exposure to temperature and sunlight, the suitability of container, and adequacy of separation if using multiple medications. Results The mean age of residents was 70 +/- 10.5 years and the majority were women (72%). A total of 168 errors out of 446 prescriptions were identified. The mean number of prescribing errors per resident was 1.68 +/- 1.23 [median, 2.00 (1.00-3.00)]. Inappropriate dosing frequencies were the highest (37.5%;63/168), followed by missing or inappropriate medications (31.5%;53/168). The mean number of dispensing errors per resident was 15.9 +/- 13.1 [median, 14.0 (6.00-22.75)] with 3.6 dispensing errors per every medication dispensed. Mean administration errors per resident was 0.95 +/- 1.5 [median, 0.00 (0.00-1.00)], with medication omissions being the predominant error (50.5%;48/95). Another lapse was incorrect storage of medications (143 storage errors), and included 83 medications not properly separated from each other (58.0%). Conclusion Multiple errors related to prescribing, dispensing, administration, and storage were identified amongst those using medication in elderly care homes. Services of a dedicated consultant pharmacist could improve the quality of medication use in elderly care homes in Sri Lanka.	[Prasanna, S. M. S.; Cader, T. S. B.; Sabalingam, S.; Shanika, L. G. T.; Samaranayake, N. R.] Univ Sri Jayewardenepura, Dept Pharm & Pharmaceut Sci, Fac Allied Hlth Sci, Nugegoda, Sri Lanka	University Sri Jayewardenepura	Samaranayake, NR (corresponding author), Univ Sri Jayewardenepura, Dept Pharm & Pharmaceut Sci, Fac Allied Hlth Sci, Nugegoda, Sri Lanka.	nithushi@sjp.ac.lk		Shanika, LGT/0000-0003-3539-4735				Alldred DP, 2011, BMJ QUAL SAF, V20, P397, DOI 10.1136/bmjqs.2010.046318; [Anonymous], 2009, NURS STAND, V23, P17, DOI DOI 10.7748/NS.23.38.17.S19; [Anonymous], 2016, BRIT NAT FORM BNF 71; [Anonymous], 2019, LOG TERM CAR PROV SE; [Anonymous], 2016, ANN HLTH B; [Anonymous], 2016, CANC DISCOV; Aslam A., 2016, J PHARM PRACT COMMUN, V2, P54; Athuraliya N, 2016, J Pharm Policy Pract, V9, P38; Australian Medicines Handbook Pty Ltd. issuing body, 2016, AUSTR MED HDB; Bao YH, 2012, J GEN INTERN MED, V27, P304, DOI 10.1007/s11606-011-1905-4; Barber ND, 2009, QUAL SAF HEALTH CARE, V18, P341, DOI 10.1136/qshc.2009.034231; Berhanu Geresu, 2014, African Journal of Pharmacy and Pharmacology, V8, P1132; Crotty Maria, 2004, Am J Geriatr Pharmacother, V2, P257, DOI 10.1016/j.amjopharm.2005.01.001; Ferrah N, 2017, J AM GERIATR SOC, V65, P433, DOI 10.1111/jgs.14683; Hanlon JT, 2004, ANN PHARMACOTHER, V38, P9, DOI 10.1345/aph.1D313; Hasan SS, 2017, MEDICINE, V96, P35; Haw C, 2007, INT J QUAL HEALTH C, V19, P210, DOI 10.1093/intqhc/mzm019; Hewson C, 2013, J PRIM HEALTH CARE, V5, P146, DOI 10.1071/HC13146; Jensen J, 2002, ANN INTERN MED, V136, P733, DOI 10.7326/0003-4819-136-10-200205210-00008; Jordan S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140203; Kapoor A, 2019, JAMA INTERN MED, V179, P1254, DOI 10.1001/jamainternmed.2019.2005; Kheir N, 2011, DRUG HEALTHC PATIENT, V3, P99, DOI 10.2147/DHPS.S25372; Mahlknecht A, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1263-3; Manchanayake MGCA, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3252-1; Martins RR, 2017, REV SAUDE PUBL, V51, DOI [10.11606/S1518-8787.2017051000053, 10.11606/s1518-8787.2017051000053]; Oliva A, 1996, INT J PHARM, V143, P163, DOI 10.1016/S0378-5173(96)04700-X; Parsons C, 2011, INT J OLDER PEOPLE N, V6, P45, DOI 10.1111/j.1748-3743.2010.00264.x; Perera Dhineli Michelle Patricia, 2017, Journal of Pharmacy Practice and Research, V47, P121, DOI 10.1002/jppr.1302; Pharmaceutical Society of Australia, 2009, AUSTR PHARM FORM HDB; Rousseau A, 2016, REV EPIDEMIOL SANTE, V64, P95, DOI 10.1016/j.respe.2015.12.016; Salmasi S, 2018, DRUGS THER PERSPECT, V34, P129, DOI 10.1007/s40267-017-0468-9; Sarkar U, 2011, HEALTH SERV RES, V46, P1517, DOI 10.1111/j.1475-6773.2011.01269.x; Shanika LGT, 2018, B WORLD HEALTH ORGAN, V96, P155, DOI 10.2471/BLT.17.198366; Siddhisena KAP, 2004, WP105 OXF I AG; Storms H, 2017, EUR J GEN PRACT, V23, P69, DOI 10.1080/13814788.2017.1288211; Szczepura A, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-82; Tariq A, 2016, BMJ QUAL SAF, V25, P704, DOI 10.1136/bmjqs-2015-004589; Thirumagal M, 2017, POSTGRAD MED J, V93, P686, DOI 10.1136/postgradmedj-2017-134848; United Nations, 2017, AGEING POPULATION SR; Verrue CLR, 2009, DRUG AGING, V26, P37, DOI 10.2165/0002512-200926010-00003; World Health Organization, 2002, ACT AG POL FRAM; World Health Organization South East Asian Regional Office, COUNTR SIT AN MED MA; Yousif M, 2002, HOME DRUG STORAGE UT; Zermansky AG, 2006, AGE AGEING, V35, P586, DOI 10.1093/ageing/afl075	44	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2020	15	6							e0233486	10.1371/journal.pone.0233486	http://dx.doi.org/10.1371/journal.pone.0233486			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MA6PX	32497110	gold, Green Published			2023-01-03	WOS:000542035200082
J	Kolin, DA; Shakur-Still, H; Bello, A; Chaudhri, R; Bates, I; Roberts, I				Kolin, David A.; Shakur-Still, Haleema; Bello, Adenike; Chaudhri, Rizwana; Bates, Imelda; Roberts, Ian			Risk factors for blood transfusion in traumatic and postpartum hemorrhage patients: Analysis of the CRASH-2 and WOMAN trials	PLOS ONE			English	Article							RED-CELL TRANSFUSIONS; WOMEN; PREDICTION; ANEMIA; POLICY; UNIT	Background Hemorrhage is a leading cause of death after trauma and childbirth. In response to severe hemorrhage, bleeding patients often receive transfusions of red blood cells, plasma, platelets, or other blood components. We examined risk factors for transfusion in acute severe bleeding in two trials of over 20,000 patients to better understand factors associated with transfusion likelihood. Study design and methods We conducted a cohort analysis of data from the CRASH-2 and WOMAN trials, two multinational trials that recruited patients with traumatic and postpartum hemorrhage, respectively. For each trial, we examined the effect of 10 factors on blood transfusion likelihood. Univariate and multivariate Poisson regressions were used to analyze the relationship between risk factors and blood transfusion. Results Of the 20,207 traumatic hemorrhage patients, 10,232 (51%) received blood components. Of the 20,060 women with postpartum hemorrhage, 10,958 (55%) received blood components. For patients who suffered from traumatic hemorrhage, those greater than three hours from injury to hospitalization were more likely to be transfused (ARR 1.37; 95% CI, 1.20-1.56). Postpartum hemorrhage patients had an increased likelihood of transfusion if they gave birth outside the hospital (ARR 1.30; 95% CI 1.22-1.39), gave birth more than three hours before hospitalization (ARR 1.09; 95% CI 1.01-1.17), had a Caesarean section (ARR 1.16; 95% CI 1.08-1.25), and if they had any identifiable causes of hemorrhage other than uterine atony. Conclusion Several risk factors are associated with an increased likelihood of transfusion in traumatic and postpartum hemorrhage patients. Altering modifiable factors, by reducing time from injury or childbirth to hospitalization, for example, might be able to reduce transfusions and their complications. Trial registration CRASH-2 is registered as ISRCTN86750102, ClinicalTrials.gov NCT00375258 and South African Clinical Trial Register DOH-27-0607-1919. WOMAN is registered as ISRCTN76912190, ClinicalTrials.gov NCT00872469, PACTR201007000192283, and EudraCT number 2008-008441-38.	[Kolin, David A.; Shakur-Still, Haleema; Roberts, Ian] London Sch Hyg & Trop Med, Dept Populat Hlth, Clin Trials Unit, London, England; [Bello, Adenike] Univ Ibadan, Dept Obstet & Gynecol, Ibadan, Nigeria; [Chaudhri, Rizwana] Rawalpindi Med Univ, Dept Obstet & Gynecol, Rawalpindi, Pakistan; [Bates, Imelda] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England	University of London; London School of Hygiene & Tropical Medicine; University of Ibadan; Liverpool School of Tropical Medicine	Kolin, DA (corresponding author), London Sch Hyg & Trop Med, Dept Populat Hlth, Clin Trials Unit, London, England.	david.kolin1@alumni.lshtm.ac.uk			UK NIHR Health Technology Assessment Programme; Pfizer; BUPA Foundation; J P Moulton Charitable Foundation; London School of Hygiene & Tropical Medicine; Department of Health [HICF-T2-0510-007]; Wellcome Trust [WT094947]; Bill & Melinda Gates Foundation [OPP1095618]; Rotary Foundation Global Grant Scholarship	UK NIHR Health Technology Assessment Programme(National Institute for Health Research (NIHR)); Pfizer(Pfizer); BUPA Foundation; J P Moulton Charitable Foundation; London School of Hygiene & Tropical Medicine; Department of Health; Wellcome Trust(Wellcome Trust); Bill & Melinda Gates Foundation(Bill & Melinda Gates FoundationCGIAR); Rotary Foundation Global Grant Scholarship	Funding for the CRASH-2 trial was provided by the UK NIHR Health Technology Assessment Programme (https://www.nihr.ac.uk/explore-nihr/funding-programmes/health-technology-assessment.htm), Pfizer (https://www.pfizer.com/), the BUPA Foundation (https://www.bupaukfoundation.org/), and the J P Moulton Charitable Foundation http://www.perscitusllp.com/moulton-charitable-foundation/). Funding for the WOMAN trial was provided by London School of Hygiene & Tropical Medicine (lshtm.ac.uk), Pfizer (https://www.pfizer.com/), Department of Health (grant number HICF-T2-0510-007) (https://www.gov.uk/government/organisations/department-of-health-and-social-care), the Wellcome Trust (grant number WT094947) (https://wellcome.ac.uk/), and The Bill & Melinda Gates Foundation (grant number OPP1095618) (https://www.gatesfoundation.org/).Additional funding support was provided by the Rotary Foundation Global Grant Scholarship. All authors received all awards, except for the Rotary Foundation Global Grant Scholarship, which was solely received by DAK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akingbola TS, 2016, HEMATOLOGY TRANSFUSI, V2; [Anonymous], 2017, LANCET HIV, V2, pe115; [Anonymous], 2015, BMJ, V350, ph1033; [Anonymous], 2014, ATMOS CHEM PHYS DISC, V14, pC9360; Balarajan Y, 2011, LANCET, V378, P2123, DOI 10.1016/S0140-6736(10)62304-5; Benedict Nwogoh, 2012, J Lab Physicians, V4, P94, DOI 10.4103/0974-2727.105589; Berger MD, 2012, HAEMATOL-HEMATOL J, V97, P116, DOI 10.3324/haematol.2011.047035; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Carroli G, 2008, BEST PRACT RES CL OB, V22, P999, DOI 10.1016/j.bpobgyn.2008.08.004; Carson JL, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002042.pub4; Chen WS, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0519-5; Cheraghali AM, 2011, HEPAT MON, V11, P422; COMBS CA, 1991, OBSTET GYNECOL, V77, P69; CRASH Trials Co-ordinating Centre Management Group, 2005, CRASH 2 CLIN RAND AN; Curry N, 2011, CRIT CARE, V15, DOI 10.1186/cc10096; Custer B, 2018, TRANSFUSION, V58, P1307, DOI 10.1111/trf.14598; Estcourt LJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011305.pub2; Evensen A, 2017, AM FAM PHYSICIAN, V95, P442; Frass KA, 2015, ALEX J MED, V51, P333, DOI 10.1016/j.ajme.2014.12.002; Frith D, 2010, J THROMB HAEMOST, V8, P1919, DOI 10.1111/j.1538-7836.2010.03945.x; Gosselin RA, 2009, B WORLD HEALTH ORGAN, V87, P246, DOI 10.2471/BLT.08.052290; Gutierrez G, 2004, CRIT CARE, V8, P373, DOI 10.1186/cc2851; Heyes J, 2017, QJM-INT J MED, V110, P735, DOI 10.1093/qjmed/hcx150; Hirano Y, 2019, CRIT CARE, V23, DOI 10.1186/s13054-019-2543-1; Hong Deok-Ho, 2016, Obstet Gynecol Sci, V59, P103, DOI 10.5468/ogs.2016.59.2.103; Kralievits KE, 2015, LANCET, V385, P28; Kyeyune-Byabazaire D, 2019, ISBT SCI SERIES, V14, P104; Magann EF, 2005, SOUTH MED J, V98, P419, DOI 10.1097/01.SMJ.0000152760.34443.86; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Mousa HA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003249.pub3; National Heart Lung and Blood Institute, BLOOD TRANSFUSION; Nunez TC, 2009, J TRAUMA, V66, P346, DOI 10.1097/TA.0b013e3181961c35; Oya Atsuko, 2008, Journal of Nippon Medical School, V75, P146, DOI 10.1272/jnms.75.146; Paydar Shahram, 2016, Bull Emerg Trauma, V4, P121; Roberts DJ, 2016, HEMATOL ONCOL CLIN N, V30, P477, DOI 10.1016/j.hoc.2015.11.011; Roberts I, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1794-1; Rossaint R, 2010, CRIT CARE, V14, DOI 10.1186/cc8943; Schroll R, 2017, INJURY; Sebghati M, 2017, WOMENS HEALTH, V13, P34, DOI 10.1177/1745505717716860; Shakur H, 2017, LANCET, V389, P2105, DOI 10.1016/S0140-6736(17)30638-4; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Sharma S, 2011, AM FAM PHYSICIAN, V83, P719; Sibinga CTS, 2019, TRANSFUSION, V59, P2155, DOI 10.1111/trf.15224; Snelgrove John W, 2009, Mcgill J Med, V12, P61; Thakkar RN, 2017, J HOSP MED, V12, P747, DOI 10.12788/jhm.2806; The WOMAN Trial Protocol Committee, 2014, TRAN AC TREATM POSTP; Trinh LTT, 2007, ASIA PAC J CLIN NUTR, V16, P310; Wikkelso AJ, 2014, J MATERN-FETAL NEO M, V27, P1661, DOI 10.3109/14767058.2013.872095; World Health Organization, 2004, SCAL PROBL GLOB BURD; World Health Organization, 2016, GLOB STAT REP BLOOD; World Health Organization, 2012, WHO REC PREV TREATM; Wu SC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216153; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090; 2015, CANC FACTS FIGURES, V2015, P4	54	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2020	15	6							e0233274	10.1371/journal.pone.0233274	http://dx.doi.org/10.1371/journal.pone.0233274			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW6ZP	32492040	Green Published, Green Accepted, gold			2023-01-03	WOS:000539293000021
J	Feng, YP; Yang, TS; Chung, CH; Chien, WC; Wong, CS				Feng, Yu-Pin; Yang, Tsorng-Shyang; Chung, Chi-Hsiang; Chien, Wu-Chien; Wong, Chih-Shung			Early childhood general anesthesia exposure associated with later developmental delay: A national population-based cohort study	PLOS ONE			English	Article							CHILDREN; AGE; LANGUAGE; SURGERY; DISORDER; OUTCOMES; SINGLE; BRAIN; RISK	Exposure to general anesthesia has been reported to induce neurotoxicity, impair learning, memory, attention, motor functions, as well as affect behavior in adult rodents and nonhuman primates. Though many have speculated similar effects in humans, previous literature has shown conflicting findings. To investigate the differences in risk of developmental delay among young children exposed to general anesthesia compared to matched unexposed individuals, a population-based cohort study was conducted with a longitudinal dataset spanning 2000 to 2013 from the Taiwan National Health Insurance Research Database (NHIRD). Procedure codes were used to identify children who received anesthesia. For each exposed child, two unexposed children matched by gender and age were enrolled into the comparison cohort. Neurocognitive outcome was measured by the presence of ICD-9-CM codes related to developmental delay (DD). Cox regression models were used to obtain hazard ratios of developing DD after varying levels of anesthesia exposure. After excluding 4,802 individuals who met the exclusion criteria, a total of 11,457 children who received general anesthesia before two years of age was compared to 22,914 children (matched by gender and age) unexposed to anesthesia. Increased risk of DD was observed in the exposure group with a hazard ratio (HR) of 1.320 (95% CI 1.143-1.522, P < 0.001). Subgroup analysis demonstrated further elevated risks of DD with multiple anesthesia exposures (1 anesthesia event: HR 1.145, 95% CI 1.010-1.246, P = 0.04; 2 anesthesia events: HR 1.476, 95% CI 1.155-1.887, P = 0.005; >= 3 anesthesia events: HR 2.222, 95% CI 1.810-2.621, P < 0.001) and longer total anesthesia durations (Total anesthesia <2 hours: HR 1.124, 95% CI 1.003-1.499, P = 0.047; Total anesthesia 2-4 hours: HR 1.450, 95% CI 1.157-1.800, P = 0.004; Total anesthesia > 4 hours: HR 1.598, 95% CI 1.343-1.982, P < 0.001) compared with children unexposed to anesthesia. These results suggest that children exposed to general anesthesia before two years of age have an increased risk of DD. This risk is further elevated with increased frequency of anesthesia, and longer total anesthesia duration. The findings of this study should prompt clinical practitioners to proceed with caution when assessing young patients and planning managements involving procedures requiring general anesthesia.	[Feng, Yu-Pin] Cathay Gen Hosp Xizhi, Dept Anesthesiol, New Taipei, Taiwan; [Yang, Tsorng-Shyang; Wong, Chih-Shung] Cathay Gen Hosp, Dept Anesthesiol, Taipei, Taiwan; [Chung, Chi-Hsiang; Chien, Wu-Chien] Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan; [Chung, Chi-Hsiang] Taiwanese Injury Prevent & Safety Promot Assoc TI, Taipei, Taiwan; [Chien, Wu-Chien] Natl Def Med Ctr, Triserv Gen Hosp, Dept Med Res, Taipei, Taiwan; [Chien, Wu-Chien] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan	Cathay General Hospital; National Defense Medical Center; National Defense Medical Center; Tri-Service General Hospital; National Defense Medical Center	Wong, CS (corresponding author), Cathay Gen Hosp, Dept Anesthesiol, Taipei, Taiwan.; Chien, WC (corresponding author), Natl Def Med Ctr, Sch Publ Hlth, Taipei, Taiwan.; Chien, WC (corresponding author), Natl Def Med Ctr, Triserv Gen Hosp, Dept Med Res, Taipei, Taiwan.; Chien, WC (corresponding author), Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan.	chienwu@ndmctsgh.edu.tw; w82556@gmail.com	Chung, Chi-Hsiang/AAY-3386-2021		Tri-Service General Hospital Research Foundation [TSGH C108-003]	Tri-Service General Hospital Research Foundation	Initials of the authors who received each award: WCC. Grant numbers awarded to each author: TSGH C108-003. The full name of each funder: Tri-Service General Hospital Research Foundation. URL of each funder website: https://www.google.com/url?sa=t&rct=j&q=&esrc= s&source=web&cd=4&cad=rja&uact=8&ved= 2ahUKEwiU1oLOiqnfAhUKE7wKHWloAvwQFjADegQICRAB&url=https%3A%2F%2Fwww.tsgh.ndmctsgh.edu.tw%2F&usg= AOvVaw16mt5MD9ugrukObCZqDCdC The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abubakar A, 2010, J CHILD PSYCHOL PSYC, V51, P652, DOI 10.1111/j.1469-7610.2009.02193.x; Amrock LG, 2015, ANESTHESIOLOGY, V122, P87, DOI 10.1097/ALN.0000000000000477; [Anonymous], 2015, MEDICINE, V94, pe1435; Baumer FM, 2018, J PEDIATR-US, V194, P13, DOI 10.1016/j.jpeds.2017.10.031; Bellinger DC, 2003, J THORAC CARDIOV SUR, V126, P1385, DOI 10.1016/S0022-5223(03)00711-6; Caplan R, 2009, EPILEPSIA, V50, P2397, DOI 10.1111/j.1528-1167.2009.02199.x; Davidson AJ, 2015, PEDIATR ANESTH, V25, P447, DOI 10.1111/pan.12652; Deng M, 2014, BRIT J ANAESTH, V113, P443, DOI 10.1093/bja/aet469; [鄂亚佳 E Yajia], 2011, [内燃机工程, Chinese Internal Combustion Engine Engineering], V32, P63; Flick RP, 2011, PEDIATRICS, V128, pE1053, DOI 10.1542/peds.2011-0351; Glatz P, 2017, JAMA PEDIATR, V171, DOI 10.1001/jamapediatrics.2016.3470; Graham MR, 2016, ANESTHESIOLOGY, V125, P667, DOI 10.1097/ALN.0000000000001245; Hong Eun Pyo, 2012, Genomics & Informatics, V10, P117, DOI 10.5808/GI.2012.10.2.117; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Ing C, 2017, BRIT J ANAESTH, V119, P532, DOI 10.1093/bja/aew413; Ing C, 2017, ANESTH ANALG, V125, P1988, DOI 10.1213/ANE.0000000000002423; Jevtovic-Todorovic V, 2003, J NEUROSCI, V23, P876, DOI 10.1523/jneurosci.23-03-00876.2003; Jevtovic-Todorovic V, 2018, ANESTHESIOLOGY, V128, P832, DOI 10.1097/ALN.0000000000002047; Ko WR, 2015, EUR J ANAESTH, V32, P303, DOI 10.1097/EJA.0000000000000130; Kuo HT, 2015, NEUROPSYCH DIS TREAT, V11, DOI 10.2147/NDT.S84088; Lee JR, 2017, BRIT J ANAESTH, V119, P492, DOI 10.1093/bja/aex219; Luna Ruth Ann, 2016, Curr Dev Disord Rep, V3, P75; Nithianantharajah Jess, 2017, Curr Dev Disord Rep, V4, P28, DOI 10.1007/s40474-017-0111-4; Noguchi KK, 2017, BRIT J ANAESTH, V119, P524, DOI 10.1093/bja/aex123; Noguchi KK, 2016, SCI REP-UK, V6, DOI 10.1038/srep22427; O'Leary JD, 2016, ANESTHESIOLOGY, V125, P272, DOI 10.1097/ALN.0000000000001200; Paule MG, 2011, NEUROTOXICOL TERATOL, V33, P220, DOI 10.1016/j.ntt.2011.01.001; Rothman KJ, 2012, MODERN EPIDEMIOLOGY; Startin CM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131604; Sun LS, 2016, JAMA-J AM MED ASSOC, V315, P2312, DOI 10.1001/jama.2016.6967; Tai D, 2006, ARCH PEDIAT ADOL MED, V160, P293, DOI 10.1001/archpedi.160.3.293; Tai YM, 2009, INT J MED INFORM, V78, pE75, DOI 10.1016/j.ijmedinf.2009.09.005; Wilder RT, 2009, ANESTHESIOLOGY, V110, P796, DOI 10.1097/01.anes.0000344728.34332.5d; Woodward M., EPIDEMIOLOGY STUDY D, VSecond ed.	34	13	13	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2020	15	9							e0238289	10.1371/journal.pone.0238289	http://dx.doi.org/10.1371/journal.pone.0238289			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY2ZZ	32970686	gold, Green Published			2023-01-03	WOS:000576265600074
J	Terada-Ikeda, C; Kitabatake, M; Hiraku, A; Kato, K; Yasui, S; Imakita, N; Ouji-Sageshima, N; Iwabuchi, N; Hamada, K; Ito, T				Terada-Ikeda, Chiyoko; Kitabatake, Masahiro; Hiraku, Akari; Kato, Kumiko; Yasui, Satsuki; Imakita, Natsuko; Ouji-Sageshima, Noriko; Iwabuchi, Noriyuki; Hamada, Kaoru; Ito, Toshihiro			Maternal supplementation with Bifidobacterium breve M-16V prevents their offspring from allergic airway inflammation accelerated by the prenatal exposure to an air pollutant aerosol	PLOS ONE			English	Article							JAPANESE CEDAR POLLINOSIS; IMMUNE-RESPONSES; GUT MICROBIOTA; ASTHMA; PARTICLES; PREGNANCY; MICE; TRANSMISSION; PROBIOTICS; SYMPTOMS	Bifidobacterium breveM-16V is a probiotic bacterial strain with efficacy in infants achieved by suppressing T-helper type (Th) 2 immune responses and modulating the systemic Th1/Th2 balance. Exposure to air pollution during pregnancy increases asthma susceptibility in offspring. The aim of this study was to investigate the effects of the maternal intake ofB.breveM-16V on susceptibility to asthma accelerated by prenatal exposure to air pollution. The intake ofB.breveM-16V in residual oil fly ash (ROFA)-exposed pregnant mice resulted in fewer eosinophils in the bronchoalveolar lavage fluid of neonatal mice and reduced allergic lung inflammation. The expressions of Th2 cytokines including IL-5 and IL-13 were decreased in neonatal mice from ROFA-exposed mothers fedB.breveM-16V. The analysis of fecal microbiota from neonatal mice revealed that the intake ofB.breveM-16V by mothers changed the composition of fecal microbiota in neonatal mice, which resulted in a decreased population ofFirmicutes. Moreover, several bacterial strains of fecal microbiota from neonatal mice had a strong correlation with Th2 cytokines and histological score. These results suggest that the maternal intake of M-16V might have beneficial effects in neonates by preventing and/or alleviating allergic reactions accelerated by prenatal exposure to air pollution.	[Terada-Ikeda, Chiyoko; Kitabatake, Masahiro; Yasui, Satsuki; Imakita, Natsuko; Ouji-Sageshima, Noriko; Ito, Toshihiro] Nara Med Univ, Dept Immunol, Kashihara, Nara, Japan; [Hiraku, Akari; Iwabuchi, Noriyuki] Morinaga Milk Ind Co Ltd, R&D Div, Food Ingredients & Technol Inst, Zama, Japan; [Kato, Kumiko] Morinaga Milk Ind Co Ltd, R&D Div, Next Generat Sci Inst, Zama, Japan; [Hamada, Kaoru] Nara Med Univ, Fac Nursing, Dept Clin & Invest Med, Kashihara, Nara, Japan	Nara Medical University; Morinaga Milk Industry Company, Ltd; Morinaga Milk Industry Company, Ltd; Nara Medical University	Ito, T (corresponding author), Nara Med Univ, Dept Immunol, Kashihara, Nara, Japan.	toshi-ito@naramed-u.ac.jp			Morinaga Milk Industry Co., Ltd.	Morinaga Milk Industry Co., Ltd.	This study was supported by research grants from Morinaga Milk Industry Co., Ltd. The funder provided support in the form of salaries for A. Hiraku, K. Kato and N. Iwabuchi, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Abe F, 2010, ANAEROBE, V16, P131, DOI 10.1016/j.anaerobe.2009.07.006; Boyle RJ, 2011, ALLERGY, V66, P509, DOI 10.1111/j.1398-9995.2010.02507.x; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Cavani A, 2003, J IMMUNOL, V171, P5760, DOI 10.4049/jimmunol.171.11.5760; Coretti L, 2017, SCI REP-UK, V7, DOI 10.1038/srep45356; Corson Lin, 2010, Allergy Asthma Clin Immunol, V6, P7, DOI 10.1186/1710-1492-6-7; Demirci M, 2019, ALLERGOL IMMUNOPATH, V47, P365, DOI 10.1016/j.aller.2018.12.009; Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x; Durack J, 2018, J ALLERGY CLIN IMMUN, V141, P82, DOI 10.1016/j.jaci.2017.05.026; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Fedulov AV, 2008, AM J RESP CELL MOL, V38, P57, DOI 10.1165/rcmb.2007-0124OC; Frati F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010123; Gern JE, 1999, J CLIN INVEST, V104, P837, DOI 10.1172/JCI8272; Gregory DJ, 2017, AM J PHYSIOL-LUNG C, V313, pL395, DOI 10.1152/ajplung.00035.2017; Hamada K, 2003, J IMMUNOL, V170, P1683, DOI 10.4049/jimmunol.170.4.1683; Hamada K, 2000, AM J RESP CRIT CARE, V161, P1285, DOI 10.1164/ajrccm.161.4.9906137; Hamada K, 2007, J TOXICOL ENV HEAL A, V70, P688, DOI 10.1080/15287390600974692; Hattori Kazuhiro, 2003, Arerugi, V52, P20; Heul AV, 2019, CLIN REV ALLERG IMMU, V57, P350, DOI 10.1007/s12016-018-8719-7; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Hougee S, 2010, INT ARCH ALLERGY IMM, V151, P107, DOI 10.1159/000236000; Imakita N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36489-8; Inoue Y, 2009, BIOL PHARM BULL, V32, P760, DOI 10.1248/bpb.32.760; ITO T, 2005, ALLERGOL INT, V54, P601; Ito T, 2007, EUR J IMMUNOL, V37, P2847, DOI 10.1002/eji.200737603; Izumi H, 2015, PEDIATR RES, V78, P407, DOI 10.1038/pr.2015.115; Julia V, 2015, NAT REV IMMUNOL, V15, P308, DOI 10.1038/nri3830; Kubo M, 2017, IMMUNOL REV, V278, P162, DOI 10.1111/imr.12557; Kuczynski J, 2012, CURR PROTOC CHEM BIO, V1, P1, DOI DOI 10.1002/9780471729259.MC01E05S27.USING; Lambrecht BN, 2019, IMMUNITY, V50, P975, DOI 10.1016/j.immuni.2019.03.018; Larose MC, 2017, FRONT MED-LAUSANNE, V4, DOI 10.3389/fmed.2017.00136; Li XX, 2020, HEPATOL RES, V50, P5, DOI 10.1111/hepr.13444; Li YD, 2004, PEDIATR INT, V46, P509, DOI 10.1111/j.1442-200x.2004.01953.x; Manners S, 2014, J ALLERGY CLIN IMMUN, V134, P63, DOI 10.1016/j.jaci.2013.10.047; McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139; Odamaki T, 2007, J MED MICROBIOL, V56, P1301, DOI 10.1099/jmm.0.47306-0; Odamaki T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18391-x; Patole SK, 2016, DIABETOL STOFFWECHS, V11, pe0150775; Ptaschinski C, 2015, PLOS PATHOG, V11, DOI 10.1371/journal.ppat.1004978; Rautava S, 2012, J ALLERGY CLIN IMMUN, V130, P1355, DOI 10.1016/j.jaci.2012.09.003; Saraf MK, 2017, MICROBIOME, V5, DOI 10.1186/s40168-017-0297-z; Sjodin KS, 2016, CURR OPIN ALLERGY CL, V16, P390, DOI 10.1097/ACI.0000000000000277; Snyder JE, 2000, TOXICOL SCI, V57, P87, DOI 10.1093/toxsci/57.1.87; Steerenberg PA, 2003, J TOXICOL ENV HEAL A, V66, P1421, DOI 10.1080/15287390306415; Taniuchi S., 2005, Journal of Applied Research, V5, P387; Tannock GW, 2013, APPL ENVIRON MICROB, V79, P3040, DOI 10.1128/AEM.03910-12; Thorburn AN, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8320; van der Aa LB, 2011, ALLERGY, V66, P170, DOI 10.1111/j.1398-9995.2010.02416.x; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Wang X, 2017, DIABETOLOGIE STOF S2, V12, pe0171721; Wong CB, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081724; Xiao JZ, 2006, CLIN EXP ALLERGY, V36, P1425, DOI 10.1111/j.1365-2222.2006.02575.x	53	12	12	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2020	15	9							e0238923	10.1371/journal.pone.0238923	http://dx.doi.org/10.1371/journal.pone.0238923			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR9MU	32915886	Green Published, gold			2023-01-03	WOS:000571887500025
J	Philip, KEJ; Katagira, W; Jones, R				Philip, Keir E. J.; Katagira, Winceslaus; Jones, Rupert			Dance for Respiratory Patients in Low-Resource Settings	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								This Arts and Medicine feature describes the integration of local dance traditions into pulmonary rehabilitation programs for COPD and tuberculosis patients in low- and middle-income countries.	[Philip, Keir E. J.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Philip, Keir E. J.] UCL, Dept Behav Sci & Hlth, London, England; [Katagira, Winceslaus; Jones, Rupert] Makerere Univ, Makerere Lung Inst, Kampala, Uganda; [Jones, Rupert] Plymouth Univ, Fac Hlth, Plymouth, Devon, England	Imperial College London; University of London; University College London; Makerere University; University of Plymouth	Philip, KEJ (corresponding author), Natl Heart & Lung Inst, Muscle Lab, Royal Brompton Campus, London SW3 6NP, England.	keir.philip@imperial.ac.uk		Philip, Keir/0000-0001-9614-3580	Imperial College Clinician Investigator Scholarship; UK National Institute for Health Research Applied Research Collaboration SouthWest Peninsula (PenARC)	Imperial College Clinician Investigator Scholarship; UK National Institute for Health Research Applied Research Collaboration SouthWest Peninsula (PenARC)	Dr Phillip is supported by the Imperial College Clinician Investigator Scholarship. Dr Jones' research is supported by the UK National Institute for Health Research Applied Research Collaboration SouthWest Peninsula (PenARC).	Ferkol Thomas, 2014, Ann Am Thorac Soc, V11, P404, DOI 10.1513/AnnalsATS.201311-405PS; Hwang PWN, 2015, ALTERN THER HEALTH M, V21, P64; Lewis A, 2016, NPJ PRIM CARE RESP M, V26, DOI 10.1038/npjpcrm.2016.80; McCarthy B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub3; Murrock CJ, 2014, J AGING PHYS ACTIV, V22, P380, DOI [10.1123/JAPA.2013-0003, 10.1123/japa.2013-0003]; Philip K, 2019, BREATHE, V15, P116, DOI 10.1183/20734735.0007-2019; Rodrigues-Krause J, 2019, ALTERN THER HEALTH M, V25, P44; Wshah A, 2019, J CARDIOPULM REHABIL, V39, pE14, DOI 10.1097/HCR.0000000000000428	8	6	6	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 8	2020	324	10					921	922		10.1001/jama.2020.15426	http://dx.doi.org/10.1001/jama.2020.15426			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NR9EX	32897325				2023-01-03	WOS:000571867000001
J	Mahoney, K; Pierce, J; Papo, S; Imran, H; Evans, S; Wu, WC				Mahoney, Kayla; Pierce, Jacqueline; Papo, Stacey; Imran, Hafiz; Evans, Samuel; Wu, Wen-Chih			Efficacy of adding activity of daily living simulation training to traditional pulmonary rehabilitation on dyspnea and health-related quality-of-life	PLOS ONE			English	Article							DISEASE; STATEMENT	Introduction Exercise modalities offered as part of traditional pulmonary rehabilitation (PR) do not always translate to successful performance of Activities of Daily Living (ADL) and may hinder gains in patient's sense of well-being. Data is lacking on the efficacy of incorporation of ADL-focused training in PR. The aim of this study was to determine the impact of incorporation of ADL simulation and energy-conservation training in PR as part of a quality-initiative on health-related-quality-of-life (HRQOL), dyspnea, fatigue, and six-minute-walk-test among PR patients. Methods Retrospective study where medical records of consecutive patients with chronic respiratory diseases who completed PR from 2016 to 2018 were reviewed. ADL-focused energy-conservation training was added to traditional PR in September 2017 by replacing three monthly sessions of traditional PR with energy-conservation training as a quality-improvement-initiative. The change from baseline on HRQOL measured by COPD assessment test (CAT), six-minute-walk-test, MMRC dyspnea score and CRQ-dyspnea and CRQ-fatigue questionnaires, were compared between patients who received traditional PR versus energy-conservation PR. Within and between group differences were calculated via repeated-measures ANOVA. Results The baseline characteristics of 91 patients who participated in traditional PR versus energy-conservation PR (n = 85) were similar (mean age = 68.6 +/- 10.4 years, 49% men). While improvement from baseline was similar and significant for both groups for MMRC, CRQ-dyspnea and CRQ-fatigue scores, and six-minute walk test, patients who participated in energy-conservation PR had significantly higher improvement in HRQOL CAT scores (p = 0.01) than those who completed traditional PR. Conclusion Tailoring patient's training programs to include energy-conservation training exercises specific to ADL in PR improved HRQOL over traditional PR in patients with chronic respiratory diseases despite no significant change in functional status. Future randomized-controlled trials will be needed to confirm these initial findings.	[Mahoney, Kayla; Pierce, Jacqueline; Imran, Hafiz; Wu, Wen-Chih] Miriam Hosp, Ctr Cardiovasc & Pulm Rehabil, Providence, RI 02906 USA; [Papo, Stacey; Evans, Samuel] Newport Hosp, Cardiovasc & Pulm Rehabil, Newport, RI USA; [Imran, Hafiz; Wu, Wen-Chih] Providence VA Med Ctr, Providence, RI 02908 USA	Lifespan Health Rhode Island; Miriam Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Providence VA Medical Center	Wu, WC (corresponding author), Miriam Hosp, Ctr Cardiovasc & Pulm Rehabil, Providence, RI 02906 USA.; Wu, WC (corresponding author), Providence VA Med Ctr, Providence, RI 02908 USA.	wen-chih_wu@brown.edu		Wu, Wen-Chih/0000-0002-2834-2024				Bestall JC, 1999, THORAX, V54, P581, DOI 10.1136/thx.54.7.581; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Garvey C, 2016, J CARDIOPULM REHABIL, V36, P75, DOI 10.1097/HCR.0000000000000171; Gruet M, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01285; Gupta N, 2014, EUR RESPIR J, V44, P873, DOI 10.1183/09031936.00025214; Holland AE, 2013, EUR RESPIR REV, V22, P577, DOI 10.1183/09059180.00005613; Kaplan Robert M, 2008, Proc Am Thorac Soc, V5, P561, DOI 10.1513/pats.200706-080ET; Martinsen U, 2017, SCAND J OCCUP THER, V24, P89, DOI 10.3109/11038128.2016.1158316; McCarthy B, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003793.pub3; Nici L, 2014, CLIN CHEST MED, V35, P279, DOI 10.1016/j.ccm.2014.02.008; Rochester CL, 2015, AM J RESP CRIT CARE, V192, P1373, DOI 10.1164/rccm.201510-1966ST; Sewell L, 2005, CHEST, V128, P1194, DOI 10.1378/chest.128.3.1194; Silva CS, 2015, CHRON RESP DIS, V12, P189, DOI 10.1177/1479972315576143; Vaes AW, 2019, J APPL PHYSIOL, V126, P607, DOI 10.1152/japplphysiol.00790.2018; Velloso Marcelo, 2006, J. bras. pneumol., V32, P580, DOI 10.1590/S1806-37132006000600017; WIJKSTRA PJ, 1994, THORAX, V49, P465, DOI 10.1136/thx.49.5.465	16	5	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2020	15	8							e0237973	10.1371/journal.pone.0237973	http://dx.doi.org/10.1371/journal.pone.0237973			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK7YQ	32853275	Green Published, gold			2023-01-03	WOS:000566948800074
J	Stauffer, WM; Alpern, JD; Walker, PF				Stauffer, William M.; Alpern, Jonathan D.; Walker, Patricia F.			COVID-19 and Dexamethasone A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material								Anticipating widespread global use of dexamethasone for COVID-19 in the wake of RECOVERY trial findings, this Viewpoint summarizes the theoretical risk of triggering Strongyloides hyperinfection/dissemination syndrome in people with asymptomatic strongyloidiasis, and proposes an algorithm to for assessing and managing the risk in outpatient and hospital settings.	[Stauffer, William M.] Univ Minnesota, Ctr Global Hlth & Social Responsibil, Minneapolis, MN USA; [Stauffer, William M.; Walker, Patricia F.] Univ Minnesota, Dept Med, Global Med, Box 736 UMHC, Minneapolis, MN 55455 USA; [Alpern, Jonathan D.; Walker, Patricia F.] HealthPartners Inst, Bloomington, MN USA; [Alpern, Jonathan D.] HealthPartners Travel & Trop Med Ctr, St Paul, MN USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; HealthPartners Institute for Education & Research	Stauffer, WM (corresponding author), Univ Minnesota, Dept Med, 420 Delaware St SE,MMC 250, Minneapolis, MN 55455 USA.	stauf005@umn.edu						[Anonymous], PRES SCREEN STRONG I; [Anonymous], CORT INCL DEX; Asundi A, 2019, LANCET GLOB HEALTH, V7, pE236, DOI 10.1016/S2214-109X(18)30490-X; Boggild A K, 2016, Can Commun Dis Rep, V42, P12; Geri G, 2015, INFECTION, V43, P691, DOI 10.1007/s15010-015-0799-1; Krolewiecki A, 2019, INFECT DIS CLIN N AM, V33, P135, DOI 10.1016/j.idc.2018.10.006; Olsen A, 2009, T ROY SOC TROP MED H, V103, P967, DOI 10.1016/j.trstmh.2009.02.013; Puthiyakunnon S, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0003018; Requena-Mendez A, 2017, AM J TROP MED HYG, V97, P645, DOI 10.4269/ajtmh.16-0923; The RECOVERY Collaborative Group, 2020, N ENGL J MED, DOI DOI 10.1056/NEJMOA2021436	10	56	56	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	2020	324	7					623	624		10.1001/jama.2020.13170	http://dx.doi.org/10.1001/jama.2020.13170			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG9GI	32761166	Bronze			2023-01-03	WOS:000564288700001
J	Al-Maliky, MA; Frentzen, M; Meister, J				Al-Maliky, Mohammed Abbood; Frentzen, Matthias; Meister, Joerg			Combined effects of a topical fluoride treatment and 445 nm laser irradiation of enamel against a demineralization challenge: A light and electron microscopicex vivostudy	PLOS ONE			English	Article							LESION FORMATION; CARIES; ARGON; BOVINE; MICROHARDNESS; RESISTANCE; RETENTION; INCREASE; SURFACE; DENTIN	This study investigated the caries-preventive effect of 445 nm laser radiation in combination with fluoride on the prevention of white spot lesions. Previously, several studies have indicated the ability of 488 nm argon ion laser irradiation to reduce early enamel demineralization. A diode laser (445 nm) could be an alternative technology for possible caries-preventive potential. Each sample of a group of seventeen caries-free bovine teeth was treated in four different ways on four different zones of the labial surface: control/no treatment (C), laser irradiation only (L) (0.3 W, 60 s and applied dose of 90 J/cm(2)), amine fluoride application only (10,000 ppm and pH 3.9) (F), and amine fluoride application followed by laser irradiation (FL). After treatment, the teeth were subjected to a demineralization solution (pH 4.3 for 48 h at 37 degrees C) to induce subsurface lesions. After sectioning, the teeth were examined by light microscopy. Three teeth were analyzed by scanning electron microscopy (SEM). The depths of the subsurface lesions in the C, L, F, and FL groups were 103.01 (+/- 13.04), 96.99 (+/- 14.51), 42.59 (+/- 17.13), and 24.35 (+/- 11.38) mu m, respectively. The pairwise group comparison showed the following results: p < 0.001 for FL versus C, FL versus L, F versus C, and F versus L, p = 0.019 for FL versus F and p = 0.930 for L versus C. The SEM micrographs support the light-microscopic examination. The results of the current study have shown that using relatively low irradiation settings of 445 nm laser on fluoridated enamel may be effective for prevention of white spot lesions.	[Al-Maliky, Mohammed Abbood; Frentzen, Matthias] Univ Bonn, Dent Fac, Dept Periodontol Operat & Prevent Dent, Bonn, Germany; [Al-Maliky, Mohammed Abbood; Frentzen, Matthias; Meister, Joerg] Univ Bonn, Ctr Appl Med Laser Res & Biomed Opt AMLaReBO, Bonn, Germany; [Al-Maliky, Mohammed Abbood] Univ Baghdad, Inst Laser Postgrad Studies, Dept Biomed Applicat, Baghdad, Iraq; [Meister, Joerg] Univ Bonn, Ctr Dentomaxillofacial Med, Bonn, Germany	University of Bonn; University of Bonn; University of Baghdad; University of Bonn	Al-Maliky, MA (corresponding author), Univ Bonn, Dent Fac, Dept Periodontol Operat & Prevent Dent, Bonn, Germany.; Al-Maliky, MA (corresponding author), Univ Bonn, Ctr Appl Med Laser Res & Biomed Opt AMLaReBO, Bonn, Germany.; Al-Maliky, MA (corresponding author), Univ Baghdad, Inst Laser Postgrad Studies, Dept Biomed Applicat, Baghdad, Iraq.	s4moalma@uni-bonn.de	Al-Maliky, Mohammed Abbood/G-9320-2015	Al-Maliky, Mohammed Abbood/0000-0003-2149-2852				Al-Maliky Mohammed Abbood, 2019, Biomed Res Int, V2019, P9101642, DOI 10.1155/2019/9101642; Ana PA, 2006, LASER PHYS, V16, P865, DOI 10.1134/S1054660X06050197; Anderson AM, 2002, AM J ORTHOD DENTOFAC, V122, P251, DOI 10.1067/mod.2002.126596; Anderson JR, 2000, J CLIN LASER MED SUR, V18, P33, DOI 10.1089/clm.2000.18.33; Ayoub HM, 2020, J DENT, V96, DOI 10.1016/j.jdent.2020.103328; BREWER H E, 1956, J Dent Res, V35, P59, DOI 10.1177/00220345560350011801; Chersoni S, 2011, CLIN ORAL INVEST, V15, P443, DOI 10.1007/s00784-010-0406-x; Correa-Afonso AM, 2012, ARCH ORAL BIOL, V57, P1153, DOI 10.1016/j.archoralbio.2012.02.004; CRABB HSM, 1966, NATURE, V209, P611, DOI 10.1038/209611a0; CRUZ R, 1992, SCAND J DENT RES, V100, P154; De Sant'anna GR, 2009, PHOTOMED LASER SURG, V27, P499, DOI 10.1089/pho.2008.2331; Duschner H, 1997, EUR J ORAL SCI, V105, P466, DOI 10.1111/j.1600-0722.1997.tb00232.x; Esteves-Oliveira M, 2017, CLIN ORAL INVEST, V21, P1243, DOI 10.1007/s00784-016-1893-1; Field JC, 2017, EUR J PROSTHODONT RE, V25, P93, DOI [10.1922/EJPRD_01660Field08, 10.1922/E1PRD_01660Field08]; Gerth HUV, 2007, DENT MATER, V23, P1521, DOI 10.1016/j.dental.2006.12.007; Gonzalez-Rodriguez A, 2011, LASER MED SCI, V26, P317, DOI 10.1007/s10103-010-0784-y; Hsu CYS, 1998, J DENT RES, V77, P418, DOI 10.1177/00220345980770021101; Ortiz-Ruiz AJ, 2018, ANN ANAT, V218, P7, DOI 10.1016/j.aanat.2017.12.012; Kim JW, 2016, PROC SPIE, V9692, DOI 10.1117/12.2218662; Lee R, 2017, PROC SPIE, V10044, DOI 10.1117/12.2256739; Lippert F, 2014, ARCH ORAL BIOL, V59, P704, DOI 10.1016/j.archoralbio.2014.04.005; Lombardo G, 2019, EUR J PAEDIATR DENT, V20, P295, DOI 10.23804/ejpd.2019.20.04.07; Maung NL, 2007, J DENT, V35, P794, DOI 10.1016/j.jdent.2007.07.012; Nammour S, 2005, LASER SURG MED, V36, P220, DOI 10.1002/lsm.20128; Nammour S, 2003, LASER SURG MED, V33, P260, DOI 10.1002/lsm.10219; Niemz MH, 2007, LASER TISSUE INTERAC; Noel L, 2003, ANGLE ORTHOD, V73, P249; Ogaard B, 2001, CARIES RES, V35, P40, DOI 10.1159/000049109; Parker S, 2011, INT J LASER DENT, V1, P1; Reis JM, 2014, BIOCHEMISTRY-US, V53, P5008, DOI 10.1021/bi500622x; Rolla G, 1990, J Dent Res, V69 Spec No, P780; SOGNNAES R F, 1965, J South Calif State Dent Assoc, V33, P328; Tavares JG, 2012, PHOTOMED LASER SURG, V30, P433, DOI 10.1089/pho.2011.3104; TENCATE JM, 1982, CARIES RES, V16, P201, DOI 10.1159/000260599; TENCATE JM, 1991, CRIT REV ORAL BIOL M, V2, P283, DOI 10.1177/10454411910020030101; Vlacic J, 2007, AUST DENT J, V52, P101, DOI 10.1111/j.1834-7819.2007.tb00472.x; Vos T, 2016, LANCET, V388, P1545, DOI [10.1016/S0140-6736(16)31012-1, 10.1016/S0140-6736(16)31678-6]; Westerman GH, 2006, J AM DENT ASSOC, V137, P638, DOI 10.14219/jada.archive.2006.0260; Westerman Gary H, 2003, Pediatr Dent, V25, P497; Westerman GH, 2004, AM J DENT, V17, P241; Westerman GH, 2002, J CLIN LASER MED SUR, V20, P257, DOI 10.1089/10445470260420768; World Health Organization, 2017, DEPR OTH COMM MENT D	42	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 7	2020	15	8							e0237195	10.1371/journal.pone.0237195	http://dx.doi.org/10.1371/journal.pone.0237195			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NC2FE	32764819	Green Published, gold			2023-01-03	WOS:000561029000026
J	Weinberger, DR; Dzirasa, K; Crumpton-Young, LL				Weinberger, Daniel R.; Dzirasa, Kafui; Crumpton-Young, Lesia L.			Missing in Action: African Ancestry Brain Research	NEURON			English	Editorial Material								Individuals of African ancestry have been starkly underrepresented in the pursuit of personalized medicine for brain illnesses. The African Ancestry Neuroscience Research Initiative will seek to generate much-needed brain gene and protein expression profiles for people of African ancestry.	[Weinberger, Daniel R.] Johns Hopkins Univ, Sch Med, Dept Psychiat, Lieber Inst Brain Dev,Maltz Res Labs, Baltimore, MD 21205 USA; [Weinberger, Daniel R.] Johns Hopkins Univ, Sch Med, Dept Neurol, Lieber Inst Brain Dev,Maltz Res Labs, Baltimore, MD 21205 USA; [Weinberger, Daniel R.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Lieber Inst Brain Dev,Maltz Res Labs, Baltimore, MD 21205 USA; [Weinberger, Daniel R.] Johns Hopkins Univ, Sch Med, Dept Med Genet, Lieber Inst Brain Dev,Maltz Res Labs, Baltimore, MD 21205 USA; [Dzirasa, Kafui] Duke Univ, Med Ctr, Dept Neurobiol, Dept Psychiat & Behav Sci,Ctr Neuroengn, Durham, NC 27710 USA; [Dzirasa, Kafui] Duke Univ, Med Ctr, Dept Biomed Engn, Dept Psychiat & Behav Sci,Ctr Neuroengn, Durham, NC 27710 USA; [Dzirasa, Kafui] Duke Univ, Med Ctr, Dept Neurosurg, Dept Psychiat & Behav Sci,Ctr Neuroengn, Durham, NC 27710 USA; [Crumpton-Young, Lesia L.] Morgan State Univ, Acad Affairs, Baltimore, MD 21251 USA; [Crumpton-Young, Lesia L.] Morgan State Univ, Engn, Baltimore, MD 21251 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Duke University; Duke University; Duke University; Morgan State University; Morgan State University	Weinberger, DR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, Lieber Inst Brain Dev,Maltz Res Labs, Baltimore, MD 21205 USA.; Weinberger, DR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurol, Lieber Inst Brain Dev,Maltz Res Labs, Baltimore, MD 21205 USA.; Weinberger, DR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, Lieber Inst Brain Dev,Maltz Res Labs, Baltimore, MD 21205 USA.; Weinberger, DR (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med Genet, Lieber Inst Brain Dev,Maltz Res Labs, Baltimore, MD 21205 USA.	drweinberger@libd.org	Dzirasa, Kafui/GQB-1424-2022		family of Connie and Stephen Lieber; family of Milton and Tamar Maltz	family of Connie and Stephen Lieber; family of Milton and Tamar Maltz	The AANRI would not have happened were it not for the tireless dedication and commitment of Kari Stoever, Becky Oldham, and Martin Knott. The Lieber Institute brain repository was funded by philanthropic gifts from the families of Connie and Stephen Lieber and Milton and Tamar Maltz and was created and is led by Tom Hyde and Joel Kleinman, who, it should be noted, also were responsible for establishing and maintaining for more than 20 years the NIMH Clinical Brain Disorder Branch brain repository, renamed in 2013 to the NIMH Human Brain Collection Core.	Bailey ZD, 2017, LANCET, V389, P1453, DOI 10.1016/S0140-6736(17)30569-X; Bentley AR, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-019-0111-x; Bigdeli TB, 2020, MOL PSYCHIATR, V25, P2455, DOI 10.1038/s41380-019-0517-y; Gandal MJ, 2018, SCIENCE, V362, P1265, DOI 10.1126/science.aat8127; Jaffe AE, 2020, NAT NEUROSCI, V23, P510, DOI 10.1038/s41593-020-0604-z; Martin AR, 2019, NAT GENET, V51, P584, DOI 10.1038/s41588-019-0379-x; Price AJ, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1805-1; Rajabli F, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007791; Sherman RM, 2019, NAT GENET, V51, P30, DOI 10.1038/s41588-018-0273-y	10	6	6	2	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0896-6273	1097-4199		NEURON	Neuron	AUG 5	2020	107	3					407	411		10.1016/j.neuron.2020.07.008	http://dx.doi.org/10.1016/j.neuron.2020.07.008			5	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	MV1PS	32710819	Bronze, Green Published			2023-01-03	WOS:000556135800006
J	Devi, S				Devi, Sharmila			Ukrainian health authorities adopt hepatitis C project	LANCET			English	Editorial Material																			0	4	4	1	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	2020	396	10246					228	228						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NK8ZY	32711786	Green Published, Bronze			2023-01-03	WOS:000567020100013
J	Kato, I; Tumaini, B; Pallangyo, K				Kato, Irene; Tumaini, Basil; Pallangyo, Kisali			Prevalence of non-communicable diseases among individuals with HIV infection by antiretroviral therapy status in Dar es Salaam, Tanzania	PLOS ONE			English	Article							DIABETES-MELLITUS; KIDNEY-DISEASE; HYPERTENSION; SMOKING; EPIDEMIOLOGY; INFLAMMATION; MECHANISMS; MANAGEMENT; GLUCOSE; COHORT	Background Long-term antiretroviral therapy has modified the clinical course of HIV infection to a chronic condition associated with increased risk of developing non-communicable diseases (NCDs). Information is scant, from sub-Saharan Africa, on the prevalence of NCDs and associated factors among individuals on ART. Methodology We consecutively enrolled individuals with HIV infection who were ART naive and those on ART for >= 5 years (LTART) attending health facilities in Dar es Salaam. Participant's blood pressure, anthropometric measurements, and fasting blood glucose were recorded. Participants with impaired fasting blood glucose underwent an oral glucose tolerance test. A venous blood sample was sent to the lab for biochemical tests. Chi-square test was used to compare proportions, Poisson regression with robust standard errors was used to determine associations between variables. Results Overall, 612 individuals with HIV infection were enrolled, half of whom were ART naive. Females comprised 71.9% and 68.0% of participants in the LTART and ART naive study arms, respectively, p = 0.290. The mean age (+/- SD) was 44.9 +/- 12.7 years and 37.5 +/- 11.8 years among LTART and ART naive participants, respectively, p<0.001. Hypertension was documented in 25.2% in those on LTART compared to 6.9% among ART naive subjects, p<0.001. Impaired glucose tolerance was found in 22.9% and 4.6% among LTART compared to ART naive subjects, p<0.001. Diabetes mellitus was detected in 17.0% of those on LTART compared to 3.9% ART naive participants, p<0.001. Hypercholesterolemia was found in 30.4% of individuals on LTART compared to 16.7% of ART naive subjects, p<0.001, and hypertriglyceridemia was found in 16.0% of participants on LTART compared to 9.5% of ART naive, p = 0.015. LTART use, age >= 40 years, history of smoking, and body mass index were independently associated with NCDs. Conclusion Hypertension, impaired glucose tolerance, diabetes mellitus, hypercholesterolemia, and hypertriglyceridemia were associated with long-term use of antiretroviral drugs.	[Kato, Irene; Tumaini, Basil; Pallangyo, Kisali] Muhimbili Univ Hlth & Allied Sci, Dept Internal Med, Dar Es Salaam, Tanzania	Muhimbili University of Health & Allied Sciences	Kato, I (corresponding author), Muhimbili Univ Hlth & Allied Sci, Dept Internal Med, Dar Es Salaam, Tanzania.	drirene86@gmail.com	Tumaini, Basil/AAD-7405-2021	Tumaini, Basil/0000-0002-2894-1684				Amberbir A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197728; Araujo S, 2014, EUR J ENDOCRINOL, V171, P545, DOI 10.1530/EJE-14-0337; Baekken M, 2008, J HYPERTENS, V26, P2126, DOI 10.1097/HJH.0b013e32830ef5fb; Beaudin M, 2019, MATH COMPUT SCI, V13, P1, DOI 10.1007/s11786-019-00391-x; Brown TT, 2005, ARCH INTERN MED, V165, P1179, DOI 10.1001/archinte.165.10.1179; Chang SA, 2012, DIABETES METAB J, V36, P399, DOI 10.4093/dmj.2012.36.6.399; Craig CL, 2003, MED SCI SPORT EXER, V35, P1381, DOI 10.1249/01.MSS.0000078924.61453.FB; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; Dimala CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148100; Donati KD, 2010, MEDITERR J HEMATOL I, V2, DOI 10.4084/MJHID.2010.0; Duprez DA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044454; El-Sadr W, 2005, HIV MED, V6, P114, DOI 10.1111/j.1468-1293.2005.00273.x; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; Fine DM, 2013, J INFECT DIS, V207, P1349, DOI 10.1093/infdis/jit044; FolefackKaze Francois, 2013, Saudi J Kidney Dis Transpl, V24, P1291, DOI 10.4103/1319-2442.121280; Gepner AD, 2011, AM HEART J, V161, DOI 10.1016/j.ahj.2010.09.023; Gutierrez AD, 2012, ENDOCRINE, V41, P1, DOI 10.1007/s12020-011-9565-z; Hejazi N., 2014, GLOB J HLTH SCI, V6, P58; Hogg R, 2008, LANCET, V372, P293, DOI 10.1016/S0140-6736(08)61113-7; Jagoe K, 2002, TOB CONTROL, V11, P210, DOI 10.1136/tc.11.3.210; Joint United Nations Programme on HIV/ AIDS (UNAIDS), 2016, GLOB AIDS UPD 2016; Kagaruki GB, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-904; Kazooba P, 2017, PAN AFR MED J, V27, DOI 10.11604/pamj.2017.27.40.9840; Levitt NS, 2016, DIABETES RES CLIN PR, V119, P41, DOI 10.1016/j.diabres.2016.03.012; Maganga E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134410; Magodoro Itai M, 2016, BMC Res Notes, V9, P379, DOI 10.1186/s13104-016-2187-z; Mallipattu SK, 2014, KIDNEY INT, V86, P259, DOI 10.1038/ki.2014.44; Mancia G, 2013, EUR HEART J, V34, P2159, DOI 10.1093/eurheartj/eht151; Mave V, 2016, J INFECT DIS, V214, P65, DOI 10.1093/infdis/jiw096; Mayosi BM, 2009, LANCET, V374, P934, DOI 10.1016/S0140-6736(09)61087-4; Mekuria Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161180; Msango L, 2011, AIDS, V25, P1421, DOI 10.1097/QAD.0b013e328348a4b1; Mugusi F, 2009, TROP MED INT HEALTH, V14, P1226, DOI 10.1111/j.1365-3156.2009.02359.x; Narayan KMV, 2014, JAIDS-J ACQ IMM DEF, V67, pS2, DOI 10.1097/QAI.0000000000000267; National Institute of Diabetes and Digestive and Kidney Diseases, MDRD AD CONV UN; Nduka C, 2015, INT J CARDIOL, V199, P307, DOI 10.1016/j.ijcard.2015.07.052; Nou E, 2016, AIDS, V30, P1495, DOI 10.1097/QAD.0000000000001109; Okafor UH, 2016, SAUDI J KIDNEY DIS T, V27, P129, DOI 10.4103/1319-2442.174155; Pao V, 2008, CURR ATHEROSCLER REP, V10, P61, DOI 10.1007/s11883-008-0010-6; Peck RN, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0125-2; Roerink ME, 2015, NETH J MED, V73, P310; */* S   1, 2017, DIABETES CARE S1, V40, pS, DOI DOI 10.2337/DC17-S001; Seaberg EC, 2005, AIDS, V19, P953, DOI 10.1097/01.aids.0000171410.76607.f8; Semu Helen, 2016, J Int Assoc Provid AIDS Care, V15, P512; Ungvari Z, 2010, J GERONTOL A-BIOL, V65, P1028, DOI 10.1093/gerona/glq113; United Republic of Tanzania, 2017, NAT GUID MAN HIV AID; Van Wijk JP, 2012, INT J VASC MED, V2012, P1; van Zoest RA, 2016, CLIN INFECT DIS, V63, P205, DOI 10.1093/cid/ciw285; Virdis A, 2010, CURR PHARM DESIGN, V16, P2518, DOI 10.2174/138161210792062920; World Health Organization (WHO), 2016, WHO DIAB COUNTR PROF	50	6	6	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2020	15	7							e0235542	10.1371/journal.pone.0235542	http://dx.doi.org/10.1371/journal.pone.0235542			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ0QU	32645054	Green Published, gold			2023-01-03	WOS:000552602700096
J	Nagai, Y; Miyakawa, N; Takuwa, H; Hori, Y; Oyama, K; Ji, B; Takahashi, M; Huang, XP; Slocum, ST; DiBerto, JF; Xiong, Y; Urushihata, T; Hirabayashi, T; Fujimoto, A; Mimura, K; English, JG; Liu, J; Inoue, K; Kumata, K; Seki, C; Ono, M; Shimojo, M; Zhang, MR; Tomita, Y; Nakahara, J; Suhara, T; Takada, M; Higuchi, M; Jin, J; Roth, BL; Minamimoto, T				Nagai, Yuji; Miyakawa, Naohisa; Takuwa, Hiroyuki; Hori, Yukiko; Oyama, Kei; Ji, Bin; Takahashi, Manami; Huang, Xi-Ping; Slocum, Samuel T.; DiBerto, Jeffrey F.; Xiong, Yan; Urushihata, Takuya; Hirabayashi, Toshiyuki; Fujimoto, Atsushi; Mimura, Koki; English, Justin G.; Liu, Jing; Inoue, Ken-ichi; Kumata, Katsushi; Seki, Chie; Ono, Maiko; Shimojo, Masafumi; Zhang, Ming-Rong; Tomita, Yutaka; Nakahara, Jin; Suhara, Tetsuya; Takada, Masahiko; Higuchi, Makoto; Jin, Jian; Roth, Bryan L.; Minamimoto, Takafumi			Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys	NATURE NEUROSCIENCE			English	Article							CLOZAPINE-N-OXIDE; RECEPTORS; BRAIN; DRUGS; INTERROGATION; VALIDATION; DOPAMINE; BINDING	The chemogenetic technology designer receptors exclusively activated by designer drugs (DREADDs) afford remotely reversible control of cellular signaling, neuronal activity and behavior. Although the combination of muscarinic-based DREADDs with clozapine-N-oxide (CNO) has been widely used, sluggish kinetics, metabolic liabilities and potential off-target effects of CNO represent areas for improvement. Here, we provide a new high-affinity and selective agonist deschloroclozapine (DCZ) for muscarinic-based DREADDs. Positron emission tomography revealed that DCZ selectively bound to and occupied DREADDs in both mice and monkeys. Systemic delivery of low doses of DCZ (1 or 3 mu g per kg) enhanced neuronal activity via hM3Dq within minutes in mice and monkeys. Intramuscular injections of DCZ (100 mu g per kg) reversibly induced spatial working memory deficits in monkeys expressing hM4Di in the prefrontal cortex. DCZ represents a potent, selective, metabolically stable and fast-acting DREADD agonist with utility in both mice and nonhuman primates for a variety of applications. Deschloroclozapine (DCZ) is a broadly useful chemogenetic agonist for studies using nonhuman primates and mice. DCZ rapidly and reversibly activates DREADDs, and its binding can be visualized noninvasively by positron emission tomography.	[Nagai, Yuji; Miyakawa, Naohisa; Takuwa, Hiroyuki; Hori, Yukiko; Oyama, Kei; Ji, Bin; Takahashi, Manami; Urushihata, Takuya; Hirabayashi, Toshiyuki; Fujimoto, Atsushi; Mimura, Koki; Seki, Chie; Ono, Maiko; Shimojo, Masafumi; Suhara, Tetsuya; Higuchi, Makoto; Minamimoto, Takafumi] Natl Inst Quantum & Radiol Sci & Technol, Natl Inst Radiol Sci, Dept Funct Brain Imaging, Chiba, Japan; [Huang, Xi-Ping; Slocum, Samuel T.; DiBerto, Jeffrey F.; English, Justin G.; Roth, Bryan L.] Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27515 USA; [Huang, Xi-Ping; Roth, Bryan L.] Univ N Carolina, Div Chem Biol & Med Chem, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA; [Xiong, Yan; Liu, Jing; Jin, Jian] Icahn Sch Med Mt Sinai, Mt Sinai Ctr Therapeut Discovery, Tisch Canc Inst, Dept Pharmacol Sci, New York, NY 10029 USA; [Xiong, Yan; Liu, Jing; Jin, Jian] Icahn Sch Med Mt Sinai, Mt Sinai Ctr Therapeut Discovery, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA; [Inoue, Ken-ichi; Takada, Masahiko] Kyoto Univ, Primate Res Inst, Syst Neurosci Sect, Inuyama, Aichi, Japan; [Inoue, Ken-ichi] Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama, Japan; [Kumata, Katsushi; Zhang, Ming-Rong] Natl Inst Quantum & Radiol Sci & Technol, Natl Inst Radiol Sci, Dept Radiopharmaceut Dev, Chiba, Japan; [Tomita, Yutaka; Nakahara, Jin] Keio Univ, Dept Neurol, Sch Med, Tokyo, Japan; [Roth, Bryan L.] Univ N Carolina, Dept Pharmacol, Natl Inst Mental Hlth Psychoact Drug Screening Pr, Chapel Hill, NC 27515 USA	National Institutes for Quantum Science & Technology; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Kyoto University; Japan Science & Technology Agency (JST); National Institutes for Quantum Science & Technology; Keio University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); University of North Carolina; University of North Carolina Chapel Hill	Minamimoto, T (corresponding author), Natl Inst Quantum & Radiol Sci & Technol, Natl Inst Radiol Sci, Dept Funct Brain Imaging, Chiba, Japan.; Roth, BL (corresponding author), Univ N Carolina, Dept Pharmacol, Sch Med, Chapel Hill, NC 27515 USA.; Roth, BL (corresponding author), Univ N Carolina, Div Chem Biol & Med Chem, Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.; Roth, BL (corresponding author), Univ N Carolina, Dept Pharmacol, Natl Inst Mental Hlth Psychoact Drug Screening Pr, Chapel Hill, NC 27515 USA.	bryan_roth@med.unc.edu; minamimoto.takafumi@qst.go.jp	Miyakawa, Naohisa/AAW-2560-2020; Roth, Bryan/ABE-7032-2020; Miyakawa, Naohisa/AAU-1467-2020; Roth, Bryan L/F-3928-2010; Minamimoto, Takafumi/D-6610-2012	Miyakawa, Naohisa/0000-0001-5057-0333; Roth, Bryan/0000-0002-0561-6520; Liu, Jing/0000-0003-4740-243X; Urushihata, Takuya/0000-0001-7192-2940; Nagai, Yuji/0000-0001-7005-0749; Minamimoto, Takafumi/0000-0003-4305-0174; English, Justin/0000-0002-1161-8928; Oyama, Kei/0000-0002-3375-7099; Fujimoto, Atsushi/0000-0002-1621-2003; Slocum, Samuel/0000-0001-5942-4367	MEXT/JSPS KAKENHI [JP15H05917, JP15K12772, JP18H04037, JP16H02454, JP19K08138, JP18H05018, JP19K07811, JP20H04596]; AMED [JP20dm0107146, JP19dm0207003, JP20dm0107094, JP18dm0207007, JP20dm0307021, JP20dm0307007, JP20dm0207072]; JST PRESTO [JPMJPR1683]; QST President's Strategic Grant (Creative Research); Cooperative Research Program at PRI, Kyoto University; National Bio-Resource Project 'Japanese Monkeys' of MEXT, Japan; NIMH Psychoactive Drug Screening Program [U24DK116195]; Michael Hooker Distinguished Professorship	MEXT/JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); AMED; JST PRESTO(Japan Science & Technology Agency (JST)); QST President's Strategic Grant (Creative Research); Cooperative Research Program at PRI, Kyoto University; National Bio-Resource Project 'Japanese Monkeys' of MEXT, Japan; NIMH Psychoactive Drug Screening Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); Michael Hooker Distinguished Professorship	We thank R. Suma, J. Kamei, R. Yamaguchi, Y. Matsuda, Y. Sugii, A. Maruyama, T. Okauchi, T. Kokufuta, Y. Iwasawa, T. Watanabe, A. Tanizawa, S. Shibata, N. Nitta, Y. Ozawa, M. Fujiwara, M. Nakano, T. Minamihisamatsu, S. Uchida and S. Sasaki for their technical assistance. We also thank S. Hiura for 3D printing of the grids. This study was supported by the following grants and organizations: MEXT/JSPS KAKENHI grant numbers JP15H05917, JP15K12772 and JP18H04037 (to T.M.), JP16H02454 (to M. Takada), JP19K08138 (to Y.N.), and JP18H05018, JP19K07811 and JP20H04596 (to N.M.); AMED grant numbers JP20dm0107146 (to T.M.), JP19dm0207003 (to M. Takada), JP20dm0107094 and JP18dm0207007 (to T.S.), JP20dm0307021 (to K.-i.I.), JP20dm0307007 (to T.H.), and JP20dm0207072 (to M.H.); JST PRESTO grant number JPMJPR1683 (to K.-i.I.); QST President's Strategic Grant (Creative Research) (to N.M.); the Cooperative Research Program at PRI, Kyoto University; the National Bio-Resource Project 'Japanese Monkeys' of MEXT, Japan; and U24DK116195, the NIMH Psychoactive Drug Screening Program and the Michael Hooker Distinguished Professorship to B.L.R.	Alexander GM, 2009, NEURON, V63, P27, DOI 10.1016/j.neuron.2009.06.014; Allen DC, 2019, J PHARMACOL EXP THER, V368, P199, DOI 10.1124/jpet.118.252031; Armbruster BN, 2007, P NATL ACAD SCI USA, V104, P5163, DOI 10.1073/pnas.0700293104; BENDER D, 1994, NUCL MED BIOL, V21, P921, DOI 10.1016/0969-8051(94)90080-9; Buzsaki G, 2012, NAT REV NEUROSCI, V13, P407, DOI 10.1038/nrn3241; Chen X, 2015, ACS CHEM NEUROSCI, V6, P476, DOI 10.1021/cn500325v; Croxson PL, 2011, NAT NEUROSCI, V14, P1510, DOI 10.1038/nn.2971; Eldridge MAG, 2016, NAT NEUROSCI, V19, P37, DOI 10.1038/nn.4192; Farrell MS, 2013, BRAIN RES, V1511, P6, DOI 10.1016/j.brainres.2012.09.043; Friden M, 2011, DRUG METAB DISPOS, V39, P353, DOI 10.1124/dmd.110.035998; GOLDMAN PS, 1970, J COMP PHYSIOL PSYCH, V70, P454, DOI 10.1037/h0028701; Gomez JL, 2017, SCIENCE, V357, P503, DOI 10.1126/science.aan2475; Grayson DS, 2016, NEURON, V91, P453, DOI 10.1016/j.neuron.2016.06.005; Ichise M, 1996, J NUCL MED, V37, P513; Ji B, 2016, J NEUROSCI, V36, P11544, DOI 10.1523/JNEUROSCI.1279-16.2016; Katzel D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4847; Kalvass JC, 2007, DRUG METAB DISPOS, V35, P660, DOI 10.1124/dmd.106.012294; Kiebel SJ, 1997, NEUROIMAGE, V5, P271, DOI 10.1006/nimg.1997.0265; Kroeze WK, 2015, NAT STRUCT MOL BIOL, V22, P362, DOI 10.1038/nsmb.3014; Magnus CJ, 2019, SCIENCE, V364, P146, DOI 10.1126/science.aav5282; Manvich DF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22116-z; Martinez MN, 2011, AAPS J, V13, P632, DOI 10.1208/s12248-011-9303-8; Maurer TS, 2005, DRUG METAB DISPOS, V33, P175, DOI 10.1124/dmd.104.001222; McLaren DG, 2009, NEUROIMAGE, V45, P52, DOI 10.1016/j.neuroimage.2008.10.058; Michaelides M, 2013, J CLIN INVEST, V123, P5342, DOI 10.1172/JCI72117; Minamimoto T, 2009, J NEUROPHYSIOL, V101, P437, DOI 10.1152/jn.90959.2008; Nagai YJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13605; Olsen RHJ, 2020, NAT CHEM BIOL, V16, P841, DOI 10.1038/s41589-020-0535-8; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; PHILLIPS ST, 1994, J MED CHEM, V37, P2686, DOI 10.1021/jm00043a008; Poremba A, 2004, NATURE, V427, P448, DOI 10.1038/nature02268; Raper J, 2017, ACS CHEM NEUROSCI, V8, P1570, DOI 10.1021/acschemneuro.7b00079; Roth BL, 2004, NAT REV DRUG DISCOV, V3, P353, DOI 10.1038/nrd1346; Roth BL, 2016, NEURON, V89, P683, DOI 10.1016/j.neuron.2016.01.040; Stachniak TJ, 2014, NEURON, V82, P797, DOI 10.1016/j.neuron.2014.04.008; Szablowski JO, 2018, NAT BIOMED ENG, V2, P475, DOI 10.1038/s41551-018-0258-2; Tajima Y, 2014, J CEREBR BLOOD F MET, V34, P1363, DOI 10.1038/jcbfm.2014.91; Takuwa H, 2011, BRAIN RES, V1369, P103, DOI 10.1016/j.brainres.2010.11.007; Thompson KJ, 2018, ACS PHARMACOL TRANSL, V1, P61, DOI 10.1021/acsptsci.8b00012; Tomita Y, 2005, J CEREBR BLOOD F MET, V25, P858, DOI 10.1038/sj.jcbfm.9600077; Tsutsui KI, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00099; Upright NA, 2018, J NEUROSCI, V38, P7969, DOI 10.1523/JNEUROSCI.1422-18.2018; Vardy E, 2015, NEURON, V86, P936, DOI 10.1016/j.neuron.2015.03.065	43	67	67	5	27	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1097-6256	1546-1726		NAT NEUROSCI	Nat. Neurosci.	SEP	2020	23	9					1157	+		10.1038/s41593-020-0661-3	http://dx.doi.org/10.1038/s41593-020-0661-3		JUL 2020	15	Neurosciences	Science Citation Index Expanded (SCI-EXPANDED)	Neurosciences & Neurology	NF3CD	32632286	Green Submitted			2023-01-03	WOS:000545918700002
J	Bouguetoch, A; Grospretre, S; Martin, A				Bouguetoch, Amandine; Grospretre, Sidney; Martin, Alain			Optimal stimulation parameters for spinal and corticospinal excitabilities during contraction, motor imagery and rest: A pilot study	PLOS ONE			English	Article							FACILITATION; REFLEX; REPRESENTATIONS; PERFORMANCE; SIMULATION; MOVEMENTS	Objectives It is commonly accepted that motor imagery (MI), i.e. the mental simulation of a movement, leads to an increased size of cortical motor evoked potentials (MEPs), although the magnitude of this effect differs between studies. Its impact on the spinal level is even more variable in the literature. Such discrepancies may be explained by many different experimental approaches. Therefore, the question of the optimal stimulation parameters to assess both spinal and corticospinal excitabilities remains open. Methods H-reflexes and MEPs of the triceps surae were evoked in 11 healthy subjects during MI, weak voluntary contraction (CON) and rest (REST). In each condition, the full recruitment curve from the response threshold to maximal potential was investigated. Results At stimulation intensities close to the maximal response, MEP amplitude was increased by CON compared to REST on the triceps surae. No effect of the different conditions was found on the H-reflex recruitment curve, except a small variation beyond maximal H-reflex in the soleus muscle. Conclusion Based on our results, we recommend to assess corticospinal excitability between 70% and 100% of maximal MEP intensity instead of the classical use of a percentage of the motor threshold and to elicit H-reflexes on the ascending part of the recruitment curve.	[Bouguetoch, Amandine; Martin, Alain] Univ Bourgogne Franche Comte, Cognit Act & Sensorimotor Plast CAPS, INSERM, Dijon, France; [Grospretre, Sidney] Univ Bourgogne Franche Comte, EA 4660 C3S Culture Sport Hlth Soc, Besancon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Bourgogne; Universite de Franche-Comte	Bouguetoch, A (corresponding author), Univ Bourgogne Franche Comte, Cognit Act & Sensorimotor Plast CAPS, INSERM, Dijon, France.	amandine.bouguetoch@free.fr		Grospretre, Sidney/0000-0003-1023-5842				Abbruzzese G, 1996, EXP BRAIN RES, V111, P465; ANNETT J, 1995, NEUROPSYCHOLOGIA, V33, P1395, DOI 10.1016/0028-3932(95)00072-B; [Anonymous], 2017, LANCET ONCOL, V18, P1, DOI 10.1016/S1470-2045(16)30642-8; [Anonymous], 1994, BRIT J 18 CENTURY ST, V17, P1, DOI DOI 10.1007/BF02724515; Bonnet M, 1997, COGNITIVE BRAIN RES, V5, P221, DOI 10.1016/S0926-6410(96)00072-9; Crammond DJ, 1997, TRENDS NEUROSCI, V20, P54, DOI 10.1016/S0166-2236(96)30019-2; CRONE C, 1990, EXP BRAIN RES, V81, P35; DECETY J, 1994, NATURE, V371, P600, DOI 10.1038/371600a0; Decety J., 1990, PSYCHOL RES, P39, DOI [10.1007/BF00867210, DOI 10.1007/BF00867210]; Ehrsson HH, 2000, EUR J NEUROSCI, V12, P3385, DOI 10.1046/j.1460-9568.2000.00209.x; FELTZ DL, 1983, J SPORT PSYCHOL, V5, P25, DOI 10.1123/jsp.5.1.25; Gandevia SC, 1997, J PHYSIOL-LONDON, V505, P259, DOI 10.1111/j.1469-7793.1997.259bc.x; Groppa S, 2012, CLIN NEUROPHYSIOL, V123, P858, DOI 10.1016/j.clinph.2012.01.010; Grospretre S, 2019, J PHYSIOL-LONDON, V597, P921, DOI 10.1113/JP276694; Grospretre S, 2016, EUR J SPORT SCI, V16, P317, DOI 10.1080/17461391.2015.1024756; Grospretre S, 2012, J NEUROPHYSIOL, V107, P1649, DOI 10.1152/jn.00611.2011; Hale BS, 2003, BEHAV BRAIN RES, V142, P81, DOI 10.1016/S0166-4328(02)00397-2; Hall C. R., 1997, J MENTAL IMAG, V21, P143, DOI DOI 10.1037/T07979-000; Hashimoto R, 1999, DYNAMIC CHANGES CORT, P75; Jeannerod M, 2001, NEUROIMAGE, V14, pS103, DOI 10.1006/nimg.2001.0832; Jeannerod M., 2004, INT J SPORT EXERC PS, V2, P376, DOI [10.1080/1612197X.2004.9671752, DOI 10.1080/1612197X.2004.9671752]; Jeannerod M., 2006, MOTOR COGNITION WHAT, DOI [10.1093/acprof:oso/9780198569657.001.0001, DOI 10.1093/ACPROF:OSO/9780198569657.001.0001]; Kasai T, 1997, BRAIN RES, V744, P147, DOI 10.1016/S0006-8993(96)01101-8; Kiers L, 1997, ELECTROMYOGR MOTOR C, V105, P262, DOI 10.1016/S0921-884X(97)00027-1; Kukke SN, 2014, J CLIN NEUROPHYSIOL, V31, P246, DOI 10.1097/WNP.0000000000000057; Miller KJ, 2010, P NATL ACAD SCI USA, V107, P7113, DOI 10.1073/pnas.1002462107; Oku K, 2011, PERCEPT MOTOR SKILL, V113, P982, DOI 10.2466/05.23.25.PMS.113.6.982-994; Park WH, 2011, NEUROSCI LETT, V494, P255, DOI 10.1016/j.neulet.2011.03.027; Pierrot-Deseilligny E, 2012, CIRCUITRY OF THE HUMAN SPINAL CORD: SPINAL AND CORTICOSPINAL MECHANISMS OF MOVEMENT, P292; PierrotDeseilligny E, 2005, CIRCUITRY OF THE HUMAN SPINAL CORD: ITS ROLE IN MOTOR CONTROL AND MOVEMENT DISORDERS, P1, DOI 10.1017/CBO9780511545047; Porro CA, 1996, J NEUROSCI, V16, P7688; Roth R, 1996, NEUROREPORT, V7, P1280, DOI 10.1097/00001756-199605170-00012; Rupp T, 2012, J NEUROPHYSIOL, V108, P1270, DOI 10.1152/jn.01162.2011; Stephan KM, 1996, NEUROCHEM RES, V21, P1105, DOI 10.1007/BF02532421; STEPHAN KM, 1995, J NEUROPHYSIOL, V73, P373, DOI 10.1152/jn.1995.73.1.373; Temesi J, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-40; Temesi J, 2013, MED SCI SPORT EXER, V45, P2243, DOI 10.1249/MSS.0b013e31829ce379; Yahagi S, 1996, PERCEPT MOTOR SKILL, V83, P288, DOI 10.2466/pms.1996.83.1.288	38	4	4	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2020	15	6							e0235074	10.1371/journal.pone.0235074	http://dx.doi.org/10.1371/journal.pone.0235074			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC8RX	32569326	Green Published, gold			2023-01-03	WOS:000543547900042
J	Liu, X; Zhang, H; Zhang, HJ; Guo, MZ; Gao, YC; Du, CY				Liu, Xian; Zhang, Huan; Zhang, Haijing; Guo, Mengzhuo; Gao, Yuanchao; Du, Chunyan			Intermittent epidural bolus versus continuous epidural infusions for labor analgesia: A meta-analysis of randomized controlled trials	PLOS ONE			English	Article							AUTOMATED MANDATORY BOLUSES; NEONATAL OUTCOMES; CESAREAN DELIVERY; BASAL INFUSION; DOUBLE-BLIND; FENTANYL	There are inconsistent results regarding the efficacy and safety of intermittent epidural bolus (IPB) versus continuous epidural infusions (CPI) for labor analgesia. This study used a meta-analytic approach to assess the safety and treatment efficacy of IPB versus CPI for labor analgesia based on randomized controlled trials (RCTs). Four electronic databases were used to identify eligible RCTs. Pooled effect estimates at 95% confidence intervals (CIs) were calculated using a random-effects model. Twenty-two RCTs with 2,573 parturients were selected for final analysis. The findings revealed no significant differences between IPB and CPI for the incidences of cesarean and instrumental delivery. IPB was shown to be associated with shorter total duration of labor [weighted mean difference (WMD): -21.46; 95% CI: -25.07 to -17.85; P < 0.001], duration of the first of stage of labor (WMD: -13.41; 95% CI: -21.01 to -5.81; P = 0.001), and duration of the second stage of labor (WMD: -4.98; 95% CI: -9.32 to -0.63; P = 0.025). Furthermore, IPB significantly reduced the incidences of required anesthetic interventions compared with CPI [relative risk (RR): 0.61; 95% CI: 0.39-0.95; P = 0.030], whereas there was no significant difference between IPB and CPI for the time required in the first anesthetic intervention (WMD: 7.73; 95% CI: -33.68-49.15; P = 0.714). The local anesthetic IPB (bupivacaine equivalents) was associated with lower milligrams per hour of local anesthetic (WMD: -0.89; 95% CI: -1.41 to -0.36; P = 0.001) and better maternal satisfaction (WMD: 8.76; 95% CI: 4.18-13.35; P < 0.001). There were no significant differences between IPB and CPI for the risk of adverse events. This study found that parturients with IPB have short total duration of labor and duration of the first and second stage of labor, reduced requirements for additional anesthetic interventions, and improved maternal satisfaction.	[Liu, Xian; Zhang, Huan; Zhang, Haijing; Guo, Mengzhuo; Gao, Yuanchao; Du, Chunyan] Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Anesthesiol, Beijing, Peoples R China	Tsinghua University	Zhang, H (corresponding author), Tsinghua Univ, Beijing Tsinghua Changgung Hosp, Sch Clin Med, Dept Anesthesiol, Beijing, Peoples R China.	zhanghuan010@126.com						Ades AE, 2005, MED DECIS MAKING, V25, P646, DOI 10.1177/0272989X05282643; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Capogna G, 2011, ANESTH ANALG, V113, P826, DOI 10.1213/ANE.0b013e31822827b8; Chua SMH, 2004, CAN J ANAESTH, V51, P581, DOI 10.1007/BF03018402; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dong-fang Z, 2019, WORLD LATEST MED INF; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; [方向东 Fang Xiangdong], 2016, [临床麻醉学杂志, Journal of Clinical Anesthestology], V32, P757; Feng SW, 2014, SAUDI MED J, V35, P1237; Fettes PDW, 2006, BRIT J ANAESTH, V97, P359, DOI 10.1093/bja/ael157; George RB, 2013, ANESTH ANALG, V116, P133, DOI 10.1213/ANE.0b013e3182713b26; Hawkins JL, 2010, NEW ENGL J MED, V362, P1503, DOI 10.1056/NEJMct0909254; Haydon ML, 2011, AM J OBSTET GYNECOL, V205, DOI 10.1016/j.ajog.2011.06.041; Heesen M, 2015, ANESTH ANALG, V121, P149, DOI 10.1213/ANE.0000000000000743; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jie JI, 2016, SHANGHAI MED J; Lavand'homme P, 2010, INT J OBSTET ANESTH, V19, P1, DOI 10.1016/j.ijoa.2009.09.003; Leighton BL, 2002, AM J OBSTET GYNECOL, V186, pS69, DOI 10.1067/mob.2002.121813; Leo S, 2010, INT J OBSTET ANESTH, V19, P357, DOI 10.1016/j.ijoa.2010.07.006; Lim Y, 2005, INT J OBSTET ANESTH, V14, P305, DOI 10.1016/j.ijoa.2005.05.004; Lim Y, 2010, ANAESTH INTENS CARE, V38, P894, DOI 10.1177/0310057X1003800514; Lin YA, 2016, THER CLIN RISK MANAG, V12, P1107, DOI 10.2147/TCRM.S106021; Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3; Maggiore ULR, 2016, INT J OBSTET ANESTH, V25, P37, DOI 10.1016/j.ijoa.2015.08.014; MELZACK R, 1984, PAIN, V19, P321, DOI 10.1016/0304-3959(84)90079-4; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nunes J, 2016, REV BRAS ANESTESIOL, V66, P439, DOI [10.1016/j.bjane.2014.12.006, 10.1016/j.bjan.2015.10.003]; Onuoha Onyi C, 2017, Anesthesiol Clin, V35, P1, DOI 10.1016/j.anclin.2016.09.003; POWER I, 1988, ANAESTHESIA, V43, P876; Salim R, 2005, OBSTET GYNECOL, V106, P301, DOI 10.1097/01.AOG.0000171109.53832.8d; Sharma SK, 2002, ANESTHESIOLOGY, V96, P546, DOI 10.1097/00000542-200203000-00007; Sia AT, 2013, ANAESTHESIA, V68, P267, DOI 10.1111/anae.12093; Sia AT, 2007, ANESTH ANALG, V104, P673, DOI 10.1213/01.ane.0000253236.89376.60; Skrablin S, 2011, J OBSTET GYNAECOL, V31, P134, DOI 10.3109/01443615.2010.542840; Sng BL, 2015, CURR OPIN ANESTHESIO, V28, P285, DOI 10.1097/ACO.0000000000000183; Tobias A., 1999, STATA TECH B, V47, P15; Ueda K, 2005, ANESTHESIOLOGY, V103, P126, DOI 10.1097/00000542-200507000-00019; Wang Y, 2019, J MED THEOR PRAC, V32, P3684; [王朝辉 Wang Zhaohui], 2017, [临床麻醉学杂志, Journal of Clinical Anesthestology], V33, P755; [王朝辉 Wang Zhaohui], 2016, [中华麻醉学杂志, Chinese Journal of Anesthesiology], V36, P1134; Wong CA, 2006, ANESTH ANALG, V102, P904, DOI 10.1213/01.ane.0000197778.57615.1a; Wong CA, 2005, NEW ENGL J MED, V352, P655, DOI 10.1056/NEJMoa042573; Xu JQ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39248-5; Zhao J, 2013, SHANGHAI MED J	46	4	4	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2020	15	6							e0234353	10.1371/journal.pone.0234353	http://dx.doi.org/10.1371/journal.pone.0234353			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6QP	32530935	gold, Green Published			2023-01-03	WOS:000542037200013
J	Fally, M; von Plessen, C; Anhoj, J; Benfield, T; Tarp, B; Clausen, LN; Kolte, L; Diernaes, E; Molzen, L; Seerup, R; Israelsen, S; Hellesoe, AMB; Ravn, P				Fally, Markus; von Plessen, Christian; Anhoj, Jacob; Benfield, Thomas; Tarp, Britta; Clausen, Lise Notander; Kolte, Lilian; Diernaes, Emma; Molzen, Line; Seerup, Regitze; Israelsen, Simone; Hellesoe, Anne-Marie Blok; Ravn, Pernille			Improved treatment of community-acquired pneumonia through tailored interventions: Results from a controlled, multicentre quality improvement project	PLOS ONE			English	Article							VENTILATOR-ASSOCIATED PNEUMONIA; ANTIBIOTIC-THERAPY; OF-CARE; GUIDELINE; MORTALITY; OUTCOMES; IMPACT; BUNDLE; ADULTS; IMPLEMENTATION	Background Community-acquired pneumonia (CAP) is one of the leading causes of healthcare utilisation and death worldwide. Treatment according to evidence-based clinical guidelines can reduce mortality, antibiotic exposure and length of hospital stay related to CAP. Local problem Several studies, including a pilot study from one of our sites, indicate that physicians show a low grade of guideline adherence when managing patients with CAP. Methods To improve the guideline-based treatment of patients with CAP admitted to hospital, we designed a quality improvement study. Four process indicators were combined in a CAP care bundle: chest X-ray, CURB-65 severity score, lower respiratory tract samples and antibiotics within 8 hours from admission. After a 4-month baseline period, we applied multiple interventions at three hospitals during 8 months. Progression in our process indicators was measured continuously and compared with a control site without interventions. After the 8-month intervention period, we continued with a 4-month follow-up period to assess the sustainability of the improvements. Results The care bundle utilisation rate within 8 hours increased from 11% at baseline to 41% in the follow-up period at the intervention sites, whereas it remained below 3% at the control site. The most considerable improvements have been observed regarding documentation of CURB-65 (34% at baseline, 68% at follow-up) and the collection of lower respiratory tract samples (43% at baseline, 63% at follow-up). Conclusion Our study has demonstrated poor adherence to CAP guidelines at all sites at baseline. After implementing multiple tailored interventions, guideline adherence increased substantially. In conclusion, we recommend that CAP guidelines should be actively adapted in order to be followed in a daily routine.	[Fally, Markus] Herlev Gentofte Hosp, Dept Internal Med, Sect Pulm Dis, Hellerup, Denmark; [von Plessen, Christian] Unisante, Lausanne, Switzerland; [von Plessen, Christian] Univ Southern Denmark, Dept Clin Res, Odense, Denmark; [Anhoj, Jacob; Hellesoe, Anne-Marie Blok] Rigshosp, Ctr Diagnost Invest, Copenhagen, Denmark; [Benfield, Thomas; Seerup, Regitze; Israelsen, Simone] Amager Hvidovre Hosp, Dept Infect Dis, Hvidovre, Denmark; [Tarp, Britta; Diernaes, Emma] Silkeborg Reg Hosp, Diagnost Ctr, Silkeborg, Denmark; [Clausen, Lise Notander; Kolte, Lilian; Molzen, Line] Nordsjaellands Hosp, Dept Resp & Infect Dis, Hillerod, Denmark; [Ravn, Pernille] Herlev Gentofte Hosp, Dept Internal Med, Sect Infect Dis, Hellerup, Denmark	University of Southern Denmark; Rigshospitalet; University of Copenhagen; Aarhus University; Silkeborg Central Hospital	Fally, M (corresponding author), Herlev Gentofte Hosp, Dept Internal Med, Sect Pulm Dis, Hellerup, Denmark.	markus.fally@regionh.dk	Tarp, Britta/R-2229-2019; Fally, Markus/GYV-3933-2022; von Plessen, Christian/AFZ-7617-2022	Tarp, Britta/0000-0003-3611-4440; Fally, Markus/0000-0002-1339-2918; von Plessen, Christian/0000-0002-6134-6780; Bastrup Israelsen, Simone/0000-0002-0653-1289; Benfield, Thomas/0000-0003-0698-9385; Anhoj, Jacob/0000-0002-7701-1774	Danish Ministry of Health	Danish Ministry of Health	The study was funded by The Danish Ministry of Health and by the participating hospitals. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; Al-Tawfiq JA, 2010, AM J INFECT CONTROL, V38, P552, DOI 10.1016/j.ajic.2010.01.008; AnhOj J, 2018, J OPEN SOURCE SOFTWA, V3, P699, DOI DOI 10.21105/JOSS.00699; Anhoj J, 2018, BMC MED RES METHODOL, V18, DOI 10.1186/s12874-018-0564-0; [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953; [Anonymous], 2013, ACAD EMERGENCY MED, V20, pS265; [Anonymous], 2017, EPLASTY, V17, pic25; Arts DL, 2016, INT J MED INFORM, V89, P55, DOI 10.1016/j.ijmedinf.2016.02.009; Athlin S, 2018, INFECT DIS-NOR, V50, P247, DOI 10.1080/23744235.2017.1399316; Benneyan JC, 2003, QUAL SAF HEALTH CARE, V12, P458, DOI 10.1136/qhc.12.6.458; Berenholtz SM, 2011, INFECT CONT HOSP EP, V32, P305, DOI 10.1086/658938; Capelastegui A, 2004, CLIN INFECT DIS, V39, P955, DOI 10.1086/423960; Chalmers JD, 2010, THORAX, V65, P878, DOI 10.1136/thx.2009.133280; Daniel P, 2016, THORAX, V71, P1061, DOI 10.1136/thoraxjnl-2016-208937; Davidoff F, 2015, BMJ QUAL SAF, V24, P228, DOI 10.1136/bmjqs-2014-003627; Dean NC, 2006, CHEST, V130, P794, DOI 10.1378/chest.130.3.794; Eom JS, 2014, AM J INFECT CONTROL, V42, P34, DOI 10.1016/j.ajic.2013.06.023; Farquhar CM, 2002, MED J AUSTRALIA, V177, P502, DOI 10.5694/j.1326-5377.2002.tb04920.x; Fine MJ, 2003, AM J MED, V115, P343, DOI 10.1016/S0002-9343(03)00395-4; Flateau C, 2018, BMC INFECT DIS, V18, DOI 10.1186/s12879-018-3515-9; Grady D, 2018, JAMA INTERN MED, V178, P187, DOI 10.1001/jamainternmed.2017.6875; Halm EA, 2000, ARCH INTERN MED, V160, P98, DOI 10.1001/archinte.160.1.98; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hortmann M, 2014, EUR J EMERG MED, V21, P429, DOI 10.1097/MEJ.0000000000000106; Houck PM, 2004, ARCH INTERN MED, V164, P637, DOI 10.1001/archinte.164.6.637; Langley GL., 2009, IMPROVEMENT GUIDE PR, V2nd; Lee JS, 2016, JAMA-J AM MED ASSOC, V315, P593, DOI 10.1001/jama.2016.0115; Lee JS, 2014, JAMA INTERN MED, V174, P1806, DOI 10.1001/jamainternmed.2014.4501; Lim WS, 2016, THORAX, V71, P288, DOI 10.1136/thoraxjnl-2015-206834; Lim WS, 2009, THORAX, V64, piii1; Lloyd M, 2019, JAMA INTERN MED, V179, P1052, DOI 10.1001/jamainternmed.2019.1438; Mandell LA, 2007, CLIN INFECT DIS, V44, pS27, DOI 10.1086/511159; Mickan S, 2011, POSTGRAD MED J, V87, P670, DOI 10.1136/pgmj.2010.116012; Morris AC, 2011, CRIT CARE MED, V39, P2218, DOI 10.1097/CCM.0b013e3182227d52; Nathwani D, 2001, CLIN INFECT DIS, V32, P728, DOI 10.1086/319216; Pena-Lopez Y, 2016, INT J INFECT DIS, V52, P43, DOI 10.1016/j.ijid.2016.09.021; Resar R, 2012, IHI INNOVATION SERIE; Sogaard M, 2014, RESP MED, V108, P1214, DOI 10.1016/j.rmed.2014.05.004; Stralin K, 2008, INT J ANTIMICROB AG, V31, P3, DOI 10.1016/j.ijantimicag.2007.06.037; Uematsu H, 2014, INT J QUAL HEALTH C, V26, P100, DOI 10.1093/intqhc/mzt078; UK NCGC, 2014, PNEUM DIAGN MAN COMM; van der Eerden MM, 2005, EUR J CLIN MICROBIOL, V24, P241, DOI 10.1007/s10096-005-1316-8; Welte T, 2012, THORAX, V67, P71, DOI 10.1136/thx.2009.129502; 2014, REG ANESTH PAIN MED, V9	44	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2020	15	6							e0234308	10.1371/journal.pone.0234308	http://dx.doi.org/10.1371/journal.pone.0234308			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6QL	32525882	Green Published, gold			2023-01-03	WOS:000542036800080
J	Prasad, N; Newbern, EC; Trenholme, AA; Thompson, MG; McArthur, C; Wong, CA; Jelley, L; Aminisani, N; Huang, QS; Grant, CC				Prasad, Namrata; Newbern, E. Claire; Trenholme, Adrian A.; Thompson, Mark G.; McArthur, Colin; Wong, Conroy A.; Jelley, Lauren; Aminisani, Nayyereh; Huang, Q. Sue; Grant, Cameron C.			The health and economic burden of respiratory syncytial virus associated hospitalizations in adults	PLOS ONE			English	Article							HUMAN METAPNEUMOVIRUS; INFLUENZA; SURVEILLANCE; INFECTIONS; PCR	Background Respiratory syncytial virus (RSV) is increasingly recognized as an important cause of illness in adults; however, data on RSV disease and economic burden in this age group remain limited. We aimed to provide comprehensive estimates of RSV disease burden among adults aged >= 18 years. Methods During 2012-2015, population-based, active surveillance of acute respiratory infection (ARI) hospitalizations enabled estimation of the seasonal incidence of RSV hospitalizations and direct health costs in adults aged >= 18 years in Auckland, New Zealand. Results Of 4,600 ARI hospitalizations tested for RSV, 348 (7.6%) were RSV positive. The median (interquartile range) length of hospital stay for RSV positive patients was 4 (2-6) days. The seasonal incidence rate (IR) of RSV hospitalizations, corrected for non-testing, was 23.6 (95% confidence intervals [CI] 21.0-26.1) per 100,000 adults aged >= 18 years. Hospitalization risk increased with age with the highest incidence among adults aged >= 80 years (IR 190.8 per 100,000, 95% CI 137.6-244.0). Being of Maori or Pacific ethnicity or living in a neighborhood with low socioeconomic status (SES) were independently associated with increased RSV hospitalization rates. We estimate RSV-associated hospitalizations among adults aged >= 18 years to cost on average NZD $4,758 per event. Conclusions RSV infection is associated with considerable disease and economic cost in adults. RSV disproportionally affects adult sub-groups defined by age, ethnicity, and neighborhood SES. An effective RSV vaccine or RSV treatment may offer benefits for older adults.	[Prasad, Namrata; Newbern, E. Claire; Jelley, Lauren; Aminisani, Nayyereh; Huang, Q. Sue] Inst Environm Sci & Res, Wellington, New Zealand; [Prasad, Namrata; Grant, Cameron C.] Univ Auckland, Dept Paediat Child & Youth Hlth, Auckland, New Zealand; [Trenholme, Adrian A.; Wong, Conroy A.] Counties Manukau Dist Hlth Board, Auckland, New Zealand; [Thompson, Mark G.] US Ctr Dis Control & Prevent, Atlanta, GA USA; [McArthur, Colin] Auckland City Hosp, Dept Crit Care Med, Auckland, New Zealand; [Aminisani, Nayyereh] Neyshabur Univ Med Sci, Noncommunicable Dis Res Ctr, Neyshabur, Iran; [Grant, Cameron C.] Starship Childrens Hosp, Gen Paediat, Auckland, New Zealand	Institute of Environmental Science & Research (ESR) - New Zealand; University of Auckland; Centers for Disease Control & Prevention - USA; Auckland City Hospital; Starship Children's Hospital	Prasad, N; Newbern, EC (corresponding author), Inst Environm Sci & Res, Wellington, New Zealand.; Prasad, N (corresponding author), Univ Auckland, Dept Paediat Child & Youth Hlth, Auckland, New Zealand.	Namrata.Prasad@esr.cri.nz; Claire.Newbern@esr.cri.nz		Huang, Q. Sue/0000-0002-3923-5195; Prasad, Namrata/0000-0002-2268-279X	US Centers of Disease Control and Prevention [1U01IP000480-01]; Pacific Health Research scholarship by the New Zealand Health Research Council; New Zealand Ministry of Health	US Centers of Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA); Pacific Health Research scholarship by the New Zealand Health Research Council; New Zealand Ministry of Health	This work was supported by the US Centers of Disease Control and Prevention funded (cooperative agreement number 1U01IP000480-01) and a Pacific Health Research scholarship by the New Zealand Health Research Council to NP. Support in kind was provided by the New Zealand Ministry of Health.	Atkinson J., 2014, NZDEP2013 INDEX DEPR; Colosia AD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182321; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Falsey AR, 2002, J CLIN MICROBIOL, V40, P817, DOI 10.1128/JCM.40.3.817-820.2002; Fleming DM, 2015, BMC INFECT DIS, V15, DOI 10.1186/s12879-015-1218-z; Fowlkes A, 2014, J INFECT DIS, V209, P1715, DOI 10.1093/infdis/jit806; Groenwold RHH, 2012, AM J EPIDEMIOL, V175, P210, DOI 10.1093/aje/kwr302; Huang QS, 2014, WEST PAC SURVEILL RE, V5, P23, DOI [10.5365/wpsar.2014.5.1.004, 10.5365/WPSAR.2014.5.1.004]; Huang QS, 2015, INFLUENZA OTHER RESP, V9, P179, DOI 10.1111/irv.12315; Institute of Environmental Science and Research Limited, 2017, INFL SURV NZ ANN REP; Karron RA, 1999, J INFECT DIS, V180, P41, DOI 10.1086/314841; Kim C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021610; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; Mazur NI, 2018, LANCET INFECT DIS, V18, pE295, DOI 10.1016/S1473-3099(18)30292-5; Ministry of Health New Zealand. New Zealand Ministry of Health, 2019, NAT COLL SURV; New Zealand Ministry of Health, 2017, NZ CAS FRAM PUBL FUN; Royston P, 2011, J STAT SOFTW, V45, P1, DOI 10.18637/jss.v045.i04; Schanzer DL, 2018, INFLUENZA OTHER RESP, V12, P113, DOI 10.1111/irv.12497; Shi T, 2020, J INFECT DIS, V222, pS577, DOI 10.1093/infdis/jiz059; Shi T, 2020, J INFECT DIS, V222, pS563, DOI 10.1093/infdis/jiy662; Shu B, 2011, J CLIN MICROBIOL, V49, P2614, DOI 10.1128/JCM.02636-10; Statistics New Zealand, 2016, SUBN POP EST AG SEX; Statistics New Zealand, 2019, NZ PERIOD LIFE TABLE; Szewczuk E, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-113; The Lancet HIV, 2016, LANCET HIV, V3, pe191; Thompson WW, 2003, JAMA-J AM MED ASSOC, V289, P179, DOI 10.1001/jama.289.2.179; Tobias M, 2008, AUST NZ J PUBL HEAL, V32, P431, DOI 10.1111/j.1753-6405.2008.00275.x; Widmer K, 2014, INFLUENZA OTHER RESP, V8, P347, DOI 10.1111/irv.12234; Widmer K, 2012, J INFECT DIS, V206, P56, DOI 10.1093/infdis/jis309; Zhou H, 2012, CLIN INFECT DIS, V54, P1427, DOI 10.1093/cid/cis211	30	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2020	15	6							e0234235	10.1371/journal.pone.0234235	http://dx.doi.org/10.1371/journal.pone.0234235			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6QL	32525898	Green Published, gold			2023-01-03	WOS:000542036800024
J	Zheng, JN; Wu, JX; Wang, CY; Zhuang, SW; Chen, JB; Ye, F				Zheng, Jiani; Wu, Jingxun; Wang, Chunyue; Zhuang, Shiwen; Chen, Jianbo; Ye, Feng			Combination cyclin-dependent kinase 4/6 inhibitors and endocrine therapy versus endocrine monotherapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: A systematic review and meta-analysis	PLOS ONE			English	Review							FULVESTRANT 500 MG; ANASTROZOLE 1 MG; 1ST-LINE TREATMENT; DOUBLE-BLIND; PALBOCICLIB; ABEMACICLIB; RECURRENCE; RIBOCICLIB; LETROZOLE; SURVIVAL	Purpose This meta-analysis aimed to assess the efficacy and safety of cyclin-dependent kinase (CDK) 4/6 inhibitors plus endocrine therapy (ET) in hormonal receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC). Methods We searched PubMed, Embase, Cochrane, ClinicalTrials.gov., ASCO, ESMO and AACR databases from inception to October 10, 2019 for randomized controlled trials (RCTs) that compared CDK 4/6 inhibitors plus ET to single-agent ET with no treatment-line restriction. The main outcomes analyzed were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), clinical benefit rate (CBR), and adverse events (AEs). Results Of 938 identified studies, 9 RCTs with 5043 women were eligible and included. Compared with ET alone, CDK 4/6 inhibitors and ET combination improved in PFS (hazard ratio (HR) 0.54, 95% confidence interval (CI) 0.50-0.59, p< 0.00001) and OS (HR 0.77, 95% CI 0.69-0.85, p< 0.00001), regardless of ET strategies (HR 0.54, 95% CI 0.50-0.59 in PFS; HR 0.77, 95% CI 0.69-0.85 in OS), treatment line of advanced disease (HR 0.52, 95% CI 0.46-0.59 in PFS; HR 0.75, 95% CI 0.66-0.85 in OS) and menopausal status (HR 0.54, 95% CI 0.50-0.58 in PFS; HR 0.76, 95% CI 0.68-0.84 in OS). Higher risk of grade 3/4 AEs (RR 2.66, 95% CI 2.44-2.90, p < 0.00001) were observed in the combination group than in the ET group. Conclusions Combination therapy with CDK 4/6 inhibitors and ET prolongs survival in HR+/ HER2- ABC. This combination is a better therapeutic strategy than endocrine monotherapy in HR+/HER2- ABC, regardless of treatment line, menopausal status and other individual characteristics.	[Zheng, Jiani; Wu, Jingxun; Wang, Chunyue; Zhuang, Shiwen; Chen, Jianbo; Ye, Feng] Fujian Med Univ, Clin Med Sch 1, Fuzhou, Peoples R China; [Zheng, Jiani; Wu, Jingxun; Wang, Chunyue; Zhuang, Shiwen; Chen, Jianbo; Ye, Feng] Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Hosp, Dept Med Oncol, Xiamen, Peoples R China; [Zheng, Jiani; Wu, Jingxun; Wang, Chunyue; Zhuang, Shiwen; Chen, Jianbo; Ye, Feng] Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Hosp, Xiamen, Peoples R China	Fujian Medical University; Xiamen University; Xiamen University	Ye, F (corresponding author), Fujian Med Univ, Clin Med Sch 1, Fuzhou, Peoples R China.; Ye, F (corresponding author), Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Hosp, Dept Med Oncol, Xiamen, Peoples R China.; Ye, F (corresponding author), Xiamen Univ, Affiliated Hosp 1, Xiamen Canc Hosp, Xiamen, Peoples R China.	yefengdoctor@xmu.edu.cn			Cancer Hospital Foundation from the First Affiliated Hospital of Xiamen University [ZLYYA201702]; Youth Scientific Research Project of Fujian Provincial Health and Family Planning Commission [2016-2-63]	Cancer Hospital Foundation from the First Affiliated Hospital of Xiamen University; Youth Scientific Research Project of Fujian Provincial Health and Family Planning Commission	This study was funded by Cancer Hospital Foundation from the First Affiliated Hospital of Xiamen University (ZLYYA201702) to CW, and Youth Scientific Research Project of Fujian Provincial Health and Family Planning Commission (2016-2-63) to JW. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2018, CANC DISCOV, V8, pOF6; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cardoso F, 2018, ANN ONCOL, V29, P1634, DOI 10.1093/annonc/mdy192; Colleoni M, 2016, J CLIN ONCOL, V34, P927, DOI 10.1200/JCO.2015.62.3504; Cristofanilli M, 2016, LANCET ONCOL, V17, P425, DOI 10.1016/S1470-2045(15)00613-0; Deng YF, 2018, CLIN BREAST CANCER, V18, pE943, DOI 10.1016/j.clbc.2018.04.017; Dong JY, 2011, J AM COLL CARDIOL, V58, P1378, DOI 10.1016/j.jacc.2011.06.024; Ellis MJ, 2015, J CLIN ONCOL, V33, P3781, DOI 10.1200/JCO.2015.61.5831; Farooq F, 2019, J CLIN ONCOLOGY, V37; Finn RS, 2016, NEW ENGL J MED, V375, P1925, DOI 10.1056/NEJMoa1607303; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Goetz MP, 2017, J CLIN ONCOL, V35, P3638, DOI 10.1200/JCO.2017.75.6155; Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]; Hortobagyi GN, 2018, ANN ONCOL, V29, P1541, DOI 10.1093/annonc/mdy155; Hortobagyi GN, 2016, NEW ENGL J MED, V375, P1738, DOI 10.1056/NEJMoa1609709; Hosford SR, 2014, PHARMACOGEN PERS MED, V7, P203, DOI 10.2147/PGPM.S52762; Howlader N, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju055; Hu WY, 2016, CLIN CANCER RES, V22, P2000, DOI 10.1158/1078-0432.CCR-15-1421; Im SA, 2019, NEW ENGL J MED, V381, P307, DOI 10.1056/NEJMoa1903765; Jiang Z., 2019, ANN ONCOLOGY S5, DOI 10.1093/annonc/mdz394.014; Johnston S, 2019, NPJ BREAST CANCER, V5, DOI 10.1038/s41523-018-0097-z; Lee KWC, 2019, BREAST CANCER RES TR, V174, P271, DOI 10.1007/s10549-018-5054-x; National Comprehensive Cancer Network, 2019, BREAST CANC VERS 3; Robertson JFR, 2016, LANCET, V388, P2997, DOI 10.1016/S0140-6736(16)32389-3; Rugo HS, 2019, BREAST CANCER RES TR, V174, P719, DOI 10.1007/s10549-018-05125-4; Sestak I, 2013, JNCI-J NATL CANCER I, V105, P1504, DOI 10.1093/jnci/djt244; Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689; Slamon DJ, 2019, ANN ONCOL, V30; Slamon DJ, 2020, NEW ENGL J MED, V382, P514, DOI 10.1056/NEJMoa1911149; Slamon DJ, 2018, J CLIN ONCOL, V36, P2465, DOI 10.1200/JCO.2018.78.9909; Sledge GW, 2017, J CLIN ONCOL, V35, P2875, DOI 10.1200/JCO.2017.73.7585; Sledge Jr. GW, 2019, JAMA ONCOLOGY; Tripathy D, 2018, LANCET ONCOL, V19, P904, DOI 10.1016/S1470-2045(18)30292-4; Turner NC, 2018, NEW ENGL J MED, V379, P1926, DOI 10.1056/NEJMoa1810527; Wang Y, 2018, J CLIN ONCOLOGY, V36	35	8	8	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2020	15	6							e0233571	10.1371/journal.pone.0233571	http://dx.doi.org/10.1371/journal.pone.0233571			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6PX	32497134	Green Published, gold			2023-01-03	WOS:000542035200051
J	Furukawa, NW; Zhu, WM; Huang, YLA; Shrestha, RK; Hoover, KW				Furukawa, Nathan W.; Zhu, Weiming; Huang, Ya-Lin A.; Shrestha, Ram K.; Hoover, Karen W.			National Trends in Drug Payments for HIV Preexposure Prophylaxis in the United States, 2014 to 2018 A Retrospective Cohort Study	ANNALS OF INTERNAL MEDICINE			English	Article							COST-EFFECTIVENESS; ANTIRETROVIRAL PROPHYLAXIS; MEN; PREVENTION; SEX; BARRIERS; RISK	Background: Use of HIV preexposure prophylaxis (PrEP) has increased nationwide, but the magnitude and distribution of PrEP medication costs across the health care system are unknown. Objective: To estimate out-of-pocket (OOP) and third-party payments using a large pharmacy database. Design: Retrospective cohort study. Setting: Prescriptions for tenofovir disoproxil fumarate with emtricitabine (TDF-FTC) for PrEP in the United States in the IQVIA Longitudinal Prescriptions database, which covers more than 90% of retail pharmacy prescriptions. Measurements: Third-party, OOP, and total payments were compared by third-party payer, classified as commercial, Medicaid, Medicare, manufacturer assistance program, or other. Missing payment data were imputed using a generalized linear model to estimate overall PrEP medication payments. Results: Annual PrEP prescriptions increased from 73 739 to 1 100 684 during 2014 to 2018. Over that period, the average total payment for 30 TDF-FTC tablets increased from $1350 to $1638 (5.0% compound annual growth rate) and the average OOP payment increased from $54 to $94 (14.9% compound annual growth rate). Of the $1638 in total payments per 30 TDF-FTC tablets in 2018, OOP payments accounted for $94 (5.7%) and third-party payments for $1544 (94.3%). Out-of-pocket payments per 30 tablets were lower among Medicaid recipients ($3) than among those with Medicare ($80) or commercial insurance ($107). Payments for PrEP medication in the IQVIA database in 2018 totaled $2.08 billion; $1.68 billion (80.7%) originated from prescriptions for persons with commercial insurance, $200 million (9.6%) for those with Medicaid, $48 million (2.3%) for those with Medicare, and $127 million (6.1%) for those with manufacturer assistance. Limitation: The IQVIA database does not capture every prescription nationwide. Conclusion: Third-party and OOP payments per 30 TDF-FTC tablets increased annually. The $2.08 billion in PrEP medication payments in 2018 is an underestimation of national costs. High costs to the health care system may hinder PrEP expansion.	[Furukawa, Nathan W.; Zhu, Weiming; Huang, Ya-Lin A.; Shrestha, Ram K.; Hoover, Karen W.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA; [Furukawa, Nathan W.; Zhu, Weiming; Huang, Ya-Lin A.; Shrestha, Ram K.; Hoover, Karen W.] 1600 Clifton Rd NE,Mailstop US8-4, Atlanta, GA 30329 USA	Centers for Disease Control & Prevention - USA	Furukawa, NW (corresponding author), 1600 Clifton Rd NE,Mailstop US8-4, Atlanta, GA 30329 USA.	nmt6@cdc.gov		Shrestha, Ram/0000-0002-2812-8933	Centers for Disease Control and Prevention	Centers for Disease Control and Prevention(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA)	Centers for Disease Control and Prevention.	[Anonymous], 2019, SUPPLEMENT APPROVAL; [Anonymous], 2019, GUID US ANT AG AD AD; [Anonymous], 2017, PREEXPOSURE PROPHYLA; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Bernard CL, 2016, ANN INTERN MED, V165, P10, DOI 10.7326/M15-2634; Brewer DJ., 2014, ENCY ED EC FINANCE; Cambiano V, 2016, CURR OPIN HIV AIDS, V11, P56, DOI 10.1097/COH.0000000000000217; Chartier Maggie, 2018, Fed Pract, V35, pS42; Choopanya K, 2013, LANCET, V381, P2083, DOI 10.1016/S0140-6736(13)61127-7; Coy KC, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25252; Dafny L, 2017, AM ECON J-ECON POLIC, V9, P91, DOI 10.1257/pol.20150588; Drabo EF, 2016, CLIN INFECT DIS, V63, P1495, DOI 10.1093/cid/ciw578; Eron JJ, 2019, ANTIVIR RES, V170, DOI 10.1016/j.antiviral.2019.104543; Fauci AS, 2019, JAMA-J AM MED ASSOC, V321, P844, DOI 10.1001/jama.2019.1343; Furukawa NW, 2020, PUBLIC HEALTH REP, V135, P202, DOI 10.1177/0033354920904085; Galbraith S, 2012, AUSTR NZ J STAT, V54, P251, DOI [10.1111/j.1467-842X.2012.00656.x, DOI 10.1111/J.1467-842X.2012.00656.X]; Gilead Sciences, 2019, Q REPORT; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Hare CB, 2019, C RETR OPP INF SEATT, P41; Harris NS, 2019, MMWR-MORBID MORTAL W, V68, P1117, DOI 10.15585/mmwr.mm6848e1; Hill A, 2019, J VIRUS ERAD, V5, P41; Huang YLA, 2018, MMWR-MORBID MORTAL W, V67, P1147, DOI 10.15585/mmwr.mm6741a3; JUUSOLA JL, 2012, ANN INTERN MED, V156, P541, DOI DOI 10.1059/0003-4819-156-8-201204170-00001; Marks SJ, 2017, AIDS PATIENT CARE ST, V31, P470, DOI 10.1089/apc.2017.0171; McKenney J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178170; Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273; Nunn AS, 2017, AIDS, V31, P731, DOI 10.1097/QAD.0000000000001385; Owens DK, 2019, JAMA-J AM MED ASSOC, V321, P2203, DOI 10.1001/jama.2019.6390; Patel RR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178737; Pilkington V, 2018, J VIRUS ERAD, V4, P215; Rolle CP, 2017, INT J STD AIDS, V28, P849, DOI 10.1177/0956462416675095; Smith DK, 2017, JAIDS-J ACQ IMM DEF, V76, P465, DOI [10.1097/QAI.0000000000001532, 10.1097/qai.0000000000001532]; Sullivan PS, 2018, ANN EPIDEMIOL, V28, P833, DOI 10.1016/j.annepidem.2018.06.009; Thigpen MC, 2012, NEW ENGL J MED, V367, P423, DOI 10.1056/NEJMoa1110711; Tseng CW, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.2739; Walensky RP, 2020, ANN INTERN MED, V172, P583, DOI [10.7326/M19-3478, 10.7326/L20-0693]; Whitfield THF, 2018, AIDS BEHAV, V22, P3566, DOI 10.1007/s10461-018-2045-1	37	13	13	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 17	2020	173	10					799	+		10.7326/M20-0786	http://dx.doi.org/10.7326/M20-0786			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OU5XD	32894696	Green Accepted			2023-01-03	WOS:000591600700015
J	Charlie-Silva, I; Feitosa, NM; Gomes, JMM; Hoyos, DCD; Mattioli, CC; Eto, SF; Fernandes, DC; Belo, MAD; Silva, JD; de Barros, ALB; Correa, JD; de Menezes, GB; Fukushima, HCS; Castro, TFD; Borra, RC; Pierezan, F; de Melo, NFS; Fraceto, LF				Charlie-Silva, Ives; Feitosa, Natalia Martins; Mendonca Gomes, Juliana Moreira; de Melo Hoyos, Daniela Chemim; Mattioli, Cristiano Campos; Eto, Silas Fernandes; Fernandes, Dayanne Carla; de Andrade Belo, Marco Antonio; Silva, Juliana de Oliveira; Branco de Barros, Andre Luis; Correa Junior, Jose Dias; de Menezes, Gustavo Batista; Silva Fukushima, Hirla Costa; Dias Castro, Tassia Flavia; Borra, Ricardo Carneiro; Pierezan, Felipe; Silva de Melo, Nathalie Ferreira; Fraceto, Leonardo Fernandes			Potential of mucoadhesive nanocapsules in drug release and toxicology in zebrafish	PLOS ONE			English	Article							PHYSICOCHEMICAL PROPERTIES; RAINBOW-TROUT; BENZOCAINE; NANOPARTICLES; VALIDATION; EFFICACY; FISH	Mucoadhesive polymeric nanocapsules have attracted interest of researchers from different fields from natural sciences because of their ability to interact with the mucosa and increase drug permeation. Anesthesia by immersion causes absorption through the skin and gills of fish, so it is important to evaluate the exposure of these organs to drug nanosystems. Benzocaine (BENZ) is one of the most popular anesthetic agents used in fish anesthesia, but it has drawbacks because of its low bioavailability, resulting in weak absorption after immersion. Here we describe method developed for preparing and characterizing chitosan-coated PLGA mucoadhesive nanoparticles containing BENZ (NPMAs) for zebrafish immersion anesthesia. We determined the lowest effective concentration, characterized the interaction of the mucoadhesive system with fish, measured the anesthetic efficacy, and evaluated possible toxic effects in embryos and adults exposed to the nanoformulations. This study opens perspectives for using nanoformulations prepared with BENZ in aquaculture, allowing reduction of dosage as well as promoting more effective anesthesia and improved interaction with the mucoadhesive system of fish.	[Charlie-Silva, Ives] Univ Sao Paulo ICB USP, Dept Pharmacol, Sao Paulo, SP, Brazil; [Feitosa, Natalia Martins] Univ Fed Rio de Janeiro UFRJ, Inst Biodiversidade & Sustentabilidade NUPEM, Lab Integrad Biociencias Translacionais LIBT, Macae, RJ, Brazil; [Mendonca Gomes, Juliana Moreira; Correa Junior, Jose Dias; de Menezes, Gustavo Batista] ICB UFMG, Dept Morphol, Belo Horizonte, MG, Brazil; [de Melo Hoyos, Daniela Chemim] Univ Fed Minas Gerais, Aquiculture Lab Laqua, Belo Horizonte, MG, Brazil; [Mattioli, Cristiano Campos; de Andrade Belo, Marco Antonio] Sao Paulo State Univ, Dept Prevent Vet Med, Jaboticabal, SP, Brazil; [Eto, Silas Fernandes] Fed Univ Roraima UFRR, Dept Postgrad Hlth SciencesPROCISA, Boa Vista, Parana, Brazil; [Fernandes, Dayanne Carla] Sao Paulo State Univ, Inst Chem, UNESP, Araraquara, SP, Brazil; [de Andrade Belo, Marco Antonio] Brasil Univ, Lab Anim Pharmacol & Toxicol, Descalvado, SP, Brazil; [Silva, Juliana de Oliveira; Branco de Barros, Andre Luis] Univ Fed Minas Gerais, Dept Clin & Toxicol Anal, Fac Pharm, Belo Horizonte, MG, Brazil; [Silva Fukushima, Hirla Costa; Dias Castro, Tassia Flavia; Borra, Ricardo Carneiro] Univ Fed Sao Carlos, Lab Appl Immunol, Sao Carlos, SP, Brazil; [Pierezan, Felipe] Univ Fed Minas Gerais, Dept Clin & Vet Surg, Sch Vet Med, Belo Horizonte, MG, Brazil; [Silva de Melo, Nathalie Ferreira] Fac Med Sao Leopoldo Mandic, Araras, SP, Brazil; [Fraceto, Leonardo Fernandes] Sao Paulo State Univ, Inst Sci & Technol Sorocaba, Sorocaba, SP, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal de Minas Gerais; Universidade Federal de Minas Gerais; Universidade Estadual Paulista; Universidade Federal de Roraima; Universidade Estadual Paulista; Universidade Federal de Minas Gerais; Universidade Federal de Sao Carlos; Universidade Federal de Minas Gerais; Faculdade Sao Leopoldo Mandic; Universidade Estadual Paulista	Charlie-Silva, I (corresponding author), Univ Sao Paulo ICB USP, Dept Pharmacol, Sao Paulo, SP, Brazil.	charliesilva4@hotmail.com	Corrêa, José Dias/P-3815-2019; Feitosa, Natalia M/B-6991-2013; Fraceto, Leonardo/C-4468-2012; Mattioli, Cristiano/AAJ-7662-2020; Gomes, Juliana Moreira Mendonça/AAG-8391-2019; Belo, Marco/H-2183-2013; de Barros, Andre Luis/O-2615-2017; Fraceto, Leonardo Fernandes/ABF-2797-2021; FAPESP, CDMF/J-3591-2015	Corrêa, José Dias/0000-0002-8623-8524; Mattioli, Cristiano/0000-0002-4271-5309; Belo, Marco/0000-0001-5845-3940; de Barros, Andre Luis/0000-0002-7641-6585; Fraceto, Leonardo Fernandes/0000-0002-2827-2038; Fernandes, Dayanne Carla/0000-0003-2037-1397; Moreira Mendonca Gomes, Juliana/0000-0002-5444-5764; FAPESP, CDMF/0000-0002-4464-0937; Chemim de Melo Hoyos, Daniela/0000-0001-6196-2404; Charlie-Silva, Ives/0000-0002-7572-2767	Sao Paulo Research Foundation [2013/25971-9, 2018/07098-0, 2019/19939-1]; Minas Gerais Research Foundation [APQ-02913-17]; National Council for Scientific and Technological Development [301473/2016-1, 477816/2013-4]; Coordination for Improvement of Higher Education Personnel	Sao Paulo Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Minas Gerais Research Foundation(Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG)); National Council for Scientific and Technological Development(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Coordination for Improvement of Higher Education Personnel	Financial and material support was provided through the Sao Paulo Research Foundation (#2013/25971-9 for author MAdAB, #2018/07098-0 and #2019/19939-1 for author ICS), by the Minas Gerais Research Foundation (#APQ-02913-17 for author JDCJ), by the National Council for Scientific and Technological Development (#301473/2016-1 for author JDCJ, #477816/2013-4 for author MAdAB), and by the Coordination for Improvement of Higher Education Personnel. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Al-Nemrawi NK, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11010028; ALLEN JL, 1988, PROG FISH CULT, V50, P59, DOI 10.1577/1548-8640(1988)050&lt;0059:ROBIRT&gt;2.3.CO;2; Anderson W, 2013, J COLLOID INTERF SCI, V405, P322, DOI 10.1016/j.jcis.2013.02.030; [Anonymous], 2016, J NANOBIOTECHNOLOGY; Barboza FM, 2014, SCI WORLD J, DOI 10.1155/2014/268107; Bolasina SN, 2017, AQUACULT REP, V6, P56, DOI 10.1016/j.aqrep.2017.04.002; Brox S, 2016, ENVIRON SCI TECHNOL, V50, P10264, DOI 10.1021/acs.est.6b04325; Charlie-Silva I, 2018, FISH SHELLFISH IMMUN; Charlie-Silva I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41312-z; Clemente-Napimoga JT, 2012, LIFE SCI, V90, P944, DOI 10.1016/j.lfs.2012.04.035; Demare P, 2012, J CHEM EDUC, V89, P147, DOI 10.1021/ed100838a; Dudhani AR, 2010, CARBOHYD POLYM, V81, P243, DOI 10.1016/j.carbpol.2010.02.026; Ehrlich O, 2019, ZEBRAFISH, V16, P451, DOI 10.1089/zeb.2019.1737; Eto SF, 2018, FISH SHELLFISH IMMUN, V76, P153, DOI 10.1016/j.fsi.2018.02.048; Fabiani BM, 2013, ACTA SCI ANIM SCI; Gholipourkanani H, 2015, J FISH AQUAT SCI; Gilderhus PA, 1987, N AM J FISH MANAGE; Gomez D, 2013, FISH SHELLFISH IMMUN, V35, P1729, DOI 10.1016/j.fsi.2013.09.032; Grillo R, 2014, INT J ENV SCI TECHNO; Grillo R, 2010, J DRUG TARGET, V18, P688, DOI 10.3109/10611861003649738; Grillo R, 2009, LAT AM J PHARM, V28, P393; Heo GJ, 2010, VET ANAESTH ANALG, V37, P132, DOI 10.1111/j.1467-2995.2009.00510.x; Khair-ul-Bariyah S, 2020, MINI-REV MED CHEM, V20, P3, DOI 10.2174/1389557519666190913145423; MacRae CA, 2015, NAT REV DRUG DISCOV, V14, P721, DOI 10.1038/nrd4627; Marques PE, 2015, NAT PROTOC, V10, P258, DOI 10.1038/nprot.2015.006; Melo NFS de, 2017, J NANOSCI NANOTECHNO; Moraes CM, 2009, MATER SCI ENG B-ADV, V165, P243, DOI 10.1016/j.mseb.2009.06.011; Nangia S, 2012, LANGMUIR, V28, P17666, DOI 10.1021/la303449d; Nusslein-Volhard C., 2002, ZEBRAFISH PRACTICAL, P2002, DOI 10.1017/S0016672303216384; Oberdorster G, 2009, J NANOSCI NANOTECHNO, V9, P4996, DOI 10.1166/jnn.2009.GR02; OECD, 2013, GUID TEST CHEM, DOI DOI 10.1787/9789264203709-EN; Olt J, 2016, J PHYSIOL-LONDON, V594, P5427, DOI 10.1113/JP271794; Park CE, 2015, FOOD SCI BIOTECHNOL, V24, P1725, DOI 10.1007/s10068-015-0224-7; Readman GD, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06917-2; Ross LG, 2008, ANAESTHETIC AND SEDATIVE TECHNIQUES FOR AQUATIC ANIMALS, 3RD EDITION, P1, DOI 10.1002/9781444302264; Shaikh R, 2011, J PHARM BIOALLIED SC, V3, P89, DOI 10.4103/0975-7406.76478; de Melo NFS, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161796; de Melo NFS, 2014, COLLOID SURFACE B, V121, P66, DOI 10.1016/j.colsurfb.2014.05.035; De Melo NFS, 2012, J PHARM SCI-US, V101, P1157, DOI 10.1002/jps.22829; de Melo NFS, 2011, PHARM RES-DORDR, V28, P1984, DOI 10.1007/s11095-011-0425-6; Simovic S, 2015, NANOMED-NANOTECHNOL, V11, P1169, DOI 10.1016/j.nano.2015.02.016; Sosnik A, 2015, BIOTECHNOL ADV, V33, P1380, DOI 10.1016/j.biotechadv.2015.01.003; Torchilin VP, 2014, NAT REV DRUG DISCOV, V13, P813, DOI 10.1038/nrd4333; Wang YF, 2017, F1000RESEARCH; WEDEMEYER G, 1970, J FISH RES BOARD CAN, V27, P909, DOI 10.1139/f70-097; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE, V4th; Wynd BM, 2017, ZEBRAFISH, V14, P1, DOI 10.1089/zeb.2016.1289	47	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2020	15	9							e0238823	10.1371/journal.pone.0238823	http://dx.doi.org/10.1371/journal.pone.0238823			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY2ZZ	32970684	Green Published, gold			2023-01-03	WOS:000576265600090
J	Nakano, H; Hasebe, H; Murakami, K; Cho, H; Kondo, D; Iino, N; Fukuchi, T				Nakano, Hideyuki; Hasebe, Hiruma; Murakami, Kenji; Cho, Hiroyuki; Kondo, Daisuke; Iino, Noriaki; Fukuchi, Takeo			Choroid structure analysis following initiation of hemodialysis by using swept-source optical coherence tomography in patients with and without diabetes	PLOS ONE			English	Article							PANRETINAL PHOTOCOAGULATION; THICKNESS; BINARIZATION; RETINOPATHY; RESPONSES; FEATURES; LIGHT; EYES	We aimed to evaluate choroid structural changes using swept-source optical coherence tomography (SS-OCT) following hemodialysis initiation in diabetic and nondiabetic patients with end-stage kidney disease (ESKD). In this multicenter, prospective, cross-sectional study, diabetic (DM group; 30 eyes; 16 patients) and nondiabetic patients (NDM group; 30 eyes; 15 patients) with ESKD were evaluated after hemodialysis initiation. SS-OCT findings were analyzed using a manual delineation technique and binarization method before the first and last hemodialysis sessions, conducted approximately 2 weeks apart. Subfoveal choroidal thickness changes and mean large choroidal vessel layer thickness were significantly greater in the DM group (-13.3% +/- 2.5% and -14.5% +/- 5.2%, respectively) than the NDM group (-9.5% +/- 3.1% and -9.2% +/- 3.4%, respectively; p = 0.049 and p = 0.02, respectively). Binarized SS-OCT analysis revealed that the mean subfoveal choroidal area was significantly larger in the DM group (-21.9% +/- 6.5%) than the NDM group (-17.2% +/- 5.9%; p = 0.032). The change ratio in mean luminal area values was significantly greater in the DM group (-27.7% +/- 8.7%) than the NDM group (-17.7% +/- 5.8%; p = 0.007). The DM group exhibited substantial changes in the choroidal layer, possibly reflecting choroidal vascular disorders caused by diabetes.	[Nakano, Hideyuki; Hasebe, Hiruma; Cho, Hiroyuki; Fukuchi, Takeo] Niigata Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Niigata, Japan; [Murakami, Kenji] Niigata City Gen Hosp, Dept Ophthalmol, Niigata, Japan; [Cho, Hiroyuki] Uonuma Kikan Hosp, Dept Ophthalmol, Minamiuonuma, Japan; [Kondo, Daisuke] Niigata City Gen Hosp, Dept Nephrol, Niigata, Japan; [Iino, Noriaki] Uonuma Kikan Hosp, Dept Nephrol, Minamiuonuma, Japan	Niigata University	Nakano, H (corresponding author), Niigata Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Niigata, Japan.	hyrn1070@med.niigata-u.ac.jp		Hooper, Jessica/0000-0002-2012-3572				Azem N, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/709862; Berkowitz BA, 2015, INVEST OPHTH VIS SCI, V56, P606, DOI 10.1167/iovs.14-15687; Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066; Chang IB, 2017, RETINA-J RET VIT DIS, V37, P896, DOI 10.1097/IAE.0000000000001262; CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649; FAUCHALD P, 1986, KIDNEY INT, V29, P895, DOI 10.1038/ki.1986.83; Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014; Gerendas BS, 2014, AM J OPHTHALMOL, V158, P1039, DOI 10.1016/j.ajo.2014.08.001; Gupta P, 2017, BRIT J OPHTHALMOL, V101, P1038, DOI 10.1136/bjophthalmol-2016-309366; HIDAYAT AA, 1985, OPHTHALMOLOGY, V92, P512; Hua R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083494; Ishibazawa A, 2015, INVEST OPHTH VIS SCI, V56, P6534, DOI 10.1167/iovs.15-16719; Lee CJ, 2011, INVEST OPHTH VIS SCI, V52, P3398, DOI 10.1167/iovs.10-6560; Lee Hyo Kyung, 2013, Korean J Ophthalmol, V27, P433, DOI 10.3341/kjo.2013.27.6.433; Lutty GA, 1997, AM J PATHOL, V151, P707; Michalewski J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/639160; Mori F, 2003, JPN J OPHTHALMOL, V47, P621, DOI 10.1016/j.jjo.2003.08.004; Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002; Querques G, 2012, INVEST OPHTH VIS SCI, V53, P6017, DOI 10.1167/iovs.12-9692; RAMSAY RC, 1979, AM J OPHTHALMOL, V87, P305, DOI 10.1016/0002-9394(79)90068-0; Regatieri CV, 2012, RETINA-J RET VIT DIS, V32, P563, DOI [10.1097/IAE.0b013e31822f5678, 10.1097/IAE.0B013E31822F5678]; Sassani JW, 2014, OCULAR PATHOLOGY; Schocket Lisa S., 2004, International Ophthalmology, V25, P89, DOI 10.1023/B:INTE.0000031744.93778.60; Shin YU, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015421; Shin YU, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-35562-6; Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005; Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447; STITT AW, 1995, GRAEF ARCH CLIN EXP, V233, P699, DOI 10.1007/BF00164672; TORNQUIST P, 1990, EYE, V4, P303, DOI 10.1038/eye.1990.41; WILSON DJ, 1987, ARCH OPHTHALMOL-CHIC, V105, P239, DOI 10.1001/archopht.1987.01060020093036	30	0	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2020	15	9							e0239072	10.1371/journal.pone.0239072	http://dx.doi.org/10.1371/journal.pone.0239072			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR9MU	32915894	gold, Green Published			2023-01-03	WOS:000571887500133
J	Falkenhain, K; Ruiz-Uribe, NE; Haft-Javaherian, M; Ali, M; Catchers, S; Michelucci, PE; Schaffer, CB; Bracko, O				Falkenhain, Kaja; Ruiz-Uribe, Nancy E.; Haft-Javaherian, Mohammad; Ali, Muhammad; Catchers, Stall; Michelucci, Pietro E.; Schaffer, Chris B.; Bracko, Oliver			A pilot study investigating the effects of voluntary exercise on capillary stalling and cerebral blood flow in the APP/PS1 mouse model of Alzheimer's disease	PLOS ONE			English	Article							PHYSICAL-ACTIVITY; COGNITIVE FUNCTION; WHITE-MATTER; A-BETA; SYNAPTIC PLASTICITY; RUNNING EXERCISE; TRANSGENIC MICE; SPATIAL MEMORY; OLDER; DECLINE	Exercise exerts a beneficial effect on the major pathological and clinical symptoms associated with Alzheimer's disease in humans and mouse models of the disease. While numerous mechanisms for such benefits from exercise have been proposed, a clear understanding of the causal links remains elusive. Recent studies also suggest that cerebral blood flow in the brain of both Alzheimer's patients and mouse models of the disease is decreased and that the cognitive symptoms can be improved when blood flow is restored. We therefore hypothesized that the mitigating effect of exercise on the development and progression of Alzheimer's disease may be mediated through an increase in the otherwise reduced brain blood flow. To test this idea, we performed a pilot study to examine the impact of three months of voluntary wheel running in a small cohort of similar to 1-year-old APP/PS1 mice on short-term memory function, brain inflammation, amyloid deposition, and baseline cerebral blood flow. Our findings that exercise led to a trend toward improved spatial short-term memory, reduced brain inflammation, markedly increased neurogenesis in the dentate gyrus, and a reduction in hippocampal amyloid-beta deposits are consistent with other reports on the impact of exercise on the progression of Alzheimer's related symptoms in mouse models. Notably, we did not observe any impact of wheel running on overall baseline blood flow nor on the incidence of non-flowing capillaries, a mechanism we recently identified as one contributing factor to cerebral blood flow deficits in mouse models of Alzheimer's disease. Overall, our findings add to the emerging picture of differential effects of exercise on cognition and blood flow in Alzheimer's disease pathology by showing that capillary stalling is not decreased following exercise.	[Falkenhain, Kaja; Ruiz-Uribe, Nancy E.; Haft-Javaherian, Mohammad; Ali, Muhammad; Schaffer, Chris B.; Bracko, Oliver] Cornell Univ, Meinig Sch Biomed Engn, Ithaca, NY 14850 USA; [Falkenhain, Kaja] Osnabruck Univ, Inst Cognit Sci, Osnabruck, Germany; [Michelucci, Pietro E.] Human Computat Inst, Ithaca, NY USA	Cornell University; University Osnabruck	Bracko, O (corresponding author), Cornell Univ, Meinig Sch Biomed Engn, Ithaca, NY 14850 USA.	ob84@cornell.edu	Schaffer, Chris B./A-7409-2008; Falkenhain, Kaja/AAZ-6981-2021; Bracko, Oliver/AAU-2753-2020; Haft-Javaherian, Mohammad/P-1379-2014	Schaffer, Chris B./0000-0002-7800-9596; Falkenhain, Kaja/0000-0002-3240-964X; Bracko, Oliver/0000-0002-9414-6590; Michelucci, Pietro/0000-0002-9819-7221; Ruiz-Uribe, Nancy E./0000-0003-0671-9617; Haft-Javaherian, Mohammad/0000-0002-8551-5008	Studienstiftung des Deutschen Volkes; BrightFocus Foundation [CA2017606, A2017488S]; National Institute on Aging [AG049952]; National Institute of Neurological Disorders and Stroke [NS108472]; Deutsche Forschungsgemeinschaft; Deutscher Akademischer Austauschdienst	Studienstiftung des Deutschen Volkes; BrightFocus Foundation(BrightFocus Foundation); National Institute on Aging(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutscher Akademischer Austauschdienst(Deutscher Akademischer Austausch Dienst (DAAD))	Studienstiftung des Deutschen Volkes_ Kaja Falkenhain BrightFocus Foundation CA2017606 Pietro E Michelucci BrightFocus Foundation A2017488S Chris B Schaffer National Institute on Aging AG049952 Chris B Schaffer National Institute of Neurological Disorders and Stroke NS108472 Chris B Schaffer Deutsche Forschungsgemeinschaft _ Oliver Bracko Deutscher Akademischer Austauschdienst _ Oliver Bracko.	Adlard PA, 2005, J NEUROSCI, V25, P4217, DOI 10.1523/JNEUROSCI.0496-05.2005; Ahlskog JE, 2011, MAYO CLIN PROC, V86, P876, DOI 10.4065/mcp.2011.0252; Ahn HJ, 2010, P NATL ACAD SCI USA, V107, P21812, DOI 10.1073/pnas.1010373107; Alfini AJ, 2019, J ALZHEIMERS DIS, V67, P671, DOI 10.3233/JAD-180728; Anderson-Hanley C, 2012, AM J PREV MED, V42, P109, DOI 10.1016/j.amepre.2011.10.016; [Anonymous], 2017, MEMORY STUDIES, V10, P144; [Anonymous], 2018, CMCLR, V4, P17; [Anonymous], 2018, DIABETES CARE S1, V2018, pS1; [Anonymous], 2002, AM J PHYSIOL, V283, pR281; [Anonymous], 2014, OBESITY SILVER SP S2, V22, pS40; [Anonymous], 2001, AM J PHYSIOL-HEART C, V280, pH2674; [Anonymous], 2003, COWPER NEWTON B, V2, P13; Assini FL, 2009, BEHAV BRAIN RES, V204, P206, DOI 10.1016/j.bbr.2009.06.005; Bailey DM, 2013, STROKE, V44, P3235, DOI 10.1161/STROKEAHA.113.002589; Bannai T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39494-7; Barker GRI, 2011, J NEUROSCI, V31, P10721, DOI 10.1523/JNEUROSCI.6413-10.2011; Barnes DE, 2003, J AM GERIATR SOC, V51, P459, DOI 10.1046/j.1532-5415.2003.51153.x; Barnes JN, 2013, J APPL PHYSIOL, V114, P1383, DOI 10.1152/japplphysiol.01258.2012; Beckervordersandforth R, 2020, CURR OPIN PHARMACOL, V50, P67, DOI 10.1016/j.coph.2019.12.002; Bennett RE, 2018, P NATL ACAD SCI USA, V115, pE1289, DOI 10.1073/pnas.1710329115; Bracko O, 2020, J CEREBR BLOOD F MET, V40, P1441, DOI 10.1177/0271678X19873658; Buchman AS, 2012, NEUROLOGY, V78, P1323, DOI 10.1212/WNL.0b013e3182535d35; Casapulla C, 2017, BUILDINGS, V7, DOI 10.3390/buildings7030069; Chao FL, 2018, BRAIN RES, V1684, P50, DOI 10.1016/j.brainres.2018.01.007; Cho J, 2015, MED SCI SPORT EXER, V47, P1814, DOI 10.1249/MSS.0000000000000612; Choi SH, 2018, SCIENCE, V361, P991, DOI 10.1126/science.aan8821; Cortes-Canteli M, 2019, J AM COLL CARDIOL, V74, P1910, DOI 10.1016/j.jacc.2019.07.081; Dai WY, 2009, RADIOLOGY, V250, P856, DOI 10.1148/radiol.2503080751; de l I, 2018, J CLIN GASTROENTEROL, V52, pe63; Decker Y, 2018, BRAIN STRUCT FUNCT, V223, P1001, DOI 10.1007/s00429-017-1595-8; Do K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190205; Eggermont L, 2006, NEUROSCI BIOBEHAV R, V30, P562, DOI 10.1016/j.neubiorev.2005.10.004; Eguchi K, 2018, BRAIN STIMUL, V11, P959, DOI 10.1016/j.brs.2018.05.012; Erdener SE, 2019, J CEREBR BLOOD F MET, V39, DOI 10.1177/0271678X17743877; Garcia-Mesa Y, 2016, J GERONTOL A-BIOL, V71, P40, DOI 10.1093/gerona/glv005; Garcia-Mesa Y, 2011, J ALZHEIMERS DIS, V24, P421, DOI 10.3233/JAD-2011-101635; Groot C, 2016, AGEING RES REV, V25, P13, DOI 10.1016/j.arr.2015.11.005; Gutierrez-Jimenez E, 2018, NEUROBIOL AGING, V62, P82, DOI 10.1016/j.neurobiolaging.2017.10.006; Haft-Javaherian M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213539; Hamel E, 2015, J CARDIOVASC PHARM, V65, P317, DOI 10.1097/FJC.0000000000000177; HAWKEY CM, 1991, BRIT J HAEMATOL, V77, P392, DOI 10.1111/j.1365-2141.1991.tb08590.x; Hernandez JCC, 2019, NAT NEUROSCI, V22, P413, DOI 10.1038/s41593-018-0329-4; Herring A, 2016, NEUROBIOL DIS, V94, P44, DOI 10.1016/j.nbd.2016.06.003; Hoffmann K, 2016, J ALZHEIMERS DIS, V50, P443, DOI 10.3233/JAD-150817; Iadecola C, 2017, NEURON, V96, P17, DOI 10.1016/j.neuron.2017.07.030; Joyner MJ, 2015, PHYSIOL REV, V95, P549, DOI 10.1152/physrev.00035.2013; Kang EB, 2013, APOPTOSIS, V18, P1332, DOI 10.1007/s10495-013-0884-9; Kisler K, 2017, NAT NEUROSCI, V20, P406, DOI 10.1038/nn.4489; Koo Jung Hoon, 2013, J Exerc Nutrition Biochem, V17, P151, DOI 10.5717/jenb.2013.17.4.151; Koo JH, 2017, EXP NEUROL, V288, P142, DOI 10.1016/j.expneurol.2016.11.014; Kramer AF, 1999, NATURE, V400, P418, DOI 10.1038/22682; Larson EB, 2006, ANN INTERN MED, V144, pI20, DOI 10.7326/0003-4819-144-2-200601170-00004; Lautenschlager NT, 2008, JAMA-J AM MED ASSOC, V300, P1027, DOI 10.1001/jama.300.9.1027; Lee T.C, 2002, CVGIP-GRAPH MODEL IM, V56, P462; Lourenco MV, 2019, NAT MED, V25, P165, DOI 10.1038/s41591-018-0275-4; Magyar MT, 2005, J NEUROIMAGING, V15, P64, DOI 10.1177/1051228404269492; Mattson MP, 2004, NATURE, V430, P631, DOI 10.1038/nature02621; Montagne A, 2018, NAT MED, V24, P326, DOI 10.1038/nm.4482; Moore KM, 2016, NEUROBIOL DIS, V85, P218, DOI 10.1016/j.nbd.2015.11.004; Mu YL, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-85; Nagamatsu Lindsay S, 2013, J Aging Res, V2013, P861893, DOI 10.1155/2013/861893; Ni RQ, 2018, PHOTOACOUSTICS, V10, P38, DOI 10.1016/j.pacs.2018.04.001; Nichol KE, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-13; Nortley R, 2019, SCIENCE, V365, P250, DOI 10.1126/science.aav9518; Oxidative stress, 2018, ONCOTARGET, V9, P17181; Puga JL, 2015, NAT METHODS, V12, P377, DOI 10.1038/nmeth.3368; Radde R, 2006, EMBO REP, V7, P940, DOI 10.1038/sj.embor.7400784; Revilla S, 2014, NEUROPHARMACOLOGY, V81, P55, DOI 10.1016/j.neuropharm.2014.01.037; Rovio S, 2005, LANCET NEUROL, V4, P705, DOI 10.1016/S1474-4422(05)70198-8; Ruiz-Uribe N. E, 2020, PROTOCOL EXCHANGE, DOI [10.21203/rs.3.pex-838/v1, DOI 10.21203/RS.3.PEX-838/V1]; Santisakultarm TP, 2012, AM J PHYSIOL-HEART C, V302, pH1367, DOI 10.1152/ajpheart.00417.2011; Serneels L, 2009, SCIENCE, V324, P639, DOI 10.1126/science.1171176; Shepherd Amy, 2018, Brain Plast, V4, P127, DOI 10.3233/BPL-180076; Sun LN, 2018, BRAIN RES, V1697, P1, DOI 10.1016/j.brainres.2018.04.040; Svensson M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58309-8; Sweeney MD, 2018, NAT REV NEUROL, V14, P133, DOI 10.1038/nrneurol.2017.188; Tachibana M, 2018, EXP NEUROL, V300, P13, DOI 10.1016/j.expneurol.2017.10.023; Tapia-Rojas C, 2016, BRAIN PATHOL, V26, P62, DOI 10.1111/bpa.12255; The Lancet HIV, 2017, LANCET HIV, V4, pe51; Um HS, 2011, NEUROSCI RES, V69, P161, DOI 10.1016/j.neures.2010.10.004; van der Kleij LA, 2018, NEUROIMAGE-CLIN, V20, P650, DOI 10.1016/j.nicl.2018.09.003; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Wiesmann M, 2017, THERANOSTICS, V7, P1277, DOI 10.7150/thno.18509; Winters BD, 2004, J NEUROSCI, V24, P5901, DOI 10.1523/JNEUROSCI.1346-04.2004; Xia J, 2019, NEUROSCI LETT, V703, P125, DOI 10.1016/j.neulet.2019.03.035; Xiong JY, 2015, BIOL SPORT, V32, P295, DOI 10.5604/20831862.1163692; Yaffe K, 2001, ARCH INTERN MED, V161, P1703, DOI 10.1001/archinte.161.14.1703; Yan QW, 2019, NEUROSCI LETT, V701, P84, DOI 10.1016/j.neulet.2019.02.030; Yuede CM, 2009, NEUROBIOL DIS, V35, P426, DOI 10.1016/j.nbd.2009.06.002; Zhang J, 2018, NEUROSCI LETT, V666, P70, DOI 10.1016/j.neulet.2017.12.025; Zhang L, 2017, CURR ALZHEIMER RES, V14, P645, DOI 10.2174/1567205014666161213121353; Zhang XL, 2019, NEUROREPORT, V30, P498, DOI 10.1097/WNR.0000000000001230; Zhao G, 2015, NEUROSCIENCE, V298, P357, DOI 10.1016/j.neuroscience.2015.04.038; Zhao N, 2018, NEUROREPORT, V29, P819, DOI 10.1097/WNR.0000000000001038; Zhou CN, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00243	95	6	6	2	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2020	15	8							e0235691	10.1371/journal.pone.0235691	http://dx.doi.org/10.1371/journal.pone.0235691			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK7YA	32857763	gold, Green Submitted, Green Published			2023-01-03	WOS:000566947200027
J	Walek, P; Gorczyca, I; Sielski, J; Wozakowska-Kaplon, B				Walek, Pawel; Gorczyca, Iwona; Sielski, Janusz; Wozakowska-Kaplon, Beata			Left atrial emptying fraction determined during atrial fibrillation predicts maintenance of sinus rhythm after direct current cardioversion in patients with persistent atrial fibrillation	PLOS ONE			English	Article							ELECTRICAL CARDIOVERSION; EUROPEAN ASSOCIATION; AMERICAN SOCIETY; FOLLOW-UP; RECURRENCE; ECHOCARDIOGRAPHY; SUCCESS; VOLUME; RECOMMENDATIONS; SUPERIOR	Echocardiography is the basic imaging technique used to determine the odds of maintaining sinus rhythm (SR) following direct current cardioversion (DCCV) for persistent atrial fibrillation (AF). However, most studies are focused on the echocardiographic parameters obtained during SR resulting from successful DCCV. The aim of this study was to assess the value of the echocardiographic parameters measured before DCCV for the prognosis of SR maintenance after DCCV. The study included 146 patients with persistent AF who underwent DCCV. Clinical and echocardiographic data were collected directly before DCCV and, for patients with SR, one month, six months, and 12 months after DCCV. We found that left atrial emptying fraction (LAEF) assessed during atrial fibrillation was significantly larger in the group with SR maintenance after 12 months than in the group with AF recurrence (30.8 +/- 8.3 vs. 24.6 +/- 10.4%; p<0.001). In multivariable logistic regression analysis with a model containing echocardiographic parameters, LAEF (OR 1.053; 95% CI 1.011-1.096; p = 0.013) and the E/e'(mean)ratio (OR 0.883; 95% CI 0.788-0.990; p = 0.033) were independent predictors of SR maintenance. Analyzing a model including clinical and echocardiographic variables, only LAEF (OR 1.046; 95% CI 1-1.095; p = 0.049) and beta-blockers used before DCCV (OR 14.694; 95% CI 1.622-133.139; p = 0.017) were independent predictors of SR maintenance after 12 months. Our results indicate that LAEF measured during AF is a significant predictor of SR maintenance in the 12 months following DCCV due to persistent AF. Our findings confirm the recently raised hypothesis about the superiority of echocardiographic parameters assessing mechanical remodeling over parameters assessing structural remodeling of left atrium in predicting sinus rhythm maintenance after electrical cardioversion.	[Walek, Pawel; Gorczyca, Iwona; Wozakowska-Kaplon, Beata] Voivodship Hosp Kielce, Clin Cardiol & Electrotherapy 1, Kielce, Poland; [Gorczyca, Iwona; Sielski, Janusz; Wozakowska-Kaplon, Beata] Jan Kochanowski Univ Humanities & Sci, Coll Med, Kielce, Poland; [Sielski, Janusz] Voivodship Hosp Kielce, Intens Cardiac Care Unit, Kielce, Poland	Jan Kochanowski University	Gorczyca, I (corresponding author), Voivodship Hosp Kielce, Clin Cardiol & Electrotherapy 1, Kielce, Poland.; Gorczyca, I (corresponding author), Jan Kochanowski Univ Humanities & Sci, Coll Med, Kielce, Poland.	iwona.gorczyca@interia.pl	Gorczyca-Głowacka, Iwona/M-9664-2013	Gorczyca-Głowacka, Iwona/0000-0002-7619-8426; Walek, Pawel/0000-0003-0632-6573; Sielski, Janusz/0000-0003-2414-0035	Ministry of Science and Higher Education, under the program "Regional Initiative of Excellence" [024/RID/2018/19]	Ministry of Science and Higher Education, under the program "Regional Initiative of Excellence"	This project was funded by the Ministry of Science and Higher Education, under the program "Regional Initiative of Excellence" (Project no. 024/RID/2018/19; amount granted: 11,999,000 PLN). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Moreno-Ruiz LA, 2019, INT J CARDIOVAS IMAG, V35, P1587, DOI 10.1007/s10554-019-01597-7; Caputo M, 2011, AM J CARDIOL, V108, P698, DOI 10.1016/j.amjcard.2011.04.018; Chen SY, 2002, BMC NEUROL, V2, DOI 10.1186/1471-2377-2-1; Chung H, 2016, YONSEI MED J, V57, P64, DOI 10.3349/ymj.2016.57.1.64; De Vos CB, 2014, HEART RHYTHM, V11, P1514, DOI 10.1016/j.hrthm.2014.04.029; Di Salvo G, 2005, CIRCULATION, V112, P387, DOI 10.1161/CIRCULATIONAHA.104.463125; DITTRICH HC, 1989, AM J CARDIOL, V63, P193, DOI 10.1016/0002-9149(89)90284-1; Doruchowska A, 2014, ADV MED SCI-POLAND, V59, P120, DOI 10.1016/j.advms.2013.10.003; EWY GA, 1980, J ELECTROCARDIOL, V13, P119, DOI 10.1016/S0022-0736(80)80042-2; Fornengo C, 2015, EUR HEART J-CARD IMG, V16, P335, DOI 10.1093/ehjci/jeu193; Giubertoni A, 2019, J CARDIOVASC MED, V20, P169, DOI 10.2459/JCM.0000000000000756; Goette A, 2016, EUROPACE, V18, P1455, DOI 10.1093/europace/euw161; Grundvold I, 2008, CARDIOLOGY, V111, P30, DOI 10.1159/000113424; Kim H, 2014, J AM SOC ECHOCARDIOG, V27, P1107, DOI 10.1016/j.echo.2014.05.013; Kirchhof P, 2016, EUROPACE, V18, DOI [10.1093/europace/euw295, 10.5603/KP.2016.0172, 10.1016/j.rec.2016.11.033]; Lang RM, 2015, EUR HEART J-CARD IMG, V16, P233, DOI 10.1093/ehjci/jev014; Limantoro I, 2014, EUROPACE, V16, P1546, DOI 10.1093/europace/euu047; Luong CL, 2016, AM J CARDIOL, V118, P1345, DOI 10.1016/j.amjcard.2016.07.066; Magnani JW, 2011, CIRCULATION, V124, P1982, DOI 10.1161/CIRCULATIONAHA.111.039677; Marchese P, 2012, ECHOCARDIOGR-J CARD, V29, P276, DOI 10.1111/j.1540-8175.2011.01580.x; Mattioli AV, 1998, AM J CARDIOL, V82, P1368, DOI 10.1016/S0002-9149(98)00643-2; Nagueh SF, 2016, J AM SOC ECHOCARDIOG, V29, P277, DOI 10.1016/j.echo.2016.01.011; Okcun B, 2002, ECHOCARDIOGR-J CARD, V19, P351, DOI 10.1046/j.1540-8175.2002.00351.x; Pastore MC, 2021, HEART FAIL REV, V26, P1371, DOI 10.1007/s10741-020-09945-9; Pisters R, 2012, EUROPACE, V14, P666, DOI 10.1093/europace/eur406; Raitt MH, 2006, AM HEART J, V151, P390, DOI 10.1016/j.ahj.2005.03.019; Shaikh AY, 2012, CARDIOVASC ULTRASOUN, V10, DOI 10.1186/1476-7120-10-48; Spiecker M, 2006, INT J CARDIOL, V113, P161, DOI 10.1016/j.ijcard.2005.11.005; Toufan M, 2017, J CARDIOVASC THORAC, V9, P54, DOI 10.15171/jcvtr.2017.08; Tsang TSM, 2006, J AM COLL CARDIOL, V47, P1018, DOI 10.1016/j.jacc.2005.08.077; Vizzardi E, 2014, J CARDIOVASC MED, V15, P235, DOI 10.2459/JCM.0b013e328358554b; Walek P, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228239; Walek P, 2020, CARDIOL J, V27, P246, DOI 10.5603/CJ.a2019.0068; Wozakowska-Kaplon B, 2015, POL ARCH MED WEWN, V125, P400, DOI 10.20452/pamw.2876; Wozakowska-Kaplon B, 2010, PACE, V33, P561, DOI 10.1111/j.1540-8159.2009.02673.x	35	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2020	15	8							e0238002	10.1371/journal.pone.0238002	http://dx.doi.org/10.1371/journal.pone.0238002			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG6GN	32822402	gold, Green Published			2023-01-03	WOS:000564080300050
J	Kumar, A; Planchais, C; Fronzes, R; Mouquet, H; Reyes, N				Kumar, Anand; Planchais, Cyril; Fronzes, Remi; Mouquet, Hugo; Reyes, Nicolas			Binding mechanisms of therapeutic antibodies to human CD20	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; CRYSTAL-STRUCTURE; PROVIDE INSIGHTS; STRUCTURAL BASIS; MOLECULAR-BASIS; B-CELLS; COMPLEMENT; OFATUMUMAB; IDENTIFICATION; VISUALIZATION	Monoclonal antibodies (mAbs) targeting human antigen CD20 (cluster of differentiation 20) constitute important immunotherapies for the treatment of B cell malignancies and autoimmune diseases. Type I and II therapeutic mAbs differ in B cell binding properties and cytotoxic effects, reflecting differential interaction mechanisms with CD20. Here we present 3.7- to 4.7-angstrom cryo-electron microscopy structures of full-length CD20 in complexes with prototypical type I rituximab and ofatumumab and type II obinutuzumab. The structures and binding thermodynamics demonstrate that upon binding to CD20, type II mAbs form terminal complexes that preclude recruitment of additional mAbs and complement components, whereas type I complexes act as molecular seeds to increase mAb local concentration for efficient complement activation. Among type I mAbs, ofatumumab complexes display optimal geometry for complement recruitment. The uncovered mechanisms should aid rational design of next-generation immunotherapies targeting CD20.	[Kumar, Anand; Reyes, Nicolas] Inst Pasteur, Membrane Prot Mech Unit, F-75015 Paris, France; [Kumar, Anand; Reyes, Nicolas] Univ Bordeaux, European Inst Chem & Biol, Membrane Prot Mech Grp, F-33607 Pessac, France; [Kumar, Anand; Fronzes, Remi; Reyes, Nicolas] CNRS, UMR 5234, Fundamental Microbiol & Pathogen, Bordeaux, France; [Planchais, Cyril; Mouquet, Hugo] Inst Pasteur, Dept Immunol, Lab Humoral Immunol, Paris, France; [Planchais, Cyril; Mouquet, Hugo] INSERM, U1222, Paris, France; [Fronzes, Remi] Univ Bordeaux, European Inst Chem & Biol, Struct & Funct Bacterial Nanomachines Grp, F-33607 Pessac, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite de Bordeaux; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	Reyes, N (corresponding author), Inst Pasteur, Membrane Prot Mech Unit, F-75015 Paris, France.; Reyes, N (corresponding author), Univ Bordeaux, European Inst Chem & Biol, Membrane Prot Mech Grp, F-33607 Pessac, France.; Reyes, N (corresponding author), CNRS, UMR 5234, Fundamental Microbiol & Pathogen, Bordeaux, France.	nicolas.reyes@u-bordeaux.fr	Mouquet, Hugo/M-2750-2014; Fronzes, Rémi/GLS-0406-2022	Mouquet, Hugo/0000-0002-4230-610X; Planchais, Cyril/0000-0002-5142-7253; Kumar, Anand/0000-0002-2997-9959; Reyes, Nicolas/0000-0001-6618-8307; Fronzes, Remi/0000-0003-3031-9824	ERC [309657]; Institut Pasteur funds; CNRS funds; G5 Institut Pasteur Program [ANR-10-LABX-69-01]; Milieu Interieur Program [ANR-10-LABX-69-01]; INSERM funds; Pasteur-Paris University (PPU) international PhD program; Fondation-ARC; CACSICE grant [ANR-11-EQPX-008]	ERC(European Research Council (ERC)European Commission); Institut Pasteur funds; CNRS funds; G5 Institut Pasteur Program; Milieu Interieur Program; INSERM funds; Pasteur-Paris University (PPU) international PhD program; Fondation-ARC; CACSICE grant	This research was supported by ERC Grant 309657 and Institut Pasteur funds to N.R.; CNRS funds to N.R. and R.F.; G5 Institut Pasteur, Milieu Interieur (ANR-10-LABX-69-01) Programs, and INSERM funds to H.M. Anand Kumar was supported by fellowships from the Pasteur-Paris University (PPU) international PhD program and Fondation-ARC. CACSICE grant (ANR-11-EQPX-008) supported access to the Institut Pasteur cryo-EM Nanoimaging Facility.	Adams PD, 2010, ACTA CRYSTALLOGR D, V66, P213, DOI 10.1107/S0907444909052925; Binder M, 2006, BLOOD, V108, P1975, DOI 10.1182/blood-2006-04-014639; Burnouf D, 2012, J AM CHEM SOC, V134, P559, DOI 10.1021/ja209057d; Cartron G, 2017, BLOOD, V130, P581, DOI 10.1182/blood-2017-03-771832; Cragg MS, 2004, BLOOD, V103, P2738, DOI 10.1182/blood-2003-06-2031; Cragg MS, 2003, BLOOD, V101, P1045, DOI 10.1182/blood-2002-06-1761; Deans JP, 1998, J BIOL CHEM, V273, P344, DOI 10.1074/jbc.273.1.344; Diebolder CA, 2014, SCIENCE, V343, P1260, DOI 10.1126/science.1248943; Du FH, 2017, AUTOIMMUN HIGHLIGHTS, V8, DOI 10.1007/s13317-017-0100-y; Du JM, 2008, MOL IMMUNOL, V45, P2861, DOI 10.1016/j.molimm.2008.01.034; Du JM, 2007, J BIOL CHEM, V282, P15073, DOI 10.1074/jbc.M701654200; EINFELD DA, 1988, EMBO J, V7, P711, DOI 10.1002/j.1460-2075.1988.tb02867.x; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Faissner S, 2019, NAT REV DRUG DISCOV, V18, P905, DOI 10.1038/s41573-019-0035-2; Goddard TD, 2018, PROTEIN SCI, V27, P14, DOI 10.1002/pro.3235; Herter S, 2013, MOL CANCER THER, V12, P2031, DOI 10.1158/1535-7163.MCT-12-1182; Horovitz A, 1996, FOLD DES, V1, pR121, DOI 10.1016/S1359-0278(96)00056-9; Ishibashi K, 2001, GENE, V264, P87, DOI 10.1016/S0378-1119(00)00598-9; Klein C, 2013, MABS-AUSTIN, V5, P22, DOI 10.4161/mabs.22771; Liang YH, 2001, GENOMICS, V72, P119, DOI 10.1006/geno.2000.6472; MALONEY DG, 1994, BLOOD, V84, P2457; Marshall MJE, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01245; Mastronarde DN, 2005, J STRUCT BIOL, V152, P36, DOI 10.1016/j.jsb.2005.07.007; Mossner E, 2010, BLOOD, V115, P4393, DOI 10.1182/blood-2009-06-225979; Munoz E, 2019, METHODS MOL BIOL, V1964, P225, DOI 10.1007/978-1-4939-9179-2_16; Niederfellner G, 2011, BLOOD, V118, P358, DOI 10.1182/blood-2010-09-305847; O'Brien S, 2010, CL LYMPH MYELOM LEUK, V10, P361, DOI 10.3816/CLML.2010.n.069; Pawluczkowycz AW, 2009, J IMMUNOL, V183, P749, DOI 10.4049/jimmunol.0900632; Petrie RJ, 2002, J IMMUNOL, V169, P2886, DOI 10.4049/jimmunol.169.6.2886; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pierpont TM, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00163; Polyak MJ, 2002, BLOOD, V99, P3256, DOI 10.1182/blood.V99.9.3256; Prigent J, 2016, EUR J IMMUNOL, V46, P2340, DOI 10.1002/eji.201646446; Punjani A., 2019, NONUNIFORM REFINEMEN, DOI 10.1101/2019.12.15.877092; Punjani A, 2017, NAT METHODS, V14, P290, DOI [10.1038/NMETH.4169, 10.1038/nmeth.4169]; Rouge L, 2020, SCIENCE, V367, P1224, DOI 10.1126/science.aaz9356; Teeling JL, 2006, J IMMUNOL, V177, P362, DOI 10.4049/jimmunol.177.1.362; Teeling JL, 2004, BLOOD, V104, P1793, DOI 10.1182/blood-2004-01-0039; Tiller T, 2008, J IMMUNOL METHODS, V329, P112, DOI 10.1016/j.jim.2007.09.017; Ugurlar D, 2018, SCIENCE, V359, P794, DOI 10.1126/science.aao4988; Wang G, 2016, MOL CELL, V63, P135, DOI 10.1016/j.molcel.2016.05.016; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wu YJ, 2013, CELL REP, V5, P1443, DOI 10.1016/j.celrep.2013.11.015; Zhang K, 2016, J STRUCT BIOL, V193, P1, DOI 10.1016/j.jsb.2015.11.003	44	41	42	3	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 14	2020	369	6505					793	+		10.1126/science.abb8008	http://dx.doi.org/10.1126/science.abb8008			34	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA3RX	32792392				2023-01-03	WOS:000559731300032
J	Eze, ND; Mateus, C; Hashiguchi, TCO				Eze, Nkiruka D.; Mateus, Ceu; Hashiguchi, Tiago Cravo Oliveira			Telemedicine in the OECD: An umbrella review of clinical and cost-effectiveness, patient experience and implementation	PLOS ONE			English	Review							INFLAMMATORY-BOWEL-DISEASE; COGNITIVE-BEHAVIOR THERAPY; TELEHEALTH INTERVENTIONS; HEART-FAILURE; PHYSICAL-ACTIVITY; HEALTH-CARE; CARDIAC REHABILITATION; CARDIOVASCULAR-DISEASE; DIABETES-MELLITUS; MOBILE HEALTH	Introduction Patients and policy makers alike have high expectations for the use of digital technologies as tools to improve health care service quality at a sustainable cost. Many countries within the Organisation for Economic Co-operation and Development (OECD) are investing in telemedicine initiatives, and a large and growing body of peer-reviewed studies on the topic has developed, as a consequence. Nonetheless, telemedicine is still not used at scale within the OECD. Seeking to provide a snapshot of the evidence on the use of telemedicine in the OECD, this umbrella review of systematic reviews summarizes findings on four areas of policy relevance: clinical and cost-effectiveness, patient experience, and implementation. Methods This review followed a prior written, unregistered protocol. Four databases (PubMed/Medline, CRD, and Cochrane Library) were searched for systematic reviews or meta-analyses published between January 2014 and February 2019. Based on the inclusion criteria, 98 systematic reviews were selected for analysis. Due to substantial heterogeneity, a meta-analysis was not conducted. The quality of included reviews was assessed using the AMSTAR 2 tool. Results Most reviews (n = 53) focused on effectiveness, followed by cost-effectiveness (n = 18), implementation (n = 17) and patient experience (n = 15). Eighty-three percent of clinical effectiveness reviews found telemedicine at least as effective as face-to-face care, and thirty-nine percent of cost-effectivenss reviews found telemedicine to be cost saving or cost-effective. Patients reported high acceptance of telemedicine and the most common barriers to implementation were usability and lack of reimbursement. However, the methodological quality of most reviews was low to critically low which limits generalizability and applicability of findings. Conclusion This umbrella review finds that telemedicine interventions can improve glycemic control in diabetic patients; reduce mortality and hospitalization due to chronic heart failure; help patients manage pain and increase their physical activity; improve mental health, diet quality and nutrition; and reduce exacerbations associated with respiratory diseases like asthma. In certain disease and specialty areas, telemedicine may be a less effective way to deliver care. While there is evidence that telemedicine can be cost-effective, generalizability is hindered by poor quality and reporting standards. This umbrella review also finds that patients report high levels of acceptance and satisfaction with telemedicine interventions, but that important barriers to wider use remain.	[Eze, Nkiruka D.; Mateus, Ceu] Univ Lancaster, Div Hlth Res, Hlth Econ Lancaster, Lancaster, England; [Hashiguchi, Tiago Cravo Oliveira] Hlth Div Org Econ Cooperat & Dev, Directorate Employment Labour & Social Affairs, Paris, France	Lancaster University	Eze, ND (corresponding author), Univ Lancaster, Div Hlth Res, Hlth Econ Lancaster, Lancaster, England.	nkiru.eze@outlook.com	Mateus, Ceu/AAC-8146-2021	Mateus, Ceu/0000-0001-6219-219X; Eze, Nkiruka/0000-0003-0749-4915				Adamse C, 2018, J TELEMED TELECARE, V24, P511, DOI 10.1177/1357633X17716576; Agostini M, 2015, J TELEMED TELECARE, V21, P202, DOI 10.1177/1357633X15572201; Akiyama Miki, 2016, J Prev Med Public Health, V49, P183, DOI 10.3961/jpmph.16.043; Alvarado MM, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.6382; Bashshur RL, 2016, TELEMED E-HEALTH, V22, P342, DOI 10.1089/tmj.2016.0045; Berrouiguet S, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5066; Berry N, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.5250; Block VAJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154335; BRADFORD NK, 2016, RURAL REMOTE HEALTH, V16; Bruce AF, 2018, J TELEMED TELECARE, V24, P75, DOI 10.1177/1357633X16686770; Brunton L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139561; Caffery LJ, 2017, AUST NZ J PUBL HEAL, V41, P48, DOI 10.1111/1753-6405.12600; Cottrell MA, 2017, CLIN REHABIL, V31, P625, DOI 10.1177/0269215516645148; Cox A, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.6575; Cruz J, 2014, INT J CLIN PRACT, V68, P369, DOI 10.1111/ijcp.12345; Cruz J, 2014, INT J MED INFORM, V83, P249, DOI 10.1016/j.ijmedinf.2014.01.008; Dario AB, 2017, SPINE J, V17, P1342, DOI 10.1016/j.spinee.2017.04.008; de la Torre-Diez I, 2015, TELEMED E-HEALTH, V21, P81, DOI 10.1089/tmj.2014.0053; Deady M, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1473-1; Direito A, 2017, ANN BEHAV MED, V51, P226, DOI 10.1007/s12160-016-9846-0; Estai M, 2018, J TELEMED TELECARE, V24, P147, DOI 10.1177/1357633X16689433; Feltner C, 2014, ANN INTERN MED, V160, P774, DOI 10.7326/M14-0083; Flodgren G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002098.pub2; Fuertes-Guiro F, 2017, J TELEMED TELECARE, V23, P657, DOI 10.1177/1357633X16660876; Gehring ND, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0608-6; Gorst SL, 2014, ANN BEHAV MED, V48, P323, DOI 10.1007/s12160-014-9607-x; Greenhalgh T, 2017, BMC CARDIOVASC DISOR, V17, DOI 10.1186/s12872-017-0594-2; Greenwood Deborah A, 2014, J Diabetes Sci Technol, V8, P378; Grist R, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.7332; Grustam AS, 2014, INT J TECHNOL ASSESS, V30, P59, DOI 10.1017/S0266462313000779; Guise V, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/s12913-014-0588-z; Hakala S, 2017, EUR J PHYS REHAB MED, V53, P953, DOI 10.23736/S1973-9087.17.04585-3; Hameed AS, 2014, APPL CLIN INFORM, V5, P612, DOI 10.4338/ACI-2014-04-RA-0037; Hamilton SJ, 2018, BMC CARDIOVASC DISOR, V18, DOI 10.1186/s12872-018-0764-x; Huang KS, 2015, EUR J PREV CARDIOL, V22, P959, DOI 10.1177/2047487314561168; Huang VW, 2014, WORLD J GASTROENTERO, V20, P829, DOI 10.3748/wjg.v20.i3.829; Huang ZR, 2015, EUR J ENDOCRINOL, V172, pR93, DOI 10.1530/EJE-14-0441; Hui CY, 2017, J AM MED INFORM ASSN, V24, P619, DOI 10.1093/jamia/ocw143; Hutchesson MJ, 2015, OBES REV, V16, P376, DOI 10.1111/obr.12268; Irving M, 2018, J TELEMED TELECARE, V24, P129, DOI 10.1177/1357633X16686776; Ito J, 2017, J TELEMED TELECARE, V23, P828, DOI 10.1177/1357633X17732801; Jackson BD, 2016, J CROHNS COLITIS, V10, P1103, DOI 10.1093/ecco-jcc/jjw059; Jeon E, 2015, STUD HEALTH TECHNOL, V210, P321, DOI 10.3233/978-1-61499-512-8-321; Joiner KL, 2017, PREV MED, V100, P194, DOI 10.1016/j.ypmed.2017.04.033; Kampmeijer R, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1522-3; Kapadia V, 2015, INT J MED INFORM, V84, P892, DOI 10.1016/j.ijmedinf.2015.07.002; Kelly JT, 2016, AM J CLIN NUTR, V104, P1693, DOI 10.3945/ajcn.116.136333; Kepplinger J, 2016, NEUROLOGY, V87, P1344, DOI 10.1212/WNL.0000000000003148; Klersy C, 2016, EUR J HEART FAIL, V18, P195, DOI 10.1002/ejhf.470; Kotb A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118681; Lee J, 2016, STUD HEALTH TECHNOL, V225, P491, DOI 10.3233/978-1-61499-658-3-491; Lee M, 2018, J THROMB THROMBOLYS, V45, P325, DOI 10.1007/s11239-018-1609-2; Liddy C, 2016, FAM PRACT, V33, P274, DOI 10.1093/fampra/cmw024; Linde K, 2015, ANN FAM MED, V13, P56, DOI 10.1370/afm.1719; Liptrott S, 2018, EUR J CANCER CARE, V27, DOI 10.1111/ecc.12643; Liu SM, 2017, J NEUROL SCI, V378, P140, DOI 10.1016/j.jns.2017.04.050; Lopez-Villegas A, 2016, REV ESP CARDIOL, V69, P125, DOI 10.1016/j.rec.2015.06.020; Lundell S, 2015, RESP MED, V109, P11, DOI 10.1016/j.rmed.2014.10.008; Macdonald EM, 2018, J TELEMED TELECARE, V24, P319, DOI 10.1177/1357633X17699990; Marx W, 2018, MATURITAS, V111, P31, DOI 10.1016/j.maturitas.2018.02.012; McDougall JA, 2017, ARTHRIT CARE RES, V69, P1546, DOI 10.1002/acr.23153; McLean G, 2016, BMC PULM MED, V16, DOI 10.1186/s12890-016-0248-7; Merriel SWD, 2014, PREV MED, V64, P88, DOI 10.1016/j.ypmed.2014.04.001; Meurk C, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.4827; Michaud TL, 2018, INT J TECHNOL ASSESS, V34, P410, DOI 10.1017/S0266462318000454; Ming WK, 2016, J MED INTERNET RES, V18, DOI 10.2196/jmir.6556; Musiat P, 2014, PSYCHOL MED, V44, P3137, DOI 10.1017/S0033291714000245; Nair U, 2018, J TELEMED TELECARE, V24, P639, DOI 10.1177/1357633X18794332; Oosterveen E, 2017, PREV MED, V99, P197, DOI 10.1016/j.ypmed.2017.01.009; Radhakrishnan K, 2016, HEALTH SERV RES, V51, P48, DOI 10.1111/1475-6773.12327; Raman P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011069.pub2; Rasekaba TM, 2015, DIABETES RES CLIN PR, V110, P1, DOI 10.1016/j.diabres.2015.07.007; Rawstorn JC, 2016, HEART, V102, P1183, DOI 10.1136/heartjnl-2015-308966; Sanyal C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198112; Seiler A, 2017, PSYCHO-ONCOLOGY, V26, P1239, DOI 10.1002/pon.4489; Seyffert M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149139; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; Sherifali D, 2017, J MED INTERNET RES, V19, DOI 10.2196/jmir.8006; Shigekawa E, 2018, HEALTH AFFAIR, V37, P1975, DOI 10.1377/hlthaff.2018.05132; Slater Helen, 2017, JBI Database System Rev Implement Rep, V15, P2047, DOI 10.11124/JBISRIR-2016-003299; Snoswell C, 2016, JAMA DERMATOL, V152, P702, DOI 10.1001/jamadermatol.2016.0525; Speyer R, 2018, J REHABIL MED, V50, P225, DOI 10.2340/16501977-2297; Stratton E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189904; Su DJ, 2016, DIABETES RES CLIN PR, V116, P136, DOI 10.1016/j.diabres.2016.04.019; Tchero H, 2017, INT J LOW EXTR WOUND, V16, P274, DOI 10.1177/1534734617739195; Thabrew H, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012489.pub2; Thomas SM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113779; Toma T, 2014, DIABETES RES CLIN PR, V106, P200, DOI 10.1016/j.diabres.2014.06.008; Trettel A, 2018, J EUR ACAD DERMATOL, V32, P215, DOI 10.1111/jdv.14341; Udsen FW, 2014, J TELEMED TELECARE, V20, P212, DOI 10.1177/1357633X14533896; van Beugen S, 2014, J MED INTERNET RES, V16, P251, DOI 10.2196/jmir.2777; van Egmond MA, 2018, PHYSIOTHERAPY, V104, P277, DOI 10.1016/j.physio.2018.04.004; Van Spall Harriette G C, 2017, Eur J Heart Fail, V19, P1427, DOI 10.1002/ejhf.765; Vigerland S, 2016, CLIN PSYCHOL REV, V50, P1, DOI 10.1016/j.cpr.2016.09.005; Wallace S, 1998, POSTGRAD MED J, V74, P721, DOI 10.1136/pgmj.74.878.721; Wickramasinghe SI, 2016, J TELEMED TELECARE, V22, P465, DOI 10.1177/1357633X16673267; Widmer RJ, 2015, MAYO CLIN PROC, V90, P469, DOI 10.1016/j.mayocp.2014.12.026; Wootton BM, 2016, CLIN PSYCHOL REV, V43, P103, DOI 10.1016/j.cpr.2015.10.001; World Health Organisation, 2020, HLTH SUST DEV TEL; Zhai YK, 2014, MEDICINE, V93, DOI 10.1097/MD.0000000000000312; Zhao J, 2015, TELEMED E-HEALTH, V21, P484, DOI 10.1089/tmj.2014.0119	102	61	62	3	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2020	15	8							e0237585	10.1371/journal.pone.0237585	http://dx.doi.org/10.1371/journal.pone.0237585			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NE5VG	32790752	gold, Green Published			2023-01-03	WOS:000562668300071
J	Djague, F; Lunga, PK; Toghueo, KRM; Melogmo, DYK; Fekam, BF				Djague, Fred; Lunga, Paul Keilah; Toghueo, Kouipou Rufin Marie; Melogmo, Dongmo Yanick Kevin; Fekam, Boyom Fabrice			Garcinia kola(Heckel) andAlchornea cordifolia(Schumach. & Thonn.) Mull. Arg. from Cameroon possess potential antisalmonellal and antioxidant properties	PLOS ONE			English	Article							ANTIBACTERIAL ACTIVITY; GLOBAL BURDEN; MECHANISMS; TOXICITY	Drug resistantSalmonellaspecies and shortcomings related to current drugs stress the urgent need to search for new antimicrobial agents to control salmonellosis. This study investigated the antisalmonellal and antioxidant potentials of methanolic and hydro-ethanolic extracts ofGarcinia kolaandAlchornea cordifoliaas potential sources of drugs to controlSalmonellaspecies and to reduce related oxidative stress. The antisalmonellal activity was assessed using the broth microdilution, membrane destabilization and time-kill kinetic assays. While, the DPPH, ABTS and FRAP assays were used for the determination of the antioxidant activities. The minimum inhibitory concentrations ranged from 125 to 1000 mu g/mL, with the methanolic root extract ofG.kolabeing the most active. The time kill kinetic assay revealed a concentration-dependent bacteriostatic activity for promising extracts. Potent extracts fromG.kolashowed the ability to destabilizeS.typhiouter membrane, with the methanolic root extract presenting the highest activity; two-fold higher than those of polymyxin B tested as reference. In addition, this methanolic root extract ofG.kolaalso provoked nucleotide leakage in a concentration-dependent manner. From the antioxidant assays, the hydro-ethanolic extract from the stem bark ofA.cordifoliapresented significant activities comparable to that of Vitamin C. The methanolic root extract ofG.kolaalso presented appreciable antioxidant activities, though less than that ofA.cordifolia. Overall, the phytochemical screening of active extracts revealed the presence of anthocyanins, flavonoids, glycosides, phenols, tannins, triterpenoids and steroids. These results provide evidence of the antibacterial potential ofG.kolaand offer great perspectives in a possible standardisation of an antisalmonellal phytomedicine.	[Djague, Fred; Lunga, Paul Keilah; Toghueo, Kouipou Rufin Marie; Melogmo, Dongmo Yanick Kevin; Fekam, Boyom Fabrice] Univ Yaounde I, Antimicrobial & Biocontrol Agents Unit AmBcAU, Lab Phytobiochem & Med Plants Studies, Fac Sci,Dept Biochem, Yaounde, Cameroon	University of Yaounde I	Lunga, PK (corresponding author), Univ Yaounde I, Antimicrobial & Biocontrol Agents Unit AmBcAU, Lab Phytobiochem & Med Plants Studies, Fac Sci,Dept Biochem, Yaounde, Cameroon.	lungapaul@yahoo.ca	Toghueo, Rufin/ABA-3152-2021; DONGMO, Yanick Kevin MELOGMO/ABB-4321-2020	Toghueo, Rufin/0000-0003-2144-0710; 	Seeding Labs' Instrumental Access Grant [SL2012-2]	Seeding Labs' Instrumental Access Grant	Authors are very grateful to the Seeding Labs' Instrumental Access Grant (SL2012-2) to Prof. Boyom. This work also received materials and equipment support from the Yaounde '-Bielefeld Bilateral Graduate School for Natural Products with Antiparasite and Antibacterial Activity (YaBiNaPA). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aaydha CV, 2019, BIOSENS BIOELECTRON, V129, P224, DOI [10.1016/j.bios.2018.09.078 30318404, DOI 10.1016/J.BIOS.2018.09.078 30318404]; Adeshina G. O., 2012, European Journal of Medicinal Plants, V2, P31; Anantharaman A, 2010, ANTIMICROB AGENTS CH, V54, P1693, DOI 10.1128/AAC.01231-09; Ao TT, 2015, EMERG INFECT DIS, V21, P941, DOI 10.3201/eid2106.140999; Benzie IFF, 1996, ANAL BIOCHEM, V239, P70, DOI 10.1006/abio.1996.0292; Campos NG, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164000; Crum-Cianflone Nancy F, 2008, Curr Gastroenterol Rep, V10, P424, DOI 10.1007/s11894-008-0079-7; Dah-Nouvlessounon D., 2015, Food and Nutrition Sciences, V6, P1395, DOI 10.4236/fns.2015.615145; de Diego-Otero Y, 2009, NEUROPSYCHOPHARMACOL, V34, P1011, DOI 10.1038/npp.2008.152; Esiegwu A. C., 2014, Global Journal of Animal Scientific Research, V2, P170; Ezeokeke E. E., 2017, J ANAL BIOANAL TECH, V8, P353; Farombi EO, 2000, FOOD RES INT, V33, P493, DOI 10.1016/S0963-9969(00)00074-0; Flora O, 2008, AFR J BIOCH RES, V11, P215; Frirdich E, 2005, J ENDOTOXIN RES, V11, P133, DOI 10.1179/096805105X46592; Gal-Mor O, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00391; Gasem MH, 2002, J MED MICROBIOL, V51, P173, DOI 10.1099/0022-1317-51-2-173; Gatsing D, 2008, ETHIOP PHARM J, V26, P83, DOI DOI 10.4314/EPJ.V26I2.43039; Gatsing D, 2010, INT J PHARMACOL, V6, P173, DOI 10.3923/ijp.2010.173.182; Global Burden of Disease Results Tool, 2018, GBD RES TOOL GHDX; Guimaraes DO, 2010, QUIM NOVA, V33, P667, DOI 10.1590/S0100-40422010000300035; Gustafsson MHG, 2002, INT J PLANT SCI, V163, P1045, DOI 10.1086/342521; Hao G, 2009, PEPTIDES, V30, P1421, DOI 10.1016/j.peptides.2009.05.016; Harborne JB, 1976, PHYTOCHEMICAL METHOD, P150; Huckstep RL, 1962, TYPHOID FEVER OTHER; Jay S., 2003, Foodborne microorganisms of public health significance, P207; Kagbo HD, 2010, INTERNET J TOXICOL, V7; Lunga PK, 2014, SPRINGERPLUS, V3, DOI 10.1186/2193-1801-3-302; Majowicz SE, 2010, CLIN INFECT DIS, V50, P882, DOI 10.1086/650733; Mambe FT, 2016, J TAIBAH UNIV MED SC, V11, P121, DOI 10.1016/j.jtumed.2015.12.001; Moukette BM, 2015, TOXICOL REP, V2, P792, DOI 10.1016/j.toxrep.2015.02.007; Naufalin R, 2017, INT FOOD RES J, V24, P379; Naufalin R., 2005, JURNAL TEKNOLOGI DAN, V16, P119; Odeyemi OA, 2011, INT J RES BIOMEDICIN, V1, P5; Okoro CK, 2012, NAT GENET, V44, P1215, DOI 10.1038/ng.2423; Pankey GA, 2004, CLIN INFECT DIS, V38, P864, DOI 10.1086/381972; Pinto NCC, 2017, AN ACAD BRAS CIENC, V89, P2053, DOI 10.1590/0001-3765201720150702; Rastaldo R, 2007, LIFE SCI, V81, P779, DOI 10.1016/j.lfs.2007.07.019; Re R, 1999, FREE RADICAL BIO MED, V26, P1231, DOI 10.1016/S0891-5849(98)00315-3; Saravanan S, 2015, INDIAN J MICROBIOL, V1, DOI [10.1007/s12088-015-0558-026843692, DOI 10.1007/S12088-015-0558-026843692]; Scherer R, 2009, FOOD CHEM, V112, P654, DOI 10.1016/j.foodchem.2008.06.026; Tamokou JDD, 2017, MEDICINAL SPICES AND VEGETABLES FROM AFRICA: THERAPEUTIC POTENTIAL AGAINST METABOLIC, INFLAMMATORY, INFECTIOUS AND SYSTEMIC DISEASES, P207, DOI 10.1016/B978-0-12-809286-6.00008-X; Tang YL, 2008, J PHARMACEUT BIOMED, V48, P1187, DOI 10.1016/j.jpba.2008.09.006; Trombetta D, 2005, ANTIMICROB AGENTS CH, V49, P2474, DOI 10.1128/AAC.49.6.2474-2478.2005; Tsuji BT, 2008, J ANTIMICROB CHEMOTH, V62, P156, DOI 10.1093/jac/dkn133; VAARA M, 1992, MICROBIOL REV, V56, P395, DOI 10.1128/MMBR.56.3.395-411.1992; WHO, 2018, SALM NONT; Xing K, 2009, CARBOHYD POLYM, V76, P17, DOI 10.1016/j.carbpol.2008.09.016	47	7	7	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 4	2020	15	8							e0237076	10.1371/journal.pone.0237076	http://dx.doi.org/10.1371/journal.pone.0237076			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA7PQ	32750082	Green Published, gold			2023-01-03	WOS:000560009200025
J	Davies, J				Davies, Jane			Perspective: Care in the age of COVID-19	NATURE			English	Editorial Material						Health care; Diseases; Therapeutics; Information technology		Lockdowns have accelerated the drive towards telemedicine for people with cystic fibrosis - but the system needs critical appraisal. Lockdowns have accelerated the drive towards telemedicine for people with cystic fibrosis - but the system needs critical appraisal.				j.c.davies@imperial.ac.uk							0	8	8	1	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 30	2020	583	7818					S15	S15		10.1038/d41586-020-02112-y	http://dx.doi.org/10.1038/d41586-020-02112-y			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MT2XH	32728255	Bronze			2023-01-03	WOS:000554831500008
J	Otaka, E; Otaka, Y; Kasuga, S; Nishimoto, A; Yamazaki, K; Kawakami, M; Ushiba, J; Liu, MG				Otaka, Eri; Otaka, Yohei; Kasuga, Shoko; Nishimoto, Atsuko; Yamazaki, Kotaro; Kawakami, Michiyuki; Ushiba, Junichi; Liu, Meigen			Reliability of the thumb localizing test and its validity against quantitative measures with a robotic device in patients with hemiparetic stroke	PLOS ONE			English	Article							LIMB POSITION SENSE; REACHING MOVEMENTS; MOTOR RECOVERY; PROPRIOCEPTION; IMPAIRMENTS; AGREEMENT; VISION; SCALE	Objectives To examine the inter-rater reliability of the thumb localizing test (TLT) and its validity against quantitative measures of proprioception. Methods The TLT was assessed by two raters in a standardized manner in 40 individuals with hemiparetic stroke. Inter-rater reliability was examined with weighted Kappa. For the quantitative measures, a bimanual matching task in a planar robotic device was performed. Without vision, each participant moved the unaffected hand to the perceived mirrored location of the affected hand, which was passively moved by the robot. Three measures were taken after 54 trials: Variability, trial-to-trial variability of the mirrored-matched locations; Area, the ratio of the area enclosed by the active hand relative to the passive hand; and Shift, systematic shifts between the passive and active hands. The correlation between the TLT and each robotic measure was examined with Spearman's rank correlation coefficient. Results The overall weighted kappa of the TLT was 0.84 (P<0.001). The TLT correlated highly with Area (r = -0.71, P<0.001) and moderately with Variability (r = 0.40, P = 0.011). No significant correlation was found between the TLT and Shift. Conclusions The TLT had a high inter-rater reliability, and was validated against quantitative measures of proprioception reflecting the perceived area of movement and variability of the limb location.	[Otaka, Eri; Otaka, Yohei; Nishimoto, Atsuko; Yamazaki, Kotaro; Kawakami, Michiyuki; Liu, Meigen] Keio Univ, Dept Rehabil Med, Sch Med, Shinjuku Ku, Tokyo, Japan; [Otaka, Yohei] Fujita Hlth Univ, Sch Med, Dept Rehabil Med 1, Toyoake, Aichi, Japan; [Kasuga, Shoko; Ushiba, Junichi] Keio Univ, Keio Inst Pure & Appl Sci KiPAS, Yokohama, Kanagawa, Japan; [Kasuga, Shoko] Keio Univ, Grad Sch Sci & Technol, Yokohama, Kanagawa, Japan; [Ushiba, Junichi] Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Yokohama, Kanagawa, Japan	Keio University; Fujita Health University; Keio University; Keio University; Keio University	Otaka, Y (corresponding author), Keio Univ, Dept Rehabil Med, Sch Med, Shinjuku Ku, Tokyo, Japan.; Otaka, Y (corresponding author), Fujita Hlth Univ, Sch Med, Dept Rehabil Med 1, Toyoake, Aichi, Japan.	otaka119@mac.com	Kawakami, Michiyuki/AAY-6325-2020		Toyota Tsusho Corporation	Toyota Tsusho Corporation	This study was supported in part by collaborative research funds from Toyota Tsusho Corporation (https://www.toyota-tsusho.com).The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Balasubramanian Sivakumar, 2012, Am J Phys Med Rehabil, V91, pS255, DOI 10.1097/PHM.0b013e31826bcdc1; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Carey L.M., 1995, CRIT REV PHYS REHABI, V7, P51, DOI [10.1615/CritRevPhysRehabilMed.v7.i1.40, DOI 10.1615/CRITREVPHYSREHABILMED.V7.I1.40]; Carey LM, 2011, J REHABIL MED, V43, P257, DOI 10.2340/16501977-0662; Carey LM, 1996, ARCH PHYS MED REHAB, V77, P1271, DOI 10.1016/S0003-9993(96)90192-6; COHEN J, 1968, PSYCHOL BULL, V70, P213, DOI 10.1037/h0026256; CORDO P, 1994, J NEUROPHYSIOL, V71, P1848, DOI 10.1152/jn.1994.71.5.1848; Dukelow SP, 2012, J NEUROENG REHABIL, V9, DOI 10.1186/1743-0003-9-72; Dukelow SP, 2010, NEUROREHAB NEURAL RE, V24, P178, DOI 10.1177/1545968309345267; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; GHEZ C, 1995, J NEUROPHYSIOL, V73, P361, DOI 10.1152/jn.1995.73.1.361; GORDON J, 1995, J NEUROPHYSIOL, V73, P347, DOI 10.1152/jn.1995.73.1.347; Guilford JP, 1942, PSYCHOMETRIKA, V7, P243, DOI 10.1007/BF02288627; Herter TM, 2019, J NEUROENG REHABIL, V16, DOI 10.1186/s12984-019-0596-7; Hirayama K, 1999, J NEUROL SCI, V167, P45, DOI 10.1016/S0022-510X(99)00136-7; Hirayama K, 1986, Rinsho Shinkeigaku, V26, P448; Hirayama Keizo, 2011, Brain and Nerve (Tokyo), V63, P851; Kessner SS, 2019, STROKE, V50, P1116, DOI 10.1161/STROKEAHA.118.023750; Kita K, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-55; Kuczynski AM, 2016, NEUROREHAB NEURAL RE, V30, P762, DOI 10.1177/1545968315624781; Kwakkel G, 2003, STROKE, V34, P2181, DOI 10.1161/01.STR.0000087172.16305.CD; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Lincoln N., 1991, CLIN REHABIL, V5, P273, DOI [DOI 10.1177/026921559100500403, 10.1177/026921559100500403]; Mrotek LA, 2017, J NEUROENG REHABIL, V14, DOI 10.1186/s12984-017-0269-3; Newport R, 2001, CURR BIOL, V11, P975, DOI 10.1016/S0960-9822(01)00266-4; Otaka E, 2015, J NEUROENG REHABIL, V12, DOI 10.1186/s12984-015-0059-8; PRESCOTT RJ, 1982, STROKE, V13, P641, DOI 10.1161/01.STR.13.5.641; Proske U, 2012, PHYSIOL REV, V92, P1651, DOI 10.1152/physrev.00048.2011; ROTHWELL JC, 1982, BRAIN, V105, P515, DOI 10.1093/brain/105.3.515; Scott SH, 1999, J NEUROSCI METH, V89, P119, DOI 10.1016/S0165-0270(99)00053-9; Scott SH, 2011, J REHABIL RES DEV, V48, P335, DOI 10.1682/JRRD.2010.04.0057; Semrau JA, 2018, CORTEX, V109, P245, DOI 10.1016/j.cortex.2018.09.022; Semrau JA, 2015, STROKE, V46, P3459, DOI 10.1161/STROKEAHA.115.010750; Simo L, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-77; Winters C, 2015, NEUROREHAB NEURAL RE, V29, P614, DOI 10.1177/1545968314562115; Zandvliet SB, 2020, NEUROREHAB NEURAL RE, V34, P403, DOI 10.1177/1545968320907075	37	5	5	2	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2020	15	7							e0236437	10.1371/journal.pone.0236437	http://dx.doi.org/10.1371/journal.pone.0236437			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	OD5ZL	32706817	Green Published, gold			2023-01-03	WOS:000579931700042
J	Terrin, G; Coscia, A; Boscarino, G; Faccioli, F; Di Chiara, M; Greco, C; Onesta, E; Oliva, S; Aloi, M; Dito, L; Cardilli, V; Regoli, D; De Curtis, M				Terrin, Gianluca; Coscia, Alessandra; Boscarino, Giovanni; Faccioli, Francesca; Di Chiara, Maria; Greco, Carla; Onesta, Elisa; Oliva, Salvatore; Aloi, Marina; Dito, Lucia; Cardilli, Viviana; Regoli, Daniela; De Curtis, Mario			Long-term effects on growth of an energy-enhanced parenteral nutrition in preterm newborn: A quasi-experimental study	PLOS ONE			English	Article							BIRTH-WEIGHT INFANTS; POSTNATAL-GROWTH; CONTROLLED-TRIAL; CORRECTED AGE; RISK	Aim To assess the best energy intake in Parenteral Nutrition (PN) for preterm newborns, considering both possible benefits for growth and risk of complications. Methods Quasi-experimental study comparing two cohorts of newborns, receiving Energy-Enhanced vs. Standard PN (Cohort A, from 1st January 2015 to 31 January 2016 and Cohort B from 1st February 2016 to 31 March 2017; respectively) after implementation of a change in the PN protocol. The primary outcome measure was growth at 24 months of life. The PN associated complications were also measured. Results We enrolled 132 newborns in two Cohorts, similar for prenatal and postnatal clinical characteristics. Although, body weight and length at 24 months of life were significantly higher (p<0.05) in the Cohort A (11.1, 95% CI 10.6 to 11.6 Kg; 85.0 95% CI 83.8 to 86.2 cm) compared with Cohort B (10.4, 95% CI 9.9 to 10.9 Kg; 81.3 95% CI 79.7 to 82.8 cm), body weight and length Z-Score in the first 24 months of life were similar between the two Cohorts. The rate of PN associated complications was very high in both study Cohorts (up to 98% of enrolments). Multivariate analysis showed that length at 24 months was significantly associated with receiving standard PN (cohort A) in the first week of life and on the energy intake in the first week of life. We also found a marginally insignificant association between Cohort A assignment and body weight at 24 months of life (p= 0.060). Conclusions Energy-enhanced PN in early life has not significant effects on long-term growth in preterm newborns. The high prevalence of PN associated complications, poses concerns about the utility of high energy intake recommended by current guidelines for PN.	[Terrin, Gianluca; Boscarino, Giovanni; Faccioli, Francesca; Di Chiara, Maria; Greco, Carla; Onesta, Elisa; Oliva, Salvatore; Aloi, Marina; Dito, Lucia; Cardilli, Viviana; Regoli, Daniela; De Curtis, Mario] Univ Roma La Sapienza, Dept Maternal & Child Hlth, Policlin Umberto 1, Rome, Italy; [Coscia, Alessandra] Univ Turin, Dept Publ Hlth & Pediat, Neonatol Unit, Turin, Italy	Sapienza University Rome; University Hospital Sapienza Rome; University of Turin	Terrin, G (corresponding author), Univ Roma La Sapienza, Dept Maternal & Child Hlth, Policlin Umberto 1, Rome, Italy.	gianluca.terrin@uniroma1.it	di chiara, maria/HDM-7883-2022; Boscarino, Giovanni/ABH-2077-2020; Oliva, Salvatore/K-1567-2016; coscia, alessandra/AFR-8018-2022	Boscarino, Giovanni/0000-0003-2481-0692; Oliva, Salvatore/0000-0003-2348-2308; coscia, alessandra/0000-0001-5094-1077; Terrin, Gianluca/0000-0003-3541-2876; Faccioli, Francesca/0000-0002-7680-748X				Block T, 2017, ATHEROSCLEROSIS, V266, P31, DOI 10.1016/j.atherosclerosis.2017.09.003; Bonsante F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186936; Christmann V, 2013, ACTA PAEDIATR, V102, P471, DOI 10.1111/apa.12188; Cormack BE, 2016, PEDIATR RES, V79, P810, DOI 10.1038/pr.2016.26; Giuliani F, 2016, AM J CLIN NUTR, V103, p635S, DOI 10.3945/ajcn.114.106310; Hiltunen H, 2018, NEONATOLOGY, V113, P100, DOI 10.1159/000480633; Ibrahim Hassan M, 2004, J Perinatol, V24, P482, DOI 10.1038/sj.jp.7211114; Joosten K, 2018, CLIN NUTR, V37, P2309, DOI 10.1016/j.clnu.2018.06.944; Leenders EKSM, 2018, NEONATOLOGY, V113, P187, DOI 10.1159/000481192; Morgan C, 2014, PEDIATRICS, V133, pE120, DOI 10.1542/peds.2013-2207; Moyses HE, 2013, AM J CLIN NUTR, V97, P816, DOI 10.3945/ajcn.112.042028; Naeem Anika, 2019, Eur Med J (Chelmsf), V4, P20; Ohnishi S, 2016, EARLY HUM DEV, V100, P35, DOI 10.1016/j.earlhumdev.2016.03.014; Parry G, 2003, LANCET, V361, P1789, DOI 10.1016/S0140-6736(03)13397-1; Passariello A, 2012, ALIMENT PHARM THER, V35, P782, DOI 10.1111/j.1365-2036.2012.05015.x; Patel AL, 2009, J PERINATOL, V29, P618, DOI 10.1038/jp.2009.55; Poindexter BB, 2006, J PEDIATR-US, V148, P300, DOI 10.1016/j.jpeds.2005.10.038; Rice TW, 2012, JAMA-J AM MED ASSOC, V307, P795, DOI 10.1001/jama.2012.137; Senterre T, 2016, TXB PEDIAT GASTROENT, P73, DOI [DOI 10.1007/978-3-319-17169-2_7, 10.1007/978-3-319-17169-2_7]; Singhal A, 2017, ANN NUTR METAB, V70, P236, DOI 10.1159/000464302; Stark AR, 2008, PEDIATRICS, V122, P1119, DOI 10.1542/peds.2008-2174; Stensvold HJ, 2015, JAMA PEDIATR, V169, P1003, DOI 10.1001/jamapediatrics.2015.1667; Tan MJ, 2008, ARCH DIS CHILD-FETAL, V93, pF337, DOI 10.1136/adc.2007.124230; Terrin G, 2016, TXB PEDIAT GASTROENT, P53, DOI [10.1007/978-3-319-17169-2_6, DOI 10.1007/978-3-319-17169-2_6]; Terrin G, 2009, ACTA PAEDIATR, V98, P31, DOI 10.1111/j.1651-2227.2008.00987.x; Terrin G, 2013, AM J CLIN NUTR, V98, P1468, DOI 10.3945/ajcn.112.054478; Tozzi MG, 2018, FRONT PEDIATR, V6, DOI 10.3389/fped.2018.00408; van Goudoever JB, 2018, CLIN NUTR, V37, P2315, DOI [10.1016/j.clnu.2018.05.029, 10.1016/j.clnu.2018.06.945]; Vanhorebeek I, 2017, LANCET RESP MED, V5, P475, DOI 10.1016/S2213-2600(17)30186-8; Villar J, 2015, LANCET GLOB HEALTH, V3, pE681, DOI 10.1016/S2214-109X(15)00163-1; Wilson DC, 1997, ARCH DIS CHILD-FETAL, V77, pF4, DOI 10.1136/fn.77.1.F4; Zhang L, 2019, ITAL J PEDIATR, V45, DOI 10.1186/s13052-018-0596-4	32	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2020	15	7							e0235540	10.1371/journal.pone.0235540	http://dx.doi.org/10.1371/journal.pone.0235540			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM3OG	32628715	Green Published, gold			2023-01-03	WOS:000550068700037
J	Hitch, D; Leech, K; Neale, S; Malcolm, A				Hitch, Danielle; Leech, Kathleen; Neale, Sharon; Malcolm, Avetta			Evaluating the implementation of an early supported discharge (ESD) program for stroke survivors: A mixed methods longitudinal case study	PLOS ONE			English	Article							REHABILITATION; HOME	Background Early supported discharge (ESD) models of care for stroke survivors coordinate inpatient and community services, with the aim of reducing length of stay. While there is an established evidence base around the clinical outcomes of ESD), less is known about the implementation of this approach into existing stroke care service. The aim of this case study was to describe staff perceptions of the implementation of an ESD model of care for stroke survivors at a large metropolitan public hospital in Australia. Methods This case study utilised a mixed methods design, which was designed in explicit alignment with the Consolidated Framework for Implementation Research (CFIR). Participants included staff that referred patients for ESD, and staff involved in the planning, implementation or delivery of ESD. Survey data was collected at three time points (ESD commencement, 3 months and 6 months), and focus groups were undertaken at the conclusion of the study. All quantitative data was analysed descriptive, while qualitative data was evaluated using thematic analysis. Results Results from both sources of data identified changes in staff perceptions of ESD implementation over time. While very few changes were statistically significant, they were diverse patterns of change across the CFIR constructs over time. The characteristics of individuals and ESD characteristics attracted consistently positive perceptions, while patient needs and resources was the most prevalent theme within the data. While perceptions of factors related to the inner setting were mixed, there was a steady improvement in perceptions about the process across the later stages of implementation. Conclusions The sophistication of knowledge translation and implementation in modern complex healthcare environments is highlighted by the multiple interactions between the CFIR domains and constructs. While the implementation process described was generally positive and effective, using the CFIR as a framework confirmed that it also entailed some challenges and unanticipated outcomes.	[Hitch, Danielle; Leech, Kathleen; Neale, Sharon; Malcolm, Avetta] Western Hlth, Allied Hlth, Sunshine, Vic, Australia; [Hitch, Danielle] Deakin Univ, Occupat Therapy, Geelong, Vic, Australia	Deakin University	Hitch, D (corresponding author), Western Hlth, Allied Hlth, Sunshine, Vic, Australia.; Hitch, D (corresponding author), Deakin Univ, Occupat Therapy, Geelong, Vic, Australia.	Danielle.Hitch@wh.org.au		Hitch, Danielle/0000-0003-2798-2246				Mas MA, 2015, INT J STROKE, V10, P7, DOI 10.1111/j.1747-4949.2012.00950.x; [Anonymous], 2013, AIDS, V27, pS159; [Anonymous], 2017, LANCET HIV, V2, pe115; [Anonymous], 2017, ONCOGENESIS, V6, pe345; Barwick M. A., 2019, TRANSL BEHAV MED, pibz005, DOI [10.1093/tbm/ibz005/5304470, DOI 10.1093/TBM/IBZ005/5304470]; Brainard J, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0492-5; Braithwaite J, 2014, INT J QUAL HEALTH C, V26, P321, DOI 10.1093/intqhc/mzu047; Cane J, 2012, IMPLEMENT SCI, V7, DOI 10.1186/1748-5908-7-37; Chouliara N, 2014, CLIN REHABIL, V28, P370, DOI 10.1177/0269215513502212; Churruca K, 2019, J EVALUATION CLIN PR; Collden C, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3488-9; Cresswell J, 2014, RES DESIGN QUALITATA; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; DeCuir-Gunby JT, 2011, FIELD METHOD, V23, P136, DOI 10.1177/1525822X10388468; Dedoose, 2018, DED VERS 8 0 35 WEB; Drug Therapeutics Bulletin, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f4147; Fisher R, 2019, IMPLEMENT SCI, V14, DOI 10.1186/s13012-019-0908-0; Fisher RJ, 2011, STROKE, V42, P1392, DOI 10.1161/STROKEAHA.110.606285; Hayes CW, 2015, BMJ QUAL SAF, V24, P100, DOI 10.1136/bmjqs-2014-003673; Kirk MA, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0437-z; Kramer BJ, 2017, IMPLEMENT SCI, V12, DOI 10.1186/s13012-017-0632-6; Kraut JC, 2014, DISABIL REHABIL, V36, P2178, DOI 10.3109/09638288.2014.893373; Kraut J, 2016, INT J THER REHABIL, V23, P464, DOI 10.12968/ijtr.2016.23.10.464; Langhorne P, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000443.pub4; May CR, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0506-3; Merriam S. B., 2015, QUALITATIVE RES GUID, V4th; Miller KK, 2019, ARCH PHYS MED REHAB, V100, P1162, DOI 10.1016/j.apmr.2018.10.017; Nanninga CS, 2015, PHYS THER, V95, P558, DOI 10.2522/ptj.20130495; Neale S, 2018, VICTORIAN STROKE CLI; Powell BJ, 2014, RES SOCIAL WORK PRAC, V24, P192, DOI 10.1177/1049731513505778; Salminen A., 2006, AUST OCCUP THER J, V53, P3, DOI [10.1111/j.1440-1630.2006.00540.x, DOI 10.1111/J.1440-1630.2006.00540.X]; Seal A, 2015, RES SOCIAL LIFE, P443; Stokes T, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-025094; Stroke Foundation, 2013, REH STROK SERV FRAM; Stroke Foundation, 2017, CLIN GUID STROK MAN, P1; Turner K, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0799-5; Varsi C, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.5091; Wutzke Sonia, 2016, BMC Res Notes, V9, P327, DOI 10.1186/s13104-016-2133-0	39	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2020	15	6							e0235055	10.1371/journal.pone.0235055	http://dx.doi.org/10.1371/journal.pone.0235055			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MF9GS	32579574	gold, Green Published			2023-01-03	WOS:000545646600031
J	Hollandsworth, HM; Amirfakhri, S; Filemoni, F; Molnar, J; Hoffman, RM; Yazaki, P; Bouvet, M				Hollandsworth, Hannah M.; Amirfakhri, Siamak; Filemoni, Filemoni; Molnar, Justin; Hoffman, Robert M.; Yazaki, Paul; Bouvet, Michael			Near-infrared photoimmunotherapy is effective treatment for colorectal cancer in orthotopic nude-mouse models	PLOS ONE			English	Article							CARCINOEMBRYONIC ANTIGEN	Background Photoimmunotherapy (PIT) employs the use of a near-infrared (NIR) laser to activate an antibody conjugated to a NIR-activatable dye to induce cancer cell death. PIT has shown to be effective in a number of studies, however, there are no data on its use in colorectal cancer in an orthotopic model. Methods Humanized anti-CEA antibody (M5A) was conjugated to NIR-activatable IRDye700DX (M5A-700). PIT was validated in vitro with a colon cancer cell-line, using a laser intensity of either 4 J/cm(2), 8 J/cm(2), or 16 J/cm(2). Orthotopic colon cancer mouse models were established by surgical implantation of LS174T tumor fragments onto the cecum. M5A-700 was administered and PIT was performed 24 hours later using a 690 nm laser. Repeat PIT was performed after 7 days in one group. Control mice received laser treatment only. Results In vitro PIT demonstrated tumor cell death in a laser intensity dose-dependent fashion. In orthotopic models, control mice demonstrated persistent tumor growth. Mice that underwent PIT one time had tumor growth arrested for one week, after which re-growth occurred. The group that received repeated PIT exposure had persistent inhibition of tumor growth. Conclusion PIT arrests tumor growth in colon cancer orthotopic nude-mouse models. Repeated PIT arrests colon cancer growth for a longer period of time. PIT may be a useful therapy in the future as an adjunct to surgical resection or as primary therapy to suppress tumor progression.	[Hollandsworth, Hannah M.; Amirfakhri, Siamak; Filemoni, Filemoni; Hoffman, Robert M.; Bouvet, Michael] Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA; [Hollandsworth, Hannah M.; Amirfakhri, Siamak; Filemoni, Filemoni; Hoffman, Robert M.; Bouvet, Michael] Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA; [Hollandsworth, Hannah M.; Amirfakhri, Siamak; Filemoni, Filemoni; Bouvet, Michael] VA San Diego Healthcare Syst, Dept Surg, San Diego, CA 92161 USA; [Molnar, Justin; Yazaki, Paul] Beckman Res Inst City Hope, Dept Mol Imaging & Therapy, Los Angeles, CA USA; [Hoffman, Robert M.] AntiCancer Inc, San Diego, CA USA	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; City of Hope; Beckman Research Institute of City of Hope; Anti Cancer Inc	Bouvet, M (corresponding author), Univ Calif San Diego, Dept Surg, San Diego, CA 92103 USA.; Bouvet, M (corresponding author), Univ Calif San Diego, Moores Canc Ctr, San Diego, CA 92103 USA.; Bouvet, M (corresponding author), VA San Diego Healthcare Syst, Dept Surg, San Diego, CA 92161 USA.	mbouvet@uscd.edu		Hollandsworth, Hannah/0000-0002-8867-6835	VA [1 I01 BX003856-01A1, 1 I01 BX004494-01]; NIH/NCI [T32CA121938]	VA(US Department of Veterans Affairs); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The research was supported by VA Merit Review grant numbers 1 I01 BX003856-01A1 and 1 I01 BX004494-01 (MB), and NIH/NCI grant number T32CA121938 (HH). The funder provided support in the form of salaries for authors [HH], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Dr. Hoffman is affiliated with the commercial company AntiCancer Inc. This commercial affiliation did not provide salaries for any authors and did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Amri R, 2015, JAMA SURG, V150, P890, DOI 10.1001/jamasurg.2015.1525; Boudreau V, 2009, PAC REV, V22, P233, DOI 10.1080/09512740902815359; DeLong JC, 2017, J SURG RES, V218, P139, DOI 10.1016/j.jss.2017.05.069; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Hiroshima Y, 2015, ANN SURG ONCOL, V22, pS1469, DOI 10.1245/s10434-015-4553-9; Hoffman RM, 2017, MEMORIAM J RYGAARD 1, P16; Jang Eun Jung, 2011, J Korean Soc Coloproctol, V27, P194, DOI 10.3393/jksc.2011.27.4.194; Kobayashi H, 2020, BIOCONJUGATE CHEM, V31, P28, DOI 10.1021/acs.bioconjchem.9b00546; Kobayashi H, 2019, ACCOUNTS CHEM RES, V52, P2332, DOI 10.1021/acs.accounts.9b00273; Maawy AA, 2015, J SURG RES, V197, P5, DOI 10.1016/j.jss.2015.02.037; Maawy AA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121989; Ogata F, 2017, ONCOTARGET, V8, P35069, DOI 10.18632/oncotarget.17047; Ogawa M, 2017, ONCOTARGET, V8, P10425, DOI 10.18632/oncotarget.14425; Sato K, 2015, ONCOTARGET, V6, P19747, DOI 10.18632/oncotarget.3850; Sato K, 2015, MOL CANCER THER, V14, P141, DOI 10.1158/1535-7163.MCT-14-0658; Tiernan JP, 2013, BRIT J CANCER, V108, P662, DOI 10.1038/bjc.2012.605; Yazaki PJ, 2004, PROTEIN ENG DES SEL, V17, P481, DOI 10.1093/protein/gzh056; Zare-Bandamiri Mohammad, 2017, Asian Pac J Cancer Prev, V18, P2465	18	6	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2020	15	6							e0234643	10.1371/journal.pone.0234643	http://dx.doi.org/10.1371/journal.pone.0234643			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC4QJ	32555717	Green Published, gold			2023-01-03	WOS:000543273200028
J	Balwani, M; Sardh, E; Ventura, P; Peiro, PA; Rees, DC; Stolzel, U; Bissell, DM; Bonkovsky, HL; Windyga, J; Anderson, KE; Parker, C; Silver, SM; Keel, SB; Wang, JD; Stein, PE; Harper, P; Vassiliou, D; Wang, B; Phillips, J; Ivanova, A; Langendonk, JG; Kauppinen, R; Minder, E; Horie, Y; Penz, C; Chen, JH; Liu, SB; Ko, JJ; Sweetser, MT; Garg, P; Vaishnaw, A; Kim, JB; Simon, AR; Gouya, L				Balwani, Manisha; Sardh, Eliane; Ventura, Paolo; Peiro, Paula Aguilera; Rees, David C.; Stoelzel, Ulrich; Bissell, D. Montgomery; Bonkovsky, Herbert L.; Windyga, Jerzy; Anderson, Karl E.; Parker, Charles; Silver, Samuel M.; Keel, Sioban B.; Wang, Jiaan-Der; Stein, Penelope E.; Harper, Pauline; Vassiliou, Daphne; Wang, Bruce; Phillips, John; Ivanova, Aneta; Langendonk, Janneke G.; Kauppinen, Raili; Minder, Elisabeth; Horie, Yutaka; Penz, Craig; Chen, Jihong; Liu, Shangbin; Ko, John J.; Sweetser, Marianne T.; Garg, Pushkal; Vaishnaw, Akshay; Kim, Jae B.; Simon, Amy R.; Gouya, Laurent		ENVISION Investigators	Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIVER-TRANSPLANTATION; RECOMMENDATIONS; MANAGEMENT; MECHANISMS; UPDATE	Background Up-regulation of hepatic delta-aminolevulinic acid synthase 1 (ALAS1), with resultant accumulation of delta-aminolevulinic acid (ALA) and porphobilinogen, is central to the pathogenesis of acute attacks and chronic symptoms in acute hepatic porphyria. Givosiran, an RNA interference therapy, inhibits ALAS1 expression. Methods In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned symptomatic patients with acute hepatic porphyria to receive either subcutaneous givosiran (2.5 mg per kilogram of body weight) or placebo monthly for 6 months. The primary end point was the annualized rate of composite porphyria attacks among patients with acute intermittent porphyria, the most common subtype of acute hepatic porphyria. (Composite porphyria attacks resulted in hospitalization, an urgent health care visit, or intravenous administration of hemin at home.) Key secondary end points were levels of ALA and porphobilinogen and the annualized attack rate among patients with acute hepatic porphyria, along with hemin use and daily worst pain scores in patients with acute intermittent porphyria. Results A total of 94 patients underwent randomization (48 in the givosiran group and 46 in the placebo group). Among the 89 patients with acute intermittent porphyria, the mean annualized attack rate was 3.2 in the givosiran group and 12.5 in the placebo group, representing a 74% lower rate in the givosiran group (P<0.001); the results were similar among the 94 patients with acute hepatic porphyria. Among the patients with acute intermittent porphyria, givosiran led to lower levels of urinary ALA and porphobilinogen, fewer days of hemin use, and better daily scores for pain than placebo. Key adverse events that were observed more frequently in the givosiran group were elevations in serum aminotransferase levels, changes in serum creatinine levels and the estimated glomerular filtration rate, and injection-site reactions. Conclusions Among patients with acute intermittent porphyria, those who received givosiran had a significantly lower rate of porphyria attacks and better results for multiple other disease manifestations than those who received placebo. The increased efficacy was accompanied by a higher frequency of hepatic and renal adverse events. (Funded by Alnylam Pharmaceuticals; ENVISION ClinicalTrials.gov number,.) In a randomized phase 3 trial involving patients with acute intermittent porphyria, the use of givosiran, an oligonucleotide drug designed to target messenger RNA encoding aminolevulinic acid synthase, led to a 74% lower annualized porphyria attack rate than the use of placebo at 6 months.	[Balwani, Manisha] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Sardh, Eliane; Harper, Pauline; Vassiliou, Daphne] Karolinska Univ Hosp, Karolinska Inst, Ctr Inherited Metab Dis, Porphyria Ctr Sweden, Stockholm, Sweden; [Ventura, Paolo] Univ Modena & Reggio Emilia, Internal Med Unit, Dept Surg & Med Sci Children & Adults, Modena, Italy; [Peiro, Paula Aguilera] Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain; [Rees, David C.; Stein, Penelope E.] Kings Coll London, Kings Coll Hosp, London, England; [Stoelzel, Ulrich] Klinikum Chemnitz, Chemnitz, Germany; [Bissell, D. Montgomery; Wang, Bruce] Univ Calif San Francisco, Ctr Liver, San Francisco, CA 94143 USA; [Bissell, D. Montgomery; Wang, Bruce] Univ Calif San Francisco, Porphyria Ctr, San Francisco, CA 94143 USA; [Bonkovsky, Herbert L.] Wake Forest Univ, North Carolina Baptist Med Ctr, Sect Gastroenterol & Hepatol, Winston Salem, NC 27101 USA; [Windyga, Jerzy] Inst Hematol & Transfus Med, Dept Hemostat Disorders & Internal Med, Warsaw, Poland; [Anderson, Karl E.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Parker, Charles; Phillips, John] Univ Utah, Salt Lake City, UT USA; [Silver, Samuel M.] Univ Michigan, Ann Arbor, MI 48109 USA; [Keel, Sioban B.] Univ Washington, Dept Med, Div Hematol, Seattle, WA 98195 USA; [Wang, Jiaan-Der] Taichung Vet Gen Hosp, Ctr Rare Dis & Hemophilia, Taichung, Taiwan; [Ivanova, Aneta] St Ivan Rilski Univ Hosp, Sofia, Bulgaria; [Langendonk, Janneke G.] Erasmus MC, Univ Med Ctr Rotterdam, Ctr Lysosomal & Metab Dis, Dept Internal Med,Porphyria Ctr Rotterdam, Rotterdam, Netherlands; [Kauppinen, Raili] Univ Hosp Helsinki, Dept Med, Helsinki, Finland; [Minder, Elisabeth] Stadtspital Triemli, Zurich, Switzerland; [Horie, Yutaka] Tottori Univ, Sch Med, Tottori, Japan; [Penz, Craig; Chen, Jihong; Liu, Shangbin; Ko, John J.; Sweetser, Marianne T.; Garg, Pushkal; Vaishnaw, Akshay; Kim, Jae B.; Simon, Amy R.] Alnylam Pharmaceut, Cambridge, MA USA; [Gouya, Laurent] Univ Paris, Paris, France; [Gouya, Laurent] Lab Excellence GR Ex, Paris, France; [Gouya, Laurent] AP HP, Ctr Reference Malad Rares Porphyries, Colombes, France	Icahn School of Medicine at Mount Sinai; Karolinska Institutet; Karolinska University Hospital; Universita di Modena e Reggio Emilia; University of Barcelona; Hospital Clinic de Barcelona; King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London; Chemnitz Clinic; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Wake Forest University; University of Texas System; University of Texas Medical Branch Galveston; Utah System of Higher Education; University of Utah; University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle; Taichung Veterans General Hospital; Medical University Sofia; Erasmus University Rotterdam; Erasmus MC; University of Helsinki; Helsinki University Central Hospital; Triemli Hospital; Tottori University; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite	Balwani, M (corresponding author), Icahn Sch Med Genet & Genom Sci, 1 Gustave L Levy Pl,Box 1497, New York, NY 10029 USA.	manisha.balwani@mssm.edu	Sardh, Eliane/AFV-2232-2022; Aguilera, Paula/AAO-5340-2021; Ventura, Paolo/AAW-2705-2020; Guillén Navarro, Encarna/AFU-6717-2022; Bonkovsky, Herbert L./AAH-1892-2021; Ventura, Paolo/AAC-1084-2019; Rees, David/B-6789-2011	Sardh, Eliane/0000-0002-2366-2213; Ventura, Paolo/0000-0003-1893-1914; Guillén Navarro, Encarna/0000-0002-2915-7381; Bonkovsky, Herbert L./0000-0001-7387-3230; Ventura, Paolo/0000-0003-1893-1914; Aguilera, Paula/0000-0002-1825-7707; Hother-Nielsen, Ole/0000-0002-8761-2784; Rees, David/0000-0003-3647-1050; Kauppinen, Raili/0000-0002-8799-3425; Ritchie, Bruce/0000-0003-4754-1050; MONROY-SANTOYO, SUSANA/0000-0002-0337-0205	Alnylam Pharmaceuticals	Alnylam Pharmaceuticals	Funded by Alnylam Pharmaceuticals.	Alnylam Pharmaceuticals, 2020, GIVL SUMM PROD CHAR; Alnylam Pharmaceuticals, 2019, GIVL GIV HIGHL PRESC; Anderson KE, 2018, 2018 AM ASS STUD LIV; Andersson C, 1996, J INTERN MED, V240, P195, DOI 10.1046/j.1365-2796.1996.21847000.x; [Anonymous], 2007, SUMM PROD CHAR NORM; [Anonymous], 2017, PANH HEM INJ; Balwani M, 2017, HEPATOLOGY, V66, P1314, DOI 10.1002/hep.29313; Balwani M, 2012, BLOOD, V120, P4496, DOI 10.1182/blood-2012-05-423186; Baumann K, 2020, MOL GENET METAB, V130, P87, DOI 10.1016/j.ymgme.2020.02.003; Bissell DM, 2015, J CLIN TRANSL HEPATO, V3, P17, DOI 10.14218/JCTH.2014.00039; Bissell DM, 2015, AM J MED, V128, P313, DOI 10.1016/j.amjmed.2014.10.026; Bonkovsky HL, 2014, AM J MED, V127, P1233, DOI 10.1016/j.amjmed.2014.06.036; Chan A, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.36; Chen B, 2016, HUM MUTAT, V37, P1215, DOI 10.1002/humu.23067; Clement ND, 2014, KNEE SURG SPORT TR A, V22, P1933, DOI 10.1007/s00167-013-2776-5; Cohen SP, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.f7656; Dowman JK, 2012, LIVER TRANSPLANT, V18, P195, DOI 10.1002/lt.22345; Dworkin RH, 2013, PAIN, V154, P2249, DOI 10.1016/j.pain.2013.06.004; Elder G, 2013, J INHERIT METAB DIS, V36, P849, DOI 10.1007/s10545-012-9544-4; Gouya L, 2020, HEPATOLOGY, V71, P1546, DOI 10.1002/hep.30936; Guy W., 1976, ECDEU ASSESSMENT MAN, P218, DOI DOI 10.1037/E591322011-001; Nair JK, 2014, J AM CHEM SOC, V136, P16958, DOI 10.1021/ja505986a; Pallet N, 2015, KIDNEY INT, V88, P386, DOI 10.1038/ki.2015.97; Parker SL, 2012, J NEUROSURG-SPINE, V16, P471, DOI 10.3171/2012.1.SPINE11842; Pischik E, 2015, APPL CLIN GENET, V8, P201, DOI 10.2147/TACG.S48605; Puy H, 2010, LANCET, V375, P924, DOI 10.1016/S0140-6736(09)61925-5; Sardh E, 2019, NEW ENGL J MED, V380, P549, DOI 10.1056/NEJMoa1807838; Schmitt C, 2018, J INTERN MED, V284, P78, DOI 10.1111/joim.12750; Setten RL, 2019, NAT REV DRUG DISCOV, V18, P421, DOI 10.1038/s41573-019-0017-4; Simon A, 2018, PATIENT, V11, P527, DOI 10.1007/s40271-018-0319-3; Stein PE, 2017, BRIT J HAEMATOL, V176, P527, DOI 10.1111/bjh.14459; Stewart MF, 2012, J CLIN PATHOL, V65, P976, DOI 10.1136/jclinpath-2012-200791; Vassiliou D, 2019, 2019 INT C PORPH POR; Wang B, 2019, HEPATOL COMMUN, V3, P193, DOI 10.1002/hep4.1297; Wang DL, 2015, CONTEMP CLIN TRIALS, V45, P13, DOI 10.1016/j.cct.2015.07.014; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Willandt B, 2016, JIMD REP, V25, P77, DOI 10.1007/8904_2015_458; Yasuda M, 2015, MOL MED, V21, P487, DOI 10.2119/molmed.2015.00099	38	195	196	4	32	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 11	2020	382	24					2289	2301		10.1056/NEJMoa1913147	http://dx.doi.org/10.1056/NEJMoa1913147			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ3TR	32521132	Bronze, Green Published			2023-01-03	WOS:000541151500009
J	Burke, LM; Sharma, AP; Heikura, IA; Forbes, SF; Holloway, M; McKay, AKA; Bone, JL; Leckey, JJ; Welvaert, M; Ross, ML				Burke, Louise M.; Sharma, Avish P.; Heikura, Ida A.; Forbes, Sara F.; Holloway, Melissa; McKay, Alannah K. A.; Bone, Julia L.; Leckey, Jill J.; Welvaert, Marijke; Ross, Megan L.			Crisis of confidence averted: Impairment of exercise economy and performance in elite race walkers by ketogenic low carbohydrate, high fat (LCHF) diet is reproducible	PLOS ONE			English	Article							ENDURANCE PERFORMANCE; RESPIRATORY QUOTIENT; ENHANCED ENDURANCE; ADAPTATION; METABOLISM; PERIODIZATION; INTENSITY; FUEL; OXIDATION; CYCLISTS	Introduction We repeated our study of intensified training on a ketogenic low-carbohydrate (CHO), high-fat diet (LCHF) in world-class endurance athletes, with further investigation of a "carryover" effect on performance after restoring CHO availability in comparison to high or periodised CHO diets. Methods After Baseline testing (10,000 m IAAF-sanctioned race, aerobic capacity and submaximal walking economy) elite male and female race walkers undertook 25 d supervised training and repeat testing (Adapt) on energy-matched diets: High CHO availability (8.6 g.kg(-1).d(-1) CHO, 2.1 g.kg(-1).d(-1) protein; 1.2 g.kg(-1).d(-1) fat) including CHO before/during/after workouts (HCHO, n = 8): similar macronutrient intake periodised within/between days to manipulate low and high CHO availability at various workouts (PCHO, n = 8); and LCHF (<50 g.d(-1) CHO; 78% energy as fat; 2.1 g.kg(-1).d(-1) protein; n = 10). After Adapt, all athletes resumed HCHO for 2.5 wk before a cohort (n = 19) completed a 20 km race. Results All groups increased VO(2)peak (ml.kg(-1).min(-1)) at Adapt (p = 0.02, 95%CI: [0.35-2.74]). LCHF markedly increased whole-body fat oxidation (from 0.6 g.min(-1) to 1.3 g.min(-1)), but also the oxygen cost of walking at race-relevant velocities. Differences in 10,000 m performance were clear and meaningful: HCHO improved by 4.8% or 134 s (95% CI: [207 to 62 s]; p < 0.001), with a trend for a faster time (2.2%, 61 s [-18 to +144 s]; p = 0.09) in PCHO. LCHF were slower by 2.3%, -86 s ([-18 to -144 s]; p < 0.001), with no evidence of superior "rebound" performance over 20 km after 2.5 wk of HCHO restoration and taper. Conclusion Our previous findings of impaired exercise economy and performance of sustained high-intensity race walking following keto-adaptation in elite competitors were repeated. Furthermore, there was no detectable benefit from undertaking an LCHF intervention as a periodised strategy before a 2.5-wk race preparation/taper with high CHO availability.	[Burke, Louise M.; Sharma, Avish P.; Heikura, Ida A.; Forbes, Sara F.; Holloway, Melissa; McKay, Alannah K. A.; Bone, Julia L.; Welvaert, Marijke; Ross, Megan L.] Australian Inst Sport, Canberra, ACT, Australia; [Burke, Louise M.; Heikura, Ida A.; Bone, Julia L.; Leckey, Jill J.; Ross, Megan L.] Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, Australia; [Sharma, Avish P.] Griffith Univ, Sch Allied Hlth Sci, Griffith Sports Physiol & Performance, Gold Coast, Australia; [McKay, Alannah K. A.] Univ Western Australia, Sch Human Sci Exercise & Sport Sci, Crawley, WA, Australia; [McKay, Alannah K. A.] Western Australian Inst Sport, Mt Claremont, WA, Australia; [Welvaert, Marijke] Univ Canberra, Res Inst Sport & Exercise, Canberra, ACT, Australia	Australian Institute of Sport; Australian Catholic University; Griffith University; University of Western Australia; University of Canberra	Burke, LM (corresponding author), Australian Inst Sport, Canberra, ACT, Australia.; Burke, LM (corresponding author), Australian Catholic Univ, Mary MacKillop Inst Hlth Res, Melbourne, Vic, Australia.	louise.burke@ausport.gov.au	Burke, Louise/ABC-5691-2020; McKay, Alannah/AAH-3738-2021; Forbes, Sara/AHE-6669-2022; Welvaert, Marijke/GOE-6151-2022; Welvaert, Marijke/K-8486-2013	Forbes, Sara/0000-0001-6726-9328; Welvaert, Marijke/0000-0002-0802-8134; McKay, Alannah/0000-0002-4184-3886; Heikura, Ida/0000-0002-1088-428X; Burke, Louise M/0000-0001-8866-5637	Australian Catholic University Research Funds [2017000034]; Australian Institute of Sport	Australian Catholic University Research Funds; Australian Institute of Sport	This study was funded by a Program Grant from the Australian Catholic University Research Funds to Professor Louise Burke (ACURF, 2017000034).; Studies of this magnitude require incredible support from a large team. We thank our research colleagues and supporters: Laura Garvican-Lewis, Amelia Carr, Brent Vallance, Rita Civil, Alice Wallett, Nicolin Tee, Victor Vuong, Nikki Jeacocke, Reid Reale, Chris Fonda, Rebekah Alcock, Michelle Minehan, Bronwen Charlesson, Bronwen Lundy, Mark Howard, Toni Franklin, Ben Parker, Aki Kawamura, Susan Boegman, Kiara Carmody, Rachel McCormick, Ned Brophy-Williams, Peter Peeling, Philo Saunders, Damon Arezzollo, Jamie Whitfield, Sarah Taylor, Sacha Tee, James Tee, Stephan Praet, Claire Tallent, Phil Reading and Lynne Mercer. The support and environment of the Australian Institute of Sport were crucial in allowing this study to be completed. Finally, the generosity and commitment to sports science of the Supernova race walkers continues to inspire us. This study would not have happened without their blood, sweat, tears and good humour.	Achten J, 2002, MED SCI SPORT EXER, V34, P92, DOI 10.1097/00005768-200201000-00015; [Anonymous], IMPR REPR EMP SCI; B Spiriev, IAAF SCORING TABLES; Badenhorst CE, 2015, EUR J APPL PHYSIOL, V115, P2521, DOI 10.1007/s00421-015-3252-3; Bartlett JD, 2015, EUR J SPORT SCI, V15, P3, DOI 10.1080/17461391.2014.920926; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Benardot D, 2016, MED SCI SPORT EXER, V48, P543; Burke LM, 2006, J APPL PHYSIOL, V100, P7, DOI 10.1152/japplphysiol.01238.2005; Burke LM, 2002, MED SCI SPORT EXER, V34, P83, DOI 10.1097/00005768-200201000-00014; Burke LM, 2000, J APPL PHYSIOL, V89, P2413, DOI 10.1152/jappl.2000.89.6.2413; Burke LM, J PHYSL; Burke LM, 2021, J PHYSIOL-LONDON, V599, P819, DOI 10.1113/JP278928; Burke LM, 2019, INT J SPORT NUTR EXE, V29, P117, DOI 10.1123/ijsnem.2019-0004; Burke LM, 2018, SCIENCE, V362, P781, DOI 10.1126/science.aau2093; Burke LM, 2018, INT J SPORT NUTR EXE, V28, P451, DOI 10.1123/ijsnem.2018-0289; Burke LM, 2017, J PHYSIOL-LONDON, V595, P2993, DOI 10.1113/JP274011; Burke LM, 2017, J PHYSIOL-LONDON, V595, P2785, DOI 10.1113/JP273230; Carlino Elisa, 2014, Handb Exp Pharmacol, V225, P149, DOI 10.1007/978-3-662-44519-8_9; Cole M, 2014, INT J SPORTS MED, V35, P265, DOI 10.1055/s-0033-1348254; Cox PJ, 2016, CELL METAB, V24, P256, DOI 10.1016/j.cmet.2016.07.010; Coyle EF, 1991, J SPORT SCI, V9, P29, DOI 10.1080/02640419108729865; DANIELS J, 1992, MED SCI SPORT EXER, V24, P483; Evans M, 2019, MED SCI SPORT EXER, V51, P2506, DOI 10.1249/MSS.0000000000002065; Evans M, 2018, MED SCI SPORT EXER, V50, P2330, DOI 10.1249/MSS.0000000000001700; Evans M, 2017, J PHYSIOL-LONDON, V595, P2857, DOI 10.1113/JP273185; Ewing L, RACEWALKER E DUNFEES; Frandsen J, 2017, INT J SPORTS MED, V38, P975, DOI 10.1055/s-0043-117178; FRAYN KN, 1983, J APPL PHYSIOL, V55, P628, DOI 10.1152/jappl.1983.55.2.628; Gejl KD, 2017, MED SCI SPORT EXER, V49, P2486, DOI 10.1249/MSS.0000000000001377; Goedecke JH, 1999, METABOLISM, V48, P1509, DOI 10.1016/S0026-0495(99)90238-X; Havemann L, 2006, J APPL PHYSIOL, V100, P194, DOI 10.1152/japplphysiol.00813.2005; Heikura IA, 2020, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00880; Hoogkamer W, 2018, SPORTS MED, V48, P1009, DOI 10.1007/s40279-017-0811-2; Huebsch T, EYE OPENING SPLITS 5; IAP: Interacademy Partnership for Health, 2016, CALL ACT IMPR REPR B; Impey SG, 2018, SPORTS MED, V48, P1031, DOI 10.1007/s40279-018-0867-7; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; Iqbal SA, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002333; Jones AM, 2018, ANNU REV NUTR, V38, P303, DOI 10.1146/annurev-nutr-082117-051622; Joyner MJ, 2008, J PHYSIOL-LONDON, V586, P35, DOI 10.1113/jphysiol.2007.143834; Karelis AD, 2010, SPORTS MED, V40, P747, DOI 10.2165/11533080-000000000-00000; Kipp S, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00079; Krogh A, 1920, BIOCHEM J, V14, P290, DOI 10.1042/bj0140290; LAMBERT EV, 1994, EUR J APPL PHYSIOL O, V69, P287, DOI 10.1007/BF00392032; Larsen HB, 2003, COMP BIOCHEM PHYS A, V136, P161, DOI 10.1016/S1095-6433(03)00227-7; Leckey JJ, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00806; Leckey JJ, 2018, FASEB J, pfj201700993R; Leverve Xavier, 2007, Novartis Found Symp, V280, P108; Lindseth I, 2017, J PHYSIOL-LONDON, V595, P2989, DOI 10.1113/JP273990; Louis JB, 2020, J APPL PHYSIOL, V128, P440, DOI 10.1152/japplphysiol.00819.2019; Marquet LA, 2016, MED SCI SPORT EXER, V48, P663, DOI 10.1249/MSS.0000000000000823; Maunder E, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00599; Maunder E, 2018, SPORTS MED, V48, P2219, DOI 10.1007/s40279-018-0938-9; McKay AKA, 2019, J SPORT SCI, V37, P553, DOI 10.1080/02640414.2018.1521712; McSwiney FT, 2018, METABOLISM, V81, P25, DOI 10.1016/j.metabol.2017.10.010; Mirtschin JG, 2018, INT J SPORT NUTR EXE, V28, P480, DOI 10.1123/ijsnem.2017-0249; Munafo MR, 2017, NAT HUM BEHAV, V1, DOI 10.1038/s41562-016-0021; Murtaza N, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030614; Noakes TD, 1990, J SPORT SCI, V8, P35, DOI 10.1080/02640419008732129; Noakes T, 2014, BRIT J SPORT MED, V48, P1077, DOI 10.1136/bjsports-2014-093824; Peake JM, 2017, J APPL PHYSIOL, V122, P1077, DOI 10.1152/japplphysiol.00622.2016; PERONNET F, 1991, CAN J SPORT SCI, V16, P23; Petersson J, 2009, FREE RADICAL BIO MED, V46, P1068, DOI 10.1016/j.freeradbiomed.2009.01.011; PHINNEY SD, 1983, METABOLISM, V32, P769, DOI 10.1016/0026-0495(83)90106-3; R Core Team, R LANG ENV STAT COMP; Robertson EY, 2010, MED SCI SPORT EXER, V42, P394, DOI 10.1249/MSS.0b013e3181b34b57; ROMIJN JA, 1992, AM J PHYSIOL, V263, pE64, DOI 10.1152/ajpendo.1992.263.1.E64; Saunders PU, 2010, INT J SPORT PHYSIOL, V5, P521, DOI 10.1123/ijspp.5.4.521; Saunders PU, 2012, PHYSL TESTS ELITE AT, P397; Scott BE, 2018, J SCI MED SPORT; Shaw DM, 2020, SPORTS MED, V50, P641, DOI 10.1007/s40279-019-01246-y; Shaw DM, 2019, MED SCI SPORT EXER, V51, P2135, DOI 10.1249/MSS.0000000000002008; Spriet LL, 2014, SPORTS MED, V44, P87, DOI 10.1007/s40279-014-0154-1; Stellingwerff T, 2006, AM J PHYSIOL-ENDOC M, V290, pE380, DOI 10.1152/ajpendo.00268.2005; The Academy of Medical Sciences, 2015, REPR REL BIOM RES IM; Tucker R., 2020, RUNNING SHOE TECH EM; Volek JS, 2016, METABOLISM, V65, P100, DOI 10.1016/j.metabol.2015.10.028; Volek JS, 2015, EUR J SPORT SCI, V15, P13, DOI 10.1080/17461391.2014.959564; Volek JS, 2012, ART SCI LOW CARBOHYD; Webster CC, 2018, SPORTS MED, V48, P2421, DOI 10.1007/s40279-018-0972-7; Webster CC, 2018, INT J SPORT PHYSIOL, V13, P957, DOI 10.1123/ijspp.2017-0392; Webster CC, 2016, J PHYSIOL-LONDON, V594, P4389, DOI 10.1113/JP271934; Zuntz N., 1901, STUDIEN PHYSIOLOGIE, P361	83	38	38	5	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2020	15	6							e0234027	10.1371/journal.pone.0234027	http://dx.doi.org/10.1371/journal.pone.0234027			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6PX	32497061	Green Published, gold			2023-01-03	WOS:000542035200047
J	Kumpula, EK; Norris, P; Pomerleau, AC				Kumpula, Eeva-Katri; Norris, Pauline; Pomerleau, Adam C.			Stocks of paracetamol products stored in urban New Zealand households: A cross-sectional study	PLOS ONE			English	Article							MEDICINES; STORAGE; IMPUTATION; EXPOSURE	Background Intentional self-harm is a common cause of hospital presentations in New Zealand and across the world, and self-poisoning is the most common method of self-harm. Paracetamol (acetaminophen) is frequently used in impulsive intentional overdoses, where ease of access may determine the choice of substance. Objective This cross-sectional study aimed to determine how much paracetamol is present and therefore accessible in urban New Zealand households, and sources from where it has been obtained. This information is not currently available through any other means, but could inform New Zealand drug policy on access to paracetamol. Methods Random cluster-sampling of households was performed in major urban areas of two cities in New Zealand, and the paracetamol-containing products, quantities, and sources were recorded. Population estimates of proportions of various types of paracetamol products were calculated. Results A total of 174 of the 201 study households (86.6%) had at least one paracetamol product. Study households had mostly prescription products (78.2% of total mass), and a median of 24.0 g paracetamol present per household (inter-quartile range 6.0-54.0 g). Prescribed paracetamol was the main source of large stock. Based on the study findings, 53% of New Zealand households had 30 g or more paracetamol present, and 36% had 30 g or more of prescribed paracetamol, specifically. Conclusions This study highlights the importance of assessing whether and how much paracetamol is truly needed when prescribing and dispensing it. Convenience of appropriate access to therapeutic paracetamol needs to be balanced with preventing unnecessary accumulation of paracetamol stocks in households and inappropriate access to it. Prescribers and pharmacists need to be aware of the risks of such accumulation and assess the therapeutic needs of their patients. Public initiatives should be rolled out at regular intervals to encourage people to return unused or expired medicines to pharmacies for safe disposal.	[Kumpula, Eeva-Katri; Pomerleau, Adam C.] Univ Otago, Natl Poisons Ctr, Dept Prevent & Social Med, Dunedin, New Zealand; [Norris, Pauline] Univ Otago, Ctr Pacific Hlth Vaa Tautai, Div Hlth Sci, Dunedin, New Zealand	University of Otago; University of Otago	Kumpula, EK (corresponding author), Univ Otago, Natl Poisons Ctr, Dept Prevent & Social Med, Dunedin, New Zealand.	eeva-katri.kumpula@otago.ac.nz		Kumpula, Eeva-Katri/0000-0003-0455-5161	Oakley Mental Health Research Foundation	Oakley Mental Health Research Foundation	This study was funded by a research grant from Oakley Mental Health Research Foundation (http://www.oakleymentalhealth.co.nz/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We would like to thank the study participants, research assistants Timothy Burrell, Jocelyn Ooi, Daniel Paterson, and Erika Sequeda for collecting the data, Andrew Gray for assistance in study design and sample size determinations, and Benoit Auvray (Airmed Ltd) for the adjusted stock proportions calculations.	Abushanab Amani S, 2013, Int J Pharm Pract, V21, P185, DOI 10.1111/j.2042-7174.2012.00250.x; Atkinson J., 2014, NZDEP2013 INDEX DEPR; Bateman DN, 2009, CLIN TOXICOL, V47, P536, DOI 10.1080/15563650903093192; Bettington E, 2018, AUST PRESCR, V41, P78, DOI 10.18773/austprescr.2018.015; Blieden M, 2014, EXPERT REV CLIN PHAR, V7, P341, DOI 10.1586/17512433.2014.904744; Braund R, 2009, PHARM WORLD SCI, V31, P664, DOI 10.1007/s11096-009-9325-9; Buykx P, 2010, AUST NZ J PUBL HEAL, V34, P401, DOI 10.1111/j.1753-6405.2010.00573.x; Cairns R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026001; Chiew AL, 2020, MED J AUSTRALIA, V212, P175, DOI 10.5694/mja2.50428; Daly C, 2018, EUR J PUBLIC HEALTH, V28, P681, DOI 10.1093/eurpub/cky031; Foroutan B, 2014, E MEDITERR HEALTH J, V20, P547, DOI 10.26719/2014.20.9.547; Gedeborg R, 2017, PHARMACOEPIDEM DR S, V26, P518, DOI 10.1002/pds.4166; Gilley M, 2020, CLIN TOXICOL, V58, P711, DOI 10.1080/15563650.2019.1687900; Griffin E, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005557; Gummin DD, 2019, CLIN TOXICOL, V57, P1220, DOI 10.1080/15563650.2019.1677022; Gwini SM, 2011, EMERG MED J, V28, P892, DOI 10.1136/emj.2009.086140; HAWTON K, 1995, BRIT MED J, V310, P164, DOI 10.1136/bmj.310.6973.164; Hawton K, 1996, BRIT J PSYCHIAT, V168, P43, DOI 10.1192/bjp.168.1.43; Hawton K, 2001, BRIT MED J, V322, P1, DOI DOI 10.1136/BMJ.322.7296.1203; Hawton K, 2012, EUR CHILD ADOLES PSY, V21, P369, DOI 10.1007/s00787-012-0269-6; Hewson C, 2013, J PRIM HEALTH CARE, V5, P146, DOI 10.1071/HC13146; Huynh A, 2018, MED J AUSTRALIA, V209, P74, DOI 10.5694/mja17.01063; Janssen L, 2018, PHARMACY, V6, DOI 10.3390/pharmacy6030074; Kelly JP, 2018, J AM PHARM ASSOC, V58, P492, DOI 10.1016/j.japh.2018.06.012; KESSEL N, 1966, P ROY SOC MED, V59, P89, DOI 10.1177/003591576605900206; Kumpula EK, 2017, AUST NZ J PUBL HEAL, V41, P535, DOI 10.1111/1753-6405.12702; Martinez RM, 2012, J COMMUN HEALTH, V37, P1249, DOI 10.1007/s10900-012-9563-y; Martins RR, 2017, REV SAUDE PUBL, V51, DOI [10.11606/S1518-8787.2017051000053, 10.11606/s1518-8787.2017051000053]; Mikhail A, 2019, CRISIS, V40, P166, DOI 10.1027/0227-5910/a000545; Ministry of Health, 2019, SUIC FACTS DAT TABL; National Ethics Advisory Committee, 2019, NAT ETH STAND HLTH D; Newcombe RG, 1998, STAT MED, V17, P873, DOI 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I; Peiris-John R, 2014, INTERN MED J, V44, P273, DOI 10.1111/imj.12364; Perry IJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031663; Rubin D. B., 2004, MULTIPLE IMPUTATION; Samuelsen PJ, 2015, BMC PHARMACOL TOXICO, V16, DOI 10.1186/s40360-015-0016-y; Sarganas G, 2015, BMC PHARMACOL TOXICO, V16, DOI 10.1186/s40360-015-0028-7; Statistics New Zealand, 2016, STAT STAND MESHBL; Stekhoven DJ, 2012, BIOINFORMATICS, V28, P112, DOI 10.1093/bioinformatics/btr597; University of Otago, NZDEP2013 MESHBL DAT; van Buuren S, 2011, J STAT SOFTW, V45, P1; Wastesson JW, 2018, BASIC CLIN PHARMACOL, V123, P301, DOI 10.1111/bcpt.13003; Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774; Wondimu A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135650; Wright MN, 2017, J STAT SOFTW, V77, P1, DOI 10.18637/jss.v077.i01	45	0	0	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2020	15	6							e0233806	10.1371/journal.pone.0233806	http://dx.doi.org/10.1371/journal.pone.0233806			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MJ2AA	32479539	gold, Green Published			2023-01-03	WOS:000547893500028
J	Leon-Lozano, MZ; Arnaez, J; Valls, A; Arca, G; Agut, T; Alarcon, A; Garcia-Alix, A				Leon-Lozano, Marisol-Zulema; Arnaez, Juan; Valls, Ana; Arca, Gemma; Agut, Thais; Alarcon, Ana; Garcia-Alix, Alfredo			Cerebrospinal fluid levels of neuron-specific enolase predict the severity of brain damage in newborns with neonatal hypoxic-ischemic encephalopathy treated with hypothermia	PLOS ONE			English	Article							NEUROBIOCHEMICAL MARKERS; THERAPEUTIC HYPOTHERMIA; TERM INFANTS; BIOMARKERS; SERUM; PROTEINS; INJURY; MRI; DYSFUNCTION; INCREASE	Objectives To investigate whether cerebrospinal fluid levels of neuron-specific enolase (CSF-NSE) during the first 72 hours correlate with other tools used to assess ongoing brain damage, including clinical grading of hypoxic-ischemic encephalopathy (HIE), abnormal patterns in amplitude integrated electroencephalography (aEEG), and magnetic resonance imaging (MRI), as well as with the neurodevelopmental outcomes at two years of age. Material and methods Prospective observational study performed in two hospitals between 2009 and 2011. Forty-three infants diagnosed with HIE within 6 hours of life were included. HIE was severe in 20 infants, moderate in 12, and mild in 11. Infants with moderate-to-severe HIE received whole-body cooling. Both the HIE cohort and a control group of 59 infants with suspected infection underwent measurement of CSF-NSE concentrations at between 12 and 72 hours after birth. aEEG monitoring was started at admission and brain MRI was performed within the first 2 weeks. Neurodevelopment was assessed at 24 months. Results The HIE group showed higher levels of CSF-NSE than the control group: median 70 ng/ml (29; 205) vs 10.6 ng/ml (7.7; 12.9); p < 0.001. Median levels of CSF-NSE in infants with severe, moderate, and mild HIE were 220.5 ng/ml (120.5; 368.8), 45.5 ng/ml (26, 75.3), and 26 ng/ml (18, 33), respectively. CSF-NSE levels correlated were significantly higher in infants with seizures, abnormal aEEG, or abnormal MRI, compared to those without abnormalities. Infants with an adverse outcome showed higher CSF-NSE levels than those with normal findings (p<0.001), and the most accurate CSF-NSE cutoff level for predicting adverse outcome in the whole cohort was 108 ng/ml and 50ng/ml in surviving infants. Conclusions In the era of hypothermia, CSF-NSE concentrations provides valuable information as a clinical surrogate of the severity of hypoxic-ischemic brain damage, and this information may be predictive of abnormal outcome at two years of age.	[Leon-Lozano, Marisol-Zulema] Assistencial Univ Manresa, Althaia Xarxa, Barcelona, Spain; [Leon-Lozano, Marisol-Zulema; Garcia-Alix, Alfredo] Univ Barcelona, Barcelona, Spain; [Arnaez, Juan] Hosp Univ Burgos, Dept Neonatol, Burgos, Spain; [Arnaez, Juan; Arca, Gemma; Agut, Thais; Garcia-Alix, Alfredo] NeNe Fdn, Madrid, Spain; [Valls, Ana; Garcia-Alix, Alfredo] Hosp St Joan de Deu, Inst Recerca St Joan de Deu, Barcelona, Spain; [Arca, Gemma] IDIBAPS, Dept Neonatol, Hosp Clin, Barcelona, Spain; [Agut, Thais; Alarcon, Ana] Hosp St Joan de Deu, Dept Neonatol, Barcelona, Spain; [Garcia-Alix, Alfredo] CIBER Enfermedades Raras, Madrid, Spain	University of Barcelona; University of Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; CIBER - Centro de Investigacion Biomedica en Red; CIBERER	Garcia-Alix, A (corresponding author), Univ Barcelona, Barcelona, Spain.; Garcia-Alix, A (corresponding author), NeNe Fdn, Madrid, Spain.; Garcia-Alix, A (corresponding author), Hosp St Joan de Deu, Inst Recerca St Joan de Deu, Barcelona, Spain.; Garcia-Alix, A (corresponding author), CIBER Enfermedades Raras, Madrid, Spain.	alfredoalix@gmail.com	Arnaez, Juan/ABF-4338-2020	Arnaez, Juan/0000-0001-8883-5181; Agut, Thais/0000-0002-5673-0016; Alarcon Allen, Ana/0000-0001-7223-2028				Agut T, 2014, BMC PEDIATR, V14, DOI 10.1186/1471-2431-14-177; Alsina M, 2017, PEDIATR CRIT CARE ME, V18, P234, DOI 10.1097/PCC.0000000000001068; Arca G, 2020, ARCH DIS CHILD-FETAL, V105, pF132, DOI 10.1136/archdischild-2018-316680; Arnaez J, 2018, THER HYPOTHERMIA TEM, V8, P24, DOI 10.1089/ther.2017.0024; BARONE FC, 1993, BRAIN RES, V623, P77, DOI 10.1016/0006-8993(93)90012-C; Bennet L, 2010, SEMIN FETAL NEONAT M, V15, P253, DOI 10.1016/j.siny.2010.05.007; Berger RP, 2010, DEV NEUROSCI-BASEL, V32, P396, DOI 10.1159/000316803; Blennow M, 2001, ACTA PAEDIATR, V90, P1171, DOI 10.1080/080352501317061594; Bonifacio SL, 2015, SEMIN FETAL NEONAT M, V20, P122, DOI 10.1016/j.siny.2014.12.011; Boudes E, 2015, ARCH DIS CHILD-FETAL, V100, pF238, DOI 10.1136/archdischild-2014-306550; Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x; Carreras N, 2018, J PEDIAT-BRAZIL, V94, P251, DOI 10.1016/j.jped.2017.05.009; Celtik C, 2004, BRAIN DEV-JPN, V26, P398, DOI 10.1016/j.braindev.2003.12.007; Chalak LF, 2014, J PEDIATR-US, V164, P468, DOI 10.1016/j.jpeds.2013.10.067; Chang T, 2012, CURR NEUROL NEUROSCI, V12, P145, DOI 10.1007/s11910-012-0254-y; Charon V, 2016, EUR J RADIOL, V85, P1366, DOI 10.1016/j.ejrad.2016.05.005; del Rio R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165744; Douglas-Escobar M, 2015, JAMA PEDIATR, V169, P397, DOI 10.1001/jamapediatrics.2014.3269; Ezgu FS, 2002, J CHILD NEUROL, V17, P824, DOI 10.1177/08830738020170111301; Garca-Alix A, 2001, ACTA PAEDIATR, V90, P1103, DOI 10.1080/080352501317061459; Garcia-Alix A, 2013, ACTA PAEDIATR, V102, P1137, DOI 10.1111/apa.12420; GARCIAALIX A, 1994, PEDIATRICS, V93, P234; Gunn AJ, 2008, J PEDIATR-US, V152, P55, DOI 10.1016/j.jpeds.2007.06.003; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hellstrom-Westas L., 2008, ATLAS AMPLITUDE INTE, V2nd; HORN M, 1995, STROKE, V26, P290, DOI 10.1161/01.STR.26.2.290; Isgro MA, 2015, ADV EXP MED BIOL, V867, P125, DOI 10.1007/978-94-017-7215-0_9; KAISER E, 1989, CLIN CHIM ACTA, V183, P13, DOI 10.1016/0009-8981(89)90268-4; Kelen D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184593; Lv HY, 2015, CLIN CHIM ACTA, V450, P282, DOI 10.1016/j.cca.2015.08.021; Echeverria-Palacio CM, 2019, PEDIATR NEUROL, V101, P71, DOI 10.1016/j.pediatrneurol.2019.02.020; Martinez-Biarge M, 2011, NEUROLOGY, V76, P2055, DOI 10.1212/WNL.0b013e31821f442d; Massaro AN, 2018, J PEDIATR-US, V194, P67, DOI 10.1016/j.jpeds.2017.10.060; Massaro AN, 2014, PEDIATR CRIT CARE ME, V15, P615, DOI 10.1097/PCC.0000000000000155; Massaro AN, 2012, J PEDIATR-US, V161, P434, DOI 10.1016/j.jpeds.2012.02.047; Merchant N, 2015, DEV MED CHILD NEUROL, V57, P8, DOI 10.1111/dmcn.12726; Merhar SL, 2016, CLIN PERINATOL, V43, P511, DOI 10.1016/j.clp.2016.04.009; Nagdyman N, 2003, PEDIATR RES, V54, P270, DOI 10.1203/01.PDR.0000072518.98189.A0; Nanavati T, 2015, PEDIATR NEONATOL, V56, P307, DOI 10.1016/j.pedneo.2014.12.005; Natarajan N, 2017, SEMIN PERINATOL, V41, P117, DOI 10.1053/j.semperi.2016.11.008; Pelinka LE, 2005, SHOCK, V24, P119, DOI 10.1097/01.shk.0000168876.68154.43; Polat M, 2013, EUR J PAEDIATR NEURO, V17, P288, DOI 10.1016/j.ejpn.2012.11.004; Polglase GR, 2016, CLIN PERINATOL, V43, P469, DOI 10.1016/j.clp.2016.04.006; Ramaswamy V, 2009, PEDIATR NEUROL, V40, P215, DOI 10.1016/j.pediatrneurol.2008.09.026; Ramont L, 2005, CLIN CHEM LAB MED, V43, P1215, DOI 10.1515/CCLM.2005.210; Rasmussen LA, 2019, J PERINATOL, V39, P278, DOI 10.1038/s41372-018-0296-3; Rescorla LA, 2005, MENT RETARD DEV D R, V11, P226, DOI 10.1002/mrdd.20071; Roka A, 2012, ACTA PAEDIATR, V101, P319, DOI 10.1111/j.1651-2227.2011.02480.x; Rundgren Malin, 2014, BMC Res Notes, V7, P726, DOI 10.1186/1756-0500-7-726; Rundgren M, 2009, RESUSCITATION, V80, P784, DOI 10.1016/j.resuscitation.2009.03.025; Rutherford M., 2002, MRI NEONATAL BRAIN; Selakovic V, 2005, J CLIN NEUROSCI, V12, P542, DOI 10.1016/j.jocn.2004.07.019; Shankaran S, 2012, J PEDIATR-US, V160, P567, DOI 10.1016/j.jpeds.2011.09.018; Shellhaas RA, 2015, J CHILD NEUROL, V30, P1526, DOI 10.1177/0883073815573319; Sun JQ, 2012, ACTA PAEDIATR, V101, pe316, DOI 10.1111/j.1651-2227.2012.02679.x; Tagin MA, 2012, ARCH PEDIAT ADOL MED, V166, P558, DOI 10.1001/archpediatrics.2011.1772; Tekgul H, 2004, PEDIATR NEUROL, V31, P326, DOI 10.1016/j.pediatrneurol.2004.05.004; THORNBERG E, 1995, ARCH DIS CHILD-FETAL, V72, pF39, DOI 10.1136/fn.72.1.F39; van Laerhoven H, 2013, PEDIATRICS, V131, P88, DOI 10.1542/peds.2012-1297; Weeke LC, 2016, EUR J PAEDIATR NEURO, V20, P855, DOI 10.1016/j.ejpn.2016.06.003; Wilkinson D, 2011, ARCH PEDIAT ADOL MED, V165, P211, DOI 10.1001/archpediatrics.2011.4; Wunderlich MT, 2006, CLIN NEUROL NEUROSUR, V108, P558, DOI 10.1016/j.clineuro.2005.12.006; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190	63	11	12	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2020	15	6							e0234082	10.1371/journal.pone.0234082	http://dx.doi.org/10.1371/journal.pone.0234082			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ2AA	32479533	Green Published, gold			2023-01-03	WOS:000547893500052
J	Cohen-Mansfield, J; Brill, S				Cohen-Mansfield, Jiska; Brill, Shai			After providing end of life care to relatives, what care options do family caregivers prefer for themselves?	PLOS ONE			English	Article							TERMINALLY-ILL PATIENTS; CANCER-PATIENTS; GOOD DEATH; EUTHANASIA; BURDEN; ASSOCIATIONS; DECISIONS; ATTITUDES; SUICIDE; CHOICE	Objectives We examined how caregivers who had cared for a relative at end of life (EoL) wished to be cared for in the event that they experienced advanced dementia or physical disability in the future, and what factors influenced their preferences for EoL care. Methods In this mixed-methods study, 83 participants, recruited from multiple sources in Israel, were interviewed concerning socio-demographic factors, health status, past experience with EoL, preference for extension of life vs. quality of life (QoL), willingness to be dependent on others, and preferences for EoL care. Results In case of advanced dementia, 58% preferred euthanasia or suicide; around a third chose those for physical disability. Care by family members was the least desired form of care in the advanced dementia scenario, although more desirable than institutional care in the physical disability scenario. QoL was rated as the highest factor impacting preferences for EoL care. Men demonstrated a higher preference than women for extension of life over QoL. Conclusion Our study points to the need for society to consider solutions to the request of participants to reject the type of EoL experienced by their relatives. Those solutions include investing in improving the quality of life at the end of life, and offering alternatives such as euthanasia, which a large proportion of our participants found ethically and medically appropriate within the current system of care in the event of severe physical disability, and more so in the event of advanced dementia.	[Cohen-Mansfield, Jiska; Brill, Shai] Tel Aviv Univ, Minerva Ctr Interdisciplinary Study End Life, Tel Aviv, Israel; [Cohen-Mansfield, Jiska] Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Hlth Promot, Tel Aviv, Israel; [Cohen-Mansfield, Jiska] Tel Aviv Univ, Herczeg Inst Aging, Tel Aviv, Israel; [Brill, Shai] Beit Rivka Med Ctr, Petah Tiqwa, Israel; [Brill, Shai] Tel Aviv Univ, Tel Aviv, Israel	Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Tel Aviv University	Cohen-Mansfield, J (corresponding author), Tel Aviv Univ, Minerva Ctr Interdisciplinary Study End Life, Tel Aviv, Israel.; Cohen-Mansfield, J (corresponding author), Tel Aviv Univ, Sackler Fac Med, Sch Publ Hlth, Dept Hlth Promot, Tel Aviv, Israel.; Cohen-Mansfield, J (corresponding author), Tel Aviv Univ, Herczeg Inst Aging, Tel Aviv, Israel.	jiska@post.tau.ac.il	cohen-mansfield, jiska/AFS-8589-2022	cohen-mansfield, jiska/0000-0003-0209-7304	Minerva-Stiftung Foundation [3158329500]	Minerva-Stiftung Foundation	JCM's work at the Minerva Center for the Interdisciplinary Study of End of Life is funded by the Minerva-Stiftung Foundation under grant number 3158329500. https://www.minerva.mpg.de/The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arber S, 2008, J AGING STUD, V22, P366, DOI 10.1016/j.jaging.2008.05.009; Asiskovitch S, 2013, ISR J HEALTH POLICY, V2, DOI 10.1186/2045-4015-2-3; Ayalon L, 2009, AGEING SOC, V29, P671, DOI 10.1017/S0144686X09008393; Balboni TA, 2007, J CLIN ONCOL, V25, P555, DOI 10.1200/JCO.2006.07.9046; BENTLER PM, 1987, SOCIOL METHOD RES, V16, P78, DOI 10.1177/0049124187016001004; BENTLER PM, 1980, PSYCHOL BULL, V88, P588, DOI 10.1037/0033-2909.107.2.238; Bolt EE, 2015, ANN FAM MED, V13, P421, DOI 10.1370/afm.1814; Braun V., 2006, QUAL RES PSYCHOL, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706QP063OA]; Brazil K, 2005, PALLIATIVE MED, V19, P492, DOI 10.1191/0269216305pm1050oa; Brazil Kevin, 2005, J Palliat Med, V8, P69, DOI 10.1089/jpm.2005.8.69; Buist-Bouwman MA, 2006, ACTA PSYCHIAT SCAND, V113, P492, DOI 10.1111/j.1600-0447.2005.00684.x; Bulow HH, 2012, INTENS CARE MED, V38, P1126, DOI 10.1007/s00134-012-2554-8; Carlet J, 2004, INTENS CARE MED, V30, P770, DOI 10.1007/s00134-004-2241-5; Carmel S, 1997, SOC SCI MED, V45, P1715, DOI 10.1016/S0277-9536(97)00104-4; Carmel Sara, 2012, Przegl Lek, V69, P49; Carr D, 2007, J GERONTOL B-PSYCHOL, V62, pS135, DOI 10.1093/geronb/62.2.S135; Chau PH, 2010, INT J GERIATR PSYCH, V25, P46, DOI 10.1002/gps.2296; Chernichovsky D., 2017, LONG TERM CARE ISRAE; Cheung KL, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4189-8; Choi J, 2010, SUPPORT CARE CANCER, V18, P1445, DOI 10.1007/s00520-009-0767-3; Clark GF, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168391; Cohen-Mansfield J, 2008, RES AGING, V30, P74, DOI 10.1177/0164027507307925; Cohen-Mansfield J, 2018, J GERONTOL A-BIOL, V73, P695, DOI 10.1093/gerona/glx195; Cohen-Mansfield J, 2017, J POPUL AGEING, V10, P363, DOI 10.1007/s12062-016-9170-2; Cohen-Mansfield J, 2013, AM J PUBLIC HEALTH, V103, pE30, DOI 10.2105/AJPH.2013.301622; COHENMANSFIELD J, 1992, GERONTOLOGIST, V32, P89, DOI 10.1093/geront/32.1.89; Cottrell L, 2016, PALLIAT SUPPORT CARE, V14, P686, DOI 10.1017/S1478951515001285; Dassel KB, 2018, AM J HOSP PALLIAT ME, V35, P52, DOI 10.1177/1049909116680990; Davison SN, 2010, CLIN J AM SOC NEPHRO, V5, P195, DOI 10.2215/CJN.05960809; Detering KM, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1345; Dwolatzky T, 2017, LANCET, V389, P2542, DOI 10.1016/S0140-6736(17)30789-4; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; Fassbender K, 2009, J PAIN SYMPTOM MANAG, V38, P75, DOI 10.1016/j.jpainsymman.2009.04.007; Fukui S, 2013, J PALLIAT CARE, V29, P22, DOI 10.1177/082585971302900104; Gardner DS, 2009, OMEGA-J DEATH DYING, V60, P273, DOI 10.2190/OM.60.3.e; Gauthier S, 2015, J MED ETHICS, V41, P611, DOI 10.1136/medethics-2014-102091; Given B, 2004, ONCOLOGY NURSING FOR; Grunfeld E, 2004, CAN MED ASSOC J, V170, P1795, DOI 10.1503/cmaj.1031205; Hertogh CMPM, 2007, AM J BIOETHICS, V7, P48, DOI 10.1080/15265160701220881; High D M, 1993, J Aging Health, V5, P497, DOI 10.1177/089826439300500405; Hirai K, 2006, J PAIN SYMPTOM MANAG, V31, P140, DOI 10.1016/j.jpainsymman.2005.06.012; Klinkenberg M, 2004, SOC SCI MED, V59, P2467, DOI 10.1016/j.socscimed.2004.04.006; Lee JE, 2015, PSYCHO-ONCOLOGY, V24, P1545, DOI 10.1002/pon.3827; Lehto Rebecca Helen, 2009, Res Theory Nurs Pract, V23, P23; llin V.P., 2003, SIB J NUM MATH, V6, P381; MacCallum RC, 1996, PSYCHOL METHODS, V1, P130, DOI 10.1037/1082-989X.1.2.130; Malhotra C, 2015, PALLIATIVE MED, V29, P842, DOI 10.1177/0269216315578803; Meier EA, 2016, AM J GERIATRIC PSYCH; Myers-JDC-Brookdale Institute, 2019, AG 65 ISR STAT YB 20; National Institute on Aging, 2017, WHAT IS LONG TERM CA; Ohr S, 2017, J CLIN NURS, V26, P1681, DOI 10.1111/jocn.13572; Picard G, 2019, J ALZHEIMERS DIS, V69, P989, DOI 10.3233/JAD-181277; Rubin D. B., 2004, MULTIPLE IMPUTATION; Schicktanz S, 2010, CAMB Q HEALTHC ETHIC, V19, P381, DOI 10.1017/S0963180110000162; Shaffer CS, 2016, PSYCHOL PUBLIC POL L, V22, P141, DOI 10.1037/law0000082; Sophie H, 2018, SWISS MED WKLY, V148, DOI 10.4414/smw.2018.14628; Steinhauser KE, 2000, ANN INTERN MED, V132, P825, DOI 10.7326/0003-4819-132-10-200005160-00011; Steinhauser KE, 2001, J PAIN SYMPTOM MANAG, V22, P727, DOI 10.1016/S0885-3924(01)00334-7; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Sudore RL, 2010, ANN INTERN MED, V153, P256, DOI 10.7326/0003-4819-153-4-201008170-00008; Sullivan MD, 2002, AM J GERIAT PSYCHIAT, V10, P365, DOI 10.1176/appi.ajgp.10.4.365; Szanto K, 2013, PSYCHIAT SERV, V64, P586, DOI 10.1176/appi.ps.003582012; Tang ST, 2003, CANCER NURS, V26, P245, DOI 10.1097/00002820-200306000-00012; TEMPLER DI, 1970, J GEN PSYCHOL, V82, P165, DOI 10.1080/00221309.1970.9920634; Thomas C, 2004, SOC SCI MED, V58, P2431, DOI 10.1016/j.socscimed.2003.09.005; Tulsky JA, 2005, JAMA-J AM MED ASSOC, V294, P359, DOI 10.1001/jama.294.3.359; van Wijngaarden E, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009895; Vanderveken L, 2019, AM J GERIAT PSYCHIAT, V27, P463, DOI 10.1016/j.jagp.2018.12.017; Williams Stephen P, 2013, J Healthc Risk Manag, V32, P35, DOI 10.1002/jhrm.21108; Wilson DM, 2000, J ADV NURS, V31, P1416, DOI 10.1046/j.1365-2648.2000.01456.x; Wong PTP, 2011, DEATH STUD, V35, P99, DOI 10.1080/07481187.2011.535377	71	1	1	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2020	15	9							e0239423	10.1371/journal.pone.0239423	http://dx.doi.org/10.1371/journal.pone.0239423			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NY3AJ	32977327	Green Published, gold			2023-01-03	WOS:000576266600044
J	Korones, DN				Korones, David N.			Am I Racist?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									[Korones, David N.] Univ Rochester, Med Ctr, Rochester, NY 14642 USA	University of Rochester	Korones, DN (corresponding author), Univ Rochester, Med Ctr, Rochester, NY 14642 USA.								0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 17	2020	383	12							e80	10.1056/NEJMpv2024766	http://dx.doi.org/10.1056/NEJMpv2024766			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NU8QD	32871064	Bronze			2023-01-03	WOS:000573901600004
J	Lin, SX; Matsakas, L; Zhao, XY; Sun, YP; Liu, H; Shang, MY; Gong, JY; Ma, QQ; Piao, GC; Yuan, HD				Lin, Shengxi; Matsakas, Leonidas; Zhao, Xiaoyan; Sun, Yunpeng; Liu, Huan; Shang, Mingyang; Gong, Jinyan; Ma, Qianqian; Piao, Guangchun; Yuan, Haidan			Inhibitory effects of compounds from the roots ofPotentilla longifoliaon lipid accumulation	PLOS ONE			English	Article							DISEASES; AMPK	Potentilla longifoliais a kind of Chaoyao medicine, which is a branch of traditional Chinese medicine. The plant is often referred to asganyancaoorganyearmcao, which means that it has a significant therapeutic effect on liver inflammation. In previous experiments, we found that a water extract ofganyearmcaoinhibited lipid accumulation. In the present study, we isolated one new (ganyearmcaoone A,1) and eight known compounds (2-9) from a water extract of the dried roots ofganyearmcao; all of the compounds were isolated for the first time from this medicinal plant. We elucidated the chemical structures of these compounds using comprehensive analyses of HR-ESI-MS and 1D, 2D NMR. We evaluated the inhibitory effects of the nine compounds on lipid accumulation in 3T3-L1 cells; we did so using photographic and quantitative assessments of the lipid content with oil red O staining and by measuring triglyceride levels. Compared with the control, compounds6and9significantly inhibited differentiation of 3T3-L1 cells and lipid accumulation. Compound1showed potential inhibitory effects on lipid accumulation. Molecular docking results indicated that compounds6and9may efficiently bind to AMPK and its downstream kinase (SCD1), thereby inhibiting lipid accumulation. Our results demonstrate thatganyearmcaoand its components may play an important role in treating diseases related to lipid accumulation in the future.	[Lin, Shengxi; Matsakas, Leonidas; Zhao, Xiaoyan; Sun, Yunpeng; Liu, Huan; Shang, Mingyang; Gong, Jinyan; Ma, Qianqian; Piao, Guangchun; Yuan, Haidan] Yanbian Univ, Coll Pharm, Yanji, Jilin, Peoples R China; [Piao, Guangchun; Yuan, Haidan] Yanbian Univ, Key Lab Nat Resources Changbai Mt & Funct Mol, Minist Educ, Yanji, Jilin, Peoples R China	Yanbian University; Yanbian University	Piao, GC; Yuan, HD (corresponding author), Yanbian Univ, Coll Pharm, Yanji, Jilin, Peoples R China.; Piao, GC; Yuan, HD (corresponding author), Yanbian Univ, Key Lab Nat Resources Changbai Mt & Funct Mol, Minist Educ, Yanji, Jilin, Peoples R China.	gcpiao@ybu.edu.cn; hdyuan@ybu.edu.cn		Guangchun, Piao/0000-0001-8181-1507	National Natural Science Foundation of China [81560698, 81660614]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by research grants (No. 81560698 and 81660614) from the National Natural Science Foundation of China. There was no additional external funding received for this study.	[Anonymous], 2016, Aesthet Surg J, V36 Suppl 1, P1, DOI 10.1093/asj/36.Supplement_1.1; [Anonymous], 2019, JMIR PUBLIC HLTH SUR, V4, pe53, DOI 10.2196/publichealth.9932; Appolinario JC, 2004, CNS DRUGS, V18, P629, DOI 10.2165/00023210-200418100-00002; Azevedo LS, 2012, CURR BIOINFORM, V7, P352; Chalasani N, 2012, HEPATOLOGY, V55, P2005, DOI 10.1002/hep.25762; Drew L, 2017, NATURE, V550, pS102, DOI 10.1038/550S102a; Gan CC, 2017, EUR J PHARMACOL, V797, P45, DOI 10.1016/j.ejphar.2017.01.009; Gonzalez-Castejon M, 2011, PHARMACOL RES, V64, P438, DOI 10.1016/j.phrs.2011.07.004; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Ha JH, 2016, INT J MOL MED, V37, P816, DOI 10.3892/ijmm.2016.2484; Hamilton GR, 2000, CAN J ANAESTH, V47, P367, DOI 10.1007/BF03020955; Ideta T, 2015, INT J MOL SCI, V16, P29207, DOI 10.3390/ijms161226156; Jeong Choon Sik, 2015, Natural Product Sciences, V21, P147; Kajita K, 2012, ENDOCR J, V59, P1107, DOI 10.1507/endocrj.EJ12-0259; Kim DJ, 2011, DIABETES METAB J, V35, P303, DOI 10.4093/dmj.2011.35.4.303; Li YQ, 2019, BIOORG CHEM, V85, P357, DOI 10.1016/j.bioorg.2019.01.013; [罗禹 Luo Yu], 2003, [天然产物研究与开发, Natural Product R & D], V15, P502; Ma QQ, 2018, J AGR FOOD CHEM, V66, P12931, DOI 10.1021/acs.jafc.8b04683; Miao Qing, 2008, Academic Journal of Second Military Medical University, V29, P1366; Moseti D, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010124; Pacheco AG, 2009, MOLECULES, V14, P1245, DOI 10.3390/molecules14031245; Piao MJ, 2012, YANBIAN PEOPLES PUBL, V8, P194; Randau KP, 2009, PHARMAZIE, V64, P350, DOI 10.1691/ph.2009.7592; Roy Nabarun, 2016, Asian Pac J Cancer Prev, V17, P4019; Ruiz-Vasquez L, 2015, PHYTOCHEMISTRY, V117, P245, DOI 10.1016/j.phytochem.2015.06.019; Shiu WKP, 2006, PHYTOCHEMISTRY, V67, P2568, DOI 10.1016/j.phytochem.2006.09.037; SS V et al. on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, 2020, CIRCULATION, V2020, pe1; Sun JF, 1996, CHIN J FOLK MED, V19, P5; Wada K, 2007, J PHARMACOL SCI, V105, P133, DOI 10.1254/jphs.FM0070034; Yuan HD, 2012, J GINSENG RES, V36, P27, DOI 10.5142/jgr.2012.36.1.27; Yuan HD, 2016, MOLECULES, V21, DOI 10.3390/molecules21050559; Yuriev E, 2015, J MOL RECOGNIT, V28, P581, DOI 10.1002/jmr.2471; 马瑜, 2006, [中草药, Chinese Traditional and Herbal Drugs], V37, P1315	33	0	0	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 9	2020	15	9							e0238917	10.1371/journal.pone.0238917	http://dx.doi.org/10.1371/journal.pone.0238917			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR4MY	32903285	gold, Green Published			2023-01-03	WOS:000571539500003
J	Khoonrit, P; Mirdogan, A; Dehlinger, A; Mekboonsonglarp, W; Likhitwitayawuid, K; Priller, J; Bottcher, C; Sritularak, B				Khoonrit, Pichayatri; Mirdogan, Alp; Dehlinger, Adeline; Mekboonsonglarp, Wanwimon; Likhitwitayawuid, Kittisak; Priller, Josef; Boettcher, Chotima; Sritularak, Boonchoo			Immune modulatory effect of a novel 4,5-dihydroxy-3,3 ',4 '-trimethoxybibenzyl from Dendrobium lindleyi	PLOS ONE			English	Article							LUNG-CANCER; CHEMICAL-CONSTITUENTS; NEONATAL SEPSIS; BIBENZYL; INFLAMMATION; MOSCATILIN; MONOCYTES	Dendrobiumbibenzyls and phenanthrenes such as chrysotoxine, cypripedin, gigantol and moscatilin have been reported to show promising inhibitory effects on lung cancer growth and metastasis inex vivohuman cell line models, suggesting their potential for clinical application in patients with lung cancer. However, it remains to be determined whether these therapeutic effects can be also seen in primary human cells and/orin vivo. In this study, we comparatively investigated the immune modulatory effects of bibenzyls and phenanthrenes, including a novelDendrobiumbibenzyl derivative, in primary human monocytes. All compounds were isolated and purified from a Thai orchidDendrobium lindleyiSteud, a new source of therapeutic compounds with promising potential of tissue culture production. We detected increased frequencies of TNF- and IL-6-expressing monocytes after treatment with gigantol and cypripedin, whereas chrysotoxine and moscatilin did not alter the expression of these cytokines in monocytes. Interestingly, the new 4,5-dihydroxy-3,3 ',4 '-trimethoxybibenzyl derivative showed dose-dependent immune modulatory effects in lipopolysaccharide (LPS)-treated CD14(lo)and CD14(hi)monocytes. Together, our findings show immune modulatory effects of the new bibenzyl derivative fromDendrobium lindleyion different monocyte sub-populations. However, therapeutic consequences of these different monocyte populations on human diseases including cancer remain to be investigated.	[Khoonrit, Pichayatri; Likhitwitayawuid, Kittisak; Sritularak, Boonchoo] Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Pharmacognosy & Pharmaceut Bot, Bangkok, Thailand; [Mirdogan, Alp; Dehlinger, Adeline; Priller, Josef; Boettcher, Chotima] Charite Univ Med Berlin, Dept Neuropsychiat, Berlin, Germany; [Mirdogan, Alp; Dehlinger, Adeline; Priller, Josef; Boettcher, Chotima] Charite Univ Med Berlin, Lab Mol Psychiat, Berlin, Germany; [Mekboonsonglarp, Wanwimon] Chulalongkorn Univ, Sci & Technol Res Equipment Ctr, Bangkok, Thailand; [Sritularak, Boonchoo] Chulalongkorn Univ, Fac Pharmaceut Sci, Nat Prod Ageing & Chron Dis Res Unit, Bangkok, Thailand	Chulalongkorn University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Chulalongkorn University; Chulalongkorn University	Sritularak, B (corresponding author), Chulalongkorn Univ, Fac Pharmaceut Sci, Dept Pharmacognosy & Pharmaceut Bot, Bangkok, Thailand.; Bottcher, C (corresponding author), Charite Univ Med Berlin, Dept Neuropsychiat, Berlin, Germany.; Bottcher, C (corresponding author), Charite Univ Med Berlin, Lab Mol Psychiat, Berlin, Germany.; Sritularak, B (corresponding author), Chulalongkorn Univ, Fac Pharmaceut Sci, Nat Prod Ageing & Chron Dis Res Unit, Bangkok, Thailand.	chotima.boettcher@charite.de; boonchoo.sr@chula.ac.th	Priller, Josef/ABW-3835-2022; likhitwitayawuid, kittisak/H-5818-2011	likhitwitayawuid, kittisak/0000-0002-0861-7617; Priller, Josef/0000-0001-7596-0979; Bottcher, Chotima/0000-0002-6226-586X; Khoonrit, Pichayatri/0000-0001-7145-8367	Graduate School, Chulalongkorn University; German Research Foundation [SFB TRR167]; Berlin Institute of Health [CRG2aSP6]; UK DRI (Momentum Award); Faculty of Pharmaceutical Sciences, Chulalongkorn University [Phar2563-RG010]	Graduate School, Chulalongkorn University(Chulalongkorn University); German Research Foundation(German Research Foundation (DFG)); Berlin Institute of Health; UK DRI (Momentum Award); Faculty of Pharmaceutical Sciences, Chulalongkorn University(Chulalongkorn University)	P.K. acknowledged the financial support of the scholarship from the Graduate School, Chulalongkorn University to commemorate the 72nd anniversary of his Majesty King Bhumibol Adulyadej. C.B. and J.P. were supported by the German Research Foundation (SFB TRR167, B05 & B07). J.P. received additional funding from the Berlin Institute of Health (CRG2aSP6) and the UK DRI (Momentum Award). B.S. is grateful to Faculty of Pharmaceutical Sciences, Chulalongkorn University for a research fund (Phar2563-RG010). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abbas A.K., 2014, CELLULAR MOL IMMUNOL; [Anonymous], 2015, BMJ, V2015, ph1887; [Anonymous], 2015, BMJ, V2015, ph1887; Arenberg DA, 2000, CANCER IMMUNOL IMMUN, V49, P63, DOI 10.1007/s002620050603; Azad N, 2008, J TOXICOL ENV HEAL B, V11, P1, DOI 10.1080/10937400701436460; Bai Y, 2006, CHIN TRADIT HERBAL D, V37, P1440; Balli D, 2012, ONCOGENE, V31, P3875, DOI 10.1038/onc.2011.549; Bhummaphan Narumol, 2018, J Pharmacol Exp Ther, V364, P332, DOI 10.1124/jpet.117.244467; Brennan FM, 1998, SPRINGER SEMIN IMMUN, V20, P133, DOI 10.1007/BF00832003; Busaranon K, 2016, J NAT MED-TOKYO, V70, P18, DOI 10.1007/s11418-015-0931-7; Campos DP, 2010, J PEDIAT-BRAZIL, V86, P509, DOI [10.1590/S0021-75572010000600011, 10.2223/JPED.2043]; Chada S, 2003, CURR OPIN MOL THER, V5, P463; Chanvorachote P, 2013, NAT PROD COMMUN, V8, P115; Chen YG, 2008, FOOD CHEM, V107, P169, DOI 10.1016/j.foodchem.2007.07.077; Chen YL, 2017, IMMUNOL LETT, V186, P52, DOI 10.1016/j.imlet.2017.04.003; Cheng J, 2019, J ETHNOPHARMACOL, V229, P81, DOI 10.1016/j.jep.2018.09.001; CITES, 2017, CRIT INCL SPEC APP 1; Cros J, 2010, IMMUNITY, V33, P375, DOI 10.1016/j.immuni.2010.08.012; Fan CQ, 2001, PHYTOCHEMISTRY, V57, P1255, DOI 10.1016/S0031-9422(01)00168-6; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Hemmann S, 2007, J HEPATOL, V46, P955, DOI 10.1016/j.jhep.2007.02.003; Honda T, 2019, ANTICANCER RES, V39, P4475, DOI 10.21873/anticanres.13621; Hou BW, 2017, SCI REP-UK, V7, DOI 10.1038/srep43525; International guidelines for groin hernia management, 2018, REV HISPANOAM HERNIA, V22, P1; MAJUMDER PL, 1987, PHYTOCHEMISTRY, V26, P2121, DOI 10.1016/S0031-9422(00)81777-X; MEADOW W, 1995, CLIN PERINATOL, V22, P519; Neovius M, 2015, ANN RHEUM DIS, V74, P354, DOI 10.1136/annrheumdis-2013-204128; Ng TB, 2012, APPL MICROBIOL BIOT, V93, P1795, DOI 10.1007/s00253-011-3829-7; Srirangan S, 2010, THER ADV MUSCULOSKEL, V2, P247, DOI 10.1177/1759720X10378372; Sritularak B, 2011, Z NATURFORSCH C, V66, P205, DOI 10.5560/ZNC.2011.66c0205; Stidham RW, 2014, ALIMENT PHARM THER, V39, P1349, DOI 10.1111/apt.12749; Sukphan P, 2014, NAT PROD COMMUN, V9, P825; Tabas I, 2015, J CELL BIOL, V209, P13, DOI 10.1083/jcb.201412052; Tanaka T, 2016, ADV EXP MED BIOL, V941, P79, DOI 10.1007/978-94-024-0921-5_4; Tang Gui-xiang, 2005, Zhongguo Zhong Yao Za Zhi, V30, P1583; Treesuwan S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25657-5; Tsubota Y, 2014, J LEUKOCYTE BIOL, V95, P191, DOI 10.1189/jlb.0513272; Unahabhokha T, 2016, EVID-BASED COMPL ALT, V2016, DOI 10.1155/2016/4561674; Vaddhanaphuti N, 2005, FIELD GUIDE WILD ORC, V4th; Wattanathamsan O, 2018, J NAT MED-TOKYO, V72, P503, DOI 10.1007/s11418-018-1176-z; Zeng S. H, 2012, LISHIZHEN MED MAT ME, V23, P468; Zeng W. Y, 2012, J WUHAN POLYTECH U, V31, P10; Zhang X, 2007, J NAT PROD, V70, P24, DOI 10.1021/np060449r; Zheng ZhiRen, 2008, Acta Agriculturae Shanghai, V24, P19; Ziegler JF, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13559-7; Ziegler-Heitbrock L, 2010, BLOOD, V116, pE74, DOI 10.1182/blood-2010-02-258558; Zilionis R, 2019, IMMUNITY, V50, P1317, DOI 10.1016/j.immuni.2019.03.009	47	6	6	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 1	2020	15	9							e0238509	10.1371/journal.pone.0238509	http://dx.doi.org/10.1371/journal.pone.0238509			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN6BT	32870935	gold, Green Published			2023-01-03	WOS:000568872300028
J	Stower, H				Stower, Hannah			A future boost for anti-PD1 responses	NATURE MEDICINE			English	Editorial Material												h.stower@us.nature.com							0	0	0	0	2	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	SEP	2020	26	9					1331	1331		10.1038/s41591-020-1065-3	http://dx.doi.org/10.1038/s41591-020-1065-3			1	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	PF3EM	32908280				2023-01-03	WOS:000598942000015
J	Swann, OV; Holden, KA; Turtle, L; Pollock, L; Fairfield, CJ; Drake, TM; Seth, S; Egan, C; Hardwick, HE; Halpin, S; Girvan, M; Donohue, C; Pritchard, M; Patel, LB; Ladhani, S; Sigfrid, L; Sinha, IP; Olliaro, PL; Nguyen-Van-Tam, JS; Horby, PW; Merson, L; Carson, G; Dunning, J; Openshaw, PJM; Baillie, JK; Harrison, EM; Docherty, AB; Semple, MG				Swann, Olivia, V; Holden, Karl A.; Turtle, Lance; Pollock, Louisa; Fairfield, Cameron J.; Drake, Thomas M.; Seth, Sohan; Egan, Conor; Hardwick, Hayley E.; Halpin, Sophie; Girvan, Michelle; Donohue, Chloe; Pritchard, Mark; Patel, Latifa B.; Ladhani, Shamez; Sigfrid, Louise; Sinha, Ian P.; Olliaro, Piero L.; Nguyen-Van-Tam, Jonathan S.; Horby, Peter W.; Merson, Laura; Carson, Gail; Dunning, Jake; Openshaw, Peter J. M.; Baillie, J. Kenneth; Harrison, Ewen M.; Docherty, Annemarie B.; Semple, Malcolm G.			Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							AGE	OBJECTIVE To characterise the clinical features of children and young people admitted to hospital with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the UK and explore factors associated with admission to critical care, mortality, and development of multisystem inflammatory syndrome in children and adolescents temporarily related to coronavirus disease 2019 (covid-19) (MIS-C). DESIGN Prospective observational cohort study with rapid data gathering and near real time analysis. SETTING 260 hospitals in England, Wales, and Scotland between 17 January and 3 July 2020, with a minimum follow-up time of two weeks (to 17 July 2020). PARTICIPANTS 651 children and young people aged less than 19 years admitted to 138 hospitals and enrolled into the International Severe Acute Respiratory and emergency Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK study with laboratory confirmed SARS-CoV-2. MAIN OUTCOME MEASURES Admission to critical care (high dependency or intensive care), in-hospital mortality, or meeting the WHO preliminary case definition for MIS-C. RESULTS Median age was 4.6 (interquartile range 0.3-13.7) years, 35% (225/651) were under 12 months old, and 56% (367/650) were male. 57% (330/576) were white, 12% (67/576) South Asian, and 10% (56/576) black. 42% (276/651) had at least one recorded comorbidity. A systemic mucocutaneousenteric cluster of symptoms was identified, which encompassed the symptoms for the WHO MIS-C criteria. 18% (116/632) of children were admitted to critical care. On multivariable analysis, this was associated with age under 1 month (odds ratio 3.21, 95% confidence interval 1.36 to 7.66; P=0.008), age 10-14 years (3.23, 1.55 to 6.99; P=0.002), and black ethnicity (2.82, 1.41 to 5.57; P=0.003). Six (1%) of 627 patients died in hospital, all of whom had profound comorbidity. 11% (52/456) met the WHO MIS-C criteria, with the first patient developing symptoms in mid-March. Children meeting MIS-C criteria were older (median age 10.7 (8.3-14.1) v 1.6 (0.2-12.9) years; P<0.001) and more likely to be of non-white ethnicity (64% (29/45) v 42% (148/355); P=0.004). Children with MIS-C were five times more likely to be admitted to critical care (73% (38/52) v 15% (62/404); P<0.001). In addition to the WHO criteria, children with MIS-C were more likely to present with fatigue (51% (24/47) v 28% (86/302); P=0.004), headache (34% (16/47) v 10% (26/263); P<0.001), myalgia (34% (15/44) v 8% (21/270); P<0.001), sore throat (30% (14/47) v (12% (34/284); P=0.003), and lymphadenopathy (20% (9/46) v 3% (10/318); P<0.001) and to have a platelet count of less than 150 x 10(9)/L (32% (16/50) v 11% (38/348); P<0.001) than children who did not have MIS-C. No deaths occurred in the MIS-C group. CONCLUSION Children and young people have less severe acute covid-19 than adults. A systemic mucocutaneousenteric symptom cluster was also identified in acute cases that shares features with MIS-C. This study provides additional evidence for refining the WHO MIS-C preliminary case definition. Children meeting the MIS-C criteria have different demographic and clinical features depending on whether they have acute SARS-CoV-2 infection (polymerase chain reaction positive) or are post-acute (antibody positive).	[Swann, Olivia, V] Univ Edinburgh, Dept Child Life & Hlth, Edinburgh, Midlothian, Scotland; [Swann, Olivia, V] Royal Hosp Sick Children, Paediat Infect Dis, Edinburgh, Midlothian, Scotland; [Holden, Karl A.; Sinha, Ian P.] Univ Liverpool, Inst Translat Med, Womens & Childrens Hlth, Fac Hlth & Life Sci, Liverpool, Merseyside, England; [Holden, Karl A.; Semple, Malcolm G.] Alder Hey Childrens NHS Fdn Trust, Resp Med, Liverpool L12 2AP, Merseyside, England; [Turtle, Lance; Hardwick, Hayley E.; Semple, Malcolm G.] Univ Liverpool, Inst Infect Vet & Ecol Sci, Fac Hlth & Life Sci, Liverpool, Merseyside, England; [Turtle, Lance] Royal Liverpool Univ Hosp, Infect Dis Unit, Liverpool, Merseyside, England; [Pollock, Louisa] Royal Hosp Children, Paediat Infect Dis, Glasgow, Lanark, Scotland; [Fairfield, Cameron J.; Drake, Thomas M.; Harrison, Ewen M.; Docherty, Annemarie B.] Univ Edinburgh, Med Informat Ctr, Usher Inst, Edinburgh, Midlothian, Scotland; [Seth, Sohan; Egan, Conor] Univ Edinburgh, Inst Adapt & Neural Computat, Sch Informat, Edinburgh, Midlothian, Scotland; [Halpin, Sophie; Girvan, Michelle; Donohue, Chloe] Univ Liverpool, Liverpool Clin Trials Ctr, Liverpool, Merseyside, England; [Pritchard, Mark] Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England; [Patel, Latifa B.] Alder Hey Childrens Hosp, Resp Med, Liverpool, Merseyside, England; [Ladhani, Shamez] Publ Hlth England, Immunisat & Countermeasures Div, Colindale, England; [Ladhani, Shamez] St George Hosp, Paediat Infect Dis, London, England; [Sigfrid, Louise; Olliaro, Piero L.; Horby, Peter W.; Merson, Laura; Carson, Gail] Univ Oxford, ISARIC Globat Support Ctr, Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England; [Nguyen-Van-Tam, Jonathan S.] Univ Nottingham, Div Epidemiol & Publ Hlth, Sch Med, Nottingham, England; [Nguyen-Van-Tam, Jonathan S.] United Kingdom Dept Hlth & Social Care, London, England; [Dunning, Jake] Publ Hlth England, Natl Infect Serv, London, England; [Dunning, Jake; Openshaw, Peter J. M.] Imperial Coll London, Natl Heart & Lung Inst, London, England; [Baillie, J. Kenneth] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland; [Baillie, J. Kenneth; Docherty, Annemarie B.] Royal Infirm Edinburgh NHS Trust, Intens Care Unit, Edinburgh, Midlothian, Scotland	University of Edinburgh; University of Liverpool; Alder Hey Children's NHS Foundation Trust; University of Liverpool; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Edinburgh; University of Edinburgh; University of Liverpool; University of Oxford; Alder Hey Children's NHS Foundation Trust; Alder Hey Children's Hospital; Public Health England; St Georges University London; University of Oxford; University of Nottingham; Public Health England; Imperial College London; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh; Royal Infirmary of Edinburgh; University of Edinburgh	Semple, MG (corresponding author), Alder Hey Childrens NHS Fdn Trust, Resp Med, Liverpool L12 2AP, Merseyside, England.; Semple, MG (corresponding author), Univ Liverpool, Inst Infect Vet & Ecol Sci, Fac Hlth & Life Sci, Liverpool, Merseyside, England.	m.g.semple@liverpool.ac.uk	Dushianthan, Ahilanandan/T-8390-2019; Dunning, Jake/U-7181-2019; Thomson, Emma C/M-8690-2017; Asiimwe, Innocent/AAD-7175-2022; Clark, Jordan/GOJ-7992-2022; Moore, Shona C/AAY-5049-2021; Baillie, Kenneth/AEK-6650-2022; Dorival, Isabel Garcia/AAX-5807-2020; Semple, Malcolm Gracie/A-8790-2008; Baillie, John Kenneth/F-3124-2011; Laha, Shondipon/AAN-9181-2020; Summers, Charlotte/A-6973-2012; Pritchard, Mark/F-3683-2017	Dushianthan, Ahilanandan/0000-0002-0165-3359; Dunning, Jake/0000-0002-4035-4562; Thomson, Emma C/0000-0003-1482-0889; Asiimwe, Innocent/0000-0002-1196-1822; Clark, Jordan/0000-0003-1790-7883; Moore, Shona C/0000-0001-8610-2806; Baillie, Kenneth/0000-0001-5258-793X; Dorival, Isabel Garcia/0000-0002-5654-5662; Semple, Malcolm Gracie/0000-0001-9700-0418; Baillie, John Kenneth/0000-0001-5258-793X; Laha, Shondipon/0000-0001-8748-9766; Noursadeghi, Mahdad/0000-0002-4774-0853; Lant, Suzannah/0000-0003-0852-7803; McDonald, Sarah/0000-0003-2776-7415; Hodgson, Luke/0000-0002-8278-9513; Sigfrid, Louise/0000-0003-2764-1177; Pollock, Louisa/0000-0002-4240-325X; Harrison, Ewen/0000-0002-5018-3066; Ustianowski, Andrew/0000-0002-6134-7855; Brealey, David/0000-0002-1982-3379; Dark, Paul/0000-0003-3309-0164; Hormis, Anil/0000-0001-5510-7639; Koukorava, Chrysa/0000-0001-5723-0390; Scott, Janet/0000-0001-8030-5223; Summers, Charlotte/0000-0002-7269-2873; Chand, Meera/0000-0001-9697-0340; Pollakis, Georgios/0000-0002-9659-5461; Thwaites, Ryan/0000-0003-3052-2793; Peters, Mark/0000-0003-3653-4808; Mok, Quen/0000-0003-4807-9275; Paxton, William/0000-0001-5200-0801; Paxton, William/0000-0002-2654-5186; Leiner, Tamas/0000-0002-7910-0084; Lett, Lauren/0000-0002-3623-0321; Donohue, Chloe/0000-0001-6379-8214; Pritchard, Mark/0000-0003-1726-8989; Mentzer, Alexander/0000-0002-4502-2209; Green, Christopher/0000-0002-1984-4014; Lillie, Patrick/0000-0002-4811-4774; Fletcher, Tom/0000-0002-3712-415X; Hartshorn, Stuart/0000-0003-0419-1564	National Institute for Health Research [CO-CIN-01]; Medical Research Council [MC_PC_19059]; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool; Public Health England (PHE); Department for International Development [215091/Z/18/Z]; Bill and Melinda Gates Foundation [OPP1209135]; Liverpool Experimental Cancer Medicine Centre [C18616/A25153]; Liverpool School or Tropical Medicine; University of Oxford (NIHR award) [200907]; Wellcome Trust; MRC [MR/V033441/1, MC_UU_12014/2, MC_PC_19025] Funding Source: UKRI; UKRI [MR/S032304/1] Funding Source: UKRI	National Institute for Health Research(National Institute for Health Research (NIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Emerging and Zoonotic Infections at University of Liverpool; Public Health England (PHE); Department for International Development; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Liverpool Experimental Cancer Medicine Centre; Liverpool School or Tropical Medicine; University of Oxford (NIHR award); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); UKRI	This work is supported by giants from the National Institute for Health Research (award CO-CIN-01) and the Medical Research Council (grant MC PC 19059) and by the National. Institute for Health Research Health Protection Research Unit (NIHR rinkL) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with I ivo-pool School or Tropical Medicine and the University 01-Oxford (11111R award 200907), Wellcome -Rust and Department lot International Development (115091/Z/18/L1, and the Bill and Melinda Gates f=oundation (OPP1209135). Liverpool Experimental Cancer Medicine Centre provided inliastructrie support for this research (giant reference: 518616/A25153). JSN-V-T is seconded to the Department of Health and Social Care, England (11FISC). The views expressed are those of the authors and not necessarily those of the DI1SC, DID, NIHR, MRC, Wellcome Trust, or [HE.	Alfaraj SH, 2019, FRONT MED-PRC, V13, P126, DOI 10.1007/s11684-017-0603-y; Arslan FD, 2016, IRAN J PEDIATR, V26, DOI 10.5812/ijp.6177; Bialek S, 2020, MMWR-MORBID MORTAL W, V69, P422, DOI 10.15585/mmwr.mm6914e4; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Dong YY, 2020, PEDIATRICS, V145, DOI 10.1542/peds.2020-0702; Dufort EM, 2020, NEW ENGL J MED, V383, P347, DOI 10.1056/NEJMoa2021756; European Centre for Disease Prevention and Control, 2020, RAP RISK ASS PAED IN; Fischbach F.T., 2009, MANUAL LAB DIAGNOSTI, V8th; Fleming S, 2011, LANCET, V377, P1011, DOI 10.1016/S0140-6736(10)62226-X; Godfred-Cato S, 2020, MMWR-MORBID MORTAL W, V69, P1074, DOI 10.15585/mmwr.mm6932e2; Gotzinger F, 2020, LANCET CHILD ADOLESC, V4, P653, DOI 10.1016/S2352-4642(20)30177-2; Harrison EM, 2020, ETHNICITY OUTCOMES C; Healthcare Improvement Scotland, 2020, PAED EARL WARN SCOR; Hon KLE, 2003, LANCET, V361, P1701, DOI 10.1016/S0140-6736(03)13364-8; Lewis KM, 2020, ARCH DIS CHILD, V105, P1061, DOI 10.1136/archdischild-2019-317902; Liu WY, 2020, NEW ENGL J MED, V382, P1370, DOI 10.1056/NEJMc2003717; Lu XX, 2020, NEW ENGL J MED, V382, P1663, DOI 10.1056/NEJMc2005073; NHS Digital, 2018, NAT CHILD MEAS PROGR; Niedzwiedz CL, 2020, ETHNIC SOCIOECONOMIC, DOI [10.1101/2020.04.22.20075663v2, DOI 10.1101/2020.04.22.20075663V2]; Office for National Statistics, 2020, COR COVID 19 REL DEA; Parri N, 2020, NEW ENGL J MED, V383, P187, DOI 10.1056/NEJMc2007617; Riphagen S, 2020, LANCET, V395, P1607, DOI [10.1016/S0140-6736(20)31094-1, 10.1016/50140-6736(20)31094-1]; Royal College of Paediatrics and Child Health, 2020, GUID PAED MULT INFL; Toubiana J, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m2094; Toulon P, 2016, THROMB HAEMOSTASIS, V116, P9, DOI 10.1160/TH15-12-0964; UK Government, 2020, UK POP ETHN POP STAT; Verdoni L, 2020, LANCET, V395, P1771, DOI 10.1016/S0140-6736(20)31103-X; Viner RM, 2020, SUSCEPTIBILITY TRANS, DOI [10.1101/2020.05.20.20108126v1, DOI 10.1101/2020.05.20.20108126V1]; Whittaker E, 2020, JAMA-J AM MED ASSOC, V324, P259, DOI 10.1001/jama.2020.10369; Williams MD, 2002, BRIT J HAEMATOL, V119, P295, DOI 10.1046/j.1365-2141.2002.03674.x; World Health Organization, 2020, SCI BRIEF 0515, DOI DOI 10.7326/M20-2003; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648	32	312	319	2	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 27	2020	370								m3249	10.1136/bmj.m3249	http://dx.doi.org/10.1136/bmj.m3249			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NI9FV	32960186	Green Published, Green Submitted, Green Accepted, hybrid			2023-01-03	WOS:000565652200003
J	Harris, C; Peacock, JL; Greenough, A				Harris, Christopher; Peacock, Janet L.; Greenough, Anne			Outcomes of the Neonatal Trial of High-Frequency Oscillation at 16 to 19 Years	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter									[Harris, Christopher; Greenough, Anne] Kings Coll London, London, England; [Peacock, Janet L.] Dartmouth Coll, Hanover, NH 03755 USA	University of London; King's College London; Dartmouth College	Greenough, A (corresponding author), Kings Coll London, London, England.	anne.greenough@kcl.ac.uk		Peacock, Janet/0000-0002-0310-2518; Bisquera, Alessandra/0000-0002-6639-2057; Greenough, Anne/0000-0002-8672-5349	National Institute for Health Research Biomedical Research Centre at Guy's and St. Thomas' National Health Service Foundation Trust and King's College London	National Institute for Health Research Biomedical Research Centre at Guy's and St. Thomas' National Health Service Foundation Trust and King's College London	Supported by the National Institute for Health Research Biomedical Research Centre at Guy's and St. Thomas' National Health Service Foundation Trust and King's College London.	Johnson AH, 2002, NEW ENGL J MED, V347, P633, DOI 10.1056/NEJMoa020432; Zivanovic S, 2014, NEW ENGL J MED, V370, P1121, DOI 10.1056/NEJMoa1309220	2	7	7	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 13	2020	383	7					689	691		10.1056/NEJMc2008677	http://dx.doi.org/10.1056/NEJMc2008677			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE7HD	32786197	Bronze			2023-01-03	WOS:000562771200027
J	Rogers, W				Rogers, Wendy			The art of medicine Moral responsibility in medicine: where are the boundaries?	LANCET			English	Editorial Material									[Rogers, Wendy] Macquarie Univ, Dept Philosophy, Sydney, NSW 2109, Australia; [Rogers, Wendy] Macquarie Univ, Dept Clin Med, Sydney, NSW 2109, Australia	Macquarie University; Macquarie University	Rogers, W (corresponding author), Macquarie Univ, Dept Philosophy, Sydney, NSW 2109, Australia.; Rogers, W (corresponding author), Macquarie Univ, Dept Clin Med, Sydney, NSW 2109, Australia.	wendy.rogers@mq.edu.au		Rogers, Wendy/0000-0001-9186-870X					0	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	2020	396	10248					373	374						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	ND0SW	32771096				2023-01-03	WOS:000561619100016
J	Kiseleva, RY; Glassman, PG; LeForte, KM; Walsh, LR; Villa, CH; Shuvaev, VV; Myerson, JW; Aprelev, PA; Marcos-Contreras, OA; Muzykantov, VR; Greineder, CF				Kiseleva, R. Yu.; Glassman, P. G.; LeForte, K. M.; Walsh, L. R.; Villa, C. H.; Shuvaev, V. V.; Myerson, J. W.; Aprelev, P. A.; Marcos-Contreras, O. A.; Muzykantov, V. R.; Greineder, C. F.			Bivalent engagement of endothelial surface antigens is critical to prolonged surface targeting and protein delivery in vivo	FASEB JOURNAL			English	Article						cell surface; endothelium; ICAM-1; PECAM-1; targeted drug delivery; thrombomodulin	CELL-ADHESION MOLECULE-1; MONOCLONAL-ANTIBODY; TISSUE DISPOSITION; THROMBOMODULIN; ICAM-1; PHARMACOKINETICS; THERAPEUTICS; MODEL; PECAM; LUNG	Targeted drug delivery to the endothelium has the potential to generate localized therapeutic effects at the blood-tissue interface. For some therapeutic cargoes, it is essential to maintain contact with the bloodstream to exert protective effects. The pharmacokinetics (PK) of endothelial surface-targeted affinity ligands and biotherapeutic cargo remain a largely unexplored area, despite obvious translational implications for this strategy. To bridge this gap, we site-specifically radiolabeled mono- (scFv) and bivalent (mAb) affinity ligands specific for the endothelial cell adhesion molecules, PECAM-1 (CD31) and ICAM-1 (CD54). Radiotracing revealed similar lung biodistribution at 30 minutes post-injection (79.3% +/- 4.2% vs 80.4% +/- 10.6% ID/g for alpha ICAM and 58.9% +/- 3.6% ID/g vs. 47.7% +/- 5.8% ID/g for alpha PECAM mAb vs. scFv), but marked differences in organ residence time, with antibodies demonstrating an order of magnitude greater area under the lung concentration vs. time curve (AUC(inf)1698 +/- 352 vs. 53.3 +/- 7.9 ID/g*hrs for alpha ICAM and 1023 +/- 507 vs. 114 +/- 37 ID/g*hrs for alpha PECAM mAb vs scFv). A physiologically based pharmacokinetic model, fit to and validated using these data, indicated contributions from both superior binding characteristics and prolonged circulation time supporting multiple binding-detachment cycles. We tested the ability of each affinity ligand to deliver a prototypical surface cargo, thrombomodulin (TM), using one-to-one protein conjugates. Bivalent mAb-TM was superior to monovalent scFv-TM in both pulmonary targeting and lung residence time (AUC(inf)141 +/- 3.2 vs 12.4 +/- 4.2 ID/g*hrs for ICAM and 188 +/- 90 vs 34.7 +/- 19.9 ID/g*hrs for PECAM), despite having similar blood PK, indicating that binding strength is more important parameter than the kinetics of binding. To maximize bivalent target engagement, we synthesized an oriented, end-to-end anti-ICAM mAb-TM conjugate and found that this therapeutic had the best lung residence time (AUC(inf)253 +/- 18 ID/g*hrs) of all TM modalities. These observations have implications not only for the delivery of TM, but also potentially all therapeutics targeted to the endothelial surface.	[Kiseleva, R. Yu.; Glassman, P. G.; LeForte, K. M.; Walsh, L. R.; Villa, C. H.; Shuvaev, V. V.; Myerson, J. W.; Aprelev, P. A.; Marcos-Contreras, O. A.; Muzykantov, V. R.] Univ Penn, Dept Pharmacol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Greineder, C. F.] Univ Michigan, Dept Emergency Med & Pharmacol, North Campus Res Complex,B10-154A, Ann Arbor, MI 48109 USA	University of Pennsylvania; Pennsylvania Medicine; University of Michigan System; University of Michigan	Greineder, CF (corresponding author), Univ Michigan, Dept Emergency Med & Pharmacol, North Campus Res Complex,B10-154A, Ann Arbor, MI 48109 USA.	coling@med.umich.edu		Kiseleva, Raisa/0000-0001-8065-3551	HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI) [K08-HL130430, RO1 HL125462, RO1 HL128398]	HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)	HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI), Grant/Award Number: K08-HL130430, RO1 HL125462 and RO1 HL128398	Agarwal P, 2015, BIOCONJUGATE CHEM, V26, P176, DOI 10.1021/bc5004982; Aird WC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006429; Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903; Betts A, 2019, AAPS J, V21, DOI 10.1208/s12248-019-0332-z; Brenner JS, 2018, PULM CIRC, V8, DOI 10.1177/2045893217752329; Brenner Jacob S, 2017, Nanomedicine, V13, P1495, DOI 10.1016/j.nano.2016.12.019; Campagne O, 2018, CLIN CANCER RES, V24, P2631, DOI 10.1158/1078-0432.CCR-17-2265; Chittasupho C, 2009, EUR J PHARM SCI, V37, P141, DOI 10.1016/j.ejps.2009.02.008; Christofidou-Solomidou M, 2003, AM J PHYSIOL-LUNG C, V285, pL283, DOI 10.1152/ajplung.00021.2003; Cilliers C, 2016, AAPS J, V18, P1117, DOI 10.1208/s12248-016-9940-z; DANILOV SM, 1991, LAB INVEST, V64, P118; Datta-Mannan A, 2007, J BIOL CHEM, V282, P1709, DOI 10.1074/jbc.M607161200; Ding BS, 2009, AM J RESP CRIT CARE, V180, P247, DOI 10.1164/rccm.200809-1433OC; Ding BS, 2005, BLOOD, V106, P4191, DOI 10.1182/blood-2005-05-2002; Drachman JG, 2013, HEMATOL-AM SOC HEMAT, P306, DOI 10.1182/asheducation-2013.1.306; Ferrer MCC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102329; Fuentes RE, 2016, J CLIN INVEST, V126, P483, DOI 10.1172/JCI81470; Gadkar K, 2016, EUR J PHARM BIOPHARM, V101, P53, DOI 10.1016/j.ejpb.2016.01.009; Ghaffarian R, 2016, J CONTROL RELEASE, V238, P221, DOI 10.1016/j.jconrel.2016.07.042; Ghaffarian R, 2014, MOL PHARMACEUT, V11, P4350, DOI 10.1021/mp500409y; Greineder CF, 2018, BIOCONJUGATE CHEM, V29, P56, DOI 10.1021/acs.bioconjchem.7b00592; Greineder CF, 2017, BLOOD ADV, V1, P1452, DOI 10.1182/bloodadvances.2017007229; Greineder CF, 2015, FASEB J, V29, P3483, DOI 10.1096/fj.15-271213; Greineder CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080110; Greineder CF, 2013, BLOOD, V122, P1565, DOI 10.1182/blood-2013-03-453498; Hayakawa M, 2017, THROMB HAEMOSTASIS, V117, P851, DOI 10.1160/TH16-07-0547; JACOBSON BS, 1992, EUR J CELL BIOL, V58, P296; Khoshnejad M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19784-2; Khot A, 2017, AAPS J, V19, P1715, DOI 10.1208/s12248-017-0131-3; Kiseleva R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169537; Kiseleva R, 2018, DRUG DELIV TRANSL RE, V8, P883, DOI 10.1007/s13346-017-0464-6; Kiseleva RY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20027-7; Lamberti G, 2012, 2012 38 ANN NE BIOEN; Leipold D, 2019, CTS-CLIN TRANSL SCI, V12, P130, DOI 10.1111/cts.12597; Lertkiatmongkol P, 2016, CURR OPIN HEMATOL, V23, P253, DOI 10.1097/MOH.0000000000000239; Marcos-Contreras OA, 2019, J CONTROL RELEASE, V301, P54, DOI 10.1016/j.jconrel.2019.03.008; Murciano JC, 2003, NAT BIOTECHNOL, V21, P891, DOI 10.1038/nbt846; Murciano JC, 2003, BLOOD, V101, P3977, DOI 10.1182/blood-2002-09-2853; Muro S, 2006, MOL THER, V13, P135, DOI 10.1016/j.ymthe.2005.07.687; Muro S, 2005, CURR PHARM DESIGN, V11, P2383, DOI 10.2174/1381612054367274; Muro S, 2005, BLOOD, V105, P650, DOI 10.1182/blood-2004-05-1714; Muro S, 2003, J CELL SCI, V116, P1599, DOI 10.1242/jcs.00367; Muzykantov VR, 1999, P NATL ACAD SCI USA, V96, P2379, DOI 10.1073/pnas.96.5.2379; Muzykantov VR., 2013, ISRN VASC MED, V2013, P1, DOI [10.1155/2013/916254, DOI 10.1155/2013/916254]; Myerson JW, 2018, ADV MATER, V30, DOI 10.1002/adma.201802373; NEWMAN PJ, 1994, ANN NY ACAD SCI, V714, P165, DOI 10.1111/j.1749-6632.1994.tb12041.x; Parhiz H, 2018, J CONTROL RELEASE, V291, P106, DOI 10.1016/j.jconrel.2018.10.015; Roki N, 2019, J CONTROL RELEASE, V305, P41, DOI 10.1016/j.jconrel.2019.05.021; Scherpereel A, 2002, J PHARMACOL EXP THER, V300, P777, DOI 10.1124/jpet.300.3.777; Schmitt C, 2015, J CARDIOVASC PHARM, V65, P611, DOI 10.1097/FJC.0000000000000233; Schneider D, 1998, EUR NEUROL, V40, P78, DOI 10.1159/000007962; Shah DK, 2014, J PHARMACOKINET PHAR, V41, P55, DOI 10.1007/s10928-013-9346-9; Shah DK, 2012, J PHARMACOKINET PHAR, V39, P67, DOI 10.1007/s10928-011-9232-2; Shuvaev VV, 2007, J CONTROL RELEASE, V118, P235, DOI 10.1016/j.jconrel.2006.12.025; Shuvaev VV, 2018, J CONTROL RELEASE, V272, P1, DOI 10.1016/j.jconrel.2017.12.025; Shuvaev VV, 2016, J CONTROL RELEASE, V234, P115, DOI 10.1016/j.jconrel.2016.05.040; Shuvaev VV, 2015, J CONTROL RELEASE, V219, P576, DOI 10.1016/j.jconrel.2015.09.055; Shuvaev VV, 2011, FASEB J, V25, P348, DOI 10.1096/fj.10-169789; Villa CH, 2016, ADV DRUG DELIVER REV, V106, P88, DOI 10.1016/j.addr.2016.02.007; Wagner NM, 2013, ARTERIOSCL THROM VAS, V33, P1943, DOI 10.1161/ATVBAHA.113.301783; Wang-Lin SX, 2018, MABS-AUSTIN, V10, P1131, DOI 10.1080/19420862.2018.1494478; Zaitsev S, 2012, BLOOD, V119, P4779, DOI 10.1182/blood-2011-12-398149	62	5	5	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2020	34	9					11577	11593		10.1096/fj.201902515RR	http://dx.doi.org/10.1096/fj.201902515RR		AUG 2020	17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NK8TC	32738178	Green Published, Green Accepted			2023-01-03	WOS:000558181900001
J	Miller, JFAP				Miller, Jacques F. A. P.			The function of the thymus and its impact on modern medicine	SCIENCE			English	Review							TO-CELL INTERACTION; HEMOLYSIN-FORMING CELLS; IMMUNE-RESPONSE; LYMPHOID ORGANS; IMMUNOLOGICAL FUNCTION; NEONATAL THYMECTOMY; CROSS-PRESENTATION; CROONIAN LECTURE; IRRADIATED MICE; BONE-MARROW	The lymphoid system is intimately involved in immunological processes. The small lymphocyte that circulates through blood into lymphoid tissues, then through the lymph and back to the blood through the thoracic duct, is able to initiate immune responses after appropriate stimulation by antigen. However, the lymphocytes found in the thymus are deficient in this ability despite the fact that the thymus plays a central role in lymphocyte production and in ensuring the normal development of immunological faculty. During embryogenesis, lymphocytes are present in the thymus before they can be identified in the circulation and in other lymphoid tissues. They become "educated" in the thymus to recognize a great diversity of peptide antigens bound to the body's own marker antigen, the major histocompatibility complex, but they are purged if they strongly react against their own self-components. Lymphocytes differentiate to become various T cell subsets and then exit through the bloodstream to populate certain areas of the lymphoid system as peripheral T lymphocytes with distinct markers and immune functions.	[Miller, Jacques F. A. P.] Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia; [Miller, Jacques F. A. P.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia	Walter & Eliza Hall Institute; University of Melbourne	Miller, JFAP (corresponding author), Walter & Eliza Hall Inst Med Res, Parkville, Vic 3052, Australia.; Miller, JFAP (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic 3010, Australia.	miller@wehi.edu.au		Miller, Jacques/0000-0002-3848-5109				Anderson MS, 2002, SCIENCE, V298, P1395, DOI 10.1126/science.1075958; ANDREASEN E, 1949, ANAT REC, V103, P401, DOI 10.1002/ar.1091030307; ARNASON BG, 1962, NATURE, V194, P99, DOI 10.1038/194099a0; Brayton H. W., 1919, BOSTON MED SURG J, V181, P740, DOI [10.1056/NEJM191912251812604, DOI 10.1056/NEJM191912251812604]; Burnet F.M., 1972, AUTOIMMUNITY AUTOIMM; BURNET M, 1962, SCI AM, V207, P50; CANTOR H, 1975, J EXP MED, V141, P1376, DOI 10.1084/jem.141.6.1376; Carpenter AC, 2010, NAT IMMUNOL, V11, P666, DOI 10.1038/ni.1887; CHEERS C, 1972, J EXP MED, V136, P1661, DOI 10.1084/jem.136.6.1661; CLAMAN HN, 1966, P SOC EXP BIOL MED, V122, P1167; COOPER MD, 1966, J EXP MED, V123, P75, DOI 10.1084/jem.123.1.75; COOPER MD, 1968, AM J MED, V44, P499, DOI 10.1016/0002-9343(68)90051-X; CROSS AM, 1964, J EXP MED, V119, P837, DOI 10.1084/jem.119.5.837; Daley SR, 2017, IMMUNOL REV, V277, P9, DOI 10.1111/imr.12532; DALMASSO AP, 1962, P SOC EXP BIOL MED, V111, P143; Davey GM, 2002, J EXP MED, V196, P947, DOI 10.1084/jem.20020827; Di Pilato M, 2019, NATURE, V570, P112, DOI 10.1038/s41586-019-1215-2; FICHTELIUS K, 1961, ACTA PATHOL MIC SC, V51, P81; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; GLICK B, 1956, POULTRY SCI, V35, P224, DOI 10.3382/ps.0350224; Godfrey DI, 2015, NAT IMMUNOL, V16, P1114, DOI 10.1038/ni.3298; Good R. A., 1969, IMMUNOLOGICAL TOLERA, P136; Gowans J. L., 1969, IMMUNOLOGICAL TOLERA, P164; GOWANS JL, 1962, NATURE, V196, P651, DOI 10.1038/196651a0; GRANT GA, 1965, NATURE, V205, P1124, DOI 10.1038/2051124a0; Gras S, 2010, P NATL ACAD SCI USA, V107, P12599, DOI 10.1073/pnas.1007270107; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HOFMAN L, 1961, RADIAT RES, V15, P30, DOI 10.2307/3571064; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; HOZUMI N, 1976, P NATL ACAD SCI USA, V73, P3628, DOI 10.1073/pnas.73.10.3628; ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; KENNEDY JC, 1965, P SOC EXP BIOL MED, V120, P868; KINCADE PW, 1970, P NATL ACAD SCI USA, V67, P1918, DOI 10.1073/pnas.67.4.1918; KISIELOW P, 1988, NATURE, V335, P730, DOI 10.1038/335730a0; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; LAFFERTY KJ, 1975, AUST J EXP BIOL MED, V53, P27, DOI 10.1038/icb.1975.3; Marchingo JM, 2014, SCIENCE, V346, P1123, DOI 10.1126/science.1260044; MARTINEZ C, 1962, P SOC EXP BIOL MED, V109, P193; Martinez C., 1964, THYMUS IMMUNOBIOLOGY, P465; MCINTIRE KR, 1964, NATURE, V204, P151, DOI 10.1038/204151a0; Medawar P. B., 1963, IMMUNOLOGICALLY COMP, P6; MEDAWAR PB, 1958, PROC R SOC SER B-BIO, V149, P145, DOI 10.1098/rspb.1958.0058; Metcalf D., 1964, THYMUS IMMUNOBIOLOGY, P150; Miller J. F., 1967, MODERN TRENDS PATHOL, P140; Miller JFAP, 2015, CANCER CELL, V27, P439, DOI 10.1016/j.ccell.2015.03.007; MILLER JF, 1961, LANCET, V2, P748; MILLER JF, 1961, NATURE, V191, P248, DOI 10.1038/191248a0; MILLER JFA, 1965, NATURE, V208, P1332, DOI 10.1038/2081332a0; MILLER JFA, 1968, J EXP MED, V128, P801, DOI 10.1084/jem.128.4.801; MILLER JFA, 1959, NATURE, V184, P1809, DOI 10.1038/1841809a0; MILLER JFA, 1962, ANN NY ACAD SCI, V99, P340, DOI 10.1111/j.1749-6632.1962.tb45319.x; MILLER JFA, 1966, BRIT MED BULL, V22, P21, DOI 10.1093/oxfordjournals.bmb.a070431; MILLER JFA, 1963, NATURE, V199, P921, DOI 10.1038/199920a0; MILLER JFA, 1967, PHYSIOL REV, V47, P437, DOI 10.1152/physrev.1967.47.3.437; MILLER JFA, 1965, NATURE, V208, P1337, DOI 10.1038/2081337a0; MILLER JFA, 1962, NATURE, V195, P1318, DOI 10.1038/1951318a0; MILLER JFA, 1964, P SOC EXP BIOL MED, V116, P323; MILLER JFA, 1967, NATURE, V214, P992, DOI 10.1038/214992a0; MILLER JFAP, 1992, PHILOS T R SOC B, V337, P105, DOI 10.1098/rstb.1992.0087; MILLER JFAP, 1962, PROC R SOC SER B-BIO, V156, P415, DOI 10.1098/rspb.1962.0048; MILLER JFAP, 1971, NATURE-NEW BIOL, V230, P267, DOI 10.1038/newbio230267a0; MILLER JFAP, 1959, NATURE, V183, P1069, DOI 10.1038/1831069a0; MILLER JFAP, 1960, NATURE, V187, P703, DOI 10.1038/187703a0; Miller JFAP, 1998, IMMUNOL REV, V165, P267, DOI 10.1111/j.1600-065X.1998.tb01244.x; MILLER JFAP, 1963, P SOC EXP BIOL MED, V112, P785; MITCHELL GF, 1968, J EXP MED, V128, P821, DOI 10.1084/jem.128.4.821; MOORE MAS, 1967, LANCET, V2, P658, DOI 10.1016/S0140-6736(67)90693-9; NAKAMURA K, 1961, BRIT J CANCER, V15, P306, DOI 10.1038/bjc.1961.38; OSMOND DG, 1986, IMMUNOL REV, V93, P103, DOI 10.1111/j.1600-065X.1986.tb01504.x; PAETKAU V, 1981, NATURE, V294, P689, DOI 10.1038/294689a0; Palmer S, 2018, P NATL ACAD SCI USA, V115, P1883, DOI 10.1073/pnas.1714478115; PANTELOURIS EM, 1971, IMMUNOLOGY, V20, P247; PARROTT DMV, 1966, J EXP MED, V123, P191, DOI 10.1084/jem.123.1.191; SIU G, 1984, CELL, V37, P393, DOI 10.1016/0092-8674(84)90369-6; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; van Ewijk W, 2000, DEVELOPMENT, V127, P1583; VOS O, 1959, J NATL CANCER I, V23, P53; WARNER NL, 1962, AUST J EXP BIOL MED, V43, P373; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; YOSHIKAI Y, 1984, NATURE, V312, P521, DOI 10.1038/312521a0; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0; ZINKERNA.RM, 1974, NATURE, V251, P547, DOI 10.1038/251547a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	89	21	21	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 31	2020	369	6503					522	+	eaba2429	10.1126/science.aba2429	http://dx.doi.org/10.1126/science.aba2429			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV7YK	32732394				2023-01-03	WOS:000556568100035
J	Svoboda, E				Svoboda, Elizabeth			Bacteria-eating viruses could provide a route to stability in cystic fibrosis	NATURE			English	Editorial Material						Infection; Diseases; Therapeutics; Medical research		Phage therapy is broadening the treatment landscape for people with drug-resistant infections. Phage therapy is broadening the treatment landscape for people with drug-resistant infections.										Dedrick RM, 2019, NAT MED, V25, P730, DOI 10.1038/s41591-019-0437-z; Djebara S, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11030265; Duplessis C. A. J., 2019, INTENSIVE CRIT CARE, V5, P11; Gibson SB, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.02537	4	4	4	2	6	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 30	2020	583	7818					S8	S9		10.1038/d41586-020-02109-7	http://dx.doi.org/10.1038/d41586-020-02109-7			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT2XH	32728257	Bronze			2023-01-03	WOS:000554831500005
J	Just, JM; Scherbaum, N; Specka, M; Puth, MT; Weckbecker, K				Just, Johannes M.; Scherbaum, Norbert; Specka, Michael; Puth, Marie-Therese; Weckbecker, Klaus			Rate of opioid use disorder in adults who received prescription opioid pain therapy-A secondary data analysis	PLOS ONE			English	Article							CHRONIC NONCANCER PAIN; DEPENDENCE; DEPRESSION; PREVALENCE; CRITERIA; MISUSE; RISKS; ABUSE	Background and aims Data on rates of prescription opioid use disorder (pOUD) in European countries is limited. The aim of this investigation was to analyze a representative population sample regarding the 1-year prevalence of opioid use disorder in patients who received prescription opioid pain therapy and to identify related risk factors. Design Cross-sectional secondary data analysis Setting Secondary data analysis based on data from the 2015 Epidemiological Survey of Substance Abuse (ESA 2015) in Germany Participants German-speaking individuals living in private households aged 18 to 64 years were investigated. A total of 9204 individuals participated in the survey, resulting in a response rate of 52.2%. Primary and secondary outcome measures Primary outcome measure was the weighted prevalence of pOUD in the subgroup of study participants who had received prescription opioids. Secondary outcome measure was an analysis of risk factors connected with pOUD in the same subgroup. Findings A total of n = 9204 participants were included in the study of which n = 275 had received an opioid prescription in the last 12 months of which n = 54 were diagnosed with pOUD. The weighted 1-year prevalence of pOUD was 21.2% (mild: 14.7% vertical bar moderate: 3.5% vertical bar severe: 2.9%). Participants who had received opioid pain therapy had significantly higher odds of pOUD if they reported signs of depression (OR: 2.69; CI 95%: 1.13-6.38), inexplicable physical complaints (OR: 2.68; CI 95%: 1.14-6.31) or a psychiatric diagnosis (OR: 4.12; CI 95%: 1.36-12.43), and significantly lower odds of pOUD if they reported the use of non-opioid painkillers (OR: 0.27; CI 95%: 0.09-0.81). Conclusions pOUD is a common phenomenon in working-age patients who receive prescription opioid pain therapy in Germany and may be related to the co-existence of psychosomatic and psychiatric disorders such as depression.	[Just, Johannes M.; Weckbecker, Klaus] Univ Witten Herdecke, Fac Hlth, Inst Gen Practice & Interprofess Care, Dept Med, Witten, Germany; [Scherbaum, Norbert; Specka, Michael] Univ Duisburg Essen, LVR Hosp Essen, Med Fac, Dept Addict Behav & Addict Med, Essen, Germany; [Puth, Marie-Therese] Univ Hosp Bonn, Dept Med Biometry Informat & Epidemiol IMBIE, Bonn, Germany	Witten Herdecke University; University of Duisburg Essen; University of Bonn	Just, JM (corresponding author), Univ Witten Herdecke, Fac Hlth, Inst Gen Practice & Interprofess Care, Dept Med, Witten, Germany.	johannes.just@uni-wh.de	Weckbecker, Klaus/AGP-8017-2022	Specka, Michael/0000-0001-5194-7876; Schmitz, Marie-Therese/0000-0003-1351-9381				American Psychiatric Association, DIAGNOSTIC STAT MANU, DOI [10.1111/j.1360-0443.2010.03144.x, DOI 10.1111/J.1360-0443.2010.03144.X]; Bair MJ, 2003, ARCH INTERN MED, V163, P2433, DOI 10.1001/archinte.163.20.2433; Boscarino JA, 2015, SUBST ABUSE REHABIL, V6, P83, DOI 10.2147/SAR.S85667; Dasgupta N., 2008, AM J PUBLIC HEALTH, V108, P182; Degenhardt L, 2015, LANCET PSYCHIAT, V2, P314, DOI 10.1016/S2215-0366(15)00005-X; Edlund MJ, 2010, DRUG ALCOHOL DEPEN, V112, P90, DOI 10.1016/j.drugalcdep.2010.05.017; European Monitoring Centre for Drugs and Drug Addiction, 2019, EMCDDA STAT B; Frieden TR, 2016, NEW ENGL J MED, V374, P1501, DOI 10.1056/NEJMp1515917; Hauser W, 2020, SCHMERZ, V34, pS8, DOI 10.1007/s00482-018-0331-5; Hauser W, 2020, SCHMERZ, V34, P204, DOI 10.1007/s00482-020-00472-y; Hauser W, 2018, PAIN, V159, P85, DOI 10.1097/j.pain.0000000000001067; Hauser W, 2016, PAIN MANAG, V6, P249, DOI 10.2217/pmt.16.5; Hasin DS, 2013, AM J PSYCHIAT, V170, P834, DOI 10.1176/appi.ajp.2013.12060782; Just JM, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-026871; Just JM, 2018, BMC FAM PRACT, V19, DOI 10.1186/s12875-018-0775-9; Marschall U, 2016, EUR J PAIN, V20, P767, DOI 10.1002/ejp.802; Novak SP, 2016, BMC PSYCHIATRY, V16, DOI 10.1186/s12888-016-0909-3; O'Brien C, 2011, ADDICTION, V106, P866, DOI 10.1111/j.1360-0443.2010.03144.x; OECD, 2019, Addressing problematic opioid use in OECD countries, DOI 10.1787/a18286f0-en; Piontek D., 2016, SUCHT, V62, P259, DOI [10.1024/0939-5911/a000444, DOI 10.1024/0939-5911/A000444, DOI 10.1024/0939-5911/a000444]; Radbruch L, 2013, SUBST ABUS, V34, P313, DOI 10.1080/08897077.2012.735216; Reinecke H, 2015, BRIT J PHARMACOL, V172, P324, DOI 10.1111/bph.12634; Scherrer JF, 2015, PAIN, V156, P348, DOI 10.1097/01.j.pain.0000460316.58110.a0; Turk DC, 2008, CLIN J PAIN, V24, P497, DOI 10.1097/AJP.0b013e31816b1070; Von Korff M, 2017, INT J DRUG POLICY, V46, P90, DOI 10.1016/j.drugpo.2017.05.053; WEBER MM, 1988, INT CLIN PSYCHOPHARM, V3, P255, DOI 10.1097/00004850-198807000-00007; Weckbecker K, 2019, BUNDESGESUNDHEITSBLA, V62, P1446, DOI 10.1007/s00103-019-03044-3	27	6	6	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 23	2020	15	7							e0236268	10.1371/journal.pone.0236268	http://dx.doi.org/10.1371/journal.pone.0236268			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NX7VK	32702036	Green Published, gold			2023-01-03	WOS:000575913700067
J	Wilson, JD; Pecker, LH; Lanzkron, S; Bediako, SM; Han, DF; Beach, MC				Wilson, J. Deanna; Pecker, Lydia H.; Lanzkron, Sophie; Bediako, Shawn M.; Han, Dingfen; Beach, Mary Catherine			Marijuana use and health behaviors in a US clinic sample of patients with sickle cell disease	PLOS ONE			English	Article							ADULTS; PREVALENCE; PAIN; CARE	Introduction As marijuana use becomes more common, it is essential clinicians understand the relationship between marijuana use and health behaviors. Methods Using a retrospective cohort of adolescents and adults with sickle cell disease (SCD) stratified into a young (<25 years) and older cohort (> = 25 years), we conducted multiple linear regression examining relationship of marijuana use (independent variable) on each dependent variable (SCD self-management score and pain management). Results Among young cohort, 16.9% used marijuana compared to 21.8% of older cohort. The younger cohort reporting marijuana use had lower mean self-care scores (beta = -2.74;p = 0.009) and were more likely to have admissions to the hospital for pain (beta = 0.87;p = 0.047) compared to non-users. In contrast, the older cohort reporting marijuana use had more days treating pain at home (beta = 0.44;p = 0.035). Conclusions Only a minority of patients with SCD reported lifetime marijuana use. Among those reporting marijuana use, there were different associations with self-care and health-related behaviors by age. The older cohort who endorsed marijuana use reported more days of treating pain at home, although this did not translate into increased acute care visits for pain crisis. Among youth, endorsing marijuana use was associated with worse SCD self-care.	[Wilson, J. Deanna] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA; [Wilson, J. Deanna] Univ Pittsburgh, Dept Pediat, Div Adolescent & Young Adult Med, Pittsburgh, PA 15260 USA; [Pecker, Lydia H.] Johns Hopkins Univ, Sch Med, Dept Pediat, Div Pediat Hematol, Baltimore, MD 21205 USA; [Lanzkron, Sophie] Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA; [Bediako, Shawn M.] Univ Maryland Baltimore Cty, Dept Psychol, Baltimore, MD 21228 USA; [Han, Dingfen; Beach, Mary Catherine] Johns Hopkins Univ, Sch Med, Dept Med, Div Gen Internal Med, Baltimore, MD 21205 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Johns Hopkins University; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore County; Johns Hopkins University	Wilson, JD (corresponding author), Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15260 USA.; Wilson, JD (corresponding author), Univ Pittsburgh, Dept Pediat, Div Adolescent & Young Adult Med, Pittsburgh, PA 15260 USA.	wilsonjd@pitt.edu	Bediako, Shawn/AAX-2402-2020; Lanzkron, Sophie/AAD-7584-2022; Lanzkron, Sophie/AFU-9516-2022	Bediako, Shawn/0000-0001-5696-2805; Lanzkron, Sophie/0000-0002-2878-0251; Lanzkron, Sophie/0000-0002-2878-0251; Wilson, J. Deanna/0000-0001-8400-9958	National Institute of Health (NIH) National Heart, Lung, and Blood Institute [R01 HL088511]; NIH National Institute on Drug Abuse [K24 DA037804-01]; NIH National Center for Advancing Translational Sciences [KL2 TR001856]	National Institute of Health (NIH) National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIH National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIH National Center for Advancing Translational Sciences	MCB was supported through the National Institute of Health (NIH) National Heart, Lung, and Blood Institute R01 HL088511 (https://www.nhlbi.nih.gov).MCB was supported by NIH National Institute on Drug Abuse K24 DA037804-01 (drugabuse.gov) and JDW was supported by NIH National Center for Advancing Translational Sciences KL2 TR001856 (https://www.nhlbi.nih.gov/).The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript.	Ballas SK, 2017, CANNABIS CANNABINOID, V2, P197, DOI 10.1089/can.2017.0011; Bonnie R., 2014, INVESTING HLTH WELL; Gotlieb VK, 2008, BLOOD, V112, P4826; Haywood C, 2014, BLOOD, V48, P1657; Haywood C, 2014, J PAIN SYMPTOM MANAG, V48, P934, DOI 10.1016/j.jpainsymman.2014.02.002; Howard J, 2005, BRIT J HAEMATOL, V131, P123, DOI 10.1111/j.1365-2141.2005.05723.x; Kalu N, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.5913.5913; Knight-Madden J, 2006, W INDIAN MED J, V55, P224; Lenoci JM, 2002, WESTERN J NURS RES, V24, P228, DOI 10.1177/01939450222045879; McLellan A.T., 1997, ADDICTION SEVERITY I; Roberts JD, 2018, CANNABIS CANNABINOID, V3; Sheidow AJ, 2012, PSYCHIATR REHABIL J, V35, P235, DOI 10.2975/35.3.2012.235.243; Smith WR, 2008, ANN INTERN MED, V148, P94, DOI 10.7326/0003-4819-148-2-200801150-00004; Ware RE, 2017, LANCET, V390, P311, DOI 10.1016/S0140-6736(17)30193-9; Winters KC, 2012, PREV RES, V18, P21	15	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 14	2020	15	7							e0235192	10.1371/journal.pone.0235192	http://dx.doi.org/10.1371/journal.pone.0235192			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ3BK	32663844	Green Published, gold			2023-01-03	WOS:000552771400015
J	Mohammed, AS; Woldekidan, NA; Mohammed, FA				Mohammed, Ammas Siraj; Woldekidan, Nigist Alemayehu; Mohammed, Fuad Adem			Knowledge, attitude, and practice of pharmacy professionals on generic medicines in Eastern Ethiopia: A cross-sectional study	PLOS ONE			English	Article							PERCEPTIONS; STUDENTS; POLICIES; DRUGS	Background Generic medicines are similar to innovator medicine in terms of safety, quality, efficacy, dosage form, strength, and route of administration. They have the same therapeutic use to innovator medicines and available at a far lower price. However, health professionals' poor knowledge and attitude may limit its utilization. The present study aimed at assessing the knowledge, attitude, and practice of pharmacy professionals towards generic medicines in Harar city, Eastern Ethiopia. Methods A cross-sectional survey was conducted among community pharmacists in Harar city. A self-administered thirty-three item questionnaire on Knowledge, attitude, and practice of community pharmacists was utilized. Logistic regression analysis was performed to predict the determinants of knowledge and attitude of pharmacists. An odds ratio at 95% confidence interval along with a p-value < 0.05 was considered significant. Results Among 80 community pharmacists' approached, 74 completed the survey, providing a response rate of 92.5%. Sixty-seven percent of the respondents knew that generic drugs are bioequivalent to brand drugs and claimed generic medicines are cheaper (86.5%). Nearly half (48.6%) of participants believe that generic medicines are less effective and slower in the onset of action (58.1%). More than half (54.1%) of study participants revealed their lack of belief in generic medicine as a factor hindering the selection and dispensing of generic medicines. In multivariate logistic regression, experience in community pharmacy practice (Adjusted odds ratio (AOR = 2.18, 95%CI: 1.21-63.1) and Sex (AOR = 3.88, 95%CI: 2.12-39.62) were significantly associated with knowledge and attitude toward generic medicines, respectively. Conclusion The current study revealed that there is a gap in the knowledge and attitude of community pharmacists towards generic and brand drugs. More than averages of the respondents have known the concept of generic medicine including their right to perform generic substitution and had a positive attitude toward generics. Female pharmacists were more likely to have a positive attitude and the overall knowledge was higher in those who have more than 5 years of work experience.	[Mohammed, Ammas Siraj; Mohammed, Fuad Adem] Haramaya Univ, Sch Pharm, Dept Clin Pharm, Coll Hlth & Med Sci, Haramaya, Ethiopia; [Woldekidan, Nigist Alemayehu] Univ Gondar, Sch Pharm, Coll Med & Hlth Sci, Gondar, Ethiopia	Haramaya University; University of Gondar	Mohammed, AS (corresponding author), Haramaya Univ, Sch Pharm, Dept Clin Pharm, Coll Hlth & Med Sci, Haramaya, Ethiopia.	Ammassiraj2337@gmail.com	Siraj, Ammas/ABF-4925-2020	Siraj, Ammas/0000-0001-9575-7556				Adelman C, 2002, LANCET, V359, P1351, DOI 10.1016/S0140-6736(02)08304-6; Al-Gedadi NA, 2008, J GENERIC MED, V5, P209, DOI DOI 10.1057/JGM.2008.7; Allenet B, 2003, PHARM WORLD SCI, V25, P197, DOI 10.1023/A:1025840920988; [Anonymous], 1993, NAT DRGU POL TRANS G; Auta A, 2014, MED PRIN PRACT, V23, P53, DOI 10.1159/000355473; Awaisu A, 2014, INT J CLIN PHARM-NET, V36, P394, DOI 10.1007/s11096-013-9909-2; Babar ZUD, 2011, RES SOC ADMIN PHARM, V7, P294, DOI 10.1016/j.sapharm.2010.06.004; Barba Z-U-D, 2008, J GENERIC MED, V5, P315; Bashaar M., 2015, J PHARM POLICY PRACT, V8, P1, DOI [10.1186/s40545-014-0024-025926989, DOI 10.1186/S40545-014-0024-025926989]; Belay Y.B., 2017, J BASIC CLIN PHARM, V8, P193; Birkett DJ, 2003, AUST PRESCR, V26; Chong CP, 2011, INT J CLIN PHARM-NET, V33, P124, DOI 10.1007/s11096-010-9470-1; Chong CP, 2010, HEALTH POLICY, V94, P68, DOI 10.1016/j.healthpol.2009.08.011; Dalton K, 2017, INTEGR PHARM RES PRA, V6, P37, DOI 10.2147/IPRP.S108047; Danzon PM, 2000, J LAW ECON, V43, P311, DOI 10.1086/467458; Danzon PM, 2000, J HEALTH ECON, V19, P159, DOI 10.1016/S0167-6296(99)00039-9; Dunne S, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-1; Ess SM, 2003, PHARMACOECONOMICS, V21, P89, DOI 10.2165/00019053-200321020-00002; Food Medicine and Healthcare Administration and Control Authority of Ethiopia, 2014, STAND TREATM GUID GE, P73; Garattini L, 2000, HEALTH POLICY, V51, P149, DOI 10.1016/S0168-8510(00)00061-0; Gebrekirstos H, 2016, EJPMR, V3, P114; Hassali MA, 2007, MED EDUC, V41, P703, DOI 10.1111/j.1365-2923.2007.02791.x; Homedes N, 2005, B WORLD HEALTH ORGAN, V83, P64; Ioannides-Demos LL, 2002, PHARMACOECONOMICS, V20, P577, DOI 10.2165/00019053-200220090-00002; Jacobzone S., 2000, PHARM POLICIES OECD; Jamshed S, 2010, TROP J PHARM RES, V9; Johnston A, 2011, BRIT J CLIN PHARMACO, V72, P727, DOI 10.1111/j.1365-2125.2011.03987.x; King DR, 2002, CROAT MED J, V43, P462; Lofgren Hans, 2004, Aust Health Rev, V27, P39; Manzoli L, 2016, EUR J EPIDEMIOL, V31, P351, DOI 10.1007/s10654-015-0104-8; McGavock H, 1997, PHARMACOECONOMICS, V12, P307, DOI 10.2165/00019053-199712030-00003; Meredith P, 2003, CLIN THER, V25, P2875, DOI 10.1016/S0149-2918(03)80340-5; Othman GQ, 2015, PHARM EDUC, V15, P93; TOKLU HZ, 2012, AGE, V25, P36; U.S. Food and Drug Administration, FACTS GEN DRIGS; US Food and Drug Administration, WHAT AR GEN DRUGS; World Health Organization (WHO), 2012, GLOSS GLOB TRAD HLTH	37	6	6	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2020	15	7							e0235205	10.1371/journal.pone.0235205	http://dx.doi.org/10.1371/journal.pone.0235205			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MQ1AQ	32658918	gold, Green Published			2023-01-03	WOS:000552629600005
J	Wang, WT; Liao, SF; Wu, ZL; Chang, CW; Wu, JY				Wang, Wei-Te; Liao, Su-Fen; Wu, Zih-Ling; Chang, Chia-Wei; Wu, Jane-Yii			Simultaneous study of antioxidant activity, DNA protection and anti-inflammatory effect ofVernonia amygdalinaleaves extracts	PLOS ONE			English	Article							NF-KAPPA-B; LPS-INDUCED INFLAMMATION; GENE-EXPRESSION; NITRIC-OXIDE; ACTIVATION; MAPK; INHIBITORS; INDUCTION; RAW264.7; SYNTHASE	Vernonia amygdalina(VA) has been reported to have antioxidant potential; however, its DNA protection and anti-inflammatory properties remain unclear. We aimed to investigate whether aqueous (WEVAL) and alcoholic (EEVAL) VA extracts exert similar antioxidant, DNA protection and anti-inflammatory effects and attempted to explore the mechanism underlying the anti-inflammatory effects. These results demonstrated that WEVAL had greater polyphenolic and flavonoid contents, as well as a stronger reducing power, DPPH radical scavenging and DNA protective activity. Moreover, both extracts reduced lipopolysaccharide (LPS)-induced expression of COX-II, iNOS, pro-inflammatory factors, including NO, TNF-alpha, IL-1 beta, and IL-10. Compared with WEVAL, EEVAL was a more potent inflammatory inhibitor. Both extracts similarly inhibited LPS-induced MAPK (p38) and NF-kappa B expression. Our findings indicate that WEVAL and EEVAL have diverse antioxidant and anti-inflammatory effects. WEVAL had a stronger antioxidant and DNA protection activity; contrastingly, EEVAL had a stronger anti-inflammatory ability. The anti-inflammatory activity involves reduced pro-inflammatory cytokines through NF-kappa B down-regulation and MAPK inhibition. These results demonstrated that production of WEVAL and EEVAL from VA leaves may provide a safe and efficacious source of pharmaceutical applications, with antioxidant, DNA protective and anti-inflammation activities.	[Wang, Wei-Te; Wu, Zih-Ling; Chang, Chia-Wei; Wu, Jane-Yii] Dayeh Univ, Dept Food Sci & Biotechnol, Changhua, Taiwan; [Wang, Wei-Te; Liao, Su-Fen] Changhua Christian Hosp, Dept Phys Med & Rehabil, Changhua, Taiwan	Da Yeh University; Changhua Christian Hospital	Wu, JY (corresponding author), Dayeh Univ, Dept Food Sci & Biotechnol, Changhua, Taiwan.	jywu@mail.dyu.edu.tw						Atangwho IJ, 2013, FOOD CHEM, V141, P3428, DOI 10.1016/j.foodchem.2013.06.047; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Burrows CJ, 1998, CHEM REV, V98, P1109, DOI 10.1021/cr960421s; Chang CC, 2002, J FOOD DRUG ANAL, V10, P178; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; Barbosa MLD, 2017, ANTI-CANCER AGENT ME, V17, P483, DOI 10.2174/1871520616666160729112854; De Falco F, 2016, BIOCHEM PHARMACOL, V104, P83, DOI 10.1016/j.bcp.2016.01.008; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Duan XW, 2007, MOLECULES, V12, P759, DOI 10.3390/12040759; Feldmann M, 1991, Eur Cytokine Netw, V2, P5; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Georgewill OA, 2010, ASIAN PAC J TROP MED, V3, P150, DOI 10.1016/S1995-7645(10)60057-0; GOLDSTEIN S, 1993, FREE RADICAL BIO MED, V15, P435, DOI 10.1016/0891-5849(93)90043-T; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Guo WX, 2012, INFLAMMATION, V35, P1764, DOI 10.1007/s10753-012-9495-9; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; Huang BP, 2014, MOL MED REP, V10, P1077, DOI 10.3892/mmr.2014.2298; Ijeh II, 2011, J MED PLANTS RES, V5, P1051; Kahkonen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l; Kim JY, 2009, FOOD CHEM TOXICOL, V47, P1610, DOI 10.1016/j.fct.2009.04.009; Kirtonia A, 2020, CELL MOL LIFE SCI, V77, P4459, DOI 10.1007/s00018-020-03536-5; KOBAYASHI S, 1990, AGR BIOL CHEM TOKYO, V54, P69, DOI 10.1080/00021369.1990.10869886; Lv LH, 2011, INFLAMMATION, V34, P620, DOI 10.1007/s10753-010-9271-7; Malireddy S, 2012, ANTIOXID REDOX SIGN, V17, P327, DOI 10.1089/ars.2012.4600; Oktay M, 2003, LEBENSM-WISS TECHNOL, V36, P263, DOI 10.1016/S0023-6438(02)00226-8; Owolabi M.A., 2008, J COMPL INTEGR MED, V5, DOI 10.2202/1553-3840.1152; OYAIZU M, 1986, Japanese Journal of Nutrition, V44, P307; Puar YR, 2018, BIOMEDICINES, V6, DOI 10.3390/biomedicines6030082; Reddy DB, 2009, BIOCHEM BIOPH RES CO, V381, P112, DOI 10.1016/j.bbrc.2009.02.022; RZYMKIEWICZ D, 1994, AM J PHYSIOL, V266, pF39, DOI 10.1152/ajprenal.1994.266.1.F39; Sabat R, 2010, CYTOKINE GROWTH F R, V21, P331, DOI 10.1016/j.cytogfr.2010.09.002; Saha RN, 2007, J IMMUNOL, V179, P7101, DOI 10.4049/jimmunol.179.10.7101; Saklatvala J, 2007, CURR DRUG TARGETS, V8, P305, DOI 10.2174/138945007779940115; Sestili P, 1998, FREE RADICAL BIO MED, V25, P196, DOI 10.1016/S0891-5849(98)00040-9; Surh YJ, 2001, MUTAT RES-FUND MOL M, V480, P243, DOI 10.1016/S0027-5107(01)00183-X; Syama HP, 2018, J FUNCT FOODS, V44, P218, DOI 10.1016/j.jff.2018.01.027; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Temneanu O R, 2011, J Med Life, V4, P244; THIEMERMANN C, 1993, P NATL ACAD SCI USA, V90, P267, DOI 10.1073/pnas.90.1.267; TOREL J, 1986, PHYTOCHEMISTRY, V25, P383, DOI 10.1016/S0031-9422(00)85485-0; Villano D, 2007, TALANTA, V71, P230, DOI 10.1016/j.talanta.2006.03.050; Wu MJ, 2003, AM J CHINESE MED, V31, P687, DOI 10.1142/S0192415X03001429; Wu YY, 2007, ACTA PHARMACOL SIN, V28, P258, DOI 10.1111/j.1745-7254.2007.00500.x; Yasmeen S., 2016, INT J PHARM PHARM SC, V8, P175	45	5	5	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 13	2020	15	7							e0235717	10.1371/journal.pone.0235717	http://dx.doi.org/10.1371/journal.pone.0235717			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ1AQ	32658905	Green Published, gold			2023-01-03	WOS:000552629600027
J	Ahsan, S; Hydrie, MZI; Naqvi, SMZH; Shaikh, MA; Shah, MZ; Jafry, SIA				Ahsan, Sadaf; Hydrie, Muhammad Zafar Iqbal; Naqvi, Syed Muhammad Zulfiqar Hyder; Shaikh, Munir Ahmed; Shah, Muhammad Zahid; Jafry, Syed Imtiaz Ahmed			Antibiotic prescription patterns for treating dental infections in children among general and pediatric dentists in teaching institutions of Karachi, Pakistan	PLOS ONE			English	Article							ANTIMICROBIAL RESISTANCE; PRESCRIBING PRACTICE; CARE; PRACTITIONERS	Background Antibiotics are regularly prescribed by dental professionals in their practice, for the purpose of dental treatment as well as for the prevention of infection. The inappropriate use of antibiotics is a significant factor in the rise of antibiotic resistance. There is an immediate need for the advancement of prescribing guidelines and instructive polices to encourage the rational and appropriate utilization of medications especially antibiotics in dentistry. Objective The aim of this study was to identify the frequency of antibiotic prescription for treating dental infections in children among dentists in teaching institutions of Karachi, Pakistan and whether they are adhering to the prescribed international guidelines. Methods A cross-sectional study was conducted in three private and two public colleges of Karachi. After taking written informed consent and checking the inclusion criteria, a total of 380 participants were interviewed using a pre-designed validated questionnaire which included demographic profile and clinical case scenarios. Data were entered and analyzed on SPSS version 20. Inferential analysis was performed using chi-square test. The significance level was set at 0.05. Results Of the 380 subjects, a majority (71.3%) treated 15 or less children per month (n = 271) while 28.7% of dentists (n = 109) treated more than 15 children per month. Overall adherence to American Academy of Pediatric Dentistry guidelines was low from 26.1% to 44.2%. The difference between adherence of dentists with low and high volume of pediatric patients was significantly different for case scenarios 1, 3, 4 and 5 (p<0.001 for all) where dentists who treated 15 or less children per month were more likely to be adherent to standard antibiotic prescription guidelines than those who treated more than 15 children per month. Conclusions This study shows that majority of dentists, particularly dentists with high volume of pediatric patients lacked adherence to professional guidelines for prescribing antibiotics for treating dental infection in children. There seem to be a lack of harmony between the recommended professional guidelines and the antibiotic prescribing pattern of dentists. Regular updates and continuing medical education for the health professionals regarding comprehensible and specific professional guidelines may lead to improved adherence of antibiotics prescription amongst dentists.	[Ahsan, Sadaf] Baqai Med Univ, Baqai Dent Coll, Karachi, Pakistan; [Hydrie, Muhammad Zafar Iqbal; Naqvi, Syed Muhammad Zulfiqar Hyder; Shaikh, Munir Ahmed; Jafry, Syed Imtiaz Ahmed] Baqai Med Univ, Dept Community Med, Karachi, Pakistan; [Shah, Muhammad Zahid] Baqai Med Univ, Dept Family Med, Karachi, Pakistan	Baqai Medical University; Baqai Medical University; Baqai Medical University	Hydrie, MZI (corresponding author), Baqai Med Univ, Dept Community Med, Karachi, Pakistan.	zafarhydrie@gmail.com	Hydrie, Muhammad Zafar Iqbal/H-8490-2017	Hydrie, Muhammad Zafar Iqbal/0000-0002-1317-6975				Abu-zineh R., 2015, ORAL HLTH DENT MANAG, V14, P337; Al-Johani K, 2017, NIGER J CLIN PRACT, V20, P804, DOI 10.4103/1119-3077.196072; Atif M, 2017, ANTIMICROB RESIST IN, V6, DOI 10.1186/s13756-017-0199-7; Baig MT, 2017, PAK J PHARM SCI, V30, P1483; Butler CC, 1998, BMJ-BRIT MED J, V317, P637, DOI 10.1136/bmj.317.7159.637; Cherry WR, 2012, J AM DENT ASSOC, V143, P31, DOI 10.14219/jada.archive.2012.0015; Cosgrove SE, 2006, CLIN INFECT DIS, V42, pS82, DOI 10.1086/499406; Dar-Odeh NS, 2010, THER CLIN RISK MANAG, V6, P301; Esposito S, 2016, INT J ANTIMICROB AG, V48, P361, DOI 10.1016/j.ijantimicag.2016.08.001; Garg AK, 2014, J ANTIMICROB CHEMOTH, V69, P526, DOI 10.1093/jac/dkt351; Kaul Rahul, 2018, Int J Clin Pediatr Dent, V11, P122, DOI 10.5005/jp-journals-10005-1497; Khan Mohammad Shoaib, 2010, J Ayub Med Coll Abbottabad, V22, P118; Klein EY, 2018, P NATL ACAD SCI USA, V115, pE3463, DOI 10.1073/pnas.1717295115; Komolafe O O, 2003, Malawi Med J, V15, P63; Kouidhi B, 2011, ARCH ORAL BIOL, V56, P127, DOI 10.1016/j.archoralbio.2010.09.010; Lewis MAO, 2008, BRIT DENT J, V205, P537, DOI 10.1038/sj.bdj.2008.984; Maira Faizullah, 2017, Journal of Applied Pharmaceutical Science, V7, P38; Malik A., 2015, J RAWALPINDI MED COL, V19, P209; Malik ZI, 2013, PAK J MED RES, V52; Marquet Kristel, 2015, Crit Care, V19, P63, DOI 10.1186/s13054-015-0795-y; McManus P, 1997, MED J AUSTRALIA, V167, P124, DOI 10.5694/j.1326-5377.1997.tb138809.x; Metlay JP, 1998, ARCH INTERN MED, V158, P1813, DOI 10.1001/archinte.158.16.1813; Montero-Aguilar M., 2017, ODOVTOS INT J DENT S, V18, P10; Nausheen S, 2013, J PAK MED ASSOC, V63, P60; Naveen N, 2015, INT J ORAL HLTH MED, V2, P8; Palmer Nikolaus O A, 2006, Prim Dent Care, V13, P31, DOI 10.1308/135576106775193941; Prokuski L, 2008, J AM ACAD ORTHOP SUR, V16, P283, DOI 10.5435/00124635-200805000-00007; Ready D, 2003, MICROB DRUG RESIST, V9, P367, DOI 10.1089/107662903322762806; Riaz H, 2011, AFR J PHARM PHARMACO, V5, P596, DOI 10.5897/AJPP11.051; Saleem Z, 2019, EXPERT REV ANTI-INFE, V17, P285, DOI 10.1080/14787210.2019.1581063; Saleem Z, 2019, AM J INFECT CONTROL, V47, P421, DOI 10.1016/j.ajic.2018.09.025; Saleem Z, 2018, LANCET INFECT DIS, V18, P1066, DOI 10.1016/S1473-3099(18)30516-4; Sermet S, 2011, CLIN EXP HEALTH SCI, V1, P35; Sivaraman SS, 2013, PEDIATR DENT, V35, P546; Sohail Saadat, 2013, Journal of the Dow University of Health Sciences, V7, P54; Fonseca SNS, 2006, ARCH SURG-CHICAGO, V141, P1109, DOI 10.1001/archsurg.141.11.1109; Tekleab AM, 2017, PEDIATR HEALTH MED T, V8, P93, DOI 10.2147/PHMT.S144796; Van der Sandt N, 2016, PRESCRIBING PRACTICE; Vardhan T.H., 2017, J NTR U HLTH SCI, V6, P149, DOI [10.4103/JDRNTRUHS.JDRNTRUHS_30_17, DOI 10.4103/JDRNTRUHS.JDRNTRUHS_30_17]; Weber JT, 2005, EMERG INFECT DIS, V11, P791, DOI 10.3201/eid1106.050471; Westgarth D, 2015, BRIT DENT J, V219, P477, DOI 10.1038/sj.bdj.2015.880	41	4	4	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2020	15	7							e0235671	10.1371/journal.pone.0235671	http://dx.doi.org/10.1371/journal.pone.0235671			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ0RG	32649689	Green Published, gold			2023-01-03	WOS:000552603900061
J	Gafaar, TO; Pesambili, M; Henke, O; Vissoci, JRN; Mmbaga, BT; Staton, C				Gafaar, Temitope O.; Pesambili, Msafiri; Henke, Oliver; Vissoci, Joao Ricardo Nickenig; Mmbaga, Blandina Theophil; Staton, Catherine			Good death: An exploratory study on perceptions and attitudes of patients, relatives, and healthcare providers, in northern Tanzania	PLOS ONE			English	Article							ADVANCE DIRECTIVES; HIV/AIDS; END; DISCLOSURE; QUALITY	Importance In the Kilimanjaro region of Tanzania, there are no advance care planning (ACP) protocols being used to document patient preferences for end-of-life (EoL) care. There is a general avoidance of the topic and contemplating ACP in healthcare-limited regions can be an ethically complex subject. Nonetheless, evidence from similar settings indicate that an appropriate quality of life is valued, even as one is dying. What differs amongst cultures is the definition of a 'good death'. Objective Evaluate perceptions of quality of death and advance EoL preparation in Moshi, Tanzania. Design 13 focus group discussions (FGDs) were conducted in Swahili using a semi-structured guide. These discussions were audio-recorded, transcribed, translated, and coded using an inductive approach. Setting Kilimanjaro Christian Medical Centre (KCMC), referral hospital for northern Tanzania. Participants A total of 122 participants, including patients with life-threatening illnesses (34), their relatives/friends (29), healthcare professionals (29; HCPs; doctors and nurses), and allied HCPs (30; community health workers, religious leaders, and social workers) from KCMC, or nearby within Moshi, participated in this study. Findings In characterizing Good Death, 7 first-order themes emerged, and, of these themes, Religious & Spiritual Wellness, Family & Interpersonal Wellness, Grief Coping & Emotional Wellness, and Optimal Timing comprised the second-order theme, EoL Preparation and Life Completion. The other first-order themes for Good Death were Minimal Suffering & Burden, Quality of Care by Formal Caregivers, and Quality of Care by Informal Caregivers. Interpretation The results of this study provide a robust thematic description of Good Death in northern Tanzania and they lay the groundwork for future clinical and research endeavors to improve the quality of EoL care at KCMC.	[Gafaar, Temitope O.] Duke Univ, Sch Med, Durham, NC 27710 USA; [Pesambili, Msafiri] Kilimanjaro Christian Med Ctr, Duke Univ Res Collaborat, Moshi, Tanzania; [Henke, Oliver; Mmbaga, Blandina Theophil] Kilimanjaro Christian Med Ctr, Canc Care Ctr, Moshi, Tanzania; [Vissoci, Joao Ricardo Nickenig; Staton, Catherine] Duke Univ, Duke Global Hlth Inst, Durham, NC USA; [Vissoci, Joao Ricardo Nickenig; Staton, Catherine] Duke Univ, Med Ctr, Duke Emergency Med, Durham, NC USA; [Mmbaga, Blandina Theophil] Kilimanjaro Clin Res Inst, Moshi, Tanzania	Duke University; Kilimanjaro Christian Medical Centre; Kilimanjaro Christian Medical Centre; Duke University; Duke University	Gafaar, TO (corresponding author), Duke Univ, Sch Med, Durham, NC 27710 USA.	tgafaar@wustl.edu	Mmbaga, Blandina Theophil/AAR-8707-2021; Henke, Oliver/HGA-7260-2022	Mmbaga, Blandina Theophil/0000-0002-5550-1916; Staton, Catherine/0000-0002-6468-2894				Airhihenbuwa CO, 2004, CULTURE AFRICAN CONT; [Anonymous], 2012, POPULATION HOUSING C; Astrow AB, 2007, IS FAILURE MEET SPIR; Becker G, 2007, PALLIATIVE MED, V21, P207, DOI 10.1177/0269216307077327; Bintabara D, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023013; Brinkman-Stoppelenburg A, 2014, PALLIATIVE MED; Brouwer CN, 2000, AIDS CARE, DOI [10.1080/09540120075000372511218540, DOI 10.1080/09540120075000372511218540]; Bull A, 2012, S AFR FAM PRACT, V54, P507, DOI 10.1080/20786204.2012.10874284; Burt R. S., 2005, BROKERAGE CLOSURE IN; Chan HM, 2004, BIOETHICS; Clark PA, 2003, JOINT COMMISSION J Q; Detering KM, 2010, BMJ; Detering KM, 2018, ADV CARE PLANNING AD; Dilger H, 2008, ANTHROPOL QUART, V81, P207, DOI 10.1353/anq.2008.0009; Downing J, 2014, BMC PALLIAT CARE, V13, DOI 10.1186/1472-684X-13-4; Erlingsson C, 2013, AFR J EMERG MED, V3, P92, DOI 10.1016/j.afjem.2012.04.005; Finlay IG, 2005, COMMUNICATION MED; Frumence G., 2017, J AGING RES HEALTHCA, V1, P1, DOI [10.14302/issn.2474-7785.jarh-16-1354, DOI 10.14302/ISSN.2474-7785.JARH-16-1354]; Gawande A, 2014, BEING MORTAL MED WHA; Grant E, 2003, J PALLIATIVE CARE, V19, P159, DOI 10.1177/082585970301900303; Gysels M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034188; Gysels M, 2011, BMC PALLIAT CARE, V10, DOI 10.1186/1472-684X-10-6; Hales S, 2010, PALLIATIVE MED, V24, P127, DOI 10.1177/0269216309351783; Hanson LC, 2002, J PALLIAT MED; Harding R, 2008, J PAIN SYMPTOM MANAG; Harris JJ, 2003, SOC SCI MED, V56, P905, DOI 10.1016/S0277-9536(02)00090-4; Heyland DK, 2010, CANADIAN MED ASS J; Jegede Ayodele Samuel, 2016, BEOnline, V3, P41, DOI 10.20541/beonline.2016.0008; Kim S, 2003, NURS ETHICS; Koehlmoos TP, 2011, INFECT DIS CLIN N AM; Lewington J, 2012, B M J SUPPORT PALLIA; Lewis EG, 2017, PALLIAT SUPPORT CARE; Lyimo RA, 2014, AIDS PATIENT CARE ST, V28, P98, DOI 10.1089/apc.2013.0306; Mamdani M, 2004, POOR PEOPLES EXPERIE, P138; Mbiti J. S., 1990, AFRICAN RELIGIONS PH, V2nd; Meier EA, 2016, AM J GERIAT PSYCHIAT, V24, P261, DOI 10.1016/j.jagp.2016.01.135; Mfinanga FA, 2018, INT J LATEST RES HUM, V1, P120; Molloy DW, 2000, JAMA-J AM MED ASSOC, V283, P1437, DOI 10.1001/jama.283.11.1437; Muka T, 2015, EUR J EPIDEMIOL; Munthree C, 2010, RES AGING, V32, P155, DOI 10.1177/0164027510361829; Njoroge RJ, 1986, PHILOS ED AFRICA INT; Nzioka C., 2000, Culture, Health & Sexuality, V2, P1, DOI 10.1080/136910500300831; Okullu Henry, 1974, CHURCH POLITICS E AF; Omondi S, 2017, BMC PALLIAT CARE, V16, DOI 10.1186/s12904-017-0186-z; Philips PL, 2013, J PALLIAT MED, V16, P1438, DOI 10.1089/jpm.2013.0114; Posel D, 2007, SCAND J PUBLIC HLT S; Rialem F., 2017, THESIS; Rietjens JAC, 2017, LANCET ONCOL; Silveira MJ, 2010, N ENGL J MED; Singer Peter A, 2002, BMC Palliat Care, V1, P4, DOI 10.1186/1472-684X-1-4; Stanford J, 2013, J PALLIAT MED, V16, P762, DOI 10.1089/jpm.2013.0051; Stanifer JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122638; Steinhauser KE, 2000, JAMA; Stjernsward J, 2003, OXFORD TXB PALLIATIV, P1199; Stroebe M. S., 2004, INT J PSYCHOL RELIG, V14, P23, DOI [10.1207/s15327582ijpr1401_2, DOI 10.1207/S15327582IJPR1401_2]; Teno JM, 2007, J AM GERIATR SOC, V55, P189, DOI 10.1111/j.1532-5415.2007.01045.x; Tenzek KE, 2017, BEHAV SCI-BASEL, V7, DOI 10.3390/bs7020025; Tetti M., 2014, INT J ED RES, V2; Thomas F., 2006, SOC SCI MED; Tong A, 2007, INT J QUAL HEALTH C, V19, P349, DOI 10.1093/intqhc/mzm042; Van Der Geest S., 2002, J CROSS CULT GERONTO; van der Geest S., 2004, SOC SCI MED; WHO, 2018, GLOB HLTH EST 2019 D; Winzelberg GS, 2005, J AM GERIATR SOC; World Health Organization, 2002, NAT CANC CONTR PROGR; Zhang BH, 2009, ARCH INTERN MED, V169, P480, DOI 10.1001/archinternmed.2008.587	66	3	3	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 10	2020	15	7							e0233494	10.1371/journal.pone.0233494	http://dx.doi.org/10.1371/journal.pone.0233494			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MQ0RG	32649715	Green Published, gold			2023-01-03	WOS:000552603900058
J	Li, QK; Chen, Q; Klauser, PC; Li, MY; Zheng, F; Wang, NX; Li, XY; Zhang, QB; Fu, XM; Wang, Q; Xu, Y; Wang, L				Li, Qingke; Chen, Qu; Klauser, Paul C.; Li, Mengyuan; Zheng, Feng; Wang, Nanxi; Li, Xiaoying; Zhang, Qianbing; Fu, Xuemei; Wang, Qian; Xu, Yang; Wang, Lei			Developing Covalent Protein Drugs via Proximity-Enabled Reactive Therapeutics	CELL			English	Article							MODIFIED T-CELLS; PD-1/PD-L1 INTERACTION; STRUCTURAL BASIS; HUMANIZED MICE; CROSS-LINKING; GENETIC-CODE; IMMUNOTHERAPY; BINDING; EPHA2; PD-1	Small molecule covalent drugs provide desirable therapeutic properties over noncovalent ones for treating challenging diseases. The potential of covalent protein drugs, however, remains unexplored due to protein's inability to bind targets covalently. We report a proximity-enabled reactive therapeutics (PERx) approach to generate covalent protein drugs. Through genetic code expansion, a latent bioreactive amino acid fluorosulfate-L-tyrosine (FSY) was incorporated into human programmed cell death protein-1 (PD-1). Only when PD-1 interacts with PD-L1 did the FSY react with a proximal histidine of PD-L1 selectively, enabling irreversible binding of PD-1 to only PD-L1 in vitro and in vivo. When administrated in immune-humanized mice, the covalent PD-1(FSY) exhibited strikingly more potent antitumor effect over the noncovalent wild-type PD-1, attaining therapeutic efficacy equivalent or superior to anti-PD-L1 antibody. PERx should provide a general platform technology for converting various interacting proteins into covalent binders, achieving specific covalent protein targeting for biological studies and therapeutic capability unattainable with conventional noncovalent protein drugs.	[Li, Qingke; Chen, Qu; Li, Mengyuan; Li, Xiaoying; Zhang, Qianbing; Xu, Yang] Southern Med Univ, Guangdong Prov Key Lab Canc Immunotherapy, Canc Res Inst, Sch Basic Med Sci, Guangzhou 510515, Guangdong, Peoples R China; [Li, Qingke; Li, Mengyuan; Zheng, Feng; Wang, Qian] Chinese Acad Sci, Tech Inst Phys & Chem, Hangzhou Res Inst, Hangzhou 310018, Peoples R China; [Klauser, Paul C.; Wang, Nanxi; Wang, Lei] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA; [Klauser, Paul C.; Wang, Nanxi; Wang, Lei] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA; [Chen, Qu; Fu, Xuemei; Xu, Yang] Sun Yat Sen Univ, Affiliated Hosp 8, Shenzhen 518033, Guangdong, Peoples R China	Southern Medical University - China; Chinese Academy of Sciences; Technical Institute of Physics & Chemistry, CAS; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Sun Yat Sen University	Xu, Y (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Canc Immunotherapy, Canc Res Inst, Sch Basic Med Sci, Guangzhou 510515, Guangdong, Peoples R China.; Wang, Q (corresponding author), Chinese Acad Sci, Tech Inst Phys & Chem, Hangzhou Res Inst, Hangzhou 310018, Peoples R China.; Wang, L (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA.; Wang, L (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94158 USA.; Xu, Y (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 8, Shenzhen 518033, Guangdong, Peoples R China.	qianwang@mail.ipc.ac.cn; xuyang65@mail.sysu.edu.cn; lei.wang2@ucsf.edu	li, xiao/GSN-6181-2022; li, xiaofeng/GXF-9442-2022; Wang, Lei/E-7912-2011	Wang, Lei/0000-0002-5859-2526; Xu, Yang/0000-0001-5574-921X; Klauser, Paul/0000-0001-7900-7659; Qingke, Li/0000-0002-3889-8827	Zhejiang Public Welfare Technology and Application Research Program [LGF19H300002]; Shenzhen Sanming Project of Medicine [SZSM201602102]	Zhejiang Public Welfare Technology and Application Research Program; Shenzhen Sanming Project of Medicine	Q.W. acknowledges support from Zhejiang Public Welfare Technology and Application Research Program (LGF19H300002). F.X. acknowledges support from Shenzhen Sanming Project of Medicine (SZSM201602102).	Akinleye A, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0779-5; Allen TM, 2019, NAT IMMUNOL, V20, P770, DOI 10.1038/s41590-019-0416-z; Bauer RA, 2015, DRUG DISCOV TODAY, V20, P1061, DOI 10.1016/j.drudis.2015.05.005; Chen WT, 2016, J AM CHEM SOC, V138, P7353, DOI 10.1021/jacs.6b02960; Chow KKH, 2013, MOL THER, V21, P629, DOI 10.1038/mt.2012.210; Coin I, 2013, CELL, V155, P1258, DOI 10.1016/j.cell.2013.11.008; De La Rochere P, 2018, TRENDS IMMUNOL, V39, P748, DOI 10.1016/j.it.2018.07.001; Dong HD, 1999, NAT MED, V5, P1365; Dong JJ, 2014, ANGEW CHEM INT EDIT, V53, P9430, DOI 10.1002/anie.201309399; Eigenbrot C, 2010, P NATL ACAD SCI USA, V107, P15039, DOI 10.1073/pnas.1005025107; Ekerljung L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049579; Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x; Jin CH, 2019, EBIOMEDICINE, V39, P173, DOI 10.1016/j.ebiom.2018.12.013; Johnson DS, 2010, FUTURE MED CHEM, V2, P949, DOI 10.4155/FMC.10.21; Kanduti Domen, 2016, Mater Sociomed, V28, P133, DOI 10.5455/msm.2016.28.133-137; Kaufman HL, 2016, LANCET ONCOL, V17, P1374, DOI 10.1016/S1470-2045(16)30364-3; Lan P, 2006, BLOOD, V108, P487, DOI 10.1182/blood-2005-11-4388; Lazar-Molnar E, 2017, EBIOMEDICINE, V17, P30, DOI 10.1016/j.ebiom.2017.02.004; Lee CM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-255; Lee JY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13354; Li CL, 2018, CANCER IMMUNOL RES, V6, P178, DOI 10.1158/2326-6066.CIR-17-0035; Li N, 2018, TRANSL ONCOL, V11, P11, DOI 10.1016/j.tranon.2017.10.009; Lin DYW, 2008, P NATL ACAD SCI USA, V105, P3011, DOI 10.1073/pnas.0712278105; Liu J, 2019, J AM CHEM SOC, V141, P9458, DOI 10.1021/jacs.9b01738; Lonsdale R, 2018, CHEM SOC REV, V47, P3816, DOI 10.1039/c7cs00220c; Mardiana S, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw2293; Maute RL, 2015, P NATL ACAD SCI USA, V112, pE6506, DOI 10.1073/pnas.1519623112; Newick K, 2017, ANNU REV MED, V68, P139, DOI 10.1146/annurev-med-062315-120245; Okazaki T, 2007, INT IMMUNOL, V19, P813, DOI 10.1093/intimm/dxm057; Orlova A, 2006, CANCER RES, V66, P4339, DOI 10.1158/0008-5472.CAN-05-3521; PLoS ONE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039314; Robertson JG, 2005, BIOCHEMISTRY-US, V44, P5561, DOI 10.1021/bi050247e; Rong ZL, 2014, CELL STEM CELL, V14, P121, DOI 10.1016/j.stem.2013.11.014; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Sanmamed MF, 2018, CELL, V175, P313, DOI 10.1016/j.cell.2018.09.035; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Sharpe AH, 2018, NAT REV IMMUNOL, V18, P153, DOI 10.1038/nri.2017.108; Shi H, 2018, J THORAC DIS, V10, P2779, DOI 10.21037/jtd.2018.04.91; Singh J, 2011, NAT REV DRUG DISCOV, V10, P307, DOI 10.1038/nrd3410; Syed YY, 2017, DRUGS, V77, P1369, DOI 10.1007/s40265-017-0782-5; Tan SG, 2016, PROTEIN CELL, V7, P866, DOI 10.1007/s13238-016-0337-7; Tang HD, 2016, CANCER CELL, V29, P285, DOI 10.1016/j.ccell.2016.02.004; Wang L, 2005, ANGEW CHEM INT EDIT, V44, P34, DOI 10.1002/anie.200460627; Wang L, 2001, SCIENCE, V292, P498, DOI 10.1126/science.1060077; Wang L, 2017, ACCOUNTS CHEM RES, V50, P2767, DOI 10.1021/acs.accounts.7b00376; Wang L, 2017, NEW BIOTECHNOL, V38, P16, DOI 10.1016/j.nbt.2016.10.003; Wang NX, 2018, J AM CHEM SOC, V140, P4995, DOI 10.1021/jacs.8b01087; Wege AK, 2018, BIODRUGS, V32, P245, DOI 10.1007/s40259-018-0275-4; Xiang Z, 2014, ANGEW CHEM INT EDIT, V53, P2190, DOI 10.1002/anie.201308794; Xiang Z, 2013, NAT METHODS, V10, P885, DOI [10.1038/nmeth.2595, 10.1038/NMETH.2595]; Xuan WM, 2017, ANGEW CHEM INT EDIT, V56, P5096, DOI 10.1002/anie.201611841; Yi ZZ, 2018, MOL THER-METH CLIN D, V9, P70, DOI 10.1016/j.omtm.2018.01.009; Zak KM, 2015, STRUCTURE, V23, P2341, DOI 10.1016/j.str.2015.09.010; Zarganes-Tzitzikas T, 2016, EXPERT OPIN THER PAT, V26, P973, DOI 10.1080/13543776.2016.1206527; Zhao TB, 2015, CELL STEM CELL, V17, P353, DOI 10.1016/j.stem.2015.07.021	55	54	56	20	96	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 9	2020	182	1					85	+		10.1016/j.cell.2020.05.028	http://dx.doi.org/10.1016/j.cell.2020.05.028			29	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	ML0RP	32579975	Bronze			2023-01-03	WOS:000549184500010
J	Suo, DQ; Wang, ZF; Li, L; Chen, QY; Zeng, TT; Liu, RY; Yun, JP; Guan, XY; Li, Y				Suo, Daqin; Wang, Zifeng; Li, Lei; Chen, Qingyun; Zeng, Tingting; Liu, Ranyi; Yun, Jingping; Guan, Xin-Yuan; Li, Yan			HOXC10 upregulation confers resistance to chemoradiotherapy in ESCC tumor cells and predicts poor prognosis	ONCOGENE			English	Article							GENE-EXPRESSION; DNA-REPAIR; CANCER; ACTIVATION; OVEREXPRESSION; CHEMOTHERAPY; INHIBITION; INVASION	Esophageal squamous cell carcinoma (ESCC) is a malignant disease and is a common cause of death in China. By performing an integrative study investigating public databases and clinical samples collected by our group, we found that HOXC10 (homeobox C10) is upregulated in ESCC tumor tissues compared with nontumor tissues and that the upregulation of HOXC10 is correlated with the poor prognosis of patients with ESCC. The enforced expression of HOXC10 promoted ESCC cell proliferation in vitro and in vivo. Our study revealed that HOXC10 could bind the promoter region of human Erb-b2 receptor tyrosine kinase 3 (ERBB3/HER3) and activate the PI3K/AKT pathway. In addition, by immunoprecipitation and mass spectrometry analysis, we found that HOXC10 could bind X-ray repair cross complementing 6 (Ku70) and accelerate the DNA repair mechanism via the nonhomologous end-joining (NHEJ) pathway. We further evaluated HOXC10 expression in ESCC patients receiving adjuvant radiotherapy or platinum-based chemotherapy. The results demonstrate that HOXC10 upregulation predicts the poor prognosis of ESCC patients receiving adjuvant radiotherapy or chemotherapy. Our study reveals that HOXC10 upregulation reflects the poor prognosis of ESCC patients and directs the selection of postoperative therapy regimens.	[Suo, Daqin; Wang, Zifeng; Li, Lei; Chen, Qingyun; Zeng, Tingting; Liu, Ranyi; Yun, Jingping; Guan, Xin-Yuan; Li, Yan] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China; [Li, Lei; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; University of Hong Kong	Guan, XY; Li, Y (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, Guangzhou, Peoples R China.; Guan, XY (corresponding author), Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China.	xyguan@hku.hk; liy6@mail.sysu.edu.cn		Li, Yan/0000-0002-8856-4083	National Key R&D Program of China [2017YFC1309000]; NSFC [81672357, 81871903, 81772554]; Open funds of State Key Laboratory of Oncology in South China [HN2019-06]	National Key R&D Program of China; NSFC(National Natural Science Foundation of China (NSFC)); Open funds of State Key Laboratory of Oncology in South China	This work was supported by National Key R&D Program of China (2017YFC1309000), NSFC (81672357, 81871903, and 81772554), and Open funds of State Key Laboratory of Oncology in South China (HN2019-06).	Akbas GE, 2004, BIOL REPROD, V70, P39, DOI 10.1095/biolreprod.102.014969; Bedenne L, 2007, J CLIN ONCOL, V25, P1160, DOI 10.1200/JCO.2005.04.7118; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cantile M, 2003, ONCOGENE, V22, P6462, DOI 10.1038/sj.onc.1206808; Cao MF, 2019, CANCER BIOL MED, V16, P595, DOI 10.20892/j.issn.2095-3941.2018.0277; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chu MC, 2004, CANCER BIOL THER, V3, P568, DOI 10.4161/cbt.3.6.848; CILLO C, 1992, INT J CANCER, V51, P892, DOI 10.1002/ijc.2910510610; Dai BW, 2019, J CANCER, V10, P4540, DOI 10.7150/jca.30645; Damia G, 2019, CANCERS, V11, DOI 10.3390/cancers11010119; de Stanchina E, 2000, J MOL BIOL, V299, P667, DOI 10.1006/jmbi.2000.3782; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; FAIELLA A, 1994, P NATL ACAD SCI USA, V91, P5335, DOI 10.1073/pnas.91.12.5335; Feng XY, 2015, MOL BIOSYST, V11, P2946, DOI 10.1039/c5mb00253b; Finn RS, 2019, CLIN CANCER RES, V19, P751; Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x; Hostikka SL, 2009, INT J BIOL SCI, V5, P397; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Jain AK, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.158360; Koyama FC, 2018, BRIT J SURG, V105, pE192, DOI 10.1002/bjs.10695; Lagergren J, 2017, LANCET, V390, P2383, DOI 10.1016/S0140-6736(17)31462-9; Leng X, 2019, ANN SURG, V12, P4932; Li JF, 2019, J WATER REUSE DESAL, V9, P1, DOI 10.2166/wrd.2017.019; Li S, 2017, ONCOTARGET, V8, P88974, DOI 10.18632/oncotarget.21634; Li Y, 2011, CANCER RES, V71, P6106, DOI 10.1158/0008-5472.CAN-10-4291; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Lin DC, 2018, GASTROENTEROLOGY, V154, P374, DOI 10.1053/j.gastro.2017.06.066; Ma J, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-105; Ma M, 2020, MOL CELL PROBE, V49, DOI 10.1016/j.mcp.2019.101491; Miwa T, 2019, ANN SURG ONCOL, V26, P1535, DOI 10.1245/s10434-019-07166-5; Nemoz C, 2018, NAT STRUCT MOL BIOL, V25, P971, DOI 10.1038/s41594-018-0133-6; Ohashi S, 2015, GASTROENTEROLOGY, V149, P1700, DOI 10.1053/j.gastro.2015.08.054; Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6; Ponz-Sarvise M, 2019, CLIN CANCER RES, V25, P11; Sadik H, 2016, CANCER RES, V76, P4443, DOI 10.1158/0008-5472.CAN-16-0774; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; Takahashi O, 2007, ONCOL REP, V17, P753; Tan ZY, 2018, THERANOSTICS, V8, P5143, DOI 10.7150/thno.27310; Tang XL, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00557; Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430; Waltregny D, 2002, PROSTATE, V50, P162, DOI 10.1002/pros.10045; Wang C, 2013, INT J RADIAT ONCOL, V86, P440, DOI 10.1016/j.ijrobp.2013.01.011; Wang XC, 2019, CLIN CANCER RES, V25, P4567, DOI 10.1158/1078-0432.CCR-18-3735; Yan T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09255-1; Yang G, 2018, NUCLEIC ACIDS RES, V46, P3446, DOI 10.1093/nar/gky088; Yang H, 2018, J CLIN ONCOL, V36, P2796, DOI 10.1200/JCO.2018.79.1483; Yao S, 2018, BIOCHEM BIOPH RES CO, V501, P628, DOI 10.1016/j.bbrc.2018.05.019; Zhang LZ, 2017, CHINESE J CANCER RES, V29, P149, DOI 10.21147/j.issn.1000-9604.2017.02.08	50	20	20	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5441	5454		10.1038/s41388-020-1375-4	http://dx.doi.org/10.1038/s41388-020-1375-4		JUN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	32587398				2023-01-03	WOS:000543299500001
J	Apidechkul, T; Chomchoei, C; Wongnuch, P; Tamornpark, R; Upala, P; Yeemard, F; Poomiphak, M; Nongkhai, N; Nachaiwieng, W; Sunsern, R				Apidechkul, Tawatchai; Chomchoei, Chalitar; Wongnuch, Pilasinee; Tamornpark, Ratipark; Upala, Panupong; Yeemard, Fartima; Poomiphak, Marisa; Nongkhai, Na; Nachaiwieng, Woottichai; Sunsern, Rachanee			Associations of childhood experiences and methamphetamine use among Akha and Lahu hill tribe youths in northern Thailand: A cross-sectional study	PLOS ONE			English	Article							AMPHETAMINE USE; INITIATION	Background Methamphetamine (MA) is a commonly used substance among youths, particularly those who are living in poor economic conditions with low levels of education and who have had bad childhood experiences. The Akha and Lahu hill tribe youths living on the Thailand-Myanmar-Laos border are identified as the group most vulnerable to MA use in Thailand. The study aimed to estimate the prevalence of MA use and determine its associations with childhood experiences among Akha and Lahu youths aged 15-24 years in northern Thailand. Methods A cross-sectional study was performed. Validated and sealed questionnaires were used to gather information from participants after obtaining the informed consent form. Questionnaires were completed by participants and their parents at home. Logistic regression was used to identify the associations between variables at the alpha = 0.05 level. Results A total of 710 participants participated in the study: 54.2% were Akha, 52.5% were females, 50.6% were aged 15-17 years, and 11.4% did not have Thai identification card (ID) cards. The overall prevalence of MA use at least once among Akha and Lahu youths was 14.5%. After controlling for all potential confounding factors, 8 variables were found to be associated with MA use. Males had a greater chance of MA use than females (AOR = 4.75; 95% CI = 2.27-9.95). Participants aged 21-24 years had a greater chance of MA use than those aged 15-17 years (AOR = 2.51; 95% CI = 1.11-5.71). Those who had a family member who used MA had a greater chance of MA use than those who did not (AOR = 5.04; 95% CI = 1.66-15.32). Those who had been physically assaulted by a family member while aged 0-5 years had a greater chance of MA use than those who had not (AOR = 2.29; 95% CI = 1.02-5.12). Those who had been physically assaulted by a family member while aged 6-14 years had a greater chance of MA use than those who had not (AOR = 3.15; 95% CI = 1.32-7.54). Those who had a close friend who used alcohol had a greater chance of MA use than those who did not (AOR = 2.24; 95% CI = 1.24-4.72). Those who had a highly confident personality had a greater chance of MA use than those who did not (AOR = 2.35; 95% CI = 1.17-4.69), and those who smoked had a greater chance of MA use than those who did not (AOR = 8.27; 95% CI = 4.42-15.46). Conclusions All relevant government and nongovernment agencies together with the Ministry of Public Health Thailand should address MA use among Akha and Lahu youths by properly developing a community health intervention that lowers risk of MA use by addressing family relationships, male youth behaviors, and focused on those individuals with a highly confident personality.	[Apidechkul, Tawatchai; Tamornpark, Ratipark; Upala, Panupong; Yeemard, Fartima] Mae Fah Luang Univ, Ctr Excellence Hill Tribe Hlth Res, Chiang Rai, Thailand; [Apidechkul, Tawatchai; Wongnuch, Pilasinee; Nongkhai, Na; Nachaiwieng, Woottichai; Sunsern, Rachanee] Mae Fah Luang Univ, Sch Hlth Sci, Chiang Rai, Thailand; [Chomchoei, Chalitar] Chulabhorn Royal Acad, Bangkok, Thailand	Mae Fah Luang University; Mae Fah Luang University; Chulabhorn Royal Academy	Apidechkul, T (corresponding author), Mae Fah Luang Univ, Ctr Excellence Hill Tribe Hlth Res, Chiang Rai, Thailand.; Apidechkul, T (corresponding author), Mae Fah Luang Univ, Sch Hlth Sci, Chiang Rai, Thailand.	Tawatchai.api@mfu.ac.th		Apidechkul, Tawatchai/0000-0001-8301-2055	National Research Council of Thailand (NRCT) [29/2561]; Center of Excellence for the Hill Tribe Health Research	National Research Council of Thailand (NRCT)(National Research Council of Thailand (NRCT)); Center of Excellence for the Hill Tribe Health Research	Funding was provided by the National Research Council of Thailand (NRCT) (Grant No.29/2561). NRCT has no role and involving any step of conducting this research.; We would like to thank the National Research Council of Thailand (NRCT), Mae Fah Luang University (MFU), and The Center of Excellence for the Hill Tribe Health Research in support grant for doing this project. We also would like to extend our thank to community leaders and participants in their cooperation along the process of data collection.	Alcohol and Drug Abuse Institute (ADAI) University of Washington United State, 2018, METH WASH; [Anonymous], 2019, CANC DISCOV, V9, pOF3, DOI 10. 1158/2159-8290. CD-NB2018-158; Apidechkul T., 2016, J PUB HLTH DEV, V14, P77; Arya R, 2012, INDIAN J PEDIATR, V79, P1482, DOI 10.1007/s12098-012-0763-3; ASEAN Narcotics Cooperation Center, 2017, ASEAN DRUG MON REP; Bethell C, 2019, JAMA PEDIATR, V173, DOI 10.1001/jamapediatrics.2019.3007; Branstetter SA, 2011, J SUBST USE, V16, P150, DOI 10.3109/14659891.2010.519421; Brecht ML, 2013, J DRUG ISSUES, V43, P468, DOI 10.1177/0022042613491098; Cacia R, 2019, METHAMPHETAMINE USE; Chan GCK, 2019, DRUG ALCOHOL DEPEN, V194, P121, DOI 10.1016/j.drugalcdep.2018.08.042; Chomchoei C, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-7226-y; Chomsri P, 2017, NURSING J, V44, P172; Chooi WT, 2017, J PSYCHOACTIVE DRUGS, V49, P326, DOI 10.1080/02791072.2017.1342152; Darke S, 2008, DRUG ALCOHOL REV, V27, P253, DOI 10.1080/09595230801923702; Department of Mental Health Ministry of Public Health, 2019, BEH YOUTHS THAIL; DiMiceli LE, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-2851-1; Ding YY, 2014, DRUG ALCOHOL DEPEN, V142, P295, DOI 10.1016/j.drugalcdep.2014.06.042; Dluzen DE, 2008, GENDER MED, V5, P24, DOI 10.1016/S1550-8579(08)80005-8; Drug Policy Research Center, 2005, EC COST METHAMPHETAM; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Galbraith N, 2015, BJPSYCH BULL, V39, P218, DOI 10.1192/pb.bp.115.050930; Guyll M, 2011, J STUD ALCOHOL DRUGS, V72, P577, DOI 10.15288/jsad.2011.72.577; Lukas H, SE ASIAN HILL TRIBES, P2017; Ma CH, 2020, J FORMOS MED ASSOC, V119, P735, DOI 10.1016/j.jfma.2019.08.026; Mburu G, 2019, INT J DRUG POLICY, V74, P136, DOI 10.1016/j.drugpo.2019.09.010; Nacotics Control Management Center Ministry of Public Health, METH TREATM PROJ; Pedersen W, 2015, DEVIANT BEHAV, V36, P146, DOI 10.1080/01639625.2014.923272; Peltzer K, 2017, CENT ASIAN J GLOB HE, V6, DOI 10.5195/cajgh.2017.288; Princess Maha Chakri Siridhorn Anthropology center, HILL TRIB; Rungnirundorn T, 2017, J ADDICT MED, V11, P19, DOI 10.1097/ADM.0000000000000262; Russell K, 2008, BMC PEDIATR, V8, DOI 10.1186/1471-2431-8-48; Saw YM, 2017, HARM REDUCT J, V14, DOI 10.1186/s12954-017-0147-0; Sege RD, 2017, ACAD PEDIATR, V17, pS79, DOI 10.1016/j.acap.2017.03.007; Sherman SG, 2008, J ADOLESCENT HEALTH, V42, P36, DOI 10.1016/j.jadohealth.2007.07.002; Stoneberg DM, 2018, INT CRIM JUSTICE REV, V28, P136, DOI 10.1177/1057567717730104; Substance Abuse and Mental Health Services Administration, 2015, NAT SURV DRUG US HLT; The Hill Tribe Welfare and Development Center, 2018, HILL TRIB POP HILL T, P23; The Narcotic Control Management Center Ministry of Public Health, TRENDS DRUGS 2019; The Transnational Institute, METH MYANM THAIL SO; Toeam A, 2016, THAI RED CROSS NURSI, V9, P88; UCL Institute of Health Equality, IMP ADV EXP HOM HLTH; United Nations, DEF YOUTH; United Nations Country Team in Thailand, THAIL COMM COUNTR AS; United Nations Office on Drugs and Crime, 2018, WORLD DRUG REP; Watt MH, 2014, INT J DRUG POLICY, V25, P219, DOI 10.1016/j.drugpo.2013.10.007; Weinberger AH, 2016, PREV MED, V92, P148, DOI 10.1016/j.ypmed.2016.05.011; World Health Organization (WHO), THAIL 2015 GLOB SCH; Zarrouq B, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3143-5; 2012, SURG OBES RELAT DIS, V8	49	7	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 18	2020	15	6							e0234923	10.1371/journal.pone.0234923	http://dx.doi.org/10.1371/journal.pone.0234923			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MC4QJ	32555604	gold, Green Published			2023-01-03	WOS:000543273200035
J	Minard-Colin, V; Auperin, A; Pillon, M; Burke, GAA; Barkauskas, DA; Wheatley, K; Delgado, RF; Alexander, S; Uyttebroeck, A; Bollard, CM; Zsiros, J; Csoka, M; Kazanowska, B; Chiang, AK; Miles, RR; Wotherspoon, A; Adamson, PC; Vassal, G; Patte, C; Gross, TG				Minard-Colin, Veronique; Auperin, Anne; Pillon, Marta; Burke, G. A. Amos; Barkauskas, Donald A.; Wheatley, Keith; Delgado, Rafael F.; Alexander, Sarah; Uyttebroeck, Anne; Bollard, Catherine M.; Zsiros, Jozsef; Csoka, Monika; Kazanowska, Bernarda; Chiang, Alan K.; Miles, Rodney R.; Wotherspoon, Andrew; Adamson, Peter C.; Vassal, Gilles; Patte, Catherine; Gross, Thomas G.		European Intergrp Childhood Non-Ho	Rituximab for High-Risk, Mature B-Cell Non-Hodgkin's Lymphoma in Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRIMARY MALIGNANCIES; ADOLESCENTS; INTERMEDIATE; LEUKEMIA; BFM; AL	BACKGROUND Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin's lymphoma are limited. METHODS We conducted an open-label, international, randomized, phase 3 trial involving patients younger than 18 years of age with high-risk, mature B-cell non-Hodgkin's lymphoma (stage III with an elevated lactate dehydrogenase level or stage IV) or acute leukemia to compare the addition of six doses of rituximab to standard lymphomes malins B (LMB) chemotherapy with standard LMB chemotherapy alone. The primary end point was event-free survival. Overall survival and toxic effects were also assessed. RESULTS Analyses were based on 328 patients who underwent randomization (164 patients per group); 85.7% of the patients had Burkitt's lymphoma. The median follow-up was 39.9 months. Events were observed in 10 patients in the rituximab-chemotherapy group and in 28 in the chemotherapy group. Event-free survival at 3 years was 93.9% (95% confidence interval [CI], 89.1 to 96.7) in the rituximab-chemotherapy group and 82.3% (95% CI, 75.7 to 87.5) in the chemotherapy group (hazard ratio for primary refractory disease or first occurrence of progression, relapse after response, death from any cause, or second cancer, 0.32; 95% CI, 0.15 to 0.66; one-sided P=0.00096, which reached the significance level required for this analysis). Eight patients in the rituximab-chemotherapy group died (4 deaths were disease-related, 3 were treatment-related, and 1 was from a second cancer), as did 20 in the chemotherapy group (17 deaths were disease-related, and 3 were treatment-related) (hazard ratio, 0.36; 95% CI, 0.16 to 0.82). The incidence of acute adverse events of grade 4 or higher after prephase treatment was 33.3% in the rituximab-chemotherapy group and 24.2% in the chemotherapy group (P=0.07); events were related mainly to febrile neutropenia and infection. Approximately twice as many patients in the rituximab-chemotherapy group as in the chemotherapy group had a low IgG level 1 year after trial inclusion. CONCLUSIONS Rituximab added to standard LMB chemotherapy markedly prolonged event-free survival and overall survival among children and adolescents with high-grade, high-risk, mature B-cell non-Hodgkin's lymphoma and was associated with a higher incidence of hypogammaglobulinemia and, potentially, more episodes of infection.	[Minard-Colin, Veronique; Patte, Catherine] Univ Paris Saclay, Gustave Roussy, Dept Pediat & Adolescent Oncol, Villejuif, France; [Vassal, Gilles] Univ Paris Saclay, Gustave Roussy, Dept Clin Res, Villejuif, France; [Minard-Colin, Veronique] Univ Paris Saclay, Gustave Roussy, INSERM, Unite 1015, Villejuif, France; [Auperin, Anne] Univ Paris Saclay, Gustave Roussy, Unit Biostat & Epidemiol, Villejuif, France; [Auperin, Anne] Univ Paris Saclay, Gustave Roussy, INSERM, Unite 1018, Villejuif, France; [Pillon, Marta] Univ Padua, Dept Pediat Hematol & Oncol, Padua, Italy; [Burke, G. A. Amos] Cambridge Univ Hosp NHS Fdn Trust, Dept Paediat Haematol Oncol & Palliat Care, Addenbrookes Hosp, Cambridge, England; [Wheatley, Keith] Univ Birmingham, Canc Res UK Clin Trials Unit, Inst Canc & Genom Sci, Coll Med & Dent Sci, Birmingham, W Midlands, England; [Wotherspoon, Andrew] Royal Marsden NHS Fdn Trust, Dept Histopathol, London, England; [Barkauskas, Donald A.] Univ Southern Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90007 USA; [Delgado, Rafael F.] Univ Valencia, Dept Pediat Hematol & Oncol, Valencia, Spain; [Alexander, Sarah] Hosp Sick Children, Div Haematol Oncol, Toronto, ON, Canada; [Uyttebroeck, Anne] Univ Hosp Leuven, Dept Pediat Hematol & Oncol, Leuven, Belgium; [Bollard, Catherine M.] Childrens Natl Hlth Syst, Ctr Canc & Immunol Res, Washington, DC USA; [Bollard, Catherine M.] George Washington Univ, Washington, DC USA; [Zsiros, Jozsef] Princess Maxima Ctr Pediat Oncol, Utrecht, Netherlands; [Csoka, Monika] Semmelweis Univ, Dept Pediat Hematol & Oncol, Budapest, Hungary; [Kazanowska, Bernarda] Wroclaw Med Univ, Dept Pediat Bone Marrow Transplantat Oncol & Hema, Wroclaw, Poland; [Chiang, Alan K.] Univ Hong Kong, Dept Pediat & Adolescent Med, Li Ka Shing Fac Med, Queen Mary Hosp, Hong Kong, Peoples R China; [Miles, Rodney R.] Univ Utah, Dept Pathol, Salt Lake City, UT USA; [Adamson, Peter C.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; [Gross, Thomas G.] NCI, Ctr Global Hlth, Rockville, MD USA	UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; University of Padua; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cancer Research UK; University of Birmingham; Royal Marsden NHS Foundation Trust; University of Southern California; University of Valencia; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); KU Leuven; University Hospital Leuven; Children's National Health System; George Washington University; Semmelweis University; Wroclaw Medical University; University of Hong Kong; Utah System of Higher Education; University of Utah; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Minard-Colin, V (corresponding author), Gustave Roussy, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	veronique.minard@gustaveroussy.fr	Csoka, Monika/AAT-8832-2021; Burke, Amos/AAT-1358-2021; Pillon, Marta/AAB-9581-2022; Astigarraga, I/I-1215-2014	Burke, Amos/0000-0003-2671-9972; Pillon, Marta/0000-0002-1190-3198; Astigarraga, I/0000-0002-5012-0137; Razzouk, Bassem/0000-0003-0536-6135; paillard, catherine/0000-0003-1662-5446; Kram, David/0000-0002-1928-001X; LENDINEZ-MOLINOS, FRANCISCO/0000-0002-1597-636X; Kazanowska, Bernarda/0000-0002-7198-9122; Bollard, Catherine M./0000-0001-5140-9090; Nagasubramanian, Ramamoorthy/0000-0003-4629-3139; dandapani, madhumita/0000-0001-8444-6007; Reis, AlessanRSS/0000-0001-8486-7469; Minard-Colin, Veronique/0000-0002-0296-5207	Clinical Research Hospital Program of the French Ministry of Health [PHRC2010]; Cancer Research UK; Clinical Research Hospital Program of the French Ministry of Health; National Institute for Health Research Clinical Research Network; Children's Cancer Foundation Hong Kong; U.S. National Cancer Institute [U10CA180886, U10CA180899]; F. Hoffmann-La RocheGenentech	Clinical Research Hospital Program of the French Ministry of Health; Cancer Research UK(Cancer Research UK); Clinical Research Hospital Program of the French Ministry of Health; National Institute for Health Research Clinical Research Network; Children's Cancer Foundation Hong Kong; U.S. National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); F. Hoffmann-La RocheGenentech(Hoffmann-La RocheRoche HoldingGenentech)	Supported by a grant (PHRC2010) from the Clinical Research Hospital Program of the French Ministry of Health, by Cancer Research UK, the National Institute for Health Research Clinical Research Network, and Children's Cancer Foundation Hong Kong, by grants (U10CA180886 and U10CA180899) from the U.S. National Cancer Institute, and by F. Hoffmann-La RocheGenentech.	[Anonymous], 2019, INT J GYNECOL CANCER, V29(Suppl4, pA1; Barth MJ, 2013, BRIT J HAEMATOL, V162, P678, DOI 10.1111/bjh.12434; Cairo MS, 2007, BLOOD, V109, P2736, DOI 10.1182/blood-2006-07-036665; DEMETS DL, 1994, STAT MED, V13, P1341, DOI 10.1002/sim.4780131308; Ehrhardt MJ, 2019, J CLIN ONCOL, V37, P2556, DOI 10.1200/JCO.19.00525; Fleury I, 2016, ANN ONCOL, V27, P390, DOI 10.1093/annonc/mdv616; Goldman S, 2013, LEUKEMIA, V27, P1174, DOI 10.1038/leu.2012.255; Havelange V, 2016, BRIT J HAEMATOL, V173, P137, DOI 10.1111/bjh.13925; Kusumoto S, 2019, BLOOD, V133, P137, DOI 10.1182/blood-2018-04-848044; Lopez C, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08578-3; Meinhardt A, 2010, J CLIN ONCOL, V28, P3115, DOI 10.1200/JCO.2009.26.6791; Minard-Colin V, 2011, ANN ONCOL, V22, P112; Minard-Colin V, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.10507; Minard-Colin V, 2015, J CLIN ONCOL, V33, P2963, DOI 10.1200/JCO.2014.59.5827; Patte C, 2007, BLOOD, V109, P2773, DOI 10.1182/blood-2006-07-036673; Patte C, 2010, PEDIATR BLOOD CANCER, V55, P795; Pearson ADJ, 2019, EUR J CANCER, V110, P74, DOI 10.1016/j.ejca.2019.01.013; Ribrag V, 2016, LANCET, V387, P2402, DOI 10.1016/S0140-6736(15)01317-3; Tao L, 2017, BRIT J HAEMATOL, V178, P72, DOI 10.1111/bjh.14638; Tout M, 2017, BLOOD, V129, P2616, DOI 10.1182/blood-2016-10-744292; Woessmann W, 2005, BLOOD, V105, P948, DOI 10.1182/blood-2004-03-0973	21	66	70	3	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 4	2020	382	23					2207	2219		10.1056/NEJMoa1915315	http://dx.doi.org/10.1056/NEJMoa1915315			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV0NI	32492302	Green Accepted, Bronze			2023-01-03	WOS:000538140600014
J	von Dach, E; Albrich, WC; Brunel, AS; Prendki, V; Cuvelier, C; Flury, D; Gayet-Ageron, A; Huttner, B; Kohler, P; Lemmenmeier, E; McCallin, S; Rossel, A; Harbarth, S; Kaiser, L; Bochud, PY; Huttner, A				von Dach, Elodie; Albrich, Werner C.; Brunel, Anne-Sophie; Prendki, Virginie; Cuvelier, Clemence; Flury, Domenica; Gayet-Ageron, Angele; Huttner, Benedikt; Kohler, Philipp; Lemmenmeier, Eva; McCallin, Shawna; Rossel, Anne; Harbarth, Stephan; Kaiser, Laurent; Bochud, Pierre-Yves; Huttner, Angela			Effect of C-Reactive Protein-Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative Bacteremia: A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROCALCITONIN; MULTICENTER; THERAPY; INFECTION; SEPSIS	Key PointsQuestionDoes antibiotic treatment with C-reactive protein (CRP)-guided duration or fixed 7-day duration, compared with fixed 14-day duration, provide noninferior clinical failure rates in patients with uncomplicated gram-negative bacteremia? FindingsIn this randomized clinical trial that included 504 adults with uncomplicated gram-negative bacteremia, 30-day clinical failure occurred in 2.4% of patients assigned to receive CRP-guided antibiotic treatment duration, 6.6% assigned to 7-day treatment, and 5.5% assigned to 14-day treatment. The differences between CRP-guided treatment and 7-day treatment compared with 14-day treatment met the noninferiority criterion of 10%, but adherence to the CRP strategy or planned follow-up did not occur in 23% of patients. MeaningCRP-guided treatment and 7-day treatment were noninferior to 14-day treatment in patients with uncomplicated gram-negative bacteremia, but interpretation is limited by the large noninferiority margin compared with the low observed event rate and lower adherence in the CRP-guided group. ImportanceAntibiotic overuse drives antibiotic resistance. Gram-negative bacteremia is a common infection that results in substantial antibiotic use. ObjectiveTo compare the clinical effectiveness of C-reactive protein (CRP)-guided, 7-day, and 14-day antibiotic durations 30, 60, and 90 days after treatment initiation. Design, Setting, and ParticipantsMulticenter, noninferiority, point-of-care randomized clinical trial including adults hospitalized with gram-negative bacteremia conducted in 3 Swiss tertiary care hospitals between April 2017 and May 2019, with follow-up until August 2019. Patients and physicians were blinded between randomization and antibiotic discontinuation. Adults (aged >= 18 years) were eligible for randomization on day 5 (1 d) of microbiologically efficacious therapy for fermenting, gram-negative bacteria in blood culture(s) if they were afebrile for 24 hours without evidence for complicated infection (eg, abscess) or severe immunosuppression. InterventionRandomization in a 1:1:1 ratio to an individualized CRP-guided antibiotic treatment duration (discontinuation once CRP declined by 75% from peak; n=170), fixed 7-day treatment duration (n=169), or fixed 14-day treatment duration (n=165). Main Outcomes and MeasuresThe primary outcome was the clinical failure rate at day 30, defined as the presence of at least 1 of the following, with a non-inferiority margin of 10%: recurrent bacteremia, local suppurative complication, distant complication (growth of the same organism causing the initial bacteremia), restarting gram-negative-directed antibiotic therapy due to clinical worsening suspected to be due to the initial organism, or death due to any cause. Secondary outcomes included the clinical failure rate on day 90 of follow-up. ResultsAmong 504 patients randomized (median [interquartile range] age, 79 [68-86] years; 306 of 503 [61%] were women), 493 (98%) completed 30-day follow-up and 448 (89%) completed 90-day follow-up. Median antibiotic duration in the CRP group was 7 (interquartile range, 6-10; range, 5-28) days; 34 of the 164 patients (21%) who completed the 30-day follow-up had protocol violations related to treatment assignment. The primary outcome occurred in 4 of 164 (2.4%) patients in the CRP group, 11 of 166 (6.6%) in the 7-day group, and 9 of 163 (5.5%) in the 14-day group (difference in CRP vs 14-day group, -3.1% [1-sided 97.5% CI, -infinity to 1.1]; P<.001; difference in 7-day vs 14-day group, 1.1% [1-sided 97.5% CI, -<infinity> to 6.3]; P<.001). By day 90, clinical failure occurred in 10 of 143 patients (7.0%) in the CRP group, 16 of 151 (10.6%) in the 7-day group, and 16 of 153 (10.5%) in the 14-day group. Conclusions and RelevanceAmong adults with uncomplicated gram-negative bacteremia, 30-day rates of clinical failure for CRP-guided antibiotic treatment duration and fixed 7-day treatment were noninferior to fixed 14-day treatment. However, interpretation is limited by the large noninferiority margin compared with the low observed event rate, as well as low adherence and wide range of treatment durations in the CRP-guided group. Trial RegistrationClinicalTrials.gov Identifier: NCT03101072 This randomized trial compares the effects of C-reactive protein (CRP)-guided antibiotic duration (discontinuation once CRP declined by 75% of peak value) vs fixed 7- vs 14-day durations on 30-day clinical failure rate among patients with gram-negative bacteremia.	[von Dach, Elodie; Huttner, Benedikt; McCallin, Shawna; Harbarth, Stephan; Kaiser, Laurent; Huttner, Angela] Geneva Univ Hosp, Fac Med, Div Infect Dis, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland; [von Dach, Elodie; Gayet-Ageron, Angele] Geneva Univ Hosp, Fac Med, Clin Res Ctr, Geneva, Switzerland; [Albrich, Werner C.; Flury, Domenica; Kohler, Philipp; Lemmenmeier, Eva] Cantonal Hosp St Gallen, Div Infect Dis & Hosp Epidemiol, St Gallen, Switzerland; [Brunel, Anne-Sophie; Bochud, Pierre-Yves] Univ Lausanne, Univ Hosp, Infect Dis Serv, Lausanne, Switzerland; [Prendki, Virginie; Cuvelier, Clemence] Geneva Univ Hosp, Fac Med, Div Internal Med Aged, Geneva, Switzerland; [Gayet-Ageron, Angele] Geneva Univ Hosp, Dept Hlth & Community Med, Div Clin Epidemiol, Geneva, Switzerland; [Rossel, Anne] Geneva Univ Hosp, Dept Internal Med, Geneva, Switzerland	University of Geneva; University of Geneva; Kantonsspital St. Gallen; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Geneva; University of Geneva; University of Geneva	Huttner, A (corresponding author), Geneva Univ Hosp, Fac Med, Div Infect Dis, Rue Gabrielle Perret Gentil 4, CH-1205 Geneva, Switzerland.	angela.huttner@hcuge.ch	Prendki, Virginie/ABI-1378-2020; Huttner, Benedikt/M-5616-2014; Rossel, Anne/GQI-2225-2022; Bochud, Pierre-Yves/ABE-5979-2020	Huttner, Benedikt/0000-0002-1749-9464; Bochud, Pierre-Yves/0000-0002-2208-4757; Kaiser, Laurent/0000-0002-0857-2252; Gayet-Ageron, Angele/0000-0002-6164-9693; Kohler, Philipp/0000-0003-0427-8934; Rossel, Anne/0000-0001-7367-2340	National Science Foundation (National Research Program 74 "Smarter Health Care" grant) [407440_167359]	National Science Foundation (National Research Program 74 "Smarter Health Care" grant)(National Science Foundation (NSF))	The study was funded by the Swiss National Science Foundation (National Research Program 74 "Smarter Health Care" grant No. 407440_167359).	Albrich WC, 2015, INTENS CARE MED, V41, P1739, DOI 10.1007/s00134-015-3978-8; Angus DC, 2016, CRIT CARE MED, V44, pE113, DOI 10.1097/CCM.0000000000001730; Bell BG, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-13; Bouadma L, 2010, LANCET, V375, P463, DOI 10.1016/S0140-6736(09)61879-1; Chotiprasitsakul D, 2018, CLIN INFECT DIS, V66, P172, DOI 10.1093/cid/cix767; de Jong E, 2016, LANCET INFECT DIS, V16, P819, DOI 10.1016/S1473-3099(16)00053-0; Fitzpatrick JM, 2016, CLIN MICROBIOL INFEC, V22, P244, DOI 10.1016/j.cmi.2015.10.034; Fuchs BB, 2018, FUTURE MICROBIOL, V13, P1537, DOI 10.2217/fmb-2018-0157; Huttner A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017996; Laupland KB, 2013, CLIN MICROBIOL INFEC, V19, P492, DOI 10.1111/1469-0691.12144; Lin KH, 2014, DIAGN MICR INFEC DIS, V80, P72, DOI 10.1016/j.diagmicrobio.2014.03.029; Oliveira CF, 2013, CRIT CARE MED, V41, P2336, DOI 10.1097/CCM.0b013e31828e969f; PITTET D, 1993, EUR J CLIN MICROBIOL, V12, P813, DOI 10.1007/BF02000400; Sandberg T, 2012, LANCET, V380, P484, DOI 10.1016/S0140-6736(12)60608-4; Spellberg B, 2012, CLIN INFECT DIS, V55, P1031, DOI 10.1093/cid/cis688; Tellier G, 2004, J ANTIMICROB CHEMOTH, V54, P515, DOI 10.1093/jac/dkh356; US Food and Drug Administration, 2016, GUID IND COLL RAC ET; Ward Caroline, 2018, BMJ Open Qual, V7, pe000391, DOI 10.1136/bmjoq-2018-000391; Yahav D, 2019, CLIN INFECT DIS, V69, P1091, DOI 10.1093/cid/ciy1054	19	63	63	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2020	323	21					2160	2169		10.1001/jama.2020.6348	http://dx.doi.org/10.1001/jama.2020.6348			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY8YS	32484534	Green Published, Bronze			2023-01-03	WOS:000540816000020
J	Agniel, D; Haviland, A; Shekelle, P; Scherling, A; Damberg, CL				Agniel, Denis; Haviland, Amelia; Shekelle, Paul; Scherling, Adam; Damberg, Cheryl L.			Distinguishing High-Performing Health Systems Using a Composite of Publicly Reported Measures of Ambulatory Care	ANNALS OF INTERNAL MEDICINE			English	Article							LEAGUE TABLES; QUALITY; PAY	Background: Payers and policymakers are rewarding high-performing health care providers on the basis of summaries of overall quality performance, and the methods they use for measuring performance are increasingly important. Objective: To develop and evaluate a measure that ranks health care systems by ambulatory care quality. Design: Systems were ranked using a composite model that summarizes individual measures of quality, accounts for their correlation, and does not require health care systems to report every measure. The composite measure's suitability was evaluated by examining whether it captured the quality indicated by component measures (validity), whether differences in rank between health care systems were larger than statistical noise (reliability), and whether year-to-year changes in rank were small (stability). Setting: California and Minnesota, 2014 to 2016. Participants: 55 health care systems. Measurements: Publicly reported measures of ambulatory care quality. Results: The composite measure was valid in that it was broadly representative of the component measures and was not dominated by any single measure. The measure was reliable because the ranks for 93% of California systems and 80% of Minnesota systems were unlikely to be more than 2 places lower or higher. The measure was stable because fewer than half of systems changed ranks by more than 2 ranks from year to year. Limitation: The analysis is limited to available measures of ambulatory care quality and includes only 2 states. Conclusion: This composite measure uses publicly reported data to produce valid, reliable, and stable ranks of ambulatory care quality for health care systems in Minnesota and California, and this approach could be used in other applications.	[Agniel, Denis; Shekelle, Paul; Scherling, Adam; Damberg, Cheryl L.] RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA; [Agniel, Denis] Harvard Med Sch, Boston, MA 02115 USA; [Haviland, Amelia] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA; [Shekelle, Paul] West Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA	RAND Corporation; Harvard University; Harvard Medical School; Carnegie Mellon University; US Department of Veterans Affairs; Veterans Health Administration (VHA); West Los Angeles VA Medical Center	Agniel, D (corresponding author), RAND Corp, 1776 Main St, Santa Monica, CA 90401 USA.	dagniel@rand.org			Agency for Healthcare Research and Quality	Agency for Healthcare Research and Quality(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)	Agency for Healthcare Research and Quality.	Adams JL, 2010, NEW ENGL J MED, V362, P1014, DOI 10.1056/NEJMsa0906323; Agresti A., 2013, CATEGORICAL DATA ANA; [Anonymous], 2019, EMB HLTH; Cefalu MS, 2019, HEALTH SERV RES, V54, P502, DOI 10.1111/1475-6773.13056; Friedberg MW, 2012, HEALTH AFFAIR, V31, P612, DOI 10.1377/hlthaff.2011.1202; Fung CH, 2008, ANN INTERN MED, V148, P111, DOI 10.7326/0003-4819-148-2-200801150-00006; Galewitz P, 2020, KAISER HLTH NEWS; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; Goldstein H, 2014, ANNU REV STAT APPL, V1, P385, DOI 10.1146/annurev-statistics-022513-115615; Integrated Healthcare Association, 2020, MEAS YEAR 2017 INT H; Kocher R, 2011, NEW ENGL J MED, V364, P1790, DOI 10.1056/NEJMp1101959; LAIRD NM, 1989, J EDUC STAT, V14, P29, DOI 10.2307/1164724; Landrum MB, 2000, HLTH SERVICES OUTCOM, V1, P23, DOI [10.1023/A:1010093701870, DOI 10.1023/A:1010093701870]; Layton TJ, 2015, HEALTH SERV RES, V50, P1810, DOI 10.1111/1475-6773.12409; Lin RH, 2009, HEALTH SERV OUTCOME, V9, P22, DOI 10.1007/s10742-008-0040-0; Lindenauer PK, 2007, NEW ENGL J MED, V356, P486, DOI 10.1056/NEJMsa064964; Muhlestein DB, 2016, HEALTH AFFAIR, V35, P1638, DOI 10.1377/hlthaff.2016.0130; Nerenz DR, 2020, AM J MED QUAL, V35, P46, DOI 10.1177/1062860619840725; Normand SLT, 2016, ANNU REV STAT APPL, V3, P21, DOI 10.1146/annurev-statistics-022513-115617; Teixeira-Pinto A, 2008, STAT MED, V27, P1329, DOI 10.1002/sim.3187; Tsiatis Anastasios A, 2007, Stat Sci, V22, P569, DOI 10.1214/07-STS227B; Xu T, 2015, JAMA-J AM MED ASSOC, V314, P1337, DOI 10.1001/jama.2015.7492	22	3	3	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 17	2020	173	10					791	+		10.7326/M20-0718	http://dx.doi.org/10.7326/M20-0718			30	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OU5XD	32956603				2023-01-03	WOS:000591600700014
J	Park, A; Kim, S; Jung, IH; Byun, JH				Park, Anna; Kim, Sangil; Jung, Il Hyo; Byun, Jong Hyuk			An immune therapy model for effective treatment on inflammatory bowel disease	PLOS ONE			English	Article							CROHNS-DISEASE; NECROSIS-FACTOR; T-CELLS; INTERLEUKIN-10; CYTOKINES; PATHOGENESIS; IL-10	Inflammatory bowel disease (IBD) is a disease that causes inflammation throughout the digestive tract. Repeated inflammation and frequent relapses cause intestinal damage and expose the patient to a higher risk. In this work, we proposed an immune therapy model for effective treatment strategy through mathematical modeling for patients with IBD. We evaluated the ability of the patient's immune system to recover during treatment. For this, we defined the interval of healthy individual, and examined the frequency of compartments such as T cells and cytokines considered in the model maintain the normal state. Based on the fact that each patient has a unique immune system, we have shown at the same drug works differently, depending on the individual immune system characteristics for every patient. It is known that IBD is related to an imbalance between pro- and anti- inflammatory cytokines as the cause of the disease. So the ratios of pro- to anti- inflammatory cytokines are used as an indicator of patient's condition and inflammation status in various diseases. We compared the ratios of pro- to anti- inflammatory cytokine according to patient's individual immune system and drugs. Since the effects of biological drugs are highly dependent on the patient's own immune system, it is essential to define the immune system status before selecting and using a biological drug.	[Park, Anna; Kim, Sangil; Jung, Il Hyo; Byun, Jong Hyuk] Pusan Natl Univ, Dept Math, Busan, South Korea; [Park, Anna; Kim, Sangil; Jung, Il Hyo] Pusan Natl Univ, Finance Fishery Manufacture Ind Math Ctr Big Data, Busan, South Korea; [Byun, Jong Hyuk] Pusan Natl Univ, Inst Math Sci, Busan, South Korea	Pusan National University; Pusan National University; Pusan National University	Byun, JH (corresponding author), Pusan Natl Univ, Dept Math, Busan, South Korea.; Byun, JH (corresponding author), Pusan Natl Univ, Inst Math Sci, Busan, South Korea.	maticax@gmail.com		JUNG, IL HYO/0000-0002-6086-5124; BYUN, JONG HYUK/0000-0001-6334-8176	National Research Foundation of Korea (NRF) - Korean Government (MSIP) [NRF-2017R1A5A1015722, 2017R1E1A1A03070224, NRF-2020R1C1C1A01004631]	National Research Foundation of Korea (NRF) - Korean Government (MSIP)	This work was supported by National Research Foundation of Korea (NRF) grants funded by the Korean Government (MSIP) and awarded to IHJ (NRF-2017R1A5A1015722), SK (2017R1E1A1A03070224), and JHB (NRF-2020R1C1C1A01004631). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Allocca M, 2013, CURR DRUG TARGETS, V14, P1508, DOI 10.2174/13894501113146660224; Andreou NP, 2020, ANN GASTROENTEROL, V33, P125, DOI 10.20524/aog.2020.0457; Baldassano R, 2003, AM J GASTROENTEROL, V98, P833, DOI 10.1016/S0002-9270(03)00007-8; Balding J, 2004, MEDIAT INFLAMM, V13, P181, DOI 10.1080/09511920410001713529; Braat H, 2006, CLIN GASTROENTEROL H, V4, P754, DOI 10.1016/j.cgh.2006.03.028; Cardoso A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00400; Chichlowski M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012220; Engel T, 2016, THER ADV CHRONIC DIS, V7, P208, DOI 10.1177/2040622316653306; Glas J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034349; Guan QD, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/4810258; Herfarth H, 2002, GUT, V50, P146, DOI 10.1136/gut.50.2.146; Ito H, 2005, J GASTROENTEROL, V40, P32, DOI 10.1007/BF02990576; Jansen JE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01283; Kam L Y, 2000, Expert Opin Pharmacother, V1, P615, DOI 10.1517/14656566.1.4.615; Kashani Amir, 2019, Gastroenterol Hepatol (N Y), V15, P255; Kilic T, 2006, HEART, V92, P1041, DOI 10.1136/hrt.2005.080382; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Li MC, 2004, WORLD J GASTROENTERO, V10, P620, DOI 10.3748/wjg.v10.i5.620; Lo WC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165782; Lo WC, 2013, B MATH BIOL, V75, P1417, DOI 10.1007/s11538-013-9853-2; Marlow GJ, 2013, WORLD J GASTROENTERO, V19, P3931, DOI 10.3748/wjg.v19.i25.3931; Matricon J, 2010, M S-MED SCI, V26, P405, DOI 10.1051/medsci/2010264405; Meng DL, 2019, EUR J INFLAMM, V17, DOI 10.1177/2058739219843405; Miranda TS, 2019, CLIN ORAL INVEST, V23, P641, DOI 10.1007/s00784-018-2471-5; Mitsuyama K, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/MI/2006/26875; Mudter J, 2007, GUT, V56, P293, DOI 10.1136/gut.2005.090464; Papadakis KA, 2000, ANNU REV MED, V51, P289, DOI 10.1146/annurev.med.51.1.289; Pripp AH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090149; Sabin J, 2019, THER ADV GASTROENTER, V12, DOI 10.1177/1756284819853208; Sanchez-Munoz F, 2008, WORLD J GASTROENTERO, V14, P4280, DOI 10.3748/wjg.14.4280; Sandborn WJ, 1999, INFLAMM BOWEL DIS, V5, P119, DOI 10.1097/00054725-199905000-00008; SCHREIBER S, 1995, GASTROENTEROLOGY, V108, P1434, DOI 10.1016/0016-5085(95)90692-4; Shanahan F, 2001, GASTROENTEROLOGY, V120, P622, DOI 10.1053/gast.2001.22122; vanDeventer SJH, 1997, GASTROENTEROLOGY, V113, P383, DOI 10.1053/gast.1997.v113.pm9247454; Wares JR, 2015, MATH BIOSCI ENG, V12, P1237, DOI 10.3934/mbe.2015.12.1237; WIEMANN B, 1994, PHARMACOL THERAPEUT, V64, P529, DOI 10.1016/0163-7258(94)90023-X; Wittig BM, 2007, CURR OPIN INVEST DR, V8, P947; Wong M, 2008, CLIN IMMUNOL, V126, P121, DOI 10.1016/j.clim.2007.08.013; Yamada A, 2016, WORLD J GASTROENTERO, V22, P2195, DOI 10.3748/wjg.v22.i7.2195	39	3	3	2	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 24	2020	15	9							e0238918	10.1371/journal.pone.0238918	http://dx.doi.org/10.1371/journal.pone.0238918			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NY2ZZ	32970698	Green Published, gold			2023-01-03	WOS:000576265600005
J	Srivastava, U; Singh, KK; Yadav, PK				Srivastava, Ujjaval; Singh, Kaushalendra Kumar; Yadav, Pawan Kumar			Disaggregated analysis of birth averted due to family planning use in India: An evidence from NFHS-4 (2015-16)	PLOS ONE			English	Article								Background and objective India contributes a major share of global unintended births. It is established that contraception plays a significant role in preventing unintended pregnancies, maternal mortality and induced abortion. In this study, to analyze the effectiveness of our family welfare program, we tried to give district-level estimates of number of births averted due to contraception. Data and methods Data for this study came from the cross-sectional, population-based data from the fourth round of National Family Health Survey (NFHS-4) conducted in 2015-16. Here, we discussed two methods based on robust regression for computing number of births averted at district level. Further, we analyzed the percentage increase in births (PIB) that would be experienced by each district in the absence of contraception. Results Findings of this study clearly showed that there was a huge variation in the estimates of number of births averted among different districts as well as states of India. Out of 640 districts, 315 districts achieved below-replacement fertility and 365 districts have contraceptive prevalence rate (CPR) more than 50 percent. Method 1 found around 22 percent districts showed less than 15 percent reduction in births while Method 2 suggested nearly 14 percent districts predominantly located in Uttar Pradesh, Bihar, Jharkhand, Arunachal Pradesh, Meghalaya and Manipur exhibited less than 30 percent reduction of births due to use of all forms of contraception. At all India level, an average estimate obtained by two methods, nearly 63 million births would have been averted by the use of contraception or 40 percent more than the number of births occurred during that period. Conclusion The study successfully identified the districts that were not performing well at the front of utilization of various family planning methods for birth control. To achieve objectives of National Population Policy (2000), poor-performing districts must be monitored like the government keeps monitoring ofAspirational districts.	[Srivastava, Ujjaval; Singh, Kaushalendra Kumar] Banaras Hindu Univ, Dept Stat, Varanasi, Uttar Pradesh, India; [Srivastava, Ujjaval] Govt India, Natl Stat Syst Training Acad, Minist Stat & Programme Implementat, Pondicherry, India; [Yadav, Pawan Kumar] Int Inst Populat Sci, Mumbai, Maharashtra, India	Banaras Hindu University (BHU); International Institute for Population Sciences	Srivastava, U (corresponding author), Banaras Hindu Univ, Dept Stat, Varanasi, Uttar Pradesh, India.; Srivastava, U (corresponding author), Govt India, Natl Stat Syst Training Acad, Minist Stat & Programme Implementat, Pondicherry, India.	ujjavalsri777@gmail.com		Srivastava, Ujjaval/0000-0002-2541-4504; YADAV, PAWAN KUMAR/0000-0002-3567-8570				Addendum Manual UN, 1986, 9 METH MEA IMP FAM P; AGARWALA SN, 1960, LAW CONTEMP PROBL, V25, P577, DOI 10.2307/1190756; [Anonymous], **NON-TRADITIONAL**; [Anonymous], 2007, AGILENT TECHNOLOGIES, V1; [Anonymous], 2012, LD3320 NEW TECHNOLOG, V2, P47; Bhattacharya B N, 1984, Sankhya, V46, P320; BONGAARTS J, 1978, POPUL DEV REV, V4, P105, DOI 10.2307/1972149; Cleland J, 2012, LANCET, V380, P149, DOI 10.1016/S0140-6736(12)60609-6; Collins John J., 2000, ENCY APOCALYPTICISM, V1, pvii; International Institute for Population Sciences, 2017, NAT FAM HLTH SURV NF; International Institute for Population Sciences, 1995, NAT FAM HLTH SURV NF; KEENY SM, 1968, STUD FAMILY PLANN, P1; KELLY WJ, 1971, STUD FAMILY PLANN, V2, P197, DOI 10.2307/1964905; Liu L, 2008, POP STUD-J DEMOG, V62, P191, DOI 10.1080/00324720801897796; Manual UN, 1979, 9 METH MES IMP FAM P; MAULDIN WP, 1968, STUD FAMILY PLANN, P1; NITI Aayog, 2018, ASP DISTR UNL POT; POTTER R G, 1970, Theoretical Population Biology, V1, P251, DOI 10.1016/0040-5809(70)90046-8; Potter RG, 1969, FERTILITY FAMILY PLA, P413; Rai PK, 2018, J DATA SCI, V647, P676; Schoumaker B, 2013, DEMOGR RES, V28, P1093, DOI 10.4054/DemRes.2013.28.38; United Nations Department of Economic and Social Affairs Population Division, 2019, POPDBCPREV2019; United Nations Department of Economic and Social Affairs Population Division, 2017, ESAPWP248; VENKATACHARYA K, 1971, DEMOGRAPHY, V8, P491, DOI 10.2307/2060685; Venkatacharya K, 1972, SANKHYA INDIAN J S B, P297; WOLFERS D, 1969, POP STUD-J DEMOG, V23, P111, DOI 10.1080/00324728.1969.10406033	26	2	2	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2020	15	9							e0239376	10.1371/journal.pone.0239376	http://dx.doi.org/10.1371/journal.pone.0239376			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NX4NF	32966322	Green Published, gold			2023-01-03	WOS:000575688700033
J	Abbott, J; Johnson, D; Wynia, M				Abbott, Jean; Johnson, Daniel; Wynia, Matthew			Ensuring Adequate Palliative and Hospice Care During COVID-19 Surges	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Abbott, Jean; Johnson, Daniel] Univ Colorado, Ctr Bioeth & Humanities, Anschutz Med Campus,13080 E 19th Ave,Ste 201, Aurora, CO 80045 USA; [Abbott, Jean; Wynia, Matthew] Univ Colorado, Sch Med, Aurora, CO USA; [Wynia, Matthew] Colorado Sch Publ Hlth, Denver, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; Colorado School of Public Health	Abbott, J (corresponding author), Univ Colorado, Ctr Bioeth & Humanities, Anschutz Med Campus,13080 E 19th Ave,Ste 201, Aurora, CO 80045 USA.	jabbott49@gmail.com						Antommaria AHM, 2020, ANN INTERN MED, V173, P188, DOI 10.7326/M20-1738; Birnstengel G, 2020, NEXT AVENUE TWIN CIT; Bowman BA, 2020, J PAIN SYMPTOM MANAG, V60, pE98, DOI 10.1016/j.jpainsymman.2020.03.028; Centers for Disease Control and Prevention, EXC DEATHS ASS COVID; Colorado Department of Public Health and Environment website, COL CONT CRIS STAND; Institute of Medicine (IOM), 2012, CRIS STAND CAR SYST, DOI [https://doi.org/10.17226/13351, DOI 10.17226/13351]; Lee J, 2020, JAMA INTERN MED, V180, P1252, DOI 10.1001/jamainternmed.2020.2713; Lynn J, 2020, J AM GERIATR SOC, V68, P1629, DOI 10.1111/jgs.16658; Powell T, 2020, AM J BIOETHICS, V20, P62, DOI 10.1080/15265161.2020.1764146; University of Nebraska Medical Center Global Center for Health Security, 2020, COMF ONL CAR UN COH	10	27	27	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2020	324	14					1393	1394		10.1001/jama.2020.16843	http://dx.doi.org/10.1001/jama.2020.16843		SEP 2020	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OS4TT	32955547	Bronze			2023-01-03	WOS:000574308600002
J	Burgstaller , JM; Held, U; Signorell, A; Blozik, E; Steurer, J; Wertli, MM				Burgstaller, Jakob M.; Held, Ulrike; Signorell, Andri; Blozik, Eva; Steurer, Johann; Wertli, Maria M.			Increased risk of adverse events in non-cancer patients with chronic and high-dose opioid use-A health insurance claims analysis	PLOS ONE			English	Article							CHRONIC DISEASE SCORE; CHRONIC PAIN; AMERICAN SOCIETY; PRESCRIPTION; OVERDOSE; RESPONSIBILITY	Background Chronic and high dose opioid use may result in adverse events. We analyzed the risk associated with chronic and high dose opioid prescription in a Swiss population. Methods Using insurance claims data covering one-sixth of the Swiss population, we analyzed recurrent opioid prescriptions (>= 2 opioid claims with at least 1 strong opioid claim) between 2006 and 2014. We calculated the cumulative dose in milligrams morphine equivalents (MED) and treatment duration. Excluded were single opioid claims, opioid use that was cancer treatment related, and opioid use in substitution programs. We assessed the association between the duration of opioid use, prescribed opioid dose, and benzodiazepine use with emergency department (ED) visits, urogenital and pulmonary infections, acute care hospitalization, and death at the end of the episode. Results In 63,642 recurrent opioid prescription episodes (acute 38%, subacute 7%, chronic 25.8%, very chronic (>360 days) episodes 29%) 18,336 ED visits, 30,209 infections, 19,375 hospitalizations, and 9,662 deaths occurred. The maximum daily MED dose was <20 mg in 15.8%, 20-<50 mg in 16.6%, 50-<100 mg in 21.6%, and >= 100 mg in 46%. Compared to acute episodes (<90 days), episode duration was an independent predictor of ED visits (chronic OR 1.09 (95% CI 1.03-1.15), very chronic (>360 days) OR 1.76 (1.67-1.86)) for adverse effects; infections (chronic OR 1.74 (1.66-1.82), very chronic 4.16 (3.95-4.37)), and hospitalization (chronic: OR 1.22 (1.16-1.29), very chronic OR 1.82 (1.73-1.93)). The risk of death decreased over time (very chronic OR 0.46 (0.43-0.50)). A dose dependent increased risk was observed for ED visits, hospitalization, and death (>= 100mg daily MED OR 1.21 (1.13-1.29), OR 1.29 (1.21-1.38), and OR 1.67, 1.50-1.85, respectively). A concomitant use of benzodiazepines increased the odds for ED visits by 46% (OR 1.46, 1.41-1.52), infections by 44% (OR 1.44, 1.41-1.52), hospitalization by 12% (OR 1.12, 1.07-1.1), and death by 45% (OR 1.45, 1.37-1.53). Conclusion The length of opioid use and higher prescribed morphine equivalent dose were independently associated with an increased risk for ED visits and hospitalizations. The risk for infections, ED visits, hospitalizations, and death also increased with concomitant benzodiazepine use.	[Burgstaller, Jakob M.; Held, Ulrike; Steurer, Johann; Wertli, Maria M.] Univ Zurich, Horten Ctr Patient Oriented Res & Knowledge Trans, Dept Internal Med, Zurich, Switzerland; [Burgstaller, Jakob M.; Blozik, Eva] Univ Zurich, Inst Primary Care, Zurich, Switzerland; [Burgstaller, Jakob M.; Blozik, Eva] Univ Hosp Zurich, Zurich, Switzerland; [Held, Ulrike] Univ Zurich, Biostat & Prevent Inst, Dept Biostat Epidemiol, Zurich, Switzerland; [Signorell, Andri; Blozik, Eva] Helsana, Dept Hlth Sci, Dubendorf, Switzerland; [Wertli, Maria M.] Univ Bern, Bern Univ Hosp, Dept Gen Internal Med, Bern, Switzerland	University of Zurich; University of Zurich; University of Zurich; University Zurich Hospital; University of Zurich; University of Bern; University Hospital of Bern	Wertli, MM (corresponding author), Univ Zurich, Horten Ctr Patient Oriented Res & Knowledge Trans, Dept Internal Med, Zurich, Switzerland.; Wertli, MM (corresponding author), Univ Bern, Bern Univ Hosp, Dept Gen Internal Med, Bern, Switzerland.	Maria.Wertli@insel.ch	Wertli, Maria/Q-3349-2017	Wertli, Maria/0000-0001-6347-0198; Held, Ulrike/0000-0003-3105-5840				[Anonymous], 1989, CANC PAIN REL PALL C; [Anonymous], 2013, GUID ATC CLASS DDD A, P16; Bedson J, 2019, EUR J PAIN; Biller-Andorno N, 2015, NEW ENGL J MED, V373, P2193, DOI 10.1056/NEJMp1508256; Curtis HJ, 2019, LANCET PSYCHIAT, V6, P140, DOI 10.1016/S2215-0366(18)30471-1; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Edlund MJ, 2014, CLIN J PAIN, V30, P557, DOI 10.1097/AJP.0000000000000021; Eriksen J, 2006, PAIN, V125, P172, DOI 10.1016/j.pain.2006.06.009; Friedman BW, 2015, JAMA-J AM MED ASSOC, V314, P1572, DOI 10.1001/jama.2015.13043; Furlan AD, 2006, CAN MED ASSOC J, V174, P1589, DOI 10.1503/cmaj.051528; Hider-Mlynarz K, 2018, BRIT J CLIN PHARMACO, V84, P1324, DOI 10.1111/bcp.13564; Hojsted J, 2012, CURR PHARM DES; Huber CA, 2013, J CLIN EPIDEMIOL, V66, P1118, DOI 10.1016/j.jclinepi.2013.04.011; Jann Michael, 2014, J Pharm Pract, V27, P5, DOI 10.1177/0897190013515001; Jena Anupam B, 2014, BMJ, V348, pg1393, DOI 10.1136/bmj.g1393; Kuo RN, 2011, MED CARE, V49, P1031, DOI 10.1097/MLR.0b013e31822ebe11; Madras BK, 2017, JAMA PSYCHIAT, V74, P441, DOI 10.1001/jamapsychiatry.2017.0163; Manchikanti L, 2017, PAIN PHYSICIAN, V20, pS3; Manchikanti L, 2014, PAIN PHYSICIAN, V17, pE1; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pS1; Manchikanti L, 2012, PAIN PHYSICIAN, V15, pES9; Miller M, 2015, JAMA INTERN MED, V175, P608, DOI 10.1001/jamainternmed.2014.8071; Nielsen S, 2015, PAIN MED, V16, P356, DOI 10.1111/pme.12594; O'Brien T, 2017, EUR J PAIN, V21, P3, DOI 10.1002/ejp.970; Pain & Policy Studies Group (PPSG), OP CONS DAT MAD WI 5; Park TW, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h2698; Paulozzi LJ, 2006, PHARMACOEPIDEM DR S, V15, P618, DOI 10.1002/pds.1276; Putnam KG, 2002, EPIDEMIOLOGY, V13, P340, DOI 10.1097/00001648-200205000-00016; Ray WA, 2016, JAMA-J AM MED ASSOC, V315, P2415, DOI 10.1001/jama.2016.7789; Ruchat David, 2018, Rev Med Suisse, V14, P1262; Ruscitto A, 2015, EUR J PAIN, V19, P59, DOI 10.1002/ejp.520; Saunders KW, 2010, J GEN INTERN MED, V25, P310, DOI 10.1007/s11606-009-1218-z; Shah NG, 2008, ADDICTION, V103, P126, DOI 10.1111/j.1360-0443.2007.02054.x; Shipton EA, 2018, PAIN THER, V7, P23, DOI 10.1007/s40122-018-0096-7; Spithoff S, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227045; Team R. C, 2018, R LANG ENV STAT COMP; United Nations Office on Drugs And Crime, 2011, NONM US PRESCR DRUGS; Volkow ND, 2014, NEW ENGL J MED, V370, P2063, DOI 10.1056/NEJMp1402780; Von Korff M, 2008, CLIN J PAIN, V24, P521, DOI 10.1097/AJP.0b013e318169d03b; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Wertli MM, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2086-6; Wertli MM, 2019, PAIN PHYS; World Health Organization, 1997, TRAIT DOUL CANC COMP	43	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2020	15	9							e0238285	10.1371/journal.pone.0238285	http://dx.doi.org/10.1371/journal.pone.0238285			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NS5RK	32925928	Green Published, Green Accepted, gold			2023-01-03	WOS:000572318000019
J	Kalantar-Zadeh, K; Wightman, A; Liao, S				Kalantar-Zadeh, Kamyar; Wightman, Aaron; Liao, Solomon			Ensuring Choice for People with Kidney Failure - Dialysis, Supportive Care, and Hope	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								For patients with advanced kidney disease, especially hospitalized patients, dialysis may be presented as the opposite end of the treatment spectrum from comfort care. Collaborative efforts and amended policies could allow patients to have a better range of options.	[Kalantar-Zadeh, Kamyar] Univ Calif Irvine, Sch Med, Div Nephrol & Hypertens & Kidney Transplantat, Orange, CA 92668 USA; [Liao, Solomon] Univ Calif Irvine, Div Palliat Med, Hospitalist Program, Orange, CA 92668 USA; [Kalantar-Zadeh, Kamyar] Tibor Rubin Vet Adm Healthcare Syst, Long Beach, CA 90822 USA; [Wightman, Aaron] Univ Washington, Sch Med, Dept Pediat, Div Bioeth & Palliat Care, Seattle, WA 98195 USA; [Wightman, Aaron] Univ Washington, Sch Med, Dept Pediat, Div Nephrol, Seattle, WA 98195 USA; [Wightman, Aaron] Seattle Childrens Hosp, Treuman Katz Ctr Pediat Bioeth, Seattle, WA USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Kalantar-Zadeh, K (corresponding author), Univ Calif Irvine, Sch Med, Div Nephrol & Hypertens & Kidney Transplantat, Orange, CA 92668 USA.; Kalantar-Zadeh, K (corresponding author), Tibor Rubin Vet Adm Healthcare Syst, Long Beach, CA 90822 USA.		Kalantar-Zadeh, Kamyar/Q-4734-2018	Kalantar-Zadeh, Kamyar/0000-0002-8666-0725; Wightman, Aaron/0000-0003-0167-0420				Ko GJ, 2019, J AM MED DIR ASSOC, V20, P743, DOI 10.1016/j.jamda.2018.11.030; Ladin K, 2018, AM J KIDNEY DIS, V71, P627, DOI 10.1053/j.ajkd.2017.11.011; Lam DY, 2019, CLIN J AM SOC NEPHRO, V14, P635, DOI 10.2215/CJN.09330818; Saran R, 2019, AM J KIDNEY DIS, V73, pSVII; Wong SPY, 2016, JAMA INTERN MED, V176, P228, DOI 10.1001/jamainternmed.2015.7412	5	62	67	1	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	2020	383	2					99	101		10.1056/NEJMp2001794	http://dx.doi.org/10.1056/NEJMp2001794			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NR9PO	32640129	Green Published			2023-01-03	WOS:000571894800007
J	Brunner-La Rocca, RH; Peden, CJ; Soong, J; Holman, PA; Bogdanovskaya, M; Barclay, L				Brunner-La Rocca, Hans-Peter; Peden, Carol J.; Soong, John; Holman, Per Arne; Bogdanovskaya, Maria; Barclay, Lorna			Reasons for readmission after hospital discharge in patients with chronic diseases-Information from an international dataset	PLOS ONE			English	Article							30-DAY READMISSION; HEART-FAILURE; RISK; PREDICTORS; REHOSPITALIZATION; PREVENTABILITY; SURGERY; ASTHMA; TRENDS	Background Chronic diseases are increasingly prevalent in Western countries. Once hospitalised, the chance for another hospitalisation increases sharply with large impact on well-being of patients and costs. The pattern of readmissions is very complex, but poorly understood for multiple chronic diseases. Methods This cohort study of administrative discharge data between 2009-2014 from 21 tertiary hospitals (eight USA, five UK, four Australia, four continental Europe) investigated rates and reasons of readmissions to the same hospital within 30 days after unplanned admission with one of the following chronic conditions; heart failure; atrial fibrillation; myocardial infarction; hypertension; stroke; chronic obstructive pulmonary disease (COPD); bacterial pneumonia; diabetes mellitus; chronic renal disease; anaemia; arthritis and other cardiovascular disease. Proportions of readmissions with similar versus different diseases were analysed. Results Of 4,901,584 admissions, 866,502 (17.7%) were due to the 12 chronic conditions. In-hospital, 43,573 (5.0%) patients died, leaving 822,929 for readmission analysis. Of those, 87,452 (10.6%) had an emergency 30-day readmission, rates ranged from 2.8% for arthritis to 18.4% for COPD. One third were readmitted with the same condition, ranging from 53% for anaemia to 11% for arthritis. Reasons for readmission were due to another chronic condition in 10% to 35% of the cases, leaving 30% to 70% due to reasons other than the original 12 conditions (most commonly, treatment related complications and infections). The chance of being readmitted with the same cause was lower in the USA, for female patients, with increasing age, more co-morbidities, during study period and with longer initial length of stay. Conclusion Readmission in chronic conditions is very common and often caused by diseases other than the index hospitalisation. Interventions to reduce readmissions should therefore focus not only on the primary condition but on a holistic consideration of all the patient's comorbidities.	[Brunner-La Rocca, Hans-Peter] Maastricht Univ, Med Ctr, Dept Cardiol, Maastricht, Netherlands; [Peden, Carol J.] Keck Med USC, Ctr Hlth Syst Innovat, Los Angeles, CA USA; [Soong, John] Imperial Coll London, Chelsea & Westminster Hosp NHS Fdn Trust, NIHR CLAHRC Northwest London Team, London, England; [Holman, Per Arne] Lovisenberg Diaconal Hosp, Dept Patients Safety & Res, Oslo, Norway; [Bogdanovskaya, Maria; Barclay, Lorna] Dr Foster Telstra Hlth, London, England	Maastricht University; Imperial College London	Brunner-La Rocca, RH (corresponding author), Maastricht Univ, Med Ctr, Dept Cardiol, Maastricht, Netherlands.	hp.brunnerlarocca@mumc.nl	Soong, John Tshon Yit/I-2008-2018	Soong, John Tshon Yit/0000-0003-4235-8505; Brunner-La Rocca, Hans-Peter/0000-0002-4356-8566				Ali AM, 2017, JAMA SURG, V152, DOI 10.1001/jamasurg.2017.3949; [Anonymous], R LANG ENV STAT COMP; [Anonymous], 2011, CMAJ, V183, pE509; Arora S, 2017, AM J CARDIOL, V119, P760, DOI 10.1016/j.amjcard.2016.11.022; Auerbach AD, 2016, JAMA INTERN MED, V176, P484, DOI 10.1001/jamainternmed.2015.7863; Axon RN, 2016, POPUL HEALTH MANAG, V19, P4, DOI 10.1089/pop.2014.0182; Bottle A, 2013, HEALTH SERV RES, V48, P2081, DOI 10.1111/1475-6773.12074; Bottle A, 2011, J CLIN EPIDEMIOL, V64, P1426, DOI 10.1016/j.jclinepi.2011.04.004; Busse R., 2010, TACKLING CHRONIC DIS; Byrne MM, 2006, MED CARE, V44, P768, DOI 10.1097/01.mlr.0000218786.44722.14; Centers for Medicare & Medicaid Services, 2018, READM RED PROGR HRRP; Dharmarajan K, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6571; Duffy S, 2015, CHRON OBSTR PULM DIS, V2, P17, DOI 10.15326/jcopdf.2.1.2014.0129; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; French DD, 2008, J AM GERIATR SOC, V56, P705, DOI 10.1111/j.1532-5415.2007.01479.x; Fudim M, 2018, EUR J HEART FAIL, V20, P304, DOI 10.1002/ejhf.1020; Garcia-Olmos L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032141; Gemmill M., 2008, RES NOTE CHRONIC DIS; Graboyes EM, 2017, LARYNGOSCOPE, V127, P337, DOI 10.1002/lary.25997; Hasegawa K, 2016, CHEST, V149, P1021, DOI 10.1016/j.chest.2015.12.039; Hernandez AF, 2010, JAMA-J AM MED ASSOC, V303, P1716, DOI 10.1001/jama.2010.533; Hisashige Akinori, 2012, Glob J Health Sci, V5, P27, DOI 10.5539/gjhs.v5n2p27; Jencks SF, 2009, NEW ENGL J MED, V360, P1418, DOI 10.1056/NEJMsa0803563; Kansagara D, 2011, JAMA-J AM MED ASSOC, V306, P1688, DOI 10.1001/jama.2011.1515; Krause David S, 2005, Dis Manag, V8, P114, DOI 10.1089/dis.2005.8.114; Kripalani S, 2014, ANNU REV MED, V65, P471, DOI 10.1146/annurev-med-022613-090415; Krumholz HM, 2017, NEW ENGL J MED, V377, P1055, DOI 10.1056/NEJMsa1702321; Laborde-Casterot H, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004399; Lemmens KMM, 2009, RESP MED, V103, P670, DOI 10.1016/j.rmed.2008.11.017; Li ZM, 2012, CIRC-CARDIOVASC QUAL, V5, P729, DOI 10.1161/CIRCOUTCOMES.112.966945; McIntyre LK, 2016, JAMA SURG, V151, P855, DOI 10.1001/jamasurg.2016.1258; McManus David D, 2012, Clin Epidemiol, V4, P115, DOI 10.2147/CLEP.S30883; Nimptsch U, 2016, HEALTH SERV RES, V51, P981, DOI 10.1111/1475-6773.12398; Oddone EZ, 1996, J GEN INTERN MED, V11, P597, DOI 10.1007/BF02599027; Rao C.R., 1995, QUESTIIO, V19, P23; Ruiz M, 2015, BMJ QUAL SAF, V24, P492, DOI 10.1136/bmjqs-2014-003467; Shams I, 2015, HEALTH CARE MANAG SC, V18, P19, DOI 10.1007/s10729-014-9278-y; (SOReg) Sosr, 2016, ARSR SOREG 2015 2, V7, P2; The Commonwealth Fund, 2016, INT HLTH CAR SYST PR; Tung YC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170061; Tuso Philip, 2014, Perm J, V18, P38, DOI 10.7812/TPP/13-062; Vaidyanathan R., 2013, RCHARTS INTERACTIVE; van Galen LS, 2017, BMJ QUAL SAF, V26, P958, DOI 10.1136/bmjqs-2017-006645	43	19	19	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2020	15	6							e0233457	10.1371/journal.pone.0233457	http://dx.doi.org/10.1371/journal.pone.0233457			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MH8EZ	32603361	gold, Green Published			2023-01-03	WOS:000546956600038
J	Adamczyk, JG; Gryko, K; Boguszewski, D				Adamczyk, Jakub Grzegorz; Gryko, Karol; Boguszewski, Dariusz			Does the type of foam roller influence the recovery rate, thermal response and DOMS prevention?	PLOS ONE			English	Article							BLOOD LACTATE CLEARANCE; ONSET MUSCLE SORENESS; VISUAL ANALOG SCALE; MASSAGER APPLICATION; ACTIVE RECOVERY; JOINT RANGE; MOTION; PERFORMANCE; EXERCISE; PAIN	Purpose Supporting post-exercise recovery requires choosing not only the right treatment but also the equipment, in which the impact is not always clear. The study aimed to determine the effect of foam rolling on the rate of lactate removal and DOMS prevention and whether the type of foam roller is effective in the context of post-exercise recovery. Methods This randomized trial enrolled 33 active healthy males divided into three groups of eleven individuals: foam rolling with a smooth (STH) or grid roller (GRID) or passive recovery (PAS). All the participants performed full squat jumps for one minute. Examination took place at rest (thermal imaging of skin temperature-[T-sk] and blood lactate-[LA]), immediately following exercise (T-sk& LA), immediately after recovery treatment (T-sk) and after 30 minutes of rest (T-sk& LA). Their pain levels were assessed using the Visual Analog Scale (VAS) 24, 48, 72, and 96 hours after exercise. Results The magnitude of lactate decrease depended on the type of recovery used. In the PAS group, the decrease in lactate concentration by 2.65 mmol/L following a half-hour rest was significantly lower than that in the other groups (STH vs. PAS p = 0.042 / GRID vs. PAS p = 0.025). For thermal responses, significant differences between both experimental groups were noted only 30 minutes after exercise. A significant decrease in pain in the STH group occurred between 48 and 96 hours, while the GRID group showed a systematic significant decrease in VAS values in subsequent measurements. Changes in VAS values in subsequent measurements in the PAS group were not statistically significant (p>0.05). Conclusions Foam rolling seems to be effective for enhancing lactate clearance and counteracting DOMS, but the type of foam roller does not seem to influence the recovery rate.	[Adamczyk, Jakub Grzegorz] Jozef Pilsudski Univ Phys Educ Warsaw, Theory Sport Dept, Warsaw, Poland; [Gryko, Karol] Jozef Pilsudski Univ Phys Educ Warsaw, Athlet & Team Sport Games Dept, Warsaw, Poland; [Boguszewski, Dariusz] Med Univ Warsaw, Physiotherapy Div, Rehabil Dept, Warsaw, Poland	Jozef Pilsudski University Physical Education in Warsaw; Jozef Pilsudski University Physical Education in Warsaw; Medical University of Warsaw	Adamczyk, JG (corresponding author), Jozef Pilsudski Univ Phys Educ Warsaw, Theory Sport Dept, Warsaw, Poland.	jakub.adamczyk@awf.edu.pl	Gryko, Karol/AAC-5325-2019; Boguszewski, Dariusz/C-8218-2013; Adamczyk, Jakub/A-5223-2018	Gryko, Karol/0000-0002-6162-4832; Adamczyk, Jakub/0000-0003-4558-1585; Boguszewski, Dariusz/0000-0002-8343-8870	Polish Ministry of Science and Higher Education [DS-273]	Polish Ministry of Science and Higher Education(Ministry of Science and Higher Education, Poland)	The study was supported by the Polish Ministry of Science and Higher Education (Grant No. AWF -DS-273).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aboodarda SJ, 2015, BMC MUSCULOSKEL DIS, V16, DOI 10.1186/s12891-015-0729-5; Adamczyk JG, 2016, J THERM BIOL, V60, P20, DOI 10.1016/j.jtherbio.2016.05.006; Adamczyk JG, 2014, KINESIOLOGY, V46, P186; Al-Nakhli HH, 2012, JOVE-J VIS EXP, P1; Bakar Y, 2015, J PHYS THER SCI, V27, P3387, DOI 10.1589/jpts.27.3387; Beier Zach, 2019, Int J Exerc Sci, V12, P839; Bielik V, 2010, BIOL SPORT, V27, P59, DOI 10.5604/20831862.907953; Boguszewski D, 2017, BIOMED HUM KINET, V9, P75, DOI 10.1515/bhk-2017-0012; Bradbury-Squires DJ, 2015, J ATHL TRAINING, V50, P133, DOI 10.4085/1062-6050-49.5.03; Cheatham SW, 2015, INT J SPORTS PHYS TH, V10, P827; Couture Grace, 2015, Open Orthop J, V9, P450, DOI 10.2174/1874325001509010450; Crowther F, 2017, BMC SPORTS SCI MED R, V9, DOI 10.1186/s13102-017-0087-8; Curran PF, 2008, J SPORT REHABIL, V17, P432, DOI 10.1123/jsr.17.4.432; D'Amico A, 2017, J HUM KINET, V57, P97, DOI 10.1515/hukin-2017-0051; de Oliveira UF, 2018, J EXERC REHABIL, V14, P451, DOI 10.12965/jer.1836056.028; Devlin J, 2014, J SPORT MED PHYS FIT, V54, P271; Drinkwater EJ, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00768; Dupuy O, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00403; Gladden LB, 2008, EXERC SPORT SCI REV, V36, P109, DOI 10.1097/JES.0b013e31817c0038; Moreira DG, 2017, J THERM BIOL, V69, P155, DOI 10.1016/j.jtherbio.2017.07.006; Grissom R.J., 2012, EFFECT SIZES RES UNI, V2nd; Haas C, 2013, BRIT J SPORT MED, V47, P83, DOI 10.1136/bjsports-2012-091211; Hausswirth C, 2011, SPORTS MED, V41, P861, DOI 10.2165/11593180-000000000-00000; Hawker GA, 2011, ARTHRIT CARE RES, V63, pS240, DOI 10.1002/acr.20543; Hinds T, 2004, MED SCI SPORT EXER, V36, P1308, DOI 10.1249/01.MSS.0000135789.47716.DB; Hodgson DD, 2018, INT J SPORTS PHYS TH, V13, P835, DOI 10.26603/ijspt20180835; Hoff J, 2016, J STRENGTH COND RES, V30, P1373, DOI 10.1519/JSC.0000000000001349; Hotfiel T, 2017, J STRENGTH COND RES, V31, P893, DOI 10.1519/JSC.0000000000001641; Jafri M Saleet, 2014, Int Sch Res Notices, V2014; Johnson J., 2018, SOFT TISSUE TRIGGER; Junker D, 2019, J SPORT SCI MED, V18, P229; Laffaye G, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01287; Laskowski R, 2012, ARCH BUDO, V8, P51, DOI 10.12659/AOB.882651; Lau WY, 2013, J MUSCULOSKELET PAIN, V21, P320, DOI 10.3109/10582452.2013.848967; Laufs U, 2015, DTSCH ARZTEBL INT, V112, P748, DOI 10.3238/arztebl.2015.0748; MacDonald GZ, 2014, MED SCI SPORT EXER, V46, P131, DOI 10.1249/MSS.0b013e3182a123db; MacDonald GZ, 2013, J STRENGTH COND RES, V27, P812, DOI 10.1519/JSC.0b013e31825c2bc1; Medbo JI, 2000, SCAND J CLIN LAB INV, V60, P367, DOI 10.1080/003655100750019279; Menzies P, 2010, J SPORT SCI, V28, P975, DOI 10.1080/02640414.2010.481721; Monteiro ER, 2016, INT J SPORTS PHYS TH, V11, P1076; Moraska AF, 2018, ARCH PHYS MED REHAB, V99, P2151, DOI 10.1016/j.apmr.2018.06.030; Murray AM, 2016, INT J SPORTS PHYS TH, V11, P765; Okamoto T, 2014, J STRENGTH COND RES, V28, P69, DOI 10.1519/JSC.0b013e31829480f5; Ozsu I., 2018, J ED TRAIN STUD, V6, P33, DOI [10.11114/jets.v6i9a.3511, DOI 10.11114/JETS.V6I9A.3511]; Peacock CA, 2015, J STRENGTH COND RES, V29, P2310, DOI 10.1519/JSC.0000000000000867; Peake JM, 2019, CURR OPIN PHYSIOL, V10, P17, DOI 10.1016/j.cophys.2019.03.007; Pearcey GEP, 2015, J ATHL TRAINING, V50, P5, DOI 10.4085/1062-6050-50.1.01; Rasooli SA, 2012, J SPORT MED PHYS FIT, V52, P122; Rey E, 2019, J STRENGTH COND RES, V33, P2194, DOI 10.1519/JSC.0000000000002277; Ring EFJ, 2012, PHYSIOL MEAS, V33, pR33, DOI 10.1088/0967-3334/33/3/R33; Roberts Langdon, 2011, Int J Ther Massage Bodywork, V4, P4; Schleip R., 2003, J BODYW MOV THER, V7, P11, DOI DOI 10.1016/S1360-8592(02)00067-0; Schroeder J, 2019, SPORTS OTHOPAEDIC TR, V35, P171, DOI [10.1016/j.orthtr.2018.11.003, DOI 10.1016/J.ORTHTR.2018.11.003]; Shalfawi SAI, 2019, SPORTS, V7, DOI 10.3390/sports7120246; Simmons GH, 2011, EXP PHYSIOL, V96, P822, DOI 10.1113/expphysiol.2010.056176; Su H, 2017, J SPORT REHABIL, V26, P469, DOI 10.1123/jsr.2016-0102; Sullivan KM, 2013, INT J SPORTS PHYS TH, V8, P228; Wiewelhove T, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.00376	58	8	8	2	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 26	2020	15	6							e0235195	10.1371/journal.pone.0235195	http://dx.doi.org/10.1371/journal.pone.0235195			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG0YE	32589670	gold, Green Published			2023-01-03	WOS:000545759800041
J	Levy, A; Rivera, S				Levy, Antonin; Rivera, Sofia			1-week hypofractionated adjuvant whole-breast radiotherapy: towards a new standard? Comment	LANCET			English	Editorial Material							RADIATION-THERAPY; CANCER		[Rivera, Sofia] Gustave Roussy Canc Campus, Dept Radiotherapy, 114 Rue Edouard Vaillant, F-94805 Villejuif, France; Univ Paris Sud, 114 Rue Edouard Vaillant, F-94805 Villejuif, France	UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay	Rivera, S (corresponding author), Gustave Roussy Canc Campus, Dept Radiotherapy, 114 Rue Edouard Vaillant, F-94805 Villejuif, France.	sofia.rivera@gustaveroussy.fr	Levy, Antonin/U-8791-2019	Levy, Antonin/0000-0003-4798-8899				Azria D, 2015, EBIOMEDICINE, V2, P1965, DOI 10.1016/j.ebiom.2015.10.024; Brunt AM, 2020, LANCET, V395, P1613, DOI 10.1016/S0140-6736(20)30932-6; Coles CE, 2020, CLIN ONCOL-UK, V32, P279, DOI 10.1016/j.clon.2020.03.006; Darby SC, 2013, NEW ENGL J MED, V368, P987, DOI 10.1056/NEJMoa1209825; Donovan E, 2007, RADIOTHER ONCOL, V82, P254, DOI 10.1016/j.radonc.2006.12.008; Haviland JS, 2013, LANCET ONCOL, V14, P1086, DOI 10.1016/S1470-2045(13)70386-3; Mamounas EP, 2019, LANCET ONCOL, V20, P88, DOI 10.1016/S1470-2045(18)30621-1; Seibold P, 2019, RADIOTHER ONCOL, V138, P59, DOI 10.1016/j.radonc.2019.04.034; Sjostrom M, 2019, J CLIN ONCOL, V37, P3340, DOI 10.1200/JCO.19.00761; Wang SL, 2019, LANCET ONCOL, V20, P352, DOI 10.1016/S1470-2045(18)30813-1; Whelan TJ, 2010, NEW ENGL J MED, V362, P513, DOI 10.1056/NEJMoa0906260	11	9	9	1	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 23	2020	395	10237					1588	1589		10.1016/S0140-6736(20)30978-8	http://dx.doi.org/10.1016/S0140-6736(20)30978-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LZ1JO	32580882	Green Published, hybrid			2023-01-03	WOS:000540986100007
J	Nikolaev, YA; Tutel'yan, AV; Loiko, NG; Buck, J; Sidorenko, SV; Lazareva, I; Gostev, V; Manzen'yuk, OY; Shemyakin, IG; Abramovich, RA; Huwyler, J; El'-Registan, GI				Nikolaev, Y. A.; Tutel'yan, A. V.; Loiko, N. G.; Buck, J.; Sidorenko, S. V.; Lazareva, I.; Gostev, V.; Manzen'yuk, O. Y.; Shemyakin, I. G.; Abramovich, R. A.; Huwyler, J.; El'-Registan, G. I.			The use of 4-Hexylresorcinol as antibiotic adjuvant	PLOS ONE			English	Article							RESISTANT ACINETOBACTER-BAUMANNII; PERSISTENT BACTERIAL-INFECTIONS; ALKYL PHENYL ALCOHOL; CHEMICAL ANALOGS; TOLERANCE; ALKYLRESORCINOLS; COMBINATION; AUTOREGULATORS; STRATEGIES; COLISTIN	Ever decreasing efficiency of antibiotic treatment due to growing antibiotic resistance of pathogenic bacteria is a critical issue in clinical practice. The two generally accepted major approaches to this problem are the search for new antibiotics and the development of antibiotic adjuvants to enhance the antimicrobial activity of known compounds. It was therefore the aim of the present study to test whether alkylresorcinols, a class of phenolic lipids, can be used as adjuvants to potentiate the effect of various classes of antibiotics. Alkylresorcinols were combined with 12 clinically used antibiotics. Growth-inhibiting activity against a broad range of pro- and eukaryotic microorganisms was determined. Test organisms did comprise 10 bacterial and 2 fungal collection strains, includingE. coliandS. aureus, and clinical isolates ofK. pneumoniae. The highest adjuvant activity was observed in the case of 4-hexylresorcinol (4-HR), a natural compound found in plants with antimicrobial activity. 50% of the minimal inhibitory concentration (MIC) of 4-HR caused an up to 50-fold decrease in the MIC of antibiotics of various classes. Application of 4-HR as an adjuvant revealed its efficiency against germination of bacterial dormant forms (spores) and prevented formation of antibiotic-tolerant persister cells. Using anin vivomouse model ofK. pneumoniae-induced sepsis, we could demonstrate that the combination of 4-HR and polymyxin was highly effective. 75% of animals were free of infection after treatment as compared to none of the animals receiving the antibiotic alone. We conclude that alkylresorcinols such as 4-HR can be used as an adjuvant to increase the efficiency of several known antibiotics. We suggest that by this approach the risk for development of genetically determined antibiotic resistance can be minimized due to the multimodal mode of action of 4-HR.	[Nikolaev, Y. A.; Loiko, N. G.; El'-Registan, G. I.] Russian Acad Sci, Fed Res Ctr Fundamentals Biotechnol, Moscow, Russia; [Tutel'yan, A. V.] Sechenov Univ, Cent Res Inst Epidemiol Russian Fed Serv Surveill, Moscow, Russia; [Tutel'yan, A. V.] Sechenov Univ, IM Sechenov First Moscow State Med Univ, Minist Hlth Russian Federat, Moscow, Russia; [Buck, J.; Huwyler, J.] Univ Basel, Dept Pharmaceut Sci, Basel, Switzerland; [Abramovich, R. A.] RUDN Univ, Peoples Friendship Univ Russia, Moscow, Russia; [Sidorenko, S. V.; Lazareva, I.; Gostev, V.] Pediat Res & Clin Ctr Infect Dis, St Petersburg, Russia; [Sidorenko, S. V.; Lazareva, I.; Gostev, V.] II Mechnikov North Western State Med Univ, St Petersburg, Russia; [Manzen'yuk, O. Y.; Shemyakin, I. G.] Russian Fed Serv Surveillance Consumer Rights Pro, State Res Ctr Appl Microbiol & Biotechnol, Obolensk, Russia	Research Center of Biotechnology RAS; Russian Academy of Sciences; Sechenov First Moscow State Medical University; Ministry of Health of the Russian Federation; Sechenov First Moscow State Medical University; University of Basel; Peoples Friendship University of Russia; North-Western State Medical University named after I.I. Mechnikov	Nikolaev, YA (corresponding author), Russian Acad Sci, Fed Res Ctr Fundamentals Biotechnol, Moscow, Russia.	nikolaevya@mail.ru	LAZAREVA, IRINA/GZM-6019-2022; Manzenyuk, Oksana/AAZ-7596-2021; Loiko, Natalia/AAZ-2904-2020; Sidorenko, Sergey/E-5870-2011; Gostev, Vladimir V/P-1949-2016; Tutel'an, Aleksei/A-4895-2017	Loiko, Natalia/0000-0001-5204-007X; Sidorenko, Sergey/0000-0003-3550-7875; Gostev, Vladimir V/0000-0002-3480-8089; Buck, Jonas/0000-0002-4676-3113; Tutel'an, Aleksei/0000-0002-2706-6689	Russian Academy of Sciences; University of Basel; Swiss National Science Foundation (SNF) [173057]; RUDN University Program 5-100; Sectoral Scientific Program of the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing	Russian Academy of Sciences(Russian Academy of Sciences); University of Basel; Swiss National Science Foundation (SNF)(Swiss National Science Foundation (SNSF)); RUDN University Program 5-100; Sectoral Scientific Program of the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing	This work was supported by internal funding from the Russian Academy of Sciences and the University of Basel. JB and JH were supported by the Swiss National Science Foundation (SNF grant No. 173057).; The publication has been prepared with the support of the "RUDN University Program 5-100". Animal Research was supported by the Sectoral Scientific Program of the Russian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing. We thank Viktoria Schreiner for editorial support. The authors declare that they have no conflict of interest.	Amoh T, 2017, J ANTIMICROB CHEMOTH, V72, P2230, DOI 10.1093/jac/dkx132; [Anonymous], 2016, CIRE ANTILLES GUYANE; [Anonymous], 1999, NEW AGR, V99, P1; Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390; Blango MG, 2010, ANTIMICROB AGENTS CH, V54, P1855, DOI 10.1128/AAC.00014-10; Brameyer S, 2015, P NATL ACAD SCI USA, V112, P572, DOI 10.1073/pnas.1417685112; Brauner A, 2016, NAT REV MICROBIOL, V14, P320, DOI 10.1038/nrmicro.2016.34; Brooks BD, 2014, ADV DRUG DELIVER REV, V78, P14, DOI 10.1016/j.addr.2014.10.027; Brown D, 2015, NAT REV DRUG DISCOV, V14, P821, DOI 10.1038/nrd4675; Buta JG, 1999, J AGR FOOD CHEM, V47, P1, DOI 10.1021/jf980712x; Butler MS, 2013, J ANTIBIOT, V66, P571, DOI 10.1038/ja.2013.86; Cabral DJ, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11010014; Cai BX, 2016, ANTIMICROB AGENTS CH, V60, P4013, DOI 10.1128/AAC.03064-15; Chen X, 2011, APPL ENVIRON MICROB, V77, P4878, DOI 10.1128/AEM.02440-10; Chhabra RS, 1988, NATL TOXICOL PROGRAM, V330, P1; Chung JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep28168; Cohen NR, 2013, CELL HOST MICROBE, V13, P632, DOI 10.1016/j.chom.2013.05.009; Davydova OK, 2007, MICROBIOLOGY+, V76, P266, DOI 10.1134/S0026261707030022; Deryabin D. G., 2013, Immunologiya, V34, P27; Domalaon R, 2018, CLIN MICROBIOL REV, V31, DOI [10.1128/CMR.00077-17, 10.1128/cmr.00077-17]; Douafer H, 2019, J MED CHEM, V62, P8665, DOI 10.1021/acs.jmedchem.8b01781; El-Registan GI, 2006, MICROBIOLOGY+, V75, P380, DOI 10.1134/S0026261706040035; ELIOPOULOS G M, 1988, Clinical Microbiology Reviews, V1, P139; Finlay J, 2003, J ANTIMICROB CHEMOTH, V52, P18, DOI 10.1093/jac/dkg286; Fisher RA, 2017, NAT REV MICROBIOL, V15, P453, DOI 10.1038/nrmicro.2017.42; Franco NH, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002399; Gill EE, 2015, CHEM BIOL DRUG DES, V85, P56, DOI 10.1111/cbdd.12478; Golod NA, 2009, MICROBIOLOGY+, V78, P678, DOI 10.1134/S0026261709060034; Gomez-Simmonds A, 2015, J CLIN MICROBIOL, V53, P2060, DOI 10.1128/JCM.03455-14; Goneau LW, 2014, ANTIMICROB AGENTS CH, V58, P2089, DOI 10.1128/AAC.02552-13; Gonzalez-Aguilar GA, 2000, J AGR FOOD CHEM, V48, P4204, DOI 10.1021/jf991384j; Gonzalez-Bello C, 2017, BIOORG MED CHEM LETT, V27, P4221, DOI 10.1016/j.bmcl.2017.08.027; Gordon D, 2010, KUCERS USE ANTIBIOTI, P187; Grant SS, 2013, VIRULENCE, V4, P273, DOI 10.4161/viru.23987; Hao YB, 2018, MOLECULES, V23, DOI 10.3390/molecules23092173; Helaine S, 2014, TRENDS MICROBIOL, V22, P417, DOI 10.1016/j.tim.2014.03.008; Kalan L, 2011, EXPERT REV MOL MED, V13, DOI 10.1017/S1462399410001766; KAPRELYANTS AS, 1987, BIOL MEMBRANY, V4, P254; Kawai Y, 2018, CELL, V172, P1038, DOI 10.1016/j.cell.2018.01.021; Kemme M, 2018, J FUNCT BIOMATER, V9, DOI 10.3390/jfb9010004; Keren I, 2004, FEMS MICROBIOL LETT, V230, P13, DOI 10.1016/S0378-1097(03)00856-5; Kim SG, 2011, ONCOL REP, V26, P1527, DOI 10.3892/or.2011.1436; Krupyanskii YF, 2012, RUSS J PHYS CHEM B+, V6, P301, DOI 10.1134/S1990793112020078; Lee HJ, 2013, ANTIMICROB AGENTS CH, V57, P3738, DOI 10.1128/AAC.00703-13; Levin-Reisman I, 2017, SCIENCE, V355, P826, DOI 10.1126/science.aaj2191; Lewis K, 2010, ANNU REV MICROBIOL, V64, P357, DOI 10.1146/annurev.micro.112408.134306; Linko AM, 2005, BRIT J NUTR, V93, P10, DOI 10.1079/BJN20041281; Liukkonen KH, 2003, P NUTR SOC, V62, P117, DOI 10.1079/PNS2002218; Luis A, 2016, MINI-REV MED CHEM, V16, P851, DOI 10.2174/1389557516666160211121437; Mart'ianov S V, 2015, Mikrobiologiia, V84, P27; Martirosova EI, 2004, MICROBIOLOGY+, V73, P609, DOI 10.1023/B:MICI.0000044252.10568.08; Mehta KC, 2014, J CLIN DIAGN RES, V8, pME5, DOI 10.7860/JCDR/2014/8778.4489; Michiels J, 2016, BACTERIAL PERSISTENC; MORRIS TH, 1995, LAB ANIM, V29, P16, DOI 10.1258/002367795780740393; Nikolaev YA, 2006, MICROBIOLOGY+, V75, P420, DOI 10.1134/S0026261706040096; O'Hara JA, 2013, ANTIMICROB AGENTS CH, V57, P2103, DOI 10.1128/AAC.02501-12; Odds FC, 2003, J ANTIMICROB CHEMOTH, V52, P1, DOI 10.1093/jac/dkg301; Omardien S, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00111; Ren H, 2015, J ANTIMICROB CHEMOTH, V70, P3267, DOI 10.1093/jac/dkv251; Ross AB, 2004, NUTR REV, V62, P81, DOI 10.1301/nr.2004.mar.81-95; Seok J, 2013, P NATL ACAD SCI USA, V110, P3507, DOI 10.1073/pnas.1222878110; Stasiuk M, 2010, CELL MOL LIFE SCI, V67, P841, DOI 10.1007/s00018-009-0193-1; Sumino M, 2002, CHEM PHARM BULL, V50, P1484, DOI 10.1248/cpb.50.1484; Sviridova T. G., 2013, Immunologiya, V34, P84; Vorobyev A.A., 1962, STAT METHODS MICROBI; Windels EM, 2019, ISME J, V13, P1239, DOI 10.1038/s41396-019-0344-9; Wright GD, 2016, TRENDS MICROBIOL, V24, P928, DOI 10.1016/j.tim.2016.07.008; Yen GC, 2003, FREE RADICAL RES, V37, P509, DOI 10.1080/1071576031000083099	69	7	9	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 22	2020	15	9							e0239147	10.1371/journal.pone.0239147	http://dx.doi.org/10.1371/journal.pone.0239147			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NW6FH	32960928	Green Published, gold			2023-01-03	WOS:000575109500020
J	Vernier, M; McGuirk, S; Dufour, CR; Wan, LXY; Audet-Walsh, E; St-Pierre, J; Giguere, V				Vernier, Mathieu; McGuirk, Shawn; Dufour, Catherine R.; Wan, Liangxinyi; Audet-Walsh, Etienne; St-Pierre, Julie; Giguere, Vincent			Inhibition of DNMT1 and ERR alpha crosstalk suppresses breast cancer via derepression ofIRF4	ONCOGENE			English	Article							ESTROGEN-RELATED RECEPTORS; ONE-CARBON METABOLISM; DNA METHYLATION; TUMOR-SUPPRESSOR; ADIPOSE-TISSUE; GENES; TARGET; DECITABINE; SERINE; CONVERSION	DNA methylation is implicated in the acquisition of malignant phenotypes, and the use of epigenetic modulating drugs is a promising anti-cancer therapeutic strategy. 5-aza-2'deoxycytidine (decitabine, 5-azadC) is an FDA-approved DNA methyltransferase (DNMT) inhibitor with proven effectiveness against hematological malignancies and more recently triple-negative breast cancer (BC). Herein, genetic or pharmacological studies uncovered a hitherto unknown feedforward molecular link between DNMT1 and the estrogen related receptor alpha (ERR alpha), a key transcriptional regulator of cellular metabolism. Mechanistically, DNMT1 promotes ERR alpha stability which in turn couples DNMT1 transcription with that of the methionine cycle and S-adenosylmethionine synthesis to drive DNA methylation. In vitro and in vivo investigation using a pre-clinical mouse model of BC demonstrated a clear therapeutic advantage for combined administration of the ERR alpha inhibitor C29 with 5-azadC. A large-scale bisulfite genomic sequencing analysis revealed specific methylation perturbations fostering the discovery that reversal of promoter hypermethylation and consequently derepression of the tumor suppressor gene,IRF4, is a factor underlying the observed BC suppressive effects. This work thus uncovers a critical role of ERR alpha in the crosstalk between transcriptional control of metabolism and epigenetics and illustrates the potential for targeting ERR alpha in combination with DNMT inhibitors for BC treatment and other epigenetics-driven malignancies.	[Vernier, Mathieu; McGuirk, Shawn; Dufour, Catherine R.; Wan, Liangxinyi; Audet-Walsh, Etienne; St-Pierre, Julie; Giguere, Vincent] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [St-Pierre, Julie; Giguere, Vincent] McGill Univ, Fac Med, Dept Biochem, Montreal, PQ H3G 1Y6, Canada; [St-Pierre, Julie; Giguere, Vincent] McGill Univ, Fac Med, Dept Med, Montreal, PQ H3G 1Y6, Canada; [St-Pierre, Julie; Giguere, Vincent] McGill Univ, Fac Med, Dept Oncol, Montreal, PQ H3G 1Y6, Canada; [Audet-Walsh, Etienne] Univ Laval, Dept Med Mol, Fac Med, Ctr Rech,CHU Quebec, Quebec City, PQ G1V 4G2, Canada; [St-Pierre, Julie] Univ Ottawa, Ottawa Inst Syst Biol, Fac Med, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada	McGill University; McGill University; McGill University; McGill University; Laval University; University of Ottawa	Vernier, M; Giguere, V (corresponding author), McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada.; Giguere, V (corresponding author), McGill Univ, Fac Med, Dept Biochem, Montreal, PQ H3G 1Y6, Canada.; Giguere, V (corresponding author), McGill Univ, Fac Med, Dept Med, Montreal, PQ H3G 1Y6, Canada.; Giguere, V (corresponding author), McGill Univ, Fac Med, Dept Oncol, Montreal, PQ H3G 1Y6, Canada.	mathieu.vernier@mail.mcgill.ca; vincent.giguere@mcgill.ca	St-Pierre, Julie/AGB-3651-2022	St-Pierre, Julie/0000-0002-2815-7099; Giguere, Vincent/0000-0001-9567-3694; Dufour, Catherine Rosa/0000-0001-7324-3458; Vernier, Mathieu/0000-0001-9356-7353	Terry Fox Research Institute Program Project Team Grant on Oncometabolism; Canadian Institutes of Health Research (CIHR); CIHR [MOP-106603]; Vanier Canada Graduate Scholarship-CIHR; CIHR	Terry Fox Research Institute Program Project Team Grant on Oncometabolism; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR)); Vanier Canada Graduate Scholarship-CIHR(Canadian Institutes of Health Research (CIHR)); CIHR(Canadian Institutes of Health Research (CIHR))	We acknowledge contributions from the Metabolomics Core Facility (MCF) of the GCRC, as well as technical assistance from Dr. Daina Avizonis, Mariana De Sa Tavares Russo, Gaelle Bridon, and Luc Choiniere. We thank all members of the V.G. laboratory for discussions, Xiaojing Li for technical assistance and Dr. David J. Papadopoli for guidance with metabolic studies. This work was supported by a Terry Fox Research Institute Program Project Team Grant on Oncometabolism (VG and JS-P), a Foundation Grant from the Canadian Institutes of Health Research (CIHR) to VG, and an operating grant from CIHR to JS-P (MOP-106603). MV was a recipient of a post-doctoral fellowship from CIHR. SM was supported by a Vanier Canada Graduate Scholarship-CIHR. EAW was a recipient of a post-doctoral fellowship from CIHR.	Acquaviva J, 2008, BLOOD, V112, P3798, DOI 10.1182/blood-2007-10-117838; Ariazi EA, 2002, CANCER RES, V62, P6510; Audet-Walsh E, 2016, CELL REP, V14, P920, DOI 10.1016/j.celrep.2015.12.086; Audet-Walsh E, 2015, ACTA PHARMACOL SIN, V36, P51, DOI 10.1038/aps.2014.121; Barcena C, 2018, CELL REP, V24, P2392, DOI 10.1016/j.celrep.2018.07.089; Barry JB, 2005, CANCER RES, V65, P6120, DOI 10.1158/0008-5472.CAN-05-0922; Bauerle MR, 2015, J BIOL CHEM, V290, P3995, DOI 10.1074/jbc.R114.607044; Cao S, 2017, CANCER RES, V77, P4185, DOI 10.1158/0008-5472.CAN-17-0262; Castellano-Castillo D, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010087; Chang CY, 2011, CANCER CELL, V20, P500, DOI 10.1016/j.ccr.2011.08.023; Chen MY, 2011, CANCER-AM CANCER SOC, V117, P4424, DOI 10.1002/cncr.26073; Cowan LA, 2010, EPIGENOMICS-UK, V2, P71, DOI 10.2217/EPI.09.44; de la Rosa J, 2017, NAT GENET, V49, P730, DOI 10.1038/ng.3817; Deblois G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12156; Deblois G, 2013, NAT REV CANCER, V13, P27, DOI 10.1038/nrc3396; Deblois G, 2009, CANCER RES, V69, P6149, DOI 10.1158/0008-5472.CAN-09-1251; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Fan J, 2014, NATURE, V510, P298, DOI 10.1038/nature13236; Farlik M, 2016, CELL STEM CELL, V19, P808, DOI 10.1016/j.stem.2016.10.019; Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3; Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Heimes AS, 2017, J CANCER RES CLIN, V143, P1123, DOI 10.1007/s00432-017-2377-7; Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermann A, 2004, J BIOL CHEM, V279, P48350, DOI 10.1074/jbc.M403427200; Huss L, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1169-1; Issa Jean-Pierre, 2005, Nat Clin Pract Oncol, V2 Suppl 1, pS24, DOI 10.1038/ncponc0355; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Jeon H, 2016, ONCOTARGET, V7, P67223, DOI 10.18632/oncotarget.11615; Komninou D, 2006, NUTR CANCER, V54, P202, DOI 10.1207/s15327914nc5402_6; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lambert SA, 2018, CELL, V175, P598, DOI 10.1016/j.cell.2018.09.045; Lee BC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4592; Li Y, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0316-3; Lindqvist BM, 2014, EPIGENETICS-US, V9, P1149, DOI 10.4161/epi.29632; Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008; Luo CY, 2018, SCIENCE, V361, P1336, DOI 10.1126/science.aat6806; Maddocks ODK, 2016, MOL CELL, V61, P210, DOI 10.1016/j.molcel.2015.12.014; Martin EM, 2018, ANNU REV PUBL HEALTH, V39, P309, DOI 10.1146/annurev-publhealth-040617-014629; McGuirk S, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-22; Mehrmohamadi M, 2014, CELL REP, V9, P1507, DOI 10.1016/j.celrep.2014.10.026; Meissner A, 2005, NUCLEIC ACIDS RES, V33, P5868, DOI 10.1093/nar/gki901; Momparler RL, 1997, ANTI-CANCER DRUG, V8, P358, DOI 10.1097/00001813-199704000-00008; Phan NLC, 2016, ONCOTARGETS THER, V9, DOI 10.2147/OTT.S96291; Nilsson E, 2014, DIABETES, V63, P2962, DOI 10.2337/db13-1459; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Park S, 2019, CELL REP, V27, P3587, DOI 10.1016/j.celrep.2019.05.066; Patch RJ, 2011, J MED CHEM, V54, P788, DOI 10.1021/jm101063h; Putiri EL, 2011, CLIN EPIGENETICS, V2, P299, DOI 10.1007/s13148-010-0017-z; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Sanchez-Mut JV, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2015.214; Sanderson SM, 2019, NAT REV CANCER, V19, P625, DOI 10.1038/s41568-019-0187-8; Schade B, 2009, J BIOL CHEM, V284, P19018, DOI 10.1074/jbc.M109.018937; Shaffer AL, 2009, CLIN CANCER RES, V15, P2954, DOI 10.1158/1078-0432.CCR-08-1845; Shlomi T, 2014, ANAL CHEM, V86, P1583, DOI 10.1021/ac4032093; Smith ZD, 2013, NAT REV GENET, V14, P204, DOI 10.1038/nrg3354; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Vernier M, 2020, GENE DEV, V34, P544, DOI 10.1101/gad.330746.119; Yu J, 2018, J CLIN INVEST, V128, P2376, DOI 10.1172/JCI97924; Zdzisinska B, 2017, ARCH IMMUNOL THER EX, V65, P21, DOI 10.1007/s00005-016-0406-x	62	12	12	4	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 8	2020	39	41					6406	6420		10.1038/s41388-020-01438-1	http://dx.doi.org/10.1038/s41388-020-01438-1		AUG 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OA1JL	32855526	hybrid, Green Published			2023-01-03	WOS:000565020000002
J	Baiula, M; Greco, R; Ferrazzano, L; Caligiana, A; Hoxha, K; Bandini, D; Longobardi, P; Spampinato, S; Tolomelli, A				Baiula, Monica; Greco, Roberto; Ferrazzano, Lucia; Caligiana, Alberto; Hoxha, Klarida; Bandini, Daniele; Longobardi, Pasquale; Spampinato, Santi; Tolomelli, Alessandra			Integrin-mediated adhesive properties of neutrophils are reduced by hyperbaric oxygen therapy in patients with chronic non-healing wound	PLOS ONE			English	Article							ISCHEMIA-REPERFUSION; GENE-EXPRESSION; ALPHA(4)BETA(1) INTEGRIN; PULMONARY SEQUESTRATION; CELL MOBILIZATION; ACTIVATION; MECHANISMS; MIGRATION; INFLAMMATION; RECRUITMENT	In recent years, several studies suggested that the ability of hyperbaric oxygen therapy (HBOT) to promote healing in patients with diabetic ulcers and chronic wounds is due to the reduction of inflammatory cytokines and to a significant decrease in neutrophils recruitment to the damaged area. alpha(4)and beta(2)integrins are receptors mediating the neutrophil adhesion to the endothelium and the comprehension of the effects of hyperbaric oxygenation on their expression and functions in neutrophils could be of great importance for the design of novel therapeutic protocols focused on anti-inflammatory agents. In this study, the alpha(4)and beta(2)integrins' expression and functions have been evaluated in human primary neutrophils obtained from patients with chronic non-healing wounds and undergoing a prolonged HBOT (150 kPa per 90 minutes). The effect of a peptidomimetic alpha(4)beta(1)integrin antagonist has been also analyzed under these conditions. A statistically significant decrease (68%) in beta(2)integrin expression on neutrophils was observed during the treatment with HBO and maintained one month after the last treatment, while alpha(4)integrin levels remained unchanged. However, cell adhesion function of both neutrophilic integrins alpha(4)beta(1)and beta(2)was significantly reduced 70 and 67%, respectively), but alpha(4)beta(1)integrin was still sensitive to antagonist inhibition in the presence of fibronectin, suggesting that a combined therapy between HBOT and integrin antagonists could have greater antinflammatory efficacy.	[Baiula, Monica; Caligiana, Alberto; Spampinato, Santi] Alma Mater Studiorum Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy; [Greco, Roberto; Ferrazzano, Lucia; Tolomelli, Alessandra] Alma Mater Studiorum Univ Bologna, Dept Chem Giacomo Ciamician, Bologna, Italy; [Hoxha, Klarida; Bandini, Daniele; Longobardi, Pasquale] Hyperbar Ctr, Ravenna, Italy; [Greco, Roberto] MediNeos Observat Res, Modena, Italy	University of Bologna; University of Bologna	Spampinato, S (corresponding author), Alma Mater Studiorum Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy.; Tolomelli, A (corresponding author), Alma Mater Studiorum Univ Bologna, Dept Chem Giacomo Ciamician, Bologna, Italy.	santi.spampinato@unibo.it; alessandra.tolomelli@unibo.it	Ferrazzano, Lucia/ABE-7948-2021; Longobardi, Pasquale/AAF-9183-2020; Ferrazzano, Lucia/AAS-4327-2020; Tolomelli, Alessandra/AAO-7869-2021	Ferrazzano, Lucia/0000-0002-7083-2211; Longobardi, Pasquale/0000-0002-2383-7431; Ferrazzano, Lucia/0000-0002-7083-2211; Tolomelli, Alessandra/0000-0003-4202-1136; Baiula, Monica/0000-0003-0363-0633	Fondazione del Monte di Bologna e Ravenna [FdM/3980, 500 bis/2015]; University of Bologna [RFO17, RFO18, RFO19]; Italian Ministry of Education, University and Research with a specific research project [20157WW5EH]; University of Bologna under the initiative Department of Excellence	Fondazione del Monte di Bologna e Ravenna(Fondazione del Monte di Bologna e Ravenna); University of Bologna; Italian Ministry of Education, University and Research with a specific research project; University of Bologna under the initiative Department of Excellence	This research study was supported by Fondazione del Monte di Bologna e Ravenna (https://www.fondazionedelmonte.it/) through a grant to AT (FdM/3980; prot. No 500 bis/2015). The authors were also supported by the University of Bologna (RFO17, RFO18, RFO19) and by Italian Ministry of Education, University and Research with a specific research project (PRIN 2015 project 20157WW5EH) and a grant to the Department of Chemistry "Giacomo Ciamician" of the University of Bologna under the initiative Department of Excellence (L.232 del 01/12/2016). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; We thank all the staff of the Hyperbaric Centre (Ravenna, Italy) and Dott. Paolo Nanni for the technical support. We thankfully acknowledge "Fondazione del Monte di Bologna e Ravenna" (FdM/3980) for a fellowship to RG. We gratefully thank all the voluntary patients for donating their samples.	Allen S, 2015, SEMIN THROMB HEMOST, V41, P563, DOI 10.1055/s-0035-1556588; Baiula M, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00489; Baiula M, 2016, J MED CHEM, V59, P9721, DOI 10.1021/acs.jmedchem.6b00576; Baiula M, 2014, DRUG DES DEV THER, V8, P745, DOI 10.2147/DDDT.S62659; Baiula M, 2012, BBA-MOL CELL RES, V1823, P1252, DOI 10.1016/j.bbamcr.2012.05.026; Bamias G, 2013, CURR DRUG TARGETS, V14, P1490, DOI 10.2174/13894501113149990158; Barrientos S, 2008, WOUND REPAIR REGEN, V16, P585, DOI 10.1111/j.1524-475X.2008.00410.x; Bedini A, 2017, BIOCHEM PHARMACOL, V140, P89, DOI 10.1016/j.bcp.2017.05.021; Bowden RA, 2002, CIRC RES, V90, P562, DOI 10.1161/01.RES.0000013835.53611.97; Buras JA, 2000, AM J PHYSIOL-CELL PH, V278, pC292, DOI 10.1152/ajpcell.2000.278.2.C292; Chandel NS, 2010, ADV EXP MED BIOL, V661, P339, DOI 10.1007/978-1-60761-500-2_22; Chen MF, 1998, LIVER, V18, P110; Jancic CC, 2012, CYTOKINE, V57, P258, DOI 10.1016/j.cyto.2011.11.013; Dattoli SD, 2018, BRIT J PHARMACOL, V175, P3891, DOI 10.1111/bph.14458; Edwards DN, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.00540; Falanga V, 2000, WOUND REPAIR REGEN, V8, P347; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Gallagher KA, 2007, J CLIN INVEST, V117, P1249, DOI 10.1172/JCI29710; Goldstein LJ, 2006, STEM CELLS, V24, P2309, DOI 10.1634/stemcells.2006-0010; Goldstein LJ, 2013, DERMATOL THER, V26, P207, DOI 10.1111/dth.12053; Gottrup Finn, 2017, J Wound Care, V26, pS1, DOI 10.12968/jowc.2017.26.Sup5.S1; Hopf HW, 2007, ANTIOXID REDOX SIGN, V9, P1183, DOI 10.1089/ars.2007.1641; Hublin JSYN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077803; Kalns J, 2002, IMMUNOL LETT, V83, P125, DOI 10.1016/S0165-2478(02)00068-8; Kendall AC, 2013, WOUND REPAIR REGEN, V21, P860, DOI 10.1111/wrr.12108; Kendall AC, 2012, EXP CELL RES, V318, P207, DOI 10.1016/j.yexcr.2011.10.014; Khiabani KT, 2008, J SURG RES, V150, P11, DOI 10.1016/j.jss.2007.12.780; Kihara K, 2005, LIVER TRANSPLANT, V11, P1574, DOI 10.1002/lt.20533; Klein KC, 2014, INDIAN J PLAST SURG, V47, P303, DOI 10.4103/0970-0358.146574; Kolaczkowska E, 2013, NAT REV IMMUNOL, V13, P159, DOI 10.1038/nri3399; Kourtzelis I, 2017, J LEUKOCYTE BIOL, V102, P677, DOI 10.1189/jlb.3MR0117-024R; Larson JL, 2000, PLAST RECONSTR SURG, V105, P1375, DOI 10.1097/00006534-200004040-00017; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Lobaton T, 2014, ALIMENT PHARM THER, V39, P579, DOI 10.1111/apt.12639; Londahl M, 2010, DIABETES CARE, V33, P998, DOI 10.2337/dc09-1754; Longobardi P, 2019, NLM MEDLINE, P216; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Marcant A, 2012, J IMMUNOL, V189, P2023, DOI 10.4049/jimmunol.1102803; Margadant C, 2011, CURR OPIN CELL BIOL, V23, P607, DOI 10.1016/j.ceb.2011.08.005; Nourshargh S, 2014, IMMUNITY, V41, P694, DOI 10.1016/j.immuni.2014.10.008; Oh Hana, 2008, J Vis Exp, DOI 10.3791/745; Peyssonnaux C, 2005, J CLIN INVEST, V115, P1806, DOI 10.1172/JCI23865; Qasem AR, 2008, BIOCHEM PHARMACOL, V76, P751, DOI 10.1016/j.bcp.2008.07.007; Qian HH, 2017, MOL MED REP, V16, P3922, DOI 10.3892/mmr.2017.7079; Reinke JM, 2012, EUR SURG RES, V49, P35, DOI 10.1159/000339613; Salama SE, 2019, INT J LOW EXTR WOUND, V18, P75, DOI 10.1177/1534734619829939; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Spandidos A, 2010, NUCLEIC ACIDS RES, V38, pD792, DOI 10.1093/nar/gkp1005; STERLING DL, 1993, CIRCULATION, V88, P1931, DOI 10.1161/01.CIR.88.4.1931; Strudwick XL, 2020, ADV WOUND CARE, V9, P637, DOI 10.1089/wound.2019.1035; Sunkari VG, 2015, WOUND REPAIR REGEN, V23, P98, DOI 10.1111/wrr.12253; Sureda A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163371; Tejada S, 2019, CURR PHARM DESIGN, V25, P1682, DOI 10.2174/1381612825666190703162648; Thom SR, 2006, AM J PHYSIOL-HEART C, V290, pH1378, DOI 10.1152/ajpheart.00888.2005; Thom SR, 1997, AM J PHYSIOL-CELL PH, V272, pC770, DOI 10.1152/ajpcell.1997.272.3.C770; THOM SR, 1990, TOXICOL APPL PHARM, V105, P340, DOI 10.1016/0041-008X(90)90195-Z; Thom SR, 2008, J BIOL CHEM, V283, P10822, DOI 10.1074/jbc.M709200200; Thom SR, 2011, PLAST RECONSTR SURG, V127, p131S, DOI 10.1097/PRS.0b013e3181fbe2bf; Tjarnstrom J, 1999, EUR SURG RES, V31, P147, DOI 10.1159/000008633; Tolomelli A, 2017, CANCERS, V9, DOI 10.3390/cancers9070078; Tolomelli A, 2015, ACS MED CHEM LETT, V6, P701, DOI 10.1021/acsmedchemlett.5b00125; Wilgus TA, 2013, ADV WOUND CARE, V2, P379, DOI 10.1089/wound.2012.0383; Winer J, 1999, ANAL BIOCHEM, V270, P41, DOI 10.1006/abio.1999.4085; YAMADA T, 1995, J PEDIATR SURG, V30, P786, DOI 10.1016/0022-3468(95)90748-3; ZAMBONI W A, 1989, Journal of Reconstructive Microsurgery, V5, P343, DOI 10.1055/s-2007-1006884; Zamboni WA, 1996, ARCH SURG-CHICAGO, V131, P756; Zarember KA, 2005, J CLIN INVEST, V115, P1702, DOI 10.1172/JCI25740	67	10	10	3	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 18	2020	15	8							e0237746	10.1371/journal.pone.0237746	http://dx.doi.org/10.1371/journal.pone.0237746			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NF7CD	32810144	gold, Green Published			2023-01-03	WOS:000563451300007
J	Barnett, ML; Hu, L; Martin, T; Grabowski, DC				Barnett, Michael L.; Hu, Lissy; Martin, Thomas; Grabowski, David C.			Mortality, Admissions, and Patient Census at SNFs in 3 US Cities During the COVID-19 Pandemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This study uses Medicare's Nursing Home Compare and a university long-term care database to compare census, admissions, discharges, and mortality at skilled nursing facilities (SNFs) in 3 metropolitan areas during March-May 2020 vs March-May 2019.	[Barnett, Michael L.] Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,Kresge 411, Boston, MA 02115 USA; [Hu, Lissy; Martin, Thomas] CarePort Hlth Inc, Boston, MA USA; [Grabowski, David C.] Harvard Med Sch, Dept Hlth Care Policy, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School	Barnett, ML (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave,Kresge 411, Boston, MA 02115 USA.	mbarnett@hsph.harvard.edu	Barnett, Michael/AAF-4017-2019; Barnett, Michael/ABA-4159-2021	Barnett, Michael/0000-0002-4884-6609; Barnett, Michael/0000-0002-4884-6609; Grabowski, David/0000-0003-2915-5770	National Institute on Aging, National Institutes of Health [K23 AG058806-01]	National Institute on Aging, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This research was supported by grant K23 AG058806-01 from the National Institute on Aging, National Institutes of Health.	[Anonymous], NY TIMES; Baum A, 2020, JAMA, DOI 10.1001/jama.2020.9972; Brown University School of Public Health, LTCFOCUS LONG TERM C; Henry J. Kaiser Family Foundation, 2020, STAT DAT POL ACT ADD; McMichael TM, 2020, NEW ENGL J MED, V382, P2005, DOI 10.1056/NEJMoa2005412	5	34	35	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	2020	324	5					507	509		10.1001/jama.2020.11642	http://dx.doi.org/10.1001/jama.2020.11642			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NC5NN	32579161	Green Published, Bronze			2023-01-03	WOS:000561261900022
J	Siemieniuk, RAC; Bartoszko, JJ; Ge, L; Zeraatkar, D; Izcovich, A; Pardo-Hernandez, H; Rochwerg, B; Lamontagne, F; Han, MA; Kum, E; Liu, Q; Agarwal, A; Agoritsas, T; Alexander, P; Chu, DK; Couban, R; Darzi, A; Devji, T; Fang, B; Fang, C; Flottorp, SA; Foroutan, F; Heels-Ansdell, D; Honarmand, K; Hou, LY; Hou, XR; Ibrahim, Q; Loeb, M; Marcucci, M; McLeod, SL; Motaghi, S; Murthy, S; Mustafa, RA; Neary, JD; Qasim, A; Rada, G; Bin Riaz, I; Sadeghirad, B; Sekercioglu, N; Sheng, LL; Switzer, C; Tendal, B; Thabane, L; Tomlinson, G; Turner, T; Vandvik, PO; Vernooij, RW; Viteri-Garcia, A; Wang, Y; Yao, L; Ye, ZK; Guyatt, GH; Brignardello-Peterson, R				Siemieniuk, Reed A. C.; Bartoszko, Jessica J.; Ge, Long; Zeraatkar, Dena; Izcovich, Ariel; Pardo-Hernandez, Hector; Rochwerg, Bram; Lamontagne, Francois; Han, Mi Ah; Kum, Elena; Liu, Qin; Agarwal, Arnav; Agoritsas, Thomas; Alexander, Paul; Chu, Derek K.; Couban, Rachel; Darzi, Andrea; Devji, Tahira; Fang, Bo; Fang, Carmen; Flottorp, Signe Agnes; Foroutan, Farid; Heels-Ansdell, Diane; Honarmand, Kimia; Hou, Liangying; Hou, Xiaorong; Ibrahim, Quazi; Loeb, Mark; Marcucci, Maura; McLeod, Shelley L.; Motaghi, Sharhzad; Murthy, Srinivas; Mustafa, Reem A.; Neary, John D.; Qasim, Anila; Rada, Gabriel; Bin Riaz, Irbaz; Sadeghirad, Behnam; Sekercioglu, Nigar; Sheng, Lulu; Switzer, Charlotte; Tendal, Britta; Thabane, Lehana; Tomlinson, George; Turner, Tari; Vandvik, Per O.; Vernooij, Robin Wm; Viteri-Garcia, Andres; Wang, Ying; Yao, Liang; Ye, Zhikang; Guyatt, Gordon H.; Brignardello-Peterson, Romina			Drug treatments for covid-19: living systematic review and network meta-analysis	BMJ-BRITISH MEDICAL JOURNAL			English	Review							MULTICENTER	OBJECTIVE To compare the effects of treatments for coronavirus disease 2019 (covid-19). DESIGN Living systematic review and network meta-analysis. DATA SOURCES US Centers for Disease Control and Prevention COVID-19 Research Articles Downloadable Database, which includes 25 electronic databases and six additional Chinese databases to 20 July 2020. STUDY SELECTION Randomised clinical trials in which people with suspected, probable, or confirmed covid-19 were randomised to drug treatment or to standard care or placebo. Pairs of reviewers independently screened potentially eligible articles. METHODS After duplicate data abstraction, a bayesian random effects network meta-analysis was conducted. Risk of bias of the included studies was assessed using a modification of the Cochrane risk of bias 2.0 tool, and the certainty of the evidence using the grading of recommendations assessment, development and evaluation (GRADE) approach. For each outcome, interventions were classified in groups from the most to the least beneficial or harmful following GRADE guidance. RESULTS 23 randomised controlled trials were included in the analysis performed on 26 June 2020. The certainty of the evidence for most comparisons was very low because of risk of bias (lack of blinding) and serious imprecision. Glucocorticoids were the only intervention with evidence for a reduction in death compared with standard care (risk difference 37 fewer per 1000 patients, 95% credible interval 63 fewer to 11 fewer, moderate certainty) and mechanical ventilation (31 fewer per 1000 patients, 47 fewer to 9 fewer, moderate certainty). These estimates are based on direct evidence; network estimates for glucocorticoids compared with standard care were less precise because of network heterogeneity. Three drugs might reduce symptom duration compared with standard care: hydroxychloroquine (mean difference -4.5 days, low certainty), remdesivir (-2.6 days, moderate certainty), and lopinavir-ritonavir (-1.2 days, low certainty). Hydroxychloroquine might increase the risk of adverse events compared with the other interventions, and remdesivir probably does not substantially increase the risk of adverse effects leading to drug discontinuation. No other interventions included enough patients to meaningfully interpret adverse effects leading to drug discontinuation. CONCLUSION Glucocorticoids probably reduce mortality and mechanical ventilation in patients with covid-19 compared with standard care. The effectiveness of most interventions is uncertain because most of the randomised controlled trials so far have been small and have important study limitations.	[Siemieniuk, Reed A. C.; Bartoszko, Jessica J.; Zeraatkar, Dena; Rochwerg, Bram; Kum, Elena; Agarwal, Arnav; Agoritsas, Thomas; Alexander, Paul; Darzi, Andrea; Devji, Tahira; Foroutan, Farid; Heels-Ansdell, Diane; Ibrahim, Quazi; Loeb, Mark; Marcucci, Maura; Motaghi, Sharhzad; Mustafa, Reem A.; Qasim, Anila; Sadeghirad, Behnam; Sekercioglu, Nigar; Switzer, Charlotte; Thabane, Lehana; Wang, Ying; Yao, Liang; Ye, Zhikang; Guyatt, Gordon H.; Brignardello-Peterson, Romina] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, 1280 Main St W, Hamilton, ON L8S 4L8, Canada; [Ge, Long; Hou, Liangying] Lanzhou Univ, Evidence Based Social Sci Res Ctr, Sch Publ Hlth, Lanzhou, Gansu, Peoples R China; [Izcovich, Ariel; Honarmand, Kimia; Neary, John D.] Hosp Aleman, Serv Clin Med, Buenos Aires, DF, Argentina; [Pardo-Hernandez, Hector] St Pau Biomed Res Inst IIB St Pau, Iberoamer Cochrane Ctr, Barcelona, Spain; [Pardo-Hernandez, Hector] CIBER Epidemiol & Salud Publ CIBERESP, Barcelona, Spain; [Rochwerg, Bram; Loeb, Mark; Marcucci, Maura; Guyatt, Gordon H.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Lamontagne, Francois] CHU Sherbrooke, Dept Med, Sherbrooke, PQ, Canada; [Lamontagne, Francois] CHU Sherbrooke, Ctr Rech, Sherbrooke, PQ, Canada; [Han, Mi Ah] Chosun Univ, Coll Med, Dept Prevent Med, Gwangju, South Korea; [Liu, Qin; Fang, Bo; Sheng, Lulu] Chongqing Med Univ, Cochrane China Network Affiliate, Chongqing, Peoples R China; [Liu, Qin; Fang, Bo; Sheng, Lulu] Chongqing Med Univ, Sch Publ Hlth & Management, Chongqing, Peoples R China; [Agarwal, Arnav] Univ Toronto, Dept Med, Toronto, ON, Canada; [Agoritsas, Thomas] Univ Hosp Geneva, Div Gen Internal Med, Geneva, Switzerland; [Agoritsas, Thomas] Univ Hosp Geneva, Div Clin Epidemiol, Geneva, Switzerland; [Couban, Rachel; Sadeghirad, Behnam] McMaster Univ, Dept Anesthesia, Hamilton, ON, Canada; [Fang, Carmen; Vandvik, Per O.] William Oster Hlth Network, Toronto, ON, Canada; [Flottorp, Signe Agnes] Norwegian Inst Publ Hlth, Oslo, Norway; [Chu, Derek K.; Flottorp, Signe Agnes] Univ Oslo, Inst Hlth & Soc, Oslo, Norway; [Foroutan, Farid] Toronto Gen Hosp, Ted Rogers Ctr Heart Res, Toronto, ON, Canada; [Hou, Xiaorong] Chongqing Med Univ, Coll Med Informat, Chongqing, Peoples R China; [McLeod, Shelley L.] Sinai Hlth, Schwartz Reisman Emergency Med Inst, Toronto, ON, Canada; [McLeod, Shelley L.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Murthy, Srinivas] Univ British Columbia, Fac Med, Dept Pediat, Vancouver, BC, Canada; [Mustafa, Reem A.] Univ Kansas, Med Ctr, Dept Med, Kansas City, MO USA; [Rada, Gabriel; Viteri-Garcia, Andres] Epistemonikos Fdn, Santiago, Chile; [Rada, Gabriel] Pontificia Univ Catolica Chile, Cochrane Chile Associated Ctr, UC Evidence Ctr, Santiago, Chile; [Bin Riaz, Irbaz] Mayo Clin Rochester, Hematol & Oncol, Rochester, MN USA; [Tendal, Britta; Turner, Tari] Monash Univ, Sch Publ Hlth & Preventat Med, Melbourne, Vic, Australia; [Tomlinson, George] Univ Hlth Network, Dept Med, Toronto, ON, Canada; [Vernooij, Robin Wm] Univ Med Ctr Utrecht, Dept Nephtol & Hypertens, Utrecht, Netherlands; [Vernooij, Robin Wm] Univ Utrecht, Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Viteri-Garcia, Andres] Univ UTE, Fac Ciencias Salud Eugenio Espejo, Ctr Invest Salud Publ & Epidemiol Clin CISPEQ, Quito, Ecuador	McMaster University; Lanzhou University; Hospital Aleman; University of Buenos Aires; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP; McMaster University; University of Sherbrooke; University of Sherbrooke; Chosun University; Chongqing Medical University; Chongqing Medical University; University of Toronto; University of Geneva; University of Geneva; McMaster University; Norwegian Institute of Public Health (NIPH); University of Oslo; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; Chongqing Medical University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; University of Toronto; University of British Columbia; University of Kansas; Pontificia Universidad Catolica de Chile; Mayo Clinic; Monash University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Siemieniuk, RAC (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, 1280 Main St W, Hamilton, ON L8S 4L8, Canada.	reed.siemieniuk@medportal.ca	Sadeghirad, Behnam/A-1772-2009; Vernooij, Robin/N-3652-2018; Zeraatkar, Dena/GNM-9600-2022; Agarwal, Arnav/J-1553-2014; Couban, Rachel/AAV-1568-2021; T, E/HII-8943-2022; Viteri-García, Andrés/AAA-4434-2021; McLeod, Shelley/AAE-9636-2019; Agoritsas, Thomas/F-4321-2014; SEKERCIOGLU, Nigar/AFR-0250-2022; Bin Riaz, Irbaz/ABB-3799-2020; Tomlinson, George/L-5432-2016; Khamis, Assem/P-8992-2017	Sadeghirad, Behnam/0000-0001-9422-5232; Vernooij, Robin/0000-0001-5734-4566; Agarwal, Arnav/0000-0002-0931-7851; Couban, Rachel/0000-0001-8672-2845; McLeod, Shelley/0000-0003-2686-6307; Agoritsas, Thomas/0000-0002-6182-9969; SEKERCIOGLU, Nigar/0000-0001-6461-8801; Bin Riaz, Irbaz/0000-0003-4249-0311; Izcovich, Ariel/0000-0001-9053-4396; Guerin, Philippe/0000-0002-6008-2963; Chu, Derek/0000-0001-8269-4496; Wang, Ying/0000-0002-2296-1991; Tomlinson, George/0000-0002-9328-6399; Qasim, Anila/0000-0001-9658-0078; Murthy, Srinivas/0000-0002-9476-839X; Khamis, Assem/0000-0002-5567-7065; Viteri-Garcia, Andres/0000-0003-0393-2404; Siemieniuk, Reed/0000-0002-3725-3031; Lamontagne, Francois/0000-0002-0360-3427; Kum, Elena/0000-0002-6548-2632; Yao, Liang/0000-0003-4068-3136	Canadian Institutes of Health Research [CIHR-IRSC:0579001321]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This study was supported by the Canadian Institutes of Health Research (grant CIHR-IRSC:0579001321).	Amat-Santos IJ, 2020, J AM COLL CARDIOL, V76, P268, DOI 10.1016/j.jacc.2020.05.040; [Anonymous], 2020, GEMTC NETWORK META A; [Anonymous], COVIDENCE SYSTEMATIC; [Anonymous], 2020, R2JAGS USING R TO RU; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Bi YB, 2020, FRONT BUS RES CHINA, V14, DOI 10.1186/s11782-020-00080-8; Borba MGS, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.8857; Borba MGS, 2020, CHLOROQUINE DIPHOSPH, DOI [10.1101/2020.04.07.20056424, 10.1101/ 2020.04.07.20056424., DOI 10.1101/2020.04.07.20056424]; Boulware DR, 2020, NEW ENGL J MED, V383, P517, DOI 10.1056/NEJMoa2016638; Boutron I, 2020, INTERVENTIONS FOR PR; Brignardello-Petersen R, 2020, GRADE APPROACH TO DR; Brignardello-Petersen R, 2019, J CLIN EPIDEMIOL, V108, P77, DOI 10.1016/j.jclinepi.2018.11.025; Brignardello-Petersen R, 2019, J CLIN EPIDEMIOL, V105, P60, DOI 10.1016/j.jclinepi.2018.08.022; Brignardello-Petersen R, 2018, J CLIN EPIDEMIOL, V93, P36, DOI 10.1016/j.jclinepi.2017.10.005; Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI 10.1056/NEJMoa2001282; Cao Yang, 2020, J Allergy Clin Immunol, V146, P137, DOI 10.1016/j.jaci.2020.05.019; Cavalcanti AB, 2020, NEW ENGL J MED, V383, P2041, DOI 10.1056/NEJMoa2019014; Chaimani A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076654; Chen C, 2020, FAVIPIRAVIR VERSUS A, DOI [10.1101/2020.03.17.20037432, DOI 10.1101/2020.03.17.20037432]; Chen CP, 2020, MEDRXIV PREPRINT 202, DOI [10.1101/2020.07.08.20148841, DOI 10.1101/2020.07.08.20148841]; Chen J, 2019, J ZHEJIANG U, V49, P215; Chen L., 2020, EFFICACY SAFETY CHLO, DOI [10.1101/2020.06.19.20136093, 10.1101/.20136093]; Chen Y-K, 2020, COMPARATIVE EFFECTIV; Chen Z, 2020, EFFICACY HYDROXYCHLO, P114, DOI [10.1101/2020.03.22.20040758, DOI 10.1101/2020.03.22.20040758]; Corral L, 2020, MEDRXIV PREPRINT 202; Cytel, 2020, GLOBAL CORONAVIRUS C; Davoodi L, 2020, INT J CLIN PRACT, V74, DOI 10.1111/ijcp.13600; Davoudi-Monfared E, 2020, EFFICACY AND SAFETY; Davoudi-Monfared E, 2020, ANTIMICROB AGENTS CH, V64, DOI 10.1128/AAC.01061-20; Deftereos SG, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.13136; Djulbegovic B, 2020, J CLIN EPIDEMIOL, V126, P164, DOI 10.1016/j.jclinepi.2020.07.002; Elliott JH, 2017, J CLIN EPIDEMIOL, V91, P23, DOI 10.1016/j.jclinepi.2017.08.010; Friedrich JO, 2011, J CLIN EPIDEMIOL, V64, P556, DOI 10.1016/j.jclinepi.2010.09.016; Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301; Guan Y., 2020, EXPLORATORY RANDOMIZ, V2020, DOI [10.1101/2020.03.19.20038984, DOI 10.1101/2020.03.19.20038984]; Guvenmez O, 2020, J POPUL THER CLIN PH, V27, pE5, DOI 10.15586/jptcp.v27iSP1.684; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Horby P, 2020, NEW ENGL J MED, DOI [10.1101/2020.06.22.20137273:24, DOI 10.1056/NEJMOA2021436, 10.1101/2020.06.22.20137273, 10.1101/2020.06.22.20137273v1, DOI 10.1101/2020.07.15.20151852]; Horby P, 2020, MEDRXIV PREPRINT 202; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Huang MX, 2020, J MOL CELL BIOL, V12, P322, DOI 10.1093/jmcb/mjaa014; Hultcrantz M, 2017, J CLIN EPIDEMIOL, V87, P4, DOI 10.1016/j.jclinepi.2017.05.006; Hung IFN, 2020, LANCET, V395, P1695, DOI 10.1016/S0140-6736(20)31042-4; Hutton B, 2015, ANN INTERN MED, V162, P777, DOI 10.7326/M14-2385; ISARIC (International Severe Acute Respiratory and Emerging Infections Consortium), 2020, COVID 19 REPORT 08 J; Juul S, 2020, SYST REV-LONDON, V9, DOI 10.1186/s13643-020-01371-0; Khalafallah A, 2010, MEDITERR J HEMATOL I, V2, DOI [10.4084/MJHID.2010.005, 10.1136/bmj.l4898]; Li YP, 2020, MED-CAMBRIDGE, V1, P105, DOI 10.1016/j.medj.2020.04.001; Lou Y, 2020, CLIN OUTCOMES PLASMA, DOI [10.1101/2020.04.29.20085761, DOI 10.1101/2020.04.29.20085761]; Marshall IJ, 2018, RES SYNTH METHODS, V9, P602, DOI 10.1002/jrsm.1287; Mitja O, 2020, HYDROXYCHLOROQUINE A; Mitja O, 2021, CLIN INFECT DIS, V73, pE4073, DOI 10.1093/cid/ciaa1009; Niaee MS, 2021, ASIAN PAC J TROP MED, V14, P266, DOI 10.4103/1995-7645.318304; Norwegian Institute of Public Health, 2020, NIPH SYSTEMATIC AND; Puhan MA, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g5630; Rochwerg B, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m2924; Rover C., 2017, ARXIV PREPRINT ARXIV; Schandelmaier S, 2020, CMAJ; SIEMIENIUK RA, 2016, BMJ-BRIT MED J, V354, DOI DOI 10.1136/BMJ.I5191; Skipper CP, 2020, ANN INTERN MED, V173, P623, DOI 10.7326/M20-4207; Spineli L, 2017, OBTAINING ABSOLUTE E; Tang W., 2020, HYDROXYCHLOROQUINE P, DOI [10.1101/2020.04.10.20060558, DOI 10.1101/2020.04.10.20060558]; Tang W, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1849; The Stephen B. Thacker CDC Library, 2020, THACKER CDC LIBRARY; Turner RM, 2015, STAT MED, V34, P984, DOI 10.1002/sim.6381; van Valkenhoef G, 2016, RES SYNTH METHODS, V7, P80, DOI 10.1002/jrsm.1167; Vandvik PO, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0596-4; Wang YM, 2020, LANCET, V395, P1569, DOI 10.1016/S0140-6736(20)31022-9; WHO, 2020, INF PREV CONTR HLTH, P1; Yuan X., 2020, PULMONARY RADIOLOGIC, DOI [10.1101/2020.04.07.20054767, DOI 10.1101/2020.04.07.20054767]; Zheng F., 2020, MEDRXIV, DOI [10.1101/2020.04.24.20077735, DOI 10.1101/2020.04.24.20077735]; Zhong M., 2020, RANDOMIZED SINGLE BL, DOI [10.1101/2020.04.15.20066266, DOI 10.1101/2020.04.15.20066266]; Zhou WaiMin, 2020, Chinese Journal of Virology, V36, P160, DOI 10.13242/j.cnki.bingduxuebao.003679	73	415	424	5	56	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 30	2020	370								m2980	10.1136/bmj.m2980	http://dx.doi.org/10.1136/bmj.m2980			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV1RG	32732190	Green Published, hybrid			2023-01-03	WOS:000556139900002
J	Shah, SS; Abdi, A; Ozcem, B; Basgut, B				Shah, Syed Sikandar; Abdi, Abdikarim; Ozcem, Barcin; Basgut, Bilgen			The rational use of thromboprophylaxis therapy in hospitalized patients and the perspectives of health care providers in Northern Cyprus	PLOS ONE			English	Article							DEEP-VEIN THROMBOSIS; RISK-ASSESSMENT; VENOUS THROMBOEMBOLISM; PREVENTION; GUIDE; CAPRINI	Background Despite the presence of effective strategies and standard guidelines for the prevention of deep vein thrombosis (DVT), a considerable proportion of patients at risk of developing thromboembolism did not receive prophylaxis during hospitalization, while others received it irrationally, thus led to unwanted side effects. Aim This study aimed to evaluate the current thromboprophylaxis practice and management of hospitalized patients at risk of developing DVT, along with the assessment of health care providers (HCPs) knowledge, and attitudes regarding DVT prevention. Methods An observational study was conducted in the general wards of two leading tertiary university hospitals in Northern Cyprus in which patients from multiple clinics were enrolled to investigate the rational use of DVT prophylaxis using the Caprini risk assessment tool. Patients were also followed for possible complications two weeks post-hospitalization. A cross-sectional study followed to assess the knowledge and attitude of HCPs regarding DVT risks and prophylaxis. Results Of the 180 patients enrolled, 47.7% were identified as irrationally managed, 52.3% were identified as rationally managed, 77.8% of patients were identified as having a high level of risk. Notably, Four of thirteen patients who received more thromboprophylaxis developed minor complications. Additionally, 73.3% of nurses had not received DVT education. Furthermore, more than 50% of physicians and nurses achieved a low knowledge score for DVT risks and prophylaxis. Conclusions A high degree of irrationality in the administration of thromboprophylaxis therapy to hospitalized patients was observed. The overall scores for HCPs indicated insufficient knowledge of DVT risk assessments and prophylaxis.	[Shah, Syed Sikandar; Abdi, Abdikarim; Basgut, Bilgen] Near East Univ, Fac Pharm, Dept Clin Pharm, Nicosia, North Cyprus, Turkey; [Ozcem, Barcin] Near East Univ Hosp, Nicosia, North Cyprus, Turkey	Near East University; Near East University	Shah, SS (corresponding author), Near East Univ, Fac Pharm, Dept Clin Pharm, Nicosia, North Cyprus, Turkey.	Sikandarshah850@gmail.com	SHAH, SYED SIKANDAR/CAG-7404-2022; Shah, Syed Sikandar/GZN-0274-2022; Basgut, Bilgen/AAR-5815-2021; Abdi, Abdikarim Mohamed/ABI-4235-2020	Abdi, Abdikarim Mohamed/0000-0002-5064-7094; SHAH, SYED SIKANDAR/0000-0003-4017-0664				Al-Mugheed KA, 2018, J VASC NURS, V36, P71, DOI 10.1016/j.jvn.2018.02.001; Alikhan R, 2014, COCHRANE DB SYST REV, V5, P1; Antony A.M., 2016, IOSR NURS HLTH SCI, V5, P18, DOI [10. 9790/1959-05171824, DOI 10.9790/1959-05171824]; Badireddy M, 2018, DEEP VENOUS THROMBOS; Burke LG, 2017, JAMA-J AM MED ASSOC, V317, P2105, DOI 10.1001/jama.2017.5702; Caprini JA, 2005, DM-DIS MON, V51, P70, DOI 10.1016/j.disamonth.2005.02.003; Caprini JA, 2010, AM J SURG, V199, pS3, DOI 10.1016/j.amjsurg.2009.10.006; Connelly L., 2008, J NURSING, V17, P411; Deng J, 2015, AM SOC HEMATOLOGY; Elham Bukhari, 2012, NATURE PRECEPTORSHIP; Fahimi F, 2008, ENOXAPARIN UTILIZATI; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Imberti D, 2018, INTERN EMERG MED, V13, P1037, DOI 10.1007/s11739-018-1802-5; Jetha L., 2007, DRUG USAGE REV THERA; Kesieme E, 2011, J BLOOD MED, V2, P59, DOI 10.2147/JBM.S19009; Kingue S, 2014, CARDIOVASC J AFR, V25, P159, DOI 10.5830/CVJA-2014-025; Liu XH, 2016, INTERACT CARDIOV TH, V23, P538, DOI 10.1093/icvts/ivw158; Mariam MG, 2016, J MENT DISORD TREAT, V2, P108; Motykie GD, 2000, J THROMB THROMBOLYS, V9, P253, DOI 10.1023/A:1018770712660; Nekoonam B, 2016, ARCH CRIT CARE MED, V1, pe8497; Novo-Veleiro I, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-021288; O'Donnell M, 2003, CAN J SURG, V46, P129; Obi AT, 2015, JAMA SURG, V150, P941, DOI 10.1001/jamasurg.2015.1841; OFORIASENSO R, 2016, PHARMACY, V4, P61295, DOI [DOI 10.3390/pharmacy4040035, DOI 10.3390/PHARMACY4040035]; Pereira Cristiano Almeida, 2008, J. vasc. bras., V7, P18, DOI 10.1590/S1677-54492008000100005; Shahian DM, 2012, ACAD MED, V87, P701, DOI 10.1097/ACM.0b013e318253676a; Sharif-Kashani Babak, 2015, Tanaffos, V14, P27; Stone J, 2017, CARDIOVASC DIAGN THE, V7, pS276, DOI 10.21037/cdt.2017.09.01; Tomkowski W, 2011, ACTA ANGIOL, V17, P49; White RH, 2003, CIRCULATION, V107, pI4, DOI 10.1161/01.CIR.0000078468.11849.66; Zeitoun AA, 2009, J THROMB THROMBOLYS, V28, P192, DOI 10.1007/s11239-008-0298-7; Zobeiri M, 2011, PROPHYLAXIS DEEP VEN	33	3	3	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 15	2020	15	7							e0235495	10.1371/journal.pone.0235495	http://dx.doi.org/10.1371/journal.pone.0235495			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB3GI	32667938	Green Published, gold			2023-01-03	WOS:000560402000017
J	Soos, J; Resch, MD; Berko, S; Kovacs, A; Katona, G; Facsko, A; Csanyi, E; Budai-Szucs, M				Soos, Judit; Resch, Miklos D.; Berko, Szilvia; Kovacs, Anita; Katona, Gabor; Facsko, Andrea; Csanyi, Erzsebet; Budai-Szucs, Maria			Comparison of hydrophilic ophthalmic media on silicone oil emulsification	PLOS ONE			English	Article							INTRAOCULAR SILICONE; COMPLICATIONS; REPLACEMENT; EYES	The aim of this study was to investigate whether and how the biological media which are in contact with silicone oil play a role in the silicone emulsification process. Commercially available Oxane 1300 silicone oil and potential hydrophilic phases of the emulsions in the eye (porcine aqueous humor, porcine vitreous and balanced salt solution) were investigated separately and in a mixture or emulsions by means of surface tension, rheological, zeta potential measurements and microscopic investigation. The surface tension of biological media (vitreous and aqueous humor) was significantly lower than that of non-biological media, especially in the case of aqueous humor, which indicates a remarkable emulsification tendency with these phases. The biological media are able to form both oil-in-water and water-in-oil emulsions, which can be observed in the clinical practice as well. It was established that the vitreous has a more expressed emulsification ability compared with the aqueous humor because smaller and more stable droplets can form with silicon oil when the vitreous is still there. It can be concluded that the vitreous has a higher impact on emulsification than the aqueous medium, which can predict that the vitreous remaining after vitrectomy has a key role in emulsion formation in the eye with silicone oil endotamponade.	[Soos, Judit; Facsko, Andrea] Univ Szeged, Dept Ophthalmol, Szeged, Hungary; [Soos, Judit] Univ Szeged, Doctoral Sch Clin Med, Szeged, Hungary; [Resch, Miklos D.] Semmelweis Univ, Dept Ophthalmol, Budapest, Hungary; [Berko, Szilvia; Kovacs, Anita; Katona, Gabor; Csanyi, Erzsebet; Budai-Szucs, Maria] Univ Szeged, Dept Pharmaceut Technol & Regulatory Affairs, Szeged, Hungary	Szeged University; Szeged University; Semmelweis University; Szeged University	Csanyi, E (corresponding author), Univ Szeged, Dept Pharmaceut Technol & Regulatory Affairs, Szeged, Hungary.	csanyi@pharm.u-szeged.hu	Berkó, Szilvia/AFM-7458-2022; Katona, Gabor/AFE-0796-2022	Berkó, Szilvia/0000-0002-3842-8876; Katona, Gabor/0000-0003-1564-4813	University of Szeged Open Access Fund [4520]	University of Szeged Open Access Fund	The publication was supported by The University of Szeged Open Access Fund (Fund Ref, Grant No. 4520) The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ARMALY MF, 1962, ARCH OPHTHALMOL-CHIC, V68, P390, DOI 10.1001/archopht.1962.00960030394013; Azen SP, 1998, OPHTHALMOLOGY, V105, P1587, DOI 10.1016/S0161-6420(98)99023-6; Brunner S, 2011, GRAEF ARCH CLIN EXP, V249, P29, DOI 10.1007/s00417-010-1464-0; Chan YK, 2017, ACTA OPHTHALMOL, V95, pE385, DOI 10.1111/aos.13258; Chan YK, 2011, INVEST OPHTH VIS SCI, V52, P9721, DOI 10.1167/iovs.11-8586; CIBIS PA, 1962, ARCH OPHTHALMOL-CHIC, V68, P590; de Silva DJ, 2005, BRIT J OPHTHALMOL, V89, P1348, DOI 10.1136/bjo.2004.063768; FEDERMAN JL, 1988, OPHTHALMOLOGY, V95, P870, DOI 10.1016/s0161-6420(88)33080-0; Halberstadt M, 2006, KLIN MONATSBL AUGENH, V223, P361, DOI 10.1055/s-2006-926594; Hanaor D, 2012, J EUR CERAM SOC, V32, P235, DOI 10.1016/j.jeurceramsoc.2011.08.015; Heidenkummer H-P, 1992, RETINA, V12, P28; HEIDENKUMMER HP, 1991, GRAEF ARCH CLIN EXP, V229, P88, DOI 10.1007/BF00172269; Ichhpujani P, 2009, GRAEF ARCH CLIN EXP, V247, P1585, DOI 10.1007/s00417-009-1155-x; Jonas JB, 2001, J GLAUCOMA, V10, P102, DOI 10.1097/00061198-200104000-00006; Kruglyakov P. M., 2000, HYDROPHILE LIPOPHILE; Lakits A, 1999, OPHTHALMOLOGY, V106, P1091, DOI 10.1016/S0161-6420(99)90261-0; Lu YJ, 2019, ACTA OPHTHALMOL, V97, P313, DOI 10.1111/aos.13982; Mezger TG, 2006, RHEOLOGY HDB, P2; Miller JB, 2014, SEMIN OPHTHALMOL, V29, P312, DOI 10.3109/08820538.2014.962181; NAKAMURA K, 1990, INVEST OPHTH VIS SCI, V31, P647; Partenhauser A, 2017, J BIOMED MATER RES B, V105, P551, DOI 10.1002/jbm.b.33575; REFOJO MF, 1988, OPHTHALMOLOGY, V95, P614; RIEDEL KG, 1990, GRAEF ARCH CLIN EXP, V228, P19, DOI 10.1007/BF02764284; Toklu Y, 2012, RETINA-J RET VIT DIS, V32, P2039, DOI 10.1097/IAE.0b013e3182561f98	24	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2020	15	6							e0235067	10.1371/journal.pone.0235067	http://dx.doi.org/10.1371/journal.pone.0235067			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC4LX	32559226	Green Accepted, gold, Green Published			2023-01-03	WOS:000543261600051
J	Price, J; Rushton, A; Tyros, I; Tyros, V; Heneghan, NR				Price, Jonathan; Rushton, Alison; Tyros, Isaak; Tyros, Vasileios; Heneghan, Nicola R.			Effectiveness and optimal dosage of exercise training for chronic non-specific neck pain: A systematic review with a narrative synthesis	PLOS ONE			English	Review							RANDOMIZED CONTROLLED-TRIAL; CERVICAL FLEXOR MUSCLES; DOSE-RESPONSE; THERAPEUTIC EXERCISE; MUSCULOSKELETAL PAIN; DISABILITY INDEX; CLINICAL-TRIAL; RESISTANCE; PROGRAMS; STRENGTH	Background Clinical guidelines make vague recommendations as to exercise training (ET) type and dosage to manage chronic non-specific neck pain (CNSNP). Objective To synthesise evidence on the effectiveness of different ET programmes to reduce CNSNP and associated disability, and whether dosage affects outcomes. Methods A systematic review and data synthesis was conducted according to a published registered protocol (PROSPERO CRD42018096187). A sensitive topic-based search was conducted of CINAHL, MEDLINE, EMBASE, PEDro, grey literature sources and key journals from inception to 6(th)January 2020 for randomised controlled trials, investigating ET for CNSNP or disability. Two reviewers independently completed eligibility screening, data extraction, risk of bias assessment (Cochrane Risk of Bias Tool) and rated the overall strength of evidence using Grading of Recommendations Assessment, Development and Evaluation. Data was tabulated for narrative synthesis and grouped by intervention, outcome and time point to compare across studies. Results Twenty-six trials from 3990 citations (n = 2288 participants) investigated fifteen ET programmes. High RoB and low sample sizes reduced evidence quality. Clinical heterogeneity prevented meta-analyses. A range of ET programmes reduce pain/disability in the short term (low to moderate evidence). Pillar exercises reduce pain/disability in the intermediate term (low level evidence). Moderate to very large pain reduction is found with ET packages that include motor control + segmental exercises (low to moderate evidence). No high-quality trials investigated long term outcomes. Increased frequency of motor control exercises and progressively increased load of pillar exercise may improve effectiveness. Conclusions Motor control + segmental exercises are the most effective ET to reduce short term pain/disability, but long-term outcomes have not been investigated. Optimal motor control + segmental exercise variables and dosage is unknown and requires clarification. An adequately powered, low RoB trial is needed to evaluate the effectiveness and optimal dosage of motor control + segmental on long term outcomes.	[Price, Jonathan] Birmingham Community Healthcare NHS Fdn Trust, Musculoskeletal Physiotherapy Serv, Birmingham, W Midlands, England; [Price, Jonathan; Rushton, Alison; Tyros, Isaak; Heneghan, Nicola R.] Univ Birmingham, Coll Life & Environm Sci, Ctr Precis Rehabil Spinal Pain CPR Spine, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England; [Tyros, Isaak; Tyros, Vasileios] Edgbaston Physiotherapy Clin, Birmingham, W Midlands, England	University of Birmingham	Heneghan, NR (corresponding author), Univ Birmingham, Coll Life & Environm Sci, Ctr Precis Rehabil Spinal Pain CPR Spine, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England.	n.heneghan@bham.ac.uk	Rushton, Alison/V-1260-2017; R Heneghan, Nicola/B-2647-2016	Rushton, Alison/0000-0001-8114-7669; Price, Jonathan/0000-0002-5505-1564; R Heneghan, Nicola/0000-0001-7599-3674	Health Education England; National Institute for Health Research (HEE/NIHR ICA Programme Pre-doctoral Clinical Academic Fellowship) [ICA-PCAF-2018-01-117]	Health Education England; National Institute for Health Research (HEE/NIHR ICA Programme Pre-doctoral Clinical Academic Fellowship)	This work was completed as part of a Clinical Health Research MRes at the University of Birmingham, UK funded by Health Education England and National Institute for Health Research (HEE/NIHR ICA Programme Pre-doctoral Clinical Academic Fellowship, Mr Jonathan Price, ICA-PCAF-2018-01-117). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Isaak Tyros and Vasileios Tyros are employed by Edgbaston Physiotherapy Clinic. The funder provided support in the form of salaries for authors IT and VT, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.The specific roles of these authors are articulated in the `author contributions' section.	Ahlgren C, 2001, J REHABIL MED, V33, P162, DOI 10.1080/165019701750300627; Andersen CH, 2014, J OCCUP REHABIL, V24, P316, DOI 10.1007/s10926-013-9441-1; Andersen CH, 2013, J STRENGTH COND RES, V27, P3322, DOI 10.1519/JSC.0b013e31828f12c6; Andersen CH, 2012, BRIT J SPORT MED, V46, P1004, DOI 10.1136/bjsports-2011-090813; Andersen LL, 2008, ARTHRIT RHEUM-ARTHR, V59, P84, DOI 10.1002/art.23256; Andersen LL, 2011, PAIN, V152, P440, DOI 10.1016/j.pain.2010.11.016; [Anonymous], 2017, PEDIAT RADIOL S2, V47, pS303; [Anonymous], 2005, MINGPAO         0130, pA4; Bier JD, 2018, PHYS THER, V98, P162, DOI 10.1093/ptj/pzx118; Bird SP, 2005, SPORTS MED, V35, P841, DOI 10.2165/00007256-200535100-00002; Blangsted AK, 2008, SCAND J WORK ENV HEA, V34, P55, DOI 10.5271/sjweh.1192; Blomgren J, 2018, BMC MUSCULOSKEL DIS, V19, DOI 10.1186/s12891-018-2324-z; Bobos P, 2016, REHABIL RES PRACT, V2016, DOI 10.1155/2016/6480826; Booth J, 2017, MUSCULOSKELET CARE, V15, P413, DOI 10.1002/msc.1191; Borisut S, 2013, J PHYS THER SCI, V25, P1157, DOI 10.1589/jpts.25.1157; Callaghan MJ, 2018, BRIT J SPORT MED, V52, P625, DOI 10.1136/bjsports-2017-098296; CARROLL LJ, 2008, SPINE S, V33, pS7, DOI DOI 10.1097/BRS.0B013E31816445BE; Chartered Society of Physiotherapy, 2018, J LIND ALL PHYS PRIO; Chen XX, 2017, BIOMICROFLUIDICS, V11, DOI 10.1063/1.4973247; Chiu TTW, 2005, CLIN REHABIL, V19, P850, DOI 10.1191/0269215505cr920oa; Chung S, 2018, PHYSIOTHER THEOR PR, V34, P916, DOI 10.1080/09593985.2018.1430876; Clarivate Analytics, 2018, ENDNOTE X9; Cochrane Training, DAT COLL FORM INT RE; Cohen J., 2013, STAT POWER ANAL BEHA; Craig P, 2019, DEV EVALUATING COMPL; Dellve Lotta, 2011, Int Arch Occup Environ Health, V84, P335, DOI 10.1007/s00420-010-0568-5; Dwan K, 2010, TRIALS, V11, DOI 10.1186/1745-6215-11-52; Dwan K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003081; Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629; Evidence Prime I, 2015, GRADEPRO GDT GRADEPR; Falla D, 2013, EUR J PAIN, V17, P1517, DOI 10.1002/j.1532-2149.2013.00321.x; Falla D, 2008, J ELECTROMYOGR KINES, V18, P255, DOI 10.1016/j.jelekin.2006.11.001; Falla D, 2017, EXERC SPORT SCI REV, V45, P105, DOI 10.1249/JES.0000000000000103; Falla Deborah, 2007, Curr Rheumatol Rep, V9, P497, DOI 10.1007/s11926-007-0080-4; Fejer R, 2006, EUR SPINE J, V15, P834, DOI 10.1007/s00586-004-0864-4; Furlan AD, 2015, SPINE, V40, P1660, DOI 10.1097/BRS.0000000000001061; Izquierdo TG, 2016, J REHABIL MED, V48, P48, DOI 10.2340/16501977-2034; Gupta BD, 2013, J CLIN DIAGN RES, V7, P2261, DOI 10.7860/JCDR/2013/6072.3487; Gupta S., 2010, INDIAN J PHYSIOTHER, V4, P76; Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1311, DOI [10.1016/j.jclinepi.2011.06.004, 10.1016/j.jclinepi.2011.03.017]; Haldeman S, 2010, J OCCUP ENVIRON MED, V52, P424, DOI 10.1097/JOM.0b013e3181d44f3b; Hayden JA, 2005, ANN INTERN MED, V142, P776, DOI 10.7326/0003-4819-142-9-200505030-00014; Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049; Hingarajia DD, 2012, INDIAN J PHYSIOTHERA, V6, P48; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Hrobjartsson A, 2014, INT J EPIDEMIOL, V43, P1272, DOI 10.1093/ije/dyu115; Hush JM, 2011, ARCH PHYS MED REHAB, V92, P824, DOI 10.1016/j.apmr.2010.12.025; Ingwersen KG, 2015, TRIALS, V16, DOI 10.1186/s13063-014-0544-6; Jan MH, 2008, PHYS THER, V88, P427, DOI 10.2522/ptj.20060300; Javanshir K, 2015, J BACK MUSCULOSKELET, V28, P833, DOI 10.3233/BMR-150593; Jette AM, 2017, PHYS THER, V97, P1043, DOI 10.1093/ptj/pzx085; Jordan A, 1998, SPINE, V23, P311, DOI 10.1097/00007632-199802010-00005; Jull G., 2018, MANAGEMENT NECK PAIN; Jull GA, 2009, MANUAL THER, V14, P696, DOI 10.1016/j.math.2009.05.004; Kaur A, 2018, INDIAN J PHYSIOTHERA, V12, P22; Kay TM, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004250.pub4; Khan M, 2014, PAK J PHARM SCI, V27, P1719; Kim JY, 2016, J PHYS THER SCI, V28, P269, DOI 10.1589/jpts.28.269; Landrine H, 2016, TOB CONTROL, V25, pe142; Lee KW, 2016, J PHYS THER SCI, V28, P175, DOI [10.1589/jpts.28.175, 10.1589/jpts.28.1569]; Li X, 2017, INT ARCH OCC ENV HEA, V90, P673, DOI 10.1007/s00420-017-1230-2; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1136/bmj.b2700, 10.7326/0003-4819-151-4-200908180-00136]; Limke JC, 2008, EUR J PHYS REHAB MED, V44, P399; Louw S, 2017, SOUTH AFR J PHYSIOTH, V73, DOI 10.4102/sajp.v73i1.392; Luime JJ, 2005, J CLIN EPIDEMIOL, V58, P407, DOI 10.1016/j.jclinepi.2004.01.022; MacDermid JC, 2009, J ORTHOP SPORT PHYS, V39, P400, DOI 10.2519/jospt.2009.2930; Martin-Gomez C, 2019, MUSCULOSKEL SCI PRAC, V42, P52, DOI 10.1016/j.msksp.2019.04.010; Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]; Moseng T, 2017, OSTEOARTHR CARTILAGE, V25, P1563, DOI 10.1016/j.joca.2017.06.004; Murray CJL, 2013, JAMA-J AM MED ASSOC, V310, P591, DOI 10.1001/jama.2013.13805; Nikander R, 2006, MED SCI SPORT EXER, V38, P2068, DOI 10.1249/01.mss.0000229105.16274.4b; O'Leary S, 2007, J PAIN, V8, P832, DOI 10.1016/j.jpain.2007.05.014; O'Leary S, 2009, J ORTHOP SPORT PHYS, V39, P324, DOI 10.2519/jospt.2009.2872; Osteras B, 2013, PHYSIOTHERAPY, V99, P311, DOI 10.1016/j.physio.2013.04.001; Osteras H, 2009, EUR J PHYSIOTHER, V11, P199, DOI 10.3109/14038190802239729; Osteras H, 2017, J BODYW MOV THER, V21, P284, DOI 10.1016/j.jbmt.2016.06.016; Parent Company Covered, 2006, MEALEYS LITIG REP IN, V20-9, P6; Pedersen MT, 2013, J STRENGTH COND RES, V27, P229, DOI 10.1519/JSC.0b013e3182541ceb; Polaski AM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210418; Popay J, 2006, GUIDANCE CONDUCT NAR, DOI DOI 10.13140/2.1.1018.4643; Price J, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-025158; Rainville James, 2002, Spine J, V2, P402, DOI 10.1016/S1529-9430(02)00462-X; Randlov A, 1998, CLIN REHABIL, V12, P200, DOI 10.1191/026921598666881319; Ratamess NA, 2009, MED SCI SPORT EXER, V41, P687, DOI 10.1249/MSS.0b013e3181915670; Rudolfsson T, 2014, J REHABIL MED, V46, P908, DOI 10.2340/16501977-1869; Ryan R., 2013, COCHRANE CONSUMERS C; Schomacher J, 2013, MANUAL THER, V18, P360, DOI 10.1016/j.math.2013.05.009; Shiravi S, 2019, SPORTS HEALTH, V11, P272, DOI 10.1177/1941738119835223; Silva PV, 2019, J ORTHOP SPORT PHYS, V49, P666, DOI 10.2519/jospt.2019.8704; Spencer S, 2016, J ATHL TRAINING, V51, P613, DOI 10.4085/1062-6050-51.10.03; Suvarnnato T, 2019, J PAIN RES, V12, P915, DOI 10.2147/JPR.S190125; Ulug N, 2018, J REHABIL MED, V50, P80, DOI 10.2340/16501977-2288; Viljanen M, 2003, BRIT MED J, V327, P475, DOI 10.1136/bmj.327.7413.475; Waling K, 2002, SPINE, V27, P789, DOI 10.1097/00007632-200204150-00002; Waling K, 2000, PAIN, V85, P201, DOI 10.1016/S0304-3959(99)00265-1; Wan X, 2014, BMC MED INFORM DECIS, V14, DOI 10.1186/s12911-014-0111-9; Wood L, 2008, BMJ-BRIT MED J, V336, P601, DOI 10.1136/bmj.39465.451748.AD; Yamato TP, 2016, PHYSIOTHERAPY, V102, P121, DOI 10.1016/j.physio.2016.03.001; Yildiz TI, 2018, J SPORT REHABIL, V27, P403, DOI 10.1123/jsr.2017-0024; Ylinen J, 2007, Eura Medicophys, V43, P161; Ylinen J, 2003, JAMA-J AM MED ASSOC, V289, P2509, DOI 10.1001/jama.289.19.2509	101	13	14	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 10	2020	15	6							e0234511	10.1371/journal.pone.0234511	http://dx.doi.org/10.1371/journal.pone.0234511			32	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC0EC	32520970	gold, Green Published			2023-01-03	WOS:000542969500007
J	Knight, M; Bunch, K; Vousden, N; Morris, E; Simpson, N; Gale, C; O'Brien, P; Quigley, M; Brocklehurst, P; Kurinczuk, JJ				Knight, Marian; Bunch, Kathryn; Vousden, Nicola; Morris, Edward; Simpson, Nigel; Gale, Chris; O'Brien, Patrick; Quigley, Maria; Brocklehurst, Peter; Kurinczuk, Jennifer J.		Uk Obstet Surveillance Syst Sars	Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: national population based cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INFLUENZA	OBJECTIVES To describe a national cohort of pregnant women admitted to hospital with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the UK, identify factors associated with infection, and describe outcomes, including transmission of infection, for mothers and infants. DESIGN Prospective national population based cohort study using the UK Obstetric Surveillance System (UKOSS). SETTING All 194 obstetric units in the UK. PARTICIPANTS 427 pregnant women admitted to hospital with confirmed SARS-CoV-2 infection between 1 March 2020 and 14 April 2020. MAIN OUTCOME MEASURES Incidence of maternal hospital admission and infant infection. Rates of maternal death, level 3 critical care unit admission, fetal loss, caesarean birth, preterm birth, stillbirth, early neonatal death, and neonatal unit admission. RESULTS The estimated incidence of admission to hospital with confirmed SARS-CoV-2 infection in pregnancy was 4.9 (95% confidence interval 4.5 to 5.4) per 1000 maternities. 233 (56%) pregnant women admitted to hospital with SARS-CoV-2 infection in pregnancy were from black or other ethnic minority groups, 281 (69%) were overweight or obese, 175 (41%) were aged 35 or over, and 145 (34%) had pre-existing comorbidities. 266 (62%) women gave birth or had a pregnancy loss; 196 (73%) gave birth at term. Forty one (10%) women admitted to hospital needed respiratory support, and five (1%) women died. Twelve (5%) of 265 infants tested positive for SARS-CoV-2 RNA, six of them within the first 12 hours after birth. CONCLUSIONS Most pregnant women admitted to hospital with SARS-CoV-2 infection were in the late second or third trimester, supporting guidance for continued social distancing measures in later pregnancy. Most had good outcomes, and transmission of SARS-CoV-2 to infants was uncommon. The high proportion of women from black or minority ethnic groups admitted with infection needs urgent investigation and explanation.	[Knight, Marian; Bunch, Kathryn; Quigley, Maria; Kurinczuk, Jennifer J.] Univ Oxford, Nuffield Dept Populat Hlth, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England; [Vousden, Nicola] Kings Coll London, Fac Life Sci & Med, London, England; [Morris, Edward] Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England; [Simpson, Nigel] Univ Leeds, Sch Med, Dept Womens & Childrens Hlth, Leeds, W Yorkshire, England; [Gale, Chris] Imperial Coll London, Sch Publ Hlth, Neonatal Med, Fac Med, London, England; [O'Brien, Patrick] UCL, Inst Womens Hlth, London, England; [Brocklehurst, Peter] Univ Birmingham, Inst Appl Hlth Res, Birmingham Clin Trials Unit, Birmingham, W Midlands, England	University of Oxford; University of London; King's College London; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital; University of Leeds; Imperial College London; University of London; University College London; University of Birmingham	Knight, M (corresponding author), Univ Oxford, Nuffield Dept Populat Hlth, Natl Perinatal Epidemiol Unit, Oxford OX3 7LF, England.	marian.knight@npeu.ox.ac.uk	Knight, Marian/B-6225-2009; Gale, Chris/F-1833-2010	Knight, Marian/0000-0002-1984-4575; Quigley, Maria/0000-0002-8058-6181; Gale, Chris/0000-0003-0707-876X	National Institute for Health Research HTA Programme [11/46/12]; MRC [MR/N008405/1] Funding Source: UKRI	National Institute for Health Research HTA Programme; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	The study was funded by the National Institute for Health Research HTA Programme (project number 11/46/12). MK is an NIHR senior investigator. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. The funder played no role in study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. The corresponding author (MK) had full access to all the data in the study and had final responsibility for the decision to submit for publication.	Alfaraj SH, 2019, J MICROBIOL IMMUNOL, V52, P501, DOI 10.1016/j.jmii.2018.04.005; ANZIC INV, 2010, BMJ-BRIT MED J, V340, pC1279, DOI DOI 10.1136/BMJ.C1279; Breslin N, 2020, AM J OBST GYNEC MFM, V2, DOI 10.1016/j.ajogmf.2020.100111; Breslin N, 2020, AM J OBST GYNEC MFM, V2, DOI 10.1016/j.ajogmf.2020.100118; Chen HJ, 2020, LANCET, V395, P809, DOI 10.1016/S0140-6736(20)30360-3; Chen L, 2020, NEW ENGL J MED, V382, DOI 10.1056/NEJMc2009226; Chen Y, 2020, J MED VIROL, V92, P731, DOI 10.1002/jmv.25787; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Dong L, 2020, JAMA-J AM MED ASSOC, V323, P1846, DOI 10.1001/jama.2020.4621; Favre G, 2020, LANCET, V395, pE40, DOI 10.1016/S0140-6736(20)30311-1; Fell DB, 2017, VACCINE, V35, P5738, DOI 10.1016/j.vaccine.2017.08.037; Harb HM, 2018, BJOG-INT J OBSTET GY, V125, P1663, DOI 10.1111/1471-0528.15255; Jamieson DJ, 2009, LANCET, V374, P451, DOI 10.1016/S0140-6736(09)61304-0; Juusela A, 2020, AM J OBST GYNEC MFM, V2, DOI 10.1016/j.ajogmf.2020.100113; Khunti K, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1548; Knight M, 2005, BJOG-INT J OBSTET GY, V112, P263, DOI 10.1111/j.1471-0528.2005.00609.x; Knight M, 2014, ACTA OBSTET GYN SCAN, V93, P127, DOI 10.1111/aogs.12316; Kurinczuk JJ, 2014, BJOG-INT J OBSTET GY, V121, P41, DOI 10.1111/1471-0528.12820; Liu Yangli, 2020, J Infect, DOI 10.1016/j.jinf.2020.02.028; Louie JK, 2010, NEW ENGL J MED, V362, P27, DOI 10.1056/NEJMoa0910444; Mullins E, 2020, ULTRASOUND OBST GYN, V55, P586, DOI 10.1002/uog.22014; National Institute for Health Research, 2020, URG PUBL HLTH COVID; National Institute for Health Research Clinical Research Network, 2020, REPR HLTH LEEDS; Oeser C, 2019, EPIDEMIOL INFECT, V147, DOI 10.1017/S0950268819001535; Pareek M, 2020, LANCET, V395, P1421, DOI 10.1016/S0140-6736(20)30922-3; Pierce M, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3214; Pierce-Williams RAM, 2020, AM J OBST GYNEC MFM, V2, DOI 10.1016/j.ajogmf.2020.100134; Royal College of Obstetricians and Gynaecologists and The Royal College of Midwives, 2020, COR COVID 19 INF PRE; Shah PKS, 2020, ACTA OBSTET GYN SCAN, V99, P565, DOI 10.1111/aogs.13870; Siston AM, 2010, JAMA-J AM MED ASSOC, V303, P1517, DOI 10.1001/jama.2010.479; Thornton J., 2020, COVID 19 PREGNANCY R; Wong SF, 2004, AM J OBSTET GYNECOL, V191, P292, DOI 10.1016/j.ajog.2003.11.019; World Health Organization, 2020, ROLLING UPDATES CORO; Yu N, 2020, LANCET INFECT DIS, V20, P559, DOI 10.1016/S1473-3099(20)30176-6; Zeng H, 2020, JAMA-J AM MED ASSOC, V323, P1848, DOI 10.1001/jama.2020.4861; Zeng LK, 2020, JAMA PEDIATR, V174, P722, DOI 10.1001/jamapediatrics.2020.0878; Zhang L, 2020, Zhonghua Fu Chan Ke Za Zhi, V55, P166, DOI 10.3760/cma.j.cn112141-20200218-00111; Zhu HP, 2020, TRANSL PEDIATR, V9, P51, DOI 10.21037/tp.2020.02.06	38	478	491	1	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 8	2020	369								m2107	10.1136/bmj.m2107	http://dx.doi.org/10.1136/bmj.m2107			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK2CI	32513659	Green Published, hybrid, Green Submitted			2023-01-03	WOS:000548593100004
J	Ard, KL; Walensky, RP				Ard, Kevin L.; Walensky, Rochelle P.			Payments for Preexposure Prophylaxis in the United States: Too Much for Too Few	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ard, KL (corresponding author), 55 Fruit St,Cox 5, Boston, MA 02114 USA.	kard@mgh.harvard.edu						Centers for Disease Control Prevention, 2018, CLIN INFECT PRACTICE, DOI [DOI 10.1016/S0040-4039(01)91800-3, DOI 10.1016/J.CLINPR.2021.100083]; Furukawa NW, 2020, ANN INTERN MED, V173, P799, DOI 10.7326/M20-0786; JUUSOLA JL, 2012, ANN INTERN MED, V156, P541, DOI DOI 10.1059/0003-4819-156-8-201204170-00001; Landovitz RJ, 2020, 23 INT AIDS C 6 10 J; Mayer KH, 2020, LANCET, V396, P239, DOI 10.1016/S0140-6736(20)31065-5; Owens DK, 2019, JAMA-J AM MED ASSOC, V321, P2203, DOI 10.1001/jama.2019.6390; Siegler AJ, 2018, ANN EPIDEMIOL, V28, P841, DOI 10.1016/j.annepidem.2018.06.005; Smith DK, 2018, ANN EPIDEMIOL, V28, P850, DOI 10.1016/j.annepidem.2018.05.003; Walensky RP, 2020, ANN INTERN MED, V172, P583, DOI [10.7326/M19-3478, 10.7326/L20-0693]	9	4	4	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 17	2020	173	10					844	+		10.7326/M20-5643	http://dx.doi.org/10.7326/M20-5643			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OU5XD	32894691				2023-01-03	WOS:000591600700026
J	Giraud, JS; Doisne, M; Wai, ACH; Majerholc, C; Fourn, E; Sejean, K; Trichereau, J; Bonan, B; Zucman, D				Giraud, Jean-Stephane; Doisne, Melanie; Wai, Aurelie Chan Hew; Majerholc, Catherine; Fourn, Erwan; Sejean, Karine; Trichereau, Julie; Bonan, Brigitte; Zucman, David			De-simplifying single-tablet antiretroviral treatments for cost savings in France: From the patient perspectives to a 6-month follow-up on generics	PLOS ONE			English	Article							HIV; DRUGS; ADHERENCE; THERAPY; REGIMEN	In developed countries, most people living with HIV/AIDS are treated with costly brand single-tablet regimens. Given the economic impact, French guidelines recommend using generic antiretroviral therapy when possible to decrease antiretroviral therapy costs. We aimed to study HIV-infected patients' acceptability to switch from a brand single-tablet regimens [abacavir/lamivudine/dolutegravir (Triumeq(R)) or emtricitabine/tenofovir disoproxil fumarate/rilpivirine (Eviplera(R))] to a treatment comprising of two pills: one is a fixed-dose generic combination of 2 Nucleoside Analogs and the second tablet is the third antiretroviral. This study was a prospective observational study in a French hospital. During their follow-up, patients on stable single-tablet regimens were made aware of the possible cost-saving. They were questioned about their willingness and barriers accepting the substitution. Participants chose between the two regimens, either to remain on single-tablet regimens or switch to the de-simplified regimen. Six months later, a second survey was given to the patient who chose to de-simplify and HIV viral load was controlled. The study included 98 patients: 60 receiving emtricitabine/tenofovir disoproxil fumarate/rilpivirine (Eviplera(R)) and 38 on abacavir/lamivudine/dolutegravir (Triumeq(R)). Forty-five patients accepted the de-simplified treatment, 37 refused and 16 were undecided and followed the decision offered by their physician. The main reason for unwillingness to switch is the number of pills (77.3%). In multivariate model analysis, male patients (p = 0.001) who have taken antiretroviral therapy for over 20 years (p = 0.04) and who retrieve their treatment in their community hospital (p = 0.03) are more likely to accept the switch. Fifty-one patients accepted to replace their single-tablet regimens and six months later, the majority was satisfied; only four returned to single-tablet regimens because of suspected side effects. Half of the people living with HIV/AIDS in our cohort accepted to switch from brand single-tablet regimens to a two-tablet regimen containing generic drugs within a process that emphasizes health expenditure savings.	[Giraud, Jean-Stephane; Doisne, Melanie; Wai, Aurelie Chan Hew; Sejean, Karine; Bonan, Brigitte] Foch Hosp, Hosp Pharm, Suresnes, France; [Majerholc, Catherine; Fourn, Erwan; Zucman, David] Foch Hosp, HIV Dept, Suresnes, France; [Trichereau, Julie] Foch Hosp, Biostat Dept, Suresnes, France	Hospital Foch; Hospital Foch; Hospital Foch	Giraud, JS (corresponding author), Foch Hosp, Hosp Pharm, Suresnes, France.	jsgiraud@gmail.com		Giraud, Jean-Stephane/0000-0001-9160-0842				Bangalore S, 2007, AM J MED, V120, P713, DOI 10.1016/j.amjmed.2006.08.033; Bressy J, 2017, PRISE CHARGE VIH REC; Engelhard Esther A N, 2016, Drugs Real World Outcomes, V3, P223; Engsig FN, 2014, JAIDS-J ACQ IMM DEF, V66, P407, DOI 10.1097/QAI.0000000000000199; Gonzalez JS, 2007, ANN BEHAV MED, V34, P46, DOI 10.1007/BF02879920; Hanna DB, 2014, JAIDS-J ACQ IMM DEF, V65, P587, DOI 10.1097/QAI.0000000000000082; Hassali Mohamed A A, 2009, Int J Pharm Pract, V17, P79; Holmes CB, 2010, JAMA-J AM MED ASSOC, V304, P313, DOI 10.1001/jama.2010.993; Jacomet C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117214; Krentz HB, 2019, HIV MED, V20, P214, DOI 10.1111/hiv.12701; Krentz HB, 2018, HIV MED, V19, P290, DOI 10.1111/hiv.12578; Manne-Goehler J, 2019, AIDS BEHAV, V23, P2072, DOI 10.1007/s10461-018-2351-7; Martin EG, 2018, NEW ENGL J MED, V378, P316, DOI 10.1056/NEJMp1710914; Nicola M, 2020, INT J SURG, V78, P185, DOI 10.1016/j.ijsu.2020.04.018; Rwagitinywa J, 2018, HEALTH POLICY, V122, P237, DOI 10.1016/j.healthpol.2018.01.002; Sloan CE, 2012, AIDS, V26, P45, DOI 10.1097/QAD.0b013e32834dce6e; Suarez-Garcia I, 2019, J ANTIMICROB CHEMOTH, pdkz439; Sutton SS, 2016, AM J MANAG CARE, V22, P242; Walensky RP, 2013, ANN INTERN MED, V158, P776, DOI 10.7326/0003-4819-158-10-201305210-00016; Yazdanpanah Y, 2016, MED MALADIES INFECT, V46, P67, DOI 10.1016/j.medmal.2016.01.003; Zucman D, 2014, AIDS, V28, P607, DOI 10.1097/QAD.0000000000000170	21	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 25	2020	15	9							e0239704	10.1371/journal.pone.0239704	http://dx.doi.org/10.1371/journal.pone.0239704			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NY3AJ	32976493	Green Published, gold			2023-01-03	WOS:000576266600033
J	Luu, AR; Wong, C; Agrawal, V; Wise, N; Handyside, B; Lo, MJ; Pacheco, G; Felix, JB; Giaramita, A; d'Azzo, A; Vincelette, J; Bullens, S; Bunting, S; Christianson, TM; Hague, CM; LeBowitz, JH; Yogalingam, G				Luu, Amanda R.; Wong, Cara; Agrawal, Vishal; Wise, Nathan; Handyside, Britta; Lo, Melanie J.; Pacheco, Glenn; Felix, Jessica B.; Giaramita, Alexander; d'Azzo, Alessandra; Vincelette, Jon; Bullens, Sherry; Bunting, Stuart; Christianson, Terri M.; Hague, Charles M.; LeBowitz, Jonathan H.; Yogalingam, Gouri			Intermittent enzyme replacement therapy prevents Neu1 deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						gene therapy; genetic disease; complex; neuraminidase; sialidase; beta-galactosidase; enzyme replacement therapy; GM1 gangliosidosis; PPCA	GANGLIOSIDOSIS	Mutations in thegalactosidase beta 1(GLB1) gene cause lysosomal beta-galactosidase (beta-Gal) deficiency and clinical onset of the neurodegenerative lysosomal storage disease, GM1 gangliosidosis. beta-Gal and neuraminidase 1 (NEU1) form a multienzyme complex in lysosomes along with the molecular chaperone, protective protein cathepsin A (PPCA). NEU1 is deficient in the neurodegenerative lysosomal storage disease sialidosis, and its targeting to and stability in lysosomes strictly depend on PPCA. In contrast, beta-Gal only partially depends on PPCA, prompting us to investigate the role that beta-Gal plays in the multienzyme complex. Here, we demonstrate that beta-Gal negatively regulates NEU1 levels in lysosomes by competitively displacing this labile sialidase from PPCA. Chronic cellular uptake of purified recombinant human beta-Gal (rh beta-Gal) or chronic lentiviral-mediated GLB1 overexpression in GM1 gangliosidosis patient fibroblasts coincides with profound secondary NEU1 deficiency. A regimen of intermittent enzyme replacement therapy dosing with rh beta-Gal, followed by enzyme withdrawal, is sufficient to augment beta-Gal activity levels in GM1 gangliosidosis patient fibroblasts without promoting NEU1 deficiency. In the absence of beta-Gal, NEU1 levels are elevated in the GM1 gangliosidosis mouse brain, which are restored to normal levels following weekly intracerebroventricular dosing with rh beta-Gal. Collectively, our results highlight the need to carefully titrate the dose and dosing frequency of beta-Gal augmentation therapy for GM1 gangliosidosis. They further suggest that intermittent intracerebroventricular enzyme replacement therapy dosing with rh beta-Gal is a tunable approach that can safely augment beta-Gal levels while maintaining NEU1 at physiological levels in the GM1 gangliosidosis brain.	[Luu, Amanda R.; Wong, Cara; Agrawal, Vishal; Wise, Nathan; Handyside, Britta; Lo, Melanie J.; Pacheco, Glenn; Felix, Jessica B.; Giaramita, Alexander; Vincelette, Jon; Bullens, Sherry; Bunting, Stuart; Christianson, Terri M.; Hague, Charles M.; LeBowitz, Jonathan H.; Yogalingam, Gouri] BioMarin Pharmaceut Inc, Res Dept, Novato, CA 94949 USA; [d'Azzo, Alessandra] St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA	BioMarin Pharmaceutical Inc.; St Jude Children's Research Hospital	Yogalingam, G (corresponding author), BioMarin Pharmaceut Inc, Res Dept, Novato, CA 94949 USA.	gyogalingam@bmrn.com		Felix, Jessica/0000-0003-2586-6591	Allievex Corp.	Allievex Corp.	This work was supported by Allievex Corp.	Annunziata I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3734; Baek RC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013468; Bonten EJ, 2014, CELL MOL LIFE SCI, V71, P2017, DOI 10.1007/s00018-013-1538-3; Bonten EJ, 2009, J BIOL CHEM, V284, P28430, DOI 10.1074/jbc.M109.031419; Brunetti-Pierri N, 2008, MOL GENET METAB, V94, P391, DOI 10.1016/j.ymgme.2008.04.012; Cardone Monica, 2008, Pathogenetics, V1, P6, DOI 10.1186/1755-8417-1-6; Champigny MJ, 2005, EXP CELL RES, V311, P157, DOI 10.1016/j.yexcr.2005.08.023; Chen JC, 2020, J BIOL CHEM, V295, P13532, DOI 10.1074/jbc.RA119.009811; Kannebley JS, 2015, JIMD REP, V24, P115, DOI 10.1007/8904_2015_451; Lawrence R, 2019, MOL GENET METAB REP, V21, DOI 10.1016/j.ymgmr.2019.100524; Martin DR, 2008, MOL GENET METAB, V94, P212, DOI 10.1016/j.ymgme.2008.02.004; McCurdy VJ, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007733; Takaura N, 2003, GENE THER, V10, P1487, DOI 10.1038/sj.gt.3302033; Utz JRJ, 2017, MOL GENET METAB, V121, P170, DOI 10.1016/j.ymgme.2017.04.011; van der Spoel A, 2000, J BIOL CHEM, V275, P10035, DOI 10.1074/jbc.275.14.10035; White EJ, 2018, J BIOL CHEM, V293, P14689, DOI 10.1074/jbc.RA118.004589; Yogalingam G, 2008, DEV CELL, V15, P74, DOI 10.1016/j.devcel.2008.05.005; Yogalingam G, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0207836; ZHOU XY, 1995, GENE DEV, V9, P2623, DOI 10.1101/gad.9.21.2623	19	7	7	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	2020	295	39					13556	13569		10.1074/jbc.RA119.010794	http://dx.doi.org/10.1074/jbc.RA119.010794			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	NY3VI	32727849	Green Published, hybrid			2023-01-03	WOS:000576321100011
J	Li, JM; Ma, Y; Kong, LJ; Liu, YL				Li, Jingmiao; Ma, Yao; Kong, Lijuan; Liu, Yulin			Comprehensive profiling of phytochemical compounds, antioxidant activities, anti-HepG2 cell proliferation, and cholinesterase inhibitory potential ofElaeagnus mollisleaf extracts	PLOS ONE			English	Article							PHENOLIC-COMPOUNDS; ZANTHOXYLUM-BUNGEANUM; CHEMICAL-COMPOSITION; ASSISTED EXTRACTION; IN-VITRO; CONSTITUENTS; ALKALOIDS; INSIGHTS; LEAVES; SOLVENT	The aim of this work was to enrich the knowledge on the potential applications ofElaeagnus mollisleaf extracts. For this purpose, the bioactive compounds (phenolic, flavonoid, alkaloid, proanthocyanidin, chlorophyll and carotene content), antioxidant activity, anti-HepG2 cell proliferation, and cholinesterase inhibitory potential (AChE and BChE) ofE.mollisleaves which obtained from different habitats were quantitatively analyzed using various solvents (water, methanol, ethanol, and n-hexane). The results showed that the methanol extracts exhibited the strongest 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical scavenging activity and the water extracts showed the best antioxidant activity in the 2,2'-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS) free radical scavenging activity, ferric reducing antioxidant power (FRAP), and reducing power (RP) assays. Moreover, the methanol extracts showed the best inhibitory activity against cholinesterase and HepG2 cancer cells. Correlation analysis revealed that the high antioxidant and anti-HepG2 cell proliferation activities were mainly attributed to the total phenolics, flavonoids, and proanthocyanidins while AChE inhibition was attributed to the total alkaloid and carotene content. The statistical results showed that the effect of habitats was lower than that of different solvents used. Additionally, the metabolic profiles ofE.mollisleaves were evaluated using HPLC-ESI-Q TRAP-MS/MS, and a total of 1,017 chemical components were detected and classified into 23 classes. The organic acids and derivatives ranked the first, followed by flavone, amino acid and derivatives, and so on. In conclusion, the effects of different solvents were more significant than the effects of different habitats and the methanol extracts ofE.mollisleaves could be used as an effective source of functional active components, provide benefits to physical health care and be applied to the food and pharmaceutical industries.	[Li, Jingmiao; Ma, Yao; Kong, Lijuan; Liu, Yulin] Northwest A&F Univ, Coll Forestry, Yangling, Shaanxi, Peoples R China	Northwest A&F University - China	Liu, YL (corresponding author), Northwest A&F Univ, Coll Forestry, Yangling, Shaanxi, Peoples R China.	liuyulin@nwafu.edu.cn			National Natural Science Foundation of China [31600549]; Doctor Faculty Inaugurating Project of Northwest AF University [2452015296]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctor Faculty Inaugurating Project of Northwest AF University	This work was supported by the National Natural Science Foundation of China (31600549) and Doctor Faculty Inaugurating Project of Northwest A&F University (2452015296).	A. AC, 2019, MOLECULES, V24, P1; Abd Hamid H, 2017, FOOD CHEM TOXICOL, V108, P451, DOI 10.1016/j.fct.2016.10.004; Ali IB, 2014, IND CROP PROD, V62, P188, DOI 10.1016/j.indcrop.2014.08.021; [Anonymous], 2019, CIRCULATION, V2019; Avello MA, 2013, REV BRAS FARMACOGN, V23, P44, DOI 10.1590/S0102-695X2012005000122; Balkan IA, 2017, IND CROP PROD, V95, P695, DOI 10.1016/j.indcrop.2016.11.038; Baloglu MC, 2019, IND CROP PROD, V134, P33, DOI 10.1016/j.indcrop.2019.03.066; Bao JZ, 2005, J AGR SCI, V26, P43; Barbouchi M, 2020, J KING SAUD UNIV SCI, V32, P302, DOI 10.1016/j.jksus.2018.05.010; Beata O, 2018, FRONT PHARM, V9, P232, DOI [10.3389/fphar.2018.00232, DOI 10.3389/FPHAR.2018.00232]; Bergantin C, 2018, MOLECULES, V23, DOI 10.3390/molecules23112791; Bhutada PR, 2016, IND CROP PROD, V82, P74, DOI 10.1016/j.indcrop.2015.12.004; Chai WM, 2018, FOOD CHEM, V260, P27, DOI 10.1016/j.foodchem.2018.04.001; Chen XQ, 2019, IND CROP PROD, V134, P225, DOI 10.1016/j.indcrop.2019.04.017; de Abreu IN, 2005, PLANT PHYSIOL BIOCH, V43, P241, DOI 10.1016/j.plaphy.2005.01.020; Dong HM, 2015, IND CROP PROD, V76, P290, DOI 10.1016/j.indcrop.2015.04.051; [冯笑笑 Feng Xiaoxiao], 2016, [食品科学, Food Science], V37, P160; Galanakis CM, 2013, INT J FOOD PROP, V16, P382, DOI 10.1080/10942912.2010.522750; Gao Xiang, 2011, Bulletin of Botanical Research, V31, P363; Ghane SG, 2018, IND CROP PROD, V125, P168, DOI 10.1016/j.indcrop.2018.08.087; Gunathilake KDPP, 2016, J FUNCT FOODS, V26, P176, DOI 10.1016/j.jff.2016.07.015; Hamidpour Rafie, 2017, J Tradit Complement Med, V7, P24, DOI 10.1016/j.jtcme.2015.09.004; Jay Mehta, 2018, ANTIOXIDANTS; Leshchyns'ka I, 2016, NEURAL PLAST, V2016, DOI 10.1155/2016/6427537; LIU CY, 2019, BIOMED PHARMACOTHER, V0120, DOI DOI 10.1016/J.BI0PHA.2019.109543; Liu HanYing, 2014, Drugs and Clinic, V29, P135; Lu J, 2018, IND CROP PROD, V122, P522, DOI 10.1016/j.indcrop.2018.06.026; Ma Y, 2019, IND CROP PROD, V142, DOI 10.1016/j.indcrop.2019.111872; Majumder D, 2019, J FUNCT FOODS, V58, P266, DOI 10.1016/j.jff.2019.05.005; Mao's Chairman, 2010, DANGDAI YATAI, V4, P118; Naczk M, 2006, J PHARMACEUT BIOMED, V41, P1523, DOI 10.1016/j.jpba.2006.04.002; Nazir N, 2020, BRAZILIAN J BOT, V2020, P1; Nazir Nausheen, 2020, BMC Complement Med Ther, V20, P143, DOI 10.1186/s12906-020-02942-3; Nazir N, 2020, ENVIRON SCI POLLUT R, V27, P7639, DOI 10.1007/s11356-019-07065-y; Nazir N, 2018, BMC COMPLEM ALTERN M, V18, DOI 10.1186/s12906-018-2381-8; Ozen T, 2017, COMB CHEM HIGH T SCR, V20, P559, DOI 10.2174/1386207320666170127161837; Murray AP, 2013, CURR NEUROPHARMACOL, V11, P388, DOI 10.2174/1570159X11311040004; Quan HF, 2017, NINGXIA MED J, V39, P980, DOI [10.13621/j.1001-5949.2017.11.0980, DOI 10.13621/J.1001-5949.2017.11.0980]; Rafinska K, 2019, FOOD CHEM, V289, P16, DOI 10.1016/j.foodchem.2019.03.025; Rezaie M, 2015, FOOD CHEM, V173, P577, DOI 10.1016/j.foodchem.2014.10.081; Roby MHH, 2013, IND CROP PROD, V43, P827, DOI 10.1016/j.indcrop.2012.08.029; Shao FenJuan, 2008, Acta Botanica Boreali-Occidentalia Sinica, V28, P1339; Tavsan Z, 2019, BIOMED PHARMACOTHER, V116, DOI 10.1016/j.biopha.2019.109004; Tian WY, 2018, IND CROP PROD, V125, P537, DOI 10.1016/j.indcrop.2018.09.045; Tlili N, 2010, PLANT FOOD HUM NUTR, V65, P260, DOI 10.1007/s11130-010-0180-6; Uysal S, 2018, FOOD CHEM TOXICOL, V111, P525, DOI 10.1016/j.fct.2017.11.058; V Shwetha, 2019, J Oral Biol Craniofac Res, V9, P215, DOI 10.1016/j.jobcr.2018.05.001; Vasco C, 2008, FOOD CHEM, V111, P816, DOI 10.1016/j.foodchem.2008.04.054; Wu YB, 2010, J ASIAN NAT PROD RES, V12, P278, DOI 10.1080/10286021003742665; Yang XG, 2008, J AGR FOOD CHEM, V56, P1689, DOI 10.1021/jf0728101	50	0	0	2	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 23	2020	15	9							e0239497	10.1371/journal.pone.0239497	http://dx.doi.org/10.1371/journal.pone.0239497			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NX4NF	32966304	Green Published, gold			2023-01-03	WOS:000575688700032
J	MacKay, S; Carney, AS; Catcheside, PG; Chai-Coetzer, CL; Chia, M; Cistulli, PA; Hodge, JC; Jones, A; Kaambwa, B; Lewis, R; Ooi, EH; Pinczel, AJ; McArdle, N; Rees, G; Singh, B; Stow, N; Weaver, EM; Woodman, RJ; Woods, CM; Yeo, A; McEvoy, RD				MacKay, Stuart; Carney, A. Simon; Catcheside, Peter G.; Chai-Coetzer, Ching Li; Chia, Michael; Cistulli, Peter A.; Hodge, John-Charles; Jones, Andrew; Kaambwa, Billingsley; Lewis, Richard; Ooi, Eng H.; Pinczel, Alison J.; McArdle, Nigel; Rees, Guy; Singh, Bhajan; Stow, Nicholas; Weaver, Edward M.; Woodman, Richard J.; Woods, Charmaine M.; Yeo, Aeneas; McEvoy, R. Doug			Effect of Multilevel Upper Airway Surgery vs Medical Management on the Apnea-Hypopnea Index and Patient-Reported Daytime Sleepiness Among Patients With Moderate or Severe Obstructive Sleep Apnea The SAMS Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMPORTANT DIFFERENCE; AMERICAN ACADEMY; LATENCY TEST; UVULOPALATOPHARYNGOPLASTY; PRESSURE; RESPONSIVENESS; QUESTIONNAIRE; PARAMETERS; EQ-5D-5L; OUTCOMES	IMPORTANCE Many adults with obstructive sleep apnea (OSA) use device treatments inadequately and remain untreated. OBJECTIVE To determine whether combined palatal and tongue surgery to enlarge or stabilize the upper airway is an effective treatment for patients with OSA when conventional device treatment failed. DESIGN, SETTING, AND PARTICIPANTS Multicenter, parallel-group, open-label randomized clinical trial of upper airway surgery vs ongoing medical management. Adults with symptomatic moderate or severe OSA in whom conventional treatments had failed were enrolled between November 2014 and October 2017, with follow-up until August 2018. INTERVENTIONS Multilevel surgery (modified uvulopalatopharyngoplasty and minimally invasive tongue volume reduction; n = 51) or ongoing medical management (eg, advice on sleep positioning, weight loss; n = 51). MAIN OUTCOMES AND MEASURES Primary outcome measureswere the apnea-hypopnea index (AHI; ie, the number of apnea and hypopnea events/h; 15-30 indicates moderate and >30 indicates severe OSA) and the Epworth Sleepiness Scale (ESS; range, 0-24; >10 indicates pathological sleepiness). Baseline-adjusted differences between groups at 6 months were assessed. Minimal clinically important differences are 15 events per hour for AHI and 2 units for ESS. RESULTS Among 102 participants who were randomized (mean [SD] age, 44.6 [12.8] years; 18 [18%] women), 91 (89%) completed the trial. The mean AHI was 47.9 at baseline and 20.8 at 6 months for the surgery group and 45.3 at baseline and 34.5 at 6 months for the medical management group (mean baseline-adjusted between-group difference at 6mo, -17.6 events/h [95% CI, -26.8 to -8.4]; P <.001). The mean ESS was 12.4 at baseline and 5.3 at 6 months in the surgery group and 11.1 at baseline and 10.5 at 6 months in the medical management group (mean baseline-adjusted between-group difference at 6mo, -6.7 [95% CI, -8.2 to -5.2]; P <.001). Two participants (4%) in the surgery group had serious adverse events (1 had amyocardial infarction on postoperative day 5 and 1 was hospitalized for observation following hematemesis of old blood). CONCLUSIONS AND RELEVANCE In this preliminary study of adults with moderate or severe OSA in whom conventional therapy had failed, combined palatal and tongue surgery, compared with medical management, reduced the number of apnea and hypopnea events and patient-reported sleepiness at 6 months. Further research is needed to confirm these findings in additional populations and to understand clinical utility, long-term efficacy, and safety of multilevel upper airway surgery for treatment of patients with OSA.	[MacKay, Stuart; Jones, Andrew] Illawarra Shoalhaven Local Hlth Dist, Wollongong, NSW, Australia; [MacKay, Stuart; Jones, Andrew] Univ Wollongong, Wollongong, NSW, Australia; [MacKay, Stuart] Illawarra ENT Head & Neck Clin, Wollongong, NSW, Australia; [Carney, A. Simon] Flinders Private Hosp, Southern ENT Adelaide Sinus Ctr, Adelaide, SA, Australia; [Carney, A. Simon; Ooi, Eng H.; Woods, Charmaine M.] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia; [Catcheside, Peter G.; Chai-Coetzer, Ching Li; Pinczel, Alison J.; McEvoy, R. Doug] Flinders Univ S Australia, Adelaide Inst Sleep Hlth, Coll Med & Publ Hlth, Adelaide, SA, Australia; [Chai-Coetzer, Ching Li; McEvoy, R. Doug] Southern Adelaide Local Hlth Network, Resp & Sleep Serv, Adelaide, SA, Australia; [Chia, Michael; Yeo, Aeneas] Royal Adelaide Hosp, Dept Thorac Med, Adelaide, SA, Australia; [Cistulli, Peter A.] Univ Sydney, Charles Perkins Ctr, Fac Med & Hlth, Sydney, NSW, Australia; [Cistulli, Peter A.] Royal North Shore Hosp, Dept Resp & Sleep Med, Sydney, NSW, Australia; [Hodge, John-Charles] Royal Adelaide Hosp, Ear Nose & Throat Dept, Adelaide, SA, Australia; [Jones, Andrew] Illawarra Sleep Med Ctr, Wollongong, NSW, Australia; [Kaambwa, Billingsley] Flinders Univ S Australia, Coll Med & Publ Hlth, Hlth Econ Unit, Adelaide, SA, Australia; [Lewis, Richard] Hollywood Med Ctr, Perth, WA, Australia; [Ooi, Eng H.; Woods, Charmaine M.] Royal Perth Hosp, Dept Otolaryngol Head Neck Surg, Perth, WA, Australia; [Singh, Bhajan] Queen Elizabeth II Med Ctr, West Australian Sleep Disorders Res Inst, Perth, WA, Australia; [McArdle, Nigel; Singh, Bhajan] Sir Charles Gairdner Hosp, Dept Pulm Physiol & Sleep Med, Perth, WA, Australia; [Rees, Guy] Mem Hosp, Adelaide, SA, Australia; [Singh, Bhajan] Univ Western Australia, Fac Human Sci, Adelaide, SA, Australia; [Stow, Nicholas] Univ Sydney, Woolcock Clin, Sydney, NSW, Australia; [Weaver, Edward M.] Univ Washington, Dept Otolaryngol Head & Neck Surg, Seattle, WA USA; [Weaver, Edward M.] Seattle Vet Affairs Med Ctr, Staff Surgeon, Seattle, WA USA; [Woodman, Richard J.] Flinders Univ S Australia, Coll Med & Publ Hlth, Flinders Ctr Epidemiol & Biostat, Adelaide, SA, Australia	University of Wollongong; Flinders University South Australia; Flinders University South Australia; Royal Adelaide Hospital; University of Sydney; Royal North Shore Hospital; Royal Adelaide Hospital; Flinders University South Australia; Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Sydney; Woolcock Institute of Medical Research; University of Washington; University of Washington Seattle; Flinders University South Australia	MacKay, S (corresponding author), Illawarra ENT Head & Neck Clin, 8-10 Victoria St,Suites 2, Wollongong, NSW 2500, Australia.	sgmackay@ozemail.com.au	Woods, Charmaine/ABC-8374-2020; Carney, A/W-8202-2019; Pinczel, Alison/ABC-1132-2020; McEvoy, Doug/ABB-8052-2020; Ooi, Eng H/H-7012-2019; Singh, Bhajan/AAA-2114-2020	Carney, A/0000-0001-7507-7983; Pinczel, Alison/0000-0001-9404-6453; Ooi, Eng H/0000-0002-7201-815X; Singh, Bhajan/0000-0001-8662-7928; KAAMBWA, BILLINGSLEY/0000-0002-2128-3404; Woodman, Richard/0000-0002-4094-1222	National Health and Medical Research Council of Australia [1059510]; Flinders University; Repat Foundation Prabha Seshadri Research Grant; National Health and Medical Research Council [GNT 1079785]; Australian Research Council Future Fellowship [FT120100510]; Unites States National Institutes of Health [R01 HL084139]; Veterans Affairs Puget Sound Health Care System	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Flinders University; Repat Foundation Prabha Seshadri Research Grant; National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Australian Research Council Future Fellowship(Australian Research Council); Unites States National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Veterans Affairs Puget Sound Health Care System	This study is supported by a project grant from the National Health and Medical Research Council of Australia (1059510). Supplementary trial funding was provided by Flinders University and The Repat Foundation Prabha Seshadri Research Grant. Dr McEvoy was supported by a practitioner fellowship of the National Health and Medical Research Council (GNT 1079785). Dr Catcheside was supported by an Australian Research Council Future Fellowship (FT120100510). Dr. Weaver's effort was supported by the Unites States National Institutes of Health (R01 HL084139, PIWeaver) and the Veterans Affairs Puget Sound Health Care System.	[Anonymous], 2019, EQ 5D 5L USER GUIDE; [Anonymous], 2000, NOT GUID CLIN SAF DA, P13; Barrett B, 2005, MED DECIS MAKING, V25, P250, DOI 10.1177/0272989X05276863; Billings ME, 2014, SLEEP, V37, P2017, DOI 10.5665/sleep.4262; Boulos MI, 2019, LANCET RESP MED, V7, P533, DOI 10.1016/S2213-2600(19)30057-8; Browaldh N, 2013, THORAX, V68, P846, DOI 10.1136/thoraxjnl-2012-202610; Caples SM, 2010, SLEEP, V33, P1396, DOI 10.1093/sleep/33.10.1396; Carney AS, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz056; Coretti S, 2014, EXPERT REV PHARM OUT, V14, P221, DOI 10.1586/14737167.2014.894462; Crook S, 2019, THORAX, V74, P390, DOI 10.1136/thoraxjnl-2018-211959; Eckert DJ, 2013, AM J RESP CRIT CARE, V188, P996, DOI 10.1164/rccm.201303-0448OC; Friedman M, 2004, LARYNGOSCOPE, V114, P454, DOI 10.1097/00005537-200403000-00013; Iber C., 2017, AASM MANUAL SCORING, V1st; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kezirian EJ, 2004, LARYNGOSCOPE, V114, P450, DOI 10.1097/00005537-200403000-00012; Khan A, 2009, MAYO CLIN PROC, V84, P795, DOI 10.1016/S0025-6196(11)60489-8; Kim AM, 2014, SLEEP, V37, P1639, DOI 10.5665/sleep.4072; Li Y, 2014, J CLIN SLEEP MED, V10, P171, DOI 10.5664/jcsm.3446; Lim PVH, 1999, J LARYNGOL OTOL, V113, P336, DOI 10.1017/S0022215100143919; Littner MR, 2005, SLEEP, V28, P113, DOI 10.1093/sleep/28.1.113; MacKay SG, 2013, J CLIN SLEEP MED, V9, P117, DOI 10.5664/jcsm.2402; Mortimore IL, 1996, AM J RESP CRIT CARE, V154, P1759, DOI 10.1164/ajrccm.154.6.8970367; Mulhern B, 2015, HEALTH QUAL LIFE OUT, V13, DOI 10.1186/s12955-015-0382-6; Nolan CM, 2016, THORAX, V71, P493, DOI 10.1136/thoraxjnl-2015-207782; Patil SP, 2019, J CLIN SLEEP MED, V15, P301, DOI 10.5664/jcsm.7638; Ravesloot MJL, 2011, SLEEP, V34, P105, DOI 10.1093/sleep/34.1.105; Robinson K, 1996, ANN OTO RHINOL LARYN, V105, P415, DOI 10.1177/000348949610500601; Saghaei M., 2011, J BIOMED SCI ENG, V4, P734, DOI [10.4236/jbise.2011.411090, DOI 10.4236/JBISE.2011.411090]; Schriger DL, 2018, ANN EMERG MED, V71, P239, DOI 10.1016/j.annemergmed.2017.05.033; Sommer JU, 2016, DTSCH ARZTEBL INT, V113, P1, DOI 10.3238/arztebl.2016.0001; Strollo PJ, 2014, NEW ENGL J MED, V370, P139, DOI 10.1056/NEJMoa1308659; Sutherland K, 2014, J CLIN SLEEP MED, V10, P215, DOI 10.5664/jcsm.3460; Tregear S, 2009, J CLIN SLEEP MED, V5, P573; van Hout B, 2012, VALUE HEALTH, V15, P708, DOI 10.1016/j.jval.2012.02.008; Vicini C, 2020, SLEEP BREATH, V24, P687, DOI 10.1007/s11325-019-01956-7; Weaver TE, 1997, SLEEP, V20, P835; Weaver Terri E, 2008, Proc Am Thorac Soc, V5, P173, DOI 10.1513/pats.200708-119MG; Woodson BT, 2003, OTOLARYNG HEAD NECK, V128, P848, DOI 10.1016/S0194-5998(03)00461-3; Xie CJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013983; Zhu YF, 2015, J DENT, V43, P1394, DOI 10.1016/j.jdent.2015.10.008	40	50	53	2	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2020	324	12					1168	1179		10.1001/jama.2020.14265	http://dx.doi.org/10.1001/jama.2020.14265		SEP 2020	12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OS4RZ	32886102	Green Published, Bronze			2023-01-03	WOS:000573786800002
J	Baydan, M; Yigit, O; Aksoy, S				Baydan, Mine; Yigit, Oznur; Aksoy, Songul			Does vestibular rehabilitation improve postural control of subjects with chronic subjective dizziness?	PLOS ONE			English	Article							SENSORY-ORGANIZATION; OUTCOMES; BALANCE; HEALTH; LIFE	Postural control is the ability to maintain equilibrium and orientation in a gravitational environment. Patients with chronic subjective dizziness have some troubles with their postural stability. The present study aimed to assess the benefit of home-based vestibular rehabilitation in patients with chronic subjective dizziness using computerized dynamic posturography. Therefore, 100 subjects, between 19 to 86 years, diagnosed with dizziness were included in the study. Computerized dynamic posturography was performed to assess postural stability. Vestibular rehabilitation programs included exercises tailored to the particular needs of each patient. After vestibular rehabilitation, patients were re-examined using the same tests. Posturographic data were analyzed and compared for before and after vestibular rehabilitation findings. The mean composite scores before the intervention (58,92 +/- 11,64) was significantly (p<0.01) lower than the mean composite scores after vestibular rehabilitation (73,83 +/- 8,26). This result is found to be statistically significant. In conclusion it could be suggested that the effectiveness of vestibular rehabilitation could be verified by means of computerized dynamic posturography as a concrete method.	[Baydan, Mine] Ankara Univ, Dept Audiol, Ankara, Turkey; [Yigit, Oznur; Aksoy, Songul] Hacettepe Univ, Dept Audiol, Ankara, Turkey	Ankara University; Hacettepe University	Baydan, M (corresponding author), Ankara Univ, Dept Audiol, Ankara, Turkey.	mine.baydan@gmail.com	Baydan, Mine/AAF-7680-2020; Baydan, Mine/AAU-4145-2021; Yigit, Oznur/P-3800-2018	Baydan, Mine/0000-0003-2836-0799; Baydan, Mine/0000-0003-2836-0799; Yigit, Oznur/0000-0003-4577-1055				Aminoff MJ., 2012, AMINOFFS ELECTRODIAG, P869; Badaracco C, 2007, OTOL NEUROTOL, V28, P809, DOI 10.1097/MAO.0b013e3180cab73f; Badke MB, 2004, ARCH PHYS MED REHAB, V85, P227, DOI 10.1016/j.apmr.2003.06.006; Baydan M, 2020, EXP GERONTOL, V130, DOI 10.1016/j.exger.2019.110785; Black FO, 2000, AM J OTOL, V21, P543; Cass SP, 1996, AM J OTOL, V17, P581; Cohen HS, 2003, OTOLARYNG HEAD NECK, V128, P60, DOI 10.1067/mhn.2003.23; Davis A, 2016, GERONTOLOGIST, V56, pS256, DOI 10.1093/geront/gnw033; &DLANGBRAC;Dermite des Tephras&drangbrac, 2013, ANN DERMATOL VENEREO, V12, pS443; Goebel JA, 1997, OTOLARYNG HEAD NECK, V117, P293, DOI 10.1016/S0194-5998(97)70116-5; Jafarzadeh Sadegh, 2018, Iran J Otorhinolaryngol, V30, P85; Jung JY, 2009, AM J OTOLARYNG, V30, P295, DOI 10.1016/j.amjoto.2008.06.013; Medeiros Ítalo R.T., 2003, J. Pediatr. (Rio J.), V79, P337, DOI 10.1590/S0021-75572003000400012; Meli A, 2006, ACTA OTO-LARYNGOL, V126, P259, DOI 10.1080/00016480500388885; Morisod B, 2017, J VESTIBUL RES-EQUIL, V27, P305, DOI 10.3233/VES-170628; Morris AE, 2008, INT J AUDIOL, V47, P169, DOI 10.1080/14992020701843129; Neurocom International I, 2000, CLIN JUST COMP DYN P; Odman M, 2008, ACTA OTO-LARYNGOL, V128, P1085, DOI 10.1080/00016480701805455; Patatas Olívia Helena Gomes, 2009, Braz. j. otorhinolaryngol., V75, P387; Soto A, 2004, HEARING RES, V196, P26, DOI 10.1016/j.heares.2004.06.010; Staab JP, 2005, ARCH OTOLARYNGOL, V131, P675, DOI 10.1001/archotol.131.8.675; Tee LH, 2005, ANN ACAD MED SINGAP, V34, P289; Tsukamoto HF, 2015, INT ARCH OTORHINOLAR, V19, P238, DOI 10.1055/s-0035-1547523; University C, NEUR SMART EQ COMP D; WOOLLACOTT MH, 1986, INT J AGING HUM DEV, V23, P97, DOI 10.2190/VXN3-N3RT-54JB-X16X; Wrisley DM, 2007, ARCH PHYS MED REHAB, V88, P1049, DOI 10.1016/j.apmr.2007.05.003; Yardley L, 1998, CLIN OTOLARYNGOLOGY, P5	27	10	10	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2020	15	9							e0238436	10.1371/journal.pone.0238436	http://dx.doi.org/10.1371/journal.pone.0238436			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN6DP	32877426	gold, Green Published			2023-01-03	WOS:000568877100010
J	Konrad, KL; Baeyens, JP; Birkenmaier, C; Ranker, AH; Widmann, J; Leukert, J; Wenisch, L; Kraft, E; Jansson, V; Wegener, B				Konrad, Karl Lorenz; Baeyens, Jean-Pierre; Birkenmaier, Christof; Ranker, Anna Helena; Widmann, Jonas; Leukert, Johannes; Wenisch, Lisa; Kraft, Eduard; Jansson, Volkmar; Wegener, Bernd			The effects of whole-body electromyostimulation (WB-EMS) in comparison to a multimodal treatment concept in patients with non-specific chronic back pain-A prospective clinical intervention study	PLOS ONE			English	Article							GROUND REACTION FORCES; MUSCLE FUNCTION; JUMPING MECHANOGRAPHY; GERMAN VERSION; VERTICAL JUMP; RELIABILITY; STRENGTH; RISK; PARAMETERS; STAIR	Background According to present guidelines, active exercise is one key component in the comprehensive treatment of nonspecific chronic back pain (NSCBP). Whole body electromyostimulation (WB-EMS) is a safe, and time-effective training method, that may be effective in NSCBP-patients. Methods In this prospective and controlled nonrandomized clinical study, two therapeutic approaches were compared. One group received 20 minutes WB-EMS per week. An active control group (ACG) received a multimodal therapy program. A third group included subjects without back pain. To all groups, the following measurement instruments were applied: Numeric Rating Scale (NRS), Oswestry Disability Index (ODI), North American Spine Society Instrument (NASS); SF 36 survey and measurements for muscular function and postural stability. In the EMS-group: T0: baseline; T1: at 6 weeks; T2: at 12 weeks and T3: at 24 weeks. In the ACG: T0 baseline and T1 after 4 weeks. Results In the intervention group, 128 patients with low back pain were enrolled, 85 in the WB-EMS group and 43 in the ACG. 34 subjects were allocated to the passive control group. The average age was 58.6 years (18-86 years). In the EMS group, the NRS (1-10) improved statistically and clinically significantly by 2 points. The ODI was reduced by 19.7 points. The NASS and most of the SF 36 items improved significantly. In the multimodal treatment group, only the muscular function improved slightly. Conclusion Our data support the hypothesis that WB-EMS is at least as effective as a multimodal treatment, which is often referred to as being the golden standard. Therefore WB-EMS may be an effective and, with 20 min./week training time, very time-efficient alternative to established multimodal treatment models.	[Konrad, Karl Lorenz; Birkenmaier, Christof; Ranker, Anna Helena; Widmann, Jonas; Leukert, Johannes; Wenisch, Lisa; Kraft, Eduard; Jansson, Volkmar; Wegener, Bernd] Ludwig Maximilians Univ Munich LMU, Dept Orthopaed Surg Phys Med & Rehabil, Munich, Germany; [Konrad, Karl Lorenz; Baeyens, Jean-Pierre; Wegener, Bernd] Vrije Univ Brussel VUB, Dept Physiotherapy Human Physiol & Anat, Brussels, Belgium	University of Munich; Vrije Universiteit Brussel	Wegener, B (corresponding author), Ludwig Maximilians Univ Munich LMU, Dept Orthopaed Surg Phys Med & Rehabil, Munich, Germany.; Wegener, B (corresponding author), Vrije Univ Brussel VUB, Dept Physiotherapy Human Physiol & Anat, Brussels, Belgium.	bernd.wegener@med.uni-muenchen.de		Baeyens, Jean-Pierre/0000-0003-2630-1912; Konrad, Karl Lorenz/0000-0002-4209-5613	miha bodytec GmbH, Siemensstr., Gersthofen (Germany)	miha bodytec GmbH, Siemensstr., Gersthofen (Germany)	The study was financial supported by miha bodytec GmbH, Siemensstr. 1, D-86368 Gersthofen (Germany). With this support staff costs and administrative expenses of the university were founded. This was an investigator-initiated study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amaro-Gahete FJ, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00720; Amorim AB, 2017, SPINE J, V17, P933, DOI 10.1016/j.spinee.2017.02.004; Andersen LB, 2006, SPINE, V31, P1740, DOI 10.1097/01.brs.0000224186.68017.e0; [Anonymous], 2012, DIABETES CARE S1, V35, pS12; [Anonymous], 2006, YB INT LAW COMMISSIO, VII; [Anonymous], 2015, BMJ, V2015, ph1887; [Anonymous], 2003, AIDS S2, V17, pS3; Baek SO, 2014, ANN REHABIL MED-ARM, V38, P506, DOI 10.5535/arm.2014.38.4.506; Baek SO, 2016, J BACK MUSCULOSKELET; Bean JF, 2007, ARCH PHYS MED REHAB, V88, P604, DOI 10.1016/j.apmr.2007.02.004; Bergsten CL, 2012, DISABIL REHABIL, V34, P852, DOI 10.3109/09638288.2011.624247; Boeckh-Behrens W, 2002, ELEKTROMYOSTIMULATIO; Borg E, 2006, SCAND J MED SCI SPOR, V16, P57, DOI 10.1111/j.1600-0838.2005.00448.x; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Buehring B, 2015, OSTEOPOROSIS INT, V26, P819, DOI 10.1007/s00198-014-2983-z; Bullinger M., 1995, J PUBLIC HEALTH-UK, V3, P21, DOI [DOI 10.1007/BF02959944, 10.1007/BF02959944]; Chenot JF, 2017, DTSCH ARZTEBL INT, V114, P883, DOI 10.3238/arztebl.2017.0883; Childs JD, 2005, SPINE, V30, P1331, DOI 10.1097/01.brs.0000164099.92112.29; Citko A, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1965807; Claeys K, 2011, EUR J APPL PHYSIOL, V111, P115, DOI 10.1007/s00421-010-1637-x; Cordova ML, 1996, J ATHL TRAINING, V31, P342; Cormack SJ, 2008, INTJ SPORT PHYSIOL, V3, P131, DOI 10.1123/ijspp.3.2.131; Denteneer L, 2018, SPINE J, V18, P190, DOI 10.1016/j.spinee.2017.08.257; Dias CP, 2015, AGE, V37, DOI 10.1007/s11357-015-9838-1; Filipovic A, 2012, J STRENGTH COND RES, V26, P2600, DOI 10.1519/JSC.0b013e31823f2cd1; Filipovic A, 2011, J STRENGTH COND RES, V25, P3218, DOI 10.1519/JSC.0b013e318212e3ce; Fritzsche D, 2010, HERZ, V35, P34, DOI 10.1007/s00059-010-3268-8; Hayden JA, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000335.pub2; Herrero JA, 2006, INT J SPORTS MED, V27, P533, DOI 10.1055/s-2005-865845; HERRMANN C, 1994, DEUT MED WOCHENSCHR, V119, P1283, DOI 10.1055/s-2008-1058834; Hildebrandt J, 2003, SCHMERZ, V17, P412, DOI 10.1007/s00482-003-0251-9; Hoy D, 2012, ARTHRITIS RHEUM-US, V64, P2028, DOI 10.1002/art.34347; Ishak NA, 2017, PAIN RES TREAT, V2017, DOI 10.1155/2017/3489617; Jee YS, 2018, J EXERC REHABIL, V14, P49, DOI 10.12965/jer.1836022.011; Jensen MP, 1999, PAIN, V83, P157, DOI 10.1016/S0304-3959(99)00101-3; Kemmler W, 2016, OSTEOPOROSIS INT, V27, P3261, DOI 10.1007/s00198-016-3662-z; Kemmler W, 2015, OSTEOLOGIE, V24, P20; Kemmler W, 2016, DTSCH Z SPORTMED, V2016, P218, DOI [DOI 10.5960/DZSM.2016.246, 10.5960/dzsm.2016.246]; Kemmler W, 2016, EVIDENCE BASED COMPL; Kemmler W, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00573; Kemmler W, 2017, EVID-BASED COMPL ALT, V2017, DOI 10.1155/2017/8480429; Kemmler W, 2014, AGE, V36, P395, DOI 10.1007/s11357-013-9575-2; Kern H, 2011, EUR J TRANSL MYOL, V21, P123; Kim TK, 2017, KOREAN J PAIN, V30, P243, DOI 10.3344/kjp.2017.30.4.243; Korsch S, 2016, REHABILITATION, V55, P210, DOI 10.1055/s-0042-106844; Leitner M, 2011, GAIT POSTURE, V34, P421, DOI 10.1016/j.gaitpost.2011.06.014; Letzel J, 2019, EUR J PHYS REHAB MED, V55, P665, DOI 10.23736/S1973-9087.18.05348-0; Maher C, 2017, LANCET, V389, P736, DOI 10.1016/S0140-6736(16)30970-9; Mannion AF, 2006, EUR SPINE J, V15, P55, DOI 10.1007/s00586-004-0815-0; Matheson LA, 2013, J MUSCULOSKEL NEURON, V13, P480; Raschner C, 2008, SPORTVERLETZ SPORTSC, V22, P100, DOI 10.1055/s-2008-1027239; Rosenthal R, 2001, ANNU REV PSYCHOL, V52, P59, DOI 10.1146/annurev.psych.52.1.59; Runge M, 2004, CLIN PHYSIOL FUNCT I, V24, P335, DOI 10.1111/j.1475-097X.2004.00567.x; Saxer S, 2015, J MUSCULOSKEL NEURON, V15, P257; Schochat T, 2000, Z RHEUMATOL, V59, P303, DOI 10.1007/s003930070052; Schofield DJ, 2008, MED J AUSTRALIA, V189, P447, DOI 10.5694/j.1326-5377.2008.tb02119.x; Searle A, 2015, CLIN REHABIL, V29, P1155, DOI 10.1177/0269215515570379; Soliman ES, 2017, J BACK MUSCULOSKELET, V30, P1023, DOI 10.3233/BMR-169588; Sribastav SS, 2018, ASIAN SPINE J, V12, P533, DOI 10.4184/asj.2018.12.3.533; Staartjes VE, 2018, J NEUROSURG-SPINE, V29, P380, DOI 10.3171/2018.2.SPINE171416; Taani MH, 2017, RES GERONTOL NURS, V10, P17, DOI 10.3928/19404921-20161209-03; Thomas C, 2015, J STRENGTH COND RES, V29, P2176, DOI 10.1519/JSC.0000000000000866; Vatter J., 2010, ELEKT MUSKELSTIMULAT; Villwock Jonas, 2017, EMS MARKT DEUTSCHLAN; Vlaeyen JWS, 2000, PAIN, V85, P317, DOI 10.1016/S0304-3959(99)00242-0; Vos T, 2015, LANCET, V386, P743, DOI 10.1016/S0140-6736(15)60692-4; Wegener V, 2019, CLIN SPINE SURG, V32, pE214, DOI 10.1097/BSD.0000000000000777; Weissenfels A, 2018, J PAIN RES, V11, P1949, DOI 10.2147/JPR.S164904	68	7	7	2	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 21	2020	15	8							e0236780	10.1371/journal.pone.0236780	http://dx.doi.org/10.1371/journal.pone.0236780			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG6GN	32822361	Green Published, gold			2023-01-03	WOS:000564080300048
J	Fredericks, LR; Lee, MD; Roslund, CR; Crabtree, AM; Allen, PB; Rowley, PA				Fredericks, Lance R.; Lee, Mark D.; Roslund, Cooper R.; Crabtree, Angela M.; Allen, Peter B.; Rowley, Paul A.			The design and implementation of restraint devices for the injection of pathogenic microorganisms into Galleria mellonella	PLOS ONE			English	Article							PSEUDOMONAS-AERUGINOSA; IMMUNE-RESPONSE; VIRULENCE; LARVAE; MODEL; INFECTION; HOST; BACTERIAL; MUTANTS; STRAINS	The injection of laboratory animals with pathogenic microorganisms poses a significant safety risk because of the potential for injury by accidental needlestick. This is especially true for researchers using invertebrate models of disease due to the required precision and accuracy of the injection. The restraint of the greater wax moth larvae (Galleria mellonella) is often achieved by grasping a larva firmly between finger and thumb. Needle resistant gloves or forceps can be used to reduce the risk of a needlestick but can result in animal injury, a loss of throughput, and inconsistencies in experimental data. Restraint devices are commonly used for the manipulation of small mammals, and in this manuscript, we describe the construction of two devices that can be used to entrap and restrainG.mellonellalarvae prior to injection with pathogenic microbes. These devices reduce the manual handling of larvae and provide an engineering control to protect against accidental needlestick injury while maintaining a high rate of injection.	[Fredericks, Lance R.; Lee, Mark D.; Roslund, Cooper R.; Crabtree, Angela M.; Rowley, Paul A.] Univ Idaho, Dept Biol Sci, Moscow, ID 83843 USA; [Allen, Peter B.] Univ Idaho, Dept Chem, Moscow, ID 83843 USA	Idaho; University of Idaho; Idaho; University of Idaho	Rowley, PA (corresponding author), Univ Idaho, Dept Biol Sci, Moscow, ID 83843 USA.	prowley@uidaho.edu		Lee, Mark/0000-0002-9083-2323; Rowley, Paul/0000-0002-3590-5139; Roslund, Cooper/0000-0003-3615-7125	Institute for Modeling Collaboration and Innovation at the University of Idaho (NIH) [P20 GM104420]; Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health [P20GM103408]; National Science Foundation Science and Technology Center [DBI-0939454]; National Science Foundation [1818368]; Office of Undergraduate Research at the University of Idaho; University of Idaho -Open Access Publishing Fund	Institute for Modeling Collaboration and Innovation at the University of Idaho (NIH); Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health; National Science Foundation Science and Technology Center(National Science Foundation (NSF)); National Science Foundation(National Science Foundation (NSF)); Office of Undergraduate Research at the University of Idaho; University of Idaho -Open Access Publishing Fund	The research was supported by funds provided to PAR by the Institute for Modeling Collaboration and Innovation at the University of Idaho (NIH grant P20 GM104420), the Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under Grant #P20GM103408, the National Science Foundation Science and Technology Center on evolution in action, DBI-0939454 and the National Science Foundation grant number 1818368.Funding was also provided by the Office of Undergraduate Research at the University of Idaho awarded to LRF and CRR. Publication of this article was funded by the University of Idaho -Open Access Publishing Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript and any opinions, findings, and conclusions or recommendations expressed in this material are those of the author (s) and do not necessarily reflect the views of the funders.	Allegra E, 2018, CHEMOSPHERE, V198, P469, DOI 10.1016/j.chemosphere.2018.01.175; Ames L, 2017, VIRULENCE, V8, P1909, DOI 10.1080/21505594.2017.1347744; Andrea A, 2019, MICROORGANISMS, V7, DOI 10.3390/microorganisms7030085; BIRD FT, 1961, CAN J MICROBIOL, V7, P827, DOI 10.1139/m61-098; Brennan M, 2002, FEMS IMMUNOL MED MIC, V34, P153, DOI 10.1111/j.1574-695X.2002.tb00617.x; Browne N, 2015, VIRULENCE, V6, P458, DOI 10.1080/21505594.2015.1021540; Champion OL, 2018, J FUNGI, V4, DOI 10.3390/jof4030108; Chertkova EA, 2018, J INVERTEBR PATHOL, V153, P203, DOI 10.1016/j.jip.2018.02.020; Chosewood CL, 2009, HHS PUBLICATION CDC; Coates CJ, 2019, CELL BIOL TOXICOL, V35, P219, DOI 10.1007/s10565-018-09448-2; Cook SM, 2013, VIRULENCE, V4, P350, DOI 10.4161/viru.25240; Cotter G, 2000, FEMS IMMUNOL MED MIC, V27, P163, DOI 10.1111/j.1574-695X.2000.tb01427.x; Dalton JP, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00099; DUDZIAK B, 1969, ACTA MICROBIOL POL, V1, P137; Dunn MJ, 2018, JOVE-J VIS EXP, DOI 10.3791/58914; Fedhila S, 2010, J INVERTEBR PATHOL, V103, P24, DOI 10.1016/j.jip.2009.09.005; Gago S, 2014, VIRULENCE, V5, P278, DOI 10.4161/viru.26973; Harding CR, 2013, JOVE-J VIS EXP, DOI 10.3791/50964; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; HOFFMANN JA, 1995, CURR OPIN IMMUNOL, V7, P4, DOI 10.1016/0952-7915(95)80022-0; Jander G, 2000, J BACTERIOL, V182, P3843, DOI 10.1128/JB.182.13.3843-3845.2000; Kavanagh Kevin, 2010, Fungal Biology Reviews, V24, P79, DOI 10.1016/j.fbr.2010.04.001; Kilkenny C, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000412; KROPINSKI AMB, 1975, CAN J MICROBIOL, V21, P2084, DOI 10.1139/m75-297; KURSTAK E, 1968, CAN J MICROBIOL, V14, P233, DOI 10.1139/m68-039; Machholz E, 2012, JOVE-J VIS EXP, DOI 10.3791/2771; Maurer E, 2019, MED MYCOL, V57, P351, DOI 10.1093/mmy/myy042; MORELLINI M, 1957, Ann Ist Carlo Forlanini, V17, P149; Mowlds P, 2008, MICROBES INFECT, V10, P628, DOI 10.1016/j.micinf.2008.02.011; OMODEI-ZORINI A, 1947, Ann Ist Carlo Forlanini, V10, P157; Ramarao N, 2012, JOVE-J VIS EXP, DOI 10.3791/4392; Seed KD, 2008, INFECT IMMUN, V76, P1267, DOI 10.1128/IAI.01249-07; Sheehan G, 2018, VIRULENCE, V9, P1625, DOI 10.1080/21505594.2018.1526531; Slater JL, 2011, MED MYCOL, V49, pS107, DOI 10.3109/13693786.2010.523852; VAIDYA VG, 1971, EXPERIENTIA, V27, P148, DOI 10.1007/BF02145861; YOELI MEIR, 1958, EXPTL PARASITOL, V7, P531, DOI 10.1016/0014-4894(58)90044-4; ZIMMERMANN G, 1986, J APPL ENTOMOL, V102, P213, DOI 10.1111/j.1439-0418.1986.tb00912.x	37	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2020	15	7							e0230767	10.1371/journal.pone.0230767	http://dx.doi.org/10.1371/journal.pone.0230767			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW2PD	32730254	Green Submitted, Green Published, gold			2023-01-03	WOS:000556884700025
J	Rethorn, ZD; Pettitt, RW; Dykstra, E; Pettitt, CD				Rethorn, Zachary D.; Pettitt, Robert W.; Dykstra, Emily; Pettitt, Cherie D.			Health and wellness coaching positively impacts individuals with chronic pain and pain-related interference	PLOS ONE			English	Article							PSYCHOSOCIAL FACTORS; MAINTENANCE; MANAGEMENT; COMMUNITY; OUTCOMES; ADULTS; TRIAL; CARE	Objectives Health and wellness coaching (HWC) interventions have been reported to improve health outcomes for individuals with chronic diseases such as diabetes, cardiovascular disease, or cancer. However, HWC also holds potential as an effective intervention within a biopsychosocial chronic pain management framework. The aim of the present study was to evaluate the effects of HWC on individuals with chronic pain. Methods Participants were referred by their primary care provider or insurance company to a comprehensive telephonic 12-month pain management HWC program. Relationships between pain outcomes and physical and psychological factors were retrospectively analyzed. Mixed linear-effects modeling explored whether physical and psychological variables were associated with pain outcomes over time. Results Four hundred nineteen participants (female, 58.9%; mean age, 54.8) enrolled in the program and 181 completed the intervention. After 12 months in the program, statistically and clinically significant reductions were observed for pain intensity (Hedges' g = 1.00) and pain-related interference (Hedges' g = 1.13). Linear mixed-effects modeling indicated that improvements in physical functioning and psychological factors were associated with improvements in pain intensity. Discussion Our results provide a novel analysis on the effects of HWC on chronic pain and pain-related interference. HWC appears to be a promising intervention to improve pain-related outcomes in a population with chronic pain. Further investigation of HWC as an intervention for chronic pain is warranted.	[Rethorn, Zachary D.] Duke Univ, Phys Therapy Div, Durham, NC 27708 USA; [Rethorn, Zachary D.; Pettitt, Robert W.; Dykstra, Emily; Pettitt, Cherie D.] Rocky Mt Univ Hlth Profess, Provo, UT 84606 USA; [Pettitt, Cherie D.] Western Governors Univ, WGU Acad, Salt Lake City, UT USA	Duke University; Rocky Mountain University Health Professions	Rethorn, ZD (corresponding author), Duke Univ, Phys Therapy Div, Durham, NC 27708 USA.; Rethorn, ZD (corresponding author), Rocky Mt Univ Hlth Profess, Provo, UT 84606 USA.	Zachary.Rethorn@gmail.com		Rethorn, Zachary/0000-0001-6412-0894				Alencar MK, 2019, J TELEMED TELECARE, V25, P151, DOI 10.1177/1357633X17745471; Bates D, 2015, J STAT SOFTW, V67, P1, DOI 10.18637/jss.v067.i01; Boonstra AM, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.01466; Clark DO, 2019, OBES SCI PRACT, V5, P111, DOI 10.1002/osp4.318; Clark ME, 2003, J REHABIL RES DEV, V40, P381, DOI 10.1682/JRRD.2003.09.0381; Curtis R, 2016, J APPL BIOBEHAV RES, V22, P1; Davis RM, 2010, DIABETES CARE, V33, P1712, DOI 10.2337/dc09-1919; Dejonghe LAL, 2017, PATIENT EDUC COUNS, V100, P1643, DOI 10.1016/j.pec.2017.04.012; Doran G.T., 1981, MANAG REV, V70, P35, DOI DOI 10.1177/004057368303900411; Dowell D, 2016, MMWR RECOMM REP, V65, P1, DOI [10.1001/jama.2016.1464, 10.15585/mmwr.rr7103a1]; Edwards RR, 2016, J PAIN, V17, pT70, DOI 10.1016/j.jpain.2016.01.001; Elliott AM, 2002, PAIN, V99, P299, DOI 10.1016/S0304-3959(02)00138-0; Fine PG, 2011, PAIN MED, V12, P996, DOI 10.1111/j.1526-4637.2011.01187.x; Gatchel RJ, 2014, AM PSYCHOL, V69, P119, DOI 10.1037/a0035514; Geneen LJ, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011279.pub3; Geurts JW, 2017, HEALTH EXPECT, V20, P1201, DOI 10.1111/hex.12527; Gunasekara FI, 2014, INT J EPIDEMIOL, V43, P264, DOI 10.1093/ije/dyt221; Haugen HA, 2007, OBESITY, V15, P3067, DOI 10.1038/oby.2007.365; Hurkmans E, 2018, JMIR MHEALTH UHEALTH, V6, DOI 10.2196/mhealth.7713; Hylands-White N, 2017, RHEUMATOL INT, V37, P29, DOI 10.1007/s00296-016-3481-8; Inst Med, 2011, RELIEVING PAIN IN AMERICA: A BLUEPRINT FOR TRANSFORMING PREVENTION, CARE, EDUCATION, AND RESEARCH, P1; Interagency Pain Research Coordinating Committee, 2016, NAT PAIN STRAT COMPR; Jacobsen L, 2001, BONICAS MANAGEMENT P; Jensen MP, 2011, ARCH PHYS MED REHAB, V92, P146, DOI 10.1016/j.apmr.2010.09.021; Kivela K, 2014, PATIENT EDUC COUNS, V97, P147, DOI 10.1016/j.pec.2014.07.026; Kristensen M, 2004, ADV PHYSIOL EDUC, V28, P2, DOI 10.1152/advan.00042.2003; Marsh I, 2012, DEMOCRATIC DECLINE AND DEMOCRATIC RENEWAL: POLITICAL CHANGE IN BRITAIN, AUSTRALIA AND NEW ZEALAND, P3; Merskey H, 1994, CLASSIFICATION CHRON; Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3; Moyers TB, 2016, J SUBST ABUSE TREAT, V65, P36, DOI 10.1016/j.jsat.2016.01.001; Mundal I, 2014, PAIN, V155, P1555, DOI 10.1016/j.pain.2014.04.033; National Board for Health & Wellness Coaching, 2019, WHAT IS HLTH WELLN C; Nicholas MK, 2008, PAIN, V134, P158, DOI 10.1016/j.pain.2007.04.007; Nicholas MK, 2019, PAIN, V160, P1156, DOI 10.1097/j.pain.0000000000001496; Olsen Jeanette M, 2010, Am J Health Promot, V25, pe1, DOI 10.4278/ajhp.090313-LIT-101; Peters SAE, 2012, J CLIN EPIDEMIOL, V65, P686, DOI 10.1016/j.jclinepi.2011.11.012; Pizzo PA, 2012, NEW ENGL J MED, V366, P197, DOI 10.1056/NEJMp1109084; Rethorn ZD, 2019, PHYS THER, V99, P1354, DOI 10.1093/ptj/pzz098; Schaller A, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1788-6; Seal K, 2017, J GEN INTERN MED, V32, P931, DOI 10.1007/s11606-017-4047-5; Sforzo GA, 2018, AM J LIFESTYLE MED, V12, P436, DOI 10.1177/1559827617708562; Smith J, 2019, PAIN MED, V20, P2385, DOI 10.1093/pm/pnz208; Spring B, 2013, JAMA INTERN MED, V173, P105, DOI 10.1001/jamainternmed.2013.1221; Thomas ML, 2012, ONCOL NURS FORUM, V39, P39, DOI 10.1188/12.ONF.39-49; Treede RD, 2015, PAIN, V156, P1003, DOI 10.1097/j.pain.0000000000000160; Vale MJ, 2003, ARCH INTERN MED, V163, P2775, DOI 10.1001/archinte.163.22.2775; Veehof MM, 2011, PAIN, V152, P533, DOI 10.1016/j.pain.2010.11.002; von Elm E, 2007, PLOS MED, V4, P1623, DOI [10.1371/journal.pmed.0040296, 10.1371/journal.pmed.0040297]; Whibley D, 2019, CLIN J PAIN, V35, P544, DOI 10.1097/AJP.0000000000000697	49	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2020	15	7							e0236734	10.1371/journal.pone.0236734	http://dx.doi.org/10.1371/journal.pone.0236734			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MV9ND	32716976	Green Published, gold			2023-01-03	WOS:000556674500008
J	Fries-Craft, K; Anast, JM; Schmitz-Esser, S; Bobeck, EA				Fries-Craft, K.; Anast, J. M.; Schmitz-Esser, S.; Bobeck, E. A.			Host immunity and the colon microbiota of mice infected with Citrobacter rodentium are beneficially modulated by lipid-soluble extract from late-cutting alfalfa in the early stages of infection	PLOS ONE			English	Article							GUT MICROBIOTA; SEQUENCE DATA; SAPONINS; DISEASE; STEM; MATURITY; POLYSACCHARIDE; INFLAMMATION; QUERCETIN; RESPONSES	Alfalfa is a forage legume commonly associated with ruminant livestock production that may be a potential source of health-promoting phytochemicals. Anecdotal evidence from producers suggests that later cuttings of alfalfa may be more beneficial to non-ruminants; however, published literature varies greatly in measured outcomes, supplement form, and cutting. The objective of this study was to measure body weight, average daily feed intake, host immunity, and the colon microbiota composition in mice fed hay, aqueous, and chloroform extracts of early (1(st)) and late (5(th)) cutting alfalfa before and after challenge withCitrobacter rodentium. Prior to inoculation, alfalfa supplementation did not have a significant impact on body weight or feed intake, but 5(th)cutting alfalfa was shown to improve body weight at 5- and 6-days post-infection compared to 1(st)cutting alfalfa (P= 0.02 and 0.01). Combined with the observation that both chloroform extracts improved mouse body weight compared to control diets in later stages ofC.rodentiuminfection led to detailed analyses of the immune system and colon microbiota in mice fed 1(st)and 5(th)cutting chloroform extracts. Immediately following inoculation, 5(th)cutting chloroform extracts significantly reduced the relative abundance ofC.rodentium(P= 0.02) and did not display the early lymphocyte recruitment observed in 1(st)cutting extract. In later timepoints, both chloroform extracts maintained lower splenic B-cell and macrophage populations while increasing the relative abundance of potentially beneficially genera such asTuricibacter(P= 0.02). At 21dpi, only 5(th)cutting chloroform extracts increased the relative abundance of beneficialAkkermansiacompared to the control diet (P= 0.02). These results suggest that lipid soluble compounds enriched in late-cutting alfalfa modulate pathogen colonization and early immune responses toCitrobacter rodentium, contributing to protective effects on body weight.	[Fries-Craft, K.; Anast, J. M.; Schmitz-Esser, S.; Bobeck, E. A.] Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA; [Anast, J. M.; Schmitz-Esser, S.] Iowa State Univ, Interdept Microbiol Grad Program, Ames, IA USA	Iowa State University; Iowa State University	Bobeck, EA (corresponding author), Iowa State Univ, Dept Anim Sci, Ames, IA 50011 USA.	eabobeck@iastate.edu		Fries-Craft, Krysten/0000-0003-3130-8166; Schmitz-Esser, Stephan/0000-0002-1907-0709; Anast, Justin/0000-0003-4701-9342				Apprill A, 2015, AQUAT MICROB ECOL, V75, P129, DOI 10.3354/ame01753; Bouchenak M, 2013, J MED FOOD, V16, P185, DOI 10.1089/jmf.2011.0238; Bronte V, 2013, IMMUNITY, V39, P806, DOI 10.1016/j.immuni.2013.10.010; Caporaso J. G, 2018, PLOS ONE, DOI DOI 10.17504/PROTOCOLS.IO.NUUDEWW; Chen L, 2016, ONCOTARGET, V7, P31226, DOI 10.18632/oncotarget.8886; Chen L, 2015, J FUNCT FOODS, V17, P892, DOI 10.1016/j.jff.2015.06.050; Chen L, 2015, J AGR FOOD CHEM, V63, P3219, DOI 10.1021/acs.jafc.5b00494; Chen L, 2015, J AGR FOOD CHEM, V63, P2970, DOI 10.1021/acs.jafc.5b00063; Choi KC, 2013, J MED FOOD, V16, P410, DOI 10.1089/jmf.2012.2679; Collins JW, 2014, NAT REV MICROBIOL, V12, P612, DOI 10.1038/nrmicro3315; Crepin VF, 2016, NAT PROTOC, V11, P1851, DOI 10.1038/nprot.2016.100; David LA, 2014, NATURE, V505, P559, DOI 10.1038/nature12820; Deng W, 2012, J ANIM PHYSIOL AN N, V96, P85, DOI 10.1111/j.1439-0396.2010.01125.x; Dong JJ, 2016, FEMS MICROBIOL LETT, V363, DOI [10.1093/femsle/fnw003, 10.1093/femsle/fnw138]; Dong XF, 2007, POULTRY SCI, V86, P1955, DOI 10.1093/ps/86.9.1955; Francis G, 2002, BRIT J NUTR, V88, P587, DOI 10.1079/BJN2002725; Howarth NC, 2001, NUTR REV, V59, P129, DOI 10.1111/j.1753-4887.2001.tb07001.x; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Ilsley SE, 2005, J ANIM SCI, V83, P82; Jiang JF, 2014, J ANIM PHYSIOL AN N, V98, P1039, DOI 10.1111/jpn.12167; Jiang SQ, 2018, J AGR SCI-CAMBRIDGE, V156, P832, DOI 10.1017/S0021859618000758; Ju SW, 2018, CELL CYCLE, V17, P53, DOI 10.1080/15384101.2017.1387701; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Li RJ, 2016, IMMUNOPHARM IMMUNOT, V38, P257, DOI 10.1080/08923973.2016.1184680; Mehta AK, 2018, CYTOKINE, V101, P14, DOI 10.1016/j.cyto.2016.08.003; OLESZEK W, 1992, J AGR FOOD CHEM, V40, P191, DOI 10.1021/jf00014a005; Ottman N, 2017, BEST PRACT RES CL GA, V31, P637, DOI 10.1016/j.bpg.2017.10.001; Parada AE, 2016, ENVIRON MICROBIOL, V18, P1403, DOI 10.1111/1462-2920.13023; Parameswaran N, 2010, CRIT REV EUKAR GENE, V20, P87, DOI 10.1615/CritRevEukarGeneExpr.v20.i2.10; Pecetti L, 2006, EUR J AGRON, V25, P187, DOI 10.1016/j.eja.2006.04.013; Pietrzak K, 2015, B VET I PULAWY, V59, P393, DOI 10.1515/bvip-2015-0058; Porras D, 2017, FREE RADICAL BIO MED, V102, P188, DOI 10.1016/j.freeradbiomed.2016.11.037; Pruesse E, 2007, NUCLEIC ACIDS RES, V35, P7188, DOI 10.1093/nar/gkm864; Saeed F, 2016, FOOD AGR IMMUNOL, V27, P205, DOI 10.1080/09540105.2015.1079600; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Schroder K, 2004, J LEUKOCYTE BIOL, V75, P163, DOI 10.1189/jlb.0603252; Segata N, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r60; Seguin P, 2004, J AGRON CROP SCI, V190, P211, DOI 10.1111/j.1439-037X.2004.00100.x; Shi LL, 2015, INT J BIOL MACROMOL, V81, P576, DOI 10.1016/j.ijbiomac.2015.08.057; Shiomi H, 2010, INFECT IMMUN, V78, P2653, DOI 10.1128/IAI.01343-09; Siegerstetter SC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0187766; Smith BN, 2017, J ANIM SCI, V95, P69, DOI 10.2527/asasmw.2017.12.146; Stochmal A, 2007, J FOOD AGRIC ENVIRON, V5, P170; Stough JMA, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01520; Thacker PA, 2008, J SCI FOOD AGR, V88, P2019, DOI 10.1002/jsfa.3314; Vitale DC, 2013, EUR J DRUG METAB PH, V38, P15, DOI 10.1007/s13318-012-0112-y; Walker A, 2014, ISME J, V8, P2380, DOI 10.1038/ismej.2014.79; Wang JW, 2018, J ANIM SCI BIOTECHNO, V9, DOI 10.1186/s40104-017-0216-y; Warnke AH, 2016, AGR WATER MANAGE, V176, P234, DOI 10.1016/j.agwat.2016.06.021; Wiles S, 2004, CELL MICROBIOL, V6, P963, DOI 10.1111/j.1462-5822.2004.00414.x; Wu GD, 2011, SCIENCE, V334, P105, DOI 10.1126/science.1208344; Yan HL, 2017, PHYTOMEDICINE, V26, P45, DOI 10.1016/j.phymed.2017.01.007; Yari M, 2013, J SCI FOOD AGR, V93, P3072, DOI 10.1002/jsfa.6141; Yeoman CJ, 2014, ANNU REV ANIM BIOSCI, V2, P469, DOI 10.1146/annurev-animal-022513-114149; Yu J, 2015, VET IMMUNOL IMMUNOP, V167, P147, DOI 10.1016/j.vetimm.2015.07.017; Yu P, 2003, CAN J ANIM SCI, V83, P279, DOI 10.4141/A02-053	56	1	1	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2020	15	7							e0236106	10.1371/journal.pone.0236106	http://dx.doi.org/10.1371/journal.pone.0236106			25	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MS0KU	32673362	Green Published, gold			2023-01-03	WOS:000553976700015
J	Ozawa, S; Higgins, CR; Yemeke, TT; Nwokike, JI; Evans, L; Hajjou, M; Pribluda, VS				Ozawa, Sachiko; Higgins, Colleen R.; Yemeke, Tatenda T.; Nwokike, Jude I.; Evans, Lawrence; Hajjou, Mustapha; Pribluda, Victor S.			Importance of medicine quality in achieving universal health coverage	PLOS ONE			English	Article							SUBSTANDARD DRUGS; POOR-QUALITY; COUNTRIES; SYSTEMS; ACCESS; COULD	Objective To assess the importance of ensuring medicine quality in order to achieve universal health coverage (UHC). Methods We developed a systems map connecting medicines quality assurance systems with UHC goals to illustrate the ensuing impact of quality-assured medicines in the implementation of UHC. The association between UHC and medicine quality was further examined in the context of essential medicines in low- and middle-income countries (LMICs) by analyzing data on reported prevalence of substandard and falsified essential medicines and established indicators for UHC. Finally, we examined the health and economic savings of improving antimalarial quality in four countries in sub-Saharan Africa: the Democratic Republic of the Congo (DRC), Nigeria, Uganda, and Zambia. Findings A systems perspective demonstrates how quality assurance of medicines supports dimensions of UHC. Across 63 LMICs, the reported prevalence of substandard and falsified essential medicines was found to be negatively associated with both an indicator for coverage of essential services (p= 0.05) and with an indicator for government effectiveness (p= 0.04). We estimated that investing in improving the quality of antimalarials by 10% would result in annual savings of $8.3 million in Zambia, $14 million in Uganda, $79 million in two DRC regions, and $598 million in Nigeria, and was more impactful compared to other potential investments we examined. Costs of substandard and falsified antimalarials per malaria case ranged from $7 to $86, while costs per death due to poor-quality antimalarials ranged from $14,000 to $72,000. Conclusion Medicines quality assurance systems play a critical role in reaching UHC goals. By ensuring the quality of essential medicines, they help deliver effective treatments that lead to less illness and result in health care savings that can be reinvested towards UHC.	[Ozawa, Sachiko; Higgins, Colleen R.; Yemeke, Tatenda T.] Univ N Carolina, UNC Eshelman Sch Pharm, Div Practice Adv & Clin Educ, Chapel Hill, NC 27515 USA; [Ozawa, Sachiko] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA; [Nwokike, Jude I.; Evans, Lawrence; Hajjou, Mustapha; Pribluda, Victor S.] US Pharmacopeial Convent USP, Promoting Qual Med PQM Program, Rockville, MD USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Ozawa, S (corresponding author), Univ N Carolina, UNC Eshelman Sch Pharm, Div Practice Adv & Clin Educ, Chapel Hill, NC 27515 USA.; Ozawa, S (corresponding author), Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA.	ozawa@unc.edu	Nwokike, Jude/GPT-1719-2022; Nwokike, Jude/M-9378-2014; Ozawa, Sachiko/D-4399-2014	Nwokike, Jude/0000-0003-4093-2606; Yemeke, Tatenda/0000-0002-1489-627X; Ozawa, Sachiko/0000-0001-7608-9038	United States Agency for International Development (USAID) through the Promoting the Quality of Medicines (PQM) Program [GHS-A-00-09-00003-00]	United States Agency for International Development (USAID) through the Promoting the Quality of Medicines (PQM) Program(United States Agency for International Development (USAID))	Research reported in this publication was supported by the United States Agency for International Development (USAID) through the Promoting the Quality of Medicines (PQM) Program via GHS-A-00-09-00003-00. Members of the PQM program are co-authors on this manuscript and contributed to its preparation and the analysis within.	Bassat Q, 2016, MALARIA J, V15, DOI 10.1186/s12936-016-1357-8; Beargie SM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217910; Bigdeli Maryam, 2015, J Pharm Policy Pract, V8, P8, DOI 10.1186/s40545-015-0028-4; Burrone E, 2019, B WORLD HEALTH ORGAN, V97, P575, DOI 10.2471/BLT.18.229179; Cameron A, 2012, VALUE HEALTH, V15, P664, DOI 10.1016/j.jval.2012.04.004; Conrad R, 2017, ESTIMATING COST SAVI; Evans DR, 2019, HEALTH POLICY PLANN, V34, P36, DOI 10.1093/heapol/czz012; Gray AL, 2015, LANCET, V386, P1601, DOI 10.1016/S0140-6736(15)00514-0; Haidari LA, 2017, VACCINE, V35, P199, DOI 10.1016/j.vaccine.2016.11.025; Hassali MA, 2014, SAUDI PHARM J, V22, P491, DOI 10.1016/j.jsps.2013.12.017; Homer J, 2016, HEALTH AFFAIR, V35, P1435, DOI 10.1377/hlthaff.2015.1043; Huang YY, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2993-1; Husoy OK, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2943-y; Johnston A, 2014, BRIT J CLIN PHARMACO, V78, P218, DOI 10.1111/bcp.12298; Kaddu G, 2018, STRENGTHENING REGULA; Kaplan WA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0217334; Koczwara A, 2017, J PHARM SCI-US, V106, P2921, DOI 10.1016/j.xphs.2017.05.018; Kohler JC, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-63; Kruk ME, 2018, LANCET, V392, P2203, DOI [10.1016/S0140-6736(18)31668-4, 10.1016/s0140-6736(18)31668-4]; Lee BY, 2017, VACCINE, V35, pA36, DOI 10.1016/j.vaccine.2016.11.033; Lee BY, 2017, NUTR REV, V75, P94, DOI 10.1093/nutrit/nuw049; Meyer JC, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00751; Mohd-Tahir NA, 2015, SAGE OPEN MED, V3, DOI 10.1177/2050312115596864; NATION RL, 1994, PHARMACOL THERAPEUT, V62, P41, DOI 10.1016/0163-7258(94)90004-3; Nayyar GML, 2019, AM J TROP MED HYG, V100, P1058, DOI 10.4269/ajtmh.18-0981; Newton PN, 2016, EXPERT REV ANTI-INFE, V14, P531, DOI 10.1080/14787210.2016.1187560; Nwokike J, 2018, B WORLD HEALTH ORGAN, V96, P135, DOI 10.2471/BLT.17.199562; Ozawa S, 2019, AM J TROP MED HYG, V100, P1149, DOI 10.4269/ajtmh.18-0334; Ozawa S, 2019, MALARIA J, V18, DOI 10.1186/s12936-018-2628-3; Ozawa S, 2018, JAMA NETW OPEN, V1, DOI 10.1001/jamanetworkopen.2018.1662; Ozawa S, 2016, BMC HEALTH SERV RES, V16, DOI 10.1186/s12913-016-1867-7; Pisani E, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l5327; Pisani Elizabeth, 2019, Wellcome Open Res, V4, P70, DOI 10.12688/wellcomeopenres.15236.1; Ravinetto R, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6004; Sarpatwari A, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001802; Simao M, 2018, LANCET, V392, P2418, DOI 10.1016/S0140-6736(18)32986-6; 't Hoen EFM, 2014, J PUBLIC HEALTH POL, V35, P137, DOI 10.1057/jphp.2013.53; UHC2030, UHC IND SDG MON FRAM; United Nations Children's Fund (UNICEF), 2019, CHILD MORT EST; United States Agency for International Development, 2019, JOURN SELF REL COUNT; Wagner AK, 2014, BMC HEALTH SERV RES, V14, DOI 10.1186/1472-6963-14-357; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; World Bank, 2018, WORLD GOV IND; World Health Organization, 2019, REG SYST STRENGTH; World Health Organization, 2019, SUST DEV GOALS SDGS; World Health Organization, 2015, UHC SERV COV; World Health Organization, 2019, WHAT IS HLTH FIN UN; World Health Organization, 2017, 70 WORLD HLTH ASS UP; World Health Organization, 2014, MED HLTH SYST ADV AC; World Health Organization, 2019, GOOD MAN PRACT; World Health Organization Organisation for Economic Co-operation and Development International Bank for Reconstruction and Development, 2018, DEL QUAL HLTH SERV G; World Health Organization (WHO), 2017, 1 10 MED PROD DEV CO; 2010, WORLD HLTH REP HLTH, P1	53	7	7	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2020	15	7							e0232966	10.1371/journal.pone.0232966	http://dx.doi.org/10.1371/journal.pone.0232966			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ0QU	32645019	Green Published, gold			2023-01-03	WOS:000552602700107
J	Jolly, SP; Chowdhury, TR; Rahman, M; Alam, A; Afsana, K				Jolly, Saira Parveen; Chowdhury, Tridib Roy; Rahman, Mahfuzar; Alam, Ariful; Afsana, Kaosar			Prevention of social exclusion and role of antenatal care by BRAC community health workers in improving safe motherhood and neonatal care in urban slums of Bangladesh	PLOS ONE			English	Article							REDUCING MATERNAL MORTALITY; EMERGENCY OBSTETRIC CARE; DELIVERY; LESSONS; STRATEGIES; EXPERIENCE; SERVICES; SURVIVAL; IMPACT; BIRTH	The transformation of the BRAC MANOSHI programme from humanitarian to a social enterprise model, has made it increasingly urgent to enumerate the minimum number of door-to-door antenatal care (ANC) visits by community health workers (CHWs), for the purpose of effectively improving facility delivery. Thus prevent social exclusion of poor slum communities in Bangladesh with regard to safe motherhood and essential newborn care (ENC). This cross-sectional study was conducted, during March-July, 2015 in slums of Chittagong, Dhaka and Sylhet city corporations of Bangladesh. A census was conducted among 25,700 households covering 10 branch offices of MANOSHI to identify women with a delivery outcome in the preceding three years of the survey. A total of 1100 respondents were interviewed randomly through a structured questionnaire. These women were stratified into three categories-1, 2 & 3, consisting of 497, 205 and 398 women respectively. Women in category-1 did not receive any ANC checkup from the BRAC CHWs, while women in category-2 and category-3 received one to three and >= four ANC checkups from BRAC CHWs respectively. Data was analysed using STATA Version 13 (Chicago Inc.). Findings revealed that women, who received >= four ANC checkups from BRAC CHWs, are 25% more likely to avail facility delivery [adjusted Prevalence Ratio (aPR) 1.25; 95% confidence interval (CI) (1.01-1.54)] compared to the women who did not receive any ANC from BRAC CHWs. Women in category-2 [aPR3.64; 95% CI (1.76-7.54)] and in category-3 [aPR5.92; 95% CI (3.04-11.53)] respectively had four and six folds higher tendency to receive postnatal care (PNC) within 48 hours after delivery. Furthermore, facility delivery improved PNC assisted by medically trained providers (MTPs) within 48 hours after delivery and ENC in both categories 2 & 3. The evidence shows that at least four ANC visits of BRAC CHWs can increase institutional delivery, and which can further facilitate PNC and ENC visits. At present, the BRAC MANOSHI programme needs to implement feasible strategies to include pregnant women in the slums in receiving at least four ANC checkups by BRAC CHWs for ensuring safe motherhood and newborn care.	[Jolly, Saira Parveen; Chowdhury, Tridib Roy; Rahman, Mahfuzar] BRAC, Res & Evaluat Div, Dhaka, Bangladesh; [Alam, Ariful; Afsana, Kaosar] BRAC, Hlth Nutr & Populat Programme, Dhaka, Bangladesh; [Jolly, Saira Parveen; Chowdhury, Tridib Roy; Afsana, Kaosar] BRAC Univ, BRAC James P Grant Sch Publ Hlth, Dhaka, Bangladesh	Bangladesh Rural Advancement Committee BRAC; Bangladesh Rural Advancement Committee BRAC; Bangladesh Rural Advancement Committee BRAC; BRAC University	Jolly, SP (corresponding author), BRAC, Res & Evaluat Div, Dhaka, Bangladesh.; Jolly, SP (corresponding author), BRAC Univ, BRAC James P Grant Sch Publ Hlth, Dhaka, Bangladesh.	sairaparveenjolly@gmail.com			BRAC	BRAC	This study was supported by BRAC. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams A, 2016, HEALTH POLICY PLANN, V31, P267, DOI 10.1093/heapol/czv053; Adams AM, 2015, HEALTH POLICY PLANN, V30, pi32, DOI 10.1093/heapol/czu094; Adams AM, 2013, LANCET, V382, P2027, DOI 10.1016/S0140-6736(13)62060-7; Adams AM, 2013, LANCET, V382, P2104, DOI 10.1016/S0140-6736(13)62150-9; Agrawal PK, 2012, HEALTH POLICY PLANN, V27, P115, DOI 10.1093/heapol/czr018; Ahmed S, 2011, SOC SCI MED, V72, P1704, DOI 10.1016/j.socscimed.2011.03.031; Ahmed SM, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-663; Alam N, 2011, 118 ICDDR; [Anonymous], 2013, BANGL URB HLTH SURV; Anwar I, 2008, B WORLD HEALTH ORGAN, V86, P252, DOI 10.2471/BLT.07.042754; Anwar I, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120309; Bangladesh Ministry of Health and Family Welfare (MoHFW), 2007, DEM SID FIN PIL MAT; Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; Berhan Y, 2014, ETHIOP J HEALTH SCI, V24, P93, DOI 10.4314/ejhs.v24i0.9S; Black RE, 2016, REPROD MATERNAL NEWB, V2; Campbell OMR, 2006, LANCET, V368, P1284, DOI 10.1016/S0140-6736(06)69381-1; Chen XK, 2007, AUST NZ J OBSTET GYN, V47, P122, DOI 10.1111/j.1479-828X.2007.00697.x; Cho S, 2019, ASIAN SOC WORK POLIC, V13, P189, DOI 10.1111/aswp.12169; Cho S, 2015, ASIAN SOC WORK POLIC, V9, P293, DOI 10.1111/aswp.12069; Choudhury N, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-791; Croghan TW, 2006, MILBANK Q, V84, P333, DOI 10.1111/j.1468-0009.2006.00450.x; Dahiru T, 2015, PAN AFR MED J, V21, DOI 10.11604/pamj.2015.21.321.6527; Dzakpasu S, 2014, HEALTH POLICY PLANN, V29, P137, DOI 10.1093/heapol/czs142; El Arifeen S, 2013, LANCET, V382, P2012, DOI 10.1016/S0140-6736(13)62149-2; Elo I T, 1992, Health Transit Rev, V2, P49; Bernardes ACF, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-266; Gill Z, 2004, INT J GYNECOL OBSTET, V85, P213, DOI 10.1016/j.ijgo.2004.01.004; Haider MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181408; Islam MT, 2006, REPROD HEALTH MATTER, V14, P61, DOI 10.1016/S0968-8080(06)27229-X; Jolly SP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162825; Jolly SP, 2017, ROLE BRAC MATERNITY; Kamal N, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0311-2; Kassebaum NJ, 2016, LANCET, V388, P1775, DOI 10.1016/S0140-6736(16)31470-2; Khanal V, 2014, BMC WOMENS HEALTH, V14, DOI 10.1186/1472-6874-14-19; Khanam R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167814; Kim E, 2017, MATERN CHILD HLTH J, V21, P2078, DOI 10.1007/s10995-017-2319-7; Lassi ZS, 2016, GLOBAL HEALTH ACTION, V9, P1, DOI 10.3402/gha.v9.31408; Lee AC, 2009, INT J GYNECOL OBS S1, V107, pS6, DOI DOI 10.1016/J.IJGO.2009.07.012; Marcil L, 2016, J URBAN HEALTH, V93, P6, DOI 10.1007/s11524-016-0026-0; Mbuagbaw L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010994.pub2; McCollum R, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3043-8; Mohanty SK, 2013, HEALTH POLICY PLANN, V28, P247, DOI 10.1093/heapol/czs057; Moran AC, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-54; Moyer Cheryl A, 2013, Afr J Reprod Health, V17, P30; Nahar S, 2011, BMC PREGNANCY CHILDB, V11, DOI 10.1186/1471-2393-11-11; National Institute of Population Research and Training (NIPORT) International Centre for Diarroheal Disease Research Bangladesh (icddrb) and MEASURE Evaluation, 2017, BANGL MAT MORT HLTH; Pagel C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-99; Pal S, 2015, SOC SCI MED, V143, P194, DOI 10.1016/j.socscimed.2015.08.003; Rahman MM, 2013, INT Q COMMUNITY HEAL, V33, P143, DOI 10.2190/IQ.33.2.d; Razzaque A, 2020, J URBAN HEALTH, V97, P158, DOI [10.1007/s11524-019-00395-9, 10.1007/s11524-019-00414-9]; Rhoden L, 2014, J SMALL BUSINESS ENT, V2, P1; Rocomparisonans C, 2006, LANCET, V368, P1189, DOI [10.1016/S0140-6736(06)69380-X17011946, DOI 10.1016/S0140-6736(06)69380-X17011946]; Roy S, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-2129-y; Shahabuddin A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169109; Sikder SS, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0832-1; Titaley CR, 2009, J EPIDEMIOL COMMUN H, V63, P827, DOI 10.1136/jech.2008.081604; Wagstaff A, 2002, B WORLD HEALTH ORGAN, V80, P97; WHO (World Health Organization), 2015, HLTH SYSTEMS TRANSIT, V5; Wilber ST, 2010, ACAD EMERG MED, V17, P649, DOI 10.1111/j.1553-2712.2010.00773.x; Wilunda C, 2015, REPROD HEALTH, V12, DOI 10.1186/s12978-015-0067-y; World Health Organization, 2001, WHO ANT CAR RAND TRI; World Health Organization, 2015, PREGN CHILDB POSTP N; World Health Organization, 2010, MONITORING BUILDING; World Health Organization, 2018, WHO REC ANT CAR POS; Zahodne LB, 2015, J INT NEUROPSYCH SOC, V21, P297, DOI 10.1017/S1355617715000193	65	2	2	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2020	15	7							e0235340	10.1371/journal.pone.0235340	http://dx.doi.org/10.1371/journal.pone.0235340			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MQ0QI	32639998	Green Published, gold			2023-01-03	WOS:000552601500014
J	Lee, KJ; Lee, SW; Woo, H; Cho, HM; Yu, DB; Jeong, SY; Joo, CH; Jeong, GS; Lee, H				Lee, Kyoung Jin; Lee, Sang Woo; Woo, Ha-Na; Cho, Hae Mi; Yu, Dae Bong; Jeong, Soo Yeon; Joo, Chul Hyun; Jeong, Gi Seok; Lee, Heuiran			Real-time monitoring of oncolytic VSV properties in a novelin vitromicrophysiological system containing 3D multicellular tumor spheroids	PLOS ONE			English	Article							VESICULAR STOMATITIS-VIRUS; VIROTHERAPY; CANCER	As a new class of cancer therapeutic agents, oncolytic viruses (OVs) have gained much attention not only due to their ability to selectively replicate in and lyse tumor cells, but also for their potential to stimulate antitumor immune responses. As a result, there is an increasing need forin vitromodeling systems capable of recapitulating the 3D physiological tumor microenvironment. Here, we investigated the potential of our recently developed microphysiological system (MPS), featuring a vessel-like channel to reflect thein vivotumor microenvironment and serving as culture spaces for 3D multicellular tumor spheroids (MCTSs). The MCTSs consist of cancer A549 cells, stromal MRC5 cells, endothelial HUVECs, as well as the extracellular matrix. 3D MCTSs residing in the MPS were infected with oncolytic VSV expressing GFP (oVSV-GFP). Post-infection, GFP signal intensity increased only in A549 cells of the MPS. On the other hand, HUVECs were susceptible to virus infection under 2D culture and IFN-beta secretion was quite delayed in HUVECs. These results thus demonstrate that OV antitumoral characteristics can be readily monitored in the MPS and that its behavior therein somewhat differs compared to its activity in 2D system. In conclusion, we present the first application of the MPS, anin vitromodel that was developed to better reflectin vivoconditions. Its various advantages suggest the 3D MCTS-integrated MPS can serve as a first line monitoring system to validate oncolytic virus efficacy.	[Lee, Kyoung Jin; Woo, Ha-Na; Cho, Hae Mi; Yu, Dae Bong; Joo, Chul Hyun; Lee, Heuiran] Univ Ulsan, Dept Microbiol, Coll Med, Seoul, South Korea; [Lee, Kyoung Jin; Woo, Ha-Na; Cho, Hae Mi; Joo, Chul Hyun; Lee, Heuiran] Univ Ulsan, Biomed Inst Technol, Coll Med, Seoul, South Korea; [Lee, Sang Woo; Jeong, Soo Yeon; Jeong, Gi Seok] Asan Med Ctr, Asan Inst Life Sci, Biomed Engn Res Ctr, Seoul, South Korea; [Yu, Dae Bong] Univ Ulsan, Dept Med Sci, Asan Med Inst Convergence Sci & Technol, Asan Med Ctr,Coll Med, Seoul, South Korea; [Jeong, Gi Seok] Univ Ulsan, Dept Convergence Med, Coll Med, Seoul, South Korea	University of Ulsan; University of Ulsan; University of Ulsan; Asan Medical Center; University of Ulsan; Asan Medical Center; University of Ulsan	Lee, H (corresponding author), Univ Ulsan, Dept Microbiol, Coll Med, Seoul, South Korea.; Lee, H (corresponding author), Univ Ulsan, Biomed Inst Technol, Coll Med, Seoul, South Korea.; Jeong, GS (corresponding author), Asan Med Ctr, Asan Inst Life Sci, Biomed Engn Res Ctr, Seoul, South Korea.; Jeong, GS (corresponding author), Univ Ulsan, Dept Convergence Med, Coll Med, Seoul, South Korea.	heuiran@amc.seoul.kr; gsjeong@amc.seoul.kr	Jeong, Gi Seok/AAB-2830-2021; Lee, Sang Woo/L-2809-2018	Woo, Ha-Na/0000-0002-6771-8151; Lee, Sang Woo/0000-0001-9913-0638	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Korea government [NRF-2016R1A2B4014912, NRF-2019R1A2C2005244, NRF-2019R1C1C1007468]	Basic Science Research Program through the National Research Foundation of Korea (NRF) - Korea government	This work was supported by grants from the Basic Science Research Program through the National Research Foundation of Korea (NRF, http://www.nrf.re.kr) granted funded by the Korea government (NRF-2016R1A2B4014912 to CH Joo; NRF-2019R1A2C2005244 to GS Jeong; NRF-2019R1C1C1007468 to KJ Lee). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Fajardo CA, 2017, CANCER RES, V77, P2052, DOI 10.1158/0008-5472.CAN-16-1708; [Anonymous], 2017, RUMIYAH 3       0106, V5, P8; [Anonymous], 2018, IEEE T SYSTEMS MAN C, P1, DOI DOI 10.2861/86313; Bishnoi S, 2018, VIRUSES-BASEL, V10, DOI 10.3390/v10020090; Breitbach CJ, 2011, MOL THER, V19, P886, DOI 10.1038/mt.2011.26; Del Bufalo F, 2016, BIOMATERIALS, V84, P76, DOI 10.1016/j.biomaterials.2016.01.030; Finkelshtein D, 2013, P NATL ACAD SCI USA, V110, P7306, DOI 10.1073/pnas.1214441110; Hamid O, 2017, CANCER IMMUNOL IMMUN, V66, P1249, DOI 10.1007/s00262-017-2025-8; Hastie E, 2012, J GEN VIROL, V93, P2529, DOI 10.1099/vir.0.046672-0; Jeong GS, 2014, LAB CHIP, V14, P4213, DOI 10.1039/c4lc00510d; Kaufman HL, 2015, NAT REV DRUG DISCOV, V14, P642, DOI 10.1038/nrd4663; Lee SW, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20886-0; Li MMH, 2015, TRENDS CELL BIOL, V25, P320, DOI 10.1016/j.tcb.2015.02.001; Ma YHV, 2018, MICROSYST NANOENG, V4, DOI 10.1038/micronano.2017.104; Marelli G, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00866; Morvan MG, 2016, NAT REV CANCER, V16, P7, DOI 10.1038/nrc.2015.5; Naik S, 2012, CANCER GENE THER, V19, P443, DOI 10.1038/cgt.2012.14; Nikolic J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03432-4; Ozduman K, 2008, J NEUROSCI, V28, P1882, DOI 10.1523/JNEUROSCI.4905-07.2008; Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236; Papaioannou NE, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.04.01; Rajani K, 2016, MOL THER, V24, P166, DOI 10.1038/mt.2015.156; Rehman H, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0158-5; Ruedas JB, 2017, METHODS MOL BIOL, V1581, P203, DOI 10.1007/978-1-4939-6869-5_12; Russell SJ, 2018, CANCER CELL, V33, P599, DOI 10.1016/j.ccell.2018.03.011; Schneider WM, 2014, ANNU REV IMMUNOL, V32, P513, DOI 10.1146/annurev-immunol-032713-120231; Song JJ, 2019, INT J HYPERTHER, V36, P344, DOI 10.1080/02656736.2019.1569731; Stojdl DF, 2000, NAT MED, V6, P821, DOI 10.1038/77558; Truskey GA, 2018, FRONT PUBLIC HEALTH, V6, DOI 10.3389/fpubh.2018.00185; Turnbull S, 2015, VIRUSES-BASEL, V7, P6291, DOI 10.3390/v7122938; van den Hengel SK, 2013, CANCER GENE THER, V20, P507, DOI 10.1038/cgt.2013.47; Zhang K, 2018, ANN BIOMED ENG, V46, P849, DOI 10.1007/s10439-018-2000-3	32	2	2	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 6	2020	15	7							e0235356	10.1371/journal.pone.0235356	http://dx.doi.org/10.1371/journal.pone.0235356			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM3OG	32628693	gold, Green Published			2023-01-03	WOS:000550068700062
J	Jennings, A; Cunnane, SC; Minihane, AM				Jennings, Amy; Cunnane, Stephen C.; Minihane, Anne Marie			Can nutrition support healthy cognitive ageing and reduce dementia risk?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							DOCOSAHEXAENOIC ACID SUPPLEMENTATION; BRAIN ENERGY-METABOLISM; ALZHEIMERS-DISEASE; DOSE-RESPONSE; FATTY-ACIDS; MOUSE MODEL; DIET; ASSOCIATION; IMPAIRMENT; DECLINE		[Jennings, Amy; Minihane, Anne Marie] Univ East Anglia, Nutr & Prevent Med Grp, Norwich Med Sch, Norwich NR4 7UK, Norfolk, England; [Cunnane, Stephen C.] Univ Sherbrooke, Res Ctr Aging, Sherbrooke, PQ, Canada; [Cunnane, Stephen C.] Univ Sherbrooke, Dept Med, Sherbrooke, PQ, Canada	University of Sherbrooke; University of Sherbrooke	Minihane, AM (corresponding author), Univ East Anglia, Nutr & Prevent Med Grp, Norwich Med Sch, Norwich NR4 7UK, Norfolk, England.	a.minihane@uea.ac.uk		Minihane, Anne Marie/0000-0001-9042-4226				Akbaraly TN, 2019, JAMA-J AM MED ASSOC, V321, P957, DOI 10.1001/jama.2019.1432; Aridi YS, 2017, NUTRIENTS, V9, DOI 10.3390/nu9070674; Arterburn LM, 2006, AM J CLIN NUTR, V83, p1467S, DOI 10.1093/ajcn/83.6.1467S; Brandt J, 2019, J ALZHEIMERS DIS, V68, P969, DOI 10.3233/JAD-180995; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; Castellano CA, 2017, J ALZHEIMERS DIS, V56, P1459, DOI 10.3233/JAD-161163; Castellano CA, 2015, J ALZHEIMERS DIS, V43, P1343, DOI 10.3233/JAD-141074; Croteau E, 2018, J ALZHEIMERS DIS, V64, P551, DOI 10.3233/JAD-180202; Cunnane SC, 2020, NAT REV DRUG DISCOV; Cunnane SC, 2016, FRONT MOL NEUROSCI, V9, DOI 10.3389/fnmol.2016.00053; Cunnane SC, 2016, ANN NY ACAD SCI, V1367, P12, DOI 10.1111/nyas.12999; De Filippis F, 2016, GUT, V65, P1812, DOI 10.1136/gutjnl-2015-309957; Fortier M, 2019, ALZHEIMERS DEMENT, V15, P625, DOI 10.1016/j.jalz.2018.12.017; Gallaway PJ, 2017, BRAIN SCI, V7, DOI 10.3390/brainsci7020022; Garcia-Mantrana I, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00890; Green KN, 2007, J NEUROSCI, V27, P4385, DOI 10.1523/JNEUROSCI.0055-07.2007; Henderson ST, 2009, NUTR METAB, V6, DOI 10.1186/1743-7075-6-31; Hosking DE, 2019, ALZHEIMERS DEMENT, V15, P581, DOI 10.1016/j.jalz.2018.12.011; Ioannidis JPA, 2018, JAMA-J AM MED ASSOC, V320, P969, DOI 10.1001/jama.2018.11025; Kashiwaya Y, 2013, NEUROBIOL AGING, V34, P1530, DOI 10.1016/j.neurobiolaging.2012.11.023; Kirkpatrick CF, 2019, J CLIN LIPIDOL, V13, P689, DOI 10.1016/j.jacl.2019.08.003; Lehtisalo J, 2019, ALZHEIMERS DEMENT, V15, P410, DOI 10.1016/j.jalz.2018.10.001; Lewis F., 2014, TRAJECTORY DEMENTIA; Li D, 2018, AGING CELL, V17, DOI 10.1111/acel.12768; Lourida I, 2019, JAMA-J AM MED ASSOC, V322, P430, DOI 10.1001/jama.2019.9879; LYINGTUNELL U, 1981, ACTA NEUROL SCAND, V63, P337; Martinez-Lapiscina EH, 2013, J NUTR HEALTH AGING, V17, P544, DOI 10.1007/s12603-013-0027-6; Martinsen A, 2019, FASEB J, V33, P10315, DOI 10.1096/fj.201900423R; Matthews FE, 2013, LANCET, V382, P1405, DOI 10.1016/S0140-6736(13)61570-6; Morris MC, 2015, ALZHEIMERS DEMENT, V11, P1007, DOI 10.1016/j.jalz.2014.11.009; Mozaffarian D, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.k822; Neth BJ, 2020, NEUROBIOL AGING, V86, P54, DOI 10.1016/j.neurobiolaging.2019.09.015; Ngandu T, 2015, LANCET, V385, P2255, DOI 10.1016/S0140-6736(15)60461-5; Norton S, 2014, LANCET NEUROL, V13, P788, DOI 10.1016/S1474-4422(14)70136-X; Ogawa M, 1996, J NEUROL SCI, V139, P78, DOI 10.1016/S0022-510X(96)00033-0; Pontifex M, 2018, NEUROBIOL AGING, V69, P209, DOI 10.1016/j.neurobiolaging.2018.05.017; Pottala JV, 2014, NEUROLOGY, V82, P435, DOI 10.1212/WNL.0000000000000080; Quinn JF, 2010, JAMA-J AM MED ASSOC, V304, P1903, DOI 10.1001/jama.2010.1510; Samieri C, 2018, AM J EPIDEMIOL, V187, P933, DOI 10.1093/aje/kwx330; Scarmeas N, 2018, LANCET NEUROL, V17, P1006, DOI 10.1016/S1474-4422(18)30338-7; Schroeder FA, 2007, BIOL PSYCHIAT, V62, P55, DOI 10.1016/j.biopsych.2006.06.036; Scientific Advisory Commission on Nutrition, 2018, STAT DIET COGN IMP D; Shannon OM, 2019, AM J CLIN NUTR, V110, P938, DOI 10.1093/ajcn/nqz114; Smith PJ, 2010, HYPERTENSION, V55, P1331, DOI 10.1161/HYPERTENSIONAHA.109.146795; Soininen H, 2017, LANCET NEUROL, V16, P965, DOI 10.1016/S1474-4422(17)30332-0; Solfrizzi V, 2018, J ALZHEIMERS DIS, V64, pS229, DOI 10.3233/JAD-179940; Sommerlad A, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002862; Stonehouse W, 2013, AM J CLIN NUTR, V97, P1134, DOI 10.3945/ajcn.112.053371; Taylor Matthew K, 2018, Alzheimers Dement (N Y), V4, P28, DOI 10.1016/j.trci.2017.11.002; Umhau JC, 2009, J LIPID RES, V50, P1259, DOI 10.1194/jlr.M800530-JLR200; Valdes Ana M, 2018, BMJ, V361, pk2179, DOI 10.1136/bmj.k2179; World Health Organization, 2019, RISK RED COGN DECL D; Wu L, 2017, SCI REP-UK, V7, DOI 10.1038/srep41317; Wu SQ, 2015, NEUROSCI BIOBEHAV R, V48, P1, DOI 10.1016/j.neubiorev.2014.11.008; Xu Q, 2020, CLIN NUTR, V39, P2092, DOI 10.1016/j.clnu.2019.10.017; Yassine HN, 2017, JAMA NEUROL, V74, P337, DOI 10.1001/jamaneurol.2016.4899; Zhang Y, 2018, J INTERN MED, V284, P399, DOI 10.1111/joim.12786; Zhang YP, 2018, J NEUROL NEUROSUR PS, V89, P382, DOI 10.1136/jnnp-2017-316176; Zhang Y, 2016, AM J CLIN NUTR, V103, P330, DOI 10.3945/ajcn.115.124081; Zilberter M, 2013, J NEUROCHEM, V125, P157, DOI 10.1111/jnc.12127	60	27	27	2	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 26	2020	369								m2269	10.1136/bmj.m2269	http://dx.doi.org/10.1136/bmj.m2269			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ7IA	32591407	hybrid, Green Accepted, Green Published			2023-01-03	WOS:000548259500010
J	De Meyer, V; Abramowicz, D; De Meester, J; Collart, F; Bosmans, JL; Cools, W; Wissing, KM				De Meyer, Vicky; Abramowicz, Daniel; De Meester, Johan; Collart, Frederic; Bosmans, Jean-Louis; Cools, Wilfried; Wissing, Karl Martin			Variability in the incidence of renal replacement therapy over time in Western industrialized countries: A retrospective registry analysis	PLOS ONE			English	Article							COMPARATIVE SURVIVAL; ELDERLY-PATIENTS; KIDNEY FAILURE; DISEASE; AUSTRALIA; DIALYSIS; ERA; MANAGEMENT; INITIATION; OUTCOMES	Introduction A growing number of patients started renal replacement therapy (RRT) in Western industrialized countries between 1980 an early 2000s. Thereafter reports from national and international registries suggest a trend towards stabilization and sometimes a decrease in the incidence rate. Aim To investigate the differences in overall and age-specific incidence rates between industrialized countries from 1998 until 2013. Secondly, to investigate changes in incidence rates over time and their association with specific age categories. Method We extracted the unadjusted overall incidence of RRT and age-specific incidence rates from renal registry reports in Europe, the United States, Canada, Australia and New Zealand. Time trends in the incidence rate by country and age categories were analyzed by Joinpoint regression analysis. Results The incidence rate in 2013 ranged from 89 per million population (pmp) in Finland to 363 pmp in the US. Incidence rates in the lower age categories (20-64 year) were similar between countries and remained stable over time. Higher incidence countries were characterized by higher numbers of patients in both the 65-74 and >= 75 year categories starting RRT. Joinpoint analysis confirmed that most countries had significant reductions in the incidence rate at the end of the study period. These reductions were explained by lower numbers of older patients starting RRT and were observed also in countries with lower overall incidence rates. Conclusion This study confirmed different incidence rates of RRT between industrialized countries worldwide. Countries with the highest overall incidence rates also had the highest incidence rates in the oldest age categories. Since the early 2000's the number of older patients starting RRT is either stabilizing or even decreasing in most countries. This reduction is universal and is also observed in countries with previously low incidence rates.	[De Meyer, Vicky; Wissing, Karl Martin] Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel, Dept Hypertens & Nephrol, Brussels, Belgium; [Abramowicz, Daniel; Bosmans, Jean-Louis] Univ Ziekenhuis Antwerpen, Dept Nephrol, Antwerp, Belgium; [Abramowicz, Daniel] Univ Antwerp, Lab Med & Pediat, Antwerp, Belgium; [De Meester, Johan] AZ Nikolaas, Dept Nephrol, St Niklaas, Belgium; [Collart, Frederic] CHU Brugmann, Dept Nephrol, Brussels, Belgium; [Cools, Wilfried] Vrije Univ Brussel VUB, Interfac Ctr Data Proc & Stat, Brussels, Belgium	University Hospital Brussels; Vrije Universiteit Brussel; University of Antwerp; University of Antwerp; Vrije Universiteit Brussel	De Meyer, V (corresponding author), Vrije Univ Brussel VUB, Univ Ziekenhuis Brussel, Dept Hypertens & Nephrol, Brussels, Belgium.	vicky.demeyer@uzbrusssel.be	cools, wilfried/AAE-4534-2019	cools, wilfried/0000-0002-3458-0336; De Meyer, Vicky/0000-0001-5408-798X; Collart, Frederic/0000-0003-1673-5450				[Anonymous], 2016, ERA EDTA REG ANN REP; Brown EA, 2011, NAT REV NEPHROL, V7, P591, DOI 10.1038/nrneph.2011.113; Canadian Institute for Health Information, 2014, CAN ORG REPL REG ANN; Canadian Institute for Health Information, 2016, CAN ORG REPL REF ANN; Caskey FJ, 2011, NEPHROL DIAL TRANSPL, V26, P2604, DOI 10.1093/ndt/gfq781; Chandna SM, 2011, NEPHROL DIAL TRANSPL, V26, P1608, DOI 10.1093/ndt/gfq630; Clayton P, 2015, 36 ANZDATA; Cooper BA, 2010, NEW ENGL J MED, V363, P609, DOI 10.1056/NEJMoa1000552; Couchoud C, 2012, NEPHROL DIAL TRANSPL, V27, P2312, DOI 10.1093/ndt/gfr639; Couchoud C, 2010, NEPHROL DIAL TRANSPL, V25, P1576, DOI 10.1093/ndt/gfp675; De Vecchi AF, 1999, NEPHROL DIAL TRANSPL, V14, P31, DOI 10.1093/ndt/14.suppl_6.31; Eggers PW, 2011, CURR OPIN NEPHROL HY, V20, P241, DOI 10.1097/MNH.0b013e3283454319; Grace BS, 2012, NEPHROLOGY, V17, P76, DOI 10.1111/j.1440-1797.2011.01512.x; Helve J, 2018, NEPHROL DIAL TRANSPL, V33, P1428, DOI 10.1093/ndt/gfy056; Hemmelgarn BR, 2006, KIDNEY INT, V69, P2155, DOI 10.1038/sj.ki.5000270; Hemmelgarn BR, 2012, JAMA-J AM MED ASSOC, V307, P2507, DOI 10.1001/jama.2012.6455; Kramer A, 2009, NEPHROL DIAL TRANSPL, V24, P3557, DOI 10.1093/ndt/gfp519; Moranne O, 2018, NEPHROL DIAL TRANSPL, V33, P2182, DOI 10.1093/ndt/gfy046; Murtagh FEM, 2007, NEPHROL DIAL TRANSPL, V22, P1955, DOI 10.1093/ndt/gfm153; O'Hare AM, 2007, J AM SOC NEPHROL, V18, P2758, DOI 10.1681/ASN.2007040422; Pippias M, 2016, NEPHROL DIAL TRANSPL, V31, P831, DOI 10.1093/ndt/gfv327; Rosansky SJ, 2019, KIDNEY INT, V95, P1273, DOI 10.1016/j.kint.2019.02.008; Rosansky SJ, 2013, J AM SOC NEPHROL, V24, P1367, DOI 10.1681/ASN.2013050458; Sparke C, 2013, AM J KIDNEY DIS, V61, P413, DOI 10.1053/j.ajkd.2012.10.012; Tamura MK, 2009, NEW ENGL J MED, V361, P1539, DOI 10.1056/NEJMoa0904655; United States Renal Data System, 2015, UN STAT REN DAT SYST; United States Renal Data System, 2013, UN STAT REN DAT SYST; van de Luijtgaarden MWM, 2013, NEPHROL DIAL TRANSPL, V28, P2604, DOI 10.1093/ndt/gft287; Verberne WR, 2016, CLIN J AM SOC NEPHRO, V11, P633, DOI 10.2215/CJN.07510715; Visser A, 2012, NEPHROL DIAL TRANSPL, V27, P338, DOI 10.1093/ndt/gfr346; Wanner C, 2018, NAT REV NEPHROL, V14, P78, DOI 10.1038/nrneph.2017.182	31	3	3	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2020	15	6							e0235004	10.1371/journal.pone.0235004	http://dx.doi.org/10.1371/journal.pone.0235004			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG0TI	32584849	gold, Green Published			2023-01-03	WOS:000545747200010
J	Furfaro, LL; Payne, MS; Chang, BJ				Furfaro, Lucy L.; Payne, Matthew S.; Chang, Barbara J.			Host range, morphological and genomic characterisation of bacteriophages with activity against clinicalStreptococcus agalactiaeisolates	PLOS ONE			English	Article							GROUP-B STREPTOCOCCI; MULTIPLEX PCR ASSAY; MOLECULAR CHARACTERIZATION; IDENTIFICATION; ENUMERATION; RESISTANCE; PHAGE; IA	Streptococcus agalactiaeor Group B Streptococcus (GBS) is a leading cause of sepsis in neonates. As a preventative measure prophylactic antibiotic administration is common in pregnant women colonised with GBS, but antibiotic-resistance and adverse effects on neonatal microbiomes may result. Use of bacteriophages (phages) is one option for targeted therapy. To this end, four phages (LF1 -LF4) were isolated from wastewater. They displayed lytic activityin vitroagainstS.agalactiaeisolates collected from pregnant women and neonates, with 190/246 isolates (77.2%) and 10/10 (100%) isolates susceptible to at least one phage, respectively. Phage genomes ranged from 32,205-44,768 bp and all phages were members of theSiphoviridaefamily. High nucleotide identity (99.9%) was observed between LF1 and LF4, which were closely related to a putative prophage ofS.agalactiae. The genome organisation of LF2 differed, and it showed similarity to a differentS.agalactiaeprophage, while LF3 was more closely related to aStreptococcus pyogenesphage. Lysogenic gene presence (integrase, repressor and regulatory modules), was suggestive of temperate phages. In a therapeutic context, temperate phages are not ideal candidates, however, the broad host range activity of these phages observed on clinical isolatesin vitrois promising for future therapeutic approaches including bioengineered phage or lysin applications.	[Furfaro, Lucy L.; Payne, Matthew S.] Univ Western Australia, Sch Med, Div Obstet & Gynaecol, Crawley, Australia; [Chang, Barbara J.] Univ Western Australia, Sch Biomed Sci, Marshall Ctr Infect Dis Res & Training, Crawley, Australia	University of Western Australia; University of Western Australia	Furfaro, LL (corresponding author), Univ Western Australia, Sch Med, Div Obstet & Gynaecol, Crawley, Australia.	lucy.furfaro@uwa.edu.au	; Furfaro, Lucy/H-5569-2018	Chang, Barbara/0000-0002-6077-1646; Furfaro, Lucy/0000-0001-7652-0713	Channel 7 Telethon Trust Fund; Australian Government Research Training Program Scholarship; Professor Gordon King Postgraduate Scholarship by the Women's and Infants' Research Foundation; NHMRC [1144040]	Channel 7 Telethon Trust Fund; Australian Government Research Training Program Scholarship(Australian GovernmentDepartment of Industry, Innovation and Science); Professor Gordon King Postgraduate Scholarship by the Women's and Infants' Research Foundation; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This research was supported by the Channel 7 Telethon Trust Fund to MSP. LLF is supported by the Australian Government Research Training Program Scholarship and the Professor Gordon King Postgraduate Scholarship provided by the Women's and Infants' Research Foundation. MSP is also supported by an NHMRC Project Grant [1144040].	Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; Aloisio I, 2016, APPL MICROBIOL BIOT, V100, P5537, DOI 10.1007/s00253-016-7410-2; Arndt D, 2016, NUCLEIC ACIDS RES, V44, pW16, DOI 10.1093/nar/gkw387; Back EE, 2012, ANTIMICROB AGENTS CH, V56, P739, DOI 10.1128/AAC.05794-11; Bai Qinqin, 2016, Weishengwu Xuebao, V56, P317; Bai QQ, 2013, ARCH VIROL, V158, P1733, DOI 10.1007/s00705-013-1667-x; Bankevich A, 2012, J COMPUT BIOL, V19, P455, DOI 10.1089/cmb.2012.0021; BETRIU C, 1994, ANTIMICROB AGENTS CH, V38, P2183, DOI 10.1128/AAC.38.9.2183; Brettin T, 2015, SCI REP-UK, V5, DOI 10.1038/srep08365; Cheng Q, 2005, ANTIMICROB AGENTS CH, V49, P111, DOI 10.1128/AAC.49.1.111-117.2005; Delcher AL, 2007, BIOINFORMATICS, V23, P673, DOI 10.1093/bioinformatics/btm009; Domelier AS, 2009, J BACTERIOL, V191, P4776, DOI 10.1128/JB.00426-09; Duplessis M, 2001, MOL MICROBIOL, V41, P325, DOI 10.1046/j.1365-2958.2001.02521.x; Furfaro LL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0223256; Furfaro LL, 2018, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.02660; Furfaro LL, 2017, DIAGN MICR INFEC DIS, V89, P7, DOI 10.1016/j.diagmicrobio.2017.06.003; Hatfull GF, 2011, CURR OPIN VIROL, V1, P298, DOI 10.1016/j.coviro.2011.06.009; Imperi M, 2010, J MICROBIOL METH, V80, P212, DOI 10.1016/j.mimet.2009.11.010; Jacobs-Sera D, 2012, VIROLOGY, V434, P187, DOI 10.1016/j.virol.2012.09.026; Kimura K, 2008, ANTIMICROB AGENTS CH, V52, P2890, DOI 10.1128/AAC.00185-08; Kropinski Andrew M., 2009, V501, P69, DOI 10.1007/978-1-60327-164-6_7; Letunic I, 2016, NUCLEIC ACIDS RES, V44, pW242, DOI 10.1093/nar/gkw290; Mazzocco Amanda, 2009, V501, P81, DOI 10.1007/978-1-60327-164-6_9; Mcshan WM, 1997, MOL MICROBIOL, V23, P719, DOI 10.1046/j.1365-2958.1997.2591616.x; Nale JY, 2018, ANTIBIOTICS-BASEL, V7, DOI 10.3390/antibiotics7010013; NCBI Resource Coordinators, 2018, NUCLEIC ACIDS RES, V46, pD8; Nobrega FL, 2015, TRENDS MICROBIOL, V23, P185, DOI 10.1016/j.tim.2015.01.006; Russell NJ, 2017, CLIN INFECT DIS, V65, pS100, DOI 10.1093/cid/cix658; Salloum M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020256; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Seki T, 2015, J ANTIMICROB CHEMOTH, V70, P2725, DOI 10.1093/jac/dkv203; Simioni J, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0724-5; Sullivan MJ, 2011, BIOINFORMATICS, V27, P1009, DOI 10.1093/bioinformatics/btr039; Verani Jennifer R., 2010, Morbidity and Mortality Weekly Report, V59, P1; Wick RR, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005595; Wommack K. Eric, 2009, V501, P3, DOI 10.1007/978-1-60327-164-6_1; 2016, CANC DISCOV, V6	37	8	8	1	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2020	15	6							e0235002	10.1371/journal.pone.0235002	http://dx.doi.org/10.1371/journal.pone.0235002			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ME9KK	32574197	Green Published, gold			2023-01-03	WOS:000544972400020
J	Al-Dahshan, A; Al-Kubiasi, N; Al-Zaidan, M; Saeed, W; Kehyayan, V; Bougmiza, I				Al-Dahshan, Ayman; Al-Kubiasi, Noora; Al-Zaidan, Manal; Saeed, Wael; Kehyayan, Vahe; Bougmiza, Iheb			Prevalence of polypharmacy and the association with non-communicable diseases in Qatari elderly patients attending primary healthcare centers: A cross-sectional study	PLOS ONE			English	Article							OLDER-ADULTS; DRUG-TREATMENT; RISK	Background Polypharmacy has become a global public health concern particularly in the elderly population. The elderly population is the most susceptible to the negative effects of polypharmacy due to their altered pharmacokinetics and decreased drug clearance. Therefore, polypharmacy can lead to poor health status and higher rates of morbidity and mortality. Objective The objective of this study was to determine the prevalence of polypharmacy (>= 5 drugs) and its association with non-communicable diseases (NCDs) in elderly (>= 65 years) Qatari patients attending Primary Healthcare (PHC) centers in Qatar. Methods A retrospective cross-sectional analysis was conducted using the Electronic Medical Record (EMR) database of all PHC centers in Qatar for six months (April-September 2017). Results Out of 5639 patients screened, 75.5% (95% CI: 74.3-76.6) were exposed to polypharmacy. Females were 1.18 times more likely to have polypharmacy compared to males (95% CI: 1.03-1.34). The multivariate analysis identified having hypertension (AOR 1.71; 95% CI: 1.38-2.13), diabetes (AOR 2.38; 95% CI: 1.97-2.87), dyslipidemia (AOR 1.29; 95% CI: 1.06-1.56), cardiovascular disease (AOR 1.56; 95% CI: 1.25-1.95) and asthma (AOR 1.39; 95% CI: 1.13-1.72) to be independent parameters associated with polypharmacy. Also, the Body Mass Index (BMI) and number of NCDs were found to be significant independent parameters associated with polypharmacy. Conclusions The prevalence of polypharmacy among Qatari elderly attending PHC Centers is very high. Our findings confirm the strong relationship between polypharmacy and BMI, and certain NCDs. Healthcare professionals should be educated about the magnitude of polypharmacy, its negative effects, and its associated factors. Best practice guidelines should be developed for improved medical practice in the prescription of medications for such a vulnerable population.	[Al-Dahshan, Ayman] Hamad Med Corp, Community Med Residency Program, Doha, Qatar; [Al-Kubiasi, Noora; Bougmiza, Iheb] Primary Hlth Care Corp, Community Med Residency Program, Doha, Qatar; [Al-Zaidan, Manal; Saeed, Wael] Primary Hlth Care Corp, Clin Affairs Dept, Doha, Qatar; [Kehyayan, Vahe] Univ Calgary Qatar, Doha, Qatar	Hamad Medical Corporation; Hamad Medical Corporation; Primary Health Care Corporation (PHCC); Hamad Medical Corporation; Primary Health Care Corporation (PHCC)	Al-Dahshan, A (corresponding author), Hamad Med Corp, Community Med Residency Program, Doha, Qatar.	Ayman.aldahshan@hotmail.com	al-dahshan, ayman/AAR-4635-2021	AL DAHSHAN, AYMAN/0000-0001-6132-3223				Al-Hashar Amna, 2016, Oman Med J, V31, P421, DOI 10.5001/omj.2016.85; Alsuwaidan A, 2019, GERIATRICS-BASEL, V4, DOI 10.3390/geriatrics4020036; Alwhaibi M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020852; Badawy NA, 2020, MED PRIN PRACT, V29, P166, DOI 10.1159/000503298; Charlesworth CJ, 2015, J GERONTOL A-BIOL, V70, P989, DOI 10.1093/gerona/glv013; Cusack Barry J, 2004, Am J Geriatr Pharmacother, V2, P274, DOI 10.1016/j.amjopharm.2004.12.005; Frazier Susan C, 2005, J Gerontol Nurs, V31, P4; Fried TR, 2014, J AM GERIATR SOC, V62, P2261, DOI 10.1111/jgs.13153; Gnjidic D, 2012, CLIN PHARMACOL THER, V91, P521, DOI 10.1038/clpt.2011.258; Gomez C, 2015, GERONTOLOGY, V61, P301, DOI 10.1159/000365328; Hu T, 2017, CAN FAM PHYSICIAN, V63, P45; Hughes LD, 2012, AGE AGEING, V41, P24; Institute for Healthcare Improvement, 2020, MED REC PREV DRUG EV; Jyrkka J, 2009, DRUG AGING, V26, P493, DOI 10.2165/00002512-200926060-00006; Kann Inger Cathrine, 2015, Drugs Real World Outcomes, V2, P193; Kim HA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098043; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; Carmona-Torres JM, 2018, J CLIN NURS, V27, P2942, DOI 10.1111/jocn.14371; Masnoon N, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0621-2; Ministry of Public Health, 2018, HLTH AG; Morin L, 2018, CLIN EPIDEMIOL, V10, P289, DOI 10.2147/CLEP.S153458; Pereira Karine Gonçalves, 2017, Rev. bras. epidemiol., V20, P335, DOI 10.1590/1980-5497201700020013; Primary Health Care Corporation, 2013, NAT PRIM HLTH CAR ST; Primary Health Care Corporation, 2018, HLTH CTR; Primary Health Care Corporation, 2019, CORP STRAT PLAN 2019; Rochon PA, 1997, BMJ-BRIT MED J, V315, P1096, DOI 10.1136/bmj.315.7115.1096; Salisbury C, 2011, BRIT J GEN PRACT, V61, DOI 10.3399/bjgp11X548929; Slabaugh SL, 2010, DRUG AGING, V27, P1019, DOI 10.2165/11584990-000000000-00000; Slater N, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020270; Syed Mohamed A, 2019, BMJ Nutr Prev Health, V2, P20, DOI 10.1136/bmjnph-2018-000014; Weng MC, 2013, QJM-INT J MED, V106, P1009, DOI 10.1093/qjmed/hct141; WHO, AN THER CHEM CLASS S; World Health Organization, 2018, AG HLTH; Wynne HA, 2010, MATURITAS, V66, P246, DOI 10.1016/j.maturitas.2010.03.004; Zidan A, 2018, PHARMACY-BASEL, V6, DOI 10.3390/pharmacy6030085; 2016, EUR HEART J, V50	36	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 11	2020	15	6							e0234386	10.1371/journal.pone.0234386	http://dx.doi.org/10.1371/journal.pone.0234386			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MA6QL	32525902	Green Published, gold			2023-01-03	WOS:000542036800091
J	Fong, WN; Li, Q; Yu, J				Fong, Winnie; Li, Qing; Yu, Jun			Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer	ONCOGENE			English	Review							LACTOBACILLUS-RHAMNOSUS GG; LACTIC-ACID BACTERIA; COLON-CANCER; PROBIOTIC LACTOBACILLUS; INTESTINAL MICROBIOTA; DOUBLE-BLIND; ACIDOPHILUS DEFICIENT; ESCHERICHIA-COLI; BARRIER FUNCTION; POTENTIAL ROLE	Research about the role of gut microbiome in colorectal cancer (CRC) is a newly emerging field of study. Gut microbiota modulation, with the aim to reverse established microbial dysbiosis, is a novel strategy for prevention and treatment of CRC. Different strategies including probiotics, prebiotics, postbiotics, antibiotics, and fecal microbiota transplantation (FMT) have been employed. Although these strategies show promising results, mechanistically by correcting microbiota composition, modulating innate immune system, enhancing gut barrier function, preventing pathogen colonization and exerting selective cytotoxicity against tumor cells, it should be noted that they are accompanied by risks and controversies that can potentially introduce clinical complications. During bench-to-bedside translation, evaluation of risk-and-benefit ratio, as well as patient selection, should be carefully performed. In view of the individualized host response to gut microbiome intervention, developing personalized microbiome therapy may be the key to successful clinical treatment.	[Fong, Winnie; Li, Qing; Yu, Jun] Chinese Univ Hong Kong, Inst Digest Dis & Dept Med & Therapeut, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, CUHK Shenzhen Res Inst, Hong Kong, Peoples R China; [Fong, Winnie] Chinese Univ Hong Kong, Sch Pharm, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis & Dept Med & Therapeut, State Key Lab Digest Dis,Li Ka Shing Inst Hlth Sc, CUHK Shenzhen Res Inst, Hong Kong, Peoples R China.	junyu@cuhk.edu.hk	Li, Qing/ABC-4649-2020; Jun, Yu/D-8569-2015	Li, Qing/0000-0002-0169-8098; Jun, Yu/0000-0001-5008-2153	National Natural Science Foundation of China (National Science Foundation of China) [81972576] Funding Source: Medline	National Natural Science Foundation of China (National Science Foundation of China)(National Natural Science Foundation of China (NSFC))		Ahmad R, 2017, ONCOGENE, V36, P6592, DOI 10.1038/onc.2017.259; Alang N, 2015, OPEN FORUM INFECT DI, V2, DOI 10.1093/ofid/ofv004; Alvarez CS, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.01981; Ambalam P, 2016, BEST PRACT RES CL GA, V30, P119, DOI 10.1016/j.bpg.2016.02.009; Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Azcarate-Peril MA, 2017, P NATL ACAD SCI USA, V114, pE367, DOI 10.1073/pnas.1606722113; Belcheva A, 2014, CELL, V158, P288, DOI 10.1016/j.cell.2014.04.051; Bermudez-Brito M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059370; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240; Bultman SJ, 2014, CELL HOST MICROBE, V16, P143, DOI 10.1016/j.chom.2014.07.011; Campana R, 2017, GUT PATHOG, V9, DOI 10.1186/s13099-017-0162-4; Canani RB, 2011, WORLD J GASTROENTERO, V17, P1519, DOI [10.3748/wjg.v17.i12. 1519, 10.3748/wjg.v17.i12.1519]; Cannon JP, 2005, EUR J CLIN MICROBIOL, V24, P31, DOI 10.1007/s10096-004-1253-y; Cao HL, 2017, INT J CANCER, V140, P2545, DOI 10.1002/ijc.30643; Cao Y, 2018, GUT, V67, P672, DOI 10.1136/gutjnl-2016-313413; Chang CW, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00983; Chen CC, 2012, BRIT J NUTR, V107, P1623, DOI 10.1017/S0007114511004934; Chen LL, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/909514; Chen ZF, 2015, FUTURE MICROBIOL, V10, P1433, DOI 10.2217/fmb.15.66; Chen ZY, 2017, MOLECULES, V22, DOI 10.3390/molecules22010107; Chung L, 2018, CELL HOST MICROBE, V23, P421, DOI 10.1016/j.chom.2018.02.004; Crook N, 2019, CELL HOST MICROBE, V25, P499, DOI 10.1016/j.chom.2019.02.005; Cui M, 2017, EMBO MOL MED, V9, P448, DOI 10.15252/emmm.201606932; Dai ZW, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0451-2; Daillere R, 2016, IMMUNITY, V45, P931, DOI 10.1016/j.immuni.2016.09.009; De Marco S, 2018, EVID-BASED COMPL ALT, V2018, DOI 10.1155/2018/1756308; Delia P, 2007, WORLD J GASTROENTERO, V13, P912, DOI 10.3748/wjg.v13.i6.912; Demers M, 2014, CLIN NUTR, V33, P761, DOI 10.1016/j.clnu.2013.10.015; Derosa L, 2018, ANN ONCOL, V29, P1437, DOI 10.1093/annonc/mdy103; Dewulf EM, 2013, GUT, V62, P1112, DOI 10.1136/gutjnl-2012-303304; Dik VK, 2016, DIGEST DIS SCI, V61, P255, DOI 10.1007/s10620-015-3828-0; Doron S, 2015, CLIN INFECT DIS, V60, pS129, DOI 10.1093/cid/civ085; Escamilla J, 2012, NUTR CANCER, V64, P871, DOI 10.1080/01635581.2012.700758; Fayol-Messaoudi D, 2005, APPL ENVIRON MICROB, V71, P6008, DOI 10.1128/AEM.71.10.6008-6013.2005; Feng Q, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7528; Food and Drug Administration, 2019, IMP SAF AL REG US FE; Forchielli ML, 2005, BRIT J NUTR, V93, pS41, DOI 10.1079/BJN20041356; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; Gamallat Y, 2016, BIOMED PHARMACOTHER, V83, P536, DOI 10.1016/j.biopha.2016.07.001; Gao J, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.00477; Geier MS, 2006, CANCER BIOL THER, V5, P1265, DOI 10.4161/cbt.5.10.3296; Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043; Ghadimi D, 2012, J LEUKOCYTE BIOL, V92, P895, DOI 10.1189/jlb.0611286; Gibson GR, 2017, NAT REV GASTRO HEPAT, V14, P491, DOI 10.1038/nrgastro.2017.75; Gibson GR, 2000, J NUTR, V130, p391S, DOI 10.1093/jn/130.2.391S; GIBSON GR, 1995, J NUTR, V125, P1401, DOI 10.1093/jn/125.6.1401; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Gillor O, 2008, APPL MICROBIOL BIOT, V81, P591, DOI 10.1007/s00253-008-1726-5; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gregory JC, 2015, J BIOL CHEM, V290, P5647, DOI 10.1074/jbc.M114.618249; Gueimonde M, 2013, FRONT MICROBIOL, V4, DOI 10.3389/fmicb.2013.00202; Hassan H, 2018, SUPPORT CARE CANCER, V26, P2503, DOI 10.1007/s00520-018-4216-z; Hattori N, 2019, CANCER SCI, V110, P147, DOI 10.1111/cas.13880; Hohmann EL, 2014, NEW ENGL J MED, V371, P668, DOI 10.1056/NEJMcpc1400842; Hu YF, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3151; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Ijssennagger N, 2015, P NATL ACAD SCI USA, V112, P10038, DOI 10.1073/pnas.1507645112; Ishikawa H, 2005, INT J CANCER, V116, P762, DOI 10.1002/ijc.21115; Ito H, 2011, J AGR FOOD CHEM, V59, P5771, DOI 10.1021/jf200859z; Jacobsen L, 2007, FEMS MICROBIOL ECOL, V59, P158, DOI 10.1111/j.1574-6941.2006.00212.x; Jacouton E, 2019, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.03281; Jeon Seong Gyu, 2012, PLoS Pathog, V8, pe1002714, DOI 10.1371/journal.ppat.1002714; Kamada N, 2012, SCIENCE, V336, P1325, DOI 10.1126/science.1222195; Khazaie K, 2012, P NATL ACAD SCI USA, V109, P10462, DOI 10.1073/pnas.1207230109; Kilkkinen A, 2008, INT J CANCER, V123, P2152, DOI 10.1002/ijc.23622; Klaenhammer TR, 2012, NAT REV IMMUNOL, V12, P728, DOI 10.1038/nri3312; Konieczna P, 2012, GUT, V61, P354, DOI 10.1136/gutjnl-2011-300936; Konishi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12365; Konstantinov SR, 2013, NAT REV GASTRO HEPAT, V10, P741, DOI 10.1038/nrgastro.2013.178; Kotzampassi K, 2015, WORLD J SURG, V39, P2776, DOI 10.1007/s00268-015-3071-z; Kroemer G, 2018, NAT REV IMMUNOL, V18, P87, DOI 10.1038/nri.2018.4; Kumar M, 2017, AM J PHYSIOL-GASTR L, V312, pG34, DOI 10.1152/ajpgi.00298.2016; Kuugbee ED, 2016, DIGEST DIS SCI, V61, P2908, DOI 10.1007/s10620-016-4238-7; Kyriacou DN, 2016, JAMA-J AM MED ASSOC, V316, P1818, DOI 10.1001/jama.2016.16435; Lenoir M, 2016, J GASTROENTEROL, V51, P862, DOI 10.1007/s00535-015-1158-9; Li HL, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00455; Lin XXB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083644; Lindsay JO, 2006, GUT, V55, P348, DOI 10.1136/gut.2005.074971; Liu C, 2009, BIOMED ENVIRON SCI, V22, P401, DOI 10.1016/S0895-3988(10)60018-9; Liu Z, 2011, ALIMENT PHARM THER, V33, P50, DOI 10.1111/j.1365-2036.2010.04492.x; Liu ZH, 2013, AM J CLIN NUTR, V97, P117, DOI 10.3945/ajcn.112.040949; Long XH, 2019, NAT MICROBIOL, V4, P2319, DOI 10.1038/s41564-019-0541-3; Mackowiak Philip A, 2013, Front Public Health, V1, P52, DOI 10.3389/fpubh.2013.00052; Maier TV, 2017, MBIO, V8, DOI [10.1128/mbio.01343-17, 10.1128/mBio.01343-17]; Martin R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41738-5; Mego M, 2015, COMPLEMENT THER MED, V23, P356, DOI 10.1016/j.ctim.2015.03.008; Mi H, 2017, CELL PHYSIOL BIOCHEM, V42, P2330, DOI 10.1159/000480005; Miller LE, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030191; Mills JP, 2018, CURR OPIN GASTROEN, V34, P3, DOI 10.1097/MOG.0000000000000410; Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101; Mohamadzadeh M, 2011, P NATL ACAD SCI USA, V108, P4623, DOI 10.1073/pnas.1005066107; Monteagudo-Mera A, 2019, APPL MICROBIOL BIOT, V103, P6463, DOI 10.1007/s00253-019-09978-7; Osterlund P, 2007, BRIT J CANCER, V97, P1028, DOI 10.1038/sj.bjc.6603990; Parkin DM, 2011, BRIT J CANCER, V105, pS77, DOI 10.1038/bjc.2011.489; Piewngam P, 2018, NATURE, V562, P532, DOI 10.1038/s41586-018-0616-y; Puppa MJ, 2011, BBA-MOL BASIS DIS, V1812, P1601, DOI 10.1016/j.bbadis.2011.08.010; Quera R, 2014, J CROHNS COLITIS, V8, P252, DOI 10.1016/j.crohns.2013.10.002; Rafter J, 2007, AM J CLIN NUTR, V85, P488, DOI 10.1093/ajcn/85.2.488; Ridaura VK, 2013, SCIENCE, V341, P1079, DOI 10.1126/science.1241214; Rocha-Ramirez LM, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/4607491; Rosshart SP, 2017, CELL, V171, P1015, DOI 10.1016/j.cell.2017.09.016; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012; Salva S, 2014, INT IMMUNOPHARMACOL, V22, P209, DOI 10.1016/j.intimp.2014.06.017; Sanders ME, 2018, CURR OPIN BIOTECH, V49, P207, DOI 10.1016/j.copbio.2017.09.007; Sanders ME, 2010, GUT MICROBES, V1, P164, DOI 10.4161/gmic.1.3.12127; Sangild PT, 2018, AM J PHYSIOL-GASTR L, V314, pG231, DOI 10.1152/ajpgi.00204.2017; Schwartz M, 2013, AM J GASTROENTEROL, V108, P1367, DOI 10.1038/ajg.2013.164; Scott AJ, 2019, GUT, V68, P1624, DOI 10.1136/gutjnl-2019-318556; Sekirov I, 2010, PHYSIOL REV, V90, P859, DOI 10.1152/physrev.00045.2009; Sethi V, 2018, GASTROENTEROLOGY, V155, P33, DOI 10.1053/j.gastro.2018.04.001; Shields CED, 2016, J INFECT DIS, V214, P122, DOI 10.1093/infdis/jiw069; Shin W, 2018, P NATL ACAD SCI USA, V115, pE10539, DOI 10.1073/pnas.1810819115; Shoaf K, 2006, INFECT IMMUN, V74, P6920, DOI 10.1128/IAI.01030-06; Sichetti M, 2018, NUTRITION, V53, P95, DOI 10.1016/j.nut.2018.02.005; Singh V, 2018, CELL, V175, P679, DOI 10.1016/j.cell.2018.09.004; Sitaraman R, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0551-z; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Skye SM, 2018, CIRC RES, V123, P1164, DOI 10.1161/CIRCRESAHA.118.313142; Smits LP, 2013, GASTROENTEROLOGY, V145, P946, DOI 10.1053/j.gastro.2013.08.058; Soler AP, 1999, CARCINOGENESIS, V20, P1425, DOI 10.1093/carcin/20.8.1425; Southcott E, 2008, DIGEST DIS SCI, V53, P1837, DOI 10.1007/s10620-008-0275-1; Taper HS, 2005, IN VIVO, V19, P201; Tong LC, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00253; Toomey N, 2009, FOODBORNE PATHOG DIS, V6, P925, DOI 10.1089/fpd.2009.0278; Triner D, 2019, GASTROENTEROLOGY, V156, P1467, DOI 10.1053/j.gastro.2018.12.003; Tuomola EM, 1999, FEMS IMMUNOL MED MIC, V26, P137, DOI 10.1111/j.1574-695X.1999.tb01381.x; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Wang F, 2018, P NATL ACAD SCI USA, V115, P157, DOI 10.1073/pnas.1712901115; Wang LH, 2014, J BIOL CHEM, V289, P20234, DOI 10.1074/jbc.M114.553800; Wang Y, 2017, MUCOSAL IMMUNOL, V10, P373, DOI 10.1038/mi.2016.57; Wang ZK, 2014, WORLD J GASTROENTERO, V20, P14805, DOI 10.3748/wjg.v20.i40.14805; Weingarden AR, 2017, GUT MICROBES, V8, P238, DOI 10.1080/19490976.2017.1290757; Willing BP, 2011, NAT REV MICROBIOL, V9, P233, DOI 10.1038/nrmicro2536; Wong JMW, 2006, J CLIN GASTROENTEROL, V40, P235, DOI 10.1097/00004836-200603000-00015; Yan F, 2012, GUT MICROBES, V3, P25, DOI 10.4161/gmic.19245; Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018; Yang YZ, 2016, ONCOTARGET, V7, P8432, DOI 10.18632/oncotarget.7045; Yeung CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138746; Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008; Zackular JP, 2016, MSPHERE, V1, DOI 10.1128/mSphere.00001-15; Zackular JP, 2013, MBIO, V4, DOI 10.1128/mBio.00692-13; Zaharuddin L, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-1047-4; Zhao S, 2019, LUNG CANCER, V130, P10, DOI 10.1016/j.lungcan.2019.01.017; Zyrek AA, 2007, CELL MICROBIOL, V9, P804, DOI 10.1111/j.1462-5822.2006.00836.x	147	167	168	25	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 25	2020	39	26					4925	4943		10.1038/s41388-020-1341-1	http://dx.doi.org/10.1038/s41388-020-1341-1		JUN 2020	19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MQ2YO	32514151	hybrid, Green Published			2023-01-03	WOS:000538969800002
J	Powles, T; Park, SH; Voog, E; Caserta, C; Valderrama, BP; Gurney, H; Kalofonos, H; Radulovic, S; Demey, W; Ullen, A; Loriot, Y; Sridhar, SS; Tsuchiya, N; Kopyltsov, E; Sternberg, CN; Bellmunt, J; Aragon-Ching, JB; Petrylak, DP; Laliberte, R; Wang, J; Huang, B; Davis, C; Fowst, C; Costa, N; Blake-Haskins, JA; di Pietro, A; Grivas, P				Powles, Thomas; Park, Se Hoon; Voog, Eric; Caserta, Claudia; Valderrama, Begona P.; Gurney, Howard; Kalofonos, Haralabos; Radulovic, Sinisa; Demey, Wim; Ullen, Anders; Loriot, Yohann; Sridhar, Srikala S.; Tsuchiya, Norihiko; Kopyltsov, Evgeny; Sternberg, Cora N.; Bellmunt, Joaquim; Aragon-Ching, Jeanny B.; Petrylak, Daniel P.; Laliberte, Robert; Wang, Jing; Huang, Bo; Davis, Craig; Fowst, Camilla; Costa, Nuno; Blake-Haskins, John A.; di Pietro, Alessandra; Grivas, Petros			Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CISPLATIN-INELIGIBLE PATIENTS; GEMCITABINE PLUS CISPLATIN; 1ST-LINE CHEMOTHERAPY; SINGLE-ARM; OPEN-LABEL; RANDOMIZED-TRIAL; DOUBLE-BLIND; MULTICENTER; ATEZOLIZUMAB; CANCER	BACKGROUND Platinum-based chemotherapy is standard-of-care first-line treatment for advanced urothelial carcinoma. However, progression-free survival and overall survival are limited by chemotherapy resistance. METHODS In a phase 3 trial, we randomly assigned patients with unresectable locally advanced or metastatic urothelial cancer who did not have disease progression with first-line chemotherapy (four to six cycles of gemcitabine plus cisplatin or carboplatin) to receive best supportive care with or without maintenance avelumab. The primary end point was overall survival, assessed among all patients who underwent randomization (overall population) and among those with tumors positive for programmed cell death ligand 1 (PD-L1). Secondary end points included progression-free survival and safety. RESULTS Among all 700 patients who underwent randomization, the addition of maintenance avelumab to best supportive care significantly prolonged overall survival as compared with best supportive care alone (control). Overall survival at 1 year was 71.3% in the avelumab group and 58.4% in the control group (median overall survival, 21.4 months vs. 14.3 months; hazard ratio for death, 0.69; 95% confidence interval [CI], 0.56 to 0.86; P=0.001). Avelumab also significantly prolonged overall survival in the PD-L1-positive population; overall survival at 1 year was 79.1% in the avelumab group and 60.4% in the control group (hazard ratio, 0.56; 95% CI, 0.40 to 0.79; P<0.001). The median progression-free survival was 3.7 months in the avelumab group and 2.0 months in the control group in the overall population (hazard ratio for disease progression or death, 0.62; 95% CI, 0.52 to 0.75) and 5.7 months and 2.1 months, respectively, in the PD-L1-positive population (hazard ratio, 0.56; 95% CI, 0.43 to 0.73). The incidence of adverse events from any cause was 98.0% in the avelumab group and 77.7% in the control group; the incidence of adverse events of grade 3 or higher was 47.4% and 25.2%, respectively. CONCLUSIONS Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who had disease that had not progressed with first-line chemotherapy.	[Powles, Thomas] Queen Mary Univ London, St Bartholomews Hosp, Expt Canc Med Ctr, Barts Canc Inst, Charterhouse Sq, London ECIM 6BQ, England; [Park, Se Hoon] Sungkyunkwan Univ, Samsung Med Ctr, Seoul, South Korea; [Voog, Eric] Ctr Jean Bernard Clin Victor Hugo, Le Mans, France; [Loriot, Yohann] Univ Paris Saclay, INSERM, Gustave Roussy, U981, Villejuif, France; [Caserta, Claudia] Azienda Osped S Maria, Med Oncol Unit, Terni, Italy; [Fowst, Camilla; di Pietro, Alessandra] Pfizer, Milan, Italy; [Valderrama, Begona P.] Hosp Univ Virgen del Rocio, Dept Med Oncol, Seville, Spain; [Gurney, Howard] Macquarie Univ, Dept Clin Med, Sydney, NSW, Australia; [Kalofonos, Haralabos] Univ Gen Hosp Patras, Div Oncol, Dept Med, Patras, Greece; [Radulovic, Sinisa] Inst Oncol & Radiol Serbia, Belgrade, Serbia; [Demey, Wim] Algemeen Ziekenhuis Klina, Dept Med Oncol, Brasschaat, Belgium; [Ullen, Anders] Karolinska Univ Hosp, Theme Canc, Patient Area Pelv Canc, Solna, Sweden; [Ullen, Anders] Karolinska Inst, Dept Oncol Pathol, Solna, Sweden; [Sridhar, Srikala S.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada; [Tsuchiya, Norihiko] Yamagata Univ, Fac Med, Dept Urol, Yamagata, Japan; [Kopyltsov, Evgeny] State Inst Healthcare Reg Clin Oncol Dispensary, Omsk, Russia; [Sternberg, Cora N.] Weill Cornell Med, Div Hematol & Med Oncol, New York, NY USA; [Bellmunt, Joaquim] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med Oncol, Boston, MA 02115 USA; [Laliberte, Robert; Wang, Jing] Pfizer, Cambridge, MA USA; [Aragon-Ching, Jeanny B.] Inova Schar Canc Inst, Fairfax, VA USA; [Petrylak, Daniel P.] Yale Canc Ctr, New Haven, CT USA; [Huang, Bo] Pfizer, Groton, CT USA; [Davis, Craig; Blake-Haskins, John A.] Pfizer, La Jolla, CA USA; [Costa, Nuno] Pfizer, Porto Salvo, Portugal; [Grivas, Petros] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA; [Grivas, Petros] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle Canc Care Alliance, 1124 Columbia St, Seattle, WA 98104 USA	University of London; Queen Mary University London; Sungkyunkwan University (SKKU); Samsung Medical Center; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy; Pfizer; Virgen del Rocio University Hospital; Macquarie University; University of Patras; Institute for Oncology & Radiology of Serbia (IORS); Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Yamagata University; Cornell University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pfizer; Yale University; Pfizer; Pfizer; Pfizer; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center; Seattle Cancer Care Alliance	Powles, T (corresponding author), Queen Mary Univ London, St Bartholomews Hosp, Expt Canc Med Ctr, Barts Canc Inst, Charterhouse Sq, London ECIM 6BQ, England.	thomas.powles1@nhs.net	Aragon-Ching, Jeanny/AAJ-4969-2020; Park, Se Hoon/GMX-1199-2022; Loriot, Yohann/W-5572-2019; Aragon-Ching, Jeanny/AAL-2501-2020; Gurney, Howard/ABF-6924-2020; Bellmunt, Joaquim/B-8151-2019; Tsuchiya, Norihiko/H-6538-2019	Aragon-Ching, Jeanny/0000-0002-6714-141X; Park, Se Hoon/0000-0001-5084-9326; Aragon-Ching, Jeanny/0000-0002-6714-141X; Gurney, Howard/0000-0003-0217-5261; Bellmunt, Joaquim/0000-0003-2328-3421; Wang, Jing/0000-0003-1580-1356	Pfizer; Merck [Darmstadt, Germany]	Pfizer(Pfizer); Merck [Darmstadt, Germany](Merck & Company)	Funded by Pfizer and Merck [Darmstadt, Germany]; JAVELIN Bladder 100 ClinicalTrials.gov number, NCT02603432.	Al-Daghri NM, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1489132; APOLO AB, 2019, J CLIN ONCOL S, V37; Apolo AB, 2017, J CLIN ONCOL, V35, P2117, DOI 10.1200/JCO.2016.71.6795; Balar AV, 2017, LANCET ONCOL, V18, P1483, DOI 10.1016/S1470-2045(17)30616-2; Balar AV, 2017, LANCET, V389, P67, DOI 10.1016/S0140-6736(16)32455-2; Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683; De Santis M, 2012, J CLIN ONCOL, V30, P191, DOI 10.1200/JCO.2011.37.3571; Dogliotti L, 2007, EUR UROL, V52, P134, DOI 10.1016/j.eururo.2006.12.029; Eckstein M, 2019, EUR J CANCER, V106, P234, DOI 10.1016/j.ejca.2018.11.007; Fradet Y, 2019, ANN ONCOL, V30, P970, DOI 10.1093/annonc/mdz127; Galsky MD, 2020, LANCET, V395, P1547, DOI 10.1016/S0140-6736(20)30230-0; Galsky MD, 2020, J CLIN ONCOL, V38, P1797, DOI 10.1200/JCO.19.03091; Garcia-Donas J, 2017, LANCET ONCOL, V18, P672, DOI 10.1016/S1470-2045(17)30242-5; Gopalakrishnan D, 2018, THER CLIN RISK MANAG, V14, DOI 10.2147/TCRM.S158753; Grivas P, 2019, TARGET ONCOL, V14, P505, DOI 10.1007/s11523-019-00665-1; Grivas PD, 2014, CANCER-AM CANCER SOC, V120, P692, DOI 10.1002/cncr.28477; GUPTA S, 2019, J CLIN ONCOL S, V37; Kim JW, 2015, CURR OPIN ONCOL, V27, P191, DOI 10.1097/CCO.0000000000000177; Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501; National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology, 2022, OV CANC INCL FALL TU; Patel MR, 2018, LANCET ONCOL, V19, P51, DOI 10.1016/S1470-2045(17)30900-2; Powles T, 2018, LANCET, V391, P748, DOI 10.1016/S0140-6736(17)33297-X; Powles T, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.2411; Powles T, 2017, J CLIN ONCOL, V35, P48, DOI 10.1200/JCO.2015.66.3468; ROSENBERG JE, 2019, P AN M AM SOC CLIN, V37, P4503, DOI DOI 10.1200/JCO.2019.37.15_suppl.4503; Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4; Schwamborn K, 2019, VIRCHOWS ARCH, V475, P599, DOI 10.1007/s00428-019-02610-z; Sharma P, 2017, LANCET ONCOL, V18, P312, DOI 10.1016/S1470-2045(17)30065-7; Sharma P, 2016, LANCET ONCOL, V17, P1590, DOI 10.1016/S1470-2045(16)30496-X; Sonpavde GP, 2018, J UROLOGY, V200, P1207, DOI 10.1016/j.juro.2018.07.035; Stenehjem DD, 2018, ONCOTARGETS THER, V11, P5973, DOI 10.2147/OTT.S135157; Szabados B, 2018, EUR UROL, V73, P149, DOI 10.1016/j.eururo.2017.08.022; van Dijk N, 2019, EUR UROL, V75, P435, DOI 10.1016/j.eururo.2018.09.022; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Zajac M, 2019, ARCH PATHOL LAB MED, V143, P722, DOI 10.5858/arpa.2017-0555-OA; Zajac M, 2019, DIAGN PATHOL, V14, DOI 10.1186/s13000-019-0873-6	37	387	395	6	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 24	2020	383	13					1218	1230		10.1056/NEJMoa2002788	http://dx.doi.org/10.1056/NEJMoa2002788			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX2KQ	32945632	Bronze			2023-01-03	WOS:000575544000011
J	Shufelt, C; LeVee, A				Shufelt, Chrisandra; LeVee, Alexis			Hormonal Contraception in Women With Hypertension	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Shufelt, Chrisandra; LeVee, Alexis] Cedars Sinai Med Ctr, Smidt Heart Inst, Barbra Streisand Womens Heart Ctr, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center	Shufelt, C (corresponding author), 8631 W Third St,Med Off Tower 740, Los Angeles, CA 90048 USA.	chrisandra.shufelt@cshs.org		Shufelt, Chrisandra/0000-0001-6886-9210	National Heart, Lung, and Blood Institute [K23HL127262]; Louis B. Mayer Foundation; Edythe L. Broad Women's Heart Research Fellowship; Barbra Streisand Women's Cardiovascular Research and Education Program, Smidt Heart Institute, Cedars-Sinai Medical Center	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Louis B. Mayer Foundation; Edythe L. Broad Women's Heart Research Fellowship; Barbra Streisand Women's Cardiovascular Research and Education Program, Smidt Heart Institute, Cedars-Sinai Medical Center	This work was supported by the National Heart, Lung, and Blood Institute (K23HL127262), the Louis B. Mayer Foundation, Edythe L. Broad Women's Heart Research Fellowship, and the Barbra Streisand Women's Cardiovascular Research and Education Program, Smidt Heart Institute, Cedars-Sinai Medical Center.	[Anonymous], 2019, Obstet Gynecol, V133, pe128, DOI 10.1097/AOG.0000000000003072; ChasanTaber L, 1996, CIRCULATION, V94, P483, DOI 10.1161/01.CIR.94.3.483; Curtis KM, 2016, MMWR RECOMM REP, V65, P3, DOI 10.15585/mmwr.rr6504a1; Curtis KM, 2006, CONTRACEPTION, V73, P179, DOI 10.1016/j.contraception.2005.08.005; Glisic M, 2018, EUR J PREV CARDIOL, V25, P1042, DOI 10.1177/2047487318774847; Muntner P, 2018, CIRCULATION, V137, P109, DOI 10.1161/CIRCULATIONAHA.117.032582; Shufelt CL, 2009, J AM COLL CARDIOL, V53, P221, DOI 10.1016/j.jacc.2008.09.042; Virani SS, 2020, CIRCULATION, V141, pE139, DOI 10.1161/CIR.0000000000000757; Whelton PK, 2018, J AM COLL CARDIOL, V71, P2199, DOI 10.1016/j.jacc.2017.11.005	9	11	11	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 13	2020	324	14					1451	1452		10.1001/jama.2020.11935	http://dx.doi.org/10.1001/jama.2020.11935		SEP 2020	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OS4TT	32955577	Green Accepted			2023-01-03	WOS:000574308600001
J	Lacasse, Y; Series, F; Corbeil, F; Baltzan, M; Paradis, B; Simao, P; Fernandez, AA; Esteban, C; Guimaraes, M; Bourbeau, J; Aaron, SD; Bernard, S; Maltais, F				Lacasse, Yves; Series, Frederic; Corbeil, Francois; Baltzan, Marc; Paradis, Bruno; Simao, Paula; Abad Fernandez, Araceli; Esteban, Cristobal; Guimaraes, Miguel; Bourbeau, Jean; Aaron, Shawn D.; Bernard, Sarah; Maltais, Francois		INOX Trial Grp	Randomized Trial of Nocturnal Oxygen in Chronic Obstructive Pulmonary Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COPD PATIENTS; SLEEP; DESATURATION; THERAPY; HEMODYNAMICS; HYPOXEMIA; MODEL	BackgroundLong-term oxygen therapy improves survival in patients with chronic obstructive pulmonary disease (COPD) and chronic severe daytime hypoxemia. However, the efficacy of oxygen therapy for the management of isolated nocturnal hypoxemia is uncertain. MethodsWe designed this double-blind, placebo-controlled, randomized trial to determine, in patients with COPD who have nocturnal arterial oxygen desaturation without qualifying for long-term oxygen therapy, whether nocturnal oxygen provided for a period of 3 to 4 years would decrease mortality or the worsening of disease such that patients meet current specifications for long-term oxygen therapy. Patients with an oxygen saturation of less than 90% for at least 30% of the recording time on nocturnal oximetry were assigned, in a 1:1 ratio, to receive either nocturnal oxygen or ambient air from a sham concentrator (placebo). The primary outcome was a composite of death from any cause or a requirement for long-term oxygen therapy as defined by the Nocturnal Oxygen Therapy Trial (NOTT) criteria in the intention-to-treat population. ResultsRecruitment was stopped prematurely because of recruitment and retention difficulties after 243 patients, of a projected 600, had undergone randomization at 28 centers. At 3 years of follow-up, 39.0% of the patients assigned to nocturnal oxygen (48 of 123) and 42.0% of those assigned to placebo (50 of 119) met the NOTT-defined criteria for long-term oxygen therapy or had died (difference, -3.0 percentage points; 95% confidence interval, -15.1 to 9.1). ConclusionsOur underpowered trial provides no indication that nocturnal oxygen has a positive or negative effect on survival or progression to long-term oxygen therapy in patients with COPD. (Funded by the Canadian Institutes of Health Research; INOX ClinicalTrials.gov number, NCT01044628.) Patients with COPD and nocturnal oxygen desaturation were assigned to nighttime oxygen supplementation or placebo. When the trial was stopped because it could not meet its enrollment goal, the incidence of death or progression of COPD was similar in the two groups.	[Lacasse, Yves; Series, Frederic; Bernard, Sarah; Maltais, Francois] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Corbeil, Francois] Ctr Hosp Univ Trois Rivieres, Trois Rivieres, PQ, Canada; [Baltzan, Marc] McGill Univ, Mt Sinai Hosp, Montreal, PQ, Canada; [Bourbeau, Jean] McGill Univ, Ctr Hlth, Montreal Chest Inst, Res Inst, Montreal, PQ, Canada; [Bourbeau, Jean] McGill Univ, Montreal, PQ, Canada; [Paradis, Bruno] Ctr Integre Sante & Serv Sociaux Laval, Laval, PQ, Canada; [Aaron, Shawn D.] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada; [Simao, Paula] Hosp Pedro Hispano, Unidade Local Saude Matosinhos, Matosinhos, Portugal; [Guimaraes, Miguel] Ctr Hosp Vila Nova de Gaia Espinho, Vila Nova De Gaia, Portugal; [Abad Fernandez, Araceli] Hosp Univ Getafe, Getafe, Spain; [Esteban, Cristobal] Hosp Galdakao, Serv Vasco Salud Osakidetza, Bizkaia, Spain	Laval University; McGill University; McGill University; McGill University; Centre Integre de Sante et de Services Sociaux de Laval; University of Ottawa; Ottawa Hospital Research Institute; Hospital Universitario de Getafe; Galdakao Hospital	Lacasse, Y (corresponding author), Inst Univ Cardiol & Pneumol Quebec, Ctr Pneumol, 2725 Chemin St Foy, Ste Foy, PQ G1V 4G5, Canada.	yves.lacasse@med.ulaval.ca		chanez, pascal/0000-0003-4059-0917; Cano-Pumarega, Irene/0000-0003-1543-7187; Guimaraes, Miguel/0000-0003-3628-7587; Egea, Carlos/0000-0002-7618-7444; Sayas Catalan, Javier/0000-0003-2399-4370	Canadian Institutes of Health Research [MCT-99512]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	Supported by the Canadian Institutes of Health Research (grant MCT-99512).	Aaron SD, 2008, THORAX, V63, P122, DOI 10.1136/thx.2007.082636; Albert RK, 2016, NEW ENGL J MED, V375, P1617, DOI 10.1056/NEJMoa1604344; [Anonymous], 1980, ANN INTERN MED, V93, P391; Becker HF, 1999, AM J RESP CRIT CARE, V159, P112, DOI 10.1164/ajrccm.159.1.9803037; CATTERALL JR, 1985, J APPL PHYSIOL, V59, P1698, DOI 10.1152/jappl.1985.59.6.1698; Chaouat A, 1997, EUR RESPIR J, V10, P1730, DOI 10.1183/09031936.97.10081730; Chaouat A, 1999, EUR RESPIR J, V14, P1002, DOI 10.1183/09031936.99.14510029; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Cranston JM, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001744.pub2; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; FLENLEY DC, 1981, LANCET, V1, P681; FLETCHER EC, 1992, AM REV RESPIR DIS, V145, P1070, DOI 10.1164/ajrccm/145.5.1070; FLETCHER EC, 1992, CHEST, V101, P649, DOI 10.1378/chest.101.3.649; Grant AM, 2005, LANCET, V365, P711; Hernan MA, 2017, NEW ENGL J MED, V377, P1391, DOI 10.1056/NEJMsm1605385; Hosselet JJ, 2001, AM J RESP CRIT CARE, V163, P398, DOI 10.1164/ajrccm.163.2.9808132; HUDGEL DW, 1983, J APPL PHYSIOL, V55, P669, DOI 10.1152/jappl.1983.55.3.669; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; Joppa P, 2006, CHEST, V130, P326, DOI 10.1378/chest.130.2.326; Lacasse Y, 2007, CAN RESPIR J, V14, P343, DOI 10.1155/2007/487831; Lacasse Y, 2017, BMC PULM MED, V17, DOI 10.1186/s12890-016-0343-9; Lacasse Y, 2011, RESP MED, V105, P1331, DOI 10.1016/j.rmed.2011.04.003; LEVIVALENSI P, 1992, EUR RESPIR J, V5, P301; LIN DY, 1993, BIOMETRIKA, V80, P557, DOI 10.2307/2337177; Macrea MM, 2019, CLIN RESPIR J, V13, P120, DOI 10.1111/crj.12992; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Orth M, 2008, Pneumologie, V62, P11, DOI 10.1055/s-2007-980129; Sergi M, 2002, RESPIRATION, V69, P117, DOI 10.1159/000056313; SK AZ, 2016, DIABETOL STOFFWECHS, V11, pS01	29	28	30	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 17	2020	383	12					1129	1138		10.1056/NEJMoa2013219	http://dx.doi.org/10.1056/NEJMoa2013219			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU8QD	32937046	Bronze			2023-01-03	WOS:000573901600012
J	Benson, L; Axiotis, N; Harvey, A				Benson, Lucy; Axiotis, Natalie; Harvey, Anna			Hannah Grace is an art therapist Hannah Grace is an art therapist at Imara, a charity that works with children and young people after a disclosure of sexual abuse	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Benson, Lucy] Univ Manchester, Manchester, Lancs, England	University of Manchester	Benson, L (corresponding author), Univ Manchester, Manchester, Lancs, England.	lucy.benson@gmail.com							0	0	0	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 7	2020	370								m2318	10.1136/bmj.m2318	http://dx.doi.org/10.1136/bmj.m2318			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NP5WA	32895228				2023-01-03	WOS:000570245300005
J	Rodgers, GP; Collins, FS				Rodgers, Griffin P.; Collins, Francis S.			Precision Nutrition-the Answer to "What to Eat to Stay Healthy"	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Rodgers, Griffin P.; Collins, Francis S.] NIH, One Ctr Dr,Bldg 1,Room 126, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA	Collins, FS (corresponding author), NIH, One Ctr Dr,Bldg 1,Room 126, Bethesda, MD 20892 USA.	collinsf@od.nih.gov						Centers for Disease Control and Prevention, HLTH EC COSTS CHRON; Gillman MW, 2005, NEW ENGL J MED, V353, P1848, DOI 10.1056/NEJMe058187; Shan ZL, 2019, JAMA-J AM MED ASSOC, V322, P1178, DOI 10.1001/jama.2019.13771; US Department of Health & Human Services; National Institutes of Health, 2020, 2020 2030 STRAT PLAN	4	73	78	8	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	2020	324	8					735	736		10.1001/jama.2020.13601	http://dx.doi.org/10.1001/jama.2020.13601			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM6UD	32766768				2023-01-03	WOS:000568230000013
J	Molgora, M; Esaulova, E; Vermi, W; Hou, JC; Chen, Y; Luo, JQ; Brioschi, S; Bugatti, M; Omodei, AS; Ricci, B; Fronick, C; Panda, SK; Takeuchi, Y; Gubin, MM; Faccio, R; Cella, M; Gilfillan, S; Unanue, ER; Artyomov, MN; Schreiber, RD; Colonna, M				Molgora, Martina; Esaulova, Ekaterina; Vermi, William; Hou, Jinchao; Chen, Yun; Luo, Jingqin; Brioschi, Simone; Bugatti, Mattia; Omodei, Andrea Salvatore; Ricci, Biancamaria; Fronick, Catrina; Panda, Santosh K.; Takeuchi, Yoshiko; Gubin, Matthew M.; Faccio, Roberta; Cella, Marina; Gilfillan, Susan; Unanue, Emil R.; Artyomov, Maxim N.; Schreiber, Robert D.; Colonna, Marco			TREM2 Modulation Remodels the Tumor Myeloid Landscape Enhancing Anti-PD-1 Immunotherapy	CELL			English	Article							IMMUNE CHECKPOINT BLOCKADE; MICROGLIAL RESPONSE; NITRIC-OXIDE; MACROPHAGES; CELLS; LYMPHOCYTES; ACTIVATION; EXPRESSION; RECEPTOR; DISEASE	Checkpoint immunotherapy unleashes T cell control of tumors, but is undermined by immunosuppressive myeloid cells. TREM2 is a myeloid receptor that transmits intracellular signals that sustain microglial responses during Alzheimer's disease. TREM2 is also expressed by tumor-infiltrating macrophages. Here, we found that Trem2(-/)(-) mice are more resistant to growth of various cancers than wild-type mice and are more responsive to anti-PD-1 immunotherapy. Furthermore, treatment with anti-TREM2 mAb curbed tumor growth and fostered regression when combined with anti-PD-1 scRNA-seq revealed that both TREM2 deletion and anti-TREM2 are associated with scant MRC1(+) and CX(3)CR1(+) macrophages in the tumor infiltrate, paralleled by expansion of myeloid subsets expressing immunostimulatory molecules that promote improved T cell responses. TREM2 was expressed in tumor macrophages in over 200 human cancer cases and inversely correlated with prolonged survival for two types of cancer. Thus, TREM2 might be targeted to modify tumor myeloid infiltrates and augment checkpoint immunotherapy.	[Molgora, Martina; Esaulova, Ekaterina; Vermi, William; Hou, Jinchao; Chen, Yun; Brioschi, Simone; Panda, Santosh K.; Takeuchi, Yoshiko; Cella, Marina; Gilfillan, Susan; Unanue, Emil R.; Artyomov, Maxim N.; Schreiber, Robert D.; Colonna, Marco] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Vermi, William; Bugatti, Mattia; Omodei, Andrea Salvatore] Univ Brescia, Dept Pathol, I-25123 Brescia, Italy; [Luo, Jingqin] Washington Univ, Siteman Canc Ctr, Sch Med, Div Publ Hlth Sci,Biostat Core, St Louis, MO 63110 USA; [Ricci, Biancamaria; Faccio, Roberta] Washington Univ, Sch Med, Dept Orthoped, St Louis, MO 63110 USA; [Fronick, Catrina] Washington Univ, Sch Med, McDonnell Genome Inst, St Louis, MO 63108 USA; [Gubin, Matthew M.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Faccio, Roberta] Shriners Childrens Hosp St Louis, St Louis, MO 63110 USA; [Schreiber, Robert D.] Washington Univ, Sch Med, Andrew M & Jane M Bursky Ctr Human Immunol & Immu, St Louis, MO 63110 USA	Washington University (WUSTL); University of Brescia; Siteman Cancer Center; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Texas System; UTMD Anderson Cancer Center; Washington University (WUSTL)	Colonna, M (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.	mcolonna@wustl.edu	Ricci, Biancamaria/AAT-9935-2021; Takeuchi, Yoshiko/ABA-5417-2020; Takeuchi, Yoshiko/GQP-2497-2022; Cella, Marina/ABA-8564-2020; Molgora, Martina/G-5591-2018	Takeuchi, Yoshiko/0000-0002-2637-7696; VERMI, WILLIAM/0000-0002-2291-2997; Schreiber, Robert/0000-0003-1590-2341; Molgora, Martina/0000-0001-7328-2844; Brioschi, Simone/0000-0002-3849-3926; Gubin, Matthew/0000-0001-7443-2752; Ricci, Biancamaria/0000-0003-1574-6043; Omodei, Andrea Salvatore/0000-0002-4217-1698; luo, jingqin/0000-0003-2759-3072	National Institutes of Health [R01 AR066551, R01 CA235096, RF1AG05148501, R21AG059176]; Cancer Research Institute-Lloyd J. Old Memorial Fellowship in Tumor Immunology; AIRC [IG23179]; Parker Institute for Cancer Immunotherapy Bridge Scholar Award; CPRIT Scholar in Cancer Research Grant [RR190017]; National Cancer Institute of the National Institutes of Health [RO1CA190700]; Parker Institute for Cancer Immunotherapy; Cancer Research Institute; Janssen Pharmaceutical Company of Johnson and Johnson; Prostate Cancer Foundation; Stand Up to Cancer-Lustgarten Foundation Pancreatic Cancer Foundation Convergence Dream Team translational research grant; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health [AI114551, DK058177]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research Institute-Lloyd J. Old Memorial Fellowship in Tumor Immunology; AIRC(Fondazione AIRC per la ricerca sul cancro); Parker Institute for Cancer Immunotherapy Bridge Scholar Award; CPRIT Scholar in Cancer Research Grant; National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Parker Institute for Cancer Immunotherapy; Cancer Research Institute; Janssen Pharmaceutical Company of Johnson and Johnson; Prostate Cancer Foundation; Stand Up to Cancer-Lustgarten Foundation Pancreatic Cancer Foundation Convergence Dream Team translational research grant; National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank the McDonnell Genome Institute at Washington University for sequencing, Ali Ellebedy, Aaron Schmitz, Daved Fremont, and Chris Nelson for advising in the generation of the recombinant antibody, David Holtzman for supporting antibody purification, and Erica Lantelme and the Flow Cytometry Core at Washington University for sorting. We also thank Wandy Beatty, director of the Molecular Microbiology Imaging Facility at Washington University, for valuable technical support. M. Colonna was supported by the National Institutes of Health (RF1AG05148501 and R21AG059176). M.M. is a recipient of the Cancer Research Institute-Lloyd J. Old Memorial Fellowship in Tumor Immunology. W.V. is supported by AIRC IG23179. R.F. was supported by grants from the National Institutes of Health (R01 AR066551 and R01 CA235096). M.M.G. was supported by a Parker Institute for Cancer Immunotherapy Bridge Scholar Award and a CPRIT Scholar in Cancer Research Grant (RR190017). R.D.S. was supported by grants from the National Cancer Institute of the National Institutes of Health (RO1CA190700), the Parker Institute for Cancer Immunotherapy, the Cancer Research Institute, Janssen Pharmaceutical Company of Johnson and Johnson, the Prostate Cancer Foundation, and a Stand Up to Cancer-Lustgarten Foundation Pancreatic Cancer Foundation Convergence Dream Team translational research grant. Stand Up to Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research. E.R.U. received support from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health (AI114551 and DK058177).	Allavena P, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/547179; Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8; Arlauckas SP, 2018, THERANOSTICS, V8, P5842, DOI 10.7150/thno.26888; Barkal AA, 2019, NATURE, V572, P392, DOI 10.1038/s41586-019-1456-0; Biswas SK, 2012, CELL METAB, V15, P432, DOI 10.1016/j.cmet.2011.11.013; Bouchon A, 2001, J EXP MED, V194, P1111, DOI 10.1084/jem.194.8.1111; Broz ML, 2015, CANCER IMMUNOL RES, V3, P313, DOI 10.1158/2326-6066.CIR-15-0041; Butler A, 2018, NAT BIOTECHNOL, V36, P411, DOI 10.1038/nbt.4096; Cassetta L, 2018, NAT REV DRUG DISCOV, V17, P887, DOI 10.1038/nrd.2018.169; Cella M, 2003, J EXP MED, V198, P645, DOI 10.1084/jem.20022220; Cochain C, 2018, CIRC RES, V122, P1661, DOI 10.1161/CIRCRESAHA.117.312509; Costa ML, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01357; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Gilfillan S, 2008, J EXP MED, V205, P2965, DOI 10.1084/jem.20081752; Gubin MM, 2018, CELL, V175, P1443, DOI 10.1016/j.cell.2018.11.003; Harjunpaa H, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1445949; HIBBS JB, 1987, SCIENCE, V235, P473, DOI 10.1126/science.2432665; Hoves S, 2018, J EXP MED, V215, P859, DOI 10.1084/jem.20171440; Hughes R, 2015, CANCER RES, V75, P3479, DOI 10.1158/0008-5472.CAN-14-3587; Hume DA, 2012, BLOOD, V119, P1810, DOI 10.1182/blood-2011-09-379214; Iribarren C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25128-x; Ito H, 2012, EUR J IMMUNOL, V42, P176, DOI 10.1002/eji.201141679; Jaitin DA, 2019, CELL, V178, P686, DOI 10.1016/j.cell.2019.05.054; Lavin Y, 2017, CELL, V169, P750, DOI 10.1016/j.cell.2017.04.014; Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734; Li XY, 2018, J CLIN INVEST, V128, P2613, DOI 10.1172/JCI98769; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lo M, 2017, J BIOL CHEM, V292, P3900, DOI 10.1074/jbc.M116.767749; Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217; Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008; Ojalvo LS, 2009, AM J PATHOL, V174, P1048, DOI 10.2353/ajpath.2009.080676; Peng QS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000500; Ramachandran P, 2019, NATURE, V575, P512, DOI 10.1038/s41586-019-1631-3; Rashidian M, 2019, P NATL ACAD SCI USA, V116, P16971, DOI 10.1073/pnas.1905005116; Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016; Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Shankaran V, 2001, NATURE, V410, P1107, DOI 10.1038/35074122; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Shi FD, 2001, J IMMUNOL, V167, P3000, DOI 10.4049/jimmunol.167.5.3000; Song QQ, 2019, CANCER MED-US, V8, P3072, DOI 10.1002/cam4.2113; Song W, 2017, ALZHEIMERS DEMENT, V13, P381, DOI 10.1016/j.jalz.2016.07.004; Stadlbauer D, 2019, SCIENCE, V366, P499, DOI 10.1126/science.aay0678; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; Su XM, 2016, CANCER RES, V76, P3484, DOI 10.1158/0008-5472.CAN-15-2663; Topalian SL, 2015, CANCER CELL, V27, P450, DOI 10.1016/j.ccell.2015.03.001; Turnbull IR, 2006, J IMMUNOL, V177, P3520, DOI 10.4049/jimmunol.177.6.3520; Ulland TK, 2018, NAT REV NEUROL, V14, P667, DOI 10.1038/s41582-018-0072-1; Ulland TK, 2017, CELL, V170, P649, DOI 10.1016/j.cell.2017.07.023; Veglia F, 2018, NAT IMMUNOL, V19, P108, DOI 10.1038/s41590-017-0022-x; Veillette A, 2018, TRENDS IMMUNOL, V39, P173, DOI 10.1016/j.it.2017.12.005; Vermi W, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4029; Wang ECE, 2019, CELL STEM CELL, V24, P654, DOI 10.1016/j.stem.2019.01.011; Wang YM, 2016, J EXP MED, V213, P667, DOI 10.1084/jem.20151948; Wang YM, 2015, CELL, V160, P1061, DOI 10.1016/j.cell.2015.01.049; Wickham H., 2016, GGPLOT2 ELEGANT GRAP, DOI [10.1007/978-3-319-24277-4, DOI 10.1007/978-3-319-24277-4]; Wiehagen KR, 2017, CANCER IMMUNOL RES, V5, P1109, DOI 10.1158/2326-6066.CIR-17-0258; Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109; Woo SR, 2012, CANCER RES, V72, P917, DOI 10.1158/0008-5472.CAN-11-1620; Wu K, 2015, J EXP MED, V212, P681, DOI 10.1084/jem.20141732; Zhong L, 2017, J EXP MED, V214, P597, DOI 10.1084/jem.20160844	63	133	136	12	62	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 20	2020	182	4					886	+		10.1016/j.cell.2020.07.013	http://dx.doi.org/10.1016/j.cell.2020.07.013			32	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	NC8UU	32783918	Bronze, Green Accepted			2023-01-03	WOS:000561488500011
J	Schiefer, JL; Schuller, H; Fuchs, PC; Bagheri, M; Grigutsch, D; Klein, M; Schulz, A				Schiefer, Jennifer Lynn; Schuller, Hannelore; Fuchs, Paul Christian; Bagheri, Mahsa; Grigutsch, Daniel; Klein, Matthias; Schulz, Alexandra			Basic life support knowledge in Germany and the influences of demographic factors	PLOS ONE			English	Article							HOSPITAL CARDIAC-ARREST; RESUSCITATION COUNCIL GUIDELINES; REGISTRY; CPR	Background In the developed world, cardiovascular diseases still contribute to mortality and morbidity, leading to significantly increased deaths in recent years. Thus, it is necessary for a layperson to provide the best possible basic life support (BLS) until professional help is available. Since information on current BLS knowledge in Germany is not available, but necessary to be able to make targeted improvements in BLS education, we conducted this study. Methods A cohort survey using convenience sampling (non-probability) method was conducted with questions found in emergency medicine education. People coming to the emergency room of two big university hospitals located in the South (Munich) and western part (Cologne) of Germany were asked to participate in the survey between 2016 and 2017. Primary outcome measures were the proportion of correct answers for each emergency scenario in relationship to age, region, profession and first-aid training. Results Altogether 1003 people (504 from Cologne; 499 from Munich) took part in the questionnaire. 54.7% were female and 45.3% were male aging from 19 to 52 with a mean of 37.2 years. Although over 90% had taken part in first aid training, many people were lacking first aid knowledge, with less than 10% choosing the correct frequency for chest compression. Hereby demographic factors had a significant influence (p<0.05) in the given answers (Friedmann-and-Wilcoxon Test). Conclusion Overall, results of our survey indicate a clear lack of BLS knowledge. With this information, targeted measures for improving BLS knowledge should be conducted. Additionally, further studies on the feasibility and efficiency of teaching methods are needed	[Schiefer, Jennifer Lynn; Schuller, Hannelore; Fuchs, Paul Christian; Bagheri, Mahsa; Schulz, Alexandra] Univ Witten Herdecke, Hosp Cologne Merheim, Clin Plast Reconstruct Hand & Burn Surg, Witten, Germany; [Grigutsch, Daniel] Univ Hosp Bonn, Clin Anesthesiol, Bonn, Germany; [Klein, Matthias] Hosp Ludwig Maximilians Univ LMU Munich, Emergency Dept, Munich, Germany; [Klein, Matthias] Hosp Ludwig Maximilians Univ LMU Munich, Dept Neurol, Munich, Germany	Witten Herdecke University; University of Bonn; University of Munich; University of Munich	Schiefer, JL (corresponding author), Univ Witten Herdecke, Hosp Cologne Merheim, Clin Plast Reconstruct Hand & Burn Surg, Witten, Germany.	schiefer.jennifer@gmail.com		Schiefer, Jennifer Lynn/0000-0002-3959-9394				Ahmad A., 2018, ALEXANDRIA J MED, V54, P555, DOI [DOI 10.1016/J.AJME.2018.04.001, 10.1016/j.ajme.2018.04.001]; An M, 2019, RESUSCITATION, V144, P145, DOI 10.1016/j.resuscitation.2019.07.011; [Anonymous], ERST HILF FRAG; Axelsson AB, 2006, RESUSCITATION, V70, P90, DOI 10.1016/j.resuscitation.2005.11.009; Bakke HK, 2017, BMC EMERG MED, V17, DOI 10.1186/s12873-017-0116-7; Berdowski J, 2010, RESUSCITATION, V81, P1479, DOI 10.1016/j.resuscitation.2010.08.006; Bialka S, 2011, RESUSCITATION, V82, P492, DOI 10.1016/j.resuscitation.2010.11.025; Derkenne C, 2020, ACAD EMERG MED, V27, P951, DOI 10.1111/acem.13987; Elif AA, 2003, RESUSCITATION, V58, P187, DOI 10.1016/S0300-9572(03)00126-6; Lozano IF, 2016, REV ESP CARDIOL, V69, P588, DOI 10.1016/j.rec.2016.03.005; Gonzalez-Salvado V., 2019, REV ESP CARDIOL; Grasner JT, 2011, RESUSCITATION, V82, P989, DOI 10.1016/j.resuscitation.2011.02.047; Grasner JT, 2009, RESUSCITATION, V80, P199, DOI 10.1016/j.resuscitation.2008.10.008; Holmberg MJ, 2017, RESUSCITATION, V120, P77, DOI 10.1016/j.resuscitation.2017.09.003; Kehl F., 2011, NOTFALLMEDIZIN FRAGE; Konstandinos HD, 2008, RES NURS HEALTH, V31, P165, DOI 10.1002/nur.20244; Meier T, 2019, EUR J EPIDEMIOL, V34, P37, DOI 10.1007/s10654-018-0473-x; Monsieurs KG, 2015, RESUSCITATION, V95, P1, DOI 10.1016/j.resuscitation.2015.07.038; Ozbilgin S, 2015, TURK J ANAESTHESIOL, V43, P396, DOI 10.5152/TJAR.2015.61587; Plata C, 2019, RESUSCITATION, V137, P87, DOI 10.1016/j.resuscitation.2019.01.039; Rasmus A, 2000, Eur J Emerg Med, V7, P39; Sarbjit G, 2018, WILEY INTERDISCIPL R, V7, pe286, DOI 10.1002/WENE.286; Schroeder DC, 2017, ANAESTHESIST, V66, P589, DOI 10.1007/s00101-017-0319-z; Sipsma K, 2011, RESUSCITATION, V82, P564, DOI 10.1016/j.resuscitation.2010.12.007; Urban J, 2013, RESUSCITATION, V84, P1574, DOI 10.1016/j.resuscitation.2013.04.014; Wagner P, 2015, EMERG MED J, V32, P547, DOI 10.1136/emermed-2014-203736; Weiner SG, 2010, RESUSCITATION, V81, P1652, DOI 10.1016/j.resuscitation.2010.07.008; Wingen S, 2018, EUR J ANAESTH, V35, P519, DOI 10.1097/EJA.0000000000000766; Wnent J, 2013, ANASTH INTENSIV NOTF, V48, P562, DOI 10.1055/s-0033-1355238	29	2	3	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2020	15	8							e0237751	10.1371/journal.pone.0237751	http://dx.doi.org/10.1371/journal.pone.0237751			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG9QD	32817673	gold, Green Published			2023-01-03	WOS:000564315600080
J	Mafham, MM; Spata, E; Goldacre, R; Gair, D; Curnow, P; Bray, M; Hollings, S; Roebuck, C; Gale, CP; Mamas, MA; Deanfield, JE; de Belder, MA; Luescher, TF; Denwood, T; Landray, MJ; Emberson, JR; Collins, R; Morris, EJA; Casadei, B; Baigent, C				Mafham, Marion M.; Spata, Enti; Goldacre, Raphael; Gair, Dominic; Curnow, Paula; Bray, Mark; Hollings, Sam; Roebuck, Chris; Gale, Chris P.; Mamas, Mamas A.; Deanfield, John E.; de Belder, Mark A.; Luescher, Thomas F.; Denwood, Tom; Landray, Martin J.; Emberson, Jonathan R.; Collins, Rory; Morris, Eva J. A.; Casadei, Barbara; Baigent, Colin			COVID-19 pandemic and admission rates for and management of acute coronary syndromes in England	LANCET			English	Article							INFARCTION	Background Several countries affected by the COVID-19 pandemic have reported a substantial drop in the number of patients attending the emergency department with acute coronary syndromes and a reduced number of cardiac procedures. We aimed to understand the scale, nature, and duration of changes to admissions for different types of acute coronary syndrome in England and to evaluate whether in-hospital management of patients has been affected as a result of the COVID-19 pandemic. Methods We analysed data on hospital admissions in England for types of acute coronary syndrome from Jan 1, 2019, to May 24, 2020, that were recorded in the Secondary Uses Service Admitted Patient Care database. Admissions were classified as ST-elevation myocardial infarction (STEMI), non-STEMI (NSTEMI), myocardial infarction of unknown type, or other acute coronary syndromes (including unstable angina). We identified revascularisation procedures undertaken during these admissions (ie, coronary angiography without percutaneous coronary intervention [PCI], PCI, and coronary artery bypass graft surgery). We calculated the numbers of weekly admissions and procedures undertaken; percentage reductions in weekly admissions and across subgroups were also calculated, with 95% CIs. Findings Hospital admissions for acute coronary syndrome declined from mid-February, 2020, falling from a 2019 baseline rate of 3017 admissions per week to 1813 per week by the end of March, 2020, a reduction of 40% (95% CI 37-43). This decline was partly reversed during April and May, 2020, such that by the last week of May, 2020, there were 2522 admissions, representing a 16% (95% CI 13-20) reduction from baseline. During the period of declining admissions, there were reductions in the numbers of admissions for all types of acute coronary syndrome, including both STEMI and NSTEMI, but relative and absolute reductions were larger for NSTEMI, with 1267 admissions per week in 2019 and 733 per week by the end of March, 2020, a percent reduction of 42% (95% CI 38-46). In parallel, reductions were recorded in the number of PCI procedures for patients with both STEMI (438 PCI procedures per week in 2019 vs 346 by the end of March, 2020; percent reduction 21%, 95% CI 12-29) and NSTEMI (383 PCI procedures per week in 2019 vs 240 by the end of March, 2020; percent reduction 37%, 29-45). The median length of stay among patients with acute coronary syndrome fell from 4 days (IQR 2-9) in 2019 to 3 days (1-5) by the end of March, 2020. Interpretation Compared with the weekly average in 2019, there was a substantial reduction in the weekly numbers of patients with acute coronary syndrome who were admitted to hospital in England by the end of March, 2020, which had been partly reversed by the end of May, 2020. The reduced number of admissions during this period is likely to have resulted in increases in out-of-hospital deaths and long-term complications of myocardial infarction and missed opportunities to offer secondary prevention treatment for patients with coronary heart disease. The full extent of the effect of COVID-19 on the management of patients with acute coronary syndrome will continue to be assessed by updating these analyses. Copyright (c) 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.	[Mafham, Marion M.; Spata, Enti; Landray, Martin J.; Emberson, Jonathan R.; Collins, Rory; Morris, Eva J. A.; Baigent, Colin] Nuffield Dept Populat Hlth, Clin Trial Serv Unit, Oxford, England; [Mafham, Marion M.; Spata, Enti; Landray, Martin J.; Emberson, Jonathan R.; Collins, Rory; Morris, Eva J. A.; Baigent, Colin] Nuffield Dept Populat Hlth, Epidemiol Studies Unit, Oxford OX3 7LF, England; [Spata, Enti; Landray, Martin J.; Emberson, Jonathan R.; Baigent, Colin] Nuffield Dept Populat Hlth, Med Res Council, Populat Hlth Res Unit, Oxford, England; [Goldacre, Raphael; Landray, Martin J.; Morris, Eva J. A.] Nuffield Dept Populat Hlth, Big Data Inst, Oxford, England; [Gair, Dominic; Curnow, Paula; Bray, Mark; Hollings, Sam; Roebuck, Chris; Denwood, Tom] NHS Digital, Leeds, W Yorkshire, England; [Gale, Chris P.] Univ Leeds, Leeds Inst Cardiovasc & Metab Med, Leeds, W Yorkshire, England; [Mamas, Mamas A.] Univ Keele, Keele Cardiovasc Res Grp, Inst Prognosis Res, Keele, Staffs, England; [Deanfield, John E.] UCL, Inst Cardiovasc Sci, London, England; [de Belder, Mark A.] Barts Hlth NHS Trust, Natl Inst Cardiovasc Outcomes Res, London, England; [Luescher, Thomas F.] Imperial Coll, Natl Heart & Lung Inst, London, England; [Luescher, Thomas F.] Royal Brompton Hosp, London, England; [Luescher, Thomas F.] Harefield Hosp, London, England; [Casadei, Barbara] John Radcliffe Hosp, Div Cardiovasc Med, Radcliffe Dept Med, Oxford, England	University of Oxford; University of Oxford; UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leeds; Keele University; University of London; University College London; Barts Health NHS Trust; Imperial College London; Royal Brompton Hospital; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital; University of Oxford	Baigent, C (corresponding author), Nuffield Dept Populat Hlth, Epidemiol Studies Unit, Oxford OX3 7LF, England.; Baigent, C (corresponding author), Nuffield Dept Populat Hlth, Med Res Council, Populat Hlth Res Unit, Clin Trial Serv Unit, Oxford OX3 7LF, England.	colin.baigent@ndph.ox.ac.uk	Mamas, Mamas Andreas/A-2549-2019; Collins, Rory/ABA-8487-2020	Mamas, Mamas Andreas/0000-0001-9241-8890; Gale, Chris/0000-0003-4732-382X; Emberson, Jonathan/0000-0001-7792-9422; Denwood, Tom/0000-0002-7337-2425; Casadei, Barbara/0000-0002-6801-1617; Morris, Eva/0000-0002-1075-6544; Landray, Martin/0000-0001-6646-827X	UK Medical Research Council; British Heart Foundation; Public Health England; Health Data Research UK; National Institute for Health Research Oxford Biomedical Research Centre; MRC [MC_PC_18033, MC_U137686860, MC_UU_00017/3, MC_UU_12026/4] Funding Source: UKRI	UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation); Public Health England; Health Data Research UK; National Institute for Health Research Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	UK Medical Research Council, British Heart Foundation, Public Health England, Health Data Research UK, and the National Institute for Health Research Oxford Biomedical Research Centre.	Bahit MC, 2018, JACC-HEART FAIL, V6, P179, DOI 10.1016/j.jchf.2017.09.015; Banerjee A, 2020, LANCET, V395, P1715, DOI 10.1016/S0140-6736(20)30854-0; British Cardiovascular Intervention Society, 2020, CARD SERV COR PAND; De Filippo O, 2020, NEW ENGL J MED, V383, P88, DOI 10.1056/NEJMc2009166; De Rosa S, 2020, EUR HEART J, V41, P2083, DOI 10.1093/eurheartj/ehaa409; Department of Health and Social Care, 2020, STAT UK CHIEF MED OF; Garcia S, 2020, J AM COLL CARDIOL, V75, P2871, DOI 10.1016/j.jacc.2020.04.011; Gorenek B, 2015, EUROINTERVENTION, V10, P1095, DOI 10.4244/EIJY14M08_19; Herz N., 2020, WHY ARE 1000S FEWER; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Krumholz HM, 2020, NY TIMES; MacIntyre CR, 2020, LANCET, V395, P1950, DOI 10.1016/S0140-6736(20)31183-1; Metzler B, 2020, EUR HEART J, V41, P1852, DOI 10.1093/eurheartj/ehaa314; NHS Digital, 2017, HLTH SURV ENGL 2017; Pessoa-Amorim G, 2020, EUR HEART J-QUAL CAR, V6, P210, DOI 10.1093/ehjqcco/qcaa046; Public Health England, 2020, RES AN COVID 19 REV; Public Health England, 2020, EM DEP SYNDR SURV SY; Roffi M, 2016, EUR HEART J, V37, P267, DOI 10.1093/eurheartj/ehv320; Solomon MD, 2020, NEW ENGL J MED, V383, P691, DOI 10.1056/NEJMc2015630; Spaulding CM, 1997, NEW ENGL J MED, V336, P1629, DOI 10.1056/NEJM199706053362302; Tam CCF, 2020, CIRC-CARDIOVASC QUAL, V13, DOI 10.1161/CIRCOUTCOMES.120.006631; Wahl-Jorgensen K., 2020, CORONAVIRUS MEDIA CO; World Health Organization, 2020, MERS SIT UPD; Wright J., 2020, CORONAVIRUS DOCTORS	24	350	359	5	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 8	2020	396	10248					381	389		10.1016/S0140-6736(20)31356-8	http://dx.doi.org/10.1016/S0140-6736(20)31356-8			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ND0SW	32679111	Green Accepted, hybrid, Green Published			2023-01-03	WOS:000561619100022
J	Williamson, T				Williamson, Theresa			The Goals of Care - Is There a (Black) Doctor in the House?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							AFRICAN-AMERICAN		[Williamson, Theresa] Duke Univ, Sch Med, Durham, NC 27710 USA	Duke University	Williamson, T (corresponding author), Duke Univ, Sch Med, Durham, NC 27710 USA.							Association of American Medical Colleges, 2018, DIV MED FACTS FIG 20; Braun UK, 2008, J GEN INTERN MED, V23, P267, DOI 10.1007/s11606-007-0487-7; Waters C M, 2000, J Community Health Nurs, V17, P25, DOI 10.1207/S15327655JCHN1701_03; Watkins YJ, 2012, J HOSP PALLIAT NURS, V14, P238, DOI 10.1097/NJH.0b013e318243920c; Williamson T, 2020, JAMA SURG, DOI 10.1001/jamasurg.2020.1790	5	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 6	2020	383	6							e43	10.1056/NEJMpv2024338	http://dx.doi.org/10.1056/NEJMpv2024338			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NB3TI	32692508	Bronze			2023-01-03	WOS:000560438400008
J	Tchounga, BK; Charpentier, C; Coffie, PA; Dabis, F; Descamps, D; Eholie, SP; Ekouevi, DK				Tchounga, Boris K.; Charpentier, Charlotte; Coffie, Patrick A.; Dabis, Francois; Descamps, Diane; Eholie, Serge P.; Ekouevi, Didier K.			Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa	PLOS ONE			English	Article							VITRO PHENOTYPIC SUSCEPTIBILITY; VIRAL LOAD ASSAY; HIV-2-INFECTED PATIENTS; REVERSE-TRANSCRIPTASE; INHIBITOR RESISTANCE; INTEGRASE INHIBITORS; SENEGAL IMPLICATIONS; CLINICAL-USE; VIRUS; THERAPY	Introduction The long-term prognosis of HIV-2-infected patients receiving antiretroviral therapy (ART) is still challenging, due to the intrinsic resistance to non-nucleoside reverse transcriptase inhibitors (NNRTI) and the suboptimal response to some protease inhibitors (PI). The objective was to describe the 5-years outcomes among HIV-2 patients harboring drug-resistant viruses. Methods A clinic-based cohort of HIV-2-patients experiencing virologic failure, with at least one drug resistance mutation was followed from January 2012 to August 2017 in Cote d'Ivoire. Follow-up data included death, lost to follow-up (LTFU), immuno-virological responses. The Kaplan-Meier curve was used to estimate survival rates. Results A total of 31 HIV-2 patients with virologic failure and with at least one drug resistance mutation were included. Two-third of them were men, 28(90.3%) were on PI-based ART-regimen at enrolment and the median age was 50 years (IQR = 46-54). The median baseline CD4 count and viral load were 456 cells/mm(3)and 3.7 log(10)c/mL respectively, and the participants have been followed-up in median 57 months (IQR = 24-60). During this period, 21 (67.7%) patients switched at least one antiretroviral drug, including two (6.5%) and three (9.7%) who switched to a PI-based and an integrase inhibitor-based regimen respectively. A total of 10(32.3%) patients died and 4(12.9%) were LTFU. The 36 and 60-months survival rates were 68.5% and 64.9%, respectively. Among the 17 patients remaining in care, six(35.3%) had an undetectable viral load (<50 c/mL) and for the 11 others, the viral load ranged from 2.8 to 5.6 log(10)c/mL. Twelve patients were receiving lopinavir at the time of first genotype, five(42%) had a genotypic susceptibility score (GSS) <= 1 and 4(33%) a GSS >2. Conclusions The 36-months survival rate among ART-experienced HIV-2 patients with drug-resistant viruses is below 70%,lower than in HIV-1. There is urgent need to improve access to second-line ART for patients living with HIV-2 in West Africa	[Tchounga, Boris K.] Programme PACCI, Site Rech ANRS Cote dIvoire, Abidjan, Cote Ivoire; [Charpentier, Charlotte; Descamps, Diane] Univ Paris, INSERM, UMR 1137, IAME, Paris, France; [Coffie, Patrick A.; Eholie, Serge P.] Univ Felix Houphouet Boigny, Dept Dermatol & Malad Infect, UFR Sci Med, Abidjan, Cote Ivoire; [Dabis, Francois; Ekouevi, Didier K.] Univ Bordeaux, Ctr Inserm 1219, Bordeaux, France; [Dabis, Francois; Ekouevi, Didier K.] Univ Bordeaux, Inst Sante Publ Epidemiol & Dev, Bordeaux, France; [Tchounga, Boris K.] Elizabeth Glazer Pediat AIDS Fdn Yaounde Off, Yaounde, Cameroon; [Dabis, Francois] Agence Natl Rech SIDA & Hepatites, Paris, France; [Ekouevi, Didier K.] Univ Lome, Fac Sci Sante, Dept Sante Publ, Lome, Togo	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; UDICE-French Research Universities; Universite de Bordeaux	Tchounga, BK (corresponding author), Programme PACCI, Site Rech ANRS Cote dIvoire, Abidjan, Cote Ivoire.; Tchounga, BK (corresponding author), Elizabeth Glazer Pediat AIDS Fdn Yaounde Off, Yaounde, Cameroon.	boris.tchounga@yahoo.fr		Tchounga, Boris Kevin/0000-0002-8747-9610	National Cancer Institute (NCI); Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID) [5U01AI069919]; EDCTP2 Training and Mobility Action [TMA 2016 CDF 1597 EDIIMark-2]	National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institute of Allergy and Infectious Diseases (NIAID)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); EDCTP2 Training and Mobility Action	The Main study was conducted under the IeDEA West Africa collaboration grants funded by the National Cancer Institute (NCI); Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institute of Allergy and Infectious Diseases (NIAID); Grant number: 5U01AI069919 awarded to Pr Francois Dabis. The specific analyses and results reported in this publication were conducted under the EDCTP2 Training and Mobility Action awarded to Dr Boris Kevin Tchounga as Career Development Fellowship grant. Grant number: TMA 2016 CDF 1597 EDIIMark-2. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2017, PAN ANT GUID AD AD G, P288; Avettand-Fenoel V, 2014, J CLIN MICROBIOL; Ba S, 2018, CLIN INFECT DIS, V67, P1588, DOI 10.1093/cid/ciy324; Balestre E, 2016, J INT AIDS SOC, V19, DOI 10.7448/IAS.19.1.20044; Benard A, 2011, CLIN INFECT DIS, V52, P1257, DOI 10.1093/cid/cir123; Borrego P, 2013, AIDS REV, V15, P49; Caixas U, 2012, J ANTIMICROB CHEMOTH, V67, P2538, DOI 10.1093/jac/dks240; Campbell-Yesufu OT, 2011, CLIN INFECT DIS, V52, P780, DOI 10.1093/cid/ciq248; Chang M, 2012, J CLIN VIROL, V55, P128, DOI 10.1016/j.jcv.2012.06.024; Charpentier C, 2014, AIDS, V28, P1161, DOI 10.1097/QAD.0000000000000244; Charpentier C, 2011, ANTIVIR THER, V16, P937, DOI 10.3851/IMP1826; Charpentier C, 2010, AIDS, V24, P2753, DOI 10.1097/QAD.0b013e32833f9e36; Damond F, 2004, ANTIVIR THER, V9, P635; Descamps D, 2015, CLIN INFECT DIS, V60, P1521, DOI 10.1093/cid/civ124; Ekouevi DK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066135; Faria NR, 2012, J GEN VIROL, V93, P889, DOI 10.1099/vir.0.038638-0; Gilleece Y, 2010, HIV MED, V11, P611, DOI 10.1111/j.1468-1293.2010.00889.x; Gottlieb GS, 2008, AIDS, V22, P2069, DOI 10.1097/QAD.0b013e32830edd44; Gottlieb GS, 2009, CLIN INFECT DIS, V48, P476, DOI 10.1086/596504; International Diabetes Federation, 2013, IDF DIABETES ATLAS, V6th ed.; Jallow S, 2009, J CLIN MICROBIOL, V47, P2200, DOI 10.1128/JCM.01654-08; Kong R, 2012, J VIROL, V86, P947, DOI 10.1128/JVI.06155-11; Matheron S, 2008, AIDS, V22, P2073, DOI 10.1097/QAD.0b013e32830edd59; Matheron S, 2018, CLIN INFECT DIS, V67, P1161, DOI 10.1093/cid/ciy245; Morlat P., 2016, PRISE CHARGE MED PER, P18; Peterson K, 2011, AIDS RES TREAT, V2011, DOI 10.1155/2011/463704; PNLS Cote d'Ivoire, 2015, DIR NAT 2015 PRIS CH; Raugi DN, 2013, ANTIMICROB AGENTS CH, V57, P2751, DOI 10.1128/AAC.00405-13; Ren J, 2002, P NATL ACAD SCI USA, V99, P14410, DOI 10.1073/pnas.222366699; Roquebert B, 2008, J ANTIMICROB CHEMOTH, V62, P914, DOI 10.1093/jac/dkn335; Roquebert B, 2008, AIDS, V22, P2045, DOI 10.1097/QAD.0b013e32830f4c7d; Smith RA, 2015, RETROVIROLOGY, V12, DOI 10.1186/s12977-015-0146-8; Smith RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045372; Styer LM, 2013, J CLIN VIROL, V58, pE127, DOI 10.1016/j.jcv.2013.09.007; Tchounga B, 2016, CURR OPIN HIV AIDS; Visseaux B, 2016, INFECT GENET EVOL J; Visseaux B, 2012, ANTIMICROB AGENTS CH, V56, P137, DOI 10.1128/AAC.05313-11; Waldrop G, 2016, TROP MED INT HEALTH, V21, P1124, DOI 10.1111/tmi.12746; (WHO) WHO, 2019, UPD REC 1 2 LIN ANT, P16; Witvrouw M, 2004, ANTIVIR THER, V9, P57; World Health Organization, 2018, 2016 CONS GUID US S, P82	41	0	0	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 5	2020	15	8							e0236642	10.1371/journal.pone.0236642	http://dx.doi.org/10.1371/journal.pone.0236642			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NB3DK	32756581	Green Published, gold			2023-01-03	WOS:000560393300062
J	Naz, R; Roberts, TH; Bano, A; Nosheen, A; Yasmin, H; Hassan, MN; Keyani, R; Ullah, S; Khan, W; Anwar, Z				Naz, Rabia; Roberts, Thomas H.; Bano, Asghari; Nosheen, Asia; Yasmin, Humaira; Hassan, Muhammad Nadeem; Keyani, Rumana; Ullah, Sami; Khan, Wajiha; Anwar, Zahid			GC-MS analysis, antimicrobial, antioxidant, antilipoxygenase and cytotoxic activities ofJacaranda mimosifoliamethanol leaf extracts and fractions	PLOS ONE			English	Article							TOTAL FLAVONOID CONTENT; ANTIBACTERIAL ACTIVITIES; CARBON-TETRACHLORIDE; PHENOLIC-COMPOUNDS; STEM BARK; L.; INHIBITION; METABOLISM; SEED; PREVENTION	Jacaranda mimosifoliatrees are grown in frost-free regions globally. The aim of this study was to evaluate the methanol crude extract and various fractions of increasing polarity ofJ.mimosifolialeaves for bioactive metabolites, as well as antimicrobial, antioxidant and anticancer activities. The anti-inflammatory potential of the various fractions ofJ.mimosifolialeaf extract was studied via the lipoxygenase (LOX) inhibitory assay. Methanol crude extract (ME), derived fractions extracted with chloroform (CF) and ethyl acetate (EAF), and residual aqueous extract (AE) of driedJ.mimosifolialeaves were assayed for polyphenolic compounds, their antioxidant, antimicrobial and lipoxygenase (LOX) inhibitory activities, and anticancer properties. Polyphenolic compounds were determined via HPLC while phytochemicals (total phenolics, flavonoids, tannins andortho-diphenol contents), antioxidant activities (DPPH, hydrogen peroxideperoxide, hydroxyl and superoxide radical anions) and LOX were measured via spectrophotometry. Methanol extracts and various fractions were evaluated for antibacterial activities againstBacillus subtilis,Klebsiella pneumonia,Pseudomonas aeruginosaandStaphylococcus aureus. Antifungal potential of the fractions was tested against three species:Aspergillus flavus,Aspergillus fumigatusandFusarium oxysporum. The highest values for total phenolic content (TPC), total flavonoid content (TFC), flavonols, tannins andortho-diphenols were in the ME, followed by CF > EAF > AE. ME also had the highest antioxidant activity with EC(50)values 48 +/- 1.3, 45 +/- 2.4, 42 +/- 1.3 and 46 +/- 1.3 mu g/mL based on the DPPH, hydrogen peroxide, hydroxyl radical and superoxide radical assays, respectively. TPC and TFC showed a significant, strong and positive correlation with the values for each of these antioxidant activities. ME exhibited anti-inflammatory potential based on its LOX inhibitory activity (IC50= 1.3 mu g/mL). ME also had the maximum antibacterial and antifungal potential, followed by EAF > CF > AE. Furthermore, ME showed the strongest cytotoxic effect (EC50= 10.7 and 17.3 mu g/mL) against human hormone-dependent prostate carcinoma (LnCaP) and human lung carcinoma (LU-1) cell lines, respectively. Bioactive compounds present in leaf methanol extracts ofJ.mimosifoliawere identified using gas chromatography-mass spectrometry (GC-MS). Fifteen compounds were identified including phenolic and alcoholic compounds, as well as fatty acids. Our results suggest thatJ.mimosifolialeaves are a good source of natural products with antioxidant, anti-inflammatory and anti-cancer properties for potential therapeutic, nutraceutical and functional food applications.	[Naz, Rabia; Nosheen, Asia; Yasmin, Humaira; Hassan, Muhammad Nadeem; Keyani, Rumana] COMSATS Univ, Dept Biosci, Islamabad, Pakistan; [Roberts, Thomas H.] Univ Sydney, Sydney Inst Agr, Plant Breeding Inst, Sydney, NSW, Australia; [Bano, Asghari] Univ Wah, Dept Biosci, Wah Cantt, Pakistan; [Ullah, Sami] Univ Peshawar, Dept Bot, Peshawar, Pakistan; [Khan, Wajiha] COMSATS Univ Islamabad, Dept Biotechnol, Abbotabad Campus, Abbotabad, Pakistan; [Anwar, Zahid] COMSATS Univ Islamabad, Dept Comp Sci, Vehari Campus, Vehari, Pakistan	COMSATS University Islamabad (CUI); University of Sydney; University of Peshawar; COMSATS University Islamabad (CUI); COMSATS University Islamabad (CUI)	Naz, R (corresponding author), COMSATS Univ, Dept Biosci, Islamabad, Pakistan.	rabia.naz@comsats.edu.pk	Yasmin, Humaira/ABB-1384-2021; Ullah, Sami/ABF-6810-2021; Hassan, Mohammad/GZA-7507-2022; Roberts, Thomas H/H-2071-2012; Hassan, Muhammad/GWZ-4054-2022	Yasmin, Humaira/0000-0002-4220-4808; Ullah, Sami/0000-0001-6525-1386; Hassan, Mohammad/0000-0002-1712-0004; Roberts, Thomas H/0000-0003-3831-3240; ullah, sami/0000-0002-3177-7360; Naz, Rabia/0000-0002-2716-2267	Higher Education Commission of Pakistan; HEC [074-0998-Av4-036]	Higher Education Commission of Pakistan(Higher Education Commission of Pakistan); HEC	Higher Education Commission of Pakistan provided the required financial support for the study to Rabia Naz. The personal identification number (PIN) for this financial support/scholarship from HEC was 074-0998-Av4-036.	Alves CQ, 2010, QUIM NOVA, V33, P2202, DOI 10.1590/S0100-40422010001000033; Amessis-Ouchemoukh N, 2017, IND CROP PROD, V95, P6, DOI 10.1016/j.indcrop.2016.10.007; Amin MU, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0580-0; Torres CA, 2018, J INTEGR MED-JIM, V16, P255, DOI 10.1016/j.joim.2018.04.009; [Anonymous], 1980, MANUAL CLIN MICROBIO; Ao CW, 2008, FOOD CONTROL, V19, P940, DOI 10.1016/j.foodcont.2007.09.007; Aparna V, 2012, CHEM BIOL DRUG DES, V80, P434, DOI 10.1111/j.1747-0285.2012.01418.x; Arruda ALA, 2011, J MED FOOD, V14, P1604, DOI 10.1089/jmf.2010.0251; Backlund MG, 2005, ONCOLOGY-BASEL, V69, P28, DOI 10.1159/000086629; Bagheri G, 2016, JUNDISHAPUR J NAT PH, V11, DOI 10.17795/jjnpp-31129; Banu H. R., 2013, Journal of Chemical and Pharmaceutical Research, V5, P279; Baydar NG, 2004, FOOD CONTROL, V15, P335, DOI 10.1016/S0956-7135(03)00083-5; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; Joray MB, 2015, EVID-BASED COMPL ALT, V2015, DOI 10.1155/2015/912484; Cabre M, 2000, CLIN EXP PHARMACOL P, V27, P694, DOI 10.1046/j.1440-1681.2000.03322.x; Casagrande JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112748; Castillo-Espana P, 2009, PHARMACOG REV, V3, P48; Chang CC, 2002, J FOOD DRUG ANAL, V10, P178; CHISHOLM MJ, 1962, J ORG CHEM, V27, P3137, DOI 10.1021/jo01056a037; Chlopicka J, 2012, LWT-FOOD SCI TECHNOL, V46, P548, DOI 10.1016/j.lwt.2011.11.009; Clinical and Laboratory Standards Institute (CLSI), 2008, M7A4 CLSI, pM7; Custodio L, 2013, IND CROP PROD, V45, P114, DOI 10.1016/j.indcrop.2012.12.011; Czapski GA, 2012, PHARMACOL REP, V64, P1179, DOI 10.1016/S1734-1140(12)70914-3; de Moraes J, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002617; de Oliveira CB, 2012, MOLECULES, V17, P1113, DOI 10.3390/molecules17011113; Department of Agriculture Agricultural Research Service, 1992, DR DUKES PHYTOCHEMIC; Djeridane A, 2006, FOOD CHEM, V97, P654, DOI 10.1016/j.foodchem.2005.04.028; Etuk EU, 2009, AFR J PHARM PHARMACO, V3, P151; Fejes S, 2000, J ETHNOPHARMACOL, V69, P259, DOI 10.1016/S0378-8741(99)00171-3; Feng YC, 2015, SEP SCI TECHNOL, V50, P1785, DOI 10.1080/01496395.2015.1014054; Figueiredo-Rinhel ASG, 2013, J ETHNOPHARMACOL, V150, P655, DOI 10.1016/j.jep.2013.09.019; Gachet MS, 2010, J NAT PROD, V73, P553, DOI 10.1021/np900528m; Gambaro V., 1988, REV LATINOAM QUIM, V19, P17; Gomez K.A., 1984, STAT PROCEDURE AGR R, V2nd; Hahn EL, 2000, J TRAUMA, V49, P1147, DOI 10.1097/00005373-200012000-00033; Henneberg Railson, 2013, Rev. Bras. Hematol. Hemoter., V35, P52, DOI 10.5581/1516-8484.20130015; Honda T, 2006, J EXP MED, V203, P325, DOI 10.1084/jem.20051310; Hossain MA, 2015, ARAB J CHEM, V8, P66, DOI 10.1016/j.arabjc.2011.01.007; Jiang H, 2008, NAT PROD RES, V22, P1650, DOI 10.1080/14786410701875686; Joselin J., 2013, Journal of Chemical and Pharmaceutical Research, V5, P106; Kahkonen MP, 1999, J AGR FOOD CHEM, V47, P3954, DOI 10.1021/jf990146l; Kalita Pallab, 2013, Journal of Drug Delivery and Therapeutics, V3, P33; Kesharwani Rajesh Kumar, 2012, Org Med Chem Lett, V2, P12, DOI 10.1186/2191-2858-2-12; Khamsan S, 2012, ACTA PHARMACEUT, V62, P181, DOI 10.2478/v10007-012-0014-1; Kraujalis P, 2013, PLANT FOOD HUM NUTR, V68, P322, DOI 10.1007/s11130-013-0375-8; Kumar P. P., 2010, African Journal of Biochemistry Research, V4, P191; Kumar S., 2015, British Journal of Medicine and Medical Research, V7, P438; Kumar S, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-112; Lavanya Kakarla, 2016, Pharmacognosy Journal, V8, P598; Levick SP, 2007, J IMMUNOL, V178, P641, DOI 10.4049/jimmunol.178.2.641; Li HY, 2015, J FOOD COMPOS ANAL, V37, P75, DOI 10.1016/j.jfca.2014.09.003; Li TY, 2016, FOOD FUNCT, V7, P1147, DOI 10.1039/c5fo01036e; Lim YY, 2007, FOOD CHEM, V103, P734, DOI 10.1016/j.foodchem.2006.09.025; Mabuchi T, 2004, NEUROREPORT, V15, P1395, DOI 10.1097/01.wnr.0000129372.89000.31; MAHRAN G H, 1991, Herba Hungarica, V30, P98; Marrelli M, 2012, FOOD CHEM TOXICOL, V50, P726, DOI 10.1016/j.fct.2011.12.025; Silva FME, 2009, MYCOSES, V52, P511, DOI 10.1111/j.1439-0507.2008.01647.x; MEYER AS, 1995, TRENDS FOOD SCI TECH, V6, P300, DOI 10.1016/S0924-2244(00)89140-2; Moreira L, 2008, FOOD CHEM TOXICOL, V46, P3482, DOI 10.1016/j.fct.2008.08.025; Naz R, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-017-1815-z; Newman DJ, 2016, J NAT PROD, V79, P629, DOI 10.1021/acs.jnatprod.5b01055; Oktay M, 2003, LEBENSM-WISS TECHNOL, V36, P263, DOI 10.1016/S0023-6438(02)00226-8; Oluyemi Kayode A, 2007, Int. J. Morphol., V25, P609, DOI 10.4067/S0717-95022007000300023; Ouattara L., 2011, Journal of Applied Sciences, V11, P157; Parka EJ, 2011, CHEM-BIOL INTERACT, V189, P37, DOI 10.1016/j.cbi.2010.10.013; Pattanayak S. P., 2011, Comparative Clinical Pathology, V20, P381, DOI 10.1007/s00580-010-1008-3; Peteros NP, 2010, J MED PLANTS RES, V4, P407; Plazonic A, 2009, MOLECULES, V14, P2466, DOI 10.3390/molecules14072466; Rabia Naz, 2013, Asian Pacific Journal of Tropical Disease, V3, P480; Rahuman A. Abdul, 2000, Fitoterapia, V71, P553, DOI 10.1016/S0367-326X(00)00164-7; Rainsford K. D., 2007, V42, P3; Raju Ilavarasan, 2005, African Journal of Traditional, Complementary and Alternative Medicines, V2, P70; Rana A, 2013, NAT PROD RES, V27, P1167, DOI 10.1080/14786419.2012.717290; Ribeiro AB, 2015, PHARM BIOL, V53, P1691, DOI 10.3109/13880209.2014.1001407; Roy S, 2014, ENVIRON TOXICOL PHAR, V37, P234, DOI 10.1016/j.etap.2013.11.008; RUCH RJ, 1989, CARCINOGENESIS, V10, P1003, DOI 10.1093/carcin/10.6.1003; Sadik CD, 2003, BIOCHEM PHARMACOL, V65, P773, DOI 10.1016/S0006-2952(02)01621-0; Saeed N, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-221; Santos Camila Carolina de Menezes Patricio, 2013, Neurosci J, V2013, P949452, DOI 10.1155/2013/949452; Seczyk L, 2016, FOOD CHEM, V194, P637, DOI 10.1016/j.foodchem.2015.08.086; Sekerler T, 2018, ANTICANCER ANTIOXIDA, V2, P1542; Sharifi-Rad J, 2017, MOLECULES, V22, DOI 10.3390/molecules22010070; Sharifi-Rad M, 2017, MOLECULES, V22, DOI 10.3390/molecules22122145; Sharma S, 2013, EXPERT OPIN INV DRUG, V22, P1063, DOI 10.1517/13543784.2013.805744; Sharma UK, 2017, CELL MOL BIOL, V63, P73, DOI 10.14715/cmb/2017.63.6.15; Skehan P, 1990, JNCI-J NATL CANCER I, P82, DOI [10.1093/jnci/82.2.82, DOI 10.1093/JNCI/82.2.82]; Sofi FR, 2016, J FOOD SCI TECH MYS, V53, P104, DOI 10.1007/s13197-015-1983-0; Stankovic M., 2011, KRAGUJEVAC J SCI, V33, P63; Subbaramaiah K, 2004, J BIOL CHEM, V279, P12647, DOI 10.1074/jbc.M312972200; Sun BS, 1998, J AGR FOOD CHEM, V46, P4267, DOI 10.1021/jf980366j; Tian B, 2006, DNA SEQUENCE, V17, P143, DOI 10.1080/10425170600699877; Tovar MJ, 2002, J SCI FOOD AGR, V82, P892, DOI 10.1002/jsfa.1122; Trease GE, 1985, PHARMACOGNOSY, P453; Umarani V, 2015, TOXICOL MECH METHOD, V25, P143, DOI 10.3109/15376516.2014.1003359; Valgas C, 2007, BRAZ J MICROBIOL, V38, P369, DOI 10.1590/S1517-83822007000200034; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Wagner H., 1984, PLANT DRUG ANAL; Wannes WA, 2010, FOOD CHEM TOXICOL, V48, P1362, DOI 10.1016/j.fct.2010.03.002; WAWERU WR, 2017, J ENTOMOL ZOOL STU B, V5, P110; Wintola OA, 2015, BMC COMPLEM ALTERN M, V15, DOI 10.1186/s12906-015-0835-9; Wojdylo A, 2007, FOOD CHEM, V105, P940, DOI 10.1016/j.foodchem.2007.04.038; Wu HQ, 1996, J MOL GRAPH MODEL, V14, P331, DOI 10.1016/S0263-7855(97)00006-4; Yedgar S, 2007, TRENDS PHARMACOL SCI, V28, P459, DOI 10.1016/j.tips.2007.07.005; Yu XL, 2015, FOOD FUNCT, V6, P3296, DOI 10.1039/c5fo00500k; Zaghloul AM, 2011, NAT PROD RES, V25, P68, DOI 10.1080/14786419.2010.511217; Zengin G, 2011, REC NAT PROD, V5, P123	106	16	16	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 29	2020	15	7							e0236319	10.1371/journal.pone.0236319	http://dx.doi.org/10.1371/journal.pone.0236319			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW2YL	32726328	gold, Green Published			2023-01-03	WOS:000556908900039
J	Li, JY; Meng, XY; Wang, CZ; Zhang, HJ; Chen, HN; Deng, PY; Liu, J; Huandike, M; Wei, J; Chai, LM				Li, Jinyu; Meng, Xiaoying; Wang, Changzhi; Zhang, Huijie; Chen, Hening; Deng, Peiying; Liu, Juan; Huandike, Meiyier; Wei, Jie; Chai, Limin			Coptidis alkaloids extracted from Coptis chinensis Franch attenuate IFN-gamma-induced destruction of bone marrow cells	PLOS ONE			English	Article							CD4(+) T-CELLS; INTERFERON-GAMMA; IMMUNE-RESPONSES; PATHOPHYSIOLOGY; EXPRESSION; APOPTOSIS; FAS	Coptidis alkaloids are the primary active components of Coptis chinensis Franch. Clinical and pharmacodynamic studies have confirmed that Coptidis alkaloids have multiple therapeutic effects including anti-inflammatory, antioxidant and antitumor effects, and they are usually used to treat various inflammatory disorders and related diseases. Mouse bone marrow cells (BMCs) were isolated from BALB/c mice. Immune-mediated destruction of BMCs was induced by interferon (IFN) -gamma. High-performance liquid chromatography-electrospray ionization/mass spectrometry was used to analyze the ingredients of the aqueous extract from Coptis chinensis Franch. The results confirmed that Coptidis alkaloids were the predominant ingredients in the aqueous extract from Coptis chinensis. The functional mechanism of Coptidis alkaloids in inhibiting immune-mediated destruction of BMCs was studied in vitro. After Coptidis alkaloid treatment, the percentages of apoptotic BMCs and the proliferation and differentiation of helper T (Th) cells and regulatory T (Treg) cells were measured by flow cytometry. The expression and distribution of T-bet in BMCs were observed by immunofluorescence. Western blotting analysis was used to assay the expression of key molecules in the Fas apoptosis and Jak/Stats signaling pathways in BMCs. We identified five alkaloids in the aqueous extract of Coptis chinensis. The apoptotic ratios of BMCs induced by IFN-gamma were decreased significantly after Coptidis alkaloid treatment. The levels of key molecules (Fas, Caspase-3, cleaved Caspase-3, Caspase-8 and Caspase-8) in Fas apoptosis signaling pathways also decreased significantly after treatment with low concentrations of Coptidis alkaloids. Coptidis alkaloids were also found to inhibit the proliferation of Th1 and Th17 cells and induce the differentiation of Th2 and Treg cells; further, the distribution of T-bet in BMCs was decreased significantly. In addition, the levels of Stat-1, phospho-Stat-1 and phospho-Stat-3 were also reduced after Coptidis alkaloid treatment. These results indicate that Coptidis alkaloids extracted by water decoction from Coptis chinensis Franch could inhibit the proliferation and differentiation of T lymphocytes, attenuate the apoptosis of BMCs, and suppress the immune-mediated destruction of the BMCs induced by pro-inflammatory cytokines.	[Li, Jinyu; Meng, Xiaoying; Wang, Changzhi; Zhang, Huijie; Chen, Hening; Deng, Peiying; Liu, Juan; Huandike, Meiyier; Chai, Limin] Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med, Minist Educ & Beijin, Beijing, Peoples R China; [Wei, Jie] Beijing Univ Chinese Med, Dongzhimen Hosp, Pharmaceut Dept, Beijing, Peoples R China	Beijing University of Chinese Medicine; Beijing University of Chinese Medicine	Chai, LM (corresponding author), Beijing Univ Chinese Med, Dongzhimen Hosp, Key Lab Chinese Internal Med, Minist Educ & Beijin, Beijing, Peoples R China.; Wei, J (corresponding author), Beijing Univ Chinese Med, Dongzhimen Hosp, Pharmaceut Dept, Beijing, Peoples R China.	weijie952157@126.com; liminchai@hotmail.com	Zhang, Hui/HHN-8494-2022; zhang, hui/GXH-6098-2022		Research special for National Chinese Medicine Clinical Research Base of State Administration of Traditional Chinese Medicine of the People's Republic of China [JDZX2015191]	Research special for National Chinese Medicine Clinical Research Base of State Administration of Traditional Chinese Medicine of the People's Republic of China	This work was supported by Research special for National Chinese Medicine Clinical Research Base of State Administration of Traditional Chinese Medicine of the People's Republic of China (Grant number: JDZX2015191, http://www.satcm.gov.cn/).The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We have uploaded the information of funding on the revised files.	Ahmad W, 2016, FOOD FUNCT, V7, P1380, DOI [10.1039/c5fo01531f, 10.1039/C5FO01531F]; Blanco JCG, 2000, J EXP MED, V191, P2131, DOI 10.1084/jem.191.12.2131; Caldenhoven E, 1999, J LEUKOCYTE BIOL, V65, P391, DOI 10.1002/jlb.65.3.391; Chen JC, 2015, BLOOD, V126, P2621, DOI 10.1182/blood-2015-06-652453; Chen SS, 2017, J EXP MED, V214, P475, DOI 10.1084/jem.20161312; de Latour RP, 2010, BLOOD, V116, P4175, DOI 10.1182/blood-2010-01-266098; Deng PY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180417; Dicay MS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118713; Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337; Giannakoulas NC, 2004, BRIT J HAEMATOL, V124, P97, DOI 10.1046/j.1365-2141.2003.04729.x; Hombach A, 2006, J IMMUNOL, V177, P5668, DOI 10.4049/jimmunol.177.8.5668; Hsu YY, 2012, EUR J PHARM SCI, V46, P415, DOI 10.1016/j.ejps.2012.03.004; Jin W, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010217; Kordasti SY, 2009, BRIT J HAEMATOL, V145, P64, DOI 10.1111/j.1365-2141.2009.07593.x; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Kurokawa M, 2009, CELL, V138, P838, DOI 10.1016/j.cell.2009.08.021; Li JY, 2017, BMC COMPLEM ALTERN M, V17, DOI 10.1186/s12906-016-1526-x; Lou LX, 2016, EXP THER MED, V11, P2054, DOI 10.3892/etm.2016.3136; Lu Y, 2012, BLOOD, V119, P1075, DOI 10.1182/blood-2010-12-322891; MACIEJEWSKI J, 1995, BLOOD, V85, P3183, DOI 10.1182/blood.V85.11.3183.bloodjournal85113183; Omokaro SO, 2009, J IMMUNOL, V182, P3414, DOI 10.4049/jimmunol.0801430; Quan GH, 2015, INT J MOL SCI, V16, P29496, DOI 10.3390/ijms161226179; Sarcon AK, 2009, EXP HEMATOL, V37, P477, DOI 10.1016/j.exphem.2008.12.001; Shi J, 2012, BLOOD, V120, P1624, DOI 10.1182/blood-2011-11-390708; Tan HL, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00362; WANG H, 2014, BIOMED RES INT, V2014, DOI DOI 10.1155/2014/798093; Wang J, 2018, CHIN MED-UK, V13, DOI 10.1186/s13020-018-0184-y; Yang YF, 2017, J CHROMATOGR SCI, V55, P556, DOI 10.1093/chromsci/bmx009; Young NS, 2006, BLOOD, V108, P2509, DOI 10.1182/blood-2006-03-010777; Zeng WH, 2001, J CLIN INVEST, V108, P765, DOI 10.1172/JCI12687; Zeng Y, 2015, CLIN EXP IMMUNOL, V180, P361, DOI 10.1111/cei.12605; Zhang YL, 2017, CHIN MED-UK, V12, DOI 10.1186/s13020-017-0140-2; Zhou JW, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/9786972	33	3	4	6	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 24	2020	15	7							e0236433	10.1371/journal.pone.0236433	http://dx.doi.org/10.1371/journal.pone.0236433			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	OD5ZL	32706801	gold, Green Published			2023-01-03	WOS:000579931700041
J	Ting, R; Edmonds, P; Higginson, IJ; Sleeman, KE				Ting, Ruth; Edmonds, Polly; Higginson, Irene J.; Sleeman, Katherine E.			Palliative care for patients with severe covid-19	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Ting, Ruth; Edmonds, Polly; Higginson, Irene J.; Sleeman, Katherine E.] Kings Coll Hosp NHS Trust, London SE5 9RS, England; [Higginson, Irene J.; Sleeman, Katherine E.] Kings Coll London, Cicely Saunders Inst, London SE5 9PJ, England	King's College Hospital NHS Foundation Trust; King's College Hospital; University of London; King's College London	Ting, R (corresponding author), Kings Coll Hosp NHS Trust, London SE5 9RS, England.		; Higginson, Irene Julie/C-7309-2012	Sleeman, Katherine/0000-0002-9777-4373; Higginson, Irene Julie/0000-0002-3687-1313	National Institute of Health Research (NIHR) Clinician Scientist Fellowship [CS-2015-15-005]; NIHR Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust	National Institute of Health Research (NIHR) Clinician Scientist Fellowship(National Institute for Health Research (NIHR)); NIHR Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust	KES is funded by a National Institute of Health Research (NIHR) Clinician Scientist Fellowship (CS-2015-15-005), IJH is an NIHR Senior Investigator Emeritus and is supported by the NIHR Applied Research Collaboration South London (NIHR ARC South London) at King's College Hospital NHS Foundation Trust. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care.	Allsop M, 2020, IS OXYGEN EFFECTIVE; Bajwah S, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00815-2020; Bowers B, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1615; COVID-19 Surveillance Group, 2020, CHAR COVID 19 PAT DY; Curtis JR, 2020, JAMA-J AM MED ASSOC, V323, P1771, DOI 10.1001/jama.2020.4894; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Ekstrom M, 2018, THORAX, V73, P88, DOI 10.1136/thoraxjnl-2016-209868; Ekstrom M, 2015, ANN AM THORAC SOC, V12, P1079, DOI 10.1513/AnnalsATS.201501-034OC; Elharrar X, 2020, JAMA-J AM MED ASSOC, V323, P2336, DOI 10.1001/jama.2020.8255; Ghelichkhani P, 2020, ARCH ACAD EMERG MED, V8, DOI 10.22037/aaem.v8i1.674; Greenhalgh T, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m1182; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00547-2020; Hart JL, 2020, J PAIN SYMPTOM MANAG, V60, pE93, DOI 10.1016/j.jpainsymman.2020.04.017; Hospice UK, 2020, CAR YOUR DYING REL H; ihub Healthcare Improvement Scotland, 2020, PEOPL LED CAR PERS C; Keeley P, 2020, BMJ SUPPORT PALLIAT, V10, P381, DOI 10.1136/bmjspcare-2020-002368; Kuntz JG, 2020, J PAIN SYMPTOM MANAG, V60, pE28, DOI 10.1016/j.jpainsymman.2020.06.001; Lovell N, 2020, J PAIN SYMPTOM MANAG, V60, pE77, DOI 10.1016/j.jpainsymman.2020.04.015; Mannix K., 2018, END MIND LIVE WELL; Mayland CR, 2020, J PAIN SYMPTOM MANAG; National Institute for Health and Care Excellence, 2020, COVID 19 RAP GUID MA; Navigante AH, 2006, J PAIN SYMPTOM MANAG, V31, P38, DOI 10.1016/j.jpainsymman.2005.06.009; Selman LE, 2020, J PAIN SYMPTOM MANAG, V60, pE81, DOI 10.1016/j.jpainsymman.2020.04.024; Sutherland AE, 2020, BMJ SUPPORT PALLIAT, V10, P271, DOI 10.1136/bmjspcare-2020-002326; Turner J, 2020, J PAIN SYMPTOM MANAG, V60, pE75, DOI 10.1016/j.jpainsymman.2020.04.031; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Wallace CL, 2020, J PAIN SYMPTOM MANAG, V60, pE70, DOI 10.1016/j.jpainsymman.2020.04.012; Wang DW, 2020, J COASTAL RES, P1, DOI [10.2112/JCR-SI109-001.1, 10.1001/jama.2020.1585]; Williamson EJ, 2020, NATURE, V584, P430, DOI 10.1038/s41586-020-2521-4; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	30	36	36	3	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 14	2020	370								m2710	10.1136/bmj.m2710	http://dx.doi.org/10.1136/bmj.m2710			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM0HD	32665316	Bronze			2023-01-03	WOS:000549840500012
J	Mwatha, AB; Mahande, M; Olomi, R; John, B; Philemon, R				Mwatha, Annette Baine; Mahande, Michael; Olomi, Raimos; John, Beatrice; Philemon, Rune			Treatment outcomes of Pumani bubble-CPAP versus oxygen therapy among preterm babies presenting with respiratory distress at a tertiary hospital in Tanzania-Randomised trial	PLOS ONE			English	Article							INFANTS; CARE	Background Respiratory distress syndrome (RDS) is the most common respiratory disease in premature babies and the major cause of morbidity and mortality among preterm babies. Effective treatment of these babies requires exogenous surfactant and/or mechanical ventilation but these are of limited availability in low and middle income countries. A cheaper, simpler and more accessible treatment for preterms with RDS called bubble-continuous positive airway pressure (bCPAP) has been reported to be effective in treating RDS in preterm babies with varying levels of effectiveness ranging from 42% to 85%. We aimed to implement and determine the efficacy of bCPAP and its immediate outcomes as compared to oxygen therapy in preterm babies presenting with respiratory distress at a tertiary hospital in Tanzania. Method A randomized control trial, conducted from December 2016 to May 2017, included all preterm babies admitted at the neonatal care unit presenting with signs of respiratory distress and meeting the inclusion criteria. The primary outcome was survival while the secondary outcomes were treatment duration, duration of hospital stay and treatment complications. Results A total of 824 babies were admitted in the neonatal care unit during the study period. Of these, 187 babies were preterm and 48 babies were recruited and randomized (25 bCPAP vs 23 oxygen). The overall survival to discharge for all eligible participants (n = 48) was 58.2% compared to those who adhered to treatment protocol (n = 45, 62.2%). Babies in the bCPAP group had higher survival (17/22; 77.3%) as compared to their counterparts in the oxygen therapy group (11/23; 47.8%). Babies treated with bCPAP had 52% lower risk of death (crude HR 0.48, 95% CI = 0.16-1.43) compared to babies receiving oxygen therapy. The median duration of treatment for babies in the oxygen therapy group was 2 (Range 0-16) days compared to 2 (Range 0-5) days in the bCPAP group. The median duration of hospital stay for babies receiving bCPAP was 14 (range 7-43) days. Nasal bleeding was commonly observed among babies in the bCPAP group as compared to those in the oxygen therapy group. Conclusion This study revealed that treatment with bCPAP had a 30% clinical improvement in survival to discharge. Our findings highlight the role of bCPAP in reducing neonatal mortality in resource limited settings but further adequately powered studies in this or similar settings are required.	[Mwatha, Annette Baine; Olomi, Raimos; Philemon, Rune] Kilimanjaro Christian Med Univ Coll, Moshi, Tanzania; [Mwatha, Annette Baine; Olomi, Raimos; Philemon, Rune] Kilimanjaro Christian Med Ctr KCMC, Dept Pediat & Child Hlth, Moshi, Tanzania; [Mwatha, Annette Baine] Gertrudes Childrens Hosp, Nairobi, Kenya; [Mahande, Michael; John, Beatrice] Kilimanjaro Christian Med Univ Coll KCMUCo, Dept Epidemiol & Biostat, Inst Publ Hlth, Moshi, Tanzania	Kilimanjaro Christian Medical Centre	Mwatha, AB (corresponding author), Kilimanjaro Christian Med Univ Coll, Moshi, Tanzania.; Mwatha, AB (corresponding author), Kilimanjaro Christian Med Ctr KCMC, Dept Pediat & Child Hlth, Moshi, Tanzania.; Mwatha, AB (corresponding author), Gertrudes Childrens Hosp, Nairobi, Kenya.	jclabab@gmail.com			Wellcome Trust [DEL-15-011, 107742/Z/15/Z]; UK government	Wellcome Trust(Wellcome TrustEuropean Commission); UK government	This study was part of a resident's research work where the source of funding was partially self-funded by ABM. Additional support was obtained by ABM from the Rice 360 Institute of Global Health project in Blantyre Malawi which contributed 2 Pumani bubble CPAP machines with their accessories. ABM was a beneficiary for the THRiVE-2 support, a DELTAS Africa grant #DEL-15-011 from Wellcome Trust grant #107742/Z/15/Z and the UK government. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.	Brown J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053622; Buckmaster AG, 2007, PEDIATRICS, V120, P509, DOI 10.1542/peds.2007-0775; Calvello EJ, 2015, B WORLD HEALTH ORGAN, V93, P417, DOI 10.2471/BLT.14.146571; Carlo WA, 2014, PEDIATRICS, V133, P171, DOI 10.1542/peds.2013-3442; Clair CS, 2008, AM J PERINAT, V25, P473, DOI 10.1055/s-0028-1085066; Crowley P, 1996, PROPHYLACTIC CORTICO; Duke T, 2014, CPAP GUIDE CLIN DEV; Dunn MS, 2011, PEDIATRICS, V128, pE1069, DOI 10.1542/peds.2010-3848; Kawaza K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086327; Martin S, 2014, ARCH DIS CHILD-FETAL, V99, pF495, DOI 10.1136/archdischild-2013-305519; Mathai S S, 2014, Med J Armed Forces India, V70, P327, DOI 10.1016/j.mjafi.2013.08.003; McAdams RM, 2015, RESP CARE, V60, P437, DOI 10.4187/respcare.03438; Mmbaga BT, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-116; Myhre J, 2016, J TROP PEDIATRICS, V62, P385, DOI 10.1093/tropej/fmw023; Nahimana E, 2015, BMC PEDIATR, V15, DOI 10.1186/s12887-015-0449-x; Narendran Vivek, 2003, J Perinatol, V23, P195, DOI 10.1038/sj.jp.7210904; Pieper CH, 2003, J TROP PEDIATRICS, V49, P148, DOI 10.1093/tropej/49.3.148; Pillow JJ, 2007, AM J RESP CRIT CARE, V176, P63, DOI 10.1164/rccm.200609-1368OC; Reuter S, 2014, PEDIATR REV, V35, P417, DOI 10.1542/pir.35-10-417; Saha LC, 2017, ACAD J PED NEONATOL, V3, P1; Stevens TP, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003063.pub3; Tagare A, 2013, J TROP PEDIATRICS, V59, P113, DOI 10.1093/tropej/fms061; World Health Organization, 2015, DEC TRACK PROGR MAT	23	11	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 30	2020	15	6							e0235031	10.1371/journal.pone.0235031	http://dx.doi.org/10.1371/journal.pone.0235031			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH8EZ	32603380	Green Published, gold			2023-01-03	WOS:000546956600048
J	Jones, A; Bronskill, SE; Seow, H; Junek, M; Feeny, D; Costa, AP				Jones, Aaron; Bronskill, Susan E.; Seow, Hsien; Junek, Mats; Feeny, David; Costa, Andrew P.			Associations between continuity of primary and specialty physician care and use of hospital-based care among community-dwelling older adults with complex care needs	PLOS ONE			English	Article							MINIMUM DATA SET; INTERPERSONAL CONTINUITY; VALIDATION; MULTIMORBIDITY; WORKFORCE; OUTCOMES; DISEASE; BURDEN; SCALE; RISK	Objective While research suggests that higher continuity of primary and specialty physician care can improve patient outcomes, their effects have rarely been examined and compared concurrently. We investigated associations between continuity of primary and specialty physician care and emergency department visits and hospital admissions among community-dwelling older adults with complex care needs. Methods We conducted a retrospective cohort study of home care patients in Ontario, Canada, from October 2014 to September 2016. We measured continuity of primary and specialty physician care over the two years prior to a home care assessment and categorized them into low, medium, and high groups using terciles of the distribution. We used Cox regression models to concurrently test the associations between continuity of primary and specialty care and risk of an emergency department visit and hospital admission within six months of assessment, controlling for potential confounders. We examined interactions between continuity of care and count of chronic conditions, count of physician specialties seen, functional impairment, and cognitive impairment. Results Of 178,686 participants, 49% had an emergency department visit during follow-up and 27% had a hospital admission. High vs. low continuity of primary care was associated with a reduced risk of an emergency department visit (HR = 0.90 (0.89-0.92)) as was continuity of specialty care (HR = 0.93 (0.91-0.95)). High vs. low continuity of primary care was associated also with a reduced risk of a hospital admission (HR = 0.94 (0.92-0.96)) as was continuity of specialty care (HR = 0.92 (0.90-0.94)). The effect of continuity of specialty care was moderately stronger among patients who saw four or more physician specialties. Conclusion Higher continuity of primary physician and specialty physician care had independent, protective effects of similar magnitude against emergency department use and hospital admissions. Improving continuity of specialty care should be a priority alongside improving continuity of primary care in complex, older adult populations with significant specialist use.	[Jones, Aaron; Seow, Hsien; Junek, Mats; Costa, Andrew P.] McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada; [Bronskill, Susan E.] ICES, Toronto, ON, Canada; [Bronskill, Susan E.] Univ Toronto, Dalla Lana Sch Publ Hlth, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Seow, Hsien] McMaster Univ, Dept Oncol, Hamilton, ON, Canada; [Feeny, David] McMaster Univ, Dept Econ, Hamilton, ON, Canada; [Costa, Andrew P.] McMaster Univ, Dept Med, Hamilton, ON, Canada	McMaster University; University of Toronto; University of Toronto; McMaster University; McMaster University; McMaster University	Jones, A (corresponding author), McMaster Univ, Dept Hlth Res Methods Evidence & Impact, Hamilton, ON, Canada.	jonesa13@mcmaster.ca	Seow, Hsien/AAQ-1438-2021; Jones, Aaron/AAG-1427-2020	Seow, Hsien/0000-0001-6701-1714; Jones, Aaron/0000-0002-6282-3614; Junek, Mats/0000-0001-8416-3955	Canadian Institutes of Health Research [148933]; ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC)	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); ICES - Ontario Ministry of Health and Long-Term Care (MOHLTC)(Ministry of Health and Long-Term Care, Ontario)	AC received a grant for this research from the Canadian Institutes of Health Research (148933) (https://cihr-irsc.gc.ca/e/193.html).This study was supported by ICES (www.ices.on.ca), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). The analyses, conclusions, opinions and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred. Parts of this material are based on data and/or information compiled and provided by the Canadian Institute for Health Information (CIHI)(www.cihi.ca).However, the analyses, conclusions, opinions and statements expressed in the material are those of the authors, and not necessarily those of CIHI. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andres C, 2016, CAN FAM PHYSICIAN, V62, P116; [Anonymous], ADV PROF CONT CAR; [Anonymous], 2014, DIABETES CARE, V1, pS14; Bauman M., 2017, MULTIPLE CHRONIC CON; Bayliss EA, 2015, ANN FAM MED, V13, P123, DOI 10.1370/afm.1739; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; Blecker S, 2014, INT J QUAL HEALTH C, V26, P530, DOI 10.1093/intqhc/mzu065; Bodenheimer T, 2009, HEALTH AFFAIR, V28, P64, DOI 10.1377/hlthaff.28.1.64; Chen LM, 2014, JAMA INTERN MED, V174, P749, DOI 10.1001/jamainternmed.2013.14331; Costa AP, 2015, J AM GERIATR SOC, V63, P763, DOI 10.1111/jgs.13336; Dall TM, 2013, HEALTH AFFAIR, V32, P2013, DOI 10.1377/hlthaff.2013.0714; Dufour I, 2019, BMC GERIATR, V19, DOI 10.1186/s12877-019-1197-9; Emond M, 2017, CAN GERIATR J, V20, P10, DOI 10.5770/cgj.20.246; Engamba SA, 2019, BRIT J GEN PRACT, V69, P92, DOI 10.3399/bjgp19X701201; Foebel AD, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-457; Gray DP, 2003, J ROY SOC MED, V96, P160, DOI 10.1258/jrsm.96.4.160; Gray E, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017593; Haggerty JL, 2012, ANN FAM MED, V10, P443, DOI 10.1370/afm.1378; Haggerty JL, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e5915; Haggerty JL, 2003, BRIT MED J, V327, P1219, DOI 10.1136/bmj.327.7425.1219; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; Hirdes JP, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-277; HOENIG HM, 1991, J AM GERIATR SOC, V39, P220, DOI 10.1111/j.1532-5415.1991.tb01632.x; Hoertel N, 2014, EUR PSYCHIAT, V29, P358, DOI 10.1016/j.eurpsy.2013.12.001; Hwang U, 2013, HEALTH AFFAIR, V32, P2116, DOI 10.1377/hlthaff.2013.0670; Justiniano CF, 2017, DIS COLON RECTUM, V60, P1147, DOI 10.1097/DCR.0000000000000919; Kuluski K, 2017, INT J INTEGR CARE, V17, DOI 10.5334/ijic.2944; Lancet Global Health, 2019, LANCET GLOB HEALTH, V7, pe1; Landi F, 2000, MED CARE, V38, P1184, DOI 10.1097/00005650-200012000-00005; McWhinney I R, 1975, J Fam Pract, V2, P373; Milenkovic M, 2006, HEALTHCARE COST UTIL; Mondor L, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002249; Morris JN, 1999, J GERONTOL A-BIOL, V54, pM546, DOI 10.1093/gerona/54.11.M546; Naert J., 2018, LIFE WORLD PERSPECTI; National Prevention Council, 2016, HLTH AG ACT ADV NAT; Nguyen Hai, 2019, J Comorb, V9, p2235042X19870934, DOI 10.1177/2235042X19870934; Nutting Paul A, 2003, Ann Fam Med, V1, P149, DOI 10.1370/afm.63; Nyweide DJ, 2013, JAMA INTERN MED, V173, P1879, DOI 10.1001/jamainternmed.2013.10059; Palmer W, 2018, IMPROVING ACCESS CON; Pefoyo AJK, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1733-2; Pollack CE, 2016, MED CARE, V54, pE30, DOI 10.1097/MLR.0000000000000018; Poss J W, 2008, Healthc Manage Forum, V21, P33; Price M, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-309; Saultz John W, 2003, Ann Fam Med, V1, P134, DOI 10.1370/afm.23; Saultz JW, 2005, ANN FAM MED, V3, P159, DOI 10.1370/afm.285; Saultz JW, 2004, ANN FAM MED, V2, P445, DOI 10.1370/afm.91; Schiotz Michaela L, 2016, J Comorb, V6, P95, DOI 10.15256/joc.2016.6.81; Starfleld B, 2005, ANN FAM MED, V3, P215, DOI 10.1370/afm.307; van Walraven C, 2010, J EVAL CLIN PRACT, V16, P947, DOI 10.1111/j.1365-2753.2009.01235.x; Vetrano DL, 2019, J GERONTOL A-BIOL, V74, P659, DOI 10.1093/gerona/gly110; Wallace E, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h176; Weir DL, 2016, MED CARE, V54, P386, DOI 10.1097/MLR.0000000000000493; Wu S-Y, 2000, PROJECTION CHRONIC I, P18	53	7	7	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 19	2020	15	6							e0234205	10.1371/journal.pone.0234205	http://dx.doi.org/10.1371/journal.pone.0234205			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MC4LX	32559214	gold, Green Published			2023-01-03	WOS:000543261600020
J	Fukunaga, M; Kadowaki, D; Mori, M; Hagiwara, S; Narita, Y; Saruwatari, J; Tanaka, R; Watanabe, H; Yamasaki, K; Taguchi, K; Ito, H; Maruyama, T; Otagiri, M; Hirata, S				Fukunaga, Masaki; Kadowaki, Daisuke; Mori, Mika; Hagiwara, Satomi; Narita, Yuki; Saruwatari, Junji; Tanaka, Ryota; Watanabe, Hiroshi; Yamasaki, Keishi; Taguchi, Kazuaki; Ito, Hiroki; Maruyama, Toru; Otagiri, Masaki; Hirata, Sumio			In vivoevaluation of drug dialyzability in a rat model of hemodialysis	PLOS ONE			English	Article							RENAL-FAILURE; DIALYSIS; VANCOMYCIN; PHARMACOKINETICS; VOLUME; ACETAMINOPHEN; DISPOSITION; PREDICTION; APRINDINE; DORIPENEM	It is important to calculate the drug removal by hemodialysis (HD) for drug dosing regimens in HD patients. However, there are limited and inconsistent information about the dialyzability of drugs by HD. Therefore, the aim of our study is to evaluate drug removal by utilizing a rat model of HD (HD rat) and to extrapolate this result to the drug removal rate in HD patients. HD rats received bilateral nephrectomy and HD for 2 h. The dialysis removal of 6 drugs was evaluated in HD rats. Dialysis efficiency, plasma protein binding rate (PBR) and distribution volume (Vd) of drugs were also measured. Furthermore, we examined the correlation between the dialyzability of drug in HD rats and humans and constructed the prediction formula of the drug dialyzability in HD patients. The clearance of urea and creatinine and normalized dialysis dose in HD rats were 0.83 +/- 0.07 mL/min, 0.70 +/- 0.08 mL/min, and 0.13 +/- 0.06, respectively. The drug dialyzability in HD rats was similar to reported clinical data except for doripenem. A higher correlation was observed between drug dialyzability in reported clinical data and HD rats which were adjusted for PBR (r(2)= 0.936;p< 0.001) compared to unadjusted (r(2)= 0.812;p= 0.009). Therefore, we constructed the prediction formula of the drug dialyzability in HD patients by utilizing the HD rat model and PBR. This study is useful for evaluating the dialyzability of high-risk drugs in a clinical setting and might provide appropriate preclinical dialyzability data for new drug.	[Fukunaga, Masaki; Mori, Mika; Hagiwara, Satomi; Narita, Yuki; Saruwatari, Junji; Watanabe, Hiroshi; Maruyama, Toru; Hirata, Sumio] Kumamoto Univ, Grad Sch Pharmaceut Sci, Kumamoto, Japan; [Fukunaga, Masaki; Kadowaki, Daisuke; Yamasaki, Keishi; Otagiri, Masaki] Sojo Univ, Fac Pharmaceut Sci, Kumamoto, Japan; [Kadowaki, Daisuke; Yamasaki, Keishi; Otagiri, Masaki] Sojo Univ, DDS Res Inst, Kumamoto, Japan; [Tanaka, Ryota; Ito, Hiroki] Oita Univ Hosp, Dept Clin Pharm, Yufu, Japan; [Taguchi, Kazuaki] Keio Univ, Fac Pharm, Minato Ku, Tokyo, Japan	Kumamoto University; Sojo University; Sojo University; Oita University; Keio University	Kadowaki, D (corresponding author), Sojo Univ, Fac Pharmaceut Sci, Kumamoto, Japan.; Kadowaki, D (corresponding author), Sojo Univ, DDS Res Inst, Kumamoto, Japan.	d-kado@ph.sojo-u.ac.jp		Yamasaki, Keishi/0000-0003-0537-2367; Narita, Yuki/0000-0003-1584-249X				Ariano RE, 2005, AM J KIDNEY DIS, V46, P681, DOI 10.1053/j.ajkd.2005.07.018; Berry LM, 2011, DRUG METAB DISPOS, V39, P2103, DOI 10.1124/dmd.111.040766; BOHLER J, 1992, EUR J CLIN PHARMACOL, V42, P635; Borzou SR, 2009, SAUDI J KIDNEY DIS T, V20, P639; Brunner LJ, 1999, J CHROMATOGR B, V732, P323, DOI 10.1016/S0378-4347(99)00290-X; Cirillo I, 2011, ANTIMICROB AGENTS CH, V55, P1187, DOI 10.1128/AAC.01063-10; COATS DA, 1952, AUST J EXP BIOL MED, V30, P21, DOI 10.1038/icb.1952.3; Dager WE, 2010, SEMIN DIALYSIS, V23, P466, DOI 10.1111/j.1525-139X.2010.00773.x; Daugirdas JT, 2017, SEMIN DIALYSIS, V30, P93, DOI 10.1111/sdi.12575; DAUGIRDAS JT, 1993, J AM SOC NEPHROL, V4, P1205; DESOI CA, 1992, AM J KIDNEY DIS, V20, P354; Furukubo T, 2004, J JPN SOC DIAL THER, V37, P1893, DOI [10.4009/jsdt.37.1893, DOI 10.4009/jsdt.37.1893]; Hori T, 2006, IN VIVO, V20, P91; Hudson JQ, 2004, NEPHROL DIAL TRANSPL, V19, P400, DOI 10.1093/ndt/gfg550; Jang SM, 2014, BMC NEPHROL, V15, DOI 10.1186/1471-2369-15-204; Kang JH, 2014, NAT MED, V20, P1211, DOI 10.1038/nm.3640; KELLER F, 1983, CLIN NEPHROL, V19, P201; KIHARA M, 1995, INTENS CARE MED, V21, P348, DOI 10.1007/BF01705414; KOBARI T, 1984, EUR J CLIN PHARMACOL, V26, P129, DOI 10.1007/BF00546721; Kranzlin B, 1996, ARTIF ORGANS, V20, P1162; Lam SW, 2013, INFECT DIS THER, V2, P217, DOI 10.1007/s40121-013-0012-8; Lam YWF, 1997, CLIN PHARMACOKINET, V32, P30, DOI 10.2165/00003088-199732010-00002; MADHAVAN T, 1976, ANTIMICROB AGENTS CH, V10, P464, DOI 10.1128/AAC.10.3.464; MARBURY TC, 1980, DIALYSIS TRANSPLANT, V9, P961; MARBURY TC, 1980, INT J ARTIF ORGANS, V3, P263, DOI 10.1177/039139888000300506; Mason NA, 2003, CLIN NEPHROL, V60, P96; Nakai S, 2010, THER APHER DIAL, V14, P505, DOI 10.1111/j.1744-9987.2010.00893.x; NAYMAN J, 1966, ANN SURG, V164, P227, DOI 10.1097/00000658-196608000-00007; Olyaei AJ, 2011, BLOOD PURIFICAT, V31, P138, DOI 10.1159/000321857; POLLARD TA, 1994, KIDNEY INT, V45, P232, DOI 10.1038/ki.1994.28; PRESCOTT LF, 1989, EUR J CLIN PHARMACOL, V36, P291, DOI 10.1007/BF00558162; QUARLES JM, 1974, INFECT IMMUN, V9, P550, DOI 10.1128/IAI.9.3.550-558.1974; ROCKEL A, 1978, RES EXP MED, V172, P187, DOI 10.1007/BF01851410; Sato T, 1996, J JPN SOC DIAL THER, V29, P1231; SAWADA Y, 1984, J PHARMACOKINET BIOP, V12, P241, DOI 10.1007/BF01061720; SILVER SM, 1992, KIDNEY INT, V42, P161, DOI 10.1038/ki.1992.273; Sombolos K, 1996, AM J KIDNEY DIS, V27, P673, DOI 10.1016/S0272-6386(96)90102-X; Tanaka R, 2017, BIOL PHARM BULL, V40, P1226, DOI 10.1248/bpb.b17-00008; Tanoue K, 2011, THER APHER DIAL, V15, P327, DOI 10.1111/j.1744-9987.2011.00914.x; The Ministry of Health LaW, 2016, JAP PHARM 17 ED ENGL, P1594; Tsuchishita Y, 2009, BIOL PHARM BULL, V32, P637, DOI 10.1248/bpb.32.637; ZACCARA G, 1988, CLIN PHARMACOKINET, V15, P367, DOI 10.2165/00003088-198815060-00002	42	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2020	15	6							e0233925	10.1371/journal.pone.0233925	http://dx.doi.org/10.1371/journal.pone.0233925			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6QP	32530952	gold, Green Published			2023-01-03	WOS:000542037200042
J	Morgan, T; Bharmal, A; Duschinsky, R; Barclay, S				Morgan, Tessa; Bharmal, Aamena; Duschinsky, Robbie; Barclay, Stephen			Experiences of oldest-old caregivers whose partner is approaching end-of-life: A mixed-method systematic review and narrative synthesis	PLOS ONE			English	Review							NURSING-HOME PLACEMENT; FAMILY CAREGIVERS; PALLIATIVE CARE; ALZHEIMERS-DISEASE; GENDER-DIFFERENCES; FRAIL ELDERS; HEALTH; IMPACT; AGE; DEMENTIA	Background and objectives Population ageing has rapidly increased the number of people requiring end-of-life care across the globe. Governments have responded by promoting end-of-life in the community. Partly as a consequence, older spouses are frequently providing for their partner's end-of-life care at home, despite potentially facing their own health issues. While there is an emerging literature on young-old caregivers, less is known about spouse carers over 75 who are likely to face specific challenges associated with their advanced age and relationship status. The aim of this review, therefore, is to identify and synthesise the literature concerning the experiences of caregiver's aged 75 and over whose partner is approaching end-of-life. We conducted a mixed-method systematic review and narrative synthesis of the empirical literature published between 1985 and May 2019, identified from six databases: Medline, PsychINFO, Cumulative Index to Nursing and Allied Health Literature, Embase, Sociological Abstracts and Social Service Abstracts. Hand searching and reference checking were also conducted. Gough's Weight of Evidence and Morgan's Feminist Quality Appraisal tool used to determine the quality of papers. From the initial 7819 titles, 10 qualitative studies and 9 quantitative studies were included. We identified three themes: 1) "Embodied impact of care" whereby caring was found to negatively impact carers physical and psychological health, with adverse effects continuing into bereavement; 2) "Caregiving spouse's conceptualisation of their role" in which caregiver's navigated their self and marriage identities in relation to their partner's condition and expectations about gender and place; 3) "Learning to care" which involved learning new skills and ways of coping to remain able to provide care. We identified a recent up-surge in published papers about very old spousal caregivers, which now comprise a small, medium-quality evidence base. This review outlines a range of potential lines of inquiry for future research including further clarification of the impact of caregiving on the likelihood of mortality, the incidence of men and women providing end-of-life care amongst this age group, and the role of anticipatory grief in shaping their perceptions of their relationship and their own longevity.	[Morgan, Tessa; Duschinsky, Robbie; Barclay, Stephen] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England; [Bharmal, Aamena] Cambridge Univ Hosp NHS Fdn Trust, Cambridge, England	University of Cambridge; University of Cambridge	Morgan, T (corresponding author), Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.	tlm32@medschl.cam.ac.uk		Duschinsky, Robbie/0000-0003-2023-5328	Wellcome Trust [WT103343MA]; Woolf Fisher Scholarship; Woolf Fisher trust	Wellcome Trust(Wellcome Trust); Woolf Fisher Scholarship; Woolf Fisher trust	The authors wish to thank the Wellcome Trust (Grant WT103343MA) for their support for work on this paper. Tessa Morgan (TM) received the Woolf Fisher Scholarship which is a New Zealand scholarship awarded annually for students in the of science or education to study for a PhD at the University of Cambridge, United Kingdom. This funding is provided to Tessa to enable her to pursue her research interests. The trustees have no control over the research produced here. The Woolf Fisher trust is recognised in the funding section and is thanked in the acknowledgements to recognise their financial and emotional support. This is the link to the website: https://www.woolffishertrust.co.nz/.	Alzheimer's Society, 2019, DEM LIF LIM ILLN; [Anonymous], 2018, LANCET, V391, P2390, DOI 10.1016/S0140-6736(18)31318-7; Baltes PB, 2006, DAEDALUS-US, V135, P32, DOI 10.1162/001152606775321086; Bangerter LR, 2019, GERONTOLOGIST, V59, pE433, DOI 10.1093/geront/gny162; Bertogg A, 2020, AGEING SOC, V40, P735, DOI 10.1017/S0144686X18001320; Black H. K., 2008, J MENS STUDIES, V16, P177, DOI DOI 10.3149/JMS.1602.177; Braun M, 2007, J CLIN ONCOL, V25, P4829, DOI 10.1200/JCO.2006.10.0909; Bravell ME, 2010, PALLIAT SUPPORT CARE, V8, P335, DOI 10.1017/S1478951510000131; Bury M, 1982, Sociol Health Illn, V4, P167, DOI 10.1111/1467-9566.ep11339939; Calasanti T, 2004, J GERONTOL B-PSYCHOL, V59, pS305, DOI 10.1093/geronb/59.6.S305; Cardona-Morrell M, 2017, EUR J INTERN MED, V45, P84, DOI 10.1016/j.ejim.2017.09.026; Chappell NL, 2015, RES AGING, V37, P623, DOI 10.1177/0164027514549258; Christensen K, 2009, LANCET, V374, P1196, DOI 10.1016/S0140-6736(09)61460-4; Cohen-Mansfield J, 2013, INT J AGING HUM DEV, V77, P37, DOI 10.2190/AG.77.1.c; Costello J, 1999, INT J PALLIAT NURS, V5, P223; Dahlberg L, 2007, HEALTH SOC CARE COMM, V15, P439, DOI 10.1111/j.1365-2524.2007.00702.x; Daly M, 2000, BRIT J SOCIOL, V51, P281, DOI 10.1111/j.1468-4446.2000.00281.x; Dassel KB, 2016, GERONTOLOGIST, V56, P444, DOI 10.1093/geront/gnu078; Dassel KB, 2017, GERONTOLOGIST, V57, P319, DOI 10.1093/geront/gnv148; Del Bono E, 2009, HEALTH SOC CARE COMM, V17, P267, DOI 10.1111/j.1365-2524.2008.00826.x; Dewing J., 2007, DEMENTIA-LONDON, V6, P11, DOI [10.1177/1471301207075625, DOI 10.1177/1471301207075625]; Dixon J., 2015, EQUITY PROVISION PAL; Dixon-Woods Mary, 2006, BMC Med Res Methodol, V6, P35, DOI 10.1186/1471-2288-6-35; Edwards H, 1998, HEALTH COMMUN, V10, P317, DOI 10.1207/s15327027hc1004_2; Epiphaniou E, 2012, INT J PALLIAT NURS, V18, P541, DOI 10.12968/ijpn.2012.18.11.541; Ewing GA L., 2018, PALLIATIVE MED, V32, P1; Exley C, 2007, SOC SCI MED, V65, P2317, DOI 10.1016/j.socscimed.2007.07.006; Faircloth CA, 2004, SOCIOL HEALTH ILL, V26, P242, DOI 10.1111/j.1467-9566.2004.00388.x; Feld S, 2010, RES AGING, V32, P499, DOI 10.1177/0164027510361461; Fleming J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150686; Forbat L, 2009, BETTER CANC CARE SYS; Gaertner J, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j2925; Gardiner C, 2014, PALLIATIVE MED, V28, P375, DOI 10.1177/0269216313510588; Giddens A., 1990, CONSEQUENCES MODERNI; Gott M, 2018, PALLIATIVE MED, V32, P268, DOI 10.1177/0269216317735248; Gough D, 2007, RES PAP EDUC, V22, P213, DOI [10.1080/02671520701296189, DOI 10.1080/02671520701296189]; Grande G, 2009, PALLIATIVE MED, V23, P339, DOI 10.1177/0269216309104875; Greenwood N, 2016, MATURITAS, V94, P161, DOI 10.1016/j.maturitas.2016.10.001; Hallberg IR, 2004, AGING CLIN EXP RES, V16, P87; Hellstrom Y, 2004, SCAND J CARING SCI, V18, P387, DOI 10.1111/j.1471-6712.2004.00291.x; Henwood M., 2017, SEEING WOOD TREES CA; Hoerger M, 2017, ONCOLOGIST, V22, P1419, DOI 10.1634/theoncologist.2017-0432; Horsfall D, 2016, HEALTH SOC CARE COMM, V24, P194, DOI 10.1111/hsc.12206; Jack BA, 2015, J CLIN NURS, V24, P131, DOI 10.1111/jocn.12695; Joyce BT, 2014, PALLIATIVE MED, V28, P1146, DOI 10.1177/0269216314535963; Julian Higgins JT, 2022, COCHRANE HDB SYSTEMA; Kafetz K, 2002, J ROY SOC MED, V95, P536, DOI 10.1258/jrsm.95.11.536; Kanacki LS, 2012, J HOSP PALLIAT NURS, V14, P414, DOI 10.1097/NJH.0b013e3182554a2c; Kang SY, 2016, J HUM BEHAV SOC ENVI, V26, P636, DOI 10.1080/10911359.2016.1241201; Kraijo H, 2015, SCAND J CARING SCI, V29, P101, DOI 10.1111/scs.12137; Larkin P., 2011, LIVING AGEING DYING, P191; Lorenz KA, 2005, J PALLIAT MED, V8, P4; MacAuley D, 2007, BMJ-BRIT MED J, V334, P546, DOI 10.1136/bmj.39141.534190.80; McGhan G, 2013, J GERONTOL NURS, V39, P45, DOI 10.3928/00989134-20130402-01; Milberg A, 2004, SUPPORT CARE CANCER, V12, P120, DOI 10.1007/s00520-003-0569-y; Milligan C, 2016, HEALTH PLACE, V38, P103, DOI 10.1016/j.healthplace.2016.01.005; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; MONTGOMERY RJV, 1994, J GERONTOL, V49, pS62, DOI 10.1093/geronj/49.2.S62; Morgan T, 2017, CRIT PUBLIC HEALTH, V27, P263, DOI 10.1080/09581596.2016.1205182; Morgan T, 2016, PALLIATIVE MED, V30, P616, DOI 10.1177/0269216315625857; Morris SM, 2015, PALLIATIVE MED, V29, P487, DOI 10.1177/0269216314565706; NAC/AARP, 2015, CAR US; National Institute for Health and Clinical Excellence, 2004, GUID CANC SERV IMPR; Navaie-Waliser M, 2002, AM J PUBLIC HEALTH, V92, P409, DOI 10.2105/AJPH.92.3.409; NHS England, 2019, NHS LTP CANC; Nicholson C, 2012, SOC SCI MED, V75, P1426, DOI 10.1016/j.socscimed.2012.06.011; Oliver D., 2014, MAKING OUR HLTH CARE; Ory MG, 1985, GENERATIONS, V10, P14; Ouzzani M, 2016, SYST REV-LONDON, V5, DOI 10.1186/s13643-016-0384-4; Peacock S, 2014, PALLIAT SUPPORT CARE, V12, P117, DOI 10.1017/S1478951512001034; Perry J, 2002, RES NURS HEALTH, V25, P307, DOI 10.1002/nur.10040; Phillips LR, 2009, CLIN NURS RES, V18, P80, DOI 10.1177/1054773808330538; Pickard S, 2001, QUALITY AGEING, V2, P3; Pinquart M, 2003, PSYCHOL AGING, V18, P250, DOI 10.1037/0882-7974.18.2.250; PISTRANG N, 1995, SOC SCI MED, V40, P789, DOI 10.1016/0277-9536(94)00136-H; Popay J, 2006, GUIDANCE CONDUCT NAR, DOI DOI 10.13140/2.1.1018.4643; Potier F, 2018, J FRALITY AGING, V7, P170, DOI 10.14283/jfa.2018.11; Potier F, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0980-3; Potier F, 2018, ARCH GERONTOL GERIAT, V75, P76, DOI 10.1016/j.archger.2017.11.013; Poysti Minna Maria, 2012, Int J Alzheimers Dis, V2012, P162960, DOI 10.1155/2012/162960; Princess Royal Trust for Carers. Always on call always concerned, 2011, SURV EXP OLD CAR; Reeve E, 2016, BRIT J GEN PRACT, V66, pE552, DOI 10.3399/bjgp16X685669; Robine JM, 2007, BRIT MED J, V334, P570, DOI 10.1136/bmj.39129.397373.BE; Robinson J, 2014, PALLIATIVE MED, V28, P18, DOI 10.1177/0269216313487568; Rodriguez-Prat A, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016659; Roth DL, 2015, GERONTOLOGIST, V55, P309, DOI 10.1093/geront/gnu177; Russell R, 2001, J AGING STUD, V15, P351, DOI 10.1016/S0890-4065(01)00028-7; Sabat S.R., 1992, AGEING SOC, V12, P443, DOI [DOI 10.1017/S0144686X00005262, 10.1017/S0144686X00005262]; Sampson EL, 2016, J PAIN SYMPTOM MANAG, V51, P839, DOI 10.1016/j.jpainsymman.2015.12.319; Sanders S, 2009, HEALTH SOC WORK, V34, P41, DOI 10.1093/hsw/34.1.41; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; SCOTT JW, 1991, CRIT INQUIRY, V17, P773, DOI 10.1086/448612; Shavit O, 2019, AGEING SOC, V39, P488, DOI 10.1017/S0144686X1700109X; Strang VR, 2001, SCAND J CARING SCI, V15, P74, DOI 10.1046/j.1471-6712.2001.1510074.x; Sutherland N, 2016, QUAL HEALTH RES, V26, P907, DOI 10.1177/1049732315609571; TENNSTEDT SL, 1989, GERONTOLOGIST, V29, P677, DOI 10.1093/geront/29.5.677; TENNSTEDT SL, 1993, J GERONTOL, V48, pS74, DOI 10.1093/geronj/48.2.S74; Thomas C, 2018, PALLIATIVE MED, V32, P950, DOI 10.1177/0269216318757134; Thome B, 2004, QUAL LIFE RES, V13, P1067, DOI 10.1023/B:QURE.0000031342.11869.2f; Turner M, 2016, AGE AGEING, V45, P421, DOI 10.1093/ageing/afw047; Twigg J, 2004, J AGING STUD, V18, P59, DOI 10.1016/j.jaging.2003.09.001; Twigg J., 1994, CARERS PERCEIVED POL; Venkatasalu MR, 2014, PALLIATIVE MED, V28, P264, DOI 10.1177/0269216313506765; Ventura AD, 2014, PALLIATIVE MED, V28, P391, DOI 10.1177/0269216313511141; Wadham O, 2016, AGING MENT HEALTH, V20, P463, DOI 10.1080/13607863.2015.1023769; WHO, 2011, PALLIATIVE CARE OLDE; Wiles J, 2019, SOC SCI MED, V227, P104, DOI 10.1016/j.socscimed.2018.06.018; Williams LA, 2017, PALLIATIVE MED, V31, P223, DOI 10.1177/0269216316653275; World Health Organisation, 2018, NONC DIS MORT MORB; World Health Organization, 2018, INT PALL CAR SYMPT R; World Health Organization, 2015, SUPP INF CAR PEOPL L; World Health Organization, 2015, AG HLTH; Wright K., 1999, AM J ALZHEIMERS DIS, V14, P79, DOI DOI 10.1177/153331759901400209; Yee JL, 2000, GERONTOLOGIST, V40, P147, DOI 10.1093/geront/40.2.147	114	4	4	2	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2020	15	6							e0232401	10.1371/journal.pone.0232401	http://dx.doi.org/10.1371/journal.pone.0232401			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LZ1GC	32516312	gold, Green Published, Green Submitted			2023-01-03	WOS:000540977000031
J	Mager, LF; Burkhard, R; Pett, N; Cooke, NCA; Brown, K; Ramay, H; Paik, S; Stagg, J; Groves, RA; Gallo, M; Lewis, IA; Geuking, MB; McCoy, KD				Mager, Lukas F.; Burkhard, Regula; Pett, Nicola; Cooke, Noah C. A.; Brown, Kirsty; Ramay, Hena; Paik, Seungil; Stagg, John; Groves, Ryan A.; Gallo, Marco; Lewis, Ian A.; Geuking, Markus B.; McCoy, Kathy D.			Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy	SCIENCE			English	Article							T-CELLS; CYTOKINE PRODUCTION; IFN-GAMMA; CANCER; RECEPTOR; TUMORS; DIFFERENTIATION; AMPLIFICATION; RESISTANCE; EXPRESSION	Several species of intestinal bacteria have been associated with enhanced efficacy of checkpoint blockade immunotherapy, but the underlying mechanisms by which the microbiome enhances antitumor immunity are unclear. In this study, we isolated three bacterial species-Bifidobacterium pseudolongum, Lactobacillus johnsonii, and Olsenella species-that significantly enhanced efficacy of immune checkpoint inhibitors in four mouse models of cancer. We found that intestinal B. pseudolongum modulated enhanced immunotherapy response through production of the metabolite inosine. Decreased gut barrier function induced by immunotherapy increased systemic translocation of inosine and activated antitumor T cells. The effect of inosine was dependent on T cell expression of the adenosine A2A receptor and required costimulation. Collectively, our study identifies a previously unknown microbial metabolite immune pathway activated by immunotherapy that may be exploited to develop microbial-based adjuvant therapies.	[Mager, Lukas F.; Pett, Nicola; Cooke, Noah C. A.; Brown, Kirsty; McCoy, Kathy D.] Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Dept Physiol & Pharmacol, Calgary, AB, Canada; [Burkhard, Regula; Geuking, Markus B.] Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Dept Microbiol Immunol & Infect Dis, Calgary, AB, Canada; [Ramay, Hena] Univ Calgary, Int Microbiome Ctr, Cumming Sch Med, Calgary, AB, Canada; [Paik, Seungil; Gallo, Marco] Univ Calgary, Alberta Childrens Hosp Res Inst, Cumming Sch Med, Charbonneau Canc Inst,Dept Biochem & Mol Biol, Calgary, AB, Canada; [Paik, Seungil; Gallo, Marco] Univ Calgary, Alberta Childrens Hosp Res Inst, Cumming Sch Med, Charbonneau Canc Inst,Dept Physiol & Pharmacol, Calgary, AB, Canada; [Stagg, John] Ctr Hosp Univ Montreal, Ctr Rech, Quebec City, PQ, Canada; [Stagg, John] Inst Canc Montreal, Quebec City, PQ, Canada; [Groves, Ryan A.; Lewis, Ian A.] Univ Calgary, Dept Biol Sci, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary; University of Calgary; Universite de Montreal; Universite de Montreal; University of Calgary	Mager, LF; McCoy, KD (corresponding author), Univ Calgary, Cumming Sch Med, Snyder Inst Chron Dis, Dept Physiol & Pharmacol, Calgary, AB, Canada.	lukas.mager@ucalgary.ca; kathy.mccoy@ucalgary.ca	McCoy, Kathy/ABD-5814-2021	Burkhard, Regula/0000-0002-5117-0937; paik, seungil/0000-0002-1748-9557; Stagg, John/0000-0001-7833-4228; Groves, Ryan/0000-0002-9737-5161; Gallo, Marco/0000-0002-8451-8207; Brown, Kirsty/0000-0003-1410-4532; Mager, Lukas/0000-0002-7426-2842	Early Postdoc Mobility Fellowship from the Swiss National Science Foundation; Canadian Institutes of Health Research (CIHR) [PJT-165930]; Canadian Foundation for Innovation (CFI) John R. Evans Leaders Fund (JELF) grant; Cumming School of Medicine; Carole May Yates Memorial Endowment for Cancer Research; CIHR [PJT-156073]; CFI-JELF [34986]; International Microbiome Centre (IMC); Canada Graduate Scholarship from the Natural Sciences and Engineering Research Council of Canada (NSERC); Alberta Innovates Translational Health Chair; CIHR grant; Terry Fox Research Institute grant; Cumming School of Medicine, University of Calgary; Western Economic Diversification (WED); Alberta Economic Development and Trade (AEDT), Canada	Early Postdoc Mobility Fellowship from the Swiss National Science Foundation(Swiss National Science Foundation (SNSF)); Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Canadian Foundation for Innovation (CFI) John R. Evans Leaders Fund (JELF) grant; Cumming School of Medicine; Carole May Yates Memorial Endowment for Cancer Research; CIHR(Canadian Institutes of Health Research (CIHR)); CFI-JELF; International Microbiome Centre (IMC); Canada Graduate Scholarship from the Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Alberta Innovates Translational Health Chair; CIHR grant(Canadian Institutes of Health Research (CIHR)); Terry Fox Research Institute grant; Cumming School of Medicine, University of Calgary; Western Economic Diversification (WED); Alberta Economic Development and Trade (AEDT), Canada	L.F.M. was supported by the Early Postdoc Mobility Fellowship from the Swiss National Science Foundation. K.D.M. is supported by a Canadian Institutes of Health Research (CIHR) grant (PJT-165930), a Canadian Foundation for Innovation (CFI) John R. Evans Leaders Fund (JELF) grant, the Cumming School of Medicine, and the Carole May Yates Memorial Endowment for Cancer Research. M.B.G. is supported by CIHR (PJT-156073) and CFI-JELF. R.A.G. is supported by a CFI-JELF (34986) and the International Microbiome Centre (IMC). K.B. is supported by a Canada Graduate Scholarship from the Natural Sciences and Engineering Research Council of Canada (NSERC). I.A.L. is supported by an Alberta Innovates Translational Health Chair. J.S. is supported by a CIHR grant and a Terry Fox Research Institute grant. The IMC is supported by the Cumming School of Medicine, University of Calgary, Western Economic Diversification (WED) and ASlberta Economic Development and Trade (AEDT), Canada.	Allard B, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1601481; Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643; Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694; Brugiroux S, 2017, NAT MICROBIOL, V2, DOI 10.1038/nmicrobiol.2016.215; Callahan BJ, 2016, NAT METHODS, V13, P581, DOI [10.1038/NMETH.3869, 10.1038/nmeth.3869]; Cekic C, 2014, CANCER RES, V74, P7239, DOI 10.1158/0008-5472.CAN-13-3581; Chraa D, 2019, J LEUKOCYTE BIOL, V105, P243, DOI 10.1002/JLB.MR0318-097R; Clasquin Michelle F, 2012, Curr Protoc Bioinformatics, VChapter 14, DOI 10.1002/0471250953.bi1411s37; Csoka B, 2008, FASEB J, V22, P3491, DOI 10.1096/fj.08-107458; Dejea CM, 2018, SCIENCE, V359, P592, DOI 10.1126/science.aah3648; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Dewhirst FE, 2001, INT J SYST EVOL MICR, V51, P1797, DOI 10.1099/00207713-51-5-1797; Frankel AE, 2017, NEOPLASIA, V19, P848, DOI 10.1016/j.neo.2017.08.004; Garris CS, 2018, IMMUNITY, V49, P1148, DOI 10.1016/j.immuni.2018.09.024; Gide TN, 2018, CLIN CANCER RES, V24, P1260, DOI 10.1158/1078-0432.CCR-17-2267; Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236; Gowda H, 2014, ANAL CHEM, V86, P6931, DOI 10.1021/ac500734c; Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115; Hasko G, 2000, J IMMUNOL, V164, P1013, DOI 10.4049/jimmunol.164.2.1013; He BK, 2017, J EXP MED, V214, P107, DOI 10.1084/jem.20160961; Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527; Jahrsdorfer Bernd, 2008, Update Cancer Ther, V3, P27, DOI 10.1016/j.uct.2007.11.003; Kozich JJ, 2013, APPL ENVIRON MICROB, V79, P5112, DOI 10.1128/AEM.01043-13; Kucherlapati MH, 2010, GASTROENTEROLOGY, V138, P993, DOI 10.1053/j.gastro.2009.11.009; Lasek W, 2015, ACTA PHARMACEUT, V65, P171, DOI 10.1515/acph-2015-0015; Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596; Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733; Lioux T, 2016, J MED CHEM, V59, P10253, DOI 10.1021/acs.jmedchem.6b01300; Lloyd-Price J, 2019, NATURE, V569, P655, DOI 10.1038/s41586-019-1237-9; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lugli GA, 2019, APPL ENVIRON MICROB, V85, DOI 10.1128/AEM.03065-18; Mager LF, 2015, J CLIN INVEST, V125, P2579, DOI 10.1172/JCI77347; Mager LF, 2017, ELIFE, V6, DOI 10.7554/eLife.28366; Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290; Melamud E, 2010, ANAL CHEM, V82, P9818, DOI 10.1021/ac1021166; Meredith MM, 2012, J EXP MED, V209, P1153, DOI 10.1084/jem.20112675; Mertz KD, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1062966; Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665; Ohta A, 2006, P NATL ACAD SCI USA, V103, P13132, DOI 10.1073/pnas.0605251103; Pridmore RD, 2008, FEMS MICROBIOL LETT, V283, P210, DOI 10.1111/j.1574-6968.2008.01176.x; Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706; Samten B, 2005, J IMMUNOL, V174, P6357, DOI 10.4049/jimmunol.174.10.6357; Samten B, 2008, J IMMUNOL, V181, P2056, DOI 10.4049/jimmunol.181.3.2056; Schliep KP, 2011, BIOINFORMATICS, V27, P592, DOI 10.1093/bioinformatics/btq706; Schwabe RF, 2013, NAT REV CANCER, V13, P800, DOI 10.1038/nrc3610; Shi YY, 2020, J EXP MED, V217, DOI 10.1084/jem.20192282; Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255; Tanoue T, 2019, NATURE, V565, P600, DOI 10.1038/s41586-019-0878-z; Tautenhahn R, 2012, ANAL CHEM, V84, P5035, DOI 10.1021/ac300698c; Turroni F, 2009, APPL ENVIRON MICROB, V75, P1534, DOI 10.1128/AEM.02216-08; Vetizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329; Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537; Vigano S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00925; Wang F, 2018, P NATL ACAD SCI USA, V115, P157, DOI 10.1073/pnas.1712901115; Ward-Hartstonge KA, 2017, CLIN TRANSL IMMUNOL, V6, DOI 10.1038/cti.2017.43; Wei SC, 2017, CELL, V170, P1120, DOI 10.1016/j.cell.2017.07.024; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; Welihinda AA, 2016, CELL SIGNAL, V28, P552, DOI 10.1016/j.cellsig.2016.02.010; Yao CC, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2684; Zheng DW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03233-9	65	297	310	39	194	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 18	2020	369	6510					1481	+		10.1126/science.abc3421	http://dx.doi.org/10.1126/science.abc3421			61	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU8RF	32792462				2023-01-03	WOS:000573904400033
J	Dummer, R; Hauschild, A; Santinami, M; Atkinson, V; Mandala, M; Kirkwood, JM; Sileni, VC; Larkin, J; Nyakas, M; Dutriaux, C; Haydon, A; Robert, C; Mortier, L; Schachter, J; Lesimple, T; Plummer, R; Dasgupta, K; Gasal, E; Tan, M; Long, GV; Schadendorf, D				Dummer, Reinhard; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandala, Mario; Kirkwood, John M.; Sileni, Vanna Chiarion; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Lesimple, Thierry; Plummer, Ruth; Dasgupta, Kohinoor; Gasal, Eduard; Tan, Monique; Long, Georgina V.; Schadendorf, Dirk			Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IPILIMUMAB; DISSECTION; NIVOLUMAB; HAZARD	BackgroundIn the previously reported primary analysis of this phase 3 trial, 12 months of adjuvant dabrafenib plus trametinib resulted in significantly longer relapse-free survival than placebo in patients with resected stage III melanoma with BRAF V600E or V600K mutations. To confirm the stability of the relapse-free survival benefit, longer-term data were needed. MethodsWe randomly assigned 870 patients who had resected stage III melanoma with BRAF V600E or V600K mutations to receive 12 months of oral dabrafenib (at a dose of 150 mg twice daily) plus trametinib (2 mg once daily) or two matched placebos. The primary end point was relapse-free survival. Here, we report 5-year results for relapse-free survival and survival without distant metastasis as the site of the first relapse. Overall survival was not analyzed, since the required number of events to trigger the final overall survival analysis had not been reached. ResultsThe minimum duration of follow-up was 59 months (median patient follow-up, 60 months for dabrafenib plus trametinib and 58 months for placebo). At 5 years, the percentage of patients who were alive without relapse was 52% (95% confidence interval [CI], 48 to 58) with dabrafenib plus trametinib and 36% (95% CI, 32 to 41) with placebo (hazard ratio for relapse or death, 0.51; 95% CI, 0.42 to 0.61). The percentage of patients who were alive without distant metastasis was 65% (95% CI, 61 to 71) with dabrafenib plus trametinib and 54% (95% CI, 49 to 60) with placebo (hazard ratio for distant metastasis or death, 0.55; 95% CI, 0.44 to 0.70). No clinically meaningful between-group difference in the incidence or severity of serious adverse events was reported during the follow-up period. ConclusionsIn the 5-year follow-up of a phase 3 trial involving patients who had resected stage III melanoma with BRAF V600E or V600K mutations, 12 months of adjuvant therapy with dabrafenib plus trametinib resulted in a longer duration of survival without relapse or distant metastasis than placebo with no apparent long-term toxic effects. (Funded by GlaxoSmithKline and Novartis; COMBI-AD ClinicalTrials.gov number, NCT01682083; EudraCT number, 2012-001266-15.) At 5 years of follow-up, the 12-month use of adjuvant therapy with dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) in patients with stage III melanoma with BRAF V600 mutations resulted in relapse-free survival of 52%, as compared with 36% with placebo.	[Dummer, Reinhard] Univ Hosp Zurich, Skin Canc Ctr, Zurich, Switzerland; [Hauschild, Axel] Univ Hosp Schleswig Holstein, Kiel, Germany; [Schadendorf, Dirk] Univ Hosp Essen, Essen, Germany; [Schadendorf, Dirk] German Canc Consortium, Heidelberg, Germany; [Santinami, Mario] Fdn IRCCS Ist Nazl Tumori, Milan, Italy; [Mandala, Mario] Papa Giovanni XXIII Canc Ctr Hosp, Bergamo, Italy; [Sileni, Vanna Chiarion] Veneto Oncol Inst IRCCS, Melanoma Oncol Unit, Padua, Italy; [Atkinson, Victoria] Univ Queensland, Princess Alexandra Hosp, Gallipoli Med Res Fdn, Brisbane, Qld, Australia; [Haydon, Andrew] Alfred Hosp, Melbourne, Vic, Australia; [Long, Georgina V.] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia; [Long, Georgina V.] Royal North Shore Hosp, Sydney, NSW, Australia; [Long, Georgina V.] Mater Hosp, Sydney, NSW, Australia; [Kirkwood, John M.] Univ Pittsburgh, Melanoma Program, UPMC Hillman Canc Ctr, Pittsburgh, PA USA; [Larkin, James] Royal Marsden NHS Fdn Trust, London, England; [Plummer, Ruth] Freeman Rd Hosp, Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England; [Plummer, Ruth] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England; [Nyakas, Marta] Norwegian Radium Hosp, Oslo Univ Hosp, Oslo, Norway; [Dutriaux, Caroline] Hop St Andre, Ctr Hosp Univ Bordeaux, Bordeaux, France; [Robert, Caroline] Gustave Roussy, Villejuif, France; [Robert, Caroline] Paris Sud Paris Saclay Univ, Villejuif, France; [Mortier, Laurent] Univ Lille, INSERM, Unite 1189, Lille, France; [Lesimple, Thierry] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France; [Schachter, Jacob] Sheba Med Ctr, Ella Lemelbaum Inst Immunooncol & Melanoma, Tel Hashomer, Israel; [Schachter, Jacob] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel; [Dasgupta, Kohinoor] Novartis Healthcare, Hyderabad, Telangana, India; [Gasal, Eduard; Tan, Monique] Novartis Pharmaceut, E Hanover, NJ USA	University of Zurich; University Zurich Hospital; University of Kiel; Schleswig Holstein University Hospital; University of Duisburg Essen; Helmholtz Association; German Cancer Research Center (DKFZ); Fondazione IRCCS Istituto Nazionale Tumori Milan; ASST Papa Giovanni XXIII; IRCCS Istituto Oncologico Veneto (IOV); University of Queensland; Florey Institute of Neuroscience & Mental Health; Melanoma Institute Australia; University of Sydney; Royal North Shore Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Royal Marsden NHS Foundation Trust; Newcastle Freeman Hospital; Newcastle University - UK; Newcastle University - UK; University of Oslo; CHU Bordeaux; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; UNICANCER; Centre Eugene Marquis; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Novartis	Dummer, R (corresponding author), Univ Zurich Hosp, Dept Dermatol, Gloriastr 31, CH-8091 Zurich, Switzerland.	reinhard.dummer@usz.ch	mandala, mario/AAB-8637-2022; Robert, Caroline/G-6157-2018; sileni, vanna chiarion/B-9042-2018; Santinami, Mario/I-3795-2017	Robert, Caroline/0000-0002-9493-0238; sileni, vanna chiarion/0000-0001-9191-9124; Santinami, Mario/0000-0001-8436-4757; Kirkwood, John/0000-0002-3570-4476; Schadendorf, Dirk/0000-0003-3524-7858; Larkin, James/0000-0001-5569-9523	GlaxoSmithKline; Novartis	GlaxoSmithKline(GlaxoSmithKline); Novartis(Novartis)	Supported by GlaxoSmithKline and Novartis.	[Anonymous], 2020, J CLIN ONCOL S; BERNSTEIN L, 1981, BIOMETRICS, V37, P513, DOI 10.2307/2530564; BERRY G, 1991, STAT MED, V10, P749, DOI 10.1002/sim.4780100510; Bershas DA, 2013, DRUG METAB DISPOS, V41, P2215, DOI 10.1124/dmd.113.053785; Cheng Y, 2017, MOLECULES, V22, DOI 10.3390/molecules22101551; Eggermont AMM, 2019, EUR J CANCER, V119, P1, DOI 10.1016/j.ejca.2019.07.001; Eggermont AMM, 2018, NEW ENGL J MED, V378, P1789, DOI 10.1056/NEJMoa1802357; Faries MB, 2017, NEW ENGL J MED, V376, P2211, DOI 10.1056/NEJMoa1613210; Hauschild A, 2018, J CLIN ONCOL, V36, P3441, DOI 10.1200/JCO.18.01219; Leiter U, 2016, LANCET ONCOL, V17, P757, DOI 10.1016/S1470-2045(16)00141-8; Long GV, 2017, NEW ENGL J MED, V377, P1813, DOI 10.1056/NEJMoa1708539; Long GV, 2019, NEW ENGL J MED, V380, P1374, DOI 10.1056/NEJMc1902228; Michielin O, 2019, ANN ONCOL, V30, P1884, DOI 10.1093/annonc/mdz411; National Comprehensive Cancer Network, 2020, CUT MEL VERS 3; Romano E, 2010, J CLIN ONCOL, V28, P3042, DOI 10.1200/JCO.2009.26.2063; Schuchter LM, 2017, NEW ENGL J MED, V377, P1888, DOI 10.1056/NEJMe1711199; Tarhini AA, 2020, J CLIN ONCOL, V38, P567, DOI 10.1200/JCO.19.01381; Weber J, 2017, NEW ENGL J MED, V377, P1824, DOI 10.1056/NEJMoa1709030; Weber JS, 2019, ANN ONCOL, V30, P533	19	125	128	2	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 17	2020	383	12					1139	1148		10.1056/NEJMoa2005493	http://dx.doi.org/10.1056/NEJMoa2005493			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NU8QD	32877599	Bronze, Green Published			2023-01-03	WOS:000573901600013
J	Kim, J; Choi, J; Shin, MS; Kim, M; Seo, E; An, M; Shim, JL; Heo, S				Kim, JinShil; Choi, Jiin; Shin, Mi-Seung; Kim, Miyeong; Seo, EunJu; An, Minjeong; Shim, Jae Lan; Heo, Seongkum			Do advance directive attitudes and perceived susceptibility and end-of-life life-sustaining treatment preferences between patients with heart failure and cancer differ?	PLOS ONE			English	Article							CARE; INTERVENTION; FEASIBILITY; BURDEN; HEALTH; IMPACT	There is limited evidence on the relationships of preference for end-of-life life-sustaining treatments [LSTs] and diagnostic contexts like heart failure [HF] or cancer, and patient attitudes toward and perceived susceptibility to use advance directives [ADs]. Thus, this study aimed to compare attitudes and perceived susceptibility between HF patients and community-dwelling patients with cancer, and examine the associations of these variables with their preference for each LST (cardiopulmonary resuscitation [CPR], ventilation support, hemodialysis, and hospice care). Secondary data were obtained from 36 outpatients with HF (mean age, 65.44 years; male, 69.4%) and 107 cancer patients (mean age, 67.39 years; male, 32.7%). More patients with HF preferred CPR than cancer patients (41.7% and 15.9%,chi(2)= 8.88,P= 0.003). Attitudes and perceived susceptibility were similar between the two diagnostic cohorts. HF patients and those with more positive attitudes had greater odds of preferring CPR (odds ratio [OR] = 3.02, confidence interval [CI] = 1.19, 7.70) and hospice care (OR = 1.14, CI = 1.06, 1.23), respectively. HF diagnosis and AD attitudes increased the preference for CPR and hospice care, respectively. This suggests that it is important to gain positive attitudes toward ADs and consider diagnostic context to facilitate informed decision-making for LSTs.	[Kim, JinShil] Gachon Univ, Coll Nursing, Incheon, South Korea; [Choi, Jiin] Seoul Natl Univ Hosp, Off Hosp Informat, Seoul, South Korea; [Shin, Mi-Seung] Gachon Univ, Coll Med, Gil Med Ctr, Dept Internal Med,Div Cardiol, Incheon, South Korea; [Kim, Miyeong] Gachon Univ, Gil Med Ctr, Incheon, South Korea; [Seo, EunJu] Natl Canc Ctr, Dept Nursing, Seoul, South Korea; [An, Minjeong] Chonnam Natl Univ, Coll Nursing, Gwangju, South Korea; [Shim, Jae Lan] Dongguk Univ, Coll Med, Dept Nursing, Gyeongju, South Korea; [Heo, Seongkum] Mercer Univ, Georgia Baptist Coll Nursing, Atlanta, GA USA	Gachon University; Seoul National University (SNU); Seoul National University Hospital; Gachon University; Gachon University; National Cancer Center - Korea (NCC); Chonnam National University; Dongguk University; Mercer University	Choi, J (corresponding author), Seoul Natl Univ Hosp, Off Hosp Informat, Seoul, South Korea.; An, M (corresponding author), Chonnam Natl Univ, Coll Nursing, Gwangju, South Korea.	chocojiin0@gmail.com; anminjeong@inu.ac.kr		Choi, Jiin/0000-0002-6156-0066	Gachon University Gil Medical Center	Gachon University Gil Medical Center	Mi-Seung Shin/JinShil Kim Grant number: 2016-17 Gachon University Gil Medical Center https://www.gilhospital.com/.	Adler ED, 2009, CIRCULATION, V120, P2597, DOI 10.1161/CIRCULATIONAHA.109.869123; Alano GJ, 2010, PALLIAT SUPPORT CARE, V8, P267, DOI 10.1017/S1478951510000064; Ambrosy AP, 2014, J AM COLL CARDIOL, V63, P1123, DOI 10.1016/j.jacc.2013.11.053; American Society of Clinical Oncology, 2020, ADV CANC TREATM 2020; Anand I, 2018, AM J CARDIOVASC DRUG, V18, P333, DOI 10.1007/s40256-018-0277-0; Bekelman DB, 2009, J GEN INTERN MED, V24, P592, DOI 10.1007/s11606-009-0931-y; Butler J, 2015, JACC-HEART FAIL, V3, P112, DOI 10.1016/j.jchf.2014.07.016; Dalal S, 2017, ONCOLOGIST, V22, P361, DOI 10.1634/theoncologist.2016-0277; Detering K, 2020, ADV CARE PLANNING AD; Duckworth KE, 2014, AM J HOSP PALLIAT ME, V31, P710, DOI 10.1177/1049909113499815; Dunlay SM, 2012, CIRC-CARDIOVASC QUAL, V5, P283, DOI 10.1161/CIRCOUTCOMES.112.966036; Dunlay SM, 2012, EUR HEART J, V33, P689, DOI 10.1093/eurheartj/ehr411; Fitzmaurice C, 2019, JAMA ONCOL, V5, P1749, DOI 10.1001/jamaoncol.2019.2996; Glaudemans JJ, 2015, FAM PRACT, V32, P16, DOI 10.1093/fampra/cmu074; Johnson S, 2016, PSYCHO-ONCOLOGY, V25, P362, DOI 10.1002/pon.3926; Jung KW, 2017, CANCER RES TREAT, V49, P292, DOI 10.4143/crt.2017.118; KIM J, 2020, HEALTHCARE-J DEL SCI, V8, DOI DOI 10.3390/HEALTHCARE8010062; Kim J, 2020, J CARD FAIL, V26, P61, DOI 10.1016/j.cardfail.2019.07.011; Kim J, 2019, INT J OLDER PEOPLE N, V14, DOI 10.1111/opn.12229; Kim J, 2020, KOREAN J INTERN MED, V35, P109, DOI 10.3904/kjim.2018.158; Kim J, 2018, J CARDIOVASC NURS, V33, P446, DOI 10.1097/JCN.0000000000000396; Kim M, 2019, J TRANSCULT NURS, V30, P587, DOI 10.1177/1043659619832080; Kim S, 2017, HOLIST NURS PRACT, V31, P234, DOI 10.1097/HNP.0000000000000216; Ko E, 2016, AM J HOSP PALLIAT ME, V33, P834, DOI 10.1177/1049909115593736; Ko E, 2009, J AGING HEALTH, V21, P967, DOI 10.1177/0898264309344179; Lau KS, 2010, J PAIN SYMPTOM MANAG, V40, P704, DOI 10.1016/j.jpainsymman.2010.02.023; Lee S. H., 2015, J HLTH INFORMATICS S, V40, P117; MacKenzie MA, 2016, J PAIN SYMPTOM MANAG, V51, P71, DOI 10.1016/j.jpainsymman.2015.09.001; Mamas MA, 2017, EUR J HEART FAIL, V19, P1095, DOI 10.1002/ejhf.822; Ministry of Health & Welfare, 2016, GUID 2017 COMM INT H; Musa I, 2015, AGE AGEING, V44, P371, DOI 10.1093/ageing/afv041; Narang AK, 2015, JAMA ONCOL, V1, P601, DOI 10.1001/jamaoncol.2015.1976; Ng QX, 2017, ANN ACAD MED SINGAP, V46, P84; Nolan MT, 1997, NURS OUTLOOK, V45, P204, DOI 10.1016/S0029-6554(97)90066-X; Park IK, 2015, AM J HOSP PALLIAT ME, V32, P797, DOI 10.1177/1049909114542646; Prentice TC, 2019, J CARD FAIL, V25, pS60, DOI 10.1016/j.cardfail.2019.07.172; Rietjens JAC, 2017, LANCET ONCOL, V18, pE543, DOI 10.1016/S1470-2045(17)30582-X; Rocque GB, 2017, J PAIN SYMPTOM MANAG, V53, P682, DOI 10.1016/j.jpainsymman.2016.11.012; Sarfati D, 2016, CA-CANCER J CLIN, V66, P338, DOI 10.3322/caac.21342; Schubart JR, 2019, J ONCOL PRACT, V15, DOI 10.1200/JOP.18.00044; Sinclair C, 2013, BMJ SUPPORT PALLIAT, V3, P358, DOI 10.1136/bmjspcare-2012-000256; Sittisombut Sudarat, 2005, Nurs Health Sci, V7, P243, DOI 10.1111/j.1442-2018.2005.00243.x; Smith GL, 2019, J NATL COMPR CANC NE, V17, P1184, DOI 10.6004/jnccn.2019.7305; Stiel S, 2015, BMC PALLIAT CARE, V14, DOI 10.1186/s12904-015-0033-z; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Yoo SH, 2018, CANCER RES TREAT, V50, P720, DOI 10.4143/crt.2017.169; Ziaeian B, 2016, NAT REV CARDIOL, V13, P368, DOI 10.1038/nrcardio.2016.25	47	0	0	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 8	2020	15	9							e0238567	10.1371/journal.pone.0238567	http://dx.doi.org/10.1371/journal.pone.0238567			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ6EE	32898165	gold, Green Published			2023-01-03	WOS:000570962500032
J	Akinlade, O				Akinlade, Oluwafunmilayo			Taking Black Pain Seriously	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								The onus of advocacy for suffering Black patients has been placed almost solely on this country's disproportionately few Black clinicians - an unsustainable situation, particularly since they are already shouldering the effects of systemic racism on their own lives.	[Akinlade, Oluwafunmilayo] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Akinlade, O (corresponding author), Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA.							Hoffman KM, 2016, P NATL ACAD SCI USA, V113, P4296, DOI 10.1073/pnas.1516047113; Meghani SH, 2012, PAIN MED, V13, P150, DOI 10.1111/j.1526-4637.2011.01310.x; Rovai A., 2005, J NEGRO EDUC, V74, P359; Villarosa L., 2019, NY TIMES MAGAZINE	4	9	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 3	2020	383	10							e68	10.1056/NEJMpv2024759	http://dx.doi.org/10.1056/NEJMpv2024759			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NO9YO	32809299	Bronze			2023-01-03	WOS:000569841600001
J	Tew, GA; Ward, L; Hewitt, C; Tiedemann, A				Tew, Garry A.; Ward, Lesley; Hewitt, Catherine; Tiedemann, Anne			Does yoga reduce the risk of falls in older people?	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							AVOIDANCE; MOBILITY; BALANCE		[Tew, Garry A.; Ward, Lesley] Northumbria Univ, Dept Sport Exercise & Rehabil, Newcastle Upon Tyne, Tyne & Wear, England; [Hewitt, Catherine] Univ York, Dept Hlth Sci, York Trials Unit, York, N Yorkshire, England; [Tiedemann, Anne] Univ Sydney, Inst Musculoskeletal Hlth, Sydney, NSW, Australia; [Tiedemann, Anne] Sydney Local Hlth Dist, Sydney, NSW, Australia	Northumbria University; University of York - UK; University of Sydney	Tew, GA (corresponding author), Northumbria Univ, Dept Sport Exercise & Rehabil, Newcastle Upon Tyne, Tyne & Wear, England.	garry.tew@northumbria.ac.uk		Hewitt, Catherine Elizabeth/0000-0002-0415-3536; Tew, Garry/0000-0002-8610-0613; Ward, Lesley/0000-0001-7285-2032				[Anonymous], 2017, BRIT J SPORT MED, DOI DOI 10.1136/bjsports-2016-096547; ANZCTR, 2019, SUCC AGEING SAGE YOG; Australian Commission on Safety and Quality in Health Care, 2009, PREV FALLS HARM FALL; Bergen G, 2016, MMWR-MORBID MORTAL W, V65, P993, DOI 10.15585/mmwr.mm6537a2; Clarke Tainya C, 2018, NCHS Data Brief, P1; Delbaere K, 2004, AGE AGEING, V33, P368, DOI 10.1093/ageing/afh106; Hopewell S, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012221.pub2; ISRCTN Registry, 2019, GENTL YEARS YOG TRIA; Keay Lisa, 2018, Pilot Feasibility Stud, V4, P74, DOI 10.1186/s40814-018-0264-x; Kenny RAM, 2011, J AM GERIATR SOC, V59, P148, DOI 10.1111/j.1532-5415.2010.03234.x; Michaelis E., 2005, HIST MODERN YOG PATA; National Institute for Health and Care Excellence, 2013, FALLS OLD PEOPL ASS; Public Health England, 2017, FALLS FRACT CONS STA; Sherrington C, 2019, COCHRANE DATABASE SY, V1; Sivaramakrishnan D, 2019, INT J BEHAV NUTR PHY, V16, DOI 10.1186/s12966-019-0789-2; Tew GA, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0520-6; Tiedemann A, 2018, PUBLIC HEALTH RES PR, V28, DOI 10.17061/phrp28011801; Tiedemann A, 2013, J GERONTOL A-BIOL, V68, P1068, DOI 10.1093/gerona/glt087; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; Wise AK, 2012, J NEURAL ENG, V9, DOI 10.1088/1741-2560/9/6/065002; Yardley L, 2002, GERONTOLOGIST, V42, P17, DOI 10.1093/geront/42.1.17; Youkhana S, 2016, AGE AGEING, V45, P21, DOI 10.1093/ageing/afv175	22	2	2	3	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 3	2020	370								m3246	10.1136/bmj.m3246	http://dx.doi.org/10.1136/bmj.m3246			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NS7CG	32883704	Green Accepted			2023-01-03	WOS:000572414700007
J	Gureje, O; Appiah-Poku, J; Bello, T; Kola, L; Araya, R; Chisholm, D; Esan, O; Harris, B; Makanjuola, V; Othieno, C; Price, L; Seedat, S				Gureje, Oye; Appiah-Poku, John; Bello, Toyin; Kola, Lola; Araya, Ricardo; Chisholm, Dan; Esan, Oluyomi; Harris, Benjamin; Makanjuola, Victor; Othieno, Caleb; Price, LeShawndra; Seedat, Soraya			Effect of collaborative care between traditional and faith healers and primary health-care workers on psychosis outcomes in Nigeria and Ghana (COSIMPO): a cluster randomised controlled trial	LANCET			English	Article							MENTAL-ILLNESS; DISORDERS; COMPLEMENTARY; PREVALENCE; SCHEDULE; MEDICINE	Background Traditional and faith healers (TFH) provide care to a large number of people with psychosis in many sub-Saharan African countries but they practise outside the formal mental health system. We aimed to assess the effectiveness and cost-effectiveness of a collaborative shared care model for psychosis delivered by TFH and primary health-care providers (PHCW). Methods In this cluster-randomised trial in Kumasi, Ghana and Ibadan, Nigeria, we randomly allocated clusters (a primary care clinic and neighbouring TFH facilities) 1:1, stratified by size and country, to an intervention group or enhanced care as usual. The intervention included a manualised collaborative shared care delivered by trained TFH and PHCW. Eligible participants were adults (aged >= 18 years) newly admitted to TFH facilities with active psychotic symptoms (positive and negative syndrome scale [PANSS] score >= 60). The primary outcome, by masked assessments at 6 months, was the difference in psychotic symptom improvement as measured with the PANSS in patients in follow-up at 3 and 6 months. Patients exposure to harmful treatment practices, such as shackling, were also assessed at 3 and 6 months. Care costs were assessed at baseline, 3-month and 6-month follow-up, and for the entire 6 months of follow-up. This trial was registered with the National Institutes of Health Clinical Trial registry, NCT02895269. Findings Between Sept 1, 2016, and May 3, 2017, 51 clusters were randomly allocated (26 intervention, 25 control) with 307 patients enrolled (166 [54%] in the intervention group and 141 [46%] in the control group). 190 (62%) of participants were men. Baseline mean PANSS score was 107.3 (SD 17.5) for the intervention group and 108.9 (18.3) for the control group. 286 (93%) completed the 6-month follow-up at which the mean total PANSS score for intervention group was 53.4 (19.9) compared with 67.6 (23.3) for the control group (adjusted mean difference -15.01 (95% CI -21.17 to -8.84; 0.0001). Harmful practices decreased from 94 (57%) of 166 patients at baseline to 13 (9%) of 152 at 6 months in the intervention group (-0.48 [-0.60 to -0.37] p<0.001) and from 59 (42%) of 141 patients to 13 (10%) of 134 in the control group (-0.33 [-0.45 to -0.21] p<0.001), with no significant difference between the two groups. Greater reductions in overall care costs were seen in the intervention group than in the control group. At the 6 month assessment, greater reductions in total health service and time costs were seen in the intervention group; however, cumulative costs over this period were higher (US $627 per patient vs $526 in the control group). Five patients in the intervention group had mild extrapyramidal side effects. Interpretation A collaborative shared care delivered by TFH and conventional health-care providers for people with psychosis was effective and cost-effective. The model of care offers the prospect of scaling up improved care to this vulnerable population in settings with low resources. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Gureje, Oye; Bello, Toyin; Kola, Lola; Esan, Oluyomi; Makanjuola, Victor] Univ Ibadan, WHO Collaborating Ctr Res & Training Mental Hlth, Dept Psychiat, Neurosci & Subst Abuse, Ibadan, Nigeria; [Appiah-Poku, John] Kwame Nkrumah Univ Sci & Technol, Dept Behav Sci, Kumasi, Ghana; [Araya, Ricardo] Kings Coll London, Dept Hlth Serv & Populat Res, London, England; [Chisholm, Dan] WHO, Dept Mental Hlth & Subst Abuse, Geneva, Switzerland; [Harris, Benjamin] Univ Liberia, Dept Psychiat, Monrovia, Liberia; [Othieno, Caleb] Univ Nairobi, Dept Psychiat, Nairobi, Kenya; [Price, LeShawndra] NIMH, US Dept HHS, NIH, Bethesda, MD 20892 USA; [Seedat, Soraya] Stellenbosch Univ, Dept Psychiat, Cape Town, South Africa	University of Ibadan; Kwame Nkrumah University Science & Technology; University of London; King's College London; World Health Organization; University of Nairobi; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Stellenbosch University	Gureje, O (corresponding author), Univ Ibadan, Collaborating Ctr Res & Training Mental Hlth Neur, Dept Psychiat, Neurosci & Subst Abuse, Ibadan 200220, Nigeria.	ogureje@com.ui.edu.ng		Araya, Ricardo/0000-0002-0420-5148; Seedat, Soraya/0000-0002-5118-786X	US National Institute of Mental Health	US National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	US National Institute of Mental Health.	Abbo C, 2012, INT J MENT HEALTH SY, V6, DOI 10.1186/1752-4458-6-13; Abbo C, 2009, AFR HEALTH SCI, V9, pS16; Abbo Catherine, 2008, WORLD CULTURAL PSYCH, V3, P132, DOI DOI 10.3402/GHA.V4I0.7117; Arias D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162305; Benjamin DJ, 2018, NAT HUM BEHAV, V2, P6, DOI 10.1038/s41562-017-0189-z; Campion J, 1997, SOC PSYCH PSYCH EPID, V32, P215, DOI 10.1007/BF00788241; Chiliza B, 2016, EARLY INTERV PSYCHIA, V10, P54, DOI 10.1111/eip.12141; Chisholm D, 2000, BRIT J PSYCHIAT, V177, pS28, DOI 10.1192/bjp.177.39.s28; Ernst E, 2000, B WORLD HEALTH ORGAN, V78, P252; Esan O, 2018, SOC PSYCHIAT PSYCHIA; Esan O, 2019, SOC PSYCH PSYCH EPID, V54, P395, DOI 10.1007/s00127-018-1630-y; Eylem O, 2020, BMC PUBLIC HEALTH, V20, DOI 10.1186/s12889-020-09199-y; First MB., STRUCTURED CLIN INTE; Gureje O, 2005, BRIT J PSYCHIAT, V186, P436, DOI 10.1192/bjp.186.5.436; Gureje O, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2187-x; Gureje O, 2015, LANCET PSYCHIAT, V2, P168, DOI 10.1016/S2215-0366(15)00013-9; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kayombo E. J., 2007, Journal of Ethnobiology and Ethnomedicine, V3; Minas Harry, 2008, Int J Ment Health Syst, V2, P8, DOI 10.1186/1752-4458-2-8; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Nortje G, 2016, LANCET PSYCHIAT, V3, P154, DOI 10.1016/S2215-0366(15)00515-5; Ofori-Atta A, 2018, BRIT J PSYCHIAT, V212, P34, DOI 10.1192/bjp.2017.12; Poole NA, 2013, TRANSCULT PSYCHIATRY, V50, P433, DOI 10.1177/1363461513483263; Ritsher JB, 2003, PSYCHIAT RES, V121, P31, DOI 10.1016/j.physchres.2003.08.008; Saeed K, 2000, SOC PSYCH PSYCH EPID, V35, P480, DOI 10.1007/s001270050267; Susser E, 2000, SCHIZOPHR RES, V42, P67, DOI 10.1016/S0920-9964(99)00088-2; Ustun TB, 2010, B WORLD HEALTH ORGAN, V88, P815, DOI 10.2471/BLT.09.067231; van der Watt ASJ, 2018, SOC PSYCH PSYCH EPID, V53, P555, DOI 10.1007/s00127-018-1519-9; van der Watt ASJ, 2017, QUAL HEALTH RES, V27, P2177, DOI 10.1177/1049732317729342; Whiteford HA, 2013, LANCET, V382, P1575, DOI 10.1016/S0140-6736(13)61611-6; WHO, 2013, WHO TRADITIONAL MED	31	27	27	1	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 29	2020	396	10251					612	622						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	OC4NF	32861306	Green Accepted			2023-01-03	WOS:000579134100021
J	Marwaa, MN; Kristensen, HK; Guidetti, S; Ytterberg, C				Marwaa, Mille Nabsen; Kristensen, Hanne Kaae; Guidetti, Susanne; Ytterberg, Charlotte			Physiotherapists' and occupational therapists' perspectives on information and communication technology in stroke rehabilitation	PLOS ONE			English	Article							EVERYDAY LIFE; 1ST YEAR; CAREGIVERS; CARE; TELEREHABILITATION; IMPLEMENTATION; PARTICIPATION; INTERVENTION; SATISFACTION; EXPERIENCES	Aim The aim of this study was to explore the current and potential use of information and communication technology (ICT) to enhance coherent person-centred rehabilitation after stroke, from the perspectives of physiotherapists and occupational therapists. Method Five occupational therapists and four physiotherapists from different phases of the Danish stroke rehabilitation process were included and two focus group interviews were carried out. A grounded theory approach was used throughout the study and a constant comparative method was used in the analysis. Results Three subcategories were identified from the analysis of interviews with participants: 1) ICT and apps as meaningful and supportive in the rehabilitation process, 2) ICT as a tool in communication and documentation and 3) Barriers to the integration of ICT and apps in the rehabilitation process. From these categories one core category emerged: The potential of a personalized app solution to facilitate coherent person-centred rehabilitation. Conclusion ICT was perceived as important to integrate in stroke rehabilitation both for assessment, training and to compensate for remaining deficits. The development of a personalized app solution could accommodate stroke survivors' and significant others' need for insight into and overview over the rehabilitation process as well as access to relevant information, which would thereby empower them. Furthermore, a personalized app solution could also facilitate follow-up after discharge and was perceived to ease the communication and documentation within and between sectors, as well as communication with both stroke survivors and significant others.	[Marwaa, Mille Nabsen] Univ Coll Southern Denmark, Dept Physiotherapy Educ, Esbjerg, Denmark; [Kristensen, Hanne Kaae; Ytterberg, Charlotte] Univ Southern Denmark, Inst Clin Res, Res Unit Rehabil, Odense, Denmark; [Guidetti, Susanne; Ytterberg, Charlotte] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Huddinge, Sweden; [Ytterberg, Charlotte] Karolinska Univ Hosp, Funct Area Occupat Therapy & Physiotherapy, Stockholm, Sweden	University of Southern Denmark; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Marwaa, MN (corresponding author), Univ Coll Southern Denmark, Dept Physiotherapy Educ, Esbjerg, Denmark.	mnma@ucsyd.dk	Marwaa, Mille Nabsen/AAX-8770-2020	Marwaa, Mille Nabsen/0000-0001-6230-1667; Kristensen, Hanne Kaae/0000-0002-9596-5571	University College South Denmark	University College South Denmark	This study has been supported by University College South Denmark.	[Anonymous], J AM GERIATR SOC; Bakas T, 2014, STROKE, V45, P2836, DOI 10.1161/STR.0000000000000033; Bergstrom AL, 2015, J REHABIL MED, V47, P508, DOI 10.2340/16501977-1964; Bishop D, 2014, TOP STROKE REHABIL, V21, pS63, DOI 10.1310/tsr21S1-S63; Brinkmann S., 2015, KVALITATIVE METODER; Brouns B, 2018, IMPLEMENT SCI, V13, DOI 10.1186/s13012-018-0827-5; Camak DJ, 2015, J CLIN NURS, V24, P2376, DOI 10.1111/jocn.12884; Charmaz K., 2014, CONSTRUCTING GROUNDE, Vsecond; Chen CC, 2011, AM J PHYS MED REHAB, V90, P415, DOI 10.1097/PHM.0b013e318214f5d8; Cogollor Jose M, 2018, JMIR Rehabil Assist Technol, V5, pe4, DOI 10.2196/rehab.8548; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Eames S, 2010, TOP STROKE REHABIL, V17, P69, DOI 10.1310/tsr1702-69; Edgar MC, 2017, TELEMED E-HEALTH, V23, P421, DOI 10.1089/tmj.2016.0129; Ekstam L, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-006784; Forducey PG, 2012, PSYCHOL SERV, V9, P144, DOI 10.1037/a0028112; Gopal A, 2019, NEUROLOGY, V92, P39; Grau-Pellicer M, 2020, TOP STROKE REHABIL, V27, P354, DOI [10.1080/10749357.2019.1605751, 10.1080/10749357.2019.1691816]; Gustavsson M, 2020, SCAND J OCCUP THER, V27, P223, DOI 10.1080/11038128.2019.1666918; Gustavsson M, 2018, DISABIL REHABIL, V40, P561, DOI 10.1080/09638288.2016.1264012; Halkier B, 2012, FOKUSGRUPPER, V2nd ed.; Hughes CML, 2020, HEALTH INFORM J, V26, P1104, DOI 10.1177/1460458219868356; Johansson T, 2011, J TELEMED TELECARE, V17, P1, DOI 10.1258/jtt.2010.100105; Kamel Boulos MN, 2014, OJPHI, V5, DOI 10.5210/ojphi.v5i3.4814; Kamwesiga JT, 2017, DISABIL REHABIL, V39, P438, DOI 10.3109/09638288.2016.1146354; Kotzian ST, 2019, TECHNOL HEALTH CARE, V27, P613, DOI 10.3233/THC-181427; Kristensen HK, 2016, DISABIL REHABIL, V38, P2564, DOI 10.3109/09638288.2016.1138550; Kristensen HK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157149; Kristensen HK, 2013, DISABIL REHABIL, V35, P2021, DOI 10.3109/09638288.2013.768301; Laver KE, 2020, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010255.pub3; Lindberg B, 2013, INT J TELEMED APPL, V2013, DOI 10.1155/2013/461829; Lindqvist E, 2012, DISABIL REHABIL-ASSI, V7, P364, DOI 10.3109/17483107.2011.638036; Lutz BJ, 2009, DISABIL REHABIL, V31, P402, DOI 10.1080/09638280802069558; Mallet K, 2019, INT J STROKE, V14, P174, DOI 10.1177/1747493018790031; Malterud K, 2012, FOKUSGRUPPER SOM FOR; Marwaa MN, 2020, DISABIL REHABIL, V42, P2115, DOI 10.1080/09638288.2018.1555614; Mawson S, 2014, DISABIL REHABIL-ASSI, V9, P521, DOI 10.3109/17483107.2013.840863; Pellerin C, 2011, DISABIL REHABIL, V33, P1055, DOI 10.3109/09638288.2010.524272; Perry L, 2011, DISABIL REHABIL, V33, P1890, DOI 10.3109/09638288.2011.553702; Platz T, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00200; Pugliese M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191566; Ranner M, 2019, DISABIL REHABIL, V41, P3025, DOI 10.1080/09638288.2018.1483434; Region Syddanmark, 2009, ERG FYS TV RSEKT GEN; Rodgers H, 2001, AGE AGEING, V30, P129, DOI 10.1093/ageing/30.2.129; Saywell N, 2015, PHYSIOTHER THEOR PR, V31, P160, DOI 10.3109/09593985.2014.982234; Socialstyrelsen, 2018, REH; Solli H, 2018, INFORM HEALTH SOC CA, V43, P207, DOI 10.1080/17538157.2017.1364245; Steiner V, 2009, TOP STROKE REHABIL, V16, P122, DOI 10.1310/tsr1602-122; Stone K, 2014, REHABIL NURS, V39, P76, DOI 10.1002/rnj.123; Sumathipala K, 2012, CHRONIC ILLN, V8, P31, DOI 10.1177/1742395311423848; Sundhedsstyrelsen (The National Board of Health Denmark)., 2011, FORL REH VOKSN MED E; Sveriges kommuner och Landsting, 2017, VIS E HALS; Tistad M, 2013, HEALTH EXPECT, V16, pE24, DOI 10.1111/hex.12095; Wade DT, 2017, CLIN REHABIL, V31, P995, DOI 10.1177/0269215517709890; Wentink M, 2019, BMC MED INFORM DECIS, V19, DOI 10.1186/s12911-019-0871-3; Wildevuur SE, 2015, J MED INTERNET RES, V17, DOI 10.2196/jmir.3687; Wingham J, 2015, CLIN REHABIL, V29, P295, DOI 10.1177/0269215514542638; Zonneveld M, 2020, DISABIL REHABIL, V42, P3416, DOI 10.1080/09638288.2019.1592246	57	6	7	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 28	2020	15	8							e0236831	10.1371/journal.pone.0236831	http://dx.doi.org/10.1371/journal.pone.0236831			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NK7YA	32857781	Green Published, gold			2023-01-03	WOS:000566947200051
J	Abujaber, A; Fadlalla, A; Gammoh, D; Abdelrahman, H; Mollazehi, M; El-Menyar, A				Abujaber, Ahmad; Fadlalla, Adam; Gammoh, Diala; Abdelrahman, Husham; Mollazehi, Monira; El-Menyar, Ayman			Using trauma registry data to predict prolonged mechanical ventilation in patients with traumatic brain injury: Machine learning approach	PLOS ONE			English	Article							ARTIFICIAL NEURAL-NETWORK; EXTERNAL VALIDATION; LATE TRACHEOSTOMY; RISK-FACTORS; IMPACT; MORTALITY; OUTCOMES; SUPPORT; SURGERY; MODELS	Objectives We aimed to build a machine learning predictive model to predict the risk of prolonged mechanical ventilation (PMV) for patients with Traumatic Brain Injury (TBI). Methods This study included TBI patients who were hospitalized in a level 1 trauma center between January 2014 and February 2019. Data were analyzed for all adult patients who received mechanical ventilation following TBI with abbreviated injury severity (AIS) score for the head region of >= 3. This study designed three sets of machine learning models: set A defined PMV to be greater than 7 days, set B (PMV > 10 days) and set C (PMV >14 days) to determine the optimal model for deployment. Patients' demographics, injury characteristics and CT findings were used as predictors. Logistic regression (LR), Artificial neural networks (ANN) Support vector machines (SVM), Random Forest (RF) and C.5 Decision Tree (C.5 DT) were used to predict the PMV. Results The number of eligible patients that were included in the study were 674, 643 and 622 patients in sets A, B and C respectively. In set A, LR achieved the optimal performance with accuracy 0.75 and Area under the curve (AUC) 0.83. SVM achieved the optimal performance among other models in sets B with accuracy/AUC of 0.79/0.84 respectively. ANNs achieved the optimal performance in set C with accuracy/AUC of 0.76/0.72 respectively. Machine learning models in set B demonstrated more stable performance with higher prediction success and discrimination power. Conclusion This study not only provides evidence that machine learning methods outperform the traditional multivariate analytical methods, but also provides a perspective to reach a consensual definition of PMV.	[Abujaber, Ahmad] Hamad Med Corp, Nursing, Doha, Qatar; [Fadlalla, Adam] Qatar Univ, Management Informat Syst Business & Econ Fac, Doha, Qatar; [Gammoh, Diala] Univ Cent Florida, Ind Engn, Orlando, FL 32816 USA; [Abdelrahman, Husham; Mollazehi, Monira] Hamad Med Corp, Dept Surg, Trauma Surg, Doha, Qatar; [El-Menyar, Ayman] Hamad Med Corp, Dept Surg Trauma Surg Clin Res, Doha, Qatar; [El-Menyar, Ayman] Weill Cornell Med Coll, Dept Clin Med, Doha, Qatar	Hamad Medical Corporation; Qatar University; State University System of Florida; University of Central Florida; Hamad Medical Corporation; Hamad Medical Corporation; Qatar Foundation (QF); Weill Cornell Medical College Qatar	El-Menyar, A (corresponding author), Hamad Med Corp, Dept Surg Trauma Surg Clin Res, Doha, Qatar.; El-Menyar, A (corresponding author), Weill Cornell Med Coll, Dept Clin Med, Doha, Qatar.	aymanco65@yahoo.com	El-Menyar, Ayman/F-6734-2015	El-Menyar, Ayman/0000-0003-2584-953X				Agle SC, 2006, AM J SURG, V192, P822, DOI 10.1016/j.amjsurg.2006.08.051; Vieira RDA, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00178; Andriolo BNG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007271.pub3; Archer KJ, 2008, COMPUT STAT DATA AN, V52, P2249, DOI 10.1016/j.csda.2007.08.015; Asehnoune K, 2018, CRIT CARE, V22, DOI 10.1186/s13054-018-1994-0; Bartels RHMA, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0479-x; Bellazzi R, 2008, INT J MED INFORM, V77, P81, DOI 10.1016/j.ijmedinf.2006.11.006; Blaser AR, 2019, CRIT CARE MED, V47, P535, DOI 10.1097/CCM.0000000000003623; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Chang YC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24028-4; Cinotti R, 2018, ANN TRANSL MED, V6, DOI 10.21037/atm.2018.08.16; Clark PA, 2013, J CRIT CARE, V28, DOI 10.1016/j.jcrc.2013.03.013; Cui SZ, 2018, COMPUT METH PROG BIO, V166, P123, DOI 10.1016/j.cmpb.2018.10.012; Dag A, 2017, DECIS SUPPORT SYST, V94, P42, DOI 10.1016/j.dss.2016.10.005; Das A, 2003, LANCET, V362, P1261, DOI 10.1016/S0140-6736(03)14568-0; Dasta JF, 2005, CRIT CARE MED, V33, P1266, DOI 10.1097/01.CCM.0000164543.14619.00; Dimopoulou I, 2003, INTENS CARE MED, V29, P1101, DOI 10.1007/s00134-003-1813-0; Esteban A, 2002, JAMA-J AM MED ASSOC, V287, P345, DOI 10.1001/jama.287.3.345; Esteban A, 2013, AM J RESP CRIT CARE, V188, P220, DOI 10.1164/rccm.201212-2169OC; Figueroa-Casas JB, 2015, J CRIT CARE, V30, P502, DOI 10.1016/j.jcrc.2015.01.020; Gershengorn HB, 2015, ANN AM THORAC SOC, V12, P1831, DOI 10.1513/AnnalsATS.201506-366BC; Ghiani A, 2019, BMC PULM MED, V19, DOI 10.1186/s12890-019-1009-1; Girard TD, 2008, LANCET, V371, P126, DOI 10.1016/S0140-6736(08)60105-1; Hale AT, 2018, NEUROSURG FOCUS, V45, DOI 10.3171/2018.8.FOCUS17773; Han J, 2012, MOR KAUF D, P1; Han JL, 2014, J NEUROTRAUM, V31, P1146, DOI 10.1089/neu.2013.3003; Hellyer Thomas P, 2016, J Intensive Care Soc, V17, P238, DOI 10.1177/1751143716644461; Herritt B, 2018, J CRIT CARE, V44, P285, DOI 10.1016/j.jcrc.2017.11.037; Mena JH, 2011, J TRAUMA, V71, P1185, DOI 10.1097/TA.0b013e31823321f8; Huttmann SE, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0384-8; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jha RM, 2019, NEUROPHARMACOLOGY, V145, P230, DOI 10.1016/j.neuropharm.2018.08.004; Jovanovic B, 2015, INT J INFECT DIS, V38, P46, DOI 10.1016/j.ijid.2015.07.005; Kao JH, 2013, RESP CARE, V58, P2093, DOI 10.4187/respcare.02273; Kim HI, 2019, TUBERC RESPIR DIS, V82, P6, DOI 10.4046/trd.2018.0041; Lai YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073743; Lakshmi BN, 2016, PROC TECH, V24, P1542, DOI 10.1016/j.protcy.2016.05.128; Luetz A, 2012, CURR OPIN ANESTHESIO, V25, P164, DOI 10.1097/ACO.0b013e32834f8ce7; Okabe Y, 2018, ACUTE MED SURG, V5, P166, DOI 10.1002/ams2.331; Pandian Vinciya, 2014, ORL Head Neck Nurs, V32, P6; Parreco J, 2018, J SURG RES, V228, P179, DOI 10.1016/j.jss.2018.03.028; Rau Cheng-Shyuan, 2018, PLoS One, V13, pe0207192, DOI 10.1371/journal.pone.0207192; Rau CS, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13121203; Rose L, 2017, RESP CARE, V62, P1324, DOI 10.4187/respcare.05485; Savitsky B, 2016, BRAIN INJURY, V30, P1194, DOI 10.1080/02699052.2016.1187290; Shaikhina T, 2019, BIOMED SIGNAL PROCES, V52, P456, DOI 10.1016/j.bspc.2017.01.012; Shi HY, 2013, J NEUROSURG, V118, P746, DOI 10.3171/2013.1.JNS121130; Trouillet JL, 2011, ANN INTERN MED, V154, P373, DOI 10.7326/0003-4819-154-6-201103150-00002; Wang CH, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009165; Wong GKC, 2013, J CLIN NEUROSCI, V20, P1693, DOI 10.1016/j.jocn.2012.12.032; Young D, 2013, JAMA-J AM MED ASSOC, V309, P2121, DOI 10.1001/jama.2013.5154; Zilberberg MD, 2012, CRIT CARE MED, V40, P18, DOI 10.1097/CCM.0b013e31822e9ffd; Zolbanin HM, 2015, DECIS SUPPORT SYST, V74, P150, DOI 10.1016/j.dss.2015.04.003; Zubrow ME, 2018, PEDIATR CRIT CARE ME, V19, pE88, DOI 10.1097/PCC.0000000000001399	54	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2020	15	7							e0235231	10.1371/journal.pone.0235231	http://dx.doi.org/10.1371/journal.pone.0235231			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ0QI	32639971	Green Published, gold			2023-01-03	WOS:000552601500039
J	Nicholson, TW; Talbot, NP; Nickol, A; Chadwick, AJ; Lawton, O				Nicholson, Thomas W.; Talbot, Nick P.; Nickol, Annabel; Chadwick, Andrew J.; Lawton, Oliver			Respiratory failure and non-invasive respiratory support during the covid-19 pandemic: an update for re-deployed hospital doctors and primary care physicians	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Nicholson, Thomas W.] Frimley Hlth Fdn Trust, Wexham Pk Hosp, Dept Thorac Med, Slough SL2 4HL, Berks, England; [Talbot, Nick P.; Nickol, Annabel] Oxford Univ Hosp NHS Fdn Trust, Churchill Hosp, Oxford Ctr Resp Med, Headington OX3 7LE, England; [Talbot, Nick P.] Univ Oxford, Dept Physiol Anat & Genet, Oxford, England; [Chadwick, Andrew J.] Oxford Univ Hosp NHS Fdn Trust, John Radcliffe Hosp, Dept Intens Care Med, Headington OX3 9DU, England; [Lawton, Oliver] Clarendon Lodge Med Practice, Royal Leamington Spa CV32 5SS, England	Oxford University Hospitals NHS Foundation Trust; University of Oxford; Oxford University Hospitals NHS Foundation Trust	Nicholson, TW (corresponding author), Frimley Hlth Fdn Trust, Wexham Pk Hosp, Dept Thorac Med, Slough SL2 4HL, Berks, England.	Thomas.nicholson2@nhs.net		Talbot, Nick/0000-0002-9186-8950					0	13	13	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2020	369								m2446	10.1136/bmj.m2446	http://dx.doi.org/10.1136/bmj.m2446			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ5FQ	32605992	Bronze, Green Submitted			2023-01-03	WOS:000548116400008
J	Palmer, BF; Clegg, DJ				Palmer, Biff F.; Clegg, Deborah J.			Salicylate Toxicity	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							WHOLE-BOWEL IRRIGATION; ACID-BASE DISTURBANCES; ACTIVATED-CHARCOAL; AMERICAN ASSOCIATION; POSITION PAPER; ASPIRIN; INTOXICATION; INHIBITION; ELECTROLYTE; ABSORPTION	ON PRESENTATION TO THE EMERGENCY DEPARTMENT, PATIENTS WITH fever, tachypnea, rales on lung examination, and acid-base disturbances are often given a suspected diagnosis of viral infection, yet persons with salicylate toxicity may present with similar symptoms. This article highlights the risk factors for salicylate toxicity; reviews the pathophysiological effects; notes the hidden sources of salicylates, including foods, drugs, and topical ointments, that if used in combination may result in unintended toxic effects; and discusses treatment strategies. Especially during the current pandemic, clinicians should be aware of the potential for salicylate poisoning,(1) which occurred in the 1918-1919 pandemic of Spanish influenza.(2)	[Palmer, Biff F.] Univ Texas Southwestern Med Ctr Dallas, Dept Med, Div Nephrol, Dallas, TX 75390 USA; [Clegg, Deborah J.] Drexel Univ, Coll Nursing & Hlth Profess, Philadelphia, PA 19104 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Drexel University	Palmer, BF (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	biff.palmer@utsouthwestern.edu						ANDERSEN R, 1978, INTENS CARE MED, V4, P211, DOI 10.1007/BF01902550; ANDERSON RJ, 1976, ANN INTERN MED, V85, P745, DOI 10.7326/0003-4819-85-6-745; ANDERSON RJ, 1981, ANN INTERN MED, V95, P188, DOI 10.7326/0003-4819-95-2-188; ARENA FP, 1978, ARCH INTERN MED, V138, P1153, DOI 10.1001/archinte.138.7.1153; BAILEY RB, 1989, J AM GERIATR SOC, V37, P556, DOI 10.1111/j.1532-5415.1989.tb05689.x; Chyka PA, 2007, CLIN TOXICOL, V45, P95, DOI 10.1080/15563650600907140; Crichton J U, 1960, Can Med Assoc J, V83, P1144; Dargan PI, 2002, EMERG MED J, V19, P206, DOI 10.1136/emj.19.3.206; Duthie GG, 2011, FOOD FUNCT, V2, P515, DOI 10.1039/c1fo10128e; EICHENHOLZ A, 1963, METABOLISM, V12, P164; Fertel BS, 2009, KIDNEY INT, V75, P1349, DOI 10.1038/ki.2008.443; FILIPPONE GA, 1987, ARCH INTERN MED, V147, P1390, DOI 10.1001/archinte.147.8.1390; GABOW PA, 1978, ARCH INTERN MED, V138, P1481, DOI 10.1001/archinte.138.10.1481; Glassock RJ, 2011, CLIN J AM SOC NEPHRO, V6, P2318, DOI 10.2215/CJN.00900111; Goodman JW, 2006, SEMIN DIALYSIS, V19, P402, DOI 10.1111/j.1525-139X.2006.00194.x; Greenberg MI, 2003, ANN EMERG MED, V41, P583, DOI 10.1067/mem.2003.128; GREER HD, 1965, J AMER MED ASSOC, V193, P555, DOI 10.1001/jama.1965.03090070005001; Gummin DD, 2019, CLIN TOXICOL, V57, P1220, DOI 10.1080/15563650.2019.1677022; Gumz ML, 2010, AM J PHYSIOL-RENAL, V298, pF12, DOI 10.1152/ajprenal.90723.2008; HAAS R, 1985, BIOCHEM PHARMACOL, V34, P901, DOI 10.1016/0006-2952(85)90774-9; Hanzik PJ, 1913, J AMER MED ASSOC, V60, P957, DOI 10.1001/jama.1913.04340130005003; HILL JB, 1973, NEW ENGL J MED, V288, P1110, DOI 10.1056/NEJM197305242882107; Hoffman RS, 2019, CLIN TOXICOL, V57, P377, DOI 10.1080/15563650.2018.1517882; HOOD VL, 1990, AM J PHYSIOL, V259, pE327, DOI 10.1152/ajpendo.1990.259.3.E327; Juurlink DN, 2015, ANN EMERG MED, V66, P165, DOI 10.1016/j.annemergmed.2015.03.031; KAPLAN EH, 1954, ARCH BIOCHEM BIOPHYS, V51, P47, DOI 10.1016/0003-9861(54)90452-X; Kashani KB, 2018, NEPHRON, V138, P186, DOI 10.1159/000484636; KIRSHENBAUM LA, 1989, CLIN PHARMACOL THER, V46, P264, DOI 10.1038/clpt.1989.137; LEATHERMAN JW, 1991, CHEST, V100, P1391, DOI 10.1378/chest.100.5.1391; LEVENTHAL LJ, 1989, AM J EMERG MED, V7, P409, DOI 10.1016/0735-6757(89)90049-1; LEVY G, 1965, J PHARM SCI, V54, P959, DOI 10.1002/jps.2600540703; LEVY G, 1972, CLIN PHARMACOL THER, V13, P317; Levy G., 1985, CLIN PHARMACOKINET, V10, P164; MCQUEEN DS, 1989, BRIT J PHARMACOL, V98, P413, DOI 10.1111/j.1476-5381.1989.tb12612.x; MONTGOMERY H, 1994, AM J EMERG MED, V12, P531, DOI 10.1016/0735-6757(94)90271-2; Montinari MR, 2019, VASC PHARMACOL, V113, P1, DOI 10.1016/j.vph.2018.10.008; Moss MJ, 2019, CLIN TOXICOL, V57, P137, DOI 10.1080/15563650.2018.1502442; Mowry JB, 2015, CLIN TOXICOL, V53, P962, DOI 10.3109/15563650.2015.1102927; Nulton-Persson AC, 2004, J CARDIOVASC PHARM, V44, P591, DOI 10.1097/00005344-200411000-00012; Palmer BF, 2019, AM J KIDNEY DIS, V74, P682, DOI 10.1053/j.ajkd.2019.03.427; Palmer BF, 2017, NEW ENGL J MED, V377, P1368, DOI 10.1056/NEJMra1704724; Palmer BF, 2015, NEW ENGL J MED, V373, P548, DOI 10.1056/NEJMra1503102; Palmer BF, 2012, AM J KIDNEY DIS, V60, P834, DOI 10.1053/j.ajkd.2012.03.025; PAUL BN, 1972, J AM GERIATR SOC, V20, P387, DOI 10.1111/j.1532-5415.1972.tb01640.x; PEI YPC, 1987, AM J MED, V82, P381, DOI 10.1016/0002-9343(87)90094-5; Proudfoot AT, 2004, J TOXICOL-CLIN TOXIC, V42, P1, DOI 10.1081/CLT-120028740; Qian K, 2015, DIABETES-METAB RES, V31, P562, DOI 10.1002/dmrr.2655; Rao R. B., 1999, Journal of Toxicology Clinical Toxicology, V37, P605; REID J, 1957, BRIT MED J, V2, P1071, DOI 10.1136/bmj.2.5053.1071; Rivera W, 2004, ANN PHARMACOTHER, V38, P1186, DOI 10.1345/aph.1D575; SMITH MJH, 1956, BIOCHEM J, V63, P524, DOI 10.1042/bj0630524; SMITH MJH, 1971, J PHARM PHARMACOL, V23, P729, DOI 10.1111/j.2042-7158.1971.tb08598.x; Starko KM, 2009, CLIN INFECT DIS, V49, P1405, DOI 10.1086/606060; STEELE TE, 1986, PSYCHOSOMATICS, V27, P455, DOI 10.1016/S0033-3182(86)72675-3; STEPHENS TW, 1983, BIOCHEM J, V212, P521, DOI 10.1042/bj2120521; SWAIN AR, 1985, J AM DIET ASSOC, V85, P950; SWEENEY KR, 1986, CLIN PHARMACOL THER, V40, P518, DOI 10.1038/clpt.1986.217; Thanacoody R, 2015, CLIN TOXICOL, V53, P5, DOI 10.3109/15563650.2014.989326; Thompson TM, 2016, WEST J EMERG MED, V17, P181, DOI 10.5811/westjem.2016.1.29262; THURSTON JH, 1970, J CLIN INVEST, V49, P2139, DOI 10.1172/JCI106431; VASUVATTAKUL S, 1995, NEPHRON, V69, P311, DOI 10.1159/000188476; WINTERS RW, 1959, PEDIATRICS, V23, P260; Wong OF, 2010, HONG KONG J EMERG ME, V17, P276, DOI 10.1177/102490791001700314; WOODS HF, 1974, CLIN EXP PHARMACOL P, V1, P535, DOI 10.1111/j.1440-1681.1974.tb00574.x; WORTZMAN DJ, 1987, ANN EMERG MED, V16, P434, DOI 10.1016/S0196-0644(87)80366-9; Yip Luke, 1994, Emergency Medicine Clinics of North America, V12, P351; YU TF, 1959, J CLIN INVEST, V38, P1298, DOI 10.1172/JCI103905	67	21	22	2	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 25	2020	382	26					2544	2555		10.1056/NEJMra2010852	http://dx.doi.org/10.1056/NEJMra2010852			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF9CW	32579814				2023-01-03	WOS:000545636400025
J	Mulinari, S; Vilhelmsson, A; Rickard, E; Ozieranski, P				Mulinari, Shai; Vilhelmsson, Andreas; Rickard, Emily; Ozieranski, Piotr			Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs	PLOS ONE			English	Article							ADVOCACY ORGANIZATIONS; EUROPE; DISCLOSURE	Background Many patient organisations collaborate with drug companies, resulting in concerns about commercial agendas influencing patient advocacy. We contribute to an international body of knowledge on patient organisation-industry relations by considering payments reported in the industry's centralised 'collaboration database' in Sweden. We also investigate possible commercial motives behind the funding by assessing its association with drug commercialisation. Methods Our primary data source were 1,337 payment reports from 2014-2018. After extraction and coding, we analysed the data descriptively, calculating the number, value and distribution of payments for various units of analysis, e.g. individual companies, diseases and payment goals. The association between drug commercialisation and patient organisation funding was assessed by, first, the concordance between leading companies marketing drugs in specific diseases and their funding of corresponding patient organisations and, second, the correlation between new drugs in broader condition areas and payments to corresponding patient organisations. Results 46 companies reported paying euro6,449.224 (median euro2,411; IQR euro1,024-4,569) to 77 patient organisations, but ten companies provided 67% of the funding. Small payments dominated, many of which covered costs of events organised by patient organisations. An association existed between drug commercialisation and industry funding. Companies supported patient organisations in diseases linked to their drug portfolios, with the top 3 condition areas in terms of funding-cancer; endocrine, nutritional and metabolic disorders; and infectious and parasitic disorders-accounting for 63% of new drugs and 56% of the funding. Conclusion This study reveals close and widespread ties between patient organisations and drug companies. A relatively few number of companies dominated the funding landscape by supporting patient organisations in disease areas linked to their drug portfolios. This commercially motivated funding may contribute to inequalities in resource and influence between patient organisations. The association between drug commercialisation and industry funding is also worrying because of the therapeutic uncertainty of many new drugs. Our analysis benefited from the existence of a centralised database of payments-which should be adopted by other countries too-but databases should be downloadable in an analysable format to permit efficient and independent analysis.	[Mulinari, Shai; Vilhelmsson, Andreas] Lund Univ, Dept Sociol, Lund, Sweden; [Rickard, Emily; Ozieranski, Piotr] Univ Bath, Dept Social & Policy Sci, Claverton Down, Bath, Avon, England	Lund University; University of Bath	Mulinari, S (corresponding author), Lund Univ, Dept Sociol, Lund, Sweden.	shai.mulinari@soc.lu.se	; Vilhelmsson, Andreas/D-3879-2018	Mulinari, Shai/0000-0001-8773-9796; Rickard, Emily/0000-0003-2251-0127; Ozieranski, Piotr/0000-0002-2023-3288; Vilhelmsson, Andreas/0000-0002-6635-8182	Swedish Research Council for Health, Working Life and Welfare [201600875]; Crafoord Foundation	Swedish Research Council for Health, Working Life and Welfare(Swedish Research CouncilSwedish Research Council for Health Working Life & Welfare (Forte)); Crafoord Foundation	This work was supported by grants from the Swedish Research Council for Health, Working Life and Welfare (www.forte.se) (FORTE #201600875 to SM (PI) and PO) and the Crafoord Foundation (www.crafoord.se) (to SM (PI) and PO and AV). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abola MV, 2016, MAYO CLIN PROC, V91, P1668, DOI 10.1016/j.mayocp.2016.08.015; Abraham J., 2000, REGULATING MED EUROP; Baggott R, 2008, HEALTH EXPECT, V11, P85, DOI 10.1111/j.1369-7625.2007.00472.x; Ball DE, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-201; Batt S, 2017, PHARM FUNDING CHANGE; Colombo C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034974; Davis C., 2013, UNHEALTHY PHARM REGU, V1st ed; Davis C, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4530; di Priolo SL, 2012, PATIENT, V5, P127, DOI 10.2165/11589210-000000000-00000; EFPIA, 2011, EFPIA COD PRACT REL; Fabbri A, 2019, INT J HEALTH SERV, V49, P273, DOI 10.1177/0020731418823376; Fabbri A, 2018, INT J HEALTH POLICY, V7, P504, DOI 10.15171/ijhpm.2018.20; Ferrario A, 2015, SOC SCI MED, V124, P39, DOI 10.1016/j.socscimed.2014.11.003; Grundy Q, 2018, HEALTH POLICY, V122, P509, DOI 10.1016/j.healthpol.2018.03.015; Haerry D, 2018, FRONT MED-LAUSANNE, V5, DOI 10.3389/fmed.2018.00230; Hemminki E, 2010, SOC SCI MED, V70, P1171, DOI 10.1016/j.socscimed.2010.01.005; Hoekman J, 2019, SOC SCI MED, V222, P76, DOI 10.1016/j.socscimed.2018.12.025; Hughes David, 2013, Healthc Policy, V9, P52; Institute for Health Metrics and Evaluation (IHME), 2018, SWED PROF; Kang SY, 2019, AM J PUBLIC HEALTH, V109, P559, DOI 10.2105/AJPH.2018.304946; Kent A, 2007, BRIT MED J, V334, P934, DOI 10.1136/bmj.39185.461968.AD; Lau E, 2019, AUST HEALTH REV, V43, P474, DOI 10.1071/AH17288; Lexchin J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212399; Li DG, 2019, JAMA DERMATOL, V155, P460, DOI 10.1001/jamadermatol.2018.5102; LIF, 2020, ETH RUL PHARM IND SW; LIF, SAM; Lofgren H, 2011, DEMOCRATIZING HEALTH: CONSUMER GROUPS IN THE POLICY PROCESS, P1; Mandeville KL, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.k5300; McCoy MS, 2017, NEW ENGL J MED, V376, P880, DOI 10.1056/NEJMsr1610625; Menon D, 2011, EXPERT REV PHARM OUT, V11, P75, DOI 10.1586/ERP.10.82; Mulinari S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-023094; Mulinari S, 2016, J PUBLIC HEALTH POL, V37, P149, DOI 10.1057/jphp.2016.6; Mulinari S, 2013, SOCIOL HEALTH ILL, V35, P761, DOI 10.1111/j.1467-9566.2012.01528.x; Myndigheten for Vardanalys, 2015, 20154 MYND VARD; Naci H, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l5221; Ozieranski P, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.6253; Ozieranski P, 2019, BMJ-BRIT MED J, V365, DOI 10.1136/bmj.l1806; Parker L, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l6694; Pearcy J, 2019, BMJ-BRIT MED J, V364, DOI 10.1136/bmj.l740; Perehudoff SK, 2011, PATIENT CONSUMER VOI; Pontes C, 2020, APPL HEALTH ECON HEA, V18, P5, DOI 10.1007/s40258-019-00527-x; Prasad V, 2015, JAMA INTERN MED, V175, P1389, DOI 10.1001/jamainternmed.2015.2829; Rickard E, 2019, HEALTH POLICY, V123, P1244, DOI 10.1016/j.healthpol.2019.08.007; Rose SL, 2017, JAMA INTERN MED, V177, P344, DOI 10.1001/jamainternmed.2016.8443; Rothman SM, 2011, AM J PUBLIC HEALTH, V101, P602, DOI 10.2105/AJPH.2010.300027; Taylor J, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.j1251; The Institute for Health Metrics and Evaluation (IHME), GLOB HLTH DAT EXCH G; Tibau A, 2018, JAMA ONCOL, V4, P1610, DOI 10.1001/jamaoncol.2018.4300; Wehling P., 2014, PUBLIC SHAPING MED R; Zetterqvist AV, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001785	50	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 24	2020	15	6							e0235021	10.1371/journal.pone.0235021	http://dx.doi.org/10.1371/journal.pone.0235021			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MF9GS	32579571	Green Published, gold			2023-01-03	WOS:000545646600045
J	Darrow, JJ; Chong, JE; Kesselheim, AS				Darrow, Jonathan J.; Chong, Jessica E.; Kesselheim, Aaron S.			Reconsidering the scope of US state laws allowing pharmacist substitution of generic drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									[Darrow, Jonathan J.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 75 Francis St, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Darrow, JJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Program Regulat Therapeut & Law PORTAL, 75 Francis St, Boston, MA 02115 USA.	jjdarrow@bwh.harvard	Chong, Jessica/GZH-1625-2022		Arnold Ventures; Harvard-MIT Center for Regulatory Science	Arnold Ventures; Harvard-MIT Center for Regulatory Science	The authors acknowledge funding support from Arnold Ventures and the Harvard-MIT Center for Regulatory Science. We thank Theresa Harnak for her contributions.		0	8	8	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 23	2020	369								m2236	10.1136/bmj.m2236	http://dx.doi.org/10.1136/bmj.m2236			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK1VB	32576554				2023-01-03	WOS:000548573500008
J	Ito, A; Wang, TS; Nakahara, R; Kawai, H; Nishitani, K; Aoyama, T; Kuroki, H				Ito, Akira; Wang, Tianshu; Nakahara, Ryo; Kawai, Hideki; Nishitani, Kohei; Aoyama, Tomoki; Kuroki, Hiroshi			Ultrasound therapy with optimal intensity facilitates peripheral nerve regeneration in rats through suppression of pro-inflammatory and nerve growth inhibitor gene expression	PLOS ONE			English	Article							SCIATIC-NERVE; PULSED ULTRASOUND; FUNCTIONAL RECOVERY; ELECTRICAL-STIMULATION; NEUROTROPHINS; NEURONS; CELLS; DIFFERENTIATION; PARAMETERS; GSK-3-BETA	Background Therapeutic ultrasound (US) is a promising physical therapy modality for peripheral nerve regeneration. However, it is necessary to identify the most effective US parameters and clarify the underlying mechanisms before its clinical application. The intensity of US is one of the most important parameters. However, the optimum intensity for the promotion of peripheral nerve regeneration has yet to be determined. Objectives To identify the optimum intensity of US necessary for the promotion of peripheral nerve regeneration after crush injuries in rats and to clarify the underlying mechanisms of US by mRNA expression analysis. Methods We inflicted sciatic nerve crush injuries on adult Lewis rats and performed ultrasound irradiation using 4 different US intensities: 0 (sham stimulation), 30, 140, and 250 mW/cm(2)with frequency (5 days/week) and duration (5 min/day). We evaluated peripheral nerve regeneration by quantitative real-time PCR one week after injury. Histomorphometric analyses and motor function analysis were evaluated 3 weeks after injury. Results US stimulation enhanced re-myelination as well as sprouting of axons, especially at an intensity of 140 mW/cm(2). mRNA expression revealed that US suppressed the expression of the inflammatory cytokines TNF and IL-6 and the axonal growth inhibitors SEMA3A and GSK3 beta. Conclusions An intensity of 140 mW/cm(2)was optimal to support regeneration of the sciatic nerve after a crush injury in rats by, in part, the suppression of pro-inflammatory and nerve growth inhibitor gene expression.	[Ito, Akira; Nakahara, Ryo; Kawai, Hideki; Kuroki, Hiroshi] Kyoto Univ, Grad Sch Med, Dept Motor Funct Anal, Human Hlth Sci, Kyoto, Japan; [Wang, Tianshu; Aoyama, Tomoki] Kyoto Univ, Grad Sch Med, Dept Dev & Rehabil Motor Funct, Human Hlth Sci, Kyoto, Japan; [Nishitani, Kohei] Kyoto Univ, Grad Sch Med, Dept Orthopaed Surg, Kyoto, Japan	Kyoto University; Kyoto University; Kyoto University	Kuroki, H (corresponding author), Kyoto Univ, Grad Sch Med, Dept Motor Funct Anal, Human Hlth Sci, Kyoto, Japan.	hiroshi.kuroki.6s@kyoto-u.ac.jp	Ito, Akira/AAA-4872-2021; Nishitani, Kohei/ABB-1788-2021	Ito, Akira/0000-0002-9645-9777; Nishitani, Kohei/0000-0002-8327-3826	Japan Society for the Promotion of Science (JSPS) KAKENHI [JP19K19793, JP18H03129, JP18K19739]	Japan Society for the Promotion of Science (JSPS) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This study was supported by Japan Society for the Promotion of Science (JSPS, http://www.jsps.go.jp/index.html) KAKENHI Grant, Number JP19K19793 to AI, and Number JP18H03129 and JP18K19739 to HK. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akhlaghi Zhamak, 2012, Iranian Biomedical Journal, V16, P107, DOI 10.6091/IBJ.942.2012; Altland OD, 2004, J THROMB HAEMOST, V2, P637, DOI 10.1111/j.1538-7836.2004.00655.x; Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496; Arslantunali D, 2014, MED DEVICES-EVID RES, V7, P405, DOI 10.2147/MDER.S59124; BAIN JR, 1989, PLAST RECONSTR SURG, V83, P129, DOI 10.1097/00006534-198901000-00024; Bosse F, 2012, CELL TISSUE RES, V349, P5, DOI 10.1007/s00441-012-1389-5; Chan JR, 2001, P NATL ACAD SCI USA, V98, P14661, DOI 10.1073/pnas.251543398; Chen WZ, 2010, ULTRASOUND MED BIOL, V36, P1109, DOI 10.1016/j.ultrasmedbio.2010.04.014; Chung JI, 2012, OSTEOARTHR CARTILAGE, V20, P314, DOI 10.1016/j.joca.2012.01.005; Cosgaya JM, 2002, SCIENCE, V298, P1245, DOI 10.1126/science.1076595; Crisci AR, 2002, ULTRASOUND MED BIOL, V28, P1335, DOI 10.1016/S0301-5629(02)00576-8; Daeschler SC, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.01057; Daeschler SC, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21540-5; DINNO MA, 1989, ULTRASOUND MED BIOL, V15, P461, DOI 10.1016/0301-5629(89)90099-9; FUNAKOSHI H, 1993, J CELL BIOL, V123, P455, DOI 10.1083/jcb.123.2.455; HEUMANN R, 1987, J CELL BIOL, V104, P1623, DOI 10.1083/jcb.104.6.1623; HONG CZ, 1988, ARCH PHYS MED REHAB, V69, P410; Huang JH, 2010, NEUROREHAB NEURAL RE, V24, P736, DOI 10.1177/1545968310368686; Ito A, 2019, NEURAL REGEN RES, V14, P2077, DOI 10.4103/1673-5374.262581; Jiang H, 2005, CELL, V120, P123, DOI 10.1016/j.cell.2004.12.033; Jiang WL, 2016, SCI REP-UK, V6, DOI 10.1038/srep22773; Kato K, 2010, J NEUROSCI RES, V88, P360, DOI 10.1002/jnr.22202; Khanna A, 2009, BRIT MED BULL, V89, P169, DOI 10.1093/bmb/ldn040; Kim JR, 2013, TISSUE ENG PT A, V19, P2674, DOI [10.1089/ten.TEA.2012.0735, 10.1089/ten.tea.2012.0735]; Kim WY, 2006, NEURON, V52, P981, DOI 10.1016/j.neuron.2006.10.031; Lv YG, 2015, BIOTECHNOL LETT, V37, P2497, DOI 10.1007/s10529-015-1939-5; Lv YG, 2013, BIOTECHNOL LETT, V35, P2201, DOI 10.1007/s10529-013-1313-4; MORTIMER AJ, 1988, ULTRASOUND MED BIOL, V14, P499, DOI 10.1016/0301-5629(88)90111-1; Mourad PD, 2001, NEUROSURGERY, V48, P1136, DOI 10.1097/00006123-200105000-00035; Munoz-Montano Juan Ramon, 1999, J Alzheimers Dis, V1, P361; Nadeau S, 2011, J NEUROSCI, V31, P12533, DOI 10.1523/JNEUROSCI.2840-11.2011; Nakayama T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19834-9; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Ni XJ, 2017, ULTRASOUND MED BIOL, V43, P461, DOI 10.1016/j.ultrasmedbio.2016.09.017; Omoto M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047716; Raso VVM, 2005, J NEUROSCI METH, V142, P185, DOI 10.1016/j.jneumeth.2004.08.016; Ren C, 2010, BIOMED ENVIRON SCI, V23, P244, DOI 10.1016/S0895-3988(10)60059-1; SCHNEIDERSCHAULIES J, 1991, NEURON, V7, P995, DOI 10.1016/0896-6273(91)90344-Y; Syed YA, 2011, J NEUROSCI, V31, P3719, DOI 10.1523/JNEUROSCI.4930-10.2011; VENTIMIGLIA R, 1995, EUR J NEUROSCI, V7, P213, DOI 10.1111/j.1460-9568.1995.tb01057.x; Wang TS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208985; Watanabe Y, 2010, J ORTHOP TRAUMA, V24, pS56, DOI 10.1097/BOT.0b013e3181d2efaf; Willand MP, 2016, NEUROREHAB NEURAL RE, V30, P490, DOI 10.1177/1545968315604399; Yang M, 2011, J RECONSTR MICROSURG, V27, P451, DOI 10.1055/s-0031-1281526; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Yurie H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171448; Zhang H, 2009, MICROSURG, V29, P479, DOI 10.1002/micr.20644	47	6	6	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2020	15	6							e0234691	10.1371/journal.pone.0234691	http://dx.doi.org/10.1371/journal.pone.0234691			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB7DG	32555658	Green Published, gold			2023-01-03	WOS:000542759600045
J	Carlin, E; Spry, E; Atkinson, D; Marley, JV				Carlin, Emma; Spry, Erica; Atkinson, David; Marley, Julia V.			Why validation is not enough: Setting the scene for the implementation of the Kimberley Mum's Mood Scale	PLOS ONE			English	Article							PRIMARY-HEALTH-CARE; DEPRESSION SCREENING TOOL; MENTAL-HEALTH; PERINATAL DEPRESSION; POSTNATAL DEPRESSION; INDIGENOUS WOMEN; RISK; SERVICES; ACCEPTABILITY; COMMUNICATION	Background The two part Kimberley Mum's Mood Scale (KMMS) has been developed and validated as a culturally appropriate perinatal depression and anxiety screening tool for Aboriginal women living in the sparsely populated Kimberley region of North West Australia. As part of implementation aspects of user acceptability were explored to improve clinical utilisation of the KMMS. Methods Eighteen health professionals involved in perinatal care participated in an online survey or a qualitative semi-structured interview. Ten Aboriginal women (who held administrative, professional or executive roles) were subsequently interviewed in depth to further explore aspects of KMMS user acceptability. Results Many of the health professionals were not using the second part of the KMMS (the psychosocial discussion tool). Time constraints and a perception that the KMMS is only appropriate for women with literacy issues were identified by health professionals as significant barriers to KMMS uptake. In contrast the Aboriginal women interviewed considered the KMMS to be important for literate Aboriginal women and placed high value on having the time and space to 'yarn' with health professionals about issues that are important to them. Conclusion Implementing the KMMS across the Kimberley region requires health professionals to be trained. It also requires strategic engagement with health services to ensure health professionals and mangers understand the rationale and significance of the KMMS and are engaged in its successful implementation.	[Carlin, Emma; Atkinson, David; Marley, Julia V.] Univ Western Australia, Rural Clin Sch Western Australia, Broome, WA, Australia; [Carlin, Emma; Spry, Erica; Marley, Julia V.] Kimberley Aboriginal Med Serv, Broome, WA, Australia	University of Western Australia	Carlin, E (corresponding author), Univ Western Australia, Rural Clin Sch Western Australia, Broome, WA, Australia.; Carlin, E (corresponding author), Kimberley Aboriginal Med Serv, Broome, WA, Australia.	emma.carlin@rcswa.edu.au	Marley, Julia V/A-9515-2009	Marley, Julia V/0000-0003-1014-4860; Carlin, Emma/0000-0002-1003-1981; Spry, Erica/0000-0001-7775-3615; Atkinson, David/0000-0001-7069-5555	Australian Government National Health and Medical Research Council [APP1132659]	Australian Government National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia)	D.A APP1132659 This research is funded through an Australian Government National Health and Medical Research Council Partnership Grant. https://www.nhmrc.gov.au/funding/find-funding/partnership-projects The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armstrong EM, 2017, INT J SPEECH-LANG PA, V19, P297, DOI 10.1080/17549507.2017.1290136; Atkinson J., 2002, TRAUMA TRAILS RECREA; Austin M.P., 2017, MENTAL HLTH CARE PER; Austin MP, 2003, ACTA PSYCHIAT SCAND, V107, P10, DOI 10.1034/j.1600-0447.2003.02024.x; Australian Government, 2008, NAT PER DEPR IN 2008; Australian Institute of Health and Welfare, 2019, HLTH WELF AUSTR AB T; Australian Institute of Health and Welfare, 2012, EXP PER DEPR DAT 201; BESSARAB D, 2010, INT J CRIT INDIG STU, V3, P13; Bowen A, 2014, TRANSCULT PSYCHIATRY, V51, P93, DOI 10.1177/1363461513501712; Bradshaw C, 2017, GLOB QUALIT NURS RES, V4, DOI 10.1177/2333393617742282; Buist AE, 2005, BEYONDBLUE NATL POST; Carlin E, 2019, INT J ENV RES PUB HE, V16, DOI 10.3390/ijerph16214253; Chambers DA, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-117; Chan AW, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-022273; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Damschroder LJ, 2009, IMPLEMENT SCI, V4, DOI 10.1186/1748-5908-4-50; Davy C, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0450-5; Dingwall KM, 2014, BMC PSYCHOL, V2, DOI [10.1186/2050-7283-2-13, DOI 10.1186/2050-7283-2-13]; Dudgeon P, 2009, MED J AUSTRALIA, V190, P546, DOI 10.5694/j.1326-5377.2009.tb02557.x; El-Den S, 2015, J AFFECT DISORDERS, V188, P284, DOI 10.1016/j.jad.2015.06.015; Esler D, 2008, AUST NZ J PUBL HEAL, V32, P317, DOI 10.1111/j.1753-6405.2008.00247.x; Esler DM, 2007, AUST NZ J PUBL HEAL, V31, P259, DOI 10.1111/j.1467-842X.2007.00058.x; Freeman T, 2014, AUST NZ J PUBL HEAL, V38, P355, DOI 10.1111/1753-6405.12231; Garvey G, 2015, CANCER-AM CANCER SOC, V121, P3018, DOI 10.1002/cncr.29433; Gausia K, 2015, GEN HOSP PSYCHIAT, V37, P335, DOI 10.1016/j.genhosppsych.2015.04.005; Gausia K, 2013, CONTEMP NURSE, V46, P73, DOI 10.5172/conu.2013.46.1.73; Gomersall JS, 2017, AUST NZ J PUBL HEAL, V41, P417, DOI 10.1111/1753-6405.12687; Government A, 2013, IMPL PLAN NAT AB TOR; Gracey M, 2009, LANCET, V374, P65, DOI 10.1016/S0140-6736(09)60914-4; Haswell MR, 2010, AUST NZ J PSYCHIAT, V44, P791, DOI 10.3109/00048674.2010.482919; Hay DF, 2008, J CHILD PSYCHOL PSYC, V49, P1079, DOI 10.1111/j.1469-7610.2008.01959.x; Huizink AC, 2004, PSYCHOL BULL, V130, P115, DOI 10.1037/0033-2909.130.1.115; Janca A, 2017, AUSTRALAS PSYCHIATRY, V25, P288, DOI 10.1177/1039856217700806; Janca A, 2015, AUSTRALAS PSYCHIATRY, V23, P287, DOI 10.1177/1039856215584514; Jongen C, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-251; Kimberley Aboriginal Health Planning Forum, 2019, PER DEPR ANX PROT; Kotz J, 2016, CONTEMP NURSE, V52, P42, DOI 10.1080/10376178.2016.1198710; Le Grande M, 2017, SOC SCI MED, V187, P164, DOI 10.1016/j.socscimed.2017.06.046; Lin I, 2016, AUST J PRIM HEALTH, V22, P377, DOI 10.1071/PY16051; LoGiudice D, 2006, INT PSYCHOGERIATR, V18, P269, DOI 10.1017/S1041610205002681; Marley JV, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168969; McHugh C, 2017, AUSTRALAS PSYCHIATRY, V25, P35, DOI 10.1177/1039856216671682; NAACHO, 2019, DEF HLTH NAT AB CONT; NSW Department of Health, SAFE START GUID IMPR, P61; Parahoo K., 2014, NURSING RES PRINCIPL; Pinnock H, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6795; Prandl KJ, 2012, ARCH WOMEN MENT HLTH, V15, P149, DOI 10.1007/s00737-012-0276-0; Schlesinger CM, 2007, DRUG ALCOHOL REV, V26, P109, DOI 10.1080/09595230601146611; Sekhon M, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2031-8; Srivastava P., 2009, INT J QUAL METH, V8, P76, DOI [10.1177/ 160940690900800107, DOI 10.1177/160940690900800107]; Stein A, 2014, LANCET, V384, P1800, DOI 10.1016/S0140-6736(14)61277-0; Stephens A, 2013, J TROP PSYCHOL, V3, DOI 10.1017/jtp.2013.2; Thewes B, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0380-2; Thomas A, 2010, AUST NZ J PSYCHIAT, V44, P40, DOI 10.3109/00048670903393589; Vicray D., 2004, AUSTR J ADVANCEMENT, V3, P103, DOI DOI 10.5172/JAMH.3.3.103; Webb L, 2012, J PSYCHIATR MENT HLT, V19, P132, DOI 10.1111/j.1365-2850.2011.01762.x; Willis DG, 2016, WESTERN J NURS RES, V38, P1185, DOI 10.1177/0193945916645499	57	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2020	15	6							e0234346	10.1371/journal.pone.0234346	http://dx.doi.org/10.1371/journal.pone.0234346			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MA6QP	32530934	Green Published, gold, Green Submitted			2023-01-03	WOS:000542037200045
J	Kerrigan, D; Karver, TS; Muraleetharan, O; Savage, V; Mbwambo, J; Donastorg, Y; Likindikoki, S; Perez, M; Gomez, H; Mantsios, A; Murray, M; Beckham, SW; Davis, W; Galai, N; Barrington, C				Kerrigan, Deanna; Karver, Tahilin Sanchez; Muraleetharan, Ohvia; Savage, Virginia; Mbwambo, Jessie; Donastorg, Yeycy; Likindikoki, Samuel; Perez, Martha; Gomez, Hoisex; Mantsios, Andrea; Murray, Miranda; Beckham, S. Wilson; Davis, Wendy; Galai, Noya; Barrington, Clare			"A dream come true": Perspectives on long-acting injectable antiretroviral therapy among female sex workers living with HIV from the Dominican Republic and Tanzania	PLOS ONE			English	Article							PREVENTION; CARE; INFECTION; ADHERENCE; STIGMA; CABOTEGRAVIR; EXPERIENCES; ENGAGEMENT; HIV/AIDS; BARRIERS	Background Long-acting injectable antiretroviral therapy (LA ART) was found to be non-inferior to daily oral ART in Phase 3 clinical trials. LA ART may offer an important alternative for people living with HIV with challenges adhering to daily oral ART or preferences for non-pill-based regimens. Methods Using a mixed methods approach integrating survey, in-depth interview and biological data from female sex workers (FSW) living with HIV in Tanzania (N = 208) and the Dominican Republic (DR) (N = 201), we assessed factors associated with the potential likelihood of LA ART use if it were available. We conducted multivariate logistic regression and thematic content analysis. Results Likelihood of LA ART use was high with 84.92% of FSW from the DR and 92.27% of FSW from Tanzania reporting they would be "likely" or "very likely" to use LA ART if available (p = 0.02). In Tanzania better HIV-related patient-provider communication (AOR 4.58; 95% CI 1.90-11.05) and quality of HIV clinical care (AOR 3.68; 95% CI 1.05-12.86) were positively associated with the high likelihood of LA ART use. In the DR, easier clinic access was associated with a higher likelihood of LA ART use (AOR 3.04; 95% CI 1.41-6.56), as was greater monthly income from sex work (AOR 2.37; 95% CI 1.27-4.41). In both settings, years on ART was significantly associated with a strong likelihood of LA ART use (TZ: AOR 1.16 per year; 95% CI 1.00-1.34/DR: AOR 1.07 per year; 95% CI 1.00-1.14). Qualitative findings underscored enthusiasm for LA ART and reinforced its potential to address sex work-specific barriers to daily oral ART adherence including work-related schedules and substance use. Conclusions We found a high likelihood of LA ART use if available among FSW in two diverse settings and documented barriers to future uptake. Community-driven approaches which include tailored health education and improved patient-provider communication and quality of care, as well as strategies to facilitate appointment adherence are needed to optimize LA ART use among FSW.	[Kerrigan, Deanna; Davis, Wendy] Amer Univ, Dept Sociol, Washington, DC 20016 USA; [Karver, Tahilin Sanchez; Beckham, S. Wilson; Galai, Noya] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Behav & Soc, Baltimore, MD USA; [Muraleetharan, Ohvia] Yale Univ, Dept Hlth Policy, New Haven, CT USA; [Savage, Virginia; Barrington, Clare] Univ N Carolina, Dept Hlth Behav, Chapel Hill, NC 27515 USA; [Mbwambo, Jessie; Likindikoki, Samuel] Muhimbili Univ Hlth & Allied Sci, Dept Psychiat, Dar Es Salaam, Tanzania; [Donastorg, Yeycy; Perez, Martha; Gomez, Hoisex] Inst Dermatol & Cirugia Piel, HIV Vaccine Trials Res Unit, Santo Domingo, Dominican Rep; [Mantsios, Andrea] Publ Hlth Innovat & Act, New York, NY USA; [Murray, Miranda] Hlth Analyt & Outcomes, London, England; [Galai, Noya] Univ Haifa, Dept Stat, Har Hakarmel, Israel	American University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Yale University; University of North Carolina; University of North Carolina Chapel Hill; Muhimbili University of Health & Allied Sciences; University of Haifa	Kerrigan, D (corresponding author), Amer Univ, Dept Sociol, Washington, DC 20016 USA.	kerrigan@american.edu	Beckham, S Wilson/AAD-1992-2021; Barrington, Clare/AAM-4909-2021; Galai, Noya/HII-8086-2022	Beckham, S Wilson/0000-0002-9694-3091; Savage, Virginia/0000-0002-4482-1383; Karver, Tahilin Sanchez/0000-0001-7362-9377	National Institute of Mental Health [R01MH110158]; ViiV Healthcare	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); ViiV Healthcare	The funders of this work include the National Institute of Mental Health (R01MH110158) and ViiV Healthcare. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Andrews CD, 2015, CURR OPIN HIV AIDS, V10, P258, DOI 10.1097/COH.0000000000000161; Anema Aranka, 2009, Curr HIV/AIDS Rep, V6, P224, DOI 10.1007/s11904-009-0030-z; [Anonymous], 2012, DIABETES CARE S1, V35, pS12; Berger BE, 2001, RES NURS HEALTH, V24, P518, DOI 10.1002/nur.10011; Bland S., 2018, LONG ACTING HIV TREA; Chakrapani V, 2009, AIDS PATIENT CARE ST, V23, P973, DOI 10.1089/apc.2009.0035; Chawla A, 2018, INFECT DIS THER, V7, P183, DOI 10.1007/s40121-018-0201-6; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; CONAVIHSIDA, 2 ENC VIG COMP CON V; CPd SIDA, 2008, 1 ENC VIG COMP VINC; Creswell J. W., 2010, DESIGNING CONDUCTING; Dandachi D, 2021, AIDS CARE, V33, P801, DOI 10.1080/09540121.2020.1764906; Decker MR, 2010, SEX TRANSM INFECT, V86, P236, DOI 10.1136/sti.2009.037846; Demena BA, 2020, AIDS PATIENT CARE ST, V34, P59, DOI 10.1089/apc.2019.0181; Donastorg Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088157; Duff P, 2016, JAIDS-J ACQ IMM DEF, V73, P83, DOI 10.1097/QAI.0000000000001022; Fehringer J, 2006, AIDS PATIENT CARE ST, V20, P637, DOI 10.1089/apc.2006.20.637; Fernandez C, 2019, HIV AIDS-RES PALLIAT, V11, P179, DOI 10.2147/HIV.S184642; Fletcher CV, 2005, JAIDS-J ACQ IMM DEF, V40, P301, DOI 10.1097/01.qai.0000180078.53321.6a; Galassi J. P., 1992, PSYCHOL ASSESSMENT, V4, P346, DOI DOI 10.1037/1040-3590.4.3.346; Gardner EM, 2011, CLIN INFECT DIS, V52, P793, DOI 10.1093/cid/ciq243; Goldenberg SM, 2014, J URBAN HEALTH, V91, P736, DOI 10.1007/s11524-014-9888-1; Halperin DT, 2009, JAIDS-J ACQ IMM DEF, V51, pS52, DOI 10.1097/QAI.0b013e3181a267e4; Hatzenbuehler ML, 2016, AM PSYCHOL, V71, P742, DOI 10.1037/amp0000068; Havlir D, 2015, CURR OPIN HIV AIDS, V10, P282, DOI 10.1097/COH.0000000000000158; Hirsch JS, 2007, AM J PUBLIC HEALTH, V97, P986, DOI 10.2105/AJPH.2006.088492; Kerrigan D, 2020, CURR HIV-AIDS REP, V17, P88, DOI 10.1007/s11904-020-00485-3; Kerrigan D, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190487; Kerrigan D, 2017, JAIDS-J ACQ IMM DEF, V74, pS60, DOI 10.1097/qai.0000000000001203; Lafort Y, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3305-5; Lancaster KE, 2016, AJAR-AFR J AIDS RES, V15, P377, DOI 10.2989/16085906.2016.1255652; Lancaster KE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147662; Layer EH, 2014, AIDS PATIENT CARE ST, V28, P483, DOI 10.1089/apc.2014.0077; Lieblich A., 1998, NARRATIVE RES READIN, P1; Mantsios A, 2019, IDWEEK, P2; Mantsios A, 2020, AIDS BEHAV, V24, P3473, DOI 10.1007/s10461-020-02918-x; Margolis DA, 2016, C RETR OPP INF CROI; Margolis DA, 2016, 21 INT AIDS C AIDS 2; Margolis DA, 2017, LANCET, V390, P1499, DOI 10.1016/S0140-6736(17)31917-7; Margolis DA, 2015, CURR OPIN HIV AIDS, V10, P246, DOI 10.1097/COH.0000000000000169; Mountain E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105645; Mountain E, 2014, EXPERT REV ANTI-INFE, V12, P1203, DOI 10.1586/14787210.2014.948422; Mtetwa S, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-698; Murray M, 2019, 10 IAS C HIV SCI JUL; Murray M, 2019, HIV RES CLIN PRACT, V20, P111, DOI 10.1080/25787489.2019.1661696; Nyato D, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219032; Pantelic M, 2019, BMC INFECT DIS, V19, DOI 10.1186/s12879-019-3704-1; Rusconi S, 2017, NEW MICROBIOL, V40, P75; Sandelowski M, 1991, Image J Nurs Sch, V23, P161, DOI 10.1111/j.1547-5069.1991.tb00662.x; Scorgie F, 2011, AFRICAN SEX WORKER A; Simoni JM, 2020, AIDS BEHAV, V24, P1226, DOI 10.1007/s10461-019-02701-7; Simoni JM, 2019, AIDS PATIENT CARE ST, V33, P104, DOI 10.1089/apc.2018.0198; Singer AW, 2015, AIDS BEHAV, V19, P1510, DOI 10.1007/s10461-014-0873-1; Spreen WR, 2013, CURR OPIN HIV AIDS, V8, P565, DOI 10.1097/COH.0000000000000002; Straus MA, 1996, J FAM ISSUES, V17, P283, DOI 10.1177/019251396017003001; TACAIDS, 2018, TANZ HIV IMP SURV TH; Tuller DM, 2010, AIDS BEHAV, V14, P778, DOI 10.1007/s10461-009-9533-2; UNAIDS, 2013, EP FACT SHEET HIV AI; Williams J, 2013, NANOMEDICINE-UK, V8, P1807, DOI 10.2217/nnm.12.214; Young S, 2014, AIDS BEHAV, V18, pS505, DOI 10.1007/s10461-013-0547-4; Zelaya CE, 2012, AIDS CARE, V24, P846, DOI 10.1080/09540121.2011.647674	61	18	18	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 12	2020	15	6							e0234666	10.1371/journal.pone.0234666	http://dx.doi.org/10.1371/journal.pone.0234666			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MA6QP	32530939	gold, Green Published			2023-01-03	WOS:000542037200046
J	Ghrayeb, H; Elias, M; Nashashibi, J; Youssef, A; Manal, M; Mahagna, L; Refaat, M; Schwartz, N; Elias, A				Ghrayeb, Hanin; Elias, Mazen; Nashashibi, Jeries; Youssef, Awni; Manal, Mari; Mahagna, Liala; Refaat, Masalha; Schwartz, Naama; Elias, Adi			Appetite and ghrelin levels in iron deficiency anemia and the effect of parenteral iron therapy: A longitudinal study	PLOS ONE			English	Article							NUTRITIONAL ASSESSMENT QUESTIONNAIRE; GASTRIC-ACID; SCREENING TOOL; LEPTIN; CHILDREN; RESISTANCE; INSULIN; SERUM; MALNUTRITION; GROWTH	Background Iron deficiency anemia (IDA) is associated with decreased appetite. The ghrelin hormone is one of the major regulators of appetite. Objectives To evaluate appetite and ghrelin levels in patients with IDA, and to investigate the change in appetite and ghrelin following intravenous iron therapy. Methods A total of 56 IDA patients and 51 controls were included in the study. Both appetite and ghrelin were assessed at baseline and following intravenous iron therapy. These were assessed at corresponding time intervals in the control group. Appetite was assessed by the SNAQ score (Simplified Nutritional Appetite Questionnaire) and fasting ghrelin levels were assessed by acylated ghrelin (AG), unacylated ghrelin (UAG) and their respective ratio AG/UAG. Results IDA patients had significantly lower SNAQ scores, yet higher AG levels and higher AG/UAG ratios compared to healthy controls; the mean SNAQ scores were 12.56 +/- 3.45 and 16.1 +/- 2, respectively (P<0.01); the median AG levels were 57.5 pg/ml and 43 pg/ml respectively (P = 0.007); and the median AG/UAG ratios were 0.48 and 0.25 respectively (P = 0.04). On multivariate linear regression analysis, IDA remained independently associated with decreased SNAQ score (beta = -0.524, P<0.001) and increased acylated ghrelin (beta = 0.289, P = 0.013). After IDA was treated, SNAQ scores increased significantly by a mean of 2 points. AG and AG/UAG ratios decreased significantly by a mean of -18.44 pg/ml and -0.2 respectively. The control group showed no significant change in SNAQ scores or ghrelin at corresponding time intervals. Conclusions IDA patients have a reduced appetite and paradoxically elevated ghrelin hormone activity compared to healthy controls. Treating IDA enhances appetite and lowers ghrelin levels. Future studies are needed to explore the mechanism of this paradoxical ghrelin activity.	[Ghrayeb, Hanin; Elias, Mazen] Emek Med Ctr, Dept Internal Med c, Afula, Israel; [Ghrayeb, Hanin; Elias, Mazen] Technion Israel Inst Technol, Rapaport Fac Med, Haifa, Israel; [Nashashibi, Jeries] Rambam Hlth Care Campus, Dept Internal Med D, Haifa, Israel; [Youssef, Awni] Bar Ilan Univ, Azrieli Fac Med, Fac Med, Safed, Israel; [Manal, Mari] Nazareth Tower Out Patients Clin Ambulatory, Clalit, Nazareth, Israel; [Mahagna, Liala; Refaat, Masalha] HaEmek Med Ctr, Endocrine Lab, Afula, Israel; [Schwartz, Naama] HaEmek Med Ctr, Clin Res Unit, Afula, Israel; [Elias, Adi] Rambam Hlth Care Campus, Dept Internal Med B, Haifa, Israel	Emek Medical Center; Technion Israel Institute of Technology; Rambam Health Care Campus; Bar Ilan University; Emek Medical Center; Emek Medical Center; Rambam Health Care Campus	Elias, A (corresponding author), Rambam Hlth Care Campus, Dept Internal Med B, Haifa, Israel.	adi.elias@gmail.com		elias, adi/0000-0002-2634-8086				Akarsu S, 2007, J PEDIAT HEMATOL ONC, V29, P384, DOI 10.1097/MPH.0b013e3180645170; Al Massadi O, 2011, PEPTIDES, V32, P2301, DOI 10.1016/j.peptides.2011.08.020; Astrup A, 2019, INT J OBESITY, V43, P219, DOI 10.1038/s41366-018-0143-9; Atalayer D, 2013, PROG NEURO-PSYCHOPH, V40, P70, DOI 10.1016/j.pnpbp.2012.08.011; Auerbach M, 2020, UPTODATE; Auerbach M, 2016, AM J HEMATOL, V91, P31, DOI 10.1002/ajh.24201; Auerbach M, 2010, HEMATOL-AM SOC HEMAT, P338, DOI 10.1182/asheducation-2010.1.338; Barazzoni R, 2007, J CLIN ENDOCR METAB, V92, P3935, DOI 10.1210/jc.2006-2527; Briggs DI, 2010, ENDOCRINOLOGY, V151, P4745, DOI 10.1210/en.2010-0556; Camaschella C, 2019, BLOOD, V133, P30, DOI 10.1182/blood-2018-05-815944; Campillos M, 2010, NUCLEIC ACIDS RES, V38, pW360, DOI 10.1093/nar/gkq371; Cui HX, 2017, NAT REV ENDOCRINOL, V13, P338, DOI 10.1038/nrendo.2016.222; Delhanty PJ, 2013, ENDOCR DEV, V25, P112, DOI 10.1159/000346059; Delhanty PJD, 2012, EUR J ENDOCRINOL, V167, P601, DOI 10.1530/EJE-12-0456; Dogan A, 2013, J CLIN LAB ANAL, V27, P81, DOI 10.1002/jcla.21566; Gao Y, 2015, J CLIN INVEST, V125, P3681, DOI 10.1172/JCI81860; Garcia JM, 2005, J CLIN ENDOCR METAB, V90, P2920, DOI 10.1210/jc.2004-1788; Germain N, 2010, J CLIN ENDOCR METAB, V95, P3057, DOI 10.1210/jc.2009-2196; Isguven P, 2007, ENDOCR J, V54, P985, DOI 10.1507/endocrj.K07-031; Kassebaum NJ, 2014, BLOOD, V123, P615, DOI 10.1182/blood-2013-06-508325; Korbonits M, 2004, FRONT NEUROENDOCRIN, V25, P27, DOI 10.1016/j.yfrne.2004.03.002; Kruizenga HM, 2005, CLIN NUTR, V24, P75, DOI 10.1016/j.clnu.2004.07.015; Kuppens RJ, 2015, ENDOCRINE, V50, P633, DOI 10.1007/s12020-015-0614-x; Lam JR, 2017, GASTROENTEROLOGY, V152, P821, DOI 10.1053/j.gastro.2016.11.023; LAWLESS JW, 1994, J NUTR, V124, P645, DOI 10.1093/jn/124.5.645; Lockie SH, 2015, PSYCHONEUROENDOCRINO, V62, P114, DOI 10.1016/j.psyneuen.2015.08.004; Luo QQ, 2018, ANN NUTR METAB, V72, P37, DOI 10.1159/000484698; Masuda Y, 2000, BIOCHEM BIOPH RES CO, V276, P905, DOI 10.1006/bbrc.2000.3568; McLean E, 2009, PUBLIC HEALTH NUTR, V12, P444, DOI 10.1017/S1368980008002401; Milman N, 2011, ANN HEMATOL, V90, P1247, DOI 10.1007/s00277-011-1279-z; Nakai Y, 2003, EUR J ENDOCRINOL, V149, pR1, DOI 10.1530/eje.0.149R001; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Otto B, 2001, EUR J ENDOCRINOL, V145, pR5; Pan WW, 2018, NAT REV NEUROSCI, V19, P95, DOI 10.1038/nrn.2017.168; Rabito EI, 2017, NUTR CLIN PRACT, V32, P526, DOI 10.1177/0884533617692527; Shimizu Y, 2003, CLIN CANCER RES, V9, P774; SKIKNE BS, 1981, GASTROENTEROLOGY, V81, P1068; Stoltzfus RJ, 2004, J NUTR, V134, P348, DOI 10.1093/jn/134.2.348; Tanaka M, 2003, PSYCHONEUROENDOCRINO, V28, P829, DOI 10.1016/S0306-4530(02)00066-5; Terawaki K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173113; Topaloglu AK, 2001, NUTRITION, V17, P657, DOI 10.1016/S0899-9007(01)00570-6; van der Lely AJ, 2004, ENDOCR REV, V25, P426, DOI 10.1210/er.2002-0029; Wilasco MIA, 2012, REGUL PEPTIDES, V173, P21, DOI 10.1016/j.regpep.2011.08.013; Wilson MMG, 2005, AM J CLIN NUTR, V82, P1074, DOI 10.1093/ajcn/82.5.1074; Wynne K, 2005, J ENDOCRINOL, V184, P291, DOI 10.1677/joe.1.05866; Yakabi K, 2008, WORLD J GASTROENTERO, V14, P6334, DOI 10.3748/wjg.14.6334; Yang J, 2008, CELL, V132, P387, DOI 10.1016/j.cell.2008.01.017	47	2	2	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 4	2020	15	6							e0234209	10.1371/journal.pone.0234209	http://dx.doi.org/10.1371/journal.pone.0234209			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MA6PX	32497136	Green Published, gold			2023-01-03	WOS:000542035200017
J	Negishi, M; Kobayashi, K; Sakuma, T; Sueyoshi, T				Negishi, Masahiko; Kobayashi, Kaoru; Sakuma, Tsutomu; Sueyoshi, Tatsuya			Nuclear receptor phosphorylation in xenobiotic signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review						Nuclear receptors; steroid hormone receptors; CAR; PXR; drug metabolism; phenobarbital; induction; phosphorylation; cell signaling; gene regulation; nuclear receptor; estrogen; phosphorylation; drug metabolism; cell signaling	CONSTITUTIVE ANDROSTANE RECEPTOR; PREGNANE X RECEPTOR; EPIDERMAL-GROWTH-FACTOR; CYP2B2 GENE-EXPRESSION; PROTEIN-KINASE-C; ACTIVE/ANDROSTANE RECEPTOR; BINDING DOMAIN; HUMAN HEPATOCYTES; CROSS-TALK; CAR	Nuclear pregnane X receptor (PXR, NR1I2) and constitutive active/androstane receptor (CAR, NR1I3) are nuclear receptors characterized in 1998 by their capability to respond to xenobiotics and activate cytochrome P450 (CYP) genes. An anti-epileptic drug, phenobarbital (PB), activates CAR and its target CYP2B genes, whereas PXR is activated by drugs such as rifampicin and statins for the CYP3A genes. Inevitably, both nuclear receptors have been investigated as ligand-activated nuclear receptors by identifying and characterizing xenobiotics and therapeutics that directly bind CAR and/or PXR to activate them. However, PB, which does not bind CAR directly, presented an alternative research avenue for an indirect ligand-mediated nuclear receptor activation mechanism: phosphorylation-mediated signal regulation. This review summarizes phosphorylation-based mechanisms utilized by xenobiotics to elicit cell signaling. First, the review presents how PB activates CAR (and other nuclear receptors) through a conserved phosphorylation motif located between two zinc fingers within its DNA-binding domain. PB-regulated phosphorylation at this motif enables nuclear receptors to form communication networks, integrating their functions. Next, the review discusses xenobiotic-induced PXR activation in the absence of the conserved DNA-binding domain phosphorylation motif. In this case, phosphorylation occurs at a motif located within the ligand-binding domain to transduce cell signaling that regulates hepatic energy metabolism. Finally, the review delves into the implications of xenobiotic-induced signaling through phosphorylation in disease development and progression.	[Negishi, Masahiko; Sueyoshi, Tatsuya] NIEHS, Pharmacogenet Sect, Reprod & Dev Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA; [Kobayashi, Kaoru] Meiji Pharmaceut Univ, Dept Biopharmaceut, Tokyo, Japan; [Sakuma, Tsutomu] Ohu Univ, Sch Pharmaceut Sci, Koriyama, Fukushima, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Meiji Pharmaceutical University	Negishi, M (corresponding author), NIEHS, Pharmacogenet Sect, Reprod & Dev Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov			Intramural Research Program of NIEHS, National Institutes of Health [Z01ES1005-01]	Intramural Research Program of NIEHS, National Institutes of Health	This work was supported by the Intramural Research Program of NIEHS, National Institutes of Health, Grant Z01ES1005-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Abe T, 2019, J PHARMACOL EXP THER, V371, P590, DOI 10.1124/jpet.119.258632; Abe T, 2018, TOXICOL SCI, V165, P408, DOI 10.1093/toxsci/kfy149; Baskin-Bey ES, 2007, WORLD J GASTROENTERO, V13, P5635, DOI 10.3748/wjg.v13.i42.5635; Bathgate RAD, 2002, J BIOL CHEM, V277, P1148, DOI 10.1074/jbc.M107882200; Bauer D, 2004, MOL PHARMACOL, V65, P172, DOI 10.1124/mol.65.1.172; Becnel LB, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah6275; Bian YY, 2014, J PROTEOMICS, V96, P253, DOI 10.1016/j.jprot.2013.11.014; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Bulutoglu B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52174-w; Carazo A, 2015, TOXICOL LETT, V233, P68, DOI 10.1016/j.toxlet.2015.01.013; Casula M, 2017, NUTR METAB CARDIOVAS, V27, P396, DOI 10.1016/j.numecd.2017.03.001; Chen FM, 2019, J PROTEOME RES, V18, P239, DOI 10.1021/acs.jproteome.8b00566; Cheng J, 2010, J PHARMACOL EXP THER, V335, P32, DOI 10.1124/jpet.110.170225; Columbano A, 2005, HEPATOLOGY, V42, P1118, DOI 10.1002/hep.20883; CONNEY AH, 1959, NATURE, V184, P363, DOI 10.1038/184363a0; CONNEY AH, 1967, PHARMACOL REV, V19, P317; Cui JY, 2016, BBA-GENE REGUL MECH, V1859, P1198, DOI 10.1016/j.bbagrm.2016.04.010; de Boussac H, 2018, DRUG METAB DISPOS, V46, P223, DOI 10.1124/dmd.117.078683; Dong B, 2009, P NATL ACAD SCI USA, V106, P18831, DOI 10.1073/pnas.0909731106; Dong BN, 2009, HEPATOLOGY, V50, P622, DOI 10.1002/hep.23025; Fashe M, 2020, MOL PHARMACOL, V97, P191, DOI 10.1124/mol.119.118273; Fashe M, 2018, FEBS LETT, V592, P2760, DOI 10.1002/1873-3468.13199; Gao J, 2015, MOL ENDOCRINOL, V29, P1558, DOI 10.1210/me.2015-1145; Gao J, 2009, J BIOL CHEM, V284, P25984, DOI 10.1074/jbc.M109.016808; Gineste R, 2008, MOL ENDOCRINOL, V22, P2433, DOI 10.1210/me.2008-0092; Gotoh S, 2017, CELL SIGNAL, V40, P200, DOI 10.1016/j.cellsig.2017.09.003; Gotoh S, 2015, SCI REP-UK, V5, DOI 10.1038/srep14076; Gotoh S, 2014, J PHARMACOL EXP THER, V348, P131, DOI 10.1124/jpet.113.209379; Guengerich FP, 1998, MUTAT RES-FUND MOL M, V402, P121, DOI 10.1016/S0027-5107(97)00289-3; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Gwag T, 2019, J HEPATOL, V70, P930, DOI 10.1016/j.jhep.2018.12.038; Han YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358; Hardesty JE, 2018, TOXICOL SCI, V162, P622, DOI 10.1093/toxsci/kfy004; Hardesty JE, 2017, XENOBIOTICA, V47, P807, DOI 10.1080/00498254.2016.1217572; Hashiguchi T, 2016, MOL ENDOCRINOL, V30, P1070, DOI 10.1210/me.2016-1105; Hassani-Nezhad-Gashti F, 2018, BIOCHEM PHARMACOL, V148, P253, DOI 10.1016/j.bcp.2018.01.001; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Hori T, 2018, MOL CANCER RES, V16, P1309, DOI 10.1158/1541-7786.MCR-18-0118; Hori T, 2016, DRUG METAB DISPOS, V44, P871, DOI 10.1124/dmd.116.070235; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; Hudson GM, 2017, BRIT J PHARMACOL, V174, P1857, DOI 10.1111/bph.13787; Humerickhouse R, 2000, CANCER RES, V60, P1189; Ikeda K, 2000, CLIN CANCER RES, V6, P4409; Ingelman-Sundberg M, 2007, PHARMACOL THERAPEUT, V116, P496, DOI 10.1016/j.pharmthera.2007.09.004; Inoue K, 2008, J BIOL CHEM, V283, P10425, DOI 10.1074/jbc.M800729200; Jiang YM, 2019, HEPATOLOGY, V69, P343, DOI 10.1002/hep.30131; Kanno Yuichiro, 2004, Nucl Recept, V2, P6, DOI 10.1186/1478-1336-2-6; Kaur G, 2016, SCI REP-UK, V6, DOI 10.1038/srep32070; Kawamoto T, 1999, MOL CELL BIOL, V19, P6318; Kawamura A, 1999, BIOCHEM BIOPH RES CO, V264, P530, DOI 10.1006/bbrc.1999.1544; Kim B, 2013, J PROTEOME RES, V12, P1359, DOI 10.1021/pr301021p; Klaassen CD, 2010, PHARMACOL REV, V62, P1, DOI 10.1124/pr.109.002014; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Knebel C, 2019, ARCH TOXICOL, V93, P1311, DOI 10.1007/s00204-019-02445-2; Kodama S, 2004, MOL CELL BIOL, V24, P7931, DOI 10.1128/MCB.24.18.7931-7940.2004; Koike C, 2007, MOL PHARMACOL, V71, P1217, DOI 10.1124/mol.107.034538; Krishna SS, 2003, NUCLEIC ACIDS RES, V31, P532, DOI 10.1093/nar/gkg161; La Vecchia C, 2014, EUR J CANCER PREV, V23, P1, DOI 10.1097/CEJ.0b013e32836014c8; LAHTELA JT, 1985, DIABETES, V34, P911, DOI 10.2337/diabetes.34.9.911; Lee GH, 1998, CANCER RES, V58, P1665; Li LH, 2019, MOL PHARMACOL, V96, P345, DOI 10.1124/mol.119.116616; Li LH, 2015, MOL PHARMACOL, V87, P674, DOI 10.1124/mol.114.097287; Lichti-Kaiser K, 2009, J PHARMACOL EXP THER, V331, P65, DOI 10.1124/jpet.109.157180; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; Ling ZL, 2016, BIOCHEM PHARMACOL, V100, P98, DOI 10.1016/j.bcp.2015.11.023; Liu XY, 2020, ACTA PHARMACOL SIN, V41, P1366, DOI 10.1038/s41401-020-0389-3; Mackowiak B, 2018, DRUG METAB DISPOS, V46, P1361, DOI 10.1124/dmd.118.081042; Maglich JM, 2003, J BIOL CHEM, V278, P17277, DOI 10.1074/jbc.M300138200; Matalon O, 2016, SCIENCE, V354, P176, DOI 10.1126/science.aai8833; Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003; MEYER SA, 1989, CANCER RES, V49, P5907; Meyer SA, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004239; Mutoh S, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003705; Mutoh S, 2009, J BIOL CHEM, V284, P34785, DOI 10.1074/jbc.M109.048108; Nadal M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14388; Nakamura K, 2007, J BIOL CHEM, V282, P9768, DOI 10.1074/jbc.M610072200; Nakano M, 2018, EXPERT OPIN DRUG MET, V14, P493, DOI 10.1080/17425255.2018.1472237; Negishi M, 2017, DRUG METAB DISPOS, V45, P532, DOI 10.1124/dmd.116.074872; Niu B, 2018, NUCLEIC ACIDS RES, V46, P8385, DOI 10.1093/nar/gky692; Ochsner SA, 2016, MOL ENDOCRINOL, V30, P937, DOI 10.1210/me.2016-1095; Ohara A, 2017, TOXICOL RES-UK, V6, P795, DOI 10.1039/c7tx00163k; Ohno M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115663; OMURA T, 1962, J BIOL CHEM, V237, P1375; Osabe M, 2011, J BIOL CHEM, V286, P35763, DOI 10.1074/jbc.M111.284596; Pinne Marija, 2017, Drug Metab Lett, V11, P128, DOI 10.2174/1872312812666171207113639; Pinto N, 2011, CURR DRUG METAB, V12, P487, DOI 10.2174/138920011795495321; Pondugula SR, 2009, DRUG METAB DISPOS, V37, P719, DOI 10.1124/dmd.108.024695; Prantera C, 2006, ALIMENT PHARM THER, V23, P1117, DOI 10.1111/j.1365-2036.2006.02879.x; REMMER H, 1963, SCIENCE, V142, P1657, DOI 10.1126/science.142.3600.1657; Rivory LP, 1996, BIOCHEM PHARMACOL, V52, P1103, DOI 10.1016/0006-2952(96)00457-1; Rosenfeld JM, 2003, MOL ENDOCRINOL, V17, P1268, DOI 10.1210/me.2002-0421; Rysa J, 2013, CLIN PHARMACOL THER, V93, P556, DOI 10.1038/clpt.2013.48; SATOH T, 1994, BIOL PHARM BULL, V17, P662; SCHENKMAN JB, 1991, METHOD ENZYMOL, V206, P325; SCHWABE JWR, 1993, STRUCTURE, V1, P187, DOI 10.1016/0969-2126(93)90020-H; Sehnal D., 2018, WORKSH MOL GRAPH VIS; Shan L, 2004, MOL CELL, V16, P907, DOI 10.1016/S1097-2765(04)00728-2; SHIMADA T, 1989, CANCER RES, V49, P3218; SHIMADA T, 1989, P NATL ACAD SCI USA, V86, P462, DOI 10.1073/pnas.86.2.462; Shindo S, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00578-x; Shindo S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084462; Shizu R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53139-9; Shizu R, 2018, J BIOL CHEM, V293, P333, DOI 10.1074/jbc.M117.806604; Shizu R, 2017, MOL CELL BIOL, V37, DOI 10.1128/MCB.00649-16; Sivertsson L, 2013, MOL PHARMACOL, V83, P659, DOI 10.1124/mol.112.082305; SONG WC, 1995, ENDOCRINOLOGY, V136, P2477, DOI 10.1210/en.136.6.2477; Srinivas H, 2006, BIOCHEM J, V395, P653, DOI 10.1042/BJ20051794; Studer RA, 2016, SCIENCE, V354, P229, DOI 10.1126/science.aaf2144; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sueyoshi T, 2019, LAB INVEST, V99, P1470, DOI 10.1038/s41374-019-0266-1; Suino K, 2004, MOL CELL, V16, P893, DOI 10.1016/S1097-2765(04)00727-0; Sukhija R, 2009, J INVEST MED, V57, P495, DOI 10.2310/JIM.0b013e318197ec8b; Sun K, 2007, MOL ENDOCRINOL, V21, P1297, DOI 10.1210/me.2006-0300; Takizawa D, 2011, CARCINOGENESIS, V32, P576, DOI 10.1093/carcin/bgq277; Tian JM, 2018, ISCIENCE, V9, P209, DOI 10.1016/j.isci.2018.10.018; Tojima H, 2012, TOXICOL LETT, V212, P288, DOI 10.1016/j.toxlet.2012.06.001; Trevino LS, 2013, TRENDS ENDOCRIN MET, V24, P515, DOI 10.1016/j.tem.2013.05.008; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; Uehara D, 2019, DIGEST LIVER DIS, V51, P226, DOI 10.1016/j.dld.2018.10.008; Wada T, 2009, TRENDS ENDOCRIN MET, V20, P273, DOI 10.1016/j.tem.2009.03.003; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Woodcroft KJ, 1997, CHEM-BIOL INTERACT, V107, P75, DOI 10.1016/S0009-2797(97)00075-6; Xu RX, 2004, MOL CELL, V16, P919, DOI 10.1016/j.molcel.2004.11.042; Yamada T, 2014, TOXICOL SCI, V142, P137, DOI 10.1093/toxsci/kfu173; Yamamoto Y, 2004, CANCER RES, V64, P7197, DOI 10.1158/0008-5472.CAN-04-1459; Yamamoto Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010121; Yamazaki Y, 2007, GUT, V56, P565, DOI 10.1136/gut.2006.093260; Yang H, 2014, MOL PHARMACOL, V85, P249, DOI 10.1124/mol.113.089763; Yasiry Z, 2012, EPILEPSIA, V53, P26, DOI 10.1111/epi.12026; Yasujima T, 2016, J PHARMACOL EXP THER, V357, P367, DOI 10.1124/jpet.116.232140; Yi M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61767-9; Yokobori K., 2020, J ENDOCR SOC, V4, pSUN, DOI 10.1210/jendso/bvaa046.2037; Yokobori K, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200498; Yokobori K, 2019, BIOCHEM PHARMACOL, V168, P26, DOI 10.1016/j.bcp.2019.06.011; Yoshida Y, 1996, BIOCHEM BIOPH RES CO, V229, P182, DOI 10.1006/bbrc.1996.1777; Zhou C, 2006, J CLIN INVEST, V116, P2280, DOI 10.1172/JCI26283	137	23	23	4	9	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 6	2020	295	45					15210	15225		10.1074/jbc.REV120.007933	http://dx.doi.org/10.1074/jbc.REV120.007933			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	OU9JM	32788213	Green Published, hybrid			2023-01-03	WOS:000591839400006
J	Wang, Q; Banerjee, S; So, C; Qiu, CT; Lam, HIC; Tse, D; Volgyi, B; Pan, F				Wang, Qin; Banerjee, Seema; So, Chunghim; Qiu, Chunting; Lam, Hang-I Christie; Tse, Dennis; Volgyi, Bela; Pan, Feng			Unmasking inhibition prolongs neuronal function in retinal degeneration mouse model	FASEB JOURNAL			English	Article						ganglion cell; inhibition; neurodegenerative disease; retina; vision	GANGLION-CELL SUBTYPES; RETINITIS-PIGMENTOSA; BIPOLAR CELLS; GAP-JUNCTIONS; GLYCINE RECEPTORS; HORIZONTAL CELLS; BETA-SUBUNIT; ROD; ORGANIZATION; SENSITIVITY	All neurodegenerative diseases involve a relatively long period of timeframe from the onset of the disease to complete loss of functions. Extending this timeframe, even at a reduced level of function, would improve the quality of life of patients with these devastating diseases. The retina, as the part of the central nervous system and a frequent site of many distressing neurodegenerative disease, provides an ideal model to investigate the feasibility of extending the functional timeframe through pharmacologic intervention. Retinitis Pigmentosa (RP) is a group of blinding diseases. Although the rate of progression and degree of visual loss varies, there is usually a prolonged time before patients totally lose their photoreceptors and vision. It is believed that inhibitory mechanisms are still intact and may become relatively strong after the gradual loss of photoreceptors in RP patients. Therefore, it is possible that light-evoked responses of retinal ganglion cells and visual information processes in retinal circuits could be "unmasked" by blocking these inhibitory mechanisms restoring some level of visual function. Our results indicate that if the inhibition in the inner retina was unmasked in the retina of the rd10 mouse (the well-characterized RP mimicking, clinically relevant mouse model), the light-evoked responses of many retinal ganglion cells can be induced and restore their normal light sensitivity. GABA A receptor plays a major role in this masking inhibition. ERG b-wave and behavioral tests of spatial vision partly recovered after the application of PTX. Hence, removing retinal inhibition unmasks signalling mediated by surviving cones, thereby restoring some degree of visual function. These results may offer a novel strategy to restore the visual function with the surviving cones in RP patients and other gradual and progressive neurodegenerative diseases.	[Wang, Qin; Banerjee, Seema; So, Chunghim; Qiu, Chunting; Lam, Hang-I Christie; Tse, Dennis; Pan, Feng] Hong Kong Polytech Univ, Sch Optometry, Kowloon, Hong Kong, Peoples R China; [Pan, Feng] Ctr Eye & Vis Res, Hong Kong, Peoples R China; [Volgyi, Bela] Univ Pecs, MTA NAP Retinal Elect Synapses Res Grp, Dept Expt Zool & Neurobiol, Szentagothai Res Ctr, Pecs, Hungary	Hong Kong Polytechnic University; University of Pecs	Pan, F (corresponding author), Hong Kong Polytech Univ, Sch Optometry, Kowloon, Hung Hom, Hong Kong, Peoples R China.	feng.a.pan@polyu.edu.hk	Banerjee, Seema/AAF-3540-2022; Banerjee, Seema/AFH-9772-2022; Volgyi, Bela/B-1016-2011	Banerjee, Seema/0000-0002-5158-7062; Banerjee, Seema/0000-0002-5158-7062; Lam, Christie Hang-i/0000-0001-8517-8796; Chung Him, So/0000-0002-7439-5741; Volgyi, Bela/0000-0001-7481-390X; PAN, Feng/0000-0002-5256-4380	Hong Kong Polytechnic University; Hong Kong Research Grants Council (ECS/RGC, Hong Kong, SAR) [25103918, 151060/18M]	Hong Kong Polytechnic University(Hong Kong Polytechnic University); Hong Kong Research Grants Council (ECS/RGC, Hong Kong, SAR)(Hong Kong Research Grants Council)	The study supported by the Hong Kong Polytechnic University grant: G-UACF; UAG4 and University Research Facility in Behavioral and Systems Neuroscience. The study was also supported by a grant from the Hong Kong Research Grants Council (ECS/RGC; 25103918; 151060/18M, Hong Kong, SAR)	Akopian A, 2017, J CLIN INVEST, V127, P2647, DOI 10.1172/JCI91948; [Anonymous], 1988, Arch Ophthalmol, V106, P1518; Arman AC, 2012, J NEUROPHYSIOL, V107, P2649, DOI 10.1152/jn.01202.2011; Baden T, 2016, NATURE, V529, P345, DOI 10.1038/nature16468; Banerjee S, 2020, FRONT CELL NEUROSCI, V14, DOI 10.3389/fncel.2020.00124; Barron HC, 2016, NEURON, V90, P191, DOI 10.1016/j.neuron.2016.02.031; Berson EL, 2007, EXP EYE RES, V85, P7, DOI 10.1016/j.exer.2007.03.001; BLOOMFIELD SA, 1982, J COMP NEUROL, V208, P288, DOI 10.1002/cne.902080306; Borowska J, 2011, J NEUROSCI, V31, P5000, DOI 10.1523/JNEUROSCI.5800-10.2011; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; Campochiaro PA, 2018, PROG RETIN EYE RES, V62, P24, DOI 10.1016/j.preteyeres.2017.08.004; Chang B, 2007, VISION RES, V47, P624, DOI 10.1016/j.visres.2006.11.020; Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8; Dancause N, 2011, PROG BRAIN RES, V192, P273, DOI 10.1016/B978-0-444-53355-5.00015-4; Deneve S, 2017, NEURON, V94, P969, DOI 10.1016/j.neuron.2017.05.016; DOSTROVSKY JO, 1976, EXP NEUROL, V52, P480, DOI 10.1016/0014-4886(76)90219-3; Dowling J. E., 2012, RETINA APPROACHABLE; DOWLING JE, 1966, PROC R SOC SER B-BIO, V166, P80, DOI 10.1098/rspb.1966.0086; Dvir L, 2010, AM J HUM GENET, V87, P258, DOI 10.1016/j.ajhg.2010.06.016; Enz R, 1996, J NEUROSCI, V16, P4479; Fahim A, 2018, CURR OPIN PEDIATR, V30, P725, DOI 10.1097/MOP.0000000000000690; Farajian R, 2011, J PHYSIOL-LONDON, V589, P4473, DOI 10.1113/jphysiol.2011.213371; FARBER DB, 1974, SCIENCE, V186, P449, DOI 10.1126/science.186.4162.449; Ferrari S, 2011, CURR GENOMICS, V12, P238, DOI 10.2174/138920211795860107; Gao HM, 2008, TRENDS IMMUNOL, V29, P357, DOI 10.1016/j.it.2008.05.002; Gargini C, 2007, J COMP NEUROL, V500, P222, DOI 10.1002/cne.21144; Geffen MN, 2007, PLOS BIOL, V5, P640, DOI 10.1371/journal.pbio.0050065; Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7; Herrmann R, 2011, NEURON, V72, P101, DOI 10.1016/j.neuron.2011.07.030; JACOBS KM, 1991, SCIENCE, V251, P944, DOI 10.1126/science.2000496; Jones BW, 2016, EXP EYE RES, V150, P149, DOI 10.1016/j.exer.2016.03.018; Lepeta K, 2016, J NEUROCHEM, V138, P785, DOI 10.1111/jnc.13713; Li L, 2000, J NEUROSCI, V20, P1893; Lin B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068084; Majumdar S, 2007, VISUAL NEUROSCI, V24, P471, DOI 10.1017/S0952523807070174; Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968-08.2008; O'Brien JJ, 2006, J NEUROSCI, V26, P11624, DOI 10.1523/JNEUROSCI.2296-06.2006; Pan F, 2007, J COMP NEUROL, V500, P815, DOI 10.1002/cne.21127; Pan F, 2016, J PHYSIOL-LONDON, V594, P6679, DOI 10.1113/JP272267; Pan F, 2010, J COMP NEUROL, V518, P911, DOI 10.1002/cne.22254; Payne HL, 2017, ELIFE, V6, DOI 10.7554/eLife.29222; Paz JT, 2015, NAT NEUROSCI, V18, P351, DOI 10.1038/nn.3950; Prado DA, 2020, CURR OPIN OPHTHALMOL, V31, P147, DOI 10.1097/ICU.0000000000000660; Prusky GT, 2000, VISION RES, V40, P2201, DOI 10.1016/S0042-6989(00)00081-X; Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541; Rajan R, 2001, CEREB CORTEX, V11, P171, DOI 10.1093/cercor/11.2.171; Stasheff SF, 2011, J NEUROPHYSIOL, V105, P3002, DOI 10.1152/jn.00704.2010; STAUFFER PL, 1993, J BIOL CHEM, V268, P19769; Tau GZ, 2010, NEUROPSYCHOPHARMACOL, V35, P147, DOI 10.1038/npp.2009.115; Tengolics AJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51756-y; THIBOS LN, 1978, J PHYSIOL-LONDON, V278, P101, DOI 10.1113/jphysiol.1978.sp012295; Toychiev AH, 2013, J NEUROSCI, V33, P13972, DOI 10.1523/JNEUROSCI.2399-13.2013; Veleri S, 2015, DIS MODEL MECH, V8, P109, DOI 10.1242/dmm.017913; Volgyi B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069426; Volgyi B, 2009, J COMP NEUROL, V512, P664, DOI 10.1002/cne.21912; Volgyi B, 2004, J NEUROSCI, V24, P11182, DOI 10.1523/JNEUROSCI.3096-04.2004; Wassle H, 2009, J NEUROSCI, V29, P106, DOI 10.1523/JNEUROSCI.4442-08.2009; WANG KC, 2014, SCI REP UK, V4; Wang PY, 2005, J NEUROPHYSIOL, V93, P3120, DOI 10.1152/jn.01228.2004; Wiegert JS, 2017, NEURON, V95, P504, DOI 10.1016/j.neuron.2017.06.050; Wood KC, 2017, CURR OPIN NEUROBIOL, V46, P200, DOI 10.1016/j.conb.2017.08.018; Zhang J, 2005, VISUAL NEUROSCI, V22, P535, DOI 10.1017/S0952523805224148; Zheng N, 2010, CEREBELLUM, V9, P56, DOI 10.1007/s12311-009-0140-6	63	1	1	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2020	34	11					15282	15299		10.1096/fj.202001315RR	http://dx.doi.org/10.1096/fj.202001315RR		SEP 2020	18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	OP5RX	32985731	Green Accepted			2023-01-03	WOS:000574548600001
J	Fox, CR; Doctor, JN; Goldstein, NJ; Meeker, D; Persel, SD; Linder, JA				Fox, Craig R.; Doctor, Jason N.; Goldstein, Noah J.; Meeker, Daniella; Persel, Stephen D.; Linder, Jeffrey A.			Details matter: predicting when nudging clinicians will succeed or fail	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PRIMARY-CARE; BEHAVIORAL INTERVENTIONS; DEFAULT OPTIONS; FEEDBACK; REDESIGN; RATES		[Fox, Craig R.; Goldstein, Noah J.] Univ Calif Los Angeles, Anderson Sch Management, Los Angeles, CA 90095 USA; [Doctor, Jason N.; Meeker, Daniella] Univ Southern Calif, Los Angeles, CA 90007 USA; [Persel, Stephen D.; Linder, Jeffrey A.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	University of California System; University of California Los Angeles; University of Southern California; Northwestern University; Feinberg School of Medicine	Fox, CR (corresponding author), Univ Calif Los Angeles, Anderson Sch Management, Los Angeles, CA 90095 USA.	cfox@anderson.ucla.edu	Linder, Jeffrey/AAF-3424-2021	Linder, Jeffrey/0000-0003-2217-184X				Avorn J, 2018, NEW ENGL J MED, V378, P689, DOI 10.1056/NEJMp1714987; Bourdeaux CP, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010129; Brown CL, 2004, J CONSUM RES, V31, P529, DOI 10.1086/425087; Chiu AS, 2018, JAMA SURG, V153, P1012, DOI 10.1001/jamasurg.2018.2083; Cialdini RB, 2009, INFLUENCE POWER PERS; COOK DM, 1968, ACAD MANAGE J, V11, P263, DOI 10.2307/254752; Delgado MK, 2018, J GEN INTERN MED, V33, P409, DOI 10.1007/s11606-017-4286-5; DEUTSCH MORTON, 1955, JOUR ABNORMAL AND SOCIAL PSYCHOL, V51-31, P629, DOI 10.1037/h0046408; Garcia SM, 2006, PERS SOC PSYCHOL B, V32, P970, DOI 10.1177/0146167206287640; Goldstein NJ, 2008, J CONSUM RES, V35, P472, DOI 10.1086/586910; Hemkens LG, 2017, JAMA INTERN MED, V177, P176, DOI 10.1001/jamainternmed.2016.8040; Johnson EJ, 2004, TRANSPLANTATION, V78, P1713, DOI 10.1097/01.TP.0000149788.10382.B2; Johnson EJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081521; Kiefe CI, 2001, JAMA-J AM MED ASSOC, V285, P2871, DOI 10.1001/jama.285.22.2871; Krijnen J. M., 2017, BEHAV SCI POLICY, V3, P1, DOI DOI 10.1353/bsp.2017.0010; Kullgren JT, 2018, BMJ QUAL SAF, V27, P355, DOI 10.1136/bmjqs-2017-006699; Lavie N, 2005, TRENDS COGN SCI, V9, P75, DOI 10.1016/j.tics.2004.12.004; Linder JA, 2017, JAMA-J AM MED ASSOC, V318, P1391, DOI 10.1001/jama.2017.11152; Madrian BC, 2001, Q J ECON, V116, P1149, DOI 10.1162/003355301753265543; Malhotra S, 2016, J AM MED INFORM ASSN, V23, P891, DOI 10.1093/jamia/ocv192; Meeker D, 2016, JAMA-J AM MED ASSOC, V315, P562, DOI 10.1001/jama.2016.0275; Meeker D, 2014, JAMA INTERN MED, V174, P425, DOI 10.1001/jamainternmed.2013.14191; Patel MS, 2016, JAMA INTERN MED, V176, P847, DOI 10.1001/jamainternmed.2016.1691; Payne TH, 2019, BMJ QUAL SAF, V28, P1, DOI 10.1136/bmjqs-2017-007737; Pichert D, 2008, J ENVIRON PSYCHOL, V28, P63, DOI 10.1016/j.jenvp.2007.09.004; Proctor E, 2011, ADM POLICY MENT HLTH, V38, P65, DOI 10.1007/s10488-010-0319-7; Sedikides C, 2008, PERSPECT PSYCHOL SCI, V3, P102, DOI 10.1111/j.1745-6916.2008.00068.x; TAYLOR SE, 1989, PSYCHOL REV, V96, P569, DOI 10.1037/0033-295X.96.4.569; Thaler R. H., 2009, NUDGE IMPROVING DECI; Thaler RH, 2004, J POLIT ECON, V112, pS164, DOI 10.1086/380085; Tsugawa Y, 2018, HARVARD BUSINESS REV; Ubel P., 2017, FORBES IS PEER PRESS; Ubel PA, 2019, NEW ENGL J MED, V380, P309, DOI 10.1056/NEJMp1806371	33	13	13	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 15	2020	370								m3256	10.1136/bmj.m3256	http://dx.doi.org/10.1136/bmj.m3256			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NY1MK	32933926				2023-01-03	WOS:000576162300012
J	Tarigan, YN; Woodman, RJ; Miller, ER; Wisaksana, R; Wignall, FS; Ward, PR				Tarigan, Yane N.; Woodman, Richard J.; Miller, Emma R.; Wisaksana, Rudi; Wignall, F. Stephen; Ward, Paul R.			Changes in the HIV continuum of care following expanded access to HIV testing and treatment in Indonesia: A retrospective population-based cohort study	PLOS ONE			English	Article							ANTIRETROVIRAL THERAPY; COMMUNITY; LINKAGE; TRIAL; STRATEGIES	Background In 2013, the Indonesian government launched the strategic use of antiretroviral therapy (SUFA) initiative with an aim to move closer to achieving the UNAIDS 90-90-90 target. This study assessed the impact of SUFA on the cascade of HIV care. Methods We performed a two-year retrospective population-based cohort study of all HIV positive individuals aged >= 18 years residing in two cities where SUFA was operational using data from HIV clinics. We analysed data for one-year pre- and one-year post-SUFA implementation. We assessed the rates of enrolment in care, assessment for eligibility for antiretroviral therapy (ART), treatment initiation, loss to follow-up (LTFU) and mortality. Multivariate Cox regression was used to determine the pre-to-post-SUFA hazard ratio. Results A total of 2,292 HIV positive individuals (1,085 and 1,207 pre and post-SUFA respectively) were followed through their cascade of care. In the pre-SUFA period, 811 (74.6%) were enrolled in care, 702 (86.6%) were found eligible for ART, 485 (69.1%) initiated treatment, 102 (21%) were LTFU and 117 (10.8%) died. In the post-SUFA period, 930 (77%) were enrolled in care, 896 (96.3%) were found eligible for ART, 627 (70%) initiated treatment, 100 (16%) were LTFU and 148 (12.3%) dead. There was an 11% increase in the rate of HIV linkage to care (HR = 1.11; 95% CI 1.001, 1.22 p<0.05), a 13% increase in the rate of eligibility for ART (HR = 1.13, 95% CI 1.02,1.25, p<0.01) and a 27% reduction in LTFU (HR = 0.73, 95%CI 0.55, 0.97, p<0.05). Rates of ART initiation and mortality did not change. Conclusion SUFA was effective in improving HIV care in relation to linkage to care, eligibility and ART retention. Therefore, the scale up across the whole of Indonesia of the SUFA currently in the form of a test and treat policy, with improvement in testing and treatment strategies is justified.	[Tarigan, Yane N.; Woodman, Richard J.; Miller, Emma R.; Ward, Paul R.] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia; [Wisaksana, Rudi] Univ Padjajaran, Hasan Sadikin Hosp, Dept Internal Med, Bandung, Indonesia; [Wignall, F. Stephen] Bali Peduli Fdn, Denpasar, Bali, Indonesia	Flinders University South Australia; Dr Hasan Sadikin General Hospital; Universitas Padjadjaran	Tarigan, YN (corresponding author), Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia.	yanenovina@gmail.com	Miller, Emma R/G-9615-2018; Miller, Emma/GXW-3128-2022	Miller, Emma R/0000-0002-6373-5720; Tarigan, Yane Novina/0000-0003-3357-955X; Ward, Paul/0000-0002-5559-9714; Woodman, Richard/0000-0002-4094-1222	Public Health at Flinders University of South Australia; College of Medicine and Public Health Flinders University Adelaide South Australia; Australian Government, Department of Foreign Affairs and Trade, Australia Awards Scholarship	Public Health at Flinders University of South Australia; College of Medicine and Public Health Flinders University Adelaide South Australia; Australian Government, Department of Foreign Affairs and Trade, Australia Awards Scholarship(Australian Government)	1. YNT received a scholarship award for pursuing a Doctor of Public Health at Flinders University of South Australia. 2. The work funding was supported by College of Medicine and Public Health Flinders University Adelaide South Australia (https://www.flinders.edu.au/college-medicinepublic-health) and the Australian Government, Department of Foreign Affairs and Trade, Australia Awards Scholarship (https://www.dfat.gov.au/people-to-people/australia-awards/Pages/australiaawards) 3. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amico KR, 2014, SEX HEALTH, V11, P155, DOI 10.1071/SH13104; [Anonymous], 2013, PANCREATOLOGY, V13, pe1; [Anonymous], 2018, CIRCULAR LETT HK 02; [Anonymous], 2018, OBSTET GYNECOL, V13, pe49; [Anonymous], 2014, REG ANESTH PAIN MED; [Anonymous], 2016, SENSORS, V16, pC1, DOI 10.1109/JSEN.2016.2517933; [Anonymous], 2016, PREV CHRONIC DIS, V13, pE40; [Anonymous], 2015, GYNECOLOGICAL SURG; [Anonymous], 2016, PREV CHRONIC DIS, V13, pE40; Ayieko J, 2018, J ACQUIRED IMMUNE DE; Barnabas RV, 2016, LANCET HIV, V3, pE212, DOI 10.1016/S2352-3018(16)00020-5; Bassett IV, 2016, JAIDS-J ACQ IMM DEF, V73, P154, DOI 10.1097/QAI.0000000000001025; Birthplace in England Collaborative Group, 2011, BMJ-BRIT MED J, V343, pd7400; Center for Public Communication Secretariat General Ministry of Health (ID), 2014, SUFA NEW INN HIV AID; Central Inteligence Agency, 2020, WORLD FACTB E AS SE; Cohen M, 2015, J INT AIDS SOC, V18, DOI 10.7448/IAS.18.5.20482; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; Delaugerre C, 2015, CLIN INFECT DIS, V60, P463, DOI 10.1093/cid/ciu834; Expert Panel on Neurologic Imaging, 2017, J AM COLL RADIOL, V14, pS550; Expert Panel on Neurologic Imaging, 2017, J AM COLL RADIOL, V14, pS550; Expert Panel on Neurologic Imaging, 2017, J AM COLL RADIOL, V14, pS550; Expert Panel on Neurologic Imaging, 2017, J AM COLL RADIOL, V14, pS550; Expert Panel on Women's I, 2018, J AM COLL RADIOL, V15, pS365; Hewett PC, 2016, BMC PUBLIC HEALTH, V16, DOI 10.1186/s12889-016-3450-x; Hosmer DW, 2008, WILEY SERIES PROBABI; Hutchinson F.E., 2016, SIJORI CROSS BORDER; Januraga PP, 2018, LANCET HIV, V5, pE560, DOI 10.1016/S2352-3018(18)30148-6; KSPJDCEMAA JB, 2015, ANN IND ACAD NEUROL, V18, pS59; Lazuardi E, 2018, SEX HEALTH, V16, P16; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Menard S., 2002, LONGITUDINAL RES; Menzies N, 2009, AIDS, V23, P395, DOI 10.1097/QAD.0b013e328321e40b; Ministry of Health, 2011, NATL GUIDELINE FAMIL, P1; Ministry of Health (ID), 2015, TECHN INSTR FILL OUT; [Ministry of Health (ID). STI SDoH-Aa], 2014, HDB STRAT US ARV SUF; [Ministry of Health (ID). Sub Directorate of HIV-AIDS and STI], 2015, SUBD HIV AIDS STI; Mizuno Y, 2019, AIDS CARE, V31, P1323, DOI 10.1080/09540121.2019.1576847; National AIDS Commission Ministry of Health (ID)., 2013, ROADM RED HIV REL MO; National Institute of Allergy and Infectious Diseases, 2015, AIDS WEEKLY, P6; Parker LA, 2015, TROP MED INT HEALTH, V20, P893, DOI 10.1111/tmi.12501; Royston P, 2008, STATA J, V7, P445, DOI [10.1177/1536867x0800700401, DOI 10.1177/1536867X0800700401]; Sharma M, 2015, NATURE, V528, pS77, DOI 10.1038/nature16044; Song JW, 2010, PLAST RECONSTR SURG, V126, P2234, DOI 10.1097/PRS.0b013e3181f44abc; Statistics Central Bureau, 2019, STAT YB IND 2019; Statistics Central Bureau, 2010, POP REG REL; Statistics of Kepulauan Riau Province, 2017, KEP RIAU PROV FIG 20; Suguitan Jr AL, 2011, PLOS ONE, V6; Suryadinata L., 2003, INDONESIAS POPULATIO; Topp Stephanie M, 2012, J Int AIDS Soc, V15, P17352, DOI 10.7448/IAS.15.2.17352; UNAIDS, 2019, UNAIDS DAT 2019; Woodward M, 2005, EPIDEMIOLOGY STUDY D; World Health Organization, 2007, GUID IN HIV TEST COU; World Health Organization, 2014, POL BRIEF CONS GUID	53	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 11	2020	15	9							e0239041	10.1371/journal.pone.0239041	http://dx.doi.org/10.1371/journal.pone.0239041			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NR9MU	32915923	Green Published, gold			2023-01-03	WOS:000571887500005
J	Abate, BB; Tilahun, BD; Kassie, AM; Kassaw, MW				Abate, Biruk Beletew; Tilahun, Befkad Deresse; Kassie, Ayelign Mengesha; Kassaw, Mesfin Wudu			Treatment outcome of Severe Acute Malnutrition and associated factors among under-five children in outpatient therapeutics unit in Gubalafto Wereda, North Wollo Zone, Ethiopia, 2019	PLOS ONE			English	Article								Background In Ethiopia, uncomplicated severe acute malnutrition is managed through the outpatient therapeutic program at health posts level. This brings the services for the management of Severe Acute Malnutrition closer to the community by making services available at decentralized treatment points within the primary health care settings. So far, evidence of the treatment outcome of the program is limited. Objective The main aim of this study was to determine the magnitude of treatment outcomes of severe acute malnutrition and associated factors among under-five children at outpatient therapeutic feeding units in Gubalafto Wereda, Ethiopia, 2019. Methods This was a retrospective cohort study conducted on 600 children who had been managed for Severe Acute Malnutrition (SAM) under Outpatient Therapeutic Program (OTP) in Gubalafto Wereda from April to May/2019. The children were selected using systematic random sampling from 9 health posts. The structured, pre-tested, and adapted questionnaire was used to collect the data. The data was entered by using EPI-data Version 4.2 and exported to SPSS version 24.0 for analysis. Bivariate and Multivariate regression was also carried out to determine the association between dependent and independent variables. Results A total of 600 records of children with a diagnosis of severe acute malnutrition were reviewed. Of these cases of malnutrition, the recovery rate was found to be 65%. The death rate, default rate, and medical transfer were 2.0, 16.0, and 17.0 respectively. Immunized children had 6.85 times higher odds of recovery than children who were not immunized (AOR = 6.85 at 95% CI (3.68-12.76)). The likelihood of recovery was 3.78 times higher among children with new admission than those with re-admission (AOR = 3.78at 95% CI ((1.77-8.07))). Likewise, children provided with amoxicillin were 3.38 times recovered than their counterparts (AOR = 3.38 at 95% CI ((1.61-7.08))). SAM treatment in OTP is beneficial because of its local access for most severe cases since children reach early before developing complications as a result fatalities will be reduced. Conclusions The recovery rate and medical transfer were lower than the sphere standard. Presence of cough, presence of diarrhea admission category, provision of amoxicillin, and immunization status were factors identified as significantly associated with treatment outcome of severe acute malnutrition. The impact on increasing the recovery rates of children treated using the OTP service indicates the potential benefits of increasing the capacity of such services across a target region on child mortality/recovery. Timely intervention is another benefit of a more local service like OTP. Building capacity of OTP service providers and regular monitoring of service provision based on the management protocol was recommended.	[Abate, Biruk Beletew; Tilahun, Befkad Deresse; Kassie, Ayelign Mengesha; Kassaw, Mesfin Wudu] Woldia Univ, Coll Hlth Sci, Dept Nursing, Woldia, Amhara Regional, Ethiopia		Abate, BB (corresponding author), Woldia Univ, Coll Hlth Sci, Dept Nursing, Woldia, Amhara Regional, Ethiopia.	birukkelemb@gmail.com	Beletew, Biruk/ABC-3508-2020	Reis, AlessanRSS/0000-0001-8486-7469	Woldia University	Woldia University	The study was funded by Woldia University. However, the funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Achadi E, 2016, GLOBAL NUTR REPORT P; [Anonymous], 2014, DIABETES CARE, V35, pS14; [Anonymous], 2014, DIABETES CARE, V35, pS14; [Anonymous], 2016, THE TOTAL AUDIENCE R; Chamois S, 2007, ETHIOPIA PROTOCOL MA; Collins S, 2007, ARCH DIS CHILD, V92, P453, DOI 10.1136/adc.2006.098327; Collins S, 2006, LANCET, V368, P1992, DOI 10.1016/S0140-6736(06)69443-9; Desta K., 2015, J NUTR DISORD THER, V5, P160, DOI DOI 10.4172/2161-0509.1000160; Desyibelew HD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171020; FHAPCO. Federal HIV Prevention AIDS Control Office, 2008, FED HIV PREV AIDS CO; Golden M, 2007, PROTOCOL MANAGEMENT; Golden M GYPftmosamEM, 2016, TREATM OUTC FACT AFF, V9, P30704; Gulati JK, 2010, ANTHROPOLOGIST, V12, P131, DOI 10.1080/09720073.2010.11891143; Harvey BM, 2017, J PEDIATR GASTR NUTR, V65, P346, DOI 10.1097/MPG.0000000000001655; Kabalo MY, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-017-0083-3; Koblinsky M, 2006, LANCET, V368, P1377, DOI 10.1016/S0140-6736(06)69382-3; Lenters LM, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-S3-S23; Mengesha MM, 2016, GLOBAL HEALTH ACTION, V9, DOI 10.3402/gha.v9.30704; Organization W.H, 1989, COMM BAS MAN SEV AC; Organization WH Initiative STDD Research SPf Diseases TiT, 2007, US RAP SYPH TESTS WH; Paxton A, 2005, INT J GYNECOL OBSTET, V88, P181, DOI 10.1016/j.ijgo.2004.11.026; Teferra TB, 2015, PAN AFR MED J, V20, DOI 10.11604/pamj.2015.20.209.4525; UNICEF, 2012, EV COMM MAN AC MALN; WHO, 2013, GUID UPD MAN SEV AC; Yebyo HG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065840	25	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 3	2020	15	9							e0238231	10.1371/journal.pone.0238231	http://dx.doi.org/10.1371/journal.pone.0238231			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NQ7QD	32881883	Green Published, gold			2023-01-03	WOS:000571063300002
J	Zhao, ZJ; Xu, ZP; Ma, YY; Ma, JD; Hong, G				Zhao, Zhan-Juan; Xu, Zeng-Ping; Ma, Ying-Ying; Ma, Jin-Duo; Hong, Ge			Photodynamic antimicrobial chemotherapy in mice withPseudomonas aeruginosa-infected wounds	PLOS ONE			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; METHYLENE-BLUE; IN-VITRO; ZINC PHTHALOCYANINES; HEALING-PROCESS; THERAPY; INACTIVATION; CANCER; LASER; LIGHT	This study examined the antibacterial effect of protoporphyrin IX-ethylenediamine derivative (PPIX-ED)-mediated photodynamic antimicrobial chemotherapy (PPIX-ED-PACT) againstPseudomonas aeruginosa in vitroandin vivo. PPIX-ED potently inhibited the growth ofPseudomonas aeruginosaby inducing reactive oxygen species production via photoactivation. Atomic force microscopy revealed that PPIX-ED-PACT induced the leakage of bacterial content by degrading the bacterial membrane and wall. As revealed using acridine orange/ethidium bromide staining, PPIX-ED-PACT altered the permeability of the bacterial membrane. In addition, the antibacterial effect of PPIX-ED-PACT was demonstrated in anin vivomodel ofP.aeruginosa-infected wounds. PPIX-ED (100 mu M) decreased the number ofP.aeruginosacolony-forming units by 4.2 log(10). Moreover, histological analysis illustrated that the wound healing rate was 98% on day 14 after treatment, which was 10% higher than that in the control group. According to the present findings, PPIX-ED-PACT can effectively inhibit the growth ofP.aeruginosa in vitroandin vivo.	[Zhao, Zhan-Juan; Ma, Jin-Duo] Hebei Univ, Sch Basic Med Sci, Baoding, Peoples R China; [Xu, Zeng-Ping; Ma, Ying-Ying; Hong, Ge] Chinese Acad Med Sci & Peking Union Med Coll, Tianjin Key Lab Biomed Mat, Inst Biomed Engn, Tianjin, Peoples R China	Hebei University; Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of BioMedical Engineering - CAMS; Peking Union Medical College	Hong, G (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Tianjin Key Lab Biomed Mat, Inst Biomed Engn, Tianjin, Peoples R China.	hongge6688@aliyun.com			national Mega-project for Innovative Drugs [2019ZX09721001-006-001]; medical and health science and technology innovation project of Chinese Academy of Medical Science [2019-I2M-1-005]	national Mega-project for Innovative Drugs; medical and health science and technology innovation project of Chinese Academy of Medical Science	This study was supported by the national Mega-project for Innovative Drugs (2019ZX09721001-006-001 to Ge Hong) and the medical and health science and technology innovation project of Chinese Academy of Medical Science (2019-I2M-1-005 to Ge Hong). The funder provided support in study design.	Vera DMA, 2012, PHOTOCHEM PHOTOBIOL, V88, P499, DOI 10.1111/j.1751-1097.2012.01087.x; Alamoudi WA, 2018, J BUON, V23, P1505; Alvarez-Mico X, 2007, CARBOHYD RES, V342, P440, DOI 10.1016/j.carres.2006.11.017; Carvalho ML, 2018, LASER MED SCI, V33, P647, DOI 10.1007/s10103-017-2344-1; Chan Y, 2003, LASER MED SCI, V18, P51, DOI 10.1007/s10103-002-0243-5; Catao MHCD, 2015, LASER MED SCI, V30, P421, DOI 10.1007/s10103-014-1687-0; Cheng XD, 2019, INFECT DIS-NOR, V51, P299, DOI 10.1080/23744235.2018.1543946; Dai TH, 2010, LASER SURG MED, V42, P38, DOI 10.1002/lsm.20887; Eaton P, 2008, ULTRAMICROSCOPY, V108, P1128, DOI 10.1016/j.ultramic.2008.04.015; El-Khordagui L, 2017, INT J PHARMACEUT, V520, P139, DOI 10.1016/j.ijpharm.2017.02.004; Ensayef S, 2009, East Mediterr Health J, V15, P219; Frimannsson DO, 2010, J MED CHEM, V53, P7337, DOI 10.1021/jm100585j; Gao YR, 2018, PHOTODIAGN PHOTODYN, V21, P316, DOI 10.1016/j.pdpdt.2018.01.003; Garcia VG, 2010, LASER MED SCI, V25, P221, DOI 10.1007/s10103-009-0694-z; Garrier J, 2011, PHOTODIAGN PHOTODYN, V8, P321, DOI 10.1016/j.pdpdt.2011.06.003; Gong GD, 2018, CHEM COMMUN, V54, DOI 10.1039/c8cc03308k; Grimsrud PA, 2008, J BIOL CHEM, V283, P21837, DOI 10.1074/jbc.R700019200; Grinhoic M, 2008, J PHOTOCH PHOTOBIO B, V90, P57, DOI 10.1016/j.jphotobiol.2007.11.002; Hamblin MR, 2016, CURR OPIN MICROBIOL, V33, P67, DOI 10.1016/j.mib.2016.06.008; Hamblin MR, 2004, PHOTOCH PHOTOBIO SCI, V3, P436, DOI 10.1039/b311900a; Imlay JA, 2003, ANNU REV MICROBIOL, V57, P395, DOI 10.1146/annurev.micro.57.030502.090938; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; Jin H, 2010, APPL MICROBIOL BIOT, V88, P761, DOI 10.1007/s00253-010-2747-4; Jori G, 2006, LASER SURG MED, V38, P468, DOI 10.1002/lsm.20361; Kashef N, 2012, PHOTODIAGN PHOTODYN, V9, P355, DOI 10.1016/j.pdpdt.2012.05.001; Khan S, 2017, IUBMB LIFE, V69, P611, DOI 10.1002/iub.1643; Lambrechts SAG, 2005, PHOTOCH PHOTOBIO SCI, V4, P503, DOI 10.1039/b502125a; Lau JTF, 2011, CHEM-EUR J, V17, P7569, DOI 10.1002/chem.201100621; Le Guern F, 2017, BIOCONJUGATE CHEM, V28, P2493, DOI 10.1021/acs.bioconjchem.7b00516; Li XM, 2019, PHOTODIAGN PHOTODYN, V25, P300, DOI 10.1016/j.pdpdt.2019.01.010; Lin SL, 2012, PHOTOCHEM PHOTOBIOL, V88, P985, DOI 10.1111/j.1751-1097.2012.01154.x; Lv F, 2013, J MATER SCI-MATER M, V24, P811, DOI 10.1007/s10856-012-4820-2; Mai BJ, 2017, INT J NANOMED, V12, P5915, DOI 10.2147/IJN.S138185; Maisch T, 2007, LASER MED SCI, V22, P83, DOI 10.1007/s10103-006-0409-7; Maiz L, 2013, EXPERT OPIN PHARMACO, V14, P1135, DOI 10.1517/14656566.2013.790366; Mbakidi JP, 2013, CARBOHYD POLYM, V91, P333, DOI 10.1016/j.carbpol.2012.08.013; Meng S, 2015, EUR J MED CHEM, V92, P35, DOI 10.1016/j.ejmech.2014.12.029; Morimoto K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105173; Nafee N, 2013, INT J PHARMACEUT, V454, P249, DOI 10.1016/j.ijpharm.2013.06.067; Norman A, 2016, GENOME ANNOUNCEMENTS, V4, DOI 10.1128/genomeA.00008-16; Prasanth CS, 2014, PHOTOCHEM PHOTOBIOL, V90, P628, DOI 10.1111/php.12198; Rudenko TG, 2014, PHOTOCHEM PHOTOBIOL, V90, P1413, DOI 10.1111/php.12340; Sahu K, 2014, PHOTOMED LASER SURG, V32, P23, DOI 10.1089/pho.2013.3577; Sahu K, 2013, LASER MED SCI, V28, P465, DOI 10.1007/s10103-012-1083-6; Sahu K, 2009, J PHOTOCH PHOTOBIO B, V96, P9, DOI 10.1016/j.jphotobiol.2009.03.008; Schaber JA, 2007, INFECT IMMUN, V75, P3715, DOI 10.1128/IAI.00586-07; Sharma SK, 2012, ISR J CHEM, V52, P691, DOI 10.1002/ijch.201100062; Sperandio FF, 2010, PHOTOMED LASER SURG, V28, P581, DOI 10.1089/pho.2009.2601; Sperandio FF, 2015, ANTIMICROBIAL PHOTOD; Sueoka K, 2018, LASER MED SCI, V33, P1455, DOI 10.1007/s10103-018-2490-0; Topaloglu N, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.2.028003; Vecchio D, 2013, J BIOPHOTONICS, V6, P733, DOI 10.1002/jbio.201200121; Wainwright M, 1998, J ANTIMICROB CHEMOTH, V42, P13, DOI 10.1093/jac/42.1.13; Whitcher JP, 1997, BRIT J OPHTHALMOL, V81, P622, DOI 10.1136/bjo.81.8.622; Wilson BC, 2008, PHYS MED BIOL, V53, pR61, DOI 10.1088/0031-9155/53/9/R01; Wunderink RG, 2007, EPIDEMIOLOGY PSEUDOM; Xu ZP, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00242; Zhao ZJ, 2014, LASER MED SCI, V29, P1131, DOI 10.1007/s10103-013-1488-x; Zhu CF, 2015, BIOORG MED CHEM LETT, V25, P558, DOI 10.1016/j.bmcl.2014.12.018	59	7	7	3	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2020	15	9							e0237851	10.1371/journal.pone.0237851	http://dx.doi.org/10.1371/journal.pone.0237851			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN6DP	32877414	gold, Green Published			2023-01-03	WOS:000568877100057
J	Broadhurst, D; Cooke, M; Sriram, D; Gray, B				Broadhurst, Daphne; Cooke, Marie; Sriram, Deepa; Gray, Brenda			Subcutaneous hydration and medications infusions (effectiveness, safety, acceptability): A systematic review of systematic reviews	PLOS ONE			English	Review							INTRAVENOUS REHYDRATION; TREAT DEHYDRATION; DOUBLE-BLIND; HYPODERMOCLYSIS; CANCER; CHILDREN; CARE; HYALURONIDASE; FLUIDS; COST	Objective To synthesize the current evidence for subcutaneous hydration and medication infusions from systematic reviews and to assess their methodological quality. Introduction Peripheral intravascular cannula/catheter insertion is a common invasive procedure for administering fluids and medications. Venous depletion is a growing concern for several patient populations. Subcutaneous access for the administration of isotonic solutions and medications is an alternative; however, vascular access assessment and planning guidelines rarely consider this route. Methods Systematic review of systematic reviews (PROSPERO CRD42018046504). We searched 6 databases published in English language from 1990 to June 2020, identifying subcutaneous infusions an alternate route for fluids or medication. Methodological quality was evaluated using AMSTAR 2 criteria and data for mechanisms of infusion and outcomes related to effectiveness, safety, efficiency and acceptability extracted. The Johanna Briggs Institute's grades of recommendation informed the strength of recommendation. Results The search yielded 1042 potential systematic reviews; 922 were excluded through abstract and duplicate screen. Of the remaining articles, 94 were excluded, and 26 were included. Overall, evidence is strong for recommending subcutaneous hydration infusions for older adults, weak for pediatric patients and inconclusive for palliative patients. There is strong evidence for 10 medications; weak evidence supporting 28 medications; however, there are eight medications with inconclusive evidence to make a recommendation and four medications not appropriate for subcutaneous delivery. Conclusion Subcutaneous access should be considered alongside intravenous therapy for hydration in older adults, and several medications. There are additional benefits in terms of ease of use and cost-effectiveness of this mode. Inclusion of subcutaneous access in clinical guidelines may promote uptake of this route to help preserve vessel health of vulnerable patients. Further high-quality research is needed to inform subcutaneous infusion therapy in a variety of populations (including pediatrics and palliative care) and medications and clarifying the mechanism of delivery.	[Broadhurst, Daphne; Cooke, Marie; Sriram, Deepa] Menzies Hlth Inst Queensland, Alliance Vasc Access Teaching & Res AVATAR Grp, Southport, Qld, Australia; [Broadhurst, Daphne] Infus Excellence Consulting, Ottawa, ON, Canada; [Cooke, Marie] Griffith Univ, Sch Nursing & Midwifery, Nathan Campus, Nathan, Qld, Australia; [Gray, Brenda] Clin Pharm Partners, Tampa, FL USA	Griffith University	Broadhurst, D (corresponding author), Menzies Hlth Inst Queensland, Alliance Vasc Access Teaching & Res AVATAR Grp, Southport, Qld, Australia.; Broadhurst, D (corresponding author), Infus Excellence Consulting, Ottawa, ON, Canada.	daphne@infusionexcellence.com			Becton Dickinson, Canada	Becton Dickinson, Canada	This project was partially supported via an unrestricted project grant provided by Becton Dickinson, Canada. A portion of the work of DS was funded as salary by the sponsor grant. DB, as a former employee of Medical Pharmacies during the conduct of this research, reports the research as work independent of her employer, with no employer contributions to the research-DB is sole proprietor of Infusion Excellence Consulting whose services are unrelated to this research. BG owns and is employed as Senior Consultant and Director of Education by Clinical Pharmacy Partners, an educational and consulting firm for infusion therapy providers and clinicians. The funders had no role in study conception, design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the `author contributions' section.	Abolhassani H, 2012, J CLIN IMMUNOL, V32, P1180, DOI 10.1007/s10875-012-9720-1; Al Nofal A, 2017, ENDOCR PRACT, V23, P17, DOI 10.4158/EP161428.OR; Alexandrou Evan, 2014, Br J Nurs, V23, pS16; Anderson SL, 2004, ANN PHARMACOTHER, V38, P1015, DOI 10.1345/aph.1D395; [Anonymous], 2017, EUR GERIATR MED, V8, pS98; Arinzon Z, 2004, ARCH GERONTOL GERIAT, V38, P167, DOI 10.1016/j.archger.2003.09.003; Aromataris E, 2015, INT J EVID-BASED HEA, V13, P132, DOI 10.1097/XEB.0000000000000055; Bell RFF, 2017, COCHRANE DB SYST REV; Bredlau AL, 2013, PAIN MED, V14, P1505, DOI 10.1111/pme.12182; Bruera E, 1999, ANN ONCOL, V10, P1255, DOI 10.1023/A:1008331727535; Bruera E, 1996, SUPPORT CARE CANCER, V4, P147, DOI 10.1007/BF01845764; Bruera E, 2013, J CLIN ONCOL, V31, P111, DOI 10.1200/JCO.2012.44.6518; Caccialanza R, 2018, JPEN-PARENTER ENTER, V42, P296, DOI 10.1177/0148607116676593; Carlson K R, 1999, J Intraven Nurs, V22, pS46; Cerchietti L, 2000, Int J Palliat Nurs, V6, P370; CHALLINER YC, 1994, POSTGRAD MED J, V70, P195, DOI 10.1136/pgmj.70.821.195; Chopra V, 2015, ANN INTERN MED, V163, pS1, DOI 10.7326/M15-0744; Colin O, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022720; DARDAINE V, 1995, J GERONTOL A-BIOL, V50, pM334, DOI 10.1093/gerona/50A.6.M334; Dasgupta M, 2000, J AM GERIATR SOC, V48, P795, DOI 10.1111/j.1532-5415.2000.tb04755.x; Duems Noriega O, 2014, REV ESPAN GERIATR GE, V49, P103, DOI DOI 10.1016/J.REGG.2013.12.003; Duems-Noriega O, 2015, REV CLIN GERONTOL, V25, P117, DOI 10.1017/S095925981500012X; Dychter SS, 2012, J INFUS MURS, V35, P84, DOI 10.1097/NAN.0b013e31824237ce; Emergency Nurses Association, 2015, CLIN PRACT GUID DIFF; FAINSINGER RL, 1994, J PAIN SYMPTOM MANAG, V9, P298, DOI 10.1016/0885-3924(94)90187-2; Fisher SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064669; Fonzo-Christe C, 2005, PALLIATIVE MED, V19, P208, DOI 10.1191/0269216304pm1006oa; Forbat L, 2017, J CLIN NURS, V26, P1204, DOI 10.1111/jocn.13683; Fortin PM, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012349.pub2; Furtado Ines, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2017-222340; Gaudet LM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031679; Gomes NS, 2017, REV BRAS ENFERM, V70, P1096, DOI 10.1590/0034-7167-2016-0424; Good P, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006273.pub3; Gorski Lisa A, 2017, Home Healthc Now, V35, P10; Hallam Carole, 2016, J Infect Prev, V17, P65, DOI 10.1177/1757177415624752; Hawes ML, 2007, J INFUS MURS, V30, P33, DOI 10.1097/00129804-200701000-00006; JAYR C, 1993, ANESTHESIOLOGY, V78, P666, DOI 10.1097/00000542-199304000-00009; Joanna Briggs Institute, JOANN BRIGGS I LEV E; Cabanero-Martinez MJ, 2016, PALLIATIVE MED, V30, P549, DOI 10.1177/0269216315616763; Junior AF, 2000, DRUG AGING, V16, P313, DOI 10.2165/00002512-200016040-00007; Kalso E, 1996, PAIN, V67, P443, DOI 10.1016/0304-3959(96)03161-2; Ker K, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011386.pub2; Lingman-Framme J, 2013, DRUGS, V73, P1307, DOI 10.1007/s40265-013-0094-3; Luk JK., 2008, ASIAN J GERONTOL GER, V3, P49; Mace SE, 2013, AM J EMERG MED, V31, P928, DOI 10.1016/j.ajem.2013.03.006; MACMILLAN K, 1994, J PAIN SYMPTOM MANAG, V9, P82, DOI 10.1016/0885-3924(94)90160-0; Marikar D, 2014, ARCH DIS CHILD, V99, P783, DOI 10.1136/archdischild-2013-305735; McGowan Donna, 2008, Br J Nurs, V17, P158; Misra S, 2019, NEUROL-GENET, V5, DOI 10.1212/NXG.0000000000000367; Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]; Moriarty D, 2001, Br J Community Nurs, V6, P437; Moureau N., 2016, J ASS VASCULAR ACCES, V21, P140; Moureau NL, 2012, J VASC ACCESS, V13, P351, DOI 10.5301/jva.5000042; OKeeffe ST, 1996, GERONTOLOGY, V42, P36; Orrell RW, 2008, AMYOTROPH LATERAL SC, V9, P195, DOI 10.1080/17482960801900032; PARAMOTHAYAN NS, 2005, COCHRANE DB SYST REV; Perry R, 2017, SYST REV-LONDON, V6, DOI 10.1186/s13643-017-0487-6; Pershad J, 2010, APPL HEALTH ECON HEA, V8, P203, DOI 10.2165/11534500-000000000-00000; Pouvreau N, 2017, ARCH PEDIATRIE, V24, P850, DOI 10.1016/j.arcped.2017.06.009; Reichmann James P, 2012, Manag Care, V21, P44; Remington R, 2007, J AM GERIATR SOC, V55, P2051, DOI 10.1111/j.1532-5415.2007.01437.x; Rochon PA, 1997, J GERONTOL A-BIOL, V52, pM169, DOI 10.1093/gerona/52A.3.M169; Rouhani S, 2011, PEDIATRICS, V127, pE748, DOI 10.1542/peds.2010-0952; Santolucito JB, 2001, J ASS VASC ACCESS, V6, P20; Schmidt-Hansen M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009596.pub4; Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008; Slesak G, 2003, J AM GERIATR SOC, V51, P155, DOI 10.1046/j.1532-5415.2003.51052.x; Spandorfer PR, 2012, CLIN THER, V34, P2232, DOI 10.1016/j.clinthera.2012.09.011; Stoner KL, 2015, PATIENT, V8, P145, DOI 10.1007/s40271-014-0075-y; Torre Maria Carrion, 2002, Br J Community Nurs, V7, P365; Turner Tari, 2004, BMC Geriatr, V4, P2, DOI 10.1186/1471-2318-4-2; Vidal M, 2016, J PAIN SYMPTOM MANAG, V52, P570, DOI 10.1016/j.jpainsymman.2016.04.009; Wilhelm K, 2017, SYSTEMATIC REV HYALU	73	7	7	3	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2020	15	8							e0237572	10.1371/journal.pone.0237572	http://dx.doi.org/10.1371/journal.pone.0237572			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NI7TB	32833979	Green Published, gold			2023-01-03	WOS:000565550400049
J	Zong, XN; Li, H; Zhang, YQ; Wu, HH				Zong, Xin-Nan; Li, Hui; Zhang, Ya-Qin; Wu, Hua-Hong			Growth performance comparison of exclusively breastfed infants with partially breastfed and formula fed infants	PLOS ONE			English	Article							PHYSICAL GROWTH; CHILDREN; CHINA	Background Little consensus exists for growth performance of different feeding patterns in infancy. The objective of this study is to assess the growth performance of exclusively breastfed, partially breastfed and formula fed infants in China. Methods Data from a total of 109,052 infants aged 1-<12 months were collected from the 4th and 5th China National Surveys in 2005 and 2015. Feeding patterns were classified into three types for infants under 6 months of age: exclusive breastfeeding, partial breastfeeding and formula feeding. Exclusive breastfeeding refers to feeding exclusively from the mother's own milk (bottle-feeding included). Results 34.0% and 43.9% of infants were exclusively breastfed and 41.5% and 36.3% were partially breastfed at 4-<6 months in 2005 and 2015 respectively. Exclusively breastfed infants were generally a little heavier than partially breastfed and formula fed infants aged 1-<6 months; however, there was not a significant statistical difference between continued breastfeeding and formula feeding infants aged 6-<12 months. No significant statistical difference for length was observed among the three groups for ages 1-<6 months; however, infants who were continued to be breastfed were a little shorter compared to those who were formula fed (ages 6-<12 months). For infants aged 1-<2 months there was not a substantial difference from the 2006 WHO growth standards; however, for infants aged 2-Conclusions Partial breastfed and formula fed infants were a little lighter than exclusively breastfed infants in the first half of the first year. Formula fed infants were a little longer than continued breastfed infants in the second half.	[Zong, Xin-Nan; Li, Hui; Zhang, Ya-Qin; Wu, Hua-Hong] Capital Inst Pediat, Dept Growth & Dev, Beijing, Peoples R China	Capital Institute of Pediatrics (CIP)	Li, H (corresponding author), Capital Inst Pediat, Dept Growth & Dev, Beijing, Peoples R China.	huiligrowth@163.com			National Health and Family Planning Commission of the People's Republic of China; National Health Commission of China	National Health and Family Planning Commission of the People's Republic of China; National Health Commission of China	The survey was supported by the National Health and Family Planning Commission of the People's Republic of China. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The NSPGDC was supported by the National Health Commission of China. We thank all infants and their parents participating in the NSPGDC.	ANDERSON MA, 1995, B WORLD HEALTH ORGAN, V73, P165; Capital Institute of Pediatrics,The Coordinating Study Group of Nine Cities on the Physical Growth and Development of Children, 2018, Zhonghua Er Ke Za Zhi, V56, P192, DOI 10.3760/cma.j.issn.0578-1310.2018.03.008; Cheng TS, 2018, PAEDIATR PERINAT EP, V32, P200, DOI 10.1111/ppe.12434; Coordinating Study Group of Nine Cities on Physical Growth and Development of Children, 2007, Zhonghua Er Ke Za Zhi, V45, P609; de Onis M, 2006, ACTA PAEDIATR, V95, P16, DOI 10.1080/08035320500495423; DIBLEY MJ, 1987, AM J CLIN NUTR, V46, P736, DOI 10.1093/ajcn/46.5.736; Garza C, 2006, ACTA PAEDIATR, V95, P56, DOI 10.1080/08035320500495514; Garza Cutberto, 2004, Food Nutr Bull, V25, pS5; HAMILL PVV, 1979, AM J CLIN NUTR, V32, P607, DOI 10.1093/ajcn/32.3.607; HR Digest, 2017, HUMAN RESOURCE MANAG, V25, P18; Li RW, 2012, ARCH PEDIAT ADOL MED, V166, P431, DOI 10.1001/archpediatrics.2011.1665; Liu Aidong, 2009, Wei Sheng Yan Jiu, V38, P555; Ministry of Health of China, 2007, CHIN FEED STRAT INF; National Health and Family Planning Commission Statistics Information Center, 2016, REP 5 NAT HLTH SERV; Pullum TW, 2014, GLOB HEALTH-SCI PRAC, V2, P355, DOI 10.9745/GHSP-D-14-00061; Victora CG, 2016, LANCET, V387, P475, DOI 10.1016/S0140-6736(15)01024-7; WATERLOW JC, 1979, LANCET, V2, P238; WHO Multicentre Growth Reference Study Group, 2006, WHO CHILD GROWTH STA; WHO-WORLD HEALTH ORGANIZATION, 2009, INF YOUNG CHILD FEED; Wu HH, 2018, ACTA PAEDIAT; ZHANG X, 1988, ANN HUM BIOL, V15, P289, DOI 10.1080/03014468800009761; Zhang YQ, 2017, AM J PHYS ANTHROPOL, V163, P497, DOI 10.1002/ajpa.23224; Zong XN, 2019, BMC PUBLIC HEALTH, V19, DOI 10.1186/s12889-019-6699-z; 1977, CHINESE MED J PEKING, V3, P364	24	7	7	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2020	15	8							e0237067	10.1371/journal.pone.0237067	http://dx.doi.org/10.1371/journal.pone.0237067			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG9QD	32817664	gold, Green Published			2023-01-03	WOS:000564315600056
J	Cherak, SJ; Soo, A; Brown, KN; Ely, EW; Stelfox, HT; Fiest, KM				Cherak, Stephana J.; Soo, Andrea; Brown, Kyla N.; Ely, E. Wesley; Stelfox, Henry T.; Fiest, Kirsten M.			Development and validation of delirium prediction model for critically ill adults parameterized to ICU admission acuity	PLOS ONE			English	Article							INTENSIVE-CARE; SCREENING CHECKLIST; CLINICAL-PRACTICE; RISK; ASSOCIATION; EXPLANATION; PREVENTION; MANAGEMENT; MORTALITY; DIAGNOSIS	Background Risk prediction models allow clinicians to forecast which individuals are at a higher risk for developing a particular outcome. We developed and internally validated a delirium prediction model for incident delirium parameterized to patient ICU admission acuity. Methods This retrospective, observational, fourteen medical-surgical ICU cohort study evaluated consecutive delirium-free adults surviving hospital stay with ICU length of stay (LOS) greater than or equal to 24 hours with both an admission APACHE II score and an admission type (e.g., elective post-surgery, emergency post-surgery, non-surgical) in whom delirium was assessed using the Intensive Care Delirium Screening Checklist (ICDSC). Risk factors included in the model were readily available in electric medical records. Least absolute shrinkage and selection operator logistic (LASSO) regression was used for model development. Discrimination was determined using area under the receiver operating characteristic curve (AUC). Internal validation was performed by cross-validation. Predictive performance was determined using measures of accuracy and clinical utility was assessed by decision-curve analysis. Results A total of 8,878 patients were included. Delirium incidence was 49.9% (n = 4,431). The delirium prediction model was parameterized to seven patient cohorts, admission type (3 cohorts) or mean quartile APACHE II score (4 cohorts). All parameterized cohort models were well calibrated. The AUC ranged from 0.67 to 0.78 (95% confidence intervals [CI] ranged from 0.63 to 0.79). Model accuracy varied across admission types; sensitivity ranged from 53.2% to 63.9% while specificity ranged from 69.0% to 74.6%. Across mean quartile APACHE II scores, sensitivity ranged from 58.2% to 59.7% while specificity ranged from 70.1% to 73.6%. The clinical utility of the parameterized cohort prediction model to predict and prevent incident delirium was greater than preventing incident delirium by treating all or none of the patients. Conclusions Our results support external validation of a prediction model parameterized to patient ICU admission acuity to predict a patients' risk for ICU delirium. Classification of patients' risk for ICU delirium by admission acuity may allow for efficient initiation of prevention measures based on individual risk profiles.	[Cherak, Stephana J.; Stelfox, Henry T.; Fiest, Kirsten M.] Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada; [Cherak, Stephana J.; Soo, Andrea; Stelfox, Henry T.; Fiest, Kirsten M.] Univ Calgary, Cumming Sch Med, Dept Crit Care Med, Calgary, AB, Canada; [Cherak, Stephana J.; Stelfox, Henry T.; Fiest, Kirsten M.] Univ Calgary, OBrien Inst Publ Hlth, Calgary, AB, Canada; [Cherak, Stephana J.; Fiest, Kirsten M.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada; [Soo, Andrea; Stelfox, Henry T.; Fiest, Kirsten M.] Alberta Hlth Serv, Calgary, AB, Canada; [Brown, Kyla N.] PolicyWise Children & Families, Calgary, AB, Canada; [Ely, E. Wesley] Tennessee Valley Vet Affairs Geriatr Res Educ Cli, Nashville, TN USA; [Ely, E. Wesley] Vanderbilt Univ, Med Ctr, Crit Illness Brain Dysfunct & Survivorship Ctr, Nashville, TN USA; Univ Calgary, Cumming Sch Med, Dept Psychiat, Calgary, AB, Canada	University of Calgary; University of Calgary; University of Calgary; University of Calgary; Alberta Health Services (AHS); University of Calgary; Geriatric Research Education & Clinical Center; Vanderbilt University; University of Calgary	Fiest, KM (corresponding author), Univ Calgary, Cumming Sch Med, Dept Community Hlth Sci, Calgary, AB, Canada.; Fiest, KM (corresponding author), Univ Calgary, Cumming Sch Med, Dept Crit Care Med, Calgary, AB, Canada.; Fiest, KM (corresponding author), Univ Calgary, OBrien Inst Publ Hlth, Calgary, AB, Canada.; Fiest, KM (corresponding author), Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.; Fiest, KM (corresponding author), Alberta Hlth Serv, Calgary, AB, Canada.; Fiest, KM (corresponding author), Univ Calgary, Cumming Sch Med, Dept Psychiat, Calgary, AB, Canada.	kmfiest@ucalgary.ca		Stelfox, Henry/0000-0003-1231-1490	Canadian Institutes of Health Research Doctoral Research Award [394654]	Canadian Institutes of Health Research Doctoral Research Award(Canadian Institutes of Health Research (CIHR))	This work was supported by a Canadian Institutes of Health Research Doctoral Research Award to SC (#394654).	Adams ST, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.d8312; Alba AC, 2017, JAMA-J AM MED ASSOC, V318, P1377, DOI 10.1001/jama.2017.12126; Altman DG, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b605; [Anonymous], 2019, CIRCULATION, V2019; Association A, 2013, CODAS, V25, P191; Barbateskovic M, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-024562; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bergeron N, 2001, INTENS CARE MED, V27, P859, DOI 10.1007/s001340100909; Brummel NE, 2013, CRIT CARE MED, V41, P2196, DOI 10.1097/CCM.0b013e31829a6f1e; Brummel NE, 2013, CRIT CARE CLIN, V29, P51, DOI 10.1016/j.ccc.2012.10.007; Bush SH, 2009, ONCOLOGIST, V14, P1039, DOI 10.1634/theoncologist.2009-0122; Chang DW, 2017, JAMA INTERN MED, V177, P280, DOI 10.1001/jamainternmed.2016.8060; Chen LM, 2012, ARCH INTERN MED, V172, P1220, DOI 10.1001/archinternmed.2012.2606; Chen Y, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000007543; Cooke CR, 2013, CRIT CARE MED, V41, P886, DOI 10.1097/CCM.0b013e31827bfc3c; Costa DK, 2015, CRIT CARE MED, V43, P2275, DOI 10.1097/CCM.0000000000001259; Dahl D, 2012, J HEALTHC MANAG, V57, P421, DOI 10.1097/00115514-201211000-00009; Devlin JW, 2018, CRIT CARE MED, V46, P1532, DOI [10.1097/CCM.0000000000003299, 10.1097/CCM.0000000000003259]; Famous KR, 2017, AM J RESP CRIT CARE, V195, P331, DOI 10.1164/rccm.201603-0645OC; Ferrante di Ruffano L, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e686; Green C, 2019, CRIT CARE MED, V47, P428, DOI 10.1097/CCM.0000000000003577; Guenther U, 2010, J CRIT CARE, V25, P144, DOI 10.1016/j.jcrc.2009.08.005; Gusmao-Flores D, 2012, CRIT CARE, V16, DOI 10.1186/cc11407; Hlatky Mark A, 2009, Circulation, V119, P2408, DOI 10.1161/CIRCULATIONAHA.109.192278; Hosie A, 2013, PALLIATIVE MED, V27, P486, DOI 10.1177/0269216312457214; Hughes CG, 2012, BEST PRACT RES-CLIN, V26, P395, DOI 10.1016/j.bpa.2012.08.004; Inouye SK, 2014, LANCET, V383, P911, DOI 10.1016/S0140-6736(13)60688-1; Janssens ACJW, 2011, EUR J CLIN INVEST, V41, P1010, DOI 10.1111/j.1365-2362.2011.02493.x; Kappen Teus H, 2018, Diagn Progn Res, V2, P11, DOI 10.1186/s41512-018-0033-6; Kappen TH, 2012, MED DECIS MAKING, V32, pE1, DOI 10.1177/0272989X12439755; Kim SM, 2018, ULTRASONOGRAPHY, V37, P36, DOI 10.14366/usg.16045; Leslie DL, 2011, J AM GERIATR SOC, V59, pS241, DOI 10.1111/j.1532-5415.2011.03671.x; Lindroth H, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019223; Marra A, 2018, CHEST, V154, P293, DOI 10.1016/j.chest.2018.03.013; Moons KGM, 2015, ADV ANAT PATHOL, V22, P303, DOI 10.1097/PAP.0000000000000072; Moons KGM, 2015, ANN INTERN MED, V162, pW1, DOI 10.7326/M14-0698; Partridge JSL, 2013, INT J GERIATR PSYCH, V28, P804, DOI 10.1002/gps.3900; Peters SAE, 2012, J CLIN EPIDEMIOL, V65, P686, DOI 10.1016/j.jclinepi.2011.11.012; Plaschke K, 2008, INTENS CARE MED, V34, P431, DOI 10.1007/s00134-007-0920-8; Pun BT, 2007, CHEST, V132, P624, DOI 10.1378/chest.06-1795; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; Robinson TN, 2009, ANN SURG, V249, P173, DOI 10.1097/SLA.0b013e31818e4776; Rousson V, 2011, BMC MED INFORM DECIS, V11, DOI 10.1186/1472-6947-11-45; Salluh JIF, 2018, ANN INTENSIVE CARE, V8, DOI 10.1186/s13613-018-0363-0; Seshan VE, 2013, STAT MED, V32, P1483, DOI 10.1002/sim.5648; Soares M, 2017, INTENS CARE MED, V43, P590, DOI 10.1007/s00134-016-4654-3; Stevens RD, 2018, CRIT CARE MED, V46, P2058, DOI 10.1097/CCM.0000000000003462; Steyerberg EW, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001381; van den Boogaard M, 2014, INTENS CARE MED, V40, P1183, DOI 10.1007/s00134-014-3393-6; van den Boogaard M, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e420; van den Boogaard M, 2010, CRIT CARE, V14, DOI 10.1186/cc9214; Vergouwe Yvonne, 2002, Semin Urol Oncol, V20, P96, DOI 10.1053/suro.2002.32521; Vranas KC, 2018, CRIT CARE MED, V46, P347, DOI 10.1097/CCM.0000000000002798; Vranas KC, 2017, CRIT CARE MED, V45, P1607, DOI 10.1097/CCM.0000000000002548; Wassenaar A, 2015, INTENS CARE MED, V41, P1048, DOI 10.1007/s00134-015-3777-2; Wassenaar A, 2019, CRIT CARE MED, V47, pE827, DOI 10.1097/CCM.0000000000003911; Zimmerman JE, 2010, J CRIT CARE, V25, P205, DOI 10.1016/j.jcrc.2009.06.010; Zimmerman JE, 2006, CRIT CARE MED, V34, P1297, DOI 10.1097/01.CCM.0000215112.84523.F0; [No title captured]	59	4	4	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 19	2020	15	8							e0237639	10.1371/journal.pone.0237639	http://dx.doi.org/10.1371/journal.pone.0237639			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG4BK	32813717	gold, Green Published			2023-01-03	WOS:000563929200017
J	Redvers, N; Blondin, S				Redvers, Nicole; Blondin, Sha			Traditional Indigenous medicine in North America: A scoping review	PLOS ONE			English	Review							HEALING PRACTICES; BIOMEDICAL SERVICES; HEALTH; INDIANS; HEALERS; OPTIONS; RIGHTS	Background Despite the documented continued use of traditional healing methods, modalities and its associated practitioners by Indigenous groups across North America, it is presumed that widespread knowledge is elusive amongst most Western trained health professionals and systems. This despite that the approximately 7.5 million Indigenous peoples who currently reside in Canada and the United States (US) are most often served by Western systems of medicine. A state of the literature is currently needed in this area to provide an accessible resource tool for medical practitioners, scholars, and communities to better understand Indigenous traditional medicine in the context of current clinical care delivery and future policy making. Methods A systematic search of multiple databases was performed utilizing an established scoping review framework. A consequent title and abstract review of articles published on traditional Indigenous medicine in the North American context was completed. Findings Of the 4,277 published studies identified, 249 met the inclusion criteria divided into the following five categorical themes: General traditional medicine, integration of traditional and Western medicine systems, ceremonial practice for healing, usage of traditional medicine, and traditional healer perspectives. Conclusions This scoping review was an attempt to catalogue the wide array of published research in the peer-reviewed and online grey literature on traditional Indigenous medicine in North America in order to provide an accessible database for medical practitioners, scholars, and communities to better inform practice, policymaking, and research in Indigenous communities.	[Redvers, Nicole] Univ North Dakota, Sch Med & Hlth Sci, Dept Family & Community Med, Grand Forks, ND 58202 USA; [Redvers, Nicole; Blondin, Sha] Arctic Indigenous Wellness Fdn, Yellowknife, NT, Canada	University of North Dakota Grand Forks	Redvers, N (corresponding author), Univ North Dakota, Sch Med & Hlth Sci, Dept Family & Community Med, Grand Forks, ND 58202 USA.; Redvers, N (corresponding author), Arctic Indigenous Wellness Fdn, Yellowknife, NT, Canada.	nicole.redvers@und.edu	Redvers, Nicole/HCI-5707-2022; Redvers, Nicole/AAD-2109-2020	Redvers, Nicole/0000-0001-8521-2130				ABBOTT M, 2009, BRIDGES, V13; Alvord L., 1999, SCALPEL SILVER BEAR; Amnesty International, UN DECL RIGHTS IND P; Arksey H., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Attneave CL, 1974, PSYCHIAT ANN, V4, P9; Baines David, 2012, J Cancer Educ, V27, pS9, DOI 10.1007/s13187-012-0319-2; Bassett Deborah, 2012, Perm J, V16, P19; Berbman R., 1973, AM J PSYCHIAT, V130, P6, DOI [10.1176/ajp.130.6.6634701956, DOI 10.1176/AJP.130.6.6634701956]; Blackstock C, 2009, FIRST PEOPLES CHILD, V4, P135; Buchwald D, 2000, MED CARE, V38, P1191, DOI 10.1097/00005650-200012000-00006; Cohen K, 2013, EXPLORE-NY, V9, P203, DOI 10.1016/j.explore.2013.04.007; Cook SJ, 2005, CAN J RURAL MED, V10, P95; Daudt HML, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-48; de Leeuw S, 2017, CAN FAM PHYSICIAN, V63, P56; Dell CA, 2011, CAN J PSYCHIAT, V56, P75, DOI 10.1177/070674371105600202; Dickerson D, 2012, AM J DRUG ALCOHOL AB, V38, P505, DOI 10.3109/00952990.2012.699565; Drost JL, 2019, J ALTERN COMPLEM MED, V25, pS69, DOI 10.1089/acm.2018.0387; Earle L., UNDERSTANDING CHRONI; Eggertson L, 2015, CAN MED ASSOC J, V187, pE153, DOI 10.1503/cmaj.109-4989; First Nations Health Authority, TRAD MED TRAD HEAL G; Gagnon Y., 1989, NATIVE STUDIES REV, V5; Garrett MT, 2011, J COUNS DEV, V89, P318, DOI 10.1002/j.1556-6678.2011.tb00096.x; Garro L C, 1991, Arctic Med Res, VSuppl, P213; Garro L C, 1988, Arctic Med Res, V47 Suppl 1, P317; George J, 2018, J COMMUN HEALTH, V43, P227, DOI 10.1007/s10900-017-0409-5; Gone JP, 2016, AM J COMMUN PSYCHOL, V58, P314, DOI 10.1002/ajcp.12046; Gone JP, 2011, J PSYCHOACTIVE DRUGS, V43, P291, DOI 10.1080/02791072.2011.628915; Gonzales PC, 2007, THESIS; Gossage JP, 2003, J PSYCHOACTIVE DRUGS, V35, P33, DOI 10.1080/02791072.2003.10399991; Greensky C, 2014, PAIN MED, V15, P1795, DOI 10.1111/pme.12488; Gurley D, 2001, PSYCHIATR SERV, V52, P68, DOI 10.1176/appi.ps.52.1.68; Harris KM, 2015, GROUP, DOI 10.1002/14651858.CD011651; Hartmann WE, 2014, AM J COMMUN PSYCHOL, V54, P274, DOI 10.1007/s10464-014-9671-1; Health Canada, 2010, STAT PROF HLTH 1 NAT; Heilbron C., 2000, CAN J COUNS PSYCHOT, V34, P3; Hill LP, 2008, THESIS; Hunter LM, 2006, J TRANSCULT NURS, V17, P13, DOI 10.1177/1043659605278937; Ijaz N, 2018, J ALTERN COMPLEM MED, V24, P307, DOI 10.1089/acm.2017.0346; Kesler DO, 2015, AM J PREV MED, V49, pS263, DOI 10.1016/j.amepre.2015.07.007; Kim C, 1998, ARCH INTERN MED, V158, P2245, DOI 10.1001/archinte.158.20.2245; Koithan Mary, 2010, J Nurse Pract, V6, P477; Kovach Margaret, 2009, INDIGENOUS METHODOLO; Lavallee LF, 2009, INT J QUAL METHODS, V8, P21, DOI [10.1177/16094069090, DOI 10.1177/160940690900800103]; Lavoie JG, 2013, INT J CIRCUMPOL HEAL, V72, DOI 10.3402/ijch.v72i0.22690; Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; LOWRY F, 1993, CAN MED ASSOC J, V148, P270; Lucero E, 2011, J PSYCHOACTIVE DRUGS, V43, P319, DOI 10.1080/02791072.2011.628925; Mainguy Barbara, 2013, Adv Mind Body Med, V27, P4; Manitowabi D, 2013, CAN J NATIVE STUD, V33, P97; Marbella AM, 1998, ARCH FAM MED, V7, P182, DOI 10.1001/archfami.7.2.182; Marsh T.N., 2016, J ADDICTION RES THER, V7, P284, DOI [10.4172/2155-6105.1000284, DOI 10.4172/2155-6105.1000284]; Marsh TN, 2018, INT INDIG POLICY J, V9, DOI 10.18584/iipj.2018.9.2.2; Marsh TN, 2015, HARM REDUCT J, V12, DOI 10.1186/s12954-015-0046-1; Mehl-Madrona LE, 1999, ALTERN THER HEALTH M, V5, P36; Mehl-Madrona L, 2008, J ALTERN COMPLEM MED, V14, P497, DOI 10.1089/acm.2007.0578; Mehl-Madrona Lewis, 2014, Perm J, V18, P4, DOI 10.7812/TPP/13-104; MERRILL JM, 1995, AM J MED SCI, V310, P87; Milne D, 2000, MED ANTHROPOL Q, V14, P543, DOI 10.1525/maq.2000.14.4.543; Moghaddam JF, 2013, J COMMUN HEALTH, V38, P1115, DOI 10.1007/s10900-013-9721-x; Moghaddam JF, 2011, SUBST USE MISUSE, V46, P1431, DOI 10.3109/10826084.2011.592441; Moorehead VD, 2015, AM J COMMUN PSYCHOL, V56, P383, DOI 10.1007/s10464-015-9747-6; Mpinga EK, 2013, HEALTH HUM RIGHTS, V15, P44; Mugabe J., 2005, INT J MINOR GROUP RI, V12, P8; National Aboriginal Health Organization (NAHO), 2008, OV TRAD KNOWL MED PU; Nauman Eileen, 2007, Cardiol Rev, V15, P35, DOI 10.1097/01.crd.0000197977.68113.32; Novins DK, 2004, MED CARE, V42, P670, DOI 10.1097/01.mlr.0000129902.29132.a6; Olson R., 2013, PIMATISIWIN J ABORIG, V10; Oulanova O., 2010, CANADIAN J COUNSELLI, V44, P346; Pham MT, 2014, RES SYNTH METHODS, V5, P371, DOI 10.1002/jrsm.1123; Plamondon KM, 2020, CRIT PUBLIC HEALTH, V30, P415, DOI 10.1080/09581596.2018.1551613; Prescott SL, 2018, CHALLENGES, V9, P10, DOI [10.3390/challe9010010, DOI 10.3390/CHALLE9010010]; Redvers N, 2018, CHALLENGES, V9, P30, DOI [DOI 10.3390/CHALLE9020030, 10.3390/challe9020030]; Redvers N, 2019, INT J CIRCUMPOL HEAL, V78, DOI 10.1080/22423982.2019.1577093; Richmond CAM, 2016, PUBLIC HEALTH REV, V37, DOI 10.1186/s40985-016-0016-5; Rowan M, 2014, SUBST ABUSE TREAT PR, V9, DOI 10.1186/1747-597X-9-34; Rybak C, 2009, COUNS PSYCHOL Q, V22, P333, DOI 10.1080/09515070903270900; Saini M., 2012, SYSTEMATIC REV W ABO; Shetty P., INTEGRATING MODERN T; Sinjela M, 2005, INT J MINOR GROUP RI, V12, P1, DOI 10.1163/1571811053890399; Stephens C, 2007, LANCET, V370, P1756, DOI 10.1016/S0140-6736(07)61742-5; Struthers R, 2000, J Holist Nurs, V18, P261, DOI 10.1177/089801010001800307; Struthers Roxanne, 2004, Complement Ther Nurs Midwifery, V10, P141, DOI 10.1016/j.ctnm.2004.05.001; Struthers Roxanne, 2005, Complement Ther Clin Pract, V11, P78, DOI 10.1016/j.ctnm.2004.05.002; Struthers Roxanne, 2004, J Holist Nurs, V22, P209, DOI 10.1177/0898010104266735; Struthers Roxanne, 2008, J Cult Divers, V15, P70; United Nations, 2009, POT TRAD MED SHOULD; United Nations, 2007, UN DECL RIGHTS IND P; University of Saskatchewan, IND STUD PORT TOOL I; Valdez Jeanine L, 2009, J Reprod Med, V54, P603; Van Sickle D, 2003, AM INDIAN ALASKA NAT, V11, P1; Vanast W J, 1992, Can Bull Med Hist, V9, P57; Waldram J B, 1990, Med Anthropol, V12, P325; Waldram JB, 2013, MED ANTHROPOL, V32, P191, DOI 10.1080/01459740.2012.714822; WALDRAM JB, 1990, AM INDIAN ALASKA NAT, V4, P9; Warne D, 2015, SOC PERSONAL PSYCHOL, V9, P567, DOI 10.1111/spc3.12198; Weber-Pillwax C., 2004, PIMATISIWIN J ABORIG, V2004, P78; Whalen DH, 2016, F1000RES, V5, DOI DOI 10.12688/F1000RESEARCH.8656.1; WHO, 2008, BEIJ DECL AD WHO C T; World Trade Organization, POL CONT ACT INN ACC; Wyrostok N., 2000, CANADIAN J COUNSELLI, V34, P14; ZUBEK EM, 1994, CAN FAM PHYSICIAN, V40, P1923	101	17	20	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 13	2020	15	8							e0237531	10.1371/journal.pone.0237531	http://dx.doi.org/10.1371/journal.pone.0237531			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NE5VG	32790714	Green Published, gold			2023-01-03	WOS:000562668300056
J	Barth, J; Geed, S; Mitchell, A; Lum, PS; Edwards, DF; Dromerick, AW				Barth, Jessica; Geed, Shashwati; Mitchell, Abigail; Lum, Peter S.; Edwards, Dorothy F.; Dromerick, Alexander W.			Characterizing upper extremity motor behavior in the first week after stroke	PLOS ONE			English	Article							UPPER-LIMB RECOVERY; ARM ACTIVITY; ACCELERATION METRICS; CORTICAL INFARCTS; SUBACUTE STROKE; REHABILITATION; ACCELEROMETRY; COMPENSATION; NONUSE; BRAIN	Background Animal models of brain recovery identify the first days after lesioning as a time of great flux in sensorimotor function and physiology. After rodent motor system lesioning, daily skill training in the less affected forelimb reduces skill acquisition in the more affected forelimb. We asked whether spontaneous human motor behaviors of the less affected upper extremity (UE) early after stroke resemble the animal training model, with the potential to suppress clinical recovery. Methods This prospective observational study used a convenience sample of patients (n = 25, mean 4.5 +/- 1.8) days after stroke with a wide severity range; Controls were hospitalized for non-neurological conditions (n = 12). Outcome measures were Accelerometry, Upper-Extremity Fugl-Meyer (UEFM), Action Research Arm Test (ARAT), Shoulder Abduction/ Finger Extension Test (SAFE), NIH Stroke Scale (NIHSS). Results Accelerometry indicated total paretic UE movement was reduced compared to controls, primarily due to a 44% reduction of bilateral UE use. Unilateral paretic movement was unchanged. Thus, movement shifted early after stroke; bilateral use was reduced and unilateral use of the non-paretic UE was increased by 77%. Low correlations between movement time and motor performance prompted an exploratory factor analysis (EFA) revealing a 2-component solution; motor performance tests load on one component (motor performance) whereas accelerometry-derived variables load on a second orthogonal component (quantity of movement). Conclusions Early after stroke, spontaneous overall UE movement is reduced, and movement shifts to unilateral use of the non-paretic UE. Two mechanisms that could influence motor recovery may already be in place 4.5 +/- 1.8 days post stroke: (1) the overuse of the less affected UE, which could set the stage for learned non-use and (2) skill acquisition in the non-paretic limb that could impede recovery. Accurate UE motor assessment requires two independent constructs: motor performance and quantity of movement. These findings provide opportunities and measurement methods for studies to develop new behaviorally-based stroke recovery treatments that begin early after onset.	[Barth, Jessica; Geed, Shashwati; Mitchell, Abigail; Dromerick, Alexander W.] MedStar Natl Rehabil Network, Washington, DC 20010 USA; [Geed, Shashwati; Dromerick, Alexander W.] Georgetown Univ, Dept Rehabil Med, Washington, DC 20057 USA; [Lum, Peter S.] Catholic Univ Amer, Dept Biomed Engn, Washington, DC 20064 USA; [Edwards, Dorothy F.] Univ Wisconsin, Dept Kinesiol & Occupat Therapy, Madison, WI USA	Georgetown University; Catholic University of America; University of Wisconsin System; University of Wisconsin Madison	Dromerick, AW (corresponding author), MedStar Natl Rehabil Network, Washington, DC 20010 USA.; Dromerick, AW (corresponding author), Georgetown Univ, Dept Rehabil Med, Washington, DC 20057 USA.	Alexander.W.Dromerick@medstar.net	Barth, Jessica/HCH-8661-2022	Barth, Jessica/0000-0001-8051-9539; Geed, Shashwati/0000-0003-0190-6923; Mitchell, Abigail/0000-0003-1951-0660	Center for Brain Plasticity and Recovery; Stroke Central Atlantic Network for Research [NINDS NS086513]; Department of Health and Human Services [NIDILRR 90REGE0004]	Center for Brain Plasticity and Recovery; Stroke Central Atlantic Network for Research; Department of Health and Human Services	The following work was funded by the following: Center for Brain Plasticity and Recovery (JB, SG, AM, PL, DE, AD) Stroke Central Atlantic Network for Research: NINDS NS086513 (JB, SG, DE, AD) Department of Health and Human Services: NIDILRR 90REGE0004 (PL, AWD) Stroke Central Atlantic Network for Research: NINDS NS086513 (JB, SG, DE, AD) Full names of commercial companies that funded the study or authors (N/A).	Allred RP, 2008, EXP NEUROL, V210, P172, DOI 10.1016/j.expneurol.2007.10.010; Allred RP, 2010, BEHAV NEUROSCI, V124, P124, DOI 10.1037/a0018457; ANDREWS K, 1979, RHEUMATOL REHABIL, V18, P43, DOI 10.1093/rheumatology/18.1.43; Bailey RR, 2015, NEUROREHAB NEURAL RE, V29, P969, DOI 10.1177/1545968315583720; Bailey RR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103135; Bailey RR, 2013, J REHABIL RES DEV, V50, P1213, DOI 10.1682/JRRD.2012.12.0222; Benjamin EJ, 2018, CIRCULATION, V137, pE67, DOI 10.1161/CIR.0000000000000558; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Carmichael ST, 2017, EXP NEUROL, V287, P384, DOI 10.1016/j.expneurol.2016.02.007; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; Carter AR, 2010, CURR NEUROL NEUROSCI, V10, P158, DOI 10.1007/s11910-010-0091-9; Cirstea MC, 2000, BRAIN, V123, P940, DOI 10.1093/brain/123.5.940; Cramer SC, 2008, CURR OPIN NEUROL, V21, P76, DOI 10.1097/WCO.0b013e3282f36cb6; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; Dromerick AW, 2003, J REHABIL RES DEV, V40, P1, DOI 10.1682/JRRD.2003.01.0001; DUNCAN PW, 1983, PHYS THER, V63, P1606, DOI 10.1093/ptj/63.10.1606; Enderby P M, 1987, Int Rehabil Med, V8, P166; Garra G, 2013, PEDIATR EMERG CARE, V29, P17, DOI 10.1097/PEC.0b013e31827b2299; Gebruers N, 2014, AM J PHYS MED REHAB, V93, P245, DOI 10.1097/PHM.0000000000000045; Gebruers N, 2013, J REHABIL RES DEV, V50, P1099, DOI 10.1682/JRRD.2012.09.0166; Geed S, 2017, J MOTOR BEHAV, V49, P312, DOI 10.1080/00222895.2016.1204265; Geed S, 2017, FRONT NEURAL CIRCUIT, V11, DOI 10.3389/fncir.2017.00007; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; Gittler M, 2018, JAMA-J AM MED ASSOC, V319, P820, DOI 10.1001/jama.2017.22036; Han CE, 2013, NEUROREHAB NEURAL RE, V27, P439, DOI 10.1177/1545968312471904; Hubbard IJ, 2009, OCCUP THER INT, V16, P175, DOI 10.1002/oti.275; Iacovelli C, 2019, J NEUROENG REHABIL, V16, DOI 10.1186/s12984-019-0603-z; Jones TA, 2017, NAT REV NEUROSCI, V18, P267, DOI 10.1038/nrn.2017.26; JReding M, 1988, STROKE; Jvreskog, 1996, APPL FACTOR ANAL NAT; KAISER HF, 1960, EDUC PSYCHOL MEAS, V20, P141, DOI 10.1177/001316446002000116; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Lang Catherine E, 2007, J Neurol Phys Ther, V31, P56; Lang CE, 2006, ARCH PHYS MED REHAB, V87, P1605, DOI 10.1016/j.apmr.2006.09.003; Lang CE, 2013, J HAND THER, V26, P104, DOI 10.1016/j.jht.2012.06.005; Levin MF, 2009, NEUROREHAB NEURAL RE, V23, P313, DOI 10.1177/1545968308328727; Leyton ASF, 1917, Q J EXP PHYSIOL, V11, P135, DOI 10.1113/expphysiol.1917.sp000240; Lum PS, 2009, TOP STROKE REHABIL, V16, P237, DOI 10.1310/tsr1604-237; Michielsen ME, 2012, ARCH PHYS MED REHAB, V93, P1975, DOI 10.1016/j.apmr.2012.03.016; National Institutes of Health Stroke Scale (NIHSS), WILEY STATSREF STAT; Nijland RHM, 2010, STROKE, V41, P745, DOI 10.1161/STROKEAHA.109.572065; Pedretti LW, 2001, OCCUPATIONAL THERAPY; Rand D, 2015, J STROKE CEREBROVASC, V24, P274, DOI 10.1016/j.jstrokecerebrovasdis.2014.07.039; Roby-Brami A, 2003, ACTA NEUROL SCAND, V107, P369, DOI 10.1034/j.1600-0404.2003.00021.x; SCANR, 2018, TRIUMPH STROK; Stinear CM, 2017, ANN CLIN TRANSL NEUR, V4, P811, DOI 10.1002/acn3.488; Stinear CM, 2017, STROKE, V48, P1011, DOI 10.1161/STROKEAHA.116.015790; Stinear CM, 2012, BRAIN, V135, P2527, DOI 10.1093/brain/aws146; Tabachnick B. G., 2012, SINGULAR SPECTRUM AN, V6h, DOI DOI 10.1007/978-1-4757-2514-8_3; TAUB E, 1994, J EXP ANAL BEHAV, V61, P281, DOI 10.1901/jeab.1994.61-281; Thrane G, 2011, J REHABIL MED, V43, P299, DOI 10.2340/16501977-0676; Urbin MA, 2015, ARCH PHYS MED REHAB, V96, P854, DOI 10.1016/j.apmr.2014.11.018; Urbin MA, 2015, J NEUROL PHYS THER, V39, P111, DOI 10.1097/NPT.0000000000000085; Uswatte G, 2006, NEUROLOGY, V67, P1189, DOI 10.1212/01.wnl.0000238164.90657.c2; Uswatte G, 2005, ARCH PHYS MED REHAB, V86, P1498, DOI 10.1016/j.apmr.2005.01.010; Uswatte G, 2000, STROKE, V31, P662, DOI 10.1161/01.STR.31.3.662; Uswatte G, 2006, ARCH PHYS MED REHAB, V87, P1340, DOI 10.1016/j.apmr.2006.06.006; Uswatte G, 2009, REHABIL PSYCHOL, V54, P398, DOI 10.1037/a0017501; Van der Lee JH, 2001, ARCH PHYS MED REHAB, V82, P14, DOI 10.1053/apmr.2001.18668; van der Pas SC, 2011, ARCH PHYS MED REHAB, V92, P1437, DOI 10.1016/j.apmr.2011.02.021; Veerbeek JM, 2011, STROKE, V42, P1482, DOI 10.1161/STROKEAHA.110.604090; WEINTRAUB S, 1988, J NEUROL NEUROSUR PS, V51, P1481, DOI 10.1136/jnnp.51.12.1481; Wong DL, 2001, PAIN, V89, P295, DOI 10.1016/S0304-3959(00)00375-4; Zeiler SR, 2019, CURR NEUROL NEUROSCI, V19, DOI 10.1007/s11910-019-0927-x; Zeiler SR, 2013, CURR OPIN NEUROL, V26, P609, DOI 10.1097/WCO.0000000000000025	67	7	7	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 10	2020	15	8							e0221668	10.1371/journal.pone.0221668	http://dx.doi.org/10.1371/journal.pone.0221668			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NC7KJ	32776927	gold, Green Published, Green Submitted			2023-01-03	WOS:000561393800011
J	Hauser, SL; Bar-Or, A; Cohen, JA; Comi, G; Correale, J; Coyle, PK; Cross, AH; de Seze, J; Leppert, D; Montalban, X; Selmaj, K; Wiendl, H; Kerloeguen, C; Willi, R; Li, B; Kakarieka, A; Tomic, D; Goodyear, A; Pingili, R; Haring, DA; Ramanathan, K; Merschhemke, M; Kappos, L				Hauser, Stephen L.; Bar-Or, Amit; Cohen, Jeffrey A.; Comi, Giancarlo; Correale, Jorge; Coyle, Patricia K.; Cross, Anne H.; de Seze, Jerome; Leppert, David; Montalban, Xavier; Selmaj, Krzysztof; Wiendl, Heinz; Kerloeguen, Cecile; Willi, Roman; Li, Bingbing; Kakarieka, Algirdas; Tomic, Davorka; Goodyear, Alexandra; Pingili, Ratnakar; Haring, Dieter A.; Ramanathan, Krishnan; Merschhemke, Martin; Kappos, Ludwig			Ofatumumab versus Teriflunomide in Multiple Sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							B-CELL DEPLETION; INTERFERON BETA-1A; ORAL TERIFLUNOMIDE; OCRELIZUMAB; EFFICACY; PLACEBO; SAFETY	BackgroundOfatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known. MethodsIn two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiple sclerosis to receive subcutaneous ofatumumab (20 mg every 4 weeks after 20-mg loading doses at days 1, 7, and 14) or oral teriflunomide (14 mg daily) for up to 30 months. The primary end point was the annualized relapse rate. Secondary end points included disability worsening confirmed at 3 months or 6 months, disability improvement confirmed at 6 months, the number of gadolinium-enhancing lesions per T1-weighted magnetic resonance imaging (MRI) scan, the annualized rate of new or enlarging lesions on T2-weighted MRI, serum neurofilament light chain levels at month 3, and change in brain volume. ResultsOverall, 946 patients were assigned to receive ofatumumab and 936 to receive teriflunomide; the median follow-up was 1.6 years. The annualized relapse rates in the ofatumumab and teriflunomide groups were 0.11 and 0.22, respectively, in trial 1 (difference, -0.11; 95% confidence interval [CI], -0.16 to -0.06; P<0.001) and 0.10 and 0.25 in trial 2 (difference, -0.15; 95% CI, -0.20 to -0.09; P<0.001). In the pooled trials, the percentage of patients with disability worsening confirmed at 3 months was 10.9% with ofatumumab and 15.0% with teriflunomide (hazard ratio, 0.66; P=0.002); the percentage with disability worsening confirmed at 6 months was 8.1% and 12.0%, respectively (hazard ratio, 0.68; P=0.01); and the percentage with disability improvement confirmed at 6 months was 11.0% and 8.1% (hazard ratio, 1.35; P=0.09). The number of gadolinium-enhancing lesions per T1-weighted MRI scan, the annualized rate of lesions on T2-weighted MRI, and serum neurofilament light chain levels, but not the change in brain volume, were in the same direction as the primary end point. Injection-related reactions occurred in 20.2% in the ofatumumab group and in 15.0% in the teriflunomide group (placebo injections). Serious infections occurred in 2.5% and 1.8% of the patients in the respective groups. ConclusionsAmong patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide. (Funded by Novartis; ASCLEPIOS I and II ClinicalTrials.gov numbers, NCT02792218 and NCT02792231.) In two identical trials involving a total of 1882 patients with multiple sclerosis, the human anti-CD20 monoclonal antibody ofatumumab was associated with a lower annualized relapse rate than the pyrimidine-synthesis inhibitor teriflunomide, as well as fewer lesions on MRI.	[Hauser, Stephen L.] Univ Calif San Francisco, Dept Neurol, UCSF Weill Inst Neurosci, 675 Nelson Rising Ln, San Francisco, CA 94158 USA; [Bar-Or, Amit] Univ Penn, Ctr Neuroinflammat & Expt Therapeut, Philadelphia, PA 19104 USA; [Bar-Or, Amit] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Cohen, Jeffrey A.] Cleveland Clin, Dept Neurol, Mellen Ctr Multiple Sclerosis, Neurol Inst, Cleveland, OH 44106 USA; [Comi, Giancarlo] Osped San Raffaele, Inst Expt Neurol, Milan, Italy; [Comi, Giancarlo] Osped San Raffaele, Multiple Sclerosis Ctr IRCCS, Milan, Italy; [Correale, Jorge] Fleni, Dept Neurol, Buenos Aires, DF, Argentina; [Coyle, Patricia K.] SUNY Stony Brook, Dept Neurol, Stony Brook, NY 11794 USA; [Cross, Anne H.] Washington Univ, Sch Med, St Louis, MO USA; [de Seze, Jerome] Univ Hosp Strasburg, Strasbourg, France; [de Seze, Jerome] INSERM 1434, Clin Invest Ctr, Strasbourg, France; [Leppert, David] Univ Hosp Basel, Basel, Switzerland; [Kerloeguen, Cecile; Willi, Roman; Kakarieka, Algirdas; Tomic, Davorka; Haring, Dieter A.; Ramanathan, Krishnan; Merschhemke, Martin] Novartis Pharmaceut, Basel, Switzerland; [Kappos, Ludwig] Univ Hosp Basel, Neurol Clin & Policlin, Dept Med, Petersgraben 4, CH-4031 Basel, Switzerland; [Kappos, Ludwig] Univ Hosp Basel, Neurol Clin & Policlin, Dept Clin Res, Petersgraben 4, CH-4031 Basel, Switzerland; [Kappos, Ludwig] Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed, Petersgraben 4, CH-4031 Basel, Switzerland; [Kappos, Ludwig] Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed Engn, Petersgraben 4, CH-4031 Basel, Switzerland; [Kappos, Ludwig] Univ Basel, Basel, Switzerland; [Montalban, Xavier] Hosp Univ Vall dHebron, Dept Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya Cemcat, Barcelona, Spain; [Selmaj, Krzysztof] Univ Warmia & Mazury, Olsztyn, Poland; [Selmaj, Krzysztof] Ctr Neurol, Lodz, Poland; [Wiendl, Heinz] Univ Munster, Inst Translat Neurol, Dept Neurol, Munster, Germany; [Li, Bingbing; Goodyear, Alexandra; Pingili, Ratnakar] Novartis Pharmaceut, E Hanover, NJ USA	University of California System; University of California San Francisco; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Cleveland Clinic Foundation; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Washington University (WUSTL); CHU Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Basel; Novartis; University of Basel; University of Basel; University of Basel; University of Basel; University of Basel; Hospital Universitari Vall d'Hebron; University of Warmia & Mazury; University of Munster; Novartis	Hauser, SL (corresponding author), Univ Calif San Francisco, Dept Neurol, UCSF Weill Inst Neurosci, 675 Nelson Rising Ln, San Francisco, CA 94158 USA.; Kappos, L (corresponding author), Univ Hosp Basel, Neurol Clin & Policlin, Dept Med, Petersgraben 4, CH-4031 Basel, Switzerland.; Kappos, L (corresponding author), Univ Hosp Basel, Neurol Clin & Policlin, Dept Clin Res, Petersgraben 4, CH-4031 Basel, Switzerland.; Kappos, L (corresponding author), Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed, Petersgraben 4, CH-4031 Basel, Switzerland.; Kappos, L (corresponding author), Univ Hosp Basel, Neurol Clin & Policlin, Dept Biomed Engn, Petersgraben 4, CH-4031 Basel, Switzerland.	stephen.hauser@ucsf.edu; kapposl-pa@usb.ch	Ozakbas, Serkan/V-6427-2019; Montalban, Xavier/J-5938-2016; Serrano-Castro, Pedro/A-7537-2008; Bar-Or, Amit/AIC-1416-2022; Wiendl, Heinz/AAX-6041-2021; Vecsei, Laszlo/B-2066-2010; van Oosten, Bob/I-7152-2012	Montalban, Xavier/0000-0002-0098-9918; Serrano-Castro, Pedro/0000-0002-3414-2707; YUCEYAR, NUR/0000-0003-4590-6423; Vecsei, Laszlo/0000-0001-8037-3672; Turcani, Peter/0000-0002-4868-6836; MARTINEZ YELAMOS, SERGIO/0000-0001-9889-2040; van Oosten, Bob/0000-0003-4536-6201; Pozzilli, Carlo/0000-0002-6360-4798; Sevim, Serhan/0000-0002-0518-3374; Cutter, Gary/0000-0002-8455-980X; Castillo-Trivino, Tamara/0000-0002-9249-3185; Reis, AlessanRSS/0000-0001-8486-7469; Derfuss, Tobias/0000-0001-8656-4250; Laplaud, David/0000-0001-6113-6938; Meca-Lallana, Virginia/0000-0001-9418-4127; Pandit, Lekha/0000-0002-2269-5312; Liow, Kore/0000-0001-6452-9227; Paz Soldan, M. Mateo/0000-0003-0521-7789; Bartosik-Psujek, Halina/0000-0002-2860-6456; Jasinska, Elzbieta/0000-0003-0016-9896; Pingili, Ratnakar/0000-0002-4553-1871; Reingold, Stephen/0000-0003-4485-8634; Willi, Roman/0000-0001-9612-9877	Novartis Pharma	Novartis Pharma	Supported by Novartis Pharma.	[Anonymous], 2016, ARZ AUT PRESCR INF; Bar-Or A, 2018, NEUROLOGY, V90, pE1805, DOI 10.1212/WNL.0000000000005516; Buron MD, 2019, NEUROLOGY, V92, pE1811, DOI 10.1212/WNL.0000000000007314; Cancer Institute N, 2017, COMMON TERMINOLOGY C; Confavreux C, 2014, LANCET NEUROL, V13, P247, DOI 10.1016/S1474-4422(13)70308-9; Disanto G, 2017, ANN NEUROL, V81, P857, DOI 10.1002/ana.24954; Engelberts PJ, 2016, J IMMUNOL, V197, P4829, DOI 10.4049/jimmunol.1600811; Fogarty E, 2016, MULT SCLER RELAT DIS, V9, P23, DOI 10.1016/j.msard.2016.06.001; Genentech, 2020, OCR OCR PRESCR INF; Hauser SL, 2017, NEW ENGL J MED, V376, P221, DOI 10.1056/NEJMoa1601277; Hauser SL, 2008, NEW ENGL J MED, V358, P676, DOI 10.1056/NEJMoa0706383; International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use, 2001, J Postgrad Med, V47, P45; Kahari L, 2019, J CLIN INVEST, V129, P3086, DOI 10.1172/JCI125740; Kalincik T, 2019, J NEUROL NEUROSUR PS, V90, P458, DOI 10.1136/jnnp-2018-319831; Kramer O, 2010, EVOL INTELL, V3, P51, DOI 10.1007/s12065-010-0035-y; Kurrasch R, 2013, J RHEUMATOL, V40, P1089, DOI 10.3899/jrheum.121118; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Leppert D, 2017, COMP BCELL RECOVERY; Lublin FD, 2014, NEUROLOGY, V83, P278, DOI 10.1212/WNL.0000000000000560; Montalban X, 2017, NEW ENGL J MED, V376, P209, DOI 10.1056/NEJMoa1606468; O'Connor P, 2011, NEW ENGL J MED, V365, P1293, DOI 10.1056/NEJMoa1014656; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Roll P, 2006, ARTHRITIS RHEUM-US, V54, P2377, DOI 10.1002/art.22019; Schach S, 2007, MULT SCLER, V13, P509, DOI 10.1177/1352458506069537; Semple KM, 2019, CTS-CLIN TRANSL SCI, V12, P283, DOI 10.1111/cts.12613; SK AZ, 2016, DIABETOL STOFFWECHS, V11, pS01; Sorensen PS, 2014, NEUROLOGY, V82, P573, DOI 10.1212/WNL.0000000000000125; Theil D, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01340; Vermersch P, 2014, MULT SCLER J, V20, P705, DOI 10.1177/1352458513507821; World Medical Association, 2006, WMA DECL HELS ETH PR	30	175	179	7	34	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 6	2020	383	6					546	557		10.1056/NEJMoa1917246	http://dx.doi.org/10.1056/NEJMoa1917246			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB3TI	32757523	Bronze, Green Published			2023-01-03	WOS:000560438400017
J	Bizimana, T; Kayumba, PC; Heide, L				Bizimana, Thomas; Kayumba, Pierre Claver; Heide, Lutz			Prices, availability and affordability of medicines in Rwanda	PLOS ONE			English	Article								Background Access to affordable and good quality medicines is a key to meeting Sustainable Development Goal No. 3 by the year 2030. Prices, availability and affordability of essential medicines have been studied in many developing countries, but no such information has been published about Rwanda yet. This study aimed at providing data on prices, availability and affordability of medicines in different health facilities of Rwanda. Methods A survey was carried out on availability, prices and affordability of 18 medicines in Kigali City and five districts of Rwanda. 44 health facilities were surveyed, including public and faith-based hospitals, public and faith-based health centers and private pharmacies. The standardized methodology developed by WHO and Health Action International (HAI) was used to collect and analyze the data. Findings Prices for generic medicines in public and faith-based health facilities were remarkably low, with median price ratios (MPRs) of 1.0 in comparison to the international procurement prices published by Management Sciences for Health. In private pharmacies, prices were twice as high (MPR = 1.99 for generics). Availability of medicines fell short of the of 80% target set by WHO, but was better than reported from many other developing countries. Availability of medicines was highest in the private sector (71.3%) and slightly lower in the faith-based (62.8%) and public (59.6%) sectors. The government procurement agency was found to work efficiently, achieving prices 30% below the international procurement price given in the International Medical Product Price Guide. Affordability of medicines was better in the public and faith-based sectors than in the private sector. Conclusion In Rwanda, medicines are affordable but poorly available in both the public and the faith-based sectors. Further improvements of the availability of medicines in the public and the faith-based health facilities represent the most important key to increase accessibility and affordability of medicines in Rwanda.	[Bizimana, Thomas] Univ Rwanda, Coll Med & Hlth Sci CMHS, Sch Med & Pharm, Dept Pharm, Kigali, Rwanda; [Kayumba, Pierre Claver] Univ Rwanda, East African Community Reg Ctr Excellence Vaccine, Kigali, Rwanda; [Heide, Lutz] Eberhard Karls Univ Tubingen, Pharmaceut Inst, Tubingen, Germany	University of Rwanda; University of Rwanda; Eberhard Karls University of Tubingen	Heide, L (corresponding author), Eberhard Karls Univ Tubingen, Pharmaceut Inst, Tubingen, Germany.	heide@uni-tuebingen.de	Bizimana, Thomas/GLV-3526-2022	Bizimana, Thomas/0000-0003-3110-1018; Heide, Lutz/0000-0001-7809-7453	Baden-WurttembergSTIPENDIUM for University Students -BWS plus, a programme of the Baden-Wu rttemberg Stiftung; Deutsche Forschungsgemeinschaft; University of Tubingen	Baden-WurttembergSTIPENDIUM for University Students -BWS plus, a programme of the Baden-Wu rttemberg Stiftung; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); University of Tubingen	The authors gratefully acknowledge financial support from the Baden-WurttembergSTIPENDIUM for University Students -BWS plus, a programme of the Baden-Wu rttemberg Stiftung. This publication was produced in the BWS plus project "Joint teaching and research on essential medicines in Rwanda". We furthermore acknowledge support for open access publication by the Deutsche Forschungsgemeinschaft and the Open Access Publishing Fund of the University of Tubingen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript".	[Anonymous], **NON-TRADITIONAL**; [Anonymous], **NON-TRADITIONAL**; [Anonymous], **NON-TRADITIONAL**; Burrone E, 2019, B WORLD HEALTH ORGAN, V97, P575, DOI 10.2471/BLT.18.229179; Cameron A, 2009, LANCET, V373, P240, DOI 10.1016/S0140-6736(08)61762-6; Fang Y, 2012, MED PRICES AVAILABIL; Kalisa I, 2015, DEV COMMUNITY BASED; Khuluza F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175399; Management Sciences for Health, 2016, MSH INT MED PROD PRI; Ministry of Health-Rwanda, 2015, NAT LIST ESS MED PAE, V1st; Ministry of Health-Rwanda, 2017, PRIV HLTH FAC RWAND; Ministry of Health-Rwanda, 2015, NAT LIST ESS MED AD, V6th; Ministry of Health-Rwanda, 2012, GYN OBST CLIN PROT T; Ministry of Health-Rwanda, 2017, LIST AUTH MED AUG 20; Nditunze L., 2015, RWANDA J, V2, P85, DOI [10.4314/rjhs.v2i1.12F, DOI 10.4314/RJHS.V2I1.12F]; Nyanwura EM, 2013, INT J SCI TECHNOL RE, V2, P208; Republic of Rwanda-Ministry of Health, 2013, MINISTRY HLTH ANN RE; UN Commission on Life-Saving Commodities for Women and Children, 2012, EV WOM EV CHILD COMM; United Nations Economic and Social Council, 2019, PROGR SUST DEV GOAL; WHO, 2017, UPD WHO REC TRAN ACI; WHO, 2013, FOLL UP POL DECL HIG; Wirtz VJ, 2017, LANCET, V389, P403, DOI 10.1016/S0140-6736(16)31599-9; World Health Organization, 2016, ASS MED PRIC REIMB S; World Health Organization, 2009, WHO MOD FORM 2008; World Health Organization, WHO MOD PRESCR INF D; World Health Organization Health Action International, 2016, MEAS MED PRIC AV AFF, V2nd; World Health Organization Rotary International Centers for Disease Control and Prevention and UNICEF, 2013, GLOB ACT PLAN PREV C	27	10	10	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 3	2020	15	8							e0236411	10.1371/journal.pone.0236411	http://dx.doi.org/10.1371/journal.pone.0236411			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NA7OS	32745100	gold, Green Published			2023-01-03	WOS:000560006800012
J	Mayer, KH; Molina, JM; Thompson, MA; Anderson, PL; Mounzer, KC; De Wet, JJ; DeJesus, E; Jessen, H; Grant, RM; Ruane, PJ; Wong, P; Ebrahimi, R; Zhong, LJ; Mathias, A; Callebaut, C; Collins, SE; Das, M; McCallister, S; Brainard, DM; Brinson, C; Clarke, A; Coll, P; Post, FA; Hare, CB				Mayer, Kenneth H.; Molina, Jean-Michel; Thompson, Melanie A.; Anderson, Peter L.; Mounzer, Karam C.; De Wet, Joss J.; DeJesus, Edwin; Jessen, Heiko; Grant, Robert M.; Ruane, Peter J.; Wong, Pamela; Ebrahimi, Ramin; Zhong, Lijie; Mathias, Anita; Callebaut, Christian; Collins, Sean E.; Das, Moupali; McCallister, Scott; Brainard, Diana M.; Brinson, Cynthia; Clarke, Amanda; Coll, Pep; Post, Frank A.; Hare, C. Bradley			Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial	LANCET			English	Article							VIROLOGICALLY SUPPRESSED ADULTS; PEAK BONE MASS; INFECTION; SAFETY; MEN; ELVITEGRAVIR; COBICISTAT; EFFICACY; RISK; RILPIVIRINE	Background Tenofovir alafenamide shows high antiviral efficacy and improved renal and bone safety compared with tenofovir disoproxil fumarate when used for HIV treatment. Here, we report primary results from a blinded phase 3 study evaluating the efficacy and safety of pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir alafenamide versus emtricitabine and tenofovir disoproxil fumarate for HIV prevention. Methods This study is an ongoing, randomised, double-blind, multicentre, active-controlled, phase 3, noninferiority trial done at 94 community, public health, and hospital-associated clinics located in regions of Europe and North America, where there is a high incidence of HIV or prevalence of people living with HIV, or both. We enrolled adult cisgender men who have sex with men and transgender women who have sex with men, both with a high risk of acquiring HIV on the basis of their self-reported sexual behaviour in the past 12 weeks or their recent history (within 24 weeks of enrolment) of bacterial sexually transmitted infections. Participants with current or previous use of PrEP with emtricitabine and tenofovir disoproxil fumarate were not excluded. We used a computer-generated random allocation sequence to randomly assign (1:1) participants to receive either emtricitabine (200 mg) and tenofovir alafenamide (25 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir alafenamide group), or emtricitabine (200 mg) and tenofovir disoproxil fumarate (300 mg) tablets daily, with matched placebo tablets (emtricitabine and tenofovir disoproxil fumarate group). As such, all participants were given two tablets. The trial sponsor, investigators, participants, and the study staff who provided the study drugs, assessed the outcomes, and collected the data were masked to group assignment. The primary efficacy outcome was incident HIV infection, which was assessed when all participants had completed 48 weeks of followup and half of all participants had completed 96 weeks of follow-up. This full analysis set included all randomly assigned participants who had received at least one dose of the assigned study drug and had at least one post-baseline HIV test. Non-inferiority of emtricitabine and tenofovir alafenamide to emtricitabine and tenofovir disoproxil fumarate was established if the upper bound of the 95.003% CI of the HIV incidence rate ratio (IRR) was less than the prespecified non-inferiority margin of 1.62. We prespecified six secondary bone mineral density and renal biomarker safety endpoints to evaluate using the safety analysis set. This analysis set included all randomly assigned participants who had received at least one dose of the assigned study drug. This trial is registered with ClinicalTrials.gov, NCT02842086, and is no longer recruiting. Findings Between Sept 13, 2016, and June 30, 2017, 5387 (92%) of 5857 participants were randomly assigned and received emtricitabine and tenofovir alafenamide (n=2694) or emtricitabine and tenofovir disoproxil fumarate (n=2693). At the time of the primary efficacy analysis (ie, when all participants had completed 48 weeks and 50% had completed 96 weeks) emtricitabine and tenofovir alafenamide was non-inferior to emtricitabine and tenofovir disoproxil fumarate for HIV prevention, as the upper limit of the 95% CI of the IRR, was less than the prespecified non-inferiority margin of 1.62 (IRR 0.47 [95% CI 0.19-1.15]). After 8756 person-years of follow-up, 22 participants were diagnosed with HIV, seven participants in the emtricitabine and tenofovir alafenamide group (0.16 infections per 100 person-years [95% CI 0.06-0.33]), and 15 participants in the emtricitabine and tenofovir disoproxil fumarate group (0.34 infections per 100 person-years [0 49-0. 56]). Both regimens were well tolerated, with a low number of participants reporting adverse events that led to discontinuation of the study drug (36 [1%] of 2694 participants in the emtricitabine and tenofovir alafenamide group vs 49 [2%] of 2693 participants in the emtricitabine and tenofovir disoproxil fumarate group). Emtricitabine and tenofovir alafenamide was superior to emtricitabine and tenofovir disoproxil fumarate in all six prespecified bone mineral density and renal biomarker safety endpoints. Interpretation Daily emtricitabine and tenofovir alafenamide shows non-inferior efficacy to daily emtricitabine and tenofovir disoproxil fumarate for HIV prevention, and the number of adverse events for both regimens was low. Emtricitabine and tenofovir alafenamide had more favourable effects on bone mineral density and biomarkers of renal safety than emtricitabine and tenofovir disoproxil fumarate. Copyright (C) 2020 Elsevier Ltd. All rights reserved.	[Mayer, Kenneth H.] Fenway Hlth, Fenway Inst, Boston, MA USA; [Mayer, Kenneth H.] Harvard Med Sch, Dept Med, Boston, MA 02115 USA; [Molina, Jean-Michel] Univ Paris, Dept Infect Dis, Hop St Louis Lariboisiere, Paris, France; [Molina, Jean-Michel] INSERM U944, Paris, France; [Thompson, Melanie A.] AIDS Res Consortium Atlanta, Atlanta, GA USA; [Anderson, Peter L.] Univ Colorado, Dept Pharmaceut Sci, Skaggs Sch Pharm & Pharmaceut Sci, Aurora, CO USA; [Mounzer, Karam C.] Philadelphia FIGHT, Philadelphia, PA USA; [De Wet, Joss J.] Spectrum Hlth, Vancouver, BC, Canada; [DeJesus, Edwin] Orlando Immunol Ctr, Orlando, FL USA; [Jessen, Heiko] Praxis Jessen2 Kollegen, Berlin, Germany; [Grant, Robert M.] San Francisco AIDS Fdn, San Francisco, CA USA; [Grant, Robert M.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Ruane, Peter J.] Ruane Med & Liver Hlth Inst, Los Angeles, CA USA; [Wong, Pamela; Ebrahimi, Ramin; Zhong, Lijie] Gilead Sci, Dept Biometr, Foster City, CA USA; [Mathias, Anita] Gilead Sci, Dept Clin Pharmacol, Foster City, CA USA; [Callebaut, Christian] Gilead Sci, Dept Virol, Foster City, CA USA; [Collins, Sean E.; Das, Moupali; McCallister, Scott; Brainard, Diana M.] Gilead Sci, Dept HIV & Emerging Viral Infect Clin Res, Foster City, CA 94404 USA; [Brinson, Cynthia] Cent Texas Clin Res, Austin, TX USA; [Clarke, Amanda] Brighton & Sussex Univ Hosp Natl Hlth Serv NHS Tr, Royal Sussex Cty Hosp, Brighton, E Sussex, England; [Coll, Pep] BCN Checkpoint & IrsiCaixa AIDS Res Inst, Barcelona, Spain; [Post, Frank A.] Kings Coll Hosp NHS Fdn Trust, Kings Coll Hosp, London, England; [Hare, C. Bradley] Kaiser Permanente San Francisco Med Ctr, Dept Adult & Family Med, San Francisco, CA USA	Fenway Health; Harvard University; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Colorado System; University of Colorado Anschutz Medical Campus; Orlando Immunology Center; University of California System; University of California San Francisco; Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences; University of Brighton; King's College Hospital NHS Foundation Trust; King's College Hospital; Kaiser Permanente	Das, M (corresponding author), Gilead Sci, Dept HIV & Emerging Viral Infect Clin Res, Foster City, CA 94404 USA.	moupali.as@gilead.com			Gilead Sciences	Gilead Sciences(Gilead Sciences)	Gilead Sciences.	Agarwal K, 2018, J HEPATOL, V68, P672, DOI 10.1016/j.jhep.2017.11.039; Anderson PL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004006; [Anonymous], GUID US ANT AG AD AD; Arribas JR, 2017, JAIDS-J ACQ IMM DEF, V75, P211, DOI 10.1097/qai.0000000000001350; AVAC, 2011, GOOD PART PRACT GUID; Baeten JM, 2012, NEW ENGL J MED, V367, P399, DOI 10.1056/NEJMoa1108524; Becasen JS, 2019, AM J PUBLIC HEALTH, V109, pE1, DOI 10.2105/AJPH.2018.304727; Borges AH, 2017, CLIN INFECT DIS, V64, P1413, DOI 10.1093/cid/cix167; Chan HLY, 2016, LANCET GASTROENTEROL, V1, P185, DOI 10.1016/S2468-1253(16)30024-3; Chen, 2018, OPEN FORUM INFECT S1, V5, pS396; Chou R, 2019, JAMA-J AM MED ASSOC, V321, P2214, DOI 10.1001/jama.2019.2591; DeJesus E, 2017, LANCET HIV, V4, pE205, DOI 10.1016/S2352-3018(17)30032-2; Elsesser SA, 2016, AIDS BEHAV, V20, P1400, DOI 10.1007/s10461-015-1238-0; Friis-Moller N, 2016, EUR J PREV CARDIOL, V23, P214, DOI 10.1177/2047487315579291; Gallant JE, 2016, LANCET HIV, V3, pE158, DOI 10.1016/S2352-3018(16)00024-2; Gilead Sciences, 2018, HIGHL PRESCR INF; Glidden DV, 2018, CLIN INFECT DIS, V67, P411, DOI 10.1093/cid/ciy083; Glidden DV, 2019, STAT COMMUN INFECT D, V11; Goff DC, 2014, J AM COLL CARDIOL, V63, P2935, DOI [10.1016/j.jacc.2013.11.005, 10.1161/01.cir.0000437741.48606.98]; Grant RM, 2010, NEW ENGL J MED, V363, P2587, DOI 10.1056/NEJMoa1011205; Grulich AE, 2018, LANCET HIV, V5, pE629, DOI 10.1016/S2352-3018(18)30215-7; Gunthard HF, 2016, JAMA-J AM MED ASSOC, V316, P191, DOI 10.1001/jama.2016.8900; Gupta SK, 2019, AIDS, V33, P1455, DOI 10.1097/QAD.0000000000002223; Highleyman L., 2018, PREP SCALES HIV INCI; Hill A, 2019, 10 INT AIDS C HIV SC; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Hodder S, 2018, JAIDS-J ACQ IMM DEF, V78, P209, DOI 10.1097/QAI.0000000000001663; Hoover, 2019, C RETR OPP INF MARCH; Huhn GD, 2020, OPEN FORUM INFECT DI, V7, DOI 10.1093/ofid/ofz472; Kearney BP, 2009, PHARMACOTHERAPY, V29, P924, DOI 10.1592/phco.29.8.924; Landovitz RJ, 2020, CLIN INFECT DIS; LaVange LM, 2008, WILEY ENCY CLIN TRIA, P31; Littman AJ, 2013, INT J OBESITY, V37, P244, DOI 10.1038/ijo.2012.46; Malhotra R, 2013, OBESITY, V21, P1923, DOI 10.1002/oby.20318; Marcus JL, 2016, JAIDS-J ACQ IMM DEF, V73, P540, DOI 10.1097/QAI.0000000000001129; Markowitz M, 2017, JAIDS-J ACQ IMM DEF, V76, pE104, DOI 10.1097/QAI.0000000000001534; Mary-Krause M, 2014, INT J EPIDEMIOL, V43, P1425, DOI 10.1093/ije/dyu002; Massud I, 2016, J INFECT DIS, V214, P1058, DOI 10.1093/infdis/jiw312; Mayer D, 2019, KNOWLEDGE, POLICY AND PRACTICE IN TEACHER EDUCATION: A CROSS-NATIONAL STUDY, P21; McCormack S, 2016, LANCET, V387, P53, DOI 10.1016/S0140-6736(15)00056-2; Mera R, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25433; Mills A, 2016, LANCET INFECT DIS, V16, P43, DOI 10.1016/S1473-3099(15)00348-5; Molina JM, 2015, NEW ENGL J MED, V373, P2237, DOI 10.1056/NEJMoa1506273; Molina JM, 2017, LANCET HIV, V4, pE402, DOI 10.1016/S2352-3018(17)30089-9; Mullick C, 2020, J INFECT DIS, V221, P214, DOI 10.1093/infdis/jiz037; New York City Department of Health and Mental Hygiene, 2018, HIV SURV ANN REP 201; Nwokolo N, 2017, LANCET HIV, V4, pE153, DOI 10.1016/S2352-3018(17)30044-9; NYC Health, 2019, ON DEM DOS PREP GUID; Orkin C, 2017, LANCET HIV, V4, pE195, DOI 10.1016/S2352-3018(17)30031-0; Parikh UM, 2016, CURR OPIN HIV AIDS, V11, P49, DOI 10.1097/COH.0000000000000209; Ruane PJ, 2013, JAIDS-J ACQ IMM DEF, V63, P449, DOI 10.1097/QAI.0b013e3182965d45; San Francisco Department of Public Health, 2019, IMP HIV PREV TREATM; San Francisco Department of Public Health Population Health Division, 2018, HIV EP ANN REP 2017; Santos JR, 2015, CLIN INFECT DIS, V61, P403, DOI 10.1093/cid/civ296; Sax PE, 2020, CLIN INFECT DIS, V71, P1379, DOI 10.1093/cid/ciz999; Sax PE, 2015, LANCET, V385, P2606, DOI 10.1016/S0140-6736(15)60616-X; Schwartz J, 2013, CERN REPORT, P21; Schwartz JL, 2018, HIV RES PREV C MADR; Spinner CD, DISCOVER STUDY HIV P; Sullivan PS., 2018, 22 INT AIDS C 23 27; Thaden JT, 2018, AIDS, V32, pF1, DOI 10.1097/QAD.0000000000001825; Tungsiripat M, 2010, AIDS, V24, P1781, DOI 10.1097/QAD.0b013e32833ad8b4; ULM K, 1990, AM J EPIDEMIOL, V131, P373, DOI 10.1093/oxfordjournals.aje.a115507; US CDC, 2015, 2015 SEX TRANSM DIS; US CDC, 2019, EFF PREV STRAT RED R; US CDC, 2018, HIV SURV REP DIAGN H; US CDC, 2018, HIV GAY BIS MEN; Volk JE, 2015, CLIN INFECT DIS, V61, P1601, DOI 10.1093/cid/civ778; Vuylsteke B, 2019, J INT AIDS SOC, V22, DOI 10.1002/jia2.25407; Walsh JS, 2009, OSTEOPOROSIS INT, V20, P355, DOI 10.1007/s00198-008-0672-5; Weaver CM, 2016, OSTEOPOROSIS INT, V27, P1281, DOI 10.1007/s00198-015-3440-3; Wiens BL, 2005, J BIOPHARM STAT, V15, P929, DOI 10.1080/10543400500265660; Wolf G, 2002, AM J KIDNEY DIS, V39, P1, DOI 10.1053/ajkd.2002.29865; World Health Organization, 2019, WHATS 2 1 1 EV DRIV	74	134	136	4	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 25	2020	396	10246					239	254						16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NK8ZY	32711800	Green Published			2023-01-03	WOS:000567020100033
J	Kaaki, B; Gupta, D				Kaaki, Bilal; Gupta, Digant			Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: A retrospective single-institution study	PLOS ONE			English	Article							URINARY URGE INCONTINENCE; ONABOTULINUMTOXINA; MULTICENTER; WOMEN	Background Sacral neuromodulation (SNM) is a minimally invasive fully reversible therapy that was approved in 1997 for overactive bladder syndrome (OAB) refractory to behavior modification and pharmacotherapy. Despite being in use for over two decades, the data on medium to long-term safety and efficacy of SNM in OAB is limited. We investigated the medium-term efficacy and safety of SNM along with the predictive factors for its success in patients with refractory OAB. Methods A retrospective consecutive case series of 66 patients undergoing SNM for refractory OAB between July 2009 and July 2018. All patients underwent a test period followed by permanent implantation, if there was > = 50% improvement in any symptom. The primary outcome was "success" defined as > = 50% improvement in any clinical parameter based on the subjective assessment of patient's response. The secondary outcomes were number of pads used in 24 hours, post-operative complications and re-operation rates. Results 66 females with an average age of 62.7 years were included. 55/66 patients (83.3%) had a successful test phase and underwent permanent implantation. After a median follow-up of 32 months, SNM was successful in 41/55 (74.5%) patients. Mean number of pads used in 24 hours decreased significantly from 3.5 preoperatively to 1.2 at last follow-up (p<0.001). 8/55 (14.5%) patients reported complications of pain, lead migration, wound dehiscence and device malfunction. 10/55 (18.2%) patients underwent revision surgeries after a median duration of 21.9 months. Device was explanted in 15/55 (27.3%) patients after a median duration of 24 months. No significant predictor for success was identified. Conclusions The success rate of SNM is 75% with a complication rate of 14.5% after a median follow-up of similar to 3 years. This study suggests medium-term efficacy and safety but a high re-operation rate of SNM in patients with refractory OAB.	[Kaaki, Bilal] Des Moines Univ, Des Moines, IA 50312 USA; [Kaaki, Bilal] UnityPoint Hlth, Dept Obstet & Gynecol, Waterloo, IA 50703 USA; [Gupta, Digant] Clin Sci Res Consulting, Chicago, IL USA		Kaaki, B (corresponding author), Des Moines Univ, Des Moines, IA 50312 USA.; Kaaki, B (corresponding author), UnityPoint Hlth, Dept Obstet & Gynecol, Waterloo, IA 50703 USA.	Bilal.Kaaki@unitypoint.org	GUPTA, DIGANT/ABA-9729-2020	GUPTA, DIGANT/0000-0002-1963-8886				Al-Zahrani AA, 2011, J UROLOGY, V185, P981, DOI 10.1016/j.juro.2010.10.054; Amundsen CL, 2018, EUR UROL, V74, P66, DOI 10.1016/j.eururo.2018.02.011; Amundsen CL, 2005, UROLOGY, V66, P746, DOI 10.1016/j.urology.2005.04.031; Basra RK, 2008, BJU INT, V102, P774, DOI 10.1111/j.1464-410X.2008.07769.x; Benner JS, 2010, BJU INT, V105, P1276, DOI 10.1111/j.1464-410X.2009.09036.x; Chancellor MB, 2016, INT UROL NEPHROL, V48, P1029, DOI 10.1007/s11255-016-1277-0; Chapple C, 2007, EUR UROL, V52, P1204, DOI 10.1016/j.eururo.2007.07.009; Coyne KS, 2011, UROLOGY, V77, P1081, DOI 10.1016/j.urology.2010.08.039; D'Ancona C, 2019, NEUROUROL URODYNAM, V38, P433, DOI 10.1002/nau.23897; Eapen RS, 2016, RES REP UROL, V8, P71, DOI 10.2147/RRU.S102441; Elkelini MS, 2010, INT UROGYNECOL J, V21, pS439, DOI 10.1007/s00192-010-1273-3; Ganz ML, 2010, UROLOGY, V75, P533, DOI [10.1016/j.urology.2009.06.096, 10.1016/j.urology.2009.08.003]; Goldman HB, 2018, NEUROUROL URODYNAM, V37, P1823, DOI 10.1002/nau.23515; Gong QQ, 2020, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01618; Haylen BT, 2010, NEUROUROL URODYNAM, V29, P4, DOI 10.1002/nau.20798; Ismail S, 2017, NEUROMODULATION, V20, P825, DOI 10.1111/ner.12696; Kalder M, 2014, OBSTET GYNECOL, V124, P794, DOI 10.1097/AOG.0000000000000468; Knowles CH, 2019, ADV THER; MacDiarmid S, 2019, J UROLOGY, V201, P967, DOI 10.1016/j.juro.2018.10.017; Marinkovic SP, 2011, INT UROGYNECOL J, V22, P407, DOI 10.1007/s00192-010-1235-9; Mauseth SA, 2013, ACTA OBSTET GYN SCAN, V92, P1208, DOI 10.1111/aogs.12196; Milsom I, 2001, BJU INT, V87, P760, DOI 10.1046/j.1464-410x.2001.02228.x; Noblett K, 2018, NEUROUROL URODYNAM, V37, P1667, DOI 10.1002/nau.23422; Noblett K, 2016, NEUROUROL URODYNAM, V35, P246, DOI 10.1002/nau.22707; Oelke M, 2019, ARCH GYNECOL OBSTET, V299, P1243, DOI 10.1007/s00404-019-05127-7; Onukwugha Ebere, 2009, Am J Manag Care, V15, pS90; Peters KM, 2010, J UROLOGY, V183, P1438, DOI 10.1016/j.juro.2009.12.036; Powell CR, 2010, J UROLOGY, V183, P173, DOI 10.1016/j.juro.2009.08.142; Reynolds WS, 2016, CURR BLADDER DYSFUNC, V11, P8, DOI 10.1007/s11884-016-0344-9; Richter HE, 2017, J UROLOGY, V198, P890, DOI 10.1016/j.juro.2017.04.103; Sherman ND, 2005, AM J OBSTET GYNECOL, V193, P2083, DOI 10.1016/j.ajog.2005.07.038; Siegel S, 2018, J UROLOGY, V199, P229, DOI 10.1016/j.juro.2017.07.010; Siegel S, 2016, UROLOGY, V94, P57, DOI 10.1016/j.urology.2016.04.024; Singh R, 2015, FEMALE PELVIC MED RE, V21, P369, DOI 10.1097/SPV.0000000000000200; Starkman JS, 2007, NEUROUROL URODYNAM, V26, P29, DOI 10.1002/nau.20360; Stewart WF, 2002, WORLD J UROL, V20, P327, DOI 10.1007/s00345-002-0301-4; Sukhu T, 2016, RES REP UROL, V8, P193, DOI 10.2147/RRU.S89544; Tahseen S, 2018, INT UROGYNECOL J, V29, P1081, DOI 10.1007/s00192-017-3546-6; van Leeuwen JHS, 2006, EUR UROL, V50, P440, DOI 10.1016/j.eururo.2006.05.014; Wagg A, 2020, EUR UROL, V77, P211, DOI 10.1016/j.eururo.2019.10.002; Wang CC, 2019, J FORMOS MED ASSOC, V118, P279, DOI 10.1016/j.jfma.2018.05.006; Yazdany T, 2011, INT UROGYNECOL J, V22, P1549, DOI 10.1007/s00192-011-1512-2; Zegrea A, 2020, TECH COLOPROCTOL, V24, P215, DOI 10.1007/s10151-020-02148-2	43	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 9	2020	15	7							e0235961	10.1371/journal.pone.0235961	http://dx.doi.org/10.1371/journal.pone.0235961			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ0QU	32645082	gold, Green Published			2023-01-03	WOS:000552602700068
J	Dreijer, AR; Kruip, MJHA; Diepstraten, J; Polinder, S; Brouwer, R; Mol, PGM; Croles, FN; Kragten, E; Leebeek, FWG; van den Bemt, PMLA				Dreijer, Albert R.; Kruip, Marieke J. H. A.; Diepstraten, Jeroen; Polinder, Suzanne; Brouwer, Rolf; Mol, Peter G. M.; Croles, F. Nanne; Kragten, Esther; Leebeek, Frank W. G.; van den Bemt, Patricia M. L. A.			Effect of antithrombotic stewardship on the efficacy and safety of antithrombotic therapy during and after hospitalization	PLOS ONE			English	Article							ATRIAL-FIBRILLATION; BLEEDING COMPLICATIONS; VENOUS THROMBOEMBOLISM; WARFARIN; ANTICOAGULATION; DEFINITION; MANAGEMENT; APIXABAN; COST	Background Although the benefits of antithrombotic drugs are indisputable to reduce thrombotic events, they carry a high risk of compromising patient safety. No previous studies investigated the implementation and (cost-) effectiveness of a hospital-based multidisciplinary antithrombotic team on bleeding and thrombotic outcomes. The primary aim of this study was to compare the proportion of patients with a composite end point consisting of one or more bleeding episodes or one or more thrombotic event from hospitalization until three months after hospitalization. Methods and findings A prospective, multicenter before-after intervention study was conducted in two Dutch hospitals. Adult patients hospitalized between October 2015 and December 2017 treated with anticoagulant therapy were included. The primary aim was to estimate the proportion of patients with a composite end point consisting of one or more bleeding episodes or one or more thrombotic event from hospitalization until three months after hospitalization. The intervention was the implementation of a multidisciplinary antithrombotic team focusing on education, medication reviews by pharmacists, implementing of local anticoagulant therapy guidelines based on national guidelines, patient counselling and medication reconciliation at admission and discharge. The primary endpoint was analysed using segmented linear regression. We obtained data for 1,886 patients: 941 patients were included in the usual care period and 945 patients in the intervention period. The S-team study showed that implementation of a multidisciplinary antithrombotic team over time significantly reduced the composite end point consisting of one or more bleeding episodes or one or more thrombotic event from hospitalization until three months after hospitalization in patients using anticoagulant drugs (-1.83% (-2.58% to -1.08%) per 2 month period). Conclusions This study shows that implementation of a multidisciplinary antithrombotic team over time significantly reduces the composite end point consisting of one or more bleeding episodes or one or more thrombotic event from hospitalization until three months after hospitalization in patients using anticoagulant drugs.	[Dreijer, Albert R.] Erasmus MC, Dept Hosp Pharm, Rotterdam, Netherlands; [Dreijer, Albert R.; Diepstraten, Jeroen] Reinier Graaf Hosp, Dept Hosp Pharm, Delft, Netherlands; [Kruip, Marieke J. H. A.; Croles, F. Nanne; Leebeek, Frank W. G.] Erasmus MC, Dept Hematol, Rotterdam, Netherlands; [Kruip, Marieke J. H. A.] Thrombosis Serv STAR SHL, Rotterdam, Netherlands; [Polinder, Suzanne] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Brouwer, Rolf; Kragten, Esther] Reinier Graaf Hosp, Dept Hematol, Delft, Netherlands; [Mol, Peter G. M.; van den Bemt, Patricia M. L. A.] Univ Groningen, Univ Med Ctr Groningen, Dept Clin Pharmacol, Groningen, Netherlands	Erasmus University Rotterdam; Erasmus MC; Reinier de Graaf Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Reinier de Graaf Hospital; University of Groningen	Dreijer, AR (corresponding author), Erasmus MC, Dept Hosp Pharm, Rotterdam, Netherlands.; Dreijer, AR (corresponding author), Reinier Graaf Hosp, Dept Hosp Pharm, Delft, Netherlands.	a.dreijer@treant.nl		Van den Bemt, Patricia/0000-0003-1418-5520; Leebeek, Frank/0000-0001-5677-1371	Stichting Phoenix Schiedam; Daiichi Sankyo; Boehringer Ingelheim; Bayer; Pfizer; Scientific Committee Reinier de Graaf Gasthuis	Stichting Phoenix Schiedam; Daiichi Sankyo(Daiichi Sankyo Company Limited); Boehringer Ingelheim(Boehringer Ingelheim); Bayer(Bayer AG); Pfizer(Pfizer); Scientific Committee Reinier de Graaf Gasthuis	Stichting Phoenix Schiedam, the pharmaceutical companies (Daiichi Sankyo, Boehringer Ingelheim, Bayer and Pfizer) and the Scientific Committee Reinier de Graaf Gasthuis provided financial support for this study in the form of unrestricted grants. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ageno W, 2013, J THROMB HAEMOST, V11, P1597, DOI 10.1111/jth.12301; [Anonymous], 2004, DIONYSIUS, V22, P29; Bajorek BV, 2005, J AM GERIATR SOC, V53, P1912, DOI 10.1111/j.1532-5415.2005.53564.x; Bond CA, 2004, PHARMACOTHERAPY, V24, P953, DOI 10.1592/phco.24.11.953.36133; Connolly SJ, 2009, NEW ENGL J MED, V361, P1139, DOI 10.1056/NEJMoa0905561; Deitelzweig SB, 2013, CLIN THER, V35, P1536, DOI 10.1016/j.clinthera.2013.08.013; Dreijer AR, 2019, INT J CLIN PHARM-NET, V41, P691, DOI 10.1007/s11096-019-00834-2; Dreijer AR, 2019, EUR J INTERN MED, V62, P17, DOI 10.1016/j.ejim.2019.01.008; Dreijer AR, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011537; DURBIN J, 1950, BIOMETRIKA, V37, P409, DOI 10.2307/2332391; Ewen EF, 2009, J INTERV CARDIOL, V22, P266, DOI 10.1111/j.1540-8183.2009.00431.x; Fernandez MM, 2015, CLINICOECONOMIC OUTC, V7, P451, DOI 10.2147/CEOR.S85635; Giugliano RP, 2013, NEW ENGL J MED, V369, P2093, DOI 10.1056/NEJMoa1310907; Gomez-Outes Antonio, 2013, Thrombosis, V2013, P640723, DOI 10.1155/2013/640723; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Hakkaart-van Roijen L, 2010, HANDLEIDING KOSTENON, P1; Hylek EM, 2014, J AM COLL CARDIOL, V63, P2141, DOI 10.1016/j.jacc.2014.02.549; Lopez-de-Andres A, 2010, BMC HEALTH SERV RES, V10, DOI [10.1186/1472-6963-10-59, 10.1186/1472-6963-10-287]; Maynard G, 2014, AM J HEALTH-SYST PH, V71, P305, DOI 10.2146/ajhp130108; Padron Maria, 2015, J Pharm Pract, V28, P93, DOI 10.1177/0897190013514091; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Reardon DP, 2015, J THROMB THROMBOLYS, V40, P379, DOI 10.1007/s11239-015-1189-3; Sacco RL, 2013, STROKE, V44, P2064, DOI 10.1161/STR.0b013e318296aeca; Schillig J, 2011, J HOSP MED, V6, P322, DOI 10.1002/jhm.910; Schulman S, 2005, J THROMB HAEMOST, V3, P692, DOI 10.1111/j.1538-7836.2005.01204.x; Schulman S, 2010, J THROMB HAEMOST, V8, P202, DOI 10.1111/j.1538-7836.2009.03678.x; Schulman S, 2008, CHEST, V133, p257S, DOI 10.1378/chest.08-0674; Sellier E, 2006, ARCH INTERN MED, V166, P2065, DOI 10.1001/archinte.166.19.2065; Thygesen K, 2012, EUR HEART J, V33, P2551, DOI 10.1093/eurheartj/ehs184; van der Hulle T, 2014, J THROMB HAEMOST, V12, P320, DOI 10.1111/jth.12485; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x; Wysowski DK, 2007, ARCH INTERN MED, V167, P1414, DOI 10.1001/archinte.167.13.1414	33	10	10	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 25	2020	15	6							e0235048	10.1371/journal.pone.0235048	http://dx.doi.org/10.1371/journal.pone.0235048			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG0TI	32584857	Green Published, gold			2023-01-03	WOS:000545747200069
J	Tefera, YG; Alemayehu, M; Mekonnen, GB				Tefera, Yonas Getaye; Alemayehu, Mekuriaw; Mekonnen, Gashaw Binega			Prevalence and determinants of polypharmacy in cardiovascular patients attending outpatient clinic in Ethiopia University Hospital	PLOS ONE			English	Article							DRUG-USE; UNITED-STATES; OLDER-ADULTS; DISEASE; PEOPLE; CRITERIA	Background While there are advances in medicine and pharmaceutical care, the burden of medication use has also grown with polypharmacy. In this regard, cardiovascular patients are subjected to polypharmacy for a longer period. Objective The present study aimed to assess the prevalence and predictors of polypharmacy in cardiovascular outpatients attending the University of Gondar Comprehensive specialized hospital, northwest Ethiopia. Methods A hospital-based cross-sectional study was employed at the University of Gondar Comprehensive Specialized Hospital from March 30-May 30, 2019. The unique medical registration number of 424 patients was selected by using systematic random sampling to trace the medical chart and followed with an interview to explore the factors related to polypharmacy. All the Statistical analysis was carried out using Statistical Package for Social Sciences (SPSS) version 22. Bivariable and multivariable logistic regressions were used to identify the predictors of polypharmacy in cardiovascular patients. Result The mean age of the respondents was 56.83 +/- 15.27 years. The mean number of medications per patient was 3.3 +/- 1.6. The prevalence of polypharmacy was 24.8% in cardiovascular outpatients while cardiovascular specific polypharmacy was 9.2%. Elderly (aged >= 65 years and above) patients were nearly two times more likely to had polypharmacy prescriptions with AOR: 1.97; 95% CI: 1.08-3.61; p = 0.027. Patients with abnormal weight (underweight AOR: 4.51; 95% CI: 1.42-14.30; p = 0.010, overweight AOR: 3.78; 95% CI: 1.83-7.83; p<0.001 and obese AOR: 5.1; 95% CI: 2.04-12.75 p<0.001) are more likely to have polypharmacy. Having a family history of CVD increase the likelihood of polypharmacy more than double; AOR: 2.40; 95% CI: 1.17-4.93; p = 0.017. A unit increase in Charlson comorbidity index score resulted in a nearly threefold likelihood of polypharmacy with AOR: 2.83; 95% CI 1.91-3.89; p<0.001. Conclusion One out of four cardiovascular patients attending the outpatient clinic was on polypharmacy. The elderly age, abnormal body mass index (non-normal weight), family history of cardiovascular diseases and increasing Charlson morbidity index were the predictors of polypharmacy in cardiovascular patients. Clinicians should ensure the relevance of all prescribed medications and pharmaceutical care targeting at the prevention of inappropriate polypharmacy would be pivotal to reduce polypharmacy associated burdens.	[Tefera, Yonas Getaye] Univ Gondar, Coll Med & Hlth Sci, Sch Pharm, Dept Clin Pharm, Gondar, Ethiopia; [Alemayehu, Mekuriaw; Mekonnen, Gashaw Binega] Univ Gondar, Coll Med & Hlth Sci, Inst Publ Hlth, Gondar, Ethiopia	University of Gondar; University of Gondar	Tefera, YG (corresponding author), Univ Gondar, Coll Med & Hlth Sci, Sch Pharm, Dept Clin Pharm, Gondar, Ethiopia.	yonas1get@gmail.com	mekonnen, Gashaw Binega/AAO-3178-2020	mekonnen, Gashaw Binega/0000-0002-2650-8668; Tefera, Yonas Getaye/0000-0002-9205-9442	University of Gondar	University of Gondar	Funding was received from University of Gondar to conduct this study.	Abebe SM, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-015496; Abolhassani N, 2018, J CLIN EPIDEMIOL, V101, P1, DOI 10.1016/j.jclinepi.2018.05.002; Admassie E, 2013, J ADV PHARM TECHNOL, V4, P183, DOI 10.4103/2231-4040.121412; Al-Arifi MN, 2014, INT J REC SCI RES, V5, P1053; Appleton SC, 2014, BMC FAM PRACT, V15, DOI 10.1186/1471-2296-15-58; Ashwell M, 2005, INT J FOOD SCI NUTR, V56, P303, DOI 10.1080/09637480500195066; Austin SR, 2015, MED CARE, V53, pE65, DOI 10.1097/MLR.0b013e318297429c; Baron-Franco B, 2017, BR J GEN PRACT; Betre M, 1997, E AFR MED J, V74, P376; Bjerrum L, 1998, EUR J CLIN PHARMACOL, V54, P197, DOI 10.1007/s002280050445; Castioni J, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2793-z; Chao C-T, 2015, MEDICINE, V94; Charlesworth CJ, 2015, J GERONTOL A-BIOL, V70, P989, DOI 10.1093/gerona/glv013; Cooper JA, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009235; Derington CG, 2019, HYPERTENSION, V74, P267, DOI 10.1161/HYPERTENSIONAHA.119.12907; Fick DM, 2003, ARCH INTERN MED, V163, P2716, DOI 10.1001/archinte.163.22.2716; Fried TR, 2014, J AM GERIATR SOC, V62, P2261, DOI 10.1111/jgs.13153; Gu Qiuping, 2010, NCHS Data Brief, P1; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Haider SI, 2009, J AM GERIATR SOC, V57, P62, DOI 10.1111/j.1532-5415.2008.02040.x; Hovstadius Bo, 2009, BMC Clin Pharmacol, V9, P11, DOI 10.1186/1472-6904-9-11; Jyrkka J, 2009, DRUG AGING, V26, P493, DOI 10.2165/00002512-200926060-00006; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; KIM H, 2014, PLOS ONE, V9; Lafeber M, 2012, EUR J PREV CARDIOL, V19, P1234, DOI 10.1177/1741826711428066; Laslett LJ, 2012, J AM COLL CARDIOL, V60, pS1, DOI 10.1016/j.jacc.2012.11.002; Lopez-Jaramillo P, 2018, THER ADV CARDIO DIS, V12, P169, DOI 10.1177/1753944718764588; Maher RL, 2014, EXPERT OPIN DRUG SAF, V13, P57, DOI 10.1517/14740338.2013.827660; Moen J, 2009, ANN PHARMACOTHER, V43, P1978, DOI 10.1345/aph.1M354; Moges B, 2014, BMC CARDIOVASC DISOR, V14, DOI 10.1186/1471-2261-14-155; Mohammed MA, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018880; Mohammed MA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010035; Moriarty F, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-008656; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Pache B, 2015, BMC PUBLIC HEALTH, V15, DOI 10.1186/s12889-015-1515-x; Pappa E, 2011, EUR J CLIN PHARMACOL, V67, P185, DOI 10.1007/s00228-010-0940-0; Rawle MJ, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0795-2; Tefera YG, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.474; Tefera YG, 2017, VASC HEALTH RISK MAN, V13, P143, DOI 10.2147/VHRM.S131259; Tegegn HG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214191; Tseng HM, 2016, QUAL LIFE RES, V25, P1295, DOI 10.1007/s11136-015-1177-2; Veehof LJG, 2000, FAM PRACT, V17, P261, DOI 10.1093/fampra/17.3.261; Volpe M, 2010, FUND CLIN PHARMACOL, V24, P9, DOI 10.1111/j.1472-8206.2009.00757.x; Walckiers D, 2015, ARCH PUBLIC HEALTH, V73, DOI 10.1186/s13690-015-0095-7	44	8	9	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2020	15	6							e0234000	10.1371/journal.pone.0234000	http://dx.doi.org/10.1371/journal.pone.0234000			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MJ2AA	32479516	gold, Green Published			2023-01-03	WOS:000547893500045
J	Daniel, H; Serchen, J; Cooney, TG				Daniel, Hilary; Serchen, Josh; Cooney, Thomas G.		Hlth Public Policy Comm Amer Coll	Policy Recommendations to Promote Prescription Drug Competition: A Position Paper From the American College of Physicians	ANNALS OF INTERNAL MEDICINE			English	Review							UNITED-STATES; CONSUMER; IMPACT; PRICES; COST	The prescription drug market in the United States relies on competition to keep prices reasonable. Although many policies have been implemented to spur competition and decrease costs for patients, these policies may be outdated and should be redesigned and updated to achieve success in the current prescription drug market. In this paper, the American College of Physicians (ACP) proposes that new policies should be implemented to prevent market manipulation, help lower-cost alternatives make it to the market faster, and ensure a robust and competitive market for generic and biosimilar drugs. The ACP believes these changes will have a meaningful effect on patients without shifting costs to other areas of the health care system.	[Daniel, Hilary; Serchen, Josh] Amer Coll Physicians, 25 Massachusetts Ave NW,Suite 700, Washington, DC 20001 USA; [Cooney, Thomas G.] Oregon Hlth & Sci Univ, Dept Med, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97239 USA	American College of Physicians; Oregon Health & Science University	Daniel, H (corresponding author), Amer Coll Physicians, 25 Massachusetts Ave NW,Suite 700, Washington, DC 20001 USA.	hilary.downey@gmail.com			ACP operating budget	ACP operating budget	Financial support for the development of this position paper came exclusively from the ACP operating budget.	Alpert A, 2015, 21714 NAT BUR EC RES; *AM COLL PHYS, 2006, DIR CONS PRESCR DRUG; Association for Accessible Medicines, 2018, GEN DRUG ACC SAV US, V8, P18; Bagley N, 2018, NEJM CATAL INNOV CAR, DOI [10.1056/CAT.18.0032, DOI 10.1056/CAT.18.0032]; Biniek JF., 2019, SPENDING INDIVIDUALS; Campbell S, 2011, POTENTIAL EFFECTS BA; Congressional Diabetes Caucus, INS LIF DRUG TOO OFT; Conrad Ryan, 2019, GENERIC COMPETITION; Daniel H, 2019, ANN INTERN MED, V171, P825, DOI 10.7326/M19-0013; Daniel H, 2019, ANN INTERN MED, V171, P823, DOI 10.7326/M19-0035; Daniel H, 2016, ANN INTERN MED, V165, P50, DOI 10.7326/M15-2768; Dave D, 2012, SOUTH ECON J, V79, P97, DOI 10.4284/0038-4038-79.1.97; DeVol RC., 2011, GLOBAL BIOMEDICAL IN; Donohue J, 2006, MILBANK Q, V84, P659, DOI 10.1111/j.1468-0009.2006.00464.x; Fain KM, 2014, MED CARE, V52, P291, DOI 10.1097/MLR.0000000000000126; Federal Trade Commission, 2009, EMERGING HLTH CARE I; Federal Trade Commission, 2010, PAY DEL DRUG CO PAY; Feldman R, 2018, J LAW BIOSCI, V5, P590, DOI 10.1093/jlb/lsy022; Gilbody S, 2005, QUAL SAF HEALTH CARE, V14, P246, DOI 10.1136/qshc.2004.012781; Harvard T.H, 2019, AM ATTITUDES CHANGIN; Helland E, 2015, ARE SETTLEMENTS PATE; Hua XY, 2016, JAMA-J AM MED ASSOC, V315, P1400, DOI 10.1001/jama.2016.0126; Initiative for Medicines Access and Knowledge, OV OV SPEC ED LANT I; Initiative for Medicines Access and Knowledge, OV OV EXC PHARM PATT; Initiative for Medicines Access and Knowledge, ACC KNOWL OV OV SPEC; IQVIA, 2018, ORPH DRUGS US GROWTH; Jayasundara K, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-018-0990-4; Kesselheim AS, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002190; Kesselheim AS, 2016, JAMA-J AM MED ASSOC, V316, P858, DOI 10.1001/jama.2016.11237; Kesselheim AS, 2011, MILBANK Q, V89, P450, DOI 10.1111/j.1468-0009.2011.00636.x; Marsh T, 2019, LIST PRICE CONDITION; Mulcahy AW., 2017, BIOSIMILAR COST SAVI; Office of the White House, BUDG FISC YEAR 2017; Peterson C., 2019, BIOSIMILARS US MORE; Pew Charitable Trusts, 2017, POL PROP RED EXCL PE; Rathore AS, 2019, NAT BIOTECHNOL, V37, P217, DOI 10.1038/s41587-019-0049-7; Rhee Taeho Greg, 2015, AMA J Ethics, V17, P776, DOI 10.1001/journalofethics.2015.17.8.pfor2-1508; Rosenfeld L, 2002, CLIN CHEM, V48, P2270; Sarpatwari A, 2018, JAMA-J AM MED ASSOC, V319, P2373, DOI 10.1001/jama.2018.7424; Sarpatwari A, 2018, HEALTH AFFAIR, V37, P732, DOI 10.1377/hlthaff.2017.1179; Schwartz LM, 2019, JAMA-J AM MED ASSOC, V321, P80, DOI 10.1001/jama.2018.19320; Seoane-Vazquez E, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-33; Shapiro C, 2001, NAVIGATING PATENT TH, DOI [10.2139/ssrn.273550, DOI 10.2139/SSRN.273550]; The Pew Charitable Trusts, 2017, POL PROP BANN LIM RE; Tribble SJ., 2017, KAISER HLTH NEWS; U.S. Food and Drug Administration, 1997, DRAFT GUID IND CONS; U.S. Food and Drug Administration, 2015, BAS DRUG ADS PROD CL; U.S. Food and Drug Administration, 2017, FDAS ORPH DRUG MOD P; United States Government Accountability Office, 2006, GAO0754; United States Government Accountability Office, 2018, GAO1983; United States Patent and Trademark Office, 2015, GEN INF PAT; US Government Accountability Office (GAO), 2016, GAO16490; Ventola C Lee, 2011, P T, V36, P669; Wilkes MS, 2000, HEALTH AFFAIR, V19, P110, DOI 10.1377/hlthaff.19.2.110; Yang WY, 2018, DIABETES CARE, V41, P917, DOI 10.2337/dci18-0007	55	2	2	2	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	2020	173	12					1002	+		10.7326/M19-3773	http://dx.doi.org/10.7326/M19-3773			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PF2SU	32926798				2023-01-03	WOS:000598911600013
J	Reale, SC; Fields, KG; Lumbreras-Marquez, MI; King, CH; Burns, SL; Huybrechts, KF; Bateman, BT				Reale, Sharon C.; Fields, Kara G.; Lumbreras-Marquez, Mario I.; King, Chih H.; Burns, Stacey L.; Huybrechts, Krista F.; Bateman, Brian T.			Association Between Number of In-Person Health Care Visits and SARS-CoV-2 Infection in Obstetrical Patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Reale, Sharon C.; Fields, Kara G.; Lumbreras-Marquez, Mario I.; King, Chih H.; Burns, Stacey L.; Bateman, Brian T.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, 75 Francis St, Boston, MA 02115 USA; [Huybrechts, Krista F.] Brigham & Womens Hosp, Div Pharmacoepidemiol, 75 Francis St, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Reale, SC (corresponding author), Brigham & Womens Hosp, 75 Francis St,CWN L1, Boston, MA 02115 USA.	screale@bwh.harvard.edu	Lumbreras-Marquez, Mario I/AAZ-5337-2021	Lumbreras-Marquez, Mario Isaac/0000-0002-5378-5724				Baum A, 2020, JAMA-J AM MED ASSOC, V324, P96, DOI 10.1001/jama.2020.9972; Commonwealth of Massachusetts, COVID 19 ESS SERV FA; Massachusetts Department of Public Health, ARCH COVID 19 CAS MA; Rubin D.B., 2004, MULTIPLE IMPUTATION, V81	4	12	13	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 22	2020	324	12					1210	1212		10.1001/jama.2020.15242	http://dx.doi.org/10.1001/jama.2020.15242			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OS4RZ	32797148	Bronze, Green Published			2023-01-03	WOS:000590153400037
J	Junger, C; Reimann, M; Krabbe, L; Gaede, KI; Lange, C; Herzmann, C; Ruller, S				Juenger, Christoph; Reimann, Maja; Krabbe, Lenka; Gaede, Karoline, I; Lange, Christoph; Herzmann, Christian; Rueller, Stephan			Non-invasive ventilation with pursed lips breathing mode for patients with COPD and hypercapnic respiratory failure: A retrospective analysis	PLOS ONE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; MECHANICAL VENTILATION; MULTICENTER	Purpose Long-term non-invasive ventilation (NIV) is recommended for patients with stable chronic obstructive lung disease (COPD) and chronic hypercapnia. High inspiratory pressure NIV (hiNIV) and a significant reduction of arterial pCO(2)have been shown to prolong survival. Often, patients on hiNIV describe severe respiratory distress, known as "deventilation syndrome", after removal of the NIV mask in the morning. Mechanical pursed lips breathing ventilation (PLBV) is a new non-invasive ventilation mode that mimics the pressure-curve of pursed lips breathing during expiration. The clinical impact of switching patients from standard NIV to PLBV has not been studied so far. Patients and methods In this hypothesis generating study, we retrospectively analysed the effects of switching COPD patients (stage GOLD III-IV) from conventional NIV to PLBV. Medical records of all patients who had an established NIV and were switched to PLBV between March 2016 and October 2017 were screened. Patients were included if they complained of shortness of breath on mask removal, used their conventional NIV regularly, and had a documented complete diagnostic workup including lung function testing, blood gas analysis and 6-minute walk test (6MWT) before and after 3-7 days of PLBV. Results Six male and 10 female patients (median age 65.4 years; IQR 64.0-71.3) with a previous NIV treatment duration of 38 months (median; IQR 20-42) were analysed. After PLVB initiation, the median inspiratory ventilation pressure needed to maintain the capillary pre-switch pCO(2)level was reduced from 19.5 mbar (IQR 16.0-26.0) to 13.8 mbar (IQR 12.5-14.9; p<0.001). The median 6MWT distance increased from 200m (IQR 153.8-266.3) to 270m (IQR 211.3-323.8; p<0.001). Median forced vital capacity (FVC) increased from 49.5% to 53.0% of the predicted value (p = 0.04), while changes in FEV(1)and residual volume (RV) were non-significant. Conclusion Based on this small retrospective analysis, we hypothesise that switching patients with COPD GOLD III-IV and chronic hypercapnia from conventional NIV to PLBV may increase exercise tolerance and FVC in the short term.	[Juenger, Christoph; Krabbe, Lenka; Gaede, Karoline, I; Lange, Christoph; Herzmann, Christian; Rueller, Stephan] Leibniz Lung Ctr, Res Ctr Borstel, Med Clin, Borstel, Germany; [Reimann, Maja; Lange, Christoph; Herzmann, Christian] German Ctr Infect Res DZIF, Lubeck, Riems, Germany; [Reimann, Maja; Lange, Christoph] Res Ctr Borstel, Div Clin Infect Dis, Borstel, Germany; [Reimann, Maja; Lange, Christoph] Univ Lubeck, Resp Med & Int Hlth, Lubeck, Germany; [Gaede, Karoline, I; Herzmann, Christian] German Ctr Lung Res DZL, Airway Res Ctr North ARCN, Giessen, Germany; [Gaede, Karoline, I] Leibniz Lung Ctr, Res Ctr Borstel, BioMaterialBank Nord, Borstel, Germany; [Lange, Christoph] Karolinska Inst, Dept Med, Stockholm, Sweden	Forschungszentrum Borstel; German Center for Infection Research; Forschungszentrum Borstel; University of Lubeck; Forschungszentrum Borstel; Karolinska Institutet	Herzmann, C (corresponding author), Leibniz Lung Ctr, Res Ctr Borstel, Med Clin, Borstel, Germany.; Herzmann, C (corresponding author), German Ctr Infect Res DZIF, Lubeck, Riems, Germany.; Herzmann, C (corresponding author), German Ctr Lung Res DZL, Airway Res Ctr North ARCN, Giessen, Germany.	cherzmann@fz-borstel.de			German Leibniz-Gemeinschaft; German Center for Lung Research	German Leibniz-Gemeinschaft; German Center for Lung Research	Fees for open access publishing were covered by a grant of the German Leibniz-Gemeinschaft, Open Access Publikation Fonds to Dr Christian Herzmann. The BioMaterialBank Nord is supported by the German Center for Lung Research. The BioMaterialBank Nord is a member of popgen 2.0 network (P2N). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The other authors received no specific funding for this work.	[Anonymous], 2019, EVALUATION NONINVASI; [Anonymous], 2019, AM J KIDNEY DIS, V73, pS1; Blanch Lluis, 2005, Respir Care, V50, P110; Budweiser S, 2006, RESP CARE, V51, P126; Clini E, 2002, EUR RESPIR J, V20, P529, DOI 10.1183/09031936.02.02162001; Dreher M, 2010, THORAX, V65, P303, DOI 10.1136/thx.2009.124263; Duiverman ML, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-112; Ergan B, 2019, EUR RESPIR J, V54, DOI 10.1183/13993003.01003-2019; Esquinas AM, 2014, SLEEP BREATH, V18, P225, DOI 10.1007/s11325-013-0931-3; JONES DJM, 1995, AM J RESP CRIT CARE, V152, P538; Kohnlein T, 2014, LANCET RESP MED, V2, P698, DOI 10.1016/S2213-2600(14)70153-5; Raveling T, 2018, INT J CHRONIC OBSTR, V13, P3625, DOI 10.2147/COPD.S169951; Singh D, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.00164-2019; Storre JH, 2008, EUR RESPIR MONOGR, P319; Team RC, 2014, LANG ENV STAT COMP; Zikyri A, 2018, INT J CHRONIC OBSTR, V13, P2191, DOI 10.2147/COPD.S152574	16	3	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2020	15	9							e0238619	10.1371/journal.pone.0238619	http://dx.doi.org/10.1371/journal.pone.0238619			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV8NR	32956395	gold, Green Published			2023-01-03	WOS:000574571500031
J	Jaccard, A; Ho, PC				Jaccard, Alison; Ho, Ping-Chih			The hidden side of PD-L1	NATURE CELL BIOLOGY			English	Editorial Material							CANCER; THERAPY	PD-L1 has been extensively described as the membrane-bound ligand of PD-1. A recent study discovered a previously unknown role for PD-L1, which is able to bind DNA and thus govern different pathways linked to either evasion of immune surveillance or tumour microenvironment inflammation.	[Jaccard, Alison; Ho, Ping-Chih] Univ Lausanne, Dept Fundamental Oncol, Lausanne, Switzerland; [Jaccard, Alison; Ho, Ping-Chih] Univ Lausanne, Ludwig Inst Canc Res, Epalinges, Switzerland	University of Lausanne; Ludwig Institute for Cancer Research; University of Lausanne	Jaccard, A; Ho, PC (corresponding author), Univ Lausanne, Dept Fundamental Oncol, Lausanne, Switzerland.; Jaccard, A; Ho, PC (corresponding author), Univ Lausanne, Ludwig Inst Canc Res, Epalinges, Switzerland.	alison.jaccard@unil.ch; ping-chih.ho@unil.ch	; Jaccard, Arnaud/O-8819-2016	Ho, Ping-Chih/0000-0003-3078-3774; Jaccard, Alison/0000-0002-7737-3118; Jaccard, Arnaud/0000-0001-7091-8253				Azuma T, 2008, BLOOD, V111, P3635, DOI 10.1182/blood-2007-11-123141; Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500; Galluzzi L, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aat7807; Gao Y, 2020, NAT CELL BIOL, V22, P1064, DOI 10.1038/s41556-020-0562-4; Li XY, 2019, NAT REV CLIN ONCOL, V16, P425, DOI 10.1038/s41571-019-0203-7; Song H, 2011, BIOCHEM BIOPH RES CO, V404, P68, DOI 10.1016/j.bbrc.2010.11.064; Tu XY, 2019, MOL CELL, V74, P1215, DOI 10.1016/j.molcel.2019.04.005; von Burstin J, 2009, GASTROENTEROLOGY, V137, P361, DOI 10.1053/j.gastro.2009.04.004; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930	11	4	4	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1465-7392	1476-4679		NAT CELL BIOL	Nat. Cell Biol.	SEP	2020	22	9					1031	1032		10.1038/s41556-020-0568-y	http://dx.doi.org/10.1038/s41556-020-0568-y		AUG 2020	2	Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Cell Biology	NJ1ME	32839550				2023-01-03	WOS:000562333600001
J	Pinto, E; Marcos, G; Walters, C; Goncalves, F; Sacarlal, J; Castro, L; Rego, G				Pinto, Emilia; Marcos, Gustavo; Walters, Camila; Goncalves, Ferraz; Sacarlal, Jahit; Castro, Luisa; Rego, Guilhermina			Palliative care in Mozambique: Physicians' knowledge, attitudes and practices	PLOS ONE			English	Article							END-OF-LIFE; INTEGRATION; DIAGNOSIS; EDUCATION	Background Palliative care is an essential part of medical practice but it remains limited, inaccessible, or even absent in low and middle income countries. Objectives To evaluate the general knowledge, attitudes, and practices of Mozambican physicians on palliative care. Methods A cross-sectional observational study was conducted between August 2018 and January 2019 in the 3 main hospitals of Mozambique, in addition to the only hospital with a standalone palliative care service. Data was collected from a self-administered survey directed to physicians in services with oncology patients. Results Two hundred and seven out of 306 physicians surveyed answered the questionnaire. The median physician age was 38 years. Fifty-five percent were males, and 49.8% residents. The most common medical specialty was surgery with 26.1%. Eighty percent of physicians answered that palliative care should be provided to patients when no curative treatments are available; 87% believed that early integration of palliative care can improve patients' quality of life; 73% regularly inform patients of a cancer diagnosis; 60% prefer to inform the diagnosis and prognosis to the family/caregivers. Fifty percent knew what a "do-not-resuscitate" order is, and 51% knew what palliative sedation is. Only 25% of the participants answered correctly all questions on palliative care general knowledge, and only 24% of the participants knew all answers about euthanasia. Conclusions Mozambican physicians in the main hospitals of Mozambique have cursory knowledge about palliative care. Paternalism and the family-centered model are the most prevalent. More interventions and training of professionals are needed to improve palliative care knowledge and practice in the country.	[Pinto, Emilia; Goncalves, Ferraz; Rego, Guilhermina] Univ Porto, Sch Med, Porto, Portugal; [Pinto, Emilia] Maputo Cent Hosp, Pain Unit, Maputo, Mozambique; [Pinto, Emilia; Marcos, Gustavo] Maputo Cent Hosp, Anesthesiol Dept, Maputo, Mozambique; [Marcos, Gustavo; Sacarlal, Jahit] Univ Eduardo Mondlane, Sch Med, Maputo, Mozambique; [Walters, Camila] Vanderbilt Univ, Dept Anesthesiol, 221 Kirkland Hall, Nashville, TN 37235 USA; [Goncalves, Ferraz] Portuguese Oncol Inst, Palliat Care Serv, Lisbon, Portugal; [Castro, Luisa] Univ Porto, Ctr Hlth Technol & Serv Res CINTESIS, Porto, Portugal	Universidade do Porto; Eduardo Mondlane University; Vanderbilt University; Portuguese Institute of Oncology; Universidade do Porto	Pinto, E (corresponding author), Univ Porto, Sch Med, Porto, Portugal.; Pinto, E (corresponding author), Maputo Cent Hosp, Pain Unit, Maputo, Mozambique.; Pinto, E (corresponding author), Maputo Cent Hosp, Anesthesiol Dept, Maputo, Mozambique.	emiquidade@gmail.com	Gonçalves, José António Ferraz/AAW-8952-2021; Castro, Luísa/K-1827-2014; Rego, Guilhermina/GRR-2433-2022; Sacarlal, Jahit/R-3172-2016; Walters, Camila/E-5885-2015	Gonçalves, José António Ferraz/0000-0002-9506-7106; Castro, Luísa/0000-0002-1312-0154; Rego, Guilhermina/0000-0002-8590-9832; Sacarlal, Jahit/0000-0003-1059-217X; Walters, Camila/0000-0001-7131-3088	Calouste Gulbenkian Foundation [144879]; Ministry of Health of Mozambique (MISAU)	Calouste Gulbenkian Foundation; Ministry of Health of Mozambique (MISAU)	EP was supported by Calouste Gulbenkian Foundation grant number No.144879. Travel expenses for data collections in the 4 hospitals was supported by the Ministry of Health of Mozambique (MISAU).	Aldridge MD, 2016, PALLIATIVE MED, V30, P224, DOI 10.1177/0269216315606645; [Anonymous], 2015, CHINA MODERN MED, V22, P32; [Anonymous], 2015, MORPH SURV REP REV N; [Anonymous], 2015, WAY FORWARD NATL FRA; [Anonymous], 2001, INGENIA, V10, P19; Clarke G, 2017, J PONE; Goncalves JF, 2001, PALLIATIVE MED, V15, P35, DOI 10.1191/026921601676515878; Hannon B, 2016, J CLIN ONCOL, V34, P62, DOI 10.1200/JCO.2015.62.1615; Inst Med, 2015, DYING IN AMERICA: IMPROVING QUALITY AND HONORING INDIVIDUAL PREFERENCES NEAR THE END OF LIFE, P1; Juth Niklas, 2010, BMC Palliat Care, V9, P20, DOI 10.1186/1472-684X-9-20; KNAUS WA, 1995, JAMA-J AM MED ASSOC, V274, P1591, DOI 10.1001/jama.1995.03530200027032; Kuroki LM, 2013, OBSTET GYNECOL, V122, P1033, DOI 10.1097/AOG.0b013e3182a9bf42; Lamba S, 2016, J PALLIAT MED, V19, P101, DOI 10.1089/jpm.2015.0292; Lim RBL, 2016, THER ADV RESPIR DIS, V10, P455, DOI 10.1177/1753465816660925; Mack JW, 2012, J CLIN ONCOL, V30, P4387, DOI 10.1200/JCO.2012.43.6055; Maltoni M, 2012, J CLIN ONCOL, V30, P1378, DOI 10.1200/JCO.2011.37.3795; Nakazawa Y, 2018, CANCER-AM CANCER SOC, V124, P626, DOI 10.1002/cncr.31071; Niu FY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2169-5; Oliva-Teles N, 2016, MEDICINE, V95; Perelygin AA, 2006, PROCEEDINGS OF THE FIFTH INTERNATIONAL CONFERENCE ON BIOINFORMATICS OF GENOME REGULATION AND STRUCTURE, VOL 3, P199; Rhee JY, 2017, LANCET ONCOL, V18, pE522, DOI [10.1016/S1470-2045(17)30420-5, 10.1016/s1470-2045(17)30420-5]; Smith TJ, 2012, J CLIN ONCOL, V30, P880, DOI 10.1200/JCO.2011.38.5161; Sweatman Louise R, 2016, Health Law Can, V36, P63; Tsang S, 2017, SAUDI J ANAESTH, V11, pS80, DOI 10.4103/sja.SJA_203_17; Waterworth Susan, 2010, Curr Opin Support Palliat Care, V4, P238, DOI 10.1097/SPC.0b013e328340684f; Worldwide Hospice Palliative Care Alliance (WHPCA), 2014, MAPP LEV PALL CAR DE	26	4	4	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 24	2020	15	8							e0238023	10.1371/journal.pone.0238023	http://dx.doi.org/10.1371/journal.pone.0238023			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NI7TB	32833987	Green Published			2023-01-03	WOS:000565550400048
J	Dettweiler, M; Marquez, L; Bao, M; Quave, CL				Dettweiler, Micah; Marquez, Lewis; Bao, Max; Quave, Cassandra L.			Quantifying synergy in the bioassay-guided fractionation of natural product extracts	PLOS ONE			English	Article							DRUG; ANTAGONISM	Mixtures of drugs often have greater therapeutic value than any of their constituent drugs alone, and such combination therapies are widely used to treat diseases such as cancer, malaria, and viral infections. However, developing useful drug mixtures is challenging due to complex interactions between drugs. Natural substances can be fruitful sources of useful drug mixtures because secondary metabolites produced by living organisms do not often act in isolationin vivo. In order to facilitate the study of interactions within natural substances, a new analytical method to quantify interactions using data generated in the process of bioassay-guided fractionation is presented here: the extract fractional inhibitory concentration index (EFICI). The EFICI method uses the framework of Loewe additivity to calculate fractional inhibitory concentration values by which interactions can be determined for any combination of fractions that make up a parent extract. The EFICI method was applied to data on the bioassay-guided fractionation ofLechea mucronataandSchinus terebinthifoliafor growth inhibition of the pathogenic bacteriumAcinetobacter baumannii. TheL.mucronataextract contained synergistic interactions (EFICI = 0.4181) and theS.terebinthifoliaextract was non-interactive overall (EFICI = 0.9129). Quantifying interactions in the bioassay-guided fractionation of natural substances does not require additional experiments and can be useful to guide the experimental process and to support the development of standardized extracts as botanical drugs.	[Dettweiler, Micah; Quave, Cassandra L.] Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA; [Marquez, Lewis] Emory Univ, Mol & Syst Pharmacol Program, Atlanta, GA 30322 USA; [Bao, Max; Quave, Cassandra L.] Emory Univ, Ctr Study Human Hlth, Atlanta, GA 30322 USA	Emory University; Emory University; Emory University	Quave, CL (corresponding author), Emory Univ, Sch Med, Dept Dermatol, Atlanta, GA 30322 USA.; Quave, CL (corresponding author), Emory Univ, Ctr Study Human Hlth, Atlanta, GA 30322 USA.	cquave@emory.edu		Marquez, Lewis/0000-0002-3782-5204	National Institutes of Health, National Institute of Allergy and Infectious Disease [R21 AI136563]; Jones Center at Ichauway	National Institutes of Health, National Institute of Allergy and Infectious Disease(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Jones Center at Ichauway	This work was supported by the National Institutes of Health, National Institute of Allergy and Infectious Disease (R21 AI136563) to CLQ and a graduate fellowship to LM was provided by the Jones Center at Ichauway. The funders had no role in the design of the study, data collection and analysis, decision to publish, or preparation of the manuscript.	Abreu AC, 2012, NAT PROD REP, V29, P1007, DOI 10.1039/c2np20035j; Agarwal A, 2014, CURR OPIN BIOTECH, V25, P39, DOI 10.1016/j.copbio.2013.08.010; [Anonymous], **NON-TRADITIONAL**; Bell A, 2005, FEMS MICROBIOL LETT, V253, P171, DOI 10.1016/j.femsle.2005.09.035; BERENBAUM MC, 1989, PHARMACOL REV, V41, P93; BERENBAUM MC, 1978, J INFECT DIS, V137, P122, DOI 10.1093/infdis/137.2.122; Caesar LK, 2019, NAT PROD REP, V36, P869, DOI 10.1039/c9np00011a; Clinical and Laboratory Standards Institute, 2013, M100S23 CLSI; Cokol M, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1701881; Cokol M, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.71; Doern CD, 2014, J CLIN MICROBIOL, V52, P4124, DOI 10.1128/JCM.01121-14; El-Halfawy OM, 2019, NAT CHEM BIOL; Eloff JN, 2004, PHYTOMEDICINE, V11, P370, DOI 10.1078/0944711041495218; Fitzgerald JB, 2006, NAT CHEM BIOL, V2, P458, DOI 10.1038/nchembio817; Foucquier J, 2015, PHARMACOL RES PERSPE, V3, P3; GRECO WR, 1995, PHARMACOL REV, V47, P331; Junio HA, 2011, J NAT PROD, V74, P1621, DOI 10.1021/np200336g; LOEWE S, 1953, ARZNEIMITTEL-FORSCH, V3, P285; Lutgring JD, 2018, J CLIN MICROBIOL, V56; Muhs A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42275; Odds FC, 2003, J ANTIMICROB CHEMOTH, V52, P1, DOI 10.1093/jac/dkg301; Peleg AY, 2008, CLIN MICROBIOL REV, V21, P538, DOI 10.1128/CMR.00058-07; Quave CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028737; Schmidt BM, 2007, NAT CHEM BIOL, V3, P360, DOI 10.1038/nchembio0707-360; Tallarida RJ, 2012, J PHARMACOL EXP THER, V342, P2, DOI 10.1124/jpet.112.193474; Tan X, 2012, NAT BIOTECHNOL, V30, P1125, DOI 10.1038/nbt.2391; van Vuuren S, 2011, PLANTA MED, V77, P1168, DOI 10.1055/s-0030-1250736; Yadav B, 2015, COMPUT STRUCT BIOTEC, V13, P504, DOI 10.1016/j.csbj.2015.09.001	28	5	5	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 14	2020	15	8							e0235723	10.1371/journal.pone.0235723	http://dx.doi.org/10.1371/journal.pone.0235723			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NE5WK	32797045	gold, Green Submitted, Green Published			2023-01-03	WOS:000562671300005
J	Lopez-Rodriguez, JA; Rogero-Blanco, E; Aza-Pascual-Salcedo, M; Lopez-Verde, F; Pico-Soler, V; Leiva-Fernandez, F; Prados-Torres, JD; Prados-Torres, A; Cura-Gonzalez, I				Lopez-Rodriguez, Juan A.; Rogero-Blanco, Eloisa; Aza-Pascual-Salcedo, Mercedes; Lopez-Verde, Fernando; Pico-Soler, Victoria; Leiva-Fernandez, Francisca; Prados-Torres, J. Daniel; Prados-Torres, Alexandra; Cura-Gonzalez, Isabel		MULTIPAP Grp	Potentially inappropriate prescriptions according to explicit and implicit criteria in patients with multimorbidity and polypharmacy. MULTIPAP: A cross-sectional study	PLOS ONE			English	Article							MEDICATION APPROPRIATENESS INDEX; DWELLING OLDER-PEOPLE; STOPP/START CRITERIA; BEERS CRITERIA; SCREENING TOOL; DRUG; OUTCOMES; ADULTS; STOPP; APPLICABILITY	Background Multimorbidity is a global health challenge that is associated with polypharmacy, increasing the risk of potentially inappropriate prescribing (PIP). There are tools to improve prescription, such as implicit and explicit criteria. Objective To estimate the prevalence of PIP in a population aged 65 to 74 years with multimorbidity and polypharmacy, according to American Geriatrics Society Beers Criteria(R)(2015, 2019), the Screening Tool of Older Person's Prescription -STOPP- criteria (2008, 2014), and the Medication Appropriateness Index -MAI- criteria in primary care. Methods This was an observational, descriptive, cross-sectional study. The sample included 593 community-dwelling elderly aged 65 to 74 years, with multimorbidity and polypharmacy, who participated in the MULTIPAP trial. Socio-demographic, clinical, professional, and pharmacological-treatment variables were recorded. Potentially inappropriate prescribing was detected by computerized prescription assistance system, and family doctors evaluated the MAI. The MAI-associated factors were analysed using a logistic regression model. Results A total of 4,386 prescriptions were evaluated. The mean number of drugs was 7.4 (2.4 SD). A total of 94.1% of the patients in the study had at least one criterion for drug inappropriateness according to the MAI. Potentially inappropriate prescribing was detected in 57.7%, 43.6%, 68.8% and 71% of 50 patients according to the explicit criteria STOPP 2014, STOPP 2008, Beers 2019 and Beers 2015 respectively. For every new drug taken by a patient, the MAI score increased by 2.41 (95% CI 1.46; 3.35) points. Diabetes, ischaemic heart disease and asthma were independently associated with lower summated MAI scores. Conclusions The prevalence of potentially inappropriate prescribing detected in the sample was high and in agreement with previous literature for populations with multimorbidity and polypharmacy. The MAI criteria detected greater inappropriateness than did the explicit criteria, but their application was more complex and difficult to automate.	[Lopez-Rodriguez, Juan A.; Rogero-Blanco, Eloisa] Primary Healthcare Ctr Gen Ricardos, Madrid, Spain; [Lopez-Rodriguez, Juan A.; Rogero-Blanco, Eloisa; Cura-Gonzalez, Isabel] Univ Rey Juan Carlos Alcorcon, Sch Hlth Sci, Med Specialties & Publ Hlth Dept, Madrid, Spain; [Lopez-Rodriguez, Juan A.; Cura-Gonzalez, Isabel] Res Support Unit, Primary Care Management, Madrid, Spain; [Lopez-Rodriguez, Juan A.; Rogero-Blanco, Eloisa; Pico-Soler, Victoria; Prados-Torres, J. Daniel; Prados-Torres, Alexandra; Cura-Gonzalez, Isabel] Hlth Serv Res Chron Patients Network REDISSEC, Madrid, Spain; [Aza-Pascual-Salcedo, Mercedes] Sect Zaragoza III, Primary Care Direct, Zaragoza, Spain; [Lopez-Verde, Fernando; Leiva-Fernandez, Francisca; Prados-Torres, J. Daniel] Unidad Docente Multiprofes Atenc Familiar & Comun, Malaga, Spain; [Lopez-Verde, Fernando] Primary Healthcare Ctr Las Delicias, Malaga, Spain; [Pico-Soler, Victoria; Prados-Torres, Alexandra] IIS Aragon, Aragon Hlth Sci Inst, EpiChron Res Grp, Zaragoza, Spain; [Pico-Soler, Victoria] Primary Healthcare Ctr Torrero La Paz, Zaragoza, Spain; [Leiva-Fernandez, Francisca; Prados-Torres, J. Daniel] Biomed Res Inst Malaga IBIMA, Malaga, Spain; [Prados-Torres, Alexandra] Miguel Servet Univ Hosp, Zaragoza, Spain	Universidad Rey Juan Carlos; Universidad de Malaga; Miguel Servet University Hospital	Rogero-Blanco, E (corresponding author), Primary Healthcare Ctr Gen Ricardos, Madrid, Spain.; Rogero-Blanco, E (corresponding author), Univ Rey Juan Carlos Alcorcon, Sch Hlth Sci, Med Specialties & Publ Hlth Dept, Madrid, Spain.; Rogero-Blanco, E (corresponding author), Hlth Serv Res Chron Patients Network REDISSEC, Madrid, Spain.	uand.padros.sspa@juntadeandalucia.es; sprados.iacs@aragon.es; mariaeloisa.rogero@salud.madrid.org	Gimeno-Miguel, Antonio/AAC-9611-2019; Prados-Torres, Alexandra/P-5818-2017; Gimeno-Feliu, Luis Andrés/E-5390-2016; Lopez-Rodriguez, Juan A/F-2322-2010; del Cura-Gonzalez, Isabel/G-9040-2018; POLENTINOS-CASTRO, ELENA/B-7373-2019	Gimeno-Miguel, Antonio/0000-0002-5440-1710; Prados-Torres, Alexandra/0000-0002-5704-6056; Gimeno-Feliu, Luis Andrés/0000-0003-2928-6623; Lopez-Rodriguez, Juan A/0000-0002-4985-2314; del Cura-Gonzalez, Isabel/0000-0002-3931-5304; Aza-Pascual-Salcedo, Mercedes/0000-0002-8937-5559; Azcoaga-Lorenzo, Amaya/0000-0003-3307-878X; Leiva-Fernandez, Francisca/0000-0001-6919-4817; Machin Hamalainen, Santiago/0000-0003-4612-1804; POLENTINOS-CASTRO, ELENA/0000-0001-9460-2966; Prados-Torres, J. Daniel/0000-0001-5204-7781; Rogero Blanco, Maria Eloisa/0000-0002-8732-6120	National Institute for Health Research ISCIII - European Regional Development Fund, (ERDF) "A way of shaping Europe" [PI15/00276, PI15/00572, PI15/00996, RD16/0001/0004, RD16/0001/0005, RD16/0001/0006]; National Plan I+D+I 2013-2016; Foundation for Biomedical Research and Innovation in Primary Care (FIIBAP); Spanish Society of Family and Community Medicine	National Institute for Health Research ISCIII - European Regional Development Fund, (ERDF) "A way of shaping Europe"; National Plan I+D+I 2013-2016; Foundation for Biomedical Research and Innovation in Primary Care (FIIBAP); Spanish Society of Family and Community Medicine	This study was funded by National Institute for Health Research ISCIII (Grant numbers PI15/00276 (APT), PI15/00572 (ICG), PI15/00996 (JDPT), RD16/0001/0004 (ICG), RD16/0001/0005 (APT), RD16/0001/0006 (JDPT)) Co-funded by European Regional Development Fund, (ERDF) "A way of shaping Europe". National Plan I+D+I 2013-2016". ERB has received a grant from the Foundation for Biomedical Research and Innovation in Primary Care (FIIBAP) for translation in its 2019 call and received funding from the Spanish Society of Family and Community Medicine -semFYC- as it won a grant for the completion of doctoral theses Isabel Fernandez 2018.	Alassaad A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007259; Anrys P, 2016, IMPLEMENT SCI, V11, DOI 10.1186/s13012-016-0394-6; Awad A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218174; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Blanco-Reina E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167586; Blanco-Reina E, 2014, J AM GERIATR SOC, V62, P1217, DOI 10.1111/jgs.12891; Bright TJ, 2012, ANN INTERN MED, V157, P29, DOI 10.7326/0003-4819-157-1-201207030-00450; Cahir C, 2010, BRIT J CLIN PHARMACO, V69, P543, DOI 10.1111/j.1365-2125.2010.03628.x; Josep PC, 2017, FARM HOSP, V41, P130, DOI 10.7399/fh.2017.41.1.10568; Cruz-Esteve I, 2017, ATEN PRIM, V49, P166, DOI 10.1016/j.aprim.2016.02.013; Delgado Silveira E, 2015, Rev Esp Geriatr Gerontol, V50, P89, DOI 10.1016/j.regg.2014.10.005; Domingo-Salvany A, 2013, GAC SANIT, V27, P263, DOI 10.1016/j.gaceta.2012.12.009; Dreesens D, 2019, HLTH POLICY NEW YORK; Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Galvan-Banqueri M, 2013, ATEN PRIM, V45, P235, DOI 10.1016/j.aprim.2012.11.010; Galvan-Banqueri M, 2013, ATEN PRIM, V45, P6, DOI 10.1016/j.aprim.2012.03.011; Gavilan Moral E, 2012, INDICE ADECUACION ME; Gillespie U, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062401; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Hanlon JT, 2011, AGE AGEING, V40, P274, DOI 10.1093/ageing/afq158; HANLON JT, 1992, J CLIN EPIDEMIOL, V45, P1045, DOI 10.1016/0895-4356(92)90144-C; Hellstrom LM, 2011, EUR J CLIN PHARMACOL, V67, P741, DOI 10.1007/s00228-010-0982-3; Hill-Taylor B, 2013, J CLIN PHARM THER, V38, P360, DOI 10.1111/jcpt.12059; Kalisch LM, 2012, INT J QUAL HEALTH C, V24, P239, DOI 10.1093/intqhc/mzs015; Kantor ED, 2015, JAMA-J AM MED ASSOC, V314, P1818, DOI 10.1001/jama.2015.13766; Kassam R, 2003, ANN PHARMACOTHER, V37, P40; Kim GJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191376; Lund BC, 2010, ANN PHARMACOTHER, V44, P957, DOI 10.1345/aph.1M657; Luo RY, 2012, J EVAL CLIN PRACT, V18, P1196, DOI 10.1111/j.1365-2753.2011.01758.x; Ministerio de Sanidad Consumo y Bienestar Social, 2017, PORT EST; Moriarty F, 2016, BRIT J CLIN PHARMACO, V82, P849, DOI 10.1111/bcp.12995; Muth C, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-017740; Nauta KJ, 2017, PHARMACOEPIDEM DR S, V26, P1242, DOI 10.1002/pds.4283; O'Halloran J, 2004, FAM PRACT, V21, P381, DOI 10.1093/fampra/cmh407; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Olsson IN, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-95; Patterson SM, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD008165.pub3, 10.1002/14651858.CD008165.pub4]; Pradityana A, 2017, AIP CONF PROC, V1840, DOI 10.1063/1.4982261; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Riordan DO, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019003; Schmader KE, 1997, ANN PHARMACOTHER, V31, P529, DOI 10.1177/106002809703100501; Sevilla-Sanchez D, 2017, INT J CLIN PHARM-NET, V39, P1018, DOI 10.1007/s11096-017-0518-3; Soiza RL, 2017, THER ADV DRUG SAF, V8, P81, DOI 10.1177/2042098616675851; Somers A, 2012, AM J GERIATR PHARMAC, V10, P101, DOI 10.1016/j.amjopharm.2012.01.003; Spinewine A, 2007, LANCET, V370, P173, DOI 10.1016/S0140-6736(07)61091-5; Steinman MA, 2007, MED CARE, V45, P95, DOI 10.1097/01.mlr.0000241111.11991.62; The Academy of Medical Sciences, 2018, MULT PRIOR GLOB HLTH; Tommelein E, 2015, EUR J CLIN PHARMACOL, V71, P1415, DOI 10.1007/s00228-015-1954-4; World Health Organization, 2008, CHALL CHANG WORLD WO, P21; Zhang XL, 2017, CLIN INTERV AGING, V12, P1697, DOI 10.2147/CIA.S146009	52	21	22	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2020	15	8							e0237186	10.1371/journal.pone.0237186	http://dx.doi.org/10.1371/journal.pone.0237186			20	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ND3HD	32785232	Green Published, gold			2023-01-03	WOS:000561793900003
J	Aniort, J; Freist, M; Piraud, A; Philipponnet, C; Abdelkader, MH; Garrouste, C; Gentes, E; Pereira, B; Heng, AE				Aniort, Julien; Freist, Marine; Piraud, Aurelien; Philipponnet, Carole; Abdelkader, Mohamed Hadj; Garrouste, Cyril; Gentes, Elodie; Pereira, Bruno; Heng, Anne-Elisabeth			Circulating 20S proteasome for assessing protein energy wasting syndrome in hemodialysis patients	PLOS ONE			English	Article							MUSCLE; UBIQUITIN; SURVIVAL; MURF1	Protein energy wasting (PEW) including muscle atrophy is a common complication in chronic hemodialysis patients. The ubiquitin proteasome system (UPS) is the main proteolytic system causing muscle atrophy in chronic kidney disease and proteasome 20S is the catalytic component of the UPS. Circulating proteasome 20S (c20S proteasome) is present in the blood and its level is related to disease severity and prognosis in several disorders. We hypothesized that c20S proteasome could be related with muscle mass, other PEW criteria and their evolution in hemodialysis patients. Stable hemodialysis patients treated at our center for more than 3 months were followed over 2 years. C20S proteasome assay was performed at baseline. Biological and clinical data were collected, muscle mass was assessed by multi-frequency bio-impedancemetry, and nutritional scores were calculated at baseline, 1 year and 2 years. Hospitalizations and mortality data were collected over the 2 years. Forty-nine patients were included. At baseline, the c20S proteasome level was 0.40 [0.26-0.55] mu g/ml. Low muscle mass as defined by a lean tissue index (LTI) < 10th in accordance with the International Society of Renal Nutrition and Metabolism guidelines was observed in 36% and PEW in 62%. Increased c20S proteasome levels were related with LTI at baseline (R = 0.43, p = 0.004) and with its 2 year-variation (R = -0.56, p = 0.003). Two-year survival rate was not different between higher and lower c20S proteasome values (78.9 vs 78.4%, p = 0.98 log-rank test). C20S proteasome is not a good marker for assessing nutritional status in hemodialysis patients and predicting patient outcomes.	[Aniort, Julien; Freist, Marine; Piraud, Aurelien; Philipponnet, Carole; Abdelkader, Mohamed Hadj; Garrouste, Cyril; Heng, Anne-Elisabeth] Gabriel Montpied Univ Hosp, Nephrol Dialysis & Transplantat Dept, Clermont Ferrand, France; [Aniort, Julien; Heng, Anne-Elisabeth] Human Nutr Unit UNH, INRA, UMR 1019, St Genes Champanelle, France; [Freist, Marine] Emile Roux Hosp, Nephrol & Dialysis Dept, Le Puy En Velay, France; [Gentes, Elodie] Gabriel Montpied Univ Hosp, Clin Nutr Dept, Clermont Ferrand, France; [Pereira, Bruno] Univ Hosp Clermont Ferrand, Biostat Unit DRCI, Clermont Ferrand, France	CHU Clermont Ferrand; INRAE; CHU Clermont Ferrand; CHU Clermont Ferrand	Aniort, J (corresponding author), Gabriel Montpied Univ Hosp, Nephrol Dialysis & Transplantat Dept, Clermont Ferrand, France.; Aniort, J (corresponding author), Human Nutr Unit UNH, INRA, UMR 1019, St Genes Champanelle, France.	janiort@chu-clermontferrand.fr						Aniort J, 2019, J CACHEXIA SARCOPENI, V10, P323, DOI 10.1002/jcsm.12376; Aniort J, 2016, INT J BIOCHEM CELL B, V79, P505, DOI 10.1016/j.biocel.2016.04.006; Baker ST, 2012, EUR J CLIN NUTR, V66, P628, DOI 10.1038/ejcn.2012.3; Canaud B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093286; Cano NJM, 2009, SEMIN NEPHROL, V29, P59, DOI 10.1016/j.semnephrol.2008.10.008; Chamney PW, 2007, AM J CLIN NUTR, V85, P80, DOI 10.1093/ajcn/85.1.80; Clarke BA, 2007, CELL METAB, V6, P376, DOI 10.1016/j.cmet.2007.09.009; Daugirdas J T, 1995, Adv Ren Replace Ther, V2, P295; Delanaye P, 2019, J RENAL NUTR, V29, P511, DOI 10.1053/j.jrn.2018.11.010; Depner TA, 1996, J AM SOC NEPHROL, V7, P780; Dessi M, 2009, NUTR METAB CARDIOVAS, V19, P811, DOI 10.1016/j.numecd.2009.01.009; Du J, 2004, J CLIN INVEST, V113, P115, DOI 10.1172/JCI200418330; Dutaud D, 2002, J IMMUNOL METHODS, V260, P183, DOI 10.1016/S0022-1759(01)00555-5; Egerer K, 2002, J RHEUMATOL, V29, P2045; Esposito P, 2019, BMC NEPHROL, V20, DOI 10.1186/s12882-019-1647-9; Fouque D, 2008, KIDNEY INT, V73, P391, DOI 10.1038/sj.ki.5002585; Fukasawa H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121352; Heubner M, 2011, GYNECOL ONCOL, V120, P233, DOI 10.1016/j.ygyno.2010.10.014; Jakob C, 2007, BLOOD, V109, P2100, DOI 10.1182/blood-2006-04-016360; Lecker SH, 2004, FASEB J, V18, P39, DOI 10.1096/fj.03-0610com; Marcelli D, 2015, CLIN J AM SOC NEPHRO, V10, P1192, DOI 10.2215/CJN.08550814; MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208; Moreau-Gaudry X, 2014, J RENAL NUTR, V24, P395, DOI 10.1053/j.jrn.2014.06.008; Niewczas MA, 2019, NAT MED, V25, P805, DOI 10.1038/s41591-019-0415-5; Polge C, 2011, FASEB J, V25, P3790, DOI 10.1096/fj.11-180968; Roth GA, 2005, EUR J CLIN INVEST, V35, P399, DOI 10.1111/j.1365-2362.2005.01508.x; Sixt SU, 2008, BBA-MOL BASIS DIS, V1782, P817, DOI 10.1016/j.bbadis.2008.06.005; Szerafin T, 2008, ANN THORAC SURG, V85, P80, DOI 10.1016/j.athoracsur.2007.06.049; Tomko RJ, 2013, ANNU REV BIOCHEM, V82, P415, DOI 10.1146/annurev-biochem-060410-150257; WADA M, 1993, J LAB CLIN MED, V121, P215; Wang F, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8361237; Wang XNH, 2014, NAT REV NEPHROL, V10, P504, DOI 10.1038/nrneph.2014.112	32	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2020	15	7							e0236948	10.1371/journal.pone.0236948	http://dx.doi.org/10.1371/journal.pone.0236948			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NO3EK	32735636	Green Published, gold			2023-01-03	WOS:000569367100064
J	Sud, A; Armas, A; Cunningham, H; Tracy, S; Foat, K; Persaud, N; Hosseiny, F; Hyland, S; Lowe, L; Zlahtic, E; Murti, R; Derue, H; Birnbaum, I; Bonin, K; Upshur, R; Nelson, MLA				Sud, Abhimanyu; Armas, Alana; Cunningham, Heather; Tracy, Shawn; Foat, Kirk; Persaud, Navindra; Hosseiny, Fardous; Hyland, Sylvia; Lowe, Leyna; Zlahtic, Erin; Murti, Rhea; Derue, Hannah; Birnbaum, Ilana; Bonin, Katija; Upshur, Ross; Nelson, Michelle L. A.			Multidisciplinary care for opioid dose reduction in patients with chronic non-cancer pain: A systematic realist review	PLOS ONE			English	Review							LOW-BACK-PAIN; FOLLOW-UP; SELF-EFFICACY; TREATMENT OUTCOMES; REHABILITATION PROGRAM; BEHAVIORAL TREATMENT; HEALTH-CARE; PSYCHOSOCIAL DISABILITIES; ANALGESIC MEDICATION; SUBSTANCE DEPENDENCE	Context Opioid related deaths are at epidemic levels in many developed nations globally. Concerns about the contribution of prescribed opioids, and particularly high-dose opioids, continue to mount as do initiatives to reduce prescribing. Evidence around opioid tapering, which can be challenging and potentially hazardous, is not well developed. A recent national guideline has recognized this and recommended referral to multidisciplinary care for challenging cases of opioid tapering. However, multidisciplinary care for opioid tapering is not well understood or defined. Objective Identify the existing literature on any multidisciplinary care programs that evaluate impact on opioid use, synthesize how these programs work and clarify whom they benefit. Study design Systematic rapid realist review. Dataset Bibliographic databases (MEDLINE, EMBASE, CINAHL, PsycINFO, Cochrane Library), grey literature, reference hand search and formal expert consultation. Results 95 studies were identified. 75% of the programs were from the United States and the majority (n = 62) were published after 2000. A minority (n = 23) of programs reported on >12 month opioid use outcomes. There were three necessary but insufficient mechanisms common to all programs: pain relief, behavior change and active medication management. Programs that did not include a combination of all three mechanisms did not result in opioid dose reductions. A concerning 20-40% of subjects resumed opioid use within one year of program completion. Conclusions Providing alternative analgesia is insufficient for reducing opioid doses. Even high quality primary care multidisciplinary care programs do not reduce prescribed opioid use unless there is active medication management accomplished by changing the primary opioid prescriber. Rates of return to use of opioids from these programs are very concerning in the current context of a highly potent and lethal street drug supply. This contextual factor may be powerful enough to undermine the modest benefits of opioid dose reduction via multidisciplinary care.	[Sud, Abhimanyu] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Armas, Alana; Tracy, Shawn; Upshur, Ross; Nelson, Michelle L. A.] Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Bridgepoint Collaboratory Res & Innovat, Toronto, ON, Canada; [Cunningham, Heather] Univ Toronto, Gerstein Sci Informat Ctr, Toronto, ON, Canada; [Persaud, Navindra] St Michaels Hosp, Dept Family & Community Med, Toronto, ON, Canada; [Persaud, Navindra] St Michaels Hosp, MAP Ctr Urban Hlth Solut, Keenan Res Ctr, Toronto, ON, Canada; [Hosseiny, Fardous; Lowe, Leyna] Canadian Mental Hlth Assoc Natl, Toronto, ON, Canada; [Hyland, Sylvia] Inst Safe Medicat Practices Canada, Toronto, ON, Canada; [Zlahtic, Erin] Western Univ, Kinesiol, London, ON, Canada; [Murti, Rhea] McMaster Univ, Arts & Sci, Hamilton, ON, Canada; [Derue, Hannah] Univ Guelph Humber, Psychol, Toronto, ON, Canada; [Birnbaum, Ilana; Bonin, Katija] Univ Toronto, Fac Med, Toronto, ON, Canada; [Upshur, Ross] Univ Toronto, Dalla Lana Sch Publ Hlth, Toronto, ON, Canada; [Nelson, Michelle L. A.] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Hosseiny, Fardous] Ctr Excellence Posttraumat Stress Disorder, Ottawa, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Western University (University of Western Ontario); McMaster University; University of Guelph; University of Toronto; University of Toronto; University of Toronto	Sud, A (corresponding author), Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.	Abhimanyu.sud@utoronto.ca		Birnbaum, Ilana/0000-0002-1306-915X; Hosseiny, Fardous/0000-0002-4448-2457; Sud, Abhimanyu/0000-0001-8354-6153; Derue, Hannah/0000-0002-2154-1880	Canadian Institutes of Health Research [OCK-156776]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	RU, MN, AS, SH, HC, NP received the Operating Grant: Opioid Crisis Knowledge Synthesis (OCK-156776) from the Canadian Institutes of Health Research (https://cihr-irsc.gc.ca/e/193.html).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Angeles RN, 2013, PAIN RES MANAG, V18, P237, DOI 10.1155/2013/491279; [Anonymous], 2017, HHS ACT SECR DECL PU; Atkins AM, 2014, J REHABIL RES DEV, V51, pVII, DOI [10.1682/JRRD.2014.08.0194, 10.1682/JRRD]; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; Barr B., 2017, DISS ABSTR INT, V78; Bass CM, 2007, QJM-INT J MED, V100, P369, DOI 10.1093/qjmed/hcm034; Becker N, 2000, PAIN, V84, P203, DOI 10.1016/S0304-3959(99)00209-2; Belkin M, 2017, AM J ADDICTION, V26, P738, DOI 10.1111/ajad.12605; Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1775, DOI 10.1001/jama.288.14.1775; Braden JB, 2009, GEN HOSP PSYCHIAT, V31, P564, DOI 10.1016/j.genhosppsych.2009.07.003; Bruce BK, 2017, CLIN J PAIN, V33, P535, DOI 10.1097/AJP.0000000000000433; Bruce BK, 2009, CURR PAIN HEADACHE R, V13, P67, DOI 10.1007/s11916-009-0014-0; Busse JW, 2017, CAN MED ASSOC J, V189, pE659, DOI 10.1503/cmaj.170363; CADTH, GREY MATT PRACT TOOL; Centers for Disease Control and Prevention, 2019, DRUG OVERDOSE DEATHS; Centre for Effective Practice, 2018, OP TAP TEMPL; Chandwani Brijesh P, 2008, J Opioid Manag, V4, P167; CHAPMAN SL, 1981, PAIN, V11, P255, DOI 10.1016/0304-3959(81)90011-7; CINCIRIPINI PM, 1982, J BEHAV MED, V5, P375, DOI 10.1007/BF00846164; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; Clarke H, 2018, CAN J PAIN, V2, P236, DOI 10.1080/24740527.2018.1501669; Cowan DT, 2003, PAIN MED, V4, P340, DOI 10.1111/j.1526-4637.2003.03038.x; Crisostomo RA, 2008, AM J PHYS MED REHAB, V87, P527, DOI 10.1097/PHM.0b013e31817c124f; Cucchiaro G, 2013, CLIN J PAIN, V29, pE42, DOI 10.1097/AJP.0b013e31829d676a; Cunningham JL, 2016, PAIN MED, V17, P1676, DOI 10.1093/pm/pnv079; Cunningham JL, 2009, PAIN MED, V10, P787, DOI 10.1111/j.1526-4637.2009.00582.x; Currie SR, 2003, J PAIN, V4, P91, DOI 10.1054/jpai.2003.17; Curtis HJ, 2019, LANCET PSYCHIAT, V6, P140, DOI 10.1016/S2215-0366(18)30471-1; DALKIN SM, 2015, IMPLEMENT SCI, V10, DOI DOI 10.1186/S13012-014-0196-7; Darchuk KM, 2010, PAIN MED, V11, P1352, DOI 10.1111/j.1526-4637.2010.00937.x; Davis MA, 2017, J AM BOARD FAM MED, V30, P407, DOI 10.3122/jabfm.2017.04.170112; Davis RT, 2018, GLOB ADV HLTH MED, V7, P1; De Williams A, 1993, BR J GEN PRACT, V43, P513; DEARDORFF WW, 1991, PAIN, V45, P35, DOI 10.1016/0304-3959(91)90162-Q; Dersh J, 2008, SPINE, V33, P2219, DOI 10.1097/BRS.0b013e31818096d1; DOLCE JJ, 1986, BEHAV RES THER, V24, P313, DOI 10.1016/0005-7967(86)90191-9; Doolin S.R., 2017, REDUCTION DAILY OPIO; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Dunn KM, 2010, ANN INTERN MED, V152, P85, DOI 10.7326/0003-4819-152-2-201001190-00006; Eng EL, 1996, HEADACHE, V36, P452, DOI 10.1046/j.1526-4610.1996.3607452.x; Fashler SR, 2016, PAIN RES MANAG, V2016, DOI 10.1155/2016/5960987; FINLAYSON RE, 1986, PAIN, V26, P167, DOI 10.1016/0304-3959(86)90072-2; FINLAYSON RE, 1986, PAIN, V26, P175, DOI 10.1016/0304-3959(86)90073-4; FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2; FORDYCE WE, 1973, ARCH PHYS MED REHAB, V54, P399; Frank JW, 2017, ANN INTERN MED, V167, P181, DOI 10.7326/M17-0598; Gilliam WP, 2018, J PAIN, V19, P678, DOI 10.1016/j.jpain.2018.02.010; Gomes T, 2018, BMJ-BRIT MED J, V362, DOI 10.1136/bmj.k3207; Groessl EJ, 2017, AM J PREV MED, V53, P599, DOI 10.1016/j.amepre.2017.05.019; GUCK TP, 1985, PAIN, V21, P295, DOI 10.1016/0304-3959(85)90093-4; Hassamal S, 2016, SCAND J PAIN, V13, P27, DOI 10.1016/j.sjpain.2016.06.007; Ho JY, 2019, POPUL DEV REV, V45, P7, DOI 10.1111/padr.12228; Hojsted J, 2006, ACTA ANAESTH SCAND, V50, P1290, DOI 10.1111/j.1399-6576.2006.01154.x; Hooten WM, 2007, PAIN MED, V8, P624, DOI 10.1111/j.1526-4637.2006.00202.x; Hooten WM, 2007, PAIN MED, V8, P8, DOI 10.1111/j.1526-4637.2007.00253.x; Hooten WM, 2010, PAIN MED, V11, P1587, DOI 10.1111/j.1526-4637.2010.00962.x; Hooten WM, 2009, ANESTH ANALG, V108, P308, DOI 10.1213/ane.0b013e31818c7b99; Hubbard JE, 1996, CLIN J PAIN, V12, P330, DOI 10.1097/00002508-199612000-00013; Huffman KL, 2017, PAIN, V158, P1380, DOI 10.1097/j.pain.0000000000000907; Huffman KL, 2013, PAIN MED, V14, P1908, DOI 10.1111/pme.12201; Hyde J, 2008, J HEALTH PSYCHOL, V13, P607, DOI 10.1177/1359105308090933; Jackson T, 2014, J PAIN, V15, P800, DOI 10.1016/j.jpain.2014.05.002; Jagosh J, 2014, RES SYNTH METHODS, V5, P131, DOI 10.1002/jrsm.1099; Jeffrey M, 2011, 11EHC064EF AG HEALTH; Jensen MK, 2006, EUR J PAIN, V10, P423, DOI 10.1016/j.ejpain.2005.06.001; Kates N, 2011, CAN J PSYCHIAT, V56, pB1; Katon W, 2001, GEN HOSP PSYCHIAT, V23, P138, DOI 10.1016/S0163-8343(01)00136-0; KEEFE FJ, 1981, PAIN, V11, P221, DOI 10.1016/0304-3959(81)90007-5; KHATAMI M, 1982, PAIN, V14, P45, DOI 10.1016/0304-3959(82)90079-3; KHATAMI M, 1979, COMPR PSYCHIAT, V20, P55, DOI 10.1016/0010-440X(79)90059-2; Kidner CL, 2009, J BONE JOINT SURG AM, V91A, P919, DOI 10.2106/JBJS.H.00286; KROENING RJ, 1985, INT J ADDICT, V20, P1347, DOI 10.3109/10826088509047771; Kroenke K, 2019, PAIN MED, V20, P724, DOI 10.1093/pm/pny307; Kroenke K, 2009, JAMA-J AM MED ASSOC, V301, P2099, DOI 10.1001/jama.2009.723; Krumova EK, 2013, CLIN J PAIN, V29, P760, DOI 10.1097/AJP.0b013e31827c7cf6; Kurklinsky S, 2016, PAIN RES TREAT, V2016, DOI 10.1155/2016/7217684; Lake AE, 2009, HEADACHE, V49, P555, DOI 10.1111/j.1526-4610.2009.01364.x; Lamarche L, 2018, PATIENT PREFER ADHER, V12, P1279, DOI 10.2147/PPA.S165749; Leifman H, 2016, DRUG RELATED DEATHS; LEVENDUSKY P, 1975, J ABNORM PSYCHOL, V84, P165, DOI 10.1037/h0076991; LINTON SJ, 1983, BEHAV PSYCHOTHER, V11, P337, DOI 10.1017/S0141347300008648; Maani CV, 2011, J TRAUMA, V71, pS114, DOI 10.1097/TA.0b013e3182219209; MacLaren JE, 2006, CLIN J PAIN, V22, P392, DOI 10.1097/01.ajp.0000208250.15572.01; Mailis-Gagnon A, 2011, CAN FAM PHYSICIAN, V57, pE97; MALEC J, 1981, ARCH PHYS MED REHAB, V62, P369; Meana M, 1999, GEN HOSP PSYCHIAT, V21, P137; Mehl-Madrona L, 2016, J ALTERN COMPLEM MED, V22, P621, DOI 10.1089/acm.2015.0212; Moore JE, 2000, PAIN, V88, P145, DOI 10.1016/S0304-3959(00)00314-6; Mudge A, 2016, AUST HEALTH REV, V40, P86, DOI 10.1071/AH14219; Murphy JL, 2016, J REHABIL RES DEV, V53, P83, DOI 10.1682/JRRD.2014.10.0250; Murphy JL, 2013, CLIN J PAIN, V29, P109, DOI 10.1097/AJP.0b013e3182579935; Nicholas M., 2017, TASK FORCE MULTIMODA; Nissen LM, 2001, BRIT J CLIN PHARMACO, V52, P693, DOI 10.1046/j.0306-5251.2001.01502.x; Office of the Chief Coroner Ontario Forensic Pathology Service and Ontario Drug Policy Research Network, 2019, OPIOID MORTALITY SUR; Oohata M, 2017, JA CLIN REP, V3, P1, DOI 10.1186/s40981-017-0130-5; Pawson Ray, 2005, J Health Serv Res Policy, V10 Suppl 1, P21, DOI 10.1258/1355819054308530; Peng P, 2007, CAN J ANAESTH, V54, P977, DOI 10.1007/BF03016631; Peterson K, 2018, J GEN INTERN MED, V33, pS71, DOI 10.1007/s11606-018-4328-7; Philips H., 1987, BEHAV RES THER, V25, P265; PORTNOW JM, 1985, INT J ADDICT, V20, P605, DOI 10.3109/10826088509044939; Presseau J, 2017, PSYCHOL HEALTH, V32, P1176, DOI 10.1080/08870446.2016.1260724; RALPHS JA, 1994, PAIN, V56, P279, DOI 10.1016/0304-3959(94)90166-X; Rieder Travis N, 2018, Narrat Inq Bioeth, V8, P225, DOI 10.1353/nib.2018.0071; Rome JD, 2004, MAYO CLIN PROC, V79, P759; Ruhe AK, 2017, CLIN J PAIN, V33, P767, DOI 10.1097/AJP.0000000000000460; Rutten LJF, 2016, ADV THER, V33, P1440, DOI 10.1007/s12325-016-0369-7; Rycroft-Malone J, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-38; Saul JE, 2013, IMPLEMENT SCI, V8, DOI 10.1186/1748-5908-8-103; Scascighini L, 2008, RHEUMATOLOGY, V47, P670, DOI 10.1093/rheumatology/ken021; Seal K, 2017, J GEN INTERN MED, V32, P931, DOI 10.1007/s11606-017-4047-5; SERES JL, 1976, J NEUROSURG, V45, P32, DOI 10.3171/jns.1976.45.1.0032; Sime A., 2004, J NEUROTHER, V8, P59, DOI [10.1300/J184v08n01_05, 10.1300/j184v08n01_05]; SMITH GB, 1988, J AUST ENTOMOL SOC, V27, P47; SNOW BR, 1986, B HOSP JOINT DIS ORT, V46, P22; SNOW BR, 1988, B HOSP JOINT DIS ORT, V48, P52; Sundaraj SR, 2005, J CLIN NEUROSCI, V12, P264, DOI 10.1016/j.jocn.2004.06.010; TAYLOR CB, 1980, PAIN, V8, P319, DOI 10.1016/0304-3959(80)90077-9; TENNANT FS, 1982, ARCH INTERN MED, V142, P1845, DOI 10.1001/archinte.142.10.1845; Thieme K, 2003, ARTHRIT RHEUM-ARTHR, V49, P314, DOI 10.1002/art.11124; Thorn BE, 2007, J PAIN, V8, P938, DOI 10.1016/j.jpain.2007.06.010; Tiippana E, 2016, SCAND J PAIN, V12, P19, DOI 10.1016/j.sjpain.2016.02.008; Tilley N., 1997, REALIST EVALUATION; TIMMING RC, 1980, WISC MED J, V79, P23; TOLLISON CD, 1985, SOUTHERN MED J, V78, P1291, DOI 10.1097/00007611-198511000-00005; Townsend CO, 2008, PAIN, V140, P177, DOI 10.1016/j.pain.2008.08.005; Townsend CO, 2006, J CLIN PSYCHOL, V62, P1433, DOI 10.1002/jclp.20322; Tracy CS, 2013, CAN FAM PHYSICIAN, V59, pE148; TYRE TE, 1981, J FAM PRACTICE, V12, P819; Upshur Ross E G, 2016, Healthc Q, V19, P24; Vines S W, 1996, Rehabil Nurs, V21, P25; Von Korff M, 2005, PAIN, V113, P323, DOI 10.1016/j.pain.2004.11.007; Weinrib AZ, 2017, J PAIN RES, V10, P747, DOI 10.2147/JPR.S124566; Williams ACD, 1996, PAIN, V66, P13, DOI 10.1016/0304-3959(96)02996-X; Williams SL, 2011, HEALTH EDUC RES, V26, P308, DOI 10.1093/her/cyr005; Worzer W., 2015, THESIS; Younger J, 2008, PAIN MED, V9, P1158, DOI 10.1111/j.1526-4637.2008.00475.x; Zheng ZD, 2018, ACM T MULTIM COMPUT, V14, DOI 10.1145/3159171; Zheng Z, 2008, EUR J PAIN, V12, P671, DOI 10.1016/j.ejpain.2007.10.003; Zhou K, 2017, SCAND J PAIN, V17, P37, DOI 10.1016/j.sjpain.2017.07.006	140	7	7	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2020	15	7							e0236419	10.1371/journal.pone.0236419	http://dx.doi.org/10.1371/journal.pone.0236419			31	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MV9ND	32716982	Green Published, gold			2023-01-03	WOS:000556674500009
J	Marks, PW; Hahn, S				Marks, Peter W.; Hahn, Stephen			Identifying the Risks of Unproven Regenerative Medicine Therapies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									[Marks, Peter W.; Hahn, Stephen] US FDA, Silver Spring, MD USA	US Food & Drug Administration (FDA)	Marks, PW (corresponding author), US FDA, Ctr Biol Evaluat & Res, 10903 New Hampshire Ave,WO71-7232, Silver Spring, MD 20993 USA.	peter.marks@fda.hhs.gov						Cossu G, 2018, LANCET, V391, P883, DOI 10.1016/S0140-6736(17)31366-1; Food and Drug Administration, REP PROD PROBL COMPL; Food and Drug Administration, MEDWATCH FORMS FDA S; Knoepfler PS, 2019, REGEN MED, V14, P735, DOI 10.2217/rme-2019-0064; Kuriyan AE, 2017, NEW ENGL J MED, V376, P1047, DOI 10.1056/NEJMoa1609583; Rubin R, 2018, JAMA-J AM MED ASSOC, V320, P1421, DOI 10.1001/jama.2018.13861; Srivastava A, 2016, CYTOTHERAPY, V18, P117, DOI 10.1016/j.jcyt.2015.11.004	7	11	11	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	2020	324	3					241	242		10.1001/jama.2020.9375	http://dx.doi.org/10.1001/jama.2020.9375			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU9CI	32629463				2023-01-03	WOS:000555963000013
J	Rezaie, A; Leite, GGS; Melmed, GY; Mathur, R; Villanueva-Millan, MJ; Parodi, G; Sin, J; Germano, JF; Morales, W; Weitsman, S; Kim, SY; Park, JH; Sakhaie, S; Pimentel, M				Rezaie, Ali; Leite, Gabriela G. S.; Melmed, Gil Y.; Mathur, Ruchi; Villanueva-Millan, Maria Jesus; Parodi, Gonzalo; Sin, Jon; Germano, Juliana F.; Morales, Walter; Weitsman, Stacy; Kim, Seung Young; Park, Jae Ho; Sakhaie, Siamak; Pimentel, Mark			Ultraviolet a light effectively reduces bacteria and viruses including coronavirus	PLOS ONE			English	Article							OXIDATIVE DNA-DAMAGE; UV-RADIATION; PHOTOTHERAPY; 8-HYDROXY-2'-DEOXYGUANOSINE; PNEUMONIA; MARKER	Antimicrobial-resistant and novel pathogens continue to emerge, outpacing efforts to contain and treat them. Therefore, there is a crucial need for safe and effective therapies. Ultraviolet-A (UVA) phototherapy is FDA-approved for several dermatological diseases but not for internal applications. We investigated UVA effects on human cellsin vitro, mouse colonic tissuein vivo, and UVA efficacy against bacteria, yeast, coxsackievirus group B and coronavirus-229E. Several pathogens and virally transfected human cells were exposed to a series of specific UVA exposure regimens. HeLa, alveolar and primary human tracheal epithelial cell viability was assessed after UVA exposure, and 8-Oxo-2'-deoxyguanosine was measured as an oxidative DNA damage marker. Furthermore, wild-type mice were exposed to intracolonic UVA as anin vivomodel to assess safety of internal UVA exposure. Controlled UVA exposure yielded significant reductions inPseudomonas aeruginosa,Klebsiella pneumoniae,Escherichia coli,Enterococcus faecalis,Clostridioides difficile,Streptococcus pyogenes,Staphylococcus epidermidis,Proteus mirabilisandCandida albicans. UVA-treated coxsackievirus-transfected HeLa cells exhibited significantly increased cell survival compared to controls. UVA-treated coronavirus-229E-transfected tracheal cells exhibited significant coronavirus spike protein reduction, increased mitochondrial antiviral-signaling protein and decreased coronavirus-229E-induced cell death. Specific controlled UVA exposure had no significant effect on growth or 8-Oxo-2'-deoxyguanosine levels in three types of human cells. Single or repeatedin vivointraluminal UVA exposure produced no discernible endoscopic, histologic or dysplastic changes in mice. These findings suggest that, under specific conditions, UVA reduces various pathogens including coronavirus-229E, and may provide a safe and effective treatment for infectious diseases of internal viscera. Clinical studies are warranted to further elucidate the safety and efficacy of UVA in humans.	[Rezaie, Ali; Leite, Gabriela G. S.; Mathur, Ruchi; Villanueva-Millan, Maria Jesus; Parodi, Gonzalo; Morales, Walter; Weitsman, Stacy; Pimentel, Mark] Cedars Sinai Med Ctr, Med Associated Sci & Technol MAST Program, Los Angeles, CA 90048 USA; [Melmed, Gil Y.] Cedars Sinai, Inflammatory Bowel & Immunobiol Res Inst, Los Angeles, CA USA; [Sin, Jon; Germano, Juliana F.] Cedars Sinai, Cedars Sinai Heart Inst, Los Angeles, CA USA; [Kim, Seung Young] Korea Univ, Div Gastroenterol, Dept Internal Med, Ansan Hosp, Ansan, South Korea; [Park, Jae Ho] Ulsan Univ Hosp, Div Gastroenterol, Dept Internal Med, Ulsan, South Korea; [Sakhaie, Siamak] Australian Clin Labs, Melbourne, Vic, Australia	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Cedars Sinai Medical Center; Korea University; Korea University Medicine (KU Medicine); University of Ulsan; Ulsan University Hospital	Rezaie, A (corresponding author), Cedars Sinai Med Ctr, Med Associated Sci & Technol MAST Program, Los Angeles, CA 90048 USA.	ali.rezaie@cshs.org	Rezaie, Ali/AAI-1659-2021; Mathur, Ruchi/AAH-7031-2021; Pimentel, Mark/AAH-7073-2021	Rezaie, Ali/0000-0002-0106-372X; Pimentel, Mark/0000-0002-0619-5115; Melmed, Gil/0000-0002-2591-5165; Mathur, Ruchi/0000-0003-1053-6557	Kenneth Rainin Foundation [2017-494]	Kenneth Rainin Foundation	This project was partly funded by a grant to AR (award number 2017-494) from the Kenneth Rainin Foundation. It provided salary support for AR and GL. https://krfoundation.org/.The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. SS is an employee of Australian Clinical Labs. Australian Clinical Labs had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bhutani Tina, 2010, Pract Dermatol, V7, P31; Biacchesi S, 2009, J VIROL, V83, P7815, DOI 10.1128/JVI.00404-09; Bialkowska AB, 2016, JOVE-J VIS EXP, DOI 10.3791/54161; Chan JFW, 2020, LANCET, V395, P514, DOI 10.1016/S0140-6736(20)30154-9; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Feuer R, 2002, J VIROL, V76, P4430, DOI 10.1128/JVI.76.9.4430-4440.2002; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; Khan AQ, 2018, ENVIRON MOL MUTAGEN, V59, P438, DOI 10.1002/em.22176; Kollef MH, 2008, JAMA-J AM MED ASSOC, V300, P805, DOI 10.1001/jama.300.7.805; Zamora LL, 2012, J R SOC INTERFACE, V9, P1892, DOI 10.1098/rsif.2011.0809; Lapolla W, 2011, J AM ACAD DERMATOL, V64, P936, DOI 10.1016/j.jaad.2009.12.054; Louis KS, 2011, METHODS MOL BIOL, V740, P7, DOI 10.1007/978-1-61779-108-6_2; MCGLAVE P, 1990, SEMIN HEMATOL, V27, P23; Murthy S, 2020, JAMA-J AM MED ASSOC, V323, P1499, DOI 10.1001/jama.2020.3633; Patrizi A, 2017, ADV EXP MED BIOL, V996, P319, DOI 10.1007/978-3-319-56017-5_27; Pilger A, 2006, INT ARCH OCC ENV HEA, V80, P1, DOI 10.1007/s00420-006-0106-7; Ponnaiya B, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192053; Reed NG, 2010, PUBLIC HEALTH REP, V125, P15, DOI 10.1177/003335491012500105; Reichrath Jorg, 2014, Adv Exp Med Biol, V810, P208; Robatto M, 2019, LASER MED SCI, V34, P1819, DOI 10.1007/s10103-019-02782-9; Roy S, 2017, ADV EXP MED BIOL, V996, P207, DOI 10.1007/978-3-319-56017-5_17; Shen L, 2020, J HAZARD MATER, V386, DOI 10.1016/j.jhazmat.2019.121968; Shi HS, 2020, LANCET INFECT DIS, V20, P425, DOI 10.1016/S1473-3099(20)30086-4; Strober Warren, 2015, Curr Protoc Immunol, V111, DOI 10.1002/0471142735.ima03bs111; Takada A, 2017, BMC ORAL HEALTH, V17, DOI 10.1186/s12903-017-0382-5; Tang BSF, 2005, J VIROL, V79, P6180, DOI 10.1128/JVI.79.10.6180-6193.2005; Tarabadkar ES, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00260; Taylor DJR, 2020, VIRUSES-BASEL, V12, DOI 10.3390/v12040373; Vatansever F, 2013, VIRULENCE, V4, P796, DOI 10.4161/viru.26475; Viros A, 2014, NATURE, V511, P478, DOI 10.1038/nature13298; Wald-Dickler N, 2018, CLIN INFECT DIS, V66, P1470, DOI 10.1093/cid/cix1127; World Health Organization, ULTR RAD UV; World Health Organization, 2007, PROTECTING WORKERS U; Xu Z, 2020, LANCET RESP MED, V8, P420, DOI 10.1016/S2213-2600(20)30076-X; Zaffina S, 2012, PHOTOCHEM PHOTOBIOL, V88, P1001, DOI 10.1111/j.1751-1097.2012.01151.x; Zhang P, 2018, LASER MED SCI, V33, P173, DOI 10.1007/s10103-017-2360-1; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	40	20	21	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 16	2020	15	7							e0236199	10.1371/journal.pone.0236199	http://dx.doi.org/10.1371/journal.pone.0236199			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MS0KU	32673355	gold, Green Published			2023-01-03	WOS:000553976700034
J	Fukuda, T; Sakurai, H; Kashiwagi, M				Fukuda, Tomohide; Sakurai, Hironori; Kashiwagi, Masanori			Efforts to reduce the length of stay in a low-intensity ICU: Changes in the ICU brought about by collaboration between Certified Nurse Specialists as head nurses and intensivists	PLOS ONE			English	Article							CRITICALLY-ILL PATIENTS; OUTCOMES	Certified Nurse Specialists (CNS) are advanced practice nurses that often play a role in management. This study aims to investigate whether cooperation between CNSs in the position of Intensive Care Unit (ICU) head nurse and intensivists change the length of stay for ICU patients. A single centered retrospective cohort study design was followed. A multivariable regression analysis was performed to determine whether there is a difference in patients' length of ICU stay for two years before and after CNS as ICU head nurse and an intensivist started collaborating. The patients' diagnosis, age, gender, scheduled/emergency admission, surgical history, length of ICU stay, usage of ventilator, and details of ICU treatment were collected from the institution's electronic medical records. During the study period (April 2015 to March 2019), 3,135 patients were admitted to ICU, with 1,471 in the before collaboration group and 1,664 in the after-collaboration group. Collaboration between the CNS as head nurse and intensivists was significantly associated with shorter length of ICU stay (coefficient -0.03 [95% CI, -0.05-0.01],p< 0.001,t-statistic -3.29). Our main finding illustrates that in low-intensity ICUs, collaboration between CNSs as head nurses and intensivists may reduce patients' length of ICU stay.	[Fukuda, Tomohide] Kyoritsu Womens Univ, Fac Nursing, Tokyo, Japan; [Sakurai, Hironori] Natl Hosp Org Tokyo Med Ctr, Dept Anesthesiol, Tokyo, Japan; [Kashiwagi, Masanori] Tokyo Saiseikai Cent Hosp, Dept Anesthesiol, Tokyo, Japan	Tokyo Saiseikai Central Hospital	Fukuda, T (corresponding author), Kyoritsu Womens Univ, Fac Nursing, Tokyo, Japan.	tfukuda@kyoritsu-wu.ac.jp	Fukuda, Tomohide/AAY-6641-2020	Fukuda, Tomohide/0000-0001-8066-4998	JSPS KAKENHI [JP 19K24268]	JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by JSPS KAKENHI Grant Number JP 19K24268. There was no additional external funding received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], NURS PRACT ADV PRACT; Asegid A, 2014, NURS RES PRACT, V2014, DOI 10.1155/2014/909768; Coen J, 2016, CRIT CARE NURS Q, V39, P335, DOI 10.1097/CNQ.0000000000000127; Crosbie R, 2014, J LARYNGOL OTOL, V128, P171, DOI 10.1017/S0022215114000024; Fukuda T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0228458; Japan Nursing Association, 2017, LIST REG PERS POS HO; Kirk AP, 2015, CLIN NURSE SPEC, V29, P321, DOI 10.1097/NUR.0000000000000163; Knowles S, 2015, BMC NURS, V14, DOI 10.1186/s12912-015-0056-z; McCallin AM, 2010, J NURS MANAGE, V18, P319, DOI 10.1111/j.1365-2834.2010.01067.x; Morita K, 2017, J CRIT CARE, V41, P209, DOI 10.1016/j.jcrc.2017.05.025; Negley KD, 2016, CLIN NURSE SPEC, V30, P271, DOI 10.1097/NUR.0000000000000231; Newhouse RP, 2011, NURS ECON, V29, P5; Pronovost PJ, 2002, JAMA-J AM MED ASSOC, V288, P2151, DOI 10.1001/jama.288.17.2151; Salamanca-Balen N, 2018, PALLIATIVE MED, V32, P447, DOI 10.1177/0269216317711570; Singer Jonathan P, 2010, J Intensive Care Med, V25, P233, DOI 10.1177/0885066610366933; Spruce K, 2017, CLIN NURSE SPEC, V31, P319, DOI 10.1097/NUR.0000000000000334; Warshawsky N, 2019, J NURS ADMIN, V49, P249, DOI 10.1097/NNA.0000000000000746	17	1	1	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 15	2020	15	6							e0234879	10.1371/journal.pone.0234879	http://dx.doi.org/10.1371/journal.pone.0234879			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB6AZ	32542030	Green Published, gold			2023-01-03	WOS:000542685100009
J	Man, SM; Xian, Y; Holmes, DN; Matsouaka, RA; Saver, JL; Smith, EE; Bhatt, DL; Schwamm, LH; Fonarow, GC				Man, Shumei; Xian, Ying; Holmes, DaJuanicia N.; Matsouaka, Roland A.; Saver, Jeffrey L.; Smith, Eric E.; Bhatt, Deepak L.; Schwamm, Lee H.; Fonarow, Gregg C.			Association Between Thrombolytic Door-to-Needle Time and 1-Year Mortality and Readmission in Patients With Acute Ischemic Stroke	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; GUIDELINES-STROKE; MYOCARDIAL-INFARCTION; HEART-ASSOCIATION; PHYSICAL-ACTIVITY; TASK-FORCE; OUTCOMES; QUALITY; PERFORMANCE; MANAGEMENT	Key PointsQuestionIs there an association between shorter door-to-needle time with thrombolytic therapy and long-term mortality and hospital readmission in patients with acute ischemic stroke? FindingsIn this US retrospective cohort study that included 61426 patients with acute ischemic stroke treated with intravenous tissue plasminogen activator, longer door-to-needle times (within 90 minutes after hospital arrival) were significantly associated with higher all-cause mortality at 1 year (hazard ratio per 15-minute increase in time, 1.04) and higher likelihood of all-cause readmission at 1 year (hazard ratio per 15-minute increase in time, 1.02). MeaningThese findings support efforts to shorten time to thrombolytic therapy. ImportanceEarlier administration of intravenous tissue plasminogen activator (tPA) in acute ischemic stroke is associated with reduced mortality by the time of hospital discharge and better functional outcomes at 3 months. However, it remains unclear whether shorter door-to-needle times translate into better long-term outcomes. ObjectiveTo examine whether shorter door-to-needle times with intravenous tPA for acute ischemic stroke are associated with improved long-term outcomes. Design, Setting, and ParticipantsThis retrospective cohort study included Medicare beneficiaries aged 65 years or older who were treated for acute ischemic stroke with intravenous tPA within 4.5 hours from the time they were last known to be well at Get With The Guidelines-Stroke participating hospitals between January 1, 2006, and December 31, 2016, with 1-year follow-up through December 31, 2017. ExposuresDoor-to-needle times for intravenous tPA. Main Outcomes and MeasuresThe primary outcomes were 1-year all-cause mortality, all-cause readmission, and the composite of all-cause mortality or readmission. ResultsAmong the 61426 patients treated with tPA within 4.5 hours, the median age was 80 years and 43.5% were male. The median door-to-needle time was 65 minutes (interquartile range, 49-88 minutes). The 48666 patients (79.2%) who were treated with tPA and had door-to-needle times of longer than 45 minutes, compared with those treated within 45 minutes, had significantly higher all-cause mortality (35.0% vs 30.8%, respectively; adjusted HR, 1.13 [95% CI, 1.09-1.18]), higher all-cause readmission (40.8% vs 38.4%; adjusted HR, 1.08 [95% CI, 1.05-1.12]), and higher all-cause mortality or readmission (56.0% vs 52.1%; adjusted HR, 1.09 [95% CI, 1.06-1.12]). The 34367 patients (55.9%) who were treated with tPA and had door-to-needle times of longer than 60 minutes, compared with those treated within 60 minutes, had significantly higher all-cause mortality (35.8% vs 32.1%, respectively; adjusted hazard ratio [HR], 1.11 [95% CI, 1.07-1.14]), higher all-cause readmission (41.3% vs 39.1%; adjusted HR, 1.07 [95% CI, 1.04-1.10]), and higher all-cause mortality or readmission (56.8% vs 53.1%; adjusted HR, 1.08 [95% CI, 1.05-1.10]). Every 15-minute increase in door-to-needle times was significantly associated with higher all-cause mortality (adjusted HR, 1.04 [95% CI, 1.02-1.05]) within 90 minutes after hospital arrival, but not after 90 minutes (adjusted HR, 1.01 [95% CI, 0.99-1.03]), higher all-cause readmission (adjusted HR, 1.02; 95% CI, 1.01-1.03), and higher all-cause mortality or readmission (adjusted HR, 1.02 [95% CI, 1.01-1.03]). Conclusions and RelevanceAmong patients aged 65 years or older with acute ischemic stroke who were treated with tissue plasminogen activator, shorter door-to-needle times were associated with lower all-cause mortality and lower all-cause readmission at 1 year. These findings support efforts to shorten time to thrombolytic therapy. This cohort study estimates associations between intravenous tissue plasminogen activator (tPA) door-to-needle times of less than 4.5 hours for acute ischemic stroke and 1-year mortality or readmission among Medicare beneficiaries aged 65 years or older.	[Man, Shumei] Cleveland Clin, Dept Neurol, Cleveland, OH 44106 USA; [Man, Shumei] Cleveland Clin, Neurol Inst, Cerebrovasc Ctr, Cleveland, OH 44106 USA; [Xian, Ying; Holmes, DaJuanicia N.; Matsouaka, Roland A.] Duke Univ, Duke Clin Res Inst, Durham, NC USA; [Matsouaka, Roland A.] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA; [Saver, Jeffrey L.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA; [Smith, Eric E.] Univ Calgary, Dept Clin Neurosci, Hotchkiss Brain Inst, Calgary, AB, Canada; [Bhatt, Deepak L.] Harvard Med Sch, Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA; [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Comprehens Stroke Ctr, Boston, MA 02114 USA; [Schwamm, Lee H.] Harvard Med Sch, Boston, MA 02115 USA; [Fonarow, Gregg C.] Univ Calif Los Angeles, Div Cardiol, Los Angeles, CA USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Duke University; Duke University; University of California System; University of California Los Angeles; University of Calgary; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of California System; University of California Los Angeles	Fonarow, GC (corresponding author), Univ Calif Los Angeles, Med Ctr, Ahmanson UCLA Cardiomyopathy Ctr, 10833 LeConte Ave, Los Angeles, CA 90095 USA.	gfonarow@mednet.ucla.edu	Smith, Eric E/C-5443-2012; Matsouaka, Roland/K-6730-2019	Smith, Eric E/0000-0003-3956-1668; Matsouaka, Roland/0000-0002-0271-5400; Xian, Ying/0000-0002-1237-1162	American Heart Association/American Stroke Association; Novartis; Boehringer Ingelheim Lilly; Novo Nordisk; Sanofi; AstraZeneca; Bayer	American Heart Association/American Stroke Association(American Heart Association); Novartis(Novartis); Boehringer Ingelheim Lilly(Boehringer IngelheimEli Lilly); Novo Nordisk(Novo Nordisk); Sanofi; AstraZeneca(AstraZeneca); Bayer(Bayer AG)	The Get With The Guidelines-Stroke (GWTG-Stroke) program is provided by the American Heart Association/American Stroke Association. GWTG-Stroke is sponsored, in part, by Novartis, Boehringer Ingelheim Lilly, Novo Nordisk, Sanofi, AstraZeneca, and Bayer.	Ali-Ahmed F, 2019, CIRC-CARDIOVASC QUAL, V12, DOI 10.1161/CIRCOUTCOMES.119.005609; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Emberson J, 2014, LANCET, V384, P1929, DOI 10.1016/S0140-6736(14)60584-5; Fonarow GC, 2014, JAMA-J AM MED ASSOC, V311, P1632, DOI 10.1001/jama.2014.3203; Fonarow GC, 2012, JAMA-J AM MED ASSOC, V308, P257, DOI 10.1001/jama.2012.7870; Fonarow GC, 2011, STROKE, V42, P2983, DOI 10.1161/STROKEAHA.111.621342; Fonarow GC, 2011, CIRCULATION, V123, P750, DOI 10.1161/CIRCULATIONAHA.110.974675; Fonarow GC, 2010, CIRC-CARDIOVASC QUAL, V3, P291, DOI 10.1161/CIRCOUTCOMES.109.921858; Franco OH, 2005, ARCH INTERN MED, V165, P2355, DOI 10.1001/archinte.165.20.2355; Hammill BG, 2009, AM HEART J, V157, P995, DOI 10.1016/j.ahj.2009.04.002; Ibanez B, 2018, KARDIOL POL, V76, P229, DOI 10.5603/KP.2018.0041; Johnston SC, 2003, STROKE, V34, P2446, DOI 10.1161/01.STR.0000090842.81076.68; Johnston SC, 2001, STROKE, V32, P1061, DOI 10.1161/01.STR.32.5.1061; Kwatkowski TG, 1999, NEW ENGL J MED, V340, P1781; Lanier JB, 2016, AM FAM PHYSICIAN, V93, P919; Lansberg MG, 2009, STROKE, V40, P2079, DOI 10.1161/STROKEAHA.108.540708; Ma H, 2019, NEW ENGL J MED, V380, P1795, DOI 10.1056/NEJMoa1813046; Messe SR, 2016, NEUROLOGY, V87, P1565, DOI 10.1212/WNL.0000000000003198; Nogueira RG, 2018, NEW ENGL J MED, V378, P11, DOI 10.1056/NEJMoa1706442; O'Gara PT, 2013, J AM COLL CARDIOL, V61, P485, DOI [10.1016/j.jacc.2012.11.018, 10.1161/CIR.0b013e3182742c84]; Poythress JC, 2020, PHARM STAT, V19, P4, DOI 10.1002/pst.1966; Reeves MJ, 2012, STROKE, V43, P44, DOI 10.1161/STROKEAHA.111.626978; Reeves MJ, 2009, STROKE, V40, P569, DOI 10.1161/STROKEAHA.108.519355; Sandercock P, 2013, LANCET NEUROL, V12, P768, DOI 10.1016/S1474-4422(13)70130-3; Saver JL, 2013, JAMA-J AM MED ASSOC, V309, P2480, DOI 10.1001/jama.2013.6959; Schoen Bandeali D, MEDICARE 50 YEARS EN; Schwamm LH, 2010, CIRCULATION, V121, P1492, DOI 10.1161/CIRCULATIONAHA.109.881490; Smith EE, 2017, CIRCULATION, V136, P2303, DOI 10.1161/CIRCULATIONAHA.117.031097; Smith EE, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.005207; Smith EE, 2010, CIRCULATION, V122, P1496, DOI 10.1161/CIRCULATIONAHA.109.932822; Therrien M, 2001, HISPANIC POPULATION; Wardlaw J M, 2003, Cochrane Database Syst Rev, pCD000213; Xian Y, 2017, CIRC-CARDIOVASC QUAL, V10, DOI 10.1161/CIRCOUTCOMES.116.003227; Xian Y, 2012, AM HEART J, V163, P392, DOI 10.1016/j.ahj.2011.12.012	34	50	52	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 2	2020	323	21					2170	2184		10.1001/jama.2020.5697	http://dx.doi.org/10.1001/jama.2020.5697			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY8YS	32484532	Bronze, Green Published			2023-01-03	WOS:000540816000021
J	Dequin, PF; Heming, N; Meziani, F; Plantefeve, G; Voiriot, G; Badie, J; Francois, B; Aubron, C; Ricard, JD; Ehrmann, S; Jouan, Y; Guillon, A; Leclerc, M; Coffre, C; Bourgoin, H; Lengelle, C; Caille-Fenerol, C; Tavernier, E; Zohar, S; Giraudeau, B; Annane, D; Le Gouge, A				Dequin, Pierre-Francois; Heming, Nicholas; Meziani, Ferhat; Plantefeve, Gaetan; Voiriot, Guillaume; Badie, Julio; Francois, Bruno; Aubron, Cecile; Ricard, Jean-Damien; Ehrmann, Stephan; Jouan, Youenn; Guillon, Antoine; Leclerc, Marie; Coffre, Carine; Bourgoin, Helene; Lengelle, Celine; Caille-Fenerol, Caroline; Tavernier, Elsa; Zohar, Sarah; Giraudeau, Bruno; Annane, Djillali; Le Gouge, Amelie		CAPE COVID Trial Grp; CRICS-TriGGERSep Network	Effect of Hydrocortisone on 21-Day Mortality or Respiratory Support Among Critically Ill Patients With COVID-19 A Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; CORTICOSTEROID TREATMENT; THERAPY; FAILURE; SCORE	IMPORTANCE Coronavirus disease 2019 (COVID-19) is associated with severe lung damage. Corticosteroids are a possible therapeutic option. OBJECTIVE To determine the effect of hydrocortisone on treatment failure on day 21 in critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and acute respiratory failure. DESIGN, SETTING, AND PARTICIPANTS Multicenter randomized double-blind sequential trial conducted in France, with interim analyses planned every 50 patients. Patients admitted to the intensive care unit (ICU) for COVID-19-related acute respiratory failure were enrolled from March 7 to June 1, 2020, with last follow-up on June 29, 2020. The study intended to enroll 290 patients but was stopped early following the recommendation of the data and safety monitoring board. INTERVENTIONS Patients were randomized to receive low-dose hydrocortisone (n = 76) or placebo (n = 73). MAIN OUTCOMES AND MEASURES The primary outcome, treatment failure on day 21, was defined as death or persistent dependency on mechanical ventilation or high-flow oxygen therapy. Prespecified secondary outcomes included the need for tracheal intubation (among patients not intubated at baseline); cumulative incidences (until day 21) of prone position sessions, extracorporeal membrane oxygenation, and inhaled nitric oxide; PaO2:FIO2 ratio measured daily from day 1 to day 7, then on days 14 and 21; and the proportion of patients with secondary infections during their ICU stay. RESULTS The study was stopped after 149 patients (mean age, 62.2 years; 30.2% women; 81.2% mechanically ventilated) were enrolled. One hundred forty-eight patients (99.3%) completed the study, and there were 69 treatment failure events, including 11 deaths in the hydrocortisone group and 20 deaths in the placebo group. The primary outcome, treatment failure on day 21, occurred in 32 of 76 patients (42.1%) in the hydrocortisone group compared with 37 of 73 (50.7%) in the placebo group (difference of proportions, -8.6%[95.48% CI, -24.9% to 7.7%]; P = .29). Of the 4 prespecified secondary outcomes, none showed a significant difference. No serious adverse events were related to the study treatment. CONCLUSIONS AND RELEVANCE In this study of critically ill patients with COVID-19 and acute respiratory failure, low-dose hydrocortisone, compared with placebo, did not significantly reduce treatment failure (defined as death or persistent respiratory support) at day 21. However, the study was stopped early and likely was underpowered to find a statistically and clinically important difference in the primary outcome.	[Dequin, Pierre-Francois; Ehrmann, Stephan; Jouan, Youenn; Guillon, Antoine] CHU Tours, Med Intens Reanimat, Tours, France; [Dequin, Pierre-Francois; Ehrmann, Stephan; Jouan, Youenn; Guillon, Antoine] Univ Tours, Ctr Etud Pathol Resp, INSERM, U1100, Tours, France; [Dequin, Pierre-Francois; Ehrmann, Stephan; Jouan, Youenn; Guillon, Antoine; Tavernier, Elsa; Giraudeau, Bruno; Le Gouge, Amelie] CHU Tours, INSERM, CIC1415, Tours, France; [Heming, Nicholas; Annane, Djillali] Univ Paris Saclay, Med Intens Reanimat, Hop Raymond Poincare, GHU APHP, Garches, France; [Heming, Nicholas; Annane, Djillali] RHU RECORDS, Garches, France; [Heming, Nicholas; Annane, Djillali] FHU SEPSIS, Garches, France; [Heming, Nicholas; Annane, Djillali] Univ Versailles SQY Univ Paris Saclay, U1173, INSERM, Garches, France; [Meziani, Ferhat] Hop Univ Strasbourg, Nouvel Hop Civil, Med Intens Reanimat, Strasbourg, France; [Meziani, Ferhat] Univ Strasbourg, INSERM, UMR 1260, Strasbourg, France; [Plantefeve, Gaetan] CH Victor Dupouy, Reanimat Polyvalente, Argenteuil, France; [Voiriot, Guillaume] Hop Tenon, AP HP, Med Intens Reanimat, Paris, France; [Voiriot, Guillaume] Sorbonne Univ, Paris, France; [Badie, Julio] Hop Nord Franche Comte, Reanimat Polyvalente, Trevenans, France; [Francois, Bruno] CHU Limoges, Reanimat Polyvalente, Limoges, France; [Francois, Bruno] Univ Limoges, INSERM, UMR 1092, Limoges, France; [Francois, Bruno; Caille-Fenerol, Caroline] CHU Limoges, INSERM, CIC 1435, Limoges, France; [Aubron, Cecile] CHRU Brest, Med Intens Reanimat, Brest, France; [Aubron, Cecile] Univ Bretagne Occidentale, Brest, France; [Ricard, Jean-Damien] Univ Paris, Hop Louis Mourier, AP HP, IAME U1137,Med Intens Reanimat,DMU ESPRIT, Colombe, France; [Leclerc, Marie; Coffre, Carine] CHU Tours, Delegat Rech Clin & lInnovat, Tours, France; [Bourgoin, Helene] CHU Tours, Pharm Usage Interne, Tours, France; [Lengelle, Celine] CHU Tours, Serv Pharmacosurveillance, Ctr Reg Pharmacovigilance & Informat Medicament, Tours, France; [Zohar, Sarah] Univ Paris, Sorbonne Univ, Ctr Rech Cordeliers, INSERM, Paris, France; [Giraudeau, Bruno] Univ Tours, Univ Nantes, SPHERE U1246, INSERM, Tours, France	CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Tours; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; CHU Limoges; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Limoges; CHU Limoges; Institut National de la Sante et de la Recherche Medicale (Inserm); CHU Brest; Universite de Bretagne Occidentale; Universite de Bretagne Occidentale; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Louis-Mourier - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU Tours; CHU Tours; CHU Tours; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite de Tours	Dequin, PF (corresponding author), Hop Bretonneau, Serv Med Intens Reanimat, F-37044 Tours 09, France.	dequin@univ-tours.fr	Zohar, Sarah/A-5026-2016; Giraudeau, Bruno/L-9003-2015; Zohar, Sarah/ACE-9228-2022; Voiriot, Guillaume/AIB-6833-2022	Giraudeau, Bruno/0000-0003-3031-8258; Zohar, Sarah/0000-0002-8429-2340; Tavernier, Elsa/0000-0003-0798-1182	French Ministry of Health, Programme Hospitalier de Recherche Clinique (PHRC)	French Ministry of Health, Programme Hospitalier de Recherche Clinique (PHRC)	This study was funded by the French Ministry of Health, Programme Hospitalier de Recherche Clinique (PHRC) (2014 [CAPE COD parent trial], 2020 [CAPE COVID subtrial]).	[Anonymous], COVID 19 DASHB; Arabi YM, 2020, INTENS CARE MED, V46, P315, DOI 10.1007/s00134-020-05943-5; Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC; Beigel JH, 2020, N ENGL J MED; Blum CA, 2015, LANCET, V385, P1511, DOI 10.1016/S0140-6736(14)62447-8; Dequin PF, 2020, STAT BIOPHARM RES, V12, P478, DOI 10.1080/19466315.2020.1800509; Fine JP, 1999, J AM STAT ASSOC, V94, P496, DOI 10.2307/2670170; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1545, DOI 10.1001/jama.2020.4031; Guillon A, 2020, INTENS CARE MED, V46, P1897, DOI 10.1007/s00134-020-06170-8; Horby P, 2021, NEW ENGL J MED, V384, P693, DOI [10.1056/NEJMoa2021436, 10.1056/NEJMoa2022926]; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Jouan Y, 2020, J EXP MED; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Moreno G, 2018, INTENS CARE MED, V44, P1470, DOI 10.1007/s00134-018-5332-4; Papazian L, 2019, ANN INTENSIVE CARE, V9, DOI 10.1186/s13613-019-0540-9; Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2; Sanders JM, 2020, JAMA-J AM MED ASSOC, V323, P1824, DOI 10.1001/jama.2020.6019; Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715; Sinha P, 2020, JAMA INTERN MED, V180, P1152, DOI 10.1001/jamainternmed.2020.3313; Sterne JAC, 2020, TRIALS, V21, DOI 10.1186/s13063-020-04641-3; Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343; Torres A, 2015, JAMA-J AM MED ASSOC, V313, P677, DOI 10.1001/jama.2015.88; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; Wu CM, 2020, JAMA INTERN MED, V180, P934, DOI 10.1001/jamainternmed.2020.0994; Wu ZY, 2020, JAMA-J AM MED ASSOC, V323, P1239, DOI 10.1001/jama.2020.2648; Yang ZW, 2020, J INFECTION, V81, pE13, DOI 10.1016/j.jinf.2020.03.062	30	222	235	2	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 6	2020	324	13					1298	1306		10.1001/jama.2020.16761	http://dx.doi.org/10.1001/jama.2020.16761			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OS4SZ	32876689	Bronze, Green Published			2023-01-03	WOS:000590156000014
J	Franz, AR; Engel, C; Bassler, D; Rudiger, M; Thome, UH; Maier, RF; Krageloh-Mann, I; Kron, M; Essers, J; Buhrer, C; Rellensmann, G; Rossi, R; Bittrich, HJ; Roll, C; Hohn, T; Ehrhardt, H; Avenarius, S; Korner, HT; Stein, A; Buxmann, H; Vochem, M; Poets, CF				Franz, Axel R.; Engel, Corinna; Bassler, Dirk; Ruediger, Mario; Thome, Ulrich H.; Maier, Rolf F.; Kraegeloh-Mann, Ingeborg; Kron, Martina; Essers, Jochen; Buehrer, Christoph; Rellensmann, Georg; Rossi, Rainer; Bittrich, Hans-Joerg; Roll, Claudia; Hoehn, Thomas; Ehrhardt, Harald; Avenarius, Stefan; Koerner, Hans Thorsten; Stein, Anja; Buxmann, Horst; Vochem, Matthias; Poets, Christian F.		Ettno Investigators	Effects of Liberal vs Restrictive Transfusion Thresholds on Survival and Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants The ETTNO Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-CELL TRANSFUSIONS; NECROTIZING ENTEROCOLITIS; RISK; RETINOPATHY; ASSOCIATIONS; DEATH	Importance Red blood cell transfusions are commonly administered to infants weighing less than 1000 g at birth. Evidence-based transfusion thresholds have not been established. Previous studies have suggested higher rates of cognitive impairment with restrictive transfusion thresholds. Objective To compare the effect of liberal vs restrictive red blood cell transfusion strategies on death or disability. Design, Setting, and Participants Randomized clinical trial conducted in 36 level III/IV neonatal intensive care units in Europe among 1013 infants with birth weights of 400 g to 999 g at less than 72 hours after birth; enrollment took place between July 14, 2011, and November 14, 2014, and follow-up was completed by January 15, 2018. Interventions Infants were randomly assigned to liberal (n = 492) or restrictive (n = 521) red blood cell transfusion thresholds based on infants' postnatal age and current health state. Main Outcome and Measures The primary outcome, measured at 24 months of corrected age, was death or disability, defined as any of cognitive deficit, cerebral palsy, or severe visual or hearing impairment. Secondary outcome measures included individual components of the primary outcome, complications of prematurity, and growth. Results Among 1013 patients randomized (median gestational age at birth, 26.3 [interquartile range {IQR}, 24.9-27.6] weeks; 509 [50.2%] females), 928 (91.6%) completed the trial. Among infants in the liberal vs restrictive transfusion thresholds groups, respectively, incidence of any transfusion was 400/492 (81.3%) vs 315/521 (60.5%); median volume transfused was 40 mL (IQR, 16-73 mL) vs 19 mL (IQR, 0-46 mL); and weekly mean hematocrit was 3 percentage points higher with liberal thresholds. Among infants in the liberal vs restrictive thresholds groups, the primary outcome occurred in 200/450 (44.4%) vs 205/478 (42.9%), respectively, for a difference of 1.6% (95% CI, -4.8% to 7.9%; P = .72). Death by 24 months occurred in 38/460 (8.3%) vs 44/491 (9.0%), for a difference of -0.7% (95% CI, -4.3% to 2.9%; P = .70), cognitive deficit was observed in 154/410 (37.6%) vs 148/430 (34.4%), for a difference of 3.2% (95% CI, -3.3% to 9.6%; P = .47), and cerebral palsy occurred in 18/419 (4.3%) vs 25/443 (5.6%), for a difference of -1.3% (95% CI, -4.2% to 1.5%; P = .37), in the liberal vs the restrictive thresholds groups, respectively. In the liberal vs restrictive thresholds groups, necrotizing enterocolitis requiring surgical intervention occurred in 20/492 (4.1%) vs 28/518 (5.4%); bronchopulmonary dysplasia occurred in 130/458 (28.4%) vs 126/485 (26.0%); and treatment for retinopathy of prematurity was required in 41/472 (8.7%) vs 38/492 (7.7%). Growth at follow-up was also not significantly different between groups. [GRAPHICS] Conclusions and Relevance Among infants with birth weights of less than 1000 g, a strategy of liberal blood transfusions compared with restrictive transfusions did not reduce the likelihood of death or disability at 24 months of corrected age.	[Franz, Axel R.; Engel, Corinna] Univ Childrens Hosp Tubingen, Ctr Pediat Clin Studies, Tubingen, Germany; [Franz, Axel R.; Poets, Christian F.] Univ Childrens Hosp, Neonatol, Tubingen, Germany; [Bassler, Dirk] Univ Zurich, Univ Zurich Hosp, Dept Neonatol, Zurich, Switzerland; [Ruediger, Mario] Tech Univ Dresden, Pediat Clin, Dept Neonatol & Pediat Intens Care Med, Fac Med, Dresden, Germany; [Thome, Ulrich H.] Univ Leipzig, Childrens Hosp, Div Neonatol, Dept ofWomen & Childrens Hlth, Leipzig, Germany; [Maier, Rolf F.] Philipps Univ Marburg, Univ Hosp, Childrens Hosp, Marburg, Germany; [Kraegeloh-Mann, Ingeborg] Univ Childrens Hosp Tubingen, Dept Paediat Neurol & Dev Med, Tubingen, Germany; [Kron, Martina] Univ Ulm, Inst Epidemiol & Med Biometry, Ulm, Germany; [Essers, Jochen] Univ Hosp Ulm, Ulm, Germany; [Buehrer, Christoph] Charite Univ Med Berlin, Berlin, Germany; [Rellensmann, Georg] Univ Hosp Munster, Pediat, Munster, Germany; [Rossi, Rainer] Vivantes Klinikum Neukolln, Berlin, Germany; [Bittrich, Hans-Joerg] Helios Klinikum Erfurt, Erfurt, Germany; [Roll, Claudia] Univ Witten Herdecke, Vest Kinder & Jugendklin Datteln, Datteln, Germany; [Hoehn, Thomas] Univ Hosp Dusseldorf, Neonatol & Pediat Intens Care, Dusseldorf, Germany; [Ehrhardt, Harald] Justus Liebig Univ Giessen, Dept Gen Pediat & Neonatol, Giessen, Germany; [Avenarius, Stefan] Univ Hosp Magdeburg, Pediat, Magdeburg, Germany; [Koerner, Hans Thorsten] Klinikum Links der Weser, Neonatol, Bremen, Germany; [Stein, Anja] Univ Duisburg Essen, Dept Paediat 1, Essen, Germany; [Buxmann, Horst] Univ Hosp Frankfurt, Frankfurt, Germany; [Vochem, Matthias] Olga Hosp, Klinikum Stuttgart, Stuttgart, Germany	Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Zurich; University Zurich Hospital; Technische Universitat Dresden; Leipzig University; Philipps University Marburg; Eberhard Karls University of Tubingen; TUBINGEN UNIVERSITY CHILDRENS HOSPITAL; Ulm University; Ulm University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munster; VIivantes Klinikum Neukolln; Helios Kliniken; Witten Herdecke University; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; Justus Liebig University Giessen; University Hospital Magdeburg; University of Duisburg Essen; Goethe University Frankfurt; Goethe University Frankfurt Hospital; General Hospital of N. Ionia Agia Olga; Klinikum Stuttgart	Franz, AR (corresponding author), Univ Childrens Hosp Tubingen, Ctr Pediat Clin Studies, Dept Neonatol, Calwerstr 7, D-72076 Tubingen, Germany.	axel.franz@med.uni-tuebingen.de	Ehrhardt, Harald/L-9007-2018; Franz, Axel/AAC-8067-2022; Greisen, Gorm/AAA-6463-2022; Schwarz, Christoph E./GQY-5743-2022	Ehrhardt, Harald/0000-0003-4587-1734; Greisen, Gorm/0000-0001-8042-3262; Schwarz, Christoph E./0000-0003-0975-1575; Stein, Anja/0000-0002-0497-4609	German Research Foundation (Deutsche Forschungsgemeinschaft) [Fr-1455/6-1, Fr-1455/6-2]	German Research Foundation (Deutsche Forschungsgemeinschaft)(German Research Foundation (DFG))	The trial was funded by German Research Foundation (Deutsche Forschungsgemeinschaft) grants Fr-1455/6-1 and Fr-1455/6-2.	Baer VL, 2011, TRANSFUSION, V51, P1170, DOI 10.1111/j.1537-2995.2010.02980.x; Bassler D, 2015, NEW ENGL J MED, V373, P1497, DOI 10.1056/NEJMoa1501917; Bell EF, 2008, ARCH DIS CHILD-FETAL, V93, P1469, DOI 10.1136/adc.2007.128819; Blau J, 2011, J PEDIATR-US, V158, P403, DOI 10.1016/j.jpeds.2010.09.015; Cans C, 2000, DEV MED CHILD NEUROL, V42, P816, DOI 10.1111/j.1469-8749.2000.tb00695.x; Cans C, 2007, DEV MED CHILD NEUROL, V49, P35, DOI 10.1111/j.1469-8749.2007.tb12626.x; Christensen RD, 2013, J MATERN-FETAL NEO M, V26, P60, DOI 10.3109/14767058.2013.830495; Di Fiore JM, 2010, J PEDIATR-US, V157, P69, DOI 10.1016/j.jpeds.2010.01.046; Ghirardello S, 2017, AM J PERINAT, V34, P88, DOI 10.1055/s-0036-1584300; Guillen U, 2012, SEMIN PERINATOL, V36, P244, DOI 10.1053/j.semperi.2012.04.004; Hay S, 2017, SEMIN PERINATOL, V41, P80, DOI 10.1053/j.semperi.2016.09.021; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Inder TE, 1997, J PEDIATR-US, V131, P541, DOI 10.1016/S0022-3476(97)70058-1; Kirpalani H, 2006, J PEDIATR-US, V149, P301, DOI 10.1016/j.jpeds.2006.05.011; Kirpalani H, 2011, J PEDIATR-US, V159, P359, DOI 10.1016/j.jpeds.2011.05.002; Lacroix J, 2007, NEW ENGL J MED, V356, P1609, DOI 10.1056/NEJMoa066240; Mohamed A, 2012, PEDIATRICS, V129, P529, DOI 10.1542/peds.2011-2872; dos Santos AMN, 2011, J PEDIATR-US, V159, P371, DOI 10.1016/j.jpeds.2011.02.040; Paul DA, 2011, PEDIATRICS, V127, P635, DOI 10.1542/peds.2010-3178; Poets CF, 2015, JAMA-J AM MED ASSOC, V314, P595, DOI 10.1001/jama.2015.8841; Silvers KM, 1998, ARCH DIS CHILD-FETAL, V78, pF214, DOI 10.1136/fn.78.3.F214; Slidsborg C, 2016, OPHTHALMOLOGY, V123, P796, DOI 10.1016/j.ophtha.2015.12.019; Stainsby D, 2008, BRIT J HAEMATOL, V141, P73, DOI 10.1111/j.1365-2141.2008.07022.x; Valieva OA, 2009, J PEDIATR-US, V155, P331, DOI 10.1016/j.jpeds.2009.02.026; Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2; Whyte R, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000512.pub2; Whyte RK, 2009, PEDIATRICS, V123, P207, DOI 10.1542/peds.2008-0338; Widness John A, 2008, Neoreviews, V9, pe520, DOI 10.1542/neo.9-11-e520	28	61	62	2	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	2020	324	6					560	570		10.1001/jama.2020.10690	http://dx.doi.org/10.1001/jama.2020.10690			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NE8HM	32780138	Bronze, Green Published			2023-01-03	WOS:000562845100018
J	Luoma, AM; Suo, SB; Williams, HL; Sharova, T; Sullivan, K; Manos, M; Bowling, P; Hodi, FS; Rahma, O; Sullivan, RJ; Boland, GM; Nowak, JA; Dougan, SK; Dougan, M; Yuan, GC; Wucherpfennig, KW				Luoma, Adrienne M.; Suo, Shengbao; Williams, Hannah L.; Sharova, Tatyana; Sullivan, Keri; Manos, Michael; Bowling, Peter; Hodi, F. Stephen; Rahma, Osama; Sullivan, Ryan J.; Boland, Genevieve M.; Nowak, Jonathan A.; Dougan, Stephanie K.; Dougan, Michael; Yuan, Guo-Cheng; Wucherpfennig, Kai W.			Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy	CELL			English	Article							T-CELLS; REGULATORY T; THERAPY; ANTI-CTLA-4; HOMEOSTASIS; IPILIMUMAB; EXPRESSION; SIGNATURES; NIVOLUMAB; COLITIS	Checkpoint blockade with antibodies specific for the PD-1 and CTLA-4 inhibitory receptors can induce durable responses in a wide range of human cancers. However, the immunological mechanisms responsible for severe inflammatory side effects remain poorly understood. Here we report a comprehensive single-cell analysis of immune cell populations in colitis, a common and severe side effect of checkpoint blockade. We observed a striking accumulation of CD8 T cells with highly cytotoxic and proliferative states and no evidence of regulatory T cell depletion. T cell receptor (TCR) sequence analysis demonstrated that a substantial fraction of colitis-associated CD8 T cells originated from tissue-resident populations, explaining the frequently early onset of colitis symptoms following treatment initiation. Our analysis also identified cytokines, chemokines, and surface receptors that could serve as therapeutic targets for colitis and potentially other inflammatory side effects of checkpoint blockade.	[Luoma, Adrienne M.; Dougan, Stephanie K.; Wucherpfennig, Kai W.] Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02215 USA; [Luoma, Adrienne M.; Dougan, Stephanie K.; Wucherpfennig, Kai W.] Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA; [Suo, Shengbao; Yuan, Guo-Cheng] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA; [Suo, Shengbao; Yuan, Guo-Cheng] Harvard Med Sch, Boston, MA 02215 USA; [Williams, Hannah L.; Manos, Michael; Bowling, Peter; Hodi, F. Stephen; Rahma, Osama] Dana Farber Canc Inst Boston, Dept Med Oncol, Boston, MA 02215 USA; [Sharova, Tatyana; Sullivan, Ryan J.; Boland, Genevieve M.] Harvard Med Sch, Canc Ctr, Massachusetts Gen Hosp, Boston, MA 02114 USA; [Sharova, Tatyana; Boland, Genevieve M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Sullivan, Keri; Dougan, Michael] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA; [Sullivan, Keri; Dougan, Michael] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; [Sullivan, Keri; Dougan, Michael] Harvard Med Sch, Boston, MA 02114 USA; [Manos, Michael; Bowling, Peter; Hodi, F. Stephen] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02115 USA; [Manos, Michael; Bowling, Peter; Hodi, F. Stephen; Wucherpfennig, Kai W.] Harvard Med Sch, Boston, MA 02115 USA; [Rahma, Osama] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Rahma, Osama] Dana Farber Harvard Canc Ctr, Boston, MA USA; [Nowak, Jonathan A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Wucherpfennig, Kai W.] Brigham & Womens Hosp, Dept Neurol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Wucherpfennig, KW (corresponding author), Dana Farber Canc Inst, Dept Canc Immunol & Virol, Boston, MA 02215 USA.; Wucherpfennig, KW (corresponding author), Harvard Med Sch, Dept Immunol, Boston, MA 02115 USA.; Dougan, M (corresponding author), Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.; Dougan, M (corresponding author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.; Dougan, M (corresponding author), Harvard Med Sch, Boston, MA 02114 USA.; Wucherpfennig, KW (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.	mldougan@partners.org; kai_wucherpfennig@dfci.harvard.edu	Boland, Genevieve/AAP-2767-2021	Williams, Hannah/0000-0003-0434-3900	Team Award from the American Cancer Society [MRAT-18-113-01]; Melanoma Research Alliance [597698]; NIH [R01 CA238039, P01 CA163222, T32CA207021]; National Institutes of Health Mentored Clinical Scientist Development Award [1K08DK114563-01]; American Gastroenterological Association Research Scholars Award	Team Award from the American Cancer Society; Melanoma Research Alliance; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health Mentored Clinical Scientist Development Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Gastroenterological Association Research Scholars Award	This work was supported by a Team Award from the American Cancer Society (MRAT-18-113-01), the Melanoma Research Alliance (597698 to K.W.W., S.K.D., M.D., G.-C.Y., and R.J.S.), NIH grants R01 CA238039 (to K.W.W.), P01 CA163222 (to K.W.W. and F.S.H.), and T32CA207021 (to A.M.L. and K.W.W.); National Institutes of Health Mentored Clinical Scientist Development Award 1K08DK114563-01 (to M.D.); and the American Gastroenterological Association Research Scholars Award (to M.D.). We would like to thank all of the patients who participated in this study and the nursing and surgical technicians from the MGH endoscopy unit who provided care for the patients and made safe biopsy collection feasible. We would further like to thank Md Aladdin Bhuiyan, Elisa Bello, Patrick Lenehan, and Max Heckler for providing specific technical assistance and Ruben Dries for helpful discussions. We thank Susannah Phillips, J. Harrison Carmichael, and Dennie Frederick for help with clinical sample collection. We thank the Center for Cancer Genome Discovery (DFCI) for sequencing of scRNA-seq libraries.	Abu-Sbeih H, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0461-4; Aibar S, 2017, NAT METHODS, V14, P1083, DOI [10.1038/nmeth.4463, 10.1038/NMETH.4463]; Aran D, 2019, NAT IMMUNOL, V20, P163, DOI 10.1038/s41590-018-0276-y; Arbour KC, 2018, J CLIN ONCOL, V36, P2872, DOI 10.1200/JCO.2018.79.0006; Badran YR, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0711-0; Becht E, 2019, NAT BIOTECHNOL, V37, P38, DOI 10.1038/nbt.4314; Blondel VD, 2008, J STAT MECH-THEORY E, DOI 10.1088/1742-5468/2008/10/P10008; CEPEK KL, 1994, NATURE, V372, P190, DOI 10.1038/372190a0; Coutzac C, 2017, J CROHNS COLITIS, V11, P1238, DOI 10.1093/ecco-jcc/jjx081; Curran MA, 2010, P NATL ACAD SCI USA, V107, P4275, DOI 10.1073/pnas.0915174107; Dougan M, 2020, J CLIN INVEST, V130, P51, DOI 10.1172/JCI131194; Dougan M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01547; Downey SG, 2007, CLIN CANCER RES, V13, P6681, DOI 10.1158/1078-0432.CCR-07-0187; Faje AT, 2018, CANCER-AM CANCER SOC, V124, P3706, DOI 10.1002/cncr.31629; Foppen MHG, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2017-000278; Foulds KE, 2002, J IMMUNOL, V168, P1528, DOI 10.4049/jimmunol.168.4.1528; Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158; Grover S, 2019, CANCER-AM CANCER SOC, V125, P1768, DOI 10.1002/cncr.32005; Gu ZG, 2014, BIOINFORMATICS, V30, P2811, DOI 10.1093/bioinformatics/btu393; Herold MJ, 2006, CELL MOL LIFE SCI, V63, P60, DOI 10.1007/s00018-005-5390-y; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Huang B, 2019, CELL, V179, P1160, DOI 10.1016/j.cell.2019.10.027; Hughes MS, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0756-0; Ilicic T, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0888-1; James Melville, 2020, Arxiv, DOI arXiv:1802.03426; Johnson DB, 2016, NEW ENGL J MED, V375, P1749, DOI 10.1056/NEJMoa1609214; Joosse ME, 2019, MUCOSAL IMMUNOL, V12, P21, DOI 10.1038/s41385-018-0113-5; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Kuehn HS, 2014, SCIENCE, V345, P1623, DOI 10.1126/science.1255904; Kumar BV, 2017, CELL REP, V20, P2921, DOI 10.1016/j.celrep.2017.08.078; La Manno G, 2018, NATURE, V560, P494, DOI 10.1038/s41586-018-0414-6; Langer V, 2019, J CLIN INVEST, V129, P4691, DOI 10.1172/JCI124884; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Lord JD, 2010, DIGEST DIS SCI, V55, P1396, DOI 10.1007/s10620-009-0839-8; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Martin JC, 2019, CELL, V178, P1493, DOI 10.1016/j.cell.2019.08.008; Masopust D, 2019, ANNU REV IMMUNOL, V37, P521, DOI 10.1146/annurev-immunol-042617-053214; McGinnis CS, 2019, CELL SYST, V8, P329, DOI 10.1016/j.cels.2019.03.003; McLane LM, 2019, ANNU REV IMMUNOL, V37, P457, DOI 10.1146/annurev-immunol-041015-055318; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Neurath MF, 2019, NAT IMMUNOL, V20, P970, DOI 10.1038/s41590-019-0415-0; Neurath MF, 2014, NAT REV IMMUNOL, V14, P329, DOI 10.1038/nri3661; Pijuan-Sala B, 2019, NATURE, V566, P490, DOI 10.1038/s41586-019-0933-9; Postow MA, 2018, NEW ENGL J MED, V378, P158, DOI [10.1056/NEJMc1801663, 10.1056/NEJMra1703481]; Postow MA, 2015, NEW ENGL J MED, V372, P2006, DOI 10.1056/NEJMoa1414428; Ridker PM, 2017, LANCET, V390, P1833, DOI 10.1016/S0140-6736(17)32247-X; Sergushichev AA, 2016, BIORXIV, DOI [10.1101/060012%0A, 10.1101/060012]; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Sharma A, 2019, CLIN CANCER RES, V25, P1233, DOI 10.1158/1078-0432.CCR-18-0762; Sherwood AM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002536; Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579; Smillie CS, 2019, CELL, V178, P714, DOI 10.1016/j.cell.2019.06.029; Solomon BL, 2018, CANCER IMMUNOL IMMUN, V67, P1659, DOI 10.1007/s00262-018-2246-5; Stuart T, 2019, CELL, V177, P1888, DOI 10.1016/j.cell.2019.05.031; Suo SB, 2018, CELL REP, V25, P1436, DOI 10.1016/j.celrep.2018.10.045; Szabo PA, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aas9673; Valsecchi ME, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMc1509660, 10.1056/NEJMoa1504030]; Walker MG, 1999, GENOME RES, V9, P1198, DOI 10.1101/gr.9.12.1198; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; West NR, 2017, NAT MED, V23, P579, DOI 10.1038/nm.4307; Wickham H., 2016, GGPLOT2 ELEGANT GRAP, DOI 10.1007/978-3-319-24277-4; Xiao G, 2015, ONCOTARGET, V6, P14165, DOI 10.18632/oncotarget.3690; Yoshino K, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6138-7; Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3; Zeissig S, 2015, GUT, V64, P1889, DOI 10.1136/gutjnl-2014-308541; Zhang ML, 2020, HISTOPATHOLOGY, V76, P233, DOI 10.1111/his.13963	66	109	112	6	41	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 6	2020	182	3					655	+		10.1016/j.cell.2020.06.001	http://dx.doi.org/10.1016/j.cell.2020.06.001			39	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MY8EK	32603654	Green Accepted, Bronze			2023-01-03	WOS:000558649000012
J	Nshimyiryo, A; Kirk, CM; Sauer, SM; Ntawuyirusha, E; Muhire, A; Sayinzoga, F; Hedt-Gauthier, B				Nshimyiryo, Alphonse; Kirk, Catherine M.; Sauer, Sara M.; Ntawuyirusha, Emmanuel; Muhire, Andrew; Sayinzoga, Felix; Hedt-Gauthier, Bethany			Health management information system (HMIS) data verification: A case study in four districts in Rwanda	PLOS ONE			English	Article							QUALITY; ACCURACY; CARE	Introduction Reliable Health Management and Information System (HMIS) data can be used with minimal cost to identify areas for improvement and to measure impact of healthcare delivery. However, variable HMIS data quality in low- and middle-income countries limits its value in monitoring, evaluation and research. We aimed to review the quality of Rwandan HMIS data for maternal and newborn health (MNH) based on consistency of HMIS reports with facility source documents. Methods We conducted a cross-sectional study in 76 health facilities (HFs) in four Rwandan districts. For 14 MNH data elements, we compared HMIS data to facility register data recounted by study staff for a three-month period in 2017. A HF was excluded from a specific comparison if the service was not offered, source documents were unavailable or at least one HMIS report was missing for the study period. World Health Organization guidelines on HMIS data verification were used: a verification factor (VF) was defined as the ratio of register over HMIS data. A VF1.10 indicated over- and under-reporting in HMIS, respectively. Results High proportions of HFs achieved acceptable VFs for data on the number of deliveries (98.7%;75/76), antenatal care (ANC1) new registrants (95.7%;66/69), live births (94.7%;72/76), and newborns who received first postnatal care within 24 hours (81.5%;53/65). This was slightly lower for the number of women who received iron/folic acid (78.3%;47/60) and tested for syphilis in ANC1 (67.6%;45/68) and was the lowest for the number of women with ANC1 standard visit (25.0%;17/68) and fourth standard visit (ANC4) (17.4%;12/69). The majority of HFs over-reported on ANC4 (76.8%;53/69) and ANC1 (64.7%;44/68) standard visits. Conclusion There was variable HMIS data quality by data element, with some indicators with high quality and also consistency in reporting trends across districts. Over-reporting was observed for ANC-related data requiring more complex calculations, i.e., knowledge of gestational age, scheduling to determine ANC standard visits, as well as quality indicators in ANC. Ongoing data quality assessments and training to address gaps could help improve HMIS data quality.	[Nshimyiryo, Alphonse; Kirk, Catherine M.; Hedt-Gauthier, Bethany] Partners Hlth Inshuti Mu Buzima, Maternal & Child Hlth Program, Kigali, Rwanda; [Sauer, Sara M.; Hedt-Gauthier, Bethany] Harvard TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA USA; [Ntawuyirusha, Emmanuel; Muhire, Andrew] Minist Hlth, Planning Hlth Financing & Informat Syst, Kigali, Rwanda; [Sayinzoga, Felix] Rwanda Biomed Ctr, Maternal Child & Community Hlth Div, Kigali, Rwanda; [Hedt-Gauthier, Bethany] Harvard Med Sch, Dept Global Hlth & Social Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Rwanda Biomedical Center; Harvard University; Harvard Medical School	Nshimyiryo, A (corresponding author), Partners Hlth Inshuti Mu Buzima, Maternal & Child Hlth Program, Kigali, Rwanda.	anshimyiryo@pih.org		Kirk, Catherine/0000-0001-9103-2611; Nshimyiryo, Alphonse/0000-0002-2683-9459	Grand Challenges Canada Saving Lives at Birth	Grand Challenges Canada Saving Lives at Birth	The author (s) received no specific funding for this work. This study was implemented as part of the All Babies Count (ABC) intervention scale-up in Rwanda between 2017 and 2019, and data collection activities were funded by Grand Challenges Canada Saving Lives at Birth.; We acknowledge the contributions of Robert M. Gatsinzi and Ibrahim Hakizimana from the monitoring and evaluation team for data collection in health facility source documents. We are also grateful to the leadership, nurses and midwives of health facilities involved in this study, for their critical support in facilitating data collection for this study.	AbouZahr C, 2005, B WORLD HEALTH ORGAN, V83, P578; Ahanhanzo YG, 2014, ARCH PUBLIC HEALTH, V72, DOI 10.1186/2049-3258-72-25; [Anonymous], R LANG ENV STAT COMP; Bhattacharya AA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211265; Black RE, 2013, LANCET, V382, P427, DOI 10.1016/S0140-6736(13)60937-X; Bosch-Capblanch X, 2009, TROP MED INT HEALTH, V14, P2, DOI 10.1111/j.1365-3156.2008.02181.x; Brandrud AS, 2011, BMJ QUAL SAF, V20, P251, DOI 10.1136/bmjqs.2009.038604; Cambodia, 2012, ASSESSMENT HLTH FACI; Day LT, 2019, J GLOB HEALTH, V9, DOI 10.7189/jogh.09.010902; Ethiopian Public Health Institute (EPHI) Ministry of Health (MOH) World Health Organization (WHO)., 2016, HLTH DAT QUAL REV SY; Foster M, 2008, B WORLD HEALTH ORGAN, V86, P939, DOI [10.2471/blt.07.049908, DOI 10.2471/BLT.07.049908]; Garrib A, 2008, SAMJ S AFR MED J, V98, P549; Gergen J, 2017, GLOB HEALTH-SCI PRAC, V5, P90, DOI 10.9745/GHSP-D-16-00239; Hodgins S, 2014, GLOB HEALTH-SCI PRAC, V2, P173, DOI 10.9745/GHSP-D-13-00176; Innocent K, 2016, INT J PUBLIC HLTH RE, V4, P5; Iyer HS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182418; Kanyangarara M, 2017, J GLOB HEALTH, V7, DOI 10.7189/jogh.07.021101; Magge H, 2017, BMC HEALTH SERV RES, V17, DOI 10.1186/s12913-017-2659-4; Maiga A, 2019, BMJ GLOB HEALTH, V4, DOI 10.1136/bmjgh-2019-001849; Makombe SD, 2008, B WORLD HEALTH ORGAN, V86, P310, DOI 10.2471/BLT.07.044685; Maokola W, 2011, TROP MED INT HEALTH, V16, P721, DOI 10.1111/j.1365-3156.2011.02751.x; Mate KS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005483; Mavimbe JC, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-108; MEASURE-Evaluation, 2017, US DHIS 2 STRENGTH H; Mitsunaga T, 2015, J COMMUN HEALTH, V40, P625, DOI 10.1007/s10900-014-9977-9; Mphatswe W, 2012, B WORLD HEALTH ORGAN, V90, P176, DOI 10.2471/BLT.11.092759; Mutale W, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-S2-S9; National Institute of Statistics of Rwanda (NISR) [Rwanda]; Ministry of Health (MOH) [Rwanda]; and ICF International, 2015, RWAND DEM HLTH SURV; Newman L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001396; Nisingizwe MP, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25829; Nyamtema AS, 2010, BMC MED INFORM DECIS, V10, DOI 10.1186/1472-6947-10-36; O'Hagan R, 2017, GLOBAL HLTH SCI PRAC, V5; Ouedraogo M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213600; Republic of Rwanda, 2016, DAT QUAL ASS PROC MA; Ronveaux O, 2005, B WORLD HEALTH ORGAN, V83, P503; Rwanda Ministry of Health, 2019, STAND OP PROC MAN RO; Rwanda Ministry of Health, 2018, 4 HLTH SECT STRAT PL; Rwanda Ministry of Health, 2017, HLTH SERV PACK PUBL; Tuncalp o, 2015, BJOG, DOI [10.1111/471-0528.13451, DOI 10.1111/471-0528.13451]; University of Oslo, 2018, DHIS2 FACTSH; Venkateswaran M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207813; Wetherill O, 2017, ROOT CAUSES POOR IMM, V2, P7; WHO, 2017, DAT QUAL REV TOOLK F; WHO, 2016, STANDARDS IMPROVING; Wickremasinghe D, 2016, HEALTH POLICY PLANN, V31, pii12, DOI 10.1093/heapol/czv124	46	12	12	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2020	15	7							e0235823	10.1371/journal.pone.0235823	http://dx.doi.org/10.1371/journal.pone.0235823			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR9PA	32678851	Green Published, gold			2023-01-03	WOS:000553920100006
J	Mishra, MV; Thayer, WM; Janssen, E; Hoppe, B; Eggleston, C; Bridges, JFP				Mishra, Mark, V; Thayer, Winter Maxwell; Janssen, Ellen; Hoppe, Bradford; Eggleston, Caitlin; Bridges, John F. P.			Patient preferences for reducing bowel adverse events following prostate radiotherapy	PLOS ONE			English	Article							DISCRETE-CHOICE EXPERIMENTS; LINEAR SCORING RULES; CONJOINT-ANALYSIS; REPORTED OUTCOMES; PROTON THERAPY; CANCER; WEIGHTS	Background The Extended Prostate Cancer Index Composite (EPIC) instrument is a commonly used patient reported outcome (PRO) tool in prostate cancer clinical trials. Summary scores for EPIC subscales are calculated by averaging patient scores for attributes (e.g., side effects), implying equal weighting of the attributes in the absence of evidence showing otherwise. Methods We estimated patient preferences for each of the attributes included in the bowel subscale of the EPIC instrument using best-worst (B-W) scaling among a cohort of men with prostate cancer. Patients were presented with multiple tasks in which they were asked to indicate which attribute they would find most and least bothersome at different levels of severity. Analysis utilized both (simple) B-W counts and scores to estimate patient preferences for each attribute as well as attribute levels. Results A total of 174 respondents from two institutions participated in the survey. Preference estimates for each of the five attributes included in the EPIC-26 bowel subscale showed wide variation preferences: 'losing control of bowel movements' was found to be the most bothersome attribute, with a B-W score of -0.48, followed by bowel urgency which also had negative B-W score (-0.04). Increased frequency of bowel movements was the least bothersome attribute, with a B-W score of +0.33, followed by bloody stools (+0.12), and pelvic/rectal pain (+0.06). Analysis of preference weights for attribute bother levels showed preference estimates be linear. Conclusions We provide novel evidence on patient preferences for side effect reduction following prostate radiotherapy. Within the bowel sub-scale of the EPIC-26 short form, we found that bowel incontinence was perceived to be the most bothersome treatment effect, while increased bowel frequency was least bothersome to patients.	[Mishra, Mark, V; Eggleston, Caitlin] Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA; [Thayer, Winter Maxwell] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; [Thayer, Winter Maxwell] Johns Hopkins Univ, Sch Nursing, Baltimore, MD USA; [Janssen, Ellen] Ctr Med Technol Policy, Baltimore, MD USA; [Hoppe, Bradford] Mayo Clin Florida, Dept Radiat Oncol, Tampa, FL USA; [Bridges, John F. P.] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Johns Hopkins University; Mayo Clinic; University System of Ohio; Ohio State University	Mishra, MV (corresponding author), Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA.	mmishra@umm.edu			American Society of Radiation Oncology (ASTRO) Comparative Effectiveness Award	American Society of Radiation Oncology (ASTRO) Comparative Effectiveness Award	MVM: American Society of Radiation Oncology (ASTRO) Comparative Effectiveness Award. The sponsor did not play a role in study design, data collection, analysis, or publication/writing of manuscript.	Basch E, 2012, J CLIN ONCOL, V30, P4249, DOI 10.1200/JCO.2012.42.5967; Beusterien K, 2014, ONCOLOGIST, V19, P127, DOI 10.1634/theoncologist.2013-0359; Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013; Bruner DW, 2015, CANCER-AM CANCER SOC, V121, P2422, DOI 10.1002/cncr.29362; Cheung KL, 2016, PHARMACOECONOMICS, V34, P1195, DOI 10.1007/s40273-016-0429-5; Davison BJ, 2012, PATIENT EDUC COUNS, V87, P369, DOI 10.1016/j.pec.2011.11.009; Donovan JL, 2016, NEW ENGL J MED, V375, P1425, DOI 10.1056/NEJMoa1606221; Hamdy FC, 2016, NEW ENGL J MED, V375, P1415, DOI 10.1056/NEJMoa1606220; Hauber AB, 2016, VALUE HEALTH, V19, P300, DOI 10.1016/j.jval.2016.04.004; Hoppe BS, 2014, CANCER-AM CANCER SOC, V120, P1076, DOI 10.1002/cncr.28536; Jayadevappa R, 2019, J CLIN ONCOL, V37, P964, DOI 10.1200/JCO.18.01091; Johnson FR, 2013, VALUE HEALTH, V16, P3, DOI 10.1016/j.jval.2012.08.2223; Johnson FR, 2006, QUAL LIFE RES, V15, P285, DOI 10.1007/s11136-005-0581-4; Khairnar R, 2018, AM J CLIN ONCOL-CANC, V41, P1069, DOI 10.1097/COC.0000000000000431; Kuchuk I, 2013, BREAST CANCER RES TR, V142, P101, DOI 10.1007/s10549-013-2727-3; Louviere J., 2015, BEST WORST SCALING; Mishra MV, 2017, INT J RADIAT ONCOL, V97, P228, DOI 10.1016/j.ijrobp.2016.10.045; Mohamed AF, 2010, PATIENT, V3, P217, DOI 10.2165/11537880-000000000-00000; Pan HY, 2018, J CLIN ONCOL, V36, P1823, DOI 10.1200/JCO.2017.75.5371; Showalter TN, 2015, PATIENT PREFER ADHER, V9, DOI 10.2147/PPA.S83333; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Tinelli M, 2012, BMC DERMATOL, V12, DOI 10.1186/1471-5945-12-19; Wei JT, 2000, UROLOGY, V56, P899, DOI 10.1016/S0090-4295(00)00858-X	23	0	0	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 8	2020	15	7							e0235616	10.1371/journal.pone.0235616	http://dx.doi.org/10.1371/journal.pone.0235616			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ0QI	32639983	gold, Green Published			2023-01-03	WOS:000552601500032
J	Pierobon, A; Granata, N; Torlaschi, V; Vailati, C; Radici, A; Maestri, R; Pavesi, C; Sommaruga, M; Gazzi, L; Bertolotti, G; Braga, SS; Monelli, M; Zanelli, E; Giardini, A				Pierobon, Antonia; Granata, Nicolo; Torlaschi, Valeria; Vailati, Chiara; Radici, Alice; Maestri, Roberto; Pavesi, Claudia; Sommaruga, Marinella; Gazzi, Lidia; Bertolotti, Giorgio; Sarzi Braga, Simona; Monelli, Mauro; Zanelli, Emanuela; Giardini, Anna			Psychomotor speed as a predictor of functional status in older chronic heart failure (CHF) patients attending cardiac rehabilitation	PLOS ONE			English	Article							REVISED ACE-R; COGNITIVE IMPAIRMENT; NORMATIVE VALUES; SELF-CARE; ANXIETY; DEPRESSION; SYMPTOMS; POPULATION; MORTALITY; BATTERY	Background The association among psychological, neuropsychological dysfunctions and functional/clinical variables in Chronic Heart Failure (CHF) has been extensively addressed in literature. However, only a few studies investigated those associations in the older population. Purpose To evaluate the psychological/neuropsychological profile of older CHF patients, to explore the interrelation with clinical/functional variables and to identify potential independent predictors of patients' functional status. Methods This study was conducted with a multi-center observational design. The following assessments were performed: anxiety (Hospital Anxiety and Depression Scale, HADS), depression (Geriatric Depression Scale, GDS), cognitive impairment (Addenbrooke's Cognitive Examination Revised, ACE-R), executive functions (Frontal Assessment Battery, FAB), constructive abilities (Clock Drawing Test, CDT), psychomotor speed and alternated attention (Trail Making Test, TMT-A/B), functional status (6-minute walking test, 6MWT) and clinical variables (New York Heart Association, NYHA; Brain Natriuretic Peptide, BNP; left ventricular ejection fraction, LVEF; left ventricular end diastolic diameter, LVEDD; left ventricular end diastolic volume, LVEDV; tricuspid annular plane systolic excursion, TAPSE). Results 100 CHF patients (mean age: 74.9 +/- 7.1 years; mean LVEF: 36.1 +/- 13.4) were included in the study. Anxious and depressive symptoms were observed in 16% and 24,5% of patients, respectively. Age was related to TMT-A and CDT (r = 0.49, p<0.001 and r = -0.32, p = 0.001, respectively), Log-BNP was related to ACE-R-Fluency subtest, (r = -0.22, p = 0.034), and 6MWT was related to ACE-R-Memory subtest and TMT-A (r = 0.24, p = 0.031 and r = -0.32, p = 0.005, respectively). Both anxiety and depression symptoms were related to ACE-R-Total score (r = -0.25, p = 0.013 and r = -0.32, p = 0.002, respectively) and depressive symptoms were related to CDT (r = -0.23, p = 0.024). At multiple regression analysis, Log-BNP and TMT-A were significant and independent predictors of functional status: worse findings on Log-BNP and TMT-A were associated with shorter distance walked at the 6MWT. Conclusions Psychological and neuropsychological screening, along with the assessment of psychomotor speed (TMT-A), may provide useful information for older CHF patients undergoing cardiac rehabilitation.	[Pierobon, Antonia; Granata, Nicolo; Torlaschi, Valeria; Vailati, Chiara; Radici, Alice; Giardini, Anna] IRCCS, Montescano Inst, Psychol Unit, Ist Clin Sci Maugeri, Pavia, Italy; [Maestri, Roberto] IRCCS, Montescano Inst, Dept Biomed Engn, Ist Clin Sci Maugeri, Pavia, Italy; [Pavesi, Claudia] IRCCS, Montescano Inst, Dept Cardiac Rehabil, Ist Clin Sci Maugeri, Pavia, Italy; [Sommaruga, Marinella] IRCCS, Camaldoli Inst, Psychol Unit, Ist Clin Sci Maugeri, Milan, Italy; [Gazzi, Lidia] IRCCS, Lumezzane Inst, Psychol Unit, Ist Clin Sci Maugeri, Brescia, Italy; [Bertolotti, Giorgio] IRCCS, Tradate Inst, Psychol Unit, Ist Clin Sci Maugeri, Brescia, Italy; [Sarzi Braga, Simona] IRCCS, Tradate Inst, Dept Cardiac Rehabil, Ist Clin Sci Maugeri, Varese, Italy; [Monelli, Mauro] IRCCS, Camaldoli Inst, Subacute Care, Ist Clin Sci Maugeri, Milan, Italy; [Zanelli, Emanuela] IRCCS, Lumezzane Inst, Dept Cardiac Rehabil, Ist Clin Sci Maugeri, Brescia, Italy	Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia; Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia; Istituti Clinici Scientifici Maugeri IRCCS; University of Pavia; Istituti Clinici Scientifici Maugeri IRCCS; IRCCS Fatebenefratelli; Istituti Clinici Scientifici Maugeri IRCCS; IRCCS Fatebenefratelli; Istituti Clinici Scientifici Maugeri IRCCS; Istituti Clinici Scientifici Maugeri IRCCS; Istituti Clinici Scientifici Maugeri IRCCS; IRCCS Fatebenefratelli; Istituti Clinici Scientifici Maugeri IRCCS	Pierobon, A (corresponding author), IRCCS, Montescano Inst, Psychol Unit, Ist Clin Sci Maugeri, Pavia, Italy.	antonia.pierobon@icsmaugeri.it	Bertolotti, Giorgio/AAJ-2692-2021; Gazzi, Lidia/AAC-1682-2020; Torlaschi, Valeria/E-9095-2019; Zanelli, Emanuela/AAC-2026-2020; Pierobon, Antonia/AAA-2859-2021; braga, simona sarzi/AAC-1002-2020; Maestri, Roberto/AAA-7585-2019; pinna, gian domenico/ABI-7618-2020; Maestri, Roberto/J-8168-2016; Monelli, Mauro/AAD-6031-2020; Sommaruga, Marinella/F-7480-2019; Giardini, Anna/G-4359-2018; Giardini, Anna/ABI-7610-2020	Bertolotti, Giorgio/0000-0002-3079-1945; Gazzi, Lidia/0000-0001-5751-4932; Torlaschi, Valeria/0000-0002-4534-3547; Zanelli, Emanuela/0000-0003-1020-5125; Pierobon, Antonia/0000-0002-4678-781X; braga, simona sarzi/0000-0001-5704-4109; Maestri, Roberto/0000-0002-2873-0430; pinna, gian domenico/0000-0001-7667-6662; Maestri, Roberto/0000-0002-2873-0430; Monelli, Mauro/0000-0002-0870-805X; Sommaruga, Marinella/0000-0003-2692-4925; Giardini, Anna/0000-0002-2845-347X; Giardini, Anna/0000-0002-2845-347X; Granata, Nicolo/0000-0001-9743-6684	Ministry of Health, Italy	Ministry of Health, Italy(Ministry of Health, Italy)	This work was partially supported by the "Ricerca Corrente" funding scheme of the Ministry of Health, Italy. There was no additional external funding received for this study. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alhurani AS, 2015, PSYCHOSOMATICS, V56, P371, DOI 10.1016/j.psym.2014.05.022; Alosco ML, 2014, INT J GERIATR PSYCH, V29, P428, DOI 10.1002/gps.4023; Appollonio I, 2005, NEUROL SCI, V26, P108, DOI 10.1007/s10072-005-0443-4; Caffarra P, 2011, J CLIN EXP NEUROPSYC, V33, P982, DOI 10.1080/13803395.2011.589373; Callegari S, 2002, Monaldi Arch Chest Dis, V58, P19; Cameron Jan, 2017, Curr Heart Fail Rep, V14, P13, DOI 10.1007/s11897-017-0317-0; Cannon JA, 2017, J CARD FAIL, V23, P464, DOI 10.1016/j.cardfail.2017.04.007; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; Chiala O, 2018, HEART LUNG, V47, P465, DOI 10.1016/j.hrtlng.2018.07.010; Damen NL, 2012, J GEN INTERN MED, V27, P345, DOI 10.1007/s11606-011-1843-1; Fattirolli F, 2018, EUR J PREV CARDIOL, V25, P1799, DOI 10.1177/2047487318789497; Forman Daniel E, 2013, Curr Heart Fail Rep, V10, P387, DOI 10.1007/s11897-013-0163-7; Frey A, 2018, JACC-HEART FAIL, V6, P583, DOI 10.1016/j.jchf.2018.03.010; Giovagnoli AR, 1996, ITAL J NEUROL SCI, V17, P305, DOI 10.1007/BF01997792; Hawkins MAW, 2014, HEART LUNG, V43, P462, DOI 10.1016/j.hrtlng.2014.05.011; Hjelm CM, 2015, HEART LUNG, V44, P113, DOI 10.1016/j.hrtlng.2014.12.003; Isella V., 2002, CLIN GERONTOLOGIST, V24, P115, DOI [10.1300/J018v24n03_10, DOI 10.1300/J018V24N03_10, https://doi.org/10.1300/J018v24n03_10]; Ismail Z, 2018, INT PSYCHOGERIATR, V30, P185, DOI 10.1017/S1041610217001880; Ismail Z, 2017, JAMA PSYCHIAT, V74, P58, DOI 10.1001/jamapsychiatry.2016.3162; Kewcharoen J, 2019, J SAUDI HEART ASSOC, V31, P170, DOI 10.1016/j.jsha.2019.06.001; Leto L, 2014, J GERIATR CARDIOL, V11, P316, DOI 10.11909/j.issn.1671-5411.2014.04.007; Long L, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003331.pub5; Lovell J, 2019, BMC CARDIOVASC DISOR, V19, DOI 10.1186/s12872-019-1077-4; Magni E, 1996, EUR J NEUROL, V3, P198, DOI 10.1111/j.1468-1331.1996.tb00423.x; Mene-Afejuku TO, 2019, CURR CARDIOL REV, V15, P291, DOI 10.2174/1573403X15666190313112841; Millan-Calenti JC, 2011, INT J GERIATR PSYCH, V26, P1071, DOI 10.1002/gps.2646; Mioshi E, 2006, INT J GERIATR PSYCH, V21, P1078, DOI 10.1002/gps.1610; Muller-Tasch T, 2018, EUR J CARDIOVASC NUR, V17, P170, DOI 10.1177/1474515117722255; Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI 10.1093/eurheartj/ehw106; Pigliautile M, 2011, DEMENT GERIATR COGN, V32, P301, DOI 10.1159/000334657; Pressler SJ, 2010, J CARD FAIL, V16, P750, DOI 10.1016/j.cardfail.2010.04.007; Rock PL, 2014, PSYCHOL MED, V44, P2029, DOI 10.1017/S0033291713002535; Siciliano M, 2016, NEUROL SCI, V37, P385, DOI 10.1007/s10072-015-2410-z; SNAITH RP, 1986, BRIT MED J, V292, P344, DOI 10.1136/bmj.292.6516.344; Sokoreli I, 2016, HEART FAIL REV, V21, P49, DOI 10.1007/s10741-015-9517-4; Sommaruga M, 2018, MONALDI ARCH CHEST D, V88, P47, DOI 10.4081/monaldi.2018.966; Taraghi Z, 2016, IRAN J PSYCHIATRY BE, V10, DOI 10.17795/ijpbs-4500; tbd, 2013, J MED INTERNET RES, V15; Yaneva-Sirakova T, 2017, NEUROPSYCH DIS TREAT, V13, P2925, DOI 10.2147/NDT.S144264	39	5	5	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 2	2020	15	7							e0235570	10.1371/journal.pone.0235570	http://dx.doi.org/10.1371/journal.pone.0235570			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MM1IV	32614895	Green Published, gold			2023-01-03	WOS:000549913100045
J	Herrera, AL; Van Hove, C; Hanson, M; Dale, JB; Tweten, RK; Huber, VC; Diel, D; Chaussee, MS				Herrera, Andrea L.; Van Hove, Christopher; Hanson, Mary; Dale, James B.; Tweten, Rodney K.; Huber, Victor C.; Diel, Diego; Chaussee, Michael S.			Immunotherapy targeting theStreptococcus pyogenesM protein or streptolysin O to treat or prevent influenza A superinfection	PLOS ONE			English	Article							CHOLESTEROL-DEPENDENT CYTOLYSINS; POLYSPECIFIC IMMUNOGLOBULIN-G; STREPTOCOCCAL M-PROTEIN; TOXIC-SHOCK-SYNDROME; INTRAVENOUS IMMUNOGLOBULIN; NEUTRALIZING ANTIBODIES; NECROTIZING FASCIITIS; IMMUNE-RESPONSES; VACCINE; INFECTION	Viral infections complicated by a bacterial infection are typically referred to as coinfections or superinfections.Streptococcus pyogenes, the group A streptococcus (GAS), is not the most common bacteria associated with influenza A virus (IAV) superinfections but did cause significant mortality during the 2009 influenza pandemic even though all isolates are susceptible to penicillin. One approach to improve the outcome of these infections is to use passive immunization targeting GAS. To test this idea, we assessed the efficacy of passive immunotherapy using antisera against either the streptococcal M protein or streptolysin O (SLO) in a murine model of IAV-GAS superinfection. Prophylactic treatment of mice with antiserum to either SLO or the M protein decreased morbidity compared to mice treated with non-immune sera; however, neither significantly decreased mortality. Therapeutic use of antisera to SLO decreased morbidity compared to mice treated with non-immune sera but neither antisera significantly reduced mortality. Overall, the results suggest that further development of antibodies targeting the M protein or SLO may be a useful adjunct in the treatment of invasive GAS diseases, including IAV-GAS superinfections, which may be particularly important during influenza pandemics.	[Herrera, Andrea L.; Van Hove, Christopher; Hanson, Mary; Huber, Victor C.; Chaussee, Michael S.] Univ South Dakota, Div Basic Biomed Sci, Sanford Sch Med, Vermillion, SD 57069 USA; [Dale, James B.] Univ Tennessee, Ctr Hlth Sci, Dept Med, Div Infect Dis, Memphis, TN 38163 USA; [Tweten, Rodney K.] Univ Oklahoma, Hlth Sci Ctr, Dept Microbiol & Immunol, Oklahoma City, OK 73190 USA; [Diel, Diego] South Dakota State Univ, Dept Vet & Biomed Sci, Brookings, SD 57007 USA; [Diel, Diego] Cornell Univ, Coll Vet Med, Dept Populat Med & Diagnost Sci, Anim Hlth Diagnost Ctr, Ithaca, NY 14853 USA	University of South Dakota; University of Tennessee System; University of Tennessee Health Science Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; South Dakota State University; Cornell University	Chaussee, MS (corresponding author), Univ South Dakota, Div Basic Biomed Sci, Sanford Sch Med, Vermillion, SD 57069 USA.	michael.chaussee@usd.edu	Diel, Diego G./ABC-6242-2021	Diel, Diego G./0000-0003-3237-8940	NIH/NIAID [5R21AI115087, 5R01AI132117]; South Dakota Center for Biologics Research & Commercialization (SD-CBRC) from the SD GOED Governors Research Center	NIH/NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); South Dakota Center for Biologics Research & Commercialization (SD-CBRC) from the SD GOED Governors Research Center	Funding for the project was provided by NIH/NIAID grants 5R21AI115087 (M.S.C) and 5R01AI132117 (J.B.D.) and the South Dakota Center for Biologics Research & Commercialization (SD-CBRC) from the SD GOED Governors Research Center (M.S.C, D.D, and V.C.H.).	Alejandria MM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001090.pub2; Ashbaugh CD, 1998, J CLIN INVEST, V102, P550, DOI 10.1172/JCI3065; Basma H, 1998, INFECT IMMUN, V66, P2279, DOI 10.1128/IAI.66.5.2279-2283.1998; Batzloff MR, 2003, J INFECT DIS, V187, P1598, DOI 10.1086/374800; BESSEN D, 1988, J EXP MED, V167, P1945, DOI 10.1084/jem.167.6.1945; BHAKDI S, 1985, INFECT IMMUN, V47, P52; Brandt ER, 2000, INFECT IMMUN, V68, P6587, DOI 10.1128/IAI.68.12.6587-6594.2000; BRONZE MS, 1992, J IMMUNOL, V148, P888; Cawley MJ, 1999, PHARMACOTHERAPY, V19, P1094, DOI 10.1592/phco.19.13.1094.31589; Chaussee MS, 2011, VACCINE, V29, P3773, DOI 10.1016/j.vaccine.2011.03.031; Chiarot E, 2013, MBIO, V4, DOI 10.1128/mBio.00387-12; Courtney HS, 2006, MOL MICROBIOL, V59, P936, DOI 10.1111/j.1365-2958.2005.04977.x; Dale JB, 1999, VACCINE, V17, P193, DOI 10.1016/S0264-410X(98)00150-9; Dale JB, 2002, INFECT IMMUN, V70, P2166, DOI 10.1128/IAI.70.4.2166-2170.2002; Darenberg J, 2004, CLIN INFECT DIS, V38, P836, DOI 10.1086/381979; de Gier B, 2019, INFLUENZA OTHER RESP, V13, P453, DOI 10.1111/irv.12658; Farrand S, 2008, BIOCHEMISTRY-US, V47, P7097, DOI 10.1021/bi8005835; Fernandes MHV, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00363; Fiorillo F, 2002, J MAGN MAGN MATER, V242, P257, DOI 10.1016/S0304-8853(01)01271-9; Hall MA, 2004, INFECT IMMUN, V72, P2507, DOI 10.1128/IAI.72.5.2507-2512.2004; Herrera AL, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29714-x; Herrera AL, 2017, MICROBIOL-SGM, V163, P1445, DOI 10.1099/mic.0.000532; Herrera AL, 2016, FRONT MICROBIOL, V7, DOI 10.3389/fmicb.2016.00342; HOLM SE, 1992, J INFECT DIS, V166, P31, DOI 10.1093/infdis/166.1.31; HOLMES SJ, 1992, J INFECT DIS, V165, pS121, DOI 10.1093/infdis/165-Supplement_1-S121; Hotze EM, 2013, INFECT IMMUN, V81, P216, DOI 10.1128/IAI.00927-12; Huang YS, 2011, J INFECT DIS, V203, P1595, DOI 10.1093/infdis/jir149; Huber VC, 2009, VACCINE, V27, P1192, DOI 10.1016/j.vaccine.2008.12.023; Jean C, 2010, CLIN INFECT DIS, V50, pE59, DOI 10.1086/652291; Kadri SS, 2017, CLIN INFECT DIS, V64, P877, DOI 10.1093/cid/ciw871; Kaul R, 1999, CLIN INFECT DIS, V28, P800, DOI 10.1086/515199; Kawabata S, 2001, INFECT IMMUN, V69, P924, DOI 10.1128/IAI.69.2.924-930.2001; Klonoski JM, 2018, VIRAL IMMUNOL, V31, P457, DOI 10.1089/vim.2017.0193; Klonoski JM, 2014, VACCINE, V32, P5241, DOI 10.1016/j.vaccine.2014.06.093; Kotloff KL, 2004, JAMA-J AM MED ASSOC, V292, P709, DOI 10.1001/jama.292.6.709; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; Lannergard J, 2011, CELL HOST MICROBE, V10, P147, DOI 10.1016/j.chom.2011.06.011; Limbago B, 2000, INFECT IMMUN, V68, P6384, DOI 10.1128/IAI.68.11.6384-6390.2000; Liu MY, 2007, INFECT IMMUN, V75, P3651, DOI 10.1128/IAI.00038-07; McCullers JA, 2006, CLIN MICROBIOL REV, V19, P571, DOI 10.1128/CMR.00058-05; McNeil SA, 2005, CLIN INFECT DIS, V41, P1114, DOI 10.1086/444458; Mehta S, 2006, CHEST, V130, P1679, DOI 10.1016/S0012-3692(15)50887-8; Morens DM, 2008, J INFECT DIS, V198, P962, DOI 10.1086/591708; Morens DM, 2007, J INFECT DIS, V195, P1018, DOI 10.1086/511989; Muller MP, 2003, ARCH INTERN MED, V163, P467, DOI 10.1001/archinte.163.4.467; Norrby-Teglund A, 1998, CLIN INFECT DIS, V26, P631, DOI 10.1086/514588; NorrbyTeglund A, 1996, J IMMUNOL, V156, P3057; NorrbyTeglund A, 1996, INFECT IMMUN, V64, P5395, DOI 10.1128/IAI.64.12.5395-5398.1996; NORRBYTEGLUND A, 1994, J INFECT DIS, V170, P585, DOI 10.1093/infdis/170.3.585; Okamoto S, 2004, INFECT IMMUN, V72, P6068, DOI 10.1128/IAI.72.10.6068-6075.2004; Okamoto S, 2004, VACCINE, V22, P2887, DOI 10.1016/j.vaccine.2003.12.024; Okamoto S, 2003, J VIROL, V77, P4104, DOI 10.1128/JVI.77.7.4104-4112.2003; Okamoto S, 2018, MICROBIOL IMMUNOL, V62, P141, DOI 10.1111/1348-0421.12577; Oligbu G, 2016, VACCINE, V34, P6126, DOI 10.1016/j.vaccine.2016.10.050; Olive C, 2002, INFECT IMMUN, V70, P2734, DOI 10.1128/IAI.70.5.2734-2738.2002; Olsen RJ, 2010, MICROB PATHOGENESIS, V49, P336, DOI 10.1016/j.micpath.2010.06.012; Pandey M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005147; Park HS, 2005, INFECT IMMUN, V73, P7878, DOI 10.1128/IAI.73.12.7878-7886.2005; Parks T, 2018, CLIN INFECT DIS, V67, P1434, DOI 10.1093/cid/ciy401; Penfound TA, 2010, VACCINE, V28, P5017, DOI 10.1016/j.vaccine.2010.05.018; Poland GA, 2018, EXPERT REV VACCINES, V17, P495, DOI 10.1080/14760584.2018.1484284; REED L. J., 1938, AMER JOUR HYG, V27, P493; Reglinski M, 2015, SCI REP-UK, V5, DOI 10.1038/srep15825; Rivera-Hernandez T, 2019, MBIO, V10, DOI 10.1128/mBio.00693-19; Saeland E, 2003, J IMMUNOL, V170, P6158, DOI 10.4049/jimmunol.170.12.6158; Sarbjit G, 2018, WILEY INTERDISCIPL R, V7, pe286, DOI 10.1002/WENE.286; Scaber J, 2011, EUROSURVEILLANCE, V16, P2; Shapiro SZ, 2019, VACCINE, V37, P3400, DOI 10.1016/j.vaccine.2019.04.005; SVENSON M, 1993, J CLIN INVEST, V92, P2533, DOI 10.1172/JCI116862; Timmer AM, 2009, J BIOL CHEM, V284, P862, DOI 10.1074/jbc.M804632200; Tweten RK, 2015, ANNU REV MICROBIOL, V69, P323, DOI 10.1146/annurev-micro-091014-104233; Weeks-Gorospe JN, 2012, J VIROL, V86, P9035, DOI 10.1128/JVI.00369-12; Zabriskie JB, 1997, ADV EXP MED BIOL, V418, P917; Zeppa JJ, 2017, P NATL ACAD SCI USA, V114, P10226, DOI 10.1073/pnas.1700858114	74	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2020	15	6							e0235139	10.1371/journal.pone.0235139	http://dx.doi.org/10.1371/journal.pone.0235139			17	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ME9KK	32574205	Green Published, gold			2023-01-03	WOS:000544972400026
J	Zhou, J; Yang, Q; Zhu, XC; Lin, T; Hao, DD; Xu, J				Zhou, Jing; Yang, Qi; Zhu, Xiaochen; Lin, Tong; Hao, Dongdong; Xu, Jing			Antioxidant activities ofClerodendrum cyrtophyllumTurcz leaf extracts and their major components	PLOS ONE			English	Article							RADICAL SCAVENGING ACTIVITY; PHENOLIC-COMPOUNDS; DIFFERENT FRACTIONS; OXIDATIVE STRESS; HYDROLYSATE; CAPACITY; ETHANOL	This study was designed to investigate the antioxidant properties of the extracts and subfractions of various polarities fromClerodendrum cyrtophyllumTurcz leaves and the related phenolic compound profiles. The ethyl acetate fraction (EAF) showed the most potent radical-scavenging activity for DPPH radicals, ABTS radicals, and superoxide anion (O-2(center dot-)) radicals as well as the highest reducing power of the fractions tested; then-butyl alcohol fraction (BAF) was the most effective in scavenging hydroxyl radical (OH center dot), and the dichloromethane fraction (DMF) exhibited the highest ferrous ion chelating activity. Twelve phenolic components were identified from the EAF ofC.cyrtophyllum. Additionally, acteoside (1) was found to be a major component (0.803 g, 0.54%) and show DPPH and ABTS radical scavenging activities with IC(50)values of 79.65 +/- 3.4 and 23.00 +/- 1.5 mu g/ml, indicating it is principally responsible for the significant total antioxidant effect ofC.cyrtophyllum. Our work offers a theoretical basis for further utilization of C.cyrtophyllumas a potential source of natural, green antioxidants derived from plants.	[Zhou, Jing; Zhu, Xiaochen; Lin, Tong; Hao, Dongdong; Xu, Jing] Hainan Univ, Sch Chem Engn & Technol, Key Lab Adv Mat Trop Isl Resources, Minist Educ, Haikou, Hainan, Peoples R China; [Zhou, Jing; Xu, Jing] Hainan Univ, Sch Life & Pharmaceut Sci, Haikou, Hainan, Peoples R China; [Yang, Qi] Hainan Univ, Sch Ecol & Environm, Haikou, Hainan, Peoples R China	Hainan University; Hainan University; Hainan University	Xu, J (corresponding author), Hainan Univ, Sch Chem Engn & Technol, Key Lab Adv Mat Trop Isl Resources, Minist Educ, Haikou, Hainan, Peoples R China.; Xu, J (corresponding author), Hainan Univ, Sch Life & Pharmaceut Sci, Haikou, Hainan, Peoples R China.	happyjing3@163.com	徐, 静/HDM-6882-2022		National Natural Science Foundation of China [81973229, 81660584]; Key Research and Development Program of Hainan Province [ZDYF2017099]; Key Project of Education Department of Hainan Province [Hnky2019ZD-6]; Research initiation fund project of Hainan University [KYQD(ZR)20001]; High-level Talents Programs of Hainan Province [2019RC006]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Research and Development Program of Hainan Province; Key Project of Education Department of Hainan Province; Research initiation fund project of Hainan University; High-level Talents Programs of Hainan Province	This work was financially supported by the National Natural Science Foundation of China (No. 81973229/81660584), Key Research and Development Program of Hainan Province (ZDYF2017099), Key Project of Education Department of Hainan Province (Hnky2019ZD-6) and Research initiation fund project of Hainan University (No.KYQD(ZR)20001).This work was financially supported by the High-level Talents Programs of Hainan Province (No. 2019RC006).	Ahmed MI, 2020, J FOOD MEAS CHARACT, V14, P799, DOI 10.1007/s11694-019-00328-9; Alu'datt MH, 2017, FOOD CHEM, V218, P99, DOI 10.1016/j.foodchem.2016.09.057; [Anonymous], 2015, NAT METHODS, V12, P1; Awah FM, 2010, FOOD CHEM, V119, P1409, DOI 10.1016/j.foodchem.2009.09.020; Banjarnahor SDS, 2014, MED J INDONES, V23, P239, DOI 10.13181/mji.v23i4.1015; Barizao EO, 2016, FOOD RES INT, V86, P24, DOI 10.1016/j.foodres.2016.05.007; Carocho M, 2013, FOOD CHEM TOXICOL, V51, P15, DOI 10.1016/j.fct.2012.09.021; Chiang CJ, 2013, LWT-FOOD SCI TECHNOL, V51, P417, DOI 10.1016/j.lwt.2012.11.014; Fatima M, 2017, CHEM NAT COMPD+, V53, P432, DOI 10.1007/s10600-017-2016-1; Gouthamchandra K, 2010, ENVIRON TOXICOL PHAR, V30, P11, DOI 10.1016/j.etap.2010.03.005; Guo T, 2011, FOOD CHEM, V127, P1634, DOI 10.1016/j.foodchem.2011.02.030; Khan SA, 2013, ASIAN J CHEM, V25, P7457, DOI 10.14233/ajchem.2013.14831; Kim NM, 2000, ARCH PHARM RES, V23, P237, DOI 10.1007/BF02976451; Li DL, 2016, J ETHNOPHARMACOL, V194, P358, DOI 10.1016/j.jep.2016.07.050; Li HB, 2007, FOOD CHEM, V102, P771, DOI 10.1016/j.foodchem.2006.06.022; Lushchak VI, 2014, CHEM-BIOL INTERACT, V224, P164, DOI 10.1016/j.cbi.2014.10.016; Pernin A, 2018, J SCI FOOD AGR, V98, P5401, DOI 10.1002/jsfa.9082; Priyankar Dey, 2012, International Journal of Pharma and Bio Sciences, V3, pP; Qian ZJ, 2008, BIORESOURCE TECHNOL, V99, P1690, DOI 10.1016/j.biortech.2007.04.005; Rehecho S, 2011, LWT-FOOD SCI TECHNOL, V44, P875, DOI 10.1016/j.lwt.2010.11.035; s NA, 2018, LANCET INFECT DIS, V18, pe228; Salla S, 2016, LWT-FOOD SCI TECHNOL, V66, P293, DOI 10.1016/j.lwt.2015.09.008; Santos JS, 2017, FOOD CHEM, V214, P515, DOI 10.1016/j.foodchem.2016.07.091; SASAKI H, 1989, PHYTOCHEMISTRY, V28, P875, DOI 10.1016/0031-9422(89)80134-7; Shi YT, 2015, CURR ORG CHEM, V19, P1935, DOI 10.2174/1385272819666150709165210; Thoo YY, 2010, FOOD CHEM, V120, P290, DOI 10.1016/j.foodchem.2009.09.064; Tian Y, 2017, FOOD CHEM, V220, P266, DOI 10.1016/j.foodchem.2016.09.145; Tiwari OP, 2007, FOOD CHEM, V100, P1170, DOI 10.1016/j.foodchem.2005.10.069; Wang B, 2012, PEPTIDES, V36, P240, DOI 10.1016/j.peptides.2012.05.013; Wang T, 2009, FOOD CHEM, V116, P240, DOI 10.1016/j.foodchem.2009.02.041; Wojdyo A, FOOD CHEM, V105, P940; Wong CC, 2006, FOOD CHEM, V97, P705, DOI 10.1016/j.foodchem.2005.05.049; Yang XB, 2015, FLORA OF HAINAN, V11, P350; Yokozawa T, 1998, BIOCHEM PHARMACOL, V56, P213, DOI 10.1016/S0006-2952(98)00128-2; Zhou J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068392	35	13	13	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 23	2020	15	6							e0234435	10.1371/journal.pone.0234435	http://dx.doi.org/10.1371/journal.pone.0234435			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ME9KK	32574221	Green Published, gold			2023-01-03	WOS:000544972400010
J	Srivastava, AB; Mariani, JJ; Levin, FR				Srivastava, A. Benjamin; Mariani, John J.; Levin, Frances R.			New directions in the treatment of opioid withdrawal	LANCET			English	Review							MEDICATION-ASSISTED TREATMENT; DOUBLE-BLIND; USE DISORDER; BUPRENORPHINE-NALOXONE; EXTENDED-RELEASE; UNITED-STATES; CHRONIC PAIN; DRUG; GABAPENTIN; PLACEBO	The treatment of opioid withdrawal is an important area of clinical concern when treating patients with chronic, non-cancer pain, patients with active opioid use disorder, and patients receiving medication for opioid use disorder. Current standards of care for medically supervised withdrawal include treatment with mu-opioid receptor agonists, (eg, methadone), partial agonists (eg, buprenorphine), and a2-adrenergic receptor agonists (eg, clonidine and lofexidine). Newer agents likewise exploit these pharmacological mechanisms, including tramadol (mu-opioid receptor agonism) and tizanidine (alpha 2 agonism). Areas for future research include managing withdrawal in the context of stabilising patients with opioid use disorder to extended-release naltrexone, transitioning patients with opioid use disorder from methadone to buprenorphine, and tapering opioids in patients with chronic, non-cancer pain.	[Srivastava, A. Benjamin; Mariani, John J.; Levin, Frances R.] Columbia Univ, NewYork State Psychiat Inst, Div Subst Use Disorders, Dept Psychiat,Irving Med Ctr, New York, NY 10023 USA	Columbia University; NewYork-Presbyterian Hospital; New York State Psychiatry Institute	Srivastava, AB (corresponding author), Columbia Univ, NewYork State Psychiat Inst, Div Subst Use Disorders, Dept Psychiat,Irving Med Ctr, New York, NY 10023 USA.	benjamin.srivastava@nyspi.columbia.edu			US National Institutes of Drug Abuse [T32 DA007294-26]	US National Institutes of Drug Abuse	This Therapeutics paper was primarily funded by the US National Institutes of Drug Abuse T32 DA007294-26 (FRL was the principal investigator).	Alper KR, 2008, J ETHNOPHARMACOL, V115, P9, DOI 10.1016/j.jep.2007.08.034; American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU; Antonio T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077262; Arout CA, 2015, CNS DRUGS, V29, P465, DOI 10.1007/s40263-015-0255-x; Bisaga A, 2018, DRUG ALCOHOL DEPEN, V187, P171, DOI 10.1016/j.drugalcdep.2018.02.023; Bisaga A, 2018, AM J ADDICTION, V27, P177, DOI 10.1111/ajad.12711; Blanco C, 2019, LANCET, V393, P1760, DOI 10.1016/S0140-6736(18)33078-2; Boyer EW, 2008, ADDICTION, V103, P1048, DOI 10.1111/j.1360-0443.2008.02209.x; Brown TK, 2018, AM J DRUG ALCOHOL AB, V44, P24, DOI 10.1080/00952990.2017.1320802; Darke S, 2017, ADDICTION, V112, P199, DOI 10.1111/add.13512; DAY E, 2005, COCHRANE DB SYST REV, V2; Dematteis M, 2017, EXPERT OPIN PHARMACO, V18, P1987, DOI 10.1080/14656566.2017.1409722; Dirks J, 2002, ANESTHESIOLOGY, V97, P560, DOI 10.1097/00000542-200209000-00007; Doughty B, 2019, ANN PHARMACOTHER, V53, P746, DOI 10.1177/1060028019828954; Dowell D, 2016, JAMA-J AM MED ASSOC, V315, P1624, DOI 10.1001/jama.2016.1464; Drug Enforcement Administration Department of Justice, 2014, Fed Regist, V79, P37623; Dunn KE, 2017, JAMA PSYCHIAT, V74, P885, DOI 10.1001/jamapsychiatry.2017.1838; Eccleston C, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010323.pub3; Fiellin DA, 2014, JAMA INTERN MED, V174, P1947, DOI 10.1001/jamainternmed.2014.5302; Fishman M, 2019, J ADDICT MED, V13, P169, DOI 10.1097/ADM.0000000000000474; Gee NS, 1996, J BIOL CHEM, V271, P5768, DOI 10.1074/jbc.271.10.5768; GOLD MS, 1981, LANCET, V1, P621; Gorodetzky CW, 2017, DRUG ALCOHOL DEPEN, V176, P79, DOI 10.1016/j.drugalcdep.2017.02.020; Gowing L, 2017, COCHRANE DB SYST REV, V5, DOI DOI 10.1002/14651858.CD002021.PUB4; Gowing L, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002025.pub5; Gowing L, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002024.pub5; Haight BR, 2019, LANCET, V393, P778, DOI 10.1016/S0140-6736(18)32259-1; JASINSKI DR, 1985, ARCH GEN PSYCHIAT, V42, P1063; Khazaeli A, 2018, J ADDICT MED, V12, P493, DOI 10.1097/ADM.0000000000000435; Kheirabadi GR, 2008, ADDICTION, V103, P1495, DOI 10.1111/j.1360-0443.2008.02248.x; Kheirabadi GR, 2018, ADDICT DISORD TREAT, V17, P55, DOI 10.1097/ADT.0000000000000127; Kleber Herbert D, 2007, Dialogues Clin Neurosci, V9, P455; Kosten TR, 2019, AM J ADDICTION, V28, P55, DOI 10.1111/ajad.12862; Kosten Thomas R, 2002, Sci Pract Perspect, V1, P13; Kosten TR, 2003, NEW ENGL J MED, V348, P1786, DOI 10.1056/NEJMra020617; KOSTEN TR, 1990, J NERV MENT DIS, V178, P217, DOI 10.1097/00005053-199004000-00001; Kraepelin E., 1899, PSYCHIAT LEHRBUCH ST; Kreek MJ, 2010, J ADDICT DIS, V29, P200, DOI 10.1080/10550881003684798; Kreek MJ, 2002, NEUROPSYCHOPHARMACOL; Lee JD, 2018, LANCET, V391, P309, DOI 10.1016/S0140-6736(17)32812-X; Lintzeris N, 2018, J ADDICT MED, V12, P234, DOI 10.1097/ADM.0000000000000396; Lofwall MR, 2018, JAMA INTERN MED, V178, P764, DOI 10.1001/jamainternmed.2018.1052; Maculaitis R, 2008, HUM EXP TOXICOL, V27, P181, DOI 10.1177/0960327107087802; Malcolm BJ, 2018, J PSYCHOACTIVE DRUGS, V50, P256, DOI 10.1080/02791072.2018.1447175; Mannelli Paolo, 2012, Curr Drug Abuse Rev, V5, P52; Matusow H, 2013, J SUBST ABUSE TREAT, V44, P473, DOI 10.1016/j.jsat.2012.10.004; Mazei-Robison MS, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a012070; McElrath K, 2018, SUBST USE MISUSE, V53, P334, DOI 10.1080/10826084.2017.1342662; Miettinen TJ, 1996, ANESTH ANALG, V82, P817, DOI 10.1097/00000539-199604000-00024; Naples JG, 2016, CLIN GERIATR MED, V32, P725, DOI 10.1016/j.cger.2016.06.006; National Institute of Diabetes and Digestive and Kidney Diseases, 2017, CLON; Noller GE, 2018, AM J DRUG ALCOHOL AB, V44, P37, DOI 10.1080/00952990.2017.1310218; Oesterle TS, 2019, MAYO CLIN PROC, V94, P2072, DOI 10.1016/j.mayocp.2019.03.029; Overbeek Daniel L, 2019, Clin Pract Cases Emerg Med, V3, P24, DOI 10.5811/cpcem.2018.11.40588; Prozialeck WC, 2012, J AM OSTEOPATH ASSOC, V112, P792; Roman PM, 2011, ADDICT BEHAV, V36, P584, DOI 10.1016/j.addbeh.2011.01.032; Rosenberg JM, 2018, PAIN MED, V19, P928, DOI 10.1093/pm/pnx203; Rosenthal RN, 2016, JAMA-J AM MED ASSOC, V316, P282, DOI 10.1001/jama.2016.9382; Rudolf G, 2018, AM J DRUG ALCOHOL AB, V44, P302, DOI 10.1080/00952990.2017.1334209; Salehi M, 2011, J CLIN PSYCHOPHARM, V31, P593, DOI 10.1097/JCP.0b013e31822bb378; Sanders NC, 2013, EXP CLIN PSYCHOPHARM, V21, P294, DOI 10.1037/a0033724; Sigmon SC, 2013, JAMA PSYCHIAT, V70, P1347, DOI 10.1001/jamapsychiatry.2013.2216; Sigmon SC, 2012, AM J DRUG ALCOHOL AB, V38, P187, DOI 10.3109/00952990.2011.653426; Stanciu CN, 2019, J PSYCHOACTIVE DRUGS, V51, P12, DOI 10.1080/02791072.2018.1562133; Taylor CP, 2007, EPILEPSY RES, V73, P137, DOI 10.1016/j.eplepsyres.2006.09.008; Terasaki D, 2019, PHARMACOTHERAPY, V39, P1023, DOI 10.1002/phar.2313; The Medical Letter, 2016, JAMA-J AM MED ASSOC, V316, P1820; Toce MS, 2018, J MED TOXICOL, V14, P306, DOI 10.1007/s13181-018-0685-1; Tofighi B, 2019, SUBST USE MISUSE, V54, P2409, DOI 10.1080/10826084.2019.1653324; U.S. Department of Health and Human Services, 2019, PAIN MAN BEST PRACT; UK Home Office, 2019, LIST MOST COMM ENC D; United States Drug Enforcement Administration, 2019, DRUG SCHED; Vazzana M, 2015, BIOMED PHARMACOTHER, V70, P234, DOI 10.1016/j.biopha.2015.01.022; Vernon MK, 2016, ADDICT BEHAV, V60, P109, DOI 10.1016/j.addbeh.2016.03.028; Volkow ND, 2016, NEW ENGL J MED, V374, P1253, DOI 10.1056/NEJMra1507771; Weiss RD, 2014, J SUBST ABUSE TREAT, V47, P140, DOI 10.1016/j.jsat.2014.03.004; Wesson DR, 2003, J PSYCHOACTIVE DRUGS, V35, P253, DOI 10.1080/02791072.2003.10400007; Winstock AR, 2009, DRUG ALCOHOL REV, V28, P686, DOI 10.1111/j.1465-3362.2009.00127.x; Woody GE, 2008, JAMA-J AM MED ASSOC, V300, P2003, DOI 10.1001/jama.2008.574; World Health Organization, 2007, SER ICD 10 INT STAT	80	27	27	2	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 20	2020	395	10241					1938	1948						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MQ2MV	32563380	Green Accepted			2023-01-03	WOS:000552732200035
J	Akamatsu, MA; Sakihara, VA; Carvalho, BP; Abrantes, AD; Takano, MAS; Adami, EA; Yonehara, FS; Carneiro, PD; Rico, S; Schanoski, A; Meros, M; Simpson, A; Phan, T; Fox, CB; Ho, PL				Akamatsu, Milena Apetito; Sakihara, Vitor Anselmo; Carvalho, Bianca Pereira; Abrantes, Aline de Paiva; Takano, Maria A. Sakauchi; Adami, Eduardo Alfredo; Yonehara, Fernando Seiji; Carneiro, Patricia dos Santos; Rico, Stefanni; Schanoski, Alessandra; Meros, Mauricio; Simpson, Adrian; Phan, Tony; Fox, Christopher B.; Ho, Paulo Lee			Preparedness against pandemic influenza: Production of an oil-in-water emulsion adjuvant in Brazil	PLOS ONE			English	Article							TECHNOLOGY-TRANSFER; VACCINE PRODUCTION; IMMUNOGENICITY; SAFETY; VIRUS; CHALLENGES; H7N9	Increasing pandemic influenza vaccine manufacturing capacity is considered strategic by WHO. Adjuvant use is key in this strategy in order to spare the vaccine doses and by increasing immune protection. We describe here the production and stability studies of a squalene based oil-in-water emulsion, adjuvant IB160, and the immune response of the H7N9 vaccine combined with IB160. To qualify the production of IB160 we produced 10 consistency lots of IB160 and the average results were: pH 6.4 +/- 0.05; squalene 48.8 +/-.0.03 mg/ml; osmolality 47.6 +/- 6.9 mmol/kg; Z-average 157 +/- 2 nm, with polydispersity index (PDI) of 0.085 +/- 0.024 and endotoxin levels <0.5 EU/mL. The emulsion particle size was stable for at least six months at 25 degrees C and 24 months at 4-8 degrees C. Two doses of H7N9 vaccine formulated at 7.5 mu g/dose or 15 mu g/dose with adjuvant IB160 showed a significant increase of hemagglutination inhibition (HAI) titers in sera of immunized BALB/c mice when compared to control sera from animals immunized with the H7N9 antigens without adjuvant. Thus the antigen-sparing capacity of IB160 can potentially increase the production of the H7N9 pandemic vaccine and represents an important achievement for preparedness against pandemic influenza and a successful North (IDRI) to South (Butantan Institute) technology transfer for the production of the adjuvant emulsion IB160.	[Akamatsu, Milena Apetito; Sakihara, Vitor Anselmo; Carvalho, Bianca Pereira; Abrantes, Aline de Paiva; Takano, Maria A. Sakauchi; Ho, Paulo Lee] Inst Butantan, Serv Bacteriol, Div BioInd, Sao Paulo, Brazil; [Adami, Eduardo Alfredo] Inst Butantan, Div BioInd, Lab Influenza, Sao Paulo, Brazil; [Yonehara, Fernando Seiji; Carneiro, Patricia dos Santos] Inst Butantan, Controle Qualidade, Sao Paulo, Brazil; [Rico, Stefanni; Schanoski, Alessandra] Inst Butantan, Lab Bacteriol, Sao Paulo, Brazil; [Meros, Mauricio] Inst Butantan, Div BioInd, Sao Paulo, Brazil; [Simpson, Adrian; Phan, Tony; Fox, Christopher B.] Infect Dis Res Inst, Seattle, WA USA	Instituto Butantan; Instituto Butantan; Instituto Butantan; Instituto Butantan; Instituto Butantan	Akamatsu, MA; Ho, PL (corresponding author), Inst Butantan, Serv Bacteriol, Div BioInd, Sao Paulo, Brazil.	milena.akarnatsu@butantan.gov.br; paulo.ho@butantan.gov.br	Akamatsu, Milena Apetito/V-8084-2017	Akamatsu, Milena Apetito/0000-0002-8193-3448	U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority - BARDA [IDSEP140022, IDSEP130015]; World Health Organization -WHO [SPHQ13LOA-316]; Brazilian agency: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo FAPESP [2015/25055-8]; Brazilian agency: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -CNPq [306992/2014-0]; Brazilian agency: Fundacao Butantan for Laboratory maintenance	U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority - BARDA; World Health Organization -WHO(World Health Organization); Brazilian agency: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); Brazilian agency: Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -CNPq(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ)); Brazilian agency: Fundacao Butantan for Laboratory maintenance	This project has been funded in whole or in part with Federal funds from the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority - BARDA (Grant no. IDSEP140022 and IDSEP130015), received by CF; an Institutional Grant to Butantan Institute from World Health Organization -WHO (grant SPHQ13LOA-316) and Brazilian agencies: Fundacao de Amparo a Pesquisa do Estado de Sao Paulo FAPESP (grant no. 2015/25055-8) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico -CNPq (grant no. 306992/2014-0) to PLH and Fundacao Butantan for Laboratory maintenance. There was no additional external funding received for this study. The content is solely the responsibility of the authors and does not necessarily represent the official views of the U.S. Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ansaldi F, 2010, VACCINE, V28, P4123, DOI 10.1016/j.vaccine.2010.04.030; Baldwin SL, 2009, VACCINE, V27, P5956, DOI 10.1016/j.vaccine.2009.07.081; Banzhoff A, 2008, INFLUENZA OTHER RESP, V2, P243, DOI 10.1111/j.1750-2659.2008.00059.x; Bart SA, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008761; De Donato S, 1999, VACCINE, V17, P3094, DOI 10.1016/S0264-410X(99)00138-3; De Franco M, 2014, PLOS NEGLECT TROP D, V8, DOI 10.1371/journal.pntd.0002862; Duan YQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099322; Fang JH, 2000, RAMACHANDRAN RADHAKR, V42, P211; Fox CB, 2013, VACCINE, V31, P1633, DOI 10.1016/j.vaccine.2012.10.048; Houser K, 2015, CELL HOST MICROBE, V17, P295, DOI 10.1016/j.chom.2015.02.012; Khurana S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000624; Leroux-Roels I, 2010, VACCINE, V28, P849, DOI 10.1016/j.vaccine.2009.10.017; Levine AC, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1671-z; Lim WS, 2017, TRIALS, V18, DOI 10.1186/s13063-017-2290-z; Lurie N, 2013, NEW ENGL J MED, V368, P1251, DOI 10.1056/NEJMsb1209510; Martin JT, 1997, BIOLOGICALS, V25, P209, DOI 10.1006/biol.1997.0086; Minutello M, 1999, VACCINE, V17, P99, DOI 10.1016/S0264-410X(98)00185-6; Miyaki C, 2011, VACCINE, V29, pA12, DOI 10.1016/j.vaccine.2011.04.127; Miyaki C, 2010, VACCINE, V28, P2505, DOI 10.1016/j.vaccine.2010.01.044; Oshitani H, 2008, EMERG INFECT DIS, V14, P875, DOI 10.3201/eid1406.070839; Ott G, 2000, METH MOLEC MED, V42, P211; Podda A, 2001, VACCINE, V19, P2673, DOI 10.1016/S0264-410X(00)00499-0; Precioso AR, 2011, VACCINE, V29, P8974, DOI 10.1016/j.vaccine.2011.09.040; Rojek AM, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0760-x; Salk JE, 1944, J IMMUNOL, V49, P87; Schultze V, 2008, VACCINE, V26, P3209, DOI 10.1016/j.vaccine.2008.03.093; Scorza FB, 2017, VACCINE, V35, P5397, DOI 10.1016/j.vaccine.2017.03.094; Stavaru C, 2016, HUM VACC IMMUNOTHER, V12, P1009, DOI 10.1080/21645515.2015.1111495; Tregoning JS, 2018, HUM VACC IMMUNOTHER, V14, P550, DOI 10.1080/21645515.2017.1415684; Tsai TF, 2011, SCAND J INFECT DIS, V43, P702, DOI 10.3109/00365548.2011.580777; Usach I, 2019, ADV THER, V36, P2986, DOI 10.1007/s12325-019-01101-6; Ventura R, 2013, VACCINE, V31, P1641, DOI 10.1016/j.vaccine.2012.07.074; Whitehead J, 2016, CLIN TRIALS, V13, P31, DOI 10.1177/1740774515617740; Wong SS, 2015, J INFECT DIS, V212, P542, DOI 10.1093/infdis/jiv099; World Health Organization, 2009, WHO PANDEMIC INFLUEN; World Health Organization (WHO), 2005, WHO TECHN REP SER, V927, P99; World Health Organization (WHO), 1959, STUD GROUP REQ BIOL; World Health Organization (WHO), 2013, SER DET AV INF A H7N; World Health Organization (WHO), 2015, 8 M INT PARTN PROSP; Wu XX, 2018, CELL PHYSIOL BIOCHEM, V46, P633, DOI 10.1159/000488631; Zheng D, 2019, HUM VACC IMMUNOTHER, V15, P80, DOI 10.1080/21645515.2018.1515454	42	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2020	15	6							e0233632	10.1371/journal.pone.0233632	http://dx.doi.org/10.1371/journal.pone.0233632			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LW6ZP	32492039	Green Published, gold			2023-01-03	WOS:000539293000018
J	Poudel, S; Ghimire, PR; Upadhaya, N; Rawal, L				Poudel, Samikshya; Ghimire, Pramesh Raj; Upadhaya, Nawaraj; Rawal, Lal			Factors associated with stillbirth in selected countries of South Asia: A systematic review of observational studies	PLOS ONE			English	Review							MIDDLE-INCOME COUNTRIES; RISK-FACTORS; PREGNANCY	Background Despite having the high rate of stillbirth in most of the countries of South Asia, there is a lack of synthesized evidence based on factors associated with stillbirth. This study systematically synthesizes the evidence on factors associated with stillbirth in the four selected countries of South Asia. Methods This review was conducted using Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Studies that examined factors associated with stillbirth in South Asia were searched using five major electronic search databases including MEDLINE, CINAHL, Embase, PsycINFO, and Scopus, published between January 2000 and December 2019. In the meta-analysis, significant heterogeneity was detected among studies (I-2>50%), and hence a random effect model was used. Results A total of 20 studies met the inclusion criteria. The pooled rate of stillbirth from the studies in Bangladesh, India, Nepal, and Pakistan was 25.15 per 1000 births. Pregnancy complications, maternal health conditions, fetal complications, lack of antenatal care, and lower Socio Economic Status (SES) were the most common factors associated with stillbirth in countries of South Asia. Conclusion This study confirmed that stillbirth in selected countries of South Asia remains high. To reduce stillbirth, a greater focus needs to be on timely management of preterm labor, maternal hypertension, and provision of financial support for quality antenatal and delivery care. The interventions should be targeted for women living in remote areas, who are less educated and those with low SES.	[Poudel, Samikshya; Ghimire, Pramesh Raj] Ratnanagar Municipal, Ujyalo Nepal, Chitwan, Nepal; [Upadhaya, Nawaraj] HealthWorks, Dept Res & Dev, Amsterdam, Netherlands; [Rawal, Lal] CQUniversity, Sch Hlth Med & Appl Sci, Sydney, NSW, Australia; [Rawal, Lal] Western Sydney Univ, Translat Hlth Res Inst THRI, Sydney, NSW, Australia	Central Queensland University; Western Sydney University	Poudel, S (corresponding author), Ratnanagar Municipal, Ujyalo Nepal, Chitwan, Nepal.	tj_sami@hotmail.com		Poudel, Samikshya/0000-0003-0850-9728; Ghimire, Pramesh/0000-0002-7902-7294				Ahmed S, 2016, LANCET GLOB HEALTH, V4, pE80, DOI 10.1016/S2214-109X(15)00290-9; Akombi BJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202603; Aminu M, 2014, BJOG-INT J OBSTET GY, V121, P141, DOI 10.1111/1471-0528.12995; Anggondowati T, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1280-1; [Anonymous], 2016, NAT METHODS, V13, P103, DOI 10.1038/nmeth.3762; [Anonymous], 2017, J PEDIAT REHAB MED, V10, ps1; [Anonymous], 2017, AM J TRANSPLANT, V17, P1, DOI DOI 10.1093/jisesa/iew097; Ashish KC, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0567-3; Association of Paediatric Anaesthetists of Great Britain and Ireland, 2012, PAEDIAT ANAESTH S1, V22, pS1; Bellad MB, 2012, J PERINATOL, V32, P431, DOI 10.1038/jp.2011.115; Bhutta ZA, 2017, PLOS MED, V14, DOI 10.1371/journal.pmed.1002364; Bhutto ZA, 2011, LANCET, V377, P1523, DOI 10.1016/S0140-6736(10)62269-6; Blencowe H, 2016, LANCET GLOB HEALTH, V4, pE98, DOI 10.1016/S2214-109X(15)00275-2; Christou A, 2017, TROP MED INT HEALTH, V22, P294, DOI 10.1111/tmi.12828; Dahiru T, 2016, OPEN ACCESS LIB J, V3, pe2747; Desai G, 2017, J HEALTH POPUL NUTR, V36, DOI 10.1186/s41043-017-0079-z; Flenady V, 2011, LANCET, V377, P1331, DOI 10.1016/S0140-6736(10)62233-7; Froen JF, 2016, LANCET, V387, P574, DOI 10.1016/S0140-6736(15)00818-1; Ghimire PR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181332; Heazell AEP, 2016, LANCET, V387, P604, DOI 10.1016/S0140-6736(15)00836-3; Giang HTN, 2019, ACTA PAEDIATR, V108, P630, DOI 10.1111/apa.14534; Hossain MS, 2018, DRUG ALCOHOL REV, V37, P414, DOI 10.1111/dar.12566; Hossain Nazli, 2009, JPMA Journal of the Pakistan Medical Association, V59, P744; Jehan I, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.07.012; Khan MN, 2017, ARCH PUBLIC HEALTH, V75, DOI 10.1186/s13690-017-0181-0; Khanam R, 2017, BMC PREGNANCY CHILDB, V17, DOI 10.1186/s12884-017-1264-1; Lakshmi PVM, 2013, ENVIRON RES, V121, P17, DOI 10.1016/j.envres.2012.12.004; Lawn Joy E, 2016, Lancet, V387, P587, DOI 10.1016/S0140-6736(15)00837-5; Lone FW, 2004, TROP MED INT HEALTH, V9, P486, DOI 10.1111/j.1365-3156.2004.01222.x; Mason E, 2014, LANCET, V384, P455, DOI 10.1016/S0140-6736(14)60750-9; Ministry of Health-MOH/Nepal New ERA/Nepal ICF., 2017, NEP DEM HLTH SURV 20; Moher D, 2015, SYST REV-LONDON, V4, DOI [10.1186/2046-4053-4-1, 10.1186/s13643-015-0087-2]; Nahar S, 2013, PAEDIATR PERINAT EP, V27, P158, DOI 10.1111/ppe.12026; National Institute of Population Research and Training (NIPORT) Mitra and Associates and ICF International, 2016, BANGL DEM HLTH SURV; National Institute of Population Studies (NIPS) [Pakistan] and ICF,, 2019, PAK DEM HLTH SURV 20; Neogi SB, 2018, BMC PREGNANCY CHILDB, V18, DOI 10.1186/s12884-018-1660-1; Neogi SB, 2016, PAEDIATR PERINAT EP, V30, P56, DOI 10.1111/ppe.12246; NFHS, 2015, NATL FAMILY HLTH SUR; Nisha MK, 2018, INT J OCCUP ENV HEAL, V24, P47, DOI 10.1080/10773525.2018.1507868; Owais A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080164; Pattinson R, 2011, LANCET, V377, P1610, DOI 10.1016/S0140-6736(10)62306-9; Samman E., 2018, SDG PROGR FRAGILITY; Shabbir S, 2014, PAK J MED HEALTH SCI, V8, P709; ten Hoope-Bender P, 2016, LANCET, V387, pE14, DOI 10.1016/S0140-6736(15)01277-5; WHO, 2014, EV NEWB ACT PLAN END; World Health Organization, 2017, GLOBAL STRATEGY WOME; Xiong T, 2018, B WORLD HEALTH ORGAN, V96, P531, DOI 10.2471/BLT.18.208447	47	4	4	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 16	2020	15	9							e0238938	10.1371/journal.pone.0238938	http://dx.doi.org/10.1371/journal.pone.0238938			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU5BZ	32936823	Green Published, gold			2023-01-03	WOS:000573658000008
J	Azam, AA; Ismail, IS; Kumari, Y; Shaikh, MF; Abas, F; Shaari, K				Azam, Amalina Ahmad; Ismail, Intan Safinar; Kumari, Yatinesh; Shaikh, Mohd Farooq; Abas, Faridah; Shaari, Khozirah			The anti-neuroinflammatory effects of Clinacanthus nutans leaf extract on metabolism elucidated through H-1 NMR in correlation with cytokines microarray	PLOS ONE			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; BRAIN; LIPOPOLYSACCHARIDE; METABOLOMICS; PURIFICATION; SPECTROSCOPY; INFLAMMATION; SECRETION; HYPOXIA; SHOCK	Clinacanthus nutans(CN) (Acanthaceae) is well-known for its anti-inflammatory properties among Asian communities; however, there are currently no data specifically focused on the anti-inflammatory effects of CN on the brain tissue. Neuroinflammation is a common consequence of toxin intrusion to any part of the central nervous system (CNS). As an innate immune response, the CNS may react through both protective and/or toxic actions due to the activation of neuron cells producing pro- and/or anti-inflammatory cytokines in the brain. The unresolved activation of the inflammatory cytokines' response is associated with the pathogenesis of neurological disorders. The present study aimed to decipher the metabolic mechanism on the effects of 14 days oral treatment with CN aqueous extract in induced-lipopolysaccharides (LPS) rats through(1)H NMR spectroscopic biomarker profiling of the brain tissue and the related cytokines. Based on the principal component analysis (PCA) of the nuclear magnetic resonance (NMR) spectral data, twenty-one metabolites in the brain tissue were profiled as biomarkers for the LPS (10 mu L)-induced neuroinflammation following intracerebroventricular injection. Among the twenty-one biomarkers in the neuroinflammed rats, CN treatment of 1000 and 500 mg/kg BW successfully altered lactate, pyruvate, phosphorylcholine, glutamine, and alpha-ketoglutarate when compared to the negative control. Likewise, statistical isolinear multiple component analysis (SIMCA) showed that treatments by CN and the positive control drug, dextromethorphan (DXM, 5 mg/kg BW), have anti-neuroinflammatory potential. A moderate correlation, in the orthogonal partial least squares (OPLS) regression model, was found between the spectral metabolite profile and the cytokine levels. The current study revealed the existence of high levels of pro-inflammatory cytokines, namely IL-1 alpha, IL-1 beta, and TNF-alpha in LPS-induced rats. Both CN dose treatments lowered IL-1 beta significantly better than DXM Interestingly, DXM and CN treatments both exhibited the upregulation of the anti-inflammatory cytokines IL-2 and 4. However, DXM has an advantage over CN in that the former also increased the expression of IL-10 of anti-inflammatory cytokines. In this study, a metabolomics approach was successfully applied to discover the mechanistic role of CN in controlling the neuroinflammatory conditions through the modulation of complex metabolite interactions in the rat brain.	[Azam, Amalina Ahmad; Ismail, Intan Safinar; Abas, Faridah; Shaari, Khozirah] Univ Putra Malaysia, Inst Biosci, Lab Nat Prod, Serdang, Selangor, Malaysia; [Kumari, Yatinesh; Shaikh, Mohd Farooq] Monash Univ Malaysia, Sch Med & Hlth Sci, Neuropharmacol Res Lab, Subang Jaya, Selangor, Malaysia	Universiti Putra Malaysia; Monash University; Monash University Sunway	Ismail, IS (corresponding author), Univ Putra Malaysia, Inst Biosci, Lab Nat Prod, Serdang, Selangor, Malaysia.	safinar@upm.edu.my	Kumari, Yatinesh/F-9755-2018; Shaikh, Mohd. Farooq/H-6029-2019; Ahmad Azam, Amalina/GRY-3276-2022; Ahmad Azam, Amalina/AFV-1323-2022	Kumari, Yatinesh/0000-0001-6544-1243; Shaikh, Mohd. Farooq/0000-0001-9865-6224; Ahmad Azam, Amalina/0000-0002-3911-7666; Safinar Ismail, Intan/0000-0003-3960-0022	Ministry of Agriculture and Agrobased Industry, Malaysia, under NKEA Research Grant scheme (NRGS) [NH1014D070]	Ministry of Agriculture and Agrobased Industry, Malaysia, under NKEA Research Grant scheme (NRGS)	ISI. Ministry of Agriculture and Agrobased Industry, Malaysia, under NKEA Research Grant scheme (NRGS: project No. NH1014D070).	[Anonymous], 2014, AB IMPERIO, V3, P22; Antharavally BS, 2009, ANAL BIOCHEM, V385, P342, DOI 10.1016/j.ab.2008.11.024; Azam AA, 2020, REC NAT PROD, V14, P231, DOI 10.25135/rnp.159.19.08.1384; Azam AA, 2019, AVICENNA J PHYTOMEDI, V9, P164; Bain L, 2018, P WORKSH, P6, DOI [10.17226/24854, DOI 10.17226/24854]; Bayer AL, 2005, J EXP MED, V201, P769, DOI 10.1084/jem.20041179; Beckonert O, 2007, NAT PROTOC, V2, P2692, DOI 10.1038/nprot.2007.376; Belanger M, 2011, CELL METAB, V14, P724, DOI 10.1016/j.cmet.2011.08.016; Benaki D, 2018, METHODS MOL BIOL, V1738, P117, DOI 10.1007/978-1-4939-7643-0_8; BEUTLER B, 1988, ADV IMMUNOL, V42, P213, DOI 10.1016/S0065-2776(08)60846-9; Carpenter J. F., 2002, CURR PROTOC PROTEIN, DOI [10.1002/0471140864.ps0406s27, DOI 10.1002/0471140864]; Cartmell T, 2003, J PHYSIOL-LONDON, V549, P653, DOI 10.1113/jphysiol.2002.037291; Cavaillon JM, 2001, CELL MOL BIOL, V47, P695; Chang Y, 2015, MOL IMMUNOL, V64, P90, DOI 10.1016/j.molimm.2014.11.002; Chung K.F., 2001, EUR RESPIR J, V34, P50, DOI DOI 10.1183/09031936.01.00229701; Conti B, 2004, FRONT BIOSCI-LANDMRK, V9, P1433, DOI 10.2741/1341; Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027; Devi LA, 2000, TRENDS PHARMACOL SCI, V21, P324, DOI 10.1016/S0165-6147(00)01519-4; DINARELLO CA, 1991, J INFECT DIS, V163, P1177, DOI 10.1093/infdis/163.6.1177; El-Ansary A, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0189-0; Eriksson L., 2013, MULTI MEGAVARIATE DA, V1; Eriksson L., 2006, MULTI MEGAVARIATE DA, DOI DOI 10.1016/j.arabjc.2013.10.006; Ferrero-Miliani L, 2007, CLIN EXP IMMUNOL, V147, P227, DOI 10.1111/j.1365-2249.2006.03261.x; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frede S, 2006, BIOCHEM J, V396, P517, DOI 10.1042/BJ20051839; Galic MA, 2012, FRONT NEUROENDOCRIN, V33, P116, DOI 10.1016/j.yfrne.2011.12.002; Glascock JJ, 2011, JOVE-J VIS EXP, DOI 10.3791/2968; Hasin Y, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-017-1215-1; Hou YL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/212910; Johnson CH, 2016, NAT REV MOL CELL BIO, V17, P451, DOI 10.1038/nrm.2016.25; Kamburov A, 2011, BIOINFORMATICS, V27, P2917, DOI 10.1093/bioinformatics/btr499; Karhausen J, 2005, CELL CYCLE, V4, P256; Kelly RS, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197049; Khoo LW, 2019, PHYTOCHEM ANALYSIS, V30, P46, DOI 10.1002/pca.2789; Khoo LW, 2015, PHYTOCHEM LETT, V14, P123, DOI 10.1016/j.phytol.2015.09.015; Li X, 2005, BIOCHEM BIOPH RES CO, V335, P1026, DOI 10.1016/j.bbrc.2005.07.175; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954; O'Shea JJ, 2002, NAT REV IMMUNOL, V2, P37, DOI 10.1038/nri702; O'Shea JJ, 2011, J IMMUNOL, V187, P5475, DOI 10.4049/jimmunol.1102913; Paban V, 2017, GENE, V600, P90, DOI 10.1016/j.gene.2016.11.022; Petroff OAC, 2002, NEUROSCIENTIST, V8, P562, DOI 10.1177/1073858402238515; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Ramesh G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/480739; Ronald Zielke H, 2009, J NEUROCHEM, V109, P24, DOI 10.1111/j.1471-4159.2009.05941.x; Saric J, 2010, J PROTEOME RES, V9, P2255, DOI 10.1021/pr901019z; Sastra Kusuma Wijaya V. S., 2015, 2015 4 INT C INSTR C, V4, P42; Serrats J, 2010, NEURON, V65, P94, DOI 10.1016/j.neuron.2009.11.032; Shah K, 2012, INT J MOL SCI, V13, P12629, DOI 10.3390/ijms131012629; Shanaiah Narasimhamurthy, 2008, P341, DOI 10.1007/978-1-59745-463-6_16; Silva C, 2019, METABOLITES, V9, DOI 10.3390/metabo9050102; Snapper C.M., 1992, IMMUNOL TODAY, V13, P466, DOI [10.1016/0167-5699(92)90082-I, DOI 10.1016/0167-5699(92)90082-I]; Sochocka M, 2017, MOL NEUROBIOL, V54, P8071, DOI 10.1007/s12035-016-0297-1; Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295; Tohidpour A, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00276; Tyrtyshnaia AA, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0747-8; Vargas-Caraveo A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13302-6; Verma A, 2016, BBA CLIN, V5, P170, DOI 10.1016/j.bbacli.2016.04.002; WALZ A, 1987, BIOCHEM BIOPH RES CO, V149, P755, DOI 10.1016/0006-291X(87)90432-3; Wishart DS, 2016, NAT REV DRUG DISCOV, V15, P473, DOI 10.1038/nrd.2016.32; Zhang M, 2015, INT J CLIN EXP PATHO, V8, P3491	62	4	4	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2020	15	9							e0238503	10.1371/journal.pone.0238503	http://dx.doi.org/10.1371/journal.pone.0238503			26	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NS5RK	32925968	gold, Green Published			2023-01-03	WOS:000572318000052
J	Olajubu, AO; Fajemilehin, BR; Olajubu, TO; Afolabi, BS				Olajubu, Aanuoluwapo Omobolanle; Fajemilehin, Boluwaji Reuben; Olajubu, Temitope Oluwafemi; Afolabi, Babajide Samuel			Effectiveness of a mobile health intervention on uptake of recommended postnatal care services in Nigeria	PLOS ONE			English	Article							MESSAGE	Studies have linked the large percentage of maternal and neonatal mortality that occur in postnatal period to low uptake of postnatal care (PNC) services. Mobile health (mHealth) intervention through message reminders has resulted in significant increase in antenatal care utilisation in previous studies. However, its use in PNC services' uptake has not been adequately investigated in Nigeria. This study aimed to evaluate the effect of a mobile health intervention on PNC attendance among mothers in selected primary healthcare facilities in Osun State, Nigeria. A quasi-experimental research design was utilised. Participants were allocated to Intervention Group and Control Group. One hundred and ninety pregnant mothers were recruited in each group. A mobile health intervention software was developed and used to send educational and reminder messages to mothers in the intervention group from the 35th week of pregnancy to six weeks after delivery. Uptake of PNC services was assessed at birth, 3 days, 10 days and 42 days after delivery. Data were analysed using descriptive statistics, chi-square and logistic regression models. About one-third (30.9%) of respondents in the intervention group had four postnatal care visits while only 3.7% in the control group had four visits (p < 0.001). After controlling for the effect of confounding variables, group membership remained a significant predictor of PNC uptake. (AOR: 10.869, 95% CI: 4.479-26.374). Mobile health intervention significantly improved utilisation of the recommended four postnatal care visits.	[Olajubu, Aanuoluwapo Omobolanle; Fajemilehin, Boluwaji Reuben] Obafemi Awolowo Univ, Coll Hlth Sci, Dept Nursing Sci, Ife, Nigeria; [Olajubu, Temitope Oluwafemi] Obafemi Awolowo Univ, Dept Family Med, Teaching Hosp Complex, Ife, Nigeria; [Afolabi, Babajide Samuel] Obafemi Awolowo Univ, Dept Comp Sci, Ife, Nigeria	Obafemi Awolowo University; Obafemi Awolowo University; Obafemi Awolowo University	Olajubu, AO (corresponding author), Obafemi Awolowo Univ, Coll Hlth Sci, Dept Nursing Sci, Ife, Nigeria.	bolajuba@gmail.com	Afolabi, Babajide/AHD-3150-2022	Afolabi, Babajide/0000-0003-1843-3181; Olajubu, Temitope/0000-0003-1781-0723	CARTA; Consortium for Advanced Research Training in Africa (CARTA); Carnegie Corporation of New York [B 8606.R02]; Sida [54100029]; DELTAS Africa Initiative [107768/Z/15/Z]; African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Welcome Trust (UK) [107768/Z/15/Z]; UK government	CARTA; Consortium for Advanced Research Training in Africa (CARTA); Carnegie Corporation of New York; Sida; DELTAS Africa Initiative; African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA); New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency); Welcome Trust (UK)(Wellcome Trust); UK government	AO received grant from CARTA. This research was supported by the Consortium for Advanced Research Training in Africa (CARTA). CARTA is jointly led by the African Population and Health Research Center and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No-B 8606.R02), Sida (Grant No:54100029), the DELTAS Africa Initiative (Grant No: 107768/Z/15/Z). The DELTAS Africa Initiative is an independent funding scheme of the African Academy of Sciences (AAS)'s Alliance for Accelerating Excellence in Science in Africa (AESA) and supported by the New Partnership for Africa's Development Planning and Coordinating Agency (NEPAD Agency) with funding from the Welcome Trust (UK) (Grant No: 107768/Z/15/Z) and the UK government."The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adanikin AI, 2014, INT J GYNECOL OBSTET, V126, P179, DOI 10.1016/j.ijgo.2014.02.009; [Anonymous], 2014, LANCET INFECT DIS, V14, P1, DOI 10.1016/S1473-3099(13)70368-2; [Anonymous], 2018, THE GUARDIAN; [Anonymous], 2013, 2300822013 ISOIEC, V1, P20; Babalola S, 2009, BMC PREGNANCY CHILDB, V9, DOI 10.1186/1471-2393-9-43; Blencowe H, 2016, LANCET GLOB HEALTH, V4, pE98, DOI 10.1016/S2214-109X(15)00275-2; Crawford J, 2014, GLOB HEALTH-SCI PRAC, V2, P35, DOI 10.9745/GHSP-D-13-00155; da Costa TM, 2010, INT J MED INFORM, V79, P65, DOI 10.1016/j.ijmedinf.2009.09.001; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Dhakal Sulochana, 2007, BMC Pregnancy Childbirth, V7, P19, DOI 10.1186/1471-2393-7-19; Eshiet I, 2019, HUMAN RIGHTS PUBLIC, P247; Fedha T, 2014, OPEN J PREV MED, P2014; Free C, 2013, PLOS MED, V10, DOI [10.1371/journal.pmed.1001363, 10.1371/journal.pmed.1001362]; Galbraith S, 2010, STUDY CLUSTERED DATA; Guy R, 2012, HEALTH SERV RES, V47, P614, DOI 10.1111/j.1475-6773.2011.01342.x; Islam M, 2007, B WORLD HEALTH ORGAN, V85, P735, DOI 10.2471/BLT.07.045963; Izugbara C, 2016, MAT HLTH NIGERIA SIT; Kante AM, 2015, BMC PREGNANCY CHILDB, V15, DOI 10.1186/s12884-015-0769-8; Kay M., 2011, WORLD HEAL ORGAN, V64, P66; Lund S, 2014, BMC PREGNANCY CHILDB, V14, DOI 10.1186/1471-2393-14-29; MAMA, 2013, MAMA MOBILE ALLIANCE; Manoj PDS, 2015, IEEE T COMPUT, V64, P3022, DOI 10.1109/TC.2015.2389827; Mekonnen A, 2003, J HEAL POPUL NUTR, V14, P32; National Population Commission, 2014, NIG DEM HLTH SURV ND, P127; Navaneetham K, 2002, SOC SCI MED, V55, P1849, DOI 10.1016/S0277-9536(01)00313-6; Oyeyemi SO, 2014, REPROD HEALTH, V11, DOI 10.1186/1742-4755-11-8; Ronsmans C, 2006, LANCET, V368, P1189, DOI 10.1016/S0140-6736(06)69380-X; Sines E., 2007, POSTNATAL CARE CRITI; Somefun DO, 2014, DETERMINANTS POSTNAT; Takai IU., 2015, SAHEL MED J, V18, P109, DOI DOI 10.4103/1118-8561.169282; Tesfahun F, 2014, MATERN CHILD HLTH J, V18, P2341, DOI 10.1007/s10995-014-1474-3; Titaley CR, 2009, J EPIDEMIOL COMMUN H, V63, P827, DOI 10.1136/jech.2008.081604; Titaley CR, 2010, BMC PREGNANCY CHILDB, V10, DOI 10.1186/1471-2393-10-61; Tsawe M, 2015, INT J EQUITY HEALTH, V14, DOI 10.1186/s12939-015-0162-2; Ugboaja Joseph O, 2013, Niger Med J, V54, P45, DOI 10.4103/0300-1652.108895; Warren C, 2010, INT J QUAL HEALTH C, V22, P24, DOI 10.1093/intqhc/mzp050; WHO (World Health Organization), 2015, TRENDS MATERNAL MORT; Wilmoth JR., 2012, STAT POLITICS POLICY, V3, DOI 10.1515/2151-7509.1038; World Health Organization, 2016, MAT MORT RAT PER 100; World Health Organization, 2014, WHO REC POSTN CAR MO	40	7	7	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 14	2020	15	9							e0238911	10.1371/journal.pone.0238911	http://dx.doi.org/10.1371/journal.pone.0238911			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NS5RK	32925971	gold, Green Published			2023-01-03	WOS:000572318000006
J	Deffland, M; Spies, C; Weiss, B; Keller, N; Jenny, M; Kruppa, J; Balzer, F				Deffland, Marc; Spies, Claudia; Weiss, Bjoern; Keller, Niklas; Jenny, Mirjam; Kruppa, Jochen; Balzer, Felix			Effects of pain, sedation and delirium monitoring on clinical and economic outcome: A retrospective study	PLOS ONE			English	Article							INTENSIVE-CARE-UNIT; PRACTICE GUIDELINES; AGITATION; MANAGEMENT; ICU; IMPLEMENTATION; MORTALITY; INDICATORS; PREDICTOR; PROTOCOL	Background Significant improvements in clinical outcome can be achieved by implementing effective strategies to optimise pain management, reduce sedative exposure, and prevent and treat delirium in ICU patients. One important strategy is the monitoring of pain, agitation and delirium (PAD bundle). We hypothesised that there is no sufficient financial benefit to implement a monitoring strategy in a Diagnosis Related Group (DRG)-based reimbursement system, therefore we expected better clinical and decreased economic outcome for monitored patients. Methods This is a retrospective observational study using routinely collected data. We used univariate and multiple linear analysis, machine-learning analysis and a novel correlation statistic (maximal information coefficient) to explore the association between monitoring adherence and resulting clinical and economic outcome. For univariate analysis we split patients in an adherence achieved and an adherence non-achieved group. Results In total 1,323 adult patients from two campuses of a German tertiary medical centre, who spent at least one day in the ICU between admission and discharge between 1. January 2016 and 31. December 2016. Adherence to PAD monitoring was associated with shorter hospital LoS (e.g. pain monitoring 13 vs. 10 days; p<0.001), ICU LoS, duration of mechanical ventilation shown by univariate analysis. Despite the improved clinical outcome, adherence to PAD elements was associated with a decreased case mix per day and profit per day shown by univariate analysis. Multiple linear analysis did not confirm these results. PAD monitoring is important for clinical as well as economic outcome and predicted case mix better than severity of illness shown by machine learning analysis. Conclusion Adherence to PAD bundles is also important for clinical as well as economic outcome. It is associated with improved clinical and worse economic outcome in comparison to non-adherence in univariate analysis but not confirmed by multiple linear analysis.	[Deffland, Marc; Spies, Claudia; Weiss, Bjoern; Keller, Niklas; Balzer, Felix] Charite Univ Med Berlin, Dept Anaesthesiol & Intens Care Med CCM, CVK, Berlin, Germany; [Deffland, Marc; Spies, Claudia; Weiss, Bjoern; Keller, Niklas; Kruppa, Jochen; Balzer, Felix] Free Univ Berlin, Berlin, Germany; [Deffland, Marc; Spies, Claudia; Weiss, Bjoern; Keller, Niklas; Kruppa, Jochen; Balzer, Felix] Humboldt Univ, Berlin, Germany; [Deffland, Marc; Spies, Claudia; Weiss, Bjoern; Keller, Niklas; Kruppa, Jochen; Balzer, Felix] Berlin Inst Hlth, Berlin, Germany; [Jenny, Mirjam] Robert Koch Inst, Sci Commun Unit, Berlin, Germany; [Jenny, Mirjam] Univ Potsdam, Fac Hlth Sci Brandenburg, Harding Ctr Risk Literacy, Potsdam, Germany; [Jenny, Mirjam] Max Planck Inst Human Dev, Ctr Adapt Rat, Berlin, Germany; [Kruppa, Jochen] Charite Univ Med Berlin, Inst Biometry & Clin Epidemiol, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Robert Koch Institute; University of Potsdam; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Spies, C (corresponding author), Charite Univ Med Berlin, Dept Anaesthesiol & Intens Care Med CCM, CVK, Berlin, Germany.; Spies, C (corresponding author), Free Univ Berlin, Berlin, Germany.; Spies, C (corresponding author), Humboldt Univ, Berlin, Germany.; Spies, C (corresponding author), Berlin Inst Hlth, Berlin, Germany.	claudia.spies@charite.de		Balzer, Felix/0000-0003-1575-2056; Kruppa, Jochen/0000-0001-8376-8864; Weiss, Bjorn/0000-0003-3139-595X	European Union [602461]	European Union(European Commission)	The research leading to these results has received funding from the European Union Seventh Framework Program [FP7/2007-2013] under grant agreement no 602461. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There was no additional external funding received for this study.	Ahlers SJ, 2008, CRIT CARE, V12, DOI 10.1186/cc6789; [Anonymous], 2017, CLIN GENITOURIN CANC; Balas MC, 2013, CRIT CARE MED, V41, pS116, DOI 10.1097/CCM.0b013e3182a17064; Balzer F, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0929-2; Carrothers KM, 2013, CRIT CARE MED, V41, pS128, DOI 10.1097/CCM.0b013e3182a2c2b1; Chanques G, 2006, CRIT CARE MED, V34, P1691, DOI 10.1097/01.CCM.0000218416.62457.56; CRIPPEN DW, 1990, CRIT CARE CLIN, V6, P369; Dale Christopher R, 2014, Ann Am Thorac Soc, V11, P367, DOI 10.1513/AnnalsATS.201306-210OC; Devlin JW, 2018, CRIT CARE MED, V46, P1532, DOI [10.1097/CCM.0000000000003299, 10.1097/CCM.0000000000003259]; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Kastrup M, 2009, J INT MED RES, V37, P1267, DOI 10.1177/147323000903700502; Klauber M, 2017, KRANKENHAUS REPORT 2; Kursa MB, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i11; Luetz A, 2016, J CRIT CARE, V35, P168, DOI 10.1016/j.jcrc.2016.05.028; Luetz A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110935; Mansouri P, 2013, J CRIT CARE, V28, P918, DOI 10.1016/j.jcrc.2013.06.019; Martin MC, 2008, MED INTENSIVA, V32, P23, DOI 10.1016/S0210-5691(08)70899-4; Mehta S, 2018, INTENS CARE MED, V44, P1141, DOI 10.1007/s00134-017-4992-9; Nachtigall I, 2009, CRIT CARE MED, V37, P159, DOI 10.1097/CCM.0b013e3181934f1b; Novaes MAFP, 1997, INTENS CARE MED, V23, P1282, DOI 10.1007/s001340050500; Payen JF, 2001, CRIT CARE MED, V29, P2258, DOI 10.1097/00003246-200112000-00004; Pun BT, 2019, CRIT CARE MED, V47, P3, DOI 10.1097/CCM.0000000000003482; Radtke FM, 2012, INTENS CARE MED, V38, P1974, DOI 10.1007/s00134-012-2658-1; Reshef DN, 2011, SCIENCE, V334, P1518, DOI 10.1126/science.1205438; Rundshagen I, 2013, ANAESTHESIST, V62, P914, DOI 10.1007/s00101-013-2232-4; Saller T, 2016, ANAESTHESIST, V65, P755, DOI 10.1007/s00101-016-0218-8; Sessler CN, 2002, AM J RESP CRIT CARE, V166, P1338, DOI 10.1164/rccm.2107138; Slooter AJC, 2017, HAND CLINIC, V141, P449, DOI 10.1016/B978-0-444-63599-0.00025-9; Tanaka LMS, 2014, CRIT CARE, V18, DOI 10.1186/cc13995; Svenningsen H, 2013, ACTA ANAESTH SCAND, V57, P288, DOI 10.1111/aas.12048; Trupkovic Tomislav, 2011, J Intensive Care Med, V26, P397, DOI 10.1177/0885066610393442; Tsuruta R, 2018, ACUTE MED SURG, V5, P207, DOI 10.1002/ams2.337; Vasilevskis EE, 2009, CHEST, V136, P89, DOI 10.1378/chest.08-2591; Vincent JL, 2016, INTENS CARE MED, V42, P962, DOI 10.1007/s00134-016-4297-4; Wang J, 2017, CHINESE MED J-PEKING, V130, P1182, DOI 10.4103/0366-6999.205852; Wright MN, 2017, J STAT SOFTW, V77, P1, DOI 10.18637/jss.v077.i01; Xi XY, 2019, J MED ECON, V22, P35, DOI 10.1080/13696998.2018.1539399; Zoremba N, 2018, ANAESTHESIST, V67, P811, DOI 10.1007/s00101-018-0497-3	39	3	3	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 2	2020	15	9							e0234801	10.1371/journal.pone.0234801	http://dx.doi.org/10.1371/journal.pone.0234801			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NN6DP	32877411	Green Published, gold			2023-01-03	WOS:000568877100022
J	Di Martino, E; Provenzani, A; Polidori, P				Di Martino, Enrica; Provenzani, Alessio; Polidori, Piera			Evidence-based application of explicit criteria to assess the appropriateness of geriatric prescriptions at admission and hospital stay	PLOS ONE			English	Article							PROTON PUMP INHIBITORS; ANTIINFLAMMATORY DRUG-USE; MEDICATIONS; PATIENT; HEALTH; RISK	Background Inappropriate prescribing in the elderly is a critical issue in primary care, causing a higher risk of Adverse Drug Reactions (ADRs) and resulting in major patient safety concerns. At international level, many tools have been developed to identify Potentially Inappropriate Medications (PIMs). Objective The aim of this study was the application of Beers, Screening Tool of Older People's Prescriptions (STOPP)/Screening Tool to Alert to Right Treatment (START) and Improving Prescribing in the Elderly Tool (IPET) criteria as key tool to improve the quality of prescribing. Methods A retrospective study was conducted using the aforementioned criteria. Two different cohorts of elderly patients were enrolled between January 2015 and December 2016, 1800 at admission and 1466 at hospital stay. The index of each criterion divided by politherapy were correlated with comorbidities (Pearson correlation). A comparison was made between admission and hospital stay through a Student'sttest of the average of the index. Results The Proton Pump Inhibitors (PPIs) were the most prescribed PIMs according Beers criteria in both patient cohorts (56%). The most detected drug-drug and drug-disease interactions at admission and at hospital stay were 3 or more drugs active on the Central Nervous System (CNS) as they can predispose to fall-risk. The most detected PIMs with STOPP criteria at admission were PPIs administered for more than 8 weeks. Inhaled beta 2-agonists or antimuscarinics were the most prescribed Potential Prescription Omissions (PPOs) according to START criteria. Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in patients with high blood pressure were the most detected PIMs according to IPET criteria during hospital stay. A significant correlation between the comorbidities and the all index at hospital stay, while at admission there was no significant correlation for Beers and IPET index. Conclusion The prescriptive criteria were a useful tool for assessing the quality of prescriptions in the geriatric population and identifying their critical issues.	[Di Martino, Enrica; Provenzani, Alessio; Polidori, Piera] Mediterranean Inst Transplantat & Adv Specialized, Clin Pharm Serv, Palermo, Italy	IRCCS Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (ISMETT)	Di Martino, E (corresponding author), Mediterranean Inst Transplantat & Adv Specialized, Clin Pharm Serv, Palermo, Italy.	enrica.dimarti@gmail.com			Italian Medicines Agency	Italian Medicines Agency	This article was created as part of a project that provided funding from the active pharmacovigilance funds 2010-2011 of the Italian Medicines Agency. The author Enrica Di Martino received a specific funding for this work.	[Anonymous], 2018, AUS NZ J OBST GYNAEC, V58, pE14; [Anonymous], 2019, WORKSH REP 2019, pviii; [Anonymous], 2012, DIABETES CARE S1, V35, pS12; [Anonymous], 2018, ESC GUIDELINES DIAGN, P1913; [Anonymous], 2015, WHO TECH REP SER; Brase C, 2018, CENGAGE LEARNING; Cazzola M, 2010, PULM PHARMACOL THER, V23, P257, DOI 10.1016/j.pupt.2010.03.003; Cohen J., 2013, STAT POWER ANAL BEHA; Cusack Barry J, 2004, Am J Geriatr Pharmacother, V2, P274, DOI 10.1016/j.amjopharm.2004.12.005; Daliri S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213593; Di Giorgio C, 2016, INT J CLIN PHARM-NET, V38, P462, DOI 10.1007/s11096-016-0284-7; Freedberg DE, 2017, GASTROENTEROLOGY, V152, P706, DOI 10.1053/j.gastro.2017.01.031; Gross N, 1998, RESPIRATION, V65, P354, DOI 10.1159/000029295; Gujjarlamudi Hima Bindu, 2016, J Midlife Health, V7, P105; Hammad EA, 2017, RES SOC ADMIN PHARM, V13, P300, DOI 10.1016/j.sapharm.2016.04.007; Hanlon JT, 2009, J GERONTOL A-BIOL, V64, P492, DOI 10.1093/gerona/gln043; Insogna KL, 2009, AM J GASTROENTEROL, V104, pS2, DOI 10.1038/ajg.2009.44; Ito Tetsuhide, 2010, Curr Gastroenterol Rep, V12, P448, DOI 10.1007/s11894-010-0141-0; Joint Commission International, 2017, INT PAT SAF GOAL 6 R, P52; Kumar B, 2015, JAMA INTERN MED, V175, P892, DOI 10.1001/jamainternmed.2015.0809; Lowe DO, 2006, CLIN INFECT DIS, V43, P1272, DOI 10.1086/508453; Lucchetti G, 2017, ARCH GERONTOL GERIAT, V68, P55, DOI 10.1016/j.archger.2016.09.003; Nassar Yousef, 2018, J Bone Metab, V25, P141, DOI 10.11005/jbm.2018.25.3.141; Naugler C T, 2000, Can J Clin Pharmacol, V7, P103; O'Mahony D, 2015, AGE AGEING, V44, P213, DOI 10.1093/ageing/afu145; Orimo Hajime, 2006, Nihon Ronen Igakkai Zasshi, V43, P27; Page RL, 2010, CLIN INTERV AGING, V5, P75; Potter K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149984; Radcliff S, 2015, J AM GERIATR SOC, V63, P2227, DOI 10.1111/jgs.13702; Resnick B, 2014, J GERONTOL NURS, V40, P2, DOI 10.3928/00989134-20131206-01; Roque MV, 2015, CLIN INTERV AGING, V10, P919, DOI 10.2147/CIA.S54304; Shi SJ, 2011, CURR DRUG METAB, V12, P601, DOI 10.2174/138920011796504527; Targownik LE, 2008, CAN MED ASSOC J, V179, P319, DOI 10.1503/cmaj.071330; Tashkin DP, 2009, COPD, V6, P17, DOI 10.1080/15412550902724073; Wongrakpanich S, 2018, AGING DIS, V9, P143, DOI 10.14336/AD.2017.0306; Yu EW, 2011, AM J MED, V124, P519, DOI 10.1016/j.amjmed.2011.01.007	37	3	3	2	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 25	2020	15	8							e0238064	10.1371/journal.pone.0238064	http://dx.doi.org/10.1371/journal.pone.0238064			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NI7UF	32841285	gold, Green Published			2023-01-03	WOS:000565553400044
J	Desmarets, M; Ayav, C; Diallo, K; Bayer, F; Imbert, F; Sauleau, EA; Monnet, E				Desmarets, Maxime; Ayav, Carole; Diallo, Kadiatou; Bayer, Florian; Imbert, Frederic; Sauleau, Erik Andre; Monnet, Elisabeth		VIGIE Study Grp	Fine-scale geographic variations of rates of renal replacement therapy in northeastern France: Association with the socioeconomic context and accessibility to care	PLOS ONE			English	Article							INFORMATION NETWORK REIN; SOCIAL INEQUALITIES; DISEASE; EPIDEMIOLOGY; POVERTY; URBAN; ESRD; DIALYSIS; PATTERNS; REGISTRY	Background The strong geographic variations in the incidence rates of renal replacement therapy (RRT) for end-stage renal disease are not solely related to variations in the population's needs, such as the prevalence of diabetes or the deprivation level. Inequitable geographic access to health services has been involved in different countries but never in France, a country with a generous supply of health services and where the effect of the variability of medical practices was highlighted in an analysis conducted at the geographic scale of districts. Our ecological study, performed at the finer scale of townships in a French area of 8,370,616 inhabitants, investigated the association between RRT incidence rates, socioeconomic environment and geographic accessibility to healthcare while adjusting for morbidity level and medical practice patterns. Methods Using data from the Renal Epidemiology and Information Network registry, we estimated age-adjusted RRT incidence rates during 2010-2014 for the 282 townships of the area. A hierarchical Bayesian Poisson model was used to examine the association between incidence rates and 18 contextual variables describing population health status, socioeconomic level and health services characteristics. Relative risks (RRs) and 95% credible intervals (95% CrIs) for each variable were estimated for a 1-SD increase in incidence rate. Results During 2010-2014, 6,835 new patients >= 18 years old (4231 men, 2604 women) living in the study area started RRT; the RRT incidence rates by townships ranged from 21 to 499 per million inhabitants. In multivariate analysis, rates were related to the prevalence of diabetes [RR (95% CrI): 1.05 (1.04-1.11)], the median estimated glomerular filtration rate at dialysis initiation [1.14 (1.08-1.20)], and the proportion of incident patients >= 85 years old [1.08 (1.03-1.14)]. After adjusting for these factors, rates in townships increased with increasing French deprivation index [1.05 (1.01-1.08)] and decreased with increasing mean travel time to reach the closest nephrologist [0.92 (0.89-0.95]). Conclusion These data confirm the influence of deprivation level, the prevalence of diabetes and medical practices on RRT incidence rates across a large French area. For the first time, an association was found with the distance to nephrology services. These data suggest possible inequitable geographic access to RRT within the French health system.	[Desmarets, Maxime; Diallo, Kadiatou; Monnet, Elisabeth] Univ Franche Comte, CHU Besancon, INSERM, CIC 1431, Besancon, France; [Desmarets, Maxime] Univ Bourgogne Franche Comte, INSERM, RIGHT UMR1098, EFS, Besancon, France; [Ayav, Carole] Univ Lorraine, CHRU Nancy, CIC Epidemiol Clin 1433, INSERM, Nancy, France; [Bayer, Florian] Agence Biomed, La Plaine St Denis, France; [Imbert, Frederic] Observ Reg Sante Alsace, Strasbourg, France; [Sauleau, Erik Andre] Univ Strasbourg, CNRS, ICube UMR 7357, Lab Biostat, Strasbourg, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; CHU Besancon; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Franche-Comte; CHU de Nancy; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Monnet, E (corresponding author), Univ Franche Comte, CHU Besancon, INSERM, CIC 1431, Besancon, France.	elisabeth.monnet@univ-fcomte.fr	Desmarets, Maxime/AAB-9897-2022; Monnet, Elisabeth/E-1989-2017	Desmarets, Maxime/0000-0002-3801-5297; Monnet, Elisabeth/0000-0002-3347-2579	French National Agency for Biomedicine [AO REIN 2015]	French National Agency for Biomedicine	This work was supported by a research grant (AO REIN 2015) from the French National Agency for Biomedicine. https://www.agencebiomedecine.fr/The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Barlet M, 2012, LOCAL POTENTIAL ACCE; Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675; Caskey FJ, 2014, NEPHROL DIAL TRANSPL, V29, P1494, DOI 10.1093/ndt/gft390; Caskey FJ, 2011, NEPHROL DIAL TRANSPL, V26, P2604, DOI 10.1093/ndt/gfq781; Castledine CI, 2012, NEPHROL DIAL TRANSPL, V27, P3943, DOI 10.1093/ndt/gfs294; Chevreul K, 2015, HEALT SYST TRANSIT, V17, P1; CLAYTON DG, 1993, INT J EPIDEMIOL, V22, P1193, DOI 10.1093/ije/22.6.1193; Colonna M, 2013, REV EPIDEMIOL SANTE, V61, P559, DOI 10.1016/j.respe.2013.07.686; Couchoud C, 2006, NEPHROL DIAL TRANSPL, V21, P411, DOI 10.1093/ndt/gfi198; Couchoud C, 2012, NEPHROL DIAL TRANSPL, V27, P2312, DOI 10.1093/ndt/gfr639; Couchoud C, 2010, NEPHROL DIAL TRANSPL, V25, P1576, DOI 10.1093/ndt/gfp675; Fan ZJ, 2007, HEALTH PLACE, V13, P179, DOI 10.1016/j.healthplace.2005.12.002; Gomez-Rubio V, 2005, J GEOGR SYST, V7, P189, DOI [10.1007/s10109-005-0156-5, DOI 10.1007/s10109-005-0156-5]; Hommel K, 2010, NEPHROL DIAL TRANSPL, V25, P2624, DOI 10.1093/ndt/gfq110; Hossain MP, 2009, AM J KIDNEY DIS, V53, P166, DOI 10.1053/j.ajkd.2007.10.047; Judge A, 2012, NEPHROL DIAL TRANSPL, V27, P1598, DOI 10.1093/ndt/gfr466; Kihal-Talantikite W, 2015, CLIN KIDNEY J, V8, P7, DOI 10.1093/ckj/sfu131; Ladin K, 2018, CLIN J AM SOC NEPHRO, V13, P1188, DOI 10.2215/CJN.01740218; Lassalle M, 2015, NEPHROL THER, V11, P78, DOI 10.1016/j.nephro.2014.08.002; Levesque JF, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-18; Lunn DJ, 2000, STAT COMPUT, V10, P325, DOI 10.1023/A:1008929526011; Occelli F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110132; OECD, 2014, GEOGRAPHIC VARIATION, DOI DOI 10.23062/2010.11.6; Peterson LE, 2010, J RURAL HEALTH, V26, P373, DOI 10.1111/j.1748-0361.2010.00309.x; Pippias M, 2017, CLIN KIDNEY J, V10, P154, DOI 10.1093/ckj/sfw135; QGIS Development Team, 2009, QGIS GEOGRAPHIC INFO; Rey G, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-33; Richardson S, 2004, ENVIRON HEALTH PERSP, V112, P1016, DOI 10.1289/ehp.6740; Rogerson PA, 2016, CH CRC HANDB MOD STA, P161; Sturtz S, 2005, J STAT SOFTW, V12, P1, DOI 10.18637/jss.v012.i03; Temam S, 2017, BMC PUBLIC HEALTH, V17, DOI 10.1186/s12889-017-4967-3; Touraine M, 2014, LANCET, V383, P1101, DOI 10.1016/S0140-6736(14)60423-2; Udayaraj UP, 2010, J EPIDEMIOL COMMUN H, V64, P535, DOI 10.1136/jech.2009.093518; United States Renal Data System, 2015, 2015 USRDS ANN DAT R; van de Luijtgaarden MWM, 2013, NEPHROL DIAL TRANSPL, V28, P1264, DOI 10.1093/ndt/gft053; van de Luijtgaarden MWM, 2012, AM J KIDNEY DIS, V60, P940, DOI 10.1053/j.ajkd.2012.07.015; Vigneron E, 2012, B ACAD NAT MED PARIS, V196, P939, DOI 10.1016/S0001-4079(19)31781-9; Volkova N, 2008, J AM SOC NEPHROL, V19, P356, DOI 10.1681/ASN.2006080934; Yan GF, 2013, CLIN J AM SOC NEPHRO, V8, P610, DOI 10.2215/CJN.07780812	39	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 28	2020	15	7							e0236698	10.1371/journal.pone.0236698	http://dx.doi.org/10.1371/journal.pone.0236698			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW3BD	32722704	Green Published, gold			2023-01-03	WOS:000556916000011
J	Thronicke, A; Reinhold, T; von Trott, P; Grah, C; Matthes, B; Matthes, H; Schad, F				Thronicke, Anja; Reinhold, Thomas; von Trott, Philipp; Grah, Christian; Matthes, Burkhard; Matthes, Harald; Schad, Friedemann			Cost-effectiveness of real-world administration of chemotherapy and add-onViscum albumL. therapy compared to chemotherapy in the treatment of stage IV NSCLC patients	PLOS ONE			English	Article							CANCER-PATIENTS; LUNG-CANCER; ONCOLOGY; CARE; SURVIVAL	Background For stage IV lung cancer patients receiving add-onViscum albumL. (VA) treatment an improved overall survival was detected. Information regarding cost-effectiveness (CE) for comparisons between chemotherapy (CTx) and CTx plus additive VA in stage IV lung cancer treatment is limited. The present study assessed the costs and cost-effectiveness of CTx plus VA (V) compared to CTx alone (C) for stage IV non-small cell lung cancer (NSCLC) patients treatment in a hospital in Germany. Methods In the observational real-world data study, data from the Network Oncology clinical registry were utilized. Enrolled stage IV lung cancer patients received the respective therapy (C or V) in a certified German Cancer Center. Cost and cost-effectiveness analyses from the hospital's perspective were investigated on the basis of overall survival (OS) and routine financial controlling data. In addition, the incremental cost-effectiveness ratio (ICER) was calculated. The primary result of the analysis was tested for robustness in a bootstrap-based sensitivity analysis. Results 118 patients (C: n = 86, V: n = 32) were included in the analysis, mean age 63.8 years, the proportion of male patients was 55.1%. Adjusted hospital's total mean costs for patients from the C and V group were euro16,289, 95%CI: 13,834euro-18,744euro (over an adjusted mean OS time of 13.4 months) and euro17,992, 95%CI: 13,658-22,326 (over an adjusted mean OS time of 19.1 months), respectively. The costs per additional OS year gained (ICER) with the V-therapy compared to C therapy were euro3,586. Conclusion The findings of the present study suggest that the combined use of chemotherapy and VA was clinically effective and comparably cost-effective to chemotherapy alone in our analysed patient sample from the hospital's perspective. Further randomized and prospective cost-effectiveness studies are necessary to complement our findings.	[Thronicke, Anja; Matthes, Harald; Schad, Friedemann] Hosp Gemeinschaftskrankenhaus Havelhohe, Res Inst Havelhohe, Berlin, Germany; [Reinhold, Thomas; Matthes, Harald] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Reinhold, Thomas; Matthes, Harald] Humboldt Univ, Freie Univ Berlin, Berlin, Germany; [Reinhold, Thomas; Matthes, Harald] Berlin Inst Hlth, Berlin, Germany; [von Trott, Philipp; Matthes, Harald; Schad, Friedemann] Hosp Gemeinschaftskrankenhaus Havelhohe, Interdisciplinary Oncol & Palliat Care, Berlin, Germany; [Grah, Christian; Matthes, Burkhard] Hosp Gemeinschaftskrankenhaus Havelhohe, Lung Canc Ctr, Berlin, Germany; [Matthes, Harald] Charite Univ Med Berlin, Med Clin Gastroenterol Infectiol & Rheumatol CBF, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Berlin Institute of Health; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schad, F (corresponding author), Hosp Gemeinschaftskrankenhaus Havelhohe, Res Inst Havelhohe, Berlin, Germany.; Schad, F (corresponding author), Hosp Gemeinschaftskrankenhaus Havelhohe, Interdisciplinary Oncol & Palliat Care, Berlin, Germany.	fschad@havelhoehe.de	Thronicke, Anja/AAZ-3508-2020; Thronicke, Anja/AAR-2482-2021; Matthes, Harald/AAR-2256-2021	Matthes, Harald/0000-0002-4053-4379; Thronicke, Anja/0000-0002-6421-8290; Reinhold, Thomas/0000-0001-5169-7029	Iscador AG Arlesheim, Switzerland; Abnoba GmbH Pforzheim, Germany; Helixor GmbH Rosenfeld, Germany	Iscador AG Arlesheim, Switzerland; Abnoba GmbH Pforzheim, Germany; Helixor GmbH Rosenfeld, Germany	The Network Oncology was funded by unrestricted research grants from Iscador AG Arlesheim, Switzerland; Abnoba GmbH Pforzheim, Germany; and Helixor GmbH Rosenfeld, Germany. By contract, researchers were independent from the funder. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aguiar PN, 2017, ANN ONCOL, V28, P2256, DOI 10.1093/annonc/mdx305; Block KI, 2009, INTEGR CANCER THER, V8, P205, DOI [10.1177/1534735409344978, 10.1177/1534735409355594]; Grant SJ, 2019, INTEGR CANCER THER, V18, DOI 10.1177/1534735418823266; Greenlee H, 2019, J ONCOL PRACT, V15, P17, DOI 10.1200/JOP.18.00755; Institute for Clinical and Economic Review. ICER, 2016, TREATM OPT ADV NONSM; Kienle GS, 2006, ANTHROPOSOPHIC MED E; Kienle GS, 2010, INTEGR CANCER THER, V9, P142, DOI 10.1177/1534735410369673; Kligler B, 2011, AM J MANAG CARE, V17, P779; Lyman GH, 2018, J CLIN ONCOL, V36, P2647, DOI 10.1200/JCO.2018.79.2721; Ostermann T, 2020, COMPLEMENT MED RES, V27, P260, DOI 10.1159/000505202; Ostermann T, 2012, EXPLORE-NY, V8, P277, DOI 10.1016/j.explore.2012.06.005; Ostermann T, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-451; Perin J, 2018, J CANCER, V9, P3038, DOI 10.7150/jca.26278; Schad F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203058; Schad F, 2013, FORSCH KOMPLEMENTMED, V20, P353, DOI 10.1159/000356204; Schwarzkopf L, 2015, LUNG CANCER, V90, P274, DOI 10.1016/j.lungcan.2015.09.005; Sobin LH, 2011, TNM CLASSIFICATION M, V7th; Souliotis K, 2019, HEALTH SERV RES MANA, V6, P1, DOI 10.1177/2333392819841223; Stussman BJ, 2020, J ALTERN COMPLEM MED, V26, P25, DOI 10.1089/acm.2019.0303; Thronicke A, 2019, ONCOL RES TREAT, V42, P273; Thronicke A, 2020, EVID-BASED COMPL ALT, V2020, DOI 10.1155/2020/3543568; Troger W, 2013, EUR J CANCER, V49, P3788, DOI 10.1016/j.ejca.2013.06.043; Verma V, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0442-7; Witt Claudia M., 2017, Journal of the National Cancer Institute Monographs, P3, DOI 10.1093/jncimonographs/lgx012; World Health Organization, 2017, GLOB HLTH OBS; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Yabroff KR, 2007, NAT CLIN PRACT ONCOL, V4, P643, DOI 10.1038/ncponc0978	27	2	2	3	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2020	15	7							e0236426	10.1371/journal.pone.0236426	http://dx.doi.org/10.1371/journal.pone.0236426			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV9ND	32716969	Green Published, Green Submitted, gold			2023-01-03	WOS:000556674500018
J	MacIntosh, A; Desailly, E; Vignais, N; Vigneron, V; Biddiss, E				MacIntosh, Alexander; Desailly, Eric; Vignais, Nicolas; Vigneron, Vincent; Biddiss, Elaine			A biofeedback-enhanced therapeutic exercise video game intervention for young people with cerebral palsy: A randomized single-case experimental design feasibility study	PLOS ONE			English	Article							INTERACTIVE COMPUTER PLAY; ASSISTING HAND ASSESSMENT; INDUCED MOVEMENT THERAPY; GROSS MOTOR FUNCTION; UPPER EXTREMITY; MANUAL ABILITY; BLOCK TEST; CHILDREN; REHABILITATION; RELIABILITY	Importance/Background Movement-controlled video games have potential to promote home-based practice of therapy activities. The success of therapy gaming interventions depends on the quality of the technology usedandthe presence of effective support structures. Aim This study assesses the feasibility of a novel intervention that combines a co-created gaming technology integrating evidence-based biofeedback and solution-focused coaching (SFC) strategies to support therapy engagement and efficacy at home. Methods Following feasibility and single-case reporting standards (and), this was a non-blind, randomized, multiple-baseline, AB, design. Nineteen (19) young people with cerebral palsy (8-18 years old) completed the 4-week home-based intervention in France and Canada. Participant motivations, personalized practice goals, and relevance of the intervention to daily activities were discussed in a Solution Focused Coaching-style conversation pre-, post-intervention and during weekly check-ins. Participants controlled a video game by completing therapeutic gestures (wrist extension, pinching) detected via electromyography and inertial sensors on the forearm (Myo Armband and custom software). Process feasibilitysuccess criteria for recruitment response, completion and adherence rates, and frequency of technical issues were establisheda priori.Scientific feasibility,effect size estimates and variance were determined for Body Functionoutcome measures: active wrist extension, grip strength and Box and Blocks Test; and forActivities and Participationmeasures: Assisting Hand Assessment (AHA), Canadian Occupational Performance Measure (COPM) and Self-Reported Experiences of Activity Settings (SEAS). Results Recruitment response (31%) and assessment completion (84%) rates were good and 74% of participants reached self-identified practice goals. As 17% of technical issues required external support to resolve, the intervention was graded asfeasible with modifications. No adverse events were reported. Moderate effects were observed in Body Function measures (active wrist extension: SMD = 1.82, 95%CI = 0.85-2.78; Grip Strength: SMD = 0.63, 95%CI = 0.65-1.91; Box and Blocks: Hedge's g = 0.58, 95%CI = -0.11-1.27) and small-moderate effects in Activities and Participation measures (AHA: Hedge's g = 0.29, 95%CI = -0.39-0.97, COPM: r = 0.60, 95%CI = 0.13-0.82, SEAS: r = 0.24, 95%CI = -0.25-0.61). Conclusion A definitive RCT to investigate the effectiveness of this novel intervention is warranted. Combining SFC-style coaching with high-quality biofeedback may positively engage youth in home rehabilitation to complement traditional therapy.	[MacIntosh, Alexander; Biddiss, Elaine] Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada; [MacIntosh, Alexander; Biddiss, Elaine] Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada; [MacIntosh, Alexander; Vignais, Nicolas] Univ Paris Saclay, Complexite Innovat Act Motrices & Sport, Sci Sport Mot & Mouvement Humain, Orsay, France; [Desailly, Eric] Fdn Ellen Poidatz, Rech & Innovat, St Fargeau Ponthierry, France; [Vignais, Nicolas] Univ Orleans, Complexite Innovat Act Motrices & Sport, Orleans, France; [Vigneron, Vincent] Univ Evry Val Essonne, Informat Bioinformat & Syst Complexes, Evry, France	University of Toronto; University Toronto Affiliates; Holland Bloorview Kids Rehabilitation Hospital; University of Toronto; UDICE-French Research Universities; Universite Paris Saclay; Universite de Orleans; UDICE-French Research Universities; Universite Paris Saclay	MacIntosh, A (corresponding author), Holland Bloorview Kids Rehabil Hosp, Bloorview Res Inst, Toronto, ON, Canada.; MacIntosh, A (corresponding author), Univ Toronto, Inst Biomat & Biomed Engn, Toronto, ON, Canada.; MacIntosh, A (corresponding author), Univ Paris Saclay, Complexite Innovat Act Motrices & Sport, Sci Sport Mot & Mouvement Humain, Orsay, France.	alexander.macintosh@mail.utoronto.ca	; vigneron, vincent/C-4719-2017	Desailly, Eric/0000-0003-3910-3755; vigneron, vincent/0000-0001-5917-6041; Vignais, Nicolas/0000-0002-7267-0236	Canadian Institutes of Health Research [RN304779 - 379428]; Campus France Eiffel Excellence Scholarship [895191H]; Mitacs GobaLink program [IT10648]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Campus France Eiffel Excellence Scholarship; Mitacs GobaLink program	This work was supported by the Canadian Institutes of Health Research [funding reference number RN304779 - 379428, Author AM], the Campus France Eiffel Excellence Scholarship [895191H, Author AM], and the Mitacs GobaLink program [IT10648, Author AM]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aarts PB, 2011, RES DEV DISABIL, V32, P271, DOI 10.1016/j.ridd.2010.10.008; Abraham C, 2009, PSYCHOL HEALTH MED, V14, P1, DOI 10.1080/13548500802537903; [Anonymous], 2020, NAT METHODS, V17, P1, DOI 10.1038/s41592-019-0703-5; [Anonymous], 2012, KIDNEY INT, V2, ps1; Arnould C, 2004, NEUROLOGY, V63, P1045, DOI 10.1212/01.WNL.0000138423.77640.37; Arnould C, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00048; Baldwin P, 2013, PHYS OCCUP THER PEDI, V33, P467, DOI 10.3109/01942638.2013.784718; Biddiss E, 2021, DISABIL REHABIL, V43, P133, DOI 10.1080/09638288.2019.1613681; Bilde PE, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-32; Bulte I, 2012, METHODOLOGY-EUR, V8, P104, DOI 10.1027/1614-2241/a000042; Chen CL, 2012, RES DEV DISABIL, V33, P1087, DOI 10.1016/j.ridd.2012.01.017; Chiu HC, 2014, CLIN REHABIL, V28, P1015, DOI 10.1177/0269215514533709; Cieza A, 2005, J REHABIL MED, V37, P212, DOI 10.1080/16501970510040263; Cup EHC, 2003, CLIN REHABIL, V17, P402, DOI 10.1191/0269215503cr635oa; Eldridge Sandra M, 2016, BMJ, V355, pi5239, DOI 10.1136/bmj.i5239; Eliasson AC, 2006, DEV MED CHILD NEUROL, V48, P549, DOI 10.1017/S0012162206001162; Elvrum AKG, 2012, BMC PEDIATR, V12, DOI 10.1186/1471-2431-12-91; Faraone Stephen V, 2008, P T, V33, P700; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Garzon LC, 2018, J REHABIL ASSIST TER, V5, DOI 10.1177/2055668318768402; Glazier JN, 1997, DEV MED CHILD NE S75, V39, P33, DOI [10.1111/j.1469-8749.1997.tb07505.x;SP:16, DOI 10.1111/J.1469-8749.1997.TB07505.X]; Hoffmann TC, 2014, BMJ-BRIT MED J, V348, DOI [10.1136/bmj.g1687, 10.1055/s-0041-111066]; Howcroft J, 2012, ARCH PHYS MED REHAB, V93, P1448, DOI 10.1016/j.apmr.2012.02.033; James S, 2016, PHYS OCCUP THER PEDI, V36, P343, DOI 10.3109/01942638.2015.1076560; James S, 2015, DEV MED CHILD NEUROL, V57, P530, DOI 10.1111/dmcn.12705; Jelsma J, 2013, DEV NEUROREHABIL, V16, P27, DOI 10.3109/17518423.2012.711781; Jong PD, 2012, INTERVIEWING SOLUTIO; Keller JW, 2017, J NEUROENG REHABIL, V14, DOI 10.1186/s12984-017-0293-3; King G, 2016, RES DEV DISABIL, V55, P242, DOI 10.1016/j.ridd.2016.04.014; King G, 2014, INT J DISABIL DEV ED, V61, P44, DOI 10.1080/1034912X.2014.878542; Klingels K, 2010, DISABIL REHABIL, V32, P409, DOI 10.3109/09638280903171469; Kratochwill T. R., 2010, ED510743; Kratochwill TR, 2010, WHAT WORKS CLGH; Law M, 1990, Can J Occup Ther, V57, P82; Levin I, 2017, PEDIATR PHYS THER, V29, P138, DOI 10.1097/PEP.0000000000000362; Louwers A, 2017, DEV MED CHILD NEUROL, V59, P926, DOI 10.1111/dmcn.13465; Louwers A, 2016, DEV MED CHILD NEUROL, V58, P1303, DOI 10.1111/dmcn.13168; MacIntosh A, 2019, DISABIL REHABIL, V41, P2369, DOI 10.1080/09638288.2018.1468933; Manolov R, 2014, NEUROPSYCHOL REHABIL, V24, P634, DOI 10.1080/09602011.2014.903199; MATHIOWETZ V, 1985, AM J OCCUP THER, V39, P386, DOI 10.5014/ajot.39.6.386; Mayring Ph, 2004, COMPANION QUALITATIV, P266; McColl Mary Ann, 2005, Can J Occup Ther, V72, P298; McPherson AC, 2018, DEV NEUROREHABIL, V21, P121, DOI 10.1080/17518423.2017.1289271; Mutlu A, 2007, MED SCI MONITOR, V13, pCR323; ODRISCOLL SW, 1992, J HAND SURG-AM, V17A, P169, DOI 10.1016/0363-5023(92)90136-D; Olama KA, 2012, EGYPTIAN J MED HUMAN, V13, P183, DOI [10.1016/j.ejmhg.2012.03.005, DOI 10.1016/J.EJMHG.2012.03.005]; Oskoui M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8949; Park ES, 2013, YONSEI MED J, V54, P516, DOI 10.3349/ymj.2013.54.2.516; Platz T, 2005, CLIN REHABIL, V19, P404, DOI 10.1191/0269215505cr832oa; Pustejovsky J. E., 2017, SINGLECASEES CALCULA; Ramstrand N, 2012, TECHNOL HEALTH CARE, V20, P531, DOI 10.3233/THC-2012-0696; Ratner H., 2012, SOLUTION FOCUSED BRI; Ravi DK, 2017, PHYSIOTHERAPY, V103, P245, DOI 10.1016/j.physio.2016.08.004; Rios DC, 2013, DEV NEUROREHABIL, V16, P398, DOI 10.3109/17518423.2013.766818; Rone-Adams Shari A, 2004, Pediatr Phys Ther, V16, P140, DOI 10.1097/01.PEP.0000136006.13449.DC; Rosenbaum Peter, 2004, Semin Pediatr Neurol, V11, P5, DOI 10.1016/j.spen.2004.01.002; Sandlund M, 2009, DEV MED CHILD NEUROL, V51, P173, DOI 10.1111/j.1469-8749.2008.03184.x; Sanger TD, 2006, PEDIATRICS, V118, P2159, DOI 10.1542/peds.2005-3016; Schiariti V, 2014, EUR J PAEDIATR NEURO, V18, P609, DOI 10.1016/j.ejpn.2014.04.009; Sevick M, 2016, BEHAV SCI, V6, DOI 10.3390/bs6020010; Shadish WR, 2014, J SCHOOL PSYCHOL, V52, P123, DOI 10.1016/j.jsp.2013.11.005; Shikako-Thomas K, 2015, DEV NEUROREHABIL, V18, P234, DOI 10.3109/17518423.2013.794166; Silva SM, 2015, BRAZ J PHYS THER, V19, P137, DOI 10.1590/bjpt-rbf.2014.0081; Solanas A, 2010, BEHAV MODIF, V34, P195, DOI 10.1177/0145445510363306; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Tate R.L., 2016, ARCH SCI PSYCHOL, V4, P10, DOI [10.1037/arc0000027, DOI 10.1037/ARC0000027]; Thabane L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-1; van Dijk H, 2005, J REHABIL MED, V37, P202, DOI 10.1080/16501970510030165; Wagner LV, 2012, CLIN ORTHOP RELAT R, V470, P1257, DOI 10.1007/s11999-011-2065-x; Wood KC, 2013, IEEE T NEUR SYS REH, V21, P300, DOI 10.1109/TNSRE.2012.2227804; Xu KS, 2012, DISABIL REHABIL, V34, P337, DOI 10.3109/09638288.2011.607213	71	9	10	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2020	15	6							e0234767	10.1371/journal.pone.0234767	http://dx.doi.org/10.1371/journal.pone.0234767			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MC8RX	32569284	Green Published, gold			2023-01-03	WOS:000543547900018
J	Ouyang, JB; Yang, MH; Gong, T; Ou, JL; Tan, YN; Zhang, Z; Li, S				Ouyang, Jiabi; Yang, Mohui; Gong, Tian; Ou, Jinlai; Tan, Yani; Zhang, Zhen; Li, Sha			Doxorubicin-loading core-shell pectin nanocell: A novel nanovehicle for anticancer agent delivery with multidrug resistance reversal	PLOS ONE			English	Article							BREAST-CANCER CELLS; DRUG-DELIVERY; LIGAND MODIFICATION; NANOPARTICLES; LIPOSOMES; ENCAPSULATION; COMBINATION; STRATEGIES; EFFICACY; ACID	Tumor is a prevalent great threat to public health worldwide and multidrug resistance (MDR) of tumor is a leading cause of chemotherapy failure. Nanomedicine has shown prospects in overcoming the problem. Doxorubicin (DOX), a broad-spectrum anticancer drug, showed limited efficacy due to MDR. Herein, a doxorubicin containing pectin nanocell (DOX-PEC-NC) of core-shell structure, a pectin nanoparticle encapsulated with liposome-like membrane was developed. The DOX-PEC-NC, spheroid in shape and sized around 150 nm, exerted better sustained release behavior than doxorubicin loading pectin nanoparticle (DOX-PEC-NP) or liposome (DOX-LIP).In vitroanticancer study showed marked accumulation of doxorubicin in different tumor cells as well as reversal of MDR in HepG2/ADR cells and MCF-7/ADR cells caused by treatment of DOX-PEC-NC. In H(22)tumor-bearing mice, DOX-PEC-NC showed higher anticancer efficacy and lower toxicity than doxorubicin. DOX-PEC-NC can improve anticancer activity and reduce side effect of doxorubicin due to increased intracellular accumulation and reversal of MDR in tumor cells, which may be a promising nanoscale drug delivery vehicle for chemotherapeutic agents.	[Ouyang, Jiabi; Yang, Mohui; Gong, Tian; Ou, Jinlai; Tan, Yani; Zhang, Zhen; Li, Sha] Jinan Univ, Coll Pharm, Guangzhou, Peoples R China; [Li, Sha] Jinan Univ, Int Cooperat Lab Tradit Chinese Med Modernizat &, Chinese Minist Educ, Coll Pharm, Guangzhou, Peoples R China; [Li, Sha] Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou, Peoples R China	Jinan University; Jinan University	Li, S (corresponding author), Jinan Univ, Coll Pharm, Guangzhou, Peoples R China.; Li, S (corresponding author), Jinan Univ, Int Cooperat Lab Tradit Chinese Med Modernizat &, Chinese Minist Educ, Coll Pharm, Guangzhou, Peoples R China.; Li, S (corresponding author), Guangdong Prov Key Lab Pharmacodynam Constituents, Guangzhou, Peoples R China.	tlisha@jnu.edu.cn			projects of Science and Technology Program of Guangzhou, China [201704020087, 201704020198]; Natural Science Foundation of Guangdong Province [2020A1515010990]	projects of Science and Technology Program of Guangzhou, China; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province)	This work was financially supported by projects of Science and Technology Program of Guangzhou, China (No. 201704020087 and No. 201704020198) and Natural Science Foundation of Guangdong Province (No. 2020A1515010990) to SL. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adamczak MI, 2016, INT J PHARMACEUT, V506, P201, DOI 10.1016/j.ijpharm.2016.04.050; Ambudkar SV, 2003, ONCOGENE, V22, P7468, DOI 10.1038/sj.onc.1206948; Arias JL, 2008, MOLECULES, V13, P2340, DOI 10.3390/molecules13102340; Bahrami B, 2017, IMMUNOL LETT, V190, P64, DOI 10.1016/j.imlet.2017.07.015; Betancourt T, 2007, NANOMEDICINE-UK, V2, P219, DOI 10.2217/17435889.2.2.219; Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5; Carmona-Ribeiro AM, 1999, COLLOID SURFACE A, V153, P355, DOI 10.1016/S0927-7757(98)00532-9; Deng ZT, 2014, J CONTROL RELEASE, V174, P109, DOI 10.1016/j.jconrel.2013.11.018; Devendiran RM, 2016, RSC ADV, V6, P29757, DOI 10.1039/c6ra01698g; Gautier J, 2013, J CONTROL RELEASE, V169, P48, DOI 10.1016/j.jconrel.2013.03.018; Gong T, 2016, J PHARM BIOMED SCI, V6, P338, DOI DOI 10.3109/02652048.2011.559286; Gu YJ, 2012, NANOMED-NANOTECHNOL, V8, P204, DOI 10.1016/j.nano.2011.06.005; Gungor-Ordueri NE, 2019, PHARMACOL REP, V71, P591, DOI 10.1016/j.pharep.2019.02.018; Injac R, 2009, BIOMATERIALS, V30, P1184, DOI 10.1016/j.biomaterials.2008.10.060; Khames A, 2017, EUR J PHARMACOL, V805, P118, DOI 10.1016/j.ejphar.2017.02.046; Khanniri E, 2016, CRIT REV FOOD SCI, V56, P484, DOI 10.1080/10408398.2013.779571; Kibria G, 2014, ARCH PHARM RES, V37, P4, DOI 10.1007/s12272-013-0276-2; Klemetsrud T, 2013, COLLOID SURFACE B, V103, P158, DOI 10.1016/j.colsurfb.2012.10.012; Kumar A, 2019, EUR J MED CHEM, V176, P268, DOI 10.1016/j.ejmech.2019.05.027; Li L, 2018, INT J PHARMACEUT, V536, P450, DOI 10.1016/j.ijpharm.2017.12.018; Liu LS, 2003, BIOMATERIALS, V24, P3333, DOI 10.1016/S0142-9612(03)00213-8; Maeki M, 2018, ADV DRUG DELIVER REV, V128, P84, DOI 10.1016/j.addr.2018.03.008; Mastria EM, 2018, J CONTROL RELEASE, V269, P364, DOI 10.1016/j.jconrel.2017.11.021; Moya S, 2000, MACROMOLECULES, V33, P4538, DOI 10.1021/ma9914974; [欧金来 Ou Jinlai], 2014, [暨南大学学报. 自然科学与医学版, Journal of Jinan University. Natural Science & Medicine Edition], V35, P330; Renu K, 2018, EUR J PHARMACOL, V818, P241, DOI 10.1016/j.ejphar.2017.10.043; Rodrigues ARO, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010010; Seidi K, 2018, J CONTROL RELEASE, V275, P142, DOI 10.1016/j.jconrel.2018.02.020; Sengupta S, 2005, NATURE, V436, P568, DOI 10.1038/nature03794; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smistad G, 2012, CARBOHYD POLYM, V90, P1337, DOI 10.1016/j.carbpol.2012.07.002; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Tao JY, 2019, MOL PHARMACEUT, V16, P786, DOI 10.1021/acs.molpharmaceut.8b01056; Thakkar S, 2020, ACTA BIOMATER, V101, P43, DOI 10.1016/j.actbio.2019.09.009; Wen ShaoHong, 2015, Journal of Pharmaceutical and Biomedical Sciences, V5, P385; Wilhelm S, 2016, NAT REV MATER, V1, DOI 10.1038/natrevmats.2016.14; Xia YQ, 2017, COLLOID SURFACE B, V159, P427, DOI 10.1016/j.colsurfb.2017.08.011; Ying XY, 2011, J MAGN MAGN MATER, V323, P1088, DOI 10.1016/j.jmmm.2010.12.019; Zahednezhad F, 2019, J CONTROL RELEASE, V305, P194, DOI 10.1016/j.jconrel.2019.05.030; Zhang YX, 2015, CARBOHYD POLYM, V133, P31, DOI 10.1016/j.carbpol.2015.06.102; Zheng WP, 2018, BIOMED PHARMACOTHER, V108, P565, DOI 10.1016/j.biopha.2018.09.039; Zhou XT, 2015, INT J PHARMACEUT, V479, P391, DOI 10.1016/j.ijpharm.2014.12.068; Zhu JZ, 2019, FOOD HYDROCOLLOID, V95, P562, DOI 10.1016/j.foodhyd.2018.04.042; Zong L, 2019, J PHARMACEUT BIOMED, V165, P268, DOI 10.1016/j.jpba.2018.11.057	44	3	3	4	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2020	15	6							e0235090	10.1371/journal.pone.0235090	http://dx.doi.org/10.1371/journal.pone.0235090			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MC8RX	32569270	Green Published, gold			2023-01-03	WOS:000543547900014
J	Banerjee, S; Ghoshal, S; Stevens, JR; McCommis, KS; Gao, S; Castro-Sepulveda, M; Mizgier, ML; Girardet, C; Kumar, KG; Galgani, JE; Niehoff, ML; Farr, SA; Zhang, JS; Butler, AA				Banerjee, Subhashis; Ghoshal, Sarbani; Stevens, Joseph R.; McCommis, Kyle S.; Gao, Su; Castro-Sepulveda, Mauricio; Mizgier, Maria L.; Girardet, Clemence; Kumar, K. Ganesh; Galgani, Jose E.; Niehoff, Michael L.; Farr, Susan A.; Zhang, Jinsong; Butler, Andrew A.			Hepatocyte expression of the micropeptide adropin regulates the liver fasting response and is enhanced by caloric restriction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article						circadian rhythm; diet; glucagon; insulin; hepatocyte; glucose metabolism; peptide hormone; stress response; signal transduction	PROTEIN-COUPLED RECEPTOR; GLUCOSE-HOMEOSTASIS; INSULIN-RESISTANCE; MELANOCORTIN-3 RECEPTORS; METABOLIC DISEASE; MICE LACKING; SENSITIVITY; KINASE; CLOCK; BMAL1	The micropeptide adropin encoded by the clock-controlled energy homeostasis-associated gene is implicated in the regulation of glucose metabolism. However, its links to rhythms of nutrient intake, energy balance, and metabolic control remain poorly defined. Using surveys of Gene Expression Omnibus data sets, we confirm that fasting suppresses liver adropin expression in lean C57BL/6J (B6) mice. However, circadian rhythm data are inconsistent. In lean mice, caloric restriction (CR) induces bouts of compulsive binge feeding separated by prolonged fasting intervals, increasing NAD-dependent deacetylase sirtuin-1 signaling important for glucose and lipid metabolism regulation. CR up-regulates adropin expression and induces rhythms correlating with cellular stress-response pathways. Furthermore, adropin expression correlates positively with phosphoenolpyruvate carboxokinase-1 (Pck1) expression, suggesting a link with gluconeogenesis. Our previous data suggest that adropin suppresses gluconeogenesis in hepatocytes. Liver-specific adropin knockout (LAdrKO) mice exhibit increased glucose excursions following pyruvate injections, indicating increased gluconeogenesis. Gluconeogenesis is also increased in primary cultured hepatocytes derived from LAdrKO mice. Analysis of circulating insulin levels and liver expression of fasting-responsive cAMP-dependent protein kinase A (PKA) signaling pathways also suggests enhanced responses in LAdrKO mice during a glucagon tolerance test (250 mu g/kg intraperitoneally). Fasting-associated changes in PKA signaling are attenuated in transgenic mice constitutively expressing adropin and in fasting mice treated acutely with adropin peptide. In summary, hepatic adropin expression is regulated by nutrient- and clock-dependent extrahepatic signals. CR induces pronounced postprandial peaks in hepatic adropin expression. Rhythms of hepatic adropin expression appear to link energy balance and cellular stress to the intracellular signal transduction pathways that drive the liver fasting response.	[Banerjee, Subhashis; Ghoshal, Sarbani; Stevens, Joseph R.; Girardet, Clemence; Zhang, Jinsong; Butler, Andrew A.] St Louis Univ, Sch Med, Dept Pharmacol & Physiol, St Louis, MO 63103 USA; [McCommis, Kyle S.] St Louis Univ, Edward A Doisy Dept Biochem & Mol Biol, Sch Med, St Louis, MO USA; [McCommis, Kyle S.] St Louis Univ, Ctr Cardiovasc Res, Sch Med, St Louis, MO USA; [McCommis, Kyle S.] St Louis Univ, Ctr Cardiovasc Res, Liver Ctr, St Louis, MO USA; [Niehoff, Michael L.; Farr, Susan A.; Butler, Andrew A.] St Louis Univ, Henry & Amelia Nasrallah Ctr Neurosci, Sch Med, St Louis, MO 63103 USA; [Niehoff, Michael L.; Farr, Susan A.] St Louis Univ, Sch Med, Div Geriatr Med, St Louis, MO 63104 USA; [Gao, Su; Kumar, K. Ganesh; Butler, Andrew A.] Scripps Res Inst, Dept Metab & Aging, Jupiter, FL 33458 USA; [Castro-Sepulveda, Mauricio] Univ Finis Terrae, Fac Med, Lab Ciencias Ejercicio, Santiago, Chile; [Mizgier, Maria L.; Galgani, Jose E.] Pontificia Univ Catolica Chile, Fac Med, Dept Ciencias Salud, Carrera Nutr & Dietet, Santiago, Chile; [Mizgier, Maria L.; Galgani, Jose E.] Pontificia Univ Catolica Chile, Fac Med, Dept Nutr Diabet & Metab, Santiago, Chile; [Niehoff, Michael L.; Farr, Susan A.] St Louis Vet Affairs Med Ctr, John Cochran Div, Res Serv, St Louis, MO USA; [Ghoshal, Sarbani] QCC CUNY, Dept Biol Sci & Geol, Bayside, NY USA; [Mizgier, Maria L.] Univ Strasbourg, Unite Mixte Rech, Diabet & Therapeut, Ctr Europeen Etud Diabet, Strasbourg, France; [Girardet, Clemence] Sorbonne Univ, CDR St Antoine UMR S 938, Paris, France; [Kumar, K. Ganesh] Taconic Biosci, Rensselaer, NY USA	Saint Louis University; Saint Louis University; Saint Louis University; Saint Louis University; Saint Louis University; Saint Louis University; Scripps Research Institute; Universidad Finis Terrae; Pontificia Universidad Catolica de Chile; Pontificia Universidad Catolica de Chile; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; UDICE-French Research Universities; Sorbonne Universite	Butler, AA (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol, St Louis, MO 63103 USA.; Butler, AA (corresponding author), St Louis Univ, Henry & Amelia Nasrallah Ctr Neurosci, Sch Med, St Louis, MO 63103 USA.; Butler, AA (corresponding author), Scripps Res Inst, Dept Metab & Aging, Jupiter, FL 33458 USA.	andrew.butler@health.slu.edu	Girardet, Clemence/GQQ-0627-2022; Mizgier, Maria/AAU-7804-2021	Farr, Susan/0000-0002-0481-2570; Zhang, Jinsong/0000-0002-8798-7316; Ghoshal, Sarbani/0000-0002-1089-084X; Mizgier, Maria Luisa/0000-0002-6396-8823; McCommis, Kyle/0000-0003-2381-1589; Girardet, Clemence/0000-0002-0302-3350	National Institutes of Health [R21NS108138, R00 HL136658]; American Diabetes Association; NovoNordisk	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Diabetes Association(American Diabetes Association); NovoNordisk(Novo Nordisk)	A. A. B. was supported by National Institutes of Health Grant R21NS108138 and funding from the American Diabetes Association and NovoNordisk. K. S. M. was supported by National Institutes of Health Grant R00 HL136658. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	Albrechtsen NJW, 2019, ENDOCR REV, V40, P1353, DOI 10.1210/er.2018-00251; Altamimi TR, 2019, METABOLISM, V98, P37, DOI 10.1016/j.metabol.2019.06.005; Anderson RM, 2008, AGING CELL, V7, P101, DOI 10.1111/j.1474-9726.2007.00357.x; Atger F, 2015, P NATL ACAD SCI USA, V112, pE6579, DOI 10.1073/pnas.1515308112; Bass J, 2016, SCIENCE, V354, P994, DOI 10.1126/science.aah4965; Begriche K, 2012, GENES BRAIN BEHAV, V11, P291, DOI 10.1111/j.1601-183X.2012.00766.x; Bremer AA, 2014, J NUTR, V144, P5, DOI 10.3945/jn.113.178061; Bruss MD, 2010, AM J PHYSIOL-ENDOC M, V298, pE108, DOI 10.1152/ajpendo.00524.2009; Burcelin R, 2004, J BIOL CHEM, V279, P1108, DOI 10.1074/jbc.M307788200; Butler AA, 2020, J LIPID RES, V61, P376, DOI 10.1194/jlr.RA119000423; Butler AA, 2019, J BIOL CHEM, V294, P9706, DOI 10.1074/jbc.RA119.007528; Butler AA, 2015, SCI REP-UK, V5, DOI 10.1038/srep14691; Butler AA, 2012, J CLIN ENDOCR METAB, V97, P3783, DOI 10.1210/jc.2012-2194; Carvunis AR, 2012, NATURE, V487, P370, DOI 10.1038/nature11184; Castello PR, 2007, J BIOL CHEM, V282, P14186, DOI 10.1074/jbc.M700827200; Celik E, 2013, J PERINAT MED, V41, P375, DOI 10.1515/jpm-2012-0227; Chang JB, 2018, OBES RES CLIN PRACT, V12, P101, DOI 10.1016/j.orcp.2017.03.001; Chen X, 2020, FASEB J, V34, P10056, DOI 10.1096/fj.202000115RR; Chen X, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.101068; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Dooley J, 2016, DIABETES, V65, P53, DOI 10.2337/db15-0770; Driessen M, 2015, TOXICOL LETT, V232, P403, DOI 10.1016/j.toxlet.2014.11.020; Estall JL, 2009, DIABETES, V58, P1499, DOI 10.2337/db08-1571; Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600; Foster SR, 2019, CELL, V179, P895, DOI 10.1016/j.cell.2019.10.010; Gao S, 2019, J BIOL CHEM, V294, P13366, DOI 10.1074/jbc.RA119.008967; Gao S, 2015, MOL METAB, V4, P310, DOI 10.1016/j.molmet.2015.01.005; Gao S, 2014, DIABETES, V63, P3242, DOI 10.2337/db14-0388; Ghoshal S, 2018, MOL METAB, V8, P51, DOI 10.1016/j.molmet.2017.12.002; Girardet C, 2017, SCI REP-UK, V7, DOI 10.1038/srep44444; Havel PJ, 2017, ILAR J, V58, P251, DOI 10.1093/ilar/ilx031; Hughey CC, 2014, MAMM GENOME, V25, P522, DOI 10.1007/s00335-014-9533-z; Hung YH, 2019, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01367; Hung YH, 2019, PHYSIOL GENOMICS, V51, P379, DOI 10.1152/physiolgenomics.00037.2019; Kakimoto PA, 2016, REDOX BIOL, V8, P216, DOI 10.1016/j.redox.2016.01.009; Khitun A, 2019, MOL OMICS, V15, P108, DOI 10.1039/c8mo00283e; Kinouchi K, 2018, CELL REP, V25, P3299, DOI 10.1016/j.celrep.2018.11.077; Kondratov RV, 2006, GENE DEV, V20, P1868, DOI 10.1101/gad.1432206; Koo SH, 2004, NAT MED, V10, P530, DOI 10.1038/nm1044; Kuhla A, 2014, J GERONTOL A-BIOL, V69, P915, DOI 10.1093/gerona/glt160; Kumar KG, 2012, OBESITY, V20, P1394, DOI 10.1038/oby.2012.31; Kumar KG, 2008, CELL METAB, V8, P468, DOI 10.1016/j.cmet.2008.10.011; Lee J, 2011, ISLETS, V3, P381, DOI 10.4161/isl.3.6.18157; Lian AJ, 2016, J MOL ENDOCRINOL, V56, P11, DOI 10.1530/JME-15-0207; Liu J, 2016, ENDOCRINOLOGY, V157, P2259, DOI 10.1210/en.2015-2027; Lovren F, 2010, CIRCULATION, V122, pS185, DOI 10.1161/CIRCULATIONAHA.109.931782; Low EXS, 2020, CLIN MOL HEPATOL, V26, P142, DOI 10.3350/cmh.2019.1003; Makarewich CA, 2017, TRENDS CELL BIOL, V27, P685, DOI 10.1016/j.tcb.2017.04.006; McCommis KS, 2015, CELL METAB, V22, P682, DOI 10.1016/j.cmet.2015.07.028; McGill MR, 2019, BBA-MOL BASIS DIS, V1865, P1031, DOI 10.1016/j.bbadis.2018.08.037; Menge BA, 2011, DIABETES, V60, P2160, DOI 10.2337/db11-0251; Naoumov NV, 2014, J HEPATOL, V61, P1166, DOI 10.1016/j.jhep.2014.07.008; Niswender CM, 2005, GENESIS, V43, P109, DOI 10.1002/gene.20159; Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236; Partridge CG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-99; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Rao A, 2017, BBA-MOL CELL RES, V1864, P1318, DOI 10.1016/j.bbamcr.2017.05.001; Rizza RA, 2010, DIABETES, V59, P2697, DOI 10.2337/db10-1032; Roden M, 2019, NATURE, V576, P51, DOI 10.1038/s41586-019-1797-8; Rodgers JT, 2007, P NATL ACAD SCI USA, V104, P12861, DOI 10.1073/pnas.0702509104; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Saghatelianr A, 2015, NAT CHEM BIOL, V11, P909, DOI 10.1038/nchembio.1964; Sargsyan A, 2019, CURR DIABETES REP, V19, DOI 10.1007/s11892-019-1195-5; Sato S, 2017, CELL, V170, P664, DOI 10.1016/j.cell.2017.07.042; St-Onge MP, 2014, OBESITY, V22, P1056, DOI 10.1002/oby.20631; Stein LM, 2016, AM J PHYSIOL-REG I, V310, pR476, DOI 10.1152/ajpregu.00511.2015; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; Stern JH, 2019, J ENDOCRINOL, V243, P149, DOI 10.1530/JOE-19-0201; Stevens JR, 2016, OBESITY, V24, P1731, DOI 10.1002/oby.21557; Thapa D, 2019, PHYSIOL REP, V7, DOI 10.14814/phy2.14043; Thapa D, 2019, J MOL CELL CARDIOL, V129, P174, DOI 10.1016/j.yjmcc.2019.02.012; Thapa D, 2018, REDOX BIOL, V18, P25, DOI 10.1016/j.redox.2018.06.003; Titchenell PM, 2016, CELL METAB, V23, P1154, DOI 10.1016/j.cmet.2016.04.022; Turek FW, 2005, SCIENCE, V308, P1043, DOI 10.1126/science.1108750; Unger RH, 2012, J CLIN INVEST, V122, P4, DOI 10.1172/JCI60016; WAKELAM MJO, 1986, NATURE, V323, P68, DOI 10.1038/323068a0; Wang PC, 2019, NAT CHEM BIOL, V15, P1110, DOI 10.1038/s41589-019-0368-5; Willis BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018772; Wong CM, 2014, J BIOL CHEM, V289, P25976, DOI 10.1074/jbc.M114.576058; Wu LZ, 2019, EXP THER MED, V18, P3307, DOI 10.3892/etm.2019.7937; Yang CJ, 2018, AGING DIS, V9, P322, DOI 10.14336/AD.2017.0523; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yu Y, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4230; Yue F, 2014, NATURE, V515, P355, DOI 10.1038/nature13992; Zang HH, 2018, ENDOCR J, V65, P685, DOI 10.1507/endocrj.EJ18-0060; Zhang CY, 2020, J ENDOCRINOL, V246, P109, DOI 10.1530/JOE-20-0077; Zhou B, 2014, HEPATOLOGY, V59, P2196, DOI 10.1002/hep.26992	87	10	10	0	8	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 2	2020	295	40					13753	13768		10.1074/jbc.RA120.014381	http://dx.doi.org/10.1074/jbc.RA120.014381			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	OB4MB	32727846	hybrid, Green Published			2023-01-03	WOS:000578444100005
J	Ochalek, TA; Cumpston, KL; Wills, BK; Gal, TS; Moeller, FG				Ochalek, Taylor A.; Cumpston, Kirk L.; Wills, Brandon K.; Gal, Tamas S.; Moeller, F. Gerard			Nonfatal Opioid Overdoses at an Urban Emergency Department During the COVID-19 Pandemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter								This study compares the numbers of nonfatal, unintentional opioid-related opioid overdoses presenting to a US urban emergency department during the early months of the coronavirus disease 2019 (COVID-19) pandemic (March-June 2020) vs 2019, overall and by age, race/ethnicity, and insurance status.	[Ochalek, Taylor A.] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA USA; [Cumpston, Kirk L.; Wills, Brandon K.] Virginia Commonwealth Univ, Dept Emergency Med, Richmond, VA USA; [Gal, Tamas S.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA; [Moeller, F. Gerard] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University	Ochalek, TA (corresponding author), Virginia Commonwealth Univ, C Kenneth & Dianne Wright Ctr Clin & Translat Res, Richmond Acad Med Bldg,1200 E Clay St, Richmond, VA 23298 USA.	taylor.ochalek@vcuhealth.org			National Institutes of Health research training grant [NIDA T32 DA7027-44]; National Institutes of Health [UL1TR002649, U54DA038999]; NCI [P30 CA016059/36]; Indivior PLC; Virginia Catalyst	National Institutes of Health research training grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Indivior PLC; Virginia Catalyst	This study was supported in part by National Institutes of Health research training grant NIDA T32 DA7027-44; National Institutes of Health grants UL1TR002649, U54DA038999, and NCI P30 CA016059/36; and funding from Indivior PLC and Virginia Catalyst.	Dowling MK, 2020, JAMA-J AM MED ASSOC, V324, P229, DOI 10.1001/jama.2020.10531; Galea S, 2020, JAMA-J AM MED ASSOC, V324, P227, DOI 10.1001/jama.2020.11132; Slavova S, 2020, DRUG ALCOHOL DEPEN, V214, DOI 10.1016/j.drugalcdep.2020.108176; Wakeman SE, 2020, NAT MED, V26, P819, DOI 10.1038/s41591-020-0898-0; Yancy CW, 2020, JAMA-J AM MED ASSOC, V323, P1891, DOI 10.1001/jama.2020.6548	5	98	97	1	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 27	2020	324	16					1673	1674		10.1001/jama.2020.17477	http://dx.doi.org/10.1001/jama.2020.17477		SEP 2020	2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OZ8NK	32945832	Bronze, Green Published			2023-01-03	WOS:000572361700002
J	Gebreweld, A; Fiseha, T; Girma, N; Haileslasie, H; Gebretsadik, D				Gebreweld, Angesom; Fiseha, Temesgen; Girma, Nibret; Haileslasie, Haftay; Gebretsadik, Daniel			Prevalence of cytopenia and its associated factors among HIV infected adults on highly active antiretroviral therapy at Mehal Meda Hospital, North Shewa Zone, Ethiopia	PLOS ONE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HEMATOLOGICAL ABNORMALITIES; ANEMIA; THROMBOCYTOPENIA; NEUTROPENIA; DISEASE; CARE	Background Cytopenias affect the outcomes of highly active anti-retroviral therapy that results in higher morbidity, mortality, and impaired quality of life. The purpose of this study was to assess the prevalence of cytopenia and its associated factors among HIV infected adults on highly active antiretroviral therapy at Mehal Meda Hospital, North Shewa Zone, Ethiopia. Method A cross-sectional health facility based study was conducted among 499 consecutively selected adult HIV infected patients taking HAART for at least six months from January to April 2018. The study participant's socio-demographic and clinical information was collected using a pre-tested questionnaire and reviewing of medical records by trained clinical nurses. Complete blood count and CD4 T cell count were determined by Sysmex KX-21 N and BD FACS count respectively. Bivariate and multivariate analysis was performed to identify the independently associated factors of cytopenia and prevalence ratios and their 95% confidence intervals were estimated using Poisson regression model with robust error variance to quantify the strength of statistical association. In all cases, a P value less than 0.05 was considered statistically significant. Result Out of the total study participants, 39.9% had at least one form of cytopenia, 23.2% had anemia, 13.8% had leukopenia, 12.4% had thrombocytopenia, 11.62% had bi-cytopenias, and only 1% had pancytopenia. In multivariate analysis, cytopenia was independently associated with older age groups, male gender, ZDV based regimen, and CD4 count less than 200 cells/mm(3). Conclusions In this study, the magnitude of any cytopenia was 40% among adult HIV infected patients taking highly active antiretroviral therapy and the prevalence increased as the CD4 count decreases. Therefore, these warrant the need for monitoring hematological parameters of HIV infected patients on HAART to reduce morbidity and mortality.	[Gebreweld, Angesom; Haileslasie, Haftay] Mekelle Univ, Coll Hlth Sci, Dept Med Lab Sci, Mekelle, Ethiopia; [Fiseha, Temesgen; Gebretsadik, Daniel] Wollo Univ, Coll Med & Hlth Sci, Dept Med Lab Sci, Dessie, Ethiopia; [Girma, Nibret] Mehal Meda Hosp, Dept Lab, Mehal Meda, Ethiopia	Mekelle University	Gebreweld, A (corresponding author), Mekelle Univ, Coll Hlth Sci, Dept Med Lab Sci, Mekelle, Ethiopia.	afsaha@gmail.com	Weldehanna, Daniel/ABA-8617-2020	Weldehanna, Daniel/0000-0001-5032-5143				Afari S, 2018, INT J VIROL AIDS, V5, P39, DOI DOI 10.23937/2469-567X/151003920; Ageru TA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221853; AGOMELATINE (Valdoxan/ Thymanax), 2013, DRUG SAFETY UPDATE, V6, pA1; [Anonymous], 2018, STANOWISKO POLSKIEGO, V4, P5; [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953; [Anonymous], 2019, CIRCULATION, V2019; [Anonymous], 2017, J DEMOCRACY, V28, P63; [Anonymous], 2016, BIOL BLOOD MARROW TR, V22, pS1; Assefa Muluken, 2015, BMC Hematol, V15, P6, DOI 10.1186/s12878-015-0024-6; Belperio PS, 2004, AM J MED, V116, P27, DOI 10.1016/j.amjmed.2003.12.010; CALENDA V, 1992, EUR J HAEMATOL, V48, P181; De Santis GC, 2011, INT J INFECT DIS, V15, pE808, DOI 10.1016/j.ijid.2011.08.001; Deressa Tekalign, 2018, EJIFCC, V29, P36; Durandt C, 2019, SAMJ S AFR MED J, V109, pS41, DOI 10.7196/SAMJ.2019.v109i8b.13829; Enawgaw Bamlaku, 2014, BMC Hematol, V14, P8, DOI 10.1186/2052-1839-14-8; Evans RH, 2000, BEST PRACT RES CL HA, V13, P215, DOI 10.1053/beha.1999.0069; Federal HIV/AIDS Prevention and Control Office (FHAPCO), 2018, HIV PREV ETH NAT ROA; Fekene Tamirat Edie, 2018, BMC Hematol, V18, P8, DOI 10.1186/s12878-018-0102-7; Firnhaber C, 2010, INT J INFECT DIS, V14, pE1088, DOI 10.1016/j.ijid.2010.08.002; Gunda DW, 2017, MALAWI MED J, V29, P43, DOI 10.4314/mmj.v29i1.9; Harris RJ, 2008, ANTIVIR THER, V13, P959; Herbst CL, 2018, J Cancer Policy, V15, P18, DOI 10.1016/j.jcpo.2017.11.005; Kathuria S., 2016, J CONT MED RES, V3, P3495, DOI DOI 10.18203/2349-3933.IJAM2019147626; Koka PS, 2004, CURR HIV RES, V2, P275, DOI 10.2174/1570162043351282; Kumar MB, 2016, INT J SCI STUDY, V3, P1, DOI 10.17354/ijss/2016/46; Kyeyune R, 2014, BMC INFECT DIS, V14, DOI 10.1186/1471-2334-14-496; Melese H, 2017, HIV AIDS-RES PALLIAT, V9, P25, DOI 10.2147/HIV.S121021; Mitra JK, 2015, INT J HLTH SCI RES, V5, P18; Nassiri R, 2006, J AM OSTEOPATH ASSOC, V106, P111; Nka AD, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4664-7; O'Brien ME, 2005, JAIDS-J ACQ IMM DEF, V40, P219, DOI 10.1097/01.qai.0000166374.16222.a2; Omoregie R, 2009, NIGERIA TANZAN J HLT, V11, P1, DOI DOI 10.4314/THRB.V11I1.43242; Opie J, 2012, SAMJ S AFR MED J, V102, P465, DOI 10.7196/SAMJ.5595; Ordre des Ingenieurs du Quebec, 2004, PLAN, V3, P1; Petraro P, 2016, AM J TROP MED HYG, V94, P384, DOI 10.4269/ajtmh.15-0587; Prazeres F, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13111097; Shi X, 2014, INT REV IMMUNOL, V33, P511, DOI 10.3109/08830185.2014.893301; SS V et al. on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee, 2020, CIRCULATION, V2020, pe1; Tamir Z, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211708; Taremwa IM, 2015, J BLOOD MED, V6, P109, DOI 10.2147/JBM.S80857; Torre D, 2008, CURR HIV RES, V6, P411, DOI 10.2174/157016208785861140; UNAIDS, GLOB HIV AIDS STAT 2; Vishnu P, 2015, BRIT J HAEMATOL, V171, P695, DOI 10.1111/bjh.13783; Volberding Paul A, 2004, Clin Infect Dis, V38, P1454, DOI 10.1086/383031; WHO, 2011, WHO TECH REP SER, V959, P1; Woldeamanuel Gashaw Garedew, 2018, BMC Hematol, V18, P9, DOI 10.1186/s12878-018-0103-6; Woldeamanuel Gashaw Garedew, 2018, BMC Hematol, V18, P7, DOI 10.1186/s12878-018-0099-y; Zerihun KW, 2019, BMC RES NOTES, V12, DOI 10.1186/s13104-019-4214-3	48	5	5	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 15	2020	15	9							e0239215	10.1371/journal.pone.0239215	http://dx.doi.org/10.1371/journal.pone.0239215			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU1BO	32931523	gold, Green Published			2023-01-03	WOS:000573375500022
J	Grunau, B; Kime, N; Leroux, B; Rea, T; Van Belle, G; Menegazzi, JJ; Kudenchuk, PJ; Vaillancourt, C; Morrison, LJ; Elmer, J; Zive, DM; Le, NM; Austin, M; Richmond, NJ; Herren, H; Christenson, J				Grunau, Brian; Kime, Noah; Leroux, Brian; Rea, Thomas; Van Belle, Gerald; Menegazzi, James J.; Kudenchuk, Peter J.; Vaillancourt, Christian; Morrison, Laurie J.; Elmer, Jonathan; Zive, Dana M.; Le, Nancy M.; Austin, Michael; Richmond, Neal J.; Herren, Heather; Christenson, Jim			Association of Intra-arrest Transport vs Continued On-Scene Resuscitation With Survival to Hospital Discharge Among Patients With Out-of-Hospital Cardiac Arrest	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BASIC LIFE-SUPPORT; CARDIOPULMONARY-RESUSCITATION; TRACHEAL INTUBATION; GUIDELINES UPDATE; CHEST COMPRESSION; QUALITY; OUTCOMES; TERMINATION; CONSENSUS	IMPORTANCE There is wide variability among emergency medical systems (EMS) with respect to transport to hospital during out-of-hospital cardiac arrest (OHCA) resuscitative efforts. The benefit of intra-arrest transport during resuscitation compared with continued on-scene resuscitation is unclear. OBJECTIVE To determine whether intra-arrest transport compared with continued on-scene resuscitation is associated with survival to hospital discharge among patients experiencing OHCA. DESIGN, SETTING, AND PARTICIPANTS Cohort study of prospectively collected consecutive nontraumatic adult EMS-treated OHCA data from the Resuscitation Outcomes Consortium (ROC) Cardiac Epidemiologic Registry (enrollment, April 2011-June 2015 from 10 North American sites; follow-up until the date of hospital discharge or death [regardless of when either event occurred]). Patients treated with intra-arrest transport (exposed) were matched with patients in refractory arrest (at risk of intra-arrest transport) at that same time (unexposed), using a time-dependent propensity score. Subgroups categorized by initial cardiac rhythm and EMS-witnessed cardiac arrests were analyzed. EXPOSURES Intra-arrest transport (transport initiated prior to return of spontaneous circulation), compared with continued on-scene resuscitation. MAIN OUTCOMES AND MEASURES The primary outcome was survival to hospital discharge, and the secondary outcome was survival with favorable neurological outcome (modified Rankin scale <3) at hospital discharge. RESULTS The full cohort included 43 969 patients with a median age of 67 years (interquartile range, 55-80), 37% were women, 86% of cardiac arrests occurred in a private location, 49% were bystander- or EMS-witnessed, 22% had initial shockable rhythms, 97% were treated by out-of-hospital advanced life support, and 26% underwent intra-arrest transport. Survival to hospital discharge was 3.8% for patients who underwent intra-arrest transport and 12.6% for those who received on-scene resuscitation. In the propensity-matched cohort, which included 27705 patients, survival to hospital discharge occurred in 4.0% of patients who underwent intra-arrest transport vs 8.5% who received on-scene resuscitation (risk difference, 4.6% [95% CI, 4.0%-5.1%]). Favorable neurological outcome occurred in 2.9% of patients who underwent intra-arrest transport vs 7.1% who received on-scene resuscitation (risk difference, 4.2% [95% CI, 3.5%-4.9%]). Subgroups of initial shockable and nonshockable rhythms as well as EMS-witnessed and unwitnessed cardiac arrests all had a significant association between intra-arrest transport and lower probability of survival to hospital discharge. CONCLUSIONS AND RELEVANCE Among patients experiencing out-of-hospital cardiac arrest, intra-arrest transport to hospital compared with continued on-scene resuscitation was associated with lower probability of survival to hospital discharge. Study findings are limited by potential confounding due to observational design.	[Grunau, Brian; Christenson, Jim] St Pauls Hosp, Dept Emergency Med, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada; [Grunau, Brian; Christenson, Jim] St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC, Canada; [Grunau, Brian; Christenson, Jim] Univ British Columbia, Vancouver, BC, Canada; [Kime, Noah; Leroux, Brian; Rea, Thomas; Van Belle, Gerald; Kudenchuk, Peter J.; Herren, Heather] Univ Washington, Dept Med, Seattle, WA USA; [Menegazzi, James J.; Elmer, Jonathan] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA USA; [Vaillancourt, Christian; Austin, Michael] Univ Ottawa, Dept Emergency Med, Ottawa, ON, Canada; [Morrison, Laurie J.] Univ Toronto, Dept Med, Div Emergency Med, Li Ka Shing Knowledge Inst,St Michaels Hosp, Toronto, ON, Canada; [Zive, Dana M.; Le, Nancy M.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Richmond, Neal J.] Metropolitan Area EMS Author Emergency Phys Adivi, Ft Worth, TX USA	St. Paul's Hospital; University of Saskatchewan; St. Paul's Hospital; University of Saskatchewan; University of British Columbia; University of Washington; University of Washington Seattle; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Ottawa; University of Toronto; Li Ka Shing Knowledge Institute; University Toronto Affiliates; Saint Michaels Hospital Toronto; Oregon Health & Science University	Grunau, B (corresponding author), St Pauls Hosp, Dept Emergency Med, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	brian.grunau@ubc.ca	Morrison, Laurie Jean/A-6325-2012	Morrison, Laurie Jean/0000-0001-8369-9774; Grunau, Brian/0000-0003-4103-1383	National Heart, Lung, and Blood Institute; National Institute of Neurological Disorders and Stroke; US Army Medical Research and Material Command; Canadian Institutes of Health Research (CIHR) -Institute of Circulatory and Respiratory Health; Defence Research and Development Canada; Heart and Stroke Foundation of Canada; American Heart Association through University ofWashington Data Coordinating Center [5U01 HL077863]; American Heart Association through Medical College of Wisconsin [HL077866]; American Heart Association through University ofWashington [HL077867]; American Heart Association through University of Pittsburgh [HL077871]; American Heart Association through St. Michael's Hospital [HL077872]; American Heart Association through Oregon Health and Science University [HL077873]; American Heart Association through University of Alabama at Birmingham [HL077881]; American Heart Association through Ottawa Health Research Institute [HL077885]; American Heart Association through University of Texas SW Medical Center/Dallas [HL077887]; American Heart Association through University of California San Diego [HL077908]	National Heart, Lung, and Blood Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); US Army Medical Research and Material Command(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Canadian Institutes of Health Research (CIHR) -Institute of Circulatory and Respiratory Health(Canadian Institutes of Health Research (CIHR)); Defence Research and Development Canada; Heart and Stroke Foundation of Canada(Heart & Stroke Foundation of Canada); American Heart Association through University ofWashington Data Coordinating Center(American Heart Association); American Heart Association through Medical College of Wisconsin; American Heart Association through University ofWashington(American Heart Association); American Heart Association through University of Pittsburgh; American Heart Association through St. Michael's Hospital(American Heart Association); American Heart Association through Oregon Health and Science University; American Heart Association through University of Alabama at Birmingham(American Heart Association); American Heart Association through Ottawa Health Research Institute(American Heart Association); American Heart Association through University of Texas SW Medical Center/Dallas; American Heart Association through University of California San Diego(American Heart Association)	The Resuscitation Outcomes Consortium was supported by the National Heart, Lung, and Blood Institute in partnership with the National Institute of Neurological Disorders and Stroke, US Army Medical Research and Material Command, the Canadian Institutes of Health Research (CIHR) -Institute of Circulatory and Respiratory Health, Defence Research and Development Canada, the Heart and Stroke Foundation of Canada, and the American Heart Association through a series of cooperative agreements with 9 regional clinical centers and 1 data coordinating center (University ofWashington Data Coordinating Center [5U01 HL077863]; Medical College of Wisconsin [HL077866]; University ofWashington [HL077867]; University of Pittsburgh [HL077871]; St. Michael's Hospital [HL077872]; Oregon Health and Science University [HL077873]; University of Alabama at Birmingham [HL077881]; Ottawa Health Research Institute [HL077885]; University of Texas SW Medical Center/Dallas [HL077887]; University of California San Diego [HL077908]).	Andersen LW, 2018, RESUSCITATION, V125, P79, DOI 10.1016/j.resuscitation.2018.02.006; Andersen LW, 2017, JAMA-J AM MED ASSOC, V317, P494, DOI 10.1001/jama.2016.20165; Andersen LW, 2016, JAMA-J AM MED ASSOC, V316, P1786, DOI 10.1001/jama.2016.14486; Belohlavek J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-163; Berg RA, 2010, CIRCULATION, V122, pS685, DOI 10.1161/CIRCULATIONAHA.110.970939; Bottiger BW, 2016, CRIT CARE, V20, DOI 10.1186/s13054-015-1156-6; Cheskes S, 2017, RESUSCITATION, V114, P34, DOI 10.1016/j.resuscitation.2017.02.016; Choi DS, 2016, RESUSCITATION, V99, P26, DOI 10.1016/j.resuscitation.2015.11.013; Deakin CD, 2010, RESUSCITATION, V81, pE93, DOI 10.1016/j.resuscitation.2010.08.027; Grunau B, 2019, RESUSCITATION, V135, P137, DOI 10.1016/j.resuscitation.2018.12.003; Grunau B, 2018, CAN J CARDIOL, V34, P146, DOI 10.1016/j.cjca.2017.08.015; Grunau B, 2016, CAN J EMERG MED, V18, P453, DOI 10.1017/cem.2016.8; Kleinman ME, 2018, CIRCULATION, V137, pE7, DOI 10.1161/CIR.0000000000000539; Krarup NH, 2011, RESUSCITATION, V82, P263, DOI 10.1016/j.resuscitation.2010.11.003; Kudenchuk PJ, 1999, NEW ENGL J MED, V341, P871, DOI 10.1056/NEJM199909163411203; Lamhaut L, 2017, RESUSCITATION, V117, P109, DOI 10.1016/j.resuscitation.2017.04.014; Larsen AI, 2007, RESUSCITATION, V75, P454, DOI 10.1016/j.resuscitation.2007.05.007; Link MS, 2015, CIRCULATION, V132, pS444, DOI 10.1161/CIR.0000000000000261; Morrison LJ, 2008, RESUSCITATION, V78, P161, DOI 10.1016/j.resuscitation.2008.02.020; Morrison LJ, 2006, NEW ENGL J MED, V355, P478, DOI 10.1056/NEJMoa052620; Morrison LJ, 2009, RESUSCITATION, V80, P324, DOI 10.1016/j.resuscitation.2008.11.014; Nakahara S, 2013, BMJ-BRIT MED J, V347, DOI 10.1136/bmj.f6829; Nichol G, 2008, JAMA-J AM MED ASSOC, V300, P1423, DOI 10.1001/jama.300.12.1423; Nichol G, 2015, NEW ENGL J MED, V373, P2203, DOI 10.1056/NEJMoa1509139; Ong MEH, 2007, RESUSCITATION, V75, P244, DOI 10.1016/j.resuscitation.2007.04.013; Panchal AR, 2019, CIRCULATION, V140, pE881, DOI 10.1161/CIR.0000000000000732; Perkins GD, 2015, CIRCULATION, V132, P1286, DOI 10.1161/CIR.0000000000000144; Reynolds JC, 2017, RESUSCITATION, V117, P24, DOI 10.1016/j.resuscitation.2017.05.024; Russi CS, 2016, WEST J EMERG MED, V17, P634, DOI 10.5811/westjem.2016.6.29949; Watanabe BL, 2019, ANN EMERG MED, V74, P101, DOI 10.1016/j.annemergmed.2018.09.032; Zive D, 2011, RESUSCITATION, V82, P277, DOI 10.1016/j.resuscitation.2010.10.022; Zou GY, 2013, STAT METHODS MED RES, V22, P661, DOI 10.1177/0962280211427759; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090	35	60	60	1	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 15	2020	324	11					1058	1067		10.1001/jama.2020.14185	http://dx.doi.org/10.1001/jama.2020.14185			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	OF2XM	32930759	Bronze, Green Published			2023-01-03	WOS:000581077300020
J	Rossi, PG; Marino, M; Formisano, D; Venturelli, F; Vicentini, M; Grilli, R				Rossi, Paolo Giorgi; Marino, Massimiliano; Formisano, Debora; Venturelli, Francesco; Vicentini, Massimo; Grilli, Roberto		Reggio Emilia COVID-19 Working Grp	Characteristics and outcomes of a cohort of COVID-19 patients in the Province of Reggio Emilia, Italy	PLOS ONE			English	Article								This is a population-based prospective cohort study on archive data describing the age- and sex-specific prevalence of COVID-19 and its prognostic factors. All 2653 symptomatic patients tested positive for SARS-CoV-2 from February 27 to April 2, 2020 in the Reggio Emilia province, Italy, were included. COVID-19 cumulative incidence, hospitalization and death rates, and adjusted hazard ratios (HR) with 95% confidence interval (95% CI) were calculated according to sociodemographic and clinical characteristics. Females had higher prevalence of infection than males below age 50 (2.61 vs. 1.84 parts per thousand), but lower in older ages (16.49 vs. 20.86 parts per thousand over age 80). Case fatality rate reached 20.7% in cases with more than 4 weeks follow up. After adjusting for age and comorbidities, men had a higher risk of hospitalization (HR 1.4 95% CI 1.2 to 1.6) and of death (HR 1.6, 95% CI 1.2 to 2.1). Patients over age 80 compared to age < 50 had HR 7.1 (95% CI 5.4 to 9.3) and HR 27.8 (95% CI 12.5 to 61.7) for hospitalization and death, respectively. Immigrants had a higher risk of hospitalization (HR 1.3, 95% CI 0.99 to 1.81) than Italians and a similar risk of death. Risk of hospitalization and of death were higher in patients with heart failure, arrhythmia, dementia, coronary heart disease, diabetes, and hypertension, while COPD increased the risk of hospitalization (HR 1.9, 95% CI 1.4 to 2.5) but not of death (HR 1.1, 95% CI 0.7 to 1.7). Previous use of ACE inhibitors had no effect on risk of death (HR 0.97, 95% CI 0.69 to 1.34). Identified susceptible populations and fragile patients should be considered when setting priorities in public health planning and clinical decision making.	[Rossi, Paolo Giorgi; Venturelli, Francesco; Vicentini, Massimo] Azienda Unita Sanit Locale IRCCS Reggio Emilia, Epidemiol Unit, Reggio Emilia, Italy; [Marino, Massimiliano; Formisano, Debora; Grilli, Roberto] Azienda Unita Sanit Locale IRCCS Reggio Emilia, Dept Clin Governance, Reggio Emilia, Italy; [Venturelli, Francesco] Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy	Universita di Modena e Reggio Emilia	Venturelli, F (corresponding author), Azienda Unita Sanit Locale IRCCS Reggio Emilia, Epidemiol Unit, Reggio Emilia, Italy.; Venturelli, F (corresponding author), Univ Modena & Reggio Emilia, Clin & Expt Med PhD Program, Modena, Italy.	francesco.venturelli@ausl.re.it	Venturelli, Francesco/T-6468-2017; Rossi, Paolo Giorgi/K-6367-2016; Marino, Massimiliano/K-1515-2016	Venturelli, Francesco/0000-0002-9190-8668; Rossi, Paolo Giorgi/0000-0001-9703-2460; Marino, Massimiliano/0000-0003-4005-0646	Italian Ministry of Health [COVID-2020-12371808]	Italian Ministry of Health(Ministry of Health, Italy)	The study has been conducted using institutional funds of the Azienda USL-IRCCS di Reggio Emilia. This study has been partially funded by the Italian Ministry of Health; grant number COVID-2020-12371808. The funder had no role in the definition of the study design neither in the interpretation and publication of the results.	a R-M, 2020, J CLIN MED, V9; Abdi A, 2020, DIABETES RES CLIN PR, V166, DOI 10.1016/j.diabres.2020.108347; [Anonymous], 2020, TASK FORCE COVID 19; Center for Systems Science and Engineering (CSSE), 2020, COVID 19 MA JOHNS HO; Cereda D., 2020, ARXIV; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Dong ES, 2020, LANCET INFECT DIS, V20, P533, DOI 10.1016/S1473-3099(20)30120-1; European Center for Disease Control and Prevention (ECDC), 2020, COR DIS 2019 COVID 1; Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8; Fang XY, 2020, AGING-US, V12, P12493, DOI 10.18632/aging.103579; Feng ZJ, 2020, CHINA CDC WEEKLY, V2, P113, DOI 10.46234/ccdcw2020.032; Ferroni E, 2020, CLIN EPIDEMIOL, V12, P1337, DOI 10.2147/CLEP.S271763; Grasselli G, 2020, JAMA-J AM MED ASSOC, V323, P1574, DOI 10.1001/jama.2020.5394; Guan W, 2020, NEW ENGL J MED, V382, P1708, DOI 10.1056/NEJMoa2002032; Istituto Superiore di Sanita, 2020, SORV PASS DAT IT SOV; Istituto Superiore di Sanita, 2020, CHAR COVID 19 PAT DY; Istituto Superiore di Sanita, 2020, SORV PASS DAT IT RIS; Liu Y, 2020, J TRAVEL MED, V27, DOI 10.1093/jtm/taaa021; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Pacelli B, 2016, EUR J EPIDEMIOL, V31, P691, DOI 10.1007/s10654-016-0177-z; Petrelli A, EPIDEMIOL PREV, V41, P1; Rajgor DD, 2020, LANCET INFECT DIS, V20, P776, DOI 10.1016/S1473-3099(20)30244-9; Rossi PG, 2020, J CLIN VIROL, V128, DOI 10.1016/j.jcv.2020.104415; Saglietto A, 2020, LANCET, V395, P1110, DOI 10.1016/S0140-6736(20)30690-5; Shet A., 2020, DIFFERENTIAL COVID 1, DOI 10.1101/2020.04.01.20049478; The Reggio Emilia COVID-19 working group, 2020, EP PREV REP; Wang L, 2020, J INFECTION, V80, P639, DOI 10.1016/j.jinf.2020.03.019; WHO, 2020, REP WHO CHIN JOINT M; Yang XB, 2020, LANCET RESP MED, V8, P475, DOI 10.1016/S2213-2600(20)30079-5; Yuan J, 2020, INT J INFECT DIS, V95, P311, DOI 10.1016/j.ijid.2020.03.050; Zhang JJ, 2020, ALLERGY, V75, P1730, DOI 10.1111/all.14238; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3	33	81	82	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 27	2020	15	8							e0238281	10.1371/journal.pone.0238281	http://dx.doi.org/10.1371/journal.pone.0238281			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NK7YQ	32853230	Green Published, gold, Green Submitted			2023-01-03	WOS:000566948800026
J	McQueenie, R; Foster, HME; Jani, BD; Katikireddi, SV; Sattar, N; Pell, JP; Ho, FK; Niedzwiedz, CL; Hastie, CE; Anderson, J; Mark, PB; Sullivan, M; O'Donnell, CA; Mair, FS; Nicholl, BI				McQueenie, Ross; Foster, Hamish M. E.; Jani, Bhautesh D.; Katikireddi, Srinivasa Vittal; Sattar, Naveed; Pell, Jill P.; Ho, Frederick K.; Niedzwiedz, Claire L.; Hastie, Claire E.; Anderson, Jana; Mark, Patrick B.; Sullivan, Michael; O'Donnell, Catherine A.; Mair, Frances S.; Nicholl, Barbara, I			Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort	PLOS ONE			English	Article								Background It is now well recognised that the risk of severe COVID-19 increases with some long-term conditions (LTCs). However, prior research primarily focuses on individual LTCs and there is a lack of data on the influence of multimorbidity (>= 2 LTCs) on the risk of COVID-19. Given the high prevalence of multimorbidity, more detailed understanding of the associations with multimorbidity and COVID-19 would improve risk stratification and help protect those most vulnerable to severe COVID-19. Here we examine the relationships between multimorbidity, polypharmacy (a proxy of multimorbidity), and COVID-19; and how these differ by sociodemographic, lifestyle, and physiological prognostic factors. Methods and findings We studied data from UK Biobank (428,199 participants; aged 37-73; recruited 2006-2010) on self-reported LTCs, medications, sociodemographic, lifestyle, and physiological measures which were linked to COVID-19 test data. Poisson regression models examined risk of COVID-19 by multimorbidity/polypharmacy and effect modification by COVID-19 prognostic factors (age/sex/ethnicity/socioeconomic status/smoking/physical activity/BMI/systolic blood pressure/renal function). 4,498 (1.05%) participants were tested; 1,324 (0.31%) tested positive for COVID-19. Compared with no LTCs, relative risk (RR) of COVID-19 in those with 1 LTC was no higher (RR 1.12 (CI 0.96-1.30)), whereas those with >= 2 LTCs had 48% higher risk; RR 1.48 (1.28-1.71). Compared with no cardiometabolic LTCs, having 1 and >= 2 cardiometabolic LTCs had a higher risk of COVID-19; RR 1.28 (1.12-1.46) and 1.77 (1.46-2.15), respectively. Polypharmacy was associated with a dose response higher risk of COVID-19. All prognostic factors were associated with a higher risk of COVID-19 infection in multimorbidity; being non-white, most socioeconomically deprived, BMI >= 40 kg/m2, and reduced renal function were associated with the highest risk of COVID-19 infection: RR 2.81 (2.09-3.78); 2.79 (2.00-3.90); 2.66 (1.88-3.76); 2.13 (1.46-3.12), respectively. No multiplicative interaction between multimorbidity and prognostic factors was identified. Important limitations include the low proportion of UK Biobank participants with COVID-19 test data (1.05%) and UK Biobank participants being more affluent, healthier and less ethnically diverse than the general population. Conclusions Increasing multimorbidity, especially cardiometabolic multimorbidity, and polypharmacy are associated with a higher risk of developing COVID-19. Those with multimorbidity and additional factors, such as non-white ethnicity, are at heightened risk of COVID-19.	[McQueenie, Ross; Foster, Hamish M. E.; Jani, Bhautesh D.; Katikireddi, Srinivasa Vittal; Pell, Jill P.; Ho, Frederick K.; Niedzwiedz, Claire L.; Hastie, Claire E.; Anderson, Jana; O'Donnell, Catherine A.; Mair, Frances S.; Nicholl, Barbara, I] Univ Glasgow, Inst Hlth & Wellbeing, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland; [Sattar, Naveed; Mark, Patrick B.; Sullivan, Michael] Univ Glasgow, British Heart Fdn, Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland	University of Glasgow; University of Glasgow	Nicholl, BI (corresponding author), Univ Glasgow, Inst Hlth & Wellbeing, Coll Med Vet & Life Sci, Glasgow, Lanark, Scotland.	barbara.nicholl@glasgow.ac.uk	Foster, Hamish/AAX-7703-2021; Sullivan, Michael/AAW-2269-2020; Ho, Frederick/AAS-2647-2021; Mark, Patrick/N-5536-2014	Sullivan, Michael/0000-0002-3800-2330; Ho, Frederick/0000-0001-7190-9025; Mark, Patrick/0000-0003-3387-2123; Anderson, Jana/0000-0001-7290-6635; Katikireddi, Srinivasa/0000-0001-6593-9092	MRC [MR/T001585/1, MR/V001671/1] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arokiasamy P, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0402-8; Barnett K, 2012, LANCET, V380, P37, DOI 10.1016/S0140-6736(12)60240-2; Batty GD, 2020, BMJ-BRIT MED J, V2020, pm131; Centers for Disease Control and Prevention, 2020, COR DIS 2019 COVID; Chiang JI, 2020, PLOS MED, V17, DOI 10.1371/journal.pmed.1003094; Collaborative TO, 2020, MEDRXIV PREPR OPENSA; Corsonello Andrea, 2007, Ther Clin Risk Manag, V3, P197, DOI 10.2147/tcrm.2007.3.1.197; de Lusignan S, 2020, LANCET INFECT DIS, V20, P1034, DOI 10.1016/S1473-3099(20)30371-6; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; Elliott P, 2008, INT J EPIDEMIOL, V37, P234, DOI 10.1093/ije/dym276; Fry A, 2017, AM J EPIDEMIOL, V186, P1026, DOI 10.1093/aje/kwx246; Garin N, 2016, J GERONTOL A-BIOL, V71, P205, DOI 10.1093/gerona/glv128; Gorbalenya AE, 2020, NAT MICROBIOL, V5, P536, DOI 10.1038/s41564-020-0695-z; Guan WJ, 2020, EUR RESPIR J, V55, DOI 10.1183/13993003.00597-2020; Guthrie B, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0322-7; Hastie CE, 2020, DIABETES METAB SYND, V14, P561, DOI 10.1016/j.dsx.2020.04.050; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Huang I, 2020, DIABETES METAB SYND, V14, P395, DOI 10.1016/j.dsx.2020.04.018; IPAQ, 2005, IPAQ SCOR PROT 2005; Ipsos, 2020, COR COVID 19 REL DEA; ISS, 2020, I SUP SAN CHAR COVID; Jani BD, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1305-x; Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006; Niedzwiedz CL, 2020, ETHNIC SOCIOECONOMIC; Onder G, 2020, JAMA-J AM MED ASSOC, V323, P1775, DOI 10.1001/jama.2020.4683; Pathirana TI, 2018, AUST NZ J PUBL HEAL, V42, P186, DOI 10.1111/1753-6405.12762; PHE, 2020, GUID SHIELD PROT PEO; Phillimore P., 1987, HLTH DEPRIVATION INE; Sattar N, 2020, CIRCULATION, V142, P4, DOI 10.1161/CIRCULATIONAHA.120.047659; Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779; Tran J, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002513; UK Cabinet Office, 2020, STAYING HOM AW OTH; UKBiobank, 2020, COVID 19 TEST RES DA; World Health Organization (Who), 2020, SITUATION REPORT; Zheng ZH, 2020, J INFECTION, V81, pE16, DOI 10.1016/j.jinf.2020.04.021; Zhu J, 2020, J MED VIROLOGY; Zou GY, 2013, STAT METHODS MED RES, V22, P661, DOI 10.1177/0962280211427759	37	41	41	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 20	2020	15	8							e0238091	10.1371/journal.pone.0238091	http://dx.doi.org/10.1371/journal.pone.0238091			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NG9QD	32817712	Green Published, Green Accepted, gold, Green Submitted			2023-01-03	WOS:000564315600081
J	Stauch, BJ; Braun, V; Hanslmayr, S				Stauch, Benjamin J.; Braun, Verena; Hanslmayr, Simon			Probing the causal involvement of dlPFC in directed forgetting using rTMS-A replication study	PLOS ONE			English	Article							MEMORY; FREQUENCY; ITEM	The forgetting of previously remembered information has, for a long time, been explained by purely passive processes. This viewpoint has been challenged by the finding that humans show worse memory for specific items that they have been instructed to forget. The dorsolateral prefrontal cortex has, through imaging, lesion and brain stimulation studies, been implied in controlling such active forgetting processes. In this study, we attempted to solidify evidence for such a causal role of the dlPFC in directed forgetting by replicating an existing rTMS study (Hanslmayr S, 2012) in a preregistered within-participant design. We stimulated participants at the dlPFC (BA9) or vertex using 45s of 1Hz rTMS after instructions to forget previously remembered words in a list-method directed forgetting paradigm and tested for effects on the amount of forgotten information. Contrary to the study we were attempting to replicate, no significant increase in forgetting under dlPFC stimulation was found in our participants. However, when combining our results with the study we were attempting to replicate, dlPFC stimulation led to significantly increased directed forgetting in both studies combined. We further explored if the rTMS parameters used here and in earlier work (Hanslmayr S, 2012) influenced inhibitory processing at their time of delivery or in a more persistent manner. Unaltered incongruency and negative priming effects in a Stroop task conducted directly after stimulation suggests that our rTMS stimulation did not continue to influence inhibitory processing after the time of stimulation. As the combined evidence for increased directed forgetting due to rTMS dlPFC stimulation is still quite weak, additional replications are necessary to show that directed forgetting is indeed causally driven by an active prefrontal process.	[Stauch, Benjamin J.] Max Planck Gesell, Ernst Strungmann Inst ESI Neurosci Cooperat, Frankfurt, Germany; [Stauch, Benjamin J.] Int Max Planck Res Sch Neural Circuits, Frankfurt, Germany; [Stauch, Benjamin J.; Braun, Verena; Hanslmayr, Simon] Univ Birmingham, Sch Psychol, Birmingham, W Midlands, England	Max Planck Society; University of Birmingham	Hanslmayr, S (corresponding author), Univ Birmingham, Sch Psychol, Birmingham, W Midlands, England.	s.hanslmayr@bham.ac.uk	Stauch, Benjamin J./AAB-2492-2022; Hanslmayr, Simon/F-9356-2010	Stauch, Benjamin J./0000-0002-4484-813X; Hanslmayr, Simon/0000-0003-4448-2147	European Research Council [647954]; Economic and Social Research Council (ESRC) [ES/R010072/1]; Deutsche Forschungsgemeinschaft [HA 5622/1-1]; ESRC [ES/R010072/1] Funding Source: UKRI	European Research Council(European Research Council (ERC)European Commission); Economic and Social Research Council (ESRC)(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); ESRC(UK Research & Innovation (UKRI)Economic & Social Research Council (ESRC))	SH was supported by the European Research Council (grant agreement No647954, https://erc.europa.eu), the Economic and Social Research Council (ESRC grant agreement NoES/R010072/1, https://esrc.ukri.org), and Deutsche Forschungsgemeinschaft (HA 5622/1-1, https://www.dfg.de/).The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper.	Anderson MC, 2014, TRENDS COGN SCI, V18, P279, DOI 10.1016/j.tics.2014.03.002; Aydin-Abidin S, 2006, J PHYSIOL-LONDON, V574, P443, DOI 10.1113/jphysiol.2006.108464; Basden BH, 1996, MEMORY, V4, P633, DOI 10.1080/741941000; BASDEN BH, 1993, J EXP PSYCHOL LEARN, V19, P603, DOI 10.1037/0278-7393.19.3.603; Bastos AM, 2015, NEURON, V85, P390, DOI 10.1016/j.neuron.2014.12.018; Bjork R.A., 1989, VARIETIES MEMORY CON, P309; Bjork RA, 1998, INTENTIONAL FORGETTING: INTERDISCIPLINARY APPROACHES, P453; Borenstein M, 2009, INTRO META ANAL, DOI [10.1007/978-3-319-14908-0_2, DOI 10.1002/9780470743386]; Braver SL, 2014, PERSPECT PSYCHOL SCI, V9, P333, DOI 10.1177/1745691614529796; COLTHEART M, 1981, Q J EXP PSYCHOL-A, V33, P497, DOI 10.1080/14640748108400805; Conway MA, 2003, CORTEX, V39, P667, DOI 10.1016/S0010-9452(08)70859-1; Freunberger R, 2009, HUM BRAIN MAPP, V30, P3417, DOI 10.1002/hbm.20766; Fuster J, 2015, PREFRONTAL CORTEX; Hanslmayr S, 2012, J NEUROSCI, V32, P14742, DOI 10.1523/JNEUROSCI.1777-12.2012; Hauswald A, 2011, SOC COGN AFFECT NEUR, V6, P450, DOI 10.1093/scan/nsq061; Jarosz AF, 2014, J PROBL SOLVING, V7, P2, DOI 10.7771/1932-6246.1167; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Leys C, 2013, J EXP SOC PSYCHOL, V49, P764, DOI 10.1016/j.jesp.2013.03.013; Ludowig E, 2010, NEUROBIOL LEARN MEM, V93, P352, DOI 10.1016/j.nlm.2009.12.001; Morey RD, 2008, TUTOR QUANT METHODS, V4, P61, DOI 10.20982/tqmp.04.2.p061; Pastotter B, 2012, MEM COGNITION, V40, P861, DOI 10.3758/s13421-012-0206-4; Rizio AA, 2013, J COGNITIVE NEUROSCI, V25, P297, DOI 10.1162/jocn_a_00310; Schuit E, 2015, SYST REV, V4, DOI 10.1186/s13643-015-0048-9; Silas J, 2016, NEUROSCI LETT, V616, P166, DOI 10.1016/j.neulet.2016.01.035; Silvanto J, 2008, BRAIN TOPOGR, V21, P1, DOI 10.1007/s10548-008-0067-0; Thielscher A, 2011, NEUROIMAGE, V54, P234, DOI 10.1016/j.neuroimage.2010.07.061; Titz C, 2010, PSYCHOL AGING, V25, P405, DOI 10.1037/a0017225; Viechtbauer W, 2010, J STAT SOFTW, V36, P1, DOI 10.18637/jss.v036.i03; Viejo-Sobera R, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00462; Wylie GR, 2008, CEREB CORTEX, V18, P670, DOI 10.1093/cercor/bhm101	30	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 12	2020	15	8							e0236287	10.1371/journal.pone.0236287	http://dx.doi.org/10.1371/journal.pone.0236287			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ND3HD	32785218	gold, Green Published, Green Accepted			2023-01-03	WOS:000561793900064
J	Cui, J; Qu, ZP; Harata-Lee, Y; Shen, HY; Aung, TN; Wang, W; Kortschak, D; Adelson, DL				Cui, Jian; Qu, Zhipeng; Harata-Lee, Yuka; Shen, Hanyuan; Aung, Thazin Nwe; Wang, Wei; Kortschak, Daniel; Adelson, David L.			The effect of compound kushen injection on cancer cells: Integrated identification of candidate molecular mechanisms	PLOS ONE			English	Article							TRADITIONAL CHINESE MEDICINE; ANTITUMOR ACTIVITIES; GENE-EXPRESSION; MOUSE MODEL; PATHWAY; MATRINE; PROLIFERATION; APOPTOSIS; PACKAGE; GROWTH	Traditional Chinese Medicine (TCM) preparations are often extracts of single or multiple herbs containing hundreds of compounds, and hence it has been difficult to study their mechanisms of action. Compound Kushen Injection (CKI) is a complex mixture of compounds extracted from two medicinal plants and has been used in Chinese hospitals to treat cancer for over twenty years. To demonstrate that a systematic analysis of molecular changes resulting from complex mixtures of bioactives from TCM can identify a core set of differentially expressed (DE) genes and a reproducible set of candidate pathways. We usedin vitrocancer models to measure the effect of CKI on cell cycle phases and apoptosis, and correlated those phenotypes with CKI induced changes in gene expression. We treated two cancer cell lines with or without CKI and assessed the resulting phenotypes by employing cell viability and proliferation assays. Based on these results, we carried out high-throughput transcriptome data analysis to identify genes and candidate pathways perturbed by CKI. We integrated these differential gene expression results with previously reported results and carried out validation of selected differentially expressed genes. CKI induced cell-cycle arrest and apoptosis in the cancer cell lines tested. In these cells CKI also altered the expression of 363 core candidate genes associated with cell cycle, apoptosis, DNA replication/repair, and various cancer pathways. Of these, 7 are clinically relevant to cancer diagnosis or therapy, 14 are cell cycle regulators, and most of these 21 candidates are downregulated by CKI. Comparison of our core candidate genes to a database of plant medicinal compounds and their effects on gene expression identified one-to-one, one-to-many and many-to-many regulatory relationships between compounds in CKI and DE genes. By identifying genes and promising candidate pathways associated with CKI treatment based on our transcriptome-based analysis, we have shown that this approach is useful for the systematic analysis of molecular changes resulting from complex mixtures of bioactives.	[Cui, Jian; Qu, Zhipeng; Harata-Lee, Yuka; Shen, Hanyuan; Aung, Thazin Nwe; Kortschak, Daniel; Adelson, David L.] Univ Adelaide, Dept Mol & Biomed Sci, Adelaide, SA, Australia; [Wang, Wei] Shanxi Zhendong Pharmaceut Co Ltd, Zhendong Res Inst, Beijing, Peoples R China	University of Adelaide	Adelson, DL (corresponding author), Univ Adelaide, Dept Mol & Biomed Sci, Adelaide, SA, Australia.	david.adelson@adelaide.edu.au	; Adelson, David/E-5506-2011	Cui, Jian/0000-0002-4267-9379; Harata-Lee, Yuka/0000-0002-5850-2471; Kortschak, Robert Daniel/0000-0001-8295-2301; Adelson, David/0000-0003-2404-5636; Qu, Zhipeng/0000-0002-6841-0773	Chinese National Project for Standardization of Chinese Materia Medica [ZYBZH-C-JIN-43]; Special International Cooperation Project of Traditional Chinese Medicine [GZYYGJ2017035]; University of Adelaide-Zhendong Australia - China Centre for Molecular Chinese Medicine	Chinese National Project for Standardization of Chinese Materia Medica; Special International Cooperation Project of Traditional Chinese Medicine; University of Adelaide-Zhendong Australia - China Centre for Molecular Chinese Medicine	WW: Chinese National Project for Standardization of Chinese Materia Medica (ZYBZH-C-JIN-43), the Special International Cooperation Project of Traditional Chinese Medicine (GZYYGJ2017035) DLA: University of Adelaide-Zhendong Australia - China Centre for Molecular Chinese Medicine. Funders had no control the experiments, study design, data collection and analysis, preparation of the manuscript or decision to publish.	Afar DEH, 2001, CANCER RES, V61, P1686; Anwar-Mohamed A, 2009, CANCER LETT, V275, P93, DOI 10.1016/j.canlet.2008.10.003; CAILLEAU R, 1974, J NATL CANCER I, V53, P661, DOI 10.1093/jnci/53.3.661; Christensen AG, 2017, ELUCIDATION ALTERED; Csardi G., 2006, INTERJ COMPLEX SYST, V1695, P1; Cui J, 2019, BMC CANCER, V19, DOI 10.1186/s12885-018-5230-8; Cui M, 2014, J TRADIT CHIN MED, V34, P518, DOI 10.1016/S0254-6272(15)30056-X; Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Efferth T, 2007, TRENDS MOL MED, V13, P353, DOI 10.1016/j.molmed.2007.07.001; Gao L, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18325-7; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hao DC, 2014, DRUG DEVELOP RES, V75, P299, DOI 10.1002/ddr.21214; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hollern DP, 2014, MOL CELL BIOL, V34, P3229, DOI 10.1128/MCB.00737-14; Jiang WY, 2005, TRENDS PHARMACOL SCI, V26, P558, DOI 10.1016/j.tips.2005.09.006; Kamburov A, 2009, NUCLEIC ACIDS RES, V37, pD623, DOI 10.1093/nar/gkn698; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Knowles B.B., 1983, U.S. Patent., Patent No. [4393133A, 4393133, US4393133A]; Li XX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043918; Liao CY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/840542; Liu Y, 2014, TUMOR BIOL, V35, P5111, DOI 10.1007/s13277-014-1680-z; Liu Z. Y, 2016, SCI REPORTS, V6; Luo M, 2010, CANCER LETT, V289, P127, DOI 10.1016/j.canlet.2009.07.005; Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285; Ma X, 2016, FRONT PHARMACOL, V7, DOI [10.3389/fphar.2015.00070, 10.3389/fphar.2016.00070]; Mitsui Y, 2016, ONCOTARGET, V7, P49107, DOI 10.18632/oncotarget.9470; Nandekar PP, 2016, EUR J MED CHEM, V115, P82, DOI 10.1016/j.ejmech.2016.02.061; Ninomiya M., 2013, MINOR FLAVONOIDS CHA, P1867, DOI [DOI 10.1007/978-3-642-22144-6_62, 10.1007/978-3-642-22144-6_62]; Ou C, 2016, RELATIONSHIP ALDOSTE; Piotrowska-Kempisty H, 2017, TOXICOL LETT, V267, P59, DOI 10.1016/j.toxlet.2016.12.018; Qu ZP, 2016, ONCOTARGET, V7, P66003, DOI 10.18632/oncotarget.11788; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Schriml LM, 2012, NUCLEIC ACIDS RES, V40, pD940, DOI 10.1093/nar/gkr972; Shu GW, 2014, TOXICOL APPL PHARM, V281, P157, DOI 10.1016/j.taap.2014.06.021; Song YN, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/989618; Sun HX, 2013, HEPATOLOGY, V57, P1088, DOI 10.1002/hep.26188; Wang P, 2013, OMICS, V17, P451, DOI 10.1089/omi.2012.0057; Wang W, 2015, ACTA PHARMACOL SIN, V36, P676, DOI 10.1038/aps.2015.24; WARREN RS, 1995, J CLIN INVEST, V95, P1789, DOI 10.1172/JCI117857; Woods K, 2007, J BIOL CHEM, V282, P2130, DOI 10.1074/jbc.C600252200; Wu CZ, 2015, MOL MED REP, V11, P4129, DOI 10.3892/mmr.2015.3338; Yang XZ, 2017, NAT PROD RES, V31, P1150, DOI 10.1080/14786419.2016.1230118; Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118; Yu PF, 2009, CYTOTECHNOLOGY, V59, P219, DOI 10.1007/s10616-009-9225-9; Zaldua N, 2016, FEBS J, V283, P647, DOI 10.1111/febs.13617; Zhang H, 2016, ONCOGENE; Zhang JQ, 2010, WORLD J GASTROENTERO, V16, P4281, DOI 10.3748/wjg.v16.i34.4281; Zhang LP, 2001, LEUKEMIA RES, V25, P793, DOI 10.1016/S0145-2126(00)00145-4; Zhang XL, 2016, IRAN J PHARM RES, V15, P491; Zhang XL, 2013, PHARMAZIE, V68, P369, DOI 10.1691/ph.2013.2845; Zhao ZZ, 2014, CANCER LETT, V355, P232, DOI 10.1016/j.canlet.2014.08.037; Zhou Y, 2016, NUTRIENTS, V8, DOI 10.3390/nu8030156	53	9	10	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2020	15	7							e0236395	10.1371/journal.pone.0236395	http://dx.doi.org/10.1371/journal.pone.0236395			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW2PD	32730293	Green Published, gold			2023-01-03	WOS:000556884700044
J	Awdish, RLA				Awdish, Rana L. A.			The Liminal Space	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material								There is so much talk of "endings" and "after this" and even of "returning" to some way that we used to be. None of those imagined times and places feel real to me. Only this timeless space feels real. This is the pause before a new beginning.	[Awdish, Rana L. A.] Henry Ford Hosp, Detroit, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital	Awdish, RLA (corresponding author), Henry Ford Hosp, Detroit, MI 48202 USA.								0	3	3	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 23	2020	383	4							e17	10.1056/NEJMp2012147	http://dx.doi.org/10.1056/NEJMp2012147			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MU1XJ	32492299	Bronze			2023-01-03	WOS:000555465900002
J	Szpitalak, M; Polczyk, R				Szpitalak, Malwina; Polczyk, Romuald			Reducing interrogative suggestibility: The role of self-affirmation and positive feedback	PLOS ONE			English	Article							CONFIDENCE; MEMORY; MISINFORMATION; PERFORMANCE; PSYCHOLOGY; RESPONSES	Interrogative suggestibility, as measured with Gudjonsson Suggestibility Scales, consists of an individual's tendency to yield to misleading questions (Yield) and to change answers after negative feedback (Shift). This study aimed to determine whether reinforced self-affirmation (RSA), a technique that aims to boost self-confidence in order to increase the tendency to rely on one's own memory instead of external cues, can reduce interrogative suggestibility. RSA consists of self-affirmation induced by means of writing down one's greatest achievements in life and of manipulated positive feedback. The efficacy of two kinds of positive feedback was explored. Shift was reduced by positive feedback relating both to memory and to the feeling that a person is very independent in their judgements, while only feedback related to memory reduced Yield. The results are discussed in terms of the different mechanisms underlying Yield and Shift. Inducing independence of judgements might not have been effective in the case of Yield because to some extent it taps opinions but not the quality of a cognitive process such as memory. An individual may believe in their own opinions and views but still be unsure about the quality of their own memory.	[Szpitalak, Malwina; Polczyk, Romuald] Jagiellonian Univ, Inst Psychol, Krakow, Poland	Jagiellonian University	Polczyk, R (corresponding author), Jagiellonian Univ, Inst Psychol, Krakow, Poland.	romuald.polczyk@uj.edu.pl			Narodowe Centrum Nauki [National Science Centre], Poland: 'Mechanisms of reinforced self-affirmation effect' [UMO-2016/23/D/HS6/01677]	Narodowe Centrum Nauki [National Science Centre], Poland: 'Mechanisms of reinforced self-affirmation effect'	This study was supported by a grant from the Narodowe Centrum Nauki [National Science Centre], Poland: 'Mechanisms of reinforced self-affirmation effect', Nr UMO-2016/23/D/HS6/01677, for Malwina Szpitalak.	Abele AE, 2007, J PERS SOC PSYCHOL, V93, P751, DOI 10.1037/0022-3514.93.5.751; Adler WP, 1990, EFFECT TASK APPROPRI; [Anonymous], 2012, MOTYWACYJNE MECHANIZ; [Anonymous], 2011, JAPANESE J HLTH PSYC, DOI [10.11560/jahp.24.1_45, DOI 10.11560/JAHP.24.1_45]; [Anonymous], 2017, POL PSYCHOL BULL, DOI [10.1515/PPB-2017-0045, DOI 10.1515/PPB-2017-0045]; Bain S. A., 2000, LEGAL CRIMINOL PSYCH, V5, P123, DOI DOI 10.1348/135532500168029; Bain SA, 2004, LEGAL CRIMINOL PSYCH, V9, P239, DOI 10.1348/1355325041719419; Bakan D., 1966, DUALITY HUMAN EXISTE; Barber N, 2008, SELF CONFIDENCE KNOW; Bartlett Frederic C., 1932, REMEMBERING; Baxter JS, 2006, PERS INDIV DIFFER, V40, P87, DOI 10.1016/j.paid.2005.06.017; Beckmann N, 2009, LEARN INDIVID DIFFER, V19, P277, DOI 10.1016/j.lindif.2008.09.008; BINET Alfred., 1900, LA SUGGESTIBILITE; Blank H, 1998, MEMORY, V6, P481, DOI 10.1080/741943086; Boon J. C. W., 2000, LEGAL CRIMINOL PSYCH, V5, P273, DOI DOI 10.1348/135532500168137; Brewer N, 2011, CURR DIR PSYCHOL SCI, V20, P24, DOI 10.1177/0963721410389169; Clark N. K., 1986, SOCIAL BEHAVIOUR, V1, P83; Elizabeth F., 1996, EYEWITNESS TESTIMONY; Frenda SJ, 2011, CURR DIR PSYCHOL SCI, V20, P20, DOI 10.1177/0963721410396620; Gudjonsson G.H., 2018, PSYCHOL FALSE CONFES; Gudjonsson G.H., 2003, PSYCHOL INTERROGATIO; Gudjonsson G.H., 1997, GUDJONSSON SUGGESTIB; Henkel LA, 2017, PSYCHOL CRIME LAW, V23, P97, DOI 10.1080/1068316X.2016.1225051; Hollenbeck GP, 2004, ORGAN DYN, V33, P254, DOI 10.1016/j.orgdyn.2004.06.003; Howe ML, 2013, MEMORY, V21, P576, DOI 10.1080/09658211.2012.725735; Keppel G., 2004, DESIGN AND ANAL; Kleitman S, 2007, LEARN INDIVID DIFFER, V17, P161, DOI 10.1016/j.lindif.2007.03.004; Linton Christopher P., 1994, Australian Journal of Clinical and Experimental Hypnosis, V22, P53; LOFTUS EF, 1978, J EXP PSYCHOL-HUM L, V4, P19, DOI 10.1037/0278-7393.4.1.19; Luna K, 2012, APPL COGNITIVE PSYCH, V26, P687, DOI 10.1002/acp.2845; MACBRIDE PD, 1965, J PSYCHOL, V60, P9, DOI 10.1080/00223980.1965.10545258; Mastroberardino S, 2013, LEGAL CRIMINOL PSYCH, V18, P274, DOI 10.1111/j.2044-8333.2012.02048.x; MCCARTY PA, 1986, ACAD MANAGE J, V29, P840, DOI 10.2307/255950; McMurtrie H, 2012, PERS INDIV DIFFER, V53, P958, DOI 10.1016/j.paid.2012.07.008; Morocco PE ., 1978, EFFECTS DESCRIPTIVE; PETRUZZELLO SJ, 1988, J SPORT EXERCISE PSY, V10, P174, DOI 10.1123/jsep.10.2.174; Polczyk R, 2005, PERS INDIV DIFFER, V38, P177, DOI 10.1016/j.paid.2004.03.018; REEDER GD, 1979, PSYCHOL REV, V86, P61, DOI 10.1037/0033-295X.86.1.61; Rosnow R. L., 1985, CONTRASTS ANAL FOCUS; Rosnow RL, 1992, METHODOLOGICAL ISSUE, P337; Schacter DL, 1999, AM PSYCHOL, V54, P182, DOI 10.1037/0003-066X.54.3.182; Schooler J.W., 1986, SOC BEHAV, V1, P105, DOI DOI 10.1006/JESP.1993.1003; Sherman DK, 2006, ADV EXP SOC PSYCHOL, V38, P183, DOI 10.1016/S0065-2601(06)38004-5; Srivastava S. K., 2013, J PSYCHOSOCIAL RES, V8, P41; Stankov L, 1997, INTELLIGENCE, V25, P93, DOI 10.1016/S0160-2896(97)90047-7; STEELE CM, 1983, J PERS SOC PSYCHOL, V45, P5, DOI 10.1037/0022-3514.45.1.5; Szpitalak M., 2012, STUD PSYCHOL, V50, P63; Szpitalak M., 2011, PROBLEMS FORENSIC SC, V85, P40; Szpitalak M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210987; Szpitalak M, 2016, PSYCHIAT PSYCHOL LAW, V23, P512, DOI 10.1080/13218719.2015.1081088; Szpitalak M, 2015, PSYCHOL CRIME LAW, V21, P911, DOI 10.1080/1068316X.2015.1077243; Thorley C, 2017, PSYCHOL CRIME LAW, V23, P342, DOI 10.1080/1068316X.2016.1258471; TOUSIGNANT JP, 1986, MEM COGNITION, V14, P329, DOI 10.3758/BF03202511; van Bergen S, 2010, APPL COGNITIVE PSYCH, V24, P885, DOI 10.1002/acp.1595; Vealey R.S., 2008, ADV SPORT PSYCHOL, V3rd, P68; Vrij A, 2000, PSYCHOL CRIME LAW, V6, P127, DOI 10.1080/10683160008410837; Wagstaff GF, 2011, J POLICE CRIM PSYCHO, V26, P152, DOI 10.1007/s11896-010-9082-7	57	2	2	2	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 21	2020	15	7							e0236088	10.1371/journal.pone.0236088	http://dx.doi.org/10.1371/journal.pone.0236088			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MS9QL	32692764	gold, Green Published			2023-01-03	WOS:000554606400023
J	Kambale, RM; Ngaboyeka, GA; Ntagazibwa, JN; Bisimwa, MHI; Kasole, LY; Habiyambere, V; Kubuya, VB; Kasongo, JK; Andre, E; van der Linden, D				Kambale, Richard Mbusa; Ngaboyeka, Gaylord Amani; Ntagazibwa, Joseph Ntagerwa; Bisimwa, Marie-Helene Igega; Kasole, Lisa Yvette; Habiyambere, Viateur; Kubuya, Victor Buunda; Kasongo, Joseph Kasongowa; Andre, Emmanuel; van der Linden, Dimitri			Severe acute malnutrition in children admitted in an Intensive Therapeutic and Feeding Centre of South Kivu, Eastern Democratic Republic of Congo: Why do our patients die?	PLOS ONE			English	Article							UPPER-ARM CIRCUMFERENCE; WEIGHT-FOR-HEIGHT; PASTE-BASED FORMULATION; ANTIRETROVIRAL THERAPY; HOSPITALIZED CHILDREN; STANDARD MILK; HIGH-RISK; MORTALITY; EFFICACY; FOOD	Background Severe acute malnutrition (SAM) remains a serious public health concern in low- and middle-income countries. Little is known about treatment outcomes of child inpatients in Intensive Therapeutic and Feeding Units. This study aimed to assess treatment outcomes of SAM and identify factors associated with mortality among children treated at Saint Joseph Nutritional Center, South Kivu, Eastern Democratic Republic of Congo. Methods A retrospective hospital-based cross-sectional study was conducted on medical records of 633 severely malnourished children followed as inpatients at Saint Joseph Nutritional Center from July 2017 to December 2018. Data were entered, thoroughly cleaned and analyzed in SPSS version 25. Univariable and multivariable logistic regression model were fitted to identify factors associated with mortality. Results Among 633 patients admitted with SAM, 13.1% were lost to follow-up and 9.2% died while in hospital. Children with late referral to the health facility (> 14 days) after the onset of main external malnutrition signs had 2.03 times higher odds of death than those referred less than 14 days [AOR = 2.03 at 95%CI (1.12, 3.68)]. The odds of death was 1.91 times higher for children with MUAC < 115 mm than for those with MUAC >= 115 mm [AOR = 1.91 at 95% CI (1.05, 3.50)]. Children infected with HIV were 3.90 times more likely to die compared to their counterparts [AOR = 3.90 at 95% CI (2.80, 9.41)]. Conclusion Particular emphasis should be placed on partnering with communities to improve information on malnutrition signs and on critical importance of early referral to the health system. While HIV incidence in DRC is still low (0.21%), its impact on mortality among severely malnourished children is increased due to the limited access to HIV testing and antiretroviral therapy.	[Kambale, Richard Mbusa; van der Linden, Dimitri] Catholic Univ Louvain, Inst Expt & Clin Res, Brussels, Belgium; [Kambale, Richard Mbusa; Ngaboyeka, Gaylord Amani; Ntagazibwa, Joseph Ntagerwa; Bisimwa, Marie-Helene Igega; Kasole, Lisa Yvette; Habiyambere, Viateur; Kubuya, Victor Buunda; Kasongo, Joseph Kasongowa] Univ Catholique Bukavu, Bukavu, Rep Congo; [Kambale, Richard Mbusa; Ngaboyeka, Gaylord Amani; Ntagazibwa, Joseph Ntagerwa] Hop Prov Gen Reference Bukavu, Dept Pediat, Bukavu, Rep Congo; [Andre, Emmanuel] Katholieke Univ Leuven, Dept Microbiol & Immunol, Lab Clin Bacteriol & Mycol, Leuven, Belgium; [van der Linden, Dimitri] Clin Univ St Luc, Dept Pediat, Pediat Infect Dis, Gen Pediat, Brussels, Belgium	Universite Catholique Louvain; KU Leuven; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc	Kambale, RM (corresponding author), Catholic Univ Louvain, Inst Expt & Clin Res, Brussels, Belgium.; Kambale, RM (corresponding author), Univ Catholique Bukavu, Bukavu, Rep Congo.; Kambale, RM (corresponding author), Hop Prov Gen Reference Bukavu, Dept Pediat, Bukavu, Rep Congo.	richkambale7@gmail.com	André, Emmanuel/AAI-4372-2021; Kambale, Richard/AHB-8435-2022	André, Emmanuel/0000-0001-8321-3770; Amani Ngaboyeka, Gaylord/0000-0003-4906-1851; KAMBALE, Richard/0000-0002-6545-2441; Van der Linden, Dimitri/0000-0002-2696-4559				Aguayo VM, 2015, PUBLIC HEALTH NUTR, V18, P3244, DOI 10.1017/S1368980015000543; [Anonymous], 2012, INT MAN CHILD ILLN I; [Anonymous], 2012, GLOB TUB REP 2012; [Anonymous], 2015, EUCAST CLIN BREAKPOI; Ashworth A., 2003, Guidelines for the inpatient treatment of severely malnourished children; Bahwere P, 2006, COMMUNITY BASED THER, V1st; Bahwere P, 2017, AM J CLIN NUTR, V106, P1100, DOI 10.3945/ajcn.117.156653; Bahwere P, 2016, AM J CLIN NUTR, V103, P1145, DOI 10.3945/ajcn.115.119537; Berkley J, 2005, JAMA-J AM MED ASSOC, V294, P591, DOI 10.1001/jama.294.5.591; Berkley JA, 2016, LANCET GLOB HEALTH, V4, pE464, DOI 10.1016/S2214-109X(16)30096-1; Bitwe R, 2006, TROP MED INT HEALTH, V11, P73, DOI 10.1111/j.1365-3156.2005.01540.x; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Briend A, 2012, MATERN CHILD NUTR, V8, P130, DOI 10.1111/j.1740-8709.2011.00340.x; Calvello EJ, 2015, B WORLD HEALTH ORGAN, V93, P417, DOI 10.2471/BLT.14.146571; Charter H, 2011, SPHERE PROJECT HDB, V1; Chiabi A, 2017, J TROP PEDIATRICS, V63, P260, DOI 10.1093/tropej/fmw083; Collins S, 2006, FOOD NUTR BULL, V27, pS49, DOI 10.1177/15648265060273S304; Department of Maternal and Child Health and Community Health Ministry of Health PRC, 2009, CHILD GROWTH STAND I; Desmonde S, 2014, AIDS, V28, P1645, DOI 10.1097/QAD.0000000000000272; Diop EHI, 2003, AM J CLIN NUTR, V78, P302, DOI 10.1093/ajcn/78.2.302; Dramaix M, 1996, AM J EPIDEMIOL, V143, P1235, DOI 10.1093/oxfordjournals.aje.a008711; Elhassan MM, 2016, INT J INFECT DIS, V43, P25, DOI 10.1016/j.ijid.2015.12.006; Fawzi WW, 1997, AM J CLIN NUTR, V65, P1062, DOI 10.1093/ajcn/65.4.1062; Grellety E, 2018, NUTR J, V17, DOI 10.1186/s12937-018-0383-5; Grellety E, 2015, PUBLIC HEALTH NUTR, V18, P2575, DOI 10.1017/S1368980015000737; INS, ENQ GRAPP IND MULT 2; Isenberg HD., 1998, ESSENTIAL PROCEDURES; Kerac M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096030; Komrska J., 2012, Field Exchange - Emergency Nutrition Network ENN, P46; LaCourse SM, 2014, PEDIATR INFECT DIS J, V33, P1200, DOI 10.1097/INF.0000000000000384; Laughton B, 2012, AIDS, V26, P1685, DOI 10.1097/QAD.0b013e328355d0ce; Lelijveld N, 2016, LANCET GLOB HEALTH, V4, pE654, DOI 10.1016/S2214-109X(16)30133-4; Lewis J, 2012, J INFECT DIS, V205, P548, DOI 10.1093/infdis/jir787; Maqbool A., 2011, NELSON TXB PEDIAT; McGrath CJ, 2011, AIDS, V25, P345, DOI 10.1097/QAD.0b013e32834171db; Ministere de la Sante Publique, 2016, PROT NAT PRIS CHARG; Mumbere M, 2018, BMC PEDIATR, V18, DOI 10.1186/s12887-018-1115-x; Musoke P, 2015, AIDS, V29, P1623, DOI [10.1097/QAD.0000000000000749, 10.1097/QAD.0000000000000590]; Narayan Shyam, 2003, Indian Journal of Pediatrics, V70, P467, DOI 10.1007/BF02723134; Ngari MM, 2017, PAEDIATR PERINAT EP, V31, P233, DOI 10.1111/ppe.12348; ONUSIDA, 2017, RAPP MOND SUIV LUTT, V208, P156; Patel K, 2008, CLIN INFECT DIS, V46, P1751, DOI 10.1086/587900; Picat MQ, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001542; Roth GA, 2018, LANCET, V392, P1736, DOI [10.1016/S0140-6736(18)32203-7, 10.1016/s0140-6736(18)32203-7]; Sachdeva S, 2016, PUBLIC HEALTH NUTR, V19, P2513, DOI 10.1017/S1368980016000719; Talbert A, 2019, BMC MED, V17, DOI 10.1186/s12916-019-1258-0; The pediatric team of the IeDEA Southern Africa IeDEA West Africa and COHERE collaborations, 2015, PEDIAT TEAM IE UNPUB; Tickell KD, 2016, B WORLD HEALTH ORGAN, V94, P642, DOI 10.2471/BLT.15.162867; UNICEF, 2018, LEVELS TRENDS CHILD, DOI [10.1016/S0266-6138(96)90067-4, DOI 10.1016/S0266-6138(96)90067-4]; UNICEF, 2013, READ US THER FOOD CH; United Nations Inter-agency Group for Child Mortality Estimation (UN IGME), 2018, LEV TREND CHILD MORT; VELLA V, 1994, EUR J CLIN NUTR, V48, P189; WHO, 2005, GUID MAN COMM ILLN L; Williams PL, 2013, AIDS, V27, P1959, DOI 10.1097/QAD.0b013e328361195b; World Health Organization, 2015, GUID START ANT THER, P1; World Health Organization, 1999, MAN SEV MALN MAN PHY; World Health Organization (WHO), 2015, GUID START ANT THER, P78; World Health Organization (WHO), 2013, UPD MAN SEV AC MAL I	58	4	4	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2020	15	7							e0236022	10.1371/journal.pone.0236022	http://dx.doi.org/10.1371/journal.pone.0236022			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR9PA	32678837	Green Published, gold			2023-01-03	WOS:000553920100032
J	Baum, A; Schwartz, MD				Baum, Aaron; Schwartz, Mark D.			Admissions to Veterans Affairs Hospitals for Emergency Conditions During the COVID-19 Pandemic	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									[Baum, Aaron] Icahn Sch Med Mt Sinai, Dept Hlth Syst Design & Global Hlth, One Gustave L Levy Pl, New York, NY 10029 USA; [Schwartz, Mark D.] NYU, Sch Med, Dept Populat Hlth, New York, NY USA	Icahn School of Medicine at Mount Sinai; New York University	Baum, A (corresponding author), Icahn Sch Med Mt Sinai, Dept Hlth Syst Design & Global Hlth, One Gustave L Levy Pl, New York, NY 10029 USA.	aaron.baum@mssm.edu		Schwartz, Mark/0000-0002-7123-0060				[Anonymous], 2020, COVID 19 RESPONSE PL; Fihn SD, 2014, HEALTH AFFAIR, V33, P1203, DOI 10.1377/hlthaff.2014.0054; Rosenbaum L, 2020, NEW ENGL J MED, V382, P2368, DOI 10.1056/NEJMms2009984	3	158	159	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	2020	324	1					96	99		10.1001/jama.2020.9972	http://dx.doi.org/10.1001/jama.2020.9972			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM5FX	32501493	Green Published, Bronze			2023-01-03	WOS:000568123600028
J	Tsai, BM; Sun, JT; Hsieh, MJ; Lin, YY; Kao, TC; Chen, LW; Ma, MHM; Chiang, WC				Tsai, Bing Min; Sun, Jen-Tang; Hsieh, Ming-Ju; Lin, Yu-You; Kao, Tsung-Chi; Chen, Lee-Wei; Ma, Matthew Huei-Ming; Chiang Wen-Chu			Optimal paramedic numbers in resuscitation of patients with out-of-hospital cardiac arrest: A randomized controlled study in a simulation setting	PLOS ONE			English	Article							EMERGENCY MEDICAL TECHNICIANS; CHEST COMPRESSIONS; ON-SCENE; OUTCOMES; SURVIVAL	Background The effect of paramedic crew size in the resuscitation of patients with out-of-hospital cardiac arrest (OHCA) remains inconclusive. We hypothesised that teams with a larger crew size have better resuscitation performance including chest compression fraction (CCF), advanced life support (ALS), and teamwork performance than those with a smaller crew size. Methods We conducted a randomized controlled study in a simulation setting. A total of 140 paramedics from New Taipei City were obtained by stratified sampling and were randomly allocated to 35 teams with crew sizes of 2, 3, 4, 5, and 6 (i.e. 7 teams in every paramedic crew size). A scenario involving an OHCA patient who experienced ventricular fibrillation and was attached to a cardiopulmonary resuscitation (CPR) machine was simulated. The primary outcome was the overall CCF; the secondary outcomes were the CCF in manual CPR periods, time from the first dose of epinephrine until the accomplishment of intubation, and teamwork performance. Tasks affecting the hands-off time during CPR were also analysed. Results In all 35 teams with crew sizes of 2, 3, 4, 5, and 6, the overall CCFs were 65.1%, 64.4%, 70.7%, 72.8%, and 71.5%, respectively (P = 0.148). Teams with a crew size of 5 (58.4%, 61.8%, 68.9%, 72.4%, and 68.7%, P<0.05) had higher CCF in manual CPR periods and better team dynamics. Time to the first dose of epinephrine was significantly shorter in teams with 4 paramedics, while time to completion of intubation was shortest in teams with 6 paramedics. Troubleshooting of M-CPR machine decreased the hands-off time during resuscitation (39 s), with teams comprising 2 paramedics having the longest hands-off time (63s). Conclusion Larger paramedic crew size (>= 4 paramedics) did not significantly increase the overall CCF in OHCA resuscitation but showed higher CCF in manual CPR period before the setup of the CPR machine. A crew size of >= 4 paramedics can also shorten the time of ALS interventions, while teams with 5 paramedics will have the best teamwork performance. Paramedic teams with a smaller crew size should focus more on the quality of manual CPR, teamwork, and training how to troubleshoot a M-CPR machine.	[Tsai, Bing Min; Lin, Yu-You] New Taipei City Fire Dept, Div Emergency Med Serv, New Taipei, Taiwan; [Sun, Jen-Tang] Far Eastern Mem Hosp, Dept Emergency Med, New Taipei, Taiwan; [Hsieh, Ming-Ju; Ma, Matthew Huei-Ming; Chiang Wen-Chu] Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan; [Kao, Tsung-Chi] New Taipei City Fire Dept, Div Chief Emergency Med Serv, New Taipei, Taiwan; [Chen, Lee-Wei] Natl Yang Ming Univ, Inst Emergency & Crit Care Med, Taipei, Taiwan; [Chen, Lee-Wei] Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung, Taiwan; [Chen, Lee-Wei] Kaohsiung Vet Gen Hosp, Dept Surg, Kaohsiung, Taiwan; [Ma, Matthew Huei-Ming; Chiang Wen-Chu] Natl Taiwan Univ Hosp, Dept Emergency Med, Yun Lin Branch, Touliu, Yunlin, Taiwan	Far Eastern Memorial Hospital; National Taiwan University; National Taiwan University Hospital; National Yang Ming Chiao Tung University; National Sun Yat Sen University; Kaohsiung Veterans General Hospital; National Taiwan University; National Taiwan University Hospital	Chiang, WC (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Taipei, Taiwan.; Chen, LW (corresponding author), Natl Yang Ming Univ, Inst Emergency & Crit Care Med, Taipei, Taiwan.; Chen, LW (corresponding author), Natl Sun Yat Sen Univ, Dept Biol Sci, Kaohsiung, Taiwan.; Chen, LW (corresponding author), Kaohsiung Vet Gen Hosp, Dept Surg, Kaohsiung, Taiwan.; Chiang, WC (corresponding author), Natl Taiwan Univ Hosp, Dept Emergency Med, Yun Lin Branch, Touliu, Yunlin, Taiwan.	lwchen@vghks.gov.tw; drchiang.tw@gmail.com	CHIANG, WEN-CHU/AAH-6057-2021	CHIANG, WEN-CHU/0000-0001-8620-7982; HSIEH, MING-JU/0000-0003-3636-6250; MA, MATTHEW HUEI-MING/0000-0002-4388-9984	Taiwan Ministry of Science and Technology [MOST 108-2314-B-002-130-MY3, MOST 105-2314-B002-200-MY3]	Taiwan Ministry of Science and Technology	This study was funded by the Taiwan Ministry of Science and Technology (MOST 108-2314-B-002-130-MY3 and MOST 105-2314-B002-200-MY3).	Ashton A, 2002, RESUSCITATION, V55, P151, DOI 10.1016/S0300-9572(02)00168-5; Chan PS, 2014, CIRCULATION, V130, P1876, DOI 10.1161/CIRCULATIONAHA.114.009711; Chiang WC, 2018, ANN EMERG MED, V71, P387, DOI 10.1016/j.annemergmed.2017.08.008; Chiang WC, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0181-4; Christenson J, 2009, CIRCULATION, V120, P1241, DOI 10.1161/CIRCULATIONAHA.109.852202; Hackman JR., 2002, LEADING TEAMS SETTIN; Hagiwara S, 2017, AM J EMERG MED, V35, P391, DOI 10.1016/j.ajem.2016.11.020; Kajino K, 2014, RESUSCITATION, V85, P59, DOI 10.1016/j.resuscitation.2013.09.002; Martin-Gill C, 2010, PREHOSP EMERG CARE, V14, P229, DOI 10.3109/10903120903572293; Rittenberger JC, 2006, RESUSCITATION, V68, P365, DOI 10.1016/j.resuscitation.2005.07.019; Rubertsson S, 2014, JAMA-J AM MED ASSOC, V311, P53, DOI 10.1001/jama.2013.282538; Staats BR, 2012, ORGAN BEHAV HUM DEC, V118, P132, DOI 10.1016/j.obhdp.2012.03.002; Sun JT, 2018, RESUSCITATION, V122, P48, DOI 10.1016/j.resuscitation.2017.11.048; Wang CY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122675; Warren SA, 2015, RESUSCITATION, V94, P40, DOI 10.1016/j.resuscitation.2015.02.019	16	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 7	2020	15	7							e0235315	10.1371/journal.pone.0235315; 10.1371/journal.pone.0235315.r001; 10.1371/journal.pone.0235315.r002; 10.1371/journal.pone.0235315.r003; 10.1371/journal.pone.0235315.r004	http://dx.doi.org/10.1371/journal.pone.0235315; 10.1371/journal.pone.0235315.r001; 10.1371/journal.pone.0235315.r002; 10.1371/journal.pone.0235315.r003; 10.1371/journal.pone.0235315.r004			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN1ZE	32634172	Green Published, gold			2023-01-03	WOS:000550645600028
J	Ni, DJ; Ai, ZY; Munoz-Sandoval, D; Suresh, R; Ellis, PR; Chen, YQ; Sharp, PA; Butterworth, PJ; Yu, Z; Corpe, CP				Ni, Dejiang; Ai, Zeyi; Munoz-Sandoval, Diana; Suresh, Reshma; Ellis, Peter R.; Chen Yuqiong; Sharp, Paul A.; Butterworth, Peter J.; Yu, Zhi; Corpe, Christopher P.			Inhibition of the facilitative sugar transporters (GLUTs) by tea extracts and catechins	FASEB JOURNAL			English	Article						catechins; facilitative glucose transporters (GLUTs); glucose uptake; sodium-dependent glucose transporter (SGLT1); tea extract	DECREASE GLUCOSE-UPTAKE; GREEN TEA; BRUSH-BORDER; BLACK TEA; DIABETES-MELLITUS; POLYPHENOLS; EXPRESSION; METABOLISM; ABSORPTION; INTESTINE	Tea polyphenolics have been suggested to possess blood glucose lowering properties by inhibiting sugar transporters in the small intestine and improving insulin sensitivity. In this report, we studied the effects of teas and tea catechins on the small intestinal sugar transporters, SGLT1 and GLUTs (GLUT1, 2 and 5). Green tea extract (GT), oolong tea extract (OT), and black tea extract (BT) inhibited glucose uptake into the intestinal Caco-2 cells with GT being the most potent inhibitor (IC50: 0.077 mg/mL), followed by OT (IC50: 0.136 mg/mL) and BT (IC50: 0.56 mg/mL). GT and OT inhibition of glucose uptake was partial non-competitive, with an inhibitor constant (K-i) = 0.0317 and 0.0571 mg/mL, respectively, whereas BT was pure non-competitive,K-i = 0.36 mg/mL. Oocytes injected to express small intestinal GLUTs were inhibited by teas, but SGLT1 was not. Furthermore, catechins present in teas were the predominant inhibitor of glucose uptake into Caco-2 cells, and gallated catechins the most potent: CG > ECG > EGCG >= GCG when compared to the non-gallated catechins (C, EC, GC, and EGC). In Caco-2 cells, individual tea catechins reduced the SGLT1 gene, but not protein expression levels. In contrast, GLUT2 gene and protein expression levels were reduced after 2 hours exposure to catechins but increased after 24 hours. These in vitro studies suggest teas containing catechins may be useful dietary supplements capable of blunting postprandial glycaemia in humans, including those with or at risk to Type 2 diabetes mellitus.	[Ni, Dejiang; Ai, Zeyi; Chen Yuqiong; Yu, Zhi] Huazhong Agr Univ, Key Lab Hort Plant Biol, Minist Educ, Wuhan, Peoples R China; [Ni, Dejiang; Ellis, Peter R.; Butterworth, Peter J.] Kings Coll London, Dept Biochem & Nutr, Fac Life Sci & Med, London, England; [Ai, Zeyi] Jiangsu Acad Agr Sci, Inst Leisure Agr, Nanjing, Peoples R China; [Munoz-Sandoval, Diana; Suresh, Reshma; Sharp, Paul A.; Corpe, Christopher P.] Kings Coll London, Fac Life Sci & Med, Dept Nutr Sci, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England	Huazhong Agricultural University; University of London; King's College London; Jiangsu Academy of Agricultural Sciences; University of London; King's College London	Corpe, CP (corresponding author), Kings Coll London, Fac Life Sci & Med, Dept Nutr Sci, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England.	Christopher.corpe@kcl.ac.uk		Sharp, Paul Anthony/0000-0003-3400-6702; Munoz Sandoval, Diana/0000-0001-8350-3989; corpe, christopher/0000-0003-1994-8312	National Natural Science Foundation of China [31270732]; Biotechnology and Biological Sciences Research Council, United Kingdom [BB/H004866/1]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Biotechnology and Biological Sciences Research Council, United Kingdom(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	National Natural Science Foundation of China, Grant/Award Number: 31270732; Biotechnology and Biological Sciences Research Council, United Kingdom, Grant/Award Number: BB/H004866/1	Ai ZY, 2017, J FOOD SCI TECH MYS, V54, P1212, DOI 10.1007/s13197-017-2558-z; Boyer S, 1996, FEBS LETT, V396, P218, DOI 10.1016/0014-5793(96)01102-7; Bryans JA, 2007, J AM COLL NUTR, V26, P471, DOI 10.1080/07315724.2007.10719638; BURANT CF, 1992, BIOCHEMISTRY-US, V31, P10414, DOI 10.1021/bi00157a032; BURANT CF, 1994, J CLIN INVEST, V93, P578, DOI 10.1172/JCI117010; Castro-Acosta ML, 2016, P NUTR SOC, V75, P342, DOI 10.1017/S0029665116000240; Chen HX, 2009, EUR FOOD RES TECHNOL, V229, P629, DOI 10.1007/s00217-009-1088-y; Corpe CP, 1996, PFLUG ARCH EUR J PHY, V432, P192, DOI 10.1007/s004240050124; Diamant Michaela, 2006, Curr Diab Rep, V6, P279, DOI 10.1007/s11892-006-0061-4; Drozdowski LA, 2006, WORLD J GASTROENTERO, V12, P1657, DOI 10.3748/wjg.v12.i11.1657; Feng WY, 2006, CURR DRUG METAB, V7, P755, DOI 10.2174/138920006778520552; Fu QY, 2017, MOLECULES, V22, DOI 10.3390/molecules22050849; GRAHAM HN, 1992, PREV MED, V21, P334, DOI 10.1016/0091-7435(92)90041-F; Grefner N. M., 2010, Cell and Tissue Biology, V4, P354, DOI 10.1134/S1990519X10040085; Harbowy ME, 1997, CRIT REV PLANT SCI, V16, P415, DOI 10.1080/713608154; Hashimoto T, 1999, BIOSCI BIOTECH BIOCH, V63, P2252, DOI 10.1271/bbb.63.2252; He Q, 2007, FOOD CHEM, V101, P1178, DOI 10.1016/j.foodchem.2006.03.020; Hirayama BA, 2001, BRIT J PHARMACOL, V134, P484, DOI 10.1038/sj.bjp.0704274; Hossain SJ, 2002, J AGR FOOD CHEM, V50, P5215, DOI 10.1021/jf020252e; Johnston K, 2005, FEBS LETT, V579, P1653, DOI 10.1016/j.febslet.2004.12.099; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; Kao YH, 2006, MOL NUTR FOOD RES, V50, P188, DOI 10.1002/mnfr.200500109; Kellett GL, 2008, ANNU REV NUTR, V28, P35, DOI 10.1146/annurev.nutr.28.061807.155518; Kellett GL, 2005, DIABETES, V54, P3056, DOI 10.2337/diabetes.54.10.3056; Kobayashi Y, 2000, J AGR FOOD CHEM, V48, P5618, DOI 10.1021/jf0006832; Koh LW, 2010, J AGR FOOD CHEM, V58, P148, DOI 10.1021/jf903011g; Kwon O, 2007, FASEB J, V21, P366, DOI 10.1096/fj.06-6620com; Liu J, 2011, J AGR FOOD CHEM, V59, P4582, DOI 10.1021/jf200355q; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lochocka K, 2015, SCI REP-UK, V5, DOI 10.1038/srep12015; Lotfy M, 2017, CURR DIABETES REV, V13, P3, DOI 10.2174/1573399812666151016101622; Ros JL, 2015, PLANTA MED, V81, P975, DOI 10.1055/s-0035-1546131; Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004; MAHRAOUI L, 1994, BIOCHEM J, V298, P629, DOI 10.1042/bj2980629; Manzano S, 2010, MOL NUTR FOOD RES, V54, P1773, DOI 10.1002/mnfr.201000019; Mi YS, 2017, FASEB J, V31, P4998, DOI 10.1096/fj.201700400RR; Moreira L, 2013, EXP CELL RES, V319, P1784, DOI 10.1016/j.yexcr.2013.05.001; Ochiai H, 2009, BIOCHEM PHARMACOL, V78, P1069, DOI 10.1016/j.bcp.2009.06.007; Qu FF, 2019, MOL NUTR FOOD RES, V63, DOI 10.1002/mnfr.201801039; ROBERTS EAH, 1949, BIOCHEM J, V45, P538, DOI 10.1042/bj0450538; Shi Z, 1997, TEA PROCESSING; Shimizu M, 2000, BIOFACTORS, V13, P61, DOI 10.1002/biof.5520130111; Snoussi C, 2014, J NUTR BIOCHEM, V25, P557, DOI 10.1016/j.jnutbio.2014.01.006; Solayman M, 2016, CURR PHARM DESIGN, V22, P549, DOI 10.2174/1381612822666151125001111; SOREQ H, 1992, METHOD ENZYMOL, V207, P225; Sterrett JJ, 2016, AM J MED SCI, V351, P342, DOI 10.1016/j.amjms.2016.01.019; Sun LJ, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201700324; Tang WP, 2013, J FUNCT FOODS, V5, P1784, DOI 10.1016/j.jff.2013.08.007; ter Horst KW, 2017, NUTRIENTS, V9, DOI 10.3390/nu9090981; Thounaojam MC, 2015, EVID-BASED COMPL ALT, V2015, P2; Wan X. C., 2003, TEA BIOCH; Wang J, 2017, ONCOTARGET, V8, P16875, DOI 10.18632/oncotarget.15171; Waring W.S, 2016, MEDICINE, V44, P138, DOI [10.1016/J.MPMED.2015.12.011, DOI 10.1016/J.MPMED.2015.12.011]; WELSCH CA, 1989, J NUTR, V119, P1698, DOI 10.1093/jn/119.11.1698; Whiteley CG, 1999, BIOCHEM EDUC, V27, P15, DOI 10.1016/S0307-4412(98)00265-9; WITHYCOMBE WA, 1965, BIOCHEM J, V94, P384, DOI 10.1042/bj0940384; WRIGHT EM, 1993, ANNU REV PHYSIOL, V55, P575, DOI 10.1146/annurev.ph.55.030193.003043; Xing LJ, 2019, J AGR FOOD CHEM, V67, P1029, DOI 10.1021/acs.jafc.8b06146; Xu HB, 2020, INT J BIOL MACROMOL, V145, P527, DOI 10.1016/j.ijbiomac.2019.12.161; Zhou DR, 2009, FOOD CHEM, V113, P110, DOI 10.1016/j.foodchem.2008.07.033; Zimmet P, 2016, NAT REV ENDOCRINOL, V12, P616, DOI 10.1038/nrendo.2016.105; Zimmet PZ, 2014, LANCET DIABETES ENDO, V2, P56, DOI 10.1016/S2213-8587(13)70112-8	62	19	19	8	31	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2020	34	8					9995	10010		10.1096/fj.202000057RR	http://dx.doi.org/10.1096/fj.202000057RR		JUN 2020	16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	NE3EW	32564472	Green Published, hybrid			2023-01-03	WOS:000541821100001
J	Ransom, CJ; Jolley, VD; Blair, TA; Sutton, LE; Hopkins, BG				Ransom, Curtis J.; Jolley, Von D.; Blair, Trenton A.; Sutton, Lloyd E.; Hopkins, Bryan G.			Nitrogen release rates from slow- and controlled-release fertilizers influenced by placement and temperature	PLOS ONE			English	Article							POLYMER-COATED UREA; NUTRIENT RELEASE; SOIL; EFFICIENCY; PATTERNS; MOISTURE; SYSTEM; YIELD; MODEL	Controlled-release and slow-release fertilizers can effectively supply nitrogen (N) while mitigating N loss. To determine the suitability of these fertilizers for plants in semi-arid environments, these fertilizers need to be evaluated under varying placement and temperature conditions. Several urea fertilizers were evaluated, including: uncoated, sulfur-coated (SCU), polymer-coated-sulfur-coated (PCSCU), and polymer-coated (PCU) with projected release timings between 45 and 180 d. Nitrogen release was measured under daily fluctuating or static temperatures applied either to the surface or buried in the soil. A second experiment consisted of two PCU sources and added a hanging bag placement comparison and low and high soil moisture treatments. For the first Experiment, the N in uncoated urea released shortly after application. The SCU and PCSCU treatments released > 80% of the N before the first sampling date. With fluctuating temperatures, the PCU 45, 75, 120, and 180 incorporated into the soil released N within +9, +9, -22, and -68 d of their expected timing. However, they released their N within 35 d when surface applied. Conversely, with static temperatures, PCU products released slowly, releasing under 80% for the entire study. The second experiment verified these results and showed no difference between low and high moisture and minimal release with fertilizer not in contact with soil. Each coated fertilizer in these studies exhibited slow/control release properties, but the PCU (surface applied) and SCU/PCSCU (surface applied or incorporated in soil) release was much more rapid than expected. Our research suggests that, although the SCU and PCSCU showed minimal slow-release properties (regardless of placement), the PCU fertilizers incorporated in the soil do have a controlled release approximate to what is expected, but have a much more rapid release when surface applied.	[Ransom, Curtis J.; Jolley, Von D.; Blair, Trenton A.; Sutton, Lloyd E.; Hopkins, Bryan G.] Brigham Young Univ, Plant & Wildlife Sci Dept, Provo, UT 84602 USA; [Ransom, Curtis J.] Univ Missouri, Div Plant Sci, Columbia, MO 65211 USA	Brigham Young University; University of Missouri System; University of Missouri Columbia	Ransom, CJ (corresponding author), Brigham Young Univ, Plant & Wildlife Sci Dept, Provo, UT 84602 USA.; Ransom, CJ (corresponding author), Univ Missouri, Div Plant Sci, Columbia, MO 65211 USA.	curtisransom@gmail.com	Hopkins, Bryan G./F-3670-2011	Hopkins, Bryan G./0000-0001-7313-055X; Ransom, Curtis/0000-0002-1268-7247	Brigham Young University	Brigham Young University	Funding for this project came from Brigham Young University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adams C, 2013, J PLANT NUTR SOIL SC, V176, P76, DOI 10.1002/jpln.201200156; budras Corinna, 2008, FRANKFURTER ALLGEMEI, V7, pC5; Buss J, 2016, POLYM COATED UREA KE; Cameron KC, 2013, ANN APPL BIOL, V162, P145, DOI 10.1111/aab.12014; Campbell G.S., 1998, INTRO ENV BIOPHYSICS, Vsecond, DOI [10.1007/978-1-4612-1626-1, DOI 10.1007/978-1-4612-1626-1]; Carroll DA, 2017, IRRIGATION SCI, V35, P549, DOI 10.1007/s00271-017-0558-4; Carson LC, 2012, HORTTECHNOLOGY, V22, P20, DOI 10.21273/HORTTECH.22.1.20; CHRISTIANSON CB, 1988, FERT RES, V16, P273, DOI 10.1007/BF01051376; Du CW, 2006, J POLYM ENVIRON, V14, P223, DOI 10.1007/s10924-006-0025-4; Ellison E., 2013, P 2013 W NUTRIENT MA, P17; Fernandez FG, 2015, J ENVIRON QUAL, V44, P415, DOI 10.2134/jeq2013.12.0496; Fujinuma R, 2009, SOIL SCI SOC AM J, V73, P2043, DOI 10.2136/sssaj2009.0085; Geary B, 2015, J PLANT NUTR, V38, P41, DOI 10.1080/01904167.2014.912323; Golden B, 2011, COMMUN SOIL SCI PLAN, V42, P1809, DOI 10.1080/00103624.2011.587568; Halvorson AD, 2014, AGRON J, V106, P681, DOI 10.2134/agronj2013.0001; Halvorson AD, 2014, AGRON J, V106, P715, DOI 10.2134/agronj2013.0081; HASHIMOTO I, 1979, SOIL SCI SOC AM J, V43, P1165, DOI 10.2136/sssaj1979.03615995004300060021x; Hopkins BG, 2020, ACHIEVING SUSTAINABL; Hopkins BG, 2007, AM J POTATO RES, V84, P19, DOI 10.1007/BF02986295; Huett DO, 2000, COMMUN SOIL SCI PLAN, V31, P959, DOI 10.1080/00103620009370490; Husby CE, 2003, HORTSCIENCE, V38, P387, DOI 10.21273/HORTSCI.38.3.387; JARRELL WM, 1979, SOIL SCI SOC AM J, V43, P1044, DOI 10.2136/sssaj1979.03615995004300050046x; Kissel DE, 1988, MANAGEMENT UREA FERT; KOCHBA M, 1990, SOIL SCI, V149, P339, DOI 10.1097/00010694-199006000-00004; LeMonte JJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204090; LeMonte JJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146761; Lenth R.V., 2021, EMMEANS ESTIMATED MA; Liu YH, 2008, POWDER TECHNOL, V183, P88, DOI 10.1016/j.powtec.2007.11.022; LUNT O. R., 1962, SOIL SCI SOC AMER PROC, V26, P584; Milesi C, 2005, ENVIRON MANAGE, V36, P426, DOI 10.1007/s00267-004-0316-2; Mulvaney RL, 2009, J ENVIRON QUAL, V38, P2295, DOI 10.2134/jeq2008.0527; Nash PR, 2012, AGRON J, V104, P1074, DOI 10.2134/agronj2011.0235; Nelson KA, 2014, J AGRON CROP SCI, V200, P54, DOI 10.1111/jac.12040; Olson BM, 2009, J ENVIRON QUAL, V38, P2218, DOI 10.2134/jeq2008.0519; Ransom CJ, 2014, NITROGEN USE EFFICIE; Shen YZ, 2015, APPL ENG AGRIC, V31, P247; SHOJI S, 1991, SOIL SCI SOC AM J, V55, P1468, DOI 10.2136/sssaj1991.03615995005500050045x; Stevens WB, 2007, AGRON J, V99, P1252, DOI 10.2134/agronj2006.0357; Tong X, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15010119; Trenkel M.E., 2010, SLOWAND CONTROLLED R, Vsecond; Trenkel ME, 1997, CONTROLLED RELEASE S; Wilson ML, 2009, HORTSCIENCE, V44, P492, DOI 10.21273/HORTSCI.44.2.492; Zhang YS, 2011, J ENVIRON MANAGE, V92, P480, DOI 10.1016/j.jenvman.2010.09.018; Zvomuya F, 2003, J ENVIRON QUAL, V32, P480, DOI 10.2134/jeq2003.0480	44	22	22	4	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 17	2020	15	6							e0234544	10.1371/journal.pone.0234544	http://dx.doi.org/10.1371/journal.pone.0234544			21	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MB7DG	32555670	Green Published, gold			2023-01-03	WOS:000542759600051
J	Ivers, NM; Schwalm, JD; Bouck, Z; McCready, T; Taljaard, M; Grace, SL; Cunningham, J; Bosiak, B; Presseau, J; Witteman, HO; Suskin, N; Wijeysundera, HC; Atzema, C; Bhatia, RS; Natarajan, M; Grimshaw, JM				Ivers, Noah M.; Schwalm, Jon-David; Bouck, Zachary; McCready, Tara; Taljaard, Monica; Grace, Sherry L.; Cunningham, Jennifer; Bosiak, Beth; Presseau, Justin; Witteman, Holly O.; Suskin, Neville; Wijeysundera, Harindra C.; Atzema, Clare; Bhatia, R. Sacha; Natarajan, Madhu; Grimshaw, Jeremy M.			Interventions supporting long term adherence and decreasing cardiovascular events after myocardial infarction (ISLAND): pragmatic randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MEDICATION ADHERENCE; CARDIAC REHABILITATION; QUALITY IMPROVEMENT; CORONARY; DISEASE; HEART; VALIDATION; MANAGEMENT; GUIDELINE	OBJECTIVE To test a scalable health system intervention to improve long term adherence to secondary prevention treatments among patients who have had a recent myocardial infarction. DESIGN Three arm, pragmatic randomised controlled trial with blinded outcome assessment. SETTING Nine cardiac centres in Ontario, Canada. PARTICIPANTS 2632 patients with obstructive coronary artery disease after a myocardial infarction, identified from a centralised cardiac registry. INTERVENTIONS Participants were randomised 1:1:1 to receive usual care, five mail-outs developed through a user centred design process, or mail-outs plus phone calls. The phone calls were delivered first by an interactive automated system to screen for non-adherence to treatment. Trained lay health workers followed up as necessary. Interventions were coordinated centrally but delivered from each patient's hospital site. MAIN OUTCOME MEASURES Co-primary outcomes were completion of cardiac rehabilitation and adherence to recommended medication. Data were collected by blinded assessors through patient report and from administrative health databases at 12 months. RESULTS 2632 patients (mean age 66, 71% male) were randomised: 878 to the full intervention (mail plus phone calls), 878 to mail only, and 876 to usual care. Of the respondents, 174 (27%) of 643 in the usual care group, 200 (32%) of 628 in the mail only group, and 196 (37%) of 531 allocated to the full intervention completed cardiac rehabilitation (adjusted odds ratio 1.55, 95% confidence interval 1.18 to 2.03). In the mail plus phone group, 11.7%, 6.0%, 14.4%, 32.9%, and 35.0% reported adherence to 0, 1, 2, 3, and 4 drug classes after one year, respectively, in comparison with 12.5%, 6.8%, 13.6%, 30.2%, and 36.8% in the mail only group, and 12.2%, 8.4%, 13.1%, 30.3%, and 36.1% in the usual care group, respectively (mail only v usual care, odds ratio 0.98, 95% confidence interval 0.81 to 1.19; full intervention v usual care, 0.99, 0.82 to 1.20). CONCLUSIONS Scalable interventions delivered by mail plus phone can increase completion of cardiac rehabilitation after myocardial infarction but not adherence to medication. More intensive interventions should be tested to improve adherence to medication and to evaluate the association between attendance at cardiac rehabilitation and adherence to medication.	[Ivers, Noah M.] Womens Coll Hosp, Dept Family & Community Med, 76 Grenville St, Toronto, ON M5S 1B2, Canada; [Ivers, Noah M.; Bouck, Zachary; Bosiak, Beth; Bhatia, R. Sacha] Womens Coll Hosp, Inst Hlth Syst Solut & Virtual Care, Toronto, ON, Canada; [Ivers, Noah M.] Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada; [Ivers, Noah M.; Wijeysundera, Harindra C.; Atzema, Clare; Bhatia, R. Sacha] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada; [Ivers, Noah M.; Wijeysundera, Harindra C.; Atzema, Clare; Bhatia, R. Sacha] ICES, Toronto, ON, Canada; [Ivers, Noah M.; Bhatia, R. Sacha] Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada; [Schwalm, Jon-David; McCready, Tara; Cunningham, Jennifer; Natarajan, Madhu] McMaster Univ, Populat Hlth Res Inst, Hamilton Hlth Sci, Hamilton, ON, Canada; [Schwalm, Jon-David; Natarajan, Madhu] Hamilton Hlth Sci, Div Cardiol, Dept Med, Hamilton, ON, Canada; [Schwalm, Jon-David; Natarajan, Madhu] McMaster Univ, Hamilton, ON, Canada; [Taljaard, Monica; Presseau, Justin; Grimshaw, Jeremy M.] Ottawa Hosp, Res Inst, Ottawa, ON, Canada; [Taljaard, Monica; Presseau, Justin; Grimshaw, Jeremy M.] Univ Ottawa, Sch Populat & Publ Hlth, Ottawa, ON, Canada; [Grace, Sherry L.] York Univ, Fac Hlth, Toronto, ON, Canada; [Grace, Sherry L.] Univ Hlth Network, KITE Res Inst, Toronto, ON, Canada; [Witteman, Holly O.] Univ Laval, Dept Family & Emergency Med, Quebec City, PQ, Canada; [Suskin, Neville] St Josephs Hlth Care London, Cardiac Rehabil & Secondary Prevent Programme, London, ON, Canada; [Suskin, Neville] Western Univ, Dept Med, Lawson Hlth Res Inst, London, ON, Canada; [Suskin, Neville] Western Univ, Dept Epidemiol, Lawson Hlth Res Inst, London, ON, Canada; [Suskin, Neville] Western Univ, Dept Biostat, Lawson Hlth Res Inst, London, ON, Canada; [Wijeysundera, Harindra C.; Atzema, Clare] Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada; [Wijeysundera, Harindra C.; Atzema, Clare; Bhatia, R. Sacha] Univ Toronto, Dept Med, Toronto, ON, Canada; [Grimshaw, Jeremy M.] Univ Ottawa, Dept Med, Ottawa, ON, Canada	University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University Toronto Affiliates; Womens College Hospital; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Womens College Hospital; McMaster University; Population Health Research Institute; McMaster University; McMaster University; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; York University - Canada; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto Rehabilitation Institute; Laval University; Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Ottawa	Ivers, NM (corresponding author), Womens Coll Hosp, Dept Family & Community Med, 76 Grenville St, Toronto, ON M5S 1B2, Canada.; Ivers, NM (corresponding author), Womens Coll Hosp, Inst Hlth Syst Solut & Virtual Care, Toronto, ON, Canada.; Ivers, NM (corresponding author), Univ Toronto, Dept Family & Community Med, Toronto, ON, Canada.; Ivers, NM (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada.; Ivers, NM (corresponding author), ICES, Toronto, ON, Canada.; Ivers, NM (corresponding author), Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada.	noah.ivers@utoronto.ca	Grace, Sherry L/H-1388-2013; Ivers, Noah/O-7643-2018	Grace, Sherry L/0000-0001-7063-3610; Taljaard, Monica/0000-0002-3978-8961; Bouck, Zachary/0000-0003-3145-1915; Ivers, Noah/0000-0003-2500-2435; Cunningham, Jennifer/0000-0001-8137-6779; Witteman, Holly/0000-0003-4192-0682	Ontario Ministry of Health and Long Term Care (MOHLTC) Health System Research Capacity Award [06683]; ICES - MOHLTC	Ontario Ministry of Health and Long Term Care (MOHLTC) Health System Research Capacity Award; ICES - MOHLTC	The study was funded by the Ontario Ministry of Health and Long Term Care (MOHLTC) Health System Research Capacity Award grant No 06683; the funder did not have a role in the methods, analysis, interpretation, or dissemination. This study was also supported by ICES, which is funded by an annual grant from MOHLTC. The analyses, conclusions, opinions, and statements expressed herein are solely those of the authors and do not reflect those of the funding or data sources; no endorsement is intended or should be inferred.	Alter DA, 2009, EUR J CARDIOV PREV R, V16, P102, DOI 10.1097/HJR.0b013e328325d662; Antman EM, 2008, J AM COLL CARDIOL, V51, P2028, DOI 10.1016/j.jacc.2007.10.001; Canadian Institutes of Health Research Natural Sciences and Engineering Research Council of Canada Social Sciences and Humanities Research Council of Canada, 2014, TRIC POL STAT ETH CO; Candido E, 2011, CAN J CARDIOL, V27, P200, DOI 10.1016/j.cjca.2011.01.008; Chan PS, 2014, CIRC-CARDIOVASC QUAL, V7, P640, DOI 10.1161/CIRCOUTCOMES.114.000967; Choo PW, 1999, MED CARE, V37, P846, DOI 10.1097/00005650-199909000-00002; Choudhry NK, 2011, NEW ENGL J MED, V365, P2088, DOI 10.1056/NEJMsa1107913; Chow CK, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019463; Degrauwe S, 2017, OPEN HEART, V4, DOI 10.1136/openhrt-2017-000651; Dmitrienko A, 2013, STAT MED, V32, P1079, DOI 10.1002/sim.5642; El-Menyar A, 2012, AM J EMERG MED, V30, P97, DOI 10.1016/j.ajem.2010.10.011; Firmino-Machado J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-017730; Fitchett DH, 2011, CAN J CARDIOL, V27, pS402, DOI 10.1016/j.cjca.2011.08.107; Gehi AK, 2007, ARCH INTERN MED, V167, P1798, DOI 10.1001/archinte.167.16.1798; Glynn RJ, 2007, MED CARE, V45, pS38, DOI 10.1097/MLR.0b013e318070c0a0; Grady D, 2018, JAMA INTERN MED, V178, P187, DOI 10.1001/jamainternmed.2017.6875; Gupta Sandeep K, 2011, Perspect Clin Res, V2, P109, DOI 10.4103/2229-3485.83221; Haynes RB, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000011.pub3; Heran BS, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001800.pub3, 10.1002/14651858.CD001800.pub2]; Ito K, 2012, HEALTH SERV RES, V47, P2097, DOI 10.1111/j.1475-6773.2012.01462.x; Ivers N, 2017, AM HEART J, V190, P64, DOI 10.1016/j.ahj.2017.05.007; Ivers NM, 2016, LANCET, V388, P547, DOI 10.1016/S0140-6736(16)31256-9; Ivers NM, 2013, CAN J CARDIOL, V29, P1408, DOI 10.1016/j.cjca.2013.04.009; Kahan BC, 2012, BMJ-BRIT MED J, V345, DOI 10.1136/bmj.e5840; Kassavou A, 2018, HEALTH PSYCHOL REV, V12, P25, DOI 10.1080/17437199.2017.1365617; Kayaniyil S, 2009, CAN J CARDIOL, V25, pE96, DOI 10.1016/S0828-282X(09)70063-7; Khan M, 2018, GLOB HEART, V13, P93, DOI 10.1016/j.gheart.2017.11.002; Kripalani S, 2007, JAMA-J AM MED ASSOC, V297, P831, DOI 10.1001/jama.297.8.831; Mancini GBJ, 2014, CAN J CARDIOL, V30, P837, DOI 10.1016/j.cjca.2014.05.013; Moghei M, 2019, J CARDIOPULM REHABIL, V39, P226, DOI 10.1097/HCR.0000000000000396; Mosleh SM, 2014, EUR J CARDIOVASC NUR, V13, P201, DOI 10.1177/1474515113491348; Nau DP, 2012, PROPORTION DAYS COVE; Nieuwkerk PT, 2012, AM J CARDIOL, V110, P666, DOI 10.1016/j.amjcard.2012.04.045; Nolan T, 2006, JAMA-J AM MED ASSOC, V295, P1168, DOI 10.1001/jama.295.10.1168; Pedroza C, 2016, BMC MED RES METHODOL, V16, DOI 10.1186/s12874-016-0217-0; Pio CSD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007131.pub4; Presseau J, 2017, PSYCHOL HEALTH, V32, P1176, DOI 10.1080/08870446.2016.1260724; Rasmussen JN, 2007, JAMA-J AM MED ASSOC, V297, P177, DOI 10.1001/jama.297.2.177; Reid RR, 2016, HEALTHCARE PAPERS, V16, P30, DOI [DOI 10.12927/HCPAP.2016.24724, 10.12927/hcpap.2016.24724]; Schwalm JD, 2016, CIRCULATION, V133, P742, DOI 10.1161/CIRCULATIONAHA.115.008721; Schwalm JD, 2015, AM HEART J, V170, P903, DOI 10.1016/j.ahj.2015.08.014; Sherrard Heather, 2009, Can J Cardiovasc Nurs, V19, P9; Smith DH, 2016, VALUE HEALTH, V19, P176, DOI 10.1016/j.jval.2015.11.013; Smith SC, 2011, J AM COLL CARDIOL, V58, P2432, DOI 10.1016/j.jacc.2011.10.824; Sniehotta FF, 2006, BRIT J HEALTH PSYCH, V11, P23, DOI 10.1348/135910705X43804; Thakkar J, 2016, JAMA INTERN MED, V176, P340, DOI 10.1001/jamainternmed.2015.7667; Treweek S, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-37; Tsoli S, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-018974; Walters Stephen J, 2004, Health Qual Life Outcomes, V2, P26, DOI 10.1186/1477-7525-2-26; Witteman Holly O, 2017, JMIR Hum Factors, V4, pe6, DOI 10.2196/humanfactors.6502; Wyer SJ, 2001, CORONARY HLTH CARE, V5, P154, DOI DOI 10.1054/CHEC.2001.0131	51	20	21	2	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 10	2020	369								m1731	10.1136/bmj.m1731	http://dx.doi.org/10.1136/bmj.m1731			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK1TC	32522811	hybrid, Green Published			2023-01-03	WOS:000548568100007
J	Slater, R; Moultrie, F; Bax, R; van den Anker, J; Bhatt, A				Slater, Rebeccah; Moultrie, Fiona; Bax, Ralph; van den Anker, John; Bhatt, Aomesh			Preterm health: time to bridge the evidence gap	LANCET			English	Editorial Material							OFF-LABEL; INFANTS; TRIALS; DRUGS; NEED		[Slater, Rebeccah; Moultrie, Fiona; Bhatt, Aomesh] Univ Oxford, Dept Paediat, Oxford OX3 9DU, England; [Bax, Ralph] European Med Agcy, Paediat Medicines Off, Sci Evidence Generat Dept, Amsterdam, Netherlands; [van den Anker, John] Univ Basel, Dept Paediat Pharmacol & Pharmacometr, Univ Childrens Hosp Basel, Basel, Switzerland; [van den Anker, John] Natl Childrens Hosp, Div Clin Pharmacol, Washington, DC USA; [van den Anker, John] Sophia Childrens Univ Hosp, Intens Care, Erasmus Med Ctr, Rotterdam, Netherlands; [van den Anker, John] Sophia Childrens Univ Hosp, Dept Pediat Surg, Erasmus Med Ctr, Rotterdam, Netherlands	University of Oxford; University of Basel; Children's National Health System; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital; Erasmus University Rotterdam; Erasmus MC; Erasmus MC - Sophia Children's Hospital	Slater, R (corresponding author), Univ Oxford, Dept Paediat, Oxford OX3 9DU, England.	rebeccah.slater@paediatrics.ox.ac.uk		Bhatt, Aomesh/0000-0001-6206-0576; Slater, Rebeccah/0000-0003-1595-4846				Allegaert K, 2017, EARLY HUM DEV, V114, P22, DOI 10.1016/j.earlhumdev.2017.09.007; Amin SB, 2008, ACCOUNT RES, V15, P168, DOI 10.1080/08989620802194392; Bellieni CV, 2016, ACTA PAEDIATR, V105, P129, DOI 10.1111/apa.13210; Davis JM, 2020, J PEDIATR-US, V219, P243, DOI 10.1016/j.jpeds.2019.09.060; Davis JM, 2012, JAMA-J AM MED ASSOC, V308, P1435, DOI 10.1001/jama.2012.12883; Dunne J, 2011, PEDIATRICS, V128, pE1242, DOI 10.1542/peds.2010-3487; European Medicines Agency, INV MED PROD TERM PR; Fleischman AR, 2016, SEMIN PERINATOL, V40, P247, DOI 10.1053/j.semperi.2015.12.014; Flint RB, 2018, BRIT J CLIN PHARMACO, V84, P1313, DOI 10.1111/bcp.13563; Green G, 2019, PAIN, V160, P493, DOI 10.1097/j.pain.0000000000001425; Krzyzaniak N, 2016, J CLIN PHARM THER, V41, P612, DOI 10.1111/jcpt.12440; Nasr VG, 2015, PEDIATR RES, V78, P2, DOI 10.1038/pr.2015.58; Olsson E, 2021, PAIN, V162, P353, DOI 10.1097/j.pain.0000000000002046; Riou S, 2015, ACTA PAEDIATR, V104, pe228, DOI 10.1111/apa.12924; Schrier L, 2020, EUR J PEDIATR, V179, P839, DOI 10.1007/s00431-019-03556-9; Slater R, 2019, LANCET CHILD ADOLESC, V3, P367, DOI 10.1016/S2352-4642(19)30118-X; Soul JS, 2019, PEDIATR RES, V85, P943, DOI 10.1038/s41390-018-0242-2; Turner S, 1999, ACTA PAEDIATR, V88, P965, DOI 10.1080/08035259950168469; Wiles JR, 2013, J PEDIATR-US, V162, P12, DOI 10.1016/j.jpeds.2012.08.034	19	7	7	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	SEP 26	2020	396	10255					872	873						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	NZ8FF	32979963				2023-01-03	WOS:000577336800016
J	Rose, M; Maurer, A; Wirtz, J; Bleilevens, A; Waldmann, T; Wenz, M; Eyll, M; Geelvink, M; Gereitzig, M; Ruchel, N; Denecke, B; Eltze, E; Herrmann, E; Toma, M; Horst, D; Grimm, T; Denzinger, S; Ecke, T; Vogeli, TA; Knuechel, R; Maurer, J; Gaisa, NT				Rose, Michael; Maurer, Angela; Wirtz, Julia; Bleilevens, Andreas; Waldmann, Tanja; Wenz, Maximilian; Eyll, Marie; Geelvink, Mirja; Gereitzig, Melanie; Ruechel, Nadine; Denecke, Bernd; Eltze, Elke; Herrmann, Edwin; Toma, Marieta; Horst, David; Grimm, Tobias; Denzinger, Stefan; Ecke, Thorsten; Voegeli, Thomas Alexander; Knuechel, Ruth; Maurer, Jochen; Gaisa, Nadine T.			EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer	ONCOGENE			English	Article							TRANSITIONAL-CELL CARCINOMA; COMPREHENSIVE MOLECULAR CHARACTERIZATION; PHASE-II; UROTHELIAL CARCINOMA; LUNG-CANCER; 1ST-LINE TREATMENT; MASS-ACTION; FAMILY; CHEMOTHERAPY; EXPRESSION	Recent findings suggested a benefit of anti-EGFR therapy for basal-like muscle-invasive bladder cancer (MIBC). However, the impact on bladder cancer with substantial squamous differentiation (Sq-BLCA) and especially pure squamous cell carcinoma (SCC) remains unknown. Therefore, we comprehensively characterized pure and mixed Sq-BLCA (n = 125) on genetic and protein expression level, and performed functional pathway and drug-response analyses with cell line models and isolated primary SCC (p-SCC) cells of the human urinary bladder. We identified abundant EGFR expression in 95% of Sq-BLCA without evidence for activatingEGFRmutations. Both SCaBER and p-SCC cells were sensitive to EGFR tyrosine kinase inhibitors (TKIs: erlotinib and gefitinib). Combined treatment with anti-EGFR TKIs and varying chemotherapeutics led to a concentration-dependent synergism in SCC cells according to the Chou-Talalay method. In addition, the siRNA knockdown of EGFR impaired SCaBER viability suggesting a putative "Achilles heel" of Sq-BLCA. The observed effects seem Sq-BLCA-specific since non-basal urothelial cancer cells were characterized by poor TKI sensitivity associated with a short-term feedback response potentially attenuating anti-tumor activity. Hence, our findings give further insights into a crucial, Sq-BLCA-specific role of the ERBB signaling pathway proposing improved effectiveness of anti-EGFR based regimens in combination with chemotherapeutics in squamous bladder cancers with wild-type EGFR-overexpression.	[Rose, Michael; Maurer, Angela; Wirtz, Julia; Wenz, Maximilian; Eyll, Marie; Geelvink, Mirja; Gereitzig, Melanie; Ruechel, Nadine; Knuechel, Ruth; Gaisa, Nadine T.] Rhein Westfal TH Aachen, Inst Pathol, Aachen, Germany; [Bleilevens, Andreas; Waldmann, Tanja; Maurer, Jochen] Univ Clin RWTH, Dept Gynecol, Aachen, Germany; [Denecke, Bernd] Rhein Westfal TH Aachen, Med Fac, IZKF Aachen, Aachen, Germany; [Eltze, Elke] Saarbrucken Rastpfuhl, Inst Pathol, Saarbrucken, Germany; [Herrmann, Edwin] Univ Hosp Munster, Dept Urol, Munster, Germany; [Toma, Marieta] Tech Univ Dresden, Inst Pathol, Univ Hosp Gustav Carus, Dresden, Germany; [Horst, David] Charite Univ Med Berlin, Inst Pathol, Berlin, Germany; [Grimm, Tobias] Ludwig Maximilians Univ Munchen, Dept Urol, Munich, Germany; [Denzinger, Stefan] Univ Regensburg, Dept Urol, Regensburg, Germany; [Ecke, Thorsten] Helios Hosp Bad Saarow, Dept Urol, Bad Saarow Pieskow, Germany; [Voegeli, Thomas Alexander] Rhein Westfal TH Aachen, Dept Urol, Aachen, Germany; [Toma, Marieta] Univ Hosp Bonn, Inst Pathol, Bonn, Germany	RWTH Aachen University; RWTH Aachen University; RWTH Aachen University Hospital; RWTH Aachen University; University of Munster; Technische Universitat Dresden; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Munich; University of Regensburg; RWTH Aachen University; University of Bonn	Gaisa, NT (corresponding author), Rhein Westfal TH Aachen, Inst Pathol, Aachen, Germany.	ngaisa@ukaachen.de	Toma, Marieta/AAI-8022-2021; Maurer, Jochen/G-4832-2018	Maurer, Jochen/0000-0003-3962-3128; Ruchel, Nadine/0000-0001-9657-8787; Wirtz, Julia/0000-0003-0220-6312	Medical Faculty of the RWTH Aachen University [42/13]	Medical Faculty of the RWTH Aachen University	The authors appreciate the contributions of all pathologists and urologists sending cases for study material, the German Study Group of Bladder Cancers (DFBK e.V.), as well as the excellent technical support of Uschi Schneider, Patrick Kuhl and Anja Steinle. We thank Timon Heide for his great support in analyzing TCGA data sets and are grateful for the publicly available TCGA research Network data sets (http://cancergenome.nih.gov). We further thank Dr. Kathrin Scheckenbach (Dusseldorf University Hospital, Germany), Prof. Wolfgang Schulz (Dusseldorf University Hospital, Germany) and Dr. Alexander Buchner (LMU Munchen, Germany) for providing cell lines. We also thank Pia Dinger and Franziska Lammert for proofreading the manuscript. Furthermore, we thank Dr. Olbrich for supporting our study. This project was partly funded by START-funds of the Medical Faculty of the RWTH Aachen University (NTG grant number: 42/13).	Ahsan A, 2010, CANCER RES, V70, P2862, DOI 10.1158/0008-5472.CAN-09-4294; Baldia PH, 2016, ONCOTARGET, V7, P71429, DOI 10.18632/oncotarget.12198; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Bergman AM, 1996, CLIN CANCER RES, V2, P521; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Casalini P, 2004, J CELL PHYSIOL, V200, P343, DOI 10.1002/jcp.20007; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen LF, 2010, CLIN CANCER RES, V16, P2489, DOI 10.1158/1078-0432.CCR-09-2318; Chin TM, 2008, CLIN CANCER RES, V14, P6867, DOI 10.1158/1078-0432.CCR-08-0093; Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Chow NH, 1997, VIRCHOWS ARCH, V430, P461, DOI 10.1007/s004280050056; Chow NH, 2001, CLIN CANCER RES, V7, P1957; Eriksson P, 2017, ONCOTARGET, V8, P48905, DOI 10.18632/oncotarget.16554; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Ferner RE, 2016, BRIT J CLIN PHARMACO, V81, P52, DOI 10.1111/bcp.12721; Freed DM, 2017, CELL, V171, P683, DOI 10.1016/j.cell.2017.09.017; Gaisa NT, 2011, J PATHOL, V225, P172, DOI 10.1002/path.2959; Gaisa NT, 2011, VIRCHOWS ARCH, V458, P301, DOI 10.1007/s00428-010-1017-2; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Hasinoff BB, 2010, TOXICOL APPL PHARM, V249, P132, DOI 10.1016/j.taap.2010.08.026; Herbst RS, 2007, J CLIN ONCOL, V25, P4743, DOI 10.1200/JCO.2007.12.3026; Humphrey PA, 2016, EUR UROL, V70, P106, DOI 10.1016/j.eururo.2016.02.028; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Kamoun A, 2019, EUR UROL; Kenakin T, 2016, BRIT J CLIN PHARMACO, V81, P41, DOI 10.1111/bcp.12810; Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817; Kramer C, 2007, CANCER-AM CANCER SOC, V109, P2016, DOI 10.1002/cncr.22627; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Ling SZ, 2011, CANCER RES, V71, P3812, DOI 10.1158/0008-5472.CAN-10-3072; Longton E, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00432; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Metzger E, 2017, CANCER RES, V77, P5900, DOI 10.1158/0008-5472.CAN-17-1754; Minato A, 2018, CANCER CONTROL, V25, DOI 10.1177/1073274818800269; Minato A, 2017, CLIN GENITOURIN CANC, V15, pE1063, DOI 10.1016/j.clgc.2017.07.008; Miyabayashi K, 2013, CANCER RES, V73, P2221, DOI 10.1158/0008-5472.CAN-12-1453; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Mooso BA, 2015, J UROLOGY, V193, P19, DOI 10.1016/j.juro.2014.07.121; O-Charoenrat P, 2000, INT J CANCER, V88, P759, DOI 10.1002/1097-0215(20001201)88:5<759::AID-IJC12>3.0.CO;2-0; Petrylak DP, 2010, BJU INT, V105, P317, DOI 10.1111/j.1464-410X.2009.08799.x; Pirker Robert, 2010, J Thorac Oncol, V5, P1706, DOI 10.1097/JTO.0b013e3181f1c8de; Pruthi RS, 2010, BJU INT, V106, P349, DOI 10.1111/j.1464-410X.2009.09101.x; Rebouissou S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008970; Robertson AG, 2017, CELL, V171, P540, DOI 10.1016/j.cell.2017.09.007; Rose M, 2018, METHODS MOL BIOL, V1655, P43, DOI 10.1007/978-1-4939-7234-0_4; Rose M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0610-2; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Seiler R, 2017, EUR UROL, V72, P544, DOI 10.1016/j.eururo.2017.03.030; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559; Tsai CM, 2011, J THORAC ONCOL, V6, P559, DOI 10.1097/JTO.0b013e3182021ff5; Weickhardt AJ, 2012, J CLIN ONCOL, V30, P1505, DOI 10.1200/JCO.2011.38.6599; Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965; Wilson KJ, 2012, GROWTH FACTORS, V30, P107, DOI 10.3109/08977194.2011.649918; Wirth LJ, 2016, ORAL ONCOL, V61, P31, DOI 10.1016/j.oraloncology.2016.07.005; Yan XT, 2019, LUNG CANCER, V128, P6, DOI 10.1016/j.lungcan.2018.12.007; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309	59	22	22	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6856	6870		10.1038/s41388-020-01465-y	http://dx.doi.org/10.1038/s41388-020-01465-y		SEP 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32978523	hybrid, Green Published			2023-01-03	WOS:000572714000004
J	Boniatti, MM; Pellegrini, JAS; Marques, LS; John, JF; Marin, LG; Maito, LRDM; Lisboa, TC; Damiani, LP; Falci, DR				Boniatti, Marcio M.; Pellegrini, Jose Augusto S.; Marques, Leonardo S.; John, Josiane F.; Marin, Luiz G.; Maito, Lina R. D. M.; Lisboa, Thiago C.; Damiani, Lucas P.; Falci, Diego R.			Early antiretroviral therapy for HIV-infected patients admitted to an intensive care unit (EARTH-ICU): A randomized clinical trial	PLOS ONE			English	Article							RISK-FACTORS; SURVIVAL; ERA; TRANSMISSION; MORTALITY; PATTERNS; OUTCOMES; ADULTS; IMPACT	Background Highly active antiretroviral therapy (HAART) has reduced HIV-related morbidity and mortality at all stages of infection and reduced transmission of HIV. Currently, the immediate start of HAART is recommended for all HIV patients, regardless of the CD4 count. There are several concerns, however, about starting treatment in critically ill patients. Unpredictable absorption of medication by the gastrointestinal tract, drug toxicity, drug interactions, limited reserve to tolerate the dysfunction of other organs resulting from hypersensitivity to drugs or immune reconstitution syndrome, and the possibility that subtherapeutic levels of drug may lead to viral resistance are the main concerns. The objective of our study was to compare the early onset (up to 5 days) with late onset (after discharge from the ICU) of HAART in HIV-infected patients admitted to the ICU. Methods This was a randomized, open-label clinical trial enrolling HIV-infected patients admitted to the ICU of a public hospital in southern Brazil. Patients randomized to the intervention group had to start treatment with HAART within 5 days of ICU admission. For patients in the control group, treatment should begin after discharge from the ICU. The patients were followed up to determine mortality in the ICU, in the hospital and at 6 months. The primary outcome was hospital mortality. The secondary outcome was mortality at 6 months. Results The calculated sample size was 344 patients. Unfortunately, we decided to discontinue the study due to a progressively slower recruitment rate. A total of 115 patients were randomized. The majority of admissions were for AIDS-defining illnesses and low CD4. The main cause of admission was respiratory failure. Regarding the early and late study groups, there was no difference in hospital (66.7% and 63.8%, p = 0.75) or 6-month (68.4% and 79.2%, p = 0.20) mortality. After multivariate analysis, the only independent predictors of in-hospital mortality were shock and dialysis during the ICU stay. For the mortality outcome at 6 months, the independent variables were shock and dialysis during the ICU stay and tuberculosis at ICU admission. Conclusions Although the early termination of the study precludes definitive conclusions being made, early HAART administration for HIV-infected patients admitted to the ICU compared to late administration did not show benefit in hospital mortality or 6-month mortality.	[Boniatti, Marcio M.; Pellegrini, Jose Augusto S.; John, Josiane F.] Univ La Salle, Hosp Clin Porto Alegre, Crit Care Dept, Porto Alegre, RS, Brazil; [Marques, Leonardo S.; Marin, Luiz G.] Hosp Nossa Senhora da Conceicao, Crit Care Dept, Porto Alegre, RS, Brazil; [Maito, Lina R. D. M.] Hosp Sao Vicente de Paulo, Crit Care Dept, Passo Fundo, RS, Brazil; [Lisboa, Thiago C.] Univ La Salle, Hosp Clin Porto Alegre, Inst Pesquisa HCor, Crit Care Dept, Porto Alegre, RS, Brazil; [Damiani, Lucas P.] Inst Pesquisa HCor, Sao Paulo, Brazil; [Falci, Diego R.] Hosp Clin Porto Alegre, Infect Dis Dept, Porto Alegre, RS, Brazil		Boniatti, MM (corresponding author), Univ La Salle, Hosp Clin Porto Alegre, Crit Care Dept, Porto Alegre, RS, Brazil.	mboniatti@hpa.edu.tr	Falci, Diego/AAW-7225-2021; Boniatti, Marcio/AAA-4195-2020; Lisboa, Thiago/W-2973-2019; Damiani, Lucas/F-8576-2015	Lisboa, Thiago/0000-0003-4306-2212; Boniatti, Marcio Manozzo/0000-0001-9921-0785; Falci, Diego/0000-0002-8683-3833; Damiani, Lucas/0000-0002-5836-3379				Akgun KM, 2016, SEMIN RESP CRIT CARE, V37, P303, DOI 10.1055/s-0036-1572561; Amancio FF, 2012, INT J STD AIDS, V23, P692, DOI 10.1258/ijsa.2012.011389; Andrade HB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186968; [Anonymous], 2008, MMWR-MORBID MORTAL W, V57, P9; Barbier F, 2009, INTENS CARE MED, V35, P1678, DOI 10.1007/s00134-009-1559-4; Boumis E, 2001, EUR J CLIN MICROBIOL, V20, P71, DOI 10.1007/s10096-001-8050-7; Casalino E, 2004, AIDS, V18, P1429, DOI 10.1097/01.aids.0000131301.55204.a7; Cohen MS, 2011, NEW ENGL J MED, V365, P493, DOI [10.1056/NEJMoa1105243, 10.1056/NEJMoa1600693]; Cribbs SK, 2015, CRIT CARE MED, V43, P1638, DOI 10.1097/CCM.0000000000001003; Croda J, 2009, CRIT CARE MED, V37, P1605, DOI 10.1097/CCM.0b013e31819da8c7; Danel C, 2015, NEW ENGL J MED, V373, P808, DOI 10.1056/NEJMoa1507198; Dickson SJ, 2007, THORAX, V62, P964, DOI 10.1136/thx.2006.072256; Heyland DK, 1996, INTENS CARE MED, V22, P1339, DOI 10.1007/BF01709548; Japiassu AM, 2010, CRIT CARE, V14, DOI 10.1186/cc9221; Kitahata MM, 2009, NEW ENGL J MED, V360, P1815, DOI 10.1056/NEJMoa0807252; Lachin JM, 2005, STAT MED, V24, P2747, DOI 10.1002/sim.2151; Lewden C, 2007, JAIDS-J ACQ IMM DEF, V46, P72; Lundgren D, 2015, NEW ENGL J MED, V373, P795, DOI 10.1056/NEJMoa1506816; Meybeck A, 2012, AIDS RES THER, V9, DOI 10.1186/1742-6405-9-27; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Moore RD, 2012, CLIN INFECT DIS, V55, P1242, DOI 10.1093/cid/cis654; Morquin D, 2012, ANN INTENSIVE CARE, V2, DOI 10.1186/2110-5820-2-25; Morris A, 2003, AIDS, V17, P73, DOI 10.1097/00002030-200301030-00010; Morris A, 2002, AM J RESP CRIT CARE, V166, P262, DOI 10.1164/rccm.2111025; Narasimhan M, 2004, CHEST, V125, P1800, DOI 10.1378/chest.125.5.1800; Palacios R, 2006, HIV MED, V7, P193, DOI 10.1111/j.1468-1293.2006.00353.x; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2018, GUID US ANT AG AD AD; Powell K, 2009, CHEST, V135, P11, DOI 10.1378/chest.08-0980; Ramos GV, 2015, J CLIN PHARM THER, V40, P63, DOI 10.1111/jcpt.12222; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Reynolds SJ, 2011, AIDS, V25, P473, DOI 10.1097/QAD.0b013e3283437c2b; Severe P, 2010, NEW ENGL J MED, V363, P257, DOI 10.1056/NEJMoa0910370; Vargas-Infante YA, 2007, ARCH MED RES, V38, P827, DOI 10.1016/j.arcmed.2007.05.007; Vincent B, 2004, INTENS CARE MED, V30, P859, DOI 10.1007/s00134-004-2158-z; Wit FWNM, 2002, J INFECT DIS, V186, P23, DOI 10.1086/341084; Wood E, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b1649	37	1	1	1	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2020	15	9							e0239452	10.1371/journal.pone.0239452	http://dx.doi.org/10.1371/journal.pone.0239452			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NV8NR	32956419	Green Published, gold			2023-01-03	WOS:000574571500016
J	Croft, S; Franzetti, B; Gill, R; Massei, G				Croft, Simon; Franzetti, Barbara; Gill, Robin; Massei, Giovanna			Too many wild boar? Modelling fertility control and culling to reduce wild boar numbers in isolated populations	PLOS ONE			English	Article							SUS-SCROFA; LITTER SIZE; FERAL SWINE; DYNAMICS; SURVIVAL; IMPACT; AREAS; DEER; REPRODUCTION; MANAGEMENT	Wild boar and feral swine number and range are increasing worldwide in parallel with their impact on biodiversity and human activities. The ecological and economic impact of this species include spread of diseases, vehicle collisions, damage to crops, amenities and infrastructures and reduction in plant and animal abundance and richness. As traditional methods such as culling have not contained the growth and spread of wild boar and feral pigs, alternative methods such as fertility control are now advocated. We used empirical data on two isolated wild boar populations to model and compare the effects of different regimes of culling and fertility control on population trends. We built a Bayesian population model and applied it to explore the implications for population control of various management options combining culling and/or contraception. The results showed that, whilst fertility control on its own was not sufficient to achieve the target reduction in wild boar number, adding fertility control to culling was more effective than culling alone. In particular, using contraceptives on 40% of the population to complement the culling of 60% of the animals, halved the time to achieve our target reduction compared with culling only. We conclude that, assuming the effort of adding fertility control to culling was found to be cost-effective in terms of population reduction, these two methods should be used simultaneously if a rapid decrease in wild boar number is required for a closed population.	[Croft, Simon; Massei, Giovanna] Anim & Plant Hlth Agcy, Natl Wildlife Management Ctr, York, N Yorkshire, England; [Franzetti, Barbara] Inst Environm Protect & Res ISPRA, Rome, Italy; [Gill, Robin] Ctr Ecosyst Soc & Biosecur Forest Res, Farnham, Surrey, England	Animal & Plant Health Agency UK; Italian Institute for Environmental Protection & Research (ISPRA)	Croft, S (corresponding author), Anim & Plant Hlth Agcy, Natl Wildlife Management Ctr, York, N Yorkshire, England.	simon.croft@apha.gov.uk			Segretariato Generale della Presidenza della Repubblica	Segretariato Generale della Presidenza della Repubblica	The original data collection used to underpin this work was funded by the Segretariato Generale della Presidenza della Repubblica.	Acevedo P, 2020, EFSA SUPP PUBL, V17, P28; AHMAD E, 1995, ACTA THERIOL, V40, P163, DOI 10.4098/AT.arch.95-17; Anderson A, 2016, CROP PROT, V89, P89, DOI 10.1016/j.cropro.2016.06.023; [Anonymous], R LANG ENV STAT COMP; [Anonymous], 2004, FILARIA J S1, V2, pS2; [Anonymous], 2017, DIABETOLOGIE STOF S2, V12, pS94, DOI 10.1055/s-0043-115953; Ballari SA, 2015, BIOL INVASIONS, V17, P1595, DOI 10.1007/s10530-014-0818-7; Barrios-Garcia MN, 2012, BIOL INVASIONS, V14, P2283, DOI 10.1007/s10530-012-0229-6; Bengsen AJ, 2016, ECOLOGY EVOLUTION MA; Bengsen AJ, 2016, MAMMAL REV, V46, P297, DOI 10.1111/mam.12070; Bengsen AJ, 2014, MAMMAL REV, V44, P135, DOI 10.1111/mam.12011; Bevins SN, 2014, BIOSCIENCE, V64, P291, DOI 10.1093/biosci/biu015; Bieber C, 2005, J APPL ECOL, V42, P1203, DOI 10.1111/j.1365-2664.2005.01094.x; Boitani L, 1995, IBEX J MT ECOL, V3, P197; Briedermann L., 1990, SCHWARZWILD, V2nd ed.; Brooks SP, 1998, J COMPUT GRAPH STAT, V7, P434, DOI 10.2307/1390675; Cahill S, 2012, ANIM BIODIV CONSERV, V35, P221; Campbell TA, 2011, PREV VET MED, V98, P243, DOI 10.1016/j.prevetmed.2010.11.018; Centner TJ, 2015, AMBIO, V44, P121, DOI 10.1007/s13280-014-0532-9; Conejero C, 2019, MAMM BIOL, V96, P68, DOI 10.1016/j.mambio.2019.04.002; Cremasco P, 2016, 5 QUEENSL PEST AN S, P103; Fernandez-Llario P, 1999, ANIM BEHAV, V58, P1079, DOI 10.1006/anbe.1999.1234; Focardi S, 1996, FOREST ECOL MANAG, V88, P7, DOI 10.1016/S0378-1127(96)03804-2; Focardi S, 2008, J MAMMAL, V89, P1113, DOI 10.1644/07-MAMM-A-164.1; Franzetti B, 2012, EUR J WILDLIFE RES, V58, P385, DOI 10.1007/s10344-011-0587-x; Frauendorf M, 2016, SCI TOTAL ENVIRON, V541, P877, DOI 10.1016/j.scitotenv.2015.09.128; Fruzinski B, 2002, Z JAGDWISS, V48, P201, DOI 10.1007/BF02192409; Gamelon M, 2017, OECOLOGIA, V183, P1065, DOI 10.1007/s00442-017-3821-8; Gamelon M, 2014, EVOLUTION, V68, P3636, DOI 10.1111/evo.12519; Gelman A., 2013, BAYESIAN DATA ANAL M; Giacomelli S, 2018, ECOL SOC, V23, DOI 10.5751/ES-10353-230412; Gill R., 2015, FERAL WILD BOAR DEER; Gill RMA, 1997, J APPL ECOL, V34, P1273, DOI 10.2307/2405237; Gill RMA, 2018, FERAL WILD BOAR DEER; Gonzalez-Crespo C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202289; Graitson E, 2019, ANIM CONSERV, V22, P165, DOI 10.1111/acv.12447; Guberti V, 2018, HDB AFRICAN SWINE FE; Bueno CG, 2010, EUR J WILDLIFE RES, V56, P765, DOI 10.1007/s10344-010-0372-2; Guo X, 2016, TRANSBOUND EMERG DIS, V63, P296, DOI 10.1111/tbed.12274; Halasa T, 2016, VET MICROBIOL, V193, P7, DOI 10.1016/j.vetmic.2016.08.004; Holland EP, 2009, ECOL MODEL, V220, P1203, DOI 10.1016/j.ecolmodel.2009.02.013; Hone J, 2002, BIOL CONSERV, V105, P231, DOI 10.1016/S0006-3207(01)00185-9; Hone J., 2012, APPL POPULATION COMM; Imperio S, 2012, OIKOS, V121, P1613, DOI 10.1111/j.1600-0706.2011.20085.x; JEZIERSKI W, 1977, ACTA THERIOL, V22, P337, DOI 10.4098/AT.arch.77-31; Keuling O, 2016, SCI TOTAL ENVIRON, V554, P311, DOI 10.1016/j.scitotenv.2016.02.159; Keuling O, 2013, EUR J WILDLIFE RES, V59, P805, DOI 10.1007/s10344-013-0733-8; Lange M, 2015, ALTERNATIVE CONTROL, V12, p843E; LANGE M, 2018, EFSA SUPPORT PUBL, V15, P1521, DOI DOI 10.2903/sp.efsa.2018.EN-1521; LESLIE PH, 1945, BIOMETRIKA, V33, P183, DOI 10.2307/2332297; MARTYS M, 1982, Z SAUGETIERKD, V47, P100; Massei G, 1996, ACTA THERIOL, V41, P307, DOI 10.4098/AT.arch.96-29; Massei Giovanna, 2004, Galemys, V16, P135; Massei G, 2015, PEST MANAG SCI, V71, P492, DOI 10.1002/ps.3965; Massei G, 2014, WILDLIFE RES, V41, P1, DOI 10.1071/WR13141; Massei G, 2012, WILDLIFE RES, V39, P378, DOI 10.1071/WR11196; Massei Giovanna, 2011, Human-Wildlife Interactions, V5, P79; Massei G, 2010, J WILDLIFE MANAGE, V74, P333, DOI 10.2193/2008-489; Mauget R., 1984, S INT SANGL C, P15; Moore N, 2004, ECOLOGY MANAGEMENT W; Moretti M, 1995, IBEX J MOUNT ECOL, V3, P192; Nahlik A, 2003, WILDLIFE BIOL, V9, P37, DOI 10.2981/wlb.2003.062; Neet C.R., 1995, IBEX J M E, V3, P188; Oliviero C, 2019, J ANIM SCI, V97, P2283, DOI 10.1093/jas/skz066; Oloff HB, 1951, BIOL OKOLOGIE SCHWAR; Parkes JP, 2010, BIOL CONSERV, V143, P634, DOI 10.1016/j.biocon.2009.11.028; Pepin KM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183441; Plummer M., 2016, RJAGS BAYESIAN GRAPH; Plummer M., 2003, P 3 INT WORKSH DISTR, V10; Raiho AM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143122; Rubin D. B., 1992, STAT SCI, V7, P457, DOI DOI 10.1111/j.1469-8137.2011.03796.x; Servanty S, 2007, BEHAV ECOL, V18, P427, DOI 10.1093/beheco/arl099; Servanty S, 2011, J APPL ECOL, V48, P835, DOI 10.1111/j.1365-2664.2011.02017.x; Shapiro L, 2016, J PEST SCI, V89, P489, DOI 10.1007/s10340-015-0706-7; SHARP T, 2004, MODEL CODE PRACTICE; SJARMIDI A, 1988, MONIT ZOOL ITAL, V22, P415; Smart JCR, 2004, MAMMAL REV, V34, P99, DOI 10.1046/j.0305-1838.2003.00026.x; Snow NP, 2017, J APPL ECOL, V54, P2022, DOI 10.1111/1365-2664.12866; Stillfried M, 2017, J APPL ECOL, V54, P272, DOI 10.1111/1365-2664.12756; Toigo C, 2008, J WILDLIFE MANAGE, V72, P1532, DOI 10.2193/2007-378; Twigg LE, 2006, WILDLIFE RES, V33, P417, DOI 10.1071/WR05098; Venables W.N., 2002, MODERN APPL STAT S; Welander J, 2000, J ZOOL, V252, P263, DOI 10.1111/j.1469-7998.2000.tb00621.x; Wilson C.J., 2014, Wildlife Biology in Practice, V10, P1	84	11	13	2	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 18	2020	15	9							e0238429	10.1371/journal.pone.0238429	http://dx.doi.org/10.1371/journal.pone.0238429			19	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	NU7WV	32946480	Green Published, gold			2023-01-03	WOS:000573851100084
J	Filbly, A				Filbly, Alexandra			WHAT YOUR PATIENT IS THINKING Don't torment me with hope	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material												alfilby@gmail.com							0	2	2	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 9	2020	370								m3016	10.1136/bmj.m3016	http://dx.doi.org/10.1136/bmj.m3016			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NP5VZ	32907822	Bronze			2023-01-03	WOS:000570245200019
J	Devlin, JR; Alonso, JA; Ayres, CM; Keller, GLJ; Bobisse, S; Vander Kooi, CW; Coukos, G; Gfeller, D; Harari, A; Baker, BM				Devlin, Jason R.; Alonso, Jesus A.; Ayres, Cory M.; Keller, Grant L. J.; Bobisse, Sara; Vander Kooi, Craig W.; Coukos, George; Gfeller, David; Harari, Alexandre; Baker, Brian M.			Structural dissimilarity from self drives neoepitope escape from immune tolerance	NATURE CHEMICAL BIOLOGY			English	Article							PEPTIDE; ANTIGEN; COMPLEX; PROTEIN; AFFINITY; VACCINE; RECOGNITION; FLEXIBILITY; MATURATION; STABILITY	T-cell recognition of peptides incorporating nonsynonymous mutations, or neoepitopes, is a cornerstone of tumor immunity and forms the basis of new immunotherapy approaches including personalized cancer vaccines. Yet as they are derived from self-peptides, the means through which immunogenic neoepitopes overcome immune self-tolerance are often unclear. Here we show that a point mutation in a non-major histocompatibility complex anchor position induces structural and dynamic changes in an immunologically active ovarian cancer neoepitope. The changes pre-organize the peptide into a conformation optimal for recognition by a neoepitope-specific T-cell receptor, allowing the receptor to bind the neoepitope with high affinity and deliver potent T-cell signals. Our results emphasize the importance of structural and physical changes relative to self in neoepitope immunogenicity. Considered broadly, these findings can help explain some of the difficulties in identifying immunogenic neoepitopes from sequence alone and provide guidance for developing novel, neoepitope-based personalized therapies.	[Devlin, Jason R.; Alonso, Jesus A.; Ayres, Cory M.; Keller, Grant L. J.; Baker, Brian M.] Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA; [Bobisse, Sara; Gfeller, David; Harari, Alexandre] Univ Lausanne, Ludwig Inst Canc Res, Dept Oncol UNIL CHUV, Lausanne, Switzerland; [Bobisse, Sara; Coukos, George; Harari, Alexandre] CHU Vaudois, Dept Oncol, Ctr Expt Therapeut, Lausanne, Switzerland; [Vander Kooi, Craig W.] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY USA; [Gfeller, David] Swiss Inst Bioinformat, Lausanne, Switzerland	University of Notre Dame; Ludwig Institute for Cancer Research; University of Lausanne; University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Kentucky; Swiss Institute of Bioinformatics	Baker, BM (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	brian-baker@nd.edu	Coukos, George/ABG-7389-2020	Keller, Grant/0000-0001-7645-121X; Devlin, Jason/0000-0001-9184-8741; Alonso, Jesus/0000-0002-1961-725X; Harari, Alexandre/0000-0002-1055-2090	NIGMS, NIH [R35GM118166]; Swiss National Science Foundation [310030-182384]; Swiss Cancer League [KFS-4104-02-2017]; Indiana CTSI - NIH [UL1TR002529]; DOE [DE-AC02-06CH11357]; NIH [P30GM124165, S10OD021527, S10RR25528, S10RR028976]	NIGMS, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Swiss Cancer League; Indiana CTSI - NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOE(United States Department of Energy (DOE)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank L. Hellman for assistance with biophysical and structural work, R. Genolet for assistance with TCR sequences and C. Klebanoff for comments on the manuscript. B.M.B. acknowledges support from the NIGMS, NIH (grant no. R35GM118166). A.H. acknowledges support from the Swiss National Science Foundation (grant no. 310030-182384). D.G. acknowledges support from Swiss Cancer League (grant no. KFS-4104-02-2017). J.R.D. and G.L.J.K. acknowledge support from the Indiana CTSI, funded by the NIH (grant no. UL1TR002529). X-ray diffraction data were collected at the Advanced Photon Source, supported by DOE contract no. DE-AC02-06CH11357, and the NE-CAT and SER-CAT beamlines, supported by member institutions and NIH grants no. P30GM124165, no. S10OD021527, no. S10RR25528 and no. S10RR028976.	[Anonymous], 2020, NAT COMMUN, DOI DOI 10.1038/S41467-020-16755-Y; [Anonymous], 2016, SCI REP UK, DOI DOI 10.1038/SREP25070; [Anonymous], 2010, BIOINFORMATION; [Anonymous], 2019, JCI INSIGHT, DOI DOI 10.1172/JCI.INSIGHT.129152; [Anonymous], 2017, FRONT MOL BIOSCI, DOI DOI 10.3389/FMOLB.2017.00002; Armstrong KM, 2007, BIOPHYS J, V93, P597, DOI 10.1529/biophysj.107.104570; Ayres CM, 2017, J CHEM INF MODEL, V57, P1990, DOI 10.1021/acs.jcim.7b00118; Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462; Bassani-Sternberg M, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005725; Bassani-Sternberg M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13404; Bjerregaard AM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01566; Bjerregaard AM, 2017, CANCER IMMUNOL IMMUN, V66, P1123, DOI 10.1007/s00262-017-2001-3; Blevins SJ, 2016, P NATL ACAD SCI USA, V113, pE1276, DOI 10.1073/pnas.1522069113; Bobisse S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03301-0; Boehr DD, 2009, NAT CHEM BIOL, V5, P789, DOI 10.1038/nchembio.232; Borbulevych OY, 2005, J IMMUNOL, V174, P4812, DOI 10.4049/jimmunol.174.8.4812; Braunlein E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01702; Calis JJA, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003266; Chowell D, 2015, P NATL ACAD SCI USA, V112, pE1754, DOI 10.1073/pnas.1500973112; Cole DK, 2016, J CLIN INVEST, V126, P2191, DOI 10.1172/JCI85679; Davis-Harrison RL, 2005, J MOL BIOL, V346, P533, DOI 10.1016/j.jmb.2004.11.063; Duan F, 2014, J EXP MED, V211, P2231, DOI 10.1084/jem.20141308; Duru AD, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008244; Englert M, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv1255; Fleri W, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00278; Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988; Hebeisen M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00154; Hellman LM, 2016, J IMMUNOL METHODS, V432, P95, DOI 10.1016/j.jim.2016.02.016; Insaidoo FK, 2011, J BIOL CHEM, V286, P40163, DOI 10.1074/jbc.M111.283564; Jurtz V, 2017, J IMMUNOL, V199, P3360, DOI 10.4049/jimmunol.1700893; Kowarz E, 2015, BIOTECHNOL J, V10, P647, DOI 10.1002/biot.201400821; Li YL, 2005, STRUCTURE, V13, P297, DOI 10.1016/j.str.2004.12.012; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; Luksza M, 2017, NATURE, V551, P517, DOI 10.1038/nature24473; Manivel V, 2000, IMMUNITY, V13, P611, DOI 10.1016/S1074-7613(00)00061-3; Menegatti Rigo M, 2015, SCI REP, V5; Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991; Riley TP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02047; Riley TP, 2018, NAT CHEM BIOL, V14, P934, DOI 10.1038/s41589-018-0130-4; Rossjohn J, 2015, ANNU REV IMMUNOL, V33, P169, DOI 10.1146/annurev-immunol-032414-112334; Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003; Schmidt AG, 2013, P NATL ACAD SCI USA, V110, P264, DOI 10.1073/pnas.1218256109; Schumacher TN, 2019, ANNU REV IMMUNOL, V37, P173, DOI 10.1146/annurev-immunol-042617-053402; Shapovalov MV, 2011, STRUCTURE, V19, P844, DOI 10.1016/j.str.2011.03.019; Slansky JE, 2000, IMMUNITY, V13, P529, DOI 10.1016/S1074-7613(00)00052-2; Spear TT, 2017, CANCER IMMUNOL IMMUN, V66, P1411, DOI 10.1007/s00262-017-2032-9; Stone JD, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00244; Sundberg EJ, 2000, BIOCHEMISTRY-US, V39, P15375, DOI 10.1021/bi000704l; Tanyi JL, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao5931; Theodossis A, 2010, P NATL ACAD SCI USA, V107, P5534, DOI 10.1073/pnas.1000032107; Tian S, 2007, J IMMUNOL, V179, P2952, DOI 10.4049/jimmunol.179.5.2952; Toor JS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00099; Vianna P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8121488; Wang Y, 2017, P NATL ACAD SCI USA, V114, pE4792, DOI 10.1073/pnas.1700459114; Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001; Zhang Y, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001018	57	18	18	0	12	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1552-4450	1552-4469		NAT CHEM BIOL	Nat. Chem. Biol.	NOV	2020	16	11					1269	+		10.1038/s41589-020-0610-1	http://dx.doi.org/10.1038/s41589-020-0610-1		AUG 2020	17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	OC0BY	32807968	Green Accepted			2023-01-03	WOS:000562210200004
J	Ruangritchankul, S; Peel, NM; Hanjani, LS; Gray, LC				Ruangritchankul, Sirasa; Peel, Nancye M.; Hanjani, Leila Shafiee; Gray, Leonard C.			Drug related problems in older adults living with dementia	PLOS ONE			English	Article							POTENTIALLY INAPPROPRIATE MEDICATIONS; COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; GERIATRIC SYNDROMES; PROSPECTIVE COHORT; ELDERLY-PEOPLE; ACUTE-CARE; POLYPHARMACY; PREVALENCE; HOSPITALIZATION	Background Compared with those without dementia, older patients with dementia admitted to acute care settings are at higher risk for triad combination of polypharmacy (PP), potentially inappropriate medication (PIM), and drug-drug interaction (DDI), which may consequently result in detrimental health. The aims of this research were to assess risk factors associated with triad combination of PP, PIM and DDI among hospitalized older patients with dementia, and to assess prevalence and characteristics of PP, PIM and DDI in this population. Methods In this retrospective cross-sectional study, 416 older inpatients diagnosed with dementia and referred for specialist geriatric consultation at a tertiary hospital in Brisbane, Australia during 2006-2016 were enrolled. Patients were categorized into two groups according to their exposure to the combination of PP, PIM and DDI: 'triad combination' and 'non-triad combination'. Data were collected using the interRAI Acute Care (AC) assessment instrument. Independent risk factors of exposure to the triad combination were evaluated using bivariate and multivariate logistic regression analyses. Results Overall, 181 (43.5%) were classified as triad combination group. The majority of the population took at least 1 PIM (56%) or experienced at least one potential DDI (76%). Over 75% of the participants were exposed to polypharmacy. The most common prescribed PIMs were antipsychotics, followed by benzodiazepines. The independent risk factors of the triad combination were the presence of atrial fibrillation diagnosis and higher medications use in cardiac therapy, psycholeptics and psychoanaleptics. Conclusions The exposure to triad combination of PP, PIM and DDI are common among people with dementia as a result of their vulnerable conditions and the greater risks of adverse events from medications use. This study identified the use of cardiac therapy, psycholeptics and psychoanaleptics as predictors of exposure to PP, PIM and DDI. Therefore, use of these medications should be carefully considered and closely monitored. Furthermore, comprehensive medication reviews to optimize medication prescribing should be initiated and continually implemented for this vulnerable population.	[Ruangritchankul, Sirasa; Peel, Nancye M.; Hanjani, Leila Shafiee; Gray, Leonard C.] Univ Queensland, Fac Med, Ctr Hlth Serv Res, Brisbane, Qld, Australia; [Ruangritchankul, Sirasa] Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Med,Div Geriatr Med, Bangkok, Thailand	University of Queensland; Mahidol University	Ruangritchankul, S (corresponding author), Univ Queensland, Fac Med, Ctr Hlth Serv Res, Brisbane, Qld, Australia.; Ruangritchankul, S (corresponding author), Mahidol Univ, Ramathibodi Hosp, Fac Med, Dept Med,Div Geriatr Med, Bangkok, Thailand.	sirasarama37@gmail.com	Hanjani, Leila Shafiee/Y-9406-2018; Peel, Nancye/F-5492-2010	Hanjani, Leila Shafiee/0000-0001-7088-9739; Peel, Nancye/0000-0002-3038-8881; Gray, Leonard/0000-0003-2141-0802				Andersen F, 2011, BMC GERIATR, V11, DOI 10.1186/1471-2318-11-58; Andrieu S, 2002, INT J GERIATR PSYCH, V17, P422, DOI 10.1002/gps.624; [Anonymous], 2013, HEALTHCARE SERIES; Australian Commission on Safety and Quality in Health Care, 2013, EV SAF QUAL ISS ASS; Azermai M, 2012, AGEING RES REV, V11, P78, DOI 10.1016/j.arr.2011.07.002; Bail K, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002770; Beers MH, 1997, ARCH INTERN MED, V157, P1531, DOI 10.1001/archinte.157.14.1531; Bell JS, 2012, AUST FAM PHYSICIAN, V41, P45; Beveridge LA, 2011, CLIN INTERV AGING, V6, P173, DOI 10.2147/CIA.S13423; Bickel H, 2018, DTSCH ARZTEBL INT, V115, P733, DOI 10.3238/arztebl.2018.0733; Blasco S, 2010, INTERRAI ACUTE CARE, DOI [10.1186/1472-6963-9-71, DOI 10.1186/1472-6963-9-71]; Bogetti-Salazar M, 2016, CLINICS, V71, P17, DOI 10.6061/clinics/2016(01)04; Bradshaw LE, 2013, INT J GERIATR PSYCH, V28, P681, DOI 10.1002/gps.3871; Briggs R, 2017, QJM-INT J MED, V110, P33, DOI 10.1093/qjmed/hcw114; Briggs R, 2016, QJM-INT J MED, V109, P41, DOI 10.1093/qjmed/hcv085; Brodaty H, 2012, INT PSYCHOGERIATR, V24, P1034, DOI 10.1017/S1041610211002924; Bunn F, 2014, BMC MED, V12, DOI 10.1186/s12916-014-0192-4; Bynum JPW, 2004, J AM GERIATR SOC, V52, P187, DOI 10.1111/j.1532-5415.2004.52054.x; Carter Mary W, 2005, Am J Alzheimers Dis Other Demen, V20, P349, DOI 10.1177/153331750502000605; Chang JT, 2004, BRIT MED J, V328, P680, DOI 10.1136/bmj.328.7441.680; Clague F, 2017, AGE AGEING, V46, P33, DOI 10.1093/ageing/afw176; Connolly S, 2015, DEMENTIA-LONDON, V14, P650, DOI 10.1177/1471301213506922; Cross AJ, 2016, DRUG AGING, V33, P37, DOI 10.1007/s40266-015-0332-3; Dementia Australia, 2017, DEM STAT VICT; Dementia Australia, 2018, DEM PREV DAT 2018 20; Department of Health, 2019, NAT FRAM ACT DEM 201; Department of Health and Ageing, 2003, UNN AV HOSP ADM OLD; Douglas IJ, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1227; Draper B, 2011, INT PSYCHOGERIATR, V23, P1649, DOI 10.1017/S1041610211001694; Eshetie TC, 2019, INT J GERIATR PSYCH, V34, P1498, DOI 10.1002/gps.5160; Eshetie TC, 2018, EXPERT OPIN DRUG SAF, V17, P825, DOI 10.1080/14740338.2018.1497156; Ferreira F, 2015, GERIATR GERONTOL AGI, V9, P21; Fick DM, 2019, J AM GERIATR SOC, V67, P674, DOI 10.1111/jgs.15767; Fogg C, 2018, INT J GERIATR PSYCH, V33, P1177, DOI 10.1002/gps.4919; Fong TG, 2012, ANN INTERN MED, V156, P848, DOI 10.7326/0003-4819-156-12-201206190-00005; Gallagher P, 2008, INT J CLIN PHARM TH, V46, P72; Gnjidic D, 2012, J CLIN EPIDEMIOL, V65, P989, DOI 10.1016/j.jclinepi.2012.02.018; Gray L, 2008, AUSTRALAS J AGEING, V27, P205, DOI 10.1111/j.1741-6612.2008.00309.x; Gray LC, 2008, J AM GERIATR SOC, V56, P536, DOI 10.1111/j.1532-5415.2007.01590.x; Gray LC, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-71; Guijarro R, 2010, NEUROEPIDEMIOLOGY, V35, P101, DOI 10.1159/000311032; Gustafsson M, 2018, PHARMACY, V6, DOI 10.3390/pharmacy6010007; Gustafsson M, 2016, EUR J CLIN PHARMACOL, V72, P1143, DOI 10.1007/s00228-016-2084-3; Gustafsson M, 2013, BMC PHARMACOL TOXICO, V14, DOI 10.1186/2050-6511-14-10; Guthrie B, 2011, BMJ-BRIT MED J, V342, DOI 10.1136/bmj.d3514; Guthrie B, 2010, AGE AGEING, V39, P637, DOI 10.1093/ageing/afq090; Gutierrez-Valencia M, 2017, GERIATR GERONTOL INT, V17, P2354, DOI 10.1111/ggi.13073; Hill J, 2005, J ALZHEIMERS DIS, V8, P43; Hoffmann F, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-190; Holt S, 2010, DTSCH ARZTEBL INT, V107, P543, DOI 10.3238/arztebl.2010.0543; Hukins D, 2019, EUR J CLIN PHARMACOL, V75, P467, DOI 10.1007/s00228-018-02612-x; ICD-10, 2016, ORG INCL SYMPT MENT; January CT, 2019, CIRCULATION, V140, pE125, DOI 10.1161/CIR.0000000000000665; Johnell K, 2015, CURR CLIN PHARMACOL, V10, P178, DOI 10.2174/1574884710666150609154741; Justin B Ng, 2013, Clin Epidemiol, V5, P135, DOI 10.2147/CLEP.S30621; Kable A, 2019, HEALTHCARE-BASEL, V7, DOI 10.3390/healthcare7010008; King B, 2006, AUSTRALAS J AGEING, V25, P20, DOI 10.1111/j.1741-6612.2006.00135.x; Koyama A, 2013, J AM GERIATR SOC, V61, P258, DOI 10.1111/jgs.12093; Kurrle S, 2012, PHYSICAL COMORBIDITIES OF DEMENTIA, P1, DOI 10.1017/CBO9780511894534; Kurrle S, 2018, PHYS COMORBIDITIES D; Lai SW, 2012, GERIATR GERONTOL INT, V12, P491, DOI 10.1111/j.1447-0594.2011.00800.x; Lai SW, 2010, MEDICINE, V89, P295, DOI 10.1097/MD.0b013e3181f15efc; Lakhan P, 2011, J AM GERIATR SOC, V59, P2001, DOI 10.1111/j.1532-5415.2011.03663.x; Lalic S, 2016, J AM MED DIR ASSOC, V17, DOI 10.1016/j.jamda.2016.08.019; Laroche ML, 2007, EUR J CLIN PHARMACOL, V63, P725, DOI 10.1007/s00228-007-0324-2; Lau DT, 2010, ALZ DIS ASSOC DIS, V24, P56, DOI 10.1097/WAD.0b013e31819d6ec9; Leelakanok N, 2019, AGING MENT HEALTH, V23, P932, DOI 10.1080/13607863.2018.1468411; Liu E, 2017, J GERIATR CARDIOL, V14, P407, DOI 10.11909/j.issn.1671-5411.2017.06.009; Liu MB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079812; MacDermott S, 2017, NATL ROLLOUT EVAL UA; Malone DC, 2009, AM J MANAG CARE, V15, P481; Mangoni AA, 2004, BRIT J CLIN PHARMACO, V57, P6, DOI 10.1046/j.1365-2125.2003.02007.x; Markota M, 2016, MAYO CLIN PROC, V91, P1632, DOI 10.1016/j.mayocp.2016.07.024; Mecocci P, 2005, DEMENT GERIATR COGN, V20, P262, DOI 10.1159/000087440; Brunet NM, 2014, EUR GERIATR MED, V5, P66, DOI 10.1016/j.eurger.2013.10.011; Montastruc F, 2013, EUR J CLIN PHARMACOL, V69, P1589, DOI 10.1007/s00228-013-1506-8; Mueller C, 2018, EXP GERONTOL, V106, P240, DOI 10.1016/j.exger.2018.02.011; Mukadam N, 2011, INT PSYCHOGERIATR, V23, P344, DOI 10.1017/S1041610210001717; Mukaetova-Ladinska EB, 2009, BRIT J PSYCHIAT, V195, P461, DOI 10.1192/bjp.195.5.461; Nagai M, 2010, AM J HYPERTENS, V23, P116, DOI 10.1038/ajh.2009.212; National Centre for Social and Economic Modelling, 2016, EC COST DEM AUSTR 20; National Health Service, 2011, OPT TREATM CAR PEOPL; Nicolazzo JA, 2010, THER DELIV, V1, P595, DOI 10.4155/TDE.10.41; Oesterhus R, 2017, INT J GERIATR PSYCH, V32, P183, DOI 10.1002/gps.4456; Pariente A, 2016, CNS DRUGS, V30, P1, DOI 10.1007/s40263-015-0305-4; Pariente A, 2012, ARCH INTERN MED, V172, P648, DOI 10.1001/archinternmed.2012.28; Park HY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169463; Park H, 2015, EUR J CLIN PHARMACOL, V71, P1429, DOI 10.1007/s00228-015-1955-3; Pasqualetti G, 2015, CLIN INTERV AGING, V10, P1457, DOI 10.2147/CIA.S87466; Payne RA, 2014, BRIT J CLIN PHARMACO, V77, P1073, DOI 10.1111/bcp.12292; Peron EP, 2017, ALZHEIMER DIS, p10e; Pfister B, 2017, BMC PHARMACOL TOXICO, V18, DOI 10.1186/s40360-017-0157-2; Pharmaceutical Care Network Europe Foundation, 2019, PCNE CLASS V 9 0 CLA; Phelan EA, 2012, JAMA-J AM MED ASSOC, V307, P165, DOI 10.1001/jama.2011.1964; Ralph SJ, 2018, J ALZHEIMERS DIS REP, V2, P1, DOI 10.3233/ADR-170042; Redston MR, 2018, J ALZHEIMERS DIS, V61, P1639, DOI 10.3233/JAD-170842; Reeve E, 2017, EXPERT OPIN DRUG MET, V13, P651, DOI 10.1080/17425255.2017.1325873; Reynish EL, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0899-0; Richardson K, 2015, AGE AGEING, V44, P90, DOI 10.1093/ageing/afu141; Richardson K, 2011, DRUG AGING, V28, P547, DOI 10.2165/11592000-000000000-00000; Sakakibara R, 2012, NEUROL INT, V4, P52, DOI 10.4081/ni.2012.e13; Sampson EL, 2009, BRIT J PSYCHIAT, V195, P61, DOI 10.1192/bjp.bp.108.055335; Scrutton J, 2016, DEMENTIA COMORBIDITI; Seritan AL, 2008, CURR PSYCHIAT, V7, P57; Sharma S, 2018, J AM MED DIR ASSOC, V19, P607, DOI 10.1016/j.jamda.2018.03.009; Sheehan B, 2013, AGE AGEING, V42, P786, DOI 10.1093/ageing/aft139; Shi S, 2008, EUR J CLIN PHARMACOL, V64, P183, DOI 10.1007/s00228-007-0422-1; Sinnige J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079641; Sonnerstam E, 2018, EUR J CLIN PHARMACOL, V74, P1351, DOI 10.1007/s00228-018-2514-5; Sonnerstam E, 2017, EUR J CLIN PHARMACOL, V73, P735, DOI 10.1007/s00228-017-2218-2; Staekenborg SS, 2016, J ALZHEIMERS DIS, V53, P135, DOI 10.3233/JAD-151063; Tate JA, 2014, CRIT CARE MED, V42, P1037, DOI 10.1097/CCM.0000000000000123; Thies W, 2011, ALZHEIMERS DEMENT, V7, P175, DOI [10.1016/j.jalz.2011.02.004, 10.1016/j.jalz.2011.02.002]; Thomazi Rafael, 2018, Dement. neuropsychol., V12, P35, DOI 10.1590/1980-57642018dn12-010005; TIMMONS S, 2015, IR AGEING STUD REV, V6, P105; Timmons S, 2015, AGE AGEING, V44, P993, DOI 10.1093/ageing/afv131; Toot S, 2013, J AM MED DIR ASSOC, V14, P463, DOI 10.1016/j.jamda.2013.01.011; Travers C, 2013, J NUTR HEALTH AGING, V17, P435, DOI 10.1007/s12603-012-0439-8; Travers C, 2013, INTERN MED J, V43, P262, DOI 10.1111/j.1445-5994.2012.02962.x; Triplitt C., 2006, DIABETES SPECTR, V19, P202, DOI [10.2337/diaspect.19.4.202, DOI 10.2337/DIASPECT.19.4.202]; von Renteln-Kruse W, 2015, DTSCH ARZTEBL INT, V112, P103, DOI 10.3238/arztebl.2015.0103; Wastesson JW, 2018, EXPERT OPIN DRUG SAF, V17, P1185, DOI 10.1080/14740338.2018.1546841; Wawruch M, 2008, J CLIN PHARM THER, V33, P381, DOI 10.1111/j.1365-2710.2008.00929.x; WHO Collaborating Centre for Drug Statistics Methodology, 2019, OSLO; Wucherer D, 2017, INT PSYCHOGERIATR, V29, P1857, DOI 10.1017/S1041610217001442; Yu NW, 2017, BMC GERIATR, V17, DOI 10.1186/s12877-017-0530-4; Zekry D, 2009, INT J GERIATR PSYCH, V24, P283, DOI 10.1002/gps.2104; Zhao Y, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-108	128	8	8	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 31	2020	15	7							e0236830	10.1371/journal.pone.0236830	http://dx.doi.org/10.1371/journal.pone.0236830			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	NO3EK	32735592	Green Published, gold			2023-01-03	WOS:000569367100051
J	Terrens, AF; Soh, SE; Morgan, P				Terrens, Aan Fleur; Soh, Sze-Ee; Morgan, Prue			The safety and feasibility of a Halliwick style of aquatic physiotherapy for falls and balance dysfunction in people with Parkinson's Disease: A single blind pilot trial	PLOS ONE			English	Article							QUALITY-OF-LIFE; FUNCTIONAL MOBILITY; PREVENT FALLS; EXERCISE; GAIT; STRATEGIES; ADHERENCE; EFFICACY; CRITIQUE; THERAPY	Background There is growing evidence that aquatic physiotherapy may be effective for people with Parkinson's Disease (PD) but most studies have investigated land based type exercises in the aquatic environment. Few studies have examined customised aquatic therapies such as the Halliwick concept which focuses on trunk rotation and core stabilisation. Objective The primary aim was to determine the feasibility of a Halliwick style aquatic physiotherapy intervention for people with PD. The secondary aim was to compare the Halliwick intervention with traditional aquatic and land based physiotherapy in terms of disease severity, balance and fear of falling. Methods Halliwick style aquatic, traditional aquatic and land based physiotherapy were trialled in a single blind pilot study. All interventions ran for 60 minutes per week over 12 weeks. Feasibility outcomes were safety, adherence and attrition. Secondary outcomes included the Unified Parkinson's Disease Rating Scale motor subsection (UPDRS-III), Berg Balance Scale (BBS), Mini BESTest and modified Falls Efficacy Scale (mFES). Results 30 participants with moderate PD were recruited. Participant mean age was 72 years (SD 8.4; range 51-86) with moderate disease severity (median Hoehn & Yahr score 3; IQR 1).No falls occurred during intervention sessions, however ten participants reported falls during the study period. No other adverse consequences were reported. All groups had adherence over 85%. No within group significant differences were found in UPDRS-III, BBS or mFES scores post-intervention for all groups, but the Halliwick aquatic group improved significantly in the Mini BESTest post-intervention (p = 0.011, 95% CI -7.36,-1.31,t(10) = -2.98). Conclusions Despite people with PD being a vulnerable population, aquatic physiotherapy, including the Halliwick style is a safe treatment option. Promising results for balance in the Halliwick aquatic group were observed, but further studies with larger sample sizes is required to increase confidence in the results.	[Terrens, Aan Fleur] Peninsula Hlth, Movement Disorder Program, Frankston, Vic, Australia; [Terrens, Aan Fleur; Soh, Sze-Ee; Morgan, Prue] Monash Univ, Dept Physiotherapy, Clayton, Vic, Australia; [Soh, Sze-Ee] Monash Univ, Dept Epidemiol & Preventat Med, Clayton, Vic, Australia	Monash University; Monash University	Terrens, AF (corresponding author), Peninsula Hlth, Movement Disorder Program, Frankston, Vic, Australia.; Terrens, AF (corresponding author), Monash Univ, Dept Physiotherapy, Clayton, Vic, Australia.	fterrens@phcn.vic.gov.au		terrens, aan/0000-0003-3957-9884	Aan F Terrens Lee Silverman Voice Treatment (LSVT)	Aan F Terrens Lee Silverman Voice Treatment (LSVT)	Aan F Terrens Lee Silverman Voice Treatment (LSVT) small student grant [2017] https://www.lsvtglobal.com/The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.; The authors would like to thank Lee Silverman Voice Treatment (LSVT) for their support with a small student grant [2017].The authors would also like to thank all participants of this trial, and Wendy Toogood who tirelessly assisted in the recruitment and organisation of this trial.	APA, 2015, AUSTR GUID AQ PHYS W; Artigas NR, 2016, ARQ NEURO-PSIQUIAT, V74, P519, DOI 10.1590/0004-282X20160074; Bartels EM, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005523.pub2; Bartolic A, 2005, EUR J NEUROL, V12, P156, DOI 10.1111/j.1468-1331.2004.00942.x; Beaulne-Seguin Z, 2016, GAIT POSTURE, V49, P443, DOI 10.1016/j.gaitpost.2016.08.002; BERG K, 1989, Physiotherapy Canada, V41, P304; Blandy LM, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00122; Bloem BR, 2016, MOVEMENT DISORD, V31, P1342, DOI 10.1002/mds.26572; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; Carroll LM, 2017, ARCH PHYS MED REHAB, V98, P631, DOI 10.1016/j.apmr.2016.12.006; Cugusi L, 2019, J PHYSIOTHER, V65, P65, DOI 10.1016/j.jphys.2019.02.003; Edwards N, 2008, DISABIL REHABIL-ASSI, V3, P193, DOI 10.1080/17483100801897198; Franchignoni F, 2010, J REHABIL MED, V42, P323, DOI 10.2340/16501977-0537; Garcia M.K., 2012, ACTA FISI TRICA, V19, P142, DOI [10.5935/0104-7795.20120022, DOI 10.5935/0104-7795.20120022]; Geytenbeek J., 2002, PHYSIOTHERAPY, V88, P514, DOI [10.1016/S0031-9406(05)60134-4, DOI 10.1016/S0031-9406(05)60134-4]; Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340; Goodwin VA, 2011, J NEUROL NEUROSUR PS, V82, P1232, DOI 10.1136/jnnp-2011-300919; Heisters Daiga, 2011, Br J Nurs, V20, P548; Hirsch L, 2016, NEUROEPIDEMIOLOGY, V46, P292, DOI 10.1159/000445751; Hubble RP, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006095; Kalilani L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161689; Karthikbabu S, 2011, NEUROSCIENCE MED, V02, P7; Keus SH., 2014, EUROPEAN PHYSIOTHERA; Leddy AL, 2011, PHYS THER, V91, P102, DOI 10.2522/ptj.20100113; Lim SY, 2018, PARKINSONISM RELAT D, V46, pS47, DOI 10.1016/j.parkreldis.2017.07.029; Martinez-Martin P, 2011, MOVEMENT DISORD, V26, P2371, DOI 10.1002/mds.23834; McMillan J., 1978, FYSIOTERAPEUTEN, V45, P87; McPhate L, 2013, J PHYSIOTHER, V59, P81, DOI 10.1016/S1836-9553(13)70160-7; Morris ME, 2009, MOVEMENT DISORD, V24, P64, DOI 10.1002/mds.22295; Morris TR, 2012, PARKINSONISM RELAT D, V18, P572, DOI 10.1016/j.parkreldis.2012.03.001; Nilsson MH, 2010, BMC GERIATR, V10, DOI 10.1186/1471-2318-10-78; Ossig C, 2015, NEUROL CLIN, V33, P19, DOI 10.1016/j.ncl.2014.09.009; Picillo M, 2017, J NEUROL, V264, P1583, DOI 10.1007/s00415-016-8384-9; Pinto C, 2018, PM R; Pinto C, 2019, PM&R, V11, P278, DOI 10.1016/j.pmrj.2018.09.031; Qutubuddin AA, 2005, ARCH PHYS MED REHAB, V86, P789, DOI 10.1016/j.apmr.2004.11.005; Ramazzina I, 2017, CLIN INTERV AGING, V12, P619, DOI 10.2147/CIA.S131903; Senard JM, 1997, J NEUROL NEUROSUR PS, V63, P584, DOI 10.1136/jnnp.63.5.584; Simek EM, 2012, PREV MED, V55, P262, DOI 10.1016/j.ypmed.2012.07.007; Streiner D, 2001, Evid Based Ment Health, V4, P70; Terrens AF, 2018, DISABIL REHABIL, V40, P2847, DOI 10.1080/09638288.2017.1362710; Thabane L, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-1; Tripp F, 2014, CLIN REHABIL, V28, P432, DOI 10.1177/0269215513504942; Zhang HB, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004056; Zhu ZZ, 2018, CLIN REHABIL, V32, P29, DOI 10.1177/0269215517715763; Zotz T.G.G., 2013, ADV PARK DIS, V2, P102, DOI [10.4236/apd.2013.24019, DOI 10.4236/APD.2013.24019, DOI 10.4236/apd.2013.24019]	46	7	7	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 30	2020	15	7							e0236391	10.1371/journal.pone.0236391	http://dx.doi.org/10.1371/journal.pone.0236391			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW2PD	32730325	Green Published, gold			2023-01-03	WOS:000556884700034
J	Royant-Parola, S; Kovess, V; Brion, A; Dagneaux, S; Hartley, S				Royant-Parola, Sylvie; Kovess, Viviane; Brion, Agnes; Dagneaux, Sylvain; Hartley, Sarah			Do hypnotics increase the risk of driving accidents or near miss accidents due to hypovigilance? The effects of sex, chronic sleepiness, sleep habits and sleep pathology	PLOS ONE			English	Article							MOTOR-VEHICLE COLLISIONS; ROAD TRAFFIC CRASHES; COGNITIVE PERFORMANCE; DAYTIME SLEEPINESS; INSOMNIA PATIENTS; SOCIAL JETLAG; CHRONIC USERS; DRIVERS; DISORDERS; ZOPICLONE	Driving accidents due to hypovigilance are common but the role of hypnotics is unclear in patients suffering from sleep disorders. Our study examined factors influencing accidents and near miss accidents attributed to sleepiness at the wheel (ANMAS). Using data from an online questionnaire aimed at patients with sleep disorders, we analysed the associations between ANMAS, sociodemographic data, symptoms of sleep disorders, severity of insomnia (Insomnia Severity Index (ISI)) symptoms of anxiety and depression (Hospital Anxiety and Depression scale with depression (HADD) and anxiety (HADA) subscales), chronic sleepiness (Epworth sleepiness scale ESS), hypnotic use and information about sleep habits. Hypnotics were hierarchically grouped into Z-drugs, sedative medication, melatonin and over the counter (OTC) alternative treatments. Of 10802 participants; 9.1% reported ANMAS (Men 11.1% women 8.3%) and 24.4% took hypnotics (Z-drugs 8.5%, sedative medication 8%, melatonin 5.6% and alternative treatments 2.5%). Logistic regression analysis identified the following risk factors for ANMAS: moderate (OR 2.4; CI: 2.10-2.79) and severe sleepiness (ESS OR 5.66; CI: 4.74-6.77), depression (HADD OR 1.2; CI: 1.03-1.47), anxiety (HADA OR 1.2;CI: 1.01-1.47), and insufficient sleep (OR1.4; CI: 1.2-1.7). Hypnotics were not associated with an increased risk of ANMAS in patients suffering from insomnia. Risk factors varied according to sex: in females, sex (OR 0.; CI: 0.55-0.74), mild insomnia (OR 0.5; CI: 0.3-0.8) and use of alternative treatments (OR 0.455, CI:0.23-0.89) were protective factors and risk was increased by sleepiness, sleep debt, social jetlag, caffeine use, anxiety and depression. In men no protective factors were identified: sleepiness, sleep debt, and severe insomnia were associated with an increased risk of ANMAS. In clinical practice, all patients with daytime sleepiness and men with severe insomnia should be counselled concerning driving risk and encouraged to avoid sleep debt.	[Royant-Parola, Sylvie; Brion, Agnes; Dagneaux, Sylvain; Hartley, Sarah] Reseau Morphee, Garches, France; [Kovess, Viviane] Paris Descartes Univ, EA 4057, Paris, France; [Hartley, Sarah] Univ Versailles St Quentin Yvelines, Hop Raymond Poincare, APHP, Sleep Ctr,EA 4047, Garches, France	UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; Universite Paris Saclay	Hartley, S (corresponding author), Reseau Morphee, Garches, France.; Hartley, S (corresponding author), Univ Versailles St Quentin Yvelines, Hop Raymond Poincare, APHP, Sleep Ctr,EA 4047, Garches, France.	sarah.hartley@reseau-morphee.fr			French sleep research society (SFRMS: Societe Francaise pour la Recherche et Medecine du Sommeil); Paris region health authority (ARS Ile de France)	French sleep research society (SFRMS: Societe Francaise pour la Recherche et Medecine du Sommeil); Paris region health authority (ARS Ile de France)	This work was supported by the French sleep research society (SFRMS: Societe Francaise pour la Recherche et Medecine du Sommeil) which contributed to the original development of the online questionnaire. The Reseau Morphee is funded by the Paris region health authority (ARS Ile de France). No specific grant for the study was obtained from any funding agency in the public, commercial or not-for-profit sectors.	Ahlner J, 2014, SCAND J PUBLIC HEALT, V42, P177, DOI 10.1177/1403494813510792; *ANSM, 2017, ET LIEUX CONS BENZ F; Bastien CH, 2011, NEUROPSYCHOL REV, V21, P22, DOI 10.1007/s11065-011-9160-3; Bayon V, 2010, MED SOMMEIL, V7, P23; Bertisch SM, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy047; Buscemi N, 2005, J GEN INTERN MED, V20, P1151, DOI 10.1111/j.1525-1497.2005.0243.x; BUTLER MA, 1992, PHARMACOGENETICS, V2, P116, DOI 10.1097/00008571-199206000-00003; Clark I, 2017, SLEEP MED REV, V31, P70, DOI 10.1016/j.smrv.2016.01.006; Connor J, 2002, BRIT MED J, V324, P1125, DOI 10.1136/bmj.324.7346.1125; Curran HV, 2003, PSYCHOL MED, V33, P1223, DOI 10.1017/S0033291703008213; Demos KE, 2016, PHYSIOL BEHAV, V164, P214, DOI 10.1016/j.physbeh.2016.06.003; Dula CS, 2010, ACCIDENT ANAL PREV, V42, P2050, DOI 10.1016/j.aap.2010.06.016; Fernandez-Mendoza J, 2010, SLEEP, V33, P459, DOI 10.1093/sleep/33.4.459; Fortier-Brochu E, 2012, SLEEP MED REV, V16, P83, DOI 10.1016/j.smrv.2011.03.008; Gagnon C, 2013, J AM BOARD FAM MED, V26, P701, DOI 10.3122/jabfm.2013.06.130064; Garbarino S, 2001, SLEEP, V24, P203; Goncalves M, 2015, J SLEEP RES, V24, P242, DOI 10.1111/jsr.12267; Hill LL, 2017, INJ EPIDEMIOL; HORNE JA, 1995, BRIT MED J, V310, P565, DOI 10.1136/bmj.310.6979.565; Howard ME, 2004, AM J RESP CRIT CARE, V170, P1014, DOI 10.1164/rccm.200312-1782oc; Hudson AN, 2019, NEUROPSYCHOPHARMACOL; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kalmbach DA, 2018, NAT SCI SLEEP, V10, P193, DOI 10.2147/NSS.S138823; Kyle SD, 2017, SLEEP MED, V38, P85, DOI 10.1016/j.sleep.2017.07.001; Lang CJ, 2018, SLEEP MED, V51, P133, DOI 10.1016/j.sleep.2018.06.014; Leger D, 2014, J SLEEP RES, V23, P143, DOI 10.1111/jsr.12104; LEPINE JP, 1985, LANCET, V2, P1425; Leufkens TRM, 2014, PSYCHOPHARMACOLOGY, V231, P2785, DOI 10.1007/s00213-014-3447-z; Leufkens TRM, 2014, PSYCHOPHARMACOLOGY, V231, P2851, DOI 10.1007/s00213-014-3455-z; Leufkens TRM, 2009, J CLIN PSYCHOPHARM, V29, P432, DOI 10.1097/JCP.0b013e3181b57b43; Liu H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100965; Liu JB, 2016, ANNU REV PHARMACOL, V56, P361, DOI 10.1146/annurev-pharmtox-010814-124742; Lowe CJ, 2017, NEUROSCI BIOBEHAV R, V80, P586, DOI 10.1016/j.neubiorev.2017.07.010; Miller CB, 2016, SLEEP, V39, P1993, DOI 10.5665/sleep.6230; Nakajima M, 1999, J BIOCHEM-TOKYO, V125, P803, DOI 10.1093/oxfordjournals.jbchem.a022352; Nevriana A, 2017, CNS DRUGS, V31, P711, DOI 10.1007/s40263-017-0445-9; Orriols L, 2016, BRIT J CLIN PHARMACO, V82, P1625, DOI 10.1111/bcp.13075; Perrier J, 2014, SLEEP, V37, P1565, DOI 10.5665/sleep.4012; Philip P, 2005, SLEEP, V28, P1511, DOI 10.1093/sleep/28.12.1511; Philip P, 1999, SLEEP, V22, P475, DOI 10.1093/sleep/22.4.475; Philip P, 2019, SLEEP MED CLIN, V14, P407, DOI 10.1016/j.jsmc.2019.07.002; Philip P, 2010, SLEEP MED, V11, P973, DOI 10.1016/j.sleep.2010.07.010; Powell NB, 2007, SLEEP, V30, P331, DOI 10.1093/sleep/30.3.331; Quera-Salva MA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012382; Regev S, 2018, J SAFETY RES, V66, P131, DOI 10.1016/j.jsr.2018.07.002; Roehrs TA, 2016, J CLIN SLEEP MED, V12, P319, DOI 10.5664/jcsm.5574; Roehrs TA, 2011, SLEEP, V34, P1647, DOI 10.5665/sleep.1426; Roth T, 2014, TRAFFIC INJ PREV, V15, P439, DOI 10.1080/15389588.2013.830211; Rudisill TM, 2016, ACCIDENT ANAL PREV, V96, P255, DOI 10.1016/j.aap.2016.08.001; Sagberg F, 2006, ACCIDENT ANAL PREV, V38, P28, DOI 10.1016/j.aap.2005.06.018; Salva MAQ, 2014, SLEEP MED, V15, P23, DOI 10.1016/j.sleep.2013.06.018; Shekleton JA, 2010, SLEEP MED REV, V14, P47, DOI 10.1016/j.smrv.2009.06.001; Sivertsen B, 2009, J CLIN SLEEP MED, V5, P349; Staner L, 2005, PSYCHOPHARMACOLOGY, V181, P790, DOI 10.1007/s00213-005-0082-8; Stutts JC, 2003, ACCIDENT ANAL PREV, V35, P321, DOI 10.1016/S0001-4575(02)00007-6; Vermeeren A, 2004, CNS DRUGS, V18, P297, DOI 10.2165/00023210-200418050-00003; Verster JC, 2006, CURR DRUG SAF, V1, P63, DOI 10.2174/157488606775252674; Ward KL, 2013, J CLIN SLEEP MED, V9, P1013, DOI 10.5664/jcsm.3072; Wild CJ, 2018, SLEEP, V41, DOI 10.1093/sleep/zsy182; Wittmann M, 2006, CHRONOBIOL INT, V23, P497, DOI 10.1080/07420520500545979; Woodall KL, 2015, J FORENSIC SCI, V60, P669, DOI 10.1111/1556-4029.12725	61	3	3	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 27	2020	15	7							e0236404	10.1371/journal.pone.0236404; 10.1371/journal.pone.0236404.r001; 10.1371/journal.pone.0236404.r002; 10.1371/journal.pone.0236404.r003; 10.1371/journal.pone.0236404.r004	http://dx.doi.org/10.1371/journal.pone.0236404; 10.1371/journal.pone.0236404.r001; 10.1371/journal.pone.0236404.r002; 10.1371/journal.pone.0236404.r003; 10.1371/journal.pone.0236404.r004			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MV9ND	32716956	Green Published, gold			2023-01-03	WOS:000556674500047
J	Nzale, SK; Weeks, WB; Ouafik, L; Rouquette, I; Beau-Faller, M; Lemoine, A; Bringuier, PP; Soriano, AGL; Barlesi, F; Ventelou, B				Nzale, Samuel Kembou; Weeks, William B.; Ouafik, L'Houcine; Rouquette, Isabelle; Beau-Faller, Michele; Lemoine, Antoinette; Bringuier, Pierre-Paul; Soriano, Anne-Gaelle Le Coroller; Barlesi, Fabrice; Ventelou, Bruno			Inequity in access to personalized medicine in France: Evidences from analysis of geo variations in the access to molecular profiling among advanced non-small-cell lung cancer patients: Results from the IFCT Biomarkers France Study	PLOS ONE			English	Article							COMMON SURGICAL-PROCEDURES; SMALL-AREA VARIATIONS; SOCIOECONOMIC DISPARITIES; GEOGRAPHIC-VARIATION; SURVIVAL; ENGLAND; RATES	In this article, we studied geographic variation in the use of personalized genetic testing for advanced non-small cell lung cancer (NSCLC) and we evaluated the relationship between genetic testing rates and local socioeconomic and ecological variables. We used data on all advanced NSCLC patients who had a genetic test between April 2012 and April 2013 in France in the frame of the IFCT Biomarqueurs-France study (n = 15814). We computed four established measures of geographic variation of the sex-adjusted rates of genetic testing utilization at the "department" (the French territory is divided into 94 administrative units called 'departements') level. We also performed a spatial regression model to determine the relationship between departement-level sex-adjusted rates of genetic testing utilization and economic and ecological variables. Our results are the following: (i) Overall, 46.87% lung cancer admission patients obtained genetic testing for NSCLC; departement-level utilization rates varied over 3.2-fold. Measures of geographic variation indicated a relatively high degree of geographic variation. (ii) there was a statistically significant relationship between genetic testing rates and per capita supply of general practitioners, radiotherapists and surgeons (negative correlation for the latter); lower genetic testing rates were also associated with higher local poverty rates. French policymakers should pursue effort toward deprived areas to obtain equal access to personalized medicine for advanced NSCLC patients.	[Nzale, Samuel Kembou; Ventelou, Bruno] Aix Marseille Univ, AMSE, Cent Marseille, CNRS,EHESS, Marseille, France; [Weeks, William B.] Dartmouth Inst Hlth Policy & Clin Practice, DHMC, Williamson Translat Bldg, Lebanon, NH USA; [Ouafik, L'Houcine] Aix Marseille Univ, AP HM, Serv Transfert Oncol Biol, Marseille, France; [Rouquette, Isabelle] Inst Univ Canc Toulouse, Serv Anat Pathol, Oncopole, Toulouse, France; [Beau-Faller, Michele] Ctr Hosp Univ Hautepierre, Lab Biochim & Biol Mol, Strasbourg, France; [Beau-Faller, Michele] Ctr Hosp Univ Hautepierre, Plate Forme Genom Canc, Strasbourg, France; [Lemoine, Antoinette] Univ Paris 11, AP HP, Serv Oncogenet Oncomolpath, Grp Hosp Hop Univ Paris Sud, Villejuif, France; [Bringuier, Pierre-Paul] Univ Claude Bernard Lyon 1, Lyon Canc Res Ctr, Serv Anat & Cytol Pathol, Hop Edouard Herriot,UMR 1057,INSERM,Hosp Civils L, Lyon, France; [Soriano, Anne-Gaelle Le Coroller] Aix Marseille Univ, Inst Res & Dev, Natl Inst Hlth & Med Res, Mixed Res Unit 912,Paoli Calmettes Inst, Marseille, France; [Barlesi, Fabrice] Aix Marseille Univ, AP HM, Multidisciplinary Oncol & Therapeut Innovat Dept, Ctr Invest Clin, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Dartmouth College; UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU Strasbourg; CHU Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; UDICE-French Research Universities; Universite Paris Saclay; CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; UNICANCER; Centre Leon Berard; Institut de Recherche pour le Developpement (IRD); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Soriano, AGL (corresponding author), Aix Marseille Univ, Inst Res & Dev, Natl Inst Hlth & Med Res, Mixed Res Unit 912,Paoli Calmettes Inst, Marseille, France.	anne-galle.le-corroller@inserm.fr	Le Corroller Soriano, Anne-Gaelle/D-7302-2016; Weeks, William/GYA-0512-2022; Beau-Faller, Michèle/R-3052-2016	Le Corroller Soriano, Anne-Gaelle/0000-0003-0072-9910; Ouafik, L'Houcine/0000-0002-4848-1232; KEMBOU, Samuel/0000-0001-6197-8625				Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477; [Anonymous], 2016, AM FR SNIIR SYST NAT; [Anonymous], 2015, ICD 10 CM CODES 2018; [Anonymous], 2013, POPULATIONS LEGALES; ANSELIN L, 1995, GEOGR ANAL, V27, P93, DOI 10.1111/j.1538-4632.1995.tb00338.x; Barlesi F, 2016, LANCET, V387, P1415, DOI 10.1016/S0140-6736(16)00004-0; Dartmouth Institute, 2018, EX IND ADJ IND ADJ D; Greenwald HP, 1998, AM J PUBLIC HEALTH, V88, P1681, DOI 10.2105/AJPH.88.11.1681; Institut National du Cancer, 2014, PLAT HOSP GEN MOL CA; Institut National du Cancer, 2014, SYNTH ACT PLAT HOSP; Jiang XQ, 2017, SOC SCI MED, V175, P52, DOI 10.1016/j.socscimed.2016.12.042; Lejeune C, 2010, INT J EPIDEMIOL, V39, P710, DOI 10.1093/ije/dyq048; Matthews RW, 2008, FORESTRY AND CLIMATE CHANGE, P91, DOI 10.1079/9781845932947.0091; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; Nay O, 2016, LANCET, V387, P2236, DOI 10.1016/S0140-6736(16)00580-8; OP026, 2016, J CROHNS COLITIS, V10, pS21; Pollock AM, 1998, BMJ-BRIT MED J, V317, P245, DOI 10.1136/bmj.317.7153.245; Weeks WB, 2016, EUR J HEALTH ECON, V17, P453, DOI 10.1007/s10198-015-0692-y; Weeks WB, 2014, HEALTH POLICY, V118, P215, DOI 10.1016/j.healthpol.2014.08.015; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; Whitcomb DC, 2012, NAT REV GASTRO HEPAT, V9, P418, DOI 10.1038/nrgastro.2012.100; Woods LM, 2006, ANN ONCOL, V17, P5, DOI 10.1093/annonc/mdj007; Yorio JT, 2012, CLIN LUNG CANCER, V13, P448, DOI 10.1016/j.cllc.2012.03.002	23	2	2	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 1	2020	15	7							e0234387	10.1371/journal.pone.0234387	http://dx.doi.org/10.1371/journal.pone.0234387			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MH8TI	32609781	gold, Green Published			2023-01-03	WOS:000546994200061
J	Ortiz-Barrios, M; Alfaro-Saiz, JJ				Ortiz-Barrios, Miguel; Alfaro-Saiz, Juan-Jose			An integrated approach for designing in-time and economically sustainable emergency care networks: A case study in the public sector	PLOS ONE			English	Article							DISCRETE-EVENT SIMULATION; WAITING TIME; 6 SIGMA; SYSTEMS	Emergency Care Networks (ECNs) were created as a response to the increased demand for emergency services and the ever-increasing waiting times experienced by patients in emergency rooms. In this sense, ECNs are called to provide a rapid diagnosis and early intervention so that poor patient outcomes, patient dissatisfaction, and cost overruns can be avoided. Nevertheless, ECNs, as nodal systems, are often inefficient due to the lack of coordination between emergency departments (EDs) and the presence of non-value added activities within each ED. This situation is even more complex in the public healthcare sector of low-income countries where emergency care is provided under constraint resources and limited innovation. Notwithstanding the tremendous efforts made by healthcare clusters and government agencies to tackle this problem, most of ECNs do not yet provide nimble and efficient care to patients. Additionally, little progress has been evidenced regarding the creation of methodological approaches that assist policymakers in solving this problem. In an attempt to address these shortcomings, this paper presents a three-phase methodology based on Discrete-event simulation, payment collateral models, and lean six sigma to support the design of in-time and economically sustainable ECNs. The proposed approach is validated in a public ECN consisting of 2 hospitals and 8 POCs (Point of Care). The results of this study evidenced that the average waiting time in an ECN can be substantially diminished by optimizing the cooperation flows between EDs.	[Ortiz-Barrios, Miguel] Univ Costa CUC, Dept Ind Management Agroind & Operat, Barranquilla, Colombia; [Alfaro-Saiz, Juan-Jose] Univ Politecn Valencia, Res Ctr Prod Management & Engn, Valencia, Spain	Universidad de la Costa; Universitat Politecnica de Valencia	Ortiz-Barrios, M (corresponding author), Univ Costa CUC, Dept Ind Management Agroind & Operat, Barranquilla, Colombia.	mortiz1@cuc.edu.co	Barrios, Miguel Ángel Ortíz/AAW-2705-2021	Ortiz Barrios, Miguel Angel/0000-0001-6890-7547				Abstracts from The Academy of Breastfeeding Medicine, 2015, BREASTFEED MED, V10, pS1; Ahmed Selim, 2013, Reviews on Environmental Health, V28, P189, DOI 10.1515/reveh-2013-0015; Al Owad A, 2014, ADV MATER RES-SWITZ, V835-836, P1893, DOI 10.4028/www.scientific.net/AMR.834-836.1893; Ortiz-Barrios MA, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17082664; [Anonymous], 2015, PS-POLIT SCI POLIT, V48, P557, DOI 10.1017/S1049096515000694; [Anonymous], 2017, ARTIFICIAL ORGANS, V41, pE141; [Anonymous], 2018, CANC DISCOV, V8, pOF6; [Anonymous], 2018, OBSTET GYNECOL, V13, pe49; [Anonymous], 2016, UNCERTAINTY MODELLIN; [Anonymous], 2016, AIP C P; [Anonymous], 2015, 6 INT C MOD SIM APPL; [Anonymous], 2018, IEEE INT C IND ENG E; Baier N, 2019, HEALTH POLICY, V123, P1, DOI 10.1016/j.healthpol.2018.11.001; Baril C, 2019, J OPER RES SOC, V70, P2019, DOI 10.1080/01605682.2018.1510805; Barrios MAO, 2016, J MED SYST, V40, DOI 10.1007/s10916-016-0577-3; Becker JB, 2015, REV ESC ENFERM USP, V49, P779, DOI 10.1590/S0080-623420150000500011; Bedoya-Valencia L, 2016, SIMUL-T SOC MOD SIM, V92, P1041, DOI 10.1177/0037549716673150; Calvello EJB, 2013, ACAD EMERG MED, V20, P1278, DOI 10.1111/acem.12266; Furterer SL, 2018, QUAL ENG, V30, P389, DOI 10.1080/08982112.2018.1464657; Gartner D, 2020, J OPER RES SOC, V71, P1087, DOI 10.1080/01605682.2019.1571005; Gaviria A, 2015, INFORM NACL CALIDAD; Gillespie J, 2016, J OPER RES SOC, V67, P1239, DOI 10.1057/jors.2015.114; Glickman SW, 2010, ACAD EMERG MED, V17, P1297, DOI 10.1111/j.1553-2712.2010.00930.x; Gul M, 2020, J OPER RES SOC, V71, P733, DOI 10.1080/01605682.2019.1582588; Habidin NF, 2015, INT J PHARM SCI REV, V35, P151; Harrop Nick, 2005, Inform Prim Care, V13, P223; Hawkins Robert C, 2007, Clin Biochem Rev, V28, P179; Hussein NA, 2017, OPER RES HEALTH CARE, V15, P1, DOI 10.1016/j.orhc.2017.06.003; Ibrahim I.M., 2018, INDIAN J PUBLIC HLTH, V9, P1558, DOI [10.5958/0976-5506.2018.01670.4, DOI 10.5958/0976-5506.2018.01670.4]; Isfahani HM, 2019, INT J LEAN SIX SIG, V10, P161, DOI 10.1108/IJLSS-05-2017-0051; Karnon J, 2012, VALUE HEALTH, V15, P821, DOI 10.1016/j.jval.2012.04.013; Kaushal A, 2015, SOCIO-ECON PLAN SCI, V50, P18, DOI 10.1016/j.seps.2015.02.002; Konder MT, 2016, INTERFACE-BOTUCATU, V20, P879, DOI 10.1590/1807-57622015.0519; Kuo YH, 2016, FLEX SERV MANUF J, V28, P120, DOI 10.1007/s10696-014-9198-7; Mandahawi N, 2017, J IND PROD ENG, V34, P495, DOI 10.1080/21681015.2017.1367728; Martinez R, 2010, ACAD EMERG MED, V17, P1346, DOI 10.1111/j.1553-2712.2010.00945.x; Modeling the Healthcare Services in Hilla Emergency Department, 2018, ICOASE 2018 INT C AD; Morley C, 2018, INT EMERG NURS, V38, P34, DOI 10.1016/j.ienj.2017.09.001; Navein J, 2003, EMERG MED J, V20, P192, DOI 10.1136/emj.20.2.192; NNDSS Annual Report Working Group, 2016, COMMUN DIS INTELL, V40, pE48; Nunez-Perez N, 2017, LECT NOTES COMPUT SC, V10586, P352, DOI 10.1007/978-3-319-67585-5_37; Ortiz Barrios Miguel, 2014, Ambient Assisted Living and Daily Activities. 6th International Work-Conference, IWAAL 2014. Proceedings: LNCS 8868, P413, DOI 10.1007/978-3-319-13105-4_62; Ortiz Barrios M.A., 2014, PROSPECTIVA, V12, P73, DOI [10.15665/RP.V12I2.291, DOI 10.15665/RP.V12I2.291]; Barrios MAO, 2015, LECT NOTES COMPUT SC, V9456, P247, DOI 10.1007/978-3-319-26508-7_24; Ortiz-Barrios MA, 2018, MANAGE DECIS, V56, P2187, DOI 10.1108/MD-09-2017-0917; Porter ME, 2019, MANAGING SUSTAINABLE, P323, DOI DOI 10.1007/978-94-024-1144-7_16; Regione Umbria, 2009, B UFFICIALE, V25, P1; Romero-Conrado Alfonso R., 2017, Dyna rev.fac.nac.minas, V84, P129, DOI 10.15446/dyna.v84n201.57504; s NA, 2018, LANCET INFECT DIS, V18, pe228; Salisbury C, 2010, EMERG MED J, V27, P186, DOI 10.1136/emj.2009.073056; Sheard S, 2018, HEALTH ECON POLICY L, V13, P226, DOI 10.1017/S1744133117000366; Steventon A, 2018, BRIEFING EMERGENCY H; Stoner MJ, 2018, ACAD EMERG MED, V25, P1336, DOI 10.1111/acem.13656; Turner J., 2015, WHAT EVIDENCE IS THE; Wilson KJ, 2013, QUAL MANAG HEALTH CA, V22, P2, DOI 10.1097/QMH.0b013e31827dea50; 2017, BEHAV SOC NETW, V15, P91	56	3	3	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 22	2020	15	6							e0234984	10.1371/journal.pone.0234984	http://dx.doi.org/10.1371/journal.pone.0234984			28	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MC8RX	32569319	Green Published, gold			2023-01-03	WOS:000543547900046
J	Yan, RB; Zhang, XL; Li, YH; Hou, JM; Chen, H; Liu, HL				Yan, Ru-bing; Zhang, Xiao-li; Li, Yong-hong; Hou, Jing-ming; Chen, Han; Liu, Hong-liang			Effect of transcranial direct-current stimulation on cognitive function in stroke patients: A systematic review and meta-analysis	PLOS ONE			English	Review							MINI-MENTAL-STATE; IMPAIRMENT; PREVALENCE; REHABILITATION; DISEASE; CORTEX; MEMORY; BLIND; TDCS	Objective Transcranial direct-current stimulation (tDCS) is a noninvasive approach that can alter brain excitability. Several studies have shown the effectiveness of tDCS in improving language and movement function in stroke patients. However, the effect of tDCS on cognitive function after stroke remains uncertain. Methods We searched Medline, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), the China National Knowledge Infrastructure, the China Science and Technology Journal Database, and the Wanfang Data Knowledge Service Platform from inception to April 2, 2019. Two reviewers independently screened the studies, extracted the data, and evaluated the quality of the included studies using the Cochrane Collaboration Risk of Bias Tool. All statistical analyses were performed in RevMan 5.3, and the mean difference (MD) or standard mean difference (SMD) were used as the pooled statistics. Results Fifteen studies involving 820 participants were included. When compared with passive tDCS, anodal tDCS was associated with improved general cognitive performance as examined by the Minimum Mental State Examination or Montreal Cognitive Assessment (SMD = 1.31, 95% CI 0.91-1.71, P < 0.00001), attention performance (SMD = 0.66, 95% CI 0.11-1.20, P = 0.02). There was no significant difference in memory performance (SMD = 0.41, 95% CI -0.67-1.50, P = 0.46). Conclusions tDCS is likely to be effective for patients with cognitive impairment after stroke. The evidence for different effects based on population characteristics and stimulation methods was limited, but a real effect cannot be ruled out. More high-quality research in this field is required to determine the potential benefits of tDCS in the treatment of cognitive deficits after stroke and to establish the optimal treatment program.	[Yan, Ru-bing; Hou, Jing-ming; Chen, Han; Liu, Hong-liang] PLA Army Med Univ, Southwest Hosp, Dept Rehabil, Chongqing, Peoples R China; [Zhang, Xiao-li] Med Journal Chinese PLA, Beijing, Peoples R China; [Li, Yong-hong] Sichuan Univ, Dept Evidence Based Med & Clin Epidemiol, West China Hosp, Chengdu, Peoples R China	Army Medical University; Sichuan University	Liu, HL (corresponding author), PLA Army Med Univ, Southwest Hosp, Dept Rehabil, Chongqing, Peoples R China.	liuhongliangkf@163.com		, Hongliang/0000-0002-8516-3014	National Key Research and Development Project [2017YFC138503]; National Nature Science Foundation of China [81671211, 81672251]; Clinical Innovation Foundation of Southwest Hospital [SWH2016ZDCX4203]	National Key Research and Development Project; National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Clinical Innovation Foundation of Southwest Hospital	This study was supported by the National Key Research and Development Project (2017YFC138503), the National Nature Science Foundation of China (grant no.81671211; 81672251), and the Clinical Innovation Foundation of Southwest Hospital (SWH2016ZDCX4203). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2015, Arthritis Res Ther, V17, P354, DOI 10.1186/s13075-015-0847-3; [Anonymous], 2017, B AEROSPACE DEFENSE, VN4, P38; [Anonymous], 2015, AM BANKR I L REV, V23, P21; Biou E, 2019, ANN PHYS REHABIL MED, V62, P104, DOI 10.1016/j.rehab.2019.01.003; Borenstein M, 2010, RES SYNTH METHODS, V1, P97, DOI 10.1002/jrsm.12; Burke JF, 2012, STROKE, V43, P2207, DOI 10.1161/STROKEAHA.112.656967; Butler AJ, 2013, J HAND THER, V26, P162, DOI 10.1016/j.jht.2012.07.002; Chen SL, 2019, CHINA MOD MED, V26, P91; Clemens B, 2013, NEUROPSYCHOLOGIA, V51, P1279, DOI 10.1016/j.neuropsychologia.2013.03.023; Cumming TB, 2013, INT J STROKE, V8, P38, DOI 10.1111/j.1747-4949.2012.00972.x; Dong YH, 2010, J NEUROL SCI, V299, P15, DOI 10.1016/j.jns.2010.08.051; Douiri A, 2013, STROKE, V44, P138, DOI 10.1161/STROKEAHA.112.670844; Elsner B, 2012, NEUROREHAB NEURAL RE, V26, P678; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Go AS, 2013, CIRCULATION, V127, P143, DOI 10.1161/CIR.0b013e318282ab8f; Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928; Hosseinzadeh SA, 2018, BIOMED RES THER, V5, P2841, DOI 10.15419/bmrat.v5i11.503; Hsu WY, 2015, NEUROBIOL AGING, V36, P2348, DOI 10.1016/j.neurobiolaging.2015.04.016; Jacquin A, 2014, J ALZHEIMERS DIS, V40, P1029, DOI 10.3233/JAD-131580; Jiang Y, 2019, PRACT J CARDIAC CERE, V27, P112; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Kang N, 2016, J NEUROL NEUROSUR PS, V87, P345, DOI 10.1136/jnnp-2015-311242; Kazuta T, 2017, AM J PHYS MED REHAB, V96, P565, DOI 10.1097/PHM.0000000000000686; Lefaucheur JP, 2017, CLIN NEUROPHYSIOL, V128, P56, DOI 10.1016/j.clinph.2016.10.087; Luo WH, 2019, J CHINA PRESCRIP DRU, V17, P119; Moher D, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000097, 10.1136/bmj.b4037]; Nitsche MA, 2000, J PHYSIOL-LONDON, V527, P633, DOI 10.1111/j.1469-7793.2000.t01-1-00633.x; Nys GMS, 2007, CEREBROVASC DIS, V23, P408, DOI 10.1159/000101464; Okundamiya MS, 2016, INT J GREEN ENERGY, V13, P505, DOI 10.1080/15435075.2014.968921; Park SH, 2013, J KOREAN NEUROSURG S, V54, P484, DOI 10.3340/jkns.2013.54.6.484; Paulus W, 2003, SUPPL CLIN NEUROPHYS, V56, P249; Potong R, 2017, CERAM INT, V43, pS75, DOI 10.1016/j.ceramint.2017.05.225; Rosso C, 2018, RESTOR NEUROL NEUROS, V36, P107, DOI 10.3233/RNN-170783; Shaker HA, 2018, EGYPT J NEUROL PSYCH, V54, DOI 10.1186/s41983-018-0037-8; Song HY, 2019, CHIN J MOD MED; The Lancet HIV, 2016, LANCET HIV, V3, pe191; Tong JX, 2019, CHIN MANIPUL REHABIL, V10, P17; Tong JX, 2018, GANSU MED J, V37, P984; van Dixhoorn Jan, 2015, ERJ Open Res, V1; Wang QJ, 2018, CHINA CONTIN MED EDU, V10, P139; Xu TC, 2009, CHIN J EVID BASED ME, V9, P181; [曾雅琴 Zeng Yaqin], 2019, [中国康复医学杂志, Chinese Journal of Rehabilitation Medicine], V34, P417; Zheng J, 2017, J LIAONING U TCM, V19, P131; 钟文昭, 2003, [循证医学, The Journal of Evidence-Based Medicine], V3, P234	44	6	7	1	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 9	2020	15	6							e0233903	10.1371/journal.pone.0233903	http://dx.doi.org/10.1371/journal.pone.0233903			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LZ1GC	32516316	Green Published, gold			2023-01-03	WOS:000540977000026
J	Tapera, R; Mbongwe, B; Mhaka-Mutepfa, M; Lord, A; Phaladze, NA; Zetola, NM				Tapera, Roy; Mbongwe, Bontle; Mhaka-Mutepfa, Magen; Lord, Andrew; Phaladze, Nthabiseng A.; Zetola, Nicola M.			The theory of planned behavior as a behavior change model for tobacco control strategies among adolescents in Botswana	PLOS ONE			English	Article							IMPLICIT ASSOCIATION TEST; FRIENDSHIP NETWORKS; PERCEIVED BARRIERS; EXTENDED THEORY; START SMOKING; INTENTIONS; ATTITUDES; PEER; ADHERENCE; CESSATION	Background Behavioral intentions (motivational factors), attitudes, subjective norm (social pressures), and perceived behavioral control promote or discourage smoking behavior among adolescents. Objective To assess students' behavioral intentions, attitudes, subjective norms and perceived behavioral control on smoking using the Theory of Planned Behavior. The prevalence of smoking among the adolescents is also calculated. Methods In this cross-sectional study, structured self-administered questionnaires were used to collect data from adolescents in primary and secondary schools. Data on demographics, behavioral intentions, attitudes, subjective norms, and perceived behavioral control towards smoking were collected. Pearson product moment correlations and logistic regression models were used to determine factors associated with current smoking. Results A total sample of 2554 (mean age = 15; Range = 12-18 years) students participated in the study. Twenty-nine percent (n = 728) of the students had tried smoking at least once. Smoking was predicted by attitudes, subjective norms, perceived behavioral control and intention.There was a strong association between having a parent or guardian, caregiver or close friend who smoked (p < 0.001) and being a smoker. The majority of students (57%) conveyed that adults talked to them about the harmful effects of cigarette smoking and 50% had discussed smoking concerns with their friends. Students who had positive attitudes towards smoking like "smoking makes you confident" were more likely to be current smokers (OR: 1.63, 95% CI: 1.03-2.59). The feeling or conviction that they could refuse a cigarette if offered was an impediment from smoking (OR: 0.18, 95% CI: 0.13-0.26). Conclusions Attitudes, subjective norms, and perceived behavioral control contributed significantly to the students' smoking. Right attitudes must be cultivated and behavioral control must be strengthened for early effective interventions to curtail smoking among adolescents.	[Tapera, Roy; Mbongwe, Bontle] Univ Botswana, Sch Publ Hlth, Dept Environm Hlth, Gaborone, Botswana; [Mhaka-Mutepfa, Magen] Univ Botswana, Fac Social Sci, Dept Psychol, Gaborone, Botswana; [Lord, Andrew] Good Business, London, England; [Phaladze, Nthabiseng A.] Univ Botswana, Sch Nursing, Gaborone, Botswana; [Zetola, Nicola M.] Univ Penn, Dept Radiat Oncol, Philadelphia, PA 19104 USA	University of Botswana; University of Botswana; University of Botswana; University of Pennsylvania	Tapera, R (corresponding author), Univ Botswana, Sch Publ Hlth, Dept Environm Hlth, Gaborone, Botswana.	ztapera@gmail.com	Mutepfa, Magen/V-1614-2019; Mbongwe, Bontle/AAF-9888-2021	Mutepfa, Magen/0000-0003-0838-817X; Tapera, Dr Roy/0000-0002-7242-8650; Mbongwe, Bontle/0000-0002-3839-1225	Bill and Melinda Gates Foundation [OPP1082662]; Ministry of Basic Education; University of Botswana Office of Research and Development	Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Ministry of Basic Education; University of Botswana Office of Research and Development	This research was commissioned by Good Business (London) as part of a social marketing programme designed to prevent teenage girls from taking up smoking in Botswana. This was funded through a grant from the Bill and Melinda Gates Foundation Grant number OPP1082662. The funder had no role in the study design, collection, analysis and interpretation of the data; writing the report or the decision to submit the report for publication. The views expressed in this paper are therefore those of the authors and do not necessarily reflect the views of the funding body.; The research team acknowledges the support received from the Ministry of Basic Education as well as the University of Botswana Office of Research and Development.	Abiru N, 2020, DIABETOL INT, V11, P1, DOI 10.1007/s13340-019-00415-8; Abraham C, 2003, BRIT J SOC PSYCHOL, V42, P495, DOI 10.1348/014466603322595248; Ajzen I, 2004, HEALTH PSYCHOL, V23, P431, DOI 10.1037/0278-6133.23.4.431; AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Ajzen I., 2008, HDB CONSUMER PSYCHOL, P525; Ajzen I., 2000, EUR REV SOC PSYCHOL, V11, P1, DOI [10.1080/14792779943000116, DOI 10.1080/14792779943000116]; Ajzen I, 2011, PSYCHOL HEALTH, V26, P1113, DOI 10.1080/08870446.2011.613995; Bandura A, 1998, PSYCHOL HEALTH, V13, P623, DOI 10.1080/08870449808407422; Chassin L, 2002, J PEDIATR PSYCHOL, V27, P485, DOI 10.1093/jpepsy/27.6.485; Chen XG, 2006, J ADOLESCENT HEALTH, V38, P359, DOI 10.1016/j.jadohealth.2005.03.010; Cheng OY, 2019, AM J HEALTH BEHAV, V43, P569, DOI 10.5993/AJHB.43.3.11; Chuang YC, 2005, J EPIDEMIOL COMMUN H, V59, P568, DOI 10.1136/jech.2004.029041; Conner M, 2003, CURR PSYCHOL, V22, P252, DOI 10.1007/s12144-003-1020-8; CONRAD KM, 1992, BRIT J ADDICT, V87, P1711; Filippidis FT, 2015, EUR J PUBLIC HEALTH, V25, P814, DOI 10.1093/eurpub/ckv068; Fishbein M, 2005, J HEALTH PSYCHOL, V10, P27, DOI 10.1177/1359105305048552; Fung XCC, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17010064; Gass R. H., 2015, PERSUASION SOCIAL IN; Gold GJ, 2011, J SOC PSYCHOL, V151, P382, DOI 10.1080/00224545.2011.563209; Guo Q, 2012, ADDICT BEHAV, V37, P273, DOI 10.1016/j.addbeh.2011.11.002; Gwaltney CJ, 2009, PSYCHOL ADDICT BEHAV, V23, P56, DOI 10.1037/a0013529; Harakeh Z, 2012, DRUG ALCOHOL DEPEN, V121, P220, DOI 10.1016/j.drugalcdep.2011.08.029; Hiemstra M, 2011, J ADOLESCENT HEALTH, V48, P597, DOI 10.1016/j.jadohealth.2010.09.011; Hirschi T., 1969, CAUSES DELINQUENCY; Hong T, 2011, WOMEN HEALTH, V51, P187, DOI 10.1080/03630242.2011.560241; Hou WL, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17030923; Huijding J, 2005, ADDICT BEHAV, V30, P949, DOI 10.1016/j.addbeh.2004.09.014; Hukkelberg SS, 2014, BRIT J HEALTH PSYCH, V19, P83, DOI 10.1111/bjhp.12034; Karimy Mahmood, 2015, Int J High Risk Behav Addict, V4, pe24715, DOI 10.5812/ijhrba.24715; Kobus K, 2003, ADDICTION, V98, P37, DOI 10.1046/j.1360-0443.98.s1.4.x; Lakon CM, 2015, J YOUTH ADOLESCENCE, V44, P1767, DOI 10.1007/s10964-014-0187-7; Lee Eunyoung, 2005, Taehan Kanho Hakhoe Chi, V35, P694; Lee HS, 2018, NICOTINE TOB RES, V20, P58, DOI 10.1093/ntr/ntw259; Lin CY, 2018, PREGNANCY HYPERTENS, V12, P84, DOI 10.1016/j.preghy.2018.04.001; Lin CY, 2017, EPILEPSY BEHAV, V74, P124, DOI 10.1016/j.yebeh.2017.06.011; Lin CY, 2017, EPILEPSY BEHAV, V68, P123, DOI 10.1016/j.yebeh.2017.01.010; Lin CY, 2016, EPILEPSY BEHAV, V61, P231, DOI 10.1016/j.yebeh.2016.05.030; Lin CY, 2019, J PSYCHOSOM OBST GYN, P8942; Maassen ITHM, 2004, HEALTH EDUC RES, V19, P551, DOI 10.1093/her/cyg077; Mohammadpoorasl A, 2012, INT J PREVENTIVE MED, V3, P880, DOI 10.4103/2008-7802.104860; Montano DE, 2002, HLTH BEHAV HLTH ED, P67; Nyagwui AE, 2012, THESIS; Nye FI, 2010, ENCY CRIMINOL THEORY, DOI [10.4135/9781412959193.n187, DOI 10.4135/9781412959193.N187]; Orlando M, 2004, J CONSULT CLIN PSYCH, V72, P400, DOI 10.1037/0022-006X.72.3.400; Robinson MD, 2005, BASIC APPL SOC PSYCH, V27, P201, DOI 10.1207/s15324834basp2703_2; Simons-Morton B, 2001, HEALTH EDUC BEHAV, V28, P95, DOI 10.1177/109019810102800109; Strong C, 2018, J SLEEP RES, V27, P23, DOI 10.1111/jsr.12566; Su XF, 2015, ADDICT BEHAV, V48, P44, DOI 10.1016/j.addbeh.2015.04.005; Swanson JE, 2001, COGNITION EMOTION, V15, P207, DOI 10.1080/0269993004200060; Topa G, 2010, SUBST ABUSE REHABIL, V23; Wang C, 2016, PSYCHOL ADDICT BEHAV, V30, P312, DOI 10.1037/adb0000163; WHO, 2019, TOB KEY FACTS, P1; WHO, 2014, TOB FREE YOUNG PEOPL; Wolff K, 2011, PSYCHOL HEALTH, V26, P1143, DOI 10.1080/08870441003763253; World Health Organization, 2017, DEPR OTH COMM MENT D; Xu XL, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-3694-z	56	9	9	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 5	2020	15	6							e0233462	10.1371/journal.pone.0233462	http://dx.doi.org/10.1371/journal.pone.0233462			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MA6QB	32502211	Green Published, gold			2023-01-03	WOS:000542035700008
J	Rowell-Cunsolo, TL; Hu, G				Rowell-Cunsolo, Tawandra L.; Hu, Gloria			Barriers to optimal antiretroviral therapy adherence among HIV-infected formerly incarcerated individuals in New York City	PLOS ONE			English	Article							MEDICATION ADHERENCE; SUBSTANCE USE; ART ADHERENCE; PRIMARY-CARE; HEALTH-CARE; PRISONERS; MEN; INTERVENTIONS; RELEASE; BEHAVIORS	In the United States (U.S.), the HIV infection rate is disproportionately high among incarcerated individuals. HIV-infected individuals typically receive antiretroviral therapy (ART) to suppress HIV and reduce the threat of transmission. Although HIV-infected individuals are generally ART-adherent while incarcerated, the public health benefits experienced during incarceration are often lost as HIV-infected individuals struggle to maintain optimal adherence post-incarceration. While the importance of maintaining adherence in the post-incarceration period has been acknowledged, research on barriers to ART adherence during this period is limited. To better understand post-release barriers to ART adherence, we conducted in-depth interviews with 20 HIV-infected formerly incarcerated individuals in New York City; we also followed up with 18 (90%) participants after three months to explore whether their adherence challenges changed over time. Viral load testing results from their most recent physician visit were also recorded at each interview. Interviews were transcribed using transcription software and reviewed for accuracy by a researcher. Thematic coding based on discussion guide prompts were then used to identify commonly mentioned barriers to adherence. The results identified four overarching themes that affected study participants' efforts to adhere to their ART regimen: medication burden, forgetfulness, mental health and emotional difficulties, and perceived conflict between substance use and medication adherence. These barriers were the most commonly cited and largely persisted at three-month follow-up. The results suggest that interventions addressing these challenges are essential for promoting ART adherence among HIV-infected formerly incarcerated individuals. Effective interventions may include mobile-based text messaging reminders and those that facilitate patient-provider communication. Additionally, interventions or programs that integrate substance use and mental health treatment into HIV-related care, along with other types of behavioral health support, may also be beneficial for this population. Such interventions should be a routine part of discharge planning and support for incarcerated individuals returning to the community.	[Rowell-Cunsolo, Tawandra L.] Columbia Univ, Sch Nursing, Social Welf Sci, New York, NY 10027 USA; [Hu, Gloria] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA	Columbia University; Columbia University	Rowell-Cunsolo, TL (corresponding author), Columbia Univ, Sch Nursing, Social Welf Sci, New York, NY 10027 USA.	tr2301@cumc.columbia.edu		Graf, Gloria/0000-0003-3538-3673; Rowell-Cunsolo, Tawandra/0000-0003-3715-8998	National Institute of Mental Health [R25MH080665]; National Institute on Drug Abuse [K01DA036411]	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	This study was support by a grant from the National Institute of Mental Health (Grant #R25MH080665; MPIs NE & EW, pilot award to TRC) and the National Institute on Drug Abuse (Grant #K01DA036411; PI: TRC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abram KM, 2017, PEDIATRICS, V139, DOI 10.1542/peds.2016-0360; Al-Dakkak I, 2013, AIDS CARE, V25, P400, DOI 10.1080/09540121.2012.712667; Amico KR, 2009, AIDS BEHAV, V13, P66, DOI 10.1007/s10461-007-9311-y; Ances BM, 2007, SEMINARS NEUROLOGY, P333; Anderson N, 2014, CTS-CLIN TRANSL SCI, V7, P127, DOI 10.1111/cts.12156; [Anonymous], 2019, GUID US ANT AG AD AD; Association AP, 2012, POS STAT SEGR PRIS M; Bhatia R, 2012, J NEUROVIROL, V18, P247, DOI 10.1007/s13365-011-0073-y; Binswanger IA, 2012, ADDICT SCI CLIN PRAC, V7, DOI 10.1186/1940-0640-7-3; Bisson GP, 2008, PLOS MED, V5, P777, DOI 10.1371/journal.pmed.0050109; Blashill AJ, 2015, AIDS BEHAV, V19, P981, DOI 10.1007/s10461-014-0925-6; Blower SM, 2000, SCIENCE, V287, P650, DOI 10.1126/science.287.5453.650; Carson EA, 2016, NCJ250229 DEP JUST B; Catz SL, 2000, HEALTH PSYCHOL, V19, P124, DOI 10.1037/0278-6133.19.2.124; Dennis AC, 2015, J ASSOC NURSE AIDS C, V26, P542, DOI 10.1016/j.jana.2015.06.001; Dolan Karen, 2015, POOR GET PRISON ALAR; Fazel S, 2006, ADDICTION, V101, P181, DOI 10.1111/j.1360-0443.2006.01316.x; Fazel S, 2017, ADDICTION, V112, P1725, DOI 10.1111/add.13877; Finitsis DJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088166; Fontana L, 2007, J HEALTH CARE POOR U, V18, P699, DOI 10.1353/hpu.2007.0058; Gallant J, 2017, J INFECT DIS, V216, P1525, DOI 10.1093/infdis/jix518; Haas AD, 2016, CLIN INFECT DIS, V63, P1227, DOI 10.1093/cid/ciw500; Haley DF, 2014, BMC PUBLIC HEALTH, V14, DOI 10.1186/1471-2458-14-1253; Hall AK, 2015, ANNU REV PUBL HEALTH, V36, P393, DOI 10.1146/annurev-publhealth-031914-122855; High KP, 1999, J ACQUIRED IMMUNE DE, V60; Hinkin CH, 2002, NEUROLOGY, V59, P1944, DOI 10.1212/01.WNL.0000038347.48137.67; Horvath DJ, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00056; Johnson ME, 2015, J CORRECT HEALTH CAR, V21, P101, DOI 10.1177/1078345815572347; Jones KT, 2008, AIDS BEHAV, V12, P41, DOI 10.1007/s10461-007-9228-5; Krishna S, 2009, TELEMED J E-HEALTH, V15, P231, DOI 10.1089/tmj.2008.0099; Leaver CA, 2007, AIDS BEHAV, V11, pS85, DOI 10.1007/s10461-007-9246-3; Lester C., 2003, Health Education Journal, V62, P341, DOI 10.1177/001789690306200406; Mallik-Kane K., 2008, HLTH PRISONER REENTR; Mbuagbaw L., 2013, BMJ OPEN, V3; McArthur JC, 2004, J NEUROIMMUNOL, V157, P3, DOI 10.1016/j.jneuroim.2004.08.042; Mellins CA, 2009, AIDS CARE, V21, P168, DOI 10.1080/09540120802001705; Meyer JP, 2014, JAMA INTERN MED, V174, P721, DOI 10.1001/jamainternmed.2014.601; Mills EJ, 2007, CLIN INFECT DIS, V45, P916, DOI 10.1086/521249; Mimiaga MJ, 2013, AM J PUBLIC HEALTH, V103, P1457, DOI 10.2105/AJPH.2012.301162; Morrow KM, 2009, AIDS CARE, V21, P235, DOI 10.1080/09540120802017586; Murphy DA, 2000, AIDS PATIENT CARE ST, V14, P47, DOI 10.1089/108729100318127; Nel A, 2011, AIDS CARE, V23, P1360, DOI 10.1080/09540121.2011.565025; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2016, GUIDELINES USE ANTIR; Park LG, 2014, J ADV NURS, V70, P1932, DOI 10.1111/jan.12400; Policy WHOoNA, 2015, NAT HIV AIDS STRAT U; Power R, 2003, AIDS PATIENT CARE ST, V17, P245, DOI 10.1089/108729103321655890; Rabuy B., 2015, PRISON POLICY INITIA, V9; Rich JD, 2001, J URBAN HEALTH, V78, P279, DOI 10.1093/jurban/78.2.279; Sacktor N, 2002, J NEUROVIROL, V8, P136, DOI 10.1080/13550280290049615; Schneider JA, 2017, AIDS, V31, P159, DOI 10.1097/QAD.0000000000001269; Simoni JM, 2007, HEALTH PSYCHOL, V26, P488, DOI 10.1037/0278-6133.26.4.488; Springer SA, 2004, CLIN INFECT DIS, V38, P1754, DOI 10.1086/421392; Steadman HJ, 2009, PSYCHIAT SERV, V60, P761, DOI 10.1176/ps.2009.60.6.761; Stephenson BL, 2006, INT J STD AIDS, V17, P103, DOI 10.1258/095646206775455775; Stephenson BL, 2005, PUBLIC HEALTH REP, V120, P84, DOI 10.1177/003335490512000114; Swan H, 2015, J DRUG ISSUES, V45, P38, DOI 10.1177/0022042614542512; Taussig J, 2006, JAMA-J AM MED ASSOC, V296, P162; Thakkar J, 2016, JAMA INTERN MED, V176, P340, DOI 10.1001/jamainternmed.2015.7667; Turner BJ, 2002, J INFECT DIS, V185, pS143, DOI 10.1086/340197; Unni EJ, 2019, PATIENT PREFER ADHER, V13, P993, DOI 10.2147/PPA.S205359; Wilhelmsen NC, 2019, EUR J HOSP PHARM, V26, P187, DOI 10.1136/ejhpharm-2018-001725; Wilper AP, 2009, AM J PUBLIC HEALTH, V99, P666, DOI 10.2105/AJPH.2008.144279; Wohl DA, 2011, AIDS BEHAV, V15, P356, DOI 10.1007/s10461-010-9843-4	63	6	6	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 1	2020	15	6							e0233842	10.1371/journal.pone.0233842	http://dx.doi.org/10.1371/journal.pone.0233842			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	MJ2AA	32479552	gold, Green Published			2023-01-03	WOS:000547893500032
J	Horby, P; Lim, WS; Emberson, JR; Mafham, M; Bell, JL; Linsell, L; Staplin, N; Brightling, C; Ustianowski, A; Elmahi, E; Prudon, B; Green, C; Felton, T; Chadwick, D; Rege, K; Fegan, C; Chappell, LC; Faust, SN; Jaki, T; Jeffery, K; Montgomery, A; Rowan, K; Juszczak, E; Baillie, JK; Haynes, R; Landray, MJ				Horby, Peter; Lim, Wei Shen; Emberson, Jonathan R.; Mafham, Marion; Bell, Jennifer L.; Linsell, Louise; Staplin, Natalie; Brightling, Christopher; Ustianowski, Andrew; Elmahi, Einas; Prudon, Benjamin; Green, Christopher; Felton, Timothy; Chadwick, David; Rege, Kanchan; Fegan, Christopher; Chappell, Lucy C.; Faust, Saul N.; Jaki, Thomas; Jeffery, Katie; Montgomery, Alan; Rowan, Kathryn; Juszczak, Edmund; Baillie, J. Kenneth; Haynes, Richard; Landray, Martin J.		RECOVERY Collaborative Grp	Dexamethasone in Hospitalized Patients with Covid-19	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORTICOSTEROID TREATMENT; CORONAVIRUS; PNEUMONIA; THERAPY	BACKGROUND Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death. METHODS In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we randomly assigned patients to receive oral or intravenous dexamethasone (at a dose of 6 mg once daily) for up to 10 days or to receive usual care alone. The primary outcome was 28-day mortality. Here, we report the final results of this assessment. RESULTS A total of 2104 patients were assigned to receive dexamethasone and 4321 to receive usual care. Overall, 482 patients (22.9%) in the dexamethasone group and 1110 patients (25.7%) in the usual care group died within 28 days after randomization (age-adjusted rate ratio, 0.83; 95% confidence interval [CI], 0.75 to 0.93; P<0.001). The proportional and absolute between-group differences in mortality varied considerably according to the level of respiratory support that the patients were receiving at the time of randomization. In the dexamethasone group, the incidence of death was lower than that in the usual care group among patients receiving invasive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51 to 0.81) and among those receiving oxygen without invasive mechanical ventilation (23.3% vs. 26.2%; rate ratio, 0.82; 95% CI, 0.72 to 0.94) but not among those who were receiving no respiratory support at randomization (17.8% vs. 14.0%; rate ratio, 1.19; 95% CI, 0.92 to 1.55). CONCLUSIONS In patients hospitalized with Covid-19, the use of dexamethasone resulted in lower 28-day mortality among those who were receiving either invasive mechanical ventilation or oxygen alone at randomization but not among those receiving no respiratory support.	[Horby, Peter] Univ Oxford, Nuffield Dept Med, Oxford, England; [Emberson, Jonathan R.; Mafham, Marion; Bell, Jennifer L.; Linsell, Louise; Staplin, Natalie; Juszczak, Edmund; Haynes, Richard; Landray, Martin J.] Univ Oxford, Nuffield Dept Populat Hlth, Oxford, England; [Emberson, Jonathan R.; Staplin, Natalie; Haynes, Richard; Landray, Martin J.] Univ Oxford, MRC Populat Hlth Res Unit, Oxford, England; [Jeffery, Katie] Oxford Univ Hosp NHS Fdn Trust, Oxford, England; [Landray, Martin J.] Natl Inst Hlth Res NIHR Oxford Biomed Res Ctr, Oxford, England; [Lim, Wei Shen] Univ Hosp NHS Trust, Dept Resp Med, Nottingham, England; [Montgomery, Alan] Univ Nottingham, Sch Med, Nottingham, England; [Brightling, Christopher] Univ Leicester, Leicester NIHR Biomed Res Ctr, Inst Lung Hlth, Leicester, Leics, England; [Ustianowski, Andrew] North Manchester Gen Hosp, Reg Infect Dis Unit, Manchester, Lancs, England; [Ustianowski, Andrew; Felton, Timothy] Univ Manchester, Manchester, Lancs, England; [Felton, Timothy] Manchester Univ NHS Fdn Trust, Manchester, Lancs, England; [Elmahi, Einas] Northampton Gen Hosp, Dept Res & Dev, Northampton, England; [Prudon, Benjamin] North Tees & Hartlepool NHS Fdn Trust, Dept Resp Med, Stockton On Tees, England; [Green, Christopher] Univ Hosp Birmingham NHS Fdn Trust, Birmingham, W Midlands, England; [Green, Christopher] Univ Birmingham, Inst Microbiol & Infect, Birmingham, W Midlands, England; [Chadwick, David] James Cook Univ Hosp, Ctr Clin Infect, Middlesbrough, Cleveland, England; [Rege, Kanchan] North West Anglia NHS Fdn Trust, Peterborough, England; [Fegan, Christopher] Dept Res & Dev, Cardiff, Wales; [Fegan, Christopher] Vale Univ Hlth Board, Cardiff, Wales; [Chappell, Lucy C.] Kings Coll London, Sch Life Course Sci, London, England; [Rowan, Kathryn] Intens Care Natl Audit & Res Ctr, London, England; [Faust, Saul N.] Univ Hosp Southampton NHS Fdn Trust, NIHR Southampton Clin Res Facil & Biomed Res Ctr, Southampton, Hants, England; [Faust, Saul N.] Univ Southampton, Southampton, Hants, England; [Jaki, Thomas] Univ Lancaster, Dept Math & Stat, Lancaster, England; [Jaki, Thomas] Univ Cambridge, MRC Biostat Unit, Cambridge, England; [Baillie, J. Kenneth] Univ Edinburgh, Roslin Inst, Edinburgh, Midlothian, Scotland	University of Oxford; University of Oxford; University of Oxford; Oxford University Hospitals NHS Foundation Trust; Nottingham University Hospital NHS Trust; University of Nottingham; University of Nottingham; University of Leicester; University of Manchester; University of Birmingham; University of Birmingham; James Cook University Hospital; University of London; King's College London; Intensive Care National Audit & Research Centre; University of Southampton; University Hospital Southampton NHS Foundation Trust; University of Southampton; Lancaster University; MRC Biostatistics Unit; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; University of Edinburgh	Horby, P; Landray, MJ (corresponding author), RECOVERY Cent Coordinating Off, Richard Doll Bldg,Old Rd Campus,Roosevelt Dr, Oxford OX3 7LF, England.	recoverytrial@ndph.ox.ac.uk; recoverytrial@ndph.ox.ac.uk	Baillie, John Kenneth/F-3124-2011; Pessoa-Amorim, Guilherme/AAV-4151-2021; Caplin, Ben/AAH-1641-2019; Baillie, Kenneth/AEK-6650-2022; Nune, Arvind/ABA-2551-2021; Gibbison, Ben/J-6611-2014; Payne, Brendan/I-1233-2016; Kudsk-Iversen, Soren/Y-9391-2018; Faust, Saul/J-9779-2014; Llewelyn, Martin/A-7194-2011; Skene, Imogen/D-6153-2018; Wu, Henry HL/B-9400-2019; Chappell, Lucy/U-4778-2018	Baillie, John Kenneth/0000-0001-5258-793X; Pessoa-Amorim, Guilherme/0000-0002-4050-6191; Caplin, Ben/0000-0001-9544-164X; Baillie, Kenneth/0000-0001-5258-793X; Landray, Martin/0000-0001-6646-827X; Hodgson, Luke/0000-0002-8278-9513; Burton, Ben/0000-0001-9579-9078; Roehr, Charles Christoph/0000-0001-7965-4637; Nune, Arvind/0000-0002-3849-614X; Barker, Joseph/0000-0002-5483-9608; Burge, Sarah/0000-0002-2506-927X; Pfeffer, Paul/0000-0003-0369-2885; Morgan, Matt/0000-0002-2357-7190; Calisti, Giorgio/0000-0003-2351-4656; Gibbison, Ben/0000-0003-3635-6212; Payne, Brendan/0000-0002-3101-3512; Kudsk-Iversen, Soren/0000-0002-7112-3548; Adamali, Huzaifa/0000-0002-8230-175X; O'Sullivan, Eoin/0000-0002-7709-6595; Sarodaya, Varun/0000-0003-4999-5144; Hum, Ryan Malcolm/0000-0003-0801-6974; Caneja, Cielito/0000-0002-6122-920X; Abu-Arafeh, Ahmad/0000-0003-2464-3871; Parmar, Chetan/0000-0002-1238-6524; Chan, Xin Hui/0000-0002-9941-6975; Price, Vivien/0000-0003-3573-5106; Blazeby, Jane/0000-0002-3354-3330; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330; Blunden, Susara/0000-0003-2328-3755; Tso, Simon/0000-0001-9221-7618; Faust, Saul/0000-0003-3410-7642; Horsley, Alex/0000-0003-1828-0058; Mentzer, Alexander/0000-0002-4502-2209; Esmail, Hanif/0000-0002-4278-9316; McKnight, Gerard/0000-0003-1546-7853; Dey, Vishal/0000-0002-5108-4158; Daunt, Anna/0000-0001-6480-8867; Robertson, Calum/0000-0002-9871-3070; imray, chris/0000-0001-8451-4102; Hormis, Anil/0000-0001-5510-7639; Torok, Mili Estee/0000-0001-9098-8590; Peters, Mark/0000-0003-3653-4808; Shelley, Ben/0000-0001-6771-9659; Puxty, Kathryn/0000-0002-5742-6171; Cooper, Jamie/0000-0003-3812-7026; Scott, Alex/0000-0001-6719-0417; Jajbhay, Danyal/0000-0002-3475-9651; Ustianowski, Andrew/0000-0002-6134-7855; Heyderman, Robert/0000-0003-4573-449X; Reynard, Charles/0000-0002-7534-2668; Mishra, Eleanor/0000-0002-5903-3005; Montgomery, Alan/0000-0003-0450-1606; Gupta-Wright, Ankur/0000-0002-5150-2970; Llewelyn, Martin/0000-0002-6811-1124; Skene, Imogen/0000-0001-5215-2899; Blencowe, Natalie/0000-0002-6111-2175; Fawke, Joe/0000-0002-5267-7107; Crocombe, Dominic/0000-0002-1401-6930; Nigel, Brunskill/0000-0002-7109-7108; Stockdale, Alexander/0000-0002-5828-3328; Adams, Richard/0000-0003-3915-7243; Ricketts, William/0000-0002-0475-0744; Brannigan, Jamie/0000-0003-1697-403X; Loke, Tuck-Kay/0000-0002-4608-2756; Ramasamy, Maheshi Nirmala/0000-0002-2119-951X; Lim, Wei Shen/0000-0002-7694-3051; Green, Christopher/0000-0002-1984-4014; Jhanji, Shaman/0000-0002-1116-628X; Rossi, Sabrina Helena/0000-0001-7048-7158; Wu, Henry HL/0000-0002-4561-0844; Todd, Stacy/0000-0003-3215-9625; Soiza, Roy/0000-0002-1397-4272; Shah, Pallav/0000-0002-9052-4638; Drysdale, Simon/0000-0002-6350-6557; Haynes, Richard/0000-0002-1179-0023; Cathie, Katrina/0000-0001-5074-0769; Bibby, Anna/0000-0001-7386-7754; Bancroft, Elizabeth/0000-0002-5482-5660; Tarning, Joel/0000-0003-4566-4030; Dosanjh, Davinder/0000-0002-9169-5607; Kametas, Nicholas/0000-0002-7992-6038; Emberson, Jonathan/0000-0001-7792-9422; Patel, Manish/0000-0003-3012-7507; Hoggett, Lee/0000-0003-1135-6232; Chappell, Lucy/0000-0001-6219-3379; Whitehouse, Tony/0000-0002-4387-3421; Hinshaw, Kim/0000-0003-0468-4326; Burden, Christy/0000-0001-6409-5238; Pathan, Nazima/0000-0001-7656-9453; vatish, manu/0000-0002-6012-2574; Dark, Paul/0000-0003-3309-0164; brightling, chris/0000-0002-9345-4903; Barnett-Vanes, Ashton/0000-0002-8088-1068; Grandjean, Louis/0000-0002-1457-8327; Rokadiya, Sakib/0000-0003-2955-4907; Rowan, Kathryn/0000-0001-8217-5602; Harwood, Catherine/0000-0002-1375-0965; Stewart, Grant D./0000-0003-3188-9140; Papineni, Padmasayee/0000-0001-6923-1542; Underwood, Jonathan/0000-0001-6963-2821; Lillie, Patrick/0000-0002-4811-4774; Rivera Ortega, Pilar/0000-0002-7960-8822	Medical Research Council of United Kingdom Research and Innovation [MC_PC_19056]; National Institute for Health Research (NIHR) [MC_PC_19056]; NIHR Oxford Biomedical Research Centre; Wellcome; Bill and Melinda Gates Foundation; Department for International Development; Health Data Research UK; Medical Research Council Population Health Research Unit; NIHR Health Protection Unit in Emerging and Zoonotic Infections; NIHR Clinical Trials Unit Support Funding; NIHR Nottingham Biomedical Research Centre; NIHR Manchester Biomedical Research Centre; UK Medical Research Council [MC_UU_0002/14]; NIHR Senior Research Fellowship [NIHR-SRF-2015-08-001]; BBSRC [BBS/E/D/20002174] Funding Source: UKRI; MRC [MC_UU_12026/4, MC_U137686861, MC_PC_18033, MC_U137686860, MC_UU_00017/3, MC_UU_00002/14] Funding Source: UKRI	Medical Research Council of United Kingdom Research and Innovation; National Institute for Health Research (NIHR)(National Institute for Health Research (NIHR)); NIHR Oxford Biomedical Research Centre(National Institute for Health Research (NIHR)); Wellcome; Bill and Melinda Gates Foundation(Bill & Melinda Gates Foundation); Department for International Development; Health Data Research UK; Medical Research Council Population Health Research Unit(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Health Protection Unit in Emerging and Zoonotic Infections; NIHR Clinical Trials Unit Support Funding; NIHR Nottingham Biomedical Research Centre; NIHR Manchester Biomedical Research Centre(National Institute for Health Research (NIHR)); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NIHR Senior Research Fellowship; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Supported by a grant (MC_PC_19056) to the University of Oxford from the Medical Research Council of United Kingdom Research and Innovation and the National Institute for Health Research (NIHR); and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the Department for International Development, Health Data Research UK, the Medical Research Council Population Health Research Unit, the NIHR Health Protection Unit in Emerging and Zoonotic Infections, and NIHR Clinical Trials Unit Support Funding. Dr. Lim is supported by core funding provided by NIHR Nottingham Biomedical Research Centre, Dr. Felton by the NIHR Manchester Biomedical Research Centre, and Dr. Jaki by a grant (MC_UU_0002/14) from the UK Medical Research Council and by an NIHR Senior Research Fellowship (NIHR-SRF-2015-08-001). Tocilizumab was provided free of charge for this study by Roche. AbbVie contributed some supplies of lopinavir-ritonavir for use in the trial. Regeneron contributed supplies of REGN-COV2 for use in the clinical trial. Other medications, including dexamethasone, that were used in the trial were supplied by the National Health Service (NHS).	[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 2020, COVID19 TREATMENT GU; Arabi YM, 2018, AM J RESP CRIT CARE, V197, P757, DOI 10.1164/rccm.201706-1172OC; Baillie JK, 2013, NEW ENGL J MED, V369, P191, DOI 10.1056/NEJMcibr1304414; Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764; Cao JL, 2020, CLIN INFECT DIS, V71, P748, DOI 10.1093/cid/ciaa243; Carsana L, 2020, LANCET INFECT DIS, V20, P1135, DOI 10.1016/S1473-3099(20)30434-5; Chen NS, 2020, LANCET, V395, P507, DOI 10.1016/S0140-6736(20)30211-7; Cheng PKC, 2004, LANCET, V363, P1699, DOI 10.1016/S0140-6736(04)16255-7; Collins R, 2020, NEW ENGL J MED, V382, P674, DOI 10.1056/NEJMsb1901642; Corral L, 2020, INFECT DIS EXCEPT HI, DOI [DOI 10.1101/2020.06.17.20133579, 10.1101/2020.06.17.20133579v1]; Dagens A, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1936; de Jong MD, 2006, NAT MED, V12, P1203, DOI 10.1038/nm1477; Docherty AB, 2020, BMJ-BRIT MED J, V369, DOI 10.1136/bmj.m1985; He X., 2020, NAT MED, V26, P672; Huang CL, 2020, LANCET, V395, P497, DOI 10.1016/S0140-6736(20)30183-5; Lamontagne F, 2020, BMJ-BRIT MED J, V370, DOI 10.1136/bmj.m3379; Lansbury LE, 2020, CRIT CARE MED, V48, pE98, DOI 10.1097/CCM.0000000000004093; Lee N, 2004, J CLIN VIROL, V31, P304, DOI 10.1016/j.jcv.2004.07.006; Lee N, 2009, J INFECT DIS, V200, P492, DOI 10.1086/600383; Moore JB, 2020, SCIENCE, V368, P473, DOI 10.1126/science.abb8925; Rojek AM, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0760-x; Ruan QR, 2020, INTENS CARE MED, V46, P846, DOI 10.1007/s00134-020-05991-x; Russell CD, 2020, LANCET, V395, P473, DOI 10.1016/S0140-6736(20)30317-2; Shang LH, 2020, LANCET, V395, P683, DOI 10.1016/S0140-6736(20)30361-5; Siemieniuk RAC, 2015, ANN INTERN MED, V163, P519, DOI 10.7326/M15-0715; Sterne JAC, 2020, JAMA-J AM MED ASSOC, V324, P1330, DOI 10.1001/jama.2020.17023; Stockman LJ, 2006, PLOS MED, V3, P1525, DOI 10.1371/journal.pmed.0030343; To KKW, 2020, LANCET INFECT DIS, V20, P565, DOI 10.1016/S1473-3099(20)30196-1; Verity R, 2020, LANCET INFECT DIS, V20, P669, DOI 10.1016/S1473-3099(20)30243-7; Wang DW, 2020, JAMA-J AM MED ASSOC, V323, P1061, DOI 10.1001/jama.2020.1585; Whitty C., 2020, DEXAMETHASONE TREATM; Wolfel R, 2020, NATURE, V581, P465, DOI 10.1038/s41586-020-2196-x; Wong CK, 2004, CLIN EXP IMMUNOL, V136, P95, DOI 10.1111/j.1365-2249.2004.02415.x; Xu XW, 2020, BMJ-BRIT MED J, V368, DOI [10.1136/bmj.m792, 10.1136/bmj.m606]; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; Zhao JP, 2020, ZHONGHUA JIE HE HE H, V43, pE007, DOI [10.3760/cma.j.issn.1001-0939.2020.03.008, 10.1016/S0140-6736(20)30361-5]; Zhou F, 2020, LANCET, V395, P1054, DOI 10.1016/S0140-6736(20)30566-3; Zhou R, 2020, INT J INFECT DIS, V96, P288, DOI 10.1016/j.ijid.2020.05.030; Zhu N, 2020, NEW ENGL J MED, V382, P727, DOI 10.1056/NEJMoa2001017	40	5494	5613	106	414	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 25	2021	384	8					693	704		10.1056/NEJMoa2021436	http://dx.doi.org/10.1056/NEJMoa2021436			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP4LK	33031652	Green Accepted, Green Published, Bronze, Green Submitted			2023-01-03	WOS:000623807600009
